PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	SC	GA	UT	PM	OA	HC	HP	DA
J	Hammond, FM; Grattan, KD; Sasser, H; Corrigan, JD; Rosenthal, M; Bushnik, T; Shull, W				Hammond, FM; Grattan, KD; Sasser, H; Corrigan, JD; Rosenthal, M; Bushnik, T; Shull, W			Five years after traumatic brain injury: A study of individual outcomes and predictors of change in function	NEUROREHABILITATION			English	Article						brain injury; outcome; function; disability rating scale; prediction; employment	DISABILITY RATING-SCALE; SEVERE HEAD-INJURY; SYSTEMATIC BIAS; FOLLOW-UP; RECOVERY; VALIDITY; MODERATE; RETURN; WORK; COMA	Objective: Study functional changes between one and five years after traumatic brain injury (TBI). Design: Prospective cohort. Setting and participants: TBI Model Systems National Database subjects using cohort with complete one and five year data (n = 301). Main outcome measures: Disability Rating Scale (DRS) Level of Functioning and Employability Items. Results: On Level of Functioning, 53 (18%) individuals improved, 228 (76%) stayed the same, and 20 (7%) worsened by more than one point from Year 1 to Year 5. On Employability, 50 (17%) individuals improved, 237 (79%) stayed the same, and 14 (5%) worsened by greater than one point. Level of Functioning improvement was predicted by FIM(TM)-Motor, FIM(TM)-Cognitive, Rey Auditory Verbal Learning Test, Symbol Digit Modalities Test (written and oral), and Wechsler Adult Intelligence Scale-Revised Block Design, and worsening predicted by Symbol Digit Modalities Test (written and oral). Improvement in Employability was predicted by race, while Glasgow Coma Scale Eye Opening was predictive of worsening. Conclusions: Although the majority did not demonstrate meaningful change on the DRS items from year 1 to 5, some individuals made dramatic gains and a minority declined. There are demographic and functional indicators present at one-year post-injury that may be predictive of subsequent change.	Carolinas HealthCare Syst, Charlotte Inst Rehabil, Dept Phys Med & Rehabil, Charlotte, NC 28203 USA; Carolinas HealthCare Syst, R Stuart Dickson Inst Hlth Studies, Charlotte, NC USA; Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA; Kessler Med Rehabil Res & Educ Corp, W Orange, NJ USA; Santa Clara Valley Med Ctr, Dept Phys Med & Rehabil, San Jose, CA 95128 USA; Univ Penn, Dept Rehabil Med, Philadelphia, PA 19104 USA	Hammond, FM (corresponding author), Carolinas HealthCare Syst, Charlotte Inst Rehabil, Dept Phys Med & Rehabil, 1100 Blythe Blvd, Charlotte, NC 28203 USA.	Flora.hammond@carolinashealthcare.org	Corrigan, John D./E-2921-2011	Bushnik, Tamara/0000-0003-3328-257X			COPE D N, 1991, Brain Injury, V5, P111, DOI 10.3109/02699059109008083; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P132, DOI 10.1016/S0003-9993(97)90253-7; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; ELIASON MR, 1984, PHYS THER, V64, P1357, DOI 10.1093/ptj/64.9.1357; FRYER LJ, 1987, J HEAD TRAUMA REHAB, V2, P51, DOI DOI 10.1097/00001199-198709000-00007; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; Hall KM, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199610000-00004; Hall KM, 2001, ARCH PHYS MED REHAB, V82, P367, DOI 10.1053/apmr.2001.21525; Hall KM., 1993, J HEAD TRAUMA REHAB, V8, DOI [DOI 10.1097/00001199-199308020-00008, 10.1097/00001199-199308020-00008]; HAMMOND F, 2000, ARCH PHYS MED REHAB, V81, P1268; HAMMOND F, 2000, ARCH PHYS MED REHAB, V81, P1259; Hammond FM, 2001, J HEAD TRAUMA REHAB, V16, P318, DOI 10.1097/00001199-200108000-00003; HEATON RK, 1981, COMPREHENSIVE NORMS; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Lezak M.D., 1983, NEUROPSYCHOLOGICAL A; LEZAK MD, 1988, J LEARN DISABIL, V21, P456, DOI 10.1177/002221948802100802; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; NOVACK TA, 1991, J HEAD TRAUMA REHAB, V6, P69, DOI DOI 10.1097/00001199-199112000-00014; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Olver JH, 1995, CURR OPIN NEUROL, V8, P443, DOI 10.1097/00019052-199512000-00008; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; RAO N, 1992, ARCH PHYS MED REHAB, V73, P911; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; *SAS I INC, 1995, SAS FUND PROGR APPR; Shiozaki T, 2001, J NEUROTRAUM, V18, P665, DOI 10.1089/089771501750357618; Smith A., 1982, SYMBOL DIGIT MODALIT; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Wagner AK, 2002, ARCH PHYS MED REHAB, V83, P107, DOI 10.1053/apmr.2002.27470; Wechsler D., 1981, WECHSLER INTELLIGENC, V3rd; WIERCISIEWSKI D, 2000, ARCH PHYS MED REHAB, V81, P1628; Zafonte RD, 1996, NEUROREHABILITATION, V6, P19, DOI 10.3233/NRE-1996-6104; Zafonte RD, 1996, AM J PHYS MED REHAB, V75, P364, DOI 10.1097/00002060-199609000-00012; Zafonte RD, 1996, AM J PHYS MED REHAB, V75, P456, DOI 10.1097/00002060-199611000-00011; 1998, TRAUMATIC BRAIN INJU	42	80	82	0	11	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2004	19	1					25	35					11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	777KA	WOS:000189176500004	14988585				2021-06-18	
J	Haydel, MJ; Shembekar, AD				Haydel, MJ; Shembekar, AD			Prediction of intracranial injury in children aged five years and older with loss of consciousness after minor head injury due to nontrivial mechanisms	ANNALS OF EMERGENCY MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY; COMPUTED-TOMOGRAPHY; PEDIATRIC-PATIENTS; NEUROLOGIC EXAMINATION; CLINICAL INDICATORS; EPIDURAL HEMATOMAS; SKULL FRACTURE; CT-SCANS; MILD; MANAGEMENT	Study objective: Indications for computed tomography (CT) in children with minor head injury remain controversial. The objective of this preliminary study is to determine whether a clinical decision rule developed for adults could be used in children aged 5 years and older. Methods: A prospective questionnaire was completed on all patients who were aged 5 to 17 years with major mechanisms of injury resulting in minor head injury (defined as normal Glasgow Coma Scale or modified coma scale in infants, plus normal brief neurologic examination) and loss of consciousness. The questionnaire documented 6 clinical variables: headache, emesis, intoxication, seizure, short-term memory deficits, and physical evidence of trauma above the clavicles. CT was obtained for all patients, findings were compared with the results of the questionnaires, and the sensitivity and specificity of the decision rule were determined. Results: Throughout a 30-month period, 175 patients were enrolled, with a mean age of 12.8 years. Fourteen (8%) patients had intracranial injury or depressed skull fracture on CT. The presence of any of the 6 criteria was significantly associated with an abnormal CT scan result (P<.05) and was 100% (95% confidence interval 73% to 100%) sensitive for identifying patients with intracranial injury. Conclusion: In this preliminary study, CT use in pediatric patients with minor head injury could have been safely reduced by 23% by using a clinical decision rule previously validated in adults.	Louisiana State Univ, Hlth Sci Ctr, Sect Emergency Med, New Orleans, LA USA	Haydel, MJ (corresponding author), Charity Hosp, Emergency Med Off, 13th Floor,1532 Tulane Ave, New Orleans, LA 70112 USA.	micellehaydel@yahoo.com					Abdel-Dayem HM, 1998, CLIN NUCL MED, V23, P309, DOI 10.1097/00003072-199805000-00009; Abu-Judeh HH, 1999, NUCL MED COMMUN, V20, P505, DOI 10.1097/00006231-199906000-00003; Aitken ME, 1998, ARCH PEDIAT ADOL MED, V152, P1176; *AM COLL SURG COMM, 1999, ADV TRAUM LIF SUPP; Bejjani GK, 1996, PEDIATR NEUROSURG, V25, P302, DOI 10.1159/000121144; Bergman DA, 1999, PEDIATRICS, V104, P1407; BONADIO WA, 1989, AM J DIS CHILD, V143, P194, DOI 10.1001/archpedi.1989.02150140084025; Cook L S, 1994, Acad Emerg Med, V1, P227; Culotta VP, 1996, NEUROSURGERY, V38, P245, DOI 10.1097/00006123-199602000-00002; DAVIES RL, 1995, PEDIATRICS, V95, P345; DIETRICH AM, 1993, ANN EMERG MED, V22, P1535, DOI 10.1016/S0196-0644(05)81254-5; DUUS BR, 1993, BRIT J SURG, V80, P988, DOI 10.1002/bjs.1800800817; Greenes DS, 1997, ANN EMERG MED, V30, P253, DOI 10.1016/S0196-0644(97)70158-6; Greenes DS, 2001, PEDIATR EMERG CARE, V17, P88, DOI 10.1097/00006565-200104000-00002; Greenes DS, 1999, PEDIATRICS, V104, P861, DOI 10.1542/peds.104.4.861; Gruskin KD, 1999, ARCH PEDIAT ADOL MED, V153, P15; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Herrera EJ, 2000, CHILD NERV SYST, V16, P585, DOI 10.1007/s003810000340; Homer CJ, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.6.e78; Iverson GL, 2000, BRAIN INJURY, V14, P1057; Jagoda AS, 2002, ANN EMERG MED, V40, P231, DOI 10.1016/j.jen.2008.12.010; KNUCKEY NW, 1989, J NEUROSURG, V70, P392, DOI 10.3171/jns.1989.70.3.0392; LEE ST, 1992, J NEUROSURG, V76, P435, DOI 10.3171/jns.1992.76.3.0435; LIVINGSTON DH, 1991, J TRAUMA, V31, P483, DOI 10.1097/00005373-199104000-00006; Lloyd DA, 1997, LANCET, V349, P821, DOI 10.1016/S0140-6736(96)09356-7; MASTERS SJ, 1987, NEW ENGL J MED, V316, P84, DOI 10.1056/NEJM198701083160205; Miller Erik C., 1997, Journal of Emergency Medicine, V15, P453, DOI 10.1016/S0736-4679(97)00071-1; Murshid WR, 1998, ACTA NEUROCHIR, V140, P56, DOI 10.1007/s007010050058; Nagy KK, 1999, J TRAUMA, V46, P268, DOI 10.1097/00005373-199902000-00012; Nee PA, 1999, J NEUROL NEUROSUR PS, V66, P470, DOI 10.1136/jnnp.66.4.470; Pretto Flores L, 2000, J Neurosurg Sci, V44, P77; Quayle KS, 1997, PEDIATRICS, V99, part. no., DOI 10.1542/peds.99.5.e11; Quayle KS, 1999, PEDIATR CLIN N AM, V46, P1189, DOI 10.1016/S0031-3955(05)70182-6; RAMUNDO ML, 1995, PEDIATR EMERG CARE, V11, P1, DOI 10.1097/00006565-199502000-00001; REINUS WR, 1993, ANN EMERG MED, V22, P1148, DOI 10.1016/S0196-0644(05)80981-3; Riesgo P, 1997, SURG NEUROL, V48, P226, DOI 10.1016/S0090-3019(97)00194-8; Schunk JE, 1996, PEDIATR EMERG CARE, V12, P160, DOI 10.1097/00006565-199606000-00004; Schutzman SA, 2001, PEDIATRICS, V107, P983, DOI 10.1542/peds.107.5.983; Schutzman SA, 2001, ANN EMERG MED, V37, P65, DOI 10.1067/mem.2001.109440; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; Shane SA, 1997, PEDIATR EMERG CARE, V13, P198, DOI 10.1097/00006565-199706000-00006; Simon B, 2001, J TRAUMA, V51, P231, DOI 10.1097/00005373-200108000-00004; Sinha M, 2001, J TRAUMA, V50, P308, DOI 10.1097/00005373-200102000-00018; STEIN SC, 1992, J TRAUMA, V33, P11, DOI 10.1097/00005373-199207000-00003; Stiell IG, 2001, ANN EMERG MED, V38, P160, DOI 10.1067/mem.2001.116796; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Summers L E, 2001, J La State Med Soc, V153, P81; Vogelbaum MA, 1998, PEDIATR NEUROSURG, V29, P96, DOI 10.1159/000028697; Wang MY, 2000, NEUROSURGERY, V46, P1093, DOI 10.1097/00006123-200005000-00014; Zahari M., 1996, Singapore Medical Journal, V37, P285	50	80	81	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644	1097-6760		ANN EMERG MED	Ann. Emerg. Med.	OCT	2003	42	4					507	514		10.1067/S0196-0644(03)00512-2			8	Emergency Medicine	Emergency Medicine	729CC	WOS:000185752700007	14520321				2021-06-18	
J	Wetzel, M; Rosenberg, GA; Cunningham, LA				Wetzel, M; Rosenberg, GA; Cunningham, LA			Tissue inhibitor of metalloproteinases-3 and matrix metalloproteinase-3 regulate neuronal sensitivity to doxorubicin-induced apoptosis	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						Fas/CD95/APO-1; neuronal apoptosis; Sheddases; Wistar rats	TRAUMATIC BRAIN INJURY; FAS LIGAND; CELL-DEATH; TNF-ALPHA; RAT-BRAIN; RHEUMATOID-ARTHRITIS; EXTRACELLULAR-MATRIX; REPERFUSION INJURY; IN-VITRO; TIMP-3	Metalloproteinase activity at the cell surface influences cellular sensitivity to extrinsic death vs. survival signals in a variety of cell types, through proteolytic shedding of cell surface signalling molecules. Tissue inhibitor of metalloproteinases-3 (TIMP-3) is a unique natural metalloproteinase inhibitor that plays a pro-apoptotic role through its ability to inhibit metalloproteinases that proteolytically cleave death receptors and their ligands from the cell surface. To study the convergence of metalloproteinase activity and death receptor signalling in neurons, we established an in vitro model of neuronal apoptosis utilizing the chemotherapeutic drug, doxorubicin (Dox). Primary cultures established from embryonic rat cerebral cortices displayed robust and selective neuronal apoptosis in response to Dox, an effect that was dependent on the activation of the death receptor, Fas. We demonstrate that both TIMP-3 and matrix metalloproteinase-3 (MMP-3) are constitutively expressed by primary cortical neurons in culture, and selectively modulated Fas-mediated neuronal apoptosis induced by Dox. Metalloproteinase inhibition by TIMP-3 was found to be necessary for Dox-induced neuronal death, whereas addition of active MMP-3 markedly attenuated apoptosis and diminished Fas-Fas ligand interaction at the cell surface. These observations implicate a physiological role for the balance of TIMP-3 and MMP-3 activity at the neuronal surface in regulating death receptor sensitivity. The convergence of metalloproteinase activity and death receptor signalling at the cell surface may influence neuronal cell death vs. survival decisions.	Univ New Mexico, Sch Med, Hlth Sci Ctr, Dept Neurosci, Albuquerque, NM 87131 USA; Univ New Mexico, Sch Med, Hlth Sci Ctr, Dept Neurol, Albuquerque, NM 87131 USA	Cunningham, LA (corresponding author), Univ New Mexico, Sch Med, Hlth Sci Ctr, Dept Neurosci, Albuquerque, NM 87131 USA.	leeanna@salud.unm.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS38655, NS21169] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021169, R01NS038655] Funding Source: NIH RePORTER		Ahonen M, 1998, CANCER RES, V58, P2310; APTE SS, 1995, J BIOL CHEM, V270, P14313, DOI 10.1074/jbc.270.24.14313; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Baker AH, 1999, BRIT J CANCER, V79, P1347, DOI 10.1038/sj.bjc.6690217; Baker AH, 1998, J CLIN INVEST, V101, P1478, DOI 10.1172/JCI1584; Bechmann I, 1999, GLIA, V27, P62, DOI 10.1002/(SICI)1098-1136(199907)27:1<62::AID-GLIA7>3.0.CO;2-S; Beer R, 2000, J CEREBR BLOOD F MET, V20, P669, DOI 10.1097/00004647-200004000-00004; Bernassola F, 1999, CELL DEATH DIFFER, V6, P652, DOI 10.1038/sj.cdd.4400537; Bond M, 2002, J BIOL CHEM, V277, P13787, DOI 10.1074/jbc.M111507200; Bond M, 2000, J BIOL CHEM, V275, P41358, DOI 10.1074/jbc.M007929200; Borland G, 1999, J BIOL CHEM, V274, P2810, DOI 10.1074/jbc.274.5.2810; Brew K, 2000, BBA-PROTEIN STRUCT M, V1477, P267, DOI 10.1016/S0167-4838(99)00279-4; Butler GS, 1999, J BIOL CHEM, V274, P10846, DOI 10.1074/jbc.274.16.10846; Cai ZW, 2000, PEDIATR RES, V47, P64, DOI 10.1203/00006450-200001000-00013; Cheema ZF, 1999, J NEUROSCI, V19, P1754; DSouza SD, 1996, J EXP MED, V184, P2361, DOI 10.1084/jem.184.6.2361; Farbman AI, 1999, J COMP NEUROL, V414, P306, DOI 10.1002/(SICI)1096-9861(19991122)414:3<306::AID-CNE2>3.0.CO;2-#; Felderhoff-Mueser U, 2000, BRAIN PATHOL, V10, P17; Fitzgerald ML, 2000, J CELL BIOL, V148, P811, DOI 10.1083/jcb.148.4.811; Fulda S, 1997, CANCER RES, V57, P3823; Garden GA, 2002, J NEUROSCI, V22, P4015, DOI 10.1523/JNEUROSCI.22-10-04015.2002; George SJ, 2000, CIRCULATION, V101, P296, DOI 10.1161/01.CIR.101.3.296; Gu ZZ, 2002, SCIENCE, V297, P1186, DOI 10.1126/science.1073634; Hansen HP, 2000, J IMMUNOL, V165, P6703, DOI 10.4049/jimmunol.165.12.6703; Hargreaves PG, 1998, BRIT J HAEMATOL, V101, P694, DOI 10.1046/j.1365-2141.1998.00754.x; HERTZ E, 1993, DISSECTION TISSUE CU, P183; HOUSLEY TJ, 1993, J BIOL CHEM, V268, P4481; Jaworski DM, 2000, J NEUROSCI RES, V61, P396, DOI 10.1002/1097-4547(20000815)61:4<396::AID-JNR6>3.0.CO;2-S; KAYAGAKI N, 1995, J EXP MED, V182, P1777, DOI 10.1084/jem.182.6.1777; Le-Niculescu H, 1999, MOL CELL BIOL, V19, P751; Linseman DA, 2002, J BIOL CHEM, V277, P24546, DOI 10.1074/jbc.M201098200; Martin-Villalba A, 2001, CELL DEATH DIFFER, V8, P679, DOI 10.1038/sj.cdd.4400882; Martin-Villalba A, 1999, J NEUROSCI, V19, P3809; Matsuno H, 2001, J RHEUMATOL, V28, P22; Matsushita K, 2000, J NEUROSCI, V20, P6879, DOI 10.1523/JNEUROSCI.20-18-06879.2000; Matsushita N, 2002, CLIN EXP IMMUNOL, V130, P156, DOI 10.1046/j.1365-2249.2002.01963.x; Mitsiades N, 2001, CANCER RES, V61, P577; Morishima Y, 2001, J NEUROSCI, V21, P7551; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; Nadeau S, 1999, J NEUROPATH EXP NEUR, V58, P61, DOI 10.1097/00005072-199901000-00008; Nath D, 2001, J CELL SCI, V114, P1213; NISHIMURA T, 1995, BRAIN RES, V695, P137, DOI 10.1016/0006-8993(95)00699-Q; OKADA Y, 1987, J RHEUMATOL, V14, P41; Oliver GW, 1997, ANAL BIOCHEM, V244, P161, DOI 10.1006/abio.1996.9895; OSBORN M, 1981, COLD SPRING HARB SYM, V46, P413, DOI 10.1101/SQB.1982.046.01.040; Pan TL, 1999, CLIN EXP IMMUNOL, V118, P180; PAVLOFF N, 1992, J BIOL CHEM, V267, P17321; Powell WC, 1999, CURR BIOL, V9, P1441, DOI 10.1016/S0960-9822(00)80113-X; Qiu JH, 2002, J NEUROSCI, V22, P3504; Raoul C, 2000, CURR OPIN NEUROBIOL, V10, P111, DOI 10.1016/S0959-4388(99)00055-0; Rose S, 2000, AM J GASTROENTEROL, V95, P1; Rosenberg GA, 2001, BRAIN RES, V893, P104, DOI 10.1016/S0006-8993(00)03294-7; Smith MR, 1997, CYTOKINE, V9, P770, DOI 10.1006/cyto.1997.0233; Tanaka M, 1998, NAT MED, V4, P31, DOI 10.1038/nm0198-031; Venters HD, 2000, TRENDS NEUROSCI, V23, P175, DOI 10.1016/S0166-2236(99)01533-7; Wallace JA, 2002, J CEREBR BLOOD F MET, V22, P1303, DOI 10.1097/01.WCB.0000040943.89393.c1; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Wang JD, 1997, J INTERF CYTOK RES, V17, P369, DOI 10.1089/jir.1997.17.369; Yeow KM, 2002, MATRIX BIOL, V21, P75, DOI 10.1016/S0945-053X(01)00180-9; Yong VW, 2001, NAT REV NEUROSCI, V2, P502, DOI 10.1038/35081571; Yu WH, 2000, J BIOL CHEM, V275, P31226, DOI 10.1074/jbc.M000907200	61	80	83	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-816X	1460-9568		EUR J NEUROSCI	Eur. J. Neurosci.	SEP	2003	18	5					1050	1060		10.1046/j.1460-9568.2003.02838.x			11	Neurosciences	Neurosciences & Neurology	719EK	WOS:000185190500004	12956705				2021-06-18	
J	Schuhmann, MU; Stiller, D; Skardelly, M; Bernarding, J; Klinge, PM; Samii, A; Samii, M; Brinker, T				Schuhmann, MU; Stiller, D; Skardelly, M; Bernarding, J; Klinge, PM; Samii, A; Samii, M; Brinker, T			Metabolic changes in the vicinity of brain contusions: a proton magnetic resonance spectroscopy and histology study	JOURNAL OF NEUROTRAUMA			English	Article						brain contusion; gliosis; LCModel; mitochondrial failure; neuronal loss; proton magnetic resonance spectroscopy; traumatic brain injury	CONTROLLED CORTICAL IMPACT; RAT-BRAIN; IN-VIVO; MR SPECTROSCOPY; AXONAL INJURY; H-1 MRS; GLUCOSE-UTILIZATION; N-ACETYLASPARTATE; FOCAL ISCHEMIA; ADULT-RATS	Proton MR spectroscopy (H-1-MRS) has been previously used to monitor metabolic changes in areas of diffuse brain injury. We studied metabolism in the close vicinity of experimental traumatic brain contusions and remote on the contralateral side from 1h to 28d post-injury. Changes of creatine and phosphocreatine (Cr&PCr), N-acetylaspartate (NAA), choline (Cho), inositol (Ino), taurine (Tau), glutamate (Glu), and lactate (Lac) were assessed and compared to neuronal, glial and inflammatory changes in histology. In the pericontusional zone Cr&PCr, NAA, and Glu decreased immediately after trauma by -35%, -60%, and -37%, respectively, related to primary cell disintegration and secondary perturbations as reflected in histology. These metabolites partially recovered at 7d (-15%, -37%, and -21% respectively), in parallel to indicators of repair in immunhistochemistry. Control levels were not regained at 28d, in correlation to a decrease of viable neurons. Cho and Ino, initially lowered by -26% and -31% respectively, increased at 7d by +74% and 31%, reflecting glial activation and proliferation. The signal including the lactate resonance increased by >1000% with a maximum at 7d, possibly related to energy failure, inflammation and glial activation. A partial contribution of lipids to this signal cannot be fully excluded. The contralateral side showed mild astroglial activation in histology, but no changes in H-1-MRS. The study demonstrates the feasibility of volume selective H-1-MRS using the LCModel (Linear Combination of Model in vitro spectra of metabolites solutions) to monitor metabolic changes close to focal traumatic lesions and suggests how metabolic alterations can be differentiated in cause.	Wayne State Univ, Childrens Hosp Michigan, Sch Med, Dept Pediat Neurosurg, Detroit, MI 48202 USA; Hannover Med Sch, Dept Neurosurg, D-3000 Hannover, Germany; Boehringer Ingelheim KG, Pharma, In Vivo MR Lab, CNS Res Div, Ingelheim, Germany; Univ Hosp Benjamin Franklin, Inst Med Informat, Berlin, Germany; Int Neurosci Inst, Hannover, Germany; Nordstadt Hosp, Dept Neurosurg, Hannover, Germany	Schuhmann, MU (corresponding author), Univ Klinikum Leipzig, Klin & Poliklin Neurochirurg, Liebigstr 20, D-04103 Leipzig, Germany.	mschuh@gmx.de	Skardelly, Marco/AAF-8680-2021				Alessandri B, 2000, NEUROL RES, V22, P705; Barkovich AJ, 1999, AM J NEURORADIOL, V20, P1399; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Bates TE, 1996, NEUROREPORT, V7, P1397, DOI 10.1097/00001756-199605310-00014; Berry I, 1986, Acta Radiol Suppl, V369, P338; Bouzier AK, 2000, J NEUROCHEM, V75, P480, DOI 10.1046/j.1471-4159.2000.0750480.x; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; Brooks WM, 1999, J RHEUMATOL, V26, P81; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; Cecil KM, 1998, J NEUROCHEM, V70, P2038; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; Chadi G, 1998, BRAZ J MED BIOL RES, V31, P231, DOI 10.1590/S0100-879X1998000200007; Chang L, 1999, J MAGN RESON IMAGING, V10, P521, DOI 10.1002/(SICI)1522-2586(199910)10:4<521::AID-JMRI4>3.3.CO;2-0; Chang L, 1999, NEUROLOGY, V53, P782, DOI 10.1212/WNL.53.4.782; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; CHEN S, 2002, J NEUROTRAUM, V19, P1282; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; DAMOISEAUX JGMC, 1994, IMMUNOLOGY, V83, P140; DESTEFANO N, 1995, MAGN RESON MED, V34, P721; Dhillon HS, 1999, J NEUROTRAUM, V16, P455, DOI 10.1089/neu.1999.16.455; ERECINSKA M, 1990, PROG NEUROBIOL, V35, P245, DOI 10.1016/0301-0082(90)90013-7; ERECINSKA M, 1988, J NEUROCHEM, V51, P892, DOI 10.1111/j.1471-4159.1988.tb01826.x; Fortuna S, 1997, NEUROCHEM INT, V31, P563, DOI 10.1016/S0197-0186(97)00005-3; Friedman SD, 1998, AM J NEURORADIOL, V19, P1879; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Gasparovic C, 2001, J NEUROTRAUM, V18, P241, DOI 10.1089/08977150151070856; Hendrich KS, 1999, MAGN RESON MED, V42, P673, DOI 10.1002/(SICI)1522-2594(199910)42:4<673::AID-MRM8>3.0.CO;2-B; Holshouser BA, 1997, RADIOLOGY, V202, P487, DOI 10.1148/radiology.202.2.9015079; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Kroppenstedt SN, 1998, J NEUROTRAUM, V15, P191, DOI 10.1089/neu.1998.15.191; KUGLER P, 1989, BIOMED RES-TOKYO, V10, P251; KUGLER P, 1988, HISTOCHEMISTRY, V90, P99, DOI 10.1007/BF00500974; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; LOPEZVILLEGAS D, 1995, MAGNET RESON MED, V34, P32, DOI 10.1002/mrm.1910340107; Magistretti P J, 2000, Rev Med Suisse Romande, V120, P739; Magistretti PJ, 1999, SCIENCE, V283, P496, DOI 10.1126/science.283.5401.496; McBride DQ, 1995, SURG NEUROL, V44, P137, DOI 10.1016/0090-3019(95)00139-5; MCINTOSH TK, 1987, J NEUROCHEM, V49, P1530; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; MIYAKE M, 1981, J NEUROCHEM, V37, P1064, DOI 10.1111/j.1471-4159.1981.tb04500.x; Paxinos G, 1998, RAT BRAIN STEREOTACT; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; PETROFF OAC, 1992, NEUROLOGY, V42, P1349, DOI 10.1212/WNL.42.7.1349; Pfeuffer J, 1999, J MAGN RESON, V141, P104, DOI 10.1006/jmre.1999.1895; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Planas AM, 1997, PROG NEUROBIOL, V51, P607, DOI 10.1016/S0301-0082(97)00004-X; POLLOCK JS, 1995, HISTOCHEM J, V27, P738; Portella G, 2000, ACT NEUR S, V76, P273; Provencher SW, 2001, NMR BIOMED, V14, P260, DOI 10.1002/nbm.698; PROVENCHER SW, 1993, MAGNET RESON MED, V30, P672, DOI 10.1002/mrm.1910300604; Reilly JF, 1996, EXP NEUROL, V140, P139, DOI 10.1006/exnr.1996.0124; ROSS B, 1994, MAGN RESON QUART, V10, P191; Ross BD, 1998, NEUROIMAG CLIN N AM, V8, P809; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; Rubin Y, 1997, J NEUROTRAUM, V14, P441, DOI 10.1089/neu.1997.14.441; SCHIFFER D, 1986, BRAIN RES, V374, P110, DOI 10.1016/0006-8993(86)90399-9; SCHROETER M, 1995, EXP BRAIN RES, V106, P1; Schuhmann MU, 2002, ACT NEUR S, V81, P209; Schuhmann MU, 2002, ACTA NEUROCHIR SUPPL, V81, P213; Schuhmann MU, 2000, ACTA NEUROCHIR SUPPL, V76, P3; Schurr A, 1999, J NEUROSCI, V19, P34; Schurr A, 2002, INT J MOL MED, V10, P131, DOI 10.3892/ijmm.10.2.131; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; Smith DH, 1998, J NEUROTRAUM, V15, P665, DOI 10.1089/neu.1998.15.665; Sorensen JC, 1996, EXP BRAIN RES, V112, P203; Stroop R, 1998, ACT NEUR S, V71, P303; TAKAMI K, 1992, EXP BRAIN RES, V90, P1; TAKAMIYA Y, 1988, DEV BRAIN RES, V38, P201, DOI 10.1016/0165-3806(88)90045-4; TALLAN HH, 1956, J BIOL CHEM, V219, P257; vanderToorn A, 1995, NMR BIOMED, V8, P245; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; VINK R, 1987, BIOCHEM BIOPH RES CO, V149, P594, DOI 10.1016/0006-291X(87)90409-8; VINK R, 1988, MAGNET RESON MED, V7, P95, DOI 10.1002/mrm.1910070111; VINK R, 1988, MAGNET RESON MED, V6, P37, DOI 10.1002/mrm.1910060105	79	80	82	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2003	20	8					725	743		10.1089/089771503767869962			19	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	712BU	WOS:000184777000004	12965052				2021-06-18	
J	Kupina, NC; Detloff, MR; Bobrowski, WF; Snyder, BJ; Hall, ED				Kupina, NC; Detloff, MR; Bobrowski, WF; Snyder, BJ; Hall, ED			Cytoskeletal protein degradation and neurodegeneration evolves differently in males and females following experimental head injury	EXPERIMENTAL NEUROLOGY			English	Article						traumatic brain injury; gender difference; cytoskeleton; calpain; neurofilament; spectrin	TRAUMATIC BRAIN INJURY; PRIMARY CORTICAL-NEURONS; CEREBRAL BLOOD-FLOW; HIPPOCAMPAL-NEURONS; OXIDATIVE STRESS; NEUROBLASTOMA-CELLS; ESTRADIOL PROTECTS; GLUTAMATE TOXICITY; GENDER DIFFERENCES; ALPHA-SPECTRIN	The resulting neuropathological degeneration that occurs following a traumatic brain injury (TBI) is a consequence of both immediate and secondary neurochemical sequelae. Proteolysis of cytoskeletal proteins, triggered by calcium-mediated events, is believed to be a particularly significant contributor to TBI-induced neuronal death. To date, efforts to associate cytoskeletal degradation and neurodegeneration in TBI have been primarily qualitative or semiquantitative. The objectives of this study were (1) to quantitatively describe, over a posttraumatic time course, the relationship and mechanisms of cytoskeletal degradation (Western blot) and neurodegeneration (silver staining) in male and female mice following a moderately severe weight-drop impact-acceleration head injury; (2) to evaluate gender differences in the response to TBI; and (3) to examine the potential therapeutic window for future pharmacological treatment strategies. In male and female mice, we report a close correlation in the time courses of neurofilament M protein degradation and alpha-spectrin breakdown products (SBDP 150 and 145) with the peak magnitude of neurodegeneration, as quantified by silver staining. Evidence from the increased patterns of SBDPs suggests that both calpain and caspase-3 are involved. In general, males incurred peak protein degradation and neurodegeneration within 3 days after injury, while in females this did not occur until 14 days. The neuroprotective effects of estrogen are believed to be key factors in the superior outcome of female vs male mice following TBI. In mice, the therapeutic window of opportunity for pharmacological intervention aimed at limiting cytoskeletal degradation might be as much as 24 h following injury. Evidence of a protracted time course of cytoskeletal degradation, especially in females, suggests a potential for an extended treatment-duration following TBI. (C) 2003 Elsevier Science (USA). All rights reserved.	Pfizer Global Res & Dev, Ann Arbor Labs, CNS Pharmacol, Ann Arbor, MI 48105 USA; Pfizer Global Res & Dev, Ann Arbor Labs, DSE, Ann Arbor, MI 48105 USA	Hall, ED (corresponding author), Univ Kentucky, Albert B Chandler Med Ctr, Spinal Cord & Brain Injury Res ctr, 232 Hlth Sci Res Bldg, Lexington, KY 40536 USA.		Hall, Edward D/F-8930-2013				Alkayed NJ, 1998, STROKE, V29, P159, DOI 10.1161/01.STR.29.1.159; Azcoitia I, 1999, J NEUROSCI RES, V58, P815, DOI 10.1002/(SICI)1097-4547(19991215)58:6<815::AID-JNR8>3.0.CO;2-R; BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; Bartus RT, 1997, NEUROSCIENTIST, V3, P314, DOI 10.1177/107385849700300513; Behl C, 1997, MOL PHARMACOL, V51, P535; BEHL C, 1995, BIOCHEM BIOPH RES CO, V216, P473, DOI 10.1006/bbrc.1995.2647; BERRY K, 1975, J NEUROL SCI, V25, P75, DOI 10.1016/0022-510X(75)90188-4; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; COTTIN P, 1991, BIOCHIM BIOPHYS ACTA, V1079, P139, DOI 10.1016/0167-4838(91)90118-J; DEOLMOS JS, 1994, NEUROTOXICOL TERATOL, V16, P545, DOI 10.1016/0892-0362(94)90033-7; Dubal DB, 1999, J NEUROSCI, V19, P6385; FERRIS DC, 1995, NEUROREPORT, V6, P1485, DOI 10.1097/00001756-199507310-00005; Garcia-Segura LM, 2001, PROG NEUROBIOL, V63, P29, DOI 10.1016/S0301-0082(00)00025-3; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; Golding EM, 1999, CLIN EXP HYPERTENS, V21, P299, DOI 10.3109/10641969909068668; Goodman YD, 1996, J NEUROCHEM, V66, P1836; GOULD E, 1990, J NEUROSCI, V10, P1286; GRAFE MR, 1980, J NEUROPATH EXP NEUR, V39, P555, DOI 10.1097/00005072-198009000-00005; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; Green PS, 1996, NEUROSCI LETT, V218, P165, DOI 10.1016/S0304-3940(96)13148-7; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; Hall E.D., 1995, CENTRAL NERVOUS SYST, P213; HALL ED, 1991, J CEREBR BLOOD F MET, V11, P292, DOI 10.1038/jcbfm.1991.61; HALL ED, 1998, CEREBROVASC DIS, P710; HARRIS AS, 1988, J NEUROSCI, V8, P2640; HAYASHI T, 1992, P NATL ACAD SCI USA, V89, P11259, DOI 10.1073/pnas.89.23.11259; HEIMER L, 1970, CONT RES METHODS NEU, P106; HURN PD, 1995, J CEREBR BLOOD F MET, V15, P666, DOI 10.1038/jcbfm.1995.82; Ikonomidou C, 2000, SCIENCE, V287, P1056, DOI 10.1126/science.287.5455.1056; KAMAKURA K, 1985, J NEUROSCI RES, V13, P391, DOI 10.1002/jnr.490130306; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; KANNEL WB, 1994, HEART INCIDENCE PREV; Kassell NF, 1996, J NEUROSURG, V84, P221, DOI 10.3171/jns.1996.84.2.0221; KONTOS HA, 1989, CHEM-BIOL INTERACT, V72, P229, DOI 10.1016/0009-2797(89)90001-X; KumeKick J, 1996, BRAIN RES, V738, P8, DOI 10.1016/0006-8993(96)00744-5; Kupina NC, 2001, J NEUROTRAUM, V18, P1229, DOI 10.1089/089771501317095269; MacManus JP, 1997, J CEREBR BLOOD F MET, V17, P815, DOI 10.1038/aj.jcbfm.9590266; McIntosh TK, 1997, NEUROSCIENTIST, V3, P169, DOI 10.1177/107385849700300310; McIntosh TK, 1996, LAB INVEST, V74, P315; MENDELSON ME, 1994, CURR OPIN CARDIOL, V9, P619, DOI 10.1097/00001573-199409000-00018; MIKKOLA T, 1995, J CLIN ENDOCR METAB, V80, P1832, DOI 10.1210/jc.80.6.1832; Moosmann B, 1999, P NATL ACAD SCI USA, V96, P8867, DOI 10.1073/pnas.96.16.8867; MORSE JK, 1986, EXP NEUROL, V94, P649, DOI 10.1016/0014-4886(86)90244-X; Murphy DD, 1998, P NATL ACAD SCI USA, V95, P11412, DOI 10.1073/pnas.95.19.11412; PAYAN HM, 1977, STROKE, V8, P194, DOI 10.1161/01.STR.8.2.194; Pelligrino DA, 1998, NEUROREPORT, V9, P3285, DOI 10.1097/00001756-199810050-00026; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; REGAN RF, 1997, BRAIN RES, V764, P130; RINK A, 1995, AM J PATHOL, V147, P1575; ROOF RL, 1993, BEHAV BRAIN RES, V57, P47, DOI 10.1016/0166-4328(93)90060-4; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; ROOF RL, 1994, NEUROTRAUMA, V11, P124; ROSS DT, 1994, EXP NEUROL, V126, P291, DOI 10.1006/exnr.1994.1067; SAATMAN KE, 1996, P NATL ACAD SCI, V93; SAATMAN KE, 1996, J NEUROPATH EXP NEUR, V55, P852; SADOSHIMA S, 1988, BRAIN RES, V454, P238, DOI 10.1016/0006-8993(88)90823-2; Shi J, 1997, EXP BRAIN RES, V117, P200, DOI 10.1007/s002210050216; SIESJO BK, 1989, J CEREBR BLOOD F MET, V9, P127, DOI 10.1038/jcbfm.1989.20; Singer CA, 1999, J NEUROSCI, V19, P2455; Singer CA, 1998, NEUROREPORT, V9, P2565, DOI 10.1097/00001756-199808030-00025; Singer CA, 1996, NEUROSCI LETT, V212, P13, DOI 10.1016/0304-3940(96)12760-9; SINGH M, 1995, ENDOCRINOLOGY, V136, P2320, DOI 10.1210/en.136.5.2320; Switzer RC, 2000, TOXICOL PATHOL, V28, P70, DOI 10.1177/019262330002800109; VERITY MA, 1992, NEUROTOXICOLOGY, V13, P139; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Watters JJ, 1997, ENDOCRINOLOGY, V138, P4030, DOI 10.1210/en.138.9.4030; Wise PM, 2001, ENDOCRINOLOGY, V142, P969, DOI 10.1210/en.142.3.969; WOOLLEY CS, 1992, J NEUROSCI, V12, P2549; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; YAMAMOTO T, 1986, BRAIN RES, V374, P419, DOI 10.1016/0006-8993(86)90442-7; YUEN PW, 1996, EXPERT OPIN INV DRUG, V5, P1291; ZHANG A, 1992, BRIT J PHARMACOL, V105, P305, DOI 10.1111/j.1476-5381.1992.tb14250.x; Zhang YQ, 1998, BRAIN RES, V784, P321, DOI 10.1016/S0006-8993(97)00502-7; Zheng JQ, 2001, J NEUROSCI, V21, P9291, DOI 10.1523/JNEUROSCI.21-23-09291.2001	79	80	84	0	2	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	MAR	2003	180	1					55	72		10.1016/S0014-4886(02)00048-1			18	Neurosciences	Neurosciences & Neurology	663UR	WOS:000182025100006	12668149				2021-06-18	
J	Wagner, AK; Kline, AE; Sokoloski, J; Zafonte, RD; Capulong, E; Dixon, CE				Wagner, AK; Kline, AE; Sokoloski, J; Zafonte, RD; Capulong, E; Dixon, CE			Intervention with environmental enrichment after experimental brain trauma enhances cognitive recovery in male but not female rats	NEUROSCIENCE LETTERS			English	Article						environmental enrichment; traumatic brain injury; controlled cortical impact; gender; cognitive recovery; spatial memory	INJURY; PROGESTERONE; EXPRESSION; ESTROGEN; CORTEX	Environmental enrichment (EE) has been repeatedly shown to affect multiple aspects of brain function, and is known to enhance cognitive recovery after experimental traumatic brain injury (TBI) in males. However, the impact of gender on how EE affects behavioral performance after experimental TBI have not been studied. Male and normally cycling female Sprague-Dawley rats underwent controlled cortical impact injury or sham surgery and then were placed in either a standard or enriched housing environment. Motor function was assessed both pre-injury and for the first 5 days after injury. Spatial memory was assessed beginning 14 days after injury. Placement in an EE after TBI enhanced spatial memory performance in male but not female rats. EE did not impact motor performance in this setting. These findings have gender specific implications for how to approach and evaluate treatments and interventions after TBI. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.	Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15213 USA	Wagner, AK (corresponding author), Univ Pittsburgh, Dept Phys Med & Rehabil, 3471 5th Ave,Kaufmann Bldg,Suite 201, Pittsburgh, PA 15213 USA.	wagnerak@msx.upmc.edu					Berchtold NC, 2001, EUR J NEUROSCI, V14, P1992, DOI 10.1046/j.0953-816x.2001.01825.x; Bland ST, 2000, STROKE, V31, P1144, DOI 10.1161/01.STR.31.5.1144; Bramlett HM, 2001, J NEUROTRAUM, V18, P891, DOI 10.1089/089771501750451811; BRYAN JM, 2001, J NEUROTRAUM, V18, P1129; BUTCHER RL, 1974, ENDOCRINOLOGY, V94, P1704, DOI 10.1210/endo-94-6-1704; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Hamm RJ, 1996, J NEUROTRAUM, V13, P41, DOI 10.1089/neu.1996.13.41; Ickes BR, 2000, EXP NEUROL, V164, P45, DOI 10.1006/exnr.2000.7415; Kline AE, 2000, NEUROSCI LETT, V280, P163, DOI 10.1016/S0304-3940(00)00797-7; KOLB B, 1995, BEHAV NEUROSCI, V109, P285, DOI 10.1037/0735-7044.109.2.285; Kolb B, 1998, NEUROSCI BIOBEHAV R, V22, P143, DOI 10.1016/S0149-7634(97)00008-0; Passineau MJ, 2001, EXP NEUROL, V168, P373, DOI 10.1006/exnr.2000.7623; Pham TM, 1999, NEUROSCIENCE, V94, P279, DOI 10.1016/S0306-4522(99)00316-4; Rampon C, 2000, P NATL ACAD SCI USA, V97, P12880, DOI 10.1073/pnas.97.23.12880; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; Teskey GC, 1999, CEREB CORTEX, V9, P675, DOI 10.1093/cercor/9.7.675; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; Winterfeld KT, 1998, J NEUROSCI RES, V52, P201, DOI 10.1002/(SICI)1097-4547(19980415)52:2<201::AID-JNR8>3.0.CO;2-E	20	80	83	0	9	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	DEC 16	2002	334	3					165	168	PII S0304-3940(02)01103-5	10.1016/S0304-3940(02)01103-5			4	Neurosciences	Neurosciences & Neurology	624MK	WOS:000179763300006	12453621				2021-06-18	
J	Donders, J; Hoffman, NA				Donders, J; Hoffman, NA			Gender differences in learning and memory after pediatric traumatic brain injury	NEUROPSYCHOLOGY			English	Article							SEX-DIFFERENCES; HEAD-INJURY; READING-DISABILITY; CHILDREN; RECOVERY; LATERALIZATION; ADOLESCENTS; PERFORMANCE; DAMAGE; MILD	Thirty boys and 30 girls who sustained a traumatic brain injury (TBI) were evaluated within I year postinjury with the California Verbal Learning Test-Children's Version (CVLT-C; D. C. Delis, J. H. Kramer, E. Kaplan, & B. A. Ober, 1994). Boys had statistically significantly lower performance on the CVLT-C than girls in the absence of statistically significant group differences on various demographic and neurological variables. Although the effect size for this difference was modest (eta(2) = .09), gender accounted for a statistically significant amount of the variance (5%) in CVLT-C scores in addition to effects of injury severity and age. It is concluded that male gender is associated with an increased risk for retrieval deficits after pediatric TBI, possibly because of reduced speed or efficiency of information processing.	Mary Free Bed Hosp, Psychol Serv, Grand Rapids, MI 49503 USA; Rehabil Ctr, Grand Rapids, MI USA	Donders, J (corresponding author), Mary Free Bed Hosp, Psychol Serv, 235 Wealthy SE, Grand Rapids, MI 49503 USA.	jdonders@mfbrc.com					ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Anderson VA, 2000, BRAIN INJURY, V14, P679; Badian NA, 1999, J LEARN DISABIL, V32, P138, DOI 10.1177/002221949903200204; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; BERNEY J, 1994, CHILD NERV SYST, V10, P517, DOI 10.1007/BF00335074; Bigler ED, 1999, J HEAD TRAUMA REHAB, V14, P406, DOI 10.1097/00001199-199908000-00009; Bjorklund D. F., 1997, DEV MEMORY CHILDHOOD, P201; BRYDEN MP, 1994, BRAIN COGNITION, V26, P103, DOI 10.1006/brcg.1994.1045; Cernak I, 1999, BRAIN INJURY, V13, P1005; Delis D, 1994, CALIFORNIA VERBAL LE; Dennis M, 2000, BRAIN COGNITION, V42, P102, DOI 10.1006/brcg.1999.1174; Dennis M, 2000, SCI PRACT NEUROPSYCH, P3; Donders J, 1999, DEV NEUROPSYCHOL, V15, P395, DOI 10.1080/87565649909540757; Donders J, 1997, ASSESSMENT, V4, P107, DOI 10.1177/107319119700400114; DONDERS J, 1998, HDB PEDIAT PSYCHOL P, V2, P166; DONDERS J, 1995, ASSESSMENT, V2, P219; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Farmer JE, 1999, DEV NEUROPSYCHOL, V15, P269, DOI 10.1080/87565649909540749; Flannery KA, 2000, J INT NEUROPSYCH SOC, V6, P433, DOI 10.1017/S1355617700644016; GESCHWIND N, 1985, ARCH NEUROL-CHICAGO, V42, P428, DOI 10.1001/archneur.1985.04060050026008; GRUMBACH MM, 1998, WILLIAMS TXB ENDOCRI, P1509; Hiscock M, 1999, J CLIN EXP NEUROPSYC, V21, P17, DOI 10.1076/jcen.21.1.17.944; Hoffman N, 2000, ARCH CLIN NEUROPSYCH, V15, P47, DOI 10.1016/S0887-6177(98)00156-5; Hostler SL, 1999, J HEAD TRAUMA REHAB, V14, P384, DOI 10.1097/00001199-199908000-00007; HUGDAHL K, 1990, NEUROPSYCHOLOGIA, V28, P673, DOI 10.1016/0028-3932(90)90122-5; Kolb B, 2000, DEV NEUROPSYCHOL, V18, P423, DOI 10.1207/S1532694208Kolb; Kolk A, 2000, J CHILD NEUROL, V15, P581, DOI 10.1177/088307380001500903; Kramer JH, 1997, NEUROPSYCHOLOGY, V11, P577, DOI 10.1037/0894-4105.11.4.577; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Levin HS, 2000, J CLIN EXP NEUROPSYC, V22, P1, DOI 10.1076/1380-3395(200002)22:1;1-8;FT001; MADIGAN KA, 1997, STUDENTS ACQUIRED BR, P123; Max JE, 1999, J INT NEUROPSYCH SOC, V5, P58, DOI 10.1017/S1355617799511089; MCGLONE J, 1977, BRAIN, V100, P775, DOI 10.1093/brain/100.4.775; MCGLONE J, 1980, BEHAV BRAIN SCI, V3, P215, DOI 10.1017/S0140525X00004398; Meyer GJ, 2001, AM PSYCHOL, V56, P128, DOI 10.1037//0003-066X.56.2.128; Meyers J., 1995, REY COMPLEX FIGURE T; Meyers JE, 1996, REY COMPLEX FIGURE T; MILLER LJ, IN PRESS REHABILITAT; Murphy KR, 1998, STAT POWER ANAL; PAPERO PH, 1993, NEUROPSYCHOL REHABIL, V3, P321, DOI 10.1080/09602019308401445; RAZ S, 1995, DEV PSYCHOL, V31, P958, DOI 10.1037/0012-1649.31.6.958; RAZ S, 1994, PSYCHOBIOLOGY, V22, P244; REITER EO, 1998, WILLIAMS TXB ENDOCRI, P1427; Roman MJ, 1998, J CLIN EXP NEUROPSYC, V20, P245, DOI 10.1076/jcen.20.2.245.1168; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Sheslow D., 1990, WIDE RANGE ASSESSMEN; SHURTLEFF HA, 1995, J HEAD TRAUMA REHAB, V10, P64, DOI 10.1097/00001199-199510000-00008; SNOW WG, 1985, J CONSULT CLIN PSYCH, V53, P940, DOI 10.1037/0022-006X.53.6.940; Sparrow S., 1984, VINELAND ADAPTIVE BE; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; SUCHING L, 1994, BRAIN INJURY, V8, P571; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Taylor HG, 2000, NEUROPSYCHOLOGY, V14, P509, DOI 10.1037/0894-4105.14.4.509; TEASDALE G, 1974, LANCET, V2, P81; Tremont G, 1999, CHILD NEUROPSYCHOL, V5, P104, DOI 10.1076/chin.5.2.104.3166; van den Burg W, 1999, ARCH CLIN NEUROPSYCH, V14, P545, DOI 10.1016/S0887-6177(98)00042-0; WABER DP, 1992, J CLIN ONCOL, V10, P810, DOI 10.1200/JCO.1992.10.5.810; WABER DP, 1990, J PEDIATR PSYCHOL, V15, P105, DOI 10.1093/jpepsy/15.1.105; Wechsler D., 1991, WECHSLER INTELLIGENC; Welsh TN, 2001, NEUROPSYCHOLOGIA, V39, P25, DOI 10.1016/S0028-3932(00)00094-4; Willcutt EG, 2000, J LEARN DISABIL, V33, P179, DOI 10.1177/002221940003300206; Woodward H, 1999, J HEAD TRAUMA REHAB, V14, P351, DOI 10.1097/00001199-199908000-00004; Woodward H, 1998, APPL NEUROPSYCHOL, V5, P113, DOI 10.1207/s15324826an0503_1; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78; Yeates KO, 2000, SCI PRACT NEUROPSYCH, P92; YLVISAKER M, 1994, ED DIMENSIONS ACQUIR, P121	67	80	81	1	7	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	OCT	2002	16	4					491	499		10.1037//0894-4105.16.4.491			9	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	601HR	WOS:000178440800005	12382988				2021-06-18	
J	Levine, B; Cabeza, R; McIntosh, AR; Black, SE; Grady, CL; Stuss, DT				Levine, B; Cabeza, R; McIntosh, AR; Black, SE; Grady, CL; Stuss, DT			Functional reorganisation of memory after traumatic brain injury: a study with (H2O)-O-15 positron emission tomography	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							CLOSED-HEAD-INJURY; INDUCED AXONAL INJURY; EPISODIC MEMORY; ALZHEIMERS-DISEASE; PREFRONTAL CORTEX; WORKING-MEMORY; TECHNETIUM-99M-HMPAO SPECT; COMPUTERIZED-TOMOGRAPHY; PET; RETRIEVAL	Objective: To study the effects of moderate to severe traumatic brain injury (TBI) on the functional neuroanatomy supporting memory retrieval. Methods: Subjects were six patients who had sustained a moderate to severe TBI about four years before scanning and had since made a good recovery. Eleven healthy young adults matched to the patients for age and education served as controls. An established (H2O)-O-15 positron emission tomography paradigm was used to elicit brain activations in response to memory retrieval. TBI patients' patterns of brain activation were compared statistically with those of control subjects. Both group and individual case data were analysed. Results: Both TBI patients and controls engaged frontal, temporal, and parietal regions known to be involved in memory retrieval, yet the TBI patients showed relative increases in frontal, anterior cingulate, and occipital activity. The hemispheric asymmetry characteristic of controls was attenuated in patients with TBI. Reduced activation was noted in the right dorsomedial thalamus. Although local aspects of this pattern were affected by the presence of focal lesions and performance differences, the overall pattern was reliable across patients and comparable to functional neuroimaging results reported for normal aging, Alzheimer's disease, and other patients with TBI. Conclusions: The TBI patients performed memory tasks using altered functional neuroanatomical networks. These changes are probably the result of diffuse axonal injury and may reflect either cortical disinhibition attributable to disconnection or compensation for inefficient mnemonic processes.	Baycrest Ctr Geriatr Care, Rotman Res Inst, Toronto, ON M6E 3A5, Canada; Univ Toronto, Dept Psychol, Toronto, ON, Canada; Univ Toronto, Dept Med Neurol, Toronto, ON, Canada; Duke Univ, Ctr Cognit Sci, Durham, NC USA	Levine, B (corresponding author), Baycrest Ctr Geriatr Care, Rotman Res Inst, 3560 Bathurst St, Toronto, ON M6E 3A5, Canada.		McIntosh, Anthony R/G-4955-2011; Levine, Brian/O-2725-2019; Levine, Brian/G-4328-2010; Black, Sandra E./C-7294-2011	Levine, Brian/0000-0003-4343-811X; Levine, Brian/0000-0003-4343-811X; McIntosh, Anthony/0000-0002-1784-5662; Black, Sandra/0000-0001-7093-8289			ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Altrocchi PH, 1996, NEUROLOGY, V46, P278; Backman L, 1999, NEUROLOGY, V52, P1861, DOI 10.1212/WNL.52.9.1861; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Barch DM, 1997, NEUROPSYCHOLOGIA, V35, P1373, DOI 10.1016/S0028-3932(97)00072-9; Becker JT, 1996, NEUROLOGY, V46, P692, DOI 10.1212/WNL.46.3.692; Bookheimer SY, 2000, NEW ENGL J MED, V343, P450, DOI 10.1056/NEJM200008173430701; Buckner RL, 1996, P NATL ACAD SCI USA, V93, P1249, DOI 10.1073/pnas.93.3.1249; Cabeza R, 2000, J COGNITIVE NEUROSCI, V12, P1, DOI 10.1162/08989290051137585; Cabeza R, 1997, J NEUROSCI, V17, P391; Cabeza R, 1997, J COGNITIVE NEUROSCI, V9, P254, DOI 10.1162/jocn.1997.9.2.254; Christman CW, 1997, ACTA NEUROPATHOL, V94, P329, DOI 10.1007/s004010050715; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; CUMMINGS JL, 1993, ARCH NEUROL-CHICAGO, V50, P873, DOI 10.1001/archneur.1993.00540080076020; DEsposito M, 1997, NEUROIMAGE, V6, P113, DOI 10.1006/nimg.1997.0281; DEVINSKY O, 1995, BRAIN, V118, P279, DOI 10.1093/brain/118.1.279; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; DUARA R, 1992, J CEREBR BLOOD F MET, V12, P927, DOI 10.1038/jcbfm.1992.129; Dupont S, 2000, BRAIN, V123, P1722, DOI 10.1093/brain/123.8.1722; Duzel E, 1999, P NATL ACAD SCI USA, V96, P1794, DOI 10.1073/pnas.96.4.1794; Engelien A, 1995, BRAIN, V118, P1395, DOI 10.1093/brain/118.6.1395; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; Friston K., 1995, HUM BRAIN MAPP, V2, P189, DOI [10.1002/hbm.460020402, DOI 10.1002/HBM.460020402]; GOLDENBERG G, 1992, J NEUROL NEUROSUR PS, V55, P362, DOI 10.1136/jnnp.55.5.362; GRADY CL, 1995, SCIENCE, V269, P218, DOI 10.1126/science.7618082; GRAY BG, 1992, J NUCL MED, V33, P52; Gross H, 1996, J NEUROPSYCH CLIN N, V8, P324; Henson RNA, 1999, BRAIN, V122, P1367, DOI 10.1093/brain/122.7.1367; ICHISE M, 1994, J NUCL MED, V35, P217; Kapur S, 1996, COGNITIVE BRAIN RES, V4, P243, DOI 10.1016/S0926-6410(96)00058-4; KAPUR S, 1994, NEUROREPORT, V5, P2193, DOI 10.1097/00001756-199410270-00051; Kirkby BS, 1996, NEUROPSYCHOLOGIA, V34, P689; KURTZKE JF, 1982, NEUROLOGY, V32, P1207, DOI 10.1212/WNL.32.11.1207; Labbe C, 1996, ALZ DIS ASSOC DIS, V10, P141, DOI 10.1097/00002093-199601030-00005; LANGFITT TW, 1986, J NEUROSURG, V64, P760, DOI 10.3171/jns.1986.64.5.0760; Lepage M, 2000, P NATL ACAD SCI USA, V97, P506, DOI 10.1073/pnas.97.1.506; LEVIN HS, 1986, J CLIN EXP NEUROPSYC, V8, P643, DOI 10.1080/01688638608405185; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; Levine B, 1998, BRAIN, V121, P1951, DOI 10.1093/brain/121.10.1951; Levine B, 2000, NEUROPSYCHOLOGY, V14, P491, DOI 10.1037/0894-4105.14.4.491; Levine B., 2002, PRINCIPLES FRONTAL L, P448; Mateer C.A., 1987, J HEAD TRAUMA REHAB, V2, P74, DOI [10.1097/00001199-198709000-00009, DOI 10.1097/00001199-198709000-00009]; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; *NAT CTR INJ PREV, 1999, TRAUM BRAIN INJ US R; Nolde SF, 1998, NEUROREPORT, V9, P3509, DOI 10.1097/00001756-199810260-00032; Nyberg L, 1996, PSYCHON B REV, V3, P135, DOI 10.3758/BF03212412; Nyberg L, 1998, BEHAV BRAIN RES, V90, P107, DOI 10.1016/S0166-4328(97)00094-6; Ogawa T, 1992, Acta Neurochir Suppl (Wien), V55, P8; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Price CJ, 1999, HUM BRAIN MAPP, V8, P102, DOI 10.1002/(SICI)1097-0193(1999)8:2/3<102::AID-HBM6>3.0.CO;2-J; Reuter-Lorenz PA, 2000, J COGNITIVE NEUROSCI, V12, P174, DOI 10.1162/089892900561814; Ricker JH, 2001, J CLIN EXP NEUROPSYC, V23, P196, DOI 10.1076/jcen.23.2.196.1204; Ricker JH, 2000, J HEAD TRAUMA REHAB, V15, P859, DOI 10.1097/00001199-200004000-00007; ROSS DT, 1993, J NEUROTRAUM, V10, P151, DOI 10.1089/neu.1993.10.151; Spreen O., 1998, COMPENDIUM NEUROPSYC; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; STUSS DT, 1988, BRAIN COGNITION, V8, P348, DOI 10.1016/0278-2626(88)90059-0; Stuss DT, 1999, J NEUROSURG, V90, P635, DOI 10.3171/jns.1999.90.4.0635; Talairach J., 1988, COPLANAR STEREOTAXIC; TEASDALE G, 1974, LANCET, V2, P81; TERAYAMA Y, 1991, J CEREBR BLOOD F MET, V11, P852, DOI 10.1038/jcbfm.1991.145; TULVING E, 1994, P NATL ACAD SCI USA, V91, P2016, DOI 10.1073/pnas.91.6.2016; Wechsler D, 1985, WECHSLER ADULT INTEL; Wechsler D., 1987, WECHSLER MEMORY SCAL; WEILLER C, 1995, ANN NEUROL, V37, P723, DOI 10.1002/ana.410370605; Woodard JL, 1998, NEUROPSYCHOLOGY, V12, P491, DOI 10.1037/0894-4105.12.4.491	70	80	80	0	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	AUG	2002	73	2					173	181		10.1136/jnnp.73.2.173			9	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	577KK	WOS:000177059900017	12122177	Bronze, Green Published			2021-06-18	
J	Shaw, GJ; Jauch, EC; Zemlan, FP				Shaw, GJ; Jauch, EC; Zemlan, FP			Serum cleaved tau protein levels and clinical outcome in adult patients with closed head injury	ANNALS OF EMERGENCY MEDICINE			English	Article							S-100; DAMAGE	Study objective: Intracranial injuries (ICI) are associated with high mortality and morbidity. Unfortunately, tools for diagnosis and risk stratification of ICIs are limited in the emergency department setting. We determine the relationship between the presence or absence of a detectable cleaved serum tau protein (tau(C)), ICI, and outcome at hospital discharge in adults with closed head injuries (CHI). Methods: This was a prospective pilot study of adult patients with CHI presenting to the ED of an urban Level I trauma center. Patients presenting within 10 hours of a CHI who underwent a head computed tomographic (CT) scan were eligible. A blood sample was collected at presentation and the tau(C) level was measured. Initial Glasgow Coma Scale scores and demographic information were recorded. A chart review was performed to determine outcome and final readings on the initial head CT scan. Results: Patients were dichotomized to 1 of 2 groups, those with an ICI (n = 17) and those with an isolated skull fracture or no CT abnormality (NICI) (n = 11). The 2 groups were similar in regard to demographic composition, mechanism of injury, and coexisting injuries. A tau(C) level of more than 0 was associated with an increased chance of an ICI on the initial head CT scan (odds ratio 11.25; 95% confidence interval [CI] 1.17 to 108.4) and a greater chance of poor outcome, defined as death while in hospital or transfer to a nursing home at hospital discharge (odds ratio 8.17; 95% Cl 1.42 to 47). Conclusion: A tau(C) level of more than 0 is associated with a greater chance of intracranial injury and poor outcome in patients with CHI.	Univ Cincinnati, Coll Med, Dept Emergency Med, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Psychiat, Cincinnati, OH 45267 USA	Shaw, GJ (corresponding author), Univ Cincinnati, Coll Med, Dept Emergency Med, 231 Albet Sabin Way, Cincinnati, OH 45267 USA.	shawge@acmail.uc.edu		Jauch, Edward/0000-0002-3533-4364			BERNSTEIN D, 1998, SOC NEUR ANN M NOV L; Fridriksson T, 2000, ACAD EMERG MED, V7, P816, DOI 10.1111/j.1553-2712.2000.tb02276.x; Raabe A, 1998, ACTA NEUROCHIR, V140, P787, DOI 10.1007/s007010050180; Rothoerl RD, 1998, J TRAUMA, V45, P765, DOI 10.1097/00005373-199810000-00025; Waterloo K, 1997, ACTA NEUROCHIR, V139, P26, DOI 10.1007/BF01850864; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977; Woertgen C, 1999, J TRAUMA, V47, P1126, DOI 10.1097/00005373-199912000-00026; YAMAZAKI Y, 1995, SURG NEUROL, V43, P267, DOI 10.1016/0090-3019(95)80012-6; Zemlan F. P., 2000, Journal of Neurotrauma, V17, P946; Zemlan FP, 1999, J NEUROCHEM, V72, P741, DOI 10.1046/j.1471-4159.1999.0720741.x	10	80	83	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644	1097-6760		ANN EMERG MED	Ann. Emerg. Med.	MAR	2002	39	3					254	257		10.1067/mem.2002.121214			4	Emergency Medicine	Emergency Medicine	529PV	WOS:000174308500006	11867977				2021-06-18	
J	de la Torre, JC				de la Torre, J. C.			Alzheimer's disease: How does it start?	JOURNAL OF ALZHEIMERS DISEASE			English	Article							NITRIC-OXIDE SYNTHASE; CEREBRAL-BLOOD-FLOW; ENDOTHELIAL GROWTH-FACTOR; MILD COGNITIVE IMPAIRMENT; TRAUMATIC BRAIN-INJURY; E EPSILON-4 ALLELE; FACTOR-KAPPA-B; VASCULAR DEMENTIA; APOLIPOPROTEIN-E; RISK-FACTORS	Presently, non-genetic Alzheimer's disease (AD) is wrongly classified as a neurodegenerative disorder. When vascular lesions are present, AD is considered to be a vascular dementia. However, compelling evidence indicates that (AD) is a vascular disorder with neurodegenerative consequences. There is an urgent clinical need to ascertain the true cause of this dementia. In this review, evidence indicating that AD is a vascular disorder comes from a number of different disciplines including studies in epidemiology, pharmacology, neuroimaging, clinical medicine, pathology, physiology and experimental research. This collective evidence also addresses many previously puzzling questions regarding: i) past and present treatment failures in AD, ii) strange association of AD risk factors with many vascular-related disorders, iii) parallel lesions, clinical symptoms risk factors and potentially interchangeable treatments present in AD and vascular dementia, iv) historical difficulty in finding neurodegenerative markers to detect AD pre-clinivally, and, v) paradoxical pathophysiologic events preceding AD neurodegenerative changes. Re-classifying AD as a vascular disorder would very likely improve the chances of finding a useful treatment for this disorder because clinical study designs could focus on more realistic and relevant pathologic targets than is presently practiced. A short summary of potential new research lines that may provide novel therapy in the treatment and management of AD is discussed.	UCSD Neuropathol Div, Escondido, CA 92026 USA	de la Torre, JC (corresponding author), UCSD Neuropathol Div, 1363 Shinly,Suite 100, Escondido, CA 92026 USA.	jdelator@nctimes.net			Alzheimer's AssociationAlzheimer's Association	This research was supported by an Investigator-Initiated Research Grant from the Alzheimer's Association.	Abdollahian NP, 1998, CYTOCHROME OXIDASE IN NEURONAL METABOLISM AND ALZHEIMER'S DISEASE, P233; Aguero-Torres H, 2000, ANN NY ACAD SCI, V903, P547, DOI 10.1111/j.1749-6632.2000.tb06412.x; Ajmani RS, 2000, NEUROBIOL AGING, V21, P257, DOI 10.1016/S0197-4580(00)00118-4; Aliev G, 2002, BRAIN PATHOL, V12, P21; Ansell B, 2002, ADV THER, V19, P61, DOI 10.1007/BF02850055; Arnaiz E, 2001, NEUROREPORT, V12, P851, DOI 10.1097/00001756-200103260-00045; Azzi A, 2002, FEBS LETT, V519, P8, DOI 10.1016/S0014-5793(02)02706-0; Banai S., 1994, NY TIMES        1026, V89, P2983; Barber R, 1999, J NEUROL NEUROSUR PS, V67, P66, DOI 10.1136/jnnp.67.1.66; Baumgartner I, 1998, CIRCULATION, V97, P1114, DOI 10.1161/01.CIR.97.12.1114; Bayorh MA, 2001, CLIN EXP HYPERTENS, V23, P611, DOI 10.1081/CEH-100107391; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; Blackwell TS, 1996, J IMMUNOL, V157, P1630; Blass JP, 2001, J NEUROSCI RES, V66, P851, DOI 10.1002/jnr.10087; Bonetta L, 2002, NAT MED, V8, P541, DOI 10.1038/nm0602-541a; Bots ML, 1998, HAEMOSTASIS, V28, P216; Bowler JV, 1997, ARCH NEUROL-CHICAGO, V54, P697, DOI 10.1001/archneur.1997.00550180021007; Bowler JV, 1998, J NEUROL NEUROSUR PS, V64, P18, DOI 10.1136/jnnp.64.1.18; Boyer M, 2000, J VASC SURG, V31, P181, DOI 10.1016/S0741-5214(00)70080-2; Bozoki A, 2001, ARCH NEUROL-CHICAGO, V58, P411, DOI 10.1001/archneur.58.3.411; Breteler MMB, 2000, NEUROBIOL AGING, V21, P153, DOI 10.1016/S0197-4580(99)00110-4; Breteler MMB, 2000, ANN NY ACAD SCI, V903, P457, DOI 10.1111/j.1749-6632.2000.tb06399.x; Breteler MMB, 1998, HAEMOSTASIS, V28, P167; Buee L, 1997, ANN NY ACAD SCI, V826, P7, DOI 10.1111/j.1749-6632.1997.tb48457.x; BUEE L, 1994, ACTA NEUROPATHOL, V87, P469; Burmester T, 2000, NATURE, V407, P520, DOI 10.1038/35035093; Callahan A, 2001, AM J CARDIOL, V88, p33J; Cameron NE, 1997, EUR J PHARMACOL, V319, P239, DOI 10.1016/S0014-2999(96)00844-8; Chen Y, 1999, J CEREBR BLOOD F MET, V19, P133; Cheung F, 1999, BIOCHEM PHARMACOL, V58, P1665, DOI 10.1016/S0006-2952(99)00255-5; Chui HC, 2000, ARCH NEUROL-CHICAGO, V57, P191, DOI 10.1001/archneur.57.2.191; Claus JJ, 1998, NEUROBIOL AGING, V19, P57, DOI 10.1016/S0197-4580(98)00004-9; Colquhoun David M, 2002, Aust Fam Physician, V31, P25; Colton CA, 2002, ANN NY ACAD SCI, V962, P212, DOI 10.1111/j.1749-6632.2002.tb04070.x; Davies MJ, 2001, AM J CARDIOL, V88, p2F; DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; Davis DG, 1999, J NEUROPATH EXP NEUR, V58, P376, DOI 10.1097/00005072-199904000-00008; Davis JN, 1997, TRENDS NEUROSCI, V20, P558; de la Monte S.M., 2001, PATHOLOGY AGING HUMA, P123; de la Torre J.C., 1997, ANN NY ACAD SCI, V826, P1; de la Torre JC, 1999, ACTA NEUROPATHOL, V98, P1, DOI 10.1007/s004010051044; de la Torre JC, 2002, STROKE, V33, P1152, DOI 10.1161/01.STR.0000014421.15948.67; de la Torre JC, 2000, BRAIN RES REV, V34, P119, DOI 10.1016/S0165-0173(00)00043-6; de la Torre JC, 2000, NEUROBIOL AGING, V21, P331, DOI 10.1016/S0197-4580(00)00111-1; de la Torre JC, 2002, ANN NY ACAD SCI, V977, P1; de Leon MJ, 2001, P NATL ACAD SCI USA, V98, P10966, DOI 10.1073/pnas.191044198; De Santi S, 2001, NEUROBIOL AGING, V22, P529, DOI 10.1016/S0197-4580(01)00230-5; DeJong GI, 1997, ANN NY ACAD SCI, V826, P56; Deklunder G, 1998, STROKE, V29, P1821, DOI 10.1161/01.STR.29.9.1821; delaTorre J. C., 2000, NEUROBIOL AGING, V21, P153; delaTorre JC, 1997, NEUROSCI LETT, V223, P165, DOI 10.1016/S0304-3940(97)13421-8; delaTorre JC, 1997, ANN NY ACAD SCI, V826, P75; DELATORRE JC, 1993, NEUROL RES, V15, P146; DELATORRE JC, 1992, BRAIN RES, V582, P186, DOI 10.1016/0006-8993(92)90132-S; DELATORRE JC, 1994, NEUROSCI BIOBEHAV R, V18, P397, DOI 10.1016/0149-7634(94)90052-3; Delles C, 2002, KIDNEY INT, V61, P1462, DOI 10.1046/j.1523-1755.2002.00260.x; Desideri G, 2002, J CLIN ENDOCR METAB, V87, P2940, DOI 10.1210/jc.87.6.2940; Devanand DP, 1996, ARCH GEN PSYCHIAT, V53, P175; Diaz-Arrastia R., 1998, ARCH NEUROL-CHICAGO, V55, P1; Dickson DW, 2001, CLIN GERIATR MED, V17, P209, DOI 10.1016/S0749-0690(05)70066-5; Dobrucki L W, 2001, Med Sci Monit, V7, P622; Doggrell SA, 2001, EXPERT OPIN INV DRUG, V10, P1755, DOI 10.1517/13543784.10.9.1755; DUARA R, 1992, J CEREBR BLOOD F MET, V12, P927, DOI 10.1038/jcbfm.1992.129; Elwood PC, 2002, AGE AGEING, V31, P43, DOI 10.1093/ageing/31.1.43; Erkinjuntti T., 2002, J GERONTOL B-PSYCHOL, V359, P1265; Fassbender K, 2001, P NATL ACAD SCI USA, V98, P5856, DOI 10.1073/pnas.081620098; FISCHER VW, 1990, ACTA NEUROPATHOL, V79, P672, DOI 10.1007/BF00294246; Gainotti G, 1998, ALZ DIS ASSOC DIS, V12, P152, DOI 10.1097/00002093-199809000-00006; Ganz P, 2002, AM J CARDIOL, V90, p11F, DOI 10.1016/S0002-9149(01)02218-4; Geerlings MI, 2000, BRIT J PSYCHIAT, V176, P568, DOI 10.1192/bjp.176.6.568; Goldsmith H.S., ANN NY ACAD IN PRESS; Goldsmith HS, 2001, NEUROL RES, V23, P555, DOI 10.1179/016164101101198893; GRAVES AB, 1991, INT J EPIDEMIOL, V20, pS48, DOI 10.1093/ije/20.Supplement_2.S48; Grosser Nina, 2002, Nitric Oxide, V6, P396; Groves WC, 2000, J NEUROPSYCH CLIN N, V12, P305, DOI 10.1176/appi.neuropsych.12.3.305; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Guo Z, 1997, BIOMED PHARMACOTHER, V51, P68, DOI 10.1016/S0753-3322(97)87729-3; Halliwell B, 1997, FEBS LETT, V411, P157, DOI 10.1016/S0014-5793(97)00469-9; Hamilton CA, 2001, HYPERTENSION, V37, P529, DOI 10.1161/01.HYP.37.2.529; Harman D, 2002, ANN NY ACAD SCI, V959, P384, DOI 10.1111/j.1749-6632.2002.tb02109.x; HATAKE K, 1990, STROKE, V21, P1039, DOI 10.1161/01.STR.21.7.1039; Hatanpaa K, 1996, ANN NEUROL, V40, P411, DOI 10.1002/ana.410400310; Heymes C, 2000, BRIT J PHARMACOL, V131, P804, DOI 10.1038/sj.bjp.0703632; Higashi Y, 1997, HYPERTENSION, V30, P252, DOI 10.1161/01.HYP.30.2.252; Hofman A, 1997, LANCET, V349, P151, DOI 10.1016/S0140-6736(96)09328-2; Holmes C, 1999, BRIT J PSYCHIAT, V174, P45, DOI 10.1192/bjp.174.1.45; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; Ihara M, 2001, J CEREBR BLOOD F MET, V21, P828, DOI 10.1097/00004647-200107000-00008; Imaoka Y, 1999, J CARDIOVASC PHARM, V33, P756, DOI 10.1097/00005344-199905000-00012; Inoue M, 1996, ANN NY ACAD SCI, V786, P224, DOI 10.1111/j.1749-6632.1996.tb39065.x; Jendroska K, 1997, Ann N Y Acad Sci, V826, P401, DOI 10.1111/j.1749-6632.1997.tb48492.x; Jick H, 2000, LANCET, V356, P1627, DOI 10.1016/S0140-6736(00)03155-X; Johnson KA, 1998, NEUROLOGY, V50, P1563, DOI 10.1212/WNL.50.6.1563; Johnson KA, 2000, NEUROBIOL AGING, V21, P289, DOI 10.1016/S0197-4580(00)00137-8; Jones AM, 1997, NUCL MED COMMUN, V18, P662, DOI 10.1097/00006231-199707000-00011; Joosten E, 2001, CLIN CHEM LAB MED, V39, P717, DOI 10.1515/CCLM.2001.119; Joscowicz A., 2002, NITRIC OXIDE-BIOL CH, V6, P408; Kalaria R.N., 2000, ANN NY ACAD SCI, V903, P1; Kalaria RN, 1999, ALZ DIS ASSOC DIS, V13, pS115, DOI 10.1097/00002093-199912003-00017; Kalaria RN, 1998, MOL BRAIN RES, V62, P101, DOI 10.1016/S0169-328X(98)00190-9; KALARIA RN, 1995, NEUROREPORT, V6, P477, DOI 10.1097/00001756-199502000-00018; Kalinowski L, 2002, CIRCULATION, V105, P933, DOI 10.1161/hc0802.104283; Kalmijn S, 1999, AM J EPIDEMIOL, V150, P283, DOI 10.1093/oxfordjournals.aje.a010000; Kalmijn S, 1997, ANN NEUROL, V42, P776, DOI 10.1002/ana.410420514; Kang ES, 2001, FREE RADICAL RES, V35, P341, DOI 10.1080/10715760100300871; KAO CH, 1993, NUCL MED COMMUN, V14, P47, DOI 10.1097/00006231-199301000-00010; Kauser Katalin, 2002, Nitric Oxide, V6, P409; Kawabata A, 1996, BRIT J PHARMACOL, V119, P346, DOI 10.1111/j.1476-5381.1996.tb15992.x; Kawabata A, 1996, BRIT J PHARMACOL, V117, P236, DOI 10.1111/j.1476-5381.1996.tb15181.x; Kilander L, 1998, STROKE, V29, P1816, DOI 10.1161/01.STR.29.9.1816; Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498; Kogure D, 2000, J NUCL MED, V41, P1155; Korczyn A., ANN NY ACAD IN PRESS; KUBES P, 1993, FASEB J, V7, P1293; KUBES P, 1992, AM J PHYSIOL, V262, pH611; KUNG CF, 1995, HYPERTENSION, V25, P194, DOI 10.1161/01.HYP.25.2.194; Laham RJ, 2002, J AM COLL CARDIOL, V39, P1, DOI 10.1016/S0735-1097(01)01691-6; Lederman R.J., 2002, J GERONTOL B-PSYCHOL, V359, P2048; Lee TJF, 2000, J BIOMED SCI, V7, P16; Li D, 2001, J Cardiovasc Pharmacol Ther, V6, P155, DOI 10.1177/107424840100600207; Liaudet L, 2000, P NATL ACAD SCI USA, V97, P10203, DOI 10.1073/pnas.170226797; Losordo DW, 1998, CIRCULATION, V98, P2800, DOI 10.1161/01.CIR.98.25.2800; Luth HJ, 2001, BRAIN RES, V913, P57, DOI 10.1016/S0006-8993(01)02758-5; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; Malek AM, 1999, NEUROSURGERY, V45, P334, DOI 10.1097/00006123-199908000-00028; MANCARDI GL, 1980, ACTA NEUROPATHOL, V49, P79, DOI 10.1007/BF00692225; Martin TR, 2000, DEMENT GERIATR COGN, V11, P239, DOI 10.1159/000017245; Matz RL, 2000, BRIT J PHARMACOL, V131, P303, DOI 10.1038/sj.bjp.0703568; Maxwell AJ, 2002, NITRIC OXIDE-BIOL CH, V6, P101, DOI 10.1006/niox.2001.0394; Mesenge C, 1996, J NEUROTRAUM, V13, P209, DOI 10.1089/neu.1996.13.209; Meyer JS, 2000, NEUROBIOL AGING, V21, P161, DOI 10.1016/S0197-4580(00)00136-6; Miyakawa T, 1997, ANN NY ACAD SCI, V826, P25, DOI 10.1111/j.1749-6632.1997.tb48458.x; Morris JC, 2000, NEUROL CLIN, V18, P773, DOI 10.1016/S0733-8619(05)70225-5; Morris JC, 2001, ARCH NEUROL-CHICAGO, V58, P397, DOI 10.1001/archneur.58.3.397; Morrison R.A., LOW BLOOD PRESSURE S; Mueller XM, 1999, SCHWEIZ MED WSCHR, V129, P1889; Munzel T, 2001, CIRCULATION, V104, P1571, DOI 10.1161/hc3801.095585; Napoli C, 2001, NITRIC OXIDE-BIOL CH, V5, P88, DOI 10.1006/niox.2001.0337; Neve RL, 1998, TRENDS NEUROSCI, V21, P15, DOI 10.1016/S0166-2236(97)01168-5; NIU XF, 1994, CIRC RES, V74, P1133, DOI 10.1161/01.RES.74.6.1133; Notkola IL, 1998, NEUROEPIDEMIOLOGY, V17, P14, DOI 10.1159/000026149; Nunomura A, 2000, J NEUROPATH EXP NEUR, V59, P1011, DOI 10.1093/jnen/59.11.1011; OHKURA T, 1994, ENDOCR J, V41, P361, DOI 10.1507/endocrj.41.361; Okamura N, 2000, Nihon Ronen Igakkai Zasshi, V37, P974; Ott A, 1997, STROKE, V28, P316, DOI 10.1161/01.STR.28.2.316; Ott A, 1998, LANCET, V351, P1840, DOI 10.1016/S0140-6736(97)07541-7; Ott A, 1996, DIABETOLOGIA, V39, P1392, DOI 10.1007/s001250050588; OTT A, 1995, BRIT MED J, V310, P970, DOI 10.1136/bmj.310.6985.970; Ott A, 1999, NEUROLOGY, V53, P1907; Ouchi Y, 1998, J NUCL MED, V39, P198; Pacher P, 2002, BRIT J PHARMACOL, V135, P1347, DOI 10.1038/sj.bjp.0704627; Pacher P, 2002, DIABETES, V51, P514, DOI 10.2337/diabetes.51.2.514; Pappas B A, 1997, Ann N Y Acad Sci, V826, P498, DOI 10.1111/j.1749-6632.1997.tb48512.x; Parnetti L, 2000, NEUROLOGY, V54, P735, DOI 10.1212/WNL.54.3.735; Passant U, 1997, INT J GERIATR PSYCH, V12, P395, DOI 10.1002/(SICI)1099-1166(199703)12:3<395::AID-GPS527>3.0.CO;2-#; Pecher P, 2000, ANN THORAC SURG, V69, P1414, DOI 10.1016/S0003-4975(00)01162-0; PENG HB, 1995, J BIOL CHEM, V270, P14214, DOI 10.1074/jbc.270.23.14214; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; POSTIGLIONE A, 1991, PHARMACOL RES, V23, P241, DOI 10.1016/S1043-6618(05)80083-0; Ransmayr G, 1998, J NEURAL TRANSM-SUPP, P79; Reuter U, 2002, ANN NEUROL, V51, P507, DOI 10.1002/ana.10159; Rodriguez G, 2000, PSYCHIAT RES-NEUROIM, V100, P65, DOI 10.1016/S0925-4927(00)00071-8; Rodriguez-Martinez MA, 1998, BRIT J PHARMACOL, V123, P113, DOI 10.1038/sj.bjp.0701595; Roman G, 2001, INT J CLIN PRACT, P9; Rosendorff C, 2002, J HUM HYPERTENS, V16, pS26, DOI 10.1038/sj.jhh.1001337; Sata M, 2001, FASEB J, V15, P2530, DOI 10.1096/fj.01-0415fje; Scheltens Philip, 2000, Current Opinion in Neurology, V13, P391, DOI 10.1097/00019052-200008000-00005; Schini-Kerth VB, 1999, TRANSFUS CLIN BIOL, V6, P355, DOI 10.1016/S1246-7820(00)88980-6; Schumacher B, 1998, CIRCULATION, V97, P645, DOI 10.1161/01.CIR.97.7.645; Seshadri S, 2002, NEW ENGL J MED, V346, P476, DOI 10.1056/NEJMoa011613; Shah Y, 2000, GERIATRICS, V55, P62; Singh N, 2002, CLIN SCI, V102, P595, DOI 10.1042/CS20010262; Skoog I, 1999, ALZ DIS ASSOC DIS, V13, pS106, DOI 10.1097/00002093-199912003-00016; Smith MA, 2002, LANCET, V359, P1864, DOI 10.1016/S0140-6736(02)08695-6; Snowdon DA, 1997, JAMA-J AM MED ASSOC, V277, P813, DOI 10.1001/jama.277.10.813; Solerte SB, 2000, NEUROBIOL AGING, V21, P271, DOI 10.1016/S0197-4580(00)00105-6; Solerte SB, 1998, NEUROBIOL AGING, V19, P191, DOI 10.1016/S0197-4580(98)00050-5; Szabo C, 1997, J CLIN INVEST, V100, P723, DOI 10.1172/JCI119585; Szabo C, 1996, P NATL ACAD SCI USA, V93, P1753, DOI 10.1073/pnas.93.5.1753; TADDEI S, 1995, CIRCULATION, V91, P1981, DOI 10.1161/01.CIR.91.7.1981; TAKESHITA S, 1994, J CLIN INVEST, V93, P662, DOI 10.1172/JCI117018; Tanaka K, 2000, NEUROCHEM RES, V25, P313, DOI 10.1023/A:1007544124794; Tanaka K, 1998, J NEUROSCI METH, V84, P63, DOI 10.1016/S0165-0270(98)00092-2; Tanaka M, 2002, J NEUROIMAGING, V12, P112, DOI 10.1111/j.1552-6569.2002.tb00106.x; Tarkowski E, 1999, J CLIN IMMUNOL, V19, P223, DOI 10.1023/A:1020568013953; Terry RD, 1996, J NEUROPATH EXP NEUR, V55, P1023, DOI 10.1097/00005072-199655100-00001; Thomas T, 1998, NEUROREPORT, V9, P2595, DOI 10.1097/00001756-199808030-00031; Thomas T, 2000, NEUROBIOL AGING, V21, P343, DOI 10.1016/S0197-4580(00)00100-7; TSUCHIYA M, 1993, EXP BRAIN RES, V95, P1; Tsurumi Y, 1996, CIRCULATION, V94, P3281, DOI 10.1161/01.CIR.94.12.3281; Tyas SL, 2001, INT J EPIDEMIOL, V30, P590, DOI 10.1093/ije/30.3.590; Urbich C, 2002, CIRC RES, V90, P737, DOI 10.1161/01.RES.0000014081.30867.F8; van der Loo B, 2000, J EXP MED, V192, P1731, DOI 10.1084/jem.192.12.1731; Vanderploeg RD, 2001, J INT NEUROPSYCH SOC, V7, P563, DOI 10.1017/S135561770175504X; VANDUIJN CM, 1995, BMJ-BRIT MED J, V310, P627, DOI 10.1136/bmj.310.6980.627; Vaughan CJ, 2001, CNS DRUGS, V15, P589, DOI 10.2165/00023210-200115080-00002; Wallin A, 1998, DEMENT GERIATR COGN, V9, P30, DOI 10.1159/000051187; Walter DH, 2002, CIRCULATION, V105, P3017, DOI 10.1161/01.CIR.0000018166.84319.55; Waring SC, 1999, NEUROLOGY, V52, P965, DOI 10.1212/WNL.52.5.965; Wentzel C, 2000, NEUROEPIDEMIOLOGY, V19, P186, DOI 10.1159/000026254; Wissink MJB, 2000, J CONTROL RELEASE, V64, P103, DOI 10.1016/S0168-3659(99)00145-5; Wolozin B, 2000, ARCH NEUROL-CHICAGO, V57, P1439, DOI 10.1001/archneur.57.10.1439; Wong A, 2001, EUR J NEUROSCI, V14, P1961, DOI 10.1046/j.0953-816x.2001.01820.x; Zhang JG, 2001, INT J GERIATR PSYCH, V16, P438, DOI 10.1002/gps.330; Zhang QX, 1997, J SURG RES, V67, P147, DOI 10.1006/jsre.1996.4983	205	80	81	0	6	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1387-2877	1875-8908		J ALZHEIMERS DIS	J. Alzheimers Dis.		2002	4	6					497	512		10.3233/jad-2002-4606			16	Neurosciences	Neurosciences & Neurology	V24ZH	WOS:000208447800006	12515901				2021-06-18	
J	Stuart, MJ; Smith, AM; Malo-Ortiguera, SA; Fischer, TL; Larson, DR				Stuart, MJ; Smith, AM; Malo-Ortiguera, SA; Fischer, TL; Larson, DR			A comparison of facial protection and the incidence of head, neck, and facial injuries in junior A hockey players - A function of individual playing time	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article; Proceedings Paper	AOSSM-NHL Team Physician Meeting on Sports Medicine and Hockey: A Summit for the NHL and Beyond	AUG, 2001	TORONTO, CANADA				ICE HOCKEY; FACE MASKS; HELMETS	A cohort of 282 elite amateur ice hockey players were analyzed to 1) record the number, type, location, and severity of head, neck, and facial injuries sustained during games; 2) examine the relationship between injuries and the type of facial protection (none, partial, or full) according to individual playing time; and 3) determine whether full or partial facial protection is associated with an increased incidence of concussions, eye injuries, and neck injuries. Fifty-two injuries (158.9 per 1000 player-game hours) occurred in players wearing no facial protection, 45 (73.5 per 1000 player-game hours) in players wearing partial facial protection (half shield), and 16 (23.2 per 1000 player-game hours) In players wearing full facial protection (full cage or shield). Players wearing no protection were injured at a rate more than twice that of players wearing partial protection and almost seven times higher than those wearing full protection. Concussions occurred in four players wearing no protection, five players wearing partial protection, and two players wearing full protection; these differences were not significant. The risk of eye injury was 4.7 times greater for players wearing no protection compared with those wearing partial protection. No eye or neck injuries occurred in players wearing full protection. This study demonstrates that both full and partial facial protection significantly reduce injuries to the eye and face without increasing neck injuries and concussions.	Mayo Clin & Mayo Fdn, Dept Orthoped, Rochester, MN 55905 USA	Stuart, MJ (corresponding author), Mayo Clin & Mayo Fdn, Dept Orthoped, 200 1st St SW, Rochester, MN 55905 USA.						BEMARD D, 1993, ASTM STP, V112, P44; Benson BW, 1999, JAMA-J AM MED ASSOC, V282, P2328, DOI 10.1001/jama.282.24.2328; GIBLERT WD, 2000, ASTM STP, V1341, P291; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kelly JP, 1997, NEUROLOGY, V48, P581; LAPRADE RF, 1995, AM J SPORT MED, V23, P773, DOI 10.1177/036354659502300624; LINDENFELD TN, 1998, AM J SPORTS MED S1, V16, pS69; LORENTZON R, 1988, AM J SPORT MED, V16, P392, DOI 10.1177/036354658801600415; Mair SD, 1996, AM J SPORT MED, V24, P137, DOI 10.1177/036354659602400203; MARCOTTE G, 1993, ASTM STP, V1212, P103, DOI DOI 10.1520/STP13128S; MURRAY TM, 1995, PEDIATRICS, V95, P419; Naunheim RS, 2000, J TRAUMA, V48, P938, DOI 10.1097/00005373-200005000-00020; Pless IB, 2000, CAN MED ASSOC J, V162, P792; PSHBY T, 1993, ASTM STP, V1212, P159; REYNEN PD, 1994, AM J SPORT MED, V22, P167, DOI 10.1177/036354659402200203; Rice SG, 2000, AM SOC TEST MATER, V1341, P3, DOI 10.1520/STP15223S; Roberts WO, 1996, ARCH PEDIAT ADOL MED, V150, P140, DOI 10.1001/archpedi.1996.02170270022003; Sim FH., 1989, J MUSCULOSKELET MED, V6, P15; Smith AM, 1997, AM J SPORT MED, V25, P500, DOI 10.1177/036354659702500413; Smith AM, 2000, AM SOC TEST MATER, V1341, P199, DOI 10.1520/STP15240S; STUART MJ, 1995, MAYO CLIN PROC, V70, P350, DOI 10.4065/70.4.350; STUART MJ, 1995, AM J SPORT MED, V23, P458, DOI 10.1177/036354659502300415; Stuart MJ, 2000, AM SOC TEST MATER, V1341, P19, DOI 10.1520/STP15224S; Tator CH, 1997, CLIN J SPORT MED, V7, P17, DOI 10.1097/00042752-199701000-00004; WALSH S, 1989, ASTM STP, V1050, P55	25	80	80	0	13	AMER ORTHOPAEDIC SOC SPORT MED	WALTHAM	230 CALVARY STREET, WALTHAM, MA 02154 USA	0363-5465			AM J SPORT MED	Am. J. Sports Med.	JAN-FEB	2002	30	1					39	44		10.1177/03635465020300012001			6	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	512XX	WOS:000173349800007	11798994				2021-06-18	
J	Takasu, A; Saitoh, D; Kaneko, N; Sakamoto, T; Okada, Y				Takasu, A; Saitoh, D; Kaneko, N; Sakamoto, T; Okada, Y			Hyperthermia: is it an ominous sign after cardiac arrest?	RESUSCITATION			English	Article						hyperthermia; cardiac arrest; brain death	GASTRIC CONTENTS; HYPOTHERMIA; ISCHEMIA; RESUSCITATION; ASPIRATION; INJURY	Objective: To clarify the clinical characteristics of hyperthermia at an early stage after resuscitation from cardiac arrest (CA). Materials and methods: We reviewed the medical records of 43 adult patients with non-traumatic out-of-hospital CA, who survived for longer than 24 h after admission to our intensive care unit (ICU) between January, 1995, and December, 1998. The patients were divided into two groups: a clinical brain death (CBD) group (n = 23) and a non-CBD group (n = 20), and various factors relating to hyperthermia were compared between the two groups. Results: The mean value of peak axillary temperatures within 72 h of admission was 39.8 +/- 0.9 degreesC for the CBD group, which was significantly greater than 38.3 +/- 0.6 degreesC for the non-CBD group (P < 0.0001). The time of occurrence of the peak axillary temperature was at 19 +/- 16 h of admission in the CBD group and 20 +/- 18 h in the non-CBD group (not significantly different). There were no significant differences in risk factors relating to the occurrence of hyperthermia. between the two groups, except for the number of patients who received epinephrine at ICU. In 23 patients with a peak axillary temperature of greater than or equal to 39 degreesC during the first 72 h of hospitalization, brain death was diagnosed in 20 patients, whereas only 3 of 20 patients having a peak axillary temperature of < 39 degreesC developed brain death (odds ratio, 37.8; 95% confidence interval, 6.72-212.2). Conclusion: Hyperthermia at an early stage after resuscitation from CA may be associated with the outcome of brain death. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.	Natl Def Med Coll, Dept Traumatol & Crit Care Med, Tokorozawa, Saitama 3598513, Japan	Takasu, A (corresponding author), Natl Def Med Coll, Dept Traumatol & Crit Care Med, 3-2 Namiki, Tokorozawa, Saitama 3598513, Japan.			Takasu, Akira/0000-0003-3430-0119			Albrecht RF, 1998, MAYO CLIN PROC, V73, P629; AZZIMONDI G, 1995, STROKE, V26, P2040, DOI 10.1161/01.STR.26.11.2040; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; BYNUM LJ, 1976, AM REV RESPIR DIS, V114, P1129; Coimbra C, 1996, STROKE, V27, P1578, DOI 10.1161/01.STR.27.9.1578; FELDBERG W, 1964, J PHYSIOL-LONDON, V173, P226, DOI 10.1113/jphysiol.1964.sp007454; FELDBERG W, 1963, NATURE, V200, P1325, DOI 10.1038/2001325a0; GUSTAFSON I, 1992, RESUSCITATION, V24, P245, DOI 10.1016/0300-9572(92)90185-F; HINDFELT B, 1976, ACTA NEUROL SCAND, V53, P72, DOI 10.1111/j.1600-0404.1976.tb04326.x; LANDAY MJ, 1978, AM J ROENTGENOL, V131, P587, DOI 10.2214/ajr.131.4.587; MINAMISAWA H, 1990, ANN NEUROL, V28, P26, DOI 10.1002/ana.410280107; TAKINO M, 1991, INTENS CARE MED, V17, P419, DOI 10.1007/BF01720680; TRUOG RD, 1992, CRIT CARE MED, V20, P1705, DOI 10.1097/00003246-199212000-00018; WASS CT, 1995, ANESTHESIOLOGY, V83, P325, DOI 10.1097/00000542-199508000-00013; Yanagawa Y, 1998, RESUSCITATION, V39, P61, DOI 10.1016/S0300-9572(98)00118-X	15	80	86	0	1	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0300-9572			RESUSCITATION	Resuscitation	JUN	2001	49	3					273	277		10.1016/S0300-9572(00)00360-9			5	Critical Care Medicine; Emergency Medicine	General & Internal Medicine; Emergency Medicine	456EY	WOS:000170071200008	11719121				2021-06-18	
J	Ono, J; Yamaura, A; Kubota, M; Okimura, Y; Isobe, K				Ono, J; Yamaura, A; Kubota, M; Okimura, Y; Isobe, K			Outcome prediction in severe head injury: analyses of clinical prognostic factors	JOURNAL OF CLINICAL NEUROSCIENCE			English	Article						clinical prognostic factor; outcome; severe head injury; CT	EVOKED-POTENTIALS; SCALE; COMA	Retrospective analysis of 272 patients with severe head injury was performed, Patient age, Glasgow Coma Scale (GCS) score, pupillary abnormalities, impaired oculocephalic response, presence of subarachnoid haemorrhage, and multiplicity of parenchymal lesions on computerised tomography (CT) were examined, The CT findings were divided into 2 groups, diffuse brain injury (DBI) and mass lesion, according to the classification of the Traumatic Coma Data Bank. The DBI, basically, has no high or mixed density lesion more than 25 mi on CT. and was classified into 4 subgroups: DBI I includes injuries where there is no visible pathology; DBI II includes all injuries in which the cisterns are present with a midline shift of less than 5 mm; DBI Iii includes injuries with swelling where the cisterns are compressed or absent and the midline shift is less than 5 mm; DBI IV includes injuries with a midline shift of more than 5 mm. The mass lesions were categorised into 3 subgroups: epidural haematoma; acute subdural haematoma: and intracerebral haematoma. Outcomes were determined at 6 months following trauma using the Glasgow Outcome Scale. All DBI I patients recovered well. in the DBI Ii group, age, GCS score and detection of multiple parenchymal lesions on CT were significantly correlated with outcome. For the DBI III and IV groups, the only significant prognostic factor was the GCS score, In patients with a mass lesion, the GCS score was the only significant prognostic factor in the epidural haematoma group, but the GCS score and the presence of subarachnoid haemorrhage were predictive factors in the acute subdural haematoma group. Outcomes were unfavourable in the majority of patients with intracerebral haematoma, GCS score could predict outcome in all groups. The confidence of the outcome prediction ranged from 75.8 to 92.1%, depending on logistic regression analysis. (C) 2001 Harcourt Publishers Ltd.	Chiba Univ, Sch Med, Dept Neurosurg, Chiba 280, Japan	Ono, J (corresponding author), Chiba Cardiovasc Ctr, Dept Neurosurg, Tsurumai 575, Ichihara 2900512, Japan.						ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; CHAN KH, 1993, NEUROSURGERY, V32, P547; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GREENBERG RP, 1981, J NEUROSURG, V55, P227, DOI 10.3171/jns.1981.55.2.0227; HOULDEN DA, 1990, NEUROSURGERY, V27, P701, DOI 10.1227/00006123-199011000-00006; JAGGI JL, 1990, J NEUROSURG, V72, P176, DOI 10.3171/jns.1990.72.2.0176; JENNETT B, 1975, LANCET, V1, P480; MARMAROU A, 1991, J NEUROSURG, V75, pS21, DOI 10.3171/sup.1991.75.1s.0s21; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; TEASDALE G, 1974, LANCET, V2, P81; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; YAMAURA A, 1981, Neurologia Medico-Chirurgica, V21, P685	15	80	88	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0967-5868	1532-2653		J CLIN NEUROSCI	J. Clin. Neurosci.	MAR	2001	8	2					120	123		10.1054/jocn.2000.0732			4	Clinical Neurology; Neurosciences	Neurosciences & Neurology	427WM	WOS:000168428500005	11484659				2021-06-18	
J	Hansen, HH; Ikonomidou, C; Bittigau, P; Hansen, SH; Hansen, HS				Hansen, HH; Ikonomidou, C; Bittigau, P; Hansen, SH; Hansen, HS			Accumulation of the anandamide precursor and other N-acylethanolamine phospholipids in infant rat models of in vivo necrotic and apoptotic neuronal death	JOURNAL OF NEUROCHEMISTRY			English	Article						anandamide; apoptosis; excitotoxicity; N-acyl-phosphatidylethanolamine; necrosis; neurodegeneration	ENDOGENOUS CANNABINOID PRECURSOR; HIPPOCAMPAL-NEURONS; CORTICAL-NEURONS; CELL-DEATH; BRAIN; RECEPTOR; NEURODEGENERATION; CALCIUM; ACYLPHOSPHATIDYLETHANOLAMINE; NEUROTOXICITY	It has been demonstrated that the endogenous cannabinoid receptor ligand, anandamide, and other N-acylethanolamines (NAEs), accumulate during neuronal injury in vitro, a process that may be linked to the neuroprotective effects of NAEs. The crucial step for generation of NAEs is the synthesis of the corresponding precursors, N-acylethanolamine phospholipids (NAPEs). However, it is unknown whether this, key event for NAE formation is regulated differently in the context of insults causing necrotic or apoptotic neuronal death. To address this question, we monitored a range of cortical NAPE species in three infant rat models of in vivo neurodegeneration: (i) necrosis caused by intrastriatal injection of NMDA (25 nmol); (ii) apoptosis induced by systemic administration of the NMDA-receptor antagonist (+)MK-801 (3 x 0.5 mg/kg, i.p.); and (iii) apoptosis following focal necrosis triggered by concussive head trauma. A marked increase of all NAPE species was observed in both hemispheres 4 and 24 h after NMDA-induced injury, with a relatively larger increase in N-stearoyl-containing NAPE species. Thus, the percentage of the anandamide precursor fell from 1.1 to 0.5 mol %. In contrast, administration of (+)MK-801 did not alter cortical NAPE levels. Concussion head trauma resulted in a similar but less pronounced upregulation of NAPE levels at both 4 and 24 h as compared to NMDA injections. Increased levels of NAPE 24 h post-trauma possibly reflect that necrosis is still ongoing at this time point. Consequently, our data suggest that excitotoxic necrotic mechanisms of neurodegeneration, as opposed to apoptotic neurodegeneration, have a profound effect on in vivo NAE precursor homeostasis.	Royal Danish Sch Pharm, Dept Pharmacol, DK-2100 Copenhagen, Denmark; Humboldt Univ, Charite Virchow Clin, Dept Paediat Neurol, Berlin, Germany; Royal Danish Sch Pharm, Dept Analyt & Pharmaceut Chem, DK-2100 Copenhagen, Denmark	Hansen, HS (corresponding author), Royal Danish Sch Pharm, Dept Pharmacol, 2 Univ Pk, DK-2100 Copenhagen, Denmark.	hsh@dfh.dk	Hansen, Steen Honore/A-5179-2011	Hansen, Harald S./0000-0001-7360-7418			Ameri A, 1999, BRIT J PHARMACOL, V126, P1831, DOI 10.1038/sj.bjp.0702478; Berrendero F, 1999, SYNAPSE, V33, P181, DOI 10.1002/(SICI)1098-2396(19990901)33:3<181::AID-SYN3>3.0.CO;2-R; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; Cadas H, 1996, J NEUROSCI, V16, P3934; Cadas H, 1997, J NEUROSCI, V17, P1226; CAMPAGNE MV, 1995, EUR J NEUROSCI, V7, P1627; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; diMarzo V, 1996, BIOCHEM J, V316, P977, DOI 10.1042/bj3160977; Gwag BJ, 1999, NEUROSCIENCE, V90, P1339, DOI 10.1016/S0306-4522(98)00508-9; Hansen HH, 2000, J NEUROCHEM, V75, P861, DOI 10.1046/j.1471-4159.2000.0750861.x; Hansen HH, 1999, J MASS SPECTROM, V34, P761, DOI 10.1002/(SICI)1096-9888(199907)34:7<761::AID-JMS832>3.0.CO;2-R; Hansen HS, 1999, LIPIDS, V34, pS327, DOI 10.1007/BF02562333; HANSEN HS, 1995, BBA-LIPID LIPID MET, V1258, P303, DOI 10.1016/0005-2760(95)00134-X; Hansen HS, 1998, BIOCHEM PHARMACOL, V55, P719, DOI 10.1016/S0006-2952(97)00396-1; Hansen HS, 1997, J NEUROCHEM, V69, P753; Ikonomidou C, 1999, SCIENCE, V283, P70, DOI 10.1126/science.283.5398.70; IKONOMIDOU C, 1989, J NEUROSCI, V9, P2809; Ikonomidou C, 1996, METAB BRAIN DIS, V11, P125, DOI 10.1007/BF02069500; Ishimaru MJ, 1999, J COMP NEUROL, V408, P461; Kempe K, 1996, J BIOL CHEM, V271, P17287, DOI 10.1074/jbc.271.29.17287; KOCH RA, 1994, J NEUROSCI, V14, P2585; Kondo S, 1998, ARCH BIOCHEM BIOPHYS, V354, P303, DOI 10.1006/abbi.1998.0688; Lee JM, 1999, NATURE, V399, pA7, DOI 10.1038/399a007; Lipton SA, 1998, NEUROSCIENTIST, V4, P345, DOI 10.1177/107385849800400516; MACKIE K, 1995, J NEUROSCI, V15, P6552; Modi I, 1995, TRENDS PHARMACOL SCI, V16, P356; Moesgaard B, 1999, J LIPID RES, V40, P515; Moesgaard B, 2000, J LIPID RES, V41, P985; MUNIR M, 1993, BRAIN RES, V616, P163, DOI 10.1016/0006-8993(93)90205-2; Nagayama T, 1999, J NEUROSCI, V19, P2987; NATARAJAN V, 1986, BIOCHIM BIOPHYS ACTA, V878, P32, DOI 10.1016/0005-2760(86)90341-3; OJICIUS DM, 1991, EXP CELL RES, V197, P43; Petersen G, 1999, FEBS LETT, V455, P41, DOI 10.1016/S0014-5793(99)00861-3; Pohl D, 1999, P NATL ACAD SCI USA, V96, P2508, DOI 10.1073/pnas.96.5.2508; Richardson JD, 1998, J NEUROSCI, V18, P451; SCHMID HHO, 1990, PROG LIPID RES, V29, P1, DOI 10.1016/0163-7827(90)90004-5; Shen MX, 1998, MOL PHARMACOL, V54, P459; Skaper SD, 1996, P NATL ACAD SCI USA, V93, P3984, DOI 10.1073/pnas.93.9.3984; Sugiura T, 1996, EUR J BIOCHEM, V240, P53, DOI 10.1111/j.1432-1033.1996.0053h.x	40	80	84	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	JAN	2001	76	1					39	46		10.1046/j.1471-4159.2001.00006.x			8	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	388AE	WOS:000166154600005	11145976	Bronze			2021-06-18	
J	Adamchik, Y; Frantseva, MV; Weisspapir, M; Carlen, PL; Velazquez, JLP				Adamchik, Y; Frantseva, MV; Weisspapir, M; Carlen, PL; Velazquez, JLP			Methods to induce primary and secondary traumatic damage in organotypic hippocampal slice cultures	BRAIN RESEARCH PROTOCOLS			English	Article						trauma; organotypic hippocampal culture; hypothermia; cell death; propidium iodide		Organotypic brain slice cultures have been used in a variety of studies on neurodegenerative processes [K.M. Abdel-Hamid, M. Tymianski, Mechanisms and effects of intracellular calcium buffering on neuronal survival in organotypic hippocampal cultures exposed to anoxia/aglycemia or to excitotoxins, J. Neurosci. 17, 1997, pp. 3538-3553; D.W. Newell, A. Earth, V. Papermaster, A.T. Malouf, Glutamate and non-glutamate receptor mediated toxicity caused by oxygen and glucose deprivation in organotypic hippocampal cultures, J. Neurosci. 15, 1995, pp. 7702-7711; J.L. Perez Velazquez, M.V. Frantseva, P.L. Carlen, In vitro ischemia promotes glutamate mediated free radical generation and intracellular calcium accumulation in pyramidal neurons of cultured hippocampal:slices, J. Neurosci. 23, 1997, pp. 9085-9094; L. Stoppini, L.A. Buchs, D. Muller, A simple method for organotypic cultures of nervous tissue, J. Neurosci. Methods 37, 1991, pp. 173-182, R.C. Tasker, J.T. Coyle, J.J. Vornov, The regional vulnerability to hypoglycemia induced neurotoxicity in organotypic hippocampal culture: protection by early tetrodotoxin or delayed MK 801, J. Neurosci. 12, 1992, pp. 4298-4308.]. We describe two methods to induce traumatic cell damage in hippocampal organotypic cultures. Primary trauma injury was achieved by rolling a stainless steel cylinder (0.9 g) on the organotypic slices. Secondary injury was followed after dropping a weight (0.137 g) on a localised area of the organotypic slice, from a height of 2 mm. The time course and extent of cell death were determined by measuring the fluorescence of the viability indicator propidium iodide (PI) at several time points after the injury. The initial localised impact damage spread 24 and 67 h after injury, cell death being 25% and 54%, respectively, when slices were kept at 37 degrees C. To validate these methods as models to assess neuroprotective strategies, similar insults were applied to slices at relatively low temperatures (30 degrees C), which is known to be neuroprotective [F.C. Barone, G.Z. Feuerstein, R.F. White, Brain cooling during transient focal ischaemia provides complete neuroprotection, Neurosci. Biobehav. Rev. 1, 1997, pp. 31-44; V.M. Bruno, M.P. Goldberg, L.L. Dugan, R.G. Giffard, D.W. Choi, Neuroprotective effect of hypothermia in cortical cultures exposed to oxygen glucose deprivation or excitatory aminoacids, J. Neurochem. 4, 1994, pp. 387-392; G.C. Newman, H. Qi, F.E. Hospod, K. Grundhmann, Preservation of hippocampal brain slices with in vivo or in vitro hypothermia, Brain Res. 1, 1992, pp. 159-163; J.Y. Yager, J. Asseline, Effect of mild hypothermia on cerebral energy metabolism during the evolution of hypoxic ischaemic brain damage in the immature rat, Stroke, 5, 1996, pp. 919-925.]. Low temperature incubation significantly reduced cell death, now being 9% at 24 h and 14% at 67 h. Our results show that these models of moderate mechanical trauma using organotypic slice cultures can be used to study neurodegeneration and neuroprotective strategies. (C) 2000 Elsevier Science B.V. All rights reserved.	Univ Toronto, Toronto Western Hosp, Playfair Neurosci Unit, Dept Med Neurol, Toronto, ON M5T 2S8, Canada	Velazquez, JLP (corresponding author), Univ Toronto, Toronto Western Hosp, Playfair Neurosci Unit, Dept Med Neurol, McL 12-413,399 Bathurst St, Toronto, ON M5T 2S8, Canada.			Carlen, Peter/0000-0002-3339-8102			AbdelHamid KM, 1997, J NEUROSCI, V17, P3538; Barone FC, 1997, NEUROSCI BIOBEHAV R, V21, P31, DOI 10.1016/0149-7634(95)00080-1; BRUNO VM, 1994, J NEUROCHEM, V4, P387; Frantseva MV, 1999, J NEUROSCI METH, V89, P25, DOI 10.1016/S0165-0270(99)00030-8; JENNETT B, 1980, TRENDS NEUROSCI, V3, P1; NEWELL DW, 1995, J NEUROSCI, V15, P7702; NEWMAN GC, 1992, BRAIN RES, V575, P159, DOI 10.1016/0006-8993(92)90438-F; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; TASKER RC, 1992, J NEUROSCI, V12, P4298; Velazquez JLP, 1997, J NEUROSCI, V17, P9085; VORNOV JJ, 1991, EXP NEUROL, V114, P112; Yager JY, 1996, STROKE, V27, P919, DOI 10.1161/01.STR.27.5.919	12	80	85	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1385-299X			BRAIN RES PROTOC	Brain Res. Protoc.	APR	2000	5	2					153	158		10.1016/S1385-299X(00)00007-6			6	Biochemical Research Methods; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	311VV	WOS:000086907300006	10775835				2021-06-18	
J	Douglas, JM; Spellacy, FJ				Douglas, JM; Spellacy, FJ			Correlates of depression in adults with severe traumatic brain injury and their carers	BRAIN INJURY			English	Article							CLOSED-HEAD-INJURY; SOCIAL SUPPORT; FAMILY; PATIENT; STRESS; HEALTH; DISABILITY; CAREGIVERS; RELATIVES; SCALE	Although it is generally accepted that social support plays a role in the maintenance of psychological well-bring, there has been relatively little direct investigation of the role that social support may play in affecting post-injury depressive symptoms and mediating the effects of traumatic brain injury (TBI). Consequently, social support was selected as the framework within which to investigate possible indicators of depression in adults with severe TBI and their carers. The authors were interested in the degree of association bt between social support and the criterion variable of depression in the context of demographic and disability-related variables that have been identified as significant correlates of depression. Thirty-five adults with severe TBI (PTA > 7 days) and their primary carts participated in the study. Time post-injury ranged from 3.5-10 years and all the participants were living in the community. Fifty-seven per cent of the adults with TBI and 60% of their carers were classified as showing significant symptoms of depression. As hypothesized, social support contributed significantly to the prediction of depression. In particular, strong-tie support appeared ru be an important indicator of well-being for both dir participants with TBI and their carers.	La Trobe Univ, Sch Human Commun Sci, Bundoora, Vic 3083, Australia; Univ Victoria, Dept Psychol, Victoria, BC V8W 2Y2, Canada	Douglas, JM (corresponding author), La Trobe Univ, Sch Human Commun Sci, Bundoora, Vic 3083, Australia.	J.Douglas@latrobe.edu.au	Douglas, Jacinta M/C-2380-2009	Douglas, Jacinta/0000-0003-0940-6624			ALLEN K, 1994, REHABIL PSYCHOL, V39, P29, DOI 10.1037/h0080313; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; BLUMENTHAL MD, 1975, ARCH GEN PSYCHIAT, V32, P985; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; Caplan RD, 1979, MENTAL HLTH EC, P89; COHEN S, 1985, PSYCHOL BULL, V98, P310, DOI 10.1037/0033-2909.98.2.310; Coughlan AK, 1988, CLIN REHABIL, V2, P207, DOI DOI 10.1177/026921558800200305; DEAN A, 1977, J NERV MENT DIS, V165, P403, DOI 10.1097/00005053-197712000-00006; DEROGATIS R, 1983, SCL90R ADM PROCEDURE; Douglas JM, 1996, BRAIN INJURY, V10, P819, DOI 10.1080/026990596123936; ELSASS L, 1987, PSYCHOL MED, V17, P67, DOI 10.1017/S003329170001299X; Ensel W., 1986, SOCIAL SUPPORT LIFE, P129; FINLAYJONES RA, 1979, BRIT J PSYCHIAT, V134, P609, DOI 10.1192/bjp.134.6.609; GOVE WR, 1979, AM SOCIOL REV, V44, P126, DOI 10.2307/2094822; Henderson S, 1981, NEUROSIS SOCIAL ENV; House J. S., 1985, SOCIAL SUPPORT HLTH, P83; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Kinsella G, 1989, Int Disabil Stud, V11, P9; Kozloff R, 1987, J HEAD TRAUMA REHAB, V2, P14, DOI DOI 10.1097/00001199-198709000-00004; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; LEZAK MD, 1986, REHABIL PSYCHOL, V31, P241, DOI 10.1037//0090-5550.31.4.241; Lin N., 1986, SOCIAL SUPPORT LIFE; Lin N., 1986, SOCIAL SUPPORT LIFE, P17, DOI DOI 10.1016/B978-0-12-450660-2.50008-2; LINN RT, 1994, BRAIN INJURY, V8, P135, DOI 10.3109/02699059409150965; Liss M, 1990, Int J Rehabil Res, V13, P309, DOI 10.1097/00004356-199012000-00004; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; MOORE A, 1993, BRAIN INJURY, V7, P247, DOI 10.3109/02699059309029677; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; PEARLIN LI, 1981, J HEALTH SOC BEHAV, V22, P337, DOI 10.2307/2136676; PETERS L C, 1990, Brain Injury, V4, P39, DOI 10.3109/02699059009026147; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Sander AM, 1997, BRAIN INJURY, V11, P235, DOI 10.1080/026990597123548; SARASON IG, 1985, PSYCHOSOM MED, V47, P156, DOI 10.1097/00006842-198503000-00007; SCHAEFER C, 1981, Journal of Behavioral Medicine, V4, P381, DOI 10.1007/BF00846149; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; THOMSEN IV, 1992, SCAND J REHABIL MED, P142; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; WILKINSON SM, 1989, CLIN REHABIL, V3, P317; YESAVAGE JA, 1983, J PSYCHIATR RES, V17, P37, DOI 10.1016/0022-3956(82)90033-4; ZUNG WW, 1974, MEASUREMENT DEPRESSI; ZUNG WWK, 1965, ARCH GEN PSYCHIAT, V12, P63, DOI 10.1001/archpsyc.1965.01720310065008	45	80	82	0	6	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JAN	2000	14	1					71	88		10.1080/026990500120943			18	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	274CY	WOS:000084747200008	10670663				2021-06-18	
J	Weber, JT; Rzigalinski, BA; Willoughby, KA; Moore, SF; Ellis, EF				Weber, JT; Rzigalinski, BA; Willoughby, KA; Moore, SF; Ellis, EF			Alterations in calcium-mediated signal transduction after traumatic injury of cortical neurons	CELL CALCIUM			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; EXPERIMENTAL BRAIN INJURY; STRETCH-INDUCED INJURY; GLUTAMATE RECEPTORS; DELAYED DEPOLARIZATION; NMDA-RECEPTORS; CELLS; MODULATION; ASTROCYTES; FURA-2	Calcium influx and elevation of intracellular free calcium ([Ca2+](i)), with subsequent activation of degradative enzymes, is hypothesized to cause cell injury and death after traumatic brain injury. We examined the effects of mild-to-severe stretch-induced traumatic injury on [Ca2+](i) dynamics in cortical neurons cultured on silastic membranes. [Ca2+](i) was rapidly elevated after injury, however, the increase was transient with neuronal [Ca2+](i) returning to basal levels by 3 h after injury, except in the most severely injured cells. Despite a return of [Ca2+](i) to basal levels, there were persistent alterations in calcium-mediated signal transduction through 24 h after injury. [Ca2+](i) elevation in response to glutamate or NMDA was enhanced after injury. We also found novel alterations in intracellular calcium store-mediated signaling. Neuronal calcium stores failed to respond to a stimulus 15 min after injury and exhibited potentiated responses to stimuli at 3 and 24 h post-injury. Thus, changes in calcium-mediated cellular signaling may contribute to the pathology that is observed after traumatic brain injury. (C) Harcourt Publishers Ltd 1999.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA	Ellis, EF (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol & Toxicol, POB 980613, Richmond, VA 23298 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027214] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-27214] Funding Source: Medline		BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BRUNO V, 1995, NEUROPHARMACOLOGY, V34, P1089, DOI 10.1016/0028-3908(95)00077-J; Casado M, 1998, J PHYSIOL-LONDON, V513, P317, DOI 10.1111/j.1469-7793.1998.317bb.x; Choi S, 1996, J NEUROSCI, V16, P36; DELAHUNTY TM, 1992, BRAIN RES, V594, P307, DOI 10.1016/0006-8993(92)91140-A; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FAROOQUI AA, 1994, J NEUROSCI RES, V38, P6, DOI 10.1002/jnr.490380103; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; FLOYD CL, 1998, J NEUROTRAUM, V15, P869; FRANDSEN A, 1991, J NEUROCHEM, V56, P1075, DOI 10.1111/j.1471-4159.1991.tb02031.x; Goforth PB, 1999, J NEUROSCI, V19, P7367, DOI 10.1523/JNEUROSCI.19-17-07367.1999; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; HAYES RL, 1992, J NEUROTRAUMA S1, V9, P173; Jayaraman T, 1997, MOL CELL BIOL, V17, P3005, DOI 10.1128/MCB.17.6.3005; JONES KH, 1985, J HISTOCHEM CYTOCHEM, V33, P77, DOI 10.1177/33.1.2578146; Kaftan EJ, 1997, J GEN PHYSIOL, V110, P529, DOI 10.1085/jgp.110.5.529; Khan AA, 1996, SCIENCE, V273, P503, DOI 10.1126/science.273.5274.503; KOSTYUK P, 1994, NEUROSCIENCE, V63, P381, DOI 10.1016/0306-4522(94)90537-1; Lamb RG, 1997, J NEUROCHEM, V68, P1904; LEI SHZ, 1992, BRAIN RES, V598, P196, DOI 10.1016/0006-8993(92)90183-A; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCINTOSH TK, 1992, J NEUROTRAUM, V9, pS201; McKinney JS, 1996, STROKE, V27, P934, DOI 10.1161/01.STR.27.5.934; Mukhin AG, 1997, NEUROREPORT, V8, P2561, DOI 10.1097/00001756-199707280-00028; Nilsson P, 1996, J CEREBR BLOOD F MET, V16, P262, DOI 10.1097/00004647-199603000-00011; Obrenovitch TP, 1997, J NEUROTRAUM, V14, P677, DOI 10.1089/neu.1997.14.677; Ozawa S, 1998, PROG NEUROBIOL, V54, P581, DOI 10.1016/S0301-0082(97)00085-3; PALMER AM, 1994, NEUROREPORT, V6, P153, DOI 10.1097/00001756-199412300-00039; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; Picard L, 1998, CELL CALCIUM, V23, P339, DOI 10.1016/S0143-4160(98)90029-X; POENIE M, 1990, CELL CALCIUM, V11, P85, DOI 10.1016/0143-4160(90)90062-Y; PRASAD MR, 1994, J NEUROCHEM, V63, P773; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; Rahman S, 1996, BRIT J PHARMACOL, V117, P675, DOI 10.1111/j.1476-5381.1996.tb15243.x; ROE MW, 1990, CELL CALCIUM, V11, P63, DOI 10.1016/0143-4160(90)90060-8; Rzigalinski BA, 1997, J NEUROCHEM, V68, P289; Rzigalinski BA, 1999, J BIOL CHEM, V274, P175, DOI 10.1074/jbc.274.1.175; Rzigalinski BA, 1998, J NEUROCHEM, V70, P2377; RZIGALINSKI BA, 1998, J NEUROTRAUM, V15, P894; Schreiber D., 1995, P 1995 INT RES C BIO, P233; Tavalin SJ, 1997, J NEUROPHYSIOL, V77, P632; Tavalin SJ, 1995, J NEUROPHYSIOL, V74, P2767; THASTRUP O, 1994, AGENTS ACTIONS, V43, P187, DOI 10.1007/BF01986687; TRUMP BF, 1995, FASEB J, V9, P219; WEI EP, 1982, J NEUROSURG, V56, P695, DOI 10.3171/jns.1982.56.5.0695; WILLIAMS DA, 1990, CELL CALCIUM, V11, P75, DOI 10.1016/0143-4160(90)90061-X; Young W, 1992, J NEUROTRAUMA S1, V9, P9; Yu SP, 1997, J PHYSIOL-LONDON, V499, P721, DOI 10.1113/jphysiol.1997.sp021964; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921	51	80	82	0	1	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0143-4160			CELL CALCIUM	Cell Calcium	DEC	1999	26	6					289	299		10.1054/ceca.1999.0082			11	Cell Biology	Cell Biology	273RN	WOS:000084721100006	10668567				2021-06-18	
J	Sanderson, KL; Raghupathi, R; Saatman, KE; Martin, D; Miller, G; McIntosh, TK				Sanderson, KL; Raghupathi, R; Saatman, KE; Martin, D; Miller, G; McIntosh, TK			Interleukin-1 receptor antagonist attenuates regional neuronal cell death and cognitive dysfunction after experimental brain injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						traumatic brain injury; cytokines; interleukins; histopathology; behavior; fluid-percussion	LONG-TERM POTENTIATION; FOCAL CEREBRAL-ISCHEMIA; RAT-BRAIN; INDUCE OVEREXPRESSION; ADENOVIRAL VECTOR; MESSENGER-RNA; HEAD-INJURY; EXPRESSION; DAMAGE; HIPPOCAMPUS	The effect of systemic administration of human recombinant interleukin-l receptor antagonist (rhIL-lra) on behavioral outcome and histopathologic damage after lateral fluid-percussion brain injury of moderate severity was evaluated. In study 1, brain-injured Sprague Dawley rats received timed subcutaneous injections beginnings 15 minutes after injury of either 100 mg/kg rhIL-lra (high dose, total dose = 1900 mg/kg), 10 mg/kg rhiIL-lra (low dose, total dose = 190 mg/kg), or vehicle over 7 days. No effect of low-dose rhIL-lra was observed in study 1. High-dose rhIL-lra significantly attenuated posttraumatic neuronal loss in the injured hippocampal CA, region (P < 0.05), dentate hilus (P < 0.05), and cortex (P < 0.05) but impaired recovery of motor function at 7 days after trauma (P < 0.05). In study 2, rats were pretrained to learn a visuospatial task in a Morris water maze, subjected to fluid- percussion brain injury or sham treatment, and randomly assigned to receive multiple subcutaneous injections at timed intervals of 100 mg/kg rhIL-lra (total dose = 900 mg/kg) or vehicle over 42 hours, followed by continuous infusion of a lower concentration of rhIL-lra (20 mg/kg/day, total dose = 100 mg/kg), or vehicle for 5 days using subcutaneously implanted osmotic minipumps, Postinjury administration of rhIL-Ira significantly attenuated cognitive deficits compared with vehicle-treated animals at 42 hours (P < 0.05) but did not affect motor function at 48 hours, 1 week, and 2 weeks. These results suggest that inhibitors of cytokine pathways may be therapeutically useful for the treatment of brain trauma.	Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; Amgen Inc, Dept Pharmacol, Thousand Oaks, CA 91320 USA	McIntosh, TK (corresponding author), Univ Penn, Sch Med, Dept Neurosurg, 105 Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.				NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01-GM34690] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50-NS08803, R01-NS26818] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS026818, P50NS008803] Funding Source: NIH RePORTER		ALBRIGHT AL, 1984, J NEUROSURG, V60, P481, DOI 10.3171/jns.1984.60.3.0481; BELAYEV L, 1998, J NEUROTRAUM, V15, P858; BELLINGER FP, 1993, BRAIN RES, V628, P227, DOI 10.1016/0006-8993(93)90959-Q; BETZ AL, 1995, J CEREBR BLOOD F MET, V15, P547, DOI 10.1038/jcbfm.1995.68; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; CARMANKRZAN M, 1991, J NEUROCHEM, V56, P636, DOI 10.1111/j.1471-4159.1991.tb08197.x; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Conti AC, 1998, J NEUROSCI, V18, P5663; DeKosky ST, 1996, ANN NEUROL, V39, P123, DOI 10.1002/ana.410390118; Fan Lei, 1995, Molecular Brain Research, V30, P125, DOI 10.1016/0169-328X(94)00287-O; GARCIA JH, 1995, AM J PATHOL, V147, P1477; GIULIAN D, 1989, J NEUROSCI, V9, P4416; GRIFFIN WST, 1994, NEUROSCI LETT, V176, P133, DOI 10.1016/0304-3940(94)90066-3; GUTIERREZ EG, 1994, J NEUROIMMUNOL, V55, P153, DOI 10.1016/0165-5728(94)90005-1; HANNUM CH, 1990, NATURE, V343, P336, DOI 10.1038/343336a0; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; HICKS RR, 1994, BRAIN RES, V655, P91, DOI 10.1016/0006-8993(94)91601-2; KADOYA C, 1995, STROKE, V26, P1035, DOI 10.1161/01.STR.26.6.1035; Lee SC, 1995, BRAIN BEHAV IMMUN, V9, P345, DOI 10.1006/brbi.1995.1032; Loddick SA, 1996, J CEREBR BLOOD F MET, V16, P932, DOI 10.1097/00004647-199609000-00017; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MARTIN D, 1994, EXP NEUROL, V130, P362, DOI 10.1006/exnr.1994.1215; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Murray CA, 1998, J NEUROSCI, V18, P2974; PELLMAR TC, 1991, NEUROSCIENCE, V44, P353, DOI 10.1016/0306-4522(91)90060-2; Pierce JES, 1996, J NEUROSCI, V16, P1083; Relton JK, 1996, EXP NEUROL, V138, P206, DOI 10.1006/exnr.1996.0059; RINK A, 1995, AM J PATHOL, V147, P1575; Rothwell NJ, 1998, NEUROSCIENTIST, V4, P195, DOI 10.1177/107385849800400315; ROTHWELL NJ, 1993, CEREBROVAS BRAIN MET, V5, P178; Scripter JL, 1997, EXP NEUROL, V145, P329, DOI 10.1006/exnr.1997.6470; Sheng JG, 1996, NEUROBIOL AGING, V17, P761; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; SINSON G, 1995, J NEUROCHEM, V65, P2209; SMITH DH, 1993, J NEUROSCI, V13, P5383; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Stroemer RP, 1998, J CEREBR BLOOD F MET, V18, P833, DOI 10.1097/00004647-199808000-00003; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; TOULMOND S, 1995, BRAIN RES, V671, P261, DOI 10.1016/0006-8993(94)01343-G; YAMASHIRO K, 1995, HUM PATHOL, V26, P67, DOI 10.1016/0046-8177(95)90116-7; Yang GY, 1998, J CEREBR BLOOD F MET, V18, P840, DOI 10.1097/00004647-199808000-00004; YOUNG AB, 1988, J NEUROSURG, V69, P375, DOI 10.3171/jns.1988.69.3.0375	43	80	81	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	OCT	1999	19	10					1118	1125		10.1097/00004647-199910000-00008			8	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	276NH	WOS:000084883900008	10532636	Bronze			2021-06-18	
J	Park, NW; Moscovitch, M; Robertson, IH				Park, NW; Moscovitch, M; Robertson, IH			Divided attention impairments after traumatic brain injury	NEUROPSYCHOLOGIA			English	Article						working memory; controlled processes; central executive; traumatic brain injury; component process model; meta-analysis	CLOSED-HEAD-INJURY; ADULT AGE-DIFFERENCES; WORKING-MEMORY; VERBAL FLUENCY; REACTION-TIME; FRONTAL-LOBE; PERFORMANCE; RECOVERY; DEFICITS; DYSFUNCTION	This research investigated whether people with severe traumatic brain injury (TBI) are impaired on divided attention tasks requiring working memory. In experiment 1, a severe TBI and control group performed two tasks requiring working memory separately and concurrently. Results showed that the TBI group had impaired divided attention when performing the two tasks concurrently, although the two groups did not differ in performance when these tasks were performed separately. Experiment 2 showed that performance on the paced auditory serial addition task improved with increases in the intertrial interval for both TBI and control groups. A meta-analysis showed that TBIs are impaired on divided attention when the tasks require controlled processing, but not when the tasks can be carried out relatively automatically. (C) 1999 Elsevier Science Ltd. All rights reserved.	Baycrest Ctr Geriatr Care, Dept Psychol, Toronto, ON M6A 2E1, Canada; Baycrest Ctr Geriatr Care, Kunin Lunenfeld Appl Res Unit, Toronto, ON M6A 2E1, Canada; Univ Toronto, Erindale Coll, Dept Psychol, Rotman Res Inst, Toronto, ON M5S 1A1, Canada; MRC, Cognit & Brain Sci Unit, Cambridge, England; Baycrest Ctr Geriatr Care, Rotman Res Unit, Toronto, ON M6A 2E1, Canada	Park, NW (corresponding author), Baycrest Ctr Geriatr Care, Dept Psychol, 3560 Bathurst St,Suite 4W-02, Toronto, ON M6A 2E1, Canada.	npark@credit.erin.utoronto.ca		Robertson, Ian H/0000-0001-8637-561X			BADDELEY A, 1992, SCIENCE, V255, P556, DOI 10.1126/science.1736359; Baddeley A., 1997, HUMAN MEMORY THEORY; Baddeley A. D., 1986, WORKING MEMORY; BADDELEY AD, 1974, RECENT ADV LEARNING, V8; BENTON AL, 1968, NEUROPSYCHOLOGIA, V6, P53, DOI 10.1016/0028-3932(68)90038-9; BROOKS DN, 1987, NEUROBEHAVIORAL RECO, P57; BROUWER WH, 1989, CORTEX, V25, P219, DOI 10.1016/S0010-9452(89)80038-3; Cohen JD, 1997, NATURE, V386, P604, DOI 10.1038/386604a0; Craik F.I.M., 1986, HUMAN MEMORY COGNITI, P409; Craik FIM, 1996, J EXP PSYCHOL GEN, V125, P159, DOI 10.1037/0096-3445.125.2.159; DESPOSITO M, 1995, NATURE, V378, P279, DOI 10.1038/378279a0; DOBBS AR, 1989, PSYCHOL AGING, V4, P500, DOI 10.1037/0882-7974.4.4.500; Donaldson W., 1972, ORG MEMORY, P381, DOI [DOI 10.1016/B978-0-12-809324-5.21037-7, DOI 10.1017/S0140525X00047257]; Gentilini M., 1989, MILD HEAD INJURY; GOLDSTEIN FC, 1990, J CLIN EXP NEUROPSYC, V12, P286, DOI 10.1080/01688639008400975; GRONWALL D, 1987, NEUROBEHAVIORAL RECO, P355; Gronwall D.M., 1974, PSYCHOL EFFECTS CONC; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; HARTMAN A, 1992, CLIN REHABIL, V6, P133; Hedges L. V., 1981, J EDUC STAT, V6, P107; HEDGES LV, 1982, PSYCHOL BULL, V92, P490, DOI 10.1037/0033-2909.92.2.490; HYDE TS, 1969, J EXP PSYCHOL, V82, P472, DOI 10.1037/h0028372; JACOBY LL, 1991, J MEM LANG, V30, P513, DOI 10.1016/0749-596X(91)90025-F; JACOBY LL, 1993, J EXP PSYCHOL GEN, V122, P139, DOI 10.1037/0096-3445.122.2.139; Jennings J. M., 1992, HDB AGING COGNITION, P51; KRAUS JF, 1989, MILD HEAD INJURY; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; LOESS H, 1967, J VERB LEARN VERB BE, V6, P455, DOI 10.1016/S0022-5371(67)80001-X; LORSBACH TC, 1990, AM J PSYCHOL, V103, P21, DOI 10.2307/1423257; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; MCKINLAY WW, 1983, J NEUROL NEUROSUR PS, V46, P1084, DOI 10.1136/jnnp.46.12.1084; MELAMED S, 1985, SCAND J REHABIL MED, P16; Miller E, 1970, Cortex, V6, P121; Milner B, 1964, FRONTAL GRANULAR COR, P313; MOSCOVITCH M, 1992, J COGNITIVE NEUROSCI, V4, P257, DOI 10.1162/jocn.1992.4.3.257; Moscovitch M., 1994, NEUROPSYCHOLOGY, V8, P524, DOI DOI 10.1037/0894-4105.8.4.524; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; PONSFORD J, 1991, NEUROPSYCHOL REHABIL, V1, P241, DOI DOI 10.1080/09602019108402257; Salthouse TA, 1996, PSYCHOL REV, V103, P403, DOI 10.1037/0033-295X.103.3.403; SchmitterEdgecombe M, 1996, NEUROPSYCHOLOGY, V10, P155; Shallice T., 1988, NEUROPSYCHOLOGY MENT; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; Spreen O., 1998, COMPENDIUM NEUROPSYC; STUSS D. T., 1988, CLIN NEUROPSYCHOL, V2, P246, DOI DOI 10.1080/13854048808520107; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; TOTH JP, 1996, APA S COGN NEUR APPL; Troyer AK, 1997, NEUROPSYCHOLOGY, V11, P138, DOI 10.1037/0894-4105.11.1.138; Troyer AK, 1998, NEUROPSYCHOLOGIA, V36, P499, DOI 10.1016/S0028-3932(97)00152-8; Van Zomeren A. H., 1984, CLOSED HEAD INJURY P, P74; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; VANZOMEREN AH, 1976, CLIN NEUROL NEUROSUR, V79, P81, DOI 10.1016/0303-8467(76)90001-9; VANZOMEREN AH, 1978, J NEUROL NEUROSUR PS, V41, P452, DOI 10.1136/jnnp.41.5.452; Winocur G, 1992, HDB AGING COGNITION, P315	56	80	81	0	7	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932	1873-3514		NEUROPSYCHOLOGIA	Neuropsychologia	SEP	1999	37	10					1119	1133		10.1016/S0028-3932(99)00034-2			15	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	235BG	WOS:000082518400003	10509834				2021-06-18	
J	Wojtys, EM; Hovda, D; Landry, G; Boland, A; Lovell, M; McCrea, M; Minkoff, J				Wojtys, EM; Hovda, D; Landry, G; Boland, A; Lovell, M; McCrea, M; Minkoff, J			Concussion in sports	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article							CEREBRAL BLOOD-FLOW; TRAUMATIC BRAIN INJURY; HEAD-INJURY; STANDARDIZED ASSESSMENT; GLUCOSE-UTILIZATION; CONTACT-SPORTS; 2ND IMPACT; RAT-BRAIN; GUIDELINES; CALCIUM		AOSSM Concuss Workshop Grp, Rosemont, IL USA	Wojtys, EM (corresponding author), Univ Michigan, POB 363, Ann Arbor, MI 48106 USA.						ACKERMANN RF, 1989, J CEREBR BLOOD F MET, V9, P774, DOI 10.1038/jcbfm.1989.111; ANDERSEN BJ, 1992, BRAIN RES, V585, P184, DOI 10.1016/0006-8993(92)91205-S; Barth JT., 1989, MILD HEAD INJURY, P257; BENTON A, 1978, MNULTILINGUAL APHASI; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Brandt J., 1991, CLIN NEUROPSYCHOL, V5, P125, DOI 10.1080/13854049108403297.; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P75, DOI 10.1080/00913847.1986.11709197; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P172; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879; CLIFTON GL, 1992, NEUROSURGERY, V31, P975, DOI 10.1227/00006123-199211000-00028; *COL MED SOC, 1991, GUID MAN CONC SPORTS; COSGROVE JW, 1987, EXP GERONTOL, V22, P187, DOI 10.1016/0531-5565(87)90039-8; Doberstein C., 1992, Society for Neuroscience Abstracts, V18, P175; DOBERSTEIN CE, 1993, ANN EMERG MED, V22, P993, DOI 10.1016/S0196-0644(05)82740-4; EVANS RW, 1994, SEMIN NEUROL, V14, P32, DOI 10.1055/s-2008-1041056; FALLGREN B, 1993, J AUTONOM NERV SYST, V44, P151, DOI 10.1016/0165-1838(93)90027-R; FICK DS, 1995, POSTGRAD MED, V97, P53; Golden C., 1978, STROOP COLOR WORD TE; GOLIGORSKY MS, 1995, AM J PHYSIOL-RENAL, V268, pF251; GRONWALL D, 1975, LANCET, V2, P995; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; HARDER DR, 1987, CIRC RES, V60, P102, DOI 10.1161/01.RES.60.1.102; HOVDA DA, 1992, ROLE OF NEUROTRANSMITTERS IN BRAIN INJURY, P327; HOVDA DA, 1990, ACT NEUR S, V51, P331; HOVDA DA, 1995, J NEUROSURG A, V376; HOVDA DA, 1993, INTRACRANIAL PRESSUR, V8, P469; HOVDA DA, 1995, NEUROTRAUMA, P1459; JACEWICZ M, 1990, J CEREBR BLOOD F MET, V10, P903, DOI 10.1038/jcbfm.1990.147; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; JENKINS LW, 1996, MECH SECONDARY BRAIN, P273; JORDAN BD, 1990, JAMA-J AM MED ASSOC, V263, P1670, DOI 10.1001/jama.263.12.1670; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; KELLY J, 1995, CURRENT THERAPY SPOR; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kelly JP, 1997, NEUROLOGY, V48, P581; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; KLOVE H, 1974, CLIN NEUROPSYCHOLOGY; LANDRY G, 1994, P MILD BRAIN INJ SUM; LEBLANC KE, 1994, AM FAM PHYSICIAN, V50, P801; LEE SM, 1995, J CEREB BLOOD FLOW M, V15, P722; LIFSHITZ J, 1995, J NEUROTRAUM, V12, P129; LO EH, 1991, NEUROSCI LETT, V131, P17, DOI 10.1016/0304-3940(91)90327-P; LO EH, 1991, J CEREBR BLOOD F MET, V11, P803, DOI 10.1038/jcbfm.1991.138; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; MCCREA M, 1997, MANUAL ADM SCORING I; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; MCQUILLEN JB, 1988, AM J FOREN MED PATH, V9, P12, DOI 10.1097/00000433-198803000-00004; MUIZELAAR JP, 1989, TXB HEAD INJURY, P221; Parkinson D, 1996, SURG NEUROL, V45, P459, DOI 10.1016/0090-3019(95)00210-3; PFENNINGER EG, 1989, J NEUROSURG, V70, P774, DOI 10.3171/jns.1989.70.5.0774; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; ROSEN P, 1998, EMERGENCY MED; SAKURADA O, 1978, AM J PHYSIOL, V234, pH59; SALMAN E, 1995, J NEUROTRAUM, V12, P141; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; Smith A., 1982, SYMBOL DIGIT MODALIT; STEINBERG GK, 1991, NEUROSCI LETT, V133, P225, DOI 10.1016/0304-3940(91)90575-E; SUTTON RL, 1994, ACTA NEUROCHIR, P446; TABRIZCHI R, 1994, ARCH INT PHARMACOD T, V328, P26; TAKENAKA T, 1993, CIRC RES, V73, P743, DOI 10.1161/01.RES.73.4.743; WALKER AE, 1994, J NEUROSURG, V81, P493, DOI 10.3171/jns.1994.81.3.0493; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D., 1997, WECHSLER MEMORY SCAL, VIII; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; YAMAKAMI I, 1990, J NEUROTRAUM, V7, P101; YOSHINO A, 1992, J CEREBR BLOOD F MET, V12, P996, DOI 10.1038/jcbfm.1992.137; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289	73	80	81	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	SEP-OCT	1999	27	5					676	687		10.1177/03635465990270052401			12	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	236ML	WOS:000082603300023	10496590				2021-06-18	
J	Marmarou, A; Nichols, J; Burgess, J; Newell, D; Troha, J; Burnham, D; Pitts, L				Marmarou, A; Nichols, J; Burgess, J; Newell, D; Troha, J; Burnham, D; Pitts, L		Amer Brain Injury Consortium Study Grp	Effects of the bradykinin antagonist Bradycor (TM) (deltibant, CP-1027) in severe traumatic brain injury: Results of a multi-center, randomized, placebo-controlled trial	JOURNAL OF NEUROTRAUMA			English	Article						bradycor; bradykinin; brain trauma; clinical trial; head injury	KALLIKREIN-KININ SYSTEM; SEVERE HEAD-INJURY; HUMAN NEUTROPHILS; CLINICAL-TRIALS; EDEMA; MEDIATOR; TISSUE; PERMEABILITY; INHIBITION; RECEPTORS	A phase II prospective, randomized, double blind clinical trial of Bradycor(TM), a bradykinin antagonist, was conducted at 31 centers within North America in severely brain injured patients, Patients of Glasgow Coma Score (GCS) 3-8 (n = 139) with at least one reactive pupil were randomized to receive either Bradycor, 3 mu g/kg/min or placebo as a continuous intravenous infusion for 5 days, with the infusion beginning within 12 h of the injury, The primary objective was to assess the efficacy of a continuous infusion of Bradycor (3.0 mc/kg/min) in preventing elevation of intracranial pressure (ICP), Other efficacy measures included the effect of Bradycor on the Therapy Intensity Level (TIL), mortality, and functional outcome. A secondary objective was to evaluate the safety of Bradycor in patients with severe brain injury, Randomization was carried out according to a computer generated randomization list. Patients were followed for the first 14 days of hospitalization with long-term outcome assessed at 3 and 6 months after injury. During the infusion and while the ICP monitor was in place, ICP measurements were recorded hourly along with blood pressure and heart rate. A modified version of the TIL was used to record therapeutic interventions hourly, while the ICP was being monitored. Outcome was assessed at 3 and 6 months after injury using the Glasgow Outcome Score (GOS). Bradycor was well tolerated in this patient population, and no adverse events were attributable to the compound, Although positive trends were seen for both ICP and Tn, in the Bradycor group, these differences analyzed on a daily basis were not significant. However a mixed model of variance which included treatment, day, treatment by day interaction, age and GCS revealed that the percentage time ICP of >15 mm Hg on days 4 and 5 was significantly lower in the Bradycor group compared to placebo (p = 0.035). There were fewer deaths in the Bradycor group, which had a 28-day all cause mortality of 20% versus 27% on placebo. Patients treated with Bradycor showed a 10.3% improvement in favorable outcome at 3 months and a 12% improvement in dichotomized GOS at 6 months (p = 0.26). The consistent positive trends seen in ICP, TIL, neuropsychological tests, and, most importantly, 3- and 6-month GOS provide supportive evidence that a bradykinin antagonist may play a neuroprotective role in severe brain injury.	Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, Richmond, VA 23298 USA; Provenant St Anthonys Cent, Denver, CO USA; Fairfax Hosp, Alexandria, VA USA; Univ Washington, Sch Med, Seattle, WA USA; Cortech Inc, Denver, CO USA; SmithKline Beecham Pharmaceut, Collegeville, PA USA; Univ Calif San Francisco, Med Ctr, San Francisco, CA 94143 USA	Marmarou, A (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, POB 980508, Richmond, VA 23298 USA.	Marmarou@abic.vcu.edu					BHOOLA KD, 1992, PHARMACOL REV, V44, P1; Bhoola KD, 1996, IMMUNOPHARMACOLOGY, V33, P247, DOI 10.1016/0162-3109(96)00067-7; Carl VS, 1996, IMMUNOPHARMACOLOGY, V33, P325, DOI 10.1016/0162-3109(96)00055-0; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279; Choi S C, 1997, J Biopharm Stat, V7, P533; CHOI SC, 1985, CONTROL CLIN TRIALS, V6, P280, DOI 10.1016/0197-2456(85)90104-7; CHOI SC, 1989, BIOMETRICS, V45, P317, DOI 10.2307/2532056; COCHRANE CG, 1973, J EXP MED, V138, P1564, DOI 10.1084/jem.138.6.1564; ELLIS EF, 1989, J NEUROSURG, V71, P437, DOI 10.3171/jns.1989.71.3.0437; ELLIS EF, 1987, STROKE, V18, P792, DOI 10.1161/01.STR.18.4.792; FIGUEROA CD, 1989, BRIT J HAEMATOL, V72, P321, DOI 10.1111/j.1365-2141.1989.tb07711.x; FIGUEROA CD, 1992, BLOOD, V79, P754; FRANCEL PC, 1992, J NEUROTRAUM, V9, pS27; GALLIN JI, 1988, INFLAMMATION BASIC P, P493; Griffin J H, 1979, Adv Exp Med Biol, V120B, P39; HALLENBECK JM, 1977, NEUROLOGY, V27, P3, DOI 10.1212/WNL.27.1.3; HENDERSON L, 1992, AGENTS ACTIONS S, V1, P590; HSU CY, 1994, NEUROBIOLOGY CENTRAL, P145; Kaplan A P, 1978, Prog Hemost Thromb, V4, P127; Kaplan A P, 1983, Adv Exp Med Biol, V156, P45; KAPLAN AP, 1987, BLOOD, V70, P1; KAPLAN AP, 1972, J EXP MED, V135, P81, DOI 10.1084/jem.135.1.81; Kochanek PM, 1997, SHOCK, SEPSIS AND ORGAN FAILURE, P197; Kreutzer JS, 1996, ARCH PHYS MED REHAB, V77, P116, DOI 10.1016/S0003-9993(96)90155-0; MAIERHAUFF K, 1984, J NEUROSURG, V61, P97, DOI 10.3171/jns.1984.61.1.0097; MARMAROU A, 1991, J NEUROSURG, V75, pS21, DOI 10.3171/sup.1991.75.1s.0s21; Marmarou A, 1996, ACT NEUR S, V66, P118; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MASET AL, 1986, INTRACRANIAL PRESSUR, V6, P647; MUIZELAAR JP, 1993, J NEUROSURG, V78, P375, DOI 10.3171/jns.1993.78.3.0375; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; Narotam PK, 1998, ACTA NEUROCHIR, V140, P793, DOI 10.1007/s007010050181; TEASDALE G, 1974, LANCET, V2, P81; UNTERBERG A, 1986, J NEUROSURG, V64, P269, DOI 10.3171/jns.1986.64.2.0269; UNTERBERG A, 1984, J NEUROSURG, V61, P87, DOI 10.3171/jns.1984.61.1.0087; WAHL M, 1983, J CEREBR BLOOD F MET, V3, P231, DOI 10.1038/jcbfm.1983.31; WAHL M, 1988, J CEREBR BLOOD F MET, V8, P621, DOI 10.1038/jcbfm.1988.109; Wahl M, 1996, IMMUNOPHARMACOLOGY, V33, P257, DOI 10.1016/0162-3109(96)00068-9; Wahl M., 1993, REGULATION CEREBRAL, P315; WARD JD, 1985, J NEUROSURG, V62, P383, DOI 10.3171/jns.1985.62.3.0383; WEISS SJ, 1989, NEW ENGL J MED, V320, P365	41	80	81	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	1999	16	6					431	444		10.1089/neu.1999.16.431			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	206LD	WOS:000080879800001	10391361				2021-06-18	
J	Nakaguchi, H; Fujimaki, T; Ueki, K; Takahashi, M; Yoshida, H; Kirino, T				Nakaguchi, H; Fujimaki, T; Ueki, K; Takahashi, M; Yoshida, H; Kirino, T			Snowboard head injury: Prospective study in Chino, Nagano, for two seasons from 1995 to 1997	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						head injury; snowboard; ski; occipital impact		Background: The popularity of snowboarding has been growing rapidly throughout the world. To date, however, the risk of head injury associated with this relatively new winter sport, especially in comparison with alpine skiing, has not been well analyzed, This study was conducted to assess the risk of head injury in snowboarding and to elucidate its features in comparison with skiing head injury. Methods: We prospectively analyzed 301 cases of head injuries related to snowboarding or skiing experienced from December of 1995 to May of 1997 at our institution, which is located close to the most popular skiing areas in Japan. Of those injuries, 143 cases were snowboard related and 158 cases were ski related. In addition to appropriate medical evaluation and medical care, detailed examination was performed on every patient to determine various factors, including ses, age, skill level, cause and mechanism of the accident, and the side of impact to the head. The data are statistically analyzed to elucidate unique features of snowboard head injury. Results: During the study period, 2.2 million snowboarders and 4.2 million skiers visited the five skiing facilities that are covered hg our hospital. Thus, the incidence of head injury was 6.5 per 100,000, visits for snowboarders and 3.8 per 100,000 visits for skiers. Beginning snowboarders more frequently sustained head injuries compared with beginning skiers (60 of 142 vs. 48 of 154, p = 0.022), Likewise, frequent causes of snowboarding head injuries were fall during jumping (43 of 139 vs. 2 of 147, p < 0.0001), falling backward (67 of 127 vs. 49 of 147, p = 0.001)! and occipital impact (67 of 126 vs, 49 Of 147).,More importantly, there were nine major head injury cases (6.3%) in snowboard head injuries in contrast to only two such cases found in skiing head injuries (1.3%). Of II major head injury cases, 10 were caused by occipital impact. Conclusion: These results indicate that snowboarders sl particularly beginners, are at higher risk for head injury, frequently involving occipital impact, and could lead to more major head injuries. We propose that measures should be taken to protect the head, especially the occiput, in snowboarding.	Tokyo Univ Hosp, Dept Neurosurg, Bunkyo Ku, Tokyo 113, Japan; Suwa Cent Hosp, Dept Neurosurg, Nagano, Japan; Suwa Cent Hosp, Dept Orthoped, Nagano, Japan	Kirino, T (corresponding author), Tokyo Univ Hosp, Dept Neurosurg, Bunkyo Ku, Hongo 7-3-1, Tokyo 113, Japan.						ABU LR, 1991, CMAJ, V145, P1097; Berghold F, 1991, Schweiz Z Sportmed, V39, P13; BIASCA N, 1995, UNFALLCHIRURG, V98, P33; Binet M H, 1994, Schweiz Z Med Traumatol, P21; BLADIN C, 1995, SPORTS MED, V19, P358, DOI 10.2165/00007256-199519050-00005; BLADIN C, 1993, AM J SPORT MED, V21, P701, DOI 10.1177/036354659302100511; BLANKMAN E, 1987, POWDER, V15, P95; CALLE SC, 1995, J PEDIATR SURG, V30, P791, DOI 10.1016/0022-3468(95)90749-1; Chow TK, 1996, J TRAUMA, V41, P321, DOI 10.1097/00005373-199608000-00021; Pigozzi F, 1997, ORTHOPEDICS, V20, P505; PINO EC, 1989, AM J SPORT MED, V17, P778, DOI 10.1177/036354658901700610; PRALL JA, 1995, INJURY, V26, P539, DOI 10.1016/0020-1383(95)00085-N; Sacco DE, 1998, J TRAUMA, V44, P654, DOI 10.1097/00005373-199804000-00016; SUMI Y, 1997, CLIN SPORTS MED, V14, P207; Zollinger H, 1994, Sportverletz Sportschaden, V8, P31, DOI 10.1055/s-2007-993450	15	80	80	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUN	1999	46	6					1066	1069		10.1097/00005373-199906000-00017			4	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	205BR	WOS:000080801900021	10372627				2021-06-18	
J	Stone, JR; Walker, SA; Povlishock, JT				Stone, JR; Walker, SA; Povlishock, JT			The visualization of a new class of traumatically injured axons through the use of a modified method of microwave antigen retrieval	ACTA NEUROPATHOLOGICA			English	Article						amyloid precursor protein immunoreactivity axonal injury; microwave antigen retrieval; traumatic brain injury; ultrastructure	AMYLOID PRECURSOR PROTEIN; DIFFUSE BRAIN INJURY; CLOSED-HEAD INJURY; ULTRASTRUCTURAL-LOCALIZATION; NEUROFILAMENT SUBUNITS; AXOLEMMAL PERMEABILITY; TISSUE-SECTIONS; BETA-APP; RAT; DAMAGE	Antibodies to the amyloid precursor proteins (APP) have become routine markers for detecting traumatically induced axonal injury (AI) in animals and man. Unfortunately, the techniques used to visualize these proteins are not compatible with routine electron microscopic (EM) analysis. In the current communication, we describe a method for the ultrastructural visualization of antibodies to APP and, using this method, we identify a previously unrecognized population of traumatically injured axons. Rats were subjected to an impact acceleration traumatic brain injury and allowed to survive 30 min to 3h postinjury. The animals were then perfused, their brains sectioned on a vibratome and the sections prepared for immunocytochemistry using a computer-controlled microwave capable of temperature regulation. The use of temperature-controlled microwave energy unmasked APP antigenic epitopes without sacrificing ultrastructural detail. The APP antibody was found in two distinct populations of reactive axons that differed in size, morphology, location, and temporal progression. Comparable to previous descriptions, one population showed traumatically related reactive changes that led to swelling and disconnection. The other population, however, revealed unanticipated changes reflected in nodal and paranodal swelling of small continuous fibers that showed no evidence of disconnection during the time periods assessed. These studies provide new insight into the complexity of the pathobiology of AI, while describing a novel approach for enhancing APP immunoreactivity at the EM level.	Virginia Commonwealth Univ, Div Neurosurg, Med Coll Virginia, Richmond, VA USA; Virginia Commonwealth Univ, Dept Anat, Med Coll Virginia, Richmond, VA 23298 USA	Povlishock, JT (corresponding author), Virginia Commonwealth Univ, Dept Anat, Med Coll Virginia, 1101 E Marshall St,POB 980709, Richmond, VA 23298 USA.	jpovlishock@gems.vcu.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS020193] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS20193] Funding Source: Medline		AbouHamden A, 1997, J NEUROTRAUM, V14, P699, DOI 10.1089/neu.1997.14.699; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Ahlgren S, 1996, ACTA NEUROPATHOL, V92, P49, DOI 10.1007/s004010050488; BENOWITZ LI, 1989, EXP NEUROL, V106, P237, DOI 10.1016/0014-4886(89)90156-8; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Christman CW, 1997, ACTA NEUROPATHOL, V94, P329, DOI 10.1007/s004010050715; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Geddes JF, 1997, NEUROPATH APPL NEURO, V23, P339, DOI 10.1046/j.1365-2990.1997.4498044.x; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; GIBERSON RT, 1995, MICROSC RES TECHNIQ, V32, P246, DOI 10.1002/jemt.1070320307; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; IGARASHI H, 1994, APMIS, V102, P295, DOI 10.1111/j.1699-0463.1994.tb04879.x; KAWAI M, 1992, AM J PATHOL, V140, P947; LEWEN A, 1995, NEUROREPORT, V6, P357, DOI 10.1097/00001756-199501000-00032; Lewen A, 1996, BRAIN RES, V719, P161, DOI 10.1016/0006-8993(96)00081-9; Lewis SB, 1996, J NEUROTRAUM, V13, P505, DOI 10.1089/neu.1996.13.505; LI GL, 1995, J NEUROTRAUM, V12, P269, DOI 10.1089/neu.1995.12.269; LOGIN GR, 1994, PROG HISTOCHEM CYTOC, V27, P1; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MCGEER PL, 1992, J NEUROSCI RES, V31, P428, DOI 10.1002/jnr.490310305; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; NEVIN NC, 1967, J NEUROPATH EXP NEUR, V26, P77, DOI 10.1097/00005072-196701000-00006; Ochs S, 1996, NEUROSCIENCE, V70, P1081, DOI 10.1016/0306-4522(95)00390-8; OCHS S, 1994, NEUROSCIENCE, V61, P361, DOI 10.1016/0306-4522(94)90237-2; PALACIOS G, 1992, MOL BRAIN RES, V15, P195, DOI 10.1016/0169-328X(92)90109-O; PEERLESS SJ, 1967, CAN MED ASSOC J, V96, P577; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Pierce JES, 1996, J NEUROSCI, V16, P1083; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; Povlishock JT, 1996, ACT NEUR S, V66, P81; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; SHERRIFF FE, 1994, NEUROREPORT, V5, P1085, DOI 10.1097/00001756-199405000-00016; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; SHI SR, 1991, J HISTOCHEM CYTOCHEM, V39, P741, DOI 10.1177/39.6.1709656; SHIGEMATSU K, 1992, BRAIN RES, V592, P353, DOI 10.1016/0006-8993(92)91697-D; STRICH SJ, 1967, J NEUROL NEUROSUR PS, P163; Suurmeyer AJH, 1993, APPL IMMUNOHISTO M M, V1, P143; VANEZIS P, 1987, FORENSIC SCI INT, V35, P1, DOI 10.1016/0379-0738(87)90018-1; WASIELEWSKI R, 1994, HISTOCHEMISTRY, V102, P165; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; YAMAGUCHI H, 1992, ACTA NEUROPATHOL, V85, P15, DOI 10.1007/BF00304629; YAMAGUCHI H, 1994, GERONTOLOGY, V40, P65; YAMAZAKI T, 1993, VIRCHOWS ARCH B, V63, P173, DOI 10.1007/BF02899258; Yamazaki T, 1996, J CELL SCI, V109, P999	53	80	80	0	3	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0001-6322			ACTA NEUROPATHOL	Acta Neuropathol.	APR	1999	97	4					335	345		10.1007/s004010050996			11	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	176XG	WOS:000079176900004	10208272				2021-06-18	
J	Kinsella, G; Ong, B; Murtagh, D; Prior, M; Sawyer, M				Kinsella, G; Ong, B; Murtagh, D; Prior, M; Sawyer, M			The role of the family for behavioral outcome in children and adolescents following traumatic brain injury	JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY			English	Article							CLOSED HEAD-INJURY; ACADEMIC-PERFORMANCE; ASSESSMENT DEVICE; PREDICTORS; VALIDITY; SEVERITY; DISTURBANCES; RELIABILITY; CHILDHOOD; SEQUELAE	This study assessed the behavioral outcome of 51 children with traumatic brain injury (TBT) up to 2 years following injury. Children with severe injuries, but not those with mild or moderate injuries, were reported by parents to have a greater incidence of behavior problems following TBI. Regression analyses indicated that the presence of a partner for the primary caregiver of the child and the acute emotional reaction of the parent to the injury were both predictive of child behavioral outcome, although not by 2-year follow-up. These findings suggest that parental coping resources may impact on the development of child behavioral sequelae following TBI, emphasizing the role of the family in the child's response and the importance of supportive intervention.	La Trobe Univ, Sch Psychol Sci, Bundoora, Vic 3083, Australia; Royal Childrens Hosp, Melbourne, Vic, Australia; Adelaide Childrens Hosp Inc, Adelaide, SA 5006, Australia	Kinsella, G (corresponding author), La Trobe Univ, Sch Psychol Sci, Bundoora, Vic 3083, Australia.		Murtagh, Donal/F-8694-2011; Kinsella, Glynda/O-6347-2017	Murtagh, Donal/0000-0003-1539-3559; Kinsella, Glynda/0000-0002-5859-0934			Achenbach TM, 1983, MANUAL CHILD BEHAV C; ACHENBACH TM, 1986, MANUAL TEACHER VERSI; ACHENBACH TM, 1987, EMPIRICALLY BASED AS; ASARNOW RF, 1991, J PEDIATR PSYCHOL, V16, P543, DOI 10.1093/jpepsy/16.5.543; BARRY P, 1992, Brain Injury, V6, P229, DOI 10.3109/02699059209029664; BASSON MD, 1991, J TRAUMA, V31, P1363, DOI 10.1097/00005373-199110000-00008; BURVENICH C, 1983, VET RES COMMUN, V7, P237, DOI 10.1007/BF02228626; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; CHEUNG P, 1994, SOC PSYCH PSYCH EPID, V29, P95; CREPEAU F, 1993, NEUROPSYCHOL REHABIL, V3, P5; DALBY PR, 1991, DEV NEUROPSYCHOL, V7, P35, DOI 10.1080/87565649109540476; Daniel A. E., 1983, POWER PRIVILEGE PRES; DONDERS J, 1992, J ABNORM CHILD PSYCH, V20, P233, DOI 10.1007/BF00916690; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; Fletcher J M, 1991, Brain Inj, V5, P337, DOI 10.3109/02699059109008106; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; FLETCHER JM, 1987, NEUROBEHAVIOURAL REC, P270; Goldberg D, 1988, USERS GUIDE GEN HLTH; Goldberg D., 1978, MANUAL GEN HLTH QUES; GOLDSTEIN FC, 1995, HDB MEMORY DISORDERS, P187; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; Kabacoff R.I., 1990, J FAMILY PSYCHOL, V3, P431, DOI [10.1037/h0080547, DOI 10.1037/H0080547]; Kehle TJ, 1996, J LEARN DISABIL, V29, P633, DOI 10.1177/002221949602900607; KINSELLA G, 1995, J PEDIATR PSYCHOL, V20, P753, DOI 10.1093/jpepsy/20.6.753; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; KNIGHTS R M, 1991, Brain Injury, V5, P339, DOI 10.3109/02699059109008107; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; MCDONALD CM, 1994, ARCH PHYS MED REHAB, V75, P328, DOI 10.1016/0003-9993(94)90038-8; MCGUIRE TL, 1986, J HEAD TRAUMA REHAB, V1, P1; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; ODDY M, 1993, NEUROPSYCHOL REHABIL, V3, P301, DOI 10.1080/09602019308401444; PERROTT SB, 1991, DEV NEUROPSYCHOL, V7, P69, DOI 10.1080/87565649109540477; PRIOER M, 1994, AUST PSYCHOL, V29, P116, DOI 10.1080/00050069408257334; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; ROMANSCLARKSON SE, 1989, AUST NZ J PSYCHIAT, V23, P187, DOI 10.3109/00048678909062135; RUTTER M, 1982, Journal of Clinical Neuropsychology, V4, P91, DOI 10.1080/01688638208401121; SAWYER MG, 1988, J MARITAL FAM THER, V14, P287, DOI 10.1111/j.1752-0606.1988.tb00748.x; TEASDALE G, 1974, LANCET, V2, P81; TOMPKINS CA, 1990, BRAIN COGNITION, V13, P86, DOI 10.1016/0278-2626(90)90042-M; Wade SL, 1996, J LEARN DISABIL, V29, P652, DOI 10.1177/002221949602900609	44	80	80	0	12	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0022-006X			J CONSULT CLIN PSYCH	J. Consult. Clin. Psychol.	FEB	1999	67	1					116	123		10.1037/0022-006X.67.1.116			8	Psychology, Clinical	Psychology	164GK	WOS:000078454700013	10028215				2021-06-18	
J	Dietrich, WD; Alonso, O; Busto, R; Prado, R; Zhao, WZ; Dewanjee, MK; Ginsberg, MD				Dietrich, WD; Alonso, O; Busto, R; Prado, R; Zhao, WZ; Dewanjee, MK; Ginsberg, MD			Posttraumatic cerebral ischemia after fluid percussion brain injury: An autoradiographic and histopathological study in rats	NEUROSURGERY			English	Article						cerebral blood flow; histopathology; ischemia; platelets; traumatic brain injury; vasoactive substances	DISSEMINATED INTRAVASCULAR COAGULATION; ACUTE SUBDURAL-HEMATOMA; ACUTE HEAD-INJURY; BLOOD-FLOW; SUBARACHNOID HEMORRHAGE; PLATELET ACCUMULATION; DAMAGE; MODEL; TRAUMA; METABOLISM	OBJECTIVES: Mild-to-moderate reductions in local cerebral blood flow (lCBF) have been reported to occur in rats after moderate (1.7-2.2 atm) fluid percussion brain injury. The purpose of this study was to determine whether evidence for severe ischemia (i.e., mean lCBF < 0.25 ml/g/min) could be demonstrated after severe brain injury. In addition, patterns of indium-labeled platelet accumulation and histopathological outcome were correlated with the hemodynamic alterations. METHODS: Sprague-Dawley rats (n = 23), anesthetized with halothane and maintained on a 70:30 mixture of nitrous oxide:oxygen and 0.5% halothane, underwent normothermic (37 degrees C) parasagittal fluid percussion brain injury (2.4-2.6 atm). Indium-111-tropolone-labeled platelets were injected 30 minutes before traumatic brain injury (TBI), while C-14-iodoantipyrine was infused 30 minutes after trauma for lCBF determination. Sham-operated animals (n = 8) underwent similar surgical procedures but were not injured. For histopathological analysis, traumatized rats (n = 5) were perfusion-fixed 3 days after TBI. RESULTS: In autoradiographic images of indium-labeled platelets, abnormal platelet accumulation that was most pronounced overlying the pial surface was commonly associated with severe reductions in lCBF within underlying cortical regions 30 minutes after TBI. For example, within the lateral parietal cortex, lCBF was significantly reduced from 1.67 +/- 0.11 ml/g per minute (mean +/- standard error of the mean) in sham-operated animals to 0.23 +/- 0.03 ml/g per minute within the traumatized group. In addition to focal severe ischemia, moderate reductions in lCBF were detected throughout the traumatized hemisphere, including the frontal and occipital cortices, hippocampus, thalamus, and striatum. Mild decreases in lCBF were also observed throughout the contralateral cerebral cortex. At 3 days after severe TBI, histopathology demonstrated intracerebral and subarachnoid hemorrhage associated with cerebral contusion and selective neuronal necrosis. CONCLUSION: These data indicate that multiple cerebrovascular abnormalities, including subarachnoid hemorrhage, focal platelet accumulation, and severe ischemia, are important early events in the pathogenesis of cortical contusion formation after TBI. Injury severity is expected to be a critical factor in determining what therapeutic strategies are attempted in the clinical setting.	Univ Miami, Sch Med, Dept Neurol D45, Neurotrauma Dis Res Ctr, Miami, FL 33101 USA; Univ Miami, Sch Med, Dept Neurol Surg, Cerebrovasc Dis Res Ctr, Miami, FL 33101 USA	Dietrich, WD (corresponding author), Univ Miami, Sch Med, Dept Neurol D45, Neurotrauma Dis Res Ctr, POB 016960, Miami, FL 33101 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027127, P01NS005820, P50NS005820, P50NS030291] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS27127, NS30291, NS05820] Funding Source: Medline		ADAMS JH, 1982, RECENT ADV NEUROPATH, V2, P165; ASTRUP J, 1977, STROKE, V8, P51, DOI 10.1161/01.STR.8.1.51; BACK T, 1995, J CEREBR BLOOD F MET, V15, P566, DOI 10.1038/jcbfm.1995.70; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; BOLANDER HG, 1989, STROKE, V20, P930, DOI 10.1161/01.STR.20.7.930; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; BULLOCK R, 1991, J NEUROSURG, V74, P794, DOI 10.3171/jns.1991.74.5.0794; Busto R, 1997, J NEUROTRAUM, V14, P35, DOI 10.1089/neu.1997.14.35; CHEN MH, 1991, J NEUROSURG, V74, P944, DOI 10.3171/jns.1991.74.6.0944; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DEWANJEE MK, 1983, MAYO CLIN PROC, V58, P307; DeWitt DS, 1997, J NEUROTRAUM, V14, P223, DOI 10.1089/neu.1997.14.223; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; DEWITT DS, 1996, NEW HORIZ, V3, P376; Dietrich WD, 1996, J CEREBR BLOOD F MET, V16, P481, DOI 10.1097/00004647-199605000-00015; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DRAYER BP, 1975, JAMA-J AM MED ASSOC, V231, P174, DOI 10.1001/jama.231.2.174; ELLIS EF, 1977, STROKE, V8, P480, DOI 10.1161/01.STR.8.4.480; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FIESCHI C, 1974, J NEUROL NEUROSUR PS, V37, P1378, DOI 10.1136/jnnp.37.12.1378; Ginsberg MD, 1997, AM J PHYSIOL-HEART C, V272, pH2859; GOODNIGHT SH, 1974, NEW ENGL J MED, V290, P1043, DOI 10.1056/NEJM197405092901903; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; HEISS WD, 1983, ANN NEUROL, V14, P294, DOI 10.1002/ana.410140307; HEKMATPANAH J, 1985, J NEUROSURG, V62, P888, DOI 10.3171/jns.1985.62.6.0888; HUBER A, 1993, INT J LEGAL MED, V106, P152, DOI 10.1007/BF01225238; ISHIGE N, 1987, J CEREBR BLOOD F MET, V7, P759, DOI 10.1038/jcbfm.1987.131; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; JIANG JY, 1991, J NEUROSURG, V74, P492, DOI 10.3171/jns.1991.74.3.0492; JONES TH, 1981, J NEUROSURG, V54, P773, DOI 10.3171/jns.1981.54.6.0773; KEIMOWITZ RM, 1973, J NEUROSURG, V39, P178, DOI 10.3171/jns.1973.39.2.0178; Lee KR, 1996, J NEUROSURG, V84, P91, DOI 10.3171/jns.1996.84.1.0091; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MILLER JD, 1990, NEUROSURGERY, V27, P433, DOI 10.1227/00006123-199009000-00016; MUIR JK, 1992, J NEUROTRAUM, V9, P355, DOI 10.1089/neu.1992.9.355; NILSSON B, 1977, J NEUROSURG, V47, P262, DOI 10.3171/jns.1977.47.2.0262; Nilsson P, 1996, J NEUROTRAUM, V13, P201, DOI 10.1089/neu.1996.13.201; OBRENOVITCH TP, 1985, STROKE, V16, P224, DOI 10.1161/01.STR.16.2.224; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; Perri BR, 1997, J NEUROTRAUM, V14, P15, DOI 10.1089/neu.1997.14.15; PFENNINGER EG, 1989, J NEUROSURG, V70, P774, DOI 10.3171/jns.1989.70.5.0774; POVLISHOCK JT, 1978, BRAIN RES, V153, P223, DOI 10.1016/0006-8993(78)90404-3; ROBERTSON CS, 1992, J NEUROTRAUM, V9, pS349; SAKURADA O, 1978, AM J PHYSIOL, V234, pH59; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; SOLOMON RA, 1985, STROKE, V16, P58, DOI 10.1161/01.STR.16.1.58; Stagliano NE, 1997, J CEREBR BLOOD F MET, V17, P1182, DOI 10.1097/00004647-199711000-00007; STEIGER HJ, 1994, NEUROSURGERY, V34, P79; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; THOMPSON JA, 1984, STROKE, V15, P1021, DOI 10.1161/01.STR.15.6.1021; TORNHEIM PA, 1984, J NEUROSURG, V60, P473, DOI 10.3171/jns.1984.60.3.0473; TORNHEIM PA, 1981, J NEUROSURG, V55, P407, DOI 10.3171/jns.1981.55.3.0407; TYSON GW, 1984, ANN NEUROL, V15, P559, DOI 10.1002/ana.410150608; UNTERBERG AW, 1988, J NEUROSURG, V68, P594, DOI 10.3171/jns.1988.68.4.0594; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; YANG GY, 1994, J NEUROSURG, V81, P93, DOI 10.3171/jns.1994.81.1.0093; Young W, 1988, J Neurotrauma, V5, P219, DOI 10.1089/neu.1988.5.219; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289; ZILLES K, 1985, CORTES RAT STEREOTAX; Zuccarello M, 1996, J NEUROSURG, V84, P503, DOI 10.3171/jns.1996.84.3.0503	67	80	81	0	1	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	SEP	1998	43	3					585	593		10.1097/00006123-199809000-00105			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	114NC	WOS:000075614700094	9733314				2021-06-18	
J	Durkin, MS; Olsen, S; Barlow, B; Virella, A; Connolly, ES				Durkin, MS; Olsen, S; Barlow, B; Virella, A; Connolly, ES			The epidemiology of urban pediatric neurological trauma: Evaluation of, and implications for, injury prevention programs	NEUROSURGERY			English	Article						epidemiology; infant; neurological; pediatric; trauma	HEAD-INJURY; UNITED-STATES; BRAIN INJURY; POPULATION; NEIGHBORHOODS; COMMUNITY; TRENDS; COUNTY	OBJECTIVE: To describe the incidence and causes of pediatric]lead, spinal cord, and peripheral nerve injuries in an urban setting and to assess the implications of these data for injury prevention programs. METHODS: Pediatric deaths and hospital admissions secondary to neurological trauma included in the Northern Manhattan Injury Surveillance System from 1983 to 1932 were linked to census counts to compute incidence rates. Rates before the implementation of a nonspecific injury prevention program were compared with rates after the implementation, and rates for die target population were compared to rates for the control population, Rates were analyzed on the basis of the cause of injury as well as the age, gender, and neighborhood income level of the injured, RESULTS: The incidence of neurological injuries resulting in hospitalization or death was 155 incidents per 100,000 population per year; the mortality rate was 6 people per 100,000 population per year. Neurological injuries represented 18% of all pediatric injuries and accounted for 23% of all traumatic deaths. Spinal cord and peripheral nerve injuries were relatively rare (5%) compared to head injuries (95%). Minor head injuries, including isolated cranial fractures, minor concussions (<7 h loss of consciousness), and unspecified minor head injuries, accounted for the majority of neurological injuries (76%), whereas severe head injuries, including severe concussion (>1 h loss of consciousness), cerebral laceration/contusion, intracerebral hemorrhage, and unspecified major injuries, were less common (18% of all neurological injuries). Boys were move often affected than girls at every age, and this preference increased with age. Children younger than 1 year showed the highest incidence of both major and minor injuries, One- to 4-year olds showed the lowest rates, with steady increases thereafter. Traffic accidents and falls were the leading causes (38 and 34%, respectively), and assaults were the next leading causes (12%). Among children admitted to surveillance system hospitals, falls were most common in children younger than 4 years, pedestrian motor vehicle accidents were most common in late childhood, and assaults were most common in early adolescence. Case:fatality rates were 5 to 7% for all age groups except 5- to 12-year-olds, for whom the case:fatality rate was 1.9%. Residence in a low-income neighborhood was associated with an increased risk of injury (rate ratio, 1.71; confidence interval, 95%, 1.54, 1.89). The average hospitalization cost per injury was $8502. Medicaid (54%) and other government sources (5%) covered the majority of expenses, including indirect reimbursement of usually uncollected self-pay billing (19%). Although injury incidence rates fell in both the control and intervention cohorts during implementation of a nonspecific injury prevention program, targeted age and population groups demonstrated greater relative reductions in injuries than nontargeted ones, suggesting a positive effect. CONCLUSIONS: Deaths and hospital admissions secondary to pediatric neurological trauma represent a significant public health problem, with the majority of the direct cost being born by government agencies. Future efforts to prevent neurological trauma in children who live in inner cities should focus on families with low incomes and provide novel education programs regarding infant abuse, infant neglect, and infant injury avoidance. Age-appropriate school-based programs should also be developed to address traffic safety and conflict resolution.	Columbia Univ Coll Phys & Surg, Harlem Hosp Ctr, Div Pediat & Pediat Surg, New York, NY 10032 USA; Columbia Univ, Sch Publ Hlth, New York State Psychiat Inst, Gertrude H Sergievsky Ctr,Fac Med,Div Epidemiol, New York, NY USA; Columbia Univ, Sch Publ Hlth, New York State Psychiat Inst, Gertrude H Sergievsky Ctr,Fac Med,Dept Neurosurg, New York, NY USA; Columbia Univ, Sch Publ Hlth, New York State Psychiat Inst, Gertrude H Sergievsky Ctr,Fac Med,Dept Pediat, New York, NY USA	Connolly, ES (corresponding author), Columbia Univ Coll Phys & Surg, Dept Neurol Surg, Neurol Inst, Room 204,710 W 168th St, New York, NY 10032 USA.		Durkin, Maureen/B-7834-2015		PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R48/CCR 205055, R49/CCR 202585] Funding Source: Medline		ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; CHIU WT, 1993, J TRAUMA, V35, P206, DOI 10.1097/00005373-199308000-00006; COOPER K D, 1983, Neuroepidemiology, V2, P70, DOI 10.1159/000110512; DAVIDSON LL, 1994, AM J PUBLIC HEALTH, V84, P580, DOI 10.2105/AJPH.84.4.580; DURKIN MS, 1994, AM J PUBLIC HEALTH, V84, P587, DOI 10.2105/AJPH.84.4.587; EDNA TH, 1984, SCAND J SOC MED, V12, P7, DOI 10.1177/140349488401200103; FIFE D, 1986, AM J PUBLIC HEALTH, V76, P773, DOI 10.2105/AJPH.76.7.773; Fleiss JL, 1981, STAT METHODS RATES P, V2nd; HARRISON CL, 1991, PARAPLEGIA, V29, P233, DOI 10.1038/sc.1991.34; JAGGER J, 1984, J TRAUMA, V24, P40, DOI 10.1097/00005373-198401000-00006; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; KALSBEEK WD, 1980, J NEUROSURG, V53, pS19; Kempe A, 1997, PEDIATRICS, V99, P338, DOI 10.1542/peds.99.3.338; KLAUBER MR, 1981, AM J EPIDEMIOL, V113, P500, DOI 10.1093/oxfordjournals.aje.a113125; KRAUS JF, 1987, PEDIATRICS, V79, P501; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; LEE LH, 1992, CHIN MED J TAPIEI, V50, P219; LEVI L, 1990, NEUROEPIDEMIOLOGY, V9, P278, DOI 10.1159/000110784; LEVY ML, 1993, NEUROSURGERY, V33, P1018; NESTVOLD K, 1988, NEUROEPIDEMIOLOGY, V7, P134, DOI 10.1159/000110147; PARKINSON D, 1985, CAN J SURG, V28, P79; Servadei F, 1985, J Neurosurg Sci, V29, P297; Singh GK, 1996, AM J PUBLIC HEALTH, V86, P505, DOI 10.2105/AJPH.86.4.505; TIRET L, 1990, INT J EPIDEMIOL, V19, P133, DOI 10.1093/ije/19.1.133; *US DEP COMM, 1981, 1980 CENS; *US DEP COMM, 1992, 1990 CENS; WHITMAN S, 1984, AM J EPIDEMIOL, V119, P570, DOI 10.1093/oxfordjournals.aje.a113774; WOLTER KM, 1991, SCIENCE, V253, P12, DOI 10.1126/science.253.5015.12; Wong Pauline P., 1993, Brain Injury, V7, P283, DOI 10.3109/02699059309034955; WOODWARD A, 1984, MED J AUSTRALIA, V141, P13, DOI 10.5694/j.1326-5377.1984.tb132660.x	30	80	83	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	0148-396X			NEUROSURGERY	Neurosurgery	FEB	1998	42	2					300	310		10.1097/00006123-199802000-00052			11	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	YV348	WOS:000071814200019	9482180				2021-06-18	
J	Lobato, RD; Gomez, PA; Alday, R; Rivas, JJ; Dominguez, J; Cabrera, A; Turanzas, FS; Benitez, A; Rivero, B				Lobato, RD; Gomez, PA; Alday, R; Rivas, JJ; Dominguez, J; Cabrera, A; Turanzas, FS; Benitez, A; Rivero, B			Sequential computerized tomography changes and related final outcome in severe head injury patients	ACTA NEUROCHIRURGICA			English	Article						head injury; computerized tomography; intracranial haematoma; intracranial pressure	LESION; COMA	The authors analysed the serial computerized tomography (CT) findings in a large series of severely head injured patients in order to assess the variability in gross intracranial pathology through the acute posttraumatic period and determine the most common patterns of CT change. A second aim was to compare the prognostic significance of the different CT diagnostic categories used in the study (Traumatic Coma Data Bank CT pathological classification) when gleaned either from the initial (postadmission) or the control CT scans, and determine the extent to which having a second CT scan provides more prognostic information than only one scan. 92 patients (13.3% of the total population) died soon after injury. Of the 587 who survived long enough to have at least one control CT scan 23.6% developed new diffuse brain swelling, and 20.9% new focal mass lesions most of which had to be evacuated. The relative risk for requiring a delayed operation as related to the diagnostic category established by using the initial CT scans was by decreasing order: diffuse injury IV (30.7%), diffuse injury III (30.5%), non evacuated mass (20%), evacuated mass (20.2%), diffuse injury II (12.1%), and diffuse injury I (8.6%). Overall, 51.2% of the patients developed significant CT changes (for worse or better) occurring either spontaneously or following surgery, and their final outcomes were more closely related to the control than to the initial CT diagnoses. In fact, the final outcome was more accurately predicted by using the control CT scans (81.2% of the cases) than by using the initial CT scans (71.5% of the cases only). Since the majority of relevant CT changes developed within 48 hours after injury a pathological categorization made by using an early control CT scan seems to be most useful for prognostic purposes. Prognosis associated with the CT pathological categories used in the study was similar independently of the moment of the acute posttraumatic period at which diagnoses were made.	UNIV COMPLUTENSE MADRID,FAC MED,E-28040 MADRID,SPAIN	Lobato, RD (corresponding author), HOSP 12 OCTUBRE,NEUROSURG SERV,CARRETERA ANDALUCIA,KM 54,E-28041 MADRID,SPAIN.		Gomez, Pedro/N-5051-2019	Gomez, Pedro/0000-0002-4185-5238			BULLOCK R, 1990, J NEUROSURG, V72, P9, DOI 10.3171/jns.1990.72.1.0009; BULLOCK R, 1989, SURG NEUROL, V322, P181; CLIFTON GL, 1980, J NEUROSURG, V52, P611, DOI 10.3171/jns.1980.52.5.0611; COOPER PR, 1979, NEUROSURGERY, V5, P566, DOI 10.1227/00006123-197911000-00004; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; JENNETT B, 1975, LANCET, V1, P480; KOBAYASHI S, 1983, SURG NEUROL, V20, P25, DOI 10.1016/0090-3019(83)90101-5; LOBATO RD, 1988, J NEUROSURG, V68, P417, DOI 10.3171/jns.1988.68.3.0417; LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762; LOBATO RD, 1988, J NEUROSURG, V68, P48, DOI 10.3171/jns.1988.68.1.0048; LOBTO RD, 1986, J NEUROSURG, V65, P784; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; ROBERSON FC, 1979, SURG NEUROL, V12, P161; SAUTREAUX JL, 1982, NEUROCHIRURGIE, V28, P263; SERVADEI F, 1995, NEUROSURGERY, V37, P899, DOI 10.1227/00006123-199511000-00008; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; TEASDALE E, 1984, J NEUROL NEUROSUR PS, V47, P600, DOI 10.1136/jnnp.47.6.600; TEASDALE G, 1974, LANCET, V2, P81; TURAZZI S, 1987, ACTA NEUROCHIR, V85, P87, DOI 10.1007/BF01456103; VANDONGEN KJ, 1983, J NEUROSURG, V59, P951, DOI 10.3171/jns.1983.59.6.0951	22	80	82	0	3	SPRINGER-VERLAG WIEN	VIENNA	SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.		1997	139	5					385	391		10.1007/BF01808871			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	XC750	WOS:A1997XC75000001	9204105				2021-06-18	
J	Douglas, JM; Spellacy, FJ				Douglas, JM; Spellacy, FJ			Indicators of long-term family functioning following severe traumatic brain injury in adults	BRAIN INJURY			English	Article							SEVERE HEAD-INJURY; ALCOHOLIC PATIENTS; LIFE EVENTS; RELATIVES; DEPRESSION; REHABILITATION; ENVIRONMENT; BEHAVIOR; CHILDREN; RECOVERY	This study investigated the degree of association between four sets of predictor variables (demographic, injury-related, patient functioning, and caregiver functioning variables) and the criterion variable of long-term family functioning following severe traumatic brain injury (TBI). Thirty families participated in the study and a minimum of 3.5 years had elapsed since the time of injury. The mean length of post-traumatic amnesia (PTA) for the brain-injured individuals was 92.4 days. Data collection took place in the family home and both the brain-injured family members and primary caregivers were involved. Standard regression analyses revealed that two sets of variables accounted for a significant amount of variance in long-term family functioning. The largest amount of variance, 55% (44% adjusted), was accounted for by the caregivers' self-report variables which measured caregivers' depression, social support, and coping as well as caregivers' perceptions of patient competency. Overall, measures of severity of injury (PTA), residual neurobehavioural function, and adequacy of social support for caregivers proved to be reliable and significant indicators of family functioning. These findings are discussed with respect to their implications for service delivery and long-term provision of support for caregivers of severely brain-injured individuals living with their families.	UNIV VICTORIA, DEPT PSYCHOL, VICTORIA, BC, CANADA	Douglas, JM (corresponding author), LA TROBE UNIV, SCH COMMUN DISORDERS, BUNDOORA, VIC 3083, AUSTRALIA.		Douglas, Jacinta M/C-2380-2009	Douglas, Jacinta/0000-0003-0940-6624			ALLEN K, 1994, REHABIL PSYCHOL, V39, P29, DOI 10.1037/h0080313; BARNETT PA, 1988, PSYCHOL BULL, V104, P97, DOI 10.1037/0033-2909.104.1.97; Billings A G, 1981, J Behav Med, V4, P139, DOI 10.1007/BF00844267; BILLINGS AG, 1984, J PERS SOC PSYCHOL, V46, P877, DOI 10.1037/0022-3514.46.4.877; BLUMENTHAL MD, 1975, ARCH GEN PSYCHIAT, V32, P985; Bond M R, 1975, Ciba Found Symp, P141; BROMET EJ, 1984, ACTA PSYCHIAT SCAND, V69, P197, DOI 10.1111/j.1600-0447.1984.tb02487.x; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; CARROLL BJ, 1973, ARCH GEN PSYCHIAT, V28, P361; CORRIGAN J D, 1990, Brain Injury, V4, P215, DOI 10.3109/02699059009026170; DOUGLAS JM, 1990, P BIENN C NZ SPEECH, P24; Ensel W., 1986, SOCIAL SUPPORT LIFE, P129; EPSTEIN NB, 1983, J MARITAL FAM THER, V9, P171, DOI 10.1111/j.1752-0606.1983.tb01497.x; FINNEY JW, 1980, J CONSULT CLIN PSYCH, V48, P17, DOI 10.1037/0022-006X.48.1.17; FORDYCE DJ, 1986, REHABIL PSYCHOL, V31, P217, DOI 10.1037//0090-5550.31.4.217; FRANK RG, 1994, BRAIN INJURY, V8, P193, DOI 10.3109/02699059409150972; Hersen M., 1988, BEHAV ASSESSMENT PRA, P313; HINKELDEY N S, 1990, Brain Injury, V4, P115, DOI 10.3109/02699059009026157; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; LEI H, 1980, J PSYCHOSOM RES, V24, P57, DOI 10.1016/0022-3999(80)90054-9; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; LEZAK MD, 1986, REHABIL PSYCHOL, V31, P241, DOI 10.1037//0090-5550.31.4.241; Lin N., 1986, SOCIAL SUPPORT LIFE; Liss M, 1990, Int J Rehabil Res, V13, P309, DOI 10.1097/00004356-199012000-00004; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; LUNGHI ME, 1977, BRIT J PSYCHIAT, V130, P598, DOI 10.1192/bjp.130.6.598; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; MOORE A, 1993, BRAIN INJURY, V7, P247, DOI 10.3109/02699059309029677; Moos R. H., 1981, FAMILY ENV SCALE MAN; MOOS RH, 1979, J STUD ALCOHOL, V40, P78, DOI 10.15288/jsa.1979.40.78; MOOS RH, 1981, J STUD ALCOHOL, V42, P383, DOI 10.15288/jsa.1981.42.383; MOOS RH, 1988, HLTH DAILY LIVING MA; Nelson H. E., 1991, NATIONAL ADULT READI; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; ODDY M, 1984, CLOSED HEAD INJURY P, P108; PESSAR LF, 1993, BRAIN INJURY, V7, P231, DOI 10.3109/02699059309029675; PETERS L C, 1992, Brain Injury, V6, P461, DOI 10.3109/02699059209008141; PETERS L C, 1990, Brain Injury, V4, P39, DOI 10.3109/02699059009026147; Prigatano G. P., 1990, CLIN NEUROPSYCHOL, V4, P163, DOI [10.1080/13854049008401509, DOI 10.1080/13854049008401509]; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; Prigatano GP, 1991, AWARENESS DEFICIT BR, P111; RESNICK C, 1993, SOC WORK HEALTH CARE, V18, P49, DOI 10.1300/J010v18n02_03; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; RIVARA JB, 1992, ARCH PHYS MED REHAB, V73, P899; RIVARA JB, 1993, ARCH PHYSICAL MED RE, V74, P1947; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; ROSS CE, 1979, J HEALTH SOC BEHAV, V20, P166, DOI 10.2307/2136437; RUSSELL WR, 1971, TRAUMATIC AMNESIAS; SARASON IG, 1985, PSYCHOSOM MED, V47, P156, DOI 10.1097/00006842-198503000-00007; SCHAEFER C, 1981, Journal of Behavioral Medicine, V4, P381, DOI 10.1007/BF00846149; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; SINES JO, 1984, J PERS ASSESS, V48, P6, DOI 10.1207/s15327752jpa4801_2; SPIEGEL D, 1983, FAM PROCESS, V22, P537, DOI 10.1111/j.1545-5300.1983.00537.x; Tausig M., 1986, SOCIAL SUPPORT LIFE, P71; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; THOMSEN IV, 1992, SCAND J REHABIL MED, P142; Willer B., 1990, CANADIAN J REHABILIT, V3, P167; ZUNG WW, 1974, MEASUREMENT DEPRESSI; ZUNG WWK, 1965, ARCH GEN PSYCHIAT, V12, P63, DOI 10.1001/archpsyc.1965.01720310065008	66	80	80	0	5	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	NOV	1996	10	11					819	839		10.1080/026990596123936			21	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	VM779	WOS:A1996VM77900004	8905160				2021-06-18	
J	Bellamy, R; Safar, P; Tisherman, SA; Basford, R; Bruttig, SP; Capone, A; Dubick, MA; Ernster, L; Hattler, BG; Hochachka, P; Klain, M; Kochanek, PM; Kofke, WA; Lancaster, JR; McGowan, FX; Oeltgen, PR; Severinghaus, JW; Taylor, MJ; Zar, H				Bellamy, R; Safar, P; Tisherman, SA; Basford, R; Bruttig, SP; Capone, A; Dubick, MA; Ernster, L; Hattler, BG; Hochachka, P; Klain, M; Kochanek, PM; Kofke, WA; Lancaster, JR; McGowan, FX; Oeltgen, PR; Severinghaus, JW; Taylor, MJ; Zar, H			Suspended animation for delayed resuscitation	CRITICAL CARE MEDICINE			English	Article; Proceedings Paper	International Resuscitation Research Conference (IRRC 94)	MAY 07-09, 1994	PITTSBURGH, PA			cerebral anoxia; cardiopulmonary resuscitation; hypothermia; ischemia; exsanguination; suspended animation; cardiac arrest; preservation; hibernation; cardiopulmonary bypass	AUTOPERFUSION MULTIORGAN PREPARATION; HYPOTHERMIC CIRCULATORY ARREST; HIBERNATION INDUCTION TRIGGER; NITRIC-OXIDE; REPERFUSION INJURY; HEMORRHAGIC-SHOCK; PARTIAL EPILEPSY; CARDIAC-ARREST; MAJOR ORGANS; ISCHEMIA	Suspended animation is defined as the therapeutic induction of a state of tolerance to temporary complete systemic ischemia, i.e., protection-preservation of the whole organism during prolonged circulatory arrest (greater than or equal to 1 hr), followed by resuscitation to survival without brain damage. The objectives of suspended animation include: a) helping to save victims of temporarily uncontrollable (internal) traumatic (e.g., combat casualties) or nontraumatic (e.g., ruptured aortic aneurysm) exsanguination, without severe brain trauma, by enabling evacuation and resuscitative surgery during circulatory arrest, followed by delayed resuscitation; b) helping to save some nontraumatic cases of sudden death, seemingly unresuscitable before definitive repair; and c) enabling selected (elective) surgical procedures to be performed which are only feasible during a state of no blood flow. In the discussion session, investigators with suspended animation relevant research interests brainstorm on present knowledge, future research potentials, and the advisability of a major research effort concerning this subject. The following topics are addressed: the epidemiologic facts of sudden death in combat casualties, which require a totally new resuscitative approach; the limits and potentials of reanimation research; complete reversibility of circulatory arrest of 1 hr in dogs under profound hypothermia (<10 degrees C), induced and reversed by portable cardiopulmonary bypass; the need for a still elusive pharmacologic or chemical induction of suspended animation in the field; asanguinous profound hypothermic low-flow with cardiopulmonary bypass; electric anesthesia; opiate therapy; lessons learned from hypoxia tolerant vertebrate animals, hibernators, and freeze tolerant animals (cryobiology); myocardial preservation during open heart surgery; organ preservation for transplantation; and reperfusion reoxygenation injury in vital organs, including the roles of nitric oxide and free radicals; and how cells (particularly cerebral neurons) die after transient prolonged ischemia and reperfusion. The majority of authors believe that seeking a breakthrough in suspended animation is not utopian, that ongoing communication between relevant research groups is indicated, and that a coordinated multicenter research effort, basic and applied, on suspended animation is justified.	UNIV PITTSBURGH, SAFAR CTR RESUSCITAT RES, PITTSBURGH, PA 15260 USA; PONTCTOC CANYON ESTATES, TUCSON, AZ 85718 USA; USA, MED RES & MAT COMMAND, SGRD PLB, FREDERICK, MD 21702 USA; SGRD USMT, HOUSTON, TX 78234 USA; UNIV STOCKHOLM, ARRHENIUS LAB, DEPT BIOCHEM, S-10691 STOCKHOLM, SWEDEN; UNIV PITTSBURGH, MED CTR, DEPT SURG, PITTSBURGH, PA 15213 USA; UNIV BRITISH COLUMBIA, DEPT ZOOL & SPORTS MED, VANCOUVER, BC V5Z 1M9, CANADA; UNIV PITTSBURGH, MED CTR, DEPT ANESTHESIOL & NEUROSURG, PITTSBURGH, PA 15260 USA; LOUISIANA STATE UNIV, MED CTR, NEW ORLEANS, LA 70112 USA; UNIV PITTSBURGH, CHILDRENS HOSP PITTSBURGH, DEPT ANESTHESIOL, CCM, PITTSBURGH, PA 15213 USA; VET ADM MED CTR, LEXINGTON, KY 40511 USA; UNIV CALIF SAN FRANCISCO, DEPT ANESTHESIOL, SAN FRANCISCO, CA 94143 USA; ALLEGHENY GEN HOSP, PITTSBURGH, PA 15212 USA	Bellamy, R (corresponding author), WALTER REED ARMY MED CTR, BORDEN INST, BLDG 11, ROOM 1-117, 6825 16TH ST NW, WASHINGTON, DC 20307 USA.		Kochanek, Patrick M/D-2371-2015; Tisherman, Samuel A./AAK-9377-2020	Kochanek, Patrick M/0000-0002-2627-913X; Tisherman, Samuel A./0000-0003-3810-3729			ADLER L, 1994, ANESTHESIOLOGY, V81, pA917; ADLER MW, 1980, LIFE SCI, V26, P497, DOI 10.1016/0024-3205(80)90312-4; ANANEV MG, 1960, ANESTHESIOLOGY, V21, P215, DOI 10.1097/00000542-196003000-00013; ARNOLD K, 1978, MIL MED, V143, P161; BAILES JE, 1991, J NEUROSURG, V74, P781, DOI 10.3171/jns.1991.74.5.0781; BAKER CC, 1986, ANN EMERG MED, V15, P1389, DOI 10.1016/S0196-0644(86)80921-0; BAKER SP, 1982, J TRAUMA, V22, P187; BARNES BM, 1989, SCIENCE, V244, P1593, DOI 10.1126/science.2740905; BECKMAN JS, 1993, BIOCHEM SOC T, V21, P330, DOI 10.1042/bst0210330; Beecher HK, 1949, RESUSCITATION ANESTH; BELLAMY RF, 1986, ANN EMERG MED, V15, P1384, DOI 10.1016/S0196-0644(86)80920-9; BELLAMY RF, 1984, MIL MED, V149, P55; Bellamy RF, 1988, ADV TRAUMA, V3, P163; BELLINGER DC, 1991, PEDIATRICS, V87, P701; BOVERIS A, 1980, P NATL ACAD SCI-BIOL, V77, P347, DOI 10.1073/pnas.77.1.347; CAPONE A, 1995, RESUSCITATION, V29, P143, DOI 10.1016/0300-9572(95)00829-I; CAPONE A, IN PRESS J TRAUMA; CAPONE A, 1995, ACAD EMERG MED, V2, P363; CAPONE AC, 1995, J AM COLL SURGEONS, V180, P49; CASCINO GD, 1993, J CLIN NEUROPHYSIOL, V10, P520, DOI 10.1097/00004691-199310000-00010; CHIEN S, 1994, J THORAC CARDIOV SUR, V107, P964; CHIEN S, 1989, ANN THORAC SURG, V47, P860, DOI 10.1016/0003-4975(89)90021-0; CHIEN S, 1993, XANTHUS INTELLIGENCE, P1; CHIEN S, 1993, 73RD ANN M AM ASS TR; CHIEN SF, 1991, J THORAC CARDIOV SUR, V102, P224; CONNOLLY JE, 1965, ANN SURG, V162, P373; DAWE AR, 1969, SCIENCE, V163, P298, DOI 10.1126/science.163.3864.298; DAWE AR, 1971, CRYOBIOLOGY, V8, P302, DOI 10.1016/0011-2240(71)90058-7; DREW CE, 1959, LANCET, V1, P748; ERNSTER L, 1988, CRIT CARE MED, V16, P947, DOI 10.1097/00003246-198810000-00005; FINKEL MS, 1993, AM J CARDIOL, V71, P1231, DOI 10.1016/0002-9149(93)90654-U; FINKEL MS, 1992, SCIENCE, V257, P387, DOI 10.1126/science.1631560; FINKEL MS, 1993, J IMMUNOL IMMUNOPHAR, V13, P1; FINKEL MS, 1994, MYOCARDIAL VIABILITY; FLACH VA, 1958, ANAESTHESIST, V7, P180; FRERICHS KU, 1994, J CEREBR BLOOD F MET, V14, P193, DOI 10.1038/jcbfm.1994.26; FRY FEJ, 1947, PUBL ONTARIO FISH RE, V68, P1; GADDIS GM, 1994, ANN EMERG MED, V23, P75, DOI 10.1016/S0196-0644(94)70012-5; GRANGER DN, 1981, GASTROENTEROLOGY, V81, P22; Haglund H, 1971, Methods Biochem Anal, V19, P1; HARDY JD, 1961, JAMA-J AM MED ASSOC, V175, P599, DOI 10.1001/jama.1961.63040070001013; HERIN RA, 1994, UST P S EL FORT COLL, P22; HJALMARSSON SG, 1975, SCI TOOLS, V22, P35; HOCHOCHKA PW, 1993, SURVIVING HYPOXIA; HORTON ND, 1995, TOXICOLOGIST, V15; JENNINGS RB, 1990, CIRCULATION, V82, P2; KEARSE LA, 1993, ELECTROEN CLIN NEURO, V87, P374, DOI 10.1016/0013-4694(93)90150-T; KERWIN JF, IN PRESS J MED CHEM; KIM SH, 1995, ACAD EMERG MED, V2, P364; KIRIMLI B, 1968, ACTA ANAESTH SCAND, VS, P183; KIRIMLI B, 1969, SURG GYNECOL OBSTETR, V129, P89; KLAIN M, 1989, CARDIOVASCULAR SCI T, P318; Kofke W. A., 1993, Society for Neuroscience Abstracts, V19, P1159; Kofke W. A., 1994, J NEUROSURG ANESTH, V6, P323; KOFKE WA, 1992, ANESTH ANALG, V75, P953; KOFKE WA, 1994, ANESTHESIOLOGY, V81, pA820; KOFKE WA, 1994, J NEUROSURG ANESTH, V6, P322; KRUMAN II, 1986, COMP BIOCHEM PHYS B, V83, P173, DOI 10.1016/0305-0491(86)90349-4; LABORIT H, 1954, PRACTICE HIBERNATION; LITTARRU GP, 1993, CLIN INVESTIGATOR, V71, P587; LUTZ PL, 1994, BRAIN OXYGEN CAUSES; LYMAN CP, 1981, SCIENCE, V212, P668, DOI 10.1126/science.7221552; MALINSKI T, 1993, J CEREBR BLOOD F MET, V13, P355, DOI 10.1038/jcbfm.1993.48; MARSHALL HP, IN PRESS J TRAUMA; MCGOWAN FX, 1994, J THORAC CARDIOV SUR, V108, P772; MYERS RD, 1981, BRAIN RES BULL, V7, P691, DOI 10.1016/0361-9230(81)90120-9; NILEKANI SP, 1990, FED PROC, V4, P854; NUSSLER AK, 1993, BIOCHEM BIOPH RES CO, V194, P826, DOI 10.1006/bbrc.1993.1896; OELTGEN PR, 1988, LIFE SCI, V43, P1565, DOI 10.1016/0024-3205(88)90406-7; OELTGEN PR, 1978, PREP BIOCHEM, V8, P171, DOI 10.1080/00327487808069058; OELTGEN PR, 1982, PHARMACOL BIOCHEM BE, V17, P1271, DOI 10.1016/0091-3057(82)90132-0; OELTGEN PR, 1987, LIFE SCI, V41, P2115, DOI 10.1016/0024-3205(87)90529-7; OELTGEN PR, 1995, FASEB J, V9, pA642; OELTGEN PR, 1981, HIBERNATION OTHER AD, P139; OHKADO A, 1994, J THORAC CARDIOV SUR, V108, P762; ORDOG GJ, 1994, J TRAUMA, V36, P106, DOI 10.1097/00005373-199401000-00017; OUGHTERSON AW, 1962, WOUND BALLISTICS; PEGG DE, 1981, ORGAN PRESERVATION T, P31; POZZATI R, 1986, SCIENCE, V84, P232; PRETTO EA, 1991, CRIT CARE MED, V19, P1188, DOI 10.1097/00003246-199109000-00016; RADI R, 1993, BIOCHEM J, V290, P51, DOI 10.1042/bj2900051; RIEDESEL ML, 1980, FED PROC, V39, P2959; SAFAR P, 1990, AM J EMERG MED, V8, P55, DOI 10.1016/0735-6757(90)90298-E; SAFAR P, 1993, ANN EMERG MED, V22, P324, DOI 10.1016/S0196-0644(05)80463-9; SAFAR P, 1988, CRIT CARE MED, V16, P919; SAFAR P, 1995, CARDIAC ARREST, pCH49; SCHOLANDER PF, 1962, HARVEY LECT, P93; SCIAMANNA MA, 1993, ARCH BIOCHEM BIOPHYS, V305, P215, DOI 10.1006/abbi.1993.1414; SHORT CE, 1964, J AM VET MED ASSOC, V145, P1104; SMITH RH, 1967, ANESTH ANAL CURR RES, V46, P109; SNEAD OC, 1981, NEUROPHARMACOLOGY, V21, P299; SNYDER J, 1966, COMMUNICATION    JAN; STOREY KB, 1987, J BIOL CHEM, V262, P1670; SU TP, 1988, FASEB J, V2, pA1074; SUSSMAN MS, 1990, METHOD ENZYMOL, V186, P711; TAKAORI M, 1967, J AMER MED ASSOC, V199, P297, DOI 10.1001/jama.199.5.297; TAKEUCHI K, IN PRESS CIRCULATION; Taylor M J, 1994, ASAIO J, V40, pM351, DOI 10.1097/00002480-199407000-00022; Taylor M. J., 1994, Cryobiology, V31, P592; TAYLOR MJ, 1995, CIRCULATION, V91, P431, DOI 10.1161/01.CIR.91.2.431; TAYLOR MJ, IN PRESS ADV LOW TEM, V3; TEMPELHOFF R, 1992, J NEUROSURG, V77, P201, DOI 10.3171/jns.1992.77.2.0201; THIEMERMANN C, 1993, P NATL ACAD SCI USA, V90, P267, DOI 10.1073/pnas.90.1.267; TISHERMAN S, 1992, Anesthesiology (Hagerstown), V77, pA285, DOI 10.1097/00000542-199209001-00285; TISHERMAN S, 1994, RESUSCITATION, V28, pS14; TISHERMAN S, 1994, RESUSCITATION, V28, pS5; TISHERMAN SA, 1991, J TRAUMA, V31, P1051, DOI 10.1097/00005373-199131080-00002; TISHERMAN SA, 1990, J TRAUMA, V30, P836, DOI 10.1097/00005373-199007000-00014; TISHERMAN SA, 1990, ACTA ANAESTH SCAND, V34, P63, DOI 10.1111/j.1399-6576.1990.tb03224.x; TISHERMAN SA, 1991, CRIT CARE MED, V19, pS89; TISHERMAN SA, 1989, ANN EMERG MED, V18, P460; TRAVIS J, 1973, CLIN CHIM ACTA, V49, P49, DOI 10.1016/0009-8981(73)90341-0; TURBES CC, 1994, 1ST P S EL FORT COLL, P52; TURKER MS, 1988, CELL BIOL TOXICOL, V4, P211, DOI 10.1007/BF00119247; Wang L.C.H., 1978, STRATEGIES COLD NATU, P109; WOLFE RR, 1982, 30TH ANN C MASS SPEC; YANG GY, 1994, STROKE, V25, P165, DOI 10.1161/01.STR.25.1.165; ZAJTCHUK R, 1995, MIL MED, V160, P1; ZAR H, 1994, FASEB J, V8, pA128; 1970, EVALUATION WOUND DAT, V3; EXERCEPTA MED INT C, V136; 1970, EVALUATION WOUND DAT, V1; 1985, ABBREVIATED INJURY S	123	80	81	2	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	FEB	1996	24	2		S			S24	S47					24	Critical Care Medicine	General & Internal Medicine	TW260	WOS:A1996TW26000004	8608704				2021-06-18	
J	Conway, MA; Tacchi, PC				Conway, MA; Tacchi, PC			Motivated confabulation	NEUROCASE			English	Article							MEMORIES; REALITY; RETRIEVAL; SELF	OP, a 73-year-old woman, suffered a closed head injury that caused bilateral damage to the temporal and frontal lobes. She had impaired access to episodic and semantic knowledge, showed some deficits in visual processing, performed at floor on tests of frontal lobe function, and was in the severely impaired range on tests of autobiographical memory. However, OP's most striking memory disturbance was that she confabulated. Her confabulated memories provided a basis for explanations of the behaviour of others towards her since her accident and in this respect were motivated confabulations. It is argued that OP has suffered an impairment to executive functions and, as a consequence, can no longer discriminate mental representations of wishes and imaginings from memories of actual experiences.	UNIV BRISTOL, DEPT PSYCHOL, BRISTOL BS8 1TN, AVON, ENGLAND							ANDERSON SJ, 1993, J EXP PSYCHOL LEARN, V19, P1178, DOI 10.1037/0278-7393.19.5.1178; Baddeley A.D., 1986, AUTOBIOGRAPHICAL MEM, P225; BADDELEY AD, 1994, SPEED CAPACITY LANGU; BADDELEY AD, 1992, DOORS PEOPLE; Burgess PW, 1996, MEMORY, V4, P359, DOI 10.1080/096582196388906; CATTEL RB, 1986, HDB 16 PERSONALITY F; Conway M.A., 1990, AUTOBIOGRAPHICAL MEM; Conway M. A., 1996, REMEMBERING OUR STUD, P67, DOI DOI 10.1017/CBO9780511527913.003; CONWAY MA, 1987, MEM COGNITION, V15, P119, DOI 10.3758/BF03197023; CONWAY MA, 1992, NATO ADV SCI INST SE, V65, P167; CONWAY MA, 1996, J EXPT PSYCHOL GEN, V125, P1; CONWAY MA, 1993, HDB NEUROPSYCHOLOGY, P175; Conway Martin A., 1993, P103; DALLABARBA G, 1993, COGN NEUROPSYCHOL, V10, P1; DALLABARBA G, 1995, BROKEN MEMORIES CASE, P101; DAMASIO AR, 1989, COGNITION, V33, P25, DOI 10.1016/0010-0277(89)90005-X; Downes J. J., 1995, BROKEN MEMORIES CASE, P115; ERICSSON KA, 1995, PSYCHOL REV, V102, P211, DOI 10.1037/0033-295X.102.2.211; HIGGINS ET, 1987, PSYCHOL REV, V94, P319, DOI 10.1037/0033-295X.94.3.319; Howard D., 1992, PYRAMIDS PALM TREES; Johnson M.K., 1996, BASIC APPL MEMORY RE, V1, P295; JOHNSON MK, 1993, PSYCHOL BULL, V114, P3, DOI 10.1037/0033-2909.114.1.3; JOHNSON MK, 1981, PSYCHOL REV, V88, P67, DOI 10.1037/0033-295X.88.1.67; Johnson-Laird PN., 1983, MENTAL MODELS; KAHNEMAN D, 1986, PSYCHOL REV, V93, P136, DOI 10.1037/0033-295X.93.2.136; Kopelman M. D., 1990, AUTOBIOGRAPHICAL MEM; Kopelman MD, 1995, NEUROCASE, V1, P71, DOI 10.1080/13554799508402348; KOPELMAN MD, 1987, J NEUROL NEUROSUR PS, V50, P1482, DOI 10.1136/jnnp.50.11.1482; KOPELMAN MD, 1995, BROKEN MEMORIES CASE, P137; LINDSAY DS, 1994, APPL COGNITIVE PSYCH, V8, P281, DOI 10.1002/acp.2350080403; LOFTUS EF, 1993, AM PSYCHOL, V48, P518, DOI 10.1037/0003-066X.48.5.518; MARKUS H, 1986, AM PSYCHOL, V41, P954, DOI 10.1037/0003-066X.41.9.954; MARSHALL JC, 1995, CORTEX, V31, P183, DOI 10.1016/S0010-9452(13)80116-5; Mayes A R, 1994, Memory, V2, P183, DOI 10.1080/09658219408258944; Moscovitch M., 1989, VARIETIES MEMORY CON, P133; Nelson H. E., 1991, NATIONAL ADULT READI; Norman D. A, 1980, ATTENTION ACTION WIL; OCONNOR M, 1992, J CLIN EXP NEUROPSYC, V14, P159, DOI 10.1080/01688639208402821; OGDEN JA, 1993, NEUROPSYCHOLOGIA, V31, P571, DOI 10.1016/0028-3932(93)90053-3; Papagno C, 1996, NEUROCASE, V2, P111; Riddoch M. J., 1993, BIRMINGHAM OBJECT RE; Robinson J.A., 1986, AUTOBIOGRAPHICAL MEM, P19, DOI DOI 10.1017/CBO9780511558313.005; ROBINSON JA, 1992, NATO ADV SCI INST SE, V65, P223; ROSS M, 1989, PSYCHOL REV, V96, P341, DOI 10.1037/0033-295X.96.2.341; Rubin D. C., 1986, AUTOBIOGRAPHICAL MEM; SCHACTER DL, 1996, IN PRESS PSYCHIAT AN; SCHACTER DL, 1995, MEMORY DISTORTION MI; SHALLICE T, 1982, PHILOS T ROY SOC LON, pB298; Shallice T., 1988, NEUROPSYCHOLOGY MENT; STEVENS M, 1979, B BRIT PSYCHOL SOC, V32, P211; STRAUMAN TJ, 1990, J PERS SOC PSYCHOL, V59, P869, DOI 10.1037/0022-3514.59.5.869; Stuss D.T., 1986, FRONTAL LOBES; Talland G.A., 1965, DERANGED MEMORY; TULVING E, 1985, CAN PSYCHOL, V26, P1, DOI 10.1037/h0080017; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Williams J.M.G., 1996, REMEMBERING OUR, P244, DOI DOI 10.1017/CB09780511527913.010; WILLIAMS MD, 1981, COGNITIVE SCI, V5, P87, DOI 10.1207/s15516709cog0502_1; Wilson B. A., 1991, RIVERMEAD BEHAV MEMO	59	80	81	0	5	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND	1355-4794			NEUROCASE	Neurocase		1996	2	4					325	338					14	Clinical Neurology; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	VL519	WOS:A1996VL51900003					2021-06-18	
J	LEONARD, JR; MARIS, DO; GRADY, MS				LEONARD, JR; MARIS, DO; GRADY, MS			FLUID PERCUSSION INJURY CAUSES LOSS OF FOREBRAIN CHOLINE-ACETYLTRANSFERASE AND NERVE GROWTH-FACTOR RECEPTOR IMMUNOREACTIVE CELLS IN THE RAT	JOURNAL OF NEUROTRAUMA			English	Article							TRAUMATIC BRAIN INJURY; FIMBRIA-FORNIX TRANSECTION; BASAL FOREBRAIN; ALZHEIMERS-DISEASE; MEDIAL SEPTUM; HIPPOCAMPAL-FORMATION; RETROGRADE TRANSPORT; SUPEROXIDE-DISMUTASE; NUCLEUS BASALIS; DIAGONAL BAND	Memory dysfunction is a common sequela of human traumatic brain injury (TBI). Cholinergic forebrain neurons are recognized for their role in memory. We tested the hypothesis that forebrain cholinergic neurons are vulnerable to fluid percussion injury (FPI), a model of human TBI. Rodents were subjected to a moderate parasagittal FPI, sham injury, or fimbria/fornix axotomy and then killed 10 days after the procedure. Additional animals underwent FPI or sham injury and were killed 7, 14, and 28 days after the procedure. Neurons in the medial septal nucleus and vertical limb of the nucleus of the diagonal band of Broca were identified and quantitated using choline acetyltransferase (ChAT) and low affinity nerve growth factor receptor (NGF-R) immunohistochemistry. Our results showed a significant decrease in ChAT (17% +/- 5%) and NGF-R (24% +/- 8%) immunoreactive cells in FPI animals killed after 10 days when compared to sham-injured animals. Animals undergoing fimbria/fornix axotomy showed a greater reduction in ChAT (53% +/- 13%) and NGF-R (55% +/- 5%) immunoreactive cells 10 days postaxotomy. The number of ChAT and NGF-R immunoreactive neurons was reduced at all time points. However, statistical significance was present 10 and 14 days postinjury for ChAT immunoreactive neurons and 10 days only for NGF-R immunoreactive neurons. These studies have shown that FPI produces transient loss of ChAT and NGF-R immunoreactive neurons.	UNIV WASHINGTON,HARBORVIEW MED CTR,DEPT NEUROL SURG,SEATTLE,WA 98104					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS001371] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 01371] Funding Source: Medline		ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; AMARAL DG, 1985, J COMP NEUROL, V240, P37, DOI 10.1002/cne.902400104; ARENDT T, 1985, NEUROSCIENCE, V14, P1, DOI 10.1016/0306-4522(85)90160-5; ARMSTRONG DM, 1991, J COMP NEUROL, V304, P596, DOI 10.1002/cne.903040407; BULLOCK R, 1992, J NEUROTRAUM, V9, pS443; DAVIES P, 1976, LANCET, V2, P1403; DAWBARN D, 1988, BRAIN RES, V440, P185, DOI 10.1016/0006-8993(88)91175-4; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; ERB DE, 1988, ACTA NEUROPATHOL, V76, P347, DOI 10.1007/BF00686971; GAGE FH, 1988, J COMP NEUROL, V269, P147, DOI 10.1002/cne.902690112; GAGE FH, 1986, NEUROSCIENCE, V19, P241, DOI 10.1016/0306-4522(86)90018-7; GNAHN H, 1983, DEV BRAIN RES, V9, P45, DOI 10.1016/0165-3806(83)90107-4; GORMAN LK, 1993, BRAIN RES, V614, P29, DOI 10.1016/0006-8993(93)91014-J; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HARRELL LE, 1987, BEHAV NEUROSCI, V101, P644, DOI 10.1037/0735-7044.101.5.644; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; JOHNSON EM, 1987, J NEUROSCI, V7, P923; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KATAYAMA Y, 1990, ACT NEUR S, V51, P271; KINJO N, 1989, NEUROSCI RES, V7, P154, DOI 10.1016/0168-0102(89)90055-2; KOLIATOS VE, 1991, EXP NEUROL, V112, P116; KRAUS JF, 1987, HEAD INJURY, P1; LEVASSEUR JE, 1989, J NEUROSURG, V71, P573, DOI 10.3171/jns.1989.71.4.0573; Levin H., 1987, HEAD INJURY, P442; LEWIS PR, 1967, BRAIN, V90, P521, DOI 10.1093/brain/90.3.521; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MARTIN LJ, 1993, J NEUROSCI, V13, P2249; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MESULAM MM, 1983, NEUROSCIENCE, V10, P1185, DOI 10.1016/0306-4522(83)90108-2; MORSE JK, 1993, J NEUROSCI, V13, P4146; MUIZELAAR JP, 1993, ANN EMERG MED, V22, P1014, DOI 10.1016/S0196-0644(05)82744-1; OBRIEN TS, 1990, BRAIN RES, V508, P249, DOI 10.1016/0006-8993(90)90403-X; Povlishock J T, 1992, Hum Cell, V5, P345; SANADA T, 1993, J NEUROTRAUM, V10, P65, DOI 10.1089/neu.1993.10.65; SCHMIDT RH, 1993, J NEUROTRAUM, V10, P415, DOI 10.1089/neu.1993.10.415; SEILER M, 1984, BRAIN RES, V300, P33, DOI 10.1016/0006-8993(84)91338-6; SENUT MC, 1990, NEUROSCI LETT, V113, P12, DOI 10.1016/0304-3940(90)90486-S; SENUT MC, 1989, NEUROSCIENCE, V30, P385, DOI 10.1016/0306-4522(89)90260-1; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SOFRONIEW MV, 1987, BRAIN RES, V411, P310, DOI 10.1016/0006-8993(87)91084-5; TUSZYNSKI MH, 1990, BRAIN RES, V508, P241, DOI 10.1016/0006-8993(90)90402-W; WHITEHOUSE PJ, 1982, SCIENCE, V215, P1237, DOI 10.1126/science.7058341; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289	50	80	82	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	AUG	1994	11	4					379	392		10.1089/neu.1994.11.379			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	PG289	WOS:A1994PG28900004	7837279				2021-06-18	
J	WUDEL, JH; MORRIS, JA; YATES, K; WILSON, A; BASS, SM				WUDEL, JH; MORRIS, JA; YATES, K; WILSON, A; BASS, SM			MASSIVE TRANSFUSION - OUTCOME IN BLUNT TRAUMA PATIENTS	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	20TH ANNUAL MEETING OF THE WESTERN TRAUMA ASSOC	FEB 26-MAR 02, 1990	CRESTED BUTTE, CO	W TRAUMA ASSOC			BLOOD TRANSFUSIONS; GERIATRIC-PATIENTS; MAJOR TRAUMA; INJURY; COAGULATION; HEMOSTASIS; CARE	Over a 54-month period 6,142 patients were consecutively admitted to our Level I trauma center. Ninety-two blunt trauma patients required massive transfusion (MT) of 20 or more units of packed red blood cells (range, 20-126). Eighty-two per cent of all transfused blood was given within 24 hours of admission. Forty-eight patients (52%) were long-term survivors. Twenty-six patients died (28%) within 24 hours and 21 of these exsanguinated. Eighteen patients died > 24 hours: nine (50%) died from multiple organ failure, and nine (50%) died from severe closed head injury (CHI). Clinical predictors of increased mortality were: shock on admission, closed head injury, and age. Forty-three survivors were followed for a mean of 2.5 years (range, 1-5 years). No patient died during followup. All patients were home at 1 year; only four patients required continued medical assistance. Thirty-two patients (74%) returned to work. We conclude that: 1) blunt and penetrating trauma patients receiving MT have similar survival rates of 50%; 2) shock, closed head injury, and age predict increased mortality but do not preclude survival; 3) long-term outcome in blunt patients requiring MT is excellent. Post-discharge death is rare and 3/4 of the survivors return to work, justifying the high cost of acute care.	VANDERBILT UNIV,SCH MED,DIV TRAUMA,2100 PIERCE AVE,NASHVILLE,TN 37212			Woolley, Tom/D-8110-2012	Woolley, Tom/0000-0001-9957-6453			BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; CHAMPION HR, 1989, AM J PUBLIC HEALTH, V79, P1278, DOI 10.2105/AJPH.79.9.1278; COLLINS JA, 1974, SURGERY, V75, P274; COUNTS RB, 1979, ANN SURG, V190, P91, DOI 10.1097/00000658-197907000-00020; FELICIANO DV, 1981, J TRAUMA, V21, P285, DOI 10.1097/00005373-198104000-00005; FINELLI FC, 1989, J TRAUMA, V29, P541, DOI 10.1097/00005373-198905000-00001; GENNARELLI TA, 1989, J TRAUMA, V29, P1193, DOI 10.1097/00005373-198909000-00002; Harke H, 1980, Bibl Haematol, P179; HARRIGAN C, 1989, J TRAUMA, V29, P1416, DOI 10.1097/00005373-198910000-00020; HARRIGAN C, 1982, AM SURGEON, V48, P393; KASHUK JL, 1982, J TRAUMA, V22, P672, DOI 10.1097/00005373-198208000-00004; MARTIN DJ, 1985, ANN SURG, V202, P505, DOI 10.1097/00000658-198510000-00010; MILLER RD, 1971, ANN SURG, V174, P794, DOI 10.1097/00000658-197111000-00010; MORRIS JA, 1990, J TRAUMA, V30, P1476, DOI 10.1097/00005373-199012000-00006; PHILLIPS TF, 1987, J TRAUMA, V27, P903, DOI 10.1097/00005373-198708000-00010; SIEGEL J H, 1989, Journal of Trauma, V29, P1731; STONE HH, 1983, AM SURGEON, V5, P532; STRING T, 1971, ARCH SURG-CHICAGO, V102, P406; WEST HC, 1989, SOUTHERN MED J, V82, P186, DOI 10.1097/00007611-198902000-00010; WILSON RF, 1971, J TRAUM, V11, P275, DOI 10.1097/00005373-197104000-00001; 1971, JAMA-J AM MED ASSOC, V215, P277	22	80	82	0	1	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JAN	1991	31	1					1	7		10.1097/00005373-199101000-00001			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	EU220	WOS:A1991EU22000001	1986111				2021-06-18	
J	DeWitt, DS; Kong, DL; Lyeth, BG; Jenkins, LW; Hayes, RL; Wooten, ED; Prough, DS				DeWitt, Douglas S.; Kong, Daniel L.; Lyeth, Bruce G.; Jenkins, Larry W.; Hayes, Ronald L.; Wooten, Esther D.; Prough, Donald S.			Experimental Traumatic Brain Injury Elevates Brain Prostaglandin E-2 and Thromboxane B-2 Levels in Rats	JOURNAL OF NEUROTRAUMA			English	Article							CEREBRAL-BLOOD-FLOW; FLUID-PERCUSSION MODEL; ARACHIDONIC-ACID; ADRENERGIC TRANSMISSION; SYNTHETASE INHIBITION; SMOOTH-MUSCLE; FREE-RADICALS; CYCLOOXYGENASE; PROSTACYCLIN; EICOSANOIDS	Prostaglandin E-2 (PGE(2)) and thromboxane B-2 (TxB(2)) levels were measured in rats following experimental traumatic brain injury. Rats (n = 36) were prepared for fluid percussion brain injury under pentobarbital anesthesia. Twenty-four hours later, rats were lightly anesthetized using methoxyflurane, injured (2.3 atm), and killed 5 or 15 min later. Twelve of the rats died before and are not included in the analyses. The following groups were used for data analysis: group I (n = 6) were sham-injured rats prepared for injury but not injured: group II (n = 6) were injured and killed 5 min later; group III (n = 12) were injured and killed 15 min posttrauma. Thirty seconds prior to sacrifice by decapitation into liquid nitrogen, all rats were injected with indomethacin (3 mg/kg, intravenously [IV]) to prevent postmortem PG synthesis. After sacrifice, brains were removed, weighed, and homogenized in a small quantity of phosphate buffer with indomethacin (50 ug/ml). PGE(2) and TxB(2) levels were determined using double-label radioimmunoassays. Posttraumatic convulsions were observed in 5 of 12 rats in group III and these rats were analyzed separately. PGE(2) and TxB(2) levels increased significantly (p < 0.05) in both hemisphere and brainstem 5 min posttrauma. Fifteen minutes after injury, both PGE(2) and TxB(2) levels remained elevated but the levels were lower than at 5 min in the rats that did not exhibit posttraumatic seizures. This decrease in PG levels at 15 min was not observed in the rats that had seizures after injury and both PGE(2) and TxB(2) levels remained high in hemispheres and brainstem. Thus, fluid percussion brain injury results in substantial elevations in PGE(2) and TxB(2) levels and posttraumatic seizures exacerbate the observed increases.	[DeWitt, Douglas S.; Kong, Daniel L.; Wooten, Esther D.; Prough, Donald S.] Bowman Gray Sch Med, Dept Anesthesia, Winston Salem, NC 27103 USA; [Lyeth, Bruce G.; Jenkins, Larry W.; Hayes, Ronald L.] Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, Richmond, VA 23298 USA	DeWitt, DS (corresponding author), Bowman Gray Sch Med, Dept Anesthesia, 300 S Hawthorne Rd, Winston Salem, NC 27103 USA.		Prough, Donald S/G-5793-2013	Prough, Donald S/0000-0001-7994-532X; Lyeth, Bruce/0000-0003-4811-1474	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS 19355, NS 19550]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS019355, R01NS019550] Funding Source: NIH RePORTER	The authors thank Ms. Jacqui Gunter and Mr. Larry Olneac for their expert technical assistance. We also thank Ms. Susan Margitic for her editorial comments and Ms. Vicky Cranfill and Ms. Debra Richards for their help in typing this manuscript. This research was funded by grants NS 19355 and NS 19550 from the NIH.	ALTURA BM, 1976, FED PROC, V35, P2360; BIRKLE DL, 1987, J NEUROCHEM, V48, P1768, DOI 10.1111/j.1471-4159.1987.tb05735.x; BRITTAIN RT, 1985, CIRCULATION, V72, P1208, DOI 10.1161/01.CIR.72.6.1208; DEGEORGE JJ, 1986, J BIOL CHEM, V261, P3428; DEMOPOULOS HB, 1980, ACTA PHYSIOL SCAND, P91; DEMOPOULOS HB, 1973, FED PROC, V32, P1903; DEMPSEY RJ, 1986, J NEUROSURG, V64, P118, DOI 10.3171/jns.1986.64.1.0118; DeWitt D.S., 1988, SOC NEUR ABSTR, V14, P691; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DUBOCOVICH ML, 1975, J PHYSIOL-LONDON, V251, P737, DOI 10.1113/jphysiol.1975.sp011119; ELLIS EF, 1981, J NEUROCHEM, V37, P892, DOI 10.1111/j.1471-4159.1981.tb04476.x; ELLIS EF, 1977, STROKE, V8, P480, DOI 10.1161/01.STR.8.4.480; FLAMM ES, 1978, STROKE, V9, P445, DOI 10.1161/01.STR.9.5.445; FOLCO GC, 1977, PROSTAG OTH LIPID M, V13, P893, DOI 10.1016/0090-6980(77)90218-0; Frame M.H., 1976, ADV PROSTAGLANDIN TH; GARCIASZABO RR, 1983, CIRC RES, V53, P214, DOI 10.1161/01.RES.53.2.214; GREENBERG RP, 1981, SURG FORUM, V32, P492; GRICE SC, 1987, STROKE, V18, P787, DOI 10.1161/01.STR.18.4.787; HAGEN AA, 1979, STROKE, V10, P306, DOI 10.1161/01.STR.10.3.306; HALES CA, 1981, J CLIN INVEST, V68, P497, DOI 10.1172/JCI110281; HAMAMDZIC M, 1977, AM J PHYSIOL, V232, pE201; Hayes R L, 1986, Cent Nerv Syst Trauma, V3, P163; Hayes R.L., 1987, J CEREB BLOOD FLO S1, V7, pS636; HAYES RL, 1984, SCIENCE, V223, P301, DOI 10.1126/science.6701514; HEDQVIST P, 1970, LIFE SCI, V9, P269, DOI 10.1016/0024-3205(70)90028-7; HORTON EW, 1964, BRIT J PHARM CHEMOTH, V22, P189, DOI 10.1111/j.1476-5381.1964.tb01558.x; Hutlemeirer P.C., 1982, CIRC RES, V50, P688; KATOAKA K, 1967, SCIENCE, V157, P1187; KELLER M, 1985, NEUROCHEM INT, V7, P655, DOI 10.1016/0197-0186(85)90063-4; KEMPSKI O, 1987, STROKE, V18, P111, DOI 10.1161/01.STR.18.1.111; KOCHANEK PM, 1987, STROKE, V18, P634, DOI 10.1161/01.STR.18.3.634; Kontos H.A., 1980, CEREBRAL MICROVASCUL; KONTOS HA, 1985, CIRC RES, V57, P142, DOI 10.1161/01.RES.57.1.142; KONTOS HA, 1981, FED PROC, V40, P2326; KONTOS HA, 1980, SCIENCE, V209, P1242, DOI 10.1126/science.7403881; KONTOS HA, 1984, CIRC RES, V55, P295, DOI 10.1161/01.RES.55.3.295; Langfitt T W, 1981, Prog Neurol Surg, V10, P14, DOI 10.1159/000384767; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; LYETH BG, 1988, BRAIN RES, V448, P88, DOI 10.1016/0006-8993(88)91104-3; LYETH BG, 1988, BRAIN RES, V452, P39, DOI 10.1016/0006-8993(88)90006-6; MACKENZIE ET, 1976, AM J PHYSIOL, V231, P483; MALIK KU, 1975, CIRC RES, V36, P599, DOI 10.1161/01.RES.36.5.599; MCCOSH EJ, 1976, PROSTAGLANDINS, V12, P471, DOI 10.1016/0090-6980(76)90028-9; MENT LR, 1986, J NEUROSURG, V65, P851, DOI 10.3171/jns.1986.65.6.0851; MONCADA S, 1979, NEW ENGL J MED, V300, P1142, DOI 10.1056/NEJM197905173002006; MOSKOWITZ MA, 1981, STROKE, V12, P696; MOUFARRIJ NA, 1984, J NEUROSURG, V61, P1107, DOI 10.3171/jns.1984.61.6.1107; MURPHY S, 1985, NEUROSCI LETT, V61, P61, DOI 10.1016/0304-3940(85)90401-X; Nilsson B., 1977, J NEUROSURG, V47; PAPPIUS HM, 1983, NEUROCHEM RES, V8, P63, DOI 10.1007/BF00965654; Pickard J.D, 1987, J CEREB BLOOD FLOW M, V1, P361; PICKARD JD, 1977, EUR J PHARMACOL, V43, P343, DOI 10.1016/0014-2999(77)90040-1; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; PROUGH DS, 1986, STROKE, V17, P1272, DOI 10.1161/01.STR.17.6.1272; REICHMAN M, 1987, J NEUROCHEM, V49, P1216, DOI 10.1111/j.1471-4159.1987.tb10013.x; ROSNER MJ, 1985, CENTRAL NERVOUS SYST, P405; SAEEDABDELHALIM M, 1980, J NEUROCHEM, V34, P1331, DOI 10.1111/j.1471-4159.1980.tb09980.x; SAIJA A, 1988, BRAIN RES, V452, P303, DOI 10.1016/0006-8993(88)90034-0; SHOHAMI E, 1987, J CEREBR BLOOD F MET, V7, P58, DOI 10.1038/jcbfm.1987.8; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; WEI EP, 1982, J NEUROSURG, V56, P695, DOI 10.3171/jns.1982.56.5.0695; WOLFE LS, 1982, J NEUROCHEM, V38, P1, DOI 10.1111/j.1471-4159.1982.tb10847.x; WOLFE LS, 1976, BIOCHEM BIOPH RES CO, V70, P907, DOI 10.1016/0006-291X(76)90677-X; Wonders T.R., 1987, T AM SOC ART INT ORG, V276, P276; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; YAMAKAMI I, 1987, Society for Neuroscience Abstracts, V13, P1501; YUAN X Q, 1988, Anesthesiology (Hagerstown), V69, pA538, DOI 10.1097/00000542-198809010-00538	68	80	80	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma		1988	5	4					303	U72		10.1089/neu.1988.5.303			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	V21VO	WOS:000208235300004	3249309				2021-06-18	
J	VINK, R; MCINTOSH, TK; DEMEDIUK, P; FADEN, AI				VINK, R; MCINTOSH, TK; DEMEDIUK, P; FADEN, AI			DECREASE IN TOTAL AND FREE MAGNESIUM CONCENTRATION FOLLOWING TRAUMATIC BRAIN INJURY IN RATS	BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS			English	Article									VET ADM MED CTR,SAN FRANCISCO,CA 94121	VINK, R (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT NEUROL,CTR NEURAL INJURY,SAN FRANCISCO,CA 94143, USA.		AM, Robert Vink/S-5616-2019; Vink, Robert/J-7351-2012	AM, Robert Vink/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [902269] Funding Source: Medline		BECKER GL, 1980, BIOCHIM BIOPHYS ACTA, V591, P234, DOI 10.1016/0005-2728(80)90155-3; CHOI DW, 1987, J NEUROSCI, V7, P369; COOPER PR, 1985, NIH CENTRAL NERVOUS, P217; CORKEY BE, 1986, J BIOL CHEM, V261, P2567; EBEL H, 1980, J CLIN CHEM CLIN BIO, V18, P257; FADEN AI, 1986, ARCH NEUROL-CHICAGO, V43, P501, DOI 10.1001/archneur.1986.00520050073026; GARFINKEL L, 1985, Magnesium, V4, P60; GUPTA RK, 1984, ANNU REV BIOPHYS BIO, V13, P221; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; KUSHMERICK MJ, 1986, J BIOL CHEM, V261, P4420; LAWSON JWR, 1979, J BIOL CHEM, V254, P6528; MALLOY CR, 1986, BIOCHIM BIOPHYS ACTA, V885, P1, DOI 10.1016/0167-4889(86)90032-7; MCINTOSH TK, 1987, J NEUROCHEM, V49, P1530; NILSSON B, 1985, NIH CENTRAL NERVOUS, P425; PRICHARD JW, 1986, ANNU REV NEUROSCI, V9, P61; ROSNER MJ, 1984, J NEUROSURG, V60, P961, DOI 10.3171/jns.1984.60.5.0961; SIESJO BK, 1985, NIH CENTRAL NERVOUS, P513; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; VINK R, 1987, IN PRESS MAGN RESON; YANG MS, 1985, J NEUROSURG, V63, P617, DOI 10.3171/jns.1985.63.4.0617	20	80	80	0	1	ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495	0006-291X			BIOCHEM BIOPH RES CO	Biochem. Biophys. Res. Commun.	DEC 16	1987	149	2					594	599		10.1016/0006-291X(87)90409-8			6	Biochemistry & Molecular Biology; Biophysics	Biochemistry & Molecular Biology; Biophysics	L2618	WOS:A1987L261800041	3426591				2021-06-18	
J	ELSASS, L; KINSELLA, G				ELSASS, L; KINSELLA, G			SOCIAL-INTERACTION FOLLOWING SEVERE CLOSED HEAD-INJURY	PSYCHOLOGICAL MEDICINE			English	Article									LA TROBE UNIV, DEPT PSYCHOL, BUNDOORA, VIC 3083, AUSTRALIA			Kinsella, Glynda/O-6347-2017	Kinsella, Glynda/0000-0002-5859-0934			BLYTH B, 1981, NEW ZEAL MED J, V93, P267; Bond M R, 1975, Ciba Found Symp, P141; BOND MR, 1976, SCAND J REHABIL MED, V8, P127; BROWN GW, 1975, SOCIOLOGY, V9, P225, DOI 10.1177/003803857500900203; Goldberg DP., 1972, DETECTION PSYCHIATRI; HAYS WL, 1973, STATISTICS SOCIAL SC; HENDERSON S, 1978, BRIT J PSYCHIAT, V132, P74, DOI 10.1192/S0007125000283001; HENDERSON S, 1978, BRIT J PSYCHIAT, V132, P463, DOI 10.1192/bjp.132.5.463; HENDERSON S, 1977, BRIT J PSYCHIAT, V131, P185, DOI 10.1192/bjp.131.2.185; HENDERSON S, 1977, NEUROSIS SOCIAL ENV; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; LISHMAN WA, 1973, PSYCHOL MED, V3, P304, DOI 10.1017/S003329170004959X; MILLER PM, 1976, SOC PSYCHIATR, V11, P51, DOI 10.1007/BF00578738; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; ROMANO MD, 1974, SCAND J REHABIL MED, V6, P1; SKEIKH K, 1979, INT REHABILITATION M, V1, P51; TENNANT C, 1977, MED J AUSTRALIA, V2, P392, DOI 10.5694/j.1326-5377.1977.tb114568.x; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019	20	80	80	0	5	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	0033-2917	1469-8978		PSYCHOL MED	Psychol. Med.	FEB	1987	17	1					67	78		10.1017/S003329170001299X			12	Psychology, Clinical; Psychiatry; Psychology	Psychology; Psychiatry	G6283	WOS:A1987G628300009	3575579				2021-06-18	
J	Pinto, NP; Rhinesmith, EW; Kim, TY; Ladner, PH; Pollack, MM				Pinto, Neethi P.; Rhinesmith, Elizabeth W.; Kim, Tae Yeon; Ladner, Peter H.; Pollack, Murray M.			Long-Term Function After Pediatric Critical Illness: Results From the Survivor Outcomes Study	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						critical care outcomes; critical illness/mortality; intensive care units; morbidity; outcome assessment (health care)/methods; pediatric; survivors	QUALITY-OF-LIFE; INTENSIVE-CARE-UNIT; TRAUMATIC BRAIN-INJURY; STATUS SCALE; CHILDREN; MORTALITY; ADMISSION; STAY	Objective: Knowledge of the long-term outcomes of survivors of pediatric critical illness is sparse but important. The aim of this study was to evaluate morbidity and mortality 6 months and 3 years after hospital discharge. Design: Prospective cohort study. Setting: Urban, inner city, academic PICU. Patients: Consecutive patients admitted to the PICU from June 2012 to August 2012. Interventions: None. Measurements and Main Results: We collected descriptive and demographic information and functional status assessments at baseline, admission, hospital discharge, 6 months and 3 years following discharge. Functional status was measured with the Functional Status Scale. New morbidity was defined as a change in Functional Status Scale score of greater than or equal to 3. Post-discharge assessments utilized scripted telephone surveys. Of 303 consecutive PICU patients, 253 were eligible and 129 parents consented. Follow-up outcomes were obtained for 77 patients (59.7%) at 6 months and 70 of these patients (54.2%) at 3 years. Both mortality and morbidity increased after discharge. Cumulative mortality increased from 3.9% (n = 3) at discharge to 7.8% (n = 6) at 6 months (p = 0.08) and 10.4% (n = 8) at 3 years (p = 0.03). New morbidity increased cumulatively from 5.2% (n = 4) at discharge to 6.5% (n = 5) at 6 months (p = 0.65) and 10.4% (n = 8) at 3 years (p = 0.16). Almost as many children demonstrated worsening of their functional status or died (38%) as children who survived without a change in functional status (44%). Less than 10% of children exhibited functional gains over time. Long-term functional outcome was associated with PICU variables including the need for invasive therapies and indicators of severity of illness such as use of mechanical ventilation, ventilator days, use of vasoactive medications, and PICU length of stay. The combined poor outcomes of new morbidity and mortality increased cumulatively from 9.1% (n = 7) at discharge to 14.3% (n = 11) at 6 months (p = 0.16) and 20.8% (n = 16) by 3 years (p = 0.01). Conclusions: Mortality and new morbidity appear to substantially increase after discharge. Critical illness is associated with a sustained impact on survival and functional status.	[Pinto, Neethi P.] Univ Chicago, Dept Pediat, Chicago, IL 60637 USA; [Rhinesmith, Elizabeth W.; Pollack, Murray M.] Childrens Natl Med Ctr, Dept Pediat, Washington, DC 20010 USA; [Kim, Tae Yeon; Ladner, Peter H.] Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA	Pinto, NP (corresponding author), 5841 S Maryland Ave,MC 1145, Chicago, IL 60637 USA.	npinto@peds.bsd.uchicago.edu			University of Chicago Bucksbaum Institute for Clinical Excellence; Pritzker School of Medicine	Dr. Pinto, Dr. Rhinesmith, Ms. Kim, and Mr. Ladner received grants to support this work from The University of Chicago Bucksbaum Institute for Clinical Excellence. Dr. Rhinesmith and Mr. Ladner were supported by the Pritzker School of Medicine Summer Research Program.	Ambuehl J, 2007, SWISS MED WKLY, V137, P312; Aspesberro F, 2015, INTENS CARE MED, V41, P1235, DOI 10.1007/s00134-015-3780-7; Bennett TD, 2015, PEDIATR CRIT CARE ME, V16, P377, DOI 10.1097/PCC.0000000000000380; BUTT W, 1990, CRIT CARE MED, V18, P961, DOI 10.1097/00003246-199009000-00011; Buysse CMP, 2008, CRIT CARE MED, V36, P596, DOI 10.1097/01.CCM.0000299740.65484.CA; Choong K, 2015, PEDIATR CRIT CARE ME, V16, P310, DOI 10.1097/PCC.0000000000000362; Colville GA, 2013, PEDIATR CRIT CARE ME, V14, pE85, DOI 10.1097/PCC.0b013e3182712997; Conlon NP, 2009, PEDIATR CRIT CARE ME, V10, P41, DOI 10.1097/PCC.0b013e31819371f6; Cunha F, 2013, PEDIATR CRIT CARE ME, V14, pE8, DOI 10.1097/PCC.0b013e31826012b4; de Mos N, 2006, CRIT CARE MED, V34, P1209, DOI 10.1097/01.CCM.0000208440.66756.C2; Ebrahim S, 2013, PEDIATR CRIT CARE ME, V14, P10, DOI 10.1097/PCC.0b013e31825b64b3; Epstein D, 2005, PEDIATR RES, V58, P987, DOI 10.1203/01.PDR.0000182822.16263.3D; Farris RWD, 2013, PEDIATR CRIT CARE ME, V14, P835, DOI 10.1097/PCC.0b013e3182a551c8; Jones S, 2006, PEDIATRICS, V118, P2101, DOI 10.1542/peds.2006-1455; Keenan HT, 2006, PEDIATRICS, V117, P317, DOI 10.1542/peds.2005-0979; Knoester H, 2008, INTENS CARE MED, V34, P1076, DOI 10.1007/s00134-008-1061-4; Knoester H, 2008, HEALTH QUAL LIFE OUT, V6, DOI 10.1186/1477-7525-6-21; Morrison Anne L, 2002, Pediatr Crit Care Med, V3, P1, DOI 10.1097/00130478-200201000-00001; Namachivayam P, 2012, PEDIATR CRIT CARE ME, V13, P520, DOI 10.1097/PCC.0b013e31824fb989; Namachivayam P, 2010, PEDIATR CRIT CARE ME, V11, P549, DOI 10.1097/PCC.0b013e3181ce7427; Namachivayam SP, 2015, CRIT CARE MED, V43, P1978, DOI 10.1097/CCM.0000000000001076; Nicholson Carol E, 2003, Pediatr Crit Care Med, V4, P196, DOI 10.1097/01.PCC.0000059728.63798.DA; Ong C, 2016, PEDIATR CRIT CARE ME, V17, pE247, DOI 10.1097/PCC.0000000000000706; Polic B, 2013, EUR J PEDIATR, V172, P85, DOI 10.1007/s00431-012-1843-0; POLLACK MM, 1994, JAMA-J AM MED ASSOC, V272, P941, DOI 10.1001/jama.272.12.941; Pollack MM, 1997, CRIT CARE MED, V25, P1637, DOI 10.1097/00003246-199710000-00011; Pollack MM, 2015, CRIT CARE MED, V43, P1699, DOI 10.1097/CCM.0000000000001081; Pollack MM, 2014, PEDIATR CRIT CARE ME, V15, P821, DOI 10.1097/PCC.0000000000000250; Pollack MM, 2014, JAMA PEDIATR, V168, P671, DOI 10.1001/jamapediatrics.2013.5316; Pollack MM, 2009, PEDIATRICS, V124, pE18, DOI 10.1542/peds.2008-1987; Quasney MW, 2015, PEDIATR CRIT CARE ME, V16, pS118, DOI 10.1097/PCC.0000000000000438; Rivara JB, 1996, ARCH PHYS MED REHAB, V77, P754, DOI 10.1016/S0003-9993(96)90253-1; Simpson Amelia J, 2012, Int J Crit Illn Inj Sci, V2, P149, DOI 10.4103/2229-5151.100893; Taylor A, 2003, INTENS CARE MED, V29, P795, DOI 10.1007/s00134-003-1690-6; Tilford JM, 1998, CRIT CARE MED, V26, P1737, DOI 10.1097/00003246-199810000-00032; van der Heide P, 2004, ACTA PAEDIATR, V93, P1070, DOI 10.1080/08035250410027580; Winthrop AL, 2005, J TRAUMA, V58, P468, DOI 10.1097/01.TA.0000153940.23471.B7	37	79	80	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1529-7535	1947-3893		PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	MAR	2017	18	3					E122	E130		10.1097/PCC.0000000000001070			9	Critical Care Medicine; Pediatrics	General & Internal Medicine; Pediatrics	FH4SG	WOS:000411150600003	28107265				2021-06-18	
J	Cantu, D; Walker, K; Andresen, L; Taylor-Weiner, A; Hampton, D; Tesco, G; Dulla, CG				Cantu, David; Walker, Kendall; Andresen, Lauren; Taylor-Weiner, Amaro; Hampton, David; Tesco, Giuseppina; Dulla, Chris G.			Traumatic Brain Injury Increases Cortical Glutamate Network Activity by Compromising GABAergic Control	CEREBRAL CORTEX			English	Article						cortical hyperexcitability; epilepsy; glutamate signaling; network reorganization; traumatic brain injury	CALCIUM-BINDING PROTEINS; GAMMA-AMINOBUTYRIC-ACID; HEAD-INJURY; POSTTRAUMATIC EPILEPSY; MITOCHONDRIAL DYSFUNCTION; EPILEPTIFORM DISCHARGES; SYNAPTIC INPUT; VISUAL-CORTEX; DENTATE GYRUS; IMPACT INJURY	Traumatic brain injury (TBI) is a major risk factor for developing pharmaco-resistant epilepsy. Although disruptions in brain circuitry are associated with TBI, the precise mechanisms by which brain injury leads to epileptiform network activity is unknown. Using controlled cortical impact (CCI) as a model of TBI, we examined how cortical excitability and glutamatergic signaling was altered following injury. We optically mapped cortical glutamate signaling using FRET-based glutamate biosensors, while simultaneously recording cortical field potentials in acute brain slices 2-4 weeks following CCI. Cortical electrical stimulation evoked polyphasic, epileptiform field potentials and disrupted the input-output relationship in deep layers of CCI-injured cortex. High-speed glutamate biosensor imaging showed that glutamate signaling was significantly increased in the injured cortex. Elevated glutamate responses correlated with epileptiform activity, were highest directly adjacent to the injury, and spread via deep cortical layers. Immunoreactivity for markers of GABAergic inter-neurons were significantly decreased throughout CCI cortex. Lastly, spontaneous inhibitory postsynaptic current frequency decreased and spontaneous excitatory postsynaptic current increased after CCI injury. Our results suggest that specific cortical neuronal microcircuits may initiate and facilitate the spread of epileptiform activity following TBI. Increased glutamatergic signaling due to loss of GABAergic control may provide a mechanism by which TBI can give rise to post-traumatic epilepsy.	[Cantu, David; Andresen, Lauren; Taylor-Weiner, Amaro; Hampton, David; Dulla, Chris G.] Tufts Univ, Sch Med, Dept Neurosci, Boston, MA 02111 USA; [Walker, Kendall; Tesco, Giuseppina] Tufts Univ, Sch Med, Alzheimers Dis Res Lab, Dept Neurosci, Boston, MA 02111 USA; [Andresen, Lauren] Tufts Univ, Sackler Sch Biomed Sci, Program Neurosci, Boston, MA 02111 USA	Dulla, CG (corresponding author), Tufts Univ, Sch Med, Dept Neurosci, 136 Harrison Ave,SC203, Boston, MA 02111 USA.	chris.dulla@tufts.edu		Lau, Lauren/0000-0003-3312-183X	Epilepsy Foundation; National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS076885]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K12GM074869]; National Institute On AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG033016]; Cure Alzheimer's Fund; Tufts Center for Neuroscience Research [P30 NS047243]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [K12GM074869] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS047243, R01NS076885] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG033016] Funding Source: NIH RePORTER	This work was supported by the Epilepsy Foundation (C.D.), National Institute of Neurological Disorders and Stroke (R01-NS076885) (C.D.), the NIH (K12GM074869) (D.C.), National Institute On Aging (R01AG033016) (G.T.), Cure Alzheimer's Fund (G.T.), and Tufts Center for Neuroscience Research (P30 NS047243).	Anderson CM, 2000, GLIA, V32, P1; Andriessen TMJC, 2010, J CELL MOL MED, V14, P2381, DOI 10.1111/j.1582-4934.2010.01164.x; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Asikainen I, 1999, EPILEPSIA, V40, P584, DOI 10.1111/j.1528-1157.1999.tb05560.x; Bolkvadze T, 2012, J NEUROTRAUM, V29, P789, DOI 10.1089/neu.2011.1954; Brill J, 2010, CEREB CORTEX, V20, P2926, DOI 10.1093/cercor/bhq040; Buckmaster PS, 2002, J NEUROSCI, V22, P6650; Buckmaster PS, 1999, J NEUROSCI, V19, P9519; Buritica E, 2009, J NEUROTRAUM, V26, P2145, DOI 10.1089/neu.2009.0894; Card JP, 2005, J NEUROTRAUM, V22, P989, DOI 10.1089/neu.2005.22.989; Cavus I, 2005, ANN NEUROL, V57, P226, DOI 10.1002/ana.20380; CELIO MR, 1986, SCIENCE, V231, P995, DOI 10.1126/science.3945815; Chamoun R, 2010, J NEUROSURG, V113, P564, DOI 10.3171/2009.12.JNS09689; Cline H, 2008, J PHYSIOL-LONDON, V586, P1509, DOI 10.1113/jphysiol.2007.150029; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Cossart R, 2001, NAT NEUROSCI, V4, P52; COWAN RL, 1990, J COMP NEUROL, V302, P197, DOI 10.1002/cne.903020202; D'Ambrosio R, 2013, ANN NEUROL, V73, P199, DOI 10.1002/ana.23764; d'Avila JC, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-31; Ding MC, 2011, J NEUROSCI, V31, P14085, DOI 10.1523/JNEUROSCI.3572-11.2011; Dulla CG, 2013, NEUROBIOL DIS, V49, P232, DOI 10.1016/j.nbd.2012.09.001; Dulla C, 2008, J NEUROSCI METH, V168, P306, DOI 10.1016/j.jneumeth.2007.10.017; FAN L, 1995, MOL BRAIN RES, V30, P125; Folkersma H, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-67; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Frugier T, 2010, J NEUROTRAUM, V27, P497, DOI 10.1089/neu.2009.1120; GLEZER II, 1993, CEREB CORTEX, V3, P249, DOI 10.1093/cercor/3.3.249; Goldshmit Y, 2010, NEUROSCIENCE, V166, P886, DOI 10.1016/j.neuroscience.2009.12.039; Helmy A, 2011, PROG NEUROBIOL, V95, P352, DOI 10.1016/j.pneurobio.2011.09.003; Hof PR, 1999, J CHEM NEUROANAT, V16, P77, DOI 10.1016/S0891-0618(98)00065-9; Holmseth S, 2009, NEUROSCIENCE, V162, P1055, DOI 10.1016/j.neuroscience.2009.03.048; Houser CR, 1996, EPILEPSY RES, V26, P207, DOI 10.1016/S0920-1211(96)00054-X; Hunt RF, 2012, EPILEPSY RES, V99, P167, DOI 10.1016/j.eplepsyres.2011.10.011; Hunt RF, 2009, EXP NEUROL, V215, P243, DOI 10.1016/j.expneurol.2008.10.005; Khan M, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-78; Kochanek PM, 2006, J CEREBR BLOOD F MET, V26, P565, DOI 10.1038/sj.jcbfm.9600218; Krajewska M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024341; Kwon HB, 2011, NATURE, V474, P100, DOI 10.1038/nature09986; Larner SF, 2005, J NEUROCHEM, V94, P97, DOI 10.1111/j.1471-4159.2005.03172.x; Li HF, 2012, NEUROBIOL DIS, V48, P429, DOI 10.1016/j.nbd.2012.06.019; LIGHTHALL J W, 1989, Journal of Neurotrauma, V6, P83, DOI 10.1089/neu.1989.6.83; Lowenstein DH, 2009, EPILEPSIA, V50, P4, DOI 10.1111/j.1528-1167.2008.02004.x; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Ma YY, 2012, NEUROBIOL DIS, V47, P102, DOI 10.1016/j.nbd.2012.03.027; Mannix RC, 2011, J CEREBR BLOOD F MET, V31, P351, DOI 10.1038/jcbfm.2010.99; MIENVILLE JM, 1987, NEUROPHARMACOLOGY, V26, P779, DOI 10.1016/0028-3908(87)90242-5; Mtchedlishvili Z, 2010, NEUROBIOL DIS, V38, P464, DOI 10.1016/j.nbd.2010.03.012; NILSSON P, 1994, BRAIN RES, V637, P227, DOI 10.1016/0006-8993(94)91237-8; Nishibe M, 2010, J NEUROTRAUM, V27, P2221, DOI 10.1089/neu.2010.1456; OBENAUS A, 1993, J NEUROSCI, V13, P4470; Pan JW, 2008, EPILEPSIA, V49, P31, DOI 10.1111/j.1528-1167.2008.01508.x; Paolin A, 2002, NEUROSURGERY, V51, P949, DOI 10.1227/01.NEU.0000027881.33381.3F; Pavlov I, 2011, NEUROSCIENCE, V194, P208, DOI 10.1016/j.neuroscience.2011.07.074; Pratico D, 2002, J NEUROCHEM, V80, P894, DOI 10.1046/j.0022-3042.2002.00777.x; Rao VLR, 1998, J NEUROCHEM, V70, P2020; Readnower RD, 2011, J NEUROTRAUM, V28, P1845, DOI 10.1089/neu.2011.1755; Rudy B, 2011, DEV NEUROBIOL, V71, P45, DOI 10.1002/dneu.20853; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; Scimemi A, 2009, J NEUROSCI, V29, P14581, DOI 10.1523/JNEUROSCI.4845-09.2009; Stafstrom CE, 2008, EPILEPSIA, V49, P97, DOI 10.1111/j.1528-1167.2008.01848.x; Statler KD, 2009, EPILEPSY RES, V86, P221, DOI 10.1016/j.eplepsyres.2009.05.006; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; Tani H, 2010, J NEUROSCI, V30, P1288, DOI 10.1523/JNEUROSCI.0106-09.2010; Telfeian AE, 1998, EPILEPSIA, V39, P700, DOI 10.1111/j.1528-1157.1998.tb01154.x; VANBREDERODE JFM, 1990, J COMP NEUROL, V298, P1, DOI 10.1002/cne.902980102; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; Walker KR, 2012, J NEUROSCI, V32, P10423, DOI 10.1523/JNEUROSCI.5491-11.2012; Ward JL, 2011, J TRAUMA, V70, P1471, DOI 10.1097/TA.0b013e31821c38bd; Xiong Y, 1998, J NEUROTRAUM, V15, P531, DOI 10.1089/neu.1998.15.531; Yang L, 2007, J NEUROPHYSIOL, V97, P178, DOI 10.1152/jn.01374.2005; Yang L, 2010, J NEUROTRAUM, V27, P1541, DOI 10.1089/neu.2009.1244; Yokobori S, 2013, CNS NEUROL DISORD-DR, V12, P1; Zhou HZ, 2012, J NEUROPATH EXP NEUR, V71, P348, DOI 10.1097/NEN.0b013e31824ea078; Zou HC, 2013, NEUROREHAB NEURAL RE, V27, P878, DOI 10.1177/1545968313491007	75	79	81	1	17	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	1047-3211	1460-2199		CEREB CORTEX	Cereb. Cortex	AUG	2015	25	8					2306	2320		10.1093/cercor/bhu041			15	Neurosciences	Neurosciences & Neurology	CO7DU	WOS:000359320000026	24610117	Green Published, Bronze			2021-06-18	
J	Kuhle, J; Gaiottino, J; Leppert, D; Petzold, A; Bestwick, JP; Malaspina, A; Lu, CH; Dobson, R; Disanto, G; Norgren, N; Nissim, A; Kappos, L; Hurlbert, J; Yong, VW; Giovannoni, G; Casha, S				Kuhle, Jens; Gaiottino, Johanna; Leppert, David; Petzold, Axel; Bestwick, Jonathan P.; Malaspina, Andrea; Lu, Ching-Hua; Dobson, Ruth; Disanto, Giulio; Norgren, Niklas; Nissim, Ahuva; Kappos, Ludwig; Hurlbert, John; Yong, V. Wee; Giovannoni, Gavin; Casha, Steven			Serum neurofilament light chain is a biomarker of human spinal cord injury severity and outcome	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							TRAUMATIC BRAIN-INJURY; NF-H; CEREBROSPINAL-FLUID; AXONAL INJURY; MINOCYCLINE; RECOVERY; PHOSPHOFORMS; DEGENERATION; MARKERS; TRIALS	Background Neurofilaments (Nf) are major structural proteins that occur exclusively in neurons. In spinal cord injury (SCI), the severity of disease is quantified by clinical measures that have limited sensitivity and reliability, and no blood-based biomarker has been established to further stratify the degree of injury. We aimed to examine a serum-based NfL immunoassay as predictor of the clinical outcome in SCI. Methods Longitudinal measurement of serum NfL was performed in patients with central cord syndrome (CCS, n=4), motor-incomplete SCI (iSCI, n=10), motor-complete SCI (cSCI, n=13) and healthy controls (HC, n=67), and correlated with clinical severity, neurological outcome, and neuroprotective effect of the drug minocycline. Results Baseline NfL levels were higher in iSCI (21 pg/mL) and cSCI (70 pg/mL) than in HC (5 pg/mL, p=0.006 and p<0.001) and CCS (6 pg/mL, p=0.025 and p=0.010). Levels increased over time (p<0.001) and remained higher in cSCI versus iSCI (p=0.011) and than in CCS (p<0.001). NfL levels correlated with American Spinal Injury Association (ASIA) motor score at baseline (r=-0.53, p=0.004) and after 24 h (r=-0.69, p<0.001) and 3-12-month motor outcome (baseline NfL: r=-0.43, p=0.026 and 24 h NfL: r=-0.72, p<0.001). Minocycline treatment showed decreased NfL levels in the subgroup of cSCI patients. Conclusions Serum NfL concentrations in SCI patients show a close correlation with acute severity and neurological outcome. Our data provide evidence that serum NfL is of prognostic value in SCI patients for the first time. Further, blood NfL levels may qualify as drug response markers in SCI.	[Kuhle, Jens; Gaiottino, Johanna; Malaspina, Andrea; Lu, Ching-Hua; Dobson, Ruth; Disanto, Giulio; Giovannoni, Gavin] Queen Mary Univ London, Barts & London Sch Med & Dent, Blizard Inst, London, England; [Kuhle, Jens; Leppert, David; Kappos, Ludwig] Univ Basel Hosp, CH-4031 Basel, Switzerland; [Petzold, Axel] UCL Inst Neurol, Dept Mol Neurosci, London, England; [Bestwick, Jonathan P.] Queen Mary Univ London, Barts & London Sch Med & Dent, Wolfson Inst Prevent Med, London, England; [Malaspina, Andrea] North East London & Essex Reg MND Care Ctr, London, England; [Norgren, Niklas] UmanDiagnostics, Umea, Sweden; [Nissim, Ahuva] Queen Mary Univ London, John Vane Sci Ctr, London, England; [Hurlbert, John; Yong, V. Wee; Casha, Steven] Univ Calgary, Dept Clin Neurosci, Calgary, AB, Canada; [Hurlbert, John; Yong, V. Wee; Casha, Steven] Univ Calgary, Hotchkiss Brain Inst, Calgary, AB, Canada	Kuhle, J (corresponding author), Queen Mary Univ London, Barts & London Sch Med & Dent, Blizard Inst, 4 Newark St, London, England.	j.kuhle@qmul.ac.uk	Petzold, Axel/C-1090-2009	Petzold, Axel/0000-0002-0344-9749	GenzymeSanofi-AventisGenzyme Corporation; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [MR/J002747/1] Funding Source: researchfish	This study was supported by an unrestricted grant from Genzyme and institutional funding. The study sponsors had no involvement in the study design; in the collection, analysis and interpretation of the data; in the writing of the report; and in the decision to submit the paper for publication.	Casha S, 2012, BRAIN, V135, P1224, DOI 10.1093/brain/aws072; Charlifue SB, 2004, J SPINAL CORD MED, V27, P151; Courtine G, 2007, NAT MED, V13, P561, DOI 10.1038/nm1595; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; DITUNNO JF, 1994, PARAPLEGIA, V32, P70, DOI 10.1038/sc.1994.13; Fawcett JW, 2007, SPINAL CORD, V45, P190, DOI 10.1038/sj.sc.3102007; Fawcett JW, 2006, CLIN MED, V6, P598, DOI 10.7861/clinmedicine.6-6-598; Fehlings MG, 2005, INJURY, V36, P113, DOI 10.1016/j.injury.2005.06.022; Festoff BW, 2006, J NEUROCHEM, V97, P1314, DOI 10.1111/j.1471-4159.2006.03799.x; Gaiottino J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075091; Geisler FH, 2001, SPINE, V26, pS87, DOI 10.1097/00007632-200112151-00015; Guez M, 2003, J NEUROTRAUM, V20, P853, DOI 10.1089/089771503322385782; Harrop James S, 2006, Spine J, V6, p198S, DOI 10.1016/j.spinee.2006.04.006; Hayakawa K, 2012, SPINAL CORD, V50, P493, DOI 10.1038/sc.2011.184; Kuhle Jens, 2011, Expert Opin Med Diagn, V5, P333, DOI 10.1517/17530059.2011.578624; Kwon Brian K, 2004, Spine J, V4, P451, DOI 10.1016/j.spinee.2003.07.007; Kwon BK, 2011, CLIN CHEM LAB MED, V49, P425, DOI 10.1515/CCLM.2011.068; Lee SM, 2003, J NEUROTRAUM, V20, P1017, DOI 10.1089/089771503770195867; Maier IC, 2006, PHILOS T R SOC B, V361, P1611, DOI 10.1098/rstb.2006.1890; Petzold A, 2005, J NEUROL SCI, V233, P183, DOI 10.1016/j.jns.2005.03.015; Petzold A, 2003, J IMMUNOL METHODS, V278, P179, DOI 10.1016/S0022-1759(03)00189-3; Petzold A, 2011, BRAIN, V134, P464, DOI 10.1093/brain/awq360; Popovic N, 2002, ANN NEUROL, V51, P215, DOI 10.1002/ana.10092; Sadowsky C, 2002, DISABIL REHABIL, V24, P680, DOI 10.1080/09638280110110640; Shaw G, 2005, BIOCHEM BIOPH RES CO, V336, P1268, DOI 10.1016/j.bbrc.2005.08.252; Stirling DP, 2004, J NEUROSCI, V24, P2182, DOI 10.1523/JNEUROSCI.5275-03.2004; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Tator CH, 2006, NEUROSURGERY, V59, P957, DOI 10.1227/01.NEU.0000245591.16087.89; Teng YD, 2004, P NATL ACAD SCI USA, V101, P3071, DOI 10.1073/pnas.0306239101; Ueno T, 2011, SPINAL CORD, V49, P333, DOI 10.1038/sc.2010.116; Wells JEA, 2003, BRAIN, V126, P1628, DOI 10.1093/brain/awg178; Yong VW, 2004, LANCET NEUROL, V3, P744, DOI 10.1016/S1474-4422(04)00937-8; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9	33	79	81	0	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	MAR	2015	86	3					273	279		10.1136/jnnp-2013-307454			7	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	CB6EX	WOS:000349720800008					2021-06-18	
J	Hudson, AE; Calderon, DP; Pfaff, DW; Proekt, A				Hudson, Andrew E.; Calderon, Diany Paola; Pfaff, Donald W.; Proekt, Alex			Recovery of consciousness is mediated by a network of discrete metastable activity states	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article						anesthesia; state transitions; spectral analysis; emergence	TRAUMATIC BRAIN-INJURY; GENERAL-ANESTHESIA; MOLECULAR TARGETS; SLEEP; SUPPRESSION; DYNAMICS; AROUSAL; ELECTROENCEPHALOGRAM; POTENTIALS; MECHANISMS	It is not clear how, after a large perturbation, the brain explores the vast space of potential neuronal activity states to recover those compatible with consciousness. Here, we analyze recovery from pharmacologically induced coma to show that neuronal activity en route to consciousness is confined to a low-dimensional subspace. In this subspace, neuronal activity forms discrete metastable states persistent on the scale of minutes. The network of transitions that links these metastable states is structured such that some states form hubs that connect groups of otherwise disconnected states. Although many paths through the network are possible, to ultimately enter the activity state compatible with consciousness, the brain must first pass through these hubs in an orderly fashion. This organization of metastable states, along with dramatic dimensionality reduction, significantly simplifies the task of sampling the parameter space to recover the state consistent with wakefulness on a physiologically relevant timescale.	[Hudson, Andrew E.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Anesthesiol & Perioperat Med, Los Angeles, CA 90095 USA; [Calderon, Diany Paola; Pfaff, Donald W.; Proekt, Alex] Rockefeller Univ, Neurobiol & Behav Lab, New York, NY 10065 USA; [Proekt, Alex] Weill Cornell Med Coll, Dept Anesthesiol, New York, NY 10021 USA	Pfaff, DW (corresponding author), Rockefeller Univ, Neurobiol & Behav Lab, New York, NY 10065 USA.	pfaff@rockefeller.edu; proekt@gmail.com	Hudson, Andrew/B-6152-2016	Hudson, Andrew/0000-0001-7292-5406; Proekt, Alexander/0000-0002-9272-5337	Foundation for Anesthesia Education and Research grant [K08 (GM106144-01)]; American Association of University Women International Fellowship; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [K08GM106144] Funding Source: NIH RePORTER	This work was supported by a Foundation for Anesthesia Education and Research grant and K08 (GM106144-01) awarded to A.P. and an American Association of University Women International Fellowship awarded to D.P.C.	Alkire MT, 2008, SCIENCE, V322, P876, DOI 10.1126/science.1149213; Alkire MT, 2007, ANESTHESIOLOGY, V107, P264, DOI 10.1097/01.anes.0000270741.33766.24; Brown EN, 2010, NEW ENGL J MED, V363, P2638, DOI 10.1056/NEJMra0808281; Clement EA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002004; Destexhe A, 1999, J NEUROSCI, V19, P4595, DOI 10.1523/jneurosci.19-11-04595.1999; Doyle PG, 2000, CARUS MATH MONOGRAPH, V22, P1; Franks NP, 2008, NAT REV NEUROSCI, V9, P370, DOI 10.1038/nrn2372; Friedman EB, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011903; Gervasoni D, 2004, J NEUROSCI, V24, P11137, DOI 10.1523/JNEUROSCI.3524-04.2004; Gibbs FA, 1937, ARCH INTERN MED, V60, P154, DOI 10.1001/archinte.1937.00180010159012; Jones EG, 1998, NEUROSCIENCE, V85, P331, DOI 10.1016/S0306-4522(97)00581-2; Kelz MB, 2008, P NATL ACAD SCI USA, V105, P1309, DOI 10.1073/pnas.0707146105; Lammi MH, 2005, ARCH PHYS MED REHAB, V86, P746, DOI 10.1016/j.apmr.2004.11.004; Langsjo JW, 2012, J NEUROSCI, V32, P4935, DOI 10.1523/JNEUROSCI.4962-11.2012; LEVINTHAL C, 1968, J CHIM PHYS PCB, V65, P44, DOI 10.1051/jcp/1968650044; Lioudyno MI, 2013, J NEUROSCI, V33, P16310, DOI 10.1523/JNEUROSCI.0344-13.2013; Nunez P.L., 2006, ELECT FIELDS BRAIN N, V2nd; OHTAHARA S, 1987, BRAIN DEV-JPN, V9, P371, DOI 10.1016/S0387-7604(87)80110-9; Percival DB, 1993, SPECTRAL ANAL PHYS A; Schiff ND, 2007, NATURE, V448, P600, DOI 10.1038/nature06041; Schiff ND, 2008, ANN NY ACAD SCI, V1129, P105, DOI 10.1196/annals.1417.029; Stecker MM, 2001, ANN THORAC SURG, V71, P14, DOI 10.1016/S0003-4975(00)01592-7; STERIADE M, 1990, ELECTROEN CLIN NEURO, V76, P481, DOI 10.1016/0013-4694(90)90001-Z; STERIADE M, 1993, J NEUROSCI, V13, P3252, DOI 10.1523/jneurosci.13-08-03252.1993; Stratmann G, 2009, ANESTH ANALG, V109, P801, DOI 10.1213/ane.0b013e3181aff364; Strogatz S.H., 1994, NONLINEAR DYNAMICS C; SWANK RL, 1949, J NEUROPHYSIOL, V12, P137; Thomke F, 2002, J CLIN NEUROPHYSIOL, V19, P24; Tuckwell H.C., 1989, STOCHASTIC PROCESSES; Victor JD, 2011, P NATL ACAD SCI USA, V108, P15631, DOI 10.1073/pnas.1012168108; Whitlock EL, 2011, ANESTHESIOLOGY, V115, P1209, DOI 10.1097/ALN.0b013e3182395dcb	31	79	79	0	8	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	JUN 24	2014	111	25					9283	9288		10.1073/pnas.1408296111			6	Multidisciplinary Sciences	Science & Technology - Other Topics	AJ5WJ	WOS:000337760600065	24927558	Bronze, Green Published			2021-06-18	
J	Danielyan, L; Beer-Hammer, S; Stolzing, A; Schafer, R; Siegel, G; Fabian, C; Kahle, P; Biedermann, T; Lourhmati, A; Buadze, M; Novakovic, A; Proksch, B; Gleiter, CH; Frey, WH; Schwab, M				Danielyan, Lusine; Beer-Hammer, Sandra; Stolzing, Alexandra; Schaefer, Richard; Siegel, Georg; Fabian, Claire; Kahle, Philipp; Biedermann, Tilo; Lourhmati, Ali; Buadze, Marine; Novakovic, Ana; Proksch, Barbara; Gleiter, Christoph H.; Frey, William H., II; Schwab, Matthias			Intranasal Delivery of Bone Marrow-Derived Mesenchymal Stem Cells, Macrophages, and Microglia to the Brain in Mouse Models of Alzheimer's and Parkinson's Disease	CELL TRANSPLANTATION			English	Article						Intranasal; Mesenchymal stem cells (MSCs); Macrophages; Alzheimer's disease; Parkinson's disease; Amyloid beta (A beta)	CENTRAL-NERVOUS-SYSTEM; AMYLOID-BETA; ALPHA-SYNUCLEIN; RAT MODEL; ERYTHROPOIETIN RECEPTOR; DOPAMINERGIC-NEURONS; COGNITIVE FUNCTIONS; IMMUNE-RESPONSE; TRANSGENIC MICE; STROMAL CELLS	In view of the rapid preclinical development of cell-based therapies for neurodegenerative disorders, traumatic brain injury, and tumors, the safe and efficient delivery and targeting of therapeutic cells to the central nervous system is critical for maintaining therapeutic efficacy and safety in the respective disease models. Our previous data demonstrated therapeutically efficacious and targeted delivery of mesenchymal stem cells (MSCs) to the brain in the rat 6-hydroxydopamine model of Parkinson's disease (PD). The present study examined delivery of bone marrow-derived MSCs, macrophages, and microglia to the brain in a transgenic model of PD [(Thyl)-h[A30P] alpha S] and an APP/PS1 model of Alzheimer's disease (AD) via intranasal application (INA). INA of microglia in naive BL/6 mice led to targeted and effective delivery of cells to the brain. Quantitative PCR analysis of eGFP DNA showed that the brain contained the highest amount of eGFP-microglia (up to 2.1 x 10(4)) after INA of lx 10(6) cells, while the total amount of cells detected in peripheral organs did not exceed 3.4x 10(3). Seven days after INA, MSCs expressing eGFP were detected in the olfactory bulb (OB), cortex, arnygdala, striatum, hippocampus, cerebellum, and brainstem of (Thyl)-h[A30P] alpha S transgenic mice, showing predominant distribution within the OB and brainstem. INA of eGFP-expressing macrophages in 13-month-old APP/PS1 mice led to delivery of cells to the OB, hippocampus, cortex, and cerebellum. Both MSCs and macrophages contained lba-1-positive population of small microglia-like cells and Iba-1-negative large rounded cells showing either intracellular amyloid beta (macrophages in APP/PS1 model) or alpha-synuclein [MS Cs in (Thyl)-h[A30P] alpha S model] immunoreactivity. Here, we show, for the first time, intranasal delivery of cells to the brain of transgenic PD and AD mouse models. Additional work is needed to determine the optimal dosage (single treatment regimen or repeated administrations) to achieve functional improvement in these mouse models with intranasal microglia/macrophages and MSCs. This manuscript is published as part of the International Association of Neurorestoratology (IANR) special issue of Cell Transplantation.	[Danielyan, Lusine; Lourhmati, Ali; Buadze, Marine; Proksch, Barbara; Gleiter, Christoph H.; Schwab, Matthias] Univ Tubingen, Eberhard Karls Univ Hosp & Clin, Dept Clin Pharmacol, D-72076 Tubingen, Germany; [Danielyan, Lusine; Beer-Hammer, Sandra; Lourhmati, Ali; Buadze, Marine; Novakovic, Ana; Proksch, Barbara; Gleiter, Christoph H.; Schwab, Matthias] Univ Tubingen, Interfac Ctr Pharmacogen & Drug Res, D-72076 Tubingen, Germany; [Beer-Hammer, Sandra; Novakovic, Ana] Univ Tubingen, Eberhard Karls Univ Hosp & Clin, Inst Expt & Clin Pharmacol & Toxicol, Dept Pharmacol & Expt Therapy, D-72076 Tubingen, Germany; [Stolzing, Alexandra; Fabian, Claire] Fraunhofer Inst Cell Therapy & Immunol, Dept Cell Therapy Stem Cell Biol, Leipzig, Germany; [Stolzing, Alexandra; Fabian, Claire] Fraunhofer Inst Cell Therapy & Immunol, Regenerat Unit, Leipzig, Germany; [Schaefer, Richard] Johann Wolfgang Goethe Univ Hosp, German Red Cross Blood Donor Serv Baden Wuttember, Inst Transfus Med & Immunohaematol, Dept Cell Therapeut & Cell Proc, Frankfurt, Germany; [Schaefer, Richard; Siegel, Georg] Univ Tubingen Hosp, Inst Clin & Expt Transfus Med IKET, Tubingen, Germany; [Kahle, Philipp] Univ Tubingen, Fac Med, Hertie Inst Clin Brain Res, Dept Neurodegenerat, D-72076 Tubingen, Germany; [Kahle, Philipp] Univ Tubingen, Fac Med, German Ctr Neurodegenerat Dis, D-72076 Tubingen, Germany; [Biedermann, Tilo] Univ Tubingen, Dept Dermatol, D-72076 Tubingen, Germany; [Frey, William H., II] Reg Hosp, Alzheimers Res Ctr, HealthPartners Ctr Memory & Aging, St Paul, MN USA; [Schwab, Matthias] Univ Tubingen, Dr Margarete FischerBosch Inst Clin Pharmacol, Stuttgart, Germany	Danielyan, L (corresponding author), Univ Tubingen, Eberhard Karls Univ Hosp & Clin, Dept Clin Pharmacol, Morgenstelle 8, D-72076 Tubingen, Germany.	lusine.danielyan@med.uni-tuebingen.de	Stolzing, Alexandra/S-4208-2019; Beer-Hammer, Sandra/AAK-4516-2020; Schwab, Matthias/ABH-7449-2020; Stolzing, Alexandra/O-7815-2016	Stolzing, Alexandra/0000-0002-2975-5736; Beer-Hammer, Sandra/0000-0001-6049-0257; Stolzing, Alexandra/0000-0002-2975-5736	Applied Clinical Research Program (AKF) [295-0-0]; Interfaculty Centre for Pharmacogenomics and Pharma Research (ICEPHA) grant from the Faculty of Medicine, University of Tubingen	We wish to thank Cornelia Grimmel (FACS core facility of the interdisciplinary center for clinical research of the University Hospital of Tubingen) and Claudia Muller for excellent technical assistance and advice on data analyses. This work was supported by Applied Clinical Research Program (AKF No. 295-0-0) and the Interfaculty Centre for Pharmacogenomics and Pharma Research (ICEPHA) grant from the Faculty of Medicine, University of Tubingen. W.H.F, L.D., and C.H.F own the patent on intranasal delivery of cells to the brain (Methods, pharmaceutical compositions, and articles of manufacture for administering therapeutic cells to the animal central nervous system. March 2009: WO/2009/035901). Authors declare no other conflict of interest for this work.	Arabpoor Zohreh, 2012, Adv Biomed Res, V1, P50, DOI 10.4103/2277-9175.100157; Assaraf MI, 2007, J NEUROPATH EXP NEUR, V66, P389, DOI 10.1097/nen.0b013e3180517b28; Avagyan H, 2009, J NEUROIMMUNOL, V210, P67, DOI 10.1016/j.jneuroim.2009.02.015; Balyasnikova IV, 2014, MOL THER, V22, P140, DOI 10.1038/mt.2013.199; Bard F, 2000, NAT MED, V6, P916, DOI 10.1038/78682; Barker RA, 1996, EXP NEUROL, V141, P79, DOI 10.1006/exnr.1996.0141; Beraud D, 2013, J NEUROIMMUNE PHARM, V8, P94, DOI 10.1007/s11481-012-9401-0; Blesch A, 1996, CLIN NEUROSCI, V3, P268; Bossolasco P, 2012, INT J NANOMED, V7, P435, DOI 10.2147/IJN.S27537; Calvo A, 2010, CNS NEUROL DISORD-DR, V9, P325, DOI 10.2174/187152710791292657; Camp DM, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-17; Chapman CD, 2013, PHARM RES-DORDR, V30, P2475, DOI 10.1007/s11095-012-0915-1; Chien YW, 1989, NASAL SYSTEMIC DRUG, P1; Coyne TM, 2007, TRANSPLANTATION, V84, P1507, DOI 10.1097/01.tp.0000288185.09601.4d; Coyne TM, 2006, STEM CELLS, V24, P2483, DOI 10.1634/stemcells.2006-0174; Dale O, 2002, ACTA ANAESTH SCAND, V46, P759, DOI 10.1034/j.1399-6576.2002.460702.x; Danielyan L, 2005, EUR J CELL BIOL, V84, P907, DOI 10.1016/j.ejcb.2005.07.001; Danielyan L, 2005, EUR J CELL BIOL, V84, P567, DOI 10.1016/j.ejcb.2004.12.030; Danielyan L, 2009, CELL DEATH DIFFER, V16, P1599, DOI 10.1038/cdd.2009.95; Danielyan L, 2011, REJUV RES, V14, P3, DOI 10.1089/rej.2010.1130; Danielyan L, 2009, EUR J CELL BIOL, V88, P315, DOI 10.1016/j.ejcb.2009.02.001; Dhuria SV, 2010, J PHARM SCI-US, V99, P1654, DOI 10.1002/jps.21924; Donega V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0051253; Ehrenreich H, 2007, MOL PSYCHIATR, V12, P206, DOI 10.1038/sj.mp.4001907; El Khoury J, 2007, NAT MED, V13, P432, DOI 10.1038/nm1555; Fiala M, 2007, P NATL ACAD SCI USA, V104, P12849, DOI 10.1073/pnas.0701267104; FINSEN BR, 1991, J NEUROIMMUNOL, V32, P159, DOI 10.1016/0165-5728(91)90008-U; Fransson M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-112; FREY WH, 1995, RESEARCH ADVANCES IN ALZHEIMER'S DISEASE AND RELATED DISORDERS, P329; Gonzalez FF, 2007, DEV NEUROSCI-BASEL, V29, P321, DOI 10.1159/000105473; Grathwohl SA, 2009, NAT NEUROSCI, V12, P1361, DOI 10.1038/nn.2432; Gutierrez-Fernandez M, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt159; Hawkes CA, 2009, P NATL ACAD SCI USA, V106, P1261, DOI 10.1073/pnas.0805453106; Hinze A, 2012, J INFLAMM-LOND, V9, DOI 10.1186/1476-9255-9-12; Hussain A A, 1989, Prog Clin Biol Res, V292, P261; Iwai M, 2007, STROKE, V38, P2795, DOI 10.1161/STROKEAHA.107.483008; Joyce N, 2010, REGEN MED, V5, P933, DOI [10.2217/rme.10.72, 10.2217/RME.10.72]; Kadota T, 2009, BRAIN RES, V1254, P120, DOI 10.1016/j.brainres.2008.11.094; Kahle PJ, 2001, AM J PATHOL, V159, P2215, DOI 10.1016/S0002-9440(10)63072-6; Karussis D, 2006, CLIN NEUROL NEUROSUR, V108, P250, DOI 10.1016/j.clineuro.2005.11.007; Kitada M, 2012, PARKINSONS DIS-US, V2012, DOI 10.1155/2012/873706; Koenigsknecht-Talboo J, 2008, J NEUROSCI, V28, P14156, DOI 10.1523/JNEUROSCI.4147-08.2008; Kozlowska H, 2007, STEM CELLS DEV, V16, P481, DOI 10.1089/scd.2007.9993; Lappalainen RS, 2008, NEUROSCI LETT, V440, P246, DOI 10.1016/j.neulet.2008.05.090; Lee HJ, 2010, J BIOL CHEM, V285, P9262, DOI 10.1074/jbc.M109.081125; Lee JK, 2010, STEM CELLS, V28, P329, DOI 10.1002/stem.277; Lee ST, 2012, J NEUROCHEM, V120, P115, DOI 10.1111/j.1471-4159.2011.07534.x; Liu Y, 2005, BRAIN, V128, P1778, DOI 10.1093/brain/awh531; Lochhead JJ, 2012, ADV DRUG DELIVER REV, V64, P614, DOI 10.1016/j.addr.2011.11.002; Lomoio S, 2012, J ALZHEIMERS DIS, V31, P285, DOI 10.3233/JAD-2012-112198; Lourhmati A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077182; Maurice T, 2013, J PSYCHOPHARMACOL, V27, P1044, DOI 10.1177/0269881113494939; MCKEON RJ, 1991, J NEUROSCI, V11, P3398; McLaurin J, 2002, NAT MED, V8, P1263, DOI 10.1038/nm790; Neumann M, 2002, J CLIN INVEST, V110, P1429, DOI 10.1172/JC1200215777; Pendharkar AV, 2010, STROKE, V41, P2064, DOI 10.1161/STROKEAHA.109.575993; PERRY VH, 1993, TRENDS NEUROSCI, V16, P268, DOI 10.1016/0166-2236(93)90180-T; Ramot Y, 2010, NANOTOXICOLOGY, V4, P98, DOI 10.3109/17435390903470093; Reitz M, 2012, STEM CELL TRANSL MED, V1, P866, DOI 10.5966/sctm.2012-0045; Saresella M, 2014, J ALZHEIMERS DIS, V38, P403, DOI 10.3233/JAD-131160; Sargin D, 2011, BMC BIOL, V9, DOI 10.1186/1741-7007-9-27; Simard AR, 2006, NEURON, V49, P489, DOI 10.1016/j.neuron.2006.01.022; SINDEN JD, 1992, CURR OPIN NEUROL NEU, V5, P902; Spillantini MG, 1998, NEUROSCI LETT, V251, P205, DOI 10.1016/s0304-3940(98)00504-7; Steiner B, 2012, NEUROSCI LETT, V513, P25, DOI 10.1016/j.neulet.2012.01.078; Stemberger S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019808; Thorne RG, 2004, NEUROSCIENCE, V127, P481, DOI 10.1016/j.neuroscience.2004.05.029; Town T, 2008, NAT MED, V14, P681, DOI 10.1038/nm1781; Tuszynski MH, 2005, NAT MED, V11, P551, DOI 10.1038/nm1239; TUSZYNSKI MH, 1995, P NATL ACAD SCI USA, V92, P4621, DOI 10.1073/pnas.92.10.4621; van Velthoven CTJ, 2010, PEDIATR RES, V68, P419, DOI 10.1203/PDR.0b013e3181f1c289; Walker PA, 2009, STEM CELL REV REP, V5, P283, DOI 10.1007/s12015-009-9081-1; Wang Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054296; Wei N, 2013, CELL TRANSPLANT, V22, P977, DOI 10.3727/096368912X657251; Wu Shuai, 2013, J Clin Cell Immunol, V4, DOI 10.4172/2155-9899.1000142; Xue YQ, 2010, GENE THER, V17, P83, DOI 10.1038/gt.2009.113; Yagi H, 2010, CELL TRANSPLANT, V19, P667, DOI 10.3727/096368910X508762; Yang B, 2013, STROKE, V44, P3463, DOI 10.1161/STROKEAHA.111.000821; Zaghi J, 2009, ACTA NEUROPATHOL, V117, P111, DOI 10.1007/s00401-008-0481-0	79	79	81	0	16	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0963-6897	1555-3892		CELL TRANSPLANT	Cell Transplant.		2014	23			1			S123	S139		10.3727/096368914X684970			17	Cell & Tissue Engineering; Medicine, Research & Experimental; Transplantation	Cell Biology; Research & Experimental Medicine; Transplantation	AY9KT	WOS:000347869500014	25302802	Green Published			2021-06-18	
J	Twamley, EW; Jak, AJ; Delis, DC; Bondi, MW; Lohr, JB				Twamley, Elizabeth W.; Jak, Amy J.; Delis, Dean C.; Bondi, Mark W.; Lohr, James B.			Cognitive Symptom Management and Rehabilitation Therapy (CogSMART) for Veterans with traumatic brain injury: Pilot randomized controlled trial	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						attention; brain injury; cognitive rehabilitation; cognitive training; depression; employment; executive functioning; memory; postconcussive symptoms; posttraumatic stress disorder; rehabilitation; unemployment	MILD HEAD-INJURY; NEUROPSYCHOLOGICAL OUTCOMES; EMPLOYMENT; METAANALYSIS; REMEDIATION; RETURN; COSTS; WORK	Traumatic brain injury (TBI) can result in cognitive impairments and persistent postconcussive symptoms that limit functional recovery, including return to work. We evaluated a 12 wk compensatory cognitive training intervention(Cognitive Symptom Management and Rehabilitation Therapy[CogSMART]) in the context of supported employment for Veterans with mild to moderate TBI. Participants were randomly assigned to receive 12 wk of supported employment plus CogSMART or enhanced supported employment that controlled for therapist attention (control). CogSMART sessions were delivered by the employment specialist and included psychoeducation regarding TBI; strategies to improve sleep, fatigue, headaches, and tension; and compensatory cognitive strategies in thedomains of prospective memory, attention, learning and memory, and executive functioning. Compared with controls, those assigned to supported employment plus CogSMART demonstrated significant reductions in postconcussive symptoms (Cohen d = 0.97) and improvements in prospective memory functioning (Cohen d = 0.72). Effect sizes favoring CogSMART for posttraumatic stress disorder symptom severity, depressive symptom severity, and attainment of competitive work within 14 wk were in the small to medium range (Cohen d = 0.35-0.49). Those who received CogSMART rated the intervention highly. Results suggest that adding CogSMART to supported employment may improve postconcussive symptoms and prospective memory. These effects, as well as smaller effects on psychiatric symptoms and ability to return to work, warrant replication in a larger trial.	[Twamley, Elizabeth W.; Jak, Amy J.; Delis, Dean C.; Lohr, James B.] Dept Vet Affairs VA San Diego Healthcare Syst, Ctr Excellence Stress & Mental Hlth, San Diego, CA USA; [Twamley, Elizabeth W.; Jak, Amy J.; Bondi, Mark W.; Lohr, James B.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA; [Jak, Amy J.; Bondi, Mark W.] VA San Diego Healthcare Syst, Psychol Serv, San Diego, CA USA	Twamley, EW (corresponding author), VA San Diego Healthcare Syst, Ctr Excellence Stress & Mental Hlth, 3350 La Jolla Village Dr 116A, San Diego, CA 92161 USA.	etwamley@ucsd.edu			DODUnited States Department of Defense [W81XWH-08-2-0193]	Funding/Support: This material was based on work supported by the DOD (award W81XWH-08-2-0193).	Andelic N, 2012, BRAIN INJURY, V26, P261, DOI 10.3109/02699052.2012.654589; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Bogdanova Y, 2012, NEUROPSYCHOL REV, V22, P4, DOI 10.1007/s11065-012-9192-3; Carney N, 1999, J HEAD TRAUMA REHAB, V14, P277, DOI 10.1097/00001199-199906000-00008; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; Dawson DR, 2007, DISABIL REHABIL, V29, P301, DOI 10.1080/09638280600756687; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Delis DC, 2000, CVLT 3 CALIFORNIA VE; Drake AI, 2000, J HEAD TRAUMA REHAB, V15, P1103, DOI 10.1097/00001199-200010000-00004; Fischer H., 2007, US MILITARY CASUALTY; HAMILTON M, 1967, BRIT J SOC CLIN PSYC, V6, P278; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; James W., 1890, PRINCIPLES PSYCHOL; Kalechstein AD, 2003, J CLIN EXP NEUROPSYC, V25, P1186, DOI 10.1076/jcen.25.8.1186.16723; Kinsella G, 1996, BRAIN INJURY, V10, P499, DOI 10.1080/026990596124214; Koehler R, 2011, COGNITIVE REHABILITATION THERAPY FOR TRAUMATIC BRAIN INJURY: EVALUATING THE EVIDENCE, P1; Kongs S.K., 2000, WCST 64 WISCONSIN CA; Kreutzer J S, 1988, Brain Inj, V2, P205, DOI 10.3109/02699058809150945; Leahy BJ, 1998, BRAIN INJURY, V12, P1025, DOI 10.1080/026990598121936; LEHMAN AF, 1988, EVAL PROGRAM PLANN, V11, P51, DOI 10.1016/0149-7189(88)90033-X; Management of Concussion/mTBI Working Group, 2009, J Rehabil Res Dev, V46, pCP1; McGurk SR, 2007, AM J PSYCHIAT, V164, P1791, DOI 10.1176/appi.ajp.2007.07060906; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Raskin S, 2004, J INT NEUROPSYCHO S1, V10, P110, DOI DOI 10.1017/S1355617704040019; Raskin SA, 2012, NEUROPSYCHOL REHABIL, V22, P40, DOI 10.1080/09602011.2011.632908; Sitzer DI, 2006, ACTA PSYCHIAT SCAND, V114, P75, DOI 10.1111/j.1600-0447.2006.00789.x; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Taylor BC, 2012, MED CARE, V50, P342, DOI 10.1097/MLR.0b013e318245a558; Tiersky LA, 2005, ARCH PHYS MED REHAB, V86, P1565, DOI 10.1016/j.apmr.2005.03.013; Twamley EW, 2012, J CLIN PSYCHIAT, V73, P1212, DOI 10.4088/JCP.12m07686; Twamley EW, 2003, SCHIZOPHRENIA BULL, V29, P359, DOI 10.1093/oxfordjournals.schbul.a007011; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Vanderploeg RD, 2001, J CLIN EXP NEUROPSYC, V23, P185, DOI 10.1076/jcen.23.2.185.1210; Vasterling JJ, 2012, BRIT J PSYCHIAT, V201, P186, DOI 10.1192/bjp.bp.111.096461; Weathers FW, 2001, DEPRESS ANXIETY, V13, P132, DOI 10.1002/da.1029; Wechsler D, 1997, WAIS 3 WECHSLER ADUL; Wehman P, 2005, J HEAD TRAUMA REHAB, V20, P115, DOI 10.1097/00001199-200503000-00001; Wehman P, 2003, ARCH PHYS MED REHAB, V84, P192, DOI 10.1053/apmr.2003.50027; Wilkinson G.S., 1993, WRAT 3 WIDE RANGE AC; Wykes T, 2011, AM J PSYCHIAT, V168, P472, DOI 10.1176/appi.ajp.2010.10060855	44	79	81	1	33	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.		2014	51	1					59	69		10.1682/JRRD.2013.01.0020			11	Rehabilitation	Rehabilitation	AF8GB	WOS:000334952600006	24805894	Bronze			2021-06-18	
J	Vanderploeg, RD; Cooper, DB; Belanger, HG; Donnell, AJ; Kennedy, JE; Hopewell, CA; Scott, SG				Vanderploeg, Rodney D.; Cooper, Douglas B.; Belanger, Heather G.; Donnell, Alison J.; Kennedy, Jan E.; Hopewell, Clifford A.; Scott, Steven G.			Screening for Postdeployment Conditions: Development and Cross-Validation of an Embedded Validity Scale in the Neurobehavioral Symptom Inventory	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						veterans; assessment; postconcussion syndrome; neuropsychology; concussions; mild traumatic brain injury	TRAUMATIC BRAIN-INJURY; VETERANS; ASSOCIATIONS; PERFORMANCE; UTILITY	Objective: To develop and cross-validate internal validity scales for the Neurobehavioral Symptom Inventory (NSI). Participants: Four existing data sets were used: (1) outpatient clinical traumatic brain injury (TBI)/neurorehabilitation database from a military site (n = 403), (2) National Department of Veterans Affairs TBI evaluation database (n = 48 175), (3) Florida National Guard nonclinical TBI survey database (n = 3098), and (4) a cross-validation outpatient clinical TBI/neurorehabilitation database combined across 2 military medical centers (n = 206). Research Design: Secondary analysis of existing cohort data to develop (study 1) and cross-validate (study 2) internal validity scales for the NSI. Main Measures: The NSI, Mild Brain Injury Atypical Symptoms, and Personality Assessment Inventory scores. Results: Study 1: Three NSI validity scales were developed, composed of 5 unusual items (Negative Impression Management [NIM5]), 6 low-frequency items (LOW6), and the combination of 10 nonoverlapping items (Validity-10). Cut scores maximizing sensitivity and specificity on these measures were determined, using a Mild Brain Injury Atypical Symptoms score of 8 or more as the criterion for invalidity. Study 2: The same validity scale cut scores again resulted in the highest classification accuracy and optimal balance between sensitivity and specificity in the cross-validation sample, using a Personality Assessment Inventory Negative Impression Management scale with a T score of 75 or higher as the criterion for invalidity. Conclusions: The NSI is widely used in the Department of Defense and Veterans Affairs as a symptom-severity assessment following TBI, but is subject to symptom overreporting or exaggeration. This study developed embedded NSI validity scales to facilitate the detection of invalid response styles. The NSI Validity-10 scale appears to hold considerable promise for validity assessment when the NSI is used as a population-screening tool.	[Vanderploeg, Rodney D.; Belanger, Heather G.; Donnell, Alison J.] Univ S Florida, Dept Mental Hlth & Behav Sci, Tampa, FL USA; [Scott, Steven G.] Univ S Florida, Dept Phys Med & Rehabil, Tampa, FL USA; [Vanderploeg, Rodney D.; Belanger, Heather G.; Scott, Steven G.] Univ S Florida, HSR&D, Rehabil Res & Dev RR&D Ctr Excellence Maximizing, Tampa, FL USA; [Vanderploeg, Rodney D.; Belanger, Heather G.; Donnell, Alison J.; Scott, Steven G.] Univ S Florida, James A Haley Vet Hosp, Def & Vet Brain Injury Ctr, Tampa, FL USA; [Vanderploeg, Rodney D.; Belanger, Heather G.] Univ S Florida, Dept Psychol, Tampa, FL 33620 USA; [Vanderploeg, Rodney D.] Univ S Florida, Tampa, FL USA; [Cooper, Douglas B.; Kennedy, Jan E.] San Antonio Mil Med Ctr, Def & Vet Brain Injury Ctr, San Antonio, TX USA; [Cooper, Douglas B.; Kennedy, Jan E.] San Antonio Mil Med Ctr, Neurol Serv, Dept Med, San Antonio, TX USA; [Hopewell, Clifford A.] Darnall Army Med Ctr, Traumat Brain Injury Clin, Killeen, TX USA	Vanderploeg, RD (corresponding author), James A Haley Vet Hosp, Psychol Serv 116B, 13000 Bruce B Downs Blvd, Tampa, FL 33612 USA.	Rodney.vanderploeg@va.gov			Department of Veterans Affairs, Veterans Health AdministrationUS Department of Veterans Affairs; Defense and Veterans Brain Injury CenterUS Department of Veterans Affairs; Department of Veterans Affairs Health Service Research DevelopmentUS Department of Veterans Affairs [CCN 06-164]; James A. Haley Veterans' Hospital and its HSR&D/RR&D center of excellence	This research was supported by the Department of Veterans Affairs, Veterans Health Administration, and Defense and Veterans Brain Injury Center and by a Department of Veterans Affairs Health Service Research & Development grant CCN 06-164 to Steven G. Scott, DO. Further support was provided by the James A. Haley Veterans' Hospital and its HSR&D/RR&D center of excellence.	Armistead-Jehle P, 2010, APPL NEUROPSYCHOL, V17, P52, DOI 10.1080/09084280903526182; Belanger HG, 2012, ARCH PHYS MED REHAB, V93, P1234, DOI 10.1016/j.apmr.2012.03.003; Ben-Porath Y.S., 2008, MMPI 2 RF MINNESOTA; Butcher JN., 2001, MINNESOTA MULTIPHASI; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Cooper DB, 2011, ARCH CLIN NEUROPSYCH, V26, P718, DOI 10.1093/arclin/acr070; Interian A, 2004, PSYCHOSOM MED, V66, P141, DOI 10.1097/01.PSY.0000107883.14385.EC; Larrabee GJ, 2012, J INT NEUROPSYCH SOC, V18, P625, DOI 10.1017/S1355617712000240; Morey LC., 2007, PERSONALITY ASSESSME; Nelson NW, 2010, ARCH CLIN NEUROPSYCH, V25, P713, DOI 10.1093/arclin/acq075; Sayer NA, 2011, J HEAD TRAUMA REHAB, V26, P454, DOI 10.1097/HTR.0b013e3181ff393c; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Tombaugh TN, 1996, TEST MEMORY MALINGER; Vanderploeg RD, 2012, ARCH PHYS MED REHAB, V93, P1887, DOI 10.1016/j.apmr.2012.05.024; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Whitney KA, 2009, ARCH CLIN NEUROPSYCH, V24, P145, DOI 10.1093/arclin/acp020; Whitney KA, 2008, ARCH CLIN NEUROPSYCH, V23, P777, DOI 10.1016/j.acn.2008.09.001	17	79	80	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2014	29	1					1	10		10.1097/HTR.0b013e318281966e			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AH1OC	WOS:000335889400001	23474880				2021-06-18	
J	Gao, K; Wang, CR; Jiang, F; Wong, AYK; Su, N; Jiang, JH; Chai, RC; Vatcher, G; Teng, JL; Chen, JG; Jiang, YW; Yu, ACH				Gao, Kai; Wang, Chen Ran; Jiang, Feng; Wong, Ann Yuen Kwan; Su, Na; Jiang, Jiao Hua; Chai, Rui Chao; Vatcher, Greg; Teng, Junlin; Chen, Jianguo; Jiang, Yu-Wu; Yu, Albert Cheung Hoi			Traumatic Scratch Injury in Astrocytes Triggers Calcium Influx to Activate the JNK/c-Jun/AP-1 Pathway and Switch on GFAP Expression	GLIA			English	Article						calcium wave; JNK; astrogliosis; glial fibrillary acidic protein; glial scar	FIBRILLARY ACIDIC PROTEIN; REACTIVE GLIOSIS; IN-VITRO; RAT-BRAIN; UP-REGULATION; GLIAL-CELLS; CULTURED ASTROCYTES; MMP-9 EXPRESSION; GENE-EXPRESSION; ASTROGLIOSIS	Astrocyte activation is a hallmark of central nervous system injuries resulting in glial scar formation (astrogliosis). The activation of astrocytes involves metabolic and morphological changes with complex underlying mechanisms, which should be defined to provide targets for astrogliosis intervention. Astrogliosis is usually accompanied by an upregulation of glial fibrillary acidic protein (GFAP). Using an in vitro scratch injury model, we scratched primary cultures of cerebral cortical astrocytes and observed an influx of calcium in the form of waves spreading away from the wound through gap junctions. Using the calcium blocker BAPTA-AM and the JNK inhibitor SP600125, we demonstrated that the calcium wave triggered the activation of JNK, which then phosphorylated the transcription factor c-Jun to facilitate the binding of AP-1 to the GFAP gene promoter to switch on GFAP upregulation. Blocking calcium mobilization with BAPTA-AM in an in vivo stab wound model reduced GFAP expression and glial scar formation, showing that the calcium signal, and the subsequent regulation of downstream signaling molecules, plays an essential role in brain injury response. Our findings demonstrated that traumatic scratch injury to astrocytes triggered a calcium influx from the extracellular compartment and activated the JNK/c-Jun/AP-1 pathway to switch on GFAP expression, identifying a previously unreported signaling cascade that is important in astrogliosis and the physiological response following brain injury.	[Gao, Kai; Wang, Chen Ran; Jiang, Feng; Wong, Ann Yuen Kwan; Su, Na; Jiang, Jiao Hua; Chai, Rui Chao; Vatcher, Greg; Yu, Albert Cheung Hoi] Peking Univ, Natl Hlth & Family Planning Commiss, Sch Basic Med Sci,Hlth Sci Ctr, Neurosci Res Inst,Minist Educ,Key Lab Neurosci,De, Beijing 100191, Peoples R China; [Teng, Junlin; Chen, Jianguo] Peking Univ, Coll Life Sci, Minist Educ, State Key Lab Biomembrane & Membrane Bioengn, Beijing 100191, Peoples R China; [Teng, Junlin; Chen, Jianguo] Peking Univ, Coll Life Sci, Minist Educ, Key Lab Cell Proliferat & Differentiat, Beijing 100191, Peoples R China; [Jiang, Yu-Wu] Peking Univ, Hosp 1, Dept Pediat, Beijing 100191, Peoples R China; [Yu, Albert Cheung Hoi] Peking Univ, Inst Syst Biomed, Lab Translat Med, Beijing 100191, Peoples R China	Yu, ACH (corresponding author), Peking Univ, Neurosci Res Inst, 38 Xue Yuan Rd, Beijing 100191, Peoples R China.	achy@hsc.pku.edu.cn	Chai, Ruichao/AAF-3361-2020; wang, chenran/N-6629-2013		Beijing Natural Science FoundationBeijing Natural Science Foundation [7091004]; National Basic Research Program of China (973 program)National Basic Research Program of China [2011CB504400]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30870818, 31070974, 31171009]; Foundation for Innovative Research Groups of the National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81221002]	Grant sponsor: Beijing Natural Science Foundation; Grant number: 7091004; Grant sponsor: National Basic Research Program of China (973 program); Grant number: 2011CB504400; Grant sponsor: National Natural Science Foundation of China; Grant numbers: 30870818, 31070974, and 31171009; Grant sponsor: Foundation for Innovative Research Groups of the National Natural Science Foundation of China; Grant number: 81221002.	Arcuino G, 2002, P NATL ACAD SCI USA, V99, P9840, DOI 10.1073/pnas.152588599; Bachetti T, 2010, ANN HUM GENET, V74, P506, DOI 10.1111/j.1469-1809.2010.00614.x; Baumgart EV, 2012, GLIA, V60, P343, DOI 10.1002/glia.22269; Buira SP, 2010, J NEUROCHEM, V115, P283, DOI 10.1111/j.1471-4159.2010.06928.x; Carbonell WS, 2003, J NEUROTRAUM, V20, P327, DOI 10.1089/089771503765172282; Cebolla B, 2006, J NEUROCHEM, V97, P1057, DOI 10.1111/j.1471-4159.2006.03804.x; Cebolla B, 2008, J NEUROSCI, V28, P6703, DOI 10.1523/JNEUROSCI.0215-08.2008; Chai RC, 2013, GLIA, V61, P1748, DOI 10.1002/glia.22555; CHARLES AC, 1991, NEURON, V6, P983, DOI 10.1016/0896-6273(91)90238-U; Chen XQ, 2005, J CEREBR BLOOD F MET, V25, P338, DOI 10.1038/sj.jcbfm.9600032; Chun JT, 2004, EXP NEUROL, V185, P109, DOI 10.1016/j.expneurol.2003.09.019; Ciccarelli R, 2004, EUR J NEUROSCI, V20, P1514, DOI 10.1111/j.1460-9568.2004.03613.x; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; Du S, 1999, EXP NEUROL, V157, P96, DOI 10.1006/exnr.1999.7041; Ebrahimi F, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-89; El-Hage N, 2005, GLIA, V50, P91, DOI 10.1002/glia.20148; Eng DL, 1997, BRAIN RES, V778, P215, DOI 10.1016/S0006-8993(97)01093-7; Eng LF, 2000, NEUROCHEM RES, V25, P1439, DOI 10.1023/A:1007677003387; ENG LF, 1971, BRAIN RES, V28, P351, DOI 10.1016/0006-8993(71)90668-8; Etienne-Manneville S, 2001, CELL, V106, P489, DOI 10.1016/S0092-8674(01)00471-8; FaberElman A, 1996, J CLIN INVEST, V97, P162, DOI 10.1172/JCI118385; Fiacco TA, 2006, GLIA, V54, P676, DOI 10.1002/glia.20396; Fields RD, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3147tr5; FINKBEINER S, 1992, NEURON, V8, P1101, DOI 10.1016/0896-6273(92)90131-V; Flint D, 2012, HUM MUTAT, V33, P1141, DOI 10.1002/humu.22094; Gadea A, 2008, J NEUROSCI, V28, P2394, DOI 10.1523/JNEUROSCI.5652-07.2008; GHIRNIKAR RS, 1994, J NEUROSCI RES, V38, P376, DOI 10.1002/jnr.490380403; Ghirnikar RS, 1998, NEUROCHEM RES, V23, P329, DOI 10.1023/A:1022453332560; Ghirnikar RS, 1996, J NEUROSCI RES, V46, P727; GIMPL G, 1992, NEUROSCI LETT, V144, P139, DOI 10.1016/0304-3940(92)90735-P; Givogri MI, 2006, DEV NEUROSCI-BASEL, V28, P81, DOI 10.1159/000090755; Glabinski AR, 1996, J IMMUNOL, V156, P4363; Gopalan SM, 2006, J BIOL CHEM, V281, P1956, DOI 10.1074/jbc.M510935200; GRAMSBERGEN JBP, 1994, BRAIN RES, V667, P216, DOI 10.1016/0006-8993(94)91499-0; Hassinger TD, 1996, P NATL ACAD SCI USA, V93, P13268, DOI 10.1073/pnas.93.23.13268; Hebert MA, 2000, ANN NY ACAD SCI, V914, P238, DOI 10.1111/j.1749-6632.2000.tb05200.x; Homkajorn B, 2010, NEUROSCI LETT, V486, P197, DOI 10.1016/j.neulet.2010.09.051; Hsuchou H, 2012, J MOL NEUROSCI, V47, P267, DOI 10.1007/s12031-012-9734-4; Huang TT, 2009, J NEUROTRAUM, V26, P1535, DOI [10.1089/neu.2008.0743, 10.1089/neu.2008-0743]; Hwang J, 2010, J NEUROIMMUNOL, V226, P66, DOI 10.1016/j.jneuroim.2010.05.037; Jin MM, 2011, NEUROSCI BULL, V27, P389, DOI 10.1007/s12264-011-1944-1; Jung CS, 2007, BRAIN, V130, P3336, DOI 10.1093/brain/awm263; Kalman M, 2013, J EXP ZOOL PART B, V320, P351, DOI 10.1002/jez.b.22505; Kam AYF, 2007, CELL SIGNAL, V19, P2106, DOI 10.1016/j.cellsig.2007.06.005; Kaminska B, 2009, ANAT REC, V292, P1902, DOI 10.1002/ar.21047; Kanemaru K, 2013, P NATL ACAD SCI USA, V110, P11612, DOI 10.1073/pnas.1300378110; Katano H, 1999, NEUROREPORT, V10, P2439, DOI 10.1097/00001756-199908200-00002; Kleinman MT, 2008, TOXICOL LETT, V178, P127, DOI 10.1016/j.toxlet.2008.03.001; Kornyei Z, 2000, J NEUROSCI RES, V61, P421, DOI 10.1002/1097-4547(20000815)61:4<421::AID-JNR8>3.0.CO;2-4; Lanosa XA, 2007, IN VITRO CELL DEV-AN, V43, P186, DOI 10.1007/s11626-007-9038-0; Lau LT, 2001, J NEUROTRAUM, V18, P351, DOI 10.1089/08977150151071035; Leung YKJ, 2010, EXP NEUROL, V221, P98, DOI 10.1016/j.expneurol.2009.10.006; Liedtke W, 1996, NEURON, V17, P607, DOI 10.1016/S0896-6273(00)80194-4; Lim JH, 2007, BRAIN RES, V1164, P1, DOI 10.1016/j.brainres.2007.06.020; Lin HW, 2006, J NEUROINFLAMM, V3, DOI 10.1186/1742-2094-3-15; Liu C, 2011, CELL MOL NEUROBIOL, V31, P259, DOI 10.1007/s10571-010-9616-7; Lu DC, 2011, J NEUROTRAUMA; Lu J, 2013, P NATL ACAD SCI USA, V110, P10747, DOI 10.1073/pnas.1308950110; MacFarlane SN, 1997, J NEUROSCI, V17, P7316; Malhotra SK, 1997, CYTOBIOS, V89, P115; MASOOD K, 1993, J NEUROCHEM, V61, P160, DOI 10.1111/j.1471-4159.1993.tb03551.x; McCall MA, 1996, P NATL ACAD SCI USA, V93, P6361, DOI 10.1073/pnas.93.13.6361; Miller G, 2005, SCIENCE, V308, P778, DOI 10.1126/science.308.5723.778; Molnar T, 2011, BMC NEUROSCI, V3, P96; Morga E, 2009, GLIA, V57, P1741, DOI 10.1002/glia.20887; MOUMDJIAN RA, 1991, BRAIN RES, V547, P223, DOI 10.1016/0006-8993(91)90965-X; Nawashiro H, 1998, NEUROREPORT, V9, P1691, DOI 10.1097/00001756-199806010-00004; NEDERGAARD M, 1994, SCIENCE, V263, P1768, DOI 10.1126/science.8134839; Newman EA, 1998, J NEUROSCI, V18, P4022; Nicole O, 2005, J NEUROSCI, V25, P4319, DOI 10.1523/JNEUROSCI.5200-04.2005; O'Toole DA, 2007, CELL MOL LIFE SCI, V64, P1303, DOI 10.1007/s00018-007-7106-y; Pan H, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/217580; PARPURA V, 1994, NATURE, V369, P744, DOI 10.1038/369744a0; Pekny M, 2005, GLIA, V50, P427, DOI 10.1002/glia.20207; Pekny M, 1999, J CELL BIOL, V145, P503, DOI 10.1083/jcb.145.3.503; PENNYPACKER KR, 1994, J NEUROSCI, V14, P3998; Perez-Ortiz JM, 2008, EUR J NEUROSCI, V27, P2453, DOI 10.1111/j.1460-9568.2008.06197.x; Puschmann TB, 2010, NEUROSIGNALS, V18, P152, DOI 10.1159/000321494; Raivich G, 2006, PROG NEUROBIOL, V78, P347, DOI 10.1016/j.pneurobio.2006.03.006; Ransom BR, 2012, METHODS MOL BIOL, V814, P3, DOI 10.1007/978-1-61779-452-0_1; Reyes RC, 2012, ASN NEURO, V4, P33, DOI 10.1042/AN20110059; Robel S, 2011, J NEUROSCI, V31, P12471, DOI 10.1523/JNEUROSCI.2696-11.2011; Robinson ESJ, 2005, J NEUROSCI METH, V147, P48, DOI 10.1016/j.jneumeth.2005.03.003; Saadoun S, 2005, J CELL SCI, V118, P5691, DOI 10.1242/jcs.02680; SARID J, 1991, J NEUROSCI RES, V28, P217, DOI 10.1002/jnr.490280209; Scemes E, 2006, GLIA, V54, P716, DOI 10.1002/glia.20374; SMITH ME, 1983, BRAIN RES, V264, P241, DOI 10.1016/0006-8993(83)90822-3; Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002; Sriram K, 2004, J BIOL CHEM, V279, P19936, DOI 10.1074/jbc.M309304200; Theodoric N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047311; Tomobe YI, 1996, NEUROSCI LETT, V214, P57; van Weering HRJ, 2010, BRAIN BEHAV IMMUN, V24, P768, DOI 10.1016/j.bbi.2009.04.007; Verkhratsky A, 2006, ACTA PHARMACOL SIN, V27, P773, DOI 10.1111/j.1745-7254.2006.00396.x; VIJAYAN VK, 1990, MOL CHEM NEUROPATHOL, V13, P107, DOI 10.1007/BF03159912; Wang HH, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-84; Wang Y, 2002, CURR EYE RES, V24, P305, DOI 10.1076/ceyr.24.4.305.8408; Wu BY, 2000, J NEUROSCI RES, V62, P730, DOI 10.1002/1097-4547(20001201)62:5<730::AID-JNR13>3.0.CO;2-K; Wu CY, 2009, GLIA, V57, P1775, DOI 10.1002/glia.20890; Wu VW, 1998, J NEUROSCI RES, V51, P675, DOI 10.1002/(SICI)1097-4547(19980315)51:6<675::AID-JNR2>3.0.CO;2-8; Yang CZ, 2012, P NATL ACAD SCI USA, V109, P6963, DOI 10.1073/pnas.1118754109; Yoshii Y, 2011, NEUROSCI RES, V70, P321, DOI 10.1016/j.neures.2011.03.006; YU ACH, 1993, J NEUROSCI RES, V34, P295, DOI 10.1002/jnr.490340306; Yuan YM, 2012, BRIT J PHARMACOL, V166, P749, DOI 10.1111/j.1476-5381.2011.01804.x; Zhang ZJ, 2007, NAT CELL BIOL, V9, P945, DOI 10.1038/ncb1620; Zhu Z, 2007, GLIA, V55, P546, DOI 10.1002/glia.20476; Zorec R, 2012, ASN NEURO, V4, P103, DOI 10.1042/AN20110061	106	79	82	4	40	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	DEC	2013	61	12					2063	2077		10.1002/glia.22577			15	Neurosciences	Neurosciences & Neurology	240RG	WOS:000326114100010	24123203				2021-06-18	
J	Rockswold, SB; Rockswold, GL; Zaun, DA; Liu, JN				Rockswold, Sarah B.; Rockswold, Gaylan L.; Zaun, David A.; Liu, Jiannong			A prospective, randomized Phase II clinical trial to evaluate the effect of combined hyperbaric and normobaric hyperoxia on cerebral metabolism, intracranial pressure, oxygen toxicity, and clinical outcome in severe traumatic brain injury Clinical article	JOURNAL OF NEUROSURGERY			English	Article						hyperbaric oxygen; normobaric hyperoxia; traumatic brain injury cerebral metabolism; intracranial pressure; oxygen toxicity; clinical outcome	HEAD-INJURY; CEREBROSPINAL-FLUID; BLOOD-FLOW; RAT MODEL; INTRACEREBRAL MICRODIALYSIS; MITOCHONDRIAL-FUNCTION; ISCHEMIC TOLERANCE; THERAPY; MECHANISMS; DAMAGE	Object. Preclinical and clinical investigations indicate that the positive effect of hyperbaric oxygen (HBO2) for severe traumatic brain injury (TBI) occurs after rather than during treatment. The brain appears better able to use baseline O-2 levels following HBO2 treatments. In this study, the authors evaluate the combination of HBO2 and normobaric hyperoxia (NBH) as a single treatment. Methods. Forty-two patients who sustained severe TBI (mean Glasgow Coma Scale [GCS] score 5.7) were prospectively randomized within 24 hours of injury to either: 1) combined HBO2/NBH (60 minutes of HBO2 at 1.5 atmospheres absolute [ATA] followed by NBH, 3 hours of 100% fraction of inspired oxygen [FiO(2)] at 1.0 ATA) or 2) control, standard care. Treatments occurred once every 24 hours for 3 consecutive days. Intracranial pressure, surrogate markers for cerebral metabolism, and O-2 toxicity were monitored. Clinical outcome was assessed at 6 months using the sliding dichotomized Glasgow Outcome Scale (GOS) score. Mixed-effects linear modeling was used to statistically test differences between the treatment and control groups. Functional outcome and mortality rates were compared using chi-square tests. Results. There were no significant differences in demographic characteristics between the 2 groups. In comparison with values in the control group, brain tissue partial pressure of O-2 (PO2) levels were significantly increased during and following combined HBO2/NBH treatments in both the noninjured and pericontusional brain (p < 0.0001). Microdialysate lactate/pyruvate ratios were significantly decreased in the noninjured brain in the combined HBO2/NBH group as compared with controls (p < 0.0078). The combined HBO2/NBH group's intracranial pressure values were significantly lower than those of the control group during treatment, and the improvement continued until the next treatment session (p < 0.0006). The combined HBO2/NBH group's levels of microdialysate glycerol were significantly lower than those of the control group in both noninjured and pericontusional brain (p < 0.001). The combined HBO2/NBH group's level of CSF F2-isoprostane was decreased at 6 hours after treatment as compared with that of controls, but the difference did not quite reach statistical significance (p < 0.0692). There was an absolute 26% reduction in mortality for the combined HBO2/NBH group (p = 0.048) and an absolute 36% improvement in favorable outcome using the sliding dichotomized GOS (p = 0.024) as compared with the control group. Conclusions. In this Phase II clinical trial, in comparison with standard care (control treatment) combined HBO2/NBH treatments significantly improved markers of oxidative metabolism in relatively uninjured brain as well as pericontusional tissue, reduced intracranial hypertension, and demonstrated improvement in markers of cerebral toxicity. There was significant reduction in mortality and improved favorable outcome as measured by GOS. The combination of HBO2 and NBH therapy appears to have potential therapeutic efficacy as compared with the 2 treatments in isolation.	[Rockswold, Sarah B.] Hennepin Cty Med Ctr, Dept Phys Med & Rehabil, Minneapolis, MN 55415 USA; [Rockswold, Sarah B.; Rockswold, Gaylan L.] Hennepin Cty Med Ctr, Dept Surg, Div Neurosurg, Minneapolis, MN 55415 USA; [Rockswold, Sarah B.] Univ Minnesota, Dept Med & Rehabil, Minneapolis, MN USA; [Rockswold, Gaylan L.] Univ Minnesota, Dept Neurosurg, Minneapolis, MN 55455 USA; [Zaun, David A.; Liu, Jiannong] Minneapolis Med Res Fdn Inc, Chron Dis Res Grp, Analyt Serv, Minneapolis, MN USA	Rockswold, GL (corresponding author), Hennepin Cty Med Ctr, 701 Pk Ave, Minneapolis, MN 55415 USA.	gaylan.rockswold@hcmed.org			National Institute of Neurological Disorders and Stroke Hyperbaric and Normobaric Oxygen in Severe Brain Injury [R01-NS042126-03S1]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042126] Funding Source: NIH RePORTER	This work was supported by the National Institute of Neurological Disorders and Stroke Hyperbaric and Normobaric Oxygen in Severe Brain Injury Grant no. R01-NS042126-03S1 (G.L.R.). Integra Life Sciences provided technical assistance and supplies related to brain tissue O<INF>2</INF> monitoring.	Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI 10.1089/neu.2009-0898; Bayir H, 2004, J NEUROTRAUM, V21, P1, DOI 10.1089/089771504772695896; Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Danton GH, 2003, J NEUROPATH EXP NEUR, V62, P127, DOI 10.1093/jnen/62.2.127; Daugherty WP, 2004, J NEUROSURG, V101, P499, DOI 10.3171/jns.2004.101.3.0499; DEATON PR, 1994, AM J PHYSIOL, V267, pL187; DEFORGE LE, 1993, J BIOL CHEM, V268, P25568; DEMOPOULOS HB, 1982, CAN J PHYSIOL PHARM, V60, P1415, DOI 10.1139/y82-210; DEMOPOULOS HB, 1982, PATHOLOGY OXYGEN, P127; DESALLES AAF, 1987, NEUROSURGERY, V21, P45, DOI 10.1227/00006123-198707000-00009; Desmarquest P, 1998, RESP MED, V92, P951, DOI 10.1016/S0954-6111(98)90195-0; Engstrom M, 2005, J NEUROSURG, V102, P460, DOI 10.3171/jns.2005.102.3.0460; Fam SS, 2003, CURR MED CHEM, V10, P1723, DOI 10.2174/0929867033457115; Finkelstein EA., 2006, INCIDENCE EC BURDEN; Frykholm P, 2001, J NEUROL NEUROSUR PS, V71, P455, DOI 10.1136/jnnp.71.4.455; Furuya Y, 2003, NEUROSURGERY, V52, P340, DOI 10.1227/01.NEU.0000043931.83041.AA; Gossett WA, 2010, UNDERSEA HYPERBAR M, V37, P35; Harch PG, 2012, J NEUROTRAUM, V29, P168, DOI 10.1089/neu.2011.1895; IKEDA Y, 1990, NEUROSURGERY, V27, P1; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Kinoshita K, 2002, J NEUROTRAUM, V19, P681, DOI 10.1089/08977150260139075; KLEIN J, 1990, ANESTH ANALG, V70, P195; Krebs E G, 1972, Curr Top Cell Regul, V5, P99; MARSHALL LF, 1983, J NEUROSURG, V59, P285, DOI 10.3171/jns.1983.59.2.0285; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MASET AL, 1987, J NEUROSURG, V67, P832, DOI 10.3171/jns.1987.67.6.0832; Menon DK, 2004, CRIT CARE MED, V32, P1384, DOI 10.1097/01.CCM.0000127777.16609.08; Merenda A, 2008, J NEUROTRAUM, V25, P527, DOI 10.1089/neu.2007.0359; METZEL E, 1971, ACTA NEUROCHIR, V25, P177, DOI 10.1007/BF01809099; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; Morrow JD, 2000, DRUG METAB REV, V32, P377, DOI 10.1081/DMR-100102340; Muehstedt SG, 2001, SURGERY, V130, P602, DOI 10.1067/msy.2001.117105; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Palzur E, 2004, J NEUROTRAUM, V21, P41, DOI 10.1089/089771504772695931; Palzur E, 2008, BRAIN RES, V1221, P126, DOI 10.1016/j.brainres.2008.04.078; REA GL, 1983, NEUROSURGERY, V12, P401, DOI 10.1227/00006123-198304000-00005; ROCKSWOLD G L, 1985, HYPERBARIC OXYGEN RE, V6, P161; ROCKSWOLD GL, 1992, J NEUROSURG, V76, P929, DOI 10.3171/jns.1992.76.6.0929; ROCKSWOLD GL, 1987, NEUROSURGERY, V21, P51, DOI 10.1227/00006123-198707000-00010; Rockswold SB, 2010, J NEUROSURG, V112, P1080, DOI 10.3171/2009.7.JNS09363; Rockswold SB, 2001, J NEUROSURG, V94, P403, DOI 10.3171/jns.2001.94.3.0403; Rogatsky GG, 2005, BRAIN RES, V1047, P131, DOI 10.1016/j.brainres.2005.02.049; Siesjo BK, 1996, EUR J ANAESTH, V13, P247, DOI 10.1046/j.1365-2346.1996.00976.x; Simard JM, 2010, J NEUROSURG, V113, P622, DOI 10.3171/2009.11.JNS081052; Simard JM, 2009, J NEUROTRAUM, V26, P2257, DOI 10.1089/neu.2009.1021; Soustiel JF, 2008, NEUROPATH APPL NEURO, V34, P412, DOI 10.1111/j.1365-2990.2007.00906.x; Stahl N, 2001, ACTA ANAESTH SCAND, V45, P977, DOI 10.1034/j.1399-6576.2001.450810.x; Tisdall MM, 2008, J NEUROSURG, V109, P424, DOI 10.3171/JNS/2008/109/9/0424; Tolias CM, 2004, J NEUROSURG, V101, P435, DOI 10.3171/jns.2004.101.3.0435; Valadka AB, 1998, J NEUROTRAUM, V15, P509, DOI 10.1089/neu.1998.15.509; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; Vespa PM, 2007, CRIT CARE MED, V35, P1153, DOI 10.1097/01.CCM.0000259466.66310.4F; Vigue B, 1999, INTENS CARE MED, V25, P445, DOI 10.1007/s001340050878; Vlodavsky E, 2006, NEUROPATH APPL NEURO, V32, P40, DOI 10.1111/j.1365-2990.2005.00698.x; Vlodavsky E, 2005, ACTA NEUROPATHOL, V110, P120, DOI 10.1007/s00401-004-0946-8; Wada K, 2001, NEUROSURGERY, V49, P160; Wada K, 1996, BRAIN RES, V740, P15; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Zhang T, 2010, BRAIN INJURY, V24, P1350, DOI 10.3109/02699052.2010.504525; Zhou ZW, 2007, J NEUROSURG, V106, P687, DOI 10.3171/jns.2007.106.4.687; ZHUANG J, 1993, J TRAUMA, V35, P415, DOI 10.1097/00005373-199309000-00014	65	79	91	0	12	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JUN	2013	118	6					1317	1328		10.3171/2013.2.JNS121468			12	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	150BY	WOS:000319366400032	23510092	Bronze			2021-06-18	
J	Xuan, WJ; Vatansever, F; Huang, LY; Wu, QH; Xuan, Y; Dai, TH; Ando, T; Xu, T; Huang, YY; Hamblin, MR				Xuan, Weijun; Vatansever, Fatma; Huang, Liyi; Wu, Qiuhe; Xuan, Yi; Dai, Tianhong; Ando, Takahiro; Xu, Tao; Huang, Ying-Ying; Hamblin, Michael R.			Transcranial Low-Level Laser Therapy Improves Neurological Performance in Traumatic Brain Injury in Mice: Effect of Treatment Repetition Regimen	PLOS ONE			English	Article							BIPHASIC DOSE-RESPONSE; ACUTE ISCHEMIC-STROKE; LIGHT THERAPY; FLUORO-JADE; ADULT BRAIN; NEURONAL DEGENERATION; SUBVENTRICULAR ZONE; STEM-CELLS; DEFICITS; NEUROGENESIS	Low-level laser (light) therapy (LLLT) has been clinically applied around the world for a spectrum of disorders requiring healing, regeneration and prevention of tissue death. One area that is attracting growing interest in this scope is the use of transcranial LLLT to treat stroke and traumatic brain injury (TBI). We developed a mouse model of severe TBI induced by controlled cortical impact and explored the effect of different treatment schedules. Adult male BALB/c mice were divided into 3 broad groups (a) sham-TBI sham-treatment, (b) real-TBI sham-treatment, and (c) real-TBI active-treatment. Mice received active-treatment (transcranial LLLT by continuous wave 810 nm laser, 25 mW/cm(2), 18 J/cm(2), spot diameter 1 cm) while sham-treatment was immobilization only, delivered either as a single treatment at 4 hours post TBI, as 3 daily treatments commencing at 4 hours post TBI or as 14 daily treatments. Mice were sacrificed at 0, 4, 7, 14 and 28 days post-TBI for histology or histomorphometry, and injected with bromodeoxyuridine (BrdU) at days 21-27 to allow identification of proliferating cells. Mice with severe TBI treated with 1-laser Tx (and to a greater extent 3-laser Tx) had significant improvements in neurological severity score (NSS), and wire-grip and motion test (WGMT). However 14-laser Tx provided no benefit over TBI-sham control. Mice receiving 1-and 3-laser Tx had smaller lesion size at 28-days (although the size increased over 4 weeks in all TBI-groups) and less Fluoro-Jade staining for degenerating neurons (at 14 days) than in TBI control and 14-laser Tx groups. There were more BrdU-positive cells in the lesion in 1-and 3-laser groups suggesting LLLT may increase neurogenesis. Transcranial NIR laser may provide benefit in cases of acute TBI provided the optimum treatment regimen is employed.	[Xuan, Weijun; Vatansever, Fatma; Huang, Liyi; Wu, Qiuhe; Xuan, Yi; Dai, Tianhong; Ando, Takahiro; Xu, Tao; Huang, Ying-Ying; Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA; [Xuan, Weijun; Vatansever, Fatma; Huang, Liyi; Wu, Qiuhe; Dai, Tianhong; Xu, Tao; Huang, Ying-Ying; Hamblin, Michael R.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA; [Xuan, Weijun] Tradit Chinese Med Univ Guangxi, Dept Otolaryngol, Nanning, Peoples R China; [Huang, Liyi] Guangxi Med Univ, Affiliated Coll & Hosp 1, Dept Infect Dis, Nanning, Peoples R China; [Wu, Qiuhe] Jinan Ctr Hosp, Dept Burn, Jinan, Peoples R China; [Xuan, Yi] Tufts Univ, Sch Engn, Medford, MA USA; [Ando, Takahiro] Keio Univ, Dept Elect & Elect Engn, Kohoku Ku, Yokohama, Kanagawa 223, Japan; [Xu, Tao] Shanghai Jiao Tong Univ, Lab Anesthesiol, Shanghai 200030, Peoples R China; [Huang, Ying-Ying] Guangxi Med Univ, Aesthet & Plast Ctr, Nanning, Peoples R China; [Hamblin, Michael R.] Harvard MIT Div Hlth Sci & Technol, Cambridge, MA USA	Hamblin, MR (corresponding author), Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.	hamblin@helix.mgh.harvard.edu	Ando, Takahiro/H-5209-2019; Huang, Ying-ying/G-3153-2011; Huang, yingying/J-7329-2012; Dai, Tianhong/P-5961-2018; Ando, Takahiro/R-8374-2019; Hamblin, Michael R/H-2758-2019	Huang, Ying-ying/0000-0003-3066-6981; Huang, yingying/0000-0002-4038-0277; Dai, Tianhong/0000-0001-8960-8896; Hamblin, Michael R/0000-0001-6431-4605; Xu, Tao/0000-0001-5868-4079	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01AI050875]; Center for Integration of Medicine and Innovative Technology [DAMD17-02-2-0006]; CDMRP Program in TBI [W81XWH-09-1-0514]; Air Force Office of Scientific Research Military Photomedicine Program [FA9550-11-1-0331]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R01AI050875] Funding Source: NIH RePORTER; Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [10J04881] Funding Source: KAKEN	NIH grant R01AI050875, Center for Integration of Medicine and Innovative Technology (DAMD17-02-2-0006), CDMRP Program in TBI (W81XWH-09-1-0514) and Air Force Office of Scientific Research Military Photomedicine Program (FA9550-11-1-0331). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ando T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026212; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Bains M, 2012, BBA-MOL BASIS DIS, V1822, P675, DOI 10.1016/j.bbadis.2011.10.017; Barker JM, 2011, EUR J NEUROSCI, V34, P963, DOI 10.1111/j.1460-9568.2011.07823.x; Bermpohl D, 2006, J CEREBR BLOOD F MET, V26, P625, DOI 10.1038/sj.jcbfm.9600258; Chen ACH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022453; Chung H, 2012, ANN BIOMED ENG, V40, P516, DOI 10.1007/s10439-011-0454-7; DeTaboada L, 2006, LASER SURG MED, V38, P70, DOI 10.1002/lsm.20256; Feeser VR, 2011, J NEUROIMMUNOL, V237, P4, DOI 10.1016/j.jneuroim.2011.06.007; Frenette AJ, 2012, J NEUROTRAUM, V29, P1, DOI 10.1089/neu.2011.1812; GRATZNER HG, 1982, SCIENCE, V218, P474, DOI 10.1126/science.7123245; Heile Anna, 2011, Dialogues Clin Neurosci, V13, P279; Huang YY, 2012, J BIOPHOTONICS, V5, P827, DOI 10.1002/jbio.201200077; Huang YY, 2011, DOSE-RESPONSE, V9, P602, DOI 10.2203/dose-response.11-009.Hamblin; Huang YY, 2009, DOSE-RESPONSE, V7, P358, DOI 10.2203/dose-response.09-027.Hamblin; Karonen JO, 1999, STROKE, V30, P1583, DOI 10.1161/01.STR.30.8.1583; KARU T, 1995, J PHOTOCH PHOTOBIO B, V27, P219, DOI 10.1016/1011-1344(94)07078-3; Karu TI, 2005, LASER SURG MED, V36, P307, DOI 10.1002/lsm.20148; Khuman J, 2012, J NEUROTRAUM, V29, P408, DOI 10.1089/neu.2010.1745; Kokaia Z, 2006, CEREB CORTEX, V16, pI162, DOI 10.1093/cercor/bhj174; Kuo JR, 2011, J TRAUMA, V71, pE87, DOI 10.1097/TA.0b013e31820932e2; Lampl Y, 2007, STROKE, V38, P1843, DOI 10.1161/STROKEAHA.106.478230; Lampl Yair, 2007, Expert Rev Neurother, V7, P961, DOI 10.1586/14737175.7.8.961; Lapchak PA, 2004, STROKE, V35, P1985, DOI 10.1161/01.STR.0000131808.69640.b7; Leddy JJ, 2007, NEUROREHABILITATION, V22, P199; Ling GSF, 2011, CURR OPIN ANESTHESIO, V24, P124, DOI 10.1097/ACO.0b013e32834458da; Ling GSF, 2005, NEUROCRIT CARE, V2, P75, DOI 10.1385/NCC:2:1:075; Lulic D, 2011, NEUROSURGERY, V68, P1172, DOI 10.1227/NEU.0b013e31820c6cdc; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; McIntosh TK, 1996, EUR J ANAESTH, V13, P291, DOI 10.1046/j.1365-2346.1996.00981.x; Muller CJ, 2009, EXP NEUROL, V219, P284, DOI 10.1016/j.expneurol.2009.05.035; Naeser MA, 2011, PHOTOMED LASER SURG, V29, P443, DOI 10.1089/pho.2011.9908; Naeser MA, 2011, PHOTOMED LASER SURG, V29, P351, DOI 10.1089/pho.2010.2814; Nichol AD, 2011, LANCET NEUROL, V10, P405, DOI 10.1016/S1474-4422(11)70085-0; Oron A, 2007, J NEUROTRAUM, V24, P651, DOI 10.1089/neu.2006.0198; Oron A, 2006, STROKE, V37, P2620, DOI 10.1161/01.STR.0000242775.14642.b8; Oron A, 2012, J NEUROTRAUM, V29, P401, DOI 10.1089/neu.2011.2062; Pascual JL, 2011, J TRAUMA, V70, P535, DOI 10.1097/TA.0b013e31820b59de; Quirk BJ, 2012, PHOTOMED LASER SURG, V30, P523, DOI 10.1089/pho.2012.3261; Rabinowit P., 2007, METHODS NUMERICAL IN; Salman H, 2004, J NEUROTRAUM, V21, P283, DOI 10.1089/089771504322972077; Schmued LC, 2005, BRAIN RES, V1035, P24, DOI 10.1016/j.brainres.2004.11.054; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Schmued LC, 2000, TOXICOL PATHOL, V28, P91, DOI 10.1177/019262330002800111; Sharma SK, 2011, LASER SURG MED, V43, P851, DOI 10.1002/lsm.21100; Stemer Andrew B, 2010, Curr Cardiol Rep, V12, P29, DOI 10.1007/s11886-009-0071-3; Streeter J, 2004, MITOCHONDRION, V4, P569, DOI 10.1016/j.mito.2004.07.037; Thored P, 2006, STEM CELLS, V24, P739, DOI 10.1634/stemcells.2005-0281; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052; Wong-Riley MTT, 2005, J BIOL CHEM, V280, P4761, DOI 10.1074/jbc.M409650200; Wu QH, 2012, LASER SURG MED, V44, P218, DOI 10.1002/lsm.22003; Xiong Y, 2010, DISCOV MED, V10, P434; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001; Zhang RL, 2008, NEUROPHARMACOLOGY, V55, P345, DOI 10.1016/j.neuropharm.2008.05.027; Zivin JA, 2009, STROKE, V40, P1359, DOI 10.1161/STROKEAHA.109.547547	55	79	82	0	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 7	2013	8	1							e53454	10.1371/journal.pone.0053454			9	Multidisciplinary Sciences	Science & Technology - Other Topics	069IS	WOS:000313429100069	23308226	DOAJ Gold, Green Published			2021-06-18	
J	Duhaime, AC; Beckwith, JG; Maerlender, AC; McAllister, TW; Crisco, JJ; Duma, SM; Brolinson, PG; Rowson, S; Flashman, LA; Chu, JJ; Greenwald, RM				Duhaime, Ann-Christine; Beckwith, Jonathan G.; Maerlender, Arthur C.; McAllister, Thomas W.; Crisco, Joseph J.; Duma, Stefan M.; Brolinson, P. Gunnar; Rowson, Steven; Flashman, Laura A.; Chu, Jeffrey J.; Greenwald, Richard M.			Spectrum of acute clinical characteristics of diagnosed concussions in college athletes wearing instrumented helmets Clinical article	JOURNAL OF NEUROSURGERY			English	Article						concussion; traumatic brain injury; biomechanics; athletes; football; hockey	TRAUMATIC BRAIN-INJURY; HEAD IMPACT EXPOSURES; RECURRENT CONCUSSION; CEREBRAL CONCUSSION; FOOTBALL; MILD; RISK; ACCELERATION; KINEMATICS; DEPRESSION	Object. Concussive head injuries have received much attention in the medical and public arenas, as concerns have been raised about the potential short- and long-term consequences of injuries sustained in sports and other activities. While many student athletes have required evaluation after concussion, the exact definition of concussion has varied among disciplines and over time. The authors used data gathered as part of a multiinstitutional longitudinal study of the biomechanics of head impacts in helmeted collegiate athletes to characterize what signs, symptoms, and clinical histories were used to designate players as having sustained concussions. Methods. Players on 3 college football teams and 4 ice hockey teams (male and female) wore helmets instrumented with Head Impact Telemetry (HIT) technology during practices and games over 2-4 seasons of play. Preseason clinical screening batteries assessed baseline cognition and reported symptoms. If a concussion was diagnosed by the team medical staff, basic descriptive information was collected at presentation, and concussed players were reevaluated serially. The specific symptoms or findings associated with the diagnosis of acute concussion, relation to specific impact events, timing of symptom onset and diagnosis, and recorded biomechanical parameters were analyzed. Results. Data were collected from 450 athletes with 486,594 recorded head impacts. Forty-eight separate concussions were diagnosed in 44 individual players. Mental clouding, headache, and dizziness were the most common presenting symptoms. Thirty-one diagnosed cases were associated with an identified impact event; in 17 cases no specific impact event was identified. Onset of symptoms was immediate in 24 players, delayed in 11, and unspecified in 13. In 8 cases the diagnosis was made immediately after a head impact, but in most cases the diagnosis was delayed (median 17 hours). One diagnosed concussion involved a 30-second loss of consciousness; all other players retained alertness. Most diagnoses were based on self-reported symptoms. The mean peak angular and rotational acceleration values for those cases associated with a specific identified impact were 86.1 +/- 42.6g (range 16.5-177.9g) and 3620 +/- 2166 rad/sec(2) (range 183-7589 rad/sec(2)), respectively. Conclusions. Approximately two-thirds of diagnosed concussions were associated with a specific contact event. Half of all players diagnosed with concussions had delayed or unclear timing of onset of symptoms. Most had no externally observed findings. Diagnosis was usually based on a range of self-reported symptoms after a variable delay. Accelerations clustered in the higher percentiles for all impact events, but encompassed a wide range. These data highlight the heterogeneity of criteria for concussion diagnosis, and in this sports context, its heavy reliance on self-reported symptoms. More specific and standardized definitions of clinical and objective correlates of a "concussion spectrum" may be needed in future research efforts, as well as in the clinical diagnostic arena. (http://thejns.org/doi/abs/10.3171/2012.8.JNS112298)	[Duhaime, Ann-Christine] Harvard Univ, Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA; [Beckwith, Jonathan G.; Chu, Jeffrey J.; Greenwald, Richard M.] Simbex, Lebanon, NH USA; [Maerlender, Arthur C.] Dartmouth Med Sch, Pediat Neuropsychol Serv, Lebanon, NH USA; [McAllister, Thomas W.; Flashman, Laura A.] Dartmouth Med Sch, Dept Psychiat, Lebanon, NH USA; [Greenwald, Richard M.] Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA; [Crisco, Joseph J.] Brown Univ, Warren Alpert Med Sch, Dept Orthopaed, Bioengn Lab, Providence, RI 02912 USA; [Crisco, Joseph J.] Rhode Isl Hosp, Providence, RI USA; [Duma, Stefan M.; Rowson, Steven] Virginia Tech, Wake Forest Ctr Injury Biomech, Blacksburg, VA USA; [Brolinson, P. Gunnar] Edward Via Virginia Coll Osteopath Med, Blacksburg, VA USA	Duhaime, AC (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Dept Neurosurg, 15 Parkman St,Wang 331, Boston, MA 02114 USA.	aduhaime@partners.org	Duma, Stefan/A-8368-2012; Rowson, Steven/B-1270-2012	Rowson, Steven/0000-0002-3227-0596	National Institute for Child Health and Human Development at the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048638]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048638] Funding Source: NIH RePORTER	The research for this study is supported by the National Institute for Child Health and Human Development at the National Institutes of Health (Grant R01HD048638).	Alla S, 2012, BRIT J SPORT MED, V46, P562, DOI 10.1136/bjsm.2010.081299; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Beckwith JG, 2010, 8 WORLD C BRAIN INJ; Beckwith JG, 2012, ANN BIOMED ENG, V40, P237, DOI 10.1007/s10439-011-0422-2; Brainard LL, 2012, MED SCI SPORT EXER, V44, P297, DOI 10.1249/MSS.0b013e31822b0ab4; CANTU RC, 1992, SPORTS MED, V14, P64, DOI 10.2165/00007256-199214010-00005; Cantu RC, 2003, NEUROSURGERY, V52, P846, DOI 10.1227/01.NEU.0000053210.76063.E4; Chu JJ, 2006, J BIOMECH S1, V39, pS534; Crisco JJ, 2004, J BIOMECH ENG-T ASME, V126, P849, DOI 10.1115/1.1824135; Crisco JJ, 2012, J APPL BIOMECH, V28, P174, DOI 10.1123/jab.28.2.174; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Duma S, 2004, 2004 ANN M AM SOC BI; FISHER CM, 1966, NEUROLOGY, V16, P826, DOI 10.1212/WNL.16.8.826; Funk J R, 2007, Annu Proc Assoc Adv Automot Med, V51, P343; Gennarelli T A, 1983, Acta Neurochir Suppl (Wien), V32, P1; Gioia GA, 2009, BRIT J SPORT MED, V43, pI13, DOI 10.1136/bjsm.2009.058255; Gioia GA, 2008, J HEAD TRAUMA REHAB, V23, P230, DOI 10.1097/01.HTR.0000327255.38881.ca; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Gwin J., 2006, J BIOMECH, V39, pS153; Gwin J. T., 2009, J ASTM INT, V6, P1; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Maerlender A, 2010, CLIN NEUROPSYCHOL, V24, P1309, DOI 10.1080/13854046.2010.516072; Manoogian S, 2006, BIOMED SCI INSTRUM, V42, P383; Marion DW, 2011, J NEUROTRAUM, V28, P517, DOI 10.1089/neu.2010.1638; McAllister TW, 2012, NEUROLOGY, V78, P1777, DOI 10.1212/WNL.0b013e3182582fe7; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McAllister TW, 2012, ANN BIOMED ENG, V40, P127, DOI 10.1007/s10439-011-0402-6; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrory P, 2009, J SCI MED SPORT, V12, P340, DOI 10.1016/j.jsams.2009.02.004; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; Rowson S, 2011, ANN BIOMED ENG, V39, P2130, DOI 10.1007/s10439-011-0322-5; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Silver JM, 2009, AM J PSYCHIAT, V166, P653, DOI 10.1176/appi.ajp.2009.08111676; Takhounts EG, 2008, STAPP CAR C, V52, P1; Valadka AB, 1996, NEUROTRAUMA, P119; YARNELL PR, 1973, NEUROLOGY, V23, P196, DOI 10.1212/WNL.23.2.196	43	79	80	1	38	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	DEC	2012	117	6					1092	1099		10.3171/2012.8.JNS112298			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	042IC	WOS:000311463900016	23030057	Green Accepted, Green Published, Bronze			2021-06-18	
J	Choi, BY; Jang, BG; Kim, JH; Lee, BE; Sohn, M; Song, HK; Suh, SW				Choi, Bo Yong; Jang, Bong Geom; Kim, Jin Hee; Lee, Bo Eun; Sohn, Min; Song, Hong Ki; Suh, Sang Won			Prevention of traumatic brain injury-induced neuronal death by inhibition of NADPH oxidase activation	BRAIN RESEARCH			English	Article						Traumatic brain injury; Apocynin; Hippocampus; NADPH oxidase; Microglia; Reactive oxygen species; Blood-brain barrier disruption	POLY(ADP-RIBOSE) POLYMERASE; NEUTROPHIL ACCUMULATION; CEREBRAL-ISCHEMIA; OXIDATIVE STRESS; APOCYNIN; ZINC; SUPEROXIDE; RATS; HYPERTHERMIA; REPERFUSION	The present study aimed to evaluate the therapeutic potential of apocynin, an NADPH oxidase assembly inhibitor, on traumatic brain injury. Rat traumatic brain injury (TBI) was performed using a weight drop model. Apocynin (100 mg/kg) was injected into the intraperitoneal space 15 min before TBI. Reactive oxygen species (ROS) in the hippocampal CA3 pyramidal neurons were detected by dihydroethidium (dHEt) at 3 h after TBI. Oxidative injury was detected by 4-hydroxy-2-nonenal (4HNE) at 6 h after TBI. Blood-brain barrier disruption was detected by IgG extravasation and neuronal death was evaluated with Fluoro Jade-B staining 24h after TBI. Microglia activation was detected by CD11b immunohistochemistry in the hippocampus at 1 week after TBI. ROS production was inhibited by apocynin administration in the hippocampal CA3 pyramidal neurons. This pre-treatment with apocynin decreased the blood-brain barrier disruption, the number of degenerating neurons in the hippocampal CA3 region and microglial activation after TBI. The present study indicates that apocynin pre-treatment prevents TBI-induced ROS production, thus decreasing BBB disruption, neuronal death and microglial activation. Therefore, the present study suggests that inhibition of NADPH oxidase by apocynin may have a high therapeutic potential to reduce traumatic brain injury-induced neuronal death. (C) 2012 Elsevier B.V. All rights reserved.	[Choi, Bo Yong; Jang, Bong Geom; Kim, Jin Hee; Lee, Bo Eun; Suh, Sang Won] Hallym Univ, Coll Med, Dept Physiol, 1 Okcheon Dong,39 Hallymdaehak Gil, Chunchon 200702, South Korea; [Suh, Sang Won] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA; [Suh, Sang Won] Vet Affairs Med Ctr, San Francisco, CA 94121 USA; [Sohn, Min] Inha Univ, Dept Nursing, Inchon, South Korea; [Song, Hong Ki] Hallym Univ, Coll Med, Dept Neurol, Chunchon 200702, South Korea	Suh, SW (corresponding author), Hallym Univ, Coll Med, Dept Physiol, 1 Okcheon Dong,39 Hallymdaehak Gil, Chunchon 200702, South Korea.	hksong0@paran.com; swsuh@hallym.ac.kr		SOHN, MIN/0000-0003-4021-2051; Choi, Bo Young/0000-0002-9579-3503	Korea Healthcare technology RAMP;D Project, Ministry of Health AMP; Welfare, Republic of Korea [A120202]	This study was supported by a grant of the Korea Healthcare technology R&D Project, Ministry of Health & Welfare, Republic of Korea (A120202). Sang Won Suh, MD, PhD is the person whom takes full responsibility for the manuscript and its originality. The authors thank Aaron M. Hamby, University of California, Berkeley, for help with preparing the manuscript and Ms, Tae Yul Kim for schematic illustration.	Brennan AM, 2009, NAT NEUROSCI, V12, P857, DOI 10.1038/nn.2334; Cai AL, 2006, EUR J NEUROSCI, V24, P2169, DOI 10.1111/j.1460-9568.2006.05110.x; Carbonell WS, 1999, ANN NY ACAD SCI, V890, P287, DOI 10.1111/j.1749-6632.1999.tb08005.x; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; DeCoursey TE, 2005, CELL MOL LIFE SCI, V62, P2173, DOI 10.1007/s00018-005-5177-1; Groemping Y, 2005, BIOCHEM J, V386, P401, DOI 10.1042/BJ20041835; Hart B A, 1992, Biotechnol Ther, V3, P119; Hayashi T, 2005, DIABETES OBES METAB, V7, P334, DOI 10.1111/j.1463-1326.2004.00393.x; Hoane MR, 2006, BRAIN RES, V1125, P185, DOI 10.1016/j.brainres.2006.10.019; Inamasu J, 2000, J NEUROIMMUNOL, V109, P66, DOI 10.1016/S0165-5728(00)00211-3; Kauppinen TM, 2008, J NEUROSCI, V28, P5827, DOI 10.1523/JNEUROSCI.1236-08.2008; Kauppinen UM, 2005, J IMMUNOL, V174, P2288, DOI 10.4049/jimmunol.174.4.2288; Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412; LaPlaca MC, 2001, J NEUROTRAUM, V18, P369, DOI 10.1089/089771501750170912; Lewen A, 1998, J NEUROTRAUM, V15, P521, DOI 10.1089/neu.1998.15.521; Lewen A, 2001, J CEREBR BLOOD F MET, V21, P914, DOI 10.1097/00004647-200108000-00003; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Mabuchi T, 2000, STROKE, V31, P1735, DOI 10.1161/01.STR.31.7.1735; Marklund N, 2001, J NEUROTRAUM, V18, P821, DOI 10.1089/089771501316919184; Mikawa S, 1996, J NEUROSURG, V85, P885, DOI 10.3171/jns.1996.85.5.0885; Murakami K, 1998, BRAIN RES, V780, P304, DOI 10.1016/S0006-8993(97)01217-1; Parikh S, 2007, INT ANESTHESIOL CLIN, V45, P119, DOI 10.1097/AIA.0b013e318078cfe7; Peters EA, 2001, FREE RADICAL BIO MED, V31, P1442, DOI 10.1016/S0891-5849(01)00725-0; RUTH RE, 1988, ACTA NEUROPATHOL, V76, P380, DOI 10.1007/BF00686975; Schroeter M, 1997, STROKE, V28, P382, DOI 10.1161/01.STR.28.2.382; Singh P, 2003, NEUROL INDIA, V51, P215; STOLK J, 1994, AM J RESP CELL MOL, V11, P95, DOI 10.1165/ajrcmb.11.1.8018341; Suh SW, 2008, J CEREBR BLOOD F MET, V28, P1697, DOI 10.1038/jcbfm.2008.61; Suh SW, 2007, J CLIN INVEST, V117, P910, DOI 10.1172/JCI30077; Suh SW, 2008, ANN NEUROL, V64, P654, DOI 10.1002/ana.21511; Suh SW, 2006, J CEREBR BLOOD F MET, V26, P161, DOI 10.1038/sj.jcbfm.9600176; Suh SW, 2003, J NEUROSCI, V23, P10681; Suh SW, 2000, BRAIN RES, V852, P268, DOI 10.1016/S0006-8993(99)02095-8; Tang XN, 2008, NEUROSCIENCE, V154, P556, DOI 10.1016/j.neuroscience.2008.03.090; Tang XAN, 2010, J NEUROSCI METH, V190, P240, DOI 10.1016/j.jneumeth.2010.05.004; Thompson HJ, 2005, J CEREBR BLOOD F MET, V25, P163, DOI 10.1038/sj.jcbfm.9600008; Van den Worm E, 2001, EUR J PHARMACOL, V433, P225, DOI 10.1016/S0014-2999(01)01516-3; Wang Q, 2006, BRAIN RES, V1090, P182, DOI 10.1016/j.brainres.2006.03.060; Weight DG, 1998, PSYCHIAT CLIN N AM, V21, P609, DOI 10.1016/S0193-953X(05)70026-5; Yenari MA, 2006, STROKE, V37, P1087, DOI 10.1161/01.STR.0000206281.77178.ac; Zhang QG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034504	41	79	80	0	14	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	OCT 24	2012	1481						49	58		10.1016/j.brainres.2012.08.032			10	Neurosciences	Neurosciences & Neurology	114AE	WOS:000316711100004	22975130				2021-06-18	
J	Dzhala, V; Valeeva, G; Glykys, J; Khazipov, R; Staley, K				Dzhala, Volodymyr; Valeeva, Guzel; Glykys, Joseph; Khazipov, Rustem; Staley, Kevin			Traumatic Alterations in GABA Signaling Disrupt Hippocampal Network Activity in the Developing Brain	JOURNAL OF NEUROSCIENCE			English	Article							CATION-CHLORIDE COTRANSPORTERS; GIANT DEPOLARIZING POTENTIALS; GRAMICIDIN-PERFORATED-PATCH; NEONATAL-RAT HIPPOCAMPUS; TEMPORAL-LOBE EPILEPSY; K-CL COTRANSPORTER; IN-VITRO ISCHEMIA; EXCITATORY ACTIONS; INTRACELLULAR CHLORIDE; ELECTROGRAPHIC SEIZURES	Severe head trauma causes widespread neuronal shear injuries and acute seizures. Shearing of neural processes might contribute to seizures by disrupting the transmembrane ion gradients that subserve normal synaptic signaling. To test this possibility, we investigated changes in intracellular chloride concentration ([Cl-](i)) associated with the widespread neural shear injury induced during preparation of acute brain slices. In hippocampal slices and intact hippocampal preparations from immature CLM-1 mice, increases in [Cl-](i) correlated with disruption of neural processes and biomarkers of cell injury. Traumatized neurons with higher [Cl-](i) demonstrated excitatory GABA signaling, remained synaptically active, and facilitated network activity as assayed by the frequency of extracellular action potentials and spontaneous network-driven oscillations. These data support a more inhibitory role for GABA in the unperturbed immature brain, demonstrate the utility of the acute brain slice preparation for the study of the consequences of trauma, and provide potential mechanisms for both GABA-mediated excitatory network events in the slice preparation and early post-traumatic seizures.	[Dzhala, Volodymyr; Glykys, Joseph; Staley, Kevin] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA; [Dzhala, Volodymyr; Glykys, Joseph; Staley, Kevin] Harvard Univ, Sch Med, Boston, MA 02114 USA; [Valeeva, Guzel; Khazipov, Rustem] Natl Inst Hlth & Med Res, INSERM, U901, F-13273 Marseille, France; [Valeeva, Guzel; Khazipov, Rustem] Kazan Fed Univ, Kazan 420008, Russia	Staley, K (corresponding author), MIND, Dept Neurol, MGH 16th St,CNY B-114,Room 2600, Charlestown, MA 02129 USA.	kstaley@partners.org	Valeeva, Guzel/B-2864-2014; Khazipov, Roustem/M-1834-2016	Valeeva, Guzel/0000-0001-6745-059X; Khazipov, Roustem/0000-0002-6763-2841; Glykys, Joseph/0000-0002-1499-9172	U.S. National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 40109-06]; FRMFondation pour la Recherche Medicale; Agence National de la RechercheFrench National Research Agency (ANR); RF Government [11.G34.31.0075]; Russian Foundation for Basic ResearchRussian Foundation for Basic Research (RFBR); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040109, R01NS074772, R01NS034700] Funding Source: NIH RePORTER	This work was supported by the U.S. National Institutes of Health and National Institute of Neurological Disorders and Stroke Grant NS 40109-06 to K. S., by FRM, Agence National de la Recherche, and RF Government 11.G34.31.0075 grants to R. K., and Russian Foundation for Basic Research grant to G. V. We thank our colleagues for discussion of the manuscript.	BAK IJ, 1980, BRAIN RES, V197, P341, DOI 10.1016/0006-8993(80)91120-8; Ben-Ari Y, 1987, Electroencephalogr Clin Neurophysiol Suppl, V39, P209; Ben-Ari Y, 2007, PHYSIOL REV, V87, P1215, DOI 10.1152/physrev.00017.2006; BENARI Y, 1989, J PHYSIOL-LONDON, V416, P303, DOI 10.1113/jphysiol.1989.sp017762; Berglund K, 2008, BRAIN CELL BIOL, V36, P101, DOI 10.1007/s11068-008-9031-x; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; Blaesse P, 2009, NEURON, V61, P820, DOI 10.1016/j.neuron.2009.03.003; Bonifazi P, 2009, SCIENCE, V326, P1419, DOI 10.1126/science.1175509; Bonislawski DP, 2007, NEUROBIOL DIS, V25, P163, DOI 10.1016/j.nbd.2006.09.002; Brandt C, 2010, J NEUROSCI, V30, P8602, DOI 10.1523/JNEUROSCI.0633-10.2010; Brumback AC, 2008, J NEUROSCI, V28, P1301, DOI 10.1523/JNEUROSCI.3378-07.2008; Cancedda L, 2007, J NEUROSCI, V27, P5224, DOI 10.1523/JNEUROSCI.5169-06.2007; CHERUBINI E, 1991, TRENDS NEUROSCI, V14, P515, DOI 10.1016/0166-2236(91)90003-D; Chiaretti A, 2002, CHILD NERV SYST, V18, P129, DOI 10.1007/s00381-002-0558-3; Claassen J, 2004, NEUROLOGY, V62, P1743, DOI 10.1212/01.WNL.0000125184.88797.62; Cohen I, 2002, SCIENCE, V298, P1418, DOI 10.1126/science.1076510; Cohen I, 2000, J PHYSIOL-LONDON, V524, P485, DOI 10.1111/j.1469-7793.2000.00485.x; Darzynkiewicz Z, 2011, METHODS MOL BIOL, V682, P103, DOI 10.1007/978-1-60327-409-8_9; Davies ML, 2007, J NEUROSCI METH, V166, P203, DOI 10.1016/j.jneumeth.2007.07.012; Delpire E, 2000, NEWS PHYSIOL SCI, V15, P309, DOI 10.1152/physiologyonline.2000.15.6.309; Delpire E, 2009, P NATL ACAD SCI USA, V106, P5383, DOI 10.1073/pnas.0812756106; Duebel J, 2006, NEURON, V49, P81, DOI 10.1016/j.neuron.2005.10.035; Dzhala VI, 2005, NAT MED, V11, P1205, DOI 10.1038/nm1301; Dzhala VI, 2003, J NEUROSCI, V23, P1840; Dzhala VI, 2008, ANN NEUROL, V63, P222, DOI 10.1002/ana.21229; Dzhala VI, 2010, J NEUROSCI, V30, P11745, DOI 10.1523/JNEUROSCI.1769-10.2010; EBIHARA S, 1995, J PHYSIOL-LONDON, V484, P77, DOI 10.1113/jphysiol.1995.sp020649; Galeffi F, 2004, J NEUROSCI, V24, P4478, DOI 10.1523/JNEUROSCI.0755-04.2004; Gamba G, 2005, PHYSIOL REV, V85, P423, DOI 10.1152/physrev.00011.2004; Ge SY, 2006, NATURE, V439, P589, DOI 10.1038/nature04404; Gilles EE, 1998, PEDIATR NEUROL, V19, P119, DOI 10.1016/S0887-8994(98)00038-1; Glickfeld LL, 2009, NAT NEUROSCI, V12, P21, DOI 10.1038/nn.2230; Glykys J, 2006, J NEUROPHYSIOL, V95, P2796, DOI 10.1152/jn.01122.2005; Glykys J, 2009, NEURON, V63, P657, DOI 10.1016/j.neuron.2009.08.022; Grashow R, 2010, J NEUROSCI, V30, P9145, DOI 10.1523/JNEUROSCI.0980-10.2010; Gulledge AT, 2003, NEURON, V37, P299, DOI 10.1016/S0896-6273(02)01146-7; Hannaert P, 2002, N-S ARCH PHARMACOL, V365, P193, DOI 10.1007/s00210-001-0521-y; Hasbani MJ, 1998, EXP NEUROL, V154, P241, DOI 10.1006/exnr.1998.6929; Hasbargen T, 2010, ANN NY ACAD SCI, V1198, P168, DOI 10.1111/j.1749-6632.2010.05462.x; Hoffmann EK, 2009, PHYSIOL REV, V89, P193, DOI 10.1152/physrev.00037.2007; Inglefield JR, 1998, J NEUROCHEM, V70, P2500; Inoue H, 2007, J NEUROSCI, V27, P1445, DOI 10.1523/JNEUROSCI.4694-06.2007; Isenring P, 1998, J BIOL CHEM, V273, P11295, DOI 10.1074/jbc.273.18.11295; Kahle KT, 2008, NAT CLIN PRACT NEURO, V4, P490, DOI 10.1038/ncpneuro0883; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; Keenan HT, 2007, PEDIATRICS, V119, pE616, DOI 10.1542/peds.2006-2313; Khalilov I, 2003, NAT NEUROSCI, V6, P1079, DOI 10.1038/nn1125; Khalilov I, 1997, NEURON, V19, P743, DOI 10.1016/S0896-6273(00)80956-3; Khalilov I, 1999, DEV NEUROSCI-BASEL, V21, P310, DOI 10.1159/000017380; Khazipov R, 2004, EUR J NEUROSCI, V19, P590, DOI 10.1111/j.0953-816X.2003.03152.x; Kirov SA, 1999, J NEUROSCI, V19, P2876; KOCH C, 1983, P NATL ACAD SCI-BIOL, V80, P2799, DOI 10.1073/pnas.80.9.2799; Kuner T, 2000, NEURON, V27, P447, DOI 10.1016/S0896-6273(00)00056-8; Lado FA, 2002, EPILEPTIC DISORD, V4, P83; Lee Brian W., 2008, V414, P109; Leinekugel X, 2002, SCIENCE, V296, P2049, DOI 10.1126/science.1071111; Leinekugel X, 1998, J NEUROSCI, V18, P6349; Leinekugel X, 1997, NEURON, V18, P243, DOI 10.1016/S0896-6273(00)80265-2; Liesemer K, 2011, J NEUROTRAUM, V28, P755, DOI 10.1089/neu.2010.1518; Maeno E, 2000, P NATL ACAD SCI USA, V97, P9487, DOI 10.1073/pnas.140216197; Mazarati A, 2009, EPILEPSIA, V50, P2117, DOI 10.1111/j.1528-1167.2009.02048.x; Monnerie H, 2010, EXP NEUROL, V224, P415, DOI 10.1016/j.expneurol.2010.05.001; Murray DM, 2008, ARCH DIS CHILD-FETAL, V93, pF187, DOI 10.1136/adc.2005.086314; Nabekura J, 2002, J NEUROSCI, V22, P4412, DOI 10.1523/JNEUROSCI.22-11-04412.2002; Nardou R, 2011, BRAIN, V134, P987, DOI 10.1093/brain/awr041; Nardou R, 2009, J NEUROPHYSIOL, V101, P2878, DOI 10.1152/jn.90761.2008; Papp E, 2008, NEUROSCIENCE, V154, P677, DOI 10.1016/j.neuroscience.2008.03.072; Payne JA, 2003, TRENDS NEUROSCI, V26, P199, DOI 10.1016/S0166-2236(03)00068-7; Plotkin MD, 1997, J NEUROBIOL, V33, P781, DOI 10.1002/(SICI)1097-4695(19971120)33:6<781::AID-NEU6>3.0.CO;2-5; Pond BB, 2006, J NEUROSCI, V26, P1396, DOI 10.1523/JNEUROSCI.1421-05.2006; Rheims S, 2008, J NEUROPHYSIOL, V100, P609, DOI 10.1152/jn.90402.2008; Rheims S, 2009, J NEUROCHEM, V110, P1330, DOI 10.1111/j.1471-4159.2009.06230.x; ROTHMAN SM, 1985, J NEUROSCI, V5, P1483; SARNAT HB, 1976, ARCH NEUROL-CHICAGO, V33, P696, DOI 10.1001/archneur.1976.00500100030012; Scher MS, 2003, PEDIATR NEUROL, V28, P277, DOI 10.1016/S0887-8994(02)00621-5; Sipila ST, 2006, J PHYSIOL-LONDON, V573, P765, DOI 10.1113/jphysiol.2006.107086; Sipila ST, 2009, J NEUROSCI, V29, P6982, DOI 10.1523/JNEUROSCI.0443-09.2009; Sipila ST, 2005, J NEUROSCI, V25, P5280, DOI 10.1523/JNEUROSCI.0378-05.2005; STALEY KJ, 1992, J NEUROPHYSIOL, V68, P197; THOMPSON SM, 1989, J NEUROPHYSIOL, V61, P512; Tsourkas A, 2005, ANAL CHEM, V77, P2862, DOI 10.1021/ac0480747; Tyzio R, 2003, J NEUROPHYSIOL, V90, P2964, DOI 10.1152/jn.00172.2003; Tyzio R, 2008, EUR J NEUROSCI, V27, P2515, DOI 10.1111/j.1460-9568.2008.06234.x; Tyzio R, 2007, EPILEPSIA, V48, P96, DOI 10.1111/j.1528-1167.2007.01295.x; Tyzio R, 2011, J NEUROSCI, V31, P34, DOI 10.1523/JNEUROSCI.3314-10.2011; Valeeva G, 2010, FRONT CELL NEUROSCI, V4, DOI 10.3389/fncel.2010.00017; vandenPol AN, 1996, J NEUROSCI, V16, P4283; Wahab A, 2011, EPILEPSIA, V52, P94, DOI 10.1111/j.1528-1167.2010.02722.x; Wang Doris D, 2008, Epilepsy Curr, V8, P137, DOI 10.1111/j.1535-7511.2008.00270.x; Wirrell EC, 2001, PEDIATR RES, V50, P445, DOI 10.1203/00006450-200110000-00005; Wusthoff CJ, 2011, J CHILD NEUROL, V26, P724, DOI 10.1177/0883073810390036	91	79	80	0	14	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	MAR 21	2012	32	12					4017	4031		10.1523/JNEUROSCI.5139-11.2012			15	Neurosciences	Neurosciences & Neurology	916RB	WOS:000302119800007	22442068	Green Accepted, Green Published, Bronze			2021-06-18	
J	Lau, BC; Collins, MW; Lovell, MR				Lau, Brian C.; Collins, Michael W.; Lovell, Mark R.			Cutoff Scores in Neurocognitive Testing and Symptom Clusters That Predict Protracted Recovery From Concussions in High School Athletes	NEUROSURGERY			English	Article						Concussion; Cutoffs; ImPACT; Prognosis; Receiver-operating characteristic curve; Return to play; Symptoms	SPORTS-RELATED CONCUSSION; FOOTBALL PLAYERS; IMPACT; SPECIFICITY; SENSITIVITY	BACKGROUND: Many studies address diagnosing concussions, but few look at predicting prognosis. A previous discriminant function analysis showed that symptom clusters derived from the Post-Concussion Symptom Scale and Immediate Post-concussion Assessment and Cognitive Testing composite scores used together improved predictions of protracted recovery after a sports-related concussion. OBJECTIVE: To determine cutoff scores in neurocognitive and Post-Concussion Symptom Scale symptom cluster scores when classifying protracted recovery in concussed athletes. METHODS: 108 male high school football athletes completed a computer-based neurocognitive test battery (Immediate Postconcussion Assessment and Cognitive Testing) within a median of 2 days after injury. Patients completed graded exertional protocols requiring athletes to be symptom free at rest and during increasing levels of activity and had recovery of neurocognitive scores before return to play. After return to play, athletes were classified as protracted recovery (>14 days, n = 58) or short-recovery (<= 14 days, n = 50). Receiver-operating characteristic curves analyzed each of the neurocognitive (verbal, visual, processing speed, and reaction time) and symptom cluster (migraine, cognitive, sleep, and neuropsychiatric) scores. RESULTS: Cutoffs for migraine cluster, cognitive cluster, visual memory, and processing speed were statistically significant. Cutoffs at 75%, 80%, and 85% sensitivity to predict protracted recovery for the migraine symptom cluster were 15 or greater, 18, 20; cognitive symptom cluster 18 or greater, 19, 22; visual memory 48 or less, 46, 44.5; and processing speed 24.5 or less, 23.46, 22.5, respectively. Eighty-percent sensitivity indicates that the corresponding cutoff correctly identify 80% of concussed athletes requiring protracted recovery. CONCLUSION: Specific cutoffs may help to set numerical thresholds for clinicians to predict which concussed athletes will have a protracted recovery.	[Lau, Brian C.] Univ Pittsburgh, Sch Med, UPMC Sports Med, Pittsburgh, PA 15203 USA; [Collins, Michael W.; Lovell, Mark R.] Univ Pittsburgh, Med Ctr, Sports Concuss Program, Dept Orthoped Surg, Pittsburgh, PA 15203 USA	Lau, BC (corresponding author), Univ Pittsburgh, Sch Med, UPMC Sports Med, 3200 S Water St, Pittsburgh, PA 15203 USA.	blau10@gmail.com					Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Collins M, 2006, NEUROSURGERY, V58, P275, DOI 10.1227/01.NEU.0000200441.92742.46; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Erlanger D, 2001, J ATHL TRAINING, V36, P280; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gerst EH, 2011, J INT NEUROPSYCHO S1, V17, P134; Gioia GA, 2011, J INT NEUROPSYCHO S1, V17, P135; Gioia GA, 2010, J INT NEUROPSYCH SOC, V16, P178; Gioia Gerard, 2010, COMMITTEE ED LABOR U; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; ImPACT, 2003, IMPACT TEST COMP NEU; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2004, J INT NEUROPSYCH SOC, V10, P904, DOI 10.1017/S1355617704106139; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Iverson G, 2007, CLIN J SPORT MED, V17, P31; Koch HJ, 2005, PATHOL ONCOL RES, V11, P50, DOI 10.1007/BF03032406; Lau B, 2009, CLIN J SPORT MED, V19, P216, DOI 10.1097/JSM.0b013e31819d6edb; Lau BC, 2011, AM J SPORT MED, V39, P1209, DOI 10.1177/0363546510392016; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Makdissi M, 2010, AM J SPORT MED, V38, P464, DOI 10.1177/0363546509349491; McCrory P, 2001, CLIN J SPORT MED, V11, P144, DOI 10.1097/00042752-200107000-00004; McCrory P, 2005, CLIN J SPORT MED, V15, P49; McCrory P, 2009, PHYSICIAN SPORTSMED, V37, P141, DOI 10.3810/psm.2009.06.1721; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Pardini D., 2004, BR J SPORTS MED, V38, P661; Randolph C, 2005, J ATHL TRAINING, V40, P139; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677; ZWEIG MH, 1993, CLIN CHEM, V39, P561	32	79	79	1	26	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	FEB	2012	70	2					371	379		10.1227/NEU.0b013e31823150f0			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	879IK	WOS:000299322700038	21841522				2021-06-18	
J	Echemendia, RJ; Bruce, JM; Bailey, CM; Sanders, JF; Arnett, P; Vargas, G				Echemendia, Ruben J.; Bruce, Jared M.; Bailey, Christopher M.; Sanders, James Forrest; Arnett, Peter; Vargas, Gray			The Utility of Post-Concussion Neuropsychological Data in Identifying Cognitive Change Following Sports-Related MTBI in the Absence of Baseline Data	CLINICAL NEUROPSYCHOLOGIST			English	Article						Concussion; MTBI; Neuropsychological testing; Baseline evaluation	TEST-RETEST RELIABILITY; TRAUMATIC BRAIN-INJURY; PERFORMANCE; IMPACT; PSYCHOTHERAPY; REGRESSION; DEFICITS	Neuropsychological tests have become commonplace in the assessment of sports-related concussion. Typically, post-injury test data are compared to pre-injury "baselines.'' Baseline testing can be expensive and logistically challenging, yet the usefulness of neuropsychological baseline testing has not been tested empirically. This paper examines the extent to which baseline testing is useful for detecting neurocognitive deficits following sports concussion in a college-age population. A total of 223 collegiate athletes from multiple sports who sustained concussions and had both baseline and post-injury testing using Immediate Post-concussion Assessment and Cognitive Testing (ImPACT) were included in the study. Reliable change (RC) in scores was determined by two approaches, the Jacobson and Truax (JT) and the Gulliksen-Lord-Novick (GLN) methods. The 90% confidence interval was used for both. Classification using these methods was compared to standard normative methods that compared post-concussion performance to baseline population means. Agreement between reliable change and normative methods was examined using Cohen's Kappa scores to determine whether post-injury scores alone could identify reliable cognitive decline. Mean time from concussion to post-injury testing was 3.40 days. The percentage of athletes who declined when using the JT method was similar to the percentage that would be expected to decline due to chance alone. Although the GLN and JT methods demonstrated moderate to substantial agreement, the GLN method consistently identified more cognitively compromised athletes than the JT method. Post-injury scores alone identified a significant majority of athletes with a reliable decline on ImPACT. Although preliminary and in need of replication across age groups and instruments, these findings suggest that the majority of collegiate athletes who experience clinically meaningful post-concussion cognitive decline can be identified without baseline data.	[Echemendia, Ruben J.] Psychol & Neurobehav Associates, State Coll, PA USA; [Echemendia, Ruben J.; Bruce, Jared M.] Univ Missouri, Dept Psychol, Kansas City, MO 64110 USA; [Bailey, Christopher M.] Case Western Reserve Univ, Sch Med, Dept Neurol, Neurol Inst, Cleveland, OH 44106 USA; [Sanders, James Forrest] Womack Army Med Ctr, Dept Behav Med, Ft Bragg, NC USA; [Arnett, Peter; Vargas, Gray] Penn State Univ, Dept Psychol, University Pk, PA 16802 USA	Echemendia, RJ (corresponding author), 204 E Calder Way,Ste 205, State Coll, PA 16801 USA.	rechemendia@comcast.net	Echemendia, Ruben/R-6939-2019	Echemendia, Ruben/0000-0001-6116-8462			Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Barr WB, 2003, ARCH CLIN NEUROPSYCH, V18, P91, DOI 10.1016/S0887-6177(01)00185-8; Barth JT, 1989, MILD HEAD INJURY; Bleiberg J, 1997, NEUROPSY NEUROPSY BE, V10, P247; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Bruce JM, 2003, NEUROPSYCHOLOGY, V17, P622, DOI 10.1037/0894-4105.17.4.622; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Comper P, 2010, BRAIN INJURY, V24, P1257, DOI 10.3109/02699052.2010.506854; Echemendia RJ, 2009, BRIT J SPORT MED, V43, pI32, DOI 10.1136/bjsm.2009.058164; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Echemendia RJ, 2001, NEUROPSYCHOL REV, V11, P69, DOI 10.1023/A:1016651217141; Echemendia RJ, 2010, B NATL ACAD NEUROPSY, V25, P5; Elbin RJ, 2011, AM J SPORT MED, V39, P2319, DOI 10.1177/0363546511417173; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Gilchrist J., 2007, Morbidity and Mortality Weekly Report, V56, P733; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Heaton R.K., 1991, COMPREHENSIVE NORMS; HSU LM, 1989, BEHAV ASSESS, V11, P459; Hsu LM, 1999, J CONSULT CLIN PSYCH, V67, P594, DOI 10.1037/0022-006X.67.4.594; HSU LM, 1995, J CONSULT CLIN PSYCH, V63, P141, DOI 10.1037/0022-006X.63.1.141; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; LOVELL M, 2002, IMPACT VERSION 2 0 C; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Mayers LB, 2012, J CLIN EXP NEUROPSYC, V34, P235, DOI 10.1080/13803395.2011.630655; McCrory Paul, 2009, J Athl Train, V44, P434, DOI 10.4085/1062-6050-44.4.434; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; NCAA, 2011, 2011 12 SPORTS MED H; Pascrell B., 2011, REP PASCRELL SEN MEN; Rabinowitz AR, 2012, J INT NEUROPSYCH SOC, V18, P139, DOI 10.1017/S1355617711001275; Randolph C, 2005, J ATHL TRAINING, V40, P139; Randolph C, 2009, J INT NEUROPSYCH SOC, V15, P512, DOI 10.1017/S135561770909064X; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; Stern R. A., 2011, PHYS MED REHABILITAT, V3, P1265; The Mild Traumatic Brain Injury Committee of the Head Injury Interdisciplinary Special Interest Group of the American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677	41	79	81	0	15	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2012	26	7					1077	1091		10.1080/13854046.2012.721006			15	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	027DE	WOS:000310331200002	23003560				2021-06-18	
J	Zurek, J; Fedora, M				Zurek, Jiri; Fedora, Michal			The usefulness of S100B, NSE, GFAP, NF-H, secretagogin and Hsp70 as a predictive biomarker of outcome in children with traumatic brain injury	ACTA NEUROCHIRURGICA			English	Article						Biomarker; Brain injury; Outcome; Children	NEURON-SPECIFIC-ENOLASE; ANEURYSMAL SUBARACHNOID HEMORRHAGE; BILATERAL FEMUR FRACTURE; HEAT-SHOCK PROTEINS; PRACTICAL SCALE; GROWTH-FACTOR; IN-VITRO; SERUM; DAMAGE; BLOOD	Predicting the long-term outcome after traumatic brain injury (TBI) is an important component of treatment strategy. Despite dramatically improved emergency management of TBI and apparent clinical recovery, most patients with TBI still may have long-term central nervous system (CNS) impairment. Sixty-three patients with TBI were enrolled into the prospective study. Venous blood samples were taken at admission and every 24 h for a maximum of 6 consecutive days. Serum concentrations of the biomarkers S100B, neuron-specific enolase (NSE), GFAP, NF-H, secretagogin and Hsp70 were quantified immuno-luminometrically or by enzyme-linked immunosorbent assay. The outcome was evaluated 6 months after TBI using the Glasgow Outcome Scale (GOS) in all patients. The S100B levels in patients with worse outcome (GOS 4 or death) were already significantly higher at D0 (p < 0.001; p = 0.002). NSE levels were significantly higher in patients who died or had worse outcomes (p < 0.001; p = 0.003). Patients who had worse outcomes (GOS) or died had higher GFAP values (p < 0.001; p < 0.001), but their dynamics were similar over the same period. NF-H grew significantly faster in patients who had a worse GOS or died (p < 0.001; p = 0.001). Although further prospective study is warranted, these findings suggest that levels of biomarkers correlate with mortality and may be useful as predictors of outcome in children with TBI.	[Zurek, Jiri; Fedora, Michal] Univ Childrens Hosp, Dept Anesthesia & Intens Care, Brno 62500, Czech Republic	Zurek, J (corresponding author), Univ Childrens Hosp, Dept Anesthesia & Intens Care, Cernopolni 9, Brno 62500, Czech Republic.	jzurek@fnbrno.cz; mfedora@fnbrno.cz		Zurek, Jiri/0000-0002-6409-2560			Anderson KJ, 2008, J NEUROTRAUM, V25, P1079, DOI 10.1089/neu.2007.0488; Bandyopadhyay S, 2005, ACAD EMERG MED, V12, P732, DOI 10.1197/j.aem.2005.02.017; Berger RP, 2007, J NEUROTRAUM, V24, P1793, DOI 10.1089/neu.2007.0316; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Ciccarelli R, 1999, GLIA, V27, P275, DOI 10.1002/(SICI)1098-1136(199909)27:3<275::AID-GLIA9>3.3.CO;2-S; Cooper E. H., 1994, International Journal of Biological Markers, V9, P205; Da Rocha AB, 2005, J NEUROTRAUM, V22, P966, DOI 10.1089/neu.2005.22.966; DONATO R, 1986, CELL CALCIUM, V7, P123, DOI 10.1016/0143-4160(86)90017-5; GALEA E, 1995, J NEUROSCI RES, V41, P452, DOI 10.1002/jnr.490410404; Gartner W, 2001, CEREB CORTEX, V11, P1161, DOI 10.1093/cercor/11.12.1161; Giza CC, 2007, CURR OPIN CRIT CARE, V13, P143, DOI 10.1097/MCC.0b013e32808255dc; Guzhova I, 2001, BRAIN RES, V914, P66, DOI 10.1016/S0006-8993(01)02774-3; Haqqani AS, 2007, J NEUROTRAUM, V24, P54, DOI 10.1089/neu.2006.0079; Heizmann CW, 2002, FRONT BIOSCI-LANDMRK, V7, pD1356, DOI 10.2741/heizmann; Herrmann M, 2003, RESTOR NEUROL NEUROS, V21, P177; Herrmann M, 2003, RESTOR NEUROL NEUROS, V21, P75; JENNETT B, 1975, LANCET, V1, P480; Lewis SB, 2008, J CEREBR BLOOD F MET, V28, P1261, DOI 10.1038/jcbfm.2008.12; LI GC, 1983, J CELL PHYSIOL, V115, P116, DOI 10.1002/jcp.1041150203; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Nahlovsky J, 2006, NEUROCHIRURGIE; Pelinka LE, 2005, SHOCK, V24, P119, DOI 10.1097/01.shk.0000168876.68154.43; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Pelinka LE, 2004, SHOCK, V22, P88, DOI 10.1097/01.shk.0000130157.34382.3f; Pelinka LE, 2004, SHOCK, V21, P72, DOI 10.1097/01.shk.0000101672.49265.14; Pelinka LE, 2003, BRIT J ANAESTH, V91, P595, DOI 10.1093/bja/aeg225; Pockley AG, 2003, LANCET, V362, P469, DOI 10.1016/S0140-6736(03)14075-5; Rogstam A, 2007, BIOCHEM J, V401, P353, DOI 10.1042/BJ20060918; Rustandi RR, 1998, BIOCHEMISTRY-US, V37, P1951, DOI 10.1021/bi972701n; Sarto C, 2000, ELECTROPHORESIS, V21, P1218, DOI 10.1002/(SICI)1522-2683(20000401)21:6<1218::AID-ELPS1218>3.3.CO;2-8; Shaw G, 2007, BIOCHEM BIOPH RES CO, V325, P619; Strong MJ, 2001, J NEUROCHEM, V76, P1315, DOI 10.1046/j.1471-4159.2001.00094.x; TEASDALE G, 1974, LANCET, V2, P81; TEPAS JJ, 1987, J PEDIATR SURG, V22, P14, DOI 10.1016/S0022-3468(87)80006-4; Townend W, 2006, J NEUROTRAUM, V23, P149, DOI 10.1089/neu.2006.23.149; Unden J, 2004, SCAND J INFECT DIS, V36, P10, DOI 10.1080/00365540310017294; USUI A, 1989, CLIN CHEM, V35, P1942; WHITAKERAZMITIA PM, 1990, BRAIN RES, V528, P155, DOI 10.1016/0006-8993(90)90210-3; Wiesmann M, 1997, ACTA NEUROCHIR, V139, P1155, DOI 10.1007/BF01410976; Zylicz M, 2001, EMBO J, V20, P4634, DOI 10.1093/emboj/20.17.4634	41	79	86	0	13	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	JAN	2012	154	1					93	103		10.1007/s00701-011-1175-2			11	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	870BE	WOS:000298643300016	21976236				2021-06-18	
J	Len, TK; Neary, JP; Asmundson, GJG; Goodman, DG; Bjornson, B; Bhambhani, YN				Len, Trevor K.; Neary, J. Patrick; Asmundson, Gordon J. G.; Goodman, David G.; Bjornson, Bruce; Bhambhani, Yagesh N.			Cerebrovascular Reactivity Impairment after Sport-Induced Concussion	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						MILD TRAUMATIC BRAIN INJURY; PATHOPHYSIOLOGY; CEREBROVASCULAR REACTIVITY; TRANSCRANIAL DOPPLER; CEREBRAL BLOOD VELOCITY; CONCUSSION	DYNAMIC CEREBRAL AUTOREGULATION; END-TIDAL CO2; BLOOD-FLOW-VELOCITY; TRANSCRANIAL DOPPLER; HEALTHY HUMANS; ARTERIAL; OXYGENATION; DIAMETER; MIDDLE; MECHANISMS	LEN, T. K., J. P. NEARY, G. J. G. ASMUNDSON, D. G. GOODMAN, B. BJORNSON, and Y. N. BHAMBHANI. Cerebrovascular Reactivity Impairment after Sport-Induced Concussion. Med. Sci. Sports Exerc., Vol. 43, No. 12, pp. 2241-2248, 2011. Purpose: This study evaluated cerebrovascular reactivity (CVR) after a sport-induced concussion, also called mild traumatic brain injury (mTBI), by monitoring middle cerebral artery blood velocity (vMCA) with transcranial Doppler ultrasonography and simultaneous end-tidal carbon dioxide (PETCO2) measurements. Methods: Thirty-one athletes (16-25 yr old) participated in this study. The participants were divided into two groups-healthy (n = 21) and mTBI (n = 10). Participants in the mTBI group suffered an mTBI within the last 7 d ((x) over bar = 4.5 +/- 1.1 d). Outcome measures included vMCA and PETCO2 in response to breath holding (5 x 20 s, 40-s rest) and hyperventilation (5 x 20 s, 40-s rest). Results: Resting vMCA values between groups were not significantly different. Percentage change of vMCA was significantly different after the recovery period of the second hyperventilation (P = 0.034). mTBI subjects failed to return to resting levels after each breath hold. PETCO2 changes mirrored the vMCA changes. Conclusions: These data suggest that normal CVR responses may be disrupted in the days immediately after occurrence of mTBI. Transcranial Doppler ultrasonography combined with expired gas measurements provides a useful method for assessing CVR impairment after mTBI. Further research, including serial monitoring after mTBI and analysis of CVR response to exercise, is warranted before any firm conclusions can be drawn.	[Len, Trevor K.; Neary, J. Patrick] Univ Regina, Fac Kinesiol & Hlth Studies, Regina, SK S4S 0A2, Canada; [Asmundson, Gordon J. G.] Univ Regina, Traumat Stress Grp, Regina, SK S4S 0A2, Canada; [Goodman, David G.] Simon Fraser Univ, Dept Biomed Physiol & Kinesiol, Burnaby, BC V5A 1S6, Canada; [Bjornson, Bruce] Univ British Columbia, Fac Med, Dept Pediat, Vancouver, BC, Canada; [Bhambhani, Yagesh N.] Univ Alberta, Dept Occupat Therapy, Edmonton, AB, Canada	Neary, JP (corresponding author), Univ Regina, Fac Kinesiol & Hlth Studies, Regina, SK S4S 0A2, Canada.	patrick.neary@uregina.ca	Bjornson, Bruce Hal/A-8616-2010	Bjornson, Bruce Hal/0000-0002-1465-6196	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); Saskatchewan Health Research Foundation	This study was supported by grants from the Canadian Institutes of Health Research (J.P.N.) and the Saskatchewan Health Research Foundation (J.P.N.).	Ainslie PN, 2007, EXP PHYSIOL, V92, P769, DOI 10.1113/expphysiol.2006.036814; Ainslie PN, 2007, J APPL PHYSIOL, V102, P658, DOI 10.1152/japplphysiol.00911.2006; Ainslie PN, 2009, AM J PHYSIOL-REG I, V296, pR1473, DOI 10.1152/ajpregu.91008.2008; Alexandrov AV, 2007, J NEUROIMAGING, V17, P11, DOI 10.1111/j.1552-6569.2006.00088.x; [Anonymous], 2006, MED SCI SPORT EXER, V38, P395, DOI 10.1249/01.mss.0000202025.48774.31; BARTON CW, 1994, ANN EMERG MED, V23, P560, DOI 10.1016/S0196-0644(94)70078-8; Bhambhani Y, 2007, RESP PHYSIOL NEUROBI, V156, P196, DOI 10.1016/j.resp.2006.08.009; Carrera E, 2009, J NEUROL SCI, V285, P191, DOI 10.1016/j.jns.2009.06.041; Cummings KJ, 2007, J APPL PHYSIOL, V102, P1891, DOI 10.1152/japplphysiol.01437.2006; Dewitt DS, 2003, J NEUROTRAUM, V20, P795, DOI 10.1089/089771503322385755; Dineen NE, 2010, J APPL PHYSIOL, V108, P604, DOI 10.1152/japplphysiol.01157.2009; Ellemberg D, 2009, J NEUROTRAUM, V26, P2365, DOI 10.1089/neu.2009.0906; Fukushima U, 1999, J VET MED SCI, V61, P1293, DOI 10.1292/jvms.61.1293; Gall B, 2004, BRIT J SPORT MED, V38, P773, DOI 10.1136/bjsm.2003.009530; Gall B, 2004, MED SCI SPORT EXER, V36, P1269, DOI 10.1249/01.MSS.0000135787.73757.4D; Geary GG, 2000, AM J PHYSIOL-HEART C, V279, pH610; GILLER CA, 1993, NEUROSURGERY, V32, P737, DOI 10.1227/00006123-199305000-00006; Golding EM, 1999, AM J PHYSIOL-HEART C, V277, pH1457; Goldstein B, 1998, AM J PHYSIOL-REG I, V275, pR1287; Gommer ED, 2008, PHYSIOL MEAS, V29, P1293, DOI 10.1088/0967-3334/29/11/005; Ide Kojiro, 2003, Journal of Applied Physiology, V95, P129; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Karadeniz U, 2005, ANN THORAC SURG, V79, P139, DOI 10.1016/j.athoracsur.2004.06.046; Len TK, 2011, CLIN PHYSIOL FUNCT I, V31, P85, DOI 10.1111/j.1475-097X.2010.00990.x; Liu HL, 2002, MAGN RESON IMAGING, V20, P643, DOI 10.1016/S0730-725X(02)00595-7; Low DA, 2008, J APPL PHYSIOL, V104, P976, DOI 10.1152/japplphysiol.01040.2007; MARKUS HS, 1992, STROKE, V23, P668, DOI 10.1161/01.STR.23.5.668; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Ogoh S, 2010, J APPL PHYSIOL, V108, P538, DOI 10.1152/japplphysiol.01235.2009; Palada I, 2007, RESP PHYSIOL NEUROBI, V157, P374, DOI 10.1016/j.resp.2007.02.002; Peebles K, 2007, J PHYSIOL-LONDON, V584, P347, DOI 10.1113/jphysiol.2007.137075; Przybylowski T, 2003, J PHYSIOL-LONDON, V548, P323, DOI 10.1113/jphysiol.2002.029678; RangeL-Castilla L, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E7; RINGELSTEIN EB, 1990, ULTRASOUND MED BIOL, V16, P745, DOI 10.1016/0301-5629(90)90039-F; Schramm P, 2011, J NEUROSURG ANESTH, V23, P41, DOI 10.1097/ANA.0b013e3181f35854; Serrador JM, 2000, STROKE, V31, P1672, DOI 10.1161/01.STR.31.7.1672; Settakis G, 2002, J NEUROIMAGING, V12, P252, DOI 10.1177/10528402012003007; Simmons GH, 2007, J PHYSIOL-LONDON, V583, P1155, DOI 10.1113/jphysiol.2007.137216; Stoll M, 1996, STROKE, V27, P1132; Takano Y, 2003, RESP MED, V97, P476, DOI 10.1053/rmed.2002.1468; Tegeler C, 2004, CEREBROVASC DIS, V17, P1; Totaro R, 1999, CEREBROVASC DIS, V9, P142, DOI 10.1159/000015943; Valdueza JM, 1997, AM J NEURORADIOL, V18, P1929; Wilson LC, 2010, AM J PHYSIOL-REG I, V298, pR1035, DOI 10.1152/ajpregu.00815.2009	44	79	79	0	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-9131	1530-0315		MED SCI SPORT EXER	Med. Sci. Sports Exerc.	DEC	2011	43	12					2241	2248		10.1249/MSS.0b013e3182249539			8	Sport Sciences	Sport Sciences	851EL	WOS:000297251100004	21606867				2021-06-18	
J	Wang, Y; Wei, YL; Oguntayo, S; Wilkins, W; Arun, P; Valiyaveettil, M; Song, J; Long, JB; Nambiar, MP				Wang, Ying; Wei, Yanling; Oguntayo, Samuel; Wilkins, William; Arun, Peethambaran; Valiyaveettil, Manojkumar; Song, Jian; Long, Joseph B.; Nambiar, Madhusoodana P.			Tightly Coupled Repetitive Blast-Induced Traumatic Brain Injury: Development and Characterization in Mice	JOURNAL OF NEUROTRAUMA			English	Article						blast exposure; neurobehavioral; neurobiological effects; neuropathology; traumatic brain injury	ADULT-RAT BRAIN; CENTRAL-NERVOUS-SYSTEM; LASTING IMPULSE NOISE; HEAD-INJURY; INTRACRANIAL-PRESSURE; OXIDATIVE STRESS; INDUCED NEUROTRAUMA; COGNITIVE FUNCTION; EXPLOSIVE BLAST; AXONAL INJURY	A mouse model of repeated blast exposure was developed using a compressed air-driven shock tube, to study the increase in severity of traumatic brain injury (bTBI) after multiple blast exposures. Isoflurane anesthetized C57BL/6J mice were exposed to 13.9, 20.6, and 25 psi single blast overpressure (BOP1) and allowed to recover for 5 days. BOP1 at 20.6 psi showed a mortality rate of 2% and this pressure was used for three repeated blast exposures (BOP3) with 1 and 30 min intervals. Overall mortality rate in BOP3 was increased to 20%. After blast exposure, righting reflex time and body-weight loss were significantly higher in BOP3 animals compared to BOP1 animals. At 4 h, brain edema was significantly increased in BOP3 animals compared to sham controls. Reactive oxygen species in the cortex were increased significantly in BOP1 and BOP3 animals. Neuropathological analysis of the cerebellum and cerebral cortex showed dense silver precipitates in BOP3 animals, indicating the presence of diffuse axonal injury. Fluoro-Jade B staining showed increased intensity in the cortex of BOP3 animals indicating neurodegeneration. Rota Rod behavioral test showed a significant decrease in performance at 10 rpm following BOP1 or BOP3 at 2 h post-blast, which gradually recovered during the 5 days. At 20 rpm, the latency to fall was significantly decreased in both BOP1 and BOP3 animals and it did not recover in the majority of the animals through 5 days of testing. These data suggest that repeated blast exposures lead to increased impairment severity in multiple neurological parameters of TBI in mice.	[Wang, Ying; Wei, Yanling; Oguntayo, Samuel; Wilkins, William; Arun, Peethambaran; Valiyaveettil, Manojkumar; Song, Jian; Long, Joseph B.; Nambiar, Madhusoodana P.] Walter Reed Army Inst Res, Blast Induced Neurotrauma Branch, Ctr Mil Psychiat & Neurosci, Silver Spring, MD 20910 USA	Nambiar, MP (corresponding author), Walter Reed Army Inst Res, Blast Induced Neurotrauma Branch, Ctr Mil Psychiat & Neurosci, Silver Spring, MD 20910 USA.	Madhusoodana.nambiar@us.army.mil	Wilkins, William/B-5476-2011				Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; Bauman RA, 1997, TOXICOLOGY, V121, P65, DOI 10.1016/S0300-483X(97)03656-1; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI 10.1089/neu.2009-0898; Bell M.K., 2008, MIL MED, V173, pv; Bhattacharjee Y, 2008, SCIENCE, V319, P406, DOI 10.1126/science.319.5862.406; Blennow K, 2011, ACTA NEUROL SCAND, V123, P245, DOI 10.1111/j.1600-0404.2010.01408.x; Cantu RC, 2010, J NEUROTRAUM, V27, P1557, DOI 10.1089/neu.2010.1334; Cernak I, 1996, J TRAUMA, V40, pS100, DOI 10.1097/00005373-199603001-00023; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak I, 2001, BRAIN INJURY, V15, P593, DOI 10.1080/02699050010009559; Cernak Ibolja, 2010, Front Neurol, V1, P151, DOI 10.3389/fneur.2010.00151; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Chavko M, 2007, J NEUROSCI METH, V159, P277, DOI 10.1016/j.jneumeth.2006.07.018; Chavko M, 2011, J NEUROSCI METH, V195, P61, DOI 10.1016/j.jneumeth.2010.11.019; Chen YC, 2009, J NEUROTRAUM, V26, P861, DOI 10.1089/neu.2008.0645; Connell S, 2011, J MED SYST, V35, P765, DOI 10.1007/s10916-010-9464-5; Courtney AC, 2009, MED HYPOTHESES, V72, P76, DOI 10.1016/j.mehy.2008.08.015; Courtney MW, 2011, NEUROIMAGE, V54, pS55, DOI 10.1016/j.neuroimage.2010.05.025; Courtney MW, 2010, REV SCI INSTRUM, V81, DOI 10.1063/1.3518970; Cripps N P, 1999, J R Nav Med Serv, V85, P13; Elder GA, 2010, PSYCHIAT CLIN N AM, V33, P757, DOI 10.1016/j.psc.2010.08.001; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; Elsayed NM, 2007, TOXICOL SCI, V95, P289, DOI 10.1093/toxsci/kfl138; Fabrizio KS, 2010, NURS CLIN N AM, V45, P569, DOI 10.1016/j.cnur.2010.06.003; Fausti SA, 2009, J REHABIL RES DEV, V46, P797, DOI 10.1682/JRRD.2008.09.0118; French LM, 2010, ANN NY ACAD SCI, V1208, P38, DOI 10.1111/j.1749-6632.2010.05696.x; Garman RH, 2011, J NEUROTRAUM, V28, P947, DOI 10.1089/neu.2010.1540; GARTH RJN, 1994, J LARYNGOL OTOL, V108, P925, DOI 10.1017/S0022215100128555; Gorbunov NV, 1997, AM J PHYSIOL-LUNG C, V272, pL320; Guy R J, 1998, J R Nav Med Serv, V84, P79; Hoane MR, 2006, BRAIN RES, V1125, P185, DOI 10.1016/j.brainres.2006.10.019; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Jones E, 2007, AM J PSYCHIAT, V164, P1641, DOI 10.1176/appi.ajp.2007.07071180; Kato K, 2007, J NEUROSURG, V106, P667, DOI 10.3171/jns.2007.106.4.667; Kennedy JE, 2010, NEUROREHABILITATION, V26, P223, DOI 10.3233/NRE-2010-0558; Khil'ko V A, 1997, Zh Vopr Neirokhir Im N N Burdenko, P35; Kocsis JD, 2009, J REHABIL RES DEV, V46, P667, DOI 10.1682/JRRD.2008.08.0100; Koliatsos VE, 2011, J NEUROPATH EXP NEUR, V70, P399, DOI 10.1097/NEN.0b013e3182189f06; Leibovici D, 1996, J TRAUMA, V41, P1030, DOI 10.1097/00005373-199612000-00015; Leonardi AD, 2011, J NEUROTRAUM, V28, P85, DOI 10.1089/neu.2010.1324; Lew HL, 2009, J REHABIL RES DEV, V46, P819, DOI 10.1682/JRRD.2008.09.0129; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Ling GSF, 2011, CURR OPIN ANESTHESIO, V24, P124, DOI 10.1097/ACO.0b013e32834458da; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Matthews S, 2011, PSYCHIAT RES-NEUROIM, V191, P76, DOI 10.1016/j.pscychresns.2010.09.013; Matthews SC, 2011, NEUROIMAGE, V54, pS69, DOI 10.1016/j.neuroimage.2010.04.269; MAZURKIEWICZKWILECKI IM, 1980, PHARMACOL BIOCHEM BE, V12, P35, DOI 10.1016/0091-3057(80)90412-8; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mellor S G, 1988, Br J Hosp Med, V39, P536; Mori T, 2006, ACTA NEUROCHIR SUPPL, V96, P40; Nakagawa A, 2011, J NEUROTRAUM, V28, P1101, DOI 10.1089/neu.2010.1442; Nakagawa A, 2008, ACTA NEUROCHIR SUPPL, V102, P421, DOI 10.1007/978-3-211-85578-2_82; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Owen-Smith M, 1982, Nurs Times, V78, P49; Park E, 2011, J NEUROTRAUM, V28, P343, DOI 10.1089/neu.2009.1050; Peskind ER, 2011, NEUROIMAGE, V54, pS76, DOI 10.1016/j.neuroimage.2010.04.008; PRATT H, 1985, AUDIOLOGY, V24, P297; Pun Pamela B L, 2011, Front Neurol, V2, P19, DOI 10.3389/fneur.2011.00019; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; RICHMOND DR, 1991, SCAND AUDIOL, P49; Risdall JE, 2011, PHILOS T R SOC B, V366, P241, DOI 10.1098/rstb.2010.0230; Ritenour AE, 2008, CRIT CARE MED, V36, pS311, DOI 10.1097/CCM.0b013e31817e2a8c; Roberto M, 1989, Ann Otol Rhinol Laryngol Suppl, V140, P23; Saljo A, 2002, J NEUROTRAUM, V19, P985, DOI 10.1089/089771502320317131; Saljo A, 2002, J NEUROTRAUM, V19, P379, DOI 10.1089/089771502753594945; Saljo A, 2000, J NEUROTRAUM, V17, P719, DOI 10.1089/089771500415454; Saljo A, 2010, J NEUROTRAUM, V27, P383, DOI 10.1089/neu.2009.1053; Saljo Annette, 2001, Pathophysiology, V8, P105, DOI 10.1016/S0928-4680(01)00067-0; Saljo A, 2009, J NEUROTRAUM, V26, P1345, DOI [10.1089/neu.2008.0856, 10.1089/neu.2008-0856]; Saljo A, 2008, J NEUROTRAUM, V25, P1397, DOI 10.1089/neu.2008.0602; Saunders LL, 2009, BRAIN INJURY, V23, P866, DOI 10.1080/02699050903283213; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; Scott SG, 2006, J AM OSTEOPATH ASSOC, V106, P265; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Snell FI, 2010, J PSYCHOSOC NURS MEN, V48, P22, DOI [10.3928/02793695-20100108-02, 10.3928/02793695-20100107-01]; SUNESON A, 1990, J TRAUMA, V30, P295, DOI 10.1097/00005373-199003000-00007; Svetlov SI, 2010, J TRAUMA, V69, P795, DOI 10.1097/TA.0b013e3181bbd885; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Vink R, 2003, ACT NEUR S, V86, P257; Wang H, 1999, FREE RADICAL BIO MED, V27, P612, DOI 10.1016/S0891-5849(99)00107-0; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Wilk JE, 2010, J HEAD TRAUMA REHAB, V25, P9, DOI 10.1097/HTR.0b013e3181bd090f; Wolf SJ, 2009, LANCET, V374, P405, DOI 10.1016/S0140-6736(09)60257-9; Xydakis MS, 2008, NEW ENGL J MED, V358, P2177, DOI 10.1056/NEJMc086083; Yang ZH, 1996, J TRAUMA, V40, pS81, DOI 10.1097/00005373-199603001-00019; YLIKOSKI ME, 1994, SCAND J WORK ENV HEA, V20, P93, DOI 10.5271/sjweh.1415	89	79	79	0	12	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2011	28	10					2171	2183		10.1089/neu.2011.1990			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	839OX	WOS:000296378500017	21770761				2021-06-18	
J	Ennen, CS; Huisman, TAGM; Savage, WJ; Northington, FJ; Jennings, JM; Everett, AD; Graham, EM				Ennen, Christopher S.; Huisman, Thierry A. G. M.; Savage, William J.; Northington, Frances J.; Jennings, Jacky M.; Everett, Allen D.; Graham, Ernest M.			Glial fibrillary acidic protein as a biomarker for neonatal hypoxic-ischemic encephalopathy treated with whole-body cooling	AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY			English	Article						fetal acidosis; glial fibrillary acidic protein; hypoxicischemic encephalopathy; neonatal seizures; whole-body cooling	TRAUMATIC BRAIN-INJURY; SYSTEMIC HYPOTHERMIA; RANDOMIZED-TRIAL; CARDIAC-ARREST; TERM INFANTS; SERUM; ASSOCIATION; LESIONS; MRI; AGE	OBJECTIVE: Glial fibrillary acidic protein (GFAP) is specific to astrocytes in the central nervous system. We hypothesized that serum GFAP would be increased in neonates with hypoxic-ischemic encephalopathy (HIE) treated with whole-body cooling. STUDY DESIGN: We measured GFAP at birth and daily for up to 7 days for neonates in the intensive care unit. We compared neonates with HIE treated with whole-body cooling to gestational age-matched controls without neurological injury and neonates with HIE by brain abnormalities on magnetic resonance imaging (MRI). RESULTS: Neonates with HIE had increased GFAP levels compared with controls. Neonates with HIE and abnormal brain imaging had elevated GFAP levels compared with neonates with HIE and normal imaging. CONCLUSION: Serum GFAP levels during the first week of life were increased in neonates with HIE and were predictive of brain injury on MRI. Biomarkers such as GFAP could help triage neonates with HIE to treatment, measure treatment efficacy, and provide prognostic information.	[Ennen, Christopher S.; Graham, Ernest M.] Johns Hopkins Univ, Sch Med, Dept Obstet & Gynecol, Div Maternal Fetal Med, Baltimore, MD 21205 USA; [Huisman, Thierry A. G. M.] Johns Hopkins Univ, Sch Med, Div Pediat Radiol, Dept Radiol & Radiol Sci, Baltimore, MD USA; [Savage, William J.] Johns Hopkins Univ, Sch Med, Dept Pathol Transfus Med, Baltimore, MD USA; [Northington, Frances J.] Johns Hopkins Univ, Sch Med, Dept Pediat, Div Neonatol, Baltimore, MD 21205 USA; [Jennings, Jacky M.] Johns Hopkins Univ, Sch Med, Dept Pediat, Div Gen Pediat & Adolescent Med, Baltimore, MD 21205 USA; [Everett, Allen D.] Johns Hopkins Univ, Sch Med, Dept Pediat, Div Cardiol, Baltimore, MD 21205 USA; [Jennings, Jacky M.] Johns Hopkins Univ, Dept Epidemiol, Bloomberg Sch Publ Hlth, Sch Med, Baltimore, MD USA	Ennen, CS (corresponding author), Johns Hopkins Univ, Sch Med, Dept Obstet & Gynecol, Div Maternal Fetal Med, Baltimore, MD 21205 USA.			jennings, jacky/0000-0002-3789-5122	National Institute of Drug AbuseUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [K01 DA022298-01A1]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R24HD042854] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [K01DA022298] Funding Source: NIH RePORTER	J.M.J. is supported by National Institute of Drug Abuse Grant no. K01 DA022298-01A1. The other authors report no conflict of interest.	American College of Obstetricians and Gynecologists American Academy of Pediatricians, 2003, NEON ENC CER PALS, P73; Barnett A, 2002, NEUROPEDIATRICS, V33, P242, DOI 10.1055/s-2002-36737; Bembea MM, 2010, PEDIATR CRIT CARE ME, V11, P723, DOI 10.1097/PCC.0b013e3181dde659; Blennow M, 2001, ACTA PAEDIATR, V90, P1171, DOI 10.1080/080352501317061594; Cowan F, 2003, LANCET, V361, P736, DOI 10.1016/S0140-6736(03)12658-X; East CE, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004075.pub3; Edwards AD, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c363; Fraser DD, 2011, PEDIATR CRIT CARE ME, V12, P319, DOI 10.1097/PCC.0b013e3181e8b32d; Glass Hannah C, 2007, Curr Treat Options Neurol, V9, P414, DOI 10.1007/s11940-007-0043-0; Gluckman PD, 2005, LANCET, V365, P663, DOI 10.1016/S0140-6736(05)17946-X; Graham EM, 2008, AM J OBSTET GYNECOL, V199, P587, DOI 10.1016/j.ajog.2008.06.094; HADLOCK FP, 1991, RADIOLOGY, V181, P129, DOI 10.1148/radiology.181.1.1887021; Hobbs C, 2008, STROKE, V39, P1307, DOI 10.1161/STROKEAHA.107.499822; Inder TE, 2004, J PEDIATR-US, V145, P835, DOI 10.1016/j.jpeds.2004.07.034; Kaneko T, 2009, RESUSCITATION, V80, P790, DOI 10.1016/j.resuscitation.2009.04.003; Kim SS, 2008, J KOREAN MED SCI, V23, P484, DOI 10.3346/jkms.2008.23.3.484; Larma JD, 2007, AM J OBSTET GYNECOL, V197, DOI 10.1016/j.ajog.2007.06.053; Lumpkins KM, 2008, J TRAUMA, V65, P778, DOI 10.1097/TA.0b013e318185db2d; Oh W, 2008, J PEDIATR-US, V153, P375, DOI 10.1016/j.jpeds.2008.03.041; Pelinka LE, 2004, J TRAUMA, V57, P1006, DOI 10.1097/01.TA.0000108998.48026.C3; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Petzold A, 2004, J IMMUNOL METHODS, V287, P169, DOI 10.1016/j.jim.2004.01.015; Pimentel-Coelho PM, 2010, STEM CELLS DEV, V19, P299, DOI 10.1089/scd.2009.0403; Ramaswamy V, 2009, PEDIATR NEUROL, V40, P215, DOI 10.1016/j.pediatrneurol.2008.09.026; Rouse DJ, 2008, NEW ENGL J MED, V359, P895, DOI 10.1056/NEJMoa0801187; Rutherford MA, 2005, PEDIATRICS, V116, P1001, DOI 10.1542/peds.2005-0328; SARNAT HB, 1976, ARCH NEUROL-CHICAGO, V33, P696, DOI 10.1001/archneur.1976.00500100030012; Shah PS, 2007, ARCH PEDIAT ADOL MED, V161, P951, DOI 10.1001/archpedi.161.10.951; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; Silva AM, 2008, J PERINAT MED, V36, P151, DOI 10.1515/JPM.2008.023; Thoresen M, 2000, Semin Neonatol, V5, P61, DOI 10.1053/siny.1999.0118; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC	32	79	82	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9378	1097-6868		AM J OBSTET GYNECOL	Am. J. Obstet. Gynecol.	SEP	2011	205	3							251.e1	10.1016/j.ajog.2011.06.025			7	Obstetrics & Gynecology	Obstetrics & Gynecology	812YF	WOS:000294330000045	21784396	Green Accepted			2021-06-18	
J	Erickson, JC				Erickson, Jay C.			Treatment Outcomes of Chronic Post-Traumatic Headaches After Mild Head Trauma in US Soldiers: An Observational Study	HEADACHE			English	Article						post-traumatic headache; concussion; mild head trauma; blast; migraine; triptan	BRAIN-INJURY; CHRONIC MIGRAINE; SUBCUTANEOUS SUMATRIPTAN; CONTROLLED-TRIALS; STRESS-DISORDER; DOUBLE-BLIND; TOPIRAMATE; GUIDELINES; SLEEP; PTSD	Background.- The effectiveness of medical therapies for chronic post-traumatic headaches (PTHs) attributable to mild head trauma in military troops has not been established. Objective.- To determine the treatment outcomes of acute and prophylactic medical therapies prescribed for chronic PTHs after mild head trauma in US Army soldiers. Methods.- A retrospective cohort study was conducted with 100 soldiers undergoing treatment for chronic PTH at a single US Army neurology clinic. Headache frequency and Migraine Disability Assessment (MIDAS) scores were determined at the initial clinic visit and then again by phone 3 months after starting headache prophylactic medication. Response rates of headache abortive medications were also determined. Treatment outcomes were compared between subjects with blast-related PTH and non-blast PTH. Results.- Ninety-nine of 100 subjects were male. Seventy-seven of 100 subjects had blast PTH and 23/100 subjects had non-blast PTH. Headache characteristics were similar for blast PTH and non-blast PTH with 96% and 95%, respectively, resembling migraine. Headache frequency among all PTH subjects decreased from 17.1 days/month at baseline to 14.5 days/month at follow-up (P = .009). Headache frequency decreased by 41% among non-blast PTH compared to 9% among blast PTH. Fifty-seven percent of non-blast PTH subjects had a 50% or greater decline in headache frequency compared to 29% of blast PTH subjects (P = .023). A significant decline in headache frequency occurred in subjects treated with topiramate (n = 29, -23%, P = .02) but not among those treated with a low-dose tricyclic antidepressant (n = 48, -12%, P = .23). Seventy percent of PTH subjects who used a triptan class medication experienced reliable headache relief within 2 hours compared to 42% of subjects using other headache abortive medications (P = .01). Triptan medications were effective for both blast PTH and non-blast PTH (66% response rate vs 86% response rate, respectively; P = .20). Headache-related disability, as measured by mean MIDAS scores, declined by 57% among all PTH subjects with no significant difference between blast PTH (-56%) and non-blast PTH (-61%). Conclusions.- Triptan class medications are usually effective for aborting headaches in military troops with chronic PTH attributed to a concussion from a blast injury or non-blast injury. Topiramate appears to be an effective headache prophylactic therapy in military troops with chronic PTH, whereas low doses of tricyclic antidepressants appear to have little efficacy. Chronic PTH triggered by a blast injury may be less responsive to commonly prescribed headache prophylactic medications compared to non-blast PTH. These conclusions require validation by prospective, controlled clinical trials.	[Erickson, Jay C.] Madigan Army Med Ctr, Neurol Serv, Tacoma, WA 98466 USA	Erickson, JC (corresponding author), Madigan Army Med Ctr, Neurol Serv, Tacoma, WA 98466 USA.	jay.erickson@us.army.mil			Uniformed Services University of Health Sciences, Bethesda, MD, USA	This study was supported by the Comprehensive National Neuroscience Program at the Uniformed Services University of Health Sciences, Bethesda, MD, USA. The author thanks Renee Mercer for her efforts in collecting the data.	Afari N, 2009, HEADACHE, V49, P1267, DOI 10.1111/j.1526-4610.2009.01517.x; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Brennan KC, 2009, SEMIN NEUROL, V29, P406, DOI 10.1055/s-0029-1237113; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; COUCH JR, 1979, ARCH NEUROL-CHICAGO, V36, P695, DOI 10.1001/archneur.1979.00500470065013; Diener HC, 2007, CEPHALALGIA, V27, P814, DOI 10.1111/j.1468-2982.2007.01326.x; Diener HC, 2009, CEPHALALGIA, V29, P1021, DOI 10.1111/j.1468-2982.2009.01859.x; Erickson JC, 2008, NEUROLOGY, V70, pA152; Evans RW, 2004, NEUROL CLIN, V22, P237, DOI 10.1016/S0733-8619(03)00097-5; Faux S, 2008, PAIN MED, V9, P1001, DOI 10.1111/j.1526-4637.2007.00404.x; GAWEL MJ, 1993, HEADACHE, V33, P96, DOI 10.1111/j.1526-4610.1993.hed3302096.x; Giza CC, 2001, J ATHL TRAINING, V36, P228; Goadsby PJ, 2009, NEUROL CLIN, V27, P335, DOI 10.1016/j.ncl.2008.11.012; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Krymchantowski AV, 2002, HEADACHE, V42, P510, DOI 10.1046/j.1526-4610.2002.02125.x; Lampl C, 2009, EUR J NEUROL, V16, P943, DOI 10.1111/j.1468-1331.2009.02631.x; Lenaerts Marc E, 2004, Curr Treat Options Neurol, V6, P507, DOI 10.1007/s11940-004-0008-5; Leung Lai Yee, 2008, Molecular & Cellular Biomechanics, V5, P155; Lew HL, 2006, AM J PHYS MED REHAB, V85, P619, DOI 10.1097/01.phm.0000223235.09931.c0; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; PACKARD RC, 1993, HEADACHE, V33, P133, DOI 10.1111/j.1526-4610.1993.hed3303133.x; Packard RC, 1999, J HEAD TRAUMA REHAB, V14, P9, DOI 10.1097/00001199-199902000-00004; Packard RC, 1997, HEADACHE, V37, P142, DOI 10.1046/j.1526-4610.1997.3703142.x; Packard RC, 2000, HEADACHE, V40, P736, DOI 10.1046/j.1526-4610.2000.00128.x; Peterlin BL, 2008, HEADACHE, V48, P517, DOI 10.1111/j.1526-4610.2008.00917.x; Peterlin BL, 2009, HEADACHE, V49, P541, DOI 10.1111/j.1526-4610.2009.01368.x; Rains JC, 2008, CURR NEUROL NEUROSCI, V8, P167, DOI 10.1007/s11910-008-0027-9; Ruff RL, 2009, J REHABIL RES DEV, V46, P1071, DOI 10.1682/JRRD.2009.05.0062; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; SHEFTELL FD, 1994, HEADACHE, V34, P67, DOI 10.1111/j.1526-4610.1994.hed3402067.x; Silberstein S, 2008, CEPHALALGIA, V28, P484, DOI 10.1111/j.1468-2982.2008.01555.x; Silberstein SD, 2000, NEUROLOGY, V55, P754, DOI 10.1212/WNL.55.6.754; Silberstein SD, 2004, CEPHALALGIA, V24, P2, DOI 10.1111/j.1468-2982.2004.00892.x; Silberstein SD, 2007, HEADACHE, V47, P170, DOI 10.1111/j.1526-4610.2006.00684.x; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; Stewart WF, 2001, NEUROLOGY, V56, pS20, DOI 10.1212/WNL.56.suppl_1.S20; Stovner LJ, 2009, EUR J NEUROL, V16, P112, DOI 10.1111/j.1468-1331.2008.02363.x; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Tfelt-Hansen P, 2000, CEPHALALGIA, V20, P765; Theeler BJ, 2010, HEADACHE, V50, P1262, DOI 10.1111/j.1526-4610.2010.01700.x; VA/DoD, 2009, CLIN PRACT GUID MAN; WEISS HD, 1991, HEADACHE, V31, P451, DOI 10.1111/j.1526-4610.1991.hed3107451.x	45	79	82	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0017-8748	1526-4610		HEADACHE	Headache	JUN	2011	51	6					932	944		10.1111/j.1526-4610.2011.01909.x			13	Clinical Neurology	Neurosciences & Neurology	772GH	WOS:000291221800011	21592097				2021-06-18	
J	Lin, MS; Lee, YH; Chiu, WT; Hung, KS				Lin, Muh-Shi; Lee, Yi-Hsuan; Chiu, Wen-Ta; Hung, Kuo-Sheng			Curcumin Provides Neuroprotection After Spinal Cord Injury	JOURNAL OF SURGICAL RESEARCH			English	Article						curcumin; spinal cord injury; hemisection; BBB scale; astrocyte primary culture; functional outcome; apoptosis; GFAP; astrocyte reactivation; neuroprotection	ASTROCYTES PROTECT NEURONS; TRAUMATIC BRAIN-INJURY; INFLAMMATORY RESPONSE; INDUCED APOPTOSIS; OXIDATIVE STRESS; GENE-EXPRESSION; METHYLPREDNISOLONE; PROLIFERATION; REGENERATION; ACTIVATION	Background. Traumatic spinal cord injury (SCI) is a major cause of long-term disability. However, therapeutic agents targeting SCI are sorely lacking. The aim of this study was to investigate whether curcumin has neuroprotective effects after SCI in rats. Materials and methods. Studies were performed in 39 male Sprague-Dawley rats after spinal cord hemisection. The animals were randomly divided into three groups: sham, vehicle, and curcumin. The Basso, Beattie, and Bresnahan (BBB) scale was used to evaluate functional outcome. Specimens were tested for histologic, terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling (TUNEL), and immunohistochemical staining. Primary cultured astrocytes were used to test the inhibitory effect of curcumin on glial reactivation. Results. The BBB scores for the affected hindlimb after hemisection were significantly improved in the curcumin-treated group compared with the vehicle group (on d 3 and 7; P < 0.001). Immunohistochemistry of NeuN revealed remarkable neuronal loss in the vehicle group after hemisection. In comparison, curcumin significantly protected neurons after SCI (curcumin compared with vehicle; P < 0.001). Furthermore, curcumin significantly attenuated apoptosis after SCI (curcumin compared with vehicle; P < 0.001). RT-PCR demonstrated that the expression of glial fibrillary acidic protein (GFAP) was significantly inhibited by curcumin. Conclusions. Curcumin inhibited apoptosis and neuron loss, quenched astrocyte activation, and significantly improved neurologic deficit 7 d after spinal cord hemisection. By down-regulating GFAP expression, curcumin seems to attenuate astrocyte reactivation, which may be beneficial for neuronal survival. This is the first report demonstrating the successful treatment of SCI by curcumin. (C) 2011 Elsevier Inc. All rights reserved.	[Lin, Muh-Shi; Chiu, Wen-Ta; Hung, Kuo-Sheng] Taipei Med Univ, Dept Neurosurg, Wan Fang Hosp, Taipei 116, Taiwan; [Lin, Muh-Shi] Taipei Cty Hosp, Dept Surg, Div Neurosurg, Taipei, Taiwan; [Lin, Muh-Shi; Chiu, Wen-Ta] Taipei Med Univ, Coll Med, Grad Inst Clin Med, Taipei 116, Taiwan; [Lee, Yi-Hsuan] Taipei Med Univ, Coll Med, Dept Physiol, Taipei 116, Taiwan; [Hung, Kuo-Sheng] Taipei Med Univ, Dept Neurosurg, Wan Fang Med Ctr, Grad Inst Injury Prevent & Control, Taipei 116, Taiwan	Hung, KS (corresponding author), Taipei Med Univ, Dept Neurosurg, Wan Fang Med Ctr, Grad Inst Injury Prevent & Control, 111 Sect 3,Hsin Long Rd, Taipei 116, Taiwan.	kshung25@gmail.com	LLM, 林牧熹 醫學博士 法學碩士 Muh-Shi Lin MD PhD/U-7004-2019	LLM, 林牧熹 醫學博士 法學碩士 Muh-Shi Lin MD PhD/0000-0002-9798-8160	National Science CouncilMinistry of Science and Technology, Taiwan [NSC 96-2314-B-010387-MY3, NSC 97-2323-B-038-004]; Department of Health, Taiwan [DOH-TD-B-111-002]	The authors acknowledge support for this work by the National Science Council (grant no. NSC 96-2314-B-010387-MY3, NSC 97-2323-B-038-004), and the Department of Health, Taiwan (grant no. DOH-TD-B-111-002).	Ambegaokar SS, 2003, NEUROENDOCRINOL LETT, V24, P469; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Benarroch EE, 2005, MAYO CLIN PROC, V80, P1326, DOI 10.4065/80.10.1326; Bethea JR, 2002, CURR OPIN NEUROL, V15, P355, DOI 10.1097/00019052-200206000-00021; Carlson SL, 1998, EXP NEUROL, V151, P77, DOI 10.1006/exnr.1998.6785; Chen J, 2006, APOPTOSIS, V11, P943, DOI 10.1007/s10495-006-6715-5; Chen YM, 2001, J NEUROCHEM, V77, P1601, DOI 10.1046/j.1471-4159.2001.00374.x; Davies SJA, 1996, EXP NEUROL, V142, P203, DOI 10.1006/exnr.1996.0192; Desagher S, 1996, J NEUROSCI, V16, P2553; Ersayli DT, 2006, SPINE, V31, P2221, DOI 10.1097/01.brs.0000232801.19965.a0; Fu YM, 2008, MOL PHARMACOL, V73, P399, DOI 10.1124/mol.107.039818; Hellmich HL, 2005, ANESTHESIOLOGY, V102, P806, DOI 10.1097/00000542-200504000-00017; Houle JD, 2003, EXP NEUROL, V182, P247, DOI 10.1016/S0014-4886(03)00029-3; Hung KS, 2005, J NEUROPATH EXP NEUR, V64, P15, DOI 10.1093/jnen/64.1.15; Hung KS, 2007, J NEUROSURG-SPINE, V6, P35, DOI 10.3171/spi.2007.6.1.7; Hurlbert RJ, 2006, SPINE, V31, pS16, DOI 10.1097/01.brs.0000218264.37914.2c; Jaruga E, 1998, BIOCHEM PHARMACOL, V56, P961, DOI 10.1016/S0006-2952(98)00144-0; Kwon Brian K, 2004, Spine J, V4, P451, DOI 10.1016/j.spinee.2003.07.007; Lin CH, 2008, J NEUROCHEM, V104, P1415, DOI 10.1111/j.1471-4159.2007.05098.x; Liu WL, 2008, GLIA, V56, P1390, DOI 10.1002/glia.20706; Mattson MP, 2006, TRENDS NEUROSCI, V29, P632, DOI 10.1016/j.tins.2006.09.001; Mattson Mark P, 2007, Dose Response, V5, P174, DOI 10.2203/dose-response.07-004.Mattson; Morino T, 2003, NEUROSCI RES, V46, P309, DOI 10.1016/S0168-0102(03)00095-6; PANCHAL HD, 2008, NEUROCHEM RES, V47, P24; Ransom B, 2003, TRENDS NEUROSCI, V26, P520, DOI 10.1016/j.tins.2003.08.006; Shapiro H, 2006, J GASTROEN HEPATOL, V21, P358, DOI 10.1111/j.1440-1746.2005.03984.x; Shin HJ, 2007, NEUROSCI LETT, V416, P49, DOI 10.1016/j.neulet.2007.01.060; Shishodia S, 2005, ANN NY ACAD SCI, V1056, P206, DOI 10.1196/annals.1352.010; Somasundaram S, 2002, CANCER RES, V62, P3868; Stichel CC, 1998, CELL TISSUE RES, V294, P1, DOI 10.1007/s004410051151; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Wang HH, 2009, GLIA, V57, P24, DOI 10.1002/glia.20732; Weber WM, 2006, BIOORGAN MED CHEM, V14, P2450, DOI 10.1016/j.bmc.2005.11.035; Wu AG, 2006, EXP NEUROL, V197, P309, DOI 10.1016/j.expneurol.2005.09.004; Xu J, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-01-j0001.2001; Yazawa K, 2006, FEBS LETT, V580, P6623, DOI 10.1016/j.febslet.2006.11.011; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	37	79	90	0	6	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804	1095-8673		J SURG RES	J. Surg. Res.	APR	2011	166	2					280	289		10.1016/j.jss.2009.07.001			10	Surgery	Surgery	732ER	WOS:000288168300034	20018302				2021-06-18	
J	Ye, R; Zhang, X; Kong, X; Han, J; Yang, Q; Zhang, Y; Chen, Y; Li, P; Liu, J; Shi, M; Xiong, L; Zhao, G				Ye, R.; Zhang, X.; Kong, X.; Han, J.; Yang, Q.; Zhang, Y.; Chen, Y.; Li, P.; Liu, J.; Shi, M.; Xiong, L.; Zhao, G.			GINSENOSIDE Rd ATTENUATES MITOCHONDRIAL DYSFUNCTION AND SEQUENTIAL APOPTOSIS AFTER TRANSIENT FOCAL ISCHEMIA	NEUROSCIENCE			English	Article						ginsenoside Rd; neuroprotection; mitochondria; stroke	CEREBRAL-ARTERY OCCLUSION; TRAUMATIC BRAIN-INJURY; RAT-BRAIN; NEURONAL APOPTOSIS; REPERFUSION INJURY; HYPERBARIC-OXYGEN; ACUTE STROKE; ADULT RATS; MODEL; NEUROPROTECTION	We previously found that ginsenoside Rd (Rd), one of the major active ingredients in Panax ginseng, protects neuronal cells from hydrogen peroxide and oxygen-glucose deprivation, an in vitro model of cerebral ischemia. In this study, we examined the protective effects of Rd in an animal model of focal cerebral ischemia. Rats administered with Rd or vehicle were subjected to transient middle cerebral artery occlusion (MCAO). Rd (50 mg/kg) significantly reduced the infarct volume by 52.8%. This reduction of injury volume was associated with an improvement in neurological function and was sustained for at least 2 weeks after the induction of ischemia. To evaluate the underlying mechanisms of Rd against stroke, brain tissues were assayed for mitochondrial enzyme activities, mitochondrial membrane potential (MMP), production of reactive oxygen species (ROS), energy metabolites, and apoptosis. Rd markedly protected mitochondria as indicated by preserved respiratory chain complex activities and aconitase activity, lowered mitochondrial hydrogen peroxide production, and hyperpolarized MMP. Microdialysis results illustrated that Rd significantly decreased the accumulation of lactate, the end product of anaerobic glycolysis, and increased pyruvate, the end product of aerobic glycolysis, hence inducing a lower lactate/pyruvate ratio. Additionally, in vitro studies further exhibited that Rd protected isolated mitochondria from calcium-induced damage by attenuating mitochondrial swelling, preserving MMP and decreasing ROS production. Moreover, Rd treatment reduced mitochondrial release of cytochrome c (CytoC) and apoptosis-inducing factor (AIF), thereby minimizing mitochondria-mediated apoptosis following ischemia. In conclusion, these findings demonstrated that Rd exerts neuroprotective effects in transient focal ischemia, which may involve an integrated process of the mitochondrial protection, energy restoration and inhibition of apoptosis. (c) 2011 IBRO. Published by Elsevier Ltd. All rights reserved.	[Ye, R.; Zhang, X.; Han, J.; Zhang, Y.; Liu, J.; Shi, M.; Zhao, G.] Fourth Mil Med Univ, Xijing Hosp, Dept Neurol, Xian 710032, Peoples R China; [Kong, X.] Fourth Mil Med Univ, Coll Stomatol, Xian 710032, Peoples R China; [Yang, Q.; Chen, Y.; Xiong, L.] Fourth Mil Med Univ, Dept Anaesthesiol, Xijing Hosp, Xian 710032, Peoples R China; [Li, P.] Fourth Mil Med Univ, Xijing Hosp, Dept Orthoped, Xian 710032, Peoples R China	Zhao, G (corresponding author), Fourth Mil Med Univ, Xijing Hosp, Dept Neurol, Xian 710032, Peoples R China.	zhaogang@fmmu.edu.cn	Shi, Ming/B-7829-2012		National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81073094]; Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [21591530, 21659287] Funding Source: KAKEN	This study was supported in part by the National Natural Science Foundation of China (Grant No. 81073094). The authors are grateful to Dongyun Feng and Shiquan Wang for their excellent technical assistance with Western blot and MCAO model experiments.	Ashwal S, 1998, STROKE, V29, P1037, DOI 10.1161/01.STR.29.5.1037; Badr AE, 2001, BRAIN RES, V916, P85, DOI 10.1016/S0006-8993(01)02867-0; Barrientos A, 1998, J BIOL CHEM, V273, P14210, DOI 10.1074/jbc.273.23.14210; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; Belayev L, 1996, STROKE, V27, P1616, DOI 10.1161/01.STR.27.9.1616; Clark RSB, 2007, J CEREBR BLOOD F MET, V27, P316, DOI 10.1038/sj.jcbfm.9600338; Dave KR, 2008, J NEUROSCI, V28, P4172, DOI 10.1523/JNEUROSCI.5471-07.2008; DERYCK M, 1989, STROKE, V20, P1383, DOI 10.1161/01.STR.20.10.1383; ESTORNELL E, 1993, FEBS LETT, V332, P127, DOI 10.1016/0014-5793(93)80498-J; Gao YQ, 2010, STROKE, V41, P166, DOI 10.1161/STROKEAHA.109.561852; GARCIA JH, 1995, STROKE, V26, P627, DOI 10.1161/01.STR.26.4.627; Gardner PR, 2002, METHOD ENZYMOL, V349, P9, DOI 10.1016/S0076-6879(02)49317-2; Ginsberg MD, 2008, NEUROPHARMACOLOGY, V55, P363, DOI 10.1016/j.neuropharm.2007.12.007; Gropen TI, 2006, NEUROLOGY, V67, P88, DOI 10.1212/01.wnl.0000223622.13641.6d; Guan YY, 2006, EUR J PHARMACOL, V548, P129, DOI 10.1016/j.ejphar.2006.08.001; Halestrap AP, 1998, BBA-BIOENERGETICS, V1366, P79, DOI 10.1016/S0005-2728(98)00122-4; Head E, 2009, EXP NEUROL, V220, P171, DOI 10.1016/j.expneurol.2009.08.014; ISAYAMA K, 1991, STROKE, V22, P1394, DOI 10.1161/01.STR.22.11.1394; KRAHENBUHL S, 1991, J BIOL CHEM, V266, P20998; Li JS, 2008, BRAIN RES, V1210, P223, DOI 10.1016/j.brainres.2008.03.007; Li XY, 2010, CLIN EXP PHARMACOL P, V37, P199, DOI 10.1111/j.1440-1681.2009.05286.x; Lian XY, 2005, ANN NEUROL, V57, P642, DOI 10.1002/ana.20450; LIN TN, 1993, STROKE, V24, P117, DOI 10.1161/01.STR.24.1.117; Lipton P, 1999, PHYSIOL REV, V79, P1431; Liu X, 2009, EUR J NEUROL, V16, P569, DOI 10.1111/j.1468-1331.2009.02534.x; Liu ZQ, 2003, J AGR FOOD CHEM, V51, P2555, DOI 10.1021/jf026228i; LU Y, 2009, CHIN J NEUROSURG DIS, V8, P496; Mackensen GB, 2001, J NEUROSCI, V21, P4582, DOI 10.1523/JNEUROSCI.21-13-04582.2001; Morin C, 2002, NEUROSCIENCE, V115, P415, DOI 10.1016/S0306-4522(02)00416-5; Murphy MP, 2009, BIOCHEM J, V417, P1, DOI 10.1042/BJ20081386; Neumar RW, 2003, J BIOL CHEM, V278, P14162, DOI 10.1074/jbc.M212255200; Sacco RL, 2007, LANCET, V369, P331, DOI 10.1016/S0140-6736(07)60155-X; Savitz SI, 2007, ANN NEUROL, V61, P396, DOI 10.1002/ana.21127; Schabitz WR, 2003, STROKE, V34, P745, DOI 10.1161/01.STR.0000057814.70180.17; Shen H, 2009, FASEB J, V23, P1958, DOI 10.1096/fj.08-123281; Sims NR, 2010, BBA-MOL BASIS DIS, V1802, P80, DOI 10.1016/j.bbadis.2009.09.003; SIMS NR, 1990, J NEUROCHEM, V55, P698, DOI 10.1111/j.1471-4159.1990.tb04189.x; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sutherland BA, 2004, FASEB J, V18, P258, DOI 10.1096/fj.04-2806fje; Tang W, 1992, CHINESE DRUGS PLANT; Vosler PS, 2009, STROKE, V40, P3149, DOI 10.1161/STROKEAHA.108.543769; Wang Q, 2008, ANESTHESIOLOGY, V108, P1071, DOI 10.1097/ALN.0b013e318173f66b; Wang Q, 2009, STROKE, V40, P2157, DOI 10.1161/STROKEAHA.108.541490; WHARTON DC, 1967, METHOD ENZYMOL, V55, P328; Yang F, 2010, J NEUROSCI RES, V88, P519, DOI 10.1002/jnr.22224; Yang L, 2007, J CHROMATOGR B, V854, P77, DOI 10.1016/j.jchromb.2007.04.014; Ye RD, 2008, BIOL PHARM BULL, V31, P1923, DOI 10.1248/bpb.31.1923; Ye RD, 2009, NEUROSCI RES, V64, P306, DOI 10.1016/j.neures.2009.03.016; YUAN L, 2010, CHIN J NEUROSURG DIS, V9, P254; Zeng X, 2010, J CLIN PHARMACOL, V50, P285, DOI 10.1177/0091270009344334; Zheng CY, 2008, J NEUROSCI RES, V86, P2432, DOI 10.1002/jnr.21681	51	79	91	0	21	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	MAR 31	2011	178						169	180		10.1016/j.neuroscience.2011.01.007			12	Neurosciences	Neurosciences & Neurology	736WK	WOS:000288525500017	21219973				2021-06-18	
J	Zatzick, DF; Rivara, FP; Jurkovich, GJ; Hoge, CW; Wang, J; Fan, MY; Russo, J; Trusz, SG; Nathens, A; Mackenzie, EJ				Zatzick, Douglas F.; Rivara, Frederick P.; Jurkovich, Gregory J.; Hoge, Charles W.; Wang, Jin; Fan, Ming-Yu; Russo, Joan; Trusz, Sarah Geiss; Nathens, Avery; Mackenzie, Ellen J.			Multisite Investigation of Traumatic Brain Injuries, Posttraumatic Stress Disorder, and Self-reported Health and Cognitive Impairments	ARCHIVES OF GENERAL PSYCHIATRY			English	Article							QUALITY-OF-LIFE; FUNCTIONAL OUTCOMES; NEUROPSYCHOLOGICAL OUTCOMES; PSYCHOMETRIC PROPERTIES; PTSD CHECKLIST; SYMPTOMS; RISK; CHILDREN; IRAQ; DEPRESSION	Context: Few large-scale, multisite investigations have assessed the development of posttraumatic stress disorder (PTSD) symptoms and health outcomes across the spectrum of patients with mild, moderate, and severe traumatic brain injury (TBI). Objectives: To understand the risk of developing PTSD symptoms and to assess the impact of PTSD on the development of health and cognitive impairments across the full spectrum of TBI severity. Design: Multisite US prospective cohort study. Setting: Eighteen level I trauma centers and 51 non-trauma center hospitals. Patients: A total of 3047 (weighted n=10 372) survivors of multiple traumatic injuries between the ages of 18 and 84 years. Main Outcome Measures: Severity of TBI was categorized from chart-abstracted International Classification of Diseases, Ninth Revision, Clinical Modification codes. Symptoms consistent with a DSM-IV diagnosis of PTSD were assessed with the PTSD Checklist 12 months after injury. Self-reported outcome assessment included the 8 Medical Outcomes Study 36-Item Short Form Health Survey health status domains and a 4-item assessment of cognitive function at telephone interviews 3 and 12 months after injury. Results: At the time of injury hospitalization, 20.5% of patients had severe TBI, 11.7% moderate TBI, 12.9% mild TBI, and 54.9% no TBI. Patients with severe (relative risk, 0.72; 95% confidence interval, 0.58-0.90) and moderate (0.63; 0.44-0.89) TBI, but not mild TBI (0.83; 0.61-1.13), demonstrated a significantly diminished risk of PTSD symptoms relative to patients without TBI. Across TBI categories, in adjusted analyses patients with PTSD demonstrated an increased risk of health status and cognitive impairments when compared with patients without PTSD. Conclusions: More severe TBI was associated with a diminished risk of PTSD. Regardless of TBI severity, injured patients with PTSD demonstrated the greatest impairments in self-reported health and cognitive function. Treatment programs for patients with the full spectrum of TBI severity should integrate intervention approaches targeting PTSD.	[Zatzick, Douglas F.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Harborview Injury Prevent & Res Ctr, Seattle, WA 98104 USA; [Hoge, Charles W.] Walter Reed Army Inst Res, Silver Spring, MD USA; [Nathens, Avery] Univ Toronto, Dept Surg, Toronto, ON, Canada; [Mackenzie, Ellen J.] Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Injury Res & Policy, Baltimore, MD USA	Zatzick, DF (corresponding author), Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Harborview Injury Prevent & Res Ctr, Campus Box 359911,325 9th Ave, Seattle, WA 98104 USA.	dzatzick@u.washington.edu			National Center for Injury Prevention and ControlUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49/CCR316840]; National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01/AG20361]; National Institute of Mental HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01/MH073613, K24/MH086814]; Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH073613, K24MH086814] Funding Source: NIH RePORTER	This work was funded by grant R49/CCR316840 from the National Center for Injury Prevention and Control and the Centers for Disease Control and Prevention, grant R01/AG20361 from the National Institute on Aging, and grants R01/MH073613 and K24/MH086814 from the National Institute of Mental Health.	*ASS ADV AUT MED C, 1990, ABBR INJ SCAL 1990 R; *ASS ADV AUT MED C, 2008, ABBR INJ SCAL 2005 U; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Bombardier CH, 2006, J NEUROPSYCH CLIN N, V18, P501, DOI 10.1176/appi.neuropsych.18.4.501; Bryant RA, 2001, CLIN PSYCHOL REV, V21, P931; Bryant RA, 2000, AM J PSYCHIAT, V157, P629, DOI 10.1176/appi.ajp.157.4.629; Bryant RA, 2003, AM J PSYCHIAT, V160, P585, DOI 10.1176/appi.ajp.160.3.585; Bryant RA, 2001, J NERV MENT DIS, V189, P109, DOI 10.1097/00005053-200102000-00006; BRYANT RA, 1995, PSYCHOL MED, V25, P869, DOI 10.1017/S0033291700035121; Bryant RA, 1999, BRAIN INJURY, V13, P15, DOI 10.1080/026990599121836; Bryant RA, 2008, NEW ENGL J MED, V358, P525, DOI 10.1056/NEJMe078235; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Bryant RA, 2009, J INT NEUROPSYCH SOC, V15, P862, DOI 10.1017/S1355617709990671; Butler J, 2001, CENTRAL NERVOUS SYST; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Civil I.D., 1985, ABBREVIATED INJURY S; Corrigan JD, 2008, JAMA-J AM MED ASSOC, V300, P720, DOI 10.1001/jama.300.6.720; Engel C.C., 1999, STRATEGIES PROTECT H, P173; Forbes D, 2001, BEHAV RES THER, V39, P977, DOI 10.1016/S0005-7967(00)00084-X; Friedman MJ, 2004, NEW ENGL J MED, V351, P75, DOI 10.1056/NEJMe048129; Gil S, 2005, AM J PSYCHIAT, V162, P963, DOI 10.1176/appi.ajp.162.5.963; Glaesser J, 2004, BMC PSYCHIATRY, V4, DOI 10.1186/1471-244X-4-5; Glynn SM, 2007, J TRAUMA, V62, P410, DOI 10.1097/01.ta.0000231556.05899.b0; Grieger TA, 2006, AM J PSYCHIAT, V163, P1777, DOI 10.1176/appi.ajp.163.10.1777; Harvey AG, 2003, J INT NEUROPSYCH SOC, V9, P663, DOI 10.1017/S1355617703940069; Hatcher MB, 2009, BRIT J HEALTH PSYCH, V14, P541, DOI 10.1348/135910708X373445; Hickling EJ, 1998, BRAIN INJURY, V12, P265, DOI 10.1080/026990598122566; Hiott DW, 2002, NEUROREHABILITATION, V17, P345; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Holbrook TL, 2005, J TRAUMA, V59, P1126, DOI 10.1097/01.ta.0000196433.61423.f2; Holbrook TL, 1999, J TRAUMA, V46, P765, DOI 10.1097/00005373-199905000-00003; Holbrook TL, 2007, J TRAUMA, V62, P577, DOI 10.1097/TA.0b013e318031aa97; Joseph S, 1999, J TRAUMA STRESS, V12, P437, DOI 10.1023/A:1024762919372; Kennedy JE, 2007, J REHABIL RES DEV, V44, P895, DOI 10.1682/JRRD.2006.12.0166; Koren D, 2006, CNS SPECTRUMS, V11, P616, DOI 10.1017/S1092852900013675; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; Love B, 1987, J Burn Care Rehabil, V8, P280, DOI 10.1097/00004630-198707000-00008; Lude P, 2005, SPINAL CORD, V43, P102, DOI 10.1038/sj.sc.3101688; MacGregor AJ, 2009, INJURY, V40, P1004, DOI 10.1016/j.injury.2009.04.006; MacKenzie EJ, 2006, NEW ENGL J MED, V354, P366, DOI 10.1056/NEJMsa052049; MacKenzie EJ, 2002, J TRAUMA, V52, P527, DOI 10.1097/00005373-200203000-00018; MacKenzie EJ, 2007, J TRAUMA, V63, pS54, DOI 10.1097/TA.0b013e31815acb09; Magaziner J, 1997, AM J EPIDEMIOL, V146, P418, DOI 10.1093/oxfordjournals.aje.a009295; Marx BP, 2009, ARCH GEN PSYCHIAT, V66, P996, DOI 10.1001/archgenpsychiatry.2009.109; McNett Molly, 2007, J Neurosci Nurs, V39, P68; Meredith JW, 2002, J TRAUMA, V53, P621, DOI 10.1097/00005373-200210000-00001; Michaels AJ, 1999, J TRAUMA, V47, P460, DOI 10.1097/00005373-199909000-00005; Mora AG, 2009, J TRAUMA, V66, pS178, DOI 10.1097/TA.0b013e31819ce2d6; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; National Institute of Neurological Disorders and Stroke, 2002, NIH PUBL; O'Donnell ML, 2008, J CONSULT CLIN PSYCH, V76, P923, DOI 10.1037/a0012918; O'Donnell ML, 2005, J TRAUMA, V59, P1328, DOI 10.1097/01.ta.0000197621.94561.4e; O'Donnell ML, 2003, CLIN PSYCHOL REV, V23, P587, DOI 10.1016/S0272-7358(03)00036-9; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; *PC CAR AM RET WOU, 2007, SERV SUPP SIMPL REP; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Ramchand R, 2008, J CONSULT CLIN PSYCH, V76, P668, DOI 10.1037/0022-006X.76.4.668; Rothman K.J., 1998, MODERN EPIDEMIOLOGY, V2nd ed.; Rubin DB., 1987, MULTIPLE IMPUTATION; Ruggiero KJ, 2006, J TRAUMA STRESS, V19, P699, DOI 10.1002/jts.20141; Ruggiero KJ, 2003, J TRAUMA STRESS, V16, P495, DOI 10.1023/A:1025714729117; Rusch MD, 2000, PLAST RECONSTR SURG, V106, P1451, DOI 10.1097/00006534-200012000-00001; Saxe GN, 2005, AM J PSYCHIAT, V162, P1299; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schnurr PP, 2007, JAMA-J AM MED ASSOC, V297, P820, DOI 10.1001/jama.297.8.820; Schnurr PP, 2009, CLIN PSYCHOL REV, V29, P727, DOI 10.1016/j.cpr.2009.08.006; Schnyder U, 2001, AM J PSYCHIAT, V158, P594, DOI 10.1176/appi.ajp.158.4.594; Shalev AY, 1996, AM J PSYCHIAT, V153, P219; Sherer M, 2008, J NEUROL NEUROSUR PS, V79, P678, DOI 10.1136/jnnp.2006.111187; Sneeuw KCA, 1997, MED CARE, V35, P490, DOI 10.1097/00005650-199705000-00006; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; Stoddard FJ, 2006, J AM ACAD CHILD PSY, V45, P87, DOI 10.1097/01.chi.0000184934.71917.3a; Stoddard FJ, 2001, J AM ACAD CHILD PSY, V40, P1128, DOI 10.1097/00004583-200110000-00007; TABER KH, 2009, J NEUROPSYCH CLIN N, V21, pR4; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Thurman DJ., 1995, GUIDELINES SURVEILLA; Ursano RJ., 2004, PRACTICE GUIDELINE T; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Vasa RA, 2004, BIOL PSYCHIAT, V55, P208, DOI 10.1016/S0006-3223(03)00708-X; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004; Wade AL, 2007, J TRAUMA, V63, P836, DOI 10.1097/01.ta.0000251453.54663.66; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Ware JE., 1993, SF 36 HLTH SURVEY MA; Weathers F.W., 1991, PTSD CHECKLIST CIVIL; Williams WH, 2002, J TRAUMA STRESS, V15, P397, DOI 10.1023/A:1020185325026; Winston FK, 2003, JAMA-J AM MED ASSOC, V290, P643, DOI 10.1001/jama.290.5.643; Zatzick D, 2004, ARCH GEN PSYCHIAT, V61, P498, DOI 10.1001/archpsyc.61.5.498; Zatzick DF, 1997, AM J PSYCHIAT, V154, P1690, DOI 10.1176/ajp.154.12.1690; Zatzick DF, 2002, ARCH SURG-CHICAGO, V137, P200, DOI 10.1001/archsurg.137.2.200; Zatzick D, 2008, ANN SURG, V248, P429, DOI 10.1097/SLA.0b013e318185a6b8; Zatzick DF, 2008, ARCH PEDIAT ADOL MED, V162, P642, DOI 10.1001/archpedi.162.7.642; Zatzick DF, 2007, PSYCHOL MED, V37, P1469, DOI 10.1017/S0033291707000943; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690; ZHENG WB, 2006, C P IEEE ENG MED BIO, V1, P1052; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	102	79	79	0	14	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0003-990X	1538-3636		ARCH GEN PSYCHIAT	Arch. Gen. Psychiatry	DEC	2010	67	12					1291	1300		10.1001/archgenpsychiatry.2010.158			10	Psychiatry	Psychiatry	690NO	WOS:000285011700013	21135329	Bronze, Green Accepted			2021-06-18	
J	Chio, CC; Lin, JW; Chang, MW; Wang, CC; Kuo, JR; Yang, CZ; Chang, CP				Chio, Chung-Ching; Lin, Jia-Wei; Chang, Ming-Wen; Wang, Che-Chuan; Kuo, Jinn-Rung; Yang, Chung-Zhing; Chang, Ching-Ping			Therapeutic evaluation of etanercept in a model of traumatic brain injury	JOURNAL OF NEUROCHEMISTRY			English	Article						apoptosis; etanercept; inflammation; traumatic brain injury; tumor necrosis factor-alpha	NECROSIS-FACTOR-ALPHA; PERISPINAL ETANERCEPT; CEREBRAL-ISCHEMIA; INTERLEUKIN-10; INFLAMMATION; IL-10; NEUROGENESIS; REGENERATION; ENDOTOXEMIA; OUTGROWTH	P>Antagonism of tumor necrosis factor-alpha with etanercept has proved to be effective in the treatment of spinal cord injury and centrally endotoxin-induced brain injury. However, etanercept may offer promise as therapy for traumatic brain injury (TBI). In this study, anesthetized rats, immediately after the onset of TBI, were divided into two major groups and given the vehicle solution (1 mL/kg of body weight) or etanercept (5 mg/kg of body weight) intraperitoneally once per 12 h for consecutive 3 days. Etanercept caused attenuation of TBI-induced cerebral ischemia (e.g., increased cellular levels of glutamate and lactate-to-pyruvate ratio), damage (e.g., increased cellular levels of glycerol) and contusion and motor and cognitive function deficits. TBI-induced neuronal apoptosis (e.g., increased numbers of terminal deoxynucleotidyl transferase alpha UTP nick-end labeling and neuronal-specific nuclear protein double-positive cells), glial apoptosis (e.g., increased numbers of terminal deoxynucleotidyl transferase alpha UTP nick-end labeling and glial fibrillary acidic protein double-positive cells), astrocytic (e.g., increased numbers of glial fibrillary acidic protein positive cells) and microglial (e.g., increased numbers of ionized calcium-binding adapter molecule 1-positive cells) activation and activated inflammation (e.g., increased levels of tumor necrosis factor-alpha, interleukin-1 beta and interleukin-6) were all significantly reduced by etanercept treatment. These findings suggest that etanercept may improve outcomes of TBI by penetrating into the cerebrospinal fluid in rats.	[Kuo, Jinn-Rung; Yang, Chung-Zhing; Chang, Ching-Ping] So Taiwan Univ, Dept Biotechnol, Tainan, Taiwan; [Chio, Chung-Ching; Wang, Che-Chuan; Kuo, Jinn-Rung] Chi Mei Med Ctr, Dept Surg, Tainan, Taiwan; [Lin, Jia-Wei] Taipei Med Univ, Dept Neurosurg, Shuang Ho Hosp, Taipei, Taiwan; [Lin, Jia-Wei] Taipei Med Univ, Grad Inst Clin Med, Taipei, Taiwan; [Chang, Ming-Wen] So Taiwan Univ, Dept Elect Engn, Tainan, Taiwan	Chang, CP (corresponding author), So Taiwan Univ, Dept Biotechnol, Tainan, Taiwan.	jessica@mail.stut.edu.tw		Chang, Ching-Ping/0000-0003-0890-9414	National Science Council of the Republic of ChinaMinistry of Science and Technology, Taiwan [NSC 98-2314-B-218 -001 -MY2, NSC 99-2314-B-384 -004 -MY3, DOH99-TD-B-111-003]	This study was funded in part by the National Science Council of the Republic of China (Grant Nos. NSC 98-2314-B-218 -001 -MY2 and NSC 99-2314-B-384 -004 -MY3, and DOH99-TD-B-111-003, Center of Excellence for Clinical Trial and Research in Neuroscience.	Aden U, 2010, BRAIN BEHAV IMMUN, V24, P747, DOI 10.1016/j.bbi.2009.10.010; Banks WA, 2004, CURR PHARM DESIGN, V10, P1365, DOI 10.2174/1381612043384862; BERG DJ, 1995, J CLIN INVEST, V96, P2339, DOI 10.1172/JCI118290; BULLOCK R, 1995, STROKE, V26, P2187, DOI 10.1161/01.STR.26.11.2187; Campbell SJ, 2007, J NEUROCHEM, V103, P2245, DOI 10.1111/j.1471-4159.2007.04928.x; Cartmell T, 2003, J PHYSIOL-LONDON, V549, P653, DOI 10.1113/jphysiol.2002.037291; Chang MW, 2008, J NEUROSCI METH, V168, P186, DOI 10.1016/j.jneumeth.2007.09.013; Chen SH, 2009, CRIT CARE MED, V37, P3097, DOI 10.1097/CCM.0b013e3181bc7986; Chio CC, 2007, SHOCK, V28, P284, DOI 10.1097/SHK.0b013e3180311e60; Chou YT, 2003, SHOCK, V19, P388, DOI 10.1097/00024382-200304000-00016; Ekdahl CT, 2003, P NATL ACAD SCI USA, V100, P13632, DOI 10.1073/pnas.2234031100; ELLIOTT MJ, 1994, LANCET, V344, P1105, DOI 10.1016/S0140-6736(94)90628-9; Francis J, 2004, AM J PHYSIOL-HEART C, V286, pH2264, DOI 10.1152/ajpheart.01072.2003; Genovese T, 2006, J PHARMACOL EXP THER, V316, P1006, DOI 10.1124/jpet.105.097188; Hailer NP, 2005, EUR J NEUROSCI, V21, P2347, DOI 10.1111/j.1460-9568.2005.04067.x; Hoehn BD, 2005, STROKE, V36, P2718, DOI 10.1161/01.STR.0000190020.30282.cc; Jiang Y, 2008, NEUROBIOL DIS, V32, P125, DOI 10.1016/j.nbd.2008.06.017; Kato K, 2010, J NEUROSCI RES, V88, P360, DOI 10.1002/jnr.22202; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Kuo JR, 2007, RESUSCITATION, V75, P506, DOI 10.1016/j.resuscitation.2007.05.011; Larsson K, 2005, SPINE, V30, P621, DOI 10.1097/01.brs.0000155410.48700.9e; Leon LR, 1999, AM J PHYSIOL-REG I, V276, pR81; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; MARCHANT A, 1994, EUR J IMMUNOL, V24, P1167, DOI 10.1002/eji.1830240524; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; Neumann H, 2002, J NEUROSCI, V22, P854, DOI 10.1523/JNEUROSCI.22-03-00854.2002; Nilsson OG, 1996, ACT NEUR S, V67, P45; Paxinos G., 1982, RAT BRAIN STEREOTAXI; Rasmussen M, 2005, ACTA ANAESTH SCAND, V49, P341, DOI 10.1111/j.1399-6576.2005.00647.x; Rennick DM, 1997, J LEUKOCYTE BIOL, V61, P389; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; STANDIFORD TJ, 1995, J IMMUNOL, V155, P2222; Tobinick E, 2010, EXPERT REV NEUROTHER, V10, P985, DOI 10.1586/ERN.10.52; Tobinick EL, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-2; vanderPoll T, 1997, J INFECT DIS, V175, P118, DOI 10.1093/infdis/175.1.118; Wang Q, 2001, AM J PHYSIOL-REG I, V281, pR1013; Wang Y, 1997, J NEUROSCI, V17, P4341; Zhou ZG, 2009, J NEUROCHEM, V110, P1617, DOI 10.1111/j.1471-4159.2009.06263.x	39	79	81	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	NOV	2010	115	4					921	929		10.1111/j.1471-4159.2010.06969.x			9	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	669UF	WOS:000283375000012	20796174	Bronze			2021-06-18	
J	Bagiella, E; Novack, TA; Ansel, B; Diaz-Arrastia, R; Dikmen, S; Hart, T; Temkin, N				Bagiella, Emilia; Novack, Thomas A.; Ansel, Beth; Diaz-Arrastia, Ramon; Dikmen, Sureyya; Hart, Tessa; Temkin, Nancy			Measuring Outcome in Traumatic Brain Injury Treatment Trials: Recommendations From the Traumatic Brain Injury Clinical Trials Network	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						clinical trial; global test procedure; outcome measures; traumatic brain injury	POSTTRAUMATIC SEIZURES; RANDOMIZED-TRIAL; SCALE; MISCLASSIFICATION; PREVENTION; PHENYTOIN; VALPROATE; 1-YEAR	Background: Traumatic brain injury (TBI) involves several aspects of a patient's condition, including physical, mental, emotional, cognitive, social, and functional changes. Therefore, a clinical trial with individuals with TBI should consider outcome measures that reflect their global status. Methods: We present the work of the National Institute of Child Health and Development-sponsored Traumatic Brain Injury Clinical Trials Network Outcome Measures subcommittee and its choice of outcome measures for a phase III clinical trial of patients with complicated mild to severe TBI. Results: Onthe basis of theoretical and practical considerations, the subcommittee recommended the adoption of a core of 9 measures that cover 2 different areas of recovery: functional and cognitive. These measures are the Extended Glasgow Outcome Scale; the Controlled Oral Word Association Test; the Trail Making Test, Parts A and B; the California Verbal Learning Test-II; the Wechsler Adult Intelligence Scale-III Digit Span subtest; the Wechsler Adult Intelligence Scale-III Processing Speed Index; and the Stroop Color-Word Matching Test, Parts 1 and 2. Conclusions: The statistical methods proposed to analyze these measures using a global test procedure, along with research and methodological and regulatory issues involved with the use of multiple outcomes in a clinical trial, are discussed.	[Bagiella, Emilia] Columbia Univ, Dept Biostat, Mailman Sch Publ Hlth, New York, NY 10032 USA; [Novack, Thomas A.] Univ Alabama Birmingham, Birmingham, AL USA; [Ansel, Beth] NICHHD, Natl Ctr Med Rehabil Res, Bethesda, MD 20892 USA; [Diaz-Arrastia, Ramon] Univ Texas SW Med Ctr Dallas, Dept Neurol, Dallas, TX 75390 USA; [Dikmen, Sureyya] Univ Washington, Sch Med, Dept Rehabil Med, Div Clin Psychol & Neuropsychol, Seattle, WA 98195 USA; [Temkin, Nancy] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Temkin, Nancy] Univ Washington, Dept Biostat, Seattle, WA 98195 USA; [Hart, Tessa] Moss Rehabil Res Inst, Philadelphia, PA USA	Bagiella, E (corresponding author), Columbia Univ, Dept Biostat, Mailman Sch Publ Hlth, 722 W 168th St, New York, NY 10032 USA.	eb51@columbia.edu		Diaz-Arrastia, Ramon/0000-0001-6051-3594	National Institute of Child Health and DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U01HD042823, U01HD042738, U01HD042687, U01HD042736, U01HD042678, U01HD042686, U01HD042653, U01HD042689, U01HD042652]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U01HD042652] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U01HD042823, U01HD042738, U01HD042678, U01HD042686, U01HD042689, U01HD042736, U01HD042687, U01HD042653] Funding Source: NIH RePORTER	The work of the Traumatic Brain Injury Clinical Trials Network Outcome Measures Subcommittee is supported by National Institute of Child Health and Development grants U01HD042823, U01HD042738, U01HD042687, U01HD042736, U01HD042678, U01HD042686, U01HD042653, U01HD042689, and U01HD042652 to 8 clinical sites and a data-coordinating center.	Benton A, 2000, MULTILINGUAL APHASIA; Benton A. L., 1994, CONTRIBUTIONS NEUROP; Choi SC, 2002, J NEUROTRAUM, V19, P17, DOI 10.1089/089771502753460204; CLIFTON GL, 1993, NEUROSURGERY, V33, P34; Delis DC, 2000, CALIFORNIA VERBAL LE; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Dikmen SS, 2000, NEUROLOGY, V54, P895, DOI 10.1212/WNL.54.4.895; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; DIKMEN SS, 1991, JAMA-J AM MED ASSOC, V265, P1271, DOI 10.1001/jama.265.10.1271; Doctor JN, 2005, J INT NEUROPSYCH SOC, V11, P747, DOI 10.1017/S1355617705050836; DODRILL CB, 1978, EPILEPSIA, V19, P611, DOI 10.1111/j.1528-1157.1978.tb05041.x; Fioravanti M, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000269.pub3; Hart T, 2003, ARCH PHYS MED REHAB, V84, P221, DOI 10.1053/apmr.2003.50023; JENNETT B, 1975, LANCET, V1, P480; Jennett B., 1997, HEAD INJURY, P439; Kersel DA, 2001, BRAIN INJURY, V15, P283, DOI 10.1080/02699050010005887; Kreutzer JS, 1993, J HEAD TRAUMA REHAB, V8, P47; LEHMACHER W, 1991, BIOMETRICS, V47, P511, DOI 10.2307/2532142; Leon-Carrion J, 2000, NEUROREHABILITATION, V14, P33; LEVIN HS, 1991, J NEUROL SCI, V103, pS39; Levin HS, 2001, J NEUROTRAUM, V18, P575, DOI 10.1089/089771501750291819; Lu J, 2008, J NEUROTRAUM, V25, P641, DOI 10.1089/neu.2007.0510; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Murray, 1998, DESIGN ANAL GROUP RA; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; Ragnarsson KT, 2006, J HEAD TRAUMA REHAB, V21, P379, DOI 10.1097/00001199-200609000-00002; Rapport LJ, 1998, ARCH PHYS MED REHAB, V79, P629, DOI 10.1016/S0003-9993(98)90035-1; Reitan R. M., 1992, TRAIL MAKING TEST MA; Reitan RM, 2004, ARCH CLIN NEUROPSYCH, V19, P281, DOI 10.1016/S0887-6177(03)00042-8; Ross S R, 1997, Appl Neuropsychol, V4, P165, DOI 10.1207/s15324826an0403_4; Sherer M, 2002, CLIN NEUROPSYCHOL, V16, P157, DOI 10.1076/clin.16.2.157.13238; Temkin NR, 2007, LANCET NEUROL, V6, P29, DOI 10.1016/S1474-4422(06)70630-5; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tilley BC, 1996, STROKE, V27, P2136, DOI 10.1161/01.STR.27.11.2136; Vanderploeg RD, 2001, J CLIN EXP NEUROPSYC, V23, P185, DOI 10.1076/jcen.23.2.185.1210; Wechsler D, 1997, ADULT INTELLIGENCE S; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wilson JT, 2001, J NEUROL NEUROSUR PS, V70, P267; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wolfson D., 1993, HALSTEAD REITAN NEUR; Zafonte R, 2009, J NEUROTRAUM, V26, P2207, DOI 10.1089/neu.2009.1015	43	79	79	0	21	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2010	25	5					375	382		10.1097/HTR.0b013e3181d27fe3			8	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	649JR	WOS:000281765400011	20216459	Green Accepted			2021-06-18	
J	Horn, SD; Gassaway, J				Horn, Susan D.; Gassaway, Julie			Practice Based Evidence Incorporating Clinical Heterogeneity and Patient-Reported Outcomes for Comparative Effectiveness Research	MEDICAL CARE			English	Article; Proceedings Paper	Symposium on Clinical and Comparative Effectiveness Research Methods II	JUN 01-02, 2009	Rockville, MD	Agcy Healthcare Res & Qual		practice-based-evidence; comparative effectiveness research; clinical heterogeneity; patient; treatment; outcome heterogeneity; severity of illness	TRAUMATIC BRAIN-INJURY; LONG-TERM-CARE; STROKE REHABILITATION; INPATIENT REHABILITATION; INFANTS; ILLNESS; BRONCHIOLITIS; RELIABILITY; IMPROVEMENT; HOSPITALS	Background: Comparative effectiveness research analyzes groups of patients and looks for associations between medical treatments and patient outcomes. To make meaningful comparisons of medical interventions, one must consider clinical heterogeneity of patient populations, intervention combinations, and outcomes. Objectives: To explain how practice-based evidence (PBE) study methodology measures and controls for heterogeneity of patients, treatments, and outcomes seen in real-world clinical settings. Research Design: Overview of PBE methodology. Conclusions: PBE study designs address comparative effectiveness by creating a comprehensive set of patient, treatment, and outcome variables, and analyzing them to identify treatments associated with better outcomes for specific types of patients. PBE studies are an alternative to randomized controlled trials, well suited to determine what works best for specific patient types, and provide clinicians with a rational basis for treatment recommendations for individual patients. They provide a holistic picture of patients, treatments, and outcomes, with no preset limits to the number of variables that can be included. Such an approach is needed for high quality comparative effectiveness research.	[Horn, Susan D.; Gassaway, Julie] Int Sever Informat Syst Inc, Inst Clin Outcomes Res, Salt Lake City, UT 84102 USA	Horn, SD (corresponding author), Int Sever Informat Syst Inc, Inst Clin Outcomes Res, 699 E South Temple,Suite 300, Salt Lake City, UT 84102 USA.	shorn@isisicor.com					Antonow JA, 2001, J NURS CARE QUAL, V15, P39, DOI 10.1097/00001786-200104000-00007; AVERILL RF, 1992, HEALTH SERV RES, V27, P587; Bergstrom N, 2005, J AM GERIATR SOC, V53, P1721, DOI 10.1111/j.1532-5415.2005.53506.x; Bergstrom N, 2008, J AM GERIATR SOC, V56, P1252, DOI 10.1111/j.1532-5415.2008.01765.x; Berwick DM, 2005, HEALTH SERV RES, V40, P317, DOI 10.1111/j.1475-6773.2005.0n359.x; Chang VT, 2000, CANCER, V88, P2164, DOI 10.1002/(SICI)1097-0142(20000501)88:9<2164::AID-CNCR24>3.0.CO;2-5; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Connor SR, 2005, J PAIN SYMPTOM MANAG, V29, P286, DOI 10.1016/j.jpainsymman.2005.01.003; Conroy B, 2005, ARCH PHYS MED REHAB, V86, pS73, DOI 10.1016/j.apmr.2005.08.129; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; DeJong G, 2009, ARCH PHYS MED REHAB, V90, P1269, DOI 10.1016/j.apmr.2008.11.021; Fielder R, 1996, FUNCTIONAL EVALUATIO, P75; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; Garber AM, 2009, NEW ENGL J MED, V360, P1925, DOI 10.1056/NEJMp0901355; Gassaway J, 2005, ARCH PHYS MED REHAB, V86, pS16, DOI 10.1016/j.apmr.2005.08.114; Gassaway J, 2009, J SPINAL CORD MED, V32, P260, DOI 10.1080/10790268.2009.11760780; HAMILTON BB, 1994, SCAND J REHABIL MED, V26, P115; HEINEMANN AW, 1995, AM J PHYS MED REHAB, V74, P315, DOI 10.1097/00002060-199507000-00011; HEINEMANN AW, 1994, ARCH PHYS MED REHAB, V75, P133; Horn S, 2007, DRUG DISCOV DEV, V10, P30; Horn SD, 2005, ARCH PHYS MED REHAB, V86, pS8, DOI 10.1016/j.apmr.2005.08.116; Horn SD, 2005, ARCH PHYS MED REHAB, V86, pS101, DOI 10.1016/j.apmr.2005.09.016; Horn SD, 2004, J AM GERIATR SOC, V52, P359, DOI 10.1111/j.1532-5415.2004.52106.x; HORN SD, 1991, MED CARE, V29, P305, DOI 10.1097/00005650-199104000-00001; Horn SD, 2007, MED CARE, V45, pS50, DOI 10.1097/MLR.0b013e318070c07b; Horn SD, 2010, ADV SKIN WOUND CARE, V23, P120, DOI 10.1097/01.ASW.0000363516.47512.67; James R, 2005, ARCH PHYS MED REHAB, V86, pS82, DOI 10.1016/j.apmr.2005.07.314; Latham NK, 2005, ARCH PHYS MED REHAB, V86, pS41, DOI 10.1016/j.apmr.2005.08.128; MacKenzie EJ, 2002, J TRAUMA, V52, P527, DOI 10.1097/00005373-200203000-00018; Ryser DK, 2005, ARCH PHYS MED REHAB, V86, P1108, DOI 10.1016/j.apmr.2004.11.041; Tunis SR, 2003, JAMA-J AM MED ASSOC, V290, P1624, DOI 10.1001/jama.290.12.1624; UB Foundation Activities Inc., 2004, IRF PAI TRAIN MAN; Westfall JM, 2007, JAMA-J AM MED ASSOC, V297, P403, DOI 10.1001/jama.297.4.403; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; Whiteneck GG, 1992, GUIDE USE CHART CRAI; Whitford DL, 2009, DIABETES CARE, V32, P251, DOI 10.2337/dc08-1200; Willson D F, 2000, Pediatr Crit Care Med, V1, P127, DOI 10.1097/00130478-200010000-00007; Willson DF, 2003, J PEDIATR-US, V143, pS142, DOI 10.1067/S0022-3476(03)00514-6; Willson DF, 2001, PEDIATRICS, V108, P851, DOI 10.1542/peds.108.4.851	39	79	79	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0025-7079			MED CARE	Med. Care	JUN	2010	48	6		1			S17	S22		10.1097/MLR.0b013e3181d57473			6	Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health	Health Care Sciences & Services; Public, Environmental & Occupational Health	603SG	WOS:000278227800005	20421825				2021-06-18	
J	Newcombe, VFJ; Williams, GB; Scoffings, D; Cross, J; Carpenter, TA; Pickard, JD; Menon, DK				Newcombe, Virginia F. J.; Williams, Guy B.; Scoffings, Daniel; Cross, Justin; Carpenter, T. Adrian; Pickard, John D.; Menon, David K.			Aetiological differences in neuroanatomy of the vegetative state: insights from diffusion tensor imaging and functional implications	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							TRAUMATIC BRAIN-INJURY; HYPOXIC-ISCHEMIC ENCEPHALOPATHY; COMA RECOVERY SCALE; CLOSED-HEAD INJURY; AXONAL INJURY; MR-IMAGES; METHYLPHENIDATE; NEUROPATHOLOGY; CONSCIOUSNESS; COMPREHENSION	Background An improved in vivo understanding of variations in neuropathology in the vegetative state (VS) may aid diagnosis, improve prognostication and help refine the selection of patients for particular treatment regimes. The authors have used diffusion tensor imaging (DTI) to characterise the extent and location of white matter loss in VS secondary to traumatic brain injury (TBI) and ischaemicehypoxic injury. Methods Twelve patients with VS (seven TBI, five ischaemic/hypoxic injuries) underwent MRI including DTI at a minimum of 3 months postinjury. Mean apparent diffusion coefficient, fractional anisotropy and eigenvalues were obtained for whole-brain grey and white matter, the pons, thalamus, ventral midbrain, dorsal midbrain and the corpus callosum. DTI measures of supratentorial damage were compared with a summed measure from the JFK modified Coma Recovery Scale (CRS-R) and with a three-point scale of functional magnetic resonance imaging (fMRI) response to an auditory paradigm to assess whether residual integrity of supratentorial white matter connectivity correlated with cortical processing. Results Conventional radiological approaches did not detect lesions in regions where quantitative DTI demonstrated abnormalities. There was evidence of marked, broadly similar, abnormalities in the supratentorial grey-and white-matter compartments from both aetiologies. In contrast, discordant findings were found in the infratentorial compartment, with DTI abnormalities in the brainstem confined to the TBI group. Supratentorial DTI abnormalities correlated with the CRS-R as well as responses to an fMRI paradigm that detected convert cognitive processing. Conclusions DTI may help to characterise differences in patients in VS. These findings may have implications for response to therapies, and should be taken into account in trials of interventions aimed at arousal in VS.	[Newcombe, Virginia F. J.; Menon, David K.] Univ Cambridge, Univ Div Anaesthesia, Cambridge CB2 2QQ, England; [Newcombe, Virginia F. J.; Williams, Guy B.; Carpenter, T. Adrian; Pickard, John D.; Menon, David K.] Univ Cambridge, Dept Clin Neurosci, Wolfson Brain Imaging Ctr, Cambridge CB2 2QQ, England; [Scoffings, Daniel; Cross, Justin] Univ Cambridge, Dept Radiol, Addenbrookes Hosp, Cambridge CB2 2QQ, England; [Pickard, John D.] Univ Cambridge, Acad Neurosurg Unit, Dept Clin Neurosci, Cambridge CB2 2QQ, England	Newcombe, VFJ (corresponding author), Univ Cambridge, Univ Div Anaesthesia, Addenbrookes Hosp, Box 93,Hills Rd, Cambridge CB2 2QQ, England.	vfjn2@wbic.cam.ac.uk		Newcombe, Virginia/0000-0001-6044-9035	UK Department of Health; Gates Cambridge Trust; NIHR Cambridge Biomedical Research CentreNational Institute for Health Research (NIHR); Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390, G0001237, G0600986] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0508-10327, ACF-2009-14-007] Funding Source: researchfish	This research was supported by: UK National Institute of Health Research Biomedical Research Centre at Cambridge Technology Platform funding provided by the UK Department of Health. VFJN was supported by the Gates Cambridge Trust and an Overseas Research Studentship. JC and DS are supported by the NIHR Cambridge Biomedical Research Centre.	Adams JH, 1999, J CLIN PATHOL, V52, P804, DOI 10.1136/jcp.52.11.804; Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; Ammermann H, 2007, J NEUROL SCI, V260, P65, DOI 10.1016/j.jns.2007.03.026; AUER RN, 2008, HYPOXIA RELATED COND, pCH2; Coleman MR, 2009, BRAIN, V132, P2541, DOI 10.1093/brain/awp183; Coleman MR, 2007, BRAIN, V130, P2494, DOI 10.1093/brain/awm170; Els T, 2004, ACTA NEUROL SCAND, V110, P361, DOI 10.1111/j.1600-0404.2004.00342.x; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; Giacino JT, 2006, ARCH PHYS MED REHAB, V87, pS67, DOI 10.1016/j.apmr.2006.07.272; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Greer DM, 2006, SEMIN NEUROL, V26, P373, DOI 10.1055/s-2006-948317; Holmes CJ, 1998, J COMPUT ASSIST TOMO, V22, P324, DOI 10.1097/00004728-199803000-00032; Juengling FD, 2005, J NEUROL SCI, V228, P179, DOI 10.1016/j.jns.2004.11.052; Kalmar K, 2005, NEUROPSYCHOL REHABIL, V15, P454, DOI 10.1080/09602010443000425; Kampfl A, 1998, J NEUROSURG, V88, P809, DOI 10.3171/jns.1998.88.5.0809; Kawahara H, 2000, J NEUROL SCI, V181, P73, DOI 10.1016/S0022-510X(00)00433-0; Kim YH, 2006, CLIN REHABIL, V20, P24, DOI 10.1191/0269215506cr927oa; KINNEY HC, 1994, J NEUROPATH EXP NEUR, V53, P548, DOI 10.1097/00005072-199411000-00002; KINNEY HC, 1994, NEW ENGL J MED, V330, P1469, DOI 10.1056/NEJM199405263302101; Leonard BE, 2004, HUM PSYCHOPHARM CLIN, V19, P151, DOI 10.1002/hup.579; McKinney AM, 2004, AM J NEURORADIOL, V25, P1659; Mori S, 1999, ANN NEUROL, V45, P265, DOI 10.1002/1531-8249(199902)45:2<265::AID-ANA21>3.0.CO;2-3; Oehmichen M, 1999, INT J LEGAL MED, V112, P261, DOI 10.1007/s004140050246; Owen AM, 2007, ARCH NEUROL-CHICAGO, V64, P1098, DOI 10.1001/archneur.64.8.1098; Owen AM, 2006, SCIENCE, V313, P1402, DOI 10.1126/science.1130197; Pavlovskaya M, 2007, BRAIN INJURY, V21, P489, DOI 10.1080/02699050701311117; Rodd JM, 2005, CEREB CORTEX, V15, P1261, DOI 10.1093/cercor/bhi009; Schiff ND, 2007, NATURE, V448, P600, DOI 10.1038/nature06041; Schiff ND, 2002, BRAIN, V125, P1210, DOI 10.1093/brain/awf131; Sherbondy A, 2005, IEEE T VIS COMPUT GR, V11, P419, DOI 10.1109/TVCG.2005.59; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Teitelman E, 2001, AM J PSYCHIAT, V158, P1341, DOI 10.1176/ajp.158.8.1341; Van Putten HP, 2005, J NEUROTRAUM, V22, P857; Voss HU, 2006, J CLIN INVEST, V116, P2005, DOI 10.1172/JCI27021; Ward P, 2006, PEDIATRICS, V117, pE619, DOI 10.1542/peds.2005-0545; Wijdicks EFM, 2001, AM J NEURORADIOL, V22, P1561; Yanagawa Y, 2000, J TRAUMA, V49, P272, DOI 10.1097/00005373-200008000-00013; Yasokawa YT, 2007, J NEUROTRAUM, V24, P163, DOI 10.1089/neu.2006.0073; Zhang YY, 2001, IEEE T MED IMAGING, V20, P45, DOI 10.1109/42.906424; ANAL SOFTWARE SYSTEM; FMRIBS DIFFSUION TOO; VTK CISG REGISTRATIO	43	79	84	0	8	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	MAY	2010	81	5					552	561		10.1136/jnnp.2009.196246			10	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	594MM	WOS:000277541800022	20460593	Bronze			2021-06-18	
J	Cole, JT; Mitala, CM; Kundu, S; Verma, A; Elkind, JA; Nissim, I; Cohen, AS				Cole, Jeffrey T.; Mitala, Christina M.; Kundu, Suhali; Verma, Ajay; Elkind, Jaclynn A.; Nissim, Itzhak; Cohen, Akiva S.			Dietary branched chain amino acids ameliorate injury-induced cognitive impairment	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article						branched chain amino acids; cognitive impairment; hippocampus; tramautic brain injury	TRAUMATIC BRAIN-INJURY; CONDITIONED FEAR; AMINOTRANSFERASE; METABOLISM; RECOVERY; LEUCINE	Neurological dysfunction caused by traumatic brain injury results in profound changes in net synaptic efficacy, leading to impaired cognition. Because excitability is directly controlled by the balance of excitatory and inhibitory activity, underlying mechanisms causing these changes were investigated using lateral fluid percussion brain injury in mice. Although injury-induced shifts in net synaptic efficacy were not accompanied by changes in hippocampal glutamate and GABA levels, significant reductions were seen in the concentration of branched chain amino acids (BCAAs), which are key precursors to de novo glutamate synthesis. Dietary consumption of BCAAs restored hippocampal BCAA concentrations to normal, reversed injury-induced shifts in net synaptic efficacy, and led to reinstatement of cognitive performance after concussive brain injury. All brain-injured mice that consumed BCAAs demonstrated cognitive improvement with a simultaneous restoration in net synaptic efficacy. Posttraumatic changes in the expression of cytosolic branched chain aminotransferase, branched chain ketoacid dehydrogenase, glutamate dehydrogenase, and glutamic acid decarboxylase support a perturbation of BCAA and neurotransmitter metabolism. Ex vivo application of BCAAs to hippocampal slices from injured animals restored post-traumatic regional shifts in net synaptic efficacy as measured by field excitatory postsynaptic potentials. These results suggest that dietary BCAA intervention could promote cognitive improvement by restoring hippocampal function after a traumatic brain injury.	[Cole, Jeffrey T.; Mitala, Christina M.; Kundu, Suhali; Cohen, Akiva S.] Childrens Hosp Philadelphia, Div Neurol, Philadelphia, PA 19104 USA; [Nissim, Itzhak] Childrens Hosp Philadelphia, Div Child Dev, Philadelphia, PA 19104 USA; [Verma, Ajay] Uniformed Serv Univ Hlth Sci, Dept Neurol & Neurosci, Bethesda, MD 20814 USA; [Elkind, Jaclynn A.; Cohen, Akiva S.] Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; [Nissim, Itzhak; Cohen, Akiva S.] Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; [Nissim, Itzhak] Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA; [Cohen, Akiva S.] Univ Penn, Sch Med, Dept Neurol, Philadelphia, PA 19104 USA	Cohen, AS (corresponding author), Childrens Hosp Philadelphia, Div Neurol, Philadelphia, PA 19104 USA.	cohena@email.chop.edu			National Institutes of Health/National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [RO1HD059288]; National Institutes of Health/National Institute of Diabetes and Digestive and Kidney DiseasesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [RO1DK053761, 5T32NS043126-07]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD059288] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01DK053761] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS069629, T32NS043126] Funding Source: NIH RePORTER	The authors are indebted to Ilana Nissim for determination of amino acids levels by HPLC and to Yevgeny Daikhin for measurement of <SUP>15</SUP>N-labeled metabolites at the GC-MS Core. We thank Drs. M.J. Schell, M. B. Robinson, and M. Yudkoff for many helpful and insightful discussions, and Drs. R. G. Kalb and D. Dinges for critiquing earlier drafts of this manuscript. This work was supported by National Institutes of Health/National Institute of Child Health and Human Development grant RO1HD059288 (A. S. C.), and by National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases grants RO1DK053761 (I.N.) and 5T32NS043126-07 (C. M. M). This work is dedicated to Maimon M. Cohen, whose suggestions were instrumental in planting the seeds for this line of investigation.	Aquilani R, 2005, ARCH PHYS MED REHAB, V86, P1729, DOI 10.1016/j.apmr.2005.03.022; Aquilani R, 2008, ARCH PHYS MED REHAB, V89, P1642, DOI 10.1016/j.apmr.2008.02.023; Bartolucci EJ, 2007, IEEE IND APPL MAG, V13, P24, DOI 10.1109/MIA.2007.322272; BOGEN IL, 2008, J NEUROCHEM, V106, P1515; Bonislawski DP, 2007, NEUROBIOL DIS, V25, P163, DOI 10.1016/j.nbd.2006.09.002; Carbonell WS, 1998, J NEUROTRAUM, V15, P217, DOI 10.1089/neu.1998.15.217; D'Ambrosio R, 1998, BRAIN RES, V786, P64, DOI 10.1016/S0006-8993(97)01412-1; De Bandt JP, 2006, J NUTR, V136, p308S, DOI 10.1093/jn/136.1.308S; Dusick JR, 2007, J CEREBR BLOOD F MET, V27, P1593, DOI 10.1038/sj.jcbfm.9600458; FANELLI FR, 1986, GUT, V27, P111, DOI 10.1136/gut.27.Suppl_1.111; GRADY MS, 1995, ANESTHETIC MANAGEMEN, P87; Lifshitz J, 2007, BEHAV BRAIN RES, V177, P347, DOI 10.1016/j.bbr.2006.11.014; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; McKenna MC, 2000, NEUROCHEM INT, V37, P229, DOI 10.1016/S0197-0186(00)00042-5; Mikics E, 2006, BEHAV PHARMACOL, V17, P223; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Richardson MA, 2004, J CLIN PSYCHIAT, V65, P92; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Sakai R, 2004, J NEUROCHEM, V88, P612, DOI 10.1111/j.1471-4159.2004.02179.x; Sato S, 2005, HEPATOL RES, V31, P232, DOI 10.1016/j.hepres.2005.01.009; SOLTESZ I, 1995, NEURON, V14, P1273, DOI 10.1016/0896-6273(95)90274-0; Sweatt AJ, 2004, J COMP NEUROL, V477, P360, DOI 10.1002/cne.20200; Tran LD, 2006, J NEUROTRAUM, V23, P1330, DOI 10.1089/neu.2006.23.1330; Vespa PM, 2007, CRIT CARE MED, V35, P1153, DOI 10.1097/01.CCM.0000259466.66310.4F; WALSER M, 1984, CLIN SCI, V66, P1; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052; Yee BK, 2004, EUR J NEUROSCI, V20, P1928, DOI 10.1111/j.1460-9568.2004.03642.x	27	79	81	0	9	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	JAN 5	2010	107	1					366	371		10.1073/pnas.0910280107			6	Multidisciplinary Sciences	Science & Technology - Other Topics	543FX	WOS:000273559200064	19995960	Green Published, Bronze			2021-06-18	
J	Tamber, AL; Wilhelmsen, KT; Strand, LI				Tamber, Anne-Lise; Wilhelmsen, Kjersti T.; Strand, Liv Inger			Measurement properties of the Dizziness Handicap Inventory by cross-sectional and longitudinal designs	HEALTH AND QUALITY OF LIFE OUTCOMES			English	Article							QUALITY-OF-LIFE; RANDOMIZED CONTROLLED-TRIAL; TRAUMATIC BRAIN-INJURY; VESTIBULAR REHABILITATION; HEALTH-STATUS; COOP/WONCA CHARTS; MULTIPLE-SCLEROSIS; CONSTRUCT-VALIDITY; DUTCH VERSION; RELIABILITY	Background: The impact of dizziness on quality of life is often assessed by the Dizziness Handicap Inventory (DHI), which is used as a discriminate and evaluative measure. The aim of the present study was to examine reliability and validity of a translated Norwegian version (DHI-N), also examining responsiveness to important change in the construct being measured. Methods: Two samples (n = 92 and n = 27) included participants with dizziness of mainly vestibular origin. A cross-sectional design was used to examine the factor structure (exploratory factor analysis), internal consistency (Cronbach's alpha), concurrent validity (Pearson's product moment correlation r), and discriminate ability (ROC curve analysis). Longitudinal designs were used to examine test-retest reliability (intraclass correlation coefficient (ICC) statistics, smallest detectable difference (SDD)), and responsiveness (Pearson's product moment correlation, ROC curve analysis; area under the ROC curve (AUC), and minimally important change (MIC)). The DHI scores range from 0 to 100. Results: Factor analysis revealed a different factor structure than the original DHI, resulting in dismissal of subscale scores in the DHI-N. Acceptable internal consistency was found for the total scale (alpha = 0.95). Concurrent correlations between the DHI-N and other related measures were moderate to high, highest with Vertigo Symptom Scale-short form-Norwegian version (r = 0.69), and lowest with preferred gait (r = -0.36). The DHI-N demonstrated excellent ability to discriminate between participants with and without 'disability', AUC being 0.89 and best cut-off point = 29 points. Satisfactory test-retest reliability was demonstrated, and the change for an individual should be >= 20 DHI-N points to exceed measurement error (SDD). Correlations between change scores of DHI-N and other self-report measures of functional health and symptoms were high (r = 0.50-0.57). Responsiveness of the DHI-N was excellent, AUC = 0.83, discriminating between self-perceived 'improved' versus 'unchanged' participants. The MIC was identified as 11 DHI-N points. Conclusions: The DHI-N total scale demonstrated satisfactory measurement properties. This is the first study that has addressed and demonstrated responsiveness to important change of the DHI, and provided values of SDD and MIC to help interpret change scores.	[Tamber, Anne-Lise] Oslo Univ Coll, Fac Hlth Sci, Oslo, Norway; [Tamber, Anne-Lise] Univ Oslo, Fac Med, Inst Gen Practice & Community Med, N-0316 Oslo, Norway; [Wilhelmsen, Kjersti T.] Bergen Univ Coll, Dept Physiotherapy, Bergen, Norway; [Wilhelmsen, Kjersti T.] Haukeland Hosp, Natl Ctr Vestibular Disorders, Dept Otorhinolaryngol Head & Neck Surg, N-5021 Bergen, Norway; [Wilhelmsen, Kjersti T.; Strand, Liv Inger] Univ Bergen, Sect Physiotherapy Sci, Dept Publ Hlth & Primary Hlth Care, N-5020 Bergen, Norway	Tamber, AL (corresponding author), Oslo Univ Coll, Fac Hlth Sci, Oslo, Norway.	AnneLise.Tamber@hf.hio.no; Kjersti.Wilhelmsen@hib.no; Liv.Strand@isf.uib.no					Ardic FN, 2006, OTOL NEUROTOL, V27, P676; ASMUNDSON GJG, 1999, J VESTIBUL RES-EQUIL, P63; Beaton DE, 2000, SPINE, V25, P3192, DOI 10.1097/00007632-200012150-00015; Bentsen BG, 1999, FAM PRACT, V16, P190, DOI 10.1093/fampra/16.2.190; Bland JM, 1996, BRIT MED J, V312, P1654, DOI 10.1136/bmj.312.7047.1654; BRUUSGAARD D, 1993, FAM PRACT, V10, P212, DOI 10.1093/fampra/10.2.212; Cattaneo D, 2007, CLIN REHABIL, V21, P771, DOI 10.1177/0269215507077602; Cattaneo D, 2006, DISABIL REHABIL, V28, P789, DOI 10.1080/09638280500404289; CHRISTOPHERSEN KA, 2003, DATABEHANDLING STATI, P247; Cohen HS, 2003, OTOLARYNG HEAD NECK, V128, P60, DOI 10.1067/mhn.2003.23; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; COSTELLO AB, 2005, PRACTICAL ASSESSMENT, P10; Crosby RD, 2003, J CLIN EPIDEMIOL, V56, P395, DOI 10.1016/S0895-4356(03)00044-1; de Vet HCW, 2007, QUAL LIFE RES, V16, P131, DOI 10.1007/s11136-006-9109-9; Domholdt E, 2000, PHYS THERAPY RES PRI; Duracinsky M, 2007, VALUE HEALTH, V10, P273, DOI 10.1111/j.1524-4733.2007.00182.x; ENLOE LJ, 1997, PHYS THER, V77; Fielder H, 1996, CLIN OTOLARYNGOL, V21, P124, DOI 10.1111/j.1365-2273.1996.tb01314.x; Finch E., 2002, PHYS REHABILITATION; Hall Courtney D, 2006, J Neurol Phys Ther, V30, P74; Hansson EE, 2006, J REHABIL MED, V38, P387, DOI 10.1080/16501970600768992; Holm I, 2005, EUR J PHYSIOTHER, V7, P40, DOI 10.1080/14038190510009423; Hosmer D. W., 2000, APPL LOGISTIC REGRES; JACOBSON GP, 1990, ARCH OTOLARYNGOL, V116, P424; Jacobson GP, 2008, BALANCE FUNCTION ASS, P99; JACOBSON GP, 1991, J AM ACAD AUDIOL, P253; Jarlsater S., 2003, ADV PHYSIOTHER, V5, P137, DOI [10.1080/14038190310004385, DOI 10.1080/14038190310004385]; Jerosch-Herold C., 2005, BRIT J OCCUP THER, V68, P347, DOI [DOI 10.1177/030802260506800803, 10.1177/030802260506800803]; Johansson M, 2001, OTOLARYNG HEAD NECK, V125, P151, DOI 10.1067/mhn.2001.118127; Kaufman KR, 2006, MED ENG PHYS, V28, P234, DOI 10.1016/j.medengphy.2005.05.005; KINNERSLEY P, 1994, BRIT J GEN PRACT, V44, P545; KREBS DE, 1993, OTOLARYNG HEAD NECK, V109, P735, DOI 10.1177/019459989310900417; LIANG MH, 1995, J RHEUMATOL, V22, P1191; Liang MH, 2000, MED CARE, V38, P84, DOI 10.1097/00005650-200009002-00013; Linaker OM, 2005, NORD J PSYCHIAT, V59, P121, DOI 10.1080/08039480510022918; Lindegaard PM, 1999, SCAND J PRIM HEALTH, V17, P145; Maneesriwongul W, 2004, J ADV NURS, V48, P175, DOI 10.1111/j.1365-2648.2004.03185.x; MRUZEK M, 1995, LARYNGOSCOPE, V105, P686, DOI 10.1288/00005537-199507000-00004; Murray K, 2001, Physiother Res Int, V6, P251, DOI 10.1002/pri.232; Perez N, 2001, ACTA OTO-LARYNGOL, P145; Poon DMY, 2004, ANN OTO RHINOL LARYN, V113, P1006, DOI 10.1177/000348940411301212; Preacher K. J., 2003, UNDERST STAT, V2, P13, DOI DOI 10.1207/S15328031US0201_02; Sartorius N., 1994, QUALITY LIFE ASSESSM, P3, DOI DOI 10.1007/978-3-642-79123-9_1; Shepard NT, 1996, PRACTICAL MANAGEMENT; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; Skoien AK, 2008, BRIT J GEN PRACT, V58, P619, DOI 10.3399/bjgp08X330744; Stratford PW, 1996, PHYS THER, V76, P1109, DOI 10.1093/ptj/76.10.1109; STREINER DL, 2003, HLTH MEASUREMENT SCA, P23; Streiner DL., 2003, HLTH MEASUREMENT SCA, V3rd; Terwee CB, 2007, J CLIN EPIDEMIOL, V60, P34, DOI 10.1016/j.jclinepi.2006.03.012; Terwee CB, 2003, QUAL LIFE RES, V12, P349, DOI 10.1023/A:1023499322593; Treleaven J, 2005, J REHABIL MED, V37, P224, DOI 10.1080/16501970510027989; van Baalen B, 2006, CLIN REHABIL, V20, P686, DOI 10.1191/0269215506cre982oa; Vereeck L, 2007, ACTA OTO-LARYNGOL, V127, P788, DOI 10.1080/00016480601075464; Vereeck L, 2006, B-ENT, V2, P75; Whitney SL, 2004, OTOL NEUROTOL, V25, P139, DOI 10.1097/00129492-200403000-00010; WHITNEY SL, 1994, PHYS THER, pS36; WHITNEY SL, 2000, VESTIBULAR REHABILIT, P371; Wilhelmsen K, 2008, BMC EAR NOSE THROAT, V8, DOI 10.1186/1472-6815-8-2; World Health Organization, 2001, INT CLASS FUNCT DIS; Yardley L, 1998, CLIN OTOLARYNGOL, V23, P442, DOI 10.1046/j.1365-2273.1998.00179.x; Yardley L, 2004, ANN INTERN MED, V141, P598, DOI 10.7326/0003-4819-141-8-200410190-00007; YARDLEY L, 2004, CLIN DISORDERS BALAN, P382; Yardley L, 2006, PSYCHOSOM MED, V68, P762, DOI 10.1097/01.psy.0000232269.17906.92; ZIMBELMAN JE, 1999, PHYS THERAPY CASE RE, V2, P232; MEASURING FUNCTIONAL	66	79	82	0	3	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1477-7525			HEALTH QUAL LIFE OUT	Health Qual. Life Outcomes	DEC 21	2009	7								101	10.1186/1477-7525-7-101			16	Health Care Sciences & Services; Health Policy & Services	Health Care Sciences & Services	544MW	WOS:000273662500001	20025754	DOAJ Gold, Green Published			2021-06-18	
J	Sakowitz, OW; Kiening, KL; Krajewski, KL; Sarrafzadeh, AS; Fabricius, M; Strong, AJ; Unterberg, AW; Dreier, JP				Sakowitz, Oliver W.; Kiening, Karl L.; Krajewski, Kara L.; Sarrafzadeh, Asita S.; Fabricius, Martin; Strong, Anthony J.; Unterberg, Andreas W.; Dreier, Jens P.			Preliminary Evidence That Ketamine Inhibits Spreading Depolarizations in Acute Human Brain Injury	STROKE			English	Article						electrocorticography; intracerebral hemorrhage; NMDA receptor antagonists; spreading depression; traumatic brain injury	DEPRESSION; RAT	Background and Purpose-Spreading depolarizations, characterized by large propagating, slow potential changes, have been demonstrated with electrocorticography in patients with cerebral hemorrhage and ischemic stroke. Whereas spreading depolarizations are harmless under normal conditions in animals, they cause or augment damage in the ischemic brain. A fraction of spreading depolarizations is abolished by N-methyl-D-aspartate receptor antagonists. Summary of Case-In 2 patients with severe acute brain injury (traumatic and spontaneous intracranial hemorrhage), spreading depolarizations were inhibited by the noncompetitive N-methyl-D-aspartate receptor antagonist ketamine. This restored electrocorticographic activity. Conclusions-These anecdotal electrocorticographic findings suggest that ketamine has an inhibitory effect on spreading depolarizations in humans. This is of potential interest for future neuroprotective trials. (Stroke. 2009; 40: e519-e522.)	[Sakowitz, Oliver W.; Kiening, Karl L.; Krajewski, Kara L.; Unterberg, Andreas W.] Univ Heidelberg, Dept Neurosurg, D-69120 Heidelberg, Germany; [Sarrafzadeh, Asita S.] Charite Univ Med Berlin, Dept Neurosurg, D-13353 Berlin, Germany; [Fabricius, Martin] Univ Copenhagen, Glostrup Hosp, Dept Clin Neurophysiol, Copenhagen, Denmark; [Strong, Anthony J.] Kings Coll London, Dept Clin Neurosci, London WC2R 2LS, England; [Dreier, Jens P.] Charite Univ Med Berlin, Dept Neurol, D-13353 Berlin, Germany; [Dreier, Jens P.] Charite Univ Med Berlin, Ctr Stroke Res, D-13353 Berlin, Germany	Sakowitz, OW (corresponding author), Univ Heidelberg, Dept Neurosurg, Neuenheimer Feld 400, D-69120 Heidelberg, Germany.	oliver.sakowitz@med.uni-heidelberg.de	Krajewski, Kara/ABH-2587-2020	Dreier, Jens/0000-0001-7459-2828	"ZNS-Hannelore Kohl Stiftung" [2004006]; Wilhelm Sander Foundation [2002.028.1]; Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG) [SFB-507A1, DFG DR 323/3-1, 323/5-1]; BMBF Berlin Neuroimaging CenterFederal Ministry of Education & Research (BMBF) [01GI9902/4]; Center for Stroke Research [01 EO 0801]; Kompetenznetz Schlaganfall	O.W.S. received grant support through "ZNS-Hannelore Kohl Stiftung" (#2004006) and the Medical Faculty of the University of Heidelberg ("Young Investigator Award"). J.P.D. was supported by the Wilhelm Sander Foundation (2002.028.1), Deutsche Forschungsgemeinschaft (SFB-507A1, DFG DR 323/3-1, 323/5-1), BMBF Berlin Neuroimaging Center (01GI9902/4)/Center for Stroke Research (01 EO 0801), and Kompetenznetz Schlaganfall.	Dohmen C, 2008, ANN NEUROL, V63, P720, DOI 10.1002/ana.21390; Dreier JP, 2006, BRAIN, V129, P3224, DOI 10.1093/brain/awl297; HERNANDEZCACERES J, 1987, BRAIN RES, V437, P360, DOI 10.1016/0006-8993(87)91652-0; Himmelseher S, 2005, ANESTH ANALG, V101, P524, DOI 10.1213/01.ANE.0000160585.43587.5B; IIJIMA T, 1992, J CEREBR BLOOD F MET, V12, P727, DOI 10.1038/jcbfm.1992.103; Kaube H, 2000, NEUROLOGY, V55, P139, DOI 10.1212/WNL.55.1.139; LEAO AAP, 1947, J NEUROPHYSIOL, V10, P409, DOI 10.1152/jn.1947.10.6.409; MARRANNES R, 1988, BRAIN RES, V457, P226, DOI 10.1016/0006-8993(88)90690-7; NEDERGAARD M, 1993, J CEREBR BLOOD F MET, V13, P568, DOI 10.1038/jcbfm.1993.74; Strong AJ, 2002, STROKE, V33, P2738, DOI 10.1161/01.STR.0000043073.69602.09	10	79	81	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0039-2499			STROKE	Stroke	AUG	2009	40	8					E519	E522		10.1161/STROKEAHA.109.549303			4	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	475UN	WOS:000268387000049	19520992	Bronze			2021-06-18	
J	Mammis, A; Mclntosh, TK; Maniker, AH				Mammis, Antonios; Mclntosh, Tracy K.; Maniker, Allen H.			Erythropoietin as a neuroprotective agent in traumatic brain injury Review	SURGICAL NEUROLOGY			English	Article						Erythropoietin; Traumatic brain injury; Apoptosis; Neuroprotection; Neurosurgery	INCREASED EXPRESSION; NEURONAL APOPTOSIS; CEREBRAL-ISCHEMIA; CORTICAL-NEURONS; ACTIVATION; MODEL; RATS	Background: In the United States, TBI remains a major cause of morbidity and mortality in children and young adults. A total of 1.5 million Americans experience head trauma every year, and the yearly economic cost of this exceeds $56 billion. The magnitude of this problem has generated a great deal of interest in elucidating the complex molecular mechanism underlying cell death and dysfunction after TBI and in the development of neuroprotective agents that will reduce morbidity and mortality. Methods: A review of recent literature on EPO, TBI, and apoptosis is conducted with analysis of pathophysiologic mechanisms of TBI. In addition, animal experiments and clinical trials pertaining to mechanisms of cell death in TBI and EPO as a neuroprotective agent are reviewed. Conclusion: The literature and evidence for EPO as a potent inhibitor of apoptosis and promising therapeutic agent in a variety of neurological insults, including trauma, are mounting. With the recent interest in clinical trials of EPO in human stroke, it is both timely and Prudent to consider the use of this pharmaceutical avenue in TBI in man, (C) 2009 Elsevier Inc. All rights reserved.	[Mammis, Antonios; Mclntosh, Tracy K.; Maniker, Allen H.] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Neurosurg, Newark, NJ 07103 USA	Mammis, A (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Neurosurg, 185 S Orange Ave, Newark, NJ 07103 USA.	mammisan@umdnj.edu		Mammis, Antonios/0000-0003-0892-9888			Abrahamson EE, 2006, EXP NEUROL, V197, P437, DOI 10.1016/j.expneurol.2005.10.011; Baciu I, 2000, Rom J Physiol, V37, P3; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Chen G, 2007, NEUROSCI LETT, V425, P177, DOI 10.1016/j.neulet.2007.08.022; Clark RSB, 1999, FASEB J, V13, P813; Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074; Dressler J, 2007, INT J LEGAL MED, V121, P365, DOI 10.1007/s00414-006-0126-6; Du LN, 2003, J BIOL CHEM, V278, P18426, DOI 10.1074/jbc.M301295200; Erbayraktar S, 2003, P NATL ACAD SCI USA, V100, P6741, DOI 10.1073/pnas.1031753100; Fisher JW, 2003, EXP BIOL MED, V228, P1; Ghezzi P, 2004, CELL DEATH DIFFER, V11, pS37, DOI 10.1038/sj.cdd.4401450; Graham DI, 1996, NEUROTRAUMA, P43; Grasso G, 2007, BRAIN RES, V1182, P99, DOI 10.1016/j.brainres.2007.08.078; Hasselblatt M, 2006, J NEUROSURG ANESTH, V18, P132, DOI 10.1097/00008506-200604000-00007; Junk AK, 2002, P NATL ACAD SCI USA, V99, P10659, DOI 10.1073/pnas.152321399; Knoblach SM, 2002, J NEUROTRAUM, V19, P1155, DOI 10.1089/08977150260337967; Larner SF, 2005, J NEUROCHEM, V94, P97, DOI 10.1111/j.1471-4159.2005.03172.x; Larner SF, 2004, J NEUROCHEM, V88, P78, DOI 10.1046/j.1471-4159.2003.02141.x; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Liao ZB, 2008, EUR J NEUROL, V15, P140, DOI 10.1111/j.1468-1331.2007.02013.x; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Luo Chun, 2002, Chin J Traumatol, V5, P299; Mahmood A, 2007, J NEUROSURG, V107, P392, DOI 10.3171/JNS-07/08/0392; Marti HH, 2004, J EXP BIOL, V207, P3233, DOI 10.1242/jeb.01049; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; *NAT CTR INJ PREV, 2001, INJ FACT BOOK 2001 2, P1; Noguchi CT, 2007, CRIT REV ONCOL HEMAT, V64, P159, DOI 10.1016/j.critrevonc.2007.03.001; O'Dell DM, 2000, J NEUROSCI, V20, P4821; Ozisik PA, 2007, SURG NEUROL, V68, P547, DOI 10.1016/j.surneu.2007.01.030; Ozturk E, 2005, PROG NEURO-PSYCHOPH, V29, P920, DOI 10.1016/j.pnpbp.2005.04.028; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Savitz SI, 1998, NEUROSURGERY, V42, P555, DOI 10.1097/00006123-199803000-00026; Silva M, 1996, BLOOD, V88, P1576, DOI 10.1182/blood.V88.5.1576.1576; Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Verdonck O, 2007, J CEREBR BLOOD F MET, V27, P1369, DOI 10.1038/sj.jcbfm.9600443; Villa P, 2007, J CEREBR BLOOD F MET, V27, P552, DOI 10.1038/sj.jcbfm.9600370; Wen TC, 2002, J NEUROSCI RES, V67, P795, DOI 10.1002/jnr.10166; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje; Zhang XP, 2005, CRIT CARE, V9, P66, DOI 10.1186/cc2950; Zhang XP, 2003, FASEB J, V17, P1367, DOI 10.1096/fj.02-1067fje	44	79	85	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0090-3019			SURG NEUROL	Surg. Neurol.	MAY	2009	71	5					527	531		10.1016/j.surneu.2008.02.040			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	439VR	WOS:000265656000005	18789503				2021-06-18	
J	Oddo, M; Milby, A; Chen, I; Frangos, S; MacMurtrie, E; Maloney-Wilensky, E; Stiefel, M; Kofke, WA; Levine, JM; Le Roux, PD				Oddo, Mauro; Milby, Andrew; Chen, Isaac; Frangos, Suzanne; MacMurtrie, Eileen; Maloney-Wilensky, Eileen; Stiefel, Michael; Kofke, W. Andrew; Levine, Joshua M.; Le Roux, Peter D.			Hemoglobin Concentration and Cerebral Metabolism in Patients With Aneurysmal Subarachnoid Hemorrhage	STROKE			English	Article						brain oxygen; cerebral microdialysis; hemoglobin; subarachnoid hemorrhage	TRAUMATIC BRAIN-INJURY; BLOOD-TRANSFUSION; CRITICALLY-ILL; MEDICAL COMPLICATIONS; HEMODILUTIONAL ANEMIA; ENERGY-METABOLISM; OXYGEN; MICRODIALYSIS; MORTALITY; ASSOCIATION	Background and Purpose-The optimal hemoglobin (Hgb) target after aneurysmal subarachnoid hemorrhage is not precisely known. We sought to examine the threshold of Hgb concentration associated with an increased risk of cerebral metabolic dysfunction in patients with poor-grade subarachnoid hemorrhage. Methods-Twenty consecutive patients with poor-grade subafachnoid hemorrhage who underwent multimodality neuromonitoring (intracranial pressure, brain tissue oxygen tension, cerebral microdialysis) were studied prospectively. Brain tissue oxygen tension and extracellular lactate/pyruvate ratio were used as markers of cerebral metabolic dysfunction and the relationship between Hgb concentrations and the incidence of brain hypoxia (defined by a brain tissue oxygen tension <20 mm Hg) and cell energy dysfunction (defined by a lactate/pyruvate ratio >40) was analyzed. Results-Compared with higher Hgb concentrations, a Hgb concentration <9 g/dL was associated with lower brain tissue oxygen tension (27.2 [interquartile range, 21.2 to 33.1] versus 19.9 [interquartile range, 7.1 to 33.1] turn Hg, P=0.02), higher lactate/pyruvate ratio (29 [interquartile range, 25 to 38] versus 36 [interquartile range, 26 to 59], P=0.16), and an increased incidence of brain hypoxia (21% versus 52%, P<0.01) and cell energy dysfunction (23% versus 43%, P=0.03). On multivariable analysis, a Hgb concentration <9 g/dL was associated with a higher risk of brain hypoxia (OR, 7.92; 95% CI, 2.32 to 27.09; P<0.01) and cell energy dysfunction (OR, 4.24; 95% Cl, 1.33 to 13.55; P=0.02) after adjusting for cerebral perfusion pressure, central venous pressure, PaO2/FIO2 ratio, and symptomatic vasospasm. Conclusions-A Hgb concentration <9 g/dL is associated with an increased incidence of brain hypoxia and cell energy dysfunction in patients with poor-grade subarachnoid hemorrhage. (Stroke. 2009;40:1275-1281.)	[Le Roux, Peter D.] Univ Penn, Med Ctr, Div Clin Res, Dept Neurosurg, Philadelphia, PA 19104 USA; [Levine, Joshua M.] Univ Penn, Med Ctr, Dept Neurol, Philadelphia, PA 19104 USA; [Kofke, W. Andrew; Levine, Joshua M.] Univ Penn, Med Ctr, Dept Anesthesia & Crit Care, Philadelphia, PA 19104 USA	Le Roux, PD (corresponding author), Univ Penn, Med Ctr, Div Clin Res, Dept Neurosurg, 3rd Floor Silverstein Bldg,3400 Spruce St, Philadelphia, PA 19104 USA.	Peter.LeRoux@uphs.upenn.edu	Oddo, Mauro/R-3370-2016	Oddo, Mauro/0000-0002-6155-2525	SICPA Foundation, Switzerland; Integra Foundation; Mary Elisabeth Groff Surgical and Medical Research Trust	This work was supported by Research Grants from the SICPA Foundation, Switzerland (M.O.), the Integra Foundation (P.D.L.), and the Mary Elisabeth Groff Surgical and Medical Research Trust (P.D.L.).	[Anonymous], 2005, AM J RESP CRIT CARE, V171, P388, DOI 10.1164/rccm.200405-644ST; BORGSTROM L, 1975, ACTA PHYSIOL SCAND, V93, P505, DOI 10.1111/j.1748-1716.1975.tb05842.x; Corwin HL, 2004, CRIT CARE MED, V32, P39, DOI 10.1097/01.CCM.0000104112.34142.79; Dexter F, 1997, BRIT J ANAESTH, V79, P346, DOI 10.1093/bja/79.3.346; Gajic O, 2007, AM J RESP CRIT CARE, V176, P886, DOI 10.1164/rccm.200702-271OC; George ME, 2008, NEUROCRIT CARE, V8, P337, DOI 10.1007/s12028-008-9066-y; Hare GMT, 2004, ANESTH ANALG, V99, P528, DOI 10.1213/01.ANE.0000136769.65960.D1; Hare GMT, 2003, J APPL PHYSIOL, V94, P2058, DOI 10.1152/japplphysiol.00931.2002; Hare GMT, 2007, J APPL PHYSIOL, V103, P1021, DOI 10.1152/japplphysiol.01315.2006; Hebert PC, 2001, CRIT CARE MED, V29, P227, DOI 10.1097/00003246-200102000-00001; Hillered L, 2005, J NEUROTRAUM, V22, P3, DOI 10.1089/neu.2005.22.3; HUNT WE, 1968, J NEUROSURG, V28, P14, DOI 10.3171/jns.1968.28.1.0014; JOHANNSSON H, 1975, ACTA PHYSIOL SCAND, V93, P515, DOI 10.1111/j.1748-1716.1975.tb05843.x; Kett-White R, 2002, NEUROSURGERY, V50, P1213, DOI 10.1097/00006123-200206000-00008; Kim JS, 2000, EUR NEUROL, V43, P201, DOI 10.1159/000008176; Koch CG, 2008, NEW ENGL J MED, V358, P1229, DOI 10.1056/NEJMoa070403; Lee EJ, 2001, J NEUROL SCI, V190, P3, DOI 10.1016/S0022-510X(01)00567-6; LEROUX PD, 1995, J NEUROSURG, V83, P394, DOI 10.3171/jns.1995.83.3.0394; LeRoux PD, 1996, J NEUROSURG, V85, P39, DOI 10.3171/jns.1996.85.1.0039; Malone DL, 2003, J TRAUMA, V54, P898, DOI 10.1097/01.TA.0000060261.10597.5C; MAYBERG MR, 1994, STROKE, V25, P2315, DOI 10.1161/01.STR.25.11.2315; McIntyre LA, 2006, NEUROCRIT CARE, V5, P4, DOI 10.1385/NCC:5:1:4; McLaren AT, 2007, AM J PHYSIOL-REG I, V292, pR403, DOI 10.1152/ajpregu.00403.2006; Muench E, 2007, CRIT CARE MED, V35, P1844, DOI 10.1097/01.CCM.0000275392.08410.DD; Naidech AM, 2007, CRIT CARE MED, V35, P2383, DOI 10.1097/01.CCM.0000284516.17580.2C; Naidech AM, 2006, NEUROSURGERY, V59, P775, DOI 10.1227/01.NEU.0000232662.86771.A9; Netzer G, 2007, CHEST, V132, P1116, DOI 10.1378/chest.07-0145; Nortje J, 2006, BRIT J ANAESTH, V97, P95, DOI 10.1093/bja/ael137; Patel MB, 2006, J TRAUMA, V61, P46, DOI 10.1097/01.ta.0000219730.71206.3a; Rigamonti A, 2008, BRIT J ANAESTH, V100, P357, DOI 10.1093/bja/aem401; Samuelsson C, 2007, J CEREBR BLOOD F MET, V27, P1309, DOI 10.1038/sj.jcbfm.9600433; Sarrafzadeh A, 2004, J NEUROSURG, V100, P400, DOI 10.3171/jns.2004.100.3.0400; Smith MJ, 2004, J NEUROSURG, V101, P1, DOI 10.3171/jns.2004.101.1.0001; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Vespa P, 2006, CRIT CARE MED, V34, P850, DOI 10.1097/01.CCM.0000201875.12245.6F; Vincent JL, 2002, JAMA-J AM MED ASSOC, V288, P1499, DOI 10.1001/jama.288.12.1499; Wartenberg KE, 2006, CURR OPIN CRIT CARE, V12, P78, DOI 10.1097/01.ccx.0000216571.80944.65; Wartenberg KE, 2006, CRIT CARE MED, V34, P617, DOI 10.1097/01.CCM.0000201903.46435.35	38	79	81	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0039-2499	1524-4628		STROKE	Stroke	APR	2009	40	4					1275	1281		10.1161/STROKEAHA.108.527911			7	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	426LJ	WOS:000264709500039	19265059	Bronze			2021-06-18	
J	Andrews, PJD; Citerio, G; Longhi, L; Polderman, K; Sahuquillo, J; Vajkoczy, P				Andrews, Peter J. D.; Citerio, Giuseppe; Longhi, Luca; Polderman, Kees; Sahuquillo, Juan; Vajkoczy, Peter		NICEM Section European Soc Intensi	NICEM consensus on neurological monitoring in acute neurological disease	INTENSIVE CARE MEDICINE			English	Article						intracranial pressure monitoring; cerebral perfusion pressure; brain tissue oxygenation; microdialysis	TRAUMATIC BRAIN-INJURY; SEVERE HEAD-INJURY; ANEURYSMAL SUBARACHNOID HEMORRHAGE; CEREBRAL PERFUSION-PRESSURE; TISSUE OXYGEN-TENSION; INTRACRANIAL-PRESSURE; MICRODIALYSIS; CARE; AUTOREGULATION; EXPERIENCE	This manuscript summarises the consensus on neuromonitoring in neuro-intensive care promoted and organised by the Neuro-Intensive Care and Emergency Medicine (NICEM) Section of the European Society of Intensive Care Medicine (ESICM). It is expected that continuous monitoring using multi-modal techniques will help to overcome the limitations of each individual method and will provide a better diagnosis. More specific treatment can then be applied; however, it remains to be determined which combination of parameters is optimal. The questions discussed and addressed in this manuscript are: (1) Who should have ICP monitoring and for how long? (2) What ICP technologies are available and what are their relative advantages/disadvantages? (3) Should CPP monitoring and autoregulation testing be used? (4) When should brain tissue oxygen tension (PbrO(2)) be monitored? (5) Should structurally normal or abnormal tissue be monitored with PbrO(2)? (6) Should microdialysis be considered in complex cases? It is hoped that this document will prove useful to clinicians working in NICU and also to those developing specialist NICU services within their hospital practice.	[Andrews, Peter J. D.] Western Gen Hosp, Edinburgh EH4 2XU, Midlothian, Scotland; [Citerio, Giuseppe] San Gerardo Hosp, Dept Perioperat Med & Intens Care, Neuroanesthesia & Neurosurg Intens Care Unit, Monza, Italy; [Longhi, Luca] Univ Milan, Osped Maggiore Policlin, Fdn IRCCS, Dept Anaesthesia & Crit Care Med,Neurosurg Intens, Milan, Italy; [Polderman, Kees] Univ Utrecht, Med Ctr, Dept Intens Care, Utrecht, Netherlands; [Sahuquillo, Juan] Univ Autonoma Barcelona, Vall Hebron Univ Hosp, Div Neurosurg, E-08193 Barcelona, Spain; [Vajkoczy, Peter] Charite, Dept Neurosurg, D-13353 Berlin, Germany	Andrews, PJD (corresponding author), Western Gen Hosp, Crewe Rd S, Edinburgh EH4 2XU, Midlothian, Scotland.	p.andrews@ed.ac.uk	Longhi, Luca/AAF-9903-2021; Viani, Rafael/V-1196-2018; Sahuquillo, Juan/B-3577-2008; Citerio, Giuseppe/B-1839-2015; Polderman, Kees H/K-3623-2012	Longhi, Luca/0000-0001-9894-8788; Sahuquillo, Juan/0000-0003-0713-5875; Citerio, Giuseppe/0000-0002-5374-3161; 			Andrews PJD, 2004, INTENS CARE MED, V30, P1730, DOI 10.1007/s00134-004-2376-4; Bardt TF, 1998, ACT NEUR S, V71, P153; Bellander BM, 2004, INTENS CARE MED, V30, P2166, DOI 10.1007/s00134-004-2461-8; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; Brain Trauma Foundation, 2007, J NEUROTRAUM, V24, pS55, DOI DOI 10.1089/NEU.2007.9988; Bratton SL, 2007, J NEUROTRAUMA S1, V24, pS45; Chaurasia CS, 2007, J CLIN PHARMACOL, V47, P589, DOI 10.1177/0091270006299091; Citerio G, 2004, INTENS CARE MED, V30, P1882, DOI 10.1007/s00134-004-2377-3; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P202, DOI 10.1097/01.WCB.0000103022.98348.24; Contant CF, 2001, J NEUROSURG, V95, P560, DOI 10.3171/jns.2001.95.4.0560; Czosnyka M, 2006, ACTA NEUROCHIR SUPPL, V96, P114; Czosnyka M, 2000, ACT NEUR S, V76, P483; Czosnyka M, 1996, NEUROSURGERY, V38, P219, DOI 10.1097/00006123-199601000-00053; Czosnyka M, 2001, J NEUROSURG, V95, P756, DOI 10.3171/jns.2001.95.5.0756; Diringer MN, 2004, CRIT CARE MED, V32, P1489, DOI 10.1097/01.CCM.0000129484.61912.84; Fergusen S, 2007, NEUROSURGERY, V60, P658, DOI 10.1227/01.NEU.0000255396.23280.31; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Gupta AK, 2002, J NEUROSURG, V96, P263, DOI 10.3171/jns.2002.96.2.0263; Hoelper BM, 2003, NEUROSURGERY, V52, P970, DOI 10.1227/01.NEU.0000053033.98317.A3; Howells T, 2005, J NEUROSURG, V102, P311, DOI 10.3171/jns.2005.102.2.0311; Hutchinson PJ, 2007, J NEUROTRAUM, V24, P1545, DOI 10.1089/neu.2007.0295; Hutchinson PJ, 2000, J NEUROSURG, V93, P37, DOI 10.3171/jns.2000.93.1.0037; Jaeger M, 2006, CRIT CARE MED, V34, P1783, DOI 10.1097/01.CCM.0000218413.51546.9E; Kett-White R, 2002, NEUROSURGERY, V50, P1213, DOI 10.1097/00006123-200206000-00008; Kett-White R, 2002, J NEUROSURG, V96, P1013, DOI 10.3171/jns.2002.96.6.1013; Koskinen LOD, 2005, NEUROSURGERY, V56, P693, DOI 10.1227/01.NEU.0000156609.95596.24; Longhi L, 2007, INTENS CARE MED, V33, P2136, DOI 10.1007/s00134-007-0845-2; LUNDBERG N, 1960, Acta Psychiatr Scand Suppl, V36, P1; MAAS AIR, 1993, ACTA NEUROCHIR, P50; Meixensberger J, 2003, J NEUROL NEUROSUR PS, V74, P760, DOI 10.1136/jnnp.74.6.760; Menon DK, 2004, CRIT CARE MED, V32, P1384, DOI 10.1097/01.CCM.0000127777.16609.08; Morgalla MH, 1999, J MED ENG TECHNOL, V23, P144; Nortje J, 2006, BRIT J ANAESTH, V97, P95, DOI 10.1093/bja/ael137; Patel HC, 2005, LANCET, V366, P1538, DOI 10.1016/S0140-6736(05)67626-X; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Scheufler KM, 2002, ANESTH ANALG, V95, P1042, DOI 10.1097/00000539-200210000-00046; SIGGAARDANDERSEN O, 1995, ACTA ANAESTH SCAND, V39, P137; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Stiefel MF, 2006, J NEUROSURG, V105, P568, DOI 10.3171/jns.2006.105.4.568; Stocchetti N, 1998, ACT NEUR S, V71, P162; The Brain Trauma Foundation. The American Association of Neurological Surgeons. The Joint Section on Neurotrauma and Critical Care, 2007, J NEUROTRAUMA S1, V24, pS59, DOI DOI 10.1089/NEU.2007.9987; Tolias CM, 2004, J NEUROSURG, V101, P435, DOI 10.3171/jns.2004.101.3.0435; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; van den Brink WA, 1998, ACT NEUR S, V71, P190; van Hulst RA, 2002, INTENS CARE MED, V28, P68, DOI 10.1007/s00134-001-1157-6; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007; ZAUNER A, 1995, NEUROSURGERY, V37, P1168, DOI 10.1227/00006123-199512000-00017; Zauner A, 1997, NEUROSURGERY, V41, P1082, DOI 10.1097/00006123-199711000-00011	50	79	83	0	6	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	AUG	2008	34	8					1362	1370		10.1007/s00134-008-1103-y			9	Critical Care Medicine	General & Internal Medicine	330IH	WOS:000257933700003	18398598				2021-06-18	
J	Bab, I; Ofek, O; Tam, J; Rehnelt, J; Zimmer, A				Bab, I.; Ofek, O.; Tam, J.; Rehnelt, J.; Zimmer, A.			Endocannabinoids and the regulation of bone metabolism	JOURNAL OF NEUROENDOCRINOLOGY			English	Article; Proceedings Paper	Workshop on Endocannabinoids in Endocrinology, Metabolism and Cardiovascular Diseases, Scientific Background and Clinical Perspectives	JUL, 2007	Padua, ITALY			bone remodelling; endocannabinoid system; sympathtic nervous system; single nucleotide polymorphism; osteoporosis	COMPONENT LINKAGE ANALYSIS; CANNABINOID RECEPTOR; MINERAL DENSITY; BRAIN-INJURY; GENE; CB2; EXPRESSION; FRACTURE; CELLS; MASS	In mammals, including humans, bone metabolism is manifested as an ongoing modelling/remodelling process whereby the bone mineralised matrix is being continuously renewed. Recently, the main components of the endocannabinoid system have been reported in the skeleton. Osteoblasts, the bone forming cells, and other cells of the osteoblastic lineage, as well as osteoclasts, the bone resorbing cells, and their precursors, synthesise the endocannabinoids anandamide and 2-arachidonoylglycerol (2-AG). CB1 cannabinoid receptors are present in sympathetic nerve terminals in close proximity to osteoblasts. Activation of these CB1 receptors by elevated bone 2-AG levels communicates brain-to-bone signals as exemplified by traumatic brain injury-induced stimulation of bone formation. In this process, the retrograde CB1 signalling inhibits noradernaline release and alleviates the tonic sympathetic restrain of bone formation. CB2 receptors are expressed by osteoblasts and osteoclasts. Their activation stimulates bone formation and suppresses bone resorption. CB2-deficient mice display a markedly accelerated age-related bone loss. Ovariectomy-induced bone loss can be both prevented and rescued by a CB2 specific agonist. Hence, synthetic CB2 ligands, which are stable and orally available, provide a basis for developing novel anti-osteoporotic therapies, free of psychotropic effects. The CNR2 gene (encoding CB2) in women is associated with low bone mineral density, offering an assay for identifying females at risk of developing osteoporosis.	[Bab, I.; Ofek, O.; Tam, J.] Hebrew Univ Jerusalem, Bone Lab, IL-91120 Jerusalem, Israel; [Rehnelt, J.; Zimmer, A.] Univ Bonn, Inst Mol Psychiat, D-5300 Bonn, Germany	Bab, I (corresponding author), Hebrew Univ Jerusalem, Bone Lab, POB 12272, IL-91120 Jerusalem, Israel.	babi@cc.huji.ac.il	Zimmer, Andreas/B-8357-2009				Abe E, 2003, CELL, V115, P151, DOI 10.1016/S0092-8674(03)00771-2; Alexander JM, 2001, J BONE MINER RES, V16, P1665, DOI 10.1359/jbmr.2001.16.9.1665; Amor S, 2005, J NEUROIMMUNOL, V165, P1, DOI 10.1016/j.jneuroim.2005.04.010; Araujo AN, 2004, EUR J ORTHODONT, V26, P515, DOI 10.1093/ejo/26.5.515; Bab IA, 2005, MIL DRUG TH, P201; Bab IA, 2007, ANN NY ACAD SCI, V1116, P414, DOI 10.1196/annals.1402.014; Baldock PA, 2002, J CLIN INVEST, V109, P915, DOI 10.1172/JCI200214588; Boes M, 2006, J BONE JOINT SURG AM, V88A, P738, DOI 10.2106/JBJS.D.02648; Correa F, 2005, BRIT J PHARMACOL, V145, P441, DOI 10.1038/sj.bjp.0706215; Devoto M, 2005, EUR J HUM GENET, V13, P781, DOI 10.1038/sj.ejhg.5201411; Devoto M, 1998, EUR J HUM GENET, V6, P151, DOI 10.1038/sj.ejhg.5200169; Devoto M, 2001, HUM MOL GENET, V10, P2447, DOI 10.1093/hmg/10.21.2447; Di Marzo V, 2001, NATURE, V410, P822, DOI 10.1038/35071088; Donahue Seth W., 2006, Critical Reviews in Biomedical Engineering, V34, P215; Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501; FORD L, 2007, P 17 ANN S INT CANN, P60; George KL, 2008, J CELL PHYSIOL, V214, P714, DOI 10.1002/jcp.21263; Gerstenfeld LC, 2003, J CELL BIOCHEM, V88, P873, DOI 10.1002/jcb.10435; Hanus L, 1999, P NATL ACAD SCI USA, V96, P14228, DOI 10.1073/pnas.96.25.14228; Idris AI, 2005, NAT MED, V11, P774, DOI 10.1038/nm1255; Karsak M, 2005, HUM MOL GENET, V14, P3389, DOI 10.1093/hmg/ddi370; Karsenty G, 2001, Novartis Found Symp, V232, P6; Lanyon LE, 1996, BONE, V18, pS37, DOI 10.1016/8756-3282(95)00378-9; Ledent C, 1999, SCIENCE, V283, P401, DOI 10.1126/science.283.5400.401; Leung D, 2006, BIOCHEMISTRY-US, V45, P4720, DOI 10.1021/bi060163l; McCaw EA, 2004, EUR J BIOCHEM, V271, P4909, DOI 10.1111/j.1432-1033.2004.04460.x; Melamed E, 2002, AM J PHYS MED REHAB, V81, P670, DOI 10.1097/00002060-200209000-00006; Monteleone P, 2005, NEUROPSYCHOPHARMACOL, V30, P1216, DOI 10.1038/sj.npp.1300695; Ofek O, 2006, P NATL ACAD SCI USA, V103, P696, DOI 10.1073/pnas.0504187103; ORZEL JA, 1985, J NUCL MED, V26, P125; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; PARFITT AM, 1987, BONE, V8, pS1; Roodman GD, 1999, EXP HEMATOL, V27, P1229, DOI 10.1016/S0301-472X(99)00061-2; Sato S, 2007, NAT MED, V13, P1234, DOI 10.1038/nm1640; Scutt A, 2007, CALCIFIED TISSUE INT, V80, P50, DOI 10.1007/s00223-006-0171-7; Seeman E, 2003, ENDOCRIN METAB CLIN, V32, P25, DOI 10.1016/S0889-8529(02)00078-6; Sun L, 2006, CELL, V125, P247, DOI 10.1016/j.cell.2006.01.051; Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092-8674(02)01049-8; Tam J, 2008, FASEB J, V22, P285, DOI 10.1096/fj.06-7957com; Tam J, 2006, MOL PHARMACOL, V70, P786, DOI 10.1124/mol.106.026435; Wildburger R, 1998, J ENDOCRINOL INVEST, V21, P78, DOI 10.1007/BF03350319; Yamada Y, 2007, INT J MOL MED, V19, P791; Yirmiya R, 2006, P NATL ACAD SCI USA, V103, P16876, DOI 10.1073/pnas.0604234103; Zhang PW, 2004, MOL PSYCHIATR, V9, P916, DOI 10.1038/sj.mp.4001560; ZHANG RW, 1995, CALCIFIED TISSUE INT, V56, P283, DOI 10.1007/BF00318048; ZHOU H, 1994, J BONE MINER RES, V9, P1489; Zimmer A, 1999, P NATL ACAD SCI USA, V96, P5780, DOI 10.1073/pnas.96.10.5780	47	79	82	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-8194	1365-2826		J NEUROENDOCRINOL	J. Neuroendocrinol.	MAY	2008	20			1			69	74		10.1111/j.1365-2826.2008.01675.x			6	Endocrinology & Metabolism; Neurosciences	Endocrinology & Metabolism; Neurosciences & Neurology	289NI	WOS:000255060800013	18426503	Bronze			2021-06-18	
J	Hanks, RA; Millis, SR; Ricker, JH; Giacino, JT; Nakese-Richardson, R; Frol, AB; Novack, TA; Kalmar, K; Sherer, M; Gordon, WA				Hanks, Robin A.; Millis, Scott R.; Ricker, Joseph H.; Giacino, Joseph T.; Nakese-Richardson, Risa; Frol, Alan B.; Novack, Toln A.; Kalmar, Kathleen; Sherer, Mark; Gordon, Wayne A.			The predictive validity of a brief inpatient neuropsychologic battery for persons with traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; neuropsychological tests; outcomes assessment (health care); psychometrics; rehabilitation	DISABILITY RATING-SCALE; SEVERE HEAD TRAUMA; GALVESTON ORIENTATION; AMNESIA TEST; PRODUCTIVITY; COMA; SUPERVISION; 1-YEAR	Objective: To examine the predictive validity of a brief neuropsychologic test battery consisting of the Galveston Orientation and Amnesia Test, the California Verbal Learning, Test-II, Trail-Making Test (TMT), Symbol Digit Modalities Test, grooved pegboard, phonemic and categorical word generation tasks, the Wechsler Test of Adult Reading (WTAR). and the Wisconsin Card Sorting Test-64 relative to functional outcome at I year in person, with traumatic brain injury. Design: Inception cohort Study. Follow-Lip period of 12 months. Setting: Seven Traumatic Brain Injury Model System centers. Neuropsychologic testing was conducted during the acute inpatient rehabilitation stay and functional outcome measures were obtained at 1-year outpatient follow-up. Participants: Adults (N = 174) who met criteria for admission to inpatient brain injury rehabilitation. Interventions: Not applicable. Main Outcome Measures: FIM instrument. Disability Rating Scale, Supervision Rating Scale. Satisfaction With Life Scale (SWLS), and Glasgow Outcome Scale-Extended. Results: Multiple regression analyses revealed that performance on the neuropsychologic test battery was predictive of outcome at I year postinjury for all outcome measures, except FIM motor scores and the SWLS. Cognitive performance Using this battery Was found to predict 1-year outcomes above and beyond functional variables and injury severity variables collected during inpatient rehabilitation, thereby indicating incremental validity for this test battery. Individual tests that were found to be significant predictors of 1-year outcomes included the WTAR and TMT part B. Conclusions: These findings support the clinical utility and ecological validity of this battery with respect to level of disability, functional independence. and supervision required.	[Hanks, Robin A.; Millis, Scott R.] Rehabil Inst Michigan, Detroit, MI 48201 USA; [Hanks, Robin A.; Millis, Scott R.] Wayne State Univ, Sch Med, Dept Phys Med & Rehabil, Detroit, MI USA; [Ricker, Joseph H.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA; [Giacino, Joseph T.; Kalmar, Kathleen] JFK Med Ctr, JFK Johnson Rehabil Inst, Edison, NJ USA; [Giacino, Joseph T.; Kalmar, Kathleen] JFK Med Ctr, New Jersey Neurosci Inst, Edison, NJ USA; [Nakese-Richardson, Risa] Univ Mississippi, Med Ctr, Jackson, MS 39216 USA; [Nakese-Richardson, Risa] Methodist Rehabil Ctr, Jackson, MS USA; [Frol, Alan B.] Baylor Inst Rehabil, Dept Phys Med & Rehabil, Dallas, TX USA; [Novack, Toln A.] Spain Rehabil Ctr, Birmingham, AL USA; [Sherer, Mark] Mem Hermann TIRR, Houston, TX USA; [Gordon, Wayne A.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA	Hanks, RA (corresponding author), Rehabil Inst Michigan, 261 Mack Blvd, Detroit, MI 48201 USA.	rhanks@med.wayne.edu	Giacino, Joseph/AAF-1952-2021	Giacino, Joseph/0000-0002-7916-9698; Ricker, Joseph/0000-0003-3415-991X	National Insulate on Disability and Rehabilitation Research [H133A020501, H133A020502, H133A020509, H133A020514, H133A020515, H133A020518, H133A020526]	Supported by the National Insulate on Disability and Rehabilitation Research (grant nos. H133A020501 H133A020502. H133A020509. H133A020514, H133A020515, H133A020518. H133A020526).	Atchison TB, 2004, CLIN NEUROPSYCHOL, V18, P249, DOI 10.1080/13854040490501475; Boake C, 1996, ARCH PHYS MED REHAB, V77, P765, DOI 10.1016/S0003-9993(96)90254-3; Boake C, 2001, ARCH PHYS MED REHAB, V82, P761, DOI 10.1053/apmr.2001.23753; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; DELIS DC, 2000, CALIFORNIA VERBAL LE; Delis DC, 2001, DELISKAPLAN EXECUTIV; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Farmer JE, 2002, DEV NEUROPSYCHOL, V22, P455, DOI 10.1207/S15326942DN2202_2; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Gordon W, 1993, J HEAD TRAUMA REHAB, V8, P26; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P1030, DOI 10.1016/S0003-9993(99)90056-4; Hart T, 2003, ARCH PHYS MED REHAB, V84, P221, DOI 10.1053/apmr.2003.50023; Heaton RK, 2004, REVISED COMPREHENSIV; Kongs SK, 2000, WISCONSIN CARD SORTI; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Neese LE, 2000, BRAIN INJURY, V14, P719; Novack TA, 2000, J HEAD TRAUMA REHAB, V15, P957, DOI 10.1097/00001199-200006000-00008; Paradee CV, 2005, CLIN NEUROPSYCHOL, V19, P55, DOI 10.1080/13854040490524173; Pastorek NJ, 2004, J INT NEUROPSYCH SOC, V10, P807, DOI 10.1017/S1355617704106012; Rappaport M, 2005, NEUROPSYCHOL REHABIL, V15, P442, DOI 10.1080/09602010443000335; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Reitan R.M., 1993, HALSTEADREITAN NEURO; Ross S R, 1997, Appl Neuropsychol, V4, P165, DOI 10.1207/s15324826an0403_4; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; RUFF RM, 1992, PERCEPT MOTOR SKILL, V75, P1311, DOI 10.2466/PMS.75.8.1311-1319; Schiff ND, 2006, J NEUROTRAUM, V23, P1436, DOI 10.1089/neu.2006.23.1436; Sherer M, 2002, CLIN NEUROPSYCHOL, V16, P157, DOI 10.1076/clin.16.2.157.13238; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; Smith A., 1982, SYMBOL DIGIT MODALIT; Taylor HG, 2004, DEV NEUROPSYCHOL, V25, P199, DOI 10.1207/s15326942dn2501&2_11; Willer B, 1993, J HEAD TRAUMA REHAB, V3, P75, DOI DOI 10.1097/00001199-199308020-00009; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	32	79	81	0	12	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAY	2008	89	5					950	957		10.1016/j.apmr.2008.01.011			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	341ST	WOS:000258735900022	18452745				2021-06-18	
J	Benton, RL; Maddie, MA; Minnillo, DR; Hagg, T; Whittemore, SR				Benton, Richard L.; Maddie, Melissa A.; Minnillo, Danielle R.; Hagg, Theo; Whittemore, Scott R.			Griffonia simplicifolia isolectin B4 identifies a specific subpopulation of angiogenic blood vessels following contusive spinal cord injury in the adult mouse	JOURNAL OF COMPARATIVE NEUROLOGY			English	Article						neovascularization; lectin; microvascular; endothelial; tight junction; adaptive angiogenesis	BRAIN-BARRIER BREAKDOWN; TIGHT JUNCTION PROTEINS; ENDOTHELIAL-CELLS; LESION DEVELOPMENT; NERVOUS-SYSTEM; LECTIN-BINDING; RAT; EXPRESSION; LOCALIZATION; SURFACE	After traumatic spinal cord injury (SCI), disruption and plasticity of the microvasculature within injured spinal tissue contribute to the pathological cascades associated with the evolution of both primary and secondary injury. Conversely, preserved vascular function most likely results in tissue sparing and subsequent functional recovery. It has been difficult to identify subclasses of damaged or regenerating blood vessels at the cellular level. Here, adult mice received a single intravenous injection of the Griffonia simplicifolia isolectin B4 (1134) at 1-28 days following a moderate thoracic (T9) contusion. Vascular binding of 1134 was maximally observed 7 days following injury, a time associated with multiple pathologic aspects of the intrinsic adaptive angiogenesis, with numbers of 1134 vascular profiles decreasing by 21 days postinjury. Quantitative assessment of 1134 binding shows that it occurs within the evolving lesion epicenter, with affected vessels expressing a temporally specific dysfunctional tight junctional phenotype as assessed by occludin, claudin-5, and ZO-1 immunoreactivities. Taken together, these results demonstrate that intravascular lectin delivery following SCI is a useful approach not only for observing the functional status of neovascular formation but also for definitively identifying specific subpopulations of reactive spinal microvascular elements. J. Comp. Neurol. 507:1031-1052, 2008. (c) 2007 Wiley-Liss, Inc.	[Benton, Richard L.; Maddie, Melissa A.; Minnillo, Danielle R.; Hagg, Theo; Whittemore, Scott R.] Univ Louisville, Sch Med, Kentucky Spinal Cord Injury Res Ctr, Louisville, KY 40292 USA; [Maddie, Melissa A.; Hagg, Theo] Univ Louisville, Sch Med, Dept Neurol Surg, Louisville, KY 40292 USA; [Benton, Richard L.; Whittemore, Scott R.] Univ Louisville, Sch Med, Dept Anat Sci & Neurobiol, Louisville, KY 40292 USA; [Minnillo, Danielle R.] Univ Louisville, Sch Med, Summer Res Scholar Program, Louisville, KY 40292 USA; [Hagg, Theo] Univ Louisville, Sch Med, Dept Pharmacol & Toxicol, Louisville, KY 40292 USA	Whittemore, SR (corresponding author), Univ Louisville, Sch Med, Kentucky Spinal Cord Injury Res Ctr, 511 S Floyd St,MDR 616, Louisville, KY 40292 USA.	swhittemore@louisville.edu			NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P20 RR015576, RR15576, P20 RR015576-09] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS045734-04, NS045734, R01 NS045734] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P20RR015576] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS045734] Funding Source: NIH RePORTER		Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824; Alliot F, 1999, J NEUROSCI RES, V58, P367; ALROY J, 1987, HISTOCHEMISTRY, V86, P603, DOI 10.1007/BF00489554; Balding P, 1975, Z Immunitatsforsch Exp Klin Immunol, V145, P156; Bao F, 2005, J NEUROCHEM, V94, P1361, DOI 10.1111/j.1471-4159.2005.03280.x; Bazzoni G, 2004, PHYSIOL REV, V84, P869, DOI 10.1152/physrev.00035.2003; BELLONI PN, 1988, J CELL PHYSIOL, V136, P398, DOI 10.1002/jcp.1041360303; Bolton SJ, 1998, NEUROSCIENCE, V86, P1245, DOI 10.1016/S0306-4522(98)00058-X; BRABEC RK, 1980, P NATL ACAD SCI-BIOL, V77, P477, DOI 10.1073/pnas.77.1.477; BULLOCK R, 1992, J NEUROTRAUM, V9, pS443; CASELLA GT, 2006, IN PRESS EXP NEUROL; Casella GTB, 2002, EXP NEUROL, V173, P63, DOI 10.1006/exnr.2001.7827; Chan-Ling T, 2004, AM J PATHOL, V165, P1301, DOI 10.1016/S0002-9440(10)63389-5; Chi L, 2007, NEUROSCIENCE, V144, P991, DOI 10.1016/j.neuroscience.2006.09.064; Debbage PL, 1998, J HISTOCHEM CYTOCHEM, V46, P627, DOI 10.1177/002215549804600508; Dobrogowska DH, 2004, J MOL HISTOL, V35, P529, DOI 10.1007/s10735-004-1318-3; Edsbagge J, 2005, DEVELOPMENT, V132, P1085, DOI 10.1242/dev.01643; FATEHI MI, 1987, BRAIN RES, V415, P30, DOI 10.1016/0006-8993(87)90266-6; Franz S, 2006, CYTOM PART A, V69A, P230, DOI 10.1002/cyto.a.20206; Fujiki M, 1996, J COMP NEUROL, V371, P469; GALILI U, 1988, J BIOL CHEM, V263, P17755; Ge SJ, 2006, J NEUROIMMUNOL, V177, P209, DOI 10.1016/j.jneuroim.2006.05.012; Glaser J, 2004, J NEUROSCI RES, V77, P701, DOI 10.1002/jnr.20204; Gris D, 2004, J NEUROSCI, V24, P4043, DOI 10.1523/JNEUROSCI.5343-03.2004; Hamm S, 2004, CELL TISSUE RES, V315, P157, DOI 10.1007/s00441-003-0825-y; Han HS, 2005, CURR NEUROVASC RES, V2, P409, DOI 10.2174/156720205774962647; HAYES CE, 1974, J BIOL CHEM, V249, P1904; Hirasawa T, 2005, J NEUROSCI RES, V81, P357, DOI 10.1002/jnr.20480; Hsu JYC, 2006, J NEUROSCI, V26, P9841, DOI 10.1523/JNEUROSCI.1993-06.2006; Hughes S, 2000, MICROCIRCULATION, V7, P317, DOI 10.1038/sj.mn.7300119; Hughes S, 2006, NEUROBIOL AGING, V27, P1838, DOI 10.1016/j.neurobiolaging.2005.10.021; Iruela-Arispe ML, 1999, MICROCIRCULATION, V6, P127, DOI 10.1038/sj.mn.7300061; Jaeger CB, 1997, EXP NEUROL, V144, P381, DOI 10.1006/exnr.1996.6405; Jakovcevski I, 2007, J NEUROSCI, V27, P7222, DOI 10.1523/JNEUROSCI.0739-07.2007; Jilani SM, 2003, J HISTOCHEM CYTOCHEM, V51, P597, DOI 10.1177/002215540305100505; Kigerl KA, 2006, J COMP NEUROL, V494, P578, DOI 10.1002/cne.20827; Kokovay E, 2006, J CEREBR BLOOD F MET, V26, P545, DOI 10.1038/sj.jcbfm.9600214; KOYANAGI I, 1993, NEUROSURGERY, V33, P285, DOI 10.1227/00006123-199308000-00016; LAITINEN L, 1987, HISTOCHEM J, V19, P225, DOI 10.1007/BF01680633; Lippoldt A, 2000, BRAIN RES, V885, P251, DOI 10.1016/S0006-8993(00)02954-1; Lowe JB, 2003, CURR OPIN CELL BIOL, V15, P531, DOI 10.1016/j.ceb.2003.08.002; Loy DN, 2002, J COMP NEUROL, V445, P308, DOI 10.1002/cne.10168; Ma MH, 2001, EXP NEUROL, V169, P239, DOI 10.1006/exnr.2001.7679; Mark KS, 2002, AM J PHYSIOL-HEART C, V282, pH1485, DOI 10.1152/ajpheart.00645.2001; Mautes AEM, 2000, PHYS THER, V80, P673, DOI 10.1093/ptj/80.7.673; Mazzetti S, 2004, EUR J HISTOCHEM, V48, P423; McEwen BS, 2004, EUR J PHARMACOL, V490, P13, DOI 10.1016/j.ejphar.2004.02.041; Morgenstern DA, 2002, PROG BRAIN RES, V137, P313; MORIOKA T, 1993, J COMP NEUROL, V327, P123, DOI 10.1002/cne.903270110; NAG S, 1984, ACTA NEUROPATHOL, V63, P276, DOI 10.1007/BF00687333; Nico B, 1998, ANAT EMBRYOL, V197, P305, DOI 10.1007/s004290050140; Nico B, 2000, DEV BRAIN RES, V119, P231, DOI 10.1016/S0165-3806(99)00177-7; Niethammer AG, 2002, NAT MED, V8, P1369, DOI 10.1038/nm794; NISHIDA S, 1986, HISTOL HISTOPATHOL, V1, P69; Nitta T, 2003, J CELL BIOL, V161, P653, DOI 10.1083/jcb.200302070; Noble LJ, 1996, J COMP NEUROL, V376, P542; NOBLE LJ, 1989, BRAIN RES, V482, P57, DOI 10.1016/0006-8993(89)90542-8; NOBLE LJ, 1985, EXP NEUROL, V88, P135, DOI 10.1016/0014-4886(85)90119-0; NOBLE LJ, 1989, EXP NEUROL, V103, P34, DOI 10.1016/0014-4886(89)90182-9; Noguera-Troise I, 2006, NATURE, V444, P1032, DOI 10.1038/nature05355; Oatway MA, 2005, J NEUROSCI, V25, P637, DOI 10.1523/JNEUROSCI.3960-04.2005; PAPAIOANNOU VE, 1993, LAB ANIM SCI, V43, P189; Pardridge WM, 2007, DRUG DISCOV TODAY, V12, P54, DOI 10.1016/j.drudis.2006.10.013; Perdiki M, 1998, ACTA NEUROPATHOL, V96, P8, DOI 10.1007/s004010050854; PETERS BP, 1979, EXP CELL RES, V120, P321, DOI 10.1016/0014-4827(79)90392-6; PONDER BAJ, 1983, DEV BIOL, V96, P535, DOI 10.1016/0012-1606(83)90191-4; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; Raub TJ, 1996, AM J PHYSIOL-CELL PH, V271, pC495; Richter MW, 2005, J NEUROSCI, V25, P10700, DOI 10.1523/JNEUROSCI.3632-05.2005; Sennino B, 2007, CANCER RES, V67, P7358, DOI 10.1158/0008-5472.CAN-07-0293; Stamatovic SM, 2005, J CEREBR BLOOD F MET, V25, P593, DOI 10.1038/sj.jcbfm.9600055; STREIT WJ, 1985, J HISTOCHEM CYTOCHEM, V33, P1042, DOI 10.1177/33.10.4045182; Thurston G, 1996, AM J PHYSIOL-HEART C, V271, pH2547; Vinores SA, 2003, DEV BRAIN RES, V140, P169, DOI 10.1016/S0165-3806(02)00581-3; Vischer UM, 2006, J THROMB HAEMOST, V4, P1186, DOI 10.1111/j.1538-7836.2006.01949.x; Vorbrodt AW, 2003, BRAIN RES REV, V42, P221, DOI 10.1016/S0165-0173(03)00177-2; VORBRODT AW, 1986, DEV BRAIN RES, V29, P69, DOI 10.1016/0165-3806(86)90083-0; VORBRODT AW, 1986, ACTA NEUROPATHOL, V70, P103, DOI 10.1007/BF00691427; Whetstone WD, 2003, J NEUROSCI RES, V74, P227, DOI 10.1002/jnr.10759; Willis CL, 2004, GLIA, V48, P1, DOI 10.1002/glia.20049; Wolburg H, 2003, ACTA NEUROPATHOL, V105, P586, DOI 10.1007/s00401-003-0688-z; Yamauchi T, 2004, J NEUROTRAUM, V21, P1017, DOI 10.1089/0897715041651042	82	79	80	1	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0021-9967	1096-9861		J COMP NEUROL	J. Comp. Neurol.	MAR 1	2008	507	1					1031	1052		10.1002/cne.21570			22	Neurosciences; Zoology	Neurosciences & Neurology; Zoology	253MT	WOS:000252523000002	18092342	Green Accepted			2021-06-18	
J	Covassin, T; Stearne, D; Elbin, R				Covassin, Tracey; Stearne, David; Elbin, Robert, III			Concussion history and postconcussion neurocognitive performance and symptoms in collegiate athletes	JOURNAL OF ATHLETIC TRAINING			English	Article						mild traumatic brain injury; ImPACT; memory; reaction time	SPORTS-RELATED CONCUSSION; SCHOOL FOOTBALL PLAYERS; RECURRENT CONCUSSION; CONTACT SPORTS; HEAD-INJURY; MANAGEMENT; RECOVERY; ASSOCIATION; STATEMENT; TRENDS	Context: Athletes are at an inherent risk for sustaining concussions. Research examining the long-term consequences of sport-related concussion has been inconsistent in demonstrating lingering neurocognitive decrements that may be associated with a previous history of concussion. Objective: To determine the relationship between concussion history and postconcussion neurocognitive performance and symptoms in collegiate athletes. Design: Repeated-measures design. Setting: Multi-center analysis of collegiate athletes. Patients or Other Participants: Fifty-seven concussed collegiate athletes (36 without concussion history, 21 with a history of 2 or more concussions). Intervention(s): All subjects were administered an Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) neurocognitive test battery, which measures verbal memory, visual memory, reaction time, and visual processing speed and 22 concussion symptoms. Main Outcome Measure(s): Subjects who sustained a concussion were administered 2 follow-up tests at days 1 and 5 postinjury. Independent variables were history of concussion (no history of concussion, 2 or more concussions) and time (baseline, day 1 postconcussion, or day 5 postconcussion). Results: A within-subjects effect (time) on ImPACT performance (P < .001), a between-subjects multivariate effect of group (P < .001), and a group-by-time interaction (P = .034) were noted. Athletes with a concussion history performed significantly worse on verbal memory (P = .01) and reaction time (P = .023) at day 5 postconcussion compared with athletes who did not report a previous concussion. No significant group differences were seen at day 5 postinjury on visual memory (P = .167), processing speed (P = .179), or total concussion symptoms (P = .87). Conclusions: Concussed collegiate athletes with a history of 2 or more concussions took longer to recover verbal memory and reaction time than athletes without a history of concussion.	[Covassin, Tracey; Stearne, David; Elbin, Robert, III] Michigan State Univ, Dept Kinesiol, E Lansing, MI 48824 USA	Covassin, T (corresponding author), Michigan State Univ, Dept Kinesiol, 105 IM Sport Circle, E Lansing, MI 48824 USA.	covassin@msu.edu					Autti T, 1997, LANCET, V349, P1144, DOI 10.1016/S0140-6736(05)63019-X; BECKER DP, 1987, PHYSL BASIS MODERN S, P763; Broglio SP, 2006, BRIT J SPORT MED, V40, P802, DOI 10.1136/bjsm.2006.028019; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Collie A, 2006, BRIT J SPORT MED, V40, P550, DOI 10.1136/bjsm.2005.019802; Collie A, 2006, J NEUROL NEUROSUR PS, V77, P241, DOI 10.1136/jnnp.2005.073155; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Gaetz M, 2000, BRAIN INJURY, V14, P1077; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Giza CC, 2001, J ATHL TRAINING, V36, P228; Giza CC, 2000, NEUROLOGIC ATHLETIC, P80; GRONWALL D, 1974, LANCET, V2, P605; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2004, NEUROSURGERY, V55, P891, DOI 10.1227/01.NEU.0000143800.49798.19; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Kelly JP, 1997, NEUROLOGY, V48, P581; Killam C, 2005, ARCH CLIN NEUROPSYCH, V20, P599, DOI 10.1016/j.acn.2005.02.001; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Moser RS, 2002, ARCH CLIN NEUROPSYCH, V17, P91, DOI 10.1016/S0887-6177(01)00108-1; Notebaert AJ, 2005, J ATHL TRAINING, V40, P320; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Tegner Y, 1996, BRIT J SPORT MED, V30, P251, DOI 10.1136/bjsm.30.3.251; THOMASSEN A, 1979, ACTA NEUROL SCAND, V60, P352, DOI 10.1111/j.1600-0404.1979.tb07661.x; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677; Wall SE, 2006, J NEUROL NEUROSUR PS, V77, P518, DOI 10.1136/jnnp.2004.061044; Zemper ED, 2003, AM J PHYS MED REHAB, V82, P653, DOI 10.1097/01.PHM.0000083666.74494.BA	35	79	80	0	35	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050			J ATHL TRAINING	J. Athl. Train.	MAR-APR	2008	43	2					119	124		10.4085/1062-6050-43.2.119			6	Sport Sciences	Sport Sciences	293TX	WOS:000255359200002	18345335	Green Published			2021-06-18	
J	Morel, N; Morel, O; Petit, L; Hugel, B; Cochard, JF; Freyssinet, JM; Sztark, F; Dabadie, P				Morel, Nicolas; Morel, Olivier; Petit, Laurent; Hugel, Benedicte; Cochard, Jean-Francois; Freyssinet, Jean-Marie; Sztark, Francois; Dabadie, Philippe			Generation of procoagulant microparticles in cerebrospinal fluid and peripheral blood after traumatic brain injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	Joint 12th Annual Meeting of the European-Society-of-Anaesthesiologists (ESA) and European-Academy-of-Anaesthesiology (EAA) (EUROANAESTHESIA)	JUN 05-08, 2004	Lisbon, PORTUGAL	European Soc Anaesthesiol, European Acad Anaesthesiol		microparticles; apoptosis; traumatic brain injury	PROGRAMMED CELL-DEATH; TISSUE FACTOR; ENDOTHELIAL-CELLS; MEMBRANE MICROPARTICLES; HEAD-INJURY; IN-VITRO; APOPTOSIS; DYSFUNCTION; ACTIVATION; THROMBIN	Background: Traumatic brain injury (TBI) can induce cell damage. Procoagulant microparticles (MPs) are reliable markers of cell stimulation. The aim of this study was to investigate the generation of procoagulant MPs in the cerebrospinal fluid (CSF) and plasma of patients with severe TBI. Material: CSF and plasma MPs of 16 patients with severe TBI were quantified by functional prothrombinase assay (i) on the day of the trauma, (ii) during a 10-day follow-up and compared with control samples. The cellular origin of NIP was determined after capture with specific antibodies. Results: The CSF and plasma of patients with severe TBI revealed a significantly increased generation of MP compared with control samples on the day of the trauma (CSF: 4.5 +/- 1.8 vs. 0.83 +/- 0.28 nanomolar PhtdSer equivalent; p = 0.01 and plasma 4.1 +/- 3.7 vs. 2.3 +/- 0.19 nanomolar PhtdSer equivalent; p = 0.02). Procoagulant MPs were mainly of platelet and endothelial origin in CSF. MPs decreased significantly in the CSF 10 days after TBI. In CSF, a sustained generation of procoagulant MP was evidenced in two patients presenting a poor clinical outcome. In the blood flow, elevated amounts of procoagulant MEN were detected in three patients presenting disseminated intravascular coagulopathy during the follow-up. Conclusion: Procoagulant MP testifying to platelet and endothelial activation are produced in the CSF and in the plasma after severe TBI. A sustained generation of procoagulant MP in the CSF could contribute to a poor clinical outcome.	[Morel, Nicolas; Dabadie, Philippe] Hop Pellegrin, Dept Urgences, Serv Reanimat Urgences, F-33076 Bordeaux, France; [Morel, Olivier; Hugel, Benedicte; Freyssinet, Jean-Marie] Univ Strasbourg, Fac Med, Inst Immunol Hematol, F-67085 Strasbourg, France; [Morel, Olivier; Hugel, Benedicte; Freyssinet, Jean-Marie] INSERM, U770, F-94272 Le Kremlin Bicetre, France; [Morel, Olivier; Hugel, Benedicte; Freyssinet, Jean-Marie] Univ Paris Sud 11, Fac Med, F-94272 Le Kremlin Bicetre, France; [Petit, Laurent; Cochard, Jean-Francois; Sztark, Francois] Hop Pellegrin, Serv Reanim Chirurg, F-33076 Bordeaux, France; [Morel, Olivier] Hop Hautepierre, Dept Cardiol, F-67000 Strasbourg, France	Morel, N (corresponding author), Serv Urgences Adultes, Place Amelie Raba Leon, F-33076 Bordeaux, France.	nicolas.morel@chu-bordeaux.fr	Freyssinet, Jean-Marie/G-2719-2013	LAURENT, PETIT/0000-0003-1530-5678			Abbott NJ, 2000, CELL MOL NEUROBIOL, V20, P131, DOI 10.1023/A:1007074420772; Aras O, 2004, BLOOD, V103, P4545, DOI 10.1182/blood-2003-03-0713; Aupeix K, 1997, J CLIN INVEST, V99, P1546, DOI 10.1172/JCI119317; Barry OP, 1997, J CLIN INVEST, V99, P2118, DOI 10.1172/JCI119385; Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Bombeli T, 1999, BLOOD, V93, P3831, DOI 10.1182/blood.V93.11.3831; Bombeli T, 1997, BLOOD, V89, P2429, DOI 10.1182/blood.V89.7.2429; Clark RSB, 2000, J PEDIATR-US, V137, P197, DOI 10.1067/mpd.2000.106903; Combes V, 1999, J CLIN INVEST, V104, P93, DOI 10.1172/JCI4985; DacharyPrigent J, 1996, SEMIN THROMB HEMOST, V22, P157, DOI 10.1055/s-2007-999004; Dempsey RJ, 2003, J NEUROSURG, V98, P867, DOI 10.3171/jns.2003.98.4.0867; Falati S, 2003, J EXP MED, V197, P1585, DOI 10.1084/jem.20021868; Gando S, 1997, CRIT CARE MED, V25, P1820, DOI 10.1097/00003246-199711000-00019; Gando S, 1999, J TRAUMA, V46, P1070, DOI 10.1097/00005373-199906000-00018; Geisbert TW, 2003, J INFECT DIS, V188, P1618, DOI 10.1086/379724; Giesen PLA, 1999, P NATL ACAD SCI USA, V96, P2311, DOI 10.1073/pnas.96.5.2311; Guettier-Sigrist S, 2002, MUSCLE NERVE, V25, P700, DOI 10.1002/mus.10081; Harter L, 2001, J NEUROIMMUNOL, V121, P76, DOI 10.1016/S0165-5728(01)00409-X; Ikegami K, 1998, J TRAUMA, V44, P789, DOI 10.1097/00005373-199805000-00008; Jacoby RC, 2001, J TRAUMA, V51, P639, DOI 10.1097/00005373-200110000-00003; Jy W, 2004, J THROMB HAEMOST, V2, P1842, DOI 10.1111/j.1538-7836.2004.00936.x; Mallat Z, 1999, CIRCULATION, V99, P348, DOI 10.1161/01.CIR.99.3.348; Martin SJ, 1996, J BIOL CHEM, V271, P28753, DOI 10.1074/jbc.271.46.28753; Molino M, 1997, J BIOL CHEM, V272, P11133; Morel O, 2004, THROMB HAEMOSTASIS, V91, P345, DOI 10.1160/TH03-05-0294; Ng I, 2000, NEUROSURGERY, V46, P949, DOI 10.1097/00006123-200004000-00034; Ng I., 1999, Annals Academy of Medicine Singapore, V28, P363; Ogura H, 2001, J TRAUMA, V50, P801, DOI 10.1097/00005373-200105000-00005; Osterud B, 2006, SEMIN THROMB HEMOST, V32, P11, DOI 10.1055/s-2006-933336; Osterud B, 2001, SEMIN THROMB HEMOST, V27, P605, DOI 10.1055/s-2001-18866; RINK A, 1995, AM J PATHOL, V147, P1575; Sapet C, 2006, BLOOD, V108, P1868, DOI 10.1182/blood-2006-04-014175; Scherer RU, 1998, CRIT CARE MED, V26, P149, DOI 10.1097/00003246-199801000-00031; *SFAR SRLF, 2002, 22 C CONS COAG INTR; Smith FM, 2000, ACTA NEUROPATHOL, V100, P537, DOI 10.1007/s004010000222; Taubman MB, 1999, THROMB HAEMOSTASIS, V82, P801; UNTERBERG A, 1984, J CEREBR BLOOD F MET, V4, P574, DOI 10.1038/jcbfm.1984.82	38	79	86	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAR	2008	64	3					698	704		10.1097/TA.0b013e31816493ad			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	274JE	WOS:000253996800028	18332810				2021-06-18	
J	Ylvisaker, M; McPherson, K; Kayes, N; Pellett, E				Ylvisaker, Mark; McPherson, Kathryn; Kayes, Nicola; Pellett, Ellen			Metaphoric identity mapping: Facilitating goal setting and engagement in rehabilitation after traumatic brain injury	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Traumatic brain injury; Rehabilitation; Identity; Goal setting; Self-regulation	SELF-REGULATION; QUALITATIVE RESEARCH; HEALTH-CARE; MOTIVATION; PEOPLE; PERSPECTIVES; NARRATIVES; CLINICIAN; ARTHRITIS	Difficulty re-establishing an organised and compelling sense of personal identity has increasingly been identified as a critical theme in outcome studies of individuals with severe traumatic brain injury (TBI) and a serious obstacle to active engagement in rehabilitation. There exists little empirical support for approaches to identity reconstruction that address common impairments associated with TBI. Similarly, there is as yet little empirical support for theoretically sound approaches to promoting engagement in goal setting for this population. This article has two purposes. First, theory and procedures associated with metaphoric identity mapping are discussed in relation to goal setting in TBI rehabilitation. Second, the results of a qualitative pilot study are presented. The study explored metaphoric identity mapping as a facilitator of personally meaningful goal setting with five individuals with significant disability many years after their injury. Drawing on principles of grounded theory, the investigators extracted data from semi-structured interviews with clients and clinicians, from focus groups with the clinicians, and from observation of client-clinician interaction. Analysis of the data yielded five general themes concerning the use of this approach: All clients and clinicians found identity mapping to be an acceptable process and also useful for deriving meaningful rehabilitation goals. Both clients and clinicians saw client-centred goals as important. Cognitive impairments posed obstacles to this goal-setting intervention and mandated creative compensations. And finally, identity-related goal setting appeared to require a "mind shift" for some clinicians and demanded clinical skills not uniformly distributed among rehabilitation professionals.	[Ylvisaker, Mark] Coll St Rose, Albany, NY USA; [McPherson, Kathryn; Kayes, Nicola] AUT Univ, Hlth & Rehabil Res Ctr, Auckland, New Zealand; [Pellett, Ellen] Pellett & Associates, Oakville, ON, Canada	Ylvisaker, M (corresponding author), 1171 Van Antwerp Rd, Schenectady, NY 12309 USA.	ylvisakm@mail.strose.edu		McPherson, Kathryn/0000-0003-1240-8882; McPherson, Kath/0000-0003-0487-8497			Barnard P., 1985, PROGR PSYCHOL LANGUA, V2, P197; Biderman D, 2006, INT J PSYCHOL, V41, P355, DOI 10.1080/00207590500345963; Boekaerts M., 1998, RES DIALOGUE LEARNIN, V1, P13, DOI [10.1016/S0959-4752(98)00008-5, DOI 10.1016/S0959-4752(98)00008-5]; Bruner Jerome, 2002, MAKING STORIES LAW L; Bulgren J.A., 2006, TEACHING ADOLESCENTS, P79; Carver C. S., 1998, SELF REGULATION BEHA; Deci EL, 2000, PSYCHOL INQ, V11, P227, DOI 10.1207/S15327965PLI1104_01; Denzin N.K., 2000, HDB QUALITATIVE RES; Emmons RA, 1996, STRIVING AND FEELING, P79; Fitzsimons GM., 2004, HDB SELF REGULATION, P151; Grafman J., 2002, PRINCIPLES FRONTAL L, P292; Hart T, 2006, J HEAD TRAUMA REHAB, V21, P142, DOI 10.1097/00001199-200603000-00007; Heller W, 2006, J REHABIL, V72, P44; HERMANS HJM, 1992, AM PSYCHOL, V47, P23, DOI 10.1037/0003-066X.47.1.23; Hill H, 1999, BRAIN INJURY, V13, P839, DOI 10.1080/026990599121043; Johansson U, 2006, AM J OCCUP THER, V60, P60, DOI 10.5014/ajot.60.1.60; Judd D, 2005, BRAIN INJURY, V19, P437, DOI 10.1080/02699050400010994; Kelly AE, 2000, PSYCHOL BULL, V126, P475, DOI 10.1037//0033-2909.126.4.475; KIRESUK TJ, 1968, COMMUNITY MENT HLT J, V4, P443, DOI 10.1007/BF01530764; Klinger L, 2005, J OCCUP SCI, V12, P9, DOI 10.1080/14427591.2005.9686543; Kovarsky Dana, 2007, Commun Med, V4, P53, DOI 10.1515/CAM.2007.029; Lakoff G., 1980, METAPHORS WE LIVE; Lakoff G., 1999, PHILOS FLESH EMBODIE; Levack WMM, 2006, BRAIN INJURY, V20, P1439, DOI 10.1080/02699050601118422; Levack WMM, 2006, CLIN REHABIL, V20, P739, DOI 10.1177/0269215506070791; Levack WMM, 2006, DISABIL REHABIL, V28, P741, DOI 10.1080/09638280500265961; Levine B, 1999, NEUROCASE, V5, P263, DOI 10.1080/13554799908402731; Locke E.A., 1990, THEORY GOAL SETTING; Maclean N, 2000, SOC SCI MED, V50, P495; Mallinson T, 1996, AM J OCCUP THER, V50, P338, DOI 10.5014/ajot.50.5.338; MARKUS H, 1987, ANNU REV PSYCHOL, V38, P299, DOI 10.1146/annurev.ps.38.020187.001503; MARKUS H, 1986, AM PSYCHOL, V41, P954, DOI 10.1037/0003-066X.41.9.954; Mays N, 2000, BMJ-BRIT MED J, V320, P50, DOI 10.1136/bmj.320.7226.50; Mays N., 1996, QUALITATIVE RES HLTH; McMullin R. E., 2000, NEW HDB COGNITIVE TH; McPherson KM, 2004, DISABIL REHABIL, V26, P988, DOI 10.1080/09638280410001702414; McPherson KM, 2001, DISABIL REHABIL, V23, P706; *MED RES COUNC, 2000, FRAM DEV EV RCTS COM; MORRIS SD, 2004, J COGN REHABIL, V22, P15; Nippold M., 1998, LATER LANGUAGE DEV S; Nochi M, 2000, SOC SCI MED, V51, P1795, DOI 10.1016/S0277-9536(00)00111-8; Nochi M, 1998, SOC SCI MED, V46, P869, DOI 10.1016/S0277-9536(97)00211-6; Patton MQ, 1999, HEALTH SERV RES, V34, P1189; Patton MQ., 1990, QUALITATIVE EVALUATI; Perna R. B., 2004, J COGNITIVE REHABILI, V22, P10; Petrella L, 2005, BRAIN INJURY, V19, P643, DOI 10.1080/02699050410001671874; Pinker S., 2007, STUFF THOUGHT LANGUA; Pope C, 2000, BMJ-BRIT MED J, V320, P114, DOI 10.1136/bmj.320.7227.114; Prigatano G. P., 1991, AWARENESS DEFICIT BR; ROGERS C, 1974, AM PSYCHOL, V2, P358; Ryan RM, 2000, AM PSYCHOL, V55, P68, DOI 10.1037/0003-066X.55.1.68; Siegert R, 2004, DISABIL REHABIL, V26, P1, DOI 10.1080/09638280410001644932; Siegert RJ, 2004, DISABIL REHABIL, V26, P1175, DOI 10.1080/09638280410001724834; Strauss A., 1998, BASICS QUALITATIVE R; Stuss DT, 2000, MEMORY, CONSCIOUSNESS, AND THE BRAIN, P215; TEASDALE G, 1974, LANCET, V2, P81; Teasdale JD., 1993, AFFECT COGNITION CHA; TEASDALE JD, 1997, TRANSFORMATION MEANI, P141; Unruh Anita M, 2004, Can J Occup Ther, V71, P290; Unruh Anita M, 2002, Can J Occup Ther, V69, P5; Vickery CD, 2005, BRAIN INJURY, V19, P657, DOI 10.1080/02699050400005218; Wade DT, 1998, CLIN REHABIL, V12, P273, DOI 10.1191/026921598678166365; White M., 1990, NARRATIVE MEANS THER; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Yeates G, 2007, NEUROPSYCHOL REHABIL, V17, P151, DOI 10.1080/09602010600696423; Ylvisaker M, 2000, BRAIN IMPAIR, V1, P12, DOI DOI 10.1375/BRIM.1.1.12; YLVISAKER M, 2007, BRAIN IMPAIR, V8, P1	67	79	82	1	18	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2008	18	5-6					713	741		10.1080/09602010802201832			29	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	360PQ	WOS:000260070200001	18629719				2021-06-18	
J	Rehni, AK; Singh, N; Jaggi, AS; Singh, M				Rehni, Ashish K.; Singh, Nirmal; Jaggi, Arnteshwar S.; Singh, Manjeet			Amniotic fluid derived stem cells ameliorate focal cerebral ischaemia-reperfusion injury induced behavioural deficits in mice	BEHAVIOURAL BRAIN RESEARCH			English	Article						stem cells; amniotic fluid; sources; cerebral ischaemia	REDUCES INFARCT SIZE; CLOSED-HEAD INJURY; ARTERY OCCLUSION; BRAIN; MODEL; MOTOR; TRANSPLANTATION; REGENERATION; ANTIOXIDANTS; RECEPTORS	The present study has been designed to investigate the effect of amniotic fluid derived stem cells on focal cerebral ischaemia-reperfusion injury induced behavioural deficits in mice. Middle cerebral artery occlusion of 60 min followed by reperfusion for 7 days was employed in present study to produce ischaemia and reperfusion induced cerebral injury in mice. Assessment of cognitive behaviour was done using elevated plus maze. Assessment of neurological severity score was employed to assess motor, sensory, reflex, and balance tests in a composite manner. Adhesive-removal somatosensory test was employed to evaluate somatosensory deficit. Partial occlusion of middle cerebral artery markedly impaired memory, motor coordination, sensorimotor ability and somatosensory functions as inferred from the results of elevated plus-maze test, adhesive-removal test and neurological severity score test. Intracerebroventricular administration of amniotic fluid derived stem cells/embryonic neuronal stem cells significantly reversed the focal cerebral ischaemia-reperfus ion induced behavioural deficit measured in terms of loss of short-term memory, motor coordination, sensorimotor ability and somatosensory functions. Therefore, it may be concluded that stem cells derived from amniotic fluid exert beneficial effect on the ischaemic brain to an extent comparable to the neuroprotective effect of embryonic neuronal stem cells. (C) 2007 Elsevier B.V. All rights reserved.	Punjabi Univ, Dept Pharmaceut Sci & Drug Res, Patiala 147002, Punjab, India	Singh, N (corresponding author), Punjabi Univ, Dept Pharmaceut Sci & Drug Res, Patiala 147002, Punjab, India.	ashishkrehni@yahoo.co.in; nirmalresearch@gmail.com	Singh, Nouratan/N-9377-2017; Singh, Nirmal/ABA-2264-2020	Singh, Nouratan/0000-0002-8063-8375; 			Assady S, 2001, DIABETES, V50, P1691, DOI 10.2337/diabetes.50.8.1691; Baker K, 1998, J PHARMACOL EXP THER, V284, P215; Bhardwaj Anish, 2003, Curr Cardiol Rep, V5, P160, DOI 10.1007/s11886-003-0085-1; BORLONGAN CV, 1995, BRAIN RES, V676, P231, DOI 10.1016/0006-8993(95)00150-O; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Chenard BL, 1999, CURR PHARM DESIGN, V5, P381; Dahlke MH, 2003, J HEPATOL, V39, P365, DOI 10.1016/S0168-8278(03)00264-2; DHINGRA D, 2003, INDIAN J PHARM, V91, P361; Dobkin B H, 1991, Clin Geriatr Med, V7, P507; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; Fischer G, 1997, J PHARMACOL EXP THER, V283, P1285; GERMANO AF, 1994, J NEUROTRAUM, V11, P345, DOI 10.1089/neu.1994.11.345; Gupta R, 2003, PHARMACOL RES, V48, P209, DOI 10.1016/S1043-6618(03)00102-6; HALEY TJ, 1957, BRIT J PHARM CHEMOTH, V12, P12, DOI 10.1111/j.1476-5381.1957.tb01354.x; Horwitz EM, 1999, NAT MED, V5, P309, DOI 10.1038/6529; in 'tAnker PS, 2003, BLOOD, V102, P1548, DOI 10.1182/blood-2003-04-1291; ITOH J, 1990, PSYCHOPHARMACOLOGY, V101, P27, DOI 10.1007/BF02253713; JENKINS LW, 1981, ACTA NEUROPATHOL, V55, P205, DOI 10.1007/BF00691320; Jeong SW, 2003, STROKE, V34, P2258, DOI 10.1161/01.STR.0000083698.20199.1F; Johansson BB, 1996, STROKE, V27, P324, DOI 10.1161/01.STR.27.2.324; Mooney C., 2005, REPUBLICAN WAR SCI; Park KI, 2000, YONSEI MED J, V41, P825, DOI 10.3349/ymj.2000.41.6.825; Polgar S, 2003, BRAIN RES BULL, V60, P1, DOI 10.1016/S0361-9230(03)00017-0; Prusa AR, 2003, HUM REPROD, V18, P1489, DOI 10.1093/humrep/deg279; Reddy DS, 1998, BRAIN RES, V799, P215, DOI 10.1016/S0006-8993(98)00419-3; Rehni AK, 2007, PHARMACOL REP, V59, P192; Rogers DC, 1997, STROKE, V28, P2060, DOI 10.1161/01.STR.28.10.2060; *ROYAL COLL PHYS, 2004, NAT CLIN GUID STOK, P31; Savitz Sean I, 2004, NeuroRx, V1, P406; Sawamoto K, 2006, SCIENCE, V311, P629, DOI 10.1126/science.1119133; Schabitz WR, 1997, J CEREBR BLOOD F MET, V17, P500, DOI 10.1097/00004647-199705000-00003; Schallert T, 1997, ADV NEUROL, V73, P229; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; Singh N, 1998, PHARMACOLOGY, V56, P46, DOI 10.1159/000028181; Strauer BE, 2002, CIRCULATION, V106, P1913, DOI 10.1161/01.CIR.0000034046.87607.1C; Tsai MS, 2006, BIOL REPROD, V74, P545, DOI 10.1095/biolreprod.105.046029; Vasudevan M, 2006, PHYTOMEDICINE, V13, P677, DOI 10.1016/j.phymed.2006.01.007; Warner DS, 2004, J EXP BIOL, V207, P3221, DOI 10.1242/jeb.01022; WELSH FA, 1987, J NEUROCHEM, V49, P846, DOI 10.1111/j.1471-4159.1987.tb00971.x; WHISNANT JP, 1984, STROKE, V15, P160, DOI 10.1161/01.STR.15.1.160; *WHO, 1978, CER DIS CLIN RES CLA, V43; Wise PM, 2001, BRAIN RES REV, V37, P313, DOI 10.1016/S0165-0173(01)00136-9; Wojcik C, 2004, STROKE, V35, P1506, DOI 10.1161/01.STR.0000126891.93919.4e; Yamashita K, 1997, METAB BRAIN DIS, V12, P271, DOI 10.1007/BF02674671; Yan J, 2006, STEM CELLS, V24, P1976, DOI 10.1634/stemcells.2005-0518; Zhang L, 2000, J NEUROL SCI, V174, P141, DOI 10.1016/S0022-510X(00)00268-9	47	79	82	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	OCT 1	2007	183	1					95	100		10.1016/j.bbr.2007.05.028			6	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	211GA	WOS:000249511100012	17619060				2021-06-18	
J	Wilde, MC; Castriotta, RJ; Lai, JM; Atanasov, S; Masel, BE; Kuna, ST				Wilde, Mark C.; Castriotta, Richard J.; Lai, Jenny M.; Atanasov, Strahil; Masel, Brent E.; Kuna, Samuel T.			Cognitive impairment in patients with traumatic brain injury and obstructive sleep apnea	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	34th Annual Meeting of the International-Neuropsychological-Society	FEB 01-04, 2006	Boston, MA	Int Neuropsychol Soc		brain injuries; hypersomnia; neuropsychology; rehabilitation; sleep apnea; obstructive; sleep disorders; trauma	PSYCHOMOTOR VIGILANCE PERFORMANCE; MILD HEAD-INJURY; DAYTIME SLEEPINESS; ADULTS; DISORDERS; RECOVERY; NIGHT	Objective: To examine the impact of comorbid obstructive sleep apnea (OSA) on the cognitive functioning of traumatic brain injury (TBI) patients. Design: A case-control study. Neuropsychologic test performances of TBI patients with OSA were compared with those who did not have OSA. The diagnosis of OSA was based on standard criteria using nocturnal polysomnography. Setting: Three academic medical centers with level I trauma centers, accredited sleep disorders centers, and rehabilitation medicine programs. Participants: Thirty-five TBI patients who were part of a project that assessed the effect of sleep disorders in a larger sample of consecutively recruited TBI patients. There were 19 patients with TBI and OSA. They were compared with 16 TBI patients without OSA who were comparable in terms of age, education, severity of injury (when available), time postinjury, and Glasgow Coma Scale scores (when available). Interventions: Not applicable. Main Outcome Measures: The Psychomotor Vigilance Test, Rey Complex Figure Test, Rey Auditory Verbal Learning Test, digit span test from the Wechsler Memory Scale-Revised, and finger-tapping test. Results: The TBI patients with OSA performed significantly worse than the non-sleep disordered TBI patients on verbal and visual delayed-recall measures. The groups performed comparably on motor, visual construction, and attention tests. The TBI patients with OSA made more attention lapses (reaction times >= 500ms), but showed comparable fastest and slowest reaction times on a measure of sustained attention. Conclusions: OSA is associated with more impairment of sustained attention and memory in TBI patients. It is possible that early identification and treatment of OSA may improve cognitive, and thus potentially functional, outcomes of TBI patients with this disease.	Univ Texas Hlth Ctr, Houston, TX USA; Mem Hermann Hosp Sleep Disorders Ctr, Houston, TX USA; Univ Texas, Med Branch, Galveston, TX USA; Transit Learning Ctr, Galveston, TX USA; Univ Penn, Sch Med, Philadelphia, PA USA; Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA	Castriotta, RJ (corresponding author), Univ Texas, Hlth Sci Ctr, Div Pulm & Crit Care & Sleep Med, 6431 Fannin St, Houston, TX 77030 USA.	Richard.J.Castriotta@uth.tmc.edu	Castriotta, Richard/B-1158-2009; Lang, Steven/AAE-8102-2021; Sanguansri, Luz/B-6630-2011	Lang, Steven/0000-0003-1669-9146; Sanguansri, Luz/0000-0003-1908-7604; Castriotta, Richard/0000-0003-3502-4558			Aloia MS, 2004, J INT NEUROPSYCH SOC, V10, P772, DOI 10.1017/S1355617704105134; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Boake C, 2001, ARCH PHYS MED REHAB, V82, P761, DOI 10.1053/apmr.2001.23753; CARSKADON MA, 1986, SLEEP, V9, P519, DOI 10.1093/sleep/9.4.519; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; Castriotta RJ, 2001, ARCH PHYS MED REHAB, V82, P1403, DOI 10.1053/apmr.2001.26081; Chesson AL, 1997, SLEEP, V20, P406; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; DIKMEN S, 1983, ARCH NEUROL-CHICAGO, V40, P333, DOI 10.1001/archneur.1983.04050060033004; DIKMEN S, 1986, ARCH PHYS MED REHAB, V67, P507; Dikmen S, 2001, J CLIN EXP NEUROPSYC, V23, P729, DOI 10.1076/jcen.23.6.729.1019; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Dinges DF, 2003, SLEEP MED, V4, P393, DOI 10.1016/S1389-9457(03)00108-4; Dinges DF, 1997, SLEEP, V20, P267; Flemons WW, 1999, SLEEP, V22, P667, DOI 10.1093/sleep/22.5.667; Guilleminault C, 2000, NEUROLOGY, V54, P653, DOI 10.1212/WNL.54.3.653; Heaton R.K., 1991, COMPREHENSIVE NORMS; High WM, 2006, ARCH PHYS MED REHAB, V87, P334, DOI 10.1016/j.apmr.2005.11.028; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; KRIBBS NB, 1993, AM REV RESPIR DIS, V147, P1162, DOI 10.1164/ajrccm/147.5.1162; LEVIN HS, 1992, J NEUROTRAUM, V9, pS359; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Masel BE, 2001, ARCH PHYS MED REHAB, V82, P1526, DOI 10.1053/apmr.2001.26093; Phipps-Nelson J, 2003, SLEEP, V26, P695; Rechtschaffen A, 1968, MANUAL STANDARDIZED; Sforza E, 2004, EUR RESPIR J, V24, P279, DOI 10.1183/09031936.04.00091903; Sherer M, 2002, CLIN NEUROPSYCHOL, V16, P157, DOI 10.1076/clin.16.2.157.13238; Webster JB, 2001, ARCH PHYS MED REHAB, V82, P316, DOI 10.1053/apmr.2001.20840; Wechsler D., 1989, WECHSLER MEMORY SCAL; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014	30	79	81	0	7	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	OCT	2007	88	10					1284	1288		10.1016/j.apmr.2007.07.012			5	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	220MT	WOS:000250161500009	17908570				2021-06-18	
J	Mechoulam, R; Shohami, E				Mechoulam, R.; Shohami, E.			Endocannabinoids and traumatic brain injury	MOLECULAR NEUROBIOLOGY			English	Article						2-AG; blood-brain barrier; brain endothelial cells; cannabinoids; cytokines; endocannabinoids; NF-kappa B; TNF-alpha; vasodilation	CLOSED-HEAD-INJURY; FACTOR-KAPPA-B; CANNABINOID CB2 RECEPTOR; NEUROPROTECTIVE ACTIONS; DEXANABINOL HU-211; MESSENGER-RNA; CELL-DEATH; ALPHA; TARGET; INHIBITOR	In response to traumatic brain injury, there is local and transient accumulation of 2-AG at the site of injury, peaking at 4 h and sustained up to at least 24 h. Neuroprotection exerted by exogenous 2-AG suggests that the formation of 2-AG may serve as a molecular regulator of pathophysiological events, attenuating the brain damage. Inhibition of this protective effect by SR-141716A, a CB1 cannabinoid receptor antagonist, and the lack of effect of 2-AG in CB1 knockout mice suggest that 2-AG and the CB1 receptor may be important in the pathophysiology of traumatic brain injury. 2-AG exerts its neuroprotective effect after traumatic brain injury, at least in part, by inhibition of NF-kappa B transactivation. 2-AG also inhibits, at an early stage (2-4 h), the expression of the main proinflammatory cytokines, TNF-alpha, IL-6, and IL-1 beta, and is accompanied by reduction of BBB permeability. Moreover, the CB1, CB2, and TRVP1 receptors are expressed on microvascular endothelial cells, and their activation by 2-AG counteracts endothelin (ET-1)-induced cerebral microvascular responses (namely, Ca2+ mobilization and cytoskeleton rearrangement). This suggests that the functional interaction between 2-AG and ET-1 may provide a potential alternative pathway for abrogating ET-1-inducible vasoconstriction after brain injury and play a role in the neuroprotective effects exerted by 2-AG, as a potent vasodilator.	Hebrew Univ Jerusalem, Fac Med, Dept Med Chem & Nat Prod, IL-91010 Jerusalem, Israel; Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel	Mechoulam, R (corresponding author), Hebrew Univ Jerusalem, Fac Med, Dept Med Chem & Nat Prod, IL-91010 Jerusalem, Israel.	mechou@cc.huji.ac.il					Ashton JC, 2007, CURR NEUROPHARMACOL, V5, P73, DOI 10.2174/157015907780866884; BeitYannai E, 1996, BRAIN RES, V717, P22, DOI 10.1016/0006-8993(95)01492-6; BeitYannai E, 1997, J CEREBR BLOOD F MET, V17, P273, DOI 10.1097/00004647-199703000-00004; Ben-Shabat S, 1998, EUR J PHARMACOL, V353, P23, DOI 10.1016/S0014-2999(98)00392-6; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Chen Y, 2000, CIRC RES, V87, P323, DOI 10.1161/01.RES.87.4.323; Chen YQ, 2000, J PHARMACOL EXP THER, V293, P807; DIMARZO V, 2006, J ENDOCRINOL INVES S, V29, P15; Fernandez-Ruiz J, 2005, MIL DRUG TH, P79; Fernandez-Ruiz J, 2007, TRENDS PHARMACOL SCI, V28, P39, DOI 10.1016/j.tips.2006.11.001; Gallily R, 2000, EUR J PHARMACOL, V406, pR5, DOI 10.1016/S0014-2999(00)00653-1; Hampson AJ, 1998, P NATL ACAD SCI USA, V95, P8268, DOI 10.1073/pnas.95.14.8268; Hansen HH, 2001, J NEUROCHEM, V78, P1415, DOI 10.1046/j.1471-4159.2001.00542.x; Hansen HS, 2002, PHARMACOL THERAPEUT, V95, P119, DOI 10.1016/S0163-7258(02)00251-6; Hanus L, 1999, P NATL ACAD SCI USA, V96, P14228, DOI 10.1073/pnas.96.25.14228; Herring AC, 1999, J PHARMACOL EXP THER, V291, P1156; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Leker RR, 2003, STROKE, V34, P2000, DOI 10.1161/01.STR.0000079817.68944.1E; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Mackie K, 2006, ANNU REV PHARMACOL, V46, P101, DOI 10.1146/annurev.pharmtox.46.120604.141254; Malek S, 2001, J BIOL CHEM, V276, P45225, DOI 10.1074/jbc.M105865200; Marsicano G, 2006, J Endocrinol Invest, V29, P27; McCarron RM, 2006, J PHYSIOL PHARMACOL, V57, P133; MCCARRON RM, 2003, ACTA NEUROCHIR SUPP, V86, P871; Mechoulam R, 2002, TRENDS MOL MED, V8, P58, DOI 10.1016/S1471-4914(02)02276-1; Milman G, 2006, P NATL ACAD SCI USA, V103, P2428, DOI 10.1073/pnas.0510676103; Molina-Holgado F, 2003, J NEUROSCI, V23, P6470; Mori T, 2002, J NEUROTRAUM, V19, P1411, DOI 10.1089/089771502320914642; Moro MA, 2003, NEUROSIGNALS, V12, P53, DOI 10.1159/000071814; Nagayama T, 1999, J NEUROSCI, V19, P2987; Pacher P, 2006, PHARMACOL REV, V58, P389, DOI 10.1124/pr.58.3.2; Panikashvili D, 2006, NEUROBIOL DIS, V22, P257, DOI 10.1016/j.nbd.2005.11.004; Panikashvili D, 2005, J CEREBR BLOOD F MET, V25, P477, DOI 10.1038/sj.jcbfm.9600047; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; Parmentier-Batteur S, 2002, J NEUROSCI, V22, P9771, DOI 10.1523/jneurosci.22-22-09771.2002; PIOMELLI D, 2005, CURR OPIN INVEST DR, V6, P622; Sancho R, 2003, MOL PHARMACOL, V63, P429, DOI 10.1124/mol.63.2.429; Shohami E, 2000, DRUG DEVELOP RES, V50, P211, DOI 10.1002/1098-2299(200007/08)50:3/4<211::AID-DDR3>3.0.CO;2-G; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; SHOHAMI E, 1989, J NEUROCHEM, V53, P1541, DOI 10.1111/j.1471-4159.1989.tb08550.x; SOFIA RD, 1974, LIFE SCI, V15, P251; Trembovler V, 1999, J INTERF CYTOK RES, V19, P791, DOI 10.1089/107999099313640; van der Stelt M, 2002, MOL NEUROBIOL, V26, P317, DOI 10.1385/MN:26:2-3:317; Vollgraf U, 1999, J NEUROCHEM, V73, P2501, DOI 10.1046/j.1471-4159.1999.0732501.x; von Gertten C, 2003, J NEUROSCI RES, V73, P803, DOI 10.1002/jnr.10729; Walter L, 2004, BRIT J PHARMACOL, V141, P775, DOI 10.1038/sj.bjp.0705667; Zimmer A, 1999, P NATL ACAD SCI USA, V96, P5780, DOI 10.1073/pnas.96.10.5780; Zingarelli B, 2003, CRIT CARE MED, V31, pS105, DOI 10.1097/00003246-200301001-00015	49	79	79	0	6	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0893-7648	1559-1182		MOL NEUROBIOL	Mol. Neurobiol.	AUG	2007	36	1					68	74		10.1007/s12035-007-8008-6			7	Neurosciences	Neurosciences & Neurology	219XI	WOS:000250121100008	17952651				2021-06-18	
J	Darrow, KN; Maison, SF; Liberman, MC				Darrow, Keith N.; Maison, Stephane F.; Liberman, M. Charles			Selective removal of lateral olivocochlear efferents increases vulnerability to acute acoustic injury	JOURNAL OF NEUROPHYSIOLOGY			English	Article							GUINEA-PIG COCHLEA; INDUCED HEARING-LOSS; NICOTINIC ACETYLCHOLINE-RECEPTORS; AUDITORY-NERVE ACTIVITY; HAIR CELL AFFERENTS; MIDDLE-EAR MUSCLES; BRAIN-STEM; SUPERIOR OLIVE; ELECTRICAL-STIMULATION; INFERIOR COLLICULUS	Cochlear sensory cells and neurons receive efferent feedback from the olivocochlear (OC) system. The myelinated medial component of the OC system and its effects on outer hair cells (OHCs) have been implicated in protection from acoustic injury. The unmyelinated lateral (L) OC fibers target ipsilateral cochlear nerve dendrites and pharmacological studies suggest the LOC's dopaminergic component may protect these dendrites from excitotoxic effects of acoustic overexposure. Here, we explore LOC function in vivo by selective stereotaxic destruction of LOC cell bodies in mouse. Lesion success in removing the LOC, and sparing the medial (M) OC, was assessed by histological analysis of brain stem sections and cochlear whole mounts. Auditory brain stem responses (ABRs), a neural-based metric, and distortion product otoacoustic emissions (DPOAEs), an OHC-based metric, were measured in control and surgical mice. In cases where the LOC was at least partially destroyed, there were increases in suprathreshold neural responses that were frequency- and level-independent and not attributable to OHC-based effects. These interaural response asymmetries were not found in controls or in cases where the lesion missed the LOC. In LOC-lesion cases, after exposure to a traumatic stimulus, temporary threshold shifts were greater in the ipsilateral ear, but only when measured in the neural response; OHC-based measurements were always bilaterally symmetric, suggesting OHC vulnerability was unaffected. Interaural asymmetries in threshold shift were not found in either unlesioned controls or in cases that missed the LOC. These findings suggest that the LOC modulates cochlear nerve excitability and protects the cochlea from neural damage in acute acoustic injury.	Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA USA; Harvard Univ, Div Hlth Sci & Technol, Program Speech & Hearing Biosci & Technol, Cambridge, MA USA; MIT, Cambridge, MA USA	Liberman, MC (corresponding author), Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, 243 Charles St, Boston, MA 02114 USA.	Charles_Liberman@meei.harvard.edu			NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [P30DC005209, T32DC000038, R01DC000188] Funding Source: NIH RePORTER; NIDCD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [T32 DC000038, P30 DC 05209, T32 DC 0038, P30 DC005209, R01 DC 00188, R01 DC000188] Funding Source: Medline		ADAMS JC, 1995, J COMP NEUROL, V361, P645, DOI 10.1002/cne.903610408; Arnold T, 1998, HEARING RES, V125, P147, DOI 10.1016/S0378-5955(98)00144-0; Bailey GP, 2000, J NEUROSCI, V20, P5163; Bao JX, 2005, J NEUROSCI, V25, P3041, DOI 10.1523/JNEUROSCI.5277-04.2005; BROWN MC, 1987, J COMP NEUROL, V260, P605, DOI 10.1002/cne.902600412; BROWN MC, 1993, J COMP NEUROL, V337, P600, DOI 10.1002/cne.903370406; CAMPBELL JP, 1988, HEARING RES, V35, P271, DOI 10.1016/0378-5955(88)90124-4; CODY AR, 1985, NATURE, V315, P662, DOI 10.1038/315662a0; Cooper NP, 2003, J PHYSIOL-LONDON, V548, P307, DOI 10.1113/jphysiol.2003.039081; Dajas-Bailador F, 2004, TRENDS PHARMACOL SCI, V25, P317, DOI 10.1016/j.tips.2004.04.006; DALDIN C, 1995, HEARING RES, V90, P202, DOI 10.1016/0378-5955(95)00167-5; Darrow KN, 2006, J COMP NEUROL, V498, P403, DOI 10.1002/cne.21050; DARROW KN, IN PRESS NAT NEUROSC; EYBALIN M, 1993, PHYSIOL REV, V73, P309; Fay, 1996, COCHLEA, P435, DOI DOI 10.1007/978-1-4612-0757-3_8; FELIX D, 1992, HEARING RES, V64, P1, DOI 10.1016/0378-5955(92)90163-H; Franklin K. B. J., 1997, MOUSE BRAIN STEREOTA; Groff JA, 2003, J NEUROPHYSIOL, V90, P3178, DOI 10.1152/jn.00537.2003; HANDROCK M, 1982, ARCH OTO-RHINO-LARYN, V234, P191, DOI 10.1007/BF00453630; HENDERSON D, 1994, HEARING RES, V74, P22, DOI 10.1016/0378-5955(94)90172-4; Kelly JB, 1998, HEARING RES, V116, P43, DOI 10.1016/S0378-5955(97)00195-0; Kirk EC, 2003, JARO-J ASSOC RES OTO, V4, P445, DOI 10.1007/s10162-002-3013-y; Kujawa SG, 1997, J NEUROPHYSIOL, V78, P3095; Le Prell CG, 2005, JARO-J ASSOC RES OTO, V6, P48, DOI 10.1007/s10162-004-5009-2; Le Prell CG, 2004, J ACOUST SOC AM, V116, P1044, DOI 10.1121/1.1772395; Le Prell CG, 2003, JARO-J ASSOC RES OTO, V4, P276, DOI 10.1007/s10162-002-3018-6; Liberman M. C., 1982, NEW PERSPECTIVES NOI, P105; LIBERMAN MC, 1990, J COMP NEUROL, V301, P443, DOI 10.1002/cne.903010309; LIBERMAN MC, 1990, HEARING RES, V49, P209, DOI 10.1016/0378-5955(90)90105-X; Liberman MC, 1997, AUDIT NEUROSCI, V3, P255; LIBERMAN MC, 1984, HEARING RES, V16, P55, DOI 10.1016/0378-5955(84)90025-X; Maison SF, 2002, J NEUROSCI, V22, P10838; Maison SF, 2000, J NEUROSCI, V20, P4701, DOI 10.1523/JNEUROSCI.20-12-04701.2000; Maison SF, 2003, J NEUROPHYSIOL, V90, P2941, DOI 10.1152/jn.00596.2003; Maison SF, 2003, J COMP NEUROL, V455, P406, DOI 10.1002/cne.10490; Mills DM, 2003, J ACOUST SOC AM, V113, P914, DOI 10.1121/1.1535942; Mulders WHAM, 2004, HEARING RES, V187, P122, DOI 10.1016/S0378-5955(03)00308-3; Muller M, 2005, HEARING RES, V202, P63, DOI 10.1016/j.heares.2004.08.011; Murugasu E, 1996, J NEUROSCI, V16, P325; Oestreicher E, 1997, HEARING RES, V107, P46, DOI 10.1016/S0378-5955(97)00023-3; OSEN KK, 1969, BRAIN RES, V16, P165, DOI 10.1016/0006-8993(69)90092-4; PUEL JL, 1994, J COMP NEUROL, V341, P241, DOI 10.1002/cne.903410209; Puel JL, 1998, NEUROREPORT, V9, P2109, DOI 10.1097/00001756-199806220-00037; RAJAN R, 1988, J NEUROPHYSIOL, V60, P549; REITER ER, 1995, J NEUROPHYSIOL, V73, P506; ROBERTSON D, 1983, HEARING RES, V9, P263, DOI 10.1016/0378-5955(83)90031-X; Ruel J, 2001, EUR J NEUROSCI, V14, P977, DOI 10.1046/j.0953-816x.2001.01721.x; RYAN AF, 1994, HEARING RES, V72, P23, DOI 10.1016/0378-5955(94)90201-1; SAHLEY TL, 1991, HEARING RES, V55, P133, DOI 10.1016/0378-5955(91)90099-U; SHIBAYAMA H, 1990, Acta Anatomica Nipponica, V65, P120; Walsh EJ, 1998, J NEUROSCI, V18, P3859; Wang Y, 2002, JARO, V3, P248, DOI 10.1007/s101620020028; Warr WB, 1997, HEARING RES, V108, P89, DOI 10.1016/S0378-5955(97)00044-0; WINTER IM, 1990, HEARING RES, V45, P191, DOI 10.1016/0378-5955(90)90120-E; Zheng XY, 1999, J COMP NEUROL, V406, P72	55	79	80	0	5	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-3077			J NEUROPHYSIOL	J. Neurophysiol.	FEB	2007	97	2					1775	1785		10.1152/jn.00955.2006			11	Neurosciences; Physiology	Neurosciences & Neurology; Physiology	134NQ	WOS:000244090500071	17093118	Green Accepted			2021-06-18	
J	Korfias, S; Stranjalis, G; Boviatsis, E; Psachoulia, C; Jullien, G; Gregson, B; Mendelow, AD; Sakas, DE				Korfias, Stefanos; Stranjalis, George; Boviatsis, Efstathios; Psachoulia, Christina; Jullien, Gerard; Gregson, Barbara; Mendelow, A. David; Sakas, Damianos E.			Serum S-100B protein monitoring in patients with severe traumatic brain injury	INTENSIVE CARE MEDICINE			English	Article						S-100B protein; severe traumatic brain injury; traumatic brain injury; outcome	SEVERE HEAD-INJURY; COMPUTERIZED-TOMOGRAPHY; PREDICTOR; PATHOLOGY; PRESSURE; MARKER	Objective: S-100B protein is a promising marker of injury severity and outcome after head injury. We examined the relationship between serum S-100B concentrations and injury severity, clinical course, survival, and treatment efficacy after severe traumatic brain injury (TBI). Design and setting: Prospective observational study in a neurosurgical intensive care unit. Patients and participants: 102 adult patients with severe TBI, admitted between June 2001 and November 2003 (30 months). Interventions: Serum S-100B levels were measured by immunoluminometric technique on admission and every 24 h thereafter for a maximum of 7 days. Measurements and results: Initial S-100B levels were significantly related to pupillary status, computed tomography severity1, and 1-month survival. Cox's proportional hazard regression analysis showed that initial S-100B was an independent predictor of 1-month survival, in the presence of dilated pupils, and with increased age. Subjects with initial levels above 1 g/l had a nearly threefold increased probability of death within 1 month. Serum S-100B alteration indicated neurological improvement or deterioration. Finally, surgical treatment reduced S-100B levels. Conclusions: Serum S-100B protein reflects injury severity and improves prediction of outcome after severe TBI. S-100B may also have a role in assessing the efficacy of treatment after severe TBI.	Univ Newcastle Upon Tyne, Newcastle Gen Hosp, Dept Neurosurg, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England; Univ Athens, Evangelismos Gen Hosp, Dept Neurosurg, Athens 10676, Greece; Evangelismos Gen Hosp, Dept Biochem, Athens 10676, Greece	Korfias, S (corresponding author), Univ Newcastle Upon Tyne, Newcastle Gen Hosp, Dept Neurosurg, Westgate Rd, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England.	Stefanos.Korfias@NUTH.NHS.UK		Gregson, Barbara/0000-0003-4868-9137			*AM ASS NEUR SURG, 2000, J NEUROTRAUM, V17, P463; Bullock MR, 1996, J NEUROTRAUM, V13, P661; Dimopoulou I, 2003, NEUROLOGY, V60, P947, DOI 10.1212/01.WNL.0000049931.77887.7F; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; INGEBRIGTSEN T, 1995, J NEUROL NEUROSUR PS, V59, P103, DOI 10.1136/jnnp.59.1.103-a; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; MARSHAK DR, 1990, PROG BRAIN RES, V86, P169; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; McKeating EG, 1998, ACT NEUR S, V71, P117; MOORE BW, 1965, BIOCHEM BIOPH RES CO, V19, P739, DOI 10.1016/0006-291X(65)90320-7; Petzold A, 2002, CRIT CARE MED, V30, P2705, DOI 10.1097/00003246-200212000-00015; Raabe A, 1999, J NEUROSURG, V91, P875, DOI 10.3171/jns.1999.91.5.0875; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; Stranjalis G, 2004, J NEUROTRAUM, V21, P1070, DOI 10.1089/0897715041651088; TEASDALE G, 1975, LANCET, V1, P480; Townend WJ, 2002, J NEUROL NEUROSUR PS, V73, P542, DOI 10.1136/jnnp.73.5.542; Woertgen C, 1999, J TRAUMA, V47, P1126, DOI 10.1097/00005373-199912000-00026	18	79	82	0	1	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013 USA	0342-4642			INTENS CARE MED	Intensive Care Med.	FEB	2007	33	2					255	260		10.1007/s00134-006-0463-4			6	Critical Care Medicine	General & Internal Medicine	133QA	WOS:000244026200008	17143637				2021-06-18	
J	McKay, C; Casey, JE; Wertheimer, J; Fichtenberg, NL				McKay, Cherisse; Casey, Joseph E.; Wertheimer, Jeffrey; Fichtenberg, Norman L.			Reliability and validity of the RBANS in a traumatic brain injured sample	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						brain injury; RBANS	NEUROPSYCHOLOGICAL STATUS; REPEATABLE BATTERY; SENSITIVITY	The RBANS has become increasingly utilized, in various populations since it reliably assesses individual neurocognitive domains in a rapid, efficient manner. The present study examined the convergent validity of the RBANS to frequently administered instruments in a moderate-severe traumatic brain injured (M-S TBI) sample. Fifty-seven individuals who sustained a M-S TBI were included in this study. The RBANS subtests showed moderate to strong internal reliability within the sample. Most of the subtests displayed moderate to strong correlations with the other neuropsychological tests, including the CVLT-II, COWAT, and WAIS-III subtests. The strongest correlations were within the RBANS Attention Index, with both the Digit Span and Coding subtests showing strong correlations with their WAIS-III counterparts. The RBANS measures distinct abilities that supplement other neuropsychological instruments that assess similar functions within a TBI sample. In addition to its administration advantages, the results of this study provide support for the use of the RBANS as a clinical valid and reliable tool in the brief screening of individuals with M-S TBI. (c) 2006 Published by Elsevier Ltd on behalf of National Academy of Neuropsychology.	Univ Windsor, Windsor, ON N9B 3P4, Canada; Rehabil Inst Michigan, Detroit, MI USA; Wayne State Univ, Detroit, MI USA	McKay, C (corresponding author), Univ Windsor, Windsor, ON N9B 3P4, Canada.	cherissemckay@hotmail.com					Axelrod BN, 2001, CLIN NEUROPSYCHOL, V15, P516, DOI 10.1076/clin.15.4.516.1884; Axelrod BN, 2006, CLIN NEUROPSYCHOL, V20, P513, DOI 10.1080/13854040590967117; Beatty WW, 2004, ARCH CLIN NEUROPSYCH, V19, P825, DOI 10.1016/j.acn.2003.12.001; BENTON AL, 1974, REVISED BENTON VISUA; Benton AL, 1978, MULTILINGUAL APHASIA; Benton AL, 1983, JUDGMENT LINE ORIENT; CARONE, 2004, 32 M INT NEUR SOC; DELIS DC, 2000, CALIFORNIA VERBAL LE; Duff K, 2005, ARCH CLIN NEUROPSYCH, V20, P281, DOI 10.1016/j.acn.2004.07.007; Duff K, 2003, CLIN NEUROPSYCHOL, V17, P351, DOI 10.1076/clin.17.3.351.18082; Gold JM, 1999, AM J PSYCHIAT, V156, P1944; Gontkovsky ST, 2002, PSYCHOL REP, V90, P858, DOI 10.2466/PR0.90.3.858-860; Kaplan E., 1983, BOSTON NAMING TEST; Killam C, 2005, ARCH CLIN NEUROPSYCH, V20, P599, DOI 10.1016/j.acn.2005.02.001; Larson EB, 2005, J CLIN EXP NEUROPSYC, V27, P16, DOI 10.1080/138033990513564; Larson Eric B, 2003, Top Stroke Rehabil, V9, P10; MCKAY CM, UNPUB REPEATABLE BAT; Meyers J., 1995, REY COMPLEX FIGURE T; Moser RS, 2002, ARCH CLIN NEUROPSYCH, V17, P91, DOI 10.1016/S0887-6177(01)00108-1; *PSYCH CORP, 1997, WECHSL AD INT SCAL; Randolph C, 1998, J CLIN EXP NEUROPSYC, V20, P310, DOI 10.1076/jcen.20.3.310.823; RANDOLPH C, 1997, CLIN GERIATRICS, V5, P77; Tombaugh TN, 1996, TEST MEMORY MALINGER	23	79	84	1	13	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	JAN	2007	22	1					91	98		10.1016/j.acn.2006.11.003			8	Psychology, Clinical; Psychology	Psychology	144RV	WOS:000244814700010	17141467	Bronze			2021-06-18	
J	Ptito, A; Chen, JK; Johnston, KM				Ptito, Alain; Chen, Jen-Kai; Johnston, Karen M.			Contributions of functional Magnetic Resonance Imaging (fMRI) to sport concussion evaluation	NEUROREHABILITATION			English	Article						concussion; functional Magnetic Resonance Imaging (fMRI); post-concussive symptoms depression	TRAUMATIC BRAIN-INJURY; WORKING-MEMORY; ELECTROPHYSIOLOGICAL EVIDENCE; FRONTAL-CORTEX; HEAD-INJURY; DEPRESSION; PERFORMANCE; IMPAIRMENT; GUIDELINES; SYMPTOMS	Mild traumatic brain injury (mTBI) in contact sport is a problem of such magnitude that improved approaches to diagnosis, investigation and management are urgent. Concussion has traditionally been described as a transient, fully reversible, cerebral dysfunction. However, this seemingly 'mild' injury sometimes results in long-lasting and disabling post-concussion symptoms (PCS) and abnormal neuropsychological profiles characteristic of frontal and/or temporal lobe dysfunction. At present, the pathological changes following concussion remain unclear, but it is now widely accepted that concussion results mainly in functional disturbance rather than structural damage. Therefore, functional imaging techniques can help in demonstrating brain abnormalities undetectable by structural imaging methods. This paper will review the use of functional magnetic resonance imaging (fMRI) in studies of concussion. Our existing and ongoing fMRI studies will be described as examples to highlight the potential and contribution of this non-invasive functional neuroimaging technique in the assessment of sports-related concussion and its management.	McGill Univ, Montreal Neurol Inst, Neuropsychol Dept, Cognit Neurosci Unit, Montreal, PQ H3A 2B4, Canada; Univ Toronto, Concuss Clin Neurorehabil Program, Toronto Rehabil Div Neurosurg, Toronto, ON, Canada	Ptito, A (corresponding author), McGill Univ, Montreal Neurol Inst, Neuropsychol Dept, Cognit Neurosci Unit, 3801 Univ St, Montreal, PQ H3A 2B4, Canada.	alain.ptito@mcgill.ca					ANDERSON SD, 1995, CAN J DIAGN, V12, P77; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Aubry Mark, 2002, Phys Sportsmed, V30, P57, DOI 10.3810/psm.2002.02.176; Cantu R, 2004, LANCET NEUROL, V3, P437; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Cantu RC, 1998, CLIN SPORT MED, V17, P45, DOI 10.1016/S0278-5919(05)70060-0; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Chen JK, 2004, CLIN J SPORT MED, V14, P379; CHEN JK, 2006, SEVERITY DEPRESSION; CHEN JK, IN PRESS ARCH GEN PS; CHEN JK, 2007, IN PRESS J NEUROL NE; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Deb S, 1998, J NEUROL NEUROSUR PS, V65, P899, DOI 10.1136/jnnp.65.6.899; Drevets WC, 1999, ANN NY ACAD SCI, V877, P614, DOI 10.1111/j.1749-6632.1999.tb09292.x; Duncan J, 2000, TRENDS NEUROSCI, V23, P475, DOI 10.1016/S0166-2236(00)01633-7; Dupuis F, 2000, NEUROREPORT, V11, P4087, DOI 10.1097/00001756-200012180-00035; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Gould RL, 2003, NEUROIMAGE, V20, P1006, DOI 10.1016/S1053-8119(03)00365-3; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; Guskiewicz KM, 2002, AM J SPORT MED, V30, P157, DOI 10.1177/03635465020300020201; HEINZE HJ, 1992, NEUROPSYCHOLOGIA, V30, P495, DOI 10.1016/0028-3932(92)90054-P; Honey CR, 1998, CLIN J SPORT MED, V8, P43, DOI 10.1097/00042752-199801000-00010; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; Johnston Karen M, 2004, Curr Sports Med Rep, V3, P316; Johnston KM, 2001, CLIN J SPORT MED, V11, P150, DOI 10.1097/00042752-200107000-00005; Johnston KM, 2000, CLIN J SPORT MED, V10, P209; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; KARZMARK P, 1995, BRAIN INJURY, V9, P21, DOI 10.3109/02699059509004567; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Leclerc S, 2001, SPORTS MED, V31, P629, DOI 10.2165/00007256-200131080-00007; Levin HS, 2005, ARCH GEN PSYCHIAT, V62, P523, DOI 10.1001/archpsyc.62.5.523; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; Liotti M, 2000, BIOL PSYCHIAT, V48, P30, DOI 10.1016/S0006-3223(00)00874-X; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; Matser JT, 2001, J CLIN EXP NEUROPSYC, V23, P770, DOI 10.1076/jcen.23.6.770.1029; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McCrory Paul, 2005, Clin J Sport Med, V15, P48; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; *NIH, 1998, NAT I HLTH CONS STAT, V15; PETRIDES M, 1982, NEUROPSYCHOLOGIA, V20, P249, DOI 10.1016/0028-3932(82)90100-2; Petrides M, 1995, ANN NY ACAD SCI, V769, P85, DOI 10.1111/j.1749-6632.1995.tb38133.x; PETRIDES M, 1991, P ROY SOC B-BIOL SCI, V246, P293, DOI 10.1098/rspb.1991.0157; PETRIDES M, 1995, J NEUROSCI, V15, P359; PETRIDES M, 1994, HDB NEUROPSYCHOLOGY, V9, P59; PIKE GB, 2000, PAIN IMAGING PROGR P, V18; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; Rose EJ, 2006, NEUROIMAGE, V29, P203, DOI 10.1016/j.neuroimage.2005.07.002; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Umile EM, 2002, ARCH PHYS MED REHAB, V83, P1506, DOI 10.1053/apmr.2002.35092	53	79	79	1	15	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2007	22	3					217	227					11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	216NM	WOS:000249884800008	17917172				2021-06-18	
J	Savaskan, NE; Rocha, L; Kotter, MR; Baer, A; Lubec, G; van Meeteren, LA; Kishi, Y; Aoki, J; Moolenaar, WH; Nitsch, R; Brauer, AU				Savaskan, N. E.; Rocha, L.; Kotter, M. R.; Baer, A.; Lubec, G.; van Meeteren, L. A.; Kishi, Y.; Aoki, J.; Moolenaar, W. H.; Nitsch, R.; Braeuer, A. U.			Autotaxin (NPP-2) in the brain: cell type-specific expression and regulation during development and after neurotrauma	CELLULAR AND MOLECULAR LIFE SCIENCES			English	Article						LPA signaling; S1P; axonal growth and regeneration; hippocampus; brain development; G protein-coupled receptors; myelination; oligodendrocyte precursor cells	NUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE FAMILY; LYSOPHOSPHATIDIC ACID PRODUCTION; LYSOPHOSPHOLIPASE-D; RAT-BRAIN; PHOSPHODIESTERASE-I; CEREBROSPINAL-FLUID; CEREBRAL-ISCHEMIA; CATALYTIC SITE; LPA RECEPTORS; IDENTIFICATION	Autotaxin is a secreted cell motility-stimulating exo-phosphodiesterase with lysophospholipase D activity that generates bioactive lysophosphatidic acid. Lysophosphatidic acid has been implicated in various neural cell functions such as neurite remodeling, demyelination, survival and inhibition of axon growth. Here, we report on the in vivo expression of autotaxin in the brain during development and following neurotrauma. We found that autotaxin is expressed in the proliferating subventricular and choroid plexus epithelium during embryonic development. After birth, autotaxin is mainly found in white matter areas in the central nervous system. In the adult brain, autotaxin is solely expressed in leptomeningeal cells and oligodendrocyte precursor cells. Following neurotrauma, autotaxin is strongly up-regulated in reactive astrocytes adjacent to the lesion. The present study revealed the cellular distribution of autotaxin in the developing and lesioned brain and implies a function of autotaxin in oligodendrocyte precursor cells and brain injuries.	Netherlands Canc Inst, Div Cellular Biochem, Amsterdam, Netherlands; Charite Univ Med Berlin, Ctr Anat, Inst Cell Biol & Neurobiol, D-10115 Berlin, Germany; Med Univ Vienna, AKH, BrainProt Neuroprotect Neuroregenerat Lab, Dept Neurosurg, Vienna, Austria; Univ Tokyo, Grad Sch Pharmaceut Sci, PRESTO, Japan Sci & Technol Agcy, Tokyo, Japan	Savaskan, NE (corresponding author), Netherlands Canc Inst, Div Cellular Biochem, Plesmanlaan 121, Amsterdam, Netherlands.	n.savaskan@nki.nl; anja.braeuer@charite.de	Braeuer, Anja/K-8339-2013; Messier, Claude/A-2322-2008; van Meeteren, Laurens/A-9890-2008; Brauer, Anja/N-3692-2019; Nitsch, Robert/AAI-9129-2021; Savaskan, Nicolai/D-2923-2018	Messier, Claude/0000-0002-4791-1763; van Meeteren, Laurens/0000-0001-9885-0668; Lubec, Gert/0000-0002-6333-9461; Aoki, Junken/0000-0001-9435-1896; Savaskan, Nicolai/0000-0003-1348-094X; Kotter, Mark/0000-0001-5145-7199	Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [18013018, 18050009] Funding Source: KAKEN		Acarin L, 2001, STROKE, V32, P2394, DOI 10.1161/hs1001.097243; Anliker B, 2004, J BIOL CHEM, V279, P20555, DOI 10.1074/jbc.R400013200; Aoki J, 2004, SEMIN CELL DEV BIOL, V15, P477, DOI 10.1016/j.semcdb.2004.05.001; Bachner D, 1999, MECH DEVELOP, V84, P121, DOI 10.1016/S0925-4773(99)00048-9; Baumforth KRN, 2005, BLOOD, V106, P2138, DOI 10.1182/blood-2005-02-0471; Bollen M, 2000, CRIT REV BIOCHEM MOL, V35, P393, DOI 10.1080/10409230091169249; Brauer AU, 2004, FEBS LETT, V563, P41, DOI 10.1016/S0014-5793(04)00244-3; Brauer AU, 2003, NEUROSCIENCE, V121, P111, DOI 10.1016/S0306-4522(03)00336-1; Clair T, 2003, CANCER RES, V63, P5446; Colognato H, 2004, J CELL BIOL, V167, P365, DOI 10.1083/jcb.200404076; Corcoran DL, 2005, GENOME RES, V15, P840, DOI 10.1101/gr.2952005; DAS AK, 1989, LIPIDS, V24, P329, DOI 10.1007/BF02535172; Dawson J, 2003, J NEUROCHEM, V87, P947, DOI 10.1046/j.1471-4159.2003.02056.x; Dehn D, 2006, GLIA, V53, P491, DOI 10.1002/glia.20307; Dennis J, 2005, J NEUROSCI RES, V82, P737, DOI 10.1002/jnr.20686; Duan RD, 2003, J BIOL CHEM, V278, P38528, DOI 10.1074/jbc.M305437200; Fox MA, 2004, MOL CELL NEUROSCI, V27, P140, DOI 10.1016/j.mcn.2004.06.002; Fox MA, 2003, MOL CELL NEUROSCI, V23, P507, DOI 10.1016/S1044-7431(03)00073-3; Fukushima N, 2000, DEV BIOL, V228, P6, DOI 10.1006/dbio.2000.9930; Fukushima N, 2001, PROSTAG OTH LIPID M, V64, P21, DOI 10.1016/S0090-6980(01)00105-8; Fuss B, 1997, J NEUROSCI, V17, P9095; Gijsbers R, 2003, FEBS LETT, V538, P60, DOI 10.1016/S0014-5793(03)00133-9; Goding JW, 1998, IMMUNOL REV, V161, P11, DOI 10.1111/j.1600-065X.1998.tb01568.x; Goding JW, 2003, BBA-MOL BASIS DIS, V1638, P1, DOI 10.1016/S0925-4439(03)00058-9; Hama K, 2004, J BIOL CHEM, V279, P17634, DOI 10.1074/jbc.M313927200; Hama K, 2002, FEBS LETT, V523, P187, DOI 10.1016/S0014-5793(02)02976-9; Hammack BN, 2004, MULT SCLER, V10, P245, DOI 10.1191/1352458504ms1023oa; Holtsberg FW, 1998, J NEUROCHEM, V70, P66; Inoue M, 2004, NAT MED, V10, P712, DOI 10.1038/nm1060; Ishii I, 2004, ANNU REV BIOCHEM, V73, P321, DOI 10.1146/annurev.biochem.73.011303.073731; Jansen S, 2005, J CELL SCI, V118, P3081, DOI 10.1242/jcs.02438; Kingsbury MA, 2003, NAT NEUROSCI, V6, P1292, DOI 10.1038/nn1157; KINOUCHI H, 1990, MOL CHEM NEUROPATHOL, V12, P215, DOI 10.1007/BF03159946; Kishi Y, 2006, J BIOL CHEM, V281, P17492, DOI 10.1074/jbc.M601803200; Koh E, 2003, CANCER RES, V63, P2042; Koike S, 2006, GENES CELLS, V11, P133, DOI 10.1111/j.1365-2443.2006.00924.x; Kusaka S, 1998, J PHYSIOL-LONDON, V506, P445, DOI 10.1111/j.1469-7793.1998.445bw.x; Lee HY, 1996, J BIOL CHEM, V271, P24408, DOI 10.1074/jbc.271.40.24408; Lee HY, 2002, FEBS LETT, V515, P137, DOI 10.1016/S0014-5793(02)02457-2; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; Meier S, 2004, CELL MOL LIFE SCI, V61, P1082, DOI 10.1007/s00018-004-3469-5; Meier S, 2003, FASEB J, V17, P1153, DOI 10.1096/fj.02-0453fje; Mills GB, 2003, NAT REV CANCER, V3, P582, DOI 10.1038/nrc1143; Moolenaar WH, 2004, BIOESSAYS, V26, P870, DOI 10.1002/bies.20081; Nam SW, 2000, ONCOGENE, V19, P241, DOI 10.1038/sj.onc.1203263; NARITA M, 1994, J BIOL CHEM, V269, P28235; Ness JK, 2005, GLIA, V50, P321, DOI 10.1002/glia.20206; Ohe Y, 2003, BIOCHEM BIOPH RES CO, V308, P719, DOI 10.1016/S0006-291X(03)01454-2; PAXINOS G, 1985, J NEUROSCI METH, V13, P139, DOI 10.1016/0165-0270(85)90026-3; Ramakers GJA, 1998, EXP CELL RES, V245, P252, DOI 10.1006/excr.1998.4224; REYNOLDS R, 1988, DEVELOPMENT, V102, P409; Sakagami H, 2005, J BIOL CHEM, V280, P23084, DOI 10.1074/jbc.M413438200; Sato K, 2005, J NEUROCHEM, V92, P904, DOI 10.1111/j.1471-4159.2004.02933.x; Sayas CL, 1999, J BIOL CHEM, V274, P37046, DOI 10.1074/jbc.274.52.37046; Schilling T, 2004, J PHYSIOL-LONDON, V557, P105, DOI 10.1113/jphysiol.2004.060632; Siess W, 1999, P NATL ACAD SCI USA, V96, P6931, DOI 10.1073/pnas.96.12.6931; Stefan C, 2005, TRENDS BIOCHEM SCI, V30, P542, DOI 10.1016/j.tibs.2005.08.005; Stefan C, 1999, BBA-MOL CELL RES, V1450, P45, DOI 10.1016/S0167-4889(99)00031-2; STRACKE ML, 1992, J BIOL CHEM, V267, P2524; Sugiura T, 1999, BBA-MOL CELL BIOL L, V1440, P194, DOI 10.1016/S1388-1981(99)00127-4; Sugiura T, 2002, J LIPID RES, V43, P2049, DOI 10.1194/jlr.M200242-JLR200; Sun GY, 2004, J NEUROCHEM, V88, P40; Tanaka M, 2006, J BIOL CHEM, V281, P25822, DOI 10.1074/jbc.M605142200; TIGYI G, 1995, AM J PHYSIOL-HEART C, V268, pH2048; Tigyi G, 2003, PROG LIPID RES, V42, P498, DOI 10.1016/S0163-7827(03)00035-3; Tokumura A, 2002, J BIOL CHEM, V277, P39436, DOI 10.1074/jbc.M205623200; Tokumura A, 1999, LIFE SCI, V65, P245, DOI 10.1016/S0024-3205(99)00243-X; TOKUMURA A, 1986, BIOCHIM BIOPHYS ACTA, V875, P31; Umemura K, 2006, NEUROSCI LETT, V400, P97, DOI 10.1016/j.neulet.2006.02.008; Umezu-Goto M, 2002, J CELL BIOL, V158, P227, DOI 10.1083/jcb.200204026; van Meeteren LA, 2005, J BIOL CHEM, V280, P21155, DOI 10.1074/jbc.M413183200; van Meeteren LA, 2006, MOL CELL BIOL, V26, P5015, DOI 10.1128/MCB.02419-05; Weiner JA, 1998, J COMP NEUROL, V398, P587; Wilhelmsson U, 2004, J NEUROSCI, V24, P5016, DOI 10.1523/JNEUROSCI.0820-04.2004; Wu VW, 1998, J NEUROCHEM, V71, P749; Xie Y, 2002, CHIN J INORG CHEM, V18, P1; Xu Y, 1995, CLIN CANCER RES, V1, P1223	77	79	81	0	4	BIRKHAUSER VERLAG AG	BASEL	VIADUKSTRASSE 40-44, PO BOX 133, CH-4010 BASEL, SWITZERLAND	1420-682X			CELL MOL LIFE SCI	Cell. Mol. Life Sci.	JAN	2007	64	2					230	243		10.1007/s00018-006-6412-0			14	Biochemistry & Molecular Biology; Cell Biology	Biochemistry & Molecular Biology; Cell Biology	128IF	WOS:000243650700013	17192809				2021-06-18	
J	Maniker, AH; Vaynman, AY; Karimi, RJ; Sabit, AO; Holland, B				Maniker, Allen H.; Vaynman, Artem Y.; Karimi, Reza J.; Sabit, Aria O.; Holland, Bart			Hemorrhagic complications of external ventricular drainage	NEUROSURGERY			English	Article						complications; drain; hematoma; intracerebral; ventricular	INTRACRANIAL-PRESSURE MONITORS; INTRACEREBRAL HEMORRHAGE; INTRAVENTRICULAR HEMORRHAGE; INFECTIOUS COMPLICATIONS; CEREBROSPINAL-FLUID; CONTROLLED-TRIAL; BLOOD-PRESSURE; DOUBLE-BLIND; HYDROCEPHALUS; VENTRICULOSTOMIES	OBJECTIVE: Despite the widespread use of external ventricular drainage (EVD), the frequency of associated hemorrhagic complications remains unclear. This retrospective study examined the frequency of hemorrhagic complications of EVD and attempted to discern associated risk factors. METHODS: Treatment records from 160 patients admitted during a 2.5-year period who required EVD placement were reviewed. Indications for placement of EVD included acute complications of cerebrovascular disease (n = 94), traumatic brain injury (n = 36), primary hydrocephalus (n = 16), and tumor (n =14). Patients received either a 3.0 or 2.5-mm outer diameter ventricular catheter (n = 82 and 78, respectively). Postinsertion computed tomographic scans were obtained within 24 hours on all patients and were analyzed for any new hemorrhage related to the ventricular catheter. Patient age, sex, catheter type, and dimensions of hemorrhage were also analyzed. RESULTS: The incidence of EVD-related hemorrhage was 33 +/- 0.04%. However, the incidence of detectable change in the clinical neurological examination was 2.5%. A significant proportion of EVD-related hemorrhages were small (< 4 CM), punctate, intraparenchymal hematomas. Patients with cerebrovascular exhibited an increased incidence (39%) of hemorrhage. The mean volume of intraparenchymal hemorrhage was larger in patients who received the 2.5-mm ventricular catheter, as well as those admitted for cerebrovascular disease. CONCLUSION: Hemorrhagic complications of EVD, placement are more common than previously suspected. Admitting diagnosis seems to have an effect on the development of an associated hemorrhage and its size. Catheter gauge has. an effect on hematoma volume. Most of the hemorrhages seen on, postinsertion computed tomographic scans do not cause detectable changes in the clinical examination.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Prevent Med & Community Hlth, Newark, NJ 07103 USA	Maniker, AH (corresponding author), Doctors Off Complex,90 Bergen St,8th Floor, Newark, NJ 07103 USA.	maniker@umdnj.edu					Anderson RCE, 2004, J NEUROSURG, V101, P53, DOI 10.3171/ped.2004.101.2.0053; AUCOIN PJ, 1986, AM J MED, V80, P369, DOI 10.1016/0002-9343(86)90708-4; Blaha M, 2003, PEDIATR NEUROSURG, V39, P27, DOI 10.1159/000070877; BLOMSTEDT GC, 1985, J NEUROSURG, V62, P694, DOI 10.3171/jns.1985.62.5.0694; Butcher K, 2003, J CLIN NEUROSCI, V10, P158, DOI 10.1016/S0967-5868(02)00324-7; CHAN KH, 1988, NEUROSURGERY, V23, P436, DOI 10.1227/00006123-198810000-00005; Forbes KP, 2003, NEURORADIOLOGY, V45, P363, DOI 10.1007/s00234-003-0995-z; Guyot LL, 1998, ACT NEUR S, V71, P47; Hader WJ, 2000, NEUROSURGERY, V46, P1149, DOI 10.1097/00006123-200005000-00025; Hoff JT, 2003, ACT NEUR S, V86, P11; KANTER RK, 1985, CRIT CARE MED, V13, P837, DOI 10.1097/00003246-198510000-00012; Khan SH, 1998, ACT NEUR S, V71, P50; KHANNA RK, 1995, J NEUROSURG, V83, P791, DOI 10.3171/jns.1995.83.5.0791; Lane PL, 2000, CAN J SURG, V43, P442; Lozier AP, 2002, NEUROSURGERY, V51, P170, DOI 10.1097/00006123-200207000-00024; Maitinez-Manas RM, 2000, J NEUROL NEUROSUR PS, V69, P82, DOI 10.1136/jnnp.69.1.82; Maruishi M, 2001, NEUROL MED-CHIR, V41, P300, DOI 10.2176/nmc.41.300; MAYFRANK L, 1994, ACTA NEUROCHIR, V126, P201; MAYFRANK L, 1993, ACTA NEUROCHIR, V122, P32, DOI 10.1007/BF01446983; Naff NJ, 2004, NEUROSURGERY, V54, P577, DOI 10.1227/01.NEU.0000108422.10842.60; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; NORTH B, 1986, NEUROSURGERY, V18, P730, DOI 10.1227/00006123-198606000-00009; Pfausler B, 2004, ACTA NEUROCHIR, V146, P477, DOI 10.1007/s00701-004-0258-8; PIETS C, 1989, AM J CARDIOL, V63, pC40; Rasool AHG, 2004, J HUM HYPERTENS, V18, P187, DOI 10.1038/sj.jhh.1001647; RHODES TT, 1987, PEDIATR NEUROSCI, V13, P255, DOI 10.1159/000120339; Roitberg BZ, 2001, BRIT J NEUROSURG, V15, P324; Ross IB, 2003, AM J NEURORADIOL, V24, P1528; Rossi S, 1998, ACT NEUR S, V71, P91; Sumer MM, 2002, NEUROL SCI, V23, P29, DOI 10.1007/s100720200020; TOUHO H, 1991, Neurologia Medico-Chirurgica, V31, P396, DOI 10.2176/nmc.31.396; Whitehead WE, 2001, PEDIATR NEUROSURG, V35, P205, DOI 10.1159/000050422; Wiesmann M, 2001, J CLIN NEUROSCI, V8, P126, DOI 10.1054/jocn.2000.0749; WINFIELD JA, 1993, NEUROSURGERY, V33, P424; Zabramski JM, 2003, J NEUROSURG, V98, P725, DOI 10.3171/jns.2003.98.4.0725; Zhong J, 2003, NEUROL RES, V25, P339, DOI 10.1179/016164103101201661	36	79	80	0	2	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	OCT	2006	59	4		S			419	424		10.1227/01.NEU.0000222817.99752.E6			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	097AV	WOS:000241419500046					2021-06-18	
J	Baguley, IJ; Heriseanu, RE; Felmingham, KL; Cameron, ID				Baguley, Ian J.; Heriseanu, Roxana E.; Felmingham, Kim L.; Cameron, Ian D.			Dysautonomia and heart rate variability following severe traumatic brain injury	BRAIN INJURY			English	Article						traumatic brain injury; dysautonomia; heart rate variability	SPECTRAL-ANALYSIS; DIENCEPHALIC SEIZURES; CIRCADIAN-RHYTHM; DEATH	Primary objective: To investigate disconnection theories postulated as the cause of dysautonomia following severe traumatic brain injury (TBI) through analysis of heart rate variability (HRV). Methods and procedures: Data were collected on age-matched subjects with and without dysautonomia ( eight subjects in each group) and 16 non-injured controls. Data included injury details, continuous electrocardiograph recordings and rehabilitation outcome. Main outcomes and results: The TBI group revealed significant differences in HRV parameters both compared to controls and between dysautonomic and non-dysautonomic subjects. Additionally, HRV parameters for dysautonomic subjects showed evidence of an uncoupling of the normal relationship between heart rate and sympathetic/parasympathetic balance. HRV changes persisted for the dysautonomia group for a mean of 14 months post-injury. Conclusions: Dysautonomic subjects revealed prolonged uncoupling of heart rate and HRV parameters compared to non-dysautonomic subjects and controls. These findings represent direct	Westmead Hosp, Brain Injury Rehabil Serv, Westmead, NSW 2145, Australia; Univ Sydney, Rehabil Studies Unit, Sydney, NSW 2006, Australia	Baguley, IJ (corresponding author), Westmead Hosp, Brain Injury Rehabil Serv, POB 533, Westmead, NSW 2145, Australia.	ianb@biru.wsahs.nsw.gov.au	Baguley, Ian/AAM-5828-2021; Baguley, Ian J/K-6878-2013	Baguley, Ian J/0000-0001-5650-3705			ADINOFF B, 1992, PSYCHIAT RES, V41, P89, DOI 10.1016/0165-1781(92)90101-8; ALBENTOSA M, 1994, AQUACULTURE, V126, P315, DOI 10.1016/0044-8486(94)90048-5; ALIMELKKILA T, 1991, ACTA ANAESTH SCAND, V35, P436, DOI 10.1111/j.1399-6576.1991.tb03324.x; Baguley I, 2000, BRAIN INJURY, V14, P505; Baguley IJ, 1999, J NEUROL NEUROSUR PS, V67, P39, DOI 10.1136/jnnp.67.1.39; Baguley IJ, 2004, BRAIN INJURY, V18, P409, DOI 10.1080/02699050310001645775; BAGULEY IJ, 2005, BRAIN INJURY S1, V19, P84; Baillard C, 2002, CRIT CARE MED, V30, P306, DOI 10.1097/00003246-200202000-00007; BEKHEIT S, 1990, AM HEART J, V119, P79, DOI 10.1016/S0002-8703(05)80085-7; Biswas AK, 2000, CRIT CARE MED, V28, P3907, DOI 10.1097/00003246-200012000-00030; Boeve BF, 1998, MAYO CLIN PROC, V73, P148; BULLARD DE, 1987, ANN NEUROL, V21, P609, DOI 10.1002/ana.410210617; COUMEL P, 1991, EUR HEART J, V12, P412, DOI 10.1093/oxfordjournals.eurheartj.a059910; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; Goldsmith RL, 2000, CORONARY ARTERY DIS, V11, P129, DOI 10.1097/00019501-200003000-00007; Goldstein B, 1998, AM J PHYSIOL-REG I, V275, pR1287; GUZZETTI S, 1994, AM J PHYSIOL, V266, pH1112; HALLIWILL JR, 1992, AM J PHYSIOL, V262, pH1719; HORTNAGL H, 1980, INTENS CARE MED, V6, P169, DOI 10.1007/BF01757299; HUIKURI HV, 1990, AM J CARDIOL, V65, P391, DOI 10.1016/0002-9149(90)90308-N; Keller C, 1993, J Neurosci Nurs, V25, P349; King ML, 1997, BRAIN INJURY, V11, P445; Korpelainen JT, 1997, STROKE, V28, P2150, DOI 10.1161/01.STR.28.11.2150; Meglic B, 2001, CEREBROVASC DIS, V11, P2, DOI 10.1159/000047605; Novak V, 1995, Clin Auton Res, V5, P24, DOI 10.1007/BF01845495; Ori Z, 1992, Cardiol Clin, V10, P499; PRANZATELLI MR, 1991, J CHILD NEUROL, V6, P115, DOI 10.1177/088307389100600204; Rapenne T, 2001, J NEUROSURG ANESTH, V13, P260, DOI 10.1097/00008506-200107000-00016; Rossitch E Jr, 1988, Br J Neurosurg, V2, P471, DOI 10.3109/02688698809029601; SINGER DH, 1988, J ELECTROCARDIOL, V21, pS46, DOI 10.1016/0022-0736(88)90055-6; STRUM S, 2004, POST HEAD INJURY AUT; Thorley RR, 2001, ARCH PHYS MED REHAB, V82, P246, DOI 10.1053/apmr.2001.18698; Vanravenswaaijarts CMA, 1993, ANN INTERN MED, V118, P436, DOI 10.7326/0003-4819-118-6-199303150-00008; Winchell RJ, 1997, J TRAUMA, V43, P927, DOI 10.1097/00005373-199712000-00010	34	79	82	0	7	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	APR	2006	20	4					437	444		10.1080/02699050600664715			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	045GN	WOS:000237730700008	16716989				2021-06-18	
J	Yurkewicz, L; Weaver, J; Bullock, MR; Marshall, LF				Yurkewicz, L; Weaver, J; Bullock, MR; Marshall, LF			The effect of the selective NMDA receptor antagonist traxprodil in the treatment of traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						neuroprotectant; NMDA receptor antagonist; traumatic brain injury	REGIONAL CEREBRAL EDEMA; ACUTE SUBDURAL-HEMATOMA; GLASGOW OUTCOME SCALE; SEVERE HEAD-INJURY; GLUTAMATE NEUROTOXICITY; CLINICAL-TRIALS; CP-101,606; RAT; ASPARTATE; DAMAGE	Traumatic brain injury (TBI) remains a major public health problem, and there is a great medical need for a pharmacological treatment that could improve long-term outcome. The excitatory neurotransmitter, glutamate, has been implicated in processes leading to neurodegeneration. Traxo- prodil (CP-101,606) is a novel and potent glutamate receptor antagonist that is highly selective for the NR2B subunit of the NMDA receptor; it has been shown to be neuroprotective in animal models of brain injury and ischemia. A randomized, double-blind, placebo-controlled study was therefore conducted to assess the efficacy and safety of a 72-h infusion of traxoprodil compared to placebo in subjects with computed tomography scan evidence of severe TBI (GCS 4-8). A total of 404 males and non-pregnant females, aged 16-70, were treated within 8 h of injury. At baseline, subjects were stratified by motor score severity. The results showed that a greater proportion of the traxoprodil-treated subjects had a favorable outcome on the dichotomized Glasgow Outcome Scale (dGOS) at 6 months (delta 5.5%, OR 1.3, p = 0.21, 95% Cl: [0.85, 2.06]) and at last visit (delta 7.5%, OR 1.47, p = 0.07, 95% CI:[0.97, 2.25]). The mortality rate with traxoprodil treatment was 7% less than with placebo treatment (OR 1.45, p = 0.08, 95% CI: [0.96, 2.18]). Differences between treatment groups were more pronounced in the severest subset (delta 11.8% for the dGOS at last visit and delta 16.6% for mortality). Traxoprodil was well tolerated. Although these results are intriguing, no definitive claim of efficacy can be made for traxoprodil for the treatment of severe TBI.	Pfizer, Global Res & Dev, CNS, Groton, CT 06340 USA; Pfizer Global Res & Dev, Groton, CT USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Neurosurg, Richmond, VA 23298 USA; Univ Calif San Diego, Ctr Med, Neurosurg Serv, San Diego, CA 92103 USA	Yurkewicz, L (corresponding author), Pfizer, Global Res & Dev, CNS, Eastern Point Rd, Groton, CT 06340 USA.	lorraine.yurkewicz@pfizer.com					*AANS, 1996, J NEUROTRAUM, V13, P640; Agresti A., 1990, CATEGORICAL DATA ANA; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; Bullock MR, 1999, ANN NY ACAD SCI, V890, P51, DOI 10.1111/j.1749-6632.1999.tb07980.x; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; CASAGRANDE JT, 1978, BIOMETRICS, V34, P483, DOI 10.2307/2530613; CHEN MH, 1991, J NEUROSURG, V74, P944, DOI 10.3171/jns.1991.74.6.0944; CHENARD BL, 1995, J MED CHEM, V38, P3138, DOI 10.1021/jm00016a017; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOI DW, 1987, J NEUROSCI, V7, P357; CHOI SC, 1995, CONTROL CLIN TRIALS, V16, P164, DOI 10.1016/0197-2456(94)00112-G; Di X, 1997, STROKE, V28, P2244, DOI 10.1161/01.STR.28.11.2244; Doppenberg EMR, 1997, J NEUROTRAUM, V14, P71, DOI 10.1089/neu.1997.14.71; Faden AI, 2001, ARCH NEUROL-CHICAGO, V58, P1553, DOI 10.1001/archneur.58.10.1553; Farin A, 2003, J NEUROSURG, V98, P32, DOI 10.3171/jns.2003.98.1.0032; FOSTER AC, 1988, J NEUROSCI, V8, P4745; Kemp JA, 2002, NAT NEUROSCI, V5, P1039, DOI 10.1038/nn936; KOCH GG, 1988, BIOPHARMACEUTICAL ST, P418; Levin HS, 2001, J NEUROTRAUM, V18, P575, DOI 10.1089/089771501750291819; Maas AIR, 2000, CNS DRUGS, V13, P139, DOI 10.2165/00023210-200013020-00007; MARAGOS WF, 1987, TRENDS NEUROSCI, V10, P65, DOI 10.1016/0166-2236(87)90025-7; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; Menniti F, 1997, EUR J PHARMACOL, V331, P117, DOI 10.1016/S0014-2999(97)10092-9; Menniti Frank S., 1998, CNS Drug Reviews, V4, P307; Menniti FS, 2000, NEUROPHARMACOLOGY, V39, P1147, DOI 10.1016/S0028-3908(99)00211-7; Merchant RE, 1999, ANN NY ACAD SCI, V890, P42, DOI 10.1111/j.1749-6632.1999.tb07979.x; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Okiyama K, 1998, BRAIN RES, V792, P291, DOI 10.1016/S0006-8993(98)00158-9; Okiyama K, 1997, J NEUROTRAUM, V14, P211, DOI 10.1089/neu.1997.14.211; Teng E L, 1994, Int Psychogeriatr, V6, P45, DOI 10.1017/S1041610294001602; *TRAUM COM DAT BAN, 1987, MAN OP; Tsuchida E, 1997, J NEUROTRAUM, V14, P409, DOI 10.1089/neu.1997.14.409; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; WOLF AL, 1993, J NEUROSURG, V78, P54, DOI 10.3171/jns.1993.78.1.0054	35	79	84	0	10	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	DEC	2005	22	12					1428	1443		10.1089/neu.2005.22.1428			16	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	000EA	WOS:000234442500006	16379581				2021-06-18	
J	Best, JP; McIntosh, AS; Savage, TN				Best, JP; McIntosh, AS; Savage, TN			Rugby World Cup 2003 injury surveillance project	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article								Objectives: To study match injury patterns and incidence during the Rugby World Cup 2003 (RWC 2003); to compare these patterns and rates with comparative rugby injury data; and to assess differences between teams playing at different levels ( eight finalists v 12 non-finalists). Methods: Data were collected prospectively during the tournament. All injuries were recorded by the 20 participating team physicians. These were submitted to the tournament medical officer. An injury was defined as an event which forced a player either to leave the field or to miss a subsequent game or both. Results: 189 injuries were recorded over 48 matches. This corresponds to 97.9 injuries per 1000 player-hours. Pool matches yielded a higher injury rate than non-pool matches. The 12 non-finalist teams sustained significantly higher injury rates than the eight finalist teams. The player positions open side flanker, inside centre, and number 8 were the most frequently injured positions. There was a low concussion rate, which may reflect under-reporting. The non-finalist teams had a higher rate of recurrent injury. Conclusions: The injury rate was higher than comparative data. Mismatches in the areas of skill, fitness, and the availability of resources for medical care of players may explain these differences.	Univ New S Wales, Sch Safety Sci, Sydney, NSW 2052, Australia; Australian Rugby Union, Sydney, NSW, Australia	McIntosh, AS (corresponding author), Univ New S Wales, Sch Safety Sci, Sydney, NSW 2052, Australia.	a.mcintosh@unsw.edu.au	Savage, Trevor N/C-5709-2019	Savage, Trevor N/0000-0001-6608-8664			Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bathgate A, 2002, BRIT J SPORT MED, V36, P265, DOI 10.1136/bjsm.36.4.265; BEST J, 2001, INJURIES 2001 21 RUG; FINCH C, 2002, PREVENTING RUGBY UNI; Garraway WM, 2000, BRIT J SPORT MED, V34, P348, DOI 10.1136/bjsm.34.5.348; Hawkins RD, 1996, BRIT J SPORT MED, V30, P165, DOI 10.1136/bjsm.30.2.165; *INT RUGB BOARD, 2003, INT RUGB BOARD LAW B; Jakoet I, 1998, S AFR MED J, V88, P45; Jones SJ, 2004, BRIT J SPORT MED, V38, P159, DOI 10.1136/bjsm.2002.002584; MCINTOSH AS, 2004, RUGBY UNION INJURY S; MILLAR S, 2003, IRB ANN REPORT; Targett SGR, 1998, CLIN J SPORT MED, V8, P280, DOI 10.1097/00042752-199810000-00005; THOMAS C, 2003, IRB ANN REPORT	13	79	81	0	19	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	NOV	2005	39	11					812	817		10.1136/bjsm.2004.016402			6	Sport Sciences	Sport Sciences	976HJ	WOS:000232723600011	16244189	Bronze, Green Published			2021-06-18	
J	Johnston, MV; Goverover, Y; Dijkers, M				Johnston, MV; Goverover, Y; Dijkers, M			Community activities and individuals' satisfaction with them: Quality of life in the first year after traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; outcome assessment (health care); program evaluation; quality of life; rehabilitation	SELF-IDENTIFIED GOALS; SYSTEMATIC BIAS; REHABILITATION; OUTCOMES; ACHIEVEMENT; INTEGRATION; MODELS; ADULTS; TBI	Objective: To investigate the relations between community activities and satisfaction with these activities, desires to change them. and global life satisfaction. Design: Interview Study with follow-up 1 month after rehabilitation discharge and 12 months postinjury. Setting: Community. Participants: One hundred sixty-two individuals hospitalized with mostly moderate-to-severe traumatic brain injury. About 90% were reached (mostly by phone) 1 month after rehabilitation discharge: 84.6%, at 12 months postinjury. Interventions: Not applicable. Main Outcome Measures: Community Integration Questionnaire-2. augmented by individuals' ratings of satisfaction or dissatisfaction with and desire to change each activity; and the Satisfaction With Life Scale. Results: Although significant correlations were found for some items. most correlations between activities and ratings of Global quality of life (QOL) were low and nonsignificant. Individuals reported that they were satisfied with most of their community activities, but there were exceptions (eg, paid work). Correlations between activity-specific satisfaction and General life satisfaction were Generally weak and nonsignificant. Dissatisfaction with an activity correlated strongly with desire to change the activity, but general life satisfaction did not con-elate With desire to change activities. Conclusions: The lack of association between frequency of activities and subjective appraisals of them is a challenge to outcomes measurement and has implications for the targeting of rehabilitative interventions and evaluation of their worth. More research is needed to understand how individualizing functional objectives might maximize the effects of rehabilitation on the QOL of persons served.	Kessler Med Rehabil Res & Educ Corp, W Orange, NJ 07052 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Phys Med & Rehabil, Newark, NJ 07103 USA; Mt Sinai Sch Med, New York, NY USA	Johnston, MV (corresponding author), Kessler Med Rehabil Res & Educ Corp, 1199 Pleasant Valley Way, W Orange, NJ 07052 USA.		Heinemann, Allen W/K-6283-2012	Heinemann, Allen W/0000-0003-2782-7326; Dijkers, Marcel/0000-0002-8362-5596			BANJA J, 1994, ARCH PHYS MED REHABI; Batavia A I, 1992, Disabil Rehabil, V14, P156; Bowling A., 1997, MEASURING HLTH REV Q, V2nd; Brown M, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199808000-00002; Brown M, 2000, BRAIN INJURY, V14, P5, DOI 10.1080/026990500120899; Burleigh SA, 1998, AM J OCCUP THER, V52, P45, DOI 10.5014/ajot.52.1.45; *COMM ACCR REH FAC, 2003, MED REH STAND MAN; Committee on Quality of Health Care in America Institute of Medicine, 2001, CROSS QUAL CHASM NEW; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P132, DOI 10.1016/S0003-9993(97)90253-7; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; Cox WM, 2003, J ADDICT DIS, V22, P93, DOI 10.1300/J069v22n01_07; DePalma J A, 2001, Crit Care Nurs Q, V23, P42; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dijkers M, 1999, AM J PHYS MED REHAB, V78, P286, DOI 10.1097/00002060-199905000-00022; Dijkers MP, 2003, ARCH PHYS MED REHAB, V84, pS3, DOI 10.1053/apmr.2003.50241; Felce D, 2000, BEHAVIORAL OBSERVATION, P159; FERRANS CE, 1992, RES NURS HLTH, V15, P19; FUHRER MJ, 1994, AM J PHYS MED REHAB, V73, P358, DOI 10.1097/00002060-199409000-00010; FUHRER MJ, 1987, REAHBILITATION OUTCO; FUHRER MJ, 1997, ASSESSING MED REHABI; GILL TM, 1994, JAMA-J AM MED ASSOC, V272, P619, DOI 10.1001/jama.272.8.619; GORDON WA, 1999, REHABILITATION ADULT, P312; Granger C. V., 1984, FUNCTIONAL ASSESSMEN; Granger CV, 1998, ARCH PHYS MED REHAB, V79, P235, DOI 10.1016/S0003-9993(98)90000-4; Granger CV, 2000, AM J PHYS MED REHAB, V79, P197, DOI 10.1097/00002060-200003000-00015; Granger CV, 2000, PHYS MED REHABILITAT, P151; Heinemann AW, 2002, ARCH PHYS MED REHAB, V83, P1052, DOI 10.1053/apmr.2002.34283; Hoofien D, 2001, BRAIN INJURY, V15, P189; JOHNSTON M V, 1991, Brain Injury, V5, P155, DOI 10.3109/02699059109008086; Johnston Mark, 2002, J Spinal Cord Med, V25, P11; Johnston MV, 2002, ARCH PHYS MED REHAB, V83, pS26, DOI 10.1053/apmr.2002.37100; JOHNSTON MV, 1997, ASSESSING MED REHABI, P1; JOYCE BM, 1994, AM J PHYS MED REHAB, V73, P10, DOI 10.1097/00002060-199473010-00003; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; Kreuter M, 1998, SPINAL CORD, V36, P252, DOI 10.1038/sj.sc.3100592; LAMAN H, 1994, DISABIL REHABIL, V16, P198, DOI 10.3109/09638289409166613; LOW M, 1990, CAN J OCCUP THER, V57, P82; MCCOLL MA, 2001, MEASURING OCCUPATION, P215; McNeny R., 1999, REHABILITATION ADULT, P242; Murawski M M, 1996, Med Interface, V9, P54; Patrick D., 1993, HLTH STATUS HLTH POL; Pavot W., 1993, PSYCHOL ASSESSMENT, V5, P164, DOI DOI 10.1037/1040-3590.5.2.164; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Seibert PS, 2002, BRAIN INJURY, V16, P837, DOI 10.1080/02699050210131939; Siegel S., 1998, NONPARAMETRIC STAT B, V2; Sprangers MAG., 2000, ADAPTATION CHANGING; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; Stineman MG, 2000, SCAND J REHABIL MED, V32, P143; Stineman MG, 2003, ARCH PHYS MED REHAB, V84, pS15, DOI 10.1053/apmr.2003.50242; Trombly CA, 1998, AM J OCCUP THER, V52, P810, DOI 10.5014/ajot.52.10.810; Trombly CA, 2002, AM J OCCUP THER, V56, P489, DOI 10.5014/ajot.56.5.489; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Willer B, 1993, J HEAD TRAUMA REHAB, V3, P75, DOI DOI 10.1097/00001199-199308020-00009; World Health Organization, 2001, INT CLASS FUNCT DIS	55	79	83	0	8	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	APR	2005	86	4					735	745		10.1016/j.apmr.2004.10.031			11	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	914ON	WOS:000228237300019	15827926				2021-06-18	
J	Shutter, L; Tong, KA; Holshouser, BA				Shutter, L; Tong, KA; Holshouser, BA			Proton MRS in acute traumatic brain injury: Role for glutamate/glutamine and choline for outcome prediction	JOURNAL OF NEUROTRAUMA			English	Article						diffuse axonal injury; glutamate; glutamine; proton magnetic resonance spectroscopy; traumatic brain injury	MAGNETIC-RESONANCE-SPECTROSCOPY; SEVERE HEAD-INJURY; SOMATOSENSORY-EVOKED POTENTIALS; METABOLISM; GLUTAMATE; CREATINE; SPECTRA; TREE	Proton magnetic resonance spectroscopy (MRS) is being used to evaluate individuals with acute traumatic brain injury and several studies have shown that changes in certain brain metabolites (N-acetylaspartate, choline) are associated with poor neurologic outcomes. The majority of previous MRS studies have been obtained relatively late after injury and none have examined the role of glutamate/glutamine (Glx). We conducted a prospective MRS study of 42 severely injured adults to measure quantitative metabolite changes early (7 days) after injury in normal appearing brain. We used these findings to predict long-term neurologic outcome and to determine if MRS data alone or in combination with clinical outcome variables provided better prediction of long-term outcomes. We found that glutamate/glutamine (Glx) and choline (Cho) were significantly elevated in occipital gray and parietal white matter early after injury in patients with poor long-term (6-12-month) outcomes. Glx and Cho ratios predicted long-term outcome with 94% accuracy and when combined with the motor Glasgow Coma Scale score provided the highest predictive accuracy (97%). Somatosensory evoked potentials were not as accurate as MRS data in predicting outcome. Elevated Glx and Cho are more sensitive indicators of injury and predictors of poor outcome when spectroscopy is done early after injury. This may be a reflection of early excitotoxic injury (i.e., elevated Glx) and of injury associated with membrane disruption (i.e., increased Cho) secondary to diffuse axonal injury.	Loma Linda Univ, Med Ctr, Loma Linda, CA 92354 USA; Loma Linda Univ, Med Ctr, Dept Radiol, Loma Linda, CA 92350 USA; Univ Cincinnati, Med Ctr, Dept Neurosurg, Cincinnati, OH 45221 USA	Holshouser, BA (corresponding author), Loma Linda Univ, Med Ctr, MRI-B624,12354 Anderson St, Loma Linda, CA 92354 USA.	bholshouser@ahs.llumc.edu	Shutter, Lori A/G-2957-2013	Shutter, Lori/0000-0002-1390-0628			Andrews PJD, 2002, J NEUROSURG, V97, P326, DOI 10.3171/jns.2002.97.2.0326; BECA J, 1995, J PEDIATR-US, V126, P44, DOI 10.1016/S0022-3476(95)70498-1; Brain Trauma Foundation American Association of Neurological Surgeons Joint Section on Neurotrauma and Critical Care, 2000, GUID MAN SEV HEAD IN; Brewer GJ, 2000, J NEUROCHEM, V74, P1968, DOI 10.1046/j.1471-4159.2000.0741968.x; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; Brown JIM, 1998, J NEUROTRAUM, V15, P253, DOI 10.1089/neu.1998.15.253; Brustovetsky N, 2001, J NEUROCHEM, V76, P425, DOI 10.1046/j.1471-4159.2001.00052.x; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; CHOE BY, 1995, INVEST RADIOL, V30, P502, DOI 10.1097/00004424-199508000-00008; CHOI SC, 1994, J NEUROSURG, V81, P169, DOI 10.3171/jns.1994.81.2.0169; CHOI SC, 1991, J NEUROSURG, V75, P251, DOI 10.3171/jns.1991.75.2.0251; CHOI SC, 1988, J NEUROSURG, V69, P381, DOI 10.3171/jns.1988.69.3.0381; Condon B, 1998, J NEUROTRAUM, V15, P563, DOI 10.1089/neu.1998.15.563; Fisher SK, 2002, J NEUROCHEM, V82, P736, DOI 10.1046/j.1471-4159.2002.01041.x; Friedman SD, 1998, AM J NEURORADIOL, V19, P1879; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Garnett MR, 2001, J NEUROTRAUM, V18, P231, DOI 10.1089/08977150151070838; GUTLING E, 1993, ELECTROEN CLIN NEURO, V88, P369, DOI 10.1016/0168-5597(93)90013-F; Holshouser BA, 1997, RADIOLOGY, V202, P487, DOI 10.1148/radiology.202.2.9015079; Lannoo E, 2000, J NEUROTRAUM, V17, P403, DOI 10.1089/neu.2000.17.403; MARION DW, 1994, J TRAUMA, V36, P89, DOI 10.1097/00005373-199401000-00014; MOULTON RJ, 1994, CLIN INVEST MED, V17, P187; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; PohlmannEden B, 1997, INTENS CARE MED, V23, P301, DOI 10.1007/s001340050332; Provencher SW, 2001, NMR BIOMED, V14, P260, DOI 10.1002/nbm.698; PROVENCHER SW, 1993, MAGNET RESON MED, V30, P672, DOI 10.1002/mrm.1910300604; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; Schuhmann MU, 2003, J NEUROTRAUM, V20, P725, DOI 10.1089/089771503767869962; Shutter LA, 2000, PROGNOSIS NEUROLOGIC, P335	31	79	90	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2004	21	12					1693	1705		10.1089/neu.2004.21.1693			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	877FY	WOS:000225554400001	15684761				2021-06-18	
J	Rovlias, A; Kotsou, S				Rovlias, A; Kotsou, S			Classification and regression tree for prediction of outcome after severe head injury using simple clinical and laboratory variables	JOURNAL OF NEUROTRAUMA			English	Article						head injury; prediction tree; prognosis	TRAUMATIC SUBARACHNOID HEMORRHAGE; SECONDARY BRAIN INJURY; COMPUTERIZED-TOMOGRAPHY; BLOOD-FLOW; HYPERGLYCEMIA; DAMAGE; LEUKOCYTES; PROGNOSIS; ADMISSION; SYSTEM	Many previous studies have constructed several predictive models for outcome after severe head injury, but these have often used expensive, time consuming, or highly specialized measurements. The goal of this study was to develop a simple, easy to use a model involving only variables that are rapidly and easily achievable in daily routine practice. To this end, a classification and regression tree (CART) technique was employed in the analysis of data from 345 patients with isolated severe brain injury who were admitted to Asclepeion General Hospital of Athens from January, 1993, to December, 2000. A total of 16 prognostic indicators were examined to predict neurological outcome at 6 months after head injury. Our results indicated that Glasgow Coma Scale was the best predictor of outcome. With regard to the other data, not only the most widely examined variables such as age, pupillary reactivity, or computed tomographic findings proved again to be strong predictors, but less commonly applied parameters, indirectly associated with brain damage, such as hyperglycemia and leukocytosis, were found to correlate significantly with prognosis too. The overall cross-validated predictive accuracy of CART model for these data was 86.84%, with a cross-validated relative error of 0.308. All variables included in this tree have been shown previously to be related to outcome. Methodologically, however, CART is quite different from the more commonly used statistical methods, with the primary benefit of illustrating the important prognostic variables as related to outcome. This technique may prove useful in developing new therapeutic strategies and approaches for patients with severe brain injury.	Asclepeion Gen Hosp, Dept Neurosurg, Athens, Greece	Rovlias, A (corresponding author), 55 Erasinidou St, Athens 17237, Greece.	ealex@tee.gr					AUER LM, 1980, ACTA NEUROCHIR, V52, P225, DOI 10.1007/BF01402078; Bednar MM, 1997, NEUROL RES, V19, P588; Chesnut R M, 1995, New Horiz, V3, P366; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHOI SC, 1994, J NEUROSURG, V81, P169, DOI 10.3171/jns.1994.81.2.0169; CHOI SC, 1983, J NEUROSURG, V59, P294, DOI 10.3171/jns.1983.59.2.0294; CHOI SC, 1991, J NEUROSURG, V75, P251, DOI 10.3171/jns.1991.75.2.0251; CHOI SC, 1988, J NEUROSURG, V69, P381, DOI 10.3171/jns.1988.69.3.0381; COCHRANE CG, 1966, J EXP MED, V124, P733, DOI 10.1084/jem.124.4.733; DESALLES AAF, 1987, NEUROSURGERY, V21, P45, DOI 10.1227/00006123-198707000-00009; Dings J, 1996, ACTA NEUROCHIR, V138, P425, DOI 10.1007/BF01420305; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; FANTONE JC, 1982, AM J PATHOL, V107, P397; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; GREENE KA, 1995, J NEUROSURG, V83, P445, DOI 10.3171/jns.1995.83.3.0445; HALLENBECK JM, 1986, STROKE, V17, P246, DOI 10.1161/01.STR.17.2.246; Hulka F, 1996, ARCH SURG-CHICAGO, V131, P923; JENNETT B, 1975, LANCET, V1, P480; Kakarieka A, 1997, NEUROL RES, V19, P230, DOI 10.1080/01616412.1997.11740804; KESKIL S, 1994, ACTA NEUROCHIR, V131, P211, DOI 10.1007/BF01808615; LAM AM, 1991, J NEUROSURG, V75, P545, DOI 10.3171/jns.1991.75.4.0545; LOKKEBERG AR, 1984, J NEUROSURG, V61, P254, DOI 10.3171/jns.1984.61.2.0254; MARGULIES DR, 1994, AM SURGEON, V60, P387; MARMAROU A, 1991, J NEUROSURG S, V75, P59; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MISSORI P, 1997, CLIN NEUROLOGY NEU S, V99, pS79; MOULTON RJ, 1994, CLIN INVEST MED, V17, P187; NORDBY HK, 1985, ACTA NEUROCHIR, V76, P131, DOI 10.1007/BF01418475; Olshen RA, 1984, CLASSIFICATION REGRE; PFENNINGER EG, 1991, ACTA ANAESTH SCAND, V35, P148, DOI 10.1111/j.1399-6576.1991.tb03263.x; Raabe A, 2000, NEUROSURG REV, V23, P136, DOI 10.1007/PL00011944; Raabe A, 1999, BRIT J NEUROSURG, V13, P56, DOI 10.1080/02688699944195; Rovlias A, 2000, NEUROSURGERY, V46, P335, DOI 10.1097/00006123-200002000-00015; Rovlias A, 2001, SURG NEUROL, V55, P190, DOI 10.1016/S0090-3019(01)00414-1; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; SIEGEL JH, 1995, J NEUROTRAUM, V12, P579, DOI 10.1089/neu.1995.12.579; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; Steinberg D, 1995, CART TREE STRUCTURED; Steinberg D., 1997, CART CLASSIFICATION; Takanashi Y, 2001, No To Shinkei, V53, P61; TEMKIN NR, 1995, J NEUROSURG, V82, P764, DOI 10.3171/jns.1995.82.5.0764; VOLMER DG, 1991, J NEUROSURG S, V75, pS37; Yang SY, 1995, SURG NEUROL, V44, P373, DOI 10.1016/0090-3019(96)80243-6; ZHUANG J, 1993, J TRAUMA, V35, P415, DOI 10.1097/00005373-199309000-00014	45	79	81	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2004	21	7					886	893		10.1089/0897715041526249			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	842AE	WOS:000222973800006	15307901				2021-06-18	
J	Cuevas, P; Carceller, F; Garcia-Gomez, I; Yan, M; Dujovny, M				Cuevas, P; Carceller, F; Garcia-Gomez, I; Yan, M; Dujovny, M			Bone marrow stromal cell implantation for peripheral nerve repair	NEUROLOGICAL RESEARCH			English	Article						sciatic nerve transection; bone marrow stromal cells; cellular therapy; regeneration	TRAUMATIC BRAIN INJURY; STEM-CELLS; RATS; TRANSPLANTATION; REGENERATION; RECOVERY; STROKE	Cell therapy using bone marrow stromal cells is a new promising therapy for regenerative medicine. Previous studies demonstrated that local bone marrow stromal cells implantation in the distal stump of transected sciatic nerve of rats promotes early functional recovery. The purpose of this study was to expand on the preliminary research by investigating the long-term efficacy of bone marrow stromal cells using the same experimental setting. Functional test and histological studies demonstrate that bone marrow stromal cell-treated rats exhibit significant improvement on a walking tract test at day 180 after surgery compared with control rats. Taken together, these data suggest that bone marrow stromal cell therapy is a safe and effective strategy for peripheral nerve injuries.	Univ Alcala de Henares, Serv Histol, Dept Invest, Hosp Univ Ramon & Cajal, E-28034 Madrid, Spain; Wayne State Univ, Dept Neurosurg, Detroit, MI USA; Hosp Jingxi, Beijing, Peoples R China	Cuevas, P (corresponding author), Univ Alcala de Henares, Serv Histol, Dept Invest, Hosp Univ Ramon & Cajal, E-28034 Madrid, Spain.	pedro.cuevas@hrc.es					Azizi SA, 1998, P NATL ACAD SCI USA, V95, P3908, DOI 10.1073/pnas.95.7.3908; Bjorklund A, 2000, NAT NEUROSCI, V3, P537, DOI 10.1038/75705; Chopp M, 2000, NEUROREPORT, V11, P3001, DOI 10.1097/00001756-200009110-00035; Cuevas P, 2002, NEUROL RES, V24, P634, DOI 10.1179/016164102101200564; CUEVAS P, 2003, CELULAS TRONCALES HU, P63; Dezawa M, 2001, EUR J NEUROSCI, V14, P1771, DOI 10.1046/j.0953-816x.2001.01814.x; Dijkstra JR, 2000, J NEUROSCI METH, V96, P89, DOI 10.1016/S0165-0270(99)00174-0; Korbling M, 2003, BONE MARROW TRANSPL, V32, pS23, DOI 10.1038/sj.bmt.1703939; Li Y, 2001, NEUROSCI LETT, V316, P67, DOI 10.1016/S0304-3940(01)02384-9; Li Y, 2000, J CEREBR BLOOD F MET, V20, P1311, DOI 10.1097/00004647-200009000-00006; Li Y, 2001, NEUROLOGY, V56, P1666, DOI 10.1212/WNL.56.12.1666; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; Siminiak T, 2003, CIRCULATION, V108, P1167, DOI 10.1161/01.CIR.0000086628.42652.8D; Varejao ASP, 2001, J NEUROSCI METH, V108, P1, DOI 10.1016/S0165-0270(01)00378-8; Wakitani S, 2003, RHEUMATOLOGY, V42, P162, DOI 10.1093/rheumatology/keg024; WALL PD, 1979, PAIN, V7, P103, DOI 10.1016/0304-3959(79)90002-2	18	79	90	1	5	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0161-6412	1743-1328		NEUROL RES	Neurol. Res.	MAR	2004	26	2					230	232		10.1179/016164104225013897			3	Clinical Neurology; Neurosciences	Neurosciences & Neurology	809BS	WOS:000220612800015	15072644				2021-06-18	
J	Lu, DY; Mahmood, A; Zhang, RL; Li, Y; Chopp, M				Lu, DY; Mahmood, A; Zhang, RL; Li, Y; Chopp, M			Upregulation of neurogenesis and reduction in functional deficits following administration of DETA/NONOate, a nitric oxide donor, after traumatic brain injury in rats	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; neurogenesis; DETA/NONOate; nitric oxide donor; rat	NEURAL STEM-CELLS; ZONE NEURONAL PRECURSORS; SUBVENTRICULAR ZONE; DENTATE GYRUS; HIPPOCAMPAL NEUROGENESIS; GENE-EXPRESSION; CORTICAL DAMAGE; ADULT-RAT; SYNTHASE; MOUSE	Object. Neurogenesis, which is upregulated by neural injury in the adult mammalian brain, may be involved in the repair of the injured brain and functional recovery. Therefore, the authors sought to identify agents that can enhance neurogenesis after brain injury, and they report that (Z)-1-[N-(2-aminoethyl)-N-(2-ammonioethyl)amino]diazen-1-ium-1,2-diolate (DETA/NONOate), a nitric oxide donor, upregulates neurogenesis and reduces functional deficits after traumatic brain injury (TBI) in rats. Methods. The agent DETA/NONOate (0.4 mg/kg) was injected intraperitoneally into 16 rats daily for 7 days, starting I day after TBI induced by controlled cortical impact. Bromodeoxyuridine (100 mg/kg) was also injected intraperitoneally daily for 14 days after TBI to label the newly generated cells in the brain. A neurological functional evaluation was pet-formed in all rats and the animals were killed at 14 or 42 days postinjury. Immunohistochemical staining was used to identify proliferating cells. Conclusions. Compared with control rats, the proliferation, survival, migration and differentiation of neural progenitor cells were all significantly enhanced in the hippocampus, subventricular zone, striatum, corpus callosum, and the boundary zone of the injured cortex, as well as in the contralateral hemisphere in rats with TBI that received DETA/NONOate treatment. Neurological functional outcomes in the DETA/NONOate-treated group were also significantly improved compared with the untreated group. These data indicate that DETA/NONOate may be useful in the treatment of TBI.	Henry Ford Hosp, Dept Neurol, Detroit, MI 48202 USA; Henry Ford Hlth Sci Ctr, Dept Neurol, Detroit, MI USA; Oakland Univ, Dept Phys, Rochester, MN USA; Henry Ford Hlth Sci Ctr, Dept Neurosurg, Detroit, MI USA	Chopp, M (corresponding author), Henry Ford Hosp, Dept Neurol, 2799 W Grand Blvd, Detroit, MI 48202 USA.	chopp@neuro.hfh.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042259] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS 42259] Funding Source: Medline; OAPP OPHS HHS [PPG NS 23393] Funding Source: Medline		Alvarez-Buylla A, 2002, BRAIN RES BULL, V57, P751, DOI 10.1016/S0361-9230(01)00770-5; Alvarez-Buylla A, 2002, J NEUROSCI, V22, P629, DOI 10.1523/JNEUROSCI.22-03-00629.2002; Anderson MF, 2002, DEV BRAIN RES, V134, P115; BARTH TM, 1990, J NEUROSCI, V10, P3449; BARTH TM, 1987, EXP NEUROL, V95, P661, DOI 10.1016/0014-4886(87)90307-4; BARTH TM, 1990, BEHAV BRAIN RES, V39, P73, DOI 10.1016/0166-4328(90)90122-U; BARTLETT PF, 1982, P NATL ACAD SCI-BIOL, V79, P2722, DOI 10.1073/pnas.79.8.2722; BEDARD A, 2001, SOC NEUROSCI, V248, P8; Bengzon J, 1997, P NATL ACAD SCI USA, V94, P10432, DOI 10.1073/pnas.94.19.10432; BREDT DS, 1994, NEURON, V13, P301, DOI 10.1016/0896-6273(94)90348-4; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; Cameron HA, 1999, NAT NEUROSCI, V2, P894, DOI 10.1038/13197; Cameron HA, 1998, NEUROSCIENCE, V82, P349; Castillo J, 2000, STROKE, V31, P852, DOI 10.1161/01.STR.31.4.852; CHAO MV, 1992, NEURON, V9, P583, DOI 10.1016/0896-6273(92)90023-7; CHAPIN JK, 1984, J COMP NEUROL, V229, P199, DOI 10.1002/cne.902290206; Chen S, 2001, METALL MATER TRANS B, V32, P11, DOI 10.1007/s11663-001-0002-1; Craig CG, 1996, J NEUROSCI, V16, P2649; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; DE CR, 1995, J CLIN INVEST, V96, P60; DeWitt DS, 1997, J NEUROTRAUM, V14, P223, DOI 10.1089/neu.1997.14.223; Ding MZ, 1997, J NEUROIMMUNOL, V77, P99, DOI 10.1016/S0165-5728(97)00065-9; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; Doetsch F, 1996, P NATL ACAD SCI USA, V93, P14895, DOI 10.1073/pnas.93.25.14895; Durante W, 1997, CIRC RES, V80, P557, DOI 10.1161/01.RES.80.4.557; Eigenthaler M, 1999, Rev Physiol Biochem Pharmacol, V135, P173, DOI 10.1007/BFb0033673; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; GIUILI G, 1994, DEV BRAIN RES, V81, P269, DOI 10.1016/0165-3806(94)90313-1; Gould E, 2000, BIOL PSYCHIAT, V48, P715, DOI 10.1016/S0006-3223(00)01021-0; Gould E, 2002, J NEUROSCI, V22, P619, DOI 10.1523/JNEUROSCI.22-03-00619.2002; Gould E, 1999, BIOL PSYCHIAT, V46, P1472, DOI 10.1016/S0006-3223(99)00247-4; Gould E, 2001, P NATL ACAD SCI USA, V98, P10910, DOI 10.1073/pnas.181354698; HABY C, 1994, J NEUROCHEM, V62, P496; Hua Y, 2002, STROKE, V33, P2478, DOI 10.1161/01.STR.0000032302.91894.0F; Huang ZH, 1996, J CEREBR BLOOD F MET, V16, P981, DOI 10.1097/00004647-199609000-00023; Iadecola C, 1997, J NEUROSCI, V17, P9157; Idriss SD, 1999, J BIOL CHEM, V274, P9489, DOI 10.1074/jbc.274.14.9489; Jin KL, 2001, P NATL ACAD SCI USA, V98, P4710, DOI 10.1073/pnas.081011098; Keilhoff G, 1996, NEUROSCIENCE, V75, P1193, DOI 10.1016/0306-4522(96)00330-2; Kempermann G, 2000, Prog Brain Res, V127, P35; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Kirschenbaum B, 1999, J NEUROSCI, V19, P2171; Laurer HL, 1999, CURR OPIN NEUROL, V12, P715, DOI 10.1097/00019052-199912000-00010; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; LEVISON SW, 1993, DEVELOPMENT, V119, P611; Lim DA, 1997, P NATL ACAD SCI USA, V94, P14832, DOI 10.1073/pnas.94.26.14832; LINDEN R, 1994, NEUROSCIENCE, V58, P671, DOI 10.1016/0306-4522(94)90447-2; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; Liu JL, 1998, J NEUROSCI, V18, P7768; LOIS C, 1994, SCIENCE, V264, P1145, DOI 10.1126/science.8178174; LOWENSTEIN CJ, 1992, CELL, V70, P705, DOI 10.1016/0092-8674(92)90301-R; Lu DY, 2002, CELL TRANSPLANT, V11, P275; LUSKIN MB, 1993, NEURON, V11, P173, DOI 10.1016/0896-6273(93)90281-U; Madsen TM, 2000, BIOL PSYCHIAT, V47, P1043, DOI 10.1016/S0006-3223(00)00228-6; Magavi SS, 2000, NATURE, V405, P951; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; Moreno-Lopez B, 2000, BRAIN RES, V869, P244, DOI 10.1016/S0006-8993(00)02474-4; MORSHEAD CM, 1992, J NEUROSCI, V12, P249; MORSHEAD CM, 1994, NEURON, V13, P1071, DOI 10.1016/0896-6273(94)90046-9; OKUSKY YP, J NEUROSCI, V20, P8435; Parent JM, 1997, J NEUROSCI, V17, P3727; Paxinos G., 1995, RAT NERVOUS SYSTEM; Peterson DA, 2002, CURR OPIN PHARMACOL, V2, P34, DOI 10.1016/S1471-4892(01)00118-7; PILZ RB, 1995, FASEB J, V9, P552; REH T, 1982, J COMP NEUROL, V211, P276, DOI 10.1002/cne.902110306; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; ROSKAMS AJ, 1994, NEURON, V13, P289; Santacana M, 1998, DEV BRAIN RES, V111, P205, DOI 10.1016/S0165-3806(98)00140-0; Scheffler B, 1999, TRENDS NEUROSCI, V22, P348, DOI 10.1016/S0166-2236(99)01416-2; Schmanke TD, 1996, J NEUROTRAUM, V13, P293, DOI 10.1089/neu.1996.13.293; Scott D E, 1997, Va Med Q, V124, P249; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; Stys PK, 1998, J CEREBR BLOOD F MET, V18, P2, DOI 10.1097/00004647-199801000-00002; Tanapat P, 1999, J NEUROSCI, V19, P5792, DOI 10.1523/JNEUROSCI.19-14-05792.1999; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; TUDER RM, 1995, J CLIN INVEST, V95, P1798, DOI 10.1172/JCI117858; Vallieres L, 2002, J NEUROSCI, V22, P486, DOI 10.1523/JNEUROSCI.22-02-00486.2002; YAGINUMA H, 1994, PROG NEUROBIOL, V44, P249, DOI 10.1016/0301-0082(94)90041-8; Zhang L, 2002, J NEUROSCI METH, V117, P207, DOI 10.1016/S0165-0270(02)00114-0; Zhang RL, 2001, ANN NEUROL, V50, P602, DOI 10.1002/ana.1249; Zhang RL, 2001, NEUROSCIENCE, V105, P33, DOI 10.1016/S0306-4522(01)00117-8	84	79	83	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	AUG	2003	99	2					351	361		10.3171/jns.2003.99.2.0351			11	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	707TN	WOS:000184526100028	12924710				2021-06-18	
J	Wennberg, RA; Tator, CH				Wennberg, RA; Tator, CH			National Hockey League reported concussions, 1986-87 to 2001-02	CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES			English	Article							MANAGEMENT; INJURIES; SPORTS	Objectives: To examine the longitudinal media reported rate of concussions in the National Hockey League (NHL) over the period 1986-87 to 2001-02. Methods: All injury reports published in the weekly sports newspaper The Hockey News for the 16 seasons 1986-87 through 200102 were reviewed for reported concussions. The Hockey News reports are based on weekly injury reports released by the NHL, which derive from reports submitted to the league by individual team offices. Results: Adjusted for changes in the number of teams and games per season over the 16 year study period, and expressed as: number of concussions per 1000 games, results by season (starting with 198687) were 4, 8, 7, 7, 5, 5, 7, 7, 6, 8, 13, 20, 30, 27, 30, 25. Comparing each season with the prior season, significant increases were reported in 1997-98 and 1998-99 (p<0.05 and 0.025, respectively), with no change since 1998-99. Conclusions: The reported concussion rate in the NHL during the last five years is more than triple that of the previous decade. Bigger, faster players, new equipment and harder boards and glass have all theoretically increased the risk of concussion in the NHL in recent years. However, the abrupt increase and subsequent plateau in concussion rate since 1997 suggests that increased recognition and reporting may be primarily responsible for the apparent increase in incidence.	Univ Toronto, Toronto Western Hosp, Div Neurol, Univ Hlth Network, Toronto, ON M5T 2S8, Canada; Univ Toronto, Toronto Western Hosp, Div Neurosurg, Univ Hlth Network, Toronto, ON M5T 2S8, Canada	Wennberg, RA (corresponding author), Univ Toronto, Toronto Western Hosp, Div Neurol, Univ Hlth Network, 5W444,399 Bathurst St, Toronto, ON M5T 2S8, Canada.						BIASCA N, 1995, UNFALLCHIRURG, V98, P283; GREENBERG J, 2000, TOTAL HOCKEY OFFICIA, P578; Groger A, 2001, SPORTVERLETZ SPORTSC, V15, P82, DOI 10.1055/s-2001-19047; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kelly JP, 1997, NEUROLOGY, V48, P581; MEEUWISSE W, 2001, BRIT J SPORT MED, V35, P375; Orchard J, 2002, BRIT J SPORT MED, V36, P16, DOI 10.1136/bjsm.36.1.16; Tegner Y, 1996, BRIT J SPORT MED, V30, P251, DOI 10.1136/bjsm.30.3.251; TEGNER Y, 2001, BRIT J SPORT MED, V35, P376	9	79	79	0	13	CANADIAN J NEUROL SCI INC	CALGARY	PO BOX 4220, STATION C EDITORIAL & SUBSCRIPTION SERV, CALGARY, AB T2T 5N1, CANADA	0317-1671			CAN J NEUROL SCI	Can. J. Neurol. Sci.	AUG	2003	30	3					206	209		10.1017/S0317167100002596			4	Clinical Neurology	Neurosciences & Neurology	711AY	WOS:000184716400006	12945942	Bronze			2021-06-18	
J	Petzold, A; Green, AJE; Keir, G; Fairley, S; Kitchen, N; Smith, M; Thompson, EJ				Petzold, A; Green, AJE; Keir, G; Fairley, S; Kitchen, N; Smith, M; Thompson, EJ			Role of serum S100B as an early predictor of high intracranial pressure and mortality in brain injury: A pilot study	CRITICAL CARE MEDICINE			English	Article; Proceedings Paper	10th Meeting of the European-Society-of-Neurology	JUN 18-22, 2000	JERUSALEM, ISRAEL	European Soc Neurol		acute brain injury; traumatic brain injury; serum; S100B; intracranial pressure; surrogate marker; subarachnoid hemorrhage; intracranial hemorrhage; Glasgow Coma Scale	NEUROBIOCHEMICAL MARKERS; CEREBROSPINAL-FLUID; HEAD-INJURY; PROTEIN; DAMAGE; RELEASE; S-100; CALCIUM; INFARCTION; SURGERY	Objective: To investigate whether serum S100B is suitable as a sensitive biomarker for early prediction of increased intracranial pressure and mortality rates after brain injury. Design: A prospective, longitudinal study. Setting: Neurosurgical intensive care unit. Patients: Twenty-one patients with acute brain injury and 13 healthy controls. Interventions. None. Measurements and Main Results: We assessed Glasgow Coma Scale score and pupil reaction on admission and quantified serum S100B (in-house enzyme-linked immunosorbent assay) and intracranial pressure on admission and the subsequent 6 days. Serum S100B concentrations on admission and day 1 were significantly higher in patients with fatal outcome (p <.05, p <.01, respectively), with a sensitivity of 100% and a specificity of 75-83%. Patients with high serum S100B on admission had an eight-fold and on day 1 a 12-fold increased relative risk of a fatal outcome. Subsequent serum S100B values predicted the development of high intracranial pressure in patients with traumatic brain injury (p <.01). Patients with high intracranial pressure on day 5 had an 11-fold and on day 6 a nine-fold increased risk of fatal outcome. Conclusions: Serum S100B is a sensitive biomarker for early prediction of the development of high intracranial pressure and fatal outcome following acute brain injury. Monitoring S100B concentrations could contribute to early detection of patients at risk of secondary increases in intracranial pressure and subsequent mortality. This would allow earlier targeting of therapy in selected patients.	Inst Neurol, Dept Neuroimmunol, London WC1N 3BG, England; UCL Natl Hosp Neurol & Neurosurg, Surg Intens Care Unit, London WC1N 3BG, England; Natl CJD Surveillance Unit, Edinburgh, Midlothian, Scotland	Petzold, A (corresponding author), Inst Neurol, Dept Neuroimmunol, Queen Sq, London WC1N 3BG, England.	a.petzold@ion.ucl.ac.uk	Smith, Martin/B-2616-2009; Green, Alison/O-7356-2019; Petzold, Axel/C-1090-2009	Petzold, Axel/0000-0002-0344-9749			Ali MS, 2000, BRIT J ANAESTH, V85, P287, DOI 10.1093/bja/85.2.287; AURELL A, 1991, STROKE, V22, P1254, DOI 10.1161/01.STR.22.10.1254; BARGER SW, 1992, J BIOL CHEM, V267, P9689; BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; Blomquist S, 1997, J CARDIOTHOR VASC AN, V11, P699, DOI 10.1016/S1053-0770(97)90160-9; Cody R P, 1997, APPL STAT SAS PROGRA; Coplin WM, 2001, NEUROL RES, V23, P277, DOI 10.1179/016164101101198433; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; ENG LF, 1994, BRAIN PATHOL, V4, P229, DOI 10.1111/j.1750-3639.1994.tb00838.x; FURLAN A, 1994, SPECIAL ASPECTS TREA, P579; Gazzolo D, 2001, CLIN CHEM, V47, P1836; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; GREEN A, 1999, THESIS U COLL LONDON; Green AJE, 1997, NEUROSCI LETT, V235, P5, DOI 10.1016/S0304-3940(97)00701-5; Green AJE, 1997, J IMMUNOL METHODS, V205, P35, DOI 10.1016/S0022-1759(97)00050-1; HALLER JA, 1983, JAMA-J AM MED ASSOC, V249, P47, DOI 10.1001/jama.249.1.47; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; Holtkamp M, 2001, J NEUROL NEUROSUR PS, V70, P226, DOI 10.1136/jnnp.70.2.226; Koura SS, 1998, ACT NEUR S, V71, P244; McKeating EG, 1998, ACT NEUR S, V71, P117; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; Otto M, 1998, BRIT MED J, V316, P577, DOI 10.1136/bmj.316.7131.577; PETZOLD A, IN PRESS BRAIN RES B; Raabe A, 1998, ACTA NEUROCHIR, V140, P787, DOI 10.1007/s007010050180; Reinert M, 2000, J NEUROSURG, V93, P800, DOI 10.3171/jns.2000.93.5.0800; RIEKE K, 1995, CRIT CARE MED, V23, P1576, DOI 10.1097/00003246-199509000-00019; Rothoerl RD, 1999, BRAIN INJURY, V13, P387; Schwab S, 1997, NEUROLOGY, V48, P412, DOI 10.1212/WNL.48.2.412; Scotto C, 1998, MOL CELL BIOL, V18, P4272, DOI 10.1128/MCB.18.7.4272; SELINFREUND RH, 1991, P NATL ACAD SCI USA, V88, P3554, DOI 10.1073/pnas.88.9.3554; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; TEASDALE G, 1974, LANCET, V2, P81; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Wardlaw JM, 2002, J NEUROL NEUROSUR PS, V72, P188, DOI 10.1136/jnnp.72.2.188; Wunderlich MT, 1999, STROKE, V30, P1190, DOI 10.1161/01.STR.30.6.1190	37	79	82	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	DEC	2002	30	12					2705	2710		10.1097/00003246-200212000-00015			6	Critical Care Medicine	General & Internal Medicine	633AP	WOS:000180257300015	12483062				2021-06-18	
J	Schatz, P; Browndyke, J				Schatz, P; Browndyke, J			Applications of computer-based neuropsychological assessment	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						assessment; computer; concussion; evaluation; Internet; neuropsychology; symptom validity	TRAUMATIC BRAIN-INJURY; SYMPTOM VALIDITY TEST; COGNITIVE ASSESSMENT; TEST-PERFORMANCE; CATEGORY TEST; TESTS; SPORTS; TECHNOLOGY; CONCUSSION; STANDARD	Objectives: To present current applications of computer-based neuropsychological assessment, including the assessment of sports-related concussion, symptom validity testing, and the remote administration of tests through the Internet. Problem areas: If computer-based assessment benefits are to become popularized, a few issues will need to be addressed: the development of psychometric data based on comparisons with long-standing empirically sound test measures; additional validation of measures by parties not involved in their commercial development; increased focus on ecological validity; exploration of the usefulness of remote data storage and automated posting to databases; and improved documentation of specific computer hardware and software used in experimental methods. Conclusions: Beyond ease of administration and data collection, computer-based assessment offers benefits over paper-and-pencil measures in the form of millisecond tinting accuracy, reliable and randomized presentation of stimuli over multiple trials and repeat administrations, and unobtrusive measurement of cognitive skills and response times during all aspects of the assessment process.	St Josephs Univ, Dept Psychol, Philadelphia, PA 19131 USA	Schatz, P (corresponding author), St Josephs Univ, Dept Psychol, 5600 City Ave,222 Post Hall, Philadelphia, PA 19131 USA.	pschatz@sju.edu	Browndyke, Jeffrey/AAE-7292-2021	Schatz, Philip/0000-0002-6222-6545; Browndyke, Jeffrey/0000-0002-8573-7073			ALLEN LM, 1997, CARB MANUAL COMPUTER; *AM PSYCH ASS, 1986, GUID COMP BAS TESTS; Ball C, 1997, J Telemed Telecare, V3, P126, DOI 10.1258/1357633971931020; Ball C, 1999, J TELEMED TELECARE, V5, P253, DOI 10.1258/1357633991933819; Ball C, 1998, J TELEMED TELECARE, V4, P36, DOI 10.1258/1357633981931362; Barak A, 1999, APPL PREV PSYCHOL, V8, P231, DOI 10.1016/S0962-1849(05)80038-1; Barth JT, 1989, MILD HEAD INJURY; BARTRAM D, 1984, J OCCUP PSYCHOL, V57, P221, DOI 10.1111/j.2044-8325.1984.tb00164.x; BEAUMONT JG, 1975, J CLIN PSYCHOL, V31, P458, DOI 10.1002/1097-4679(197507)31:3<458::AID-JCLP2270310320>3.0.CO;2-I; BENNETT RE, 1999, ED MEASUREMENT I FAL, P5; Berg EA, 1948, J GEN PSYCHOL, V39, P15, DOI 10.1080/00221309.1948.9918159; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P19, DOI 10.1076/clin.15.1.19.1907; BROOKS J, 1998, EPIDEMIOLOGY PREVENT; Browndyke JN, 1999, ARCH CLIN NEUROPSYCH, V14, P26, DOI 10.1093/arclin/14.1.26; BROWNDYKE JN, 2001, REMOTE NEUROPSYCHOLO; BURKE MJ, 1987, PROF PSYCHOL-RES PR, V18, P42, DOI 10.1037/0735-7028.18.1.42; Campbell KA, 1999, ASSESSMENT, V6, P21, DOI 10.1177/107319119900600103; Choca J., 1992, CLIN NEUROPSYCHOL, V6, P9, DOI [10.1080/13854049208404112, DOI 10.1080/13854049208404112]; CHOCA J, 1987, CATEGORY TEST COMPUT; CHUTE DL, 1996, POWER LAB; Coffin RJ, 1999, COMPUT HUM BEHAV, V15, P549, DOI 10.1016/S0747-5632(99)00036-9; *COGST LTD, 1999, COGSP; COHEN J, 1993, BEHAV RES METH INSTR, V25, P257, DOI 10.3758/BF03204507; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; COLLINS M, 2001, 21 ANN C NAT AC NEUR; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P2283, DOI 10.1001/jama.282.24.2283; COONS WH, 1956, ONTARIO PSYCHOL ASS, V12, P33; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Echemendia RJ, 2001, NEUROPSYCHOL REV, V11, P69, DOI 10.1023/A:1016651217141; ELWOOD DL, 1972, J CONSULT CLIN PSYCH, V38, P9, DOI 10.1037/h0032416; Epstein J, 2001, COMPUT HUM BEHAV, V17, P295, DOI 10.1016/S0747-5632(01)00004-8; Erlanger D, 2001, J ATHL TRAINING, V36, P280; ERLANGER DM, IN PRESS ARCH CLIN N; Erlanger DM, 1999, CONCUSSION RESOLUTIO; Etcoff LM, 1996, NEUROPSYCHOL REV, V6, P171, DOI 10.1007/BF01874896; Feldstein SN, 1999, CLIN NEUROPSYCHOL, V13, P303, DOI 10.1076/clin.13.3.303.1744; Fortuny LA, 1996, CLIN NEUROPSYCHOL, V10, P419, DOI 10.1080/13854049608406702; FRENCH CC, 1987, BRIT J CLIN PSYCHOL, V26, P267, DOI 10.1111/j.2044-8260.1987.tb01360.x; Green P, 1999, BRAIN INJURY, V13, P813, DOI 10.1080/026990599121205; GREEN P, 2000, WORD MEMORY TEST; Grote CL, 2000, J CLIN EXP NEUROPSYC, V22, P709, DOI 10.1076/jcen.22.6.709.958; Guilmette T J, 1990, Arch Clin Neuropsychol, V5, P373, DOI 10.1016/0887-6177(90)90016-I; Gur RC, 2001, NEUROPSYCHOPHARMACOL, V25, P766, DOI 10.1016/S0893-133X(01)00278-0; Gur RC, 2000, BRAIN LANG, V74, P157, DOI 10.1006/brln.2000.2325; Gutierrez JM, 1998, CRIT ISS NE, P81; HARTLAGE LC, 1980, INT J CLIN NEUROPSYC, V2, P200; Heaton R., 1991, HRB COMPREHENSIVE NO; HEATON R K, 1981, Journal of Clinical Neuropsychology, V3, P121, DOI 10.1080/01688638108403118; Heaton RK., 1999, WISCONSIN CARD SORTI; HISCOCK M, 1989, J CLIN EXP NEUROPSYC, V11, P967, DOI 10.1080/01688638908400949; HONAKER LM, 1988, CLIN PSYCHOL REV, V8, P561, DOI 10.1016/0272-7358(88)90081-5; Horowitz T, 1997, ARCH CLIN NEUROPSYCH, V12, P338, DOI 10.1093/arclin/12.4.338a; Iverson G L, 2001, Appl Neuropsychol, V8, P167, DOI 10.1207/S15324826AN0803_6; Iverson GL, 1996, J CLIN EXP NEUROPSYC, V18, P38, DOI 10.1080/01688639608408260; *JARV B MED, 2002, DIRECTRT; Jerome LW, 2000, AM PSYCHOL, V55, P407, DOI [10.1037/0003-066X.55.4.407, 10.1037//0003-066X.55.4.407]; JOHNSON DF, 1980, J APPL PSYCHOL, V65, P357, DOI 10.1037/0021-9010.65.3.357; Kane R. L., 1997, NEUROPSYCHOLOGY HDB, V1, P423; KANE RL, 1992, NEUROPSYCHOL REV, V3, P1, DOI 10.1007/BF01108787; KELLER FF, 1998, CARF SORT VER 1 0 CO; Lee JH, 2000, ALZ DIS ASSOC DIS, V14, P94, DOI 10.1097/00002093-200004000-00007; LeesHaley PR, 1996, ARCH CLIN NEUROPSYCH, V11, P45, DOI 10.1016/0887-6177(95)00011-9; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR., 2000, IMPACT IMMEDIATE POS; Makdissi M, 2001, BRIT J SPORT MED, V35, P354, DOI 10.1136/bjsm.35.5.354; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; Matthews E, 1991, GLOBAL BIOGEOCHEM CY, V5, P3, DOI 10.1029/90GB02311; MCCRAE M, 1997, STANDARDIZED ASSESSM; McMinn MR, 1999, PROF PSYCHOL-RES PR, V30, P165, DOI 10.1037/0735-7028.30.2.165; MEAD AD, 1993, PSYCHOL BULL, V114, P449, DOI 10.1037/0033-2909.114.3.449; Mercer WN, 1997, CLIN NEUROPSYCHOL, V11, P174, DOI 10.1080/13854049708407047; MILLER DC, 1993, COMPUTERIZED VERSION; Montani C, 1997, J Telemed Telecare, V3, P140, DOI 10.1258/1357633971931048; Moser RS, 2002, ARCH CLIN NEUROPSYCH, V17, P91, DOI 10.1016/S0887-6177(01)00108-1; NEWBURGER EC, 2001, CURRENT POPULATION R; PANKRATZ L, 1983, PERCEPT MOTOR SKILL, V57, P367, DOI 10.2466/pms.1983.57.2.367; REED AV, 1979, BEHAV RES METH INSTR, V11, P572, DOI 10.3758/BF03201384; Rosen L.D., 1992, MEASURING TECHNOPHOB; Rosen LD, 1996, PROF PSYCHOL-RES PR, V27, P635, DOI 10.1037/0735-7028.27.6.635; Schatz P, 1999, ARCH CLIN NEUROPSYCH, V14, P747; Schatz P, 1999, ARCH CLIN NEUROPSYCH, V14, P159, DOI 10.1093/arclin/14.1.159; Schatz P, 2001, ARCH CLIN NEUROPSYCH, V16, P746; Schultheis MT, 2001, REHABIL PSYCHOL, V46, P296, DOI 10.1037/0090-5550.46.3.296; Schultheis MT, 1999, ARCH CLIN NEUROPSYCH, V14, P794; Slick DJ, 2000, J CLIN EXP NEUROPSYC, V22, P569, DOI 10.1076/1380-3395(200010)22:5;1-9;FT569; Slick DJ, 1996, J CLIN EXP NEUROPSYC, V18, P911, DOI 10.1080/01688639608408313; Slick DJ, 1995, VICTORIA SYMPTOM VAL; SPACE LG, 1975, BEHAV RES METH INSTR, V7, P191, DOI 10.3758/BF03201323; SPACE LG, 1981, BEHAV RES METH INSTR, V13, P595, DOI 10.3758/BF03202072; Strauss E, 1999, CLIN NEUROPSYCHOL, V13, P420, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT420; Sturges JW, 1998, PROF PSYCHOL-RES PR, V29, P183, DOI 10.1037/0735-7028.29.2.183; Tien Allen Y., 1996, Kaohsiung Journal of Medical Sciences, V12, P479; VINCENT KR, 1980, J CLIN PSYCHOL, V36, P437, DOI 10.1002/jclp.6120360209; WALKER NW, 1985, J SCHOOL PSYCHOL, V23, P51, DOI 10.1016/0022-4405(85)90034-2; WATERFALL RC, 1979, J AUDIOV MEDIA MED, V2, P21, DOI 10.3109/17453057909153878; WESTALL RF, 1989, BEHAV RES METH INSTR, V21, P540, DOI 10.3758/BF03202886; WILSON SL, 1991, MICROCOMPUTERS CLIN, P79; Wolfson D., 1993, HALSTEAD REITAN NEUR	99	79	87	0	20	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	OCT	2002	17	5					395	410		10.1097/00001199-200210000-00003			16	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	610DD	WOS:000178944700003	12802251				2021-06-18	
J	Mauler, F; Mittendorf, J; Horvath, E; De Vry, J				Mauler, F; Mittendorf, J; Horvath, E; De Vry, J			Characterization of the diarylether sulfonylester (-)-(R)-3-(2-hydroxymethylindanyl-4-oxy)phenyl-4,4,4-trifluoro-1-sulfonate (BAY 38-7271) as a potent cannabinoid receptor agonist with neuroprotective properties	JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS			English	Article							DISCRIMINATIVE STIMULUS PROPERTIES; ANTAGONIST SR141716A; HIPPOCAMPAL-NEURONS; RAT-BRAIN; IN-VIVO; CB1; PHARMACOLOGY; ACTIVATION; RELEASE; DELTA-9-TETRAHYDROCANNABINOL	(-)-( R)-3-(2-Hydroxymethylindanyl-4-oxy)phenyl-4,4,4-trifluoro-1-sulfonate (BAY 38-7271) is a new high-affinity cannabinoid receptor subtype 1 (CB1 receptor) ligand (K-i = 0.46-1.85 nM; rat brain, human cortex, or recombinant human CB1 receptor), structurally unrelated to any cannabinoid receptor ligand known so far. BAY 38-7271 was characterized as a CB1 receptor agonist in 5-[gamma(35)S]-thiophosphate triethylammonium salt binding assays using rat or human CB1 receptors. In the rat hypothermia assay, BAY 38-7271 induced a dose-dependent reduction in body temperature (minimal effective dose = 6 mug/kg, i.v.); whereas in rats trained to discriminate the CB1/CB2 receptor agonist (-)-cis-3-[2-hydroxy-4(1,1-dimethylheptyl)phenyl]-trans-4-(3-hydroxypropyl) cyclohexanol (CP 55,940; 0.03 mg/kg, i.p.) from vehicle, BAY 38-7271 induced complete generalization (3 mug/kg, i.v.). In both in vivo models, a specific CB1 receptor-mediated mechanism was confirmed by demonstrating that the effects of CP 55,940 and BAY 38-7271 were blocked by pretreatment with the selective CB1 receptor antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamidehydrochloride. In the rat traumatic brain injury model, BAY 38-7271 demonstrated highly potent and efficient neuroprotective properties when administered as a 4- h infusion immediately after induction of subdural hematoma (70% infarct volume reduction at 100 ng/kg/h). Even when applied with a 3-h delay, a significant neuroprotective efficacy could be observed (59% infarct volume reduction at 300 ng/kg/h). The neuroprotective potential of BAY 38-7271 was confirmed in a rat model of focal cerebral ischemia induced by permanent occlusion of the middle cerebral artery. It is concluded that the CB1/CB2 receptor agonist BAY 38-7271 shows pronounced neuroprotective properties that do not result from drug-induced hypothermia and that occur in a dose range devoid of typical cannabinoid-like side effects.	Bayer AG, Business Grp Pharma, CNS Res, D-42096 Wuppertal, Germany; Bayer AG, Business Grp Pharma, Med Chem, D-42096 Wuppertal, Germany	Mauler, F (corresponding author), Bayer AG, Business Grp Pharma, CNS Res, PH-R,Aprather Weg 18A, D-42096 Wuppertal, Germany.						Abood ME, 2001, NEUROSCI LETT, V309, P197, DOI 10.1016/S0304-3940(01)02065-1; Barth F, 1998, EXPERT OPIN THER PAT, V8, P301, DOI 10.1517/13543776.8.3.301; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; Boxer PA, 1997, DRUG DISCOV TODAY, V2, P219, DOI 10.1016/S1359-6446(97)01045-3; Burkey TH, 1997, EUR J PHARMACOL, V336, P295, DOI 10.1016/S0014-2999(97)01255-7; Compton DR, 1996, J PHARMACOL EXP THER, V277, P586; De Vry J, 1998, EUR J PHARMACOL, V357, P1, DOI 10.1016/S0014-2999(98)00503-2; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; GAOINI Y, 1964, J AM CHEM SOC, V86, P1646; Gerdeman G, 2001, J NEUROPHYSIOL, V85, P468; Glass M, 1997, NEUROSCIENCE, V77, P299, DOI 10.1016/S0306-4522(96)00428-9; Hampson AJ, 1998, P NATL ACAD SCI USA, V95, P8268, DOI 10.1073/pnas.95.14.8268; Hampson AJ, 2000, ANN NY ACAD SCI, V899, P274, DOI 10.1111/j.1749-6632.2000.tb06193.x; HANUS L, 1993, J MED CHEM, V36, P3032, DOI 10.1021/jm00072a026; Jin KL, 2000, ANN NEUROL, V48, P257, DOI 10.1002/1531-8249(200008)48:2<257::AID-ANA18>3.3.CO;2-G; Joy JE, 1999, MARIJUANA MED ASSESS; KALLMAN MJ, 1984, FED PROC, V43, P952; Kim DJ, 2000, BRAIN RES, V852, P398, DOI 10.1016/S0006-8993(99)02210-6; Lipton P, 1999, PHYSIOL REV, V79, P1431; Mansbach RS, 1996, PSYCHOPHARMACOLOGY, V124, P315, DOI 10.1007/BF02247436; MARTIN BR, 1991, PHARMACOL BIOCHEM BE, V40, P471, DOI 10.1016/0091-3057(91)90349-7; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; Mauler F, 2001, BRAIN RES, V888, P150, DOI 10.1016/S0006-8993(00)03074-2; MILLER JD, 1990, NEUROSURGERY, V27, P433, DOI 10.1227/00006123-199009000-00016; Mu J, 1999, J PHARMACOL EXP THER, V291, P893; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; Nagayama T, 1999, J NEUROSCI, V19, P2987; Paxinos G., 1982, RAT BRAIN STEREOTAXI; Perio A, 1996, BEHAV PHARMACOL, V7, P65; Pertwee RG, 1997, PHARMACOL THERAPEUT, V74, P129, DOI 10.1016/S0163-7258(97)82001-3; Pertwee RG, 1999, CURR MED CHEM, V6, P635; Petitet F, 1998, LIFE SCI, V63, pPL1, DOI 10.1016/S0024-3205(98)00238-0; Piomelli D, 2000, TRENDS PHARMACOL SCI, V21, P218, DOI 10.1016/S0165-6147(00)01482-6; Prather PL, 2000, MOL PHARMACOL, V57, P1000; RINALDICARMONA M, 1994, FEBS LETT, V350, P240, DOI 10.1016/0014-5793(94)00773-X; Shen MX, 1998, MOL PHARMACOL, V54, P459; SUGIURA T, 1995, BIOCHEM BIOPH RES CO, V215, P89, DOI 10.1006/bbrc.1995.2437; WILEY JL, 1995, J PHARMACOL EXP THER, V275, P1; WILEY JL, 1995, NEUROPHARMACOLOGY, V34, P669, DOI 10.1016/0028-3908(95)00027-4	39	79	81	1	5	AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0022-3565			J PHARMACOL EXP THER	J. Pharmacol. Exp. Ther.	JUL	2002	302	1					359	368	UNSP 4852/990837	10.1124/jpet.302.1.359			10	Pharmacology & Pharmacy	Pharmacology & Pharmacy	562DW	WOS:000176183000046	12065738				2021-06-18	
J	Cattelani, R; Tanzi, F; Lombardi, F; Mazzucchi, A				Cattelani, R; Tanzi, F; Lombardi, F; Mazzucchi, A			Competitive re-employment after severe traumatic brain injury: clinical, cognitive and behavioural predictive variables	BRAIN INJURY			English	Article							VOCATIONAL-REHABILITATION; HEAD-INJURY; FOLLOW-UP; WORK; RETURN; OUTCOMES	Primary objective: To contribute to the identification of relationships between the return to pre-trauma competitive activities at the final discharge from rehabilitation facilities, and neuroanatomical, neuropsychological and behavioural data collected at different phases of the recovery from a traumatic brain injury (TBI). Methods and procedures: Thirty-five severe TBI subjects were retrospectively selected from 228 consecutive admissions over a 3-year period, according to pre-morbid, clinical and demographic characteristics matching the established selection criteria, and submitted to comprehensive neurophysiological, intellectual, cognitive and behavioural examinations carried out at different stages of the recovery (acute, subacute and chronic phases). Experimental interventions: Barthel Activity of Daily Living (BADL) index, Wechsler Adult Intelligence Scale-Revised (WAIS-R), checklists aimed to detect cognitive and behavioural dysfunction, Main outcomes and results: TBI subjects successfully re-employed obtained significantly better scores on length of coma and PTA, intellectual status, cognitive functioning and behavioural competence. Other specific measures of injury severity (CT-scan abnormalities, GCS score level, BADL index) resulted as being unrelated to the resumption of pre-trauma competitive activities. Conclusions: Findings seem to confirm the opinion that a significant relationship exists between the initial TBI severity level, especially as indicated by the duration of coma and PTA, and eventual return to work at the final discharge from facilities.	Univ Parma, Ist Neurol, Dept Neurol, I-43100 Parma, Italy; S Sebastiano Hosp Correggio, Reggio Emilia, Italy; Cardinal Ferrari Rehabil Ctr Fontanellato, Parma, Italy	Cattelani, R (corresponding author), Univ Parma, Ist Neurol, Dept Neurol, Str Quartiere 4, I-43100 Parma, Italy.			LOMBARDI, Francesco/0000-0002-7184-6391			Abrams D., 1993, J HEAD TRAUMA REHAB, V8, P59; Asikainen I, 1998, BRAIN INJURY, V12, P95, DOI 10.1080/026990598122737; BENYISHAY Y, 1987, J HEAD TRAUMA REHAB, V2, P45; Burke W H, 1988, Brain Inj, V2, P313, DOI 10.3109/02699058809150902; Cattelani R, 1998, BRAIN INJURY, V12, P283, DOI 10.1080/026990598122584; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; COPE DN, 1995, BRAIN INJURY, V9, P649, DOI 10.3109/02699059509008224; CREPEAU F, 1993, NEUROPSYCHOL REHABIL, V3, P5; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; FABIANO RJ, 1995, REHABIL PSYCHOL, V40, P223, DOI 10.1037/0090-5550.40.3.223; FRASER RT, 1995, NEUROREHABILITATION, V5, P39, DOI 10.3233/NRE-1995-5104; Girard D, 1996, BRAIN INJURY, V10, P663, DOI 10.1080/026990596124089; Greenspan AI, 1996, BRAIN INJURY, V10, P207, DOI 10.1080/026990596124520; Gurka JA, 1999, J HEAD TRAUMA REHAB, V14, P247, DOI 10.1097/00001199-199906000-00005; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; Johnstone B, 1999, J HEAD TRAUMA REHAB, V14, P220, DOI 10.1097/00001199-199906000-00003; KLONOFF PS, 1986, J CLIN EXP NEUROPSYC, V8, P469, DOI 10.1080/01688638608405171; MAHONEY F I, 1965, Md State Med J, V14, P61; Marshall SB, 1991, J NEUROSURG S, V75, P14; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; MCLEAN A, 1993, ARCH PHYS MED REHAB, V74, P1041, DOI 10.1016/0003-9993(93)90059-J; MCMORDIE W R, 1990, Brain Injury, V4, P57, DOI 10.3109/02699059009026149; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Orsini A, 1997, WAIS R CONTRIBUTO TA; RAO N, 1990, Brain Injury, V4, P49, DOI 10.3109/02699059009026148; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; Sander AM, 1997, J HEAD TRAUMA REHAB, V12, P28, DOI 10.1097/00001199-199710000-00004; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wehman Paul, 1993, Brain Injury, V7, P31, DOI 10.3109/02699059309008154; WEHMAN PH, 1990, ARCH PHYS MED REHAB, V71, P1047	33	79	82	0	8	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK,, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JAN	2002	16	1					51	64		10.1080/02699050110088821			14	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	515BM	WOS:000173475600005	11796099				2021-06-18	
J	Markgraf, CG; Clifton, GL; Moody, MR				Markgraf, CG; Clifton, GL; Moody, MR			Treatment window for hypothermia in brain injury	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; impact injury; edema; hypothermia; rat	CONTROLLED CORTICAL IMPACT; SEVERE HEAD-INJURY; POSTTRAUMATIC HYPOTHERMIA; MODERATE HYPOTHERMIA; INTRACRANIAL HYPERTENSION; MILD HYPOTHERMIA; RAT; MODEL; GLUTAMATE; PRESSURE	Object. The goal of this study was to evaluate the therapeutic window for hypothermia treatment following experimental brain injury by measuring edema formation and functional outcome. Methods. Traumatic brain injury (TBI) was produced in anesthetized rats by using cortical impact injury. Edema was measured in the ipsilateral and contralateral hemispheres by subtracting dry weight from wet weight, and neurological function was assessed using a battery of behavioral tests 24 hours after TBI In injured rats, it was found that brain water levels were elevated at I hour postinjury, compared with those in sham-injured control animals, and that edema peaked at 24 hours and remained elevated for 4 days. Hypothermia (3 hours at 30 degreesC) induced either immediately after TBI or 60 minutes after TBI significantly reduced early neurological deficits. Delay of treatment by 90 or 120 minutes postinjury did not result in this neurological protection. Immediate administration of hypothermia also significantly decreased the peak magnitude of edema at 24 hours and 48 hours postinjury, compared with that in normothermic injured control animals. When delayed by 90 minutes, hypothermia did not affect the pattern of edema formation. Conclusions. When hypothermia was administered immediately or 60 minutes after TBI, injured rats showed an improvement in functional outcome and a decrease in edema. Delayed hypothermia treatment had no effect on functional outcome or on edema.	Univ Texas, Hlth Sci Ctr, Dept Neurosurg, Houston, TX USA; Univ Texas, Hlth Sci Ctr, Vivian L Smith Fdn Neurol Res, Houston, TX USA	Markgraf, CG (corresponding author), Schering Plough Corp, POB 32,144 Route 94, Lafayette, NJ 07848 USA.						BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; BETZ A L, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P133; Clark RSB, 1996, J CEREBR BLOOD F MET, V16, P253, DOI 10.1097/00004647-199603000-00010; CLASEN RA, 1968, ARCH NEUROL-CHICAGO, V19, P472, DOI 10.1001/archneur.1968.00480050042004; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Dixon CE, 1998, J NEUROTRAUM, V15, P95, DOI 10.1089/neu.1998.15.95; DIXON CE, 1991, J NEUROSCI METH, V39, P253; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; GREEN EJ, 1992, BRAIN RES, V580, P197, DOI 10.1016/0006-8993(92)90945-6; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; Kaibara T, 1999, J NEUROSURG, V90, P339, DOI 10.3171/jns.1999.90.2.0339; Kawai N, 2000, J NEUROTRAUM, V17, P193, DOI 10.1089/neu.2000.17.193; LASKOWSKI EJ, 1960, NEUROLOGY, V10, P499, DOI 10.1212/WNL.10.5.499; Markgraf CG, 2001, J NEUROTRAUM, V18, P175, DOI 10.1089/08977150150502604; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; PALMER AM, 1993, J NEUROTRAUM, V10, P363, DOI 10.1089/neu.1993.10.363; Poca MA, 1998, ACT NEUR S, V71, P27; ROSOMOFF HL, 1960, SURG GYNECOL OBSTET, V110, P27; Sakamoto KI, 1997, J NEUROTRAUM, V14, P349, DOI 10.1089/neu.1997.14.349; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; Smith SL, 1996, J NEUROTRAUM, V13, P1, DOI 10.1089/neu.1996.13.1; TAFT WC, 1993, J CEREBR BLOOD F MET, V13, P796, DOI 10.1038/jcbfm.1993.101; UNTERBERG A, 1993, NEUROSURGERY, V32, P17, DOI 10.1227/00006123-199301000-00003	25	79	83	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	DEC	2001	95	6					979	983		10.3171/jns.2001.95.6.0979			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	499HA	WOS:000172564600010	11765843				2021-06-18	
J	Dikmen, S; Machamer, J; Miller, B; Doctor, J; Temkin, N				Dikmen, S; Machamer, J; Miller, B; Doctor, J; Temkin, N			Functional status examination: A new instrument for assessing outcome in traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						functional status; measurement development; outcome assessment; psychometric properties; psychosocial; quality of life; traumatic brain injury	HEAD-INJURY; POSTTRAUMATIC SEIZURES; SCALE; COMA	The Functional Status Examination (FSE) is a new measure designed to evaluate change in activities of everyday life as a function of an event or illness, including traumatic brain injury. The measure covers physical, social, and psychological domains. The FSE is based on a structured interview and includes levels of functioning that accommodate the full spectrum of possible outcomes, from death through recovery to preinjury functioning. Based on 133 prospectively studied patients with moderate to severe traumatic brain injury, the FSE has favorable psychometric properties including good test-retest reliability (r = 0.80) and close correspondence of assessments provided by the patient and their significant other (SO; r = 0.80). The FSE correlated significantly with each of three severity indices with closest relationships occurring between the FSE assessed by the SO and posttraumatic amnesia (r = 0.76). The FSE assessed by the SO was significantly (p < 0.05) more closely related to each severity index than the Glasgow Outcome Scale (GOS) or Sickness Impact Profile and, for two of the three indices, than the SF-36. All measures showed significant change from 1 to 6 months after injury with the FSE showing the largest effect sizes. The FSE is significantly related to important constructs such as family burden, SO depression, and sacrifices the family makes, as well as overall indices of recovery and satisfaction with level of functioning. The latter relationships are significantly stronger than for the GOS. The FSE has demonstrated good reliability, validity, and sensitivity, and appears to be a promising instrument for monitoring recovery and assessing functional status in clinical trials.	Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA; Univ Washington, Dept Biostat, Seattle, WA 98195 USA	Dikmen, S (corresponding author), Univ Washington, Dept Rehabil Med, Box 356490, Seattle, WA 98195 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD033677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS019643] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD33677] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS19643] Funding Source: Medline		BERGNER M, 1976, MED CARE, V14, P57, DOI 10.1097/00005650-197601000-00006; CHOI SC, 1977, BIOMETRIKA, V64, P645, DOI 10.2307/2345351; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; COMSTOCK GW, 1976, PSYCHOL MED, V6, P551, DOI 10.1017/S0033291700018171; DACEY R, 1991, J TRAUMA, V31, P217, DOI 10.1097/00005373-199131020-00011; DEYO RA, 1984, CONTROL CLIN TRIALS, V5, P223, DOI 10.1016/0197-2456(84)90026-6; DIKMEN S, 1990, J CLIN EXP NEUROPSYC, V12, P507, DOI 10.1080/01688639008400997; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; DIKMEN SS, 1991, JAMA-J AM MED ASSOC, V265, P1271, DOI 10.1001/jama.265.10.1271; Fuhrer MJ, 1987, REHABILITATION OUTCO, P137; Hall KM, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199610000-00004; JENNETT B, 1975, LANCET, V1, P480; MARSHALL LF, 1991, J NEUROSURG S, V75, P28; Patrick D., 1993, HLTH STATUS HLTH POL; PATRICK DL, 1988, J GEN INTERN MED, V3, P218, DOI 10.1007/BF02596335; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; TEASDALE G, 1974, LANCET, V2, P81; TEMKIN N, 1988, J CLIN EPIDEMIOL, V41, P47, DOI 10.1016/0895-4356(88)90008-X; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593; TEMKIN NR, 1989, MED CARE, V27, pS44, DOI 10.1097/00005650-198903001-00004; TERI L, 1997, J GERONTOL B-PSYCHOL, V52, P159, DOI DOI 10.1093/GER0NB/52B.4.P159; Ware JE., 1993, SF 36 HLTH SURVEY MA; Willer B, 1993, J HEAD TRAUMA REHAB, V3, P75, DOI DOI 10.1097/00001199-199308020-00009; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; World Health Organization, 1993, INT CLASS IMP DIS HA; ZARIT SH, 1980, GERONTOLOGIST, V20, P649, DOI 10.1093/geront/20.6.649	29	79	79	0	8	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	FEB	2001	18	2					127	140		10.1089/08977150150502578			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	402PW	WOS:000166998200002	11229707				2021-06-18	
J	Ben Arzi, N; Solomon, Z; Dekel, R				Ben Arzi, N; Solomon, Z; Dekel, R			Secondary traumatization among wives of PTSD and post-concussion casualties: distress, caregiver burden and psychological separation	BRAIN INJURY			English	Article							POSTTRAUMATIC-STRESS-DISORDER; MALE VIETNAM VETERANS; INDIVIDUATION; VALIDATION; INJURY; SCL-90; TRAUMA	This study has two aims. First, it assesses the implication of husbands' post-traumatic stress disorder (PTSD) and post-concussion syndrome (PC) on their wives' sense of burden and emotional distress. The second aim was to examine the implication of the women's separation-individuation on their adjustment. Sixty women participated in study: 20 women married to war veterans diagnosed as suffering to PTSD, 20 women married to war veterans suffering from PC, and 20 women married to healthy controls. Data was collected using self report questionnaires assessing psychiatric symptomatology, caregiver burden and psychological separation-individuation. Results indicate that women from both research groups suffer from higher levels of burden and distress than controls. The level of separation-individuation was found to be correlated to levels of burden and distress. The complex implications of living with a traumatized spouse are discussed.	Tel Aviv Univ, Bob Shapell Sch Social Work, IL-69978 Tel Aviv, Israel; Bar Ilan Univ, Sch Social Work, Ramat Gan, Israel	Solomon, Z (corresponding author), Tel Aviv Univ, Bob Shapell Sch Social Work, IL-69978 Tel Aviv, Israel.	solomon@post.tau.ac.il					BERROL S, 1992, PHYSICAL MED REHABIL; Biegel DE., 1991, FAMILY CAREGIVING CH; Blos P., 1979, ADOLESCENT PASSAGE; Bowen M., 1978, FAMILY THERAPY CLIN; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; Coughlan K, 1987, J Psychosoc Nurs Ment Health Serv, V25, P25; Danieli Y., 1982, STRESS ANXIETY, V8, P405; DEKEL R, IN PRESS J TRAUMATIC; DEROGATIS LR, 1977, J CLIN PSYCHOL, V33, P981, DOI 10.1002/1097-4679(197710)33:4<981::AID-JCLP2270330412>3.0.CO;2-0; DEROGATIS LR, 1976, BRIT J PSYCHIAT, V128, P280, DOI 10.1192/bjp.128.3.280; DEROGATIS RL, 1977, SCL90R MANUAL, V1; Dicks HV, 1967, MARITAL TENSIONS; Figley C. H., 1983, STRESS FAMILY COPING, V2, P3; FIGLEY CR, 1986, TRAUMA ITS WAKE, V2, P39; FLORIAN V, 1991, NEUROPSYCHOLOGY, V5, P267, DOI DOI 10.1037/0894-4105.5.4.267; HOFFMAN JA, 1987, J COUNS PSYCHOL, V34, P157; Horowitz M. J., 1986, STRESS RESPONSE SYND; JORDAN BK, 1992, J CONSULT CLIN PSYCH, V60, P916, DOI 10.1037/0022-006X.60.6.916; KARPEL M, 1976, FAM PROCESS, V15, P65, DOI 10.1111/j.1545-5300.1976.00065.x; KAY T, 1992, PHYSICAL MED REHABIL; LEVINSON OJ, 1979, SEASONS MANS LIFE; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; LYONS JA, 1986, ANN CONV AM PSYCH AS; Mahler Margaret S. Fred, 1975, PSYCHOL BIRTH HUMAN; MALONEY LJ, 1988, SMITH COLL STUD SOC, V58, P122, DOI 10.1080/00377318809516639; Marks NF, 1996, FAM RELAT, V45, P27, DOI 10.2307/584767; Mauss-Clum N, 1981, J Neurosurg Nurs, V13, P165; McAllister Thomas W., 1994, P357; MERIKANGAS KR, 1983, ARCH GEN PSYCHIAT, V40, P795; NOVAK M, 1989, GERONTOLOGIST, V29, P798, DOI 10.1093/geront/29.6.798; Ohry A, 1996, BRAIN INJURY, V10, P687, DOI 10.1080/026990596124106; OSHANICK GJ, 1994, NEUROPSYCHIATRY TRAU, P163; Riggs DS, 1998, J TRAUMA STRESS, V11, P87, DOI 10.1023/A:1024409200155; ROSENBAUM M, 1987, J CONSULT CLIN PSYCH, V44, P881; ROSENHECK R, 1985, HOSP COMMUNITY PSYCH, V36, P538; ROSENHECK R, 1986, FAM PROCESS, V25, P559, DOI 10.1111/j.1545-5300.1986.00559.x; SABATELLI RM, 1985, ADOLESCENCE, V20, P619; SBOODONE R, 1995, BRAIN INJURY, V9, P405; SCHAUBEN LJ, 1995, PSYCHOL WOMEN QUART, V19, P49, DOI 10.1111/j.1471-6402.1995.tb00278.x; SHEAN C, 1987, FAM RELAT, V36, P55; SOLOMON Z, 1992, FAM PROCESS, V31, P289, DOI 10.1111/j.1545-5300.1992.00289.x; SOLOMON Z, 1992, J MARRIAGE FAM, V54, P316, DOI 10.2307/353063; Solomon Z., 1993, COMBAT STRESS REACTI; SUTHERLAND JD, 1980, J AM PSYCHOANAL ASS, V28, P829, DOI 10.1177/000306518002800404; Taylor Craig A., 1994, P81; TOUR A, 1992, THESIS BAR ILAN U; Verbosky S J, 1988, Issues Ment Health Nurs, V9, P95, DOI 10.3109/01612848809140912; WILLIAMS CM, 1980, POST TRAUMATIC STRES, P79	48	79	79	0	1	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	AUG	2000	14	8					725	736					12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	342XT	WOS:000088672000006	10969891				2021-06-18	
J	Stover, JF; Schoning, B; Beyer, TF; Woiciechowsky, C; Unterberg, AW				Stover, JF; Schoning, B; Beyer, TF; Woiciechowsky, C; Unterberg, AW			Temporal profile of cerebrospinal fluid glutamate, interleukin-6, and tumor necrosis factor-alpha in relation to brain edema and contusion following controlled cortical impact injury in rats	NEUROSCIENCE LETTERS			English	Article						brain edema; contusion; cytokines; excitotoxicity; traumatic brain injury	CLOSED-HEAD INJURY; TNF-ALPHA; CYTOKINE PRODUCTION; MESSENGER-RNA; EXPRESSION; MICE; IL-6	Traumatic brain injury is associated with release of the excitotoxin glutamate and production of pro-inflammatory cytokines IL-6 and tumor necrosis factor-alpha (TNF-alpha). Following controlled cortical impact injury, cerebrospinal fluid (CSF) glutamate, IL-6, and TNF-alpha concentrations were measured to investigate their relationship to evolving tissue damage. Compared to non-traumatized rats CSF glutamate, IL-6 and TNF-alpha: levels were significantly increased by 8 h after trauma (P < 0.005). Parallel to Increasing brain swelling and contusion CSF glutamate was significantly elevated over time, reaching highest levels by 48 h (33 +/- 4 mu M) while IL-6 and TNF-alpha showed maximum values at 24 h after trauma (42 +/- 7 and 4.7 +/- 1 pg/ml) (P < 0.005). The observed different temporal profile of CSF glutamate, IL-6, and TNF-alpha following focal traumatic brain injury could be of therapeutic importance. (C) 2000 Elsevier Science Ireland Ltd. All rights reserved.	Charite Virchow Med Ctr, Dept Neurosurg, D-13353 Berlin, Germany	Stover, JF (corresponding author), Charite Virchow Med Ctr, Dept Neurosurg, Augustenburger Pl 01, D-13353 Berlin, Germany.						Baskaya MK, 2000, J NEUROTRAUM, V17, P93, DOI 10.1089/neu.2000.17.93; CAMPBELL IL, 1993, P NATL ACAD SCI USA, V90, P10061, DOI 10.1073/pnas.90.21.10061; Carlson NG, 1999, J IMMUNOL, V163, P3963; CHIANG CS, 1994, DEV NEUROSCI-BASEL, V16, P212, DOI 10.1159/000112109; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Fine SM, 1996, J BIOL CHEM, V271, P15303, DOI 10.1074/jbc.271.26.15303; Galasso JM, 2000, NEUROREPORT, V11, P231, DOI 10.1097/00001756-200002070-00002; Hans VHJ, 1999, J CEREBR BLOOD F MET, V19, P184; Holmin S, 2000, J NEUROSURG, V92, P108, DOI 10.3171/jns.2000.92.1.0108; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Obrenovitch TP, 1997, PROG NEUROBIOL, V51, P39, DOI 10.1016/S0301-0082(96)00049-4; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Schiefer J, 1998, J NEUROIMMUNOL, V89, P168, DOI 10.1016/S0165-5728(98)00133-7; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Stover JF, 2000, J NEUROSURG, V92, P853, DOI 10.3171/jns.2000.92.5.0853; Van Wagoner NJ, 1999, J NEUROIMMUNOL, V100, P124, DOI 10.1016/S0165-5728(99)00187-3; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S	20	79	84	0	0	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	JUL 7	2000	288	1					25	28		10.1016/S0304-3940(00)01187-3			4	Neurosciences	Neurosciences & Neurology	329PT	WOS:000087916600007	10869807				2021-06-18	
J	Minard, G; Kudsk, KA; Melton, S; Patton, JH; Tolley, EA				Minard, G; Kudsk, KA; Melton, S; Patton, JH; Tolley, EA			Early versus delayed feeding with an immune-enhancing diet in patients with severe head injuries	JOURNAL OF PARENTERAL AND ENTERAL NUTRITION			English	Article; Proceedings Paper	22nd Clinical Congress of the American-Society-of-Parenteral-and-Enteral-Nutrition	JAN 18-21, 1998	ORLANDO, FLORIDA	Amer Soc Parenteral & Enteral Nutr			MAJOR ABDOMINAL-TRAUMA; ENTERAL NUTRITION; SEPTIC COMPLICATIONS; CANCER-PATIENTS; ARGININE; BENEFITS; OMEGA-3-FATTY-ACIDS; PNEUMONIA; MORBIDITY; RNA	Background: Although early enteral feeding clearly reduces septic morbidity after blunt and penetrating trauma, data for head-injured patients are conflicting. This study examines the effects of early us delayed enteral feedings on outcome in patients with severe closed-head injuries with a Glasgow Coma Scale (GCS) score greater than 3 and less than 11. Methods: Thirty patients were prospectively randomized to receive an immune-enhancing diet (Impact with fiber) early (initiated < 72 hours after trauma) delivered via an endoscopically placed nasoenteric tube (Stay-Put)or late (administered after gastric ileus resolved). This formula was continued for 14 days or until the patient tolerated oral feeding. Goal rate of nutrition was 21 nonprotein cal/kg/d and 0.3 g N/kg/d. Results: Two patients in the early group were excluded due to inability to place the tube, and one patient in the late group died before 72 hours. Five of the remaining 27 died, 1 in the early group and 4 in the late group. There were no significant differences between the groups in length of stay, intensive care unit (ICU) days, significant infection, or GCS score. However, major infection correlated inversely with admission GCS score (R = -0.6, p <.003). Time to reach a GCS score of 14 was significantly longer in patients with significant infections compared with those without (p <.02). Conclusions: No difference in length of stay or infectious complications is shown in patients with severe closed-head injury when they are given early us delayed feeding using an immune-enhancing formula. Severity of the head injury is closely associated with significant infection.	Univ Tennessee, Dept Surg, Memphis, TN USA; Univ Tennessee, Dept Biostat & Epidemiol, Memphis, TN USA	Minard, G (corresponding author), 956 Court Ave,Suite E228, Memphis, TN 38163 USA.						BORZOTTA AP, 1994, J TRAUMA, V37, P459, DOI 10.1097/00005373-199409000-00022; Braga M, 1996, EUR J SURG, V162, P105; CERRA FB, 1991, NUTRITION, V7, P193; DALY JM, 1992, SURGERY, V112, P56; DALY JM, 1995, ANN SURG, V221, P327, DOI 10.1097/00000658-199504000-00002; FELICIANO D V, 1991, Contemporary Surgery, V39, P30; GOTTSCHLICH MM, 1990, JPEN-PARENTER ENTER, V14, P225, DOI 10.1177/0148607190014003225; GRAHM TW, 1989, NEUROSURGERY, V25, P729, DOI 10.1227/00006123-198911000-00007; HSIEH AHH, 1992, AM REV RESPIR DIS, V146, P290, DOI 10.1164/ajrccm/146.2.290; KEMEN M, 1995, CRIT CARE MED, V23, P652, DOI 10.1097/00003246-199504000-00012; KUDSK KA, 1992, ANN SURG, V215, P503, DOI 10.1097/00000658-199205000-00013; Kudsk KA, 1996, ANN SURG, V224, P531, DOI 10.1097/00000658-199610000-00011; Mendez C, 1997, J TRAUMA, V42, P933, DOI 10.1097/00005373-199705000-00026; Mendez C, 1996, SHOCK, V6, P7, DOI 10.1097/00024382-199607000-00003; MOORE EE, 1986, J TRAUMA, V26, P874, DOI 10.1097/00005373-198610000-00003; MOORE FA, 1989, J TRAUMA, V29, P916, DOI 10.1097/00005373-198907000-00003; MOORE FA, 1992, ANN SURG, V216, P172, DOI 10.1097/00000658-199208000-00008; MOORE FA, 1994, J TRAUMA, V37, P607, DOI 10.1097/00005373-199410000-00014; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; QUATTROCCHI KB, 1992, J NEUROTRAUM, V9, P1, DOI 10.1089/neu.1992.9.1; RAPP RP, 1983, J NEUROSURG, V58, P906, DOI 10.3171/jns.1983.58.6.0906; RODRIGUEZ JL, 1991, J TRAUMA, V31, P907, DOI 10.1097/00005373-199107000-00005; Schilling J, 1996, NUTRITION, V12, P423, DOI 10.1016/S0899-9007(96)00096-2; TRICE S, 1997, NUTR CLIN PRACT, V12, P114; Woratyla S P, 1995, Conn Med, V59, P643; YOUNG B, 1987, J NEUROSURG, V67, P668, DOI 10.3171/jns.1987.67.5.0668	26	79	89	0	4	AMER SOC PARENTERAL & ENTERAL NUTRITION	SILVER SPRING	8630 FENTON STREET SUITE 412, SILVER SPRING, MD 20910 USA	0148-6071			JPEN-PARENTER ENTER	J. Parenter. Enter. Nutr.	MAY-JUN	2000	24	3					145	149		10.1177/0148607100024003145			5	Nutrition & Dietetics	Nutrition & Dietetics	355MK	WOS:000089389300003	10850938				2021-06-18	
J	Pike, BR; Zhao, XR; Newcomb, JK; Glenn, CC; Anderson, DK; Hayes, RL				Pike, BR; Zhao, XR; Newcomb, JK; Glenn, CC; Anderson, DK; Hayes, RL			Stretch injury causes calpain and caspase-3 activation and necrotic and apoptotic cell death in septo-hippocampal cell cultures	JOURNAL OF NEUROTRAUMA			English	Article						apoptosis; calpain; caspase-3; cell culture; neuron; spectrin (fodrin); traumatic brain injury	TRAUMATIC BRAIN INJURY; MICROTUBULE-ASSOCIATED PROTEIN-2; SPINAL-CORD INJURY; CORTICAL NEURONAL INJURY; CEREBRAL-ISCHEMIA; DNA FRAGMENTATION; DELAYED DEPOLARIZATION; SPECTRIN BREAKDOWN; MECHANICAL INJURY; REACTIVE GLIOSIS	Traumatic brain injury (TBI) results in numerous central and systemic responses that complicate interpretation of the effects of the primary mechanical trauma. For this reason, several in vitro models of mechanical cell injury have recently been developed that allow more precise control over intra- and extracellular environments than is possible in vivo. Although we recently reported that calpain and caspase-3 proteases are activated after TBI in rats, the role of calpain and/or caspase-3 has not been examined in any in vitro model of mechanical cell injury. In this investigation, varying magnitudes of rapid mechanical cell stretch were used to examine processing of the cytoskeletal protein alpha-spectrin (280 kDa) to a signature 145-kDa fragment by calpain and to the apoptotic-linked 120-kDa fragment by caspase-3 in septo-hippocampal cell cultures. Additionally, effects of stretch injury on cell viability and morphology were assayed. One hour after injury, maximal release of cytosolic lactate dehydrogenase and nuclear propidium iodide uptake were associated with peak accumulations of the calpain-specific 145-kDa fragment to alpha-spectrin at each injury level. The acute period of calpain activation (1-6 h) was associated with subpopulations of nuclear morphological alterations that appeared necrotic (hyperchromatism) or apoptotic (condensed, shrunken nuclei). In contrast, caspase-3 processing of alpha-spectrin to the apoptotic-linked 120-kDa fragment was only detected 24 h after moderate, but not mild or severe injury. The period of caspase-3 activation was predominantly associated with nuclear shrinkage, fragmentation, and apoptotic body formation characteristic of apoptosis. Results of this study indicate that rapid mechanical stretch injury to septo-hippocampal cell cultures replicates several important biochemical and morphological alterations commonly observed in vivo brain injury, although important differences were also noted.	Univ Florida, Dept Neurosci, Inst Brain, Ctr Traumat Brain Injury Studies, Gainesville, FL 32610 USA; Univ Texas, Hlth Sci Ctr, Dept Neurosurg, Vivian L Smith Ctr Neurol Res, Houston, TX USA; Univ Florida, Coll Med, Dept Neurol Surg, Gainesville, FL USA; Malcom Randall Vet Affairs Med Ctr, Gainesville, FL USA	Pike, BR (corresponding author), Univ Florida, Dept Neurosci, Inst Brain, Ctr Traumat Brain Injury Studies, 100 S Newell Dr,Box 100244, Gainesville, FL 32610 USA.	pike@ufbi.ufl.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021458, F32NS010584] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS21458, F32-NS10584] Funding Source: Medline		Banik NL, 1997, BRAIN RES, V752, P301, DOI 10.1016/S0006-8993(96)01488-6; Cargill RS, 1996, J NEUROTRAUM, V13, P395, DOI 10.1089/neu.1996.13.395; Charriaut-Marlangue C, 1998, BIOMED PHARMACOTHER, V52, P264, DOI 10.1016/S0753-3322(98)80012-7; Chen J, 1998, J NEUROSCI, V18, P4914; CHOI DW, 1987, J NEUROSCI, V7, P357; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Conti AC, 1998, J NEUROSCI, V18, P5663; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; DECAMILLI P, 1984, NEUROSCIENCE, V11, P819, DOI 10.1016/0306-4522(84)90194-5; Eldadah BA, 1996, NUCLEIC ACIDS RES, V24, P4092, DOI 10.1093/nar/24.20.4092; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Enari M, 1998, NATURE, V391, P43; Endres H, 1998, J CEREBR BLOOD F MET, V18, P238, DOI 10.1097/00004647-199803000-00002; FISCHER I, 1991, NEUROCHEM RES, V16, P891, DOI 10.1007/BF00965538; Folkerts MM, 1998, J NEUROTRAUM, V15, P349, DOI 10.1089/neu.1998.15.349; Gennarelli T.A., 1985, CENTRAL NERVOUS SYST, P391; GOLDBERG MP, 1988, J PHARMACOL EXP THER, V245, P1081; GROSS GW, 1983, J NEUROSCI, V3, P1979; HARRIS AS, 1988, J BIOL CHEM, V263, P15754; Henkels KM, 1997, CANCER RES, V57, P4488; HICKS RR, 1995, BRAIN RES, V678, P151, DOI 10.1016/0006-8993(95)00179-T; Hill SJ, 1996, J NEUROPATH EXP NEUR, V55, P1221, DOI 10.1097/00005072-199612000-00005; HONG SC, 1994, STROKE, V25, P663, DOI 10.1161/01.STR.25.3.663; Janicke RU, 1998, J BIOL CHEM, V273, P15540, DOI 10.1074/jbc.273.25.15540; JOHNSON GVW, 1991, J NEUROCHEM, V56, P1630, DOI 10.1111/j.1471-4159.1991.tb02061.x; JONES KH, 1985, J HISTOCHEM CYTOCHEM, V33, P77, DOI 10.1177/33.1.2578146; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Kato H, 1997, J THORAC CARDIOV SUR, V114, P609, DOI 10.1016/S0022-5223(97)70051-5; Katoh K, 1996, NEUROSCI LETT, V216, P9; Kaya SS, 1999, BRAIN RES, V818, P23, DOI 10.1016/S0006-8993(98)01204-9; Kitagawa H, 1998, STROKE, V29, P1417, DOI 10.1161/01.STR.29.7.1417; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Lamb RG, 1997, J NEUROCHEM, V68, P1904; LaPlaca MC, 1997, J NEUROTRAUM, V14, P355, DOI 10.1089/neu.1997.14.355; LEE KS, 1991, P NATL ACAD SCI USA, V88, P7233, DOI 10.1073/pnas.88.16.7233; Lewen A, 1996, BRAIN RES, V719, P161, DOI 10.1016/0006-8993(96)00081-9; LI ZH, 1995, NEUROCHEM INT, V27, P425, DOI 10.1016/0197-0186(95)00024-3; Linnik MD, 1996, PHARMACOLOGY OF CEREBRAL ISCHEMIA 1996, P33; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Liu XZ, 1997, J NEUROSCI, V17, P5395; LUCAS J H, 1990, Journal of Neurotrauma, V7, P169, DOI 10.1089/neu.1990.7.169; MALHOTRA SK, 1990, CYTOBIOS, V61, P133; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; MATESIC DF, 1994, J NEUROCHEM, V63, P1012; MONYER H, 1989, BRAIN RES, V483, P347, DOI 10.1016/0006-8993(89)90179-0; Morrison B, 1998, J NEUROTRAUM, V15, P911, DOI 10.1089/neu.1998.15.911; Morrison B, 1998, ANN BIOMED ENG, V26, P381, DOI 10.1114/1.61; Mukhin AG, 1998, J NEUROSCI RES, V51, P748, DOI 10.1002/(SICI)1097-4547(19980315)51:6<748::AID-JNR8>3.0.CO;2-B; MURPHY EJ, 1994, NEUROBIOLOGY CENTRAL, P28; Namura S, 1998, J NEUROSCI, V18, P3659; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; Nath R, 1996, NEUROREPORT, V8, P249, DOI 10.1097/00001756-199612200-00050; Nath R, 1998, J NEUROCHEM, V71, P186; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; NORTON WT, 1992, NEUROCHEM RES, V17, P877, DOI 10.1007/BF00993263; OCALLAGHAN JP, 1993, ANN NY ACAD SCI, V679, P195, DOI 10.1111/j.1749-6632.1993.tb18299.x; Park JS, 1996, NEUROBIOL DIS, V3, P215, DOI 10.1006/nbdi.1996.0022; Pike BR, 1998, J NEUROSCI RES, V52, P505, DOI 10.1002/(SICI)1097-4547(19980601)52:5<505::AID-JNR3>3.3.CO;2-Y; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Piwocka K, 1999, EXP CELL RES, V249, P299, DOI 10.1006/excr.1999.4480; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; Posmantur RM, 1996, J NEUROTRAUM, V13, P125, DOI 10.1089/neu.1996.13.125; Posmantur RM, 1996, J NEUROPATH EXP NEUR, V55, P68, DOI 10.1097/00005072-199601000-00007; Pravdenkova SV, 1996, BRAIN RES, V729, P151, DOI 10.1016/0006-8993(96)00222-3; PURANAM KL, 1999, CRC METH NEUROSCI S, P129; RINK A, 1995, AM J PATHOL, V147, P1575; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; Rzigalinski BA, 1997, J NEUROCHEM, V68, P289; RZIGALINSKI BA, 1998, J NEUROTRAUM, V15, P894; RZIGALINSKI BA, 1996, FASEB J, V10, pA280; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Schmechel D.E., 1999, CRC METH NEUROSCI S, P161; SEUBERT P, 1989, BRAIN RES, V492, P366, DOI 10.1016/0006-8993(89)90921-9; SHEPARD SR, 1991, J SURG RES, V51, P417, DOI 10.1016/0022-4804(91)90144-B; SIMAN R, 1988, NEURON, V1, P279, DOI 10.1016/0896-6273(88)90076-1; Springer JE, 1997, J NEUROCHEM, V69, P1592, DOI 10.1046/j.1471-4159.1997.69041592.x; TAFT WC, 1993, J CEREBR BLOOD F MET, V13, P796, DOI 10.1038/jcbfm.1993.101; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; Tang D, 1998, J BIOL CHEM, V273, P28549, DOI 10.1074/jbc.273.44.28549; Tavalin SJ, 1997, J NEUROPHYSIOL, V77, P632; Tavalin SJ, 1995, J NEUROPHYSIOL, V74, P2767; Wang KKW, 1998, J BIOL CHEM, V273, P22490, DOI 10.1074/jbc.273.35.22490; WILLOUGHBY KA, 1998, J NEUROTRAUM, V15, P902; Wolf BB, 1999, BLOOD, V94, P1683, DOI 10.1182/blood.V94.5.1683.417k37_1683_1692; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Zhao X, 1999, NEUROCHEM RES, V24, P371, DOI 10.1023/A:1020933616351; ZHAO X, 1998, J NEUROTRAUM, V15, P904	94	79	83	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2000	17	4					283	298		10.1089/neu.2000.17.283			16	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	302LA	WOS:000086365500003	10776913				2021-06-18	
J	Levin, HS; Benavidez, DA; Verger-Maestre, K; Perachio, N; Song, J; Mendelsohn, DB; Fletcher, JM				Levin, HS; Benavidez, DA; Verger-Maestre, K; Perachio, N; Song, J; Mendelsohn, DB; Fletcher, JM			Reduction of corpus callosum growth after severe traumatic brain injury in children	NEUROLOGY			English	Article						corpus callosum; traumatic brain injury; children	DIFFUSE AXONAL INJURY; CLOSED-HEAD-INJURY; COMA; MRI	Objective: To study effects of closed head injury (CHI) severity on development of corpus callosum (CC) in children, using MRI. Background: Vulnerability of CC to diffuse axonal injury has been shown in adults and children by neuropathologic and MRI studies. Given continued development of CC through the second decade, serial MRI could characterize effects of CHI on CC growth in children. Methods: MRI performed at 3 and 36 months after severe (mean age = 10.3 years, n = 25) and mild to moderate (mean age = 9.7 years, n = 28) CHI. Mild to moderate and severe CHI groups did not differ in demographic features. Morphometry of T1-weighted midsagittal CC by two operators with satisfactory interrater reliability yielded uncorrected and corrected CC volume. Results: An interaction of occasion with CW severity was present as CC area decreased from 3 to 36 months in severely injured children and increased in the mild to moderate CHI group. Uncorrected CC area was correlated with acute CHI severity and functional outcome at 36 months postinjury. Conclusions: Morphometric measurement of CC area provides a useful index of diffuse injury, which is related to functional outcome of CHI in children.	Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; Baylor Coll Med, Dept Psychiat, Houston, TX 77030 USA; Univ Barcelona, Dept Psychol, E-08007 Barcelona, Spain; Univ Texas, SW Med Sch, Dept Radiol, Dallas, TX 75230 USA; Univ Texas, Hlth Sci Ctr, Dept Pediat, Houston, TX 77225 USA	Levin, HS (corresponding author), Baylor Coll Med, Dept Phys Med & Rehabil, 1333 Moursund Ave,Room A205, Houston, TX 77030 USA.		fletcher, jack/Q-5975-2019; Fletcher, Jack/AAX-2931-2020		NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR002558] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01-RR02558] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS21889] Funding Source: Medline		ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GIEDD JN, 1996, DEV BRAIN RES, V91, P274; GRAHAM DI, 1989, J CLIN PATHOL, V42, P18, DOI 10.1136/jcp.42.1.18; HILLMAN GR, 1991, J COMPUT ASSIST TOMO, V15, P640, DOI 10.1097/00004728-199107000-00021; JENNETT B, 1975, LANCET, V1, P480; JOHNSON SC, 1994, NEUROPSYCHOLOGY, V8, P1; LEVIN HS, 1990, J NEUROSURG, V73, P77, DOI 10.3171/jns.1990.73.1.0077; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; LINDENBERG R, 1955, AM J PATHOL, V31, P297; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MENDELSOHN DB, 1992, NEURORADIOLOGY, V34, P384, DOI 10.1007/BF00596495; Pandya D. N., 1986, 2 HEMISPHERES ONE BR, P47; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; PUJOL J, 1993, ANN NEUROL, V34, P71, DOI 10.1002/ana.410340113; Rajapakse JC, 1996, BRAIN DEV-JPN, V18, P379, DOI 10.1016/0387-7604(96)00034-4; ROKNE J, 1991, GRAPHICS GEMS, V3, P5; Sparrow S., 1984, VINELAND ADAPTIVE BE; STONE MG, 1986, AM MATH MON, V93, P479, DOI 10.2307/2323479; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; TEASDALE G, 1974, LANCET, V2, P81; WITELSON SF, 1989, BRAIN, V112, P799, DOI 10.1093/brain/112.3.799; Yakovlev P.I., 1967, RETIONAL DEV BRAIN E, P3	26	79	80	1	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0028-3878			NEUROLOGY	Neurology	FEB 8	2000	54	3					647	653		10.1212/WNL.54.3.647			7	Clinical Neurology	Neurosciences & Neurology	281KZ	WOS:000085160300020	10680798				2021-06-18	
J	McDonald, S				McDonald, S			Exploring the process of inference generation in sarcasm: A review of normal and clinical studies	BRAIN AND LANGUAGE			English	Article							RIGHT-HEMISPHERE DAMAGE; CLOSED-HEAD-INJURY; AUTISTIC-CHILD; IRONY; MIND; BRAIN; KNOWLEDGE; PRETENSE; REQUESTS; DEFICITS	This article evaluates two theoretical accounts of how sarcasm is understood; the traditional model, which asserts that listeners derive a counterfactual inference from the sarcastic comment, and relevance theory, which asserts that listeners recognize sarcasm as a scornful echo of a previous assertion. Evidence from normal speakers provides only partial support for both theories. Evidence from brain-injured populations suggests that aspects of the pragmatic process can be arrested in ways not predicted by either theory. It is concluded that sarcasm is more effortful to process than nonsarcastic comments and that inferences about the facts of the situation and the mental state of the speaker (e.g., attitudes, knowledge, and intentions) are important to comprehending sarcasm. It is questioned whether inferences about mental state are relatively more difficult for brain-injured subjects and, if so, whether this is a continuum of difficulty or reflects reliance upon different cognitive processes. (C) 1999 Academic Press.	Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia	McDonald, S (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.		McDonald, Skye/G-4118-2014	McDonald, Skye/0000-0003-0723-6094			Bara BG, 1997, BRAIN LANG, V59, P7, DOI 10.1006/brln.1997.1812; BARONCOHEN S, 1992, J CHILD PSYCHOL PSYC, V33, P1141, DOI 10.1111/j.1469-7610.1992.tb00934.x; BARONCOHEN S, 1985, COGNITION, V21, P37, DOI 10.1016/0010-0277(85)90022-8; BENOWITZ LI, 1990, NEUROPSYCHOLOGIA, V28, P231, DOI 10.1016/0028-3932(90)90017-I; Brown Penelope, 1978, POLITENESS SOME UNIV, V2nd; CLARK HH, 1984, J EXP PSYCHOL GEN, V113, P121, DOI 10.1037/0096-3445.113.1.121; CLARK HH, 1980, COGNITION, V8, P111, DOI 10.1016/0010-0277(80)90009-8; CROSSON B, 1987, CLIN NEUROPSYCHOL, V1, P335, DOI DOI 10.1080/13854048708520069; DELIS DC, 1983, CORTEX, V19, P43, DOI 10.1016/S0010-9452(83)80049-5; DEWS S, 1995, METAPHOR SYMB ACT, V10, P3, DOI 10.1207/s15327868ms1001_2; EISENMAJER R, 1991, BRIT J DEV PSYCHOL, V9, P351, DOI 10.1111/j.2044-835X.1991.tb00882.x; EPPEL ML, 1983, J GENET PSYCHOL, V143, P143, DOI 10.1080/00221325.1983.10533544; FLANAGAN S, 1997, P 21 ANN BRAIN IMP C; FLANAGAN S, 1995, TREATMENT ISSUES LON; FOLDI NS, 1987, BRAIN LANG, V31, P88, DOI 10.1016/0093-934X(87)90062-9; Frith U, 1989, AUTISM EXPLAINING EN; GIBBS RW, 1995, DISCOURSE PROCESS, V20, P187, DOI 10.1080/01638539509544937; GIBBS RW, 1991, J PRAGMATICS, V16, P523, DOI 10.1016/0378-2166(91)90101-3; GIBBS RW, 1986, ACTA PSYCHOL, V62, P41, DOI 10.1016/0001-6918(86)90004-1; GIBBS RW, 1986, J EXP PSYCHOL GEN, V115, P3, DOI 10.1037/0096-3445.115.1.3; GIORA R, 1995, DISCOURSE PROCESS, V19, P239, DOI 10.1080/01638539509544916; GORDON D, 1975, SYNTAX SEMANTICS SPE, V3; GRICE HP, 1975, SYNTAX SEMANTICS SPE, V3; GRICE HP, 1978, SYNTAX SEMANTICS PRA, V9; Happe F, 1996, NEUROREPORT, V8, P197, DOI 10.1097/00001756-199612200-00040; HAPPE FGE, 1993, COGNITION, V48, P101, DOI 10.1016/0010-0277(93)90026-R; HAVERKATE H, 1990, J PRAGMATICS, V14, P77, DOI 10.1016/0378-2166(90)90065-L; Jorgensen J, 1996, J PRAGMATICS, V26, P613, DOI 10.1016/0378-2166(95)00067-4; JORGENSEN J, 1984, J EXP PSYCHOL GEN, V113, P112, DOI 10.1037/0096-3445.113.1.112; KAPLAN JA, 1990, BRAIN LANG, V38, P315, DOI 10.1016/0093-934X(90)90117-Y; KRUEZ RJ, 1989, J EXPT PSYCHOL GEN, V118, P374; Leech Geoffrey, 1983, PRINCIPALS PRAGMATIC; LEEKAM SR, 1991, COGNITION, V40, P203, DOI 10.1016/0010-0277(91)90025-Y; LESLIE AM, 1994, COGNITION, V50, P211, DOI 10.1016/0010-0277(94)90029-9; LEVINE MJ, 1993, BRAIN INJURY, V7, P153, DOI 10.3109/02699059309008169; Levinson S.C., 1983, PRAGMATICS; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; LUCARIELLO J, 1994, J EXP PSYCHOL GEN, V123, P129, DOI 10.1037/0096-3445.123.2.129; MARSH DT, 1981, J GENET PSYCHOL, V138, P37, DOI 10.1080/00221325.1981.10532840; MCDONALD S, 1993, COGNITIVE NEUROPSYCH, V10, P297, DOI 10.1080/02643299308253466; MCDONALD S, 1992, APPL PSYCHOLINGUIST, V13, P295, DOI 10.1017/S0142716400005658; McDonald S, 1996, BRAIN LANG, V53, P81, DOI 10.1006/brln.1996.0038; MILTON SB, 1986, CLIN NEUROPSYCHOLOGY; NEWMAN D, 1986, DEV REV, V6, P122, DOI 10.1016/0273-2297(86)90008-0; Ozonoff S, 1996, BRAIN LANG, V52, P411, DOI 10.1006/brln.1996.0022; OZONOFF S, 1994, J CHILD PSYCHOL PSYC, V35, P1015, DOI 10.1111/j.1469-7610.1994.tb01807.x; PREMINGER A, 1974, PRINCETON ENCY POETR; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; PRIOR M, 1990, J AUTISM DEV DISORD, V15, P23; RUMSEY JM, 1985, J AUTISM DEV DISORD, V20, P581; SANTORO J, 1994, BRAIN INJURY, V8, P265, DOI 10.3109/02699059409150978; SAVER JL, 1991, NEUROPSYCHOLOGIA, V29, P1241, DOI 10.1016/0028-3932(91)90037-9; SEARLE JR, 1975, SYNTAX SEMANTICS SPE, V3; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; SIEGAL M, 1991, COGNITION, V38, P1, DOI 10.1016/0010-0277(91)90020-5; Siegal M, 1996, BRAIN LANG, V53, P40, DOI 10.1006/brln.1996.0035; Slugoski B. R., 1988, J LANG SOC PSYCHOL, V7, P101, DOI DOI 10.1177/0261927X8800700202; SPERBER D, 1984, J EXP PSYCHOL GEN, V113, P130, DOI 10.1037/0096-3445.113.1.130; SPERBER D, 1987, BEHAV BRAIN SCI, V10, P697, DOI 10.1017/S0140525X00055345; Sperber D., 1986, RELEVANCE COMMUNICAT; Sperber Dan, 1981, RADICAL PRAGMATICS; SPIERS MV, 1994, BRAIN INJURY, V8, P463, DOI 10.3109/02699059409150998; SULLIVAN K, 1995, BRIT J DEV PSYCHOL, V13, P191, DOI 10.1111/j.2044-835X.1995.tb00673.x; TAGERFLUSBERG H, 1995, APPL PSYCHOLINGUIST, V16, P241, DOI 10.1017/S0142716400007281; TOMPKINS CA, 1985, BRAIN LANG, V24, P185, DOI 10.1016/0093-934X(85)90130-0; Van Horn K R, 1992, Brain Inj, V6, P15, DOI 10.3109/02699059209008118; Walsh K. W, 1991, UNDERSTANDING BRAIN; WAPNER W, 1981, BRAIN LANG, V14, P15, DOI 10.1016/0093-934X(81)90061-4; WILLIAMS JP, 1984, J EXP PSYCHOL GEN, V113, P127, DOI 10.1037/0096-3445.113.1.127; Winner E, 1998, BRAIN LANG, V62, P89, DOI 10.1006/brln.1997.1889; WINNER E, 1991, BRIT J DEV PSYCHOL, V9, P257, DOI 10.1111/j.2044-835X.1991.tb00875.x	71	79	81	0	18	ACADEMIC PRESS INC	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0093-934X			BRAIN LANG	Brain Lang.	JUL	1999	68	3					486	506		10.1006/brln.1999.2124			21	Audiology & Speech-Language Pathology; Linguistics; Neurosciences; Psychology, Experimental	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Psychology	226TE	WOS:000082037100007	10441190				2021-06-18	
J	Collin, GR				Collin, GR			Decreasing catheter colonization through the use of an antiseptic-impregnated catheter - A continuous quality improvement project	CHEST			English	Article						antiseptic-impregnated catheter; bloodstream infection; catheter-related; central venous catheterization; chlorhexidine; colonization; catheter; cost savings; infection; catheter-related infection control; intensive care unit; silver sulfadiazine	PULMONARY-ARTERY CATHETERS; BLOOD-STREAM INFECTION; RANDOMIZED TRIAL; BARRIER PRECAUTIONS; PREVENTION; SEPSIS; COMPLICATIONS; PATHOGENESIS; EPIDEMIOLOGY; MANAGEMENT	Study objectives: To evaluate the use of an antiseptic-impregnated (chlorhexidine and silver sulfadiazine) catheter for the prevention of catheter colonization and catheter-related bloodstream infection (CR-BSI). Then, based on these findings, to implement changes in hospital policy and to assess their effect on a hospital service. Design: Prospective, randomized, controlled (phase I); prospective, concurrent data collection (phase II). Setting: Tertiary referral hospital with level 1 trauma center. Patients: Patients > 12 years of age with central venous catheters placed while they were in the emergency room, neurotrauma ICU, or medical/surgical ICU from May through December, 1995 (phase I). All patients > 12 years of age on the trauma service admitted from November 16, 1996, through November 15, 1997 (phase II). Interventions: Randomization table determined whether the patient would receive an antiseptic-impregnated catheter (AIC) or nonimpregnated catheter (NIC) (phase I). All removed or exchanged catheters were sent for semiquantitative culture. In phase II, only AICs were used; "length of time" and "fever" were discouraged as reasons for catheter exchange or removal; and only the tip was sent for culture. Measurements and results: In phase I, there were 139 catheters placed in 60 patients in the NIC group and 98 catheters placed in 55 patients in the AIC group. Two catheters (2.0/100 catheters) in the AIC group were found to be colonized, compared with 25 (18.0/100 catheters) in the NIC group (p = 0.001). The catheter colonization rates were 2.27/1,000 catheter days (AIC) and 24.68/1,000 catheter days (NIC) (p < 0.001), while the CR-BSI rates were 1.14/1,000 catheter days (AIC) and 3.95/1,000 catheter days (NIC) (p = 0.31). The reason for each catheter removal/exchange was noted, and only "positive blood culture" was statistically significant overall. The tip segment was found to be positive more often than the intracutaneous segment. In phase II, there were 213 AICs place in 101 patients. The colonization rate was 3.8/100 catheters (4.52/1,000 catheter days), and CR-BSI rate was 1.0/100 catheters (0.6/1,000 catheter days). The colonization rate for catheters left in place remained low for catheters left in place < 14 days (1.6/100 catheters). Only 11% of catheters were exchanged/removed for reason of "fever," as compared with 23% in phase I. Conclusions: AICs significantly reduce the rate of central venous catheter colonization. In addition, the apparent protective effects of the catheter over time permit less frequent exchanges or removals of the catheters, decreasing both patient risk and hospital cost.	Carilion Roanoke Mem Hosp, Dept Med Educ, Roanoke, VA 24033 USA	Collin, GR (corresponding author), Carilion Roanoke Mem Hosp, Dept Med Educ, POB 13367, Roanoke, VA 24033 USA.						BALL S, 1995, CRIT CARE MED S, V23, pA250; BOOTH FVM, 1996, CRIT CARE MED S1, V24, pA45; CARLSON R, 1992, ONCOL TIMES, V14, P56; Ciresi DL, 1996, AM SURGEON, V62, P641; Civetta JM, 1996, CRIT CARE MED, V24, P1660, DOI 10.1097/00003246-199610000-00010; CLEMENCE MA, 1993, 33 INT C ANT AG CHEM, P416; DION L, 1988, CRIT CARE MED, V16, P436, DOI 10.1097/00003246-198804000-00154; EVANS M, 1984, ARCH SURG-CHICAGO, V119, P109; FARBER TM, 1992, ARROWGARD ANTISEPTIC; FEINSTEIN AR, 1977, CLIN STAT; FLOWERS RH, 1989, JAMA-J AM MED ASSOC, V261, P878, DOI 10.1001/jama.261.6.878; GARRISON RN, 1994, SURG CLIN N AM, V74, P557, DOI 10.1016/S0039-6109(16)46329-2; GREENFIELD J, 1993, 33 INT C ANT AG CHEM, P415; HEARD SO, 1997, CRIT CARE MED S, V25, pA117; HOFFMANN KK, 1992, JAMA-J AM MED ASSOC, V267, P2072, DOI 10.1001/jama.267.15.2072; JOHNSON A, 1992, J HOSP INFECT, V20, P67, DOI 10.1016/0195-6701(92)90108-X; Kruse J A, 1993, Nutr Clin Pract, V8, P163, DOI 10.1177/0115426593008004163; MAKI DG, 1991, LANCET, V338, P339, DOI 10.1016/0140-6736(91)90479-9; MAKI DG, 1994, INFECT CONT HOSP EP, V15, P227; MAKI DG, 1994, CRIT CARE MED, V22, P1729; Maki DG, 1997, ANN INTERN MED, V127, P257, DOI 10.7326/0003-4819-127-4-199708150-00001; MAKI DG, 1977, NEW ENGL J MED, V296, P1305, DOI 10.1056/NEJM197706092962301; MAKI DG, 1991, 31ST INT C ANT AG CH, P176; Maki DG., 1992, HOSP INFECT, P849; MERMEL LA, 1991, AM J MED, V91, pS197, DOI 10.1016/0002-9343(91)90369-9; MERMEL LA, 1994, AM J RESP CRIT CARE, V149, P1020, DOI 10.1164/ajrccm.149.4.8143037; Mimoz O, 1996, CRIT CARE MED, V24, P1818, DOI 10.1097/00003246-199611000-00010; MODAK SM, 1992, COMPLICATIONS SURG, V11, P22; NORWOOD S, 1991, CHEST, V99, P968, DOI 10.1378/chest.99.4.968; Pemberton LB, 1996, ARCH SURG-CHICAGO, V131, P986; PITTET D, 1994, JAMA-J AM MED ASSOC, V271, P1598, DOI 10.1001/jama.271.20.1598; RAAD II, 1992, CLIN INFECT DIS, V15, P197, DOI 10.1093/clinids/15.2.197; RAAD II, 1994, INFECT CONT HOSP EP, V15, P231; *SAS I, 1990, STAT AN SYST US GUID; Segura M, 1996, ANN SURG, V223, P363, DOI 10.1097/00000658-199604000-00004	35	79	85	0	4	AMER COLL CHEST PHYSICIANS	NORTHBROOK	3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA	0012-3692			CHEST	Chest	JUN	1999	115	6					1632	1640		10.1378/chest.115.6.1632			9	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	206FX	WOS:000080867600027	10378561				2021-06-18	
J	Barnes, MA; Dennis, M; Wilkinson, M				Barnes, MA; Dennis, M; Wilkinson, M			Reading after closed head injury in childhood: Effects on accuracy, fluency, and comprehension	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article							TRAUMATIC BRAIN INJURY; WORD RECOGNITION; NAMING SPEED; DEVELOPMENTAL DYSLEXIA; CHILDREN; AGE; INFORMATION; SKILLS; ADOLESCENTS; PERFORMANCE	Two studies of reading decoding, reading fluency, and reading comprehension after childhood head injury are reported. Study 1 tested whether age at head injury and the type of contusional brain damage were related to reading outcomes. Fifty-five children with head injuries were tested on measures of word decoding accuracy and reading comprehension. Children who sustained head injuries in the preschool years before basic word decoding skills are acquired or in the early primary grades when decoding skills are being taught, and children with bilateral or left-sided contusions were most at risk for difficulties in acquiring basic word decoding and reading comprehension skills. In particular, children injured before 6 1/2 years of age were most at risk for difficulties in acquiring reading decoding skills in comparison to children injured after this age. Study 2 tested whether deficits in processing speed after head injury are also found in reading. Forty-three head-injured children were matched with controls on a pair-by-pair basis for age, grade, and word decoding accuracy. The children with head injuries were slower at naming words, particularly those with less common orthographic patterns, although the groups did not differ on speeded naming of pronounceable nonwords. Reading fluency in the head-injured group was related to reading comprehension, suggesting that slow word-level processing has negative consequences for text comprehension in these individuals. The results are discussed with respect to how head injuries affect the development of skills yet to be acquired and the further acquisition of those skills that are in a rapid phase of development at time of injury. The results are also discussed with reference to models of how head injury affects speeded processing.	Hosp Sick Children, Dept Psychol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Toronto, ON, Canada	Barnes, MA (corresponding author), Hosp Sick Children, Dept Psychol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	mbarnes@sickkids.on.ca					ADAMS MJ, 1990, BEGINNING READ; ALAJOUANINE T, 1965, BRAIN, V88, P653, DOI 10.1093/brain/88.4.653; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; BACKMAN J, 1984, J EXP CHILD PSYCHOL, V38, P114, DOI 10.1016/0022-0965(84)90022-5; Barnes MA, 1996, J EXP CHILD PSYCHOL, V61, P216, DOI 10.1006/jecp.1996.0015; BARNES MA, 1992, J PEDIATR PSYCHOL, V17, P445, DOI 10.1093/jpepsy/17.4.445; BAWDEN HN, 1985, J CLIN EXP NEUROPSYC, V7, P39, DOI 10.1080/01688638508401241; BOWERS PG, 1993, J READING BEHAV, V25, P133, DOI 10.1080/10862969309547807; BOWERS PG, 1991, J EXP CHILD PSYCHOL, V51, P195, DOI 10.1016/0022-0965(91)90032-N; BOWERS PG, 1993, READ WRIT, V5, P69, DOI 10.1007/BF01026919; Bradley L., 1985, RHYME REASON READING; BRINK JD, 1970, DEV MED CHILD NEUROL, V12, P565; BRYANT P, 1990, APPL PSYCHOLINGUIST, V11, P237, DOI 10.1017/S0142716400008870; CARR TH, 1990, READING ITS DEV COMP; CASEY R, 1986, PEDIATRICS, V78, P497; DENCKLA MB, 1976, NEUROPSYCHOLOGIA, V14, P471, DOI 10.1016/0028-3932(76)90075-0; Dennis M, 1996, DEV NEUROPSYCHOL, V12, P77, DOI 10.1080/87565649609540641; DENNIS M, 1988, MASTER LECT SERIES, V7, P89; DENNIS M, 1990, BRAIN LANG, V39, P203; Dennis M., 1995, TRAUMATIC HEAD INJUR, P165; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; FLETCHER JM, 1987, NEUROBEHAVIORAL RECO, P277; FOX B, 1984, J EDUC PSYCHOL, V76, P1059; GOLDSTEIN FC, 1990, J CLIN EXP NEUROPSYC, V12, P286, DOI 10.1080/01688639008400975; HAALAND KY, 1994, J CLIN EXP NEUROPSYC, V16, P448, DOI 10.1080/01688639408402655; HASLAM C, 1995, NEUROPSYCHOLOGY, V9, P599, DOI 10.1037/0894-4105.9.4.599; Haut M W, 1990, Arch Clin Neuropsychol, V5, P299, DOI 10.1016/0887-6177(90)90028-N; HAUT MW, 1991, BRAIN COGNITION, V17, P31, DOI 10.1016/0278-2626(91)90064-F; HEBB D. O., 1942, PROC AMER PHIL SOC, V85, P275; Hetherington CR, 1996, BRAIN INJURY, V10, P473, DOI 10.1080/026990596124197; KINSELLA G, 1995, J PEDIATR PSYCHOL, V20, P753, DOI 10.1093/jpepsy/20.6.753; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; KRIEL RL, 1989, PEDIATR NEUROL, V5, P296, DOI 10.1016/0887-8994(89)90021-0; LABERGE D, 1974, COGNITIVE PSYCHOL, V6, P293, DOI 10.1016/0010-0285(74)90015-2; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; LEVIN HS, 1988, SCANDINAVIAN J REH S, V20, P33; LIEHLAI MW, 1992, J PEDIATR-US, V120, P195, DOI 10.1016/S0022-3476(05)80426-3; LOVETT MW, 1992, HDB NEUROPSYCHOLOGY, V7, P163; MAHONEY WJ, 1983, PEDIATRICS, V71, P756; MCKEOWN MG, 1983, J READING BEHAV, V15, P3, DOI 10.1080/10862968309547474; NICOLSON RI, 1990, COGNITION, V35, P159, DOI 10.1016/0010-0277(90)90013-A; Oakhill J., 1988, BECOMING SKILLED REA; Oakhill J, 1993, EDUC PSYCHOL REV, V5, P223, DOI 10.1007/BF01323045; Paris R., 1974, CLIN NEUROPSYCHOLOGY, P179; Perfetti C.A., 1985, READING ABILITY; RANKIN JL, 1993, J READING BEHAV, V25, P261, DOI 10.1080/10862969009547817; RUTTER M, 1980, PSYCHOL MED, V10, P633, DOI 10.1017/S0033291700054933; SEGALOWITZ S, 1992, J CLIN EXPT NEUROPSY, V14, P73; SEIDENBERG MS, 1989, PSYCHOL REV, V96, P523, DOI 10.1037/0033-295X.96.4.523; SEIDENBERG MS, 1984, J VERB LEARN VERB BE, V23, P383, DOI 10.1016/S0022-5371(84)90270-6; SHAFFER D, 1980, J AM ACAD CHILD PSY, V19, P592, DOI 10.1016/S0002-7138(09)60964-X; SHINN MR, 1992, SCHOOL PSYCHOL REV, V21, P459; SPRING C, 1988, APPL PSYCHOLINGUIST, V9, P315, DOI 10.1017/S0142716400008031; STANOVICH KE, 1986, READ RES QUART, V21, P360, DOI 10.1598/RRQ.21.4.1; STANOVICH KE, 1984, READ RES QUART, V19, P278, DOI 10.2307/747822; TROMP E, 1991, J CLIN EXP NEUROPSYC, V13, P821, DOI 10.1080/01688639108405100; TUNMER WE, 1985, J EDUC PSYCHOL, V77, P417, DOI 10.1037/0022-0663.77.4.417; vansZomeren AH, 1987, NEUROBEHAVIORAL RECO, P398; WATERS GS, 1985, MEM COGNITION, V13, P557, DOI 10.3758/BF03198326; WATERS GS, 1984, MEM COGNITION, V12, P293, DOI 10.3758/BF03197678; Wechsler D., 1974, MANUAL WECHSLER INTE; Wechsler D., 1991, WECHSLER INTELLIGENC; WOLF M, 1992, BRAIN LANG, V42, P219, DOI 10.1016/0093-934X(92)90099-Z; WOLF M, 1986, CHILD DEV, V57, P988, DOI 10.1111/j.1467-8624.1986.tb00260.x; WOLFF PH, 1990, BRAIN LANG, V39, P556, DOI 10.1016/0093-934X(90)90162-A; Woodcock R.W., 1987, WOODCOCK READING MAS; WOODCOCK RW, 1989, TEST COGNITIVE ABILI; WRIGHTSON P, 1995, J NEUROL NEUROSUR PS, V59, P375, DOI 10.1136/jnnp.59.4.375	68	79	79	0	9	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	8756-5641	1532-6942		DEV NEUROPSYCHOL	Dev. Neuropsychol.		1999	15	1					1	24		10.1080/87565649909540737			24	Psychology, Developmental; Psychology; Psychology, Experimental	Psychology	165BC	WOS:000078497900001					2021-06-18	
S	Huang, TT; Carlson, EJ; Raineri, M; Gillespie, AM; Kozy, H; Epstein, CJ		Blass, JP; McDowell, FH		Huang, TT; Carlson, EJ; Raineri, M; Gillespie, AM; Kozy, H; Epstein, CJ			The use of transgenic and mutant mice to study oxygen free radical metabolism	OXIDATIVE/ENERGY METABOLISM IN NEURODEGENERATIVE DISORDERS	Annals of the New York Academy of Sciences		English	Article; Proceedings Paper	Conference on Oxidative/Energy Metabolism in Neurodegenerative Disorders	MAR 19-22, 1999	NEW YORK, NY	New York Acad Sci, Winifred Masterson Burke Med Res Inst Inc, NIA, NIH, MitoKor, Amer Fed Aging Res, Warner Lambert Co, Parke Davis Pharmaceut Res			CUZN-SUPEROXIDE-DISMUTASE; FOCAL CEREBRAL-ISCHEMIA; HSP70 MESSENGER-RNA; PERINATAL HYPOXIA-ISCHEMIA; TRAUMATIC BRAIN INJURY; MU-OPIOID RECEPTORS; METHYLENEDIOXYMETHAMPHETAMINE MDMA; NEUROMUSCULAR-JUNCTION; DEFICIENT MICE; DOWNS-SYNDROME	To distinguish the role of Mn superoxide dismutase (MnSOD) from that of cytoplasmic CuZn superoxide dismutase (CuZnSOD), the mouse MnSOD gene (Sod2) mas inactivated by homologous recombination. Sod2 -/- mice on a CD1 (outbred) genetic background die within the first 10 days of life (mean, 5.4 days) with a complex phenotype that includes dilated cardiomyopathy, accumulation of lipid in liver and skeletal muscle, metabolic acidosis and ketosis, and a severe reduction in succinate dehydrogenase (complex II) and aconitase (a TCA cycle enzyme) activities in the heart and, to a lesser extent, in other organs. These findings indicate that MnSOD is required to maintain the integrity of mitochondrial enzymes susceptible to direct inactivation by superoxide. On the other hand, Lebovitz et al. reported an independently derived MnSod null mouse (Sod2tmlLeb) on a mixed C57BL/6 and 129Sv background with a different phenotype. Because a difference in genetic background is the most likely explanation for the phenotypic differences, the two mutant lines were crossed into different genetic backgrounds for further analyses. To study the phenotype of Sod2tmlLeb mice CD1 background, the Sod2tmlLeb mice were crossed to CD1 for two generations before the -/+ mice were intercrossed to generate -/- mice. The life span distribution of CD1<Sod2-/->Leb was shifted to the left, indicating a shortened life span on the CD1 background. Furthermore, the CD1<Sod2-/->Leb mice develop metabolic acidosis at an early stage as was observed with CD1<Sod2-/->Cje. When Sod2tmlCje was placed on C57BL/6J (B6) background, the -/- mice were found to die either during midgestation or within the first 4 days after birth. However, when the B6<Sod2-/+>Cje mere crossed with DBA/2J (D2) for the generation of B6D2F2<Sod2-/->Cje mice, an entirely different phenotype, similar to that described by Lebovitz et at, was observed. The F2 Sod -/- mice were able to survive up to 18 days, and the animals that Lived for more than 15 days displayed neurological abnormalities including ataxia and seizures. Their hearts were not as severely affected as were those of the CD1 mice, and neurological degeneration rather than heart defect appears to be the cause of death.	Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA	Epstein, CJ (corresponding author), Univ Calif San Francisco, Dept Pediat, 531 Parnassus,U585L, San Francisco, CA 94143 USA.	cepst@itsa.ucsf.edu			NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG008938, R03AG015151, R01AG016998] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG-08938, AG-16998, AG-15151] Funding Source: Medline		Andrews AM, 1996, MOL PHARMACOL, V50, P1511; AVRAHAM KB, 1991, J NEUROCYTOL, V20, P208, DOI 10.1007/BF01186993; AVRAHAM KB, 1988, CELL, V54, P823, DOI 10.1016/S0092-8674(88)91153-1; BEAL MF, 1995, J NEUROCHEM, V65, P919; CADET JL, 1995, SYNAPSE, V21, P169, DOI 10.1002/syn.890210210; CADET JL, 1994, BRAIN RES, V655, P259, DOI 10.1016/0006-8993(94)91624-1; CADET JL, 1994, J NEUROCHEM, V62, P380; CHAN PH, 1993, NEUROREPORT, V5, P293, DOI 10.1097/00001756-199312000-00028; CHAN PH, 1991, ANN NEUROL, V29, P482, DOI 10.1002/ana.410290506; Chan PH, 1998, J NEUROSCI, V18, P8292, DOI 10.1523/jneurosci.18-20-08292.1998; Chen ZY, 1998, J MOL CELL CARDIOL, V30, P2281, DOI 10.1006/jmcc.1998.0789; Ditelberg JS, 1996, PEDIATR RES, V39, P204, DOI 10.1203/00006450-199602000-00003; ELMER GI, 1995, EUR J PHARMACOL, V283, P227, DOI 10.1016/0014-2999(95)00365-R; Elmer GI, 1996, BEHAV PHARMACOL, V7, P628; EPSTEIN CJ, 1987, P NATL ACAD SCI USA, V84, P8044, DOI 10.1073/pnas.84.22.8044; Friedlich A. L., 1993, Society for Neuroscience Abstracts, V19, P1036; Fullerton HJ, 1998, ANN NEUROL, V44, P357, DOI 10.1002/ana.410440311; GARDNER PR, 1994, P NATL ACAD SCI USA, V91, P12248, DOI 10.1073/pnas.91.25.12248; HIRATA H, 1995, BRAIN RES, V677, P345, DOI 10.1016/0006-8993(95)00218-F; Hirata H, 1996, BRAIN RES, V714, P95, DOI 10.1016/0006-8993(95)01502-7; Ho YS, 1998, AM J RESP CELL MOL, V18, P538, DOI 10.1165/ajrcmb.18.4.2959; Huang TT, 1997, ARCH BIOCHEM BIOPHYS, V344, P424, DOI 10.1006/abbi.1997.0237; Huang TT, 1998, AGE, V21, P83, DOI 10.1007/s11357-998-0011-y; HUANG TT, 1999, IN PRESS J GERONTOL; KAMII H, 1994, BRAIN RES, V662, P240, DOI 10.1016/0006-8993(94)90818-4; KAMII H, 1994, J CEREBR BLOOD F MET, V14, P478, DOI 10.1038/jcbfm.1994.59; KINOUCHI H, 1991, P NATL ACAD SCI USA, V88, P11158, DOI 10.1073/pnas.88.24.11158; Klivenyi P, 1998, NEUROBIOL DIS, V5, P253, DOI 10.1006/nbdi.1998.0191; Kondo T, 1997, J NEUROSCI, V17, P4180; Kondo T, 1997, J CEREBR BLOOD F MET, V17, P241, DOI 10.1097/00004647-199703000-00001; Kondo T, 1996, BRAIN RES, V737, P321, DOI 10.1016/0006-8993(96)00949-3; KUJIRAI K, 1994, SYNAPSE, V17, P76, DOI 10.1002/syn.890170203; Lebovitz RM, 1996, P NATL ACAD SCI USA, V93, P9782, DOI 10.1073/pnas.93.18.9782; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; Li YB, 1998, BRAIN RES, V814, P164, DOI 10.1016/S0006-8993(98)01082-8; Melov S, 1999, P NATL ACAD SCI USA, V96, P846, DOI 10.1073/pnas.96.3.846; Mena MA, 1997, J NEUROCHEM, V69, P21; Mikawa S, 1996, J NEUROSURG, V85, P885, DOI 10.3171/jns.1996.85.5.0885; MIKAWA S, 1995, MOL BRAIN RES, V33, P288, DOI 10.1016/0169-328X(95)00146-J; Murakami K, 1998, J NEUROSCI, V18, P205; Murakami K, 1997, STROKE, V28, P1797, DOI 10.1161/01.STR.28.9.1797; NAKAO N, 1995, NAT MED, V1, P226, DOI 10.1038/nm0395-226; PRZEDBORSKI S, 1992, J NEUROSCI, V12, P1658; Przedborski S, 1996, J NEUROCHEM, V67, P1383; Raber J, 1996, VIROLOGY, V226, P362, DOI 10.1006/viro.1996.0664; Reaume AG, 1996, NAT GENET, V13, P43, DOI 10.1038/ng0596-43; ROBERTS JR, 1994, J BIOL CHEM, V269, P17841; Roberts JR, 1996, J BIOL CHEM, V271, P24604, DOI 10.1074/jbc.271.40.24604; Rozmahel R, 1996, NAT GENET, V12, P280, DOI 10.1038/ng0396-280; SanchezRamos JR, 1997, J NEUROCHEM, V68, P58; Sun JT, 1999, MOL CELL BIOL, V19, P216; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; Van Remmen H, 1999, ARCH BIOCHEM BIOPHYS, V363, P91, DOI 10.1006/abbi.1998.1060; Williams MD, 1998, J BIOL CHEM, V273, P28510, DOI 10.1074/jbc.273.43.28510; YANG GY, 1994, STROKE, V25, P165, DOI 10.1161/01.STR.25.1.165; Yen HC, 1999, ARCH BIOCHEM BIOPHYS, V362, P59, DOI 10.1006/abbi.1998.1011; ZHANG Y, 1990, J BIOL CHEM, V265, P16330	57	79	81	0	3	NEW YORK ACAD SCIENCES	NEW YORK	2 EAST 63RD ST, NEW YORK, NY 10021 USA	0077-8923		1-57331-209-6	ANN NY ACAD SCI	Ann.NY Acad.Sci.		1999	893						95	112		10.1111/j.1749-6632.1999.tb07820.x			18	Biochemistry & Molecular Biology; Endocrinology & Metabolism; Multidisciplinary Sciences; Neurosciences; Ornithology	Biochemistry & Molecular Biology; Endocrinology & Metabolism; Science & Technology - Other Topics; Neurosciences & Neurology; Zoology	BP50E	WOS:000085330600009	10672232				2021-06-18	
J	Lewen, A; Hillered, L				Lewen, A; Hillered, L			Involvement of reactive oxygen species in membrane phospholipid breakdown and energy perturbation after traumatic brain injury in the rat	JOURNAL OF NEUROTRAUMA			English	Article						drug therapy; free radicals; glucose; glycerol; lactate; microdialysis; rat; traumatic brain injury	FREE FATTY-ACIDS; BUTYL-NITRONE PBN; CEREBRAL BLOOD-FLOW; PRECURSOR PROTEIN IMMUNOREACTIVITY; PHOSPHATIDYLINOSITOL BISPHOSPHATE; SUPEROXIDE PRODUCTION; RESPIRATORY ACTIVITY; ARACHIDONIC-ACID; CORTICAL-NEURONS; REGIONAL LEVELS	Interstitial glycerol may be a useful marker for posttraumatic and postischemic membrane phospholipid (PL) breakdown, Degradation of membrane PLs is thought to be triggered by both calcium and reactive oxygen species (ROS)-mediated mechanisms and to be associated with disturbed energy metabolism. In this study, we investigated the temporal changes of interstitial glycerol, lactate, and glucose after traumatic brain injury in the rat and the effect of pretreatment with the free radical spin trap alpha-phenyl-N-tert-butyl nitrone (PBN; 30 mg/kg i.v.). Microdialysate was sampled continuously in 10-min fractions from 1 h before, until 2 h after a cortical contusion injury produced by the weight-drop technique, The maximal concentration of interstitial glycerol (a ninefold increase) was seen 10-30 min after trauma and subsided during the following 2 h, but remained above base line as compared to sham operated animals, Concomitantly, there was an increase in interstitial lactate (fivefold) and a fall in interstitial glucose, indicating a posttraumatic energy perturbation. PEN treatment significantly attenuated the interstitial accumulation of glycerol and lactate. The results support the concept that ROS are involved in posttraumatic membrane PL breakdown and that PEN improves mitochondrial function after CNS injury. Monitoring of interstitial glycerol with microdialysis may be a valuable tool for studies on membrane PL degradation and the efficacy of neuroprotective drugs in acute CNS injury.	Univ Uppsala Hosp, Dept Neurosci, S-75185 Uppsala, Sweden; Univ Uppsala Hosp, Dept Neurosurg, S-75185 Uppsala, Sweden; Univ Uppsala Hosp, Dept Med, S-75185 Uppsala, Sweden; Univ Uppsala Hosp, Dept Clin Chem, S-75185 Uppsala, Sweden	Lewen, A (corresponding author), Univ Uppsala Hosp, Dept Neurosci, S-75185 Uppsala, Sweden.		Lewen, Anders/A-5156-2013	Lewen, Anders/0000-0003-4925-1348			ABE K, 1987, J NEUROCHEM, V48, P503, DOI 10.1111/j.1471-4159.1987.tb04121.x; AGARDH CD, 1981, J CEREBR BLOOD F MET, V1, P267, DOI 10.1038/jcbfm.1981.31; Agranoff Bernard W., 1994, P97; ALTHAUS JS, 1993, MOL CHEM NEUROPATHOL, V20, P147, DOI 10.1007/BF02815368; ANDERSON DK, 1994, NEUROBIOLOGY CENTRAL, P131; AU AM, 1985, J CELL BIOCHEM, V27, P449, DOI 10.1002/jcb.240270413; BAZAN NG, 1971, J NEUROCHEM, V18, P1379, DOI 10.1111/j.1471-4159.1971.tb00002.x; BAZAN NG, 1970, BIOCHIM BIOPHYS ACTA, V218, P1, DOI 10.1016/0005-2760(70)90086-X; BENVENISTE H, 1989, J NEUROCHEM, V52, P1667, DOI 10.1111/j.1471-4159.1989.tb07243.x; BERTRAND N, 1992, NEUROSCI LETT, V148, P81, DOI 10.1016/0304-3940(92)90809-L; CARNEY JM, 1991, J MOL NEUROSCI, V3, P47, DOI 10.1007/BF02896848; CHAN PH, 1982, J NEUROCHEM, V38, P525, DOI 10.1111/j.1471-4159.1982.tb08659.x; CHEN GM, 1990, FREE RADICAL RES COM, V9, P317, DOI 10.3109/10715769009145690; CHENG Y, 1994, NEUROCHEM RES, V19, P1557, DOI 10.1007/BF00969006; DHILLON HS, 1994, J NEUROTRAUM, V11, P405, DOI 10.1089/neu.1994.11.405; Dhillon HS, 1997, EXP NEUROL, V146, P240, DOI 10.1006/exnr.1997.6524; DHILLON HS, 1995, BRAIN RES, V698, P100, DOI 10.1016/0006-8993(95)00840-M; Farooque M, 1997, J NEUROTRAUM, V14, P469, DOI 10.1089/neu.1997.14.469; FAROOQUI AA, 1994, INT REV NEUROBIOL, V36, P267, DOI 10.1016/S0074-7742(08)60306-2; FOLBERGROVA J, 1995, P NATL ACAD SCI USA, V92, P5057, DOI 10.1073/pnas.92.11.5057; FOSTER KJ, 1978, CLIN CHEM, V24, P1568; GERCKEN G, 1973, PFLUG ARCH EUR J PHY, V344, P207, DOI 10.1007/BF00588461; GERCKEN G, 1969, J NEUROCHEM, V16, P761, DOI 10.1111/j.1471-4159.1969.tb06454.x; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; HILLERED L, 1984, J CEREBR BLOOD F MET, V4, P430, DOI 10.1038/jcbfm.1984.62; HILLERED L, 1983, J CEREBR BLOOD F MET, V3, P207, DOI 10.1038/jcbfm.1983.28; Hillered L, 1998, J NEUROL NEUROSUR PS, V64, P486, DOI 10.1136/jnnp.64.4.486; HILLERED L, 1988, J NEUROSCI RES, V19, P94, DOI 10.1002/jnr.490190113; Hinzen D H, 1970, Pflugers Arch, V318, P119; Homayoun P, 1997, J NEUROCHEM, V69, P199; IKEDA M, 1986, J NEUROCHEM, V47, P123; INANAMI O, 1995, FREE RADICAL RES, V23, P33, DOI 10.3109/10715769509064017; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; KIHARA T, 1995, J NEUROCHEM, V65, P282; KIM DK, 1995, BIOCHEM J, V310, P83, DOI 10.1042/bj3100083; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; Kuroda S, 1996, NEUROBIOL DIS, V3, P149, DOI 10.1006/nbdi.1996.0015; KUWASHIMA J, 1976, BRAIN RES, V110, P547, DOI 10.1016/0006-8993(76)90865-9; LAFONCAZAL M, 1993, NATURE, V364, P535, DOI 10.1038/364535a0; LEWEN A, 1995, NEUROREPORT, V6, P357, DOI 10.1097/00001756-199501000-00032; Lewen A, 1996, BRAIN RES, V719, P161, DOI 10.1016/0006-8993(96)00081-9; LEWEN A, 1996, J NEUROTRAUM, V13, P600; LLOYD B, 1978, CLIN CHEM, V24, P1724; Lyeth BG, 1996, BRAIN RES, V742, P63, DOI 10.1016/S0006-8993(96)01002-5; Marklund N, 1997, NEUROREPORT, V8, P1457, DOI 10.1097/00001756-199704140-00026; NAKAHARA I, 1991, J NEUROCHEM, V57, P839, DOI 10.1111/j.1471-4159.1991.tb08227.x; Nemoto E M, 1983, Am J Emerg Med, V1, P175, DOI 10.1016/0735-6757(83)90086-4; NEMOTO EM, 1982, J CEREBR BLOOD F MET, V2, P475, DOI 10.1038/jcbfm.1982.54; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; Nilsson P, 1996, J NEUROTRAUM, V13, P201, DOI 10.1089/neu.1996.13.201; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; NILSSON P, 1994, BRAIN RES, V637, P227, DOI 10.1016/0006-8993(94)91237-8; OTANI H, 1987, CIRCULATION, V76, P161; PASCHEN W, 1986, METAB BRAIN DIS, V1, P37, DOI 10.1007/BF00998475; PELLEGRINIGIAMPIETRO DE, 1990, J NEUROSCI, V10, P1035, DOI 10.1523/jneurosci.10-03-01035.1990; PRASAD MR, 1994, J NEUROCHEM, V63, P1086; PRASAD MR, 1994, J NEUROCHEM, V63, P773; SHOHAMI E, 1989, J NEUROCHEM, V53, P1541, DOI 10.1111/j.1471-4159.1989.tb08550.x; SIESJO BK, 1992, ADV EXP MED BIOL, V318, P41; SUN DD, 1994, NEUROCHEM RES, V19, P525, DOI 10.1007/BF00967333; SUN DD, 1994, J NEUROCHEM, V62, P1921; TAPIAARANCIBIA L, 1992, EUR J PHARM-MOLEC PH, V225, P253, DOI 10.1016/0922-4106(92)90027-S; Tayag EC, 1996, BRAIN RES, V733, P287, DOI 10.1016/0006-8993(96)00669-5; TURRENS JF, 1991, FREE RADICAL RES COM, V12-3, P681, DOI 10.3109/10715769109145847; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; Vink R, 1990, J NEUROTRAUM, V7, P21, DOI 10.1089/neu.1990.7.21; WEI EP, 1982, J NEUROSURG, V56, P695, DOI 10.3171/jns.1982.56.5.0695; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289; ZHANG Y, 1993, SURG NEUROL, V39, P297, DOI 10.1016/0090-3019(93)90009-P	73	79	79	0	3	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUL	1998	15	7					521	530		10.1089/neu.1998.15.521			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	ZY374	WOS:000074614700006	9674555				2021-06-18	
J	Serio, CD; Kreutzer, JS; Witol, AD				Serio, CD; Kreutzer, JS; Witol, AD			Family needs after traumatic brain injury: A factor analytic study of the Family Needs Questionnaire	BRAIN INJURY			English	Article							CRITICALLY ILL PATIENTS; HEAD-INJURY; RELATIVES	The present investigation examined the empirical and theoretical validity of an instrument developed to assess family members' perceptions of needs following the brain injury of a relative. The Family Needs Questionnaire (FNQ) consists of 40 items reflecting commonly reported family needs. The development of the items was based on the literature describing family reactions to brain injury and other medical disabilities. A principal-components factor analysis was executed based on the FNQ responses of 178 family members. A six-factor solution was selection as the best fit for the data, yielding the following independent subscales: (1) Need for Health Information; (2) Need for Emotional Support; (3) Need for Instrumental Support; (4) Need for Professional Support; (5) Need for a Support Network; and (6) Need for Involvement with Care. Further analysis indicated at least adequate internal reliability for each scale. Overall, the measure appears to offer unique information relevant to family members' needs after brain injury.	VIRGINIA COMMONWEALTH UNIV MED COLL VIRGINIA,DEPT PHYS MED & REHABIL,RICHMOND,VA; VIRGINIA COMMONWEALTH UNIV MED COLL VIRGINIA,DIV NEUROL SURG,RICHMOND,VA							Campbell C H, 1988, Rehabil Nurs, V13, P320; CAMPLAIR P, 1989, 13 ANN POSTG COURS R; CATTELL RB, 1966, MULTIVAR BEHAV RES, V1, P245, DOI 10.1207/s15327906mbr0102_10; Comrey, 1973, 1 COURSE FACTOR ANAL; Engli M, 1993, J Neurosci Nurs, V25, P78; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; KAISER HF, 1958, PSYCHOMETRIKA, V23, P187, DOI 10.1007/BF02289233; Kozloff R, 1987, J HEAD TRAUMA REHAB, V2, P14, DOI DOI 10.1097/00001199-198709000-00004; KREUTZER JS, 1994, J HEAD TRAUMA REHAB, V9, P104, DOI 10.1097/00001199-199409000-00009; Kreutzer JS, 1990, COMMUNITY INTEGRATIO; LESKE JS, 1986, HEART LUNG, V15, P189; LEZAK M, 1978, J CLIN PSYCHIAT, V39, P111; LEZAK MD, 1988, J CLIN EXP NEUROPSYC, V10, P111, DOI 10.1080/01688638808405098; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; Mathis M, 1984, J Neurosurg Nurs, V16, P36; Mauss-Clum N, 1981, J Neurosurg Nurs, V13, P165; MOLTER NC, 1979, HEART LUNG, V8, P332; NORRIS LO, 1986, HEART LUNG, V15, P194; Nunnally J.C., 1978, PSYCHOMETRIC THEORY; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; Panting A., 1972, REHABILITATION, V38, P33; SERIO CD, 1995, J HEAD TRAUMA REHAB, V10, P32, DOI 10.1097/00001199-199504000-00005; Tabachnick B.G., 1989, USING MULTIVARIATE S	23	79	80	0	9	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	JAN	1997	11	1					1	9		10.1080/026990597123764			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	WB723	WOS:A1997WB72300001	9012547				2021-06-18	
J	Kimura, H; Meaney, DF; McGowan, JC; Grossman, RI; Lenkinski, RE; Ross, DT; McIntosh, TK; Gennarelli, TA; Smith, DH				Kimura, H; Meaney, DF; McGowan, JC; Grossman, RI; Lenkinski, RE; Ross, DT; McIntosh, TK; Gennarelli, TA; Smith, DH			Magnetization transfer imaging of diffuse axonal injury following experimental brain injury in the pig: Characterization by magnetization transfer ratio with histopathologic correlation	JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY			English	Article						animal studies; brain, wounds and injuries; magnetization transfer; magnetization imaging	HEAD-INJURY; CLINICAL-APPLICATIONS; MR; TRAUMA; CT	Purpose: Our goal was to evaluate the use of the magnetization transfer ratio (MTR) in the detection of diffuse axonal injury (DAI) resulting from traumatic brain injury in a swine model, Method: DAI was created by applying a nonimpact, coronal plane, rotational acceleration to the heads of miniature swine (n = 4). GE imaging was performed with and without off-resonance MT saturation. Histologic correlation of axonal injury with MRI was performed 7 days postinjury, Thirty-one subcortical white matter regions and 10 deep white matter regions were selected for the direct comparison of histologic data and MTR measurements, Results: Nineteen of 41 examined locations exhibited histologic evidence of axonal injury, The mean MTR in regions with axonal damage was significantly less than in regions without axonal damage. These changes were observed both in regions demonstrating high signal intensity on T2-weighted images (T2WI) (p < 0.0001, n = 6) and in regions with no signal intensity change on T2WI (p < 0.05, n = 13). Conclusion: These results suggest that the measurement of MTR may have the potential for evaluating axonal damage in DAI following traumatic brain injury even when conventional T2WI does not demonstrate the lesion.	UNIV PENN,SCH MED,HOSP UNIV PENN,DEPT RADIOL,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,HOSP UNIV PENN,DEPT BIOENGN,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,HOSP UNIV PENN,DIV NEUROSURG,PHILADELPHIA,PA 19104			Lenkinski, Robert/F-9045-2014; smith, douglas/A-1321-2007	Meaney, David/0000-0002-0954-4122; Lenkinski, Robert/0000-0001-7371-5048	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803, P01NS008803] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 08803] Funding Source: Medline		ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; ADAMS JH, 1984, GREENFIELDS NEUROPAT, P85; ATLAS SW, 1988, RADIOLOGY, V168, P803, DOI 10.1148/radiology.168.3.3406410; BALABAN R S, 1992, Magnetic Resonance Quarterly, V8, P116; BULLOCK R, 1992, J NEUROTRAUM, V9, pS443; Bullock Ross, 1993, Journal of Emergency Medicine, V11, P23; CROOKS DA, 1991, J PATHOL, V165, P5, DOI 10.1002/path.1711650103; DOUSSET V, 1992, RADIOLOGY, V182, P483, DOI 10.1148/radiology.182.2.1732968; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; GENTILE NT, 1993, ANN EMERG MED, V22, P1028, DOI 10.1016/S0196-0644(05)82746-5; GENTRY LR, 1988, AM J ROENTGENOL, V150, P673, DOI 10.2214/ajr.150.3.673; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1991, MAGNETIC RESONANCE I, P439; GOMORI JM, 1993, AM J NEURORADIOL, V14, P871; GROSSMAN RI, 1994, RADIOGRAPHICS, V14, P279, DOI 10.1148/radiographics.14.2.8190954; HICKS RR, 1995, BRAIN RES, V678, P151, DOI 10.1016/0006-8993(95)00179-T; *MAGN RES MED, 1991, TECHN MAGN TRANSF IM, P175; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; NG HK, 1994, CLIN NEUROL NEUROSUR, V96, P24, DOI 10.1016/0303-8467(94)90025-6; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; POVLISHOCK JT, 1985, LAB INVEST, V52, P540; ROSS DT, 1994, EXP NEUROL, V126, P291, DOI 10.1006/exnr.1994.1067; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; SHREIBER DI, 1995, J NEUROTRAUM, V12, P689; WOLFF SD, 1989, MAGNET RESON MED, V10, P135, DOI 10.1002/mrm.1910100113	29	79	82	0	4	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0363-8715			J COMPUT ASSIST TOMO	J. Comput. Assist. Tomogr.	JUL-AUG	1996	20	4					540	546		10.1097/00004728-199607000-00007			7	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	UY664	WOS:A1996UY66400007	8708052				2021-06-18	
J	Dietrich, WD; Alonso, O; Busto, R; Finklestein, SP				Dietrich, WD; Alonso, O; Busto, R; Finklestein, SP			Posttreatment with intravenous basic fibroblast growth factor reduces histopathological damage following fluid-percussion brain injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						basic fibroblast growth factor; traumatic brain injury; fluid-percussion; histopathology	FOCAL CEREBRAL-ISCHEMIA; CENTRAL-NERVOUS-SYSTEM; MODERATE HYPOTHERMIA; HIPPOCAMPAL-NEURONS; FACTOR PROTECTS; FACTOR BFGF; ADULT-RATS; BLOOD-FLOW; EXCITOTOXICITY; DEGENERATION	The purpose of this study was to determine whether treatment with intravenous basic fibroblast growth factor (bFGF) would protect histopathologically in a rat model of traumatic brain injury (TBI). Twenty-four hours prior to TBI, the fluid-percussion interface was positioned parasagittally over the right cerebral cortex. On the second day, fasted rats were anesthetized with 70% nitrous oxide, 1% halothane, and 30% oxygen. Under controlled physiological conditions and normothermic brain temperature (37-37.5 degrees C), rats were injured with a fluid-percussion pulse ranging from 1.6 to 1.9 atm. Rats were randomized into two groups where either bFGF (45 mu g/kg/h) in vehicle (n = 7) or vehicle alone (n = 7) was infused intravenously for 3 h, beginning 30 min after TBI. Three days later, brains were perfusion-fixed for histopathological assessment and quantitative analysis of contusion volume and numbers of necrotic cortical neurons. In vehicle-treated animals, necrotic neurons were observed throughout the lateral cerebral cortex remote from the impact site. In addition, an intracerebral contusion was present in all rats at the gray-white interface underlying the injured cortical areas. Posttraumatic administration of bFGF significantly reduced the numbers of damaged cortical neuron profiles at several coronal levels and reduced the total number of damaged neurons (696 +/- 148 vs. 1,248 +/- 198, means +/- SEM), p < 0.05, ANOVA). In addition, contusion areas at several coronal levels as well as total contusion volume was significantly reduced (1.13 +/- 0.39 mm(3) vs. 3.18 +/- 0.81 mm(3), p < 0.05). These data demonstrate neuroprotection with intravenous bFGF infusion in the posttraumatic setting.	MASSACHUSETTS GEN HOSP,DEPT NEUROL,CNS GROWTH FACTOR RES LAB,BOSTON,MA 02129; HARVARD UNIV,SCH MED,BOSTON,MA 02129	Dietrich, WD (corresponding author), UNIV MIAMI,SCH MED,DEPT NEUROL D45,NEUROTRAUMA RES CTR,POB 016960,MIAMI,FL 33101, USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-30291, NS-27127] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027127, P50NS030291] Funding Source: NIH RePORTER		ANDERSON KJ, 1988, NATURE, V332, P360, DOI 10.1038/332360a0; BAROTTE C, 1989, NEUROSCI LETT, V101, P197, DOI 10.1016/0304-3940(89)90530-2; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; COGGESHALL RE, 1996, J COMP NEUROL, V354, P6; CORTEZ SC, 1989, BRAIN RES, V482, P272; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; Dietrich WD, 1996, J CEREBR BLOOD F MET, V16, P481, DOI 10.1097/00004647-199605000-00015; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FINKLESTEIN SP, 1988, BRAIN RES, V460, P253, DOI 10.1016/0006-8993(88)90370-8; FINKLESTEIN SP, 1993, STROKE S1, V24; FISHER M, 1995, J CEREBR BLOOD F MET, V15, P953, DOI 10.1038/jcbfm.1995.121; FRANK E, 1995, NEUROL RES, V17, P129, DOI 10.1080/01616412.1995.11740300; FREESE A, 1992, BRAIN RES, V575, P351, DOI 10.1016/0006-8993(92)90104-H; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; HAYES RL, 1988, J NEUROTRAUM, V5, P287; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; JIANG JY, 1991, J NEUROSURG, V74, P492, DOI 10.3171/jns.1991.74.3.0492; KAWAMATA K, 1996, J CEREB FLOOD FLOW M, V16, P542; KIRSCHNER PB, 1995, J CEREBR BLOOD F MET, V15, P619, DOI 10.1038/jcbfm.1995.76; KOKETSU N, 1994, ANN NEUROL, V35, P451, DOI 10.1002/ana.410350413; LOGAN A, 1992, J NEUROSCI, V12, P3828; MATTSON MP, 1990, INT J DEV NEUROSCI, V8, P399, DOI 10.1016/0736-5748(90)90073-B; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; MATTSON MP, 1993, J NEUROSCI, V13, P4575; MATTSON MP, 1989, J NEUROSCI, V9, P3728; MATTSON MP, 1995, CEREBROVASCULAR DIS, P371; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MOCCHETTI I, 1995, J NEUROTRAUM, V12, P853, DOI 10.1089/neu.1995.12.853; NAKATA N, 1993, BRAIN RES, V605, P354, DOI 10.1016/0006-8993(93)91766-L; NIETOSAMPEDRO M, 1988, NEUROSCI LETT, V86, P361, DOI 10.1016/0304-3940(88)90511-3; NOZAKI K, 1993, J CEREBR BLOOD F MET, V13, P221, DOI 10.1038/jcbfm.1993.27; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; POVLISHOCK JT, 1978, BRAIN RES, V153, P223, DOI 10.1016/0006-8993(78)90404-3; ROSENBLATT S, 1994, J CEREBR BLOOD F MET, V14, P70, DOI 10.1038/jcbfm.1994.11; Salzman SK, 1994, NEUROBIOLOGY CENTRAL; TANNO H, 1992, J NEUROTRAUM, V9, P335, DOI 10.1089/neu.1992.9.335; TATTER SB, 1995, NEUROSCIENTIST, V1, P286; WALICKE PA, 1988, J NEUROSCI, V8, P2618; WANAKA A, 1990, NEURON, V5, P267, DOI 10.1016/0896-6273(90)90164-B; YAMADA K, 1991, J CEREBR BLOOD F MET, V11, P472, DOI 10.1038/jcbfm.1991.90; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; ZILLES KJL, 1985, CORTEX BRAIN STEREOT	49	79	82	0	1	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUN	1996	13	6					309	316		10.1089/neu.1996.13.309			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	UZ052	WOS:A1996UZ05200003	8835798				2021-06-18	
J	Lewen, A; Li, GL; Olsson, Y; Hillered, L				Lewen, A; Li, GL; Olsson, Y; Hillered, L			Changes in microtubule-associated protein 2 and amyloid precursor protein immunoreactivity following traumatic brain injury in rat: Influence of MK-801 treatment	BRAIN RESEARCH			English	Article						microtubule-associated protein 2; beta-amyloid precursor protein; beta-amyloid; MK-801; traumatic brain injury; dendrite; axon	EXCITATORY AMINO-ACIDS; MIDDLE CEREBRAL-ARTERY; FOREBRAIN ISCHEMIA; NERVOUS-SYSTEM; HEAD TRAUMA; PHOSPHORYLATION; HIPPOCAMPUS; CELLS; NMDA; VULNERABILITY	We investigated by immunohistochemistry dendritic and axonal changes occurring in the rat brain after mild focal cortical trauma produced by the weight drop technique. One and 3 days after injury, nerve cell bodies and dendrites in the perimeter of the impact site displayed decreased microtubule-associated protein 2 (MAP2) immunoreactivity. Some dendrites in the immediate adjacent region were more intensely stained and distorted. The dentate hilar region of the hippocampus showed a reduction of immunoreactive nerve cell bodies and dendrites. Twenty-one days after injury the strongly stained cortical dendrites and the reduction of immunoreactivity in the hippocampus remained, whereas the reduced staining in the perimeter of the lesion had normalised. These results indicate that there is a long-lasting disturbed dendritic organisation implicating impaired neurotransmission after this type of mild brain trauma, beta-Amyloid precursor protein (APP) immunohistochemistry revealed numerous stained axons in the ipsilateral subcortical white matter and thalamus indicating local and remote axonal injuries with disturbed axonal transport, Twenty-one days after injury, numerous small immunostained profiles appeared in the neuropil of the cortical impact sire and in the ipsilateral thalamus. The axonal changes indicate disturbed connectivity between the site of the impact and other brain regions, chiefly the thalamus, The presence of beta-amyloid was investigated 21 days after trauma. There were no signs of beta-amyloid depositions in the brain after injury. Finally, we tested if the non-competitive NMDA receptor antagonist dizocilpine maleate (MK-801) could influence the observed MAP2 and APP changes, Pretreatment with this compound did not affect the early MAP2 and APP alterations. Instead, an increased expression of the APP antigen in the thalamus was observed 21 days after trauma in the MK-801-treated animals, The cause of this phenomenon is not known but may be related to a delayed neurotoxic action of MK-801 treatment.	UNIV UPPSALA HOSP,DEPT CLIN CHEM,S-75185 UPPSALA,SWEDEN; UNIV UPPSALA HOSP,NEUROPATHOL LAB,S-75185 UPPSALA,SWEDEN	Lewen, A (corresponding author), UNIV UPPSALA HOSP,DEPT NEUROSURG,S-75185 UPPSALA,SWEDEN.		Lewen, Anders/A-5156-2013	Lewen, Anders/0000-0003-4925-1348			BEESON JG, 1994, J COMP NEUROL, V342, P69, DOI 10.1002/cne.903420108; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; DECAMILLI P, 1984, NEUROSCIENCE, V11, P819, DOI 10.1016/0306-4522(84)90194-5; DIDIER M, 1990, J NEUROSCI RES, V27, P25, DOI 10.1002/jnr.490270105; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; GEISERT EE, 1990, P NATL ACAD SCI USA, V87, P3967, DOI 10.1073/pnas.87.10.3967; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GINSBERG MD, 1992, CEREBROVAS BRAIN MET, V4, P189; HANCOCK MB, 1984, J HISTOCHEM CYTOCHEM, V32, P311, DOI 10.1177/32.3.6198359; HICKS RR, 1995, BRAIN RES, V678, P151, DOI 10.1016/0006-8993(95)00179-T; INUZUKA T, 1990, BRAIN RES, V526, P177, DOI 10.1016/0006-8993(90)90269-H; INUZUKA T, 1990, STROKE, V21, P917, DOI 10.1161/01.STR.21.6.917; ITOH K, 1979, BRAIN RES, V175, P341, DOI 10.1016/0006-8993(79)91013-8; KALARIA RN, 1993, ANN NY ACAD SCI, V695, P190, DOI 10.1111/j.1749-6632.1993.tb23050.x; KITAGAWA K, 1989, NEUROSCIENCE, V31, P401, DOI 10.1016/0306-4522(89)90383-7; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; KOZLOWSKI DA, 1994, RESTOR NEUROL NEUROS, V7, P119, DOI 10.3233/RNN-1994-7207; KUDO T, 1990, STROKE, V21, P1205, DOI 10.1161/01.STR.21.8.1205; LEWEN A, 1995, NEUROREPORT, V6, P35; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LYNCH G, 1988, BRAIN RES BULL, V21, P363, DOI 10.1016/0361-9230(88)90148-7; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; MATUS A, 1994, TRENDS NEUROSCI, V17, P19, DOI 10.1016/0166-2236(94)90030-2; MIYAZAWA T, 1993, ACTA NEUROPATHOL, V85, P526; NAKAMURA K, 1993, BRAIN RES, V613, P181, DOI 10.1016/0006-8993(93)90898-W; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; NILSSON P, 1994, BRAIN RES, V637, P227, DOI 10.1016/0006-8993(94)91237-8; Nilsson P, 1996, J CEREBR BLOOD F MET, V16, P262, DOI 10.1097/00004647-199603000-00011; OLNEY JW, 1989, SCIENCE, V244, P1360, DOI 10.1126/science.2660263; OLNEY JW, 1991, SCIENCE, V254, P1515, DOI 10.1126/science.1835799; OTSUKA N, 1991, BRAIN RES, V568, P335, DOI 10.1016/0006-8993(91)91422-W; REGAN RF, 1994, NEUROBIOLOGY CENTRAL, P173; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; SAKIMURA K, 1995, NATURE, V373, P151, DOI 10.1038/373151a0; SHENG JG, 1994, J NEUROCHEM, V63, P1872; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; SHU SY, 1988, NEUROSCI LETT, V85, P169, DOI 10.1016/0304-3940(88)90346-1; Steward O., 1994, NEUROBIOLOGY CENTRAL, P266; TAFT WC, 1993, J CEREBR BLOOD F MET, V13, P796, DOI 10.1038/jcbfm.1993.101; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; THEURKAUF WE, 1983, J BIOL CHEM, V258, P7883; THEURKAUF WE, 1982, J CELL BIOL, V95, pA340; VALLEE R, 1980, P NATL ACAD SCI-BIOL, V77, P3206, DOI 10.1073/pnas.77.6.3206; WIGSTROM H, 1986, NEUROSCIENCE, V17, P1105, DOI 10.1016/0306-4522(86)90080-1; YAMAUCHI T, 1982, BIOCHEM BIOPH RES CO, V109, P975, DOI 10.1016/0006-291X(82)92035-6; YANAGIHARA T, 1990, ACTA NEUROPATHOL, V80, P499, DOI 10.1007/BF00294610	51	79	81	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	MAY 6	1996	719	1-2					161	171		10.1016/0006-8993(96)00081-9			11	Neurosciences	Neurosciences & Neurology	UP705	WOS:A1996UP70500021	8782876				2021-06-18	
J	YANG, K; MU, XS; XUE, JJ; WHITSON, J; SALMINEN, A; DIXON, CE; LIU, PK; HAYES, RL				YANG, K; MU, XS; XUE, JJ; WHITSON, J; SALMINEN, A; DIXON, CE; LIU, PK; HAYES, RL			INCREASED EXPRESSION OF C-FOS MESSENGER-RNA AND AP-1 TRANSCRIPTION FACTORS AFTER CORTICAL IMPACT INJURY IN RATS	BRAIN RESEARCH			English	Article						IMMEDIATE EARLY GENE EXPRESSION; C-FOS; AP-1 TRANSCRIPTION FACTOR; IN SITU HYBRIDIZATION; RT-PCR; BRAIN TRAUMA	TRAUMATIC BRAIN INJURY; NERVE GROWTH-FACTOR; CEREBELLAR GRANULE CELLS; MESSENGER-RNA; INSITU HYBRIDIZATION; PRIMARY CULTURES; PC12 CELLS; HIPPOCAMPUS; INDUCTION; JUN	Levels of c-fos mRNA and AP-1 transcription factors co-expression were measured in a controlled lateral cortical impact model of traumatic brain injury (TBI) in rats. Ipsilateral cerebral cortex and bilateral hippocampal c-fos mRNA increases were revealed by in situ hybridization after lateral cortical impact injury. Based on regional in situ hybridization data, we employed semi-quantitative RT-PCR methods to study the temporal profile of changes in the ipsilateral cortex at the site of injury. We found that TBI produces transient increases of c-fos mRNP; expression in the ipsilateral cerebral cortex at 5 min postinjury, which peaks at 1 h postinjury and subsides by 1 day postinjury. Gel shift nuclear protein binding assays showed that AP-1 transcription factor binding was robustly increased in injured cerebral cortex at 1 h, 3 h, 5 h and 1 day after injury. These data indicate that TBI can produce significant increases in c-fos expression and subsequent upregulation of the AP-1 transcription factors. Thus, AP-1 transcription factors modulation of downstream gene expression may be an important component of pathophysiological responses to TBT.	UNIV TEXAS,HLTH SCI CTR,DEPT NEUROSURG,HOUSTON,TX 77030; BAYLOR COLL MED,DIV RESTORAT NEUROL & HUMAN NEUROBIOL,HOUSTON,TX 77030					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS031998, R01NS021458] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01 NS3199801, NS21458] Funding Source: Medline		AN G, 1993, ANN NEUROL, V33, P457, DOI 10.1002/ana.410330508; CELI FS, 1993, NUCLEIC ACIDS RES, V21, P1047, DOI 10.1093/nar/21.4.1047; CHAN RKW, 1993, J NEUROSCI, V13, P5126; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DASH PK, 1993, 23RD ANN M SOC NEUR; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DRAGUNOW M, 1987, NEUROSCI LETT, V82, P157, DOI 10.1016/0304-3940(87)90121-2; DRAGUNOW M, 1988, BRAIN RES, V455, P295, DOI 10.1016/0006-8993(88)90088-1; DRAGUNOW M, 1987, NATURE, V329, P441, DOI 10.1038/329441a0; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENBERG ME, 1986, SCIENCE, V234, P80, DOI 10.1126/science.3749894; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HENGERER B, 1990, P NATL ACAD SCI USA, V87, P3899, DOI 10.1073/pnas.87.10.3899; HUGHES P, 1993, NEUROSCI LETT, V150, P122, DOI 10.1016/0304-3940(93)90122-2; KAMINSKA B, 1993, NEUROSCI LETT, V153, P189, DOI 10.1016/0304-3940(93)90319-G; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; LYETH B G, 1991, Society for Neuroscience Abstracts, V17, P165; MACHIDA CM, 1989, NEURON, V2, P1587, DOI 10.1016/0896-6273(89)90047-0; MORGAN JI, 1991, TRENDS PHARMACOL SCI, V12, P343, DOI 10.1016/0165-6147(91)90594-I; MORGAN JI, 1986, NATURE, V322, P552, DOI 10.1038/322552a0; MORGAN JI, 1987, SCIENCE, V237, P192, DOI 10.1126/science.3037702; MORGAN PF, 1991, NEUROREPORT, V2, P251, DOI 10.1097/00001756-199105000-00009; PENNYPACKER KR, 1994, J NEUROSCI, V14, P3998; PHILLIPS LL, 1992, J NEUROTRAUM, V9, P323, DOI 10.1089/neu.1992.9.323; ROBINSON SE, 1990, BRAIN RES, V511, P141, DOI 10.1016/0006-8993(90)90233-2; RUZDIJIC S, 1993, BRAIN RES, V69, P230; SAIJA A, 1988, BRAIN RES, V452, P303, DOI 10.1016/0006-8993(88)90034-0; SIMMONS DM, 1989, J HISTOTECHNOL, V12, P169; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; SONNENBERG JL, 1989, NEURON, V3, P359, DOI 10.1016/0896-6273(89)90260-2; SONNENBERG JL, 1989, SCIENCE, V246, P1622, DOI 10.1126/science.2512642; SZEKELY AM, 1989, MOL PHARMACOL, V35, P401; SZEKELY AM, 1987, NEUROPHARMACOLOGY, V26, P1779, DOI 10.1016/0028-3908(87)90132-8; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; TURNER R, 1989, SCIENCE, V243, P1659; YANG K, 1993, 23RD ANN M SOC NEUR; YANG KY, 1993, J NEUROTRAUM, V10, P287, DOI 10.1089/neu.1993.10.287; ZHENG M, 1988, MOL BRAIN RES, V3, P133, DOI 10.1016/0169-328X(88)90058-7	43	79	96	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	NOV 21	1994	664	1-2					141	147		10.1016/0006-8993(94)91964-X			7	Neurosciences	Neurosciences & Neurology	PR431	WOS:A1994PR43100019	7895023				2021-06-18	
J	GRUNDL, PD; BIAGAS, KV; KOCHANEK, PM; SCHIDING, JK; BARMADA, MA; NEMOTO, EM				GRUNDL, PD; BIAGAS, KV; KOCHANEK, PM; SCHIDING, JK; BARMADA, MA; NEMOTO, EM			EARLY CEREBROVASCULATURE RESPONSE TO HEAD-INJURY IN IMMATURE AND MATURE RATS	JOURNAL OF NEUROTRAUMA			English	Article							CEREBRAL BLOOD-FLOW; TRAUMATIC BRAIN INJURY; FREELY MOVING RATS; COMPUTERIZED-TOMOGRAPHY; INTRACRANIAL-PRESSURE; C-14 IODOANTIPYRINE; FREE-RADICALS; EDEMA; CHILDREN; METABOLISM	Clinical studies suggest that children respond to head injury with more pronounced cerebral edema and hyperemia than do adults. We hypothesized that these age-related differences could be demonstrated in an animal model. Anesthetized and ventilated mature (2-3 months) and immature (3.5-4.5 weeks) male Wistar rats were traumatized by weight drop onto the exposed right parietal cortex. Trauma severity was adjusted to keep the ratio of force to brain weight constant. This resulted in an energy delivered to the brain of about 9 x 10(3) ergs. mm(-2).g(-1) brain in both age groups. Percent right hemispheric brain water (%RBW) was measured at 2, 24, 48, and 168 h posttrauma. Infarct area, intracranial pressure (ICP), and C-14-iodoantipyrine autoradiographic local cerebral blood flow (ICBF) were measured at 2 h or 24 h posttrauma. In mature rats, %RBW was unchanged at 2 h, but increased at 24 and 48 h (both p < 0.05). In immature rats, %RBW increased at 2 h and remained elevated at 24 and 48 h (all p < 0.05). Traumatic infarct area as a percent of hemispheric area at 24 h did not differ between age groups. In mature rats, at 2 h posttrauma ICBF was reduced (p < 0.05) in 16 of 17 regions but in only 4 of 17 regions in immature rats. ICBF as a percent of age-matched control values showed a greater reduction in mature vs immature rats in 9 of 16 regions (p < 0.05). ICP increased at 24 h posttrauma in both age groups. In immature rats posttrauma, brain water increased earlier and cerebral hypoperfusion was less marked than in mature rats.	UNIV PITTSBURGH, SCH MED, DEPT PEDIAT, PITTSBURGH, PA 15261 USA; UNIV PITTSBURGH, SCH MED, DEPT PATHOL, PITTSBURGH, PA 15261 USA; UNIV PITTSBURGH, SCH MED, DEPT ANESTHESIOL CRIT CARE MED, PITTSBURGH, PA 15261 USA			Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X			ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; BERGER MS, 1985, J NEUROSURG, V62, P194, DOI 10.3171/jns.1985.62.2.0194; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMAN HJ, 1979, BRAIN RES BULL, V4, P575, DOI 10.1016/0361-9230(79)90045-5; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; CARLSSON CA, 1968, J NEUROSURG, V29, P242, DOI 10.3171/jns.1968.29.3.0242; CHAN PH, 1987, ANN NEUROL, V21, P540, DOI 10.1002/ana.410210604; CHAN PH, 1984, NEUROLOGY, V34, P315, DOI 10.1212/WNL.34.3.315; COLE DJ, 1990, AM J PHYSIOL, V259, pH211; Donaldson HH, 1931, J COMP NEUROL, V53, P263, DOI 10.1002/cne.900530202; DURWARD QJ, 1983, J NEUROSURG, V59, P803, DOI 10.3171/jns.1983.59.5.0803; EIBEN CF, 1984, ARCH PHYS MED REHAB, V65, P168; FEUSTEL PJ, 1987, J SURG RES, V43, P86, DOI 10.1016/0022-4804(87)90051-5; Goldman H, 1991, J NEUROTRAUM, V8, P129, DOI 10.1089/neu.1991.8.129; GUPTA D, 1975, STEROIDS, V25, P33, DOI 10.1016/S0039-128X(75)80005-5; HAMM RJ, 1991, J NEUROSURG, V75, P916, DOI 10.3171/jns.1991.75.6.0916; HEISKANEN O, 1970, ACTA NEUROL SCAND, V46, P343, DOI 10.1111/j.1600-0404.1970.tb05798.x; IKEDA Y, 1989, NEUROSURGERY, V24, P679, DOI 10.1227/00006123-198905000-00004; ISSEKUTZ AC, 1984, LAB INVEST, V50, P605; JENKINS HG, 1988, J NEUROCHEM, V51, P1634, DOI 10.1111/j.1471-4159.1988.tb01134.x; Kasapi M., 1992, Society for Neuroscience Abstracts, V18, P1088; KASOFF SS, 1972, J NEUROSURG, V36, P463, DOI 10.3171/jns.1972.36.4.0463; KLATZO I, 1987, ACTA NEUROPATHOL, V72, P236, DOI 10.1007/BF00691095; KOCHANEK P, 1992, J NEUROTRAUM, V9, P390; Kochanek P, 1991, J NEUROTRAUM, V8, P19, DOI 10.1089/neu.1991.8.19; KRUM JM, 1991, SOC NEUR ABSTR, V17, P329; LEE VWK, 1975, J REPROD FERTIL, V42, P121, DOI 10.1530/jrf.0.0420121; LOBATO RD, 1991, J NEUROSURG, V75, P256, DOI 10.3171/jns.1991.75.2.0256; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MCDONALD JW, 1987, EUR J PHARMACOL, V140, P359, DOI 10.1016/0014-2999(87)90295-0; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; NEHLIG A, 1989, J CEREBR BLOOD F MET, V9, P579, DOI 10.1038/jcbfm.1989.83; NILSSON B, 1977, J NEUROSURG, V47, P262, DOI 10.3171/jns.1977.47.2.0262; NORTON WT, 1973, J NEUROCHEM, V21, P759, DOI 10.1111/j.1471-4159.1973.tb07520.x; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OBRIST WD, 1979, J NEUROSURG, V51, P292, DOI 10.3171/jns.1979.51.3.0292; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; OVERGAARD J, 1976, J NEUROSURG, V45, P292, DOI 10.3171/jns.1976.45.3.0292; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PFENNINGER EG, 1989, J NEUROSURG, V70, P774, DOI 10.3171/jns.1989.70.5.0774; RICHARDS HK, 1987, J CEREBR BLOOD F MET, V7, P124, DOI 10.1038/jcbfm.1987.18; SAKURADA O, 1978, AM J PHYSIOL, V234, pH59; SAUNDERS ML, 1979, J NEUROSURG, V51, P18, DOI 10.3171/jns.1979.51.1.0018; SCHLEIEN CL, 1991, STROKE, V22, P477, DOI 10.1161/01.STR.22.4.477; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; SHAPIRA Y, 1988, J CEREBR BLOOD F MET, V8, P395, DOI 10.1038/jcbfm.1988.75; STREICHE.E, 1965, NEUROLOGY, V15, P833, DOI 10.1212/WNL.15.9.833; SUMI SM, 1968, ACTA NEUROPATHOL, V10, P324, DOI 10.1007/BF00690707; TAMURA A, 1981, J CEREBR BLOOD F MET, V1, P61, DOI 10.1038/jcbfm.1981.7; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P140; TORNHEIM PA, 1981, J NEUROSURG, V55, P407, DOI 10.3171/jns.1981.55.3.0407; UHL M W, 1990, Critical Care Medicine, V18, pS274; UNTERBERG AW, 1988, J NEUROSURG, V68, P594, DOI 10.3171/jns.1988.68.4.0594; UZZELL BP, 1986, J NEUROSURG, V65, P630, DOI 10.3171/jns.1986.65.5.0630; VERHEUL HB, 1993, J CEREB BLOOD FLOW M, V13, pS307; WOOTTON R, 1983, CAN J PHYSIOL PHARM, V61, P595, DOI 10.1139/y83-091; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; YOSHIDA S, 1983, NEUROLOGY, V33, P166, DOI 10.1212/WNL.33.2.166; YOUNG H, 1992, CRITICAL CARE STATE, V13, P427; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289	61	79	80	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	1994	11	2					135	148		10.1089/neu.1994.11.135			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	NR684	WOS:A1994NR68400001	7932794				2021-06-18	
J	FORTUNE, JB; FEUSTEL, PJ; WEIGLE, CGM; POPP, AJ				FORTUNE, JB; FEUSTEL, PJ; WEIGLE, CGM; POPP, AJ			CONTINUOUS MEASUREMENT OF JUGULAR VENOUS OXYGEN-SATURATION IN RESPONSE TO TRANSIENT ELEVATIONS OF BLOOD-PRESSURE IN HEAD-INJURED PATIENTS	JOURNAL OF NEUROSURGERY			English	Article						TRAUMATIC BRAIN INJURY; CEREBRAL BLOOD FLOW; AUTOREGULATION; CEREBRAL PERFUSION PRESSURE; JUGULAR VENOUS OXYGEN SATURATION; OXIMETRY	ACUTE BRAIN INJURY; CEREBRAL HEMODYNAMIC RESERVE; INTERNAL CAROTID-ARTERY; AUTO-REGULATION; FLOW; METABOLISM; HYPERTENSION; MANNITOL; CHILDREN; CBF	Following traumatic brain injury, continuous jugular venous oxygen saturation (SjvO(2)) measurements have been made and used to assess cerebral oxygenation. Transients of SjvO(2) may reflect cerebral blood flow (CBF) changes if measurements are made over a short period of time during which cerebral metabolic rate for oxygen is assumed unchanged. In response to alterations in perfusion pressure, transients of SjvO(2) may indicate the extent to which autoregulation has been preserved after injury. The effect of arterial pressure changes on SjvO(2) was measured in 14 severely head-injured patients (Glasgow Coma Scale score < 8) within 36 hours of injury. Mean arterial blood pressure (MABP), arterial oxygen saturation, and intracranial pressure (ICP) data were also continuously recorded by a computer at the patients' bedside. The reliability of the SjvO(2) oximetry measurements varied among patients, and an average 38% of SjvO(2) measurements were off by more than 6% saturation, necessitating recalibration. During periods of satisfactory catheter performance, 120 instances were found in which MABP was elevated more than 8 torr (mean +/- standard deviation: 32 +/- 13 torr) due to endotracheal suctioning. In 94 of these measurements, there was an associated increase in the ICP of 5 torr or more, averaging 16.6 +/- 10.2 torr. The SjvO(2) was 0.62 +/- 0.10 before the increase in MABP and rose to a peak of 0.77 +/- 0.10 during the maximum MABP elevation, suggesting increased CBF during the transient hypertension. In 34 of 37 instances of persistent blood pressure elevations lasting for more than 10 minutes (mean 16.0 +/- 8.0 minutes), the SjvO(2) elevation persisted (average duration 15.0 +/- 12.4 minutes), suggesting impaired or lost autoregulatory vasoconstriction. The presence or absence of hyperemia was unrelated to the extent of the autoregulation response. Results indicate that SjvO(2) rises with increasing perfusion pressure during and after endotracheal suctioning, suggesting a feeble or absent autoregulatory response following traumatic brain injury.	ALBANY MED CTR, DEPT SURG, DIV NEUROSURG, ALBANY, NY USA; ALBANY MED CTR, DEPT PEDIAT, PEDIAT INTENS CARE SECT, ALBANY, NY USA	FORTUNE, JB (corresponding author), ALBANY MED CTR, DEPT SURG, TRAUMA SURG SECT, ALBANY, NY 12208 USA.			Feustel, Paul/0000-0002-6963-4349	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [30303] Funding Source: Medline		ANDERSEN BJ, 1988, J NEUROSURG, V68, P601, DOI 10.3171/jns.1988.68.4.0601; ANDREWS PJD, 1990, BRIT J ANAESTH, V64, pP393; BOUMA GJ, 1990, J NEUROSURG, V73, P368, DOI 10.3171/jns.1990.73.3.0368; COLD GE, 1981, ACTA ANAESTH SCAND, V25, P379; Cruz J, 1988, Acta Neurochir Suppl (Wien), V42, P35; CRUZ J, 1991, NEUROSURGERY, V29, P743, DOI 10.1227/00006123-199111000-00017; CRUZ J, 1985, CRIT CARE MED, V13, P284, DOI 10.1097/00003246-198504000-00047; CRUZ J, 1990, J NEUROSURG, V73, P725, DOI 10.3171/jns.1990.73.5.0725; CRUZ J, 1992, J TRAUMA, V32, P629, DOI 10.1097/00005373-199205000-00015; CRUZ J, 1992, CRIT CARE MED S, V20, P109; CRUZ J, 1991, J TRAUMA, V31, P1714; CRUZ J, 1986, NEUROTRAUMA TREATMEN, P55; ENEVOLDSEN EM, 1976, J NEUROSURG, V44, P191, DOI 10.3171/jns.1976.44.2.0191; FEUSTEL PJ, 1987, J SURG RES, V43, P86, DOI 10.1016/0022-4804(87)90051-5; FEUSTEL PJ, IN PRESS AM REV RESP; FORTUNE JB, 1992, J TRAUMA, V32, P618, DOI 10.1097/00005373-199205000-00014; ISHIGE N, 1987, NEUROSURGERY, V20, P854, DOI 10.1227/00006123-198706000-00006; KONTOS HA, 1978, AM J PHYSIOL, V234, pH371; LEOPOLD PW, 1987, BRIT J SURG, V74, P630, DOI 10.1002/bjs.1800740734; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; MUIZELAAR JP, 1984, J NEUROSURG, V61, P700, DOI 10.3171/jns.1984.61.4.0700; MUIZELAAR JP, 1989, J NEUROSURG, V71, P72, DOI 10.3171/jns.1989.71.1.0072; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212	25	79	81	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAR	1994	80	3					461	468		10.3171/jns.1994.80.3.0461			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	MY483	WOS:A1994MY48300007	8113859				2021-06-18	
J	LEVIN, HS				LEVIN, HS			MEMORY DEFICIT AFTER CLOSED-HEAD INJURY	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article										LEVIN, HS (corresponding author), UNIV TEXAS,MED BRANCH,JOHN SEALY HOSP 9 112,DIV NEUROSURG,GALVESTON,TX 77550, USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER		ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; ALBERT MS, 1979, ARCH NEUROL-CHICAGO, V36, P211, DOI 10.1001/archneur.1979.00500400065010; ARTIOLA I, 1980, J NEUROL NEUROSUR PS, V43, P377; BADDELEY A, 1987, NEUROBEHAVIORAL RECO, P295; BENTON AL, 1964, J NERV MENT DIS, V139, P110, DOI 10.1097/00005053-196408000-00003; BRODIE B, 1854, PSYCHOL ENQUIRIES; BROOKS D N, 1975, Cortex, V11, P329; BROOKS DN, 1976, NEUROPSYCHOLOGIA, V14, P111, DOI 10.1016/0028-3932(76)90012-9; BROOKS DN, 1974, J NEUROL NEUROSUR PS, V37, P794, DOI 10.1136/jnnp.37.7.794; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; Butters N, 1980, ALCOHOLIC KORSAKOFFS; COHEN NJ, 1980, SCIENCE, V210, P207, DOI 10.1126/science.7414331; CORKIN S, 1968, NEUROPSYCHOLOGIA, V6, P255, DOI 10.1016/0028-3932(68)90024-9; CRAIK FIM, 1972, J VERB LEARN VERB BE, V11, P671, DOI 10.1016/S0022-5371(72)80001-X; CROSSON B, 1984, J CLIN NEUROPSYCHOL, V6, P287, DOI 10.1080/01688638408401219; CROVITZ HF, 1979, CORTEX, V15, P225, DOI 10.1016/S0010-9452(79)80027-1; DANIEL WF, 1987, CORTEX, V23, P169, DOI 10.1016/S0010-9452(87)80030-8; DIKMEN S, 1987, J NEUROL NEUROSUR PS, V50, P1613, DOI 10.1136/jnnp.50.12.1613; EISENBERG HM, UNPUB J NEUROSURGERY; ESLINGER PJ, 1986, J NEUROSCI, V6, P3006; EWERT J, 1989, ARCH NEUROL-CHICAGO, V46, P911, DOI 10.1001/archneur.1989.00520440105027; FREEDMAN M, 1986, BRAIN COGNITION, V5, P108, DOI 10.1016/0278-2626(86)90063-1; GLASGOW RE, 1977, J CLIN PSYCHOL, V33, P1049, DOI 10.1002/1097-4679(197710)33:4<1049::AID-JCLP2270330429>3.0.CO;2-V; GLISKY EL, 1986, NEUROPSYCHOLOGIA, V24, P313, DOI 10.1016/0028-3932(86)90017-5; GLISKY EL, 1988, NEUROPSYCHOLOGIA, V26, P173, DOI 10.1016/0028-3932(88)90041-3; GOLDSTEIN FC, IN PRESS CORTEX; GOLDSTEIN FC, IN PRESS J CLIN EXPT; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; GRONWALL D, 1980, Journal of Clinical Neuropsychology, V2, P51, DOI 10.1080/01688638008403780; GRONWALL D, 1974, LANCET, V2, P605; HANNAY HJ, 1979, CORTEX, V15, P269, DOI 10.1016/S0010-9452(79)80031-3; Harris J E, 1981, Int Rehabil Med, V3, P206; HASHER L, 1979, J EXP PSYCHOL GEN, V108, P356, DOI 10.1037/0096-3445.108.3.356; HIGH WM, IN PRESS J CLIN EXPT; HIRST W, 1982, PSYCHOL BULL, V91, P435, DOI 10.1037/0033-2909.91.3.435; JENNETT WB, 1969, SPECIAL PUBLICATION, V4; KOVNER R, 1983, J CLIN NEUROPSYCHOL, V5, P65, DOI 10.1080/01688638308401151; LANGFITT TW, 1986, J NEUROSURG, V64, P760, DOI 10.3171/jns.1986.64.5.0760; LEVIN HS, 1988, J NEUROSURG, V69, P861, DOI 10.3171/jns.1988.69.6.0861; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P14, DOI 10.1136/jnnp.51.1.14; LEVIN HS, 1985, J NEUROL NEUROSUR PS, V48, P556, DOI 10.1136/jnnp.48.6.556; LEVIN HS, 1986, J CLIN EXP NEUROPSYC, V8, P643, DOI 10.1080/01688638608405185; LEVIN HS, 1983, CORTEX, V19, P427, DOI 10.1016/S0010-9452(83)80025-2; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1985, ARCH NEUROL-CHICAGO, V42, P963, DOI 10.1001/archneur.1985.04060090045012; LEVIN HS, 1988, BRAIN COGNITION, V7, P283, DOI 10.1016/0278-2626(88)90003-6; LEVIN HS, 1981, BRAIN LANG, V12, P360, DOI 10.1016/0093-934X(81)90025-0; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; LEVIN HS, UNPUB J NEUROSURGERY; LEVIN HS, 1979, J NEUROSURG, V50, P42; MARTONE M, 1984, ARCH NEUROL-CHICAGO, V41, P965, DOI 10.1001/archneur.1984.04050200071020; MILNER B, 1968, NEUROPSYCHOLOGIA, V6, P215, DOI 10.1016/0028-3932(68)90021-3; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PAPANICOLAOU AC, 1984, NEUROSURGERY, V14, P676, DOI 10.1227/00006123-198406000-00005; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; Ribot T., 1882, DISEASES MEMORY ESSA; RICHARDSON JTE, 1979, BRIT J SOC CLIN PSYC, V18, P319, DOI 10.1111/j.2044-8260.1979.tb00342.x; RUFF RM, UNPUB J NEUROSURGERY; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; RUSSELL WR, 1946, BRAIN, V69, P183; RUSSELL WR, 1971, TRAUMATIC AMNESIAS; SCHACTER DL, 1977, CORTEX, V8, P150; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; SHIMAMURA AP, 1984, J EXP PSYCHOL GEN, V113, P556, DOI 10.1037/0096-3445.113.4.556; SQUIRE LR, 1981, J NEUROSCI, V1, P635; SQUIRE LR, 1982, J EXP PSYCHOL LEARN, V8, P560, DOI 10.1037/0278-7393.8.6.560; SQUIRE LR, 1975, J EXPT PSYCHOL HUMAN, V1, P50, DOI DOI 10.1037/0278-7393.1.1.50; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P164; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; SUNDERLAND A, 1983, J VERB LEARN VERB BE, V22, P341, DOI 10.1016/S0022-5371(83)90229-3; TEASDALE G, 1974, LANCET, V2, P81; THOMSEN IV, 1977, SCAND J REHABIL MED, V9, P73; TWEEDY JR, 1987, J CLIN EXP NEUROPSYC, V9, P19; WEINGARTNER H, 1983, SCIENCE, V221, P380, DOI 10.1126/science.6867715; Weinstein E. A., 1955, DENIAL ILLNESS SYMBO; WILSON B, CLIN MANAGEMENT MEMO; WILSON B, 1985, RIVERMEAD BEHAVIOURA; ZATORRE RJ, 1983, BRAIN COGNITION, V2, P331, DOI 10.1016/0278-2626(83)90017-9	82	79	80	0	7	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	JAN	1990	12	1					129	153		10.1080/01688639008400960			25	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	CK557	WOS:A1990CK55700466	2406280				2021-06-18	
J	PONSFORD, JL; KINSELLA, G				PONSFORD, JL; KINSELLA, G			EVALUATION OF A REMEDIAL PROGRAM FOR ATTENTIONAL DEFICITS FOLLOWING CLOSED-HEAD INJURY	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article									BETHESDA HOSP,MELBOURNE,AUSTRALIA; LATROBE UNIV,MELBOURNE,AUSTRALIA			Kinsella, Glynda/O-6347-2017	Kinsella, Glynda/0000-0002-5859-0934			BENYISHAY Y, 1978, REHABILITATION MONOG, V59, P63; BLACK P, 1975, CIBA ELSEVIER S, V34, P65; BROOKS DN, 1984, CLOSED HEAD INJURY P, P44; CONKEY RC, 1938, ARCH PSYCHOL, V33; Gianutsos R, 1981, COMPUTER PROGRAMS CO; Gottman J. M., 1981, TIME SERIES ANAL COM; Gronwall D.M., 1974, PSYCHOL EFFECTS CONC; LEVIN HS, 1982, NEUROBEHAVIOURAL CON; MALEC J, 1984, COGNITIVE REHABILITA, V2, P18; Miller E, 1970, Cortex, V6, P121; NAYLOR GFK, 1972, NAYLORHARWOOD ADULT; NEWCOMBE F, 1982, INJURY, V14, P111, DOI 10.1016/0020-1383(82)90046-8; OCONNOR M, 1987, NEUROPSYCHOL REHABIL, P260; PONSFORD JL, 1985, 10TH P ANN BRAIN IMP, P17; POSNER MI, 1971, PSYCHOL REV, V78, P391, DOI 10.1037/h0031333; Posner MI, 1975, HDB PSYCHOBIOLOGY, P441, DOI DOI 10.1016/B978-0-12-278656-3.50019-3; PRIBRAM KH, 1975, PSYCHOL REV, V82, P116, DOI 10.1037/h0076780; Ruesch J, 1944, AM J PSYCHIAT, V100, P480, DOI 10.1176/ajp.100.4.480; RUSSELL WR, 1971, TRAUMATIC AMNESIAS; Schacter DL, 1986, CLIN NEUROPSYCHOLOGY, P257; Smith A., 1973, SYMBOL DIGIT MODALIT; SOHLBERG MM, 1987, J CLIN EXP NEUROPSYC, V9, P117, DOI 10.1080/01688638708405352; Van Zomeren A. H., 1981, REACTION TIME ATTENT; Van Zomeren A. H., 1984, CLOSED HEAD INJURY P, P74; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; WATSON PJ, 1981, J BEHAV THER EXP PSY, V12, P257, DOI 10.1016/0005-7916(81)90055-0; WOOD RL, 1984, 4 S MOD TECHN COGN R	27	79	79	0	6	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	DEC	1988	10	6					693	708		10.1080/01688638808402808			16	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	R2917	WOS:A1988R291700002	3235646				2021-06-18	
J	Leddy, JJ; Haider, MN; Ellis, MJ; Mannix, R; Darling, SR; Freitas, MS; Suffoletto, HN; Leiter, J; Cordingley, DM; Willer, B				Leddy, John J.; Haider, Mohammad N.; Ellis, Michael J.; Mannix, Rebekah; Darling, Scott R.; Freitas, Michael S.; Suffoletto, Heidi N.; Leiter, Jeff; Cordingley, Dean M.; Willer, Barry			Early Subthreshold Aerobic Exercise for Sport-Related Concussion A Randomized Clinical Trial	JAMA PEDIATRICS			English	Article							QUALITY-OF-LIFE; POSTCONCUSSION SYNDROME; ADOLESCENTS; SYMPTOMS; BALANCE; REHABILITATION; RELIABILITY; MEDICINE; CHILDREN; RECOVERY	IMPORTANCE: Sport-related concussion (SRC) is a significant public health problem without an effective treatment. OBJECTIVE: To assess the effectiveness of subsymptom threshold aerobic exercise vs a placebo-like stretching program prescribed to adolescents in the acute phase of recovery from SRC. DESIGN, SETTING, AND PARTICIPANTS: This multicenter prospective randomized clinical trial was conducted at university concussion centers. Male and female adolescent athletes (age 13-18 years) presenting within 10 days of SRC were randomly assigned to aerobic exercise or a placebo-like stretching regimen. INTERVENTIONS: After systematic determination of treadmill exercise tolerance on the first visit, participants were randomly assigned to a progressive subsymptom threshold aerobic exercise or a progressive placebo-like stretching program (that would not substantially elevate heart rate). Both forms of exercise were performed approximately 20 minutes per day, and participants reported daily symptoms and compliance with exercise prescription via a website. MAIN OUTCOMES AND MEASURES: Days from injury to recovery; recovery was defined as being asymptomatic, having recovery confirmed through an assessment by a physician blinded to treatment group, and returning to normal exercise tolerance on treadmill testing. Participants were also classified as having normal (<30 days) or delayed (>30 days) recovery. RESULTS: A total of 103 participants were included (aerobic exercise: n = 52; 24 female [46%]; stretching, n = 51; 24 female [47%]). Participants in the aerobic exercise group were seen a mean (SD) of 4.9 (2.2) days after the SRC, and those in the stretching group were seen a mean (SD) of 4.8 (2.4) days after the SRC. There were no differences in age, sex, previous concussions, time from injury, initial symptom severity score, or initial exercise treadmill test and physical examination results. Aerobic exercise participants recovered in a median of 13 (interquartile range [IQR], 10-18.5) days, whereas stretching participants recovered in 17 (IQR, 13-23) days (P = .009 by Mann-Whitney test). There was a nonsignificant lower incidence of delayed recovery in the aerobic exercise group (2 participants [4%] in the aerobic group vs 7 [14%] in the placebo group; P = .08). CONCLUSIONS AND RELEVANCE: This is, to our knowledge, the first RCT to show that individualized subsymptom threshold aerobic exercise treatment prescribed to adolescents with concussion symptoms during the first week after SRC speeds recovery and may reduce the incidence of delayed recovery.	[Leddy, John J.; Haider, Mohammad N.; Darling, Scott R.; Freitas, Michael S.; Suffoletto, Heidi N.] SUNY Buffalo, Jacobs Sch Med & Biomed Sci, UBMD Orthopaed & Sports Med, Buffalo, NY USA; [Haider, Mohammad N.] SUNY Buffalo, Jacobs Sch Med & Biomed Sci, Dept Neurosci, Buffalo, NY USA; [Ellis, Michael J.] Univ Manitoba, Div Surg, Sect Neurosurg, Winnipeg, MB, Canada; [Ellis, Michael J.] Univ Manitoba, Dept Pediat & Child Hlth, Winnipeg, MB, Canada; [Ellis, Michael J.] Childrens Hosp, Res Inst Manitoba, Pan Am Clin Fdn, Pan Am Concuss Program, Winnipeg, MB, Canada; [Ellis, Michael J.] Univ Manitoba, Winnipeg, MB, Canada; [Mannix, Rebekah] Boston Childrens Hosp, Div Emergency Med, Boston, MA USA; [Leiter, Jeff; Cordingley, Dean M.] Pan Am Clin Fdn, Winnipeg, MB, Canada; [Willer, Barry] SUNY Buffalo, Jacobs Sch Med & Biomed Sci, Dept Psychiat, Buffalo, NY USA	Leddy, JJ (corresponding author), SUNY Buffalo, UBMD Orthopaed & Sports Med, 160 Farber Hall, Buffalo, NY 14214 USA.	leddy@buffalo.edu	Mannix, Rebekah/AAD-8702-2020		National Institute of Neurological Disorders and Stroke of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1R01NS094444]; National Center for Advancing Translational Sciences of the National Institutes of Health (State University of New York at Buffalo) [UL1TR001412]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001412] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS094444] Funding Source: NIH RePORTER	This study was supported by the National Institute of Neurological Disorders and Stroke of the National Institutes of Health (grant 1R01NS094444) and the National Center for Advancing Translational Sciences of the National Institutes of Health (grant UL1TR001412; the State University of New York at Buffalo).	Alsalaheen BA, 2010, J NEUROL PHYS THER, V34, P87, DOI 10.1097/NPT.0b013e3181dde568; Baker JG, 2015, CLIN PEDIATR, V54, P961, DOI 10.1177/0009922815588820; Baker JG, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/705309; Carson J, CAN FAM PHYS; Carter JB, 2003, SPORTS MED, V33, P33, DOI 10.2165/00007256-200333010-00003; Clausen M, 2016, J HEAD TRAUMA REHAB, V31, P215, DOI 10.1097/HTR.0000000000000145; Darling SR, 2014, CLIN J SPORT MED, V24, P128, DOI 10.1097/JSM.0000000000000026; Echemendia RJ, 2017, BRIT J SPORT MED, V51, P848, DOI 10.1136/bjsports-2017-097506; Ellis MJ, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00136; Erickson KI, 2011, P NATL ACAD SCI USA, V108, P3017, DOI 10.1073/pnas.1015950108; Fineblit S, 2016, J NEUROTRAUM, V33, P1561, DOI 10.1089/neu.2015.4292; Giza CC, 2001, J ATHL TRAINING, V36, P228; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Grool AM, 2016, JAMA-J AM MED ASSOC, V316, P2504, DOI 10.1001/jama.2016.17396; Guskiewicz KM, 2013, BRIT J SPORT MED, V47, P289, DOI 10.1136/bjsports-2013-092225; Houston MN, 2016, BRAIN INJURY, V30, P891, DOI 10.3109/02699052.2016.1146960; Iverson GL, 2016, PHYS MED REH CLIN N, V27, P429, DOI 10.1016/j.pmr.2015.12.002; Johnson BD, 2018, PHYSIOL REP, V6, DOI 10.14814/phy2.13694; Kawasaki T, 2011, HYPERTENS RES, V34, P1059, DOI 10.1038/hr.2011.81; Kozlowski KF, 2013, J ATHL TRAINING, V48, P627, DOI 10.4085/1062-6050-48.5.02; Kurowski BG, 2017, J HEAD TRAUMA REHAB, V32, P79, DOI 10.1097/HTR.0000000000000238; La Fountaine MF, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00013; Laker SR, 2011, PM&R, V3, pS354, DOI 10.1016/j.pmrj.2011.07.017; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Leddy J, 2016, PM&R, V8, pS91, DOI 10.1016/j.pmrj.2015.10.017; Leddy JJ, 2018, CURR SPORT MED REP, V17, P262, DOI 10.1249/JSR.0000000000000505; Leddy JJ, 2018, CLIN J SPORT MED, V28, P13, DOI 10.1097/JSM.0000000000000431; Leddy JJ, 2013, CURR SPORT MED REP, V12, P370, DOI 10.1249/JSR.0000000000000008; Leddy JJ, 2013, J HEAD TRAUMA REHAB, V28, P241, DOI 10.1097/HTR.0b013e31826da964; Leddy JJ, 2012, SPORTS HEALTH, V4, P147, DOI 10.1177/1941738111433673; Leddy JJ, 2011, CLIN J SPORT MED, V21, P89, DOI 10.1097/JSM.0b013e3181fdc721; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Maerlender A, 2015, DEV NEUROPSYCHOL, V40, P273, DOI 10.1080/87565641.2015.1067706; Matuszak JM, 2016, SPORTS HEALTH, V8, P260, DOI 10.1177/1941738116641394; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; Schneider KJ, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2016-097475; Silverberg ND, 2013, J HEAD TRAUMA REHAB, V28, P250, DOI 10.1097/HTR.0b013e31825ad658; Thomas DG, 2015, PEDIATRICS, V135, P213, DOI 10.1542/peds.2014-0966; Whaley MH, 2006, ACSMS GUIDELINES EXE; Zemek R, 2016, JAMA-J AM MED ASSOC, V315, P1014, DOI 10.1001/jama.2016.1203	42	78	79	2	20	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6203	2168-6211		JAMA PEDIATR	JAMA Pediatr.	APR	2019	173	4					319	325		10.1001/jamapediatrics.2018.4397			7	Pediatrics	Pediatrics	HU3HD	WOS:000465162600008	30715132	Green Published, Bronze	Y	N	2021-06-18	
J	Cooper, DJ; Nichol, AD; Bailey, M; Bernard, S; Cameron, PA; Pili-Floury, S; Forbes, A; Gantner, D; Higgins, AM; Huet, O; Kasza, J; Murray, L; Newby, L; Presneill, JJ; Rashford, S; Rosenfeld, JV; Stephenson, M; Vallance, S; Varma, D; Webb, SAR; Trapani, T; McArthur, C				Cooper, D. James; Nichol, Alistair D.; Bailey, Michael; Bernard, Stephen; Cameron, Peter A.; Pili-Floury, Sebastien; Forbes, Andrew; Gantner, Dashiell; Higgins, Alisa M.; Huet, Olivier; Kasza, Jessica; Murray, Lynne; Newby, Lynette; Presneill, Jeffrey J.; Rashford, Stephen; Rosenfeld, Jeffrey V.; Stephenson, Michael; Vallance, Shirley; Varma, Dinesh; Webb, Steven A. R.; Trapani, Tony; McArthur, Colin		POLAR Trial Investigators ANZICS	Effect of Early Sustained Prophylactic Hypothermia on Neurologic Outcomes Among Patients With Severe Traumatic Brain Injury The POLAR Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							THERAPEUTIC HYPOTHERMIA; MILD HYPOTHERMIA; MODERATE HYPOTHERMIA; MANAGEMENT; PATHOPHYSIOLOGY; RESUSCITATION; GUIDELINES; SALINE	IMPORTANCE After severe traumatic brain injury, induction of prophylactic hypothermia has been suggested to be neuroprotective and improve long-term neurologic outcomes. OBJECTIVE To determine the effectiveness of early prophylactic hypothermia compared with normothermic management of patients after severe traumatic brain injury. DESIGN, SETTING, AND PARTICIPANTS The Prophylactic Hypothermia Trial to Lessen Traumatic Brain Injury-Randomized Clinical Trial (POLAR-RCT) was a multicenter randomized trial in 6 countries that recruited 511 patients both out-of-hospital and in emergency departments after severe traumatic brain injury. The first patient was enrolled on December 5. 2010, and the last on November 10.2017. The final date of follow-up was May 15, 2018. INTERVENTIONS There were 266 patients randomized to the prophylactic hypothermia group and 245 to normothermic management. Prophylactic hypothermia targeted the early induction of hypothermia (33 degrees C-35 degrees C) for at least 72 hours and up to 7 days if intracranial pressures were elevated, followed by gradual rewarming. Normothermia targeted 37 degrees C, using surface-cooling wraps when required. Temperature was managed in both groups for 7 days. All other care was at the discretion of the treating physician. MAIN OUTCOMES AND MEASURES The primary outcome was favorable neurologic outcomes or independent living (Glasgow Outcome Scale-Extended score, 5-8 [scale range, 1-8]) obtained by blinded assessors 6 months after injury. RESULTS Among 511 patients who were randomized. 500 provided ongoing consent (mean age, 34.5 years [SD. 13.4); 402 men [80.2%]) and 466 completed the primary outcome evaluation. Hypothermia was initiated rapidly after injury (median, 1.8 hours [IQR, 1.0-2.7 hours]) and rewarming occurred slowly (median, 22.5 hours [IQR, 16-27 hours)). Favorable outcomes (Glasgow Outcome Scale-Extended score, 5-8) at 6 months occurred in 117 patients (48.8%) in the hypothermia group and 111(49.1%) in the normothermia group (risk difference, 0.4% [95% CI, -9.4% to 8.7%]; relative risk with hypothermia, 0.99 [95% CI, 0.82-1.19]; P = .94). In the hypothermia and normothermia groups, the rates of pneumonia were 55.0% vs 51.3%, respectively, and rates of increased intracranial bleeding were 18.1% vs 15.4%, respectively. CONCLUSIONS AND RELEVANCE Among patients with severe traumatic brain injury, early prophylactic hypothermia compared with normothermia did not improve neurologic outcomes at 6 months. These findings do not support the use of early prophylactic hypothermia for patients with severe traumatic brain injury.	[Cooper, D. James; Nichol, Alistair D.; Bailey, Michael; Gantner, Dashiell; Higgins, Alisa M.; Huet, Olivier; Murray, Lynne; Newby, Lynette; Presneill, Jeffrey J.; Stephenson, Michael; Vallance, Shirley; Webb, Steven A. R.; Trapani, Tony; McArthur, Colin] Monash Univ, Australian & New Zealand Intens Care Res Ctr, Melbourne, Vic, Australia; [Cooper, D. James; Nichol, Alistair D.; Bernard, Stephen; Gantner, Dashiell; Vallance, Shirley; Trapani, Tony] Alfred Hosp, Dept Intens Care, Melbourne, Vic, Australia; [Nichol, Alistair D.] St Vincents Univ Hosp, Univ Coll Dublin, Clin Res Ctr, Irish Crit Care Clin Trials Network, Dublin, Ireland; [Nichol, Alistair D.] St Vincents Univ Hosp, Dept Anaesthesia & Intens Care Med, Dublin, Ireland; [Nichol, Alistair D.] Univ Coll Dublin, Sch Med & Med Sci, Dublin, Ireland; [Bernard, Stephen; Stephenson, Michael] Ambulance Victoria, Melbourne, Vic, Australia; [Cameron, Peter A.; Forbes, Andrew; Kasza, Jessica] Monash Univ, Sch Publ Hlth & Prevent Med, Melbourne, Vic, Australia; [Cameron, Peter A.; Gantner, Dashiell] Monash Univ, Ctr Excellence Traumat Brain Injury Res, Melbourne, Vic, Australia; [Cameron, Peter A.] Hamad Med Corp, Emergency Med, Dhueta, Qatar; [Cameron, Peter A.] Alfred Hosp, Emergency & Trauma Ctr, Melbourne, Vic, Australia; [Pili-Floury, Sebastien] CHU Besancon, Serv Reanimat Chirurg, Pole Anesthesie & Reanimat, Besancon, France; [Huet, Olivier] CHRU Brest, Hop La Cavale Blanche, Dept Anaesthesia & Intens Care Med, Brest, France; [Huet, Olivier] Univ Bretagne Occidenta, UFR Med & Sci Sante, Brest, France; [Newby, Lynette; McArthur, Colin] Auckland City Hosp, Dept Crit Care Med, Auckland, New Zealand; [Presneill, Jeffrey J.] Royal Melbourne Hosp, Intens Care Unit, Melbourne, Vic, Australia; [Presneill, Jeffrey J.] Univ Melbourne, Dept Med, Melbourne, Vic, Australia; [Rashford, Stephen] Queensland Ambulance Serv, Brisbane, Qld, Australia; [Rosenfeld, Jeffrey V.] Alfred Hosp, Neurosurg, Melbourne, Vic, Australia; [Rashford, Stephen; Varma, Dinesh] Monash Univ, Dept Surg, Melbourne, Vic, Australia; [Rosenfeld, Jeffrey V.] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Surg, Bethesda, MD 20814 USA; [Varma, Dinesh] Alfred Hosp, Radiol, Melbourne, Vic, Australia; [Webb, Steven A. R.] Royal Perth Hosp, Intens Care Unit, Perth, WA, Australia	Cooper, DJ (corresponding author), Monash Univ, ANZIC Res Ctr, 553 St Kilda Rd,Level 3, Melbourne, Vic 3004, Australia.	jamie.cooper@monash.edu	Haenggi, Matthias/O-2642-2019; /AAB-3060-2019; Higgins, Alisa/AAM-8088-2020; Cooper, D. James/G-7961-2013; Haenggi, Matthias/A-8073-2008	Haenggi, Matthias/0000-0001-5845-031X; Higgins, Alisa/0000-0001-8295-7559; Cooper, D. James/0000-0002-5872-9051; Haenggi, Matthias/0000-0001-5845-031X; Alsolamy, Sami/0000-0002-0127-0307; Nichol, Alistair/0000-0002-4689-1238; Forbes, Andrew/0000-0003-4269-914X	National Health and Medical Research Council of AustraliaNational Health and Medical Research Council of AustraliaUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [545901, 1121037]; Victorian Neurotrauma Initiative (VNI) [VNI D162]; Teaching Hospital of Besancon, France; Health Research Board of Ireland Clinical Trial Network Program	This trial was supported by grants from the National Health and Medical Research Council of Australia (545901 and 1121037); the Victorian Neurotrauma Initiative (VNI for the Transport Accident Commission, Victoria, Australia) (VNI D162); the Teaching Hospital of Besancon, France; and Health Research Board of Ireland Clinical Trial Network Program.	Access Economics Pty Limited for the Victorian Neurotrauma Initiative, 2009, EC COST SPIN CORD IN; Andrews PJD, 2015, NEW ENGL J MED, V373, P2403, DOI 10.1056/NEJMoa1507581; Bramlett HM, 2012, THER HYPOTHERMIA TEM, V2, P14, DOI 10.1089/ther.2012.0002; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; Clifton GL, 2011, LANCET NEUROL, V10, P131, DOI 10.1016/S1474-4422(10)70300-8; Cooper DJ, 2004, JAMA-J AM MED ASSOC, V291, P1350, DOI 10.1001/jama.291.11.1350; Dengler B, 2015, J CRIT CARE, V30, P823, DOI 10.1016/j.jcrc.2015.03.027; Geurts M, 2014, CRIT CARE MED, V42, P231, DOI 10.1097/CCM.0b013e3182a276e8; Liu YH, 2015, EXP THER MED, V9, P464, DOI 10.3892/etm.2014.2130; Maas AIR, 2017, LANCET NEUROL, V16, P987, DOI 10.1016/S1474-4422(17)30371-X; Maekawa T, 2015, J NEUROTRAUM, V32, P422, DOI 10.1089/neu.2013.3197; Marion DW, 2014, CRIT CARE, V18, DOI 10.1186/cc13955; McGinn MJ, 2016, NEUROSURG CLIN N AM, V27, P397, DOI 10.1016/j.nec.2016.06.002; Myburgh J, 2007, NEW ENGL J MED, V357, P874; Nichol A, 2015, LANCET, V386, P2499, DOI 10.1016/S0140-6736(15)00386-4; Nichol A, 2015, CRIT CARE RESUSC, V17, P92; Nichol AD, 2011, LANCET NEUROL, V10, P405, DOI 10.1016/S1474-4422(11)70085-0; Olah E, 2018, J NEUROTRAUM, V35, P2407, DOI 10.1089/neu.2018.5649; Polderman KH, 2009, CRIT CARE MED, V37, pS186, DOI 10.1097/CCM.0b013e3181aa5241; Polderman KH, 2002, INTENS CARE MED, V28, P1563, DOI 10.1007/s00134-002-1511-3; Presneill J, 2018, TRIALS, V19, DOI 10.1186/s13063-018-2610-y; Sahuquillo J, 2007, CURR PHARM DESIGN, V13, P2310; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; Smrcka M, 2005, ACT NEUR S, V95, P273; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Tang CH, 2017, J CRIT CARE, V39, P267, DOI 10.1016/j.jcrc.2016.12.012; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Zhao QJ, 2011, J CRIT CARE, V26, P311, DOI 10.1016/j.jcrc.2010.08.014; Zhao WY, 2017, BRAIN RES, V1669, P141, DOI 10.1016/j.brainres.2017.06.006; Zhi DS, 2003, SURG NEUROL, V59, P381, DOI 10.1016/S0090-3019(03)00148-4	33	78	84	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 4	2018	320	21					2211	2220		10.1001/jama.2018.17075			10	Medicine, General & Internal	General & Internal Medicine	HD4MB	WOS:000452500600012	30357266	Bronze, Green Published			2021-06-18	
J	Kao, AW; Mckay, A; Singh, PP; Brunet, A; Huang, EJ				Kao, Aimee W.; McKay, Andrew; Singh, Param Priya; Brunet, Anne; Huang, Eric J.			Progranulin, lysosomal regulation and neurodegenerative disease	NATURE REVIEWS NEUROSCIENCE			English	Article							FRONTOTEMPORAL LOBAR DEGENERATION; TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; HEXANUCLEOTIDE REPEAT; NEURITE OUTGROWTH; TNF RECEPTORS; HOST-DEFENSE; GENE LEADS; MUTATIONS; PROTEIN	The discovery that heterozygous and homozygous mutations in the gene encoding progranulin are causally linked to frontotemporal dementia and lysosomal storage disease, respectively, reveals previously unrecognized roles of the progranulin protein in regulating lysosome biogenesis and function. Given the importance of lysosomes in cellular homeostasis, it is not surprising that progranulin deficiency has pleiotropic effects on neural circuit development and maintenance, stress response, innate immunity and ageing. This Progress article reviews recent advances in progranulin biology emphasizing its roles in lysosomal function and brain innate immunity, and outlines future avenues of investigation that may lead to new therapeutic approaches for neurodegeneration.	[Kao, Aimee W.] Univ Calif San Francisco, Dept Neurol, 675 Nelson Rising Lane, San Francisco, CA 94158 USA; [McKay, Andrew; Singh, Param Priya; Brunet, Anne] Stanford Univ, Dept Genet, 300 Pasteur Dr, Stanford, CA 94305 USA; [Huang, Eric J.] Univ Calif San Francisco, Dept Pathol, 513 Parnassus Avenue, San Francisco, CA 94143 USA; [Huang, Eric J.] San Francisco VA Med Ctr, Pathol Serv 113B, 513 Parnassus Avenue, San Francisco, CA 94143 USA	Kao, AW (corresponding author), Univ Calif San Francisco, Dept Neurol, 675 Nelson Rising Lane, San Francisco, CA 94158 USA.; Huang, EJ (corresponding author), Univ Calif San Francisco, Dept Pathol, 513 Parnassus Avenue, San Francisco, CA 94143 USA.; Huang, EJ (corresponding author), San Francisco VA Med Ctr, Pathol Serv 113B, 513 Parnassus Avenue, San Francisco, CA 94143 USA.	aimee.kao@ucsf.edu; eric.huang2@ucsf.edu	Singh, Param P/AAU-7841-2020; Huang, Eric J./AAH-7997-2019	Huang, Eric J./0000-0002-5381-3801	US Public Health ServiceUnited States Department of Health & Human ServicesUnited States Public Health Service [NS095257, NS098516]; Tau Consortium; Consortium for Frontotemporal Dementia Research; VA Merit AwardUS Department of Veterans Affairs [BX002978]; Glenn Foundation for Medical Research; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS095257, R21NS082709, R01NS098516, K08NS059604] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01RX002133, I01BX002978] Funding Source: NIH RePORTER	The authors thank W. W. Seeley, E. H. Bigio and I. R. Mackenzie for sharing the neuropathology findings in patients with frontotemporal lobar degeneration with mutations in the gene encoding progranulin. This work has been supported by US Public Health Service grants NS095257 (A.W.K.) and NS098516 (E.J.H.), the Tau Consortium (A.W.K.), the Consortium for Frontotemporal Dementia Research (E.J.H.), VA Merit Award BX002978 (E.J.H.), and the Glenn Foundation for Medical Research (A.M., P.P.S. and A.B.)	Aharon-Peretz J., NEUROLOGY, V65; Ahmed Z, 2010, AM J PATHOL, V177, P311, DOI 10.2353/ajpath.2010.090915; Almeida MR, 2016, NEUROBIOL AGING, V41, DOI 10.1016/j.neurobiolaging.2016.02.019; Almeida S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026454; Arai T, 2006, BIOCHEM BIOPH RES CO, V351, P602, DOI 10.1016/j.bbrc.2006.10.093; Bai XH, 2009, MOL CELL BIOL, V29, P4201, DOI 10.1128/MCB.00056-09; Baker M, 2006, NATURE, V442, P916, DOI 10.1038/nature05016; Bateman A, 2009, BIOESSAYS, V31, P1245, DOI 10.1002/bies.200900086; Belcastro V, 2011, NUCLEIC ACIDS RES, V39, P8677, DOI 10.1093/nar/gkr593; Butler GS, 2008, MOL CELL BIOL, V28, P4896, DOI 10.1128/MCB.01775-07; Capell A, 2011, J NEUROSCI, V31, P1885, DOI 10.1523/JNEUROSCI.5757-10.2011; Carcel-Trullols J, 2015, BBA-MOL BASIS DIS, V1852, P2242, DOI 10.1016/j.bbadis.2015.04.027; Cenik B, 2012, J BIOL CHEM, V287, P32298, DOI 10.1074/jbc.R112.399170; Cenik B, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.193433; Chen X, 2013, J NEUROSCI, V33, P9202, DOI 10.1523/JNEUROSCI.5336-12.2013; Cruts Marc, 2006, Current Alzheimer Research, V3, P485, DOI 10.2174/156720506779025251; Cruts M, 2006, NATURE, V442, P920, DOI 10.1038/nature05017; Daniel R, 2000, J HISTOCHEM CYTOCHEM, V48, P999, DOI 10.1177/002215540004800713; Daniel R, 2003, DEV DYNAM, V227, P593, DOI 10.1002/dvdy.10341; De Muynck L, 2013, NEUROBIOL AGING, V34, P2541, DOI 10.1016/j.neurobiolaging.2013.04.022; DeJesus-Hernandez M, 2011, NEURON, V72, P245, DOI 10.1016/j.neuron.2011.09.011; Filiano AJ, 2013, J NEUROSCI, V33, P5352, DOI 10.1523/JNEUROSCI.6103-11.2013; Finch N, 2009, BRAIN, V132, P583, DOI 10.1093/brain/awn352; Finn RD, 2014, NUCLEIC ACIDS RES, V42, pD222, DOI [10.1093/nar/gkt263, 10.1093/nar/gkt1223]; Gao X, 2010, PROTEIN CELL, V1, P552, DOI 10.1007/s13238-010-0067-1; Gass J, 2006, HUM MOL GENET, V15, P2988, DOI 10.1093/hmg/ddl241; Gass J, 2012, MOL NEURODEGENER, V7, DOI 10.1186/1750-1326-7-33; Gotzl JK, 2014, ACTA NEUROPATHOL, V127, P845, DOI 10.1007/s00401-014-1262-6; Gowrishankar S, 2015, P NATL ACAD SCI USA, V112, pE3699, DOI 10.1073/pnas.1510329112; Guerra RR, 2007, GROWTH FACTORS, V25, P280, DOI 10.1080/08977190701781222; Hassan AJ, 2004, MOL REPROD DEV, V68, P476, DOI 10.1002/mrd.20096; Herrero J, 2016, DATABASE-OXFORD, DOI [10.1093/database/bav096, 10.1093/database/baw053]; Hiesberger T, 1998, EMBO J, V17, P4617, DOI 10.1093/emboj/17.16.4617; Holler CJ, 2016, MOL NEURODEGENER, V11, DOI 10.1186/s13024-016-0114-3; Hsiung GYR, 2011, J NEUROL SCI, V300, P28, DOI 10.1016/j.jns.2010.10.009; Hu FH, 2010, NEURON, V68, P654, DOI 10.1016/j.neuron.2010.09.034; Hulkova H, 2001, HUM MOL GENET, V10, P927, DOI 10.1093/hmg/10.9.927; Jiao J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010551; Kanazawa M, 2015, BRAIN, V138, P1932, DOI 10.1093/brain/awv079; Kao AW, 2011, P NATL ACAD SCI USA, V108, P4441, DOI 10.1073/pnas.1100650108; Kelley BJ, 2009, NEUROBIOL AGING, V30, P739, DOI 10.1016/j.neurobiolaging.2007.08.022; Kessenbrock K, 2008, J CLIN INVEST, V118, P2438, DOI 10.1172/JCI34694; KISHIMOTO Y, 1992, J LIPID RES, V33, P1255; Knopman DS, 2011, J MOL NEUROSCI, V45, P330, DOI 10.1007/s12031-011-9538-y; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Lavergne V, 2012, CURR TOP MED CHEM, V12, P1514, DOI 10.2174/156802612802652411; Lefrancois S, 2003, EMBO J, V22, P6430, DOI 10.1093/emboj/cdg629; Liddelow SA, 2017, NATURE, V541, P481, DOI 10.1038/nature21029; Lui HS, 2016, CELL, V165, P921, DOI 10.1016/j.cell.2016.04.001; Mackenzie IRA, 2011, ACTA NEUROPATHOL, V122, P87, DOI 10.1007/s00401-011-0838-7; Mackenzie IRA, 2010, ACTA NEUROPATHOL, V119, P1, DOI 10.1007/s00401-009-0612-2; Martens LH, 2012, J CLIN INVEST, V122, P3955, DOI 10.1172/JCI63113; Meyer RC, 2014, BRAIN RES, V1585, P1, DOI 10.1016/j.brainres.2014.08.022; Minami SS, 2014, NAT MED, V20, P1157, DOI 10.1038/nm.3672; Neill T, 2016, J CELL BIOL, V215, P687, DOI 10.1083/jcb.201603079; Neumann M, 2007, ARCH NEUROL-CHICAGO, V64, P1388, DOI 10.1001/archneur.64.10.1388; Neumann M, 2006, SCIENCE, V314, P130, DOI 10.1126/science.1134108; Nicholson AM, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11992; Nicholson AM, 2014, NEUROLOGY, V82, P1871, DOI 10.1212/WNL.0000000000000445; Nixon RA, 2013, NAT MED, V19, P983, DOI 10.1038/nm.3232; Palfree RGE, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133749; Park B, 2011, IMMUNITY, V34, P505, DOI 10.1016/j.immuni.2011.01.018; Perry DC, 2013, JAMA NEUROL, V70, P774, DOI 10.1001/2013.jamaneurol.393; Petoukhov E, 2013, J CELL SCI, V126, P5412, DOI 10.1242/jcs.132076; Pickford F, 2011, AM J PATHOL, V178, P284, DOI 10.1016/j.ajpath.2010.11.002; Rademakers R, 2008, HUM MOL GENET, V17, P3631, DOI 10.1093/hmg/ddn257; Rademakers R, 2007, LANCET NEUROL, V6, P857, DOI 10.1016/S1474-4422(07)70221-1; Ramirez A, 2006, NAT GENET, V38, P1184, DOI 10.1038/ng1884; Renton AE, 2011, NEURON, V72, P257, DOI 10.1016/j.neuron.2011.09.010; Salazar DA, 2015, J NEUROSCI, V35, P9315, DOI 10.1523/JNEUROSCI.4808-14.2015; Sardiello M, 2009, SCIENCE, V325, P473, DOI 10.1126/science.1174447; Schuur M, 2011, NEUROBIOL AGING, V32, P1607, DOI 10.1016/j.neurobiolaging.2009.10.011; Settembre C, 2011, SCIENCE, V332, P1429, DOI 10.1126/science.1204592; Shankaran SS, 2008, J BIOL CHEM, V283, P1744, DOI 10.1074/jbc.M705115200; Singh PP, 2012, CELL REP, V2, P1387, DOI 10.1016/j.celrep.2012.09.034; Smith KR, 2012, AM J HUM GENET, V90, P1102, DOI 10.1016/j.ajhg.2012.04.021; Songsrirote K, 2010, J PROTEOMICS, V73, P1479, DOI 10.1016/j.jprot.2010.02.013; Suh HS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035115; Tanaka Y, 2013, NEUROSCIENCE, V250, P8, DOI 10.1016/j.neuroscience.2013.06.049; Tanaka Y, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/s40478-014-0078-x; Tang W, 2011, SCIENCE, V332, P478, DOI 10.1126/science.1199214; Tapia L, 2011, J NEUROSCI, V31, P11126, DOI 10.1523/JNEUROSCI.6244-10.2011; Tolkatchev D, 2008, PROTEIN SCI, V17, P711, DOI 10.1110/ps.073295308; Valenzano DR, 2015, CELL, V163, P1539, DOI 10.1016/j.cell.2015.11.008; Van Damme P, 2008, J CELL BIOL, V181, P37, DOI 10.1083/jcb.200712039; van Swieten JC, 2008, LANCET NEUROL, V7, P965, DOI 10.1016/S1474-4422(08)70194-7; Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406; Wang J, 2010, J NEUROCHEM, V112, P1305, DOI 10.1111/j.1471-4159.2009.06546.x; Wang WX, 2010, AM J PATHOL, V177, P334, DOI 10.2353/ajpath.2010.091202; Ward ME, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aah5642; Yin FF, 2010, FASEB J, V24, P4639, DOI 10.1096/fj.10-161471; Yin FF, 2010, J EXP MED, V207, P117, DOI 10.1084/jem.20091568; Zeng JB, 2009, EXP CELL RES, V315, P3112, DOI 10.1016/j.yexcr.2009.08.016; Zhang Y, 2014, J NEUROSCI, V34, P11929, DOI [10.11772/j.issn.1001-9081.2014.07.1929, 10.1523/JNEUROSCI.1860-14.2014]; Zhou XL, 2015, J CELL BIOL, V210, P991, DOI 10.1083/jcb.201502029; Zhu J, 2002, CELL, V111, P867, DOI 10.1016/S0092-8674(02)01141-8	96	78	80	0	19	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1471-003X	1471-0048		NAT REV NEUROSCI	Nat. Rev. Neurosci.	JUN	2017	18	6					325	333		10.1038/nrn.2017.36			9	Neurosciences	Neurosciences & Neurology	EV1PA	WOS:000401517300006	28435163	Green Accepted			2021-06-18	
J	Agoston, DV; Shutes-David, A; Peskind, ER				Agoston, Denes V.; Shutes-David, Andrew; Peskind, Elaine R.			Biofluid biomarkers of traumatic brain injury	BRAIN INJURY			English	Article						(that are not already included in title): mild traumatic brain injury (mTBI); cerebrospinal fluid (CSF)	NEURON-SPECIFIC ENOLASE; TIME-DEPENDENT CHANGES; TERMINAL HYDROLASE L1; CEREBROSPINAL-FLUID; INTRACRANIAL-PRESSURE; REVEALS COMPLEX; AXONAL INJURY; SERUM; S100B; SYSTEM	Primary objective: The purpose of this paper is to review the clinical and research utility and applications of blood, cerebrospinal fluid (CSF), and cerebral microdialysis biomarkers in traumatic brain injury (TBI). Research design: Not applicable. Methods and procedures: A selective review was performed on these biofluid biomarkers in TBI. Main outcome and results: Neurofilament heavy chain protein (NF-H), glial fibrillary acidic protein (GFAP), ubiquitin C-terminal hydrolase-L1 (UCHL1), neuron-specific enolase (NSE), myelin basic protein (MBP), tau, and s100 beta blood biomarkers are elevated during the acute phase of severe head trauma but have key limitations in their research and clinical applications to mild TBI (mTBI). CSF biomarkers currently provide the best reflection of the central nervous system (CNS) pathobiological processes in TBI. Both animal and human studies of TBI have demonstrated the importance of serial sampling of biofluids and suggest that CSF biomarkers may be better equipped to characterize both TBI severity and temporal profiles. Conclusions: The identification of biofluid biomarkers could play a vital role in identifying, diagnosing, and treating the underlying individual pathobiological changes of TBI. CNS-derived exosomes analyzed by ultra-high sensitivity detection, methods have the potential to identify blood biomarkers for the range of TBI severity and time course.	[Agoston, Denes V.] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD USA; [Agoston, Denes V.] Karolinska Inst, Dept Neurosci, Stockholm, Sweden; [Shutes-David, Andrew; Peskind, Elaine R.] Vet Affairs Puget Sound Hlth Care Syst, VA Northwest Network Mental Illness Res, Educ & Clin Ctr, Seattle, WA USA; [Shutes-David, Andrew] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA; [Peskind, Elaine R.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA	Peskind, ER (corresponding author), VA Puget Sound Hlth Care Syst, 1660 So Columbian Way,5-116-MIRECC, Seattle, WA 98108 USA.	peskind@uw.edu			VA Puget Sound Health Care SystemUS Department of Veterans Affairs; Veterans AffairsUS Department of Veterans Affairs [I01RX000521, I01RX001612] Funding Source: NIH RePORTER	This material is the result of work supported with resources and the use of facilities at the VA Puget Sound Health Care System.	Agoston DVK, 2015, BRAIN NEUROTRAUMA MO; Ahmed F, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00114; Ahmed F, 2012, ELECTROPHORESIS, V33, P3705, DOI 10.1002/elps.201200299; Ahmed F, 2013, BIOMACROMOLECULES, V14, P3850, DOI 10.1021/bm400938n; Aspelund A, 2015, J EXP MED, V212, P991, DOI 10.1084/jem.20142290; Bedekovics T, 2016, BLOOD, V127, P1564, DOI 10.1182/blood-2015-07-656678; BENJAMINS JA, 1978, NEUROCHEM RES, V3, P137, DOI 10.1007/BF00964057; Bloomfield SM, 2007, NEUROCRIT CARE, V6, P121, DOI 10.1007/s12028-007-0008-x; Brenner LA, 2009, REHABIL PSYCHOL, V54, P239, DOI 10.1037/a0016908; Browne KD, 2011, J NEUROTRAUM, V28, P1747, DOI 10.1089/neu.2011.1913; Cernak I, 2002, J CLIN NEUROSCI, V9, P565, DOI 10.1054/jocn.2002.1132; Clay MB, 2013, J CHIROPR MED, V12, P230, DOI 10.1016/j.jcm.2012.11.005; Dewitt DS, 2003, J NEUROTRAUM, V20, P795, DOI 10.1089/089771503322385755; Doolan AW, 2012, ANN BIOMED ENG, V40, P106, DOI 10.1007/s10439-011-0413-3; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10210; Engstrom M, 2005, J NEUROSURG, V102, P460, DOI 10.3171/jns.2005.102.3.0460; Ercole A, 2016, BMC NEUROL, V16, DOI 10.1186/s12883-016-0614-3; Finnie JW, 2013, INFLAMMOPHARMACOLOGY, V21, P309, DOI 10.1007/s10787-012-0164-2; Gatson JW, 2014, J NEUROSURG, V121, P1232, DOI 10.3171/2014.7.JNS132474; Gyorgy A, 2011, J NEUROTRAUM, V28, P1121, DOI 10.1089/neu.2010.1561; Haqqani AS, 2007, J NEUROTRAUM, V24, P54, DOI 10.1089/neu.2006.0079; Helmy A, 2011, PROG NEUROBIOL, V95, P352, DOI 10.1016/j.pneurobio.2011.09.003; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Hill CS, 2016, TRENDS NEUROSCI, V39, P311, DOI 10.1016/j.tins.2016.03.002; Hillered L, 2006, CURR OPIN CRIT CARE, V12, P112, DOI 10.1097/01.ccx.0000216576.11439.df; Hladky SB, 2016, FLUIDS BARRIERS CNS, V13, DOI 10.1186/s12987-016-0040-3; Hladky SB, 2014, FLUIDS BARRIERS CNS, V11, DOI 10.1186/2045-8118-11-26; Huang XJ, 2015, J NEUROTRAUM, V32, P1179, DOI 10.1089/neu.2015.3873; Huber BR, 2013, J ALZHEIMERS DIS, V37, P309, DOI 10.3233/JAD-130182; Jessen NA, 2015, NEUROCHEM RES, V40, P2583, DOI 10.1007/s11064-015-1581-6; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Johnston M, 2002, NEWS PHYSIOL SCI, V17, P227, DOI 10.1152/nips.01400.2002; Kalani A, 2014, MOL NEUROBIOL, V49, P590, DOI 10.1007/s12035-013-8544-1; Karr JE, 2014, NEUROPSYCHOL REV, V24, P428, DOI 10.1007/s11065-014-9271-8; Kleindienst A, 2006, J NEUROTRAUM, V23, P1185, DOI 10.1089/neu.2006.23.1185; Kulbe JR, 2016, EXP NEUROL, V275, P334, DOI 10.1016/j.expneurol.2015.05.004; Lafrenaye AD, 2014, J CEREBR BLOOD F MET, V34, P1628, DOI 10.1038/jcbfm.2014.122; Laker SR, 2011, PM&R, V3, pS354, DOI 10.1016/j.pmrj.2011.07.017; Lescot T, 2010, J NEUROTRAUM, V27, P85, DOI 10.1089/neu.2009.0982; Li J, 2015, AM J EMERG MED, V33, P1191, DOI 10.1016/j.ajem.2015.05.023; Ling H, 2015, MOL CELL NEUROSCI, V66, P114, DOI 10.1016/j.mcn.2015.03.012; Logsdon AF, 2015, COMPR PHYSIOL, V5, P1147, DOI 10.1002/cphy.c140057; Louveau A, 2015, NATURE, V523, P337, DOI 10.1038/nature14432; Manley GT, 2006, J NEUROTRAUM, V23, P128, DOI 10.1089/neu.2006.23.128; MARANGOS PJ, 1987, ANNU REV NEUROSCI, V10, P269, DOI 10.1146/annurev.ne.10.030187.001413; Marklund N, 2009, J NEUROSURG, V110, P1227, DOI 10.3171/2008.9.JNS08584; Menon DK, 2015, NAT REV NEUROL, V11, P71, DOI 10.1038/nrneurol.2014.261; Metting Z, 2012, NEUROLOGY, V78, P1428, DOI 10.1212/WNL.0b013e318253d5c7; Microdialysis-Principles UU, 1991, J INTERN MED, V230, P365, DOI [10.1111/j.1365-2796.1991.tb00459.x., DOI 10.1111/J.1365-2796.1991.TB00459.X]; Mitchell AJ, 2009, J NEUROL NEUROSUR PS, V80, P966, DOI 10.1136/jnnp.2008.167791; Mondello S, 2012, J NEUROTRAUM, V29, P1096, DOI 10.1089/neu.2011.2092; Nakagawa A, 2011, J NEUROTRAUM, V28, P1101, DOI 10.1089/neu.2010.1442; Neselius S, 2015, KNEE SURG SPORT TR A, V23, P2536, DOI 10.1007/s00167-014-3066-6; Neselius S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099870; Newcombe VFJ, 2016, NEUROREHAB NEURAL RE, V30, P49, DOI 10.1177/1545968315584004; Nortje J, 2004, CURR OPIN NEUROL, V17, P711, DOI 10.1097/00019052-200412000-00011; Nwachuku EL, 2016, CLIN NEUROL NEUROSUR, V149, P1, DOI 10.1016/j.clineuro.2016.06.009; O'Bryant SE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028092; OTT L, 1987, JPEN-PARENTER ENTER, V11, P488, DOI 10.1177/0148607187011005488; Papa L, 2016, JAMA NEUROL, V73, P551, DOI 10.1001/jamaneurol.2016.0039; Papa L, 2014, J NEUROTRAUM, V31, P1815, DOI 10.1089/neu.2013.3245; Peskind ER, 2015, JAMA NEUROL, V72, P1103, DOI 10.1001/jamaneurol.2015.1789; Pham N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012691; Pineda JA, 2004, BRAIN PATHOL, V14, P202, DOI 10.1111/j.1750-3639.2004.tb00054.x; Plog BA, 2015, J NEUROSCI, V35, P518, DOI 10.1523/JNEUROSCI.3742-14.2015; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Prins ML, 2016, J CHILD NEUROL, V31, P28, DOI 10.1177/0883073814549244; Ren ZG, 2013, J CEREBR BLOOD F MET, V33, P834, DOI 10.1038/jcbfm.2013.30; Risdall JE, 2011, PHILOS T R SOC B, V366, P241, DOI 10.1098/rstb.2010.0230; Rosenthal G, 2008, J NEUROSURG, V108, P575, DOI 10.3171/JNS/2008/108/3/0575; Rostami E, 2013, RESP PHYSIOL NEUROBI, V189, P537, DOI 10.1016/j.resp.2013.08.010; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Schroder C, 2013, J CANCER RES CLIN, V139, P1745, DOI 10.1007/s00432-013-1496-z; Shahim P, 2016, J NEUROTRAUM, V33, P1995, DOI 10.1089/neu.2014.3741; Shahim P, 2015, BRAIN INJURY, V29, P872, DOI 10.3109/02699052.2015.1018324; Sharma R, 2012, CURR NEUROL NEUROSCI, V12, P560, DOI 10.1007/s11910-012-0301-8; Simon DW, 2017, NAT REV NEUROL, V13, P171, DOI 10.1038/nrneurol.2017.13; Strathmann FG, 2014, CLIN BIOCHEM, V47, P876, DOI 10.1016/j.clinbiochem.2014.01.028; Tarasoff-Conway JM, 2015, NAT REV NEUROL, V11, P457, DOI 10.1038/nrneurol.2015.119; Thelin EP, 2014, NEUROCRIT CARE, V20, P217, DOI 10.1007/s12028-013-9916-0; Thelin EP, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1450-y; Thelin EP, 2013, J NEUROTRAUM, V30, P519, DOI 10.1089/neu.2012.2553; THOMAS D G T, 1978, Lancet, V1, P113; Tsilioni I, 2014, CLIN THER, V36, P882, DOI 10.1016/j.clinthera.2014.05.005; Ungerstedt U, 2004, CURR PHARM DESIGN, V10, P2145, DOI 10.2174/1381612043384105; Voss JD, 2015, CURR PAIN HEADACHE R, V19, DOI 10.1007/s11916-015-0506-z; Wakeland W, 2005, ACT NEUR S, V95, P321; YAMAZAKI Y, 1995, SURG NEUROL, V43, P267, DOI 10.1016/0090-3019(95)80012-6; Yang HH, 2015, INT J CLIN EXP PATHO, V8, P13957; Yokobori S, 2013, CNS NEUROSCI THER, V19, P556, DOI 10.1111/cns.12127; ZELENIKA D, 1993, J NEUROCHEM, V60, P1574, DOI 10.1111/j.1471-4159.1993.tb03325.x; Zetterberg H, 2017, NEUROPATH APPL NEURO, V43, P194, DOI 10.1111/nan.12378; Zetterberg H, 2016, NAT REV NEUROL, V12, P563, DOI 10.1038/nrneurol.2016.127; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9; Zetterberg H, 2009, BRAIN INJURY, V23, P723, DOI 10.1080/02699050903120399; Zhao BQ, 2007, STROKE, V38, P748, DOI 10.1161/01.STR.0000253500.32979.d1; Zurek J, 2012, ACTA NEUROCHIR, V154, P93, DOI 10.1007/s00701-011-1175-2	97	78	82	1	11	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2017	31	9			SI		1195	1203		10.1080/02699052.2017.1357836			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	FK0NN	WOS:000413176600006	28981341	Other Gold			2021-06-18	
J	Woerman, AL; Aoyagi, A; Patel, S; Kazmi, SA; Lobach, I; Grinberg, LT; Mckee, AC; Seeley, WW; Olson, SH; Prusiner, SB				Woerman, Amanda L.; Aoyagi, Atsushi; Patel, Smita; Kazmi, Sabeen A.; Lobach, Iryna; Grinberg, Lea T.; McKee, Ann C.; Seeley, William W.; Olson, Steven H.; Prusiner, Stanley B.			Tau prions from Alzheimer's disease and chronic traumatic encephalopathy patients propagate in cultured cells	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article						argyrophilic grain disease; corticobasal degeneration; Pick's disease; progressive supranuclear palsy; tauopathies	MICROTUBULE-ASSOCIATED PROTEIN; PAIRED HELICAL FILAMENTS; SHARE ANTIGENIC DETERMINANTS; FRONTOTEMPORAL DEMENTIA; TRANSGENIC MICE; NEUROFIBRILLARY TANGLES; PICKS-DISEASE; ABNORMAL PHOSPHORYLATION; BRAIN-INJURY; MOUSE-BRAIN	Tau prions are thought to aggregate in the central nervous system, resulting in neurodegeneration. Among the tauopathies, Alzheimer's disease (AD) is the most common, whereas argyrophilic grain disease (AGD), corticobasal degeneration (CBD), chronic traumatic encephalopathy (CTE), Pick's disease (PiD), and progressive supranuclear palsy (PSP) are less prevalent. Brain extracts from deceased individuals with PiD, a neurodegenerative disorder characterized by three-repeat (3R) tau prions, were used to infect HEK293T cells expressing 3R tau fused to yellow fluorescent protein (YFP). Extracts from AGD, CBD, and PSP patient samples, which contain four-repeat (4R) tau prions, were transmitted to HEK293T cells expressing 4R tau fused to YFP. These studies demonstrated that prion propagation in HEK cells requires isoform pairing between the infecting prion and the recipient substrate. Interestingly, tau aggregates in AD and CTE, containing both 3R and 4R isoforms, were unable to robustly infect either 3R-or 4R-expressing cells. However, AD and CTE prions were able to replicate in HEK293T cells expressing both 3R and 4R tau. Unexpectedly, increasing the level of 4R isoform expression alone supported the propagation of both AD and CTE prions. These results allowed us to determine the levels of tau prions in AD and CTE brain extracts.	[Woerman, Amanda L.; Aoyagi, Atsushi; Patel, Smita; Kazmi, Sabeen A.; Olson, Steven H.; Prusiner, Stanley B.] Univ Calif San Francisco, Inst Neurodegenerat Dis, Weill Inst Neurosci, San Francisco, CA 94143 USA; [Woerman, Amanda L.; Grinberg, Lea T.; Seeley, William W.; Olson, Steven H.; Prusiner, Stanley B.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; [Aoyagi, Atsushi] Daiichi Sankyo Co Ltd, Tokyo 1408710, Japan; [Lobach, Iryna] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; [Grinberg, Lea T.; Seeley, William W.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA; [McKee, Ann C.] Boston Univ, Sch Med, Chron Traumat Encephalopathy Program, Alzheimers Dis Ctr, Boston, MA 02118 USA; [McKee, Ann C.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; [McKee, Ann C.] Boston Univ, Sch Med, Dept Pathol, Boston, MA 02118 USA; [McKee, Ann C.] US Dept Vet Affairs, Vet Affairs Boston Healthcare Syst, Jamaica Plain, MA 02130 USA; [McKee, Ann C.] US Dept Vet Affairs, Med Ctr, Bedford, MA 01730 USA; [Prusiner, Stanley B.] Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	Prusiner, SB (corresponding author), Univ Calif San Francisco, Inst Neurodegenerat Dis, Weill Inst Neurosci, San Francisco, CA 94143 USA.; Prusiner, SB (corresponding author), Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA.; Prusiner, SB (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA.	stanley.prusiner@ucsf.edu		Kazmi, Sabeen/0000-0002-3913-6170	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AG002132, AG031220, AG023501, AG19724]; Daiichi SankyoDaiichi Sankyo Company Limited; Dana Foundation; Glenn Foundation; Sherman Fairchild Foundation; Tau Consortium; Consortium for Frontotemporal Dementia Research; Department of Veterans Affairs, National Institute of Neurological Disorders and Stroke, National Institute of Biomedical Imaging and Bioengineering [NS086559]; National Institute on Aging, Boston University Alzheimer's Disease Center [AG13846, 0572063345-5]; Concussion Legacy Foundation; Andlinger Foundation; World Wrestling Entertainment, Inc; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS086659] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R37AG031220, P01AG019724, P01AG002132, P50AG023501, P30AG013846] Funding Source: NIH RePORTER	We thank George A. Carlson for his thoughtful revisions and comments, and Brittany N. Dugger for microdissecting the CTE patient samples. This work was supported by NIH Grants AG002132 and AG031220, Daiichi Sankyo, Dana Foundation, Glenn Foundation, Sherman Fairchild Foundation, and a gift from the Rainwater Charitable Foundation. Control, AD, AGD, CBD, PiD, and PSP tissue samples were provided by the University of California, San Francisco, Neurodegenerative Disease Brain Bank, which is supported by NIH Grants AG023501 and AG19724 (to W.W.S.), Tau Consortium, and Consortium for Frontotemporal Dementia Research. CTE tissue samples were provided by the Boston University Alzheimer's Disease Center Chronic Traumatic Encephalopathy Center, which is supported by the Department of Veterans Affairs, National Institute of Neurological Disorders and Stroke, National Institute of Biomedical Imaging and Bioengineering (NS086559), National Institute on Aging, Boston University Alzheimer's Disease Center (AG13846; Supplement 0572063345-5), Concussion Legacy Foundation, Andlinger Foundation, and World Wrestling Entertainment, Inc. Additional control samples were provided by the University of Miami Brain Endowment Bank.	Ahmed Z, 2014, ACTA NEUROPATHOL, V127, P667, DOI 10.1007/s00401-014-1254-6; ANDREADIS A, 1992, BIOCHEMISTRY-US, V31, P10626, DOI 10.1021/bi00158a027; BRION JP, 1985, ARCH BIOL, V96, P229; Buee L, 2000, BRAIN RES REV, V33, P95, DOI 10.1016/S0165-0173(00)00019-9; CARLSON GA, 1989, P NATL ACAD SCI USA, V86, P7475, DOI 10.1073/pnas.86.19.7475; CARLSON GA, 1994, P NATL ACAD SCI USA, V91, P5690, DOI 10.1073/pnas.91.12.5690; Clavaguera F, 2014, ACTA NEUROPATHOL, V127, P299, DOI 10.1007/s00401-013-1231-5; Clavaguera F, 2013, P NATL ACAD SCI USA, V110, P9535, DOI 10.1073/pnas.1301175110; Clavaguera F, 2009, NAT CELL BIOL, V11, P909, DOI 10.1038/ncb1901; D'Souza I, 1999, P NATL ACAD SCI USA, V96, P5598, DOI 10.1073/pnas.96.10.5598; Delacourte A, 1996, J NEUROPATH EXP NEUR, V55, P159, DOI 10.1097/00005072-199602000-00004; Dinkel PD, 2011, BIOCHEMISTRY-US, V50, P4330, DOI 10.1021/bi2004685; FLAMENT S, 1991, ACTA NEUROPATHOL, V81, P591, DOI 10.1007/BF00296367; FRASER H, 1973, J COMP PATHOL, V83, P29, DOI 10.1016/0021-9975(73)90024-8; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GOEDERT M, 1989, EMBO J, V8, P393, DOI 10.1002/j.1460-2075.1989.tb03390.x; GOEDERT M, 1992, NEURON, V8, P159, DOI 10.1016/0896-6273(92)90117-V; Goedert M, 2015, SCIENCE, V349, DOI 10.1126/science.1255555; GOLDFARB LG, 1992, SCIENCE, V258, P806, DOI 10.1126/science.1439789; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; Harada R, 2016, BIOMOLECULES, V6, DOI 10.3390/biom6010007; HOF PR, 1992, ACTA NEUROPATHOL, V85, P23, DOI 10.1007/BF00304630; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hong M, 1998, SCIENCE, V282, P1914, DOI 10.1126/science.282.5395.1914; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; Iba M, 2015, ACTA NEUROPATHOL, V130, P349, DOI 10.1007/s00401-015-1458-4; Iba M, 2013, J NEUROSCI, V33, P1024, DOI 10.1523/JNEUROSCI.2642-12.2013; IQBAL K, 1986, LANCET, V2, P421; Jansen WJ, 2015, JAMA-J AM MED ASSOC, V313, P1924, DOI 10.1001/jama.2015.4668; Kfoury N, 2012, J BIOL CHEM, V287, P19440, DOI 10.1074/jbc.M112.346072; KIDD M, 1963, NATURE, V197, P192, DOI 10.1038/197192b0; Kim EJ, 2012, CEREB CORTEX, V22, P251, DOI 10.1093/cercor/bhr004; KOSIK KS, 1986, P NATL ACAD SCI USA, V83, P4044, DOI 10.1073/pnas.83.11.4044; Kovacs GG, 2016, ACTA NEUROPATHOL, V131, P87, DOI 10.1007/s00401-015-1509-x; KSIEZAKREDING H, 1994, AM J PATHOL, V145, P1496; Lee VMY, 1999, NEURON, V24, P507, DOI 10.1016/S0896-6273(00)81106-X; Mackenzie IRA, 2010, ACTA NEUROPATHOL, V119, P1, DOI 10.1007/s00401-009-0612-2; Mair W, 2016, ANAL CHEM, V88, P3704, DOI 10.1021/acs.analchem.5b04509; Marquie M, 2015, ANN NEUROL, V78, P787, DOI 10.1002/ana.24517; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Morris M, 2015, NAT NEUROSCI, V18, P1183, DOI 10.1038/nn.4067; Nonaka T, 2010, J BIOL CHEM, V285, P34885, DOI 10.1074/jbc.M110.148460; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Peretz D, 2001, PROTEIN SCI, V10, P854, DOI 10.1110/ps.39201; POLLOCK NJ, 1986, LANCET, V2, P1211; Poorkaj P, 1998, ANN NEUROL, V43, P815, DOI 10.1002/ana.410430617; PRUSINER SB, 1983, CELL, V35, P349, DOI 10.1016/0092-8674(83)90168-X; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; Prusiner SB, 2015, P NATL ACAD SCI USA, V112, pE5308, DOI 10.1073/pnas.1514475112; Prusiner SB, 2013, ANNU REV GENET, V47, P601, DOI 10.1146/annurev-genet-110711-155524; Safar J, 1998, NAT MED, V4, P1157, DOI 10.1038/2654; Sander K., 2016, ALZHEIMERS DEMENT; Sanders DW, 2014, NEURON, V82, P1271, DOI 10.1016/j.neuron.2014.04.047; Serrano-Pozo A, 2016, J NEUROPATH EXP NEUR, V75, P516, DOI 10.1093/jnen/nlw026; Shively SB, 2016, LANCET NEUROL, V15, P944, DOI 10.1016/S1474-4422(16)30057-6; Stanford PM, 2004, J NEUROL, V251, P1098, DOI 10.1007/s00415-004-0489-x; Stein TD, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt234; Telling GC, 1996, SCIENCE, V274, P2079, DOI 10.1126/science.274.5295.2079; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Thomas SN, 2012, ACTA NEUROPATHOL, V123, P105, DOI 10.1007/s00401-011-0893-0; VONSATTEL JPG, 1995, J NEUROPATH EXP NEUR, V54, P42; WISCHIK CM, 1988, P NATL ACAD SCI USA, V85, P4506, DOI 10.1073/pnas.85.12.4506; Woerman AL, 2015, P NATL ACAD SCI USA, V112, pE4949, DOI 10.1073/pnas.1513426112; WOOD JG, 1986, P NATL ACAD SCI USA, V83, P4040, DOI 10.1073/pnas.83.11.4040; Yoshiyama Y, 2007, NEURON, V53, P337, DOI 10.1016/j.neuron.2007.01.010; Zhong Q, 2012, J BIOL CHEM, V287, P20711, DOI 10.1074/jbc.M112.364067; Zhukareva V, 2002, ANN NEUROL, V51, P730, DOI 10.1002/ana.10222; Zhukareva V, 2001, ACTA NEUROPATHOL, V101, P518	71	78	79	0	23	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	DEC 13	2016	113	50					E8187	E8196		10.1073/pnas.1616344113			10	Multidisciplinary Sciences	Science & Technology - Other Topics	EE6CQ	WOS:000389696700022	27911827	Green Published, Bronze			2021-06-18	
J	Scott, G; Ramlackhansingh, AF; Edison, P; Hellyer, P; Cole, J; Veronese, M; Leech, R; Greenwood, RJ; Turkheimer, FE; Gentleman, SM; Heckemann, RA; Matthews, PM; Brooks, DJ; Sharp, DJ				Scott, Gregory; Ramlackhansingh, Anil F.; Edison, Paul; Hellyer, Peter; Cole, James; Veronese, Mattia; Leech, Rob; Greenwood, Richard J.; Turkheimer, Federico E.; Gentleman, Steve M.; Heckemann, Rolf A.; Matthews, Paul M.; Brooks, David J.; Sharp, David J.			Amyloid pathology and axonal injury after brain trauma	NEUROLOGY			English	Article							ALZHEIMERS-DISEASE; DEMENTIA; NETWORK; REGISTRATION; DYSFUNCTION; PROGRESSION; DEPOSITION; SEVERITY; ANATOMY; ATROPHY	Objective:To image -amyloid (A) plaque burden in long-term survivors of traumatic brain injury (TBI), test whether traumatic axonal injury and A are correlated, and compare the spatial distribution of A to Alzheimer disease (AD).Methods:Patients 11 months to 17 years after moderate-severe TBI underwent C-11-Pittsburgh compound B (C-11-PiB)-PET, structural and diffusion MRI, and neuropsychological examination. Healthy aged controls and patients with AD underwent PET and structural MRI. Binding potential (BPND) images of C-11-PiB, which index A plaque density, were computed using an automatic reference region extraction procedure. Voxelwise and regional differences in BPND were assessed. In TBI, a measure of white matter integrity, fractional anisotropy, was estimated and correlated with C-11-PiB BP(ND.)Results:Twenty-eight participants (9 with TBI, 9 controls, 10 with AD) were assessed. Increased C-11-PiB BPND was found in TBI vs controls in the posterior cingulate cortex and cerebellum. Binding in the posterior cingulate cortex increased with decreasing fractional anisotropy of associated white matter tracts and increased with time since injury. Compared to AD, binding after TBI was lower in neocortical regions but increased in the cerebellum.Conclusions:Increased A burden was observed in TBI. The distribution overlaps with, but is distinct from, that of AD. This suggests a mechanistic link between TBI and the development of neuropathologic features of dementia, which may relate to axonal damage produced by the injury.	[Scott, Gregory; Ramlackhansingh, Anil F.; Edison, Paul; Hellyer, Peter; Cole, James; Leech, Rob; Gentleman, Steve M.; Heckemann, Rolf A.; Matthews, Paul M.; Brooks, David J.; Sharp, David J.] Univ London Imperial Coll Sci Technol & Med, Dept Med, Div Brain Sci, London SW7 2AZ, England; [Hellyer, Peter; Veronese, Mattia; Turkheimer, Federico E.] Kings Coll London, Inst Psychiat Psychol & Neurosci, London WC2R 2LS, England; [Greenwood, Richard J.] UCL, Inst Neurol, London WC1E 6BT, England; [Heckemann, Rolf A.] Gothenburg Univ, Sahlgrenska Univ Hosp, MedTech West, S-41124 Gothenburg, Sweden; [Brooks, David J.] Aarhus Univ, Inst Clin Med, DK-8000 Aarhus C, Denmark	Sharp, DJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Med, Div Brain Sci, London SW7 2AZ, England.	david.sharp@imperial.ac.uk	Veronese, Mattia/A-6012-2013; Veronese, Mattia/S-3114-2019; Heckemann, Rolf Andreas/H-9022-2019; Leech, Robert/AAE-8254-2019; Turkheimer, Federico E/B-9485-2012; Sharp, David J/A-2119-2013; Hellyer, Peter J/F-7112-2013; Cole, James H/I-5197-2019	Veronese, Mattia/0000-0003-3562-0683; Heckemann, Rolf Andreas/0000-0003-3582-3683; Leech, Robert/0000-0002-5801-6318; Turkheimer, Federico E/0000-0002-3766-3815; Hellyer, Peter J/0000-0002-5139-3401; Cole, James H/0000-0003-1908-5588; Scott, Gregory/0000-0001-8063-5871; Brooks, David/0000-0003-2602-2518; Edison, Paul/0000-0002-6551-2002	Wellcome Trust-GlaxoSmithKline Translational Medicine Training Programme; Imperial College Healthcare Trust Biomedical Research Centre; MRC PET programme grantUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G1100809/1]; MS Society of Great Britain; Progressive MS Alliance; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC); GlaxoSmithKlineGlaxoSmithKline; National Institute for Health ResearchNational Institute for Health Research (NIHR); Medical Research Council (UK)UK Research & Innovation (UKRI)Medical Research Council UK (MRC); Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G1100810, G0900897, G0701951, G1100809, MC_U120036861, MC_U120085814, MR/L022141/1] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NIHR-RP-011-048, NF-SI-0514-10022] Funding Source: researchfish	G. Scott was supported by a clinical research fellowship awarded in the Wellcome Trust-GlaxoSmithKline Translational Medicine Training Programme. This work was supported by the Imperial College Healthcare Trust Biomedical Research Centre. A. Ramlackhansingh, P. Edison, P. Hellyer, and J. Cole report no disclosures relevant to the manuscript. M. Veronese is supported by an MRC PET programme grant (G1100809/1). R. Leech and R. Greenwood report no disclosures relevant to the manuscript. F. Turkheimer is supported by an MRC PET programme grant (G1100809/1). S. Gentleman and R. Heckemann report no disclosures relevant to the manuscript. P. Matthews has consulted or received honoraria for lectures from GlaxoSmithKline, Biogen, IDEC, IXICO, and Novartis, and has research support from the MS Society of Great Britain, the Progressive MS Alliance, the MRC, and GlaxoSmithKline, and personal support from the Edmond J. Safra Foundation and from Lily Safra. Matthews is an NIHR Senior Investigator. D. Brooks has been a consultant and part time employee for GE Healthcare in the past. D. Sharp receives personal and research support from the National Institute for Health Research and the Medical Research Council (UK). Go to Neurology.org for full disclosures.	Ashburner J, 2007, NEUROIMAGE, V38, P95, DOI 10.1016/j.neuroimage.2007.07.007; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; Cole JH, 2015, ANN NEUROL, V77, P571, DOI 10.1002/ana.24367; Crossley NA, 2014, BRAIN, V137, P2382, DOI 10.1093/brain/awu132; Fleminger S, 2005, BRIT MED J, V331, P1419, DOI 10.1136/bmj.331.7530.1419; Frisoni GB, 2011, ALZHEIMERS DEMENT, V7, P171, DOI 10.1016/j.jalz.2010.06.007; Harris JA, 2010, NEURON, V68, P428, DOI 10.1016/j.neuron.2010.10.020; Heckemann RA, 2010, NEUROIMAGE, V51, P221, DOI 10.1016/j.neuroimage.2010.01.072; Hong YT, 2014, JAMA NEUROL, V71, P23, DOI 10.1001/jamaneurol.2013.4847; Hua K, 2008, NEUROIMAGE, V39, P336, DOI 10.1016/j.neuroimage.2007.07.053; Ikoma Y, 2013, J CEREBR BLOOD F MET, V33, P1725, DOI 10.1038/jcbfm.2013.133; Ikonomovic MD, 2008, BRAIN, V131, P1630, DOI 10.1093/brain/awn016; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Klein A, 2009, NEUROIMAGE, V46, P786, DOI 10.1016/j.neuroimage.2008.12.037; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Magnoni S, 2015, BRAIN, V138, P2263, DOI 10.1093/brain/awv152; Malec JF, 2007, J NEUROTRAUM, V24, P1417, DOI 10.1089/neu.2006.0245; Polymenidou M, 2012, J EXP MED, V209, P889, DOI 10.1084/jem.20120741; Ponsford J, 2011, J NEUROTRAUM, V28, P1683, DOI 10.1089/neu.2010.1623; Quigley H, 2011, INT J GERIATR PSYCH, V26, P991, DOI 10.1002/gps.2640; Raj A, 2012, NEURON, V73, P1204, DOI 10.1016/j.neuron.2011.12.040; Rowe CC, 2007, NEUROLOGY, V68, P1718, DOI 10.1212/01.wnl.0000261919.22630.ea; Rowe CC, 2011, J NUCL MED, V52, P1733, DOI 10.2967/jnumed.110.076315; Rowe CC, 2010, NEUROBIOL AGING, V31, P1275, DOI 10.1016/j.neurobiolaging.2010.04.007; Sharp DJ, 2014, NAT REV NEUROL, V10, P156, DOI 10.1038/nrneurol.2014.15; Sharp DJ, 2011, CURR OPIN NEUROL, V24, P558, DOI 10.1097/WCO.0b013e32834cd523; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Stein TD, 2015, ACTA NEUROPATHOL, V130, P21, DOI 10.1007/s00401-015-1435-y; Thal DR, 2002, NEUROLOGY, V58, P1791, DOI 10.1212/WNL.58.12.1791; Tosun D, 2011, BRAIN, V134, P1077, DOI 10.1093/brain/awr044; Whitnall L, 2006, J NEUROL NEUROSUR PS, V77, P640, DOI 10.1136/jnnp.2005.078246	36	78	79	0	21	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	MAR 1	2016	86	9					821	828		10.1212/WNL.0000000000002413			8	Clinical Neurology	Neurosciences & Neurology	DF4TG	WOS:000371343100002	26843562	Other Gold, Green Published			2021-06-18	
J	Fol, R; Braudeau, J; Ludewig, S; Abel, T; Weyer, SW; Roederer, JP; Brod, F; Audrain, M; Bemelmans, AP; Buchholz, CJ; Korte, M; Cartier, N; Muller, UC				Fol, Romain; Braudeau, Jerome; Ludewig, Susann; Abel, Tobias; Weyer, Sascha W.; Roederer, Jan-Peter; Brod, Florian; Audrain, Mickael; Bemelmans, Alexis-Pierre; Buchholz, Christian J.; Korte, Martin; Cartier, Nathalie; Mueller, Ulrike C.			Viral gene transfer of APPs alpha rescues synaptic failure in an Alzheimer's disease mouse model	ACTA NEUROPATHOLOGICA			English	Article						Alzheimer; Gene therapy; Amyloid precursor protein; APPs alpha; Synaptic plasticity; Spines; Behavior; Microglia; AAV	AMYLOID-PRECURSOR-PROTEIN; CEREBROSPINAL-FLUID LEVELS; TRAUMATIC BRAIN-INJURY; A-BETA; SECRETED FORMS; MESSENGER-RNA; MEMORY; EXPRESSION; MICE; ACTIVATION	Alzheimer's disease (AD) is characterized by synaptic failure, dendritic and axonal atrophy, neuronal death and progressive loss of cognitive functions. It is commonly assumed that these deficits arise due to beta-amyloid accumulation and plaque deposition. However, increasing evidence indicates that loss of physiological APP functions mediated predominantly by neurotrophic APPs alpha produced in the non-amyloidogenic alpha-secretase pathway may contribute to AD pathogenesis. Upregulation of APPs alpha production via induction of alpha-secretase might, however, be problematic as this may also affect substrates implicated in tumorigenesis. Here, we used a gene therapy approach to directly overexpress APPs alpha in the brain using AAV-mediated gene transfer and explored its potential to rescue structural, electrophysiological and behavioral deficits in APP/PS1a dagger E9 AD model mice. Sustained APPs alpha overexpression in aged mice with already preexisting pathology and amyloidosis restored synaptic plasticity and partially rescued spine density deficits. Importantly, AAV-APPs alpha treatment also resulted in a functional rescue of spatial reference memory in the Morris water maze. Moreover, we demonstrate a significant reduction of soluble A beta species and plaque load. In addition, APPs alpha induced the recruitment of microglia with a ramified morphology into the vicinity of plaques and upregulated IDE and TREM2 expression suggesting enhanced plaque clearance. Collectively, these data indicate that APPs alpha can mitigate synaptic and cognitive deficits, despite established pathology. Increasing APPs alpha may therefore be of therapeutic relevance for AD.	[Fol, Romain; Braudeau, Jerome; Audrain, Mickael; Cartier, Nathalie] INSERM U1169 MIRCen CEA, F-92265 Fontenay Aux Roses, France; [Fol, Romain; Braudeau, Jerome; Audrain, Mickael; Bemelmans, Alexis-Pierre; Cartier, Nathalie] Univ Paris Saclay, Univ Paris 11, F-91400 Orsay, France; [Fol, Romain; Audrain, Mickael] Univ Paris 05, F-75006 Paris, France; [Bemelmans, Alexis-Pierre] Commissariat Energie Atom & Energies Alternat CEA, DSV, Inst Imagerie Biomed I2BM, Mol Imaging Res Ctr MIRCen, F-92260 Fontenay Aux Roses, France; [Abel, Tobias; Brod, Florian; Buchholz, Christian J.] CNRS, UMR 9199, Neurodegenerat Dis Lab, F-92260 Fontenay Aux Roses, France; [Ludewig, Susann; Korte, Martin] Paul Ehrlich Inst, Mol Biotechnol & Gene Therapy, D-63225 Langen, Germany; [Korte, Martin] TU Braunschweig, Inst Zool, Div Cellular Neurobiol, Braunschweig, ME, Germany; [Korte, Martin] AG NIND, Helmholtz Ctr Infect Res, Inhoffenstr 7, D-38124 Braunschweig, Germany; [Weyer, Sascha W.; Roederer, Jan-Peter; Mueller, Ulrike C.] Heidelberg Univ, Dept Bioinformat & Funct Genom, Inst Pharm & Mol Biotechnol, Neuenheimer Feld 364, D-69120 Heidelberg, Germany	Cartier, N (corresponding author), INSERM U1169 MIRCen CEA, F-92265 Fontenay Aux Roses, France.; Cartier, N (corresponding author), Univ Paris Saclay, Univ Paris 11, F-91400 Orsay, France.; Muller, UC (corresponding author), Heidelberg Univ, Dept Bioinformat & Funct Genom, Inst Pharm & Mol Biotechnol, Neuenheimer Feld 364, D-69120 Heidelberg, Germany.	nathalie.cartier@inserm.fr; u.mueller@urz.uni-heidelberg.de	Brod, Florian/AAF-3193-2021; cartier, nathalie/C-3103-2012; Bemelmans, Alexis-Pierre/H-4476-2019; Audrain, Mickael/L-9894-2016	Brod, Florian/0000-0003-4779-3733; cartier, nathalie/0000-0003-2298-5261; Bemelmans, Alexis-Pierre/0000-0001-7605-5225; Audrain, Mickael/0000-0001-9941-7380; Braudeau, Jerome/0000-0002-9920-4112	Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG) [MU 1457/9-1, MU 1457/9-2, KO 1674/3-1, KO 1674/3-2]; ERA-Net Neuron [01EW1305A]; LOEWE Center for Cell and Gene Therapy Frankfurt - Hessisches Ministerium fur Wissenschaft und Kunst [III L 4-518/17.004 (2010)]	This work was supported by the Deutsche Forschungsgemeinschaft Grants (MU 1457/9-1, 9-2 to UCM; KO 1674/3-1, 3-2 to MK), the ERA-Net Neuron (01EW1305A to CJB, NC and UCM), and the LOEWE Center for Cell and Gene Therapy Frankfurt funded by Hessisches Ministerium fur Wissenschaft und Kunst (III L 4-518/17.004 (2010)) to CJB.	Abramov E, 2009, NAT NEUROSCI, V12, P1567, DOI 10.1038/nn.2433; Ahmed RR, 2010, J NEUROCHEM, V112, P1045, DOI 10.1111/j.1471-4159.2009.06528.x; Almkvist O, 1997, ARCH NEUROL-CHICAGO, V54, P641, DOI 10.1001/archneur.1997.00550170111022; Anderson JJ, 1999, NEUROSCIENCE, V93, P1409, DOI 10.1016/S0306-4522(99)00244-4; Aurnhammer C, 2012, HUM GENE THER METHOD, V23, P18, DOI 10.1089/hgtb.2011.034; Austin S. A., 2008, P13, DOI 10.1007/978-0-387-73894-9_2; Aydin D, 2012, EXP BRAIN RES, V217, P423, DOI 10.1007/s00221-011-2861-2; Barger SW, 1997, NATURE, V388, P878, DOI 10.1038/42257; Bell KFS, 2008, NEUROBIOL AGING, V29, P554, DOI 10.1016/j.neurobiolaging.2006.11.004; Berger A, 2015, MOL THER, V23, P918, DOI 10.1038/mt.2015.11; Billings LM, 2005, NEURON, V45, P675, DOI 10.1016/j.neuron.2005.01.040; Bodles AM, 2005, NEUROBIOL AGING, V26, P9, DOI 10.1016/j.neurobiolaging.2004.02.022; Borchelt DR, 1997, NEURON, V19, P939, DOI 10.1016/S0896-6273(00)80974-5; Bour A, 2004, NEUROBIOL LEARN MEM, V81, P27, DOI 10.1016/S1074-7427(03)00071-6; Caille I, 2004, DEVELOPMENT, V131, P2173, DOI 10.1242/dev.01103; Casanova F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094919; Claasen AM, 2009, NEUROSCI LETT, V460, P92, DOI 10.1016/j.neulet.2009.05.040; Copanaki E, 2010, MOL CELL NEUROSCI, V44, P386, DOI 10.1016/j.mcn.2010.04.007; Corrigan F, 2012, J NEUROCHEM, V122, P208, DOI 10.1111/j.1471-4159.2012.07761.x; Cousins SL, 2013, J NEUROCHEM, V126, P554, DOI 10.1111/jnc.12280; Cousins SL, 2009, J NEUROCHEM, V111, P1501, DOI 10.1111/j.1471-4159.2009.06424.x; Dobrowolska JA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089998; Doody RS, 2013, NEW ENGL J MED, V369, P341, DOI 10.1056/NEJMoa1210951; Drummond ES, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059166; Endres K, 2012, EXP BRAIN RES, V217, P343, DOI 10.1007/s00221-011-2885-7; Frank S, 2008, GLIA, V56, P1438, DOI 10.1002/glia.20710; Furukawa K, 1996, J NEUROCHEM, V67, P1882, DOI 10.1046/j.1471-4159.1996.67051882.x; Furukawa K, 1998, NEUROSCIENCE, V83, P429, DOI 10.1016/S0306-4522(97)00398-9; Furukawa K, 1996, NATURE, V379, P74, DOI 10.1038/379074a0; Guerreiro R, 2013, NEW ENGL J MED, V368, P117, DOI 10.1056/NEJMoa1211851; Heneka MT, 2013, NATURE, V493, P674, DOI 10.1038/nature11729; Hick M, 2015, ACTA NEUROPATHOL, V129, P21, DOI 10.1007/s00401-014-1368-x; Hoe HS, 2012, CNS NEUROSCI THER, V18, P47, DOI 10.1111/j.1755-5949.2010.00221.x; Hoey SE, 2009, J NEUROSCI, V29, P4442, DOI 10.1523/JNEUROSCI.6017-08.2009; Holsinger RMD, 2002, ANN NEUROL, V51, P783, DOI 10.1002/ana.10208; Ishida A, 1997, NEUROREPORT, V8, P2133, DOI 10.1097/00001756-199707070-00009; Jankowsky JL, 2004, HUM MOL GENET, V13, P159, DOI 10.1093/hmg/ddh019; Jay TR, 2015, J EXP MED, V212, P287, DOI 10.1084/jem.20142322; Jonsson T, 2013, NEW ENGL J MED, V368, P107, DOI 10.1056/NEJMoa1211103; Kamphuis W, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042823; Klevanski M, 2014, MOL CELL NEUROSCI, V61, P201, DOI 10.1016/j.mcn.2014.06.004; Kogel D, 2012, EXP BRAIN RES, V217, P471, DOI 10.1007/s00221-011-2932-4; LANNFELT L, 1995, NAT MED, V1, P829, DOI 10.1038/nm0895-829; Lassek M, 2013, J NEUROCHEM, V127, P48, DOI 10.1111/jnc.12358; Lee KJ, 2010, NEUROSCIENCE, V169, P344, DOI 10.1016/j.neuroscience.2010.04.078; Leissring MA, 2003, NEURON, V40, P1087, DOI 10.1016/S0896-6273(03)00787-6; Leyssen M, 2005, EMBO J, V24, P2944, DOI 10.1038/sj.emboj.7600757; Li ZW, 1996, P NATL ACAD SCI USA, V93, P6158, DOI 10.1073/pnas.93.12.6158; Lichtenthaler SF, 2011, J NEUROCHEM, V117, P779, DOI 10.1111/j.1471-4159.2011.07248.x; Lu B, 2013, NAT REV NEUROSCI, V14, P401, DOI 10.1038/nrn3505; Marcello E, 2007, J NEUROSCI, V27, P1682, DOI 10.1523/JNEUROSCI.3439-06.2007; Meziane H, 1998, P NATL ACAD SCI USA, V95, P12683, DOI 10.1073/pnas.95.21.12683; Mileusnic R, 2004, EUR J NEUROSCI, V19, P1933, DOI 10.1111/j.1460-9568.2004.03276.x; Milosch N, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.352; Miners JS, 2011, J NEUROPATH EXP NEUR, V70, P944, DOI 10.1097/NEN.0b013e3182345e46; Mucke L, 1996, ANN NY ACAD SCI, V777, P82, DOI 10.1111/j.1749-6632.1996.tb34405.x; Murakami N, 1998, J NEUROTRAUM, V15, P993, DOI 10.1089/neu.1998.15.993; Nhan HS, 2015, ACTA NEUROPATHOL, V129, P1, DOI 10.1007/s00401-014-1347-2; Obregon D, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1781; Pennanen L, 2006, GENES BRAIN BEHAV, V5, P369, DOI 10.1111/j.1601-183X.2005.00165.x; Prokop Stefan, 2013, Acta Neuropathol, V126, P461; Prox J, 2012, EXP BRAIN RES, V217, P331, DOI 10.1007/s00221-011-2952-0; Ramirez MJ, 2001, BRAIN RES, V907, P222, DOI 10.1016/S0006-8993(01)02580-X; Ring S, 2007, J NEUROSCI, V27, P7817, DOI 10.1523/JNEUROSCI.1026-07.2007; ROCH JM, 1994, P NATL ACAD SCI USA, V91, P7450, DOI 10.1073/pnas.91.16.7450; Roozendaal B, 2001, NAT NEUROSCI, V4, P1169, DOI 10.1038/nn766; Savonenko A, 2005, NEUROBIOL DIS, V18, P602, DOI 10.1016/j.nbd.2004.10.022; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; Shankar GM, 2008, NAT MED, V14, P837, DOI 10.1038/nm1782; Shankar GM, 2007, J NEUROSCI, V27, P2866, DOI 10.1523/JNEUROSCI.4970-06.2007; SMITHSWINTOSKY VL, 1994, J NEUROCHEM, V63, P781, DOI 10.1046/j.1471-4159.1994.63020781.x; Spires-Jones T, 2012, NEURAL PLAST, V2012, DOI 10.1155/2012/319836; Suh J, 2013, NEURON, V80, P385, DOI 10.1016/j.neuron.2013.08.035; Tang W, 2009, J NEUROSCI, V29, P8621, DOI 10.1523/JNEUROSCI.0359-09.2009; Taylor CJ, 2008, NEUROBIOL DIS, V31, P250, DOI 10.1016/j.nbd.2008.04.011; TERRY RD, 1991, ANN NEUROL, V30, P572, DOI 10.1002/ana.410300410; Thornton E, 2006, BRAIN RES, V1094, P38, DOI 10.1016/j.brainres.2006.03.107; Van den Heuvel C, 1999, EXP NEUROL, V159, P441, DOI 10.1006/exnr.1999.7150; Vassar R, 2014, J NEUROCHEM, V130, P4, DOI 10.1111/jnc.12715; Villemagne VL, 2013, LANCET NEUROL, V12, P357, DOI 10.1016/S1474-4422(13)70044-9; Wang YM, 2015, CELL, V160, P1061, DOI 10.1016/j.cell.2015.01.049; Wang ZL, 2009, J NEUROSCI, V29, P10788, DOI 10.1523/JNEUROSCI.2132-09.2009; Weyer SW, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/2051-5960-2-36; Weyer SW, 2011, EMBO J, V30, P2266, DOI 10.1038/emboj.2011.119; Wilhelm BG, 2014, SCIENCE, V344, P1023, DOI 10.1126/science.1252884; Xiong HQ, 2011, NEUROSCI BULL, V27, P221, DOI 10.1007/s12264-011-1015-7; Yang L, 2009, J NEUROSCI, V29, P15660, DOI 10.1523/JNEUROSCI.4104-09.2009	87	78	80	1	51	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0001-6322	1432-0533		ACTA NEUROPATHOL	Acta Neuropathol.	FEB	2016	131	2					247	266		10.1007/s00401-015-1498-9			20	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	DB5DT	WOS:000368535000006	26538149				2021-06-18	
J	Nelson, LD; LaRoche, AA; Pfaller, AY; Lerner, EB; Hammeke, TA; Randolph, C; Barr, WB; Guskiewicz, K; McCrea, MA				Nelson, Lindsay D.; LaRoche, Ashley A.; Pfaller, Adam Y.; Lerner, E. Brooke; Hammeke, Thomas A.; Randolph, Christopher; Barr, William B.; Guskiewicz, Kevin; McCrea, Michael A.			Prospective, Head-to-Head Study of Three Computerized Neurocognitive Assessment Tools (CNTs): Reliability and Validity for the Assessment of Sport-Related Concussion	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Concussion; Sport; Computerized testing; ANAM; Axon Sports; ImPACT	TEST-RETEST RELIABILITY; FALSE DISCOVERY RATE; BASE-LINE; HIGH-SCHOOL; NEUROPSYCHOLOGICAL ASSESSMENT; COGNITIVE IMPAIRMENT; ONLINE VERSION; IMPACT; RECOVERY; SENSITIVITY	Limited data exist comparing the performance of computerized neurocognitive tests (CNTs) for assessing sport-related concussion. We evaluated the reliability and validity of three CNTsANAM, Axon Sports/Cogstate Sport, and ImPACTin a common sample. High school and collegiate athletes completed two CNTs each at baseline. Concussed (n=165) and matched non-injured control (n=166) subjects repeated testing within 24 hr and at 8, 15, and 45 days post-injury. Roughly a quarter of each CNT's indices had stability coefficients (M=198 day interval) over .70. Group differences in performance were mostly moderate to large at 24 hr and small by day 8. The sensitivity of reliable change indices (RCIs) was best at 24 hr (67.8%, 60.3%, and 47.6% with one or more significant RCIs for ImPACT, Axon, and ANAM, respectively) but diminished to near the false positive rates thereafter. Across time, the CNTs' sensitivities were highest in those athletes who became asymptomatic within 1 day before neurocognitive testing but was similar to the tests' false positive rates when including athletes who became asymptomatic several days earlier. Test-retest reliability was similar among these three CNTs and below optimal standards for clinical use on many subtests. Analyses of group effect sizes, discrimination, and sensitivity and specificity suggested that the CNTs may add incrementally (beyond symptom scores) to the identification of clinical impairment within 24 hr of injury or within a short time period after symptom resolution but do not add significant value over symptom assessment later. The rapid clinical recovery course from concussion and modest stability probably jointly contribute to limited signal detection capabilities of neurocognitive tests outside a brief post-injury window. (JINS, 2016, 22, 24-37)	[Nelson, Lindsay D.; LaRoche, Ashley A.; Pfaller, Adam Y.; Lerner, E. Brooke; Hammeke, Thomas A.; McCrea, Michael A.] Med Coll Wisconsin, Milwaukee, WI 53226 USA; [Hammeke, Thomas A.; McCrea, Michael A.] Clement J Zablocki VA Med Ctr, Milwaukee, WI USA; [Randolph, Christopher] Loyola Univ, Sch Med, Maywood, IL 60153 USA; [Barr, William B.] NYU, Sch Med, New York, NY USA; [Guskiewicz, Kevin] Univ N Carolina, Chapel Hill, NC USA	Nelson, LD (corresponding author), 8701 West Watertown Plank Rd, Milwaukee, WI USA.	linelson@mcw.edu		Barr, William/0000-0001-7711-7758	U.S. Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [W81XWH-12-1-0004]; Clinical and Translational Science Institute [1UL1-RR031973 (-01)]; National Center for Advancing Translational Sciences, National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [8UL1TR000055]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000055] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR031973] Funding Source: NIH RePORTER	This work was supported by the U.S. Army Medical Research and Materiel Command under award number W81XWH-12-1-0004. Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army. The REDCap electronic database service used for the study was supported by the Clinical and Translational Science Institute grant 1UL1-RR031973 (-01) and by the National Center for Advancing Translational Sciences, National Institutes of Health grant 8UL1TR000055. The manuscript's contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. The authors have no conflicts of interest to report.	Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Benjamini Y, 2001, ANN STAT, V29, P1165; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Broglio SP, 2009, J NEUROTRAUM, V26, P1463, DOI [10.1089/neu.2008.0766, 10.1089/neu.2008-0766]; Bruce J, 2014, CLIN NEUROPSYCHOL, V28, P14, DOI 10.1080/13854046.2013.866272; Cernich A, 2007, ARCH CLIN NEUROPSYCH, V22, pS101, DOI 10.1016/j.acn.2006.10.008; Chelune GJ, 1993, NEUROPSYCHOLOGY, V7, P41, DOI DOI 10.1037/0894-4105.7.1.41; Cole WR, 2013, ARCH CLIN NEUROPSYCH, V28, P732, DOI 10.1093/arclin/act040; Collie A, 2003, CLIN J SPORT MED, V13, P28, DOI 10.1097/00042752-200301000-00006; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; Covassin T, 2009, J ATHL TRAINING, V44, P639, DOI 10.4085/1062-6050-44.6.639; Covassin T, 2009, J ATHL TRAINING, V44, P400, DOI 10.4085/1062-6050-44.4.400; Crawford JR, 2007, NEUROPSYCHOLOGY, V21, P419, DOI 10.1037/0894-4105.21.4.419; Derogatis LR, 2001, BRIEF SYMPTOM INVENT; Dettwiler A, 2014, J NEUROTRAUM, V31, P180, DOI 10.1089/neu.2013.2983; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Echemendia RJ, 2013, BRIT J SPORT MED, V47, P294, DOI 10.1136/bjsports-2013-092186; Eckner JT, 2011, J ATHL TRAINING, V46, P409; Elbin RJ, 2011, AM J SPORT MED, V39, P2319, DOI 10.1177/0363546511417173; Green P, 2003, GREENS MED SYMPTOM V; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Helmick K, 2006, DEFENSE VETERANS BRA; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; LaRoche AA, 2016, CLIN J SPORT MED, V26, P33, DOI 10.1097/JSM.0000000000000192; Lichtenstein JD, 2014, AM J SPORT MED, V42, P479, DOI 10.1177/0363546513509225; Louey AG, 2014, ARCH CLIN NEUROPSYCH, V29, P432, DOI 10.1093/arclin/acu020; MacDonald J, 2015, CLIN J SPORT MED, V25, P367, DOI 10.1097/JSM.0000000000000139; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; Meehan WP, 2012, PEDIATRICS, V129, P38, DOI 10.1542/peds.2011-1972; Mondello S, 2014, MED RES REV, V34, P503, DOI 10.1002/med.21295; Moser RS, 2007, ARCH CLIN NEUROPSYCH, V22, P909, DOI 10.1016/j.acn.2007.09.004; Moser RS, 2015, APPL NEUROPSYCH-CHIL, V4, P41, DOI 10.1080/21622965.2013.791825; Moser RS, 2011, AM J SPORT MED, V39, P2325, DOI 10.1177/0363546511417114; Nakayama Y, 2014, AM J SPORT MED, V42, P2000, DOI 10.1177/0363546514535901; Nelson L.D., J ATHLETIC IN PRESS; Nelson LD, 2015, AM J SPORT MED, V43, P2018, DOI 10.1177/0363546515587714; Nelson LD, 2013, NEUROPSYCHOL REV, V23, P285, DOI 10.1007/s11065-013-9240-7; Prichep LS, 2013, J HEAD TRAUMA REHAB, V28, P266, DOI 10.1097/HTR.0b013e318247b54e; Rahman-Filipiak AAM, 2013, NEUROPSYCHOL REV, V23, P314, DOI 10.1007/s11065-013-9241-6; Randolph C, 2005, J ATHL TRAINING, V40, P139; Register-Mihalik JK, 2013, J HEAD TRAUMA REHAB, V28, P274, DOI 10.1097/HTR.0b013e3182585d37; Register-Mihalik JK, 2012, J ATHL TRAINING, V47, P297, DOI 10.4085/1062-6050-47.3.13; Resch J, 2013, J ATHL TRAINING, V48, P506, DOI 10.4085/1062-6050-48.3.09; Resch JE, 2013, NEUROPSYCHOL REV, V23, P335, DOI 10.1007/s11065-013-9242-5; Rousson V, 2002, STAT MED, V21, P3431, DOI 10.1002/sim.1253; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2013, ARCH CLIN NEUROPSYCH, V28, P499, DOI 10.1093/arclin/act034; Schatz P, 2013, AM J SPORT MED, V41, P321, DOI 10.1177/0363546512466038; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; Schretlen DJ, 2008, J INT NEUROPSYCH SOC, V14, P436, DOI 10.1017/S1355617708080387; Segalowitz SJ, 2007, NEUROREHABILITATION, V22, P243; Sim A, 2008, J NEUROSURG, V108, P511, DOI 10.3171/JNS/2008/108/3/0511; Straume-Naesheim TM, 2005, BRIT J SPORT MED, V39, pI64, DOI 10.1136/bjsm.2005.019620; Thomas DG, 2015, PEDIATRICS, V135, P213, DOI 10.1542/peds.2014-0966; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677; Vincent AS, 2012, MIL MED, V177, P248, DOI 10.7205/MILMED-D-11-00156; Wechsler D., 2001, WECHSLER TEST ADULT; Weir JP, 2005, J STRENGTH COND RES, V19, P231, DOI 10.1519/15184.1; Yuh Esther L, 2014, Neurosurgery, V75 Suppl 4, pS50, DOI 10.1227/NEU.0000000000000491; Zhu DC, 2015, J NEUROTRAUM, V32, P327, DOI 10.1089/neu.2014.3413	69	78	78	0	15	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JAN	2016	22	1					24	37		10.1017/S1355617715001101			14	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	DA1XW	WOS:000367590300003	26714883	Bronze, Green Accepted			2021-06-18	
J	Han, LJ; Cai, W; Mao, LL; Liu, J; Li, PY; Leak, RK; Xu, Y; Hu, XM; Chen, J				Han, Lijuan; Cai, Wei; Mao, Leilei; Liu, Jia; Li, Peiying; Leak, Rehana K.; Xu, Yun; Hu, Xiaoming; Chen, Jun			Rosiglitazone Promotes White Matter Integrity and Long-Term Functional Recovery After Focal Cerebral Ischemia	STROKE			English	Article						bromodeoxyuridine; inflammation; polarization; stroke; white matter	ACTIVATED-RECEPTOR-GAMMA; MICROGLIA/MACROPHAGE POLARIZATION DYNAMICS; TRAUMATIC BRAIN-INJURY; PPAR-GAMMA; OLIGODENDROCYTE DIFFERENTIATION; INTRACEREBRAL HEMORRHAGE; AGONIST ROSIGLITAZONE; NEUROPROTECTION; CELLS; PROGENITORS	Background and Purpose-Oligodendrogenesis is essential for white matter repair after stroke. Although agonists of peroxisome proliferator-activated receptors. confer neuroprotection in models of cerebral ischemia, it is not known whether this effect extends to white matter protection. This study tested the hypothesis that the peroxisome proliferator-activated receptors. agonist rosiglitazone enhances oligodendrogenesis and improves long-term white matter integrity after ischemia/reperfusion. Methods-Male adult C57/BL6 mice (25-30 g) were subjected to 60-minute middle cerebral artery occlusion and reperfusion. Rosiglitazone (3 mg/kg) was injected intraperitoneally once daily for 14 days beginning 2 hours after reperfusion. Sensorimotor and cognitive functions were evaluated <= 21 days after middle cerebral artery occlusion. Immunostaining was used to assess infarct volume, myelin loss, and microglial activation. Bromodeoxyuridine (BrdU) was injected for measurements of proliferating NG2(+) oligodendrocyte precursor cells (OPCs) and newly generated adenomatous polyposis coli(+) oligodendrocytes. Mixed glial cultures were used to confirm the effect of rosiglitazone on oligodendrocyte differentiation and microglial polarization. Results-Rosiglitazone significantly reduced brain tissue loss, ameliorated white matter injury, and improved sensorimotor and cognitive functions for at least 21 days after middle cerebral artery occlusion. Rosiglitazone enhanced OPC proliferation and increased the numbers of newly generated mature oligodendrocytes after middle cerebral artery occlusion. Rosiglitazone treatment also reduced the numbers of Iba1(+)/CD16(+) M1 microglia and increased the numbers of Iba1(+)/CD206(+) M2 microglia after stroke. Glial culture experiments confirmed that rosiglitazone promoted oligodendrocyte differentiation, perhaps by promoting microglial M2 polarization. Conclusions-Rosiglitazone treatment improves long-term white matter integrity after cerebral ischemia, at least, in part, by promoting oligodendrogenesis and facilitating microglial polarization toward the beneficial M2 phenotype.	[Han, Lijuan; Xu, Yun] Nanjing Univ, Sch Med, Drum Tower Hosp, Dept Neurol, Nanjing 21008, Jiangsu, Peoples R China; [Han, Lijuan; Cai, Wei; Mao, Leilei; Hu, Xiaoming; Chen, Jun] Univ Pittsburgh, Sch Med, Dept Neurol, Ctr Cerebrovasc Dis Res, Pittsburgh, PA 15213 USA; [Liu, Jia; Li, Peiying; Hu, Xiaoming; Chen, Jun] Fudan Univ, State Key Lab Med Neurobiol, Shanghai 200433, Peoples R China; [Liu, Jia; Li, Peiying; Hu, Xiaoming; Chen, Jun] Fudan Univ, Inst Brain Sci, Shanghai 200433, Peoples R China; [Cai, Wei] Sun Yat Sen Univ, Affiliated Hosp 3, Multiple Sclerosis Ctr, Dept Neurol, Guangzhou 510275, Guangdong, Peoples R China; [Leak, Rehana K.] Duquesne Univ, Div Pharmaceut Sci, Pittsburgh, PA 15219 USA; [Hu, Xiaoming; Chen, Jun] Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA	Chen, J (corresponding author), Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA.	xuyun20042001@aliyun.com; chenj2@upmc.edu	Leak, Rehana K/I-2607-2019	Leak, Rehana K/0000-0003-2817-7417; Li, Peiying/0000-0002-5721-9914	National institutes of Health/National Institute of neurological disorders and strokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS095671, NS045048, NS036736, NS089534, NS092618]; US Department of Veterans Affairs Research Career Scientist Award and RRD Merit ReviewUS Department of Veterans Affairs [I01RX000420]; American Heart AssociationAmerican Heart Association [13SDG14570025]; Chinese Scholarship CouncilChina Scholarship Council; China Natural Science FoundationNational Natural Science Foundation of China (NSFC) [81230026, 81171085]; Science and Technology Commission of Shanghai MunicipalityScience & Technology Commission of Shanghai Municipality (STCSM) [13ZR1452200]; National Natural Science FoundationNational Natural Science Foundation of China (NSFC) [81400956]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS089534, R01NS036736, R01NS045048, R01NS095671, R01NS092618] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01RX000420] Funding Source: NIH RePORTER	This work was supported by the National institutes of Health/National Institute of neurological disorders and stroke grants NS095671, NS045048, NS036736, and NS089534 (to Dr Chen) and NS092618 (to Dr Hu), US Department of Veterans Affairs Research Career Scientist Award and RR&D Merit Review I01RX000420 (to Dr Chen), and grant 13SDG14570025 from the American Heart Association (to Dr Hu). Dr Han was supported by predoctoral fellowship from the Chinese Scholarship Council. Dr Xu was supported by China Natural Science Foundation grants (No. 81230026 and No. 81171085). Dr Li was supported by the Science and Technology Commission of Shanghai Municipality (13ZR1452200) and National Natural Science Foundation grant (No. 81400956).	Bernardo A, 2013, BIOL CHEM, V394, P1607, DOI 10.1515/hsz-2013-0152; Chen YC, 2012, MOL NEUROBIOL, V46, P114, DOI 10.1007/s12035-012-8259-8; Chu Min, 2012, Front Biosci (Elite Ed), V4, P1926; Dewar D, 2003, J CEREBR BLOOD F MET, V23, P263, DOI 10.1097/01.WCB.0000053472.41007.F9; Doonan F, 2009, J NEUROCHEM, V109, P631, DOI 10.1111/j.1471-4159.2009.05995.x; Falcao AM, 2012, FRONT CELL NEUROSCI, V6, DOI 10.3389/fncel.2012.00034; Gensert JM, 1997, NEURON, V19, P197, DOI 10.1016/S0896-6273(00)80359-1; Goldman SA, 2014, NAT NEUROSCI, V17, P483, DOI 10.1038/nn.3685; Gonzalez-Perez O, 2011, BRAIN RES REV, V67, P147, DOI 10.1016/j.brainresrev.2011.01.001; Ho PW, 2005, STROKE, V36, P2742, DOI 10.1161/01.STR.0000189748.52500.a7; Hu XM, 2015, NAT REV NEUROL, V11, P56, DOI 10.1038/nrneurol.2014.207; Hu XM, 2012, STROKE, V43, P3063, DOI 10.1161/STROKEAHA.112.659656; Cuartero MI, 2013, STROKE, V44, P3498, DOI 10.1161/STROKEAHA.113.002470; Kinouchi T, 2012, STROKE, V43, P478, DOI 10.1161/STROKEAHA.111.618926; Lee J, 2007, NEUROCHEM RES, V32, P635, DOI 10.1007/s11064-006-9138-3; Luo YM, 2006, J NEUROCHEM, V97, P435, DOI 10.1111/j.1471-4159.2006.03758.x; Maki T, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00275; Mandrekar-Colucci S, 2012, J NEUROSCI, V32, P10117, DOI 10.1523/JNEUROSCI.5268-11.2012; McIver SR, 2010, NEUROSCIENCE, V169, P1364, DOI 10.1016/j.neuroscience.2010.04.070; Miron VE, 2013, NAT NEUROSCI, V16, P1211, DOI 10.1038/nn.3469; Miyamoto N, 2013, STROKE, V44, P3516, DOI 10.1161/STROKEAHA.113.002813; Ortega F, 2013, NAT CELL BIOL, V15, P602, DOI 10.1038/ncb2736; Paintlia AS, 2010, GLIA, V58, P1669, DOI 10.1002/glia.21039; Pantoni L, 1996, STROKE, V27, P1641, DOI 10.1161/01.STR.27.9.1641; Pu HJ, 2013, J CEREBR BLOOD F MET, V33, P1474, DOI 10.1038/jcbfm.2013.108; Romera C, 2007, J CEREBR BLOOD F MET, V27, P1327, DOI 10.1038/sj.jcbfm.9600438; Roth AD, 2003, J NEUROSCI RES, V72, P425, DOI 10.1002/jnr.10596; Sim FJ, 2008, GLIA, V56, P954, DOI 10.1002/glia.20669; Sozmen EG, 2009, J NEUROSCI METH, V180, P261, DOI 10.1016/j.jneumeth.2009.03.017; Wang CX, 2009, J CEREBR BLOOD F MET, V29, P1683, DOI 10.1038/jcbfm.2009.87; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Zhang L, 2002, J NEUROSCI METH, V117, P207, DOI 10.1016/S0165-0270(02)00114-0; Zhang RL, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00201; Zhao XR, 2007, ANN NEUROL, V61, P352, DOI 10.1002/ana.21097; Zhao XR, 2006, J CEREBR BLOOD F MET, V26, P811, DOI 10.1038/sj.jcbfm.9600233; Zuhayra M, 2011, NEUROPATH APPL NEURO, V37, P738, DOI 10.1111/j.1365-2990.2011.01169.x	36	78	83	0	15	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0039-2499	1524-4628		STROKE	Stroke	SEP	2015	46	9					2628	2636		10.1161/STROKEAHA.115.010091			9	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	CQ9FZ	WOS:000360919700046	26243225	Green Accepted			2021-06-18	
J	Mirza, MA; Ritzel, R; Xu, Y; McCullough, LD; Liu, FD				Mirza, Mehwish A.; Ritzel, Rodney; Xu, Yan; McCullough, Louise D.; Liu, Fudong			Sexually dimorphic outcomes and inflammatory responses in hypoxic-ischemic encephalopathy	JOURNAL OF NEUROINFLAMMATION			English	Article						Hypoxic-ischemic encephalopathy; Neonate; Inflammation; Infarct; Microglia	TRAUMATIC BRAIN-INJURY; EXPERIMENTAL STROKE; TESTOSTERONE SURGE; NEONATAL STROKE; IMMATURE MOUSE; MICROGLIA; SEX; MICE; INFANTS; GENDER	Background: Neonatal hypoxic-ischemic encephalopathy (HIE) is an important cause of motor and cognitive impairment in children. Clinically, male infants are more vulnerable to ischemic insults and suffer more long-term deficits than females; however, the mechanisms underlying this sex difference remain elusive. Inflammatory processes initiated by microglial activation are fundamental in the pathophysiology of ischemia. Recent studies report a sexual dimorphism in microglia numbers and expression of activation markers in the neonatal brain under normal conditions. How these basal sex differences in microglia affect HIE remains largely unexplored. This study investigated sex differences in ischemic outcomes and inflammation triggered by HIE. We hypothesize that ischemia induces sex-specific brain injury in male and female neonates and that microglial activation and inflammatory responses play an important role in this sexual dimorphism. Methods: Male and female C57BL6 mice were subjected to 60-min Rice-Vanucci modeling (RVM) at post-natal day 10 (P10) to induce HIE. Stroke outcomes were measured 1, 3, 7, and 30 days after stroke. Microglial activation and inflammatory responses were evaluated by flow cytometry and cytokine analysis. Results: On day 1 of HIE, no difference in infarct volumes or seizure scores was seen between male and female neonates. However, female neonates exhibited significantly smaller infarct size and fewer seizures compared to males 3 days after HIE. Females also had less brain tissue loss and behavioral deficits compared to males at the chronic stage of HIE. Male animals demonstrated increased microglial activation and up-regulated inflammatory response compared to females at day 3. Conclusions: HIE leads to an equivalent primary brain injury in male and female neonates at the acute stage that develops into sexually dimorphic outcomes at later time points. An innate immune response secondary to the primary injury may contribute to sexual dimorphism in HIE.	[Mirza, Mehwish A.; Ritzel, Rodney; Xu, Yan; McCullough, Louise D.; Liu, Fudong] Univ Connecticut, Ctr Hlth, Dept Neurosci, Farmington, CT 06030 USA; [McCullough, Louise D.] Univ Connecticut, Ctr Hlth, Dept Neurol, Farmington, CT 06030 USA	Liu, FD (corresponding author), Univ Connecticut, Ctr Hlth, Dept Neurosci, 263 Farmington Ave, Farmington, CT 06030 USA.	fliu@uchc.edu	McCullough, Louise/R-2824-2019	Ritzel, Rodney/0000-0002-0160-2930	NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS050505, NS055215]; American Heart AssociationAmerican Heart Association [12SDG9030000]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS055215, R01NS050505, F31NS083244] Funding Source: NIH RePORTER	This work was supported by the NIH/NINDS (grants NS050505 and NS055215 to Louise D MCCULLOUGH), and by the American Heart Association (grant 12SDG9030000 to Fudong LIU). We thank Kathryn Bentivegna for her assistance with flow cytometry.	Arnold AP, 2009, FRONT NEUROENDOCRIN, V30, P1, DOI 10.1016/j.yfrne.2008.11.001; Cheong JLY, 2009, SEMIN FETAL NEONAT M, V14, P267, DOI 10.1016/j.siny.2009.07.009; Cherry JD, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-98; Comi AM, 2004, PEDIATR NEUROL, V31, P254, DOI 10.1016/j.pediatrneurol.2004.04.010; CORBIER P, 1992, ARCH INT PHYSIOL BIO, V100, P127, DOI 10.3109/13813459209035274; Courties G, 2014, J AM COLL CARDIOL, V63, P1556, DOI 10.1016/j.jacc.2013.11.023; Crain JM, 2013, J NEUROSCI RES, V91, P1143, DOI 10.1002/jnr.23242; Crain JM, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-24; DELBIGIO MR, 1994, NEUROPATH APPL NEURO, V20, P144, DOI 10.1111/j.1365-2990.1994.tb01173.x; Deng H, 2003, STROKE, V34, P2495, DOI 10.1161/01.STR.0000091269.67384.E7; Denker SP, 2007, J NEUROCHEM, V100, P893, DOI 10.1111/j.1471-4159.2006.04162.x; Di Napoli M, 2014, NEUROINFLAMMATION NE, P199, DOI [10.1007/978-1-4939-1071-7_11, DOI 10.1007/978-1-4939-1071-7_11]; Donders J, 2002, NEUROPSYCHOLOGY, V16, P491, DOI 10.1037//0894-4105.16.4.491; Enzmann G, 2013, ACTA NEUROPATHOL, V125, P395, DOI 10.1007/s00401-012-1076-3; Foster-Barber A, 2001, DEV NEUROSCI-BASEL, V23, P213, DOI 10.1159/000046146; Galasso JM, 2000, NEUROREPORT, V11, P231, DOI 10.1097/00001756-200002070-00002; Golomb MR, 2004, J CHILD NEUROL, V19, P493, DOI 10.1177/08830738040190070301; Hesp BR, 2007, EPILEPSY RES, V76, P103, DOI 10.1016/j.eplepsyres.2007.07.003; Hill CA, 2012, NEUROL RES INT, V2012, DOI 10.1155/2012/867531; Hu XM, 2012, STROKE, V43, P3063, DOI 10.1161/STROKEAHA.112.659656; Iadecola C, 2011, NAT MED, V17, P796, DOI 10.1038/nm.2399; Ikegami S, 2001, CLIN ENDOCRINOL, V55, P789, DOI 10.1046/j.1365-2265.2001.01416.x; Jin R, 2010, J LEUKOCYTE BIOL, V87, P779, DOI 10.1189/jlb.1109766; Kadam SD, 2009, BEHAV BRAIN RES, V197, P77, DOI 10.1016/j.bbr.2008.08.003; Kalay S, 2014, EXP THER MED, V7, P734, DOI 10.3892/etm.2014.1470; Knox R, 2013, NEUROBIOL DIS, V51, P113, DOI 10.1016/j.nbd.2012.10.024; Koellhoffer EC, 2013, TRANSL STROKE RES, V4, P390, DOI 10.1007/s12975-012-0230-5; Kohman RA, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-114; Konkle ATM, 2011, ENDOCRINOLOGY, V152, P223, DOI 10.1210/en.2010-0607; Lai MC, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/609813; Lauterbach MD, 2001, NEUROPSYCHOLOGY, V15, P411, DOI 10.1037/0894-4105.15.3.411; Lee Y, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/297241; Lenz KM, 2013, J NEUROSCI, V33, P2761, DOI 10.1523/JNEUROSCI.1268-12.2013; Li XL, 2004, EXP NEUROL, V187, P94, DOI 10.1016/j.expneurol.2004.01.004; Liu FD, 2013, ACTA PHARMACOL SIN, V34, P1121, DOI 10.1038/aps.2013.89; Liu FD, 2012, NEUROCHEM INT, V61, P1255, DOI 10.1016/j.neuint.2012.10.003; Liu FD, 2012, AGE, V34, P157, DOI 10.1007/s11357-011-9214-8; Liu F, 2009, J NEUROSCI METH, V179, P1, DOI 10.1016/j.jneumeth.2008.12.028; Manwani B, 2013, EXP NEUROL, V249, P120, DOI 10.1016/j.expneurol.2013.08.011; Mirza MA, 2013, BRAIN RES BULL, V98, P111, DOI 10.1016/j.brainresbull.2013.07.011; Oertelt-Prigione S, 2012, AUTOIMMUN REV, V11, pA479, DOI 10.1016/j.autrev.2011.11.022; Oygur N, 1998, ARCH DIS CHILD-FETAL, V79, pF190, DOI 10.1136/fn.79.3.F190; Patel Anita R, 2013, Int J Physiol Pathophysiol Pharmacol, V5, P73; Peruzzotti-Jametti L, 2014, NEUROSCIENCE, V283, P210, DOI 10.1016/j.neuroscience.2014.04.036; Petrone AB, 2014, AGING DIS, V5, P340, DOI 10.14336/AD.2014.0500340; Raz S, 2010, J INT NEUROPSYCH SOC, V16, P169, DOI 10.1017/S1355617709991147; RICE JE, 1981, ANN NEUROL, V9, P131, DOI 10.1002/ana.410090206; Rosenzweig JM, 2014, FRONT PEDIATR, V2, DOI 10.3389/fped.2014.00108; Stoll G, 1999, PROG NEUROBIOL, V58, P233, DOI 10.1016/S0301-0082(98)00083-5; Traa BS, 2008, PEDIATR RES, V64, P81, DOI 10.1203/PDR.0b013e318174e70e; Turtzo LC, 2008, CEREBROVASC DIS, V26, P462, DOI 10.1159/000155983; Venna VR, 2012, ACTA NEUROPATHOL, V124, P425, DOI 10.1007/s00401-012-0990-8; Vexler ZS, 2006, CLIN NEUROSCI RES, V6, P293, DOI 10.1016/j.cnr.2006.09.008; Vogelgesang A, 2014, ACTA NEUROL SCAND, V129, P1, DOI 10.1111/ane.12165; Wang Q, 2007, J NEUROIMMUNOL, V184, P53, DOI 10.1016/j.jneuroim.2006.11.014; Ward IL, 2003, HORM BEHAV, V43, P531, DOI 10.1016/S0018-506X(03)00061-8; White TE, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-282; Wu YW, 2011, AM J OBSTET GYNECOL, V204, DOI 10.1016/j.ajog.2010.09.022	58	78	83	0	13	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	FEB 20	2015	12								32	10.1186/s12974-015-0251-6			10	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	CD3FA	WOS:000350962200001	25889641	DOAJ Gold, Green Published			2021-06-18	
J	Han, ZL; Chen, FL; Ge, XT; Tan, J; Lei, P; Zhang, JN				Han, Zhaoli; Chen, Fanglian; Ge, Xintong; Tan, Jin; Lei, Ping; Zhang, Jianning			miR-21 alleviated apoptosis of cortical neurons through promoting PTEN-Akt signaling pathway in vitro after experimental traumatic brain injury	BRAIN RESEARCH			English	Article						TBI; Neuron; miR-21; Apoptosis; PTEN; Akt	CELL APOPTOSIS; EXPRESSION; MICRORNA-21; PROTECTS; OVEREXPRESSION; INHIBITION; MECHANISM; RECOVERY; DAMAGE; STRESS	Traumatic brain injury (TBI) is a major cause of chronic disability and death in young adults worldwide. Multiple cellular, molecular and biochemical changes impact the development and outcome of TBI. Neuronal cell apoptosis, which is an important pathological change in secondary brain damage, is crucial to determine the functional recovery after TBI. miR-21, a widely-reported oncogene, which can reduce cell apoptosis in cancer, has been confirmed to be a pronounced up-regulated miRNA after TBI in animal model. Our study is designed to investigate whether miR-21 has the function of antiapoptosis in experimental TBI model in vitro and to explore the possible regulatory mechanism of miR-21 on neuronal apoptosis. The scratch cell injury was performed to mimic TBI-induced apoptosis in neurons, and miR-21 agomir/antagomir was transfected to up-/down-regulate the miR-21 level. Our data suggests that miR-21 can reduce the number of TUNEL-positive neurons. Meanwhile, miR-21 decreased the expression level of PTEN, and increased the phosphorylation of Akt significantly. In neurons transfected with miR-21 agomir, the expression of Bcl-2 was promoted while the caspase-3, caspase-9 and Bax level were down-regulated, which are crucially the downstream apoptosis-related proteins of PTEN-Akt signaling pathway. In conclusion, miR-21 can exert the function of reducing neuronal apoptosis through activating the PTEN-Akt signaling pathway. Our research provides new insights into the molecular mechanisms of neuronal apoptosis following TBI, which reminds that miR-21may be a potential therapeutic target for TBI treatment. (C) 2014 Published by Elsevier B.V.	[Han, Zhaoli; Chen, Fanglian; Ge, Xintong; Lei, Ping; Zhang, Jianning] Tianjin Med Univ, Tianjin Neurol Inst, Dept Neurosurg, Gen Hosp, Tianjin 300352, Peoples R China; [Tan, Jin; Lei, Ping] Tianjin Med Univ, Tianjin Inst Geriatr, Gen Hosp, Tianjin 300352, Peoples R China	Lei, P (corresponding author), Tianjin Med Univ, Tianjin Neurol Inst, Dept Neurosurg, Gen Hosp, Tianjin 300352, Peoples R China.	leiping1974@163.com	Ge, Xintong/X-4889-2019	Ge, Xintong/0000-0001-7153-952X	Tianjin Municipal Science and Technology Commission natural fund Project [13JCYBJC23700]; National Clinical Key Subject Construction Project of NHFPC Fund	This work was supported by Tianjin Municipal Science and Technology Commission natural fund Project (13JCYBJC23700) and National Clinical Key Subject Construction Project of NHFPC Fund.	Bao HJ, 2012, NEUROCHEM RES, V37, P2856, DOI 10.1007/s11064-012-0880-4; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Farook JM, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.280; Fluiter K, 2014, J IMMUNOL, V192, P2339, DOI 10.4049/jimmunol.1302793; Garcia-Junco-Clemente Pablo, 2014, Commun Integr Biol, V7, pe28358, DOI 10.4161/cib.28358; Glass C, 2011, MOL CELL BIOCHEM, V357, P135, DOI 10.1007/s11010-011-0883-5; Greer JE, 2013, ACTA NEUROPATHOL, V126, P59, DOI 10.1007/s00401-013-1119-4; Gwak HS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047449; Hong Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096212; Huang TT, 2009, J NEUROTRAUM, V26, P1535, DOI [10.1089/neu.2008.0743, 10.1089/neu.2008-0743]; Ji Hui, 2013, Zhonghua Wei Zhong Bing Ji Jiu Yi Xue, V25, P546, DOI 10.3760/cma.j.issn.2095-4352.2013.09.010; Kim GS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088962; Klawitter J, 2013, CARDIOVASC RES, V97, P66, DOI 10.1093/cvr/cvs302; Lei P, 2009, BRAIN RES, V1284, P191, DOI 10.1016/j.brainres.2009.05.074; Liao CX, 2013, ONCOL RES, V21, P129, DOI 10.3727/096504013X13832473329999; Liu HZ, 2014, INT J MOL SCI, V15, P4007, DOI 10.3390/ijms15034007; Liu HX, 2014, NEUROSCI LETT, V569, P110, DOI 10.1016/j.neulet.2014.03.071; Liu Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065431; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Luo XJ, 2013, ALCOHOL, V47, P481, DOI 10.1016/j.alcohol.2013.05.005; Ma YH, 2011, BRAIN RES BULL, V86, P441, DOI 10.1016/j.brainresbull.2011.07.007; Mao WF, 2014, INT J NEUROSCI, V124, P281, DOI 10.3109/00207454.2013.838236; Noshita N, 2002, NEUROBIOL DIS, V9, P294, DOI 10.1006/nbdi.2002.0482; Ou YW, 2013, CANCER BIOL THER, V14, P45, DOI 10.4161/cbt.22627; Pan XA, 2010, CANCER BIOL THER, V10, P1224, DOI 10.4161/cbt.10.12.14252; Pont-Lezica Lorena, 2013, Methods Mol Biol, V1041, P55, DOI 10.1007/978-1-62703-520-0_7; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Redell JB, 2011, J NEUROSCI RES, V89, P212, DOI 10.1002/jnr.22539; Redell JB, 2009, J NEUROSCI RES, V87, P1435, DOI 10.1002/jnr.21945; Ruan Q, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.47; Sabirzhanov B, 2012, J NEUROCHEM, V123, P542, DOI 10.1111/j.1471-4159.2012.07927.x; Shi L, 2010, BRAIN RES, V1352, P255, DOI 10.1016/j.brainres.2010.07.009; Si ML, 2007, ONCOGENE, V26, P2799, DOI 10.1038/sj.onc.1210083; Sun WF, 2014, INFLAMM RES, V63, P287, DOI 10.1007/s00011-013-0699-8; Tagawa H, 2013, CANCER SCI, V104, P801, DOI 10.1111/cas.12160; Truettner JS, 2013, BRAIN RES, V1533, P122, DOI 10.1016/j.brainres.2013.08.011; Umschwief G, 2010, J CEREBR BLOOD F MET, V30, P616, DOI 10.1038/jcbfm.2009.234; Wang GH, 2013, NEUROTHERAPEUTICS, V10, P124, DOI 10.1007/s13311-012-0157-2; Wang R, 2012, CHIN J INTEGR MED, V18, P934, DOI 10.1007/s11655-012-1297-z; Wei C, 2014, FREE RADICAL RES, V48, P282, DOI 10.3109/10715762.2013.865839; Wu FJ, 2013, J OLEO SCI, V62, P717, DOI 10.5650/jos.62.717; Wu XM, 2013, INT J CLIN EXP PATHO, V6, P1282; Xu XL, 2012, KIDNEY INT, V82, P1167, DOI 10.1038/ki.2012.241; Yang Q, 2014, MOL MED REP, V9, P2213, DOI 10.3892/mmr.2014.2068; Ye X, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004070; Yu D, 2014, J MOL NEUROSCI, V53, P242, DOI 10.1007/s12031-014-0293-8; Zeng J, 2013, EXP CLIN ENDOCR DIAB, V121, P425, DOI 10.1055/s-0033-1345169; Zhang H, 2013, INT J CLIN EXP MED, V6, P546; Zhao YB, 2012, EXP NEUROL, V237, P489, DOI 10.1016/j.expneurol.2012.07.004; Zou CS, 2013, NEUROCHEM INT, V62, P965, DOI 10.1016/j.neuint.2013.03.013	50	78	83	0	13	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	SEP 25	2014	1582						12	20		10.1016/j.brainres.2014.07.045			9	Neurosciences	Neurosciences & Neurology	AR1PM	WOS:000343357100002	25108037				2021-06-18	
J	Depreitere, B; Guiza, F; Van den Berghe, G; Schuhmann, MU; Maier, G; Piper, I; Meyfroidt, G				Depreitere, Bart; Gueiza, Fabian; Van den Berghe, Greet; Schuhmann, Martin U.; Maier, Gottlieb; Piper, Ian; Meyfroidt, Geert			Pressure autoregulation monitoring and cerebral perfusion pressure target recommendation in patients with severe traumatic brain injury based on minute-by-minute monitoring data Clinical article	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; cerebral perfusion pressure; autoregulation; intracranial pressure	CEREBROVASCULAR AUTOREGULATION; INTRACRANIAL-PRESSURE; REACTIVITY; VALIDATION	Object. In severe traumatic brain injury, a universal target for cerebral perfusion pressure (CPP) has been abandoned. Attempts to identify a dynamic CPP target based on the patient's cerebrovascular autoregulatory capacity have been promising so far. Bedside monitoring of pressure autoregulatory capacity has become possible by a number of methods, Czosnyka's pressure reactivity index (PRx) being the most frequently used. The PRx is calculated as the moving correlation coefficient between 40 consecutive 5-second averages of intracranial pressure (ICP) and mean arterial blood pressure (MABP) values. Plotting PRx against CPP produces a U-shaped curve in roughly two-thirds of monitoring time, with the bottom of this curve representing a CPP range corresponding with optimal autoregulatory capacity (CPPopt). In retrospective series, keeping CPP close to CPPopt corresponded with better outcomes. Monitoring of PRx requires high-frequency signal processing. The aim of the present study is to investigate how the processing of the information on cerebrovascular pressure reactivity that can be obtained from routine minute-by-minute ICP and MABP data can be enhanced to enable CPPopt recommendations that do not differ from those obtained by the PRx method, show the same associations with outcome, and can be generated in more than two-thirds of monitoring time. Methods. The low-frequency autoregulation index (LAx) was defined as the moving minute-by-minute ICP/MABP correlation coefficient calculated over time intervals varying from 3 to 120 minutes. The CPPopt calculation was based on LAx-CPP plots and done for time windows between 1 and 24 hours and for each LAx type. The resulting matrix of CPPopts were then averaged in a weighted manner, with the weight based on the goodness of fit of a U-shape and the lower value of the LAx corresponding to the U-bottom, to result in a final CPPopt recommendation. The association between actual CPP/CPPopt and outcome was assessed in the multicenter Brain Monitoring with Information Technology Research Group (BrainIT) database (n = 180). In the Leuven-Tubingen database (60-Hz waveform data, n = 21), LAx- and PRx-based CPPopts were compared. Results. In the BrainIT database, CPPopt recommendations were generated in 95% of monitoring time. Actual CPP being close to LAx-based CPPopt was associated with increased survival. In a multivariate model using the Corticosteroid Randomization After Significant Head Injury (CRASH) model as covariates, the average absolute difference between actual CPP and CPPopt was independently associated with increased mortality. In the high-frequency data set no significant difference was observed between PRx-based and LAx-based CPPopts. The new method issued a CPPopt recommendation in 97% of monitoring time, as opposed to 44% for PRx-based CPPopt. Conclusions. Minute-by-minute ICP/MABP data contain relevant information for autoregulation monitoring. In this study, the authors' new method based on minute-by-minute data resolution allowed for CPPopt calculation in nearly the entire monitoring time. This will facilitate the use of pressure reactivity monitoring in all ICUs.	[Depreitere, Bart; Gueiza, Fabian; Van den Berghe, Greet; Meyfroidt, Geert] Univ Hosp Leuven, B-3000 Louvain, Belgium; [Schuhmann, Martin U.; Maier, Gottlieb] Univ Klinikum Tubingen, Neurochirurg Klin, Tubingen, Germany; [Piper, Ian] So Gen Hosp, Glasgow G51 4TF, Lanark, Scotland	Depreitere, B (corresponding author), Univ Hosp Leuven, Herestr 49, B-3000 Louvain, Belgium.	bart.depreitere@uzleuven.be	Van den Berghe, Greet/J-6788-2018; Depreitere, Bart/AAA-9846-2020	Van den Berghe, Greet/0000-0002-5320-1362; Depreitere, Bart/0000-0002-7458-0648; Guiza, Fabian/0000-0001-7026-0957	Foundation for Scientific Research Flanders (Fonds voor Wetenschappelijk Onderzoek Vlaanderen, FWO) [G. 0904.11]; FWOFWO [1846113N]; Flemish GovernmentEuropean Commission [METH/08/07]; European Framework Programma [FP5-QLRI-2000-00454, QLG-2002-00160, FP7-IST-2007-217049]	The present study was supported by the Foundation for Scientific Research Flanders (Fonds voor Wetenschappelijk Onderzoek Vlaanderen, FWO) (Research project G. 0904.11). Geert Meyfroidt receives funding from FWO as senior clinical investigator (1846113N). Greet Van den Berghe receives long-term structural research financing via the Methusalem program funded by the Flemish Government (METH/08/07). BrainIT data collection was supported by The European Framework Programma (FP5-QLRI-2000-00454, QLG-2002-00160, and FP7-IST-2007-217049). The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.	AASLID R, 1989, STROKE, V20, P45, DOI 10.1161/01.STR.20.1.45; Aries MJH, 2012, CRIT CARE MED, V40, P2456, DOI 10.1097/CCM.0b013e3182514eb6; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Czosnyka M, 1996, STROKE, V27, P1829, DOI 10.1161/01.STR.27.10.1829; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Eker C, 1998, CRIT CARE MED, V26, P1881, DOI 10.1097/00003246-199811000-00033; Guiza F, 2013, CRIT CARE MED, V41, P554, DOI 10.1097/CCM.0b013e3182742d0a; Howells T, 2005, J NEUROSURG, V102, P311, DOI 10.3171/jns.2005.102.2.0311; Jaeger M, 2006, CRIT CARE MED, V34, P1783, DOI 10.1097/01.CCM.0000218413.51546.9E; Johnson U, 2011, NEUROSURGERY, V68, P714, DOI 10.1227/NEU.0b013e3182077313; Kellie George, 1824, Trans Med Chir Soc Edinb, V1, P84; Lam JMK, 1997, J NEUROSURG, V86, P438, DOI 10.3171/jns.1997.86.3.0438; Lodi CA, 1998, AM J PHYSIOL-HEART C, V274, pH1729; Monro Alexander, 1783, OBSERVATIONS STRUCTU; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Piper I, 2003, ACTA NEUROCHIR, V145, P615, DOI 10.1007/s00701-003-0066-6; Ragauskas A, 2005, ACTA NEUROCHIR SUPPL, V95, P367; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; Santos E, 2011, ACTA NEUROCHIR, V153, P2189, DOI 10.1007/s00701-011-1148-5; Shaw M, 2008, ACTA NEUROCHIR SUPPL, V102, P217, DOI 10.1007/978-3-211-85578-2_42; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Sviri GE, 2009, J NEUROSURG, V111, P695, DOI 10.3171/2008.10.17686; TIECKS FP, 1995, STROKE, V26, P1014, DOI 10.1161/01.STR.26.6.1014; Ursino M, 2010, ANN BIOMED ENG, V38, P955, DOI 10.1007/s10439-010-9923-7; Zweifel C, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E2	27	78	79	0	7	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JUN	2014	120	6					1451	1457		10.3171/2014.3.JNS131500			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	AH7ZA	WOS:000336352700022	24745709				2021-06-18	
J	Martin, KD; Franz, B; Kirsch, M; Polanski, W; von der Hagen, M; Schackert, G; Sobottka, SB				Martin, K. Daniel; Franz, Benjamin; Kirsch, Matthias; Polanski, Witold; von der Hagen, Maja; Schackert, Gabriele; Sobottka, Stephan B.			Autologous bone flap cranioplasty following decompressive craniectomy is combined with a high complication rate in pediatric traumatic brain injury patients	ACTA NEUROCHIRURGICA			English	Article						Bone flap resorption; Autologous bone flap cranioplasty; Pediatric traumatic brain injury; Decompressive craniectomy	SEVERE HEAD-INJURY; SINKING SKIN FLAP; INTRACRANIAL HYPERTENSION; CLINICAL ARTICLE; HINGE CRANIOTOMY; CHILDREN	Decompressive craniectomy (DC) is a last treatment option of refractory intracranial hypertension in traumatic brain injury (TBI) patients. Replacement of the autologous bone flap is the preferred method to cover the cranial defect after brain swelling has subsided. Long term outcomes and complications after replacement of the autologous bone flap in pediatric patients were studied in comparison to young, healthy adults. Medical records of 27 pediatric patients who underwent DC and subsequent replacement of the bone flap between 1998 and 2011 were reviewed retrospectively. Patients were divided into two age groups (group 1: 18 children < 15 years; group 2:9 adolescents 15-18 years). For comparative reasons, a young adult control group of 39 patients between 18 and 30 years was additionally evaluated. With 81.8 % resorption of the bone flap, this was the major complication in young children. In up to 54.4 % of patients, a surgical revision of the osteolytic bone flap became necessary. However, in some pediatric patients, the osteolysis resolved spontaneously and further operations were not required. Probable enabling factors for bone flap resorption were young age (0-7 years), size of craniectomy, permanent shunt placement, and extent of dural opening/duraplasty. Other complications were bone flap infections, loosening of the re-inserted bone flap, and postoperative hematomas. There is an unacceptably high complication rate after reimplantation of the autologous bone following DC in pediatric TBI patients, especially in young children up to seven years of age. Artificial or synthetic cranioplasties may be considered as alternatives to initial bone flap reimplantation in the growing child. Despite the fact that DC is an effective treatment in TBI with persistent intracranial hypertension, it is important to realize that DC is not only combined with replacement of the autologous bone flap but also with a high rate of additional complications especially in pediatric patients.	[Martin, K. Daniel; Franz, Benjamin; Kirsch, Matthias; Polanski, Witold; Schackert, Gabriele; Sobottka, Stephan B.] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dept Neurol Surg, D-01307 Dresden, Germany; [von der Hagen, Maja] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Childrens Hosp, Dept Paediat Neurol, D-01307 Dresden, Germany	Martin, KD (corresponding author), Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dept Neurol Surg, Fetscherstr 74, D-01307 Dresden, Germany.	hippocampus@dr-daniel-martin.com	Kirsch, Matthias/F-2824-2014; Polanski, Witold H/C-9657-2010; Polanski, Witold/C-9657-2010	Polanski, Witold H/0000-0002-9214-150X; Polanski, Witold/0000-0002-6603-5375			Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; Aydin S, 2011, J NEUROSCI RURAL PRA, V2, P162, DOI 10.4103/0976-3147.83584; Bao YH, 2010, J NEUROTRAUM, V27, P341, DOI 10.1089/neu.2009.1040; Bowers CA, 2013, J NEUROSURG-PEDIATR, V11, P526, DOI 10.3171/2013.1.PEDS12483; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; FODSTAD H, 1984, ACTA NEUROCHIR, V70, P21, DOI 10.1007/BF01406039; Frassanito P, 2012, ACTA NEUROCHIR, V154, P927, DOI 10.1007/s00701-011-1253-5; Gooch MR, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0962; Grant GA, 2004, J NEUROSURG, V100, P163, DOI 10.3171/ped.2004.100.2.0163; GRUBER R, 1988, Z KINDERCHIR, V43, P375; Honeybul S, 2011, J NEUROTRAUM, V28, P929, DOI 10.1089/neu.2010.1612; Jagannathan J, 2007, J NEUROSURG, V106, P268, DOI 10.3171/ped.2007.106.4.268; JENNETT B, 1975, LANCET, V1, P480; Josan VA, 2006, CHILD NERV SYST, V22, P1268, DOI 10.1007/s00381-006-0064-0; Kan P, 2006, J NEUROSURG, V105, P337, DOI 10.3171/ped.2006.105.5.337; Kenning TJ, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.4.FOCUS0960; Li LM, 2010, ANESTH ANALG, V111, P736, DOI 10.1213/ANE.0b013e3181e75cd1; Suarez EP, 2011, J TRAUMA, V71, P133, DOI 10.1097/TA.0b013e318211071f; Piedra MP, 2012, J NEUROSURG-PEDIATR, V10, P268, DOI 10.3171/2012.6.PEDS1268; Sakamoto S, 2006, CLIN NEUROL NEUROSUR, V108, P583, DOI 10.1016/j.clineuro.2005.03.012; Schmidt JH, 2007, J NEUROSURG, V107, P678, DOI 10.3171/JNS-07/09/0678; Schorl M, 2009, CENT EUR NEUROSURG, V70, P68, DOI 10.1055/s-0028-1093355; Shoakazemi A, 2009, NEUROSURGERY, V65, P505, DOI 10.1227/01.NEU.0000350870.69891.86; Stiver SI, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.4.FOCUS0965; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; Wen L, 2007, J CRANIOFAC SURG, V18, P526; Winkler PA, 2000, J NEUROSURG, V93, P53, DOI 10.3171/jns.2000.93.1.0053; Yadla S, 2011, NEUROSURGERY, V68, P1124, DOI 10.1227/NEU.0b013e31820a5470; Yang Xue-Jun, 2003, Chin J Traumatol, V6, P99	30	78	79	0	11	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	APR	2014	156	4					813	824		10.1007/s00701-014-2021-0			12	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	AD3GV	WOS:000333127200028	24532225				2021-06-18	
J	Gibson, S; Nigrovic, LE; O'Brien, M; Meehan, WP				Gibson, Sarah; Nigrovic, Lise E.; O'Brien, Michael; Meehan, William P., III			The effect of recommending cognitive rest on recovery from sport-related concussion	BRAIN INJURY			English	Article						Sport-related concussion; cognitive rest; mild traumatic brain injury	HIGH-SCHOOL; PERFORMANCE; MANAGEMENT; SYMPTOMS	Objective: To determine whether recommending cognitive rest to athletes after a sport-related concussion affects time to symptom resolution. Methods: A retrospective cohort study was conducted of 184 patients who presented to a sports concussion clinic in an academic medical centre between 1 November 2007 and 31 July 2009. The effect of recommending cognitive rest on symptom duration (days) was measured after adjusting for age, gender, initial PCSS score, history of amnesia, history of loss of consciousness and number of previous concussions. Using multivariate logistic regression, independent predictors of prolonged symptoms were identified, defined as >30 days. Results: Of the 135 study patients with complete medical records, 85 (63%) had cognitive rest recommended. Of those, 79 (59%) had prolonged symptoms. In the multivariate analysis, only initial PCSS score was associated with the duration of concussion symptoms (adjusted odds ratio (AOR) = 1.03; 95% CI = 1.01-1.05). The recommendation for cognitive rest was not significantly associated with time to concussion symptom resolution (AOR 0.5; 95% CI = 0.18-1.37). Conclusions: Given the limited evidence regarding the effects of cognitive rest on recovery from concussion, recommendations of prolonged periods of cognitive rest, particularly absences from school, should be approached cautiously.	[Gibson, Sarah] Meli Orthoped, Ft Lauderdale, FL USA; [Nigrovic, Lise E.; Meehan, William P., III] Childrens Hosp, Dept Med, Div Emergency Med, Boston, MA 02115 USA; [O'Brien, Michael; Meehan, William P., III] Childrens Hosp, Div Sports Med, Sports Concuss Clin, Dept Orthoped, Boston, MA 02115 USA; [Meehan, William P., III] Micheli Ctr Sports Injury Prevent, Waltham, MA USA; [Meehan, William P., III] Childrens Hosp, Brain Injury Ctr, Boston, MA 02115 USA	Meehan, WP (corresponding author), Childrens Hosp, Div Sports Med, Sports Concuss Clin, 319 Longwood Ave,Floor 6, Boston, MA 02115 USA.	william.meehan@childrens.harvard.edu		Nigrovic, Lise/0000-0002-6369-3997	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32 HD040128-06A1]; Hood Children's Research Grant; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040128] Funding Source: NIH RePORTER	Supported by NIH grant T32 HD040128-06A1 (WPM III) and Hood Children's Research Grant (LEN). The authors report no conflicts of interest.	Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; GRONWALL D, 1975, LANCET, V2, P995; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory Paul, 2009, J Athl Train, V44, P434, DOI 10.4085/1062-6050-44.4.434; McGrath N, 2010, J ATHL TRAINING, V45, P492, DOI 10.4085/1062-6050-45.5.492; Meehan WP, 2011, AM J SPORT MED, V39, P2304, DOI 10.1177/0363546511423503; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Meehan WP, 2011, AM J SPORTS MED; Moonie S, 2008, J SCHOOL HEALTH, V78, P140, DOI 10.1111/j.1746-1561.2007.00276.x	12	78	78	0	26	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JUL	2013	27	7-8					839	842		10.3109/02699052.2013.775494			4	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	169UO	WOS:000320806200010	23758286				2021-06-18	
J	Resch, J; Driscoll, A; McCaffrey, N; Brown, C; Ferrara, MS; Macciocchi, S; Baumgartner, T; Walpert, K				Resch, Jacob; Driscoll, Aoife; McCaffrey, Noel; Brown, Cathleen; Ferrara, Michael S.; Macciocchi, Stephen; Baumgartner, Ted; Walpert, Kimberly			ImPact Test-Retest Reliability: Reliably Unreliable?	JOURNAL OF ATHLETIC TRAINING			English	Article						intraclass correlation; concussions; mild traumatic brain injuries; neuropsychological testing; athletes	INTERNATIONAL-CONFERENCE; AGREEMENT STATEMENT; CONCUSSION; SPORT; SENSITIVITY; MANAGEMENT	Context: Computerized neuropsychological testing is commonly used in the assessment and management of sport-related concussion. Even though computerized testing is widespread, psychometric evidence for test-retest reliability is somewhat limited. Additional evidence for test-retest reliability is needed to optimize clinical decision making after concussion. Objective: To document test-retest reliability for a commercially available computerized neuropsychological test battery (ImPACT) using 2 different clinically relevant time intervals. Design: Cross-sectional study. Setting: Two research laboratories. Patients or Other Participants: Group 1 (n = 46) consisted of 25 men and 21 women (age = 22.4 +/- 1.89 years). Group 2 (n = 45) consisted of 17 men and 28 women (age = 20.9 +/- 1.72 years). Intervention(s): Both groups completed ImPACT forms 1, 2, and 3, which were delivered sequentially either at 1-week intervals (group 1) or at baseline, day 45, and day 50 (group 2). Group 2 also completed the Green Word Memory Test (WMT) as a measure of effort. Main Outcome Measures: Intraclass correlation coefficients (ICCs) were calculated for the composite scores of ImPACT between time points. Repeated-measures analysis of variance was used to evaluate changes in ImPACT and WMT results over time. Results: The ICC values for group 1 ranged from 0.26 to 0.88 for the 4 ImPACT composite scores. The ICC values for group 2 ranged from 0.37 to 0.76. In group 1, ImPACT classified 37.0% and 46.0% of healthy participants as impaired at time points 2 and 3, respectively. In group 2, ImPACT classified 22.2% and 28.9% of healthy participants as impaired at time points 2 and 3, respectively. Conclusions: We found variable test-retest reliability for ImPACT metrics. Visual motor speed and reaction time demonstrated greater reliability than verbal and visual memory. Our current data support a multifaceted approach to concussion assessment using clinical examinations, symptom reports, cognitive testing, and balance assessment.	[Resch, Jacob] Univ Texas Arlington, Arlington, TX 76102 USA; [Driscoll, Aoife; McCaffrey, Noel] Dublin City Univ, Dublin 9, Ireland; [Brown, Cathleen; Ferrara, Michael S.; Baumgartner, Ted] Univ Georgia, Athens, GA 30602 USA; [Macciocchi, Stephen] Shepherd Ctr, Atlanta, GA USA; [Walpert, Kimberly] Georgia Neurol Surg, Athens, Greece	Resch, J (corresponding author), Univ Texas Arlington, Box 19259,113 Maverick Act Ctr, Arlington, TX 76102 USA.	resch@uta.edu	Brown, Cathleen/A-6626-2013	Brown, Cathleen/0000-0002-3414-7938; Resch, Jacob/0000-0001-6031-3197			Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Baumgartner T.A., 2001, MEAS PHYS EDUC EXERC, V5, P179, DOI [10.1207/S15327841MPEE0503_4, DOI 10.1207/S15327841MPEE0503_4]; Baumgartner TA, 2007, MEASUREMENT EVALUATI, V8th; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Brown CN, 2007, J ATHL TRAINING, V42, P515; Cernich AN, 2007, ARCH CLIN NEUROPSYCH, V22, pS39, DOI 10.1016/j.acn.2006.10.004; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; Elbin RJ, 2011, AM J SPORT MED, V39, P2319, DOI 10.1177/0363546511417173; Erlanger D, 2003, ARCH CLIN NEUROPSYCH, V18, P293, DOI 10.1016/S0887-6177(02)00138-5; Green P., 2005, GREENS WORD MEMORY T; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Lovell M, 2007, IMPACT 2007 6 0 CLIN; Lovell M.R, 2007, IMPACT 2007 6 0 SOFT; Maxwell S. E., 2003, DESIGNING EXPT ANAL; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McGraw KO, 1996, PSYCHOL METHODS, V1, P30, DOI 10.1037/1082-989X.1.4.390; Pedhazu EJ, 1991, MEASUREMENT DESIGN A; Portney LG., 1993, FDN CLIN RES APPL PR, V3rd; Randolph C, 2005, J ATHL TRAINING, V40, P139; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677	25	78	78	1	21	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	JUL-AUG	2013	48	4					506	511		10.4085/1062-6050-48.3.09			6	Sport Sciences	Sport Sciences	211GX	WOS:000323895400010	23724770	Green Published			2021-06-18	
J	Evans, KN; Forsberg, JA; Potter, BK; Hawksworth, JS; Brown, TS; Andersen, R; Dunne, JR; Tadaki, D; Elster, EA				Evans, Korboi N.; Forsberg, Jonathan A.; Potter, Benjamin K.; Hawksworth, Jason S.; Brown, Trevor S.; Andersen, Romney; Dunne, James R.; Tadaki, Douglas; Elster, Eric A.			Inflammatory Cytokine and Chemokine Expression is Associated With Heterotopic Ossification in High-Energy Penetrating War Injuries	JOURNAL OF ORTHOPAEDIC TRAUMA			English	Article						inflammatory cytokines and chemokines; heterotopic ossification; high energy way injuries	TRAUMATIC BRAIN-INJURY; BONE-FORMATION; RISK-FACTORS; SPINAL-CORD; DIFFERENTIATION; OSTEOBLASTS; PREVALENCE; CELLS; INTERLEUKIN-6; INDOMETHACIN	Objective: Heterotopic ossification (HO) develops frequently after modern high-energy penetrating war injuries. The purpose of this prospective study was to identify and characterize the unique cytokine and chemokine profile associated with the development of HO as it pertained to the systemic inflammatory response after penetrating combat-related trauma. Methods: Patients with high-energy penetrating extremity wounds were prospectively enrolled. Surgical debridement along with the use of a pulse lavage and vacuum-assisted-closure device was performed every 48-72 hours until definitive wound closure. Wound bed tissue biopsy, wound effluent, and serum were collected before each debridement. Effluent and serum were analyzed for 22 relevant cytokines and chemokines. Tissue was analyzed quantitatively for bacterial colonization. Correlations between specific wound and patient characteristics were also analyzed. The primary clinical outcome measure was the formation of HO as confirmed by radiographs at a minimum of 2 months of follow-up. Results: Thirty-six penetrating extremity war wounds in 24 patients were investigated. The observed rate of HO in the study population was 38%. Of the 36 wounds, 13 (36%) demonstrated HO at a minimum follow-up of 2 months. An elevated injury severity score was associated with the development of HO (P = 0.006). Wound characteristics that correlated with the development of HO included impaired healing (P = 0.005) and bacterial colonization (P < 0.001). Both serum (interleukin-6, interleukin-10, and MCP-1) and wound effluent (IP-10 and MIP-1 alpha) cytokine and chemokine bioprofiles were individually associated and suggestive of the development of HO (P < 0.05). Conclusions: A severe systemic and wound-specific inflammatory state as evident by elevated levels of inflammatory cytokines, elevated injury severity score, and bacterial wound colonization is associated with the development of HO. These findings suggest that the development of HO in traumatic combat-related wounds is associated with a hyper-inflammatory systemic response to injury.	[Evans, Korboi N.; Hawksworth, Jason S.; Elster, Eric A.] USN, Regenerat Med Dept, Med Res Ctr, Silver Spring, MD 20910 USA; [Evans, Korboi N.; Forsberg, Jonathan A.; Potter, Benjamin K.; Brown, Trevor S.; Andersen, Romney; Tadaki, Douglas] Walter Reed Natl Mil Med Ctr, Integrated Dept Orthoped & Rehabil, Bethesda, MD USA; [Evans, Korboi N.; Forsberg, Jonathan A.; Potter, Benjamin K.; Andersen, Romney; Dunne, James R.; Elster, Eric A.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA; [Hawksworth, Jason S.; Dunne, James R.; Elster, Eric A.] Walter Reed Natl Mil Med Ctr, Integrated Dept Surg, Bethesda, MD USA	Elster, EA (corresponding author), USN, Regenerat Med Dept, Med Res Ctr, Silver Spring, MD 20910 USA.	eric.elster@med.navy.mil	Brown, Trevor/K-4703-2012; Brown, Trevor/F-7392-2015; Potter, Benjamin/U-1769-2019	Brown, Trevor/0000-0001-7042-785X; Brown, Trevor/0000-0001-7042-785X; Elster, Eric/0000-0002-0981-2748; Potter, MD, Benjamin K./0000-0002-8771-0317	US Navy Bureau of Medicine and Surgery under the Medical Development Program [PE 0604771N];  [601153N.4508.5180.A0508]	Supported by the US Navy Bureau of Medicine and Surgery under the Medical Development Program (PE 0604771N). This work was funded by work unit number: 601153N.4508.5180.A0508 and approved by the National Naval Medical Center Institutional Review Board in compliance with all Federal regulations governing the protection of human subjects. The NNMC IRB number is NNMC>2005.0069, and the protocol title is "The Use of Vacuum Assisted Wound Closure Device in treating Extremity Wounds."	Andermahr J, 2006, J NEUROTRAUM, V23, P708, DOI 10.1089/neu.2006.23.708; Billings PC, 2008, J BONE MINER RES, V23, P305, DOI 10.1359/JBMR.071030; Board TN, 2007, J BONE JOINT SURG BR, V89B, P434, DOI 10.1302/0301-620X.89B4.18845; Bosse A, 1997, Veroff Pathol, V146, P1; Boyd JI, 2004, CLIN ORTHOP RELAT R, P13, DOI 10.1097/01.blo.0000144859.73074.45; BROOKER AF, 1973, J BONE JOINT SURG AM, VA 55, P1629; Burd TA, 2001, J BONE JOINT SURG AM, V83A, P1783, DOI 10.2106/00004623-200112000-00003; Carano RAD, 2003, DRUG DISCOV TODAY, V8, P980, DOI 10.1016/S1359-6446(03)02866-6; Chandrasenan Jeevan, 2008, J Shoulder Elbow Surg, V17, pe15, DOI 10.1016/j.jse.2007.06.018; Claes L, 2002, J ORTHOP RES, V20, P1099, DOI 10.1016/S0736-0266(02)00044-X; Diefenderfer DL, 2003, J BONE JOINT SURG AM, V85A, P19, DOI 10.2106/00004623-200300003-00005; Erices A, 2002, EXP CELL RES, V280, P24, DOI 10.1006/excr.2002.5627; Forsberg JA, 2008, J BONE JOINT SURG AM, V90A, P580, DOI 10.2106/JBJS.G.00265; Forsberg JA, 2009, J BONE JOINT SURG AM, V91A, P1084, DOI 10.2106/JBJS.H.00792; Franchimont N, 2005, BONE, V37, P601, DOI 10.1016/j.bone.2005.06.002; GARLAND DE, 1988, CLIN ORTHOP RELAT R, P86; Gautschi OP, 2007, J NEUROTRAUM, V24, P154, DOI 10.1089/neu.2006.0166; GREENHALGH DG, 1987, SURGERY, V102, P306; Hawksworth JS, 2009, ANN SURG, V250, P1002, DOI 10.1097/SLA.0b013e3181b248d9; Jacobs S, 2008, J PLAST RECONSTR AES; Kaplan FS, 2004, J AM ACAD ORTHOP SUR, V12, P116, DOI 10.5435/00124635-200403000-00007; Kirt NT, 1942, JAMA-J AM MED ASSOC, P120; LARSON JM, 1981, RHEUMATOL REHABIL, V20, P193, DOI 10.1093/rheumatology/20.4.193; Melamed E, 2002, AM J PHYS MED REHAB, V81, P670, DOI 10.1097/00002060-200209000-00006; Moore KD, 1998, J BONE JOINT SURG BR, V80B, P259, DOI 10.1302/0301-620X.80B2.8157; Olmsted-Davis E, 2007, AM J PATHOL, V170, P620, DOI 10.2353/ajpath.2007.060692; Otis GA., 1883, THE MEDICAL AND SURG, V1883, P880; Posner LJ, 1997, BONE, V21, P321, DOI 10.1016/S8756-3282(97)00154-3; Potter Benjamin K, 2006, J Am Acad Orthop Surg, V14, pS188; Potter BK, 2007, J BONE JOINT SURG AM, V89A, P476, DOI 10.2106/JBJS.F.00412; RIFAS L, 1989, CONNECT TISSUE RES, V23, P163, DOI 10.3109/03008208909002416; Sears BW, 2009, J AM ACAD ORTHOP SUR, V17, P255, DOI 10.5435/00124635-200904000-00006; Shapiro F, 2008, EUR CELLS MATER, V15, P53, DOI 10.22203/eCM.v015a05; Sharp JG, 2005, CLIN ORTHOP RELAT R, P52, DOI 10.1097/01.blo.0000165733.64757.f2; Simonsen LL, 2007, INJURY, V38, P1146, DOI 10.1016/j.injury.2007.03.019; Taguchi Y, 1998, P ASSOC AM PHYSICIAN, V110, P559; Thornton FJ, 1997, SHOCK, V8, P391, DOI 10.1097/00024382-199712000-00001; Waydhas C, 1996, J TRAUMA, V40, P624, DOI 10.1097/00005373-199604000-00018; Webb Lawrence X, 2002, J Am Acad Orthop Surg, V10, P303	39	78	84	0	15	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0890-5339			J ORTHOP TRAUMA	J. Orthop. Trauma	NOV	2012	26	11					E204	E213		10.1097/BOT.0b013e31825d60a5			10	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	028WR	WOS:000310456200002	22588530				2021-06-18	
J	Wang, YQ; Wang, L; Zhang, MY; Wang, T; Bao, HJ; Liu, WL; Dai, DK; Zhang, L; Chang, P; Dong, WW; Chen, XP; Tao, LY				Wang, Yao-Qi; Wang, Long; Zhang, Ming-Yang; Wang, Tao; Bao, Hai-Jun; Liu, Wei-Li; Dai, Ding-Kun; Zhang, Lu; Chang, Pan; Dong, Wen-Wen; Chen, Xi-Ping; Tao, Lu-Yang			Necrostatin-1 Suppresses Autophagy and Apoptosis in Mice Traumatic Brain Injury Model	NEUROCHEMICAL RESEARCH			English	Article						Traumatic brain injury; Autophagy; Apoptosis; Necrostatin-1; Necroptosis	NECROTIC CELL-DEATH; CONTROLLED CORTICAL IMPACT; TUMOR-NECROSIS-FACTOR; INDUCED NECROPTOSIS; HT-22 CELLS; L929 CELLS; BECLIN 1; KAPPA-B; RECEPTOR; RAT	Traumatic brain injury (TBI) results in neuronal apoptosis, autophagic cell death and necroptosis. Necroptosis is a newly discovered caspases-independent programmed necrosis pathway which can be triggered by activation of death receptor. Previous works identified that necrostatin-1 (NEC-1), a specific necroptosis inhibitor, could reduce tissue damage and functional impairment through inhibiting of necroptosis process following TBI. However, the role of NEC-1 on apoptosis and autophagy after TBI is still not very clear. In this study, the amount of TBI-induced neural cell deaths were counted by PI labeling method as previously described. The expression of autophagic pathway associated proteins (Beclin-1, LC3-II, and P62) and apoptotic pathway associated proteins (Bcl-2 and caspase-3) were also respectively assessed by immunoblotting. The data showed that mice pretreated with NEC-1 reduced the amount of PI-positive cells from 12 to 48 h after TBI. Immunoblotting results showed that NEC-1 suppressed TBI-induced Beclin-1 and LC3-II activation which maintained p62 at high level. NEC-1 pretreatment also reversed TBI-induced Bcl-2 expression and caspase-3 activation, as well as the ratio of Beclin-1/Bcl-2. Both 3-MA and NEC-1 suppressed TBI-induced caspase-3 activation and LC3-II formation, Z-VAD only inhibited caspase-3 activation but increased LC3-II expression at 24 h post-TBI. All these results revealed that multiple cell death pathways participated in the development of TBI, and NEC-1 inhibited apoptosis and autophagy simultaneously. These coactions may further explain how can NEC-1 reduce TBI-induced tissue damage and functional deficits and reflect the interrelationship among necrosis, apoptosis and autophagy.	[Wang, Yao-Qi; Wang, Long; Zhang, Ming-Yang; Wang, Tao; Bao, Hai-Jun; Liu, Wei-Li; Dai, Ding-Kun; Zhang, Lu; Chang, Pan; Dong, Wen-Wen; Chen, Xi-Ping; Tao, Lu-Yang] Soochow Univ, Coll Med, Dept Forens Sci, Suzhou 215123, Jiangsu, Peoples R China; [Wang, Yao-Qi; Wang, Long; Zhang, Ming-Yang; Wang, Tao; Bao, Hai-Jun; Liu, Wei-Li; Dai, Ding-Kun; Zhang, Lu; Chang, Pan; Dong, Wen-Wen; Chen, Xi-Ping; Tao, Lu-Yang] Soochow Univ, Coll Med, Lab Neural Injury, Suzhou 215123, Jiangsu, Peoples R China; [Zhang, Ming-Yang] Nantong Univ, Coll Med, Dept Forens Sci, Nantong 226001, Jiangsu, Peoples R China	Chen, XP (corresponding author), Soochow Univ, Coll Med, Dept Forens Sci, Suzhou 215123, Jiangsu, Peoples R China.	xiping.chen@163.com; luyang.tao@163.com	Mingyang, Zhang/J-7412-2019	Mingyang, Zhang/0000-0001-7084-6237	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30872666, 81172911]; Shanghai Forensic Key Lab Foundation [KF1005]	This work was financially supported by the National Natural Science Foundation of China (30872666 and 81172911) and the Shanghai Forensic Key Lab Foundation (KF1005).	Bell BD, 2008, P NATL ACAD SCI USA, V105, P16677, DOI 10.1073/pnas.0808597105; Ch'en IL, 2008, P NATL ACAD SCI USA, V105, P17463, DOI 10.1073/pnas.0808043105; Cheema ZF, 1999, J NEUROSCI, V19, P1754; Christofferson DE, 2010, CURR OPIN CELL BIOL, V22, P263, DOI 10.1016/j.ceb.2009.12.003; Clark RSB, 2008, AUTOPHAGY, V4, P88, DOI 10.4161/auto.5173; Declercq W, 2009, CELL, V138, P229, DOI 10.1016/j.cell.2009.07.006; Degterev A, 2005, NAT CHEM BIOL, V1, P112, DOI 10.1038/nchembio711; Degterev A, 2008, NAT CHEM BIOL, V4, P313, DOI 10.1038/nchembio.83; Denecker G, 2001, CELL MOL LIFE SCI, V58, P356, DOI 10.1007/PL00000863; Denecker G, 2001, CELL DEATH DIFFER, V8, P829, DOI 10.1038/sj.cdd.4400883; Edinger AL, 2004, CURR OPIN CELL BIOL, V16, P663, DOI 10.1016/j.ceb.2004.09.011; Erlich S, 2006, AUTOPHAGY, V2, P49, DOI 10.4161/auto.2156; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Festjens N, 2007, CELL DEATH DIFFER, V14, P400, DOI 10.1038/sj.cdd.4402085; Graham SH, 2000, J NEUROTRAUM, V17, P831, DOI 10.1089/neu.2000.17.831; Han WD, 2009, APOPTOSIS, V14, P674, DOI 10.1007/s10495-009-0334-x; Itakura E, 2008, MOL BIOL CELL, V19, P5360, DOI 10.1091/mbc.E08-01-0080; Kabeya Y, 2004, J CELL SCI, V117, P2805, DOI 10.1242/jcs.01131; Kim Sunja, 2010, Int J Physiol Pathophysiol Pharmacol, V2, P137; Komatsu M, 2007, CELL, V131, P1149, DOI 10.1016/j.cell.2007.10.035; Luo CL, 2011, NEUROSCIENCE, V184, P54, DOI 10.1016/j.neuroscience.2011.03.021; Luo CL, 2010, J NEUROSCI RES, V88, P2847, DOI 10.1002/jnr.22453; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Meloni BP, 2011, J NEUROSCI METH, V195, P67, DOI 10.1016/j.jneumeth.2010.11.023; Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Pattingre S, 2006, CANCER RES, V66, P2885, DOI 10.1158/0008-5472.CAN-05-4412; Qin ZH, 1999, J NEUROSCI, V19, P4023; Rosenbaum DM, 2010, J NEUROSCI RES, V88, P1569, DOI 10.1002/jnr.22314; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Sadasivan S, 2008, BIOCHEM BIOPH RES CO, V373, P478, DOI 10.1016/j.bbrc.2008.05.031; Tanida Isei, 2008, V445, P77, DOI 10.1007/978-1-59745-157-4_4; Vanden Berghe T, 2004, J BIOL CHEM, V279, P7925, DOI 10.1074/jbc.M307807200; Vanden Berghe T, 2003, J BIOL CHEM, V278, P5622, DOI 10.1074/jbc.M208925200; Vanden Berghe Tom, 2004, Methods Mol Med, V98, P101; Vercammen D, 1998, J EXP MED, V188, P919, DOI 10.1084/jem.188.5.919; Vercammen D, 1997, CYTOKINE, V9, P801, DOI 10.1006/cyto.1997.0252; Vercammen D, 1998, J EXP MED, V187, P1477, DOI 10.1084/jem.187.9.1477; Wang Y, 2008, AUTOPHAGY, V4, P214, DOI 10.4161/auto.5369; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Whalen MJ, 2008, J CEREBR BLOOD F MET, V28, P490, DOI 10.1038/sj.jcbfm.9600544; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Xu XS, 2007, J NEUROCHEM, V103, P2004, DOI 10.1111/j.1471-4159.2007.04884.x; Xu XS, 2010, BRAIN RES, V1355, P189, DOI 10.1016/j.brainres.2010.07.080; Xu XS, 2010, BRAIN RES, V1343, P206, DOI 10.1016/j.brainres.2010.04.080; You ZR, 2008, J CEREBR BLOOD F MET, V28, P1564, DOI 10.1038/jcbfm.2008.44; Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645; Zhang N, 2011, AUTOPHAGY, V7, P598, DOI 10.4161/auto.7.6.15103; Zhang XP, 2005, CRIT CARE, V9, P66, DOI 10.1186/cc2950; Zhu S, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2010.94; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	51	78	86	0	19	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190	1573-6903		NEUROCHEM RES	Neurochem. Res.	SEP	2012	37	9					1849	1858		10.1007/s11064-012-0791-4			10	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	985PP	WOS:000307280100003	22736198				2021-06-18	
J	Labib, N; Nouh, T; Winocour, S; Deckelbaum, D; Banici, L; Fata, P; Razek, T; Khwaja, K				Labib, Noura; Nouh, Thamer; Winocour, Sebastian; Deckelbaum, Dan; Banici, Laura; Fata, Paola; Razek, Tarek; Khwaja, Kosar			Severely Injured Geriatric Population: Morbidity, Mortality, and Risk Factors	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Elderly; Trauma; Geriatric; ISS; GCS; Complication; Morbidity; MVC; Intensive care; Fall; Traumatic brain injury; Outcomes; Mortality	ELDERLY TRAUMA PATIENTS; JUSTIFY AGGRESSIVE MANAGEMENT; HOST FACTORS; SEVERITY; OLDER; CARE; AGE; POLYTRAUMA; SURVIVAL; DEATH	Background: With an increasing life expectancy and more active elderly population, management of geriatric trauma patients continues to evolve. The aim was to describe the mechanism and injuries of severely injured geriatric patients and to identify risk factors associated with mortality. Methods: The Trauma Registry at a Canadian Level I trauma center was queried for all trauma patients older than 65 years and injury severity score >15 from 2004 to 2006, resulting in a retrospective chart review of 276 patients. The data were subsequently analyzed using univariate and multivariate analysis. Results: Average age was 81.5 years (mean injury severity score of 25). Most common comorbid illness was hypertension (57.3%) and most frequent mechanism of injury was falls (72.3%). The overall mortality was comparable with the US National Trauma Data Bank (26.8% vs. 32.0%, confidence interval, 0.00-0.10). Geriatric patients requiring intubation, blood transfusions, or suffering from head, C-spine, or chest trauma had an increased likelihood of death. In-hospital respiratory, gastrointestinal, or infectious complications also had higher likelihood of death. Conclusions: Falls continue to be the most frequent mechanism of injury in severely injured geriatric patients. Risk factors associated with a higher likelihood of death are identified. More research is needed to better understand this important and increasing group of trauma patients.	[Winocour, Sebastian; Deckelbaum, Dan; Banici, Laura; Khwaja, Kosar] McGill Univ, Ctr Hlth, Dept Surg, Montreal, PQ H3G 1A4, Canada; [Labib, Noura] McMaster Univ, Dept Emergency Med, Hamilton, ON, Canada	Khwaja, K (corresponding author), McGill Univ, Ctr Hlth, Dept Surg, 1650 Cedar Ave,L9-411, Montreal, PQ H3G 1A4, Canada.	kosar.khwaja@mcgill.ca	Nouh, Thamer/G-2655-2010	Nouh, Thamer/0000-0002-7118-7453			Aldrian S, 2005, WIEN KLIN WOCHENSCHR, V117, P145, DOI 10.1007/s00508-004-0290-y; [Anonymous], 2006, 2006 CENSUS PORTRAIT; Battistella FD, 1998, J TRAUMA, V44, P618, DOI 10.1097/00005373-199804000-00010; BROOS PLO, 1993, INJURY, V24, P365, DOI 10.1016/0020-1383(93)90096-O; Centers for Disease Control, 1999, CTR DIS CONTR 3 LEAD; CHAMPION HR, 1989, AM J PUBLIC HEALTH, V79, P1278, DOI 10.2105/AJPH.79.9.1278; DEMARIA EJ, 1987, ANN SURG, V206, P738, DOI 10.1097/00000658-198712000-00009; Gubler KD, 1997, ARCH SURG-CHICAGO, V132, P1010; HOWARD MA, 1989, J NEUROSURG, V71, P858, DOI 10.3171/jns.1989.71.6.0858; KNUDSON MM, 1994, ARCH SURG-CHICAGO, V129, P448; Kuhne CA, 2005, WORLD J SURG, V29, P1476, DOI 10.1007/s00268-005-7796-y; LONNER JH, 1995, CLIN ORTHOP RELAT R, P136; Miller R, 1998, J TRAUMA, V44, P623; MILZMAN DP, 1992, J TRAUMA, V32, P236, DOI 10.1097/00005373-199202000-00021; Milzman DP, 1992, J TRAUMA, V32, P243; MORRIS JA, 1990, JAMA-J AM MED ASSOC, V263, P1942, DOI 10.1001/jama.263.14.1942; MORRIS JA, 1990, J TRAUMA, V30, P1476, DOI 10.1097/00005373-199012000-00006; OSLER T, 1988, AM J SURG, V156, P537, DOI 10.1016/S0002-9610(88)80548-8; PELLICANE JV, 1992, J TRAUMA, V33, P440, DOI 10.1097/00005373-199209000-00018; Perdue PW, 1998, J TRAUMA, V45, P805, DOI 10.1097/00005373-199810000-00034; SHABOT MM, 1995, J TRAUMA, V39, P254, DOI 10.1097/00005373-199508000-00011; Shabot MM, 1995, J TRAUMA, V39, P259; Taylor MD, 2002, J TRAUMA, V53, P407, DOI 10.1097/00005373-200209000-00001; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x; Tornetta P, 1999, J TRAUMA, V46, P702, DOI 10.1097/00005373-199904000-00024; van der Sluis CK, 1997, INJURY, V28, P588, DOI 10.1016/S0020-1383(97)00094-6; Weigelt JA, 1997, TRAUMA ADV TRAUMA LI, P26; ZIETLOW SP, 1994, J TRAUMA, V37, P985, DOI 10.1097/00005373-199412000-00020	28	78	79	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	DEC	2011	71	6					1908	1914		10.1097/TA.0b013e31820989ed			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	869RT	WOS:000298616400081	21537212				2021-06-18	
J	Brenner, DJ; Shuryak, I; Einstein, AJ				Brenner, David J.; Shuryak, Igor; Einstein, Andrew J.			Impact of Reduced Patient Life Expectancy on Potential Cancer Risks from Radiologic Imaging	RADIOLOGY			English	Article							LONG-TERM SURVIVAL; TRAUMATIC BRAIN-INJURY; COMPUTED-TOMOGRAPHY; RADIATION-EXPOSURE; CORONARY-ANGIOGRAPHY; COLORECTAL-CANCER; UNITED-STATES; LUNG-CANCER; FOLLOW-UP; CT	Purpose: To quantify the effect of reduced life expectancy on cancer risk by comparing estimated lifetime risks of lung cancer attributable to radiation from commonly used computed tomographic (CT) examinations in patients with and those without cancer or cardiac disease. Materials and Methods: With the use of clinically determined life tables, reductions in radiation-attributable lung cancer risks were estimated for coronary CT angiographic examinations in patients with multivessel coronary artery disease who underwent coronary artery bypass graft (CABG) surgery and for surveillance CT examinations in patients treated for colon cancer. Statistical uncertainties were estimated for the risk ratios in patients who underwent CABG surgery and patients with colon cancer versus the general population. Results: Patients with decreased life expectancy had decreased radiation-associated cancer risks. For example, for a 70-year-old patient with colon cancer, the estimated reduction in lifetime radiation-associated lung cancer risk was approximately 92% for stage IV disease, versus 8% for stage 0 or I disease. For a patient who had been treated with CABG surgery, the estimated reduction in lifetime radiation-associated lung cancer risk was approximately 57% for a 55-year-old patient, versus 12% for a 75-year-old patient. Conclusion: The importance of radiation exposure in determining optimal imaging usage is much reduced for patients with markedly reduced life expectancies: Imaging justification and optimization criteria for patients with substantially reduced life expectancies should not necessarily be the same as for those with normal life expectancies.	[Brenner, David J.; Shuryak, Igor] Columbia Univ, Coll Phys & Surg, Med Ctr, Ctr Radiol Res, New York, NY 10032 USA; [Einstein, Andrew J.] Columbia Univ, Coll Phys & Surg, Med Ctr, Dept Med, New York, NY 10032 USA; [Einstein, Andrew J.] Columbia Univ, Coll Phys & Surg, Med Ctr, Dept Radiol, New York, NY 10032 USA	Brenner, DJ (corresponding author), Columbia Univ, Coll Phys & Surg, Med Ctr, Ctr Radiol Res, 630 W 168th St,VC 11-235, New York, NY 10032 USA.	djb3@columbia.edu			Spectrum Dynamics; GE HealthcareGE Healthcare; Toshiba America Medical Systems; INVIA	D.J.B. No potential conflicts of interest to disclose. I. S. No potential conflicts of interest to disclose. A.J.E. Financial activities related to the present article: none to disclose. Financial activities not related to the present article: is a consultant for the International Atomic Energy Agency; has grants or grants pending from Spectrum Dynamics and GE Healthcare; receives travel, accommodations, and/or meeting expenses from Toshiba America Medical Systems and INVIA. Other relationships: none to disclose.	Angel E, 2009, AM J ROENTGENOL, V193, P1340, DOI 10.2214/AJR.09.2886; Arias Elizabeth, 2002, Natl Vital Stat Rep, V51, P1; Boysen G, 2009, NEUROEPIDEMIOLOGY, V33, P254, DOI 10.1159/000229780; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Brenner DJ, 2005, GASTROENTEROLOGY, V129, P328, DOI 10.1053/j.gastro.2005.05.021; Brenner DJ, 2004, RADIOLOGY, V231, P440, DOI 10.1148/radiol.2312030880; Brenner DJ, 2004, RADIOLOGY, V232, P735, DOI 10.1148/radiol.2323031095; Brenner DJ, 2001, AM J ROENTGENOL, V176, P289, DOI 10.2214/ajr.176.2.1760289; Brown AW, 2004, NEUROREHABILITATION, V19, P37; Capewell S, 2006, HEART, V92, P1563, DOI 10.1136/hrt.2005.085399; Chau I, 2004, J CLIN ONCOL, V22, P1420, DOI 10.1200/JCO.2004.05.041; de Gonzalez AB, 2008, J MED SCREEN, V15, P153, DOI 10.1258/jms.2008.008052; de Gonzalez AB, 2010, CIRCULATION, V122, P2403, DOI 10.1161/CIRCULATIONAHA.110.941625; de Gonzalez AB, 2009, ARCH INTERN MED, V169, P2071, DOI 10.1001/archinternmed.2009.440; Desch CE, 2005, J CLIN ONCOL, V23, P8512, DOI 10.1200/JCO.2005.04.0063; Einstein AJ, 2007, JAMA-J AM MED ASSOC, V298, P317, DOI 10.1001/jama.298.3.317; Ellison Lany F, 2006, Health Rep, V17, P19; Fujii K, 2007, BRIT J RADIOL, V80, P657, DOI 10.1259/bjr/97260522; Gao GQ, 2006, ANN THORAC SURG, V82, P806, DOI 10.1016/j.athoracsur.2006.04.032; Gatsonis CA, 2011, RADIOLOGY, V258, P243, DOI 10.1148/radiol.10091808; Goske MJ, 2008, AM J ROENTGENOL, V190, P273, DOI 10.2214/AJR.07.3526; Gustafsson F, 2004, EUR HEART J, V25, P1711, DOI 10.1016/j.ehj.2004.07.007; Hall EJ, 2008, BRIT J RADIOL, V81, P362, DOI 10.1259/bjr/01948454; Hamon M, 2008, RADIOLOGY, V247, P679, DOI 10.1148/radiol.2473071132; HORNER MJ, 1975, SEER CANC STAT REV; Kim KP, 2009, ARCH INTERN MED, V169, P1188, DOI 10.1001/archinternmed.2009.162; LEW EA, 1987, T SOC ACTUARIES, V39, P107; Madonna M B, 1997, Semin Pediatr Surg, V6, P105; MAILLIE HD, 1994, HEALTH PHYS, V66, P615, DOI 10.1097/00004032-199406000-00001; Merrill RM, 2000, ANN EPIDEMIOL, V10, P88, DOI 10.1016/S1047-2797(99)00051-4; Mettler FA, 2009, RADIOLOGY, V253, P520, DOI 10.1148/radiol.2532082010; *NAT COUNC RAD PRO, 1997, 126 NAT COUNC RAD PR; *NAT CTR HLTH STAT, 1975, US DEC LIF TABL 1969, V2; National Research Council, 2006, HLTH RISKS EXP LOW L; Pena BMG, 2004, PEDIATRICS, V113, P24, DOI 10.1542/peds.113.1.24; REYNOLDS S, 2010, NCI CANC B, V7, P8; Shuryak I, 2010, JNCI-J NATL CANCER I, V102, P1628, DOI 10.1093/jnci/djq346; Smith-Bindman R, 2009, ARCH INTERN MED, V169, P2078, DOI 10.1001/archinternmed.2009.427; Smolarz K, 1998, NUKLEARMED, V37, P286; Stein SC, 2009, ANN EMERG MED, V53, P180, DOI 10.1016/j.annemergmed.2008.01.002; van Domburg RT, 2009, EUR HEART J, V30, P453, DOI 10.1093/eurheartj/ehn530; Ward KC YJ, 2007, NIH PUB; Weustink AC, 2009, JACC-CARDIOVASC IMAG, V2, P816, DOI 10.1016/j.jcmg.2009.02.010	43	78	81	0	1	RADIOLOGICAL SOC NORTH AMERICA	OAK BROOK	820 JORIE BLVD, OAK BROOK, IL 60523 USA	0033-8419			RADIOLOGY	Radiology	OCT	2011	261	1					193	198		10.1148/radiol.11102452			6	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	822IW	WOS:000295039000021	21771956				2021-06-18	
J	Labombarda, F; Gonzalez, S; Lima, A; Roig, P; Guennoun, R; Schumacher, M; De Nicola, AF				Labombarda, Florencia; Gonzalez, Susana; Lima, Analia; Roig, Paulina; Guennoun, Rachida; Schumacher, Michael; De Nicola, Alejandro F.			Progesterone attenuates astro- and microgliosis and enhances oligodendrocyte differentiation following spinal cord injury	EXPERIMENTAL NEUROLOGY			English	Article						Progesterone; Spinal cord injury; Astrogliosis; Microgliosis; Oligodendrocytes; Neuroprotection	TRAUMATIC BRAIN-INJURY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; MYELIN BASIC-PROTEIN; CELL-PROLIFERATION; NEUROTROPHIC FACTOR; FACTOR EXPRESSION; STEROID-HORMONES; NERVOUS-SYSTEM; SEX STEROIDS; MOUSE MODEL	Reactive gliosis, demyelination and proliferation of NG2+ oligodendrocyte precursor cells (OPC) are common responses to spinal cord injury (SCI). We previously reported that short-term progesterone treatment stimulates OPC proliferation whereas chronic treatment enhances OPC differentiation after SCI. Presently, we further studied the proliferation/differentiation of glial cells involved in inflammation and remyelination in male rats with SCI subjected to acute (3 days) or chronic (21 days) progesterone administration. Rats received several pulses of bromodeoyuridine (BrdU) 48 and 72 h post-SCI, and sacrificed 3 or 21 days post-SCI. Double colocalization of BrdU and specific cell markers showed that 3 days of SCI induced a strong proliferation of S100 beta+ astrocytes, OX-42+ microglia/macrophages and NG2+ cells. At this stage, the intense GFAP+ astrogliosis was BrdU negative. Twenty one days of SCI enhanced maturation of S100 beta+ cells into GFAP+ astrocytes, but decreased the number of CC1+ oligodendrocytes. Progesterone treatment inhibited astrocyte and microglia /macrophage proliferation and activation in the 3-day SCI group, and inhibited activation in the 21-day SCI group. BrdU/NG2 double labeled cells were increased by progesterone at 3 days, indicating a proliferation stimulus, but decreased them at 21 days. However, progesterone-enhancement of CC1+/BrdU+ oligodendrocyte density, suggest differentiation of OPC into mature oligondendrocytes. We conclude that progesterone effects after SCI involves: a) inhibition of astrocyte proliferation and activation; b) anti-inflammatory effects by preventing microglial activation and proliferation, and c) early proliferation of NG2+ progenitors and late remyelination. Thus, progesterone behaves as a glioactive factor favoring remyelination and inhibiting reactive gliosis. (C) 2011 Elsevier Inc. All rights reserved.	[Labombarda, Florencia; Gonzalez, Susana; De Nicola, Alejandro F.] Inst Biol & Med Expt, Lab Neuroendocrine Biochem, RA-1428 Buenos Aires, DF, Argentina; [Labombarda, Florencia; Gonzalez, Susana; Lima, Analia; Roig, Paulina; De Nicola, Alejandro F.] Univ Buenos Aires, Fac Med, Dept Human Biochem, RA-1425 Buenos Aires, DF, Argentina; [Guennoun, Rachida; Schumacher, Michael] INSERM, UMR 788, F-94276 Le Kremlin Bicetre, France; [Guennoun, Rachida; Schumacher, Michael] Univ Paris 11 Steroids Neuroprotect & Neuroregene, F-94276 Le Kremlin Bicetre, France	De Nicola, AF (corresponding author), Inst Biol & Med Expt, Lab Neuroendocrine Biochem, Obligado 2490, RA-1428 Buenos Aires, DF, Argentina.	alejandrodenicola@gmail.com	Guennoun, Rachida/F-2420-2011; Messier, Claude/A-2322-2008; Schumacher, Michael/G-3581-2013	Guennoun, Rachida/0000-0002-9219-7300; Messier, Claude/0000-0002-4791-1763; Schumacher, Michael/0000-0001-6117-5371	CONICETConsejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET) [PIP 5542]; University of Buenos AiresUniversity of Buenos Aires [MO16, M611]; FONCYTFONCyT [01044, 00291]; INSERMInstitut National de la Sante et de la Recherche Medicale (Inserm)European Commission	This work was supported by grants from CONICET (PIP 5542), the University of Buenos Aires (MO16 and M611), FONCYT (PICT 2007 no 01044 and PICT 2006 no 00291) and a Cooperative Program between CONICET and INSERM.	Alonso G, 2005, GLIA, V49, P318, DOI 10.1002/glia.20121; Arevalo M. A., 2009, BIOCHIM BIOPHYS ACTA, V1800, P1106; Arnold S, 2008, J MOL ENDOCRINOL, V41, P289, DOI 10.1677/JME-08-0085; Azcoitia I, 2003, NEUROBIOL AGING, V24, P853, DOI 10.1016/S0197-4580(02)00234-8; Barker JM, 2008, NEUROSCIENCE, V152, P888, DOI 10.1016/j.neuroscience.2007.10.071; Batchelor PE, 2008, J NEUROTRAUM, V25, P1217, DOI 10.1089/neu.2007.0308; Baumann N, 2001, PHYSIOL REV, V81, P871; Benarroch EE, 2005, MAYO CLIN PROC, V80, P1326, DOI 10.4065/80.10.1326; Bezzi P, 2001, CURR OPIN NEUROBIOL, V11, P387, DOI 10.1016/S0959-4388(00)00223-3; Brambilla R, 2005, J EXP MED, V202, P145, DOI 10.1084/jem.20041918; Brambilla R, 2009, J IMMUNOL, V182, P2628, DOI 10.4049/jimmunol.0802954; Brozzi F, 2009, J BIOL CHEM, V284, P8788, DOI 10.1074/jbc.M805897200; Buffo A, 2008, P NATL ACAD SCI USA, V105, P3581, DOI 10.1073/pnas.0709002105; Ciriza I, 2004, J NEUROENDOCRINOL, V16, P58, DOI 10.1111/j.1365-2826.2004.01121.x; Coughlan T, 2005, J NEUROCHEM, V93, P932, DOI 10.1111/j.1471-4159.2005.03068.x; Crossin KL, 1997, P NATL ACAD SCI USA, V94, P2687, DOI 10.1073/pnas.94.6.2687; Cutler SM, 2007, J NEUROTRAUM, V24, P1475, DOI 10.1089/neu.2007.0294; De Nicola AF, 2006, J MOL NEUROSCI, V28, P3, DOI 10.1385/JMN:28:1:3; De Nicola AF, 2009, FRONT NEUROENDOCRIN, V30, P173, DOI 10.1016/j.yfrne.2009.03.001; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Djebaili M, 2001, MOL BRAIN RES, V93, P190, DOI 10.1016/S0169-328X(01)00197-8; Drew PD, 2000, J NEUROIMMUNOL, V111, P77, DOI 10.1016/S0165-5728(00)00386-6; Gago N, 2004, J NEUROSCI RES, V78, P770, DOI 10.1002/jnr.20348; Gago N, 2001, GLIA, V36, P295, DOI 10.1002/glia.1117; Garay L, 2008, NEUROIMMUNOMODULAT, V15, P76, DOI 10.1159/000135627; Garay L, 2007, J STEROID BIOCHEM, V107, P228, DOI 10.1016/j.jsbmb.2007.03.040; Garcia-Estrada J, 1999, INT J DEV NEUROSCI, V17, P145, DOI 10.1016/S0736-5748(98)00065-3; Garcia-Segura LM, 2006, GLIA, V54, P485, DOI 10.1002/glia.20404; Ghoumari AM, 2006, FASEB J, V20, P1377, DOI 10.1096/fj.05-5832com; Ghoumari AM, 2005, NEUROSCIENCE, V135, P47, DOI 10.1016/j.neuroscience.2005.05.023; Ghoumari AM, 2003, J NEUROCHEM, V86, P848, DOI 10.1046/j.1471-4159.2003.01881.x; Deniselle MCG, 2007, EXP NEUROL, V203, P406, DOI 10.1016/j.expneurol.2006.08.019; Gonzalez SL, 2004, NEUROSCIENCE, V125, P605, DOI 10.1016/j.neuroscience.2004.02.024; Gonzalez SL, 2009, CELL MOL NEUROBIOL, V29, P27, DOI 10.1007/s10571-008-9291-0; Grossman SD, 2001, EXP NEUROL, V168, P273, DOI 10.1006/exnr.2001.7628; Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997; Hausmann O, 2003, SPINAL CORD, V41, P369, DOI 10.1038/sj.sc.3101483; Horky LL, 2006, J COMP NEUROL, V498, P525, DOI 10.1002/cne.21065; Hu R, 2010, J NEUROSURG-SPINE, V13, P169, DOI 10.3171/2010.3.SPINE09190; Ibanez C, 2004, NEUROPATH APPL NEURO, V30, P80, DOI 10.1046/j.0305-1846.2003.00515.x; JungTestas I, 1996, J STEROID BIOCHEM, V58, P77, DOI 10.1016/0960-0760(96)00009-X; Kipp M, 2007, J NEUROENDOCRINOL, V19, P819, DOI 10.1111/j.1365-2826.2007.01588.x; KOENIG HL, 1995, SCIENCE, V268, P1500, DOI 10.1126/science.7770777; Labombarda F, 2006, ENDOCRINOLOGY, V147, P1847, DOI 10.1210/en.2005-0955; Labombarda F, 2006, J NEUROTRAUM, V23, P181, DOI 10.1089/neu.2006.23.181; Labombarda F, 2010, NEUROSCIENCE, V166, P94, DOI 10.1016/j.neuroscience.2009.12.012; Labombarda F, 2002, J NEUROTRAUM, V19, P343, DOI 10.1089/089771502753594918; Labombarda F, 2000, NEUROSCI LETT, V288, P29, DOI 10.1016/S0304-3940(00)01191-5; Labombarda F, 2000, J STEROID BIOCHEM, V73, P159, DOI 10.1016/S0960-0760(00)00064-9; Labombarda F, 2010, NEUROIMMUNOMODULAT, V17, P146, DOI 10.1159/000258709; Labombarda F, 2009, GLIA, V57, P884, DOI 10.1002/glia.20814; Leonelli E, 2007, NEUROSCIENCE, V144, P1293, DOI 10.1016/j.neuroscience.2006.11.014; Levine JM, 2001, TRENDS NEUROSCI, V24, P39, DOI 10.1016/S0166-2236(00)01691-X; LING EA, 1990, ANAT EMBRYOL, V182, P481; Lorenz L, 2009, J NEUROENDOCRINOL, V21, P841, DOI 10.1111/j.1365-2826.2009.01903.x; McDonald JW, 2006, J NEUROTRAUM, V23, P345, DOI 10.1089/neu.2006.23.345; McTigue DM, 2001, J NEUROSCI, V21, P3392, DOI 10.1523/JNEUROSCI.21-10-03392.2001; Melcangi RC, 1998, EXP GERONTOL, V33, P827, DOI 10.1016/S0531-5565(98)00020-5; Meyer M, 2010, CELL MOL NEUROBIOL, V30, P123, DOI 10.1007/s10571-009-9437-8; Mitterling KL, 2010, J COMP NEUROL, V518, P2729, DOI 10.1002/cne.22361; Morin-Richaud C, 1998, BRAIN RES, V783, P85, DOI 10.1016/S0006-8993(97)01282-1; Muller E, 2006, NEUROENDOCRINOL LETT, V27, P675; NORENBERG MD, 1994, J NEUROPATH EXP NEUR, V53, P213, DOI 10.1097/00005072-199405000-00001; OGATA T, 1993, NEUROSCIENCE, V55, P445, DOI 10.1016/0306-4522(93)90513-F; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; Rabchevsky AG, 2007, GLIA, V55, P831, DOI 10.1002/glia.20508; Revsin Y, 2005, BRAIN RES, V1038, P22, DOI 10.1016/j.brainres.2004.12.032; Robertson CL, 2006, EXP NEUROL, V197, P235, DOI 10.1016/j.expneurol.2005.09.014; Roglio I, 2008, BRAIN RES REV, V57, P460, DOI 10.1016/j.brainresrev.2007.04.010; Rosenberg LJ, 2005, GLIA, V49, P107, DOI 10.1002/glia.20096; Siegenthaler MM, 2007, J NEUROTRAUM, V24, P1631, DOI 10.1089/neu.2007.0302; Sierra A, 2008, GLIA, V56, P659, DOI 10.1002/glia.20644; Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002; Stein DG, 2005, ANN NY ACAD SCI, V1052, P152, DOI 10.1196/annals.1347.011; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Stein DG, 2008, BRAIN RES REV, V57, P386, DOI 10.1016/j.brainresrev.2007.06.012; Stein DG, 2010, EXPERT OPIN INV DRUG, V19, P847, DOI 10.1517/13543784.2010.489549; Suyama K, 2007, J NEUROTRAUM, V24, P1013, DOI 10.1089/neu.2006.0151; Totoiu MO, 2005, J COMP NEUROL, V486, P373, DOI 10.1002/cne.20517; Trivedi A, 2006, CLIN NEUROSCI RES, V6, P283, DOI 10.1016/j.cnr.2006.09.007; Wang DD, 2008, PROG NEUROBIOL, V86, P342, DOI 10.1016/j.pneurobio.2008.09.015; Waters EM, 2008, J COMP NEUROL, V511, P34, DOI 10.1002/cne.21826; WATSON C, 2009, ANN EMERG MED, V49, P391; Wu JF, 2010, GLIA, V58, P410, DOI 10.1002/glia.20932; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; Zai LJ, 2005, BRAIN RES, V1052, P147, DOI 10.1016/j.brainres.2005.05.071; Zai LJ, 2005, GLIA, V50, P247, DOI 10.1002/glia.20176	87	78	82	0	10	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	SEP	2011	231	1					135	146		10.1016/j.expneurol.2011.06.001			12	Neurosciences	Neurosciences & Neurology	810DX	WOS:000294106700016	21704617				2021-06-18	
J	Nigrovic, LE; Schunk, JE; Foerster, A; Cooper, A; Miskin, M; Atabaki, SM; Hoyle, J; Dayan, PS; Holmes, JF; Kuppermann, N				Nigrovic, Lise E.; Schunk, Jeff E.; Foerster, Adele; Cooper, Arthur; Miskin, Michelle; Atabaki, Shireen M.; Hoyle, John; Dayan, Peter S.; Holmes, James F.; Kuppermann, Nathan		Pediat Emergency Care Appl Res Net	The Effect of Observation on Cranial Computed Tomography Utilization for Children After Blunt Head Trauma	PEDIATRICS			English	Article						traumatic brain injury; computed tomography; clinical observation	CT; INJURY	OBJECTIVE: Children with minor blunt head trauma often are observed in the emergency department before a decision is made regarding computed tomography use. We studied the impact of this clinical strategy on computed tomography use and outcomes. METHODS: We performed a subanalysis of a prospective multicenter observational study of children with minor blunt head trauma. Clinicians completed case report forms indicating whether the child was observed before making a decision regarding computed tomography. We defined clinically important traumatic brain injury as an intracranial injury resulting in death, neurosurgical intervention, intubation for longer than 24 hours, or hospital admission for 2 nights or longer. To compare computed tomography rates between children observed and those not observed before a decision was made regarding computed tomography use, we used a generalized estimating equation model to control for hospital clustering and patient characteristics. RESULTS: Of 42 412 children enrolled in the study, clinicians noted if the patient was observed before making a decision on computed tomography in 40 113 (95%). Of these, 5433 (14%) children were observed. The computed tomography use rate was lower in those observed than in those not observed (31.1% vs 35.0%; difference: -3.9% [95% confidence interval: -5.3 to -2.6]), but the rate of clinically important traumatic brain injury was similar (0.75% vs 0.87%; difference: -0.1% [95% confidence interval: -0.4 to 0.1]). After adjustment for hospital and patient characteristics, the difference in the computed tomography use rate remained significant (adjusted odds ratio for obtaining a computed tomography in the observed group: 0.53 [95% confidence interval: 0.43-0.66]). CONCLUSIONS: Clinical observation was associated with reduced computed tomography use among children with minor blunt head trauma and may be an effective strategy to reduce computed tomography use. Pediatrics 2011; 127:1067-1073	[Nigrovic, Lise E.] Harvard Univ, Sch Med, Childrens Hosp Boston, Div Emergency Med, Boston, MA 02115 USA; [Schunk, Jeff E.] Primary Childrens Med Ctr, Dept Pediat, Salt Lake City, UT 84103 USA; [Schunk, Jeff E.; Miskin, Michelle] Univ Utah, Sch Med, Salt Lake City, UT USA; [Foerster, Adele] Holy Cross Hosp, Silver Spring, MD USA; [Cooper, Arthur] Columbia Univ Coll Phys & Surg, Harlem Hosp Med Ctr, Dept Surg, New York, NY 10032 USA; [Dayan, Peter S.] Columbia Univ Coll Phys & Surg, Morgan Stanley Childrens Hosp New York Presbyteri, Dept Pediat, New York, NY 10032 USA; [Atabaki, Shireen M.] George Washington Univ, Sch Med, Dept Pediat, Childrens Natl Med Ctr, Washington, DC 20052 USA; [Atabaki, Shireen M.] George Washington Univ, Sch Med, Dept Emergency Med, Childrens Natl Med Ctr, Washington, DC USA; [Hoyle, John] Michigan State Univ, Sch Med, Helen DeVos Childrens Hosp, Div Emergency Med, Grand Rapids, MI USA; [Holmes, James F.; Kuppermann, Nathan] Univ Calif Davis, Davis Sch Med, Davis Med Ctr, Dept Emergency Med, Davis, CA 95616 USA; [Kuppermann, Nathan] Univ Calif Davis, Davis Sch Med, Davis Med Ctr, Dept Pediat, Davis, CA 95616 USA	Nigrovic, LE (corresponding author), Harvard Univ, Sch Med, Childrens Hosp Boston, Div Emergency Med, 300 Longwood Ave, Boston, MA 02115 USA.	lise.nigrovic@childrens.harvard.edu		Nigrovic, Lise/0000-0002-6369-3997	Health Resources and Services Administration/Maternal and Child Health Bureau, Division of Research, Training, and EducationUnited States Department of Health & Human ServicesUnited States Health Resources & Service Administration (HRSA); Emergency Medical Services of Children Program [R40MC02461]; Health Resources and Services Administration/Maternal and Child Health BureauUnited States Department of Health & Human ServicesUnited States Health Resources & Service Administration (HRSA) [U03MC00001, U03MC00003, U03MC00006, U03MC00007, U03MC00008]	This work was supported by a grant from the Health Resources and Services Administration/Maternal and Child Health Bureau, Division of Research, Training, and Education, and the Emergency Medical Services of Children Program (R40MC02461). The PECARN is supported by cooperative agreements U03MC00001, U03MC00003, U03MC00006, U03MC00007, and U03MC00008 from the Emergency Medical Services of Children Program of the Health Resources and Services Administration/Maternal and Child Health Bureau.	Beaudin M, 2007, J PEDIATR SURG, V42, P849, DOI 10.1016/j.jpedsurg.2006.12.038; Blackwell CD, 2007, ANN EMERG MED, V49, P320, DOI 10.1016/j.annemergmed.2006.09.025; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Brenner DJ, 2002, PEDIATR RADIOL, V32, P228, DOI 10.1007/s00247-002-0671-1; DAVIS RL, 1994, ANN EMERG MED, V24, P640, DOI 10.1016/S0196-0644(94)70273-X; Frush DP, 2008, NEW ENGL J MED, V358, P851; Frush DP, 2008, PEDIATR RADIOL, V38, pS629, DOI 10.1007/s00247-008-1006-7; Hamilton M, 2010, PEDIATRICS, V126, pE33, DOI 10.1542/peds.2009-0692; Hillman BJ, 2010, NEW ENGL J MED, V363, P4, DOI 10.1056/NEJMp1003173; Klassen TP, 2000, ACAD EMERG MED, V7, P739, DOI 10.1111/j.1553-2712.2000.tb02260.x; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Maguire JL, 2009, PEDIATRICS, V124, pE145, DOI 10.1542/peds.2009-0075; McCollough CH, 2009, RADIOL CLIN N AM, V47, P27, DOI 10.1016/j.rcl.2008.10.006; Osmond MH, 2010, CAN MED ASSOC J, V182, P341, DOI 10.1503/cmaj.091421; Palchak MJ, 2003, ANN EMERG MED, V42, P492, DOI 10.1067/S0196-0644(03)00425-6; Reilly BM, 2006, ANN INTERN MED, V144, P201, DOI 10.7326/0003-4819-144-3-200602070-00009; SCHUTZMAN SA, 1993, ANN EMERG MED, V22, P535, DOI 10.1016/S0196-0644(05)81938-9; Shrimpton PC, 1998, BRIT J RADIOL, V71, P1, DOI 10.1259/bjr.71.841.9534691; Smith-Bindman R, 2010, NEW ENGL J MED, V363, P1, DOI 10.1056/NEJMp1002530; SNOEK JW, 1984, BRAIN, V107, P15, DOI 10.1093/brain/107.1.15; Varnholt H, 2008, NEW ENGL J MED, V358, P852	22	78	80	0	3	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	JUN	2011	127	6					1067	1073		10.1542/peds.2010-3373			7	Pediatrics	Pediatrics	771GV	WOS:000291146100047	21555498	Bronze			2021-06-18	
J	Ryang, YM; Fahlenkamp, AV; Rossaint, R; Wesp, D; Loetscher, PD; Beyer, C; Coburn, M				Ryang, Yu-Mi; Fahlenkamp, Astrid V.; Rossaint, Rolf; Wesp, Dominik; Loetscher, Philip D.; Beyer, Cordian; Coburn, Mark			Neuroprotective effects of argon in an in vivo model of transient middle cerebral artery occlusion in rats	CRITICAL CARE MEDICINE			English	Article						argon; neuroprotection; middle cerebral artery occlusion	TRAUMATIC BRAIN-INJURY; VITRO MODEL; ISCHEMIA; XENON; REPERFUSION; ANESTHESIA; NEURONS; STROKE; GASES	Objective: The neuroprotective effects of the noble gas xenon are well known. Argon, in contrast to xenon, is abundant, inexpensive, and therefore widely applicable. In this study, we analyzed the possible neuroprotective role of argon in an in vivo rat model of acute focal cerebral ischemia. Design: Controlled laboratory study. Setting: Academic research laboratory. Subjects: Male adult Sprague-Dawley rats. Interventions: Twenty-two rats underwent 2 hrs of transient middle cerebral artery occlusion using the endoluminal thread model. One hr after transient middle cerebral artery occlusion induction, spontaneously breathing rats received either 50 vol % argon/50 vol % O-2 (argon group, n = 11) or 50 vol % N-2/50 vol % O-2 (control group, n = 11) for 1 hr through a face mask. Twenty-four hrs after reperfusion, rats were neurologically and behaviorally tested and euthanized. Rat brains were stained with 2,3,5-triphenyltetrazolium chloride and infarct volumes determined by planimetry. Measurements and Main Results: After 2 hrs of transient middle cerebral artery occlusion in the rat, we found in the argon group a significant reduction in the overall (p = .004) and after subdivision in the cortical (p = .007) and the basal ganglia (p = .02) infarct volumes. Argon treatment resulted in a significant improvement of the composite adverse outcome (p = .034). However, there was no advantage in acute survival 24 hrs after transient middle cerebral artery occlusion (p = .361). Conclusion: We were able to demonstrate argon's neuroprotective effects in an in vivo experimental rat model of acute focal cerebral ischemia. Animals breathing spontaneously 50 vol % argon 1 hr after induction of transient middle cerebral artery occlusion for 1 hr by face mask showed significantly reduced infarct volumes and composite adverse outcomes. (Crit Care Med 2011; 39: 1448-1453)	[Ryang, Yu-Mi] Hosp Tech Univ Munich, Dept Neurosurg, Klinikum Rechts Isar, Munich, Germany; [Ryang, Yu-Mi; Wesp, Dominik] Univ Hosp RWTH Aachen, Dept Neurosurg, Aachen, Germany; [Fahlenkamp, Astrid V.; Rossaint, Rolf; Loetscher, Philip D.; Coburn, Mark] Univ Hosp RWTH Aachen, Dept Anesthesiol, Aachen, Germany; [Fahlenkamp, Astrid V.; Beyer, Cordian] Rhein Westfal TH Aachen, Fac Med, Inst Neuroanat, Aachen, Germany	Ryang, YM (corresponding author), Hosp Tech Univ Munich, Dept Neurosurg, Klinikum Rechts Isar, Munich, Germany.	mcoburn@ukaachen.de	Ryang, Yu-Mi/Q-8373-2016	Ryang, Yu-Mi/0000-0002-9045-5038; Coburn, Mark/0000-0002-7930-0270	Medical Faculty of the RWTH Aachen, Aachen	This research was conducted with funding by the Rotationsprogramm of the Medical Faculty of the RWTH Aachen, Aachen.	Abraini JH, 2003, ANESTH ANALG, V96, P746, DOI 10.1213/01.ANE.0000050282.14291.38; ASCHER P, 1987, TRENDS NEUROL SCI, V10, P8; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; Belayev L, 1996, STROKE, V27, P1616, DOI 10.1161/01.STR.27.9.1616; Belayev L, 2003, STROKE, V34, P758, DOI 10.1161/01.STR.0000056169.45365.15; Bickler PE, 2003, ANESTH ANALG, V97, P564, DOI 10.1213/01.ANE.0000068880.82739.7B; Chopp M, 2008, ACTA NEUROCHIR SUPPL, V105, P79; Coburn M, 2008, CRIT CARE MED, V36, P588, DOI 10.1097/01.CCM.0B013E3181611F8A6; David HN, 2008, FASEB J, V22, P1275, DOI 10.1096/fj.07-9420com; Dickinson R, 2010, CRIT CARE, V14, DOI 10.1186/cc9051; DIEMER NH, 1993, PROG BRAIN RES, V96, P105; Franks NP, 2008, NAT REV NEUROSCI, V9, P370, DOI 10.1038/nrn2372; Galeffi F, 2000, J NEUROCHEM, V75, P1242, DOI 10.1046/j.1471-4159.2000.0751242.x; Jawad N, 2009, NEUROSCI LETT, V460, P232, DOI 10.1016/j.neulet.2009.05.069; Koizumi J., 1986, NOSOTCHU, V8, P1, DOI DOI 10.3995/JSTROKE.8.1; Kramer M, 2010, J NEUROSCI METH, V187, P84, DOI 10.1016/j.jneumeth.2009.12.020; Lipton P, 1999, PHYSIOL REV, V79, P1431; Loetscher PD, 2009, CRIT CARE, V13, DOI 10.1186/cc8214; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; Ma D, 2002, BRIT J ANAESTH, V89, P739, DOI 10.1093/bja/aef258; Moustafa RR, 2008, BRIT J PHARMACOL, V153, pS44, DOI 10.1038/sj.bjp.0707530; Pavlov BN, 1997, HIGH PRESSURE BIOL M, P133; Preckel B, 2000, ANESTH ANALG, V91, P1327, DOI 10.1097/00000539-200012000-00003; Sanders RD, 2010, CRIT CARE, V14, DOI 10.1186/cc8847; Schwartz-Bloom RD, 2000, NEUROSCIENCE, V98, P471, DOI 10.1016/S0306-4522(00)00144-5; Sosin DM, 1996, BRAIN INJURY, V10, P47; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Xu J, 2008, NEUROPHARMACOLOGY, V54, P1029, DOI 10.1016/j.neuropharm.2008.01.014; Zausinger S, 2000, BRAIN RES, V863, P94, DOI 10.1016/S0006-8993(00)02100-4; Zhang F, 2007, NEUROSCIENCE, V150, P938, DOI 10.1016/j.neuroscience.2007.09.070	30	78	80	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	JUN	2011	39	6					1448	1453		10.1097/CCM.0b013e31821209be			6	Critical Care Medicine	General & Internal Medicine	765NM	WOS:000290715000031	21336110				2021-06-18	
J	Gosseries, O; Schnakers, C; Ledoux, D; Vanhaudenhuyse, A; Bruno, MA; Demertzi, A; Noirhomme, Q; Lehembre, R; Damas, P; Goldman, S; Peeters, E; Moonen, G; Laureys, S				Gosseries, Olivia; Schnakers, Caroline; Ledoux, Didier; Vanhaudenhuyse, Audrey; Bruno, Marie-Aurelie; Demertzi, Athena; Noirhomme, Quentin; Lehembre, Remy; Damas, Pierre; Goldman, Serge; Peeters, Erika; Moonen, Gustave; Laureys, Steven			Automated EEG entropy measurements in coma, vegetative state/unresponsive wakefulness syndrome and minimally conscious state	FUNCTIONAL NEUROLOGY			English	Article						coma; EEG entropy; electroencephalography; minimally conscious state; unresponsive wakefulness syndrome; vegetative state	BISPECTRAL INDEX; SPECTRAL ENTROPY; ELECTROENCEPHALOGRAM; REHABILITATION; RECOVERY; SEVOFLURANE; ACCURACY; PROPOFOL	Monitoring the level of consciousness in brain-injured patients with disorders of consciousness is crucial as it provides diagnostic and prognostic information. Behavioral assessment remains the gold standard for assessing consciousness but previous studies have shown a high rate of misdiagnosis. This study aimed to investigate the usefulness of electroencephalography (EEG) entropy measurements in differentiating unconscious (coma or vegetative) from minimally conscious patients. Left fronto-temporal EEG recordings (10-minute resting state epochs) were prospectively obtained in 56 patients and 16 age-matched healthy volunteers. Patients were assessed in the acute (<= 1 month post-injury; n=29) or chronic (>1 month post-injury; n=27) stage. The etiology was traumatic in 23 patients. Automated online EEG entropy calculations (providing an arbitrary value ranging from 0 to 91) were compared with behavioral assessments (Coma Recovery Scale-Revised) and outcome. EEG entropy correlated with Coma Recovery Scale total scores (r=0.49). Mean EEG entropy values were higher in minimally conscious (73 +/- 19; mean and standard deviation) than in vegetative/unresponsive wakefulness syndrome patients (45 +/- 28). Receiver operating characteristic analysis revealed an entropy cut-off value of 52 differentiating acute unconscious from minimally conscious patients (sensitivity 89% and specificity 90%). In chronic patients, entropy measurements offered no reliable diagnostic information. EEG entropy measurements did not allow prediction of outcome. User-independent time-frequency balanced spectral EEG entropy measurements seem to constitute an interesting diagnostic - albeit not prognostic - tool for assessing neural network complexity in disorders of consciousness in the acute setting. Future studies are needed before using this tool in routine clinical practice, and these should seek to improve automated EEG quantification paradigms in order to reduce the remaining false negative and false positive findings.	[Gosseries, Olivia; Schnakers, Caroline; Ledoux, Didier; Vanhaudenhuyse, Audrey; Bruno, Marie-Aurelie; Demertzi, Athena; Noirhomme, Quentin; Lehembre, Remy; Laureys, Steven] Univ Liege, Cyclotron Res Ctr, Coma Sci Grp, B-4000 Liege, Belgium; [Gosseries, Olivia; Schnakers, Caroline; Vanhaudenhuyse, Audrey; Bruno, Marie-Aurelie; Noirhomme, Quentin; Lehembre, Remy; Moonen, Gustave; Laureys, Steven] Sart Tilman Univ, Ctr Hosp, Dept Neurol, Liege, Belgium; [Ledoux, Didier; Damas, Pierre] Sart Tilman Univ, Ctr Hosp, Dept Intens Care, Liege, Belgium; [Goldman, Serge] Univ Brussels, Erasme Hosp, Dept Nucl Med, Brussels, Belgium; [Peeters, Erika] Inkendaal Hosp, Rehabil Ctr, Vlezenbeek, Belgium	Laureys, S (corresponding author), Univ Liege, Cyclotron Res Ctr, Coma Sci Grp, Sart Tilman B30, B-4000 Liege, Belgium.	steven.laureys@ulg.ac.be	Gosseries, Olivia/AAB-6469-2020; Demertzi, Athena/I-1251-2019; Laureys, Steven/AAN-2097-2021; Laureys, Steven/A-3349-2011; Vanhaudenhuyse, Audrey/AAP-2455-2020	Demertzi, Athena/0000-0001-8021-3759; Laureys, Steven/0000-0002-3096-3807; Noirhomme, Quentin/0000-0001-8247-4493; Gosseries, Olivia/0000-0001-9011-7496; Ledoux, Didier/0000-0002-9314-6564; Goldman, Serge/0000-0002-9917-8735	Belgian National Funds for Scientific Research (FNRS)Fonds de la Recherche Scientifique - FNRS; European CommissionEuropean CommissionEuropean Commission Joint Research Centre; James McDonnell Foundation; Mind Science Foundation; French Speaking Community Concerted Research Action; Foundation Medicale Reine Elisabeth; University and University Hospital of Liege	This research was funded by the Belgian National Funds for Scientific Research (FNRS), the European Commission (COST, DISCOS, MINDBRIDGE, DECODER), the James McDonnell Foundation, the Mind Science Foundation, the French Speaking Community Concerted Research Action, the Foundation Medicale Reine Elisabeth and the University and University Hospital of Liege.	Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; *ASP MED SYST, 2000, BISP IND MON SYST OP; Bein B, 2006, BEST PRACT RES-CLIN, V20, P101, DOI 10.1016/j.bpa.2005.07.009; Brenner RP, 2005, NEUROLOGIST, V11, P271, DOI 10.1097/01.nrl.0000178756.44055.f6; Bruhn J, 2001, ANESTHESIOLOGY, V95, P30, DOI 10.1097/00000542-200107000-00010; Bruhn J, 2000, ANESTHESIOLOGY, V92, P715, DOI 10.1097/00000542-200003000-00016; CHILDS NL, 1993, NEUROLOGY, V43, P1465, DOI 10.1212/WNL.43.8.1465; Choi YS, 2009, IEEE ENG MED BIO, P4715, DOI 10.1109/IEMBS.2009.5334199; Drummond JC, 2000, ANESTHESIOLOGY, V93, P876, DOI 10.1097/00000542-200009000-00039; Giacino JT, 2006, ARCH PHYS MED REHAB, V87, pS67, DOI 10.1016/j.apmr.2006.07.272; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Gilbert TT, 2001, CRIT CARE MED, V29, P1996, DOI 10.1097/00003246-200110000-00024; Gill M, 2003, ACAD EMERG MED, V10, P175, DOI 10.1197/aemj.10.2.175; Glass PS, 1997, ANESTHESIOLOGY, V86, P836, DOI 10.1097/00000542-199704000-00014; Hans P, 2005, BRIT J ANAESTH, V94, P336, DOI 10.1093/bja/aei047; Husain AM, 2006, J CLIN NEUROPHYSIOL, V23, P208, DOI 10.1097/01.wnp.0000220094.60482.b5; INOUYE T, 1991, ELECTROEN CLIN NEURO, V79, P204, DOI 10.1016/0013-4694(91)90138-T; Kulkarni VP, 2007, J CLIN NEUROPHYSIOL, V24, P433, DOI 10.1097/WNP.0b013e31815c2810; Laureys S, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-68; Lin MA, 2005, P ANN INT IEEE EMBS, P4580, DOI 10.1109/IEMBS.2005.1615489; Luccichenti G, 2009, FUNCT NEUROL, V24, P189; Martorano PP, 2006, J NEUROSURG ANESTH, V18, P205; Monti MM, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c3765; Navarro X, 2009, INT REV NEUROBIOL, V87, P483, DOI 10.1016/S0074-7742(09)87027-X; PALANCE BJ, 2009, CURR OPIN ANESTHESIO, V22, P533; PINCUS SM, 1991, J CLIN MONITOR, V7, P335, DOI 10.1007/BF01619355; Pistarini C, 2009, FUNCT NEUROL, V24, P169; Plum F., 1983, DIAGNOSIS STUPOR COM; Rezek IA, 1998, IEEE T BIO-MED ENG, V45, P1186, DOI 10.1109/10.709563; Sara M, 2010, NONLIN DYNAM PSYCHOL, V14, P1; Schnakers C, 2005, NEUROPSYCHOL REHABIL, V15, P381, DOI 10.1080/09602010443000524; Schnakers C, 2008, BRAIN INJURY, V22, P926, DOI 10.1080/02699050802530565; SCHNAKERS C, 2004, REANIMATION, V13, P368; Schnakers C, 2008, BRAIN INJURY, V22, P786, DOI 10.1080/02699050802403557; Schnakers C, 2006, ANN NEUROL, V60, P744, DOI 10.1002/ana.20919; Schnakers C, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-35; SHANNON CE, 1948, BELL SYST TECH J, V27, P623, DOI 10.1002/j.1538-7305.1948.tb00917.x; Vakkuri A, 2004, ACTA ANAESTH SCAND, V48, P145, DOI 10.1111/j.0001-5172.2004.00323.x; Viertio-Oja H, 2004, ACTA ANAESTH SCAND, V48, P154, DOI 10.1111/j.0001-5172.2004.00322.x; Vivien B, 2007, INTENS CARE MED, V33, P919, DOI 10.1007/s00134-007-0607-1; Wennervirta J, 2007, INTENS CARE MED, V33, P133, DOI 10.1007/s00134-006-0429-6; Wheeler P, 2005, J NEUROSURG ANESTH, V17, P86, DOI 10.1097/01.ana.0000151408.62650.b5; Wu DY, 2011, CLIN NEUROPHYSIOL, V122, P490, DOI 10.1016/j.clinph.2010.05.036; Young GB, 2000, J CLIN NEUROPHYSIOL, V17, P473, DOI 10.1097/00004691-200009000-00006; Zandbergen EGJ, 1998, LANCET, V352, P1808, DOI 10.1016/S0140-6736(98)04076-8; ZWEIG MH, 1993, CLIN CHEM, V39, P561	48	78	85	0	14	C I C-EDIZIONI INT SRL	ROME	CORSO TRIESTE, 42, 00198 ROME, ITALY	0393-5264	1971-3274		FUNCT NEUROL	Funct. Neurol.	JAN-MAR	2011	26	1					25	30					6	Clinical Neurology	Neurosciences & Neurology	789OJ	WOS:000292524900004	21693085				2021-06-18	
J	Wade, SL; Cassedy, A; Walz, NC; Taylor, HG; Stancin, T; Yeates, KO				Wade, Shari L.; Cassedy, Amy; Walz, Nicolay C.; Taylor, H. Gerry; Stancin, Terry; Yeates, Keith Owen			The Relationship of Parental Warm Responsiveness and Negativity to Emerging Behavior Problems Following Traumatic Brain Injury in Young Children	DEVELOPMENTAL PSYCHOLOGY			English	Article						brain injury; parent-child interactions; externalizing behavior; responsiveness; negativity	CLOSED-HEAD-INJURY; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; EXTERNALIZING PROBLEMS; EARLY-CHILDHOOD; PSYCHIATRIC-DISORDERS; CONDUCT PROBLEMS; SHORT-TERM; PERSONALITY-CHANGE; OUTCOMES; ADOLESCENTS	Parenting behaviors play a critical role in the child's behavioral development, particularly for children with neurological deficits. This study examined the relationship of parental warm responsiveness and negativity to changes in behavior following traumatic brain injury (TBI) in young children relative to an age-matched cohort of children with orthopedic injuries (OI). It was hypothesized that responsive parenting would buffer the adverse effects of TBI on child behavior, whereas parental negativity would exacerbate these effects. Children, ages 3-7 years, hospitalized for TBI (n = 80) or 01(n = 113), were seen acutely and again 6 months later. Parent-child dyads were videotaped during free play. Parents completed behavior ratings (Child Behavior Checklist; T. M. Achenbach & L. A. Rescorla, 2001) at both visits, with baseline ratings reflecting preinjury behavior. Hypotheses were tested using multiple regression, with preinjury behavior ratings, race, income, child IQ, family functioning, and acute parental distress serving as covariates. Parental responsiveness and negativity had stronger associations with emerging externalizing behaviors and attention-deficit/hyperactivity disorder symptoms among children with severe TBI. Findings suggest that parenting quality may facilitate or impede behavioral recovery following early TBI. Interventions that increase positive parenting may partially ameliorate emerging behavior problems.	[Wade, Shari L.] Cincinnati Childrens Hosp, Med Ctr, Div Pediat Phys Med & Rehabil, Dept Pediat, Cincinnati, OH 45229 USA; [Wade, Shari L.; Cassedy, Amy; Walz, Nicolay C.] Univ Cincinnati, Coll Med, Cincinnati, OH 45221 USA; [Taylor, H. Gerry] Rainbow Babies & Childrens Hosp, Dept Pediat, Cleveland, OH 44106 USA; [Taylor, H. Gerry; Stancin, Terry] Case Western Reserve Univ, Cleveland, OH 44106 USA; [Stancin, Terry] Metrohlth Med Ctr, Dept Pediat, Cleveland, OH USA; [Stancin, Terry] Metrohlth Med Ctr, Dept Psychiat, Cleveland, OH USA; [Yeates, Keith Owen] Nationwide Childrens Hosp, Dept Pediat, Columbus, OH USA; [Yeates, Keith Owen] Nationwide Childrens Hosp, Dept Psychol, Columbus, OH USA; [Yeates, Keith Owen] Nationwide Childrens Hosp, Dept Psychiat, Columbus, OH USA; [Yeates, Keith Owen] Ohio State Univ, Columbus, OH 43210 USA	Wade, SL (corresponding author), Cincinnati Childrens Hosp, Med Ctr, Div Pediat Phys Med & Rehabil, Dept Pediat, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	shari.wade@cchmc.org	Yeates, Keith/AAJ-4223-2020; Stancin, Terry/L-7993-2019	Yeates, Keith/0000-0001-7680-2892	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD042729] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR008084] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01 RR008084] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD042729] Funding Source: Medline		Achenbach TM, 2001, MANUAL ASEBA SCH AGE; Ackerman BP, 2003, CHILD DEV, V74, P694, DOI 10.1111/1467-8624.00563; Anderson V, 2005, BRAIN INJURY, V19, P699, DOI 10.1080/02699050400025281; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Anderson VA, 2006, NEUROPSYCHOLOGY, V20, P42, DOI 10.1037/0894-4105.20.1.42; BAKEMAN R, 1980, CHILD DEV, V51, P437, DOI 10.2307/1129277; Barnes MA, 1999, DEV NEUROPSYCHOL, V15, P1, DOI 10.1080/87565649909540737; Bloom DR, 2001, J AM ACAD CHILD PSY, V40, P572, DOI 10.1097/00004583-200105000-00017; Bradley RH, 2001, CHILD DEV, V72, P1868, DOI 10.1111/1467-8624.t01-1-00383; Bradley RH, 2007, DEV PSYCHOL, V43, P1390, DOI 10.1037/0012-1649.43.6.1390; Chronis AM, 2007, DEV PSYCHOL, V43, P70, DOI 10.1037/0012-1649.43.1.70; Davidov M, 2006, CHILD DEV, V77, P44, DOI 10.1111/j.1467-8624.2006.00855.x; Deater-Deckard K, 1998, DEV PSYCHOPATHOL, V10, P469, DOI 10.1017/S0954579498001709; Deater-Deckard K, 2006, PARENT-SCI PRACT, V6, P59, DOI 10.1207/s15327922par0601_3; Dennis M., 1995, TRAUMATIC HEAD INJUR, P165; DEROGATIS LR, 1982, BRIEF SYMPTOM INVENT, V1; DODGE KA, 1994, CHILD DEV, V65, P649, DOI 10.2307/1131407; Eisenberg N, 2005, CHILD DEV, V76, P1055, DOI 10.1111/j.1467-8624.2005.00897.x; Elliott C.D., 1990, DIFFERENTIAL ABILITY; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Ewing-Cobbs L, 2006, J NEUROSURG, V105, P287, DOI 10.3171/ped.2006.105.4.287; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; Eyberg S., 1988, CHILD FAM BEHAV THER, V10, P33, DOI [DOI 10.1300/J019V10N01_04, 10.1300/J019v10n01_04]; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Goldstrohm SL, 2005, ARCH CLIN NEUROPSYCH, V20, P675, DOI 10.1016/j.acn.2005.02.005; Kinsella G, 1999, J CONSULT CLIN PSYCH, V67, P116, DOI 10.1037/0022-006X.67.1.116; Landry SH, 1997, DEV PSYCHOL, V33, P1040, DOI 10.1037/0012-1649.33.6.1040; Landry SH, 2006, DEV PSYCHOL, V42, P627, DOI 10.1037/0012-1649.42.4.627; Landry SH, 2002, DEV NEUROPSYCHOL, V21, P15, DOI 10.1207/S15326942DN2101_2; Landry SH, 2001, DEV PSYCHOL, V37, P387, DOI 10.1037//0012-1649.37.3.387; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Max JE, 2005, J AM ACAD CHILD PSY, V44, P1032, DOI 10.1097/01.chi.0000173293.05817.b1; Max JE, 2005, J AM ACAD CHILD PSY, V44, P1041, DOI 10.1097/01.chi.0000173292.05817.f8; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; Max JE, 2000, J INT NEUROPSYCH SOC, V6, P279, DOI 10.1017/S1355617700633039; Max JE, 1997, J NERV MENT DIS, V185, P394, DOI 10.1097/00005053-199706000-00006; MCCLELLAND GH, 1993, PSYCHOL BULL, V114, P376, DOI 10.1037/0033-2909.114.2.376; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; Nowak C, 2008, CLIN CHILD FAM PSYCH, V11, P114, DOI 10.1007/s10567-008-0033-0; Patterson G.R., 1982, SOCIAL LEARNING APPR, V3; ROTHBAUM F, 1994, PSYCHOL BULL, V116, P55, DOI 10.1037/0033-2909.116.1.55; Rubin KH, 2003, DEV PSYCHOL, V39, P164, DOI 10.1037//0012-1649.39.1.164; RUTTER M, 1980, PSYCHOL MED, V10, P633, DOI 10.1017/S0033291700054933; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; Shaw DS, 1998, J ABNORM CHILD PSYCH, V26, P95, DOI 10.1023/A:1022665704584; Shaw DS, 2003, DEV PSYCHOL, V39, P189, DOI 10.1037/0012-1649.39.2.189; Statistical Solutions, 2001, SOLAS MISS DAT AN; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; TAYLOR HG, 1997, J INT NEUROPSYCH SOC, V3, P1; TEASDALE G, 1974, LANCET, V2, P81; Vasa RA, 2002, J AM ACAD CHILD PSY, V41, P148, DOI 10.1097/00004583-200202000-00008; Verger K, 2000, BRAIN INJURY, V14, P495; Wade SL, 2008, REHABIL PSYCHOL, V53, P180, DOI 10.1037/0090-5550.53.2.180; Wade SL, 2003, J HEAD TRAUMA REHAB, V18, P164, DOI 10.1097/00001199-200303000-00007; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514; Yeates KO, 2010, PEDIAT NEUROPSYCHOLO, P112	63	78	78	2	29	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0012-1649	1939-0599		DEV PSYCHOL	Dev. Psychol.	JAN	2011	47	1					119	133		10.1037/a0021028			15	Psychology, Developmental	Psychology	710BS	WOS:000286486500012	21244154	Green Accepted			2021-06-18	
J	Manley, GT; Diaz-Arrastia, R; Brophy, M; Engel, D; Goodman, C; Gwinn, K; Veenstra, TD; Ling, G; Ottens, AK; Tortella, F; Hayes, RL				Manley, Geoffrey T.; Diaz-Arrastia, Ramon; Brophy, Mary; Engel, Doortje; Goodman, Clay; Gwinn, Katrina; Veenstra, Timothy D.; Ling, Geoffrey; Ottens, Andrew K.; Tortella, Frank; Hayes, Ronald L.			Common Data Elements for Traumatic Brain Injury: Recommendations From the Biospecimens and Biomarkers Working Group	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Biological Markers; Brain Injuries; Rehabilitation	HUMAN CEREBROSPINAL-FLUID; GENOTYPE; POLYMORPHISM; ASSOCIATION; PROTEOMICS; PROTEINS; EVENTS; APOE	Recent advances in genomics, proteomics, and biotechnology have provided unprecedented opportunities for translational research and personalized medicine. Human biospecimens and biofluids represent an important resource from which molecular data can be generated to detect and classify injury and to identify molecular mechanisms and therapeutic targets. To date, there has been considerable variability in biospecimen and biofluid collection, storage, and processing in traumatic brain injury (TBI) studies. To realize the full potential of this important resource, standardization and adoption of best practice guidelines are required to insure the quality and consistency of these specimens. The aim of the Biospecimens and Biomarkers Working Group was to provide recommendations for core data elements for TBI research and develop best practice guidelines to standardize the quality and accessibility of these specimens. Consensus recommendations were developed through interactions with focus groups and input from stakeholders participating in the interagency workshop on Standardization of Data Collection in TBI and Psychological Health held in Washington, DC, in March 2009. With the adoption of these standards and best practices, future investigators will be able to obtain data across multiple studies with reduced costs and effort and accelerate the progress of genomic, proteomic, and metabolomic research in TBI.	[Manley, Geoffrey T.] Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94110 USA; [Diaz-Arrastia, Ramon] Univ Texas SW Med Sch, Dallas, TX USA; [Brophy, Mary] Dept Vet Affairs Cooperat Studies Program, Boston, MA USA; [Engel, Doortje] Univ Heidelberg Hosp, Heidelberg, Germany; [Goodman, Clay; Gwinn, Katrina] Baylor Coll Med, Houston, TX 77030 USA; [Veenstra, Timothy D.] NCI, Sci Applicat Int Corp Frederick Inc, Frederick, MD 21701 USA; [Ling, Geoffrey] Uniformed Serv Univ Hlth Sci, Bethesda, MD USA; [Tortella, Frank] Walter Reed Army Inst Res, Silver Spring, MD USA; [Ottens, Andrew K.] Virginia Commonwealth Univ, Dept Anat & Neurobiol, Richmond, VA USA; [Ottens, Andrew K.] Virginia Commonwealth Univ, Dept Biochem, Richmond, VA USA; [Hayes, Ronald L.] Banyan Biomarkers Inc, Alachua, FL USA	Manley, GT (corresponding author), Univ Calif San Francisco, Dept Neurosurg, 1001 Potrero Ave,Bldg 1,Room 101, San Francisco, CA 94110 USA.	manleyg@neurosurg.ucsf.edu	Ottens, Andrew/K-3352-2012; Gwinn, Katrina A/C-2508-2009	Ottens, Andrew/0000-0002-2118-3796; Diaz-Arrastia, Ramon/0000-0001-6051-3594; Gwinn, Katrina/0000-0002-8277-651X			Bergquist J, 2002, MASS SPECTROM REV, V21, P2, DOI 10.1002/mas.10016; BLENNOW K, 1993, EUR NEUROL, V33, P126, DOI 10.1159/000116918; Carrette O, 2005, PROTEOMICS, V5, P3060, DOI 10.1002/pmic.200402039; de Frias CM, 2005, J COGNITIVE NEUROSCI, V17, P1018, DOI 10.1162/0898929054475136; Diaz-Arrastia R, 2006, J HEAD TRAUMA REHAB, V21, P361, DOI 10.1097/00001199-200607000-00007; Egan MF, 2001, P NATL ACAD SCI USA, V98, P6917, DOI 10.1073/pnas.111134598; Eiseman E., 2003, CASE STUDIES EXISTIN; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; GOOSSENS W, 1991, CLIN LAB HAEMATOL, V13, P291; Hadjigeorgiou GM, 2005, NEUROLOGY, V65, P1077, DOI 10.1212/01.wnl.0000178890.93795.0e; Hesse C, 2000, NEUROCHEM RES, V25, P511, DOI 10.1023/A:1007516210548; Huhmer AF, 2006, DIS MARKERS, V22, P3; *INT SOC BIOL ENV, 2005, CELL PRESERV TECHNOL, V3, P5; Isoniemi H, 2006, J NEUROTRAUM, V23, P1600, DOI 10.1089/neu.2006.23.1600; Lipsky RH, 2005, J NEUROPSYCH CLIN N, V17, P465, DOI 10.1176/appi.neuropsych.17.4.465; Maurer MH, 2010, MASS SPECTROM REV, V29, P17, DOI 10.1002/mas.20213; Organisation for Economic Co-operation and Development, 2007, OECD BEST PRACT GUID; Ottens AK, 2007, PROG BRAIN RES, V161, P401, DOI 10.1016/S0079-6123(06)61029-7; Pineda JA, 2007, J NEUROTRAUM, V24, P354, DOI 10.1089/neu.2006.003789; Prieto DA, 2008, EXPERT REV PROTEOMIC, V5, P283, DOI 10.1586/14789450.5.2.283; Schrohl AS, 2008, MOL CELL PROTEOMICS, V7, P2061, DOI 10.1074/mcp.R800010-MCP200; Shore PM, 2004, J NEUROTRAUM, V21, P1113; Shores KS, 2007, J PROTEOME RES, V6, P3739, DOI 10.1021/pr070293w; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Teunissen CE, 2009, NEUROLOGY, V73, P1914, DOI 10.1212/WNL.0b013e3181c47cc2; *US DEP HHS NIH, 2007, NIH PUB; Vanderstichele H, 2000, AMYLOID, V7, P245, DOI 10.3109/13506120009146438; Wagner AK, 2007, J NEUROSURG, V106, P538, DOI 10.3171/jns.2007.106.4.538; Xie PX, 2009, ARCH GEN PSYCHIAT, V66, P1201, DOI 10.1001/archgenpsychiatry.2009.153; Zhang J, 2007, PROTEOM CLIN APPL, V1, P805, DOI 10.1002/prca.200700081; Zhou WD, 2008, J NEUROTRAUM, V25, P279, DOI 10.1089/neu.2007.0489	31	78	78	0	8	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	NOV	2010	91	11					1667	1672		10.1016/j.apmr.2010.05.018			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	681UQ	WOS:000284346400006	21044710	Green Published			2021-06-18	
J	Govind, V; Gold, S; Kaliannan, K; Saigal, G; Falcone, S; Arheart, KL; Harris, L; Jagid, J; Maudsley, AA				Govind, Varan; Gold, Stuart; Kaliannan, Krithica; Saigal, Gaurav; Falcone, Steven; Arheart, Kristopher L.; Harris, Leo; Jagid, Jonathan; Maudsley, Andrew A.			Whole-Brain Proton MR Spectroscopic Imaging of Mild-to-Moderate Traumatic Brain Injury and Correlation with Neuropsychological Deficits	JOURNAL OF NEUROTRAUMA			English	Article						brain; magnetic resonance spectroscopic imaging; magnetic resonance spectroscopy; neuropsychological test; traumatic brain injury	MAGNETIC-RESONANCE-SPECTROSCOPY; DIFFUSE AXONAL INJURY; HEAD-INJURY; IN-VIVO; LIPID-SYNTHESIS; ACETYL GROUPS; H-1 MRS; SEVERITY; CT; ABNORMALITIES	Changes in the distribution of the magnetic resonance (MR)-observable brain metabolites N-acetyl aspartate (NAA), total choline (Cho), and total creatine (Cre), following mild-to-moderate closed-head traumatic brain injury (mTBI) were evaluated using volumetric proton MR spectroscopic imaging (MRSI). Studies were carried out during the subacute time period following injury, and associations of metabolite indices with neuropsychological test (NPT) results were evaluated. Twenty-nine subjects with mTBI and Glasgow Coma Scale (GCS) scores of 10-15 were included. Differences in individual metabolite and metabolite ratio distributions relative to those of age-matched control subjects were evaluated, as well as analyses by hemispheric lobes and tissue types. Primary findings included a widespread decrease of NAA and NAA/Cre, and increases of Cho and Cho/NAA, within all lobes of the TBI subject group, and with the largest differences seen in white matter. Examination of the association between all of the metabolite measures and the NPT scores found the strongest negative correlations to occur in the frontal lobe and for Cho/NAA. No significant correlations were found between any of the MRSI or NPT measures and the GCS. These results demonstrate that significant and widespread alterations of brain metabolites occur as a result of mild-to-moderate TBI, and that these measures correlate with measures of cognitive performance.	[Govind, Varan; Kaliannan, Krithica; Saigal, Gaurav; Falcone, Steven; Harris, Leo; Maudsley, Andrew A.] Univ Miami, Sch Med, Dept Radiol, Profess Arts Ctr, Miami, FL 33136 USA; [Harris, Leo; Jagid, Jonathan] Univ Miami, Sch Med, Dept Neurosurg, Miami, FL 33136 USA; [Gold, Stuart] Univ Miami, Sch Med, Dept Neurol, Miami, FL 33136 USA; [Arheart, Kristopher L.] Univ Miami, Sch Med, Dept Epidemiol, Miami, FL 33136 USA	Govind, V (corresponding author), Univ Miami, Sch Med, Dept Radiol, Profess Arts Ctr, 1150 NW 14th St,Suite 713, Miami, FL 33136 USA.	VGovind@med.miami.edu		Govind, Varan/0000-0002-1205-5194; Maudsley, Andrew/0000-0001-7653-3063	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS055107, R01EB000822]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB000822] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS055107] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health grants R01NS055107 and R01EB000822. The authors thank Sulaiman Sheriff for his help in creating the figures.	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Baldo JV, 2001, J INT NEUROPSYCH SOC, V7, P586, DOI 10.1017/S1355617701755063; Bates TE, 1996, NEUROREPORT, V7, P1397, DOI 10.1097/00001756-199605310-00014; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; Benton A., 1994, MULTILINGUAL APHASIA; Bigler ED, 2003, ARCH CLIN NEUROPSYCH, V18, P595; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P227, DOI 10.1016/S0887-6177(00)00081-0; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; BURRI R, 1991, DEV NEUROSCI-BASEL, V13, P403, DOI 10.1159/000112191; Carpentier A, 2006, J NEUROTRAUM, V23, P674, DOI 10.1089/neu.2006.23.674; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Cecil KM, 1998, J NEUROCHEM, V70, P2038; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; Chakraborty G, 2001, J NEUROCHEM, V78, P736, DOI 10.1046/j.1471-4159.2001.00456.x; Collins DL, 1998, IEEE T MED IMAGING, V17, P463, DOI 10.1109/42.712135; Dautry W, 2000, J CEREBR BLOOD F MET, V20, P789, DOI 10.1097/00004647-200005000-00005; Friedman SD, 1998, AM J NEURORADIOL, V19, P1879; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; Frost JA, 1999, BRAIN, V122, P199, DOI 10.1093/brain/122.2.199; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Garnett MR, 2001, J NEUROTRAUM, V18, P231, DOI 10.1089/08977150151070838; Gasparovic C, 2001, J NEUROTRAUM, V18, P241, DOI 10.1089/08977150151070856; Gasparovic C, 2009, J NEUROTRAUM, V26, P1635, DOI [10.1089/neu.2009.0896, 10.1089/neu.2009-0896]; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GOLDBERG E, 1994, J NEUROPSYCH CLIN N, V6, P371; Govindaraju V, 2004, AM J NEURORADIOL, V25, P730; Govindaraju V, 2000, NMR BIOMED, V13, P129, DOI 10.1002/1099-1492(200005)13:3<129::AID-NBM619>3.0.CO;2-V; Halstead WC, 1985, HALSTEAD REITAN NEUR; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Holshouser BA, 2006, J MAGN RESON IMAGING, V24, P33, DOI 10.1002/jmri.20607; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Jones NR, 1998, J CLIN NEUROSCI, V5, P73, DOI 10.1016/S0967-5868(98)90207-7; Kirov I, 2007, BRAIN INJURY, V21, P1147, DOI 10.1080/02699050701630383; Kurca E, 2006, NEURORADIOLOGY, V48, P661, DOI 10.1007/s00234-006-0109-9; Kwok FY, 2008, BRAIN INJURY, V22, P740, DOI 10.1080/02699050802336989; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; Macmillan CSA, 2002, ACTA NEUROCHIR, V144, P853, DOI 10.1007/s00701-002-0966-x; Marino S, 2007, J NEUROL NEUROSUR PS, V78, P501, DOI 10.1136/jnnp.2006.099796; Maudsley AA, 2006, NMR BIOMED, V19, P492, DOI 10.1002/nbm.1025; Maudsley AA, 2009, MAGN RESON MED, V61, P548, DOI 10.1002/mrm.21875; MAUDSLEY AA, 2009, NMR BIOMED, V22, P1; McAllister TW, 2001, J CLIN EXP NEUROPSYC, V23, P775, DOI 10.1076/jcen.23.6.775.1026; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Shutter L, 2004, J NEUROTRAUM, V21, P1693, DOI 10.1089/neu.2004.21.1693; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; Signoretti S, 2002, ACT NEUR S, V81, P373; Signoretti S, 2010, MOL CELL BIOCHEM, V333, P269, DOI 10.1007/s11010-009-0228-9; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; Stroobant N, 2009, BEHAV BRAIN RES, V199, P190, DOI 10.1016/j.bbr.2008.11.040; Uzan M, 2003, J NEUROL NEUROSUR PS, V74, P33, DOI 10.1136/jnnp.74.1.33; Wechsler D., 2002, WAIS 3 WMS 3 TECHNIC; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391	62	78	82	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2010	27	3					483	496		10.1089/neu.2009.1159			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	575PJ	WOS:000276079100003	20201668	Green Published			2021-06-18	
J	Halamek, J; Windmiller, JR; Zhou, J; Chuang, MC; Santhosh, P; Strack, G; Arugula, MA; Chinnapareddy, S; Bocharova, V; Wang, J; Katz, E				Halamek, Jan; Windmiller, Joshua Ray; Zhou, Jian; Chuang, Min-Chieh; Santhosh, Padmanabhan; Strack, Guinevere; Arugula, Mary A.; Chinnapareddy, Soujanya; Bocharova, Vera; Wang, Joseph; Katz, Evgeny			Multiplexing of injury codes for the parallel operation of enzyme logic gates	ANALYST			English	Article							TRAUMATIC BRAIN-INJURY; NOISE-REDUCTION; BIOCHEMICAL LOGIC; LACTATE; NOREPINEPHRINE; BIOSENSOR; GLUCOSE; DEHYDROGENASE; BATTLEFIELD; EPINEPHRINE	The development of a highly parallel enzyme logic sensing concept employing a novel encoding scheme for the determination of multiple pathophysiological conditions is reported. The new concept multiplexes a contingent of enzyme-based logic gates to yield a distinct 'injury code' corresponding to a unique pathophysiological state as prescribed by a truth table. The new concept is illustrated using an array of NAND and AND gates to assess the biomedical significance of numerous biomarker inputs including creatine kinase, lactate dehydrogenase, norepinephrine, glutamate, alanine transaminase, lactate, glucose, glutathione disulfide, and glutathione reductase to assess soft-tissue injury, traumatic brain injury, liver injury, abdominal trauma, hemorrhagic shock, and oxidative stress. Under the optimal conditions, physiological and pathological levels of these biomarkers were detected through either optical or electrochemical techniques by monitoring the level of the outputs generated by each of the six logic gates. By establishing a pathologically meaningful threshold for each logic gate, the absorbance and amperometric assays tendered the diagnosis in a digitally encoded 6-bit word, defined as an 'injury code'. This binary 'injury code' enabled the effective discrimination of 64 unique pathological conditions to offer a comprehensive high-fidelity diagnosis of multiple injury conditions. Such processing of relevant biomarker inputs and the subsequent multiplexing of the logic gate outputs to yield a comprehensive 'injury code' offer significant potential for the rapid and reliable assessment of varied and complex forms of injury in circumstances where access to a clinical laboratory is not viable. While the new concept of parallel and multiplexed enzyme logic gates is illustrated here in connection to multi-injury diagnosis, it could be readily extended to a wide range of practical medical, industrial, security and environmental applications.	[Halamek, Jan; Zhou, Jian; Strack, Guinevere; Arugula, Mary A.; Chinnapareddy, Soujanya; Bocharova, Vera; Katz, Evgeny] Clarkson Univ, Dept Chem & Biomol Sci, Potsdam, NY 13699 USA; [Windmiller, Joshua Ray; Chuang, Min-Chieh; Santhosh, Padmanabhan; Wang, Joseph] Univ Calif San Diego, Dept NanoEngn, La Jolla, CA 92093 USA	Wang, J (corresponding author), Clarkson Univ, Dept Chem & Biomol Sci, Potsdam, NY 13699 USA.	josephwang@ucsd.edu; ekatz@clarkson.edu	Padmanabhan, Santhosh/A-6930-2009; Wang, Joseph/C-6175-2011	Padmanabhan, Santhosh/0000-0003-2418-5284; 	Office of Naval ResearchOffice of Naval Research [N00014-08-1-1202]	This work was supported by the Office of Naval Research (Award #N00014-08-1-1202).	Ahn CH, 2004, P IEEE, V92, P154, DOI 10.1109/JPROC.2003.820548; Bashir R, 2004, ADV DRUG DELIVER REV, V56, P1565, DOI 10.1016/j.addr.2004.03.002; Bhasale A, 1998, FAM PRACT, V15, P308, DOI 10.1093/fampra/15.4.308; Bourner G, 2005, Lab Hematol, V11, P285, DOI 10.1532/LH96.05036; Champion HR, 2003, J TRAUMA, V54, pS13, DOI 10.1097/01.TA.0000057151.02906.27; Clark ME, 2007, J REHABIL RES DEV, V44, P179, DOI 10.1682/JRRD.2006.05.0057; Ettinger A, 1999, ANN THORAC SURG, V68, P2196, DOI 10.1016/S0003-4975(99)00849-8; EYER P, 1986, ANAL BIOCHEM, V153, P57, DOI 10.1016/0003-2697(86)90061-8; Giannoudis PV, 2003, J BONE JOINT SURG BR, V85B, P478, DOI 10.1302/0301-620X.85B4.14217; Katz E, 2010, FOURTH INTERNATIONAL CONFERENCE ON QUANTUM, NANO AND MICRO TECHNOLOGIES: ICQNM 2010, PROCEEDINGS, P1, DOI 10.1109/ICQNM.2010.8; Katz E, 2010, CHEM SOC REV, V39, P1835, DOI 10.1039/b806038j; Keel M, 2005, INJURY, V36, P691, DOI 10.1016/j.injury.2004.12.037; Kline JA, 1997, J MOL CELL CARDIOL, V29, P2465, DOI 10.1006/jmcc.1997.0483; Kratz A, 2004, NEW ENGL J MED, V351, P1548, DOI 10.1056/NEJMcpc049016; KUDSK KA, 1992, ANN SURG, V215, P503, DOI 10.1097/00000658-199205000-00013; Lakstein D, 2003, J TRAUMA, V54, pS221, DOI 10.1097/01.TA.0000047227.33395.49; LANZINO G, 1993, J NEUROSURG, V79, P885, DOI 10.3171/jns.1993.79.6.0885; Ligler FS, 2007, ANAL SCI, V23, P5, DOI 10.2116/analsci.23.5; Ling GSF, 1999, P SOC PHOTO-OPT INS, V3712, P1, DOI 10.1117/12.353012; Manesh KM, 2009, BIOSENS BIOELECTRON, V24, P3569, DOI 10.1016/j.bios.2009.05.019; MANGER WM, 1957, AM J PHYSIOL, V190, P310; Maynard ND, 1997, CHEST, V111, P180, DOI 10.1378/chest.111.1.180; Melnikov D, 2009, J PHYS CHEM B, V113, P10472, DOI 10.1021/jp904585x; MICHAELI D, 1979, J ROY SOC MED, V72, P370; Moser I, 2002, BIOSENS BIOELECTRON, V17, P297, DOI 10.1016/S0956-5663(01)00298-6; Moser I, 1997, SENSOR ACTUAT B-CHEM, V44, P377, DOI 10.1016/S0925-4005(97)00228-1; OLERUD JE, 1976, ARCH INTERN MED, V136, P692, DOI 10.1001/archinte.136.6.692; Papa Linda, 2008, Expert Opin Med Diagn, V2, P937, DOI 10.1517/17530059.2.8.937; Pineda JA, 2004, BRAIN PATHOL, V14, P202, DOI 10.1111/j.1750-3639.2004.tb00054.x; Pita M, 2009, SENSOR ACTUAT B-CHEM, V139, P631, DOI 10.1016/j.snb.2009.03.001; PRASAD MR, 1994, J NEUROCHEM, V63, P1086; Privman M, 2009, J AM CHEM SOC, V131, P1314, DOI 10.1021/ja8088108; Privman V, 2008, J PHYS CHEM B, V112, P11777, DOI 10.1021/jp802673q; Privman V, 2009, BIOSENS BIOELECTRON, V25, P695, DOI 10.1016/j.bios.2009.08.014; Privman V, 2009, J PHYS CHEM B, V113, P5301, DOI 10.1021/jp810743w; RIGNAULT DP, 1992, WORLD J SURG, V16, P940, DOI 10.1007/BF02066996; ROSENBERG J, 1961, ANN SURG, V154, P611, DOI 10.1097/00000658-196110000-00011; Rossi R, 2002, CLIN CHEM, V48, P742; Scott SG, 2006, J AM OSTEOPATH ASSOC, V106, P265; Sies H, 1997, EXP PHYSIOL, V82, P291, DOI 10.1113/expphysiol.1997.sp004024; SPRULES SD, 1995, ANAL CHIM ACTA, V304, P17, DOI 10.1016/0003-2670(94)00565-4; Strack G, 2008, CHEMBIOCHEM, V9, P1260, DOI 10.1002/cbic.200700762; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Tam TK, 2009, SENSOR ACTUAT B-CHEM, V140, P1, DOI 10.1016/j.snb.2009.04.010; Tan KK, 2009, INJURY, V40, P978, DOI 10.1016/j.injury.2009.02.023; Thevenot DR, 2001, ANAL LETT, V34, P635, DOI 10.1081/AL-100103209; WANG J, 1994, ANAL CHEM, V66, P1007, DOI 10.1021/ac00079a013; Wang J, 2010, ANAL BIOANAL CHEM, V398, P1591, DOI 10.1007/s00216-010-3746-0; Wedmore I, 2006, J TRAUMA, V60, P655, DOI 10.1097/01.ta.0000199392.91772.44; Weinstein T, 2000, NEPHROL DIAL TRANSPL, V15, P883, DOI 10.1093/ndt/15.6.883; Wheeler AP, 1999, NEW ENGL J MED, V340, P207, DOI 10.1056/NEJM199901213400307; Wilson M, 2003, J EMERG MED, V24, P413, DOI 10.1016/S0736-4679(03)00042-8; WINTERBORN RJ, 2003, SURGERY OXFORD, V21, pA240, DOI DOI 10.1383/SURG.21.9.240.16923; Zhou J, 2009, J PHYS CHEM B, V113, P16065, DOI 10.1021/jp9079052; Zink BJ, 1999, BRAIN RES, V837, P1, DOI 10.1016/S0006-8993(99)01646-7	55	78	78	0	23	ROYAL SOC CHEMISTRY	CAMBRIDGE	THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND	0003-2654	1364-5528		ANALYST	Analyst		2010	135	9					2249	2259		10.1039/c0an00270d			11	Chemistry, Analytical	Chemistry	639WM	WOS:000281007300008	20617272				2021-06-18	
J	Iverson, GL; Brooks, BL; Ashton, VL; Lange, RT				Iverson, Grant L.; Brooks, Brian L.; Ashton, V. Lynn; Lange, Rael T.			Interview Versus Questionnaire Symptom Reporting in People With the Postconcussion Syndrome	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						mild traumatic brain injury; open-ended interview; postconcussion syndrome; recall bias	TRAUMATIC BRAIN-INJURY; POST-CONCUSSION SYNDROME; EMOTIONAL RISK-FACTORS; COMPLAINT BASE RATES; MILD HEAD-INJURY; COGNITIVE PERFORMANCE; DIAGNOSIS THREAT; SELF-REPORT; EXPECTATION; NOCEBO	Objective: To compare spontaneous, interview-based, postconcussion symptom reporting to endorsement of symptoms on a standardized questionnaire. Participants: Sixty-one patients referred to a concussion clinic following mild traumatic brain injury. Procedure: Patients recalled their current symptoms and problems via open-ended interview and then completed a structured postconcussion checklist. Main Outcome Measures: Open-ended interview and the British Columbia Postconcussion Symptom Inventory (BC-PSI). Results: On average, patients endorsed 3.3 symptoms (SD = 1.9) during open-ended interview and 9.1 symptoms (SD = 3.2) on the BC-PSI (P < .001). Approximately 44% endorsed 4 or more symptoms during interview compared with 92% on the BC-PSI. The percentage of patients endorsing items on the BC-PSI compared with interview was significantly greater on all 13 items. It was common for patients to endorse symptoms as moderate-severe on the BC-PSI, despite not spontaneously reporting those symptoms during the interview. Conclusions: Clinicians need to be cautious when interpreting questionnaires and be aware of the possibility of nonspecific symptom endorsement, symptom overendorsement, symptom expectations influencing symptom endorsement, and the nocebo effect.	[Iverson, Grant L.] Univ British Columbia, Dept Psychiat, Vancouver, BC V6T 2A1, Canada; [Iverson, Grant L.; Lange, Rael T.] British Columbia Mental Hlth & Addict Serv, Vancouver, BC, Canada; [Ashton, V. Lynn] Coquitlam & Royal Columbian Hosp, Fraser Hlth Concuss Clin, New Westminster, BC, Canada; [Brooks, Brian L.] Univ Calgary, Calgary, AB T2N 1N4, Canada	Iverson, GL (corresponding author), Univ British Columbia, Dept Psychiat, 2255 Wesbrook Mall, Vancouver, BC V6T 2A1, Canada.	giverson@interchange.ubc.ca		Iverson, Grant/0000-0001-7348-9570	University of British Columbia Behavioural Research Ethics Board	This research was granted ethical clearance by the University of British Columbia Behavioural Research Ethics Board.	Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Boake C, 2005, NEUROSURGERY, V56, P994, DOI 10.1227/01.NEU.0000158319.38230.C3; Boake C, 2004, J NEUROPSYCH CLIN N, V16, P493, DOI 10.1176/appi.neuropsych.16.4.493; Bootzin RR, 2005, J CLIN PSYCHOL, V61, P871, DOI 10.1002/jclp.20131; Bowling A, 2005, J PUBLIC HEALTH-UK, V27, P281, DOI 10.1093/pubmed/fdi031; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Davis CH, 2002, AM J PHYS MED REHAB, V81, P609, DOI 10.1097/00002060-200208000-00009; DUNN JT, 1995, J CLIN PSYCHOL, V51, P577, DOI 10.1002/1097-4679(199507)51:4<577::AID-JCLP2270510418>3.0.CO;2-E; Evans RW, 2003, HEADACHE, V43, P1113, DOI 10.1046/j.1526-4610.2003.03216.x; Evered L, 2003, ASSESSMENT, V10, P420, DOI 10.1177/1073191103259539; Ferguson RJ, 1999, NEUROPSYCHOLOGY, V13, P582, DOI 10.1037/0894-4105.13.4.582; Foa EB, 1997, PSYCHOL ASSESSMENT, V9, P445, DOI 10.1037/1040-3590.9.4.445; FOX DD, 1995, CLIN NEUROPSYCHOL, V9, P89, DOI 10.1080/13854049508402064; Gasquoine P G, 2000, Appl Neuropsychol, V7, P83, DOI 10.1207/S15324826AN0702_3; GERBER DJ, 1995, J HEAD TRAUMA REHAB, V10, P28, DOI 10.1097/00001199-199508000-00004; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; Greiffenstein MF, 2001, CLIN NEUROPSYCHOL, V15, P162, DOI 10.1076/clin.15.2.162.1895; Gunstad J, 2004, ARCH CLIN NEUROPSYCH, V19, P391, DOI 10.1016/S0887-6177(03)00073-8; Gunstad J, 2001, J INT NEUROPSYCH SOC, V7, P323, DOI 10.1017/S1355617701733061; GURNEY JG, 1992, J TRAUMA, V33, P709, DOI 10.1097/00005373-199211000-00020; Hahn RA, 1997, PREV MED, V26, P607, DOI 10.1006/pmed.1996.0124; Hibbard MR, 2000, BRAIN INJURY, V14, P45, DOI 10.1080/026990500120925; Hilsabeck RC, 1998, J CLIN EXP NEUROPSYC, V20, P328, DOI 10.1076/jcen.20.3.328.813; Homsi J, 2006, SUPPORT CARE CANCER, V14, P444, DOI 10.1007/s00520-005-0009-2; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Iverson GL, 2004, STUD NEUROPSYCHOL DE, P323; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Kashluba S, 2006, J INT NEUROPSYCH SOC, V12, P111, DOI 10.1017/S1355617706060036; KENNEDY W P, 1961, Med World, V95, P203; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; Machulda MM, 1998, ARCH CLIN NEUROPSYCH, V13, P415, DOI 10.1016/S0887-6177(97)00031-0; MCCAULEY SR, 2007, J CLIN EXP NEUROPSYC, V30, P1; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Mickeviciene D, 2004, EUR J NEUROL, V11, P411, DOI 10.1111/j.1468-1331.2004.00816.x; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Nolin P, 2006, BRAIN INJURY, V20, P1147, DOI 10.1080/02699050601049247; RADANOV BP, 1992, SPINE, V17, P127, DOI 10.1097/00007632-199202000-00001; Rees PM, 2003, ARCH PHYS MED REHAB, V84, P1885, DOI 10.1016/j.apmr.2003.03.001; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Ryder AG, 2008, J ABNORM PSYCHOL, V117, P300, DOI 10.1037/0021-843X.117.2.300; Sawchyn JM, 2000, ARCH CLIN NEUROPSYCH, V15, P1, DOI 10.1016/S0887-6177(98)00041-9; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Stapleton E, 2008, J LARYNGOL OTOL, V122, P139, DOI 10.1017/S0022215107009073; Suhr JA, 2005, J INT NEUROPSYCH SOC, V11, P23, DOI 10.1017/S1355617705050010; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P448, DOI 10.1076/jcen.24.4.448.1039; Trahan DE, 2001, ARCH CLIN NEUROPSYCH, V16, P435, DOI 10.1016/S0887-6177(00)00051-2; Tsanadis J, 2008, CLIN NEUROPSYCHOL, V22, P1080, DOI 10.1080/13854040701796928; Wang Y, 2006, ARCH CLIN NEUROPSYCH, V21, P339, DOI 10.1016/j.acn.2006.03.006; WONG JL, 1994, ARCH CLIN NEUROPSYCH, V9, P411, DOI 10.1016/0887-6177(94)90004-3; World Health Organization, 1992, ICD 10 INT STAT CLAS	55	78	79	0	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2010	25	1					23	30		10.1097/HTR.0b013e3181b4b6ab			8	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	550XC	WOS:000274165800004	19680134				2021-06-18	
J	Wolfe, PL; Millis, SR; Hanks, R; Fichtenberg, N; Larrabee, GJ; Sweet, JJ				Wolfe, Penny L.; Millis, Scott R.; Hanks, Robin; Fichtenberg, Norman; Larrabee, Glenn J.; Sweet, Jerry J.			Effort Indicators within the California Verbal Learning Test-II (CVLT-II)	CLINICAL NEUROPSYCHOLOGIST			English	Article						Effort indicators; CVLT-II; Malingering	TRAUMATIC BRAIN-INJURY; MILD HEAD-INJURY; MALINGERED NEUROCOGNITIVE DYSFUNCTION; ADULT INTELLIGENCE SCALE; RECOGNITION MEMORY TEST; MODEL SELECTION; PERFORMANCE PATTERNS; INCOMPLETE EFFORT; RESPONSE BIAS; IDENTIFICATION	This study determined whether performance patterns on the California Verbal Learning Test-II (CVLT-II) could differentiate participants with traumatic brain injury (TBI) showing adequate effort from those with mild TBI exhibiting poor effort using a case-control design. The TBI group consisted of 124 persons with moderate to severe traumatic brain injury (TBI). The poor effort group consisted of 77 persons with mild head injury who were involved in litigation (LG) and failed at least one stand-alone symptom validity measure (SVT) and also either a second SVT or an effort indicator embedded within a standard clinical test. A total of 18 CVLT-II variables were investigated using Bayesian model averaging (BMA) for logistic regression to determine which variables best differentiated the groups. The CVLT-II variables having the most support were Long-Delay Free Recall, Total Recognition Discriminability (d'), and Total Recall Discriminability.	[Wolfe, Penny L.; Millis, Scott R.; Hanks, Robin; Fichtenberg, Norman] Rehabil Inst Michigan, Detroit, MI USA; [Wolfe, Penny L.; Millis, Scott R.; Hanks, Robin; Fichtenberg, Norman] Wayne State Univ, Sch Med, Detroit, MI USA; [Sweet, Jerry J.] Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA	Wolfe, PL (corresponding author), Natl Rehabil Hosp, Dept Psychol, 102 Irving St NW, Washington, DC 20010 USA.	penny.wolfe@medstar.net					Ashendorf L, 2003, CLIN NEUROPSYCHOL, V17, P255, DOI 10.1076/clin.17.2.255.16502; Bauer L, 2005, APPL NEUROPSYCHOL, V12, P202, DOI 10.1207/s15324826an1204_3; BINDER LM, 1993, ARCH CLIN NEUROPSYCH, V8, P137, DOI 10.1016/0887-6177(93)90031-U; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; CONDOR R, 1992, COMPUTERIZED ASSESSM; Corwin J, 1994, NEUROPSYCHOLOGY, V8, P110, DOI 10.1037/0894-4105.8.1.110; Curtis KL, 2006, ASSESSMENT, V13, P46, DOI 10.1177/1073191105285210; Delis DC, 2000, CALIFORNIA VERBAL LE; Delis DC, 1987, CALIFORNIA VERBAL LE; Forrest TJ, 2004, CLIN NEUROPSYCHOL, V18, P334, DOI 10.1080/13854040490501673; Green P., 2003, GREENS WORD MEMORY T; GREEN P, 1996, WORD MEMORY TEST MAN; Greiffenstein M F, 1996, J Int Neuropsychol Soc, V2, P477; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve KW, 2008, CLIN NEUROPSYCHOL, V22, P896, DOI 10.1080/13854040701565208; Harrell Frank E., 2001, REGRESSION MODELING; Hoeting JA, 1999, STAT SCI, V14, P382, DOI 10.1214/ss/1009212519; Hosmer D. W., 2000, APPL LOGISTIC REGRES; Iverson GL, 2003, ARCH CLIN NEUROPSYCH, V18, P1, DOI 10.1016/S0887-6177(01)00176-7; KASS RE, 1995, J AM STAT ASSOC, V90, P773, DOI 10.1080/01621459.1995.10476572; Killgore WDS, 2000, J CLIN EXP NEUROPSYC, V22, P761; King JH, 2002, CLIN NEUROPSYCHOL, V16, P506, DOI 10.1076/clin.16.4.506.13912; Langeluddecke PM, 2003, ARCH CLIN NEUROPSYCH, V18, P181, DOI 10.1016/S0887-6177(01)00195-0; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ, 2008, CLIN NEUROPSYCHOL, V22, P666, DOI 10.1080/13854040701494987; Larrabee GJ, 2009, CLIN NEUROPSYCHOL, V23, P167, DOI 10.1080/13854040801968443; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Lu PH, 2003, CLIN NEUROPSYCHOL, V17, P426, DOI 10.1076/clin.17.3.426.18083; MADIGAN D, 1994, J AM STAT ASSOC, V89, P1535, DOI 10.2307/2291017; Meyers JE, 1998, APPL NEUROPSYCHOL, V5, P120, DOI 10.1207/s15324826an0503_2; Millis S. R., 2004, PRINCIPLES PRACTICE, P1077; Millis SR, 1995, PSYCHOL ASSESSMENT, V7, P463; Millis SR, 2001, J CLIN EXP NEUROPSYC, V23, P809, DOI 10.1076/jcen.23.6.809.1017; MILLIS SR, 1994, PERCEPT MOTOR SKILL, V79, P384, DOI 10.2466/pms.1994.79.1.384; Millis SR., 2001, J FORENSIC NEUROPSYC, V2, P1, DOI [10.1300/J151v02n01_01, DOI 10.1300/J151V02N01_]; MILLIS SR, 1992, CLIN NEUROPSYCHOL, V6, P406; MITTENBERG W, 1995, PROF PSYCHOL-RES PR, V26, P491, DOI 10.1037/0735-7028.26.5.491; Mittenberg W, 2001, CLIN NEUROPSYCHOL, V15, P440; R Development Core Team, 2007, R LANG ENV STAT COMP; Raftery AE, 1995, SOCIOL METHODOL, V25, P111, DOI 10.2307/271063; REITAN RM, 2002, J FORENSIC NEUROPSYC, V3, P275; Rey A, 1964, EXAMEN CLIN PSYCHOL; Reynolds CR, 1998, CRIT ISS NE, P261; Slick D., 1997, VICTORIA SYMPTOM VAL; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Sullivan K, 2002, ARCH CLIN NEUROPSYCH, V17, P223, DOI 10.1016/S0887-6177(01)00110-X; Sweet J. J., 2002, J FORENSIC NEUROPSYC, V3, P241; Sweet JJ, 1999, STUD NEUROPSYCHOL DE, P255; Sweet JJ, 2000, ARCH CLIN NEUROPSYCH, V15, P105, DOI 10.1016/S0887-6177(98)00153-X; Tombaugh TN, 1996, TEST MEMORY MALINGER; TRUEBLOOD W, 1994, J CLIN EXP NEUROPSYC, V16, P597, DOI 10.1080/01688639408402671; TRUEBLOOD W, 1993, J CLIN EXP NEUROPSYC, V15, P578, DOI 10.1080/01688639308402580; Viallefont V, 2001, STAT MED, V20, P3215, DOI 10.1002/sim.976.abs; Vickery CD, 2001, ARCH CLIN NEUROPSYCH, V16, P45, DOI 10.1016/S0887-6177(99)00058-X; Wang DL, 2004, STAT MED, V23, P3451, DOI 10.1002/sim.1930; Wasserman L, 2000, J MATH PSYCHOL, V44, P92, DOI 10.1006/jmps.1999.1278; Willis SC., 1991, PSYCHOL ASSESSMENT J, V3, P175, DOI [10.1037/1040-3590.3.2.175, DOI 10.1037/1040-3590.3.2.175]	57	78	79	0	17	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2010	24	1					153	168	PII 914741366	10.1080/13854040903107791			16	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	535MK	WOS:000272972300012	19750408				2021-06-18	
J	Chastain, CA; Oyoyo, UE; Zipperman, M; Joo, E; Ashwal, S; Shutter, LA; Tong, KA				Chastain, Cody A.; Oyoyo, Udochukwu E.; Zipperman, Michelle; Joo, Elliot; Ashwal, Stephen; Shutter, Lori A.; Tong, Karen A.			Predicting Outcomes of Traumatic Brain Injury by Imaging Modality and Injury Distribution	JOURNAL OF NEUROTRAUMA			English	Article						brain regions; CT; FLAIR; MRI; outcomes; SWI; TBI; T2	DIFFUSE AXONAL INJURY; WHITE-MATTER INJURY; CLOSED-HEAD INJURY; STEM LESIONS; CLINICAL-APPLICATIONS; COMPUTED-TOMOGRAPHY; MR; CT; VENOGRAPHY; CLASSIFICATION	Early prediction of outcomes after traumatic brain injury (TBI) is often difficult. To improve prognostic accuracy soon after trauma, we compared different radiological modalities and anatomical injury distribution in a group of adult TBI patients. The four methods studied were computed tomography (CT), magnetic resonance imaging (MRI) with T2-weighted imaging (T2WI), fluid-attenuated inversion recovery (FLAIR) imaging, and susceptibility weighted imaging (SWI). The objective of this study was to identify which modality and anatomic model best predict outcome. The patient population consisted of 38 adults admitted between February 2001 and May 2003. Early CT, T2WI, FLAIR, and SWI were obtained for each patient as well as a Glasgow Outcome Score (GOS) between 0.1 and 22 months (mean 9.2 months) after injury. Using a semi-automated computer method, intraparenchymal lesions were traced, measured, and converted to lesion volumes based on slice thickness and pixel size. Lesions were assigned to zones and regions. Outcomes were dichotomized into good (GOS 4-5) and poor (GOS 1-3) outcome groups. Brain injury detected by imaging was analyzed by median total lesion volume, median volume per lesion, and median number of lesions per outcome group. T2WI and FLAIR imaging most consistently discriminated between good and poor outcomes by median total lesion volume, median volume per lesion, and median number of lesions. In addition, T2WI and FLAIR imaging most consistently discriminated between good and poor outcomes by zonal distribution. While SWI rarely discriminated by outcome, it was very sensitive to intraparenchymal injury and its optimal use in evaluating TBI is unclear. SWI and other new imaging modalities should be further studied to fully evaluate their prognostic utility in TBI evaluation.	[Oyoyo, Udochukwu E.; Tong, Karen A.] Loma Linda Univ, Med Ctr, Dept Radiol, Div Neuroradiol, Loma Linda, CA 92354 USA; [Joo, Elliot] Loma Linda Univ, Med Ctr, Dept Med, Loma Linda, CA 92354 USA; [Chastain, Cody A.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; [Zipperman, Michelle] Univ So Calif, Keck Sch Med, Dept Radiol, Los Angeles, CA 90033 USA; [Ashwal, Stephen] Loma Linda Univ, Childrens Hosp, Div Child Neurol, Dept Pediat, Loma Linda, CA 92354 USA; [Shutter, Lori A.] Univ Cincinnati, Dept Neurosurg, Cincinnati, OH USA; [Shutter, Lori A.] Univ Cincinnati, Dept Neurol, Cincinnati, OH USA	Tong, KA (corresponding author), Loma Linda Univ, Med Ctr, Dept Radiol, Div Neuroradiol, 11234 Anderson St, Loma Linda, CA 92354 USA.	ktong@.llu.edu	Shutter, Lori A/G-2957-2013	Shutter, Lori/0000-0002-1390-0628			Ashikaga R, 1997, NEURORADIOLOGY, V39, P239, DOI 10.1007/s002340050401; Ashwal S, 2006, ARCH PHYS MED REHAB, V87, pS50, DOI 10.1016/j.apmr.2006.07.275; Bhatoe HS, 1999, ACTA NEUROCHIR, V141, P515, DOI 10.1007/s007010050333; CHO ZH, 1992, MAGNET RESON MED, V28, P25, DOI 10.1002/mrm.1910280104; de la Plata CM, 2007, J NEUROTRAUM, V24, P591, DOI 10.1089/neu.2006.0214; Eder HG, 2000, CHILD NERV SYST, V16, P21, DOI 10.1007/s003810050005; Firsching R, 2002, NEUROL RES, V24, P145, DOI 10.1179/016164102101199684; Firsching R, 2001, ACTA NEUROCHIR, V143, P263; Gerber DJ, 2004, BRAIN INJURY, V18, P1083, DOI 10.1080/02699050410001672341; HASHIMOTO T, 1993, NEUROSURG REV, V16, P291, DOI 10.1007/BF00383839; Hoelper BM, 2000, ACTA NEUROCHIR SUPPL, V76, P21; Hou DJ, 2007, J NEUROTRAUM, V24, P1558, DOI 10.1089/neu.2007.0339; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; JENNETT B, 1975, LANCET, V1, P480; KELLY AB, 1988, AM J NEURORADIOL, V9, P699; KIDO DK, 1992, RADIOLOGY, V182, P777, DOI 10.1148/radiology.182.3.1535893; King JT, 2005, J NEUROTRAUM, V22, P947, DOI 10.1089/neu.2005.22.947; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Langbein John H., 2006, TRAUMATIC BRAIN INJU, P1; Lee BCP, 1999, AM J NEURORADIOL, V20, P1239; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; LEVIN HS, 1988, J NEUROSURG, V69, P861, DOI 10.3171/jns.1988.69.6.0861; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; Mannion RJ, 2007, J NEUROTRAUM, V24, P128, DOI 10.1089/neu.2006.0127; Morrison Wynne E, 2004, Pediatr Crit Care Med, V5, P145, DOI 10.1097/01.PCC.0000112373.71645.2A; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Ogawa T, 1992, Acta Neurochir Suppl (Wien), V55, P8; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; ORRISON WW, 1994, AM J NEURORADIOL, V15, P351; Reichenbach JR, 1997, RADIOLOGY, V204, P272, DOI 10.1148/radiology.204.1.9205259; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Scheid R, 2007, J NEUROTRAUM, V24, P1811, DOI 10.1089/neu.2007.0382; Sehgal V, 2005, J MAGN RESON IMAGING, V22, P439, DOI 10.1002/jmri.20404; Shen YM, 2007, MAGN RESON IMAGING, V25, P219, DOI 10.1016/j.mri.2006.09.018; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Sigmund GA, 2007, PEDIATR NEUROL, V36, P217, DOI 10.1016/j.pediatrneurol.2007.01.003; Tong KA, 2008, AM J NEURORADIOL, V29, P9, DOI 10.3174/ajnr.A0786; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; TSAI FY, 1980, J COMPUT ASSIST TOMO, V4, P291, DOI 10.1097/00004728-198006000-00002; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; Wardlaw JM, 2002, J NEUROL NEUROSUR PS, V72, P188, DOI 10.1136/jnnp.72.2.188; Wedekind C, 2002, BRIT J NEUROSURG, V16, P256, DOI 10.1080/02688690220148842; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208	46	78	84	0	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2009	26	8					1183	1196		10.1089/neu.2008.0650			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	479AF	WOS:000268629900002	19317591				2021-06-18	
J	Pape, TLB; Rosenow, J; Lewis, G; Ahmed, G; Walker, M; Guernon, A; Roth, H; Patil, V				Pape, Theresa Louise-Bender; Rosenow, Joshua; Lewis, Gwyn; Ahmed, Ghada; Walker, Matthew; Guernon, Ann; Roth, Heidi; Patil, Vijaya			Repetitive transcranial magnetic stimulation-associated neurobehavioral gains during coma recovery	BRAIN STIMULATION			English	Article						neual stimulation; coma; treatment; intervention; traumatic brain injury	MINIMALLY CONSCIOUS STATES; EVENT-RELATED POTENTIALS; EVOKED POTENTIALS; PREFRONTAL CORTEX; VEGETATIVE STATE; ATTENTION; NEUROPATHOLOGY; NETWORKS	Background Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive method to induce changes in cortical neural excitability. This report presents findings from the first participant of a safety and efficacy study that examined a therapeutic rTMS protocol for persons with severe traumatic brain injury (TBI). Objective The primary hypothesis was that there will be no adverse events related to the provision of a 6-week rTMS protocol for persons with severe TBI who remain, at best, in a minimally conscious state for longer than 3 months. The secondary hypothesis was that the rTMS protocol Would induce significant neurobehavioral gains during treatment and that these gains would persist at 6-week follow-up. Methods A 6-week rTMS protocol (30 sessions) was delivered to a 26-year-old man who remained in a vegetative state 287 days after severe TBI. Stimulation was directed over the right dorsolateral prefrontal cortex. Repeated safety measures, neurobehavioral assessments, clinical examinations, and evoked potentials (EP) were obtained at baseline, every fifth rTMS session (weekly), and at a 6-week follow-up. Results There were no adverse events related to the provision of rTMS treatment. A trend toward significant (P = .066) neurobehavioral gains was temporally related to provision of rTMS. Left-sided brain stem auditory EP wave V latencies and waves I to V interpeak latencies improved along with neurobehavioral gains during provision of rTMS, suggesting that improved neural conduction in the pathway Mediated the neurobehavioral improvements. Conclusions Repetitive TMS merits further investigation as a safe therapeutic intervention to after neural activity, to modulate neural activity, and/or to facilitate recovery in persons with disordered consciousness subsequent to severe TBI. (C) 2009 Elsevier Inc. All rights reserved.	[Pape, Theresa Louise-Bender; Patil, Vijaya] Edward Hines Jr VA Hosp, Res Serv, Dept Vet Affairs, Hines, IL 60141 USA; [Pape, Theresa Louise-Bender; Guernon, Ann] Marianjoy Rehabil Hosp, Wheaton, IL USA; [Pape, Theresa Louise-Bender; Lewis, Gwyn; Ahmed, Ghada] Northwestern Univ, Feinberg Sch Med, Dept Phys Med & Rehabil, Chicago, IL USA; [Pape, Theresa Louise-Bender] Northwestern Univ, Feinberg Sch Med, Inst Hlth Care Studies, Chicago, IL USA; [Pape, Theresa Louise-Bender; Lewis, Gwyn; Ahmed, Ghada] Northwestern Univ, Feinberg Sch Med, Dept Neurosurg, Chicago, IL USA; [Lewis, Gwyn] AUT Univ, Hlth & Rehabil Res Ctr, Auckland, New Zealand; [Lewis, Gwyn; Roth, Heidi] Rehabil Inst Chicago, Chicago, IL 60611 USA; [Walker, Matthew] Northwestern Univ, Feinberg Sch Med, Dept Radiol, Chicago, IL USA; [Walker, Matthew] NW Mem Hosp, Dept Neuroradiol, Chicago, IL 60611 USA; [Patil, Vijaya] Loyola Univ, Med Ctr, Maywood, IL 60153 USA	Pape, TLB (corresponding author), Edward Hines Jr VA Hosp, Res Serv, Dept Vet Affairs, POB 5000,MC 151H, Hines, IL 60141 USA.	Theresa.Pape@va.gov		Bender Pape, Theresa/0000-0001-7738-5963	Department of Veterans Affairs, Office of Research and Development, Rehabilitation Research and Development ServiceUS Department of Veterans Affairs [B3302K, B4949N]; General Clinical Research Center (GCRC) of Northwestern University Feinberg School of MedicineUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR); National Center for Research ResourcesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01 RR-00048]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000048] Funding Source: NIH RePORTER	Funding was provided by the Department of Veterans Affairs, Office of Research and Development, Rehabilitation Research and Development Service through an advanced research career development award (B3302K) and a career development transition award (B4949N). The research described in this article was also supported by the General Clinical Research Center (GCRC) of Northwestern University Feinberg School of Medicine. The GCRC is supported by Grant M01 RR-00048 from the National Center for Research Resources, National Institutes of Health. The Nick Kot Charity, a not-for-profit, also provided an unrestricted grant to support this project. Substantial in-kind contributions from the Departments of Neurosurgery and Physical Medicine and Rehabilitation, of Northwestern University Feinberg School of Medicine, and Marianjoy Rehabilitation Hospital also made this research possible. Additional in-kind contributions from Northwestern Memorial Hospital and the Rehabilitation Institute of Chicago are appreciated.	Adams JH, 1999, J CLIN PATHOL, V52, P804, DOI 10.1136/jcp.52.11.804; Cohen E, 1999, J NEUROL NEUROSUR PS, V67, P129, DOI 10.1136/jnnp.67.1.129; Di Lazzaro V, 2007, CLIN NEUROPHYSIOL, V118, P1193, DOI 10.1016/j.clinph.2007.02.020; Eker C, 2000, BRAIN INJURY, V14, P605; George MS, 2003, NEUROSURG CLIN N AM, V14, P283, DOI 10.1016/S1042-3680(02)00120-1; Giacino J, 2005, J HEAD TRAUMA REHAB, V20, P30, DOI 10.1097/00001199-200501000-00005; Giacino JT, 1997, J HEAD TRAUMA REHAB, V12, P36, DOI 10.1097/00001199-199708000-00005; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; GOLDMANRAKIC PS, 1984, TRENDS NEUROSCI, V7, P419, DOI 10.1016/S0166-2236(84)80146-0; GOLDMANRAKIC PS, 1988, ANNU REV NEUROSCI, V11, P137, DOI 10.1146/annurev.neuro.11.1.137; Harris-Love ML, 2006, ARCH PHYS MED REHAB, V87, pS84, DOI 10.1016/j.apmr.2006.08.330; Hausmann A, 2004, J CLIN PSYCHIAT, V65, P772; Jennett B, 2001, NEUROLOGY, V56, P486, DOI 10.1212/WNL.56.4.486; Jorge RE, 2004, BIOL PSYCHIAT, V55, P398, DOI 10.1016/j.biopsych.2003.08.017; Laureys S, 2004, LANCET NEUROL, V3, P537, DOI 10.1016/S1474-4422(04)00852-X; Laureys S, 1999, NEUROIMAGE, V9, P377, DOI 10.1006/nimg.1998.0414; Lew HL, 2006, J HEAD TRAUMA REHAB, V21, P350, DOI 10.1097/00001199-200607000-00006; Lew HL, 2004, AM J PHYS MED REHAB, V83, P210, DOI 10.1097/01.PHM.0000113402.85460.59; Lew HL, 2003, AM J PHYS MED REHAB, V82, P53, DOI 10.1097/01.PHM.0000043771.90606.81; LINACRE M, 1999, WINSTEPS; MESULAM MM, 1981, ANN NEUROL, V10, P309, DOI 10.1002/ana.410100402; MESULAM MM, 1990, ANN NEUROL, V28, P597, DOI 10.1002/ana.410280502; Muri RM, 1996, J NEUROPHYSIOL, V76, P2102; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Owen AM, 2006, SCIENCE, V313, P1402, DOI 10.1126/science.1130197; PAPE T, PHYS MED RE IN PRESS; Pape T, 2006, J HEAD TRAUMA REHAB, V21, P417, DOI 10.1097/00001199-200609000-00025; Pape TLB, 2006, J HEAD TRAUMA REHAB, V21, P437, DOI 10.1097/00001199-200609000-00063; Pape TLB, 2005, J REHABIL RES DEV, V42, P19, DOI 10.1682/JRRD.2004.03.0033; Pape TLB, 2005, J REHABIL RES DEV, V42, P1, DOI 10.1682/JRRD.2004.03.0032; Pascual-Leone A., 2002, HDB TRANSCRANIAL MAG; PascualLeone A, 1996, NEUROLOGY, V46, P499, DOI 10.1212/WNL.46.2.499; Schiff ND, 2005, NEUROLOGY, V64, P514, DOI 10.1212/01.WNL.0000150883.10285.44; Schiff ND, 2002, BRAIN, V125, P1210, DOI 10.1093/brain/awf131; Thickbroom GW, 2006, CLIN NEUROPHYSIOL, V117, P61, DOI 10.1016/j.clinph.2005.09.010; Wagner M, 2006, J PSYCHIATR RES, V40, P315, DOI 10.1016/j.jpsychires.2005.06.001; Wassermann EM, 1996, ELECTROMYOGR MOTOR C, V101, P412; Wassermann EM, 2001, CLIN NEUROPHYSIOL, V112, P1367, DOI 10.1016/S1388-2457(01)00585-5	38	78	79	0	14	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1935-861X	1876-4754		BRAIN STIMUL	Brain Stimul.	JAN	2009	2	1					22	35		10.1016/j.brs.2008.09.004			14	Clinical Neurology; Neurosciences	Neurosciences & Neurology	406OG	WOS:000263304200004	20633400				2021-06-18	
J	Muscara, F; Catroppa, C; Anderson, V				Muscara, Frank; Catroppa, Cathy; Anderson, Vicki			Social problem-solving skills as a mediator between executive function and long-term social outcome following paediatric traumatic brain injury	JOURNAL OF NEUROPSYCHOLOGY			English	Article							SEVERE HEAD-INJURY; CHILDREN; COMPETENCE; ADJUSTMENT; CHILDHOOD; MODELS	There is debate regarding the relationship between executive function and social outcome following paediatric traumatic brain injury (TBI), due to inconsistent findings in the literature. It has been suggested that these contradictory results may reflect the absence of an established mechanism to explain this relationship. Yeates and colleagues (2004) proposed a possible model in which the maturity of social problem-solving skills mediates the relationship between executive function and social outcome. The current study aimed to explore this model and determine whether social problem solving mediates the relationship between executive function and social outcome in a TBI population. The sample consisted of 36 adolescents and young adults who sustained a TBI between 8 and 12 years of age. They ranged between 16 and 22 years of age and were 7-10 years post-injury. Findings indicated that a higher level of executive dysfunction was associated with less sophisticated social problem-solving skills and poorer social outcome. Further, the maturity of social problem-solving skills was found to mediate the relationship between executive function and social outcome in this group.	[Muscara, Frank] Royal Childrens Hosp, Murdoch Childrens Res Inst, Australian Ctr Child Neuropsychol Studies, Melbourne, Vic 3052, Australia; [Muscara, Frank; Catroppa, Cathy; Anderson, Vicki] Univ Melbourne, Melbourne, Vic, Australia	Muscara, F (corresponding author), Royal Childrens Hosp, Murdoch Childrens Res Inst, Australian Ctr Child Neuropsychol Studies, Flemington Rd, Melbourne, Vic 3052, Australia.	frank.muscara@mcri.edu.au					Andrews TK, 1998, BRAIN INJURY, V12, P133, DOI 10.1080/026990598122755; BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; Cattelani R, 1998, BRAIN INJURY, V12, P283, DOI 10.1080/026990598122584; CRICK NR, 1994, PSYCHOL BULL, V115, P74, DOI 10.1037/0033-2909.115.1.74; Daniel A. E., 1983, POWER PRIVILEGE PRES; DELLS DC, 2001, DELIS KAPLAN EXECUTI; DZURILLA TJ, 1998, MANUAL SOCIAL PROBLE; FORDYCE DJ, 1983, J NEUROL NEUROSUR PS, V46, P620, DOI 10.1136/jnnp.46.7.620; Gioia G.A., 2000, BEHAV RATING INVENTO; Guralnick MJ, 1999, MENT RETARD DEV D R, V5, P21; HAIR JF, 1998, MULTIVARIATE DATA AN; Harrison P., 2003, ADAPTIVE BEHAV ASSES; Holmbeck GN, 1997, J CONSULT CLIN PSYCH, V65, P599, DOI 10.1037/0022-006X.65.4.599; Janusz JA, 2002, CHILD NEUROPSYCHOL, V8, P179, DOI 10.1076/chin.8.3.179.13499; LEVIN HS, 1991, DEV NEUROPSYCHOL, V7, P377, DOI 10.1080/87565649109540499; LEVINE MJ, 1993, BRAIN INJURY, V7, P153, DOI 10.3109/02699059309008169; Manchester D, 2004, BRAIN INJURY, V18, P1067, DOI 10.1080/02699050410001672387; MARSH NV, 1991, J CLIN EXP NEUROPSYC, V13, P729, DOI 10.1080/01688639108401086; McGann W, 1997, BRAIN INJURY, V11, P621, DOI 10.1080/026990597123179; MUSCARA F, DEV NEUROPS IN PRESS; MUSCARA F, IMPACT INJURY UNPUB; NEWTON A, 1985, BRIT J CLIN PSYCHOL, V24, P225, DOI 10.1111/j.2044-8260.1985.tb00655.x; Rose BM, 2004, J DEV BEHAV PEDIATR, V25, P58, DOI 10.1097/00004703-200402000-00013; RUTTER M, 1981, AM J PSYCHIAT, V138, P1533; Sbordone RJ, 1998, BRAIN INJURY, V12, P505, DOI 10.1080/026990598122467; SELMAN RL, 1986, DEV PSYCHOL, V22, P450, DOI 10.1037/0012-1649.22.4.450; SOBEL ME, 1982, SOCIOL METHODOL, V12, P290; Sparrow S., 1984, VINELAND ADAPTIVE BE; SUNDERLAND A, 1984, J CLIN NEUROPSYCHOL, V6, P127, DOI 10.1080/01688638408401204; Tabachnick B., 2001, USING MULTIVARIATE S; TATE RL, 1991, J NERV MENT DIS, V179, P117, DOI 10.1097/00005053-199103000-00001; Taylor HG, 2000, CHILD DEV, V71, P1495, DOI 10.1111/1467-8624.00242; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; TEASDALE G, 1974, LANCET, V2, P81; Warschausky S, 2003, REHABIL PSYCHOL, V48, P250, DOI 10.1037/0090-5550.48.4.250; Warschausky S, 1997, Pediatr Rehabil, V1, P77; Wechsler D, 1997, WAIS 3 ADM SCORING M; WELSH MC, 1991, DEV NEUROPSYCHOL, V7, P131, DOI 10.1080/87565649109540483; WILLIAMS D, 1992, BRAIN COGNITION, V20, P196, DOI 10.1016/0278-2626(92)90069-X; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093	40	78	78	0	23	BRITISH PSYCHOLOGICAL SOC	LEICESTER	ST ANDREWS HOUSE, 48 PRINCESS RD EAST, LEICESTER LE1 7DR, LEICS, ENGLAND	1748-6645			J NEUROPSYCHOL	J. Neuropsychol.	SEP	2008	2						445	461		10.1348/174866407X250820			17	Psychology; Psychology, Experimental	Psychology	499XI	WOS:000270259700008	19824165				2021-06-18	
J	Field, S; Treleaven, J; Jull, G				Field, Sandra; Treleaven, Julia; Jull, Gwendolen			Standing balance: A comparison between idiopathic and whiplash-induced neck pain	MANUAL THERAPY			English	Article						balance; whiplash; neck pain; proprioception; wavelet analysis; RMS	SUSPECTED CERVICAL ORIGIN; POSTURAL CONTROL; DYNAMIC POSTUROGRAPHY; PERSISTENT WHIPLASH; VESTIBULAR LOSS; MILD HEAD; STABILITY; DISORDERS; INJURY; DIZZINESS	Disturbances of balance have been found both in patients with whiplash-associated disorders and idiopathic neck pain. This study directly compared balance between these groups to determine if neck pain precipitated by trauma resulted in greater or different balance impairments. The study was a comparative, observational design. Thirty subjects with whiplash, 30 with idiopathic neck pain and 30 healthy controls, took part in the study. Subjects performed balance tests in comfortable, narrow and tandem stances. Balance disturbances (sway energy and/or root mean squared (RMS) amplitude) were evident in several tests between subjects with neck pain and controls. Direct comparison between the neck pain groups revealed that the whiplash group had significantly greater sway energy and RMS amplitude than the idiopathic group in comfortable stance tests on a soft surface (F > 4.4, p < 0.04). Further, the whiplash group had greater RMS, but significantly less sway energy than the idiopathic group in most narrow stance tests in the anterior posterior direction F > 5.8, p < 0.02). Both neck pain groups were also significantly less able to complete the eyes closed, tandem test compared to control subjects. In conclusion, the study has found that balance deficits exist in both subjects with whiplash-associated disorders and idiopathic neck pain compared to controls; however, differences in balance strategies may exist between the neck pain groups. Overall, subjects who have experienced trauma appear to have greater balance disturbances. (c) 2007 Elsevier Ltd. All rights reserved.	[Field, Sandra; Treleaven, Julia; Jull, Gwendolen] Univ Queensland, Sch Hlth & Rehabil Sci, Div Physiotherapy, Brisbane, Qld 4072, Australia	Treleaven, J (corresponding author), Univ Queensland, Sch Hlth & Rehabil Sci, Div Physiotherapy, Brisbane, Qld 4072, Australia.	j.treleaven@uq.edu.au	Jull, Gwendolen/F-4233-2010; Treleaven, Julia/N-1379-2019; Treleaven, Julia M/F-8734-2010	Jull, Gwendolen/0000-0003-2670-1318; Treleaven, Julia/0000-0002-6258-3972; Treleaven, Julia M/0000-0002-6258-3972			Ageberg Eva, 2002, J Electromyogr Kinesiol, V12, P205, DOI 10.1016/S1050-6411(02)00022-6; Allum JHJ, 2001, GAIT POSTURE, V14, P217, DOI 10.1016/S0966-6362(01)00142-4; ALUND M, 1991, ACTA OTO-LARYNGOL, P601; Alund M, 1993, J Vestib Res, V3, P383; Bove M, 2002, J NEUROPHYSIOL, V88, P2232, DOI 10.1152/jn.00198.2002; CHESTER JB, 1991, SPINE, V16, P716, DOI 10.1097/00007632-199107000-00004; Courtine G, 2003, NEUROREPORT, V14, P2365, DOI 10.1097/00001756-200312190-00015; Dault MC, 2001, GAIT POSTURE, V14, P248, DOI 10.1016/S0966-6362(01)00130-8; DEJONG PI, 1977, ANN NEUROL, P240; DELLAVOLPE R, 2005, GAIT POSTURE    1124; El-Kahky AM, 2000, ACTA OTO-LARYNGOL, V120, P508, DOI 10.1080/000164800750046018; Fattori B, 1996, ACUPUNCTURE ELECTRO, V21, P207, DOI 10.3727/036012996816356861; FISCHER AJEM, 1995, J NEUROL SCI, V132, P35, DOI 10.1016/0022-510X(95)00118-L; Gosselin G, 2004, CLIN BIOMECH, V19, P473, DOI 10.1016/j.clinbiomech.2004.02.001; Heikkila H, 1996, SCAND J REHABIL MED, V28, P133; HINOKI M, 1975, ACTA OTOLARYNGOL STO, V419, P9; HORAK FB, 1990, EXP BRAIN RES, V82, P167; Huskisson EE, 1983, VISUAL ANALOGUE SCAL, P33; Ishikawa K, 1998, ACTA OTO-LARYNGOL, P6; KARLBERG M, 1995, ACTA OTO-LARYNGOL, P440; Karlberg M, 1996, ARCH PHYS MED REHAB, V77, P874, DOI 10.1016/S0003-9993(96)90273-7; Karlberg M, 1996, J VESTIBUL RES-EQUIL, V6, P37; Kavounoudias A, 1999, EXP BRAIN RES, V124, P80, DOI 10.1007/s002210050602; Koskimies K, 1997, ACTA OTO-LARYNGOL, P95; Kristjansson E, 2003, CLIN REHABIL, V17, P768, DOI 10.1191/0269215503cr676oa; Le Pera D, 2001, CLIN NEUROPHYSIOL, V112, P1633, DOI 10.1016/S1388-2457(01)00631-9; Lekhel H, 1998, GAIT POSTURE, V7, P228, DOI 10.1016/S0966-6362(98)00012-5; MALLINSON AI, 1996, J MUSCULOSKELET PAIN, V4, P105, DOI DOI 10.1300/J094V04N04_10; MARTEAU T, 1992, BR J CLIN PSYCHOL, V3, P301; McIlroy WE, 1997, CLIN BIOMECH, V12, P66, DOI 10.1016/S0268-0033(96)00040-X; McPartland JM, 1997, J MANIP PHYSIOL THER, V20, P24; Michaelson P, 2003, J REHABIL MED, V35, P229, DOI 10.1080/16501970306093; NASHNER LM, 1990, NEUROL CLIN, V8, P331, DOI 10.1016/S0733-8619(18)30359-1; Persson L, 1996, J VESTIBUL RES-EQUIL, V6, P439; Peterson BW, 2004, PROG BRAIN RES, V143, P369, DOI 10.1016/S0079-6123(03)43035-5; Prieto TE, 1996, IEEE T BIO-MED ENG, V43, P956, DOI 10.1109/10.532130; Pyykko I, 1989, Acta Otolaryngol Suppl, V468, P175; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Rocchi L, 2004, MED BIOL ENG COMPUT, V42, P71, DOI 10.1007/BF02351013; Rocchi L, 2002, J NEUROL NEUROSUR PS, V73, P267, DOI 10.1136/jnnp.73.3.267; RUBIN AM, 1995, AM J OTOL, V16, P216; Schieppati M, 2003, NEUROSCIENCE, V121, P277, DOI 10.1016/S0306-4522(03)00439-1; SCOTT D, 2005, CLIN J PAIN, V21; SHUMWAYCOOK A, 1986, PHYS THER, V66, P1548, DOI 10.1093/ptj/66.10.1548; Sjostrom H, 2003, SPINE, V28, P1725, DOI 10.1097/00007632-200308010-00018; Speers RA, 1998, GAIT POSTURE, V7, P207, DOI 10.1016/S0966-6362(98)00006-X; Spitzer W, 1995, SPINE, V20, P1, DOI DOI 10.1097/00007632-199504151-00001; Thunberg J, 2001, PAIN, V91, P15, DOI 10.1016/S0304-3959(00)00415-2; Tjell C, 2003, J WHIPLASH ASS DISOR, V1, P9; Treleaven J, 2005, J REHABIL MED, V37, P224, DOI 10.1080/16501970510027989; Treleaven J, 2005, GAIT POSTURE, V21, P395, DOI 10.1016/j.gaitpost.2004.04.008; TRELEAVEN J, IN PRESS ARCH PHYS M; Vernon H, 1996, J MUSCULOSKELET PAIN, V4, P95, DOI DOI 10.1300/J094V04N04_; Wenngren BI, 1998, NEUROSCI RES, V32, P119, DOI 10.1016/S0168-0102(98)00074-1	54	78	83	0	14	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	1356-689X			MANUAL THER	Man. Ther.	JUN	2008	13	3					183	191		10.1016/j.math.2006.12.005			9	Rehabilitation	Rehabilitation	303AV	WOS:000256012600002	17306599				2021-06-18	
J	Turegano-Fuentes, F; Caba-Doussoux, P; Jover-Navalon, JM; Martin-Perez, E; Fernandez-Luengas, D; Diez-Valladares, L; Perez-Diaz, D; Yuste-Garcia, P; Labajo, HG; Rios-Blanco, R; Hernando-Trancho, F; Nisa, FGM; Sanz-Sanchez, M; Garcia-Fuentes, C; Martinez-Virto, A; Leon-Baltasar, JL; Vazquez-Estevez, J				Turegano-Fuentes, Fernando; Caba-Doussoux, P.; Jover-Navalon, J. M.; Martin-Perez, E.; Fernandez-Luengas, D.; Diez-Valladares, L.; Perez-Diaz, D.; Yuste-Garcia, P.; Guadalajara Labajo, H.; Rios-Blanco, R.; Hernando-Trancho, F.; Garcia-Moreno Nisa, F.; Sanz-Sanchez, M.; Garcia-Fuentes, C.; Martinez-Virto, A.; Leon-Baltasar, J. L.; Vazquez-Estevez, J.			Injury patterns from major urban terrorist bombings in trains: The madrid experience	WORLD JOURNAL OF SURGERY			English	Article							BLAST; EXPLOSION; TRAUMA	Background Terrorist urban mass casualty incidents (MCI) in the last 3 years have targeted commuter trains at rush hour, producing large numbers of casualties. Civilian care providers are usually not familiar with the types of blast injuries sustained by victims of these MCI. Methods We focus on the injury patterns sustained by casualties of the Madrid, 11 March 2004, terrorist bombings, at the seven hospitals that received most victims. Data were gathered of casualties who had injuries other than superficial bruises, transient hearing loss from barotrauma without eardrum perforation, and/or emotional shock. The degree of severity in critical patients was assessed with the ISS. Results The bombings resulted in 177 immediate fatalities, 9 early deaths, and 5 late deaths. Most survivors had noncritical injuries, but 72 (14%) of 512 casualties assessed had an Injury Severity Score (ISS) > 15. The critical mortality rate was of 19.5%. The most frequently injured body regions were the head-neck and face. Almost 50% of casualties had ear-drum perforation, and 60% of them were bilateral. There were 43 documented cases of blast lung injury, with a survival rate of 88.3%. Maxillofacial and open long-bone fractures were most prevalent. Gustillo's grade III of severity predominated in tibia-fibular and humeral fractures. Upper thoracic fractures (D1-6 segment) represented 65% of all vertebral fractures and were associated with severe blast to the torso. Severe burns were uncommon. Eye injuries were frequent, although most were of a mild-to-moderate severity. Abdominal visceral lesions were present in 25 (5%) patients. A multidisciplinary approach was necessary in most operated patients, and orthopedic trauma procedures accounted for 50% of the caseload in the first 24 h. Conclusions Ninety-three percent of the fatalities of the Madrid trains terrorist bombings were immediate, and most survivors had noncritical injuries. Closed doors increased the immediate fatality rate in the trains. Severely wounded casualties presented specific patterns of injuries, some of them life-threatening and unusual in other types of trauma mechanisms. Ear-lobe amputations and upper thoracic spine fractures were markers of critical injuries.	[Turegano-Fuentes, Fernando; Perez-Diaz, D.; Sanz-Sanchez, M.; Vazquez-Estevez, J.] Hosp Gen Gregorio Maranon, Dept Gen Surg, Madrid 28040, Spain; [Caba-Doussoux, P.; Yuste-Garcia, P.; Garcia-Fuentes, C.; Leon-Baltasar, J. L.] Hosp 12 Octubre, E-28041 Madrid, Spain; [Jover-Navalon, J. M.; Rios-Blanco, R.] Hosp Getafe, Madrid, Spain; [Martin-Perez, E.] Hosp Princesa, Madrid, Spain; [Fernandez-Luengas, D.; Guadalajara Labajo, H.; Martinez-Virto, A.] Hosp La Paz, Madrid, Spain; [Diez-Valladares, L.; Hernando-Trancho, F.] Hosp Clin Madrid, Madrid, Spain; [Garcia-Moreno Nisa, F.] Hosp Ramon & Cajal, E-28034 Madrid, Spain	Turegano-Fuentes, F (corresponding author), Hosp Gen Gregorio Maranon, Dept Gen Surg, Plaza Ciudad Viena 6, Madrid 28040, Spain.	fturegano.hgugm@salud.madrid.org; pedrocabado@gmail.com; josemjover@aecirujanos.es; elemartin203@aecirujanos.es; dfernandezl.hulp@salud.madrid.org; lidiez@hotmail.com; lolaperezdiaz@hotmail.com; pyuste.hdoc@salud.madrid.org; h.guadalajara@yahoo.es; raquelriosblanco@yahoo.es; fhtrancho@hotmail.com; plpunisa@mixmail.com; mersanz@mundofree.com; cgarciaf.hdoc@salud.madrid.org; ammvirto@yahoo.es; jleonb@terra.es; jvazqueze.hgugm@salud.madrid.org	MARTIN-PEREZ, ELENA/ABC-5039-2020; PEREZ, ELENA MARTIN/D-5735-2018; nisa, francisca f garcia-moreno/J-3906-2015; Luengas, David Fernandez/ABD-2527-2020	MARTIN-PEREZ, ELENA/0000-0002-4933-738X; PEREZ, ELENA MARTIN/0000-0002-4933-738X; nisa, francisca f garcia-moreno/0000-0001-5360-0577; garcia-moreno nisa, francisca/0000-0002-2194-4647; Guadalajara, Hector/0000-0001-6297-9347			Almogy G, 2006, J AM COLL SURGEONS, V202, P313, DOI 10.1016/j.jamcollsurg.2005.10.011; Almogy G, 2004, ANN SURG, V239, P295, DOI 10.1097/01.sla.0000114014.63423.55; Aschkenasy-Steuer G, 2005, CRIT CARE, V9, P490, DOI 10.1186/cc3762; Avidan V, 2005, AM J SURG, V190, P927, DOI 10.1016/j.amjsurg.2005.08.022; Aylwin CJ, 2006, LANCET, V368, P2219, DOI 10.1016/S0140-6736(06)69896-6; Born CT, 2005, SCAND J SURG, V94, P279, DOI 10.1177/145749690509400406; Cooper G J, 1989, J R Army Med Corps, V135, P58; Cushman JG, 2003, J TRAUMA, V54, P147, DOI 10.1097/00005373-200301000-00018; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Einav S, 2006, ANN SURG, V243, P533, DOI 10.1097/01.sla.0000206417.58432.48; ELKHOURY GY, 1993, AM J ROENTGENOL, V160, P95, DOI 10.2214/ajr.160.1.8416656; Frykberg ER, 2002, J TRAUMA, V53, P201, DOI 10.1097/00005373-200208000-00001; GUSTILO RB, 1976, J BONE JOINT SURG AM, V58, P453, DOI 10.2106/00004623-197658040-00004; Gutierrez de Ceballos J Peral, 2005, Crit Care Med, V33, pS107; Hamilton-Farrell M, 2004, INJURY, V35, P359, DOI 10.1016/j.injury.2003.08.020; KATZ E, 1989, ANN SURG, V209, P484, DOI 10.1097/00000658-198904000-00016; KIRSCHENBAUM L, 2001, CRIT CARE MED, V33, pS48; Koizumi Munehisa, 2002, Spine (Phila Pa 1976), V27, pE467, DOI 10.1097/00007632-200211010-00020; Kuhn F, 1996, OPHTHALMOLOGY, V103, P240; Leibovici D, 1996, J TRAUMA, V41, P1030, DOI 10.1097/00005373-199612000-00015; Lockey DJ, 2005, RESUSCITATION, V66, pIX, DOI 10.1016/j.resuscitation.2005.07.005; MELLOR SG, 1992, WORLD J SURG, V16, P893, DOI 10.1007/BF02066988; Miguel-Tobal JJ, 2006, J TRAUMA STRESS, V19, P69, DOI 10.1002/jts.20091; Peleg K, 2003, AM J EMERG MED, V21, P258, DOI 10.1016/S0735-6757(03)00043-3; Peleg K, 2004, ANN SURG, V239, P311, DOI 10.1097/01.sla.0000114012.84732.be; Pizov R, 1999, CHEST, V115, P165, DOI 10.1378/chest.115.1.165; Stein M, 2005, SCAND J SURG, V94, P286, DOI 10.1177/145749690509400407; Stein M, 1999, SURG CLIN N AM, V79, P1537, DOI 10.1016/S0039-6109(05)70091-8; Wong JML, 2006, J TRAUMA, V60, P402, DOI 10.1097/01.ta.0000203715.31280.65; ZWIMPFER TJ, 1990, J NEUROSURG, V72, P894, DOI 10.3171/jns.1990.72.6.0894	30	78	82	0	2	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0364-2313	1432-2323		WORLD J SURG	World J.Surg.	JUN	2008	32	6					1168	1175		10.1007/s00268-008-9557-1			8	Surgery	Surgery	303JN	WOS:000256036900033	18365272				2021-06-18	
J	Renolleau, S; Fau, S; Charriaut-Marlangue, C				Renolleau, Sylvain; Fau, Sebastien; Charriaut-Marlangue, Christiane			Gender-related differences in apoptotic pathways after neonatal cerebral ischemia	NEUROSCIENTIST			English	Article						female; male; caspase inhibitor; mitochondria; cytochrome c; cell death	TRAUMATIC BRAIN INJURY; Q-VD-OPH; HYPOXIA-ISCHEMIA; CELL-DEATH; RAT-BRAIN; CASPASE-3 ACTIVATION; NITRIC-OXIDE; POLY(ADP-RIBOSE) POLYMERASE; NUCLEAR TRANSLOCATION; MITOCHONDRIAL PATHWAY	Many central nervous system (CNS) diseases display sexual dimorphism, specifically a predilection for one gender or a gender-dependent response to treatment. Exposure to circulating sex steroids is felt to be a chief contributor to this phenomenon. However, CNS diseases of childhood and of the elderly also demonstrate gender predominance and/or sexual dimorphism response to therapies. In this short update, we provide information concerning one of the most interesting new emerging concepts related to the influence of the sex in the pathogenesis of developmental brain injuries leading to different levels of neuroprotection between genders after cerebral hypoxia-ischemia or ischemia.	[Renolleau, Sylvain; Fau, Sebastien; Charriaut-Marlangue, Christiane] Univ Paris 06, F-75252 Paris 05, France; [Renolleau, Sylvain; Fau, Sebastien] Univ Paris 06, Hop Armand Trousseau, Serv Reanimat Neonatale & Pediat, F-75252 Paris 05, France	Charriaut-Marlangue, C (corresponding author), CNRS, UMR 7102, HICD Case 14,9 Quai St Bernard, F-75005 Paris, France.	Christiane.Marlangue@snv.jussieu.fr	, CHARRIAUT-MARLANGUE/H-3249-2019				Alkayed NJ, 1998, STROKE, V29, P159, DOI 10.1161/01.STR.29.1.159; Alkayed NJ, 2000, STROKE, V31, P161, DOI 10.1161/01.STR.31.1.161; Benjelloun N, 2003, NEUROPATH APPL NEURO, V29, P350, DOI 10.1046/j.1365-2990.2003.00467.x; Blomgren K, 2001, J BIOL CHEM, V276, P10191, DOI 10.1074/jbc.M007807200; Bona E, 1998, PEDIATR RES, V43, P738, DOI 10.1203/00006450-199806000-00005; Bramlett Helen M, 2005, Pathophysiology, V12, P17, DOI 10.1016/j.pathophys.2005.02.009; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Carruth LL, 2002, NAT NEUROSCI, V5, P933, DOI 10.1038/nn922; Caserta TM, 2003, APOPTOSIS, V8, P345, DOI 10.1023/A:1024116916932; Chauvier D, 2007, CELL DEATH DIFFER, V14, P387, DOI 10.1038/sj.cdd.4402044; Cheng Y, 1998, J CLIN INVEST, V101, P1992, DOI 10.1172/JCI2169; Culmsee C, 2005, J NEUROSCI, V25, P10262, DOI 10.1523/JNEUROSCI.2818-05.2005; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Daugas E, 2000, FASEB J, V14, P729; Dewing P, 2003, MOL BRAIN RES, V118, P82, DOI 10.1016/S0169-328X(03)00339-5; Dhote VV, 2007, LIFE SCI, V81, P188, DOI 10.1016/j.lfs.2007.05.010; Donders J, 2002, NEUROPSYCHOLOGY, V16, P491, DOI 10.1037//0894-4105.16.4.491; Du LN, 2004, J BIOL CHEM, V279, P38563, DOI 10.1074/jbc.M405461200; Dubal DB, 1998, J CEREBR BLOOD F MET, V18, P1253, DOI 10.1097/00004647-199811000-00012; Ducrocq S, 2000, J NEUROCHEM, V74, P2504, DOI 10.1046/j.1471-4159.2000.0742504.x; Edwards AD, 2000, PEDIATR RES, V47, P431, DOI 10.1203/00006450-200004000-00003; Edwards D, 2004, J PEDIATR-US, V145, P723, DOI 10.1016/j.jpeds.2004.08.062; Felderhoff-Mueser U, 2002, NEUROBIOL DIS, V11, P231, DOI 10.1006/nbdi.2002.0521; Ferrand-Drake M, 2003, J NEUROCHEM, V85, P1431, DOI 10.1046/j.1471-4159.2003.01794.x; Goel A, 2007, CARDIOVASC RES, V76, P351, DOI 10.1016/j.cardiores.2007.06.029; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Hagberg H, 2004, J NEUROCHEM, V90, P1068, DOI 10.1111/j.1471-4159.2004.02547.x; Halestrap AP, 2006, BIOCHEM SOC T, V34, P232, DOI 10.1042/BST0340232; HALL ED, 1991, J CEREBR BLOOD F MET, V11, P292, DOI 10.1038/jcbfm.1991.61; Hawk T, 1998, BRAIN RES, V796, P296, DOI 10.1016/S0006-8993(98)00327-8; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; HURN PD, 1995, J CEREBR BLOOD F MET, V15, P666, DOI 10.1038/jcbfm.1995.82; Hurn PD, 2005, STROKE, V36, P193, DOI 10.1161/01.STR.0000153064.41332.f6; Hurn PD, 2000, J CEREBR BLOOD F MET, V20, P631, DOI 10.1097/00004647-200004000-00001; Igarashi T, 2001, EXP NEUROL, V172, P332, DOI 10.1006/exnr.2001.7820; Joashi UC, 1999, EUR J NEUROSCI, V11, P91, DOI 10.1046/j.1460-9568.1999.00409.x; Joly LM, 2004, J CEREBR BLOOD F MET, V24, P124, DOI 10.1097/01.WCB.0000100061.36077.5F; Joly LM, 2003, PEDIATR RES, V53, P776, DOI 10.1203/01.PDR.0000059751.00465.F6; Jones NM, 2004, J NEUROCHEM, V89, P157, DOI 10.1111/j.1471-4159.2004.02324.x; Kluck RM, 1999, J CELL BIOL, V147, P809, DOI 10.1083/jcb.147.4.809; Kondo Y, 1997, NEUROSCI LETT, V238, P45, DOI 10.1016/S0304-3940(97)00847-1; Lesuisse C, 2002, J CEREBR BLOOD F MET, V22, P935, DOI 10.1097/00004647-200208000-00005; Mabley JG, 2005, J PHARMACOL EXP THER, V315, P812, DOI 10.1124/jpet.105.090480; Manabat C, 2003, STROKE, V34, P207, DOI 10.1161/01.STR.0000047101.87575.3C; McCullough LD, 2003, TRENDS ENDOCRIN MET, V14, P228, DOI 10.1016/S1043-2760(03)00076-6; McCullough LD, 2005, J CEREBR BLOOD F MET, V25, P502, DOI 10.1038/sj.jcbfm.9600059; Momoi T, 2004, J CHEM NEUROANAT, V28, P101, DOI 10.1016/j.jchemneu.2004.05.008; Morrison Wynne E, 2004, Pediatr Crit Care Med, V5, P145, DOI 10.1097/01.PCC.0000112373.71645.2A; Murph E, 2007, CARDIOVASC RES, V75, P478, DOI 10.1016/j.cardiores.2007.03.025; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nijboer CHA, 2007, J CEREBR BLOOD F MET, V27, P282, DOI 10.1038/sj.jcbfm.9600342; Northington FJ, 2001, J NEUROSCI, V21, P1931, DOI 10.1523/JNEUROSCI.21-06-01931.2001; Pelligrino DA, 1998, NEUROREPORT, V9, P3285, DOI 10.1097/00001756-199810050-00026; Plesnila N, 2004, J CEREBR BLOOD F MET, V24, P458, DOI 10.1097/00004647-200404000-00011; Renolleau S, 2007, J NEUROCHEM, V100, P1062, DOI 10.1111/j.1471-4159.2006.04269.x; Roth KA, 2001, MENT RETARD DEV D R, V7, P261, DOI 10.1002/mrdd.1036; Rusa R, 1999, STROKE, V30, P1665, DOI 10.1161/01.STR.30.8.1665; Sampei K, 2000, STROKE, V31, P738, DOI 10.1161/01.STR.31.3.738; Satchell MA, 2005, J CEREBR BLOOD F MET, V25, P919, DOI 10.1038/sj.jcbfm.9600088; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; Simpkins JW, 1997, J NEUROSURG, V87, P724, DOI 10.3171/jns.1997.87.5.0724; Spierings D, 2005, SCIENCE, V310, P66, DOI 10.1126/science.1117105; Subramanian M, 2007, J IMMUNOL, V179, P2330, DOI 10.4049/jimmunol.179.4.2330; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Toung TJK, 1998, STROKE, V29, P1666, DOI 10.1161/01.STR.29.8.1666; Wang ML, 2003, J THEOR COMPUT CHEM, V2, P351, DOI 10.1142/S0219633603000562; Wang Q, 1999, STROKE, V30, P630, DOI 10.1161/01.STR.30.3.630; Wang XY, 2001, BIOL NEONATE, V79, P172; Weil MD, 1998, JAMA-J AM MED ASSOC, V279, P1474, DOI 10.1001/jama.279.18.1474; Wen TC, 2006, NEUROSCIENCE, V139, P803, DOI 10.1016/j.neuroscience.2006.02.057; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; Zhang L, 2003, NEUROSCI LETT, V337, P65, DOI 10.1016/S0304-3940(02)01179-5; Zhu CL, 2003, J NEUROCHEM, V86, P306, DOI 10.1046/j.1471-4159.2003.01832.x; Zhu CL, 2006, J NEUROCHEM, V96, P1016, DOI 10.1111/j.1471-4159.2005.03639.x	75	78	78	1	6	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1073-8584	1089-4098		NEUROSCIENTIST	Neuroscientist	FEB	2008	14	1					46	52		10.1177/1073858407308889			7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	251VL	WOS:000252403600013	17971506				2021-06-18	
J	Baguley, IJ; Slewa-Younan, S; Heriseanu, RE; Nott, MT; Mudaliar, Y; Nayyar, V				Baguley, Ian J.; Slewa-Younan, Shameran; Heriseanu, Roxana E.; Nott, Melissa T.; Mudaliar, Yugan; Nayyar, Vineet			The incidence of dysautonomia and its relationship with autonomic arousal following traumatic brain injury	BRAIN INJURY			English	Article						dysautonomia; traumatic brain injury; incidence; autonomic overactivity; outcome	SEVERE HEAD-INJURY; SCALE; MANAGEMENT; COMA	Primary objective: To determine the incidence of autonomic arousal vs. Dysautonomia following traumatic brain injury ( TBI) in an Intensive Care Unit ( ICU) setting and to prospectively evaluate these groups against injury severity and outcome variables. Research design: Prospective observational group comparison (cohort) study of consecutive ICU admissions to a major trauma hospital over a 2-year period. Main outcomes and results: Eighty-nine of 113 subjects met inclusion and exclusion criteria, with consent gained for 79 subjects ( 61 male, 18 female: 89% of potential subjects). During the first 7 days post-injury, elevated autonomic parameters were almost universal in the sample ( 92%), predominantly hypertension and tachycardia. Nineteen of 79 subjects ( 24%) were autonomically aroused on day 7 ( that is, had elevated heart rate, respiratory rate, blood pressure and temperature). Dysautonomia was diagnosed on day 14 post-injury in six of 79 subjects ( 8%) using previously published criteria. Autonomically aroused subjects had significantly more severe injuries, poorer outcomes and greater estimated costs than non-aroused subjects. Furthermore, Dysautonomic subjects within the autonomically aroused group had significantly worse outcome and, excluding early deaths, a greater period of hospitalization and higher estimated costs. Conclusions: The 8% incidence of Dysautonomia during ICU admission was in broad agreement with previous research. While day 7 autonomic arousal indicated a greater degree of injury, the diagnosis of Dysautonomia provided additional prognostic information. A coordinated multi-centre research effort into this condition appears appropriate.	Westmead Hosp, Intens Care Unit, Westmead, NSW 2145, Australia; Westmead Hosp, Brain Injury Rehabil Serv, Westmead, NSW 2145, Australia	Baguley, IJ (corresponding author), Westmead Hosp, Brain Injury Rehabil Serv, POB 533, Wentworthville, NSW 2145, Australia.	ianb@biru.wsahs.nsw.gov.au	Nott, Melissa T/M-6778-2018; Baguley, Ian/AAM-5828-2021; Baguley, Ian J/K-6878-2013	Nott, Melissa T/0000-0001-7088-5826; Baguley, Ian J/0000-0001-5650-3705			Baguley IJ, 2007, J NEUROL NEUROSUR PS, V78, P539, DOI 10.1136/jnnp.2006.096388; Baguley IJ, 2006, BRAIN INJURY, V20, P437, DOI 10.1080/02699050600664715; Baguley IJ, 1999, J NEUROL NEUROSUR PS, V67, P39, DOI 10.1136/jnnp.67.1.39; Baguley IJ, 2004, BRAIN INJURY, V18, P409, DOI 10.1080/02699050310001645775; Baguley IJ, 1999, MAYO CLIN PROC, V74, P105, DOI 10.4065/74.1.105; Blackman JA, 2004, ARCH NEUROL-CHICAGO, V61, P321, DOI 10.1001/archneur.61.3.321; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; Fernandez-Ortega JF, 2006, J TRAUMA, V61, P1129, DOI 10.1097/01.ta.0000197634.83217.80; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1977, LANCET, V1, P878; KISHNER S, 2006, POST HEAD INJURY AUT; Lemke DM, 2007, CRIT CARE NURSE, V27, P30; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x	14	78	81	0	1	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	OCT	2007	21	11					1175	1181		10.1080/02699050701687375			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	222WX	WOS:000250329900009	17952716				2021-06-18	
J	Stocchetti, N; Colombo, A; Ortolano, F; Videtta, W; Marchesi, R; Longhi, L; Zanier, ER				Stocchetti, Nino; Colombo, Angelo; Ortolano, Fabrizio; Videtta, Walter; Marchesi, Roberta; Longhi, Luca; Zanier, Elisa R.			Time course of intracranial hypertension after traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						clinical management of CNS injury; intracranial pressure; traumatic brain injury	HEAD-INJURY; CELLULAR EDEMA; PRESSURE; SECONDARY; DEXANABINOL	High intracranial pressure (HICP) may be a very early event after traumatic brain injury (TBI), but in most cases, especially when contusions and edema develop over time, HICP will worsen over succeeding days. This study describes the incidence and severity of elevated intracranial pressure (ICP) after TBI and attempts to document its time course. In this prospective study, 201 TBI patients in whom ICP was monitored for more than 12 h were evaluated. ICP was measured, digitalized, and analyzed after manual filtering. The number of episodes of HICP and the mean ICP value for every 12-h interval were calculated. When monitoring was concluded, the highest mean ICP collected in every patient was identified. A total of 21,000 h of ICP monitoring were recorded. Active treatment to prevent or reduce HICP was used in 200 patients. HICP was documented in 155 cases. Half of the patients had their highest mean ICP during the first 3 days after injury, but many showed delayed ICP elevation, with 25% showing highest mean ICP after day 5. In these cases, HICP was significantly worse and required more intense therapies.	Univ Milan, Fdn IRCCS Osped Maggiore Policlin Mangiagalli & R, Neurosci ICU, I-20122 Milan, Italy	Stocchetti, N (corresponding author), Univ Milan, Fdn IRCCS Osped Maggiore Policlin Mangiagalli & R, Neurosci ICU, Via F Sforza 35, I-20122 Milan, Italy.	stocchet@policlinico.mi.it	Stocchetti, Nino/O-7444-2017; Zanier, Elisa/AAA-8095-2020; Longhi, Luca/AAF-9903-2021	Stocchetti, Nino/0000-0003-3250-6834; Longhi, Luca/0000-0001-9894-8788; Zanier, Elisa/0000-0002-3011-8718; Ortolano, Fabrizio/0000-0003-1996-948X			Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Bloomfield GL, 1995, J TRAUMA, V39, P1168, DOI 10.1097/00005373-199512000-00028; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; CLARK WC, 1989, NEUROSURGERY, V25, P20; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; KLAUBER MR, 1984, J NEUROSURG, V61, P695, DOI 10.3171/jns.1984.61.4.0695; Knoller N, 2002, CRIT CARE MED, V30, P548, DOI 10.1097/00003246-200203000-00009; LOBATO RD, 1983, INTRACRANIAL PRESSUE, P543; Maas AIR, 2006, LANCET NEUROL, V5, P38, DOI 10.1016/S1474-4422(05)70253-2; MARMAROU A, 1991, J NEUROSURG, V75, pS21, DOI 10.3171/sup.1991.75.1s.0s21; Marmarou A, 2006, J NEUROSURG, V104, P720, DOI 10.3171/jns.2006.104.5.720; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MASET AL, 1987, J NEUROSURG, V67, P832, DOI 10.3171/jns.1987.67.6.0832; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; Rebuck JA, 2000, J NEUROL NEUROSUR PS, V69, P381, DOI 10.1136/jnnp.69.3.381; Souter MJ, 1999, CRIT CARE MED, V27, P177, DOI 10.1097/00003246-199901000-00048; Stocchetti N, 1999, INTENS CARE MED, V25, P371, DOI 10.1007/s001340050860; UNTERBERG A, 1993, NEUROSURGERY, V32, P17, DOI 10.1227/00006123-199301000-00003; Verweij BH, 2001, J NEUROSURG, V95, P569, DOI 10.3171/jns.2001.95.4.0569; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Zanier ER, 2007, CRIT CARE, V11, DOI 10.1186/cc5155; 2000, J NEUROTRAUMA, V17, P479	23	78	80	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2007	24	8					1339	1346		10.1089/neu.2007.0300			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	202QQ	WOS:000248918500005	17711395				2021-06-18	
J	Kato, T; Nakayama, N; Yasokawa, Y; Okumura, A; Shinoda, J; Iwama, T				Kato, Takayuki; Nakayama, Noriyuki; Yasokawa, Yuto; Okumura, Ayumi; Shinoda, Jun; Iwama, Toru			Statistical image analysis of cerebral glucose metabolism in patients with cognitive impairment following diffuse traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						cognitive function; metabolism; positron emission tomography; traumatic brain injury	CLOSED HEAD-INJURY; ANTERIOR CINGULATE CORTEX; AXONAL INJURY; BLOOD-FLOW; SUSTAINED ATTENTION; FRONTAL-CORTEX; FDG-PET; SPECT; MRI; LOCALIZATION	The aim of this study was to explore the regional cerebral glucose metabolism (rCM) in patients with chronic stage traumatic brain injury (TBI) compared with normal controls. We also investigated the relationship between regional cerebral glucose metabolism and cognitive function. We performed 2-[F-18]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) study using statistical parametric mapping (SPM) analysis in 36 diffuse axonal injury (DAI) patients (mean age +/- SD, 36.3 +/- 9.8 years). At 6 months or more after head injury, all patients underwent FDG-PET study and neuropsychological batteries to assess cognitive function. Thirty healthy, gender-matched control subjects who were comparable in age were also studied. Between the TBI patients and normal controls, group comparisons showed regional metabolic decreases in the bilateral frontal lobes, temporal lobes, thalamus, as well as the right cerebellum in the TBI group. Only full-scale Intelligence Quotient (IQ) (mean +/- SD, 78.5 +/- 11.9) correlated positively with rCM in the right cingulate gyrus and the bilateral medial frontal gyrus. In other examinations, the correlation was not provided. DAI may induce functional disconnection and decreased neuronal activity, and finally lead to diffuse glucose hypometabolism. Low full-scale IQ scores may be related to significantly different underlying cognitive impairment. In supporting cognitive function following TBI, which showed diffuse cerebral metabolic reduction compared with normal controls, medial prefrontal cortex and anterior cingulate cortex may be an important component.	Kizawa Mem Hosp, Chubu Med Ctr Prolonged Traumat Brain Dysfunct, Gifu 5050034, Japan; Gifu Univ, Grad Sch Med, Dept Neurosurg, Gifu, Japan	Kato, T (corresponding author), Kizawa Mem Hosp, Chubu Med Ctr Prolonged Traumat Brain Dysfunct, 630 Shimokobi Kobi-machi,Minokamo City, Gifu 5050034, Japan.	nou-taka@a.email.ne.jp			Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [19790994] Funding Source: KAKEN		ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Alavi A, 1989, J Neuropsychiatry Clin Neurosci, V1, pS45; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Bagley LJ, 2000, J MAGN RESON IMAGING, V11, P1, DOI 10.1002/(SICI)1522-2586(200001)11:1<1::AID-JMRI1>3.0.CO;2-H; Bergsneider M, 2001, J HEAD TRAUMA REHAB, V16, P135, DOI 10.1097/00001199-200104000-00004; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; Cabeza R, 2000, J COGNITIVE NEUROSCI, V12, P1, DOI 10.1162/08989290051137585; Casey BJ, 1997, DEV PSYCHOBIOL, V30, P61, DOI 10.1002/(SICI)1098-2302(199701)30:1<61::AID-DEV6>3.3.CO;2-B; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; Dehaene S, 1998, P NATL ACAD SCI USA, V95, P14529, DOI 10.1073/pnas.95.24.14529; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; Gehring WJ, 2001, J NEUROSCI, V21, P9430, DOI 10.1523/JNEUROSCI.21-23-09430.2001; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; GOLDENBERG G, 1992, J NEUROL NEUROSUR PS, V55, P362, DOI 10.1136/jnnp.55.5.362; Haier RJ, 2004, NEUROIMAGE, V23, P425, DOI 10.1016/j.neuroimage.2004.04.025; Karussis D, 2000, J NEUROL SCI, V172, P25, DOI 10.1016/S0022-510X(99)00267-1; Lewin JS, 1996, J COMPUT ASSIST TOMO, V20, P695, DOI 10.1097/00004728-199609000-00002; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.080523; NEWTON MR, 1992, J NEUROL NEUROSUR PS, V55, P92, DOI 10.1136/jnnp.55.2.92; ODER W, 1992, J NEUROL NEUROSUR PS, V55, P475, DOI 10.1136/jnnp.55.6.475; PARDO JV, 1991, NATURE, V349, P61, DOI 10.1038/349061a0; Paus T, 2001, NAT REV NEUROSCI, V2, P417, DOI 10.1038/35077500; Peterson BS, 2000, JAMA-J AM MED ASSOC, V284, P1939, DOI 10.1001/jama.284.15.1939; Petrides M, 1995, ANN NY ACAD SCI, V769, P85, DOI 10.1111/j.1749-6632.1995.tb38133.x; Pinter JD, 2001, AM J PSYCHIAT, V158, P1659, DOI 10.1176/appi.ajp.158.10.1659; Rushton JP, 1995, CAN J EXP PSYCHOL, V49, P562, DOI 10.1037/1196-1961.49.4.562; Smith DH, 2000, J NEUROSURG, V93, P315, DOI 10.3171/jns.2000.93.2.0315; Swick D, 2002, NEUROPSYCHOLOGIA, V40, P1240, DOI 10.1016/S0028-3932(01)00226-3; Wilke M, 2003, NEUROIMAGE, V20, P202, DOI 10.1016/S1053-8119(03)00199-X; Yamaki T, 1996, J TRAUMA, V40, P50, DOI 10.1097/00005373-199601000-00010; Zysset S, 2002, NEUROIMAGE, V15, P983, DOI 10.1006/nimg.2001.1008	36	78	82	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2007	24	6					919	926		10.1089/neu.2006.0203			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	184EA	WOS:000247622700001	17600509				2021-06-18	
J	Matsumoto, H; Kumon, Y; Watanabe, H; Ohnishi, T; Shudou, M; Ii, C; Takahashi, H; Imai, Y; Tanaka, J				Matsumoto, Hiroaki; Kumon, Yoshiaki; Watanabe, Hideaki; Ohnishi, Takanori; Shudou, Masachika; Ii, Chisato; Takahashi, Hisaaki; Imai, Yoshinori; Tanaka, Junya			Antibodies to CD11b, CD68, and lectin label neutrophils rather than microglia in traumatic and ischemic brain lesions	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						MCAO; stab wound; microglia; macrophage; Iba1; NO; proinflammatory cytokines	CEREBRAL-ARTERY OCCLUSION; NITRIC-OXIDE SYNTHASE; SPINAL-CORD-INJURY; NG2 PROTEOGLYCAN; FOCAL ISCHEMIA; CELLS; EXPRESSION; REPERFUSION; CORTEX; OLIGODENDROCYTES	Resident quiescent microglia have been thought to respond rapidly to various pathologic events in the brain by proliferating and producing many bioactive substances, including proinflammatory cytokines and nitric oxide (NO). In this study, we investigated the reaction of microglia in traumatic and ischemic lesions caused by stab wounds and the transient 90-min occlusion of middle cerebral artery in a mature rat brain. Although many lba1(+) resident microglia underwent apoptotic degeneration in the lesion core within 24 hr after the onset of the brain insult as revealed by TUNEL staining, numerous small, round, isolectin B4(+)/CD11b(+)/CD68(+) cells were localized in the lesion core. These small, round cells with diameters of 7-9 mu m and polymorph nuclei expressed neutrophil-specific elastase, alkaline phosphatase, and platelet-activating factor receptor. Accordingly, they were not activated microglia but neutrophils. Immunohistochemical staining with antibodies to inducible NO synthase (iNOS) showed that most iNOS(+) cells were neutrophils. The results from spatial and kinetic analyses using RT-PCR and immunoblotting were consistent with the immunohistochemical observations. These results suggest the necessity of reevaluating the traditional view on the roles of activated microglia in severe neuropathologic events. Note that the traditional microglial markers isolectin B4, CD11b, and CD68 are not specific for microglia, particularly in a pathologic brain. (c) 2007 Wiley-Liss, Inc.	Ehime Univ, Grad Sch Med, Dept Mol & Cellular Physiol, Toon, Ehime 7910295, Japan; Ehime Univ, Grad Sch Med, Dept Neurosurg, Toon, Ehime 7910295, Japan; Ehime Univ, Integrated Ctr Sci, Toon, Ehime 7910295, Japan	Tanaka, J (corresponding author), Ehime Univ, Grad Sch Med, Dept Mol & Cellular Physiol, Toon, Ehime 7910295, Japan.	jtanaka@in.ehime-u.ac.jp	Tanaka, Junya/Y-1033-2019	Tanaka, Junya/0000-0003-1056-5948			BANATI RB, 1993, GLIA, V7, P111, DOI 10.1002/glia.440070117; BARONE FC, 1992, STROKE, V23, P1337, DOI 10.1161/01.STR.23.9.1337; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; Beray-Berthat V, 2003, BRAIN RES, V987, P32, DOI 10.1016/S0006-8993(03)03224-4; Bu J, 2001, GLIA, V34, P296, DOI 10.1002/glia.1063; Carlson SL, 1998, EXP NEUROL, V151, P77, DOI 10.1006/exnr.1998.6785; Gibson CL, 2005, GLIA, V50, P417, DOI 10.1002/glia.20143; Gowing G, 2006, GLIA, V53, P331, DOI 10.1002/glia.20288; Hashimoto H, 1999, ACTA NEUROPATHOL, V98, P603, DOI 10.1007/s004010051125; Heppner FL, 2005, NAT MED, V11, P146, DOI 10.1038/nm1177; HWANG SB, 1988, J BIOL CHEM, V263, P3225; Iadecola C, 1997, J NEUROSCI, V17, P9157; Imai Y, 1996, BIOCHEM BIOPH RES CO, V224, P855, DOI 10.1006/bbrc.1996.1112; Ito D, 2001, STROKE, V32, P1208, DOI 10.1161/01.STR.32.5.1208; Ito D, 1998, MOL BRAIN RES, V57, P1, DOI 10.1016/S0169-328X(98)00040-0; Jones LL, 2002, J NEUROSCI, V22, P2792, DOI 10.1523/JNEUROSCI.22-07-02792.2002; Kato H, 1996, BRAIN RES, V734, P203, DOI 10.1016/S0006-8993(96)00636-1; Kitamura Y, 1996, GLIA, V18, P233, DOI 10.1002/(SICI)1098-1136(199611)18:3<233::AID-GLIA7>3.0.CO;2-#; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Kuwabara Y, 2003, J NEUROSCI RES, V73, P22, DOI 10.1002/jnr.10637; LING EA, 1993, GLIA, V7, P9, DOI 10.1002/glia.440070105; Mobberley-Schuman PS, 2005, INFECT IMMUN, V73, P7317, DOI 10.1128/IAI.73.11.7317-7323.2005; Mori K, 2002, NEUROPHARMACOLOGY, V43, P1026, DOI 10.1016/S0028-3908(02)00211-3; MORIOKA T, 1991, J CEREBR BLOOD F MET, V11, P966, DOI 10.1038/jcbfm.1991.162; Nakajima K., 2005, NEUROGLIA, V2, P443; Neudenberger J, 2006, BRIT J HAEMATOL, V133, P337, DOI 10.1111/j.1365-2141.2006.06013.x; Paietta E, 1998, BRIT J HAEMATOL, V100, P265, DOI 10.1046/j.1365-2141.1998.00561.x; PERSSON L, 1976, VIRCHOWS ARCH B, V22, P21; SAITO N, 1991, AM J PATHOL, V139, P1053; Schroeter M, 1997, STROKE, V28, P382, DOI 10.1161/01.STR.28.2.382; Shibano M, 1999, AM J HEMATOL, V60, P12, DOI 10.1002/(SICI)1096-8652(199901)60:1<12::AID-AJH3>3.3.CO;2-G; Shimakura A, 2000, BRAIN RES, V858, P55, DOI 10.1016/S0006-8993(99)02431-2; Simard AR, 2006, NEURON, V49, P489, DOI 10.1016/j.neuron.2006.01.022; Strbian D, 2006, J CEREBR BLOOD F MET, V26, P605, DOI 10.1038/sj.jcbfm.9600228; Streit W. J., 2005, NEUROGLIA, P60; Sugishita H, 2001, J NEUROSCI RES, V64, P392, DOI 10.1002/jnr.1090; Tanaka J, 1997, GLIA, V19, P286; Tanaka J, 1996, EXP NEUROL, V137, P367, DOI 10.1006/exnr.1996.0038; Tanaka R, 2003, NEUROSCIENCE, V117, P531, DOI 10.1016/S0306-4522(02)00954-5; Wang Y, 2007, EXP NEUROL, V203, P168, DOI 10.1016/j.expneurol.2006.08.006; Weston RM, 2007, J CEREBR BLOOD F MET, V27, P100, DOI 10.1038/sj.jcbfm.9600324; Wu CT, 2003, HEPATOLOGY, V38, P1018, DOI 10.1053/jhep.2003.50407; Yokoyama A, 2006, GLIA, V53, P754, DOI 10.1002/glia.20332; Yokoyama A, 2004, GLIA, V45, P96, DOI 10.1002/glia.10306; Zai LJ, 2005, GLIA, V50, P247, DOI 10.1002/glia.20176; Zhang ZG, 1997, BRAIN RES, V744, P189, DOI 10.1016/S0006-8993(96)01085-2	46	78	80	2	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	APR	2007	85	5					994	1009		10.1002/jnr.21198			16	Neurosciences	Neurosciences & Neurology	157NK	WOS:000245726700008	17265469				2021-06-18	
J	Patel, AV; Mihalik, JP; Notebaert, AJ; Guskiewicz, KM; Prentice, WE				Patel, Akshay V.; Mihalik, Jason P.; Notebaert, Andrew J.; Guskiewicz, Kevin M.; Prentice, William E.			Neuropsychological performance, postural stability, and symptoms after dehydration	JOURNAL OF ATHLETIC TRAINING			English	Article						cognition; balance; mild traumatic brain injury	COLLEGIATE FOOTBALL PLAYERS; CEREBRAL CONCUSSION; NCAA CONCUSSION; BRAIN-INJURY; HEAT-STRESS; EXERCISE; VASOPRESSIN; HYDRATION; SPORT; RATS	Context: Dehydration and concussion are common in athletic performance. Some experts have speculated that dehydration may negatively influence performance on tests commonly used for concussion assessment. Objective: To determine how the signs and symptoms, neuropsychological performance, and postural stability are affected by dehydration. Design: Repeated-measures design assessing subjects in the euhydrated and dehydrated conditions. Setting: Sports Medicine Research Laboratory. Patients or Other Participants: Twenty-four healthy, male recreational athletes participated in the study. Intervention(s): Subjects participated in 2 counterbalanced sessions (euhydrated and dehydrated) separated by at least 7 days. Subjects were dehydrated using fluid restriction and an exercise task. No direct intervention was provided for the euhydrated condition. Main Outcome Measure(s): We used the Standardized Assessment of Concussion to test mental status, the Automated Neuropsychological Assessment Metrics (ANAM) to evaluate neuropsychological performance, the NeuroCom Sensory Organization Test and Balance Error Scoring System to test postural stability, the Graded Symptom Checklist to assess symptom presence and severity in our participants, and urine specific gravity and body mass to determine hydration status. Results: No differences were noted for the Standardized Assessment of Concussion, total Balance Error Scoring System errors, composite Sensory Organization Test, and composite ANAM scores between conditions. Subjects in the dehydrated condition had significant deterioration in visual memory (t(23) = 2.130, P <.001) and fatigue measures (t(23) = -7.880, P <.001) as assessed by ANAM. The dehydrated condition resulted in subjects reporting a significantly higher number (t23 = -8.585, P <.001) and severity (t(23) = -7.673, P <.001) of symptoms than the euhydrated subjects on the Graded Symptom Checklist. Conclusions: Our results suggest that moderate dehydration (-2.5 +/- 0.63%) significantly influenced the self-report of symptoms commonly associated with concussion. Dehydration resulted in a deterioration of visual memory and increases in the self-report of fatigue. Despite these findings, dehydration did not affect other neuropsychological and postural stability objective testing measures for concussion.	Univ N Carolina, Sports Med Res Lab, Fetzer Gymnasium, Chapel Hill, NC 27599 USA	Guskiewicz, KM (corresponding author), Univ N Carolina, Sports Med Res Lab, Fetzer Gymnasium, CB 8700,South Rd, Chapel Hill, NC 27599 USA.	gus@email.unc.edu		Mihalik, Jason/0000-0001-6085-8322; Guskiewicz, Kevin/0000-0002-8682-2130			ARMSTRONG L E, 1987, Annals of Sports Medicine, V3, P182; Bleiberg J, 2000, CLIN NEUROPSYCHOL, V14, P287, DOI 10.1076/1385-4046(200008)14:3;1-P;FT287; CANTU RC, 1992, SPORTS MED, V14, P64, DOI 10.2165/00007256-199214010-00005; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Casa DJ, 2000, J ATHL TRAINING, V35, P212; Cian C, 2001, INT J PSYCHOPHYSIOL, V42, P243, DOI 10.1016/S0167-8760(01)00142-8; Davranche K, 2004, J SPORT SCI, V22, P419, DOI 10.1080/02640410410001675289; Derave W, 1998, ERGONOMICS, V41, P782, DOI 10.1080/001401398186630; ELSABBAN F, 1995, INT J BIOMETEOROL, V38, P92, DOI 10.1007/BF01270666; ENGLAND AC, 1982, ANN INTERN MED, V97, P196, DOI 10.7326/0003-4819-97-2-196; Gauchard GC, 2002, INT J NEUROSCI, V112, P1191, DOI 10.1080/00207450290026157; Giza CC, 2001, J ATHL TRAINING, V36, P228; GOPINATHAN PM, 1988, ARCH ENVIRON HEALTH, V43, P15, DOI 10.1080/00039896.1988.9934367; GROSS PM, 1985, BRAIN RES, V330, P329, DOI 10.1016/0006-8993(85)90693-6; Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; GUSKIEWICZ KM, 1997, MED SCI SPORTS EXERC, V29, P213; KARVONEN MJ, 1957, ANN MED EXP BIOL FEN, V35, P307; KOOB GF, 1989, BRAIN RES BULL, V23, P359, DOI 10.1016/0361-9230(89)90222-0; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; Maroon Joseph C, 2002, Clin Neurosurg, V49, P319; McArdle WD, 2001, EXERCISE PHYSL ENERG; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2001, J ATHL TRAINING, V36, P274; McEwen B. B., 2004, ADV PHARMACOL, V50, p[531, 655], DOI DOI 10.1016/S1054-3589(04)50001-7; PACKARD MG, 1985, REGUL PEPTIDES, V11, P51, DOI 10.1016/0167-0115(85)90031-X; PARDINI D, 2004, 2 INT S CONC SPORT N; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Reghunandanan V., 1998, Indian Journal of Experimental Biology, V36, P635; Riemann BL, 1999, J SPORT REHABIL, V8, P71, DOI 10.1123/jsr.8.2.71; Shirreffs SM, 2004, BRIT J NUTR, V91, P951, DOI 10.1079/BJN20041149; Szinnai G, 2005, AM J PHYSIOL-REG I, V289, pR275, DOI 10.1152/ajpregu.00501.2004; Tomporowski PD, 2003, ACTA PSYCHOL, V112, P297, DOI 10.1016/S0001-6918(02)00134-8	37	78	79	0	22	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	JAN-MAR	2007	42	1					66	75					10	Sport Sciences	Sport Sciences	158BS	WOS:000245766500012	17597946				2021-06-18	
J	Jones, K; Sharp, C; Mangram, AJ; Dunn, EL				Jones, Kory; Sharp, Collin; Mangram, Alicia J.; Dunn, Ernest L.			The effects of preinjury clopidogrel use on older trauma patients with head injuries	AMERICAN JOURNAL OF SURGERY			English	Article; Proceedings Paper	58th Annual Meeting of the Southwestern-Surgical-Congress	APR 03-07, 2006	Kauai, HI	SW Surg Congress		clopidogrel; trauma; head injury	INTRACRANIAL HEMORRHAGE; ELDERLY-PATIENTS; WARFARIN USE; MORTALITY; OUTCOMES	Background: This Study was designed to determine whether or not older trauma patients on clopidogrel have an increased risk of morbidity and mortality. Methods: A retrospective review was performed on all trauma patients >= 50 years of age between January 1, 2002, and August 31, 2005. The charts of those patients who had documented preinjury use of clopidogrel were further reviewed. A control group of patients with no history of clopidogrel use was matched for age, sex, mechanism of injury, and injury severity score. Results: During this time period, there were 1,020 trauma patients >= 50 years of age admitted, 43 of which had documented preinjury clopiclogrel use (P). A higher percentage of patients in the P group underwent cranial Surgery, had episodes of rebleeds, and required transfusions of blood products than in the control group. The mortality and length of stay were comparable in both groups. Conclusion: This study indicates that the preinjury use of clopidogrel may cause significant morbidity in patients with closed-head injuries. Further studies are needed to suggest specific treatment modalities. (c) 2006 Excerpta Medica Inc. All rights reserved.	Med Educ Dept, Dept Surg, Methodist Hlth Syst, Dallas, TX 75203 USA	Dunn, EL (corresponding author), Med Educ Dept, Dept Surg, Methodist Hlth Syst, 1441 N Beckley Ave, Dallas, TX 75203 USA.	bertaturner@mhd.com					ABUHAJIR M, 1999, ANESTHESIOL CLIN N A, V17, P749; Ferrera PC, 1999, AM J EMERG MED, V17, P154, DOI 10.1016/S0735-6757(99)90050-5; Gallagher SF, 2003, AM J SURG, V185, P131, DOI 10.1016/S0002-9610(02)01208-4; Ivascu FA, 2005, J TRAUMA, V59, P1131, DOI 10.1097/01.ta.0000189067.16368.83; Kennedy DM, 2000, J TRAUMA, V48, P451, DOI 10.1097/00005373-200003000-00012; Lavoie A, 2004, J TRAUMA, V56, P802, DOI 10.1097/01.TA.0000066183.02177.AF; Ohm C, 2005, J TRAUMA, V58, P518, DOI 10.1097/01.TA.0000151671.35280.8B; SCHWAB CW, 1992, ARCH SURG-CHICAGO, V127, P701; Spektor S, 2003, J NEUROSURG, V99, P661, DOI 10.3171/jns.2003.99.4.0661; STEIN J, 1995, ARCH PHYS MED REHAB, V76, P840, DOI 10.1016/S0003-9993(95)80549-4	10	78	79	0	1	EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC	BRIDGEWATER	685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA	0002-9610	1879-1883		AM J SURG	Am. J. Surg.	DEC	2006	192	6					743	745		10.1016/j.amjsurg.2006.08.037			3	Surgery	Surgery	118FS	WOS:000242928400015	17161086				2021-06-18	
J	Manley, GT; Rosenthal, G; Lam, M; Morabito, D; Yan, DH; Derugin, N; Bollen, A; Knudson, MM; Panter, SS				Manley, GT; Rosenthal, G; Lam, M; Morabito, D; Yan, DH; Derugin, N; Bollen, A; Knudson, MM; Panter, SS			Controlled cortical impact in swine: Pathophysiology and biomechanics	JOURNAL OF NEUROTRAUMA			English	Article						CCI; head injury; TBI model; neuromonitoring	TRAUMATIC BRAIN-INJURY; FLUID-PERCUSSION; RAT; MILD; PIGS; HIPPOCAMPUS; PROTEIN; MARKER; CORTEX; GLIA	Investigations of the basic pathological, cellular, and molecular mechanisms of traumatic brain injury (TBI) over the past two decades have been carried out primarily in rodents. Unfortunately, these studies have not translated into improved outcome in patients with TBI. To better model human TBI, a swine model of controlled cortical impact (CCI) was developed. A CCI device was used to generate a focal lesion in 23 anesthetized male Yorkshire swine. In 10 swine, CCI parameters of velocity and dwell time were varied to achieve a consistent injury (3.5 m/sec, 400 msec, respectively). In 13 swine, depth of depression was varied from 9 to 12 mm. Physiological data, including heart rate (HR), mean arterial blood pressure (MAP), intracranial pressure (ICP), and cerebral perfusion pressure (CPP), were collected for 10 h after injury. Following injury, ICP and HR increased above baseline values in all swine, with a more pronounced elevation in animals impacted to a depth of depression of 12 mm. An 11-mm depth of depression was found to most closely mimic pathological features of human TBI with edema, infiltration of inflammatory cells, pericapillary hemorrhage, and petechial hemorrhages in the white matter. Injury to a depth of depression of 12 mm resulted in cortical laceration obscuring these features. Immunohistological staining with Neu-N, MAP-2, and Fluoro Jade B revealed evidence of degenerating neurons, axonal disruption, and impending cell death. These results indicate that the swine model of CCI results in a defined and reproducible injury with pathological features similar to human TBI. Physiological parameters after injury are readily monitored in a setting mimicking conditions of an intensive care unit, establishing a more clinically relevant experimental model for future investigations.	Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94110 USA; Univ Calif San Francisco, Dept Surg, San Francisco, CA 94110 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94110 USA	Manley, GT (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, 1001 Potrero Ave,Bldg 1,Rm 101, San Francisco, CA 94110 USA.	manley@itsa.ucsf.edu			PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49, CCR903697] Funding Source: Medline		Alessandri B, 2003, J NEUROTRAUM, V20, P1293, DOI 10.1089/089771503322686094; BASS NH, 1971, J COMP NEUROL, V143, P481, DOI 10.1002/cne.901430405; Bonde C, 2002, NEUROSCI LETT, V327, P49, DOI 10.1016/S0304-3940(02)00382-8; Brodhun M, 2001, ACTA NEUROPATHOL, V101, P424; Dawson DA, 1996, J CEREBR BLOOD F MET, V16, P170, DOI 10.1097/00004647-199601000-00020; DIXON C E, 1988, Journal of Neurotrauma, V5, P91, DOI 10.1089/neu.1988.5.91; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Duhaime AC, 2000, J NEUROSURG, V93, P455, DOI 10.3171/jns.2000.93.3.0455; Fakhry SM, 2004, J TRAUMA, V56, P492, DOI 10.1097/01.TA.0000115650.07193.66; Finnie JW, 2002, VET PATHOL, V39, P679, DOI 10.1354/vp.39-6-679; Folkerts MM, 1998, J NEUROTRAUM, V15, P349, DOI 10.1089/neu.1998.15.349; FREIDE VR, 1954, ACTA ANAT, V20, P290; Gefen A, 2003, J NEUROTRAUM, V20, P1163, DOI 10.1089/089771503770802853; GRAHAM DI, 2002, GREENFIELDS NEUROPAT, V1, P823; Grate LL, 2003, J NEUROSCI METH, V123, P201, DOI 10.1016/S0165-0270(02)00361-8; HANNON JP, 1990, LAB ANIM SCI, V40, P293; HAWKINS A, 1957, SCIENCE, V126, P76, DOI 10.1126/science.126.3263.76; HICKS RR, 1995, BRAIN RES, V678, P151, DOI 10.1016/0006-8993(95)00179-T; King DR, 2004, SURGERY, V136, P355, DOI 10.1016/j.surg.2004.05.011; KITAGAWA K, 1989, NEUROSCIENCE, V2, P401; KRAUS JF, 1994, SEMIN NEUROL, V14, P1, DOI 10.1055/s-2008-1041052; LIGHTHALL J W, 1989, Journal of Neurotrauma, V6, P83, DOI 10.1089/neu.1989.6.83; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; Thibault KL, 1998, J BIOMECH, V31, P1119, DOI 10.1016/S0021-9290(98)00122-5	28	78	81	0	11	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	FEB	2006	23	2					128	139		10.1089/neu.2006.23.128			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	020HX	WOS:000235900600002	16503797				2021-06-18	
J	Smith, DC; Modglin, AA; Roosevelt, RW; Neese, SL; Jensen, RA; Browning, RA; Clough, RW				Smith, DC; Modglin, AA; Roosevelt, RW; Neese, SL; Jensen, RA; Browning, RA; Clough, RW			Electrical stimulation of the vagus nerve enhances cognitive and motor recovery following moderate fluid percussion injury in the rat	JOURNAL OF NEUROTRAUMA			English	Article						fluid percussion; memory; norepinephrine; recovery of function; skilled reaching; traumatic brain injury; vagus nerve stimulation	TRAUMATIC BRAIN-INJURY; UNILATERAL SENSORIMOTOR CORTEX; NOREPINEPHRINE TURNOVER; FUNCTIONAL RECOVERY; LOCOMOTOR FUNCTION; PROMOTES RECOVERY; LOCUS-COERULEUS; AMPHETAMINE; VAGAL; EPILEPSY	Intermittent, chronically delivered electrical stimulation of the vagus nerve (VNS) is an FDA-approved procedure for the treatment of refractory complex/partial epilepsy in humans. Stimulation of the vagus has also been shown to enhance memory storage processes in laboratory rats and human subjects. Recent evidence suggests that some of these effects of VNS may be due to the activation of neurons in the nucleus locus coeruleus resulting in the release of norepinephrine (NE) throughout the neuraxis. Because antagonism of NE systems has been shown to delay recovery of function following brain damage, it is possible that enhanced release of NE in the CNS may facilitate recovery of function. To evaluate this hypothesis the lateral fluid percussion injury (LFP) model of traumatic brain injury was used and a variety of motor and cognitive behavioral tests were employed to assess recovery in pre-trained stimulated, control, and sham-injured laboratory rats. Two hours following moderate LFP, vagus nerve stimulation (30.0-sec trains of 0.5 mA, 20.0 Hz, biphasic pulses) was initiated. Stimulation continued in each animal's home cage at 30-min intervals for a period of 14 days, with the exception of brief periods when the animals were disconnected for behavioral assessments. Motor behaviors were evaluated every other day following LFP and tests included beam walk, locomotor placing, and skilled forelimb reaching. In each measure an enhanced rate of recovery and/or level of final performance was observed in the VNS-LFP animals compared to nonstimulated LFP controls. Behavior in the Morris water maze was assessed on days 11-14 following injury. Stimulated LFP animals showed significantly shorter latencies to rind the hidden platform than did controls. Despite these behavioral effects, neurohistological examination did not reveal significant differences in lesion extent, density of fluorojade positive neurons, reactive astrocytes or numbers of spared neurons in the CA3 subarea of the hippocampus, at least at the one time point studied 15 days post-injury. These results support the idea that vagus nerve stimulation enhances the neural plasticity that underlies recovery of function following brain damage and provides indirect support for the hypothesis that enhanced NE release may mediate the effect. Importantly, since VNS facilitated both the rate of recovery and the extent of motor and cognitive recovery, these findings suggest that electrical stimulation of the vagus nerve may prove to be an effective non-pharmacological treatment for traumatic brain injury.	So Illinois Univ, Sch Med, Dept Psychol, Brain & Cognit Sci Program, Carbondale, IL 62901 USA; So Illinois Univ, Sch Med, Dept Physiol, Carbondale, IL 62901 USA; So Illinois Univ, Sch Med, Dept Anat, Carbondale, IL 62901 USA	Smith, DC (corresponding author), So Illinois Univ, Sch Med, Dept Psychol, Brain & Cognit Sci Program, Carbondale, IL 62901 USA.	dcsmith@siu.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS041551-04, R01 NS041551, R01 NS041551-03, R01 NS041551-02, R01 NS041551-01A1, NS 41551] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS041551] Funding Source: NIH RePORTER		ARDELL JL, 1986, AM J PHYSIOL, V251, pH764; BOYESON MG, 1990, PHARMACOL BIOCHEM BE, V35, P497, DOI 10.1016/0091-3057(90)90279-Q; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; BROWNING RA, 1987, NEUROTRANSMITTERS EP, P277; Bury SD, 2002, J NEUROSCI, V22, P8597; Clark KB, 1998, NEUROBIOL LEARN MEM, V70, P364, DOI 10.1006/nlme.1998.3863; CLARK KB, 1995, NEUROBIOL LEARN MEM, V63, P213, DOI 10.1006/nlme.1995.1024; Clark KB, 1999, NAT NEUROSCI, V2, P94; CRISOSTOMO EA, 1988, ANN NEUROL, V23, P94, DOI 10.1002/ana.410230117; CRONBACH LJ, 1951, PSYCHOMETRIKA, V16, P297; D'Ambrosio R, 2005, BRAIN, V128, P174, DOI 10.1093/brain/awh337; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; Dietrich WD, 1996, NEUROTRAUMA, P1491; DUNNMEYNELL A, 1994, BRAIN RES, V660, P88, DOI 10.1016/0006-8993(94)90842-7; FEENEY DM, 1990, CAN J PSYCHOL, V44, P233, DOI 10.1037/h0084243; Feeney DM, 1998, RESTORATIVE NEUROLOGY, P35; FEENEY DM, 1985, BRAIN RES, V342, P352, DOI 10.1016/0006-8993(85)91135-7; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FEENEY DM, 1987, CRIT REV NEUROBIOL, V3, P135; FEENEY DM, 1985, PHYSIOL PSYCHOL, V13, P197; FEENEY DM, 1983, PSYCHOPHARMACOLOGY, V79, P67, DOI 10.1007/BF00433018; FEENEY DM, 1988, PHARM APPROACHES TRE, P121; Fisher RS, 1999, NEUROLOGY, V53, P666, DOI 10.1212/WNL.53.4.666; Floyd CL, 2002, J NEUROTRAUM, V19, P303, DOI 10.1089/089771502753594873; Friedberg MH, 1999, J NEUROPHYSIOL, V81, P2243; Gladstone DJ, 2000, CAN J NEUROL SCI, V27, P97; Goldstein LB, 1998, RESTORATIVE NEUROLOGY, P241; Goldstein LB, 1997, PHARMACOL BIOCHEM BE, V58, P1151, DOI 10.1016/S0091-3057(97)00324-9; GOLDSTEIN M, 1990, ANN NEUROL, V27, P327, DOI 10.1002/ana.410270315; Groves DA, 2005, NEUROSCI BIOBEHAV R, V29, P493, DOI 10.1016/j.neubiorev.2005.01.004; Groves DA, 2005, NEUROSCI LETT, V379, P174, DOI 10.1016/j.neulet.2004.12.055; GUEDEL AE, 1920, INHALATIONAL ANESTHE, P10; Hassert DL, 2004, BEHAV NEUROSCI, V118, P79, DOI 10.1037/0735-7044.118.1.79; Hatton J, 2001, CNS DRUGS, V15, P553, DOI 10.2165/00023210-200115070-00005; HERMANN GE, 1985, J AUTONOM NERV SYST, V13, P1, DOI 10.1016/0165-1838(85)90002-5; Hernandez TD, 1997, NEUROLOGY, V48, P803, DOI 10.1212/WNL.48.4.803; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Hoane MR, 2004, J NEUROTRAUM, V21, P163, DOI 10.1089/089771504322778622; Hoane MR, 1997, RESTOR NEUROL NEUROS, V11, P71, DOI 10.3233/RNN-1997-111208; Hoover RC, 2004, J NEUROTRAUM, V21, P501, DOI 10.1089/089771504774129847; HOVDA DA, 1984, BRAIN RES, V298, P358, DOI 10.1016/0006-8993(84)91437-9; JOBE PC, 1986, LIFE SCI, V39, P775, DOI 10.1016/0024-3205(86)90455-8; Jobe PC, 2003, EPILEPSY BEHAV, V4, pS14, DOI 10.1016/j.yebeh.2003.08.020; KASAMATSU T, 1976, SCIENCE, V194, P206, DOI 10.1126/science.959850; Kikuchi K, 2000, BRAIN RES, V860, P130, DOI 10.1016/S0006-8993(00)02034-5; Krahl S. E., 1994, Society for Neuroscience Abstracts, V20, P1453; Krahl SE, 1998, EPILEPSIA, V39, P709, DOI 10.1111/j.1528-1157.1998.tb01155.x; LEVIN BE, 1995, BRAIN RES, V674, P307, DOI 10.1016/0006-8993(95)00032-L; Li HH, 2004, J NEUROTRAUM, V21, P1141, DOI 10.1089/0897715041953777; MARKLUND N, 2004, EXCITOTOXICITY NEURO, P189; Maynert E W, 1975, Adv Neurol, V13, P79; MCINTOSH TK, 1994, J NEUROCHEM, V63, P1426; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Metz GAS, 2000, BEHAV BRAIN RES, V116, P111, DOI 10.1016/S0166-4328(00)00245-X; MEYER PM, 1963, J COMP PHYSIOL PSYCH, V56, P402, DOI 10.1037/h0049297; NARITOKU DK, 1995, EPILEPSY RES, V22, P53, DOI 10.1016/0920-1211(95)00035-9; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Queen SA, 1997, BRAIN RES, V777, P42, DOI 10.1016/S0006-8993(97)00717-8; ROOSEVELT RW, 2004, SOC NEUROSCI; ROOSEVELT RW, 2000, SOC NEUROSCI ABSTRAC; Saatman KE, 1997, EXP NEUROL, V147, P418, DOI 10.1006/exnr.1997.6629; Schachter SC, 1998, EPILEPSIA, V39, P677, DOI 10.1111/j.1528-1157.1998.tb01151.x; Schmanke TD, 1996, J NEUROTRAUM, V13, P293, DOI 10.1089/neu.1996.13.293; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; SMITH DC, 2005, NAT NEUR SOC S WASH; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Statler KD, 2001, J NEUROTRAUM, V18, P1195, DOI 10.1089/089771501317095232; Sutton RL, 2000, NEURAL PLAST, V7, P109, DOI 10.1155/NP.2000.109; SUTTON RL, 1989, BEHAV NEUROSCI, V103, P837, DOI 10.1037/0735-7044.103.4.837; SUTTON RL, 1987, J HEAD TRAUMA REHAB, V2, P50; TAKIGAWA M, 1977, BRAIN RES, V135, P217, DOI 10.1016/0006-8993(77)91027-7; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; WALKERBATSON D, 1995, STROKE, V26, P2254, DOI 10.1161/01.STR.26.12.2254; Whishaw IQ, 2002, BEHAV BRAIN RES, V134, P323, DOI 10.1016/S0166-4328(02)00051-7; Whishaw IQ, 2004, J NEUROTRAUM, V21, P1584, DOI 10.1089/neu.2004.21.1584; WOODBURY DM, 1990, EPILEPSIA, V31, pS7, DOI 10.1111/j.1528-1157.1990.tb05852.x	79	78	91	0	16	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2005	22	12					1485	1502		10.1089/neu.2005.22.1485			18	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	000EA	WOS:000234442500010	16379585	Green Accepted			2021-06-18	
J	Fuller, CW; Junge, A; Dvorak, J				Fuller, CW; Junge, A; Dvorak, J			A six year prospective study of the incidence and causes of head and neck injuries in international football	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							PROFESSIONAL FOOTBALL; ANKLE INJURIES; BRAIN-INJURY; SOCCER; MECHANISMS; CONCUSSION; RISK	Objective: To identify those risk factors that have the greatest impact on the incidence of head and neck injuries in international football. Method: A case-control study of players sustaining head and neck injuries during 20 FIFA tournaments (men and women) from 1998 to 2004. Video recordings of incidents were used to identify a range of parameters associated with the incidents. Team physicians provided medical reports describing the nature of each injury. chi(2) tests (p <= 0.01) and 95% confidence intervals were used to assess differences in distribution and incidence of injury, respectively. Results: In total, 248 head and neck injuries were recorded of which 163 were identified and analysed on video sequences. The commonest injuries were contusions (53%), lacerations (20%), and concussions (11%). The incidence of all head and neck injuries was 12.5/1000 player hours (men 12.8, women 11.5) and 3.7 for lost-time injuries (men 3.5, women 4.1). The commonest causes of injury involved aerial challenges (55%) and the use of the upper extremity (33%) or head (30%). The unfair use of the upper extremity was significantly more likely to cause an injury than any other player action. Only one injury (a neck muscle strain) occurred as a result of heading the ball throughout the 20 tournaments equivalent to 0.05 injuries/ 1000 player hours. Conclusions: Players' actions most likely to cause a head or neck injury were the use of the upper extremity or the head but in the majority of cases these challenges were deemed to be fair and within the laws of the game.	Univ Leicester, Scarman Ctr, Leicester, Leics, England; Schulthess Clin, Zurich, Switzerland	Fuller, CW (corresponding author), Univ Leicester, Scarman Ctr, Leicester, Leics, England.	cwf2@le.ac.uk					Andersen TE, 2004, BRIT J SPORT MED, V38, P690, DOI 10.1136/bjsm.2003.009357; Andersen TE, 2003, BRIT J SPORT MED, V37, P226, DOI 10.1136/bjsm.37.3.226; Andersen TE, 2004, AM J SPORT MED, V32, p69S, DOI 10.1177/0363546503262023; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; Cantu RC, 1996, BRIT J SPORT MED, V30, P289, DOI 10.1136/bjsm.30.4.289; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; DEMETRIADES AK, 2003, BRIT J SPORT MED, V30, P289; Dvorak J, 2000, AM J SPORT MED, V28, pS3; ETTLINGER CF, 1995, AM J SPORT MED, V23, P531, DOI 10.1177/036354659502300503; FAUDE O, IN PRESS AM J SPORTS; *FIFA, 2004, REP STAT FIFA TOURN; *FOOTB ASS, 2004, RUL ASS LAWS GAM SEA; Fuller CW, 2004, AM J SPORT MED, V32, p17S, DOI 10.1177/0363546503261249; Fuller CW, 2004, AM J SPORT MED, V32, p43S, DOI 10.1177/0363546503261248; Fuller CW, 2004, AM J SPORT MED, V32, p28S, DOI 10.1177/0363546503261247; Fuller CW, 1997, SAFETY SCI, V27, P115; Giza E, 2003, AM J SPORT MED, V31, P550, DOI 10.1177/03635465030310041201; Guskiewicz KM, 2002, AM J SPORT MED, V30, P157, DOI 10.1177/03635465020300020201; Hawkins RD, 1998, BRIT J SPORT MED, V32, P326, DOI 10.1136/bjsm.32.4.326; Hawkins RD, 1996, BRIT J SPORT MED, V30, P165, DOI 10.1136/bjsm.30.2.165; Hawkins RD, 1999, BRIT J SPORT MED, V33, P196, DOI 10.1136/bjsm.33.3.196; Johnston KM, 2001, CLIN J SPORT MED, V11, P150, DOI 10.1097/00042752-200107000-00005; Junge A, 2004, AM J SPORT MED, V32, p80S, DOI 10.1177/0363546503261245; Kirkendall DT, 2001, SPORTS MED, V31, P369, DOI 10.2165/00007256-200131050-00006; Lewin G., 1989, PHYSIOTHERAPY, V75, P601; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; McCrory PR, 2003, BRIT MED J, V327, P351, DOI 10.1136/bmj.327.7411.351; McCrory PR, 1997, BRIT MED J, V314, P171, DOI 10.1136/bmj.314.7075.171; Putukian M, 2000, CLIN J SPORT MED, V10, P104, DOI 10.1097/00042752-200004000-00004; Putukian Margot, 2004, Curr Sports Med Rep, V3, P9; Rahnama N, 2002, BRIT J SPORT MED, V36, P354, DOI 10.1136/bjsm.36.5.354; Rutherford A, 2003, NEUROPSYCHOL REV, V13, P153, DOI 10.1023/A:1025525613477; TYSVAER AT, 1992, SPORTS MED, V14, P200, DOI 10.2165/00007256-199214030-00006; Wilson B D, 1999, J Sci Med Sport, V2, P153, DOI 10.1016/S1440-2440(99)80195-9; Wojtys EM, 1999, AM J SPORT MED, V27, P676, DOI 10.1177/03635465990270052401	38	78	79	1	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	AUG	2005	39			1			I3	I9		10.1136/bjsm.2005.018937			7	Sport Sciences	Sport Sciences	954KI	WOS:000231153600002	16046353	Green Published, Bronze			2021-06-18	
J	Levin, HS; McCauley, SR; Josic, CP; Boake, C; Brown, SA; Goodman, HS; Merritt, SG; Brundage, SI				Levin, HS; McCauley, SR; Josic, CP; Boake, C; Brown, SA; Goodman, HS; Merritt, SG; Brundage, SI			Predicting depression following mild traumatic brain injury	ARCHIVES OF GENERAL PSYCHIATRY			English	Article							MINOR HEAD-INJURY; MAJOR DEPRESSION; COMMUNITY SAMPLE; PSYCHIATRIC-DISORDERS; MOOD DISORDERS; UNITED-STATES; SYMPTOMS; PREVALENCE; SCALE; RELIABILITY	Context: Minimizing negative consequences of major depression following traumatic brain injury is an important public health objective. Identifying high-risk patients and referring them for treatment could reduce morbidity and loss of productivity. Objective: To develop a model for early screening of patients at risk for major depressive episode at 3 months after traumatic brain injury. Design: Prediction model using receiver operating characteristic curve. Setting: Level I trauma center in a major metropolitan area. Participants: Prospective cohort of 129 adults with mild traumatic brain injury. Main Outcome Measures: Center for Epiderniologic Studies Depression Scale score and current major depressive episode module of the Structured Clinical Interview for the DSM-IV. Results: A prediction model including higher I-week Center for Epiderniologic Studies Depression Scale score, older age, and computed tomographic scans of intracranial lesions yielded 93% sensitivity and 62% specificity. Conclusion: This study supports the feasibility of identifying patients with mild traumatic brain injury who are at high risk for developing major depressive episode by 3 months' postinjury, which could facilitate selective referral for potential treatment and reduction of negative outcomes.	Baylor Coll Med, Cognit Neurosci Lab, Phys Med & Rehabil Alliance, Houston, TX 77030 USA; Univ Texas, Sch Med, Houston, TX USA; Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; Baylor Coll Med, Dept Psychiat & Behav Sci, Houston, TX 77030 USA; Baylor Coll Med, Dept Surg, Houston, TX 77030 USA	Levin, HS (corresponding author), Baylor Coll Med, Cognit Neurosci Lab, Phys Med & Rehabil Alliance, 6560 Fannin St,Suite 1144, Houston, TX 77030 USA.	hlevin@bcm.tmc.edu			ODCDC CDC HHS [R49/CCR612707] Funding Source: Medline		American Psychiatric Association, 1994, DIAGN STAT MAN MENT; BEEKMAN ATF, 1997, TIJDSCHRIFT PSYCHIAT, V0039; BLAZER DG, 1994, AM J PSYCHIAT, V151, P979; BOAKE C, IN PRESS NEUROSURGER; BOYD JH, 1982, ARCH GEN PSYCHIAT, V39, P1195; Cocco KM, 1998, PSYCHOL ASSESSMENT, V10, P408, DOI 10.1037/1040-3590.10.4.408; *COMM INJ SCAL, 1990, ABBR INJ SCAL; DAVIDSON H, 1994, J GERONTOL, V49, pP159, DOI 10.1093/geronj/49.4.P159; Deb S, 1998, J NEUROL NEUROSUR PS, V65, P899, DOI 10.1136/jnnp.65.6.899; Deb S, 1999, AM J PSYCHIAT, V156, P374; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; First M.B., 1996, STRUCTURED CLIN INTE; GOLDING JM, 1991, J CLIN PSYCHOL, V47, P61, DOI 10.1002/1097-4679(199101)47:1<61::AID-JCLP2270470110>3.0.CO;2-E; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; GUTH PE, 2000, DISS ABSTR INT, V51, P1803; Haarasilta L, 2001, PSYCHOL MED, V31, P1169, DOI 10.1017/S0033291701004573; HIMMELFARB S, 1983, J GERONTOL, V38, P333, DOI 10.1093/geronj/38.3.333; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Iwata N, 2002, PSYCHIAT RES, V110, P281, DOI 10.1016/S0165-1781(02)00102-6; Jonas BS, 2003, SOC PSYCH PSYCH EPID, V38, P618, DOI 10.1007/s00127-003-0682-8; Jorge R, 2003, INT REV PSYCHIATR, V15, P317, DOI 10.1080/09540260310001606700; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; Langlois Jean A, 2003, MMWR Surveill Summ, V52, P1; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; MacKenzie E., 1991, J HEAD TRAUMA REHAB, V6, P76, DOI [10.1097/00001199-199106000-00010, DOI 10.1097/00001199-199106000-00010]; Maisto SA, 2000, PSYCHOL ASSESSMENT, V12, P186, DOI 10.1037/1040-3590.12.2.186; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MYERS JK, 1980, AM J PSYCHIAT, V137, P1081; MYERS JK, 1984, ARCH GEN PSYCHIAT, V41, P959; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; REGIER DA, 1988, ARCH GEN PSYCHIAT, V45, P977; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROBERTS RE, 1980, PSYCHIAT RES, V2, P125, DOI 10.1016/0165-1781(80)90069-4; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; *SAS I INC, 2001, STAT AN SOFTW WIND C; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; SCHOENHUBER R, 1988, J NEUROL NEUROSUR PS, V51, P722, DOI 10.1136/jnnp.51.5.722; Schopp LH, 2001, J CLIN PSYCHOL MED S, V8, P181, DOI 10.1023/A:1011369620254; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; SHINAR D, 1986, STROKE, V17, P241, DOI 10.1161/01.STR.17.2.241; TEASDALE G, 1974, LANCET, V2, P81; VERA M, 1991, AM J EPIDEMIOL, V134, P502, DOI 10.1093/oxfordjournals.aje.a116122; WEISSMAN MM, 1977, AM J EPIDEMIOL, V106, P203, DOI 10.1093/oxfordjournals.aje.a112455; WHITMAN S, 1984, AM J EPIDEMIOL, V119, P570, DOI 10.1093/oxfordjournals.aje.a113774; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014	52	78	78	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0003-990X			ARCH GEN PSYCHIAT	Arch. Gen. Psychiatry	MAY	2005	62	5					523	528		10.1001/archpsyc.62.5.523			6	Psychiatry	Psychiatry	923JG	WOS:000228905600008	15867105	Bronze			2021-06-18	
J	Ozdemir, D; Uysal, N; Gonenc, S; Acikgoz, O; Sonmez, A; Topcu, A; Ozdemir, N; Duman, M; Semin, I; Ozkan, H				Ozdemir, D; Uysal, N; Gonenc, S; Acikgoz, O; Sonmez, A; Topcu, A; Ozdemir, N; Duman, M; Semin, I; Ozkan, H			Effect of melatonin on brain oxidative damage induced by traumatic brain injury in immature rats	PHYSIOLOGICAL RESEARCH			English	Article						traumatic brain injury (TBI); immature rat; lipid peroxidation; superoxide dismutase (SOD); glutathione peroxidase (GPx); melatonin	INDUCED LIPID-PEROXIDATION; EXPERIMENTAL HEAD TRAUMA; GLUTATHIONE-PEROXIDASE; SUPEROXIDE-DISMUTASE; FREE-RADICALS; DNA-DAMAGE; IN-VITRO; STRESS; PROTECTS; CHILDREN	Progressive compromise of antioxidant defenses and free radical-mediated lipid peroxidation, which is one of the major mechanisms of secondary traumatic brain injury (TBI), has also been reported in pediatric head trauma. In the present study, we aimed to demonstrate the effect of melatonin, which is a potent free radical scavenger, on brain oxidative damage in 7-day-old rat pups subjected to contusion injury. Whereas TBI significantly increased thiobarbituric acid reactive substances (TBARS) levels, there was no compensatory increase in the antioxidant enzymes such as superoxide dismutase (SOD) and glutathione peroxidase (GPx) 24 hours after TBI in 7-day-old rats. Melatonin administered as a single dose of 5 mg/kg prevented the increase in TBARS levels in both non-traumatized and traumatized brain hemispheres. In conclusion, melatonin protects against oxidative damage induced by TBI in the immature brain.	Dokuz Eylul Univ, Sch Med, Dept Pediat, Inciralti, Turkey; Dokuz Eylul Univ, Sch Med, Dept Physiol, Inciralti, Turkey; Ataturk Training & Res Hosp, Dept Neurosurg, Izmir, Turkey	Ozkan, H (corresponding author), Dokuz Eylul Univ, Sch Med, Dept Pediat, TR-35340 Izmir, Turkey.	hasan.ozkan@deu.edu.tr		ACIKGOZ, OSMAN/0000-0003-1444-5847; Ozkan, Hasan/0000-0003-2542-7441; Duman, Murat/0000-0001-6767-5748; Semin, Ilgi/0000-0001-8747-5145; Uysal, Nazan/0000-0002-2348-7427			Adelson PD, 1998, J CHILD NEUROL, V13, P2, DOI 10.1177/088307389801300102; Bayir H, 2003, CRIT CARE CLIN, V19, P529, DOI 10.1016/S0749-0704(03)00014-9; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; Buonocore G, 2002, PEDIATR RES, V52, P46, DOI 10.1203/01.PDR.0000016664.46604.01; Buonocore G, 2001, BIOL NEONATE, V79, P180; CARRILLO MC, 1991, LIFE SCI, V48, P517, DOI 10.1016/0024-3205(91)90466-O; Cirak B, 1999, PEDIATR NEUROSURG, V31, P298, DOI 10.1159/000028879; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Cuzzocrea S, 2001, EUR J PHARMACOL, V426, P1, DOI 10.1016/S0014-2999(01)01175-X; DELMASBEAUVIEUX MC, 1995, CLIN BIOCHEM, V28, P163, DOI 10.1016/0009-9120(94)00071-3; EVANS PH, 1993, BRIT MED BULL, V49, P577, DOI 10.1093/oxfordjournals.bmb.a072632; Fan P, 2003, J NEUROTRAUM, V20, P437, DOI 10.1089/089771503765355513; Feuerstein GZ, 1997, ANN NY ACAD SCI, V825, P179, DOI 10.1111/j.1749-6632.1997.tb48428.x; Garcia JJ, 1997, FEBS LETT, V408, P297, DOI 10.1016/S0014-5793(97)00447-X; Gilad E, 1997, LIFE SCI, V60, pPL169, DOI 10.1016/S0024-3205(97)00008-8; HAGEMAN JJ, 1992, CHEM-BIOL INTERACT, V82, P243, DOI 10.1016/0009-2797(92)90001-2; Kabuto H, 1998, EPILEPSIA, V39, P237, DOI 10.1111/j.1528-1157.1998.tb01367.x; Kasprzak HA, 2001, J NEUROTRAUM, V18, P793, DOI 10.1089/089771501316919157; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; MELCHIORRI D, 1995, FASEB J, V9, P1205; Okatani Y, 2000, J PINEAL RES, V28, P89, DOI 10.1034/j.1600-079X.2001.280204.x; PAGLIA DE, 1967, J LAB CLIN MED, V70, P158; Pekarkova I, 2001, PHYSIOL RES, V50, P595; REHNCRONA S, 1980, J NEUROCHEM, V34, P1630, DOI 10.1111/j.1471-4159.1980.tb11254.x; Reiter RJ, 2000, BIOL SIGNAL RECEPT, V9, P160; Reiter RJ, 2000, J BIOMED SCI, V7, P444, DOI 10.1159/000025480; REITERRJ, 1998, PROG NEUROBIOL, V56, P359; Rodriguez C, 2004, J PINEAL RES, V36, P1, DOI 10.1046/j.1600-079X.2003.00092.x; Rogerio F, 2002, BRAIN RES, V926, P33, DOI 10.1016/S0006-8993(01)03286-3; SEWERYNEK E, 1995, FREE RADICAL BIO MED, V19, P903, DOI 10.1016/0891-5849(95)00101-3; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; Solar P, 1999, Cesk Fysiol, V48, P27; Stein SC, 1995, PEDIATR NEUROSURG, V23, P299, DOI 10.1159/000120975; Tan DX, 2000, FREE RADICAL BIO MED, V29, P1177, DOI 10.1016/S0891-5849(00)00435-4; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Undeger U, 2004, EXP TOXICOL PATHOL, V55, P379, DOI 10.1078/0940-2993-00332; Ustun ME, 2001, J TRAUMA, V51, P22, DOI 10.1097/00005373-200107000-00004; Ustun ME, 2001, J NEUROSURG ANESTH, V13, P227; Wakatsuki A, 1999, J PINEAL RES, V26, P147, DOI 10.1111/j.1600-079X.1999.tb00576.x; Wakatsuki A, 2001, J PINEAL RES, V31, P167, DOI 10.1034/j.1600-079x.2001.310211.x; Wakatsuki A, 2001, J PINEAL RES, V30, P22, DOI 10.1034/j.1600-079X.2001.300103.x; WATANABE N, 1986, CLIN CHEM, V32, P1551; Yamamoto H, 1996, J PINEAL RES, V21, P108, DOI 10.1111/j.1600-079X.1996.tb00277.x; Yamamoto HA, 2002, TOXICOLOGY, V179, P29, DOI 10.1016/S0300-483X(02)00244-5	44	78	83	0	13	ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY	PRAGUE 4	VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC	0862-8408	1802-9973		PHYSIOL RES	Physiol. Res.		2005	54	6					631	637					7	Physiology	Physiology	000RV	WOS:000234481000008	15720160	DOAJ Gold			2021-06-18	
J	Togher, L; McDonald, S; Code, C; Grant, S				Togher, L; McDonald, S; Code, C; Grant, S			Training communication partners of people with traumatic brain injury: A randomised controlled trial	APHASIOLOGY			English	Article							SOCIAL-SKILLS; HEAD-INJURY; APHASIA; CONVERSATION; DISCOURSE; ADULTS; REHABILITATION; INDIVIDUALS; IMPAIRMENT; VOLUNTEERS	Background : Communication disorders after traumatic brain injury (TBI) are difficult to modify due to the cognitive limitation imposed by frontal lobe damage. As an alternative approach, this paper describes a training programme designed to improve communication partners' responsiveness to people with TBI during routine service inquiries with a community agency. Aims : To evaluate the effectiveness of a training programme aimed at improving the communication of police officers during service encounters with people with TBI. Methods & Procedures : A total of 20 police officers were randomly assigned to two groups (training or control). Prior to the 6-week training programme, participants with TBI made a routine telephone inquiry to the police officers. Training focused on specific aspects of telephone inquiries previously documented to be aberrant in service encounters of people with TBI. Following the training programme, police subjects received another telephone service inquiry. Service encounters were transcribed and analysed using generic structure potential analysis. Outcome & Results : Comparison of pre- and post-training measures indicated that trained police had learned strategies to successfully establish the nature of the inquiry, provide a clear answer to the inquiry, and ensure appropriate leave taking, resulting in more efficient, focused interactions in the post-training telephone calls. People with TBI also altered their communication in the post-training calls, with reduced episodes of unrelated utterances and an increased proportion of the interaction devoted to completing the service encounter. This appeared to be in response to the communicative options they were given. Conclusions : This study demonstrates the efficacy of an approach based on training communication partners rather than people with TBI themselves. Training communication partners led to the provision of appropriate feedback, support, and structure of everyday interactions. Service encounters account for a significant amount of everyday communication exchanges, therefore training service providers has the potential to have a significant impact on the communicative effectiveness of people with TBI.	Univ Sydney, Fac Hlth Sci, Sch Commun Sci & Disorders, Lidcombe, NSW 2199, Australia; Univ NSW, Kensington, NSW, Australia; Univ Sydney, Sydney, NSW 2006, Australia; Univ Exeter, Exeter EX4 4QJ, Devon, England; Hanse Inst Adv Study, Delmenhorst, Germany	Togher, L (corresponding author), Univ Sydney, Fac Hlth Sci, Sch Commun Sci & Disorders, POB 170, Lidcombe, NSW 2199, Australia.	l.togher@fhs.usyd.edu.au	Togher, Leanne/AAC-7083-2019; Code, Chris/F-4259-2010; McDonald, Skye/G-4118-2014	McDonald, Skye/0000-0003-0723-6094; Togher, Leanne/0000-0002-4518-6748			Boles L, 1998, J COMMUN DISORD, V31, P261, DOI 10.1016/S0021-9924(98)00005-7; Booth S, 1999, INT J LANG COMM DIS, V34, P291, DOI 10.1080/136828299247423; Booth S, 1999, APHASIOLOGY, V13, P283, DOI 10.1080/026870399402109; Bourgeois MS, 2001, AUGMENT ALTERN COMM, V17, P196, DOI DOI 10.1080/714043383; BRAUNLINGMCMORROW D, 1986, J REHABIL, V52, P39; BRENNAN M, 1994, CLEAR TALK POLICE RE; BROTHERTON FA, 1988, ARCH PHYS MED REHAB, V69, P827; Burgio LD, 2001, GERONTOLOGIST, V41, P449, DOI 10.1093/geront/41.4.449; BYNG S, 2000, ACQUIRED NEUROLOGICA; Carnevale GJ, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199602000-00005; Carney N, 1999, J HEAD TRAUMA REHAB, V14, P277, DOI 10.1097/00001199-199906000-00008; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; Coelho CA, 1996, J SPEECH HEAR RES, V39, pS5, DOI 10.1044/jshr.3905.s5; Coelho CA, 1991, J HEAD TRAUMA REHAB, V6, P92, DOI DOI 10.1097/00001199-199106000-00011; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; EGGINS S, 1997, ANAL CONVERSATION; FLANAGAN S, 1995, BRAIN INJURY, V9, P321, DOI 10.3109/02699059509005773; Frattali C M, 1993, Disabil Rehabil, V15, P1; GAJAR A, 1984, J APPL BEHAV ANAL, V17, P353, DOI 10.1901/jaba.1984.17-353; Godfrey HPD, 2000, APHASIOLOGY, V14, P433, DOI 10.1080/026870300401441; Halliday M., 1994, INTRO FUNCTIONAL GRA, V3rd; Hartley L. L., 1995, COGNITIVE COMMUNICAT; Hasan R, 1985, LANGUAGE CONTEXT TEX; HELFFENSTEIN DA, 1982, INT J CLIN NEUROPSYC, V4, P139; Holland D, 1998, BRAIN INJURY, V12, P993, DOI 10.1080/026990598121918; Hopper T, 2002, APHASIOLOGY, V16, P745, DOI 10.1080/02687030244000059; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; JOHNSON DA, 1987, BRIT J CLIN PSYCHOL, V26, P289, DOI 10.1111/j.2044-8260.1987.tb01362.x; Kagan A, 2001, J SPEECH LANG HEAR R, V44, P624, DOI 10.1044/1092-4388(2001/051); LEWIS FD, 1988, BEHAV THER, V19, P203, DOI 10.1016/S0005-7894(88)80043-1; Lock S, 2001, INT J LANG COMM DIS, V36, P25, DOI 10.3109/13682820109177853; Luiselli JK, 2000, INT J OFFENDER THER, V44, P647, DOI 10.1177/0306624X00446002; Lyon JG, 1997, APHASIOLOGY, V11, P693, DOI 10.1080/02687039708249416; MARSH NV, 1999, BRAIN DAM B, P175; Martin J. R., 1992, ENGLISH TEXT SYSTEM; McDonald S, 1998, BRAIN LANG, V61, P88, DOI 10.1006/brln.1997.1846; MCDONALD S, 1993, BRAIN LANG, V44, P28, DOI 10.1006/brln.1993.1003; MCDONALD S, 2003, PSYCHOL INTERACTION, V13, P47; McDonald S, 1999, COMMUNICATION DISORD; MENTIS M, 1991, J SPEECH HEAR RES, V34, P583, DOI 10.1044/jshr.3403.583; NEWHOFF M, 1981, CLIN APHASIOLOGY, V11, P234; *NHIF, 1989, ED MAN WHAT ED NEED; OLVER J, 2001, 6 ANN BRAIN INJ REH; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; POUND C, 2000, APHASIA THERAPIES LI; Poynton C., 1985, LANGUAGE GENDER MAKI; PRUTTING CA, 1987, J SPEECH HEAR DISORD, V52, P105, DOI 10.1044/jshd.5202.105; Ripich D. N., 1999, CLIN GERONTOLOGIST, V21, P37, DOI DOI 10.1300/J018V21N01; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Schiffrin Deborah., 1987, DISCOURSE MARKERS; SCHLOSS PJ, 1985, APPL RES MENT RETARD, V6, P269, DOI 10.1016/0270-3092(85)90001-3; SIMMONS N, 1987, CLIN APHASIOLOGY, V17, P106; Simmons-Mackie N, 1999, APHASIOLOGY, V13, P807, DOI 10.1080/026870399401894; Simmons-Mackie N., 2000, NEUROGENIC COMMUNICA, P162; SMITH L, 1986, B COLLEGE SPEECH THE, V409, P10; SNOW P, 1995, APHASIOLOGY, V9, P365, DOI 10.1080/02687039508248210; STRATTON MC, 1994, BRAIN INJURY, V8, P631, DOI 10.3109/02699059409151016; Szekeres Shirley F., 1992, Seminars in Speech and Language, V13, P293, DOI 10.1055/s-2008-1064204; Tate RL, 1998, AUST NZ J PUBL HEAL, V22, P419, DOI 10.1111/j.1467-842X.1998.tb01406.x; Togher L, 1997, BRAIN INJURY, V11, P169, DOI 10.1080/026990597123629; Togher L, 1999, APHASIOLOGY, V13, P709, DOI 10.1080/026870399401821; Togher L, 1998, APHASIOLOGY, V12, P755, DOI 10.1080/02687039808249571; Togher L, 1997, APHASIOLOGY, V11, P491, DOI 10.1080/02687039708248486; Togher L, 1996, DISABIL REHABIL, V18, P559, DOI 10.3109/09638289609166317; Wilkinson IAG, 1998, READ RES QUART, V33, P144, DOI 10.1598/RRQ.33.2.1; Wood RL, 1997, BRAIN INJURY, V11, P491, DOI 10.1080/713802183; World Health Organization, 2001, INT CLASSIFICATION F; Worrall L, 2000, APHASIOLOGY, V14, P911, DOI 10.1080/02687030050127711; Ylvisaker M., 1998, TRAUMATIC BRAIN INJU; YVISAKER M, 1993, STAFF DEV CLIN INTER, P57	70	78	82	0	20	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0268-7038	1464-5041		APHASIOLOGY	Aphasiology	APR	2004	18	4					313	335		10.1080/02687030344000535			23	Audiology & Speech-Language Pathology; Linguistics; Clinical Neurology; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Rehabilitation	814FG	WOS:000220960000002					2021-06-18	
J	Dimopoulou, L; Tsagarakis, S; Kouyialis, AT; Roussou, P; Assithianakis, G; Christoforaki, M; Ilias, I; Sakas, DE; Thalassinos, N; Roussos, C				Dimopoulou, L; Tsagarakis, S; Kouyialis, AT; Roussou, P; Assithianakis, G; Christoforaki, M; Ilias, I; Sakas, DE; Thalassinos, N; Roussos, C			Hypothalamic-pituitary-adrenal axis dysfunction in critically ill patients with traumatic brain injury: Incidence, pathophysiology, and relationship to vasopressor dependence and peripheral interleukin-6 levels	CRITICAL CARE MEDICINE			English	Article						traumatic brain injury; low-dose corticotropin stimulation test; human corticotropin releasing hormone test; primary adrenal dysfunction; interleukin-6	CORTICOTROPIN-RELEASING HORMONE; SEVERE CRANIOCEREBRAL TRAUMA; 250 MU-G; HEAD-INJURY; SEPTIC SHOCK; INSUFFICIENCY; HYPOPITUITARISM; ABNORMALITIES; STIMULATION; SYSTEM	Objective: To investigate hypothalamic-pituitary-adrenal axis function in patients requiring mechanical ventilation for traumatic brain injury and to assess the relation of hypothalamic-pituitary-adrenal axis abnormalities with vasopressor dependence and peripheral cytokine levels. Design: Prospective study. Setting: General intensive care unit in a university teaching hospital. Patients: Forty patients (33 men and 7 women) with moderate to severe traumatic brain injury (mean age, 37 +/- 16 yrs) were studied the day after termination of mechanical ventilation (7-60 days after trauma). Interventions: First, a morning blood sample was obtained to measure baseline cortisol, corticotropin, interleukin-6, and tumor necrosis factor alpha. Subsequently, 1 mug of synthetic corticotropin was injected intravenously, and 30 mins later, a second blood sample was drawn to determine stimulated plasma cortisol. Based on data derived from healthy volunteers, patients having stimulated cortisol levels <18 mug/dL were defined as nonresponders to the low-dose stimulation test. Thirty-one patients underwent also a human corticotropin releasing hormone test. Measurements and Main Results: In traumatic brain injury patients, mean baseline and low-dose stimulation test-stimulated cortisol levels were 17.2 +/- 5.4 mug/dL and 24.0 +/- 6.6 mug/dL, respectively. The median increment in cortisol was 5.9 mug/dL Basal corticotropin levels ranged from 3.9 to 118.5 pg/mL Six of the 40 patients (15%) failed the low-dose stimulation test The human corticotropin releasing hormone test (performed in 26 responders and five nonresponders) revealed diminished cortisol release only in the low-dose stimulation test nonresponder patients. Corticotropin responses to corticotropin releasing hormone were consistent with both primary (three patients) and/or secondary (two patients) adrenal dysfunction. In retrospect, nonresponders to the low-dose stimulation test more frequently required vasopressors (6/6 [100%] vs. 16/34 [47%]; p = .02) and for a longer time interval (median, 0 vs. 293 hrs; p = .006) compared with responders. Furthermore, nonresponders had higher interleukin-6 levels compared with responders (56.03 vs. 28.04 pg/mL; p = .01), whereas tumor necrosis factor alpha concentrations were similar in the two groups (2.42 vs. 1.55 pg/mL; p = .53). Conclusions: Adrenal cortisol secretion after dynamic stimulation is deficient in a subset of critically ill patients with moderate to severe head injury. This disorder is associated with prior vasopressor dependency and higher interleukin-6 levels.	Evangelismos Med Ctr, Dept Crit Care Med, Athens, Greece; Evangelismos Med Ctr, Dept Diabet Endocrinol & Metab, Athens, Greece; Evangelismos Med Ctr, Dept Neurosurg, Athens, Greece; Univ Athens, Athens Chest Hosp, Dept Internal Med, Athens, Greece	Dimopoulou, L (corresponding author), Evangelismos Med Ctr, Dept Crit Care Med, Athens, Greece.		Ilias, Ioannis/AAA-2927-2020; ILIAS, IOANNIS/AAI-4033-2020	ILIAS, IOANNIS/0000-0001-5718-7441			Ambrosi B, 1998, EUR J ENDOCRINOL, V139, P575, DOI 10.1530/eje.0.1390575; BARRECA T, 1980, J CLIN ENDOCR METAB, V51, P1279, DOI 10.1210/jcem-51-6-1279; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Bondanelli M, 2002, METABOLISM, V51, P1363, DOI 10.1053/meta.2002.34714; Bornstein SR, 1999, J CLIN ENDOCR METAB, V84, P1729; CLARK JDA, 1988, CLIN ENDOCRINOL, V29, P153, DOI 10.1111/j.1365-2265.1988.tb00257.x; CLARK JDA, 1992, CLIN ENDOCRINOL, V36, P481, DOI 10.1111/j.1365-2265.1992.tb02249.x; Della Corte F, 1998, CRIT CARE MED, V26, P1419; DICKSTEIN G, 1991, J CLIN ENDOCR METAB, V72, P773, DOI 10.1210/jcem-72-4-773; Dimopoulou I, 2003, CRIT CARE MED, V31, P1113, DOI 10.1097/01.CCM.0000059644.54819.67; Dimopoulou L, 2002, INTENS CARE MED, V28, P1168, DOI 10.1007/s00134-002-1360-0; EDWARDS OM, 1986, MEDICINE, V65, P281; Gonzalbez J, 2000, CLIN ENDOCRINOL, V53, P199; GOTTARDIS M, 1990, INTENS CARE MED, V16, P163, DOI 10.1007/BF01724795; GRINSPOON SK, 1994, J CLIN ENDOCR METAB, V79, P923, DOI 10.1210/jc.79.4.923; HACKL JM, 1991, INTENS CARE MED, V17, P25, DOI 10.1007/BF01708405; Hoen S, 2002, ANESTHESIOLOGY, V97, P807, DOI 10.1097/00000542-200210000-00010; Keh D, 2003, AM J RESP CRIT CARE, V167, P512, DOI 10.1164/rccm.200205-446OC; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; KING LR, 1981, NEUROSURGERY, V9, P229, DOI 10.1227/00006123-198109000-00002; KING LR, 1970, ANN SURG, V172, P975, DOI 10.1097/00000658-197012000-00008; Koiv L, 1997, ACTA NEUROL SCAND, V96, P52; Lamberts SWJ, 1997, NEW ENGL J MED, V337, P1285, DOI 10.1056/NEJM199710303371807; LENZEN J, 1993, NEUROSURG REV, V16, P183, DOI 10.1007/BF00304325; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Marik PE, 2003, CRIT CARE MED, V31, P141, DOI 10.1097/00003246-200301000-00022; Marik PE, 2002, CHEST, V122, P1784, DOI 10.1378/chest.122.5.1784; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MASTORAKOS G, 1993, J CLIN ENDOCR METAB, V77, P1690, DOI 10.1210/jc.77.6.1690; MATSUURA H, 1985, NEUROSURGERY, V16, P791, DOI 10.1227/00006123-198506000-00009; Oelkers W, 1996, NEW ENGL J MED, V335, P1206, DOI 10.1056/NEJM199610173351607; Papanicolaou DA, 1996, J CLIN ENDOCR METAB, V81, P2303, DOI 10.1210/jc.81.6.2303; SCHLAGHECKE R, 1992, NEW ENGL J MED, V326, P226, DOI 10.1056/NEJM199201233260403; Schroeder S, 2001, CRIT CARE MED, V29, P310, DOI 10.1097/00003246-200102000-00017; SONI A, 1995, AM J MED, V98, P266, DOI 10.1016/S0002-9343(99)80373-8; STEINBOK P, 1979, NEUROSURGERY, V5, P559, DOI 10.1227/00006123-197911000-00003; TEASDALE G, 1974, LANCET, V2, P81; Tordjman K, 2000, CLIN ENDOCRINOL, V52, P633, DOI 10.1046/j.1365-2265.2000.00984.x; Tsagarakis S, 1998, CRIT REV ONCOL HEMAT, V28, P73, DOI 10.1016/S1040-8428(98)00005-5; Vincent JL, 1998, CRIT CARE MED, V26, P1793, DOI 10.1097/00003246-199811000-00016; WOOLF PD, 1986, CLIN ENDOCRINOL, V25, P265, DOI 10.1111/j.1365-2265.1986.tb01691.x	41	78	84	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	FEB	2004	32	2					404	408		10.1097/01.CCM.0000108885.37811.CA			5	Critical Care Medicine	General & Internal Medicine	774ME	WOS:000188982600012	14758155				2021-06-18	
J	Hattori, N; Huang, SC; Wu, HM; Yeh, E; Glenn, TC; Vespa, PM; McArthur, D; Phelps, ME; Hovda, DA; Bergsneider, M				Hattori, N; Huang, SC; Wu, HM; Yeh, E; Glenn, TC; Vespa, PM; McArthur, D; Phelps, ME; Hovda, DA; Bergsneider, M			Correlation of regional metabolic rates of glucose with Glasgow coma scale after traumatic brain injury	JOURNAL OF NUCLEAR MEDICINE			English	Article						PET; cerebral glucose metabolism; concussion; coma; head injury; diffuse axonal injury	POSITRON-EMISSION-TOMOGRAPHY; CEREBRAL BLOOD-FLOW; DIFFUSE AXONAL INJURY; FDG LUMPED CONSTANT; SEVERE HEAD-INJURY; TIME UPTAKE DATA; GRAPHICAL EVALUATION; PRACTICAL SCALE; HUMANS; CONSCIOUSNESS	After traumatic brain injury (TBI), subcortical white matter damage may induce a functional disconnection leading to a dissociation of regional cerebral metabolic rate of glucose (CMRglc) between the cerebral cortex and deeper brain regions. Therefore, thalamic and brain stem CMRglc may have a closer correlation than does the cerebral cortex with depth of coma after TBI. Methods: Eleven adult healthy volunteers and 23 adult patients with TBI (median initial Glasgow Coma Scale score [GCSini], 8) underwent F-18-FDG PET within 5 d after injury. The CMRglc of cortical areas (remote from hemorrhagic lesions), striatum, thalamus, brain stem, cerebellar cortex, and whole brain was compared with severity of injury and the level of consciousness evaluated using GCSini and the Glasgow Coma Scale score at the time of PET (GCSpet). Results: The regional CMRglc of the brain stem is relatively unaffected by the TBI. Compared with healthy volunteers, TBI patients exhibited significantly depressed CMRglc in the striatum (3.9 +/- 1.3 vs. 5.1 +/- 0.9 mg/100 g/min, P < 0.05) and thalamus (3.1 +/- 1.0 vs. 4.3 +/- 0.9 mg/100 g/min, P < 0.05). CMRglc levels were not statistically lower in the cerebellum (2.9 +/- 0.8 vs. 3.5 +/- 0.8 mg/100 g/min, P = NS) and brain stem (2.5 +/- 0.5 vs. 2.6 +/- 0.5 mg/100 g/min, P NS). However, compared between comatose and noncomatose patients, ClVlRg1c values in the thalamus (2.7 +/- 0.7 vs. 3.6 +/-1.2 mg/100 g/min, P < 0.05), brain stem (2.2 +/- 0.4 vs. 2.8 +/- 0.5 mg/100 g/min, P < 0.01), and cerebellar cortex (2.6 +/- 0.5 vs. 3.4 +/- 1.0 mg/100 g/min, P < 0.05) were significantly lower in comatose patients. When individual values of regional ClVlRglc were plotted against posttraumatic level of consciousness, ClVlRglc values for the thalamus, brain stem, and cerebellum significantly correlated with the level of consciousness at the time of PET (r = 0.58, P < 0.01; r = 0.66, P < 0.01; r = 0.64, P < 0.01, respectively). CT or MRI findings were normal for the analyzed structures except for 3 patients with diffuse axonal injury of the brain stem. The presence of shear injury was associated with poor GCSini (P < 0.05.) but was not related to GCSpet and brain stem CMRglc. Conclusion: A PET investigation using F-18 FDG demonstrated a significant difference in glucose metabolism in the thalamus, brain stem, and cerebellum between comatose and noncomatose patients acutely after TBI. The metabolic rate of glucose in these regions significantly correlated with the level of consciousness at the time of PET.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, David Geffen Sch Med, US DOE, Ctr Mol Med, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, David Geffen Sch Med, Brain Injury Res Ctr, Div Neurosurg, Los Angeles, CA 90024 USA	Hattori, N (corresponding author), Box 956948, Los Angeles, CA 90095 USA.	nhattori@mednet.ucla.edu	Hattori, Naoya/AAR-6405-2020; Hattori, Naoya/G-2298-2012	Glenn, Thomas/0000-0003-4273-3408	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [30308] Funding Source: Medline		ALKIRE MT, 1995, ANESTHESIOLOGY, V82, P393, DOI 10.1097/00000542-199502000-00010; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bergsneider M, 2001, J HEAD TRAUMA REHAB, V16, P135, DOI 10.1097/00001199-200104000-00004; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; Braun AR, 1997, BRAIN, V120, P1173, DOI 10.1093/brain/120.7.1173; Fiset P, 1999, J NEUROSCI, V19, P5506; FOSTER NL, 1987, J CEREBR BLOOD F MET, V7, P415, DOI 10.1038/jcbfm.1987.84; Garnett MR, 2001, J NEUROTRAUM, V18, P231, DOI 10.1089/08977150151070838; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Goodman JC, 1999, CRIT CARE MED, V27, P1965, DOI 10.1097/00003246-199909000-00041; Graham MM, 2002, J NUCL MED, V43, P1157; Hasselbalch SG, 1998, J CEREBR BLOOD F MET, V18, P154, DOI 10.1097/00004647-199802000-00005; Hasselbalch SG, 2001, J CEREBR BLOOD F MET, V21, P995, DOI 10.1097/00004647-200108000-00012; HATTORI N, 2002, J NEUROTRAUM, V19, P1273; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HAYES RL, 1984, SCIENCE, V223, P301, DOI 10.1126/science.6701514; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; HUANG SC, 1980, AM J PHYSIOL, V238, pE69; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; Hutchinson PJ, 2002, J CEREBR BLOOD F MET, V22, P735, DOI 10.1097/00004647-200206000-00012; Ichimi K, 1999, NEUROL RES, V21, P579, DOI 10.1080/01616412.1999.11740980; ICHISE M, 1994, J NUCL MED, V35, P217; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1976, LANCET, V1, P1031; Laureys S, 2000, LANCET, V355, P1790, DOI 10.1016/S0140-6736(00)02271-6; LIN KP, 1994, IEEE T NUCL SCI, V41, P2850, DOI 10.1109/23.340657; LLOYD KG, 1977, BRAIN RES, V127, P269, DOI 10.1016/0006-8993(77)90540-6; LONDON ED, 1990, ARCH GEN PSYCHIAT, V47, P73; McIntosh TK, 1996, LAB INVEST, V74, P315; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; NOLTE J, 1999, HUMAN BRAIN INTRO FU, P260; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; PATLAK CS, 1985, J CEREBR BLOOD F MET, V5, P584, DOI 10.1038/jcbfm.1985.87; PATLAK CS, 1983, J CEREBR BLOOD F MET, V3, P1, DOI 10.1038/jcbfm.1983.1; PHELPS ME, 1979, ANN NEUROL, V6, P371, DOI 10.1002/ana.410060502; POWELL MJD, 1964, COMPUT J, V7, P155, DOI 10.1093/comjnl/7.2.155; Press WH, 1992, NUMERICAL RECIPES C, P394; Sihver S, 2001, J NEUROCHEM, V78, P417, DOI 10.1046/j.1471-4159.2001.00428.x; Smith DH, 2000, J NEUROSURG, V93, P315, DOI 10.3171/jns.2000.93.2.0315; TEASDALE G, 1974, LANCET, V2, P81; TENJIN H, 1990, NEUROSURGERY, V26, P971, DOI 10.1227/00006123-199006000-00009; WU HM, 2001, J CEREB BLOOD FLOW S, V21, pS180; Yamaki T, 1996, J NUCL MED, V37, P1166	44	78	85	0	7	SOC NUCLEAR MEDICINE INC	RESTON	1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA	0161-5505	1535-5667		J NUCL MED	J. Nucl. Med.	NOV	2003	44	11					1709	1716					8	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	741YV	WOS:000186488700010	14602850				2021-06-18	
J	Mattiasson, G; Friberg, H; Hansson, M; Elmer, E; Wieloch, T				Mattiasson, G; Friberg, H; Hansson, M; Elmer, E; Wieloch, T			Flow cytometric analysis of mitochondria from CA1 and CA3 regions of rat hippocampus reveals differences in permeability transition pore activation	JOURNAL OF NEUROCHEMISTRY			English	Article						cell death; flow cytometry; hippocampus; mitochondria; permeability transition; reactive oxygen species	TRANSIENT FOREBRAIN ISCHEMIA; TRAUMATIC BRAIN-INJURY; MOUSE-LIVER MITOCHONDRIA; SINGLE ORGANELLE LEVEL; CYCLOSPORINE-A; UNCOUPLING PROTEIN-2; CEREBRAL-ISCHEMIA; OXIDATIVE STRESS; CELL-DEATH; CYTOCHROME-C	Mitochondria are important in the pathophysiology of several neurodegenerative diseases, and mitochondrial production of reactive oxygen species (ROS), membrane depolarization, permeability changes and release of apoptogenic proteins are involved in these processes. Following brain insults, cell death often occurs in discrete regions of the brain, such as the subregions of the hippocampus. To analyse mitochondrial structure and function in such subregions, only small amounts of mitochondria are available. We developed a protocol for flow cytometric analysis of very small samples of isolated brain mitochondria, and analysed mitochondrial swelling and formation of ROS in mitochondria from the CA1 and CA3 regions of the hippocampus. Calcium-induced mitochondrial swelling was measured, and fluorescent probes were used to selectively stain mitochondria ( nonyl acridine orange), to measure membrane potential (tetramethylrhodamine-methylester, 1,1', 3,3,3',3'-hexamethylindodicarbocyanine-iodide) and to measure production of ROS (2',7'-dichlorodihydrofluorescein-diacetate). We found that formation of ROS and mitochondrial permeability transition pore activation were higher in mitochondria from the CA1 than from the CA3 region, and propose that differences in mitochondrial properties partly underlie the selective vulnerability of the CA1 region to brain insults. We also conclude that flow cytometry is a useful tool to analyse the role of mitochondria in cell death processes.	Lund Univ, Wallenberg Neurosci Ctr, Expt Brain Res Lab, SE-22184 Lund, Sweden	Mattiasson, G (corresponding author), Lund Univ, Wallenberg Neurosci Ctr, Expt Brain Res Lab, BMC A13, SE-22184 Lund, Sweden.	Gustav.Mattiasson@Expbr.lu.se	Hansson, Magnus/G-4486-2014; Elmer, Eskil/F-9341-2014	Hansson, Magnus/0000-0002-0201-0638; Elmer, Eskil/0000-0001-7901-1826; Wieloch, Tadeusz/0000-0002-7669-2520			Anderson MF, 2000, BRAIN RES PROTOC, V5, P95, DOI 10.1016/S1385-299X(99)00060-4; Arsenijevic D, 2000, NAT GENET, V26, P435, DOI 10.1038/82565; Bernardi P, 1999, EUR J BIOCHEM, V264, P687, DOI 10.1046/j.1432-1327.1999.00725.x; Bernardi P, 1998, BIOFACTORS, V8, P273, DOI 10.1002/biof.5520080315; Bindokas VP, 1996, J NEUROSCI, V16, P1324; Casteilla L, 2001, IUBMB LIFE, V52, P181, DOI 10.1080/15216540152845984; Chen J, 1998, J NEUROSCI, V18, P4914; CHEN LB, 1989, METHOD CELL BIOL, V29, P103; CONNERN CP, 1994, BIOCHEM J, V302, P321, DOI 10.1042/bj3020321; Cossarizza A, 1996, EXP CELL RES, V222, P84, DOI 10.1006/excr.1996.0011; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Cunningham R E, 1999, Methods Mol Biol, V115, P249; DYKENS JA, 1994, J NEUROCHEM, V63, P584; Elmer E, 1998, NEUROSCIENCE, V83, P351, DOI 10.1016/S0306-4522(97)00387-4; Fiskum G, 1999, J CEREBR BLOOD F MET, V19, P351, DOI 10.1097/00004647-199904000-00001; Friberg H, 1999, J NEUROCHEM, V72, P2488, DOI 10.1046/j.1471-4159.1999.0722488.x; Friberg H, 2002, NEUROSCI LETT, V334, P111, DOI 10.1016/S0304-3940(02)01116-3; Friberg H, 1998, J NEUROSCI, V18, P5151; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; Greenamyre JT, 1999, BIOCHEM SOC SYMP, V66, P85, DOI 10.1042/bss0660085; GRIFFITHS EJ, 1995, BIOCHEM J, V307, P93, DOI 10.1042/bj3070093; Gylys KH, 2000, J NEUROSCI RES, V61, P186, DOI 10.1002/1097-4547(20000715)61:2<186::AID-JNR9>3.0.CO;2-X; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Halestrap AP, 1998, BBA-BIOENERGETICS, V1366, P79, DOI 10.1016/S0005-2728(98)00122-4; Hansson MJ, 2003, BRAIN RES, V960, P99, DOI 10.1016/S0006-8993(02)03798-8; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; ITO U, 1975, ACTA NEUROPATHOL, V32, P209, DOI 10.1007/BF00696570; Jacobson J, 2002, J NEUROCHEM, V82, P224, DOI 10.1046/j.1471-4159.2002.00945.x; Jaroszeski MJ, 1999, MOL BIOTECHNOL, V11, P37, DOI 10.1007/BF02789175; KATO H, 1995, J CEREBR BLOOD F MET, V15, P60, DOI 10.1038/jcbfm.1995.7; KNIGHT VA, 1981, BIOCHIM BIOPHYS ACTA, V637, P146, DOI 10.1016/0005-2728(81)90220-6; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; LAPIDUS RG, 1994, J BIOL CHEM, V269, P18931; Lenaz G, 2001, IUBMB LIFE, V52, P159, DOI 10.1080/15216540152845957; LOPEZMEDIAVILLA C, 1992, EXP CELL RES, V203, P134, DOI 10.1016/0014-4827(92)90048-D; LOPEZMEDIAVILLA C, 1995, BBA-BIOENERGETICS, V1232, P27, DOI 10.1016/0005-2728(95)00105-8; LOPEZMEDIAVILLA C, 1989, FEBS LETT, V254, P115, DOI 10.1016/0014-5793(89)81020-8; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; MATEOS A, 1995, ALCOHOL CLIN EXP RES, V19, P1327, DOI 10.1111/j.1530-0277.1995.tb01620.x; Matsumoto S, 1999, J CEREBR BLOOD F MET, V19, P736, DOI 10.1097/00004647-199907000-00002; Medina JM, 2002, FEBS LETT, V510, P127, DOI 10.1016/S0014-5793(01)03260-4; Metivier D, 1998, IMMUNOL LETT, V61, P157, DOI 10.1016/S0165-2478(98)00013-3; Murphy AN, 1999, J CEREBR BLOOD F MET, V19, P231, DOI 10.1097/00004647-199903000-00001; NegreSalvayre A, 1997, FASEB J, V11, P809; Nicholls DG, 2000, PHYSIOL REV, V80, P315; OCONNOR JE, 1988, CELL TISSUE KINET, V21, P331, DOI 10.1111/j.1365-2184.1988.tb00791.x; OCONNOR JE, 1988, BIOCHEM BIOPH RES CO, V151, P568, DOI 10.1016/0006-291X(88)90632-8; Ouyang YB, 1999, J CEREBR BLOOD F MET, V19, P1126, DOI 10.1097/00004647-199910000-00009; PETIT JM, 1994, EUR J BIOCHEM, V220, P871, DOI 10.1111/j.1432-1033.1994.tb18690.x; PETIT PX, 1990, EUR J BIOCHEM, V194, P389, DOI 10.1111/j.1432-1033.1990.tb15632.x; Piccotti L, 2002, J BIOL CHEM, V277, P12075, DOI 10.1074/jbc.M200029200; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Richard D, 2001, BIOCHEM SOC T, V29, P812, DOI 10.1042/BST0290812; ROTHE G, 1990, J LEUKOCYTE BIOL, V47, P440; Salvioli S, 2000, CYTOMETRY, V40, P189, DOI 10.1002/1097-0320(20000701)40:3<189::AID-CYTO3>3.0.CO;2-6; Shapiro HM, 2000, METHODS, V21, P271, DOI 10.1006/meth.2000.1007; SIMS NR, 1991, J NEUROCHEM, V56, P1836, DOI 10.1111/j.1471-4159.1991.tb03438.x; SIMS NR, 1990, J NEUROCHEM, V55, P698, DOI 10.1111/j.1471-4159.1990.tb04189.x; Sullivan PG, 2000, EXP NEUROL, V161, P631, DOI 10.1006/exnr.1999.7282; Swift LM, 2000, AM J PHYSIOL-HEART C, V278, pH982; Teranishi M, 2000, EXP MOL PATHOL, V68, P104, DOI 10.1006/exmp.1999.2288; Uchino H, 1995, ACTA PHYSIOL SCAND, V155, P469, DOI 10.1111/j.1748-1716.1995.tb09999.x; Uchino H, 1998, BRAIN RES, V812, P216, DOI 10.1016/S0006-8993(98)00902-0; VegaNunez E, 1997, ENDOCRINOLOGY, V138, P3771, DOI 10.1210/en.138.9.3771; Votyakova TV, 2001, J NEUROCHEM, V79, P266, DOI 10.1046/j.1471-4159.2001.00548.x; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23	66	78	82	1	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	OCT	2003	87	2					532	544		10.1046/j.1471-4159.2003.02026.x			13	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	726JN	WOS:000185596100026	14511130				2021-06-18	
J	Smith, C; Graham, DI; Murray, LS; Nicoll, JAR				Smith, C; Graham, DI; Murray, LS; Nicoll, JAR			Tau immunohistochemistry in acute brain injury	NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY			English	Article						Alzheimer's disease; tau; traumatic brain injury	AMYLOID PROTEIN DEPOSITION; HEAD-INJURY; ALZHEIMERS-DISEASE; RISK-FACTORS; BETA; DEMENTIA; TRAUMA; CONSEQUENCE; ADULTHOOD; ONSET	Epidemiological studies have identified a history of head injury as a risk factor for Alzheimer's disease. However, the neuropathological mechanism underlying this relationship is as yet unclear. Neuronal cytoskeletal changes in the form of neurofibrillary tangles and neuropil threads have recently been demonstrated in young men who had sustained repetitive head injury and subsequently died in their 20s. In addition, recent experimental studies have found accumulation of tau within neuronal somata and damaged axons following diffuse brain injury. We hypothesized that tau-immunoreactive tangles may be present in the brains of patients who died after a single acute blunt head injury. A total of 45 cases of fatal head injury were immunostained for tau. They comprised nine groups (n = 5 for each group) separated by age (0-19 years, 20-50 years, 50+ years) and survival time (<24 h, 24 h-1 week, 1 week-1 month) and were compared with age-matched controls. Subtle alterations in tau immunoreactivity, for example, in oligodendrocytes, were present in some head injury cases but not controls. However, neurofibrillary tangles did not appear more prevalent after traumatic brain injury (TBI) when compared with age-matched controls. Although alterations in tau immunoreactivity may occur which warrant further study, neurofibrillary tangles were not more prevalent after a single fatal episode of TBI.	Univ Edinburgh, Western Gen Hosp, Dept Pathol, Neuropathol Lab, Edinburgh EH4 2XU, Midlothian, Scotland; Univ Glasgow, So Gen Hosp, Dept Neuropathol, Glasgow, Lanark, Scotland; Univ Glasgow, Western Infirm, Dept Med & Therapeut, Glasgow G11 6NT, Lanark, Scotland; Univ Southampton, Southampton Gen Hosp, Div Clin Neurosci, Southampton, Hants, England	Smith, C (corresponding author), Univ Edinburgh, Western Gen Hosp, Dept Pathol, Neuropathol Lab, Edinburgh EH4 2XU, Midlothian, Scotland.	col.smith@ed.ac.uk	Nicoll, James/I-9253-2017	Nicoll, James/0000-0002-9444-7246			AdleBiassette H, 1996, NEUROBIOL AGING, V17, P415, DOI 10.1016/0197-4580(96)00029-2; Carmel G, 1996, J BIOL CHEM, V271, P32789, DOI 10.1074/jbc.271.51.32789; CORKIN S, 1989, J NEUROSCI, V9, P3876; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; FRATIGLIONI L, 1993, ANN NEUROL, V33, P258, DOI 10.1002/ana.410330306; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; Gentleman SM, 1997, NEUROREPORT, V8, P1519, DOI 10.1097/00001756-199704140-00039; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Horsburgh K, 2000, NEUROPATH APPL NEURO, V26, P124, DOI 10.1046/j.1365-2990.2000.026002124.x; Irving EA, 1996, NEUROSCI LETT, V213, P189; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Launer LJ, 1999, NEUROLOGY, V52, P78, DOI 10.1212/WNL.52.1.78; MAYEUX R, 1993, ANN NEUROL, V33, P494, DOI 10.1002/ana.410330513; Mehta KM, 1999, NEUROLOGY, V53, P1959, DOI 10.1212/WNL.53.9.1959; MENDEZ MF, 1992, NEUROLOGY, V42, P770, DOI 10.1212/WNL.42.4.770; MORTIMER JA, 1985, NEUROLOGY, V35, P264, DOI 10.1212/WNL.35.2.264; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; NEWMAN SJ, 1995, RESEARCH ADVANCES IN ALZHEIMER'S DISEASE AND RELATED DISORDERS, P397; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; WILLIAMS DB, 1991, NEUROLOGY, V41, P1554, DOI 10.1212/WNL.41.10.1554; Zemlan FP, 1999, J NEUROCHEM, V73, P437; Zhukareva V, 2001, ACTA NEUROPATHOL, V101, P518	28	78	79	1	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0305-1846	1365-2990		NEUROPATH APPL NEURO	Neuropathol. Appl. Neurobiol.	OCT	2003	29	5					496	502		10.1046/j.1365-2990.2003.00488.x			7	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	774WY	WOS:000189010400008	14507341				2021-06-18	
J	Naunheim, RS; Bayly, PV; Standeven, J; Neubauer, JS; Lewis, LM; Genin, GM				Naunheim, RS; Bayly, PV; Standeven, J; Neubauer, JS; Lewis, LM; Genin, GM			Linear and angular head accelerations during heading of a soccer ball	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						kinematic measurements; kinematic modeling; brain injury; impact modeling	PLAYERS; INJURY; BRAIN; CONCUSSION; CRITERION; FOOTBALL; IMPACT; DAMAGE	Purpose: Cognitive deficits observed in professional soccer players may be related to heading of a soccer ball. To assess the severity of a single instance of heading a soccer ball, this study experimentally and theoretically evaluated the linear and angular accelerations experienced by the human head during a frontal heading maneuver. Methods: Accelerations were measured using a set of three triaxial accelerometers mounted to the head of each of four adult male subjects. These measurements (nine signals) were used to estimate the linear acceleration of the mass center and the angular acceleration of the head. Results were obtained for ball speeds of 9 and 12 m(.)s(-1) (approximately 20 and 26 mph). A simple mathematical model was derived for comparison. Results: At 9 m(.)s(-1), peak linear acceleration of the head was 158 +/- 19 m(.)s(-2) (mean +/- standard deviation) and peak angular acceleration was 1302 +/- 324 rad-s(-2); at 12 m(.)s(-1), the values were 199 +/- 27 m(.)w(-2) and 1457 +/- 297 rad(.)s(-2), respectively. The initial acceleration pulses lasted approximately 25 ms. Measured head accelerations confirmed laboratory headform measurements reported in the literature and fell within the ranges predicted by the theoretical model. Conclusions: Linear and angular acceleration levels for a single heading maneuver were well below those thought to be associated with traumatic brain injury, as were computed values of the Gadd Severity Index and the Head Injury Criterion. However, the effect of repeated acceleration at this relatively low level is unknown.	Washington Univ, Henry Edwin Sever Sch Engn & Appl Sci, Dept Mech Engn, St Louis, MO 63130 USA; Washington Univ, Div Emergency Med, St Louis, MO USA; Washington Univ, Dept Biomed Engn, St Louis, MO USA	Genin, GM (corresponding author), Washington Univ, Henry Edwin Sever Sch Engn & Appl Sci, Dept Mech Engn, Campus Box 1185, St Louis, MO 63130 USA.	gmg@me.wustl.edu		Bayly, Philip/0000-0003-4303-0704			Adams J H, 1983, Acta Neurochir Suppl (Wien), V32, P15; Anderson SJ, 2000, PEDIATRICS, V105, P659, DOI 10.1542/peds.105.3.640; Bailey B. N., 1989, TXB HEAD INJURY, P308; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Baroff GS, 1998, J HEAD TRAUMA REHAB, V13, P45, DOI 10.1097/00001199-199804000-00007; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; Gadd CW., 1966, 660793 SAE; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; Gennarelli T A, 1983, Acta Neurochir Suppl (Wien), V32, P1; GINSBERG G, 1995, DYNAMICS; Green GA, 1998, CLIN SPORT MED, V17, P795, DOI 10.1016/S0278-5919(05)70120-4; Guskiewicz KM, 2002, AM J SPORT MED, V30, P157, DOI 10.1177/03635465020300020201; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; KING AI, 1995, BIOMEDICAL ENG HDB, P357; KROSS R, 1983, EEG-EMG-Z ELEK ELEKT, V14, P209; MARGULIES S S, 1989, Journal of Biomechanical Engineering, V111, P241; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Naunheim RS, 2000, J TRAUMA, V48, P938, DOI 10.1097/00005373-200005000-00020; Naunheim RS, 2003, ACAD EMERG MED, V10, P85, DOI 10.1197/aemj.10.1.85; Newman J. A., 1980, 801317 SAE; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; ONUSIC H, 1995, INT J VEHICLE DES, V16, P194; SORTLAND O, 1989, NEURORADIOLOGY, V31, P44; TYSVAER AT, 1989, ACTA NEUROL SCAND, V80, P151, DOI 10.1111/j.1600-0404.1989.tb03858.x; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109	27	78	79	1	19	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-9131	1530-0315		MED SCI SPORT EXER	Med. Sci. Sports Exerc.	AUG	2003	35	8					1406	1412		10.1249/01.MSS.0000078933.84527.AE			7	Sport Sciences	Sport Sciences	707UE	WOS:000184527600023	12900697				2021-06-18	
J	Chuckowree, JA; Vickers, JC				Chuckowree, JA; Vickers, JC			Cytoskeletal and morphological alterations underlying axonal sprouting after localized transection of cortical neuron Axons in vitro	JOURNAL OF NEUROSCIENCE			English	Article						Alzheimer's disease; axonal sprouting; axonal transection; beta III-tubulin; brain trauma; cortical neuron culture; cytoskeleton; growth cone; microtubules; neurite development; posttraumatic epilepsy; neurofilament; tau; taxol	TRAUMATIC BRAIN INJURY; CENTRAL-NERVOUS-SYSTEM; BETA-TUBULIN ISOTYPE; GROWTH CONE GUIDANCE; ALZHEIMERS-DISEASE; HIPPOCAMPAL-NEURONS; NEUROFILAMENT TRANSPORT; PHYSICAL INJURY; RADIAL GROWTH; ADULT CAT	We examined the cytoskeletal dynamics that characterize neurite sprouting after axonal injury to cortical neurons maintained in culture for several weeks and compared these with initial neurite development. Cultured neocortical neurons, derived from embryonic day 18 rats, were examined at 3 d in vitro (DIV) and at various time points after axotomy at 21 DIV. The postinjury neuritic response was highly dynamic, progressing through an initial phase of retraction, followed by substantial axonal sprouting within 4-6 hr. Postinjury sprouts were motile and slender with expanded growth cone-like end structures. Microtubule markers were localized to sprout shafts and the proximal regions of putative growth cones and filamentous actin was distributed throughout growth cones, whereas neurofilament proteins were restricted to sprout shafts. A similar distribution of cytoskeletal proteins was present in developing neurites at 3 DIV. Exposure of developing and mature, injured cultures to the microtubule stabilizing agent taxol (10 mug/ml) caused growth inhibition, process distension, the transformation of growth cones into bulbous structures, and abnormal neurite directionality. Microtubule and neurofilament segregation occurred after taxol exposure in developing neurites and postinjury sprouts. Exposure to the microtubule destabilizing agent nocodazole (100 mug/ml) resulted in substantial morphological alteration of developing neurons and inhibited neurite growth and postinjury axonal sprouting. Our results indicate that the axons of cortical neurons have an intrinsic ability to sprout after transection, and similar cytoskeletal dynamics underlie neurite development and postinjury axonal sprouting.	Univ Tasmania, Fac Hlth Sci, Discipline Pathol, Hobart, Tas 7000, Australia	Vickers, JC (corresponding author), Univ Tasmania, Fac Hlth Sci, Discipline Pathol, 43 Collins St, Hobart, Tas 7000, Australia.	james.vickers@utas.edu.au	Vickers, James C/J-7464-2014	Vickers, James C/0000-0001-5671-4879; Chuckowree, Jyoti/0000-0002-1245-1402			Adlard PA, 2000, ACTA NEUROPATHOL, V100, P183, DOI 10.1007/s004019900160; Arendt T, 2001, NEUROSCIENCE, V102, P723, DOI 10.1016/S0306-4522(00)00516-9; Bandtlow CE, 2000, GLIA, V29, P175, DOI 10.1002/(SICI)1098-1136(20000115)29:2<175::AID-GLIA11>3.0.CO;2-F; Banks WM, 1998, PROF ENG, V11, P36; BERRY M, 1994, EYE, V8, P245, DOI 10.1038/eye.1994.53; BLACK MM, 1987, J NEUROSCI, V7, P3695; Brandt R, 1998, CELL TISSUE RES, V292, P181, DOI 10.1007/s004410051049; BREWER GJ, 1995, J NEUROSCI RES, V42, P674, DOI 10.1002/jnr.490420510; Brewer GJ, 1997, J NEUROSCI METH, V71, P143, DOI 10.1016/S0165-0270(96)00136-7; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; BURKE WJ, 1994, LIFE SCI, V55, pPL313, DOI 10.1016/0024-3205(94)90074-4; Christman CW, 1997, ACTA NEUROPATHOL, V94, P329, DOI 10.1007/s004010050715; Deller T, 1997, PROG NEUROBIOL, V53, P687, DOI 10.1016/S0301-0082(97)00044-0; Dent EW, 2001, J NEUROSCI, V21, P9757, DOI 10.1523/JNEUROSCI.21-24-09757.2001; Dickson TC, 2000, J NEUROTRAUM, V17, P1095, DOI 10.1089/neu.2000.17.1095; Dinter A, 1998, HISTOCHEM CELL BIOL, V109, P571, DOI 10.1007/s004180050256; Fawcett JW, 1997, CELL TISSUE RES, V290, P371, DOI 10.1007/s004410050943; Figueroa-Masot XA, 2001, J NEUROSCI, V21, P4657, DOI 10.1523/JNEUROSCI.21-13-04657.2001; FURUKAWA K, 1995, J NEUROCHEM, V65, P1061; Gallo G, 1998, J NEUROBIOL, V35, P121; Gallo G, 2000, J NEUROBIOL, V44, P159, DOI 10.1002/1097-4695(200008)44:2<159::AID-NEU6>3.0.CO;2-H; GEORGE EB, 1988, CELL MOTIL CYTOSKEL, V9, P48, DOI 10.1002/cm.970090106; Goldberg JL, 2000, NATURE, V403, P369, DOI 10.1038/35000309; Gotaskie G E, 1994, Cancer Pract, V2, P27; HOFFMAN PN, 1984, J CELL BIOL, V99, P705, DOI 10.1083/jcb.99.2.705; HOFFMAN PN, 1987, P NATL ACAD SCI USA, V84, P3472, DOI 10.1073/pnas.84.10.3472; HOFFMAN PN, 1985, J NEUROSCI, V5, P2920; HOFFMAN PN, 1988, P NATL ACAD SCI USA, V85, P4530, DOI 10.1073/pnas.85.12.4530; Jafari SS, 1998, J NEUROTRAUM, V15, P955, DOI 10.1089/neu.1998.15.955; Jafari SS, 1997, J NEUROCYTOL, V26, P207, DOI 10.1023/A:1018588114648; Jiang XM, 1996, ACTA NEUROPATHOL, V92, P467, DOI 10.1007/s004010050548; JULIEN JP, 1991, STRUCTURE EXPRESSION, P215; Kalil K, 2000, J NEUROBIOL, V44, P145, DOI 10.1002/1097-4695(200008)44:2<145::AID-NEU5>3.3.CO;2-O; King CE, 2000, ALZHEIMERS REP, V3, P31; King CE, 1997, NEUROREPORT, V8, P1663; King CE, 2001, NEUROPATH APPL NEURO, V27, P115, DOI 10.1046/j.1365-2990.2001.00317.x; Korey CA, 2000, J NEUROBIOL, V44, P184, DOI 10.1002/1097-4695(200008)44:2<184::AID-NEU8>3.3.CO;2-E; LARNER AJ, 1995, SEIZURE, V4, P249, DOI 10.1016/S1059-1311(95)80001-8; LEE MK, 1990, CELL MOTIL CYTOSKEL, V17, P118, DOI 10.1002/cm.970170207; Lee MK, 1996, ANNU REV NEUROSCI, V19, P187, DOI 10.1146/annurev.ne.19.030196.001155; LETOURNEAU PC, 1987, CELL MOTIL CYTOSKEL, V8, P193, DOI 10.1002/cm.970080302; LETOURNEAU PC, 1984, J CELL BIOL, V98, P1355, DOI 10.1083/jcb.98.4.1355; Levavasseur F, 1999, MOL BRAIN RES, V69, P104, DOI 10.1016/S0169-328X(99)00104-7; MASLIAH E, 1992, BRAIN RES, V574, P312, DOI 10.1016/0006-8993(92)90831-S; MASLIAH E, 1991, NEURON, V6, P729, DOI 10.1016/0896-6273(91)90170-5; MATTSON MP, 1992, BRAIN RES, V582, P107, DOI 10.1016/0006-8993(92)90323-2; Maxwell WL, 1997, J NEUROTRAUM, V14, P603, DOI 10.1089/neu.1997.14.603; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MCHALE MK, 1995, J COMP NEUROL, V353, P25, DOI 10.1002/cne.903530105; McKinney RA, 1997, NAT MED, V3, P990, DOI 10.1038/nm0997-990; MELLER D, 1993, J NEUROL SCI, V117, P164, DOI 10.1016/0022-510X(93)90169-Y; Michaelis ML, 1998, J NEUROCHEM, V70, P1623; NIXON RA, 1991, TRENDS NEUROSCI, V14, P501, DOI 10.1016/0166-2236(91)90062-Y; OKABE S, 1990, NATURE, V343, P479, DOI 10.1038/343479a0; Pastor AM, 2000, J COMP NEUROL, V427, P370, DOI 10.1002/1096-9861(20001120)427:3<370::AID-CNE5>3.0.CO;2-M; PerezEspejo MA, 1996, SURG NEUROL, V46, P350, DOI 10.1016/S0090-3019(96)00200-5; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Qiu J, 2000, GLIA, V29, P166, DOI 10.1002/(SICI)1098-1136(20000115)29:2<166::AID-GLIA10>3.3.CO;2-7; Suter DM, 2000, J NEUROBIOL, V44, P97, DOI 10.1002/1097-4695(200008)44:2<97::AID-NEU2>3.3.CO;2-L; Szebenyi G, 1998, J NEUROSCI, V18, P7930; TANAKA E, 1995, CELL, V83, P171, DOI 10.1016/0092-8674(95)90158-2; Theiss C, 2000, CELL TISSUE RES, V299, P213, DOI 10.1007/s004419900120; Vickers JC, 2000, PROG NEUROBIOL, V60, P139, DOI 10.1016/S0301-0082(99)00023-4; Walker KL, 2001, J NEUROSCI, V21, P9655, DOI 10.1523/JNEUROSCI.21-24-09655.2001; Zhang WD, 2001, J NEUROSCI, V21, P5169, DOI 10.1523/JNEUROSCI.21-14-05169.2001; Zhu QZ, 1997, EXP NEUROL, V148, P299, DOI 10.1006/exnr.1997.6654	67	78	78	0	9	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	MAY 1	2003	23	9					3715	3725					11	Neurosciences	Neurosciences & Neurology	675MX	WOS:000182700100018	12736342				2021-06-18	
J	Buki, A; Farkas, O; Doczi, T; Povlishock, JT				Buki, A; Farkas, O; Doczi, T; Povlishock, JT			Preinjury administration of the calpain inhibitor MDL-28170 attenuates traumatically induced axonal injury	JOURNAL OF NEUROTRAUMA			English	Article						axonal injury; calpain; MDL-28170; spectrin; traumatic brain injury	EXPERIMENTAL BRAIN-INJURY; CYCLOSPORINE-A; POSTTRAUMATIC HYPOTHERMIA; NEUROFILAMENT COMPACTION; SPECTRIN PROTEOLYSIS; DAMAGE; MODEL; BREAKDOWN; ACTIVATION; ANTIBODIES	Traumatic brain injury (TBI) evokes diffuse (traumatic) axonal injury (TAI), which contributes to morbidity and mortality. Damaged axons display progressive alterations gradually evolving to axonal disconnection. In severe TAI, the tensile forces of injury lead to a focal influx of Ca2+, initiating a series of proteolytic processes wherein the cysteine proteases, calpain and caspase modify the axonal cytoskeleton, causing irreversible damage over time postinjury. Although several studies have demonstrated that the systemic administration of calpain inhibitors reduces the extent of ischemic and traumatic contusional injury a direct beneficial effect on TAI has not been established to date. The current study was initiated to address this issue in an impact acceleration rat-TBI model in order to provide further evidence on the contribution of calpain-mediated proteolytic processes in the pathogenesis of TAI, while further supporting the utility of calpain-inhibitors. A single tail vein bolus injection of 30 mg/kg MDL-28170 was administered to Wistar rats 30 min preinjury. After injury the rats were allowed to survive 120 min when they were perfused with aldehydes. Brains were processed for immunohistochemical localization of damaged axonal profiles displaying either amyloid precursor protein (APP)- or RMO-14-immunoreactivity (IR), both considered markers of specific features of TAL Digital data acquisition and statistical analysis demonstrated that preinjury administration of MDL-28170 significantly reduced the mean number of damaged RMO-14- as well as APP-IR axonal profiles in the brainstem fiber tracts analyzed. These results further underscore the role of calpain-mediated proteolytic processes in the pathogenesis of DAI and support the potential use of cell permeable calpain-inhibitors as a rational therapeutic approach in TBI.	Virginia Commonwealth Univ, VCU Neurosci Ctr, Dept Anat & Neurobiol, Richmond, VA 23298 USA; Univ Pecs, Fac Med, Dept Neurosurg, Pecs, Hungary	Povlishock, JT (corresponding author), Virginia Commonwealth Univ, VCU Neurosci Ctr, Dept Anat & Neurobiol, Med Coll Virginia Campus,POB 980709,1101 E Marsha, Richmond, VA 23298 USA.	jpovlish@hsc.vcu.edu	Buki, Andras/B-1960-2010; Doczi, Tamas/C-5750-2009		FIC NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC) [1-R03-TW0131302A1] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS20193] Funding Source: Medline; FOGARTY INTERNATIONAL CENTERUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC) [R03TW001313] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS020193] Funding Source: NIH RePORTER		ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; Banik NL, 1998, ANN NY ACAD SCI, V844, P131, DOI 10.1111/j.1749-6632.1998.tb08228.x; BARTUS RT, 1994, STROKE, V25, P2265, DOI 10.1161/01.STR.25.11.2265; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; Buki A, 1999, EXP NEUROL, V159, P319, DOI 10.1006/exnr.1999.7139; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Buki A, 2000, J NEUROSCI, V20, P2825; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; HONG SC, 1994, STROKE, V25, P663, DOI 10.1161/01.STR.25.3.663; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; Lee KS, 1997, ANN NY ACAD SCI, V825, P95, DOI 10.1111/j.1749-6632.1997.tb48419.x; LEE VMY, 1987, J NEUROSCI, V7, P3474; Markgraf CG, 1998, STROKE, V29, P152, DOI 10.1161/01.STR.29.1.152; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McCracken E, 1999, J NEUROTRAUM, V16, P749, DOI 10.1089/neu.1999.16.749; Meaney DF, 2001, J NEUROSURG, V95, P1108; Okonkwo DO, 1998, BRAIN RES, V784, P1, DOI 10.1016/S0006-8993(97)01075-5; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Pike BR, 2001, J NEUROCHEM, V78, P1297, DOI 10.1046/j.1471-4159.2001.00510.x; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Saatman KE, 2000, J CEREBR BLOOD F MET, V20, P66, DOI 10.1097/00004647-200001000-00010; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; Stone JR, 1999, ACTA NEUROPATHOL, V97, P335, DOI 10.1007/s004010050996; Stone JR, 2001, EXP NEUROL, V172, P320, DOI 10.1006/exnr.2001.7818; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001	43	78	82	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2003	20	3					261	268		10.1089/089771503321532842			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	661GU	WOS:000181883500004	12820680				2021-06-18	
J	Pelinka, LE; Toegel, E; Mauritz, W; Redl, H				Pelinka, LE; Toegel, E; Mauritz, W; Redl, H			Serum S100B: A marker of brain damage in traumatic brain injury with and without multiple trauma	SHOCK			English	Article						traumatic brain injury; secondary brain damage; multiple trauma; S100B	SEVERE HEAD-INJURY; S-100 PROTEIN; CEREBROSPINAL-FLUID; RELEASE; ENOLASE; PLASMA; EXTENT	This prospective clinical study was conducted to determine whether S 100 B is a reliable serum marker for traumatic brain injury (TBI) with and without multiple trauma. Fifty-five trauma patients (Injury Severity Score [ISS] greater than or equal to24 and Glasgow Coma Score [GCS] less than or equal to8) were classified by radiography, computer tomography, ultrasound, and neurology as TBI without multiple trauma (n = 23), TBI with multiple trauma (n = 23), or multiple trauma without TBI (n = 9). S 100 B was measured initially after trauma and daily for a maximum of 21 days. Both survivors and nonsurvivors had markedly increased S 100 B initially. All survivors returned to normal or moderately increased S 100 B levels within the first 48 h after trauma. In contrast, all nonsurvivors; of isolated TBI had S 100 B values that either increased consistently or dropped and then increased again 48 h after the initial increase after trauma. There was no relationship between localization, extent, or severity of TBI and S 100 B. According to receiver operating characteristic curve analysis and calculation of the area under the curve (AUC), S 100 B is equally accurate for mortality prediction at 24, 48, and 72 h after trauma and is most accurate >84 h after trauma. Sensitivity/specificity for mortality prediction are more accurate in TBI without multiple trauma (AUC 0.802-0.971) than in TBI with multiple trauma (AUC 0.693-0.783). Thus, though S 100 B may be a reliable marker of brain damage in TBI without multiple trauma 24 h after trauma and thereafter, it appears to be less reliable in TBI with multiple trauma.	Ludwig Boltzmann Inst Expt & Clin Traumatol, Res Ctr Traumatol, Austrian Workers Compensat Board, A-1200 Vienna, Austria; Lorenz Boehler Trauma Ctr, Austrian Workers Compensat Board, Dept Anesthesiol & Crit Care Med, A-1200 Vienna, Austria	Pelinka, LE (corresponding author), Ludwig Boltzmann Inst Expt & Clin Traumatol, Res Ctr Traumatol, Austrian Workers Compensat Board, Donaueschingenstr 13, A-1200 Vienna, Austria.		Redl, Heinz/AAD-8157-2019	Mauritz, Walter/0000-0001-9043-3712			Abraha HD, 1997, ANN CLIN BIOCHEM, V34, P366, DOI 10.1177/000456329703400405; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Ashikaga R, 1997, NEURORADIOLOGY, V39, P239, DOI 10.1007/s002340050401; BAKAY RAE, 1983, J NEUROSURG, V58, P27, DOI 10.3171/jns.1983.58.1.0027; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; Biberthaler P, 2001, SHOCK, V16, P97, DOI 10.1097/00024382-200116020-00002; Chesnut RM, 1997, J TRAUMA, V42, pS4, DOI 10.1097/00005373-199705001-00002; Elting JW, 2000, J NEUROL SCI, V181, P104, DOI 10.1016/S0022-510X(00)00442-1; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; ISOBE T, 1984, J NEUROCHEM, V43, P1494, DOI 10.1111/j.1471-4159.1984.tb05415.x; Kilminster S, 1999, STROKE, V30, P1869, DOI 10.1161/01.STR.30.9.1869; Maier B, 2001, SHOCK, V15, P421, DOI 10.1097/00024382-200115060-00002; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; Raabe A, 2000, NEUROSURG REV, V23, P136, DOI 10.1007/PL00011944; Raabe A, 1998, ACTA NEUROCHIR, V140, P787, DOI 10.1007/s007010050180; Raabe A, 1999, J NEUROSURG, V91, P875, DOI 10.3171/jns.1999.91.5.0875; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; RAO CJ, 1978, J NEUROL NEUROSUR PS, V41, P948, DOI 10.1136/jnnp.41.10.948; Romner B, 2000, J NEUROTRAUM, V17, P641, DOI 10.1089/089771500415391; Rose S, 2000, SHOCK, V13, P92, DOI 10.1097/00024382-200013020-00002; Rosen H, 1998, STROKE, V29, P473, DOI 10.1161/01.STR.29.2.473; Rothoerl RD, 1998, J TRAUMA, V45, P765, DOI 10.1097/00005373-199810000-00025; Rothoerl RD, 2000, ACTA NEUROCHIR, V142, P199, DOI 10.1007/s007010050024; THOMAS DGT, 1977, LANCET, V1, P113; USUI A, 1989, CLIN CHEM, V35, P1942; Wiesmann M, 1997, ACTA NEUROCHIR, V139, P1155, DOI 10.1007/BF01410976; Wong CH, 1999, ANN THORAC SURG, V67, P1911, DOI 10.1016/S0003-4975(99)00425-7; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	31	78	90	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1073-2322	1540-0514		SHOCK	Shock	MAR	2003	19	3					195	200		10.1097/00024382-200303000-00001			6	Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease	General & Internal Medicine; Hematology; Surgery; Cardiovascular System & Cardiology	648UG	WOS:000181168500001	12630517				2021-06-18	
J	Hergan, K; Schaefer, PW; Sorensen, AG; Gonzalez, RG; Huisman, TAGM				Hergan, K; Schaefer, PW; Sorensen, AG; Gonzalez, RG; Huisman, TAGM			Diffusion-weighted MRI in diffuse axonal injury of the brain	EUROPEAN RADIOLOGY			English	Article						diffusion-weighted imaging; diffuse axonal injury; brain injury	HEAD-INJURY; EDEMA; TRAUMA	The goal of this study was to identify and describe the different types and patterns of tissue injury which are encountered by diffusion-weighted imaging (DWI) in diffuse axonal injury (DAI) of the brain. The DWI data sets of 98 patients who suffered from a closed-head injury were retrospectively evaluated. Medical records were reviewed to rule out pre-existing neurological diseases. Lesions were studied for their DWI signal characteristics and lesion size or extension. Traumatic lesions were classified into three categories depending on their signal characteristica on DWI and apparent diffusion coefficient (ADC) maps: type 1, DWI- and ADC-hyperintense most likely representing lesions with vasogenic edema; type 2, DWI-hyperintense, ADC-hypointense indicating cytotoxic edema; type 3, central hemorrhagic lesion surrounded by an area of increased diffusion. According to the size and extent of lesions, injury was classified into three groups: group A, focal injury; group B, regional/confluent injury; and group C, extensive/diffuse injury. Our study showed that diffusion-weighted imaging differentiates between lesions with decreased and increased diffusion in patients with DAI. Different degrees of tissue injury extent were noticed. Future prospective studies should study if this additional information can be used as a predictor of injury reversibility, final outcome and prognosis.	Massachusetts Gen Hosp, Dept Radiol, Neuroradiol Sect, Boston, MA 02129 USA; Massachusetts Gen Hosp, MGH NMR Ctr, Boston, MA 02129 USA; Harvard Univ, Sch Med, Boston, MA 02129 USA; LKH Feldkirch, Dept Radiol, Feldkirch, Austria	Huisman, TAGM (corresponding author), Massachusetts Gen Hosp, Dept Radiol, Neuroradiol Sect, Bldg 149,13th St,Mailcode 149-2301, Boston, MA 02129 USA.	thierry@nmr.mgh.harvard.edu	Schaefer, Pamela/AAA-1323-2019				ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; Anderson CV, 1996, J NEUROTRAUM, V13, P59, DOI 10.1089/neu.1996.13.59; GALE SD, 1995, J NEUROTRAUM, V12, P151, DOI 10.1089/neu.1995.12.151; GEAN AD, 1994, IMAGING HEAD TRAUMA, P217; GENNARELLI TA, 1991, J EMERGENCY MED, V11, P5; Gonzalez RG, 1999, RADIOLOGY, V210, P155, DOI 10.1148/radiology.210.1.r99ja02155; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; Kawamata T, 2000, ACTA NEUROCHIR SUPPL, V76, P9; KELLY AB, 1988, AM J NEURORADIOL, V9, P699; MARION DW, 1999, TRAUMATIC BRAIN INJU, P31; Marmarou A, 2000, ACT NEUR S, V76, P349; Nakahara M, 2001, ACTA RADIOL, V42, P365, DOI 10.1034/j.1600-0455.2001.420404.x; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; Paterakis K, 2000, J TRAUMA, V49, P1071, DOI 10.1097/00005373-200012000-00016; Schaefer PW, 2000, RADIOLOGY, V217, P331, DOI 10.1148/radiology.217.2.r00nv24331; STRICH SJ, 1961, LANCET, V2, P443; Suh DY, 2001, NEUROSURGERY, V49, P309, DOI 10.1097/00006123-200108000-00011; Takayama H, 2000, CLIN NEUROL NEUROSUR, V102, P135, DOI 10.1016/S0303-8467(00)00079-2; Unterberg AW, 1997, ACT NEUR S, V70, P106	20	78	87	0	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0938-7994	1432-1084		EUR RADIOL	Eur. Radiol.	OCT	2002	12	10					2536	+		10.1007/s00330-002-1333-2			6	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	606EG	WOS:000178720500018	12271396				2021-06-18	
J	Bernstein, DM				Bernstein, DM			Information processing difficulty long after self-reported concussion	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						mild head injury; P300; information processing	MILD HEAD-INJURY; TRAUMATIC BRAIN INJURY; NEUROPSYCHOLOGICAL DEFICITS; AUDITORY-STIMULI; TASK-DIFFICULTY; P300 LATENCY; ATTENTION; RECOVERY; SYMPTOMS; DETERMINANTS	Recovery of cognitive function after mild head injury (MHI) is thought to be relatively swift and complete. The present study replicates and extends previous work in which university students with self-reported concussion demonstrated reduced P300 amplitude on a set of easy and difficult attention tasks, in addition to performing more poorly than controls on demanding cognitive tasks many years after injury. In the present study, 13 students with self-reported concussion (MHl group: M time since injury = 8 years) and 10 controls were matched for age, sex, education, and a variety of cognitive, physical and emotional complaints. Controls outperformed the MHI group on the Digit Symbol substitution task and on a difficult dual task involving tone discrimination and visual working memory. Additionally, controls exhibited larger P300 amplitudes on both an easy and a difficult auditory discrimination task. A combination of electrophysiological, neuropsychological and self-report indices predicted group membership (MHI vs. control) with 88% accuracy. The present results, coupled with previous work, offer preliminary evidence that the combination of event-related potentials and demanding behavioral measures might reveal long-lasting, subtle cognitive problems associated with MHI. These findings may challenge existing notions of complete recovery after MHI.	Simon Fraser Univ, Burnaby, BC V5A 1S6, Canada	Bernstein, DM (corresponding author), Univ Washington, Dept Psychol, POB 351525, Seattle, WA 98105 USA.	db6@u.washington.edu					ARCIA E, 1994, BRAIN INJURY, V8, P395, DOI 10.3109/02699059409150991; Baddeley, 1998, HUMAN MEMORY THEORY; Bernstein DM, 2000, BRAIN COGNITION, V44, P50, DOI 10.1006/brcg.1999.1209; Bernstein DM, 1999, BRAIN INJURY, V13, P151, DOI 10.1080/026990599121683; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Dupuis F, 2000, NEUROREPORT, V11, P4087, DOI 10.1097/00001756-200012180-00035; Ford MR, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199606000-00004; Gaetz M, 2000, BRAIN INJURY, V14, P815; Gaetz M, 2001, J HEAD TRAUMA REHAB, V16, P386, DOI 10.1097/00001199-200108000-00008; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; Granovsky Y, 1998, EVOKED POTENTIAL, V108, P554, DOI 10.1016/S0168-5597(98)00036-7; GRONWALL D, 1975, LANCET, V2, P995; HOCHHAUS L, 1972, PSYCHOL BULL, V77, P375, DOI 10.1037/h0032459; Kahneman D., 1973, ATTENTION EFFORT; Klem G H, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P3; Kushner D, 1998, ARCH INTERN MED, V158, P1617, DOI 10.1001/archinte.158.15.1617; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Mateer C.A., 1987, J HEAD TRAUMA REHAB, V2, P74, DOI [10.1097/00001199-198709000-00009, DOI 10.1097/00001199-198709000-00009]; MCCARTHY G, 1981, SCIENCE, V211, P77, DOI 10.1126/science.7444452; PARASURAMAN R, 1991, J CLIN EXP NEUROPSYC, V13, P789, DOI 10.1080/01688639108401090; Park NW, 1999, NEUROPSYCHOLOGIA, V37, P1119, DOI 10.1016/S0028-3932(99)00034-2; Pinkston JB, 2000, BRAIN COGNITION, V44, P74; POLICH J, 1986, ELECTROEN CLIN NEURO, V63, P251, DOI 10.1016/0013-4694(86)90093-3; POLICH J, 1987, ELECTROEN CLIN NEURO, V68, P311, DOI 10.1016/0168-5597(87)90052-9; Potter DD, 1999, J PSYCHOPHYSIOL, V13, P173, DOI 10.1027//0269-8803.13.3.173; PRATAPCHAND R, 1988, ACTA NEUROL SCAND, V78, P185, DOI 10.1111/j.1600-0404.1988.tb03643.x; PRITCHARD WS, 1981, PSYCHOL BULL, V89, P506, DOI 10.1037/0033-2909.89.3.506; Reinvang I, 2000, NEUROPSYCHOLOGIA, V38, P995, DOI 10.1016/S0028-3932(99)00153-0; Ryan L M, 1996, Appl Neuropsychol, V3, P49, DOI 10.1207/s15324826an0302_1; Sangal RB, 1996, BIOL PSYCHIAT, V39, P305, DOI 10.1016/0006-3223(95)00447-5; Satz P, 1999, J CLIN EXP NEUROPSYC, V21, P620, DOI 10.1076/jcen.21.5.620.870; Segalowitz SJ, 2001, BRAIN COGNITION, V45, P342, DOI 10.1006/brcg.2000.1263; SEGALOWITZ SJ, 1995, J LEARN DISABIL, V28, P309, DOI 10.1177/002221949502800507; Solbakk AK, 2000, J CLIN EXP NEUROPSYC, V22, P743, DOI 10.1076/jcen.22.6.743.953; Solbakk AK, 1999, PSYCHOPHYSIOLOGY, V36, P802; SPSS Inc, SPSS WIND; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; TANNER WP, 1954, PSYCHOL REV, V61, P401, DOI 10.1037/h0058700; TEECE JJ, 1993, ELECTROENCEPHALOGRAP, P887; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wilson GF, 1998, BIOL PSYCHOL, V47, P137, DOI 10.1016/S0301-0511(97)00021-5; WINGFIELD A, 1981, PSYCHOL HUMAN MEMORY	50	78	78	0	19	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JUL	2002	8	5					673	682		10.1017/S1355617702801400			10	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	578FA	WOS:000177105700006	12164676				2021-06-18	
J	Jamieson, WRE; Janusz, MT; Gudas, VM; Burr, LH; Fradet, GJ; Henderson, C				Jamieson, WRE; Janusz, MT; Gudas, VM; Burr, LH; Fradet, GJ; Henderson, C			Traumatic rupture of the thoracic aorta: third decade of experience	AMERICAN JOURNAL OF SURGERY			English	Article; Proceedings Paper	88th Annual Meeting of the North-Pacific-Surgical-Association	NOV 09-10, 2001	VICTORIA, CANADA	N Pacific Surg Assoc		traumatic aortic injury; heparinless cardiopulmonary bypass	METAANALYSIS; CIRCULATION; PARAPLEGIA; DIAGNOSIS; MORTALITY; REPAIR; BYPASS; TEARS; PUMP	Background: Traumatic rupture of the thoracic aorta is a relatively common injury of deceleration accidents, usually high-speed motor vehicle accidents. Spinal cord injury has been a well-documented complication of surgical management. The use of nonheparnized partial bypass with a centrifugal pump was evaluated for protection against spinal cord injury and reduction of risk of associated injuries. Methods: From 1989 to 1999, the third decade of the authors' experience, traumatic rupture was diagnosed in 58 patients (male 46 and female 12; mean age 39.9 years, range 17 to 85). Associated injuries were documented in 98.3% (57 patients). In all, 45 patients (77.6%) had the opportunity for definitive surgical management; 42 (93.3%) were managed with partial cardiopulmonary bypass, 35 without the use of heparin. Full cardiopulmonary bypass was utilized in 1 patient while 2 had repair without cardiopulmonary bypass support. Thirteen patients did not have the opportunity for definitive surgical management, 1 death on arrival, 8 (61.5%) suspected, and 4 (30.8%) diagnosed. Results: There were 6 deaths in the surgical group, 5 in nonheparinized patients. The causes were intraoperative hypovolemia (2), anoxic brain death after intraoperative cardiac arrest (1), sepsis (1), and adult respiratory distress syndrome (1). The other was in the simple aortic cross-clamp group from intraoperative pulmonary compromise. There was one spinal cord injury, paraparesis in 1 of the 2 patients managed without bypass support. The total hospital stay ranged from 8 to 112 days, primarily owing to management of associated injuries. Of the 13 patients who did not have the opportunity for definitive surgical management, 5 had unsuccessful emergency thoracotomy and 3 survived the hospital course without surgery. Of the total population, the overall mortality was 27.6%, whereas the mortality of the potentially operable patients was 25.8%. Of the surgical group, the intraoperative mortality was 6.7% and 30-day mortality was 13.3%. Conclusions: Spinal cord injury was prevented by the use of partial cardiopulmonary bypass. Nonheparinized bypass was likely to be a contributory factor to lack of mortality directly related to associated injuries. (C) 2002 Excerpta Medica, Inc. All rights reserved.	Univ British Columbia, St Pauls Hosp, Dept Surg, Vancouver, BC V6Z 1Y6, Canada	Jamieson, WRE (corresponding author), Univ British Columbia, St Pauls Hosp, Dept Surg, 331-332 Burrard Bldg,1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.						Duke BJ, 1997, J TRAUMA, V42, P1135, DOI 10.1097/00005373-199706000-00026; Fishman JE, 2000, J THORAC IMAG, V15, P97, DOI 10.1097/00005382-200004000-00004; Franchello A, 1997, INT SURG, V82, P79; Gammie JS, 1998, ANN THORAC SURG, V66, P1295, DOI 10.1016/S0003-4975(98)00778-4; Glock Y, 1996, Rev Esp Cardiol, V49 Suppl 4, P100; HESS PJ, 1989, ANN THORAC SURG, V48, P6, DOI 10.1016/0003-4975(89)90167-7; HILLS MW, 1994, AUST NZ J SURG, P64312; JAMIESON WRE, 1996, SURG TECHNOL INT, P305; JANUSZ MT, 1994, AM J SURG, V167, P501, DOI 10.1016/0002-9610(94)90244-5; KODALI S, 1991, CIRCULATION, V84, P11140; MAGGISANO R, 1995, ANN VASC SURG, V9, P44, DOI 10.1007/BF02015316; Mengozzi E, 2000, Radiol Med, V100, P139; OLIVIER HF, 1984, ANN THORAC SURG, V38, P586, DOI 10.1016/S0003-4975(10)62315-6; PATE JW, 1995, ANN THORAC SURG, V59, P90, DOI 10.1016/0003-4975(94)00719-N; VONOPPELL UO, 1994, J CARDIAC SURG, V9, P685; VONOPPELL UO, 1994, ANN THORAC SURG, V58, P585, DOI 10.1016/0003-4975(94)92270-5; VONOPPELL UO, 1991, S AFR MED J, V79, P595; Wicky S, 1998, EUR RADIOL, V8, P828, DOI 10.1007/s003300050480	18	78	81	0	1	EXCERPTA MEDICA INC	NEW YORK	650 AVENUE OF THE AMERICAS, NEW YORK, NY 10011 USA	0002-9610			AM J SURG	Am. J. Surg.	MAY	2002	183	5					571	575	PII S0002-9610(02)00851-6	10.1016/S0002-9610(02)00851-6			5	Surgery	Surgery	557EG	WOS:000175894700018	12034396				2021-06-18	
J	Max, JE; Fox, PT; Lancaster, JL; Kochunov, P; Mathews, K; Manes, FF; Robertson, BAM; Arndt, S; Robin, DA; Lansing, AE				Max, JE; Fox, PT; Lancaster, JL; Kochunov, P; Mathews, K; Manes, FF; Robertson, BAM; Arndt, S; Robin, DA; Lansing, AE			Putamen lesions and the development of attention-deficit/hyperactivity symptomatology	JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY			English	Article						attention-deficit/hyperactivity disorder; childhood stroke; putamen	DEFICIT HYPERACTIVITY DISORDER; FUNCTIONAL MAGNETIC-RESONANCE; CLOSED-HEAD INJURY; SPATIAL NORMALIZATION; HUMAN BRAIN; CHILDREN; RELIABILITY; VALIDITY; GIRLS	Objective: To investigate the association between focal stroke lesions of the putamen and either attention-deficit/hyperactivity disorder or traits of the disorder (ADHD/Traits). Method: Twenty-five children with focal stroke lesions were studied with standardized psychiatric assessments and anatomic brain magnetic resonance imaging. The pattern of lesion overlap in subjects with ADHD/Traits was determined. Results: Fifteen of 25 subjects had ADHD/Traits. The densest area of overlapping lesions (n = 7) in subjects with ADHD/Traits included the posterior ventral putamen. The median lesion volume was 9.7 cm(3), and the distribution was highly skewed. Lesion volume was not associated with ADHD/Traits. Therefore the following analyses focused on the 13 subjects with lesions < 10 cm(3): ADHD/Traits were exhibited in 617 subjects with putamen lesions versus 2/6 with no putamen lesions (Fisher exact test p = .1). Half (4/8) of the subjects with ADHD/Traits had overlapping lesions encompassing the posterior ventral putamen. None of the 5 subjects without ADHD/Traits had lesions in this empirically derived region of interest (Fisher exact test p = .1). Conclusions: Lesions within the dopamine-rich ventral putamen, which is part of the ventral or limbic striatum, tended to increase the risk of ADHD/Traits. ADHD/Traits may therefore be a disinhibition syndrome associated with dysfunction in this cortical-striato-thalamocortical loop.	Univ Calif San Diego, Dept Psychiat, San Diego, CA 92123 USA; Childrens Hosp & Hlth Ctr, San Diego, CA USA; Univ Texas, Hlth Sci Ctr, San Antonio, TX USA; Univ Iowa, Iowa City, IA USA; Raul Carrea Inst Neurol Res, FLENI, Buenos Aires, DF, Argentina; San Diego State Univ, San Diego, CA 92182 USA	Max, JE (corresponding author), Univ Calif San Diego, Dept Psychiat, 3665 Kearny Villa Rd,Suite 101, San Diego, CA 92123 USA.		Fox, Peter/B-4725-2010; Lancaster, Jack L/F-2994-2010; Robin, Donald/F-2109-2010; Kochunov, Peter/E-4711-2010; Arndt, Stephan/A-6976-2013	Fox, Peter/0000-0002-0465-2028; Arndt, Stephan/0000-0003-0783-8204; mathews, katherine/0000-0003-4160-0435	NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [P20MH052176, P01MH052176, T32MH018399] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [5 P02 MH52176-07, T32 MH18399] Funding Source: Medline		AFIFI AK, 1998, TXB PEDIAT NEUROPSYC, P65; American Psychiatric Association, 1987, DIAGN STAT MAN MENT; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; ANDREASEN NC, 1977, ARCH GEN PSYCHIAT, V34, P1229; Castellanos FX, 2001, ARCH GEN PSYCHIAT, V58, P289, DOI 10.1001/archpsyc.58.3.289; Castellanos FX, 1997, CLIN PEDIATR, V36, P381, DOI 10.1177/000992289703600702; Castellanos FX, 1996, ARCH GEN PSYCHIAT, V53, P607; De Weerd P, 1999, NAT NEUROSCI, V2, P753, DOI 10.1038/11234; Ebaugh FG, 1923, AM J DIS CHILD, V25, P89; Ernst M, 1997, J AM ACAD CHILD PSY, V36, P1399, DOI 10.1097/00004583-199710000-00022; Filipek PA, 1997, NEUROLOGY, V48, P589, DOI 10.1212/WNL.48.3.589; Gerring J, 2000, BRAIN INJURY, V14, P205; Giroud M, 1997, J NEUROL NEUROSUR PS, V63, P611, DOI 10.1136/jnnp.63.5.611; Heinz A, 1999, SYNAPSE, V32, P71, DOI 10.1002/(SICI)1098-2396(199905)32:2<71::AID-SYN1>3.3.CO;2-H; Hendren RL, 2000, J AM ACAD CHILD PSY, V39, P815, DOI 10.1097/00004583-200007000-00010; Herskovits EH, 1999, RADIOLOGY, V213, P389, DOI 10.1148/radiology.213.2.r99nv45389; HYND GW, 1993, J CHILD NEUROL, V8, P339, DOI 10.1177/088307389300800409; Kaufman J, 1997, J AM ACAD CHILD PSY, V36, P980, DOI 10.1097/00004583-199707000-00021; Kochunov P, 2001, J COMPUT ASSIST TOMO, V25, P805, DOI 10.1097/00004728-200109000-00023; Lancaster JL, 1995, HUM BRAIN MAPP, V3, P209, DOI 10.1002/hbm.460030305; Lancaster JL, 1997, HUM BRAIN MAPP, V5, P238, DOI 10.1002/(SICI)1097-0193(1997)5:4<238::AID-HBM6>3.0.CO;2-4; Lancaster JL, 2000, HUM BRAIN MAPP, V10, P120, DOI 10.1002/1097-0193(200007)10:3<120::AID-HBM30>3.0.CO;2-8; Levy F, 1997, J AM ACAD CHILD PSY, V36, P737, DOI 10.1097/00004583-199706000-00009; Lippitz BE, 1999, NEUROSURGERY, V44, P452, DOI 10.1097/00006123-199903000-00005; Max JE, 2002, J AM ACAD CHILD PSY, V41, P555, DOI 10.1097/00004583-200205000-00013; MERJANIAN P M, 1989, Society for Neuroscience Abstracts, V15, P302; Obeso JA, 2000, NEUROLOGY, V55, pS7; OUNSTED C, 1955, LANCET, V2, P303; Paus T, 1996, J COMP NEUROL, V376, P664, DOI 10.1002/(SICI)1096-9861(19961223)376:4<664::AID-CNE12>3.0.CO;2-M; Roach ES, 1995, PEDIAT CEREBROVASCUL, P35; ROACH ES, 1995, PEDIAT CEREBROVASCUL, P121; SZATMARI P, 1989, J CHILD PSYCHOL PSYC, V30, P219, DOI 10.1111/j.1469-7610.1989.tb00236.x; Teicher MH, 2000, NAT MED, V6, P470, DOI 10.1038/74737; *US DHHS, 1994, INT CLASS DIS; Vaidya CJ, 1998, P NATL ACAD SCI USA, V95, P14494, DOI 10.1073/pnas.95.24.14494; Wechsler D., 1991, WECHSLER INTELLIGENC	36	78	79	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0890-8567			J AM ACAD CHILD PSY	J. Am. Acad. Child Adolesc. Psychiatr.	MAY	2002	41	5					563	571		10.1097/00004583-200205000-00014			9	Psychology, Developmental; Pediatrics; Psychiatry	Psychology; Pediatrics; Psychiatry	544YF	WOS:000175188900014	12014789				2021-06-18	
J	Port, A; Willmott, C; Charlton, J				Port, A; Willmott, C; Charlton, J			Self-awareness following traumatic brain injury and implications for rehabilitation	BRAIN INJURY			English	Article							SEVERE HEAD-INJURY; CLOSE RELATIVES; DEFICITS; MEMORY; QUESTIONNAIRE; COMPLAINTS; ADULTS	Primary objective: Many studies investigating self-awareness following traumatic brain injury (TBI) have been conducted more than 2 years post-injury, thereby providing limited information regarding the implications of insight for rehabilitation. The present study aimed to investigate awareness of deficits in a group of patients who were less than 2 years post-injury and still involved in rehabilitation. Research design: Thirty patients with a history of moderate or severe TBI and their significant other (SO) were studied in a cross-sectional analysis. A sub-group also participated in an interdisciplinary Memory Group at the Bethesda Rehabilitation Centre. Methods and procedures: Level of insight was measured by the degree of agreement between self and significant other (SO) report on the Awareness of Deficit questionnaire (ADQ), assessing various domains of daily functioning. Results: There was substantial agreement between patients and their SO, although the patients with TBI were less likely to acknowledge executive problems. Interestingly, both groups reported only low-to-moderate levels of difficulty. Conclusions: The data indicate that SO's awareness may also be limited in the early recovery stages. A sub-group of the patients obtained benefit from participation in the Memory Group in a rehabilitation setting.	Epworth Med Fdn, Dept Psychol, Bethesda Rehabil Ctr, Richmond, Vic 3121, Australia; Deakin Univ, Melbourne, Vic, Australia; Monash Univ, Melbourne, Vic 3004, Australia; Deakin Univ, Burwood, Australia	Willmott, C (corresponding author), Epworth Med Fdn, Dept Psychol, Bethesda Rehabil Ctr, 89 Bridge Rd, Richmond, Vic 3121, Australia.	cathyw@epworth.org.au	Willmott, Catherine/AAA-5105-2019	Willmott, Catherine/0000-0001-8517-9035; Charlton, Judith/0000-0002-5990-2151			ADAMS JH, 1985, NEUROPATH APPL NEURO, V11, P299, DOI 10.1111/j.1365-2990.1985.tb00027.x; Anderson S. W., 1989, CLIN NEUROPSYCHOL, V3, P327, DOI DOI 10.1080/13854048908401482; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; CAVALLO M M, 1992, Brain Injury, V6, P327, DOI 10.3109/02699059209034947; Crosson B., 1989, J HEAD TRAUMA REHAB, V4, P46, DOI [10.1097/00001199-198909000-00008, DOI 10.1097/00001199-198909000-00008]; ELSASS L, 1991, THESIS LA TROBE U ME; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; Fleming JM, 1996, BRAIN INJURY, V10, P1; FLEMMING, 1999, P 21 ANN BRAIN IMP C; FORDYCE DJ, 1986, REHABIL PSYCHOL, V31, P217, DOI 10.1037//0090-5550.31.4.217; Heilbronner R L, 1989, Brain Inj, V3, P387, DOI 10.3109/02699058909004562; HENDRYX PM, 1989, ARCH PHYS MED REHAB, V70, P526; Hillier SL, 1997, BRAIN INJURY, V11, P525, DOI 10.1080/713802189; KAY T, 1995, J HEAD TRAUMA REHAB, V10, P12, DOI 10.1097/00001199-199504000-00004; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; Lam C S, 1988, Brain Inj, V2, P235, DOI 10.3109/02699058809150947; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; MCWILLIAMS S, 1991, BRIT J OCCUPATIONAL, V54, P246; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Ponsford J, 1999, NEUROPSYCHOL REHABIL, V9, P517, DOI 10.1080/096020199389563; Prigatano G. P., 1991, AWARENESS DEFICIT BR; PRIGATANO GP, 1995, J HEAD TRAUMA REHAB, V10, P87; SANTORO J, 1994, BRAIN INJURY, V8, P265, DOI 10.3109/02699059409150978; Santos ME, 1998, BRAIN INJURY, V12, P759, DOI 10.1080/026990598122151; Sbordone RJ, 1998, BRAIN INJURY, V12, P505, DOI 10.1080/026990598122467; SCHACTER DL, 1977, CORTEX, V13, P150, DOI 10.1016/S0010-9452(77)80006-3; SHEERER M, 1996, J INT NEUROPSYCH SOC, V2, P17; Sherer M, 1998, BRAIN INJURY, V12, P63, DOI 10.1080/026990598122863; Sohlberg M. M., 1989, INTRO COGNITIVE REHA; Stuss DT., 1991, AWARENESS DEFICIT BR, P63; SUNDERLAND A, 1983, J VERB LEARN VERB BE, V22, P341, DOI 10.1016/S0022-5371(83)90229-3; SUNDERLAND A, 1984, J CLIN NEUROPSYCHOL, V6, P127, DOI 10.1080/01688638408401204; Teasdale TW, 1997, BRAIN INJURY, V11, P543, DOI 10.1080/026990597123250; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; Wallace CA, 2000, BRAIN INJURY, V14, P549; Wilson BA, 1996, BEHAV ASSESSMENT DYS	40	78	79	0	12	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	APR	2002	16	4					277	289		10.1080/02699050110103274			13	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	541CM	WOS:000174967700001	11953000				2021-06-18	
J	Flashman, LA; McAllister, TW				Flashman, LA; McAllister, TW			Lack of awareness and its impact in traumatic brain injury	NEUROREHABILITATION			English	Article						unawareness; lack of insight; traumatic brain injury; frontal-parietal circuitry	CLOSED HEAD-INJURY; IMPAIRED AWARENESS; SELF-AWARENESS; RATING-SCALE; REHABILITATION; UNAWARENESS; DEFICITS; INSIGHT; APATHY; SCHIZOPHRENIA	Research suggests that up to 45% severe TBI demonstrate reduced awareness or complete lack of awareness of their deficits. We describe dimensions and distinctions within the concept of lack of awareness -- including whether an individual has knowledge of a specific deficit, the emotional response an individual manifests to a specific deficit, the ability to comprehend the impact or consequences of the deficit on day to day life, and how an individual explains or accounts for any deficits -- and various methods of assessing for lack of awareness in this population. Finally, a review of the literature studying lack of awareness in TBI, its relationship to injury severity, the impact of lack of awareness on outcome, and intervention approaches is presented.	Dartmouth Hitchcock Med Ctr, Dept Psychiat, Neuropsychiat Sect, Dartmouth Med Sch, Lebanon, NH 03756 USA; New Hampshire Hosp, Concord, NH USA	Flashman, LA (corresponding author), Dartmouth Hitchcock Med Ctr, Dept Psychiat, Neuropsychiat Sect, Dartmouth Med Sch, 1 Med Ctr Dr, Lebanon, NH 03756 USA.	Laura.A.Flashman@dartmouth.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS40472-01] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040472] Funding Source: NIH RePORTER		Alexy WD, 1983, COGNITIVE REHABILITA, V1, P8; ALLEN C C, 1990, Brain Injury, V4, P7, DOI 10.3109/02699059009026143; Andersson S, 1999, BRAIN INJURY, V13, P393, DOI 10.1080/026990599121458; Babinski MJ., 1914, REV NEUROL, V27, P845; BARIN JJ, 1985, HEAD INJURY REHABILI, P362; BENYISHAY Y, 1987, J HEAD TRAUMA REHAB, V2, P35, DOI DOI 10.1097/00001199-198703000-00007; Bergquist Thomas F., 1993, Brain Injury, V7, P275, DOI 10.3109/02699059309029680; Bond M R, 1975, Ciba Found Symp, P141; BROOKS N, 1991, Brain Injury, V5, P103, DOI 10.3109/02699059109008082; Buckley PF, 2001, COMPR PSYCHIAT, V42, P39, DOI 10.1053/comp.2001.16569; CAVALLO M M, 1992, Brain Injury, V6, P327, DOI 10.3109/02699059209034947; Chittum WR, 1996, BRAIN INJURY, V10, P763; DEATON AV, 1978, REHABIL PSYCHOL, V31, P231; DEKOSKY ST, 1998, SEMIN CLIN NEUROPSYC, V3, P176; DELUCA J, 1996, MAGAZINE, V4, P14; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; FAHY TJ, 1967, LANCET, V2, P475; Feinberg TE, 1997, NEUROCASE, V3, P73, DOI 10.1093/neucas/3.1.73; Flashman L. A., 1998, SEMINARS CLIN NEUROP, V3, P201; FLASHMAN LA, 1997, J NEUROPSYCHIATRY CL, V9, P670; Fleming JM, 1996, BRAIN INJURY, V10, P1; FORD B, 1976, MED J AUSTRALIA, V1, P603, DOI 10.5694/j.1326-5377.1976.tb140904.x; FORDYCE DJ, 1986, REHABIL PSYCHOL, V31, P217, DOI 10.1037//0090-5550.31.4.217; Freeland J, 1996, MAGAZINE, V4, P32; GENARELLI TA, 1998, SEMINARS CLIN NEUROP, V3, P160; Giacino JT, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199810000-00003; Gordon WR, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199812000-00006; GRAY JM, 1994, CLIN REHABIL, V8, P188, DOI DOI 10.1080/09602010902949207; GROSWASSER Z, 1977, SCAND J REHABIL MED, V9, P147; Heilbronner R L, 1989, Brain Inj, V3, P387, DOI 10.3109/02699058909004562; Heilman K., 1991, AWARENESS DEFICIT BR, P53; Herbert CM, 1989, CLIN REHABIL, V3, P125; Hillier SL, 1997, BRAIN INJURY, V11, P525, DOI 10.1080/713802189; Kant R, 1998, BRAIN INJURY, V12, P87, DOI 10.1080/026990598122908; KENT H, 1999, J HEAD TRAUMA REHAB, V13, P62; Kozloff R, 1987, J HEAD TRAUMA REHAB, V2, P14, DOI DOI 10.1097/00001199-198709000-00004; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Lam C S, 1988, Brain Inj, V2, P235, DOI 10.3109/02699058809150947; Leathem JM, 1998, J CLIN EXP NEUROPSYC, V20, P694, DOI 10.1076/jcen.20.5.694.1122; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; LEVINE DN, 1990, BRAIN COGNITION, V13, P233, DOI 10.1016/0278-2626(90)90052-P; LYSAKER P, 1994, J NERV MENT DIS, V182, P656, DOI 10.1097/00005053-199411000-00010; LYSAKER P, 1998, ADV PSYCHOSOCIAL TRE, P307; MALEC JF, 1993, BRAIN INJURY, V7, P383, DOI 10.3109/02699059309029682; MARIN RS, 1991, J NEUROPSYCH CLIN N, V3, P243; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; MILLER H, 1965, LANCET, V1, P225; Mohamed S, 1999, J NERV MENT DIS, V187, P525, DOI 10.1097/00005053-199909000-00001; Newman AC, 2000, BRAIN INJURY, V14, P333; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; OTA Y, 1969, LATE EFFECTS HEAD IN; Prigatano G. P., 1990, CLIN NEUROPSYCHOL, V4, P163, DOI [10.1080/13854049008401509, DOI 10.1080/13854049008401509]; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Prigatano GP, 1998, J HEAD TRAUMA REHAB, V13, P29, DOI 10.1097/00001199-199810000-00005; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; Prigatano GP, 1991, AWARENESS DEFICIT BR, P111; PRIGATANO GP, 1987, BNI Q, V3, P10; RATTOK J, 1992, NEUROPSYCHOLOGIA, V6, P395, DOI DOI 10.1037/0894-4105.6.4.395; ROMANO MD, 1974, SCAND J REHABIL MED, V6, P1; SACKEIM HA, 1986, ARCH GEN PSYCHIAT, V43, P553; Sbordone RJ, 1998, BRAIN INJURY, V12, P505, DOI 10.1080/026990598122467; Schilder P, 1934, AM J PSYCHIAT, V91, P155, DOI 10.1176/ajp.91.1.155; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; Sherer M., 1995, J INT NEUROPSYCH SOC, V1, P163; Smith TE, 2000, SCHIZOPHRENIA BULL, V26, P193, DOI 10.1093/oxfordjournals.schbul.a033439; Sohlberg MM, 1998, J HEAD TRAUMA REHAB, V13, P62, DOI 10.1097/00001199-199810000-00008; Stuss D.T., 1986, FRONTAL LOBES; Stuss DT., 1991, AWARENESS DEFICIT BR, P63; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; Tournois J., 2000, EUR REV APPL PSYCHOL, V50, P219; Trivers R, 2000, ANN NY ACAD SCI, V907, P114; TRUDEL TM, 1996, NEW HAMPSH BRAIN INJ; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; WALKER DE, 1987, J CLIN PSYCHOL, V43, P699, DOI 10.1002/1097-4679(198711)43:6<699::AID-JCLP2270430610>3.0.CO;2-9; WATSON RT, 1981, ARCH NEUROL-CHICAGO, V38, P501, DOI 10.1001/archneur.1981.00510080063009; WATSON RT, 1994, ARCH NEUROL-CHICAGO, V51, P1014, DOI 10.1001/archneur.1994.00540220060015; Weinstein E. A., 1955, DENIAL ILLNESS SYMBO; YOUNG DA, 1993, SCHIZOPHR RES, V10, P117, DOI 10.1016/0920-9964(93)90046-L; Zhou J, 1996, J HEAD TRAUMA REHAB, V11, P51, DOI 10.1097/00001199-199602000-00007	85	78	79	0	10	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2002	17	4					285	296					12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	636GA	WOS:000180445200003	12547977				2021-06-18	
J	Hicks, RR; Zhang, L; Atkinson, A; Stevenon, M; Veneracion, M; Seroogy, KB				Hicks, RR; Zhang, L; Atkinson, A; Stevenon, M; Veneracion, M; Seroogy, KB			Environmental enrichment attenuates cognitive deficits, but does not alter neurotrophin gene expression in the hippocampus following lateral fluid percussion brain injury	NEUROSCIENCE			English	Article						neurotrophins; neural plasticity; traumatic brain injury	FACTOR MESSENGER-RNA; NERVE GROWTH-FACTOR; RAT HIPPOCAMPUS; SPATIAL MEMORY; FULL-LENGTH; BDNF; FOREBRAIN; INCREASES; RECOVERY; NEURONS	Environmental enrichment attenuates neurological deficits associated with experimental brain injury. The molecular events that mediate these environmentally induced improvements in function after injury are largely unknown, but neurotrophins have been hypothesized to be a neural substrate because of their role in cell survival and neural plasticity. Furthermore, exposure to complex environments in normal animals increases neurotrophin gene expression. However, following an ischemic injury, environmental enrichment decreases neurotrophin mRNA levels. Whether these contrasting findings are attributable to differences between injured and uninjured animals or are dependent upon the specific type of brain injury has not been determined. We examined the effects of 14 days of environmental enrichment following a lateral fluid percussion brain injury on behavior and gene expression of brain-derived neurotrophic factor, its high-affinity receptor, TrkB, and neurotrophin-3 in the rat hippocampus. Environmental enrichment attenuated learning deficits in the injured animals, but neither the injury nor housing conditions influenced neurotrophin/receptor mRNA levels. From these data we suggest that following brain trauma, improvements in learning associated with environmental enrichment are not mediated by alterations in brain-derived neurotrophic factor, TrkB or neurotrophin-3 gene expression. (C) 2002 IBRO. Published by Elsevier Science Ltd. All rights reserved.	Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA; Univ Kentucky, Div Phys Therapy, Lexington, KY 40536 USA	Hicks, RR (corresponding author), Univ Washington, Dept Rehabil Med, Box 356490,1959 NE Pacific St, Seattle, WA 98195 USA.	rhicks@u.washington.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS035164] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS35164] Funding Source: Medline		Almli CR, 2000, EXP NEUROL, V166, P99, DOI 10.1006/exnr.2000.7492; Black IB, 1999, J NEUROBIOL, V41, P108, DOI 10.1002/(SICI)1097-4695(199910)41:1<108::AID-NEU14>3.0.CO;2-U; Blaha GR, 2000, NEUROSCIENCE, V99, P483, DOI 10.1016/S0306-4522(00)00214-1; EINON DF, 1980, Q J EXP PSYCHOL, V32, P137, DOI 10.1080/00335558008248239; ERNFORS P, 1990, NEURON, V5, P511, DOI 10.1016/0896-6273(90)90090-3; ESCANDON E, 1994, J NEUROSCI, V14, P2054; FALKENBERG T, 1992, NEUROSCI LETT, V138, P153, DOI 10.1016/0304-3940(92)90494-R; Fryer RH, 1996, J COMP NEUROL, V374, P21, DOI 10.1002/(SICI)1096-9861(19961007)374:1<21::AID-CNE2>3.0.CO;2-P; FULLER KS, 1998, PATHOLOGY IMPLICATIO, P763; GALL CM, 1992, TRENDS PHARMACOL SCI, V13, P401, DOI 10.1016/0165-6147(92)90123-N; Goodness TP, 1997, EUR J NEUROSCI, V9, P1574, DOI 10.1111/j.1460-9568.1997.tb01515.x; Hamm RJ, 1996, J NEUROTRAUM, V13, P41, DOI 10.1089/neu.1996.13.41; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Hicks RR, 1998, RESTOR NEUROL NEUROS, V12, P41; Hicks RR, 1997, MOL BRAIN RES, V48, P401, DOI 10.1016/S0169-328X(97)00158-7; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Ickes BR, 2000, EXP NEUROL, V164, P45, DOI 10.1006/exnr.2000.7415; ISACKSON PJ, 1991, NEURON, V6, P937, DOI 10.1016/0896-6273(91)90234-Q; Jennett B., 1997, HEAD INJURY, P439; KatohSemba R, 1997, J NEUROCHEM, V69, P34; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Kesslak JP, 1998, BEHAV NEUROSCI, V112, P1012, DOI 10.1037/0735-7044.112.4.1012; Kokaia Z, 1996, MOL BRAIN RES, V38, P139, DOI 10.1016/0169-328X(96)00002-2; Kolb B, 1991, CEREB CORTEX, V1, P189, DOI 10.1093/cercor/1.2.189; LAUTERBORN JC, 1994, MOL CELL NEUROSCI, V5, P46, DOI 10.1006/mcne.1994.1005; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Lu B, 1999, J NEUROSCI RES, V58, P76, DOI 10.1002/(SICI)1097-4547(19991001)58:1<76::AID-JNR8>3.3.CO;2-S; McAllister AK, 1997, NEURON, V18, P767, DOI 10.1016/S0896-6273(00)80316-5; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Nilsson M, 1999, J NEUROBIOL, V39, P569, DOI 10.1002/(SICI)1097-4695(19990615)39:4<569::AID-NEU10>3.0.CO;2-F; OHLSSON AL, 1995, STROKE, V26, P644, DOI 10.1161/01.STR.26.4.644; OKIYAMA K, 1992, J NEUROSURG, V77, P607, DOI 10.3171/jns.1992.77.4.0607; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; ROBERTS AH, 1979, SEVERE ACCIDENTAL HE; Rosenzweig MR, 1996, BEHAV BRAIN RES, V78, P57, DOI 10.1016/0166-4328(95)00216-2; SCHWARTZ S, 1964, J COMP PHYSIOL PSYCH, V57, P72, DOI 10.1037/h0045518; SEROOGY KB, 1994, J COMP NEUROL, V342, P321, DOI 10.1002/cne.903420302; Torasdotter M, 1998, BEHAV BRAIN RES, V93, P83, DOI 10.1016/S0166-4328(97)00142-3; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; WHISHAW IQ, 1984, BEHAV NEURAL BIOL, V42, P183, DOI 10.1016/S0163-1047(84)91046-X; WILL BE, 1976, PHYSIOL BEHAV, V16, P603, DOI 10.1016/0031-9384(76)90221-3; Yang K, 1996, J NEUROSCI RES, V44, P157, DOI 10.1002/(SICI)1097-4547(19960415)44:2<157::AID-JNR8>3.0.CO;2-C; Young D, 1999, NAT MED, V5, P448; Zhang L, 2000, MOL BRAIN RES, V79, P174, DOI 10.1016/S0169-328X(00)00124-8; Zhao LR, 2000, NEUROSCIENCE, V97, P177, DOI 10.1016/S0306-4522(00)00023-3	47	78	79	0	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience		2002	112	3					631	637	PII S0306-4522(02)00104-5	10.1016/S0306-4522(02)00104-5			7	Neurosciences	Neurosciences & Neurology	572JF	WOS:000176770200013	12074904				2021-06-18	
S	Riccio, CA; Reynolds, CR		Wasserstein, J; Wolf, LE; LeFever, FF		Riccio, CA; Reynolds, CR			Continuous performance tests are sensitive to ADHD in adults but lack specificity - A review and critique for differential diagnosis	ADULT ATTENTION DEFICIT DISORDER: BRAIN MECHANISMS AND LIFE OUTCOMES	Annals of the New York Academy of Sciences		English	Article						continuous performance tests; attention; executive control; ADHD	DEFICIT-HYPERACTIVITY DISORDER; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; CHILDHOOD-ONSET SCHIZOPHRENIA; IDENTICAL PAIRS VERSION; FRONTAL-LOBE FUNCTIONS; GLUCOSE METABOLIC-RATE; CLOSED-HEAD-INJURY; SUSTAINED ATTENTION; BIPOLAR DISORDER; COLLEGE-STUDENTS	Historically, the focus for Attention Deficit Hyperactivity Disorder (ADHD) has been on children, with considerable research and many opinions available in this area. More recently, the focus has been expanded to include ADHD in adults. Assessment of ADHD in adults is complicated by the high rate of co-occurring disorders as well as symptom overlap with a number of disorders. One popular family of measures for the assessment of attention and executive control is the continuous performance test (CPT). A review of the available research on CPTs reveals that they are quite sensitive to CNS dysfunction. This is both a strength and a limitation of CPTs in that multiple disorders can result in impaired performance on a CPT. The high sensitivity of CPTs is further complicated by the multiple variations of CPTs available, some of which may be more sensitive or demonstrate better specificity to ADHD in adults than others. If CPTs are to be used clinically, further research will be needed to answer the questions raised by this review.	Texas A&M Univ, Dept Educ Psychol, College Stn, TX 77843 USA	Riccio, CA (corresponding author), Texas A&M Univ, Dept Educ Psychol, Mail Stop 4225, College Stn, TX 77843 USA.	criccio@acs.tamu.edu					Addington J, 1998, SCHIZOPHR RES, V32, P171, DOI 10.1016/S0920-9964(98)00042-5; ADDINGTON J, 1998, J ABNORM CHILD PSYCH, V17, P371; ALEXANDER DA, 1973, PSYCHOL REP, V32, P229, DOI 10.2466/pr0.1973.32.1.229; ALLEN LF, 1993, THESIS TEXAS A M U C; AMAN MG, 1991, J AUTISM DEV DISORD, V21, P211, DOI 10.1007/BF02284761; AMAN MG, 1993, J AUTISM DEV DISORD, V23, P491, DOI 10.1007/BF01046052; American Educational Research Association American Psychological Association National Council of Measurement in Education Joint Committee on Standards for Educational Psychological Testing (US), 1999, STAND ED PSYCH TEST; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; ANDERSON VE, 1969, J ABNORM PSYCHOL, V74, P358, DOI 10.1037/h0027611; ARCIA E, 1994, BRAIN INJURY, V8, P395, DOI 10.3109/02699059409150991; Arthur G., 1947, POINT SCALE PERFORMA; ASARNOW RF, 1978, J ABNORM PSYCHOL, V87, P597, DOI 10.1037/0021-843X.87.6.597; AUGUST GJ, 1989, J AM ACAD CHILD PSY, V28, P739, DOI 10.1097/00004583-198909000-00016; AYLWARD GP, 1990, J PSYCHOEDUC ASSESS, V8, P497, DOI 10.1177/073428299000800405; BAER RA, 1987, J APPL BEHAV ANAL, V20, P225, DOI 10.1901/jaba.1987.20-225; Barkley R.A, 2006, ATTENTION DEFICIT HY; BARKLEY RA, 1991, J AM ACAD CHILD PSY, V30, P752, DOI 10.1016/S0890-8567(10)80010-3; BARKLEY RA, 1992, J ABNORM CHILD PSYCH, V20, P163, DOI 10.1007/BF00916547; BARKLEY RA, 1990, J CONSULT CLIN PSYCH, V58, P775, DOI 10.1037/0022-006X.58.6.775; BARKLEY RA, 1994, CLIN NEUROPSYCHOL, V8, P121, DOI 10.1080/13854049408401552; Barkley RA, 1997, J DEV BEHAV PEDIATR, V18, P271; Barkley RA, 1996, J ATTEN DISORD, V1, P41, DOI DOI 10.1177/108705479600100104; BEALE IL, 1987, J ABNORM CHILD PSYCH, V15, P229, DOI 10.1007/BF00916351; BENEDICT RHB, 1994, SCHIZOPHRENIA BULL, V20, P537, DOI 10.1093/schbul/20.3.537; BERGMAN A, 1991, RITALIN THEORY PATIE, P223; BERNSTEIN GA, 1994, J AM ACAD CHILD PSY, V33, P407, DOI 10.1097/00004583-199403000-00016; Biederman J, 1998, J AFFECT DISORDERS, V51, P101, DOI 10.1016/S0165-0327(98)00177-3; BOCK RD, 1982, THESIS NEW YORK U NE; BOWEN L, 1994, J PSYCHIAT RES, V28, P289, DOI 10.1016/0022-3956(94)90012-4; BREEN MJ, 1989, J CHILD PSYCHOL PSYC, V30, P711, DOI 10.1111/j.1469-7610.1989.tb00783.x; Brown TE., 1996, BROWN ATTENTION DEFI; BRUMM VL, 1994, THESIS U SO CALIFORN; Buchanan RW, 1997, AM J PSYCHIAT, V154, P363; BUCHSBAUM MS, 1990, BRIT J PSYCHIAT, V156, P216, DOI 10.1192/bjp.156.2.216; BUCHSBAUM MS, 1992, ARCH GEN PSYCHIAT, V49, P935; BURG JS, 1995, BRAIN INJURY, V9, P395, DOI 10.3109/02699059509005779; BURKLAND SG, 1985, THESIS U WATERLOO CA; BYRNE DG, 1976, BRIT J SOC CLIN PSYC, V15, P267, DOI 10.1111/j.2044-8260.1976.tb00034.x; Carlson GA, 1998, J AFFECT DISORDERS, V51, P177, DOI 10.1016/S0165-0327(98)00179-7; CARTER CS, 1995, PSYCHIAT RES, V56, P59, DOI 10.1016/0165-1781(94)02509-H; CHEE P, 1989, EFFECTS EVENT RATE D; Chen WJ, 1997, J ABNORM PSYCHOL, V106, P649, DOI 10.1037/0021-843X.106.4.649; Chen WJ, 1998, SCHIZOPHRENIA BULL, V24, P163, DOI 10.1093/oxfordjournals.schbul.a033308; CICCHETTI DV, 1994, J CLIN EXP NEUROPSYC, V16, P155, DOI 10.1080/01688639408402625; Clure C, 1999, AM J DRUG ALCOHOL AB, V25, P441, DOI 10.1081/ADA-100101871; COHEN MJ, 1994, J EMOT BEHAV DISORD, V2, P31, DOI 10.1177/106342669400200104; Cohen R. A., 1993, NEUROPSYCHOLOGY ATTE; COHLER BJ, 1977, J CHILD PSYCHOL PSYC, V18, P115, DOI 10.1111/j.1469-7610.1977.tb00424.x; Conners C.K., 1998, CONNERS ADULT ADHD R; Conners C. K., 1995, CONNERS CONTINUOUS P; Conners C. K., 1999, ATTENTION DEFICIT HY; Conners C. K., 1992, CONNERS CONTINUOUS P; Conners CK, 1996, J AM ACAD CHILD PSY, V35, P1314, DOI 10.1097/00004583-199610000-00018; CONNERS CK, 1993, DEV HIST FORM ADHD R; Conners CK., 1999, J ATTEN DISORD, V3, P141, DOI [DOI 10.1177/108705479900300303, 10.1177/108705479900300303.]; Cornblatt B., 1989, SCHIZOPHRENIA SCI PR, P83; CORNBLATT BA, 1989, PSYCHIAT RES, V29, P65, DOI 10.1016/0165-1781(89)90188-1; CRAIG S, 1983, THESIS BOSTON U BOST; Cuffe S.P., 1994, J CHILD FAM STUD, V3, P327, DOI DOI 10.1007/BF02234689; DAS JP, 1992, J PSYCHOEDUC ASSESS, V10, P37, DOI 10.1177/073428299201000103; Denckla MB, 1996, J DEV BEHAV PEDIATR, V17, P114; DERAGOTIS LR, 1986, MANUAL SYMPTOM CHECK; Downey KK, 1997, J NERV MENT DIS, V185, P32, DOI 10.1097/00005053-199701000-00006; Downey KK, 1996, J SUBST ABUSE, V8, P129, DOI 10.1016/S0899-3289(96)90139-X; DRAEGER S, 1986, J ABNORM CHILD PSYCH, V14, P411, DOI 10.1007/BF00915435; DUPAUL GJ, 1992, J CLIN CHILD PSYCHOL, V21, P394, DOI 10.1207/s15374424jccp2104_10; DYKMAN RA, 1993, EXCEPT CHILDREN, V60, P132, DOI 10.1177/001440299306000207; EARLEBOYER EA, 1991, PSYCHIAT RES, V37, P47, DOI 10.1016/0165-1781(91)90105-X; EBERT J, 1995, J PSYCHOL PRACTICE, V1, P81; Edwards G, 1998, ADHD REPORT, V6, P11; ELIASON MJ, 1987, J LEARN DISABIL, V20, P614, DOI 10.1177/002221948702001007; Epstein JN, 1998, CLIN NEUROPSYCHOL, V12, P155, DOI 10.1076/clin.12.2.155.2000; Erhardt D., 1999, J ATTEN DISORD, V3, P153, DOI [DOI 10.1177/108705479900300304, 10.1177/108705479900300304]; ERLENMEYERKIMLING L, 1978, J PSYCHIAT RES, V14, P93, DOI 10.1016/0022-3956(78)90011-0; Ernst M, 1997, NEUROPSYCHOPHARMACOL, V16, P276, DOI 10.1016/S0893-133X(96)00243-6; ESTRIN WJ, 1988, CLIN PHARMACOL THER, V43, P86, DOI 10.1038/clpt.1988.15; FEINBERG AG, 2000, ATTENTION, V6, P20; Finkelstein JRJ, 1997, J ABNORM PSYCHOL, V106, P203; FISCHER M, 1995, J CLIN CHILD PSYCHOL, V24, P427, DOI 10.1207/s15374424jccp2404_6; FISCHER M, 1990, J CONSULT CLIN PSYCH, V58, P580, DOI 10.1037/0022-006X.58.5.580; FITZPATRICK PA, 1998, J AM ACAD CHILD ADOL, V31, P226; FLEMING KL, 1991, THESIS CALIFORNIA SC; FRANKE P, 1994, PSYCHIAT RES, V54, P259, DOI 10.1016/0165-1781(94)90020-5; FRIED PA, 1992, NEUROTOXICOL TERATOL, V14, P299, DOI 10.1016/0892-0362(92)90036-A; GARFINKEL BD, 1986, J AM ACAD CHILD PSY, V25, P503, DOI 10.1016/S0002-7138(10)60009-X; Garfinkel BD., 1983, PSYCHIATR HOSP, V14, P163; GARRETSON HB, 1985, THESIS BOSTON U BOST; GIRARDI NL, 1995, PEDIATR RES, V38, P539, DOI 10.1203/00006450-199510000-00011; Golier J, 1997, INTEGR PHYS BEH SCI, V32, P52, DOI 10.1007/BF02688613; Gordon M., 1998, ATTENTION DEFICIT HY, P294; GORDON M, 1999, ADHD REPORT, V7, P1; Gordon M., 1983, GORDON DIAGNOSTIC SY; GORENSTEIN EE, 1989, J CLIN PSYCHOL, V45, P619, DOI 10.1002/1097-4679(198907)45:4<619::AID-JCLP2270450419>3.0.CO;2-M; GREENBERG LM, 1993, J CHILD PSYCHOL PSYC, V34, P1019, DOI 10.1111/j.1469-7610.1993.tb01105.x; GREENBERG LM, 1988, TEST VARIABLES ATTEN; GREENBERG OLM, 1996, TOVA TEST VARIABLES; GRIBBLE MW, 1989, THESIS OHIO STATE U; GRODZINSKY GM, 1992, DEV NEUROPSYCHOL, V8, P427, DOI 10.1080/87565649209540536; GRONWALL D, 1974, LANCET, V2, P605; Gronwall D.M., 1974, PSYCHOL EFFECTS CONC; Grove WM, 1996, PSYCHOL PUBLIC POL L, V2, P293, DOI 10.1037/1076-8971.2.2.293; GUICH SM, 1989, SCHIZOPHR RES, V2, P439, DOI 10.1016/0920-9964(89)90012-1; HAIN C, 1993, PSYCHOPATHOLOGY, V26, P62, DOI 10.1159/000284801; Halperin J. M., 1991, PSYCHOL ASSESSMENT, V3, P803; HALPERIN JM, 1990, J CHILD PSYCHOL PSYC, V31, P455, DOI 10.1111/j.1469-7610.1990.tb01582.x; HALPERIN JM, 1988, J AM ACAD CHILD PSY, V27, P326, DOI 10.1097/00004583-198805000-00010; HALPERIN JM, 1991, DEV NEUROPSYCHOL, V7, P207, DOI 10.1080/87565649109540488; HARPER GW, 1992, J CHILD PSYCHOL PSYC, V33, P1365, DOI 10.1111/j.1469-7610.1992.tb00956.x; Hart RP, 1998, J CLIN EXP NEUROPSYC, V20, P111, DOI 10.1076/1380-3395(199802)20:1;1-P;FT111; Hathaway S. R., 1989, MANUAL ADM SCORING M; HAZLETT EA, 1993, J ABNORM PSYCHOL, V102, P39, DOI 10.1037/0021-843X.102.1.39; Heaton R., 1981, MANUAL WISCONSIN CAR; HOOKS K, 1994, J CLIN CHILD PSYCHOL, V23, P69, DOI 10.1207/s15374424jccp2301_9; Horner B, 1996, PSYCHOL ADDICT BEHAV, V10, P55, DOI 10.1037/0893-164X.10.1.55; HOY E, 1978, J ABNORM CHILD PSYCH, V6, P311, DOI 10.1007/BF00924734; Ito M, 1997, SCHIZOPHR RES, V23, P205, DOI 10.1016/S0920-9964(96)00108-9; JERISON HJ, 1967, HUM FACTORS, V9, P285, DOI 10.1177/001872086700900310; Karatekin C, 1998, PSYCHIAT RES, V80, P165, DOI 10.1016/S0165-1781(98)00061-4; Karatekin C, 1998, J ABNORM CHILD PSYCH, V26, P367, DOI 10.1023/A:1021903923120; KARDELL EG, 1994, THESIS PACE U NEW YO; KEEFE R, 1990, THESIS NEW YORK U NE; Keilp JG, 1997, PSYCHIAT RES-NEUROIM, V74, P35, DOI 10.1016/S0925-4927(96)02881-8; Kern R. M., 1999, J INDIV PSYCHOL, V55, P186; KLEE SH, 1986, PSYCHIAT ANN, V16, P52, DOI 10.3928/0048-5713-19860101-12; KLORMAN R, 1991, J ABNORM CHILD PSYCH, V19, P263, DOI 10.1007/BF00911231; KOELEGA HS, 1989, HUM FACTORS, V31, P45; KORNETSKY C, 1978, J PSYCHIAT RES, V14, P69, DOI 10.1016/0022-3956(78)90009-2; Kovner R, 1998, INT J NEUROSCI, V96, P225, DOI 10.3109/00207459808986470; LAIDLAW TM, 1993, INT J CLIN EXP HYP, V41, P97, DOI 10.1080/00207149308414541; LAM CM, 1991, REM SPEC EDUC, V12, P40, DOI 10.1177/074193259101200208; LEVAV ML, 1991, THESIS U MARYLAND CO; Levin ED, 1996, PSYCHOPHARMACOLOGY, V123, P55, DOI 10.1007/BF02246281; Levin ED, 1998, PSYCHOPHARMACOLOGY, V140, P135, DOI 10.1007/s002130050750; Levy F, 1997, J PAEDIATR CHILD H, V33, P384; Lezak M.D., 1983, NEUROPSYCHOLOGICAL A; Lin CCH, 1999, J ABNORM CHILD PSYCH, V27, P403, DOI 10.1023/A:1021932119311; LIST MA, 1985, THESIS U WATERLOO CA; Liu SK, 1997, SCHIZOPHR RES, V25, P211, DOI 10.1016/S0920-9964(97)00026-1; Lomas B, 1999, PSYCHIATR SERV, V50, P705, DOI 10.1176/ps.50.5.705; LOWE PA, 1998, ANN C NAT AC NEUR WA; Luria A. R., 1966, HIGHER CORTICAL FUNC; MAHAN SM, 1996, THESIS INDIANA STATE; Mancini C, 1999, PSYCHOL MED, V29, P515, DOI 10.1017/S0033291798007697; Mansour CS, 1996, PERS INDIV DIFFER, V20, P183, DOI 10.1016/0191-8869(95)00167-0; Marks DJ, 1999, J ABNORM CHILD PSYCH, V27, P167, DOI 10.1023/A:1021967632515; Marshall RM, 1997, J LEARN DISABIL, V30, P635, DOI 10.1177/002221949703000607; MCGRATH NF, 1985, THESIS NW U EVANSTON; MICHAELS KL, 1996, THESIS U GEORGIA ATH; Milin R, 1997, PSYCHIAT SERV, V48, P1378; MILNER B, 1971, BRIT MED BULL, V27, P272, DOI 10.1093/oxfordjournals.bmb.a070866; MIRSKY A F, 1991, Neuropsychology Review, V2, P109, DOI 10.1007/BF01109051; Mirsky A. F., 1989, INTEGRATING THEORY P, P75; MIRSKY AF, 1987, ENVIRON HEALTH PERSP, V74, P191, DOI 10.2307/3430449; Morgan AE, 1996, J AM ACAD CHILD PSY, V35, P325, DOI 10.1097/00004583-199603000-00014; MORROW LA, 1992, NEUROPSYCHOLOGIA, V30, P911, DOI 10.1016/0028-3932(92)90035-K; *MULT SYST INC, 1994, STRUCT CLIN INT DSM; Murphy K, 1996, COMPR PSYCHIAT, V37, P393, DOI 10.1016/S0010-440X(96)90022-X; Murphy K., 1996, J ATTEN DISORD, DOI [10.1177/108705479600100303, DOI 10.1177/108705479600100303]; MUSSGAY L, 1990, SCHIZOPHR RES, V3, P303, DOI 10.1016/0920-9964(90)90014-X; NEHEMKIS AM, 1972, PERCEPT MOTOR SKILL, V35, P787, DOI 10.2466/pms.1972.35.3.787; Nelson EB, 1998, AM J PSYCHIAT, V155, P137, DOI 10.1176/ajp.155.1.137; NUECHTERLEIN KH, 1983, J ABNORM PSYCHOL, V92, P4, DOI 10.1037/0021-843X.92.1.4; OBIOLS JE, 1992, PSYCHOL REP, V71, P1131, DOI 10.2466/pr0.1992.71.3f.1131; OBRIEN JD, 1992, J DEV BEHAV PEDIATR, V13, P274; ODOUGHERTY M, 1984, J ABNORM PSYCHOL, V93, P178, DOI 10.1037/0021-843X.93.2.178; Oie M, 1999, NEUROPSYCHOLOGIA, V37, P1351, DOI 10.1016/S0028-3932(99)00043-3; PARASURAMAN R, 1979, SCIENCE, V205, P924, DOI 10.1126/science.472714; PARSONS OA, 1978, J CONSULT CLIN PSYCH, V46, P608, DOI 10.1037/0022-006X.46.4.608; PASS HL, 1980, BIOL PSYCHIAT, V15, P9; PATERNITE CE, 1996, J ATTEN DISORD, V1, P70; Pennington BF, 1996, J CHILD PSYCHOL PSYC, V37, P51, DOI 10.1111/j.1469-7610.1996.tb01380.x; Porteus SD, 1965, PORTEUS MAZE TESTS 5; QUILLAN RE, 1994, THESIS MIAMI U OXFOR; RAPOPORT JL, 1980, ARCH GEN PSYCHIAT, V37, P933; RASILE DA, 1995, INT J PSYCHOL, V30, P35, DOI 10.1080/00207599508246972; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Reschly D. J., 1989, HDB CLIN CHILD NEURO, P503; Reynolds C. R., 1997, HDB CLIN CHILD NEURO, P296; REYNOLDS CR, 1986, SCHOOL PSYCHOL REV, V15, P256; REYNOLDS CR, 1999, J FORENSIC NEUROPSYC, V1, P55; REYNOLDS CR, 1982, NEUROPSYCHOLOGY COGN, V3, P55; REYNOLDS CR, HDB NEURODEVELOPMENT; Riccio CA, 1996, J LEARN DISABIL, V29, P561, DOI 10.1177/002221949602900510; RICCIO CA, IN PRESS ARCH CLIN N; Richards TL, 1999, J COLL STUDENT DEV, V40, P299; Riordan HJ, 1999, ARCH CLIN NEUROPSYCH, V14, P217, DOI 10.1016/S0887-6177(98)00015-8; RIS MD, 1994, J CLIN EXP NEUROPSYC, V16, P21, DOI 10.1080/01688639408402615; ROBINS PM, 1992, J ABNORM CHILD PSYCH, V20, P65, DOI 10.1007/BF00927117; ROSVOLD HE, 1956, J CONSULT PSYCHOL, V20, P343, DOI 10.1037/h0043220; RoyByrne P, 1997, COMPR PSYCHIAT, V38, P133, DOI 10.1016/S0010-440X(97)90065-1; Rueckert L, 1996, NEUROPSYCHOLOGIA, V34, P953, DOI 10.1016/0028-3932(96)00016-4; Rund BR, 1998, SCAND J PSYCHOL, V39, P101, DOI 10.1111/1467-9450.00062; RUND BR, 1992, ACTA PSYCHIAT SCAND, V86, P207, DOI 10.1111/j.1600-0447.1992.tb03253.x; RUTSCHMANN J, 1977, ARCH GEN PSYCHIAT, V34, P571; Sachdev P, 1999, PSYCHOL MED, V29, P507, DOI 10.1017/S003329179800720X; SANDFORD JA, 1994, INTEGRATED VISUAL AU; SANDOVAL J, 1981, ANN M AM PSYCH ASS A; Saykin A J, 1995, Appl Neuropsychol, V2, P79, DOI 10.1207/s15324826an0202_5; SCHECHTER MD, 1985, J CLIN PHARMACOL, V25, P269, DOI 10.1002/j.1552-4604.1985.tb02837.x; SCHEIN JD, 1962, J CONSULT PSYCHOL, V26, P115, DOI 10.1037/h0047461; SEIDEL WT, 1990, CLIN NEUROPSYCHOL, V5, P53; SEIDMAN LJ, 1995, J AM ACAD CHILD PSY, V34, P1015, DOI 10.1097/00004583-199508000-00011; Seidman LJ, 1997, J CONSULT CLIN PSYCH, V65, P150, DOI 10.1037/0022-006X.65.1.150; Seidman LJ, 1998, SCHIZOPHR RES, V34, P101, DOI 10.1016/S0920-9964(98)00097-8; SERPER MR, 1990, PSYCHIAT RES, V32, P281, DOI 10.1016/0165-1781(90)90033-2; SLICKER EK, 1991, THESIS TEXAS A M U C; SMITH A, 1967, ARCH NEUROL-CHICAGO, V17, P78, DOI 10.1001/archneur.1967.00470250082008; Smith A., 1968, SYMBOL DIGIT MODALIT; Smith EV, 1998, MEAS EVAL COUNS DEV, V31, P164, DOI 10.1080/07481756.1998.12068963; STANFORD LD, 1994, J LEARN DISABIL, V27, P243, DOI 10.1177/002221949402700406; Stein MA, 1999, J AM ACAD CHILD PSY, V38, P940, DOI 10.1097/00004583-199908000-00004; Stein MA, 1999, J AM ACAD CHILD PSY, V38, P1208, DOI 10.1097/00004583-199910000-00004; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Suslow T, 1997, PSYCHIAT RES, V72, P103, DOI 10.1016/S0165-1781(97)00104-2; Suzuki Masahiko, 1995, Research Communications in Biological Psychology and Psychiatry, V20, P29; Teicher MH, 1996, J AM ACAD CHILD PSY, V35, P334, DOI 10.1097/00004583-199603000-00015; TEIXEIRA LCH, 1993, THESIS U RHODE ISLAN; THOMPSON TL, 1988, THESIS TEXAS A M U C; TROMMER BL, 1988, J DEV BEHAV PEDIATR, V9, P339; Tsai SY, 1996, NEUROTOXICOL TERATOL, V18, P463, DOI 10.1016/0892-0362(96)00035-9; TUPLER LA, 1989, THESIS EMORY U ATLAN; van der Feltz-Cornelis CM, 1999, J NERV MENT DIS, V187, P243, DOI 10.1097/00005053-199904000-00008; WAGENER DK, 1986, PSYCHIAT RES, V18, P365, DOI 10.1016/0165-1781(86)90021-1; WALKER E, 1982, J ABNORM PSYCHOL, V91, P261, DOI 10.1037/0021-843X.91.4.261; Wechsler D, 1997, WAIS 3 ADM SCORING M; WEINGARTNER H, 1980, J ABNORM PSYCHOL, V89, P25, DOI 10.1037/0021-843X.89.1.25; WEINSTEIN JA, 1996, THESIS EMORY U ATLAN; WELLER EB, 1995, J AM ACAD CHILD PSY, V34, P709, DOI 10.1097/00004583-199506000-00010; Wender PH, 1995, ATTENTION DEFICIT HY; WERRY JS, 1987, J ABNORM CHILD PSYCH, V15, P409, DOI 10.1007/BF00916458; Weyandt LL, 1998, DEV NEUROPSYCHOL, V14, P643, DOI 10.1080/87565649809540734; WEYANDT LL, 1995, J PSYCHOPATHOL BEHAV, V17, P293, DOI 10.1007/BF02229304; WIEGARTZ PS, 1996, J ATTEN DISORD, V1, P87; WILLIAMS MA, 1997, CRIT ISS NE, P231; WILLSON VL, 1982, CLIN NEUROPSYCHOLOGY, V4, P134; WOLGIN DM, 1994, THESIS U HOUSTON HOU	236	78	82	0	16	NEW YORK ACAD SCIENCES	NEW YORK	2 EAST 63RD ST, NEW YORK, NY 10021 USA	0077-8923		1-57331-255-X	ANN NY ACAD SCI	Ann.NY Acad.Sci.		2001	931						113	139					27	Multidisciplinary Sciences	Science & Technology - Other Topics	BT11H	WOS:000172009700007	11462737				2021-06-18	
J	Grote, CL; Kooker, EK; Garron, DC; Nyenhuis, DL; Smith, CA; Mattingly, ML				Grote, CL; Kooker, EK; Garron, DC; Nyenhuis, DL; Smith, CA; Mattingly, ML			Performance of compensation seeking and non-compensation seeking samples on the Victoria Symptom Validity Test: Cross-validation and extension of a standardization study	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article								Previous research suggests that the Victoria Symptom Validity Test (VSVT) is effective in confirming or disconfirming the validity of a patient's reported cognitive impairments. We sought to cross-validate the Findings of the VSVT standardization study, and to determine cut-off scores that are most efficient in discriminating our samples of compensation-seeking patients, primarily with mild traumatic brain injury (CS; n = 53), and non-compensation seeking patients with intractable seizures (NCS; n = 30). All patients in the NCS sample scored in the "valid" range on the VSVT difficult memory items, compared to only 58.5% of the CS sample. We also identified VSVT measures and cut-off scores maximally efficient in discriminating these samples. This study confirms previous research that non-compensation seeking patients do well on the VSVT, but that many compensation seeking patients perform poorly on this measure.	Rush Presbyterian St Lukes Med Ctr, Dept Psychol, Chicago, IL 60612 USA; Cornell Univ, Weill Med Coll, New York, NY USA; Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA	Grote, CL (corresponding author), Rush Presbyterian St Lukes Med Ctr, Dept Psychol, 1653 W Congress Pkwy, Chicago, IL 60612 USA.	cgrote@rush.edu					BINDER LM, 1993, J CLIN EXP NEUROPSYC, V15, P170, DOI 10.1080/01688639308402555; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Guilmette TJ, 1996, PERCEPT MOTOR SKILL, V83, P1007, DOI 10.2466/pms.1996.83.3.1007; GUILMETTE TJ, 1993, CLIN NEUROPSYCHOL, V7, P59, DOI 10.1080/13854049308401888; MARTIN RC, 1993, J CLIN EXP NEUROPSYC, V15, P867, DOI 10.1080/01688639308402604; Perrine K, 1999, NEUROLOGY, V53, pS39; PRIGATANO GP, 1993, J CLIN EXP NEUROPSYC, V15, P537, DOI 10.1080/01688639308402577; Psychological Corporation, 1997, WAIS 3 WMS 3 TECHN M; Rees LM, 1998, PSYCHOL ASSESSMENT, V10, P10, DOI 10.1037/1040-3590.10.1.10; ROSE FE, 1995, CLIN NEUROPSYCHOL, V9, P124, DOI 10.1080/13854049508401594; Rose FE, 1998, ARCH CLIN NEUROPSYCH, V13, P349, DOI 10.1016/S0887-6177(97)00025-5; Slick D., 1997, VICTORIA SYMPTOM VAL; Slick DJ, 1996, J CLIN EXP NEUROPSYC, V18, P911, DOI 10.1080/01688639608408313; Sweet JJ, 1999, STUD NEUROPSYCHOL DE, P255; Wechsler D., 1981, WAIS R MANUAL WECHSL; YOUNGJOHN JR, 1995, CLIN NEUROPSYCHOL, V9, P112, DOI 10.1080/13854049508401593	16	78	78	0	11	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	DEC	2000	22	6					709	719		10.1076/jcen.22.6.709.958			11	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	403QT	WOS:000167054500001	11320430				2021-06-18	
J	Levine, B; Dawson, D; Boutet, I; Schwartz, ML; Stuss, DT				Levine, B; Dawson, D; Boutet, I; Schwartz, ML; Stuss, DT			Assessment of strategic self-regulation in traumatic brain injury: Its relationship to injury severity and psychosocial outcome	NEUROPSYCHOLOGY			English	Article							CLOSED-HEAD-INJURY; FRONTAL-LOBE DAMAGE; HUMAN PREFRONTAL CORTEX; POSTTRAUMATIC AMNESIA; EPISODIC MEMORY; WORKING-MEMORY; LESIONS; DYSFUNCTION; ATTENTION; DISSOCIATION	Standard neuropsychological tests administered in a constrained and artificial laboratory environment are often insensitive to the real-life deficits faced by patients with traumatic brain injury (TBI). The Revised Strategy Application Test (R-SAT) creates an unstructured environment in the laboratory in which environmental cues and internal habits oppose the most efficient strategy, thus mimicking the real-life situations that are problematic for patients with TBI. In this study, R-SAT performance was related both to severity of TBI (i.e., depth of coma) sustained 2-3 years earlier and to quality of life outcome as assessed by the Sickness Impact Profile. This relationship held after accounting for variance attributable to TBI-related slowing and inattention. These findings support the validity of the R-SAT and suggest that behavioral correlates of quality of life outcome in TBT can be assessed in the laboratory with unstructured tasks.	Baycrest Ctr Geriatr Care, Rotman Res Inst, Toronto, ON M6A 2E1, Canada; Univ Toronto, Dept Psychol, Toronto, ON M5S 1A1, Canada; Univ Toronto, Dept Med Neurol, Toronto, ON M5S 1A1, Canada; Univ Toronto, Dept Psychol, Toronto, ON M5S 1A1, Canada; Univ Toronto, Dept Occupat Therapy, Toronto, ON M5S 1A1, Canada; Sunnybrook Hlth Sci Ctr, Dept Neurosurg, Toronto, ON M4N 3M5, Canada; Univ Toronto, Dept Surg, Toronto, ON, Canada	Levine, B (corresponding author), Baycrest Ctr Geriatr Care, Rotman Res Inst, 3560 Bathurst St, Toronto, ON M6A 2E1, Canada.	blevine@rotman-baycrest.on.ca	Levine, Brian/O-2725-2019; Dawson, Deirdre R/I-8882-2014; Levine, Brian/G-4328-2010; Boutet, Isabelle/Q-2333-2016	Levine, Brian/0000-0003-4343-811X; Dawson, Deirdre R/0000-0001-7517-6121; Levine, Brian/0000-0003-4343-811X; Boutet, Isabelle/0000-0002-1943-0970			ALEXANDER MP, 1984, NEUROLOGY, V34, P752, DOI 10.1212/WNL.34.6.752; ALEXANDER MP, 1982, PSYCHIATRIC ASPECTS, V2, P219; Army Individual Test Battery, 1944, MAN DIR SCOR; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bechara A, 1998, J NEUROSCI, V18, P428; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; BERGNER M, 1976, MED CARE, V14, P57, DOI 10.1097/00005650-197601000-00006; BERRYHILL P, 1995, NEUROSURGERY, V37, P392, DOI 10.1227/00006123-199509000-00004; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Burgess P. W., 1996, BEHAV ASSESSMENT DYS; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Burgess PW, 2000, NEUROPSYCHOLOGIA, V38, P848, DOI 10.1016/S0028-3932(99)00134-7; Courville C. B., 1937, PATHOLOGY CENTRAL 4; DAWSON DR, IN PRESS J NEUROLOGY; Dias R, 1996, NATURE, V380, P69, DOI 10.1038/380069a0; Dias R, 1996, BEHAV NEUROSCI, V110, P872, DOI 10.1037/0735-7044.110.5.872; DIKMEN S, 1996, NEUROPSYCHOLOGICAL A, P552; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Duncan J, 1997, COGNITIVE NEUROPSYCH, V14, P713, DOI 10.1080/026432997381420; DUNCAN J, 1986, COGNITIVE NEUROPSYCH, V3, P271, DOI 10.1080/02643298608253360; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; Freedman M, 1998, CEREB CORTEX, V8, P18, DOI 10.1093/cercor/8.1.18; Gansler DA, 1996, BRAIN COGNITION, V30, P194, DOI 10.1006/brcg.1996.0012; GENTRY LR, 1988, AM J NEURORADIOL, V9, P101, DOI 10.2214/ajr.150.3.663; Goel V, 1997, BRAIN, V120, P1805, DOI 10.1093/brain/120.10.1805; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; Harlow J. M., 1993, HIST PSYCHIATR, V4, P274, DOI [10.1177/0957154X9300401407, DOI 10.1177/0957154X9300401407]; JENKINS A, 1986, LANCET, V2, P445; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; KIMBERG DY, 1993, J EXP PSYCHOL GEN, V122, P411, DOI 10.1037/0096-3445.122.4.411; KLONOFF PS, 1986, NEUROSURGERY, V19, P735, DOI 10.1227/00006123-198611000-00004; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; LEVIN HS, 1994, J CHILD NEUROL, V9, P81, DOI 10.1177/088307389400900121; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LEVIN HS, 1992, J NEUROTRAUM, V9, pS359; LEVIN HS, 1994, NEUROPSYCHOLOGY, V8, P171, DOI DOI 10.1037/0894-4105.8.2.171; Levine B, 1998, BRAIN, V121, P1951, DOI 10.1093/brain/121.10.1951; Levine B, 2000, MEMORY, CONSCIOUSNESS, AND THE BRAIN, P200; Levine B, 1997, NEUROPSYCHOLOGY, V11, P367, DOI 10.1037/0894-4105.11.3.367; Levine B, 1999, NEUROCASE, V5, P263, DOI 10.1080/13554799908402731; Levine B, 1998, J INT NEUROPSYCH SOC, V4, P247, DOI 10.1017/S1355617798002471; Levine B, 1996, CLIN NEUROPSYCHOL, V10, P350; LEVINE B, 1999, UNPUB HLTH ADULTS PE; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; MILLER BL, 1993, DEMENTIA, V4, P204, DOI 10.1159/000107324; MILNER B, 1963, ARCH NEUROL-CHICAGO, V9, P90, DOI 10.1001/archneur.1963.00460070100010; MISHKIN M, 1964, FRONTAL GRANULAR COR, P219; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; Prigatano GP, 1996, CLIN NEUROPSYCHOL, V10, P191, DOI 10.1080/13854049608406680; Prigatano GP, 1991, AWARENESS DEFICIT BR, P111; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; ROLLS ET, 1994, J NEUROL NEUROSUR PS, V57, P1518, DOI 10.1136/jnnp.57.12.1518; Rolls ET, 1996, PHILOS T ROY SOC B, V351, P1433, DOI 10.1098/rstb.1996.0128; Rueckert L, 1996, NEUROPSYCHOLOGIA, V34, P953, DOI 10.1016/0028-3932(96)00016-4; Schwartz MF, 1999, NEUROPSYCHOLOGIA, V37, P51; Schwartz MF, 1998, NEUROPSYCHOLOGY, V12, P13, DOI 10.1037/0894-4105.12.1.13; Schwartz ML, 1998, CAN J NEUROL SCI, V25, P108, DOI 10.1017/S0317167100033709; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Sherer M, 1998, NEUROREHABILITATION, V10, P25, DOI 10.3233/NRE-1998-10104; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Stuss D.T., 1994, NEUROPSYCHOLOGY, V8, P355, DOI [DOI 10.1037/0894-4105.8.3.355, 10.1037/0894-4105.8.3.355]; Stuss DT, 2000, NEUROPSYCHOLOGIA, V38, P388, DOI 10.1016/S0028-3932(99)00093-7; Stuss DT, 1998, J INT NEUROPSYCH SOC, V4, P265, DOI 10.1017/S1355617798002653; Stuss DT, 1999, J NEUROSURG, V90, P635, DOI 10.3171/jns.1999.90.4.0635; Stuss DT, 2000, NEUROLOGY, V54, P1337, DOI 10.1212/WNL.54.6.1337; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; TEASDALE G, 1974, LANCET, V2, P81; Wechsler D, 1985, WECHSLER ADULT INTEL; WHYTE J, 1995, NEUROPSYCHOLOGIA, V33, P797, DOI 10.1016/0028-3932(95)00029-3	73	78	81	0	7	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	OCT	2000	14	4					491	500		10.1037/0894-4105.14.4.491			10	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	363HZ	WOS:000089831000001	11055251				2021-06-18	
J	Clark, RSB; Kochanek, PM; Adelson, PD; Bell, MJ; Carcillo, JA; Chen, M; Wisniewski, SR; Janesko, K; Whalen, MJ; Graham, SH				Clark, RSB; Kochanek, PM; Adelson, PD; Bell, MJ; Carcillo, JA; Chen, M; Wisniewski, SR; Janesko, K; Whalen, MJ; Graham, SH			Increases in bcl-2 protein in cerebrospinal fluid and evidence for programmed cell death in infants and children after severe traumatic brain injury	JOURNAL OF PEDIATRICS			English	Article							SEVERE HEAD-INJURY; BCL-2-DEFICIENT MICE; REGULATING APOPTOSIS; NEURONAL APOPTOSIS; CYTOCHROME-C; EXPRESSION; BAX; SURVIVAL; RAT; OVEREXPRESSION	Objectives: To determine whether bcl-2, a protein that inhibits apoptosis, would be increased in cerebrospinal fluid (CSF) in infants and children after traumatic brain injury (TBI) and to examine the association of bcl-2 concentration with clinical variables. Study design: Bcl-2 was measured in CSF from 23 children (aged 2 months-16 years) with severe TBI and from 19 children without TBI or meningitis (control subjects) by enzyme-linked immunosorbent assay CSF oligonucleosome concentration was also determined as a marker of DNA degradation. Brain samples from 2 patients undergoing emergent decompressive craniectomies were analyzed for bcl-2 with Western blot and for DNA fragmentation with TUNEL (terminal deoxynucleotidyl-transerase mediated biotin-dUTP nick-end labeling). Results: CSF bcl-2 concentrations were increased in patients with TBI versus control subjects (P = .01). Bcl-2 was increased in patients with TBI who survived versus those who died (P = .02). CSF oligonucleosome concentration tended to be increased after TBI (P = .07) and was not associated with bcl-2. Brain tissue samples showed an increase in bcl-2 in patients with TBI versus adult brain bank control samples and evidence of DNA fragmentation within cells with apoptotic morphology Conclusions: Bcl-2 may participate in the regulation of cell, death after TBI in infants and children. The increase in bcl-2 seen in patients who survived is consistent with a protective role for this anti-apoptotic protein after TBI.	Childrens Hosp Pittsburgh, Div Pediat Crit Care, Dept Anesthesiol & Crit Care Med, Pittsburgh, PA 15213 USA; Childrens Hosp Pittsburgh, Dept Pediat, Pittsburgh, PA 15213 USA; Childrens Hosp Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15213 USA; Childrens Hosp Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15213 USA; Childrens Hosp Pittsburgh, Dept Neurol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Pittsburgh, PA USA; VA Pittsburgh Hlth Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA	Clark, RSB (corresponding author), Childrens Hosp Pittsburgh, Div Pediat Crit Care, Dept Anesthesiol & Crit Care Med, 3705 5th Ave, Pittsburgh, PA 15213 USA.		Adelson, David/W-2083-2019; Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; Wisniewski, Stephen/0000-0002-3877-9860	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30HD028836] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038620, K08NS001946] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [5P30 HD28836] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [KO8 NS01946, R01 NS38620] Funding Source: Medline		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Adelson PD, 1997, PEDIATR NEUROSURG, V26, P200; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Bell MJ, 1999, CRIT CARE MED, V27, P493, DOI 10.1097/00003246-199903000-00023; BORNER C, 1994, J CELL BIOL, V126, P1059, DOI 10.1083/jcb.126.4.1059; BRADBURY MW, 1963, CLIN SCI, V25, P97; Chen J, 1997, J CEREBR BLOOD F MET, V17, P2, DOI 10.1097/00004647-199701000-00002; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; Clark RSB, 1997, J NEUROSCI, V17, P9172; Clark RSB, 1999, FASEB J, V13, P813; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; Edwards AD, 1996, NEUROPATH APPL NEURO, V22, P494, DOI 10.1111/j.1365-2990.1996.tb01122.x; Graham SH, 1996, RESTOR NEUROL NEUROS, V9, P243, DOI 10.3233/RNN-1996-9407; Hochman A, 1998, J NEUROCHEM, V71, P741; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Ikonomidou C, 1999, SCIENCE, V283, P70, DOI 10.1126/science.283.5398.70; KANE DJ, 1995, J NEUROSCI RES, V40, P269, DOI 10.1002/jnr.490400216; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kitamura Y, 1998, BRAIN RES, V780, P260, DOI 10.1016/S0006-8993(97)01202-X; KRAJEWSKI S, 1995, J NEUROSCI, V15, P6364; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LINNIK MD, 1995, STROKE, V26, P1670, DOI 10.1161/01.STR.26.9.1670; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Marmarou A, 1997, ACT NEUR S, V70, P68; Mogi M, 1996, NEUROSCI LETT, V215, P137, DOI 10.1016/0304-3940(96)12961-X; MUIZELAAR JP, 1984, J NEUROSURG, V61, P700, DOI 10.3171/jns.1984.61.4.0700; NAKAYAMA K, 1994, P NATL ACAD SCI USA, V91, P3700, DOI 10.1073/pnas.91.9.3700; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; PorteraCailliau C, 1997, J COMP NEUROL, V378, P88, DOI 10.1002/(SICI)1096-9861(19970203)378:1<88::AID-CNE5>3.0.CO;2-G; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; RINK A, 1995, AM J PATHOL, V147, P1575; ROSNER B, 1984, BIOMETRICS, V40, P1025, DOI 10.2307/2531153; Rosse T, 1998, NATURE, V391, P496; Ruppel R., 1998, Society for Neuroscience Abstracts, V24, P253; SAUNDERS JW, 1966, SCIENCE, V154, P604, DOI 10.1126/science.154.3749.604; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Tarkowski E, 1999, STROKE, V30, P321, DOI 10.1161/01.STR.30.2.321; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; Waters KA, 1999, PEDIATR RES, V45, P166, DOI 10.1203/00006450-199902000-00002; WAXWEILER RJ, 1996, TRAUMATIC BRAIN INJU, P1; Whalen MJ, 1998, J NEUROTRAUM, V15, P777, DOI 10.1089/neu.1998.15.777; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; ZHONG LT, 1993, P NATL ACAD SCI USA, V90, P4533, DOI 10.1073/pnas.90.10.4533; 1998, NIH CONSENSUS STATEM	48	78	81	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0022-3476	1097-6833		J PEDIATR-US	J. Pediatr.	AUG	2000	137	2					197	204		10.1067/mpd.2000.106903			8	Pediatrics	Pediatrics	345TZ	WOS:000088832400013	10931412				2021-06-18	
J	Fee, D; Grzybicki, D; Dobbs, M; Ihyer, S; Clotfelter, J; Macvilay, S; Hart, MN; Sandor, M; Fabry, Z				Fee, D; Grzybicki, D; Dobbs, M; Ihyer, S; Clotfelter, J; Macvilay, S; Hart, MN; Sandor, M; Fabry, Z			Interleukin 6 promotes vasculogenesis of murine brain microvessel endothelial cells	CYTOKINE			English	Article						cytokine; brain injury; development; growth factor; vascularization	MYELIN OLIGODENDROCYTE GLYCOPROTEIN; AUTOIMMUNE ENCEPHALOMYELITIS; IN-VITRO; IL-6-DEFICIENT MICE; TIE2 RECEPTOR; GROWTH-FACTOR; ANGIOGENESIS; CYTOKINES; EXPRESSION; GP130	Interleukin 6 (IL-6) is a cytokine that acts on a wide range of tissues influencing cell growth and differentiation. Here we show that IL-6 plays a role in the early vascular development (vasculogenesis) in the central nervous system (CNS). We report that IL-6 induces the proliferation of brain microvascular endothelial cells in vitro. Furthermore, IL-6 significantly accelerates the formation of tube-like structures by these cells in Matrigel basement matrix. Moreover, IL-6 mRNA is expressed in vivo in two physiological conditions in which vascularization in the CNS is important: (1) during normal brain development, (2) during the healing process of a traumatic brain injury. Expression of IL-6 mRNA coincides with the expression of vascular endothelial growth factor (VEGF) mRNA in the developing brain with decreasing expression following birth. However, IL-6 mRNA can be detected in the healing adult murine brain tissue by in situ hybridization coinciding with the period of intense tissue reorganization. The transient upregulation of IL-6 mRNA during normal brain development and at brain injury site and the effect of IL-6 on in vitro vasculogenesis suggest that IL-6 may play a role in normal physiology of vascularization in the CNS, (C) 2000 Academic Press.	Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53706 USA; Univ Wisconsin, Dept Neurol, Madison, WI 53706 USA; Duquesne Univ, Sch Hlth Sci, Pittsburgh, PA 15219 USA; Univ Iowa, Dept Pathol, Iowa City, IA 52242 USA	Fabry, Z (corresponding author), Univ Wisconsin, Dept Pathol & Lab Med, 1300 Univ Ave, Madison, WI 53706 USA.	zfabry@facstaff.wisc.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS024621] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS24621] Funding Source: Medline		AUERBACH R, 1991, INT J RADIAT BIOL, V60, P1, DOI 10.1080/09553009114551401; BERNAD A, 1994, IMMUNITY, V1, P725, DOI 10.1016/S1074-7613(94)80014-6; Betz UAK, 1998, J EXP MED, V188, P1955, DOI 10.1084/jem.188.10.1955; Campbell IL, 1998, ANN NY ACAD SCI, V840, P83, DOI 10.1111/j.1749-6632.1998.tb09552.x; CAMPBELL IL, 1993, P NATL ACAD SCI USA, V90, P10061, DOI 10.1073/pnas.90.21.10061; Cohen T, 1996, J BIOL CHEM, V271, P736, DOI 10.1074/jbc.271.2.736; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; DEBAULT KE, 1980, ADV EXP MED BIOL, V131, P69; DEBAULT LE, 1980, SCIENCE, V207, P653, DOI 10.1126/science.6101511; DEBAULT LE, 1981, IN VITRO CELL DEV B, V17, P480; Eugster HP, 1998, EUR J IMMUNOL, V28, P2178, DOI 10.1002/(SICI)1521-4141(199807)28:07<2178::AID-IMMU2178>3.0.CO;2-D; FABRY Z, 1993, J NEUROIMMUNOL, V47, P23, DOI 10.1016/0165-5728(93)90281-3; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; Folkman J, 1985, Important Adv Oncol, P42; Folkman J, 1997, EXS, V79, P1; FRATERSCHRODER M, 1987, P NATL ACAD SCI USA, V84, P5277, DOI 10.1073/pnas.84.15.5277; Fukushi J, 1998, BIOCHEM BIOPH RES CO, V250, P444, DOI 10.1006/bbrc.1998.9334; GAMBLE JR, 1993, J CELL BIOL, V121, P931, DOI 10.1083/jcb.121.4.931; Giraudo E, 1996, J IMMUNOL, V157, P2618; HART MN, 1987, J NEUROPATH EXP NEUR, V46, P141, DOI 10.1097/00005072-198703000-00003; IruelaArispe ML, 1997, THROMB HAEMOSTASIS, V78, P672; Klein MA, 1997, GLIA, V19, P227, DOI 10.1002/(SICI)1098-1136(199703)19:3<227::AID-GLIA5>3.0.CO;2-W; KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0; Kumar R, 1998, INT J ONCOL, V12, P749; Loganadane LD, 1997, CYTOKINE, V9, P740, DOI 10.1006/cyto.1997.0229; Mendel I, 1998, EUR J IMMUNOL, V28, P1727, DOI 10.1002/(SICI)1521-4141(199805)28:05<1727::AID-IMMU1727>3.0.CO;2-#; MOORE SA, 1990, J NEUROCHEM, V55, P391, DOI 10.1111/j.1471-4159.1990.tb04150.x; MOORE SA, 1988, AM J PHYSIOL, V254, pC37; MOTRO B, 1990, P NATL ACAD SCI USA, V87, P3092, DOI 10.1073/pnas.87.8.3092; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; Okuda Y, 1998, INT IMMUNOL, V10, P703, DOI 10.1093/intimm/10.5.703; PETZELBAUER P, 1995, CYTOKINE, V7, P267, DOI 10.1006/cyto.1995.0031; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; ROBINSON RA, 1986, BRAIN RES, V384, P114, DOI 10.1016/0006-8993(86)91226-6; Romano M, 1997, IMMUNITY, V6, P315, DOI 10.1016/S1074-7613(00)80334-9; SAHAGUN G, 1989, AM J PATHOL, V134, P1227; Sambrook J., 1989, MOL CLONING LAB MANU, V3; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; Takashima S, 1996, J BIOL CHEM, V271, P24901, DOI 10.1074/jbc.271.40.24901; Vallieres L, 1997, J NEUROCHEM, V69, P1668, DOI 10.1046/j.1471-4159.1997.69041668.x; Volpert OV, 1998, J EXP MED, V188, P1039, DOI 10.1084/jem.188.6.1039; Yoshida K, 1996, P NATL ACAD SCI USA, V93, P407, DOI 10.1073/pnas.93.1.407; Zhao BY, 1998, J NEUROSCI RES, V52, P7, DOI 10.1002/(SICI)1097-4547(19980401)52:1<7::AID-JNR2>3.0.CO;2-I	44	78	85	0	3	ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL RD, LONDON NW1 7DX, ENGLAND	1043-4666	1096-0023		CYTOKINE	Cytokine	JUN	2000	12	6					655	665		10.1006/cyto.1999.0599			11	Biochemistry & Molecular Biology; Cell Biology; Immunology	Biochemistry & Molecular Biology; Cell Biology; Immunology	321YC	WOS:000087482100014	10843741				2021-06-18	
J	Hibbard, MR; Bogdany, J; Uysal, S; Kepler, K; Silver, JM; Gordon, WA; Haddad, L				Hibbard, MR; Bogdany, J; Uysal, S; Kepler, K; Silver, JM; Gordon, WA; Haddad, L			Axis II psychopathology in individuals with traumatic brain injury	BRAIN INJURY			English	Article							SEVERE HEAD-INJURY; PERSONALITY-DISORDERS; FOLLOW-UP; PSYCHIATRIC-DISORDERS; SOCIAL-ADJUSTMENT; RELATIVES; CATECHOLAMINES	Primary Objectives: To determine the frequency and nature of post-TBI personality disorders (PDs) in a community-based sample of individuals with TBI. Research design: One hundred individuals with TBI were administered a structural clinical interview to determine Axis II psychopathology. Methods of procedures: The Structured Clinical Interview for DSM-IV Personality Disorders, Clinician Version (SCID II) was used to determine 12 Axis II personality disorders. SCID II questions were modified so that symptom onset could be rated as occurring pre-injury vs. posr-TBI Data were analysed using student T-tests, chi-square analysis and one way analyses of variance. Outcomes and results: Pre-TBI PDs were diagnosed in 24% of the sample; antisocial PD and obsessive-compulsive PD were the most common diagnoses. Post-TBI, 66% of the: sample met criteria for at least une PD, with PDs independent of TBI severity, age at injury, and time since injury. The most common post-TBI PDs were: borderline, avoidant, paranoid, obsessive-compulsive and narcissistic. Men were more likely to be diagnosed with antisocial PD and narcissistic PD. Individuals with pre TBI PDs were at greater risk of acquiring additional psychopathology posr-TBI. Personalty traits endorsed by more than 30% of the sample post-TBI reflected loss of self-confidence, attempts to cope with cognitive and interpersonal failures and negative affect. Conclusion: These findings argue against a specific TBI personality syndrome,but rather a diversity of personality disorders reflective of the: persistent challenges and compensatory coping strategies developed by individuals post-TBI. Prospective need for clinical assessment, pro-active education and focused treatment. approaches are discussed.	CUNY Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA; Lenox Hill Hosp, New York, NY 10021 USA	Hibbard, MR (corresponding author), CUNY Mt Sinai Sch Med, Dept Rehabil Med, Box 1240,1425 Madison Ave, New York, NY 10029 USA.		Carneiro D'Albuquerque, Luiz Augusto/A-8812-2013	Carneiro D'Albuquerque, Luiz Augusto/0000-0001-7607-7168			[Anonymous], 1994, DIAGNOSTIC STAT MANU, V4th; BOND RM, 1986, NEUROPSYCHOLOGICAL A, P347; BOURDON KH, 1992, PUBLIC HEALTH REP, V107, P663; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; BROOKS DN, 1986, J NEUROL NEUROSUR PS, V46, P764; Brooks N, 1988, Acta Neurochir Suppl (Wien), V44, P59; BURNS S, 1994, BRAIN INJURY, V8, P412; CLIFTON GL, 1981, NEUROSURGERY, V8, P10, DOI 10.1227/00006123-198101000-00003; CLONINGER CR, 1987, ARCH GEN PSYCHIAT, V44, P573; DENIS JF, 1990, CAN J PSYCHIAT, V35, P208, DOI 10.1177/070674379003500302; EPSTEIN RS, 1994, NEUROPSYCHIATRY TRAU, P228; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; First M.B., 1996, STRUCTURED CLIN INTE; FIRST MB, 1995, J PERS DISORD, V9, P92, DOI 10.1521/pedi.1995.9.2.92; FORDYCE DJ, 1983, J NEUROL NEUROSUR PS, V46, P620, DOI 10.1136/jnnp.46.7.620; FROSCH JP, 1983, HOSP COMMUNITY PSYCH, V34, P243; GALLOP R, 1989, HOSP COMMUNITY PSYCH, V40, P815; GERSHANIK O, 1983, NEUROLOGY, V33, P1489, DOI 10.1212/WNL.33.11.1489; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; KAITARO T, 1995, BRAIN INJURY, V9, P713, DOI 10.3109/02699059509008227; KAY T, 1986, NATL HEAD INJURY FDN; KINSELLA G, 1988, PSYCHOL MED, V18, P57, DOI 10.1017/S0033291700001884; Kinsella G, 1989, Int Disabil Stud, V11, P9; KURSTZ JE, 1998, J HEAD TRAUMA REHAB, V13, P1; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; Lezak M. D., 1989, ASSESSMENT BEHAV CON, P113; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; LISHMAN WA, 1973, PSYCHOL MED, V3, P304, DOI 10.1017/S003329170004959X; MAIER W, 1992, J PERS DISORD, V6, P187, DOI 10.1521/pedi.1992.6.3.187; MALIA K, 1995, BRAIN INJURY, V9, P697, DOI 10.3109/02699059509008226; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; OLDHAM JM, 1994, JAMA-J AM MED ASSOC, V272, P1770, DOI 10.1001/jama.272.22.1770; OSHANICK GJ, 1994, NEUROPSYCHIATRY TRAU, P163; Parker RS, 1996, BRAIN INJURY, V10, P287, DOI 10.1080/026990596124467; PERLINE H, 1979, COMPUTER INTERPRETED; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; SIEVER LJ, 1991, AM J PSYCHIAT, V148, P1647; SILVER JM, 1992, AM PSYCHIAT PRESS TX, P363; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340; Varney NR, 1987, NEUROPSYCHOLOGY, V1, P7, DOI 10.1037//0894-4105.1.1.7; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; WEISSMAN MM, 1993, J PERS DISORD, V7, P44; WOOLF PD, 1987, J NEUROSURG, V66, P875, DOI 10.3171/jns.1987.66.6.0875; 1996, SPSS WINDOWS 95 V 7	52	78	81	0	8	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JAN	2000	14	1					45	61		10.1080/026990500120925			17	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	274CY	WOS:000084747200006	10670661				2021-06-18	
J	Nakagawa, Y; Nakamura, M; McIntosh, TK; Rodriguez, A; Berlin, JA; Smith, DH; Saatman, KE; Raghupathi, R; Clemens, J; Saido, TC; Schmidt, ML; Lee, VMY; Trojanowski, JQ				Nakagawa, Y; Nakamura, M; McIntosh, TK; Rodriguez, A; Berlin, JA; Smith, DH; Saatman, KE; Raghupathi, R; Clemens, J; Saido, TC; Schmidt, ML; Lee, VMY; Trojanowski, JQ			Traumatic brain injury in young, amyloid-beta peptide overexpressing transgenic mice induces marked ipsilateral hippocampal atrophy and diminished A beta deposition during aging	JOURNAL OF COMPARATIVE NEUROLOGY			English	Article						Alzheimer's disease; amyloid plaques; head trauma; neuron degeneration	FAMILIAL ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; HEAD-INJURY; SENILE PLAQUES; CORTICAL IMPACT; MEMORY DEFICITS; AXONAL INJURY; NEURONAL LOSS; EXPRESSION; DEATH	Traumatic brain injury (TBI) is an epigenetic risk factor for Alzheimer's disease (AD). To test the hypothesis that TBI contributes to the onset andior progression of AD-like beta-amyloid peptide (AP) deposits, we studied the long-term effects of TBI in transgenic mice that overexpress human A beta from a mutant A beta precursor protein (APP) minigene driven by a platelet derived (PD) growth factor promoter (PDAPP mice). TBI was induced in 4-month-old PDAPP and wild type (WT) mice by controlled cortical impact (CCI). Because A beta begins to deposit progressively in the PDAPP brain by 6 months, we examined WT and PDAPP mice at 2, 5, and 8 months after TBI or sham treatment (i.e., at 6, 9, and 12 months of age). Hippocampal atrophy in the PDAPP mice was more severe ipsilateral versus contralateral to TBI, and immunohistochemical studies with antibodies to different A beta peptides demonstrated a statistically significant reduction in hippocampus and cingulate cortex A beta deposits ipsilateral versus contralateral to CCI in 9-12 month-old PDAPP mice. Hippocampal atrophy and reduced Ap deposits were not seen in hippocampus or cingulate cortex of sham-injured PDAPP mice or in any WT mice. These data suggest that the vulnerability of brain cells to A beta toxicity increases and that the accumulation of AP deposits decrease in the penumbra of CCI months after TBI. Thus, in addition to providing unique opportunities for elucidating genetic mechanisms of AD, transgenic mice that recapitulate AD pathology also may be relevant animal models for investigating the poorly understood role that TBI and other epigenetic risk factors play in the onset and/or progression of AD. (C) 1999 Wiley-Liss. Inc.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Div Anat Pathol,Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Biostat & Epidemiol, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA; Eli Lilly Inc, Indianapolis, IN 46285 USA; RIKEN, Brain Sci Inst, Proteolyt Neurosci Lab, Wako, Saitama 3510198, Japan	Trojanowski, JQ (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, Hosp Univ Penn,Ctr Neurodegenerat Dis Res, Maloney 3rd Floor,3400 Spruce St, Philadelphia, PA 19104 USA.		smith, douglas/A-1321-2007; Saido, Takaomi C/N-5472-2015; Sado, Takaomi/AAN-2759-2021	Saido, Takaomi C/0000-0003-1970-6903; Sado, Takaomi/0000-0003-1970-6903	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG11542, AG09215] Funding Source: Medline; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [GM34690] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG011542, P01AG009215] Funding Source: NIH RePORTER		ARAI H, 1990, P NATL ACAD SCI USA, V87, P2249, DOI 10.1073/pnas.87.6.2249; Arnold SE, 1998, ARCH GEN PSYCHIAT, V55, P225, DOI 10.1001/archpsyc.55.3.225; BUXBAUM JD, 1993, BIOCHEM BIOPH RES CO, V197, P639, DOI 10.1006/bbrc.1993.2527; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; Clark RSB, 1997, J NEUROSCI, V17, P9172; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Conti AC, 1998, J NEUROSCI, V18, P5663; Cummings BJ, 1996, NEUROBIOL AGING, V17, P921, DOI 10.1016/S0197-4580(96)00170-4; Dickson DW, 1997, J NEUROPATH EXP NEUR, V56, P321, DOI 10.1097/00005072-199704000-00001; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GOEDERT M, 1997, MOL GENETIC BASIS NE, P613; Greenberg BD, 1996, NEUROBIOL AGING, V17, P153, DOI 10.1016/0197-4580(96)00001-2; Guillery RW, 1997, J COMP NEUROL, V386, P2, DOI 10.1002/(SICI)1096-9861(19970915)386:1<2::AID-CNE2>3.0.CO;2-6; Hoffmann R, 1997, BIOCHEMISTRY-US, V36, P8114, DOI 10.1021/bi970380+; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; HSIAO KK, 1997, MOL MECH DEMENTIA, P39; Irizarry MC, 1997, J NEUROPATH EXP NEUR, V56, P965, DOI 10.1097/00005072-199709000-00002; Irizarry MC, 1997, J NEUROSCI, V17, P7053; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; Iwatsubo T, 1996, AM J PATHOL, V149, P1823; Johnson D, 1997, EDN, V42, P94; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; LEBLANC A, 1997, MOL MECH DEMENTIA, P57; LEE VMY, 1984, J NEUROCHEM, V42, P25, DOI 10.1111/j.1471-4159.1984.tb09692.x; LEWEN A, 1995, NEUROREPORT, V6, P357, DOI 10.1097/00001756-199501000-00032; Loring JF, 1996, NEUROBIOL AGING, V17, P173, DOI 10.1016/0197-4580(95)02076-4; Masliah E, 1996, J NEUROSCI, V16, P5795; MATSUO ES, 1994, NEURON, V13, P989, DOI 10.1016/0896-6273(94)90264-X; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; Mayeux R, 1998, NEW ENGL J MED, V338, P506, DOI 10.1056/NEJM199802193380804; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; MORRISONBOGORAD M, 1997, MOL GENETIC BASIS NE, P581; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, P28; Murai H, 1998, J COMP NEUROL, V392, P428, DOI 10.1002/(SICI)1096-9861(19980323)392:4<428::AID-CNE2>3.0.CO;2-2; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; PEARSON BE, 1993, P NATL ACAD SCI USA, V90, P10578, DOI 10.1073/pnas.90.22.10578; Pierce JES, 1996, J NEUROSCI, V16, P1083; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Reaume AG, 1996, J BIOL CHEM, V271, P23380, DOI 10.1074/jbc.271.38.23380; RINK A, 1995, AM J PATHOL, V147, P1575; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; ROCKENSTEIN EM, 1995, J BIOL CHEM, V270, P28257; Saido TC, 1996, NEUROSCI LETT, V215, P173, DOI 10.1016/0304-3940(96)12970-0; Saido TC, 1998, NEUROBIOL AGING, V19, pS69, DOI 10.1016/S0197-4580(98)00033-5; SAIDO TC, 1995, NEURON, V14, P1; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Schmidt ML, 1998, ACTA NEUROPATHOL, V95, P117, DOI 10.1007/s004010050774; SCHMIDT ML, 1994, FEBS LETT, V344, P69, DOI 10.1016/0014-5793(94)00259-2; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; SELKOE DJ, 1997, MOL GENETIC BASIS NE, P601; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; Shin RW, 1997, J NEUROSCI, V17, P8187; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; SturchlerPierrat C, 1997, P NATL ACAD SCI USA, V94, P13287, DOI 10.1073/pnas.94.24.13287; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; TOKUDA T, 1991, ACTA NEUROPATHOL, V82, P281; YACHNIS AT, 1993, J COMP NEUROL, V334, P356, DOI 10.1002/cne.903340303	63	78	78	0	2	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA	0021-9967			J COMP NEUROL	J. Comp. Neurol.	AUG 30	1999	411	3					390	398					9	Neurosciences; Zoology	Neurosciences & Neurology; Zoology	221JV	WOS:000081724700003	10413774				2021-06-18	
J	Napieralski, JA; Raghupathi, R; McIntosh, TK				Napieralski, JA; Raghupathi, R; McIntosh, TK			The tumor-suppressor gene, p53, is induced in injured brain regions following experimental traumatic brain injury	MOLECULAR BRAIN RESEARCH			English	Article						p53; cyclin D1; cell cycle; cell death; apoptosis; traumatic brain injury	CYCLIN D1; MESSENGER-RNA; CELL-CYCLE; DENTATE GYRUS; RAT-BRAIN; FOREBRAIN ISCHEMIA; DNA FRAGMENTATION; C-JUN; EXPRESSION; APOPTOSIS	A growing body of evidence suggests that neurons undergo apoptotic cell death following traumatic brain injury (TBI). Since the expression of several tumor suppressor and cell cycle genes have been implicated in neuronal apoptosis, the present study used in situ hybridization (ISH) histochemistry to evaluate the regional and temporal patterns of expression of the mRNAs for the tumor suppressor gene, p53, and the cell cycle gene, cyclin DI, following lateral fluid-percussion (FP) brain injury in the rat. Anesthetized adult male Sprague-Dawley rats (n = 16) were subjected to lateral FP brain injury of moderate severity (2.3-2.7 atm), while sham controls (n = 6) were surgically prepared but did not receive brain injury. Animals were killed by decapitation at 6 h (n = 6 injured and 2 sham), 24 h (n = 6 injured and 2 sham), or 3 days (n = 4 injured and 2 sham), and their brains processed for ISH. Little to no expression of p53 mRNA was observed in sham brains. At 6 h post-injury, p53 mRNA was induced predominantly in cells that are vulnerable to TBI, such as those in the contused cortex, lateral and medial geniculate nuclei of the thalamus, and the CA, and hilar neurons of the hippocampus. Increased p53 mRNA was also detected in hippocampal CA, neurons, cells that are relatively resistant to FP brain injury. Levels of p53 mRNA returned to sham levels in all regions of the injured brain by 24 h. In contrast to p53, cyclin D1 mRNA was detectable in the brains of uninjured animals and was not altered by brain injury. These results suggest that the tumor suppressor gene p53, but not cyclin D1, is upregulated and may participate in molecular response to TBI. (C) 1999 Elsevier Science B.V. All rights reserved.	Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA	McIntosh, TK (corresponding author), Univ Penn, Sch Med, Dept Neurosurg, 105B Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.				NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01-GM34690] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS26818, P50-NS08803] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803, R01NS026818] Funding Source: NIH RePORTER		BIENZ B, 1984, EMBO J, V3, P2179, DOI 10.1002/j.1460-2075.1984.tb02110.x; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Bredesen DE, 1995, ANN NEUROL, V38, P839, DOI 10.1002/ana.410380604; CHESSELET MF, 1996, IN SITU HYBRIDIZATIO, P79; CHOPP M, 1992, BIOCHEM BIOPH RES CO, V182, P1201, DOI 10.1016/0006-291X(92)91859-O; Clark RSB, 1997, J NEUROSCI, V17, P9172; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Conti AC, 1998, J NEUROSCI, V18, P5663; CRUMRINE RC, 1994, J CEREBR BLOOD F MET, V14, P887, DOI 10.1038/jcbfm.1994.119; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; EL DW, 1993, CELL, V75, P817; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Fan Lei, 1995, Molecular Brain Research, V30, P125, DOI 10.1016/0169-328X(94)00287-O; FREEMAN RS, 1994, NEURON, V12, P343, DOI 10.1016/0896-6273(94)90276-3; Guegan C, 1997, NEUROREPORT, V8, P1003, DOI 10.1097/00001756-199703030-00037; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Hughes PE, 1996, NEUROSCIENCE, V74, P1143, DOI 10.1016/S0306-4522(96)00174-1; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JORDAN J, 1996, J NEUROSCI, V17, P1405; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kranenburg O, 1996, EMBO J, V15, P46, DOI 10.1002/j.1460-2075.1996.tb00332.x; Li Y, 1997, J NEUROL SCI, V150, P93, DOI 10.1016/S0022-510X(97)00075-0; LI Y, 1994, STROKE, V25, P849, DOI 10.1161/01.STR.25.4.849; Liu W, 1996, NEUROREPORT, V7, P2785, DOI 10.1097/00001756-199611040-00076; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MANEV H, 1994, NEUROREPORT, V5, P2661, DOI 10.1097/00001756-199412000-00064; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MIYASHITA T, 1995, CELL, V80, P293; Morrison RS, 1996, J NEUROSCI, V16, P1337; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OLTVAI ZN, 1993, CELL, V74, P619; PAXINOS G, 1994, RAT BRAIN STEREOTAXI; PHILLIPS LL, 1992, J NEUROTRAUM, V9, P323, DOI 10.1089/neu.1992.9.323; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Postigo JA, 1998, NEUROSCI LETT, V241, P107, DOI 10.1016/S0304-3940(97)00981-6; Preston GA, 1996, MOL CELL BIOL, V16, P211; RAGHUPATHI R, 1995, J CEREBR BLOOD F MET, V15, P467, DOI 10.1038/jcbfm.1995.58; Raghupathi R, 1996, MOL BRAIN RES, V37, P134, DOI 10.1016/0169-328X(95)00289-5; RAGHUPATHI R, 1997, J CEREB BLOOD FLOW M, V17, pS494; RINK A, 1995, AM J PATHOL, V147, P1575; SAKHI S, 1994, P NATL ACAD SCI USA, V91, P7525, DOI 10.1073/pnas.91.16.7525; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; Wiessner C, 1996, NEUROSCIENCE, V72, P947, DOI 10.1016/0306-4522(95)00601-X; Yakovlev AG, 1997, J NEUROSCI, V17, P7415	48	78	83	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0169-328X			MOL BRAIN RES	Mol. Brain Res.	JUL 23	1999	71	1					78	86		10.1016/S0169-328X(99)00155-2			9	Neurosciences	Neurosciences & Neurology	218PB	WOS:000081560000009	10407189				2021-06-18	
J	Tate, RL; Broe, GA				Tate, RL; Broe, GA			Psychosocial adjustment after traumatic brain injury: what are the important variables?	PSYCHOLOGICAL MEDICINE			English	Article							BLUNT HEAD-INJURY; COGNITIVE RISK-TAKING; TEMPORAL LOBECTOMY; CONSECUTIVE SERIES; FOLLOW-UP; PREDICTORS; IMPAIRMENT; TESTS; INDEPENDENCE; INFORMATION	Background. The common legacy of severe degrees of traumatic brain injury is varying degrees and types of impairments, which impact significantly upon the individual's resumption of pre-morbid psychosocial roles. Yet there are few data to indicate the relative contribution of these and other non-injury related variables. Methods. Seventy individuals with varying levels of disability after severe traumatic brain injury were examined neurologically and neuropsychologically, on average at 6 years post-trauma. A range of biographical, injury, impairment and psychological variables were examined with multiple regression analyses to identify those that contributed to successful psychosocial reintegration. Results. Severity of injury and impairments. along with chronicity and level of self-esteem were significant predictors of psychosocial adjustment. Further analyses revealed that within the neuropsychological domain, the variable measuring behavioural regulation of abilities was the most significant. Examination of specific domains of psychosocial functioning (occupational activities, interpersonal relationships and independent living skills) revealed different patterns of significant predictor variables, in addition to indices of the severity of initial injury: neurophysical impairments and memory functioning predicted successful occupational activities; chronicity, cognitive speed and behavioural regulation predicted success in interpersonal relationships; and neurophysical impairments, behavioural regulation and memory functioning predicted independent living skills. Conclusions. These results reinforce the overriding importance of injury severity and neurological factors (both neurophysical as well as neuropsychological) in predicting psychosocial adjustment after traumatic brain injury. Support for the contribution of non-neurological factors was also found.	Univ Sydney, Dept Med, Rehabil Studies Unit, Royal Rehabil Ctr, Sydney, NSW 2006, Australia; Ctr Educ & Res Aging, Sydney, NSW, Australia	Tate, RL (corresponding author), Univ Sydney, Rehabil Studies Unit, Dept Med, Royal Rehabil Ctr, POB 6, Ryde, NSW 1680, Australia.						ADAMS JH, 1985, NEUROPATH APPL NEURO, V11, P299, DOI 10.1111/j.1365-2990.1985.tb00027.x; Blumer D., 1975, PSYCHIAT ASPECTS NEU, P151; BOKS N, 1989, BRAIN INJURY, V3, P325; Bond M R, 1975, Ciba Found Symp, P141; BOND MR, 1976, ACTA NEUROCHIR, V34, P57, DOI 10.1007/BF01405863; Bowman ML, 1996, CLIN NEUROPSYCHOL, V10, P382, DOI 10.1080/13854049608406699; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Burgess PW, 1996, NEUROPSYCHOLOGIA, V34, P263, DOI 10.1016/0028-3932(95)00104-2; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; Coopersmith S., 1981, SEI SELF ESTEEM INVE; CROWE SF, 1992, J CLIN EXP NEUROPSYC, V14, P327, DOI 10.1080/01688639208402832; Daniel A. E., 1983, POWER PRIVILEGE PRES; DeFilippis NA, 1979, BOOKLET CATEGORY TES; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; Godfrey HPD, 1996, J HEAD TRAUMA REHAB, V11, P29, DOI 10.1097/00001199-199612000-00006; Heaton R., 1993, WISCONSIN CARD SORTI; HEINEMANN AW, 1995, J HEAD TRAUMA REHAB, V10, P54, DOI 10.1097/00001199-199508000-00006; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Johnstone B, 1996, BRAIN INJURY, V10, P627, DOI 10.1080/026990596124052; Kendall E, 1996, NEUROPSYCHOL REHABIL, V6, P101, DOI 10.1080/713755502; KLONOFF PS, 1986, J CLIN EXP NEUROPSYC, V8, P469, DOI 10.1080/01688638608405171; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; Lazarus R.S., 1984, STRESS APPRAISAL COP; LISHMAN WA, 1973, PSYCHOL MED, V3, P304, DOI 10.1017/S003329170004959X; Luria A. R, 1973, WORKING BRAIN; Luria A. R., 1969, HDB CLINICAL NEUROLO, V2, P725; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; MCLEAN A, 1993, ARCH PHYS MED REHAB, V74, P1041, DOI 10.1016/0003-9993(93)90059-J; MILLER L, 1985, NEUROPSYCHOLOGIA, V23, P359, DOI 10.1016/0028-3932(85)90022-3; MILLER L, 1985, NEUROPSYCHOLOGIA, V23, P371, DOI 10.1016/0028-3932(85)90023-5; Milner B, 1964, FRONTAL GRANULAR COR, P313; Moore A D, 1989, Brain Inj, V3, P171, DOI 10.3109/02699058909004549; MOORE AD, 1995, BRAIN INJURY, V9, P109, DOI 10.3109/02699059509008185; MOORE AD, 1991, NEUROPSYCHOL REHABIL, V1, P185, DOI DOI 10.1080/09602019108520164; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; Prigatano GP, 1991, AWARENESS DEFICIT BR, P111; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; Schacter D. L., 1990, NEUROPSYCHOLOGY EVER, P231; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; SmithKnapp K, 1996, BRAIN INJURY, V10, P651, DOI 10.1080/026990596124070; Tate RL, 1998, AUST NZ J PUBL HEAL, V22, P419, DOI 10.1111/j.1467-842X.1998.tb01406.x; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; TATE RL, 1989, ACTA NEUROL SCAND, V79, P97, DOI 10.1111/j.1600-0404.1989.tb03719.x; TATE RL, 1999, IN PRESS CORTEX; TATE RL, 1996, INT PERSPECTIVES TRA, P415; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; VILKKI J, 1994, J CLIN EXP NEUROPSYC, V16, P325, DOI 10.1080/01688639408402643; Vogenthaler D R, 1989, Brain Inj, V3, P369, DOI 10.3109/02699058909004561; Walsh K. W, 1991, UNDERSTANDING BRAIN	54	78	79	0	6	CAMBRIDGE UNIV PRESS	NEW YORK	40 WEST 20TH STREET, NEW YORK, NY 10011-4211 USA	0033-2917			PSYCHOL MED	Psychol. Med.	MAY	1999	29	3					713	725		10.1017/S0033291799008466			13	Psychology, Clinical; Psychiatry; Psychology	Psychology; Psychiatry	205CE	WOS:000080803100021	10405093				2021-06-18	
J	Heath, DL; Vink, R				Heath, DL; Vink, R			Improved motor outcome in response to magnesium therapy received up to 24 hours after traumatic diffuse axonal brain injury in rats	JOURNAL OF NEUROSURGERY			English	Article						neurotrauma; magnesium sulfate; brain injury; treatment evaluation; therapeutic window; rat	ACUTE MYOCARDIAL-INFARCTION; INTRAVENOUS-MAGNESIUM; HEAD-INJURY; NEURONS; SULFATE; METABOLISM; REDUCTION; DAMAGE; DEATH; MODEL	Object. The goal of this study was to establish the therapeutic window during which delayed therapy with MgSO4 improves neurological motor outcome in rats that have suffered severe traumatic axonal brain injury. Methods. Severe brain injury was induced in male Sprague-Dawley rats by using the impact-acceleration model of severe traumatic diffuse axonal brain injury. Injured animals were subsequently treated with MgSO4 (750 mu mol/kg) infused intramuscularly at 30 minutes or at 8, 12, or 24 hours after trauma and were tested for neurological motor outcome during the following week by using the rotarod test. Injured untreated (control) animals demonstrated highly significant (p < 0.001) neurological motor deficits that were sustained over the 1-week assessment period. Animals treated with MgSO4 at 30 minutes or at 8 or 12 hours postinjury demonstrated significantly improved motor outcomes compared with untreated control animals at all time points (0.001 < p < 0.05). Animals treated with MgSO4 at 24 hours had motor scores that were similar to those of untreated control animals early in the week, but demonstrated a significantly more rapid recovery in function and, by the end of the assessment period, they demonstrated significantly improved motor scores (p < 0.01). Repeated administration of MgSO4 over the 1-week observation period did not further improve outcome. Conclusions. The present results demonstrate that Mg++ plays a neuroprotective role following severe diffuse traumatic axonal brain injury. Moreover, Mg++ therapy significantly improved motor outcome when administered up to 24 hours after injury, with early treatments providing the most significant benefit. Repeated administration beyond 24 hours postinjury did not provide additional neuroprotection.	James Cook Univ N Queensland, Dept Physiol & Pharmacol, Townsville, Qld 4811, Australia	Vink, R (corresponding author), James Cook Univ N Queensland, Dept Physiol & Pharmacol, Townsville, Qld 4811, Australia.	Robert.Vink@jcu.edu.au	Vink, Robert/J-7351-2012; AM, Robert Vink/S-5616-2019	Vink, Robert/0000-0002-4885-0667; AM, Robert Vink/0000-0002-4885-0667			ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ALTURA B M, 1985, Magnesium, V4, P226; Bara M, 1984, MAGNESIUM, V3, P212; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; EBEL H, 1980, J CLIN CHEM CLIN BIO, V18, P257; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FADEN AI, 1989, UPDATE INTENSIVE CAR, V9, P14; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; FuchsBuder T, 1997, J NEUROSURG ANESTH, V9, P324, DOI 10.1097/00008506-199710000-00006; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Heath DL, 1998, SCAND J CLIN LAB INV, V58, P161, DOI 10.1080/00365519850186751; Heath DL, 1996, BRAIN RES, V738, P150, DOI 10.1016/0006-8993(96)00957-2; Heath DL, 1998, J NEUROTRAUM, V15, P183, DOI 10.1089/neu.1998.15.183; Heath DL, 1995, J NEUROTRAUM, V12, P1027, DOI 10.1089/neu.1995.12.1027; HEATH DL, 1997, CHARACTERISATION NEU; Hoane MR, 1998, BRAIN RES BULL, V45, P45, DOI 10.1016/S0361-9230(97)00288-8; ISERI LT, 1984, AM HEART J, V108, P188, DOI 10.1016/0002-8703(84)90572-6; IZUMI Y, 1991, J CEREBR BLOOD F MET, V11, P1025, DOI 10.1038/jcbfm.1991.170; KASS IS, 1988, ANESTHESIOLOGY, V69, P710, DOI 10.1097/00000542-198811000-00012; KWACK H, 1992, CURR TOP CELL REGUL, V33, P185; Lenkinski R. E., 1995, Journal of Neurotrauma, V12, P351; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MCDONALD JW, 1990, NEUROSCI LETT, V109, P234, DOI 10.1016/0304-3940(90)90569-U; MCINTOSH TK, 1989, BRAIN RES, V482, P252, DOI 10.1016/0006-8993(89)91188-8; MCINTOSH TK, 1992, EXCITATORY AMINO ACI, P247; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; MUIR KW, 1995, STROKE, V26, P1183, DOI 10.1161/01.STR.26.7.1183; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; Povlishock J.T., 1994, NEUROBIOLOGY CENTRAL, P109; RAM Z, 1991, STROKE, V22, P922, DOI 10.1161/01.STR.22.7.922; Ritter C, 1996, SCAND J CLIN LAB INV, V56, P275, DOI 10.3109/00365519609088647; ROBERTSON CS, 1986, J NEUROSURG, V64, P633, DOI 10.3171/jns.1986.64.4.0633; ROTHMAN SM, 1983, SCIENCE, V220, P536, DOI 10.1126/science.6836300; SCHANNE FAX, 1993, BIOCHIM BIOPHYS ACTA, V1158, P257, DOI 10.1016/0304-4165(93)90023-2; Schendel DE, 1996, JAMA-J AM MED ASSOC, V276, P1805, DOI 10.1001/jama.276.22.1805; SMITH DH, 1993, NEUROSCI LETT, V157, P211, DOI 10.1016/0304-3940(93)90739-8; TEO KK, 1991, BMJ-BRIT MED J, V303, P1499, DOI 10.1136/bmj.303.6816.1499; TSUDA T, 1991, NEUROSCIENCE, V44, P335, DOI 10.1016/0306-4522(91)90058-V; VINK R, 1993, MOL CHEM NEUROPATHOL, V18, P279, DOI 10.1007/BF03160120; WOODS KL, 1992, LANCET, V339, P1553, DOI 10.1016/0140-6736(92)91828-V; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921	43	78	83	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAR	1999	90	3					504	509		10.3171/jns.1999.90.3.0504			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	170KX	WOS:000078805800010	10067920				2021-06-18	
J	Herrmann, M; Curio, N; Jost, S; Wunderlich, MT; Synowitz, H; Wallesch, CW				Herrmann, M; Curio, N; Jost, S; Wunderlich, MT; Synowitz, H; Wallesch, CW			Protein S-100B and neuron specific enolase as early neurobiochemical markers of the severity of traumatic brain injury	RESTORATIVE NEUROLOGY AND NEUROSCIENCE			English	Article						NSE; protein S-100B; traumatic brain injury; outcome	CALCIUM-BINDING PROTEINS; MINOR HEAD-INJURY; DAMAGE; INFARCTION; FAMILY	The present study aimed at the predictive value of early release patterns of protein S-100B and neuron specific enolase (NSE) in patients with traumatic brain injury. We investigated 69 patients who were admitted to the Department of Neurosurgery following traumatic brain injury. Both NSE and S-100B serum concentrations during the first three days after admission were highly and significantly correlated with Glasgow Coma and Coma Remission Scale scores at the respective blood sampling times as well as 2 weeks later. Signs of intracranial pathology as evaluated by CCT or MRI scans showed no association with NSE or S-100B release patterns. Our data support the hypothesis that NSE and protein S-100B are useful and sensitive neurobiochemical markers for the early clinical outcome of traumatic brain injury.	Otto Von Guericke Univ, Div Neuropsychol & Behav Neurol, D-39120 Magdeburg, Germany; Otto Von Guericke Univ, Dept Neurol, Magdeburg, Germany; Otto Von Guericke Univ, Dept Neurosurg, Magdeburg, Germany	Herrmann, M (corresponding author), Otto Von Guericke Univ, Div Neuropsychol & Behav Neurol, Leipziger Str 44, D-39120 Magdeburg, Germany.		Herrmann, Manfred/H-3931-2011	Herrmann, Manfred/0000-0003-1872-8406			Buttner T, 1997, STROKE, V28, P1961, DOI 10.1161/01.STR.28.10.1961; CUNNINGHAM RT, 1991, EUR J CLIN INVEST, V21, P497, DOI 10.1111/j.1365-2362.1991.tb01401.x; DONATO R, 1991, CELL CALCIUM, V12, P713, DOI 10.1016/0143-4160(91)90040-L; FANO G, 1995, PROG NEUROBIOL, V46, P71, DOI 10.1016/0301-0082(94)00062-M; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; GRILL M, 1998, PHARMACOPSYCHIATRY, V31, pR18; HATFIELD RH, 1992, BRAIN RES, V577, P249, DOI 10.1016/0006-8993(92)90280-M; Heierhorst J, 1996, NATURE, V380, P636, DOI 10.1038/380636a0; Ilg EC, 1996, INT J CANCER, V68, P325, DOI 10.1002/(SICI)1097-0215(19961104)68:3<325::AID-IJC10>3.3.CO;2-0; Ingebrigtsen T, 1997, J CLIN NEUROSCI, V4, P29, DOI 10.1016/S0967-5868(97)90007-2; Johnsson P, 1996, J CARDIOTHOR VASC AN, V10, P120, DOI 10.1016/S1053-0770(96)80187-X; KAHN HJ, 1991, MODERN PATHOL, V4, P698; MARANGOS PJ, 1987, ANNU REV NEUROSCI, V10, P269, DOI 10.1146/annurev.ne.10.030187.001413; MARSHALL LF, 1992, J NEUROTRAUMA, V9, P287; POTTS BC, 1995, NATURE STRUCTURAL BI, V9, P790; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; SCHONLE PW, 1995, NEUROL REHABIL, V2, P87; SKOGSEID IM, 1992, ACTA NEUROCHIR, V115, P106, DOI 10.1007/BF01406367; SMITH DH, 1995, J NEUROTRAUM, V12, P573, DOI 10.1089/neu.1995.12.573; TEASDALE G, 1974, LANCET, V2, P81; Thatcher RW, 1997, J NEUROTRAUM, V14, P1, DOI 10.1089/neu.1997.14.1; Waterloo K, 1997, ACTA NEUROCHIR, V139, P26, DOI 10.1007/BF01850864; Westaby S, 1996, ANN THORAC SURG, V61, P88, DOI 10.1016/0003-4975(95)00904-3; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977; Yang QE, 1996, DEV BRAIN RES, V91, P181, DOI 10.1016/0165-3806(95)00180-8; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	26	78	79	0	2	IOS PRESS	AMSTERDAM	VAN DIEMENSTRAAT 94, 1013 CN AMSTERDAM, NETHERLANDS	0922-6028			RESTOR NEUROL NEUROS	Restor. Neurol. Neurosci.		1999	14	2-3					109	114					6	Neurosciences	Neurosciences & Neurology	183XN	WOS:000079579700005	22387506				2021-06-18	
J	Prins, ML; Hovda, DA				Prins, ML; Hovda, DA			Traumatic brain injury in the developing rat: Effects of maturation on Morris water maze acquisition	JOURNAL OF NEUROTRAUMA			English	Article						brain injury; cognition; concussion; development; fluid percussion; Morris water maze	FLUID-PERCUSSION MODEL; HIPPOCAMPAL-FORMATION; SPATIAL LOCALIZATION; BEHAVIORAL DEFICITS; ASSOCIATION CORTEX; CHOLINERGIC SYSTEM; SENSORIMOTOR TESTS; PLACE NAVIGATION; DENTATE GYRUS; FETAL KITTENS	Previous work has demonstrated that postnatal and adult rats show different physiological responses to lateral fluid percussion (FP) brain injury. Compared to adult animals, the younger rats showed longer apnea and shorter unconsciousness, and sustained hypotension at all injury severities, with higher mortality following severe traumatic brain injury (TBI), To determine if these younger rats exhibit differential cognitive impairments, the Morris water maze (MWM) was used to compare the degree of spatial learning deficits between moderately injured postnatal day 17 (P17), P28, and adult rats, as well as their age-matched controls. Comparisons between shams of different ages showed a maturational time course for MWM acquisition, where adult rats learned the task 34-58% faster than younger age groups. Injured adults showed escape latency deficits throughout the entire training period, took 39% fewer direct paths to the platform during training, took 24% longer to reach criterion performance, and showed poor probe trial performance than adult shams, Injured P28s exhibited escape latency deficits during the first week, with 23% more trials to criterion and 24% fewer direct paths compared to P28 shams. In contrast, injured P17 rats showed no significant difference from age-matched controls in terms of escape latency, number of direct paths taken, or time to criterion performance. This work suggests that, upon surviving the insult, P17 injured rats show remarkable sparing compared to P28 and adult injured animals.	Univ Calif Los Angeles, Sch Med, Div Neurosurg, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Med, Inst Brain Res, Los Angeles, CA 90024 USA	Prins, ML (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Anat, Box 980709, Richmond, VA 23298 USA.		Prins, Mayumi/J-9571-2015	Prins, Mayumi/0000-0001-7694-9739	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS27544] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027544] Funding Source: NIH RePORTER		Adelson PD, 1997, J NEUROTRAUM, V14, P99, DOI 10.1089/neu.1997.14.99; Adelson PD, 1996, J NEUROSURG, V85, P877, DOI 10.3171/jns.1996.85.5.0877; ARMSTEAD WM, 1994, J NEUROTRAUM, V11, P487, DOI 10.1089/neu.1994.11.487; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; COTMAN C, 1973, BRAIN RES, V63, P205, DOI 10.1016/0006-8993(73)90089-9; CRAIN B, 1973, BRAIN RES, V63, P195, DOI 10.1016/0006-8993(73)90088-7; DIMATTIA BD, 1988, BEHAV NEUROSCI, V102, P471, DOI 10.1037/0735-7044.102.4.471; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GOLDMAN PS, 1978, BRAIN RES, V152, P451, DOI 10.1016/0006-8993(78)91103-4; Gorman LK, 1996, J NEUROTRAUM, V13, P457, DOI 10.1089/neu.1996.13.457; GRUNDL PD, 1994, J NEUROTRAUM, V11, P135, DOI 10.1089/neu.1994.11.135; HAMM RJ, 1993, COGNITIVE BRAIN RES, V1, P223, DOI 10.1016/0926-6410(93)90006-Q; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HOVDA DA, 1996, NEUROTRAUMA, P1459; JARRARD LE, 1993, BEHAV NEURAL BIOL, V60, P9, DOI 10.1016/0163-1047(93)90664-4; Kennard MA, 1936, AM J PHYSIOL, V115, P138; Kennard MA, 1938, J NEUROPHYSIOL, V1, P477; KOLB B, 1983, BEHAV NEUROSCI, V97, P13, DOI 10.1037/0735-7044.97.1.13; KOLB B, 1993, BEHAV NEUROSCI, V107, P799, DOI 10.1037/0735-7044.107.5.799; KOLB B, 1978, BRAIN RES, V151, P135, DOI 10.1016/0006-8993(78)90956-3; KRAEMER PJ, 1995, PSYCHOBIOLOGY, V23, P144; LEE SM, 1993, SOC NEUR ABSTR, V3, P1882; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LYETH BG, 1993, J NEUROTRAUM, V10, P57, DOI 10.1089/neu.1993.10.57; LYETH BG, 1988, BRAIN RES, V452, P39, DOI 10.1016/0006-8993(88)90006-6; Mansfield RT, 1996, J CEREBR BLOOD F MET, V16, P244, DOI 10.1097/00004647-199603000-00009; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MEIBACH RC, 1981, BRAIN RES, V204, P431, DOI 10.1016/0006-8993(81)90603-X; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; OLTON DS, 1979, BEHAV BRAIN SCI, V2, P313, DOI 10.1017/S0140525X00062713; Panigrahy A., 1995, Society for Neuroscience Abstracts, V21, P2119; Pike BR, 1997, EXP NEUROL, V147, P55, DOI 10.1006/exnr.1997.6582; Pike BR, 1997, PHARMACOL BIOCHEM BE, V57, P785, DOI 10.1016/S0091-3057(96)00453-4; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/0165-3806(96)00098-3; RAUCH TM, 1989, PHYSIOL BEHAV, V46, P315, DOI 10.1016/0031-9384(89)90273-4; ROSEN GD, 1995, BRAIN RES, V681, P177, DOI 10.1016/0006-8993(95)00312-E; RUDY JW, 1987, BEHAV NEUROSCI, V101, P62, DOI 10.1037/0735-7044.101.1.62; SCHAPIRO S, 1970, SCIENCE, V168, P147, DOI 10.1126/science.168.3927.147; SCHENK F, 1985, BEHAV NEURAL BIOL, V43, P69, DOI 10.1016/S0163-1047(85)91510-9; SMITH DH, 1993, J NEUROSCI, V13, P5383; SMITH ML, 1995, J CEREB BLOOD FLOW M, V15, pS723; SUTHERLAND RJ, 1983, BEHAV BRAIN RES, V7, P133, DOI 10.1016/0166-4328(83)90188-2; SUTHERLAND RJ, 1982, NEUROSCI LETT, V31, P271, DOI 10.1016/0304-3940(82)90032-5; TAKANO N, 1979, JPN J PHYSIOL, V29, P173; VANDERWOLF CH, 1978, J COMP PHYSIOL PSYCH, V92, P156, DOI 10.1037/h0077447; VICEDOMINI JP, 1982, PHYSIOL BEHAV, V28, P797, DOI 10.1016/0031-9384(82)90196-2; VILLABLANCA JR, 1993, BEHAV BRAIN RES, V57, P63, DOI 10.1016/0166-4328(93)90062-U; VILLABLANCA JR, 1986, BEHAV BRAIN RES, V19, P205, DOI 10.1016/0166-4328(86)90021-5; VILLABLANCA JR, 1993, BEHAV BRAIN RES, V57, P79, DOI 10.1016/0166-4328(93)90063-V; WHISHAW IQ, 1984, BEHAV BRAIN RES, V11, P123, DOI 10.1016/0166-4328(84)90135-9	54	78	78	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	1998	15	10					799	811		10.1089/neu.1998.15.799			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	132LW	WOS:000076632400005	9814636				2021-06-18	
J	Townsend, RN; Lheureau, T; Protetch, J; Riemer, B; Simon, D				Townsend, RN; Lheureau, T; Protetch, J; Riemer, B; Simon, D			Timing fracture repair in patients with severe brain injury (Glasgow Coma Scale Score < 9)	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	57th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 24-27, 1997	WAIKOLOA, HI	Amer Assoc Surg Trauma		resuscitation; femur fracture; head injury	SEVERE HEAD-INJURY; FAT-EMBOLISM; INTRACRANIAL-PRESSURE; MULTIPLE TRAUMA; FIXATION; DISABILITY; DEATH	Background: Trauma patients with severe brain injury are at risk of secondary brain injury, Femur fractures, if present, should be repaired when potential causes of secondary brain injury have been corrected. Methods: Sixty-one patients with severe or moderate closed head injury and femur fractures were identified, Patients were divided into groups by time until femur fracture reduction. Results: An inversely proportional trend was demonstrated when comparing time until surgery with the percentage of patients who experienced hypotensive events during surgery, Patients in the 0- to 2-hour group were eight times more likely to become hypotensive during femur repair than patients in the > 24-hour group. Seventy-four percent of patients with intracranial pressure monitoring experienced cerebral perfusion pressure < 70 mm Hg. Conclusions: Operation in similar patients should be done when risks are minimized by adequate resuscitation, Secondary brain injury is more common in early femur repair, Operation delay of 24 hours may be necessary to prevent hypoxia, hypotension, and low cerebral perfusion pressure.	Allegheny Gen Hosp, Pittsburgh, PA 15212 USA; Kaplan Hosp, IL-76100 Rehovot, Israel	Townsend, RN (corresponding author), 420 East North Ave,Suite 304, Pittsburgh, PA 15212 USA.						BECKMAN SB, 1989, AM SURGEON, V55, P356; BEHRMAN SW, 1990, J TRAUMA, V30, P792, DOI 10.1097/00005373-199007000-00005; BONE LB, 1989, J BONE JOINT SURG AM, V71A, P336, DOI 10.2106/00004623-198971030-00004; BROOS PLO, 1987, INJURY, V18, P235, DOI 10.1016/0020-1383(87)90004-0; BURGESS RR, 1993, RESOURCES OPTIMAL CA, P47; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; DERLET R W, 1989, Journal of Emergency Medicine, V7, P5; FABIAN TC, 1990, CRIT CARE MED, V18, P42; HENK JD, 1988, J TRAUMA, V28, P383; Jaicks RR, 1997, J TRAUMA, V42, P1, DOI 10.1097/00005373-199701000-00001; JENNETT B, 1975, LANCET, V1, P480; JOHNSON KD, 1985, J TRAUMA, V25, P375, DOI 10.1097/00005373-198505000-00001; KREGOR PJ, 1993, J BONE JOINT SURG AM, V75A, P1774, DOI 10.2106/00004623-199312000-00006; LEVY D, 1990, CLIN ORTHOP RELAT R, V61, P281; PAPE HC, 1993, J TRAUMA, V35, P709, DOI 10.1097/00005373-199311000-00010; PELL ACH, 1993, J BONE JOINT SURG BR, V75, P921; PIETROPAOLI JA, 1992, J TRAUMA, V33, P403, DOI 10.1097/00005373-199209000-00011; POOLE GV, 1992, J TRAUMA, V32, P654, DOI 10.1097/00005373-199205000-00019; RISKA EB, 1982, J TRAUMA, V22, P891, DOI 10.1097/00005373-198211000-00001; SEIBEL R, 1985, ANN SURG, V202, P283, DOI 10.1097/00000658-198509000-00003; SHACKFORD SR, 1992, J NEUROSURG, V76, P91, DOI 10.3171/jns.1992.76.1.0091; SIEGEL JH, 1993, J TRAUMA, V35, P920, DOI 10.1097/00005373-199312000-00019; SIEGEL JH, 1991, CRIT CARE MED, V19, P1252, DOI 10.1097/00003246-199110000-00007; SMITH JS, 1990, J TRAUMA, V30, P1533, DOI 10.1097/00005373-199012000-00017; SPERRY RJ, 1992, ANESTHESIOLOGY, V77, P416, DOI 10.1097/00000542-199209000-00002; WALD SL, 1993, J TRAUMA, V34, P377, DOI 10.1097/00005373-199303000-00012; WEISNER DH, 1993, ADV TRAUMA CRIT CARE, V8, P183	27	78	78	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUN	1998	44	6					977	982		10.1097/00005373-199806000-00008			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	ZU123	WOS:000074164600007	9637152				2021-06-18	
J	Colantonio, A; Dawson, DR; McLellan, BA				Colantonio, A; Dawson, DR; McLellan, BA			Head injury in young adults: Long-term outcome	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							TRAUMATIC BRAIN INJURY; SICKNESS IMPACT PROFILE; FOLLOW-UP; ADOLESCENTS; RECOVERY; SCALE; COMMUNITY; CHILDREN; SEVERITY; LIFE	Objective: To describe the long-term outcome 5 years after injury of young adults who were 15 to 19 years old at the time of their head injuries. Design: A retrospective cohort. The health records of 62 consecutive eligible subjects were abstracted for baseline sociodemographic, health, and injury variables. A telephone interview was administered to assess quality of life, impairment, disability, and handicap. Setting: Canada's largest trauma center, Sunnybrook Health Science Centre, Toronto, Canada. Subjects: Of the 58 subjects (94%) who were traced at follow-up, 51 agreed to participate. Main Outcome Measures: The Medical Outcomes Study SF-36, Head Injury Symptom Checklist, selected disability measures, Community Integration Questionnaire. Results: Of the 8 summary items of the Medical Outcomes Study SF-36, subjects scored lowest on mental health. There were no significant differences between mild and more severely injured groups in all quality of life measures. Subjects classified with mild head injury overall reported more symptoms from the Head Injury Symptom Checklist. Subjects with more severe injuries had lower community integration scores (p < .05). Conclusions: Overall, mental health is an important area of concern at follow-up for all subjects. Adolescents with apparent mild head injury can have disabling symptoms many years after injury. (C) 1998 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	Univ Toronto, Dept Occupat Therapy, Toronto, ON M5T 1W5, Canada; Univ Toronto, Dept Surg, Toronto, ON M5T 1W5, Canada; Sunnybrook Hlth Sci Ctr, Dept Occupat Therapy, Toronto, ON M4N 3M5, Canada; Sunnybrook Hlth Sci Ctr, Trauma Program, Toronto, ON M4N 3M5, Canada	Colantonio, A (corresponding author), Univ Toronto, Dept Occupat Therapy, 256 McCaul St, Toronto, ON M5T 1W5, Canada.		Dawson, Deirdre R/I-8882-2014	Dawson, Deirdre R/0000-0001-7517-6121; Colantonio, Angela/0000-0003-2094-4765			Badley E M, 1993, Disabil Rehabil, V15, P161; BENYISHAY Y, 1987, J HEAD TRAUMA REHAB, V2, P35, DOI DOI 10.1097/00001199-198703000-00007; BERGNER M, 1976, MED CARE, V14, P57, DOI 10.1097/00005650-197601000-00006; BOYER MG, 1991, INJURY, V22, P315, DOI 10.1016/0020-1383(91)90014-6; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; BURKE W H, 1990, Brain Injury, V4, P371, DOI 10.3109/02699059009026190; DAWSON DR, 1995, BRAIN INJURY, V9, P339, DOI 10.3109/02699059509005774; DEJONG G, 1982, ARCH PHYS MED REHAB, V63, P68; DIKMEN S, 1986, ARCH PHYS MED REHAB, V67, P507; FAHY TJ, 1967, LANCET, V2, P475; FURRIE A, 1987, NATL DATABASE DISABL; GREENSPAN L, 1985, J TRAUMA, V25, P60, DOI 10.1097/00005373-198501000-00010; Hays RD, 1995, USERS MANUAL MED OUT; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; KLASBEEK WD, 1980, J NEUROSURG, V53, P519; KLONOFF PS, 1986, NEUROSURGERY, V19, P735, DOI 10.1227/00006123-198611000-00004; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P185; LEWIN W, 1979, BRIT MED J, V2, P1533, DOI 10.1136/bmj.2.6204.1533; MARION DW, 1994, J TRAUMA, V36, P89, DOI 10.1097/00005373-199401000-00014; MARMAROU A, 1991, J NEUROSURG S, V75, P59; MCLEAN A, 1993, ARCH PHYS MED REHAB, V74, P1041, DOI 10.1016/0003-9993(93)90059-J; MCLEAN A, 1984, NEUROSURGERY, V14, P393, DOI 10.1227/00006123-198404000-00001; MOORE A, 1993, BRAIN INJURY, V7, P247, DOI 10.3109/02699059309029677; *NAT HEAD INJ FDN, 1981, SIL EP; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; ROBERTS AH, 1976, P ROY SOC MED, V69, P137, DOI 10.1177/003591577606900228; RUSK H A, 1969, Medical Clinics of North America, V53, P677; RUSONIS ES, 1990, MED CLIN N AM, V74, P1311, DOI 10.1016/S0025-7125(16)30518-1; SLATER EJ, 1988, AM J DIS CHILD, V142, P1048, DOI 10.1001/archpedi.1988.02150100042022; SLATER EJ, 1989, J ADOLESCENT HEALTH, V10, P237, DOI 10.1016/0197-0070(89)90240-4; *STAT CAN, 1991, LAB FORC ACT CAT 324; STEADMAN JH, 1970, P ROY SOC MED, V63, P23, DOI 10.1177/003591577006300109; TEMKIN NR, 1989, MED CARE, V27, pS44, DOI 10.1097/00005650-198903001-00004; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Vogenthaler D R, 1989, Brain Inj, V3, P369, DOI 10.3109/02699058909004561; WARE JE, 1987, J CHRON DIS, V40, P473; Ware JE., 1993, SF 36 HLTH SURVEY MA; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Willer B, 1993, J HEAD TRAUMA REHAB, V3, P75, DOI DOI 10.1097/00001199-199308020-00009; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014	42	78	78	0	3	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAY	1998	79	5					550	558		10.1016/S0003-9993(98)90072-7			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	ZM198	WOS:000073514500014	9596398				2021-06-18	
J	Taverni, JP; Seliger, G; Lichtman, SW				Taverni, JP; Seliger, G; Lichtman, SW			Donepezil mediated memory improvement in traumatic brain injury during post acute rehabilitation	BRAIN INJURY			English	Article								Memory dysfunction is a recognized and difficult to treat complication of traumatic brain injury (TBI). Since medial-temporal lobe injury is a frequent contributor to memory dysfunction in TBI, it is likely that an acetylcholine deficit contributes to memory dysfunction in this population. Recently, Donepezil, an acetylcholine-esterase inhibitor which has demonstrated a high selectivity for neural Ach-esterase (with minimal side effects), was approved for use in dementia in Alzheimer's patients. Due to its promising results in Alzheimer's patients, and reports in the literature describing the use of physostigmine (an anti-cholinesterase with significant cardiovascular and autonomic side effects) to treat memory deficits in closed head injury, we decided to begin a trial of Donepezil in two patients with TBI who were experiencing long term static memory dysfunction refractory to conventional treatment. Both patients were admitted to our facility for physical and cognitive rehabilitation, and were started on a trial of Donepezil. Modified memory tests and subjective observations by both family and staff pointed to an improvement in memory within three weeks of starting Donepezil. Should these initial results be supported in larger trials, Donepezil may prove to be a valuable tool for the treatment of memory dysfunction in TBI.	Helen Hayes Hosp, Dept Internal Med & Cardiol, W Haverstraw, NY 10993 USA; Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY 10027 USA; Columbia Univ, Coll Phys & Surg, Dept Phys Med & Rehabil, New York, NY 10027 USA; Columbia Univ, Coll Phys & Surg, Dept Neurol, New York, NY 10027 USA	Seliger, G (corresponding author), Helen Hayes Hosp, Dept Internal Med & Cardiol, Route 9W, W Haverstraw, NY 10993 USA.						*CTR FUNCT ASS RES, 1990, GUID US UN DAT SET M; DUCHEN LW, 1992, GREENFIELDS NEUROPAT; Gennarelli TA, 1993, HEAD INJURY; GOLDBERG E, 1982, ARCH NEUROL-CHICAGO, V39, P581, DOI 10.1001/archneur.1982.00510210051012; Granger CV, 1986, TOP GERIATR REHABIL, V1, P59, DOI 10.1097/00013614-198604000-00007; HAMILTON B B, 1991, Archives of Physical Medicine and Rehabilitation, V72, P790; Levin H S, 1986, Cent Nerv Syst Trauma, V3, P333; MAYUEX R, 1995, MERRITTS TXB NEUROLO; RODGERS SL, 1996, DEMENTIA, V7, P293; ROGER SL, 1991, CHOLEMERGINIC BASIS; ROSS JD, 1976, ROSS TEST HIGHER PRO; Weinberg R M, 1987, Brain Inj, V1, P57, DOI 10.3109/02699058709034445; Wilson B. A., 1985, RIVERMEAD BEHAV MEMO	13	78	80	0	5	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JAN	1998	12	1					77	80					4	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	YT347	WOS:000071592500008	9483340				2021-06-18	
J	An, SF; Giometto, B; Groves, M; Miller, RF; Beckett, AAJ; Gray, F; Tavolato, B; Scaravilli, F				An, SF; Giometto, B; Groves, M; Miller, RF; Beckett, AAJ; Gray, F; Tavolato, B; Scaravilli, F			Axonal damage revealed by accumulation of beta-APP in HIV-positive individuals without AIDS	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						axonal changes; beta-APP; HIV-positive asymptomatic patients; immune activation; neuropsychological disorder; polymerase chain reaction (PCR); reversible	ACQUIRED-IMMUNODEFICIENCY-SYNDROME; AMYLOID PRECURSOR PROTEIN; TRAUMATIC BRAIN INJURY; RAT-BRAIN; HEAD-INJURY; CEREBROSPINAL-FLUID; ENVELOPE PROTEIN; PRE-AIDS; INFECTION; EXPRESSION	The presence of neuropsychological disturbances in HIV-positive, pre-symptomatic individuals is a controversial issue. Neuroimaging studies have not shown brain atrophy or hyperintensity in the white matter, whereas proton magnetic resonance spectroscopy has revealed some abnormality of cerebral biochemistry. Using an antibody to beta-amyloid precursor protein (beta-APP), we previously demonstrated frequent and widespread axonal changes in the brains of AIDS patients. In this study, we extended the use of beta-APP to asymptomatic patients in order to establish a possible morphological correlation with neuropsychological disorders. Brain samples from 29 patients were examined. Results showed bundles of beta-APP-positive axons in 8/29 cases (27%). The changes, seen in both superficial and deep white matter, were either focal or diffuse, could not be visualized by silver or ubiquitin stains, and did not coexist with any change in distribution or morphology of astrocytes and microglial cells. We conclude that in HIV-positive asymptomatic individuals, axonal changes: (a) may be related to the state of immune activation with consequent presence of toxic substances, including cytokines, observed in these patients; (b) may represent mild changes that could undergo repair, unless other pathological events, such as the supervening of the AIDS stage and the specific encephalitis, make them permanent.	INST NEUROL,DEPT NEUROPATHOL,LONDON WC1N 3BG,ENGLAND; UNIV PADUA,NEUROL CLIN 2,PADUA,ITALY; UCL,SCH MED,MORTIMER MARKET CTR,DIV PATHOL & INFECT DIS,DEPT SEXUALLY TRANSMITTED DIS,LONDON WC1E 6AU,ENGLAND; HOP HENRI MONDOR,DEPT NEUROPATHOL,F-94010 CRETEIL,FRANCE			Giometto, Bruno/AAG-3236-2019	Miller, Robert/0000-0003-2067-4291; giometto, bruno/0000-0003-2311-9752			An SF, 1996, ACTA NEUROPATHOL, V91, P169, DOI 10.1007/s004010050409; An SF, 1996, ANN NEUROL, V40, P611, DOI 10.1002/ana.410400411; AN SF, 1994, J CLIN PATHOL, V47, P990, DOI 10.1136/jcp.47.11.990; An SF, 1996, ACTA NEUROPATHOL, V91, P494, DOI 10.1007/s004010050457; BORNSTEIN RA, 1993, AIDS, V7, P1607, DOI 10.1097/00002030-199312000-00010; BRENNEMAN DE, 1988, NATURE, V335, P639, DOI 10.1038/335639a0; BRENNEMAN DE, 1990, SOC NEUR ABSTR, V16, P615; BUZY J, 1992, BRAIN RES, V598, P10, DOI 10.1016/0006-8993(92)90161-2; CHONG WK, 1994, AM J NEURORADIOL, V15, P21; CHONG WK, 1993, RADILOGY, V43, P509; COCHRAN E, 1991, AM J PATHOL, V139, P485; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DREYER EB, 1990, SCIENCE, V248, P364, DOI 10.1126/science.2326646; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GIANGASPERO F, 1988, ARCH PATHOL LAB MED, V112, P1259; Giometto B, 1997, ANN NEUROL, V42, P34, DOI 10.1002/ana.410420108; GLASS JD, 1993, NEUROLOGY, V43, P2230, DOI 10.1212/WNL.43.11.2230; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; GRANT I, 1987, ANN INTERN MED, V107, P828, DOI 10.7326/0003-4819-107-6-828; GRAY F, 1992, J NEUROPATH EXP NEUR, V51, P177, DOI 10.1097/00005072-199203000-00007; HARRISON MJG, 1995, AIDS NEUROLOGY, P31; HAYES RL, 1991, J NEUROTRAUM, V8, pS173; HO DD, 1985, NEW ENGL J MED, V313, P1493, DOI 10.1056/NEJM198512123132401; Jenkins LW, 1988, J NEUROTRAUM, V5, P275, DOI 10.1089/neu.1988.5.275; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; KAISER PK, 1990, NEUROLOGY, V40, P1757, DOI 10.1212/WNL.40.11.1757; KARLSEN NR, 1992, ACTA NEUROL SCAND, V86, P242, DOI 10.1111/j.1600-0404.1992.tb05078.x; KAWARABAYASHI T, 1991, BRAIN RES, V563, P334, DOI 10.1016/0006-8993(91)91558-I; Lipton SA, 1991, BRAIN PATHOL, V1, P193, DOI 10.1111/j.1750-3639.1991.tb00659.x; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; NAKAMURA Y, 1992, NEUROSCI LETT, V136, P95, DOI 10.1016/0304-3940(92)90656-R; NEWTON TF, 1994, CLIN ELECTROENCEPHAL, V25, P18, DOI 10.1177/155005949402500107; NUWER MR, 1992, NEUROLOGY, V42, P1214, DOI 10.1212/WNL.42.6.1214; OHGAMI T, 1992, NEUROSCI LETT, V136, P75, DOI 10.1016/0304-3940(92)90651-M; OTSUKA N, 1991, BRAIN RES, V568, P335, DOI 10.1016/0006-8993(91)91422-W; PANLILIO L V, 1990, Society for Neuroscience Abstracts, V16, P1330; PERT C B, 1989, Society for Neuroscience Abstracts, V15, P1387; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Pittaluga A, 1996, AIDS, V10, P463, DOI 10.1097/00002030-199605000-00003; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; Price RW, 1991, BRAIN PATHOL, V1, P155, DOI 10.1111/j.1750-3639.1991.tb00655.x; ROTHWELL NJ, 1993, CEREBROVAS BRAIN MET, V5, P178; SCARAVILLI F, 1993, NEUROPATHOLOGY HIV I, P99; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; TENHULA WN, 1992, AM J OPHTHALMOL, V113, P14, DOI 10.1016/S0002-9394(14)75746-0; TYOR WR, 1992, ANN NEUROL, V31, P349, DOI 10.1002/ana.410310402; VIONDURY J, 1995, LANCET, V345, P60, DOI 10.1016/S0140-6736(95)91184-7; WESSELINGH SL, 1993, ANN NEUROL, V33, P576, DOI 10.1002/ana.410330604; Wilkinson ID, 1997, AIDS, V11, P289, DOI 10.1097/00002030-199703110-00005; WILKINSON ID, 1997, IN PRESS J NEUROL NE; WILT SG, 1995, ANN NEUROL, V37, P381, DOI 10.1002/ana.410370315; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S	55	78	80	0	1	AMER ASSN NEUROPATHOLOGISTS INC	LAWRENCE	1041 NEW HAMPSHIRE ST, LAWRENCE, KS 66044	0022-3069			J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	NOV	1997	56	11					1262	1268		10.1097/00005072-199711000-00011			7	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	YG291	WOS:A1997YG29100011	9370237	Bronze			2021-06-18	
J	Eclancher, F; Kehrli, P; Labourdette, G; Sensenbrenner, M				Eclancher, F; Kehrli, P; Labourdette, G; Sensenbrenner, M			Basic fibroblast growth factor (bFGF) injection activates the glial reaction in the injured adult rat brain	BRAIN RESEARCH			English	Article						brain injury; astrocyte; glial fibrillary acidic protein; glial fibrillary acidic protein mRNA; basic fibroblast growth factor; rat	FIBRILLARY ACIDIC PROTEIN; FACTOR-LIKE IMMUNOREACTIVITY; MOUSE CEREBRAL-CORTEX; MESSENGER-RNA; CELL-PROLIFERATION; ASTROGLIAL RESPONSE; NERVOUS-SYSTEM; STAB WOUNDS; CNS INJURY; FACTOR FGF	Reactive gliosis is a reaction of glial cells to trauma which is characterized by a phenotypic modification of astrocytes, as well as by a proliferation and a migration of some of these cells to form a glial scar. This scar is currently considered as a physical impediment to neuronal regrowth but it may also be involved in wound healing since the astrocytes beside microglia play a phagocytic role in the clearance of post-traumatic debris. Growth factors are released in the area of the injury and at least some of them could be involved in gliosis. In order to test directly this possibility, we have injected one of them, the basic fibroblast growth factor (bFGF), into several brain areas (cortex, striatum, hippocampus or corpus calIosum) of adult 2-month-old rats in the absence of lesion. A glial reaction was observed after 3 days and was maximum after 7 days. It was characterized by an increase in astrocyte proliferation and in glial fibrillary acidic protein (GFAP) expression, resulting in a higher number of GFAP-positive cells per surface unit, and by an increase in the size and branching of the astroglial processes. The GFAP mRNA levels were also strongly increased following the bFGF injection. These effects resemble the reactive gliosis observed after lesion and suggest that bFGF is actually involved in the triggering of glial reactions which follow brain injury. In further experiments, bFGF was injected in the site of electrolytic lesions made in the same various parts of the brain. These injections did not increase significantly the normal reactive gliosis induced by the lesion alone, but it accelerated some of the effects. It also resulted in a higher labeling index and GFAP mRNA levels were strongly enhanced after a 3-day-post-operative delay. This last observation strengthens the idea that one of the main factors driving the astrogliosis is the bFGF normally released in and around the site of the lesion.		Eclancher, F (corresponding author), CNRS,CTR NEUROCHIM,LAB NEUROBIOL ONTOGEN,5 RUE BLAISE PASCAL,F-67084 STRASBOURG,FRANCE.						ADRIAN EK, 1978, J COMP NEUROL, V180, P815, DOI 10.1002/cne.901800412; AMADUCCI L, 1981, NEUROSCI LETT, V21, P27, DOI 10.1016/0304-3940(81)90052-5; AQUINO DA, 1988, J NEUROCHEM, V51, P1085, DOI 10.1111/j.1471-4159.1988.tb03072.x; BAKHIT C, 1991, BRAIN RES, V560, P76, DOI 10.1016/0006-8993(91)91217-O; BARRETT CP, 1984, EXP NEUROL, V84, P374, DOI 10.1016/0014-4886(84)90234-6; Berry M, 1983, Acta Neurochir Suppl (Wien), V32, P31; BIGNAMI A, 1977, J HISTOCHEM CYTOCHEM, V25, P466, DOI 10.1177/25.6.69656; BIGNAMI A, 1976, NEUROPATH APPL NEURO, V2, P99, DOI 10.1111/j.1365-2990.1976.tb00488.x; BILLINGSLEY ML, 1982, BRAIN RES, V247, P325, DOI 10.1016/0006-8993(82)91257-4; BOCHELEN D, 1992, NEUROSCIENCE, V51, P827, DOI 10.1016/0306-4522(92)90523-5; CADAY CG, 1990, DEV BRAIN RES, V52, P241, DOI 10.1016/0165-3806(90)90240-Y; CAVANAGH JB, 1970, J ANAT, V106, P471; CINTRA A, 1991, NEUROREPORT, V2, P597, DOI 10.1097/00001756-199110000-00011; CONDORELLI DF, 1989, METAB BRAIN DIS, V4, P41, DOI 10.1007/BF00999492; CONDORELLI DF, 1990, J NEUROSCI RES, V26, P251, DOI 10.1002/jnr.490260216; DUBOIS M, 1985, CELL TISSUE RES, V242, P17, DOI 10.1007/BF00225558; DUSART I, 1991, NEUROSCIENCE, V45, P541, DOI 10.1016/0306-4522(91)90269-T; ECLANCHER F, 1990, GLIA, V3, P502, DOI 10.1002/glia.440030609; ENG LF, 1982, ADV CELL NEUROBIOL, V3, P145; ERNFORS P, 1990, J NEUROSCI RES, V27, P10, DOI 10.1002/jnr.490270103; FINKLESTEIN SP, 1988, BRAIN RES, V460, P253, DOI 10.1016/0006-8993(88)90370-8; FRAUTSCHY SA, 1991, BRAIN RES, V553, P291, DOI 10.1016/0006-8993(91)90837-L; GAGE FH, 1988, EXP NEUROL, V102, P2, DOI 10.1016/0014-4886(88)90073-8; GALL C, 1979, J COMP NEUROL, V183, P539, DOI 10.1002/cne.901830306; GIULIAN D, 1985, SCIENCE, V228, P497, DOI 10.1126/science.3872478; GOSPODAROWICZ D, 1984, P NATL ACAD SCI-BIOL, V81, P6963, DOI 10.1073/pnas.81.22.6963; GRAEBER MB, 1988, NEUROSCI LETT, V85, P317, DOI 10.1016/0304-3940(88)90585-X; GROTHE C, 1991, J COMP NEUROL, V305, P328, DOI 10.1002/cne.903050213; HATTEN ME, 1991, GLIA, V4, P233, DOI 10.1002/glia.440040215; HERRERA DG, 1992, NEUROSCIENCE, V49, P781, DOI 10.1016/0306-4522(92)90356-7; HOMMES OR, 1967, J COMP NEUROL, V129, P269, DOI 10.1002/cne.901290304; HOZUMI I, 1990, BRAIN RES, V524, P64, DOI 10.1016/0006-8993(90)90492-T; HOZUMI I, 1990, BRAIN RES, V534, P291, DOI 10.1016/0006-8993(90)90142-X; KALMAN M, 1989, EXP BRAIN RES, V78, P147; KITAMURA T, 1980, PATHOL RES PRACT, V168, P301, DOI 10.1016/S0344-0338(80)80271-8; KITAMURA T, 1978, ACTA NEUROPATHOL, V44, P31, DOI 10.1007/BF00691636; KIYOTA Y, 1991, BRAIN RES, V545, P322, DOI 10.1016/0006-8993(91)91307-M; KONIGSMARK BW, 1965, J NEUROPATH EXP NEUR, V24, P142; KORR H, 1975, J COMP NEUROL, V160, P477, DOI 10.1002/cne.901600405; KOTHAVALE A, 1995, GLIA, V14, P216, DOI 10.1002/glia.440140307; KRAUSRUP.R, 1973, J COMP NEUROL, V148, P211, DOI 10.1002/cne.901480206; LABOURDETTE G, 1990, J CELL PHYSIOL, V144, P473, DOI 10.1002/jcp.1041440315; LATOV N, 1979, DEV BIOL, V72, P381, DOI 10.1016/0012-1606(79)90127-1; LINDHOLM D, 1987, NATURE, V330, P658, DOI 10.1038/330658a0; LINDHOLM D, 1992, J CELL BIOL, V117, P395, DOI 10.1083/jcb.117.2.395; LOGAN A, 1986, NEUROSCI LETT, V69, P162, DOI 10.1016/0304-3940(86)90596-3; LOGAN A, 1992, BRAIN RES, V587, P216, DOI 10.1016/0006-8993(92)91000-5; LUDWIN SK, 1985, LAB INVEST, V52, P20; MATSUYAMA A, 1992, BRAIN RES, V587, P49, DOI 10.1016/0006-8993(92)91427-G; MCCARTHY GF, 1988, J COMP NEUROL, V271, P589, DOI 10.1002/cne.902710409; MIYAKE T, 1988, BRAIN RES, V451, P133, DOI 10.1016/0006-8993(88)90757-3; MIYAKE T, 1989, BRAIN RES, V489, P31, DOI 10.1016/0006-8993(89)90005-X; MORI S, 1969, J COMP NEUROL, V137, P197, DOI 10.1002/cne.901370206; MORSHEAD CM, 1990, BRAIN RES, V535, P237, DOI 10.1016/0006-8993(90)91606-H; NIETOSAMPEDRO M, 1988, NEUROSCI LETT, V91, P276, DOI 10.1016/0304-3940(88)90693-3; NIETOSAMPEDRO M, 1985, BRAIN RES, V343, P320, DOI 10.1016/0006-8993(85)90750-4; NIETOSAMPEDRO M, 1987, J NEUROSCI RES, V17, P214, DOI 10.1002/jnr.490170303; PATERSON JA, 1973, J COMP NEUROL, V149, P83, DOI 10.1002/cne.901490106; PERSSON L, 1976, VIRCHOWS ARCH B, V22, P21; PETTMANN B, 1985, FEBS LETT, V189, P102, DOI 10.1016/0014-5793(85)80851-6; PETTMANN B, 1986, NEUROSCI LETT, V68, P175, DOI 10.1016/0304-3940(86)90137-0; PRESTA M, 1988, NEUROSCI LETT, V90, P608; RIVA MA, 1991, DEV BRAIN RES, V62, P45, DOI 10.1016/0165-3806(91)90188-O; ROSE G, 1976, BRAIN RES BULL, V1, P87, DOI 10.1016/0361-9230(76)90052-6; SHEHAB SAS, 1990, BRAIN RES, V518, P347, DOI 10.1016/0006-8993(90)90996-O; SKOFF RP, 1971, J COMP NEUROL, V141, P133, DOI 10.1002/cne.901410202; TAKAMIYA Y, 1988, DEV BRAIN RES, V38, P201, DOI 10.1016/0165-3806(88)90045-4; TAKAMIYA Y, 1986, BRAIN RES, V383, P305, DOI 10.1016/0006-8993(86)90029-6; TREHERNE JE, 1988, CELL TISSUE RES, V251, P339, DOI 10.1007/BF00215842; VIJAYAN VK, 1990, MOL CHEM NEUROPATHOL, V13, P107, DOI 10.1007/BF03159912; WESTERMARK B, 1976, BIOCHEM BIOPH RES CO, V69, P304, DOI 10.1016/0006-291X(76)90522-2; YAMAGUCHI F, 1991, NEUROSCI LETT, V128, P273, DOI 10.1016/0304-3940(91)90278-2	72	78	80	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	OCT 21	1996	737	1-2					201	214		10.1016/0006-8993(96)00732-9			14	Neurosciences	Neurosciences & Neurology	VR614	WOS:A1996VR61400024	8930367				2021-06-18	
J	GRANGER, CV; DIVAN, N; FIEDLER, RC				GRANGER, CV; DIVAN, N; FIEDLER, RC			FUNCTIONAL ASSESSMENT SCALES - A STUDY OF PERSONS AFTER TRAUMATIC BRAIN INJURY	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						FUNCTIONAL ASSESSMENT; TRAUMATIC BRAIN INJURY; FUNCTIONAL INDEPENDENCE MEASURE; DISABILITY		The purpose of this study was to investigate disability in persons after traumatic brain injury (TBI) by using combinations of functional assessment item, subscale, domain, and full-scale scores to predict (1) the need for assistance in performance of specific physical care tasks measured in minutes of help per day provided by another person in the home and (2) the subject's level of satisfaction with life in general. This study also sought to account for the amount of supervision that persons with TBI may require beyond that needed for physical care tasks. The Functional Independence Measure (FIM) contributed to prediction of subjects' physical care needs. A single-point change in total FIM score was equivalent to an average of about 5 min of help from another person per day. Satisfaction with life in general was predicted mainly by the depression subscale of the Brief Symptom inventory. However, this latter prediction was only true when subjects who required constant supervision were removed from analysis. Thus, the amount of supervision required by persons with TBI is an important variable to study in this population. Three categories of supervision were identified: constant (all of the time), periodic (daily or weekly), or not at all. The need for supervision and physical assistance from another person and a subject's satisfaction with life in general are important standards by which functional assessment instruments may be compared to reflect, in pragmatic terms, the impact of disability on the lives of individuals and on human and economic resources of the community.	SUNY BUFFALO,SCH MED & BIOMED SCI,DEPT REHABIL MED,BUFFALO,NY 14214	GRANGER, CV (corresponding author), SUNY BUFFALO,CTR FUNCT ASSESSMENT RES,232 PARKER HALL,SUNY S CAMPUS,BUFFALO,NY 14214, USA.						BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; COOPER K D, 1983, Neuroepidemiology, V2, P70, DOI 10.1159/000110512; DEROGATIS LR, 1983, PSYCHOL MED, V13, P595, DOI 10.1017/S0033291700048017; DEROGATIS LR, 1977, SCL90 CLIN PSYCH RE; DITTMAR SS, 1991, J HEALTHCARE TRAININ, V6, P16; GRANGER CV, 1993, ARCH PHYS MED REHAB, V74, P133; GRANGER CV, 1990, ARCH PHYS MED REHAB, V71, P870; GRANGER CV, 1993, AM J PHYS MED REHAB, V72, P84, DOI 10.1097/00002060-199304000-00005; HALL KM, J HEAD TRAUMA REHABI; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V48, P1121; MELLERUP E, 1981, ACTA NEUROL SCAND, V64, P130, DOI 10.1111/j.1600-0404.1981.tb05549.x; NELSON EC, 1990, MED CARE, V28, P1111, DOI 10.1097/00005650-199012000-00001; NIE NH, 1975, STATISTICAL PACKAGE; ROSENTHAL M, 1990, REHABILITATION ADULT; THICKMAN M, 1986, TOPICS ACUTE CARE TR, V1, P32; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Willer B, 1993, J HEAD TRAUMA REHAB, V3, P75, DOI DOI 10.1097/00001199-199308020-00009; WILLER B, 1990, NEUROBEHAVIOURAL SEQ, P19; WRIGHT BD, 1991, BIGSTEPS RASCH MODEL; 1985, MRD MINIMAL RECORD D; 1994, GUIDE USE UNIFORM DA	21	78	79	0	2	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0894-9115			AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	MAR-APR	1995	74	2					107	113					7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	QU579	WOS:A1995QU57900003	7710723				2021-06-18	
J	STABLUM, F; LEONARDI, G; MAZZOLDI, M; UMILTA, C; MORRA, S				STABLUM, F; LEONARDI, G; MAZZOLDI, M; UMILTA, C; MORRA, S			ATTENTION AND CONTROL DEFICITS FOLLOWING CLOSED-HEAD INJURY	CORTEX			English	Article							SUSTAINED ATTENTION; RECOVERY; TASK	This study was aimed at identifying the impaired attentional components in patients who had sustained a severe CHI several years before. A group of 14 CHI patients and a Control group (matched for age, sex and education) were tested. Experiment 1 used a dual-task paradigm (Umilta et al., 1992). The double task-single task difference was greater for the CHI group, indicating a specific damage at a central executive stage where decision are made and responses are coordinated. Experiment 2 used a task-shifting paradigm (Morra and Roncato, 1986). The cost of shifting from one task to the other was greater for the CHI group, but only in the Short Series Condition where a new task-program could be pre-activated. Experiment 3 studied visual selective attention using Navon paradigm (1977); in this case, there was no difference between patients and controls.	UNIV TRIESTE,DIPARTIMENTO PSICOL,TRIESTE,ITALY; OSPED GEN BOLZANO,SERV PSICOL,BOLZANO,ITALY; UNIV CAGLIARI,IST PSICOL,CAGLIARI,ITALY	STABLUM, F (corresponding author), UNIV PADUA,DIPARTIMENTO PSICOL GEN,PIAZZA CAPITANIATO 3,I-35139 PADUA,ITALY.		Leonardi, Giuseppe/F-9052-2018; Morra, Sergio/ABF-7487-2020; Leonardi, Giuseppe/S-4088-2019	MORRA, SERGIO/0000-0001-8537-181X; Leonardi, Giuseppe/0000-0003-0159-4851; Stablum, Franca/0000-0003-0123-5090			Allport A., 1989, FDN COGNITIVE SCI, P631; BIRREN JE, 1974, AM PSYCHOL, V29, P808, DOI 10.1037/h0037433; BOOKS N, 1987, BRAIN INJURY, V1, P5; BROUWER WH, 1985, CORTEX, V21, P111, DOI 10.1016/S0010-9452(85)80019-8; BUCHTEL HA, 1987, NEUROBEHAVIORAL RECO, P372; CERELLA J, 1991, J EXP PSYCHOL GEN, V120, P215, DOI 10.1037/0096-3445.120.2.215; CERELLA J, 1985, PSYCHOL BULL, V98, P67, DOI 10.1037/0033-2909.98.1.67; CREMONAMETEYARD SL, 1992, NEUROPSYCHOLOGIA, V30, P123, DOI 10.1016/0028-3932(92)90022-E; Davies D.R., 1982, PSYCHOL VIGILANCE; DELIS DC, 1986, NEUROPSYCHOLOGIA, V24, P205, DOI 10.1016/0028-3932(86)90053-9; DENKER SJ, 1958, ACTA PSYCHIATRICA S, V33, P122; DOYON J, 1991, NEUROPSYCHOLOGIA, V29, P343, DOI 10.1016/0028-3932(91)90024-3; Eisenberg, 1987, NEUROBEHAVIORAL RECO, P215; EWING R, 1980, Journal of Clinical Neuropsychology, V2, P147, DOI 10.1080/01688638008403789; FOOTE SL, 1987, ANNU REV NEUROSCI, V10, P67, DOI 10.1146/annurev.ne.10.030187.000435; GENTILINI M, 1989, MILD HEAD INJURY, P163; GOLDBERG E, 1989, CORTEX, V25, P687, DOI 10.1016/S0010-9452(89)80029-2; GRANT I, 1987, NEUROBEHAVIORAL RECO, P232; Gronwall D, 1989, MILD HEAD INJURY, P153; GRONWALL D, 1987, NEUROBEHAVIORAL RECO, P355; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; GRONWALL DMA, 1981, J NEUROL NEUROSUR PS, V44, P880; HARTLEY AA, 1991, HDB AGING COGNITION, P3; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; JENNETT B, 1975, J NEUROL NEUROSUR PS, V39, P647; JOHNSTON WA, 1986, ANNU REV PSYCHOL, V37, P43, DOI 10.1146/annurev.ps.37.020186.000355; KAIL R, 1991, ADV CHILD DEV BEHAV, P151; LAMB MR, 1988, NEUROPSYCHOLOGIA, V27, P471; LEVIN HS, 1988, BRAIN COGNITION, V7, P283, DOI 10.1016/0278-2626(88)90003-6; Luria A.R., 1980, HIGHER CORTICAL FUNC, V2nd; Miller E, 1970, Cortex, V6, P121; MORRA S, 1988, GIORNALE ITALIANO PS, V15, P101; MORRA S, 1986, 4 C DIV SIPS RIC BAS, P193; NAVON D, 1977, COGNITIVE PSYCHOL, V9, P353, DOI 10.1016/0010-0285(77)90012-3; NEWCOMBE F, 1979, HDB BEHAVIORAL NEURO, V2; NORMAN DA, 1986, CONSCIOUSNESS SELF R, P1, DOI DOI 10.1007/978-1-4757-0629-1_1; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; PARASURAMAN R, 1991, J CLIN EXP NEUROPSYC, V13, P789, DOI 10.1080/01688639108401090; Parasuraman R., 1984, VARIETIES ATTENTION; PASCUALLEONE J, 1987, INT J PSYCHOL, V22, P531, DOI 10.1080/00207598708246795; Plum F., 1980, DIAGNOSIS STUPOR COM, V3; POSNER MI, 1985, ATTENTION PERFORMANC, V11; Prigatano G., 1985, NEUROPSYCHOLOGICAL R; ROBERTSON LC, 1988, J NEUROSCI, V8, P3757; Salthouse T. A., 1985, THEORY COGNITIVE AGI; Shallice T., 1988, NEUROPSYCHOLOGY MENT; Spinnler H., 1987, ITALIAN J NEUROLOGIC; Stuss D. T, 1987, NEUROBEHAVIORAL RECO, V166; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; TEASDALE G, 1974, LANCET, V13, P81; UMILTA C, 1992, EUR J COGN PSYCHOL, V4, P21, DOI 10.1080/09541449208406241; Umilta C, 1988, HDB NEUROPSYCHOLOGY, P175; Umilta C., 1988, CONSCIOUSNESS CONT S, P334; vansZomeren AH, 1987, NEUROBEHAVIORAL RECO, P398; VANZOMEREN AH, 1984, CLOSED HEAD INJURY P, P75; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P41	58	78	78	0	8	MASSON DIVISIONE PERIODICI	MILAN	VIA STATUTO 2/4, 20121 MILAN, ITALY	0010-9452			CORTEX	Cortex	DEC	1994	30	4					603	618		10.1016/S0010-9452(13)80238-9			16	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	PY931	WOS:A1994PY93100004	7697987				2021-06-18	
J	WILLIAMS, IM; PICTON, A; FARRELL, A; MEAD, GE; MORTIMER, AJ; MCCOLLUM, CN				WILLIAMS, IM; PICTON, A; FARRELL, A; MEAD, GE; MORTIMER, AJ; MCCOLLUM, CN			LIGHT-REFLECTIVE CEREBRAL OXIMETRY AND JUGULAR BULB VENOUS OXYGEN-SATURATION DURING CAROTID ENDARTERECTOMY	BRITISH JOURNAL OF SURGERY			English	Article								A novel instrument using reflected near-infra-red light spectroscopy to measure cerebral oxygen saturation noninvasively was evaluated during carotid endarterectomy; cerebral perfusion was compared with jugular bulb venous oxygen saturation and transcranial Doppler ultrasonographic measurements. Initially, oximetry sensors with light source-detector separation distances of 10 and 27 mm were positioned over the frontal area, while a cannula positioned in the jugular bulb permitted sampling for jugular bulb venous oxygen saturation. To increase cerebral oxygen saturation sensitivity, modified sensors with light source-detector separation distances of 30 and 40 mm were relocated over the middle cerebral artery territory. The changes in cerebral and jugular bulb venous oxygen saturation, and in peak blood flow velocity before and 30 s after carotid clamping and declamping were recorded. The modified cerebral perfusion system achieved improved correlations between cerebral and jugular bulb venous oxygen saturation changes during carotid clamping and declamping (r=0.92, P<0.001). The correlation between change in cerebral oxygen saturation and the percentage change in peak flow velocity on both cross-clamping and declamping was equally strong (r=0.90, P<0.001). Near-infra-red cerebral spectroscopy reliably detects changes in cerebral oxygen saturation during carotid endarterectomy and may have wide applications in monitoring brain perfusion during neurosurgery and cardiopulmonary bypass surgery, and in closed head injury.	UNIV S MANCHESTER HOSP,DEPT ANAESTHET,MANCHESTER M20 8LR,LANCS,ENGLAND	WILLIAMS, IM (corresponding author), UNIV S MANCHESTER HOSP,DEPT SURG,NELL LANE,MANCHESTER M20 8LR,LANCS,ENGLAND.		Mead, Gillian E/F-7648-2011				ANDREWS PJD, 1991, BRIT J ANAESTH, V67, P553, DOI 10.1093/bja/67.5.553; CLAUSS RH, 1965, NEW ENGL J MED, V273, P1127, DOI 10.1056/NEJM196511182732104; LARSON CP, 1967, SURGERY, V62, P31; LYONS C, 1964, ANN SURG, V160, P561, DOI 10.1097/00000658-196410000-00001; MCCORMICK P, 1990, HOSPIMEDICA      JUL, P39; MCCORMICK PW, 1992, J NEUROSURG, V76, P315, DOI 10.3171/jns.1992.76.2.0315; MCCORMICK PW, 1991, CRIT CARE MED, V19, P89, DOI 10.1097/00003246-199101000-00020; MCCORMICK PW, 1991, STROKE, V22, P597; Mchedlishvili G., 1986, ARTERIAL BEHAVIOR BL, P56; SCHNEIDER PA, 1988, J VASC SURG, V7, P223, DOI 10.1067/mva.1988.avs0070223; WILLIAMS IM, 1994, BRIT J SURG, V81, P960, DOI 10.1002/bjs.1800810711; Williams PL, 1989, GRAYS ANATOMY, P793	12	78	85	0	0	BLACKWELL SCIENCE LTD	OXFORD	OSNEY MEAD, OXFORD, OXON, ENGLAND OX2 0EL	0007-1323			BRIT J SURG	Br. J. Surg.	SEP	1994	81	9					1291	1295		10.1002/bjs.1800810911			5	Surgery	Surgery	PE376	WOS:A1994PE37600009	7953390				2021-06-18	
J	TRELEAVEN, J; JULL, G; ATKINSON, L				TRELEAVEN, J; JULL, G; ATKINSON, L			CERVICAL MUSCULOSKELETAL DYSFUNCTION IN POST-CONCUSSIONAL HEADACHE	CEPHALALGIA			English	Article						CERVICAL SPINE DYSFUNCTION; PHYSICAL EXAMINATION; POST-CONCUSSIONAL HEADACHE	CERVICOGENIC HEADACHE; SPINE; PAIN	Persistent headache is a common symptom following a minor head injury or concussion, possibly related to simultaneous injury of structures of the cervical spine. This study measured aspects of cervical musculoskeletal function in a group of patients (IZ) with post-concussional headache (PCH) and in a normal control group. The PCH group was distinguished from the control group by the presence of painful upper cervical segmental joint dysfunction, less endurance in the neck flexor muscles and a higher incidence of moderately tight neck musculature. Active range of cervical motion and postural attitude were not significantly different between groups. As upper cervical joint dysfunction is a feature of cervicogenic causes of headache, the results of this study support the inclusion of a precise physical examination of the cervical region in differential diagnosis of patients suffering persistent headache following concussion.	PRINCESS ALEXANDRA HOSP,DEPT NEUROSURG,BRISBANE,QLD 4102,AUSTRALIA	TRELEAVEN, J (corresponding author), UNIV QUEENSLAND,DEPT PHYSIOTHERAPY,BRISBANE,QLD 4072,AUSTRALIA.		Treleaven, Julia M/F-8734-2010; Jull, Gwendolen/F-4233-2010; Treleaven, Julia/N-1379-2019	Treleaven, Julia M/0000-0002-6258-3972; Jull, Gwendolen/0000-0003-2670-1318; Treleaven, Julia/0000-0002-6258-3972			AMEVO B, 1992, SPINE, V7, P748; APPENZELLER O, 1987, WOLFFS HEADACHE OTHE, P291; BOGDUK N, 1986, J NEUROL NEUROSUR PS, V49, P775, DOI 10.1136/jnnp.49.7.775; Bogduk N, 1986, MODERN MANUAL THERAP, P289; Bourdillon JF, 1992, SPINAL MANIPULATION; BOVIM G, 1992, PAIN, V49, P315, DOI 10.1016/0304-3959(92)90237-6; BRAAF MM, 1975, J TRAUMA, V15, P441, DOI 10.1097/00005373-197505000-00011; DVORAK JU, 1988, SPINE, V7, P748; Edgar D, 1994, Aust J Physiother, V40, P99, DOI 10.1016/S0004-9514(14)60456-6; EHNI G, 1984, J NEUROSURG, V61, P961, DOI 10.3171/jns.1984.61.5.0961; Evjenth O, 1984, MUSCLE STRETCHING MA, VII; EVJENTH O, 1984, MUSCLE STRECTCHING M, V1; FREDRIKSEN TA, 1987, CEPHALALGIA, V7, P147, DOI 10.1046/j.1468-2982.1987.0702147.x; JAEGER B, 1989, CEPHALALGIA, V9, P157, DOI 10.1046/j.1468-2982.1989.0903157.x; Janda V, 1988, PHYS THERAPY CERVICA, P153; JENSEN OK, 1990, CEPHALALGIA, V10, P241, DOI 10.1046/j.1468-2982.1990.1005241.x; JENSEN OK, 1990, CEPHALALGIA, V109, P295; JULL G, 1988, MED J AUSTRALIA, V148, P233, DOI 10.5694/j.1326-5377.1988.tb99431.x; JULL G, 1994, PHYSICAL THERAPY CER; JULL GA, 1986, MODERN MANUAL THERAP, P315; JULL GA, 1986, MODERN MANUAL THERAP, P322; KELLY RE, 1986, HDB CLIN NEUROLOGY, V4, P383; KERR FW, 1961, EXP NEUROL, V4, P134, DOI 10.1016/0014-4886(61)90036-X; LIDVALL H F, 1974, Acta Neurologica Scandinavica Supplementum, V50, P1; MAITLAND G, 1986, VERTEBRAL MANIPULATI; MAYER ET, 1985, CEPHALALGIA, V5, P237, DOI 10.1046/j.1468-2982.1985.0504237.x; MILLER H, 1968, HDB CLIN NEUROLOGY, P178; PFAFFENRATH V, 1987, HEADACHE, V27, P495, DOI 10.1111/j.1526-4610.1987.hed2709495.x; SAKUTA M, 1989, CEPHALALGIA S10, V9, P119; SILVERMAN JL, 1991, ARCH PHYS MED REHAB, V72, P679; SJAASTAD O, 1983, CEPHALALGIA, V3, P249, DOI 10.1046/j.1468-2982.1983.0304249.x; SJAASTAD O, 1992, CLIN NEUROL NEUROSUR, V94, pS147; SJAASTAD O, 1990, HEADACHE, V30, P725, DOI 10.1111/j.1526-4610.1990.hed3011725.x; SPEED WG, 1989, HEADACHE, V29, P643, DOI 10.1111/j.1526-4610.1989.hed2910643.x; TREVOR-JONES R, 1964, S Afr Med J, V38, P392; TRUCCI S, 1986, ARCH PHYS MED REHAB, V67, P225; WATSON DH, 1993, CEPHALALGIA, V13, P272, DOI 10.1046/j.1468-2982.1993.1304272.x; WEISS H, 1991, HEADACHE, V7, P451; YOUDAS JW, 1991, PHYS THER, V71, P98, DOI 10.1093/ptj/71.2.98; 1988, CEPHALALGIA S7, V8, P10	40	78	79	0	12	SCANDINAVIAN UNIVERSITY PRESS	OSLO	PO BOX 2959 TOYEN, JOURNAL DIVISION CUSTOMER SERVICE, N-0608 OSLO, NORWAY	0333-1024			CEPHALALGIA	Cephalalgia	AUG	1994	14	4					273	279		10.1046/j.1468-2982.1994.1404273.x			7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	PC322	WOS:A1994PC32200008	7954756				2021-06-18	
J	LEE, KF; WAGNER, LK; LEE, YE; SUH, JH; LEE, SR				LEE, KF; WAGNER, LK; LEE, YE; SUH, JH; LEE, SR			THE IMPACT-ABSORBING EFFECTS OF FACIAL FRACTURES IN CLOSED-HEAD INJURIES - AN ANALYSIS OF 210 PATIENTS	JOURNAL OF NEUROSURGERY			English	Article									UNIV TEXAS,HLTH SCI CTR,DEPT OPHTHALMOL,HOUSTON,TX 77030; YONSEI UNIV,MED CTR,SEOUL,SOUTH KOREA; HANYANG UNIV,MED CTR,DEPT RADIOL,SEOUL,SOUTH KOREA	LEE, KF (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT RADIOL,6431 FANNIN,HOUSTON,TX 77030, USA.						BRANTZAWADZKI MN, 1982, AM J ROENTGENOL, V138, P477, DOI 10.2214/ajr.138.3.477; COOPER PR, 1979, NEUROSURGERY, V5, P566, DOI 10.1227/00006123-197911000-00004; CRUSE CW, 1980, J TRAUMA, V20, P551, DOI 10.1097/00005373-198007000-00003; DOLAN KD, 1978, SEMIN ROENTGENOL, V13, P37, DOI 10.1016/S0037-198X(78)80017-0; DOLAN KD, 1984, RADIOGRAPHICS, V4, P576; FRENCH BN, 1977, SURG NEUROL, V7, P171; GENTRY LR, 1983, AM J ROENTGENOL, V140, P533, DOI 10.2214/ajr.140.3.533; GENTRY LR, 1983, AM J ROENTGENOL, V140, P523, DOI 10.2214/ajr.140.3.523; Halazonetis J A, 1968, Br J Oral Surg, V6, P37, DOI 10.1016/S0007-117X(68)80025-3; HARRIS JH, 1984, CRC CR REV DIAGN IM, V21, P105; HUELKE DF, 1969, J ORAL SURG, V27, P451; JENNETT B, 1975, LANCET, V1, P480; KISHORE PRS, 1981, AM J ROENTGENOL, V137, P829, DOI 10.2214/ajr.137.4.829; KISHORE PRS, 1981, AM J NEURORADIOL, V2, P307; Le Fort R, 1972, PLAST RECONSTR SURG, V50, P600; LEE KF, 1984, PROGR CRITICAL CARE, V1, P80; LEE KF, 1984, PROGR CRITICAL CARE, V1, P97; LIPPER MH, 1985, AM J ROENTGENOL, V144, P483, DOI 10.2214/ajr.144.3.483; LUCE EA, 1979, PLAST RECONSTR SURG, V63, P26, DOI 10.1097/00006534-197901000-00005; MATRAS H, 1980, J MAXILLOFAC SURG, V8, P52, DOI 10.1016/S0301-0503(80)80072-5; MCCOY FJ, 1962, PLAST RECONSTR SURG, V29, P381; Murray J F, 1975, Clin Plast Surg, V2, P131; Nahum A M, 1975, Clin Plast Surg, V2, P59; NAKAMURA T, 1973, ARCH OTOLARYNGOL, V97, P288; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; SALEM JE, 1968, ORAL SURG ORAL MED O, V26, P390, DOI 10.1016/0030-4220(68)90412-X; SCHULTZ R C, 1970, Review of Surgery, V27, P394; SCHULTZ RC, 1977, SURG CLIN N AM, V57, P987; Swearingen John, 1965, TOLERANCES HUMAN FAC; TEASDALE G, 1974, LANCET, V2, P81	30	78	79	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.	APR	1987	66	4					542	547		10.3171/jns.1987.66.4.0542			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	G6498	WOS:A1987G649800009	3559719				2021-06-18	
J	Ashayeri, K; Jackson, EM; Huang, J; Brem, H; Gordon, CR				Ashayeri, Kimberly; Jackson, Eric M.; Huang, Judy; Brem, Henry; Gordon, Chad R.			Syndrome of the Trephined: A Systematic Review	NEUROSURGERY			English	Article						Craniofacial reconstruction; Cranioplasty; Decompressive craniectomy; Neurosurgery; Rehabilitation; Syndrome of the trephined; Systematic review	SINKING SKIN-FLAP; DECOMPRESSIVE CRANIECTOMY; PARADOXICAL HERNIATION; CRANIOPLASTY; SECONDARY; COMPLICATIONS; RECOVERY; BRAIN; IMPROVEMENT; HEMICRANIECTOMY	BACKGROUND: Syndrome of the trephined (SoT) is a rare, important complication of a craniectomy characterized by neurological dysfunction that improves with cranioplasty. Its varied symptoms include motor, cognitive, and language deficits. Its exact characterization appears suboptimal, with differing approaches of evaluation. Accordingly, this topic is in great need of further investigation. OBJECTIVE: To accurately describe SoT and explore methods of an objective diagnosis/evaluation. METHODS: Electronic searches of PubMed, MEDLINE, Web of Knowledge, and Psy-cINFO databases used the key words "syndrome of the trephined" and "sinking skin flap." Non-English-language and duplicate articles were eliminated. Title and abstract reviews were selected for relevance. Full-text reviews were selected for articles providing individual characteristics of SoT patients. RESULTS: This review identified that SoT most often occurs in male patients (60%) at 5.1 +/- 10.8 months after craniectomy for neurotrauma (38%). The average reported craniectomy is 88.3 +/- 34.4 cm(2) and usually exists with a "sunken skin flap" (93%). Symptoms most commonly include motor, cognitive, and language deficits (57%, 41%, 28%, respectively), with improvement after cranioplasty within 3.8 +/- 3.9 days. Functional independence with activities of daily living is achieved by 54.9% of patients after 2.9 +/- 3.4 months of rehabilitation. However, evaluation of SoT is inconsistent, with only 53% of reports documenting objective studies. DISCUSSION: SoT is a variable phenomenon associated with a prolonged time to cranioplasty. Due to current weaknesses in objectivity, we hypothesize that SoT is often underdiagnosed and recommend a multifaceted approach for consistent evaluation. CONCLUSION: SoT is a serious complication that lacks exact characterization and deserves future investigation. Improved understanding and recognition have important implications for early intervention and patient outcomes.	[Ashayeri, Kimberly] Albert Einstein Coll Med, New York, NY USA; [Jackson, Eric M.; Huang, Judy; Brem, Henry; Gordon, Chad R.] Johns Hopkins Univ, Sch Med, Dept Neurosurg, Baltimore, MD USA; [Gordon, Chad R.] Johns Hopkins Univ, Sch Med, Dept Plast & Reconstruct Surg, Baltimore, MD USA	Gordon, CR (corresponding author), Johns Hopkins Sch Med, Multidisciplinary Adult Cranioplasty Ctr, Dept Plast Surg & Neurosurg, 601 N Caroline St,8th Floor, Baltimore, MD 21287 USA.	cgordon@jhmi.edu		Huang, Judy/0000-0002-0675-1935			Abdou A, 2015, ANN PHYS REHABIL MED, V58, P183, DOI 10.1016/j.rehab.2014.11.003; Alibhai MK, 2013, INT J ORAL MAX SURG, V42, P559, DOI 10.1016/j.ijom.2013.01.001; Annan Mariam, 2014, Pract Neurol, V14, P266, DOI 10.1136/practneurol-2013-000704; Bijlenga P, 2007, J NEUROL NEUROSUR PS, V78, P430, DOI 10.1136/jnnp.2006.099242; Calvi AR, 2015, J HEAD TRAUMA REHAB, V30, pE111; Carota A, 2011, EUR NEUROL, V66, P227, DOI 10.1159/000331939; Cecchi PC, 2008, ACTA NEUROCHIR, V150, P409, DOI 10.1007/s00701-007-1459-8; Chalouhi N, 2012, NEUROLOGIST, V18, P423, DOI 10.1097/NRL.0b013e318272f7be; Chamilos C, 2012, BRAIN INJURY, V26, P617; Chieregato A, 2006, INTENS CARE MED, V32, P1668, DOI 10.1007/s00134-006-0302-7; Coelho F, 2014, NEUROPSYCH DIS TREAT, V10, P695, DOI 10.2147/NDT.S52875; Corallo F, 2014, FUNCT NEUROL, V29, P273, DOI 10.11138/FNeur/2014.29.4.273; Corallo F, 2015, TURK NEUROSURG, V25, P193, DOI 10.5137/1019-5149.JTN.10618-14.2; de Araujo AS, 2013, ARQ NEURO-PSIQUIAT, V71, P963, DOI 10.1590/0004-282X20130176; de Quintana-Schmidt C, 2011, REV NEUROLOGIA, V52, P661, DOI 10.33588/rn.5211.2010732; Delaunois E, 2015, ANN PHYS REHABIL MED, V58, P186, DOI 10.1016/j.rehab.2015.04.006; Di Stefano C, 2012, BRIT J NEUROSURG, V26, P827, DOI 10.3109/02688697.2012.692838; dos Santos JFA, 2011, J NEUROL, V258, P131; Dujovny M, 1997, SURG NEUROL, V47, P238, DOI 10.1016/S0090-3019(96)00013-4; Dujovny M, 1999, CRIT REV NEUROSURG, V9, P271, DOI 10.1007/s003290050143; Dujovny M, 1997, NEUROL RES, V19, P311, DOI 10.1080/01616412.1997.11740818; FODSTAD H, 1984, ACTA NEUROCHIR, V70, P21, DOI 10.1007/BF01406039; Francel P C, 1992, J Craniofac Surg, V3, P145, DOI 10.1097/00001665-199211000-00006; Gadde Judith, 2012, Del Med J, V84, P213; Gordon CR, 2014, OPER NEUROSURG, V10, P179, DOI 10.1227/NEU.0000000000000296; Gottlob Irene, 2002, Strabismus, V10, P271, DOI 10.1076/stra.10.4.271.13830; Grant FC, 1939, ANN SURG, V110, P488, DOI 10.1097/00000658-193910000-00002; GRANTHAM EG, 1948, J NEUROSURG, V5, P19, DOI 10.3171/jns.1948.5.1.0019; Han PY, 2008, J KOREAN NEUROSURG S, V43, P51, DOI 10.3340/jkns.2008.43.1.51; Higgins JPT, COCHRANE HDB SYSTEMA; Hodozuka A, 2000, NEUROL SURG TOKYO, V28, P245; Honeybul S, 2013, BRAIN INJURY, V27, P1732, DOI 10.3109/02699052.2013.830194; Honeybul S, 2013, BRIT J NEUROSURG, V27, P636, DOI 10.3109/02688697.2013.817532; Ibrahim Z, 2016, J CRANIOFAC SURG, V27, P229, DOI 10.1097/SCS.0000000000002289; Isago T, 2004, ANN PLAS SURG, V53, P288, DOI 10.1097/01.sap.0000106433.89983.72; Janzen C, 2012, BRAIN INJURY, V26, P101, DOI 10.3109/02699052.2011.635357; Jeyaraj P, 2015, J MAXILLOFAC ORAL SU, V14, P666, DOI 10.1007/s12663-014-0673-1; Joseph V, 2009, J NEUROSURG, V111, P650, DOI 10.3171/2009.3.JNS0984; Kamiya-Matsuoka C, 2014, BMJ CASE REP, V2014; Kemmling A, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-80; Krishnan P, 2015, J NEUROSCI RURAL PRA, V6, P225, DOI 10.4103/0976-3147.150281; Kumar GSS, 2004, NEUROL INDIA, V52, P504; Lim J, 2014, INT J STROKE, V9, P244; Lopez J, 2016, PLAST RECONSTR SURG, V137, p394E, DOI 10.1097/01.prs.0000475770.14396.1e; Narro-Donate JM, 2015, NEUROCIRUGIA, V26, P95, DOI 10.1016/j.neucir.2014.09.006; Ng D, 1997, J CLIN NEUROSCI, V4, P346, DOI 10.1016/S0967-5868(97)90103-X; Paredes I, 2015, NEUROCIRUGIA, V26, P115, DOI 10.1016/j.neucir.2014.10.001; Picard N, 2015, J NEUROSCI RURAL PRA, V6, P298, DOI 10.4103/0976-3147.154583; Picard NA, 2013, ACTA NEUROCHIR, V155, P2149, DOI 10.1007/s00701-013-1838-2; Romero FR, 2013, INT J SURG CASE REP, V4, P1007, DOI 10.1016/j.ijscr.2013.08.013; Sakamoto S, 2006, CLIN NEUROL NEUROSUR, V108, P583, DOI 10.1016/j.clineuro.2005.03.012; Sankey EW, 2016, PLAST RECONSTR SURG, V137, P595, DOI 10.1097/01.prs.0000475773.99148.ba; Sarov M, 2010, STROKE, V41, P560, DOI 10.1161/STROKEAHA.109.568543; Schiffer J, 1997, SURG NEUROL, V47, P231, DOI 10.1016/S0090-3019(96)00376-X; Schorl M, 2008, AKTUEL NEUROL, V35, P340, DOI 10.1055/s-2008-1067463; Sedney CL, 2015, J NEUROSCI RURAL PRA, V6, P438, DOI 10.4103/0976-3147.158778; Silva M, 2012, ARCH CLIN NEUROPSYCH, V27, P628; SNOW RB, 1991, NEUROSURGERY, V28, P880, DOI 10.1227/00006123-199106000-00016; Stiver SI, 2008, J NEUROSURG, V109, P245, DOI 10.3171/JNS/2008/109/8/0245; SUZUKI N, 1993, ACTA NEUROCHIR, V122, P49, DOI 10.1007/BF01446986; Voss HU, 2011, CLIN IMAG, V35, P253, DOI 10.1016/j.clinimag.2010.07.008; Wee HY, 2014, INT MED CASE REP J, V7, P67, DOI 10.2147/IMCRJ.S59410; Winkler PA, 2000, NEUROSURG FOCUS, V8, pe9, DOI DOI 10.3171/INS.2000.93.1.0053; YAMAURA A, 1977, Neurologia Medico-Chirurgica, V17, P43, DOI 10.2176/nmc.17pt1.43; Yang XF, 2008, ACTA NEUROCHIR, V150, P1241, DOI 10.1007/s00701-008-0145-9; Zhao JC, 2015, CLIN NEUROL NEUROSUR, V133, P6, DOI 10.1016/j.clineuro.2015.03.010	66	77	86	1	8	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	OCT	2016	79	4					525	533		10.1227/NEU.0000000000001366			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	DX5RK	WOS:000384439200026	27489166	Bronze			2021-06-18	
J	Meabon, JS; Huber, BR; Cross, DJ; Richards, TL; Minoshima, S; Pagulayan, KF; Li, G; Meeker, KD; Kraemer, BC; Petrie, EC; Raskind, MA; Peskind, ER; Cook, DG				Meabon, James S.; Huber, Bertrand R.; Cross, Donna J.; Richards, Todd L.; Minoshima, Satoshi; Pagulayan, Kathleen F.; Li, Ge; Meeker, Kole D.; Kraemer, Brian C.; Petrie, Eric C.; Raskind, Murray A.; Peskind, Elaine R.; Cook, David G.			Repetitive blast exposure in mice and combat veterans causes persistent cerebellar dysfunction	SCIENCE TRANSLATIONAL MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY; CEREBROSPINAL-FLUID; INDUCED NEUROTRAUMA; GLUCOSE-METABOLISM; COGNITIVE FUNCTION; HEAD-INJURY; DIFFUSION; CONCUSSION; INVOLVEMENT; DISEASE	m Blast exposure can cause mild traumatic brain injury (TBI) in mice and other mammals. However, there are important gaps in our understanding of the neuropathology underlying repetitive blast exposure in animal models compared to the neuroimaging abnormalities observed in blast-exposed veterans. Moreover, how an increase in the number of blast exposures affects neuroimaging endpoints in blast-exposed humans is not well understood. We asked whether there is a dose-response relationship between the number of blast-related mild TBIs and uptake of F-18-fluorodeoxyglucose (FDG), a commonly used indicator of neuronal activity, in the brains of blast-exposed veterans with mild TBI. We found that the number of blast exposures correlated with FDG uptake in the cerebellum of veterans. In mice, blast exposure produced microlesions in the blood-brain barrier (BBB) predominantly in the ventral cerebellum. Purkinje cells associated with these BBB microlesions displayed plasma membrane disruptions and aberrant expression of phosphorylated tau protein. Purkinje cell loss was most pronounced in the ventral cerebellar lobules, suggesting that early-stage breakdown of BBB integrity may be an important factor driving long-term brain changes. Blast exposure caused reactive gliosis in mouse cerebellum, particularly in the deep cerebellar nuclei. Diffusion tensor imaging tractography of the cerebellum of blast-exposed veterans revealed that mean diffusivity correlated negatively with the number of blast-related mild TBIs. Together, these results argue that the cerebellum is vulnerable to repetitive mild TBI in both mice and humans.	[Meabon, James S.; Pagulayan, Kathleen F.; Li, Ge; Petrie, Eric C.; Raskind, Murray A.; Peskind, Elaine R.] VA Puget Sound Hlth Care Syst VA Puget Sound, Mental Illness Res Educ & Clin Ctr, Seattle, WA 98108 USA; [Meabon, James S.; Pagulayan, Kathleen F.; Li, Ge; Petrie, Eric C.; Raskind, Murray A.; Peskind, Elaine R.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA; [Huber, Bertrand R.] Boston Univ, Sch Med, VA Jama Plain, Dept Neurol, Jamaica Plain, MA 02130 USA; [Cross, Donna J.; Richards, Todd L.] Univ Washington, Dept Radiol, Seattle, WA 98195 USA; [Minoshima, Satoshi] Univ Utah, Dept Radiol, Salt Lake City, UT 84132 USA; [Li, Ge; Meeker, Kole D.; Kraemer, Brian C.; Cook, David G.] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA; [Kraemer, Brian C.; Cook, David G.] Univ Washington, Dept Med, Seattle, WA 98195 USA; [Cook, David G.] Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA	Cook, DG (corresponding author), VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA.; Cook, DG (corresponding author), Univ Washington, Dept Med, Seattle, WA 98195 USA.; Cook, DG (corresponding author), Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA.	dgcook@u.washington.edu	Pagulayan, Kati/AAR-9225-2020	Cross, Donna/0000-0003-1918-2214; Minoshima, Satoshi/0000-0002-0043-3047; Petrie, Eric/0000-0003-1188-6321	Department of Veterans Affairs Office of Research and Development Medical Research ServiceUS Department of Veterans Affairs; VA Rehabilitation Research & Development Service; University of Washington Friends of Alzheimer's Research; University of Washington Royalty Research FundUniversity of Washington; Northwest Network Mental Illness Research, Education and Clinical Center; Office of Academic Affiliations Advanced Fellowship Program Mental Illness Research and Treatment, Department of Veterans Affairs; VA Clinical Science R&D Career Development Award Program [CX00516]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM007750] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [T32AG000258] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01RX000521, I01BX002311, I01RX001612, IK2CX000516, I01BX002619] Funding Source: NIH RePORTER	This work was supported by the Department of Veterans Affairs Office of Research and Development Medical Research Service (D.G.C. and B.C.K.); VA Rehabilitation Research & Development Service (E.R.P.); University of Washington Friends of Alzheimer's Research (D.G.C. and E.R.P.); University of Washington Royalty Research Fund (D.G.C.); Northwest Network Mental Illness Research, Education and Clinical Center (J.S.M., B.R.H., K.F.P., E.C.P., M.A.R., and E.R.P.); Office of Academic Affiliations Advanced Fellowship Program Mental Illness Research and Treatment, Department of Veterans Affairs (B.R.H.); NIH T32 AG000258 (J.S.M.); and VA Clinical Science R&D Career Development Award Program # CX00516 (K.F.P.). Author contributions: J.S.M. and B.R.H. conducted blast procedures, biochemistry experiments, and microscopy. K.D.M. conducted biochemistry experiments. J.S.M., B.R.H., D.J.C., T.L.R., S.M., G.L., E.C.P., M.A.R., E.R.P., and D.G.C. contributed to study design. J.S.M., D.J.C., E.R.P., G.L., E.R.P., M.A.R., and D.G.C. performed data analysis and data interpretation. J.S.M., D.J.C., T.L.R., K.F.P., G.L., B.C.K., E.C.P., M.A.R., E.R.P., and D.G.C. drafted the manuscript and/or edited it critically for important intellectual content.	Agosta F, 2010, AM J NEURORADIOL, V31, P1457, DOI 10.3174/ajnr.A2105; Ahlers Stephen Thomas, 2012, Front Neurol, V3, P32, DOI 10.3389/fneur.2012.00032; Ahmed F, 2012, ELECTROPHORESIS, V33, P3705, DOI 10.1002/elps.201200299; Anderova M, 2011, J CEREBR BLOOD F MET, V31, P894, DOI 10.1038/jcbfm.2010.168; Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; Baugh CM, 2014, CURR TREAT OPTION NE, V16, DOI 10.1007/s11940-014-0306-5; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI 10.1089/neu.2009-0898; Bayir H, 2007, J NEUROCHEM, V101, P168, DOI 10.1111/j.1471-4159.2006.04353.x; Bazarian JJ, 2013, J HEAD TRAUMA REHAB, V28, P1, DOI 10.1097/HTR.0b013e318256d3d3; Bell RS, 2009, J TRAUMA, V66, pS104, DOI 10.1097/TA.0b013e31819d88c8; Bernard JA, 2014, CEREB CORTEX, V24, P2151, DOI 10.1093/cercor/bht065; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Buckner RL, 2013, NEURON, V80, P807, DOI 10.1016/j.neuron.2013.10.044; Bush K, 1998, ARCH INTERN MED, V158, P1789, DOI 10.1001/archinte.158.16.1789; Caverzasi E, 2014, NEUROIMAGE-CLIN, V4, P426, DOI 10.1016/j.nicl.2014.01.011; Caverzasi E, 2014, BRAIN, V137, P3339, DOI 10.1093/brain/awu298; Cernak I, 1999, J TRAUMA, V47, P96, DOI 10.1097/00005373-199907000-00021; Cernak I, 1996, J TRAUMA, V40, pS100, DOI 10.1097/00005373-199603001-00023; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak I, 2001, BRAIN INJURY, V15, P593, DOI 10.1080/02699050010009559; Cernak I, 1997, Vojnosanit Pregl, V54, P91; Cernak I, 2000, MAGNESIUM RES, V13, P29; Cernak I, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00128; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Coughlin JM, 2015, NEUROBIOL DIS, V74, P58, DOI 10.1016/j.nbd.2014.10.019; De Gasperi Rita, 2012, Front Neurol, V3, P177, DOI 10.3389/fneur.2012.00177; DUNHAM NW, 1957, J AM PHARM ASSOC, V46, P208, DOI 10.1002/jps.3030460322; Erlanger DM, 1999, CLIN NEUROPSYCHOL, V13, P193, DOI 10.1076/clin.13.2.193.1963; Farkas O, 2006, J NEUROSCI, V26, P3130, DOI 10.1523/JNEUROSCI.5119-05.2006; Field A., 2005, DISCOVERING STAT USI, P777; Fischer BL, 2014, J NEUROTRAUM, V31, P169, DOI 10.1089/neu.2013.2877; Friess SH, 2009, J NEUROTRAUM, V26, P1111, DOI [10.1089/neu.2008.0845, 10.1089/neu.2008-0845]; Garman RH, 2011, J NEUROTRAUM, V28, P947, DOI 10.1089/neu.2010.1540; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Huber BR, 2013, J ALZHEIMERS DIS, V37, P309, DOI 10.3233/JAD-130182; Jayadev S, 2013, GENET MED, V15, P673, DOI 10.1038/gim.2013.28; JONES BJ, 1968, J PHARM PHARMACOL, V20, P302, DOI 10.1111/j.2042-7158.1968.tb09743.x; Jorge RE, 2012, AM J PSYCHIAT, V169, P1284, DOI 10.1176/appi.ajp.2012.12050600; Kamnaksh A, 2014, SCI REP-UK, V4, DOI 10.1038/srep04809; Karr JE, 2014, NEUROPSYCHOL REV, V24, P428, DOI 10.1007/s11065-014-9271-8; Kim EJ, 2004, NAT REV NEUROSCI, V5, P771, DOI 10.1038/nrn1517; Koliatsos VE, 2011, J NEUROPATH EXP NEUR, V70, P399, DOI 10.1097/NEN.0b013e3182189f06; Krave U, 2011, J NEUROTRAUM, V28, P57, DOI 10.1089/neu.2010.1431; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; LAMPERT PW, 1984, JAMA-J AM MED ASSOC, V251, P2676, DOI 10.1001/jama.251.20.2676; Liu W, 2013, NMR BIOMED, V26, P651, DOI 10.1002/nbm.2910; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Lu J, 2012, J NEUROTRAUM, V29, P1434, DOI 10.1089/neu.2010.1591; Mac Donald C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055823; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Mayorga MA, 1997, TOXICOLOGY, V121, P17, DOI 10.1016/S0300-483X(97)03652-4; McKee AC, 2014, ALZHEIMERS DEMENT, V10, pS242, DOI 10.1016/j.jalz.2014.04.003; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; Meabon JS, 2012, J HISTOCHEM CYTOCHEM, V60, P139, DOI 10.1369/0022155411430095; Mendez MF, 2013, NEUROREHABILITATION, V32, P397, DOI 10.3233/NRE-130861; Mendez MF, 2013, BRAIN INJURY, V27, P10, DOI 10.3109/02699052.2012.722252; MINOSHIMA S, 1995, J NUCL MED, V36, P1238; MINOSHIMA S, 1994, J NUCL MED, V35, P949; MINOSHIMA S, 1994, J NUCL MED, V35, P1528; MINOSHIMA S, 1995, J COMPUT ASSIST TOMO, V19, P541, DOI 10.1097/00004728-199507000-00006; Morey RA, 2013, HUM BRAIN MAPP, V34, P2986, DOI 10.1002/hbm.22117; Moss WC, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.108702; MURTHY JMK, 1979, J NEUROSURG, V50, P260, DOI 10.3171/jns.1979.50.2.0260; Nonaka H, 2002, ACTA NEUROPATHOL, V104, P608, DOI 10.1007/s00401-002-0592-y; Oguz I, 2014, FRONT NEUROINFORM, V8, DOI 10.3389/fninf.2014.00004; Oishi K., 2011, MRI ATLAS HUMAN WHIT; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; Peskind ER, 2011, NEUROIMAGE, V54, pS76, DOI 10.1016/j.neuroimage.2010.04.008; Petrie EC, 2014, J NEUROTRAUM, V31, P425, DOI [10.1089/NEU.2013.2952, 10.1089/neu.2013.2952]; Petrie EC, 2009, ARCH NEUROL-CHICAGO, V66, P632, DOI 10.1001/archneurol.2009.59; Pierpaoli C, 2001, NEUROIMAGE, V13, P1174, DOI 10.1006/nimg.2001.0765; Rostami Elham, 2012, Front Neurol, V3, P115, DOI 10.3389/fneur.2012.00115; Ryan NS, 2013, BRAIN, V136, P1399, DOI 10.1093/brain/awt065; Saljo A, 2000, J NEUROTRAUM, V17, P719, DOI 10.1089/089771500415454; Sarna JR, 2003, PROG NEUROBIOL, V70, P473, DOI 10.1016/S0301-0082(03)00114-X; Song SK, 2002, NEUROIMAGE, V17, P1429, DOI 10.1006/nimg.2002.1267; Stocker RPJ, 2014, NEUROIMAGE, V99, P207, DOI 10.1016/j.neuroimage.2014.05.067; Stoodley CJ, 2012, NEUROIMAGE, V59, P1560, DOI 10.1016/j.neuroimage.2011.08.065; Stoodley CJ, 2012, CEREBELLUM, V11, P352, DOI 10.1007/s12311-011-0260-7; Stoodley CJ, 2010, CORTEX, V46, P831, DOI 10.1016/j.cortex.2009.11.008; Taber KH, 2015, J HEAD TRAUMA REHAB, V30, pE15, DOI 10.1097/HTR.0000000000000030; Talairach J., 1988, COPLANAR STEREOTAXIC; Taylor PA, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3118765; THACH WT, 1972, BRAIN RES, V40, P89, DOI 10.1016/0006-8993(72)90112-6; Tonra James R, 2002, Cerebellum, V1, P57, DOI 10.1080/147342202753203096; Van Overwalle F, 2014, NEUROIMAGE, V86, P554, DOI 10.1016/j.neuroimage.2013.09.033; Viano DC, 2005, NEUROSURGERY, V57, P891, DOI 10.1227/01.NEU.0000186950.54075.3B; Wang Y, 2011, J NEUROTRAUM, V28, P2171, DOI 10.1089/neu.2011.1990; Wang Y, 2011, BRAIN, V134, P3587, DOI 10.1093/brain/awr307; Warden DL, 2009, NEUROIMAGE, V47, pT152, DOI 10.1016/j.neuroimage.2009.01.060; Winer BJ, 1991, STAT PRINCIPLES EXPT, P1057; WORSLEY KJ, 1992, J CEREBR BLOOD F MET, V12, P900, DOI 10.1038/jcbfm.1992.127; Yang ZH, 2014, J CEREBR BLOOD F MET, V34, P1444, DOI 10.1038/jcbfm.2014.105; Yeh PH, 2014, HUM BRAIN MAPP, V35, P2652, DOI 10.1002/hbm.22358	99	77	77	1	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	1946-6234	1946-6242		SCI TRANSL MED	Sci. Transl. Med.	JAN 13	2016	8	321								10.1126/scitranslmed.aaa9585			15	Cell Biology; Medicine, Research & Experimental	Cell Biology; Research & Experimental Medicine	DB4VD	WOS:000368510800004	26764157	Bronze			2021-06-18	
J	McCuen, E; Svaldi, D; Breedlove, K; Kraz, N; Cummiskey, B; Breedlove, EL; Traver, J; Desmond, KF; Hannemann, RE; Zanath, E; Guerra, A; Leverenz, L; Talavage, TM; Nauman, EA				McCuen, Emily; Svaldi, Diana; Breedlove, Katherine; Kraz, Nicole; Cummiskey, Brian; Breedlove, Evan L.; Traver, Jessica; Desmond, Katherine F.; Hannemann, Robert E.; Zanath, Erica; Guerra, Alexandra; Leverenz, Larry; Talavage, Thomas M.; Nauman, Eric A.			Collegiate women's soccer players suffer greater cumulative head impacts than their high school counterparts	JOURNAL OF BIOMECHANICS			English	Article						Traumatic brain Injury; TBI; Subconcussive head impacts	DEFAULT MODE NETWORK; FOOTBALL PLAYERS; BRAIN-INJURY; CONCUSSIONS; FMRI; IMPAIRMENT; DEFICITS; ATHLETE; BALL	Soccer is the source of the highest concussion rates among female athletes and is associated with neurological deficits at many levels of play. Despite its importance to our understanding of head trauma in female athletes, little is known about the number and magnitude of head impacts experienced by female soccer players. Head impacts experienced by high school and collegiate athletes were quantified using xPatch sensors (X2 Biosystems) affixed behind the right ear of each player. The average peak translational acceleration (PTA) sustained by players at th high school level was significantly lower than that of the collegiate players, but the average peak angular accelerations (PAA) were not significantly different. Given that the collegiate players took many more impacts throughout the season, their mean cumulative exposure to translational (cPTA) and angular accelerations (cPAA) were significantly higher than those of the high school players. Additional research is required to determine whether the differences in cumulative exposure are responsible for the elevated risk of concussion in collegiate soccer players or if there are additional risk factors. (C) 2015 Elsevier Ltd. All rights reserved.	[McCuen, Emily; Svaldi, Diana; Hannemann, Robert E.; Zanath, Erica; Guerra, Alexandra; Talavage, Thomas M.; Nauman, Eric A.] Purdue Univ, Weldon Sch Biomed Engn, W Lafayette, IN 47907 USA; [Breedlove, Katherine; Leverenz, Larry] Purdue Univ, Dept Hlth & Kinesiol, W Lafayette, IN 47907 USA; [Kraz, Nicole] Purdue Univ, Dept Athlet, W Lafayette, IN 47907 USA; [Cummiskey, Brian; Breedlove, Evan L.; Traver, Jessica; Desmond, Katherine F.; Nauman, Eric A.] Purdue Univ, Sch Mech Engn, W Lafayette, IN 47907 USA; [Hannemann, Robert E.] Purdue Univ, Sch Chem Engn, W Lafayette, IN 47907 USA; [Talavage, Thomas M.] Purdue Univ, Sch Elect & Comp Engn, W Lafayette, IN 47907 USA; [Nauman, Eric A.] Purdue Univ, Dept Basic Med Sci, W Lafayette, IN 47907 USA	Nauman, EA (corresponding author), 585 Purdue Mall West, W Lafayette, IN 47907 USA.	enauman@purdue.edu			Indiana State Department of Health Spinal Cord and Brain Injury Research Fund; Indiana Clinical and Translational Sciences Institute; Purdue's Office of the Vice President for Research	The authors would like to thank Dr. Gregory G. Tamer, Jr., for assistance in data collection. This work was supported in part by grants from the Indiana State Department of Health Spinal Cord and Brain Injury Research Fund, a Core Facility Grant from the Indiana Clinical and Translational Sciences Institute, and Purdue's Office of the Vice President for Research.	Abbas K, 2015, BRAIN CONNECT, V5, P91, DOI 10.1089/brain.2014.0279; Abbas K, 2015, DEV NEUROPSYCHOL, V40, P51, DOI 10.1080/87565641.2014.990455; Babbs C F, 2001, ScientificWorldJournal, V1, P281; Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Breedlove KM., 2014, ATHLETIC TRAIN SPORT, V6, P119, DOI [10.3928/19425864-20140507-02, DOI 10.3928/19425864-20140507-02]; Broglio SP, 2012, ANN BIOMED ENG, V40, P37, DOI 10.1007/s10439-011-0396-0; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Chun IY, 2015, DEV NEUROPSYCHOL, V40, P92, DOI 10.1080/87565641.2015.1020945; Covassin T, 2003, APPL NEUROPSYCHOL, V10, P12, DOI 10.1207/S15324826AN1001_3; Covassin T, 2003, J ATHL TRAINING, V38, P238; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Higgins M.J., 2009, SPORTS ENG TECHNOL, V223, P117; Johnson B, 2014, J NEUROTRAUM, V31, P1907, DOI 10.1089/neu.2014.3415; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Nauman EA, 2015, DEV NEUROPSYCHOL, V40, P85, DOI 10.1080/87565641.2015.1016161; Naunheim RS, 2003, MED SCI SPORT EXER, V35, P1406, DOI 10.1249/01.MSS.0000078933.84527.AE; Naunheim RS, 2003, ACAD EMERG MED, V10, P85, DOI 10.1197/aemj.10.1.85; O'Kane JW, 2014, JAMA PEDIATR, V168, P258, DOI 10.1001/jamapediatrics.2013.4518; Poole VN, 2015, DEV NEUROPSYCHOL, V40, P12, DOI 10.1080/87565641.2014.984810; Poole VN, 2014, DEV NEUROPSYCHOL, V39, P459, DOI 10.1080/87565641.2014.940619; Robinson ME, 2015, DEV NEUROPSYCHOL, V40, P74, DOI 10.1080/87565641.2015.1012204; Shenk TE, 2015, DEV NEUROPSYCHOL, V40, P63, DOI 10.1080/87565641.2015.1014088; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Witol AD, 2003, ARCH CLIN NEUROPSYCH, V18, P397, DOI 10.1016/S0887-6177(02)00151-8	28	77	77	1	13	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9290	1873-2380		J BIOMECH	J. Biomech.	OCT 15	2015	48	13					3720	3723		10.1016/j.jbiomech.2015.08.003			4	Biophysics; Engineering, Biomedical	Biophysics; Engineering	CX0DS	WOS:000365367700022	26329462				2021-06-18	
J	Koerte, IK; Lin, AP; Muehlmann, M; Merugumala, S; Liao, HJ; Starr, T; Kaufmann, D; Mayinger, M; Steffinger, D; Fisch, B; Karch, S; Heinen, F; Ertl-Wagner, B; Reiser, M; Stern, RA; Zafonte, R; Shenton, ME				Koerte, Inga K.; Lin, Alexander P.; Muehlmann, Marc; Merugumala, Sai; Liao, Huijun; Starr, Tyler; Kaufmann, David; Mayinger, Michael; Steffinger, Denise; Fisch, Barbara; Karch, Susanne; Heinen, Florian; Ertl-Wagner, Birgit; Reiser, Maximilian; Stern, Robert A.; Zafonte, Ross; Shenton, Martha E.			Altered Neurochemistry in Former Professional Soccer Players without a History of Concussion	JOURNAL OF NEUROTRAUMA			English	Article						brain metabolism; repetitive subconcussive brain trauma; MR spectroscopy; soccer	TRAUMATIC BRAIN-INJURY; SPECTROSCOPY; MYOINOSITOL; IMPAIRMENT; DEFICITS; TRAIL; RISK	Soccer is played by more than 250 million people worldwide. Repeatedly heading the ball may place soccer players at high risk for repetitive subconcussive head impacts (RSHI). This study evaluates the long-term effects of RSHI on neurochemistry in athletes without a history of clinically diagnosed concussion, but with a high exposure to RSHI. Eleven former professional soccer players (mean age 52.0 +/- 6.8 years) and a comparison cohort of 14 age- and gender-matched, former non-contact sport athletes (mean age 46.9 +/- 7.9 years) underwent 3T magnetic resonance spectroscopy (MRS) and neurocognitive evaluation. In the soccer players a significant increase was observed in both choline (Cho), a membrane marker, and myo-inositol (ml), a marker of glial activation, compared with control athletes. Additionally, ml and glutathione (GSH) were significantly correlated with lifetime estimate of RSHI within the soccer group. There was no significant difference in neurocognitive tests between groups. Results of this study suggest an association between RSHI in soccer players and MRS markers of neuroinflammation, suggesting that even subconcussive head impacts affect the neurochemistry of the brain and may precede neurocognitive changes. Future studies will need to determine the role of neuroinflammation in RSHI and the effect on neurocognitive function.	[Koerte, Inga K.; Lin, Alexander P.; Muehlmann, Marc; Mayinger, Michael; Shenton, Martha E.] Brigham & Womens Hosp, Psychiat Neuroimaging Lab, Boston, MA 02215 USA; [Lin, Alexander P.; Merugumala, Sai; Liao, Huijun; Starr, Tyler; Shenton, Martha E.] Brigham & Womens Hosp, Dept Radiol, Boston, MA 02215 USA; [Shenton, Martha E.] Brigham & Womens Hosp, Dept Psychiat, Boston, MA 02215 USA; [Shenton, Martha E.] Harvard Univ, Sch Med, Boston, MA USA; [Koerte, Inga K.; Muehlmann, Marc; Kaufmann, David; Mayinger, Michael; Steffinger, Denise; Fisch, Barbara; Ertl-Wagner, Birgit; Reiser, Maximilian] Univ Munich, Dr von Hauner Childrens Hospital, Inst Clin Radiol, Munich, Germany; [Koerte, Inga K.; Muehlmann, Marc] Univ Munich, Dr von Hauner Childrens Hospital, Dept Child & Adolescent Psychiat Psychosomat & Ps, Munich, Germany; [Karch, Susanne] Univ Munich, Dept Psychiat, Dr von Hauner Childrens Hospital, D-80539 Munich, Germany; [Heinen, Florian] Univ Munich, Dr von Hauner Childrens Hospital, Dept Pediat Neurol, Munich, Germany; [Kaufmann, David] Charite, Dept Radiol, Berlin, Germany; [Stern, Robert A.] Boston Univ, Sch Med, Dept Neurol, Boston Univ Alzheimers Dis Ctr, Boston, MA 02118 USA; [Stern, Robert A.] Boston Univ, Sch Med, Boston Univ Alzheimers Dis Ctr, Dept Neurosurg, Boston, MA 02118 USA; [Stern, Robert A.] Boston Univ, Sch Med, Dept Anat & Neurobiol, Boston Univ Alzheimers Dis Ctr, Boston, MA 02118 USA; [Zafonte, Ross] Harvard Univ, Brigham & Womens Hosp, Massachusetts Gen Hosp, Spaulding Rehabil Hosp,Dept Phys Med & Rehabil,Sc, Boston, MA 02115 USA; [Shenton, Martha E.] VA Boston Healthcare Syst, Boston, MA USA	Koerte, IK (corresponding author), Brigham & Womens Hosp, Psychiat Neuroimaging Lab, 1249 Boylston St, Boston, MA 02215 USA.	ikoerte@bwh.harvard.edu	Ertl-Wagner, Birgit/AAD-5708-2020; Shenton, Martha/V-8780-2019; Heinen, Florian/B-6594-2015; , Bob/ABA-8507-2020	Heinen, Florian/0000-0002-3872-6136; Ertl-Wagner, Birgit/0000-0002-7896-7049; Stern, Robert/0000-0002-5008-077X	Else Kroner-Fresenius-Stiftung, Germany; Department of DefenseUnited States Department of Defense [W81XWH-10-1-0835, W81XWH-07-CC-CSDoD]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01-NS078337]; VA Merit AwardUS Department of Veterans Affairs; Petraeic Legate Foundation, Germany; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS078337] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG013846] Funding Source: NIH RePORTER	This study was supported by the Else Kroner-Fresenius-Stiftung, Germany (I.K.). This work was also partially funded by grants from the Department of Defense (W81XWH-10-1-0835: A.P.L.; W81XWH-07-CC-CSDoD: R.Z., M.E.S.), the National Institutes of Health (R01-NS078337: A.P.L., M.E.S., R.A.S.) and a VA Merit Award (M.E.S.). Michael Mayinger was supported by the Petraeic Legate Foundation, Germany.	Ashendorf L, 2008, ARCH CLIN NEUROPSYCH, V23, P129, DOI 10.1016/j.acn.2007.11.005; Ashwal S, 2004, PEDIATR RES, V56, P630, DOI 10.1203/01.PDR.0000139928.60530.7D; Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Bell DR, 2011, SPORTS HEALTH, V3, P287, DOI 10.1177/1941738111403122; Bjorneboe J, 2014, BRIT J SPORT MED, V48, P774, DOI 10.1136/bjsports-2012-091856; Blanksby B A, 1988, Br J Sports Med, V22, P57; Bonnelle V, 2011, J NEUROSCI, V31, P13442, DOI 10.1523/JNEUROSCI.1163-11.2011; Bowie CR, 2006, NAT PROTOC, V1, P2277, DOI 10.1038/nprot.2006.390; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; Chamard E, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12305; Chio A, 2009, AMYOTROPH LATERAL SC, V10, P205, DOI 10.1080/17482960902721634; DANIELS J, 1992, MED SCI SPORT EXER, V24, P483; Duffy SL, 2014, ALZHEIMERS DEMENT, V10, P67, DOI 10.1016/j.jalz.2013.01.005; EKBLOM B, 1986, SPORTS MED, V3, P50, DOI 10.2165/00007256-198603010-00005; Garnett MR, 2001, J NEUROTRAUM, V18, P231, DOI 10.1089/08977150151070838; Hanlon EM, 2012, MED SCI SPORT EXER, V44, P1102, DOI 10.1249/MSS.0b013e3182444d7d; Johnson B, 2012, J NEUROTRAUM, V29, P2297, DOI 10.1089/neu.2011.2294; Kierans AS, 2014, NEUROLOGY, V82, P521, DOI 10.1212/WNL.0000000000000105; Koerte IK, 2012, JAMA-J AM MED ASSOC, V308, P1859, DOI 10.1001/jama.2012.13735; Kreisl WC, 2013, BRAIN, V136, P2228, DOI 10.1093/brain/awt145; Lin AP, 2012, BRAIN IMAGING BEHAV, V6, P208, DOI 10.1007/s11682-012-9181-4; Lin Alexander, 2005, NeuroRx, V2, P197, DOI 10.1602/neurorx.2.2.197; Lin A, 2012, SEMIN NEUROL, V32, P432, DOI 10.1055/s-0032-1331814; Lin AP, 2015, ALZHEIMERS RES THER, V7, DOI 10.1186/s13195-015-0094-5; Lipton ML, 2013, RADIOLOGY, V268, P850, DOI 10.1148/radiol.13130545; Maher ME, 2014, BRAIN INJURY, V28, P271, DOI 10.3109/02699052.2013.865269; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Nakashima T, 2007, AM J NEURORADIOL, V28, P236; Naunheim RS, 2003, MED SCI SPORT EXER, V35, P1406, DOI 10.1249/01.MSS.0000078933.84527.AE; O'Kane JW, 2014, JAMA PEDIATR, V168, P258, DOI 10.1001/jamapediatrics.2013.4518; Poole VN, 2014, DEV NEUROPSYCHOL, V39, P459, DOI 10.1080/87565641.2014.940619; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; Rutherford A, 2009, J CLIN EXP NEUROPSYC, V31, P664, DOI 10.1080/13803390802484755; Shin MS, 2006, NAT PROTOC, V1, P892, DOI 10.1038/nprot.2006.115; Straume-Naesheim TM, 2005, BRIT J SPORT MED, V39, pI70, DOI 10.1136/bjsm.2005.019646; Suchomel A., 2010, INT J TABLE TENNIS S, V6, P79; Tonnessen E, 2013, INT J SPORT PHYSIOL, V8, P323, DOI 10.1123/ijspp.8.3.323; Tremblay S, 2013, CEREB CORTEX, V23, P1159, DOI 10.1093/cercor/bhs102; Tysvaer A, 1981, Br J Sports Med, V15, P163; TYSVAER AT, 1989, ACTA NEUROL SCAND, V80, P151, DOI 10.1111/j.1600-0404.1989.tb03858.x; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200	42	77	77	0	38	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP 1	2015	32	17					1287	1293		10.1089/neu.2014.3715			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CP0KP	WOS:000359564500001	25843317	Green Published			2021-06-18	
J	Ledig, C; Heckemann, RA; Hammers, A; Lopez, JC; Newcombe, VFJ; Makropoulos, A; Lotjonen, J; Menon, DK; Rueckert, D				Ledig, Christian; Heckemann, Rolf A.; Hammers, Alexander; Lopez, Juan Carlos; Newcombe, Virginia F. J.; Makropoulos, Antonios; Loetjoenen, Jyrki; Menon, David K.; Rueckert, Daniel			Robust whole-brain segmentation: Application to traumatic brain injury	MEDICAL IMAGE ANALYSIS			English	Article						Traumatic brain injury; Magnetic resonance imaging; Multi-atlas segmentation; Brain image segmentation; Expectation-maximisation	MULTI-ATLAS SEGMENTATION; COST FUNCTION MASKING; MR-IMAGES; AXONAL INJURY; VENTRICLE SEGMENTATION; NONRIGID REGISTRATION; DIFFUSION-TENSOR; LABEL FUSION; CLASSIFICATION; HIPPOCAMPUS	We propose a framework for the robust and fully-automatic segmentation of magnetic resonance (MR) brain images called "Multi-Atlas-Label Propagation with Expectation-Maximisation based refinement" (MALP-EM). The presented approach is based on a robust registration approach (MAPER), highly performant label fusion (joint label fusion) and intensity-based label refinement using EM. We further adapt this framework to be applicable for the segmentation of brain images with gross changes in anatomy. We propose to account for consistent registration errors by relaxing anatomical priors obtained by multi-atlas propagation and a weighting scheme to locally combine anatomical atlas priors and intensity-refined posterior probabilities. The method is evaluated on a benchmark dataset used in a recent MICCAI segmentation challenge. In this context we show that MALP-EM is competitive for the segmentation of MR brain scans of healthy adults when compared to state-of-the-art automatic labelling techniques. To demonstrate the versatility of the proposed approach, we employed MALP-EM to segment 125 MR brain images into 134 regions from subjects who had sustained traumatic brain injury (TBI). We employ a protocol to assess segmentation quality if no manual reference labels are available. Based on this protocol, three independent, blinded raters confirmed on 13 MR brain scans with pathology that MALP-EM is superior to established label fusion techniques. We visually confirm the robustness of our segmentation approach on the full cohort and investigate the potential of derived symmetry-based imaging biomarkers that correlate with and predict clinically relevant variables in TBI such as the Marshall Classification (MC) or Glasgow Outcome Score (GOS). Specifically, we show that we are able to stratify TBI patients with favourable outcomes from non-favourable outcomes with 64.7% accuracy using acute-phase MR images and 66.8% accuracy using follow-up MR images. Furthermore, we are able to differentiate subjects with the presence of a mass lesion or midline shift from those with diffuse brain injury with 76.0% accuracy. The thalamus, putamen, pallidum and hippocampus are particularly affected. Their involvement predicts TBI disease progression. (C) 2014 The Authors. Published by Elsevier B.V.	[Ledig, Christian; Makropoulos, Antonios; Rueckert, Daniel] Univ London Imperial Coll Sci Technol & Med, Dept Comp, Biomed Image Anal Grp, London SW7 2AZ, England; [Heckemann, Rolf A.; Hammers, Alexander] CERMEP, Neurodis Fdn, Lyon, France; [Heckemann, Rolf A.; Hammers, Alexander] Univ London Imperial Coll Sci Technol & Med, Fac Med, Div Brain Sci, London, England; [Hammers, Alexander] St Thomas Hosp, Kings Coll London, Div Imaging Sci & Biomed Engn, PET Ctr, London, England; [Heckemann, Rolf A.; Lopez, Juan Carlos] Univ Gothenburg, MedTech West, Inst Neurosci & Physiol, Gothenburg, Sweden; [Loetjoenen, Jyrki] VTT Tech Res Ctr Finland, Knowledge Intens Serv, Tampere, Finland; [Newcombe, Virginia F. J.; Menon, David K.] Univ Cambridge, Addenbrookes Hosp, Univ Div Anaesthesia, Cambridge CB2 2QQ, England	Ledig, C (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Comp, 180 Queens Gate, London SW7 2AZ, England.	christian.ledig@imperial.ac.uk	Heckemann, Rolf Andreas/H-9022-2019; Hammers, Alexander/D-9982-2015	Heckemann, Rolf Andreas/0000-0003-3582-3683; Hammers, Alexander/0000-0001-9530-4848; Ledig, Christian/0000-0003-4862-3138; Newcombe, Virginia/0000-0001-6044-9035	7th Framework Programme by the European Commission; National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) based at Imperial College Healthcare NHS Trust; Imperial College London; Department of Health via the NIHR comprehensive BRC award; King's College London; Kings College Hospital NHS Foundation Trust; Medical Research Council (UK) Program Grant; UK National Institute of Health Research Biomedical Research Centre at CambridgeNational Institute for Health Research (NIHR); Technology Platform - UK Department of Health; EPSRC PathwaysUK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC); Health Foundation/Academy of Medical Sciences Clinician Scientist Fellowship; NIHR Senior Investigator Award;  [G9439390 ID 658831]; Academy of Medical Sciences (AMS)Academy of Medical Sciences (AMS) [AMS-CSF4-Newcombe] Funding Source: researchfish; Engineering and Physical Sciences Research CouncilUK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC) [EP/I000445/1, EP/K503733/1] Funding Source: researchfish; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390, G0001354, G0001354B, G1000183B] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0512-10090] Funding Source: researchfish	This work was partially funded under the 7th Framework Programme by the European Commission (http://cordis.europa.eu/ist/, TBIcare: http://www.tbicare.eu/, last accessed: 8 December 2014). The research was further supported by the National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) based at Imperial College Healthcare NHS Trust and Imperial College London. AH is supported by the Department of Health via the NIHR comprehensive BRC award to Guy's 82 St Thomas' NHS Foundation Trust in partnership with King's College London and Kings College Hospital NHS Foundation Trust. This work was further supported by a Medical Research Council (UK) Program Grant (Acute brain injury: heterogeneity of mechanisms, therapeutic targets and outcome effects [G9439390 ID 658831), the UK National Institute of Health Research Biomedical Research Centre at Cambridge, the Technology Platform funding provided by the UK Department of Health and an EPSRC Pathways to Impact award. VFJN is supported by a Health Foundation/Academy of Medical Sciences Clinician Scientist Fellowship. DKM is supported by an NIHR Senior Investigator Award. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. The funders had no role in study design, data collection and analyses, decision to publish, or preparation of the manuscript.	Aljabar P, 2009, NEUROIMAGE, V46, P726, DOI 10.1016/j.neuroimage.2009.02.018; Andersen SM, 2010, NEUROIMAGE, V53, P78, DOI 10.1016/j.neuroimage.2010.06.003; Artaechevarria X, 2009, IEEE T MED IMAGING, V28, P1266, DOI 10.1109/TMI.2009.2014372; Asman AJ, 2013, MED PHYS, V40, DOI 10.1118/1.4794478; Asman AJ, 2013, MED IMAGE ANAL, V17, P194, DOI 10.1016/j.media.2012.10.002; Asman AJ, 2011, IEEE T MED IMAGING, V30, P1779, DOI 10.1109/TMI.2011.2147795; Avants BB, 2008, MED IMAGE ANAL, V12, P26, DOI 10.1016/j.media.2007.06.004; Bauer S, 2013, PHYS MED BIOL, V58, pR97, DOI 10.1088/0031-9155/58/13/R97; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Bonilha L, 2014, FRONT PSYCHIATRY, V4, DOI 10.3389/fpsyt.2013.00186; Brett M, 2001, NEUROIMAGE, V14, P486, DOI 10.1006/nimg.2001.0845; Brodersen Kay H, 2010, Proceedings of the 2010 20th International Conference on Pattern Recognition (ICPR 2010), P3121, DOI 10.1109/ICPR.2010.764; Cabezas M, 2011, COMPUT METH PROG BIO, V104, pE158, DOI 10.1016/j.cmpb.2011.07.015; Cardoso M.J., 2013, P MICCAI CHALL WORKS, P23; Cardoso MJ, 2013, MED IMAGE ANAL, V17, P671, DOI 10.1016/j.media.2013.02.006; Cardoso MJ, 2013, NEUROIMAGE, V65, P97, DOI 10.1016/j.neuroimage.2012.08.009; Cardoso MJ, 2011, NEUROIMAGE, V56, P1386, DOI 10.1016/j.neuroimage.2011.02.013; Chitphakdithai N, 2010, LECT NOTES COMPUT SC, V6361, P367; Coupe P, 2011, NEUROIMAGE, V54, P940, DOI 10.1016/j.neuroimage.2010.09.018; DICE LR, 1945, ECOLOGY, V26, P297, DOI 10.2307/1932409; Ding K, 2008, J NEUROTRAUM, V25, P1433, DOI 10.1089/neu.2008.0683; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; GALABURDA AM, 1987, NEUROPSYCHOLOGIA, V25, P853, DOI 10.1016/0028-3932(87)90091-1; Hammers A, 2003, HUM BRAIN MAPP, V19, P224, DOI 10.1002/hbm.10123; Heckemann RA, 2006, NEUROIMAGE, V33, P115, DOI 10.1016/j.neuroimage.2006.05.061; Heckemann RA, 2011, NEUROIMAGE, V56, P2024, DOI 10.1016/j.neuroimage.2011.03.014; Heckemann RA, 2010, NEUROIMAGE, V51, P221, DOI 10.1016/j.neuroimage.2010.01.072; Irimia A, 2012, NEUROIMAGE-CLIN, V1, P1, DOI 10.1016/j.nicl.2012.08.002; Irimia A, 2011, J NEUROTRAUM, V28, P2287, DOI 10.1089/neu.2011.1920; JENNETT B, 1975, LANCET, V1, P480; Kempton MJ, 2011, NEUROIMAGE, V58, P1051, DOI 10.1016/j.neuroimage.2011.06.080; Landman B. A., 2012, MICCAI 2012 WORKSH M; Landman BA, 2012, IEEE T MED IMAGING, V31, P512, DOI 10.1109/TMI.2011.2172215; Ledig C, 2014, PROC CVPR IEEE, P3065, DOI 10.1109/CVPR.2014.392; Ledig C, 2012, 2012 9TH IEEE INTERNATIONAL SYMPOSIUM ON BIOMEDICAL IMAGING (ISBI), P896, DOI 10.1109/ISBI.2012.6235693; Liu XX, 2014, LECT NOTES COMPUT SC, V8675, P97, DOI 10.1007/978-3-319-10443-0_13; Lotjonen JMP, 2010, NEUROIMAGE, V49, P2352, DOI 10.1016/j.neuroimage.2009.10.026; Marcus DS, 2007, J COGNITIVE NEUROSCI, V19, P1498, DOI 10.1162/jocn.2007.19.9.1498; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Modat M, 2010, COMPUT METH PROG BIO, V98, P278, DOI 10.1016/j.cmpb.2009.09.002; Niethammer M, 2011, LECT NOTES COMPUT SC, V6892, P639, DOI 10.1007/978-3-642-23629-7_78; Nugent AC, 2013, HUM BRAIN MAPP, V34, P2313, DOI 10.1002/hbm.22068; Periaswamy S, 2006, MED IMAGE ANAL, V10, P452, DOI 10.1016/j.media.2005.03.006; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Rao A, 2014, I S BIOMED IMAGING, P333, DOI 10.1109/ISBI.2014.6867876; Ribbens A, 2014, IEEE T MED IMAGING, V33, P201, DOI 10.1109/TMI.2013.2270114; Rohlfing T, 2004, IEEE T MED IMAGING, V23, P983, DOI 10.1109/TMI.2004.830803; Rohlfing T, 2004, NEUROIMAGE, V21, P1428, DOI 10.1016/j.neuroimage.2003.11.010; Rousseau F, 2011, IEEE T MED IMAGING, V30, P1852, DOI 10.1109/TMI.2011.2156806; Rueckert D, 1999, IEEE T MED IMAGING, V18, P712, DOI 10.1109/42.796284; Sabuncu MR, 2010, IEEE T MED IMAGING, V29, P1714, DOI 10.1109/TMI.2010.2050897; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; Stefanescu R, 2004, LECT NOTES COMPUT SC, V3216, P704; Strangman GE, 2010, FRONT HUM NEUROSCI, V4, DOI 10.3389/fnhum.2010.00182; TEASDALE G, 1974, LANCET, V2, P81; Tong T, 2013, NEUROIMAGE, V76, P11, DOI 10.1016/j.neuroimage.2013.02.069; Tustison NJ, 2010, IEEE T MED IMAGING, V29, P1310, DOI 10.1109/TMI.2010.2046908; van der Lijn F, 2008, NEUROIMAGE, V43, P708, DOI 10.1016/j.neuroimage.2008.07.058; Van Leemput K, 1999, IEEE T MED IMAGING, V18, P897, DOI 10.1109/42.811270; Wang HZ, 2013, IEEE T PATTERN ANAL, V35, P611, DOI 10.1109/TPAMI.2012.143; Wang HZ, 2011, NEUROIMAGE, V55, P968, DOI 10.1016/j.neuroimage.2011.01.006; Wang L, 2014, NEUROIMAGE, V84, P141, DOI 10.1016/j.neuroimage.2013.08.008; Warfield SK, 2004, IEEE T MED IMAGING, V23, P903, DOI 10.1109/TMI.2004.828354; Warner MA, 2010, J NEUROTRAUM, V27, P2121, DOI 10.1089/neu.2010.1429; Warner MA, 2010, ARCH NEUROL-CHICAGO, V67, P1336, DOI 10.1001/archneurol.2010.149; Wells WM, 1996, IEEE T MED IMAGING, V15, P429, DOI 10.1109/42.511747; Wolz R, 2010, NEUROIMAGE, V52, P109, DOI 10.1016/j.neuroimage.2010.04.006; Wolz R, 2010, NEUROIMAGE, V49, P1316, DOI 10.1016/j.neuroimage.2009.09.069; Zacharaki EI, 2009, NEUROIMAGE, V46, P762, DOI 10.1016/j.neuroimage.2009.01.051; ZHANG J, 1992, IEEE T SIGNAL PROCES, V40, P2570, DOI 10.1109/78.157297; Zhang YY, 2001, IEEE T MED IMAGING, V20, P45, DOI 10.1109/42.906424	74	77	77	0	17	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1361-8415	1361-8423		MED IMAGE ANAL	Med. Image Anal.	APR	2015	21	1					40	58		10.1016/j.media.2014.12.003			19	Computer Science, Artificial Intelligence; Computer Science, Interdisciplinary Applications; Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging	Computer Science; Engineering; Radiology, Nuclear Medicine & Medical Imaging	CD0PU	WOS:000350777200004	25596765	Green Published, Other Gold			2021-06-18	
J	Yin, TC; Britt, JK; De Jesus-Cortes, H; Lu, Y; Genova, RM; Khan, MZ; Voorhees, JR; Shao, JQ; Katzman, AC; Huntington, PJ; Wassink, C; McDaniel, L; Newell, EA; Dutca, LM; Naidoo, J; Cui, HX; Bassuk, AG; Harper, MM; McKnight, SL; Ready, JM; Pieper, AA				Yin, Terry C.; Britt, Jeremiah K.; De Jesus-Cortes, Hector; Lu, Yuan; Genova, Rachel M.; Khan, Michael Z.; Voorhees, Jaymie R.; Shao, Jianqiang; Katzman, Aaron C.; Huntington, Paula J.; Wassink, Cassie; McDaniel, Latisha; Newell, Elizabeth A.; Dutca, Laura M.; Naidoo, Jacinth; Cui, Huxing; Bassuk, Alexander G.; Harper, Matthew M.; McKnight, Steven L.; Ready, Joseph M.; Pieper, Andrew A.			P7C3 Neuroprotective Chemicals Block Axonal Degeneration and Preserve Function after Traumatic Brain Injury	CELL REPORTS			English	Article							MOUSE MODEL; AMINOPROPYL CARBAZOLES; EFFICACY; BIOSYNTHESIS; DISCOVERY; ISCHEMIA	The P7C3 class of neuroprotective aminopropyl carbazoles has been shown to block neuronal cell death in models of neurodegeneration. We now show that P7C3 molecules additionally preserve axonal integrity after injury, before neuronal cell death occurs, in a rodent model of blast-mediated traumatic brain injury (TBI). This protective quality may be linked to the ability of P7C3 molecules to activate nicotinamide phosphoribosyltransferase, the rate-limiting enzyme in nicotinamide adenine dinucleotide salvage. Initiation of daily treatment with our recently reported lead agent, P7C3-S243, 1 day after blast-mediated TBI blocks axonal degeneration and preserves normal synaptic activity, learning and memory, and motor coordination in mice. We additionally report persistent neurologic deficits and acquisition of an anxiety-like phenotype in untreated animals 8 months after blast exposure. Optimized variants of P7C3 thus offer hope for identifying neuroprotective agents for conditions involving axonal damage, neuronal cell death, or both, such as occurs in TBI.	[Yin, Terry C.; Britt, Jeremiah K.; De Jesus-Cortes, Hector; Lu, Yuan; Genova, Rachel M.; Khan, Michael Z.; Voorhees, Jaymie R.; Katzman, Aaron C.; Wassink, Cassie; McDaniel, Latisha; Cui, Huxing; Pieper, Andrew A.] Univ Iowa, Dept Psychiat, Iowa City, IA 52242 USA; [Newell, Elizabeth A.; Bassuk, Alexander G.] Univ Iowa, Dept Pediat, Iowa City, IA 52242 USA; [Bassuk, Alexander G.; Pieper, Andrew A.] Univ Iowa, Dept Neurol, Iowa City, IA 52242 USA; [Bassuk, Alexander G.] Univ Iowa, Dept Pediat Neurol, Iowa City, IA 52242 USA; [Voorhees, Jaymie R.; Pieper, Andrew A.] Univ Iowa, Interdisciplinary Grad Program Human Toxicol, Iowa City, IA 52242 USA; [Shao, Jianqiang] Univ Iowa, Cent Microscopy Facil, Iowa City, IA 52242 USA; [Voorhees, Jaymie R.; Dutca, Laura M.; Harper, Matthew M.; Pieper, Andrew A.] Univ Iowa, Dept Ophthalmol & Visual Sci, Dept Vet Affairs Ctr Prevent & Treatment Visual L, Iowa City, IA 52242 USA; [Huntington, Paula J.; Naidoo, Jacinth; McKnight, Steven L.; Ready, Joseph M.] Univ Texas SW Med Ctr Dallas, Dept Biochem, Dallas, TX 75390 USA; [De Jesus-Cortes, Hector] Univ Texas SW Med Ctr Dallas, Grad Program Neurosci, Dallas, TX 75390 USA	Pieper, AA (corresponding author), Univ Iowa, Dept Psychiat, 200 Hawkins Dr, Iowa City, IA 52242 USA.	andrew-pieper@uiowa.edu	De Jesus-Cortes, Hector/ABC-9091-2020; Pieper, Andrew A/R-5552-2016; Britt, Jeremiah/L-9441-2015	De Jesus-Cortes, Hector/0000-0001-6983-6963; Britt, Jeremiah/0000-0003-4010-662X; Newell, Elizabeth/0000-0002-1476-033X; Cui, Huxing/0000-0002-8627-8534; Harper, Matthew/0000-0003-3395-2406; Pieper, Andrew/0000-0001-6299-6577; Bassuk, Alexander/0000-0002-4067-2157	NIMHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [5-RO1-MH087986]; Welch FoundationThe Welch Foundation [I-1612]; Edward N. and Della C. Thome Memorial Foundation; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1R21MH100086-01, 5R01NS064159-05]; Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development Service (Center for the Treatment and Prevention of Visual Loss, RR&D Career Development Award and Merit Award) [RX000427]; National Science Foundation Graduate Research FellowshipNational Science Foundation (NSF); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM007337] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R21MH100086, R01MH087986] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS064159] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01RX000427] Funding Source: NIH RePORTER	We thank Mike Welsh and Randy Kardon for advice and encouragement and Noelle Williams for pharmacologic studies. Medical illustration was provided by Teresa A. Ruggle (Department of Internal Medicine Design Center, University of Iowa Hospitals and Clinics) and Victor Powell (Medical Media, Iowa City VA Health Care System). The work was funded by a grant awarded to A.A.P. and S.L.M. from the NIMH (5-RO1-MH087986); grant awards from the Welch Foundation (I-1612) and the Edward N. and Della C. Thome Memorial Foundation to J.M.R.; unrestricted funds provided to S.L.M. by an anonymous donor; NIH grants 1R21MH100086-01 and 5R01NS064159-05 to A.G.B.; the Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development Service (Center for the Treatment and Prevention of Visual Loss, RR&D Career Development Award [to M.M.H.] and Merit Award RX000427); and a National Science Foundation Graduate Research Fellowship to H.D.J.-C.	Araki T, 2004, SCIENCE, V305, P1010, DOI 10.1126/science.1098014; Blaya MO, 2014, J NEUROTRAUM, V31, P476, DOI [10.1089/NEU.2013.3135, 10.1089/neu.2013.3135]; Clausen F, 2009, EUR J NEUROSCI, V30, P385, DOI 10.1111/j.1460-9568.2009.06820.x; Coleman PD, 2003, NEUROBIOL AGING, V24, P1023, DOI 10.1016/j.neurobiolaging.2003.09.001; De Jesus-Cortes H, 2012, P NATL ACAD SCI USA, V109, P17010, DOI 10.1073/pnas.1213956109; Fischer LR, 2004, EXP NEUROL, V185, P232, DOI 10.1016/j.expneurol.2003.10.004; Goldstein L.E., 2012, SCI TRANSL MED, V4; Gunawardena S, 2005, ARCH NEUROL-CHICAGO, V62, P46, DOI 10.1001/archneur.62.1.46; Hawkins BT, 2006, J NEUROSCI METH, V151, P262, DOI 10.1016/j.jneumeth.2005.08.006; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Li H, 2001, J NEUROSCI, V21, P8473; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; LUNN ER, 1989, EUR J NEUROSCI, V1, P27, DOI 10.1111/j.1460-9568.1989.tb00771.x; Luo LQ, 2005, ANNU REV NEUROSCI, V28, P127, DOI 10.1146/annurev.neuro.28.061604.135632; Luong TN, 2011, JOVE-J VIS EXP, DOI 10.3791/2376; MacMillan KS, 2011, J AM CHEM SOC, V133, P1428, DOI 10.1021/ja108211m; Magnuson J, 2012, CURR NEUROL NEUROSCI, V12, P570, DOI 10.1007/s11910-012-0303-6; Mohan K, 2013, INVEST OPHTH VIS SCI, V54, P3440, DOI 10.1167/iovs.12-11522; Naidoo J, 2014, J MED CHEM, V57, P3746, DOI 10.1021/jm401919s; Naidoo J, 2013, TETRAHEDRON LETT, V54, P4429, DOI 10.1016/j.tetlet.2013.06.024; Nakagawa A, 2011, J NEUROTRAUM, V28, P1101, DOI 10.1089/neu.2010.1442; Northington FJ, 2001, NEUROBIOL DIS, V8, P207, DOI 10.1006/nbdi.2000.0371; Pieper A.A., 2014, CHEM SOC REV; Pieper AA, 2010, CELL, V142, P39, DOI 10.1016/j.cell.2010.06.018; PREISS J, 1958, J BIOL CHEM, V233, P488; Raff MC, 2002, SCIENCE, V296, P868, DOI 10.1126/science.1068613; Sasaki Y, 2006, J NEUROSCI, V26, P8484, DOI 10.1523/JNEUROSCI.2320-06.2006; Shively S, 2012, ARCH NEUROL-CHICAGO, V69, P1245, DOI 10.1001/archneurol.2011.3747; Tesla R, 2012, P NATL ACAD SCI USA, V109, P17016, DOI 10.1073/pnas.1213960109; UYAMA O, 1988, J CEREBR BLOOD F MET, V8, P282, DOI 10.1038/jcbfm.1988.59; Walker A.K., 2014, MOL PSYCHIAT; Wang G, 2014, CELL, V158, P1324, DOI 10.1016/j.cell.2014.07.040; Wang J, 2005, J CELL BIOL, V170, P349, DOI 10.1083/jcb.200504028; Wolf SJ, 2009, LANCET, V374, P405, DOI 10.1016/S0140-6736(09)60257-9; Xu P, 2013, P NATL ACAD SCI USA, V110, P10759, DOI 10.1073/pnas.1308195110; Yan TT, 2010, NEUROCHEM INT, V56, P529, DOI 10.1016/j.neuint.2010.01.013	36	77	77	0	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	2211-1247			CELL REP	Cell Reports	SEP 25	2014	8	6					1731	1740		10.1016/j.celrep.2014.08.030			10	Cell Biology	Cell Biology	AR9BZ	WOS:000343867400015	25220467	DOAJ Gold, Green Accepted			2021-06-18	
J	James, LM; Strom, TQ; Leskela, J				James, Lisa M.; Strom, Thad Q.; Leskela, Jennie			Risk-Taking Behaviors and Impulsivity Among Veterans With and Without PTSD and Mild TBI	MILITARY MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH PROBLEMS; PERSONALITY QUESTIONNAIRE; MAJOR DEPRESSION; SYMPTOM SEVERITY; WAR VETERANS; SUICIDE RISK; PREVALENCE; SOLDIERS	Military personnel commonly experience post-traumatic stress disorder (PTSD) and mild traumatic brain injury (mTBI), both of which are associated with premature mortality. The present study examined two factors that may play a role in premature mortality-impulsivity and risk-taking behaviors-in a sample of 234 veterans screening positive for PTSD, mTBI, PTSD + mTBI, and controls. Analyses of variance demonstrated that veterans with PTSD, regardless of mTBI status, reported engaging in more frequent risky behaviors and reported a greater tendency to engage in impulsive behaviors when in a negative affective state. They also reported more premilitary delinquent behaviors and more suicide-related behaviors than controls. The present study highlights associations between impulsivity, risk-taking behaviors, and PTSD, and suggests continuity across the lifespan in terms of a predisposition to engage in impulsive and/or risky behaviors. Thorough evaluation of impulsivity and potentially risky behaviors is important in clinical settings to guide interventions and reduce the mortality and public health impact of high-risk behaviors in veterans.	[James, Lisa M.; Strom, Thad Q.; Leskela, Jennie] Minneapolis Vet Affairs Hlth Care Syst, Minneapolis, MN 55417 USA; [James, Lisa M.; Strom, Thad Q.; Leskela, Jennie] Univ Minnesota, Dept Psychiat, Minneapolis, MN 55455 USA; [James, Lisa M.; Strom, Thad Q.; Leskela, Jennie] Univ Minnesota, Ctr Cognit Sci, Minneapolis, MN 55455 USA	James, LM (corresponding author), Minneapolis Vet Affairs Hlth Care Syst, One Vet Dr, Minneapolis, MN 55417 USA.			Strom, Thad/0000-0001-6743-9999			Alexander M.P., 1992, J HEAD TRAUMA REHAB, V7, P60, DOI DOI 10.1097/00001199-199206000-00009; Boscarino JA, 2006, ANN EPIDEMIOL, V16, P248, DOI 10.1016/j.annepidem.2005.03.009; Brenner LA, 2009, REHABIL PSYCHOL, V54, P390, DOI 10.1037/a0017802; Brown AW, 2004, NEUROREHABILITATION, V19, P37; Bryan CJ, 2013, JAMA PSYCHIAT, V70, P686, DOI 10.1001/jamapsychiatry.2013.1093; Cyders MA, 2007, PSYCHOL ASSESSMENT, V19, P107, DOI 10.1037/1040-3590.19.1.107; Donnellan MB, 2005, J RES PERS, V39, P458, DOI 10.1016/j.jrp.2004.05.004; Eisen SA, 2004, MIL MED, V169, P896, DOI 10.7205/MILMED.169.11.896; Freeman TW, 2003, SOUTH MED J, V96, P240, DOI 10.1097/01.SMJ.0000054421.36880.6E; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2006, JAMA-J AM MED ASSOC, V295, P1023, DOI 10.1001/jama.295.9.1023; Hoyert DL, 2012, NATL VITAL STAT REPO, V2012, P6; Jakupcak M, 2007, J TRAUMA STRESS, V20, P945, DOI 10.1002/jts.20258; Joiner T. E., 2005, WHY PEOPLE DIE SUICI; Kang HK, 2003, AM J EPIDEMIOL, V157, P141, DOI 10.1093/aje/kwf187; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kehle SM, 2012, PSYCHOL ADDICT BEHAV, V26, P42, DOI 10.1037/a0024663; Kelley AM, 2012, J PSYCHIATR RES, V46, P582, DOI 10.1016/j.jpsychires.2012.01.017; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593; Kilgore WDS, 2008, J PSYCHIATR RES, V42, P399; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; Kotler M, 2001, J NERV MENT DIS, V189, P162, DOI 10.1097/00005053-200103000-00004; Krueger RF, 2001, PERS INDIV DIFFER, V30, P1245, DOI 10.1016/S0191-8869(00)00106-9; Lew HL, 2008, J REHABIL RES DEV, V45, pXI, DOI 10.1682/JRRD.2008.05.0064; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Mann JJ, 1999, AM J PSYCHIAT, V156, P181; Mathias CW, 2011, SUICIDE LIFE-THREAT, V41, P277, DOI 10.1111/j.1943-278X.2011.00027.x; Miller MW, 2004, J ABNORM PSYCHOL, V113, P636, DOI 10.1037/0021-843X.113.4.636; Miller MW, 2003, CLIN PSYCHOL-SCI PR, V10, P373, DOI 10.1093/clipsy/bpg040; Miller MW, 2003, PSYCHOL ASSESSMENT, V15, P205, DOI 10.1037/1040-3590.15.2.205; Newcombe VFJ, 2011, BRAIN, V134, P759, DOI 10.1093/brain/awq388; Nock MK, 2006, J ABNORM PSYCHOL, V115, P616, DOI 10.1037/0021-843X.115.3.616; O'Jile JR, 2004, APPL NEUROPSYCHOL, V11, P107, DOI 10.1207/s15324826an1102_7; Oquendo M, 2005, AM J PSYCHIAT, V162, P560, DOI 10.1176/appi.ajp.162.3.560; Orcutt HK, 2003, J TRAUMA STRESS, V16, P381, DOI 10.1023/A:1024470103325; Parry-Jones BL, 2006, NEUROPSYCHOL REHABIL, V16, P537, DOI 10.1080/09602010500231875; Pat-Horenczyk R, 2007, AM J PSYCHIAT, V164, P66, DOI 10.1176/appi.ajp.164.1.66; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Rao V, 2009, J NEUROPSYCH CLIN N, V21, P420, DOI 10.1176/appi.neuropsych.21.4.420; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; Sacks MB, 2008, J PSYCHIATR RES, V42, P487, DOI 10.1016/j.jpsychires.2007.05.001; SCHLENGER WE, 1992, J TRAUMA STRESS, V5, P333, DOI 10.1002/jts.2490050303; Schwab KA, 2006, NEUROLOGY, V66, pA235; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Strom TQ, 2012, MIL MED, V177, P390, DOI 10.7205/MILMED-D-11-00133; Swick D, 2012, J INT NEUROPSYCH SOC, V18, P1, DOI DOI 10.1017/S13556177120000458; Tanelian T, 2004, INVISIBLE WOUNDS WAR; Tellier A, 2009, BRAIN INJURY, V23, P879, DOI 10.1080/02699050903200555; Teten AL, 2010, J INTERPERS VIOLENCE, V25, P1612, DOI 10.1177/0886260509354583; Thomas JL, 2010, ARCH GEN PSYCHIAT, V67, P614, DOI 10.1001/archgenpsychiatry.2010.54; Tull MT, 2007, J NERV MENT DIS, V195, P580, DOI 10.1097/NMD.0b013e318093ed5f; U.S. Department of Veterans Affairs National Center for Posttraumatic Stress Disorder, US PTSD CHECKL; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Warden DL, 2005, J NEUROTRAUM, V22, P1178; Watanabe Kevin K., 1995, Annals of Epidemiology, V5, P407, DOI 10.1016/1047-2797(95)00039-A; Weathers F. W., 1993, ANN M INT SOC TRAUM; Whiteside SP, 2001, PERS INDIV DIFFER, V30, P669, DOI 10.1016/S0191-8869(00)00064-7; Zuckerman M., 1994, BEHAV EXPRESSION BIO	59	77	77	0	16	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0026-4075	1930-613X		MIL MED	Milit. Med.	APR	2014	179	4					357	363		10.7205/MILMED-D-13-00241			7	Medicine, General & Internal	General & Internal Medicine	AN7UK	WOS:000340806300002	24690958	Bronze			2021-06-18	
J	Luo, J; Nguyen, A; Villeda, S; Zhang, H; Ding, ZQ; Lindsey, D; Bieri, G; Castellano, JM; Beaupre, GS; Wyss-Coray, T				Luo, Jian; Nguyen, Andy; Villeda, Saul; Zhang, Hui; Ding, Zhaoqing; Lindsey, Derek; Bieri, Gregor; Castellano, Joseph M.; Beaupre, Gary S.; Wyss-Coray, Tony			Long-term cognitive impairments and pathological alterations in a mouse model of repetitive mild traumatic brain injury	FRONTIERS IN NEUROLOGY			English	Article						mild traumatic brain injury; long-term; neurobehavior; bioluminescence; astrogliosis		Mild traumatic brain injury (mTBI, also referred to as concussion) accounts for the majority of all traumatic brain injuries. The consequences of repetitive mTBI have become of particular concern for individuals engaged in certain sports or in military operations. Many mTBI patients suffer long-lasting neurobehavioral impairments. In order to expedite pre-clinical research and therapy development, there is a need for animal models that reflect the long-term cognitive and pathological features seen in patients. In the present study, we developed and characterized a mouse model of repetitive mTBI, induced onto the closed head over the left frontal hemisphere with an electromagnetic stereotaxic impact device. Using GFAP-luciferase bioluminescence reporter mice that provide a readout of astrocyte activation, we observed an increase in bioluminescence relative to the force delivered by the impactor after single impact and cumulative effects of repetitive mTBI. Using the injury parameters established in the reporter mice, we induced a repetitive mTBI in wild type C57BL/6J mice and characterized the long-term outcome. Animals received repetitive mTBI showed a significant impairment in spatial learning and memory when tested at 2 and 6 months after injury. A robust astrogliosis and increased p-Tau immunoreactivity were observed upon post-mortem pathological examinations. These findings are consistent with the deficits and pathology associated with mTBI in humans and support the use of this model to evaluate potential therapeutic approaches.	[Luo, Jian; Nguyen, Andy; Villeda, Saul; Zhang, Hui; Ding, Zhaoqing; Bieri, Gregor; Castellano, Joseph M.; Wyss-Coray, Tony] Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA; [Luo, Jian; Nguyen, Andy; Villeda, Saul; Zhang, Hui; Ding, Zhaoqing; Lindsey, Derek; Bieri, Gregor; Castellano, Joseph M.; Beaupre, Gary S.; Wyss-Coray, Tony] VA Palo Alto Hlth Care Syst, Ctr Tissue Regenerat Repair & Restorat, Palo Alto, CA USA	Luo, J (corresponding author), Stanford Univ, VA Palo Alto Hlth Care Syst, Sch Med, Dept Neurol & Neurol Sci, 3801 Miranda Ave,Bldg 100,Room D3-111, Palo Alto, CA 94304 USA.	jianl@stanford.edu; twc@stanford.edu	Wyss-Coray, Tony/AAF-3380-2019; Lindsey, Derek/K-2579-2019; Luo, Jian/B-8449-2014; Beaupre, Gary/B-9880-2013	Wyss-Coray, Tony/0000-0001-5893-0831; Lindsey, Derek/0000-0003-2699-8190; Luo, Jian/0000-0002-2064-8467; Beaupre, Gary/0000-0002-6211-7621; Castellano, Joseph/0000-0002-8026-6292	Center for Tissue Regeneration, Repair and Restoration, VA Palo Alto Health Care System; Department of Veterans AffairsUS Department of Veterans Affairs [RX001218]; Veterans AffairsUS Department of Veterans Affairs [I01RX001218] Funding Source: NIH RePORTER	This work was supported by the Center for Tissue Regeneration, Repair and Restoration, VA Palo Alto Health Care System, and a grant from the Department of Veterans Affairs (RX001218, to Tony Wyss-Coray).	Atkins CM, 2009, NEUROSCI LETT, V459, P52, DOI 10.1016/j.neulet.2009.04.064; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Britschgi M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-220; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Coutellier L, 2011, BEHAV BRAIN RES, V222, P265, DOI 10.1016/j.bbr.2011.02.043; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; DeWitt DS, 2013, J NEUROTRAUM, V30, P688, DOI 10.1089/neu.2012.2349; Faizi M, 2012, BRAIN BEHAV, V2, P142, DOI 10.1002/brb3.41; Galarneau MR, 2008, J NEUROSURG, V108, P950, DOI 10.3171/JNS/2008/108/5/0950; Gerberding JL, 2003, REP C MILD TRAUM BRA; Gold EM, 2013, REGEN MED, V8, P483, DOI 10.2217/rme.13.41; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hu BR, 2004, J CEREBR BLOOD F MET, V24, P934, DOI 10.1097/01.WCB.0000125888.56462.A1; Hughes RN, 2004, NEUROSCI BIOBEHAV R, V28, P497, DOI 10.1016/j.neubiorev.2004.06.006; Kandel ER, 2001, SCIENCE, V294, P1030, DOI 10.1126/science.1067020; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; Khroyan TV, 2012, CLIN EXP PHARMACOL P, V39, P614, DOI 10.1111/j.1440-1681.2012.05719.x; Kibby MY, 1996, BRAIN INJURY, V10, P159, DOI 10.1080/026990596124494; Konrad KN, 2000, BRAIN INJURY, V14, P859; Lin AH, 2005, J IMMUNOL, V175, P547, DOI 10.4049/jimmunol.175.1.547; Lonze BE, 2002, NEURON, V35, P605, DOI 10.1016/S0896-6273(02)00828-0; Luo J, 2007, J CLIN INVEST, V117, P3306, DOI 10.1172/JCI31763; Luo J, 2006, P NATL ACAD SCI USA, V103, P18326, DOI 10.1073/pnas.0605077103; Luo J, 2013, J EXP MED, V210, P157, DOI 10.1084/jem.20120412; Luo J, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-6; Mandillo S, 2008, PHYSIOL GENOMICS, V34, P243, DOI 10.1152/physiolgenomics.90207.2008; Marklund N, 2011, BRIT J PHARMACOL, V164, P1207, DOI 10.1111/j.1476-5381.2010.01163.x; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Paxinos G., 2001, MOUSE BRAIN STEREOTA; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; Rigg JL, 2011, PM&R, V3, pS380, DOI 10.1016/j.pmrj.2011.08.005; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Silver JM, 2009, AM J PSYCHIAT, V166, P653, DOI 10.1176/appi.ajp.2009.08111676; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004; Villeda SA, 2011, NATURE, V477, P90, DOI 10.1038/nature10357; Weber JT, 2007, PROG BRAIN RES, V161, P253, DOI 10.1016/S0079-6123(06)61018-2; Williams WH, 2010, J NEUROL NEUROSUR PS, V81, P1116, DOI 10.1136/jnnp.2008.171298; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Zhu LY, 2004, NEUROSCI LETT, V367, P210, DOI 10.1016/j.neulet.2004.06.020; Zohar O, 2011, ACTA NEUROBIOL EXP, V71, P36	47	77	77	0	12	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.		2014	5								12	10.3389/fneur.2014.00012			13	Clinical Neurology; Neurosciences	Neurosciences & Neurology	V42QW	WOS:000209629300012	24550885	DOAJ Gold, Green Published			2021-06-18	
J	Covassin, T; Moran, R; Wilhelmy, K				Covassin, Tracey; Moran, Ryan; Wilhelmy, Kristyn			Concussion Symptoms and Neurocognitive Performance of High School and College Athletes Who Incur Multiple Concussions	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						multiple concussions; cognitive testing; symptoms	TEST-RETEST RELIABILITY; BASE-LINE; IMPACT; EPIDEMIOLOGY; RECOVERY	Background: Multiple concussions have been associated with prolonged symptoms, recovery time, and risk for future concussions. However, very few studies have examined the effect of multiple concussions on neurocognitive performance and the recently revised symptom clusters using a large database. Purpose: To examine concussed athletes with a history of 0, 1, 2, or 3 concussions on neurocognitive performance and the recently revised symptom clusters. Study Design: Cohort study (prognosis); Level of evidence, 2. Methods: The independent variables were concussion group (0, 1, 2, and 3 concussions) and time (baseline, 3 days, and 8 days). The dependent variables were neurocognitive test scores as measured by the Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) neurocognitive test battery (verbal and visual memory, processing speed, and reaction time) and 4 concussion symptom clusters (migraine-cognitive-fatigue, affective, somatic, and sleep). All concussed athletes (n = 596) were administered the ImPACT test at a mean 2.67 1.98 and 7.95 4.46 days after injury. A series of 4 (concussion group) x 3 (time) repeated-measures analyses of covariance (age = covariate) were performed on ImPACT composite scores and symptom clusters. Results: Concussed athletes with 3 concussions were still impaired 8 days after a concussion compared with baseline scores on verbal memory (P < .001), reaction time (P < .001), and migraine-cognitive-fatigue symptoms (P < .001). There were no significant findings on the remaining dependent variables. Conclusion: Concussed athletes with a history of 3 concussions take longer to recover than athletes with 1 or no previous concussion. Future research should concentrate on validating the new symptom clusters on multiple concussed athletes, examining longer recovery times (ie, >8 days) among athletes with multiple concussions.	[Covassin, Tracey; Moran, Ryan; Wilhelmy, Kristyn] Michigan State Univ, Dept Kinesiol, E Lansing, MI 48824 USA	Covassin, T (corresponding author), Michigan State Univ, Dept Kinesiol, 308 West Circle Dr,Room 105, E Lansing, MI 48824 USA.	covassin@msu.edu					[Anonymous], 2011, MED SCI SPORT EXER, V43, P2412, DOI 10.1249/MSS.0b013e3182342e64; Chrisman SP, 2013, BRAIN INJURY, V27, P1, DOI 10.3109/02699052.2012.722251; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Covassin T, 2008, J ATHL TRAINING, V43, P119, DOI 10.4085/1062-6050-43.2.119; Elbin RJ, 2011, AM J SPORT MED, V39, P2319, DOI 10.1177/0363546511417173; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Iverson GL, 2012, REHABIL RES PRACT, V2012; Kontos AP, 2012, AM J SPORT MED, V40, P2375, DOI 10.1177/0363546512455400; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Macciocchi SN, 2001, J ATHL TRAINING, V36, P303; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2011, NEUROSURGERY, V68, P1562, DOI 10.1227/NEU.0b013e31820e382e; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; Slobounov S, 2007, NEUROSURGERY, V61, P338, DOI 10.1227/01.NEU.0000280001.03578.FF; Sport Injury Prevention Research Centre and Canadian Academy of Sport and Exercise Medicine, 2012, CLIN J SPORT MED, V22, P304; Stephens R, 2010, J NEUROPSYCH CLIN N, V22, P295, DOI 10.1176/appi.neuropsych.22.3.295; Terry DP, 2012, BRAIN INJURY, V26, P1684, DOI 10.3109/02699052.2012.722259; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677; Zemper ED, 2003, AM J PHYS MED REHAB, V82, P653, DOI 10.1097/01.PHM.0000083666.74494.BA	24	77	77	2	55	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	DEC	2013	41	12					2885	2889		10.1177/0363546513499230			5	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	258QH	WOS:000327473300022	23959963				2021-06-18	
J	Whittaker, B; Christiaans, SC; Altice, JL; Chen, MK; Bartolucci, AA; Morgan, CJ; Kerby, JD; Pittet, JF				Whittaker, Brent; Christiaans, Sarah C.; Altice, Jessica L.; Chen, Mike K.; Bartolucci, Alfred A.; Morgan, Charity J.; Kerby, Jeffrey D.; Pittet, Jean-Francois			EARLY COAGULOPATHY IS AN INDEPENDENT PREDICTOR OF MORTALITY IN CHILDREN AFTER SEVERE TRAUMA	SHOCK			English	Article						Pediatric trauma; coagulopathy; traumatic brain injury; tissue hypoperfusion; mortality	ACTIVATED PROTEIN-C; BRAIN-INJURY; RISK; DEFINITION; ADMISSION; SCALE	To determine whether early coagulopathy affects the mortality associated with severe civilian pediatric trauma, trauma patients younger than 18 years admitted to a pediatric intensive care unit from 2001 to 2010 were evaluated. Patients with burns, primary asphyxiation, preexisting bleeding diathesis, lack of coagulation studies, or transferred from other hospitals more than 24 h after injury were excluded. Age, sex, race, mechanism of injury, initial systolic blood pressure, Glasgow Coma Scale score, Injury Severity Score, prothrombin time, partial thromboplastin time, platelet count, and international normalized ratio were recorded. An arterial or venous blood gas was performed, if clinically indicated. Coagulopathy was defined as an international normalized ratio greater than 1.2. The primary outcome was in-hospital mortality. Secondary outcomes were lengths of intensive care unit and hospital stay. Eight hundred three patients were included in the study. Overall mortality was 13.4%. The incidence of age-adjusted hypotension was 5.4%. Early coagulopathy was observed in 37.9% of patients. High Injury Severity Score and/or hypotension were associated with early coagulopathy and higher mortality. Early coagulopathy was associated with a modest increase in mortality in pediatric trauma patients without traumatic brain injury (TBI). In contrast, the combination of TBI and early coagulopathy was associated with a fourfold increase in mortality in this patient population. Early coagulopathy is an independent predictor of mortality in civilian pediatric patients with severe trauma. The increase in mortality was particularly significant in patients with TBI either isolated or combined with other injuries, suggesting that a rapid correction of this coagulopathy could substantially decrease the mortality after TBI in pediatric trauma patients.	[Whittaker, Brent] Univ Alabama Birmingham, Dept Pediat, Birmingham, AL 35249 USA; [Christiaans, Sarah C.; Altice, Jessica L.; Pittet, Jean-Francois] Univ Alabama Birmingham, Dept Anesthesiol, Birmingham, AL 35249 USA; [Chen, Mike K.; Kerby, Jeffrey D.; Pittet, Jean-Francois] Univ Alabama Birmingham, Dept Surg, Birmingham, AL 35249 USA; [Bartolucci, Alfred A.; Morgan, Charity J.] Univ Alabama Birmingham, Dept Biostat, Birmingham, AL 35249 USA	Pittet, JF (corresponding author), Univ Alabama Birmingham, Dept Anesthesiol, 619 S 19th St,JT926, Birmingham, AL 35249 USA.	pittetj@uab.edu		Morgan, Charity J/0000-0003-0693-4739	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 GM086416]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM086416] Funding Source: NIH RePORTER	Funding support was received from the National Institutes of Health (RO1 GM086416 [to J.-F.P.]).	Brohi K, 2003, J TRAUMA, V54, P1127, DOI 10.1097/01.TA.0000069184.82147.06; Brohi K, 2007, ANN SURG, V245, P812, DOI 10.1097/01.sla.0000256862.79374.31; Chesebro BB, 2009, SHOCK, V32, P659, DOI 10.1097/SHK.0b013e3181a5a632; CIAVARELLA D, 1987, BRIT J HAEMATOL, V67, P365, DOI 10.1111/j.1365-2141.1987.tb02359.x; Cohen MJ, 2012, ANN SURG, V255, P379, DOI 10.1097/SLA.0b013e318235d9e6; COUNTS RB, 1979, ANN SURG, V190, P91, DOI 10.1097/00000658-197907000-00020; Davenport R, 2011, CRIT CARE MED, V39, P2652, DOI 10.1097/CCM.0b013e3182281af5; Davis JW, 1996, J TRAUMA, V41, P769, DOI 10.1097/00005373-199611000-00001; Eberhard LW, 2000, CRIT CARE MED, V28, P125, DOI 10.1097/00003246-200001000-00021; Frith D, 2010, J THROMB HAEMOST, V8, P1919, DOI 10.1111/j.1538-7836.2010.03945.x; Gruen RL, 2012, LANCET, V380, P1099, DOI 10.1016/S0140-6736(12)61224-0; Hendrickson JE, 2012, J PEDIATR-US, V160, P204, DOI 10.1016/j.jpeds.2011.08.019; MacLeod JBA, 2003, J TRAUMA, V55, P39, DOI 10.1097/01.TA.0000075338.21177.EF; Maegele M, 2012, SHOCK, V38, P450, DOI 10.1097/SHK.0b013e31826dbd23; Matos RI, 2008, PEDIATRICS, V122, pE959, DOI 10.1542/peds.2008-1244; Mitra B, 2012, INJURY, V43, P22, DOI 10.1016/j.injury.2010.10.015; MURRAY DJ, 1995, ANESTH ANALG, V80, P336, DOI 10.1097/00000539-199502000-00022; Patregnani JT, 2012, PEDIATR CRIT CARE ME, V13, P273, DOI 10.1097/PCC.0b013e31822f1727; Peiniger S, 2012, PEDIATR CRIT CARE ME, V13, P455, DOI 10.1097/PCC.0b013e31823893c5; RUTHERFORD EJ, 1992, J TRAUMA, V33, P417, DOI 10.1097/00005373-199209000-00014; Stewart TC, 2011, J TRAUMA, V71, P1801, DOI 10.1097/TA.0b013e31823c484a; Talving P, 2011, J TRAUMA, V71, P1205, DOI 10.1097/TA.0b013e31820d151d; Melo JRT, 2010, NEUROSURGERY, V67, P1542, DOI 10.1227/NEU.0b013e3181fa7049; Vavilala MS, 2001, J NEUROSURG ANESTH, V13, P13, DOI 10.1097/00008506-200101000-00003	24	77	78	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1073-2322			SHOCK	Shock	MAY	2013	39	5					421	426		10.1097/SHK.0b013e31828e08cb			6	Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease	General & Internal Medicine; Hematology; Surgery; Cardiovascular System & Cardiology	127XE	WOS:000317731400004	23591559	Green Accepted			2021-06-18	
J	Walcott, BP; Kwon, CS; Sheth, SA; Fehnel, CR; Koffie, RM; Asaad, WF; Nahed, BV; Coumans, JV				Walcott, Brian P.; Kwon, Churl-Su; Sheth, Sameer A.; Fehnel, Corey R.; Koffie, Robert M.; Asaad, Wael F.; Nahed, Brian V.; Coumans, Jean-Valery			Predictors of cranioplasty complications in stroke and trauma patients Clinical article	JOURNAL OF NEUROSURGERY			English	Article						cranioplasty; trauma; infection; complication; stroke; decompressive; craniectomy; traumatic brain injury; vascular disorders	RESISTANT STAPHYLOCOCCUS-AUREUS; CEREBRAL-ARTERY INFARCTION; INTENSIVE-CARE UNITS; DECOMPRESSIVE CRANIECTOMY; RISK-FACTORS; WOUND-INFECTION; ISCHEMIC-STROKE; BRAIN-INJURY; CONTROLLED-TRIAL; CARDIAC-SURGERY	Object. Decompressive craniectomy mandates subsequent cranioplasty. Complications of cranioplasty may be independent of the initial craniectomy, or they may be contingent upon the craniectomy. Authors of this study aimed to identify surgery- and patient-specific risk factors related to the development of surgical site infection and other complications following cranioplasty. Methods. A consecutive cohort of patients of all ages and both sexes who had undergone cranioplasty following craniectomy for stroke or trauma at a single institution in the period from May 2004 to May 2012 was retrospectively established. Patients who had undergone craniectomy for infectious lesions or neoplasia were excluded. A logistic regression analysis was performed to model and predict determinants related to infection following cranioplasty. Results. Two hundred thirty-nine patients met the study criteria. The overall rate of complication following cranioplasty was 23.85% (57 patients). Complications included, predominantly, surgical site infection, hydrocephalus, and new-onset seizures. Logistic regression analysis identified previous reoperation (OR 3.25, 95% CI 1.30-8.11, p = 0.01) and therapeutic indication for stroke (OR 2.45, 95% CI 1.11-5.39, p = 0.03) as significantly associated with the development of cranioplasty infection. Patient age, location of cranioplasty, presence of an intracranial device, bone flap preservation method, cranioplasty material, booking method, and time interval > 90 days between initial craniectomy and cranioplasty were not predictive of the development of cranioplasty infection. Conclusions. Cranioplasty complications are common. Cranioplasty infection rates are, predicted by reoperation following craniectomy and therapeutic indication (stroke). These variables may be associated with patient-centered risk factors that increase cranioplasty infection risk. (http://thejns.org/doi/abs/10.3171/2013.1.JNS121626)	[Walcott, Brian P.; Kwon, Churl-Su; Sheth, Sameer A.; Koffie, Robert M.; Nahed, Brian V.; Coumans, Jean-Valery] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA; [Walcott, Brian P.; Kwon, Churl-Su; Sheth, Sameer A.; Koffie, Robert M.; Nahed, Brian V.; Coumans, Jean-Valery] Harvard Univ, Sch Med, Boston, MA USA; [Fehnel, Corey R.] Brown Univ, Dept Neurol, Alpert Med Sch, Providence, RI 02912 USA; [Fehnel, Corey R.] Rhode Isl Hosp, Providence, RI USA; [Asaad, Wael F.] Dept Neurosurg, Providence, RI USA; [Asaad, Wael F.] Brown Inst Brain Sci, Providence, RI USA	Walcott, BP (corresponding author), Massachusetts Gen Hosp, 55 Fruit St,White Bldg Room 502, Boston, MA 02114 USA.	walcott.brian@mgh.harvard.edu	Asaad, Wael/I-8485-2012; Nahed, Brian/E-4239-2014	Asaad, Wael/0000-0003-4406-9096; Fehnel, Corey/0000-0003-1726-5809; Nahed, Brian/0000-0001-8537-106X			Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; Beauchamp KM, 2010, J TRAUMA, V69, P270, DOI 10.1097/TA.0b013e3181e491c2; Cepeda JA, 2005, LANCET, V365, P295, DOI 10.1016/S0140-6736(05)17783-6; Chang V, 2010, J NEUROSURG, V112, P1120, DOI 10.3171/2009.6.JNS09133; Chiang HY, 2011, J NEUROSURG, V114, P1746, DOI 10.3171/2011.1.JNS10782; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Engelman DT, 1999, J THORAC CARDIOV SUR, V118, P866, DOI 10.1016/S0022-5223(99)70056-5; Folsom AR, 1999, DIABETES CARE, V22, P1077, DOI 10.2337/diacare.22.7.1077; Furnary AP, 1999, ANN THORAC SURG, V67, P352, DOI 10.1016/S0003-4975(99)00014-4; Gillitzer R, 2001, J LEUKOCYTE BIOL, V69, P513; Gooch MR, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0962; Grau AJ, 2001, STROKE, V32, P2559, DOI 10.1161/hs1101.098524; Greene K A, 1991, J Arthroplasty, V6, P321, DOI 10.1016/S0883-5403(06)80183-X; Hofmeijer J, 2009, LANCET NEUROL, V8, P326, DOI 10.1016/S1474-4422(09)70047-X; HORAN TC, 1992, INFECT CONT HOSP EP, V13, P606; Juttler E, 2007, STROKE, V38, P2518, DOI 10.1161/STROKEAHA.107.485649; Klein JD, 1996, ORTHOP CLIN N AM, V27, P33; Kuo JR, 2004, J CLIN NEUROSCI, V11, P486, DOI 10.1016/j.jocn.2003.06.005; Levitt MR, 2011, NEUROSURGERY, V69, pE773, DOI 10.1227/NEU.0b013e31821964ba; Lucet JC, 2005, INTENS CARE MED, V31, P1051, DOI 10.1007/s00134-005-2679-0; Mann G, 2000, CEREBROVASC DIS, V10, P380, DOI 10.1159/000016094; Marion DW, 2006, NEUROSURGERY, V58, P655; NAGACHINTA T, 1987, J INFECT DIS, V156, P967, DOI 10.1093/infdis/156.6.967; Nakamura K, 2005, NUTRITION, V21, P639, DOI 10.1016/j.nut.2005.03.001; O'Neill PA, 1998, STROKE, V29, P1480; O'Sullivan NP, 2000, J HOSP INFECT, V45, P206, DOI 10.1053/jhin.2000.0759; Romero CM, 2011, NEW ENGL J MED, V365, P373, DOI 10.1056/NEJMc1106421; Russell L, 2001, Br J Nurs, V10, pS44; SACCO RL, 1995, NEUROLOGY, V45, pS10; Sakamoto S, 2006, CLIN NEUROL NEUROSUR, V108, P583, DOI 10.1016/j.clineuro.2005.03.012; Sanan A, 1997, NEUROSURGERY, V40, P588, DOI 10.1097/00006123-199703000-00033; Schuss P, 2012, J NEUROTRAUM, V29, P1090, DOI 10.1089/neu.2011.2176; SEGAL DH, 1994, NEUROSURGERY, V34, P729, DOI 10.1227/00006123-199404000-00024; Shiono Y, 2012, SPINE, V37, P523, DOI 10.1097/BRS.0b013e318224d7b2; Simard JM, 2011, CURR TREAT OPTION NE, V13, P217, DOI 10.1007/s11940-010-0110-9; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; Smith ER, 2002, NEUROSURGERY, V51, P117, DOI 10.1097/00006123-200207000-00018; Smithard DG, 1996, STROKE, V27, P1200, DOI 10.1161/01.STR.27.7.1200; Sorensen LT, 2003, ANN SURG, V238, P1, DOI 10.1097/01.SLA.0000074980.39700.31; Suk SH, 2003, STROKE, V34, P1586, DOI 10.1161/01.STR.0000075294.98582.2F; Tabachnick B., 2001, USING MULTIVARIATE S; Vahedi K, 2007, STROKE, V38, P2506, DOI 10.1161/STROKEAHA.107.485235; von Baum H, 2002, INFECT CONT HOSP EP, V23, P511, DOI 10.1086/502098; Walcott BP, 2012, J NEUROTRAUM, V29, P1879, DOI 10.1089/neu.2012.2382; Walcott BP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029193; Waziri A, 2007, NEUROSURGERY, V61, P489, DOI 10.1227/01.NEU.0000290894.85072.37; Wen L, 2007, J CRANIOFAC SURG, V18, P526; Wukich DK, 2010, J BONE JOINT SURG AM, V92A, P287, DOI 10.2106/JBJS.I.00080; Yadla S, 2011, NEUROSURGERY, V68, P1124, DOI 10.1227/NEU.0b013e31820a5470; Yoshida K, 1996, J NEUROL NEUROSUR PS, V61, P166, DOI 10.1136/jnnp.61.2.166; Zerr KJ, 1997, ANN THORAC SURG, V63, P356	51	77	81	0	10	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	APR	2013	118	4					757	762		10.3171/2013.1.JNS121626			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	114BT	WOS:000316715700012	23394335				2021-06-18	
J	McIntyre, A; Mehta, S; Aubut, J; Dijkers, M; Teasell, RW				McIntyre, Amanda; Mehta, Swati; Aubut, Joanne; Dijkers, Marcel; Teasell, Robert W.			Mortality among older adults after a traumatic brain injury: A meta-analysis	BRAIN INJURY			English	Article						older adult; mortality; Glasgow Coma Scale; traumatic brain injury	SEVERE HEAD-INJURY; ELDERLY-PATIENTS; PREEXISTING CONDITIONS; GERIATRIC TRAUMA; AGE; RISK; POPULATION; SEVERITY; CARE; PREDICTOR	Primary objective: To examine mortality rates among older adults (>= 60 years) post-traumatic brain injury (TBI). Research design: Systematic review and meta-analysis. Methods and procedures: Using multiple databases, a literature search was conducted for articles on mortality after TBI published up to July 2011. Information on patient characteristics (age, Glasgow Coma Scale (GCS), injury aetiology, etc.), mortality rates, time to death and study design was extracted and pooled. Main outcomes and results: Twenty-four studies had an overall mortality rate of 38.3% (CI 27.1-50.9%). The odds of mortality for those over 75 years compared to those of 65-74 years was 1.734 (CI=1.311-2.292; p<0.0001). Pooled mortality rates for mild (GCS 13-15), moderate (GCS 9-12) and severe (GCS 3-8) head injuries were 12.3% (CI=6.1-23.3%), 34.3% (CI=19.5-53.0%) and 65.3% (CI=53.1-75.9), respectively. Odds ratios comparing severe to mild and moderate to mild head injuries were 12.69 (CI=5.29-30.45; p<0.0001) and 5.31 (CI=3.41-8.29; p<0.0001), respectively. There was no significant difference in the odds of death between severe and moderate injuries (p=0.116). Conclusions: These mortality rates associated with moderate and severe injuries may be attributed to complications, chronic disease prevalence, conservative management techniques or the consequences of biological ageing.	[McIntyre, Amanda; Mehta, Swati; Aubut, Joanne; Teasell, Robert W.] St Josephs Parkwood Hosp, Lawson Hlth Res Inst, London, ON, Canada; [Dijkers, Marcel] Mt Sinai, Dept Rehabil Med, New York, NY USA; [Teasell, Robert W.] Univ Western Ontario, Dept Phys Med & Rehabil, London, ON, Canada	Teasell, RW (corresponding author), Parkwood Hosp, Dept Phys Med & Rehabil, Hobbins Bldg,Suite 404,801 Commissioners Rd E, London, ON N6C 5J1, Canada.	robert.teasell@sjhc.london.on.ca	Heinemann, Allen W/K-6283-2012	Heinemann, Allen W/0000-0003-2782-7326; Dijkers, Marcel/0000-0002-8362-5596			Battistella FD, 1998, J TRAUMA, V44, P618, DOI 10.1097/00005373-199804000-00010; Bouras T, 2007, J NEUROTRAUM, V24, P1355, DOI 10.1089/neu.2005.370; Bowen RL, 2004, GERONTOLOGY, V50, P265, DOI 10.1159/000079125; Canadian Institute for Health Information, 2006, HEAD INJ CAN DEC CHA; Colantonio A, 2008, J TRAUMA, V64, P876, DOI 10.1097/TA.0b013e31804d493e; CRAIK FIM, 1992, HDB AGING COGNITION; de la Plata CAM, 2008, ARCH PHYS MED REHAB, V89, P896, DOI 10.1016/j.apmr.2007.12.030; Dijkers M, 2008, BRAIN INJURY PROFESS, V5, P8; Engberg AW, 2001, EUR J EPIDEMIOL, V17, P437, DOI 10.1023/A:1013733107520; Ferrell Richard B, 2002, Curr Psychiatry Rep, V4, P354; Flaada JT, 2007, J NEUROTRAUM, V24, P435, DOI 10.1089/neu.2006.0119; Gan BK, 2004, ANN ACAD MED SINGAP, V33, P63; Gomez PA, 2000, ACTA NEUROCHIR, V142, P373, DOI 10.1007/s007010050445; Grossman MD, 2002, J TRAUMA, V52, P242, DOI 10.1097/00005373-200202000-00007; Hartl R, 2008, J NEUROSURG, V109, P50, DOI 10.3171/JNS/2008/109/7/0050; Harris C, 2003, J AM COLL SURGEONS, V197, P711, DOI 10.1016/S1072-7515(03)00729-4; HAYFLICK L, 1994, WHY WE AGE; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; KLAUBER MR, 1989, NEUROSURGERY, V24, P31, DOI 10.1227/00006123-198901000-00005; Kuhne CA, 2005, WORLD J SURG, V29, P1476, DOI 10.1007/s00268-005-7796-y; Lane P, 2003, ACAD EMERG MED, V10, P244, DOI 10.1111/j.1553-2712.2003.tb01998.x; Linn S, 2007, ANN EPIDEMIOL, V17, P142, DOI 10.1016/j.annepidem.2006.08.004; Lix LM, 2008, PUBLIC HLTH AGENCY C, V18; MILZMAN DP, 1992, J TRAUMA, V32, P236, DOI 10.1097/00005373-199202000-00021; Mohindra S, 2008, SURG NEUROL, V69, P474, DOI 10.1016/j.surneu.2007.02.031; MORRIS JA, 1990, JAMA-J AM MED ASSOC, V263, P1942, DOI 10.1001/jama.263.14.1942; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Murdoch BE., 2001, TRAUMATIC BRAIN INJU; Patel HC, 2010, ACTA NEUROCHIR, V152, P1353, DOI 10.1007/s00701-010-0666-x; Rapoport MJ, 2000, BRAIN INJURY, V14, P749; Ratcliff G, 2005, DISABIL REHABIL, V27, P305, DOI 10.1080/09638280400018338; Ritchie PD, 2000, J CLIN NEUROSCI, V7, P301, DOI 10.1054/jocn.1999.0198; Sanchez-Olmedo JI, 2005, TRANSPL P, V37, P1990, DOI 10.1016/j.transproceed.2005.03.048; Sarani B, 2009, J TRAUMA, V67, P954, DOI 10.1097/TA.0b013e3181ae6d39; Selassie AW, 2005, J HEAD TRAUMA REHAB, V20, P257, DOI 10.1097/00001199-200505000-00008; Shavelle R, 2000, J Insur Med, V32, P163; Siram SM, 2011, J SURG RES, V167, P14, DOI 10.1016/j.jss.2010.10.007; Skoglund TS, 2005, ACTA ANAESTH SCAND, V49, P337, DOI 10.1111/j.1399-6576.2005.00624.x; Spaniolas K, 2010, J TRAUMA, V69, P821, DOI 10.1097/TA.0b013e3181efc6c6; SPENCE AP, 1995, BIOL HUMAN AGING; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; TEASDALE G, 1974, LANCET, V2, P81; Thompson HJ, 2008, CRIT CARE MED, V36, P282, DOI 10.1097/01.CCM.0000297884.86058.8A; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x; Tokutomi T, 2008, J NEUROTRAUM, V25, P1407, DOI 10.1089/neu.2008.0577; Ushewokunze S, 2004, BRIT J NEUROSURG, V18, P604, DOI 10.1080/02688690400022763; Utomo WK, 2009, INJURY, V40, P973, DOI 10.1016/j.injury.2009.05.034; Ventura T, 2010, ARCH PHYS MED REHAB, V91, P20, DOI 10.1016/j.apmr.2009.08.151; Wagner AK, 2001, PHYS MED REHABIL STA, V15, P245	50	77	77	0	15	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JAN	2013	27	1					31	40		10.3109/02699052.2012.700086			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	059IY	WOS:000312699300004	23163240				2021-06-18	
J	Zhao, YB; Luo, P; Guo, QD; Li, SZ; Zhang, L; Zhao, MM; Xu, HX; Yang, YF; Poon, WS; Fei, Z				Zhao, Yongbo; Luo, Peng; Guo, Qindong; Li, Sanzhong; Zhang, Lei; Zhao, Mingming; Xu, Haoxiang; Yang, Yuefan; Poon, Waisang; Fei, Zhou			Interactions between SIRT1 and MAPK/ERK regulate neuronal apoptosis induced by traumatic brain injury in vitro and in vivo	EXPERIMENTAL NEUROLOGY			English	Article						SIRT1; ERK; Salermide; Traumatic brain injury; Apoptosis	RAT CORTICAL-NEURONS; CLOSED-HEAD INJURY; CELL-DEATH; HISTONE DEACETYLASE; GLUCOSE DEPRIVATION; OXIDATIVE TOXICITY; KINASE; SIRTUINS; PROTECTS; NEUROPROTECTION	Traumatic brain injury (TBI) is a serious insult that frequently leads to neurological dysfunction or death. Silent information regulator family protein 1 (SIRT1), as the founding member of nicotinamide adenine dinucleotide (NAD)-dependent deacetylases, has recently been demonstrated to have neuroprotective effect in several models of neurodegenerative diseases. The present study attempts to determine whether SIRT1 has a neuroprotective effect in the model of TBI, and further to investigate the possible regulatory mechanism of neuron death. Thus, we employ transection model in vitro and weight-drop model in vivo to mimic the insults of TBI. The study shows that the expressions of SIRT1, phosphorylation extracellular signal-regulated kinase (p-ERK) and cleaved Caspase-3 are induced after trauma injury in vitro or in vivo. Furthermore, inhibiting SIRT1 by pharmacological inhibitor salermide or SIRT1 siRNA significantly promotes apoptotic neuron death and reduces ERK1/2 activation induced by mechanical injury in vitro and in vivo. Inhibition of ERK1/2 activation with PD98059 or U0126 (two mitogen activated protein kinase kinase inhibitors) in vitro and in vivo significantly attenuates the SIRT1 and cleaved Caspase-3 expression to protect neuron against TBI-induced apoptosis. These results reveal that SIRT1 plays a neuroprotective effect against neuronal apoptosis induced by TBI. The interactions between SIRT1 and MAPK/ERK pathway regulate neuronal apoptosis induced by mechanical trauma injury in vitro and in vivo. (c) 2012 Elsevier Inc. All rights reserved.	[Poon, Waisang] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Surg, Div Neurosurg, Shatin Nt, Hong Kong, Peoples R China; [Zhao, Yongbo; Luo, Peng; Guo, Qindong; Li, Sanzhong; Zhang, Lei; Zhao, Mingming; Xu, Haoxiang; Yang, Yuefan; Fei, Zhou] Fourth Mil Med Univ, Xijing Hosp, Inst Neurosurg, Xian 710032, Shaanxi Provinc, Peoples R China; [Zhao, Yongbo] 323th Hosp PLA, Dept Neurosurg, Xian 710032, Shaanxi Provinc, Peoples R China	Poon, WS (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Surg, Div Neurosurg, Shatin Nt, Hong Kong, Peoples R China.	wpoon@cuhk.edu.hk; zhoufei@fmmu.edu.cn	Poon, Wai Sang/F-1558-2011; Yang, Yuefan/AAJ-9136-2020	Luo, Peng/0000-0003-0746-939X	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30670796, 30930093]; 863 High-Tech ProjectNational High Technology Research and Development Program of China [2009AA02Z419]	We would like to give our thanks to Wenbo Liu, Tao Chen, Ning Su, Yihui Ma, Kai Wang, Kai Huo, Junli Huo, Juan Li, Xiaoyan Chen, and Yufen Shi for technical assistance. The work was supported by the National Natural Science Foundation of China (No. 30670796 and No. 30930093) and the 863 High-Tech Project (2009AA02Z419).	Alessandrini A, 1999, P NATL ACAD SCI USA, V96, P12866, DOI 10.1073/pnas.96.22.12866; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Chen Da-qing, 2007, Chin J Traumatol, V10, P105; Chen J, 2005, J BIOL CHEM, V280, P40364, DOI 10.1074/jbc.M509329200; Chen T, 2011, NEUROSCIENCE, V183, P203, DOI 10.1016/j.neuroscience.2011.03.038; Chen WY, 2005, CELL, V123, P437, DOI 10.1016/j.cell.2005.08.011; Chong ZZ, 2008, CURR NEUROVASC RES, V5, P159, DOI 10.2174/156720208785425666; Chong ZZ, 2005, CURR NEUROVASC RES, V2, P271, DOI 10.2174/156720205774322584; Della-Morte D, 2009, NEUROSCIENCE, V159, P993, DOI 10.1016/j.neuroscience.2009.01.017; Fei Z, 2005, NEUROSCI LETT, V380, P280, DOI 10.1016/j.neulet.2005.01.063; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Fukunaga K, 1998, MOL NEUROBIOL, V16, P79, DOI 10.1007/BF02740604; Gan L, 2008, NEURON, V58, P10, DOI 10.1016/j.neuron.2008.03.015; Grewal SS, 1999, CURR OPIN NEUROBIOL, V9, P544, DOI 10.1016/S0959-4388(99)00010-0; Grozinger CM, 2001, J BIOL CHEM, V276, P38837, DOI 10.1074/jbc.M106779200; Guerra B, 2004, J NEUROCHEM, V91, P99, DOI 10.1111/j.1471-4159.2004.02695.x; Haigis MC, 2006, GENE DEV, V20, P2913, DOI 10.1101/gad.1467506; Hisahara S, 2008, P NATL ACAD SCI USA, V105, P15599, DOI 10.1073/pnas.0800612105; Huang TT, 2009, J NEUROTRAUM, V26, P1535, DOI [10.1089/neu.2008.0743, 10.1089/neu.2008-0743]; Irving EA, 2002, J CEREBR BLOOD F MET, V22, P631, DOI 10.1097/00004647-200206000-00001; Jin QH, 2007, J CELL PHYSIOL, V213, P88, DOI 10.1002/jcp.21091; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Kim EJ, 2007, MOL CELL, V28, P277, DOI 10.1016/j.molcel.2007.08.030; Kuroki Y, 2001, EUR J NEUROSCI, V13, P472, DOI 10.1046/j.0953-816x.2000.01409.x; Lara E, 2009, ONCOGENE, V28, P781, DOI 10.1038/onc.2008.436; Lesuisse C, 2002, J CEREBR BLOOD F MET, V22, P935, DOI 10.1097/00004647-200208000-00005; Li Y, 2008, CELL METAB, V8, P38, DOI 10.1016/j.cmet.2008.05.004; Liu D, 2009, NEUROMOL MED, V11, P28, DOI 10.1007/s12017-009-8058-1; Luo P, 2012, FREE RADICAL RES, V46, P766, DOI 10.3109/10715762.2012.678340; Luo Y, 2006, J BIOL CHEM, V281, P16436, DOI 10.1074/jbc.M512430200; Ma YH, 2011, BRAIN RES BULL, V86, P441, DOI 10.1016/j.brainresbull.2011.07.007; Michishita E, 2005, MOL BIOL CELL, V16, P4623, DOI 10.1091/mbc.E05-01-0033; Milne JC, 2008, CURR OPIN CHEM BIOL, V12, P11, DOI 10.1016/j.cbpa.2008.01.019; Morris KC, 2011, J CEREBR BLOOD F MET, V31, P1003, DOI 10.1038/jcbfm.2010.229; Outeiro TF, 2008, BBA-MOL BASIS DIS, V1782, P363, DOI 10.1016/j.bbadis.2008.02.010; Parker JA, 2005, NAT GENET, V37, P349, DOI 10.1038/ng1534; Peck B, 2010, MOL CANCER THER, V9, P844, DOI 10.1158/1535-7163.MCT-09-0971; Pfister JA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004090; Ramadori G, 2008, J NEUROSCI, V28, P9989, DOI 10.1523/JNEUROSCI.3257-08.2008; Raval AP, 2006, J CEREBR BLOOD F MET, V26, P1141, DOI 10.1038/sj.jcbfm.9600262; Sakamoto J, 2004, FEBS LETT, V556, P281, DOI 10.1016/S0014-5793(03)01444-3; Saunders LR, 2007, ONCOGENE, V26, P5489, DOI 10.1038/sj.onc.1210616; Shindler KS, 2007, INVEST OPHTH VIS SCI, V48, P3602, DOI 10.1167/iovs.07-0131; Stanciu M, 2000, J BIOL CHEM, V275, P12200, DOI 10.1074/jbc.275.16.12200; Subramaniam S, 2006, NEUROSCIENCE, V138, P1055, DOI 10.1016/j.neuroscience.2005.12.013; Subramaniam S, 2010, FEBS J, V277, P22, DOI 10.1111/j.1742-4658.2009.07367.x; Sun C, 2007, CELL METAB, V6, P307, DOI 10.1016/j.cmet.2007.08.014; Tanno M, 2007, J BIOL CHEM, V282, P6823, DOI 10.1074/jbc.M609554200; TECOMA ES, 1989, NEURON, V2, P1541, DOI 10.1016/0896-6273(89)90042-1; Tsenter J, 2008, J NEUROTRAUM, V25, P324, DOI 10.1089/neu.2007.0452; Wang J, 2011, NEUROSCI LETT, V503, P250, DOI 10.1016/j.neulet.2011.08.047; Wang L, 2009, EUR J PHARMACOL, V609, P40, DOI 10.1016/j.ejphar.2009.03.033; Wang SP, 2008, STROKE, V39, P2587, DOI 10.1161/STROKEAHA.107.509158; Zhang HP, 2010, ANESTH ANALG, V111, P506, DOI 10.1213/ANE.0b013e3181e45519; Zhang J, 2007, J BIOL CHEM, V282, P34356, DOI 10.1074/jbc.M706644200; Zhang W, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002429; Zhen HN, 2005, CANCER-AM CANCER SOC, V104, P2775, DOI 10.1002/cncr.21490	57	77	82	0	25	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	OCT	2012	237	2					489	498		10.1016/j.expneurol.2012.07.004			10	Neurosciences	Neurosciences & Neurology	009OJ	WOS:000309034800027	22828134				2021-06-18	
J	Meeker, RB; Williams, K; Killebrew, DA; Hudson, LC				Meeker, Rick B.; Williams, Kimberly; Killebrew, Deirdre A.; Hudson, Lola C.			Cell trafficking through the choroid plexus	CELL ADHESION & MIGRATION			English	Article						cerebrospinal fluid; pleocytosis; monocytes; macrophages; dendritic cells; T cells; inflammation; adhesion molecules; chemokines	CENTRAL-NERVOUS-SYSTEM; FELINE IMMUNODEFICIENCY VIRUS; CEREBROSPINAL-FLUID PRODUCTION; TRAUMATIC BRAIN-INJURY; CD4(+) T-CELLS; ADHESION MOLECULES; DIFFERENTIAL EXPRESSION; IMMUNE SURVEILLANCE; EPIPLEXUS CELLS; DENDRITIC CELLS	The choroid plexus is a multifunctional organ that sits at the interface between the blood and cerebrospinal fluid (CSF). It serves as a gateway for immune cell trafficking into the CSF and is in an excellent position to provide continuous immune surveillance by CD4(+) T cells, macrophages and dendritic cells and to regulate immune cell trafficking in response to disease and trauma. However, little is known about the mechanisms that control trafficking through this structure. Three cell types within the choroid plexus, in particular, may play prominent roles in controlling the development of immune responses within the nervous system: the epithelial cells, which form the blood-CSF barrier, and resident macrophages and dendritic cells in the stromal matrix. Adhesion molecule and chemokine expression by the epithelial cells allows substantial control over the selection of cells that transmigrate. Macrophages and dendritic cells can present antigen within the choroid plexus and/or transmigrate into the cerebral ventricles to serve a variety of possible immune functions. Studies to better understand the diverse functions of these cells are likely to reveal new insights that foster the development of novel pharmacological and macrophage-based interventions for the control of CNS immune responses.	[Meeker, Rick B.; Williams, Kimberly; Killebrew, Deirdre A.] Univ N Carolina, Dept Neurol, Chapel Hill, NC 27515 USA; [Meeker, Rick B.; Williams, Kimberly] Univ N Carolina, Curriculum Neurobiol, Chapel Hill, NC USA; [Hudson, Lola C.] N Carolina State Univ, Coll Vet Med, Dept Mol Biomed Sci, Raleigh, NC USA	Meeker, RB (corresponding author), Univ N Carolina, Dept Neurol, Chapel Hill, NC 27515 USA.	meekerr@neurology.unc.edu			NIH GrantUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01-MH063646]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH085606, F31MH101019, R01MH063646] Funding Source: NIH RePORTER	This work was supported by NIH Grant R01-MH063646.	Adam P, 2007, FOLIA MICROBIOL, V52, P529, DOI 10.1007/BF02932115; Brown PD, 2004, NEUROSCIENCE, V129, P957, DOI 10.1016/j.neuroscience.2004.07.003; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279; Carrithers MD, 2000, BRAIN, V123, P1092, DOI 10.1093/brain/123.6.1092; Chinnery HR, 2010, J NEUROPATH EXP NEUR, V69, P896, DOI 10.1097/NEN.0b013e3181edbc1a; de Graaf MT, 2011, CYTOM PART B-CLIN CY, V80B, P43, DOI 10.1002/cyto.b.20542; DECKERTSCHLUTER M, 1994, J NEUROPATH EXP NEUR, V53, P457, DOI 10.1097/00005072-199409000-00005; Dou H, 2006, BLOOD, V108, P2827, DOI 10.1182/blood-2006-03-012534; Engelhardt B, 2001, MICROSC RES TECHNIQ, V52, P112, DOI 10.1002/1097-0029(20010101)52:1<112::AID-JEMT13>3.0.CO;2-5; FIGARELLABRANGER D, 1995, ACTA NEUROPATHOL, V89, P248; GORDON LB, 1992, J NEUROIMMUNOL, V40, P81, DOI 10.1016/0165-5728(92)90215-7; Gras G, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-30; Hanly A, 1998, HUM PATHOL, V29, P88, DOI 10.1016/S0046-8177(98)90395-1; Ichiyama T, 2009, J INFECTION, V58, P28, DOI 10.1016/j.jinf.2008.10.012; Johanson C, 2011, TOXICOL PATHOL, V39, P186, DOI 10.1177/0192623310394214; Johanson CE, 2008, FLUIDS BARRIERS CNS, V5, DOI 10.1186/1743-8454-5-10; Kivisakk P, 2003, P NATL ACAD SCI USA, V100, P8389, DOI 10.1073/pnas.1433000100; Kleine TO, 2006, CYTOM PART A, V69A, P147, DOI 10.1002/cyto.a.20225; LING EA, 1979, J ANAT, V129, P479; Ling EA, 1998, MICROSC RES TECHNIQ, V41, P43, DOI 10.1002/(SICI)1097-0029(19980401)41:1<43::AID-JEMT5>3.3.CO;2-D; Liu P, 2006, J NEUROVIROL, V12, P294, DOI 10.1080/13550280600889567; McMenamin PG, 1999, J COMP NEUROL, V405, P553, DOI 10.1002/(SICI)1096-9861(19990322)405:4<553::AID-CNE8>3.0.CO;2-6; Meeker RB, 2012, CELL TISSUE RES, V347, P443, DOI 10.1007/s00441-011-1301-8; Meeker RB, 2011, J NEUROVIROL, V17, P258, DOI 10.1007/s13365-011-0034-5; NATHANSON JA, 1989, P NATL ACAD SCI USA, V86, P1684, DOI 10.1073/pnas.86.5.1684; Neuenburg JK, 2005, AIDS, V19, P1351, DOI 10.1097/01.aids.0000181008.39514.ee; Provencio JJ, 2005, J NEUROIMMUNOL, V163, P179, DOI 10.1016/j.jneuroim.2005.03.003; Rezai-Zadeh K, 2009, J NEUROIMMUNE PHARM, V4, P462, DOI 10.1007/s11481-009-9166-2; Ryan G, 2005, J NEUROVIROL, V11, P337, DOI 10.1080/13550280500186445; Silverberg GD, 2001, NEUROLOGY, V57, P1763, DOI 10.1212/WNL.57.10.1763; Steffen BJ, 1996, AM J PATHOL, V148, P1819; Szmydynger-Chodobska J, 2009, J CEREBR BLOOD F MET, V29, P1503, DOI 10.1038/jcbfm.2009.71; Vercellino M, 2008, J NEUROIMMUNOL, V199, P133, DOI 10.1016/j.jneuroim.2008.04.035; Wilson EH, 2010, J CLIN INVEST, V120, P1368, DOI 10.1172/JCI41911; Wolburg K, 1999, CELL TISSUE RES, V296, P259, DOI 10.1007/s004410051287	35	77	80	0	9	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA		1933-6926		CELL ADHES MIGR	Celll Adhes. Migr.	SEP-OCT	2012	6	5					390	396		10.4161/cam.21054			7	Cell Biology	Cell Biology	032IW	WOS:000310711000002	22902764	Green Published, Bronze			2021-06-18	
J	Anderson, E; Kian, EM				Anderson, Eric; Kian, Edward M.			Examining Media Contestation of Masculinity and Head Trauma in the National Football League	MEN AND MASCULINITIES			English	Article						media; sports; violence; health; hegemonic masculinity	INCLUSIVE MASCULINITY; WOMENS SPORTS; COVERAGE	American football has long been central to the construction of masculinity in the United States. Of the multiple masculine scripts promoting professional players' hegemonic masculine status, sacrificing one's body for the sake of sporting glory is a key tenet. Sport journalists have traditionally used their media platform to reify this social script, an act which simultaneously promotes their own masculine capital. However, this article investigates a crack in this hegemonic system. Through a media analysis of the reporting on Aaron Rodgers' self-withdrawal (after hitting his head) from an important National Football League (NFL) game, we argue that increasing cultural awareness as to the devastating effects of concussions, in the form of chronic traumatic encephalopathy, combined with a softening of American masculinity is beginning to permit some prominent players to distance themselves from the self-sacrifice component of sporting masculinity. Concerning concussions, we conclude major sport media are beginning to support the notion of health over a masculine warrior narrative.	[Anderson, Eric] Univ Winchester, Winchester SO22 4NR, NR, England; [Kian, Edward M.] Univ Cent Florida, Dept Sport & Exercise Sci, Orlando, FL 32816 USA	Anderson, E (corresponding author), Univ Winchester, Sparkford Rd, Winchester SO22 4NR, NR, England.	ericandersonphd@aol.com					Adams A, 2011, J HOMOSEXUAL, V58, P579, DOI 10.1080/00918369.2011.563654; Adams A, 2010, J LANG SOC PSYCHOL, V29, P278, DOI 10.1177/0261927X10368833; Anderson E, 2005, SOCIOL PERSPECT, V48, P337, DOI 10.1525/sop.2005.48.3.337; Anderson E, 2009, ROUTL RES GEND SOC, P1; Anderson E, 2008, SEX ROLES, V58, P104, DOI 10.1007/s11199-007-9337-7; Anderson E, 2010, J GENDER STUD, V19, P249, DOI 10.1080/09589236.2010.494341; [Anonymous], 2010, ESPN INTERNET   1216; [Anonymous], 2010, ESPN INTERNET   1019; [Anonymous], 2010, FOXSPORTS COM   1216; Battista J., 2010, NY TIMES        1020; Bouchette E., 2009, PITTSBURGH POST 0324; Bouchette E., 2010, PITTSBURGH POST 1019; Brown S., 2010, PITTSBURGH TRIB 1116; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Connell RW, 1995, MASCULINITIES; Creswell JW, 2003, RES DESIGN QUANTITAT; Deggans, 2011, ST PETERSBURG T 0207; Delaney JS, 2008, BRIT J SPORT MED, V42, P110, DOI 10.1136/bjsm.2007.037689; Duncan MC., 2006, HDB SPORTS MEDIA, P231; Florio M., 2010, PRO FOOTBALL TA 1216; Glasser B., 1967, DISCOVERY GROUNDED T; Gramsci A., 1971, SELECTIONS PRISON NO; Hagel B, 2004, CLIN J SPORT MED, V14, P193, DOI 10.1097/00042752-200407000-00001; Hardin M, 2005, JOURNALISM MASS COMM, V82, P62, DOI 10.1177/107769900508200105; Hardin Marie, 2006, CRITICAL STUDIES MAS, V23, P332; Hargreaves J., 1994, SPORTING FEMALES CRI; Ibson John, 2002, PICTURING MEN CENTUR; Keown T., 2010, ESPN INTERNET   0204; Kian E.M., 2009, INT J SPORT COMMUN, V2, P185, DOI [10.1123/ijsc.2.2.185, DOI 10.1123/IJSC.2.2.185]; Kian EM, 2011, J HOMOSEXUAL, V58, P680, DOI 10.1080/00918369.2011.563672; Kian EM, 2008, SOCIOL SPORT J, V25, P223, DOI 10.1123/ssj.25.2.223; Kian EM, 2009, J BROADCAST ELECTRON, V53, P477, DOI 10.1080/08838150903102519; Kian Edward (Ted) M., 2007, SMART J, V4, P5; Kuypers Jim A., 2002, PRESS BIAS POLITICS; Lapchick RA, 2011, 2010 11 ASS PRESS SP; McCormack M, 2011, SOCIOL PERSPECT, V54, P83, DOI 10.1525/sop.2011.54.1.83; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McDonough W., 1999, NFL CENTURY; McIntosh AS, 2009, MED SCI SPORT EXER, V41, P306, DOI 10.1249/MSS.0b013e3181864bee; McKee Alan, 2001, METRO, V127, P138; Messner M.A., 2002, TAKING FIELD WOMEN M; Messner MichaelA., 1992, POWER PLAY SPORTS PR; Nylund D, 2004, J SPORT SOC ISSUES, V28, P136, DOI 10.1177/0193723504264409; O'Brien J., 2004, LAMBERT MAN MIDDLE O; Pedersen P. M., 2002, International Review for the Sociology of Sport, V37, P303, DOI 10.1177/1012690202037004895; Pronger B., 1990, ARENA MASCULINITY SP; Rader Benjamin, 2008, AM SPORTS AGE FOLK G; Sanderson A. R., 2002, Journal of Sports Economics, V3, P204, DOI 10.1177/152700250200300206; Schwarz A., 2011, NY TIMES        0502; Schwarz A., 2010, NY TIMES        0204; Schwarz A., 2011, NY TIMES        0204; Shea D., 2010, WALL STREET J T 0426; Smith M. D., 2011, PRO FOOTBALL TA 0419; Smith S., 2009, CNNHEALTH COM   0127; SPARKES A, 1992, RES PHYS ED SPORT EX, P271; TRUJILLO N, 1991, CRIT STUD MASS COMM, V8, P290, DOI 10.1080/15295039109366799; Tuchman Gaye, 1978, HEARTH HOME IMAGES W, P3; TURNER BA, 1981, QUAL QUANT, V15, P225; Viano DC, 2007, NEUROSURGERY, V61, P313, DOI 10.1227/01.NEU.0000279969.02685.D0; Viera M., 2010, NY TIMES        1217; Vincent J., 2002, International Review for the Sociology of Sport, V37, P319, DOI 10.1177/101269020203700312; Vincent J, 2004, SOCIOL SPORT J, V21, P435, DOI 10.1123/ssj.21.4.435; Vincent J., 2008, INT J SPORT COMMUNIC, V1, P78, DOI DOI 10.1123/IJSC.1.1.78	63	77	77	1	41	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1097-184X	1552-6828		MEN MASC	Men Masc.	JUN	2012	15	2					152	173		10.1177/1097184X11430127			22	Sociology	Sociology	952UO	WOS:000304818700004					2021-06-18	
J	Burk, AM; Martin, M; Flierl, MA; Rittirsch, D; Helm, M; Lampl, L; Bruckner, U; Stahl, GL; Blom, AM; Perl, M; Gebhard, F; Huber-Lang, M				Burk, Anne-Maud; Martin, Myriam; Flierl, Michael A.; Rittirsch, Daniel; Helm, Matthias; Lampl, Lorenz; Bruckner, Uwe; Stahl, Gregory L.; Blom, Anna M.; Perl, Mario; Gebhard, Florian; Huber-Lang, Markus			EARLY COMPLEMENTOPATHY AFTER MULTIPLE INJURIES IN HUMANS	SHOCK			English	Article						Multiple injuries; complement; C5a; C3a; MAC; neutrophils	TRAUMA PATIENTS; C4B-BINDING PROTEIN; ACTIVATION; C5A; SEPSIS; GENERATION; PATHOPHYSIOLOGY; INHIBITION; SEVERITY; FAILURE	After severe tissue injury, innate immunity mounts a robust systemic inflammatory response. However, little is known about the immediate impact of multiple trauma on early complement function in humans. In the present study, we hypothesized that multiple trauma results in immediate activation, consumption, and dysfunction of the complement cascade and that the resulting severe "complementopathy" may be associated with morbidity and mortality. Therefore, a prospective multicenter study with 25 healthy volunteers and 40 polytrauma patients (mean injury severity score = 30.3 +/- 2.9) was performed. After polytrauma, serum was collected as early as possible at the scene, on admission to the emergency room (ER), and 4, 12, 24, 120, and 240 h post-trauma and analyzed for the complement profile. Complement hemolytic activity (CH-50) was massively reduced within the first 24 h after injury, recovered only 5 days after trauma, and discriminated between lethal and nonlethal 28-day outcome. Serum levels of the complement activation products C3a and C5a were significantly elevated throughout the entire observation period and correlated with the severity of traumatic brain injury and survival. The soluble terminal complement complex SC5b-9 and mannose-binding lectin showed a bi-phasic response after trauma. Key fluid-phase inhibitors of complement, such as C4b-binding protein and factor I, were significantly diminished early after trauma. The present data indicate an almost synchronical rapid activation and dysfunction of complement, suggesting a trauma-induced complementopathy early after injury. These events may participate in the impairment of the innate immune response observed after severe trauma.	[Burk, Anne-Maud; Flierl, Michael A.; Rittirsch, Daniel; Bruckner, Uwe; Perl, Mario; Gebhard, Florian; Huber-Lang, Markus] Univ Hosp Ulm, Dept Traumatol Hand Plast & Reconstruct Surg, D-89075 Ulm, Germany; [Martin, Myriam; Blom, Anna M.] Lund Univ, Skane Univ Hosp, Dept Lab Med, Malmo, Sweden; [Helm, Matthias; Lampl, Lorenz] Mil Hosp Ulm, Dept Anaesthesiol, Ulm, Germany; [Stahl, Gregory L.] Harvard Univ, Brigham & Womens Hosp, Ctr Expt Therapeut & Reperfus Injury, Dept Anaesthesiol Perioperat & Pain Med,Sch Med, Boston, MA 02115 USA	Huber-Lang, M (corresponding author), Univ Hosp Ulm, Dept Traumatol Hand Plast & Reconstruct Surg, Steinhoevelstr 9, D-89075 Ulm, Germany.	markus.huber-lang@uniklinik-ulm.de	Huber-Lang, Markus/AAJ-2209-2020; Blom, Anna M/B-9607-2009	Blom, Anna M/0000-0002-1348-1734; Rittirsch, Daniel/0000-0002-1185-2431; Stahl, Gregory/0000-0002-4805-8119	European Shock Society/Novo NordiskNovo Nordisk; Deutsche Forschungsgemeinschaft (DFG)German Research Foundation (DFG) [HU 823/2-2, HU 823/3-1, PE 908/2-1]; Swedish Research CouncilSwedish Research CouncilEuropean Commission; BMVg InSan I [0294-V-1299]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HL056086, HL52886, HL099130, AI089781]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL056086, R01HL052886, R56HL056086, RC1HL099130, R29HL052886] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R01AI089781, R56AI089781] Funding Source: NIH RePORTER	This work was supported by grants from the European Shock Society Award/Novo Nordisk 2006; the Deutsche Forschungsgemeinschaft (DFG HU 823/2-2, HU 823/3-1, PE 908/2-1); the Swedish Research Council; the BMVg InSan I 0294-V-1299; and the National Institutes of Health (HL056086, HL52886, HL099130, AI089781).	Amara U, 2010, J IMMUNOL, V185, P5628, DOI 10.4049/jimmunol.0903678; Amara U, 2010, SHOCK, V33, P568, DOI 10.1097/SHK.0b013e3181c799d4; Boldt J, 2000, CRIT CARE MED, V28, P445, DOI 10.1097/00003246-200002000-00026; Bossi F, 2004, J IMMUNOL, V173, P6921, DOI 10.4049/jimmunol.173.11.6921; Carlsson S, 2010, J BIOL CHEM, V285, P32038, DOI 10.1074/jbc.M110.148452; Chan RK, 2003, BRIT J SURG, V90, P1470, DOI 10.1002/bjs.4408; Demetriades D, 2004, J AM COLL SURGEONS, V198, P20, DOI 10.1016/j.jamcollsurg.2003.09.003; Dries D J, 1996, New Horiz, V4, P276; Fleming SD, 2008, J SURG RES, V150, P196, DOI 10.1016/j.jss.2008.02.010; Flierl MA, 2008, SHOCK, V29, P25, DOI 10.1097/shk.0b013e3180556a0b; FOSSE E, 1987, ACTA CHIR SCAND, V153, P325; Fosse E, 1998, INJURY, V29, P509, DOI 10.1016/S0020-1383(98)00113-2; Ganter MT, 2007, SHOCK, V28, P29, DOI 10.1097/shk.0b013e3180342439; Garcia de Frutos P, 1994, Blood, V84, P815; Gebhard F, 2008, LANGENBECK ARCH SURG, V393, P825, DOI 10.1007/s00423-008-0334-2; Gebhard F, 2000, LANGENBECK ARCH SURG, V385, P406, DOI 10.1007/s004230000152; Gerard C, 2003, NEW ENGL J MED, V348, P167, DOI 10.1056/NEJMcibr022995; Happonen KE, 2009, J IMMUNOL, V182, P1518, DOI 10.4049/jimmunol.182.3.1518; Hecke F, 1997, CRIT CARE MED, V25, P2015, DOI 10.1097/00003246-199712000-00019; HEIDEMAN M, 1984, J TRAUMA, V24, P1038, DOI 10.1097/00005373-198412000-00006; Huber-Lang M, 2001, J IMMUNOL, V166, P1193, DOI 10.4049/jimmunol.166.2.1193; Huber-Lang M, 2006, NAT MED, V12, P682, DOI 10.1038/nm1419; Keel M, 2005, INJURY, V36, P691, DOI 10.1016/j.injury.2004.12.037; Kohl J, 2006, IMMUNOL RES, V34, P157, DOI 10.1385/IR:34:2:157; Leinhase I, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-13; Liener UC, 2002, SHOCK, V17, P169, DOI 10.1097/00024382-200203000-00002; Martin M, 2009, J VASC SURG, V50, P100, DOI 10.1016/j.jvs.2008.12.033; Matzinger P, 2002, SCIENCE, V296, P301, DOI 10.1126/science.1071059; MOORE FA, 1991, J TRAUMA, V31, P629, DOI 10.1097/00005373-199105000-00006; Napolitano LM, 1999, SURG CLIN N AM, V79, P1385, DOI 10.1016/S0039-6109(05)70084-0; Nilsson SC, 2007, MOL IMMUNOL, V44, P1835, DOI 10.1016/j.molimm.2006.10.005; Nordahl EA, 2004, P NATL ACAD SCI USA, V101, P16879, DOI 10.1073/pnas.0406678101; PARSONS PE, 1990, AM REV RESPIR DIS, V141, P98, DOI 10.1164/ajrccm/141.1.98; RISBERG B, 1986, CRIT CARE MED, V14, P917, DOI 10.1097/00003246-198611000-00001; ROUMEN RMH, 1995, CRIT CARE MED, V23, P474, DOI 10.1097/00003246-199503000-00010; Schaeffer V, 2007, SHOCK, V27, P623, DOI 10.1097/SHK.0b013e31802fa0bd; Sjoberg AP, 2009, TRENDS IMMUNOL, V30, P83, DOI 10.1016/j.it.2008.11.003; TENNENBERG SD, 1987, ARCH SURG-CHICAGO, V122, P26; WATKINS J, 1985, KLIN WOCHENSCHR, V63, P1019, DOI 10.1007/BF01737639; Younger JG, 2001, J APPL PHYSIOL, V90, P441; ZILOW G, 1992, CRIT CARE MED, V20, P468, DOI 10.1097/00003246-199204000-00006; Zimmermann T, 1989, Prog Clin Biol Res, V308, P291	42	77	80	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1073-2322	1540-0514		SHOCK	Shock	APR	2012	37	4					348	354		10.1097/SHK.0b013e3182471795			7	Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease	General & Internal Medicine; Hematology; Surgery; Cardiovascular System & Cardiology	910XH	WOS:000301681400003	22258234	Green Accepted			2021-06-18	
J	Caeyenberghs, K; Leemans, A; Heitger, MH; Leunissen, I; Dhollander, T; Sunaert, S; Dupont, P; Swinnen, SP				Caeyenberghs, Karen; Leemans, Alexander; Heitger, Marcus H.; Leunissen, Inge; Dhollander, Thijs; Sunaert, Stefan; Dupont, Patrick; Swinnen, Stephan P.			Graph analysis of functional brain networks for cognitive control of action in traumatic brain injury	BRAIN			English	Article						traumatic brain injury; cognitive control; functional MRI; task switching; functional network	BIMANUAL COORDINATION TASK; SMALL-WORLD NETWORKS; PREFRONTAL CORTEX; WHITE-MATTER; INTRINSIC CONNECTIONS; PREMOTOR AREAS; NORMATIVE DATA; RHESUS-MONKEY; NEURAL BASIS; HEAD-INJURY	Patients with traumatic brain injury show clear impairments in behavioural flexibility and inhibition that often persist beyond the time of injury, affecting independent living and psychosocial functioning. Functional magnetic resonance imaging studies have shown that patients with traumatic brain injury typically show increased and more broadly dispersed frontal and parietal activity during performance of cognitive control tasks. We constructed binary and weighted functional networks and calculated their topological properties using a graph theoretical approach. Twenty-three adults with traumatic brain injury and 26 age-matched controls were instructed to switch between coordination modes while making spatially and temporally coupled circular motions with joysticks during event-related functional magnetic resonance imaging. Results demonstrated that switching performance was significantly lower in patients with traumatic brain injury compared with control subjects. Furthermore, although brain networks of both groups exhibited economical small-world topology, altered functional connectivity was demonstrated in patients with traumatic brain injury. In particular, compared with controls, patients with traumatic brain injury showed increased connectivity degree and strength, and higher values of local efficiency, suggesting adaptive mechanisms in this group. Finally, the degree of increased connectivity was significantly correlated with poorer switching task performance and more severe brain injury. We conclude that analysing the functional brain network connectivity provides new insights into understanding cognitive control changes following brain injury.	[Caeyenberghs, Karen; Heitger, Marcus H.; Leunissen, Inge; Swinnen, Stephan P.] Biomed Sci Grp, Dept Kinesiol, Movement Control & Neuroplast Res Grp, B-3000 Louvain, Belgium; [Leemans, Alexander] Univ Med Ctr Utrecht, Image Sci Inst, NL-3564 CX Utrecht, Netherlands; [Dhollander, Thijs] Ctr Proc Speech & Images, ESAT PSI, Dept Elect Engn ESAT, Sci Engn & Technol Grp, B-3000 Louvain, Belgium; [Sunaert, Stefan] Biomed Sci Grp, Dept Imaging & Pathol, B-3000 Louvain, Belgium; [Dupont, Patrick] Biomed Sci Grp, Dept Neurosci, Res Grp Expt Neurol, Lab Cognit Neurol, B-3000 Louvain, Belgium	Caeyenberghs, K (corresponding author), Katholieke Univ Leuven, Grp Biomed Sci, Res Ctr Motor Control & Neuroplast, Lab Motor Control, B-3001 Heverlee, Belgium.	Karen.Caeyenberghs@faber.kuleuven.be	Leemans, Alexander/A-1784-2011; Dupont, Patrick/B-8044-2009	Leemans, Alexander/0000-0002-9306-6126; Dupont, Patrick/0000-0003-1980-2540; Caeyenberghs, Karen/0000-0001-7009-6843; Leunissen, Inge/0000-0002-3977-3620; Dhollander, Thijs/0000-0003-3088-3636	Research Foundation - Flanders (FWO)FWO [G.0482.010, G.A114.11]; Belgian federal government [P6/29]	Support for this study was provided through a grant from the Research Program of the Research Foundation - Flanders (FWO) (Levenslijn G.0482.010 and G.A114.11) and Grant P6/29 from the Interuniversity Attraction Poles program of the Belgian federal government. Caeyenberghs K. is funded by a postdoctoral fellowship of the Research Foundation - Flanders (FWO).	Ashburner J, 2005, NEUROIMAGE, V26, P839, DOI 10.1016/j.neuroimage.2005.02.018; Azouvi P, 2004, NEUROPSYCHOLOGIA, V42, P1260, DOI 10.1016/j.neuropsychologia.2004.01.001; Bamiou DE, 2003, BRAIN RES REV, V42, P143, DOI 10.1016/S0165-0173(03)00172-3; BARBAS H, 1989, J COMP NEUROL, V286, P353, DOI 10.1002/cne.902860306; Bartolomei F, 2006, ANN NEUROL, V59, P128, DOI 10.1002/ana.20710; Bartolomei F, 2006, CLIN NEUROPHYSIOL, V117, P2039, DOI 10.1016/j.clinph.2006.05.018; Bosma I, 2008, J NEURO-ONCOL, V88, P77, DOI 10.1007/s11060-008-9535-3; Bullmore ET, 2009, NAT REV NEUROSCI, V10, P186, DOI 10.1038/nrn2575; Cao C, 2010, IEEE T NEUR SYS REH, V18, P11, DOI 10.1109/TNSRE.2009.2027704; Castellanos NP, 2011, NEUROIMAGE, V55, P1189, DOI 10.1016/j.neuroimage.2010.12.046; Castellanos NP, 2010, BRAIN, V133, P2365, DOI 10.1093/brain/awq174; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Corbetta M, 2002, NAT REV NEUROSCI, V3, P201, DOI 10.1038/nrn755; Corbetta M, 2008, NEURON, V58, P306, DOI 10.1016/j.neuron.2008.04.017; Coxon JP, 2010, CEREB CORTEX, V20, P2368, DOI 10.1093/cercor/bhp306; Crinion J, 2007, NEUROIMAGE, V37, P866, DOI 10.1016/j.neuroimage.2007.04.065; Fallani FD, 2007, BRAIN TOPOGR, V19, P125, DOI 10.1007/s10548-007-0019-0; Debaere F, 2001, NEUROIMAGE, V14, P947, DOI 10.1006/nimg.2001.0892; Debaere F, 2004, NEUROPSYCHOLOGIA, V42, P855, DOI 10.1016/j.neuropsychologia.2003.12.010; DEIBER MP, 1991, EXP BRAIN RES, V84, P393; DESROSIERS J, 1995, DISABIL REHABIL, V17, P217, DOI 10.3109/09638289509166638; DESROSIERS J, 1995, ARCH PHYS MED REHAB, V76, P1125, DOI 10.1016/S0003-9993(95)80120-0; Dosenbach NUF, 2006, NEURON, V50, P799, DOI 10.1016/j.neuron.2006.04.031; Duann JR, 2009, J NEUROSCI, V29, P10171, DOI 10.1523/JNEUROSCI.1300-09.2009; DUM RP, 1991, J NEUROSCI, V11, P667; Ehrsson HH, 2002, J NEUROSCI, V22, P5074, DOI 10.1523/JNEUROSCI.22-12-05074.2002; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; FRISTON KJ, 1995, NEUROIMAGE, V2, P45, DOI 10.1006/nimg.1995.1007; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; Garth J, 1997, Pediatr Rehabil, V1, P99; Goble DJ, 2011, HUM BRAIN MAPP, P22; Godefroy O, 2003, J NEUROL, V250, P1, DOI 10.1007/s00415-003-0918-2; GOLDMANRAKIC PS, 1982, SCIENCE, V216, P755, DOI 10.1126/science.6177037; Guye M, 2010, MAGN RESON MATER PHY, V23, P409, DOI 10.1007/s10334-010-0205-z; Hampson M, 2002, HUM BRAIN MAPP, V15, P247, DOI 10.1002/hbm.10022; Heuninckx S, 2005, J NEUROSCI, V25, P6787, DOI 10.1523/JNEUROSCI.1263-05.2005; Hillary FG, 2002, J HEAD TRAUMA REHAB, V17, P411, DOI 10.1097/00001199-200210000-00004; Hillary FG, 2008, J INT NEUROPSYCH SOC, V14, P526, DOI 10.1017/S1355617708080788; Hillary FG, 2011, FRONT SYST NEUROSCI, V5, DOI 10.3389/fnsys.2011.00024; Iturria-Medina Y, 2008, NEUROIMAGE, V40, P1064, DOI 10.1016/j.neuroimage.2007.10.060; KELSO JAS, 1995, CHAOS, V5, P64, DOI 10.1063/1.166087; Kennedy MRT, 2009, J INT NEUROPSYCH SOC, V15, P130, DOI 10.1017/S1355617708090024; Kim YH, 2009, NEUROREHAB NEURAL RE, V23, P468, DOI 10.1177/1545968308328728; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Larson MJ, 2006, J CLIN EXP NEUROPSYC, V28, P968, DOI 10.1080/13803390600646860; Latora V, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.198701; Lee L, 2006, NEUROIMAGE, V30, P1243, DOI 10.1016/j.neuroimage.2005.11.007; Leunissen I, 2012, HUM BRAIN MAPP, P30; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; Levin HS, 2004, J CLIN EXP NEUROPSYC, V26, P589, DOI 10.1080/13803390490504434; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; Lewis PA, 2004, NEUROPSYCHOLOGIA, V42, P1301, DOI 10.1016/j.neuropsychologia.2004.03.001; Liu Y, 2008, BRAIN, V131, P945, DOI 10.1093/brain/awn018; Mecklinger A, 1999, J CLIN EXP NEUROPSYC, V21, P606, DOI 10.1076/jcen.21.5.606.873; Medaglia JD, 2011, HUM BRAIN MAPP; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Miller EK, 2000, NAT REV NEUROSCI, V1, P59, DOI 10.1038/35036228; Nakamura T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008220; Newsome MR, 2008, NEUROPSYCHOLOGY, V22, P419, DOI 10.1037/0894-4105.22.4.419; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; PANDYA DN, 1990, PROG BRAIN RES, V85, P63; Park BS, 2009, APPL NEUROPSYCHOL, V16, P1, DOI 10.1080/09084280802636371; Perlstein WM, 2006, NEUROPSYCHOLOGIA, V44, P260, DOI 10.1016/j.neuropsychologia.2005.05.009; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; Petrides M, 1999, EUR J NEUROSCI, V11, P1011, DOI 10.1046/j.1460-9568.1999.00518.x; Picard N, 2001, CURR OPIN NEUROBIOL, V11, P663, DOI 10.1016/S0959-4388(01)00266-5; Platel H, 1997, BRAIN, V120, P229, DOI 10.1093/brain/120.2.229; Powell KB, 2004, J CHILD NEUROL, V19, P785, DOI 10.1177/08830738040190100801; Puttemans V, 2005, J NEUROSCI, V25, P4270, DOI 10.1523/JNEUROSCI.3866-04.2005; Rees L, 2007, BRAIN INJURY, V21, P161, DOI 10.1080/02699050701201813; Rubinov M, 2010, NEUROIMAGE, V52, P1059, DOI 10.1016/j.neuroimage.2009.10.003; Sadato N, 1997, J NEUROSCI, V17, P9667; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Salvador R, 2005, PHILOS T R SOC B, V360, P937, DOI 10.1098/rstb.2005.1645; Scheibel RS, 2007, NEUROREHAB NEURAL RE, V21, P36, DOI 10.1177/1545968306294730; Schroeter ML, 2007, NEUROPSYCHOLOGIA, V45, P3149, DOI 10.1016/j.neuropsychologia.2007.07.004; SELTZER B, 1989, J COMP NEUROL, V290, P451, DOI 10.1002/cne.902900402; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Smith SM, 2011, NEUROIMAGE, V54, P875, DOI 10.1016/j.neuroimage.2010.08.063; Stam CJ, 2010, J NEUROL SCI, V289, P128, DOI 10.1016/j.jns.2009.08.028; Stephen KM, 1999, EXP BRAIN RES, V128, P243, DOI 10.1007/s002210050844; TEASDALE G, 1974, LANCET, V2, P81; Thaut MH, 2003, ANN NY ACAD SCI, V999, P364, DOI 10.1196/annals.1284.044; Thoenissen D, 2002, J NEUROSCI, V22, P9024; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Toni I, 1999, CEREB CORTEX, V9, P35, DOI 10.1093/cercor/9.1.35; Tsirka V, 2011, INT J PSYCHOPHYSIOL, V79, P89, DOI 10.1016/j.ijpsycho.2010.09.006; van Wijk BCM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013701; Verhagen L, 2008, J NEUROSCI, V28, P4726, DOI 10.1523/JNEUROSCI.0057-08.2008; Wenderoth N, 2009, J NEUROPHYSIOL, V102, P302, DOI 10.1152/jn.91090.2008; Zalesky A, 2010, NEUROIMAGE, V53, P1197, DOI 10.1016/j.neuroimage.2010.06.041	92	77	83	0	21	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	APR	2012	135		4				1293	1307		10.1093/brain/aws048			15	Clinical Neurology; Neurosciences	Neurosciences & Neurology	927ZH	WOS:000302948700031	22427332	Bronze			2021-06-18	
J	Morissette, SB; Woodward, M; Kimbrel, NA; Meyer, EC; Kruse, MI; Dolan, S; Gulliver, SB				Morissette, Sandra B.; Woodward, Matthew; Kimbrel, Nathan A.; Meyer, Eric C.; Kruse, Marc I.; Dolan, Sara; Gulliver, Suzy Bird			Deployment-Related TBI, Persistent Postconcussive Symptoms, PTSD, and Depression in OEF/OIF Veterans	REHABILITATION PSYCHOLOGY			English	Article						PTSD; TBI; postconcussive symptoms; veterans	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH PROBLEMS; IRAQ WAR VETERANS; UNITED-STATES; PSYCHOMETRIC PROPERTIES; LIFE SATISFACTION; MILD; SOLDIERS; COMBAT	Objective: A substantial proportion of the more than 2 million service members who have served in Operation Enduring Freedom (OEF) and Operation Iraqi Freedom (OIF) have experienced a traumatic brain injury (TBI). Understanding the long-term impact of TBI is complicated by the nonspecific nature of postconcussive symptoms (PCSs) and the high rates of co-occurrence among TBI, posttraumatic stress disorder (PTSD), and depression. The goal of the present research was to examine the relations among TB!, persistent PCSs, and symptoms of PTSD and depression among returning OEF/OIF veterans. Method: 213 OEF/OIF veterans (87% male) completed a semistructured screening interview assessing deployment-related TBI and current, persistent PCSs. Participants also completed self-report measures of combat exposure and current symptoms of PTSD and depression. Results: Nearly half (46%) of sampled veterans screened positive for TBI, the majority of whom (85%) reported at least one persistent PCS after removing PCSs that overlapped with PTSD and depression. Veterans with deployment-related TBI reported higher levels of combat exposure and symptoms of PTSD and depression. Structural equation modeling was used to assess the fit of 3 models of the relationships among TBI, combat exposure, persistent PCSs, PTSD, and depression. Consistent with hypotheses, the best-fitting model was one in which the effects of TBI on both PTSD and depression were fully mediated by nonoverlapping persistent PCSs. Conclusions: These findings highlight the importance of addressing persistent PCSs in order to facilitate the functional recovery of returning war veterans.	[Morissette, Sandra B.; Woodward, Matthew; Kimbrel, Nathan A.; Meyer, Eric C.; Kruse, Marc I.; Gulliver, Suzy Bird] Ctr Excellence Res Returning War Vet, Dept Vet Affairs VISN 17, Waco, TX USA; [Morissette, Sandra B.; Kimbrel, Nathan A.; Meyer, Eric C.; Kruse, Marc I.; Gulliver, Suzy Bird] Texas A&M Hlth Sci Ctr, Coll Med, Bryan, TX USA; [Dolan, Sara] Baylor Univ, Dept Psychol & Neurosci, Waco, TX 76798 USA	Morissette, SB (corresponding author), 4800 Mem Dr,151C, Waco, TX 76711 USA.	sandra.morissette@va.gov	Woodward, Matthew J./L-2971-2019; Kimbrel, Nathan/P-3109-2016; Gulliver, Suzy/X-9776-2019	Kimbrel, Nathan/0000-0001-7218-1005; Dolan, Sara/0000-0002-0156-8226; Gulliver, Suzy Bird/0000-0002-6476-9447	RRD VA [I01 RX000304] Funding Source: Medline; VAUS Department of Veterans Affairs [5I01RX000304-02] Funding Source: Federal RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01RX000304] Funding Source: NIH RePORTER		Alderfer BS, 2005, J HEAD TRAUMA REHAB, V20, P544, DOI 10.1097/00001199-200511000-00006; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Arbuckle J. L, 2006, AMOS 7 0 USERS GUIDE; Armed Forces Health Surveillance Center, 2011, DOD NUMB TRAUM BRAIN; Bagozzi RP, 1994, STRUCT EQU MODELING, V1, P35, DOI 10.1080/10705519409539961; Barth JT, 2006, PSYCHOLOGICAL KNOWLEDGE IN COURT: PTSD, PAIN, AND TBI, P271, DOI 10.1007/0-387-25610-5_15; Beck A. T., 1996, BECK DEPRESSION INVE, VII; Beck AT, 1996, J PERS ASSESS, V67, P588, DOI 10.1207/s15327752jpa6703_13; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Brenner LA, 2010, J HEAD TRAUMA REHAB, V25, P307, DOI 10.1097/HTR.0b013e3181cada03; Bryant RA, 2003, AM J PSYCHIAT, V160, P585, DOI 10.1176/appi.ajp.160.3.585; Bullman TA, 1996, AM J PUBLIC HEALTH, V86, P662, DOI 10.2105/AJPH.86.5.662; BURT DB, 1995, PSYCHOL BULL, V117, P285, DOI 10.1037/0033-2909.117.2.285; Carlson KF, 2011, J HEAD TRAUMA REHAB, V26, P103, DOI 10.1097/HTR.0b013e3181e50ef1; Carlson KF, 2010, J TRAUMA STRESS, V23, P17, DOI 10.1002/jts.20483; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Defense Manpower Data Center, 2009, OEF OIF DEPL SEPT 11; Dikmen S, 2001, J CLIN EXP NEUROPSYC, V23, P729, DOI 10.1076/jcen.23.6.729.1019; Enders C. K., 2010, APPL MISSING DATA AN; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Fann JR, 2001, PSYCHOSOMATICS, V42, P48, DOI 10.1176/appi.psy.42.1.48; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Forbes D, 2001, BEHAV RES THER, V39, P977, DOI 10.1016/S0005-7967(00)00084-X; Gerberding J.L., 2003, REPORT C MILD TRAUMA; Gordon SN, 2011, CLIN NEUROPSYCHOL, V25, P337, DOI 10.1080/13854046.2010.550634; Grieger TA, 2006, AM J PSYCHIAT, V163, P1777, DOI 10.1176/appi.ajp.163.10.1777; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hessen E, 2007, BRAIN INJURY, V21, P963, DOI 10.1080/02699050701528454; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; HOLLNAGEL H, 1980, Ugeskrift for Laeger, V142, P3071; Howe LLS, 2009, CLIN NEUROPSYCHOL, V23, P1315, DOI 10.1080/13854040903266928; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Jaffee CMS, 2009, CLIN NEUROPSYCHOL, V23, P1291, DOI 10.1080/13854040903307250; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; Kang HK, 2008, JAMA-J AM MED ASSOC, V300, P652, DOI 10.1001/jama.300.6.652; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Keen SM, 2008, J REHABIL RES DEV, V45, P465, DOI 10.1682/JRRD.2007.09.0138; Kline R.B., 2005, PRINCIPLES PRACTICE, V2nd; Lees-Haley PR, 2001, ARCH CLIN NEUROPSYCH, V16, P689, DOI 10.1016/S0887-6177(00)00092-5; Leone L, 2001, EUR J PERSONALITY, V15, P373, DOI 10.1002/per.415; Lippa SM, 2010, J INT NEUROPSYCH SOC, V16, P856, DOI 10.1017/S1355617710000743; Meares S, 2011, NEUROPSYCHOLOGY, V25, P454, DOI 10.1037/a0022580; Milliken CS, 2007, JAMA-J AM MED ASSOC, V298, P2141, DOI 10.1001/jama.298.18.2141; Pagulayan KF, 2008, ARCH PHYS MED REHAB, V89, P1887, DOI 10.1016/j.apmr.2008.03.019; Peskind ER, 2011, NEUROIMAGE, V54, pS76, DOI 10.1016/j.neuroimage.2010.04.008; Pomerantz AS, 2010, FAM SYST HEALTH, V28, P114, DOI 10.1037/a0020261; Porto PR, 2009, J NEUROPSYCH CLIN N, V21, P114, DOI 10.1176/appi.neuropsych.21.2.114; Qureshi SU, 2011, J NEUROPSYCH CLIN N, V23, P16, DOI 10.1176/appi.neuropsych.23.1.16; Rao V, 2010, J NEUROPSYCH CLIN N, V22, P100, DOI 10.1176/appi.neuropsych.22.1.100; Rapoport MJ, 2005, J NEUROPSYCH CLIN N, V17, P61, DOI 10.1176/appi.neuropsych.17.1.61; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; Resch JA, 2009, REHABIL PSYCHOL, V54, P51, DOI 10.1037/a0015051; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schwab KA, 2006, NEUROLOGY, V66, pA235; Snell D, 2009, J CLIN EXP NEUROPSYC, V31, P20, DOI 10.1080/13803390801978849; Sosin DM, 1996, BRAIN INJURY, V10, P47; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; Thomas JL, 2010, ARCH GEN PSYCHIAT, V67, P614, DOI 10.1001/archgenpsychiatry.2010.54; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Underhill AT, 2003, BRAIN INJURY, V17, P973, DOI 10.1080/0269905031000110418; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Vasterling J. J., 2008, TBI SCREENING UNPUB; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004; Veterans Benefits Administration, 2010, VET BEN ADM ANN BEN; Veterans Health Administration Office of Public Health and Environmental Hazards, 2010, AN VA HLTH CAR UT US; Weathers F. W., 1993, ANN M INT SOC TRAUM; Wilk JE, 2010, J HEAD TRAUMA REHAB, V25, P9, DOI 10.1097/HTR.0b013e3181bd090f; Wright KM, 2009, PSYCHOL SERV, V6, P108, DOI 10.1037/a0012620; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac	78	77	78	0	19	EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550	1939-1544		REHABIL PSYCHOL	Rehabil. Psychol.	NOV	2011	56	4					340	350		10.1037/a0025462			11	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	862AQ	WOS:000298062600007	22121940	Green Accepted			2021-06-18	
J	Baratz, R; Tweedie, D; Rubovitch, V; Luo, WM; Yoon, JS; Hoffer, BJ; Greig, NH; Pick, CG				Baratz, Renana; Tweedie, David; Rubovitch, Vardit; Luo, Weiming; Yoon, Jeong Seon; Hoffer, Barry J.; Greig, Nigel H.; Pick, Chaim G.			Tumor necrosis factor-alpha synthesis inhibitor, 3,6 '-dithiothalidomide, reverses behavioral impairments induced by minimal traumatic brain injury in mice	JOURNAL OF NEUROCHEMISTRY			English	Article						etanercept; neuroinflammation; thalidomide; thiothalidomide; TNF-alpha; traumatic brain injury	CLOSED-HEAD INJURY; CELL-DEATH MECHANISMS; TNF-ALPHA; MESSENGER-RNA; COGNITIVE DEFICITS; FACTOR RECEPTORS; RAT-BRAIN; THALIDOMIDE; MEMORY; SEQUELAE	Mild traumatic brain injury (mTBI) patients do not show clear structural brain defects and, in general, do not require hospitalization, but frequently suffer from long-lasting cognitive, behavioral and emotional difficulties. Although there is no current effective treatment or cure for mTBI, tumor necrosis factor-alpha (TNF-alpha), a cytokine fundamental in the systemic inflammatory process, represents a potential drug target. TNF-alpha levels increase after mTBI and may induce or exacerbate secondary damage to brain tissue. The present study evaluated the efficacy of the experimental TNF-alpha synthesis inhibitor, 3,6'-dithiothalidomide, on recovery of mice from mTBI in a closed head weight-drop model that induces an acute elevation in brain TNF-alpha and an impairment in cognitive performance, as assessed by the Y-maze, by novel object recognition and by passive avoidance paradigms at 72 h and 7 days after injury. These impairments were fully ameliorated in mice that received a one time administration of 3,6'-dithiothalidomide at either a low (28 mg/kg) or high (56 mg/kg) dose provided either 1 h prior to injury, or at 1 or 12 h post-injury. Together, these results implicate TNF-alpha as a drug target for mTBI and suggests that 3,6'-dithiothalidomide may act as a neuroprotective drug to minimize impairment.	[Greig, Nigel H.] NIA, Drug Design & Dev Sect, Neurosci Lab, Intramural Res Program,NIH, Baltimore, MD 21224 USA; [Baratz, Renana; Rubovitch, Vardit; Pick, Chaim G.] Tel Aviv Univ, Sackler Sch Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel; [Hoffer, Barry J.] Natl Inst Drug Abuse, Cellular Neurobiol Branch, Intramural Res Program, NIH, Baltimore, MD USA; [Hoffer, Barry J.] Case Western Reserve Univ, Sch Med, Dept Neurosurg, Cleveland, OH USA	Greig, NH (corresponding author), NIA, Drug Design & Dev Sect, Neurosci Lab, Intramural Res Program,NIH, BRC Room 05C220,251 Bayview Blvd, Baltimore, MD 21224 USA.	greign@grc.nia.nih.gov			Sackler School of Medicine, Tel-Aviv University; National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA); National Institute on Drug Abuse, National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA); NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [ZIAAG000311] Funding Source: NIH RePORTER	This research was supported in part by the Sackler School of Medicine, Tel-Aviv University, and the Intramural Research Programs of both the National Institute on Aging and National Institute on Drug Abuse, National Institutes of Health. This work was performed in partial fulfillment of the requirements for a Ph.D. degree of Renana Baratz, Sackler Faculty of Medicine, Tel Aviv University, Israel.	Andersson M, 2006, ANN RHEUM DIS, V65, P1237, DOI 10.1136/ard.2006.055194; Aragon-Ching JB, 2007, RECENT PAT ANTI-CANC, V2, P167, DOI 10.2174/157489207780832478; Baratz R, 2010, J NEUROTRAUM, V27, P555, DOI 10.1089/neu.2009.0891; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Cederberg D, 2010, CHILD NERV SYST, V26, P221, DOI 10.1007/s00381-009-1029-x; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; DELLU F, 1992, BRAIN RES, V588, P132, DOI 10.1016/0006-8993(92)91352-F; Dix SL, 1999, BEHAV BRAIN RES, V99, P191, DOI 10.1016/S0166-4328(98)00079-5; Edut S, 2011, PSYCHOPHARMACOLOGY, V214, P877, DOI 10.1007/s00213-010-2098-y; Esposito E, 2009, CURR MED CHEM, V16, P3152, DOI 10.2174/092986709788803024; Frank-Cannon TC, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-47; Frankola KA, 2011, CNS NEUROL DISORD-DR, V10, P391; Garner Jeff, 2007, Anesthesiol Clin, V25, P147; Ghajar J, 2008, NEUROREHAB NEURAL RE, V22, P217, DOI 10.1177/1545968308315600; Greig NH, 2004, ACTA NEUROBIOL EXP, V64, P1; Hesdorffer DC, 2009, J HEAD TRAUMA REHAB, V24, P452, DOI 10.1097/HTR.0b013e3181c133fd; Hyakkoku K, 2009, NEUROSCIENCE, V159, P760, DOI 10.1016/j.neuroscience.2008.12.043; Israelsson C, 2009, J NEUROTRAUM, V26, P1307, DOI [10.1089/neu.2008.0676, 10.1089/neu.2008-0676]; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Khera TK, 2010, PROG RETIN EYE RES, V29, P610, DOI 10.1016/j.preteyeres.2010.08.003; Kiraly MA, 2007, THESCIENTIFICWORLDJO, V7, P1768, DOI 10.1100/tsw.2007.269; Knight R, 2005, SEMIN ONCOL, V32, pS24, DOI 10.1053/j.seminoncol.2005.06.018; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Koopmans GC, 2009, EXP NEUROL, V216, P490, DOI 10.1016/j.expneurol.2009.01.005; Lecca D, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003579; Lee CJ, 2007, SPINAL CORD, V45, P149, DOI 10.1038/sj.sc.3101931; Lu J, 2009, FRONT BIOSCI-LANDMRK, V14, P3795, DOI 10.2735/3489; Luo WM, 2008, SYNTHESIS-STUTTGART, P3415, DOI 10.1055/s-0028-1083179; McTighe SM, 2010, SCIENCE, V330, P1408, DOI 10.1126/science.1194780; Melchert M, 2007, INT J BIOCHEM CELL B, V39, P1489, DOI 10.1016/j.biocel.2007.01.022; Messier C, 1997, NEUROBIOL LEARN MEM, V67, P172, DOI 10.1006/nlme.1996.3755; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Moppett IK, 2007, BRIT J ANAESTH, V99, P18, DOI 10.1093/bja/aem128; MOREIRA AL, 1993, J EXP MED, V177, P1675, DOI 10.1084/jem.177.6.1675; Pan WH, 2003, EXP BRAIN RES, V149, P195, DOI 10.1007/s00221-002-1355-7; Patil CS, 2008, MOL THER, V16, P1657, DOI 10.1038/mt.2008.163; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Reale M, 2009, MINI-REV MED CHEM, V9, P1229, DOI 10.2174/138955709789055199; Reyes-Alva HJ, 2009, ACTA NEUROBIOL EXP, V69, P494; Rubovitch V, 2010, NEUROBIOL DIS, V38, P299, DOI 10.1016/j.nbd.2010.01.021; SAMPAIO EP, 1991, J EXP MED, V173, P699, DOI 10.1084/jem.173.3.699; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Shannon EJ, 1996, IMMUNOPHARM IMMUNOT, V18, P59, DOI 10.3109/08923979609007110; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stamou P, 2010, CURR DIR AUTOIMMUN, V11, P61, DOI 10.1159/000289197; Stoica BA, 2010, NEUROTHERAPEUTICS, V7, P3, DOI 10.1016/j.nurt.2009.10.023; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Svetlov SI, 2009, J NEUROTRAUM, V26, P913, DOI 10.1089/neu.2008.0609; Tadesse A, 2006, IMMUNOPHARM IMMUNOT, V28, P431, DOI 10.1080/08923970600928023; Tansey MG, 2010, NEUROBIOL DIS, V37, P491, DOI 10.1016/j.nbd.2009.12.004; Tansey MG, 2009, DRUG DISCOV TODAY, V14, P1082, DOI 10.1016/j.drudis.2009.10.002; Tashlykov V, 2009, J MOL NEUROSCI, V37, P16, DOI 10.1007/s12031-008-9094-2; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Taylor PC, 2010, CURR OPIN PHARMACOL, V10, P308, DOI 10.1016/j.coph.2010.01.005; Teo SK, 2004, CLIN PHARMACOKINET, V43, P311, DOI 10.2165/00003088-200443050-00004; Tobinick E, 2010, EXPERT REV NEUROTHER, V10, P985, DOI 10.1586/ERN.10.52; TWEEDIE D, OPEN BIOCH IN PRESS; Tweedie D, 2007, CURR ALZHEIMER RES, V4, P378, DOI 10.2174/156720507781788873; Tweedie D, 2007, J NEUROSCI RES, V85, P805, DOI 10.1002/jnr.21160; Tweedie D, 2009, J NEUROSCI METH, V183, P182, DOI 10.1016/j.jneumeth.2009.06.034; Uryu K, 2003, EXP NEUROL, V184, P214, DOI 10.1016/S0014-4886(03)00245-0; Vakil E, 2005, J CLIN EXP NEUROPSYC, V27, P977, DOI 10.1080/13803390490919245; Yan YP, 2009, BRAIN RES, V1288, P116, DOI 10.1016/j.brainres.2009.06.073; Yang JS, 2010, J NEUROTRAUM, V27, P1037, DOI 10.1089/neu.2009.1229; Zhou QH, 2011, DRUG METAB DISPOS, V39, P71, DOI 10.1124/dmd.110.036012; Zhu XX, 2003, J MED CHEM, V46, P5222, DOI 10.1021/jm030152f; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	71	77	77	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	SEP	2011	118	6					1032	1042		10.1111/j.1471-4159.2011.07377.x			11	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	820JB	WOS:000294900600009	21740439	Green Accepted, Bronze			2021-06-18	
J	Cottler, LB; Ben Abdallah, A; Cummings, SM; Barr, J; Banks, R; Forchheimer, R				Cottler, Linda B.; Ben Abdallah, Arbi; Cummings, Simone M.; Barr, John; Banks, Rayna; Forchheimer, Ronnie			Injury, pain, and prescription opioid use among former National Football League (NFL) players	DRUG AND ALCOHOL DEPENDENCE			English	Article						Opioid use; Opioid misuse; Prescription pain pills; NFL players; Concussions	DRUG-USERS; RELIABILITY; CONCUSSION; BEHAVIORS; MISUSE; ABUSE	Background: Athletes with injury-related pain, especially National Football League (NFL) players, are at increased risk for opioid use and misuse which may result in medical, psychiatric and social problems. This is the first study to evaluate the intersection of sports pain and opioid use and misuse among former NFL players. Methods: A telephone survey of 644 retired NFL players from the 2009 Retired Players Association Directory was conducted (53.4% completion rate) from March to August 2010. Results: Over half (52%) used opioids during their NFL career with 71% reporting misuse. Additionally, 15% of NFL misusers currently misused vs. 5% among players who used just as prescribed during their NFL career. Prevalence of current opioid use was 7%-3 times the rate of the general population. Multivariate analyses indicated that significant NFL pain increased the adjusted odds (AOR) of any current opioid use vs. non-use (AOR 6.76, 95%CI 2.88-15.87), as did moderate to severe mental impairment (AOR 1.88, 95%CI 1.19-2.98) and heavy drinking in the past week (AOR 2.15, 95%CI 1.17-3.98). Undiagnosed concussions singly predicted current misuse vs. use just as prescribed (AOR 4.25, 95%CI 1.12-16.22). Three variables predicted current misuse vs. non-use: significant pain (AOR 8.33, 95%CI 1.98-35.04), undiagnosed concussions (AOR 3.51, 95%CI 1.98-35.04) and heavy drinking (AOR 3.48, 95%CI 1.63-7.41). Conclusions: Players who misused during their NFL career were most likely to misuse currently compared to others. Current misuse was associated with more NFL pain, undiagnosed concussions and heavy drinking. Longitudinal studies are needed to determine the long term effects of opioid misuse among athletes. (C) 2011 Elsevier Ireland Ltd. All rights reserved.	[Cottler, Linda B.; Ben Abdallah, Arbi; Cummings, Simone M.] Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63108 USA; [Barr, John; Banks, Rayna; Forchheimer, Ronnie] ESPN Prod Inc, ESPN Enterprise Unit, Bristol, CT 06010 USA	Cottler, LB (corresponding author), Washington Univ, Sch Med, Dept Psychiat, 40 N Kingshighway,Suite 4, St Louis, MO 63108 USA.	cottler@epi.wustl.edu			ESPN (Entertainment and Sports Programming Network); National Institute on Drug Abuse of the National Institutes of Health (NIDA)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA); NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R01DA020791] Funding Source: NIH RePORTER	This study (Survey of Retired NFL Football Players; LB Cottler, PI) was funded by ESPN (Entertainment and Sports Programming Network). Additional funding was provided by the National Institute on Drug Abuse of the National Institutes of Health (NIDA; Research Supplement for Retired Professional NFL Football Players; Prescription Drug Misuse, Abuse and Dependence, DA020791-04S2; LB Cottler, PI). ESPN staff Barr, Banks and Forchheimer contributed to the study concept and participated in revisions of the manuscript. They had no role in the collection, analysis or interpretation of data. NIDA had no role in the study design, in the collection, analysis or interpretation of data, in the writing of the report, or in the decision to submit the paper for publication.	Alaranta A, 2008, SPORTS MED, V38, P449, DOI 10.2165/00007256-200838060-00002; Casson IR, 2009, PHYS MED REH CLIN N, V20, P195, DOI 10.1016/j.pmr.2008.10.006; Compton WM, 2006, DRUG ALCOHOL DEPEN, V81, P103, DOI 10.1016/j.drugalcdep.2005.05.009; Denisco RA, 2008, EXP CLIN PSYCHOPHARM, V16, P417, DOI 10.1037/a0013636; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; HALCHIN LE, 2008, C RES SERV REP C APR; Ives TJ, 2006, BMC HEALTH SERV RES, V6, DOI 10.1186/1472-6963-6-46; National Institute on Alcohol Abuse and Alcoholism, 2010, RETH DRINK ALC YOUR; NEEDLE R, 1995, PSYCHOL ADDICT BEHAV, V9, P242, DOI 10.1037/0893-164X.9.4.242; *NIDA, 2001, NIH PUBL; Okie S, 2010, NEW ENGL J MED, V363, P1981, DOI 10.1056/NEJMp1011512; Orchard J, 2002, BRIT J SPORT MED, V36, P39, DOI 10.1136/bjsm.36.1.39; Schwenk TL, 2007, MED SCI SPORT EXER, V39, P599, DOI 10.1249/mss.0b013e31802fa679; Selden MA, 2009, AM J MED, V122, P811, DOI 10.1016/j.amjmed.2009.03.027; Shacham E, 2010, ARCH SEX BEHAV, V39, P1331, DOI 10.1007/s10508-009-9539-x; Simoni-Wastila L, 2004, AM J PUBLIC HEALTH, V94, P266, DOI 10.2105/AJPH.94.2.266; Substance Abuse and Mental Health Services Administration, 2009, NSDUH SER H; Zacny J, 2003, DRUG ALCOHOL DEPEN, V69, P215, DOI 10.1016/S0376-8716(03)00003-6	18	77	77	0	38	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0376-8716			DRUG ALCOHOL DEPEN	Drug Alcohol Depend.	JUL 1	2011	116	1-3					188	194		10.1016/j.drugalcdep.2010.12.003			7	Substance Abuse; Psychiatry	Substance Abuse; Psychiatry	784SY	WOS:000292179700028	21277121	Green Accepted			2021-06-18	
J	Highton, D; Elwell, C; Smith, M				Highton, David; Elwell, Clare; Smith, Martin			Noninvasive cerebral oximetry: is there light at the end of the tunnel?	CURRENT OPINION IN ANESTHESIOLOGY			English	Article						cerebral ischemia; cerebral oximetry; near infrared spectroscopy; neuromonitoring	NEAR-INFRARED SPECTROSCOPY; TRAUMATIC BRAIN-INJURY; TIDAL CARBON-DIOXIDE; CAROTID-ENDARTERECTOMY; OXYGEN-SATURATION; CARDIAC-SURGERY; INSPIRED OXYGEN; NIRO 300; ISCHEMIA; PERFUSION	Purpose of review There is increasing interest in the application of near infrared spectroscopy (NIRS) as a noninvasive monitor of cerebral oxygenation. This review will briefly describe the principles of NIRS and examine current evidence for its clinical application as a monitor of the adequacy of cerebral oxygenation in adults. Recent findings There has been a recent surge of interest in the clinical application of NIRS following studies that have quantified the benefits of NIRS-guided management of cerebral oxygenation during cardiopulmonary bypass. However, there are limited data to support its widespread application in other clinical scenarios. New NIRS systems are being introduced to the market and technological advancements have improved their accuracy and extended the range of variables measured. Summary NIRS offers noninvasive monitoring of cerebral oxygenation over multiple regions of interest in a wide range of clinical scenarios. It has many potential advantages over other neuromonitoring techniques, but further technological advances are necessary before it can be introduced more widely into clinical practice.	[Highton, David; Smith, Martin] Univ Coll London Hosp, Natl Hosp Neurol & Neurosurg, Dept Neurocrit Care, London WC1N 3BG, England; [Elwell, Clare; Smith, Martin] UCL, Dept Med Phys & Bioengn, London, England	Smith, M (corresponding author), Univ Coll London Hosp, Natl Hosp Neurol & Neurosurg, Dept Neurocrit Care, London WC1N 3BG, England.	martin.smith@uclh.nhs.uk	Smith, Martin/B-2616-2009; Highton, David/K-9544-2017	Highton, David/0000-0002-4608-4081; Elwell, Clare/0000-0002-7281-7234	Department of Health's Institute for Health Research Centres; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0701458] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [ACF-2009-18-001] Funding Source: researchfish	M.S. is partially funded by the Department of Health's Institute for Health Research Centres funding scheme.	Al-Rawi PG, 2001, STROKE, V32, P2492, DOI 10.1161/hs1101.098356; Al-Rawi PG, 2006, STROKE, V37, P2720, DOI 10.1161/01.STR.0000244807.99073.ae; Banaji M, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000212; de Letter JAM, 1998, NEUROL RES, V20, pS23; DUNCAN A, 1995, PHYS MED BIOL, V40, P295, DOI 10.1088/0031-9155/40/2/007; Dunham CM, 2004, J TRAUMA, V56, P482, DOI 10.1097/01.TA.0000114537.52540.95; Fedorow C, 2010, CURR OPIN ANESTHESIO, V23, P89, DOI 10.1097/ACO.0b013e3283346d10; Fischer GW, 2010, BRIT J ANAESTH, V104, P59, DOI 10.1093/bja/aep335; Fischer GW, 2009, PAIN PRACT, V9, P304, DOI 10.1111/j.1533-2500.2009.00282.x; Germon TJ, 1999, BRIT J ANAESTH, V82, P831; GILL A, 2010, J NEUROSURG, DOI DOI 10.3171/2010/.2.JNS091017; Giustiniano E, 2010, J CARDIOVASC MED, V11, P522, DOI 10.2459/JCM.0b013e32833246e7; Goldman S, 2004, HEART SURG FORUM, V7, pE376, DOI 10.1532/HSF98.20041062; Hirofumi O, 2003, J CLIN NEUROSCI, V10, P79, DOI 10.1016/S0967-5868(02)00268-0; Hoshi Y, 2003, PSYCHOPHYSIOLOGY, V40, P511, DOI 10.1111/1469-8986.00053; Hueber DM, 2001, PHYS MED BIOL, V46, P41, DOI 10.1088/0031-9155/46/1/304; Hunt K, 2006, PHYSIOL MEAS, V27, P777, DOI 10.1088/0967-3334/27/9/002; Kakihana Y, 2008, J BIOMED OPT, V13, DOI 10.1117/1.2940583; Kurth CD, 2002, J CEREBR BLOOD F MET, V22, P335, DOI 10.1097/00004647-200203000-00011; Lee JK, 2009, STROKE, V40, P1820, DOI 10.1161/STROKEAHA.108.536094; Li ZY, 2010, MICROVASC RES, V80, P142, DOI 10.1016/j.mvr.2010.02.004; Manwaring ML, 2010, VASC ENDOVASC SURG, V44, P252, DOI 10.1177/1538574410361785; Mille T, 2004, EUR J VASC ENDOVASC, V27, P646, DOI 10.1016/j.ejvs.2004.02.012; Moritz S, 2007, ANESTHESIOLOGY, V107, P563, DOI 10.1097/01.anes.0000281894.69422.ff; Murkin J M, 2009, Br J Anaesth, V103 Suppl 1, pi3, DOI 10.1093/bja/aep299; Murkin JM, 2009, J EXTRA-CORP TECHNOL, V41, P11; Murkin JM, 2007, ANESTH ANALG, V104, P51, DOI 10.1213/01.ane.0000246814.29362.f4; Newman MF, 2006, LANCET, V368, P694, DOI 10.1016/S0140-6736(06)69254-4; Pennekamp CWA, 2009, EUR J VASC ENDOVASC, V38, P539, DOI 10.1016/j.ejvs.2009.07.008; Picton P, 2010, ANESTH ANALG, V110, P581, DOI 10.1213/ANE.0b013e3181c5f160; Pugliese F, 2009, EUR J ANAESTH, V26, P643, DOI 10.1097/EJA.0b013e32832b89c2; Rigamonti A, 2005, J CLIN ANESTH, V17, P426, DOI 10.1016/j.jclinane.2004.09.007; ROBERTSON CS, 1995, J NEUROTRAUM, V12, P591, DOI 10.1089/neu.1995.12.591; Samra SK, 2000, ANESTHESIOLOGY, V93, P964, DOI 10.1097/00000542-200010000-00015; Slater JP, 2009, ANN THORAC SURG, V87, P36, DOI 10.1016/j.athoracsur.2008.08.070; Smith M, 2008, NEUROSURG CLIN N AM, V19, P489, DOI 10.1016/j.nec.2008.07.008; Smith M, 2009, ANESTH ANALG, V108, P1055, DOI 10.1213/ane.0b013e31819a0301; Springett RJ, 2003, ADV EXP MED BIOL, V530, P555; SUZUKI S, 1999, SPIE P, V3597, P592; Thavasothy M, 2002, ANAESTHESIA, V57, P999, DOI 10.1046/j.1365-2044.2002.02826.x; Tisdall MM, 2007, BRIT J ANAESTH, V99, P61, DOI 10.1093/bja/aem143; Tisdall MM, 2008, J NEUROSURG, V109, P424, DOI 10.3171/JNS/2008/109/9/0424; Tisdall MM, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2718541; Tisdall MM, 2009, ANESTH ANALG, V109, P906, DOI 10.1213/ane.0b013e3181aedcdc; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vohra Hunaid A, 2009, Interact Cardiovasc Thorac Surg, V9, P318, DOI 10.1510/icvts.2009.206367; Wabnitz H, 2010, ADV EXP MED BIOL, V662, P143, DOI 10.1007/978-1-4419-1241-1_20; Wolf M, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2804899	48	77	77	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0952-7907	1473-6500		CURR OPIN ANESTHESIO	Curr. Opin. Anesthesiol.	OCT	2010	23	5					576	581		10.1097/ACO.0b013e32833e1536			6	Anesthesiology	Anesthesiology	646RR	WOS:000281560500007	20830845				2021-06-18	
J	Carmona, A; Omenaca, F; Tejedor, JC; Merino, JM; Vaman, T; Dieussaert, I; Gillard, P; Aristegui, J				Carmona, Alfonso; Omenaca, Felix; Tejedor, Juan C.; Merino, Jose M.; Vaman, Tejaswini; Dieussaert, Ilse; Gillard, Paul; Aristegui, Javier			Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months	VACCINE			English	Article						Influenza vaccines; Adjuvant; Children	CRITICALLY-ILL PATIENTS; PANDEMIC INFLUENZA; ANTIBODY-RESPONSES; YOUNG-CHILDREN; H5N1; CANDIDATE; INFECTION; A(H1N1); VIRUS; STRATEGIES	We report on the evaluation of the immunogenicity and reactogenicity/safety of AS03-adjuvanted vaccine against pandemic influenza A/H1N1/2009 in young children. In this open-label, randomized study, 157 healthy children aged 6-35 months received two doses (21 days apart) of split-virion inactivated A/California/7/2009 H1N1 vaccine containing either (i) 1.9 mu g hemagglutinin (HA) and AS03(B) (5.93 mg tocopherol)(N = 104) or (ii) 3.75 mu g HA and AS03(A) (11.86 mg tocopherol) (N = 53). At 21 days following the first dose of AS03(B)-adjuvanted vaccine (1.9 mu g HA) the percentage of children with hemagglutination-inhibition titers of >= 40 against the vaccine strain rose from 3.0% before vaccination to 100%. The seroconversion rate was 99% and the geometric mean titer (GMT) increased from 6 to 313. After the second dose the GMT increased further to 2008. The higher dose AS03(A)-adjuvanted 3.75 g HA vaccine did not further increase the immune response. Solicited symptoms reported within 7 days following vaccination were mainly mild to moderate. After the first dose of AS03(B)-adjuvanted vaccine (1.9 mu g HA) the most common solicited symptoms were pain at the injection site (35.6%) and irritability (31.7%). Fever (axillary >= 37.5 degrees C) was reported with an incidence of 20.2%. After the second dose reactogenicity tended to increase (injection site pain: 41.3%; irritability: 46.2%; fever >= 37.5 degrees C: 67.3%). Spontaneously reported adverse events with an intensity that prevented normal activities were documented for 2.9-6.7% of doses with only one event (vomiting) considered related to vaccination. There was one serious adverse event reported in the AS03(A)-adjuvanted 3.75 mu g HA vaccine group (traumatic brain injury) which was not considered as related to vaccination. In conclusion, these data suggest that a first dose of AS03(B)-adjuvanted A/H1N1/2009 vaccine containing 1.9 mu g HA in children 6-35 months old is highly immunogenic and that the overall reactogenicity profile is acceptable although reactions including fever tend to increase after a second dose. (C) 2010 Elsevier Ltd. All rights reserved.	[Carmona, Alfonso] Inst Hispalense & Pediat, Seville, Spain; [Omenaca, Felix] Hosp La Paz, Madrid, Spain; [Tejedor, Juan C.] Mostoles Hosp, Madrid, Spain; [Merino, Jose M.] Hosp Gen Yague, Burgos, Spain; [Vaman, Tejaswini; Dieussaert, Ilse; Gillard, Paul] GlaxoSmithKline Biol, Wavre, Belgium; [Aristegui, Javier] Basurto Hosp, Bilbao, Spain	Omenaca, F (corresponding author), Univ Hosp La Paz, Neonatol Unit, Paseo Castellana 241, Madrid, Spain.	fomenaca.hulp@salud.madrid.org	Tejedor, Juan Carlos/G-5111-2015	Tejedor, Juan Carlos/0000-0002-1748-6663			*AM AC PED, 2007, PAND INFL WARN CHILD; Banzhoff A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004384; Basta NE, 2009, AM J EPIDEMIOL, V170, P679, DOI 10.1093/aje/kwp237; Bhat N, 2005, NEW ENGL J MED, V353, P2559, DOI 10.1056/NEJMoa051721; Chu DWS, 2009, VACCINE, V27, P7428, DOI 10.1016/j.vaccine.2009.07.102; Clark TW, 2009, NEW ENGL J MED, V361, P2424, DOI 10.1056/NEJMoa0907650; Coffin SE, 2007, PEDIATRICS, V119, P740, DOI 10.1542/peds.2006-2679; Davies A, 2009, JAMA-J AM MED ASSOC, V302, P1888, DOI 10.1001/jama.2009.1535; Dawood FS, 2009, NEW ENGL J MED, V360, P2605, DOI 10.1056/NEJMoa0903810; Diez-Domingo J, 2010, PEDIATR INFECT DIS J, V29, pE35, DOI 10.1097/INF.0b013e3181daf921; Dominguez-Cherit G, 2009, JAMA-J AM MED ASSOC, V302, P1880, DOI 10.1001/jama.2009.1536; Donaldson LJ, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b5213; Echevarria-Zuno S, 2009, LANCET, V374, P2072, DOI 10.1016/S0140-6736(09)61638-X; Englund JA, 2005, PEDIATRICS, V115, P1039, DOI 10.1542/peds.2004-2373; *EUR COMM PROPR ME, 2006, EMEACHMPVWP263499200; Ferguson NM, 2006, NATURE, V442, P448, DOI 10.1038/nature04795; Fraser C, 2009, SCIENCE, V324, P1557, DOI 10.1126/science.1176062; Germann TC, 2006, P NATL ACAD SCI USA, V103, P5935, DOI 10.1073/pnas.0601266103; Gonzalez M, 2000, ARCH DIS CHILD, V83, P488, DOI 10.1136/adc.83.6.488; Greenberg ME, 2009, NEW ENGL J MED, V361, P2405, DOI 10.1056/NEJMoa0907413; Grijalva C. G., 2009, Morbidity and Mortality Weekly Report, V58, P1; Hancock K, 2009, NEW ENGL J MED, V361, P1945, DOI 10.1056/NEJMoa0906453; Hehme NW, 2002, CLIN DRUG INVEST, V22, P751, DOI 10.2165/00044011-200222110-00004; Jennings LC, 2008, LANCET INFECT DIS, V8, P650, DOI 10.1016/S1473-3099(08)70232-9; King JC, 2009, VACCINE, V27, P6589, DOI 10.1016/j.vaccine.2009.08.032; Kumar A, 2009, JAMA-J AM MED ASSOC, V302, P1872, DOI 10.1001/jama.2009.1496; Leroux-Roels I, 2007, LANCET, V370, P580, DOI 10.1016/S0140-6736(07)61297-5; Levie K, 2008, J INFECT DIS, V198, P642, DOI 10.1086/590913; Loeb M, 2010, JAMA-J AM MED ASSOC, V303, P943, DOI 10.1001/jama.2010.250; Mitchell DK, 2005, PEDIATR INFECT DIS J, V24, P925, DOI 10.1097/01.inf.0000180978.66362.d9; Nicoll A, 2008, ARCH DIS CHILD, V93, P433, DOI 10.1136/adc.2006.101477; *NIH, NIH B; Nolan T, 2010, JAMA-J AM MED ASSOC, V303, P37, DOI 10.1001/jama.2009.1911; *NOV SWIN OR INFL, 2009, NEW ENGL J MED, V361, P102; Osterhaus ADME, 2007, VACCINE, V25, P4983, DOI 10.1016/j.vaccine.2007.05.033; Plennevaux E, 2010, LANCET, V375, P41, DOI 10.1016/S0140-6736(09)62026-2; Rojo JC, 2006, PEDIATR INFECT DIS J, V25, P596, DOI 10.1097/01.inf.0000220208.59965.95; Roman F, 2010, VACCINE, V28, P1740, DOI 10.1016/j.vaccine.2009.12.014; Rowe T, 1999, J CLIN MICROBIOL, V37, P937, DOI 10.1128/JCM.37.4.937-943.1999; Rumke HC, 2008, VACCINE, V26, P2378, DOI 10.1016/j.vaccine.2008.02.068; SCHWARZ TF, 2009, INFLUENZA VACCINES W; Schwarz TF, 2009, VACCINE, V27, P6284, DOI 10.1016/j.vaccine.2009.01.040; *US FDA, 2007, FDA GUID IND CLIN DA; Vesikari T, 2009, PEDIATR INFECT DIS J, V28, P563, DOI 10.1097/INF.0b013e31819d6394; World Health Organization, AV CAND REASS VACC V; Zarocostas J, 2009, BRIT MED J, V339, DOI 10.1136/bmj.b4313; Zhu FC, 2009, NEW ENGL J MED, V361, P2414, DOI 10.1056/NEJMoa0908535; STUDY NO 100351 056; STUDY NO 104858 FLUA	49	77	78	0	6	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	AUG 16	2010	28	36					5837	5844		10.1016/j.vaccine.2010.06.065			8	Immunology; Medicine, Research & Experimental	Immunology; Research & Experimental Medicine	645IW	WOS:000281449000011	20600478				2021-06-18	
J	Mustafa, AG; Singh, IN; Wang, JA; Carrico, KM; Hall, ED				Mustafa, Ayman G.; Singh, Indrapal N.; Wang, Juan; Carrico, Kimberly M.; Hall, Edward D.			Mitochondrial protection after traumatic brain injury by scavenging lipid peroxyl radicals	JOURNAL OF NEUROCHEMISTRY			English	Article						3-nitrotyrosine; 4-hydroxynonenal; lipid peroxidation; mitochondria; traumatic brain injury; U-83836E	PERMEABILITY TRANSITION; OXIDATIVE DAMAGE; IMPAIRS GLUTAMATE; PEROXIDATION; PEROXYNITRITE; DYSFUNCTION; MEMBRANE; CELLS; RAT; ANTIOXIDANT	P>Mitochondrial dysfunction after traumatic brain injury (TBI) is manifested by increased levels of oxidative damage, loss of respiratory functions and diminished ability to buffer cytosolic calcium. This study investigated the detrimental effects of lipid peroxyl radicals (LOO center dot) and lipid peroxidation (LP) in brain mitochondria after TBI by examining the protective effects of U-83836E, a potent and selective scavenger of LOO center dot radicals. Male CF1 mice were subjected to severe controlled cortical impact TBI (CCI-TBI) and treated with either vehicle or U-83836E initiated i.v. at 15 min post-injury. Calcium (Ca++) buffering capacity and respiratory function were measured in isolated cortical mitochondrial samples taken from the ipsilateral hemisphere at 3 and 12 h post-TBI, respectively. In vehicle-treated injured mice, the cortical mitochondrial Ca++ buffering capacity was reduced by 60% at 3 h post-injury (p < 0.001) and the respiratory control ratio was decreased by 27% at 12 h post-TBI, relative to sham, non-injured mice. U-83836E treatment significantly (p < 0.05) preserved Ca++ buffering capacity and attenuated the reduction in respiratory control ratio values. Consistent with the functional effects of U-83836E being as a result of an attenuation of mitochondrial oxidative damage, the compound significantly (p < 0.001) reduced LP-generated 4-hydroxynonenal levels in both cortical homogenates and mitochondria at both 3 and 12 h post-TBI. Unexpectedly, U-83836E also reduced peroxynitrite-generated 3-nitrotyrosine in parallel with the reduction in 4-hydroxynonenal. The results demonstrate that LOO center dot radicals contribute to secondary brain mitochondrial dysfunction after TBI by propagating LP and protein nitrative damage in cellular and mitochondrial membranes.	[Mustafa, Ayman G.; Singh, Indrapal N.; Wang, Juan; Carrico, Kimberly M.; Hall, Edward D.] Univ Kentucky, Coll Med, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA	Hall, ED (corresponding author), Univ Kentucky, Coll Med, Spinal Cord & Brain Injury Res Ctr, 741 S Limestone St,BBSRB Room 483, Lexington, KY 40536 USA.	edhall@uky.edu	Hall, Edward D/F-8930-2013		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS058484, R01NS046566, P30NS051220] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01 NS058484, R01 NS046566, P30 NS051220] Funding Source: Medline		Alvarez B, 2003, AMINO ACIDS, V25, P295, DOI 10.1007/s00726-003-0018-8; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; Brown MR, 2004, J NEUROSCI METH, V137, P299, DOI 10.1016/j.jneumeth.2004.02.028; Brustovetsky N, 2002, J NEUROCHEM, V80, P207, DOI 10.1046/j.0022-3042.2001.00671.x; Budd SL, 1996, J NEUROCHEM, V66, P403, DOI 10.1046/j.1471-4159.1996.66010403.x; Deng Y, 2007, EXP NEUROL, V205, P154, DOI 10.1016/j.expneurol.2007.01.023; Deng-Bryant Y, 2008, J CEREBR BLOOD F MET, V28, P1114, DOI 10.1038/jcbfm.2008.10; Denicola A, 1996, ARCH BIOCHEM BIOPHYS, V333, P49, DOI 10.1006/abbi.1996.0363; Durmaz R, 2003, CAN J NEUROL SCI, V30, P143, DOI 10.1017/S0317167100053415; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Gadelha FR, 1997, ARCH BIOCHEM BIOPHYS, V345, P243, DOI 10.1006/abbi.1997.0259; GrasbonFrodl EM, 1996, J NEUROCHEM, V67, P1653; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; HALL ED, 1988, J NEUROSURG, V68, P462, DOI 10.3171/jns.1988.68.3.0462; HALL ED, 1991, J PHARMACOL EXP THER, V258, P688; Hall Edward D, 2004, NeuroRx, V1, P80, DOI 10.1602/neurorx.1.1.80; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; HALLIWELL B, 1993, AM J CLIN NUTR, V57, pS724; Halliwell Barry, 1993, American Journal of Clinical Nutrition, V57, p715S, DOI 10.1093/ajcn/57.5.715S; Hansson MJ, 2008, FREE RADICAL BIO MED, V45, P284, DOI 10.1016/j.freeradbiomed.2008.04.021; Jouaville LS, 1998, MOL CELL BIOCHEM, V184, P371, DOI 10.1023/A:1006850121769; Kabadere S, 2004, ACTA NEUROBIOL EXP, V64, P461; Karlsson J, 2002, BRAIN RES, V955, P268, DOI 10.1016/S0006-8993(02)03601-6; Keller JN, 1997, NEUROSCIENCE, V80, P685, DOI 10.1016/S0306-4522(97)00065-1; KIMURA M, 1992, BRIT J PHARMACOL, V107, P488, DOI 10.1111/j.1476-5381.1992.tb12772.x; Kowaltowski AJ, 1999, FREE RADICAL BIO MED, V26, P463, DOI 10.1016/S0891-5849(98)00216-0; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; Madikians A, 2006, INDIAN J NEUROTRAUM, V3, P9; Mbye LH, 2008, EXP NEUROL, V209, P243, DOI 10.1016/j.expneurol.2007.09.025; MUNNS PL, 1995, FREE RADICAL BIO MED, V18, P467, DOI 10.1016/0891-5849(94)00163-E; Pedersen WA, 1999, EXP NEUROL, V155, P1, DOI 10.1006/exnr.1998.6890; Racay P, 1997, BIOCHEM MOL BIOL INT, V41, P647; Radi R, 1998, CHEM RES TOXICOL, V11, P720, DOI 10.1021/tx980096z; Rohn TT, 1998, EUR J PHARMACOL, V353, P329, DOI 10.1016/S0014-2999(98)00399-9; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; SHI FL, 1995, FREE RADICAL BIO MED, V19, P349, DOI 10.1016/0891-5849(95)00049-4; Singh IN, 2007, J NEUROSCI RES, V85, P2216, DOI 10.1002/jnr.21360; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Spiteller G, 2006, FREE RADICAL BIO MED, V41, P362, DOI 10.1016/j.freeradbiomed.2006.03.013; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2003, ANN NEUROL, V53, P711, DOI 10.1002/ana.10543; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Sureda FX, 1999, TOXICOL APPL PHARM, V156, P1, DOI 10.1006/taap.1998.8613; Thajeb P, 2006, J CLIN NEUROSCI, V13, P467, DOI 10.1016/j.jocn.2005.05.019; Violi F, 1999, DIABETES-METAB RES, V15, P283, DOI 10.1002/(SICI)1520-7560(199907/08)15:4<283::AID-DMRR42>3.0.CO;2-U; Xiong Y, 1997, J NEUROTRAUM, V14, P907, DOI 10.1089/neu.1997.14.907; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23	47	77	80	0	3	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0022-3042			J NEUROCHEM	J. Neurochem.	JUL	2010	114	1					271	280		10.1111/j.1471-4159.2010.06749.x			10	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	608FA	WOS:000278567100025	20403083	Green Accepted			2021-06-18	
J	Sozda, CN; Hoffman, AN; Olsen, AS; Cheng, JP; Zafonte, RD; Kline, AE				Sozda, Christopher N.; Hoffman, Ann N.; Olsen, Adam S.; Cheng, Jeffrey P.; Zafonte, Ross D.; Kline, Anthony E.			Empirical Comparison of Typical and Atypical Environmental Enrichment Paradigms on Functional and Histological Outcome after Experimental Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						behavior; controlled cortical impact; enrichment; recovery; spatial learning; water maze	FACTOR MESSENGER-RNA; RECEPTOR AGONIST 8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; SPINAL-CORD-INJURY; MORRIS WATER MAZE; COGNITIVE DEFICITS; SPATIAL MEMORY; DENTATE GYRUS; SYNAPTOPHYSIN LEVELS; PHYSICAL-ACTIVITY; TREATMENT REGIMEN	Several studies have shown that housing rats in an enriched environment (EE) after traumatic brain injury (TBI) improves functional and histological outcome. The typical EE includes exploratory, sensory, and social components in cages that are often vastly larger than standard (STD) housing. It is uncertain, however, whether a single or specific component is sufficient to confer these benefits after TBI, or if all, perhaps in an additive or synergistic manner, are necessary. To clarify this ambiguity, anesthetized adult male rats were subjected to either a controlled cortical impact or sham injury, and then were randomly assigned to five different housing paradigms: (1) EE (typical), (2) EE (-social), (3) EE (-stimuli), (4) STD (typical), and (5) STD (+stimuli). Motor and cognitive function were assessed using conventional motor (beam-balance/traversal) and cognitive (spatial learning in a Morris water maze) tests on postoperative days 1-5 and 14-19, respectively, and cortical lesion volume and CA1/CA3 cell loss were quantified at 3 weeks. No significant differences were observed among the sham groups in any comparison and thus their data were pooled (i.e., SHAM). In the TBI groups, typical EE improved beam-balance versus both STD (+stimuli) and EE (-social), it facilitated the acquisition of spatial learning and memory retention versus all other housing conditions (p<0.003), and it reduced lesion volume and CA3 cell loss versus STD (typical) housing. While rats in the three atypical EE conditions exhibited slightly better cognitive performance and histological protection versus the typical STD group, the overall effects were not significant. These data suggest that exposing TBI rats to any of the three components individually may be more advantageous than no enrichment, but only exposure to typical EE yields optimal benefits.	[Kline, Anthony E.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Dept Rehabil Res, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA; [Kline, Anthony E.] Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15213 USA; [Kline, Anthony E.] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15213 USA; [Kline, Anthony E.] Univ Pittsburgh, Ctr Neural Basis Cognit, Pittsburgh, PA 15213 USA; [Zafonte, Ross D.] Harvard Univ, Sch Med, Boston, MA USA; [Zafonte, Ross D.] Spaulding Rehabil Hosp, Boston, MA USA; [Zafonte, Ross D.] Massachusetts Gen Hosp, Boston, MA 02114 USA	Kline, AE (corresponding author), Univ Pittsburgh, Safar Ctr Resuscitat Res, Dept Rehabil Res, Dept Phys Med & Rehabil, 3471 5th Ave,Suite 201, Pittsburgh, PA 15213 USA.	klineae@upmc.edu		Olsen, Adam/0000-0003-0957-9867; Cheng, Jeffrey/0000-0001-8285-3207	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HD046700, NS060005]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD046700] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS060005] Funding Source: NIH RePORTER	This work was supported, in part, by National Institutes of Health grants HD046700 and NS060005, awarded to A.E.K.	Bales JW, 2009, NEUROSCI BIOBEHAV R, V33, P981, DOI 10.1016/j.neubiorev.2009.03.011; BENNETT EL, 1969, SCIENCE, V163, P825, DOI 10.1126/science.163.3869.825; Berrocal Y, 2007, J NEUROTRAUM, V24, P1761, DOI 10.1089/neu.2007.0327; Briones TL, 2009, J NEUROTRAUM, V26, P613, DOI 10.1089/neu.2008.0707; Bruel-Jungerman E, 2005, EUR J NEUROSCI, V21, P513, DOI 10.1111/j.1460-9568.2005.03875.x; Buchhold B, 2007, RESTOR NEUROL NEUROS, V25, P467; Burke DA, 2007, J AM ASSOC LAB ANIM, V46, P34; Cheng JP, 2008, BEHAV BRAIN RES, V194, P79, DOI 10.1016/j.bbr.2008.06.025; Cracchiolo JR, 2007, NEUROBIOL LEARN MEM, V88, P277, DOI 10.1016/j.nlm.2007.07.007; Dahlqvist P, 2004, EUR J NEUROSCI, V19, P2288, DOI 10.1111/j.0953-816X.2004.03248.x; Dixon CE, 1999, RESTOR NEUROL NEUROS, V14, P285; Dixon CE, 2003, CRIT CARE MED, V31, P2222, DOI 10.1097/01.CCM.0000080493.04978.73; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Elliott BM, 2005, BEHAV BRAIN RES, V165, P187, DOI 10.1016/j.bbr.2005.06.025; Faherty CJ, 2005, MOL BRAIN RES, V134, P170, DOI 10.1016/j.molbrainres.2004.08.008; FALKENBERG T, 1992, NEUROSCI LETT, V138, P153, DOI 10.1016/0304-3940(92)90494-R; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FEENEY DM, 1987, CRIT REV NEUROBIOL, V3, P135; Fischer FR, 2007, J SPINAL CORD MED, V30, P147, DOI 10.1080/10790268.2007.11753926; Frick KM, 2003, NEUROBIOL AGING, V24, P615, DOI 10.1016/S0197-4580(02)00138-0; Gabriel AF, 2010, BEHAV BRAIN RES, V208, P90, DOI 10.1016/j.bbr.2009.11.015; Gaulke LJ, 2005, MOL BRAIN RES, V141, P138, DOI 10.1016/j.molbrainres.2005.08.011; GENTILE AM, 1987, BEHAV NEURAL BIOL, V47, P321, DOI 10.1016/S0163-1047(87)90435-3; Giza CC, 2005, BEHAV BRAIN RES, V157, P11, DOI 10.1016/j.bbr.2004.06.003; Griesbach GS, 2009, BRAIN RES, V1288, P105, DOI 10.1016/j.brainres.2009.06.045; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hamm RJ, 1996, J NEUROTRAUM, V13, P41, DOI 10.1089/neu.1996.13.41; HELD JM, 1985, BEHAV NEUROSCI, V99, P678, DOI 10.1037/0735-7044.99.4.678; Hicks RR, 2002, NEUROSCIENCE, V112, P631, DOI 10.1016/S0306-4522(02)00104-5; Hoffman AN, 2008, NEUROSCI LETT, V431, P226, DOI 10.1016/j.neulet.2007.11.042; Ickes BR, 2000, EXP NEUROL, V164, P45, DOI 10.1006/exnr.2000.7415; Ip EYY, 2002, J NEUROTRAUM, V19, P573, DOI 10.1089/089771502753754055; Jankowsky JL, 2005, J NEUROSCI, V25, P5217, DOI 10.1523/JNEUROSCI.5080-04.2005; Johansson BB, 1996, EXP NEUROL, V139, P322, DOI 10.1006/exnr.1996.0106; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Kleim JA, 2003, NEUROCHEM RES, V28, P1757, DOI 10.1023/A:1026025408742; Kline AE, 2004, J NEUROTRAUM, V21, P175, DOI 10.1089/089771504322778631; Kline AE, 2002, NEUROSCI LETT, V333, P179, DOI 10.1016/S0304-3940(02)01101-1; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Kline AE, 2001, NEUROSCIENCE, V106, P547, DOI 10.1016/S0306-4522(01)00300-1; Kline AE, 2004, J NEUROTRAUM, V21, P1712, DOI 10.1089/0897715042664849; Kline AE, 2007, BEHAV BRAIN RES, V177, P186, DOI 10.1016/j.bbr.2006.11.036; Kokiko ON, 2007, BRAIN INJURY, V21, P259, DOI 10.1080/02699050701209964; Lambert TJ, 2005, NEUROBIOL LEARN MEM, V83, P206, DOI 10.1016/j.nlm.2004.12.001; Leggio MG, 2005, BEHAV BRAIN RES, V163, P78, DOI 10.1016/j.bbr.2005.04.009; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Nilsson M, 1999, J NEUROBIOL, V39, P569, DOI 10.1002/(SICI)1097-4695(19990615)39:4<569::AID-NEU10>3.0.CO;2-F; Nithianantharajah J, 2004, NEUROBIOL LEARN MEM, V81, P200, DOI 10.1016/j.nlm.2004.02.002; Olson AK, 2006, HIPPOCAMPUS, V16, P250, DOI 10.1002/hipo.20157; Parton A, 2005, CURR OPIN NEUROL, V18, P675, DOI 10.1097/01.wco.0000189872.54245.13; Passineau MJ, 2001, EXP NEUROL, V168, P373, DOI 10.1006/exnr.2000.7623; ROSE FD, 1987, BEHAV BRAIN RES, V24, P195, DOI 10.1016/0166-4328(87)90057-X; ROSENZWEIG MR, 1978, BRAIN RES, V153, P563, DOI 10.1016/0006-8993(78)90340-2; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Schrijver NCA, 2004, BEHAV BRAIN RES, V152, P307, DOI 10.1016/j.bbr.2003.10.016; Torasdotter M, 1998, BEHAV BRAIN RES, V93, P83, DOI 10.1016/S0166-4328(97)00142-3; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; Wagner AK, 2002, NEUROSCI LETT, V334, P165, DOI 10.1016/S0304-3940(02)01103-5; Will B, 2004, PROG NEUROBIOL, V72, P167, DOI 10.1016/j.pneurobio.2004.03.001; Zhao LR, 2000, NEUROSCIENCE, V97, P177, DOI 10.1016/S0306-4522(00)00023-3; Zhao LR, 2001, NEUROSCI LETT, V305, P169, DOI 10.1016/S0304-3940(01)01837-7	62	77	79	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2010	27	6					1047	1057		10.1089/neu.2010.1313			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	612VO	WOS:000278933300008	20334496	Green Published			2021-06-18	
J	Zhang, ZQ; Larner, SF; Liu, MC; Zheng, WR; Hayes, RL; Wang, KKW				Zhang, Zhiqun; Larner, Stephen F.; Liu, Ming Cheng; Zheng, Wenrong; Hayes, Ronald L.; Wang, Kevin K. W.			Multiple alphaII-spectrin breakdown products distinguish calpain and caspase dominated necrotic and apoptotic cell death pathways	APOPTOSIS			English	Article						alpha II-spectrin; Breakdown product; Calpain; Caspase; Apoptosis; Oncosis; Necrosis; Proteolysis; Biomarker	TRAUMATIC BRAIN-INJURY; II-SPECTRIN; NEUROBLASTOMA-CELLS; PROTEASE ACTIVATION; NEURONAL APOPTOSIS; CYTOLYTIC PORE; NEONATAL-RATS; PC12 CELLS; IN-VIVO; NECROSIS	Apoptosis and oncotic necrosis in neuronal and glial cells have been documented in many neurological diseases. Distinguishing between these two major types of cell death in different neurological diseases is needed in order to better reveal the injury mechanisms so as to open up opportunities for therapy development. Accumulating evidence suggests apoptosis and oncosis epitomize the extreme ends of a broad spectrum of morphological and biochemical events. Biochemical markers that can distinguish between the calpain and caspase dominated types of cell death would help in this process. In this study, three chemical agents, maitotoxin (MTX), staurosporine (STS) and thylenediaminetetraacetic acid (EDTA), were used to induce different types of cell death in PC12 neuronal-like cells. MTX-induced necrosis, as determined by the increased levels of calpain-specific cleaved fragments of spectrin by antibodies specific to the calpain-cleaved 150 kDa alpha II-spectrin breakdown product (SBDP150) and 145 kDa alpha II-spectrin breakdown product (SBDP145). In this paradigm, there were no detectable SBDP150i and SBDP120 fragments as determined by antibodies specific to the caspase-cleaved specific fragments similar to those seen in the EDTA-mediated apoptotic PC-12 cells. In contrast to the calpain specific MTX necrosis treatment and the caspase EDTA apoptotic treatment is the STS treatment which induced both proteases as shown by the increase in all the SBDP fragments. Furthermore, compared to SBDP150, SBDP145 appears to be a more specific and sensitive biomarker for calpain activation. Taken together, our results suggested calpains and caspases which dominate the two major types of cell death could be independently discriminated by specifically examining the multiple alpha II-spectrin cleavage breakdown products.	[Zhang, Zhiqun; Larner, Stephen F.; Liu, Ming Cheng; Zheng, Wenrong; Hayes, Ronald L.; Wang, Kevin K. W.] Banyan Biomarkers Inc, Ctr Innovat Res, Alachua, FL 32615 USA	Zhang, ZQ (corresponding author), Banyan Biomarkers Inc, Ctr Innovat Res, 12085 Res Dr, Alachua, FL 32615 USA.	zqzhang@banyanbio.com; kwang@banyanbio.com		Wang, Kevin/0000-0002-9343-6473	Department of DefenseUnited States Department of Defense [DAMMED-03-1-0066]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS049175-01-A1, R01 NS051431]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS049175, R01NS051431] Funding Source: NIH RePORTER	We wish to thank Meghan O'Donoghue for her technical assistance. This work was supported by the Department of Defense grant DAMMED-03-1-0066, National Institutes of Health grants R01 NS049175-01-A1 and R01 NS051431. K. K. W. Wang and R. L. Hayes own stock of Banyan Biomarkers Inc., and may benefit financially as a result of the outcome of this research or the work reported in this publication.	Abud HE, 2004, CELL DEATH DIFFER, V11, P788, DOI 10.1038/sj.cdd.4401402; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; Behl C, 2000, J NEURAL TRANSM, V107, P1325, DOI 10.1007/s007020070021; Blomgren K, 2001, J BIOL CHEM, V276, P10191, DOI 10.1074/jbc.M007807200; Bouvry D, 2006, AM J RESP CELL MOL, V35, P519, DOI 10.1165/rcmb.2005-0478OC; Cardali S, 2006, J Neurosurg Sci, V50, P25; Castillo MR, 1998, NEUROSCIENCE, V86, P1133, DOI 10.1016/S0306-4522(98)00070-0; Chiesa R, 1998, J NEUROCHEM, V70, P1474; Clark RSB, 1997, J NEUROSCI, V17, P9172; Criddle DN, 2007, CELL DEATH DIFFER, V14, P1285, DOI 10.1038/sj.cdd.4402150; Das A, 2008, J PINEAL RES, V45, P117, DOI 10.1111/j.1600-079X.2008.00582.x; Del Rio P, 2008, NEUROCHEM RES, V33, P1475, DOI 10.1007/s11064-008-9612-1; Demets D.L., 1998, FUNDAMENTALS CLIN TR; Deshmukh M, 2000, CELL DEATH DIFFER, V7, P250, DOI 10.1038/sj.cdd.4400641; Dutta S, 2002, BIOL CHEM, V383, P785, DOI 10.1515/BC.2002.082; FARBER E, 1994, MODERN PATHOL, V7, P605; Fukiage C, 1997, BBA-MOL BASIS DIS, V1361, P304, DOI 10.1016/S0925-4439(97)00043-4; Hirsch T, 1997, ONCOGENE, V15, P1573, DOI 10.1038/sj.onc.1201324; Huh GY, 2001, NEUROSCI LETT, V316, P41, DOI 10.1016/S0304-3940(01)02371-0; Kawamura M, 2005, BRAIN RES, V1037, P59, DOI 10.1016/j.brainres.2004.12.050; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kim YJ, 2002, J DENT RES, V81, P788, DOI 10.1177/154405910208101113; KOH JY, 1995, EXP NEUROL, V135, P153, DOI 10.1006/exnr.1995.1074; Koumura A, 2008, NEUROSCIENCE, V157, P309, DOI 10.1016/j.neuroscience.2008.09.007; Kupina NC, 2001, J NEUROTRAUM, V18, P1229, DOI 10.1089/089771501317095269; Lecoeur H, 2001, CYTOMETRY, V44, P65, DOI 10.1002/1097-0320(20010501)44:1<65::AID-CYTO1083>3.0.CO;2-Q; Levin S, 1998, TOXICOL SCI, V41, P155; Lewis SB, 2007, J NEUROSURG, V107, P792, DOI 10.3171/JNS-07/10/0792; Li C, 2002, P NATL ACAD SCI USA, V99, P9830, DOI 10.1073/pnas.152571899; Lockshin RA, 2004, ONCOGENE, V23, P2766, DOI 10.1038/sj.onc.1207514; MAJNO G, 1995, AM J PATHOL, V146, P3; McGinnis KM, 1999, J NEUROCHEM, V72, P1853, DOI 10.1046/j.1471-4159.1999.0721853.x; Meary F, 2007, J BIOL CHEM, V282, P14226, DOI 10.1074/jbc.M700028200; MEUCCI O, 1992, J NEUROCHEM, V59, P679, DOI 10.1111/j.1471-4159.1992.tb09422.x; Muller GJ, 2004, BRAIN PATHOL, V14, P415; Nath R, 2000, NEUROCHEM INT, V36, P119, DOI 10.1016/S0197-0186(99)00112-6; NATH R, 1925, BIOCHEM BIOPH RES CO, V274, P16; Neumar RW, 2003, J BIOL CHEM, V278, P14162, DOI 10.1074/jbc.M212255200; Pike BR, 2004, J CEREBR BLOOD F MET, V24, P98, DOI 10.1097/01.WCB.0000098520.11962.37; Pike BR, 2001, J NEUROCHEM, V78, P1297, DOI 10.1046/j.1471-4159.2001.00510.x; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Povlishock JT, 2001, HEAD TRAUMA, P281; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Rathmell JC, 1999, ANNU REV IMMUNOL, V17, P781, DOI 10.1146/annurev.immunol.17.1.781; Reed JC, 2000, AM J PATHOL, V157, P1415, DOI 10.1016/S0002-9440(10)64779-7; RIEDERER BM, 1986, J CELL BIOL, V102, P2088, DOI 10.1083/jcb.102.6.2088; Ringger NC, 2004, J NEUROTRAUM, V21, P1443, DOI 10.1089/neu.2004.21.1443; Rotter B, 2004, BIOCHEM J, V378, P161, DOI 10.1042/BJ20030955; Sakabe I, 1998, CELL STRUCT FUNCT, V23, P95, DOI 10.1247/csf.23.95; SCHILLING WP, 2002, AM J PHYSIOL, V277, pC755; SCHILLING WP, 2002, AM J PHYSIOL, V277, pC766; Seo SR, 2009, EXP MOL MED, V41, P269, DOI 10.3858/emm.2009.41.4.030; Serper A, 2001, J Oral Sci, V43, P233; Short DM, 2007, PROTEOMICS, V7, P3085, DOI 10.1002/pmic.200600964; SOERGEL DG, 1992, MOL PHARMACOL, V41, P487; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Tamada Y, 2005, BRAIN RES, V1050, P148, DOI 10.1016/j.brainres.2005.05.048; Van Cruchten S, 2002, ANAT HISTOL EMBRYOL, V31, P214, DOI 10.1046/j.1439-0264.2002.00398.x; Vanderklish PW, 2000, INT J EXP PATHOL, V81, P323, DOI 10.1046/j.1365-2613.2000.00169.x; Wang KKW, 1998, J BIOL CHEM, V273, P22490, DOI 10.1074/jbc.273.35.22490; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Wang KKW, 1996, ARCH BIOCHEM BIOPHYS, V331, P208, DOI 10.1006/abbi.1996.0300; Wang Y, 2008, J CELL PHYSIOL, V215, P676, DOI 10.1002/jcp.21350; Zhang XD, 2004, MOL CANCER THER, V3, P187; Zhang Z, 2006, CELL MOL BIOL LETT, V11, P12, DOI 10.2478/s11658-006-0002-x	67	77	79	0	7	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	1360-8185	1573-675X		APOPTOSIS	Apoptosis	NOV	2009	14	11					1289	1298		10.1007/s10495-009-0405-z			10	Biochemistry & Molecular Biology; Cell Biology	Biochemistry & Molecular Biology; Cell Biology	503MX	WOS:000270540800004	19771521				2021-06-18	
J	Barker-Collo, SL; Feigin, VL; Lawes, CMM; Parag, V; Senior, H; Rodgers, A				Barker-Collo, Suzanne L.; Feigin, Valery L.; Lawes, Carlene M. M.; Parag, Varsha; Senior, Hugh; Rodgers, Anthony			Reducing Attention Deficits After Stroke Using Attention Process Training A Randomized Controlled Trial	STROKE			English	Article						attention; rehabilitation; neuropsychology; randomized clinical trial; stroke	QUALITY-OF-LIFE; COGNITIVE IMPAIRMENT; BRAIN-INJURY; REHABILITATION; ASSOCIATION; PERFORMANCE; COMMUNITY; RECOVERY; EFFICACY; PROGRAM	Background and Purpose-Impaired attention contributes to poor stroke outcomes. Attention process training (APT) reduces attention deficits after traumatic brain injury. There was no evidence for effectiveness of APT in stroke patients. This trial evaluated effectiveness of APT in improving attention and broader outcomes in stroke survivors 6 months after stroke. Methods-Participants in this prospective, single-blinded, randomized, clinical trial were 78 incident stroke survivors admitted over 18 months and identified via neuropsychological assessment as having attention deficit. Participants were randomly allocated to standard care plus up to 30 hours of APT or standard care alone. Both groups were impaired (z <=-2.0) across measures of attention at baseline, with the exception of Paced Auditory Serial Addition Test, which was below average (z <=-1.0). Outcome assessment occurred at 5 weeks and 6 months after randomization. The primary outcome was Integrated Visual Auditory Continuous Performance Test Full-Scale Attention Quotient. Results-APT resulted in a significantly greater (P<0.01) improvement on the primary outcome than standard care. Difference in change on the Cognitive Failures Questionnaire approached significance (P=0.07). Differences on other measures of attention and broader outcomes were not significant. Conclusion-APT is a viable and effective means of improving attention deficits after incident stroke. (Stroke. 2009;40:3293-3298.)	[Barker-Collo, Suzanne L.] Univ Auckland, Dept Psychol, Clin Training Programme, Fac Sci, Auckland, New Zealand; [Feigin, Valery L.] AUT Univ, Natl Res Ctr Stroke Appl Neurosci & Neurorehabil, Fac Hlth & Environm Studies, Auckland, New Zealand; [Lawes, Carlene M. M.; Parag, Varsha] Univ Auckland, Clin Trials Res Unit, Sch Populat Hlth, Fac Med & Hlth Sci, Auckland 1, New Zealand; [Senior, Hugh; Rodgers, Anthony] Univ Sydney, George Inst Int Hlth, Sydney, NSW 2006, Australia	Barker-Collo, SL (corresponding author), Univ Auckland, Dept Psychol, Clin Training Programme, Fac Sci, Tamaki Campus,Private Bag 92019, Auckland, New Zealand.	s.barker-collo@auckland.ac.nz	Senior, Hugh/H-1579-2011; Feigin, Valery/AAF-2313-2019	Senior, Hugh/0000-0002-7081-2499; Feigin, Valery L./0000-0002-6372-1740; Rodgers, Anthony/0000-0003-1282-1896	New Zealand Health Research CouncilHealth Research Council of New Zealand [06/063C, 07/070C]; National Heart Foundation (New Zealand)	This work was supported by the New Zealand Health Research Council (HRC Refs 06/063C and 07/070C). Dr C. M. M. Lawes is supported by a National Heart Foundation (New Zealand) Fellowship.	AHO K, 1980, B WORLD HEALTH ORGAN, V58, P113; BAMFORD JM, 1989, STROKE, V20, P828, DOI 10.1161/01.STR.20.6.828; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; Butler RW, 2002, J INT NEUROPSYCH SOC, V8, P115, DOI 10.1017/S1355617701020112; Dorman P, 1998, STROKE, V29, P63, DOI 10.1161/01.STR.29.1.63; Duncan PW, 2005, STROKE, V36, pE100, DOI 10.1161/01.STR.0000180861.54180.FF; GAUTHIER L, 1989, INT J CLIN NEUROPSYC, V11, P49; Goldberg P., 1978, MANUAL GEN HLTH QUES; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Hackett ML, 2000, STROKE, V31, P440, DOI 10.1161/01.STR.31.2.440; Harding Karen L, 2003, Altern Med Rev, V8, P319; Hochstenbach J, 1998, J CLIN EXP NEUROPSYC, V20, P503, DOI 10.1076/jcen.20.4.503.1471; Hochstenbach JB, 2001, ARCH PHYS MED REHAB, V82, P1360, DOI 10.1053/apmr.2001.25970; Hyndman D, 2008, J NEUROL NEUROSUR PS, V79, P656, DOI 10.1136/jnnp.2007.125609; Hyndman D, 2003, DISABIL REHABIL, V25, P817, DOI 10.1080/0963828031000122221; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Lincoln NB, 2000, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002842; Lynch JW, 1997, NEW ENGL J MED, V337, P1889, DOI 10.1056/NEJM199712253372606; MATEER CA, 1990, COGNITIVE REHABILITA, P68; Mazer BL, 2003, ARCH PHYS MED REHAB, V84, P541, DOI 10.1053/apmr.2003.50085; McDowd JM, 2003, J GERONTOL B-PSYCHOL, V58, pP45, DOI 10.1093/geronb/58.1.P45; McDowell I, 1996, MEASURING HLTH GUIDE; MORRIS PLP, 1993, AM J PSYCHIAT, V150, P124; NIEMANN H, 1990, J CONSULT CLIN PSYCH, V58, P811, DOI 10.1037/0022-006X.58.6.811; NYS GMS, 2005, THESIS U UTRECHT NED; Paolucci S, 1996, EUR NEUROL, V36, P385, DOI 10.1159/000117298; Park NW, 2001, NEUROPSYCHOLOGY, V15, P199, DOI 10.1037/0894-4105.15.2.199; Park NW, 1999, NEUROPSYCHOL REHABIL, V9, P135, DOI 10.1080/713755595; Patel MD, 2002, J AM GERIATR SOC, V50, P700, DOI 10.1046/j.1532-5415.2002.50165.x; Penkman Louise, 2004, Pediatr Rehabil, V7, P111, DOI 10.1080/13638490310001649417; Robertson IH, 1997, NEUROPSYCHOLOGY, V11, P290, DOI 10.1037/0894-4105.11.2.290; Ruff R. M., 1989, J HEAD TRAUMA REHAB, V4, P20, DOI [10.1097/00001199-198909000-00006, DOI 10.1097/00001199-198909000-00006]; Sandford J.A., 2000, INTEGRATED VISUAL AU; Schmidt R. A., 1988, MOTOR CONTROL LEARNI; Schottke H, 1997, VERHALTENSTHERAPIE, V7, P21, DOI 10.1159/000259005; SOHLBERG MM, 1987, J CLIN EXP NEUROPSYC, V9, P117, DOI 10.1080/01688638708405352; Sohlberg MM, 2000, J CLIN EXP NEUROPSYC, V22, P656, DOI 10.1076/1380-3395(200010)22:5;1-9;FT656; Sohlberg MM, 2001, ATTENTION PROCESS TR; Stapleton T, 2001, CLIN REHABIL, V15, P437, DOI 10.1191/026921501678310243; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Sturm W, 1997, NEUROPSYCHOL REHABIL, V7, P81, DOI 10.1080/713755526; STURM W, 1993, COMPUTER ASSISTED RE; Sturm W, 1991, NEUROPSYCHOL REHABIL, V1, P259, DOI DOI 10.1080/09602019108402258; THOMSON J, 2001, PAY ATTENTION ATTENT; Tinius TP, 2003, ARCH CLIN NEUROPSYCH, V18, P199, DOI 10.1016/S0887-6177(01)00196-2; Williams LS, 1999, NEUROLOGY, V53, P1839, DOI 10.1212/WNL.53.8.1839; Wood R L, 1987, Int Disabil Stud, V9, P149; ZAK ML, 2000, DISS ABSTR INT B, V60, P5799; Zhu L, 1998, STROKE, V29, P2094, DOI 10.1161/01.STR.29.10.2094	49	77	80	1	32	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0039-2499	1524-4628		STROKE	Stroke	OCT	2009	40	10					3293	3298		10.1161/STROKEAHA.109.558239			6	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	499NV	WOS:000270229800024	19628801	Bronze			2021-06-18	
J	Smits, M; Dippel, DWJ; Houston, GC; Wielopolski, PA; Koudstaal, PJ; Hunink, MGM; van der Lugt, A				Smits, Marion; Dippel, Diederik W. J.; Houston, Gavin C.; Wielopolski, Piotr A.; Koudstaal, Peter J.; Hunink, M. G. Myriam; van der Lugt, Aad			Postconcussion Syndrome After Minor Head Injury: Brain Activation of Working Memory and Attention	HUMAN BRAIN MAPPING			English	Article						postconcussion syndrome; cognitive impairment; concussion; MRI/fMRI; functional neuroimaging	EVENT-RELATED FMRI; NEUROPSYCHOLOGICAL DEFICITS; COGNITIVE REHABILITATION; FUNCTIONAL MRI; STROOP TASK; MILD; SYMPTOMS; PERFORMANCE; IMPAIRMENT; LOAD	After minor head injury (MHI) postconcussive Symptoms (PCS) Such as memory and attention deficits frequently occur. It has been hypothesised Thai PCS are Caused by microstructural damage to the brain due to shearing injury, which is not detectable with conventional imaging, and may be responsible for a functional deficit. The purpose of this Study was to correlate functional magnetic resonance imaging brain activation of working memory and selective attention with PCS. 21 MHI patients and 12 healthy controls were scanned at 3T. Stimulation paradigms were the n-back and Counting Stroop tasks to engage working memory and selective attention, respectively. Functional data analysis consisted of random effects group analyses, correlating brain activation patterns with the severity of PCS as evaluated with the Rivermead postconcussion symptoms questionnaire. At minimal working memory load, activation was seen in patients with greater severity of PCS in the working memory network. With an increase of working memory load, increase of activation was more pronounced in patients with greater severity of PCS. At high and increased working memory load, activation associated with the severity of PCS was seen in the posterior parietal area, parahippocampal gyrus, and posterior cingulate gyrus. Activation related to selective attention processing was increased with greater severity of PCS. The increased activity in relation to working memory and attention, and the recruitment of brain areas outside the working memory network at high working memory load, may be considered a reflection of the brain's compensatory, response to microstructural injury in patients with PCS. Hum Brain Mapp 30:2789-2803, 2009. (C) 2008 Wiley-Liss, Inc.	[Smits, Marion; Wielopolski, Piotr A.; Hunink, M. G. Myriam; van der Lugt, Aad] Erasmus MC Univ Med Ctr Rotterdam, Dept Radiol, NL-3000 CA Rotterdam, Netherlands; [Dippel, Diederik W. J.; Koudstaal, Peter J.] Erasmus MC Univ Med Ctr Rotterdam, Dept Neurol, NL-3000 CA Rotterdam, Netherlands; [Houston, Gavin C.] GE Healthcare, Appl Sci Lab, Shertogenbosch, Netherlands; [Hunink, M. G. Myriam] Erasmus MC Univ Med Ctr Rotterdam, Dept Epidemiol & Biostat, NL-3000 CA Rotterdam, Netherlands; [Hunink, M. G. Myriam] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA	Smits, M (corresponding author), Erasmus MC Univ Med Ctr Rotterdam, Dept Radiol HS 224, POB 2040, NL-3000 CA Rotterdam, Netherlands.	marion.smits@erasmusmc.nl	Dippel, Diederik/AAJ-2192-2020; Smits, Marion/AAB-3985-2019; Smits, Marion/E-4795-2011	Dippel, Diederik/0000-0002-9234-3515; Smits, Marion/0000-0001-5563-2871; 			Alexander M. P., 1997, SEMIN CLIN NEUROPSYC, V2, P177; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Ashburner J, 1999, HUM BRAIN MAPP, V7, P254, DOI 10.1002/(SICI)1097-0193(1999)7:4<254::AID-HBM4>3.0.CO;2-G; Association AP, 1994, DIAGN STAT MAN MENT; Audoin B, 2003, HUM BRAIN MAPP, V20, P51, DOI 10.1002/hbm.10128; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Bigler ED, 2003, ARCH CLIN NEUROPSYCH, V18, P595; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; BOHNEN N, 1992, J NERV MENT DIS, V180, P683, DOI 10.1097/00005053-199211000-00002; BOHNEN N, 1992, ACTA NEUROL SCAND, V85, P116, DOI 10.1111/j.1600-0404.1992.tb04009.x; BOHNEN N, 1994, BRAIN INJURY, V8, P701, DOI 10.3109/02699059409151024; BOHNEN N, 1992, NEUROSURGERY, V30, P692; Bordini EJ, 2002, NEUROREHABILITATION, V17, P93; Bush G, 1998, HUM BRAIN MAPP, V6, P270, DOI 10.1002/(SICI)1097-0193(1998)6:4<270::AID-HBM6>3.3.CO;2-H; Calder AJ, 2001, NAT REV NEUROSCI, V2, P352, DOI 10.1038/35072584; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Cicerone KD, 2002, CLIN NEUROPSYCHOL, V16, P280, DOI 10.1076/clin.16.3.280.13849; D'Esposito M, 1998, COGNITIVE BRAIN RES, V7, P1, DOI 10.1016/S0926-6410(98)00004-4; D'Esposito M, 2000, EXP BRAIN RES, V133, P3, DOI 10.1007/s002210000395; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DONALDSON DI, 2002, FUNCTIONAL MRI INTRO, P177; Duncan J, 2000, SCIENCE, V289, P457, DOI 10.1126/science.289.5478.457; Egner T, 2005, NEUROIMAGE, V24, P539, DOI 10.1016/j.neuroimage.2004.09.007; EVANS RW, 1992, NEUROL CLIN, V10, P815; Eyler LT, 2004, PSYCHIAT RES-NEUROIM, V130, P245, DOI 10.1016/j.pscychresns.2004.01.003; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Friston KJ, 1996, MAGNET RESON MED, V35, P346, DOI 10.1002/mrm.1910350312; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; Jonides J, 1997, J COGNITIVE NEUROSCI, V9, P462, DOI 10.1162/jocn.1997.9.4.462; King N, 1997, BRIT J CLIN PSYCHOL, V36, P161, DOI 10.1111/j.2044-8260.1997.tb01405.x; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 2003, BRIT J PSYCHIAT, V183, P276, DOI 10.1192/bjp.183.4.276; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; Laatsch LK, 2004, BRAIN INJURY, V18, P957, DOI 10.1080/02699050410001672369; Lange G, 2005, NEUROIMAGE, V26, P513, DOI 10.1016/j.neuroimage.2005.02.011; Levine B, 2002, J NEUROL NEUROSUR PS, V73, P173, DOI 10.1136/jnnp.73.2.173; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; Manoach DS, 1997, NEUROREPORT, V8, P545, DOI 10.1097/00001756-199701200-00033; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; Newsome MR, 2007, CORTEX, V43, P95, DOI 10.1016/S0010-9452(08)70448-9; Owen AM, 2005, HUM BRAIN MAPP, V25, P46, DOI 10.1002/hbm.20131; Owen AM, 1998, P NATL ACAD SCI USA, V95, P7721, DOI 10.1073/pnas.95.13.7721; Qin SZ, 2007, NEUROIMAGE, V38, P212, DOI 10.1016/j.neuroimage.2007.07.020; Smith EE, 1998, P NATL ACAD SCI USA, V95, P12061, DOI 10.1073/pnas.95.20.12061; Soeda A, 2005, NEURORADIOLOGY, V47, P501, DOI 10.1007/s00234-005-1372-x; Strangman G, 2005, AM J PHYS MED REHAB, V84, P62, DOI 10.1097/01.PHM.0000150787.26860.12; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Sweet LH, 2006, HUM BRAIN MAPP, V27, P28, DOI 10.1002/hbm.20163; SZYMANSKI HV, 1992, INT J PSYCHIAT MED, V22, P357, DOI 10.2190/XARA-B1EF-J2HC-VAE0; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; Walsh ND, 2007, BIOL PSYCHIAT, V62, P1236, DOI 10.1016/j.biopsych.2006.12.022; World Health Organisation, 1993, ICD 10 CLASSIFICATIO; Yetkin FZ, 2006, EUR RADIOL, V16, P193, DOI 10.1007/s00330-005-2794-x	59	77	80	1	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1065-9471	1097-0193		HUM BRAIN MAPP	Hum. Brain Mapp.	SEP	2009	30	9					2789	2803		10.1002/hbm.20709			15	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	490OK	WOS:000269510200007	19117278	Green Published			2021-06-18	
J	Amorini, AM; Petzold, A; Tavazzi, B; Eikelenboom, J; Keir, G; Belli, A; Giovannoni, G; Di Preto, V; Polman, C; D'Urso, S; Vagnozzi, R; Uitdehaag, B; Lazzarino, G				Amorini, Angela M.; Petzold, Axel; Tavazzi, Barbara; Eikelenboom, Judith; Keir, Geoffrey; Belli, Antonio; Giovannoni, Gavin; Di Preto, Valentina; Polman, Chris; D'Urso, Serafina; Vagnozzi, Roberto; Uitdehaag, Bernard; Lazzarino, Giuseppe			Increase of uric acid and purine compounds in biological fluids of multiple sclerosis patients	CLINICAL BIOCHEMISTRY			English	Article						Multiple sclerosis; Uric acid; Purine compounds; Cerebrospinal fluid; Serum; HPLC; Energy metabolism; Oxidative stress; Nitrosative stress	TRAUMATIC BRAIN-INJURY; CEREBROSPINAL-FLUID; MITOCHONDRIAL DYSFUNCTION; OXIDATIVE STRESS; LIPID-PEROXIDATION; NITROSATIVE STRESS; CYCLOSPORINE-A; ENERGY-STATE; HYPOXANTHINE; XANTHINE	Objectives: In this study, the concentrations of uric acid, purine profile and creatinine in samples of cerebrospinal fluid and serum of multiple sclerosis (MS) patients were measured by HPLC and compared with corresponding values recorded in patients Without MS (cerebrospinal fluid) and healthy subjects (serum). Design and methods: All samples were deproteinized with ultrafiltration (which ensures minimal sample manipulation and efficient protein removal) and then assayed for the synchronous HPLC separation of uric acid, hypoxanthine, xanthine, inosine, adenosine, guanosine and creatinine. Results: The values of all compounds assayed were significantly higher in both biological fluids of MS patients with respect to values measured in controls. In particular, serum hypoxanthine, xanthine, uric acid and sum of oxypurines were, respectively, 3.17, 3.11, 1.23 and 1.27-fold higher in these patients than corresponding values recorded in controls (p < 0.001). Conclusions: Differently from what previously reported, we here demonstrate that all purine compounds, including uric acid, are elevated in biological fluids of MS patients. Reinforced by the trend observed for creatinine, this corroborates the notion of sustained purine catabolism, possibly due to imbalance in ATP homeostasis, under these pathological conditions. These results cast doubt oil the hypothesis that uric acid is depleted in MS because of increased oxidative stress, rather suggesting that this disease causes a generalized increase in purine catabolism. As observed in other pathological states, uric acid, purine compounds and creatinine, can be considered markers of metabolic energy imbalance rather than of reactive oxygen species, even in MS. (c) 2009 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.	[D'Urso, Serafina; Lazzarino, Giuseppe] Univ Catania, Biochem Lab, Dept Chem Sci, I-95125 Catania, Italy; [Amorini, Angela M.; Tavazzi, Barbara; Di Preto, Valentina] Catholic Univ Rome Sacro Cuore, Inst Biochem & Clin Biochem, Rome, Italy; [Petzold, Axel; Keir, Geoffrey] UCL, Inst Neurol, Neuroimmunol & CSF Unit, Dept Neuroinflammat, London, England; [Eikelenboom, Judith; Polman, Chris; Uitdehaag, Bernard] Univ Amsterdam, Dept Neurol, VU Med Ctr, Amsterdam, Netherlands; [Belli, Antonio] Univ Southampton, Div Clin Neurosci, Southampton, Hants, England; [Giovannoni, Gavin] Royal London Hosp, Dept Neurol, London E1 1BB, England; [Vagnozzi, Roberto] Univ Roma Tor Vergata, Dept Neurosci, Rome, Italy	Lazzarino, G (corresponding author), Univ Catania, Biochem Lab, Dept Chem Sci, Viale A Dorio 6, I-95125 Catania, Italy.	lazzarig@unict.it	TAVAZZI, BARBARA/AAB-9830-2019; Petzold, Axel/C-1090-2009; Belli, Antonio/I-3799-2015; lazzarino, giuseppe/K-2277-2015	TAVAZZI, BARBARA/0000-0001-8743-0895; Petzold, Axel/0000-0002-0344-9749; Belli, Antonio/0000-0002-3211-9933; lazzarino, giuseppe/0000-0002-5917-7279; Di Pietro, Valentina/0000-0001-9430-4723; AMORINI, Angela Maria/0000-0003-3525-9955	Catania University, of Catholic University of Rome;  [MIUR - PRIN 2007JBHZ5F]	This work has been supported in part by research funds of Catania University, of Catholic University of Rome "Sacro Cuore", and by MIUR - PRIN 2007JBHZ5F grant,	Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005; Bayir H, 2005, J CEREBR BLOOD F MET, V25, P673, DOI 10.1038/sj.jcbfm.9600068; Besler HT, 2003, NUTR NEUROSCI, V6, P189, DOI 10.1080/1028415031000115945; Bizzozero OA, 2005, J NEUROSCI RES, V81, P687, DOI 10.1002/jnr.20587; CADOUXHUDSON TAD, 1991, J NEUROL NEUROSUR PS, V54, P1004, DOI 10.1136/jnnp.54.11.1004; Calabrese V, 2002, J NEUROSCI RES, V70, P580, DOI 10.1002/jnr.10408; Carlson NG, 2006, CNS DRUGS, V20, P433, DOI 10.2165/00023210-200620060-00001; Chan DC, 2006, CELL, V125, P1241, DOI 10.1016/j.cell.2006.06.010; Cristofori L, 2005, CLIN BIOCHEM, V38, P97, DOI 10.1016/j.clinbiochem.2004.09.013; Cristofori L, 2001, J INVEST MED, V49, P450, DOI 10.2310/6650.2001.33790; Czauderna M, 1997, J CHROMATOGR B, V704, P89, DOI 10.1016/S0378-4347(97)00459-3; Drulovic J, 2001, J NEUROL, V248, P121, DOI 10.1007/s004150170246; Dutta R, 2006, ANN NEUROL, V59, P478, DOI 10.1002/ana.20736; GIARDINA B, 1993, AM J CARDIOL, V71, P788, DOI 10.1016/0002-9149(93)90825-W; Gu Z, 2005, CELL DEATH DIFFER, V12, P1202, DOI 10.1038/sj.cdd.4401705; Guerrero AL, 2008, EUR J NEUROL, V15, P394, DOI 10.1111/j.1468-1331.2008.02087.x; Hao Q, 2005, J ALZHEIMERS DIS, V8, P161; Hartmann S, 2006, CLIN CHEM, V52, P1127, DOI 10.1373/clinchem.2005.058842; Jolivalt CG, 2003, J NEUROIMMUNOL, V138, P56, DOI 10.1016/S0165-5728(03)00097-3; Koch M, 2006, NEUROL RES, V28, P316, DOI 10.1179/016164106X98215; KOJIMA T, 1987, CLIN CHEM, V33, P2052; Kuracka L, 1996, CLIN CHEM, V42, P756; la Marca G, 2006, J MASS SPECTROM, V41, P1442, DOI 10.1002/jms.1115; Lazzarino G, 2003, ANAL BIOCHEM, V322, P51, DOI 10.1016/j.ab.2003.07.013; LAZZARINO G, 1994, CIRCULATION, V90, P291, DOI 10.1161/01.CIR.90.1.291; Lublin FD, 1996, NEUROLOGY, V46, P907, DOI 10.1212/WNL.46.4.907; Mancuso M, 2006, J ALZHEIMERS DIS, V10, P59; Mastrocola R, 2005, J ENDOCRINOL, V187, P37, DOI 10.1677/joe.1.06269; Minniti G, 1998, ADV EXP MED BIOL, V431, P843; MOSERT JP, 2005, J NEUROL SCI, V231, P41; NIKLASSON F, 1983, CLIN CHEM, V29, P1543; Noiri E, 2001, AM J PHYSIOL-RENAL, V281, pF948, DOI 10.1152/ajprenal.0071.2001; Petzold A, 2006, MULT SCLER J, V12, P325, DOI 10.1191/135248505ms1277oa; Qi XP, 2006, J BIOL CHEM, V281, P31950, DOI 10.1074/jbc.M603717200; Ramsaransing GSM, 2005, EUR J NEUROL, V12, P514, DOI 10.1111/j.1468-1331.2005.01009.x; Rejdak K, 2004, NEUROLOGY, V63, P1439; Rentzos M, 2006, CLIN NEUROL NEUROSUR, V108, P527, DOI 10.1016/j.clineuro.2005.08.004; Roxburgh RHSR, 2005, NEUROLOGY, V64, P1144, DOI 10.1212/01.WNL.0000156155.19270.F8; SHARMA KR, 1995, MUSCLE NERVE, V18, P1403, DOI 10.1002/mus.880181210; Signoretti S, 2004, J NEUROTRAUM, V21, P1154, DOI 10.1089/neu.2004.21.1154; Sotgiu S, 2002, NEUROL SCI, V23, P183, DOI 10.1007/s100720200059; Squadrito GL, 2000, ARCH BIOCHEM BIOPHYS, V376, P333, DOI 10.1006/abbi.2000.1721; Stover JF, 1997, NEUROSCI LETT, V238, P25, DOI 10.1016/S0304-3940(97)00840-9; Tavazzi B, 2005, CLIN BIOCHEM, V38, P997, DOI 10.1016/j.clinbiochem.2005.08.002; Taylor NF, 2006, DISABIL REHABIL, V28, P1119, DOI 10.1080/09638280500531834; Vagnozzi R, 1997, EXP BRAIN RES, V117, P411, DOI 10.1007/s002210050235; Vagnozzi R, 1999, J NEUROTRAUM, V16, P903, DOI 10.1089/neu.1999.16.903; Vidotto C, 2003, CLIN CHIM ACTA, V335, P27, DOI 10.1016/S0009-8981(03)00291-2	48	77	78	2	15	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0009-9120	1873-2933		CLIN BIOCHEM	Clin. Biochem.	JUL	2009	42	10-11					1001	1006		10.1016/j.clinbiochem.2009.03.020			6	Medical Laboratory Technology	Medical Laboratory Technology	461NN	WOS:000267274300011	19341721				2021-06-18	
J	Friess, SH; Ichord, RN; Ralston, J; Ryall, K; Helfaer, MA; Smith, C; Margulies, SS				Friess, Stuart H.; Ichord, Rebecca N.; Ralston, Jill; Ryall, Karen; Helfaer, Mark A.; Smith, Colin; Margulies, Susan S.			Repeated Traumatic Brain Injury Affects Composite Cognitive Function in Piglets	JOURNAL OF NEUROTRAUMA			English	Article						axonal injury; neurobehavioral assessment; pediatric brain injury; traumatic brain injury	CLOSED-HEAD INJURY; COLLEGIATE FOOTBALL PLAYERS; AXONAL INJURY; NEONATAL PIG; RECURRENT CONCUSSION; NCAA CONCUSSION; CHILDREN; RECOVERY; SPORT; CONTROVERSIES	Cumulative effects of repetitive mild head injury in the pediatric population are unknown. We have developed a cognitive composite dysfunction score that correlates white matter injury severity in neonatal piglets with neurobehavioral assessments of executive function, memory, learning, and problem solving. Anesthetized 3- to 5-day-old piglets were subjected to single (n=7), double one day apart (n=7), and double one week apart (n=7) moderate (190 rad/s) rapid non-impact axial rotations of the head and compared to instrumented shams (n=7). Animals experiencing two head rotations one day apart had a significantly higher mortality rate (43%) compared to the other groups and had higher failures rates in visual-based problem solving compared to instrumented shams. White matter injury, assessed by beta-APP staining, was significantly higher in the double one week apart group compared to that with single injury and sham. Worsening performance on cognitive composite score correlated well with increasing severity of white matter axonal injury. In our immature large animal model of TBI, two head rotations produced poorer outcome as assessed by neuropathology and neurobehavioral functional outcomes compared to that with single rotations. More importantly, we have observed an increase in injury severity and mortality when the head rotations occur 24 h apart compared to 7 days apart. These observations have important clinical translation to infants subjected to repeated inflicted head trauma.	[Ralston, Jill; Ryall, Karen; Margulies, Susan S.] Univ Penn, Sch Engn & Appl Sci, Dept Bioengn, Philadelphia, PA 19104 USA; [Friess, Stuart H.; Helfaer, Mark A.] Childrens Hosp Philadelphia, Dept Anesthesiol & Crit Care Med, Philadelphia, PA 19104 USA; [Ichord, Rebecca N.] Childrens Hosp Philadelphia, Dept Neurol, Philadelphia, PA 19104 USA; [Smith, Colin] Western Gen Hosp, Dept Neuropathol, Edinburgh EH4 2XU, Midlothian, Scotland	Margulies, SS (corresponding author), Univ Penn, Sch Engn & Appl Sci, Dept Bioengn, 240 Skirkanich Hall,210 S 33rd St, Philadelphia, PA 19104 USA.	margulie@seas.upenn.edu		Smith, Colin/0000-0002-4507-5132	The Children's Hospital of Philadelphia; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01-NS39679]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039679] Funding Source: NIH RePORTER	These studies were supported by an endowed chair in critical care medicine from The Children's Hospital of Philadelphia (M.A.H.) and an NIH grant (no. R01-NS39679 [S.S.M.]). The authors are grateful to Ahn Truong and Kristin Owens for their assistance in behavior testing and data analysis.	ARMSTEAD WM, 1994, J NEUROTRAUM, V11, P487, DOI 10.1089/neu.1994.11.487; Barrow IM, 2006, BRAIN INJURY, V20, P845, DOI 10.1080/02699050600832445; Biasca N, 2007, PROG BRAIN RES, V161, P263, DOI 10.1016/S0079-6123(06)61019-4; Bolhuis JE, 2004, BEHAV BRAIN RES, V152, P351, DOI 10.1016/j.bbr.2003.10.024; De Monte VE, 2005, J CLIN EXP NEUROPSYC, V27, P224, DOI 10.1080/13803390490515766; DeRoss AL, 2002, J TRAUMA, V52, P708, DOI 10.1097/00005373-200204000-00017; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; Duhaime AC, 2000, J NEUROSURG, V93, P455, DOI 10.3171/jns.2000.93.3.0455; Ewing-Cobbs L, 2000, CHILD NERV SYST, V16, P25, DOI 10.1007/s003810050006; Frei FJ, 1997, ANAESTHESIA, V52, P1056, DOI 10.1111/j.1365-2044.1997.257-az0376.x; Friess SH, 2007, EXP NEUROL, V204, P234, DOI 10.1016/j.expneurol.2006.10.010; Giza CC, 2001, J ATHL TRAINING, V36, P228; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; HOEHNER PJ, 1994, STROKE, V25, P2060, DOI 10.1161/01.STR.25.10.2060; HOEHNER PJ, 1994, STROKE, V25, P2066; Hoyert Donna L, 2006, Natl Vital Stat Rep, V54, P1; Huh JW, 2007, J NEUROTRAUM, V24, P15, DOI 10.1089/neu.2006.0072; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Malojcic B, 2008, J NEUROTRAUM, V25, P30, DOI 10.1089/neu.2007.0384; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; Power T, 2007, BRAIN INJURY, V21, P279, DOI 10.1080/02699050701253095; Raghupathi R, 2004, J NEUROTRAUM, V21, P307, DOI 10.1089/089771504322972095; Raghupathi R, 2002, J NEUROTRAUM, V19, P843, DOI 10.1089/08977150260190438; Schnadower D, 2007, CURR OPIN PEDIATR, V19, P258, DOI 10.1097/MOP.0b013e3281084e85; Standaert CJ, 2007, ARCH PHYS MED REHAB, V88, P1077, DOI 10.1016/j.apmr.2007.06.002; Wall SE, 2006, J NEUROL NEUROSUR PS, V77, P518, DOI 10.1136/jnnp.2004.061044; Wilkinson AE, 1999, ACTA NEUROPATHOL, V98, P197, DOI 10.1007/s004010051069	35	77	78	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2009	26	7					1111	1121		10.1089/neu.2008.0845			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	470HJ	WOS:000267965500016	19275468	Green Published			2021-06-18	
J	Nelson, LA; Yoash-Gantz, RE; Pickett, TC; Campbell, TA				Nelson, Lonnie A.; Yoash-Gantz, Ruth E.; Pickett, Treven C.; Campbell, Thomas A.			Relationship Between Processing Speed and Executive Functioning Performance Among OEF/OIF Veterans: Implications for Postdeployment Rehabilitation	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						neuropsychology; processing speed; psychiatric; PTSD; rehabilitation; Stroop; TBI	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; COGNITIVE REHABILITATION; DEPRESSION; SOLDIERS; MEMORY; TRAIL; TESTS; TRIAL	Background: Comorbid mild traumatic brain injury (mTBI) with posttraumatic stress disorder (PTSD) is a common clinical presentation among troops returning from Operation Enduring Freedom and Operation Iraqi Freedom (OEF/OIF). This study examined processing speed and executive functioning in a sample of OEF/OIF veterans who had sustained mTBI, a subset of whom also had comorbid PTSD. Methods: Fifty-three OEF/OIF veterans with a history of mTBI completed Wechsler Adult Intelligence Scale-III Symbol Search and Digit Symbol-Coding subscales, Stroop Word, color and color-word trials, and Trail Making Test, Parts A and B as part of a comprehensive neuropsychological test battery. Results: Excluding from analysis those who scored poorly on effort testing, multiple regression showed that measures of processing speed accounted for 43% of the variance in performance on the Trail Making Test, Part B and 50% of the variance in performance on the Stroop task. Significant differences in processing speed and executive functioning were found on the basis of presence of comorbid PTSD. Stroop Color (F = 9.27, df = 52, P < .004) and Stroop Color Word (F = 7.19, df = 52, P < .01) scores differed significantly between the groups. Those having comorbid PTSD (+TBI/+PTSD) scored significantly poorer than the mTBI-only group (+TBI/-PTSD). Implications for treatment of the comorbid conditions are discussed.	[Yoash-Gantz, Ruth E.] Hefner VA Med Ctr, Salisbury, NC 28144 USA; [Nelson, Lonnie A.; Pickett, Treven C.; Campbell, Thomas A.] Hunter Holmes McGuire Dept Vet Affairs Med Ctr, Mental Hlth Serv, Richmond, VA USA; [Nelson, Lonnie A.; Pickett, Treven C.] Def & Vet Brain Injury Ctr, Richmond, VA USA; [Yoash-Gantz, Ruth E.; Pickett, Treven C.] VISN6, MIRECC, Richmond, NC USA; [Pickett, Treven C.] Virginia Commonwealth Univ, Sch Med, Dept Phys Med & Rehabil, Richmond, NC USA; [Yoash-Gantz, Ruth E.] Wake Forest Univ, Bowman Gray Sch Med, Dept Psychiat & Behav Sci, Winston Salem, NC USA	Yoash-Gantz, RE (corresponding author), Hefner VA Med Ctr, Mental Hlth & Behav Sci 11M-2,1601 Brenner Ave, Salisbury, NC 28144 USA.	ruth.yoash-gantz@va.gov					Bliese PD, 2008, J CONSULT CLIN PSYCH, V76, P272, DOI 10.1037/0022-006X.76.2.272; Bryant RA, 2008, ARCH GEN PSYCHIAT, V65, P659, DOI 10.1001/archpsyc.65.6.659; Bryant RA, 2008, NEW ENGL J MED, V358, P525, DOI 10.1056/NEJMe078235; BURNAM MA, 2008, INVISIBLE WOUNDS WAR, P3; Cicerone KD, 2004, ARCH PHYS MED REHAB, V85, P943, DOI 10.1016/j.apmr.2003.07.019; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone K, 2006, J COGNITIVE NEUROSCI, V18, P1212, DOI 10.1162/jocn.2006.18.7.1212; Demakis GJ, 2004, J CLIN EXP NEUROPSYC, V26, P441, DOI 10.1080/13803390490510149; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; Everly George S Jr, 2003, Int J Emerg Ment Health, V5, P179; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Golden C., 1978, STROOP COLOR WORD TE; Grieger TA, 2006, AM J PSYCHIAT, V163, P1777, DOI 10.1176/appi.ajp.163.10.1777; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; JORGE RE, 1994, J NEUROSURG, V81, P726, DOI 10.3171/jns.1994.81.5.0726; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Mathias JL, 2004, J INT NEUROPSYCH SOC, V10, P286, DOI 10.1017/S1355617704102117; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; Michel J A, 2006, Eura Medicophys, V42, P59; Rassovsky Y, 2006, J CLIN EXP NEUROPSYC, V28, P581, DOI 10.1080/13803390500434474; Ravnkilde B, 2002, J CLIN EXP NEUROPSYC, V24, P534, DOI 10.1076/jcen.24.4.534.1033; Reitan R. M, 1985, HALLSTED REITAN NEUR; Resick PA, 2008, J CONSULT CLIN PSYCH, V76, P243, DOI 10.1037/0022-006X.76.2.243; Ruffolo LF, 2000, CLIN NEUROPSYCHOL, V14, P223, DOI 10.1076/1385-4046(200005)14:2;1-Z;FT223; Sim A, 2008, J NEUROSURG, V108, P511, DOI 10.3171/JNS/2008/108/3/0511; SOHLBERG MM, 1987, J CLIN EXP NEUROPSYC, V9, P117, DOI 10.1080/01688638708405352; Stuss DT, 2001, NEUROPSYCHOLOGIA, V39, P771, DOI 10.1016/S0028-3932(01)00013-6; SUSAN D, 2002, J CLIN PSYCHOL, V58, P947; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Tanielian T., 2008, INVISIBLE WOUNDS WAR, P3; Wechsler D, 1997, WAIS 3 ADM SCORING M	32	77	77	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2009	24	1					32	40		10.1097/HTR.0b013e3181957016			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	427GT	WOS:000264768500006	19158594				2021-06-18	
J	Till, C; Colella, B; Verwegen, J; Green, RE				Till, Christine; Colella, Brenda; Verwegen, Joel; Green, Robin E.			Postrecovery Cognitive Decline in Adults With Traumatic Brain Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Cognition; Follow-up studies; Neuropsychological tests; Recovery of function; Rehabilitation	SEVERE HEAD-INJURY; NEUROPSYCHOLOGICAL RECOVERY; INFLAMMATORY RESPONSE; ALZHEIMER-DISEASE; AGED BRAIN; FOLLOW-UP; PLASTICITY; MEMORY; REHABILITATION; PERFORMANCE	Objective: To assess prospectively the degree of postrecovery long-term cognitive decline after moderate to severe traumatic brain injury (TBI). Design: Observational cohort. Setting: Inpatient rehabilitation hospital. Participants: Adults (N=33) with moderate and severe TB I from a well characterized sample with low attrition: Interventions: Not applicable. Main Outcome Measures: Recovery of functioning was ascertained through repeat neuropsychological assessments over the first 5 years postinjury. Cognitive decline from a baseline of 12 months postinjury to a follow-up evaluation conducted on average +/- SD 2.1 +/- 0.99 years later. Change was calculated using the reliable change index (RCI) for 12 neuropsychological tests commonly used in the assessment of TBI. Results: At the group level, negligible changes in cognitive function were observed over tune. However, application of the RCI using 90% confidence intervals showed statistically significant cognitive decline on at least 2 neuropsychological measures in 27.3% of study participants. Decline was most commonly observed on a test of verbal fluency and the delayed recall portion of a test of verbal list learning (Rey Auditory Verbal Learning Test), although substantial variability existed across patients. Decline was significantly correlated with hours of therapy received at 5 months postinjury (P<.02). Conclusions: Consistent with a small number of previous studies, cognitive deterioration may follow an initial period of recovery. Overall, the pattern of decline across tests varied across individuals. Possible mechanisms of decline are discussed. Further research is needed to understand the stability of this finding and its functional implications.	[Till, Christine; Verwegen, Joel; Green, Robin E.] Toronto Rehabil Inst, Toronto, ON, Canada; [Green, Robin E.] Univ Toronto, Dept Rehabil Sci, Toronto, ON, Canada	Till, C (corresponding author), York Univ, Dept Psychol, 4700 Keele St, N York, ON M3J 1P3, Canada.	ctill@yorku.ca	Lang, Steven/AAE-8102-2021	Lang, Steven/0000-0003-1669-9146; Green, Robin/0000-0001-9451-3963; Till, Christine/0000-0001-5030-3155	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [MOP-67072]; Physicians' Services Incorporated [05-50]; Ontario Mental Health Foundation.	Supported by the Canadian Institutes of Health Research (grant no. MOP-67072), Physicians' Services Incorporated (grant no. 05-50), and the Ontario Mental Health Foundation.	Basso MR, 2001, CLIN NEUROPSYCHOL, V15, P471, DOI 10.1076/clin.15.4.471.1883; Bayona Nestor A, 2005, Top Stroke Rehabil, V12, P27; Beck A.T., 1996, MANUAL BECK DEPRESSI; Beck A.T., 1993; Benton AL, 1978, MULTILINGUAL APHASIA; Bigler ED, 1996, BRAIN INJURY, V10, P197, DOI 10.1080/026990596124511; Blair JR., 1989, CLIN NEUROPSYCHOL, V3, P129; Boake C, 2001, ARCH PHYS MED REHAB, V82, P761, DOI 10.1053/apmr.2001.23753; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Brooks D N, 1979, Int Rehabil Med, V1, P166; Burton CL, 2002, CLIN NEUROPSYCHOL, V16, P264, DOI 10.1076/clin.16.3.264.13854; BUTTERS N, 1985, J CLIN EXP NEUROPSYC, V7, P181, DOI 10.1080/01688638508401252; Chu BC, 2007, J CLIN EXP NEUROPSYC, V29, P617, DOI 10.1080/13803390600878893; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; Cohen J., 1983, APPL MULTIPLE REGRES; Dancause N, 2005, J NEUROSCI, V25, P10167, DOI 10.1523/JNEUROSCI.3256-05.2005; Dancause N, 2006, J NEUROPHYSIOL, V96, P3506, DOI 10.1152/jn.00792.2006; DIKMEN S, 1990, J CLIN EXP NEUROPSYC, V12, P507, DOI 10.1080/01688639008400997; DIKMEN S, 1983, ARCH NEUROL-CHICAGO, V40, P333, DOI 10.1001/archneur.1983.04050060033004; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Ferrer E, 2004, PSYCHOL AGING, V19, P243, DOI 10.1037/0882-7974.19.2.243; FRANCIS DJ, 1991, J CONSULT CLIN PSYCH, V59, P27, DOI 10.1037/0022-006X.59.1.27; Frost SB, 2003, J NEUROPHYSIOL, V89, P3205, DOI 10.1152/jn.01143.2002; GEFFEN GM, 1994, ARCH CLIN NEUROPSYCH, V9, P303, DOI 10.1016/0887-6177(94)90018-3; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Hamm RJ, 1996, J NEUROTRAUM, V13, P41, DOI 10.1089/neu.1996.13.41; Hammond FM, 2004, NEUROREHABILITATION, V19, P25; Heaton R., 1992, COMPREHENSIVE NORMS; Heaton R., 1993, WISCONSIN CARD SORTI; Helzner EP, 2007, ARCH NEUROL-CHICAGO, V64, P1749, DOI 10.1001/archneur.64.12.1749; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; Hinkebein JH, 2003, BRAIN INJURY, V17, P1035, DOI 10.1080/0269905031000110490; HOLLINGSHEAD AB, 1975, 4 FACTORS SOCIAL STA; Isoniemi H, 2006, J NEUROTRAUM, V23, P1600, DOI 10.1089/neu.2006.23.1600; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; Jones AS, 2007, J STUD ALCOHOL DRUGS, V68, P266, DOI 10.15288/jsad.2007.68.266; Kesler SR, 2003, APPL NEUROPSYCHOL, V10, P153, DOI 10.1207/S15324826AN1003_04; Kim H, 2006, CAN J NEUROL SCI, V33, P48, DOI 10.1017/S0317167100004686; Klein M, 1996, J NERV MENT DIS, V184, P459, DOI 10.1097/00005053-199608000-00002; Lange RT, 2007, NEUROPSYCHOLOGY, V21, P590, DOI 10.1037/0894-4105.21.5.590; Levine AJ, 2004, CLIN NEUROPSYCHOL, V18, P373, DOI 10.1080/1385404049052420; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Mahncke HW, 2006, PROG BRAIN RES, V157, P81, DOI 10.1016/S0079-6123(06)57006-2; Mahncke HW, 2006, P NATL ACAD SCI USA, V103, P12523, DOI 10.1073/pnas.0605194103; MANDLEBERG IA, 1976, J NEUROL NEUROSUR PS, V39, P1001, DOI 10.1136/jnnp.39.10.1001; Mateer CA, 2000, BRAIN COGNITION, V42, P106, DOI 10.1006/brcg.1999.1175; Mauri M, 2006, FUNCT NEUROL, V21, P223; Millis S R, 1994, Int J Neurosci, V79, P165; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Morey L. C., 1991, PERSONALITY ASSESSME; Novack TA, 2000, BRAIN INJURY, V14, P987; Nudo Randolph J, 2006, NeuroRx, V3, P420; Nudo RJ, 2007, STROKE, V38, P840, DOI 10.1161/01.STR.0000247943.12887.d2; Onyszchuk G, 2008, J NEUROTRAUM, V25, P153, DOI 10.1089/neu.2007.0430; Petcu EB, 2008, GERONTOLOGY, V54, P6, DOI 10.1159/000112845; Popa-Wagner A, 2007, CURR NEUROVASC RES, V4, P216; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Robertson IH, 1999, PSYCHOL BULL, V125, P544, DOI 10.1037/0033-2909.125.5.544; RUFF RM, 1991, J NEUROSURG, V75, pS50, DOI 10.3171/sup.1991.75.1s.0s50; Salmond CH, 2006, NEUROPSYCHOLOGIA, V44, P1995, DOI 10.1016/j.neuropsychologia.2006.03.013; SALTHOUSE TA, 1991, PSYCHOL AGING, V6, P118, DOI 10.1037/0882-7974.6.1.118; Sander AM, 2001, J HEAD TRAUMA REHAB, V16, P356, DOI 10.1097/00001199-200108000-00006; Sankoh AJ, 1997, STAT MED, V16, P2529, DOI 10.1002/(SICI)1097-0258(19971130)16:22<2529::AID-SIM692>3.0.CO;2-J; Sawrie S M, 1996, J Int Neuropsychol Soc, V2, P556; Scarmeas Nikolaos, 2004, Curr Neurol Neurosci Rep, V4, P374, DOI 10.1007/s11910-004-0084-7; Schmidt M., 1996, REY AUDITORY VERBAL; Schmidt OI, 2007, ORTHOPADE, V36, P248, DOI 10.1007/s00132-007-1061-z; Smith A., 1982, SYMBOL DIGIT MODALIT; Smith DH, 2003, NEUROMOL MED, V4, P59, DOI 10.1385/NMM:4:1-2:59; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; TEASDALE G, 1974, LANCET, V2, P81; Tombough T., 1996, TEST MEMORY MALINGER; TURNER GR, NEUROPSYCHO IN PRESS; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Wechsler D., 2011, WECHLSER ABBREVIATED; Wechsler D., 2001, WECHSLER TEST ADULT; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Wechsler D, 1997, WAIS 3 ADM SCORING M; Whiteneck GG, 2004, J HEAD TRAUMA REHAB, V19, P191, DOI 10.1097/00001199-200405000-00001; Wilson RS, 2007, NEUROLOGY, V69, P1911, DOI 10.1212/01.wnl.0000271087.67782.cb; WONT PP, 2001, BRAIN INJURY, V15, P519; Yager JY, 2006, BEHAV BRAIN RES, V173, P171, DOI 10.1016/j.bbr.2006.06.019	83	77	83	0	11	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	DEC	2008	89	12		2			S25	S34		10.1016/j.apmr.2008.07.004			10	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	388DB	WOS:000261999400004	19081438				2021-06-18	
J	Angst, MS; Clark, JD; Carvalho, B; Tingle, M; Schmelz, M; Yeomans, DC				Angst, M. S.; Clark, J. D.; Carvalho, B.; Tingle, M.; Schmelz, M.; Yeomans, D. C.			Cytokine profile in human skin in response to experimental inflammation, noxious stimulation, and administration of a COX-inhibitor: A microdialysis study	PAIN			English	Article						Microdialysis; Skin; Human; Ultraviolet B; Sunburn; Inflammation; Cytokines; Interleukins; Chemokines; Nerve Growth Factor; Cyclooxygenase Inhibitor; lbuprofen; Hyperalgesia; Heat; Mechanical; Analgesia; Anti-hyperalgesia; Anti-inflammatory	NERVE GROWTH-FACTOR; NECROSIS-FACTOR-ALPHA; OPIOID AGONIST REMIFENTANIL; TRAUMATIC BRAIN-INJURY; GENE-RELATED PEPTIDE; PAIN SYNDROME TYPE-1; BEAD ARRAY ASSAYS; ULTRAVIOLET-B; IN-VIVO; PROINFLAMMATORY CYTOKINES	Animal studies have documented a critical role for cytokines in cell signaling events underlying inflammation and pain associated with tissue injury. While clinical reports indicate an important role of cytokines in inflammatory pain, methodological limitations have made systematic human studies difficult. This study examined the utility of a human in vivo bioassay combining rnicrodialysis with multiplex immunoassay techniques for measuring cytokine arrays in tissue. The first experiment measured cytokines in interstitial fluid collected from non-inflamed and experimentally inflamed skin (UVB). The effects of noxious heat on cytokine release were also assessed. The second experiment examined whether anti-hyperalgesic effects of the COX-inhibitor ibuprofen were associated with decreased tissue levels of the pro-inflammatory cytokines IL-1 beta and IL-6. In the first experiment, inflammation significantly increased IL-1 beta, IL-6, IL-8, IL-10, G-CSF, and MIP-1 beta. Noxious heat but not experimental inflammation significantly increased IL-7 and IL-13. In the second experiment, an oral dose of 400 and 800 mg ibuprofen produced similar anti-hyperalgesic effects Suggesting a ceiling effect. Tissue levels of IL-1 beta and IL-6 were not affected after the 400 mg dose but decreased significantly (44 +/- 32% and 38 +/- 13%) after the 800 mg dose. These results Support the utility of explored method for tracking cytokines in human tissue and suggest that anti-hyperalgesic and anti-inflammatory effects of ibuprofen are at least partially dissociated. The data further suggest that high clinical doses of ibuprofen exert anti-inflammatory effects by down-regulating tissue cytokine levels. Explored human bioassay is a promising tool for studying the pathology and pharmacology of inflammatory and chronic pain conditions. (C) 2008 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.	[Angst, M. S.; Clark, J. D.; Carvalho, B.; Tingle, M.; Yeomans, D. C.] Stanford Univ, Sch Med, Dept Anesthesia, Stanford, CA 94305 USA; [Clark, J. D.] Vet Affiairs Palo Alto Hlth Care Syst, Dept Anesthesia, Palo Alto, CA 94304 USA; [Schmelz, M.] Univ Heidelberg, Dept Anesthesiol, D-6800 Mannheim, Germany	Angst, MS (corresponding author), Stanford Univ, Sch Med, Dept Anesthesia, 300 Pasteur Dr, Stanford, CA 94305 USA.	ang@stanford.edu	Schmelz, Martin/A-9327-2013	Schmelz, Martin/0000-0002-9736-7241			Angst MS, 2004, ANESTHESIOLOGY, V101, P744, DOI 10.1097/00000542-200409000-00024; Angst MS, 2003, PAIN, V106, P49, DOI 10.1016/S0304-3959(03)00276-8; Angst MS, 2000, ANESTHESIOLOGY, V92, P312, DOI 10.1097/00000542-200002000-00011; Averbeck M, 2006, EXP DERMATOL, V15, P447, DOI 10.1111/j.0906-6705.2006.00429.x; AVGERINOS A, 1990, CHIRALITY, V2, P249, DOI 10.1002/chir.530020410; Bahlmann L, 2004, INTENS CARE MED, V30, P889, DOI 10.1007/s00134-004-2199-3; Basu S, 2005, P NATL ACAD SCI USA, V102, P5120, DOI 10.1073/pnas.0407780102; Bessler H, 2006, NEUROSCI LETT, V404, P154, DOI 10.1016/j.neulet.2006.05.030; Biedermann T, 2004, J INVEST DERM SYMP P, V9, P5, DOI 10.1111/j.1087-0024.2004.00829.x; Bowman PD, 1997, AM J PHYSIOL-CELL PH, V272, pC1988; Buvanendran A, 2006, ANESTHESIOLOGY, V104, P403, DOI 10.1097/00000542-200603000-00005; Cataisson C, 2006, J CLIN INVEST, V116, P2757, DOI 10.1172/JCI27514; Clark JD, 2006, ANESTHESIOLOGY, V104, P1274, DOI 10.1097/00000542-200606000-00024; Clingen PH, 2001, BRIT J DERMATOL, V145, P54, DOI 10.1046/j.1365-2133.2001.04281.x; Clough GF, 2007, J INVEST DERMATOL, V127, P2799, DOI 10.1038/sj.jid.5700930; CROFFORD LJ, 1994, J CLIN INVEST, V93, P1095, DOI 10.1172/JCI117060; CUNHA FQ, 1992, BRIT J PHARMACOL, V107, P660, DOI 10.1111/j.1476-5381.1992.tb14503.x; Cunha FQ, 1999, BRIT J PHARMACOL, V126, P45, DOI 10.1038/sj.bjp.0702266; Dallos A, 2006, NEUROPEPTIDES, V40, P251, DOI 10.1016/j.npep.2006.06.002; Denda M, 2007, J INVEST DERMATOL, V127, P654, DOI 10.1038/sj.jid.5700590; Di Nuzzo S, 1998, J INVEST DERMATOL, V110, P978, DOI 10.1046/j.1523-1747.1998.00220.x; DIMARCO E, 1991, J BIOL CHEM, V266, P21718; Elshal MF, 2006, METHODS, V38, P317, DOI 10.1016/j.ymeth.2005.11.010; ENK CD, 1995, J IMMUNOL, V154, P4851; Fang Y, 2007, BRIT J DERMATOL, V157, P458, DOI 10.1111/j.1365-2133.2007.07979.x; Feldmeyer L, 2007, CURR BIOL, V17, P1140, DOI 10.1016/j.cub.2007.05.074; FERREIRA SH, 1979, PROSTAGLANDINS, V18, P179, DOI 10.1016/0090-6980(79)90103-5; FERREIRA SH, 1988, NATURE, V334, P698, DOI 10.1038/334698a0; FITZPATRICK TB, 1988, ARCH DERMATOL, V124, P869, DOI 10.1001/archderm.124.6.869; Flodgren GM, 2006, EUR J APPL PHYSIOL, V97, P557, DOI 10.1007/s00421-006-0216-7; FUKUOKA H, 1994, BRAIN RES, V657, P133, DOI 10.1016/0006-8993(94)90960-1; HAWK JLM, 1988, BRIT J DERMATOL, V118, P27, DOI 10.1111/j.1365-2133.1988.tb01746.x; Heijmans-Antonissen C, 2006, MEDIAT INFLAMM, V2006, DOI 10.1155/MI/2006/28398; Hillered L, 2006, CURR OPIN CRIT CARE, V12, P112, DOI 10.1097/01.ccx.0000216576.11439.df; Hino R, 2007, BRIT J DERMATOL, V156, P830, DOI 10.1111/j.1365-2133.2007.07774.x; Holzheimer R G, 2000, Eur J Med Res, V5, P347; Imokawa G, 1996, BIOCHEM J, V313, P625, DOI 10.1042/bj3130625; Inaoka M, 2006, EXP DERMATOL, V15, P981, DOI 10.1111/j.1600-0625.2006.00505.x; Joussen AM, 2002, FASEB J, V16, P438, DOI 10.1096/fj.01-0707fje; Kang JS, 2007, J INVEST DERMATOL, V127, P698, DOI 10.1038/sj.jid.5700572; KANG KF, 1994, J IMMUNOL, V153, P5256; Khan SS, 2004, CYTOM PART B-CLIN CY, V61B, P35, DOI 10.1002/cyto.b.20021; KILO S, 1995, PAIN, V62, P187, DOI 10.1016/0304-3959(94)00265-G; Li WH, 2007, J INVEST DERMATOL, V127, P2328, DOI 10.1038/sj.jid.5700880; Lindenlaub T, 2003, ACTA NEUROPATHOL, V105, P593, DOI 10.1007/s00401-003-0689-y; LONNROTH P, 1987, AM J PHYSIOL, V253, pE228; Lorenzetti BB, 2001, EUR CYTOKINE NETW, V12, P260; Lotsch J, 2003, PAIN, V102, P151, DOI 10.1016/S0304-3959(02)00349-4; LOTZ M, 1994, J UROLOGY, V152, P869, DOI 10.1016/S0022-5347(17)32594-6; Munnikes RJM, 2005, MEDIAT INFLAMM, P366, DOI 10.1155/MI.2005.366; Murdolo G, 2007, J CLIN ENDOCR METAB, V92, P2688, DOI 10.1210/jc.2006-2814; Obreja O, 2005, BRAIN, V128, P1634, DOI 10.1093/brain/awh490; Opree A, 2000, J NEUROSCI, V20, P6289, DOI 10.1523/JNEUROSCI.20-16-06289.2000; POOLE S, 1995, BRIT J PHARMACOL, V115, P684, DOI 10.1111/j.1476-5381.1995.tb14987.x; Purwar R, 2006, J INVEST DERMATOL, V126, P1043, DOI 10.1038/sj.jid.5700085; Rosenbloom AJ, 2006, J IMMUNOL METHODS, V309, P55, DOI 10.1016/j.jim.2005.11.013; Saade NE, 2000, BRIT J PHARMACOL, V131, P1317, DOI 10.1038/sj.bjp.0703699; Salemi S, 2003, J RHEUMATOL, V30, P146; Samuelsson A, 2006, CRIT CARE, V10, DOI 10.1186/cc5124; Sandqvist M, 2006, EUR J CLIN INVEST, V36, P383, DOI 10.1111/j.1365-2362.2006.01647.x; Sauerstein K, 2000, J PHYSIOL-LONDON, V529, P803, DOI 10.1111/j.1469-7793.2000.00803.x; Saunders CIM, 2007, MOL IMMUNOL, V44, P1429, DOI 10.1016/j.molimm.2006.04.027; Schmelz M, 1999, CLIN EXP ALLERGY, V29, P695; Shah JP, 2005, J APPL PHYSIOL, V99, P1977, DOI 10.1152/japplphysiol.00419.2005; Silva MA, 2005, TRANSPLANTATION, V79, P828, DOI 10.1097/01.TP.0000153156.38617.97; Sommer C, 2004, NEUROSCI LETT, V361, P184, DOI 10.1016/j.neulet.2003.12.007; Sopasakis VR, 2004, OBES RES, V12, P454, DOI 10.1038/oby.2004.51; Strickland I, 1997, J INVEST DERMATOL, V108, P763, DOI 10.1111/1523-1747.ep12292156; Takahashi T, 1998, ORAL SURG ORAL MED O, V85, P135, DOI 10.1016/S1079-2104(98)90415-2; Terui T, 2001, ACTA DERM-VENEREOL, V81, P8, DOI 10.1080/000155501750208100; Teunissen MBM, 2002, J IMMUNOL, V168, P3732, DOI 10.4049/jimmunol.168.8.3732; TRON VA, 1990, J CLIN INVEST, V85, P1085, DOI 10.1172/JCI114539; Verdant CL, 2006, ANN SURG, V244, P994, DOI 10.1097/01.sla.0000225092.45734.e6; Verri WA, 2006, PHARMACOL THERAPEUT, V112, P116, DOI 10.1016/j.pharmthera.2006.04.001; Waelgaard L, 2006, SCAND J IMMUNOL, V64, P345, DOI 10.1111/j.1365-3083.2006.01826.x; Wagner LA, 1999, EUR J IMMUNOL, V29, P2530, DOI 10.1002/(SICI)1521-4141(199908)29:08<2530::AID-IMMU2530>3.0.CO;2-2; Wang Y, 1997, BIOCHEM BIOPH RES CO, V239, P676, DOI 10.1006/bbrc.1997.7533; Winter CD, 2004, BRAIN, V127, P315, DOI 10.1093/brain/awh039; Wu CR, 2007, ANESTHESIOLOGY, V107, P128, DOI 10.1097/01.anes.0000267512.08619.bd; Yamaki K, 2005, INT J IMMUNOPATH PH, V18, P133, DOI 10.1177/039463200501800114	80	77	78	0	8	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0304-3959			PAIN	Pain	SEP 30	2008	139	1					15	27		10.1016/j.pain.2008.02.028			13	Anesthesiology; Clinical Neurology; Neurosciences	Anesthesiology; Neurosciences & Neurology	361WV	WOS:000260159200003	18396374				2021-06-18	
J	Chen, Q; Nakajima, A; Choi, SH; Xiong, XL; Sisodia, SS; Tang, YP				Chen, Qian; Nakajima, Akira; Choi, Se Hoon; Xiong, Xiaoli; Sisodia, Sangram S.; Tang, Ya-Ping			Adult neurogenesis is functionally associated with AD-like neurodegeneration	NEUROBIOLOGY OF DISEASE			English	Article						Alzheimer's disease; adult neurogenesis; neuronal loss; presenilin 1; neurodegeneration; conditional knockout; mice	FAMILIAL ALZHEIMERS-DISEASE; TRAUMATIC BRAIN-INJURY; NEURAL STEM-CELLS; HIPPOCAMPAL NEUROGENESIS; DENTATE GYRUS; MOUSE MODEL; NEUROFIBRILLARY TANGLES; SENILE DEMENTIA; CEREBRAL-CORTEX; GRANULE CELLS	Alzheimer's disease (AD) is predominantly characterized by progressive neuronal loss in the brain. It has been recently found that adult neurogenesis in the hippocampal dentate gyrus of AD patients is significantly enhanced, while its functional significance is still unknown. By using an AD-like neurodegeneration mouse model, we show here that neurogenesis in the dentate gyrus was neurodegenerative stage-dependent. At early stages of neurodegeneration, neurogenesis was significantly enhanced and newly generated neurons migrated into the local neuronal network. Up to late stages of neurodegeneration, however, the survival of newly generated neurons was impaired so that the enhanced neurogenesis could not be detected anymore. Most interestingly, these dynamic changes in neurogenesis were correlated with the severity of neuronal loss in the dentate gyros, indicating that neurogenesis may work as a self-repairing mechanism to compensate for neurodegeneration. Therefore, to enhance endogenous neurogenesis at early stages of neurodegeneration may be a valuable strategy to delay neurodegenerative progress. (C) 2007 Elsevier Inc. All rights reserved.	[Chen, Qian; Nakajima, Akira; Xiong, Xiaoli; Tang, Ya-Ping] Univ Chicago, Dept Psychiat, Chicago, IL 60637 USA; [Choi, Se Hoon; Sisodia, Sangram S.] Univ Chicago, Dept Neurobiol, Chicago, IL 60637 USA	Tang, YP (corresponding author), Knapp Learning Ctr, 924 E 57th St,R-020, Chicago, IL 60637 USA.	yptang@bsd.uchicago.edu	Nakajima, Akira/I-7077-2014; Tang, Ya-Ping/A-1035-2011		NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH066243] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG027854, R01AG040185] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01 AG027854-01A1, AG027854, R01 AG027854, R01 AG040185] Funding Source: Medline; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH066243, R01 MH066243-02, R01 MH066243-04, R01 MH066243-01A1, R01 MH066243-05, R01 MH066243, R01 MH066243-03] Funding Source: Medline		Aimone JB, 2006, NAT NEUROSCI, V9, P723, DOI 10.1038/nn1707; ALTMAN J, 1965, J COMP NEUROL, V124, P319, DOI 10.1002/cne.901240303; Amrein I, 2004, HIPPOCAMPUS, V14, P1000, DOI 10.1002/hipo.20018; ARRIAGADA PV, 1992, NEUROLOGY, V42, P631, DOI 10.1212/WNL.42.3.631; Barber R, 2001, DEMENT GERIATR COGN, V12, P198, DOI 10.1159/000051258; Becker M, 2007, P NATL ACAD SCI USA, V104, P1691, DOI 10.1073/pnas.0610180104; BONDAREFF W, 1982, NEUROLOGY, V32, P164, DOI 10.1212/WNL.32.2.164; Bondolfi L, 2004, NEUROBIOL AGING, V25, P333, DOI 10.1016/S0197-4580(03)00083-6; Bussiere T, 2003, J COMP NEUROL, V463, P281, DOI 10.1002/cne.10760; Cameron HA, 2001, J COMP NEUROL, V435, P406, DOI 10.1002/cne.1040; Chevallier NL, 2005, AM J PATHOL, V167, P151, DOI 10.1016/S0002-9440(10)62962-8; Chui DH, 1999, NAT MED, V5, P560; Curtis MA, 2003, P NATL ACAD SCI USA, V100, P9023, DOI 10.1073/pnas.1532244100; Dayer AG, 2003, J COMP NEUROL, V460, P563, DOI 10.1002/cne.10675; Donovan MH, 2006, J COMP NEUROL, V495, P70, DOI 10.1002/cne.20840; Donoviel DB, 1999, GENE DEV, V13, P2801, DOI 10.1101/gad.13.21.2801; Duman RS, 2004, BIOL PSYCHIAT, V56, P140, DOI 10.1016/j.biopsych.2004.02.033; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Feng RB, 2004, P NATL ACAD SCI USA, V101, P8162, DOI 10.1073/pnas.0402733101; Feng RB, 2001, NEURON, V32, P911, DOI 10.1016/S0896-6273(01)00523-2; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; GomezIsla T, 1997, ANN NEUROL, V41, P17, DOI 10.1002/ana.410410106; Gould E, 1999, SCIENCE, V286, P548, DOI 10.1126/science.286.5439.548; Greenberg DA, 2007, INT REV NEUROBIOL, V77, P1, DOI 10.1016/S0074-7742(06)77001-5; Haughey NJ, 2002, J NEUROCHEM, V83, P1509, DOI 10.1046/j.1471-4159.2002.01267.x; Hayes NL, 2002, DEV BRAIN RES, V134, P77, DOI 10.1016/S0165-3806(01)00324-8; HESTON LL, 1981, ARCH GEN PSYCHIAT, V38, P1085; Hoglinger GU, 2004, NAT NEUROSCI, V7, P726, DOI 10.1038/nn1265; Itoh T, 2005, NEUROREPORT, V16, P1687, DOI 10.1097/01.wnr.0000183330.44112.ab; Jin KL, 2004, P NATL ACAD SCI USA, V101, P13363, DOI 10.1073/pnas.0403678101; Jin KL, 2004, P NATL ACAD SCI USA, V101, P343, DOI 10.1073/pnas.2634794100; Kempermann G, 2003, DEVELOPMENT, V130, P391, DOI 10.1242/dev.00203; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Kokaia Z, 2003, CURR OPIN NEUROBIOL, V13, P127, DOI 10.1016/S0959-4388(03)00017-5; Lledo PM, 2006, NAT REV NEUROSCI, V7, P179, DOI 10.1038/nrn1867; Ming GL, 2005, ANNU REV NEUROSCI, V28, P223, DOI 10.1146/annurev.neuro.28.051804.101459; Mirescu C, 2006, HIPPOCAMPUS, V16, P233, DOI 10.1002/hipo.20155; Overstreet-Wadiche LS, 2006, J NEUROSCI, V26, P4095, DOI 10.1523/JNEUROSCI.5508-05.2006; Qiu L, 2007, J CEREBR BLOOD F MET, V27, P785, DOI 10.1038/sj.jcbfm.9600385; Rampon C, 2000, NAT NEUROSCI, V3, P238; Rice AC, 2003, EXP NEUROL, V183, P406, DOI 10.1016/S0014-4886(03)00241-3; SAMUEL W, 1994, ARCH NEUROL-CHICAGO, V51, P772, DOI 10.1001/archneur.1994.00540200048015; Santarelli L, 2003, SCIENCE, V301, P805, DOI 10.1126/science.1083328; Saura CA, 2004, NEURON, V42, P23, DOI 10.1016/S0896-6273(04)00182-5; Shors TJ, 2001, NATURE, V410, P372, DOI 10.1038/35066584; TEHANTCHOU F, 2007, FASEB J; Thompson PM, 2004, NEUROIMAGE, V22, P1754, DOI 10.1016/j.neuroimage.2004.03.040; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; VERRET L, 2007, PSYCHONEUROENDOCRINO, V27, P6771; Wang R, 2004, NEUROSCIENCE, V126, P305, DOI 10.1016/j.neuroscience.2004.03.048; Warner-Schmidt JL, 2006, HIPPOCAMPUS, V16, P239, DOI 10.1002/hipo.20156; Wen PH, 2004, EXP NEUROL, V188, P224, DOI 10.1016/j.expneurol.2004.04.002; WHITEHOUSE PJ, 1982, SCIENCE, V215, P1237, DOI 10.1126/science.7058341; Zhang C, 2007, EXP NEUROL, V204, P77, DOI 10.1016/j.expneurol.2006.09.018	54	77	84	0	6	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	FEB	2008	29	2					316	326		10.1016/j.nbd.2007.09.005			11	Neurosciences	Neurosciences & Neurology	255GW	WOS:000252647000015	17980611	Green Accepted			2021-06-18	
J	Baguley, IJ				Baguley, Ian J.			The excitatory : inhibitory ratio model (EIR model): An integrative explanation of acute autonomic overactivity syndromes	MEDICAL HYPOTHESES			English	Article							TRAUMATIC BRAIN-INJURY; INTRATHECAL BACLOFEN; DYSAUTONOMIA; MANAGEMENT; DYSREFLEXIA; DYSFUNCTION; MECHANISMS; SPASTICITY; HYPERTENSION; ORGANIZATION	Numerous medical conditions present with acute and severe autonomic and muscular overactivity. These syndromes include Neuroleptic Malignant Syndrome, Serotonin Syndrome, Dysautonomia (or paroxysmal sympathetic storms) following acquired brain injury, Autonomic Dysreflexia, Parkinsonian-Hyperpyrexia Syndrome, Malignant Catatonia, intrathecal baclofen withdrawal, Malignant Hyperthermia, Stiff Man Syndrome and Irukandji Syndrome. In their worst forms, each of these syndromes are relatively rare, are treated by different medical specialties and show widely varying pathophysiology. Most are considered to be medical emergencies and share significant mortality rates. Previous authors have noted similarities between some of these conditions, prompting the suggestion that a single common mechanism may underlie their clinical presentation. However, the development of such an integrative model has not occurred. This paper presents a short review of the clinical syndromes, grouped by the location of pathology and mechanism of action. From this background, an integrative framework termed the excitatory: inhibitory ratio (EIR) model is presented. The EIR model consists of two inter-retated networks operating at spinal and brainstem levels. The model is evaluated against pre-clinical scientific research, known pathways, each disorder's pathophysiology (where this is known) and variable severity, and used to explain the reasons behind the efficacy of current treatment regimes. Circumstantial evidence for an expanded aetiology for Malignant Hyperthermia is provided and generic treatment strategies for a number of other conditions are suggested. Finally, minor modifications to this model provide a basis to begin to explain less severe, regional "overlap" syndromes. (C) 2007 Elsevier Ltd. All rights reserved.	Westmead Hosp, Brain Injury Rehabil Serv, Wentworthville, NSW 2145, Australia	Baguley, IJ (corresponding author), Westmead Hosp, Brain Injury Rehabil Serv, POB 533, Wentworthville, NSW 2145, Australia.	ianb@biru.wsahs.nsw.gov.au	Baguley, Ian J/K-6878-2013; Baguley, Ian/AAM-5828-2021	Baguley, Ian J/0000-0001-5650-3705; 			Baguley IJ, 2006, BRAIN INJURY, V20, P437, DOI 10.1080/02699050600664715; Baguley IJ, 1999, J NEUROL NEUROSUR PS, V67, P39, DOI 10.1136/jnnp.67.1.39; Baguley IJ, 2005, BRAIN INJURY, V19, P545, DOI 10.1080/02699050400025075; Baguley IJ, 2004, BRAIN INJURY, V18, P409, DOI 10.1080/02699050310001645775; BAGULEY IJ, 2006, BRAIN INJ; Barwood S, 2000, DEV MED CHILD NEUROL, V42, P116, DOI 10.1017/S0012162200000220; BAUGLEY IJ, 2007, J NEUROL NEUROSURG P; Becker R, 2000, J CLIN NEUROSCI, V7, P316, DOI 10.1054/jocn.1999.0227; BENARROCH EE, 1993, MAYO CLIN PROC, V68, P988, DOI 10.1016/S0025-6196(12)62272-1; Bensmail D, 2006, NEUROLOGY, V67, P1432, DOI 10.1212/01.wnl.0000239827.38036.23; Boyer EW, 2005, NEW ENGL J MED, V352, P1112, DOI 10.1056/NEJMra041867; CAMPAGNOLO DI, AUTONOMIC DYSREFLEXI; Cervero F, 1996, PAIN, V68, P13, DOI 10.1016/S0304-3959(96)03165-X; Coffey RJ, 2002, ARCH PHYS MED REHAB, V83, P735, DOI 10.1053/apmr.2002.32820; Cuny E, 2001, BRAIN INJURY, V15, P917, DOI 10.1080/02699050110065277; Do D, 2000, J NEUROL NEUROSUR PS, V69, P832, DOI 10.1136/jnnp.69.6.832; Elliott S, 2006, SPINAL CORD, V44, P386, DOI 10.1038/sj.sc.3101847; Ener RA, 2003, PAIN MED, V4, P63, DOI 10.1046/j.1526-4637.2003.03005.x; Fenner PJ, 2002, MED J AUSTRALIA, V177, P362, DOI 10.5694/j.1326-5377.2002.tb04838.x; Fill M, 2002, PHYSIOL REV, V82, P893, DOI 10.1152/physrev.00013.2002; Green LB, 1999, ARCH PHYS MED REHAB, V80, P1600, DOI 10.1016/S0003-9993(99)90337-4; Guillaume D, 2005, ARCH PHYS MED REHAB, V86, P2165, DOI 10.1016/j.apmr.2005.05.018; Isbister GK, 2005, CLIN NEUROPHARMACOL, V28, P205, DOI 10.1097/01.wnf.0000177642.89888.85; Kipps CM, 2005, MOVEMENT DISORD, V20, P322, DOI 10.1002/mds.20325; KROIN JS, 1993, J NEUROSURG, V79, P544, DOI 10.3171/jns.1993.79.4.0544; Linderoth B, 1999, NEUROMODULATION, V2, P150, DOI 10.1046/j.1525-1403.1999.00150.x; Macrokanis CJ, 2004, MED J AUSTRALIA, V181, P699, DOI 10.5694/j.1326-5377.2004.tb06527.x; McCarthy E Jane, 2004, AACN Clin Issues, V15, P231, DOI 10.1097/00044067-200404000-00009; Meinck HM, 2002, MOVEMENT DISORD, V17, P853, DOI 10.1002/mds.10279; Mohammed Imran, 2004, BMC Clin Pharmacol, V4, P6, DOI 10.1186/1472-6904-4-6; MOULTON RJ, 2001, J BIOCH, V354, P597; Onofrj M, 2005, NEUROLOGY, V64, P1162, DOI 10.1212/01.WNL.0000157058.17871.7B; Ouardouz M, 2003, NEURON, V40, P53, DOI 10.1016/j.neuron.2003.08.016; PHILBRICK KL, 1994, J NEUROPSYCH CLIN N, V6, P1; PRANZATELLI MR, 1991, J CHILD NEUROL, V6, P115, DOI 10.1177/088307389100600204; Price DD, 2000, SCIENCE, V288, P1769, DOI 10.1126/science.288.5472.1769; Priebe MM, 1997, SPINAL CORD, V35, P171, DOI 10.1038/sj.sc.3100366; Rabchevsky AG, 2006, PROG BRAIN RES, V152, P265, DOI 10.1016/S0079-6123(05)52017-X; Rossitch E Jr, 1988, Br J Neurosurg, V2, P471, DOI 10.3109/02688698809029601; Russo RN, 2000, J PAEDIATR CHILD H, V36, P283, DOI 10.1046/j.1440-1754.2000.00485.x; SANDEL ME, 1986, ARCH PHYS MED REHAB, V67, P469; Sandrini G, 2005, PROG NEUROBIOL, V77, P353, DOI 10.1016/j.pneurobio.2005.11.003; SIDDALL PJ, 1998, NEURAL BLOCKADE CLIN; SOLOMON GE, 1973, J PEDIATR-US, V83, P277, DOI 10.1016/S0022-3476(73)80492-5; Sutton KG, 2002, BRIT J PHARMACOL, V135, P257, DOI 10.1038/sj.bjp.0704439; TALMAN WT, 1988, ARCH NEUROL-CHICAGO, V45, P1037, DOI 10.1001/archneur.1988.00520330129022; Teasell RW, 2000, ARCH PHYS MED REHAB, V81, P506, DOI 10.1053/mr.2000.3848; Thorley RR, 2001, ARCH PHYS MED REHAB, V82, P246, DOI 10.1053/apmr.2001.18698; Van Hilten BJ, 2000, NEW ENGL J MED, V343, P625, DOI 10.1056/NEJM200008313430905; Weaver LC, 2006, PROG BRAIN RES, V152, P245, DOI 10.1016/S0079-6123(05)52016-8; Wilkowsky D, 1999, SSA J-J SEMICOND SAF, V13, P12; Winkel KD, 2005, CLIN EXP PHARMACOL P, V32, P777, DOI 10.1111/j.1440-1681.2005.04258.x; Wissel J, 2000, J PAIN SYMPTOM MANAG, V20, P44, DOI 10.1016/S0885-3924(00)00146-9; Wrathall JR, 2003, NAT MED, V9, P1347, DOI 10.1038/nm1103-1347	54	77	84	0	3	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0306-9877	1532-2777		MED HYPOTHESES	Med. Hypotheses		2008	70	1					26	35		10.1016/j.mehy.2007.04.037			10	Medicine, Research & Experimental	Research & Experimental Medicine	245IU	WOS:000251929100007	17583440				2021-06-18	
J	Meyer-Heim, A; Borggraefe, I; Ammann-Reiffer, C; Berweck, S; Sennhauser, FH; Colombo, G; Knecht, B; Heinen, F				Meyer-Heim, A.; Borggraefe, I.; Ammann-Reiffer, C.; Berweck, St; Sennhauser, F. H.; Colombo, G.; Knecht, B.; Heinen, F.			Feasibility of robotic-assisted locomotor training in children with central gait impairment	DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY			English	Article							WEIGHT-SUPPORTED TREADMILL; RANDOMIZED CLINICAL-TRIAL; TRAUMATIC BRAIN-INJURY; SPASTIC CEREBRAL-PALSY; GROSS MOTOR FUNCTION; OUTCOME ASSESSMENTS; REHABILITATION; STROKE; PEOPLE	Intensive, task-specific training enabled by a driven gait orthosis (DGO) may be a cost-effective means of improving walking performance in children. A paediatric DGO has recently been developed. This study was the first paediatric trial aimed to determine the feasibility of robotic-assisted treadmill training in children with central gait impairment (n=26; 11 females, 15 males; mean age 10y 1mo [SD 4y]; range 5y 2mo-19y 5mo). Diagnoses of the study group included cerebral palsy (n=19; Gross Motor Function Classification System Levels I-IV), traumatic brain injury (n=1), Guillain-Barre syndrome (n=2), incomplete paraplegia (n=2), and haemorrhagic shock (n=1), and encephalopathy (n=1). Sixteen children were in-patients and 10 were outpatients. Twenty-four of the 26 patients completed the training which consisted of a mean of 19 sessions (SD 2.2; range 13-21) in the in-patient group and 12 sessions (SD 1.0; range 10-13) in the outpatient group. Gait speed and 6-Minute Walking Test increased significantly (p < 0.01). Functional Ambulation Categories and Standing dimension (in-patient group p < 0.01; outpatient group p < 0.05) of the Gross Motor Function Measure improved significantly. DGO training was successfully integrated into the rehabilitation programme and findings suggest an improvement of locomotor performance.	Univ Childrens Hosp Zurich, CH-8910 Affoltern Am Albis, Switzerland; Univ Childrens Hosp Zurich, Rehabil Ctr, Zurich, Switzerland; Univ Munich, Dr von Haunersches Childrens Hosp, Dept Paediat Neurol & Dev Med, Munich, Germany; AG Hocoma, Volketswil, Switzerland	Meyer-Heim, A (corresponding author), Univ Childrens Hosp Zurich, Muhlebergstr 104, CH-8910 Affoltern Am Albis, Switzerland.	Andreas.Meyer-Heim@kispi.unizh.ch	Borggraefe, Ingo/AAC-4966-2020; Berweck, Steffen/N-1422-2013; Heinen, Florian/B-6594-2015	Heinen, Florian/0000-0002-3872-6136; Ammann-Reiffer, Corinne/0000-0003-1766-7023			Bagley AM, 2007, DEV MED CHILD NEUROL, V49, P181, DOI 10.1111/j.1469-8749.2007.00181.x; Barbeau H, 2003, ARCH PHYS MED REHAB, V84, P1458, DOI 10.1016/S0003-9993(03)00361-7; Behmran AL, 2000, PHYS THER, V80, P688, DOI 10.1093/ptj/80.7.688; Blundell SW, 2003, CLIN REHABIL, V17, P48, DOI 10.1191/0269215503cr584oa; Brown TH, 2005, J HEAD TRAUMA REHAB, V20, P402, DOI 10.1097/00001199-200509000-00002; Cherng RJ, 2007, AM J PHYS MED REHAB, V86, P548, DOI 10.1097/PHM.0b013e31806dc302; Colombo G, 2000, J REHABIL RES DEV, V37, P693; Damiano DL, 1998, ARCH PHYS MED REHAB, V79, P119, DOI 10.1016/S0003-9993(98)90287-8; Day Jane A, 2004, Pediatr Phys Ther, V16, P106, DOI 10.1097/01.PEP.0000127569.83372.C8; Dietz V, 2004, J APPL PHYSIOL, V96, P1954, DOI 10.1152/japplphysiol.00942.2003; Dobkin B, 2006, NEUROLOGY, V66, P484, DOI 10.1212/01.wnl.0000202600.72018.39; Dobkin BH, 2005, NEW ENGL J MED, V352, P1677, DOI 10.1056/NEJMcp043511; Dodd KJ, 2003, DEV MED CHILD NEUROL, V45, P652, DOI 10.1017/S0012162203001221; Duncan P, 2003, STROKE, V34, P2173, DOI 10.1161/01.STR.0000083699.95351.F2; Edgerton V R, 1997, Adv Neurol, V72, P233; Hesse S, 2001, NEUROREHABILITATION, V16, P133; Hesse S, 2003, CURR OPIN NEUROL, V16, P705, DOI 10.1097/00019052-200312000-00010; Johansson BB, 2000, STROKE, V31, P223, DOI 10.1161/01.STR.31.1.223; McNevin NH, 2000, ARCH PHYS MED REHAB, V81, P525, DOI 10.1053/mr.2000.4429; Oeffinger D, 2007, DEV MED CHILD NEUROL, V49, P172, DOI 10.1111/j.1469-8749.2007.00172.x; Riener R, 2005, IEEE T NEUR SYS REH, V13, P380, DOI 10.1109/TNSRE.2005.848628; Russell DJ, 2000, PHYS THER, V80, P873, DOI 10.1093/ptj/80.9.873; Schindl MR, 2000, ARCH PHYS MED REHAB, V81, P301, DOI 10.1053/apmr.2000.0810301; Song WH, 2003, ARCH PHYS MED REHAB, V84, pE2; Wade DT, 1992, MEASUREMENT NEUROLOG; Wilson DJ, 2006, AM J PHYS MED REHAB, V85, P68, DOI 10.1097/01.phm.0000193507.28759.37; Winchester Patricia, 2006, Phys Med Rehabil Clin N Am, V17, P159, DOI 10.1016/j.pmr.2005.10.008; Wirz M, 2005, ARCH PHYS MED REHAB, V86, P672, DOI 10.1016/j.apmr.2004.08.004	28	77	77	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0012-1622	1469-8749		DEV MED CHILD NEUROL	Dev. Med. Child Neurol.	DEC	2007	49	12					900	906		10.1111/j.1469-8749.2007.00900.x			7	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	234TR	WOS:000251187400007	18039236				2021-06-18	
J	Yeo, JE; Kang, SK				Yeo, Jee Eun; Kang, Soo Kyung			Selenium effectively inhibits ROS-mediated apoptotic neural precursor cell death in vitro and in vivo in traumatic brain injury	BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE			English	Article						brain trauma; hydrogen peroxide; neuroprotection; oxidation; sodium selenite	MAMMALIAN THIOREDOXIN REDUCTASE; SPINAL-CORD-INJURY; PARKINSONS-DISEASE; LIPID-PEROXIDATION; SIGNAL-TRANSDUCTION; RADICAL HYPOTHESIS; OXIDATIVE STRESS; MITOCHONDRIA; BCL-2; INDUCTION	This study was designed to investigate possible prevention of apoptotic cell death by selenium, an antioxidant, using cultured brain-derived neural progenitor cells (NPCs) and an experimental mouse brain trauma (BT) model. We tested some of the neuroprotective effects of sodium selenite in NPC cells by monitoring thioredoxin reductase (TR) expression, optimum H2O2 removal, and consequent inhibition of pro-apoptotic events including cytochrome c release and caspase 3 and 9 activation. Analysis of key apoptotic regulators during H2O2-induced apoptosis of NPCs showed that selenite blocks the activation of c-jun N-terminal protein kinase (JNK)/P38 mitogen-activated protein kinase (MAPK), and Akt survival protein. Moreover, selenite activates p44/42 MAPK and inhibits the downregulation of Bcl2 in selenite-treated NPC cells. For in vivo experiments, the effects of selenite on H2O2 neurotoxicity were tested using several biochemical and morphologic markers. Here we show that selenite potentially inhibits H2O2-induced apoptosis of NPCs and in traumatic brain injury. This in vivo protective function was also associated with inhibition of H2O2-induced reactive oxygen species (ROS) generation, cytochrome c release and caspase 3 and 9 activation. Our data show that the protective function of selenite through attenuation of secondary pathological events most likely results from its comprehensive effects that block apoptotic cell death, resulting in the maintenance of functional neurons and in inhibition of astrogliosis. The finding that selenite administration prevents secondary pathological events in an animal model of traumatic brain injury, as well as its efficacy, may provide novel drug targets for treating brain trauma. (c) 2007 Elsevier B.V. All rights reserved.	[Yeo, Jee Eun; Kang, Soo Kyung] Pusan Natl Univ, Sch Med, Dept Physiol, Pusan 602739, South Korea	Kang, SK (corresponding author), Pusan Natl Univ, Sch Med, Dept Physiol, 1-10 Ami Dong, Pusan 602739, South Korea.	skkang@pusan.ac.kr					Anderson CNG, 1999, J NEUROSCI, V19, P664; ARMAN D, 1993, FREE RADICALS AGING, P205; BELLAVITE P, 1988, FREE RADICAL BIO MED, V4, P225, DOI 10.1016/0891-5849(88)90044-5; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Bruce-Keller AJ, 1998, J NEUROCHEM, V70, P31; Carlson SL, 1998, EXP NEUROL, V151, P77, DOI 10.1006/exnr.1998.6785; Cornett CR, 1998, NEUROTOXICOLOGY, V19, P339; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; DEXTER DT, 1989, J NEUROCHEM, V52, P1830, DOI 10.1111/j.1471-4159.1989.tb07264.x; DEXTER DT, 1989, J NEUROCHEM, V52, P381, DOI 10.1111/j.1471-4159.1989.tb09133.x; Facchinetti F, 1998, CELL MOL NEUROBIOL, V18, P667, DOI 10.1023/A:1020221919154; Faden AI, 2002, CURR OPIN NEUROL, V15, P707, DOI 10.1097/00019052-200212000-00008; GIULIAN D, 1993, J NEUROSCI, V13, P29; HALLIWELL B, 1992, FEBS LETT, V307, P108, DOI 10.1016/0014-5793(92)80911-Y; HALLIWELL B, 1984, LANCET, V1, P1396; Imam SZ, 1999, BRAIN RES, V818, P575, DOI 10.1016/S0006-8993(98)01311-0; ITOH N, 1993, J IMMUNOL, V151, P621; Jones LL, 2003, EXP NEUROL, V182, P399, DOI 10.1016/S0014-4886(03)00087-6; Jurynec MJ, 2003, MOL CELL NEUROSCI, V23, P69, DOI 10.1016/S1044-7431(03)00019-8; Kang SK, 2006, STEM CELLS DEV, V15, P165, DOI 10.1089/scd.2006.15.165; Kim TS, 2002, BIOCHEM BIOPH RES CO, V294, P1130, DOI 10.1016/S0006-291X(02)00612-5; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Lee SR, 2000, P NATL ACAD SCI USA, V97, P2521, DOI 10.1073/pnas.050579797; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; LIU X, 1996, CELL, V86, P145; Marcocci L, 1997, BIOFACTORS, V6, P351, DOI 10.1002/biof.5520060305; Murphy MP, 2000, ADV DRUG DELIVER REV, V41, P235, DOI 10.1016/S0169-409X(99)00069-1; Nakahara S, 1999, J NEUROPATH EXP NEUR, V58, P442, DOI 10.1097/00005072-199905000-00003; OLANOW CW, 1993, TRENDS NEUROSCI, V16, P439, DOI 10.1016/0166-2236(93)90070-3; OLANOW CW, 1992, ANN NEUROL, V32, pS2, DOI 10.1002/ana.410320703; Ozawa H, 1999, NEUROSCI LETT, V262, P57, DOI 10.1016/S0304-3940(99)00034-8; Ragusa RJ, 1997, NEUROMUSCULAR DISORD, V7, P379, DOI 10.1016/S0960-8966(97)00096-5; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; RICHTER C, 1993, TOXICOL LETT, V67, P119, DOI 10.1016/0378-4274(93)90050-8; RICHTER C, 1991, CHEM-BIOL INTERACT, V77, P1, DOI 10.1016/0009-2797(91)90002-O; ROTRUCK JT, 1973, SCIENCE, V179, P588, DOI 10.1126/science.179.4073.588; Sagara Y, 1998, NEUROTOXICOLOGY, V19, P339; Sarker KP, 2003, J NEUROCHEM, V87, P1345, DOI 10.1046/j.1471-4159.2003.02096.x; SCHEID MP, 2003, EXP NEUROL, V166, P115; Shamloo M, 1999, NEUROSCIENCE, V93, P81, DOI 10.1016/S0306-4522(99)00137-2; SMITH CD, 1991, P NATL ACAD SCI USA, V88, P10540, DOI 10.1073/pnas.88.23.10540; Svensson B, 1998, J NEUROSCI RES, V52, P453, DOI 10.1002/(SICI)1097-4547(19980515)52:4<453::AID-JNR9>3.0.CO;2-8; TAN S, 1995, J NEUROCHEM, V71, P95; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yakovlev Alexander G, 2004, NeuroRx, V1, P5, DOI 10.1007/BF03206563; YU BP, 1994, PHYSIOL REV, V74, P139	46	77	83	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0925-4439			BBA-MOL BASIS DIS	Biochim. Biophys. Acta-Mol. Basis Dis.	DEC	2007	1772	11-12					1199	1210		10.1016/j.bbadis.2007.09.004			12	Biochemistry & Molecular Biology; Biophysics; Cell Biology	Biochemistry & Molecular Biology; Biophysics; Cell Biology	249OR	WOS:000252238800003	17997286				2021-06-18	
J	Yuan, W; Holland, SK; Schnnithorst, VJ; Walz, NC; Cecil, KM; Jones, BV; Karunanayaka, P; Michaud, L; Wade, SL				Yuan, W.; Holland, S. K.; Schnnithorst, V. J.; Walz, N. C.; Cecil, K. M.; Jones, B. V.; Karunanayaka, P.; Michaud, L.; Wade, S. L.			Diffusion tensor MR Imaging reveals persistent white matter alteration after traumatic brain injury experienced during early childhood	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article							CLOSED-HEAD-INJURY; CORPUS-CALLOSUM; CHILDREN; ADOLESCENCE; ANISOTROPY; RECOVERY; OUTCOMES; LESIONS; AGE	BACKGROUND AND PURPOSE: Diffusion tensor imaging (DTI) can noninvasively quantify white matter (WM) integrity. Although its application in adult traumatic brain injury (TBI) is common, few studies in children have been reported. The purposes of this study were to examine the alteration of fractional anisotropy (FA) in children with TBI experienced during early childhood and to quantify the association between FA and injury severity. MATERIALS AND METHODS: FA was assessed in 9 children with TBI (age = 7.89 +/- 1.00 years; Glasgow Coma Scale [GCS] = 10.11 +/- 4.68) and a control group of 12 children with orthopedic injuries without central nervous system involvement (age = 7.51 +/- 0.95 years). All of the subjects were at minimum 12 months after injury. We examined group differences in a series of predetermined WM regions of interest with t test analysis. We subsequently conducted a voxel-wise comparison with Spearman partial correlation analysis. Correlations between FA and injury severity were also calculated on a voxel-wise basis. RESULTS: FA values were significantly reduced in the TBI group in genu of corpus callosum (CC), posterior limb of internal capsule (PLIC), superior longitudinal fasciculus (SLF), superior fronto-occipital fasciculus (SFO), and centrum semiovale (CS). GCS scores were positively correlated with FA in several WM areas including CC, PLIC, SLF, CS, SFO, and inferior fronto-occipital fasciculus (IFO). CONCLUSION: This DTI study provides evidence that WM integrity remains abnormal in children with moderate-to-severe TBI experienced during early childhood and that injury severity correlated strongly with FA.	Univ Cincinnati, Childrens Hosp & Med Ctr, Coll Med, Div Phys Med & Rehabil, Cincinnati, OH 45229 USA; Univ Cincinnati, Childrens Hosp & Med Ctr, Coll Med, Dept Radiol, Cincinnati, OH USA; Univ Cincinnati, Childrens Hosp & Med Ctr, Coll Med, Dept Pediat, Cincinnati, OH USA	Wade, SL (corresponding author), Univ Cincinnati, Childrens Hosp & Med Ctr, Coll Med, Div Phys Med & Rehabil, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	shari.wade@cchmc.org		Holland, Scott/0000-0003-3719-0875; Cecil, Kim/0000-0001-8233-5485	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD042729] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R43HD044279] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P01CA112181] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR008084] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [P01ES011261] Funding Source: NIH RePORTER; NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P01 CA112181, R01 CA112181] Funding Source: Medline; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01 RR 08084, M01 RR008084] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD044279, R43 HD044279, R01 HD042729] Funding Source: Medline; NIEHS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [P01 ES011261, R21 ES012524] Funding Source: Medline		Anderson VA, 2000, BRAIN INJURY, V14, P679; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Barnea-Goraly N, 2005, CEREB CORTEX, V15, P1848, DOI 10.1093/cercor/bhi062; Brett M, 2001, NEUROIMAGE, V13, pS85; Ewing-Cobbs L, 2006, AM J NEURORADIOL, V27, P879; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; HASAN KM, 2004, DIFFUSION TENSOR MRI, P1350; HEMOYE L, 2006, NEUROIMAGE, V29, P493; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Janusz JA, 2002, CHILD NEUROPSYCHOL, V8, P179, DOI 10.1076/chin.8.3.179.13499; Jiang HY, 2006, COMPUT METH PROG BIO, V81, P106, DOI 10.1016/j.cmpb.2005.08.004; Le Bihan D, 2001, J MAGN RESON IMAGING, V13, P534, DOI 10.1002/jmri.1076; Le TH, 2005, NEUROSURGERY, V56, P189, DOI 10.1227/01.NEU.0000144846.00569.3A; LEVIN HS, 1990, J NEUROSURG, V73, P77, DOI 10.3171/jns.1990.73.1.0077; Levin HS, 2001, NEUROPSYCHOLOGIA, V39, P122, DOI 10.1016/S0028-3932(00)00111-1; Levin HS, 2000, NEUROLOGY, V54, P647, DOI 10.1212/WNL.54.3.647; MENDELSOHN DB, 1992, NEURORADIOLOGY, V34, P384, DOI 10.1007/BF00596495; Neil J, 2002, NMR BIOMED, V15, P543, DOI 10.1002/nbm.784; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Schmithorst VJ, 2006, NEUROIMAGE, V31, P1366, DOI 10.1016/j.neuroimage.2006.01.010; Schmithorst VJ, 2002, RADIOLOGY, V222, P212, DOI 10.1148/radiol.2221010626; SCHMITHORST VJ, 2005, SEX DIFFERENCES WHIT; Shaw K, 2001, CLIN NEUROPATHOL, V20, P106; Snook L, 2005, NEUROIMAGE, V26, P1164, DOI 10.1016/j.neuroimage.2005.03.016; Suzuki Y, 2003, NMR BIOMED, V16, P257, DOI 10.1002/nbm.848; TALAIRACH J, 1988, COPLANAR STERCOTAXIC; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Williams S, 2001, ACTA NEUROPATHOL, V102, P581, DOI 10.1007/s004010100410; XU J, 2006, 12 ANN M HUM BRAIN M	33	77	79	0	7	AMER SOC NEURORADIOLOGY	DENVILLE	PO BOX 3000, DENVILLE, NJ 07834-9349 USA	0195-6108	1936-959X		AM J NEURORADIOL	Am. J. Neuroradiol.	NOV-DEC	2007	28	10					1919	1925		10.3174/ajnr.A0698			7	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	234XT	WOS:000251198600024	17905895	Green Accepted, Other Gold, Green Published			2021-06-18	
J	Donders, J; Warschausky, S				Donders, Jacobus; Warschausky, Seth			Neurobehavioral outcomes after early versus late childhood traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						childhood; outcome; traumatic brain injury	CLOSED-HEAD-INJURY; FOLLOW-UP; SHORT-TERM; CHILDREN; ADOLESCENTS; RECOVERY; REHABILITATION; PREDICTORS; STABILITY; VARIABLES	Objectives: To examine differences in outcomes at transition age (17-21 years) between individuals who sustained complicated mild-to-severe traumatic brain injury (TBI) in early or middle childhood and those who were injured in late adolescence. Participants: Fifteen persons who sustained TBI between the ages of 6 and 12 years (early-onset) and 30 persons who sustained TBI between the ages of 16 and 20 years (late-onset). Measures: Peabody Picture Vocabulary Test-Third. Edition, Trail-Making Test, Buschke Selective Reminding Test, Benton Visual Retention Test, Dysexecutive Questionnaire, Community Integration Questionnaire, Satisfaction with Life Scale. Results: The groups did not differ in overall cognitive ability level, postinjury education or vocational accomplishments, or current living situation. However the early-onset group demonstrated worse outcomes in higher-level cognitive skills, social integration, driving, and legal guardianship. Conclusions: Complicated mild-to-severe TBI earlier in childhood is associated with worse long-term neurocognitive and psychosocial outcomes than injury sustained in late adolescence. Findings provide further support for theories that early brain injury onset interferes with development of immature or rapidly developing skills, and may be associated with further magnification of deficits during the course of later development.	Free Bed Rehabil Hosp, Psychol Serv, Grand Rapids, MI 49503 USA; Univ Michigan, Dept Phys Med & Rehabil, Ann Arbor, MI 48109 USA	Donders, J (corresponding author), Free Bed Rehabil Hosp, Psychol Serv, 235 Wealthy,SE, Grand Rapids, MI 49503 USA.	jacobus.donders@maryfreebed.com			PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [H133G000038] Funding Source: Medline		Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; Anderson VA, 2004, BRAIN, V127, P2608, DOI 10.1093/brain/awh320; Asikainen I, 1996, BRAIN INJURY, V10, P883, DOI 10.1080/026990596123864; Bijur PE, 1996, J DEV BEHAV PEDIATR, V17, P143, DOI 10.1097/00004703-199606000-00001; Cattelani R, 1998, BRAIN INJURY, V12, P283, DOI 10.1080/026990598122584; Dennis M, 2001, J INT NEUROPSYCH SOC, V7, P683, DOI 10.1017/S1355617701766040; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dijkers M, 1997, J HEAD TRAUMA REHAB, V12, P74, DOI 10.1097/00001199-199712000-00007; Donders J., 2006, TREATING NEURODEVELO, P23; Dunn L. M., 1997, PPVT 3 PEABODY PICTU; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V26, P487, DOI 10.1207/s15326942dn2601_7; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Goldstein G, 1989, CLIN NEUROPSYCHOL, V3, P265, DOI DOI 10.1080/13854048908404088; HANNAY HJ, 1985, J CLIN EXP NEUROPSYC, V7, P251, DOI 10.1080/01688638508401258; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; Kieslich M, 2001, DISABIL REHABIL, V23, P665; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; Levin HS, 2004, J INT NEUROPSYCH SOC, V10, P305, DOI 10.1017/S1355617704102129; Light R, 1998, J CONSULT CLIN PSYCH, V66, P1023; Martin TA, 2003, APPL NEUROPSYCHOL, V10, P163, DOI 10.1207/S15324826AN1003_05; Mataro M, 2001, J NEUROTRAUM, V18, P869, DOI 10.1089/089771501750451794; Max JE, 1999, J INT NEUROPSYCH SOC, V5, P58, DOI 10.1017/S1355617799511089; Max JE, 2006, J NEUROPSYCH CLIN N, V18, P21, DOI 10.1176/appi.neuropsych.18.1.21; Moses P, 2002, DEV PSYCHOBIOL, V40, P266, DOI 10.1002/dev.10031; Nybo T, 2004, J INT NEUROPSYCH SOC, V10, P719, DOI 10.1017/S1355617704105109; Nybo T, 1999, BRAIN INJURY, V13, P759; Pavot W., 1993, PSYCHOL ASSESSMENT, V5, P164, DOI DOI 10.1037/1040-3590.5.2.164; Rivara JB, 1996, ARCH PHYS MED REHAB, V77, P754, DOI 10.1016/S0003-9993(96)90253-1; Sander AM, 2002, BRAIN INJURY, V16, P649, DOI 10.1080/02699050210128889; Sherer M, 2000, J HEAD TRAUMA REHAB, V15, P767, DOI 10.1097/00001199-200004000-00002; Sivan AB., 1992, BENTON VISUAL RETENT; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Van Heugten CM, 2006, BRAIN INJURY, V20, P895, DOI 10.1080/02699050600832015; Willer B., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI DOI 10.1097/00001199-199308020-00009; Wilson BA, 1998, NEUROPSYCHOL REHABIL, V8, P213, DOI 10.1080/713755570; Wolfson D., 1993, HALSTEAD REITAN NEUR; Woodhead J C, 1985, Semin Adolesc Med, V1, P171; Woodward H, 1999, J HEAD TRAUMA REHAB, V14, P351, DOI 10.1097/00001199-199908000-00004; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514	44	77	77	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2007	22	5					296	302		10.1097/01.HTR.0000290974.01872.82			7	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	216RA	WOS:000249895500005	17878771				2021-06-18	
J	Tashlykov, V; Katz, Y; Gazit, V; Zohar, O; Schreiber, S; Pick, CG				Tashlykov, Vadim; Katz, Yeshayahu; Gazit, Vered; Zohar, Ofer; Schreiber, Shaul; Pick, Chaim G.			Apoptotic changes in the cortex and hippocampus following minimal brain trauma in mice	BRAIN RESEARCH			English	Article						apoptosis; neurodegeneration; traumatic brain injury; mice	CELL-DEATH; TEMPORAL CHARACTERIZATION; HEAD-INJURY; NEURONS; EXPRESSION; GLUTAMATE; PATTERNS; MODEL; RATS; CA3	interpretation of the cellular and molecular pathogenic basis of post-minimal traumatic brain injury is a significant clinical and scientific problem, especially due to the high prevalence of motor vehicle-and other accidents. Pathogenetic brain mechanisms following traumatic impact are usually investigated by using models of severe or moderate trauma. Apoptotic neuronal degeneration after notable brain trauma is a well-known phenomenon, but the source of its activation is not clear, especially after mild, subclinical brain trauma. In the present study, we used a closed head weight-drop model to induce minimal brain injury in mice. Pellets of 5,10,15,20,25 and 30 g were dropped on the right side of mice's head kept under light ether anesthesia. No abnormal behavioral or neurophysiological changes were seen following the head trauma. Morphological assessment was done 72 h after the traumatic impact using TUNEL assay and silver staining. We found gradual increase of TUNEL-positive and silver-impregnated cells number in different cortical and hippocampal regions of both injured and contralateral hemispheres. The threshold of traumatic impact that caused a significant activation was 10-15 g pellets (evident by silver staining), and 15-20 g for apoptosis. The most sensitive zones for trauma were anterior cingulate cortex and CA3 area of hippocampus. No bilateral hemispheric differences were found. Our results demonstrate that even closed head minimal traumatic brain injury can cause diffused neuronal damage and apoptosis. This results correlate well with cognitive and behavioral deficits described for mice suffering similar mTBI and can also explain the wide variety of mental disturbances described for post-concussion syndrome in patients who suffered mild head injury. (c) 2006 Elsevier B.V. All rights reserved.	Tel Aviv Univ, Dept Anat & Anthropol, Sackler Fac Med, IL-69978 Tel Aviv, Israel; Technion Israel Inst Technol, Lab Anesthesia Pain & Neural Res, Bruce Rappaport Fac Med, Haifa, Israel; Chaim Sheba Med Ctr, Dept Neurol, Ramat Gan, Israel; Rambam Med Ctr, Dept Anesthesiol, Haifa, Israel; Johns Hopkins Univ, Blanchette Rockefeller Neurosci Inst, Rockville, MD 20850 USA; Tel Aviv Sourasky Med Ctr, Dept Psychiat, Tel Aviv, Israel	Pick, CG (corresponding author), Tel Aviv Univ, Dept Anat & Anthropol, Sackler Fac Med, IL-69978 Tel Aviv, Israel.	pickc@post.tau.ac.il	Pick, Chaim/D-4789-2009; Schreiber, Shaul/E-5821-2010	Schreiber, Shaul/0000-0002-2189-0693			Beer R, 2001, J NEUROCHEM, V78, P862, DOI 10.1046/j.1471-4159.2001.00460.x; Bernabeu R, 2000, J CEREBR BLOOD F MET, V20, P1669, DOI 10.1097/00004647-200012000-00006; Carbonnel WS, 1999, ACTA NEUROPATHOL, V98, P396, DOI 10.1007/s004010051100; Cernak I, 2002, J CLIN NEUROSCI, V9, P565, DOI 10.1054/jocn.2002.1132; Chatfield DA, 2002, BRIT J NEUROSURG, V16, P471, DOI 10.1080/0268869021000030285; Chen JW, 2000, J BIOMED SCI, V7, P459, DOI 10.1007/BF02253361; Hamner M B, 1999, Depress Anxiety, V9, P1; INAGAKI M, 2006, J AFFECT DISORD; Johnson EA, 2005, EXP BRAIN RES, V167, P17, DOI 10.1007/s00221-005-2362-2; LaPlaca MC, 1999, J NEUROCHEM, V73, P205, DOI 10.1046/j.1471-4159.1999.0730205.x; LEDOUX JE, 1990, J NEUROSCI, V10, P1043; Lee I, 2004, HIPPOCAMPUS, V14, P66, DOI 10.1002/hipo.10167; Lu J, 2000, NEUROSCI LETT, V290, P89, DOI 10.1016/S0304-3940(00)01307-0; Lu J, 2003, NEUROPHARMACOLOGY, V44, P253, DOI 10.1016/S0028-3908(02)00380-5; MacDonald AW, 2006, BIOL PSYCHIAT, V60, P1241, DOI 10.1016/j.biopsych.2006.04.041; MAGARINOS AM, 1995, NEUROSCIENCE, V69, P89, DOI 10.1016/0306-4522(95)00259-L; Margulies S, 2000, J CLIN NEUROSCI, V7, P400, DOI 10.1054/jocn.1999.0681; Martin LJ, 2001, J COMP NEUROL, V433, P299, DOI 10.1002/cne.1141; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; NEUHAUS AH, 2006, J PSYCHIAT RES; O'Dell DM, 2000, J NEUROSCI, V20, P4821; Orme-Johnson DW, 2006, NEUROREPORT, V17, P1359, DOI 10.1097/01.wnr.0000233094.67289.a8; Pan WH, 2003, EXP BRAIN RES, V149, P195, DOI 10.1007/s00221-002-1355-7; Pohl D, 1999, P NATL ACAD SCI USA, V96, P2508, DOI 10.1073/pnas.96.5.2508; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; RINK A, 1995, AM J PATHOL, V147, P1575; Runnerstam M, 2001, J NEUROTRAUM, V18, P259, DOI 10.1089/08977150151070892; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Smith FM, 2000, ACTA NEUROPATHOL, V100, P537, DOI 10.1007/s004010000222; Soblosky JS, 1996, BEHAV BRAIN RES, V79, P79, DOI 10.1016/0166-4328(95)00264-2; Stadelmann C, 2001, BRAIN PATHOL, V11, P273; SYMONDS C, 1962, LANCET, V1, P1; TWEEDIE D, IN PRESS J NEUROSCIE; ZELMAN FP, 2002, BRAIN RES, V947, P131; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	35	77	80	0	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JAN 26	2007	1130	1					197	205		10.1016/j.brainres.2006.10.032			9	Neurosciences	Neurosciences & Neurology	134GT	WOS:000244072200022	17174280				2021-06-18	
J	Matheis, RJ; Schultheis, MT; Tiersky, LA; DeLuca, J; Millis, SR; Rizzo, A				Matheis, Robert J.; Schultheis, Maria T.; Tiersky, Lana A.; DeLuca, John; Millis, Scott R.; Rizzo, Albert			Is learning and memory different in a virtual environment?	CLINICAL NEUROPSYCHOLOGIST			English	Article						ecological validity; learning and memory; neuropsychological assessment; traumatic brain injury (TBI); virtual reality (VR)	TRAUMATIC BRAIN-INJURY; CARD SORTING TEST; ECOLOGICAL VALIDITY; NEUROPSYCHOLOGICAL TESTS; EXECUTIVE FUNCTION; REALITY; REHABILITATION; PERFORMANCE; RELIABILITY; MODERATE	It has been suggested that virtual reality may provide a medium for producing neuropsychological measures with greater ecological validity. The present study examined the usefulness of virtual reality (VR) to assess learning and memory in individuals with traumatic brain injury (TB). A total of 20 TBI participants were compared with 20 healthy controls on their ability to learn and recall 16 target items presented within a VR-based generic office environment. The results indicated that VR memory testing accurately distinguished the TBI group from controls. Additionally, non-memory-impaired TBI participants acquired targets at the same rate as HC participants. Finally, there was a significant relationship between the VR Office and a standard neuropsychological measure of memory, suggesting the construct validity of the task. These findings suggest that the VR Office provides a viable medium for measuring learning and memory. The present results provide provide preliminary support for the ecological validity of the VR Of can improve assessment of real-world functioning following TBI.	Fairleigh Dickinson Univ, Sch Psychol, Teaneck, NJ USA; Kessler Med Rehabil Res & Educ Corp, REAL, W Orange, NJ USA; Kessler Med Rehabil Res & Educ Corp, Neurosci Res, W Orange, NJ USA; Univ Med & Dent New Jersey, Dept Phys Med & Rehabil, Newark, NJ 07103 USA; Univ So Calif, Integrated Media Syst Ctr, Los Angeles, CA USA	Schultheis, MT (corresponding author), Drexel Univ, Dept Psychol, 3141 Chestnut St, Philadelphia, PA 19104 USA.	schultheis@drexel.edu		Schultheis, Maria/0000-0002-6558-548X			Benedict RHB, 1996, PSYCHOL ASSESSMENT, V8, P145, DOI 10.1037/1040-3590.8.2.145; Bennett TL, 2001, ARCH CLIN NEUROPSYCH, V16, P237, DOI 10.1016/S0887-6177(00)00082-2; Bowman ML, 1996, CLIN NEUROPSYCHOL, V10, P382, DOI 10.1080/13854049608406699; Brooks BM, 2004, BRAIN INJURY, V18, P391, DOI 10.1080/02699050310001619855; Buckwalter J G, 1997, Stud Health Technol Inform, V39, P17; CROSSON B, 1988, J CLIN EXP NEUROPSYC, V10, P754, DOI 10.1080/01688638808402812; Delis D, 1997, CALIFORNIA VERBAL LE; DeLuca J, 2000, ARCH PHYS MED REHAB, V81, P1327, DOI 10.1053/apmr.2000.9390; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Elkind JS, 2001, CYBERPSYCHOL BEHAV, V4, P489, DOI 10.1089/109493101750527042; Farias ST, 2003, ARCH CLIN NEUROPSYCH, V18, P655, DOI 10.1016/S0887-6177(02)00159-2; FRICK RW, 1984, MEM COGNITION, V12, P507, DOI 10.3758/BF03198313; Gioia GA, 2004, DEV NEUROPSYCHOL, V25, P135, DOI 10.1207/s15326942dn2501&2_8; Heaton R. K, 1981, WISCONSIN CARD SORTI; Hooper, 1983, HOOPER VISUAL ORG TE; Kaplan E., 1983, BOSTON NAMING TEST; Kibby MY, 1998, ARCH CLIN NEUROPSYCH, V13, P523, DOI 10.1016/S0887-6177(97)00038-3; Ku J, 2003, CYBERPSYCHOL BEHAV, V6, P397, DOI 10.1089/109493103322278781; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Long CJ., 1996, ECOLOGICAL VALIDITY; Mayer RE, 1997, EDUC PSYCHOL-US, V32, P1, DOI 10.1207/s15326985ep3201_1; Moreno R, 1999, J EDUC PSYCHOL, V91, P358, DOI 10.1037/0022-0663.91.2.358; NEWNAN OS, 1978, PERCEPT MOTOR SKILL, V46, P635, DOI 10.2466/pms.1978.46.2.635; PIOK M, 2004, HALS NASEN OHREN HEI, V10, P443; Reitan RM, 1955, J CONSULT PSYCHOL, V19, P393, DOI 10.1037/h0044509; Riva G, 1997, ST HEAL T, V44, P71; Rizzo AA, 1997, ST HEAL T, V44, P123; Schultheis MT, 2002, J HEAD TRAUMA REHAB, V17, P378, DOI 10.1097/00001199-200210000-00002; Schultheis MT, 2001, REHABIL PSYCHOL, V46, P296, DOI 10.1037/0090-5550.46.3.296; Spreen O., 1998, COMPENDIUM NEUROPSYC; Vakil E, 1996, BRAIN COGNITION, V31, P75, DOI 10.1006/brcg.1996.0026; Vriezen ER, 2002, CHILD NEUROPSYCHOL, V8, P296, DOI 10.1076/chin.8.4.296.13505; Wechsler ., 1997, WECHSLER ADULT INTEL; Wechsler, 1999, WECHSLER ABBREVIATED; Zhang L, 2003, ARCH PHYS MED REHAB, V84, P1118, DOI 10.1016/S0003-9993(03)00203-X; Zhang L, 2001, AM J PHYS MED REHAB, V80, P597, DOI 10.1097/00002060-200108000-00010	36	77	78	0	9	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	JAN	2007	21	1					146	161		10.1080/13854040601100668			16	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	135UU	WOS:000244180200009	17366282				2021-06-18	
J	Nadebaum, C; Anderson, V; Catroppa, C				Nadebaum, Caroline; Anderson, Vicki; Catroppa, Cathy			Executive function outcomes following traumatic brain injury in young children: A five year follow-up	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article							CHILDHOOD HEAD-INJURY; BEHAVIOR RATING INVENTORY; PROBLEM-SOLVING SKILLS; LONG-TERM OUTCOMES; COGNITIVE-DEVELOPMENT; WORKING-MEMORY; WHITE-MATTER; FRONTAL-LOBE; PERFORMANCE; RECOVERY	Little is known about the long-term effects of traumatic brain injury (TBI) in very young children. This study used a prospective, cross-sectional design to investigate the impact of TBI on executive function (EF) outcomes in children who sustained a TBI before the age of seven. The study aimed to identify specific or global EF deficits five years post-TBI, and to explore factors that predicted outcomes. Fifty-four children with a TBI and 17 uninjured comparison children participated. Their performance on several cognitive and behavioral EF measures was examined. Results suggested that executive difficulties were present following severe TBI, however children with mild and moderate injuries were relatively unaffected. Skills that develop early appeared to be relatively robust. Injury severity was found to be most predictive of long-term EF, however other injury, child and family-related variables also contributed to outcomes.	Univ Melbourne, Dept Psychol, Murdoch Childrens Res Inst, Australian Ctr Child Neuropsychol Studies, Parkville, Vic 3052, Australia; Royal Childrens Hosp, Dept Psychol, Murdoch Childrens Res Inst, Melbourne, Vic, Australia	Anderson, V (corresponding author), Royal Childrens Hosp, Dept Psychol, Flemington Rd, Parkville, Vic 3052, Australia.	vicki.anderson@rch.org.au					Anderson P, 2002, CHILD NEUROPSYCHOL, V8, P71, DOI 10.1076/chin.8.2.71.8724; Anderson V, 1998, NEUROPSYCHOL REHABIL, V8, P319, DOI 10.1080/713755568; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson V A, 1999, Pediatr Rehabil, V3, P159; Anderson V.A, 2001, DEV NEUROPSYCHOLOGY; Anderson VA, 2004, BRAIN, V127, P2608, DOI 10.1093/brain/awh320; Anderson VA, 2002, CHILD NEUROPSYCHOL, V8, P231, DOI 10.1076/chin.8.4.231.13509; Anderson VA, 2001, DEV NEUROPSYCHOL, V20, P385, DOI 10.1207/S15326942DN2001_5; Anderton S, 2005, CHEM WORLD-UK, V2, P19; Andrews TK, 1998, BRAIN INJURY, V12, P133, DOI 10.1080/026990598122755; Azouvi P, 2004, NEUROPSYCHOLOGIA, V42, P1260, DOI 10.1016/j.neuropsychologia.2004.01.001; Barnes MA, 2001, BRAIN LANG, V76, P253, DOI 10.1006/brln.2000.2385; BELL MA, 1992, CHILD DEV, V63, P1142, DOI 10.1111/j.1467-8624.1992.tb01685.x; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; Brookshire B, 2004, DEV NEUROPSYCHOL, V25, P61, DOI 10.1207/s15326942dn2501&2_5; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879; Casey BJ, 2000, BIOL PSYCHOL, V54, P241, DOI 10.1016/S0301-0511(00)00058-2; Catroppa C, 1999, J INT NEUROPSYCH SOC, V5, P48, DOI 10.1017/S1355617799511077; Catroppa C, 2004, BRAIN LANG, V88, P68, DOI 10.1016/S0093-934X(03)00159-7; Catroppa C, 2003, NEUROPSYCHOL REHABIL, V13, P517, DOI 10.1080/09602010343000084; Catroppa C, 2002, BRAIN INJURY, V16, P369, DOI 10.1080/02699050110104444; Catroppa C, 1999, Pediatr Rehabil, V3, P167; Cattelani R, 1998, BRAIN INJURY, V12, P283, DOI 10.1080/026990598122584; Chapman SB, 2000, J COMMUN DISORD, V33, P333, DOI 10.1016/S0021-9924(00)00029-0; Chapman SB, 2004, DEV NEUROPSYCHOL, V25, P37, DOI 10.1207/s15326942dn2501&2_4; Chapman SB, 2001, J HEAD TRAUMA REHAB, V16, P441, DOI 10.1097/00001199-200110000-00004; Chugani HT, 1998, PREV MED, V27, P184, DOI 10.1006/pmed.1998.0274; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; DANIEL A, 1983, POWER PRIVELEGE OCCU; Dennis M, 1996, DEV NEUROPSYCHOL, V12, P77, DOI 10.1080/87565649609540641; Dennis M, 2001, BRAIN LANG, V78, P1, DOI 10.1006/brln.2000.2431; Dennis M, 2000, APHASIOLOGY, V14, P391, DOI 10.1080/026870300401423; Dennis M., 1989, CLIN NEUROPSYCHOLOGY, P89; Donders J, 2002, NEUROPSYCHOLOGY, V16, P491, DOI 10.1037//0894-4105.16.4.491; Evans DW, 2004, BRAIN COGNITION, V55, P220, DOI 10.1016/s0278-2626(03)00274-4; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V26, P487, DOI 10.1207/s15326942dn2601_7; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; Fenwick T, 1999, CHILD NEUROPSYCHOL, V5, P213, DOI 10.1076/0929-7049(199912)05:04;1-R;FT213; Fuster J M, 1993, Curr Opin Neurobiol, V3, P160, DOI 10.1016/0959-4388(93)90204-C; Gioia GA, 2004, DEV NEUROPSYCHOL, V25, P135, DOI 10.1207/s15326942dn2501&2_8; Gioia GA, 2002, CHILD NEUROPSYCHOL, V8, P121, DOI 10.1076/chin.8.2.121.8727; Gioia GA, 2000, CHILD NEUROPSYCHOL, V6, P235, DOI 10.1076/chin.6.3.235.3152; GREENSPAN AI, 1994, PEDIATRICS, V94, P425; Hanten G, 2002, CHILD NEUROPSYCHOL, V8, P107, DOI 10.1076/chin.8.2.107.8729; Hawley CA, 2004, BRAIN INJURY, V18, P645, DOI 10.1080/02699050310001646189; HUTTENLOCHER PR, 1997, DEV ANATOMY PREFRONT; Jacobs R, 2002, CHILD NEUROPSYCHOL, V8, P93, DOI 10.1076/chin.8.2.93.8726; Janusz JA, 2002, CHILD NEUROPSYCHOL, V8, P179, DOI 10.1076/chin.8.3.179.13499; Jordan FM, 1996, BRAIN INJURY, V10, P91, DOI 10.1080/026990596124575; Kirkwood M, 2000, CHILD NEUROPSYCHOL, V6, P195, DOI 10.1076/chin.6.3.195.3157; Klingberg T, 1999, NEUROREPORT, V10, P2817, DOI 10.1097/00001756-199909090-00022; Kolb B, 2000, DEV NEUROPSYCHOL, V18, P423, DOI 10.1207/S1532694208Kolb; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Lehnung M, 2001, CHILD NEUROPSYCHOL, V7, P59, DOI 10.1076/chin.7.2.59.3129; Levin H S, 1997, J Int Neuropsychol Soc, V3, P598; Levin HS, 1996, DEV NEUROPSYCHOL, V12, P17, DOI 10.1080/87565649609540638; Levin HS, 2004, J CLIN EXP NEUROPSYC, V26, P589, DOI 10.1080/13803390490504434; Levin HS, 2004, J INT NEUROPSYCH SOC, V10, P305, DOI 10.1017/S1355617704102129; Levin HS, 2004, NEUROPSYCHOLOGY, V18, P240, DOI 10.1037/0894-4105.18.2.240; LEVIN HS, 1991, DEV NEUROPSYCHOL, V7, P377, DOI 10.1080/87565649109540499; Levin HS, 2001, NEUROPSYCHOLOGY, V15, P557, DOI 10.1037//0894-4105.15.4.557; Levin HS, 2001, NEUROPSYCHOLOGIA, V39, P122, DOI 10.1016/S0028-3932(00)00111-1; LEVIN HS, 1994, NEUROPSYCHOLOGY, V8, P171, DOI DOI 10.1037/0894-4105.8.2.171; Luis CA, 2002, J CLIN EXP NEUROPSYC, V24, P270, DOI 10.1076/jcen.24.3.270.982; Mangeot S, 2002, CHILD NEUROPSYCHOL, V8, P271, DOI 10.1076/chin.8.4.271.13503; MANLY T, 1999, TEST EVERDAY ATTENTI; Mathias JL, 2004, APPL NEUROPSYCHOL, V11, P134, DOI 10.1207/s15324826an1103_2; McDonald BC, 2002, NEUROREHABILITATION, V17, P333; McKinlay A, 2002, J NEUROL NEUROSUR PS, V73, P281, DOI 10.1136/jnnp.73.3.281; Noller P, 1988, ICPS FAMILY FUNCTION; Nybo T, 1999, BRAIN INJURY, V13, P759; OCONNOR P, 2002, HOSP DUE TRAUMATIC B; Passler MA, 1985, DEV NEUROPSYCHOL, V1, P349, DOI 10.1080/87565648509540320; Pennington BF, 1996, J CHILD PSYCHOL PSYC, V37, P51, DOI 10.1111/j.1469-7610.1996.tb01380.x; Pentland L, 1998, NEUROPSYCHOL REHABIL, V8, P301, DOI 10.1080/713755572; PETTERSEN L, 1991, PERCEPT MOTOR SKILL, V73, P1139, DOI 10.2466/pms.1991.73.3f.1139; Roncadin C, 2004, DEV NEUROPSYCHOL, V25, P21; Schachar R, 2004, DEV NEUROPSYCHOL, V25, P179, DOI 10.1207/s15326942dn2501&2_10; Segalowitz SJ, 2004, BRAIN COGNITION, V55, P116, DOI 10.1016/s0278-2626(03)00283-5; Slomine BS, 2002, BRAIN INJURY, V16, P759, DOI 10.1080/02699050210127286; Smidts DP, 2004, DEV NEUROPSYCHOL, V26, P385, DOI 10.1207/s15326942dn2601_2; Sparrow S., 1984, VINELAND ADAPTIVE BE; Stancin T, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e34; Stanton B R, 1999, Pediatr Rehabil, V3, P193, DOI 10.1080/136384999289469; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; TAYLOR HG, 2005, INT NEUR M DUBL; TEASDALE G, 1974, LANCET, V2, P81; Tremont G, 1999, CHILD NEUROPSYCHOL, V5, P104, DOI 10.1076/chin.5.2.104.3166; WELSH MC, 1991, DEV NEUROPSYCHOL, V7, P131, DOI 10.1080/87565649109540483; Weschler D., 1992, MANUAL WESCHLER INTE, V3rd ed; Willmott C, 2000, DEV NEUROPSYCHOL, V17, P361, DOI 10.1207/S15326942DN1703_5	95	77	77	0	18	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	8756-5641	1532-6942		DEV NEUROPSYCHOL	Dev. Neuropsychol.		2007	32	2					703	728		10.1080/87565640701376086			26	Psychology, Developmental; Psychology; Psychology, Experimental	Psychology	212NJ	WOS:000249603000006	17931126				2021-06-18	
J	Ashman, TA; Gordon, WA; Cantor, JB; Hibbard, MR				Ashman, Teresa A.; Gordon, Wayne A.; Cantor, Joshua B.; Hibbard, Mary R.			Neurobehavioral consequences of traumatic brain injury	MOUNT SINAI JOURNAL OF MEDICINE			English	Article						traumatic brain injury; neuropsychiatry; rehabilitation; axis I disorders; psychiatric disorders	MILD HEAD-INJURY; UNITED-STATES; PSYCHIATRIC-DISORDERS; FOLLOW-UP; AXIS-I; COGNITIVE REHABILITATION; POSTCONCUSSION SYNDROME; NATURAL-HISTORY; SILENT EPIDEMIC; DEPRESSION	At least 1.4 million people die, or receive hospital or emergency care every year in the United States as a result of traumatic brain injury (TBI). Many more are treated in other settings or receive no treatment at all. Thus TBI is often unidentified, with subsequent cognitive, behavioral, emotional and physical sequelae that are not linked to the injury. Yet, over 5.3 million Americans live with TBI-related disabilities that interfere with their overall performance and social roles within the community. The pathophysiolog and consequences of TBI are discussed, as are functional changes and psychiatric manifestations after TBI. Finally, implications and recommendations for clinical practice are reviewed, including the importance of screening for TBI.	CUNY Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA	Ashman, TA (corresponding author), CUNY Mt Sinai Sch Med, Dept Rehabil Med, Box 1240,1 Gustave L Levy Pl, New York, NY 10029 USA.	teresa.ashman@mssm.edu	Ashman, Teresa/B-1621-2013				Alexander M. P., 1997, SEMIN CLIN NEUROPSYC, V2, P177; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; ARCINIEGAS DB, 2000, CURRENT TREATMENT OP, V2, P169; Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; Bernstein DM, 1999, BRAIN INJURY, V13, P151, DOI 10.1080/026990599121683; Bigler ED, 2003, ARCH CLIN NEUROPSYCH, V18, P595; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; BOHNEN NI, 1995, BRAIN INJURY, V9, P27, DOI 10.3109/02699059509004568; Bordini EJ, 2002, NEUROREHABILITATION, V17, P93; Borgaro SR, 2005, J HEAD TRAUMA REHAB, V20, P416, DOI 10.1097/00001199-200509000-00003; Brown CG, 2003, GEOTIMES, V48, P4; Brown M, 1999, MT SINAI J MED, V66, P160; Bryant RA, 2000, BRAIN INJURY, V14, P175, DOI 10.1080/026990500120826; Burg JS, 1996, J CLIN PSYCHOL MED S, V3, P243, DOI 10.1007/BF01993910; Callahan CD, 1999, J HEAD TRAUMA REHAB, V14, P581, DOI 10.1097/00001199-199912000-00006; Cantor JB, 2005, J HEAD TRAUMA REHAB, V20, P527, DOI 10.1097/00001199-200511000-00005; *CDCP, FACTS TRAUM BRAIN IN; Chan RCK, 2000, BRAIN INJURY, V14, P227, DOI 10.1080/026990500120709; Cicerone KD, 2004, ARCH PHYS MED REHAB, V85, P943, DOI 10.1016/j.apmr.2003.07.019; Cicerone KD, 2002, BRAIN INJURY, V16, P185, DOI 10.1080/02699050110103959; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Deb S, 1999, AM J PSYCHIAT, V156, P374; DIJKERS M, ARCH PHYS MED REH S2, V85, pS21; DIKMEN S, 1989, J NEUROL NEUROSUR PS, V49, P1227; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; EVANS RW, 1992, NEUROL CLIN, V10, P815; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Fann JR, 2001, PSYCHOSOMATICS, V42, P48, DOI 10.1176/appi.psy.42.1.48; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; Feinstein A, 2000, CAN J PUBLIC HEALTH, V91, P325, DOI 10.1007/BF03404799; Fortin S, 2003, CORTEX, V39, P273, DOI 10.1016/S0010-9452(08)70109-6; GOLDSTEIN M, 1990, ANN NEUROL, V27, P327, DOI 10.1002/ana.410270315; Gordon WA, 2006, AM J PHYS MED REHAB, V85, P343, DOI 10.1097/01.phm.0000202106.01654.61; Gordon WR, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199812000-00006; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; Hall RCW, 2005, PSYCHOSOMATICS, V46, P195, DOI 10.1176/appi.psy.46.3.195; Hammond FM, 2004, J HEAD TRAUMA REHAB, V19, P314, DOI 10.1097/00001199-200407000-00006; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P47, DOI 10.1097/00001199-199808000-00005; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hibbard MR, 2000, BRAIN INJURY, V14, P45, DOI 10.1080/026990500120925; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Holtzer R, 2000, BRAIN INJURY, V14, P959, DOI 10.1080/02699050050191904; Hoofien D, 2001, BRAIN INJURY, V15, P189; JENNETT B, 1990, REHABILITATION ADULT, P3; Jorge R, 2003, INT REV PSYCHIATR, V15, P317, DOI 10.1080/09540260310001606700; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Mahmood O, 2004, J HEAD TRAUMA REHAB, V19, P378, DOI 10.1097/00001199-200409000-00003; Marr A, 2002, CENTRAL NERVOUS SYST; Mateer CA, 2005, J HEAD TRAUMA REHAB, V20, P62, DOI 10.1097/00001199-200501000-00007; MAYOU R, 1993, BRIT MED J, V307, P646; Mayou RA, 2000, BRIT J PSYCHIAT, V177, P540, DOI 10.1192/bjp.177.6.540; McAllister TW, 1997, COMMUNITY MENT HLT J, V33, P341, DOI 10.1023/A:1025055426260; McAllister TW, 2002, NEUROREHABILITATION, V17, P265; McDermott S, 2005, DISABIL REHABIL, V27, P117, DOI 10.1080/09638280400007380; McGuire LM, 1998, BRAIN INJURY, V12, P207, DOI 10.1080/026990598122683; MCLEAN A, 1983, J CLIN NEUROPSYCHOL, V5, P361, DOI 10.1080/01688638308401185; Mittenberg W, 2000, J HEAD TRAUMA REHAB, V15, P783, DOI 10.1097/00001199-200004000-00003; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Nicholson K, 2004, J HEAD TRAUMA REHAB, V19, P2, DOI 10.1097/00001199-200401000-00002; O'Connor C, 2005, PSYCHOL REP, V97, P169, DOI 10.2466/PR0.97.5.169-179; Olver John, 2005, Aust Fam Physician, V34, P269; Ouellet MC, 2004, NEUROREHAB NEURAL RE, V18, P187, DOI 10.1177/1545968304271405; Patterson C M, 1998, J Ark Med Soc, V95, P109; Potter DD, 2001, NEUROPSYCHOLOGIA, V39, P1464, DOI 10.1016/S0028-3932(01)00057-4; Rao V, 2002, PSYCHIAT CLIN N AM, V25, P43, DOI 10.1016/S0193-953X(03)00052-2; Rees PM, 2003, ARCH PHYS MED REHAB, V84, P1885, DOI 10.1016/j.apmr.2003.03.001; RIMEL RW, 1995, NEUROSURGERY, P221; Schootman M, 2000, BRAIN INJURY, V14, P373; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Simpson G, 2005, J NERV MENT DIS, V193, P680, DOI 10.1097/01.nmd.0000180743.65943.c8; Sosin DM, 1996, BRAIN INJURY, V10, P47; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; Thaxton L, 2002, J HEAD TRAUMA REHAB, V17, P335, DOI 10.1097/00001199-200208000-00007; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Warriner Erin M, 2006, Curr Psychiatry Rep, V8, P73, DOI 10.1007/s11920-006-0083-2; Wehman P, 2005, J HEAD TRAUMA REHAB, V20, P115, DOI 10.1097/00001199-200503000-00001; Wehman P, 2003, ARCH PHYS MED REHAB, V84, P192, DOI 10.1053/apmr.2003.50027; Yasuda S, 2001, AM J PHYS MED REHAB, V80, P852, DOI 10.1097/00002060-200111000-00011	85	77	80	0	18	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0027-2507	1931-7581		MT SINAI J MED	Mt. Sinai J. Med.	NOV	2006	73	7					999	1005					7	Medicine, General & Internal	General & Internal Medicine	116BB	WOS:000242776400010	17195886				2021-06-18	
J	Sifri, ZC; Homnick, AT; Vaynman, A; Lavery, R; Liao, W; Mohr, A; Hauser, CJ; Manniker, A; Livingston, D				Sifri, Ziad C.; Homnick, Adena T.; Vaynman, Artem; Lavery, Robert; Liao, Wesley; Mohr, Alicia; Hauser, Carl J.; Manniker, Allen; Livingston, David			A prospective evaluation of the value of repeat cranial computed tomography in patients with minimal head injury and an intracranial bleed	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						traumatic brain injury; cranial computed axial tomography; neurologic status; neurosurgical intervention; intracranial bleed	TRAUMATIC BRAIN-INJURY; CT SCANS; MANAGEMENT; UTILITY; PREDICTORS; ADMISSION; MODERATE; TRENDS	Background: Patients with minimal head injury (MHI) and intracranial bleed (ICB) detected on cranial computed tomography (CT) scan routinely undergo a repeat cranial CT within 24 hours after injury to assess for progression of intracranial injuries. While this is clearly beneficial in patients with a deteriorating neurologic status, it is of questionable value in patients with a normal neurologic examination. The goal of this study was to prospectively assess the value of a repeat cranial CT in patients with a MHI and an ICB who have a normal neurologic examination. Methods. A prospective analysis of all adult patients admitted to a Level I trauma center after blunt trauma causing a MHI (defined as the loss of consciousness or posttraumatic amnesia with a Glasgow Coma Scale (GCS) score of greater or equal to 13) and an ICB on the initial cranial CT during a 12-month period (July 2002 through July 2003) was performed. All patients with MHI were prospectively evaluated and followed until discharge. Data collected included demographics, neurologic examination and findings on the initial and repeat cranial CT scan. Outcome data included neurologic deterioration, neurosurgical intervention, and Glasgow Outcome Scale (GOS) on discharge. Results: In all, 161 consecutive patients with MM and a positive cranial CT scan were identified. The initial cranial CT lead to a neurosurgical intervention (1 craniotomy, 4 intracranial pressure monitors) in 4% of cases. The remaining 130 patients who met inclusion criteria, underwent a repeat cranial CT scan within 24 hours post-admission. Ninety nine (76%) patients had a normal neurologic examination at the time of their repeat cranial CT. After the repeat cranial CT none required immediate neurosurgical intervention or had delayed neurologic deterioration related to their head injury. Fifteen patients underwent additional neuroradiologic studies but none showed further progression of their ICB or lead to a change in management. One patient died from non-traumatic brain injury related causes and of the remaining 26 patients, 98% had an overall favorable GOS score (> 3) on discharge. In this group of patients with MHI and ICB, the negative predictive value of a normal neurologic examination was 100%. Conclusions: Repeat cranial CT, in patients with a MHI and a normal neurologic examination, resulted in no change in management or neurosurgical intervention and is therefore not indicated. A multicenter prospective study would further validate these conclusions, reduce unnecessary CT scans, and likely improve our current standard of care in these patients.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Surg, Newark, NJ 07103 USA	Sifri, ZC (corresponding author), 150 Bergen St,M-229, Newark, NJ 07103 USA.	sifrizi@umdnj.edu	Mohr, Alicia M/E-3016-2015; Hauser, Carl J./Y-1189-2019	Mohr, Alicia/0000-0003-1732-1313; Hauser, Carl/0000-0003-3167-1846			*AG HLTH CAR POL R, 1998, REH TRAUM BRAIN INJ; Brown CVR, 2004, J TRAUMA, V57, P939, DOI 10.1097/01.TA.0000149492.92558.03; Chao A, 2001, J TRAUMA, V51, P870, DOI 10.1097/00005373-200111000-00008; Cushman JG, 2001, J TRAUMA, V51, P1016, DOI 10.1097/00005373-200111000-00034; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Kaups KL, 2004, J TRAUMA, V56, P475, DOI 10.1097/01.TA.0000114304.56006.D4; Lee TT, 1997, ACTA NEUROCHIR, V139, P1042, DOI 10.1007/BF01411558; Livingston DH, 2005, J TRAUMA, V59, P1298, DOI 10.1097/01.ta.0000196002.03681.18; LIVINGSTON DH, 1991, J TRAUMA, V31, P483, DOI 10.1097/00005373-199104000-00006; LIVINGSTON DH, 1991, AM SURGEON, V57, P14; Livingston DH, 2000, ANN SURG, V232, P126, DOI 10.1097/00000658-200007000-00018; Marik PE, 2002, CHEST, V122, P699, DOI 10.1378/chest.122.2.699; Miller Erik C., 1997, Journal of Emergency Medicine, V15, P453, DOI 10.1016/S0736-4679(97)00071-1; MORAN SG, 1994, AM SURGEON, V60, P533; Nagy KK, 1999, J TRAUMA, V46, P268, DOI 10.1097/00005373-199902000-00012; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; Sifri ZC, 2004, AM J SURG, V187, P338, DOI 10.1016/j.amjsurg.2003.12.015; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Tabori U, 2000, CRIT CARE MED, V28, P840, DOI 10.1097/00003246-200003000-00038; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; VALADKA AB, 2000, TRAUMA, P377	24	77	82	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	OCT	2006	61	4					862	867		10.1097/01.ta.0000224225.54982.90			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	096YU	WOS:000241413700019	17033552				2021-06-18	
J	Root, JC; Robbins, RN; Chang, L; Van Gorp, WG				Root, James C.; Robbins, Reuben N.; Chang, Luke; Van Gorp, Wilfred G.			Detection of inadequate effort on the California Verbal Learning Test-Second edition: Forced Choice Recognition and Critical Item Analysis	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						malingering; neuropsychological tests; memory; forensic; assessment; neuropsychology	MEMORY MALINGERING TOMM; TRAUMATIC BRAIN-INJURY; NEUROPSYCHOLOGICAL EVALUATION; HEAD-INJURY; PERFORMANCE; PREDICTORS; DEFICITS; INTERNET; RATES	The Forced Choice Recognition (FCR) and the Critical Item Analysis (CIA) indices of the California Verbal Learning Test-II (CVLT II) have been identified by the CVLT-II test developers as potentially useful, brief screening indicators of effort in neuropsychological assessment. This retrospective study analyzes performance on these measures in three groups: (1) clinically referred individuals; (2) forensically referred individuals not suspected of inadequate effort; and (3) forensically referred individuals whose performance on freestanding tests of effort suggested inadequate effort. Performances on FCR were analyzed for their relation to actual memory impairment and with regard to concrete and abstract distractor endorsement. FCR and CIA performances were analyzed for agreement with formal tests of inadequate effort and their test characteristics. Incremental validity was assessed by hierarchical logistic regression with previously identified indices for detection of inadequate effort on the CVLT. Results indicate that (1) FCR and CIA performances are not related to decreased memory performance; (2) FCR and CIA indices exhibit higher specificity and lower sensitivity, with higher positive predictive value than negative predictive value; and (3) FCR and CIA indices exhibit modest incremental validity with previously identified indices. Implications for use of FCR and CIA indices in inadequate effort detection are discussed.	Cornell Univ, Weill Med Coll, Dept Psychiat, New York, NY 10021 USA; Fordham Univ, Dept Psychol, Bronx, NY 10458 USA; New Sch Social Res, Dept Psychol, New York, NY USA; Columbia Univ, Dept Psychiat, New York, NY USA	Root, JC (corresponding author), Cornell Univ, Weill Med Coll, Dept Psychiat, 1300 York Ave,F1302, New York, NY 10021 USA.	jcr2003@med.cornell.edu	Robbins, Reuben/AAI-7146-2021	Robbins, Reuben/0000-0003-0774-2245; CHANG, LUKE/0000-0002-7177-4711; Chang, Luke/0000-0002-6621-8120			ARNETT PA, 1995, CLIN NEUROPSYCHOL, V9, P17, DOI 10.1080/13854049508402052; Ashendorf L, 2003, CLIN NEUROPSYCHOL, V17, P255, DOI 10.1076/clin.17.2.255.16502; Bauer L, 2006, ARCH CLIN NEUROPSYCH, V21, P121, DOI 10.1016/j.acn.2005.06.010; BINDER LM, 1993, J CLIN EXP NEUROPSYC, V15, P170, DOI 10.1080/01688639308402555; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Coleman RD, 1998, J CLIN EXP NEUROPSYC, V20, P201, DOI 10.1076/jcen.20.2.201.1164; CONDER R, 1992, COMPUTERIZED ASSESSM; Connor D. J., 1997, AM AC NEUR BOST; Delis DC, 2000, CALIFORNIA VERBAL LE; Delis DC, 1987, CALIFORNIA VERBAL LE; Frederick R.I., 1997, VALIDITY INDICATOR P; Frederick RI, 1994, NEUROPSYCHOLOGY, V8, P118, DOI 10.1037/0894-4105.8.1.118; Gervais RO, 2004, ARCH CLIN NEUROPSYCH, V19, P475, DOI 10.1016/j.acn.2003.05.001; Green P., 1996, WORD MEMORY TEST USE; Greve KW, 2004, ARCH CLIN NEUROPSYCH, V19, P533, DOI 10.1016/j.acn.2003.08.002; HEATON RK, 1978, J CONSULT CLIN PSYCH, V46, P892, DOI 10.1037/0022-006X.46.5.892; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Lee G.P., 1992, PSYCHOL ASSESSMENT, V4, P43, DOI [10.1037/1040-3590.4.1.43, DOI 10.1037/1040-3590.4.1.43]; Millis SR, 1995, PSYCHOL ASSESSMENT, V7, P463; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Moore BA, 2004, BRAIN INJURY, V18, P975, DOI 10.1080/02699050410001672350; Rees LM, 1998, PSYCHOL ASSESSMENT, V10, P10, DOI 10.1037/1040-3590.10.1.10; Rosenfeld B, 2000, ARCH CLIN NEUROPSYCH, V15, P349, DOI 10.1016/S0887-6177(99)00025-6; Royston P, 2006, STAT MED, V25, P127, DOI 10.1002/sim.2331; Ruiz MA, 2002, PROF PSYCHOL-RES PR, V33, P294, DOI 10.1037//0735-7028.33.3.294; SCHRETLEN DJ, 1988, CLIN PSYCHOL REV, V8, P451, DOI 10.1016/0272-7358(88)90074-8; Sweet JJ, 2000, ARCH CLIN NEUROPSYCH, V15, P105, DOI 10.1016/S0887-6177(98)00153-X; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260; Tombaugh TN, 1996, TEST MEMORY MALINGER; TRUEBLOOD W, 1993, J CLIN EXP NEUROPSYC, V15, P578, DOI 10.1080/01688639308402580; Vallabhajosula B, 2001, J AM ACAD PSYCHIATRY, V29, P207	31	77	78	1	6	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	SEP	2006	12	5					688	696		10.1017/S1355617706060838			9	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	081ZE	WOS:000240355300011	16961950	Green Published			2021-06-18	
J	Shao, CX; Roberts, KN; Markesbery, WR; Scheff, SW; Lovell, MA				Shao, ChangXing; Roberts, Kelly N.; Markesbery, William R.; Scheff, Stephen W.; Lovell, Mark A.			Oxidative stress in head trauma in aging	FREE RADICAL BIOLOGY AND MEDICINE			English	Article						acrolein; glutathione peroxidase; glutathione reductase; glutathione transferase; 4-hydroxynonenal; traumatic brain injury; superoxide dismutase	ANTIOXIDANT ENZYME-ACTIVITY; LIPID-PEROXIDATION PRODUCT; CONTROLLED CORTICAL IMPACT; BRAIN-INJURY; GLUTATHIONE-PEROXIDASE; SUPEROXIDE DISMUTASES; IMPAIRED MITOCHONDRIAL; HYDROXYL RADICALS; TIME-COURSE; HIPPOCAMPAL	Oxidative damage is proposed as a key mediator of exacerbated morphological responses and deficits in behavioral recovery in aged subjects with traumatic brain injury (TBI). In the present study, we show exacerbated loss of tissue in middle aged (12 months) and aged (22 months) Fisher-344 rats compared to young animals (3 months) subjected to moderate TBI. Analysis of 4-hydroxynonenal (4-HNE) and acrolein, neurotoxic by-products of lipid peroxidation, shows significant (P < 0.05) age-dependent increases in ipsilateral (IP) hippocampus 1 and 7 days post injury. In IP cortex, 4-HNE was significantly elevated 1 day post injury in all age groups, and both 4-HNE and acrolein were elevated in middle aged and aged animals 7 days post injury. Comparison of antioxidant enzyme activities shows significant (P < 0.05) age-dependent decreases of manganese superoxide dismutase in IP hippocampus and cortex 1 and 7 days post injury. Glutathione reductase activity also showed an age-dependent decrease. Overall, our data show increased levels of oxidative damage, diminished antioxidant capacities, and increased tissue loss in TBI in aging. (c) 2006 Elsevier Inc. All rights reserved.	Univ Kentucky, Dept Chem, Lexington, KY 40536 USA; Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA	Lovell, MA (corresponding author), 135 Sanders Brown Bldg,800 S,Limestone St, Lexington, KY 40536 USA.	malove2@email.uky.edu			NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG021981] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG21981] Funding Source: Medline		Anderson KJ, 2005, EXP NEUROL, V193, P125, DOI 10.1016/j.expneurol.2004.11.025; Awasthi D, 1997, SURG NEUROL, V47, P575, DOI 10.1016/S0090-3019(96)00461-2; Azbill RD, 1997, BRAIN RES, V765, P283, DOI 10.1016/S0006-8993(97)00573-8; Baldwin SA, 1996, GLIA, V16, P266; Baldwin SA, 1998, J NEUROSURG, V88, P874, DOI 10.3171/jns.1998.88.5.0874; Baud O, 2004, J NEUROSCI, V24, P1531, DOI 10.1523/JNEUROSCI.3989-03.2004; BECKMAN JS, 1993, NATURE, V364, P584, DOI 10.1038/364584a0; BIROS M, 1998, HEAD TRAUMA; Camandola S, 2000, J NEUROCHEM, V74, P159, DOI 10.1046/j.1471-4159.2000.0740159.x; Cooper P., 1985, DELAYED BRAIN INJURY, P217; DeKosky ST, 2004, J NEUROTRAUM, V21, P491, DOI 10.1089/089771504774129838; Engle MR, 2004, TOXICOL APPL PHARM, V194, P296, DOI 10.1016/j.taap.2003.10.001; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; FADEN AI, 1993, CRIT REV NEUROBIOL, V7, P175; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fridovich I, 1997, J BIOL CHEM, V272, P18515, DOI 10.1074/jbc.272.30.18515; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; HAMM RJ, 1992, NEUROSURGERY, V31, P1072, DOI 10.1227/00006123-199212000-00013; HAMM RJ, 1991, J NEUROSURG, V75, P916, DOI 10.3171/jns.1991.75.6.0916; Ho YS, 1997, J BIOL CHEM, V272, P16644, DOI 10.1074/jbc.272.26.16644; Hoane MR, 2004, BEHAV BRAIN RES, V153, P189, DOI 10.1016/j.bbr.2003.11.012; Hoffman SW, 1996, J NEUROSCI METH, V68, P133; Hsiang JNK, 1997, ACTA NEUROCHIR, V139, P464, DOI 10.1007/BF01808884; Inci S, 1998, NEUROSURGERY, V43, P330, DOI 10.1097/00006123-199808000-00095; Klein M, 1996, J NERV MENT DIS, V184, P459, DOI 10.1097/00005053-199608000-00002; Liu YH, 2003, CHEM RES TOXICOL, V16, P1589, DOI 10.1021/tx034160a; Long Y, 2003, J NEUROSCI RES, V71, P710, DOI 10.1002/jnr.10524; Lovell MA, 1997, NEUROBIOL AGING, V18, P457, DOI 10.1016/S0197-4580(97)00108-5; LOVELL MA, 1995, NEUROLOGY, V45, P1594, DOI 10.1212/WNL.45.8.1594; Lovell MA, 2001, NEUROBIOL AGING, V22, P187, DOI 10.1016/S0197-4580(00)00235-9; Maier CM, 2002, NEUROSCIENTIST, V8, P323, DOI 10.1177/107385840200800408; Matsushita M, 1997, J COMP NEUROL, V377, P251, DOI 10.1002/(SICI)1096-9861(19970113)377:2<251::AID-CNE7>3.0.CO;2-2; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; Matzilevich DA, 2002, J NEUROSCI RES, V67, P646, DOI 10.1002/jnr.10157; Maughan PH, 2000, J NEUROTRAUM, V17, P1141, DOI 10.1089/neu.2000.17.1141; McCall J M, 1987, Acta Anaesthesiol Belg, V38, P373; Medina-Navarro R, 2004, HUM EXP TOXICOL, V23, P101, DOI 10.1191/0960327104ht416oa; MICHEL RP, 1988, J MICROSC-OXFORD, V150, P117, DOI 10.1111/j.1365-2818.1988.tb04603.x; MISRA HP, 1972, J BIOL CHEM, V247, P3170; MIZUNO Y, 1984, EXP NEUROL, V84, P58, DOI 10.1016/0014-4886(84)90006-2; Nishio S, 1997, ACT NEUR S, V70, P84; Okado-Matsumoto A, 2001, J BIOL CHEM, V276, P38388, DOI 10.1074/jbc.M105395200; PAGLIA DE, 1967, J LAB CLIN MED, V70, P158; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; RICCI G, 1994, ANAL BIOCHEM, V218, P463, DOI 10.1006/abio.1994.1209; SAIKI RK, 1986, NATURE, V324, P163, DOI 10.1038/324163a0; Shetty AK, 2004, J NEUROSCI RES, V78, P520, DOI 10.1002/jnr.20302; SIESJO BK, 1995, J NEUROTRAUM, V12, P943, DOI 10.1089/neu.1995.12.943; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; Springer JE, 1997, J NEUROCHEM, V68, P2469; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; TATOR C, 1994, ISCHEMIA SECONDARY N; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P140; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Uchida K, 1998, J BIOL CHEM, V273, P16058, DOI 10.1074/jbc.273.26.16058; Valentine JS, 1998, CURR OPIN CHEM BIOL, V2, P253, DOI 10.1016/S1367-5931(98)80067-7; Wagner AK, 2004, J NEUROTRAUM, V21, P125, DOI 10.1089/089771504322778596; Wang H, 2003, J NEUROCHEM, V87, P1527, DOI 10.1046/j.1471-4159.2003.02123.x; Xie CS, 2001, FREE RADICAL BIO MED, V31, P73, DOI 10.1016/S0891-5849(01)00553-6	64	77	80	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0891-5849	1873-4596		FREE RADICAL BIO MED	Free Radic. Biol. Med.	JUL 1	2006	41	1					77	85		10.1016/j.freeradbiomed.2006.03.007			9	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Biochemistry & Molecular Biology; Endocrinology & Metabolism	058LV	WOS:000238667400009	16781455				2021-06-18	
J	Kelley, BJ; Farkas, O; Lifshitz, J; Povlishock, JT				Kelley, BJ; Farkas, O; Lifshitz, J; Povlishock, JT			Traumatic axonal injury in the perisomatic domain triggers ultrarapid secondary axotomy and Wallerian degeneration	EXPERIMENTAL NEUROLOGY			English	Article							OPTIC-NERVE FIBERS; BRAIN-INJURY; STRETCH-INJURY; AXOLEMMAL PERMEABILITY; SPINAL-CORD; MYELIN; DEATH; PIG; PATHOLOGY; EVENTS	Traumatic axonal injury (TAI) arising from diffuse brain injury (DBI) results in focally impaired axonal transport with progressive swelling and delayed disconnection over several hours within brainstem axons. Neocortical DBI-mediated perisomatic axotomy does not result in neuronal death, suggesting that a comparably delayed axotomy progression was responsible for this unanticipated response. To evaluate delayed perisomatic axotomy, the current study was initiated. Rats received intracerebroventricular 10-kDa dextran followed by moderate midline/central fluid percussion injury (FPI) or FPI alone. At 15, 303 60, and 180 min post-injury, light and transmission electron microscopy identified impaired axonal transport via antibodies targeting amyloid precursor protein (APP), while double-label fluorescent microscopy explored concomitant focal, axolemmal alterations via dextran-APP co-localization. At 15 min post-injury. perisomatic TAI was identified with LM within dorsolateral and ventral posterior thalamic nuclei. Using TEM, many sustaining somata and related proximal/distal axonal segments revealed normal ultrastructural detail that was Continuous with focal axonal swellings characterized by cytoskeletal and organelle pathology. In other cases, axotomy was confirmed by loss of axonal continuity distal to the swelling. By 30 min post-injury, perisomatic axotomy predominated. By 60-180 min, somatic, proximal axonal segment, and swelling ultrastructure were comparable to earlier time points although swelling diameter increased. Distal axonal segment ultrastructure now revealed the initial stages of Wallerian degeneration. The site of perisomatic axotomy did not internalize dextran, suggesting that its pathogenesis occurred independent of altered axolemmal permeability. Collectively, this DBI-mediated ultrarapid perisomatic axotomy and its sequelae further illustrate the varied axonal responses to trauma. (C) 2005 Elsevier Inc. All rights reserved.	Virginia Commonwealth Univ, Dept Anat & Neurobiol, Richmond, VA 23298 USA; Univ Pecs, Fac Med, Dept Neurosurg, Pecs, Hungary	Povlishock, JT (corresponding author), 1101 E Marshal St,Sanger Hall,Room 11-044,POB 980, Richmond, VA 23298 USA.	jtpovlis@vcu.edu			NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [F32 HD049343] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS045824, 5P30NS047463, T32NS007288] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [F32HD049343] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS047463, T32NS007288, R01NS045824] Funding Source: NIH RePORTER		Adams JH, 1992, GREENFIELDS NEUROPAT, P106; Ahmed FAKM, 2001, EXP NEUROL, V167, P451, DOI 10.1006/exnr.2000.7562; BARRON KD, 1983, SPINAL CORD RECONSTR, P7; BECERRA JL, 1995, AM J NEURORADIOL, V16, P125; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Buki A, 2000, J NEUROSCI, V20, P2825; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; Buss A, 2004, BRAIN, V127, P34, DOI 10.1093/brain/awh001; CHRISTIAN GD, 1994, J FLOW INJECTION ANA, V11, P2; CONRADI S, 1969, ACTA PHYSIOL SCAND, P65; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Graham D I, 2002, GREENFIELDS NEUROPAT, P823; Hardman JM, 2002, NEUROIMAG CLIN N AM, V12, P175, DOI 10.1016/S1052-5149(02)00009-6; KRAUS JF, 1996, NEUROTRAUMA, P13; Kreutzberg Georg W., 1995, P355; Langlois JA., 2004, TRAUMATIC BRAIN INJU; LoPachin RM, 1997, TOXICOL APPL PHARM, V143, P233, DOI 10.1006/taap.1997.8106; Maxwell WL, 1997, J NEUROTRAUM, V14, P603, DOI 10.1089/neu.1997.14.603; Maxwell WL, 1999, J NEUROTRAUM, V16, P273, DOI 10.1089/neu.1999.16.273; Maxwell WL, 2003, J NEUROTRAUM, V20, P151, DOI 10.1089/08977150360547071; McNeil PL, 2001, CELL TISSUE RES, V304, P141, DOI 10.1007/s004410000286; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Okonkwo DO, 1998, BRAIN RES, V784, P1, DOI 10.1016/S0006-8993(97)01075-5; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; POVISHLOK J, 1996, ACTA NEUROCHIR SUPP, V66, P81; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Singleton RH, 2004, J NEUROSCI, V24, P3543, DOI 10.1523/JNEUROSCI.5048-03.2004; Singleton RH, 2002, J NEUROSCI, V22, P791, DOI 10.1523/JNEUROSCI.22-03-00791.2002; Smith DH, 1999, J NEUROSCI, V19, P4263; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; Stone JR, 2004, EXP NEUROL, V190, P59, DOI 10.1016/j.expneurol.2004.05.022; Stone JR, 1999, ACTA NEUROPATHOL, V97, P335, DOI 10.1007/s004010050996; STRICH SJ, 1968, J NEUROL NEUROSUR PS, V31, P110, DOI 10.1136/jnnp.31.2.110; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Terasaki M, 1997, J CELL BIOL, V139, P63, DOI 10.1083/jcb.139.1.63; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001	40	77	81	0	4	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	APR	2006	198	2					350	360		10.1016/j.expneurol.2005.12.017			11	Neurosciences	Neurosciences & Neurology	033RJ	WOS:000236866400008	16448652				2021-06-18	
J	Townend, W; Dibble, C; Abid, K; Vail, A; Sherwood, R; Lecky, F				Townend, W; Dibble, C; Abid, K; Vail, A; Sherwood, R; Lecky, F			Rapid elimination of protein S-100B from serum after minor head trauma	JOURNAL OF NEUROTRAUMA			English	Article						biomarkers; blood; clearance; craniocerebral trauma; half-life; mild traumatic brain injury; protein S-100B	BRAIN-INJURY; OUTCOME PREDICTION; CARDIAC-SURGERY; MARKER; S100B; DAMAGE; RELEASE	Protein S-100B is released into the circulation after traumatic brain injury, and its serum concentration relates to measures of injury severity and outcome. These properties have led to interest in its development as a marker for clinical use, particularly in the prediction of adverse outcome for those with apparently trivial injuries. Before it can be used in populations of patients with head injuries, however, more needs to be understood about its release and elimination. This study was designed to estimate the elimination half-life of S-100B from the circulation after minor head trauma. We studied 14 patients with minor head injuries and measured serum S-100B serially after initial assessment in the Emergency Department of an inner city teaching hospital. We used curve-fit analysis to estimate the elimination constant that best fitted our data, and from this estimated the elimination half-life of protein S-100B. We estimated the mean half-life in this setting to be 97 min (95% confidence interval [CI] of 75-136 min). S-100B is cleared rapidly, relative to the time elapsed between injury and initial assessment in the Emergency Department. Variation in the time elapsed between injury and sampling is likely to influence the accuracy of head injury outcome prediction based on S-100B concentrations in serum, and should he considered when designing future studies.	Hull Royal Infirm, Emergency Dept, Kingston Upon Hull HU3 2JZ, N Humberside, England; Hope Hosp, Salford M6 8HD, Lancs, England; Univ Manchester, Med Stat Grp, Manchester, Lancs, England; Kings Coll Hosp London, London, England	Townend, W (corresponding author), Hull Royal Infirm, Emergency Dept, Kingston Upon Hull HU3 2JZ, N Humberside, England.	William.Townend@hey.nhs.uk		Vail, Andy/0000-0001-8274-2726			Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Biberthaler P, 2001, SHOCK, V16, P97, DOI 10.1097/00024382-200116020-00002; Blomquist S, 1997, J CARDIOTHOR VASC AN, V11, P699, DOI 10.1016/S1053-0770(97)90160-9; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; Ingebrigtsen T, 1996, J NEUROSURG, V85, P945, DOI 10.3171/jns.1996.85.5.0945; Jackson RGM, 2000, CLIN CHEM LAB MED, V38, P1165, DOI 10.1515/CCLM.2000.179; Jonsson H, 2000, J CARDIOTHOR VASC AN, V14, P698, DOI 10.1053/jcan.2000.18444; Jonsson H, 1999, ANN THORAC SURG, V68, P2202, DOI 10.1016/S0003-4975(99)00851-6; Li Ning, 2004, Chin J Traumatol, V7, P156; Pelinka LE, 2004, SHOCK, V21, P72, DOI 10.1097/01.shk.0000101672.49265.14; Pelinka LE, 2003, BRIT J ANAESTH, V91, P595, DOI 10.1093/bja/aeg225; Pelinka LE, 2003, SHOCK, V19, P195, DOI 10.1097/00024382-200303000-00001; Raabe A, 2000, NEUROSURG REV, V23, P136, DOI 10.1007/PL00011944; Raabe A, 1999, BRIT J NEUROSURG, V13, P56, DOI 10.1080/02688699944195; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Raabe A, 2003, RESTOR NEUROL NEUROS, V21, P159; Rothoerl RD, 1999, BRAIN INJURY, V13, P387; Rothoerl RD, 2000, ACT NEUR S, V76, P97; Sapsed-Byrne S, 1997, PERFUSION-UK, V12, P167, DOI 10.1177/026765919701200304; Savola O, 2003, EUR J NEUROL, V10, P175, DOI 10.1046/j.1468-1331.2003.00552.x; Stranjalis G, 2004, J NEUROTRAUM, V21, P1070, DOI 10.1089/0897715041651088; Townend WJ, 2002, J NEUROL NEUROSUR PS, V73, P542, DOI 10.1136/jnnp.73.5.542; USUI A, 1989, CLIN CHEM, V35, P1942; Woertgen C, 1999, J TRAUMA, V47, P1126, DOI 10.1097/00005373-199912000-00026; Woertgen C, 2002, BRAIN INJURY, V16, P807, DOI 10.1080/02699050210128933	25	77	78	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	FEB	2006	23	2					149	155		10.1089/neu.2006.23.149			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	020HX	WOS:000235900600004	16503799				2021-06-18	
J	Truettner, JS; Alonso, OF; Dietrich, WD				Truettner, JS; Alonso, OF; Dietrich, WD			Influence of therapeutic hypothermia on matrix metal loproteinase activity after traumatic brain injury in rats	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						blood-brain barrier; brain trauma; extracellular matrix; fluid-percussion injury; hypothermia; MMPs; proteolysis	NECROSIS-FACTOR-ALPHA; FOCAL CEREBRAL-ISCHEMIA; CENTRAL-NERVOUS-SYSTEM; GENE KNOCK-OUT; MODERATE HYPOTHERMIA; POSTTRAUMATIC HYPOTHERMIA; INTRACEREBRAL HEMORRHAGE; ENDOTHELIAL-CELLS; GROWTH-FACTOR; METALLOPROTEINASE EXPRESSION	Recent evidence suggests that matrix metal loproteinases (MMPs) contribute to acute edema and lesion formation following ischemic and traumatic brain injuries (TBI). Experimental and clinical studies have also reported the beneficial effects of posttraurnatic hypothermia on histopathological and behavioral outcome. The purpose of this study was to determine whether therapeutic hypothermia would affect the activity of MMPs after TBI. Male Sprague-Dawley rats were traumatized by moderate parasagittal fluid-percussion (F-P) brain injury. Seven groups (n=5/ group) of animals were investigated: sham-operated, TBI with normothermia (37 degrees C), and TBI with hypothermia (33 degrees C). Normothermia animals were killed at 4, 24, 72h and 5 days, and hypothermia animals at 24 or 72 h. Brain temperature was reduced to target temperature 30 mins after trauma and maintained for 4h. lpsilateral and contralateral cortical, hippocampal, and thalamic regions were analyzed by gelatin and in situ zymography. In traumatized normothermic animals, TBI significantly (P<0.005) increased MMP-9 levels in ipsilateral (right) cortical and hippocampal regions, compared with contralateral or sham animals, beginning at 4 h and persisting to 5 days. At 1, 3, and 5 days after TBI, significant increases in MMP-2 levels were observed. In contrast to these findings observed with normothermia, posttraumatic hypothermia significantly reduced MMP-9 levels. Hypothermic treatment, however, did not affect the delayed activation of MMP-2. Clarifying the mechanisms underlying the beneficial effects of posttraumatic hypothermia is an active area of research. Posttraumatic hypothermia may attenuate the deleterious consequences of brain trauma by reducing MMP activation acutely.	Univ Miami, Sch Med, Miami Project Cure Paralysis, Dept Neurol Surg,Neurotrauma Res Ctr, Miami, FL 33101 USA	Dietrich, WD (corresponding author), Univ Miami, Sch Med, Miami Project Cure Paralysis, Dept Neurol Surg,Neurotrauma Res Ctr, POB 016960,R-48, Miami, FL 33101 USA.	ddietrich@miami.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30291, NS42133] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030291, R01NS042133] Funding Source: NIH RePORTER		Asahi M, 2001, J NEUROSCI, V21, P7724; Asahi M, 2001, NEUROREPORT, V12, P3003, DOI 10.1097/00001756-200109170-00050; Asensio VC, 1999, TRENDS NEUROSCI, V22, P504, DOI 10.1016/S0166-2236(99)01453-8; Bradham WS, 2002, CARDIOVASC RES, V53, P822, DOI 10.1016/S0008-6363(01)00503-X; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; Chatzipanteli K, 1999, J NEUROCHEM, V72, P2047, DOI 10.1046/j.1471-4159.1999.0722047.x; Chatzipanteli K, 2000, J CEREBR BLOOD F MET, V20, P531, DOI 10.1097/00004647-200003000-00012; Chen ZL, 1997, CELL, V91, P917, DOI 10.1016/S0092-8674(00)80483-3; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Corbel M, 2001, EUR J PHARMACOL, V426, P113, DOI 10.1016/S0014-2999(01)01209-2; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; del Zoppo GJ, 2003, J CEREBR BLOOD F MET, V23, P879, DOI 10.1097/01.WCB.0000078322.96027.78; DIETRICH WD, 1990, J NEUROPATH EXP NEUR, V49, P486, DOI 10.1097/00005072-199009000-00004; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Dietrich WD, 1996, NEUROTRAUMA, P1491; Ding YH, 2004, NEUROSCI LETT, V372, P35, DOI 10.1016/j.neulet.2004.09.010; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Fowlkes JL, 2002, CYTOKINE GROWTH F R, V13, P277, DOI 10.1016/S1359-6101(02)00005-9; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Gasche Y, 2001, J CEREBR BLOOD F MET, V21, P1393, DOI 10.1097/00004647-200112000-00003; Gasche Y, 1999, J CEREBR BLOOD F MET, V19, P1020, DOI 10.1097/00004647-199909000-00010; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; Gursoy-Ozdemir Y, 2004, J CLIN INVEST, V113, P1447, DOI 10.1172/JCI200421227; Hamann GF, 2004, STROKE, V35, P764, DOI 10.1161/01.STR.0000116866.60794.21; Han HS, 2003, J CEREBR BLOOD F MET, V23, P589, DOI 10.1097/01.WCB.0000059566.39780.8D; Han HS, 2002, J NEUROSCI, V22, P3921, DOI 10.1523/JNEUROSCI.22-10-03921.2002; HANEMAAIJER R, 1993, BIOCHEM J, V296, P803, DOI 10.1042/bj2960803; HAYASHI N, 2004, BRAIN HYPOTHERMIA TR; Horstmann S, 2003, STROKE, V34, P2165, DOI 10.1161/01.STR.0000088062.86084.F2; Jiang H, 2000, T NONFERR METAL SOC, V10, P87; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; Kinoshita K, 2002, J NEUROSURG, V97, P945, DOI 10.3171/jns.2002.97.4.0945; Kinoshita K, 2002, NEUROSURGERY, V51, P195, DOI 10.1097/00006123-200207000-00027; Knittel T, 1999, J HEPATOL, V30, P48, DOI 10.1016/S0168-8278(99)80007-5; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; Lee SR, 2004, J CEREBR BLOOD F MET, V24, P720, DOI 10.1097/01.WCB.0000122747.72175.47; Lee SR, 2004, J NEUROSCI, V24, P671, DOI 10.1523/JNEUROSCI.4243-03.2004; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Levkau B, 2002, CELL DEATH DIFFER, V9, P1360, DOI 10.1038/sj.cdd.4401106; Lo EH, 2002, J NEUROSCI RES, V69, P1, DOI 10.1002/jnr.10270; Lotocki G, 2004, J NEUROSCI, V24, P11010, DOI 10.1523/JNEUROSCI.3823-04.2004; Lukes A, 1999, MOL NEUROBIOL, V19, P267, DOI 10.1007/BF02821717; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Mori T, 2002, J NEUROTRAUM, V19, P1411, DOI 10.1089/089771502320914642; Mun-Bryce S, 1998, J CEREBR BLOOD F MET, V18, P1163, DOI 10.1097/00004647-199811000-00001; Neumar RW, 2003, J BIOL CHEM, V278, P14162, DOI 10.1074/jbc.M212255200; Noble LJ, 2002, J NEUROSCI, V22, P7526; Opdenakker G, 2001, J LEUKOCYTE BIOL, V69, P851; Pagenstecher A, 1998, AM J PATHOL, V152, P729; Parks WC, 2001, RESP RES, V2, P10, DOI 10.1186/rr33; Paxinos G., 1982, RAT BRAIN STEREOTAXI; Polderman KH, 2002, INTENS CARE MED, V28, P1563, DOI 10.1007/s00134-002-1511-3; Power C, 2003, ANN NEUROL, V53, P731, DOI 10.1002/ana.10553; Rajagopalan S, 1996, J CLIN INVEST, V98, P2572, DOI 10.1172/JCI119076; RESNICK DK, 1994, NEUROSURGERY, V34, P252, DOI 10.1227/00006123-199402000-00007; Romanic AM, 1998, STROKE, V29, P1020, DOI 10.1161/01.STR.29.5.1020; Rosenberg GA, 1996, J CEREBR BLOOD F MET, V16, P360, DOI 10.1097/00004647-199605000-00002; Rosenberg GA, 2002, GLIA, V39, P279, DOI 10.1002/glia.10108; Rosenberg GA, 1997, NEUROLOGY, V48, P921, DOI 10.1212/WNL.48.4.921; ROSENBERG GA, 1995, J NEUROTRAUM, V12, P833, DOI 10.1089/neu.1995.12.833; ROSENBERG GA, 1992, BRAIN RES, V576, P203, DOI 10.1016/0006-8993(92)90681-X; Rosenberg GA, 2001, BRAIN RES, V893, P104, DOI 10.1016/S0006-8993(00)03294-7; Rosenberg GA, 1998, STROKE, V29, P2189, DOI 10.1161/01.STR.29.10.2189; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Smith SL, 1996, J NEUROTRAUM, V13, P1, DOI 10.1089/neu.1996.13.1; Suehiro E, 2004, J NEUROTRAUM, V21, P1706, DOI 10.1089/0897715042664957; Sumii T, 2002, STROKE, V33, P831, DOI 10.1161/hs0302.104542; Sutcliffe IT, 2001, J CEREBR BLOOD F MET, V21, P1310, DOI 10.1097/00004647-200111000-00007; Suzuki T, 2003, EXP NEUROL, V184, P1017, DOI 10.1016/S0014-4886(03)00389-3; Szklarczyk A, 2002, J NEUROSCI, V22, P920, DOI 10.1523/JNEUROSCI.22-03-00920.2002; Tang S, 2004, CHINESE J ORG CHEM, V24, P1133; Vitarbo EA, 2004, NEUROSURGERY, V55, P416, DOI 10.1227/01.NEU.0000130036.52521.2C; von Gertten C, 2003, J NEUROSCI RES, V73, P803, DOI 10.1002/jnr.10729; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Wells JEA, 2003, J NEUROSCI, V23, P10107, DOI 10.1523/jneurosci.23-31-10107.2003; Winkler MK, 2002, AM J PHYSIOL-LUNG C, V283, pL1, DOI 10.1152/ajplung.00489.2001; Yong VW, 2001, NAT REV NEUROSCI, V2, P502, DOI 10.1038/35081571; Yong VW, 1998, TRENDS NEUROSCI, V21, P75; Zalewska T, 2003, BRAIN RES, V977, P62, DOI 10.1016/S0006-8993(03)02742-2; Zalewska T, 2002, ACTA NEUROBIOL EXP, V62, P53	85	77	81	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	NOV	2005	25	11					1505	1516		10.1038/sj.jcbfm.9600150			12	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	977PF	WOS:000232815000010	15959464	Bronze			2021-06-18	
J	Jorge, RE; Starkstein, SE; Arndt, S; Moser, D; Crespo-Facorro, B; Robinson, RG				Jorge, RE; Starkstein, SE; Arndt, S; Moser, D; Crespo-Facorro, B; Robinson, RG			Alcohol misuse and mood disorders following traumatic brain injury	ARCHIVES OF GENERAL PSYCHIATRY			English	Article							STRUCTURED CLINICAL INTERVIEW; SEROTONIN TRANSPORTER; ANTERIOR CINGULATE; SUBSTANCE-ABUSE; PREFRONTAL CORTEX; ACUTE PREDICTORS; DRUG-ADDICTION; FRONTAL-CORTEX; POLYMORPHISMS; DEPRESSION	Context: Alcohol abuse and/or dependence (AA/D) and mood disturbance are co-occurring conditions among patients who have had a traumatic brain injury (TBI). However, the relationship between these disorders has not been extensively studied. Objective: To examine the relationship of AA/D and post-TBI mood disorders and the effect of these conditions on psychosocial outcome. Design: Prospective, case-control surveillance study conducted during the first year following trauma. Settings: University hospital level I trauma centers and specialized rehabilitation units. Patients: One hundred fifty-eight TBI patients with closed head injury with and without a history of AA/D. Methods: We prospectively compared psychiatric, neuropsychological, and psychosocial outcomes among the patients, who were evaluated at baseline and at 3, 6, and 12 months after trauma. Psychiatric diagnosis was made using a structured clinical interview and DSM-IV criteria. Neuropsychological testing results and quantitative magnetic resonance images were obtained at the 3-month follow-up. Results: A history of AA/D was significantly more frequent among patients who developed mood disorders during the first year following TBI. There was also a significantly higher frequency of mood disorders among patients with alcohol abuse relapse. Patients with a history of AA/D had significantly reduced frontal gray matter volumes than did patients without a history of alcohol abuse. in addition, patients who resumed alcohol abuse had decreased medial frontal gray matter volumes and impaired performance in executive tasks. Both AA/D and mood disorders following TBI were associated with a poor vocational outcome. Conclusions: Previous alcohol abuse increases the risk of developing mood disorders after TBI, and emotional disturbance, in turn, increases the risk of alcohol abuse relapse. Alcohol's neurotoxic effects and TBI likely interact to produce greater disruption of the neural circuits that modulate reward, mood, and executive function. Patients with a history of AA/D who also developed mood disorders following TBI had major difficulties resuming a productive life.	Univ Iowa, Dept Psychiat, Iowa City, IA 52242 USA; Univ Western Australia, Sch Psychiat & Clin Neurosci, Perth, WA 6009, Australia	Jorge, RE (corresponding author), 500 Newton Rd, Iowa City, IA 52242 USA.	ricardo-jorge@uiowa.edu	Arndt, Stephan/A-6976-2013; Robinson, Robert/AAF-6191-2021	Arndt, Stephan/0000-0003-0783-8204; Moser, David/0000-0003-4102-5266; , BENEDICTO/0000-0003-0033-7132	NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH-53592, MH-40355, MH-52879] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH052879, R01MH053592, R01MH040355] Funding Source: NIH RePORTER		Anderson SW, 2000, DEV NEUROPSYCHOL, V18, P281, DOI 10.1207/S1532694202Anderson; ANDREASEN NC, 1994, P NATL ACAD SCI USA, V91, P93, DOI 10.1073/pnas.91.1.93; ANDREASEN NC, 1992, J NEUROPSYCH CLIN N, V4, P125; Andreasen NC, 1996, J COMPUT ASSIST TOMO, V20, P98, DOI 10.1097/00004728-199601000-00018; ANDREASEN NC, 1993, J NEUROPSYCH CLIN N, V5, P121; ANDREASEN NC, 1977, ARCH GEN PSYCHIAT, V34, P1229; Bechara A, 2000, CEREB CORTEX, V10, P295, DOI 10.1093/cercor/10.3.295; Benton A., 1994, MULTILINGUAL APHASIA; Berns GS, 1997, SCIENCE, V276, P1272, DOI 10.1126/science.276.5316.1272; Bombardier CH, 2003, ARCH PHYS MED REHAB, V84, P185, DOI 10.1053/apmr.2003.50002; Bombardier CH, 2002, ARCH PHYS MED REHAB, V83, P1765, DOI 10.1053/apmr.2002.36085; Caspi A, 2003, SCIENCE, V301, P386, DOI 10.1126/science.1083968; Cherner M, 2001, ARCH PHYS MED REHAB, V82, P780, DOI 10.1053/apmr.2001.23263; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; COHEN G, 1992, PSYCHIAT RES-NEUROIM, V45, P33, DOI 10.1016/0925-4927(92)90012-S; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; Crespo-Facorro B, 1999, NEUROIMAGE, V10, P500, DOI 10.1006/nimg.1999.0489; Davidson RJ, 2002, BIOL PSYCHIAT, V51, P68, DOI 10.1016/S0006-3223(01)01328-2; Davidson RJ, 2003, AM J PSYCHIAT, V160, P64, DOI 10.1176/appi.ajp.160.1.64; Davidson RJ, 2002, BIOL PSYCHIAT, V52, P478, DOI 10.1016/S0006-3223(02)01458-0; Dawson DR, 2004, BRAIN INJURY, V18, P221, DOI 10.1080/02699050310001617406; DERENZI E, 1962, BRAIN, V85, P665, DOI 10.1093/brain/85.4.665; DIKMEN SS, 1995, ANN EMERG MED, V26, P167, DOI 10.1016/S0196-0644(95)70147-8; Donnemiller E, 2000, EUR J NUCL MED, V27, P1410, DOI 10.1007/s002590000308; Drevets WC, 2001, CURR OPIN NEUROBIOL, V11, P240, DOI 10.1016/S0959-4388(00)00203-8; Drevets WC, 2002, EUR NEUROPSYCHOPHARM, V12, P527, DOI 10.1016/S0924-977X(02)00102-5; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gerra G, 2004, AM J MED GENET B, V126B, P37, DOI 10.1002/ajmg.b.20111; Gilman S, 1998, ANN NEUROL, V44, P326, DOI 10.1002/ana.410440307; Golden C., 1978, STROOP COLOR WORD TE; Goldstein RZ, 2002, AM J PSYCHIAT, V159, P1642, DOI 10.1176/appi.ajp.159.10.1642; Gorwood P, 2000, BIOL PSYCHIAT, V48, P259, DOI 10.1016/S0006-3223(00)00840-4; Greenspan AI, 1996, BRAIN INJURY, V10, P207, DOI 10.1080/026990596124520; Harris G, 1999, J COMPUT ASSIST TOMO, V23, P144, DOI 10.1097/00004728-199901000-00030; Heaton R., 1993, WISCONSIN CARD SORTI; Heinz A, 2003, MOL PSYCHIATR, V8, P231, DOI 10.1038/sj.mp.4001214; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hill EM, 2002, PSYCHIAT GENET, V12, P143, DOI 10.1097/00041444-200209000-00005; Hinson JM, 2002, COGN AFFECT BEHAV NE, V2, P341, DOI 10.3758/CABN.2.4.341; Johnson PA, 2003, J NEUROPSYCH CLIN N, V15, P397, DOI 10.1176/appi.neuropsych.15.4.397; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kaplan E., 1983, BOSTON NAMING TEST; KAUFMAN AS, 1999, ESSENTIALS WAIS 3 AS, V8; Kerns JG, 2004, SCIENCE, V303, P1023, DOI 10.1126/science.1089910; Kolakowsky-Hayner S, 2002, BRAIN INJURY, V16, P583, DOI 10.1080/02699050110119475; Kolakowsky-Hayner SA, 1999, BRAIN INJURY, V13, P571; Kreutzer JS, 1996, J LEARN DISABIL, V29, P643, DOI 10.1177/002221949602900608; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; Lakatos K, 2003, MOL PSYCHIATR, V8, P90, DOI 10.1038/sj.mp.4001212; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; Lezak M.D., 1983, NEUROPSYCHOLOGICAL A; Magnotta VA, 1999, RADIOLOGY, V211, P781, DOI 10.1148/radiology.211.3.r99ma07781; Magnotta VA, 1999, CEREB CORTEX, V9, P151, DOI 10.1093/cercor/9.2.151; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; Morgan D, 2002, NAT NEUROSCI, V5, P169, DOI 10.1038/nn798; Patkar AA, 2002, PSYCHIAT RES, V110, P103, DOI 10.1016/S0165-1781(02)00098-7; Peoples LL, 2002, SCIENCE, V296, P1623, DOI 10.1126/science.1072997; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; REITAN RM, 1971, PERCEPT MOTOR SKILL, V33, P575, DOI 10.2466/pms.1971.33.2.575; Ridderinkhof KR, 2002, SCIENCE, V298, P2209, DOI 10.1126/science.1076929; ROBINSON RG, 1981, ANN NEUROL, V9, P447, DOI 10.1002/ana.410090506; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P138, DOI 10.1016/S0003-9993(97)90254-9; Shidara M, 2002, SCIENCE, V296, P1709, DOI 10.1126/science.1069504; SPITZER RL, 1992, ARCH GEN PSYCHIAT, V49, P624; Starr L B, 1982, Soc Work Res Abstr, V18, P28; STARR LB, 1983, EXP AGING RES, V9, P101, DOI 10.1080/03610738308258434; Szabo Z, 2004, BIOL PSYCHIAT, V55, P766, DOI 10.1016/j.biopsych.2003.11.023; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; Turner AP, 2003, ARCH PHYS MED REHAB, V84, P358, DOI 10.1053/apmr.2003.50107; Volkow ND, 2002, NEUROBIOL LEARN MEM, V78, P610, DOI 10.1006/nlme.2002.4099; Volkow ND, 2003, J CLIN INVEST, V111, P1444, DOI 10.1172/JCI200318533; Wager TD, 2004, SCIENCE, V303, P1162, DOI 10.1126/science.1093065; Wagner AK, 2002, ARCH PHYS MED REHAB, V83, P107, DOI 10.1053/apmr.2002.27470; Wilde EA, 2004, J NEUROTRAUM, V21, P137, DOI 10.1089/089771504322778604; WILLIAMS JBW, 1992, ARCH GEN PSYCHIAT, V49, P630; WING JK, 1990, ARCH GEN PSYCHIAT, V47, P589; Yan HQ, 2002, NEUROREPORT, V13, P1899, DOI 10.1097/00001756-200210280-00013	80	77	79	0	13	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0003-990X	1538-3636		ARCH GEN PSYCHIAT	Arch. Gen. Psychiatry	JUL	2005	62	7					742	749		10.1001/archpsyc.62.7.742			8	Psychiatry	Psychiatry	943KJ	WOS:000230352100007	15997015	Bronze			2021-06-18	
J	Killam, C; Cautin, RL; Santucci, AC				Killam, C; Cautin, RL; Santucci, AC			Assessing the enduring residual neuropsychological effects of head trauma in college athletes who participate in contact sports	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						concussion; memory; Postconcussion Syndrome Checklist; processing speed; Repeatable Battery for the Assessment of Neuropsychological Status; stroop task	MILD BRAIN INJURY; REPEATABLE BATTERY; POSTCONCUSSION SYMPTOMS; FOOTBALL PLAYERS; HIGH-SCHOOL; CONCUSSION; RECOVERY; VALIDITY; SCHIZOPHRENIA; IMPAIRMENT	The present study examined the enduring residual neuropsychological effects of head trauma in college athletes using the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), Postconcussion Syndrome Checklist, and the Stroop task. Based on a brief self-report concussion history survey, male and female athletes who participated in ice hockey, field hockey, lacrosse, and/or soccer were assigned to one of three concussion-history conditions: Non-concussed, Non-recent concussed (i.e., more than 2 years since last concussion), or Recent concussed (i.e., 2 years or less since last concussion). A fourth group of subjects consisting of non-concussed/non-athletes served in the control condition. Group differences emerged on the RBANS when immediate memory, delayed memory, and total scores were analyzed. Specifically, recent concussed athletes and, surprisingly, non-concussed athletes scored lower than control subjects in the two memory domains, whereas all three athlete groups had lower total RBANS scores than those of control subjects. Moreover, recent concussed athletes not only had lower immediate memory scores than control subjects, but also were impaired relative to non-recent concussed athlete subjects in this memory domain. No group differences were detected on the Stroop task or on the Postconcussion Syndrome Checklist. Interestingly, however, the severity of the Postconcussion Syndrome Checklist scores for the two athlete-concussed groups, taken in aggregate, correlated negatively with RBANS scores for attention (r= -.65) and delayed memory (r= -.61), and with the total RBANS score (r = -.59). In recent concussed athletes, lower in contact sports may produce sub-clinical cognitive impairments in the absence of a diagnosable concussion presumably resulting from the cumulative consequences produced by multiple mild head trauma delayed memory scores correlated with more severe Postconcussion Symptom Checklist scores (r = -.90), while more severe/higher number of concussions correlated with increased processing speed on the Stroop interference task (r =.90). These findings indicate that recent head injury produces alterations in neuropsychological function, especially that of memory, that resolve with time. More provocatively, the data also suggest that participation in contact sports may produce sub-clinical cognitive impairments in the absence of a diagnosable concussion presumably resulting from the cumulative consequences produced by multiple mild head trauma. (c) 2005 National Academy of Neuropsychology. Published by Elsevier Ltd. All rights reserved.	Manhattanville Coll, Dept Psychol, Purchase, NY 10577 USA	Santucci, AC (corresponding author), Manhattanville Coll, Dept Psychol, 2900 Purchase St, Purchase, NY 10577 USA.	santuccia@mville.edu					*AM AC NEUR, 1997, PRACT PAR MAN CONC S; Beatty WW, 2003, ARCH CLIN NEUROPSYCH, V18, P509, DOI 10.1016/S0887-6177(02)00148-8; BIRDSONG WH, 1992, J OCCUP ENVIRON MED, V34, P940; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Echemendia RJ, 2003, APPL NEUROPSYCHOL, V10, P48, DOI 10.1207/S15324826AN1001_7; EWING R, 1980, Journal of Clinical Neuropsychology, V2, P147, DOI 10.1080/01688638008403789; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gold JM, 1999, AM J PSYCHIAT, V156, P1944; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Hinton-Bayre AD, 2002, NEUROLOGY, V59, P1068, DOI 10.1212/WNL.59.7.1068; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Liberman JN, 2002, NEUROLOGY, V58, P1038, DOI 10.1212/WNL.58.7.1038; Machulda MM, 1998, ARCH CLIN NEUROPSYCH, V13, P415, DOI 10.1016/S0887-6177(97)00031-0; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McKeever CK, 2003, APPL NEUROPSYCHOL, V10, P4, DOI 10.1207/S15324826AN1001_2; Moser RS, 2002, ARCH CLIN NEUROPSYCH, V17, P91, DOI 10.1016/S0887-6177(01)00108-1; Randolph C, 1998, J CLIN EXP NEUROPSYC, V20, P310, DOI 10.1076/jcen.20.3.310.823; Randolph C, 1998, REPEATABLE BATTERY A; Rutherford A, 2003, NEUROPSYCHOL REV, V13, P153, DOI 10.1023/A:1025525613477; Sawchyn JM, 2000, ARCH CLIN NEUROPSYCH, V15, P1, DOI 10.1016/S0887-6177(98)00041-9; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Tang YP, 1997, J NEUROTRAUM, V14, P851, DOI 10.1089/neu.1997.14.851; Trahan DE, 2001, ARCH CLIN NEUROPSYCH, V16, P435, DOI 10.1016/S0887-6177(00)00051-2; Wilk CM, 2002, AM J PSYCHIAT, V159, P838, DOI 10.1176/appi.ajp.159.5.838; ZHOU YL, 1995, PHYSIOL BEHAV, V57, P1107, DOI 10.1016/0031-9384(95)00019-F	31	77	78	0	16	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	JUL	2005	20	5					599	611		10.1016/j.acn.2005.02.001			13	Psychology, Clinical; Psychology	Psychology	942EY	WOS:000230266900004	15939185	Bronze			2021-06-18	
J	Kraus, MF; Smith, GS; Butters, M; Donnell, AJ; Dixon, E; Yilong, C; Marion, D				Kraus, MF; Smith, GS; Butters, M; Donnell, AJ; Dixon, E; Yilong, C; Marion, D			Effects of the dopaminergic agent and NMDA receptor antagonist amantadine on cognitive function, cerebral glucose metabolism and D2 receptor availability in chronic traumatic brain injury: A study using positron emission tomography (PET)	BRAIN INJURY			English	Article; Proceedings Paper	9th Annual Meeting of the Organization-for-Human-Brain-Mapping	JUN 18-22, 2003	New York, NY	Org Human Brain Mapping		amantadine; traumatic brain injury; frontal lobes; executive function; positron emission tomography; dopamine	PREFRONTAL CORTEX; MILD; MEMANTINE; PERFUSION; RELEASE	Primary objective: This study was performed to assess effects of amantadine (AMH), a dopaminergic agent and NMDA antagonist, on chronic traumatic brain injury (TBI). The primary hypotheses were that amantadine treatment would result in executive function improvement and increased activity in pre-frontal cortex. Research design: An open-label design was used. Methods: Twenty-two subjects underwent neuropsychological testing pre- and post-12 week treatment. Six subjects also underwent PET scanning. Intervention: Amantadine 400 mg was administered per day. Results: Significant improvements on tests of executive function were observed with treatment. Analysis of PET data demonstrated a significant increase in left pre- frontal cortex glucose metabolism. There was a significant positive correlation between executive domain scores and left pre- frontal glucose metabolism. Conclusions: This is the first known study to assess amantadine in chronic TBI using PET and the data are consistent with the hypotheses. The conduction of further studies is warranted.	Univ Illinois, Dept Psychiat, Ctr Cognit Med, Chicago, IL 60612 USA; N Shore Long Isl Jewish Hlth Syst, Zucker Hillside Hosp, New York, NY USA; N Shore Long Isl Jewish Hlth Syst, Ctr Neurosci, N Shore Long Isl Jewish Res Inst, New York, NY USA; Univ Pittsburgh, Med Ctr, Dept Psychiat, Pittsburgh, PA USA; Univ Pittsburgh, Med Ctr, Dept Neurosurg, Pittsburgh, PA USA; Boston Univ, Med Ctr, Dept Neurol Surg, Boston, MA USA	Kraus, MF (corresponding author), Univ Illinois, Dept Psychiat, Ctr Cognit Med, 912 S Wood St,Suite 235,MC 913, Chicago, IL 60612 USA.	mkraus@psych.uic.edu	Butters, Meryl/AAR-2863-2021		PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [100849] Funding Source: Medline		Abdel-Dayem HM, 1998, CLIN NUCL MED, V23, P309, DOI 10.1097/00003072-199805000-00009; Abu-Judeh HH, 1998, J NUCL MED, V39, P1357; ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; Andersson Stein, 1992, Tidsskrift for den Norske Laegeforening, V112, P2070; AOKI FY, 1988, CLIN PHARMACOKINET, V14, P35, DOI 10.2165/00003088-198814010-00003; Baldo JV, 2001, J INT NEUROPSYCH SOC, V7, P586, DOI 10.1017/S1355617701755063; Benton A., 1994, MULTILINGUAL APHASIA; Benton A. L., 1994, CONTRIBUTIONS NEUROP; Blanpied TA, 1997, J NEUROPHYSIOL, V77, P309; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; CHUGANI HT, 1991, J NUCL MED, V32, P23; Conners C., 2000, CONNERS CONTINUOUS P; Deep P, 1999, SYNAPSE, V34, P313, DOI 10.1002/(SICI)1098-2396(19991215)34:4<313::AID-SYN7>3.0.CO;2-1; Delis DC, 2000, CALIFORNIA VERBAL LE; Dixon CE, 1999, RESTOR NEUROL NEUROS, V14, P285; Donnemiller E, 2000, EUR J NUCL MED, V27, P1410, DOI 10.1007/s002590000308; Eker C, 2000, BRAIN INJURY, V14, P605; FRISTON KJ, 1995, J CEREBR BLOOD F MET, V15, P361, DOI 10.1038/jcbfm.1995.45; GIANUTSOS G, 1985, EUR J PHARMACOL, V110, P357, DOI 10.1016/0014-2999(85)90564-3; GOLDMAN PS, 1971, EXP NEUROL, V32, P366, DOI 10.1016/0014-4886(71)90005-7; Gronwall D, 1989, MILD HEAD INJURY, P153; Gross H, 1996, J NEUROPSYCH CLIN N, V8, P324; GUALTIERI T, 1989, CLIN NEUROPHARMACOL, V12, P258, DOI 10.1097/00002826-198908000-00003; HAMILL RW, 1987, ANN NEUROL, V21, P438, DOI 10.1002/ana.410210504; HERRMANN EC, 1960, P SOC EXP BIOL MED, V103, P625; Hesselink MB, 1999, J NEURAL TRANSM, V106, P803, DOI 10.1007/s007020050201; Hoofien D, 2001, BRAIN INJURY, V15, P189; Kegeles LS, 2002, SYNAPSE, V43, P19, DOI 10.1002/syn.10010; KRAUS JF, 1998, REHABILITATION ADULT, P3; Kraus MF, 1997, J NEUROPSYCH CLIN N, V9, P222; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; Logan J, 2001, J CEREBR BLOOD F MET, V21, P307, DOI 10.1097/00004647-200103000-00014; MCINTOSH TK, 1994, J NEUROCHEM, V63, P1426; Moresco RM, 2002, J NEURAL TRANSM, V109, P1265, DOI 10.1007/s00702-002-0694-7; NICKELS JL, 1994, BRAIN INJURY, V8, P709, DOI 10.3109/02699059409151025; Passler MA, 1985, DEV NEUROPSYCHOL, V1, P349, DOI 10.1080/87565648509540320; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; SCHWAB RS, 1969, J AMER MED ASSOC, V208, P1168, DOI 10.1001/jama.208.7.1168; Smith GS, 1998, NEUROPSYCHOPHARMACOL, V18, P18; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; *WAR DEP, 1944, ARM IND TEST BATT; Winblad B, 1999, INT J GERIATR PSYCH, V14, P135, DOI 10.1002/(SICI)1099-1166(199902)14:2<135::AID-GPS906>3.0.CO;2-0; Yan HQ, 2001, NEUROREPORT, V12, P2323, DOI 10.1097/00001756-200108080-00009	45	77	81	0	6	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUL	2005	19	7					471	479		10.1080/02699050400025059			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	933IQ	WOS:000229622500001	16134735				2021-06-18	
J	Craft, JM; Watterson, DM; Frautschy, SA; Van Eldik, LJ				Craft, JM; Watterson, DM; Frautschy, SA; Van Eldik, LJ			Aminopyridazines inhibit beta-amyloid-induced glial activation and neuronal damage in vivo	NEUROBIOLOGY OF AGING			English	Article						Alzheimer's disease; neuroinflammation; glia; drug discovery; animal model; aminopyridazine; amyloid; hippocampus	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CEREBROSPINAL-FLUID S100B; TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; PROTEIN; INFLAMMATION; INTERLEUKIN-1; DISCOVERY; NEUROPATHOLOGY; HEPATOTOXICITY	The critical role of chronic inflammation in disease progression continues to be increasingly appreciated across multiple disease areas, especially in neurodegenerative disorders such as Alzheimer's disease. We report that late intervention with a recently discovered aminopyridazine suppressor of glial activation, developed to inhibit both oxidative and inflammatory cytokine pathways, attenuates human amyloid beta (Abeta)-induced glial activation in a murine model. Peripheral administration of the aminopyridazine MW01-070C, beginning 3 weeks after the start of intracerebroventricular infusion of human Abeta 1-42, decreased the number of activated astrocytes and microglia and the levels of proinflammatory cytokines interleukin-1beta, tumor necrosis factor-a and S 10013 in the hippocampus. Inhibition of neuroinflammation correlated with a decreased neuron loss, restoration towards control levels of synaptic dysfunction biomarkers in the hippocampus, and diminished amyloid plaque deposition. The results from this in vivo chemical biology approach provide a proof of concept that targeting of key glia inflammatory cytokine pathways can suppress Abeta-induced neuroinflammation in vivo, with resultant attenuation of neuronal damage. (C) 2004 Elsevier Inc. All rights reserved.	Northwestern Univ, Feinberg Sch Med, Drug Discovery Program, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Dept Mol Pharmacol, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Dept Biol Chem, Chicago, IL 60611 USA; Univ Calif Los Angeles, Dept Med, VAGLAHS Sepulveda GRECC, North Hills, CA USA; Univ Calif Los Angeles, Dept Neurol, North Hills, CA USA	Van Eldik, LJ (corresponding author), Northwestern Univ, Feinberg Sch Med, Drug Discovery Program, Chicago, IL 60611 USA.	vaneldik@northwestern.edu		Frautschy, Sally A./0000-0003-0194-0363; Watterson, Daniel/0000-0001-7605-5866	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R25GM067071] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS047586] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG010685, R37AG013939, T32AG000260, U01AG028583, R01AG020243, R01AG013939, P50AG016570, P01AG021184] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG20243, AG21184, T32 AG00260, U01 AG028583, P01 AG021184, AG13939, P50 AG016570, AG10685, R01 AG010685] Funding Source: Medline; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R25 GM067071] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS47586] Funding Source: Medline		Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Chitturi S, 2002, SEMIN LIVER DIS, V22, P169, DOI 10.1055/s-2002-30102; Choi DW, 2002, NAT NEUROSCI, V5, P1023, DOI 10.1038/nn930; Dahlgren KN, 2002, J BIOL CHEM, V277, P32046, DOI 10.1074/jbc.M201750200; Ehl C, 2003, INT J MOL MED, V11, P235; Feinklestein SP, 1999, STROKE, V30, P2752, DOI 10.1161/01.STR.30.12.2752; Frautschy SA, 2001, NEUROBIOL AGING, V22, P993, DOI 10.1016/S0197-4580(01)00300-1; Frautschy SA, 1996, NEUROBIOL AGING, V17, P311, DOI 10.1016/0197-4580(95)02073-X; Griffin WST, 1998, BRAIN PATHOL, V8, P65; Jantzen PT, 2002, J NEUROSCI, V22, P2246, DOI 10.1523/JNEUROSCI.22-06-02246.2002; Launer LJ, 2003, JAMA-J AM MED ASSOC, V289, P2865, DOI 10.1001/jama.289.21.2865; Lee WM, 2003, NEW ENGL J MED, V349, P474, DOI 10.1056/NEJMra021844; Li YK, 2003, J NEUROSCI, V23, P1605; Lim GP, 2000, J NEUROSCI, V20, P5709; Manley PW, 2002, EXPERT OPIN INV DRUG, V11, P1715, DOI 10.1517/13543784.11.12.1715; Migaud M, 1998, NATURE, V396, P433; Mirzoeva S, 1999, BRAIN RES, V844, P126, DOI 10.1016/S0006-8993(99)01911-3; Mirzoeva S, 2002, J MED CHEM, V45, P563, DOI 10.1021/jm015573g; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Mrak RE, 2001, NEUROBIOL AGING, V22, P915, DOI 10.1016/S0197-4580(01)00293-7; Mrak RE, 2001, NEUROBIOL AGING, V22, P903, DOI 10.1016/S0197-4580(01)00287-1; Nathan C, 2002, NATURE, V420, P846, DOI 10.1038/nature01320; Orr CF, 2002, PROG NEUROBIOL, V68, P325, DOI 10.1016/S0301-0082(02)00127-2; Pasinetti GM, 2002, J ALZHEIMERS DIS, V4, P435, DOI 10.3233/JAD-2002-4510; Peskind ER, 2001, NEUROCHEM INT, V39, P409, DOI 10.1016/S0197-0186(01)00048-1; Petzold A, 2003, NEUROSCI LETT, V336, P167, DOI 10.1016/S0304-3940(02)01257-0; Rogers JT, 1999, J BIOL CHEM, V274, P6421, DOI 10.1074/jbc.274.10.6421; Schlaf G, 1998, J IMMUNOL METHODS, V213, P191, DOI 10.1016/S0022-1759(98)00027-1; Scorer CA, 2001, DRUG DISCOV TODAY, V6, P1207, DOI 10.1016/S1359-6446(01)02042-6; Spinella PC, 2003, CRIT CARE MED, V31, P939, DOI 10.1097/01.CCM.0000053644.16336.52; Van Eldik LJ, 2003, RESTOR NEUROL NEUROS, V21, P97; VANELDIK LJ, 1994, BBA-MOL CELL RES, V1223, P398, DOI 10.1016/0167-4889(94)90101-5; Velentza AV, 2003, BIOORG MED CHEM LETT, V13, P3465, DOI 10.1016/S0960-894X(03)00733-9; Wainwright MS, 2003, P NATL ACAD SCI USA, V100, P6233, DOI 10.1073/pnas.1031595100; Watterson DM, 2002, J MOL NEUROSCI, V19, P89, DOI 10.1007/s12031-002-0016-4; Wermuth CG, 1998, J HETEROCYCLIC CHEM, V35, P1091, DOI 10.1002/jhet.5570350508	36	77	81	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0197-4580	1558-1497		NEUROBIOL AGING	Neurobiol. Aging	NOV-DEC	2004	25	10					1283	1292		10.1016/j.neurobiolaging.2004.01.006			10	Geriatrics & Gerontology; Neurosciences	Geriatrics & Gerontology; Neurosciences & Neurology	864UY	WOS:000224659600003	15465624				2021-06-18	
J	Scheuer, ML; Wilson, SB				Scheuer, ML; Wilson, SB			Data analysis for continuous EEG monitoring in the ICU: Seeing the forest and the trees	JOURNAL OF CLINICAL NEUROPHYSIOLOGY			English	Article						electroencephalography; continuous; quantitative; ICU; seizure; detection	INTENSIVE-CARE-UNIT; NONCONVULSIVE STATUS EPILEPTICUS; CEREBRAL FUNCTION MONITOR; TRAUMATIC BRAIN-INJURY; SEIZURE DETECTION; BISPECTRAL ANALYSIS; CRITICALLY-ILL; NEURAL-NETWORK; ANESTHESIA; DEVICE	Continuous EEG monitoring (CEEG) is a powerful tool for evaluating cerebral function in obtunded and comatose critically ill patients. The ongoing analysis of CEEG data is a major task because of the volume of data generated during monitoring and the need for near real-time interpretation of a patient's EEG patterns. Advances in digital EEG data acquisition, computer processing, data transmission, and data display have made CEEG monitoring in the intensive care unit technically feasible. A variety of quantitative EEG tools such as Fourier analysis and amplitude-integrated EEG, and other methods of data analysis Such as computerized seizure detection, increasingly allow for focused review of EEG epochs of potential interest. These tools reduce the tremendous time burdens that accompany analysis of the complete CEEG data stream, and allow bedside personnel and nonexpert staff to potentially recognize significant EEG changes in a timely fashion. This article uses literature review and clinical case examples to illustrate techniques for the display and analysis of intensive care unit CEEG recordings. Areas requiring further research and development are discussed.	Persyst Dev Corp, Prescott, AZ USA; Univ Pittsburgh, Epilepsy Ctr, Pittsburgh, PA USA	Scheuer, ML (corresponding author), Dept Neurol, Suite 811,Kaufmann Med Bldg,3471 5th Ave, Pittsburgh, PA 15213 USA.	scheuer@pitt.edu					Bruhn J, 2000, J Clin Monit Comput, V16, P593, DOI 10.1023/A:1012216600170; Bullock TH, 1997, ELECTROEN CLIN NEURO, V103, P661, DOI 10.1016/S0013-4694(97)00087-4; Claassen J, 2004, NEUROLOGY, V62, P1743, DOI 10.1212/01.WNL.0000125184.88797.62; CLAASSEN J, IN PRESS CLIN NEUROP; DeLorenzo RJ, 1998, EPILEPSIA, V39, P833, DOI 10.1111/j.1528-1157.1998.tb01177.x; Epstein CM, 2003, CLIN NEUROPHYSIOL, V114, P1974, DOI 10.1016/S1388-2457(03)00168-8; Gabor AJ, 1998, ELECTROEN CLIN NEURO, V107, P27, DOI 10.1016/S0013-4694(98)00043-1; Hagihira S, 2001, ANESTH ANALG, V93, P966, DOI 10.1097/00000539-200110000-00032; Hirsch LJ, 2004, EPILEPSIA, V45, P109, DOI 10.1111/j.0013-9580.2004.38103.x; Jeleazcov C, 2003, BIOMED TECH, V48, P269, DOI 10.1515/bmte.2003.48.10.269; Jordan KG, 1999, J CLIN NEUROPHYSIOL, V16, P14, DOI 10.1097/00004691-199901000-00002; Jordan KG, 1999, J CLIN NEUROPHYSIOL, V16, P332, DOI 10.1097/00004691-199907000-00005; Leistritz L, 1999, J CLIN MONIT COMPUT, V15, P357, DOI 10.1023/A:1009990629797; MAYNARD D, 1969, ELECTROEN CLIN NEURO, V27, P672; MAYNARD D, 1969, BRIT MED J, V4, P545, DOI 10.1136/bmj.4.5682.545-a; MAYNARD DE, 1984, ANAESTHESIA, V39, P678, DOI 10.1111/j.1365-2044.1984.tb06477.x; Miller A, 2004, BRIT J ANAESTH, V92, P8, DOI 10.1093/bja/aeh003; Nikias C. L., 1993, HIGHER ORDER SPECTRA; NING T, 1993, IEEE T BIO-MED ENG, V40, P870, DOI 10.1109/10.245607; Ortolani O, 2002, BRIT J ANAESTH, V88, P644, DOI 10.1093/bja/88.5.644; PAURI F, 1992, ELECTROEN CLIN NEURO, V82, P1, DOI 10.1016/0013-4694(92)90175-H; Procaccio F, 2001, Curr Opin Crit Care, V7, P74, DOI 10.1097/00075198-200104000-00004; Rampil IJ, 1998, ANESTHESIOLOGY, V89, P980, DOI 10.1097/00000542-199810000-00023; Rennie JM, 2004, ARCH DIS CHILD-FETAL, V89, pF37, DOI 10.1136/fn.89.1.F37; Salinsky MC, 1997, ELECTROEN CLIN NEURO, V103, P445, DOI 10.1016/S0013-4694(97)00025-4; Sarkela Mika, 2002, J Clin Monit Comput, V17, P125, DOI 10.1023/A:1016393904439; Scheuer ML, 2002, EPILEPSIA, V43, P114, DOI 10.1046/j.1528-1157.43.s.3.7.x; SEBEL PS, 1983, BRIT J ANAESTH, V55, P1265, DOI 10.1093/bja/55.12.1265; Sleigh JW, 2001, BRIT J ANAESTH, V86, P50, DOI 10.1093/bja/86.1.50; Takeichi T, 2002, CLIN TRANSPLANT, V16, P273, DOI 10.1034/j.1399-0012.2002.01138.x; ter Horst H, 2004, PEDIATR RES, V55, P1026, DOI 10.1203/01.pdr.0000127019.52562.8c; Toet MC, 2002, PEDIATRICS, V109, P772, DOI 10.1542/peds.109.5.772; Tufte E. R., 2001, VISUAL DISPLAY QUANT; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; Vespa PM, 1997, ELECTROEN CLIN NEURO, V103, P607, DOI 10.1016/S0013-4694(97)00071-0; Vespa PM, 2002, J NEUROSURG, V97, P84, DOI 10.3171/jns.2002.97.1.0084; Vespa PM, 1999, J CLIN NEUROPHYSIOL, V16, P1, DOI 10.1097/00004691-199901000-00001; Wilson SB, 2004, CLIN NEUROPHYSIOL, V115, P2280, DOI 10.1016/j.clinph.2004.05.018; Wilson SB, 2003, CLIN NEUROPHYSIOL, V114, P2156, DOI 10.1016/S1388-2457(03)00212-8	39	77	78	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0736-0258			J CLIN NEUROPHYSIOL	J. Clin. Neurophysiol.	SEP-OCT	2004	21	5					353	378					26	Clinical Neurology; Neurosciences	Neurosciences & Neurology	878TO	WOS:000225670000006	15592009				2021-06-18	
J	Guilmette, TJ; Paglia, MF				Guilmette, TJ; Paglia, MF			The public's misconceptions about traumatic brain injury: a follow up survey	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article; Proceedings Paper	Annual Meeting of the American-Psychological-Association	AUG, 2002	CHICAGO, IL	Amer Psychol Assoc		traumatic brain injury; public's misconceptions; surveys; TBI plaintiffs	JUROR BIAS; REHABILITATION	Two prior surveys from rural Louisiana, Canada, and New York [Arch. Clin. Neuropsychol. 3 (1988) 331; Arch. Clin. Neuropsychol. 8 (1993) 461] revealed that a high portion of the population endorses misconceptions about the sequelae of traumatic brain injury (TBI). The purpose of this study was to assess the public's perceptions of head trauma in an urban setting in the Northeast region of the country and to compare those results with surveys from other geographical areas conducted 8 and 13 years ago. This study also examined the prevalence of perceptions about TBI that may be relevant to personal injury litigation with TBI plaintiffs. Data were collected at an office of the Department of Motor Vehicles from persons conducting business there. Participants (n = 179) voluntarily completed a 19-item survey covering several facets of brain injury. This sample endorsed misconceptions at a level consistent with previous studies, indicating a comparable lack of knowledge about moderate to severe TBI. With regard to mild TBI, however, our sample generally endorsed fewer misconceptions than previous samples. The public also holds perceptions of TBI that may be relevant to personal injury litigation involving TBI plaintiffs. (C) 2003 National Academy of Neuropsychology. Published by Elsevier Science Ltd. All rights reserved.	So New England Rehabil Ctr, Dept Psychol, Providence, RI 02903 USA; Providence Coll, Providence, RI 02918 USA	Guilmette, TJ (corresponding author), So New England Rehabil Ctr, Dept Psychol, Providence, RI 02903 USA.	tguilmet@providence.edu					De Lisa A., 1994, LAW PSYCHOL REV, V18, P309; Erian M., 1998, AM J FORENSIC PSYCH, V16, P25; Farmer JE, 1997, REHABIL PSYCHOL, V42, P273; GOODMAN J, 1991, LAW SOC REV, V25, P263, DOI 10.2307/3053799; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P331; Hux K, 1996, LANG SPEECH HEAR SER, V27, P171, DOI 10.1044/0161-1461.2702.171; KASSIN SM, 1983, J RES PERS, V17, P423, DOI 10.1016/0092-6566(83)90070-3; PETROCELLI RW, 1994, TRAUMATIC BRAIN INJU; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Sommers SR, 2001, PSYCHOL PUBLIC POL L, V7, P201, DOI 10.1037/1076-8971.7.1.201; Swift TL, 2001, BRAIN INJURY, V15, P149, DOI 10.1080/026990501458380; WEIR JA, 1990, J APPL SOC PSYCHOL, V20, P901, DOI 10.1111/j.1559-1816.1990.tb01467.x; WILLER B, 1993, ARCH CLIN NEUROPSYCH, V8, P461, DOI 10.1016/0887-6177(93)90009-P; Wrightsman L., 2002, PSYCHOL LEGAL SYSTEM; Wuensch KL, 2002, J SOC PSYCHOL, V142, P587, DOI 10.1080/00224540209603920	15	77	77	0	4	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	MAR	2004	19	2					183	189		10.1016/S0887-6177(03)00025-8			7	Psychology, Clinical; Psychology	Psychology	804RD	WOS:000220314900003	15010084	Bronze			2021-06-18	
J	Azouvi, P; Couillet, J; Leclercq, M; Martin, Y; Asloun, S; Rousseaux, M				Azouvi, P; Couillet, J; Leclercq, M; Martin, Y; Asloun, S; Rousseaux, M			Divided attention and mental effort after severe traumatic brain injury	NEUROPSYCHOLOGIA			English	Article						divided attention; central executive; working memory; executive functions; traumatic brain injury	CLOSED-HEAD INJURY; DUAL-TASK PERFORMANCE; RANDOM NUMBER GENERATION; WORKING-MEMORY; DEFICITS; IMPAIRMENTS; TESTS	The aim of this study was to assess dual-task performance in TBI patients, under different experimental conditions, with or without explicit emphasis on one of two tasks. Results were compared with measurement of the subjective mental effort required to perform each task. Forty-three severe TBI patients at the subacute or chronic phase performed two tasks under single- and dual-task conditions: (a) random generation; (b) visual go-no go reaction time task. Three dual-task conditions were given, requiring either to consider both tasks as equally important or to focus preferentially on one of them. Patients were compared to matched controls. Subjective mental effort was rated on a visual analogic scale. TBI patients showed a disproportionate increase in reaction time in the go-no go task under the dual-task condition. However, they were just as able as controls to adapt performance to the specific instructions about the task to be emphasised. Patients reported significantly higher subjective mental effort, but the variation of mental effort according to task condition was similar to that of controls. These results suggest that the divided attention deficit of TBI patients is related to a reduction in available processing resources rather than an impairment of strategic processes responsible for attentional allocation and switching. The higher level of subjective mental effort may explain why TBI patients frequently complain of mental fatigue, although this subjective complaint seems to be relatively independent of cognitive impairment. (C) 2004 Elsevier Ltd. All rights reserved.	Univ Versailles St Quentin, Hop Raymond Poincare, Fac Med Paris Ile France Quest, Serv Reeducat Neurol, F-92380 Garches, France; Ctr Neurol William Lennox, Louvain, Belgium; Ctr Reeducat Espoir, Lille Hellemmes, France; Hop Swynghedauw, Serv Reeducat Neurol, Lille, France	Azouvi, P (corresponding author), Univ Versailles St Quentin, Hop Raymond Poincare, Fac Med Paris Ile France Quest, Serv Reeducat Neurol, F-92380 Garches, France.	philippe.azouvi@rpc.ap-hop-paris.fr					Adcock RA, 2000, P NATL ACAD SCI USA, V97, P3567, DOI 10.1073/pnas.060588897; Azouvi P, 1996, J CLIN EXP NEUROPSYC, V18, P317, DOI 10.1080/01688639608408990; Baddeley A. D., 1986, WORKING MEMORY; Baddeley A, 2010, CURR BIOL, V20, pR136, DOI 10.1016/j.cub.2009.12.014; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brouwer W, 2001, BRAIN COGNITION, V46, P54, DOI 10.1016/S0278-2626(01)80033-6; BROUWER WH, 1989, CORTEX, V25, P219, DOI 10.1016/S0010-9452(89)80038-3; Brouwer WH, 2002, J HEAD TRAUMA REHAB, V17, P1, DOI 10.1097/00001199-200202000-00003; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; CHATFIELD C, 1984, ANAL TIME SERIES; Collette F, 2002, NEUROSCI BIOBEHAV R, V26, P105, DOI 10.1016/S0149-7634(01)00063-X; CREPEAU F, 1993, NEUROPSYCHOL REHABIL, V3, P5; DESPOSITO M, 1995, NATURE, V378, P279, DOI 10.1038/378279a0; EVANS FJ, 1978, B PSYCHONOMIC SOC, V12, P35; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; Herath P, 2001, CEREB CORTEX, V11, P796, DOI 10.1093/cercor/11.9.796; KENDALL MG, 1973, TIMES SERIES; Klingberg T, 1998, CEREB CORTEX, V8, P593, DOI 10.1093/cercor/8.7.593; Koechlin E, 1999, NATURE, V399, P148; Leclercq M, 2000, J CLIN EXP NEUROPSYC, V22, P339, DOI 10.1076/1380-3395(200006)22:3;1-V;FT339; Leclercq M, 2002, APPLIED NEUROPSYCHOLOGY OF ATTENTION: THEORY DIAGNOSIS AND REHABILITATION, P257; LECLERCQ M, 1990, NORMALISATION 3 EPRE; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Park NW, 1999, NEUROPSYCHOLOGIA, V37, P1119, DOI 10.1016/S0028-3932(99)00034-2; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; Riese H, 1999, NEUROPSYCHOL REHABIL, V9, P189, DOI 10.1080/713755600; ROSENBERG S, 1990, PSYCHOL MED, V20, P953, DOI 10.1017/S0033291700036643; Shallice T., 1988, NEUROPSYCHOLOGY MENT; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; STABLUM F, 1994, CORTEX, V30, P603, DOI 10.1016/S0010-9452(13)80238-9; Van Zomeren A. H., 1984, CLOSED HEAD INJURY P, P74; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Veltman JC, 1996, NEUROPSYCHOLOGY, V10, P357, DOI 10.1037/0894-4105.10.3.357; Vilkki J, 1996, NEUROPSYCHOLOGIA, V34, P1051, DOI 10.1016/0028-3932(96)00028-0; VILKKI J, 1994, J CLIN EXP NEUROPSYC, V16, P325, DOI 10.1080/01688639408402643; WITHAAR FK, 2000, THESIS RIJSKUNIVERSI	39	77	80	0	13	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932	1873-3514		NEUROPSYCHOLOGIA	Neuropsychologia		2004	42	9					1260	1268		10.1016/j.neuropsychologia.2004.01.001			9	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	834NN	WOS:000222417900012	15178177				2021-06-18	
J	Lusardi, TA; Wolf, JA; Putt, ME; Smith, DH; Meaney, DF				Lusardi, TA; Wolf, JA; Putt, ME; Smith, DH; Meaney, DF			Effect of acute calcium influx after mechanical stretch injury in vitro on the viability of hippocampal neurons	JOURNAL OF NEUROTRAUMA			English	Article						calcium; cell death; cell mechanics; hippocampus; neuron; traumatic brain injury	INTRACELLULAR FREE CALCIUM; METHYL-D-ASPARTATE; TRAUMATIC INJURY; BRAIN-INJURY; CULTURED ASTROCYTES; CORTICAL-NEURONS; NMDA RECEPTORS; CELL-DEATH; MODEL; HEAD	We use a new in vitro model to examine the effect of mechanical deformation on neurons. We examined acute changes in cytosolic calcium concentrations ([Ca2+](i)) caused by a rapid stretch of cultured hippocampal neurons, using mechanical loading conditions that mimic brain deformations during trauma. We found that stretch-injury of neurons induces a strain-dependent increase in [Ca2+](i). Remarkably, the extent of this calcium response exceeded the levels initiated by chemical toxicity with NMDA (100 muM) or glutamate (5 mM) exposure. Propidium iodide labeling at 24 h following stretch showed neuronal death occurred only at the most severe level of mechanical injury. Although NMDA-induced toxicity could be inhibited in calcium free media or by treatment with MK-801, stretch-induced neuronal death was not similarly reduced with either treatment. Unexpectedly, reduction of the acute stretch-induced calcium transient with calcium-free media or MK-801 resulted in an increase in neuronal death at lower stretch levels. These data suggest that mechanical stretch can initiate calcium influx in hippocampal neurons, but substantially modulating the early calcium flux from the extracellular space or through the NMDA channel does not provide an effective means for improving neuronal survival.	Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA	Meaney, DF (corresponding author), Univ Penn, Dept Bioengn, 3320 Smith Walk,Room 120,Hayden Hall, Philadelphia, PA 19104 USA.	dmeaney@seas.upenn.edu	smith, douglas/A-1321-2007; Wolf, John A/A-1034-2007	Wolf, John A/0000-0002-6950-2303; Lusardi, Theresa/0000-0003-0699-5662; Meaney, David/0000-0002-0954-4122	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG21527] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS35712] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [41699] Funding Source: Medline; ODCDC CDC HHS [R49/CCR 312712] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS035712] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K08AG021527] Funding Source: NIH RePORTER		AbdelHamid KM, 1997, J NEUROSCI, V17, P3538; Ahmed SM, 2002, J NEUROTRAUM, V19, P1619, DOI 10.1089/089771502762300274; Ahmed SM, 2000, J NEUROCHEM, V74, P1951, DOI 10.1046/j.1471-4159.2000.741951000000000.x; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; Cargill RS, 1996, J NEUROTRAUM, V13, P395, DOI 10.1089/neu.1996.13.395; CHOI DW, 1987, J NEUROSCI, V7, P369; CHOI DW, 1995, TRENDS NEUROSCI, V18, P58; Citron BA, 1997, NEUROSCI LETT, V230, P25, DOI 10.1016/S0304-3940(97)00468-0; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Floyd CL, 2001, GLIA, V33, P12, DOI 10.1002/1098-1136(20010101)33:1<12::AID-GLIA1002>3.0.CO;2-V; Geddes DM, 2003, EXP NEUROL, V184, P420, DOI 10.1016/S0014-4886(03)00254-1; Geddes DM, 2001, J BIOMECH ENG-T ASME, V123, P247, DOI 10.1115/1.1374201; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; Goforth PB, 1999, J NEUROSCI, V19, P7367, DOI 10.1523/JNEUROSCI.19-17-07367.1999; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hasbani MJ, 2001, NEUROREPORT, V12, P2731, DOI 10.1097/00001756-200108280-00028; Hyrc K, 1997, J NEUROSCI, V17, P6669; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Kiedrowski L, 1999, MOL PHARMACOL, V56, P619; King AI, 2000, ANNU REV BIOMED ENG, V2, P55, DOI 10.1146/annurev.bioeng.2.1.55; KOTAPKA MJ, 1992, ACTA NEUROPATHOL, V83, P530, DOI 10.1007/BF00310031; KOTAPKA MJ, 1994, J NEUROTRAUM, V11, P317, DOI 10.1089/neu.1994.11.317; Kristian T, 1998, STROKE, V29, P705, DOI 10.1161/01.STR.29.3.705; Kutner M. H., 1996, APPL LINEAR STAT MOD; Lamb RG, 1997, J NEUROCHEM, V68, P1904; LaPlaca MC, 1997, ANN BIOMED ENG, V25, P665, DOI 10.1007/BF02684844; LaPlaca MC, 1997, J NEUROTRAUM, V14, P355, DOI 10.1089/neu.1997.14.355; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Leski ML, 1999, BRAIN RES, V828, P27, DOI 10.1016/S0006-8993(99)01270-6; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; McCulloch C. E, 2001, GENERALIZED LINEAR M; McKinney JS, 1996, STROKE, V27, P934, DOI 10.1161/01.STR.27.5.934; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; Pike BR, 2000, J NEUROTRAUM, V17, P283, DOI 10.1089/neu.2000.17.283; ROTHMAN SM, 1995, TRENDS NEUROSCI, V18, P57; Rzigalinski BA, 1997, J NEUROCHEM, V68, P289; Rzigalinski BA, 1998, J NEUROCHEM, V70, P2377; Sapolsky RM, 2001, J NEUROCHEM, V76, P1601, DOI 10.1046/j.1471-4159.2001.00203.x; Sattler R, 1998, J NEUROCHEM, V71, P2349; Sattler R, 2000, J NEUROSCI, V20, P22, DOI 10.1523/JNEUROSCI.20-01-00022.2000; Shi R, 2000, NEUROSCIENCE, V98, P157, DOI 10.1016/S0306-4522(00)00096-8; Shreiber DI, 1999, J NEUROPATH EXP NEUR, V58, P153, DOI 10.1097/00005072-199902000-00005; Smith DH, 1999, J NEUROSCI, V19, P4263; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Tavalin SJ, 1997, J NEUROPHYSIOL, V77, P632; Tavalin SJ, 1995, J NEUROPHYSIOL, V74, P2767; VENABLES WN, 1999, MODERN APPL STAT S P; Vergun O, 2001, J PHYSIOL-LONDON, V531, P147, DOI 10.1111/j.1469-7793.2001.0147j.x; Weber JT, 1999, CELL CALCIUM, V26, P289, DOI 10.1054/ceca.1999.0082; White BC, 2000, J NEUROL SCI, V179, P1, DOI 10.1016/S0022-510X(00)00386-5; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Yuan Q, 1998, SPINE, V23, P1677, DOI 10.1097/00007632-199808010-00012; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921; ZHOU C, 1994, STAPP CAR CRASH C SO	60	77	78	0	13	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2004	21	1					61	72		10.1089/089771504772695959			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	766GU	WOS:000188368700007	14987466				2021-06-18	
J	Shum, D; Ungvari, GS; Tang, WK; Leung, JP				Shum, D; Ungvari, GS; Tang, WK; Leung, JP			Performance of schizophrenia patients on time-, event-, and activity-based prospective memory tasks	SCHIZOPHRENIA BULLETIN			English	Article						prospective memory; schizophrenia; prefrontal lobe function; rehabilitation	TRAUMATIC BRAIN-INJURY; FORMS	The present study aimed to determine whether individuals with long-term schizophrenia have impaired prospective memory (PM), the ability to remember to perform intended actions in the future. Three PM tasks (time-, event-, and activity-based) were administered to 60 schizophrenia patients and 60 matched controls. Patients performed significantly more poorly than controls on all three tasks. The between-group difference was disproportionately larger on the time-based task, a task that required a prefrontal. lobe process called self-initiated retrieval. To examine the relationship between PM and prefrontal lobe functions, subjects were also administered the Design Fluency Test (DFT), the Tower of London (TOL), and the Wisconsin Card Sorting Test (WCST). For patients, performance on the event-based task was found to correlate significantly with performance on the DFT, and performance on the time-based task was found to correlate significantly with performance on the TOL. Results of this study support the importance and contribution of prefrontal lobe processes in prospective remembering and have implications for the assessment and treatment of individuals with schizophrenia.	Shatin Hosp, Dept Psychiat, Shatin, Hong Kong, Peoples R China; Griffith Univ, Sch Psychol, Brisbane, Qld 4111, Australia; Chinese Univ Hong Kong, Dept Psychiat, Sha Tin 100083, Peoples R China; Chinese Univ Hong Kong, Dept Psychol, Sha Tin 100083, Peoples R China	Ungvari, GS (corresponding author), Shatin Hosp, Dept Psychiat, Shatin, Hong Kong, Peoples R China.	gsungvari@cuhk.edu.hk	Shum, David/A-3914-2008	Shum, David/0000-0002-4810-9262			*AM PSYCH ASS, 1994, DSM, V4; BRANDIMONTE M, 1996, PROSPECTIVE MEMORY T, pR9; Burgess PW, 2001, NEUROPSYCHOLOGIA, V39, P545, DOI 10.1016/S0028-3932(00)00149-4; Chen EYH, 1996, SCHIZOPHRENIA NEUROP, P107; EINSTEIN GO, 1995, J EXP PSYCHOL LEARN, V21, P996, DOI 10.1037/0278-7393.21.4.996; EINSTEIN GO, 1990, J EXP PSYCHOL LEARN, V16, P717, DOI 10.1037/0278-7393.16.4.717; ESLINGER PJ, 1993, NEUROPSYCHOLOGIA, V31, P17, DOI 10.1016/0028-3932(93)90077-D; GLISKY EL, 1996, PROSPECTIVE MEMORY T, P249; GOLD JM, 1992, J ABNORM PSYCHOL, V101, P487, DOI 10.1037/0021-843X.101.3.487; GOLD JM, 1992, CLIN NEUROPSYCHOL, V6, P367; GOLDMAN RS, 1996, NEUROPSYCHOLOGICAL A, P504; Gourovitch ML, 1996, SCHIZOPHRENIA NEUROP, P72; Graf P, 2001, CONSCIOUS COGN, V10, P437, DOI 10.1006/ccog.2001.0504; Heaton R., 1993, WISCONSIN CARD SORTI; JONESGOTMAN M, 1977, NEUROPSYCHOLOGIA, V15, P653, DOI 10.1016/0028-3932(77)90070-7; Kvavilashvili L., 1996, PROSPECTIVE MEMORY T, P23; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A, P657; Okuda J, 1998, NEUROSCI LETT, V253, P127, DOI 10.1016/S0304-3940(98)00628-4; Paulsen J S, 1995, J Int Neuropsychol Soc, V1, P88; SHALLICE T, 1982, BIOL SCI, V298, P199, DOI DOI 10.1098/RSTB.1982.0082; Shum D, 2000, BRAIN COGNITION, V44, P59; Shum D, 1999, J CLIN EXP NEUROPSYC, V21, P49, DOI 10.1076/jcen.21.1.49.943; Shum D., 2002, BRAIN IMPAIR, V3, DOI [https://doi.org/10.1375/brim.3.1.1, DOI 10.1375/BRIM.3.1.1]; Spreen O., 1998, COMPENDIUM NEUROPSYC; TAMLYN D, 1992, PSYCHOL MED, V22, P101, DOI 10.1017/S0033291700032773; TAYLOR D, 1999, BETHLEM MAUDSLEY NHS; Tunstall J., 1999, THESIS GRIFFITH U BR; WEINBERGER DR, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P275	28	77	89	0	6	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0586-7614	1745-1701		SCHIZOPHRENIA BULL	Schizophr. Bull.		2004	30	4					693	701		10.1093/oxfordjournals.schbul.a007123			9	Psychiatry	Psychiatry	910FN	WOS:000227916000003	15954184	Bronze			2021-06-18	
J	Vavilala, MS; Bowen, A; Lam, AM; Uffman, JC; Powell, J; Winn, HR; Rivara, FP				Vavilala, MS; Bowen, A; Lam, AM; Uffman, JC; Powell, J; Winn, HR; Rivara, FP			Blood pressure and outcome after severe pediatric traumatic brain injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						head injury; children; blood pressure	HEAD-INJURY; CHILDREN; HYPOTENSION	Background. The relationship between systolic blood pressure and outcome in children after severe traumatic brain injury (TBI) is unclear. We examined the relationship between age-appropriate systolic blood pressure (AASBP) percentile and outcome after severe pediatric TBI. Methods. We examined the association between AASBP percentiles and outcome in 172 children younger than 14 years of age with a Glasgow Coma Scale score < 9. Outcome was evaluated using discharge Glasgow Outcome Scale score. Poor outcome was defined as a Glasgow Outcome Scale score < 4. Results. Poor outcome was associated with AASBP < 75th percentile (odds ratio, 4.2; 95% confidence interval, 2.1-8.3). Patients with systolic blood pressure (SBP) ! 90 turn Hg and AASBP < 75th percentile had a higher odds for poor outcome compared with patients with SBP greater than or equal to 90 mm Hg and AASBP greater than or equal to 75th percentile (odds ratio, 3.5; 95% confidence interval, 1.7-7.3). Conclusion. AASBP < 75th percentile was associated with poor outcome after severe pediatric TBI, even when SBP was greater than or equal to 90 min Hg.	Univ Washington, Dept Anesthesiol, Seattle, WA 98195 USA; Univ Washington, Dept Pediat, Seattle, WA 98195 USA; Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA	Vavilala, MS (corresponding author), Harborview Med Ctr, Dept Anesthesiol, 325 9th Ave,Box 359724, Seattle, WA 98104 USA.	vavilala@u.washington.edu					Biswas AK, 2000, CRIT CARE MED, V28, P3907, DOI 10.1097/00003246-200012000-00030; BLUMENTHAL S, 1977, PEDIATRICS, V59, P797; BLUMENTHAL S, 1987, PEDIATRICS, V79, P1; Bouma GJ, 1998, ACT NEUR S, V71, P272; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P471; *BRAIN TRAUM FDN, GUID PREHOSPITAL MAN; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P507; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; DESWIET M, 1980, PEDIATRICS, V65, P1028; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; JENNETT B, 1975, LANCET, V1, P480; KOHL YM, 1984, INJURY, V16, P25; Kokoska ER, 1998, J PEDIATR SURG, V33, P333, DOI 10.1016/S0022-3468(98)90457-2; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; Robertson CS, 2001, ANESTHESIOLOGY, V95, P1513, DOI 10.1097/00000542-200112000-00034; RULEY EJ, 1993, TXB CRITICAL CARE, P602; VASSAR MJ, 1991, ARCH SURG-CHICAGO, V126, P1065; Vavilala MS, 2001, J NEUROSURG ANESTH, V13, P13, DOI 10.1097/00008506-200101000-00003; WAGSTYL J, 1987, J PEDIATR SURG, V22, P127, DOI 10.1016/S0022-3468(87)80427-X; White JRM, 2001, CRIT CARE MED, V29, P534, DOI 10.1097/00003246-200103000-00011; Zwienenberg M, 1999, J NEUROTRAUM, V16, P937, DOI 10.1089/neu.1999.16.937	22	77	78	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	DEC	2003	55	6					1039	1044		10.1097/01.TA.0000101759.23607.57			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	758TL	WOS:000187666200007	14676648				2021-06-18	
J	Uryu, K; Giasson, BI; Longhi, L; Martinez, D; Murray, I; Conte, V; Nakamura, M; Saatman, K; Talbot, K; Horiguchi, T; McIntosh, T; Lee, VMY; Trojanowski, JQ				Uryu, K; Giasson, BI; Longhi, L; Martinez, D; Murray, I; Conte, V; Nakamura, M; Saatman, K; Talbot, K; Horiguchi, T; McIntosh, T; Lee, VMY; Trojanowski, JQ			Age-dependent synuclein pathology following traumatic brain injury in mice	EXPERIMENTAL NEUROLOGY			English	Article						traumatic brain injury; mouse brain; neurodegenerative disease; synuclein	SPORADIC PARKINSONS-DISEASE; CORTICAL LEWY BODIES; A-BETA DEPOSITION; ALPHA-SYNUCLEIN; TRANSGENIC MICE; LIPID-PEROXIDATION; DROSOPHILA MODEL; HEAD TRAUMA; DEMENTIA; BODY	Synucleins (Syn), a family of synaptic proteins, includes alpha-Syn, which plays a pivotal role in Parkinson's disease and related neurodegenerative diseases (synucleinopathics) by forming distinct brain pathologies (Lewy bodies and neurites). Since traumatic brain injury (TBI) is a poorly understood risk factor for Parkinson's disease, we examined the effects of TBI in the young and aged mouse brain on alpha-, beta-, and gamma-Syn. Immunohistochemical analysis showed that brains from sham-injured young and aged mice had normal alpha- and beta-Syn immunoreactivity (lR) in neuropil of cortex, striatum, and hippocampus with little or no gamma-Syn IR. At 1 week post TBI, the aged mouse brain showed a transient increase of alpha- and beta-Syn IR in the neuropil as well as an induction of gamma-Syn IR in subcortical axons. This was associated with strong labeling of striatal axon bundles by antibodies to altered or nitrated epitopes in a-Syn as well as by antibodies to inducible nitric oxide synthase. However, these TBI-induced changes disappeared by 16 weeks post TBI, and altered Syn IR was not seen in young mice subjected to TBI nor in alpha-Syn knockout mice while Western blots confirmed that TBI induced transient alterations of alpha-Syn in the mouse brains. This model of age-dependent TBI-induced transient alterations in alpha-Syn provides an opportunity to examine possible links between TBI and mechanisms of disease in synucleinopathies. (C) 2003 Elsevier Science (USA). All rights reserved.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Neurosurg, Head Injury Ctr, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Psychiat, Head Injury Ctr, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Inst Aging, Philadelphia, PA 19104 USA	Trojanowski, JQ (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, Ctr Neurodegenerat Dis Res, HUP Maloney 3rd Floor, Philadelphia, PA 19104 USA.		Longhi, Luca/AAF-9903-2021; Murray, Ian/O-5983-2015	Longhi, Luca/0000-0001-9894-8788; Murray, Ian/0000-0003-1196-1360	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG-09215] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-08803] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803, P01NS008803] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG009215] Funding Source: NIH RePORTER		Abeliovich A, 2000, NEURON, V25, P239, DOI 10.1016/S0896-6273(00)80886-7; Arawaka S, 1998, NEUROLOGY, V51, P887, DOI 10.1212/WNL.51.3.887; Arima K, 1998, BRAIN RES, V808, P93, DOI 10.1016/S0006-8993(98)00734-3; Auluck PK, 2002, SCIENCE, V295, P865, DOI 10.1126/science.1067389; Baba M, 1998, AM J PATHOL, V152, P879; Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; Braak H, 1999, NEUROSCI LETT, V265, P67, DOI 10.1016/S0304-3940(99)00208-6; Braak H, 2003, NEUROBIOL AGING, V24, P197, DOI 10.1016/S0197-4580(02)00065-9; Clark RSB, 2001, J NEUROTRAUM, V18, P675, DOI 10.1089/089771501750357627; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; DEKOSKY ST, 1994, EXP NEUROL, V130, P173, DOI 10.1006/exnr.1994.1196; Duda JE, 2002, ANN NEUROL, V52, P205, DOI 10.1002/ana.10279; FACTOR SA, 1991, MOVEMENT DISORD, V6, P225, DOI 10.1002/mds.870060306; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; Fujiwara H, 2002, NAT CELL BIOL, V4, P160, DOI 10.1038/ncb748; Giasson BI, 2000, SCIENCE, V290, P985, DOI 10.1126/science.290.5493.985; Giasson BI, 2000, J NEUROSCI RES, V59, P528, DOI 10.1002/(SICI)1097-4547(20000215)59:4<528::AID-JNR8>3.0.CO;2-0; Giasson BI, 2001, EXP NEUROL, V172, P354, DOI 10.1006/exnr.2001.7805; HUBBLE JP, 1993, NEUROLOGY, V43, P1693, DOI 10.1212/WNL.43.9.1693; Hurtig HI, 2000, NEUROLOGY, V54, P1916, DOI 10.1212/WNL.54.10.1916; Irizarry MC, 1998, J NEUROPATH EXP NEUR, V57, P334, DOI 10.1097/00005072-199804000-00005; Ishihara T, 1999, NEURON, V24, P751, DOI 10.1016/S0896-6273(00)81127-7; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561; Liu PK, 2002, ANN NY ACAD SCI, V962, P226, DOI 10.1111/j.1749-6632.2002.tb04071.x; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Mesenge C, 1998, EUR J PHARMACOL, V353, P53, DOI 10.1016/S0014-2999(98)00432-4; Murai H, 1998, J COMP NEUROL, V392, P428, DOI 10.1002/(SICI)1096-9861(19980323)392:4<428::AID-CNE2>3.0.CO;2-2; Nakagawa Y, 1999, J COMP NEUROL, V411, P390; Nakagawa Y, 2000, EXP NEUROL, V163, P244, DOI 10.1006/exnr.2000.7375; NAYERNOURI T, 1985, SURG NEUROL, V24, P263, DOI 10.1016/0090-3019(85)90035-7; Newell KL, 1999, J NEUROPATH EXP NEUR, V58, P1263, DOI 10.1097/00005072-199912000-00007; NORRIS EH, 2003, IN PRESS J BIOL CHEM; Paxinou E, 2001, J NEUROSCI, V21, P8053; PERRY EK, 1994, NEUROREPORT, V5, P747, DOI 10.1097/00001756-199403000-00002; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Pratico D, 2002, J NEUROCHEM, V80, P894, DOI 10.1046/j.0022-3042.2002.00777.x; Przedborski S, 1998, MOVEMENT DISORD, V13, P35; Romijn HJ, 1999, J HISTOCHEM CYTOCHEM, V47, P229, DOI 10.1177/002215549904700211; Souza JM, 2000, J BIOL CHEM, V275, P18344, DOI 10.1074/jbc.M000206200; Souza JM, 2000, FEBS LETT, V474, P116, DOI 10.1016/S0014-5793(00)01563-5; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Stefanis L, 2001, J NEUROCHEM, V76, P1165, DOI 10.1046/j.1471-4159.2001.00114.x; STERN MB, 1991, MOVEMENT DISORD, V6, P95, DOI 10.1002/mds.870060202; TANNER CM, 1989, NEUROLOGY, V39, P660, DOI 10.1212/WNL.39.5.660; Tanner CM, 1999, JAMA-J AM MED ASSOC, V281, P341, DOI 10.1001/jama.281.4.341; Trojanowski JQ, 2002, NEUROTOXICOLOGY, V23, P457, DOI 10.1016/S0161-813X(02)00065-7; Tu PH, 1998, ANN NEUROL, V44, P415, DOI 10.1002/ana.410440324; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002	53	77	78	0	9	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	NOV	2003	184	1					214	224		10.1016/S0014-4886(03)00245-0			11	Neurosciences	Neurosciences & Neurology	747KZ	WOS:000186804800025	14637093	Green Published			2021-06-18	
J	Figaji, AA; Fieggen, AG; Peter, JC				Figaji, AA; Fieggen, AG; Peter, JC			Early decompressive craniotomy in children with severe traumatic brain injury	CHILDS NERVOUS SYSTEM			English	Article						decompressive craniectomy; decompressive craniotomy; acute deterioration; raised intracranial pressure	SEVERE HEAD-INJURIES; CEREBRAL EDEMA; INTRACRANIAL HYPERTENSION; HEMISPHERIC INFARCTION; SURGICAL DECOMPRESSION; CRANIECTOMY; PRESSURE; MANAGEMENT; SURGERY; CONSCIOUSNESS	Introduction. Decompressive craniectomy remains a controversial procedure in the treatment of raised intracranial pressure (ICP) associated with post-traumatic brain swelling. Although there are a number of studies in adults published in the literature on this topic, most commonly as a salvage procedure in the treatment of refractory raised ICP, there are few that investigate it primarily in children with head injuries. Aim. Our aim was to report the experience with decompressive craniotomy in children with severe traumatic brain injury (TBI) at the Red Cross Children's' hospital. Methods. This study reports five patients in whom decompressive craniectomy or craniotomy with duraplasty was used as an early, aggressive treatment of raised ICP causing secondary acute neurological deterioration after head injury. The rationale was to save the patient from acute cerebral herniation and to prevent exposure to a prolonged course of intracranial hypertension. Results. All patients benefited from the procedure, demonstrating control of ICP, radiological improvement and neurological recovery. Long-term follow-up was available, with outcome assessed at a minimum of 14 months after injury. Discussion. The early approach to the use of decompressive craniotomy in the treatment of severe traumatic brain injury (TBI) with secondary deterioration due to raised ICP is emphasised. A favourable outcome was achieved in all of the cases presented. The potential benefit of decompressive craniectomy/craniotomy in the management of children with severe TBI is discussed.	Univ Cape Town, Div Paediat Neurosci Neurosurg, Sch Child & Adolescent Hlth, ZA-7700 Rondebosch, South Africa; Red Cross Childrens Hosp, ZA-7700 Rondebosch, South Africa	Figaji, AA (corresponding author), Univ Cape Town, Div Paediat Neurosci Neurosurg, Sch Child & Adolescent Hlth, Klipfontein Rd, ZA-7700 Rondebosch, South Africa.	afigaji@uctgsh1.uct.ac.za		Figaji, Anthony/0000-0002-3357-6490; Fieggen, Graham/0000-0001-6541-8377			ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; Alexander E, 1987, Br J Neurosurg, V1, P427, DOI 10.3109/02688698708999632; BERGER MS, 1985, J NEUROSURG, V62, P194, DOI 10.3171/jns.1985.62.2.0194; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; Carter BS, 1997, NEUROSURGERY, V40, P1168, DOI 10.1097/00006123-199706000-00010; Cho DY, 1995, PEDIATR NEUROSURG, V23, P192, DOI 10.1159/000120958; CLARK K, 1968, J NEUROSURG, V29, P367, DOI 10.3171/jns.1968.29.4.0367; Cooper P R, 1976, Surg Neurol, V5, P25; COOPER PR, 1979, NEUROSURGERY, V4, P296, DOI 10.1227/00006123-197904000-00004; Coplin WM, 2001, J TRAUMA, V50, P1050, DOI 10.1097/00005373-200106000-00013; Cruz J, 1996, J NEUROSURG, V85, P758, DOI 10.3171/jns.1996.85.5.0758; CRUZ J, 1990, J NEUROSURG, V73, P725, DOI 10.3171/jns.1990.73.5.0725; Doerfler A, 1996, J NEUROSURG, V85, P853, DOI 10.3171/jns.1996.85.5.0853; FORSTING M, 1995, STROKE, V26, P259, DOI 10.1161/01.STR.26.2.259; GAAB M, 1979, CHILD BRAIN, V5, P484; GAAB MR, 1990, ACT NEUR S, V51, P326; GOWER DJ, 1988, NEUROSURGERY, V23, P417, DOI 10.1227/00006123-198810000-00002; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; HASE U, 1978, ACTA NEUROCHIR, V45, P1, DOI 10.1007/BF01774379; HATASHITA S, 1985, STROKE, V16, P661, DOI 10.1161/01.STR.16.4.661; HATASHITA S, 1987, J NEUROSURG, V67, P573, DOI 10.3171/jns.1987.67.4.0573; Hieu PD, 1996, CHILD NERV SYST, V12, P270; JENNETT B, 1975, LANCET, V1, P480; Johnson DL, 1998, PEDIATR NEUROSURG, V28, P167, DOI 10.1159/000028643; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; KAUFMANN AM, 1992, J NEUROSURG, V77, P584, DOI 10.3171/jns.1992.77.4.0584; KERR FWL, 1968, MAYO CLIN PROC, V43, P852; KJELLBERG RN, 1971, J NEUROSURG, V34, P488, DOI 10.3171/jns.1971.34.4.0488; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; Meyer P, 1999, CHILD NERV SYST, V15, P732, DOI 10.1007/s003810050462; MOODY RA, 1968, J NEUROSURG, V29, P586, DOI 10.3171/jns.1968.29.6.0586; Munch E, 2000, NEUROSURGERY, V47, P315; Pillai S, 2001, PEDIATR NEUROSURG, V34, P98, DOI 10.1159/000056002; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; POPLE IK, 1995, PEDIATR NEUROSURG, V23, P64, DOI 10.1159/000120938; Prasad MR, 2002, PEDIATR NEUROSURG, V36, P64, DOI 10.1159/000048355; Rekate Harold L., 2001, Child's Nervous System, V17, P632, DOI 10.1007/s003810100487; RENGACHARY SS, 1981, NEUROSURGERY, V8, P321, DOI 10.1227/00006123-198103000-00004; RIEKE K, 1995, CRIT CARE MED, V23, P1576, DOI 10.1097/00003246-199509000-00019; RINALDI A, 1990, ACT NEUR S, V51, P394; ROPPER AH, 1986, NEW ENGL J MED, V314, P953, DOI 10.1056/NEJM198604103141504; ROSS DA, 1989, J NEUROSURG, V71, P498, DOI 10.3171/jns.1989.71.4.0498; SHAPIRO K, 1982, J NEUROSURG, V56, P819, DOI 10.3171/jns.1982.56.6.0819; SHAPIRO K, 1985, J NEUROSURG, V63, P76, DOI 10.3171/jns.1985.63.1.0076; Simma B, 2002, INTENS CARE MED, V28, P1000, DOI 10.1007/s00134-002-1333-3; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; VANDONGEN KJ, 1983, J NEUROSURG, V59, P951, DOI 10.3171/jns.1983.59.6.0951; VENES JL, 1975, J NEUROSURG, V42, P429, DOI 10.3171/jns.1975.42.4.0429; Whitfield PC, 2001, BRIT J NEUROSURG, V15, P500, DOI 10.1080/02688690120105110; Yoo DS, 1999, J NEUROSURG, V91, P953, DOI 10.3171/jns.1999.91.6.0953	53	77	80	0	6	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0256-7040	1433-0350		CHILD NERV SYST	Childs Nerv. Syst.	SEP	2003	19	9					666	673		10.1007/s00381-003-0804-3			8	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	717MW	WOS:000185094500005	12908115				2021-06-18	
J	Spinella, PC; Dominguez, T; Drott, HR; Huh, J; McCormick, L; Rajendra, A; Argon, J; McIntosh, T; Helfaer, M				Spinella, PC; Dominguez, T; Drott, HR; Huh, J; McCormick, L; Rajendra, A; Argon, J; McIntosh, T; Helfaer, M			S-100 beta protein-serum levels in healthy children and its association with outcome in pediatric traumatic brain injury	CRITICAL CARE MEDICINE			English	Article						brain injuries; prognosis; child; nerve tissue protein S-100; human; Severity of Illness Index	INTENSIVE-CARE-UNIT; CEREBROSPINAL-FLUID; HEAD; SEVERITY; S100; NEURONS; AGE; MORTALITY; APOPTOSIS; RELEASE	Objective., To describe normal serum levels of S-100beta in healthy children and determine whether serum S-100beta levels after traumatic brain injury are associated with outcome. Design., Prospective cohort study. Setting., Urban, tertiary care, children's teaching hospital. Patients., A total of 136 healthy children and 27 children with traumatic brain injury. Methods. Serum S-100beta levels were measured in 136 healthy children. A total of 27 children with traumatic brain injury had S-100beta levels collected within 12 hrs of injury. Other indices of severity of injury measured were admission Glasgow Coma Scale score, and Pediatric Risk of Mortality score at 24 hrs (PRISM 24). Outcome was measured by the Pediatric Cerebral Performance Category (PCPC) score at hospital discharge and 6 months postinjury or at death. Measurements and Main Results. S-100beta levels in healthy children had a mean of 0.3 mug/L (90% confidence interval, 0.03-1.47) and inversely correlated with age, (r = -.32, p < .001). In children with traumatic brain injury, 6-month postinjury outcome inversely correlated with Glasgow Coma Scale score (r = -.47, p = .01) and correlated with PRISM 24 score (r = .83, p < .001) and S-100beta levels (r = .75, p < .001). Six months postinjury, comparing good outcome (PCPC less than or equal to 3, n = 20) vs. poor outcome (PCPC greater than or equal to 4, n = 7), median admission Glasgow Coma Scale scores were 8 (range, 3-15) and 3 (range, 3-7, p = .01), median PRISM 24 scores were 7 (range, 0-19) and 30 (range, 18-35, p < .001), and median S-100beta levels were 0.85 mug/L. (range, 0.08-4.8 mug/L) and 3.6 mug/L (range, 1.4-20 mug/L, p < .001), respectively. A serum S-100beta level of greater than or equal to2.0 mug/L is associated with poor outcome, with a sensitivity of 86% and a specificity of 95%. The area under the receiver operating curve for S-100beta was 0.94 (+/-0.05). Conclusions. Serum S-100beta levels in healthy children have a moderate inverse correlation with age. After traumatic brain injury in children, the acute assessment of serum S-100beta levels seems to be associated with outcome.	Childrens Hosp Philadelphia, Dept Anesthesiol, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Dept Crit Care Med, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA	Spinella, PC (corresponding author), Childrens Hosp Philadelphia, Dept Anesthesiol, Philadelphia, PA 19104 USA.						Ahlemeyer B, 2000, BRAIN RES, V858, P121, DOI 10.1016/S0006-8993(99)02438-5; AKTAR JI, 2001, CRIT CARE MED S12, V29, P459; AMWHALIN, 2001, CLIN CHIM ACTA, V304, P57; Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Asikainen I, 1998, BRAIN INJURY, V12, P95, DOI 10.1080/026990598122737; Berger Rachel, 2001, Pediatric Research, V49, p157A; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; BHATTACHARYYA A, 1992, J NEUROBIOL, V23, P451, DOI 10.1002/neu.480230410; DIECKMANN RA, 1995, PEDIATRICS, V95, P901; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; FANO G, 1995, PROG NEUROBIOL, V46, P71, DOI 10.1016/0301-0082(94)00062-M; Fiser DH, 2000, CRIT CARE MED, V28, P2616, DOI 10.1097/00003246-200007000-00072; FISER DH, 1992, J PEDIATR-US, V121, P68, DOI 10.1016/S0022-3476(05)82544-2; Fiser DH, 2000, CRIT CARE MED, V28, P1173, DOI 10.1097/00003246-200004000-00043; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Fulle S, 2000, EXP PHYSIOL, V85, P243; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Haglid KG, 1997, BRAIN RES, V753, P196, DOI 10.1016/S0006-8993(96)01463-1; HASLAM RHA, 1996, TXB PEDIAT, P1719; Herrmann M, 2000, STROKE, V31, P2670, DOI 10.1161/01.STR.31.11.2670; Hu JR, 1997, J NEUROCHEM, V69, P2294; Iwasaki Y, 1997, J NEUROL SCI, V151, P7, DOI 10.1016/S0022-510X(97)00073-7; KLIGMAN D, 1985, P NATL ACAD SCI USA, V82, P7136, DOI 10.1073/pnas.82.20.7136; LESCOHIER I, 1993, PEDIATRICS, V91, P721; Lindberg L, 1998, J THORAC CARDIOV SUR, V116, P281, DOI 10.1016/S0022-5223(98)70128-X; MARIGGIO MA, 1994, NEUROSCIENCE, V60, P29, DOI 10.1016/0306-4522(94)90201-1; Maschmann J, 2000, ACTA PAEDIATR, V89, P553, DOI 10.1080/080352500750027844; McAdory BS, 1998, BRAIN RES, V813, P211, DOI 10.1016/S0006-8993(98)01014-2; MCDONALD CM, 1994, ARCH PHYS MED REHAB, V75, P328, DOI 10.1016/0003-9993(94)90038-8; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; Nagdyman N, 2001, PEDIATR RES, V49, P502, DOI 10.1203/00006450-200104000-00011; Nygaard O, 1997, CLIN CHEM, V43, P541; Pollack MM, 1996, CRIT CARE MED, V24, P743, DOI 10.1097/00003246-199605000-00004; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Romner B, 2000, J NEUROTRAUM, V17, P641, DOI 10.1089/089771500415391; Rothoerl RD, 1998, J TRAUMA, V45, P765, DOI 10.1097/00005373-199810000-00025; TEPAS JJ, 1990, J PEDIATR SURG, V25, P92, DOI 10.1016/S0022-3468(05)80170-8; UEDA S, 1995, MOL BRAIN RES, V29, P365, DOI 10.1016/0169-328X(94)00269-K; VANELDIK LJ, 1991, BRAIN RES, V542, P280, DOI 10.1016/0006-8993(91)91579-P; Verger K, 2000, BRAIN INJURY, V14, P495; WALKER ML, 1984, CHILD BRAIN, V11, P387; WHITAKERAZMITIA PM, 1990, BRAIN RES, V528, P155, DOI 10.1016/0006-8993(90)90210-3; WINNINGHAMMAJOR F, 1989, J CELL BIOL, V109, P3063, DOI 10.1083/jcb.109.6.3063; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977; Woertgen C, 1999, J TRAUMA, V47, P1126, DOI 10.1097/00005373-199912000-00026	45	77	77	1	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	MAR	2003	31	3					939	945		10.1097/01.CCM.0000053644.16336.52			7	Critical Care Medicine	General & Internal Medicine	660RP	WOS:000181846800043	12627009				2021-06-18	
J	Zhang, LJ; Ravdin, LD; Relkin, N; Zimmerman, RD; Jordan, B; Lathan, WE; Ulug, AM				Zhang, LJ; Ravdin, LD; Relkin, N; Zimmerman, RD; Jordan, B; Lathan, WE; Ulug, AM			Increased diffusion in the brain of professional boxers: A preclinical sign of traumatic brain injury?	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article							AXONAL INJURY; HEAD-INJURY; DAMAGE	BACKGROUND AND PURPOSE: Professional boxing is associated with chronic, repetitive head blows that may cause brain injuries. Diffusion-weighted imaging is sensitive to microscopic changes and may be a useful tool to quantify the microstructural integrity of the brain. In this study, we sought to quantify microscopic alterations associated with chronic traumatic brain injury in professional boxers. METHODS: MR and diffusion-weighted imaging were performed in 24 boxers and in 14 age and sex-matched control subjects with no history of head trauma. Using distribution analysis, the average diffusion constant of the entire brain (BDav) and diffusion distribution width (a) were calculated for each subject; findings in professional boxers were compared with those of control subjects. In the boxer group, correlations between diffusion changes and boxing history and diffusion changes and MR imaging findings were assessed. RESULTS: The measured diffusion values in the boxer group were significantly higher than those measured in the control group (BDav, P < .0001; sigma, P <.01). In the boxer group, a robust correlation was found between increased BD., and frequency of hospitalization for boxing injuries (r = 0.654, P < .05). The most common MR finding in the boxer group was volume loss inappropriate to age followed by cavum septum pellucidum, subcortical white matter disease, and periventricular white matter disease. CONCLUSION. Boxers had higher diffusion constants than those in control subjects. Our data suggest that microstructural damage of the brain associated with chronic traumatic brain injury may elevate whole-brain diffusion. This global elevation can exist even when routine MR findings are normal.	Cornell Univ, Weill Med Coll, Dept Radiol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Neurol & Neurosci, New York, NY 10021 USA; Burke Rehabil Hosp, New York, NY USA; New York State Athlet Commiss, New York, NY USA	Ulug, AM (corresponding author), Cornell Univ, Weill Med Coll, Dept Radiol, Box 141, New York, NY 10021 USA.		Ulug, Aziz M/F-6592-2011	Ulug, Aziz M/0000-0002-2315-0322			ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Assaf Y, 1999, J NEUROTRAUM, V16, P1165, DOI 10.1089/neu.1999.16.1165; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Bodensteiner JB, 1997, SPORTS MED, V24, P361, DOI 10.2165/00007256-199724060-00002; Chun T, 2000, AM J NEURORADIOL, V21, P1078; CHUN T, 2000, P 8 M INT SOC MAGN R; CORSELLIS JAN, 1989, BRIT MED J, V298, P105, DOI 10.1136/bmj.298.6666.105; DORAN M, 1990, J COMPUT ASSIST TOMO, V14, P865, DOI 10.1097/00004728-199011000-00001; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; HAGLUND Y, 1990, ACTA NEUROL SCAND, V82, P297; Jones DK, 2000, NEUROSURGERY, V47, P306, DOI 10.1097/00006123-200008000-00008; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; JORDAN BD, 1988, ARCH NEUROL-CHICAGO, V45, P1207, DOI 10.1001/archneur.1988.00520350045014; Jordan BD, 2000, SEMIN NEUROL, V20, P179, DOI 10.1055/s-2000-9826; JORDAN BD, 1992, J NEUROIMAGING, V2, P181; LeBihan D, 1995, NMR BIOMED, V8, P375; LEBIHAN D, 1992, AM J ROENTGENOL, V159, P591, DOI 10.2214/ajr.159.3.1503032; McGowan JC, 1999, MAGN RESON MED, V41, P727, DOI 10.1002/(SICI)1522-2594(199904)41:4<727::AID-MRM11>3.3.CO;2-Y; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; MOONEN CTW, 1991, MAGNET RESON MED, V19, P327, DOI 10.1002/mrm.1910190223; Moseley IF, 2000, NEURORADIOLOGY, V42, P1, DOI 10.1007/s002340050001; MOSELEY ME, 1990, RADIOLOGY, V176, P439, DOI 10.1148/radiology.176.2.2367658; NG HK, 1994, CLIN NEUROL NEUROSUR, V96, P24, DOI 10.1016/0303-8467(94)90025-6; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; Takayama H, 2000, CLIN NEUROL NEUROSUR, V102, P135, DOI 10.1016/S0303-8467(00)00079-2; Ulug AM, 1999, JMRI-J MAGN RESON IM, V9, P804; ULUG AM, 2001, P 30 ANN M AM AG ASS, P72	28	77	79	1	7	AMER SOC NEURORADIOLOGY	DENVILLE	PO BOX 3000, DENVILLE, NJ 07834-9349 USA	0195-6108	1936-959X		AM J NEURORADIOL	Am. J. Neuroradiol.	JAN	2003	24	1					52	57					6	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	645EC	WOS:000180962400012	12533327				2021-06-18	
J	Roche, NL; Fleming, JM; Shum, DHK				Roche, NL; Fleming, JM; Shum, DHK			Self-awareness of prospective memory failure in adults with traumatic brain injury	BRAIN INJURY			English	Article							SEVERE HEAD-INJURY; EVERYDAY MEMORY; PERFORMANCE; DEFICITS; BOOK	The frequency of prospective memory failure in individuals with severe traumatic brain injury (TBI) was investigated by comparison with a non-brain-injured control group. Self-awareness of prospective memory function was also assessed by comparing self-ratings with ratings by significant others. Study participants included 33 individuals with severe TBI and 29 non-brain-injured persons. Each participant nominated a close friend or relative who completed the informant's version of the questionnaire. Participants and their significant others both rated the participants' frequency of prospective memory lapses using the Comprehensive Assessment of Prospective Memory (CAPM). An independent groups design was adopted to compare the TBI and control groups. No significant difference was found between the TBI and control participants' self-ratings of frequency of prospective memory failure, but ratings by significant others were significantly different. The TBI group demonstrated less self-awareness (i.e. underestimated the frequency of prospective memory failure compared to significant others) than the control group.	Univ Queensland, Dept Occupat Therapy, Brisbane, Qld 4072, Australia; Princess Alexandra Hosp, Dept Occupat Therapy, Woolloongabba, Qld, Australia; Griffith Univ, Sch Appl Psychol & Neuropsychol, Nathan, Qld 4111, Australia	Fleming, JM (corresponding author), Univ Queensland, Dept Occupat Therapy, Brisbane, Qld 4072, Australia.		Fleming, Jennifer M/B-4436-2011; Shum, David/A-3914-2008	Shum, David/0000-0002-4810-9262			Andrewes DG, 1998, NEUROPSYCHOL REHABIL, V8, P377, DOI 10.1080/713755582; Barco P.P., 1991, COGNITIVE REHABILITA, P129; BOAKE C, 1995, BRAIN INJURY, V9, P273, DOI 10.3109/02699059509008198; BROWN DSO, 1992, ARCH PHYS MED REHAB, V73, P758; BURKE JM, 1994, BRAIN INJURY, V8, P71, DOI 10.3109/02699059409150960; Cockburn J, 1996, J CLIN EXP NEUROPSYC, V18, P304, DOI 10.1080/01688639608408284; Crosson B., 1989, J HEAD TRAUMA REHAB, V4, P46, DOI [10.1097/00001199-198909000-00008, DOI 10.1097/00001199-198909000-00008]; DEATON AV, 1986, REHABIL PSYCHOL, V31, P231, DOI 10.1037//0090-5550.31.4.231; Einstein GO, 1997, PSYCHOL AGING, V12, P479, DOI 10.1037/0882-7974.12.3.479; Fleming JM, 1996, BRAIN INJURY, V10, P1; Fluharty George, 1993, Brain Injury, V7, P85, DOI 10.3109/02699059309008160; Fortune N, 1999, DEFINITION INCIDENCE; GLISKY EL, 1996, PROSPECTIVE MEMORY T, P249; GOLDSTEIN LH, 1992, BRIT J CLIN PSYCHOL, V31, P75, DOI 10.1111/j.2044-8260.1992.tb00969.x; GRIEVE J, 2000, NEUROPSYCHOLOGY OCCU, P148; Hannon R, 1995, REHABIL PSYCHOL, V40, P289, DOI 10.1037/0090-5550.40.4.289; HENDRYX PM, 1989, ARCH PHYS MED REHAB, V70, P526; HERRMANN DJ, 1982, PSYCHOL BULL, V92, P434, DOI 10.1037/0033-2909.92.2.434; Hutchinson J, 1997, TOP LANG DISORD, V18, P45, DOI 10.1097/00011363-199711000-00006; Kinsella G, 1996, BRAIN INJURY, V10, P499, DOI 10.1080/026990596124214; Mateer C.A., 1987, J HEAD TRAUMA REHAB, V2, P74, DOI [10.1097/00001199-198709000-00009, DOI 10.1097/00001199-198709000-00009]; Maylor E. A., 1993, ADULT INFORMATION PR, P529; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; Prigatano G. P., 1990, CLIN NEUROPSYCHOL, V4, P163, DOI [10.1080/13854049008401509, DOI 10.1080/13854049008401509]; Prigatano GP, 1998, CLIN NEUROPSYCHOL, V12, P56, DOI 10.1076/clin.12.1.56.1721; Prigatano GP, 1996, CLIN NEUROPSYCHOL, V10, P191, DOI 10.1080/13854049608406680; SCHWARTZ AF, 1989, CORTEX, V25, P665, DOI 10.1016/S0010-9452(89)80026-7; Shum D, 1999, J CLIN EXP NEUROPSYC, V21, P49, DOI 10.1076/jcen.21.1.49.943; Strong J., 1995, BRIT J OCCUPATIONAL, V58, P55, DOI DOI 10.1177/030802269505800204; Stuss D.T., 1986, FRONTAL LOBES; SUNDERLAND A, 1983, J VERB LEARN VERB BE, V22, P341, DOI 10.1016/S0022-5371(83)90229-3; SUNDERLAND A, 1984, J CLIN NEUROPSYCHOL, V6, P127, DOI 10.1080/01688638408401204; THOMPSON SBN, 1996, BRIT J OCCUPATIONAL, V59, P418; Varney N. R., 1993, J HEAD TRAUMA REHAB, V8, P32, DOI DOI 10.1097/00001199-199303000-00005; WAUGH N, 1999, THESIS GRIFFITH U	35	77	79	0	7	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	NOV	2002	16	11					931	945		10.1080/02699050210138581			15	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	609PQ	WOS:000178914500001	12443545				2021-06-18	
J	Levy, AS; Hawkes, AP; Hemminger, LM; Knight, S				Levy, AS; Hawkes, AP; Hemminger, LM; Knight, S			An analysis of head injuries among skiers and snowboarders	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	Annual Meeting of the American-College-of-Surgeons	JUN 10-12, 1999	BRECKENRIDGE, CO	Amer Coll Surg		skiing; snowboarding; traumatic brain injury; head injury; helmets	SKIING INJURIES; CHILDREN	Background. Head injury is the leading cause of death and critical injury in skiing and snowboarding accidents. Methods Data relating to head injuries occurring on the ski slopes were collected from the trauma registry of a Level I trauma center located near a number of ski resorts. Results: From 1982 to 1998, 350 skiers and snowboarders with head injuries were admitted to our Level I trauma center. Most of the injuries were mild, with Glasgow Coma Scale (GCS) scores of 13 to 15 in 81% and simple concussion in 69%. However, 14% of patients had severe brain injuries, with GCS scores of 3 to 8, and the overall mortality rate was 4%. Collision with a tree or other stationary object (skier-tree) was the mechanism of injury in 47% of patients; simple falls in 37%; collision with another skier (skier-skier) in 13%; and major falls in 3%. Skier-tree collision and major falls resulted in a higher percentage of severe injuries, with GCS scores of 3 to 8 in 24% and 20%, respectively, and mean Injury Severity Scores of 14 and 17, respectively. Mortality from skier-tree collision was 7.2%, compared with 1.6% in simple falls and no deaths from skier-skier collision or major falls. The risk of sustaining a head injury was 2.23 times greater for male subjects compared with female subjects, 2.81 times higher for skiers/boarders less than or equal to 35 years of age compared with those > 35 years, and 3.04 times higher for snowboarders compared with skiers. Conclusion. Skier-tree collision was the most common mechanism for head injuries in patients admitted to our Level I trauma center, and resulted in the most severe injuries and the highest mortality rate. Because most traumatic brain injuries treated at our facility resulted from a direct impact mechanism, we believe that the use of helmets can reduce the incidence and severity of head injuries occurring on the ski slopes.	St Anthony Cent Hosp, Trauma Serv, Denver, CO USA	Levy, AS (corresponding author), Intermt Neurosurg & Neurosci, 4101 W Conejos Pl,Suite 225, Denver, CO 80204 USA.						ABULABAN RB, 1991, CAN MED ASSOC J, V145, P1097; BLADIN C, 1995, SPORTS MED, V19, P358, DOI 10.2165/00007256-199519050-00005; BLITZER CM, 1984, AM J SPORT MED, V12, P142, DOI 10.1177/036354658401200210; *COL DEP PUBL HLTH, 2000, RECR FAT COL 1996 19, P35; *COL DEP PUBL HLTH, 1996, REC FAT COL 1993 199, P8; Davidson TM, 1996, WESTERN J MED, V164, P231; Davidson TM, 1996, WESTERN J MED, V164, P310; Dean AG., 1994, EPI INFO VERSION 6 W; Deibert MC, 1998, J BONE JOINT SURG AM, V80A, P25, DOI 10.2106/00004623-199801000-00006; FURRER M, 1995, J TRAUMA, V39, P737, DOI 10.1097/00005373-199510000-00024; Macnab A J, 1996, Inj Prev, V2, P286, DOI 10.1136/ip.2.4.286; MORROW PL, 1988, J TRAUMA, V28, P95, DOI 10.1097/00005373-198801000-00014; MYLES ST, 1992, CAN J SURG, V35, P643; Nakaguchi H, 1999, J TRAUMA, V46, P1066, DOI 10.1097/00005373-199906000-00017; PRALL JA, 1995, INJURY, V26, P539, DOI 10.1016/0020-1383(95)00085-N; Sacco DE, 1998, J TRAUMA, V44, P654, DOI 10.1097/00005373-199804000-00016; Sahlin Y, 1989, Br J Sports Med, V23, P241; SANDEGAARD J, 1991, ASTM STP, V1104, P170; *SAS I INC, 1998, STATV; SHERRY E, 1988, MED J AUSTRALIA, V149, P615, DOI 10.5694/j.1326-5377.1988.tb120803.x; Shorter NA, 1996, J TRAUMA, V40, P997, DOI 10.1097/00005373-199606000-00024; Sutherland AG, 1996, INJURY, V27, P423, DOI 10.1016/0020-1383(96)00026-5; TOUGH SC, 1993, AM J FOREN MED PATH, V14, P12, DOI 10.1097/00000433-199303000-00003; *UCHSC COL TRAUM I, 1995, SKI SNOWB INJ, P1; UNGERHOLM S, 1983, INT J SPORTS MED, V4, P236, DOI 10.1055/s-2008-1026041; US Consumer Product Safety Commission, 1999, SKIING HELM EV POT R	26	77	77	0	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	OCT	2002	53	4					695	704		10.1097/00005373-200210000-00013			10	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	604JZ	WOS:000178618400017	12394869				2021-06-18	
J	Hukkelhoven, CWPM; Steyerberg, EW; Farace, E; Habbema, JDF; Marshall, LF; Maas, AIR				Hukkelhoven, CWPM; Steyerberg, EW; Farace, E; Habbema, JDF; Marshall, LF; Maas, AIR			Regional differences in patient characteristics, case management, and outcomes in traumatic brain injury: experience from the tirilazad trials	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; clinical trial; case management; referral policy; geographic region; Glasgow Outcome Scale	CLINICAL-TRIALS; NEUROPROTECTIVE AGENTS; HEAD-INJURY; EFFICACY; COMA; CARE	Object. Regional differences have been shown in patient characteristics and case management within multiple unselected series of patients suffering from traumatic brain injury (TBI). One might expect that such regional heterogeneity would be small in a more selected population of a randomized clinical trial. The goal of this study was to examine what regional differences in patient characteristics, case management, and outcomes exist between continents and among countries within a patient population included in a randomized clinical trial. Methods. Data were extracted from two concurrently conducted randomized clinical trials of the drug tirilazad; the designs of these studies were similar. The studies included 1701 patients with severe and 476 patients with moderate TBI. Differences were primarily investigated between studies performed in Europe and North America, but also among European regions and between Canada and the United States. Associations among regions and outcomes (6-month mortality rate and Glasgow Outcome Scale scores) were studied using multivariable logistic regression analysis. Comparisons between continents and among regions within Europe showed differences in the distribution of patient ages, causes of injury, and several clinical characteristics (motor score, pupillary reactivity, hypoxia, hypotension, intracranial pressure [ICP]), and findings on computerized tomography scans. Secondary referrals occurred 2.5 times more frequently in Europe. Within Europe secondary referral was mainly associated with an increased proportion of patients with mass lesions (46% in the European Study compared with 40% in the North American Study). Therapy for lowering ICP was more frequently applied in North America. After adjustments for case mix and management, mortality and unfavorable outcomes were significantly higher in Europe (odds ratios = 1.58 and 1.46, respectively). Significant differences in outcome between regions within Europe or within North America were not observed. Conclusions. Despite the use of a strict study protocol, considerable differences in patient characteristics and case management exist between continents and among countries, reflecting variations in social, cultural, and organizational aspects. Outcomes of TBI may be worse in Europe compared with North America, but this finding requires further study.	Erasmus MC, Dept Publ Hlth, Ctr Clin Decis Sci, NL-3000 DR Rotterdam, Netherlands; Erasmus MC, Dept Neurol Surg, Ctr Clin Decis Sci, NL-3000 DR Rotterdam, Netherlands; Univ Virginia, Hlth Sci Ctr, Dept Neurol Surg, Charlottesville, VA USA; Univ Calif San Diego, Dept Neurol Surg, San Diego, CA 92103 USA	Hukkelhoven, CWPM (corresponding author), Erasmus MC, Dept Publ Hlth, Ctr Clin Decis Sci, Ee20-42,POB 1738, NL-3000 DR Rotterdam, Netherlands.	hukkelhoven@mgz.fgg.eur.nl	Maas, Andrew IR/C-5584-2013; Steyerberg, Ewout/C-1509-2018	Maas, Andrew IR/0000-0003-1612-1264; Hukkelhoven, Chantal/0000-0002-0015-1883; Steyerberg, Ewout/0000-0002-7787-0122			Bullock RM, 2000, J NEUROTRAUM, V17, P449; Chesnut RM, 2000, J NEUROTRAUM, V17, P555; Clifton GL, 2001, J NEUROSURG, V95, P751, DOI 10.3171/jns.2001.95.5.0751; FOULKES MA, 1991, J NEUROSURG, V75, pS8, DOI 10.3171/sup.1991.75.1s.00s8; GENNARELLI TA, 1982, J TRAUMA, V22, P680, DOI 10.1097/00005373-198208000-00005; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; GUTMAN MB, 1992, J NEUROSURG, V77, P9, DOI 10.3171/jns.1992.77.1.0009; HALL ED, 1992, J NEUROTRAUM, V9, pS425; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; Jeevaratnam DR, 1996, BRIT MED J, V312, P944; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; JENNETT B, 1975, LANCET, V1, P480; LITTLE RJA, 1992, J AM STAT ASSOC, V87, P1227, DOI 10.2307/2290664; Maas AIR, 1999, NEUROSURGERY, V44, P1286, DOI 10.1097/00006123-199906000-00076; Machado SG, 1999, J NEUROTRAUM, V16, P1131, DOI 10.1089/neu.1999.16.1131; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Matta B, 1996, CRIT CARE MED, V24, P1743, DOI 10.1097/00003246-199610000-00023; Murphy LS, 1999, BRIT J NEUROSURG, V13, P564, DOI 10.1080/02688699943060; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; ROBINSON LD, 1991, INT STAT REV, V59, P227, DOI 10.2307/1403444; Steyerberg EW, 2000, AM HEART J, V139, P745, DOI 10.1016/S0002-8703(00)90001-2; TEASDALE G, 1974, LANCET, V2, P81	24	77	81	0	11	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	SEP	2002	97	3					549	557		10.3171/jns.2002.97.3.0549			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	593JA	WOS:000177986400008	12296638				2021-06-18	
J	Vespa, PM; Boscardin, WJ; Hovda, DA; McArthur, DL; Nuwer, MR; Martin, NA; Nenov, V; Glenn, TC; Bergsneider, M; Kelly, DF; Becker, DP				Vespa, PM; Boscardin, WJ; Hovda, DA; McArthur, DL; Nuwer, MR; Martin, NA; Nenov, V; Glenn, TC; Bergsneider, M; Kelly, DF; Becker, DP			Early and persistent impaired percent alpha variability on continuous electroencephalography monitoring as predictive of poor outcome after traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; neurosurgery intensive care unit; percentage of alpha variability; secondary insult; prognosis	SEVERE HEAD-INJURY; CEREBRAL BLOOD-FLOW; SOMATOSENSORY-EVOKED-POTENTIALS; COMPRESSED SPECTRAL ARRAY; STATUS-EPILEPTICUS; PROGNOSTIC VALUE; COMA; EEG; SCALE; VASOSPASM	Object. Early prediction Of Outcomes in patients after they suffer traumatic brain injury (TBI) is often nonspecific and based on initial imaging and clinical findings alone, without direct physiological testing. Improved outcome prediction is desirable for ethical, social. and financial reasons. The goal of this Study was to determine the usefulness of continuous electroencephalography (EEG) monitoring in determining prognosis early after TBI. while the patient is in the intensive care unit. Methods. The authors hypothesized that the reduced percentage of alpha variability (PAV) in continuous EEG tracings indicates a poor prognosis. Prospective continuous EEG monitoring was performed in 89 consecutive patients with moderate to severe TBI (Glasgow Coma Scale [GCS] Scores 3-12) from 0 to 10 days after injury. The PAV was calculated daily, and the time course and trends of the PAV were analyzed in comparison with the patient's Glasgow Outcome Scale (GOS) score at the time of discharge. In patients with GCS scores of 8 or lower, a PAV value of 0.1 or lower is highly predictive of a poor outcome or death (positive predictive value 86%). The determinant PAV value was obtained by Day 3 after injury. Persistent PAV values of 0.1 or lower over several days or worsening of the PAV to a Value of 0.1 or lower indicated a high likelihood of poor Outcome (GOS Scores 1 and 2). In comparison with the combination of traditional initial clinical indicators of outcome (GCS score, pupillary response to light, patient age, results of computerized tomography scanning, and early hypotension or hypoxemia), the early PAV value during the initial 3 days after injury independently improved prognostic ability (P < 0.01). Conclusions. Continuous EEG monitoring performed with particular attention paid to the PAV is a sensitive and specific method of prognosis that can indicate Outcomes in patients with moderate to severe TBI within 3 days postinjury.	Univ Calif Los Angeles, Sch Med, Div Neurosurg, Dept Neurol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Div Neurosurg, Dept Med & Mol Pharmacol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Biostat, Sch Publ Hlth, Los Angeles, CA 90095 USA	Vespa, PM (corresponding author), Univ Calif Los Angeles, Sch Med, Div Neurosurg, Dept Neurol, 10833 LeConte Ave,CHS 18-218, Los Angeles, CA 90095 USA.	Pvespa@mednet.ucla.edu	McArthur, David/E-6442-2013	McArthur, David/0000-0003-3385-1314; Martin, Neil/0000-0002-6565-4131; Glenn, Thomas/0000-0003-4273-3408			Alster Jason, 1993, Brain Injury, V7, P191, DOI 10.3109/02699059309029672; BERGAMASCO B, 1968, ELECTROEN CLIN NEURO, V24, P374, DOI 10.1016/0013-4694(68)90198-3; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; BICKFORD RG, 1973, AUTOMATION CLIN ELEC, P56; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BRICOLO A, 1978, ELECTROEN CLIN NEURO, V45, P211, DOI 10.1016/0013-4694(78)90005-6; CHAN KH, 1993, NEUROSURGERY, V32, P547; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; CHOI SC, 1994, J NEUROSURG, V81, P169, DOI 10.3171/jns.1994.81.2.0169; CHOI SC, 1983, J NEUROSURG, V59, P294, DOI 10.3171/jns.1983.59.2.0294; CHOI SC, 1991, J NEUROSURG, V75, P251, DOI 10.3171/jns.1991.75.2.0251; CHOI SC, 1988, J NEUROSURG, V69, P381, DOI 10.3171/jns.1988.69.3.0381; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CUSUMANO S, 1992, ELECTROEN CLIN NEURO, V84, P499, DOI 10.1016/0168-5597(92)90039-E; EVANS BM, 1995, J NEUROL NEUROSUR PS, V59, P17, DOI 10.1136/jnnp.59.1.17; FACCO E, 1986, CHILD NERV SYST, V2, P67; GUTLING E, 1994, ELECTROEN CLIN NEURO, V92, P568, DOI 10.1016/0168-5597(94)90141-4; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HILZ MJ, 1991, INTENS CARE MED, V17, P87, DOI 10.1007/BF01691429; HULIHAN JF, 1994, NEUROLOGY, V44, P758, DOI 10.1212/WNL.44.4.758; JAGGI JL, 1990, J NEUROSURG, V72, P176, DOI 10.3171/jns.1990.72.2.0176; Jaitly R, 1997, J CLIN NEUROPHYSIOL, V14, P326, DOI 10.1097/00004691-199707000-00005; JENNETT B, 1975, LANCET, V1, P480; JENNETT WB, 1960, J NEUROL NEUROSUR PS, V23, P295, DOI 10.1136/jnnp.23.4.295; JUDSON JA, 1990, CRIT CARE MED, V18, P363, DOI 10.1097/00003246-199004000-00003; KARNAZE DS, 1982, NEUROLOGY, V32, P289, DOI 10.1212/WNL.32.3.289; Kelly DF, 1997, J NEUROSURG, V86, P633, DOI 10.3171/jns.1997.86.4.0633; KIDO DK, 1992, RADIOLOGY, V182, P777, DOI 10.1148/radiology.182.3.1535893; KRIEGER D, 1995, CRIT CARE MED, V23, P1123, DOI 10.1097/00003246-199506000-00020; Lee JH, 1997, J NEUROSURG, V87, P221, DOI 10.3171/jns.1997.87.2.0221; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVY ML, 1994, NEUROSURGERY, V35, P77, DOI 10.1227/00006123-199407000-00012; Littell R. C. G. A., 1996, SAS SYSTEM MIXED MOD; LOBATO RD, 1986, J NEUROSURG, V65, P784, DOI 10.3171/jns.1986.65.6.0784; Lowenstein DH, 1998, NEW ENGL J MED, V338, P970, DOI 10.1056/NEJM199804023381407; LOWENSTEIN DH, 1993, NEUROLOGY, V43, P483, DOI 10.1212/WNL.43.3_Part_1.483; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; Miller J D, 1994, Neurosurg Clin N Am, V5, P661; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; Olshen RA, 1984, CLASSIFICATION REGRE; Palmer S, 2001, J TRAUMA, V50, P657, DOI 10.1097/00005373-200104000-00010; RAEGRANT AD, 1991, ELECTROEN CLIN NEURO, V79, P349, DOI 10.1016/0013-4694(91)90199-E; ROBERTSON CS, 1992, J NEUROL NEUROSUR PS, V55, P594, DOI 10.1136/jnnp.55.7.594; RUMPL E, 1979, ELECTROEN CLIN NEURO, V46, P487, DOI 10.1016/0013-4694(79)90002-6; Steudel W I, 1979, Acta Neurochir Suppl (Wien), V28, P40; SYNEK VM, 1988, J CLIN NEUROPHYSIOL, V5, P161, DOI 10.1097/00004691-198804000-00003; TEASDALE G, 1974, LANCET, V2, P81; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Thatcher R W, 1991, Ann N Y Acad Sci, V620, P82, DOI 10.1111/j.1749-6632.1991.tb51576.x; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; Vespa PM, 1997, ELECTROEN CLIN NEURO, V103, P607, DOI 10.1016/S0013-4694(97)00071-0; YAFFE K, 1993, NEUROLOGY, V43, P895, DOI 10.1212/WNL.43.5.895; YOUNG GB, 1994, ELECTROEN CLIN NEURO, V91, P93, DOI 10.1016/0013-4694(94)90030-2	56	77	84	1	6	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JUL	2002	97	1					84	92		10.3171/jns.2002.97.1.0084			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	570NU	WOS:000176665000013	12134937				2021-06-18	
J	Wagner, AK; Hammond, FM; Sasser, HC; Wiercisiewski, D				Wagner, AK; Hammond, FM; Sasser, HC; Wiercisiewski, D			Return to productive activity after traumatic brain injury: Relationship with measures of disability, handicap, and community integration	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; disabled persons; employment; productivity; rehabilitation; work	QUALITY-OF-LIFE; SUPPORTED EMPLOYMENT; WORK	Objectives: To identify which factors are associated with successful return to productive activity (RTPA) 1 year after hospitalization with traumatic brain injury (TBI) and to examine the relations between successful RTPA and other measures of impairment, disability, handicap, and integration into the community. Design: Prospective study with 1-year follow-up. Setting: Level I trauma center. Participants: One hundred five respondents from a cohort of 378 adults hospitalized with TBI admitted between September 1997 and May 1998. Interventions: Not applicable. Main Outcome Measures: Return to productive work 1 year after injury; Disability Rating Scale (DRS); and Community Integration Scale (CIQ). Results: Of the 105 participants, 72% achieved RTPA. Logistic regression showed an association between RPTA and the following factors: premorbid educational level, premorbid psychiatric history, violent mechanism of injury, discharge status after acute hospitalization, prior alcohol and drug use, and injury severity. Handicap and community integration at 1-year postinjury, as measured by subscales of the DRS and the CIQ, were also associated with RTPA. Conclusion: Premorbid and injury-related variables and measures of handicap and community integration were associated with RTPA at 1 year. To understand and effectively support vocational pursuits in the TBI population, future studies are needed to define further causality and origin of these relationships.	Charlotte Inst Rehabil, Dept Phys Med & Rehabil, Charlotte, NC USA; Carolinas Med Ctr, Dept Res Epidemiol, Charlotte, NC 28203 USA	Wagner, AK (corresponding author), Univ Pittsburgh, Dept Phys Med & Rehabil, 3471 5th Ave,Kaufmann Bldg Ste 901, Pittsburgh, PA 15213 USA.						Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; Greenspan AI, 1996, BRAIN INJURY, V10, P207, DOI 10.1080/026990596124520; Hall KM, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199610000-00004; Hall KM., 1993, J HEAD TRAUMA REHAB, V8, DOI [DOI 10.1097/00001199-199308020-00008, 10.1097/00001199-199308020-00008]; HEINEMANN AW, 1995, J HEAD TRAUMA REHAB, V10, P54, DOI 10.1097/00001199-199508000-00006; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; O'Neill J, 1998, J HEAD TRAUMA REHAB, V13, P68, DOI 10.1097/00001199-199808000-00007; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Ruffolo CF, 1999, ARCH PHYS MED REHAB, V80, P392, DOI 10.1016/S0003-9993(99)90275-7; Sander AM, 1999, ARCH PHYS MED REHAB, V80, P1303, DOI 10.1016/S0003-9993(99)90034-5; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Vogenthaler D R, 1989, Brain Inj, V3, P355, DOI 10.3109/02699058909004560; Wagner AK, 2000, J TRAUMA, V49, P411, DOI 10.1097/00005373-200009000-00005; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; WEHMAN P, 1993, AM J PHYS MED REHAB, V72, P355; Wehman Paul, 1993, Brain Injury, V7, P31, DOI 10.3109/02699059309008154; WEHMAN PH, 1991, ARCH PHYS MED REHAB, V72, P101; Willer B, 1993, J HEAD TRAUMA REHAB, V3, P75, DOI DOI 10.1097/00001199-199308020-00009	20	77	80	0	6	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JAN	2002	83	1					107	114		10.1053/apmr.2002.27470			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	509JU	WOS:000173145300017	11782840				2021-06-18	
J	Siessegger, M; Mischkowski, RA; Schneider, BT; Krug, B; Klesper, B; Zoller, JE				Siessegger, M; Mischkowski, RA; Schneider, BT; Krug, B; Klesper, B; Zoller, JE			Image guided surgical navigation for removal of foreign bodies in the head and neck	JOURNAL OF CRANIO-MAXILLOFACIAL SURGERY			English	Article							INTRAOPERATIVE NAVIGATION; GUNSHOT WOUNDS; BODY	Introduction: The removal of foreign bodies in the head and neck area is often a surgical challenge due to a combination of difficult access and a close anatomical relationship of the foreign body to vital structures. Recent developments in computer-assisted surgery (CAS) have brought major improvements to the operating rooms for maxillofacial surgeons. The purpose of this paper is to report our experience in computer assisted removal of foreign bodies from the head and neck area, based on various clinical cases. Patients: Computer assisted removal of foreign bodies from the head and neck area was performed in 11 patients. Three patients sustained gun shot wounds with remaining projectiles or fragments in the soft tissue. In six cases, objects related to a preceding surgical intervention were removed. Two patients presented with dislocated teeth in the facial or cervical soft tissues after 3rd molar surgery. Method: For surgical planning and intra-operative navigation, a computer based image guided surgery system (VectorVision(2(R)), BrainLab) was used. Results: In 10 of 11 cases the foreign bodies could be removed without major complications by a minimal invasive manner. More than 40 % of surgery time could be saved compared to similar interventions operated upon using conventional methods. Conclusion: In our opinion, the use of a computer based image guided surgical system is of great benefit when removing foreign bodies from the head and neck area. The minimally invasive access helps to prevent major complications such as injury to vital structures and allows a quicker operation. (C) 2001 European Association for Cranio-Maxillofacial Surgery.	Univ Cologne, Dept Maxillofacial Surg, D-50937 Cologne, Germany; Univ Cologne, Dept Radiol, D-50937 Cologne, Germany	Siessegger, M (corresponding author), Univ Cologne, Dept Maxillofacial Surg, Kerpener Str 62, D-50937 Cologne, Germany.		Krug, Kathrin Barbara/ABA-5087-2020				Amirjamshidi A, 1997, SURG NEUROL, V47, P331, DOI 10.1016/S0090-3019(96)00357-6; Balbani APS, 1998, INT J PEDIATR OTORHI, V46, P37, DOI 10.1016/S0165-5876(98)00118-9; Coales UF, 1999, J LARYNGOL OTOL, V113, P683, DOI 10.1017/S0022215100144858; Enislidis G, 1997, BRIT J ORAL MAX SURG, V35, P271, DOI 10.1016/S0266-4356(97)90046-2; Gonul E, 1999, MINIM INVAS NEUROSUR, V42, P207, DOI 10.1055/s-2008-1053401; Gumprecht HK, 1999, NEUROSURGERY, V44, P97, DOI 10.1097/00006123-199901000-00056; HASSFELD S, 1995, INT J ORAL MAX SURG, V24, P111; Hyckel P, 1999, Mund Kiefer Gesichtschir, V3, P102, DOI 10.1007/s100060050106; Potapov AA, 1996, J CRANIOFAC SURG, V7, P224, DOI 10.1097/00001665-199605000-00011; Reiss M, 1998, SCHWEIZ RUNDSCH MED, V87, P832; Wenzel M., 1994, Ophthalmologe, V91, P31; Winkler D, 2000, INT CONGR SER, V1214, P161; Yetiser S, 1998, MIL MED, V163, P346	13	77	82	0	1	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	1010-5182			J CRANIO MAXILL SURG	J. Cranio-MaxilloFac. Surg.	DEC	2001	29	6					321	325		10.1054/jcms.2001.0254			5	Dentistry, Oral Surgery & Medicine; Surgery	Dentistry, Oral Surgery & Medicine; Surgery	516CW	WOS:000173535100001	11777348				2021-06-18	
J	Naredi, S; Olivecrona, M; Lindgren, C; Ostlund, AL; Grande, PO; Koskinen, LOD				Naredi, S; Olivecrona, M; Lindgren, C; Ostlund, AL; Grande, PO; Koskinen, LOD			An outcome study of severe traumatic head injury using the "Lund therapy" with low-dose prostacyclin	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						head injury; outcome; prostacyclin	BRAIN VOLUME REGULATION; PRINCIPLES; MANAGEMENT; EDEMA	Background: There are two independent head injury outcome studies using the "Lund concept", and both showed a mortality rate of about 10%, and a favourable outcome (Glasgow outcome scale, GOS 4 and 5) of about 70%. The Lund concept aims at controlling intracranial pressure, and improving microcirculation around contusions. Intracranial pressure is controlled by maintaining a normal colloid osmotic pressure and reducing the hydrostatic capillary pressure. Microcirculation is improved by ensuring strict normovolaemia and reducing sympathetic discharge. The endogenous substance prostacyclin with its antiaggregatory/antiadhesive effects may further improve microcirculation, which finds support from a microdialysis-based clinical study and an experimental brain trauma study. The present clinical outcome study aims at evaluating whether the previously obtained good outcome with the Lund therapy can be reproduced, and whether the addition of prostacyclin has any adverse side-effects. Methods: All 31 consecutive patients with severe head injury, Glasgow coma scale (GCS) less than or equal to8, admitted to the University Hospital of Umea during 1998 were included. The Lund therapy including prostacyclin infusion for the first three days at a dose of 0.5 ng kg(-1) min(-1). Outcome was evaluated according to the GOS >10 months after the injury. Results: One patient died, another suffered vegetative state and 7 severe disability. Of the 22 patients with favourable outcome, 19 showed good recovery and 3 moderate disability. No adverse side-effects of prostacyclin were observed. Conclusion: The outcome results from previous studies using the Lund therapy were reproduced, and no adverse side-effects of low-dose prostacyclin were observed.	Univ Umea Hosp, Dept Anaesthesia & Intens Care, SE-90185 Umea, Sweden; Univ Umea Hosp, Dept Neurosurg, SE-90185 Umea, Sweden; Lund Univ, Dept Anaesthesia & Intens Care, Lund, Sweden; Univ Lund Hosp, Dept Anaesthesia & Intens Care, S-22185 Lund, Sweden	Naredi, S (corresponding author), Univ Umea Hosp, Dept Anaesthesia & Intens Care, SE-90185 Umea, Sweden.	silvana.naredi.us@vll.se	Koskinen, Lars-Owe/AAQ-8957-2020	Naredi, Silvana/0000-0002-4409-6089; Koskinen, Lars-Owe/0000-0003-3528-8502; Lindgren, Cecilia/0000-0002-4903-9374			ASGEIRSSON B, 1994, INTENS CARE MED, V20, P260, DOI 10.1007/BF01708961; BENTZER P, 1999, J NEUROTRAUM, V16, pA979; Chesnut RM, 1997, J TRAUMA, V42, pS4, DOI 10.1097/00005373-199705001-00002; Eker C, 1998, CRIT CARE MED, V26, P1881, DOI 10.1097/00003246-199811000-00033; Eker C, 2000, BRAIN INJURY, V14, P605; Grande PO, 2000, ACTA ANAESTH SCAND, V44, P886, DOI 10.1034/j.1399-6576.2000.440718.x; Grande PO, 1997, J TRAUMA, V42, pS23, DOI 10.1097/00005373-199705001-00005; GRYGLEWSKI RJ, 1983, STROKE, V14, P197, DOI 10.1161/01.STR.14.2.197; JENNETT B, 1975, LANCET, V1, P480; JONES G, 1984, J PATHOL, V142, P51, DOI 10.1002/path.1711420110; Moller AD, 1997, AM J PHYSIOL-HEART C, V273, pH200; MONCADA S, 1976, NATURE, V263, P663, DOI 10.1038/263663a0; MONCADA S, 1978, PHARMACOL REV, V30, P293; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Naredi S, 1998, INTENS CARE MED, V24, P446, DOI 10.1007/s001340050594; ORFEO T, 1994, J TRAUMA, V37, P347, DOI 10.1097/00005373-199409000-00003; PLUTA R, 1994, ACTA NEUROCHIR, P303; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Scheeren T, 1997, INTENS CARE MED, V23, P146, DOI 10.1007/s001340050309; VANE JR, 1995, AM J CARDIOL, V75, pA3, DOI 10.1016/S0002-9149(99)80377-4	20	77	79	1	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	APR	2001	45	4					402	406		10.1034/j.1399-6576.2001.045004402.x			5	Anesthesiology	Anesthesiology	417PQ	WOS:000167843700002	11300376				2021-06-18	
J	Suehiro, E; Povlishock, JT				Suehiro, E; Povlishock, JT			Exacerbation of traumatically induced axonal injury by rapid posthypothermic rewarming and attenuation of axonal change by cyclosporin A	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; hypothermia; cyclosporin A; axonal injury; rat	AMYLOID PRECURSOR PROTEIN; DIFFUSE BRAIN INJURY; POSTTRAUMATIC HYPOTHERMIA; HEAD-INJURY; INTRACRANIAL HYPERTENSION; THERAPEUTIC HYPOTHERMIA; MODERATE HYPOTHERMIA; MILD HYPOTHERMIA; DAMAGE; MODEL	Object. Although considerable attention has been focused on the use of posttraumatic hypothermia, little consideration has been given to the issue of posthypothermic rewarming and its potentially damaging consequences. In this communication, the authors examine the issue of rapid posthypothermic rewarming compared with gradual rewarming while exploring the potential utility of cyclosporin A (CsA) administration for attenuatings any rapid rewarming-induced axonal change. Methods. Male Sprague-Dawley rats were subjected to impact-acceleration injury and then their body temperature was lowered to 32 degreesC for 1 hour postinjury. After hypothermia, rewarming to normothermic levels was accomplished either within a 20-minute period (rapid rewarming) or over a 90-minute period (slow rewarming). Some animals in the rapid rewarming group received intrathecal infusion of either CsA or its vehicle, whereas the rats in the slow rewarming group received vehicle alone. Both the CsA and its vehicle were administered immediately before initiation of rewarming. Twenty-four hours postinjury the animals' brains were processed for visualization of amyloid precursor protein (APP), a marker of traumatic axonal injury. The APP-positive axonal density in the gradual ly rewarmed group receiving vehicle was statistically significantly reduced in comparison with the rapidly rewarmed, vehicle-treated group. For the group undergoing rapid rewarming and treatment with CsA, a statistically significant reduction was also found in the density of the APP profiles compared with the rapidly rewarmed, vehicle-treated group. Conclusions. The results of this study show that rapid rewarming exacerbates traumatically induced axonal injury, which can be significantly attenuated by administering CsA.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Anat, Richmond, VA 23298 USA; Yamaguchi Univ, Sch Med, Dept Neurosurg, Yamaguchi, Japan	Povlishock, JT (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Anat, Virginia Campus,POB 980709, Richmond, VA 23298 USA.		Suehiro, Eiichi/I-5852-2019		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS020193] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 20193] Funding Source: Medline		BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Buki A, 1999, EXP NEUROL, V159, P319, DOI 10.1006/exnr.1999.7139; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Clark RSB, 1996, J CEREBR BLOOD F MET, V16, P253, DOI 10.1097/00004647-199603000-00010; CLIFTON GL, 1995, J NEUROTRAUM, V12, P923, DOI 10.1089/neu.1995.12.923; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Huh PW, 2000, J NEUROSURG, V92, P91, DOI 10.3171/jns.2000.92.1.0091; JIANG JY, 1991, J NEUROSURG, V74, P492, DOI 10.3171/jns.1991.74.3.0492; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; KOIZUMI H, IN PRESS BRAIN RES; LeDucq N, 1998, BIOCHEM J, V336, P501, DOI 10.1042/bj3360501; Marion DW, 1996, J NEUROTRAUM, V13, P139, DOI 10.1089/neu.1996.13.139; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MARSH DC, 1991, HEPATOLOGY, V13, P500, DOI 10.1002/hep.1840130318; Nakamura T, 1999, J NEUROSURG, V91, P114, DOI 10.3171/jns.1999.91.1.0114; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; PALMER AM, 1993, J NEUROTRAUM, V10, P363, DOI 10.1089/neu.1993.10.363; Povlishock JT, 1996, ACT NEUR S, V66, P81; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Sabatini DM, 1997, MOL NEUROBIOL, V15, P223, DOI 10.1007/BF02740635; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; Stone JR, 1999, ACTA NEUROPATHOL, V97, P335, DOI 10.1007/s004010050996; Tateishi A, 1998, NEUROSURGERY, V42, P1065, DOI 10.1097/00006123-199805000-00066; Wakiyama S, 1997, BRIT J SURG, V84, P459; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	31	77	79	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	MAR	2001	94	3					493	498		10.3171/jns.2001.94.3.0493			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	405KB	WOS:000167157600018	11235956				2021-06-18	
J	Elting, JW; de Jager, AEJ; Teelken, AW; Schaaf, MJ; Maurits, NM; van der Naalt, J; Sibinga, CTS; Sulter, GA; De Keyser, J				Elting, JW; de Jager, AEJ; Teelken, AW; Schaaf, MJ; Maurits, NM; van der Naalt, J; Sibinga, CTS; Sulter, GA; De Keyser, J			Comparison of serum S-100 protein levels following stroke and traumatic brain injury	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article						S-100; serum; stroke; traumatic brain injury; TIA; comparison	MINOR HEAD-INJURY; ASTROGLIAL 5-HT1A RECEPTORS; NEURON-SPECIFIC ENOLASE; POSITIVE GLIAL-CELLS; SPONTANEOUS REPERFUSION; PROLIFERATIVE RESPONSE; CEREBROSPINAL-FLUID; CEREBRAL INFARCTS; ISCHEMIC STROKE; NERVOUS-SYSTEM	Temporal changes in serum S-100 protein levels were compared between patients with ischemic stroke, transient ischemic attack (TIA) and traumatic brain injury (TBI). In addition, S-100 levels were correlated with clinical severity and outcome. Measurements were done with a LIA-mat Sangtec(R) 100 using an automated immunoluminometric assay. Serum S-100 was measured in 21 stroke patients, 18 TIA patients and ten TBI patients on days 1 (0-24 h), 2, 3, 4, 5 or 6 and 8 or 9. In a control group of 28 healthy volunteers one measurement was done. For the stroke and TIA patients, National Institutes of Health Stroke Scale (NIHSS) scores were obtained on admission and on day 10. For the TBI patients, Glasgow Coma Scale (GCS) scores were obtained on admission and Glasgow Outcome Scale (GOS) scores were obtained after 6 months:. Changes in serum S-100 levels over the first 3 days were significantly different between stroke and TBI patients (P = 0.014) and between stroke and TIA patients (P = 0.006). Peak concentrations of S-100 were most often observed on day 3 or 4 after stroke and on day 1 or 2 after TBI. In the stroke patients individual S-100 peak levels correlated well with the NIHSS score on admission (r = 0.58 P = 0.014) and the change in NIHSS score between day 10 and day 1 (r = 0.65, P = 0.005). In the TBI patients a good correlation between individual peak levels of S-100 and the GCS score on admission (r = -0.81, P = 0.010) and the GOS score 6 months after the trauma was found (r = -0.87, P = 0.004). We conclude that there is a significant difference in temporal changes of S-100 levels between ischemic stroke and TBI patients. This suggests different pathophysiological mechanisms. The results of this study further confirm that peak levels of serum S-100 correlate with neurological deficit resulting from either stroke or TBI. (C) 2000 Elsevier Science B.V. All rights reserved.	Univ Groningen Hosp, Dept Neurol, NL-9700 RB Groningen, Netherlands; Blood Bank Noord Nederland, NL-9713 GG Groningen, Netherlands	Elting, JW (corresponding author), Univ Groningen Hosp, Dept Neurol, Hanzenpl 1,POB 30-001, NL-9700 RB Groningen, Netherlands.		De Keyser, Jacques/D-3725-2013	De Keyser, Jacques/0000-0002-3394-7757; Maurits, Natasha/0000-0001-6231-7044			Abraha HD, 1997, ANN CLIN BIOCHEM, V34, P366, DOI 10.1177/000456329703400405; AURELL A, 1991, STROKE, V22, P1254, DOI 10.1161/01.STR.22.10.1254; AZMITIA EC, 1991, J CLIN PSYCHIAT, V52, P4; Bowler JV, 1998, J NEUROL NEUROSUR PS, V64, P90, DOI 10.1136/jnnp.64.1.90; Buttner T, 1997, STROKE, V28, P1961, DOI 10.1161/01.STR.28.10.1961; Ciccarelli R, 1999, GLIA, V27, P275, DOI 10.1002/(SICI)1098-1136(199909)27:3<275::AID-GLIA9>3.3.CO;2-S; DUNNETT CW, 1980, J AM STAT ASSOC, V75, P796, DOI 10.2307/2287161; Fassbender K, 1997, J NEUROL SCI, V148, P101, DOI 10.1016/S0022-510X(96)05351-8; HACHITANDA Y, 1992, ACTA PATHOL JAPON, V42, P639; HAYASHI K, 1991, ACTA NEUROPATHOL, V81, P657, DOI 10.1007/BF00296376; HEADRICK JP, 1994, J CEREBR BLOOD F MET, V14, P853, DOI 10.1038/jcbfm.1994.107; HIDAKA H, 1983, J BIOL CHEM, V258, P2705; Ingebrigtsen T, 1996, J NEUROSURG, V85, P945, DOI 10.3171/jns.1996.85.5.0945; Ingebrigtsen T, 1997, J CLIN NEUROSCI, V4, P29, DOI 10.1016/S0967-5868(97)90007-2; ISHIGURO Y, 1983, CANCER RES, V43, P6080; ISOBE T, 1984, J NEUROCHEM, V43, P1494, DOI 10.1111/j.1471-4159.1984.tb05415.x; JANECZKO K, 1994, INT J DEV NEUROSCI, V12, P431, DOI 10.1016/0736-5748(94)90027-2; JANECZKO K, 1991, BRAIN RES, V564, P86, DOI 10.1016/0006-8993(91)91355-5; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; JORGENSEN HS, 1994, ARCH NEUROL-CHICAGO, V51, P865, DOI 10.1001/archneur.1994.00540210037011; MARSHAK DR, 1990, PROG BRAIN RES, V86, P169; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230; Missler U, 1997, STROKE, V28, P1956, DOI 10.1161/01.STR.28.10.1956; MIYAKE T, 1989, BRAIN RES, V489, P31, DOI 10.1016/0006-8993(89)90005-X; NAKAJIMA T, 1982, BIOMED RES, V8, P226; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; PERSSON L, 1987, STROKE, V18, P911, DOI 10.1161/01.STR.18.5.911; Postler E, 1997, GLIA, V19, P27, DOI 10.1002/(SICI)1098-1136(199701)19:1<27::AID-GLIA3>3.0.CO;2-7; Rothoerl RD, 1998, J TRAUMA, V45, P765, DOI 10.1097/00005373-199810000-00025; RUDOLPHI KA, 1992, CEREBROVAS BRAIN MET, V4, P346; SHASHOUA VE, 1984, J NEUROCHEM, V42, P1536, DOI 10.1111/j.1471-4159.1984.tb12739.x; SMIDTKASTNER R, 1990, NEUROSCIENCE, V38, P527; STEFANSSON K, 1982, AM J PATHOL, V106, P261; STEFANSSON K, 1982, NATURE, V295, P63, DOI 10.1038/295063a0; SUZUKI F, 1987, J NEUROCHEM, V49, P1557, DOI 10.1111/j.1471-4159.1987.tb01027.x; TAKANA H, 1992, EXP NEUROL, V116, P264; Waterloo K, 1997, ACTA NEUROCHIR, V139, P26, DOI 10.1007/BF01850864; WHITAKERAZMITIA PM, 1994, PERSPECT DEV NEUROBI, V2, P233; WHITAKERAZMITIA PM, 1990, BRAIN RES, V528, P155, DOI 10.1016/0006-8993(90)90210-3; Wiesmann M, 1997, ACTA NEUROCHIR, V139, P1155, DOI 10.1007/BF01410976; WITYK RJ, 1994, STROKE, V25, P362, DOI 10.1161/01.STR.25.2.362; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977	44	77	91	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0022-510X			J NEUROL SCI	J. Neurol. Sci.	DEC 1	2000	181	1-2					104	110		10.1016/S0022-510X(00)00442-1			7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	384HK	WOS:000165936600015	11099719				2021-06-18	
J	Csuka, E; Hans, VHJ; Ammann, E; Trentz, O; Kossmann, T; Morganti-Kossmann, MC				Csuka, E; Hans, VHJ; Ammann, E; Trentz, O; Kossmann, T; Morganti-Kossmann, MC			Cell activation and inflammatory response following traumatic axonal injury in the rat	NEUROREPORT			English	Article						astrocytes; experimental; immunohistochemistry; impact-acceleration; inflammation; MHC class II; microglia; rat; traumatic brain injury	DIFFUSE BRAIN INJURY; CEREBROSPINAL-FLUID; MESSENGER-RNA; HEAD-INJURY; ASTROCYTES; MODEL; EXPRESSION	In a rat model of traumatic brain injury cell activation was characterized immunohistochemically from 2 h up to 2 weeks. Reactive astrocytosis became apparent perivascularly and in the grey matter within 4 h after trauma. Increased OX42 immunoreactivity indicated microglial activation in cortex and hippocampus as early as 4 h, whereas up-regulation of MHC class II (OX6) was evident in white matter tracts at 24 h. Although macrophage (EDI) numbers increased in the meninges and perivascularly, brain infiltration appeared marginal. Accumulation of lymphocytes and granulocytes was not observed. Our results show that traumatic axonal injury induces a rapid and sustained glial activation in the absence of leukocyte infiltration. Thus, cell activation following diffuse trauma strongly differs from that found after focal brain damage, awaiting further functional characterization. NeuroReport 11:2587-2590 (C) 2000 Lippincott Williams & Wilkins.	Univ Spital Zurich, Dept Chirurg, Forsch Abt, CH-8091 Zurich, Switzerland; Univ Spital Zurich, Unfallchirurg Klin, CH-8091 Zurich, Switzerland; Univ Kliniken Bonn, Inst Neuropathol, D-53105 Bonn, Germany	Morganti-Kossmann, MC (corresponding author), Univ Spital Zurich, Dept Chirurg, Forsch Abt, Ramistr 100, CH-8091 Zurich, Switzerland.			Morganti-Kossmann, Cristina/0000-0002-0807-2063			ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; Engel S, 1996, Acta Neurochir Suppl, V66, P89; Engelborghs K, 1998, J NEUROSURG, V89, P796, DOI 10.3171/jns.1998.89.5.0796; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; GRAEBER MB, 1988, J NEUROSCI RES, V21, P18, DOI 10.1002/jnr.490210104; Hans VHJ, 1999, J CEREBR BLOOD F MET, V19, P184; Hausmann R, 1999, INT J LEGAL MED, V112, P227, DOI 10.1007/s004140050241; Hill SJ, 1996, J NEUROPATH EXP NEUR, V55, P1221, DOI 10.1097/00005072-199612000-00005; Holmin S, 1999, NEUROREPORT, V10, P1889, DOI 10.1097/00001756-199906230-00017; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; MORGANTIKOSSMAN.MC, 1995, IMMUNE RESPONSES NER, P159; Neumann H, 1996, EUR J NEUROSCI, V8, P2582, DOI 10.1111/j.1460-9568.1996.tb01552.x; PAXINOS G, 1998, RAT BRAIN STEREOTAXI; SEKIYA S, 1989, J LEUKOCYTE BIOL, V46, P96; Soares HD, 1995, J NEUROSCI, V15, P8223; Stahel PF, 1997, MOL BRAIN RES, V50, P205, DOI 10.1016/S0169-328X(97)00189-7	20	77	80	1	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0959-4965			NEUROREPORT	Neuroreport	AUG 3	2000	11	11					2587	2590		10.1097/00001756-200008030-00047			4	Neurosciences	Neurosciences & Neurology	340ZY	WOS:000088567600049	10943727				2021-06-18	
J	Thomas, S; Prins, ML; Samii, M; Hovda, DA				Thomas, S; Prins, ML; Samii, M; Hovda, DA			Cerebral metabolic response to traumatic brain injury sustained early in development: A 2-deoxy-D-glucose autoradiographic study	JOURNAL OF NEUROTRAUMA			English	Article						age; cerebral glucose metabolism; concussion; 2-deoxy-D-glucose; development; fluid percussion	CLOSED HEAD-INJURY; EXCITATORY AMINO-ACIDS; FLUID-PERCUSSION MODEL; FREELY MOVING RATS; METHYL-D-ASPARTATE; GLUCOSE-UTILIZATION; BLOOD-FLOW; CORTICAL-LESIONS; NERVOUS-SYSTEM; VISUAL-CORTEX	Following fluid percussion (FP) traumatic brain injury (TBI), adult rats exhibit dynamic regional changes in cerebral glucose metabolism characterized by an acute (hours) increase and subsequent chronic (weeks) decrease in metabolic rates, The injury-induced hyperglycolysis is the result of ionic fluxes across cell membranes and the degree and extent of metabolic depression is predictive of neurobehavioral deficits, Given that younger animals appear to exhibit similar physiological responses to injury yet show an improved rate of recovery compared to adults, we wanted to determine if this injury-induced dynamic metabolic response to TBI is different if the injury is sustained early in life, Local cerebral metabolic rates for glucose (ICMRglc: mu mol/100 g/min) using [C-14]2-deoxy-D-glucose were measured immediately, 30 min, 1 day, and 3 days following a mild to moderate level of lateral FP injury in postnatal day 17 (P17) rats. Even though gross morphological damage was not evident, injured pups exhibited ipsilateral hyperglycolysis immediately after injury, predominantly in cortical regions (ranging from 59.2% to 116.5% above controls), This hyperglycolytic state subsided within 30 min, and by I day all cerebral structures, except the ipsilateral cerebellar cortex, showed lower rates of glucose metabolism (ranging from 5.7% to 63.0% below controls). This period of posttraumatic metabolic depression resolved within 3 days for all structures measured, Compared to previous adult studies these results suggest that the young rat pup, although exhibiting acute hyperglycolysis, is not subjected to a prolonged period of metabolic depression, which supports the findings that at this level of injury severity, these young animals show remarkable neurological sparing following TBI.	Univ Calif Los Angeles, Sch Med, Div Neurosurg, Dept Surg, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; Hannover Med Sch, D-3000 Hannover, Germany; Norstadt Med Ctr, Hannover, Germany	Hovda, DA (corresponding author), Univ Calif Los Angeles, Sch Med, Div Neurosurg, Dept Surg, Room 18-228,Box 957039, Los Angeles, CA 90095 USA.	dhovda@mednet.ucla.edu	Prins, Mayumi/J-9571-2015	Prins, Mayumi/0000-0001-7694-9739	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027544, P50NS030308] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30308, NS27544] Funding Source: Medline		Adelson PD, 1997, J NEUROTRAUM, V14, P99, DOI 10.1089/neu.1997.14.99; Adelson PD, 1996, J NEUROSURG, V85, P877, DOI 10.3171/jns.1996.85.5.0877; ADELSON PD, 1998, J NEUROTRAUM, V18, P853; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Biagas KV, 1996, J NEUROTRAUM, V13, P189, DOI 10.1089/neu.1996.13.189; BLUE ME, 1983, J NEUROCYTOL, V12, P599, DOI 10.1007/BF01181526; BLUE ME, 1983, J NEUROCYTOL, V12, P697, DOI 10.1007/BF01181531; BRUCE DA, 1978, J NEUROSURG, V48, P679, DOI 10.3171/jns.1978.48.5.0679; BRUCE DA, 1979, CHILD BRAIN, V5, P174; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; COYLE JT, 1976, BRAIN RES, V111, P119, DOI 10.1016/0006-8993(76)91053-2; D'Ambrosio R, 1999, J NEUROSCI, V19, P8152; Dalmady-Israel Christina, 1993, Brain Injury, V7, P263, DOI 10.3109/02699059309029679; Dhillon HS, 1999, J NEUROTRAUM, V16, P455, DOI 10.1089/neu.1999.16.455; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; EDMOND J, 1992, CAN J PHYSIOL PHARM, V70, pS118, DOI 10.1139/y92-253; EIBEN CF, 1984, ARCH PHYS MED REHAB, V65, P168; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FILLEY CM, 1987, ARCH NEUROL-CHICAGO, V44, P194, DOI 10.1001/archneur.1987.00520140058018; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Ginsberg MD, 1997, AM J PHYSIOL-HEART C, V272, pH2859; GRUNDL PD, 1994, J NEUROTRAUM, V11, P135, DOI 10.1089/neu.1994.11.135; HAHN JS, 1988, P NATL ACAD SCI USA, V85, P6556, DOI 10.1073/pnas.85.17.6556; HATASHITA S, 1988, STROKE, V19, P91, DOI 10.1161/01.STR.19.1.91; HOVDA DA, 1989, BEHAV BRAIN RES, V32, P231, DOI 10.1016/S0166-4328(89)80056-7; HOVDA DA, 1992, ROLE OF NEUROTRANSMITTERS IN BRAIN INJURY, P327; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; HOVDA DA, 1990, NIMODIPINE PHARM CLI, P235; HOVDA DA, 1996, NEUROTRAUMA, P1459; INAO S, 1988, J NEUROSURG, V69, P736, DOI 10.3171/jns.1988.69.5.0736; INSEL TR, 1990, NEUROSCIENCE, V35, P31, DOI 10.1016/0306-4522(90)90117-M; JENNETT B, 1972, DEV MED CHILD NEUROL, V14, P137; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; Kennard MA, 1936, AM J PHYSIOL, V115, P138; Kennard MA, 1938, J NEUROPHYSIOL, V1, P477; Kennard MA, 1942, ARCH NEURO PSYCHIATR, V48, P227, DOI 10.1001/archneurpsyc.1942.02290080073002; KOLB B, 1986, BRAIN RES, V397, P315, DOI 10.1016/0006-8993(86)90633-5; KOLB B, 1988, BEHAV BRAIN RES, V28, P259, DOI 10.1016/0166-4328(88)90129-5; KOLB B, 1985, BEHAV BRAIN RES, V17, P25, DOI 10.1016/0166-4328(85)90005-1; KREISMAN NR, 1993, BRAIN RES, V376, P67; KRIEL RL, 1989, PEDIATR NEUROL, V5, P296, DOI 10.1016/0887-8994(89)90021-0; LANDRY CF, 1990, J NEUROSCI RES, V25, P194, DOI 10.1002/jnr.490250207; LEVIN HS, 1979, CHILD BRAIN, V5, P281; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; LYETH BG, 1993, J NEUROTRAUM, V10, P57, DOI 10.1089/neu.1993.10.57; MARTINS AN, 1977, J NEUROSURG, V47, P346, DOI 10.3171/jns.1977.47.3.0346; MCDONALD JW, 1990, BRAIN RES REV, V15, P41, DOI 10.1016/0165-0173(90)90011-C; MCDONALD JW, 1990, EXP NEUROL, V110, P237, DOI 10.1016/0014-4886(90)90035-Q; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MOSS ML, 1972, ACTA ANAT, V81, P161; NEHLIG A, 1989, J CEREBR BLOOD F MET, V9, P579, DOI 10.1038/jcbfm.1989.83; NEHLIG A, 1993, PROG NEUROBIOL, V40, P163, DOI 10.1016/0301-0082(93)90022-K; NEHLIG A, 1988, J NEUROSCI, V8, P2321; NEHLIG A, 1987, J CEREB BLOOD FLO S1, V7, pS522; OSTEEN C, 1998, J NEUROTRAUM, V15, P889; PICCOLI F, 1971, J NEUROCHEM, V18, P1135, DOI 10.1111/j.1471-4159.1971.tb12042.x; PRASAD MR, 1994, J NEUROCHEM, V63, P1086; PRINS MI, 1997, J NEUROTRAUM, V14, P780; Prins ML, 1998, J NEUROTRAUM, V15, P799, DOI 10.1089/neu.1998.15.799; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/0165-3806(96)00098-3; ROBINSON SE, 1990, BRAIN RES, V509, P41, DOI 10.1016/0006-8993(90)90306-V; SCHULZE C, 1992, DEV BRAIN RES, V69, P85, DOI 10.1016/0165-3806(92)90125-G; SMITH DH, 1993, J NEUROSCI, V13, P5383; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; SOKOLOFF L, 1993, DEV NEUROSCI-BASEL, V15, P194, DOI 10.1159/000111335; SPATZ M, 1978, BRAIN RES, V151, P619, DOI 10.1016/0006-8993(78)91097-1; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; Villablanca JR, 2000, NEUROSCIENCE, V95, P625; VILLABLANCA JR, 1993, BEHAV BRAIN RES, V57, P63, DOI 10.1016/0166-4328(93)90062-U; WHISHAW IQ, 1988, BRAIN RES, V451, P97, DOI 10.1016/0006-8993(88)90753-6; Xiong Y, 1998, J NEUROTRAUM, V15, P531, DOI 10.1089/neu.1998.15.531; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; Yamamoto T, 1988, J NEUROTRAUM, V5, P69, DOI 10.1089/neu.1988.5.69; YANG MS, 1985, J NEUROSURG, V63, P617, DOI 10.3171/jns.1985.63.4.0617; YOSHINO A, 1992, J CEREBR BLOOD F MET, V12, P996, DOI 10.1038/jcbfm.1992.137; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289; Zwienenberg M, 1999, J NEUROTRAUM, V16, P937, DOI 10.1089/neu.1999.16.937	83	77	77	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2000	17	8					649	665		10.1089/089771500415409			17	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	347WF	WOS:000088951600003	10972242				2021-06-18	
J	Weyland, A; Buhre, W; Grund, S; Ludwig, H; Kazmaier, S; Weyland, W; Sonntag, H				Weyland, A; Buhre, W; Grund, S; Ludwig, H; Kazmaier, S; Weyland, W; Sonntag, H			Cerebrovascular tone rather than intracranial pressure determines the effective downstream pressure of the cerebral circulation in the absence of intracranial hypertension	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Article						cerebral perfusion pressure; effective downstream pressure; intracranial pressure; pressure-flow relationship; cerebrovascular tone; cerebrovascular CO2 reactivity	CRITICAL CLOSING PRESSURE; VELOCITY RELATIONSHIPS; PERFUSION-PRESSURE; STARLING RESISTOR; FLOW; MANAGEMENT; HINDLIMB; MODEL; DOG	Cerebral perfusion pressure is commonly calculated from the difference between mean arterial pressure and intracranial pressure because intracranial pressure is known to represent the effective downstream pressure of the cerebral circulation. Studies of other organs, however, have shown that effective downstream pressure is determined by a critical closing pressure located at the arteriolar level. This study was designed to investigate the effects of PCO2-induced variations in cerebrovascular tone on the effective downstream pressure of the cerebral circulation. Sixteen patients recovering from head injury were studied. Intracranial pressure was assessed by epidural pressure transducers. Blood flow velocity in the middle cerebral artery was monitored by transcranial Doppler sonography. Effective downstream pressure was derived from the zero flow pressure as extrapolated by regression analysis of instantaneous arterial pressure/middle cerebral artery flow velocity relationships. PaCO2 was varied between 30 and 47 mm Hg in randomized sequence. Intracranial pressure decreased from 18.5 +/- 5.2 mm Hg, during hypercapnia to 9.9 +/- 3.1 mm Hg during hypocapnia. In contrast, effective downstream pressure increased from 13.7 +/- 9.6 mm Hg to 23.4 +/- 8.6 mm Hg and exceeded intracranial pressure at hypocapnic PaCO2 levels. Our results demonstrate that, in the absence of intracranial hypertension, intracranial pressure does not necessarily represent the effective downstream pressure of the cerebral circulation. Instead, the tone of cerebral resistance vessels seems to determine effective downstream pressure. This suggests a modified model of the cerebral circulation based on the existence of two Starling resistors in a series connection.	Univ Gottingen, Dept Anesthesiol Emergency & Intens Care Med, D-3400 Gottingen, Germany; Univ Gottingen, Dept Neurosurg, D-3400 Gottingen, Germany	Weyland, A (corresponding author), Staedt Kliniken Oldenburg, Dept Anesthesia & Intens Care Med, Dr Eden Str 10, D-26133 Oldenburg, Germany.		Buhre, Wolfgang/X-9192-2018				BELLAMY RF, 1978, CIRC RES, V43, P92, DOI 10.1161/01.RES.43.1.92; BRAAKMAN R, 1990, AM J PHYSIOL, V258, pH1806; BURTON AC, 1951, AM J PHYSIOL, V164, P319; Czosnyka M, 1999, J NEUROL NEUROSUR PS, V66, P606, DOI 10.1136/jnnp.66.5.606; DEWEY RC, 1974, J NEUROSURG, V41, P597, DOI 10.3171/jns.1974.41.5.0597; DOLE WP, 1984, CARDIOVASC RES, V18, P548, DOI 10.1093/cvr/18.9.548; EARLY CB, 1974, J NEUROSURG, V41, P590, DOI 10.3171/jns.1974.41.5.0590; GREENFIELD JC, 1965, J CLIN INVEST, V44, P1343, DOI 10.1172/JCI105239; GRUBB RL, 1974, STROKE, V5, P630, DOI 10.1161/01.STR.5.5.630; HASINOFF I, 1990, J APPL PHYSIOL, V68, P462; HOLM S, 1979, SCAND J STAT, V6, P65; JACKMAN AP, 1990, ANN BIOMED ENG, V18, P89, DOI 10.1007/BF02368419; LEEMAN M, 1990, J APPL PHYSIOL, V69, P293; LOPEZMUNIZ R, 1968, J APPL PHYSIOL, V24, P625; LUCE JM, 1982, J APPL PHYSIOL, V53, P1496; MAGDER S, 1990, CIRC RES, V67, P209, DOI 10.1161/01.RES.67.1.209; MICHEL E, 1995, NEUROL RES, V17, P149, DOI 10.1080/01616412.1995.11740304; PANERAI RB, 1993, PHYSIOL MEAS, V14, P411, DOI 10.1088/0967-3334/14/4/002; PERMUTT S, 1963, J APPL PHYSIOL, V18, P924; RILEY RL, 1982, CIRCULATION, V66, P683, DOI 10.1161/01.CIR.66.4.683; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; SHRIER I, 1995, J APPL PHYSIOL, V79, P1531; SILVESTER JT, 1981, CIRC RES, V49, P980; WAGNER EM, 1986, CRIT CARE MED, V14, P484, DOI 10.1097/00003246-198605000-00011; WEYLAND A, 1996, ANASTHESIOL INTENSIV, V31, P453	26	77	82	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0898-4921			J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	JUL	2000	12	3					210	216		10.1097/00008506-200007000-00002			7	Anesthesiology; Clinical Neurology; Surgery	Anesthesiology; Neurosciences & Neurology; Surgery	330PB	WOS:000087969500002	10905568				2021-06-18	
J	Lee, YL; Shih, K; Bao, P; Ghirnikar, RS; Eng, LF				Lee, YL; Shih, K; Bao, P; Ghirnikar, RS; Eng, LF			Cytokine chemokine expression in contused rat spinal cord	NEUROCHEMISTRY INTERNATIONAL			English	Article						cytokines; chemokines; spinal cord injury	MONOCYTE CHEMOATTRACTANT PROTEIN-1; CENTRAL-NERVOUS-SYSTEM; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; WOUND BRAIN INJURY; MESSENGER-RNA; ASTROCYTE EXPRESSION; GENE-EXPRESSION; INTERLEUKIN-8; MICROGLIA	Spinal cord injury within the first few hours, is complicated by inflammatory mechanisms, including the influx of monocyte/macrophages as well as the activation of resident spinal microglia and astrocytes. Numerous studies have suggested that the initial infiltration of the hematogenous cells may be due to the secretion of cytokines and chemokines in the injured CNS. In order to elucidate which chemotactic factors may be expressed following traumatic spinal cord contusion, the presence of mRNA for a number of cytokines, chemokines and growth factors was examined in contused rat spinal cord by reverse transcriptase-polymerase chain reaction and immunohistochemistry. Spinal injury was accompanied by an increase in glial fibrillary acidic protein mRNA suggesting astrocyte activation and astrogliosis. TNF alpha message levels were upregulated as early as 1 h post injury and returned to baseline levels by 3 days post injury (DPI). By immunocytochemistry, staining for TNF, increased at 1 and 3 dpi and was predominantly diffuse in the necrotic tissue. The chemokines IP-10, MCP-1, and MIP-la were also detected in the injured spinal cord. mRNA levels of IP-10 peaked around 6 h post injury and were upregulated up to 7 dpi. MCP-1 mRNA was detected at 1 h post injury and its levels returned to baseline by 14 dpi. An increase in MCP-I staining was observed from 1 to 7 dpi. The staining was also diffuse in the necrotic tissue and also localized to cells near the site of injury. The presence of aFGF and bFGF was also detected in the injured spinal cord. mRNA for aFGF was detected at 0 time, increased at 6 h post injury, peaked at 3 days, and remained elevated up to 21 days. bFGF mRNA was initially detected at 1 h post injury, increased between 6 h and 3 days, declined thereafter and returned to baseline levels by 21 days. (C) 2000 Elsevier Science Ltd. All rights reserved.	VAPA Hlth Care Syst, Dept Pathol, Palo Alto, CA USA; Stanford Univ, Sch Med, Stanford, CA 94305 USA	Eng, LF (corresponding author), VAPA Hlth Care Syst, Dept Pathol, 3801 Miranda Ave, Palo Alto, CA USA.	Ifeng@leland.stanford.edu					Amichay D, 1996, J IMMUNOL, V157, P4511; BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265; BAGGIOLINI M, 1992, FEBS LETT, V307, P97, DOI 10.1016/0014-5793(92)80909-Z; BARNA BP, 1994, J NEUROIMMUNOL, V50, P101, DOI 10.1016/0165-5728(94)90220-8; Berman JW, 1996, J IMMUNOL, V156, P3017; BROSNAN CF, 1993, ADV NEUROL, V59, P349; Eng LF, 1999, J NEUROCHEM, V73, pS194; FURIE MB, 1995, AM J PATHOL, V146, P1287; Ghirnikar RS, 1998, NEUROSCI LETT, V247, P21, DOI 10.1016/S0304-3940(98)00268-7; Ghirnikar RS, 1996, J NEUROSCI RES, V46, P727; GHIRNIKAR RS, 1999, IN PRESS J NEUROSCI; Glabinski AR, 1996, J IMMUNOL, V156, P4363; GODISKA R, 1995, J NEUROIMMUNOL, V58, P167, DOI 10.1016/0165-5728(95)00008-P; HULKOWER K, 1993, J IMMUNOL, V150, P2525; HURWITZ AA, 1995, J NEUROIMMUNOL, V57, P193, DOI 10.1016/0165-5728(95)00011-P; KARPUS WJ, 1995, J IMMUNOL, V155, P5003; KLEIN RM, 1996, SOC NEUR ABSTR, V22, P843; Lee YL, 1997, J NEUROCHEM, V69, pS144; Majumder S, 1996, J NEUROSCI RES, V45, P758, DOI 10.1002/(SICI)1097-4547(19960915)45:6<758::AID-JNR12>3.0.CO;2-S; McTigue DM, 1998, J NEUROSCI RES, V53, P368, DOI 10.1002/(SICI)1097-4547(19980801)53:3<368::AID-JNR11>3.0.CO;2-1; MURPHY GM, 1993, J NEUROSCI RES, V35, P643, DOI 10.1002/jnr.490350607; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; RANSOHOFF RM, 1993, FASEB J, V7, P592; SHYY YJ, 1993, J CLIN INVEST, V92, P1745, DOI 10.1172/JCI116762; STOECKLE M Y, 1990, New Biologist, V2, P313; Streit WJ, 1998, EXP NEUROL, V152, P74, DOI 10.1006/exnr.1998.6835; TANI M, 1994, BRAIN PATHOL, V4, P135, DOI 10.1111/j.1750-3639.1994.tb00824.x; TAUB DD, 1993, J EXP MED, V177, P1809, DOI 10.1084/jem.177.6.1809; VANGURI P, 1994, J IMMUNOL, V152, P1411; VANGURI P, 1995, J NEUROIMMUNOL, V56, P35, DOI 10.1016/0165-5728(94)00131-7; WANG XK, 1995, STROKE, V26, P661, DOI 10.1161/01.STR.26.4.661; WILSON SD, 1990, J EXP MED, V171, P1301, DOI 10.1084/jem.171.4.1301; WRATHALL JR, 1985, EXP NEUROL, V88, P108, DOI 10.1016/0014-4886(85)90117-7	33	77	92	1	9	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0197-0186	1872-9754		NEUROCHEM INT	Neurochem. Int.	APR	2000	36	4-5					417	425		10.1016/S0197-0186(99)00133-3			9	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	293RQ	WOS:000085867300016	10733009				2021-06-18	
J	Agrawal, SK; Nashmi, R; Fehlings, MG				Agrawal, SK; Nashmi, R; Fehlings, MG			Role of L- and N-type calcium channels in the pathophysiology of traumatic spinal cord white matter injury	NEUROSCIENCE			English	Article						rat; conotoxin; calcium channels; glia; astrocytes; oligodendrocytes	CENTRAL-NERVOUS-SYSTEM; RAT OPTIC-NERVE; CA2+ CHANNEL; GLIAL-CELLS; GLUTAMATE RECEPTORS; ANOXIC INJURY; NA+-CA2+ EXCHANGER; SECONDARY INJURY; CALPAIN-I; AXONS	Recent work has suggested a potential role for voltage-gated Ca2+ channels in the pathophysiology of anoxic central nervous system whits matter injury. To examine the relevance of these findings to neurotrauma, we conducted electrophysiological studies with inorganic Ca2+ channels blockers and L- and N-subtype-specific calcium channel antagonists in an in vitro model of spinal cord injury. Confocal immunohistochemistry was used to examine for localization of L- and N-type calcium channels in spinal cord white matter tracts. A 30-mm length of dorsal column was isolated from the spinal cord of adult rats, pinned in an in vitro recording chamber and injured with a modified clip (2 g closing force) for 15 s. The functional integrity of the dorsal column was monitored electrophysiologically by quantitatively measuring the compound action potential at two points with glass microelectrodes. The compound action potential decreased to 71.4 +/- 2.0% of control (P < 0.05) after spinal cord injury. Removal of extracellular Ca2+ promoted significantly greater recovery of compound action potential amplitude (86.3 +/- 7.6% of control; P < 0.05) after injury. Partial blockade of voltage-gated Ca2+ channels with cobalt (20 mu M) or cadmium (200 mu M) conferred improvement in compound action potential amplitude. Application of the L-type Ca2+ channel blockers diltiazem (50 mu M) or verapamil (90 mu M), and the N-type antagonist omega-conotoxin GVIA (1 mu M), significantly enhanced the recovery of compound action potential amplitude postinjury. Go-application of the L-type antagonist diltiazem with the N-type blocker omega-conotoxin GVIA showed significantly greater (P < 0.05) improvement in compound action potential amplitude than application of either drug alone. Confocal immunohistochemistry with double labelling for glial fibrillary acidic protein, GalC and NF200 demonstrated L- and N-type Ca2+ channels on astrocytes and oligodendrocytes, but not axons, in spinal cord white matter. In conclusion, the injurious effects of Ca2+ in traumatic central nervous system white matter injury appear to be partially mediated by voltage-gated Ca2+ channels. The presence of L- and N-type Ca2+ channels on periaxonal astrocytes and oligodendrocytes suggests a role for these cells in post-traumatic axonal conduction failure. (C) 2000 IBRO. Published by Elsevier Science Ltd. All rights reserved.	Toronto Western Res Inst, Div Cell & Mol Biol, Toronto, ON, Canada; Univ Toronto, Univ Hlth Network, Div Neurosurg, Toronto, ON M5T 2S8, Canada	Fehlings, MG (corresponding author), Toronto Western Res Inst, Div Cell & Mol Biol, Toronto, ON, Canada.			Fehlings, Michael/0000-0002-5722-6364; Nashmi, Raad/0000-0001-6596-2620			Agrawal SK, 1998, J NEUROTRAUM, V15, P929, DOI 10.1089/neu.1998.15.929; Agrawal SK, 1996, J NEUROSCI, V16, P545; Agrawal SK, 1997, J NEUROSCI, V17, P1055; BALENTINE JD, 1977, ANN NEUROL, V2, P520, DOI 10.1002/ana.410020612; BARRES BA, 1990, NEURON, V4, P507, DOI 10.1016/0896-6273(90)90109-S; BARRES BA, 1989, J NEUROSCI, V9, P3169; BARRES BA, 1990, NEURON, V5, P527, DOI 10.1016/0896-6273(90)90091-S; BARRES BA, 1988, GLIA, V1, P10, DOI 10.1002/glia.440010104; Bengtsson F, 1990, CEREBRAL ISCHEMIA RE, P215; BERGER T, 1992, EUR J NEUROSCI, V4, P1271, DOI 10.1111/j.1460-9568.1992.tb00153.x; BORGES K, 1995, J NEUROSCI RES, V40, P591, DOI 10.1002/jnr.490400504; CATTERALL WA, 1992, TRENDS PHARMACOL SCI, V13, P256, DOI 10.1016/0165-6147(92)90079-L; CHIU SY, 1994, GLIA, V11, P191, DOI 10.1002/glia.440110213; Choi DW, 1996, CURR OPIN NEUROBIOL, V6, P667, DOI 10.1016/S0959-4388(96)80101-2; Fehlings MG, 1997, J NEUROSCI METH, V71, P215, DOI 10.1016/S0165-0270(96)00147-1; FEHLINGS MG, 1989, J NEUROSURG, V71, P403, DOI 10.3171/jns.1989.71.3.0403; Fern R, 1998, J NEUROSCI, V18, P7232; FERN R, 1995, J NEUROPHYSIOL, V74, P369; GEAN PW, 1991, BRAIN RES, V560, P306, DOI 10.1016/0006-8993(91)91248-Y; HAPPEL RD, 1981, BRAIN RES, V211, P476, DOI 10.1016/0006-8993(81)90976-8; Hille B., 1992, IONIC CHANNELS EXCIT; HOFMANN F, 1994, ANNU REV NEUROSCI, V17, P399, DOI 10.1146/annurev.ne.17.030194.002151; Huguenard JR, 1996, ANNU REV PHYSIOL, V58, P329, DOI 10.1146/annurev.ph.58.030196.001553; Huh KH, 1999, J BIOL CHEM, V274, P151, DOI 10.1074/jbc.274.1.151; Imaizumi T, 1999, BRAIN RES, V817, P84, DOI 10.1016/S0006-8993(98)01214-1; KRIEGLER S, 1993, J NEUROSCI, V13, P4229, DOI 10.1523/jneurosci.13-10-04229.1993; LACINOVA L, 1995, J PHARMACOL EXP THER, V274, P54; LEVITAN ES, 1995, J BIOL CHEM, V270, P6036, DOI 10.1074/jbc.270.11.6036; LEVRAM V, 1995, J NEUROSCI, V15, P2628; LEVRAM V, 1987, BIOPHYS J, V52, P571, DOI 10.1016/S0006-3495(87)83246-0; LEVRAM V, 1986, P NATL ACAD SCI USA, V83, P6651, DOI 10.1073/pnas.83.17.6651; Li S, 1999, J Neurosci, V19, pRC16; Li SX, 2000, J NEUROSCI, V20, P1190, DOI 10.1523/JNEUROSCI.20-03-01190.2000; LUNDY PM, 1994, BRAIN RES, V643, P204, DOI 10.1016/0006-8993(94)90026-4; Luscher C, 1999, NEURON, V24, P649, DOI 10.1016/S0896-6273(00)81119-8; MACVICAR BA, 1984, SCIENCE, V226, P1345, DOI 10.1126/science.6095454; Marrero H, 1996, GLIA, V16, P285; MAUBECIN VA, 1995, J NEUROCHEM, V64, P2544; OJCIUS DM, 1991, EXP CELL RES, V197, P43, DOI 10.1016/0014-4827(91)90477-C; Philippi M, 1996, GLIA, V17, P72; REGAN RF, 1991, NEUROSCIENCE, V43, P585, DOI 10.1016/0306-4522(91)90317-H; SATO K, 1993, BIOCHEM BIOPH RES CO, V194, P1292, DOI 10.1006/bbrc.1993.1964; Schumacher PA, 1999, NEUROSCIENCE, V91, P733, DOI 10.1016/S0306-4522(98)00552-1; Siesjo BK, 1996, ADV NEUROL, V71, P209; SIMAN R, 1988, NEURON, V1, P279, DOI 10.1016/0896-6273(88)90076-1; Smirnov SV, 1998, EUR J PHARMACOL, V360, P81, DOI 10.1016/S0014-2999(98)00656-6; STYS PK, 1990, NEUROSCI LETT, V115, P293, DOI 10.1016/0304-3940(90)90471-K; Stys PK, 1998, J CEREBR BLOOD F MET, V18, P2, DOI 10.1097/00004647-199801000-00002; STYS PK, 1992, J NEUROSCI, V12, P430; Sun BB, 1999, J NEUROSCI, V19, P5185; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Theriault E., 1994, Society for Neuroscience Abstracts, V20, P1071; Tymianski M, 1996, NEUROSURGERY, V38, P1176; VERKHRATSKY AN, 1990, NEUROSCI LETT, V112, P194, DOI 10.1016/0304-3940(90)90202-K; VONBLANKENFELD G, 1992, EUR J NEUROSCI, V4, P1035; Wan Q, 1997, NATURE, V388, P686, DOI 10.1038/41792; WAXMAN SG, 1993, ANN NEUROL, V33, P121, DOI 10.1002/ana.410330202; WERTH JL, 1994, J NEUROSCI, V14, P348	58	77	79	0	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522			NEUROSCIENCE	Neuroscience		2000	99	1					179	188		10.1016/S0306-4522(00)00165-2			10	Neurosciences	Neurosciences & Neurology	343GA	WOS:000088692300017	10924962				2021-06-18	
J	Shiozaki, T; Kato, A; Taneda, M; Hayakata, T; Hashiguchi, N; Tanaka, H; Shimazu, T; Sugimoto, H				Shiozaki, T; Kato, A; Taneda, M; Hayakata, T; Hashiguchi, N; Tanaka, H; Shimazu, T; Sugimoto, H			Little benefit from mild hypothermia therapy for severely head injured patients with low intracranial pressure	JOURNAL OF NEUROSURGERY			English	Article						severe head injury; intracranial pressure; mild hypothermia; normothermia	TRAUMATIC BRAIN INJURY; EXCITATORY AMINO-ACIDS; ACUTE SUBDURAL-HEMATOMA; MODERATE HYPOTHERMIA; CEREBROSPINAL-FLUID; RELEASE; MORTALITY; ISCHEMIA; RAT	Object. This study was performed to determine whether mild hypothermia therapy is essential for the treatment of severely head injured patients in whom intracranial pressure (ICP) can be maintained below 20 mm Hg by using conventional therapies. Methods. Sixteen consecutive severely head injured patients fulfilled the following criteria: the patient's ICP was maintained below 20 mm Hg by using fluid restriction, hyperventilation, and high-dose barbiturate therapy; and the patient had a Glasgow Coma Scale score of 8 or less on admission. After conventional therapies had been applied, the patients were divided randomly into two groups: the mild hypothermia group (HT group; eight patients) and the normothermia group (NT group; eight patients). The HT group received mild hypothermia (intracranial temperature 34 degrees C) therapy for 48 hours followed by rewarming at 1 degrees C per day for 3 days, whereas the NT group received normothermia (intracranial temperature 37 degrees C) therapy for 5 days. Specimens of cerebrospinal fluid (CSF) taken from an intraventricular catheter every 24 hours were analyzed for the presence of excitatory amino acids ([EAAs] glutamate, aspartate, and glycine) and cytokines (tumor necrosis factor-alpha, interleukin [IL]-1 beta, IL-6, IL-8, and IL-10). The two groups did not differ significantly in patient age, neurological status, or level of ICP. There were no significant differences in daily changes in CSF concentrations of EAAs and cytokines between the two groups. The incidence of pneumonia was slightly higher in the HT group compared with the NT group (p = 0.059). The incidence of diabetes insipidus associated with hypernatremia was significantly higher in the HT group compared with that in the NT group (p < 0.01). The two groups did not differ with respect to their clinical outcomes. Conclusions. The authors recommend normothermia therapy for the treatment of severely head injured patients in whom ICP can be maintained at lower than 20 mm Hg by using conventional therapies, because mild hypothermia therapy does not convey any advantage over normothermia therapy in such patients.	Osaka Univ, Sch Med, Dept Traumatol, Suita, Osaka 565, Japan; Osaka Univ, Sch Med, Dept Neurosurg, Suita, Osaka 565, Japan; Kinki Univ, Sch Med, Dept Neurosurg, Osaka 589, Japan	Shiozaki, T (corresponding author), Osaka Univ, Sch Med, Dept Traumatol, 2-2 Yamadaoka, Suita, Osaka 565, Japan.						BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; DIETRICH WD, 1990, J NEUROPATH EXP NEUR, V49, P486, DOI 10.1097/00005072-199009000-00004; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; JENNETT B, 1975, LANCET, V1, P480; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kurz A, 1996, NEW ENGL J MED, V334, P1209, DOI 10.1056/NEJM199605093341901; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; Metz C, 1996, J NEUROSURG, V85, P533, DOI 10.3171/jns.1996.85.4.0533; MILLER JD, 1982, CLIN NEUR, V29, P162; Ogura H, 1999, J TRAUMA, V46, P774, DOI 10.1097/00005373-199905000-00004; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; SAUL TG, 1987, CLIN NEUROSURG, V34, P560; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; SEGAR WE, 1956, AM J PHYSIOL, V185, P528; Shiozaki T, 1998, J NEUROSURG, V89, P206, DOI 10.3171/jns.1998.89.2.0206; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; SMITH D H, 1990, Society for Neuroscience Abstracts, V16, P779; Smith SL, 1996, J NEUROTRAUM, V13, P1, DOI 10.1089/neu.1996.13.1; TEASDALE G, 1974, LANCET, V2, P81; WILBERGER JE, 1991, J NEUROSURG, V74, P212, DOI 10.3171/jns.1991.74.2.0212	26	77	78	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	AUG	1999	91	2					185	191		10.3171/jns.1999.91.2.0185			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	220RT	WOS:000081681800003	10433305				2021-06-18	
J	LaPlaca, MC; Raghupathi, R; Verma, A; Saatman, KE; Snyder, SH; McIntosh, TK				LaPlaca, MC; Raghupathi, R; Verma, A; Saatman, KE; Snyder, SH; McIntosh, TK			Temporal patterns of poly(ADP-ribose) polymerase activation in the cortex following experimental brain injury in the rat	JOURNAL OF NEUROCHEMISTRY			English	Article						poly(ADP-ribose) polymerase; DNA repair; traumatic brain injury; nicotinamide adenine dinucleotide; caspases; apoptosis	DNA STRAND BREAKS; FOCAL CEREBRAL-ISCHEMIA; NEURONAL CELL-DEATH; DAMAGE; APOPTOSIS; SYNTHETASE; REPAIR; CLEAVAGE; FRAGMENTATION; INHIBITION	The activation of poly(ADP-ribose) polymerase, a DNA base excision repair enzyme, is indicative of DNA damage. This enzyme also undergoes site-specific proteolysis during apoptosis. Because both DNA fragmentation and apoptosis are known to occur following experimental brain injury, we investigated the effect of lateral fluid percussion brain injury on poly(ADP-ribose) polymerase activity and cleavage. Male Sprague-Dawley rats (n = 52) were anesthetized, subjected to fluid percussion brain injury of moderate severity (2.5-2.8 atm), and killed at 30 min, 2 h, 6 h, 24 h, 3 days, or 7 days postinjury. Genomic DNA from injured cortex at 24 h, but not at 30 min, was both fragmented and able to stimulate exogenous poly(ADP-ribose) polymerase. Endogenous poly(ADP-ribose) polymerase activity, however, was enhanced in the injured cortex at 30 min but subsequently returned to baseline levels. Slight fragmentation of poly(ADP-ribose) polymerase was detected in the injured cortex in the first 3 days following injury, but significant cleavage was detected at 7 days postinjury. Taken together, these data suggest that poly(ADP-ribose) polymerase-mediated DNA repair is initiated in the acute posttraumatic period but that subsequent poly(ADP-ribose) polymerase activation does not occur, possibly owing to delayed apoptosis-associated proteolysis, which may impair the repair of damaged DNA.	Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; Uniformed Serv Univ Hlth Sci, Dept Neurol, Bethesda, MD 20814 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA	McIntosh, TK (corresponding author), Univ Penn, Sch Med, Dept Neurosurg, 3320 Smith Walk,105B Hayden Hall, Philadelphia, PA 19104 USA.		Pieper, Andrew A/R-5552-2016	Pieper, Andrew/0000-0001-6299-6577	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS026818, P01NS008803] Funding Source: NIH RePORTER; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01-GM3690] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS26818, P01-NS08803] Funding Source: Medline		Ashkenas J, 1996, J EXP MED, V183, P1947, DOI 10.1084/jem.183.5.1947; BANASIK M, 1992, J BIOL CHEM, V267, P1569; BENJAMIN RC, 1980, J BIOL CHEM, V255, P502; Budihardjo II, 1998, MOL CELL BIOCHEM, V178, P245, DOI 10.1023/A:1006808001462; Chen J, 1997, J NEUROCHEM, V69, P232; Chopp M, 1996, STROKE, V27, P363, DOI 10.1161/01.STR.27.3.363; Clark RSB, 1997, J NEUROSCI, V17, P9172; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Conti AC, 1998, J NEUROSCI, V18, P5663; Didier M, 1996, J NEUROSCI, V16, P2238; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; Endres M, 1997, J CEREBR BLOOD F MET, V17, P1143, DOI 10.1097/00004647-199711000-00002; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GAUBATZ JW, 1994, ANN NY ACAD SCI, V719, P97, DOI 10.1111/j.1749-6632.1994.tb56822.x; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; GRADWOHL G, 1990, P NATL ACAD SCI USA, V87, P2990, DOI 10.1073/pnas.87.8.2990; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kaufmann WK, 1996, FASEB J, V10, P238; LAMARRE D, 1986, BIOCHEM CELL BIOL, V64, P368, DOI 10.1139/o86-051; LAPLACE MC, 1997, J NEUROTRAUM, V14, P785; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LI Y, 1995, MOL BRAIN RES, V28, P164, DOI 10.1016/0169-328X(94)00220-9; LINDAHL T, 1995, PHILOS T ROY SOC B, V347, P57, DOI 10.1098/rstb.1995.0009; LINDAHL T, 1995, TRENDS BIOCHEM SCI, V20, P405, DOI 10.1016/S0968-0004(00)89089-1; Lindahl T, 1995, J CELL SCI, P73; LINNIK MD, 1995, MOL BRAIN RES, V32, P116, DOI 10.1016/0169-328X(95)00069-5; Liu PK, 1996, J NEUROSCI, V16, P6795; Lo EH, 1998, STROKE, V29, P830, DOI 10.1161/01.STR.29.4.830; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MACMANUS JP, 1995, J CEREBR BLOOD F MET, V15, P728, DOI 10.1038/jcbfm.1995.93; Mandavilli BS, 1996, J NEUROCHEM, V67, P1559; MAZZARELLO P, 1992, J NEUROL SCI, V112, P4, DOI 10.1016/0022-510X(92)90125-5; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NILSSON P, 1990, J CEREB BLOOD FLOW M, V10, P607; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Pieper A. A., 1997, Society for Neuroscience Abstracts, V23, P2178; PURNELL MR, 1980, BIOCHEM J, V185, P775, DOI 10.1042/bj1850775; Raghupathi R, 1996, MOL BRAIN RES, V37, P134, DOI 10.1016/0169-328X(95)00289-5; RAO KS, 1992, MUTAT RES, V275, P317; RINK A, 1995, AM J PATHOL, V147, P1575; ROBBINS JH, 1988, JAMA-J AM MED ASSOC, V260, P384; Rosenthal DS, 1997, EXP CELL RES, V232, P313, DOI 10.1006/excr.1997.3536; Sallmann FR, 1997, BIOCHEM CELL BIOL, V75, P451, DOI 10.1139/bcb-75-4-451; SATOH MS, 1994, CANCER RES, V54, pS1899; SATOH MS, 1993, J BIOL CHEM, V268, P5480; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; SCHANRAUFSTATTE.IU, 1986, J CLIN INVEST, V77, P1312; Schwartz LM, 1996, TRENDS NEUROSCI, V19, P555, DOI 10.1016/S0166-2236(96)10067-9; Shah GM, 1996, BIOCHEM BIOPH RES CO, V229, P838, DOI 10.1006/bbrc.1996.1889; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; Soares HD, 1995, J NEUROSCI, V15, P8223; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Szabo C, 1998, TRENDS PHARMACOL SCI, V19, P287, DOI 10.1016/S0165-6147(98)01193-6; Takahashi K, 1997, J CEREBR BLOOD F MET, V17, P1137, DOI 10.1097/00004647-199711000-00001; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TILLY JL, 1993, J CELL PHYSIOL, V154, P519, DOI 10.1002/jcp.1041540310; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; ZHANG J, 1995, J NEUROCHEM, V65, P1411; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500	67	77	77	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	JUL	1999	73	1					205	213		10.1046/j.1471-4159.1999.0730205.x			9	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	207PV	WOS:000080946000024	10386972				2021-06-18	
J	Dias, MS; Backstrom, J; Falk, M; Li, V				Dias, MS; Backstrom, J; Falk, M; Li, V			Serial radiography in the infant shaken impact syndrome	PEDIATRIC NEUROSURGERY			English	Article						computerized tomography; magnetic resonance imaging; child abuse; shaken baby syndrome; traumatic brain injury; skull fractures; subdural hemorrhage; epidural hemorrhage; cerebral hemorrhage; cerebral edema	CRANIAL COMPUTED-TOMOGRAPHY; NONACCIDENTAL HEAD-INJURY; CHILD-ABUSE SYNDROME; CRANIOCEREBRAL TRAUMA; SUBDURAL-HEMATOMA; CT FINDINGS; SHAKING	Certain CT and/or MRI abnormalities have been used medicolegally to time intracranial injuries from the infant shaken impact syndrome (ISIS). For example, parenchymal hypodensities on CT scans are said to arise only after 6-48 h have elapsed postinjury, and the presence of chronic or mixed subdural hematomas suggests injury that occured 1-4 weeks prior. However, these statements are based largely upon inference from data obtained in other conditions such as ischemic anoxic injury and chronic subdural hemorrhage in adults. Direct evidence about the evolution of intracranial injuries in infants with ISIS is sparse, and the radiographic changes following ISIS have never been systematically studied on serial imaging studies. One hundred-seventeen serial CT and MRI scans obtained from 33 infants with ISIS were reviewed retrospectively. The exact scan dates and times were obtained directly from the scans. Acute subdural hemorrhage was the most common intracranial abnormality and was present in 27 (81 %) of the 33 infants. Other intracranial abnormalities included chronic subdural collections, subarachnoid hemorrhage, epidural hematomas, parenchymal hypodensities, edema and contusions, and atrophy and encephalomalacia. In 15 of the 33 infants, the injury could be timed with reasonable certainty, and the evolution of the radiographic changes followed over time. Six of the 15 infants had evidence of prior cranial trauma such as chronic subdural collections (5 infants) or mild atrophy (1 infant). Of the remaining 9 infants, parenchymal abnormalities such as hypodensities, edema and contusion appeared in virtually all of the initial scans performed approximately 3 h following the report of injury. One 'chronic' subdural collection was absent on the first scan performed 2.75 h postinjury, but appeared on a second scan performed 17 h later, suggesting that some 'chronic' subdural fluid collections may arise much sooner than previously thought. These findings challenge some of the current dogma about the timing of radiographic changes following abuse and are important in timing the alleged abuse for legal purposes.	SUNY Buffalo, Childrens Hosp Buffalo, Dept Neurosurg, Buffalo, NY USA; SUNY Buffalo, Childrens Hosp Buffalo, Dept Radiol, Buffalo, NY USA; SUNY Buffalo, Childrens Hosp Buffalo, Dept Pediat, Buffalo, NY USA	Dias, MS (corresponding author), Childrens Hosp Buffalo, Dept Neurosurg, 219 Bryant St, Buffalo, NY 14222 USA.	mdias@chob.edu					ALEXANDER RC, 1986, J PEDIATR-US, V109, P975, DOI 10.1016/S0022-3476(86)80279-7; ARONYK KE, 1994, PEDIAT NEUROSURGERY, P279; BALL WS, 1989, RADIOLOGY, V173, P609, DOI 10.1148/radiology.173.3.2813759; BARKOVICH AJ, 1995, PEDIAT NEUROIMAGING, P107; BERNARDI B, 1993, TOP MAGN RESON IMAG, V5, P161; BROWN JK, 1993, DEV MED CHILD NEUROL, V35, P849; BRUCE DA, 1989, PEDIATR ANN, V18, P482, DOI 10.3928/0090-4481-19890801-07; Carter J E, 1983, Child Abuse Negl, V7, P279, DOI 10.1016/0145-2134(83)90005-4; COHEN RA, 1986, AM J ROENTGENOL, V146, P97, DOI 10.2214/ajr.146.1.97; Cox L A, 1996, Radiol Technol, V67, P513; ELLISON PH, 1978, PEDIATRICS, V62, P151; ENGLISH PC, 1983, PEDIATR ANN, V12, P870, DOI 10.3928/0090-4481-19831201-04; FELDMAN KW, 1995, CHILD ABUSE NEGLECT, V19, P307, DOI 10.1016/S0145-2134(94)00130-8; FOBBEN ES, 1989, AM J NEURORADIOL, V10, P687; GIANGIACOMO J, 1988, OPHTHALMOLOGY, V95, P295; HAHN YS, 1983, CHILD BRAIN, V10, P229; HAN BK, 1989, AM J NEURORADIOL, V10, P1191; HARWOODNASH DC, 1992, AM J NEURORADIOL, V13, P569; Hymel KP, 1997, PEDIATR RADIOL, V27, P743, DOI 10.1007/s002470050215; JASPAN T, 1992, PEDIATR RADIOL, V22, P237, DOI 10.1007/BF02019848; Johnson DL, 1995, PEDIATR NEUROSURG, V23, P305, DOI 10.1159/000120976; KLEINMAN PK, 1987, DIAGNOSTIC IMAGING C, P159; KRUGMAN RD, 1993, PEDIATRICS, V92, P872; LEVIN A V, 1989, Pediatric Emergency Care, V5, P181, DOI 10.1097/00006565-198909000-00011; LUDWIG S, 1984, ANN EMERG MED, V13, P104, DOI 10.1016/S0196-0644(84)80571-5; LUERSSEN TG, 1991, CONC PED N, V11, P87; MERTEN DF, 1984, PEDIATR RADIOL, V14, P272, DOI 10.1007/BF01601874; MERTEN DF, 1983, PEDIATR ANN, V12, P882, DOI 10.3928/0090-4481-19831201-06; MERTEN DF, 1983, RADIOLOGY, V146, P377, DOI 10.1148/radiology.146.2.6849085; Sargent S, 1996, J FORENSIC SCI, V41, P314; SATO Y, 1989, RADIOLOGY, V173, P653, DOI 10.1148/radiology.173.3.2813768; SINAL SH, 1987, SOUTHERN MED J, V80, P1505, DOI 10.1097/00007611-198712000-00006; STARLING SP, 1995, PEDIATRICS, V95, P259; TSAI FY, 1980, CT-J COMPUT TOMOGR, V4, P277; ZEPP F, 1992, NEUROPEDIATRICS, V23, P188, DOI 10.1055/s-2008-1071338; Zimmerman R A, 1994, Neuroimaging Clin N Am, V4, P349; ZIMMERMAN RA, 1979, RADIOLOGY, V130, P687, DOI 10.1148/130.3.687; ZIMMERMAN RA, 1978, NEURORADIOLOGY, V16, P39, DOI 10.1007/BF00395197	38	77	78	0	6	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1016-2291	1423-0305		PEDIATR NEUROSURG	Pediatr. Neurosurg.	AUG	1998	29	2					77	85		10.1159/000028694			9	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	138CZ	WOS:000076955000006	9792961				2021-06-18	
J	Rothweiler, B; Temkin, NR; Dikmen, SS				Rothweiler, B; Temkin, NR; Dikmen, SS			Aging effect on psychosocial outcome in traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							MINOR HEAD-INJURY; OLDER ADULTS; CONSEQUENCES; SURVIVAL; RECOVERY	Objective: To examine the effects of age on outcome in persons with traumatic brain injury. Design: Longitudinal cohort design. Setting: Level I trauma center. Patients: A total of 411 hospitalized subjects with mild to severe traumatic brain injury prospectively studied to 1 year; their age range was 18 to 89 years. Main Outcome Measures: Glasgow Outcome Scale, living situation, and employment. Results: Increasing age is associated with increasing levels of psychosocial limitations, especially in persons 60 years of age and older. Part of the reason is the greater severity of injury sustained by older persons as reflected in longer coma (despite equivalent initial coma depth) and greater numbers of complications and surgeries for subdural hematomas. However, the consequences of traumatic brain injuries appear to worsen with increasing age: at each level of brain injury severity examined, including the milder injuries. Conclusions: Older adults clearly show less complete recovery 1 year after brain injury than younger adults, either because they have reduced reserves with which to tolerate brain injury or because their physiologic status creates a more destructive injury. Glasgow Coma Scale alone may underestimate the severity of brain injury in the aged as well as its associated consequences. Caution is advised in generalizing findings based principally on younger individuals to older adults with traumatic brain injuries. (C) 1998 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; Univ Washington, Dept Biostat, Seattle, WA 98195 USA; Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA	Dikmen, SS (corresponding author), Univ Washington, Dept Rehabil Med, Rehabil Med Box 356490, Seattle, WA 98195 USA.				AGENCY FOR HEALTHCARE RESEARCH AND QUALITYUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [R01HS006497] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD033677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS019643] Funding Source: NIH RePORTER; AHRQ HHSUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [HS06497] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD33677] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 19643] Funding Source: Medline		ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; AMACHER AL, 1987, NEUROSURGERY, V20, P954; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; CHAMPION HR, 1989, AM J PUBLIC HEALTH, V79, P1278, DOI 10.2105/AJPH.79.9.1278; DACEY R, 1991, J TRAUMA, V31, P217, DOI 10.1097/00005373-199131020-00011; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Frankowski R F, 1986, Adv Psychosom Med, V16, P153; GOLDSTEIN FC, 1995, J HEAD TRAUMA REHAB, V10, P57, DOI 10.1097/00001199-199502000-00007; GOLDSTEIN FC, 1994, J NEUROL NEUROSUR PS, V57, P961, DOI 10.1136/jnnp.57.8.961; HOWARD MA, 1989, J NEUROSURG, V71, P858, DOI 10.3171/jns.1989.71.6.0858; JENNETT B, 1975, LANCET, V1, P480; KOTWICA Z, 1992, ACTA NEUROCHIR, V118, P98, DOI 10.1007/BF01401293; KRAUS JF, 1987, HEAD INJURY, P1; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; Mamelak AN, 1996, J TRAUMA, V41, P91, DOI 10.1097/00005373-199607000-00014; Marascuilo LA., 1977, NONPARAMETRIC DISTRI; MCLEAN A, 1993, ARCH PHYS MED REHAB, V74, P1041, DOI 10.1016/0003-9993(93)90059-J; MILLER J D, 1989, Neurosurgical Review, V12, P441; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; PENNINGS JL, 1993, ARCH SURG-CHICAGO, V128, P787; PENTLAND B, 1986, AGE AGEING, V15, P193, DOI 10.1093/ageing/15.4.193; PUTNAM SH, 1996, NEUROPSYCHOLOGICAL A, P429; Ross A M, 1992, J Neurosci Nurs, V24, P88; ROY CW, 1986, INJURY, V17, P220, DOI 10.1016/0020-1383(86)90222-6; SCHWAB CW, 1992, ARCH SURG-CHICAGO, V127, P701; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P140; TEASDALE G, 1974, LANCET, V2, P81; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; ZAR JH, 1995, BIOSTATISTICAL ANAL; ZWIMPFER TJ, 1993, CRIT CARE CLIN, V9, P727	35	77	79	0	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	AUG	1998	79	8					881	887		10.1016/S0003-9993(98)90082-X			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	108MJ	WOS:000075269800001	9710157				2021-06-18	
J	Nawashiro, H; Messing, A; Azzam, N; Brenner, M				Nawashiro, H; Messing, A; Azzam, N; Brenner, M			Mice lacking GFAP are hypersensitive to traumatic cerebrospinal injury	NEUROREPORT			English	Article						astrocytes ultrastructure; glial fibrillary acidic protein deficiency; glial fibrillary acidic protein genetics; hemorrhage; sequence deletion; spinal cord injuries; transgenic mice; traumatic brain injury	BRAIN INJURY; INTERMEDIATE FILAMENTS; RAT; ARCHITECTURE; INCREASES; RECEPTORS; DEVELOP	GLIAL fibrillary acidic protein (GFAP) is an intermediate filament protein expressed primarily in astrocytes. We have tested whether GFAP protects against mechanical stress by inducing percussive head injury in GFAP-null mice with a weight drop device. When mice were positioned on a foam bed which allowed head movement at impact, all 14 wild-type mice tested survived, but 12 of 15 GFAP-null mice died within a few minutes. The cause of death appeared to be upper cervical spinal cord injury resulting in respiratory arrest. When the foam bed was replaced by a firm support, both GFAP-null and wild-type mice survived. These results indicate that mice lacking GFAP are hypersensitive to cervical spinal cord injury caused by sudden acceleration of the head. (C) 1998 Rapid Science Ltd.	NINDS, Stroke Branch, NIH, Bethesda, MD 20892 USA; Univ Wisconsin, Sch Vet Med, Madison, WI 53706 USA	Brenner, M (corresponding author), NINDS, Stroke Branch, NIH, Bldg 36,Room 4A03,6 Convent Dr,MSC 4128, Bethesda, MD 20892 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-22475] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS022475] Funding Source: NIH RePORTER		DELATORRE JC, 1995, NEUROSURGERY, V37, P273, DOI 10.1227/00006123-199508000-00012; ENG LF, 1994, BRAIN PATHOL, V4, P229, DOI 10.1111/j.1750-3639.1994.tb00838.x; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; FUCHS E, 1994, J CELL BIOL, V125, P511, DOI 10.1083/jcb.125.3.511; GOMI H, 1995, NEURON, V14, P29, DOI 10.1016/0896-6273(95)90238-4; GOSHGARIAN HG, 1981, J COMP NEUROL, V201, P441, DOI 10.1002/cne.902010309; HADLEY MN, 1989, NEUROSURGERY, V24, P536, DOI 10.1227/00006123-198904000-00008; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Katoh H, 1997, BRAIN RES, V758, P153, DOI 10.1016/S0006-8993(97)00213-8; Li ZL, 1996, DEV BIOL, V175, P362, DOI 10.1006/dbio.1996.0122; Liedtke W, 1996, NEURON, V17, P607, DOI 10.1016/S0896-6273(00)80194-4; Liedtke W, 1998, AM J PATHOL, V152, P251; LIU MY, 1995, J FORMOS MED ASSOC, V94, P386; McCall MA, 1996, P NATL ACAD SCI USA, V93, P6361, DOI 10.1073/pnas.93.13.6361; Milner DJ, 1996, J CELL BIOL, V134, P1255, DOI 10.1083/jcb.134.5.1255; NAWASHIRO H, 1995, NEUROL RES, V17, P455, DOI 10.1080/01616412.1995.11740363; OKUYAMA S, 1993, RES COMMUN CHEM PATH, V82, P91; PEKNY M, 1995, EMBO J, V14, P1590, DOI 10.1002/j.1460-2075.1995.tb07147.x; POVLISHOCK JT, 1994, J NEUROTRAUM, V11, P723, DOI 10.1089/neu.1994.11.723; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; Shibuki K, 1996, NEURON, V16, P587, DOI 10.1016/S0896-6273(00)80078-1; SUN FY, 1994, BRAIN RES, V661, P63, DOI 10.1016/0006-8993(94)91181-9	23	77	79	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	0959-4965			NEUROREPORT	Neuroreport	JUN 1	1998	9	8					1691	1696		10.1097/00001756-199806010-00004			6	Neurosciences	Neurosciences & Neurology	ZU455	WOS:000074198700004	9665584				2021-06-18	
J	Gollaher, K; High, W; Sherer, M; Bergloff, P; Boake, C; Young, ME; Ivanhoe, C				Gollaher, K; High, W; Sherer, M; Bergloff, P; Boake, C; Young, ME; Ivanhoe, C			Prediction of employment outcome one to three years following traumatic brain injury (TBI)	BRAIN INJURY			English	Article							SEVERE HEAD-INJURY; DISABILITY RATING-SCALE; GLASGOW COMA SCALE; PROGNOSIS; RECOVERY; SELECTION; COMMUNITY; CHILDREN; RETURN; WORK	The current study investigated the relationship between age, education (EDUC), pre-injury productivity (PIP), Glasgow Coma Scale score, and a functional rating score at admittance and discharge from rehabilitation (Disability Rating Scale [DRS]) to employment status at one to three years following traumatic brain injury. EDUC, admit DRS, discharge DRS, and PIP all correlated significantly with follow-up employment status, 0.29, -0.32, -0.36, and 0.25 respectively. ALI possible combinations were then evaluated by Mallow's C-p statistic. The best fitting model was then used in a discriminant function analysis. The discriminant function correctly classified 84% of the employed subjects, 66% of the unemployed, and 75% across both groups. The current results compare favourably with those obtained in previous studies.	Baylor Coll Med, Dept Psychiat, Houston, TX 77030 USA; Inst Res & Rehabil, Houston, TX USA	Gollaher, K (corresponding author), Baylor Coll Med, Dept Psychiat, 1 Baylor Plaza, Houston, TX 77030 USA.						BAXT WG, 1987, J TRAUMA, V27, P602, DOI 10.1097/00005373-198706000-00003; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BORN JD, 1985, NEUROSURGERY, V16, P595, DOI 10.1227/00006123-198505000-00002; BRAAKMAN R, 1980, NEUROSURGERY, V6, P362, DOI 10.1227/00006123-198004000-00002; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; BROWN DSO, 1992, ARCH PHYS MED REHAB, V73, P758; CARLSSON CA, 1968, J NEUROSURG, V29, P242, DOI 10.3171/jns.1968.29.3.0242; CORTHELL D, 1988, CLIENT INVOLVEMENT P; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; HOCKING RR, 1976, BIOMETRICS, V32, P1, DOI 10.2307/2529336; HUMPHREY M, 1980, INJURY, V12, P107, DOI 10.1016/0020-1383(80)90133-3; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; JAGGER J, 1983, LANCET, V2, P97; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; JENNETT B, 1975, LANCET, V1, P480; Jennett B, 1981, MANAGEMENT HEAD INJU; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; LEVATI A, 1982, J NEUROSURG, V57, P779, DOI 10.3171/jns.1982.57.6.0779; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; LIEHLAI MW, 1992, J PEDIATR-US, V120, P195, DOI 10.1016/S0022-3476(05)80426-3; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; OVERGAARD J, 1973, LANCET, V2, P631; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; RAO N, 1990, Brain Injury, V4, P49, DOI 10.3109/02699059009026148; RAO N, 1992, ARCH PHYS MED REHAB, V73, P911; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; SAS Inst. Inc, 1988, SAS STAT US GUID REL; TEASDALE G, 1974, LANCET, V2, P81; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; YOUNG B, 1981, J NEUROSURG, V54, P300, DOI 10.3171/jns.1981.54.3.0300; YOUNG ME, 1994, REHABIL COUNS BULL, V37, P229	38	77	78	0	3	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	APR	1998	12	4					255	263		10.1080/026990598122557			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	ZF942	WOS:000072948700001	9562908				2021-06-18	
J	Assaf, Y; BeitYannai, E; Shohami, E; Berman, E; Cohen, Y				Assaf, Y; BeitYannai, E; Shohami, E; Berman, E; Cohen, Y			Diffusion- and T-2-weighted MRI of closed-head injury in rats: A time course study and correlation with histology	MAGNETIC RESONANCE IMAGING			English	Article						magnetic resonance imaging (MRI); T-2 and diffusion MRI; closed-head injury; head trauma	EXPERIMENTAL CEREBRAL-ISCHEMIA; ACUTE HUMAN STROKE; BRAIN INJURY; SPECTROSCOPY; CATS; PERFUSION; DAMAGE; ECHOES; TISSUE	Diffusion- and T-2-weighted MRI were used to evaluate changes in brain water characteristics following closed-head injury in rats, Images were collected within the first 2 h and at 24 h and 7 days following the traumatic event and then compared with histology, The ratios between the apparent diffusion coefficients (ADCs) of the traumatized tissues and normal brain tissues were significantly different from unity and were found to be 0.79 +/- 0.25 (p < 0.01), 0,49 +/- 0.33 (p < 0.0002), and 3.47 +/- 1.36 (p < 10(-6)) at 1-2 h, 24 h, and 1 week after the trauma, respectively, In severe trauma, areas of hyperintensity which were not apparent on the T-2-weighted images could he detected on the diffusion-weighted images within 1-2 h after the trauma, At 24 h following the traumatic event, large areas of hyperintensity are observed in both types of images, One week following the trauma, the ADCs of the traumatized tissues (1,84 +/- 0.69 x 10(-5) cm(2)/s) are much larger than those of normal brain (0.57 +/- 0.19 x 10(-5) cm(2)/s) and approach the value of free water, At 7 days, the areas of hyperintensity in the T-2-weighted images seem to underestimate the injured areas found by histology, At this time point a good correlation is obtained between the areas of hypointensity observed on the diffusion-weighted images and the infarct areas obtained by histology (r = 0.88), (C) 1997 Elsevier Science Inc.	TEL AVIV UNIV,SCH CHEM,IL-69978 RAMAT AVIV,ISRAEL			Beit-Yannai, Elie/F-2141-2012	Beit-Yannai, Elie/0000-0001-9347-822X; assaf, yaniv/0000-0001-6828-7595			ALSOP DC, 1994, 2 ANN M SOC MAGN RES, V3, P1370; BACK T, 1994, STROKE, V25, P494, DOI 10.1161/01.STR.25.2.494; BENVENISTE H, 1992, STROKE, V23, P746, DOI 10.1161/01.STR.23.5.746; BOSE B, 1988, STROKE, V19, P28, DOI 10.1161/01.STR.19.1.28; BOUMA GJ, 1992, CENT NERVOUS SYSTEM, P333; BRANTZAWADZKI M, 1987, AM J ROENTGENOL, V148, P579, DOI 10.2214/ajr.148.3.579; BUSZA AL, 1992, STROKE, V23, P1602, DOI 10.1161/01.STR.23.11.1602; CHIEN D, 1992, AM J NEURORADIOL, V13, P1097; DARDZINKI BJ, 1994, MAGNET RESON MED, V30, P318; DAVIS D, 1994, MAGNET RESON MED, V31, P454, DOI 10.1002/mrm.1910310416; DECRESPIGNY AJ, 1995, MAGN RESON MED, V33, P720, DOI 10.1002/mrm.1910330518; EHMAN RL, 1989, RADIOLOGY, V173, P255, DOI 10.1148/radiology.173.1.2781017; FRAHM J, 1985, J MAGN RESON, V65, P130, DOI 10.1016/0022-2364(85)90381-6; GENTRY LR, 1994, RADIOLOGY, V191, P1; GILL R, 1995, J CEREBR BLOOD F MET, V15, P1, DOI 10.1038/jcbfm.1995.1; HANSTOCK CC, 1994, STROKE, V25, P843, DOI 10.1161/01.STR.25.4.843; HELPERN JA, 1993, MAGN RESON IMAGING, V11, P241, DOI 10.1016/0730-725X(93)90028-C; KNIGHT RA, 1991, STROKE, V22, P802, DOI 10.1161/01.STR.22.6.802; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; LATOUR L, 1994, P NATL ACAD SCI USA, V84, P4910; LEBIHAN D, 1986, RADIOLOGY, V161, P401, DOI 10.1148/radiology.161.2.3763909; LEBIHAN D, 1988, RADIOLOGY, V168, P497, DOI 10.1148/radiology.168.2.3393671; LEBIHAN D, 1992, AM J ROENTGENOL, V159, P591, DOI 10.2214/ajr.159.3.1503032; MANSFIELD P, 1977, J PHYS C SOLID STATE, V10, pL55, DOI 10.1088/0022-3719/10/3/004; MERBOLDT KD, 1992, MAGNET RESON MED, V23, P179, DOI 10.1002/mrm.1910230119; MOSELEY ME, 1990, AM J NEURORADIOL, V11, P423; MOSELEY ME, 1990, MAGN RESON MED, V14, P330, DOI 10.1002/mrm.1910140218; MOSELEY ME, 1992, NEUROIMAG CLIN N AM, V2, P693; ORDIDGE RJ, 1994, MAGN RESON IMAGING, V12, P455, DOI 10.1016/0730-725X(94)92539-9; SCHWARTING R, 1987, NEUROPHARMACOLOGY, V26, P457, DOI 10.1016/0028-3908(87)90027-X; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; SIESJO BK, 1988, CRIT CARE MED, V16, P954, DOI 10.1097/00003246-198810000-00006; STEJSKAL EO, 1965, J CHEM PHYS, V42, P288, DOI 10.1063/1.1695690; TAKAHASHI M, 1993, MAGNET RESON MED, V30, P485, DOI 10.1002/mrm.1910300411; TURNER R, 1990, J MAGN RESON, V86, P445, DOI 10.1016/0022-2364(90)90023-3; UMEDA M, 1994, 2 ANN M SOC MAGN RES, V3, P1372; VANBRUGGEN N, 1992, STROKE, V23, P576, DOI 10.1161/01.STR.23.4.576; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; VINK R, 1988, J BIOL CHEM, V263, P757; WARACH S, 1992, NEUROLOGY, V42, P1717, DOI 10.1212/WNL.42.9.1717; WARACH S, 1995, ANN NEUROL, V37, P231, DOI 10.1002/ana.410370214	41	77	77	0	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB	0730-725X			MAGN RESON IMAGING	Magn. Reson. Imaging		1997	15	1					77	85		10.1016/S0730-725X(96)00246-9			9	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	WP120	WOS:A1997WP12000010	9084028				2021-06-18	
J	LEVY, ML; MASRI, LS; LAVINE, S; APUZZO, MLJ				LEVY, ML; MASRI, LS; LAVINE, S; APUZZO, MLJ			OUTCOME PREDICTION AFTER PENETRATING CRANIOCEREBRAL INJURY IN A CIVILIAN POPULATION - AGGRESSIVE SURGICAL-MANAGEMENT IN PATIENTS WITH ADMISSION GLASGOW-COMA-SCALE OF SCORE-3, SCORE-4, OR SCORE-5	NEUROSURGERY			English	Article						HEAD INJURY; OUTCOME; PENETRATING CRANIOCEREBRAL INJURY	GUNSHOT WOUNDS; LEBANESE CONFLICT; MISSILE INJURIES; HEAD-INJURY; DATA-BANK; BRAIN	In an attempt to evaluate the response of patients who have low admission Glasgow Coma Scale scores (CCS) after a penetrating craniocerebral injury to aggressive management, we evaluated a series of 190 patients with penetrating injuries who presented with a GCS score of 3, 4, or 5 during a 6-year period. Entrance criteria required replicable neurological examinations that were not altered by the presence of hypotension, drugs/toxins, or systemic injury. The surgical patients included 21 patients with an admission CCS score of 3, 24 with an admission GCS score of 4, and 15 with an admission CCS score of 5. All patients underwent surgical intervention and aggressive perioperative management in the neurosurgical intensive care, including resuscitative protocols. Five of the patients with a CCS score of 3 survived, all with poor outcomes. Seven of the patients with a GCS score of 4 survived, although only one had a good outcome. Eleven of the patients with a GCS score of 5 survived. Five had a Glasgow Outcome Score of 2, five had a Glasgow Outcome Score of 3, and one had a Glasgow Outcome Score of 4. We have devised a prospective model of outcome based on our series in an attempt to predict nonsurvivors at admission (while overpredicting for survivors). The variables most predictive of mortality include admission GCS score and subarachnoid hemorrhage in one model and admission CCS score and pupillary changes in a second, when pupillary response was definitive at admission (P less than or equal to 0.00005). Important variables most predictive of morbidity include admission GCS score, bihemispheric injury when associated with intraventricular hemorrhage, and diffuse fragmentation (P < 0.001). It should be noted that disseminated intravascular coagulation was not included in our model. Disseminated intravascular coagulation was always associated with poor outcome when present in any traumatic injury. In considering outcome, we conclude that patients with admission GCS scores of 3, 4, or 5 are not likely to benefit (have a good outcome) from surgical intervention. Patients presenting with admission GCS scores of 3, 4, or 5 without radiological evidence of subarachnoid hemorrhage, ventricular involvement, or fragmentation in the presence of reactive pupils potentially should be followed more closely. We will continue to expand our series to define those prognostic variables that suggest good outcome in patients with GCS scores of 5 or higher.	UNIV SO CALIF, SCH MED, DEPT NEUROL SURG, LOS ANGELES, CA 90033 USA							AARABI B, 1990, NEUROSURGERY, V27, P692, DOI 10.1227/00006123-199011000-00004; BENZEL EC, 1991, NEUROSURGERY, V29, P67, DOI 10.1227/00006123-199107000-00011; BRANDT F, 1983, NEUROCHIRURGIA, V26, P164; BRANDVOLD B, 1990, J NEUROSURG, V72, P15, DOI 10.3171/jns.1990.72.1.0015; CAVALIERE R, 1988, ACTA NEUROCHIR, V94, P133, DOI 10.1007/BF01435866; CLARK WC, 1986, J NEUROSURG, V65, P9, DOI 10.3171/jns.1986.65.1.0009; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; GRAHM TW, 1990, NEUROSURGERY, V27, P696, DOI 10.1227/00006123-199011000-00005; HELLING TS, 1992, J TRAUMA, V32, P398, DOI 10.1097/00005373-199203000-00019; KAUFMAN HH, 1991, SURG NEUROL, V36, P370, DOI 10.1016/0090-3019(91)90026-6; KAUFMAN HH, 1986, NEUROSURGERY, V18, P689, DOI 10.1227/00006123-198606000-00002; KAUFMAN HH, 1983, ACTA NEUROCHIR, V67, P115, DOI 10.1007/BF01401671; KAUFMAN HH, 1991, NEUROSURGERY, V29, P479; LEVI L, 1990, ISRAEL J MED SCI, V26, P548; LEVI L, 1991, BRIT J NEUROSURG, V5, P617, DOI 10.3109/02688699109002885; LEVY ML, 1993, NEUROSURGERY, V32, P532, DOI 10.1227/00006123-199304000-00007; MANCAL P, 1988, Journal of Hygiene Epidemiology Microbiology and Immunology (Prague), V32, P189; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; NAGIB MG, 1986, NEUROSURGERY, V18, P533, DOI 10.1227/00006123-198605000-00003; ONUBA O, 1987, ARCH EMERG MED, V4, P73; SELDEN BS, 1988, ANN EMERG MED, V17, P247, DOI 10.1016/S0196-0644(88)80117-3; SHAFFREY ME, 1991, AM ASS NEUROLOGICAL; SICCARDI D, 1991, SURG NEUROL, V35, P455, DOI 10.1016/0090-3019(91)90179-D; SUDDABY L, 1987, CAN J NEUROL SCI, V14, P268, DOI 10.1017/S0317167100026597; TAHA JM, 1991, NEUROSURGERY, V29, P380, DOI 10.1227/00006123-199109000-00007; TAHA JM, 1991, NEUROSURGERY, V29, P864, DOI 10.1227/00006123-199112000-00010	26	77	81	0	4	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JUL	1994	35	1					77	84		10.1227/00006123-199407000-00012			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	NV277	WOS:A1994NV27700034	7936156				2021-06-18	
J	RESNICK, DK; MARION, DW; DARBY, JM				RESNICK, DK; MARION, DW; DARBY, JM			THE EFFECT OF HYPOTHERMIA ON THE INCIDENCE OF DELAYED TRAUMATIC INTRACEREBRAL HEMORRHAGE	NEUROSURGERY			English	Article						COAGULOPATHY; DELAYED TRAUMATIC HEMORRHAGE; HEAD INJURY; HYPOTHERMIA	INDUCED PLATELET-AGGREGATION; BRAIN INJURY; TEMPERATURE; COLD	HYPOTHERMIA HAS BEEN shown to cause coagulation abnormalities, primarily related to platelet dysfunction. We reviewed coagulation function and the incidence of delayed traumatic intracerebral hemorrhage in a series of 36 patients with severe head injuries (Glasgow Coma Scale 3-7) enrolled in a prospective, randomized, clinical trial of therapeutic moderate hypothermia. Patients were randomized to a normothermic group (n = 16) or to a group cooled to 32 to 33 degrees C within 6 hours of injury (n = 20). Prothrombin times, partial thromboplastin times, and platelet counts were obtained in the emergency room and then again within 24 hours of randomization. Delayed traumatic intracerebral hemorrhage occurred in 6 of 20 (30%) hypothermic patients and 5 of 16 (31%) normothermic patients. In the hypothermic group, 9 of 17 patients had an increased prothrombin time during hypothermic therapy, as opposed to 11 of 16 in the normothermic group during the corresponding time period. The partial thromboplastin time was prolonged in 2 of 17 hypothermic patients and 2 of 16 normothermic patients. Three patients in the hypothermic group and one in the normothermic group developed thrombocytopenia (a platelet count of less than 100,000). There were no significant differences between the two groups in the incidence of delayed traumatic intracerebral hemorrhage, in measured coagulopathy, or in the mean values of measured coagulation parameters. Although the possibility of a hypothermia-induced coagulopathy has not yet been excluded, the short-term use of hypothermia does not appear to increase the risk for intracranial hemorrhagic complications in head injuries.	UNIV PITTSBURGH,SCH MED,DEPT ANESTHESIA CRIT CARE,PITTSBURGH,PA 15213	RESNICK, DK (corresponding author), UNIV PITTSBURGH,SCH MED,DEPT NEUROL SURG,230 LOTHROP ST,ROOM F948,PITTSBURGH,PA 15213, USA.		Marion, Donald/AAR-5749-2021	Marion, Donald/0000-0003-4627-7702	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P20NS030318] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1 P20 NS30318-01] Funding Source: Medline		BERNABEI AF, 1992, J TRAUMA, V33, P835, DOI 10.1097/00005373-199212000-00007; BIGELOW WG, 1950, ANN SURG, V132, P849, DOI 10.1097/00000658-195011000-00001; Brass LF, 1991, HEMATOLOGY BASIC PRI, P1176; CLIFTON GL, 1980, J NEUROSURG, V52, P611, DOI 10.3171/jns.1980.52.5.0611; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; COHEN IJ, 1987, BRIT J HAEMATOL, V65, P331, DOI 10.1111/j.1365-2141.1987.tb06862.x; DIAZ FG, 1979, J NEUROSURG, V50, P217, DOI 10.3171/jns.1979.50.2.0217; FAY T, 1940, NY STATE J MED  0915, P1351; FAY T, 1943, ASS RES NERV MENT DI, V24, P611; GINSBERG MD, 1992, CEREBROVAS BRAIN MET, V4, P189; GUDEMAN SK, 1979, NEUROSURGERY, V5, P309, DOI 10.1227/00006123-197909000-00002; KATTLOVE HE, 1971, BLOOD-J HEMATOL, V38, P39, DOI 10.1182/blood.V38.1.39.39; KEIMOWITZ RM, 1973, J NEUROSURG, V39, P178, DOI 10.3171/jns.1973.39.2.0178; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MINER ME, 1985, NEUROSURGERY, P1666; REED RL, 1992, J TRAUMA, V33, P465, DOI 10.1097/00005373-199209000-00022; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; TRENCHARD PM, 1989, CLIN PHYS PHYSIOL M, V10, P65, DOI 10.1088/0143-0815/10/1/007; VALERI CR, 1987, ANN SURG, V205, P175, DOI 10.1097/00000658-198702000-00012; VANDERSANDE JJ, 1981, J NEUROSURG, V55, P718, DOI 10.3171/jns.1981.55.5.0718; WOODMAN RC, 1990, BLOOD, V76, P1680	21	77	80	0	7	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0148-396X			NEUROSURGERY	Neurosurgery	FEB	1994	34	2					252	255		10.1227/00006123-199402000-00007			4	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	MU697	WOS:A1994MU69700021	8177385				2021-06-18	
J	HAMM, RJ; ODELL, DM; PIKE, BR; LYETH, BG				HAMM, RJ; ODELL, DM; PIKE, BR; LYETH, BG			COGNITIVE IMPAIRMENT FOLLOWING TRAUMATIC BRAIN INJURY - THE EFFECT OF PRE-INJURY AND POSTINJURY ADMINISTRATION OF SCOPOLAMINE AND MK-801	COGNITIVE BRAIN RESEARCH			English	Article						TRAUMATIC BRAIN INJURY; MORRIS WATER MAZE; SCOPOLAMINE; MK-801; RAT	CLOSED HEAD-INJURY; EXTRACELLULAR POTASSIUM; AMINO-ACIDS; RAT	In order to examine the effectiveness of pre- and post-injury administration of muscarinic cholinergic and NMDA antagonists in reducing cognitive deficits following traumatic brain injury (TBI), rats were injected with either scopolamine (1 mg/kg) or MK-801 (0.3 mg/kg) 15 min prior to or 15 min after fluid percussion TBI. Cognitive performance was assessed with the Morris water maze procedure on days 11-15 after TBI or sham injury. When scopolamine and MK-801 were injected 15 min before injury, Morris water maze deficits were significantly reduced (P < 0.01 and P < 0.05, respectively). When scopolamine and MK-801 were injected 15 min after TBI, neither drug was effective in attenuating Morris water maze deficits. Consistent with other research, these results suggest that the cognitive deficits produced by TBI are the consequence of a brief period of excessive excitation of cholinergic and NMDA receptor systems. The results of this experiment also suggest that the temporal therapeutic window for the treatment of cognitive dysfunction with receptor antagonist intervention appears to be quite brief (< 15 min) in the rat.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT NEUROSURG,RICHMOND,VA 23284	HAMM, RJ (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PSYCHOL,VCU BOX 2018,RICHMOND,VA 23284, USA.			Lyeth, Bruce/0000-0003-4811-1474	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS12587] Funding Source: Medline		BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; BROOKS D N, 1975, Cortex, V11, P329; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GORMAN LK, 1989, J NEUROTRAUM, V6, P203; HAYES RL, 1988, J NEUROTRAUM, V5, P287; HUBSCHMANN OR, 1983, J NEUROSURG, V59, P289, DOI 10.3171/jns.1983.59.2.0289; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LEVIN HS, 1992, J NEUROTRAUM, V9, pS359; LYETH B G, 1989, Society for Neuroscience Abstracts, V15, P1113; LYETH BG, 1992, BRAIN RES, V569, P281, DOI 10.1016/0006-8993(92)90640-U; LYETH BG, 1988, BRAIN RES, V452, P39, DOI 10.1016/0006-8993(88)90006-6; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; ROBINSON SE, 1990, BRAIN RES, V511, P141, DOI 10.1016/0006-8993(90)90233-2; TABADDOR K, 1984, NEUROSURGERY, V14, P702; TAKAHASHI H, 1981, J NEUROSURG, V55, P708, DOI 10.3171/jns.1981.55.5.0708; TAKAHASHI H, 1981, J NEUROSURG, V55, P717; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; WEHMAN A, 1989, J HEAT TRAUMA REHAB, V4, P6	22	77	78	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0926-6410			COGNITIVE BRAIN RES	Cognit. Brain Res.	DEC	1993	1	4					223	226		10.1016/0926-6410(93)90006-Q			4	Computer Science, Artificial Intelligence; Neurosciences; Neuroimaging	Computer Science; Neurosciences & Neurology	ND501	WOS:A1993ND50100004	8003921				2021-06-18	
J	DEWITT, DS; PROUGH, DS; TAYLOR, CL; WHITLEY, JM; DEAL, DD; VINES, SM				DEWITT, DS; PROUGH, DS; TAYLOR, CL; WHITLEY, JM; DEAL, DD; VINES, SM			REGIONAL CEREBROVASCULAR RESPONSES TO PROGRESSIVE HYPOTENSION AFTER TRAUMATIC BRAIN INJURY IN CATS	AMERICAN JOURNAL OF PHYSIOLOGY			English	Article						CEREBRAL BLOOD FLOW; RADIOACTIVE MICROSPHERES; HEMORRHAGIC SHOCK; HEMORRHAGIC TRAUMA; CENTRAL NERVOUS SYSTEM	CEREBRAL BLOOD-FLOW; SEVERE HEAD-INJURY; AUTO-REGULATION; AUTOREGULATION; METABOLISM; ANESTHESIA; ISOFLURANE; HALOTHANE; PRESSURE; ISCHEMIA	We investigated the effects of hypotension on cerebral blood flow (CBF) after traumatic brain injury (TBI) in cats. Isoflurane-anesthetized cats were prepared for TBI and for microsphere measurements of total (T) and regional (r) CBF. Four groups were studied: sham injury (group I, n = 6); TBI (group II, n = 6); isoflurane anesthesia, no TBI or hypotension (group III, n = 4); and isoflurane and TBI, no hypotension (group IV, n = 8). After TBI or sham trauma, mean arterial pressure (MAP) was reduced to 80, 60, and 40 mmHg by hemorrhage. Group I TCBF did not change significantly from baseline until MAP reached 40 mmHg, but rCBF was more dependent on MAP in anterior hemispheric than in brain stem regions. Group II TCBF was significantly lower than baseline, and group I TCBF at all levels of hypotension and autoregulation was impaired at higher MAP levels in anterior than in posterior brain regions. Groups III and IV indicated that decreases in TCBF were not due to duration of the preparation or to TBI in the absence of hemorrhagic hypotension. We conclude that global and regional autoregulation are absent in response to hemorrhagic hypotension after TBI.	WAKE FOREST UNIV, BOWMAN GRAY SCH MED, MED CTR, DEPT ANESTHESIA, WINSTON SALEM, NC 27157 USA; WAKE FOREST UNIV, BOWMAN GRAY SCH MED, MED CTR, DEPT ANAT, WINSTON SALEM, NC 27157 USA; WAKE FOREST UNIV, BOWMAN GRAY SCH MED, MED CTR, DEPT PUBL HLTH SCI, WINSTON SALEM, NC 27157 USA			Prough, Donald S/G-5793-2013	Prough, Donald S/0000-0001-7994-532X			ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; BOUMA GJ, 1990, J NEUROSURG, V73, P368, DOI 10.3171/jns.1990.73.3.0368; BRUCE DA, 1973, J NEUROSURG, V38, P131, DOI 10.3171/jns.1973.38.2.0131; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; ENEVOLDSEN EM, 1978, J NEUROSURG, V48, P689, DOI 10.3171/jns.1978.48.5.0689; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; HAYES RL, 1984, SCIENCE, V223, P301, DOI 10.1126/science.6701514; HOFFBRAND BI, 1969, CARDIOVASC RES, V3, P426, DOI 10.1093/cvr/3.4.426; HOSSMANN KA, 1978, J NEUROL, V218, P275, DOI 10.1007/BF00312883; ISHIGE N, 1988, J NEUROSURG, V68, P129, DOI 10.3171/jns.1988.68.1.0129; KONTOS HA, 1978, AM J PHYSIOL, V234, pH371; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MILETICH DJ, 1976, ANESTH ANALG, V55, P100; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; MILLER JD, 1985, BRIT J ANAESTH, V57, P120, DOI 10.1093/bja/57.1.120; MUIZELAAR JP, 1984, J NEUROSURG, V61, P700, DOI 10.3171/jns.1984.61.4.0700; MUIZELAAR JP, 1989, J NEUROSURG, V71, P72, DOI 10.3171/jns.1989.71.1.0072; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; PRIOR PF, 1978, BRIT J ANAESTH, V50, P993, DOI 10.1093/bja/50.10.993; ROSNER MJ, 1984, J NEUROSURG, V61, P76, DOI 10.3171/jns.1984.61.1.0076; RUDOLPH AM, 1967, CIRC RES, V21, P163, DOI 10.1161/01.RES.21.2.163; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; TEASDALE G, 1974, LANCET, V2, P81; TODD MM, 1984, ANESTHESIOLOGY, V60, P276, DOI 10.1097/00000542-198404000-00002; VANAKEN H, 1986, ANESTH ANALG, V65, P565; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; YOSHIDA K, 1991, J NEUROSURG, V74, P87, DOI 10.3171/jns.1991.74.1.0087	31	77	77	0	1	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0002-9513			AM J PHYSIOL	Am. J. Physiol.	OCT	1992	263	4	2				H1276	H1284					9	Physiology	Physiology	JU806	WOS:A1992JU80600038					2021-06-18	
J	NELL, V; BROWN, DSO				NELL, V; BROWN, DSO			EPIDEMIOLOGY OF TRAUMATIC BRAIN INJURY IN JOHANNESBURG .2. MORBIDITY, MORTALITY AND ETIOLOGY	SOCIAL SCIENCE & MEDICINE			English	Article						EPIDEMIOLOGY; TRAUMATIC BRAIN INJURY; MORBIDITY; MORTALITY; ETIOLOGY; JOHANNESBURG	HEAD			NELL, V (corresponding author), UNIV S AFRICA,HLTH PSYCHOL UNIT,POB 392,PRETORIA,SOUTH AFRICA.						ANDERSON DW, 1980, J NEUROSURG, V53, pS32; ARMITAGE P, 1971, STATISTICAL METHODS; AUSTIN RL, 1983, J CRIM JUST, V11, P93, DOI 10.1016/0047-2352(83)90045-4; AUSTIN RL, 1987, J CRIM JUST, V15, P437, DOI 10.1016/0047-2352(87)90001-8; BAKER SP, 1985, INJURY FACT BOOK; BOND MR, 1976, SCAND J REHABIL MED, V8, P127; BRADSHAW D, 1987, REV S AFRICAN MORTAL; BULHAN HA, 1981, RACE CLASS, V23, P25, DOI 10.1177/030639688102300102; BULHAN HA, 1979, RACE CLASS, V20, P243; BULHAN HUSSEIN ABDILAHI, 1985, FRANTZ FANON PSYCHOL; BUTCHART RA, 1991, SA MED J, V79, P472; Joffe J.M., 1984, READINGS PRIMARY PRE; KALSBEEK WD, 1980, J NEUROSURG, V53, pS19; MCLEAN A, 1984, NEUROSURGERY, V14, P393, DOI 10.1227/00006123-198404000-00001; Morton RF, 1979, STUDY GUIDE EPIDEMIO; NELL V, 1989, CRITICAL HLTH, V28, P44; RIMEL RW, 1983, REHABILITATION BRAIN; SANDERCOCK P, 1989, J NEUROL NEUROSUR PS, V52, P817, DOI 10.1136/jnnp.52.7.817	18	77	81	0	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB	0277-9536			SOC SCI MED	Soc. Sci. Med.		1991	33	3					289	296		10.1016/0277-9536(91)90363-H			8	Public, Environmental & Occupational Health; Social Sciences, Biomedical	Public, Environmental & Occupational Health; Biomedical Social Sciences	GA785	WOS:A1991GA78500008	1925693				2021-06-18	
J	Engler-Chiurazzi, EB; Brown, CM; Povroznik, JM; Simpkins, JW				Engler-Chiurazzi, E. B.; Brown, C. M.; Povroznik, J. M.; Simpkins, J. W.			Estrogens as neuroprotectants: Estrogenic actions in the context of cognitive aging and brain injury	PROGRESS IN NEUROBIOLOGY			English	Article; Proceedings Paper	International Conference on Aging and Disease (ICAD)	NOV 01-02, 2014	Beijing, PEOPLES R CHINA	Int Soc Aging & Dis, Xuanwu Hosp, Beijing Capital Univ, Wenzhou Med Univ, First Affiliated Hosp		Estrogen; Neuroprotection; Aging; Cognition; Stroke; Traumatic brain injury	CONJUGATED EQUINE ESTROGENS; CEREBRAL-ARTERY OCCLUSION; AGED FEMALE RAT; POSTMENOPAUSAL HORMONE-THERAPY; FOREBRAIN CHOLINERGIC NEURONS; MESSENGER-RIBONUCLEIC-ACID; ESTRADIOL-MEDIATED PROTECTION; SPATIAL REFERENCE MEMORY; DENDRITIC SPINE DENSITY; NITRIC-OXIDE SYNTHASE	There is ample empirical evidence to support the notion that the biological impacts of estrogen extend beyond the gonads to other bodily systems, including the brain and behavior. Converging preclinical findings have indicated a neuroprotective role for estrogen in a variety of experimental models of cognitive function and brain insult. However, the surprising null or even detrimental findings of several large clinical trials evaluating the ability of estrogen-containing hormone treatments to protect against age-related brain changes and insults, including cognitive aging and brain injury, led to hesitation by both clinicians and patients in the use of exogenous estrogenic treatments for nervous system outcomes. That estrogen-containing therapies are used by tens of millions of women for a variety of health-related applications across the lifespan has made identifying conditions under which benefits with estrogen treatment will be realized an important public health issue. Here we provide a summary of the biological actions of estrogen and estrogen-containing formulations in the context of aging, cognition, stroke, and traumatic brain injury. We have devoted special attention to highlighting the notion that estrogen appears to be a conditional neuroprotectant whose efficacy is modulated, by several interacting factors. By developing criteria standards for desired beneficial peripheral and neuroprotective outcomes among unique patient populations, we can optimize estrogen treatments for attenuating the consequences of, and perhaps even preventing, cognitive aging, and brain injury. (C) 2016 Elsevier Ltd. All rights reserved.	[Engler-Chiurazzi, E. B.; Brown, C. M.; Povroznik, J. M.; Simpkins, J. W.] West Virginia Univ, Ctr Basic & Translat Stroke Res, POB 9229, Morgantown, WV 26506 USA; [Engler-Chiurazzi, E. B.; Simpkins, J. W.] West Virginia Univ, Dept Physiol & Pharmacol, Morgantown, WV 26506 USA; [Brown, C. M.] West Virginia Univ, Dept Neurobiol & Anat, Morgantown, WV 26506 USA; [Povroznik, J. M.] West Virginia Univ, Dept Pediat, Morgantown, WV 26506 USA	Engler-Chiurazzi, EB (corresponding author), West Virginia Univ, Ctr Basic & Translat Stroke Res, POB 9229, Morgantown, WV 26506 USA.	elengler@hsc.wvu.edu; cdbrown2@hsc.wvu.edu; jpovrozn@mix.wvu.edu; jwsimpkins@hsc.wvu.edu	Brown, Candice/AAD-4982-2019	Brown, Candice/0000-0001-5845-0221	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P20 GM109098, P01 AG022550, P01 AG027956, K01 NS081015];  [U54 GM109492]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P20GM109098, U54GM104942] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K01NS081014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG027956, P01AG022550] Funding Source: NIH RePORTER	The writing of this review was supported by the National Institutes of Health (JWS = P20 GM109098, P01 AG022550, and P01 AG027956; CMB = K01 NS081015). This work was also supported U54 GM109492. This content is solely the responsibility of the authors.	Acaz-Fonseca E, 2014, MOL CELL ENDOCRINOL, V389, P48, DOI 10.1016/j.mce.2014.01.009; Acosta JI, 2013, BRAIN RES, V1514, P18, DOI 10.1016/j.brainres.2013.01.016; Acosta JI, 2009, HORM BEHAV, V55, P454, DOI 10.1016/j.yhbeh.2008.11.008; Acosta JI, 2010, ENDOCRINOLOGY, V151, P3795, DOI 10.1210/en.2010-0055; Acosta JI, 2009, ENDOCRINOLOGY, V150, P4248, DOI 10.1210/en.2008-1802; Adams MM, 2002, J NEUROSCI, V22, P3608; Aimone JB, 2014, PHYSIOL REV, V94, P991, DOI 10.1152/physrev.00004.2014; Alkayed NJ, 2001, J NEUROSCI, V21, P7543; Almeida OP, 2005, AM J GERIAT PSYCHIAT, V13, P142, DOI 10.1176/appi.ajgp.13.2.142; Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701; Arevalo MA, 2015, NAT REV NEUROSCI, V16, P17, DOI 10.1038/nrn3856; Arevalo MA, 2010, BBA-GEN SUBJECTS, V1800, P1106, DOI 10.1016/j.bbagen.2009.10.002; Arnold AP, 2009, HORM BEHAV, V55, P570, DOI 10.1016/j.yhbeh.2009.03.011; Asl SZ, 2013, J NEUROSURG, V119, P353, DOI 10.3171/2013.4.JNS121636; Asthana S, 1999, PSYCHONEUROENDOCRINO, V24, P657, DOI 10.1016/S0306-4530(99)00020-7; Ayres S, 1996, J LAB CLIN MED, V128, P367, DOI 10.1016/S0022-2143(96)80008-4; Baba Y, 2010, MENOPAUSE, V17, P506, DOI 10.1097/gme.0b013e3181c7dd41; Baddeley A, 2010, CURR BIOL, V20, pR136, DOI 10.1016/j.cub.2009.12.014; Bagger YZ, 2005, MENOPAUSE, V12, P12, DOI 10.1097/00042192-200512010-00005; Bake S, 2004, ENDOCRINOLOGY, V145, P5471, DOI 10.1210/en.2004-0984; Bake S, 2009, MICROVASC RES, V78, P413, DOI 10.1016/j.mvr.2009.06.009; Barha CK, 2009, J NEUROENDOCRINOL, V21, P155, DOI 10.1111/j.1365-2826.2008.01809.x; Barha CK, 2013, NEUROBIOL AGING, V34, P986, DOI 10.1016/j.neurobiolaging.2012.07.009; Barha CK, 2010, NEUROPSYCHOPHARMACOL, V35, P547, DOI 10.1038/npp.2009.161; Barrett-Connor E, 1999, J AM GERIATR SOC, V47, P1289, DOI 10.1111/j.1532-5415.1999.tb07427.x; Bazarian JJ, 2010, J NEUROTRAUM, V27, P527, DOI 10.1089/neu.2009.1068; Bechmann I, 2007, TRENDS IMMUNOL, V28, P5, DOI 10.1016/j.it.2006.11.007; Behl C, 1997, MOL PHARMACOL, V51, P535; Berchtold Nicole C., 2009, P1, DOI 10.1007/978-1-59745-422-3_1; Berry B, 1997, BEHAV NEUROSCI, V111, P267, DOI 10.1037/0735-7044.111.2.267; Berry C, 2009, J TRAUMA, V67, P950, DOI 10.1097/TA.0b013e3181ba3354; Berthold A., 1849, TEXTS DOC, P399; Bhavnani BR, 2003, J STEROID BIOCHEM, V85, P473, DOI 10.1016/S0960-0760(03)00220-6; Biernaskie J, 2001, MAGNET RESON MED, V46, P827, DOI 10.1002/mrm.1263; Bimonte HA, 1999, PSYCHONEUROENDOCRINO, V24, P161, DOI 10.1016/S0306-4530(98)00068-7; Bimonte HA, 2003, NEUROBIOL AGING, V24, P37, DOI 10.1016/S0197-4580(02)00015-5; Bimonte-Nelson HA, 2004, NEUROREPORT, V15, P2659, DOI 10.1097/00001756-200412030-00021; Bimonte-Nelson HA, 2004, BEHAV NEUROSCI, V118, P707, DOI 10.1037/0735-7044.118.4.707; Bimonte-Nelson HA, 2003, BEHAV NEUROSCI, V117, P1395, DOI 10.1037/0735-7044.117.6.1395; Bimonte-Nelson HA, 2006, EUR J NEUROSCI, V24, P229, DOI 10.1111/j.1460-9568.2006.04867.x; Bingham D, 2005, J CEREBR BLOOD F MET, V25, P414, DOI 10.1038/sj.jcbfm.9600031; Blaustein JD, 2008, ENDOCRINOLOGY, V149, P2697, DOI 10.1210/en.2008-0396; BLAUSTEIN MP, 1993, AM J PHYSIOL, V264, pC1367; BLEECKER ML, 1988, J CLIN PSYCHOL, V44, P403, DOI 10.1002/1097-4679(198805)44:3<403::AID-JCLP2270440315>3.0.CO;2-0; Bliss T., 2007, HIPPOCAMPUS BOOK, P343; Bottner M, 2014, J STEROID BIOCHEM, V139, P245, DOI 10.1016/j.jsbmb.2013.03.003; Bohacek J, 2009, J NEUROENDOCRINOL, V21, P640, DOI 10.1111/j.1365-2826.2009.01882.x; Bramlett HM, 2001, J NEUROTRAUM, V18, P891, DOI 10.1089/089771501750451811; Brinton RD, 2000, NEUROBIOL AGING, V21, P475, DOI 10.1016/S0197-4580(00)00109-3; Brinton RD, 1997, EXP NEUROL, V147, P211, DOI 10.1006/exnr.1997.6619; Brinton RD, 2000, MATURITAS, V34, pS35, DOI 10.1016/S0378-5122(00)00107-9; Brinton RD, 2001, LEARN MEMORY, V8, P121, DOI 10.1101/lm.39601; Brinton RD, 2008, TRENDS NEUROSCI, V31, P529, DOI 10.1016/j.tins.2008.07.003; Brinton RD, 2008, FRONT NEUROENDOCRIN, V29, P313, DOI 10.1016/j.yfrne.2008.02.001; Brown CM, 2008, EXP NEUROL, V210, P782, DOI 10.1016/j.expneurol.2007.11.021; Brown CM, 2010, ENDOCRINOLOGY, V151, P4916, DOI 10.1210/en.2010-0371; Brown CM, 2009, SEMIN REPROD MED, V27, P240, DOI 10.1055/s-0029-1216277; Brown TJ, 1996, NEUROENDOCRINOLOGY, V63, P53, DOI 10.1159/000126935; Bruce-Keller AJ, 2007, J NEUROTRAUM, V24, P203, DOI 10.1089/neu.2006.0163; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Burek M, 2010, ARTERIOSCL THROM VAS, V30, P298, DOI 10.1161/ATVBAHA.109.197582; Bushnell C, 2014, ANN INTERN MED, V160, P853, DOI 10.7326/M14-0762; Bushnell C, 2014, STROKE, V45, P1545, DOI 10.1161/01.str.0000442009.06663.48; Bushnell CD, 2006, STROKE, V37, P2387, DOI 10.1161/01.STR.0000236053.37695.15; CAMPBELL S, 1977, CLIN OBSTET GYNAECOL, V4, P31; Carlson LE, 1998, PSYCHONEUROENDOCRINO, V23, P583; Carswell HVO, 2010, CLIN SCI, V118, P375, DOI 10.1042/CS20090018; Carswell HV, 2004, J CEREBR BLOOD F MET, V24, P298, DOI 10.1097/01.WCB.0000112322.75217.FD; Casals JB, 2011, COMPARATIVE MED, V61, P305; Chakrabarti M, 2014, BRAIN RES BULL, V109, P22, DOI 10.1016/j.brainresbull.2014.09.004; Chen SH, 2009, CRIT CARE MED, V37, P3097, DOI 10.1097/CCM.0b013e3181bc7986; Cipolla MJ, 2009, MICROCIRCULATION, V16, P685, DOI 10.3109/10739680903164131; Coimbra R, 2003, J TRAUMA, V54, P689, DOI 10.1097/01.TA.0000058314.31655.5F; Cook DJ, 2012, NEUROTHERAPEUTICS, V9, P371, DOI 10.1007/s13311-012-0115-z; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Daniel JM, 2013, HORM BEHAV, V63, P231, DOI 10.1016/j.yhbeh.2012.05.003; Daniel JM, 1999, PHYSIOL BEHAV, V66, P11, DOI 10.1016/S0031-9384(98)00272-8; Daniel JM, 2006, ENDOCRINOLOGY, V147, P607, DOI 10.1210/en.2005-0998; Daniel JM, 1997, HORM BEHAV, V32, P217, DOI 10.1006/hbeh.1997.1433; Daniel JM, 2001, J NEUROSCI, V21, P6949; Davies AM, 1996, PHILOS T ROY SOC B, V351, P389, DOI 10.1098/rstb.1996.0033; Day M, 2005, NEUROBIOL LEARN MEM, V83, P13, DOI 10.1016/j.nlm.2004.06.009; Day NL, 2013, J NEUROTRAUM, V30, P1531, DOI 10.1089/neu.2013.2854; Deroo BJ, 2006, J CLIN INVEST, V116, P561, DOI 10.1172/JCI27987; Deutsch ER, 2013, BRAIN RES, V1530, P82, DOI 10.1016/j.brainres.2013.07.014; Dey P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128239; Dubal DB, 1999, J NEUROSCI, V19, P6385; Dubal DB, 1998, J CEREBR BLOOD F MET, V18, P1253, DOI 10.1097/00004647-199811000-00012; Dubal DB, 2001, P NATL ACAD SCI USA, V98, P1952, DOI 10.1073/pnas.041483198; Dubal DB, 2006, ENDOCRINOLOGY, V147, P3076, DOI 10.1210/en.2005-1177; Duckles SP, 2011, ACTA PHYSIOL, V203, P149, DOI 10.1111/j.1748-1716.2010.02184.x; Dumas J, 2008, HORM BEHAV, V53, P159, DOI 10.1016/j.yhbeh.2007.09.011; Durukan A, 2007, PHARMACOL BIOCHEM BE, V87, P179, DOI 10.1016/j.pbb.2007.04.015; Dykens J. A., 1995, OXYGEN PARADOX, P453; Dykens JA, 2003, EXP GERONTOL, V38, P101, DOI 10.1016/S0531-5565(02)00162-6; Eichenbaum H, 2000, NAT REV NEUROSCI, V1, P41, DOI 10.1038/35036213; El-Bakri NK, 2004, J CELL MOL MED, V8, P537, DOI 10.1111/j.1582-4934.2004.tb00478.x; Elkabes S, 2014, EXP NEUROL, V259, P28, DOI 10.1016/j.expneurol.2014.01.008; EMERSON CS, 1993, BRAIN RES, V608, P95, DOI 10.1016/0006-8993(93)90778-L; Engler E. B., 2007, SOC NEUROSCIENCE; Engler-Chiurazzi E, 2011, NEUROBIOL AGING, V32, P680, DOI 10.1016/j.neurobiolaging.2009.09.005; Engler-Chiurazzi EB, 2012, HORM BEHAV, V62, P1, DOI 10.1016/j.yhbeh.2012.04.004; Ennaceur A, 2010, BEHAV BRAIN RES, V215, P244, DOI 10.1016/j.bbr.2009.12.036; Espeland MA, 2004, JAMA-J AM MED ASSOC, V291, P2959, DOI 10.1001/jama.291.24.2959; Espeland MA, 2013, JAMA INTERN MED, V173, P1429, DOI 10.1001/jamainternmed.2013.7727; Fader AJ, 1999, PHARMACOL BIOCHEM BE, V62, P711, DOI 10.1016/S0091-3057(98)00219-6; Fader AJ, 1998, NEUROBIOL LEARN MEM, V69, P225, DOI 10.1006/nlme.1998.3820; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Farin A, 2003, J NEUROSURG, V98, P32, DOI 10.3171/jns.2003.98.1.0032; Farrag AF, 2002, DEMENT GERIATR COGN, V13, P193, DOI 10.1159/000048652; Feng Z, 2004, J PINEAL RES, V37, P198, DOI 10.1111/j.1600-079X.2004.00158.x; Fester L, 2014, BRAIN RES, V1621, P1; Fisher M, 2009, STROKE, V40, P2244, DOI 10.1161/STROKEAHA.108.541128; Foster TC, 2003, NEUROBIOL AGING, V24, P839, DOI 10.1016/S0197-4580(03)00014-9; Foster TC, 2008, MOL THER, V16, P1587, DOI 10.1038/mt.2008.140; Foster TC, 2012, HIPPOCAMPUS, V22, P656, DOI 10.1002/hipo.20935; Foy MR, 1999, J NEUROPHYSIOL, V81, P925; Freedman MA, 2002, J WOMEN HEALTH GEN-B, V11, P703, DOI 10.1089/15409990260363661; Frick KM, 2002, NEUROSCIENCE, V115, P547, DOI 10.1016/S0306-4522(02)00377-9; Frick KM, 2001, BEHAV NEUROSCI, V115, P229, DOI 10.1037//0735-7044.115.1.229; Frye CA, 2007, NEUROBIOL LEARN MEM, V88, P208, DOI 10.1016/j.nlm.2007.04.003; Gabryel B, 2012, PHARMACOL REP, V64, P1; GALEA LAM, 1993, PERS INDIV DIFFER, V14, P53, DOI 10.1016/0191-8869(93)90174-2; Gan BK, 2004, ANN ACAD MED SINGAP, V33, P63; Garry PS, 2015, EXP NEUROL, V263, P235, DOI 10.1016/j.expneurol.2014.10.017; Gatson JW, 2012, J NEUROTRAUM, V29, P2209, DOI 10.1089/neu.2011.2274; Gibbs RB, 2000, NEUROBIOL AGING, V21, P107, DOI 10.1016/S0197-4580(00)00103-2; Gibbs RB, 1999, HORM BEHAV, V36, P222, DOI 10.1006/hbeh.1999.1541; Gibbs RB, 1997, BRAIN RES, V757, P10, DOI 10.1016/S0006-8993(96)01432-1; Gibbs RB, 2002, HORM BEHAV, V42, P245, DOI 10.1006/hbeh.2002.1825; Gibbs RB, 2007, HORM BEHAV, V52, P352, DOI 10.1016/j.yhbeh.2007.05.011; Gibbs RB, 2010, ENDOCR REV, V31, P224, DOI 10.1210/er.2009-0036; Gibson CL, 2013, J CEREBR BLOOD F MET, V33, P1355, DOI 10.1038/jcbfm.2013.102; Gleason CE, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001833; Goldstein LB, 2011, STROKE, V42, P517, DOI 10.1161/STR.0b013e3181fcb238; Good M, 1999, EUR J NEUROSCI, V11, P4476, DOI 10.1046/j.1460-9568.1999.00920.x; Gordon KB, 2005, BRAIN RES, V1036, P155, DOI 10.1016/j.brainres.2004.12.052; Gould E., 2007, HIPPOCAMPUS BOOK, P343; Granholm AC, 2000, EXPERT OPIN INV DRUG, V9, P685, DOI 10.1517/13543784.9.4.685; Green PS, 1998, NEUROSCIENCE, V84, P7, DOI 10.1016/S0306-4522(97)00595-2; Green PS, 1997, J NEUROSCI, V17, P511; Green PS, 2001, ENDOCRINOLOGY, V142, P400, DOI 10.1210/en.142.1.400; Greendale GA, 2010, AM J EPIDEMIOL, V171, P1214, DOI 10.1093/aje/kwq067; GREENE GL, 1986, SCIENCE, V231, P1150, DOI 10.1126/science.3753802; Gresack JE, 2004, NEUROSCIENCE, V128, P459, DOI 10.1016/j.neuroscience.2004.06.011; Gresack JE, 2007, NEUROBIOL LEARN MEM, V88, P393, DOI 10.1016/j.nlm.2007.07.015; Gridley KE, 1998, MOL PHARMACOL, V54, P874; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; Gurman P, 2015, CLIN PHARMACOL THER, V97, P274, DOI 10.1002/cpt.33; Gustafsson JA, 1999, J ENDOCRINOL, V163, P379, DOI 10.1677/joe.0.1630379; Habib P, 2015, J STEROID BIOCHEM, V146, P3, DOI 10.1016/j.jsbmb.2014.02.018; Hall CB, 2000, STAT MED, V19, P1555, DOI 10.1002/(SICI)1097-0258(20000615/30)19:11/12<1555::AID-SIM445>3.0.CO;2-3; Hammond R, 2009, HORM BEHAV, V56, P309, DOI 10.1016/j.yhbeh.2009.06.008; HAMPSON E, 1990, PSYCHONEUROENDOCRINO, V15, P97, DOI 10.1016/0306-4530(90)90018-5; Handa RJ, 2012, J NEUROENDOCRINOL, V24, P160, DOI 10.1111/j.1365-2826.2011.02206.x; Harms C, 2001, J NEUROSCI, V21, P2600, DOI 10.1523/JNEUROSCI.21-08-02600.2001; Hawk T, 1998, BRAIN RES, V796, P296, DOI 10.1016/S0006-8993(98)00327-8; Hawkes K, 2003, AM J HUM BIOL, V15, P380, DOI 10.1002/ajhb.10156; Henderson VW, 2012, CLIMACTERIC, V15, P229, DOI 10.3109/13697137.2012.656254; Henderson VW, 2007, MENOPAUSE, V14, P572, DOI 10.1097/gme.0b013e31803df49c; Henderson VW, 2013, P NATL ACAD SCI USA, V110, P20290, DOI 10.1073/pnas.1312353110; Hendrix SL, 2006, CIRCULATION, V113, P2425, DOI 10.1161/CIRCULATIONAHA.105.594077; Hersh AL, 2004, JAMA-J AM MED ASSOC, V291, P47, DOI 10.1001/jama.291.1.47; Holmes MM, 2002, BEHAV NEUROSCI, V116, P928, DOI 10.1037//0735-7044.116.5.928; Horsburgh K, 2002, J CEREBR BLOOD F MET, V22, P1189; Hruska Z, 2007, HORM BEHAV, V52, P297, DOI 10.1016/j.yhbeh.2007.05.010; Inagaki T, 2010, HORM BEHAV, V58, P415, DOI 10.1016/j.yhbeh.2010.05.013; Jacome LF, 2010, NEUROBIOL LEARN MEM, V94, P488, DOI 10.1016/j.nlm.2010.08.016; JARRARD LE, 1984, BEHAV NEUROSCI, V98, P946, DOI 10.1037/0735-7044.98.6.946; JENSEN EV, 1962, RECENT PROG HORM RES, V18, P387; Jones J., 2012, NATL HLTH STAT REPOR; Jover T., 2002, J NEUROSCI; KASSIS JA, 1981, J BIOL CHEM, V256, P7378; Kesslak JP, 1998, BEHAV NEUROSCI, V112, P1012, DOI 10.1037/0735-7044.112.4.1012; Khaksari M, 2013, CAN J PHYSIOL PHARM, V91, P700, DOI 10.1139/cjpp-2012-0359; Khaksari M, 2011, CAN J PHYSIOL PHARM, V89, P31, DOI 10.1139/y10-103; Kimura Doreen, 2002, Neuro Endocrinol Lett, V23 Suppl 4, P67; Kittner SJ, 1996, NEW ENGL J MED, V335, P768, DOI 10.1056/NEJM199609123351102; Koellhoffer EC, 2013, TRANSL STROKE RES, V4, P390, DOI 10.1007/s12975-012-0230-5; Kok HS, 2006, MENOPAUSE, V13, P19, DOI 10.1097/01.gme.0000196592.36711.a0; Kritz-Silverstein D, 2002, J AM GERIATR SOC, V50, P55, DOI 10.1046/j.1532-5415.2002.50008.x; Kuhl H, 2005, CLIMACTERIC, V8, P3, DOI 10.1080/13697130500148875; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Laughlin GA, 2000, J CLIN ENDOCR METAB, V85, P645, DOI 10.1210/jc.85.2.645; Lebesgue D, 2006, J NEUROTRAUM, V23, P1814, DOI 10.1089/neu.2006.23.1814; Lebrun CEI, 2005, CLIN ENDOCRINOL, V63, P50, DOI 10.1111/j.1365-2265.2005.02297.x; Leon RL, 2012, ENDOCRINOLOGY, V153, P3386, DOI 10.1210/en.2011-1859; LERNER SP, 1990, BIOL REPROD, V42, P633, DOI 10.1095/biolreprod42.4.633; Levin-Allerhand J A, 2002, J Nutr Health Aging, V6, P315; Lewis DK, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2011.11.007; Lewis MC, 2008, BEHAV NEUROSCI, V122, P716, DOI 10.1037/0735-7044.122.3.716; Li RN, 2014, MOL CELL ENDOCRINOL, V389, P13, DOI 10.1016/j.mce.2013.12.018; Li XL, 2004, EXP NEUROL, V187, P94, DOI 10.1016/j.expneurol.2004.01.004; Liang Y, 2001, BRAIN RES BULL, V54, P661, DOI 10.1016/S0361-9230(01)00483-X; Lisabeth L, 2012, LANCET NEUROL, V11, P82, DOI 10.1016/S1474-4422(11)70269-1; Littleton-Kearney MT, 2005, J CEREBR BLOOD F MET, V25, P421, DOI 10.1038/sj.jcbfm.9600052; Liu F, 2012, J NEUROENDOCRINOL, V24, P319, DOI 10.1111/j.1365-2826.2011.02248.x; Liu F, 2008, NAT NEUROSCI, V11, P334, DOI 10.1038/nn2057; Liu FD, 2009, STROKE, V40, P1842, DOI 10.1161/STROKEAHA.108.538686; Liu R, 2002, STROKE, V33, P2485, DOI 10.1161/01.STR.0000030317.43597.C8; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; LU KH, 1979, BIOL REPROD, V21, P193, DOI 10.1095/biolreprod21.1.193; LUINE V, 1994, BEHAV NEURAL BIOL, V62, P230, DOI 10.1016/S0163-1047(05)80021-4; LUINE V, 1990, BRAIN RES, V523, P321, DOI 10.1016/0006-8993(90)91507-D; Luine VN, 2014, HORM BEHAV, V66, P602, DOI 10.1016/j.yhbeh.2014.08.011; Luine VN, 2003, ENDOCRINOLOGY, V144, P2836, DOI 10.1210/en.2003-0004; Ma VY, 2014, ARCH PHYS MED REHAB, V95, P986, DOI 10.1016/j.apmr.2013.10.032; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; MacLusky NJ, 2005, ENDOCRINOLOGY, V146, P287, DOI 10.1210/en.2004-0730; Macrae IM, 2011, BRIT J PHARMACOL, V164, P1062, DOI 10.1111/j.1476-5381.2011.01398.x; Maghool F, 2013, BRAIN RES, V1497, P61, DOI 10.1016/j.brainres.2012.12.014; Magnotti LJ, 2008, J AM COLL SURGEONS, V206, P984, DOI 10.1016/j.jamcollsurg.2007.12.038; Maki PM, 2012, ENDOCRINOLOGY, V153, P3564, DOI 10.1210/en.2012-1175; Maki PM, 2006, NEUROSCIENCE, V138, P1027, DOI 10.1016/j.neuroscience.2006.01.001; Manson JE, 2013, JAMA-J AM MED ASSOC, V310, P1353, DOI 10.1001/jama.2013.278040; Manwani B, 2011, WOMENS HEALTH, V7, P319, DOI [10.2217/WHE.11.22, 10.2217/whe.11.22]; Maren S, 2001, ANNU REV NEUROSCI, V24, P897, DOI 10.1146/annurev.neuro.24.1.897; Markowska AL, 1999, J NEUROSCI, V19, P8122; Markowska AL, 2002, J NEUROSCI, V22, P10985; Mayer LP, 2005, ARTERIOSCL THROM VAS, V25, P1910, DOI 10.1161/01.ATV.0000175767.46520.6a; Mayer LP, 2002, REPROD TOXICOL, V16, P775, DOI 10.1016/S0890-6238(02)00048-5; McClean J, 2008, EXP NEUROL, V210, P41, DOI 10.1016/j.expneurol.2007.09.027; McClure RES, 2013, HORM BEHAV, V63, P144, DOI 10.1016/j.yhbeh.2012.09.011; McCullough LD, 2001, STROKE, V32, P796, DOI 10.1161/01.STR.32.3.796; McLaughlin KJ, 2008, HORM BEHAV, V54, P386, DOI 10.1016/j.yhbeh.2008.04.010; McMillan PJ, 1996, J NEUROSCI, V16, P1860; Mehra RD, 2005, BRAIN RES, V1056, P22, DOI 10.1016/j.brainres.2005.06.073; Mennenga SE, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00294; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Miller CP, 1996, STEROIDS, V61, P305, DOI 10.1016/0039-128X(95)00234-H; Miller NR, 2005, ENDOCRINOLOGY, V146, P3070, DOI 10.1210/en.2004-1515; Milner TA, 2005, J COMP NEUROL, V491, P81, DOI 10.1002/cne.20724; Milner TA, 2001, J COMP NEUROL, V429, P355; MOORADIAN AD, 1993, J STEROID BIOCHEM, V45, P509, DOI 10.1016/0960-0760(93)90166-T; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MOZAFFARIAN D, 2015, CIRCULATION, V131, pE29, DOI [DOI 10.1161/CIR.0000000000000152, 10.1161/CIR.0000000000000152]; Nakagami F, 2010, ATHEROSCLEROSIS, V211, P41, DOI 10.1016/j.atherosclerosis.2010.01.016; Nappi RE, 1999, GYNECOL OBSTET INVES, V47, P29, DOI 10.1159/000010058; Neal-Perry G, 2010, MATURITAS, V67, P34, DOI 10.1016/j.maturitas.2010.04.016; Neese SL, 2010, HORM BEHAV, V58, P878, DOI 10.1016/j.yhbeh.2010.08.017; Neves-e-Castro M, 1975, Med Hypotheses, V1, P132, DOI 10.1016/0306-9877(75)90054-7; Nilsen J, 2002, BRAIN RES, V930, P216, DOI 10.1016/S0006-8993(02)02254-0; Nilsen J, 2003, P NATL ACAD SCI USA, V100, P2842, DOI 10.1073/pnas.0438041100; O'Connor CA, 2005, BRAIN RES, V1062, P171, DOI 10.1016/j.brainres.2005.09.011; Offner H, 2006, ANN NY ACAD SCI, V1089, P343, DOI 10.1196/annals.1386.021; OHKURA T, 1995, DEMENTIA, V6, P99, DOI 10.1159/000106929; OLTON DS, 1979, AM PSYCHOL, V34, P583, DOI 10.1037/0003-066X.34.7.583; Ormerod BK, 2003, J NEUROBIOL, V55, P247, DOI 10.1002/neu.10181; Packard MG, 1996, BEHAV NEUROSCI, V110, P626; Packard MG, 1998, HORM BEHAV, V34, P126, DOI 10.1006/hbeh.1998.1464; Paganini-Hill A, 2001, MATURITAS, V38, P243, DOI 10.1016/S0378-5122(01)00167-0; Pan YL, 1999, P SOC EXP BIOL MED, V221, P118, DOI 10.1046/j.1525-1373.1999.d01-64.x; Park EM, 2006, J CEREBR BLOOD F MET, V26, P392, DOI 10.1038/sj.jcbfm.9600194; PENG MT, 1972, FERTIL STERIL, V23, P535; PENTLAND B, 1986, AGE AGEING, V15, P193, DOI 10.1093/ageing/15.4.193; Perez E, 2005, DRUG DEVELOP RES, V66, P78, DOI 10.1002/ddr.20047; Perez E, 2005, BRAIN RES, V1038, P216, DOI 10.1016/j.brainres.2005.01.026; Peterson CM, 2000, J SOC GYNECOL INVEST, V7, pS3, DOI 10.1177/1071557600007001S03; Petrea RE, 2009, STROKE, V40, P1032, DOI 10.1161/STROKEAHA.108.542894; Petrone AB, 2014, MOL CELL ENDOCRINOL, V389, P40, DOI 10.1016/j.mce.2013.12.017; Pike CJ, 1999, J NEUROCHEM, V72, P1552, DOI 10.1046/j.1471-4159.1999.721552.x; Prokai L, 2003, P NATL ACAD SCI USA, V100, P11741, DOI 10.1073/pnas.2032621100; Prokai L, 2003, DRUG METAB DISPOS, V31, P701, DOI 10.1124/dmd.31.6.701; Prokai L, 2007, PHARMACOL THERAPEUT, V114, P1, DOI 10.1016/j.pharmthera.2007.01.006; Prossnitz ER, 2014, MOL CELL ENDOCRINOL, V389, P71, DOI 10.1016/j.mce.2014.02.002; RANNEVIK G, 1995, MATURITAS, V21, P103, DOI 10.1016/0378-5122(94)00869-9; Rapp PR, 2003, J NEUROSCI, V23, P5708; Rau SW, 2003, J NEUROSCI, V23, P11420; Reeves MJ, 2008, LANCET NEUROL, V7, P915, DOI 10.1016/S1474-4422(08)70193-5; Rhodes ME, 2006, NEUROBIOL LEARN MEM, V85, P183, DOI 10.1016/j.nlm.2005.10.003; Rissman EF, 2002, P NATL ACAD SCI USA, V99, P3996, DOI 10.1073/pnas.012032699; Ritzel RM, 2013, HORM BEHAV, V63, P238, DOI 10.1016/j.yhbeh.2012.04.007; Rocca WA, 2007, NEUROLOGY, V69, P1074, DOI 10.1212/01.wnl.0000276984.19542.e6; Rocca W. A., 2014, MOL CELL ENDOCRINOL, V18, P1199; Rocca WA, 2011, BRAIN RES, V1379, P188, DOI 10.1016/j.brainres.2010.10.031; Rodefer J. S., 2007, BRAIN AGING MODELS M; Rodgers SP, 2010, ENDOCRINOLOGY, V151, P1194, DOI 10.1210/en.2009-1245; Rodriguiz R. M., 2006, ANIMAL MODELS COGNIT; Romer W, 1997, STEROIDS, V62, P688, DOI 10.1016/S0039-128X(97)00068-8; Romer W, 1997, STEROIDS, V62, P304, DOI 10.1016/S0039-128X(96)00224-3; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; ROSSER M, 1993, BIOL REPROD, V48, P89, DOI 10.1095/biolreprod48.1.89; Rossouw JE, 2007, JAMA-J AM MED ASSOC, V297, P1465, DOI 10.1001/jama.297.13.1465; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Rouchaud A, 2011, STROKE, V42, P1289, DOI 10.1161/STROKEAHA.110.599399; Ruiz-Palmero I, 2013, MOL CELL ENDOCRINOL, V372, P105, DOI 10.1016/j.mce.2013.03.018; Rusa R, 1999, STROKE, V30, P1665, DOI 10.1161/01.STR.30.8.1665; Sarkar S, 2015, BRAIN RES, V1616, P101, DOI 10.1016/j.brainres.2015.04.059; Sarkar SN, 2008, P NATL ACAD SCI USA, V105, P15148, DOI 10.1073/pnas.0802379105; Sawada H, 1998, J NEUROSCI RES, V54, P707, DOI 10.1002/(SICI)1097-4547(19981201)54:5<707::AID-JNR16>3.0.CO;2-T; Selvamani A, 2010, J NEUROSCI, V30, P6852, DOI 10.1523/JNEUROSCI.0761-10.2010; Selvamani A, 2010, NEUROBIOL AGING, V31, P1618, DOI 10.1016/j.neurobiolaging.2008.08.014; Sherwin BB, 2008, FRONT NEUROENDOCRIN, V29, P88, DOI 10.1016/j.yfrne.2007.08.002; SHERWIN BB, 1988, PSYCHONEUROENDOCRINO, V13, P345, DOI 10.1016/0306-4530(88)90060-1; Shughrue PJ, 1997, J COMP NEUROL, V388, P507, DOI 10.1002/(SICI)1096-9861(19971201)388:4<507::AID-CNE1>3.0.CO;2-6; Shughrue PJ, 2000, NEUROSCIENCE, V96, P41, DOI 10.1016/S0306-4522(99)00520-5; Shumaker SA, 2004, JAMA-J AM MED ASSOC, V291, P2947, DOI 10.1001/jama.291.24.2947; Shumaker SA, 2003, JAMA-J AM MED ASSOC, V289, P2651, DOI 10.1001/jama.289.20.2651; Shuster LT, 2010, MATURITAS, V65, P161, DOI 10.1016/j.maturitas.2009.08.003; Simpkins J. W., 1997, AM J MED, V103, p19S, DOI 10.1016/s0002-9343(97)00260-x; Simpkins JW, 2008, BRAIN RES REV, V57, P421, DOI 10.1016/j.brainresrev.2007.04.007; Simpkins JW, 2008, ALZHEIMERS DEMENT, V4, pS131, DOI 10.1016/j.jalz.2007.10.009; Simpkins JW, 1997, J NEUROSURG, V87, P724, DOI 10.3171/jns.1997.87.5.0724; Singer CA, 1998, NEUROREPORT, V9, P2565, DOI 10.1097/00001756-199808030-00025; SINGH M, 1995, ENDOCRINOLOGY, V136, P2320, DOI 10.1210/en.136.5.2320; SINGH M, 1994, BRAIN RES, V644, P305, DOI 10.1016/0006-8993(94)91694-2; Singh M, 2013, HORM BEHAV, V63, P284, DOI 10.1016/j.yhbeh.2012.06.003; Sitruk-Ware R, 2002, MENOPAUSE, V9, P6, DOI 10.1097/00042192-200201000-00003; Slewa-Younan S, 2004, ARCH PHYS MED REHAB, V85, P376, DOI 10.1016/j.apmr.2003.05.007; Slowik A, 2015, J STEROID BIOCHEM, V153, P135, DOI 10.1016/j.jsbmb.2015.02.013; Smith CC, 2010, P NATL ACAD SCI USA, V107, P19543, DOI 10.1073/pnas.1009307107; Smith KM, 2014, EXP NEUROL, V259, P44, DOI 10.1016/j.expneurol.2014.03.010; SOHRABJI F, 1995, P NATL ACAD SCI USA, V92, P11110, DOI 10.1073/pnas.92.24.11110; Sohrabji F, 2013, J NEUROENDOCRINOL, V25, P1173, DOI 10.1111/jne.12059; Sohrabji F, 2013, NEUROCHEM INT, V63, P291, DOI 10.1016/j.neuint.2013.06.013; Sohrabji F, 2013, HORM BEHAV, V63, P222, DOI 10.1016/j.yhbeh.2012.06.002; Soustiel JF, 2005, J NEUROTRAUM, V22, P345, DOI 10.1089/neu.2005.22.345; Spary EJ, 2009, J CHEM NEUROANAT, V38, P185, DOI 10.1016/j.jchemneu.2009.05.008; Stackman RW, 1997, NEUROBIOL LEARN MEM, V67, P167, DOI 10.1006/nlme.1996.3753; Strom JO, 2013, SCI REP-UK, V3, DOI 10.1038/srep03111; Strom JO, 2011, INT J MOL SCI, V12, P1533, DOI 10.3390/ijms12031533; Suzuki S, 2007, P NATL ACAD SCI USA, V104, P6013, DOI 10.1073/pnas.0610394104; Suzuki S, 2007, J COMP NEUROL, V500, P1064, DOI 10.1002/cne.21240; Suzuki T, 2004, J NEUROTRAUM, V21, P842, DOI 10.1089/0897715041526186; Talboom JS, 2008, NEUROBIOL LEARN MEM, V90, P155, DOI 10.1016/j.nlm.2008.04.002; Talboom JS, 2010, HORM BEHAV, V58, P917, DOI 10.1016/j.yhbeh.2010.09.002; Tanapat P, 1999, J NEUROSCI, V19, P5792, DOI 10.1523/JNEUROSCI.19-14-05792.1999; Tanapat P, 2005, J COMP NEUROL, V481, P252, DOI 10.1002/cne.20385; Tang MY, 1996, METABOLISM, V45, P411, DOI 10.1016/S0026-0495(96)90212-7; Timiras P., 1995, HORMONES AGING; TOFT D, 1966, P NATL ACAD SCI USA, V55, P1574, DOI 10.1073/pnas.55.6.1574; Toran-Allerand CD, 2005, ENDOCRINOLOGY, V146, P3843, DOI 10.1210/en.2004-1616; Toung TJK, 1998, STROKE, V29, P1666, DOI 10.1161/01.STR.29.8.1666; US Census Bureau, 2008, NP2008 T2 US CENS BU; VANDENBERG SG, 1978, PERCEPT MOTOR SKILL, V47, P599, DOI 10.2466/pms.1978.47.2.599; Vedder LC, 2014, NEUROBIOL AGING, V35, P2183, DOI 10.1016/j.neurobiolaging.2014.04.004; Vegeto E, 2008, FRONT NEUROENDOCRIN, V29, P507, DOI 10.1016/j.yfrne.2008.04.001; Viscoli CM, 2001, NEW ENGL J MED, V345, P1243, DOI 10.1056/NEJMoa010534; Wagner AK, 2002, NEUROSCI LETT, V334, P165, DOI 10.1016/S0304-3940(02)01103-5; Wagner AK, 2004, BRAIN RES, V998, P113, DOI 10.1016/j.brainres.2003.11.027; Walf AA, 2008, NEUROREPORT, V19, P789, DOI 10.1097/WNR.0b013e3282fe209c; Walf AA, 2006, NEUROBIOL LEARN MEM, V86, P35, DOI 10.1016/j.nlm.2006.01.004; Wallace M, 2006, BRAIN RES, V1126, P176, DOI 10.1016/j.brainres.2006.07.064; Wang J, 2001, J NEUROCHEM, V77, P804, DOI 10.1046/j.1471-4159.2001.00271.x; Wang Q, 1999, STROKE, V30, P630, DOI 10.1161/01.STR.30.3.630; Wang X., 2003, TOX SOC NEUR ABSTR, V29, P635; Wang XF, 2003, INVEST OPHTH VIS SCI, V44, P2067, DOI 10.1167/iovs.02-0841; Wang XF, 2006, MOL PHARMACOL, V70, P395, DOI 10.1124/mol.106.022384; Warren SG, 1997, BEHAV NEUROSCI, V111, P259, DOI 10.1037/0735-7044.111.2.259; Warren SG, 1995, BRAIN RES, V703, P26, DOI 10.1016/0006-8993(95)01059-9; Waters EM, 2011, BRAIN RES, V1379, P86, DOI 10.1016/j.brainres.2010.09.069; Wei J, 2013, ACTA PHARMACOL SIN, V34, P1485, DOI 10.1038/aps.2013.160; WISE PM, 1980, NEUROENDOCRINOLOGY, V30, P15, DOI 10.1159/000122968; Wise PM, 2000, J NEUROCYTOL, V29, P401, DOI 10.1023/A:1007169408561; Witty CF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051385; Wolf OT, 2002, HORM BEHAV, V41, P259, DOI 10.1006/hbeh.2002.1770; Woolley CS, 1997, J NEUROSCI, V17, P1848; WOOLLEY CS, 1992, J NEUROSCI, V12, P2549; WOOLLEY CS, 1994, J NEUROSCI, V14, P7680; WOOLLEY CS, 1990, J NEUROSCI, V10, P4035; Workman JL, 2012, BEHAV NEUROSCI, V126, P54, DOI 10.1037/a0025538; Yamaguchi-Shima N, 2007, BRAIN RES, V1155, P34, DOI 10.1016/j.brainres.2007.04.016; Yang SH, 2004, P NATL ACAD SCI USA, V101, P4130, DOI 10.1073/pnas.0306948101; Yang SH, 2000, STROKE, V31, P745, DOI 10.1161/01.STR.31.3.745; Yasui T, 1999, J CLIN LAB ANAL, V13, P266, DOI 10.1002/(SICI)1098-2825(1999)13:6<266::AID-JCLA3>3.3.CO;2-R; Yi KD, 2011, BRAIN RES, V1379, P61, DOI 10.1016/j.brainres.2010.11.058; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac; Zhang B, 2010, J IMMUNOL, V184, P4087, DOI 10.4049/jimmunol.0902339; Zhang F, 2004, NEUROL RES, V26, P835, DOI 10.1179/016164104X3824; Zhang QG, 2014, MOL CELL ENDOCRINOL, V389, P84, DOI 10.1016/j.mce.2013.12.019; Zhang YQ, 1998, BRAIN RES, V784, P321, DOI 10.1016/S0006-8993(97)00502-7; Zhang YM, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-49; Zhao LQ, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-24; Zhao LQ, 2004, BRAIN RES, V1010, P22, DOI 10.1016/j.brainres.2004.02.066; Zheng JB, 1999, J STEROID BIOCHEM, V68, P65, DOI 10.1016/S0960-0760(98)00161-7; Zheng JB, 1999, EUR J PHARMACOL, V368, P95, DOI 10.1016/S0014-2999(99)00012-6	379	76	79	2	63	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0301-0082	1873-5118		PROG NEUROBIOL	Prog. Neurobiol.	OCT	2017	157				SI		188	211		10.1016/j.pneurobio.2015.12.008			24	Neurosciences	Neurosciences & Neurology	FJ7TG	WOS:000412961200011	26891883	Green Accepted			2021-06-18	
J	Rubenstein, R; Chang, BG; Yue, JK; Chiu, A; Winkler, EA; Puccio, A; Diaz-Arrastia, R; Yuh, EL; Mukherjee, P; Valadka, AB; Gordon, WA; Okonkwo, DO; Davies, P; Agarwal, S; Lin, F; Sarkis, G; Yadikar, H; Yang, ZH; Manley, GT; Wang, KKW				Rubenstein, Richard; Chang, Binggong; Yue, John K.; Chiu, Allen; Winkler, Ethan A.; Puccio, Avam.; Diaz-Arrastia, Ramon; Yuh, Esther L.; Mukherjee, Pratik; Valadka, Alex B.; Gordon, Wayne A.; Okonkwo, David O.; Davies, Peter; Agarwal, Sanjeev; Lin, Fan; Sarkis, George; Yadikar, Hamad; Yang, Zhihui; Manley, Geoffrey T.; Wang, Kevin K. W.		TRACK-TBI Investigators	Comparing Plasma Phospho Tau, Total Tau, and Phospho Tau-Total Tau Ratio as Acute and Chronic Traumatic Brain Injury Biomarkers	JAMA NEUROLOGY			English	Article							FIBRILLARY ACIDIC PROTEIN; C-TERMINAL HYDROLASE-L1; COMMON DATA ELEMENTS; ALZHEIMERS-DISEASE; CEREBROSPINAL-FLUID; TRANSFORMING RESEARCH; CLINICAL KNOWLEDGE; AMYLOID-BETA; AMYLOID-BETA-1-42; ENCEPHALOPATHY	IMPORTANCE Annually in the United States, at least 3.5 million people seek medical attention for traumatic brain injury (TBI). The development of therapies for TBI is limited by the absence of diagnostic and prognostic biomarkers. Microtubule-associated protein tau is an axonal phosphoprotein. To date, the presence of the hypophosphorylated tau protein (P-tau) in plasma from patients with acute TBI and chronic TBI has not been investigated. OBJECTIVE To examine the associations between plasma P-tau and total-tau (T-tau) levels and injury presence, severity, type of pathoanatomic lesion (neuroimaging), and patient outcomes in acute and chronic TBI. DESIGN, SETTING, AND PARTICIPANTS In the TRACK-TBI Pilot study, plasma was collected at a single time point from 196 patients with acute TBI admitted to 3 level I trauma centers (< 24 hours after injury) and 21 patients with TBI admitted to inpatient rehabilitation units (mean [SD], 176.4 [44.5] days after injury). Control samples were purchased from a commercial vendor. The TRACK-TBI Pilot study was conducted from April 1, 2010, to June 30, 2012. Data analysis for the current investigation was performed from August 1, 2015, to March 13, 2017. MAIN OUTCOMES AND MEASURES Plasma samples were assayed for P-tau (using an antibody that specifically recognizes phosphothreonine-231) and T-tau using ultra-high sensitivity laser-based immunoassay multi-arrayed fiberoptics conjugated with rolling circle amplification. RESULTS In the 217 patients with TBI, 161 (74.2%) were men; mean (SD) age was 42.5 (18.1) years. The P-tau and T-tau levels and P-tau-T-tau ratio in patients with acute TBI were higher than those in healthy controls. Receiver operating characteristic analysis for the 3 tau indices demonstrated accuracy with area under the curve (AUC) of 1.000, 0.916, and 1.000, respectively, for discriminating mild TBI (GlasgowComa Scale [GCS] score, 13-15, n = 162) from healthy controls. The P-tau level and P-tau-T-tau ratiowere higher in individuals with more severe TBI (GCS, <= 12 vs 13-15). The P-tau level and P-tau-T-tau ratio outperformed the T-tau level in distinguishing cranial computed tomography-positive from - negative cases (AUC = 0.921, 0.923, and 0.646, respectively). Acute P-tau levels and P-tau-T-tau ratioweakly distinguished patients with TBI who had good outcomes (Glasgow Outcome Scale-Extended GOS-E, 7-8) (AUC = 0.663 and 0.658, respectively) and identified those with poor outcomes (GOS-E, <= 4 vs > 4) (AUC = 0.771 and 0.777, respectively). Plasma samples from patients with chronic TBI also showed elevated P-tau levels and a P-tau-T-tau ratio significantly higher than that of healthy controls, with both P-tau indices strongly discriminating patients with chronic TBI from healthy controls (AUC = 1.000 and 0.963, respectively). CONCLUSIONS AND RELEVANCE Plasma P-tau levels and P-tau-T-tau ratio outperformed T-tau level as diagnostic and prognostic biomarkers for acute TBI. Compared with T-tau levels alone, P-tau levels and P-tau-T-tau ratios show more robust and sustained elevations among patients with chronic TBI.	[Rubenstein, Richard; Chang, Binggong; Chiu, Allen] Suny Downstate Med Ctr, Dept Neurol, Lab Neurodegenerat Dis & CNS Biomarker Discovery, Brooklyn, NY 11203 USA; [Rubenstein, Richard; Chang, Binggong; Chiu, Allen] Suny Downstate Med Ctr, Dept Physiol Pharmacol, Lab Neurodegenerat Dis & CNS Biomarker Discovery, Brooklyn, NY 11203 USA; [Yue, John K.; Winkler, Ethan A.; Yuh, Esther L.; Mukherjee, Pratik; Manley, Geoffrey T.] San Francisco Gen Hosp, Brain & Spinal Injury Ctr, San Francisco, CA 94110 USA; [Winkler, Ethan A.; Manley, Geoffrey T.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA; [Puccio, Avam.; Okonkwo, David O.] Univ Pittsburgh, Med Ctr, Dept Neurosurg, Pittsburgh, PA USA; [Diaz-Arrastia, Ramon] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA; [Yuh, Esther L.; Mukherjee, Pratik] Univ Calif San Francisco, Dept Radiol, San Francisco, CA USA; [Valadka, Alex B.] Virginia Commonwealth Univ, Dept Neurosurg, Richmond, VA 23284 USA; [Gordon, Wayne A.] Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10029 USA; [Davies, Peter] Feinstein Inst Med Res, Litwin Zucker Ctr Res Alzheimers Dis, Manhasset, NY USA; [Agarwal, Sanjeev] Suny Downstate Med Ctr, Dept Orthoped Surg & Rehabil Med, Brooklyn, NY 11203 USA; [Lin, Fan; Sarkis, George; Yadikar, Hamad; Yang, Zhihui; Wang, Kevin K. W.] Univ Florida, Dept Emergency Med Psychiat & Chem, Program Neurotrauma Neuroprote & Biomarker Res, Gainesville, FL USA; [Sarkis, George] Alexandria Univ, Fac Sci, Dept Chem, Alexandria, Egypt; [Yadikar, Hamad] Kuwait Univ, Dept Biochem, Khadiya, Kuwait	Rubenstein, R (corresponding author), Suny Downstate Med Ctr, Dept Neurol, 450 Clarkson Ave,POB 1213, Brooklyn, NY 11203 USA.	richard.rubenstein@downstate.edu	Yue, John K/P-1348-2015	Yue, John K/0000-0001-9694-7722; Cooper, Shelly/0000-0003-0026-6688; Wang, Kevin/0000-0002-9343-6473	Office of the Assistant Secretary of Defense for Health Affairs through the Department of Defense (DOD) Broad Agency Announcement [W81XWH-11-2-0069, W81XWH-14-2-0166]; National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RC2 NS069409]; NIH grantUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1U01 NS086090-01, R21NS085455-01]; US DOD grant [W81XWH-14-2-0176]; US DODUnited States Department of Defense [W81XWH-13-1-04]; University of Florida McKnight Brain Institute BSCIRTF fund; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS086090, RC2NS069409] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG022102] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01RX001859] Funding Source: NIH RePORTER	This study was supported in part by the Office of the Assistant Secretary of Defense for Health Affairs through the Department of Defense (DOD) Broad Agency Announcement under award numbers W81XWH-11-2-0069 (Dr Rubenstein) and W81XWH-14-2-0166 (Dr Rubenstein). It was also supported in part by National Institutes of Health (NIH) grant RC2 NS069409 (Dr Manley), NIH grant 1U01 NS086090-01 (Dr Manley), US DOD grant W81XWH-14-2-0176 (Dr Manley), US DOD grant W81XWH-13-1-04 (Dr Manley), NIH grant R21NS085455-01 (Dr Wang), and University of Florida McKnight Brain Institute BSCIRTF fund (DrWang).	Blennow K, 2004, NEUROLOGY, V62, P159, DOI 10.1212/WNL.62.1.159; Brophy GM, 2011, J NEUROTRAUM, V28, P861, DOI 10.1089/neu.2010.1564; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; CRITCHLEY M, 1957, BMJ-BRIT MED J, V1, P357, DOI 10.1136/bmj.1.5015.357; Dani M, 2016, EUR J NUCL MED MOL I, V43, P1139, DOI 10.1007/s00259-015-3231-2; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; Diniz BSO, 2008, WORLD J BIOL PSYCHIA, V9, P172, DOI 10.1080/15622970701535502; Duan YL, 2012, TRANSL NEURODEGENER, V1, DOI 10.1186/2047-9158-1-24; Forslund MV, 2013, ACTA NEUROL SCAND, V128, P220, DOI 10.1111/ane.12130; Franz G, 2003, NEUROLOGY, V60, P1457, DOI 10.1212/01.WNL.0000063313.57292.00; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Horiguchi T, 2003, AM J PATHOL, V163, P1021, DOI 10.1016/S0002-9440(10)63462-1; Jagoda AS, 2002, ANN EMERG MED, V40, P231, DOI 10.1016/j.jen.2008.12.010; Johnson U, 2014, NEUROCRIT CARE, V21, P259, DOI 10.1007/s12028-014-9954-2; Kochanek PM, 1998, SEMIN CLIN NEUROPSYC, P176; Liu MC, 2011, ASN NEURO, V3, P25, DOI 10.1042/AN20100012; Manley GT, 2010, ARCH PHYS MED REHAB, V91, P1667, DOI 10.1016/j.apmr.2010.05.018; MARTLAND HS, 1928, JAMA-J AM MED ASSOC, V91, P1103, DOI DOI 10.1001/JAMA.1928.02700150029009; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Montenigro PH, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/s13195-014-0068-z; Nonnis S, 2008, NEUROCHEM RES, V33, P518, DOI 10.1007/s11064-007-9467-x; Olivera A, 2015, JAMA NEUROL, V72, P1109, DOI 10.1001/jamaneurol.2015.1383; Omalu Bennet I, 2010, J Forensic Nurs, V6, P130, DOI 10.1111/j.1939-3938.2010.01078.x; Omalu Bennet I, 2010, J Forensic Nurs, V6, P40, DOI 10.1111/j.1939-3938.2009.01064.x; Papa L, 2016, JAMA NEUROL, V73, P551, DOI 10.1001/jamaneurol.2016.0039; Park SY, 2007, NEUROSCIENCE, V144, P119, DOI 10.1016/j.neuroscience.2006.09.012; Reyes JF, 2008, NEUROBIOL DIS, V31, P198, DOI 10.1016/j.nbd.2008.04.005; Rohn TT, 2002, NEUROBIOL DIS, V11, P341, DOI 10.1006/nbdi.2002.0549; Rubenstein R, 2015, J NEUROTRAUM, V32, P342, DOI 10.1089/neu.2014.3548; Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367; Sivanandam TM, 2012, NEUROSCI BIOBEHAV R, V36, P1376, DOI 10.1016/j.neubiorev.2012.02.013; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Spillantini MG, 2013, LANCET NEUROL, V12, P609, DOI 10.1016/S1474-4422(13)70090-5; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Tabaraud F, 2012, ACTA NEUROL SCAND, V125, P416, DOI 10.1111/j.1600-0404.2011.01592.x; Toledo JB, 2015, BRAIN, V138, P2701, DOI 10.1093/brain/awv199; Tsitsopoulos PP, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00079; Wang KKW, 2016, J NEUROTRAUM, V33, P1270, DOI 10.1089/neu.2015.3881; Welch RD, 2016, J NEUROTRAUM, V33, P203, DOI 10.1089/neu.2015.4149; Wright DW, 2013, MMWR-MORBID MORTAL W, V62, P549; Yang ZH, 2015, SCI REP-UK, V5, DOI 10.1038/srep11178; Yuan Q, 2015, CRIT CARE MED, V43, P1405, DOI 10.1097/CCM.0000000000000965; Yue JK, 2013, J NEUROTRAUM, V30, P1831, DOI 10.1089/neu.2013.2970; Zhong C, 2017, CANCER EPIDEMIOL, V46, P9, DOI 10.1016/j.canep.2016.10.007	47	76	78	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6149	2168-6157		JAMA NEUROL	JAMA Neurol.	SEP	2017	74	9					1063	1072		10.1001/jamaneurol.2017.0655			10	Clinical Neurology	Neurosciences & Neurology	FG5LM	WOS:000410358700011	28738126	Green Published, Bronze, Green Accepted			2021-06-18	
J	Olivier, J; Creighton, P				Olivier, Jake; Creighton, Prudence			Bicycle injuries and helmet use: a systematic review and meta-analysis	INTERNATIONAL JOURNAL OF EPIDEMIOLOGY			English	Article						Cycling; injury; helmet; meta-analysis; systematic review	TRAUMATIC BRAIN-INJURY; PREVENTING HEAD-INJURY; NEW-SOUTH-WALES; SAFETY HELMETS; PUBLICATION BIAS; ALCOHOL-CONSUMPTION; RISK-FACTORS; ROAD TRAUMA; ACCIDENTS; CYCLISTS	Background: The research literature was systematically reviewed and results were summarized from studies assessing bicycle helmet effectiveness to mitigate head, serious head, face, neck and fatal head injury in a crash or fall. Methods: Four electronic databases (MEDLINE, EMBASE, COMPENDEX and SCOPUS) were searched for relevant, peer-reviewed articles in English. Included studies reported medically diagnosed head, face and neck injuries where helmet use was known. Non-approved helmets were excluded where possible. Summary odds ratios (OR) were obtained using multivariate meta-regression models stratified by injury type and severity. Time trends and publication bias were assessed. Results: A total of 43 studies met inclusion criteria and 40 studies were included in the meta-analysis with data from over 64 000 injured cyclists. For cyclists involved in a crash or fall, helmet use was associated with odds reductions for head (OR = 0.49, 95% confidence interval (CI): 0.42-0.57), serious head (OR = 0.31, 95% CI: 0.25-0.37), face (OR = 0.67, 95% CI: 0.56-0.81) and fatal head injury (OR = 0.35, 95% CI: 0.14-0.88). No clear evidence of an association between helmet use and neck injury was found (OR = 0.96, 95% CI: 0.74-1.25). There was no evidence of time trends or publication bias. Conclusions: Bicycle helmet use was associated with reduced odds of head injury, serious head injury, facial injury and fatal head injury. The reduction was greater for serious or fatal head injury. Neck injury was rare and not associated with helmet use. These results support the use of strategies to increase the uptake of bicycle helmets as part of a comprehensive cycling safety plan.	[Olivier, Jake; Creighton, Prudence] Univ New South Wales, Sch Math & Stat, Sydney, NSW, Australia	Olivier, J (corresponding author), Univ New South Wales, Sch Math & Stat, Red Ctr, Sydney, NSW 2052, Australia.	j.olivier@unsw.edu.au	Olivier, Jake/D-2034-2012	Olivier, Jake/0000-0002-3144-4507			Abu-Zidan FM, 2007, EMERG MED AUSTRALAS, V19, P366, DOI 10.1111/j.1742-6723.2007.00967.x; Acton C H, 1995, Inj Prev, V1, P86, DOI 10.1136/ip.1.2.86; Acton CHC, 1996, MED J AUSTRALIA, V165, P249, DOI 10.5694/j.1326-5377.1996.tb124957.x; Adams J, 2001, Inj Prev, V7, P89, DOI 10.1136/ip.7.2.89; Airaksinen N, 2010, ASS 4 ADV AUT MED 54; Amoros E, 2009, CYCLISTES VICTIMES 2, P28; Amoros E, 2012, INJURY PREV, V18, P27, DOI 10.1136/ip.2011.031815; Attewell RG, 2001, ACCIDENT ANAL PREV, V33, P345, DOI 10.1016/S0001-4575(00)00048-8; Bambach MR, 2013, ACCIDENT ANAL PREV, V53, P78, DOI 10.1016/j.aap.2013.01.005; Bambach M.R, 2011, J TRANSP SAF SECUR, V3, DOI [10.1080/19439962.2011.587940, DOI 10.1080/19439962.2011.587940]; BEGG DJ, 1991, NEW ZEAL MED J, V104, P60; Bergenstal John, 2012, W V Med J, V108, P78; Bonander C, 2014, J SAFETY RES, V51, P15, DOI 10.1016/j.jsr.2014.07.001; Borglund S T, 1999, J Emerg Nurs, V25, P496, DOI 10.1016/S0099-1767(99)70013-9; Brand S, 2013, TRAFFIC INJ PREV, V14, P56, DOI 10.1080/15389588.2012.688152; Bressan S, 2015, EMERG MED AUSTRALAS, V27, P1; Brown RL, 2002, J PEDIATR SURG, V37, P375, DOI 10.1053/jpsu.2002.30826; Castle SL, 2012, J SURG RES, V173, P327, DOI 10.1016/j.jss.2010.10.031; COOKE CT, 1993, MED J AUSTRALIA, V159, P783, DOI 10.5694/j.1326-5377.1993.tb141349.x; Cripton PA, 2014, ACCIDENT ANAL PREV, V70, P1, DOI 10.1016/j.aap.2014.02.016; Crocker P, 2012, J EMERG MED, V43, P244, DOI 10.1016/j.jemermed.2011.05.029; Crocker P, 2010, AM J EMERG MED, V28, P68, DOI 10.1016/j.ajem.2008.09.011; CUSHMAN R, 1990, CAN MED ASSOC J, V143, P108; Dagher JH, 2016, CAN J NEUROL SCI, V43, P56, DOI 10.1017/cjn.2015.281; Davidson JA, 2005, EUR J EMERG MED, V12, P24, DOI 10.1097/00063110-200502000-00007; De Silva L, 2014, J NEUROTRAUM, V31, pA34; Dennis J, 2013, BMJ, V346; Dinh MM, 2015, EMERG MED AUSTRALAS, V27, P323, DOI 10.1111/1742-6723.12407; Dinh MM, 2013, MED J AUSTRALIA, V198, P415, DOI 10.5694/mja12.11580; Dinh MM, 2010, MED J AUSTRALIA, V193, P619, DOI 10.5694/j.1326-5377.2010.tb04078.x; DORSCH MM, 1987, ACCIDENT ANAL PREV, V19, P183, DOI 10.1016/0001-4575(87)90002-9; Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x; Eid H. O., 2007, SMJ Singapore Medical Journal, V48, P884; Elvik R, 2011, ACCIDENT ANAL PREV, V43, P1245, DOI 10.1016/j.aap.2011.01.007; Elvik R, 2013, ACCIDENT ANAL PREV, V60, P245, DOI 10.1016/j.aap.2012.12.003; Fahlstedt M, 2016, ACCIDENT ANAL PREV, V91, P135, DOI 10.1016/j.aap.2016.02.025; Finvers KA, 1996, CLIN J SPORT MED, V6, P102, DOI 10.1097/00042752-199604000-00007; FRANK E, 1995, ACAD EMERG MED, V2, P200, DOI 10.1111/j.1553-2712.1995.tb03198.x; Furukawa M, 2013, CLIN J SPORT MED, V23, P138; Grauke L, 2010, EMERG RADIOL, V17, P522; Grimard G, 1995, Inj Prev, V1, P21, DOI 10.1136/ip.1.1.21; Gulack BC, 2015, SURGERY, V158, P556, DOI 10.1016/j.surg.2015.02.025; Hagel BE, 2015, ACCIDENT ANAL PREV, V78, P165, DOI 10.1016/j.aap.2015.03.002; Hansen Kari Schroder, 2003, Traffic Inj Prev, V4, P285, DOI 10.1080/714040486; Harada MY, 2015, INT J SURG, V24, P14, DOI 10.1016/j.ijsu.2015.10.013; Hausotter W., 2000, VERSICHERUNGSMEDIZIN, V52; Heng K. W. J., 2006, SMJ Singapore Medical Journal, V47, P367; Heyer JH, 2015, AM J PUBLIC HEALTH, V105, P2131, DOI 10.2105/AJPH.2015.302738; Hooten KG, 2014, J NEUROTRAUM, V31, P1329, DOI 10.1089/neu.2013.3253; Hooten KG, 2013, J NEUROSURG, V119, pA570; Hwang K, 2015, ARCH PLAST SURG-APS, V42, P407, DOI 10.5999/aps.2015.42.4.407; Jacobson GA, 1998, AUST NZ J PUBL HEAL, V22, P451, DOI 10.1111/j.1467-842X.1998.tb01413.x; Javouhey E, 2006, ACCIDENT ANAL PREV, V38, P225, DOI 10.1016/j.aap.2005.08.001; Joseph B, 2014, EUR J TRAUMA EMERG S, V40, P729, DOI 10.1007/s00068-014-0453-0; Juhra C, 2012, INJURY, V43, P2026, DOI 10.1016/j.injury.2011.10.016; Karkhaneh M, 2013, ACCIDENT ANAL PREV, V59, P206, DOI 10.1016/j.aap.2013.05.027; Kaushik R, 2015, INJURY EPIDEMIOL, V2, P1; KIBURZ D, 1986, AM J SPORT MED, V14, P416, DOI 10.1177/036354658601400516; Kiss K, 2010, ACCIDENT ANAL PREV, V42, P1566, DOI 10.1016/j.aap.2010.03.014; Kleiven S, 2003, J NEUROTRAUM, V20, P365, DOI 10.1089/089771503765172327; LI GH, 1995, J TRAUMA, V38, P871, DOI 10.1097/00005373-199506000-00007; Lima SM, 2012, J ORAL MAXIL SURG, V70, P577, DOI 10.1016/j.joms.2011.03.035; Lindsay H, 2014, CHRON DIS INJ CAN, V34, P74; Linn S, 1998, Inj Prev, V4, P122; Liu HT, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2075-9; MACKELLAR A, 1989, J PEDIATR SURG, V24, P577, DOI 10.1016/S0022-3468(89)80510-X; Macpherson A, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005401.pub3; MAIMARIS C, 1994, BRIT MED J, V308, P1537, DOI 10.1136/bmj.308.6943.1537; Malczyk A, 2014, INT RES COUNC BIOM I; Marshall SW, 2008, EPIDEMIOLOGY, V19, P277, DOI 10.1097/EDE.0b013e3181632700; Matsui Y, 2015, SAE 2015 WORLD C EXH; MCDERMOTT FT, 1993, J TRAUMA, V34, P834, DOI 10.1097/00005373-199306000-00015; McIntosh AS, 2013, J AUSTRALAS COLL ROA, V24, P11; McIntosh AS, 2013, TRAFFIC INJ PREV, V14, P501, DOI 10.1080/15389588.2012.727217; McNally DS, 2013, ACCIDENT ANAL PREV, V60, P15, DOI 10.1016/j.aap.2013.07.011; Messiah A, 2012, AM J PUBLIC HEALTH, V102, pS204, DOI 10.2105/AJPH.2012.300711; Moher D, 2009, PLOS MED, V6, DOI [10.1136/bmj.b2535, 10.1371/journal.pmed.1000097, 10.1016/j.ijsu.2010.02.007]; NAKAYAMA DK, 1990, AM J DIS CHILD, V144, P928, DOI 10.1001/archpedi.1990.02150320092035; Nicaj L, 2009, TRAFFIC INJ PREV, V10, P157, DOI 10.1080/15389580802641761; Olivier J, 2014, J AUSTRALAS COLL ROA, V25, P10; Olofsson E, 2015, SAFETY SCI, DOI [10.1016/j.ssci.2015.11.024, DOI 10.1016/J.SSCI.2015.11.024.]; Orsi C, 2014, ACCIDENT ANAL PREV, V65, P97, DOI 10.1016/j.aap.2013.12.019; Otte D, 2014, SAE INT J TRANSP SAF, V2, P257, DOI 10.4271/2014-01-0517; Otte D, 2010, INT J CRASHWORTHINES, V15, P211, DOI 10.1080/13588260903102484; Persaud N, 2012, CAN MED ASSOC J, V184, pE921, DOI 10.1503/cmaj.120988; Poulos RG, 2015, ACCIDENT ANAL PREV, V78, P29, DOI 10.1016/j.aap.2015.02.009; Powell EC, 1997, ANN EMERG MED, V30, P260, DOI 10.1016/S0196-0644(97)70159-8; Puranik S, 1998, SOUTHERN MED J, V91, P1033, DOI 10.1097/00007611-199811000-00008; Richter M, 2007, J TRAUMA, V62, P1118, DOI 10.1097/01.ta.0000221060.78894.cb; Rivara F P, 1997, Inj Prev, V3, P110, DOI 10.1136/ip.3.2.110; Rivara FP, 1997, J FAM PRACTICE, V44, P481; Rizzi M, 2013, INT RES COUNC BIOM I; ROWE BH, 1995, CAN MED ASSOC J, V152, P45; SELBST SM, 1987, AM J DIS CHILD, V141, P140, DOI 10.1001/archpedi.1987.04460020030021; Sethi M, 2015, INJURY, V46, P2483, DOI 10.1016/j.injury.2015.07.030; Shafi S, 1998, J PEDIATR SURG, V33, P317, DOI 10.1016/S0022-3468(98)90454-7; Simonsohn U, 2014, PERSPECT PSYCHOL SCI, V9, P666, DOI 10.1177/1745691614553988; Skarin D, 2015, EMERG MED AUSTRALAS, V27, P30; SPAITE DW, 1995, J TRAUMA, V38, P287, DOI 10.1097/00005373-199502000-00028; SPAITE DW, 1991, J TRAUMA, V31, P1510, DOI 10.1097/00005373-199111000-00008; Standards Australia, 2008, 2063 ASNZS; Sweeting MJ, 2004, STAT MED, V23, P1351, DOI 10.1002/sim.1761; Sze NN, 2011, HONG KONG J EMERG ME, V18, P136; Terrin N, 2003, STAT MED, V22, P2113, DOI 10.1002/sim.1461; THOMAS S, 1994, BRIT MED J, V308, P173, DOI 10.1136/bmj.308.6922.173; Thompson D C, 2001, Inj Prev, V7, P86, DOI 10.1136/ip.7.2.86; THOMPSON DC, 1990, AM J PUBLIC HEALTH, V80, P1471, DOI 10.2105/AJPH.80.12.1471; Thompson DC, 1996, JAMA-J AM MED ASSOC, V276, P1974, DOI 10.1001/jama.276.24.1974; Thompson DC, 1996, JAMA-J AM MED ASSOC, V276, P1968, DOI 10.1001/jama.276.24.1968; Thompson DC, 2000, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001855; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1361, DOI 10.1056/NEJM198905253202101; Viechtbauer W, 2010, J STAT SOFTW, V36, P1, DOI 10.18637/jss.v036.i03; Wagner J, 2012, AM SURGEON, V78, P1066; Wall SP, 2015, ANN EMERG MED, V1, pS124; Walter SR, 2011, ACCIDENT ANAL PREV, V43, P2064, DOI 10.1016/j.aap.2011.05.029; Wang C, 2015, TRAFFIC INJ PREV, V16, P507, DOI 10.1080/15389588.2014.969802; WASSERMAN RC, 1988, AM J PUBLIC HEALTH, V78, P1220, DOI 10.2105/AJPH.78.9.1220; WASSERMAN RC, 1990, AM J SPORT MED, V18, P96, DOI 10.1177/036354659001800116; Webman R, 2013, J TRAUMA ACUTE CARE, V75, P877, DOI 10.1097/TA.0b013e3182a85f97; Yeung JHH, 2009, INJURY, V40, P555, DOI 10.1016/j.injury.2008.08.015; Yilmaz P, 2013, INJURY, V44, P848, DOI 10.1016/j.injury.2013.03.007; Zibung E, 2015, EUR J TRAUMA EMERG S, V41, P517, DOI 10.1007/s00068-014-0471-y	122	76	77	5	40	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0300-5771	1464-3685		INT J EPIDEMIOL	Int. J. Epidemiol.	FEB	2017	46	1					278	292		10.1093/ije/dyw153			15	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	EW7VB	WOS:000402724100038	27450862	Bronze	Y	N	2021-06-18	
J	Barkhoudarian, G; Hovda, DA; Giza, CC				Barkhoudarian, Garni; Hovda, David A.; Giza, Christopher C.			The Molecular Pathophysiology of Concussive Brain Injury - an Update	PHYSICAL MEDICINE AND REHABILITATION CLINICS OF NORTH AMERICA			English	Article						Concussion; Traumatic brain injury; Pathophysiology; Molecular mechanisms	CHRONIC TRAUMATIC ENCEPHALOPATHY; FLUID PERCUSSION INJURY; LONG-TERM POTENTIATION; CORTICAL IMPACT INJURY; REPETITIVE HEAD-INJURY; TEMPORAL WINDOW; MITOCHONDRIAL DYSFUNCTION; RECURRENT CONCUSSION; COGNITIVE IMPAIRMENT; GLUCOSE-UTILIZATION	Concussion, or mild traumatic brain injury (TBI), affects millions of patients worldwide. Understanding the pathophysiology of TBI can help manage its repercussions. The brain is significantly altered immediately following mild TBI because of metabolic, hemodynamic, structural, and electrophysiologic changes. This process affects cognition and behavior and can leave the brain vulnerable for worse injury in the setting of repeat insult. This article is an update of our previously published review, reporting relevant and current studies from the bench to the bedside of mild TBI. Understanding the pathobiology can help prevent and treat mild TBI.	[Barkhoudarian, Garni] Providence St Johns Hlth Ctr, John Wayne Canc Inst, Pacific Pituitary Disorders Ctr, 2200 Santa Monica Blvd, Santa Monica, CA 90404 USA; [Hovda, David A.] Univ Calif Los Angeles, David Geffen Sch Med, UCLA Brain Injury Res Ctr, Dept Neurosurg,Interdept Program Neurosci,Semel I, Room 18-228A,10833 Le Conte Blvd, Los Angeles, CA 90095 USA; [Hovda, David A.] Univ Calif Los Angeles, David Geffen Sch Med, UCLA Brain Injury Res Ctr,Semel Inst, Interdept Program Neurosci,Dept Med & Mol Pharmac, Room 18-228A,10833 Le Conte Blvd, Los Angeles, CA 90095 USA; [Giza, Christopher C.] Univ Calif Los Angeles, David Geffen Sch Med, UCLA Brain Injury Res Ctr,Semel Inst,Mattel Child, Interdept Programs Neurosci & Biomed Engn,Dept Ne, Room 18-218B,10833 Le Conte Blvd, Los Angeles, CA 90095 USA; [Giza, Christopher C.] Univ Calif Los Angeles, David Geffen Sch Med,Dept Pediat, UCLA Brain Injury Res Ctr,Semel Inst,Mattel Child, Interdept Programs Neurosci & Biomed Engn,Div Ped, Room 18-218B,10833 Le Conte Blvd, Los Angeles, CA 90095 USA	Barkhoudarian, G (corresponding author), Providence St Johns Hlth Ctr, John Wayne Canc Inst, Pacific Pituitary Disorders Ctr, 2200 Santa Monica Blvd, Santa Monica, CA 90404 USA.	barkhoudariang@jwci.org					Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; ANDERSEN BJ, 1992, BRAIN RES, V585, P184, DOI 10.1016/0006-8993(92)91205-S; Appelberg KS, 2009, J NEUROTRAUM, V26, P497, DOI 10.1089/neu.2008.0664; Arun P, 2010, J NEUROTRAUM, V27, P293, DOI 10.1089/neu.2009.0994; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Bartnik-Olson BL, 2014, J NEUROTRAUM, V31, P1497, DOI 10.1089/neu.2013.3213; Bavisetty S, 2008, NEUROSURGERY, V62, P1080, DOI 10.1227/01.neu.0000325870.60129.6a; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bieniek KF, 2015, ACTA NEUROPATHOL, V130, P877, DOI 10.1007/s00401-015-1502-4; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Bouzat P, 2014, INTENS CARE MED, V40, P412, DOI 10.1007/s00134-013-3203-6; Byrnes Kimberly R, 2014, Front Neuroenergetics, V5, P13, DOI 10.3389/fnene.2013.00013; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Cantu RC, 2010, J NEUROTRAUM, V27, P1557, DOI 10.1089/neu.2010.1334; Ceballos R, 1966, Ala J Med Sci, V3, P185; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P202, DOI 10.1097/01.WCB.0000103022.98348.24; CRITCHLEY M, 1957, BMJ-BRIT MED J, V1, P357, DOI 10.1136/bmj.1.5015.357; Cull-Candy S, 2001, CURR OPIN NEUROBIOL, V11, P327, DOI 10.1016/S0959-4388(00)00215-4; Davis LM, 2008, J NEUROSCI RES, V86, P1812, DOI 10.1002/jnr.21628; DeFord SM, 2002, J NEUROTRAUM, V19, P427, DOI 10.1089/08977150252932389; Dennis EL, 2015, J NEUROSCI, V35, P10202, DOI 10.1523/JNEUROSCI.1595-15.2015; DeRoss AL, 2002, J TRAUMA, V52, P708, DOI 10.1097/00005373-200204000-00017; DiFiori JP, 2010, CURR SPORT MED REP, V9, P35, DOI 10.1249/JSR.0b013e3181caba67; Ellis M. U., 2015, J NEUROTRAUMA; Fabricius M, 2008, CLIN NEUROPHYSIOL, V119, P1973, DOI 10.1016/j.clinph.2008.05.025; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Farkas O, 2006, J NEUROSCI, V26, P3130, DOI 10.1523/JNEUROSCI.5119-05.2006; Gardner A, 2014, J NEUROTRAUM, V31, P1, DOI 10.1089/neu.2013.3079; Genis L, 2000, J NEUROSCI RES, V60, P559, DOI 10.1002/(SICI)1097-4547(20000515)60:4<559::AID-JNR15>3.0.CO;2-K; Giza CC, 2001, J ATHL TRAINING, V36, P228; Giza CC, 2006, J NEUROTRAUM, V23, P950, DOI 10.1089/neu.2006.23.950; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Greco T, 2013, J NEUROTRAUM, V30, P1983, DOI 10.1089/neu.2013.2990; Gurkoff GG, 2009, NEUROSCIENCE, V164, P862, DOI 10.1016/j.neuroscience.2009.08.021; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hartings JA, 2009, J NEUROTRAUM, V26, P1857, DOI [10.1089/neu.2009.0961, 10.1089/neu.2009-0961]; Hartman RE, 2002, J NEUROSCI, V22, P10083; Hazrati LN, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00222; Henninger N, 2007, CRIT CARE MED, V35, P2607, DOI 10.1097/01.CCM.0000286395.79654.8D; Herrmann BL, 2006, EXP CLIN ENDOCR DIAB, V114, P316, DOI 10.1055/s-2006-924254; Hillered L, 2005, J NEUROTRAUM, V22, P3, DOI 10.1089/neu.2005.22.3; Hoshino S, 1998, NEUROREPORT, V9, P1879, DOI 10.1097/00001756-199806010-00039; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; Huang MX, 2009, J NEUROTRAUM, V26, P1213, DOI 10.1089/neu.2008.0672; Immonen R, 2010, J CEREBR BLOOD F MET, V30, P1318, DOI 10.1038/jcbfm.2010.15; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; JOHNSON GVW, 1991, NEUROCHEM RES, V16, P869, DOI 10.1007/BF00965535; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Jordan BD, 2000, SEMIN NEUROL, V20, P179, DOI 10.1055/s-2000-9826; Kalimo H, 1981, Acta Neuropathol Suppl, V7, P20; Kanayama G, 1996, METHOD FIND EXP CLIN, V18, P105; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; Kelly DF, 2014, J NEUROTRAUM, V31, P1161, DOI 10.1089/neu.2013.3212; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kelly JP, 1997, NEUROLOGY, V48, P581; Kissick J, 2005, CLIN J SPORT MED, V15, P426, DOI 10.1097/01.jsm.0000186683.59158.8b; KORNBLUM RN, 1969, ARCH PATHOL, V88, P242; KUBOTA M, 1989, Neurosurgical Review, V12, P393, DOI 10.1007/BF01790681; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Leal-Cerro A, 2005, CLIN ENDOCRINOL, V62, P525, DOI 10.1111/j.1365-2265.2005.02250.x; LEAO AAP, 1947, J NEUROPHYSIOL, V10, P409, DOI 10.1152/jn.1947.10.6.409; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Liu LD, 2004, SCIENCE, V304, P1021, DOI 10.1126/science.1096615; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Lovell MR, 2007, NEUROSURGERY, V61, P352, DOI 10.1227/01.NEU.0000279985.94168.7F; Lovell MR, 2007, NEUROSURGERY, V61, P359; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Magistretti PJ, 1999, PHILOS T R SOC B, V354, P1155, DOI 10.1098/rstb.1999.0471; Mannix R, 2013, ANN NEUROL, V74, P65, DOI 10.1002/ana.23858; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; MATA M, 1986, J NEUROBIOL, V17, P449, DOI 10.1002/neu.480170508; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; Maxwell WL, 1995, J NEUROCYTOL, V24, P925, DOI 10.1007/BF01215643; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; Mayer AR, 2012, J NEUROSCI, V32, P17961, DOI 10.1523/JNEUROSCI.3379-12.2012; McAllister TW, 2001, J CLIN EXP NEUROPSYC, V23, P775, DOI 10.1076/jcen.23.6.775.1026; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2012, CURR SPORT MED REP, V11, P21, DOI 10.1249/JSR.0b013e3182423bfd; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meehan WP, 2012, NEUROSURGERY, V71, P885, DOI 10.1227/NEU.0b013e318265a439; Meier TB, 2015, JAMA NEUROL, V72, P530, DOI 10.1001/jamaneurol.2014.4778; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Mori T, 2006, ACTA NEUROCHIR SUPPL, V96, P40; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; NAKAMURA Y, 1990, BIOCHEM BIOPH RES CO, V169, P744, DOI 10.1016/0006-291X(90)90394-3; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; NIXON RA, 1993, BRAIN PATHOL, V3, P29, DOI 10.1111/j.1750-3639.1993.tb00723.x; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Omalu Bennet I, 2010, J Forensic Nurs, V6, P40, DOI 10.1111/j.1939-3938.2009.01064.x; Pardini JE, 2010, NEUROSURGERY, V67, P1020, DOI 10.1227/NEU.0b013e3181ee33e2; Pasco A, 2007, J NEUROTRAUM, V24, P1321, DOI 10.1089/neu.2006.0136; Peskind ER, 2011, NEUROIMAGE, V54, pS76, DOI 10.1016/j.neuroimage.2010.04.008; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; Povlishock JT, 1996, ACT NEUR S, V66, P81; Prins ML, 2010, DEV NEUROSCI-BASEL, V32, P510, DOI 10.1159/000316800; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; Prins ML, 2009, J NEUROTRAUM, V26, P1083, DOI [10.1089/neu.2008.0769, 10.1089/neu.2008-0769]; Prins ML, 2005, J NEUROSCI RES, V82, P413, DOI 10.1002/jnr.20633; Provenzano FA, 2010, NUCL MED COMMUN, V31, P952, DOI 10.1097/MNM.0b013e32833e37c4; Putukian Margot, 2006, Curr Sports Med Rep, V5, P15; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; REEVES TM, 1995, EXP BRAIN RES, V106, P248; Robertson CL, 2007, J NEUROCHEM, V101, P1248, DOI 10.1111/j.1471-4159.2007.04489.x; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; Sanders MJ, 2000, BRAIN RES, V861, P69, DOI 10.1016/S0006-8993(00)01986-7; Schrader Harald, 2009, BMC Med Imaging, V9, P11, DOI 10.1186/1471-2342-9-11; Schurr A, 2007, NEUROSCIENCE, V147, P613, DOI 10.1016/j.neuroscience.2007.05.002; Schurr A, 2012, FRONT PHARMACOL, V2, DOI 10.3389/fphar.2011.00096; Sick TJ, 1998, BRAIN RES, V785, P287, DOI 10.1016/S0006-8993(97)01418-2; Signoretti S, 2010, MOL CELL BIOCHEM, V333, P269, DOI 10.1007/s11010-009-0228-9; Smith C, 2003, NEUROPATH APPL NEURO, V29, P496, DOI 10.1046/j.1365-2990.2003.00488.x; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; SOMJEN GG, 1985, J NEUROPHYSIOL, V53, P1098; Spain A, 2010, J NEUROTRAUM, V27, P1429, DOI 10.1089/neu.2010.1288; STERNBERGER NH, 1983, ANN NY ACAD SCI, V420, P90, DOI 10.1111/j.1749-6632.1983.tb22192.x; Strong AJ, 2002, STROKE, V33, P2738, DOI 10.1161/01.STR.0000043073.69602.09; SUNAMI K, 1989, Neurosurgical Review, V12, P400, DOI 10.1007/BF01790682; Tang YP, 2001, NEUROPHARMACOLOGY, V41, P779, DOI 10.1016/S0028-3908(01)00122-8; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; Tavazzi B, 2007, NEUROSURGERY, V61, P390, DOI 10.1227/01.NEU.0000255525.34956.3F; Tremblay S, 2014, CLIN NEUROPHYSIOL, V125, P1371, DOI 10.1016/j.clinph.2013.11.040; Tsacopoulos M, 1996, J NEUROSCI, V16, P877; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Vagnozzi R, 2005, NEUROSURGERY, V57, P164, DOI 10.1227/01.NEU.0000163413.90259.85; Vagnozzi R, 2007, NEUROSURGERY, V61, P388, DOI DOI 10.1227/01.NEU.0000280002.41696; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; Vespa P, 2006, CRIT CARE MED, V34, P850, DOI 10.1097/01.CCM.0000201875.12245.6F; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Ware JE., 2001, SF 36 PHYS MENTAL HL, V2; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; YOSHINO A, 1992, J CEREBR BLOOD F MET, V12, P996, DOI 10.1038/jcbfm.1992.137; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Zhang L, 2006, AM J NEURORADIOL, V27, P2000	158	76	76	2	49	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1047-9651	1558-1381		PHYS MED REH CLIN N	Phys. Med. Rehabil. Clin. N. Am.	MAY	2016	27	2					373	+		10.1016/j.pmr.2016.01.003			22	Rehabilitation	Rehabilitation	DN4RU	WOS:000377055700003	27154851				2021-06-18	
J	Stern, RA; Tripodis, Y; Baugh, CM; Fritts, NG; Martin, BM; Chaisson, C; Cantu, RC; Joyce, JA; Shah, S; Ikezu, T; Zhang, J; Gercel-Taylor, C; Taylor, DD				Stern, Robert A.; Tripodis, Yorghos; Baugh, Christine M.; Fritts, Nathan G.; Martin, Brett M.; Chaisson, Christine; Cantu, Robert C.; Joyce, James A.; Shah, Sahil; Ikezu, Tsuneya; Zhang, Jing; Gercel-Taylor, Cicek; Taylor, Douglas D.			Preliminary Study of Plasma Exosomal Tau as a Potential Biomarker for Chronic Traumatic Encephalopathy	JOURNAL OF ALZHEIMERS DISEASE			English	Article						Biomarker; chronic traumatic encephalopathy; diagnosis; exosome; football; neurodegeneration; plasma; tau	REPETITIVE BRAIN TRAUMA; RESEARCH DIAGNOSTIC-CRITERIA; COLLEGIATE FOOTBALL PLAYERS; ALZHEIMERS-DISEASE; COGNITIVE IMPAIRMENT; PATHOGENIC PROTEINS; MILITARY PERSONNEL; 1ST EXPOSURE; INJURY; BLOOD	Background: Chronic traumatic encephalopathy (CTE) is a tauopathy associated with prior exposure to repetitive head impacts, such as those incurred through American football and other collision sports. Diagnosis is made through neuropathological examination. Many of the clinical features of CTE are common in the general population, with and without a history of head impact exposure, making clinical diagnosis difficult. As is now common in the diagnosis of other neurodegenerative disorders, such as Alzheimer's disease, there is a need for methods to diagnose CTE during life through objective biomarkers. Objective: The aim of this study was to examine tau-positive exosomes in plasma as a potential CTE biomarker. Methods: Subjects were 78 former National Football League (NFL) players and 16 controls. Extracellular vesicles were isolated from plasma. Fluorescent nanoparticle tracking analysis was used to determine the number of vesicles staining positive for tau. Results: The NFL group had higher exosomal tau than the control group (p < 0.0001). Exosomal tau discriminated between the groups, with 82% sensitivity, 100% specificity, 100% positive predictive value, and 53% negative predictive value. Within the NFL group, higher exosomal tau was associated with worse performance on tests of memory (p = 0.0126) and psychomotor speed (p = 0.0093). Conclusion: These preliminary findings suggest that exosomal tau in plasma may be an accurate, noninvasive CTE biomarker.	[Stern, Robert A.; Tripodis, Yorghos; Baugh, Christine M.; Fritts, Nathan G.; Martin, Brett M.; Chaisson, Christine; Cantu, Robert C.] Boston Univ, Alzheimers Dis & CTE Ctr, Boston, MA 02118 USA; [Stern, Robert A.; Cantu, Robert C.; Ikezu, Tsuneya] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; [Stern, Robert A.; Cantu, Robert C.] Boston Univ, Sch Med, Dept Neurosurg, Boston, MA 02118 USA; [Stern, Robert A.] Boston Univ, Sch Med, Dept Anat & Neurobiol, Boston, MA 02118 USA; [Tripodis, Yorghos; Chaisson, Christine] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02118 USA; [Martin, Brett M.; Chaisson, Christine] Boston Univ, Sch Publ Hlth, Data Coordinating Ctr, Boston, MA 02118 USA; [Cantu, Robert C.] Emerson Hosp, Dept Neurosurg, Concord, MA USA; [Joyce, James A.] Aethlon Med, San Diego, CA USA; [Shah, Sahil; Gercel-Taylor, Cicek; Taylor, Douglas D.] Exosome Sci, San Diego, CA USA; [Ikezu, Tsuneya] Boston Univ, Sch Med, Dept Pharmacol & Expt Therapeut, Boston, MA 02118 USA; [Zhang, Jing] Univ Washington, Dept Pathol, Seattle, WA 98195 USA; [Baugh, Christine M.] Harvard Univ, Interfac Initiat Hlth Policy, Cambridge, MA 02138 USA; [Fritts, Nathan G.] OHSU Collaborat Life Sci Bldg, Portland, OR USA; [Gercel-Taylor, Cicek; Taylor, Douglas D.] Theragnostex Inc, Monmouth Jct, NJ USA	Stern, RA (corresponding author), Boston Univ, Sch Med, Alzheimers Dis & CTE Ctr, Dept Neurol, 71 East Concord St, Boston, MA 02118 USA.; Stern, RA (corresponding author), Boston Univ, Sch Med, Alzheimers Dis & CTE Ctr, Dept Neurosurg, 71 East Concord St, Boston, MA 02118 USA.; Stern, RA (corresponding author), Boston Univ, Sch Med, Alzheimers Dis & CTE Ctr, Dept Anat & Neurobiol, 71 East Concord St, Boston, MA 02118 USA.	bobstern@bu.edu	Baugh, Christine/AAG-2324-2020; , Bob/ABA-8507-2020	Baugh, Christine/0000-0002-9340-6338; Tripodis, Yorghos/0000-0003-2190-7608; Ikezu, Tsuneya/0000-0002-3979-8596	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS 078337, R56 NS 078337, P30 AG13846]; National Institutes of Mental HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [T32MH019733]; JetBlue Airlines; National Football League; NFL Players Association; Exosome Sciences, Inc., a subsidiary of Aethlon Medical, Inc.; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [T32MH019733] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS093334, R56NS078337, R01NS078337] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG019610, P30AG013846] Funding Source: NIH RePORTER	This study was supported by grants from the National Institutes of Health (R01 NS 078337; R56 NS 078337; P30 AG13846). Christine Baugh is currently supported by the National Institutes of Mental Health under award number T32MH019733. Participant travel was funded by gifts from JetBlue Airlines, the National Football League, and the NFL Players Association. All procedures related to exosome isolation and measurement were conducted at, and fully funded by Exosome Sciences, Inc., a subsidiary of Aethlon Medical, Inc.	Apostolova LG, 2015, NEUROLOGY, V84, P729, DOI 10.1212/WNL.0000000000001231; Aryani A, 2016, MOL NEUROBIOL, V53, P818, DOI 10.1007/s12035-014-9054-5; Asai H, 2015, NAT NEUROSCI, V18, P1584, DOI 10.1038/nn.4132; Baayen RH, 2008, J MEM LANG, V59, P390, DOI 10.1016/j.jml.2007.12.005; BARRATT ES, 1965, PSYCHOL REP, V16, P547, DOI 10.2466/pr0.1965.16.2.547; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BECK AT, 1974, J CONSULT CLIN PSYCH, V42, P861, DOI 10.1037/h0037562; Bieniek KF, 2015, ACTA NEUROPATHOL, V130, P877, DOI 10.1007/s00401-015-1502-4; BUSS AH, 1957, J CONSULT PSYCHOL, V21, P343, DOI 10.1037/h0046900; Chien DT, 2014, J ALZHEIMERS DIS, V38, P171, DOI 10.3233/JAD-130098; Crisco JJ, 2011, J BIOMECH, V44, P2673, DOI 10.1016/j.jbiomech.2011.08.003; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; DeKosky ST, 2013, NAT REV NEUROL, V9, P192, DOI 10.1038/nrneurol.2013.36; Dubois B, 2014, LANCET NEUROL, V13, P614, DOI 10.1016/S1474-4422(14)70090-0; Esteves-Villanueva JO, 2015, BIOCHEMISTRY-US, V54, P293, DOI 10.1021/bi501272x; Fiandaca MS, 2015, ALZHEIMERS DEMENT, V11, P600, DOI 10.1016/j.jalz.2014.06.008; Gandy Sam, 2014, F1000Res, V3, P229, DOI 10.12688/f1000research.5372.1; Gardner A, 2014, BRIT J SPORT MED, V48, P84, DOI 10.1136/bjsports-2013-092646; Gardner RC, 2016, J NEUROTRAUM, V33, P157, DOI 10.1089/neu.2014.3805; Goetzl EJ, 2015, NEUROLOGY, V85, P40, DOI 10.1212/WNL.0000000000001702; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Grant DA., 1981, WISCONSIN CARD SORTI; Gu YJ, 1996, J NEUROCHEM, V67, P1235; Guo JL, 2014, NAT MED, V20, P130, DOI 10.1038/nm.3457; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Hampshire A, 2013, SCI REP-UK, V3, DOI 10.1038/srep02972; Hart J, 2013, JAMA NEUROL, V70, P326, DOI 10.1001/2013.jamaneurol.340; Iverson GL, 2015, NEUROSCI BIOBEHAV R, V56, P276, DOI 10.1016/j.neubiorev.2015.05.008; Jordan BD, 2013, NAT REV NEUROL, V9, P222, DOI 10.1038/nrneurol.2013.33; Kang JH, 2015, ALZHEIMERS DEMENT, V11, P772, DOI 10.1016/j.jalz.2015.05.003; Kang JH, 2013, CLIN CHEM, V59, P903, DOI 10.1373/clinchem.2013.202937; Kiernan PT, 2015, SEMIN NEUROL, V35, P20, DOI 10.1055/s-0035-1545080; Klein C, 2002, J NEUROSCI, V22, P698, DOI 10.1523/JNEUROSCI.22-03-00698.2002; Koerte IK, 2016, J NEUROTRAUM, V33, P346, DOI 10.1089/neu.2015.3880; Koerte IK, 2015, BRAIN PATHOL, V25, P318, DOI 10.1111/bpa.12249; Kondo A, 2015, NATURE, V523, P431, DOI 10.1038/nature14658; LaValley MP, 2008, CIRCULATION, V117, P2395, DOI 10.1161/CIRCULATIONAHA.106.682658; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Lin AP, 2015, ALZHEIMERS RES THER, V7, DOI 10.1186/s13195-015-0094-5; LUBKE U, 1994, AM J PATHOL, V145, P175; Molinuevo JL, 2014, ALZHEIMERS DEMENT, V10, P808, DOI 10.1016/j.jalz.2014.03.003; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2015, BRAIN PATHOL, V25, P350, DOI 10.1111/bpa.12248; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McKhann GM, 2011, ALZHEIMERS DEMENT, V7, P263, DOI 10.1016/j.jalz.2011.03.005; Menendez-Gonzalez M, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00065; Montenigro PH, 2015, ANNU REV CLIN PSYCHO, V11, P309, DOI 10.1146/annurev-clinpsy-032814-112814; Montenigro PH, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/s13195-014-0068-z; Ng TSC, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt239; O'Bryant SE, 2015, ALZHEIMERS DEMENT, V11, P549, DOI 10.1016/j.jalz.2014.08.099; Olazaran J, 2015, J ALZHEIMERS DIS, V45, P1157, DOI 10.3233/JAD-142925; Olivera A, 2015, JAMA NEUROL, V72, P1109, DOI 10.1001/jamaneurol.2015.1383; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Peskind ER, 2015, JAMA NEUROL, V72, P1103, DOI 10.1001/jamaneurol.2015.1789; Properzi F, 2013, BIOMARK MED, V7, P769, DOI 10.2217/bmm.13.63; Reitan R. M., 1992, TRAIL MAKING TEST MA; Ren Y, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00102; Roth R., 2005, BRIEF A BEHAV RATING; Schey KL, 2015, METHODS, V87, P75, DOI 10.1016/j.ymeth.2015.03.018; Schneider P, 2009, CNS NEUROSCI THER, V15, P358, DOI 10.1111/j.1755-5949.2009.00104.x; Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Stamm JM, 2015, J NEUROTRAUM, V32, P1768, DOI 10.1089/neu.2014.3822; Stamm JM, 2015, NEUROLOGY, V84, P1114, DOI 10.1212/WNL.0000000000001358; Stein TD, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt234; STERN RA, 1999, BOSTON QUALITATIVE S; Stern RA, 2003, NEUROPSYCHOLOGICAL A; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Strain JF, 2015, JAMA NEUROL, V72, P773, DOI 10.1001/jamaneurol.2015.0206; Tashiro K, 1997, NEUROREPORT, V8, P2797, DOI 10.1097/00001756-199708180-00029; TAYLOR DD, 1979, ANAL BIOCHEM, V98, P53, DOI 10.1016/0003-2697(79)90704-8; Taylor DD, 2015, METHODS, V87, P1, DOI 10.1016/j.ymeth.2015.08.006; Taylor DD, 2015, METHODS, V87, P3, DOI 10.1016/j.ymeth.2015.02.019; Taylor DD, 2011, SEMIN IMMUNOPATHOL, V33, P441, DOI 10.1007/s00281-010-0234-8; TRAMS EG, 1981, BIOCHIM BIOPHYS ACTA, V645, P63, DOI 10.1016/0005-2736(81)90512-5; TROJANOWSKI JQ, 1989, J HISTOCHEM CYTOCHEM, V37, P209, DOI 10.1177/37.2.2492045; Turner RC, 2013, FRONT NEUROL, V3, DOI 10.3389/fneur.2012.00186; Villemagne VL, 2015, LANCET NEUROL, V14, P114, DOI 10.1016/S1474-4422(14)70252-2; Villemagne VL, 2014, ALZHEIMERS DEMENT, V10, pS254, DOI 10.1016/j.jalz.2014.04.013; Voyle N, 2015, J ALZHEIMERS DIS, V46, P947, DOI 10.3233/JAD-150020; Wang G, 2014, J PROTEOME RES, V13, P2649, DOI 10.1021/pr5000895; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Weiner Michael W, 2015, Alzheimers Dement, V11, pe1, DOI 10.1016/j.jalz.2014.11.001; Zetterberg H, 2013, ALZHEIMERS RES THER, V5, DOI 10.1186/alzrt163	85	76	78	2	33	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1387-2877	1875-8908		J ALZHEIMERS DIS	J. Alzheimers Dis.		2016	51	4					1099	1109		10.3233/JAD-151028			11	Neurosciences	Neurosciences & Neurology	DJ5ID	WOS:000374239300015	26890775	Green Accepted, Green Published, Bronze			2021-06-18	
J	Baratz, R; Tweedie, D; Wang, JY; Rubovitch, V; Luo, WM; Hoffer, BJ; Greig, NH; Pick, CG				Baratz, Renana; Tweedie, David; Wang, Jia-Yi; Rubovitch, Vardit; Luo, Weiming; Hoffer, Barry J.; Greig, Nigel H.; Pick, Chaim G.			Transiently lowering tumor necrosis factor-alpha synthesis ameliorates neuronal cell loss and cognitive impairments induced by minimal traumatic brain injury in mice	JOURNAL OF NEUROINFLAMMATION			English	Article							CLOSED-HEAD INJURY; CONTROLLED CORTICAL IMPACT; TNF-ALPHA; SIGNAL-TRANSDUCTION; SYNTHESIS INHIBITOR; DENTATE GYRUS; HIPPOCAMPAL NEUROGENESIS; SYNAPTIC PLASTICITY; FACTOR RECEPTORS; GENE-EXPRESSION	Background: The treatment of traumatic brain injury (TBI) represents an unmet medical need, as no effective pharmacological treatment currently exists. The development of such a treatment requires a fundamental understanding of the pathophysiological mechanisms that underpin the sequelae resulting from TBI, particularly the ensuing neuronal cell death and cognitive impairments. Tumor necrosis factor-alpha (TNF-alpha) is a cytokine that is a master regulator of systemic and neuroinflammatory processes. TNF-alpha levels are reported to become rapidly elevated post TBI and, potentially, can lead to secondary neuronal damage. Methods: To elucidate the role of TNF-alpha in TBI, particularly as a drug target, the present study evaluated (i) time-dependent TNF-alpha levels and (ii) markers of apoptosis and gliosis within the brain and related these to behavioral measures of 'well being' and cognition in a mouse closed head 50 g weight drop mild TBI (mTBI) model in the presence and absence of post-treatment with an experimental TNF-alpha synthesis inhibitor, 3,6'-dithiothalidomide. Results: mTBI elevated brain TNF-alpha levels, which peaked at 12 h post injury and returned to baseline by 18 h. This was accompanied by a neuronal loss and an increase in astrocyte number (evaluated by neuronal nuclei (NeuN) and glial fibrillary acidic protein (GFAP) immunostaining), as well as an elevation in the apoptotic death marker BH3-interacting domain death agonist (BID) at 72 h. Selective impairments in measures of cognition, evaluated by novel object recognition and passive avoidance paradigms - without changes in well being, were evident at 7 days after injury. A single systemic treatment with the TNF-alpha synthesis inhibitor 3,6'-dithiothalidomide 1 h post injury prevented the mTBI-induced TNF-alpha elevation and fully ameliorated the neuronal loss (NeuN), elevations in astrocyte number (GFAP) and BID, and cognitive impairments. Cognitive impairments evident at 7 days after injury were prevented by treatment as late as 12 h post mTBI but were not reversed when treatment was delayed until 18 h. Conclusions: These results implicate that TNF-alpha in mTBI induced secondary brain damage and indicate that pharmacologically limiting the generation of TNF-alpha post mTBI may mitigate such damage, defining a time-dependent window of up to 12 h to achieve this reversal.	[Baratz, Renana; Rubovitch, Vardit; Pick, Chaim G.] Tel Aviv Univ, Sackler Sch Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel; [Tweedie, David; Luo, Weiming; Greig, Nigel H.] NIA, Drug Design & Dev Sect, Translat Gerontol Branch, Intramural Res Program,NIH, Baltimore, MD 21224 USA; [Wang, Jia-Yi] Taipei Med Univ, Coll Med, Grad Inst Med Sci, Taipei, Taiwan; [Hoffer, Barry J.] Case Western Reserve Univ, Sch Med, Dept Neurosurg, Cleveland, OH USA	Greig, NH (corresponding author), NIA, Drug Design & Dev Sect, Translat Gerontol Branch, Intramural Res Program,NIH, BRC Room 05C220,251 Bayview Blvd, Baltimore, MD 21224 USA.	greign@grc.nia.nih.gov		Wang, Jia-Yi/0000-0002-9106-3351	Intramural Research Program, National Institute on Aging, NIH, Baltimore, USA; Tel-Aviv University, Tel-Aviv, Israel; Ministry of Science and Technology, TaiwanMinistry of Science and Technology, Taiwan [MOST103-2321-B-038-002]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [ZIAAG000994, ZIAAG000311] Funding Source: NIH RePORTER	This study was supported in part by the Intramural Research Program, National Institute on Aging, NIH, Baltimore, USA; by Tel-Aviv University, Tel-Aviv, Israel; and by a grant from the Ministry of Science and Technology, Taiwan (MOST103-2321-B-038-002 to JY Wang). None of the authors have any competing interests in the manuscript.	Ali MS, 2013, J CEREBR BLOOD F MET, V33, P1564, DOI 10.1038/jcbfm.2013.109; Amaral DG, 2007, PROG BRAIN RES, V163, P3, DOI 10.1016/S0079-6123(07)63001-5; Baratz R, 2011, J NEUROCHEM, V118, P1032, DOI 10.1111/j.1471-4159.2011.07377.x; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Barnes DE, 2014, NEUROLOGY, V83, P312, DOI 10.1212/WNL.0000000000000616; Becker RE, 2014, NAT REV DRUG DISCOV, V13, P157, DOI 10.1038/nrd3842-c2; Belarbi K, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-23; Bermpohl D, 2007, J CEREBR BLOOD F MET, V27, P1806, DOI 10.1038/sj.jcbfm.9600487; Bussey TJ, 2008, LEARN MEMORY, V15, P516, DOI 10.1101/lm.987808; CDER U, 2005, GUID IND EST MAX SAF; Chio CC, 2010, J NEUROCHEM, V115, P921, DOI 10.1111/j.1471-4159.2010.06969.x; Clark IA, 2010, PHARMACOL THERAPEUT, V128, P519, DOI 10.1016/j.pharmthera.2010.08.007; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; DELLU F, 1992, BRAIN RES, V588, P132, DOI 10.1016/0006-8993(92)91352-F; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P135, DOI 10.1089/neu.2013.3019; Dix SL, 1999, BEHAV BRAIN RES, V99, P191, DOI 10.1016/S0166-4328(98)00079-5; Edut S, 2011, PSYCHOPHARMACOLOGY, V214, P877, DOI 10.1007/s00213-010-2098-y; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Finnie JW, 2013, J CLIN NEUROSCI, V20, P1759, DOI 10.1016/j.jocn.2013.03.010; Finnie JW, 2002, VET PATHOL, V39, P679, DOI 10.1354/vp.39-6-679; Fontaine V, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-07-j0001.2002; Frankola KA, 2011, CNS NEUROL DISORD-DR, V10, P391; Frugier T, 2010, J NEUROTRAUM, V27, P497, DOI 10.1089/neu.2009.1120; Gabbita SP, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-99; Gardner RC, 2014, JAMA NEUROL; Genovese T, 2008, SHOCK, V30, P231, DOI 10.1097/shk.0b013e318162d290; Ghajar J, 2008, NEUROREHAB NEURAL RE, V22, P217, DOI 10.1177/1545968308315600; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Gourin CG, 1997, J TRAUMA, V42, P1101, DOI 10.1097/00005373-199706000-00020; Greig NH, 2014, ALZHEIMERS DEMENT, V10, pS62, DOI 10.1016/j.jalz.2013.12.011; Grell M, 1998, P NATL ACAD SCI USA, V95, P570, DOI 10.1073/pnas.95.2.570; GRELL M, 1995, CELL, V83, P793, DOI 10.1016/0092-8674(95)90192-2; Grell M, 1996, J INFLAMM, V47, P8; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Han XD, 2011, J NEUROTRAUM, V28, P995, DOI 10.1089/neu.2010.1563; Hogg S, 1996, PHARMACOL BIOCHEM BE, V54, P21, DOI 10.1016/0091-3057(95)02126-4; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Ignatowski TA, 2014, CNS DRUGS, V28, P679, DOI 10.1007/s40263-014-0174-2; Israelsson C, 2008, J NEUROTRAUM, V25, P959, DOI 10.1089/neu.2008.0562; Israelsson C, 2009, J NEUROTRAUM, V26, P1307, DOI [10.1089/neu.2008.0676, 10.1089/neu.2008-0676]; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Koopmans GC, 2009, EXP NEUROL, V216, P490, DOI 10.1016/j.expneurol.2009.01.005; Kumar A, 2013, NEUROBIOL AGING, V34, P1397, DOI 10.1016/j.neurobiolaging.2012.11.013; Lee CJ, 2007, SPINAL CORD, V45, P149, DOI 10.1038/sj.sc.3101931; Li JX, 2013, ADV IMMUNOL, V119, P135, DOI 10.1016/B978-0-12-407707-2.00005-9; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Longhi L, 2008, ACTA NEUROCHIR SUPPL, V102, P409, DOI 10.1007/978-3-211-85578-2_80; Longhi L, 2013, J CEREBR BLOOD F MET, V33, P1182, DOI 10.1038/jcbfm.2013.65; Lu J, 2009, FRONT BIOSCI-LANDMRK, V14, P3795, DOI 10.2735/3489; Mahony C, 2013, P NATL ACAD SCI USA, V110, P12703, DOI 10.1073/pnas.1307684110; Marchetti L, 2004, J BIOL CHEM, V279, P32869, DOI 10.1074/jbc.M311766200; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; Mccoy MK, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-45; McGarry LJ, 2002, J TRAUMA, V53, P1152, DOI 10.1097/00005373-200212000-00020; Messier C, 1997, NEUROBIOL LEARN MEM, V67, P172, DOI 10.1006/nlme.1996.3755; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Moppett IK, 2007, BRIT J ANAESTH, V99, P18, DOI 10.1093/bja/aem128; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Morris GP, 2013, NEUROBIOL LEARN MEM, V105, P40, DOI 10.1016/j.nlm.2013.07.002; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Park KM, 2010, CELL SIGNAL, V22, P977, DOI 10.1016/j.cellsig.2010.01.010; Peredeny JV, 2013, FRONT NEURAL CIRCUIT, V7, DOI 10.3389/fncir.2013.00017; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; Russo I, 2012, J NEUROCHEM, V122, P1181, DOI 10.1111/j.1471-4159.2012.07846.x; Ryu WHA, 2009, CAN J NEUROL SCI, V36, P429, DOI 10.1017/S0317167100007745; Saab BJ, 2009, NEURON, V63, P643, DOI 10.1016/j.neuron.2009.08.014; Santello M, 2012, TRENDS NEUROSCI, V35, P638, DOI 10.1016/j.tins.2012.06.001; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Schreiber S, 2008, SLEEP MED, V9, P481, DOI 10.1016/j.sleep.2007.04.014; Setnik L, 2007, BRAIN INJURY, V21, P1, DOI 10.1080/02699050601111419; Sharp DJ, 2014, NAT REV NEUROL, V10, P156, DOI 10.1038/nrneurol.2014.15; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Starke RM, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-77; Stoica BA, 2009, NEUROTOX RES, V16, P221, DOI 10.1007/s12640-009-9050-0; Stoll G, 2002, ADV EXP MED BIOL, V513, P87; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Tashlykov V, 2009, J MOL NEUROSCI, V37, P16, DOI 10.1007/s12031-008-9094-2; Tashlykov V, 2007, BRAIN RES, V1130, P197, DOI 10.1016/j.brainres.2006.10.032; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Tobinick E, 2012, CNS DRUGS, V26, P1051, DOI 10.1007/s40263-012-0013-2; Tuttolomondo A, 2014, DRUG DES DEV THER, V8, P2221, DOI 10.2147/DDDT.S67655; Tuttolomondo A, 2008, CURR PHARM DESIGN, V14, P3574, DOI 10.2174/138161208786848739; Tweedie D, 2007, CURR ALZHEIMER RES, V4, P378, DOI 10.2174/156720507781788873; Tweedie D, 2007, J NEUROSCI RES, V85, P805, DOI 10.1002/jnr.21160; Tweedie D, 2013, NEUROBIOL DIS, V54, P1, DOI 10.1016/j.nbd.2013.02.006; Tweedie D, 2013, EXP NEUROL, V239, P170, DOI 10.1016/j.expneurol.2012.10.001; Tweedie D, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-106; Vargesson N, 2013, P NATL ACAD SCI USA, V110, pE4820, DOI 10.1073/pnas.1318475110; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; Wakade C, 2010, J NEUROSURG, V113, P1195, DOI 10.3171/2010.3.JNS091212; Wallister TW, 2008, WORLD PSYCHIATRY, V7, P3; Yang JS, 2010, J NEUROTRAUM, V27, P1037, DOI 10.1089/neu.2009.1229; Yang LB, 2002, J NEUROSCI, V22, P3025, DOI 10.1523/JNEUROSCI.22-08-03025.2002; Yoon JS, 2013, J NEUROSCI RES, V91, P671, DOI 10.1002/jnr.23190; Yu SJ, 2009, BRAIN RES, V1287, P157, DOI 10.1016/j.brainres.2009.06.067; Zhu XX, 2003, J MED CHEM, V46, P5222, DOI 10.1021/jm030152f; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	102	76	78	0	7	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1742-2094		J NEUROINFLAMM	J. Neuroinflamm.	MAR 7	2015	12								45	10.1186/s12974-015-0237-4			14	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	CD3FQ	WOS:000350963800001	25879458	DOAJ Gold, Green Published			2021-06-18	
J	Vavilala, MS; Kernic, MA; Wang, J; Kannan, N; Mink, RB; Wainwright, MS; Groner, JI; Bell, MJ; Giza, CC; Zatzick, DF; Ellenbogen, RG; Boyle, LN; Mitchell, PH; Rivara, FP				Vavilala, Monica S.; Kernic, Mary A.; Wang, Jin; Kannan, Nithya; Mink, Richard B.; Wainwright, Mark S.; Groner, Jonathan I.; Bell, Michael J.; Giza, Christopher C.; Zatzick, Douglas F.; Ellenbogen, Richard G.; Boyle, Linda Ng; Mitchell, Pamela H.; Rivara, Frederick P.		Pediat Guideline Adherence	Acute Care Clinical Indicators Associated With Discharge Outcomes in Children With Severe Traumatic Brain Injury	CRITICAL CARE MEDICINE			English	Article						brain injury; indicators; injury; outcomes; pediatrics; trauma	HEAD-INJURY; HYPOTENSION; HYPOXIA; MORTALITY; MODERATE; CENTERS; TRIALS	Objective: The effect of the 2003 severe pediatric traumatic brain injury (TBI) guidelines on outcomes has not been examined. We aimed to develop a set of acute care guideline-influenced clinical indicators of adherence and tested the relationship between these indicators during the first 72 hours after hospital admission and discharge outcomes. Design: Retrospective multicenter cohort study. Setting: Five regional pediatric trauma centers affiliated with academic medical centers. Patients: Children under 18 years with severe traumatic brain injury (admission Glasgow Coma Scale score <= 8, International Classification of Diseases, 9th Edition, diagnosis codes of 800.0-801.9, 803.0-804.9, 850.0-854.1, 959.01, 950.1-950.3, 995.55, maximum head abbreviated Injury Severity Score >= 3) who received tracheal intubation for at least 48 hours in the ICU between 2007 and 2011 were examined. Interventions: None. Measurements and Main Results: Total percent adherence to the clinical indicators across all treatment locations (prehospital, emergency department, operating room, and ICU) during the first 72 hours after admission to study center were determined. Main outcomes were discharge survival and Glasgow Outcome Scale score. Total adherence rate across all locations and all centers ranged from 68% to 78%. Clinical indicators of adherence were associated with survival (adjusted hazard ratios, 0.94; 95% CI, 0.91-0.96). Three indicators were associated with survival: absence of prehospital hypoxia (adjusted hazard ratios, 0.20; 95% CI, 0.08-0.46), early ICU start of nutrition (adjusted hazard ratios, 0.06; 95% CI, 0.01-0.26), and ICU Paco(2) more than 30 mm Hg in the absence of radiographic or clinical signs of cerebral herniation (adjusted hazard ratios, 0.22; 95% CI, 0.06-0.8). Clinical indicators of adherence were associated with favorable Glasgow Outcome Scale among survivors (adjusted hazard ratios, 0.99; 95% CI, 0.98-0.99). Three indicators were associated with favorable discharge Glasgow Outcome Scale: all operating room cerebral perfusion pressure more than 40 mm Hg (adjusted relative risk, 0.61; 95% CI, 0.58-0.64), all ICU cerebral perfusion pressure more than 40 mm Hg (adjusted relative risk, 0.73; 95% CI, 0.63-0.84), and no surgery (any type; adjusted relative risk, 0.68; 95% CI, 0.53-0.86). Conclusions: Acute care clinical indicators of adherence to the Pediatric Guidelines were associated with significantly higher discharge survival and improved discharge Glasgow Outcome Scale. Some indicators were protective, regardless of treatment location, suggesting the need for an interdisciplinary approach to the care of children with severe traumatic brain injury.	[Vavilala, Monica S.; Kannan, Nithya] Univ Washington, Dept Anesthesiol, Seattle, WA 98195 USA; [Vavilala, Monica S.; Kannan, Nithya] Univ Washington, Dept Pain Med, Seattle, WA 98195 USA; [Vavilala, Monica S.; Wang, Jin; Rivara, Frederick P.] Univ Washington, Dept Pediat, Seattle, WA 98195 USA; [Vavilala, Monica S.; Ellenbogen, Richard G.] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Vavilala, Monica S.; Ellenbogen, Richard G.] Univ Washington, Dept Global Hlth Med, Seattle, WA 98195 USA; [Kernic, Mary A.; Rivara, Frederick P.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; [Mink, Richard B.] Harbor UCLA, Dept Pediat, Torrance, CA USA; [Mink, Richard B.] Los Angeles BioMed Res Inst, Torrance, CA USA; [Wainwright, Mark S.] Ann & Robert H Lurie Childrens Hosp Chicago, Dept Pediat, Chicago, IL USA; [Groner, Jonathan I.] Ohio State Univ, Coll Med, Dept Surg, Columbus, OH 43210 USA; [Bell, Michael J.] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA USA; [Giza, Christopher C.] Univ Calif Los Angeles, Mattel Childrens Hosp, Dept Neurosurg, Los Angeles, CA USA; [Giza, Christopher C.] Univ Calif Los Angeles, Mattel Childrens Hosp, Div Pediat Neurol, Los Angeles, CA USA; [Zatzick, Douglas F.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA; [Boyle, Linda Ng] Univ Washington, Dept Ind & Syst Engn, Seattle, WA 98195 USA; [Mitchell, Pamela H.] Univ Washington, Sch Nursing, Seattle, WA 98195 USA; Univ Washington, Harborview Med Ctr, Lead & Data Coordinating Ctr, Seattle, WA 98104 USA; Childrens Hosp Pittsburgh, Pittsburgh, PA 15213 USA; Ann & Robert H Lurie Childrens Hosp Chicago, Chicago, IL USA; Harbor UCLA Med Ctr, Torrance, CA 90509 USA; Nationwide Childrens Hosp, Columbus, OH USA	Vavilala, MS (corresponding author), Univ Washington, Dept Anesthesiol, Seattle, WA 98195 USA.	vavilala@u.washington.edu			National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; National Institutes of Neurological Diseases and Stroke (NINDS) [R01 NS072308-03]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); National Institute of Alcohol Abuse and Alcoholism (NIAAA)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); National Institute of Justice (NIJ); Joseph Drown Foundation; NCAA; Paul Allen Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS072308] Funding Source: NIH RePORTER	Dr. Vavilala received support for article research from the National Institutes of Health (NIH). She received support for this work including design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript from the National Institutes of Neurological Diseases and Stroke (NINDS) (R01 NS072308-03). Her institution received grant support from the NIH. Dr. Kernic is employed by the University of Washington (receives salary support for work on grants as principal investigator or co-investigator) and received support for article research from the NIH. Her institution received grant support from the NINDS, the National Institute of Alcohol Abuse and Alcoholism (NIAAA), and National Institute of Justice (NIJ) (Dr. Kernic is principal investigator on two federal grants-NIAAA and NIJ-in an area unrelated to the NINDS grant that supported the work to produce this manuscript). Dr. Kannan received support for article research from the NIH. Her institution received grant support from the NIH. Dr. Mink received support for travel from American Academy of Pediatrics Section on Critical Care and received support for article research from the NIH. He and his institution received grant support from the NIH. Dr. Wainwright received support for article research from the NIH. His institution received grant support from the NINDS. Dr. Groner received support for article research from the NIH. His institution received grant support from the NIH (grant title: Implementation Science to Increase Use of Evidence Based Pediatric Brain Injury Guidelines [PEGASUS Study]-multicenter study). Dr. Bell received support for article research from the NIH. His institution received grant support from the NINDS. Dr. Giza consulted for the California State Athletic Commission (received support for attending and traveling to California State Athletic Commission meetings); provides expert testimony for medicolegal cases; lectured for the Medical Education Speakers Network and various institutions; received royalties from Blackwell Publishing (book: Neurological Differential Diagnosis); received support for travel from National Collegiate Athletic Association (NCAA), Major League Soccer, National Football League, and the Ontario Neurotrauma Foundation (serves on advisory board or as consulted and receives support for travel); and received support for article research from the NIH. His institution received grant support from the NIH, Joseph Drown Foundation, and NCAA (research grants). Dr. Ellenbogen is employed by the University of Washington, received grant support from the Paul Allen Foundation, and received royalties from Elsevier. Dr. Boyle received support for article research from the NIH. Her institution received grant support from the NIH. Dr. Mitchell received support for article research from the NIH. Her institution received grant support from the NIH. Dr. Rivara received support for article research from NIH. Her institution received grant support from NIH. The remaining authors have disclosed that they do not have any potential conflicts of interest.	Adelson P David, 2003, Pediatr Crit Care Med, V4, pS72; Altman D, 1991, PRACTICAL STAT MED R; Buck CJ, 2010, INT CLASSIFICATION D; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Chi JH, 2006, J TRAUMA, V61, P1134, DOI 10.1097/01.ta.0000196644.64653.d8; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; Doig GS, 2013, JAMA-J AM MED ASSOC, V309, P2130, DOI 10.1001/jama.2013.5124; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fleiss Joseph L., 2003, STAT METHODS RATES P; Franschman G, 2009, RESUSCITATION, V80, P1147, DOI 10.1016/j.resuscitation.2009.06.029; Hesdorffer DC, 2007, J TRAUMA, V63, P841, DOI 10.1097/TA.0b013e318123fc21; JENNETT B, 1976, LANCET, V1, P1031; Kernic MA, 2013, J NEUROTRAUM, V30, P1129, DOI 10.1089/neu.2012.2716; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; Kokoska ER, 1998, J PEDIATR SURG, V33, P333, DOI 10.1016/S0022-3468(98)90457-2; Kouznetsov E, 2012, PEDIATR NEUROSURG, V48, P1, DOI 10.1159/000340068; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; McNutt LA, 2003, AM J EPIDEMIOL, V157, P940, DOI 10.1093/aje/kwg074; National Institutes of Health ( NIH), NINDS COMM DAT EL WE; Peppercorn JM, 2004, LANCET, V363, P263, DOI 10.1016/S0140-6736(03)15383-4; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; Pollack MM, 2013, PEDIATR CRIT CARE ME, V14, P1; Pronovost PJ, 2004, J CRIT CARE, V19, P158, DOI 10.1016/j.jcrc.2004.07.003; Rivara FP, 2011, PEDIATRICS, V128, pE1129, DOI 10.1542/peds.2011-0840; Rogers E. M., 2010, DIFFUSION INNOVATION; Rusnak M, 2007, WIEN KLIN WOCHENSCHR, V119, P64, DOI 10.1007/s00508-006-0765-0; Samant UB, 2008, J NEUROTRAUM, V25, P495, DOI 10.1089/neu.2007.0491; Sills MR, 2005, ARCH PEDIAT ADOL MED, V159, P665, DOI 10.1001/archpedi.159.7.665; *STATACORP LP, 2009, STAT STAT SOFTW COMP; Zebrack M, 2009, PEDIATRICS, V124, P56, DOI 10.1542/peds.2008-1006; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	31	76	76	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	OCT	2014	42	10					2258	2266		10.1097/CCM.0000000000000507			9	Critical Care Medicine	General & Internal Medicine	AP7BC	WOS:000342231500014	25083982	Green Accepted			2021-06-18	
J	Rivara, FP; Schiff, MA; Chrisman, SP; Chung, SK; Ellenbogen, RG; Herring, SA				Rivara, Frederick P.; Schiff, Melissa A.; Chrisman, Sara P.; Chung, Shana K.; Ellenbogen, Richard G.; Herring, Stanley A.			The Effect of Coach Education on Reporting of Concussions Among High School Athletes After Passage of a Concussion Law	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						sports concussion; injury incidence; soccer; concussive symptoms	TRAUMATIC BRAIN-INJURY; SPORT-RELATED CONCUSSION; INTERNATIONAL-CONFERENCE; CONSENSUS STATEMENT; FOOTBALL PLAYERS; UNITED-STATES; EPIDEMIOLOGY; COLLEGIATE; ZURICH	Background: Increasing attention has been paid to concussions and especially sports-related concussions in youth. To prevent an inappropriate return to play while symptomatic, nearly all states have now passed legislation on youth sports-related concussions. Purpose: To determine (1) the incidence of sports-related concussions in high school athletes using a unique system to collect reports on concussions, (2) the proportion of athletes with concussions who play with concussive symptoms, and (3) the effect of the type and modality of coach education on the likelihood of athletes reporting symptoms to the coach or playing with concussive symptoms. Study Design: Cohort study; Level of evidence, 2. Methods: This study was conducted with high school football and girls' soccer athletes playing in fall 2012 and their coaches and parents in 20 urban or rural high schools in Washington State. The main outcome was the incidence of concussions per 1000 athlete-exposures (AEs), the proportion of concussed athletes who played with concussive symptoms, and the association of coach concussion education with coach awareness of athletes with concussive symptoms. Results: Among the 778 athletes, the rate of concussions was 3.6 per 1000 AEs and was identical for the 2 sports studied. The cumulative concussion incidence over the course of the season was similar in girls' soccer (11.1%) and football (10.4%). Sixty-nine percent of concussed athletes reported playing with symptoms, and 40% reported that their coach was not aware of their concussion. Most measures of coach concussion education were not associated with coach awareness of concussions in their athletes, although the modalities of a video and quiz were associated with a lower likelihood of coach awareness. Conclusion: More objective and accurate methods are needed to identify concussions. Changes in athlete attitudes on reporting concussive symptoms will likely not be accomplished through legislation alone.	[Rivara, Frederick P.; Schiff, Melissa A.; Chrisman, Sara P.; Chung, Shana K.; Ellenbogen, Richard G.; Herring, Stanley A.] Univ Washington, Seattle, WA 98104 USA	Rivara, FP (corresponding author), Univ Washington, Harborview Med Ctr, Harborview Injury Prevent & Res Ctr, 325 Ninth Ave,Box 359960, Seattle, WA 98104 USA.	fpr@uw.edu	Meijer, Anna/K-5118-2016	Chrisman, Sara/0000-0001-5373-7223	Public Health Law Research Program of the Robert Wood Johnson Foundation	One or more of the authors has declared the following potential conflict of interest or source of funding: The study was supported by the Public Health Law Research Program of the Robert Wood Johnson Foundation. The grant went to the University of Washington and not to any of the individual authors.	Buzzini SRR, 2006, CURR OPIN PEDIATR, V18, P376, DOI 10.1097/01.mop.0000236385.26284.ec; Chrisman SP, 2013, J ADOLESCENT HEALTH, V52, P330, DOI 10.1016/j.jadohealth.2012.10.271; Chrisman SP, 2011, CLIN PEDIATR, V50, P1031, DOI 10.1177/0009922811410970; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Finch CF, 2013, BRIT J SPORT MED, V47, P12, DOI 10.1136/bjsports-2012-091796; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Gioia GA, 2009, BRIT J SPORT MED, V43, pI13, DOI 10.1136/bjsm.2009.058255; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Hailu A, 2009, GUIDELINES USING RUR; Harvey HH, 2013, AM J PUBLIC HEALTH, V103, P1249, DOI 10.2105/AJPH.2012.301107; Institute of Medicine and National Research Council, 2013, SPORTS REL CONC YOUT; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2001, CLIN J SPORT MED, V11, P176, DOI 10.1097/00042752-200107000-00008; McCrea M, 2009, NEUROSURGERY, V65, P876, DOI 10.1227/01.NEU.0000350155.89800.00; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Powell JW, 1999, J ATHL TRAINING, V34, P277; Randolph C, 2009, ARCH CLIN NEUROPSYCH, V24, P219, DOI 10.1093/arclin/acp025; Register-Mihalik JK, 2013, BRAIN INJURY, V27, P878, DOI 10.3109/02699052.2013.775508; USA Football, 2013, SEE YOUR STAT STANDS; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832	28	76	76	1	27	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	MAY	2014	42	5					1197	1203		10.1177/0363546514521774			7	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	AG6ZM	WOS:000335567700023	24569704				2021-06-18	
J	King, LA; Horak, FB; Mancini, M; Pierce, D; Priest, KC; Chesnutt, J; Sullivan, P; Chapman, JC				King, Laurie A.; Horak, Fay B.; Mancini, Martina; Pierce, Donald; Priest, Kelsey C.; Chesnutt, James; Sullivan, Patrick; Chapman, Julie C.			Instrumenting the Balance Error Scoring System for Use With Patients Reporting Persistent Balance Problems After Mild Traumatic Brain Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain concussion; Brain injuries; Postural balance; Rehabilitation	SPORTS-RELATED CONCUSSION; HIGH-SCHOOL; INTERNATIONAL-CONFERENCE; CONSENSUS STATEMENT; PARKINSONS-DISEASE; FOOTBALL PLAYERS; HEAD-INJURY; PERFORMANCE; ACCELEROMETER; IMPAIRMENT	Objective: To determine whether alterations to the Balance Error Scoring System (BESS), such as modified conditions and/or instrumentation, would improve the ability to correctly classify traumatic brain injury (TBI) status in patients with mild TBI with persistent self-reported balance complaints. Design: Cross-sectional study. Setting: Outpatient clinic. Participants: Subjects (n=13; age, 16.3 +/- 2y) with a recent history of concussion (mild TBI group) and demographically matched control subjects (n=13; age, 16.7 +/- 2y; control group). Interventions: Not applicable. Main Outcome Measures: Outcome measures included the BESS, modified BESS, instrumented BESS, and instrumented modified BESS. All subjects were tested on the noninstrumented BESS and modified BESS and were scored by visual observation of instability in 6 and 3 stance conditions, respectively. Instrumentation of these 2 tests used 1 inertial sensor with an accelerometer and gyroscope to quantify bidirectional body sway. Results: Scores from the BESS and the modified BESS tests were similar between groups. However, results from the instrumented measures using the inertial sensor were significantly different between groups. The instrumented modified BESS had superior diagnostic classification and the largest area under the curve when compared with the other balance measures. Conclusions: A concussion may disrupt the sensory processing required for optimal postural control, which was measured by sway during quiet stance. These results suggest that the use of portable inertial sensors may be useful in the move toward more objective and sensitive measures of balance control postconcussion, but more work is needed to increase sensitivity. (C) 2014 by the American Congress of Rehabilitation Medicine	[King, Laurie A.; Horak, Fay B.; Mancini, Martina; Priest, Kelsey C.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA; [Pierce, Donald] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent, Div Biostat, Portland, OR 97201 USA; [Chesnutt, James] Oregon Hlth & Sci Univ, Dept Sports Med, Portland, OR 97201 USA; [Chapman, Julie C.] DC Vet Affairs Med Ctr, War Related Illness & Injury Study Ctr, Washington, DC USA; [Sullivan, Patrick; Chapman, Julie C.] Georgetown Univ, Sch Med, Dept Neurol, Washington, DC USA	King, LA (corresponding author), Parkinson Ctr Oregon OP32, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	kingla@ohsu.edu	Priest, Kelsey/O-9359-2019	Priest, Kelsey/0000-0003-3929-8177; Mancini, Martina/0000-0002-4532-3984; King, Laurie/0000-0001-9802-4446	National Center for Medical Rehabilitation Research at the Eunice Kennedy Shriver National Institute of Child Health and Human Development; Center for Translation of Rehabilitation Engineering Advances and Technology [NIH R24HD065703]; Oregon Clinical and Translational Research Institute from the National Center for Advancing Translational Sciences at the National Institutes of Health [UL1TR000128, KL2TR000152]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R24HD065703] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000128, KL2TR000152] Funding Source: NIH RePORTER	Supported by the National Center for Medical Rehabilitation Research at the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the Center for Translation of Rehabilitation Engineering Advances and Technology (grant no. NIH R24HD065703); the Oregon Clinical and Translational Research Institute (grant nos. UL1TR000128 and KL2TR000152) from the National Center for Advancing Translational Sciences at the National Institutes of Health.	Alsalaheen BA, 2010, J NEUROL PHYS THER, V34, P87, DOI 10.1097/NPT.0b013e3181dde568; [Anonymous], 2012, NIH BALANCE TOOLBOX; [Anonymous], 2013, APDM MOVEMENT MONITO; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Broglio SP, 2007, J ATHL TRAINING, V42, P504; Broglio SP, 2009, J ATHL TRAINING, V44, P497, DOI 10.4085/1062-6050-44.5.497; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Finnoff JT, 2009, PM&R, V1, P50, DOI 10.1016/j.pmrj.2008.06.002; Furman GR, 2013, AM J SPORT MED, V41, P1404, DOI 10.1177/0363546513484446; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Herdman SJ, 1994, CURR OPIN NEUROL, V13, P3; Horak F, 1996, HDB PHYSL 12, P255; Iverson GL, 2013, BRAIN INJURY, V27, P596, DOI 10.3109/02699052.2013.772237; Janes H, 2009, STATA J, V9, P17, DOI 10.1177/1536867X0900900102; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P196, DOI 10.1097/00001199-200505000-00003; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Mak MK, 2003, ARCH PHYS MED REHAB, V84, P683, DOI 10.1016/S0003-9993(03)04810-4; Mancini M, 2012, J BIOENG BIOMED SCI, VS1; Mancini M, 2012, J NEUROENG REHABIL, V9, DOI 10.1186/1743-0003-9-59; Mancini M, 2011, PARKINSONISM RELAT D, V17, P557, DOI 10.1016/j.parkreldis.2011.05.010; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2009, J CLIN NEUROSCI, V16, P755, DOI 10.1016/j.jocn.2009.02.002; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McCrory P, 2011, CLIN J SPORT MED, V21, P6, DOI 10.1097/JSM.0b013e318204db50; McLeod TCV, 2012, AM J SPORT MED, V40, P927, DOI 10.1177/0363546511431573; Mulligan IJ, 2013, SPORTS HEALTH, V5, P22, DOI 10.1177/1941738112467755; Palmerini L, 2013, IEEE T NEUR SYS REH, V21, P664, DOI 10.1109/TNSRE.2012.2236577; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Spain RI, 2012, GAIT POSTURE, V35, P573, DOI 10.1016/j.gaitpost.2011.11.026; Valovich TC, 2003, J ATHL TRAINING, V38, P51; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677; Weiss A, 2011, PHYSIOL MEAS, V32, P2003, DOI 10.1088/0967-3334/32/12/009; Wetjen NM, 2010, J AM COLL SURGEONS, V211, P553, DOI 10.1016/j.jamcollsurg.2010.05.020; Wilkins JC, 2004, J ATHL TRAINING, V39, P156	36	76	76	1	28	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	FEB	2014	95	2					353	359		10.1016/j.apmr.2013.10.015			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	AA2LW	WOS:000330927100021	24200875	Green Accepted			2021-06-18	
J	Hicks, R; Giacino, J; Harrison-Felix, C; Manley, G; Valadka, A; Wilde, EA				Hicks, Ramona; Giacino, Joseph; Harrison-Felix, Cynthia; Manley, Geoffrey; Valadka, Alex; Wilde, Elisabeth A.			Progress in Developing Common Data Elements for Traumatic Brain Injury Research: Version Two - The End of the Beginning	JOURNAL OF NEUROTRAUMA			English	Article						acute; chronic; collaboration; concussion; data standardization; epidemiology; rehabilitation	WORKING GROUP; PEDIATRIC CONSIDERATIONS; PSYCHOLOGICAL HEALTH; CLINICAL-ASSESSMENT; OUTCOME MEASURES; RECOMMENDATIONS; DEMOGRAPHICS; BIOSPECIMENS; SCORE	To accelerate data sharing and research on traumatic brain injury (TBI), several federal agencies have been collaborating to support the development and implementation of common data elements (CDEs). The first recommendations for CDEs were made in 2010, and were well suited for hospital-based studies of acute TBI in adults. To broaden the utility of the TBI CDEs, experts were asked to update the recommendations to make them relevant to all ages, levels of injury severity, and phases of recovery. The second version of the TBI CDEs (v.2) was organized around four major study types: 1) epidemiological research; 2) studies on acute, hospitalized patients; 3) studies of the rehabilitation for moderate/severe TBI; and 4) mild TBI/concussion research. Given the heterogeneity of TBI, only a small set of core CDEs were found to be relevant across all study types. However, within groups, a much larger set of highly relevant CDEs were identified, and these were called basic CDEs. In addition, an expanded number of supplemental CDEs were specified and recommended for use depending upon the study goals. Version 2 provides a rich data dictionary for TBI research with about 900 CDEs. Many of the CDEs overlap across the study types, which will facilitate comparisons and meta-analysis across studies. Further modifications of the CDEs should be based on evaluation of their usefulness following implementation across a range of studies.	[Hicks, Ramona] NINDS, Bethesda, MD 20892 USA; [Giacino, Joseph] Harvard Univ, Sch Med, Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Boston, MA USA; [Harrison-Felix, Cynthia] Craig Hosp, Dept Phys Med & Rehabil, Englewood, CO USA; [Harrison-Felix, Cynthia] Univ Colorado, Dept Phys Med & Rehabil, Denver, CO 80202 USA; [Manley, Geoffrey] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA; [Valadka, Alex] Seton Brain & Spine Inst, Austin, TX USA; [Wilde, Elisabeth A.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Wilde, Elisabeth A.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA; [Wilde, Elisabeth A.] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA; [Wilde, Elisabeth A.] Michael E DeBakey VA Med Ctr, Houston, TX USA	Hicks, R (corresponding author), NINDS, NIH, 6001 Execut Blvd,Room 2206, Bethesda, MD 20892 USA.	hicksra@mail.nih.gov	Giacino, Joseph/AAF-1952-2021	Giacino, Joseph/0000-0002-7916-9698			Adelson PD, 2012, J NEUROTRAUM, V29, P639, DOI 10.1089/neu.2011.1952; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Berger RP, 2012, J NEUROTRAUM, V29, P672, DOI 10.1089/neu.2011.1861; Carrillo MC, 2012, ALZHEIMERS DEMENT, V8, P337, DOI 10.1016/j.jalz.2012.04.007; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; Duhaime AC, 2012, J NEUROTRAUM, V29, P629, DOI 10.1089/neu.2011.1927; Duhaime AC, 2010, ARCH PHYS MED REHAB, V91, P1661, DOI 10.1016/j.apmr.2010.07.238; Federal Interagency TBI Research (FITBIR) Informatics System, 2013, FED INT TBI RES FITB; Finster M, 2005, ANESTHESIOLOGY, V102, P855, DOI 10.1097/00000542-200504000-00022; Gerring JP, 2012, J NEUROTRAUM, V29, P621, DOI 10.1089/neu.2011.2234; Gershon RC, 2012, QUAL LIFE RES, V21, P475, DOI 10.1007/s11136-011-9958-8; Gershon RC, 2010, LANCET NEUROL, V9, P138, DOI 10.1016/S1474-4422(09)70335-7; Haacke EM, 2010, J MAGN RESON IMAGING, V32, P516, DOI 10.1002/jmri.22259; Hunter JV, 2012, J NEUROTRAUM, V29, P654, DOI 10.1089/neu.2011.1906; Maas AI, 2010, ARCH PHYS MED REHAB, V91, P1641, DOI 10.1016/j.apmr.2010.07.232; Manley GT, 2010, ARCH PHYS MED REHAB, V91, P1667, DOI 10.1016/j.apmr.2010.05.018; McCauley SR, 2012, J NEUROTRAUM, V29, P678, DOI 10.1089/neu.2011.1838; Miller AC, 2012, J NEUROTRAUM, V29, P634, DOI 10.1089/neu.2011.1932; National Institute of Neurological Disorders and Stroke, 2013, NINDS COMM DAT EL TR; National Institute of Neurological Disorders and Stroke, 2013, NINDS COMM DAT EL; National Research Council, 2011, PREC MED BUILD KNOWL; Steiner LA, 2006, BRIT J ANAESTH, V97, P26, DOI 10.1093/bja/ael110; Thurmond VA, 2010, ARCH PHYS MED REHAB, V91, P1633, DOI 10.1016/j.apmr.2010.06.034; Whyte J, 2010, ARCH PHYS MED REHAB, V91, P1692, DOI 10.1016/j.apmr.2010.06.031; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783	26	76	76	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV 15	2013	30	22					1852	1861		10.1089/neu.2013.2938			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	243PH	WOS:000326328400003	23725058	Green Published			2021-06-18	
J	Harris, K; Armstrong, SP; Campos-Pires, R; Kiru, L; Franks, NP; Dickinson, R				Harris, Katie; Armstrong, Scott P.; Campos-Pires, Rita; Kiru, Louise; Franks, Nicholas P.; Dickinson, Robert			Neuroprotection against Traumatic Brain Injury by Xenon, but Not Argon, Is Mediated by Inhibition at the N-Methyl-D-Aspartate Receptor Glycine Site	ANESTHESIOLOGY			English	Article							HIPPOCAMPAL SLICE CULTURES; IN-VITRO MODEL; INHALATIONAL GENERAL-ANESTHETICS; CEREBRAL-ARTERY OCCLUSION; COMPETITIVE-INHIBITION; HYPOXIA-ISCHEMIA; ORGANOTYPIC CULTURES; INTRACELLULAR CA2+; NEONATAL ASPHYXIA; NEURONAL INJURY	Background: Xenon, the inert anesthetic gas, is neuroprotective in models of brain injury. The authors investigate the neuroprotective mechanisms of the inert gases such as xenon, argon, krypton, neon, and helium in an in vitro model of traumatic brain injury. Methods: The authors use an in vitro model using mouse organotypic hippocampal brain slices, subjected to a focal mechanical trauma, with injury quantified by propidium iodide fluorescence. Patch clamp electrophysiology is used to investigate the effect of the inert gases on N-methyl-d-aspartate receptors and TREK-1 channels, two molecular targets likely to play a role in neuroprotection. Results: Xenon (50%) and, to a lesser extent, argon (50%) are neuroprotective against traumatic injury when applied after injury (xenon 431% protection at 72h after injury [N = 104]; argon 30 +/- 6% protection [N = 44]; mean +/- SEM). Helium, neon, and krypton are devoid of neuroprotective effect. Xenon (50%) prevents development of secondary injury up to 48h after trauma. Argon (50%) attenuates secondary injury, but is less effective than xenon (xenon 50 +/- 5% reduction in secondary injury at 72h after injury [N = 104]; argon 34 +/- 8% reduction [N = 44]; mean +/- SEM). Glycine reverses the neuroprotective effect of xenon, but not argon, consistent with competitive inhibition at the N-methyl-d-aspartate receptor glycine site mediating xenon neuroprotection against traumatic brain injury. Xenon inhibits N-methyl-d-aspartate receptors and activates TREK-1 channels, whereas argon, krypton, neon, and helium have no effect on these ion channels. Conclusions: Xenon neuroprotection against traumatic brain injury can be reversed by increasing the glycine concentration, consistent with inhibition at the N-methyl-d-aspartate receptor glycine site playing a significant role in xenon neuroprotection. Argon and xenon do not act via the same mechanism.	[Harris, Katie; Armstrong, Scott P.; Campos-Pires, Rita; Kiru, Louise; Franks, Nicholas P.; Dickinson, Robert] Univ London Imperial Coll Sci Technol & Med, Anaesthet Pain Med & Intens Care Sect, Dept Surg & Canc, London SW7 2AZ, England	Dickinson, R (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sir Ernst Chain Bldg, London SW7 2AZ, England.	r.dickinson@imperial.ac.uk		Franks, Nicholas/0000-0003-4874-4212	European Society for Anaesthesiology, Brussels, Belgium; Royal College of Anaesthetists, London, United Kingdom; Westminster Medical School Research Trust, London, United Kingdom; Medical Research Council, London, United KingdomUK Research & Innovation (UKRI)Medical Research Council UK (MRC); Fundacao para a Ciencia e a Tecnologia, Lisbon, PortugalPortuguese Foundation for Science and Technology; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [1247958] Funding Source: researchfish	Support was provided by the European Society for Anaesthesiology, Brussels, Belgium; The Royal College of Anaesthetists, London, United Kingdom; and Westminster Medical School Research Trust, London, United Kingdom. Katie Harris is the recipient of a studentship from the Westminster Medical School Research Trust, London, United Kingdom. Scott Armstrong is the recipient of a studentship from the Medical Research Council, London, United Kingdom. Dr. Campos-Pires is the recipient of a doctoral training award from the Fundacao para a Ciencia e a Tecnologia, Lisbon, Portugal. Professor Franks has a financial interest in the use of xenon as a neuroprotectant, through an agreement with Air Products and Chemicals, Inc., Allentown, Pennsylvania.	Adamchik Y, 2000, BRAIN RES PROTOC, V5, P153, DOI 10.1016/S1385-299X(00)00007-6; Adembri C, 2004, J NEUROTRAUM, V21, P1103, DOI 10.1089/0897715041651079; Armstrong SP, 2012, ANESTHESIOLOGY, V117, P38, DOI 10.1097/ALN.0b013e31825ada2e; BAHR BA, 1995, J NEUROSCI RES, V42, P294, DOI 10.1002/jnr.490420303; Banks P, 2010, BRIT J ANAESTH, V104, P526; Banks P, 2010, ANESTHESIOLOGY, V112, P614, DOI 10.1097/ALN.0b013e3181cea398; Berger AJ, 1998, J NEUROPHYSIOL, V80, P3336; Bickler PE, 2012, ANESTHESIOLOGY, V117, P280, DOI 10.1097/ALN.0b013e318260a7b9; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Bullock R, 1995, ANN NY ACAD SCI, V765, P290, DOI 10.1111/j.1749-6632.1995.tb16586.x; Coburn M, 2008, CRIT CARE MED, V36, P588, DOI 10.1097/01.CCM.0B013E3181611F8A6; Crain SM, 1998, METHODS, V16, P228, DOI 10.1006/meth.1998.0681; David HN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030934; David HN, 2009, J CEREBR BLOOD F MET, V29, P1159, DOI 10.1038/jcbfm.2009.40; de Sousa SLM, 2000, ANESTHESIOLOGY, V92, P1055, DOI 10.1097/00000542-200004000-00024; Dickinson R, 2007, ANESTHESIOLOGY, V107, P756, DOI 10.1097/01.anes.0000287061.77674.71; Dickinson R, 2010, CRIT CARE, V14, DOI 10.1186/cc9051; Dingley J, 2006, STROKE, V37, P501, DOI 10.1161/01.STR.0000198867.31134.ac; Dopico JG, 2006, NEUROPHARMACOLOGY, V50, P548, DOI 10.1016/j.neuropharm.2005.10.014; Downie DL, 1996, BRIT J PHARMACOL, V118, P493, DOI 10.1111/j.1476-5381.1996.tb15430.x; Dyker AG, 1999, STROKE, V30, P986, DOI 10.1161/01.STR.30.5.986; Fahlenkamp AV, 2012, EUR J PHARMACOL, V674, P104, DOI 10.1016/j.ejphar.2011.10.045; Finley M, 2004, BRAIN RES, V1001, P125, DOI 10.1016/j.brainres.2003.12.009; Franks NP, 1998, NATURE, V396, P324, DOI 10.1038/24525; Frantseva M, 2002, PROG BRAIN RES, V137, P171; Frantseva MV, 2002, J CEREBR BLOOD F MET, V22, P453, DOI 10.1097/00004647-200204000-00009; Fries M, 2008, CRIT CARE MED, V36, P2420, DOI 10.1097/CCM.0b013e3181802874; Gray JJ, 2005, ANESTHESIOLOGY, V102, P606, DOI 10.1097/00000542-200503000-00020; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Gruss M, 2004, MOL PHARMACOL, V65, P443, DOI 10.1124/mol.65.2.443; Head BP, 2007, CURR OPIN ANESTHESIO, V20, P395, DOI 10.1097/ACO.0b013e3282efa69d; Hemmings HC, 2008, ANESTHESIOLOGY, V109, P954, DOI 10.1097/ALN.0b013e31818d4964; Heurteaux C, 2004, EMBO J, V23, P2684, DOI 10.1038/sj.emboj.7600234; Homi HM, 2003, ANESTHESIOLOGY, V99, P876, DOI 10.1097/00000542-200310000-00020; Jawad N, 2009, NEUROSCI LETT, V460, P232, DOI 10.1016/j.neulet.2009.05.069; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Ling GSF, 2008, NEUROL CLIN, V26, P409, DOI 10.1016/j.ncl.2008.02.001; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Loetscher PD, 2009, CRIT CARE, V13, DOI 10.1186/cc8214; Ma D, 2002, BRIT J ANAESTH, V89, P739, DOI 10.1093/bja/aef258; Ma DQ, 2005, ANN NEUROL, V58, P182, DOI 10.1002/ana.20547; MACKLIS JD, 1990, J NEUROSCI METH, V31, P43, DOI 10.1016/0165-0270(90)90007-3; Montero M, 2007, BRAIN RES, V1177, P124, DOI 10.1016/j.brainres.2007.08.038; Morrison B, 1998, J NEUROTRAUM, V15, P911, DOI 10.1089/neu.1998.15.911; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Oei GTML, 2010, ANESTHESIOLOGY, V112, P1503, DOI 10.1097/ALN.0b013e3181d9cb5e; Pan Y, 2007, EXP NEUROL, V205, P587, DOI 10.1016/j.expneurol.2007.03.023; Patel P, 2004, ANESTHESIOLOGY, V100, P1049, DOI 10.1097/00000542-200405000-00003; Preckel B, 2002, BRIT J ANAESTH, V88, P264, DOI 10.1093/bja/88.2.264; Preckel B, 2006, ANESTHESIOLOGY, V105, P187, DOI 10.1097/00000542-200607000-00029; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Ryang YM, 2011, CRIT CARE MED, V39, P1448, DOI 10.1097/CCM.0b013e31821209be; Sanders RD, 2003, BRIT J ANAESTH, V91, P709, DOI 10.1093/bja/aeg232; SERVADEI F, 1995, NEUROSURGERY, V37, P899, DOI 10.1227/00006123-199511000-00008; Sheng SP, 2012, ANESTHESIOLOGY, V117, P1262, DOI 10.1097/ALN.0b013e3182746b81; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; Sullivan BL, 2002, ANESTHESIOLOGY, V96, P189, DOI 10.1097/00000542-200201000-00033; Teasdale GM, 1998, NEUROSURGERY, V43, P723, DOI 10.1097/00006123-199810000-00001; Teasdale GM, 1998, NEUROSURGERY, V43, P1373, DOI 10.1097/00006123-199812000-00068; Tolias Christos M, 2004, NeuroRx, V1, P71, DOI 10.1602/neurorx.1.1.71; Turtzo LC, 2013, NMR BIOMED, V26, P468, DOI 10.1002/nbm.2886; Wang KKW, 2006, CURR OPIN NEUROL, V19, P514, DOI 10.1097/WCO.0b013e3280102b10; Warner DS, 2004, ANESTH ANALG, V99, P1208, DOI 10.1213/01.ANE.0000139930.04010.0D; White CL, 2009, J TRAUMA, V67, P508, DOI 10.1097/TA.0b013e3181b2519f; Wilhelm S, 2002, ANESTHESIOLOGY, V96, P1485, DOI 10.1097/00000542-200206000-00031; Yarin YM, 2005, HEARING RES, V201, P1, DOI 10.1016/j.heares.2004.09.015; Zhuang L, 2012, CRIT CARE MED, V40, P1724, DOI 10.1097/CCM.0b013e3182452164	68	76	79	0	17	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-3022	1528-1175		ANESTHESIOLOGY	Anesthesiology	NOV	2013	119	5					1137	1148		10.1097/ALN.0b013e3182a2a265			12	Anesthesiology	Anesthesiology	290ZS	WOS:000329797900021	23867231				2021-06-18	
J	Morey, RA; Haswell, CC; Selgrade, ES; Massoglia, D; Liu, CL; Weiner, J; Marx, CE; Cernak, I; McCarthy, G				Morey, Rajendra A.; Haswell, Courtney C.; Selgrade, Elizabeth S.; Massoglia, Dino; Liu, Chunlei; Weiner, Jonathan; Marx, Christine E.; Cernak, Ibolja; McCarthy, Gregory		MIRECC Work Grp	Effects of Chronic Mild Traumatic Brain Injury on White Matter Integrity in Iraq and Afghanistan War Veterans	HUMAN BRAIN MAPPING			English	Article						mild traumatic brain injury; high angular resolution diffusion imaging; white matter; crossing fibers; posttraumatic stress disorder	POSTTRAUMATIC-STRESS-DISORDER; MULTIPLE FIBER ORIENTATIONS; DIFFUSION-TENSOR; COGNITIVE IMPAIRMENT; AXONAL INJURY; OUTCOMES; TESTS; ABNORMALITIES; UNCERTAINTY; DEPENDENCE	Mild traumatic brain injury (TBI) is a common source of morbidity from the wars in Iraq and Afghanistan. With no overt lesions on structural MRI, diagnosis of chronic mild TBI in military veterans relies on obtaining an accurate history and assessment of behavioral symptoms that are also associated with frequent comorbid disorders, particularly posttraumatic stress disorder (PTSD) and depression. Military veterans from Iraq and Afghanistan with mild TBI (n = 30) with comorbid PTSD and depression and non-TBI participants from primary (n = 42) and confirmatory (n = 28) control groups were assessed with high angular resolution diffusion imaging (HARDI). White matter-specific registration followed by whole-brain voxelwise analysis of crossing fibers provided separate partial volume fractions reflecting the integrity of primary fibers and secondary (crossing) fibers. Loss of white matter integrity in primary fibers (P < 0.05; corrected) was associated with chronic mild TBI in a widely distributed pattern of major fiber bundles and smaller peripheral tracts including the corpus callosum (genu, body, and splenium), forceps minor, forceps major, superior and posterior corona radiata, internal capsule, superior longitudinal fasciculus, and others. Distributed loss of white matter integrity correlated with duration of loss of consciousness and most notably with feeling dazed or confused, but not diagnosis of PTSD or depressive symptoms. This widespread spatial extent of white matter damage has typically been reported in moderate to severe TBI. The diffuse loss of white matter integrity appears consistent with systemic mechanisms of damage shared by blast- and impact-related mild TBI that involves a cascade of inflammatory and neurochemical events. Hum Brain Mapp 34:2986-2999, 2013. (c) 2012 Wiley Periodicals, Inc.	[Morey, Rajendra A.; Haswell, Courtney C.; Selgrade, Elizabeth S.; Liu, Chunlei] Duke Univ, Med Ctr, Duke UNC Brain Imaging & Anal Ctr, Durham, NC USA; [Morey, Rajendra A.; Marx, Christine E.] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC USA; [Morey, Rajendra A.; Haswell, Courtney C.; Selgrade, Elizabeth S.; Weiner, Jonathan; Marx, Christine E.; McCarthy, Gregory] Durham VA Med Ctr, Mental Illness Res Educ & Clin Ctr Post Deploymen, Durham, NC 27705 USA; [Massoglia, Dino] Duke Univ, Med Ctr, Div Neuroradiol, Durham, NC USA; [Cernak, Ibolja] Johns Hopkins Univ, Appl Phys Lab, Natl Secur Technol Dept, Laurel, MD USA; [McCarthy, Gregory] Yale Univ, Dept Psychol, New Haven, CT 06520 USA	Morey, RA (corresponding author), Durham VA Med Ctr, 508 Fulton St,Bldg 5, Durham, NC 27705 USA.	morey@biac.duke.edu	Morey, Rajendra A/P-3079-2018	Morey, Rajendra A/0000-0002-6517-6969; Liu, Chunlei/0000-0001-8816-4832; Ibolja, Cernak/0000-0003-3214-698X	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K23 MH073091]; Department of Veterans Affairs, Mental Illness Research Education and Clinical Center Grant for Post-Deployment Mental Health; Department of Veterans Health Affairs, from Rehabilitation Research and Development (RRD) [RX000389-01]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R00EB007182] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K23MH073091] Funding Source: NIH RePORTER	Contract grant sponsor: National Institutes of Health; Contract grant number: K23 MH073091; Contract grant sponsor: Department of Veterans Affairs, Mental Illness Research Education and Clinical Center Grant for Post-Deployment Mental Health; Contract grant sponsor: Department of Veterans Health Affairs, from Rehabilitation Research and Development (RR & D); Contract grant number: RX000389-01.	ABOITIZ F, 1992, BRAIN RES, V598, P143, DOI 10.1016/0006-8993(92)90178-C; Anderson MJ, 2001, AUST NZ J STAT, V43, P75, DOI 10.1111/1467-842X.00156; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Bazarian JJ, 2009, J HEAD TRAUMA REHAB, V24, P439, DOI 10.1097/HTR.0b013e3181c15600; Behrens TEJ, 2007, NEUROIMAGE, V34, P144, DOI 10.1016/j.neuroimage.2006.09.018; Behrens TEJ, 2003, NAT NEUROSCI, V6, P750, DOI 10.1038/nn1075; Behrens TEJ, 2003, MAGN RESON MED, V50, P1077, DOI 10.1002/mrm.10609; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Cernak Ibolja, 2010, Front Neurol, V1, P151, DOI 10.3389/fneur.2010.00151; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Dedert EA, 2009, J PSYCHIATR RES, V43, P830, DOI 10.1016/j.jpsychires.2009.01.004; Gondusky JS, 2005, MIL MED, V170, P546, DOI 10.7205/MILMED.170.6.546; Hayes JP, 2011, NEUROCASE; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hosey T, 2005, MAGN RESON MED, V54, P1480, DOI 10.1002/mrm.20723; Hsu JL, 2008, NEUROIMAGE, V39, P566, DOI 10.1016/j.neuroimage.2007.09.017; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Ivins BJ, 2003, J TRAUMA, V55, P617, DOI 10.1097/01.TA.0000052368.97573.D4; Jbabdi S, 2010, NEUROIMAGE, V49, P247, DOI 10.1016/j.neuroimage.2009.08.039; Jones DK, 2003, MAGN RESON MED, V49, P7, DOI 10.1002/mrm.10331; Jones DK, 1999, MAGNET RESON MED, V42, P515, DOI 10.1002/(SICI)1522-2594(199909)42:3<515::AID-MRM14>3.3.CO;2-H; Kanaan R, 2009, BRIT J PSYCHIAT, V194, P236, DOI 10.1192/bjp.bp.108.054320; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; KENNEDY PE, 1995, J BUS ECON STAT, V13, P85, DOI 10.2307/1392523; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Levin HS, 2008, J HEAD TRAUMA REHAB, V23, P197, DOI 10.1097/01.HTR.0000327252.54128.7c; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Madden DJ, 2004, NEUROIMAGE, V21, P1174, DOI 10.1016/j.neuroimage.2003.11.004; Marx BP, 2009, ARCH GEN PSYCHIAT, V66, P996, DOI 10.1001/archgenpsychiatry.2009.109; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Moore DF, 2009, 6 ANN WORLD C BRAIN; Mori S., 2005, MRI ATLAS HUMAN WHIT; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; O'Donnell ML, 2004, AM J PSYCHIAT, V161, P1390, DOI 10.1176/appi.ajp.161.8.1390; Palacios EM, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-24; Pierpaoli C, 2001, NEUROIMAGE, V13, P1174, DOI 10.1006/nimg.2001.0765; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Scholz J, 2009, NAT NEUROSCI, V12, P1370, DOI 10.1038/nn.2412; Schuff N, 2011, NEUROIMAGE, V54, pS62, DOI 10.1016/j.neuroimage.2010.05.024; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; Sponheim S, 2011, NEUROIMAGE IN PRESS; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Tuch DS, 2002, MAGNET RESON MED, V48, P577, DOI 10.1002/mrm.10268; Versace A, 2008, ARCH GEN PSYCHIAT, V65, P1041, DOI 10.1001/archpsyc.65.9.1041; Weber JT, 2007, PROG BRAIN RES, V161, P253, DOI 10.1016/S0079-6123(06)61018-2; Xu JS, 2010, NEUROPSYCHOPHARMACOL, V35, P1541, DOI 10.1038/npp.2010.25; Yang FPG, 2011, P INT SOC MAGN RES I; Yeh PH, 2009, PSYCHIAT RES-NEUROIM, V173, P22, DOI 10.1016/j.pscychresns.2008.07.012; Zhuang L, 2010, NEUROIMAGE, V53, P16, DOI 10.1016/j.neuroimage.2010.05.068	61	76	76	0	33	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1065-9471	1097-0193		HUM BRAIN MAPP	Hum. Brain Mapp.	NOV	2013	34	11					2986	2999		10.1002/hbm.22117			14	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	295FG	WOS:000330101400020	22706988	Green Accepted, Green Published			2021-06-18	
J	Parsey, CM; Schmitter-Edgecombe, M				Parsey, Carolyn M.; Schmitter-Edgecombe, Maureen			Applications of Technology in Neuropsychological Assessment	CLINICAL NEUROPSYCHOLOGIST			English	Article						Neuropsychological assessment; Technology; Computerized Testing; Virtual Reality	MILD COGNITIVE IMPAIRMENT; TRAUMATIC BRAIN-INJURY; SPATIAL WORKING-MEMORY; VIRTUAL-REALITY; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; ASSESSMENT METRICS; OLDER-ADULTS; TEST BATTERY; DRIVING PERFORMANCE	Most neuropsychological assessments include at least one measure that is administered, scored, or interpreted by computers or other technologies. Despite supportive findings for these technology-based assessments, there is resistance in the field of neuropsychology to adopt additional measures that incorporate technology components. This literature review addresses the research findings of technology-based neuropsychological assessments, including computer- and virtual reality-based measures of cognitive and functional abilities. We evaluate the strengths and limitations of each approach, and examine the utility of technology-based assessments to obtain supplemental cognitive and behavioral information that may be otherwise undetected by traditional paper-and-pencil measures. We argue that the potential of technology use in neuropsychological assessment has not yet been realized, and continued adoption of new technologies could result in more comprehensive assessment of cognitive dysfunction and in turn, better informed diagnosis and treatments. Recommendations for future research are also provided.	[Parsey, Carolyn M.; Schmitter-Edgecombe, Maureen] Washington State Univ, Dept Psychol, Pullman, WA 99164 USA	Parsey, CM (corresponding author), Washington State Univ, Dept Psychol, POB 644820, Pullman, WA 99164 USA.	cparsey@wsu.edu	Parsey, Carolyn/J-2720-2019	Parsey, Carolyn/0000-0002-8555-6512	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB015853, R01EB009675] Funding Source: NIH RePORTER; NIBIB NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01 EB009675, R01 EB015853] Funding Source: Medline		Adams R, 2009, CHILD NEUROPSYCHOL, V15, P120, DOI 10.1080/09297040802169077; Alderman N, 2003, J INT NEUROPSYCH SOC, V9, P31, DOI 10.1017/S1355617703910046; Allen BJ, 2011, BRAIN INJURY, V25, P179, DOI 10.3109/02699052.2010.541897; Aprahamian I, 2011, INT J GERIATR PSYCH, V26, P403, DOI 10.1002/gps.2540; Aprahamian I, 2011, INT PSYCHOGERIATR, V23, P96, DOI 10.1017/S104161021000116X; Asimakopulos J, 2012, AUST OCCUP THER J, V59, P402, DOI 10.1111/j.1440-1630.2011.00963.x; Athey RJ, 2006, INT J GERIATR PSYCH, V21, P977, DOI 10.1002/gps.1595; Athey RJ, 2005, AGE AGEING, V34, P268, DOI 10.1093/ageing/afi098; Bauer RM, 2012, CLIN NEUROPSYCHOL, V26, P177, DOI 10.1080/13854046.2012.663001; Bleiberg J, 1997, NEUROPSY NEUROPSY BE, V10, P247; Bleiberg J, 2000, CLIN NEUROPSYCHOL, V14, P287, DOI 10.1076/1385-4046(200008)14:3;1-P;FT287; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Bryan C, 2012, J HEAD TRAUMA REHAB, V27, P45, DOI 10.1097/HTR.0b013e318238f146; Buchman AS, 2011, AM J GERIAT PSYCHIAT, V19, P571, DOI 10.1097/JGP.0b013e3181ef7a2e; Burton EJ, 2004, BRAIN, V127, P791, DOI 10.1093/brain/awh088; Cain AE, 2009, J PSYCHIATR RES, V43, P987, DOI 10.1016/j.jpsychires.2009.01.014; Calhoun VD, 2012, NEUROIMAGE, V59, P25, DOI 10.1016/j.neuroimage.2011.06.037; Chamberlain SR, 2011, BIOL PSYCHIAT, V69, P1192, DOI 10.1016/j.biopsych.2010.08.019; Chen CM, 2000, J AM SOC INFORM SCI, V51, P529, DOI 10.1002/(SICI)1097-4571(2000)51:6<529::AID-ASI5>3.3.CO;2-6; Collie A, 2003, J INT NEUROPSYCH SOC, V9, P419, DOI 10.1017/S1355617703930074; Conde-Sala JL, 2012, INT PSYCHOGERIATR, V24, P948, DOI 10.1017/S1041610211002158; Courtney KL, 2008, METHOD INFORM MED, V47, P76, DOI 10.3414/ME9104; Crandall A. S., 2012, P 8 INT C INT ENV IE, P169; Cumming TB, 2012, J NEUROL SCI, V322, P102, DOI 10.1016/j.jns.2012.07.004; Daniel JC, 1999, NEUROPSY NEUROPSY BE, V12, P167; Darby D, 2002, NEUROLOGY, V59, P1042, DOI 10.1212/WNL.59.7.1042; Dassel KB, 2008, GERONTOLOGIST, V48, P781, DOI 10.1093/geront/48.6.781; De Jager CA, 2005, NEUROCASE, V11, P72, DOI 10.1080/13554790490896820; de Koning I, 2005, J NEUROL NEUROSUR PS, V76, P263, DOI 10.1136/jnnp.2004.039511; Demiris G, 2008, INT J TECHNOL ASSESS, V24, P120, DOI 10.1017/S0266462307080154; Doniger Glen M, 2006, Am J Alzheimers Dis Other Demen, V21, P28; Doniger GM, 2009, ALZHEIMERS DEMENT, V5, P439, DOI 10.1016/j.jalz.2009.03.003; DOWNES JJ, 1989, NEUROPSYCHOLOGIA, V27, P1329, DOI 10.1016/0028-3932(89)90128-0; Dwolatzky T, 2004, J MOL NEUROSCI, V24, P33, DOI 10.1385/JMN:24:1:033; Dwolatzky T., 2003, BIOMED CENTRAL BMC G, V2, P3; Dwolatzky T, 2010, INT PSYCHOGERIATR, V22, P795, DOI 10.1017/S1041610210000621; Edwards S, 1996, PHARMACOL BIOCHEM BE, V54, P309, DOI 10.1016/0091-3057(95)02116-7; Egerhazi A, 2007, PROG NEURO-PSYCHOPH, V31, P746, DOI 10.1016/j.pnpbp.2007.01.011; Elkind JS, 2001, CYBERPSYCHOL BEHAV, V4, P489, DOI 10.1089/109493101750527042; Falleti MG, 2006, J CLIN EXP NEUROPSYC, V28, P1095, DOI 10.1080/13803390500205718; Feldstein SN, 1999, CLIN NEUROPSYCHOL, V13, P303, DOI 10.1076/clin.13.3.303.1744; Fillit HM, 2008, ALZHEIMERS DEMENT, V4, P14, DOI 10.1016/j.jalz.2007.09.008; Flynn D, 2003, CYBERPSYCHOL BEHAV, V6, P591, DOI 10.1089/109493103322725379; Fowler KS, 2002, J INT NEUROPSYCH SOC, V8, P58, DOI 10.1017/S1355617701020069; Fredrickson J, 2010, NEUROEPIDEMIOLOGY, V34, P65, DOI 10.1159/000264823; Gaggioli A, 2012, STUD HEALTH TECHNOL, V181, P177, DOI 10.3233/978-1-61499-121-2-177; Gaspar J. G., 2013, J AGING RES, V2013; Gau SSF, 2010, J CHILD PSYCHOL PSYC, V51, P838, DOI 10.1111/j.1469-7610.2010.02215.x; Gualtieri CT, 2006, ARCH CLIN NEUROPSYCH, V21, P623, DOI 10.1016/j.acn.2006.05.007; Gualtieri C Thomas, 2005, Am J Alzheimers Dis Other Demen, V20, P359; Gualtieri C Thomas, 2008, Medscape J Med, V10, P90; Guevara MA, 2009, COMPUT METH PROG BIO, V95, P158, DOI 10.1016/j.cmpb.2009.02.007; Hagler S, 2010, IEEE T BIO-MED ENG, V57, P813, DOI 10.1109/TBME.2009.2036732; Hanna-Pladdy B, 2010, INT J NEUROSCI, V120, P538, DOI 10.3109/00207454.2010.496539; Harel BT, 2011, NEUROPSYCHOLOGY, V25, P752, DOI 10.1037/a0024237; Hawkins KA, 2012, PARKINSONISM RELAT D, V18, P864, DOI 10.1016/j.parkreldis.2012.04.021; Hayes TL, 2008, ALZHEIMERS DEMENT, V4, P395, DOI 10.1016/j.jalz.2008.07.004; Heinik J, 2004, ARCH GERONTOL GERIAT, V38, P77, DOI 10.1016/j.archger.2003.08.004; Hobson P, 1999, AGE AGEING, V28, P39, DOI 10.1093/ageing/28.1.39; Iverson GL, 2009, J CLIN EXP NEUROPSYC, V31, P594, DOI 10.1080/13803390802372125; Ivins BJ, 2009, J HEAD TRAUMA REHAB, V24, P24, DOI 10.1097/HTR.0b013e3181957042; Jones M, 2011, J HEALTH SERV RES PO, V16, P172, DOI 10.1258/jhsrp.2010.010016; Junkkila J, 2012, DEMENT GERIATR COGN, V34, P83, DOI 10.1159/000342116; Kane RL, 2007, ARCH CLIN NEUROPSYCH, V22, pS115, DOI 10.1016/j.acn.2006.10.006; Kang YJ, 2008, CYBERPSYCHOL BEHAV, V11, P329, DOI 10.1089/cpb.2007.0116; Koski L, 2011, HIV MED, V12, P472, DOI 10.1111/j.1468-1293.2010.00910.x; Kush JC, 2012, BEHAV RES METHODS, V44, P125, DOI 10.3758/s13428-011-0136-2; Law AS, 2006, ACTA PSYCHOL, V122, P27, DOI 10.1016/j.actpsy.2005.09.002; Leeds L, 2001, AGE AGEING, V30, P251, DOI 10.1093/ageing/30.3.251; Levinson D, 2005, ARCH CLIN NEUROPSYCH, V20, P403, DOI 10.1016/j.acn.2004.09.001; Levinson DM, 1997, ARCH CLIN NEUROPSYCH, V12, P155, DOI 10.1016/S0887-6177(96)00026-1; Lew HL, 2005, BRAIN INJURY, V19, P177, DOI 10.1080/02699050400017171; Lovell M, 2004, CLIN SPORT MED, V23, P421, DOI 10.1016/j.csm.2004.04.001; Lovell Mark R, 2002, Curr Sports Med Rep, V1, P7; Lowe C, 1998, NEUROPSYCHOLOGIA, V36, P915, DOI 10.1016/S0028-3932(98)00036-0; Lundqvist A, 2000, APPL COGNITIVE PSYCH, V14, P135, DOI 10.1002/(SICI)1099-0720(200003/04)14:2<135::AID-ACP628>3.0.CO;2-S; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Maerlender A, 2010, CLIN NEUROPSYCHOL, V24, P1309, DOI 10.1080/13854046.2010.516072; Marcotte TD., 2010, NEUROPSYCHOLOGY PRED, P5; Maruff P, 2004, DEMENT GERIATR COGN, V18, P342, DOI 10.1159/000080229; Maruff P, 2009, ARCH CLIN NEUROPSYCH, V24, P165, DOI 10.1093/arclin/acp010; Mataix-Cols David, 2002, Appl Neuropsychol, V9, P117, DOI 10.1207/S15324826AN0902_8; Matheis RJ, 2007, CLIN NEUROPSYCHOL, V21, P146, DOI 10.1080/13854040601100668; Mayhew DR, 2011, J SAFETY RES, V42, P267, DOI 10.1016/j.jsr.2011.06.004; McGough EL, 2011, PHYS THER, V91, P1198, DOI 10.2522/ptj.20100372; McKinlay A, 2009, APPL NEUROPSYCHOL, V16, P177, DOI 10.1080/09084280903098661; MORRIS RG, 1988, J NEUROL NEUROSUR PS, V51, P757, DOI 10.1136/jnnp.51.6.757; Mullen NW, 2010, AM J OCCUP THER, V64, P288, DOI 10.5014/ajot.64.2.288; Nichols S, 2002, APPL ERGON, V33, P251, DOI 10.1016/S0003-6870(02)00020-0; Noyes JM, 2008, ERGONOMICS, V51, P1352, DOI 10.1080/00140130802170387; Noyes JM, 2003, COMPUT HUM BEHAV, V19, P579, DOI 10.1016/S0747-5632(03)00002-5; Nunes PV, 2008, INT J GERIATR PSYCH, V23, P1127, DOI 10.1002/gps.2038; O'Connell H, 2004, INT J GERIATR PSYCH, V19, P1207, DOI 10.1002/gps.1180; Osher Y, 2011, PSYCHOTHER PSYCHOSOM, V80, P298, DOI 10.1159/000324508; Parsons TD, 2008, CYBERPSYCHOL BEHAV, V11, P17, DOI 10.1089/cpb.2007.9934; Parsons TD, 2007, CHILD NEUROPSYCHOL, V13, P363, DOI 10.1080/13825580600943473; Parsons Thomas D, 2012, Stud Health Technol Inform, V173, P331; Parsons TD, 2011, STUD HEALTH TECHNOL, V163, P433, DOI 10.3233/978-1-60750-706-2-433; Parsons TD, 2008, STUD HEALTH TECHNOL, V132, P351; Patomella AH, 2006, J REHABIL MED, V38, P273, DOI 10.1080/16501970600632594; Pietrzak RH, 2008, ARCH CLIN NEUROPSYCH, V23, P433, DOI 10.1016/j.acn.2008.03.002; PUGNETTI L, 1995, COMPUT BIOL MED, V25, P213, DOI 10.1016/0010-4825(94)00040-W; Rajendran G, 2011, J AUTISM DEV DISORD, V41, P1445, DOI 10.1007/s10803-010-1151-3; Rand D, 2009, NEUROPSYCHOL REHABIL, V19, P583, DOI 10.1080/09602010802469074; Rashidi P, 2011, IEEE T KNOWL DATA EN, V23, P527, DOI 10.1109/TKDE.2010.148; Raspelli S, 2010, STUD HEALTH TECHNOL, V154, P115, DOI 10.3233/978-1-60750-561-7-115; Reeves DL, 2007, ARCH CLIN NEUROPSYCH, V22, pS15, DOI 10.1016/j.acn.2006.10.013; Retzlaff P. D., 2000, CLIN GUIDE NEUROPSYC, P277; Riva G, 2003, METHOD INFORM MED, V42, P524; Rizzo AA, 2006, CNS SPECTRUMS, V11, P35, DOI 10.1017/S1092852900024196; Rizzo AA, 1997, ST HEAL T, V44, P123; Rizzo M, 2001, ALZ DIS ASSOC DIS, V15, P10, DOI 10.1097/00002093-200101000-00002; Robbins TW, 1998, J INT NEUROPSYCH SOC, V4, P474, DOI 10.1017/s1355617798455073; ROBBINS TW, 1994, DEMENTIA, V5, P266, DOI 10.1159/000106735; ROSSER A, 1994, J NEUROL NEUROSUR PS, V57, P1389, DOI 10.1136/jnnp.57.11.1389; SAHAKIAN BJ, 1992, J ROY SOC MED, V85, P399; SAHAKIAN BJ, 1988, BRAIN, V111, P695, DOI 10.1093/brain/111.3.695; Sahgal A, 1991, DEMENTIA, V2, P150; Salnaitis CL, 2011, APPL NEUROPSYCHOL, V18, P37, DOI 10.1080/09084282.2010.523381; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2002, J HEAD TRAUMA REHAB, V17, P395, DOI 10.1097/00001199-200210000-00003; Schmitter-Edgecombe M, 2013, POSITIVE NEUROPSYCHO; Schultheis MT, 2007, ASSIST TECHNOL, V19, P1, DOI 10.1080/10400435.2007.10131860; Schultheis Maria T, 2006, Conf Proc IEEE Eng Med Biol Soc, V2006, P4921; Schultheis MT, 2009, ARCH PHYS MED REHAB, V90, P975, DOI 10.1016/j.apmr.2008.12.017; Schweiger A, 2007, J CLIN EXP NEUROPSYC, V29, P100, DOI 10.1080/13803390500519738; Seelye Adriana M, 2012, IEEE Rev Biomed Eng, V5, P29, DOI 10.1109/RBME.2012.2196691; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Shiffman S, 2008, ANNU REV CLIN PSYCHO, V4, P1, DOI 10.1146/annurev.clinpsy.3.022806.091415; Singla G, 2010, J AMB INTEL HUM COMP, V1, P57, DOI 10.1007/s12652-009-0007-1; Smyth J. M., 2003, J HAPPINESS STUD, V4, P35, DOI [10.1023/A:1023657221954, DOI 10.1023/A:1023657221954]; Stanley KG, 2011, ANN FAM MED, V9, P296, DOI 10.1370/afm.1292; Steinmetz JP, 2010, PSYCHOL ASSESSMENT, V22, P199, DOI 10.1037/a0017661; Stone Arthur S., 1994, Annals of Behavioral Medicine, V16, P199; Suchy Y, 2011, J CLIN EXP NEUROPSYC, V33, P92, DOI 10.1080/13803395.2010.493148; Suchy Y, 2010, J GERONTOL B-PSYCHOL, V65, P542, DOI 10.1093/geronb/gbq037; Tien Allen Y., 1996, Kaohsiung Journal of Medical Sciences, V12, P479; Tun PA, 2010, PSYCHOL AGING, V25, P560, DOI 10.1037/a0019543; Vincent AS, 2012, MIL MED, V177, P256, DOI 10.7205/MILMED-D-11-00289; Wald J, 2000, Stud Health Technol Inform, V70, P365; Wang Y, 2010, ERGONOMICS, V53, P404, DOI 10.1080/00140130903464358; Wild K, 2008, ALZHEIMERS DEMENT, V4, P428, DOI 10.1016/j.jalz.2008.07.003; Wild KV, 2012, ALZHEIMERS DEMENT, V8, P544, DOI 10.1016/j.jalz.2011.12.008; Williams DJ, 2007, COMPUT HUM BEHAV, V23, P258, DOI 10.1016/j.chb.2004.10.011; Winkel-Witlox ACMT, 2008, DISABIL REHABIL, V30, P1386, DOI 10.1080/09638280701623000; Zhang L, 2003, ARCH PHYS MED REHAB, V84, P1118, DOI 10.1016/S0003-9993(03)00203-X; Zhang L, 2001, AM J PHYS MED REHAB, V80, P597, DOI 10.1097/00002060-200108000-00010	147	76	77	7	62	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	NOV 1	2013	27	8					1328	1361		10.1080/13854046.2013.834971			34	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	273KW	WOS:000328534700009	24041037	Green Accepted			2021-06-18	
J	Leigh, R; Oishi, K; Hsu, J; Lindquist, M; Gottesman, RF; Jarso, S; Crainiceanu, C; Mori, S; Hillis, AE				Leigh, Richard; Oishi, Kenichi; Hsu, John; Lindquist, Martin; Gottesman, Rebecca F.; Jarso, Samson; Crainiceanu, Ciprian; Mori, Susumu; Hillis, Argye E.			Acute lesions that impair affective empathy	BRAIN			English	Article						empathy; stroke; emotion perception; magnetic resonance imaging; prosody	VENTROMEDIAL PREFRONTAL CORTEX; TRAUMATIC BRAIN-INJURY; FRONTOTEMPORAL DEMENTIA; EMOTIONAL EMPATHY; COGNITIVE EMPATHY; TEMPOROPARIETAL JUNCTION; AFFECTIVE PROSODY; MIND; DEFICITS; DISSOCIATION	Functional imaging studies of healthy participants and previous lesion studies have provided evidence that empathy involves dissociable cognitive functions that rely on at least partially distinct neural networks that can be individually impaired by brain damage. These studies converge in support of the proposal that affective empathy-making inferences about how another person feels-engages at least the following areas: prefrontal cortex, orbitofrontal gyrus, anterior insula, anterior cingulate cortex, temporal pole, amygdala and temporoparietal junction. We hypothesized that right-sided lesions to any one of these structures, except temporoparietal junction, would cause impaired affective empathy (whereas bilateral damage to temporoparietal junction would be required to disrupt empathy). We studied 27 patients with acute right hemisphere ischaemic stroke and 24 neurologically intact inpatients on a test of affective empathy. Acute impairment of affective empathy was associated with infarcts in the hypothesized network, particularly temporal pole and anterior insula. All patients with impaired affective empathy were also impaired in comprehension of affective prosody, but many patients with impairments in prosodic comprehension had spared affective empathy. Patients with impaired affective empathy were older, but showed no difference in performance on tests of hemispatial neglect, volume of infarct or sex distribution compared with patients with intact affective empathy.	[Leigh, Richard; Gottesman, Rebecca F.; Hillis, Argye E.] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; [Leigh, Richard; Oishi, Kenichi; Hsu, John; Jarso, Samson; Mori, Susumu] Johns Hopkins Univ, Sch Med, Dept Radiol, Baltimore, MD 21205 USA; [Lindquist, Martin; Gottesman, Rebecca F.; Crainiceanu, Ciprian] Johns Hopkins Univ, Dept Biostat, Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA; [Hillis, Argye E.] Johns Hopkins Univ, Sch Med, Dept Phys Med & Rehabil, Baltimore, MD USA; [Hillis, Argye E.] Johns Hopkins Univ, Dept Cognit Sci, Krieger Sch Arts & Sci, Baltimore, MD 21218 USA	Hillis, AE (corresponding author), Johns Hopkins Univ Hosp, Dept Neurol, Meyer 6-113,600 North Wolfe St, Baltimore, MD 21287 USA.	argye@JHMI.edu	Leigh, Richard/K-8401-2013; Oishi, Kenichi/H-1371-2013; Gottesman, Rebecca/ABA-8468-2020	Leigh, Richard/0000-0002-8285-1815; Oishi, Kenichi/0000-0002-1200-8611; 	National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [RO1NS47691]; Yousem Family Research Fund; NICHDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD065955]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD065955] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [P41EB015909] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS047691] Funding Source: NIH RePORTER	This work was supported by: National Institute of Neurological Disorders and Stroke, RO1NS47691 (to A. E. H.), and The Yousem Family Research Fund and NICHD R01 HD065955 (to K.O.).	Balconi M, 2012, APPL PSYCHOPHYS BIOF, V37, P161, DOI 10.1007/s10484-012-9188-z; Bodini B, 2004, CURR OPIN NEUROL, V17, P55, DOI 10.1097/00019052-200402000-00010; Brune M, 2006, NEUROSCI BIOBEHAV R, V30, P437, DOI 10.1016/j.neubiorev.2005.08.001; Brunnlieb C, 2013, BRAIN RES, V1499, P29, DOI 10.1016/j.brainres.2013.01.009; Bzdok D, 2012, BRAIN STRUCT FUNCT, V217, P783, DOI 10.1007/s00429-012-0380-y; Carr L, 2003, P NATL ACAD SCI USA, V100, P5497, DOI 10.1073/pnas.0935845100; Caviness VS, 2002, STROKE, V33, P2549, DOI 10.1161/01.STR.0000036083.90045.08; Corbetta M, 2008, NEURON, V58, P306, DOI 10.1016/j.neuron.2008.04.017; Couto B, 2013, CORTEX, V49, P1420, DOI 10.1016/j.cortex.2012.08.006; Cox CL, 2012, SOC COGN AFFECT NEUR, V7, P727, DOI 10.1093/scan/nsr051; Dara C, 2012, NEUROCASE; DAVIS MH, 1983, J PERS SOC PSYCHOL, V44, P113, DOI 10.1037/0022-3514.44.1.113; de Waal FBM, 2012, SCIENCE, V336, P874, DOI 10.1126/science.1220999; Decety J, 2003, CONSCIOUS COGN, V12, P577, DOI 10.1016/S1053-8100(03)00076-X; Decety J, 2007, NEUROSCIENTIST, V13, P580, DOI 10.1177/1073858407304654; Decety Jean, 2004, Behav Cogn Neurosci Rev, V3, P71, DOI 10.1177/1534582304267187; Dziobek I, 2008, J AUTISM DEV DISORD, V38, P464, DOI 10.1007/s10803-007-0486-x; Eslinger PJ, 2011, J NEUROPSYCH CLIN N, V23, P74, DOI 10.1176/appi.neuropsych.23.1.74; Eslinger PJ, 2005, J NEUROL NEUROSUR PS, V76, P1630, DOI 10.1136/jnnp.2004.053157; Eslinger PJ, 1998, EUR NEUROL, V39, P193, DOI 10.1159/000007933; Fellows LK, 2005, J COGNITIVE NEUROSCI, V17, P850, DOI 10.1162/0898929054021139; Finley A, 2003, STROKE, V34, P259; Gorno-Tempini ML, 2001, NEUROIMAGE, V14, P465, DOI 10.1006/nimg.2001.0811; Gu XS, 2012, BRAIN, V135, P2726, DOI 10.1093/brain/aws199; Hurlemann R, 2010, J NEUROSCI, V30, P4999, DOI 10.1523/JNEUROSCI.5538-09.2010; Hynes CA, 2006, NEUROPSYCHOLOGIA, V44, P374, DOI 10.1016/j.neuropsychologia.2005.06.011; Jimura K, 2010, BRAIN RES, V1328, P104, DOI 10.1016/j.brainres.2010.03.016; Kipps CM, 2006, SOC NEUROSCI-UK, V1, P235, DOI 10.1080/17470910600989847; Lamm C, 2011, NEUROIMAGE, V54, P2492, DOI 10.1016/j.neuroimage.2010.10.014; Lee J, 2011, PSYCHOL MED, V41, P2297, DOI 10.1017/S0033291711000614; Lee SE, 2012, NEUROCASE, V18, P305, DOI 10.1080/13554794.2011.604637; Leopold A, 2012, SOC COGN AFFECT NEUR, V7, P871, DOI 10.1093/scan/nsr071; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; Narvid J, 2009, NEUROCASE, V15, P190, DOI 10.1080/13554790802632967; Neumann D, 2012, ARCH PHYS MED REHAB, V93, P1414, DOI 10.1016/j.apmr.2012.03.009; Oishi K, 2009, NEUROIMAGE, V46, P486, DOI 10.1016/j.neuroimage.2009.01.002; Ota H, 2001, NEUROLOGY, V57, P2064, DOI 10.1212/WNL.57.11.2064; Rankin KP, 2006, BRAIN, V129, P2945, DOI 10.1093/brain/awl254; Rankin KP, 2005, COGN BEHAV NEUROL, V18, P28, DOI 10.1097/01.wnn.0000152225.05377.ab; Roldan Gerschcovich E, 2011, NEUROCASE, V17, P270, DOI 10.1080/13554791003730618; Ross ED, 1997, BRAIN LANG, V56, P27, DOI 10.1006/brln.1997.1731; Ross ED, 2008, BRAIN LANG, V104, P51, DOI 10.1016/j.bandl.2007.04.007; Samson D, 2005, BRAIN, V128, P1102, DOI 10.1093/brain/awh464; Samson D, 2004, NAT NEUROSCI, V7, P499, DOI 10.1038/nn1223; Samson D, 2007, NEUROPSYCHOLOGIA, V45, P2561, DOI 10.1016/j.neuropsychologia.2007.03.013; Saxe R, 2004, ANNU REV PSYCHOL, V55, P87, DOI 10.1146/annurev.psych.55.090902.142044; Saxe R, 2003, NEUROIMAGE, V19, P1835, DOI 10.1016/S1053-8119(03)00230-1; Schnell K, 2011, NEUROIMAGE, V54, P1743, DOI 10.1016/j.neuroimage.2010.08.024; Sebastian CL, 2012, SOC COGN AFFECT NEUR, V7, P53, DOI 10.1093/scan/nsr023; Shamay-Tsoory SG, 2005, COGN BEHAV NEUROL, V18, P55, DOI 10.1097/01.wnn.0000152228.90129.99; Shamay-Tsoory SG, 2003, J COGNITIVE NEUROSCI, V15, P324, DOI 10.1162/089892903321593063; Shamay-Tsoory SG, 2007, NEUROPSYCHOLOGIA, V45, P3054, DOI 10.1016/j.neuropsychologia.2007.05.021; Shamay-Tsoory SG, 2007, SCHIZOPHR RES, V90, P274, DOI 10.1016/j.schres.2006.09.020; Shamay-Tsoory SG, 2011, NEUROSCIENTIST, V17, P18, DOI 10.1177/1073858410379268; Shamay-Tsoory SG, 2009, BRAIN, V132, P617, DOI 10.1093/brain/awn279; Stone VE, 2003, NEUROPSYCHOLOGIA, V41, P209, DOI 10.1016/S0028-3932(02)00151-3; STOTLAND E, 1963, J ABNORM PSYCHOL, V66, P532, DOI 10.1037/h0042891; Stuss DT, 2004, BRAIN COGNITION, V55, P69, DOI 10.1016/s0278-2626(03)00271-9; Thompson-Schill SL, 1998, P NATL ACAD SCI USA, V95, P15855, DOI 10.1073/pnas.95.26.15855; Viskontas IV, 2007, ANN NY ACAD SCI, V1121, P528, DOI 10.1196/annals.1401.025	60	76	78	1	27	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	AUG	2013	136		8				2539	2549		10.1093/brain/awt177			11	Clinical Neurology; Neurosciences	Neurosciences & Neurology	190KG	WOS:000322338000024	23824490	Green Published			2021-06-18	
J	Bitner, BR; Marcano, DC; Berlin, JM; Fabian, RH; Cherian, L; Culver, JC; Dickinson, ME; Robertson, CS; Pautler, RG; Kent, TA; Tour, JM				Bitner, Brittany R.; Marcano, Daniela C.; Berlin, Jacob M.; Fabian, Roderic H.; Cherian, Leela; Culver, James C.; Dickinson, Mary E.; Robertson, Claudia S.; Pautler, Robia G.; Kent, Thomas A.; Tour, James M.			Antioxidant Carbon Particles Improve Cerebrovascular Dysfunction Following Traumatic Brain Injury	ACS NANO			English	Article						traumatic brain injury; cerebral blood flow; antioxidants; hydrophilic carbon clusters; nanoparticles	IN-VIVO; SUPEROXIDE-DISMUTASE; OXIDE NANOPARTICLES; OXIDATIVE STRESS; GRAPHENE OXIDE; NITRIC-OXIDE; RAT MODEL; CELLS; DRUG; CARBOXYFULLERENES	Injury to the neurovasculature is a feature of brain injury and must be addressed to maximize opportunity for improvement. Cerebrovascular dysfunction, manifested by reduction in cerebral blood flow (CBF), is a key factor that worsens outcome after traumatic brain injury (TBI), most notably under conditions of hypotension. We report here that a new class of antioxidants, poly(ethylene glycol)-functionalized hydrophilic carbon dusters (PEG-HCCs), which are nontoxic carbon particles, rapidly restore CBF in a mild TBI/hypotension/resuscitation rat model when administered during resuscitation-a clinically relevant time point. Along with restoration of CBE, there is a concomitant normalization of superoxide and nitric oxide levels. Given the role of poor CBF in determining outcome, this finding is of major importance for improving patient health under clinically relevant conditions during resuscitative care, and it has direct implications for the current TBI/hypotension war-fighter victims in the Afghanistan and Middle East theaters. The results also have relevancy in other related acute circumstances such as stroke and organ transplantation.	[Bitner, Brittany R.; Dickinson, Mary E.; Pautler, Robia G.; Kent, Thomas A.] Baylor Coll Med, Interdept Program Translat Biol & Mol Med, Houston, TX 77030 USA; [Bitner, Brittany R.; Culver, James C.; Dickinson, Mary E.; Pautler, Robia G.] Baylor Coll Med, Dept Mol Physiol & Biophys, Houston, TX 77030 USA; [Marcano, Daniela C.; Berlin, Jacob M.; Tour, James M.] Rice Univ, Dept Chem, Houston, TX 77005 USA; [Marcano, Daniela C.; Berlin, Jacob M.; Tour, James M.] Rice Univ, Smalley Inst Nanoscale Sci & Technol, Houston, TX 77005 USA; [Fabian, Roderic H.; Cherian, Leela; Robertson, Claudia S.] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; [Fabian, Roderic H.; Kent, Thomas A.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA; [Kent, Thomas A.] Michael E DeBakey VA Med Ctr, Houston, TX 77030 USA	Kent, TA (corresponding author), Baylor Coll Med, Interdept Program Translat Biol & Mol Med, 1 Baylor Plaza, Houston, TX 77030 USA.	tkent@bcm.edu; tour@rice.edu	Nanozymes, Nanozymes/D-8197-2019	Tour, James/0000-0002-8479-9328; Kent, Thomas/0000-0002-9877-7584; Marcano, Daniela C./0000-0002-3446-8010	Mission Connect Mild Traumatic Brain Injury Consortium; Department of DefenseUnited States Department of Defense [W81XWH-08-2-0141, W81XWH-08-2-0143, W81XWH-08-2-0132]; Alliance for NanoHealth through University of Texas Health Science Center, Houston (Department of Defense) [W8XWH-07-2-0101]; Nanoscale Science and Engineering Initiative of the National Science Foundation under NSF through the NSF Center for Biological and Environmental Nanotechnology [EEC-0647452]; National Science FoundationNational Science Foundation (NSF) [Track 2, 0440525]; BCM DERC [P30DK079638-02]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 HL095586]; BCM Cytometry and Cell Sorting Core; NIH (NCRR)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [S10RR024574, NIAID AI036211, NCI P30CA125123]; NIH from the National Heart, Lung, and Blood InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [T32 HL007676]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30CA125123] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [S10RR024574] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL095586, T32HL007676] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [P30AI036211] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [P30DK079638] Funding Source: NIH RePORTER	Funding was provided by the Mission Connect Mild Traumatic Brain Injury Consortium, funded by the Department of Defense: W81XWH-08-2-0141, W81XWH-08-2-0143, and W81XWH-08-2-0132. We also thank the support of the Alliance for NanoHealth through a subcontract from the University of Texas Health Science Center, Houston (Department of Defense: W8XWH-07-2-0101); Nanoscale Science and Engineering Initiative of the National Science Foundation under NSF Award EEC-0647452 for funding through the NSF Center for Biological and Environmental Nanotechnology; the Graduate Fellows in K-12 education at Baylor College of Medicine, funded by the National Science Foundation (Track 2, 0440525); the BCM DERC Pilot and Feasibility Award (P30DK079638-02); NIH R01 HL095586; the BCM Cytometry and Cell Sorting Core with funding from the NIH (NCRR Grant S10RR024574, NIAID AI036211, and NCI P30CA125123); and an NIH Training Grant from the National Heart, Lung, and Blood Institute (T32 HL007676).	Ali SS, 2008, NANOMED-NANOTECHNOL, V4, P283, DOI 10.1016/j.nano.2008.05.003; Ali SS, 2004, FREE RADICAL BIO MED, V37, P1191, DOI 10.1016/j.freeradbiomed.2004.07.002; Ansari MA, 2008, J NEUROTRAUM, V25, P513, DOI 10.1089/neu.2007.0451; Aykin-Burns N, 2009, BIOCHEM J, V418, P29, DOI 10.1042/BJ20081258; Berlin JM, 2010, ACS NANO, V4, P4621, DOI 10.1021/nn100975c; Butcher I, 2007, J NEUROTRAUM, V24, P294, DOI 10.1089/neu.2006.0032; Das M, 2007, BIOMATERIALS, V28, P1918, DOI 10.1016/j.biomaterials.2006.11.036; Dewitt DS, 2003, J NEUROTRAUM, V20, P795, DOI 10.1089/089771503322385755; Dugan LL, 2001, PARKINSONISM RELAT D, V7, P243, DOI 10.1016/S1353-8020(00)00064-X; Dugan LL, 1997, P NATL ACAD SCI USA, V94, P9434, DOI 10.1073/pnas.94.17.9434; FABIAN RH, 1995, J CEREBR BLOOD F MET, V15, P242, DOI 10.1038/jcbfm.1995.30; Fabian RH, 2008, AM J PHYSIOL-HEART C, V295, pH1809, DOI 10.1152/ajpheart.00301.2007; Girase B, 2012, ADV ENG MATER, V14, pB101, DOI 10.1002/adem.201180028; Halliwell B, 1996, ANNU REV NUTR, V16, P33, DOI 10.1146/annurev.nu.16.070196.000341; Hampel S, 2008, NANOMEDICINE-UK, V3, P175, DOI 10.2217/17435889.3.2.175; Han D, 2001, BIOCHEM J, V353, P411, DOI 10.1042/0264-6021:3530411; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Hirst SM, 2009, SMALL, V5, P2848, DOI 10.1002/smll.200901048; Huang ST, 2008, BIOORGAN MED CHEM, V16, P8619, DOI 10.1016/j.bmc.2008.08.004; KEHRER JP, 1993, CRIT REV TOXICOL, V23, P21, DOI 10.3109/10408449309104073; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; Liu Z, 2008, J AM CHEM SOC, V130, P10876, DOI 10.1021/ja803688x; Lo EH, 2008, BRIT J PHARMACOL, V153, pS396, DOI 10.1038/sj.bjp.0707626; Lucente-Schultz RM, 2009, J AM CHEM SOC, V131, P3934, DOI 10.1021/ja805721p; Lv M, 2012, NANOSCALE, V4, P3861, DOI 10.1039/c2nr30407d; Makarova EG, 2012, J NANOSCI NANOTECHNO, V12, P119, DOI 10.1166/jnn.2012.5709; Marcano D. C., J NEUROTRAU IN PRESS; Marklund N, 2001, J CEREBR BLOOD F MET, V21, P1259, DOI 10.1097/00004647-200111000-00002; Martin R, 2010, ACS NANO, V4, P6957, DOI 10.1021/nn1019412; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MONTESANO R, 1990, CELL, V62, P435, DOI 10.1016/0092-8674(90)90009-4; MUIZELAAR JP, 1993, J NEUROSURG, V78, P375, DOI 10.3171/jns.1993.78.3.0375; Murakami T, 2008, NANOMEDICINE-UK, V3, P453, DOI 10.2217/17435889.3.4.453; Nakamura M, 2011, NANOTECHNOLOGY, V22, DOI 10.1088/0957-4484/22/46/465102; Navarro JC, 2012, J NEUROTRAUM, V29, P322, DOI 10.1089/neu.2011.1979; PAULSON OB, 1990, CEREBROVAS BRAIN MET, V2, P161; Quick KL, 2008, NEUROBIOL AGING, V29, P117, DOI 10.1016/j.neurobiolaging.2006.09.014; Sano D, 2012, ACS NANO, V6, P2497, DOI 10.1021/nn204885f; Schubert D, 2006, BIOCHEM BIOPH RES CO, V342, P86, DOI 10.1016/j.bbrc.2006.01.129; Toda N, 2009, PHARMACOL REV, V61, P62, DOI 10.1124/pr.108.000547; Wang XY, 1999, PROG LIPID RES, V38, P309, DOI 10.1016/S0163-7827(99)00008-9; Yudoh K, 2009, INT J NANOMED, V4, P217; Zhang Y, 2010, DRUG DISCOV TODAY, V15, P428, DOI 10.1016/j.drudis.2010.04.005	43	76	76	7	71	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	1936-0851	1936-086X		ACS NANO	ACS Nano	SEP	2012	6	9					8007	8014		10.1021/nn302615f			8	Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science, Multidisciplinary	Chemistry; Science & Technology - Other Topics; Materials Science	009QP	WOS:000309040600051	22866916	Green Accepted			2021-06-18	
J	Spitz, G; Ponsford, JL; Rudzki, D; Maller, JJ				Spitz, Gershon; Ponsford, Jennie L.; Rudzki, Dion; Maller, Jerome J.			Association Between Cognitive Performance and Functional Outcome Following Traumatic Brain Injury: A Longitudinal Multilevel Examination	NEUROPSYCHOLOGY			English	Article						TBI; cognition; functional outcome	SEVERE HEAD-INJURY; RECOVERY; PRODUCTIVITY; REHABILITATION; PREDICTORS; INTEGRATION; SEVERITY; BATTERY; RETURN; TBI	Objective: Individuals' cognitive abilities predict functional outcomes following traumatic brain injury (TBI). However, it is not known to what extent concurrent cognitive abilities affect the magnitude or the rate of functional recovery. The current study modeled the progression of functional outcome as it related to background, injury severity, and cognitive variables over the first year postinjury. Method: This study comprised 111 individuals with moderate-to-severe TBI assessed on average at 3, 6, and 13 months postinjury. In addition, 79 healthy controls were assessed at a single time point. Each assessment consisted of an administration of a neuropsychological battery-comprising measures of memory, information processing speed, and executive functions-as well as an administration of the Mayo-Portland Adaptability Inventory to examine functional outcomes. Results: Older age, lower levels of education, and greater days of posttraumatic amnesia were associated with poorer functional outcomes. The addition of cognitive variables resulted in better models than simply considering background and injury severity variables. However, the results showed that the model comprising executive functions best characterized the progression of functional outcomes. Conclusions: The findings indicate that consideration of cognitive ability, rather than reliance on demographic and injury severity variables, provide a more accurate representation of functional outcome over the first year postinjury. In addition, the results suggest that specific cognitive domains, particularly executive functions, are likely to have the strongest effect on functional outcomes.	[Spitz, Gershon; Ponsford, Jennie L.] Monash Univ, Sch Psychol & Psychiat, Melbourne, Vic 3004, Australia; [Spitz, Gershon; Ponsford, Jennie L.] Epworth Med Fdn, Monash Epworth Rehabil Res Ctr, Melbourne, Vic, Australia; [Maller, Jerome J.] Monash Univ, Cent Clin Sch, Melbourne, Vic 3004, Australia; [Maller, Jerome J.] Alfred Hosp, Monash Alfred Psychiat Res Ctr, Melbourne, Vic, Australia	Spitz, G (corresponding author), Monash Univ, Sch Psychol & Psychiat, Clayton, Vic 3800, Australia.	Gershon.Spitz@monash.edu	Spitz, Gershon/H-7755-2014; Maller, Jerome J/H-4963-2014	Spitz, Gershon/0000-0002-7810-1480; Maller, Jerome J/0000-0003-4685-1508			Atchison TB, 2004, CLIN NEUROPSYCHOL, V18, P249, DOI 10.1080/13854040490501475; BECKER B, 1975, J CLIN PSYCHOL, V31, P307, DOI 10.1002/1097-4679(197504)31:2<307::AID-JCLP2270310231>3.0.CO;2-Y; Benton A., 1994, MULTILINGUAL APHASIA; Bercaw EL, 2011, CLIN NEUROPSYCHOL, V25, P72, DOI 10.1080/13854046.2010.532813; Boake C, 2001, ARCH PHYS MED REHAB, V82, P761, DOI 10.1053/apmr.2001.23753; Christensen BK, 2008, ARCH PHYS MED REHAB, V89, pS3, DOI 10.1016/j.apmr.2008.10.002; Chu BC, 2007, J CLIN EXP NEUROPSYC, V29, P617, DOI 10.1080/13803390600878893; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Draper K, 2008, NEUROPSYCHOLOGY, V22, P618, DOI 10.1037/0894-4105.22.5.618; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; DRUDGE OW, 1984, J CLIN PSYCHOL, V40, P259, DOI 10.1002/1097-4679(198401)40:1<259::AID-JCLP2270400149>3.0.CO;2-C; Fitzmaurice GM., 2004, APPL LONGITUDINAL AN; Green RE, 2008, ARCH PHYS MED REHAB, V89, pS51, DOI 10.1016/j.apmr.2008.09.552; Green RE, 2008, ARCH PHYS MED REHAB, V89, pS16, DOI 10.1016/j.apmr.2008.09.551; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P1030, DOI 10.1016/S0003-9993(99)90056-4; Hanks RA, 2008, ARCH PHYS MED REHAB, V89, P950, DOI 10.1016/j.apmr.2008.01.011; Johnson JB, 2004, TRENDS ECOL EVOL, V19, P101, DOI 10.1016/j.tree.2003.10.013; Kersel DA, 2001, BRAIN INJURY, V15, P283, DOI 10.1080/02699050010005887; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Malec JF., 1994, J HEAD TRAUMA REHAB, V9, P1, DOI [10. 1097/ 00001199- 199412000- 00003, DOI 10.1097/00001199-199412000-00003]; MANDLEBERG IA, 1976, J NEUROL NEUROSUR PS, V39, P1001, DOI 10.1136/jnnp.39.10.1001; MANDLEBERG IA, 1975, J NEUROL NEUROSUR PS, V38, P1121, DOI 10.1136/jnnp.38.11.1121; Millis S R, 1994, Int J Neurosci, V79, P165; Novack TA, 2000, BRAIN INJURY, V14, P987; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; Reitan R., 1988, HALSTEAD REITAN NEUR; Ross S R, 1997, Appl Neuropsychol, V4, P165, DOI 10.1207/s15324826an0403_4; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; Sigurdardottir S, 2009, J INT NEUROPSYCH SOC, V15, P740, DOI 10.1017/S1355617709990452; Singer J.D., 2003, APPL LONGITUDINAL DA; Sloan S., 2004, BRAIN IMPAIR, V5, P12, DOI DOI 10.1375/BRIM.5.1.12.35399; Smith A., 1982, SYMBOL DIGIT MODALIT; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Wilson BA, 1996, BEHAV ASSESSMENT DYS; Wong PP, 2001, BRAIN INJURY, V15, P519, DOI 10.1080/02699050010005995	39	76	79	0	33	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105			NEUROPSYCHOLOGY	Neuropsychology	SEP	2012	26	5					604	612		10.1037/a0029239			9	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	994ME	WOS:000307934100006	22799747				2021-06-18	
J	Demirtas-Tatlidede, A; Vahabzadeh-Hagh, AM; Bernabeu, M; Tormos, JM; Pascual-Leone, A				Demirtas-Tatlidede, Asli; Vahabzadeh-Hagh, Andrew M.; Bernabeu, Montserrat; Tormos, Jose M.; Pascual-Leone, Alvaro			Noninvasive Brain Stimulation in Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						DAI; diffuse axonal injury; LLLT; low-level laser therapy; rTMS; TBI; TBS; TCD; tDCS; theta burst stimulation; TMS; transcranial direct current stimulation; transcranial Doppler sonography; transcranial magnetic stimulation; traumatic brain injury	TRANSCRANIAL MAGNETIC STIMULATION; DIFFUSE AXONAL INJURY; HUMAN MOTOR CORTEX; SPINAL-CORD-INJURY; DORSOLATERAL PREFRONTAL CORTEX; EMITTING-DIODE IRRADIATION; MAJOR DEPRESSIVE DISORDER; THETA-BURST STIMULATION; EXCITATORY AMINO-ACIDS; ACUTE ISCHEMIC-STROKE	Objective: To review novel techniques of noninvasive brain stimulation (NBS), which may have value in assessment and treatment of traumatic brain injury (TBI). Methods: Review of the following techniques: transcranial magnetic stimulation, transcranial direct current stimulation, low-level laser therapy, and transcranial Doppler sonography. Furthermore, we provide a brief overview of TMS studies to date. Main findings: We describe the rationale for the use of these techniques in TBI, discuss their possible mechanisms of action, and raise a number of considerations relevant to translation of these methods to clinical use. Depending on the stimulation parameters, NBS may enable suppression of the acute glutamatergic hyperexcitability following TBI and/or counter the excessive GABAergic effects in the subacute stage. In the chronic stage, brain stimulation coupled to rehabilitation may enhance behavioral recovery, learning of new skills, and cortical plasticity. Correlative animal models and comprehensive safety trials seem critical to establish the use of these modalities in TBI. Conclusions: Different forms of NBS techniques harbor the promise of diagnostic and therapeutic utility, particularly to guide processes of cortical reorganization and enable functional restoration in TBI. Future lines of safety research and well-designed clinical trials in TBI are warranted to determine the capability of NBS to promote recovery and minimize disability.	[Demirtas-Tatlidede, Asli; Vahabzadeh-Hagh, Andrew M.; Pascual-Leone, Alvaro] Harvard Univ, Sch Med, Berenson Allen Ctr Noninvas Brain Stimulat, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; [Bernabeu, Montserrat; Tormos, Jose M.; Pascual-Leone, Alvaro] Univ Autonoma Barcelona, Guttmann Univ, Inst Neurorehabil, Badalona, Spain	Pascual-Leone, A (corresponding author), Harvard Univ, Sch Med, Berenson Allen Ctr Noninvas Brain Stimulat, Beth Israel Deaconess Med Ctr, 330 Brookline Ave,KS-158, Boston, MA 02215 USA.	apleone@bidmc.harvard.edu	Pascual-Leone, Alvaro/AAC-5101-2019; Pascual-Leone, Alvaro/G-6566-2011	Pascual-Leone, Alvaro/0000-0001-8975-0382; Demirtas-Tatlidede, MD, PhD, Asli/0000-0003-2050-5674; Tormos Munoz, Jose Maria/0000-0002-8764-2289	BBVA Translational Research Chair in BiomedicineBBVA Foundation; International Brain Research Foundation (IBRF); National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K 24 RR018875]; Instituto de Salud Carlos IIIInstituto de Salud Carlos IIIEuropean Commission [PI082004]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [K24RR018875] Funding Source: NIH RePORTER	Supported in part by a BBVA Translational Research Chair in Biomedicine, a grant from the International Brain Research Foundation (IBRF), and National Institutes of Health grant K 24 RR018875 to A. P. L., and grant PI082004 from the Instituto de Salud Carlos III. A.M.V.-H. is a Howard Hughes Medical Institute medical research training fellow.	Alexandrov AV, 2009, STROKE, V40, pS107, DOI 10.1161/STROKEAHA.108.530931; Bachtold MR, 1998, ULTRASOUND MED BIOL, V24, P557, DOI 10.1016/S0301-5629(98)00014-3; BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; Barba C, 2006, NEUROCASE, V12, P232, DOI 10.1080/13554790600878879; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Becerra GD, 2007, BEHAV BRAIN RES, V179, P118, DOI 10.1016/j.bbr.2007.01.024; Bellner J, 2004, SURG NEUROL, V62, P45, DOI 10.1016/j.surneu.2003.12.007; Bernabeu M, 2009, J NEUROTRAUM, V26, P2185, DOI 10.1089/neu.2008.0859; Bestmann S, 2008, TRENDS COGN SCI, V12, P81, DOI 10.1016/j.tics.2007.12.002; BLINC A, 1993, BLOOD, V81, P2636; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; Boggio PS, 2007, RESTOR NEUROL NEUROS, V25, P123; Boggio PS, 2006, NEUROSCI LETT, V404, P232, DOI 10.1016/j.neulet.2006.05.051; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Brighina F, 2003, NEUROSCI LETT, V336, P131, DOI 10.1016/S0304-3940(02)01283-1; Byrnes KR, 2005, LASER SURG MED, V36, P171, DOI 10.1002/lsm.20143; Calabresi P, 2003, LANCET NEUROL, V2, P622, DOI 10.1016/S1474-4422(03)00532-5; Centonze D, 2007, NEUROLOGY, V68, P1045, DOI 10.1212/01.wnl.0000257818.16952.62; Centonze D, 2005, J PSYCHIATR NEUROSCI, V30, P127; CHAN KH, 1992, J NEUROSURG, V77, P55, DOI 10.3171/jns.1992.77.1.0055; Chen R, 1997, ELECTROMYOGR MOTOR C, V105, P415, DOI 10.1016/S0924-980X(97)00036-2; Chew E, 2009, 5 WORLD C ISPRM 13 1; Chistyakov AV, 2001, J NEUROL NEUROSUR PS, V70, P580, DOI 10.1136/jnnp.70.5.580; Chistyakov AV, 1998, ACTA NEUROCHIR, V140, P467, DOI 10.1007/s007010050126; Chistyakov AV, 1999, CLIN NEUROPHYSIOL, V110, P1080, DOI 10.1016/S1388-2457(99)00029-2; Crossley M, 2005, BRAIN INJURY, V19, P729, DOI 10.1080/02699050400013733; Datta A, 2010, NEUROIMAGE, V52, P1268, DOI 10.1016/j.neuroimage.2010.04.252; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Di Lazzaro V, 2005, J PHYSIOL-LONDON, V565, P945, DOI 10.1113/jphysiol.2005.087288; Dockery CA, 2009, J NEUROSCI, V29, P7271, DOI 10.1523/JNEUROSCI.0065-09.2009; Soler MD, 2010, BRAIN, V133, P2565, DOI 10.1093/brain/awq184; Edwards DJ, 2009, RESTOR NEUROL NEUROS, V27, P199, DOI 10.3233/RNN-2009-0470; Eells JT, 2003, P NATL ACAD SCI USA, V100, P3439, DOI 10.1073/pnas.0534746100; Eggers J, 2005, NEUROLOGY, V64, P1052, DOI 10.1212/01.WNL.0000154599.45969.D6; Eggers R, 2009, ULTRASOUND MED BIOL, V35, P523, DOI 10.1016/j.ultrasmedbio.2008.09.009; ERB DE, 1991, EXP BRAIN RES, V83, P253; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fecteau S, 2007, J NEUROSCI, V27, P12500, DOI 10.1523/JNEUROSCI.3283-07.2007; Fecteau S, 2010, SUBST USE MISUSE, V45, P1766, DOI 10.3109/10826084.2010.482434; Ferrucci R, 2008, NEUROLOGY, V71, P493, DOI 10.1212/01.wnl.0000317060.43722.a3; Floel A, 2007, BRAIN RES REV, V53, P250, DOI 10.1016/j.brainresrev.2006.08.006; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; Forster C, 1999, ACTA NEUROPATHOL, V97, P215, DOI 10.1007/s004010050977; Fregni F, 2005, EXP BRAIN RES, V166, P23, DOI 10.1007/s00221-005-2334-6; Fregni F, 2005, NEUROREPORT, V16, P1551, DOI 10.1097/01.wnr.0000177010.44602.5e; Fregni F, 2006, COGN BEHAV NEUROL, V19, P21, DOI 10.1097/00146965-200603000-00003; Fregni F, 2007, LANCET NEUROL, V6, P188, DOI 10.1016/S1474-4422(07)70032-7; Fregni F, 2006, MOVEMENT DISORD, V21, P1693, DOI 10.1002/mds.21012; Fregni F, 2006, PAIN, V122, P197, DOI 10.1016/j.pain.2006.02.023; Fujiki M, 2006, NEUROSCI LETT, V405, P226, DOI 10.1016/j.neulet.2006.07.005; Gandiga PC, 2006, CLIN NEUROPHYSIOL, V117, P845, DOI 10.1016/j.clinph.2005.12.003; GARRAGHTY PE, 1991, SOMATOSENS MOT RES, V8, P347, DOI 10.3109/08990229109144757; George MS, 2010, ARCH GEN PSYCHIAT, V67, P507, DOI 10.1001/archgenpsychiatry.2010.46; George MS, 2010, NEUROPSYCHOPHARMACOL, V35, P301, DOI 10.1038/npp.2009.87; Hallett M, 2007, NEURON, V55, P187, DOI 10.1016/j.neuron.2007.06.026; Hesse S, 2007, RESTOR NEUROL NEUROS, V25, P9; Holtz ML, 2001, BRAIN RES, V898, P49, DOI 10.1016/S0006-8993(01)02140-0; Hoskison MM, 2009, NEUROSCIENCE, V159, P483, DOI 10.1016/j.neuroscience.2008.12.050; Huang YZ, 2005, NEURON, V45, P201, DOI 10.1016/j.neuron.2004.12.033; Hummel F, 2005, NEUROREHAB NEURAL RE, V19, P14, DOI 10.1177/1545968304272698; Ilic S, 2006, PHOTOMED LASER SURG, V24, P458, DOI 10.1089/pho.2006.24.458; Iyer MB, 2005, NEUROLOGY, V64, P872, DOI 10.1212/01.WNL.0000152986.07469.E9; Jaffres P, 2005, INTENS CARE MED, V31, P785, DOI 10.1007/s00134-005-2630-4; Jang SH, 2005, RESTOR NEUROL NEUROS, V23, P51; Janicak PG, 2008, J CLIN PSYCHIAT, V69, P222, DOI 10.4088/JCP.v69n0208; Jo JM, 2009, AM J PHYS MED REHAB, V88, P404, DOI 10.1097/PHM.0b013e3181a0e4cb; Karu T, 1999, J PHOTOCH PHOTOBIO B, V49, P1, DOI 10.1016/S1011-1344(98)00219-X; Karu TI, 2005, LASER SURG MED, V36, P307, DOI 10.1002/lsm.20148; KATSURA K, 1994, BIOCHEM SOC T, V22, P991, DOI 10.1042/bst0220991; Knoch D, 2006, J NEUROSCI, V26, P6469, DOI 10.1523/JNEUROSCI.0804-06.2006; Knoch D, 2008, CEREB CORTEX, V18, P1987, DOI 10.1093/cercor/bhm237; Kobayashi M, 2003, LANCET NEUROL, V2, P145, DOI 10.1016/S1474-4422(03)00321-1; Kobori N, 2006, J NEUROSCI, V26, P4236, DOI 10.1523/JNEUROSCI.4687-05.2006; Kristian T, 1998, STROKE, V29, P705, DOI 10.1161/01.STR.29.3.705; Lampl Y, 2007, STROKE, V38, P1843, DOI 10.1161/STROKEAHA.106.478230; Lang N, 2005, EUR J NEUROSCI, V22, P495, DOI 10.1111/j.1460-9568.2005.04233.x; Le Bihan D, 2001, J MAGN RESON IMAGING, V13, P534, DOI 10.1002/jmri.1076; Leung MCP, 2002, LASER SURG MED, V31, P283, DOI 10.1002/lsm.10096; Liebetanz D, 2002, BRAIN, V125, P2238, DOI 10.1093/brain/awf238; Lim W, 2007, LASER SURG MED, V39, P614, DOI 10.1002/lsm.20533; Litscher G, INTERNET J NEUROMONI; Lo EH, 2008, NAT MED, V14, P497, DOI 10.1038/nm1735; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Machii K, 2006, CLIN NEUROPHYSIOL, V117, P455, DOI 10.1016/j.clinph.2005.10.014; Madhavan S, 2011, EXP BRAIN RES, V209, P9, DOI 10.1007/s00221-010-2511-0; Martin Paula I., 2004, Seminars in Speech and Language, V25, P181; Meairs S, 2007, PROG BIOPHYS MOL BIO, V93, P354, DOI 10.1016/j.pbiomolbio.2006.07.019; Mochizuki-Oda N, 2002, NEUROSCI LETT, V323, P207, DOI 10.1016/S0304-3940(02)00159-3; Monti A, 2008, J NEUROL NEUROSUR PS, V79, P451, DOI 10.1136/jnnp.2007.135277; Moosavi SH, 1999, J NEUROL SCI, V164, P179, DOI 10.1016/S0022-510X(99)00065-9; Mori F, 2010, EUR J NEUROL, V17, P295, DOI 10.1111/j.1468-1331.2009.02806.x; Mori F, 2009, PROG BRAIN RES, V175, P429, DOI 10.1016/S0079-6123(09)17528-3; Naeser MA, 2005, BRAIN LANG, V93, P95, DOI 10.1016/j.bandl.2004.08.004; NAVEH N, 1990, J NEUROSCI RES, V26, P386, DOI 10.1002/jnr.490260316; Nedelmann M, 2008, ULTRASOUND MED BIOL, V34, P2019, DOI 10.1016/j.ultrasmedbio.2008.06.003; Nitsche MA, 2003, SUPPL CLIN NEUROPHYS, V56, P255; Nitsche MA, 2001, NEUROLOGY, V57, P1899, DOI 10.1212/WNL.57.10.1899; Nitsche MA, 2000, J PHYSIOL-LONDON, V527, P633, DOI 10.1111/j.1469-7793.2000.t01-1-00633.x; Nitsche MA, 2009, EXP NEUROL, V219, P14, DOI 10.1016/j.expneurol.2009.03.038; Nogawa S, 1997, J NEUROSCI, V17, P2746; O'Dell DM, 2000, BRAIN RES, V861, P325, DOI 10.1016/S0006-8993(00)02055-2; O'Reardon JP, 2007, BIOL PSYCHIAT, V62, P1208, DOI 10.1016/j.biopsych.2007.01.018; Oliveri M, 2001, NEUROLOGY, V57, P1338, DOI 10.1212/WNL.57.7.1338; Oron A, 2006, STROKE, V37, P2620, DOI 10.1161/01.STR.0000242775.14642.b8; PALMER AM, 1994, NEUROREPORT, V6, P153, DOI 10.1097/00001756-199412300-00039; Pape TLB, 2009, BRAIN STIMUL, V2, P22, DOI 10.1016/j.brs.2008.09.004; PARK CK, 1989, J CEREBR BLOOD F MET, V9, P617, DOI 10.1038/jcbfm.1989.88; Pascual JM, 2007, J NEUROTRAUM, V24, P944, DOI 10.1089/neu.2006.0190; Pascual-Leone A, 2005, ANNU REV NEUROSCI, V28, P377, DOI 10.1146/annurev.neuro.27.070203.144216; Pascual-Leone A., 2002, HDB TRANSCRANIAL MAG; PASCUALLEONE A, 1993, ELECTROEN CLIN NEURO, V89, P120, DOI 10.1016/0168-5597(93)90094-6; Paus T, 1997, J NEUROSCI, V17, P3178; Pierpaoli C, 1996, RADIOLOGY, V201, P637, DOI 10.1148/radiology.201.3.8939209; Poreisz C, 2007, BRAIN RES BULL, V72, P208, DOI 10.1016/j.brainresbull.2007.01.004; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Priori A, 2003, CLIN NEUROPHYSIOL, V114, P589, DOI 10.1016/S1388-2457(02)00437-6; PURPURA DP, 1965, J NEUROPHYSIOL, V28, P166; Raymont V, 2006, PROG BRAIN RES, V157, P199, DOI 10.1016/S0079-6123(06)57013-X; Reis J, 2008, J PHYSIOL-LONDON, V586, P325, DOI 10.1113/jphysiol.2007.144824; Ricci Raffaella, 2008, Ther Clin Risk Manag, V4, P1127; Ridding MC, 2007, NAT REV NEUROSCI, V8, P559, DOI 10.1038/nrn2169; RINALDI PC, 1991, BRAIN RES, V558, P36, DOI 10.1016/0006-8993(91)90711-4; Rioult-Pedotti MS, 1998, NAT NEUROSCI, V1, P230, DOI 10.1038/678; Robertson IH, 1999, PSYCHOL BULL, V125, P544, DOI 10.1037/0033-2909.125.5.544; Ropper AH, 2005, ADAMS VICTORS PRINCI; Rossi S, 2009, CLIN NEUROPHYSIOL, V120, P2008, DOI 10.1016/j.clinph.2009.08.016; Rossini PM, 2007, NEUROLOGY, V68, P484, DOI 10.1212/01.wnl.0000250268.13789.b2; Rotenberg A, 2008, 3 INT C TRANSCR MAGN; Rotenberg A, 2007, CLIN NEUROPHYSIOL, V118, P2536, DOI 10.1016/j.clinph.2007.08.003; Rotenberg A, 2009, CLIN NEUROPHYSIOL, V120, P1417, DOI 10.1016/j.clinph.2009.05.004; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Sack AT, 2007, CEREB CORTEX, V17, P2841, DOI 10.1093/cercor/bhm013; Sandrini M, 2008, NEUROPSYCHOLOGIA, V46, P2056, DOI 10.1016/j.neuropsychologia.2008.02.003; Shulga A, 2008, J NEUROSCI, V28, P6996, DOI 10.1523/JNEUROSCI.5268-07.2008; Silvanto J, 2008, BRAIN TOPOGR, V21, P1, DOI 10.1007/s10548-008-0067-0; Son AHPWV, 2007, CLIN REHABIL, V21, P1024, DOI 10.1177/0269215507077603; SORENSON SB, 1991, J HEAD TRAUMA REHAB, V6, P1, DOI DOI 10.1097/00001199-199106000-00003; Stern WM, 2007, J NEUROPSYCH CLIN N, V19, P179, DOI 10.1176/appi.neuropsych.19.2.179; STEWARD O, 1989, Journal of Neurotrauma, V6, P99, DOI 10.1089/neu.1989.6.99; STROEMER RP, 1995, STROKE, V26, P2135, DOI 10.1161/01.STR.26.11.2135; Syntichaki P, 2003, NAT REV NEUROSCI, V4, P672, DOI 10.1038/nrn1174; Takeuchi N, 2006, BRAIN INJURY, V20, P991, DOI 10.1080/02699050600909771; Tyler WJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003511; Valero-Cabre A, 2005, IEEE ENG MED BIOL, V24, P29, DOI 10.1109/MEMB.2005.1384097; Valero-Cabre A, 2007, EXP BRAIN RES, V176, P603, DOI 10.1007/s00221-006-0639-8; Vanderhasselt MA, 2006, EXP BRAIN RES, V172, P561, DOI 10.1007/s00221-006-0540-5; Vespa P, 2003, NEUROSURG FOCUS, V15, P1, DOI DOI 10.3171/foc.2003.15.6.4; Vykhodtseva N, 2008, ULTRASONICS, V48, P279, DOI 10.1016/j.ultras.2008.04.004; Wagner T, 2007, NEUROIMAGE, V35, P1113, DOI 10.1016/j.neuroimage.2007.01.027; Wagner T, 2007, ANNU REV BIOMED ENG, V9, P527, DOI 10.1146/annurev.bioeng.9.061206.133100; Wassermann EM, 1996, ELECTROMYOGR MOTOR C, V101, P412; Wassermann EM, 1998, EVOKED POTENTIAL, V108, P1, DOI 10.1016/S0168-5597(97)00096-8; Whelan HT, 2001, J CLIN LASER MED SUR, V19, P305, DOI 10.1089/104454701753342758; Williams JA, 2010, PHYS THER, V90, P398, DOI 10.2522/ptj.20090075; Yasokawa YT, 2007, J NEUROTRAUM, V24, P163, DOI 10.1089/neu.2006.0073; Yurkewicz L, 2005, J NEUROTRAUM, V22, P1428, DOI 10.1089/neu.2005.22.1428; Zhang Q, 2000, J BIOMED OPT, V5, P206, DOI 10.1117/1.429988; Zivin JA, 2009, STROKE, V40, P1359, DOI 10.1161/STROKEAHA.109.547547	160	76	80	0	45	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2012	27	4					274	292		10.1097/HTR.0b013e318217df55			19	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	975PJ	WOS:000306523000005	21691215	Green Accepted			2021-06-18	
J	Sparvero, LJ; Amoscato, AA; Dixon, CE; Long, JB; Kochanek, PM; Pitt, BR; Bayir, H; Kagan, VE				Sparvero, Louis J.; Amoscato, Andrew A.; Dixon, C. Edward; Long, Joseph B.; Kochanek, Patrick M.; Pitt, Bruce R.; Bayir, Huelya; Kagan, Valerian E.			Mapping of phospholipids by MALDI imaging (MALDI-MSI): realities and expectations	CHEMISTRY AND PHYSICS OF LIPIDS			English	Article						Lipidomics; MALDI imaging; Traumatic brain injury; Acute lung injury; Lipid peroxidation; Docosahexaenoic acid	LASER-DESORPTION-IONIZATION; MASS-SPECTROMETRIC CHARACTERIZATION; TRAUMATIC BRAIN-INJURY; OXIDATIVE LIPIDOMICS; ELECTROSPRAY-IONIZATION; STRUCTURAL-CHARACTERIZATION; SHOTGUN LIPIDOMICS; MOUSE MODEL; MATRIX; CARDIOLIPIN	Matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI) has emerged as a novel powerful MS methodology that has the ability to generate both molecular and spatial information within a tissue section. Application of this technology as a new type of biochemical lipid microscopy may lead to new discoveries of the lipid metabolism and biomarkers associated with area-specific alterations or damage under stress/disease conditions such as traumatic brain injury or acute lung injury, among others. However there are limitations in the range of what it can detect as compared with liquid chromatography-MS (LC-MS) of a lipid extract from a tissue section. The goal of the current work was to critically consider remarkable new opportunities along with the limitations and approaches for further improvements of MALDI-MSI. Based on our experimental data and assessments, improvements of the spectral and spatial resolution, sensitivity and specificity towards low abundance species of lipids are proposed. This is followed by a review of the current literature, including methodologies that other laboratories have used to overcome these challenges. (C) 2012 Elsevier Ireland Ltd. All rights reserved.	[Sparvero, Louis J.; Amoscato, Andrew A.; Bayir, Huelya; Kagan, Valerian E.] Ctr Free Rad & Antioxidant Hlth, Pittsburgh, PA 15213 USA; [Dixon, C. Edward; Kochanek, Patrick M.; Bayir, Huelya] Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA; [Sparvero, Louis J.; Amoscato, Andrew A.; Pitt, Bruce R.; Bayir, Huelya; Kagan, Valerian E.] Dept Environm & Occupat Hlth, Pittsburgh, PA 15213 USA; [Kochanek, Patrick M.; Bayir, Huelya] Dept Crit Care Med, Pittsburgh, PA 15213 USA; [Dixon, C. Edward] Univ Pittsburgh, Dept Neurosurg, Pittsburgh, PA 15213 USA; [Long, Joseph B.] Walter Reed Army Inst Res, Ctr Mil Psychiat & Neurosci, Silver Spring, MD 21910 USA	Sparvero, LJ (corresponding author), Univ Pittsburgh, Dept Environm & Occupat Hlth, Ctr Free Rad & Antioxidant Hlth, 100 Technol Dr,Suite 350, Pittsburgh, PA 15219 USA.	ljs39@pitt.edu; amoscatoaa@upmc.edu; dixoec@upmc.edu; joseph.long@us.army.mil; kochanekpm@ccm.upmc.edu; brucep@pitt.edu; bayihx@ccm.upmc.edu; kagan@pitt.edu	Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; Kagan, Valerian E./0000-0002-7245-1885; Amoscato, Andrew/0000-0002-1340-9150	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [U19AI068021, HL70755, HL094488, ES020693, ES021068, NS076511]; Cancer Center Support Grant (CCSG) [P30 CA047904]; NIOSHUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USANational Institute for Occupational Safety & Health (NIOSH) [OH008282]; US ArmyUnited States Department of Defense [W81XWH-09-2-0187]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30CA047904] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R37HL065697, R01HL070755, R01HL094488] Funding Source: NIH RePORTER; NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTHUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USANational Institute for Occupational Safety & Health (NIOSH) [R01OH008282] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [U19AI068021] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [R21ES021068, R01ES020693] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS061817, R01NS076511, P01NS030318, P50NS030318] Funding Source: NIH RePORTER	This study was supported in part by grants from NIH (U19AI068021, HL70755, HL094488, ES020693, ES021068, and NS076511); Cancer Center Support Grant (CCSG) P30 CA047904; NIOSH (OH008282) and the US Army (W81XWH-09-2-0187).	Aerni HR, 2006, ANAL CHEM, V78, P827, DOI 10.1021/ac051534r; Aizikov K, 2011, REV SCI INSTRUM, V82, DOI 10.1063/1.3594099; Angel PM, 2012, ANAL CHEM, V84, P1557, DOI 10.1021/ac202383m; Axelsen PH, 2010, J LIPID RES, V51, P660, DOI [10.1194/jlr.d001750, 10.1194/jlr.D001750]; Bayir H, 2007, ANN NEUROL, V62, P154, DOI 10.1002/ana.21168; Belayev L, 2009, STROKE, V40, P3121, DOI 10.1161/STROKEAHA.109.555979; Benabdellah F, 2010, ANAL BIOANAL CHEM, V396, P151, DOI 10.1007/s00216-009-3031-2; Bernhard W, 1997, AM J RESP CELL MOL, V17, P41, DOI 10.1165/ajrcmb.17.1.2594; Berry KAZ, 2011, CHEM REV, V111, P6491, DOI 10.1021/cr200280p; Berry KAZ, 2011, J LIPID RES, V52, P1551, DOI 10.1194/jlr.M015750; Boggio KJ, 2011, EXPERT REV PROTEOMIC, V8, P591, DOI [10.1586/EPR.11.53, 10.1586/epr.11.53]; Bouschen W, 2010, RAPID COMMUN MASS SP, V24, P355, DOI 10.1002/rcm.4401; Brunelle A, 2009, ANAL BIOANAL CHEM, V393, P31, DOI 10.1007/s00216-008-2367-3; Burnum KE, 2009, J LIPID RES, V50, P2290, DOI 10.1194/jlr.M900100-JLR200; Carter CL, 2011, J AM SOC MASS SPECTR, V22, P1991, DOI 10.1007/s13361-011-0227-4; Chaurand P, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.O110.004259; Crossman L, 2006, RAPID COMMUN MASS SP, V20, P284, DOI 10.1002/rcm.2259; Debois D, 2009, ANAL CHEM, V81, P2823, DOI 10.1021/ac900045m; Deininger SO, 2011, ANAL BIOANAL CHEM, V401, P167, DOI 10.1007/s00216-011-4929-z; Delvolve AM, 2011, J MASS SPECTROM, V46, P1046, DOI 10.1002/jms.1986; Delvolve AM, 2011, ANAL METHODS-UK, V3, P1729, DOI 10.1039/c1ay05107e; Domingues MRM, 2008, CHEM PHYS LIPIDS, V156, P1, DOI 10.1016/j.chemphyslip.2008.07.003; Eberlin LS, 2011, ANAL CHEM, V83, P8366, DOI 10.1021/ac202016x; Eberlin LS, 2011, BBA-MOL CELL BIOL L, V1811, P946, DOI 10.1016/j.bbalip.2011.05.006; Eibisch M, 2011, RAPID COMMUN MASS SP, V25, P2619, DOI 10.1002/rcm.5161; Fernandez JA, 2011, ANAL BIOANAL CHEM, V401, P29, DOI 10.1007/s00216-011-4696-x; Fernandez-Lima FA, 2011, ANAL CHEM, V83, P8448, DOI 10.1021/ac201481r; Fletcher JS, 2011, MASS SPECTROM REV, V30, P142, DOI 10.1002/mas.20275; Fuchs B, 2011, CHEM PHYS LIPIDS, V164, P782, DOI 10.1016/j.chemphyslip.2011.09.006; Fuchs B, 2010, PROG LIPID RES, V49, P450, DOI 10.1016/j.plipres.2010.07.001; Garrett TJ, 2007, INT J MASS SPECTROM, V260, P166, DOI 10.1016/j.ijms.2006.09.019; Garrett TJ, 2010, METHODS MOL BIOL, V656, P209, DOI 10.1007/978-1-60761-746-4_12; Girotti AW, 1998, J LIPID RES, V39, P1529; Goodwin RJA, 2011, RAPID COMMUN MASS SP, V25, P969, DOI 10.1002/rcm.4939; Goto-Inoue N, 2011, BBA-MOL CELL BIOL L, V1811, P961, DOI 10.1016/j.bbalip.2011.03.004; Greving MP, 2011, ANAL CHEM, V83, P2, DOI 10.1021/ac101565f; Gross JH, 2011, MASS SPECTROMETRY; Grove KJ, 2011, J AM SOC MASS SPECTR, V22, P192, DOI 10.1007/s13361-010-0013-8; Guichardant M, 2011, CHEM PHYS LIPIDS, V164, P544, DOI 10.1016/j.chemphyslip.2011.05.002; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Han XL, 2007, FRONT BIOSCI, V12, P2601, DOI 10.2741/2258; Han XL, 2012, MASS SPECTROM REV, V31, P134, DOI 10.1002/mas.20342; Hankin JA, 2007, J AM SOC MASS SPECTR, V18, P1646, DOI 10.1016/j.jasms.2007.06.010; Hankin JA, 2011, J AM SOC MASS SPECTR, V22, P1014, DOI 10.1007/s13361-011-0122-z; Hankin JA, 2010, ANAL CHEM, V82, P8476, DOI 10.1021/ac101079v; Hayasaka T, 2008, RAPID COMMUN MASS SP, V22, P3415, DOI 10.1002/rcm.3751; Hayasaka T, 2010, J AM SOC MASS SPECTR, V21, P1446, DOI 10.1016/j.jasms.2010.04.005; Hsu FF, 2005, J AM SOC MASS SPECTR, V16, P1510, DOI 10.1016/j.jasms.2005.04.018; Jackson SN, 2007, J MASS SPECTROM, V42, P1093, DOI 10.1002/jms.1245; Jackson SN, 2007, J AM SOC MASS SPECTR, V18, P17, DOI 10.1016/j.jasms.2006.08.015; Jackson SN, 2008, J AM SOC MASS SPECTR, V19, P1655, DOI 10.1016/j.jasms.2008.07.005; Jackson SN, 2005, ANAL CHEM, V77, P4523, DOI 10.1021/ac050276v; Johanson RA, 2007, ANAL BIOCHEM, V362, P155, DOI 10.1016/j.ab.2006.12.026; JOHNSON KJ, 1981, J CLIN INVEST, V67, P983, DOI 10.1172/JCI110149; Jurchen JC, 2005, J AM SOC MASS SPECTR, V16, P1654, DOI 10.1016/j.jasms.2005.06.006; Kagan VE, 2005, NAT CHEM BIOL, V1, P223, DOI 10.1038/nchembio727; Kaneko Y, 2011, EXP MOL PATHOL, V91, P614, DOI 10.1016/j.yexmp.2011.07.002; Kertesz V, 2010, J MASS SPECTROM, V45, P252, DOI 10.1002/jms.1709; Kiebish MA, 2008, J LIPID RES, V49, P2545, DOI 10.1194/jlr.M800319-JLR200; Kim J, 2011, J LIPID RES, V52, P125, DOI 10.1194/jlr.M010520; Kim Y, 2010, EXP MOL MED, V42, P1, DOI 10.3858/emm.2010.42.1.001; Kiss A, 2011, ANAL BIOANAL CHEM, V399, P2623, DOI 10.1007/s00216-010-4644-1; Koeniger SL, 2011, RAPID COMMUN MASS SP, V25, P503, DOI 10.1002/rcm.4891; Koizumi S, 2010, NEUROSCIENCE, V168, P219, DOI 10.1016/j.neuroscience.2010.03.056; Korytowski W, 2011, J BIOL CHEM, V286, P26334, DOI 10.1074/jbc.M110.188516; Lagarrigue M, 2012, BIOL REPROD, V86, DOI 10.1095/biolreprod.111.094896; Landgraf RR, 2011, RAPID COMMUN MASS SP, V25, P3178, DOI 10.1002/rcm.5189; Landgraf RR, 2009, ANAL CHEM, V81, P8488, DOI 10.1021/ac901387u; Liu W, 2011, FREE RADICAL BIO MED, V50, P166, DOI 10.1016/j.freeradbiomed.2010.10.709; Lobasso S, 2010, LIPIDS, V45, P593, DOI 10.1007/s11745-010-3432-1; Marcheselli VL, 2003, J BIOL CHEM, V278, P43807, DOI 10.1074/jbc.M305841200; Milasinovic S, 2012, ANAL CHEM, V84, P3945, DOI 10.1021/ac300557a; Minkler PE, 2010, J LIPID RES, V51, P856, DOI 10.1194/jlr.D002857; Murphy RC, 2011, BBA-MOL CELL BIOL L, V1811, P776, DOI 10.1016/j.bbalip.2011.06.019; Murphy RC, 2011, BBA-MOL CELL BIOL L, V1811, P970, DOI 10.1016/j.bbalip.2011.04.012; Murphy RC, 2009, J LIPID RES, V50, pS317, DOI 10.1194/jlr.R800051-JLR200; Niemoller TD, 2010, PROSTAG OTH LIPID M, V91, P85, DOI 10.1016/j.prostaglandins.2009.09.005; Northen TR, 2007, NATURE, V449, P1033, DOI 10.1038/nature06195; Passarelli MK, 2011, BBA-MOL CELL BIOL L, V1811, P976, DOI 10.1016/j.bbalip.2011.05.007; Picariello G, 2009, J AGR FOOD CHEM, V57, P5391, DOI 10.1021/jf9008795; Puolitaival SM, 2008, J AM SOC MASS SPECTR, V19, P882, DOI 10.1016/j.jasms.2008.02.013; Ramrakhiani L, 2011, APPL BIOCHEM BIOTECH, V164, P991, DOI 10.1007/s12010-011-9190-6; Samhan-Arias A.K., 2012, BIOCH BIOPHYSICA ACT; Scherer M, 2010, ANAL CHEM, V82, P8794, DOI 10.1021/ac1021826; Schiller J, 2002, ANAL BIOCHEM, V309, P311, DOI 10.1016/S0003-2697(02)00308-1; Schuhmann K, 2011, ANAL CHEM, V83, P5480, DOI 10.1021/ac102505f; Shevchenko A, 2010, NAT REV MOL CELL BIO, V11, P593, DOI 10.1038/nrm2934; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Sparvero L.J., 2011, SOC TOX 50 ANN M WAS; Sparvero LJ, 2010, J NEUROCHEM, V115, P1322, DOI 10.1111/j.1471-4159.2010.07055.x; Spraggins JM, 2011, J AM SOC MASS SPECTR, V22, P1022, DOI 10.1007/s13361-011-0121-0; Stegemann C, 2011, CIRC-CARDIOVASC GENE, V4, P232, DOI 10.1161/CIRCGENETICS.110.959098; Stubiger G, 2007, ANAL CHEM, V79, P3206, DOI 10.1021/ac062236c; Sun G, 2008, ANAL CHEM, V80, P7576, DOI 10.1021/ac801200w; Sun G, 2007, ANAL CHEM, V79, P6629, DOI 10.1021/ac070843+; Teuber K, 2010, CHEM PHYS LIPIDS, V163, P552, DOI 10.1016/j.chemphyslip.2010.04.005; Thomas A, 2012, ANAL CHEM, V84, P2048, DOI 10.1021/ac2033547; Touboul D, 2011, BIOCHIMIE, V93, P113, DOI 10.1016/j.biochi.2010.05.013; Tyurin VA, 2008, METHOD ENZYMOL, V442, P375, DOI [10.1016/S0076-6879(08)01419-5, 10.1017/S0076-6879(08)01419-5]; Tyurin VA, 2010, METHODS MOL BIOL, V610, P353, DOI 10.1007/978-1-60327-029-8_21; Tyurin VA, 2009, J CHROMATOGR B, V877, P2863, DOI 10.1016/j.jchromb.2009.03.007; Tyurin VA, 2008, J NEUROCHEM, V107, P1614, DOI 10.1111/j.1471-4159.2008.05728.x; Tyurina YY, 2011, ACS NANO, V5, P7342, DOI 10.1021/nn202201j; Tyurina YY, 2010, AM J PHYSIOL-LUNG C, V299, pL73, DOI 10.1152/ajplung.00035.2010; Urban PL, 2011, ANAL CHEM, V83, P3918, DOI 10.1021/ac200481j; Vaishnav RA, 2010, J NEUROTRAUM, V27, P1311, DOI 10.1089/neu.2009.1172; Valko M, 2005, CURR MED CHEM, V12, P1161, DOI 10.2174/0929867053764635; van Hove ERA, 2010, J CHROMATOGR A, V1217, P3946, DOI 10.1016/j.chroma.2010.01.033; Vidova V, 2010, J LIPID RES, V51, P2295, DOI 10.1194/jlr.M005488; Vidova V, 2010, ANAL CHEM, V82, P4994, DOI 10.1021/ac100661h; Wang HYJ, 2007, J AM SOC MASS SPECTR, V18, P567, DOI 10.1016/j.jasms.2006.10.023; Wang HYJ, 2010, RAPID COMMUN MASS SP, V24, P2057, DOI 10.1002/rcm.4620; Wang HYJ, 2008, INT J MASS SPECTROM, V278, P143, DOI 10.1016/j.ijms.2008.04.005; Weber LWD, 2003, CRIT REV TOXICOL, V33, P105, DOI 10.1080/713611034; Whitehead SN, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020808; Woods AS, 2010, METHODS MOL BIOL, V656, P99, DOI 10.1007/978-1-60761-746-4_5; Yang JH, 2011, ANAL CHEM, V83, P5728, DOI 10.1021/ac200998a; Yin HY, 2011, CHEM REV, V111, P5944, DOI 10.1021/cr200084z; Zhang JR, 1996, J NEUROCHEM, V66, P355	120	76	78	0	95	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0009-3084	1873-2941		CHEM PHYS LIPIDS	Chem. Phys. Lipids	JUL	2012	165	5					545	562		10.1016/j.chemphyslip.2012.06.001			18	Biochemistry & Molecular Biology; Biophysics	Biochemistry & Molecular Biology; Biophysics	004KX	WOS:000308681700006	22692104	Green Accepted			2021-06-18	
J	Anderson, V; Godfrey, C; Rosenfeld, JV; Catroppa, C				Anderson, Vicki; Godfrey, Celia; Rosenfeld, Jeffrey V.; Catroppa, Cathy			10 years outcome from childhood traumatic brain injury	INTERNATIONAL JOURNAL OF DEVELOPMENTAL NEUROSCIENCE			English	Article						Traumatic brain injury; Children; Recovery of function; Long term adolescence	HEAD-INJURY; PSYCHOSOCIAL OUTCOMES; INTELLECTUAL ABILITY; FUNCTIONAL RECOVERY; TERM; CHILDREN; PREDICTORS; PLASTICITY; MEMORY; SKILLS	Childhood traumatic brain injury (TBI) is a common, acquired disability, which has significant implications for subsequent development, and for later quality of life. To date few studies have documented outcomes in these children into adolescence, when academic, social and personal demands increase. The objective of this study was to document functional outcomes at 10 years post-injury, and to identify predictors of outcome including injury, socio-demographic and pre-injury characteristics. The study employed consecutive recruitment to a prospective, longitudinal study. Children with a diagnosis of TBI between 2 and 12 years were initially recruited and divided according to injury severity (mild, moderate, severe). The sample was reviewed at 10 years post-injury and intellectual, adaptive, executive and social domains were investigated. Results indicated that, at 10 years post child TBI, survivors' functional abilities fell overall within the low average to average range regardless of injury severity, suggesting no extreme impairments at a group level for any of the domains under investigation. Significant group differences were identified, though, for adaptive abilities and for speed of processing, with more severe injury associated with poorer performances in each instance. Further, a similar trend was identified for measures of intellectual ability and executive functions. Individual rates of impairment were considerably higher than population expectations across all severity groups for these domains. Although rates of social impairment were also elevated, they were less related to injury factors, suggesting that cognitive/adaptive outcomes and social consequences of TBI may have different bases. (C) 2011 Published by Elsevier Ltd on behalf of ISDN.	[Anderson, Vicki; Godfrey, Celia; Catroppa, Cathy] Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Anderson, Vicki; Catroppa, Cathy] Royal Childrens Hosp, Parkville, Vic 3052, Australia; [Anderson, Vicki; Catroppa, Cathy] Univ Melbourne, Melbourne, Vic 3010, Australia; [Rosenfeld, Jeffrey V.] Monash Univ, Melbourne, Vic 3004, Australia; [Rosenfeld, Jeffrey V.] Alfred Hosp, Melbourne, Vic, Australia	Anderson, V (corresponding author), Royal Childrens Hosp, Dept Psychol, Flemington Rd, Parkville, Vic 3052, Australia.	vicki.anderson@rch.org.au; celia.godfrey@mcri.edu.au; J.Rosenfeld@alfred.org.au; cathy.catroppa@mcri.edu.au	Rosenfeld, Jeffrey V/B-7249-2011		Australian National Health and Medical Research CouncilNational Health and Medical Research Council of Australia; Victorian Government OIS	This research was supported by a grant to the authors from the Australian National Health and Medical Research Council, and by the Victorian Government OIS Scheme.	Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Anderson V., 2009, PEDIATRICS, V124, p[6, 1064]; Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; Anderson VA, 2006, NEUROPSYCHOLOGY, V20, P42, DOI 10.1037/0894-4105.20.1.42; Anderson VA, 2004, BRAIN, V127, P2608, DOI 10.1093/brain/awh320; Anderson V, 2010, J NEUROTRAUM, V27, P863, DOI 10.1089/neu.2009.1169; Anderson V, 2009, J HEAD TRAUMA REHAB, V24, P303, DOI 10.1097/HTR.0b013e3181ada830; Anderson V, 2009, BRAIN, V132, P45, DOI 10.1093/brain/awn293; Asikainen I, 1996, BRAIN INJURY, V10, P883, DOI 10.1080/026990596123864; Bayreuther J, 2009, ARCH DIS CHILDHOOD-E, V94, P37, DOI 10.1136/adc.2007.132787; Belsky J, 2011, J CHILD PSYCHOL PSYC, V52, P409, DOI 10.1111/j.1469-7610.2010.02281.x; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; Casey BJ, 2000, BIOL PSYCHOL, V54, P241, DOI 10.1016/S0301-0511(00)00058-2; Catroppa C, 2008, J PEDIATR PSYCHOL, V33, P707, DOI 10.1093/jpepsy/jsn006; Catroppa C, 2007, J PEDIATR PSYCHOL, V32, P354, DOI 10.1093/jpepsy/jsl019; Catroppa C, 2007, CHILD NEUROPSYCHOL, V13, P240, DOI 10.1080/09297040600837362; Cattelani R, 1998, BRAIN INJURY, V12, P283, DOI 10.1080/026990598122584; Crowe L, 2009, J PAEDIATR CHILD H, V45, P346, DOI 10.1111/j.1440-1754.2009.01499.x; Daniel A. E., 1983, POWER PRIVILEGE PRES; Dennis M, 2001, BRAIN LANG, V78, P1, DOI 10.1006/brln.2000.2431; Dennis M., 1995, TRAUMATIC HEAD INJUR, P165; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; Gioia G.A., 2000, BEHAV RATING INVENTO; Giza CC, 2006, DEV NEUROSCI-BASEL, V28, P364, DOI 10.1159/000094163; Greenham M., 2010, FRONT HUM NEUROSCI, V4; Hanten G, 2008, NEUROPSYCHOLOGY, V22, P357, DOI 10.1037/0894-4105.22.3.357; Hessen E, 2007, BRAIN INJURY, V21, P963, DOI 10.1080/02699050701528454; Hoofien D, 2001, BRAIN INJURY, V15, P189; Jonsson CA, 2004, BRAIN INJURY, V18, P921, DOI 10.1080/02699050410001671900; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; Kraus J., 1995, TRAUMATIC HEAD INJUR, P117; Levin H., 1979, J PEDIATR PSYCHOL, V4, P389, DOI DOI 10.1093/JPEPSY/4.4.389; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; Maller JJ, 2007, HIPPOCAMPUS, V17, P1023, DOI 10.1002/hipo.20339; McKinlay A, 2002, J NEUROL NEUROSUR PS, V73, P281, DOI 10.1136/jnnp.73.3.281; Mitra B, 2007, J PAEDIATR CHILD H, V43, P154, DOI 10.1111/j.1440-1754.2007.01035.x; Muscara F, 2008, J NEUROPSYCHOL, V2, P445, DOI 10.1348/174866407X250820; Noller P, 1988, ICPS FAMILY FU UNPUB; Nybo T, 2004, J INT NEUROPSYCH SOC, V10, P719, DOI 10.1017/S1355617704105109; Nybo T, 1999, BRAIN INJURY, V13, P759; Oakland T, 2008, PRACT RESOUR MENT, P1; Rosema S., J NEUROTRAU IN PRESS; Satz P, 2001, CURR DIR PSYCHOL SCI, V10, P106, DOI 10.1111/1467-8721.00127; Sparrow S., 1984, VINELAND ADAPTIVE BE; Taylor H.G., 1995, TRAUMATIC HEAD INJUR, P188; Taylor HG, 2003, REHABIL PSYCHOL, V48, P227, DOI 10.1037/0090-5550.48.4.227; TEASDALE G, 1974, LANCET, V2, P81; Wechsler D, 1991, MANUAL WECHSLER SCAL; Wechsler D., 1997, MANUAL WECHSLER ADUL; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates KO, 2010, NEUROPSYCHOLOGY, V24, P345, DOI 10.1037/a0018387; Yeates KO, 2005, J AM ACAD CHILD PSY, V44, P574, DOI 10.1097/01.chi.0000159947.50523.64; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093	57	76	76	1	29	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0736-5748	1873-474X		INT J DEV NEUROSCI	Int. J. Dev. Neurosci.	MAY	2012	30	3			SI		217	224		10.1016/j.ijdevneu.2011.09.008			8	Developmental Biology; Neurosciences	Developmental Biology; Neurosciences & Neurology	936XH	WOS:000303622800007	22100364				2021-06-18	
J	Loov, C; Hillered, L; Ebendal, T; Erlandsson, A				Loov, Camilla; Hillered, Lars; Ebendal, Ted; Erlandsson, Anna			Engulfing Astrocytes Protect Neurons from Contact-Induced Apoptosis following Injury	PLOS ONE			English	Article							TRAUMATIC BRAIN-INJURY; CAENORHABDITIS-ELEGANS; NERVOUS-SYSTEM; DENTATE GYRUS; WHITE-MATTER; GLIAL-CELLS; ADULT RAT; C-ELEGANS; OLIGODENDROCYTES; ENGULFMENT	Clearing of dead cells is a fundamental process to limit tissue damage following brain injury. Engulfment has classically been believed to be performed by professional phagocytes, but recent data show that non-professional phagocytes are highly involved in the removal of cell corpses in various situations. The role of astrocytes in cell clearance following trauma has however not been studied in detail. We have found that astrocytes actively collect and engulf whole dead cells in an in vitro model of brain injury and thereby protect healthy neurons from bystander cell death. Time-lapse experiments showed that migrating neurons that come in contact with free-floating cell corpses induced apoptosis, while neurons that migrate through groups of dead cells, garnered by astrocytes, remain unaffected. Furthermore, apoptotic cells are present within astrocytes in the mouse brain following traumatic brain injury (TBI), indicating a possible role for astrocytes in engulfment of apoptotic cells in vivo. qRT-PCR analysis showed that members of both ced pathways and Megf8 are expressed in the cell culture, indicating their possible involvement in astrocytic engulfment. Moreover, addition of dead cells had a positive effect on the protein expression of MEGF10, an ortholog to CED1, known to initiate phagocytosis by binding to phosphatidylserine. Although cultured astrocytes have an immense capacity for engulfment, seemingly without adverse effects, the ingested material is stored rather than degraded. This finding might explain the multinuclear astrocytes that are found at the lesion site in patients with various brain disorders.	[Loov, Camilla; Hillered, Lars; Ebendal, Ted; Erlandsson, Anna] Uppsala Univ, Dept Neurosci, Uppsala, Sweden	Loov, C (corresponding author), Uppsala Univ, Dept Neurosci, Uppsala, Sweden.	anna.erlandsson@neuro.uu.se		Hillered, Lars/0000-0002-2808-9292	Swedish Research CouncilSwedish Research CouncilEuropean Commission; Uppsala University Hospital; Tore Nilssons Foundation; Jeanssons Foundation; Magnus Bergvall Foundation; Swedish Society of Medicine	This study was supported by grants from the Swedish Research Council, the Uppsala University Hospital, Tore Nilssons Foundation, Jeanssons Foundation, Magnus Bergvall Foundation and The Swedish Society of Medicine. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Acarin L, 2007, GLIA, V55, P954, DOI 10.1002/glia.20518; Buffo A, 2010, BIOCHEM PHARMACOL, V79, P77, DOI 10.1016/j.bcp.2009.09.014; Cahoy JD, 2008, J NEUROSCI, V28, P264, DOI 10.1523/JNEUROSCI.4178-07.2008; Chang GHF, 2000, NEURO-ONCOLOGY, V2, P174, DOI 10.1093/neuonc/2.3.174; Colodner KJ, 2005, J NEUROPATH EXP NEUR, V64, P163, DOI 10.1093/jnen/64.2.163; Cusato K, 2003, J NEUROSCI, V23, P6413; Erwig LP, 2008, CELL DEATH DIFFER, V15, P243, DOI 10.1038/sj.cdd.4402184; Fullard JF, 2009, APOPTOSIS, V14, P1029, DOI 10.1007/s10495-009-0335-9; GALL C, 1979, J COMP NEUROL, V183, P539, DOI 10.1002/cne.901830306; GHATAK NR, 1992, J NEUROPATH EXP NEUR, V51, P40, DOI 10.1097/00005072-199201000-00006; Haase G, 2008, CURR OPIN NEUROBIOL, V18, P284, DOI 10.1016/j.conb.2008.07.013; Hanayama R, 2005, P NATL ACAD SCI USA, V102, P16886, DOI 10.1073/pnas.0508599102; Henson PM, 2001, CURR BIOL, V11, pR795, DOI 10.1016/S0960-9822(01)00474-2; Hirt UA, 2003, CELL DEATH DIFFER, V10, P1156, DOI 10.1038/sj.cdd.4401286; Israelsson C, 2008, J NEUROTRAUM, V25, P959, DOI 10.1089/neu.2008.0562; Kinchen JM, 2005, NATURE, V434, P93, DOI 10.1038/nature03263; Kranich J, 2010, J EXP MED, V207, P2271, DOI 10.1084/jem.20092401; Kurant E, 2008, CELL, V133, P498, DOI 10.1016/j.cell.2008.02.052; LEE KS, 1977, EXP BRAIN RES, V29, P475; LEMKEYJOHNSTON N, 1976, J COMP NEUROL, V167, P481, DOI 10.1002/cne.901670406; Lettre G, 2006, NAT REV MOL CELL BIO, V7, P97, DOI 10.1038/nrm1836; Magnus T, 2002, J NEUROPATH EXP NEUR, V61, P760, DOI 10.1093/jnen/61.9.760; Mangahas PM, 2005, SEMIN CELL DEV BIOL, V16, P295, DOI 10.1016/j.semcdb.2004.12.005; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; MATTHEWS DA, 1976, BRAIN RES, V115, P23, DOI 10.1016/0006-8993(76)90820-9; Miksa M, 2009, J IMMUNOL METHODS, V342, P71, DOI 10.1016/j.jim.2008.11.019; Monks J, 2008, BIOL REPROD, V78, P586, DOI 10.1095/biolreprod.107.065045; Mothersill C, 1998, RADIAT RES, V149, P256, DOI 10.2307/3579958; Nakanishi Y, 2004, BIOL PHARM BULL, V27, P13, DOI 10.1248/bpb.27.13; Nishie M, 2006, NEUROPATHOLOGY, V26, P62, DOI 10.1111/j.1440-1789.2006.00633.x; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; Poon IKH, 2010, CELL DEATH DIFFER, V17, P381, DOI 10.1038/cdd.2009.195; RAINE CS, 1976, J NEUROL SCI, V30, P13, DOI 10.1016/0022-510X(76)90251-3; RONNEVI LO, 1978, CELL TISSUE RES, V189, P203; Shintaku M, 2004, ACTA NEUROPATHOL, V108, P201, DOI 10.1007/s00401-004-0880-9; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; Song JH, 2006, J NEUROSCI, V26, P3299, DOI 10.1523/JNEUROSCI.5572-05.2006; Suzuki E, 2007, EXP CELL RES, V313, P3729, DOI 10.1016/j.yexcr.2007.06.015; TRAPP BD, 1975, NEUROBIOLOGY, V5, P235; Venegas V, 2007, MOL BIOL CELL, V18, P3180, DOI 10.1091/mbc.E07-02-0138; WU E, 1992, LAB INVEST, V67, P88; Wu HH, 2009, NAT NEUROSCI, V12, P1534, DOI 10.1038/nn.2446; Wyss-Coray T, 2003, NAT MED, V9, P453, DOI 10.1038/nm838; Zhang Y, 2010, CURR OPIN NEUROBIOL, V20, P588, DOI 10.1016/j.conb.2010.06.005	45	76	77	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 26	2012	7	3							e33090	10.1371/journal.pone.0033090			14	Multidisciplinary Sciences	Science & Technology - Other Topics	943KB	WOS:000304118900009	22461890	DOAJ Gold, Green Published			2021-06-18	
J	Hillary, FG; Slocomb, J; Hills, EC; Fitzpatrick, NM; Medaglia, JD; Wang, J; Good, DC; Wylie, GR				Hillary, F. G.; Slocomb, J.; Hills, E. C.; Fitzpatrick, N. M.; Medaglia, J. D.; Wang, J.; Good, D. C.; Wylie, G. R.			Changes in resting connectivity during recovery from severe traumatic brain injury	INTERNATIONAL JOURNAL OF PSYCHOPHYSIOLOGY			English	Article						Resting connectivity; Plasticity; Reorganization; Longitudinal; TBI	WORKING-MEMORY LOAD; CEREBRAL-BLOOD-FLOW; FUNCTIONAL CONNECTIVITY; DEFAULT-MODE; COGNITIVE-CONTROL; PREFRONTAL CORTEX; BIPOLAR DISORDER; AXONAL INJURY; MOTOR CORTEX; SEVERE TBI	In the present study we investigate neural network changes after moderate and severe traumatic brain injury (TBI) through the use of resting state functional connectivity (RSFC) methods. Using blood oxygen level dependent functional MRI, we examined RSFC at 3 and 6 months following resolution of posttraumatic amnesia. The goal of this study was to examine how regional off-task connectivity changes during a critical period of recovery from significant neurological disruption. This was achieved by examining regional changes in the intrinsic, or "resting", BOLD fMRI signal in separate networks: 1) regions linked to goal-directed (or external-state) networks and 2) default mode (or internal-state) networks. Findings here demonstrate significantly increased resting connectivity internal-state networks in the TBI sample during the first 6 months following recovery. The most consistent finding was increased connectivity in both internal and external state networks to the insula and medial temporal regions during recovery. These findings were dissociable from repeat measurements in a matched healthy control sample. (C) 2011 Elsevier B.V. All rights reserved.	[Hillary, F. G.; Medaglia, J. D.] Penn State Univ, Dept Psychol, University Pk, PA 16802 USA; [Hillary, F. G.; Slocomb, J.; Fitzpatrick, N. M.; Good, D. C.] Hershey Med Ctr, Dept Neurol, Hershey, PA USA; [Wang, J.] Hershey Med Ctr, Dept Radiol, Hershey, PA USA; [Hills, E. C.] Hershey Med Ctr, Dept Phys Med & Rehabil, Hershey, PA USA; [Wylie, G. R.] Kessler Fdn Res Ctr, W Orange, NJ 07052 USA	Hillary, FG (corresponding author), Penn State Univ, Dept Psychol, University Pk, PA 16802 USA.	fhillary@psu.edu; gwylie@kesslerfoundation.org	Hillary, Frank/AAN-8622-2021				Beaupre MG, 2005, J CROSS CULT PSYCHOL, V36, P355, DOI 10.1177/0022022104273656; BISWAL B, 1995, MAGNET RESON MED, V34, P537, DOI 10.1002/mrm.1910340409; Biswal BB, 2010, P NATL ACAD SCI USA, V107, P4734, DOI 10.1073/pnas.0911855107; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Camchong J, 2011, SCHIZOPHRENIA BULL, V37, P640, DOI 10.1093/schbul/sbp131; Carter AR, 2010, ANN NEUROL, V67, P365, DOI 10.1002/ana.21905; Chepenik LG, 2010, PSYCHIAT RES-NEUROIM, V182, P207, DOI 10.1016/j.pscychresns.2010.04.002; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Cole MW, 2010, NEUROIMAGE, V49, P3132, DOI 10.1016/j.neuroimage.2009.11.001; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; Craig AD, 2009, NAT REV NEUROSCI, V10, P59, DOI 10.1038/nrn2555; Di Martino A, 2008, CEREB CORTEX, V18, P2735, DOI 10.1093/cercor/bhn041; Fox MD, 2005, P NATL ACAD SCI USA, V102, P9673, DOI 10.1073/pnas.0504136102; Fox MD, 2007, NEURON, V56, P171, DOI 10.1016/j.neuron.2007.08.023; Fujiwara E, 2008, NEUROPSYCHOLOGIA, V46, P461, DOI 10.1016/j.neuropsychologia.2007.08.027; Glahn DC, 2002, NEUROIMAGE, V17, P201, DOI 10.1006/nimg.2002.1161; Greicius MD, 2004, J COGNITIVE NEUROSCI, V16, P1484, DOI 10.1162/0898929042568532; Greicius MD, 2003, P NATL ACAD SCI USA, V100, P253, DOI 10.1073/pnas.0135058100; Gusnard DA, 2001, NAT REV NEUROSCI, V2, P685, DOI 10.1038/35094500; Hamilton J.P., 2010, MOL PSYCHIAT; Hampson M, 2002, HUM BRAIN MAPP, V15, P247, DOI 10.1002/hbm.10022; Hampson M, 2010, MAGN RESON IMAGING, V28, P1051, DOI 10.1016/j.mri.2010.03.021; Hillary FG, 2002, BRAIN INJURY, V16, P729, DOI 10.1080/02699050110119844; Hillary FG, 2008, J INT NEUROPSYCH SOC, V14, P526, DOI 10.1017/S1355617708080788; Hillary FG, 2011, BRAIN, V134, P1555, DOI 10.1093/brain/awr043; Hillary FG, 2010, BRAIN IMAGING BEHAV, V4, P141, DOI 10.1007/s11682-010-9094-z; Kelly AMC, 2008, NEUROIMAGE, V39, P527, DOI 10.1016/j.neuroimage.2007.08.008; Kelly C, 2009, J NEUROSCI, V29, P7364, DOI 10.1523/JNEUROSCI.0810-09.2009; Kim J, 2010, J NEUROTRAUM, V27, P1399, DOI 10.1089/neu.2009.1215; Koch W, 2010, NEUROIMAGE, V51, P280, DOI 10.1016/j.neuroimage.2009.12.008; Kurth F, 2010, BRAIN STRUCT FUNCT, V214, P519, DOI 10.1007/s00429-010-0255-z; Larson MJ, 2007, J INT NEUROPSYCH SOC, V13, P961, DOI 10.1017/S1355617707071305; Larson MJ, 2006, J CLIN EXP NEUROPSYC, V28, P968, DOI 10.1080/13803390600646860; LOWE MJ, 1997, HUMAN BRAIN MAPPING, V5, pS194, DOI DOI 10.1002/(SICI)1097-0193(1997)5:3<LESSTHAN>194::AID-HBM4<GREATERTHAN>3.0.CO;2-Z; Ma N, 2011, PLOS ONE, V26; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; Medaglia J.D., 2011, HUM BRAIN MAPP   APR; Mennes M, 2010, NEUROIMAGE, V50, P1690, DOI 10.1016/j.neuroimage.2010.01.002; Menon V, 2010, BRAIN STRUCT FUNCT, V214, P655, DOI 10.1007/s00429-010-0262-0; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Murphy K, 2009, NEUROIMAGE, V44, P893, DOI 10.1016/j.neuroimage.2008.09.036; Nakamura T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008220; Newsome MR, 2007, CORTEX, V43, P95, DOI 10.1016/S0010-9452(08)70448-9; Ongur D, 2010, PSYCHIAT RES-NEUROIM, V183, P59, DOI 10.1016/j.pscychresns.2010.04.008; Pagulayan KF, 2006, ARCH PHYS MED REHAB, V87, P611, DOI 10.1016/j.apmr.2006.01.018; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; Price CJ, 2006, J MAGN RESON IMAGING, V23, P816, DOI 10.1002/jmri.20580; Price CJ, 2002, NEUROCASE, V8, P345, DOI 10.1076/neur.8.4.345.16186; Pyka M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007198; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Ralchle ME, 2007, NEUROIMAGE, V37, P1083, DOI 10.1016/j.neuroimage.2007.02.041; Rocca MA, 2010, NEUROLOGY, V74, P1252, DOI 10.1212/WNL.0b013e3181d9ed91; Rotarska-Jagiela A, 2010, SCHIZOPHR RES, V117, P21, DOI 10.1016/j.schres.2010.01.001; Sanchez-Carrion R, 2008, J NEUROTRAUM, V25, P479, DOI 10.1089/neu.2007.0417; Sanchez-Carrion R, 2008, NEUROIMAGE, V43, P421, DOI 10.1016/j.neuroimage.2008.08.003; Scheibel RS, 2009, J NEUROTRAUM, V26, P1447, DOI 10.1089/neu.2008.0736; Scheibel RS, 2007, NEUROREHAB NEURAL RE, V21, P36, DOI 10.1177/1545968306294730; Sheline YI, 2010, P NATL ACAD SCI USA, V107, P11020, DOI 10.1073/pnas.1000446107; Skudlarski P, 2010, BIOL PSYCHIAT, V68, P61, DOI 10.1016/j.biopsych.2010.03.035; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Spreng RN, 2010, NEUROIMAGE, V53, P303, DOI 10.1016/j.neuroimage.2010.06.016; Sumowski JF, 2010, BRAIN, V133, P362, DOI 10.1093/brain/awp307; TEASDALE G, 1974, LANCET, V2, P81; Van Dijk KRA, 2010, J NEUROPHYSIOL, V103, P297, DOI 10.1152/jn.00783.2009; Vanhaudenhuyse A, 2010, BRAIN, V133, P161, DOI 10.1093/brain/awp313; Wager TD, 2003, COGN AFFECT BEHAV NE, V3, P255, DOI 10.3758/CABN.3.4.255; Whyte J., 1998, REHABILITATION MED P; Wu HM, 2004, NEUROSURGERY, V55, P1306, DOI 10.1227/01.NEU.0000143028.08719.42; Xiong J., 1998, P INT SOC MAGN RES M, P201; Xiong JH, 1999, HUM BRAIN MAPP, V8, P151, DOI 10.1002/(SICI)1097-0193(1999)8:2/3<151::AID-HBM13>3.0.CO;2-5; Zhou Bing, 2010, Zhong Nan Da Xue Xue Bao Yi Xue Ban, V35, P17, DOI 10.3969/j.issn.1672-7347.2010.01.003; Zhou J, 2010, BRAIN, V133, P1352, DOI 10.1093/brain/awq075; Zou QH, 2009, NEUROIMAGE, V48, P515, DOI 10.1016/j.neuroimage.2009.07.006	75	76	76	0	20	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0167-8760	1872-7697		INT J PSYCHOPHYSIOL	Int. J. Psychophysiol.	OCT	2011	82	1			SI		115	123		10.1016/j.ijpsycho.2011.03.011			9	Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental	Psychology; Neurosciences & Neurology; Physiology	859PZ	WOS:000297889600013	21473890				2021-06-18	
J	Thom, M; Liu, JY; Thompson, P; Phadke, R; Narkiewicz, M; Martinian, L; Marsdon, D; Koepp, M; Caboclo, L; Catarino, CB; Sisodiya, SM				Thom, Maria; Liu, Joan Y. W.; Thompson, Pam; Phadke, Rahul; Narkiewicz, Marta; Martinian, Lillian; Marsdon, Derek; Koepp, Matthias; Caboclo, Luis; Catarino, Claudia B.; Sisodiya, Sanjay M.			Neurofibrillary tangle pathology and Braak staging in chronic epilepsy in relation to traumatic brain injury and hippocampal sclerosis: a post-mortem study	BRAIN			English	Article						Braak stage; epilepsy; head trauma; hippocampal sclerosis	TEMPORAL-LOBE EPILEPSY; ALZHEIMERS-DISEASE; TDP-43 IMMUNOREACTIVITY; ILAE COMMISSION; DEMENTIA; TAU; CLASSIFICATION; DEGENERATION; SEIZURES; ENCEPHALOPATHY	The long-term pathological effects of chronic epilepsy on normal brain ageing are unknown. Previous clinical and epidemiological studies show progressive cognitive decline in subsets of patients and an increased prevalence of Alzheimer's disease in epilepsy. In a post-mortem series of 138 patients with long-term, mainly drug-resistant epilepsy, we carried out Braak staging for Alzheimer's disease neurofibrillary pathology using tau protein immunohistochemistry. The stages were compared with clinicopathological factors, including seizure history and presence of old traumatic brain injury. Overall, 31% of cases were Braak Stage 0, 36% Stage I/II, 31% Stage III/IV and 2% Stage V/VI. The mean age at death was 56.5 years and correlated with Braak stage (P < 0.001). Analysis of Braak stages within age groups showed a significant increase in mid-Braak stages (III/IV), in middle age (40-65 years) compared with data from an ageing non-epilepsy series (P < 0.01). There was no clear relationship between seizure type (generalized or complex partial), seizure frequency, age of onset and duration of epilepsy with Braak stage although higher Braak stages were noted with focal more than with generalized epilepsy syndromes (P < 0.01). In 30% of patients, there was pathological evidence of traumatic brain injury that was significantly associated with higher Braak stages (P < 0.001). Cerebrovascular disease present in 40.3% and cortical malformations in 11.3% were not significantly associated with Braak stage. Astrocytic-tau protein correlated with the presence of both traumatic brain injury (P < 0.01) and high Braak stage (P < 0.001). Hippocampal sclerosis, identified in 40% (bilateral in 48%), was not associated with higher Braak stages, but asymmetrical patterns of tau protein accumulation within the sclerotic hippocampus were noted. In over half of patients with cognitive decline, the Braak stage was low indicating causes other than Alzheimer's disease pathology. In summary, there is evidence of accelerated brain ageing in severe chronic epilepsy although progression to high Braak stages was infrequent. Traumatic brain injury, but not seizures, was associated with tau protein accumulation in this series. It is likely that Alzheimer's disease pathology is not the sole explanation for cognitive decline associated with epilepsy.	[Thom, Maria; Liu, Joan Y. W.; Thompson, Pam; Martinian, Lillian; Koepp, Matthias; Caboclo, Luis; Catarino, Claudia B.; Sisodiya, Sanjay M.] UCL, Inst Neurol, Dept Clin & Expt Epilepsy, London WC1N 3BG, England; [Thom, Maria; Liu, Joan Y. W.; Thompson, Pam; Phadke, Rahul; Narkiewicz, Marta; Martinian, Lillian; Marsdon, Derek; Koepp, Matthias; Caboclo, Luis; Catarino, Claudia B.; Sisodiya, Sanjay M.] Natl Hosp Neurol & Neurosurg, London WC1N 3BG, England; [Thom, Maria; Phadke, Rahul; Narkiewicz, Marta; Martinian, Lillian; Marsdon, Derek] UCL, Inst Neurol, Div Neuropathol, London WC1N 3BG, England; [Thompson, Pam; Koepp, Matthias; Catarino, Claudia B.; Sisodiya, Sanjay M.] Natl Soc Epilepsy, Gerrards Cross SL9 0RJ, Bucks, England; [Koepp, Matthias; Caboclo, Luis; Catarino, Claudia B.; Sisodiya, Sanjay M.] UCL, Inst Neurol, Div Clin Neurol, London WC1N 3BG, England	Thom, M (corresponding author), UCL, Inst Neurol, Dept Clin & Expt Epilepsy, Queen Sq, London WC1N 3BG, England.	m.thom@ion.ucl.ac.uk	Catarino, Claudia B/AAD-5165-2021; Phadke, Rahul/U-6960-2019; Catarino, Claudia Bacanhim/A-7719-2010; Caboclo, Luis Otavio S F/G-6880-2012	Catarino, Claudia B/0000-0002-6528-7570; Catarino, Claudia Bacanhim/0000-0002-6528-7570; Liu, Joan/0000-0002-0777-5189	Department of Health's NIHR Biomedical Research CentresNational Institute for Health Research (NIHR); Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [0600934]; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0600934] Funding Source: researchfish	This work was undertaken at UCLH/UCL, which received a proportion of funding from the Department of Health's NIHR Biomedical Research Centres funding scheme; the study was supported by the Medical Research Council (grant 0600934).	Alafuzoff I, 2008, BRAIN PATHOL, V18, P484, DOI 10.1111/j.1750-3639.2008.00147.x; Amador-Ortiz C, 2007, ANN NEUROL, V61, P435, DOI 10.1002/ana.21154; [Anonymous], 1989, EPILEPSIA, V30, P389, DOI 10.1111/j.1528-1157.1989.tb05316.x; Ball M, 1997, NEUROBIOL AGING, V18, pS1, DOI 10.1016/s0197-4580(97)00057-2; Baxendale SA, 1998, EPILEPSIA, V39, P158, DOI 10.1111/j.1528-1157.1998.tb01353.x; Berg AT, 2010, EPILEPSIA, V51, P676, DOI 10.1111/j.1528-1167.2010.02522.x; Bernhardt BC, 2009, NEUROLOGY, V72, P1747, DOI 10.1212/01.wnl.0000345969.57574.f5; Blanc F, 2011, EPILEPSIA, V52, P10, DOI 10.1111/j.1528-1167.2010.02773.x; Blumcke I, 2007, ACTA NEUROPATHOL, V113, P235, DOI 10.1007/s00401-006-0187-0; Blumcke I, 2009, EPILEPSY BEHAV, V15, P34, DOI 10.1016/j.yebeh.2009.02.033; Bothwell M, 2000, CELL, V102, P271, DOI 10.1016/S0092-8674(00)00032-5; Braak H, 1997, NEUROBIOL AGING, V18, P351, DOI 10.1016/S0197-4580(97)00056-0; Braak H, 2006, ACTA NEUROPATHOL, V112, P389, DOI 10.1007/s00401-006-0127-z; Breteler MMB, 1995, AM J EPIDEMIOL, V142, P1300, DOI 10.1093/oxfordjournals.aje.a117597; Bruton CJ, 1988, NEUROPATHOLOGY TEMPO; Catarino CB, 2011, BRAIN, V134, P2982, DOI 10.1093/brain/awr129; Cormack F, 2005, NEUROIMAGE, V27, P635, DOI 10.1016/j.neuroimage.2005.05.023; CORSELLIS JAN, 1989, BRIT MED J, V298, P105, DOI 10.1136/bmj.298.6666.105; CORSELLIS JAN, 1959, J MENT SCI, V105, P714; CORSELLIS JAN, 1957, BRAIN, V80, P193, DOI 10.1093/brain/80.2.193; DICKSON DW, 1994, ACTA NEUROPATHOL, V88, P212; Duvernoy HM, 2005, HUMAN HIPPOCAMPUS FU; Duyckaerts C, 1997, ACTA NEUROPATHOL, V93, P501, DOI 10.1007/s004010050645; Duyckaerts C, 2009, ACTA NEUROPATHOL, V118, P5, DOI 10.1007/s00401-009-0532-1; Engel J, 2006, EPILEPSIA, V47, P1558, DOI 10.1111/j.1528-1167.2006.00215.x; French JA, 2007, EPILEPSIA, V48, P3, DOI 10.1111/j.1528-1167.2007.00992.x; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Frost B, 2009, J BIOL CHEM, V284, P12845, DOI 10.1074/jbc.M808759200; Gaitatzis A, 2004, BRAIN, V127, P2427, DOI 10.1093/brain/awh267; Gaitatzis A, 2004, EPILEPSIA, V45, P1613, DOI 10.1111/j.0013-9580.2004.17504.x; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; Gouras GK, 1997, ANN NEUROL, V41, P402, DOI 10.1002/ana.410410317; Helmstaedter C, 2009, BRAIN, V132, P2822, DOI 10.1093/brain/awp182; Hermann B, 2008, EPILEPSIA, V49, P731, DOI 10.1111/j.1528-1167.2007.01435.x; Hermann B, 2008, LANCET NEUROL, V7, P151, DOI 10.1016/S1474-4422(08)70018-8; Hermann Bruce, 2007, Epilepsy Curr, V7, P1, DOI 10.1111/j.1535-7511.2007.00151.x; Hermann BP, 2006, ANN NEUROL, V60, P80, DOI 10.1002/ana.20872; HOUSER CR, 1990, J NEUROSCI, V10, P267; Iqbal K, 2008, J CELL MOL MED, V12, P38, DOI 10.1111/j.1582-4934.2008.00225.x; Iqbal K, 2010, BIOCHEM SOC T, V38, P962, DOI 10.1042/BST0380962; Jellinger KA, 2004, CURR OPIN NEUROL, V17, P719, DOI 10.1097/00019052-200412000-00012; Keller SS, 2008, EPILEPSIA, V49, P741, DOI 10.1111/j.1528-1167.2007.01485.x; Keller SS, 2009, EPILEPSY BEHAV, V15, P186, DOI 10.1016/j.yebeh.2009.03.005; Kwan P, 2010, EPILEPSIA, V51, P1069, DOI 10.1111/j.1528-1167.2009.02397.x; Lace G, 2009, BRAIN, V132, P1324, DOI 10.1093/brain/awp059; Lee EB, 2008, ACTA NEUROPATHOL, V115, P305, DOI 10.1007/s00401-007-0331-5; Lim ACB, 2003, J ALZHEIMERS DIS, V5, P329, DOI 10.3233/JAD-2003-5409; Lin JJ, 2007, CEREB CORTEX, V17, P2007, DOI 10.1093/cercor/bhl109; MACKENZIE IRA, 1994, ACTA NEUROPATHOL, V87, P504; MARGERISON JH, 1966, BRAIN, V89, P499, DOI 10.1093/brain/89.3.499; Marques CM, 2007, EPILEPSY BEHAV, V10, P477, DOI 10.1016/j.yebeh.2007.02.002; Mattsson N, 2010, NEUROSCI RES, V66, P330, DOI 10.1016/j.neures.2009.11.012; McDonald CR, 2008, EPILEPSIA, V49, P794, DOI 10.1111/j.1528-1167.2008.01539.x; McIntosh AM, 2001, EPILEPSIA, V42, P1288, DOI 10.1046/j.1528-1157.2001.02001.x; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meencke H J, 1996, Epilepsy Res Suppl, V12, P335; Mendez M F, 1994, J Geriatr Psychiatry Neurol, V7, P230; MORRIS JC, 1993, NEUROLOGY, V43, P2412, DOI 10.1212/WNL.43.11.2412-a; Oyegbile TO, 2004, NEUROLOGY, V62, P1736, DOI 10.1212/01.WNL.0000125186.04867.34; Palop JJ, 2009, ARCH NEUROL-CHICAGO, V66, P435, DOI 10.1001/archneurol.2009.15; Probst A, 2007, ACTA NEUROPATHOL, V114, P335, DOI 10.1007/s00401-007-0262-1; Riederer F, 2008, NEUROLOGY, V71, P419, DOI 10.1212/01.wnl.0000324264.96100.e0; Schultz C, 2004, NEUROBIOL AGING, V25, P397, DOI 10.1016/S0197-4580(03)00113-1; Sen A, 2006, J NEUROPATH EXP NEUR, V65, P55, DOI 10.1097/01.jnen.0000195940.48033.a2; Sen A, 2008, DEV NEUROSCI-BASEL, V30, P96, DOI 10.1159/000109855; Sen A, 2007, NEUROREPORT, V18, P511, DOI 10.1097/WNR.0b013e3280586879; Sen A, 2007, EPILEPSIA, V48, P1447, DOI 10.1111/j.1528-1167.2007.01107.x; Spencer S, 2008, LANCET NEUROL, V7, P525, DOI 10.1016/S1474-4422(08)70109-1; Tellez-Zenteno JF, 2005, EPILEPSIA, V46, P1955, DOI 10.1111/j.1528-1167.2005.00344.x; Thom M, 2005, BRAIN, V128, P1344, DOI 10.1093/brain/awh475; Thom M, 2009, NEUROLOGY, V73, P1033, DOI 10.1212/WNL.0b013e3181b99a07; Thom M, 2010, ANN NEUROL, V68, P424, DOI 10.1002/ana.22142; Thom M, 2010, EPILEPSIA, V51, P1801, DOI 10.1111/j.1528-1167.2010.02681.x; Wang JZ, 2008, PROG NEUROBIOL, V85, P148, DOI 10.1016/j.pneurobio.2008.03.002; Wieser HG, 2004, EPILEPSIA, V45, P32; Zarow C, 2008, CURR NEUROL NEUROSCI, V8, P363, DOI 10.1007/s11910-008-0057-3	76	76	79	0	13	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	OCT	2011	134		10				2969	2981		10.1093/brain/awr209			13	Clinical Neurology; Neurosciences	Neurosciences & Neurology	830TZ	WOS:000295681400016	21903728	Green Published, Other Gold			2021-06-18	
J	McMillan, TM; Teasdale, GM; Weir, CJ; Stewart, E				McMillan, T. M.; Teasdale, G. M.; Weir, C. J.; Stewart, E.			Death after head injury: the 13 year outcome of a case control study	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							TRAUMATIC BRAIN-INJURY; PROSPECTIVE COHORT; YOUNG-PEOPLE; FARE WORSE; MORTALITY; AGE; EPIDEMIOLOGY; POPULATION; DISABILITY; VARIABLES	Background Head injury is common, and the risk of subsequent disability and death is high. Increased risk of death years after injury might be explained by factors associated with, but not a consequence of, the head injury. This unique prospective study investigates mortality over 13 years after injury. Methods A cohort of n=767 with head injury was compared with two case control groups, matched for age, gender and deprivation, and in one control group, matched for duration of hospital admission following (non-head) injury. Results Two-fifths of the head injury cohort had died. The death rate (30.99 per 1000 per year) was much higher than in community controls (13.72 per 1000 per year). More than 1 year after injury, the death rate in younger (15-54 years) adults was much higher than in community controls (17.36 vs 2.36 per 1000 per year) whereas in older adults the difference was more marginal (61.47 vs 42.36). Death rate was elevated after mild and after more severe head injury, including in younger adults after mild head injury (14.82 per 1000 per year mild head injury vs 2.21 community). Female gender and greater deprivation were not associated with increased death rates after head injury. Late after injury, deaths occurred from the same main causes as for the general population. Conclusion Head injury is associated with increased vulnerability to death from a variety of causes for at least 13 years after hospital admission. There is a need to understand how head injury influences mortality, particularly in younger adults and after mild head injury.	[McMillan, T. M.; Stewart, E.] Univ Glasgow, Fac Med, Glasgow G12 0XH, Lanark, Scotland; [Teasdale, G. M.] NHS Qual Improvement Scotland, Glasgow, Lanark, Scotland; [Weir, C. J.] Univ Edinburgh, Ctr Populat Hlth Sci, MRC Hub Trials Methodol Res, Edinburgh, Midlothian, Scotland	McMillan, TM (corresponding author), Univ Glasgow, Gartnavel Royal Hosp, Fac Med, 1055 Great Western Rd, Glasgow G12 0XH, Lanark, Scotland.	t.m.mcmillan@clinmed.gla.ac.uk		Weir, Christopher/0000-0002-6494-4903	Chief Scientist Office [CZG/2/397, K/OPR/2/2/D229]; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0800803] Funding Source: researchfish; Chief Scientist Office [CZH/4/674] Funding Source: researchfish	The 13 year follow-up was funded by the Chief Scientist Office (CZG/2/397). The original prospective study was also funded by the Chief Scientist Office (K/OPR/2/2/D229).	Baguley I, 2000, BRAIN INJURY, V14, P505; Coimbra R, 2003, J TRAUMA, V54, P689, DOI 10.1097/01.TA.0000058314.31655.5F; CONROY C, 1988, NEUROEPIDEMIOLOGY, V7, P13, DOI 10.1159/000110131; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Farin A, 2003, J NEUROSURG, V98, P32, DOI 10.3171/jns.2003.98.1.0032; Flaada JT, 2007, J NEUROTRAUM, V24, P435, DOI 10.1089/neu.2006.0119; GENNARELLI TA, 1989, J TRAUMA, V29, P1193, DOI 10.1097/00005373-198909000-00002; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; Gujral IB, 2006, BRAIN INJURY, V20, P283, DOI 10.1080/02699050500488058; Harrison-Felix C, 2006, J HEAD TRAUMA REHAB, V21, P22, DOI 10.1097/00001199-200601000-00003; Harrison-Felix C, 2004, NEUROREHABILITATION, V19, P45; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; Kraus J F, 2000, Neurosurg Focus, V8, pe5; LEWIN W, 1979, BRIT MED J, V2, P1533, DOI 10.1136/bmj.2.6204.1533; McMillan TM, 2007, BRAIN, V130, P2520, DOI 10.1093/brain/awm185; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Mushkudiani NA, 2007, J NEUROTRAUM, V24, P259, DOI 10.1089/neu.2006.0028; Pentland B, 2005, J NEUROL NEUROSUR PS, V76, P395, DOI 10.1136/jnnp.2004.037861; *SCOTT EX, 2006, SCOTT IND MULT DEPR; *SCOTT EX, 2007, ALL OUR FUT PLANN SC, V3; Shavelle RM, 2001, AM J PHYS MED REHAB, V80, P510, DOI 10.1097/00002060-200107000-00009; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Tate R, 1997, J HEAD TRAUMA REHAB, V12, P16, DOI 10.1097/00001199-199712000-00003; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; Whitnall L, 2006, J NEUROL NEUROSUR PS, V77, P640, DOI 10.1136/jnnp.2005.078246	30	76	76	0	8	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	AUG	2011	82	8					931	935		10.1136/jnnp.2010.222232			5	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	789TE	WOS:000292538400069	21282727				2021-06-18	
J	King, NS; Kirwilliam, S				King, Nigel S.; Kirwilliam, Simon			Permanent post-concussion symptoms after mild head injury	BRAIN INJURY			English	Article						Mild head injury; permanent post-concussion symptoms	RANDOMIZED CONTROLLED-TRIAL; ROUTINE FOLLOW-UP; BRAIN-INJURY; QUESTIONNAIRE; RECOVERY	Objective: A small minority of individuals experience long-term or permanent post-concussion symptoms (PCS) after a mild head injury (MHI). There has been no systematic, quantitative research examining a wide range of variables in a representative sample of such patients (i.e. with PCS for more than 18 months). This study explores a broad spectrum of demographic, cognitive, emotional and psychosocial factors (known to be important in the development of early PCS) in a representative sample of patients with permanent PCS. Method: One hundred consecutively referred patients to a Community Head Injury Service in Buckinghamshire, UK for the treatment of persistent PCS, at least 18 months post-MHI, were identified and invited to participate. An exploratory design evaluated a range of demographic, cognitive, emotional and psychosocial variables and their relationship to PCS severity and quality-of-life (QoL). Results: Twenty-four participants, with a mean time post-injury of 6.9 years, responded. They were characterized by: (i) older age compared to those typically presenting with MHI, (ii) very high levels of PCS, (iii) high post-injury unemployment, (iv) pre- or post-morbid factors which might exacerbate post-concussional difficulties, (v) elevated levels of anxiety and depression and (vi) mildly reduced scores on tests of short-term memory and speed of information processing. Post-hoc analysis of the total sample (n = 100) confirmed older age and a high proportion having pre- or post-morbid factors. QoL negatively correlated with PCS severity, and anxiety scores accounted for 45.9% of the variance in PCS severity. Conclusions: Very high levels of PCS, high post-injury unemployment and measurable cognitive deficits can be permanent features of MHI. Quality-of-life is directly related to symptom severity. Age, pre-/post-morbid concomitant factors, neuropsychological deficits and emotional status are key variables in understanding the phenomenon of permanent PCS. Important vulnerability factors in the development of such may therefore be older age and any additional compromise to an individual's emotional or cognitive capacities.	[King, Nigel S.] Camborne Ctr, Community Head Injury Serv, Aylesbury HP21 7ET, Bucks, England; [King, Nigel S.] Univ Oxford, Warneford Hosp, Oxford Doctoral Course Clin Psychol, Oxford, England; [Kirwilliam, Simon] Charing Cross Hosp, Clin Hlth Psychol & Neuropsychol Team, London, England	King, NS (corresponding author), Camborne Ctr, Community Head Injury Serv, Aylesbury HP21 7ET, Bucks, England.	nigel.king@hmc.ox.ac.uk					BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binder LM, 1996, AM J PSYCHIAT, V153, P7; BOHNEN N, 1994, BRAIN INJURY, V8, P701, DOI 10.3109/02699059409151024; BOHNEN N, 1992, NEUROSURGERY, V30, P692; EDNA TH, 1987, ACTA NEUROCHIR, V86, P12, DOI 10.1007/BF01419498; ENGLANDER J, 1992, Brain Injury, V6, P161, DOI 10.3109/02699059209029654; GRONWALL D, 1975, LANCET, V2, P995; Jakola AS, 2007, ACTA NEUROL SCAND, V115, P398, DOI 10.1111/j.1600-0404.2007.00827.x; Jennett BFrankowskiR, 1990, HDB CLIN NEUROLOGY, V13, P1; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; King N, 1997, BRIT J CLIN PSYCHOL, V36, P161, DOI 10.1111/j.2044-8260.1997.tb01405.x; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 2003, BRIT J PSYCHIAT, V183, P276, DOI 10.1192/bjp.183.4.276; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; MELZACK R, 1975, PAIN, V1, P277, DOI 10.1016/0304-3959(75)90044-5; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Sigurdardottir S, 2009, BRAIN INJURY, V23, P489, DOI 10.1080/02699050902926309; Wade DT, 1997, J NEUROL NEUROSUR PS, V62, P478, DOI 10.1136/jnnp.62.5.478; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; Weiss DS., 1997, ASSESSING PSYCHOL TR, P399, DOI DOI 10.1037/T12199-000; WHO, 2001, WHO INT CLASS FUNCT; World Health Organization, 1993, MNH7PSF939 WHO; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	26	76	76	0	11	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAY	2011	25	5					462	470		10.3109/02699052.2011.558042			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	745KQ	WOS:000289164700004	21401372				2021-06-18	
J	Mills, JD; Hadley, K; Bailes, JE				Mills, James D.; Hadley, Kevin; Bailes, Julian E.			Dietary Supplementation With the Omega-3 Fatty Acid Docosahexaenoic Acid in Traumatic Brain Injury?	NEUROSURGERY			English	Article						Amyloid precursor protein (APP); Caspase-3 CD68; Docosahexaenoic acid (DHA); Omega-3 fatty acids; Traumatic brain injury	POLYUNSATURATED FATTY-ACIDS; PHOSPHOLIPID DEGRADATION; ISCHEMIC-STROKE; AXONAL INJURY; ANTIPLATELET; DYSFUNCTION; MECHANISMS; STATINS; GROWTH; MODEL	BACKGROUND: Although various strategies for prevention of brain disease have been implemented, no substance has been found to be advantageous for prophylaxis against brain injury. OBJECTIVE: While previous work in our laboratory and others have shown positive effects using the omega-3 fatty acid docosahexaenoic acid (DHA) in post-injury treatment following traumatic and ischemic insults, we wished to test its effects when given prior to injury. We have attempted to measure anatomical, cellular, and behavioral outcomes with a prophylactic administration of DHA. METHODS: Five groups of 16 adult male Sprague-Dawley rats were subjected to an impact acceleration traumatic brain after having received a prior administration of DHA in doses of 3, 12, and 40 mg/kg for 30 days prior. Serum fatty acid levels were determined from isolated plasma phospholipids at baseline and at the end of 30 days supplementation. Following sacrifice 1 week after injury, brainstem white matter tracts underwent fluorescent immunohistochemical processing for labeling of beta amyloid precursor protein (APP), an anatomical marker of brain injury, as well as measurements of CD68 and caspase-3 levels, and water maze testing was used for behavioral assessment. RESULTS: Dietary supplementation with DHA resulted in increased serum DHA levels proportionate with the escalating dosage. Immunohistochemical analysis revealed significantly (P<.05) decreased numbers of APP levels in all groups of animals receiving pre-injury supplementation with DHA of 4, 12, and 40 mg/kg at 13955, 4186, and 2827 axons per mm(3), respectively, vs 37442 in unsupplemented animals, as measured by stereological methodology. Using a selective measuring technique, only the highest dosage group, 40 mg/kg showed significantly (P<.05) decreased numbers of APP positive axons, at 1.15 axons per high power field vs 6.78 in unsupplemented animals. CD-68, caspase-3, and water maze testing all were significantly (P<.05) improved in the high dose group. CONCLUSION: Dietary supplementation with DHA increases serum levels and, if given prior to traumatic brain injury, reduces the injury response, as measured by axonal injury counts, markers for cellular injury and apoptosis, and memory assessment by water maze testing. This uniform response was seen for the highest dosage group, 40 mg/kg given over 30 days prior to injury, but when measured by stereological counting methodology there was a positive response to anatomical injury across low to high doses of DHA. The potential for DHA to provide prophylactic benefit to the brain against traumatic injury appears promising and requires further investigation.	[Mills, James D.; Bailes, Julian E.] W Virginia Univ, Dept Neurosurg, Sch Med, Morgantown, WV 26506 USA; [Hadley, Kevin] Martek Biosci Corp, Columbia, MD USA	Bailes, JE (corresponding author), W Virginia Univ, Dept Neurosurg, Sch Med, POB 9183, Morgantown, WV 26506 USA.	jbailes@hsc.wvu.edu			Martek, Inc.	This research was supported by a grant from Martek, Inc. Dr Bailes is a consultant for Martek, Inc. The authors have no personal financial or institutional interest in any of the drugs, materials, or devices described in this article.	Babcock AA, 2006, J NEUROSCI, V26, P12826, DOI 10.1523/JNEUROSCI.4937-05.2006; Bailes JE, 2010, J NEUROTRAUM, V27, P1617, DOI 10.1089/neu.2009.1239; Bazan NG, 2005, BRAIN PATHOL, V15, P159; Belayev L, 2009, STROKE, V40, pE223; Berman DR, 2009, AM J OBSTET GYNECOL, V200, DOI 10.1016/j.ajog.2009.01.020; Blondeau N, 2002, NEUROSCIENCE, V109, P231, DOI 10.1016/S0306-4522(01)00473-0; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Calder PC, 2003, BRAZ J MED BIOL RES, V36, P433, DOI 10.1590/S0100-879X2003000400004; Calderon F, 2004, J NEUROCHEM, V90, P979, DOI 10.1111/j.1471-4159.2004.02520.x; Cao DH, 2004, PHARMACOL BIOCHEM BE, V79, P651, DOI 10.1016/j.pbb.2004.09.016; Choi JS, 2006, NEUROSCI LETT, V409, P187, DOI 10.1016/j.neulet.2006.09.053; Cucchiara B, 2001, J NEUROL SCI, V187, P81, DOI 10.1016/S0022-510X(01)00529-9; Desire L, 2000, J NEUROCHEM, V75, P151, DOI 10.1046/j.1471-4159.2000.0750151.x; Diener HC, 2000, NEUROL CLIN, V18, P343, DOI 10.1016/S0733-8619(05)70196-1; Doraiswamy PM, 2002, CNS DRUGS, V16, P811, DOI 10.2165/00023210-200216120-00003; Freiberg JJ, 2008, JAMA-J AM MED ASSOC, V300, P2142, DOI 10.1001/jama.2008.621; He CW, 2009, P NATL ACAD SCI USA, V106, P11370, DOI 10.1073/pnas.0904835106; Heller AR, 2006, CRIT CARE MED, V34, P972, DOI 10.1097/01.CCM.0000206309.83570.45; Hogyes E, 2003, NEUROSCIENCE, V119, P999, DOI 10.1016/S0306-4522(03)00198-2; Homayoun P, 1997, J NEUROCHEM, V69, P199; Huang WL, 2007, BRAIN, V130, P3004, DOI 10.1093/brain/awm223; Jain KK, 2008, DRUG DISCOV TODAY, V13, P1082, DOI 10.1016/j.drudis.2008.09.006; Jump DB, 2002, CURR OPIN LIPIDOL, V13, P155, DOI 10.1097/00041433-200204000-00007; Lauritzen I, 2000, EMBO J, V19, P1784, DOI 10.1093/emboj/19.8.1784; Leys D, 2009, CEREBROVASC DIS, V27, P120, DOI 10.1159/000200449; Li WK, 2009, J NEUROCHEM, V110, P1339, DOI 10.1111/j.1471-4159.2009.06224.x; Lonergan PE, 2004, J NEUROCHEM, V91, P20, DOI 10.1111/j.1471-4159.2004.02689.x; Marklund N, 1997, NEUROREPORT, V8, P1457, DOI 10.1097/00001756-199704140-00026; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MARTINEZ M, 1992, J PEDIATR-US, V120, pS129, DOI 10.1016/S0022-3476(05)81247-8; Mills JD, 2003, J BIOMED OPT, V8, P347, DOI 10.1117/1.1584443; Mills JD, 2010, J NEUROSURG     0716; Moreira Paula I, 2006, Expert Rev Neurother, V6, P897, DOI 10.1586/14737175.6.6.897; Mukherjee PK, 2004, P NATL ACAD SCI USA, V101, P8491, DOI 10.1073/pnas.0402531101; NEEDLEMAN P, 1979, P NATL ACAD SCI USA, V76, P944, DOI 10.1073/pnas.76.2.944; Pan HC, 2009, J NUTR BIOCHEM, V20, P715, DOI 10.1016/j.jnutbio.2008.06.014; Rajanikant GK, 2007, CURR MED CHEM, V14, P103, DOI 10.2174/092986707779313462; Roberts L, 2008, J AM COLL SURGEONS, V207, P276, DOI 10.1016/j.jamcollsurg.2008.02.015; Salem N, 2001, LIPIDS, V36, P945, DOI 10.1007/s11745-001-0805-6; Shah RS, 2008, BIOMED PHARMACOTHER, V62, P199, DOI 10.1016/j.biopha.2008.02.005; Stone JR, 1999, ACTA NEUROPATHOL, V97, P335, DOI 10.1007/s004010050996; Vaughan CJ, 1999, STROKE, V30, P1969, DOI 10.1161/01.STR.30.9.1969; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Wang XY, 2003, J AM SOC NEPHROL, V14, p729A; Wilcock DM, 2008, J ALZHEIMERS DIS, V15, P555; Wolff T, 2009, ANN INTERN MED, V150, P632, DOI 10.7326/0003-4819-150-9-200905050-00010; Wu AG, 2007, J NEUROTRAUM, V24, P1587, DOI 10.1089/neu.2007.0313	47	76	78	0	12	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	FEB	2011	68	2					474	481		10.1227/NEU.0b013e3181ff692b			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	703QJ	WOS:000285994300080	21135750				2021-06-18	
J	Meehan, WP				Meehan, William P., III			Medical Therapies for Concussion	CLINICS IN SPORTS MEDICINE			English	Article						Concussion; Mild traumatic brain injury; Head injury; Trauma; Injury; Sports	TRAUMATIC BRAIN-INJURY; MILD HEAD-INJURY; RANDOMIZED CONTROLLED-TRIAL; SCHOOL FOOTBALL PLAYERS; POSTTRAUMATIC HEADACHE; EARLY INTERVENTION; ATTENTION DEFICITS; AMANTADINE; METHYLPHENIDATE; RECOVERY	Clinicians who manage sport-related concussions have excellent guidelines by which most injuries can be managed. Because sport-related concussions typically resolve within a short time frame, most can be managed with physical and cognitive rest alone. However, clinicians who specialize in the assessment and management of this diagnosis encounter patients with prolonged recovery courses, persistent symptoms, and significant deficits in cognitive functioning. These patients require more involved therapy, which may include additional education, academic accommodations, physical therapy, cognitive rehabilitation, and medication. This article reviews the main medical therapies for the management of concussive brain injury.	[Meehan, William P., III] Childrens Hosp Boston, Sports Concuss Clin, Div Sports Med, Dept Orthoped, Boston, MA 02115 USA; [Meehan, William P., III] Childrens Hosp Boston, Dept Med, Div Emergency Med, Boston, MA 02115 USA	Meehan, WP (corresponding author), Childrens Hosp Boston, Sports Concuss Clin, Div Sports Med, Dept Orthoped, 319 Longwood Ave, Boston, MA 02115 USA.	william.meehan@childrens.harvard.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32 HD040128-06A1]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040128] Funding Source: NIH RePORTER	This manuscript was supported by the National Institutes of Health through a T32 Award to Dr Meehan (T32 HD040128-06A1).	[Anonymous], 2003, J NEUROPSYCH CLIN N, V15, P383, DOI 10.1176/appi.neuropsych.15.3.383; Arciniegas David B, 2005, Neuropsychiatr Dis Treat, V1, P311; Beauchamp K, 2008, MOL MED, V14, P731, DOI 10.2119/2008-00050.Beauchamp; Beers SR, 2005, J HEAD TRAUMA REHAB, V20, P450, DOI 10.1097/00001199-200509000-00006; Chew E, 2009, J REHABIL RES DEV, V46, P851, DOI 10.1682/JRRD.2008.09.0120; Cicerone KD, 2002, BRAIN INJURY, V16, P185, DOI 10.1080/02699050110103959; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; Couch JR, 2001, HEADACHE, V41, P559, DOI 10.1046/j.1526-4610.2001.041006559.x; DINAN TG, 1992, ACTA PSYCHIAT SCAND, V85, P292, DOI 10.1111/j.1600-0447.1992.tb01472.x; Fann JR, 2001, PSYCHOSOMATICS, V42, P48, DOI 10.1176/appi.psy.42.1.48; Faux S, 2008, PAIN MED, V9, P1001, DOI 10.1111/j.1526-4637.2007.00404.x; Ganong WF, 1999, REV MED PHYSL; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Green LB, 2004, AM J PHYS MED REHAB, V83, P893, DOI 10.1097/01.PHM.0000143400.15346.C8; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Haas DC, 1996, CEPHALALGIA, V16, P486, DOI 10.1046/j.1468-2982.1996.1607486.x; Ho MR, 1997, ARCH CLIN NEUROPSYCH, V12, P1; Horsfield SA, 2002, INT J PSYCHIAT MED, V32, P337, DOI 10.2190/KQ48-XT0L-2H14-5UMV; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Kaelin DL, 1996, ARCH PHYS MED REHAB, V77, P6, DOI 10.1016/S0003-9993(96)90211-7; Kapural M, 2002, BRAIN RES, V940, P102, DOI 10.1016/S0006-8993(02)02586-6; Kaye NS, 2003, J NEUROPSYCHIATRY CL, V15; Kraus MF, 2005, BRAIN INJURY, V19, P471, DOI 10.1080/02699050400025059; LABEL L S, 1991, Neurology, V41, P247; Lane Judy C., 2002, Curr Treat Options Neurol, V4, P89, DOI 10.1007/s11940-002-0007-3; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Lee H, 2005, HUM PSYCHOPHARM CLIN, V20, P97, DOI 10.1002/hup.668; Lee LK, 2007, PEDIATR EMERG CARE, V23, P580, DOI 10.1097/PEC.0b013e31813444ea; Lenaerts Marc E, 2004, Curr Treat Options Neurol, V6, P507, DOI 10.1007/s11940-004-0008-5; Leone H, 2005, J CLIN PHARM THER, V30, P101, DOI 10.1111/j.1365-2710.2005.00628.x; LEVIN HS, 1991, J NEUROL SCI, V103, pS39; Lew HL, 2006, AM J PHYS MED REHAB, V85, P619, DOI 10.1097/01.phm.0000223235.09931.c0; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; Maldonado MD, 2007, J PINEAL RES, V42, P1, DOI 10.1111/j.1600-079X.2006.00376.x; Masanic CA, 2001, ARCH PHYS MED REHAB, V82, P896, DOI 10.1053/apmr.2001.23833; MCBEATH JG, 1994, HEADACHE, V34, P148, DOI 10.1111/j.1526-4610.1994.hed3403148.x; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; McCrory P, 2009, J SCI MED SPORT, V12, P340, DOI 10.1016/j.jsams.2009.02.004; McCrory Paul, 2009, J Athl Train, V44, P434, DOI 10.4085/1062-6050-44.4.434; Meythaler JM, 2002, J HEAD TRAUMA REHAB, V17, P300, DOI 10.1097/00001199-200208000-00004; Mittenberg W, 2001, J CLIN EXP NEUROPSYC, V23, P829, DOI 10.1076/jcen.23.6.829.1022; MITTENBERG W, 1994, BRAIN INJURY, V8, P429, DOI 10.3109/02699059409150994; Morey CE, 2003, BRAIN INJURY, V17, P809, DOI 10.1080/0269905031000088586; Napolitano E, 2005, MED SCI MONITOR, V11, pRA212; Packard RC, 1999, J HEAD TRAUMA REHAB, V14, P9, DOI 10.1097/00001199-199902000-00004; Packard RC, 2000, HEADACHE, V40, P736, DOI 10.1046/j.1526-4610.2000.00128.x; Paniak C, 2002, ARCH CLIN NEUROPSYCH, V17, P319, DOI 10.1016/S0887-6177(01)00115-9; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Ponsford J, 2001, PEDIATRICS, V108, P1297, DOI 10.1542/peds.108.6.1297; Rao Vani, 2002, Curr Treat Options Neurol, V4, P77, DOI 10.1007/s11940-002-0006-4; Reddy CC, 2004, BRAIN INJURY PROFESS, V4, P24; Salazar AM, 2002, J NEUROL NEUROSUR PS, V73, P239, DOI 10.1136/jnnp.73.3.239; Samantaray S, 2009, J PINEAL RES, V47, P134, DOI 10.1111/j.1600-079X.2009.00703.x; SARAN A, 1988, INT J PSYCHIAT MED, V18, P75, DOI 10.2190/15AH-JB7Q-U94T-JEAF; Sawyer E, 2008, ANN PHARMACOTHER, V42, P247, DOI 10.1345/aph.1K284; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schneider WN, 1999, BRAIN INJURY, V13, P863; Siddall ORM, 2005, ANN PHARMACOTHER, V39, P1309, DOI 10.1345/aph.1E637; Silver JM, 2009, AM J PSYCHIAT, V166, P653, DOI 10.1176/appi.ajp.2009.08111676; Silver JM, 2009, BRAIN INJURY, V23, P123, DOI 10.1080/02699050802649696; Sivan M, 2010, CLIN REHABIL, V24, P110, DOI 10.1177/0269215509343234; Tenovuo O, 2005, PROG NEURO-PSYCHOPH, V29, P61, DOI 10.1016/j.pnpbp.2004.10.006; Tenovuo O, 2006, CURR OPIN NEUROL, V19, P528, DOI 10.1097/WCO.0b013e328010944f; Tsaousides T, 2009, MT SINAI J MED, V76, P173, DOI 10.1002/msj.20099; TYLER GS, 1980, HEADACHE, V20, P213, DOI 10.1111/j.1526-4610.1980.hed2004213.x; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; Walker W, 2004, BRAIN INJURY, V18, P739, DOI 10.1080/02699050310001646224; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; WEISS HD, 1991, HEADACHE, V31, P451, DOI 10.1111/j.1526-4610.1991.hed3107451.x; Whelan F J, 2000, Ann Clin Psychiatry, V12, P131; Whyte J, 2004, AM J PHYS MED REHAB, V83, P401, DOI 10.1097/01.PHM.0000128789.75375.D3; Whyte J, 1997, AM J PHYS MED REHAB, V76, P440, DOI 10.1097/00002060-199711000-00002; Williams SE, 1998, J HEAD TRAUMA REHAB, V13, P73, DOI 10.1097/00001199-199806000-00007; Williams SE, 2007, BRAIN INJURY, V21, P885, DOI 10.1080/02699050701553213; Zafonte RD, 1996, NEUROREHABILITATION, V7, P189, DOI 10.3233/NRE-1996-7304; Zafonte R, 2009, J NEUROTRAUM, V26, P2207, DOI 10.1089/neu.2009.1015; Zhang L, 2004, ARCH PHYS MED REHAB, V85, P1050, DOI 10.1016/j.apmr.2003.10.014	84	76	76	0	33	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0278-5919	1556-228X		CLIN SPORT MED	Clin. Sports Med.	JAN	2011	30	1					115	+		10.1016/j.csm.2010.08.003			11	Sport Sciences	Sport Sciences	691XR	WOS:000285114800011	21074086	Green Accepted			2021-06-18	
J	Mills, JD; Bailes, JE; Sedney, CL; Hutchins, H; Sears, B				Mills, James D.; Bailes, Julian E.; Sedney, Cara L.; Hutchins, Heather; Sears, Barry			Omega-3 fatty acid supplementation and reduction of traumatic axonal injury in a rodent head injury model Laboratory investigation	JOURNAL OF NEUROSURGERY			English	Article						omega-3 fatty acids; traumatic brain injury; amyloid precursor protein; dietary supplementation	POLYUNSATURATED FATTY-ACIDS; NEURONAL CELL-DEATH; SPINAL-CORD-INJURY; BRAIN-INJURY; OXIDATIVE STRESS; RAT HIPPOCAMPUS; APOPTOSIS; INFLAMMATION; DYSFUNCTION; FAILURE	Object. Traumatic brain injury remains the most common cause of death in persons under 45 years of age in the Western world. Recent evidence from animal studies suggests that supplementation with omega-3 fatty acid (O3FA) (particularly eicosapentaenoic acid [EPA] and docosahexaenoic acid [DHA]) improves functional outcomes following focal neural injury. The purpose of this study is to determine the benefits of O3FA supplementation following diffuse axonal injury in rats. Methods. Forty adult male Sprague-Dawley rats were used. Three groups of 10 rats were subjected to an impact acceleration injury and the remaining group underwent a sham-injury procedure (surgery, but no impact injury). Two of the groups subjected to the injury were supplemented with 10 or 40 mg/kg/day of O3FA; the third injured group served as an unsupplemented control group. The sham-injured rats likewise received no O3FA supplementation. Serum fatty acid levels were determined from the isolated plasma phospholipids prior to the injury and at the end of the 30 days of supplementation. After the animals had been killed, immunohistochemical analysis of brainstem white matter tracts was performed to assess the presence of beta-amyloid precursor protein (APP), a marker of axonal injury. Immunohistochemical analyses of axonal injury mechanisms including analysis for caspase-3, a marker of apoptosis; RMO-14, a marker of neurofilament compaction; and cytochrome c, a marker of mitochondrial injury- were performed. Results. Dietary supplementation with a fish oil concentrate rich in EPA and DHA for 30 days resulted in significant increases in O3FA serum levels: 11.6% +/- 4.9% over initial levels in the 10 mg/kg/day group and 30.7% +/- 3.6% in the 40 mg/kg/day group. Immunohistochemical analysis revealed significantly (p<0.05) decreased numbers of APP-positive axons in animals receiving O3FA supplementation: 7.7 +/- 14.4 axons per mm(2) in the 10 mg/kg/day group and 6.2 +/- 11.4 axons per mm2 in the 40 mg/kg/day group, versus 182.2 +/- 44.6 axons per mm2 in unsupplemented animals. Sham-injured animals had 4.1 +/- 1.3 APP-positive axons per mm(2). Similarly, immunohistochemical analysis of caspase-3 expression demonstrated significant (p<0.05) reduction in animals receiving O3FA supplementation, 18.5 +/- 28.3 axons per mm2 in the 10 mg/kg/day group and 13.8 +/- 18.9 axons per mm(2) in the 40 mg/kg/day group, versus 129.3 +/- 49.1 axons per mm(2) in unsupplemented animals. Conclusions. Dietary supplementation with a fish oil concentrate rich in the O3FAs EPA and DHA increases serum levels of these same fatty acids in a dose-response effect. Omega-3 fatty acid supplementation significantly reduces the number of APP-positive axons at 30 days postinjury to levels similar to those in uninjured animals. Omega-3 fatty acids are safe, affordable, and readily available worldwide to potentially reduce the burden of traumatic brain injury. (DOI: 10.3171/2010.5.JNS08914)	[Mills, James D.] W Virginia Univ, Hlth Sci Ctr, Dept Neurosurg, Sch Med, Morgantown, WV 26506 USA; [Hutchins, Heather; Sears, Barry] Inflammat Res Fdn, Marblehead, MA USA	Mills, JD (corresponding author), W Virginia Univ, Hlth Sci Ctr, Dept Neurosurg, Sch Med, POB 9183, Morgantown, WV 26506 USA.	jmills@hsc.wvu.edu		Sedney, Cara/0000-0003-1290-7083			Bazan NG, 2005, BRAIN PATHOL, V15, P159; Blondeau N, 2002, NEUROSCIENCE, V109, P231, DOI 10.1016/S0306-4522(01)00473-0; Buki A, 2000, J NEUROSCI, V20, P2825; Calder PC, 2003, BRAZ J MED BIOL RES, V36, P433, DOI 10.1590/S0100-879X2003000400004; Calderon F, 2004, J NEUROCHEM, V90, P979, DOI 10.1111/j.1471-4159.2004.02520.x; Cao DH, 2004, PHARMACOL BIOCHEM BE, V79, P651, DOI 10.1016/j.pbb.2004.09.016; Danthi SJ, 2005, BIOCHEM BIOPH RES CO, V327, P485, DOI 10.1016/j.bbrc.2004.12.033; Doppenberg EMR, 1997, ANN NY ACAD SCI, V825, P305, DOI 10.1111/j.1749-6632.1997.tb48441.x; DUSART I, 1994, EUR J NEUROSCI, V6, P712, DOI 10.1111/j.1460-9568.1994.tb00983.x; Eldadah BA, 2000, J NEUROTRAUM, V17, P811, DOI 10.1089/neu.2000.17.811; Emsley R, 2003, CNS DRUGS, V17, P1081, DOI 10.2165/00023210-200317150-00003; Hogyes E, 2003, NEUROSCIENCE, V119, P999, DOI 10.1016/S0306-4522(03)00198-2; HOLUB BJ, 1987, METHOD ENZYMOL, V141, P234; Jump DB, 2002, CURR OPIN LIPIDOL, V13, P155, DOI 10.1097/00041433-200204000-00007; Lang-Lazdunski L, 2003, J VASC SURG, V38, P564, DOI 10.1016/S0741-5214(03)00473-7; Lauritzen I, 2000, EMBO J, V19, P1784, DOI 10.1093/emboj/19.8.1784; Lonergan PE, 2004, J NEUROCHEM, V91, P20, DOI 10.1111/j.1471-4159.2004.02689.x; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Mills JD, 2003, J BIOMED OPT, V8, P347, DOI 10.1117/1.1584443; Mukherjee PK, 2004, P NATL ACAD SCI USA, V101, P8491, DOI 10.1073/pnas.0402531101; MURPHY EJ, 1994, MOL CHEM NEUROPATHOL, V23, P13, DOI 10.1007/BF02858504; Nakagawa Y, 1999, J COMP NEUROL, V411, P390; NEEDLEMAN P, 1979, P NATL ACAD SCI USA, V76, P944, DOI 10.1073/pnas.76.2.944; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Roberts L, 2008, J AM COLL SURGEONS, V207, P276, DOI 10.1016/j.jamcollsurg.2008.02.015; Sarsimaz M, 2003, NEUROSCI RES COMMUN, V33, P114, DOI 10.1002/nrc.10087; Schlanger S, 2002, EPILEPSIA, V43, P103, DOI 10.1046/j.1528-1157.2002.13601.x; Schwab JM, 2007, NATURE, V447, P869, DOI 10.1038/nature05877; Songur A, 2004, PROG NEURO-PSYCHOPH, V28, P693, DOI 10.1016/j.pnpbp.2004.05.006; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Stone JR, 1999, ACTA NEUROPATHOL, V97, P335, DOI 10.1007/s004010050996; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Wang XY, 2003, J AM SOC NEPHROL, V14, p729A; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509; Wu A, 2004, J NEUROTRAUM, V21, P1457, DOI 10.1089/neu.2004.21.1457; Wu AG, 2007, J NEUROTRAUM, V24, P1587, DOI 10.1089/neu.2007.0313; Xu GY, 2004, EXP NEUROL, V187, P329, DOI 10.1016/j.expneurol.2004.01.029	38	76	81	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JAN	2011	114	1					77	84		10.3171/2010.5.JNS08914			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	699NG	WOS:000285669500019	20635852				2021-06-18	
J	Reneer, DV; Hisel, RD; Hoffman, JM; Kryscio, RJ; Lusk, BT; Geddes, JW				Reneer, Dexter V.; Hisel, Richard D.; Hoffman, Joshua M.; Kryscio, Richard J.; Lusk, Braden T.; Geddes, James W.			A Multi-Mode Shock Tube for Investigation of Blast-Induced Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						helium; overpressure; oxyhydrogen; pressure-time signature; RDX	EXPLOSIVE BLAST; RAT-BRAIN; PRESSURE; OVERPRESSURE; EXPOSURE; MODEL; WAVE; NEUROTRAUMA; CARE	Blast-induced mild traumatic brain injury (bTBI) has become increasingly common in recent military conflicts. The mechanisms by which non-impact blast exposure results in bTBI are incompletely understood. Current small animal bTBI models predominantly utilize compressed air-driven membrane rupture as their blast wave source, while large animal models use chemical explosives. The pressure-time signature of each blast mode is unique, making it difficult to evaluate the contributions of the different components of the blast wave to bTBI when using a single blast source. We utilized a multi-mode shock tube, the McMillan blast device, capable of utilizing compressed air- and compressed helium-driven membrane rupture, and the explosives oxyhydrogen and cyclotrimethylenetrinitramine (RDX, the primary component of C-4 plastic explosives) as the driving source. At similar maximal blast overpressures, the positive pressure phase of compressed air-driven blasts was longer, and the positive impulse was greater, than those observed for shockwaves produced by other driving sources. Helium-driven shockwaves more closely resembled RDX blasts, but by displacing air created a hypoxic environment within the shock tube. Pressure-time traces from oxyhydrogen-driven shockwaves were very similar those produced by RDX, although they resulted in elevated carbon monoxide levels due to combustion of the polyethylene bag used to contain the gases within the shock tube prior to detonation. Rats exposed to compressed air-driven blasts had more pronounced vascular damage than those exposed to oxyhydrogen-driven blasts of the same peak overpressure, indicating that differences in blast wave characteristics other than peak overpressure may influence the extent of bTBI. Use of this multi-mode shock tube in small animal models will enable comparison of the extent of brain injury with the pressure-time signature produced using each blast mode, facilitating evaluation of the blast wave components contributing to bTBI.	[Reneer, Dexter V.; Geddes, James W.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA; [Reneer, Dexter V.; Geddes, James W.] Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA; [Hoffman, Joshua M.; Lusk, Braden T.] Univ Kentucky, Dept Min Engn, Lexington, KY 40536 USA; [Kryscio, Richard J.] Univ Kentucky, Dept Biostat, Lexington, KY 40536 USA; [Kryscio, Richard J.] Univ Kentucky, Dept Stat, Lexington, KY 40536 USA; [Hisel, Richard D.] GLR Enterprises LLC, Nicholasville, KY USA	Geddes, JW (corresponding author), Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, B477 Biomed & Biol Sci Res Bldg BBSRB,741 S Limes, Lexington, KY 40536 USA.	jgeddes@uky.edu	Ritter, Stefanie L/D-9312-2012		National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32DA022738, P30NS051220]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS051220] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [T32DA022738] Funding Source: NIH RePORTER	D.V.R. was supported by National Institutes of Health (NIH) grant T32DA022738. We would also like to thank GLR Enterprises, L.L.C., for their generous donation of time and materials, without which this work would not have been possible. Additional support was provided by NIH grant P30NS051220.	Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; Baker WE., 1973, EXPLOSIONS AIR; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI 10.1089/neu.2009-0898; Benzinger TLS, 2009, J NEUROTRAUM, V26, P2127, DOI 10.1089/neu.2009-0885; CASSEN BK, 1950, J AVIAT MED, V23; CELANDER H, 1955, ACTA PHYSIOL SCAND, V33, P6, DOI 10.1111/j.1748-1716.1955.tb01188.x; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Chavko M, 2007, J NEUROSCI METH, V159, P277, DOI 10.1016/j.jneumeth.2006.07.018; Chavko M, 2006, J TRAUMA, V61, P933, DOI 10.1097/01.ta.0000233742.75450.47; Cheng JM, 2010, J NEUROL SCI, V294, P23, DOI 10.1016/j.jns.2010.04.010; Clemedson C.J., 1949, ACTA PHYSL SCAND S61, V18; CLEMEDSON CJ, 1956, PHYSIOL REV, V36, P336; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; Elsayed NM, 1997, TOXICOLOGY, V121, P1, DOI 10.1016/S0300-483X(97)03651-2; Garner JP, 2009, WORLD J SURG, V33, P2194, DOI 10.1007/s00268-009-0105-4; Gruss E, 2006, J TRAUMA, V60, P1284, DOI 10.1097/01.ta.0000220015.21948.ec; Health Effects, 1995, TOX PROF RDX; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Kato K, 2007, J NEUROSURG, V106, P667, DOI 10.3171/jns.2007.106.4.667; KOPP C, 2008, DEFENCE TODAY, P46; LEVI L, 1990, ISRAEL J MED SCI, V26, P555; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Lu FK, 2003, SHOCK WAVES, V12, P457, DOI 10.1007/s00193-003-0186-1; Marks ME, 2002, EMERGENCY RESPONDERS, P30; Mayorga MA, 1997, TOXICOLOGY, V121, P17, DOI 10.1016/S0300-483X(97)03652-4; MICHAL J, 1983, FIRE MATER, V7, P163, DOI 10.1002/fam.810070402; Moochhala SM, 2004, J TRAUMA, V56, P393, DOI 10.1097/01.TA.0000066181.50879.7A; MURTHY JMK, 1979, J NEUROSURG, V50, P260, DOI 10.3171/jns.1979.50.2.0260; Richmond D. R., 1967, 1854 DASA FISS PROD, P1; RICHMOND DR, 1968, ANN NY ACAD SCI, V152, P103, DOI 10.1111/j.1749-6632.1968.tb11970.x; Saljo A, 2009, J NEUROTRAUM, V26, P1345, DOI [10.1089/neu.2008.0856, 10.1089/neu.2008-0856]; Saljo A, 2008, J NEUROTRAUM, V25, P1397, DOI 10.1089/neu.2008.0602; SCOTT BA, 1986, NEUROSURGERY, V18, P107, DOI 10.1227/00006123-198601000-00020; Suneson A, 2000, MIL MED, V165, P119, DOI 10.1093/milmed/165.2.119; Svetlov SI, 2010, J TRAUMA, V69, P795, DOI 10.1097/TA.0b013e3181bbd885; *USA, 1984, 91300214 TM US ARM; WARREN WR, 1970, P 7 INT SHOCK TUB S, P143; Zhang JK, 1996, J TRAUMA, V40, pS77	40	76	77	0	22	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2011	28	1					95	104		10.1089/neu.2010.1513			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	710DT	WOS:000286491800009	21083431	Green Published			2021-06-18	
J	Kim, DH; Ko, IG; Kim, BK; Kim, TW; Kim, SE; Shin, MS; Kim, CJ; Kim, H; Kim, KM; Baek, SS				Kim, Dong-Hyun; Ko, Il-Gyu; Kim, Bo-Kyun; Kim, Tae-Woon; Kim, Sung-Eun; Shin, Mal-Soon; Kim, Chang-Ju; Kim, Hong; Kim, Kyeong-Mi; Baek, Seung-Soo			Treadmill exercise inhibits traumatic brain injury-induced hippocampal apoptosis	PHYSIOLOGY & BEHAVIOR			English	Article						Traumatic brain injury; Treadmill exercise; Short term memory; Apoptosis; Hippocampus	PROGRAMMED CELL-DEATH; COGNITIVE IMPAIRMENT; BCL-2 FAMILY; RATS; EXPRESSION; ISCHEMIA; DISEASE; MEMORY; BAX; MITOCHONDRIA	Traumatic brain injury (TBI) occurs when an outside force impacts the brain The main problem associated with TBI is neuronal cell death of the brain and the outcome of TBI ranges from complete recovery to permanent disability and sometimes death Physical exercise is known to ameliorate neurologic impairment induced by various brain insults In the present study we investigated the effects of treadmill exercise on short-term memory and apoptosis in the hippocampus following TBI in rats TBI was induced by an electromagnetic-controlled cortical impact The rats in the exercise group were forced to run on a treadmill for 30 min once daily for 10 consecutive days beginning 2 days after induction of TBI For the current study a step-down avoidance task terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay Western blot for Bcl 2 and Bax and immunohistochemistry for caspase-3 were conducted The present results revealed that TBI impaired short term memory and increased DNA fragmentation and caspase-3 expression in the hippocampus Induction of TBI also enhanced expression of pro-apoptotic factor Bax protein and suppressed expression of anti-apoptotic factor Bcl-2 protein in the hippocampus Treadmill exercise alleviated short term memory impairment and decreased DNA fragmentation and caspase-3 expression in the hippocampus In addition treadmill exercise remarkably suppressed expression of Bax protein and slightly increased expression of Bcl 2 protein in TBI-induced rats The present study showed that treadmill exercise might overcome TBI-induced apoptotic neuronal cell death thus facilitating recovery following TBI Published by Elsevier Inc	[Baek, Seung-Soo] Sang Myung Univ, Dept Phys Educ, Coll Arts & Phys Educ, Seoul 110743, South Korea; [Kim, Dong-Hyun; Ko, Il-Gyu; Kim, Bo-Kyun; Kim, Tae-Woon; Kim, Sung-Eun; Shin, Mal-Soon; Kim, Chang-Ju] Kyung Hee Univ, Dept Physiol, Coll Med, Seoul 130701, South Korea; [Kim, Dong-Hyun; Kim, Tae-Woon] Sungkyunkwan Univ, Sch Sport Sci, Kyonggi Do 440746, South Korea; [Kim, Hong] Daegu Haany Univ, Dept Oriental Sports Med, Coll Hlth & Therapy, Gyeongbuk 712715, South Korea; [Kim, Kyeong-Mi] Inje Univ, Dept Occupat Therapy, Gyeongnam 621749, South Korea	Baek, SS (corresponding author), Sang Myung Univ, Dept Phys Educ, Coll Arts & Phys Educ, 7 Hongji Dong, Seoul 110743, South Korea.		Kim, Chang Ju/M-4216-2017; Kim, Dong-Hyun/AAH-3043-2020	Kim, Chang Ju/0000-0003-4749-5795; 	Korean GovernmentKorean Government [KRF-2009-332-1-G00090]	This work was supported by the Korea Research Foundation Grant funded by the Korean Government (KRF-2009-332-1-G00090)	Ang ET, 2007, CURR MED CHEM, V14, P2564, DOI 10.2174/092986707782023280; Bayir H, 2003, CRIT CARE CLIN, V19, P529, DOI 10.1016/S0749-0704(03)00014-9; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Carro E, 2001, J NEUROSCI, V21, P5678; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Devine JM, 2009, PM&R, V1, P560, DOI 10.1016/j.pmrj.2009.03.015; Ding Q, 2006, NEUROSCIENCE, V140, P823, DOI 10.1016/j.neuroscience.2006.02.084; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; Graham SH, 2000, J NEUROTRAUM, V17, P831, DOI 10.1089/neu.2000.17.831; Grealy MA, 1999, ARCH PHYS MED REHAB, V80, P661, DOI 10.1016/S0003-9993(99)90169-7; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Greve KW, 2003, ARCH CLIN NEUROPSYCH, V18, P245, DOI 10.1016/S0887-6177(02)00137-3; Griesbach GS, 2007, J NEUROTRAUM, V24, P1161, DOI 10.1089/neu.2006.0255; Guezennec CY, 1998, INT J SPORTS MED, V19, P323, DOI 10.1055/s-2007-971925; Hassett LM, 2009, J REHABIL MED, V41, P247, DOI 10.2340/16501977-0316; Hu ZG, 2009, BRAIN INJURY, V23, P459, DOI 10.1080/02699050902788469; Jee YS, 2008, NEUROSCI LETT, V443, P188, DOI 10.1016/j.neulet.2008.07.078; Jia F, 2009, J NEUROTRAUM, V26, P243, DOI 10.1089/neu.2008.0670; Ko CH, 2006, HUM MOL GENET, V15, pR271, DOI 10.1093/hmg/ddl207; KRAJEWSKI S, 1994, AM J PATHOL, V145, P1323; Laurin D, 2001, ARCH NEUROL-CHICAGO, V58, P498, DOI 10.1001/archneur.58.3.498; Masley S, 2009, J CLIN PSYCHOL MED S, V16, P186, DOI 10.1007/s10880-009-9159-6; PINILLA FG, 1998, NEUROSCIENCE, V85, P53; Ploughman M, 2009, STROKE, V40, P1490, DOI 10.1161/STROKEAHA.108.531806; Raghupathi R, 2003, J NEUROTRAUM, V20, P421, DOI 10.1089/089771503765355504; Sim YJ, 2004, NEUROSCI LETT, V372, P256, DOI 10.1016/j.neulet.2004.09.060; Tehranian R, 2008, J NEUROTRAUM, V25, P755, DOI 10.1089/neu.2007.0441; Teles AVFF, 2008, NEUROSCI LETT, V438, P59, DOI 10.1016/j.neulet.2008.03.062; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Tong LQ, 2001, NEUROBIOL DIS, V8, P1046, DOI 10.1006/nbdi.2001.0427; Um HS, 2008, INT J MOL MED, V22, P529, DOI 10.3892/ijmm_00000052; Upadhyay D, 2003, AM J RESP CELL MOL, V29, P180, DOI 10.1165/rcmb.2002-0269OC; Vakil E, 2005, J CLIN EXP NEUROPSYC, V27, P977, DOI 10.1080/13803390490919245; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052; Yang CC, 2007, J TRAUMA, V62, P657, DOI 10.1097/01.ta.0000203577.68764.b8	39	76	80	0	6	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0031-9384			PHYSIOL BEHAV	Physiol. Behav.	DEC 2	2010	101	5					660	665		10.1016/j.physbeh.2010.09.021			6	Psychology, Biological; Behavioral Sciences	Psychology; Behavioral Sciences	692BK	WOS:000285126300017	20888848				2021-06-18	
J	Xiong, Y; Mahmood, A; Meng, YL; Zhang, YL; Qu, CS; Schallert, T; Chopp, M				Xiong, Ye; Mahmood, Asim; Meng, Yuling; Zhang, Yanlu; Qu, Changsheng; Schallert, Timothy; Chopp, Michael			Delayed administration of erythropoietin reducing hippocampal cell loss, enhancing angiogenesis and neurogenesis, and improving functional outcome following traumatic brain injury in rats: comparison of treatment with single and triple dose	JOURNAL OF NEUROSURGERY			English	Article						angiogenesis; cell proliferation; erythropoietin; neurogenesis; rat; sensorimotor function; spatial learning; traumatic brain injury	SUBVENTRICULAR ZONE; CORTICAL IMPACT; SPATIAL MEMORY; ADULT RATS; STROKE; MICE; NEUROPROTECTION; NEURONS; DAMAGE; EXPRESSION	Object. This efficacy study was designed to investigate traumatic brain injury (TBI) in rats treated with delayed erythropoietin (EPO) administered in a single dose compared with a triple dose. Methods. Young adult male Wistar rats were randomly divided into the following groups: 1) sham group (6 animals); 2) TBI/saline group (6 animals); 3) TBI/EPOx1 group (6 animals); and 4) TBI/EPOx3 group (7 animals). Traumatic brain injury was induced by controlled cortical impact over the left parietal cortex. Erythropoietin (5000 U/kg) or saline was administered intraperitoneally on Day 1 (EPOx1 group) or on Days 1,2, and 3 (EPOx3 group) postinjury. Neurological function was assessed using a modified neurological severity score, foot-fault, and Morris water maze tests. Animals were killed 35 days after injury and brain sections were stained for immunohistochemistry. Results. Compared with the saline treatment, EPO treatment in both the EPOx1 and EPOx3 groups significantly reduced hippocampal cell loss, enhanced angiogenesis and neurogenesis in the injured cortex and hippocampus, and significantly improved neurological functional outcome. The EPOx3 group exhibited significantly improved functional and histological outcomes compared with the EPOx1 group. Conclusions. These data demonstrate that delayed posttraumatic administration of EPO significantly improved histological and long-term functional outcomes in rats after TBI. The triple doses of delayed EPO treatment produced better histological and functional outcomes in rats, although a single dose provided substantial benefits compared with saline treatment. (DOI: 10.3171/2009.9.JNS09844)	[Xiong, Ye; Mahmood, Asim; Meng, Yuling; Zhang, Yanlu; Qu, Changsheng] Henry Ford Hlth Syst, Dept Neurosurg, Detroit, MI 48202 USA; [Chopp, Michael] Oakland Univ, Dept Phys, Rochester, MI USA; [Chopp, Michael] Henry Ford Hlth Syst, Dept Neurol, Detroit, MI 48202 USA; [Schallert, Timothy] Univ Texas Austin, Dept Psychol, Austin, TX 78712 USA; [Schallert, Timothy] Univ Texas Austin, Inst Neurosurg, Austin, TX 78712 USA	Xiong, Y (corresponding author), Henry Ford Hlth Syst, Dept Neurosurg, E&R Bldg,Room 3096,2799 W Grand Blvd, Detroit, MI 48202 USA.	nsxye@neuro.hfh.edu	Zhang, Yanlu/H-1275-2011	Xiong, Ye/0000-0001-9770-6031	National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [RO1 NS62002, PO1 NS42345]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS042345, R01NS062002] Funding Source: NIH RePORTER	Support was received from the National Institute of Neurological Disorders and Stroke (grants RO1 NS62002 [to Dr. Xiong.] and PO1 NS42345 [to Drs. Mahmood and Chopp]).	BARTH TM, 1990, BEHAV BRAIN RES, V39, P73, DOI 10.1016/0166-4328(90)90122-U; Baskin YK, 2003, J NEUROSCI METH, V129, P87, DOI 10.1016/S0165-0270(03)00212-7; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Celik M, 2002, P NATL ACAD SCI USA, V99, P2258, DOI 10.1073/pnas.042693799; Cerami A, 2001, SEMIN HEMATOL, V38, P33, DOI 10.1053/shem.2001.27484; Chen JL, 2005, J CEREBR BLOOD F MET, V25, P281, DOI 10.1038/sj.jcbfm.9600034; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Cherian L, 2007, J PHARMACOL EXP THER, V322, P789, DOI 10.1124/jpet.107.119628; Choi SH, 2006, J NEUROSCI METH, V156, P182, DOI 10.1016/j.jneumeth.2006.03.002; Davis A E, 2000, Crit Care Nurs Q, V23, P1; Day LB, 1999, BEHAV NEUROSCI, V113, P914, DOI 10.1037/0735-7044.113.5.914; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Goings GE, 2004, BRAIN RES, V996, P213, DOI 10.1016/j.brainres.2003.10.034; Gonzalez FF, 2007, DEV NEUROSCI-BASEL, V29, P321, DOI 10.1159/000105473; Grasso G, 2006, J NEUROSURG-SPINE, V4, P310, DOI 10.3171/spi.2006.4.4.310; Grasso G, 2005, NEUROSURGERY, V56, P821, DOI 10.1227/01.NEU.0000156493.00904.7E; Grasso G, 2007, BRAIN RES, V1182, P99, DOI 10.1016/j.brainres.2007.08.078; Hartley CE, 2008, J NEUROSURG, V109, P708, DOI 10.3171/JNS/2008/109/10/0708; Kaya SS, 1999, BRAIN RES, V818, P23, DOI 10.1016/S0006-8993(98)01204-9; Liao ZB, 2008, EUR J NEUROL, V15, P140, DOI 10.1111/j.1468-1331.2007.02013.x; Lu DY, 2007, NEUROSURGERY, V61, P596, DOI 10.1227/01.NEU.0000290908.38438.B2; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Lu DY, 2003, J NEUROSURG, V99, P351, DOI 10.3171/jns.2003.99.2.0351; Mahmood A, 2004, NEUROSURGERY, V55, P1185, DOI 10.1227/01.NEU.0000141042.14476.3C; Mahmood A, 2007, J NEUROSURG, V107, P392, DOI 10.3171/JNS-07/08/0392; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Okutan O, 2008, SURG NEUROL, V70, P498, DOI 10.1016/j.surneu.2007.07.061; Royo NC, 2003, J NEUROPATH EXP NEUR, V62, P801, DOI 10.1093/jnen/62.8.801; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Schallert Timothy, 2006, NeuroRx, V3, P497, DOI 10.1016/j.nurx.2006.08.001; Statler PA, 2007, PEDIATR RES, V61, P671, DOI 10.1203/pdr.0b013e31805341dc; Sun D, 2007, EXP NEUROL, V204, P264, DOI 10.1016/j.expneurol.2006.11.005; Sundholm-Peters NL, 2005, J NEUROPATH EXP NEUR, V64, P1089, DOI 10.1097/01.jnen.0000190066.13312.8f; SUTHERLAND RJ, 1982, NEUROSCI LETT, V31, P271, DOI 10.1016/0304-3940(82)90032-5; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Wang L, 2004, STROKE, V35, P1732, DOI 10.1161/01.STR.0000132196.49028.a4; Xiong Y, 2008, BRAIN RES, V1230, P247, DOI 10.1016/j.brainres.2008.06.127; Xiong Y, 2008, J NEUROSURG, V109, P510, DOI 10.3171/JNS/2008/109/9/0510; Zhang RL, 2004, J CEREBR BLOOD F MET, V24, P441, DOI 10.1097/00004647-200404000-00009; Zhang RL, 2002, STROKE, V33, P2675, DOI 10.1161/01.STR.0000034399.95249.59; Zhang RL, 2004, J NEUROSCI, V24, P5810, DOI 10.1523/JNEUROSCI.1109-04.2004; Zhang RL, 2008, NEUROPHARMACOLOGY, V55, P345, DOI 10.1016/j.neuropharm.2008.05.027; Zhang ZG, 2009, LANCET NEUROL, V8, P491, DOI 10.1016/S1474-4422(09)70061-4	47	76	83	0	10	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085			J NEUROSURG	J. Neurosurg.	SEP	2010	113	3					598	608		10.3171/2009.9.JNS09844			11	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	641FV	WOS:000281111100025	19817538	Green Accepted			2021-06-18	
J	Koike, MA; Green, KN; Blurton-Jones, M; LaFerla, FM				Koike, Maya A.; Green, Kim N.; Blurton-Jones, Mathew; LaFerla, Frank M.			Oligemic Hypoperfusion Differentially Affects Tau and Amyloid-beta	AMERICAN JOURNAL OF PATHOLOGY			English	Article							MIDDLE CEREBRAL-ARTERY; TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; COGNITIVE DECLINE; VASCULAR-LESIONS; A-BETA; DEMENTIA; ISCHEMIA; RISK	Decreased blood flow to the brain in humans is associated with altered Alzheimer's disease (AD)-related pathology, although the underlying mechanisms by which hypoperfusion influences AD neuropathology remains unknown. To try to address this question, we developed an oligemic model of cerebral hypoperfusion in the 3xTg-AD mouse model of AD. We bilaterally and transiently occluded the common carotid artery and then examined the molecular and cellular pathways by which hypoperfusion influenced tau and amyloid-beta proteins. We report the novel finding that a single, mild, transient hypoperfusion insult acutely increases A beta levels by enhancing beta-secretase protein expression. In contrast, transient hypoperfusion markedly decreases total tau levels, coincident with activation of macroautophagy and ubiquitin-proteosome pathways. Furthermore, we find that oligemia results in a significant increase specifically in tau phosphorylated at serine(212) and threonine(214), a tau epitope associated with paired helical filaments in AD patients. Despite the mild and transient nature of this hypoperfusion injury, the pattern of decreased total tau, altered phosphorylated tau, and increased amyloid-beta persisted for several weeks postoligemia. Our study indicates that a single, mild, cerebral hypoperfusion event produces profound and long lasting effects on both tau and amyloid-beta. This finding may have implications for the pathogenesis of AD, as it indicates for the first time that total tau and amyloid-beta are differentially impacted by mild hypoperfusion. (Am J Pathol 2010, 177:300-310; DOI: 10.2353/ajpath.2010.090750)	[Koike, Maya A.; Green, Kim N.; Blurton-Jones, Mathew; LaFerla, Frank M.] Univ Calif Irvine, Inst Memory Impairments & Neurol Disorders, Dept Neurobiol & Behav, Irvine, CA 92697 USA	LaFerla, FM (corresponding author), Univ Calif Irvine, Inst Memory Impairments & Neurol Disorders, Dept Neurobiol & Behav, 3212 Biol Sci 3, Irvine, CA 92697 USA.	laferla@uci.edu		Blurton-Jones, Mathew/0000-0002-7770-7157	National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AG-021982, 1F31NS063650-01A1, AG-029378]; Southern California ARCS; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F31NS063650] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K01AG029378, R01AG021982] Funding Source: NIH RePORTER	Supported in part by grants from the National Institute of Health AG-021982 to F.M.L. and National Institute of Health 1F31NS063650-01A1 and Southern California ARCS award to M.A.K., and National Institute of Health AG-029378 to M.B.J.	Anders A, 2001, FASEB J, V15, P1837, DOI 10.1096/fj.01-0007fje; Blasko I, 2004, J NEURAL TRANSM, V111, P523, DOI 10.1007/s00702-003-0095-6; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; CLINTON J, 1991, NEUROPATH APPL NEURO, V17, P69, DOI 10.1111/j.1365-2990.1991.tb00695.x; de Leon MJ, 2001, P NATL ACAD SCI USA, V98, P10966, DOI 10.1073/pnas.191044198; Gordon-Krajcer W, 2007, NEUROCHEM RES, V32, P729, DOI 10.1007/s11064-006-9199-3; Goulding JMR, 1999, J NEUROL NEUROSUR PS, V67, P654, DOI 10.1136/jnnp.67.5.654; Green KN, 2002, J PHYSIOL-LONDON, V541, P1013, DOI 10.1113/jphysiol.2002.017582; Green KN, 2001, J NEUROCHEM, V77, P953, DOI 10.1046/j.1471-4159.2001.00338.x; Hamano T, 2008, EUR J NEUROSCI, V27, P1119, DOI 10.1111/j.1460-9568.2008.06084.x; Hebert LE, 2003, ARCH NEUROL-CHICAGO, V60, P1119, DOI 10.1001/archneur.60.8.1119; Honig LS, 2003, ARCH NEUROL-CHICAGO, V60, P1707, DOI 10.1001/archneur.60.12.1707; Ikeda K, 2000, NEUROSCI LETT, V284, P187, DOI 10.1016/S0304-3940(00)01009-0; Jellinger KA, 2001, EUR J NEUROL, V8, P707, DOI 10.1046/j.1468-1331.2001.00322.x; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kalaria RN, 2003, INT PSYCHOGERIATR, V15, P47, DOI 10.1017/S1041610203008950; Kalaria RN, 2000, NEUROBIOL AGING, V21, P321, DOI 10.1016/S0197-4580(00)00125-1; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Ksiezak-Reding H, 2000, CELL MOTIL CYTOSKEL, V47, P236, DOI 10.1002/1097-0169(200011)47:3<236::AID-CM6>3.0.CO;2-K; Lee JH, 2000, ARCH NEUROL-CHICAGO, V57, P1474, DOI 10.1001/archneur.57.10.1474; Lee PH, 2006, NEUROCHEM RES, V31, P821, DOI 10.1007/s11064-006-9086-y; Li L, 2009, NEUROBIOL AGING, V30, P1091, DOI 10.1016/j.neurobiolaging.2007.10.011; LOEB C, 1992, STROKE, V23, P1225, DOI 10.1161/01.STR.23.9.1225; Makinen S, 2008, J CEREBR BLOOD F MET, V28, P263, DOI 10.1038/sj.jcbfm.9600529; Moroney JT, 1996, STROKE, V27, P1283, DOI 10.1161/01.STR.27.8.1283; Mosconi L, 2008, ANN NY ACAD SCI, V1147, P180, DOI 10.1196/annals.1427.007; Nihashi T, 2001, ACTA NEUROCHIR, V143, P287, DOI 10.1007/s007010170109; O'Rourke MF, 2007, J AM COLL CARDIOL, V50, P1, DOI 10.1016/j.jacc.2006.12.050; Oddo S, 2003, NEURON, V39, P409, DOI 10.1016/S0896-6273(03)00434-3; Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200; Riekse RG, 2004, J AM GERIATR SOC, V52, P1442, DOI 10.1111/j.1532-5415.2004.52405.x; Schneider JA, 2007, ANN NEUROL, V62, P59, DOI 10.1002/ana.21142; Sun X, 2006, P NATL ACAD SCI USA, V103, P18727, DOI 10.1073/pnas.0606298103; TATEMICHI TK, 1994, NEUROLOGY, V44, P1885, DOI 10.1212/WNL.44.10.1885; Tesco G, 2007, NEURON, V54, P721, DOI 10.1016/j.neuron.2007.05.012; Tseng BP, 2008, NEUROBIOL AGING, V29, P1607, DOI 10.1016/j.neurobiolaging.2007.04.014; van Groen T, 2005, STROKE, V36, P1551, DOI 10.1161/01.STR.0000169933.88903.cf; Vermeer SE, 2003, NEW ENGL J MED, V348, P1215, DOI 10.1056/NEJMoa022066; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Webster CM, 2009, NEUROBIOL DIS, V33, P301, DOI 10.1016/j.nbd.2008.11.001; Wen Y, 2004, BRAIN RES, V1022, P30, DOI 10.1016/j.brainres.2004.05.106; Wen Y, 2007, BBA-MOL BASIS DIS, V1772, P473, DOI 10.1016/j.bbadis.2006.10.011; Zhang X, 2007, J BIOL CHEM, V282, P10873, DOI 10.1074/jbc.M608856200; Zheng-Fischhofer QY, 1998, EUR J BIOCHEM, V252, P542, DOI 10.1046/j.1432-1327.1998.2520542.x; ZHIYOU C, 2009, NEUROCHEM RES, V7, P1226	45	76	78	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	JUL	2010	177	1					300	310		10.2353/ajpath.2010.090750			11	Pathology	Pathology	624GM	WOS:000279805100032	20472896	Bronze, Green Published			2021-06-18	
J	Stephens, FL; Mossop, CM; Bell, RS; Tigno, T; Rosner, MK; Kumar, A; Moores, LE; Armonda, RA				Stephens, Frederick L.; Mossop, Correy M.; Bell, Randy S.; Tigno, Teodoro, Jr.; Rosner, Michael K.; Kumar, Anand; Moores, Leon E.; Armonda, Rocco A.			Cranioplasty complications following wartime decompressive craniectomy	NEUROSURGICAL FOCUS			English	Article						cranioplasty; craniectomy; traumatic brain injury	DELAYED CRANIOPLASTY; GRAFT INFECTION; TECHNICAL NOTE; BONE-GRAFTS; SKULL BONE; EXPERIENCE	Object. In support of Operation Iraqi Freedom (OIF) and Operation Enduring Freedom-Afghanistan (OEF-A), military neurosurgeons in the combat theater are faced with the daunting task of stabilizing patients in such a way as to prevent irreversible neurological injury from cerebral edema while simultaneously allowing for prolonged transport stateside (5000-7000 miles). It is in this setting that decompressive craniectomy has become a mainstay of far-forward neurosurgical management of traumatic brain injury (TBI). As such, institutional experience with cranioplasty at the Walter Reed Army Medical Center (WRAMC) and the National Naval Medical Center (NNMC) has expanded concomitantly. Battlefield blast explosions create cavitary injury zones that often extend beyond the border of the exposed surface wound, and this situation has created unique reconstruction challenges not often seen in civilian TBI. The loss of both soft-tissue and skull base support along with the need for cranial vault reconstruction requires a multidisciplinary approach involving neurosurgery, plastics, oral-maxillofacial surgery, and ophthalmology. With this situation in mind, the authors of this paper endeavored to review the cranial reconstruction complications encountered in these combat-related injuries. Methods. A retrospective database review was conducted for all soldiers injured in OIF and OEF-A who had undergone decompressive craniectomy with subsequent cranioplasty between April 2002 and October 2008 at the WRAMC and NNMC. During this time, both facilities received a total of 408 OIF/OEF-A patients with severe head injuries; 188 of these patients underwent decompressive craniectomies in the theater before transfer to the US. Criteria for inclusion in this study consisted of either a closed or a penetrating head injury sustained in combat operations, resulting in the performance of a decompressive craniectomy and subsequent cranioplasty at either the WRAMC or NNMC. Excluded from the study were patients for whom primary demographic data could not be verified. Demographic data, indications for craniectomy, as well as preoperative, intraoperative, and postoperative parameters following cranioplasty, were recorded. Perioperative and postoperative complications were also recorded. Results. One hundred eight patients (male/female ratio 107: 1) met the inclusion criteria for this study, 93 with a penetrating head injury and 15 with a closed head injury. Explosive blast injury was the predominant mechanism of injury, occurring in 72 patients (67%). The average time that elapsed between injury and cranioplasty was 190 days (range 7-546 days). An overall complication rate of 24% was identified. The prevalence of perioperative infection (12%), seizure (7.4%), and extraaxial hematoma formation (7.4%) was noted. Twelve patients (11%) required prosthetic removal because of either extraaxial hematoma formation or infection. Eight of the 13 cases of infection involved cranioplasties performed between 90 and 270 days from the date of injury (p = 0.06). Conclusions. This study represents the largest to date in which cranioplasty and its complications have been evaluated in a trauma population that underwent decompressive craniectomy. The overall complication rate of 24% is consistent with rates reported in the literature (16-34%); however, the perioperative infection rate of 12% is higher than the rates reported in other studies. This difference is likely related to aspects of the initial injury pattern-such as skull base injury, orbitofacial fractures, sinus injuries, persistent fluid collection, and CSF leakage-which can predispose these patients to infection. (DOI: 10.3171/2010.2.FOCUS1026)	[Stephens, Frederick L.] Walter Reed Army Med Ctr, Dept Neurosurg, Washington, DC 20307 USA; Natl Naval Med Ctr, Dept Neurosurg, Bethesda, MD USA	Stephens, FL (corresponding author), Walter Reed Army Med Ctr, Dept Neurosurg, Washington, DC 20307 USA.	frederick.stephens@us.army.mil					CARVI Y, 2006, NEUROL RES, V28, P139, DOI DOI 10.1179/016164106X98008; Cheng YK, 2008, J CLIN NEUROSCI, V15, P1115, DOI 10.1016/j.jocn.2007.09.022; Gooch MR, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0962; Grossman N., 2007, Cell and Tissue Banking, V8, P243, DOI 10.1007/s10561-006-9032-x; Iwama T, 2003, NEUROSURGERY, V52, P591, DOI 10.1227/01.NEU.0000047891.86938.46; Jho DH, 2007, J NEUROSURG, V107, P440, DOI 10.3171/JNS-07/08/0440; Kawaguchi T, 2003, NEUROL MED-CHIR, V43, P320, DOI 10.2176/nmc.43.320; Kriegel RJ, 2007, ZBL NEUROCHIR, V68, P182, DOI 10.1055/s-2007-985857; Liao CC, 2002, J CLIN NEUROSCI, V9, P553, DOI 10.1054/jocn.2002.1116; Marchac D, 2008, J PLAST RECONSTR AES, V61, P744, DOI 10.1016/j.bjps.2007.10.055; Matsuno A, 2006, ACTA NEUROCHIR, V148, P535, DOI 10.1007/s00701-006-0740-6; Moreira-Gonzalez A, 2003, J CRANIOFAC SURG, V14, P144, DOI 10.1097/00001665-200303000-00003; Movassaghi K, 2006, PLAST RECONSTR SURG, V117, P202, DOI 10.1097/01.prs.0000187152.48402.17; Staffa G, 2007, ACTA NEUROCHIR, V149, P161, DOI 10.1007/s00701-006-1078-9; Wen L, 2007, J CRANIOFAC SURG, V18, P526; Wurm G, 2004, SURG NEUROL, V62, P510, DOI 10.1016/j.surneu.2004.01.025	16	76	79	1	8	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1092-0684			NEUROSURG FOCUS	Neurosurg. Focus	MAY	2010	28	5							E3	10.3171/2010.2.FOCUS1026			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	589ZU	WOS:000277193600003	20568943				2021-06-18	
J	Perlbarg, V; Puybasset, L; Tollard, E; Lehericy, S; Benali, H; Galanaud, D				Perlbarg, Vincent; Puybasset, Louis; Tollard, Eleonore; Lehericy, Stephane; Benali, Habib; Galanaud, Damien			Relation Between Brain Lesion Location and Clinical Outcome in Patients with Severe Traumatic Brain Injury: A Diffusion Tensor Imaging Study Using Voxel-Based Approaches	HUMAN BRAIN MAPPING			English	Article						traumatic brain injury; clinical outcome; diffusion tensor imaging; tract-based spatial statistics	WHITE-MATTER INJURY; AXONAL INJURY; ANISOTROPY	The early prediction of consciousness recovery from traumatic brain injury (TBI) is crucial to make decisions about the appropriate use of prolonged intensive care. Diffusion tensor imaging (DTI) has been proposed as a biomarker of white matter injury that could be used in a classification purpose. Instead of region-of-interest-based approach, we applied voxel-based approaches (voxel-based DTI and tract-based spatial statistics) on 30 patients with TBI to identify, without any prior, the brain regions that were specifically damaged in unfavorable 1-year outcome group compared to the favorable one. DTI were acquired at mean 23 days (5-53 days) and two DTI-derived indices, fractional anisotropy (FA) and apparent diffusion coefficient (ADC), were tested. Our results showed that (1) ADC is not a relevant biomarker for early 1-year outcome prognosis; (2) FA measured in inferior longitudinal fasciculus, in cerebral peduncle, in posterior limb of the internal capsule, and in posterior corpus callosum is specifically decreased in unfavorable outcome group compare to the favorable one; (3) a linear discriminant analysis using the FA measured in these four regions showed good classification performance (sensitivity = 86% and specificity = 86%). These findings confirm the relevance of the use of DTI as biomarkers for consciousness recovery after TBI and support the possible use of these biomarkers for early classification of patients. Hum Brain Mapp 30:3924-3933, 2009. (C) 2009 Wiley-Liss, Inc.	[Perlbarg, Vincent] Univ Paris 06, INSERM, UMRS 678, Lab Imagerie Fonctionnelle, F-75634 Paris 13, France; [Perlbarg, Vincent; Benali, Habib] UPMC Univ Paris 06, UMRS 678, Lab Imagerie Fonctionnelle, Paris, France; [Puybasset, Louis] UPMC Univ Paris 06, Pitie Salpetriere Hosp, AP HP, Surg Neurointens Care Unit, Paris, France; [Tollard, Eleonore] UPMC Univ Paris 06, Pitie Salpetriere Hosp, AP HP, Dept Neuroradiol, Paris, France; [Lehericy, Stephane; Galanaud, Damien] Univ Hosp Rouen, Dept Radiol, Rouen, France; [Lehericy, Stephane] UPMC Univ Paris 06, CENIR, Paris, France	Perlbarg, V (corresponding author), Univ Paris 06, INSERM, UMRS 678, Lab Imagerie Fonctionnelle, 91 Blvd Hop, F-75634 Paris 13, France.	vperlbar@imed.jussieu.fr					Albrecht J, 2007, J NEUROL NEUROSUR PS, V78, P964, DOI 10.1136/jnnp.2006.112987; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Chan JHM, 2003, NEURORADIOLOGY, V45, P34, DOI 10.1007/s00234-002-0891-y; Coles JP, 2007, BRIT J ANAESTH, V99, P49, DOI 10.1093/bja/aem141; GIACINO JT, 1995, J HEAD TRAUMA REHAB, V10, P40; Goetz P, 2004, J NEUROTRAUM, V21, P645, DOI 10.1089/0897715041269731; Hou DJ, 2007, J NEUROTRAUM, V24, P1558, DOI 10.1089/neu.2007.0339; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Jones DK, 2005, NEUROIMAGE, V26, P546, DOI 10.1016/j.neuroimage.2005.02.013; Kumar R, 2008, J MAGN RESON IMAGING, V27, P1061, DOI 10.1002/jmri.21342; Lescot T, 2008, CURR OPIN CRIT CARE, V14, P129, DOI 10.1097/MCC.0b013e3282f63c51; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Parvizi J, 2001, COGNITION, V79, P135, DOI 10.1016/S0010-0277(00)00127-X; Pierpaoli C, 1996, MAGNET RESON MED, V36, P893, DOI 10.1002/mrm.1910360612; Ptak T, 2003, AM J ROENTGENOL, V181, P1401, DOI 10.2214/ajr.181.5.1811401; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Thivard L, 2007, J NEUROL NEUROSUR PS, V78, P889, DOI 10.1136/jnnp.2006.101758; Weiss GA, 2007, CURR OPIN CHEM BIOL, V11, P241, DOI 10.1016/j.cbpa.2007.05.022; Weiss N, 2008, J NEUROL, V255, P217, DOI 10.1007/s00415-008-0658-4	24	76	78	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1065-9471	1097-0193		HUM BRAIN MAPP	Hum. Brain Mapp.	DEC	2009	30	12					3924	3933		10.1002/hbm.20817			10	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	530IW	WOS:000272584000007	19507154	Green Published			2021-06-18	
J	Hunt, TN; Ferrara, MS; Bornstein, RA; Baumgartner, TA				Hunt, Tamerah N.; Ferrara, Michael S.; Bornstein, Robert A.; Baumgartner, Ted A.			The Reliability of the Modified Balance Error Scoring System	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						balance; head injury; concussion; BESS; youth	MILD HEAD-INJURY; POSTURAL STABILITY; CONCUSSION; STATEMENT; SPORT	Objective: Study I investigated the intraclass reliability and percent variance associated with each component within the traditional Balance Error Scoring System (BESS) protocol. Study 2 investigated the reliability of subsequent modifications of the BESS. Design: Prospective cross-sectional examination of the traditional and modified BESS protocols. Setting: Schools participating in Georgia High School Athletics Association. Intervention: The modified BESS consisted of 2 surfaces (firm and foam) and 2 stances (single-leg and tandem-leg stance) repeated for a total of three 20-second trials. Participants: Participants consisted of 2 independent samples of high school athletes aged 13 to 19 years. Main Outcome Measures: Percent variance for each condition of the BESS was obtained using GENOVA 3.1. An intraclass reliability coefficient and repeated measures analysis of variance were calculated using SPSS 13.0. Results: Study 1 obtained an intraclass correlation coefficient (r = 0.60) with stance accounting for 55% of the total variance. Removing the double-leg stance increased the intraclass correlation coefficient (r = 0.71). Study 2 found a statistically significant difference between trials I and 2 (F(1.65 286) = 4.890, P = 0.013) and intraclass reliability coefficient of r = 0.88 for 3 trials of 4 conditions. Conclusions: The variance associated with the double-leg stance was very small, and when removed, the intraclass reliability coefficient of the BESS increased. Removal of the double-leg stance and addition of 3 trials of 4 conditions provided an easily administered, cost-effective, time-efficient tool that provides reliable objective information for clinicians to base clinical decisions upon.	[Hunt, Tamerah N.] Ohio State Univ, Ctr Sports Med, Sch Allied Med Profess, Columbus, OH 43221 USA; [Ferrara, Michael S.; Baumgartner, Ted A.] Univ Georgia, Dept Kinesiol, Athens, GA 30602 USA; [Bornstein, Robert A.] Ohio State Univ, Dept Psychiat, Columbus, OH 43221 USA	Hunt, TN (corresponding author), Ohio State Univ, Ctr Sports Med, Sch Allied Med Profess, 2050 Kenny Rd,Ste 3100, Columbus, OH 43221 USA.	tamerah.hunt@osumc.edu	Hunt, Tamerah/E-3281-2011				Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; BAUMGARTNER TA, 2003, MEASUREMENT EVALUATI, P96; Brennan R. L., 1992, ELEMENTS GEN THEORY; CRICK JE, 1982, GENOVA GEN ANAL VARI; EKDAHL C, 1989, SCAND J REHABIL MED, V21, P187; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; Guskiewicz KM, 1996, J SPORT REHABIL, V5, P45, DOI 10.1123/jsr.5.1.45; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; INGERSOLL CD, 1992, MED SCI SPORT EXER, V24, P739; JANSEN EC, 1982, ACTA NEUROL SCAND, V66, P93; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory Paul, 2005, Clin J Sport Med, V15, P48; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; McLeod TCV, 2004, CLIN J SPORT MED, V14, P287, DOI 10.1097/00042752-200409000-00007; Riemann BL, 1999, J SPORT REHABIL, V8, P71, DOI 10.1123/jsr.8.2.71; Riemann BL, 1997, J SPORT REHABIL, V6, P283, DOI 10.1123/jsr.6.3.283; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Susco TM, 2004, J ATHL TRAINING, V39, P241; Valovich TC, 2003, J ATHL TRAINING, V38, P51; VALOVICH TC, 2002, THESIS U VIRGINIA CH; Wilkins JC, 2004, J ATHL TRAINING, V39, P156	22	76	76	0	16	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	NOV	2009	19	6					471	475		10.1097/JSM.0b013e3181c12c7b			5	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	520NB	WOS:000271850500006	19898074				2021-06-18	
J	Salim, A; Ley, EJ; Cryer, HG; Margulies, DR; Ramicone, E; Tillou, A				Salim, Ali; Ley, Eric J.; Cryer, H. Gill; Margulies, Daniel R.; Ramicone, Emily; Tillou, Areti			Positive Serum Ethanol Level and Mortality in Moderate to Severe Traumatic Brain Injury	ARCHIVES OF SURGERY			English	Article							BETA-BLOCKER EXPOSURE; HEAD-INJURY; HEMORRHAGIC-SHOCK; ALCOHOL; INTOXICATION; OUTCOMES; IMPACT; MODEL; RATS; ASSOCIATION	Hypothesis: Ethanol exposure is associated with decreased mortality in patients with moderate to severe traumatic brain injury. Design: Retrospective database review. Setting: Trauma centers contributing to the National Trauma Data Bank (NTDB). Patients: Version 6.2 of the NTDB (2000-2005) was queried for all patients with moderate to severe traumatic brain injury (head Abbreviated Injury Score >= 3) and ethanol levels measured on admission. Demographics and outcomes were compared between patients with traumatic brain injuries with and without ethanol in their blood. Logistic regression analysis was used to investigate the relationship between mortality and ethanol. Main Outcome Measures: Mortality and complications. Results: A total of 38 019 patients with severe traumatic brain injuries were evaluated. Thirty-eight percent tested positive for ethanol. Ethanol-positive patients were younger (mean [SD], 37.7 [15.1] vs; 44.1 [22.0] years, P<.001), had a lower Injury Severity Score (22.3 [10.0] vs 23.0 [10.3], P<.001), and a lower Glasgow Coma Scale score (10.0 [5.1] vs 11.0 [4.9], P<.001) compared with their ethanol-negative counterparts. After logistic regression analysis, ethanol was associated with reduced mortality (adjusted odds ratio, 0.88; 95% confidence interval, 0.80-0.96; P=.005) and higher complications (adjusted odds ratio, 1.24; 95% confidence interval, 1.15-1.33; P<.001). Conclusions: Serum ethanol is independently associated with decreased mortality in patients with moderate to severe head injuries. Additional research is warranted to investigate the potential therapeutic implications of this association.	[Salim, Ali; Ley, Eric J.; Margulies, Daniel R.; Ramicone, Emily] Cedars Sinai Med Ctr, Dept Surg, Div Trauma & Crit Care, Los Angeles, CA 90048 USA; [Cryer, H. Gill; Tillou, Areti] Univ Calif Los Angeles, Div Trauma, Los Angeles, CA USA	Salim, A (corresponding author), Cedars Sinai Med Ctr, Dept Surg, Div Trauma & Crit Care, 8700 Beverly Blvd,Ste 8215N, Los Angeles, CA 90048 USA.	ali.salim@cshs.org					Alexander S, 2004, J NEUROTRAUM, V21, P575, DOI 10.1089/089771504774129900; Arbabi S, 2007, J TRAUMA, V62, P56, DOI 10.1097/TA.0b013e31802d972b; Cotton BA, 2007, J TRAUMA, V62, P26, DOI 10.1097/TA.0b013e31802d02d0; Cunningham RM, 2002, ALCOHOL ALCOHOLISM, V37, P236, DOI 10.1093/alcalc/37.3.236; Dash PK, 2004, J NEUROTRAUM, V21, P1573, DOI 10.1089/neu.2004.21.1573; Fabbri A, 2002, EMERG MED J, V19, P210, DOI 10.1136/emj.19.3.210; Fabian MJ, 2002, J TRAUMA, V53, P864, DOI 10.1097/00005373-200211000-00010; Gottesfeld Z, 2002, J NEUROTRAUM, V19, P317, DOI 10.1089/089771502753594882; Inaba K, 2008, J AM COLL SURGEONS, V206, P432, DOI 10.1016/j.jamcollsurg.2007.10.005; Janis LS, 1998, J NEUROTRAUM, V15, P105, DOI 10.1089/neu.1998.15.105; Kelly DF, 2000, J NEUROTRAUM, V17, P261, DOI 10.1089/neu.2000.17.261; Kelly DF, 1997, J NEUROSURG, V86, P876, DOI 10.3171/jns.1997.86.5.0876; Li GH, 1997, J TRAUMA, V42, P562, DOI 10.1097/00005373-199703000-00032; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; *NAT HIGHW TRAFF A, 2000, EC IMP MOT VEH CRASH; O'Phelan K, 2008, J TRAUMA, V65, P674, DOI 10.1097/TA.0b013e31817db0a5; Plurad D, 2006, J AM COLL SURGEONS, V202, P919, DOI 10.1016/j.jamcollsurg.2006.02.024; PORIES SE, 1992, J TRAUMA, V32, P60, DOI 10.1097/00005373-199201000-00013; Riordan WP, 2007, J TRAUMA, V63, P503, DOI 10.1097/TA.0b013e3181271c34; Salim A, 2008, J TRAUMA, V64, P46, DOI 10.1097/TA.0b013e31815eb15a; Shih HC, 2003, AM J EMERG MED, V21, P91, DOI 10.1053/ajem.2003.50025; Stewart RM, 2003, J TRAUMA, V54, P66, DOI 10.1097/00005373-200301000-00009; Tien HCN, 2006, ARCH SURG-CHICAGO, V141, P1185, DOI 10.1001/archsurg.141.12.1185; Tureci E, 2004, NEUROL RES, V26, P108, DOI 10.1179/016164104225013699; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509; WOOLF PD, 1991, J TRAUMA, V31, P1271, DOI 10.1097/00005373-199109000-00012; ZINK BJ, 1995, J NEUROSURG, V82, P822, DOI 10.3171/jns.1995.82.5.0822; ZINK BJ, 1993, J NEUROTRAUM, V10, P275, DOI 10.1089/neu.1993.10.275; Zink BJ, 1999, BRAIN RES, V837, P1, DOI 10.1016/S0006-8993(99)01646-7; Zink BJ, 2001, ALCOHOL CLIN EXP RES, V25, P916; Zink BJ, 1998, J NEUROSURG, V89, P983, DOI 10.3171/jns.1998.89.6.0983	31	76	79	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0004-0010			ARCH SURG-CHICAGO	Arch. Surg.	SEP	2009	144	9					865	871		10.1001/archsurg.2009.158			7	Surgery	Surgery	494RQ	WOS:000269833500012	19797113	Bronze			2021-06-18	
J	Park, E; Bell, JD; Siddiq, IP; Baker, AJ				Park, Eugene; Bell, Joshua D.; Siddiq, Ishita P.; Baker, Andrew J.			An analysis of regional microvascular loss and recovery following two grades of fluid percussion trauma: a role for hypoxia-inducible factors in traumatic brain injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						FPI; HIF1 alpha; microangiography; microvasculature; PHD2; VEGF	ENDOTHELIAL GROWTH-FACTOR; CEREBRAL-BLOOD-FLOW; CORPUS-CALLOSUM; GENE-EXPRESSION; HEAD TRAUMA; FACTOR VEGF; RAT; VULNERABILITY; CALPONIN; COMPLEX	Secondary hypoxic/ischemic injuries, stemming from reductions in cerebral blood flow are important contributing factors in progressive neuronal dysfunction after brain trauma. A greater preclinical understanding of how brain trauma leads to secondary hypoxia/ischemia is necessary in the development of posttraumatic brain injury (TBI) therapeutics. To this end, we examined the density of microvascular coverage in the injured and contralateral cortical hemispheres using two intensities of fluid percussion trauma in rats. A silicone microangiography technique showed a significant loss in microvascular density in 2 atmosphere (atm) (16.9 +/- 3.8%) and 3 atm (15.7 +/- 1.3%) injured animals relative to sham animals (29.9 +/- 2.5%; P < 0.01). RECA-1 immunohistochemistry indicated that capillary changes involved a reduction in capillary number and diameter. Reduction in microvascular density was shown to be a diffuse phenomenon occurring up to 4mm rostral and caudal to the injury epicenter. Recovery of microvasculature occurred by 2 weeks after injury only in the 2 atm injury group. Expression of HIF1 alpha and increased vascular endothelial growth factor expression were observed in the ipsilateral hippocampus suggesting sufficiently impaired microcirculation resulting in the expression of hypoxic-response proteins. Collectively, the results indicate diffuse and heterogeneous microvascular alterations as well as endogenous expression of neuroprotective and neovascularization pathways after TBI.	[Park, Eugene; Bell, Joshua D.; Siddiq, Ishita P.; Baker, Andrew J.] St Michaels Hosp, Keenan Res Ctr, Li Ka Shing Knowledge Inst, Cara Phelan Ctr Trauma Res, Toronto, ON M5B 1W8, Canada; [Bell, Joshua D.; Siddiq, Ishita P.; Baker, Andrew J.] Univ Toronto, Toronto, ON, Canada	Park, E (corresponding author), St Michaels Hosp, Keenan Res Ctr, Li Ka Shing Knowledge Inst, Cara Phelan Ctr Trauma Res, 30 Bond St,7-086 Bond Wing, Toronto, ON M5B 1W8, Canada.	parke@smh.toronto.on.ca					Baker AJ, 2002, J NEUROTRAUM, V19, P587, DOI 10.1089/089771502753754064; Berra E, 2006, EMBO REP, V7, P41, DOI 10.1038/sj.embor.7400598; Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P471; Chodobski A, 2003, NEUROSCIENCE, V122, P853, DOI 10.1016/j.neuroscience.2003.08.055; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Dore-Duffy P, 2007, NEUROL RES, V29, P395, DOI 10.1179/016164107X204729; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; Golding EM, 1999, CLIN EXP HYPERTENS, V21, P299, DOI 10.3109/10641969909068668; Gora-Kupilas K, 2005, FOLIA NEUROPATHOL, V43, P31; Huh JW, 2008, EXP NEUROL, V213, P84, DOI 10.1016/j.expneurol.2008.05.009; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kreipke CW, 2007, NEUROL RES, V29, P369, DOI 10.1179/016164107X204684; Kreipke CW, 2006, MICROVASC RES, V71, P197, DOI 10.1016/j.mvr.2006.02.002; Lazarovici P, 2006, CURR PHARM DESIGN, V12, P2609, DOI 10.2174/138161206777698738; Lin B, 2001, J NEUROTRAUM, V18, P389, DOI 10.1089/089771501750170958; Longhi L, 2007, INTENS CARE MED, V33, P2136, DOI 10.1007/s00134-007-0845-2; Maeda T, 2005, J NEUROTRAUM, V22, P763, DOI 10.1089/neu.2005.22.763; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Morgan R, 2007, NEUROL RES, V29, P375, DOI 10.1179/016164107X204693; Muellner A, 2003, J NEUROTRAUM, V20, P745, DOI 10.1089/089771503767869971; Park E, 2007, EXP NEUROL, V204, P49, DOI 10.1016/j.expneurol.2006.09.012; Park E, 2006, J NEUROPATH EXP NEUR, V65, P226, DOI 10.1097/01.jnen.0000202888.29705.93; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Petrov T, 2001, NEUROL RES, V23, P139, DOI 10.1179/016164101101198479; Pugh C W, 1999, Adv Nephrol Necker Hosp, V29, P191; Ratcliffe PJ, 1998, J EXP BIOL, V201, P1153; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; Shen FX, 2006, STROKE, V37, P2601, DOI 10.1161/01.STR.0000240407.14765.e8; Shen YM, 2007, MAGN RESON IMAGING, V25, P219, DOI 10.1016/j.mri.2006.09.018; Skold MK, 2006, EUR J NEUROSCI, V23, P21, DOI 10.1111/j.1460-9568.2005.04527.x; Skold MK, 2005, J NEUROTRAUM, V22, P353, DOI 10.1089/neu.2005.22.353; Stein SC, 2002, J NEUROSURG, V97, P1373, DOI 10.3171/jns.2002.97.6.1373; Verweij BH, 2007, PROG BRAIN RES, V161, P111, DOI 10.1016/S0079-6123(06)61008-X; Vespa Paul, 2003, Neurosurg Focus, V15, pE4; Wan YQ, 2007, J NEUROSCI RES, V85, P73, DOI 10.1002/jnr.21091; Wu HM, 2004, NEUROSURGERY, V55, P1306, DOI 10.1227/01.NEU.0000143028.08719.42; Yamamoto T, 1988, J NEUROTRAUM, V5, P69, DOI 10.1089/neu.1988.5.69; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289	40	76	80	0	7	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	MAR	2009	29	3					575	584		10.1038/jcbfm.2008.151			10	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	412KD	WOS:000263722800013	19088740	Bronze			2021-06-18	
J	Behan, LA; Phillips, J; Thompson, CJ; Agha, A				Behan, L. A.; Phillips, J.; Thompson, C. J.; Agha, A.			Neuroendocrine disorders after traumatic brain injury	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							GROWTH-HORMONE DEFICIENCY; ANTI-DIURETIC HORMONE; ANTERIOR-PITUITARY INSUFFICIENCY; SEVERE HEAD-INJURY; QUALITY-OF-LIFE; INAPPROPRIATE SECRETION; BODY-COMPOSITION; POSTTRAUMATIC HYPOPITUITARISM; SUBARACHNOID HEMORRHAGE; ADULT PATIENTS	Traumatic brain injury (TBI) is the most common cause of death and disability in young adults living in industrialised countries, in which 180-250 persons per 100 000 per year die or are hospitalised as a result. Neuroendocrine derangements after TBI have received increasing recognition in recent years because of their potential contribution to morbidity, and possibly mortality, after trauma. Marked changes of the hypothalamo-pituitary axis have been documented in the acute phase of TBI, with as many as 80% of patients showing evidence of gonadotropin deficiency, 18% of growth hormone deficiency, 16% of corticotrophin deficiency and 40% of patients demonstrating vasopressin abnormalities leading to diabetes insipidus or the syndrome of inappropriate anti-diuresis. Longitudinal prospective studies have shown that some of the early abnormalities are transient, whereas new endocrine dysfunctions become apparent in the post-acute phase. There remains a high frequency of hypothalamic-pituitary hormone deficiencies among long-term survivors of TBI, with approximately 25% patients showing one or more pituitary hormone deficiencies. This is a higher frequency than previously thought and suggests that most cases of post-traumatic hypopituitarism (PTHP) remain undiagnosed and untreated. PTHP has been associated with adverse outcome both in the acute and chronic phases after injury. These data underscore the need for the identification and appropriate timely management of hormone deficiencies, in order to optimise patient recovery from head trauma, improve quality of life and avoid the long-term adverse consequences of untreated hypopituitarism.	[Behan, L. A.; Thompson, C. J.; Agha, A.] Beaumont Hosp, Acad Dept Endocrinol, Dublin 9, Ireland; [Behan, L. A.; Phillips, J.; Thompson, C. J.; Agha, A.] RCSI Med Sch, Dublin, Ireland; [Phillips, J.] Beaumont Hosp, Acad Dept Neurosurg, Dublin 9, Ireland	Agha, A (corresponding author), Beaumont Hosp, Acad Dept Endocrinol, Dublin 9, Ireland.	amaragha@beaumont.ie					Acerini CL, 2006, EUR J ENDOCRINOL, V155, P663, DOI 10.1530/eje.1.02284; Agha A, 2006, CLIN ENDOCRINOL, V64, P481, DOI 10.1111/j.1365-2265.2006.02517.x; Agha A, 2005, QJM-INT J MED, V98, P463, DOI 10.1093/qjmed/hci075; Agha A, 2005, EUR J ENDOCRINOL, V152, P371, DOI 10.1530/eje.1.01861; Agha A, 2004, J CLIN ENDOCR METAB, V89, P5987, DOI 10.1210/jc.2004-1058; Agha A, 2004, CLIN ENDOCRINOL, V60, P584, DOI 10.1111/j.1365-2265.2004.02023.x; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Agha Amar, 2005, Am J Med, V118, P1416; Aimaretti G, 2005, J ENDOCRINOL INVEST, V28, P984, DOI 10.1007/BF03345336; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; ASA S, 2002, PITUITARY, P4; Barlow KM, 2005, PEDIATRICS, V116, pE174, DOI 10.1542/peds.2004-2739; BECKER RM, 1973, J TRAUMA, V13, P112, DOI 10.1097/00005373-197302000-00003; BENVENGA S, J CLIN ENDOCRINOL ME, V85, P1353; BESHYAH SA, 1995, CLIN ENDOCRINOL, V42, P179, DOI 10.1111/j.1365-2265.1995.tb01860.x; BINNERTS A, 1992, AM J CLIN NUTR, V55, P918; Bondanelli M, 2005, EUR J ENDOCRINOL, V152, P679, DOI 10.1530/eje.1.01895; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; BORN JD, 1985, SURG NEUROL, V23, P383, DOI 10.1016/0090-3019(85)90212-5; Boughey JC, 2004, AM SURGEON, V70, P500; Breuil V, 2001, JOINT BONE SPINE, V68, P26, DOI 10.1016/S1297-319X(00)00235-9; Ceballos R, 1966, Ala J Med Sci, V3, P185; Cernak I, 1999, BRAIN INJURY, V13, P1005; CITTADINI A, 1994, AM J PHYSIOL, V267, pE219; Cohan P, 2005, CRIT CARE MED, V33, P2358, DOI 10.1097/01.CCM.0000181735.51183.A7; Colao A, 1999, J CLIN ENDOCR METAB, V84, P1919, DOI 10.1210/jc.84.6.1919; CROMPTON MR, 1971, BRAIN, V94, P165, DOI 10.1093/brain/94.1.165; CUNEO RC, 1991, J APPL PHYSIOL, V70, P695; CUNEO RC, 1992, CLIN ENDOCRINOL, V37, P387, DOI 10.1111/j.1365-2265.1992.tb02347.x; CYRAN E, 1918, DEUT MED WOCHENSCHR, V44, P261; DANIEL PM, 1959, LANCET, V2, P927; DASHE AM, 1963, JAMA-J AM MED ASSOC, V185, P699, DOI 10.1001/jama.1963.03060090031011; DEBOER H, 1992, J CLIN ENDOCR METAB, V75, P833, DOI 10.1210/jc.75.3.833; Della Corte F, 1998, CRIT CARE MED, V26, P1419; DOCZI T, 1982, NEUROSURGERY, V10, P685, DOI 10.1227/00006123-198206010-00001; EDWARDS OM, 1986, MEDICINE, V65, P281; EINAUDI S, 2006, J PAEDIAT ENDOCRINOL, V19, P687; Escamilla RF, 1942, J CLIN ENDOCRINOL, V2, P65, DOI 10.1210/jcem-2-2-65; FEIBEL J, 1983, J CLIN ENDOCR METAB, V57, P1245, DOI 10.1210/jcem-57-6-1245; HACKL JM, 1991, INTENS CARE MED, V17, P25, DOI 10.1007/BF01708405; HARPER CG, 1986, J CLIN PATHOL, V39, P769, DOI 10.1136/jcp.39.7.769; Herrmann BL, 2006, EXP CLIN ENDOCR DIAB, V114, P316, DOI 10.1055/s-2006-924254; HOLMES SJ, 1994, J CLIN ENDOCR METAB, V78, P669, DOI 10.1210/jc.78.3.669; Kalantaridou SN, 1998, ENDOCRIN METAB CLIN, V27, P989, DOI 10.1016/S0889-8529(05)70051-7; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Khan F, 2003, MED J AUSTRALIA, V178, P290, DOI 10.5694/j.1326-5377.2003.tb05199.x; KLASBEEK WD, 1980, J NEUROSURG, V53, P519; Klose M, 2007, J CLIN ENDOCR METAB, V92, P3861, DOI 10.1210/jc.2007-0901; Klose M, 2007, CLIN ENDOCRINOL, V67, P193, DOI 10.1111/j.1365-2265.2007.02860.x; KORNBLUM RN, 1969, ARCH PATHOL, V88, P242; Lanfranco F, 2004, LANCET, V364, P273, DOI 10.1016/S0140-6736(04)16678-6; Leal-Cerro A, 2005, CLIN ENDOCRINOL, V62, P525, DOI 10.1111/j.1365-2265.2005.02250.x; LEE SC, 1994, BRAIN INJURY, V8, P571; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Lissett CA, 2003, CLIN ENDOCRINOL, V59, P773, DOI 10.1046/j.1365-2265.2003.01884.x; Masel BE, 2004, GROWTH HORM IGF RES, V14, pS108, DOI 10.1016/j.ghir.2004.03.024; Mazaux JM, 1998, DISABIL REHABIL, V20, P435, DOI 10.3109/09638289809166108; McKenna SP, 1999, QUAL LIFE RES, V8, P373, DOI 10.1023/A:1008987922774; MEROLA B, 1993, J CLIN ENDOCR METAB, V77, P1658, DOI 10.1210/jc.77.6.1658; NELSON PB, 1981, J NEUROSURG, V55, P938, DOI 10.3171/jns.1981.55.6.0938; Niederland T, 2007, J NEUROTRAUM, V24, P119, DOI 10.1089/neu.2005.369ER; Oh MS, 1999, NEPHRON, V82, P110, DOI 10.1159/000045385; PETERS JP, 1950, T ASSOC AM PHYSICIAN, V63, P57; Popovic V, 2004, J ENDOCRINOL INVEST, V27, P1048, DOI 10.1007/BF03345308; RAO RH, 1987, METABOLISM, V36, P658, DOI 10.1016/0026-0495(87)90150-8; Ropper AH, 2007, NEW ENGL J MED, V356, P166, DOI 10.1056/NEJMcp064645; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Schneider HJ, 2006, EUR J ENDOCRINOL, V154, P259, DOI 10.1530/eje.1.02071; Schneider M, 2008, CLIN ENDOCRINOL, V68, P206, DOI 10.1111/j.1365-2265.2007.03020.x; Seoane LM, 2006, J ENDOCRINOL INVEST, V29, DOI 10.1007/BF03344190; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; TWIJNSTRA A, 1980, CLIN NEUROL NEUROSUR, V82, P263, DOI 10.1016/0303-8467(80)90018-9; Van Baalen B, 2003, DISABIL REHABIL, V25, P9, DOI 10.1080/713813430; VIGERHOETS F, 1988, ACTA NEUROCHIR, V91, P50; Wong M. F. M., 1998, Annals Academy of Medicine Singapore, V27, P340; YUAN XQ, 1991, FRONT NEUROENDOCRIN, V12, P209; 1998, NIH             1026, P1	79	76	81	0	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	JUL	2008	79	7					753	759		10.1136/jnnp.2007.132837			7	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	314LI	WOS:000256810500006	18559460				2021-06-18	
J	Tanriverdi, F; Ulutabanca, H; Unluhizarci, K; Selcuklu, A; Casanueva, FF; Kelestimur, F				Tanriverdi, Fatih; Ulutabanca, Halil; Unluhizarci, Kursad; Selcuklu, Ahmet; Casanueva, Felipe F.; Kelestimur, Fahrettin			Three years prospective investigation of anterior pituitary function after traumatic brain injury: a pilot study	CLINICAL ENDOCRINOLOGY			English	Article							ADRENOCORTICOTROPIN TEST; SUBARACHNOID HEMORRHAGE; ADRENAL AXIS; HIGH-RISK; HYPOPITUITARISM; ADULTS; DYSFUNCTION; PREVALENCE; HORMONE; INSUFFICIENCY	Objective It has been recently demonstrated that traumatic brain injury (TBI)-mediated hypopituitarism could be more frequent than previously known. However, most of the previous data were obtained from retrospective studies, and the natural history of the hypopituitarism due to TBI is still unclear. So far no study has been reported in which the pituitary function of the same patients has been investigated more than 1 year after TBI. Therefore, we report the results of 3 years prospective follow-up of anterior pituitary function in patients with mild, moderate and severe TBI. Patients and design Thirty patients (25 males, 5 females; age 37.2 +/- 2.4 years) with TBI were included in the study. Pituitary function was evaluated at 1 and 3 years after TBI. Results After individual evaluation of GH deficiency from 1 year to 3 years after TBI, 7 of 13 (53.8%) GH-deficient patients at 1st year recovered after 3 years of TBI, and GH deficiency detected at 3 years in one patient was new onset. Additionally, five of six (83.3%) ACTH-deficient patients at 1st year recovered after 3 years of TBI, and ACTH deficiency detected at 3 years in one patient was new onset. Conclusions GH deficiency is the most common pituitary deficit 1 and 3 years after TBI. In patients with mild and moderate TBI, pituitary function improves over time in a considerable number of patients, but it may also worsen rarely over the 3-year period. In patients with severe TBI, ACTH and GH deficiencies at 1st year evaluation persist at 3rd year.	[Tanriverdi, Fatih; Unluhizarci, Kursad] Erciyes Univ, Sch Med, Dept Endocrinol, TR-38039 Kayseri, Turkey; [Ulutabanca, Halil; Selcuklu, Ahmet; Kelestimur, Fahrettin] Erciyes Univ, Sch Med, Dept Neurosurg, TR-38039 Kayseri, Turkey; [Casanueva, Felipe F.] Sch Med, Dept Med, Santiago De Compostela, Spain; [Casanueva, Felipe F.] Univ Santiago Compostela, Complejo Hosp Univ Santiago, Santiago De Compostela, Spain	Kelestimur, F (corresponding author), Erciyes Univ, Sch Med, Dept Endocrinol, TR-38039 Kayseri, Turkey.	fktimur@erciyes.edu.tr					Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Agha Amar, 2005, Am J Med, V118, P1416; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; BURKE CW, 1992, CLIN ENDOCRINOL, V36, P133, DOI 10.1111/j.1365-2265.1992.tb00946.x; Ceballos R, 1966, Ala J Med Sci, V3, P185; CROWLEY S, 1991, J ENDOCRINOL, V130, P475, DOI 10.1677/joe.0.1300475; DICKSTEIN G, 1991, J CLIN ENDOCR METAB, V72, P773, DOI 10.1210/jcem-72-4-773; Dokmetas HS, 2000, J CLIN ENDOCR METAB, V85, P3713, DOI 10.1210/jc.85.10.3713; Gomez JM, 2002, CLIN ENDOCRINOL, V56, P329, DOI 10.1046/j.1365-2265.2002.01472.x; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Lamberts SWJ, 1998, LANCET, V352, P127; Leal-Cerro A, 2005, CLIN ENDOCRINOL, V62, P525, DOI 10.1111/j.1365-2265.2005.02250.x; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Mazaux JM, 1998, DISABIL REHABIL, V20, P435, DOI 10.3109/09638289809166108; Oelkers W, 1996, EUR J ENDOCRINOL, V135, P27, DOI 10.1530/eje.0.1350027; Popovic V, 2000, LANCET, V356, P1137, DOI 10.1016/S0140-6736(00)02755-0; Schneider HJ, 2006, EUR J ENDOCRINOL, V154, P259, DOI 10.1530/eje.1.02071; Streeten DHP, 1996, J CLIN ENDOCR METAB, V81, P285, DOI 10.1210/jc.81.1.285; Tanriverdi F, 2007, CLIN ENDOCRINOL, V66, P360, DOI 10.1111/j.1365-2265.2006.02737.x; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; TEASDALE G, 1974, LANCET, V2, P81	24	76	82	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0300-0664	1365-2265		CLIN ENDOCRINOL	Clin. Endocrinol.	APR	2008	68	4					573	579		10.1111/j.1365-2265.2007.03070.x			7	Endocrinology & Metabolism	Endocrinology & Metabolism	274BW	WOS:000253977800012	17970777				2021-06-18	
J	Chafetz, MD				Chafetz, Michael D.			Malingering on the social security disability consultative exam: Predictors and base rates	CLINICAL NEUROPSYCHOLOGIST			English	Article						disability; evidence-based assessment; malingering; mental retardation; social security	TRAUMATIC BRAIN-INJURY; NEUROCOGNITIVE DYSFUNCTION; MENTAL-RETARDATION; SCALE; PERFORMANCE; INDICATORS; VALIDATION; SYMPTOMS; MMPI-2	The Disability Determinations Service (DDS) obtains evidence about an applicant from sources that may include the Psychological Consultative Examination (PCE), which usually includes a mental status examination and Wechsler Scale findings. Although evidence for good effort is necessary to validate the findings, psychologists have been officially discouraged from determining effort by the use of formal tests. In Chafetz, Abrahams, and Kohlmaier (2007), indicators of effort within the PCE in WAIS-age (adults) and WISC-age (children) claimants were determined, and a PCE Malingering Rating Scale was developed. In the present study, this new scale was used along with established symptom validity tests (SVTs) to determine base rates and additional predictors of malingering within the PCE. Claimants were apportioned into separate effort groups in a "dose-response" manner: Definite Malingerers, Chance-Level, Fail Both (SVT and Rating Scale), Fail One, Fail Indicators, and Not Fail. Data from separate studies using the Test of Memory Malingering (TOMM), and the Medical Symptom Validity Test (MSVT) were used to assign claimants into separate effort groups. An evidence-based assessment approach utilized these base-rates to calculate post-test odds. Other predictors of effort within the PCE include the presence of conduct disorder symptoms, and the number of other family members on Disability.	[Chafetz, Michael D.] New Orleans Psychotherapy Associates, New Orleans, LA USA	Chafetz, MD (corresponding author), 3520 Gen DeGaulle Dr 4098, New Orleans, LA 70114 USA.	mikechaf@yahoo.com	Chafetz, Michael/AAC-2579-2020				American Psychiatric Association, 1994, DIAGN STAT MAN MENT; ARDOLF BR, IN PRESS CLIN NEUROP; Chafetz M. D., 2006, RANDOM LETT TEST PRE; CHAFETZ MD, 2006, MALINGERING SOCIAL S; CHAFETZ MD, 2005, ANN M AM AC CLIN NEU; CHAFETZ MD, 2005, ANN M NAT AC NEUR OC; Chafetz MD, 2007, ARCH CLIN NEUROPSYCH, V22, P1, DOI 10.1016/j.acn.2006.10.003; Cohen J., 1983, APPL MULTIPLE REGRES; Drob S. L., 2000, AM J FORENSIC PSYCH, V18, P37; DUNLOP T, 2005, UNPUB COMMUNICATION; FRAZIER TW, 2006, WORKSH 4 NAT AC NEUR; GOUVIER WD, 1998, DETECTION MALINGERIN; Green P, 2003, CHILD NEUROPSYCHOL, V9, P189, DOI 10.1076/chin.9.3.189.16460; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve KW, 2006, CLIN NEUROPSYCHOL, V20, P491, DOI 10.1080/13854040590967144; Greve KW, 2004, ARCH CLIN NEUROPSYCH, V19, P533, DOI 10.1016/j.acn.2003.08.002; Greve KW, 2003, ARCH CLIN NEUROPSYCH, V18, P245, DOI 10.1016/S0887-6177(02)00137-3; Hammond J., 2006, ANN M NAT AC NEUR OC; Hurley KE, 2006, MENT RETARD, V44, P112, DOI 10.1352/0047-6765(2006)44[112:AIMMUW]2.0.CO;2; Keyes D, 1997, MENT RETARD, V35, P59, DOI 10.1352/0047-6765(1997)035<0059:PWMRAD>2.0.CO;2; Larrabee G.J., 2005, FORENSIC NEUROPSYCHO; LEESHALEY PR, 1991, PSYCHOL REP, V68, P203, DOI 10.2466/PR0.68.1.203-210; Lu PH, 2002, CLIN NEUROPSYCHOL, V16, P90, DOI 10.1076/clin.16.1.90.8328; Merten T, 2007, J CLIN EXP NEUROPSYC, V29, P308, DOI 10.1080/13803390600693607; Meyers JE, 2003, ARCH CLIN NEUROPSYCH, V18, P261, DOI 10.1016/S0887-6177(02)00136-1; MILLER LS, 2006, PREVALENCE SUBOPTIMA; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Richman J., 2006, J OCCUPATIONAL ENV M, V48, P1; Rogers R, 1990, Bull Am Acad Psychiatry Law, V18, P323; Rohling M., 2004, NEWSLETTER, V22, P21; Rohling M. L., 2004, NEWSLETTER, V22, P21; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Strub R.L., 1993, MENTAL STATUS EXAMIN; Teichner G, 2004, ARCH CLIN NEUROPSYCH, V19, P455, DOI 10.1016/S0887-6177(03)00078-7; Tombaugh T.N., 1996, TOMM TEST MEMORY MAL; Victor T. L., 2007, ASSESSMENT FEIGNED C	36	76	77	0	5	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2008	22	3					529	546		10.1080/13854040701346104			18	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	298LU	WOS:000255690000192	17853151				2021-06-18	
J	Langevoort, G; Myklebust, G; Dvorak, J; Junge, A				Langevoort, G.; Myklebust, G.; Dvorak, J.; Junge, A.			Handball injuries during major international tournaments	SCANDINAVIAN JOURNAL OF MEDICINE & SCIENCE IN SPORTS			English	Article						team handball; sports injury; incidence rate; international tournaments	CRUCIATE LIGAMENT INJURIES; YOUNG FEMALE PLAYERS; TEAM HANDBALL; PREVENTION; SPORTS; INTERVENTION; RISK	Background. Several authors have analyzed the incidence of handball injuries in amateur players but information of handball injury in top-level players is very limited. The aim of the study was to analyze the incidence, circumstances and characteristics of handball injuries during major international tournaments. Methods: Injuries during six international handball tournaments were analyzed, using an established injury report system. The physicians of all participating teams were asked to report all injuries after each match on a standardized injury report form. The response rate was on average 87%. Results: The incidence of injury was on average 108 injuries/1000 player hours (95% confidence interval (0): 98-117) or 1.5 injuries/ match (95% CI: 1.4-1.6). The injuries affected most frequently the lower extremity (42%), followed by injuries of the head (23%), upper extremity (18%) and trunk (14%). The most frequent diagnosis was contusion of head (14%) or ankle sprain (8%). The majority of injuries were caused by contact with another player. The incidence of time loss injuries was on average 27/1000 player hours (95% CI: 2232), and significantly higher in men than in women. Conclusion: Preventive program proven effective should be implemented. Fair Play is an essential aspect of injury prevention. Therefore, close cooperation with the referees is also necessary to make handball a safer sport.	IHF, Bern, Switzerland; OSTRC, Oslo, Norway; NIMI, Norwegian Inst Sports Med, Oslo, Norway; F MARC, Zurich, Switzerland; Schulthess Klin, Zurich, Switzerland	Junge, A (corresponding author), Schulthess Klin, Lengghalde 2, CH-8008 Zurich, Switzerland.	Astrid.Junge@kws.ch					Andersen TE, 2004, BRIT J SPORT MED, V38, P690, DOI 10.1136/bjsm.2003.009357; Asembo JM, 1998, E AFR MED J, V75, P113; BACKX FJG, 1991, AM J SPORT MED, V19, P124, DOI 10.1177/036354659101900206; Caraffa A, 1996, Knee Surg Sports Traumatol Arthrosc, V4, P19, DOI 10.1007/BF01565992; FULLE RCW, 2005, BR J SPORTS MED S1, V39, pI3; Hewett TE, 1999, AM J SPORT MED, V27, P699, DOI 10.1177/03635465990270060301; Junge A, 2006, AM J SPORT MED, V34, P565, DOI 10.1177/0363546505281807; JUNGE A, 2002, AM J SPORTS MED, V32, P23; Junge A, 2004, AM J SPORT MED, V32, p80S, DOI 10.1177/0363546503261245; Leidinger A, 1990, Sportverletz Sportschaden, V4, P65, DOI 10.1055/s-2007-993600; Mandelbaum BR, 2005, AM J SPORT MED, V33, P1003, DOI 10.1177/0363546504272261; Myklebust G, 1998, SCAND J MED SCI SPOR, V8, P149, DOI 10.1111/j.1600-0838.1998.tb00185.x; Myklebust G, 2003, CLIN J SPORT MED, V13, P71, DOI 10.1097/00042752-200303000-00002; Myklebust G, 1997, SCAND J MED SCI SPOR, V7, P289, DOI 10.1111/j.1600-0838.1997.tb00155.x; NIELSEN AB, 1988, INT J SPORTS MED, V9, P341, DOI 10.1055/s-2007-1025037; Oehlert K, 2004, SPORTVERLETZ SPORTSC, V18, P80, DOI 10.1055/s-2004-813031; Olsen OE, 2005, BRIT MED J, V330, P449, DOI 10.1136/bmj.38330.632801.8F; Olsen OE, 2003, SCAND J MED SCI SPOR, V13, P299, DOI 10.1034/j.1600-0838.2003.00329.x; Petersen W, 2002, SPORTVERLETZ SPORTSC, V16, P122, DOI 10.1055/s-2002-34753; Reckling C, 2003, SPORTVERLETZ SPORTSC, V17, P112; Seil R, 1997, Sportverletz Sportschaden, V11, P58, DOI 10.1055/s-2007-993367; Seil R, 1998, AM J SPORT MED, V26, P681, DOI 10.1177/03635465980260051401; Wedderkopp N, 1999, SCAND J MED SCI SPOR, V9, P41; Wedderkopp N, 2003, SCAND J MED SCI SPOR, V13, P371, DOI 10.1046/j.1600-0838.2003.00336.x; Wedderkopp N, 1997, SCAND J MED SCI SPOR, V7, P342; Yde J, 1990, Br J Sports Med, V24, P51; Yoon YS, 2004, AM J SPORT MED, V32, p36S, DOI 10.1177/0095399703258781	27	76	81	0	16	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0905-7188	1600-0838		SCAND J MED SCI SPOR	Scand. J. Med. Sci. Sports	AUG	2007	17	4					400	407		10.1111/j.1600-0838.2006.00587.x			8	Sport Sciences	Sport Sciences	196KW	WOS:000248481300015	17038157				2021-06-18	
J	Keenan, HT; Hooper, SR; Wetherington, CE; Nocera, M; Runyan, DK				Keenan, Heather T.; Hooper, Stephen R.; Wetherington, Crista E.; Nocera, Maryalice; Runyan, Desmond K.			Neurodevelopmental consequences of early traumatic brain injury in 3-year-old children	PEDIATRICS			English	Article						abuse; traumatic brain injury; shaken baby syndrome; injury; developmental disabilities	YOUNG-CHILDREN; ENVIRONMENTAL RISK; SCORES; OUTCOMES	OBJECTIVES. The purpose of this work was to determine cognitive and adaptive behavioral outcomes of children with traumatic brain injury acquired before age 2 years and to compare outcomes between inflicted versus noninflicted brain injury. PATIENTS AND METHODS. All North Carolina children hospitalized in an ICU for a traumatic brain injury before age 2 years between the years 2000 and 2001 were eligible for study entry. A total of 112 surviving children were prospectively identified, 52 ( 46%) of whom had complete follow- up. Thirty- one control children were recruited from preschool settings. Control subjects were chosen to be demographically similar to case subjects. Child measures of cognition and adaptive behavior at age 3 years were measured and compared between children with and without traumatic brain injury and children with inflicted and noninflicted traumatic brain injury. RESULTS. Sixty percent of injured children were > 1 SD below normal on cognitive testing. Forty percent of injured children scored > 1 SD below normal on adaptive behavior testing. Children with inflicted traumatic brain injury performed more poorly on tests of cognition and adaptive behavior. Glasgow Coma Scale >= 13, absence of seizures, income above twice the poverty guidelines, and high social capital were associated with improved outcomes. Injured children had lower scores than uninjured control children after adjustment for socioeconomic status. CONCLUSIONS. Very young children with mild- to- severe traumatic brain injury as measured by the Glasgow Coma Scale are at risk for global cognitive deficits more than a year after the time of injury. Inflicted brain injury is associated with more severe injury and worse outcomes. This is less optimistic than findings in this same cohort 1 year after injury. Family characteristics seem to play a role in recovery after injury.	Univ Utah, Dept Pediat, Salt Lake City, UT USA; Univ N Carolina, Clin Ctr Study Dev & Learning, Dept Psychiat, Chapel Hill, NC USA; Univ N Carolina, Sch Educ, Chapel Hill, NC 27599 USA; Univ N Carolina, Injury Prevent Res Ctr, Chapel Hill, NC USA; Univ N Carolina, Dept Social Med, Chapel Hill, NC USA; Univ N Carolina, Dept Pediat, Chapel Hill, NC USA	Keenan, HT (corresponding author), 295 Chipeta Way,POB 581289, Salt Lake City, UT 84158 USA.	heather.keenan@hsc.utah.edu	Hooper, Stephen/X-8171-2019; Runyan, Desmond/S-3974-2016	Runyan, Desmond/0000-0001-5571-9029	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23 HD041040-01A2, K23 HD041040-05, K23 HD041040] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD041040] Funding Source: NIH RePORTER		Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; AYLWARD GP, 1992, J DEV BEHAV PEDIATR, V13, P222; Barlow KM, 2005, PEDIATRICS, V116, pE174, DOI 10.1542/peds.2004-2739; Braveman PA, 2005, JAMA-J AM MED ASSOC, V294, P2879, DOI 10.1001/jama.294.22.2879; Bruininks R.H., 1996, SCALES INDEPENDENT B; COLEMAN JS, 1988, AM J SOCIOL, V94, pS95, DOI 10.1086/228943; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; Keenan HT, 2006, PEDIATRICS, V117, P1291, DOI 10.1542/peds.2005-1883; Keenan HT, 2006, PEDIATRICS, V117, P317, DOI 10.1542/peds.2005-0979; Keenan HT, 2004, PEDIATRICS, V114, P633, DOI 10.1542/peds.2003-1020-L; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; King WJ, 2003, CAN MED ASSOC J, V168, P155; Langlois JA, 2000, TRAUMATIC BRAIN INJU; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Mullen E. M., 1995, MULLEN SCALES EARLY; Newgard CD, 2004, ACAD EMERG MED, V11, P953, DOI 10.1197/j.aem.2004.02.530; NICHOLS DG, 1996, GOLDEN HOUR HDB ADV; POLITZ K, CONSUMERS GUIDE GETT; Rubin DB, 1997, ANN INTERN MED, V127, P757, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00064; Runyan DK, 1998, PEDIATRICS, V101, P12, DOI 10.1542/peds.101.1.12; SAMEROFF AJ, 1987, PEDIATRICS, V79, P343; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Taylor HG, 2000, DEV NEUROPSYCHOL, V17, P289, DOI 10.1207/S15326942DN1703_2; TEASDALE G, 1974, LANCET, V2, P81; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617	27	76	76	0	14	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	MAR	2007	119	3					E616	E623		10.1542/peds.2006-2313			8	Pediatrics	Pediatrics	141LK	WOS:000244579800057	17332181	Green Accepted			2021-06-18	
J	Krpan, KM; Levine, B; Stuss, DT; Dawson, DR				Krpan, Katherine M.; Levine, Brian; Stuss, Donald T.; Dawson, Deirdre R.			Executive function and coping at one-year post traumatic brain injury	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							HUMAN PREFRONTAL CORTEX; SEVERE HEAD-INJURY; LESION LOCATION; DECISION-MAKING; SELF-REGULATION; SCHIZOPHRENIA; DISSOCIATION; PERFORMANCE; STRATEGIES; DAMAGE	The purpose of this study was to examine the relationship between executive function and coping at one-year-post traumatic brain injury (TBI). TBI and matched control groups completed a coping questionnaire and a neuropsychological test series. In the TBI group, better executive performance was related to the use of problem focused coping (considered more adaptive). Conversely, lower executive performance was related to the use of emotion focused coping (considered more maladaptive). Planned hierarchical regression showed that executive function contributed significantly to the use of problem focused coping above and beyond pre-morbid intelligence and injury severity. Implications for cognitive rehabilitation are discussed.	Univ Toronto, Kunin Lunenfeld Appl Res Unit, Toronto, ON M6A 2E1, Canada; Univ Toronto, Rotman Res Inst, Toronto, ON M5S 1A1, Canada; Univ Toronto, Dept Psychol, Toronto, ON M5S 1A1, Canada; Univ Toronto, Dept Occupat Sci & Occupat Therapy, Toronto, ON M5S 1A1, Canada; Univ Toronto, Grad Dept Rehabil Sci, Toronto, ON M5S 1A1, Canada; Univ Toronto, Dept Med Neurol, Toronto, ON M5S 1A1, Canada	Dawson, DR (corresponding author), Univ Toronto, Kunin Lunenfeld Appl Res Unit, 3560 Bathurst St, Toronto, ON M6A 2E1, Canada.	ddawson@klaru-baycrest.on.ca	Levine, Brian/G-4328-2010; Levine, Brian/O-2725-2019; Dawson, Deirdre R/I-8882-2014	Levine, Brian/0000-0003-4343-811X; Levine, Brian/0000-0003-4343-811X; Dawson, Deirdre R/0000-0001-7517-6121			ANDERSON SW, 2002, HDB NEUROPSYCHOLOGY, V7, P145; [Anonymous], 1999, TRAUMATIC BRAIN INJU; Baddeley A. D., 1986, WORKING MEMORY; Bechara A, 2000, BRAIN, V123, P2189, DOI 10.1093/brain/123.11.2189; Bechara A, 1998, J NEUROSCI, V18, P428; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; Bechara A, 1997, SCIENCE, V275, P1293, DOI 10.1126/science.275.5304.1293; BROWN J, 1958, Q J EXP PSYCHOL, V10, P12, DOI 10.1080/17470215808416249; Burgess P. W., 2002, PRINCIPLES FRONTAL L, P557, DOI 10.1093/acprof:oso/9780195134971.003.0033; CARVER CS, 1989, J PERS SOC PSYCHOL, V56, P267, DOI 10.1037/0022-3514.56.2.267; COMALLI PE, 1962, J GENET PSYCHOL, V100, P47, DOI 10.1080/00221325.1962.10533572; COURVILLE CB, 1937, PATHOLOGY CENTRAL NE; CRAIK FIM, 1990, ADV NEUROL, V51, P210; CREPEAU F, 1993, NEUROPSYCHOL REHABIL, V3, P5; Curran CA, 2000, J HEAD TRAUMA REHAB, V15, P1256, DOI 10.1097/00001199-200012000-00006; Dawson D.R., 2004, ARCH PHYS MED REHAB, V85, pE8; Dawson DR, 2006, BRAIN COGNITION, V60, P214; Dawson DR, 2004, BRAIN INJURY, V18, P221, DOI 10.1080/02699050310001617406; DIKMEN S, 1983, ARCH NEUROL-CHICAGO, V40, P333, DOI 10.1001/archneur.1983.04050060033004; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Eisenberg, 1987, NEUROBEHAVIORAL RECO, P215; Finset A, 2000, BRAIN INJURY, V14, P887; Folkman S., 1988, WAYS COPING QUESTION; GENTRY LR, 1988, AM J NEURORADIOL, V9, P101, DOI 10.2214/ajr.150.3.663; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Jennett B, 1981, MANAGEMENT HEAD INJU; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Lazarus R.S., 1984, STRESS APPRAISAL COP; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; LEVIN HS, 1991, NEUROSURG CLIN N AM, V2, P217; Levine B, 2005, COGN BEHAV NEUROL, V18, P45, DOI 10.1097/01.wnn.0000152227.13001.c3; Levine B, 1998, J INT NEUROPSYCH SOC, V4, P247, DOI 10.1017/S1355617798002471; Levine B, 2000, NEUROPSYCHOLOGY, V14, P491, DOI 10.1037/0894-4105.14.4.491; Levine B., 2002, PRINCIPLES FRONTAL L, P448; LUBUSKO AA, 1994, BRAIN INJURY, V8, P65, DOI 10.3109/02699059409150959; MILIA K, 1995, BRAIN INJURY, V9, P607; Moore A D, 1989, Brain Inj, V3, P171, DOI 10.3109/02699058909004549; MOORE AD, 1995, BRAIN INJURY, V9, P109, DOI 10.3109/02699059509008185; MOORE AD, 1994, BRAIN INJURY, V7, P193; NEVIN NC, 1967, J NEUROPATH EXP NEUR, V26, P77, DOI 10.1097/00005072-196701000-00006; NICHOLSON IR, 1992, AM J ORTHOPSYCHIAT, V62, P117, DOI 10.1037/h0079307; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Ownsworth T, 2004, NEUROPSYCHOL REHABIL, V14, P535, DOI 10.1080/09602010343000538; Ownsworth TL, 2002, BRAIN INJURY, V16, P291, DOI 10.1080/02699050110103986; PETERSON LR, 1959, J EXP PSYCHOL, V58, P193, DOI 10.1037/h0049234; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; Rath JF, 2003, NEUROPSYCHOL REHABIL, V13, P461, DOI 10.1080/09602010343000039; Spreen O., 1998, COMPENDIUM NEUROPSYC; Stuss D.T., 1986, FRONTAL LOBES; Stuss DT, 2000, NEUROPSYCHOLOGIA, V38, P388, DOI 10.1016/S0028-3932(99)00093-7; Stuss DT, 2002, ANNU REV PSYCHOL, V53, P401, DOI 10.1146/annurev.psych.53.100901.135220; Stuss DT, 2001, PSYCHOL ASSESSMENT, V13, P230, DOI 10.1037//1040-3590.13.2.230; Stuss DT, 1999, NEUROPSYCHOLOGIA, V37, P1005, DOI 10.1016/S0028-3932(98)00158-4; Stuss DT, 2001, NEUROPSYCHOLOGIA, V39, P771, DOI 10.1016/S0028-3932(01)00013-6; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; TEASDALE G, 1974, LANCET, V2, P81; TEMKIN NR, 1995, J NEUROSURG, V82, P764, DOI 10.3171/jns.1995.82.5.0764; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; vandenBosch RJ, 1997, COMPR PSYCHIAT, V38, P341, DOI 10.1016/S0010-440X(97)90930-5; Wilder-Willis KE, 2002, SCHIZOPHR RES, V55, P259, DOI 10.1016/S0920-9964(01)00211-0; ZACHARY RA, 1982, SHIPLEY I LIVING SCA; 1994, MANUAL DIRCETIONS SC	66	76	76	0	20	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	JAN	2007	29	1					36	46		10.1080/13803390500376816			11	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	115XS	WOS:000242767700004	17162720				2021-06-18	
J	O'Keeffe, F; Dockree, P; Moloney, P; Carton, S; Robertson, IH				O'Keeffe, Fiadhnait; Dockree, Paul; Moloney, Pauline; Carton, Simone; Robertson, Ian H.			Awareness of deficits in traumatic brain injury: A multidimensional approach to assessing metacognitive knowledge and online-awareness	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						impaired self-awareness; traumatic brain injury; neuropsychological deficits; error-monitoring; executive functions; behavior	IMPAIRED SELF-AWARENESS; SUSTAINED ATTENTION; BEHAVIORAL LIMITATIONS; EXECUTIVE FUNCTION; SIGNIFICANT OTHERS; REHABILITATION; PERFORMANCE; QUESTIONNAIRE; DISTURBANCES; PERCEPTIONS	Recent models of impaired awareness in brain injury draw a distinction between metacognitive knowledge of difficulties and online awareness of errors (emergent and anticipatory). We examined performance of 31 Traumatic Brain Injury (TBI) participants and 31 healthy controls using a three-strand approach to assessing awareness. Metacognitive knowledge was assessed with an awareness interview and discrepancy scores on three questionnaires-Patient Competency Rating Scale, Frontal Systems Behavioral Scale and the Cognitive Failures Questionnaire. Online Emergent Awareness was assessed using an online error-monitoring task while participants performed tasks of sustained attention. Online anticipatory awareness was examined using prediction performance on two cognitive tasks. Results indicated that the TBI Low Self-Awareness (SA) group and High SA group did not differ in terms of severity, chronicity or standard neuropsychological tasks but those with Low SA were more likely to exhibit disinhibition, interpersonal problems and more difficulties in total competency. Sustained attention abilities were associated with both types of online awareness (emergent and anticipatory). There was a strong, relationship between online emergent and online anticipatory awareness. Metacognitive knowledge did not correlate with the other two measures. This study highlights the necessity in adopting a multidimensional approach to assessing the multifaceted phenomenon of awareness of deficits.	Trinity Coll Dublin, Inst Neurosci, Dublin 2, Ireland; Trinity Coll Dublin, Dept Psychol, Dublin 2, Ireland; Natl Rehabilitat Hosp, Dept Clin Neuropsychol, Dublin, Ireland	Robertson, IH (corresponding author), Trinity Coll Dublin, Inst Neurosci, Dublin 2, Ireland.	iroberts@tcd.ie		Robertson, Ian H/0000-0001-8637-561X			Abreu BC, 2001, ARCH PHYS MED REHAB, V82, P49, DOI 10.1053/apmr.2001.9167; ALLEN C C, 1990, Brain Injury, V4, P7, DOI 10.3109/02699059009026143; Anderson S. W., 1989, CLIN NEUROPSYCHOL, V3, P327, DOI DOI 10.1080/13854048908401482; Bogod NM, 2003, J INT NEUROPSYCH SOC, V9, P450, DOI 10.1017/S1355617703930104; Boone KB, 1999, J INT NEUROPSYCH SOC, V5, P616, DOI 10.1017/S1355617799577047; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; Coben RA, 1995, ARCH CLIN NEUROPSYCH, V10, P309; Crosson B., 1989, J HEAD TRAUMA REHAB, V4, P46, DOI [10.1097/00001199-198909000-00008, DOI 10.1097/00001199-198909000-00008]; Dockree PM, 2006, EXP BRAIN RES, V168, P218, DOI 10.1007/s00221-005-0079-x; Dubois B, 2000, NEUROLOGY, V55, P1621, DOI 10.1212/WNL.55.11.1621; Enderby P M, 1987, Int Rehabil Med, V8, P166; Fischer S, 2004, BRAIN INJURY, V18, P547, DOI 10.1080/02699050310001645793; Fischer S, 2004, J INT NEUROPSYCH SOC, V10, P190, DOI 10.1017/S1355617704102051; Fleming J, 1999, OCCUP THER J RES, V19, P3, DOI 10.1177/153944929901900101; Fleming JM, 1996, BRAIN INJURY, V10, P1; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; Gauggel S, 2002, J CLIN EXP NEUROPSYC, V24, P1070, DOI 10.1076/jcen.24.8.1070.8377; Grace J, 2002, FRONTAL SYSTEMS BEHA; Hart T, 1998, J HEAD TRAUMA REHAB, V13, P16, DOI 10.1097/00001199-199810000-00004; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P333, DOI 10.1097/00001199-200507000-00005; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P285, DOI 10.1097/00001199-200507000-00001; Hoofien D, 2004, J CLIN EXP NEUROPSYC, V26, P278, DOI 10.1076/jcen.26.2.278.28084; Lam C S, 1988, Brain Inj, V2, P235, DOI 10.3109/02699058809150947; Levine B, 2000, NEUROPSYCHOLOGY, V14, P491, DOI 10.1037/0894-4105.14.4.491; Malec JF, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199706000-00002; Manly T, 2003, NEUROCASE, V9, P340, DOI 10.1076/neur.9.4.340.15553; Markova IS, 2001, PSYCHOPATHOLOGY, V34, P245, DOI 10.1159/000049317; McAvinue L, 2005, NEUROPSYCHOL REHABIL, V15, P569, DOI 10.1080/09602010443000119; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; MEHRABIAN A, 1972, J PERS, V40, P525, DOI 10.1111/j.1467-6494.1972.tb00078.x; Nelson HE, 1982, NATL ADULT READING T; Noe E, 2005, J NEUROL, V252, P168, DOI 10.1007/s00415-005-0625-2; O'Keeffe FM, 2004, COGNITIVE BRAIN RES, V22, P101, DOI 10.1016/j.cogbrainres.2004.07.012; Ownsworth T, 2005, J HEAD TRAUMA REHAB, V20, P315, DOI 10.1097/00001199-200507000-00004; Ownsworth TL, 2000, CLIN NEUROPSYCHOL, V14, P76, DOI 10.1076/1385-4046(200002)14:1;1-8;FT076; Ownsworth TL, 2002, BRAIN INJURY, V16, P291, DOI 10.1080/02699050110103986; OWNSWORTH TL, IN PRESS NEUROPSYCHO; Prigatano G., 1999, PRINCIPLES NEUROPSYC, P265; Prigatano G. P., 1991, AWARENESS DEFICIT BR; Prigatano G. P., 1990, CLIN NEUROPSYCHOL, V4, P163, DOI [10.1080/13854049008401509, DOI 10.1080/13854049008401509]; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; Prigatano GP, 2005, J HEAD TRAUMA REHAB, V20, P19, DOI 10.1097/00001199-200501000-00004; Prigatano GP, 1996, CLIN NEUROPSYCHOL, V10, P191, DOI 10.1080/13854049608406680; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Prigatano GP, 1997, NEUROPSY NEUROPSY BE, V10, P135; Prigatano GP, 1998, J HEAD TRAUMA REHAB, V13, P29, DOI 10.1097/00001199-199810000-00005; PRIGATANO GP, 1986, NUROPSYCHOLOGICAL RE; Robertson I H, 1996, J Int Neuropsychol Soc, V2, P525; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Sawchyn JM, 2005, J HEAD TRAUMA REHAB, V20, P301, DOI 10.1097/00001199-200507000-00003; SCHACTER DL, 1990, J CLIN EXP NEUROPSYC, V12, P155, DOI 10.1080/01688639008400962; Schmitz TW, 2006, NEUROPSYCHOLOGIA, V44, P762, DOI 10.1016/j.neuropsychologia.2005.07.012; Sherer M, 2005, J HEAD TRAUMA REHAB, V20, P287, DOI 10.1097/00001199-200507000-00002; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Sherer M, 1998, BRAIN INJURY, V12, P63, DOI 10.1080/026990598122863; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; Sohlberg MM, 1998, J HEAD TRAUMA REHAB, V13, P62, DOI 10.1097/00001199-199810000-00008; Spreen O., 1998, COMPENDIUM NEUROPSYC; Spreen O, 1969, NEUROSENSORY CTR COM; STUSS D, 2001, FRONTAL LOBES NEUROP; Toglia J, 2000, NEUROREHABILITATION, V15, P57; Trudel TM, 1998, REHABIL PSYCHOL, V43, P267, DOI 10.1037/0090-5550.43.4.267; WALKER D, 2003, THESIS U READING REA; Wallace CA, 2000, BRAIN INJURY, V14, P549; WECHSLER D, 1998, WECHSLER MEMORY SCAL, V3; Wilson, 1991, NATL ADULT READING T; Wise K, 2005, BRAIN INJURY, V19, P765, DOI 10.1080/0269905050019977; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	68	76	76	0	11	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JAN	2007	13	1					38	49		10.1017/S1355617707070075			12	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	127PO	WOS:000243599000005	17166302	Green Published			2021-06-18	
J	Pierce, CA; Hanks, RA				Pierce, Christopher A.; Hanks, Robin A.			Life satisfaction after traumatic brain injury and the World Health Organization model of disability	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						brain injuries; quality of life; health; World Health Organization	QUALITY-OF-LIFE; SCALE; DISABLEMENT; OUTCOMES	Objective: To determine which components of the World Health Organization's International Classification of Functioning, Disability, and Health (ICF) are most predictive of global life satisfaction after traumatic brain injury (TBI). Design: Prospective evaluation of 180 individuals enrolled in a TBI model system project site. Results: Multiple regression analysis indicated that the combination of ICF components (body function and structure, activities, and participation) and demographic factors significantly predicted life satisfaction and accounted for 17% of the variance. Participation was the strongest predictor; activities were a significant, but weaker predictor; and body function and structure did not add to the prediction of life satisfaction. Of all the individual variables evaluated, only social integration and productivity were found to be significant, unique predictors. Conclusions: When considering the effects of various aspects of disabling conditions on the life satisfaction of individuals who have suffered a TBI, restriction of participation in life activities was found to have the greatest impact. Although the model accounted for a significant percentage in the variation of life satisfaction, a large proportion of the predictive picture (> 82%) remains unclear. Doubtless, other variables impinge on life satisfaction that would further clarify the complex relationship between disabling conditions and life satisfaction in TBI.	Denver Hlth Med Ctr, Dept Behav Hlth Serv, Denver, CO 80204 USA; Wayne State Univ, Sch Med, Dept Phys Med & Rehabil, Detroit, MI USA; Rehabil Inst Michigan, Dept Rehabil Psychol & Neuropsychol, Detroit, MI USA	Pierce, CA (corresponding author), Denver Hlth Med Ctr, Dept Behav Hlth Serv, 777 Bannock St,Unit 9,OBHS,Mail Code 3450, Denver, CO 80204 USA.						*AM SPIN INJ ASS, 1990, AM SPIN INJ ASS STAN; ARRINDELL WA, 1991, PERS INDIV DIFFER, V12, P117, DOI 10.1016/0191-8869(91)90094-R; BLAIS MR, 1989, CAN J BEHAV SCI, V21, P210, DOI 10.1037/h0079854; Burleigh SA, 1998, AM J OCCUP THER, V52, P45, DOI 10.5014/ajot.52.1.45; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dijkers M, 1997, SPINAL CORD, V35, P829, DOI 10.1038/sj.sc.3100571; Dijkers M, 1999, AM J PHYS MED REHAB, V78, P286, DOI 10.1097/00002060-199905000-00022; DIJKERS M, 2006, COMMUNITY INTEGRATIO; FUHRER MJ, 1994, AM J PHYS MED REHAB, V73, P358, DOI 10.1097/00002060-199409000-00010; Fuhrer MJ, 1987, REHABILITATION OUTCO, P137; Fuhrer MJ, 1996, TOPICS SPINAL CORD I, V4, P56; HEINEMANN AW, 1995, J HEAD TRAUMA REHAB, V10, P54, DOI 10.1097/00001199-199508000-00006; JUDGE TA, 1990, THESIS U ILLINOIS UR; Pavot W., 1993, PSYCHOL ASSESSMENT, V5, P164, DOI DOI 10.1037/1040-3590.5.2.164; Pierce C. A., 1999, SCI PSYCHOSOCIAL PRO, V12, P124; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; Smead V. S., 1991, ANN CONV AM ASS APPL; Smith J, 1998, CANADIAN J REHABILIT, V11, P131; Tabachnick BG, 2013, USING MULTIVARIATE S; *WHO, 1999, INT CLASS FUNCT DIS; Willer B, 1993, J HEAD TRAUMA REHAB, V3, P75, DOI DOI 10.1097/00001199-199308020-00009; Withrow SJ, 1998, CLIN TECH SMALL AN P, V13, P1; World Health Organization, 1980, INT CLASS IMP DIS HA; World Health Organization, 2001, INT CLASS FUNCT DIS	26	76	76	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0894-9115			AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	NOV	2006	85	11					889	898		10.1097/01.phm.0000242615.43129.ae			10	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	098OL	WOS:000241532400005	17079961				2021-06-18	
J	Babikian, T; Freier, MC; Ashwal, S; Riggs, ML; Burley, T; Holshouser, BA				Babikian, Talin; Freier, M. Catherin; Ashwal, Stephen; Riggs, Matt L.; Burley, Todd; Holshouser, Barbara A.			MR spectroscopy: Predicting long-term neuropsychological outcome following pediatric TBI	JOURNAL OF MAGNETIC RESONANCE IMAGING			English	Article						MR spectroscopy; neuroimaging; neuropsychology; pediatrics; traumatic brain injury	TRAUMATIC BRAIN-INJURY; PROTON-MAGNETIC-RESONANCE; CLOSED-HEAD INJURY; EXECUTIVE FUNCTION; N-ACETYLASPARTATE; AXONAL INJURY; CHILDREN; CHILDHOOD; SEVERITY; MEMORY	Purpose: To identify useful acute indicators of long-term neurocognitive outcome beyond clinical variables for children and adolescents treated for a traumatic brain injury (TBI). Materials and Methods: The efficacy of magnetic resonance spectroscopy (MRS) acquired 6-4 days after TBI in 20 children/ adolescents in predicting intellectual and neuropsychological functioning one to four years post injury was assessed. Short echo-time single voxel MRS (SVS) from normal-appearing brain was compared to intermediate echo-time multivoxel MR spectroscopic imaging (MRSI) from normal-appearing and visibly-injured brain acquired through the level of the corpus callosum (CC). Results: N-acetyl aspartate (NAA) was moderate to strongly correlated with cognitive scores. Mean NAA/creatine (Cre) from MRSI alone explained over 40% of the variance in cognitive scores and 18% of the variance above and beyond demographic and clinical variables alone. Mild to moderate associations were noted between SVS metabolites (glutamate/glutamine [Glx] and myoinositol [ml]) and cognitive scores, with no such associations apparent for choline (Cho) or Cre. Exploratory analyses revealed trends for regional neuroimaging data and specific cognitive abilities. Conclusion: Acute MR spectroscopy of the pediatric brain injury patient improves prognostic ability and may provide valuable information for early treatment and intervention planning.	Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Sch Med, Los Angeles, CA 90024 USA; Loma Linda Univ, Dept Psychol, Loma Linda, CA 92350 USA; Loma Linda Univ, Dept Pediat, Sch Med, Loma Linda, CA 92350 USA; Loma Linda Univ, Dept Radiol, Sch Med, Loma Linda, CA 92350 USA; Portland State Univ, Dept Quantitat Psychol, Portland, OR 97207 USA	Babikian, T (corresponding author), Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Sch Med, 760 Westwood Pl,Room 58-217, Los Angeles, CA 90024 USA.	tbabikian@rnednet.ucla.edu					Adelson PD, 1998, J CHILD NEUROL, V13, P2, DOI 10.1177/088307389801300102; Anderson V, 2005, BRAIN INJURY, V19, P699, DOI 10.1080/02699050400025281; Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Ashwal S, 2004, PEDIATR RES, V56, P630, DOI 10.1203/01.PDR.0000139928.60530.7D; Ashwal S, 2000, PEDIATR NEUROL, V23, P114, DOI 10.1016/S0887-8994(00)00176-4; Ashwal S, 2004, J NEUROTRAUM, V21, P1539, DOI 10.1089/neu.2004.21.1539; Babikian T, 2005, PEDIATR NEUROL, V33, P184, DOI 10.1016/j.pediatrneurol.2005.03.015; Bigler ED, 1999, J HEAD TRAUMA REHAB, V14, P406, DOI 10.1097/00001199-199908000-00009; Brenner T, 2003, PEDIATR NEUROL, V28, P104, DOI 10.1016/S0887-8994(02)00491-5; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; Brookshire B, 2004, DEV NEUROPSYCHOL, V25, P61, DOI 10.1207/s15326942dn2501&2_5; Cecil KM, 1998, J NEUROCHEM, V70, P2038; Chapman SB, 2000, J COMMUN DISORD, V33, P333, DOI 10.1016/S0021-9924(00)00029-0; Chapman SB, 2001, J HEAD TRAUMA REHAB, V16, P441, DOI 10.1097/00001199-200110000-00004; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Demougeot C, 2001, J NEUROCHEM, V77, P408, DOI 10.1046/j.1471-4159.2001.00285.x; Dennis M, 2004, DEV NEUROPSYCHOL, V25, P1, DOI 10.1207/s15326942dn2501&2_1; Duval J, 2002, BRAIN COGNITION, V48, P337, DOI 10.1006/brcg.2001.1373; Ewing-Cobbs L, 1998, J CLIN EXP NEUROPSYC, V20, P769, DOI 10.1076/jcen.20.6.769.1109; Ewing-Cobbs L, 1998, CHILD NEUROPSYCHOL, V4, P35, DOI 10.1076/chin.4.1.35.3194; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; Geddes JF, 2001, BRAIN, V124, P1299, DOI 10.1093/brain/124.7.1299; GILLES EE, 1999, PEDIAT NEUROLOGY PRI, P898; Hanten G, 2004, DEV NEUROPSYCHOL, V25, P85, DOI 10.1207/s15326942dn2501&2_6; Holshouser BA, 1997, RADIOLOGY, V202, P487, DOI 10.1148/radiology.202.2.9015079; Holshouser BA, 2005, AM J NEURORADIOL, V26, P1276; Hunter JV, 2005, AM J NEURORADIOL, V26, P482; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Laurent-Vannier A, 2000, CHILD NERV SYST, V16, P760, DOI 10.1007/s003810000349; Levin HS, 2002, ANN NEUROL, V52, P82, DOI 10.1002/ana.10252; Levin HS, 2001, NEUROPSYCHOLOGIA, V39, P122, DOI 10.1016/S0028-3932(00)00111-1; McAllister TW, 2001, J CLIN EXP NEUROPSYC, V23, P775, DOI 10.1076/jcen.23.6.775.1026; PROVENCHER SW, 1993, MAGNET RESON MED, V30, P672, DOI 10.1002/mrm.1910300604; Schuhmann MU, 2003, J NEUROTRAUM, V20, P725, DOI 10.1089/089771503767869962; Shutter L, 2004, J NEUROTRAUM, V21, P1693, DOI 10.1089/neu.2004.21.1693; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; Slomine BS, 2002, BRAIN INJURY, V16, P759, DOI 10.1080/02699050210127286; Taylor HG, 2004, DEV NEUROPSYCHOL, V25, P199, DOI 10.1207/s15326942dn2501&2_11; Ward H, 2002, J CLIN EXP NEUROPSYC, V24, P458, DOI 10.1076/jcen.24.4.458.1032; Zipfel GJ, 2000, J NEUROTRAUM, V17, P857, DOI 10.1089/neu.2000.17.857	41	76	78	0	5	JOHN WILEY & SONS INC	HOBOKEN	111 RIVER ST, HOBOKEN, NJ 07030 USA	1053-1807			J MAGN RESON IMAGING	J. Magn. Reson. Imaging	OCT	2006	24	4					801	811		10.1002/jmri.20696			11	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	089LL	WOS:000240882000010	16941608				2021-06-18	
J	Maxwell, WL; MacKinnon, MA; Smith, DH; McIntosh, TK; Graham, DI				Maxwell, William L.; MacKinnon, Mary Anne; Smith, Douglas H.; McIntosh, Tracy K.; Graham, David I.			Thalamic nuclei after human blunt head injury	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						blunt head injury; glia; intralaminar nuclei; thalamus	TRAUMATIC BRAIN-INJURY; UNBIASED STEREOLOGICAL ESTIMATION; CELL LOSS; NEURONS; MODERATE; INTRALAMINAR; MEDIODORSAL; RESPONSES; DISEASE; NUMBER	Paraffin-embedded blocks from the thalamus of 9 control patients, 9 moderately disabled, 12 severely disabled, and 10 vegetative head-injured patients assessed using the Glasgow Outcome Scale and identified from the Department of Neuropathology archive. Neurons, astrocytes, macrophages, and activated microglia were differentiated by Luxol fast blue/cresyl violet, GFAP, CD68, and CR3/43 staining and stereological techniques used to estimate cell number in a 28-mu m-thick coronal section. Counts were made in subnuclei of the mediodorsal, lateral posterior, and ventral posterior nuclei, the intralaminar nuclei, and the related internal lamina. Neuronal loss occurred from mediodorsal parvocellularis, rostral center medial, central lateral and paracentral nuclei in moderately disabled patients; and from mediodorsal magnocellularis, caudal center medial, rhomboid, and parafascicular nuclei in severely disabled patients; and all of the above and the centre median nucleus in vegetative patients. Neuronal loss occurred primarily from cognitive and executive function nuclei, a lesser loss from somatosensory nuclei and the least loss from limbic motor nuclei. There was an increase in the number of reactive astrocytes, activated microglia, and macrophages with increasing severity of injury. The study provides novel quantitative evidence for differential neuronal loss, with survival after human head injury, from thalamic nuclei associated with different aspects of cortical activation.	Univ Penn, Dept Neurosurg, Ctr Brain Injury & Repair, Philadelphia, PA 19104 USA; So Gen Hosp, Acad Unit Neuropathol, Glasgow G51 4TF, Lanark, Scotland; Univ Glasgow, IBLS, Div Neurosci & Biomed Syst, Dept Anat, Glasgow, Lanark, Scotland	Maxwell, WL (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, Thomson Bldg, Glasgow G12 8QQ, Lanark, Scotland.	wmaxwell@bio.gla.ac.uk	smith, douglas/A-1321-2007		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038104, P01NS008803, P50NS008803] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG012527] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG12527] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS38104, NS08803] Funding Source: Medline		Adams JH, 2001, J NEUROL NEUROSUR PS, V71, P521, DOI 10.1136/jnnp.71.4.521; Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; Benes FM, 2001, TRENDS NEUROSCI, V24, P11, DOI 10.1016/S0166-2236(00)01660-X; CAMMERMEYER JAN, 1961, ACTA NEUROPATHOL, V1, P245; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; GRAHAM DI, 1995, NEUROPATH APPL NEURO, V21, P27, DOI 10.1111/j.1365-2990.1995.tb01025.x; Hawley CA, 2003, BRAIN INJURY, V17, P105, DOI 10.1080/0269905021000010131; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; Henderson JM, 2000, ANN NEUROL, V47, P345, DOI 10.1002/1531-8249(200003)47:3<345::AID-ANA10>3.0.CO;2-V; Henderson JM, 2000, BRAIN, V123, P1410, DOI 10.1093/brain/123.7.1410; HIRAI T, 1989, BRAIN RES REV, V14, P1, DOI 10.1016/0165-0173(89)90007-6; HOWARD CV, 1998, UNBIASED STEREOLOGY; JENNETT B, 1975, LANCET, V1, P480; Jennett B, 2001, NEUROLOGY, V56, P486, DOI 10.1212/WNL.56.4.486; Kemether EM, 2003, ARCH GEN PSYCHIAT, V60, P983, DOI 10.1001/archpsyc.60.9.983; KLUVER H, 1953, J NEUROPATH EXP NEUR, V12, P400; Koshinaga M, 2000, J NEUROTRAUM, V17, P185, DOI 10.1089/neu.2000.17.185; Levine B, 2002, J NEUROL NEUROSUR PS, V73, P173, DOI 10.1136/jnnp.73.2.173; Maxwell WL, 2004, BRAIN, V127, P2470, DOI 10.1093/brain/awh294; Morel A, 1997, J COMP NEUROL, V387, P588, DOI 10.1002/(SICI)1096-9861(19971103)387:4<588::AID-CNE8>3.0.CO;2-Z; MOUTON PR, 2002, PRINCIPLES PRACTICES; Nakamura Y, 2002, BIOL PHARM BULL, V25, P945, DOI 10.1248/bpb.25.945; NORENBERG MD, 1994, J NEUROPATH EXP NEUR, V53, P213, DOI 10.1097/00005072-199405000-00001; PAKKENBERG B, 1992, SCHIZOPHR RES, V7, P95, DOI 10.1016/0920-9964(92)90038-7; Parent M, 2005, J COMP NEUROL, V481, P127, DOI 10.1002/cne.20348; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Popken GJ, 2000, P NATL ACAD SCI USA, V97, P9276, DOI 10.1073/pnas.150243397; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Stark AK, 2004, AM J PSYCHIAT, V161, P882, DOI 10.1176/appi.ajp.161.5.882; Van der Werf YD, 1999, J NEUROL NEUROSUR PS, V66, P36; Van der Werf YD, 2002, BRAIN RES REV, V39, P107, DOI 10.1016/S0165-0173(02)00181-9; WEST MJ, 1990, J COMP NEUROL, V296, P1, DOI 10.1002/cne.902960102; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; WILLIAMS RW, 1988, J COMP NEUROL, V278, P344, DOI 10.1002/cne.902780305; Wilson S, 2004, J NEUROTRAUM, V21, P239, DOI 10.1089/089771504322972031; XUEREB JH, 1991, BRAIN, V114, P1363	36	76	77	0	2	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	MAY	2006	65	5					478	488		10.1097/01.jnen.0000229241.28619.75			11	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	100TO	WOS:000241692000006	16772871	Bronze			2021-06-18	
J	Macpherson, A; Rothman, L; Howard, A				Macpherson, A; Rothman, L; Howard, A			Body-checking rules and childhood injuries in ice hockey	PEDIATRICS			English	Article						sports; hockey; body-checking rules		BACKGROUND. Body checking is the predominant mechanism of youth ice hockey injuries. The Canadian Hockey Association has allowed body checking from ages 12 to 13 (peewee level) and up. One Canadian province (Ontario) introduced body checking at ages 10 to 11 (atom level) in the competitive leagues, whereas in Quebec body checking has only been allowed at ages 14 to 15 (bantam Level). The purpose of this study was to compare body-checking injuries, fractures, and concussions in boys' minor hockey between jurisdictions in which checking is allowed and jurisdictions in which body checking is not allowed. METHODS. Data from the Canadian Hospitals Injury Reporting and Prevention Program (CHIRPP) were used to characterize children's ice hockey injuries from September 1995 to the end of August 2002. Children treated at CHIRPP hospitals in areas in which checking was allowed were compared with children in areas in which checking was not allowed. RESULTS. Of the 4736 hockey injuries, 3006 (63%) were in Ontario and 1730 (37%) were in Quebec. Most of the injuries occurred in areas in which checking was allowed (2824 [59.6%]). At ages 10 to 13, players had significantly greater odds of suffering a checking injury where checking was allowed (odds ratio [OR]: 1.86; 95% confidence interval [CI]: 1.6 - 2.11). Players in this age group were also more likely to suffer a concussion (OR: 1.42; 95% CI: 0.98 - 2.05) or fracture (OR: 1.25; 95% CI: 1.06 - 1.47) where checking was allowed. Among older players, when checking was allowed in both provinces, there were higher odds (OR: 1.90; 95% CI: 1.36 - 2.66) of receiving a checking injury in the province that had introduced checking at a younger age, suggesting that there is no protective effect from learning to check earlier. CONCLUSIONS. Increased injuries attributable to checking were observed where checking was allowed. This study supports policies that disallow body checking to reduce ice hockey injuries in children.	York Univ, Bethune Coll 337, Sch Kinesiol & Hlth Sci, Toronto, ON M3J 1P3, Canada; Inst Clin Evaluat Sci, Toronto, ON, Canada; Hosp Sick Children, Div Orthopaed Surg, Toronto, ON M5G 1X8, Canada	Macpherson, A (corresponding author), York Univ, Bethune Coll 337, Sch Kinesiol & Hlth Sci, 4700 Keele St, Toronto, ON M3J 1P3, Canada.	alison3@yorku.ca	Howard, Andrew/C-7163-2009	Howard, Andrew/0000-0001-7226-6471			Anderson AJ, 2000, PEDIATRICS, V105, P657; BRUST JD, 1992, AM J DIS CHILD, V146, P741, DOI 10.1001/archpedi.1992.02160180101026; *CAN AC SPORT MED, 1998, VIOL INJ ICE HOCK; *CAN I HLTH INF, NEWS EV HOCK INJ; GOULET C, 1997, SAFETY CANADIAN CHIL; Kelly KD, 2001, CLIN J SPORT MED, V11, P77, DOI 10.1097/00042752-200104000-00003; Macarthur C, 1997, AM J EPIDEMIOL, V145, P834; Mackenzie S G, 1999, Inj Prev, V5, P208; Marchie A, 2003, CAN MED ASSOC J, V169, P124; MCFAULL S, 2001, CHIRPP NEWS, V19, P1; Pickett W, 2000, Inj Prev, V6, P9, DOI 10.1136/ip.6.1.9; REGNIER G, 1986, ASTM STP, V1050, P84; Reid SR, 1999, PEDIATR EMERG CARE, V15, P310, DOI 10.1097/00006565-199910000-00002; Tator CH, 1998, CLIN SPORT MED, V17, P183, DOI 10.1016/S0278-5919(05)70072-7	14	76	76	0	12	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	FEB	2006	117	2					E143	E147		10.1542/peds.2005-1163			5	Pediatrics	Pediatrics	014PC	WOS:000235491100055	16452323	Bronze			2021-06-18	
J	Zygun, DA; Zuege, DJ; Boiteau, PJE; Loupland, KB; Henderson, EA; Kortbeek, JB; Doig, CJ				Zygun, David A.; Zuege, Danny J.; Boiteau, Paul J. E.; Loupland, Kevin B.; Henderson, Elizabeth A.; Kortbeek, John B.; Doig, Christopher J.			Ventilator-associated pneumonia in severe traumatic brain injury	NEUROCRITICAL CARE			English	Article						craniocerebral trauma; pneumonia; multiple organ failure; treatment outcome; critical care	ORGAN DYSFUNCTION; HEAD-INJURY; STAPHYLOCOCCUS-AUREUS; NOSOCOMIAL PNEUMONIA; RISK-FACTORS; COMPLICATIONS; COLONIZATION; CARE; MODERATE; OUTCOMES	Introduction: Pneumonia is an important cause of morbidity following severe traumatic brain injury (TBI). However, previous studies have been limited by inclusion of specific patient subgroups or by selection bias. The primary objective of this study was to describe the incidence, risk factors for, and outcome of ventilator-associated pneumonia in an unselected population-based cohort of patients with severe TBI. An additional goal was to define the relationship of ventilator-associated pneumonia (VAP) with nonneurological organ dysfunction. Methods: A prospective, observational cohort study was performed at Foothills Medical Centre, the sole adult tertiary-care trauma center servicing southern Alberta. All patients with severe TBI requiring ventilation for more than 48 hours between May 1, 2000 and December 30, 2002 were included. Results: A total of 60 patients (45%) acquired VAP for an incidence density of 42.7/1000 ventilator days. Patients with polytrauma were at higher risk (risk ratio 1.7,95% confidence interval, 0.9-3.1) for development of VAP than those with isolated head injury. Development of VAP was associated with a significantly greater degree of nonneurological organ system dysfunction. Although VAP was not associated with increased hospital mortality, patients who developed VAP had a longer duration of mechanical ventilation (15 versus 8 days, p < 0.0001), longer intensive care unit (17 versus 9 days, p < 0.0001) and hospital (60 versus 28 days, p = 0.003) lengths of stay, and more often required tracheostomy (35 versus 18%, p = 0.003). Conclusions: VAP occurs frequently and is associated with significant morbidity in requests to: patients with severe TBI.	Univ Calgary, Dept Crit Care Med, Calgary, AB T2N 1N4, Canada; Univ Calgary, Dept Clin Neurosci, Calgary, AB T2N 1N4, Canada; Univ Calgary, Dept Med, Calgary, AB T2N 1N4, Canada; Univ Calgary, Dept Surg, Calgary, AB T2N 1N4, Canada; Univ Calgary, Dept Community Hlth Sci, Calgary, AB T2N 1N4, Canada	Zygun, DA (corresponding author), Foothills Med Ctr, Room EG23,1403-29 St NW, Calgary, AB T2N 2T9, Canada.	david.zygun@calgaryhealthregion.ca	Doig, Christopher/AAC-7949-2020; Kortbeek, John B/AAO-5298-2020; Zuege, Danny J./L-5368-2017	Doig, Christopher/0000-0002-8576-9139; Zuege, Danny J./0000-0003-2033-5847			Adekoya Nelson, 2002, MMWR Surveill Summ, V51, P1; Artigas AT, 2001, CRIT CARE MED, V29, P304, DOI 10.1097/00003246-200102000-00015; Berrouane Y, 1998, J HOSP INFECT, V40, P275, DOI 10.1016/S0195-6701(98)90303-6; Bronchard G, 2004, ANESTHESIOLOGY, V100, P234, DOI 10.1097/00000542-200402000-00009; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Campbell W, 1999, CRIT CARE MED, V27, P798, DOI 10.1097/00003246-199904000-00039; Cazzadori A, 1997, RESP MED, V91, P193, DOI 10.1016/S0954-6111(97)90038-X; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Doig CJ, 2004, CRIT CARE MED, V32, P384, DOI 10.1097/01.CCM.0000108881.14082.10; Eggimann P, 2003, INTENS CARE MED, V29, P2086, DOI 10.1007/s00134-003-1991-9; EMORI TG, 1991, AM J INFECT CONTROL, V19, P19, DOI 10.1016/0196-6553(91)90157-8; Ewig S, 1999, AM J RESP CRIT CARE, V159, P188, DOI 10.1164/ajrccm.159.1.9803097; Friedman JA, 2003, NEUROSURGERY, V52, P1025, DOI 10.1227/01.NEU.0000058222.59289.F1; HSIEH AHH, 1992, AM REV RESPIR DIS, V146, P290, DOI 10.1164/ajrccm/146.2.290; Kerwin AJ, 2000, J TRAUMA, V48, P878, DOI 10.1097/00005373-200005000-00011; Kollef MH, 1999, NEW ENGL J MED, V340, P627, DOI 10.1056/NEJM199902253400807; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; Laupland KB, 2003, CLIN INFECT DIS, V37, P933, DOI 10.1086/377735; Leone M, 2002, CRIT CARE MED, V30, P1741, DOI 10.1097/00003246-200208000-00011; MACKENZIE EJ, 1988, J TRAUMA, V28, P281, DOI 10.1097/00005373-198803000-00003; Masson F, 1997, J CLIN EPIDEMIOL, V50, P595, DOI 10.1016/S0895-4356(97)00012-7; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; McGarry LJ, 2002, J TRAUMA, V53, P1152, DOI 10.1097/00005373-200212000-00020; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Mostafa G, 2002, J TRAUMA, V53, P430, DOI 10.1097/00005373-200209000-00006; Napolitano LM, 2002, J TRAUMA, V53, P434; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; Rello J, 2002, CHEST, V122, P656, DOI 10.1378/chest.122.2.656; RELLO J, 1992, EUR RESPIR J, V5, P1249; RODRIGUEZ JL, 1991, J TRAUMA, V31, P907, DOI 10.1097/00005373-199107000-00005; Sirvent JM, 2000, INTENS CARE MED, V26, P1369, DOI 10.1007/s001340000611; Sirvent JM, 1997, AM J RESP CRIT CARE, V155, P1729, DOI 10.1164/ajrccm.155.5.9154884; SNOW WG, 1988, CAN J SURG, V31, P191; Solomon S, 2003, AM J INFECT CONTROL, V31, P481; TIRET L, 1990, INT J EPIDEMIOL, V19, P133, DOI 10.1093/ije/19.1.133; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; Vitaz TW, 2003, SURG NEUROL, V60, P285, DOI 10.1016/S0090-3019(03)00378-1; Warren DK, 2003, CRIT CARE MED, V31, P1312, DOI 10.1097/01.CCM.0000063087.93157.06; Wartenberg KE, 2006, CRIT CARE MED, V34, P617, DOI 10.1097/01.CCM.0000201903.46435.35; Wehler M, 2003, CRIT CARE MED, V31, P1094, DOI 10.1097/01.CCM.0000059642.97686.8B; Wong Pauline P., 1993, Brain Injury, V7, P283, DOI 10.3109/02699059309034955; Zygun DA, 2005, CRIT CARE MED, V33, P654, DOI 10.1097/01.ccm.0000155911.01844.54; Zygun DA, 2005, CAN J NEUROL SCI, V32, P87, DOI 10.1017/S0317167100016930; ZYGUN DA, 2005, IN PRESS CRIT CARE M; 2000, J NEUROTRAUMA, V17, P479	45	76	80	0	11	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care		2006	5	2					108	114		10.1385/NCC:5:2:108			7	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	098ZN	WOS:000241562400006	17099256				2021-06-18	
J	Testa, JA; Malec, JF; Moessner, AM; Brown, AW				Testa, JA; Malec, JF; Moessner, AM; Brown, AW			Outcome after traumatic brain injury: Effects of aging on recovery	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; aging; rehabilitation	CLOSED-HEAD INJURY; PORTLAND ADAPTABILITY INVENTORY; DISABILITY RATING-SCALE; ALZHEIMERS-DISEASE; OLDER-ADULTS; NEUROBEHAVIORAL CONSEQUENCES; COGNITIVE IMPAIRMENT; SIGNIFICANT OTHERS; UNITED-STATES; RISK-FACTORS	Objective: To identify differences in outcome after traumatic brain injury (TBI) compared with orthopedic injuries as a function of age. Design: Longitudinal data analyses from an inception cohort. Setting: Outpatient rehabilitation program. P articipants: Eighty-two orthopedic injury patients and 195 TBI patients. Interventions: Not applicable. Main Outcome Measures: Independent living, employment, and level of functioning 1 to 2 years after injury. Results: Older patients and those with TBI were more likely to have increased dependence postinjury. Older TBI patients were more likely to have changes in employment status compared with orthopedic injury patients younger or TBI. The Mayo-Portland Adaptability Inventory and Disability Rating Scale were moderately predictive of level of functioning, return to employment, and independent living status 1 to 2 years postinjury. Injury severity was only mildly predictive of outcome. Conclusions: The effect of age on outcome affects recovery from neurologic injuries and, to a lesser extent, orthopedic injuries. Outcome after TBI is best predicted by patients' age and estimates of level of function at discharge. Findings suggest that older patients and those with TBI have a greater likelihood of becoming physically and financially dependent on others. Rehabilitation efforts should focus on maximizing levels of independence to limit financial and emotional costs to patients and their families.	Mayo Clin, Dept Psychiat & Psychol, Rochester, MN 55905 USA; Mayo Clin, Dept Phys Med & Rehabil, Rochester, MN 55905 USA; Mayo Clin, Dept Nursing, Rochester, MN 55905 USA	Testa, JA (corresponding author), Mayo Clin, Dept Psychiat & Psychol, 200 1st St SW, Rochester, MN 55905 USA.	testa.julie@mayo.edu		Brown, Allen W./0000-0001-7228-3351			AharonPeretz J, 1997, BRAIN INJURY, V11, P871; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; Bohac DL, 1997, BRAIN INJURY, V11, P469, DOI 10.1080/713802185; Brown AW, 2004, NEUROREHABILITATION, V19, P37; Centers for Disease Control and Prevention, 1999, TRAUM BRAIN INJ US R; Cifu D X, 1993, Clin Geriatr Med, V9, P473; Cifu D X, 1993, Arch Phys Med Rehabil, V74, pS406; Cifu DX, 1996, ARCH PHYS MED REHAB, V77, P883, DOI 10.1016/S0003-9993(96)90274-9; Coleman P, 2004, NEUROBIOL AGING, V25, P3, DOI 10.1016/j.neurobiolaging.2003.10.001; Felmingham KL, 2001, ARCH PHYS MED REHAB, V82, P435, DOI 10.1053/apmr.2001.21985; GEDYE A, 1989, J AM GERIATR SOC, V37, P970, DOI 10.1111/j.1532-5415.1989.tb07283.x; GOLDSTEIN FC, 1994, J NEUROL NEUROSUR PS, V57, P961, DOI 10.1136/jnnp.57.8.961; Goldstein FC, 2001, J CLIN EXP NEUROPSYC, V23, P739, DOI 10.1076/jcen.23.6.739.1028; Goldstein FC, 2001, J INT NEUROPSYCH SOC, V7, P373, DOI 10.1017/S1355617701733115; Goldstein FC, 1999, J NEUROPSYCH CLIN N, V11, P38, DOI 10.1176/jnp.11.1.38; GOLEBURN CR, 2001, J CLIN GEROPSYCHOLOG, V7, P161; Gollaher K, 1998, BRAIN INJURY, V12, P255, DOI 10.1080/026990598122557; GOODMAN H, 1992, PHYS MED REH CLIN N, V3, P441; Graafmans WC, 1996, AM J EPIDEMIOL, V143, P1129; GRAVES AB, 1990, AM J EPIDEMIOL, V131, P491, DOI 10.1093/oxfordjournals.aje.a115523; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; Hall KM, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199610000-00004; Hall KM, 2001, ARCH PHYS MED REHAB, V82, P367, DOI 10.1053/apmr.2001.21525; Harris C, 2003, J AM COLL SURGEONS, V197, P711, DOI 10.1016/S1072-7515(03)00729-4; Hoofien D, 2002, BRAIN INJURY, V16, P9, DOI 10.1080/02699050110088227; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; JOHNSTON M V, 1991, Brain Injury, V5, P155, DOI 10.3109/02699059109008086; Johnstone B, 1998, BRAIN INJURY, V12, P569, DOI 10.1080/026990598122331; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; LINACRE JM, 2003, FACETS WINDOWS; Luukinen H, 1999, NEUROLOGY, V52, P557, DOI 10.1212/WNL.52.3.557; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; MacKenzie E., 1991, J HEAD TRAUMA REHAB, V6, P76, DOI [10.1097/00001199-199106000-00010, DOI 10.1097/00001199-199106000-00010]; Malec JF, 2004, BRAIN INJURY, V18, P563, DOI 10.1080/02699050310001646134; Malec JF, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199706000-00002; Malec JF, 2000, J HEAD TRAUMA REHAB, V15, P670, DOI 10.1097/00001199-200002000-00006; Malec JF, 2001, ARCH PHYS MED REHAB, V82, P885, DOI 10.1053/apmr.2001.23895; MALEC JF, 1995, MAYO CLIN PROC, V70, P1165, DOI 10.4065/70.12.1165; Malec JF, 2000, ARCH PHYS MED REHAB, V81, P1007, DOI 10.1053/apmr.2000.6980; Malec JF., 1994, J HEAD TRAUMA REHAB, V9, P1, DOI [10. 1097/ 00001199- 199412000- 00003, DOI 10.1097/00001199-199412000-00003]; Malec JF, 2005, MANUAL MAYO PORTLAND; MAX W, 1990, INQUIRY-J HEALTH CAR, V27, P332; MORRIS JC, 1987, J GERONTOL, V42, P412, DOI 10.1093/geronj/42.4.412; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; PENNINGS JL, 1993, ARCH SURG-CHICAGO, V128, P787; Rapoport MJ, 2001, BRAIN INJURY, V15, P857, DOI 10.1080/02699050110065303; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Rothweiler B, 1998, ARCH PHYS MED REHAB, V79, P881, DOI 10.1016/S0003-9993(98)90082-X; Saunders RL, 2002, J TRAUMA, V53, P391, DOI 10.1097/00005373-200208000-00040; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; Shaw FE, 2003, BRIT MED J, V326, P73, DOI 10.1136/bmj.326.7380.73; Shaw FE, 2002, CLIN GERIATR MED, V18, P159, DOI 10.1016/S0749-0690(02)00003-4; Shimamura M, 2004, MOL BRAIN RES, V122, P47, DOI 10.1016/j.molbrainres.2003.11.015; Sosin DM, 1996, BRAIN INJURY, V10, P47; SULLIVAN P, 1987, JAMA-J AM MED ASSOC, V257, P2289, DOI 10.1001/jama.1987.03390170045014; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Tate RL, 2004, ARCH PHYS MED REHAB, V85, P538, DOI 10.1016/j.apmr.2003.08.078; TEASDALE GM, 1979, ACTA NEUROCHIR S, V75, pS37; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; TINETTI ME, 1988, NEW ENGL J MED, V319, P1701, DOI 10.1056/NEJM198812293192604; Uryu K, 2003, EXP NEUROL, V184, P214, DOI 10.1016/S0014-4886(03)00245-0; Wilson J A, 1987, Brain Inj, V1, P183, DOI 10.3109/02699058709034456	63	76	77	1	7	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	SEP	2005	86	9					1815	1823		10.1016/j.apmr.2005.03.010			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	962QM	WOS:000231747300017	16181948				2021-06-18	
J	Lin, AH; Luo, J; Mondshein, LH; ten Dijke, P; Vivien, D; Contag, CH; Wyss-Coray, T				Lin, AH; Luo, J; Mondshein, LH; ten Dijke, P; Vivien, D; Contag, CH; Wyss-Coray, T			Global analysis of Smad2/3-dependent TGF-beta signaling in living mice reveals prominent tissue-specific responses to injury	JOURNAL OF IMMUNOLOGY			English	Article							GROWTH-FACTOR-BETA; IN-VIVO; TRANSGENIC MICE; WILD-TYPE; EXPRESSION; GENE; SMAD2; ACTIVATION; PROTEINS; RECEPTOR	Smad2 and Smad3 (Smad2/3) proteins are key signaling molecules for TGF-beta and some related family members regulating the transcription of several hundred genes. TGF-beta have key roles in development, tissue homeostasis, and the pathogenesis of many human diseases, including cancer, fibrotic disorders, developmental defects, and neurodegeneration. To study the temporal and spatial patterns of Smad2/3-dependent signaling in normal and pathological conditions in the living organism, we engineered transgenic mice with a Smad-responsive luciferase reporter construct (SBE-luc mice). Using bioluminescent imaging, we assessed Smad2/3 signaling activity noninvasively in living mice. At baseline, this activity was highest in brain, intestine, heart, and skin, and correlated with biochemical measurements of reporter activity. Primary astrocytes cultured from SBE-luc mice showed specific activation of the reporter in response to Smad2/3-activating TGF-beta family members. Treatment of mice with the endotoxin LPS resulted in a fast and vigorous, but transient activation of the reporter in the intestine. Although the response was similarly rapid in brain, it remained increased, indicating important but different cellular responses to endotoxin. challenge in these organs. Traumatic brain injury with a needle stab resulted in local activation of Smad2/3-dependent genes and a severalfold increase in bioluminescence in living mice. SBE-luc mice can therefore be used to study temporal, tissue-specific activation of Smad2/3-dependent signaling in living mice in normal or pathological conditions as well as for the identification of endogenous or synthetic modulators of this pathway.	Stanford Univ, Dept Neurol & Neurol Sci, Sch Med, Stanford, CA 94305 USA; Stanford Univ, Div Neonatal & Dev Med, Dept Pediat, Stanford, CA 94305 USA; Stanford Univ, Dept Microbiol & Immunol, Stanford, CA 94305 USA; Stanford Univ, Dept Radiol, Stanford, CA 94305 USA; Netherlands Canc Inst, Div Cellular Biochem, NL-1066 CX Amsterdam, Netherlands; Univ Caen, INSERM Avenir, GIP Cyceron, F-14032 Caen, France; Vet Affairs Palo Alto Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Palo Alto, CA 94304 USA	Wyss-Coray, T (corresponding author), Stanford Univ, Dept Neurol & Neurol Sci, Sch Med, SUMC Room A343, Stanford, CA 94305 USA.	twc@stanford.edu	Dijke, Peter ten/AAG-4660-2021; Luo, Jian/B-8449-2014; Wyss-Coray, Tony/AAF-3380-2019	Dijke, Peter ten/0000-0002-7234-342X; Luo, Jian/0000-0002-2064-8467; Wyss-Coray, Tony/0000-0001-5893-0831; VIVIEN, DENIS/0000-0002-7636-2185; Contag, Christopher/0000-0002-1011-8278	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG20603] Funding Source: Medline; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG020603] Funding Source: NIH RePORTER		Boche D, 2003, J CEREBR BLOOD F MET, V23, P1174, DOI 10.1097/01.WCB.0000090080.64176.44; BORDER WA, 1992, J CLIN INVEST, V90, P1, DOI 10.1172/JCI115821; Brionne TC, 2003, NEURON, V40, P1133, DOI 10.1016/S0896-6273(03)00766-9; Buckwalter MS, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-10; Carlsen H, 2002, J IMMUNOL, V168, P1441, DOI 10.4049/jimmunol.168.3.1441; Carmel JB, 2001, PHYSIOL GENOMICS, V7, P201, DOI 10.1152/physiolgenomics.00074.2001; Contag CH, 2002, ANNU REV BIOMED ENG, V4, P235, DOI 10.1146/annurev.bioeng.4.111901.093336; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Dennler S, 2002, J LEUKOCYTE BIOL, V71, P731; Dunn NR, 2005, GENE DEV, V19, P152, DOI 10.1101/gad.1243205; Flanders KC, 1998, PROG NEUROBIOL, V54, P71, DOI 10.1016/S0301-0082(97)00066-X; Flanders KC, 2001, DEV DYNAM, V220, P141, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1096>3.3.CO;2-W; Goumans MJ, 2002, EMBO J, V21, P1743, DOI 10.1093/emboj/21.7.1743; Herber DL, 2004, EXP NEUROL, V190, P245, DOI 10.1016/j.expneurol.2004.07.007; Huang SX, 2000, GENE, V258, P43, DOI 10.1016/S0378-1119(00)00396-6; JAKOWLEW SB, 1994, DIFFERENTIATION, V55, P105, DOI 10.1046/j.1432-0436.1994.5520105.x; Kusanagi K, 2000, MOL BIOL CELL, V11, P555, DOI 10.1091/mbc.11.2.555; Ling ZD, 2004, NEUROSCIENCE, V124, P619, DOI 10.1016/j.neuroscience.2003.12.017; Lopes SMCD, 2003, GENE EXPR PATTERNS, V3, P355, DOI 10.1016/S1567-133X(03)00029-2; MacDonald TT, 2005, SCIENCE, V307, P1920, DOI 10.1126/science.1106442; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Mazerbourg S, 2004, MOL ENDOCRINOL, V18, P653, DOI 10.1210/me.2003-0393; Monteiro RM, 2004, J CELL SCI, V117, P4653, DOI 10.1242/jcs.01337; Moore FA, 1999, AM J SURG, V178, P449, DOI 10.1016/S0002-9610(99)00231-7; Oh SP, 2002, GENE DEV, V16, P2749, DOI 10.1101/gad.1021802; Rebbapragada A, 2003, MOL CELL BIOL, V23, P7230, DOI 10.1128/MCB.23.20.7230-7242.2003; Reissmann E, 2001, GENE DEV, V15, P2010, DOI 10.1101/gad.201801; Sadikot RT, 2003, J IMMUNOL, V170, P1091, DOI 10.4049/jimmunol.170.2.1091; Sancho E, 2004, ANNU REV CELL DEV BI, V20, P695, DOI 10.1146/annurev.cellbio.20.010403.092805; Sanyal S, 2004, NEURON, V41, P845, DOI 10.1016/S0896-6273(04)00152-7; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Sly LM, 2004, IMMUNITY, V21, P227, DOI 10.1016/j.immuni.2004.07.010; Wahl SM, 2004, J LEUKOCYTE BIOL, V76, P15, DOI 10.1189/jlb.1103539; Wang XJ, 1999, P NATL ACAD SCI USA, V96, P8483, DOI 10.1073/pnas.96.15.8483; Wyss-Coray T, 2001, NAT MED, V7, P612, DOI 10.1038/87945; WYSSCORAY T, 1995, AM J PATHOL, V147, P53; Xu X, 1999, P NATL ACAD SCI USA, V96, P7547, DOI 10.1073/pnas.96.13.7547; Yagi K, 1999, J BIOL CHEM, V274, P703, DOI 10.1074/jbc.274.2.703; Yang YC, 2003, P NATL ACAD SCI USA, V100, P10269, DOI 10.1073/pnas.1834070100	39	76	82	0	2	AMER ASSOC IMMUNOLOGISTS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-1767	1550-6606		J IMMUNOL	J. Immunol.	JUL 1	2005	175	1					547	554		10.4049/jimmunol.175.1.547			8	Immunology	Immunology	939CW	WOS:000230050900069	15972691	Bronze			2021-06-18	
J	McDonald, S; Saunders, JC				McDonald, S; Saunders, JC			Differential impairment in recognition of emotion across different media in people with severe traumatic brain injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						emotion perception; traumatic brain injury	FRONTAL-LOBE DAMAGE; MISSILE HEAD-INJURY; LANGUAGE FUNCTIONS; SOCIAL-PERCEPTION; RIGHT-HEMISPHERE; AMYGDALA DAMAGE; NEURAL SYSTEMS; FACIAL EMOTION; EXPRESSION; FACES	Recent evidence suggests that there may be dissociable systems for recognizing emotional expressions from different media including audio and visual channels, and still versus moving displays. In this study, 34 adults with severe traumatic brain injuries (TBI) and 28 adults without brain injuries were assessed for their capacity to recognize emotional expressions from dynamic audiovisual displays, conversational tone alone, moving facial displays, and still photographs. The TBI group were significantly impaired in their interpretation of both audio and audiovisual displays. In addition, eight of the 34 were significantly impaired in their capacity to recognize still facial expressions. In contrast, only one individual was impaired in the recognition of moving visual displays. Information processing speed was not found to play a significant role in producing problems with dynamic emotional expression. Instead the results suggest that visual moving displays may enlist different brain systems to those engaged with still displays, for example, the parietal cortices. Problems with the processing of affective prosody, while present, were not clearly related to other emotion processing problems. While this may attest to the independence of the auditory affective system, it may also reflect problems with the dual demands of listening to conversational meaning and affective tone.	Univ New S Wales, Sch Psychol, Sydney, NSW, Australia	McDonald, S (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW, Australia.	s.mcdonald@unsw.edu.au	McDonald, Skye/G-4118-2014	McDonald, Skye/0000-0003-0723-6094			ADAMS JH, 1989, SCOT MED J, V34, P399, DOI 10.1177/003693308903400106; ADAMS JH, 1985, NEUROPATH APPL NEURO, V11, P299, DOI 10.1111/j.1365-2990.1985.tb00027.x; Adolphs R, 2000, J NEUROSCI, V20, P2683; Adolphs R, 2002, CURR OPIN NEUROBIOL, V12, P169, DOI 10.1016/S0959-4388(02)00301-X; Adolphs R, 2004, J COGNITIVE NEUROSCI, V16, P453, DOI 10.1162/089892904322926782; Adolphs R, 2001, NEUROPSYCHOLOGY, V15, P396, DOI 10.1037//0894-4105.15.3.396; Adolphs R, 2003, BRAIN COGNITION, V52, P61, DOI 10.1016/S0278-2626(03)00009-5; Adolphs R, 1996, J NEUROSCI, V16, P7678; Adolphs R, 1999, PSYCHOL SCI, V10, P167, DOI 10.1111/1467-9280.00126; Adolphs R, 2002, EMOTION, V2, P23, DOI 10.1037/1528-3542.2.1.23; Angrilli A, 1999, NEUROREPORT, V10, P1741, DOI 10.1097/00001756-199906030-00021; BASSILI JN, 1978, J EXP PSYCHOL HUMAN, V4, P373, DOI 10.1037/0096-1523.4.3.373; Borod J., 1993, NEUROPSYCHOLOGY, V7, P445, DOI DOI 10.1037/0894-4105.7.4.445; BOROD JC, 1986, NEUROPSYCHOLOGIA, V24, P169; Breitenstein C, 1998, BEHAV NEUROL, V11, P29, DOI 10.1155/1998/579029; Broks P, 1998, NEUROPSYCHOLOGIA, V36, P59, DOI 10.1016/S0028-3932(97)00105-X; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; Buchanan TW, 2004, BEHAV NEUROSCI, V118, P429, DOI 10.1037/0735-7044.118.2.429; CICONE M, 1980, CORTEX, V16, P145, DOI 10.1016/S0010-9452(80)80029-3; Courville CB, 1945, PATHOLOGY NERVOUS SY; CROKER V, IN PRESS BRAIN INJUR; Eckman P, 1976, PICTURES FACIAL AFFE; Green REA, 2004, NEUROPSYCHOLOGIA, V42, P133, DOI 10.1016/j.neuropsychologia.2003.07.005; Hornak J, 1996, NEUROPSYCHOLOGIA, V34, P247, DOI 10.1016/0028-3932(95)00106-9; HUMPHREYS GW, 1993, NEUROPSYCHOLOGIA, V31, P173, DOI 10.1016/0028-3932(93)90045-2; JACKSON HF, 1987, CORTEX, V23, P293, DOI 10.1016/S0010-9452(87)80039-4; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; Marquardt TP, 2001, APHASIOLOGY, V15, P1091, DOI 10.1080/02687040143000429; McDonald S, 2003, J HEAD TRAUMA REHAB, V18, P219, DOI 10.1097/00001199-200305000-00001; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; McDonald S, 1996, BRAIN LANG, V53, P81, DOI 10.1006/brln.1996.0038; McDonald S., 2002, AWARENESS SOCIAL INF; McHugo GJ, 1996, MOTIV EMOTION, V20, P85, DOI 10.1007/BF02253867; MCMORDIE W R, 1990, Brain Injury, V4, P57, DOI 10.3109/02699059009026149; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; Pearce S, 1998, BRAIN COGNITION, V38, P150, DOI 10.1006/brcg.1998.1018; Phillips ML, 2003, BIOL PSYCHIAT, V54, P504, DOI 10.1016/S0006-3223(03)00168-9; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; PRIGATANO GP, 1982, J PERCEPTUAL MOTOR S, V54, P859; Ross ED, 1997, BRAIN LANG, V56, P27, DOI 10.1006/brln.1997.1731; ROSS ED, 1979, ARCH NEUROL-CHICAGO, V36, P144, DOI 10.1001/archneur.1979.00500390062006; Spell LA, 2000, J NONVERBAL BEHAV, V24, P285, DOI 10.1023/A:1006675230193; Sprengelmeyer R, 1996, BRAIN, V119, P1647, DOI 10.1093/brain/119.5.1647; TATE RL, 1991, J NERV MENT DIS, V179, P117, DOI 10.1097/00005053-199103000-00001; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; Tranel D, 2002, CORTEX, V38, P589, DOI 10.1016/S0010-9452(08)70024-8; vansZomeren AH, 1987, NEUROBEHAVIORAL RECO, P398; Wertz RT, 1998, J NEUROLINGUIST, V11, P89, DOI 10.1016/S0911-6044(98)00007-4	49	76	78	0	11	CAMBRIDGE UNIV PRESS	NEW YORK	40 WEST 20TH ST, NEW YORK, NY 10011-4211 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JUL	2005	11	4					392	399		10.1017/S1355617705050447			8	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	948UY	WOS:000230742400006	16209419				2021-06-18	
J	Bourgoin, A; Albanese, J; Leone, M; Sampol-Manos, E; Viviand, X; Martin, C				Bourgoin, A; Albanese, J; Leone, M; Sampol-Manos, E; Viviand, X; Martin, C			Effects of sufentanil or ketamine administered in target-controlled infusion on the cerebral hemodynamics of severely brain-injured patients	CRITICAL CARE MEDICINE			English	Article						severe head injury management; target-controlled infusion; ketamine; sufentanil; intensive care unit; intracranial pressure; cerebral perfusion pressure	BISPECTRAL INDEX; INTRACRANIAL-PRESSURE; HEAD TRAUMA; PROPOFOL; ANESTHESIA; MIDAZOLAM; FENTANYL; PHARMACOKINETICS; REMIFENTANIL; ALFENTANIL	Objective: The manual injection of a bolus of opioid in patients with brain injury induces an increase in intracranial pressure related to a decrease in mean arterial pressure. Such an effect has not been observed with the use of ketamine. The use of target-controlled infusion would minimize or suppress this adverse effect of opioid. This study evaluated the effects of an increase in plasma concentrations of sufentanil or ketamine administered by target-controlled infusion on cerebral hemodynamics. Design: Prospective, randomized study. Setting: Intensive care unit in a trauma center. Patients: Thirty patients with severe traumatic brain injury. Interventions. Patients were assigned to receive sedation consisting of sufentanil-midazolam or ketamine-midazolam using target-controlled infusion. Twenty-four hours after the onset of sedation, the target concentrations of sufentanil or ketamine were doubled for 15 mins. Blood samples were collected to determine the actual plasma concentration of sufentanil and ketamine, before and 15 mins after concentration change. Measurements and Main Results: The baseline values of intracranial pressure and cerebral perfusion pressure were similar in both groups. The two-fold increase in drug concentrations did not involve a significant change for intracranial pressure, cerebral perfusion pressure, and mean velocity of middle cerebral artery in both the ketamine and the sufentanil groups. The measured plasma concentrations of sufentanil and ketamine were 0.4 &PLUSMN; 0.2 ng/mL and 2.6 &PLUSMN; 2.2 &mu; g/mL, respectively, before the increase in concentrations and 0.7 &PLUSMN; 0.4 ng/mL and 5.5 &PLUSMN; 3.8 &mu; g/mL after. Conclusions. The present study shows that the increase in sufentanil or ketamine plasma concentrations using a target-controlled infusion is not associated with adverse effects on cerebral hemodynamics in patients with severe. brain injury. The use of target-controlled infusion could be of interest in the management of severely brain-injured patients. However, there is a need for specific pharmacokinetic models designed for intensive care unit patients.	Nord Hosp, Dept Anesthesiol & Intens Care, Toulouse, France; Nord Hosp, Ctr Trauma, Toulouse, France; Marseille Univ Hosp Syst, Timone Hosp, Dept Pharmacokinet, Marseille, France	Bourgoin, A (corresponding author), Nord Hosp, Dept Anesthesiol & Intens Care, Toulouse, France.		Leone, Marc/P-4835-2016	Leone, Marc/0000-0002-3097-758X			AKESON J, 1993, ACTA ANAESTH SCAND, V37, P525, DOI 10.1111/j.1399-6576.1993.tb03759.x; Albanese J, 1997, ANESTHESIOLOGY, V87, P1328, DOI 10.1097/00000542-199712000-00011; ALBANESE J, 1993, ANESTHESIOLOGY, V79, P493, DOI 10.1097/00000542-199309000-00012; Albanese J, 1999, CRIT CARE MED, V27, P407, DOI 10.1097/00003246-199902000-00050; ALVIS JM, 1985, ANESTHESIOLOGY, V63, P41, DOI 10.1097/00000542-198507000-00006; AVRAM MJ, 1983, CLIN PHARMACOL THER, V34, P505, DOI 10.1038/clpt.1983.205; BELOPAVLOVIC M, 1982, ACTA ANAESTH SCAND, V26, P458, DOI 10.1111/j.1399-6576.1982.tb01799.x; Bourgoin A, 2003, CRIT CARE MED, V31, P711, DOI 10.1097/01.CCM.0000044505.24727.16; Bullock Ross, 1996, Journal of Neurotrauma, V13, P639; De Castro V, 2003, ANESTH ANALG, V96, P33, DOI 10.1097/00000539-200301000-00008; DOMINO EF, 1984, CLIN PHARMACOL THER, V36, P645, DOI 10.1038/clpt.1984.235; GEISSLINGER G, 1991, J CHROMATOGR-BIOMED, V568, P165, DOI 10.1016/0378-4347(91)80350-L; Guignard B, 2000, ANESTH ANALG, V90, P161, DOI 10.1097/00000539-200001000-00034; Hirota K, 1999, EUR J ANAESTH, V16, P779; HUDSON RJ, 1989, ANESTHESIOLOGY, V70, P426, DOI 10.1097/00000542-198903000-00011; Kolenda H, 1996, ACTA NEUROCHIR, V138, P1193, DOI 10.1007/BF01809750; LEONE M, IN PRESS ANESTH ANAL; MARSHALL LF, 1992, J NEUROTRAUMA, V9, P287; MICHIELS M, 1983, J PHARM PHARMACOL, V35, P86, DOI 10.1111/j.2042-7158.1983.tb04275.x; Payen JF, 2001, CRIT CARE MED, V29, P2258, DOI 10.1097/00003246-200112000-00004; Sakai T, 1999, ACTA ANAESTH SCAND, V43, P212, DOI 10.1034/j.1399-6576.1999.430216.x; TOMASINI JL, 1985, J CHROMATOGR, V343, P369, DOI 10.1016/S0378-4347(00)84605-8; VANDALEN R, 1990, INTENS CARE MED, V16, pS235, DOI 10.1007/BF01709707; Vereecke HEM, 2003, ANAESTHESIA, V58, P957, DOI 10.1046/j.1365-2044.2003.03403.x; Veselis RA, 1997, ANESTHESIOLOGY, V87, P1106, DOI 10.1097/00000542-199711000-00015; VIVIAND X, 1993, ANN FR ANESTH, V12, P38; Vivien B, 2003, ANESTHESIOLOGY, V99, P9, DOI 10.1097/00000542-200307000-00006; WERNER C, 1995, ANESTHESIOLOGY, V83, P721, DOI 10.1097/00000542-199510000-00011; Zheng D, 1998, ANESTH ANALG, V86, P1109	29	76	83	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0090-3493			CRIT CARE MED	Crit. Care Med.	MAY	2005	33	5					1109	1113		10.1097/01.CCM.0000162491.26292.98			5	Critical Care Medicine	General & Internal Medicine	925PO	WOS:000229065200029	15891344				2021-06-18	
J	Langlois, JA; Marr, A; Mitchko, J; Johnson, RL				Langlois, JA; Marr, A; Mitchko, J; Johnson, RL			Tracking the silent epidemic and educating the public - CDC's traumatic brain injury-associated activities under the TBI act of 1996 and the children's health act of 2000	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injury; craniocerebral trauma; education; surveillance	HOSPITALIZATIONS; SERVICES; TRENDS; NEEDS	The Traumatic Brain Injury Act of 1996 and the Children's Health Act of 2000 authorized the Centers for Disease Control and Prevention to conduct several activities associated with traumatic brain injury. This aricle describes how the Centers for Disease Control and Prevention responded to the legislation in 2 key areas: traumatic brain injury surveillance, and education and awareness.	Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA	Langlois, JA (corresponding author), 4770 Buford Highway,NE,MS F-41, Atlanta, GA 30341 USA.	JAL7@cdc.gov					Adekoya Nelson, 2002, MMWR Surveill Summ, V51, P1; Binder S, 2005, J HEAD TRAUMA REHAB, V20, P189, DOI 10.1097/00001199-200505000-00002; Brooks CA, 1997, ARCH PHYS MED REHAB, V78, pS26, DOI 10.1016/S0003-9993(97)90152-0; Butler J, 2001, CENTRAL NERVOUS SYST; BUTLER JA, 2002, CENTRAL NERVOUS SYST; *CDCP, 1999, TRAUM BRAIN INJ US; *CDCP, 2003, MMWR-MORBID MORTAL W, V52, P276; *CDCP, 1996, MMWR-MORBID MORTAL W, V45, P209; *CDCP NAT CTR HLTH, SURV DAT COLL SYST; *CDCP NAT CTR HLTH, 1999, FACTS CONC BRAIN INJ; *CDCP NAT CTR HLTH, 2002, INF AC LES CER LEV; *CDCP NAT CTR HLTH, 2003, HEADS BRAIN INJ YOUR; Centers for Disease Control and Prevention, 2003, MILD TRAUM BRAIN INJ; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P8; Coronado VG, 2005, J HEAD TRAUMA REHAB, V20, P215, DOI 10.1097/00001199-200505000-00005; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; Corrigan JD, 2004, J HEAD TRAUMA REHAB, V19, P205, DOI 10.1097/00001199-200405000-00002; Cusick CP, 2003, BRAIN INJURY, V17, P931, DOI 10.1080/0269905031000110391; Cusick CP, 2001, ARCH PHYS MED REHAB, V82, P1018, DOI 10.1053/apmr.2001.25098; Gabella B, 1997, ANN EPIDEMIOL, V7, P207, DOI 10.1016/S1047-2797(96)00150-0; Gerhart KA, 2003, J TRAUMA, V55, P1045, DOI 10.1097/01.TA.0000044353.69681.96; *HARR INT INC, PUBL PERC BRAIN HEAD; Kegler SR, 2003, J HEAD TRAUMA REHAB, V18, P469, DOI 10.1097/00001199-200311000-00001; Klaucke DN, 1988, MMWR S5, V37, P1; Langlois J, 2005, TRAUMATIC BRAIN INJU; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Langlois Jean A, 2003, MMWR Surveill Summ, V52, P1; Leith KH, 2004, BRAIN INJURY, V18, P1191, DOI 10.1080/02699050410001719943; Marr AL., 2004, CENTRAL NERVOUS SYST; McCarthy ML, 2005, J TRAUMA, V58, P154, DOI 10.1097/01.TA.0000119690.32257.B0; McCarthy ML, 2002, ACAD EMERG MED, V9, P684; Mellick D, 2003, BRAIN INJURY, V17, P55, DOI 10.1080/0269905021000010159; *NIH, 2002, MAK HLTH COMM PROGR; PICKELSIMER E, 2002, BRIAN INJ SOURCE, V6, P18; Reid SR, 2001, ARCH PEDIAT ADOL MED, V155, P784, DOI 10.1001/archpedi.155.7.784; Rutland-Brown W, 2005, J HEAD TRAUMA REHAB, V20, P205, DOI 10.1097/00001199-200505000-00004; Sample PL, 2005, J HEAD TRAUMA REHAB, V20, P270, DOI 10.1097/00001199-200505000-00009; Sample PL, 2004, BRAIN INJURY, V18, P1177, DOI 10.1080/02699050410001719925; Selassie AW, 2005, J HEAD TRAUMA REHAB, V20, P257, DOI 10.1097/00001199-200505000-00008; Selassie AW, 2003, ACAD EMERG MED, V10, P1260, DOI 10.1197/S1069-6563(03)00497-4; SHORE AD, IN PRESS BRAIN INJ; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Thurman DJ., 1995, GUIDELINES SURVEILLA; *US DEP HHS, 1989, INT CLASS DIS; Whiteneck G, 2001, COLORADO TRAUMATIC B; WHITTY RW, 1985, SOFTW MICROSYST, V4, P2, DOI 10.1049/sm.1985.0002; *WHO, 2001, INT CLASS DIS REL HL	48	76	78	1	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2005	20	3					196	204		10.1097/00001199-200505000-00003			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	926ZZ	WOS:000229163500003	15908820				2021-06-18	
J	Monson, KL; Goldsmith, W; Barbaro, NM; Manley, GT				Monson, KL; Goldsmith, W; Barbaro, NM; Manley, GT			Significance of source and size in the mechanical response of human cerebral blood vessels	JOURNAL OF BIOMECHANICS			English	Article						traumatic brain injury; cerebral vessel mechanical properties; cadaver tissue; autopsy tissue	BRIDGING VEINS; BRAIN INJURY; FAILURE; FRESH	Cerebral blood vessels are frequently damaged in traumatic brain injury. Mechanical properties of fresh human cerebral vessels obtained through surgeries have been reported. Because surgical sources of human specimens are rare and produce a limited amount of material, we sought to compare the properties of more readily available cerebral arteries and veins obtained from cadavers to fresh vessel data. Additionally, because the previous study was limited to small vessels available in surgery, it was unknown how generally applicable the results were to larger cerebral arteries and veins. In the current study, large and small cerebral vessels from autopsy were stretched axially. Data from these and similar tests on fresh vessels were combined to determine the significance of source and size on mechanical properties. Structural comparisons of histological samples were additionally utilized to characterize differences. Results indicate that specimens from autopsy and surgery behave similarly except that vessels from autopsy tend to be less extensible. While tests on large vessels were limited, small arteries obtained from autopsy tended to be slightly stiffer than large arteries. In contrast, bridging veins from cadavers were typically stiffer and stretched less before structural failure than cortical veins from the same source. These effects are, however, secondary to differences identified between arteries and veins in the previous study. (c) 2004 Elsevier Ltd. All rights reserved.	Univ Calif Berkeley, Dept Mech Engn, Berkeley, CA 94720 USA; Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA	Monson, KL (corresponding author), Univ Calif Berkeley, Dept Neurol Surg, 2163 Etcheverry Hall, Berkeley, CA 94720 USA.	kmonson@me.berkeley.edu	Monson, Ken/L-4702-2019	Monson, Ken/0000-0002-8461-6034	ODCDC CDC HHS [R49 CCR919722-01] Funding Source: Medline		ALCOLADO R, 1988, NEUROPATH APPL NEURO, V14, P1, DOI 10.1111/j.1365-2990.1988.tb00862.x; Bandak F.A., 1994, P 38 STAPP CAR CRASH; Brossollet LJ, 1997, J BIOMECH ENG-T ASME, V119, P1, DOI 10.1115/1.2796059; BUSBY DE, 1965, CAN J PHYSIOL PHARM, V43, P185, DOI 10.1139/y65-018; CHALUPNIK JD, 1971, MATERIAL PROPERTIES; Gentner JM, 1998, CELL MOL BIOL, V44, P251; Graham DI, 1996, NEUROTRAUMA, P43; KRAUS JF, 1994, SEMIN NEUROL, V14, P1, DOI 10.1055/s-2008-1041052; LEE MC, 1989, J BIOMECH, V22, P537, DOI 10.1016/0021-9290(89)90005-5; Monson KL, 2003, J BIOMECH ENG-T ASME, V125, P288, DOI 10.1115/1.1554412; Pang Q, 2001, J VASC RES, V38, P83, DOI 10.1159/000051033; SCOTT S, 1972, CAN J PHYSIOL PHARM, V50, P328, DOI 10.1139/y72-049; SMITH RW, 1979, P 23 STAPP CAR CRASH, P545; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; VOSSOUGHI J, 1996, TRAUMATIC BRAIN INJU, pCH23; YAMASHIMA T, 1984, J NEUROL NEUROSUR PS, V47, P121, DOI 10.1136/jnnp.47.2.121; Zhang Liying, 2002, Stapp Car Crash J, V46, P145	17	76	76	0	12	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9290			J BIOMECH	J. Biomech.	APR	2005	38	4					737	744		10.1016/j.jbiomech.2004.05.004			8	Biophysics; Engineering, Biomedical	Biophysics; Engineering	905SQ	WOS:000227590400011	15713294				2021-06-18	
J	Shacka, JJ; Roth, KA				Shacka, John J.; Roth, Kevin A.			Regulation of Neuronal Cell Death and Neurodegeneration by Members of the Bcl-2 Family: Therapeutic Implications	CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS			English	Article								The Bcl-2 family of proteins contains both anti and pro-apoptotic members that have been shown to regulate neuronal cell death during development and in many models of acute and chronic neurodegeneration. This family of proteins can be divided into three distinct classes based on structure and function: the antiapoptotic sub-group; the pro-apoptotic, multi-domain sub-group; and the pro-apoptotic, BH3 domain-only sub-group. Alterations in the expression of Bcl-2 family members occur in several animal and human neurodegenerative diseases including Alzheimer's, Huntington's and Parkinson's diseases and Amyotrophic Lateral Sclerosis. Similar changes are seen in in vivo and in vitro models of acute neurodegeneration, including stroke and traumatic brain injury. Methods to increase the overall expression and/or function of anti-apoptotic Bcl-2 family members, and thus promote neuron survival, have been studied extensively in these models. Most treatment efforts focus on either the targeted delivery via viral vectors of anti-apoptotic members of Bcl-2 family members into the affected brain regions of interest, the generation of direct interactions of small molecule inhibitors with Bcl-2 family members, or the induced expression of Bcl-2 family members secondary to pharmacological manipulation. Although many challenges exist in the design of safe and efficacious Bcl-2 family mimetics for the treatment of neurodegeneration, such strategies offer great promise for preserving neuron viability, and hopefully function, in a variety of human neurological diseases.	[Shacka, John J.; Roth, Kevin A.] Univ Alabama Birmingham, Dept Pathol, Div Neuropathol, Birmingham, AL 35294 USA	Shacka, JJ (corresponding author), Univ Alabama Birmingham, Dept Pathol, Div Neuropathol, Birmingham, AL 35294 USA.	jshacka@path.uab.edu		Roth, Kevin/0000-0002-0643-995X			Aleyasin H, 2004, J NEUROSCI, V24, P2963, DOI 10.1523/JNEUROSCI.0155-04.2004; Alkayed NJ, 2001, J NEUROSCI, V21, P7543; Anglade P, 1997, HISTOL HISTOPATHOL, V12, P25; Antonawich FJ, 1999, EXP NEUROL, V156, P130, DOI 10.1006/exnr.1998.7004; Antonawich FJ, 2002, BRAIN RES BULL, V57, P647, DOI 10.1016/S0361-9230(01)00761-4; Antonawich FJ, 1998, J CEREBR BLOOD F MET, V18, P882, DOI 10.1097/00004647-199808000-00008; Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; Arango-Davila CA, 2004, NEUROREPORT, V15, P1437, DOI 10.1097/01.wnr.0000131010.74494.75; Ay I, 2001, MOL BRAIN RES, V87, P71, DOI 10.1016/S0169-328X(00)00285-0; Azzouz M, 2000, HUM MOL GENET, V9, P803, DOI 10.1093/hmg/9.5.803; Baba N, 1999, BRAIN RES, V827, P122, DOI 10.1016/S0006-8993(99)01315-3; Bahr BA, 2002, J NEUROCHEM, V83, P481, DOI 10.1046/j.1471-4159.2002.01192.x; Basanez G, 2001, J BIOL CHEM, V276, P31083, DOI 10.1074/jbc.M103879200; Bassik MC, 2004, EMBO J, V23, P1207, DOI 10.1038/sj.emboj.7600104; Belcredito S, 2001, BRAIN RES REV, V37, P335, DOI 10.1016/S0165-0173(01)00138-2; Biswas SC, 2002, J BIOL CHEM, V277, P49511, DOI 10.1074/jbc.M208086200; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BORNER C, 1994, BIOCHEM CELL BIOL, V72, P463, DOI 10.1139/o94-062; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; Cain K, 2000, J BIOL CHEM, V275, P6067, DOI 10.1074/jbc.275.9.6067; Cantara S, 2004, J VASC RES, V41, P202, DOI 10.1159/000077408; Cao GD, 2002, J NEUROSCI, V22, P5423; Cao YJ, 2002, GENE THER, V9, P415, DOI 10.1038/sj.gt.3301676; Cardona-Gomez GP, 2001, BRAIN RES REV, V37, P320, DOI 10.1016/S0165-0173(01)00137-0; Cartron PF, 2004, J BIOL CHEM, V279, P11503, DOI 10.1074/jbc.M311922200; Castro R.E, 2004, J PHARM EXP THER; Cataldo AM, 1996, J NEUROSCI, V16, P186; Chae HJ, 2004, MOL CELL, V15, P355, DOI 10.1016/j.molcel.2004.06.038; Chen G, 1999, J NEUROCHEM, V72, P879, DOI 10.1046/j.1471-4159.1999.720879.x; CHEN J, 1995, NEUROREPORT, V6, P394, DOI 10.1097/00001756-199501000-00040; Chen J, 1997, J CEREBR BLOOD F MET, V17, P2, DOI 10.1097/00004647-199701000-00002; Chen RW, 1999, J BIOL CHEM, V274, P6039, DOI 10.1074/jbc.274.10.6039; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; Chiu SM, 2003, BRIT J CANCER, V89, P1590, DOI 10.1038/sj.bjc.6601298; Choi JM, 2002, J PHARMACOL EXP THER, V300, P787, DOI 10.1124/jpet.300.3.787; Chuang DM, 2002, BIPOLAR DISORD, V4, P129, DOI 10.1034/j.1399-5618.2002.01179.x; D'Sa C, 2003, J NEUROSCI RES, V74, P435, DOI 10.1002/jnr.10738; D'Sa-Eipper C, 2001, DEVELOPMENT, V128, P137; Danial NN, 2003, NATURE, V424, P952, DOI 10.1038/nature01825; Datta SR, 2002, DEV CELL, V3, P631, DOI 10.1016/S1534-5807(02)00326-X; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Deckwerth TL, 1996, NEURON, V17, P401, DOI 10.1016/S0896-6273(00)80173-7; Degenhardt K, 2002, J BIOL CHEM, V277, P14127, DOI 10.1074/jbc.M109939200; Degterev A, 2001, NAT CELL BIOL, V3, P173, DOI 10.1038/35055085; delPeso L, 1997, SCIENCE, V278, P687; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Deverman BE, 2002, CELL, V111, P51, DOI 10.1016/S0092-8674(02)00972-8; Dhar S, 2002, ANN NEUROL, V51, P448, DOI 10.1002/ana.10143; Dubal DB, 1999, J NEUROSCI, V19, P6385; Eberspacher E, 2003, J NEUROSURG ANESTH, V15, P200, DOI 10.1097/00008506-200307000-00007; Ekegren T, 1999, ACTA NEUROL SCAND, V100, P317; Embacher N, 2001, ACTA NEUROPATHOL, V102, P426; Enyedy IJ, 2001, J MED CHEM, V44, P4313, DOI 10.1021/jm010016f; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; Fernando RI, 2004, MOL BIOL CELL, V15, P3266, DOI 10.1091/mbc.E03-11-0823; FERRANTE RJ, 1991, J NEUROSCI, V11, P3877; Ferrer I, 2003, J NEUROPATH EXP NEUR, V62, P329, DOI 10.1093/jnen/62.4.329; Ferrer I, 1998, EXP BRAIN RES, V121, P167, DOI 10.1007/s002210050448; Fink DJ, 2003, EXP NEUROL, V184, pS19, DOI 10.1016/S0014-4886(03)00358-3; Frankel SR, 2003, SEMIN ONCOL, V30, P300, DOI 10.1053/sonc.2003.50041; Galas MC, 2004, NEUROBIOL DIS, V15, P152, DOI 10.1016/j.nbd.2003.09.013; Ghribi O, 2001, NEUROBIOL DIS, V8, P764, DOI 10.1006/nbdi.2001.0429; GILLARDON F, 1994, EUR J NEUROSCI, V6, P1641, DOI 10.1111/j.1460-9568.1994.tb00555.x; Gillardon F, 1996, J NEUROSCI RES, V43, P726, DOI 10.1002/(SICI)1097-4547(19960315)43:6<726::AID-JNR9>3.3.CO;2-Z; Gillardon F, 1996, BRAIN RES, V739, P244, DOI 10.1016/S0006-8993(96)00829-3; Gillardon F, 1996, NEUROSCI LETT, V207, P113, DOI 10.1016/0304-3940(96)12508-8; Gilley J, 2003, J CELL BIOL, V162, P613, DOI 10.1083/jcb.200303026; GONZALEZGARCIA M, 1995, P NATL ACAD SCI USA, V92, P4304, DOI 10.1073/pnas.92.10.4304; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; Graham SH, 2000, J NEUROTRAUM, V17, P831, DOI 10.1089/neu.2000.17.831; Green PS, 2000, INT J DEV NEUROSCI, V18, P347, DOI 10.1016/S0736-5748(00)00017-4; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Guegan C, 2002, MOL CELL NEUROSCI, V20, P553, DOI 10.1006/mcne.2002.1136; Guegan C, 1998, EXP NEUROL, V154, P371, DOI 10.1006/exnr.1998.6913; Guo B, 2003, NATURE, V423, P456, DOI 10.1038/nature01627; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; Harris C, 2002, J NEUROCHEM, V83, P992, DOI 10.1046/j.1471-4159.2002.01219.x; Hartmann A, 2002, NEUROBIOL DIS, V10, P28, DOI 10.1006/nbdi.2002.0494; Hartmann A, 2001, J NEUROCHEM, V76, P1785, DOI 10.1046/j.1471-4159.2001.00160.x; Hashimoto Y, 2001, J NEUROSCI, V21, P9235, DOI 10.1523/JNEUROSCI.21-23-09235.2001; Hashimoto Y, 2001, P NATL ACAD SCI USA, V98, P6336, DOI 10.1073/pnas.101133498; Hata R, 1999, METAB BRAIN DIS, V14, P117, DOI 10.1023/A:1020709814456; Hayashi K, 2001, GENE THER, V8, P1167, DOI 10.1038/sj.gt.3301498; Higuchi H, 2001, J PHARMACOL EXP THER, V299, P866; Honda K, 2001, J NEUROSCI RES, V64, P466, DOI 10.1002/jnr.1098; Hong KW, 2002, J PHARMACOL EXP THER, V301, P210, DOI 10.1124/jpet.301.1.210; Horowitz JM, 2003, BRAIN RES BULL, V62, P55, DOI 10.1016/j.brainresbull.2003.08.005; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Huang DCS, 1998, EMBO J, V17, P1029, DOI 10.1093/emboj/17.4.1029; Hunter JJ, 1996, J BIOL CHEM, V271, P8521, DOI 10.1074/jbc.271.15.8521; Ibrado AM, 1996, CELL GROWTH DIFFER, V7, P1087; Imaizumi K, 1999, J BIOL CHEM, V274, P7975, DOI 10.1074/jbc.274.12.7975; Imaizumi K, 2004, J NEUROSCI, V24, P3721, DOI 10.1523/JNEUROSCI.5101-03.2004; Imaizumi K, 1997, J BIOL CHEM, V272, P18842, DOI 10.1074/jbc.272.30.18842; Ingall Timothy, 2004, J Insur Med, V36, P143; Inohara N, 1997, EMBO J, V16, P1686, DOI 10.1093/emboj/16.7.1686; Isenmann S, 1997, EUR J NEUROSCI, V9, P1763, DOI 10.1111/j.1460-9568.1997.tb01534.x; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; Jellinger KA, 2000, J NEURAL TRANSM, V107, P1, DOI 10.1007/s007020050001; Ji JF, 2002, J NEUROSCI RES, V69, P406, DOI 10.1002/jnr.10300; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kanazawa K, 1998, MOL BRAIN RES, V54, P316, DOI 10.1016/S0169-328X(97)00360-4; Kawatani M, 2003, J BIOL CHEM, V278, P19732, DOI 10.1074/jbc.M213038200; Kelekar A, 1997, MOL CELL BIOL, V17, P7040, DOI 10.1128/MCB.17.12.7040; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; Kilic E, 2002, NEUROBIOL DIS, V11, P275, DOI 10.1006/nbdi.2002.0552; Kim ES, 1998, MOL BRAIN RES, V62, P122, DOI 10.1016/S0169-328X(98)00217-4; Kim GW, 2001, STROKE, V32, P1401, DOI 10.1161/01.STR.32.6.1401; Kim KY, 2004, EUR J PHARMACOL, V497, P267, DOI 10.1016/j.ejphar.2004.06.058; Kirsch DG, 1999, J BIOL CHEM, V274, P21155, DOI 10.1074/jbc.274.30.21155; Kitamura Y, 1998, BRAIN RES, V780, P260, DOI 10.1016/S0006-8993(97)01202-X; Klasa RJ, 2002, ANTISENSE NUCLEIC A, V12, P193, DOI 10.1089/108729002760220798; Kopnisky KL, 2003, NEUROSCIENCE, V116, P425, DOI 10.1016/S0306-4522(02)00573-0; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; KRAJEWSKI S, 1995, J NEUROSCI, V15, P6364; Kupsch A, 2001, J NEURAL TRANSM, V108, P985, DOI 10.1007/s007020170018; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; LASSMANN H, 1995, ACTA NEUROPATHOL, V89, P35, DOI 10.1007/BF00294257; Lawrence MS, 1997, J CEREBR BLOOD F MET, V17, P740; Lee LC, 1996, J BIOL CHEM, V271, P23284, DOI 10.1074/jbc.271.38.23284; Leinninger G.M, 2004, FASEB J; Lenhard T, 2002, MOL CELL NEUROSCI, V20, P181, DOI 10.1006/mcne.2002.1134; Leonard JR, 2001, DEV BRAIN RES, V128, P187, DOI 10.1016/S0165-3806(01)00174-2; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; LINNIK MD, 1995, STROKE, V26, P1670, DOI 10.1161/01.STR.26.9.1670; Linseman DA, 2002, J NEUROSCI, V22, P9287; Luetjens CM, 2001, NEUROSCIENCE, V102, P139, DOI 10.1016/S0306-4522(00)00458-9; Luo Chun, 2002, Chin J Traumatol, V5, P299; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Marani M, 2002, MOL CELL BIOL, V22, P3577, DOI 10.1128/MCB.22.11.3577-3589.2002; Marshall KA, 1997, BIOCHEM BIOPH RES CO, V240, P84, DOI 10.1006/bbrc.1997.7604; Martin LJ, 1999, J NEUROPATH EXP NEUR, V58, P459, DOI 10.1097/00005072-199905000-00005; Maruyama W, 2002, NEUROTOXICOL TERATOL, V24, P675, DOI 10.1016/S0892-0362(02)00221-0; MERRY DE, 1994, DEVELOPMENT, V120, P301; Michaelidis TM, 1996, NEURON, V17, P75, DOI 10.1016/S0896-6273(00)80282-2; Minami M, 2000, NEUROSCI LETT, V279, P193, DOI 10.1016/S0304-3940(99)00987-8; Minn AJ, 1996, J BIOL CHEM, V271, P6306, DOI 10.1074/jbc.271.11.6306; Mladenovic A, 2004, BRAIN RES, V996, P237, DOI 10.1016/j.brainres.2003.10.035; Mogi M, 1996, NEUROSCI LETT, V215, P137, DOI 10.1016/0304-3940(96)12961-X; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Mu XJ, 1996, ANN NEUROL, V40, P379, DOI 10.1002/ana.410400307; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Natsume A, 2001, EXP NEUROL, V169, P231, DOI 10.1006/exnr.2001.7671; Niikura T, 2004, J NEUROSCI RES, V77, P54, DOI 10.1002/jnr.20139; Nilsen J, 2003, P NATL ACAD SCI USA, V100, P2842, DOI 10.1073/pnas.0438041100; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; O'Reilly LA, 2000, AM J PATHOL, V157, P449, DOI 10.1016/S0002-9440(10)64557-9; OBarr S, 1996, NEUROBIOL AGING, V17, P131, DOI 10.1016/0197-4580(95)02024-1; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Offen D, 2001, NEUROSCI LETT, V316, P129, DOI 10.1016/S0304-3940(01)02344-8; Okuno S, 2004, J NEUROSCI, V24, P7879, DOI 10.1523/JNEUROSCI.1745-04.2004; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Otake Yoko, 2004, Curr Opin Investig Drugs, V5, P616; Panizzon KL, 1998, NEUROREPORT, V9, P4131, DOI 10.1097/00001756-199812210-00024; Paradis E, 1996, J NEUROSCI, V16, P7533; PEGORARO L, 1984, P NATL ACAD SCI-BIOL, V81, P7166, DOI 10.1073/pnas.81.22.7166; Pepper C, 2002, LEUKEMIA LYMPHOMA, V43, P2003, DOI 10.1080/1042819021000015961; Perovic S, 1998, MECH AGEING DEV, V101, P1, DOI 10.1016/S0047-6374(97)00152-8; Pike CJ, 1999, J NEUROCHEM, V72, P1552, DOI 10.1046/j.1471-4159.1999.721552.x; Plesnila N, 2002, EUR SURG RES, V34, P37, DOI 10.1159/000048885; Prehn JHM, 1996, MOL PHARMACOL, V49, P319; Przedborski S, 2004, NEUROLOGIST, V10, P1, DOI 10.1097/01.nrl.0000106920.84668.37; Pugazhenthi S, 2000, J BIOL CHEM, V275, P10761, DOI 10.1074/jbc.275.15.10761; Putcha GV, 2002, J CELL BIOL, V157, P441, DOI 10.1083/jcb.200110108; Putcha GV, 2003, NEURON, V38, P899, DOI 10.1016/S0896-6273(03)00355-6; Putcha GV, 2001, NEURON, V29, P615, DOI 10.1016/S0896-6273(01)00238-0; Raghupathi R, 2003, J NEUROTRAUM, V20, P421, DOI 10.1089/089771503765355504; Ramalho RM, 2004, J NEUROCHEM, V90, P567, DOI 10.1111/j.1471-4159.2004.02517.x; Ranger AM, 2003, P NATL ACAD SCI USA, V100, P9324, DOI 10.1073/pnas.1533446100; REGEUR L, 1994, NEUROBIOL AGING, V15, P347, DOI 10.1016/0197-4580(94)90030-2; Reimertz C, 2003, J CELL BIOL, V162, P587, DOI 10.1083/jcb.200305149; Rodrigues CMP, 2003, P NATL ACAD SCI USA, V100, P6087, DOI 10.1073/pnas.1031632100; Rosse T, 1998, NATURE, V391, P496; Roth KA, 2000, P NATL ACAD SCI USA, V97, P466, DOI 10.1073/pnas.97.1.466; Roth KA, 2001, J NEUROPATH EXP NEUR, V60, P829, DOI 10.1093/jnen/60.9.829; Roth W, 2003, CELL DEATH DIFFER, V10, P1178, DOI 10.1038/sj.cdd.4401287; Sagi Y, 2003, J NEUROCHEM, V86, P290, DOI 10.1046/j.1471-4159.2003.01801.x; Saille C, 1999, NEUROSCIENCE, V92, P1455, DOI 10.1016/S0306-4522(99)00089-5; SATOU T, 1995, BRAIN RES, V697, P35, DOI 10.1016/0006-8993(95)00748-F; Sawada M, 2003, NAT CELL BIOL, V5, P352, DOI 10.1038/ncb955; Sawada M, 2003, NAT CELL BIOL, V5, P320, DOI 10.1038/ncb950; Schabitz WR, 2000, STROKE, V31, P2212, DOI 10.1161/01.STR.31.9.2212; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Selznick LA, 2000, J NEUROPATH EXP NEUR, V59, P271, DOI 10.1093/jnen/59.4.271; Sengupta TK, 2004, J BIOL CHEM, V279, P10855, DOI 10.1074/jbc.M309111200; Seo S.Y, 2004, J BIOL CHEM; Seo YW, 2003, J BIOL CHEM, V278, P48292, DOI 10.1074/jbc.M308785200; Shibata M, 2002, J CEREBR BLOOD F MET, V22, P810, DOI 10.1097/00004647-200207000-00006; Shibue T, 2003, GENE DEV, V17, P2233, DOI 10.1101/gad.1103603; Shimazaki K, 2000, GENE THER, V7, P1244, DOI 10.1038/sj.gt.3301211; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P3100, DOI 10.1073/pnas.97.7.3100; Shimohama S, 1998, BIOCHEM BIOPH RES CO, V252, P92, DOI 10.1006/bbrc.1998.9577; Shindler KS, 1998, CELL DEATH DIFFER, V5, P901, DOI 10.1038/sj.cdd.4400421; Shinoe T, 2001, NEUROSCI LETT, V313, P153, DOI 10.1016/S0304-3940(01)02250-9; Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598; Sribnick EA, 2004, J NEUROSCI RES, V76, P688, DOI 10.1002/jnr.20124; Stadelmann C, 1999, AM J PATHOL, V155, P1459, DOI 10.1016/S0002-9440(10)65460-0; Stern MB, 2004, MOVEMENT DISORD, V19, P916, DOI 10.1002/mds.20145; Stoka V, 2001, J BIOL CHEM, V276, P3149, DOI 10.1074/jbc.M008944200; Su JH, 2001, BRAIN RES, V898, P350, DOI 10.1016/S0006-8993(01)02018-2; Su JH, 1996, NEUROREPORT, V7, P437, DOI 10.1097/00001756-199601310-00015; Su JH, 1997, J NEUROPATH EXP NEUR, V56, P86, DOI 10.1097/00005072-199701000-00009; Sugioka R, 2003, ONCOGENE, V22, P8432, DOI 10.1038/sj.onc.1207180; Sun W, 2003, J NEUROSCI, V23, P7298, DOI 10.1523/jneurosci.23-19-07298.2003; Sun Y, 2003, GENE THER, V10, P115, DOI 10.1038/sj.gt.3301868; Terradillos O, 2002, FEBS LETT, V522, P29, DOI 10.1016/S0014-5793(02)02871-5; TERRY RD, 1991, ANN NEUROL, V30, P572, DOI 10.1002/ana.410300410; Tortosa A, 1998, ACTA NEUROPATHOL, V95, P407, DOI 10.1007/s004010050817; Tortosa A, 1997, NEUROSCI LETT, V238, P78, DOI 10.1016/S0304-3940(97)00837-9; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; Tsuruta F, 2002, J BIOL CHEM, V277, P14040, DOI 10.1074/jbc.M108975200; Tsuzuki N, 2001, NEUROL RES, V23, P417, DOI 10.1179/016164101101198659; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; Vila M, 2001, P NATL ACAD SCI USA, V98, P2837, DOI 10.1073/pnas.051633998; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Vis JC, 2001, NEUROPATH APPL NEURO, V27, P68, DOI 10.1046/j.0305-1846.2001.00305.x; Vukosavic S, 1999, J NEUROCHEM, V73, P2460, DOI 10.1046/j.1471-4159.1999.0732460.x; Vyas S, 1997, J NEUROCHEM, V69, P223; Walensky LD, 2004, SCIENCE, V305, P1466, DOI 10.1126/science.1099191; Wang GQ, 2001, J EXP MED, V194, P1325, DOI 10.1084/jem.194.9.1325; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wang LH, 2004, ANNU REV PHARMACOL, V44, P451, DOI 10.1146/annurev.pharmtox.44.101802.121840; Wang R, 2001, NEUROREPORT, V12, P2629, DOI 10.1097/00001756-200108280-00009; Wang R, 2001, EUR J PHARMACOL, V421, P149, DOI 10.1016/S0014-2999(01)01030-5; Wang ZM, 2002, OTOL NEUROTOL, V23, P397, DOI 10.1097/00129492-200205000-00029; Wei H, 2001, NEUROSCIENCE, V106, P603, DOI 10.1016/S0306-4522(01)00311-6; Wei HF, 2000, EUR J PHARMACOL, V392, P117, DOI 10.1016/S0014-2999(00)00127-8; Wei MC, 2000, GENE DEV, V14, P2060; Wen TC, 2002, J NEUROSCI RES, V67, P795, DOI 10.1002/jnr.10166; Wennersten A, 2003, ACTA NEUROPATHOL, V105, P281, DOI 10.1007/s00401-002-0649-y; White FA, 1998, J NEUROSCI, V18, P1428; Wiessner C, 1999, NEUROSCI LETT, V268, P119, DOI 10.1016/S0304-3940(99)00392-4; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Yamada M, 2001, EXP NEUROL, V168, P225, DOI 10.1006/exnr.2000.7597; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yan CH, 2000, J CEREBR BLOOD F MET, V20, P620, DOI 10.1097/00004647-200003000-00020; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yin XM, 2002, J BIOL CHEM, V277, P42074, DOI 10.1074/jbc.M204991200; Yin XM, 1999, NATURE, V400, P886; Youdim MBH, 2004, NEUROPHARMACOLOGY, V46, P1130, DOI 10.1016/j.neuropharm.2004.02.005; Youdim MBH, 2003, BIOCHEM PHARMACOL, V66, P1635, DOI 10.1016/S0006-2952(03)00535-5; Youdim MBH, 2001, CELL MOL NEUROBIOL, V21, P555, DOI 10.1023/A:1015131516649; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100; Zaidi AU, 2001, J NEUROSCI, V21, P169, DOI 10.1523/JNEUROSCI.21-01-00169.2001; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang H, 2000, P NATL ACAD SCI USA, V97, P2597, DOI 10.1073/pnas.97.6.2597; Zhang HM, 2003, APOPTOSIS, V8, P229, DOI 10.1023/A:1023616620970; Zhang HY, 2003, NEUROSCI LETT, V340, P91, DOI 10.1016/S0304-3940(03)00023-5; Zhang Y, 2002, J CELL BIOL, V156, P519, DOI 10.1083/jcb.200110119; Zhang Y, 2003, J NEUROCHEM, V87, P1184, DOI 10.1046/j.1471-4159.2003.02105.x; Zhao H, 2003, J NEUROCHEM, V85, P1026, DOI 10.1046/j.1471-4159.2003.01756.x; Zhao LQ, 2004, BRAIN RES, V1010, P22, DOI 10.1016/j.brainres.2004.02.066; Zhu WW, 2004, MOL BRAIN RES, V126, P45, DOI 10.1016/j.molbrainres.2004.03.019; Zhu Y, 2002, J NEUROSCI, V22, P3898, DOI 10.1523/JNEUROSCI.22-10-03898.2002; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	263	76	77	0	1	BENTHAM SCIENCE PUBL	BUSUM	PO BOX 294, BUSUM, 1400 AG, NETHERLANDS	1871-5273	1996-3181		CNS NEUROL DISORD-DR	CNS Neurol. Disord.-Drug Targets		2005	4	1					25	39		10.2174/1568007053005127			15	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	VI5XE	WOS:000497826100003	15723611				2021-06-18	
J	Holloway, AC; Keene, JL; Noakes, DG; Moccia, RD				Holloway, AC; Keene, JL; Noakes, DG; Moccia, RD			Effects of clove oil and MS-222 on blood hormone profiles in rainbow trout Oncorhynchus mykiss, Walbaum	AQUACULTURE RESEARCH			English	Article						clove oil; eugenol; MS-222; anaesthesia; blood plasma; hormones; trout	CATFISH ICTALURUS-PUNCTATUS; TRICAINE METHANESULFONATE; ANESTHESIA; EUGENOL; FISH; RESPONSES; EFFICACY; RECOVERY; SALMON; STRESS	Clove oil has been demonstrated to be an effective, inexpensive anaesthetic and euthanizing agent for a number of fish species, including rainbow trout, used in aquaculture and fisheries research. However, the potential for clove oil to cause perturbations in important plasma hormone concentrations has not been investigated. The effect of anaesthesia and euthanasia in trout with eugenol (the active ingredient in clove oil) on plasma cortisol, glucose, growth hormone (GH) and two thyroid hormones [tri-iodothyronine (T-3) and thyroxine (T-4)] was compared with tricaine methanesulfonate (MS-222) anaesthesia, and stunning by cranial concussion in two experiments. Effects on blood chemistry were different when comparing the particular anaesthetic method being used. Stunning fish significantly increased plasma cortisol and glucose levels (both P<0.05), while euthanizing fish using either clove oil or MS-222 had no effect on these hormone levels. In contrast, the levels of GH, T-3 and T-4 hormones were unaffected regardless of whether fish were euthanized by stunning, MS-222 or clove oil. Variation in effects between hormones were observed using clove oil eugenol. In fish sampled 10 min after anaesthetizing with 150 mg L-1 of eugenol, cortisol levels were significantly decreased (P<0.03), while there were no differences in either glucose or GH levels. Tri-iodothyronine and T-4 also showed significantly elevated levels (P<0.05) after 10-min exposure to eugenol. These results highlight the importance of investigating the potential effects of any new anaesthetic or euthanizing compounds on blood plasma parameters, prior to using them in a research setting, or when comparing results to other studies which have utilized alternative anaesthetic compounds.	Univ Guelph, Aquaculture Ctr, Dept Anim & Poultry Sci, Guelph, ON N1G 2W1, Canada; Univ Guelph, Dept Biomed Sci, Guelph, ON N1G 2W1, Canada; Univ Guelph, Axelrod Inst Ichthyol, Dept Zool, Guelph, ON N1G 2W1, Canada	Moccia, RD (corresponding author), Univ Guelph, Aquaculture Ctr, Dept Anim & Poultry Sci, Guelph, ON N1G 2W1, Canada.	Rmoccia@uoguelph.ca					Bernstein PS, 1997, AM J OPHTHALMOL, V124, P843, DOI 10.1016/S0002-9394(14)71705-2; Chanseau M, 2002, B FR PECHE PISCIC, P579, DOI 10.1051/kmae:2002054; Curtis E K, 1990, Bull Hist Dent, V38, P9; Davidson GW, 2000, J WORLD AQUACULT SOC, V31, P105, DOI 10.1111/j.1749-7345.2000.tb00704.x; *DEP HLTH SOC SEC, 1993, BRIT PHARM; ENDO T, 1972, B JPN SOC SCI FISH, V38, P761; FARBRIDGE KJ, 1991, GEN COMP ENDOCR, V83, P7, DOI 10.1016/0016-6480(91)90100-K; *FDA, 2002, GUID IND STAT CLOV O; FISCHER IU, 1990, XENOBIOTICA, V20, P209, DOI 10.3109/00498259009047156; GINGERICH WH, 1989, GEN COMP ENDOCR, V73, P390, DOI 10.1016/0016-6480(89)90196-2; HARRINGTON AJ, 1991, LIPIDS, V26, P774, DOI 10.1007/BF02535630; HIKASA Y, 1986, JPN J VET SCI, V48, P341; Houston AH, 1997, T AM FISH SOC, V126, P879, DOI 10.1577/1548-8659(1997)126&lt;0879:RATCHV&gt;2.3.CO;2; JOLLY DW, 1972, VET REC, V91, P424, DOI 10.1136/vr.91.18.424; Keene JL, 1998, AQUAC RES, V29, P89, DOI 10.1111/j.1365-2109.1998.tb01113.x; LIU EH, 1977, ANAL BIOCHEM, V79, P597, DOI 10.1016/0003-2697(77)90439-0; MARKING LL, 1985, FISHERIES, V10, P2, DOI 10.1577/1548-8446(1985)010<0002:ABANIF>2.0.CO;2; MAURA A, 1989, MUTAT RES, V227, P125, DOI 10.1016/0165-7992(89)90008-0; McFARLAND WILLIAM N., 1959, PUBL INST MARINE SCI, V6, P23; MILLER EC, 1983, CANCER RES, V43, P1124; PRINCE A, 2000, N AM J FISH MANAGE, V20, P1019; Small BC, 2003, AQUACULTURE, V218, P177, DOI 10.1016/S0044-8486(02)00302-2; Soto CG, 1995, AQUACULTURE, V136, P149, DOI 10.1016/0044-8486(95)01051-3; Summerfelt R.C., 1990, P213; Taylor PW, 1999, N AM J AQUACULT, V61, P150, DOI 10.1577/1548-8454(1999)061<0150:COAAAF>2.0.CO;2; Wagner E, 2002, AQUACULTURE, V211, P353, DOI 10.1016/S0044-8486(01)00878-X; Wagner GN, 2003, AQUAC RES, V34, P1139, DOI 10.1046/j.1365-2109.2003.00916.x; Waterstrat PR, 1999, J WORLD AQUACULT SOC, V30, P250, DOI 10.1111/j.1749-7345.1999.tb00872.x; Woody CA, 2002, J FISH BIOL, V60, P340, DOI 10.1006/jfbi.2001.1842	29	76	81	2	33	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1355-557X	1365-2109		AQUAC RES	Aquac. Res.	SEP 10	2004	35	11					1025	1030		10.1111/j.1365-2109.2004.01108.x			6	Fisheries	Fisheries	845ZF	WOS:000223283500002					2021-06-18	
J	Cruz, J; Minoja, G; Okuchi, K; Facco, E				Cruz, J; Minoja, G; Okuchi, K; Facco, E			Successful use of the new high-dose mannitol treatment in patients with Glasgow Coma Scale scores of 3 and bilateral abnormal pupillary widening: a randomized trial	JOURNAL OF NEUROSURGERY			English	Article						head injury; brain swelling; impending brain death; mannitol; outcome	CEREBRAL BLOOD-FLOW; ACUTE BRAIN INJURY; SEVERE HEAD-INJURY; INTRACRANIAL HYPERTENSION; PERFUSION-PRESSURE; MANAGEMENT STRATEGIES; OXYGEN-CONSUMPTION; PRACTICAL SCALE; METABOLIC-RATE; ACUTE ANEMIA	Object. The authors evaluated long-term clinical outcomes in selected acutely comatose patients with severe diffuse brain swelling and recent clinical signs of impending brain death who received a novel high-dose mannitol treatment compared with those who received conventional-dose mannitol in the emergency room. Methods. Forty-four adult patients with traumatic, nonmissile-inflicted, acute, severe diffuse brain swelling were prospectively and randomly evaluated. All patients were selected based on the presence of recent clinical signs of impending brain death on the first emergency room evaluation. These signs included bilateral abnormal pupillary widening and lack of motor responses to painful stimulation (Glasgow Coma Scale score of 3). The study group (23 patients) received ultra-early and fast intravenous high-dose mannitol treatment (similar to1.4 g/kg), whereas the control group (21 patients) received half that dose (similar to0.7 g/kg). Ultra-early improvement of bilateral abnormal pupillary widening was significantly more frequent in the high-dose mannitol group than in the conventional-dose group (p < 0.02). High-dose mannitol treatment in the emergency room was also associated with significantly better 6-month clinical outcomes (p < 0.02); the best rate of favorable outcomes was 43.5%, compared with only 9.5% in the conventional-dose mannitol group. The two groups of patients were well matched with respect to all emergency room and head computerized tomography findings, as well as the timing of initial mannitol treatment (similar to80-90 minutes after the first evaluation at the scene of the injury). Comparative evaluation of bilateral pupillary widening between the scene of the injury and the emergency room showed no significant differences between groups, whereas mannitol dose dependence was statistically significant (p < 0.05), insofar as early pupillary improvement in the emergency room was concerned. Conclusions. Ultra-early high-dose mannitol administration in the emergency room is the first known treatment strategy significantly to reverse recent clinical signs of impending brain death, and also to contribute directly to improved long-term clinical outcomes for these patients who have previously been considered unsalvageable.	Comprehens Int Ctr Neuroemergencies, BR-04093970 Sao Paulo, Brazil; Univ Fed Sao Paulo, Sao Paulo, Brazil; Univ Insubria, Dept Anesthesiol & Crit Care Med, Varese, Italy; Nara Med Univ, Dept Emergency & Crit Care Med, Nara, Japan; Univ Padua E Meneghetti, Dept Pharmacol & Anesthesiol, Padua, Italy	Cruz, J (corresponding author), Comprehens Int Ctr Neuroemergencies, POB Cx Postal 57011, BR-04093970 Sao Paulo, Brazil.						BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BRUCE DA, 1973, J NEUROSURG, V38, P131, DOI 10.3171/jns.1973.38.2.0131; Bullock MR, 1999, NEUROSURGERY, V45, P207, DOI 10.1097/00006123-199908000-00001; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CRUZ J, 1994, CRIT CARE MED, V22, P1465, DOI 10.1097/00003246-199409000-00018; Cruz J, 1996, J NEUROSURG, V85, P758, DOI 10.3171/jns.1996.85.5.0758; CRUZ J, 1993, CRIT CARE MED, V21, P1218, DOI 10.1097/00003246-199308000-00024; CRUZ J, 1993, J NEUROSURG, V79, P228, DOI 10.3171/jns.1993.79.2.0228; CRUZ J, 1995, CRIT CARE MED, V23, P1412, DOI 10.1097/00003246-199508000-00016; Cruz J, 1998, CRIT CARE MED, V26, P344, DOI 10.1097/00003246-199802000-00039; Cruz J, 1996, CRIT CARE MED, V24, P953, DOI 10.1097/00003246-199606000-00013; CRUZ J, 1995, J NEUROSURG, V82, P379, DOI 10.3171/jns.1995.82.3.0379; CRUZ J, 1994, J NEUROSURG, V80, P143, DOI 10.3171/jns.1994.80.1.0143; Cruz J, 2002, NEUROSURGERY, V51, P628, DOI 10.1097/00006123-200209000-00006; Cruz J, 2002, NEUROSURGERY, V50, P774, DOI 10.1097/00006123-200204000-00017; CRUZ J, 1991, NEUROSURGERY, V29, P743, DOI 10.1227/00006123-199111000-00017; CRUZ J, 1993, CRIT CARE MED, V21, P1225, DOI 10.1097/00003246-199308000-00025; CRUZ J, 1990, J NEUROSURG, V73, P725, DOI 10.3171/jns.1990.73.5.0725; Cruz J, 2001, NEUROSURGERY, V49, P864; CRUZ J, 1998, NEUROLOGIC NEUROSURG, P405; Diringer MN, 2002, J NEUROSURG, V96, P103, DOI 10.3171/jns.2002.96.1.0103; FINNERTY FA, 1954, J CLIN INVEST, V33, P1227, DOI 10.1172/JCI102997; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; Iida K, 2003, J NEUROSURG, V98, P793, DOI 10.3171/jns.2003.98.4.0793; JAGGI JL, 1990, J NEUROSURG, V72, P176, DOI 10.3171/jns.1990.72.2.0176; JENNETT B, 1975, LANCET, V1, P480; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; KETY SS, 1948, J CLIN INVEST, V27, P476, DOI 10.1172/JCI101994; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; Narayan RK, 2001, NEW ENGL J MED, V344, P602, DOI 10.1056/NEJM200102223440810; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; Polderman KH, 2001, J NEUROSURG, V94, P697, DOI 10.3171/jns.2001.94.5.0697; Ritter AM, 1999, NEUROSURGERY, V44, P941, DOI 10.1097/00006123-199905000-00005; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; SCHRODER ML, 1994, J NEUROSURG, V80, P324, DOI 10.3171/jns.1994.80.2.0324; SHALIT MN, 1972, NEUROLOGY, V22, P155, DOI 10.1212/WNL.22.2.155; TABADDOR K, 1972, J TRAUMA, V12, P1053, DOI 10.1097/00005373-197212000-00006; TEASDALE G, 1974, LANCET, V2, P81; Tokutomi T, 2003, NEUROSURGERY, V52, P102, DOI 10.1097/00006123-200301000-00013	40	76	79	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	MAR	2004	100	3					376	383		10.3171/jns.2004.100.3.0376			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	802TS	WOS:000220186400006	15035271				2021-06-18	
J	Larner, SF; Hayes, RL; McKinsey, DM; Pike, BR; Wang, KKW				Larner, SF; Hayes, RL; McKinsey, DM; Pike, BR; Wang, KKW			Increased expression and processing of caspase-12 after traumatic brain injury in rats	JOURNAL OF NEUROCHEMISTRY			English	Article						apoptosis; calpain; caspase; traumatic brain injury; unfolded protein response	ENDOPLASMIC-RETICULUM STRESS; UNFOLDED-PROTEIN RESPONSE; CORTICAL IMPACT INJURY; PROGRAMMED CELL-DEATH; KAR2 BIP GENE; NERVOUS-SYSTEM; RESIDENT CASPASE; CALCIUM STORES; NEURONAL DEATH; ALPHA-SPECTRIN	Traumatic brain injury (TBI) disrupts tissue homeostasis resulting in pathological apoptotic activation. Recently, caspase-12 was reported to be induced and activated by the unfolded protein response following excess endoplasmic reticulum (ER) stress. This study examined rat caspase-12 expression using the controlled cortical impact TBI model. Immunoblots of fractionalized cell lysates found elevated caspase-12 proform (similar to60 kDa) and processed form (similar to12 kDa), with peak induction observed within 24 h post-injury in the cortex (418% and 503%, respectively). Hippocampus caspase-12 proform induction peaked at 24 h post-injury (641%), while processed form induction peaked at 6 h (620%). Semi-quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) analysis confirmed elevated caspase-12 mRNA levels after TBI. Injury severity (1.0, 1.2 or 1.6 mm compression) was associated with increased caspase-12 mRNA expression, peaking at 5 days in the cortex (657%, 651% and 1259%, respectively) and 6 h in the hippocampus (435%, 451% and 460%, respectively). Immunohistochemical analysis revealed caspase-12 induction in neurons in both the cortex and hippocampus as well as in astrocytes at the contusion site. This is the first report of increased expression of caspase-12 following TBI. Our results suggest that the caspase-12-mediated ER apoptotic pathway may play a role in rat TBI pathology independent of the receptor- or mitochondria-mediated apoptotic pathways.	Univ Florida, Dept Psychiat, Evelyn F & William L McKnight Brain Inst, Gainesville, FL 32611 USA; Univ Florida, Dept Neurosci, Evelyn F & William L McKnight Brain Inst, Ctr Traumat Brain Injury Studies, Gainesville, FL 32611 USA	Wang, KKW (corresponding author), Univ Florida, Dept Psychiat, Evelyn F & William L McKnight Brain Inst, POB 100256, Gainesville, FL 32611 USA.	kwang1@ufl.edu	Pike, Bruce/K-5562-2014	Pike, Bruce/0000-0001-8924-683X; Wang, Kevin/0000-0002-9343-6473	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039091, R01NS040182] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS39091, R01-NS40182] Funding Source: Medline		Aridor M, 1999, NAT MED, V5, P745, DOI 10.1038/10466; Beer R, 2000, J CEREBR BLOOD F MET, V20, P669, DOI 10.1097/00004647-200004000-00004; Bertolotti A, 2000, NAT CELL BIOL, V2, P326; Bitko V, 2001, J CELL BIOCHEM, V80, P441, DOI 10.1002/1097-4644(20010301)80:3<441::AID-JCB170>3.0.CO;2-C; Bradley JR, 2001, ONCOGENE, V20, P6482, DOI 10.1038/sj.onc.1204788; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clark RSB, 1999, FASEB J, V13, P813; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Conti AC, 1998, J NEUROSCI, V18, P5663; Daniel PT, 2000, LEUKEMIA, V14, P2035, DOI 10.1038/sj.leu.2401940; DeGracia DJ, 2002, J CEREBR BLOOD F MET, V22, P127, DOI 10.1097/00004647-200202000-00001; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Fischer H, 2002, BIOCHEM BIOPH RES CO, V293, P722, DOI 10.1016/S0006-291X(02)00289-9; Harding HP, 1999, NATURE, V397, P271; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Henshall DC, 2000, J NEUROCHEM, V74, P1215; Imaizumi K, 2001, BBA-MOL BASIS DIS, V1536, P85, DOI 10.1016/S0925-4439(01)00049-7; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Johnson FB, 1999, CELL, V96, P291, DOI 10.1016/S0092-8674(00)80567-X; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; KOHNO K, 1993, MOL CELL BIOL, V13, P877, DOI 10.1128/MCB.13.2.877; Mattson MP, 2000, TRENDS NEUROSCI, V23, P222, DOI 10.1016/S0166-2236(00)01548-4; MORI K, 1992, EMBO J, V11, P2583, DOI 10.1002/j.1460-2075.1992.tb05323.x; Morishima N, 2002, J BIOL CHEM, V277, P34287, DOI 10.1074/jbc.M204973200; Mouw G, 2003, NEUROREPORT, V14, P183, DOI 10.1097/00001756-200302100-00004; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Nakamura K, 2000, J CELL BIOL, V150, P731, DOI 10.1083/jcb.150.4.731; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.neuro.14.1.453; Paschen W, 1999, J CEREBR BLOOD F MET, V19, P1, DOI 10.1097/00004647-199901000-00001; Pelletier MR, 1999, J NEUROPHYSIOL, V81, P3054; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Qiu JH, 2002, J NEUROSCI, V22, P3504; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Rao RV, 2002, J BIOL CHEM, V277, P21836, DOI 10.1074/jbc.M202726200; Rao RV, 2001, J BIOL CHEM, V276, P33869, DOI 10.1074/jbc.M102225200; RINK A, 1995, AM J PATHOL, V147, P1575; Shibata M, 2003, NEUROSCIENCE, V118, P491, DOI 10.1016/S0306-4522(02)00910-7; Soto C, 2003, NAT REV NEUROSCI, V4, P49, DOI 10.1038/nrn1007; Tada K, 2001, J BIOL CHEM, V276, P36530, DOI 10.1074/jbc.M104837200; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Tinhofer I, 2002, FASEB J, V16, P1295, DOI 10.1096/fj.02-0020fje; Tolentino PJ, 2002, J NEUROCHEM, V80, P579, DOI 10.1046/j.0022-3042.2001.00726.x; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Weber JT, 2001, J BIOL CHEM, V276, P1800, DOI 10.1074/jbc.M009209200; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Yakovlev AG, 2001, MOL NEUROBIOL, V24, P131; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; YANG MS, 1985, J NEUROSURG, V63, P617, DOI 10.3171/jns.1985.63.4.0617; Yie Q, 2002, HEPATOLOGY, V36, P592, DOI 10.1053/jhep.2002.35441; Yoneda T, 2001, J BIOL CHEM, V276, P13935, DOI 10.1074/jbc.M010677200; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741; Yu ZF, 1999, EXP NEUROL, V155, P302, DOI 10.1006/exnr.1998.7002; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739	60	76	82	1	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	JAN	2004	88	1					78	90		10.1046/j.1471-4159.2003.02141.x			13	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	753YJ	WOS:000187275700009	14675152				2021-06-18	
J	Bazarian, JJ; Pope, C; McClung, J; Cheng, YT; Flesher, W				Bazarian, JJ; Pope, C; McClung, J; Cheng, YT; Flesher, W			Ethnic and racial disparities in emergency department care for mild traumatic brain injury	ACADEMIC EMERGENCY MEDICINE			English	Article; Proceedings Paper	5th World Congress on Traumatic Brain Injury	MAY, 2003	STOCKHOLM, SWEDEN			ethnic groups; African Americans; Hispanic Americans; whites; minority groups; brain injuries; brain concussion; emergency services	MINOR HEAD-INJURY; CARDIOVASCULAR PROCEDURES; RACE; HEALTH; SYMPTOMS; SEQUELAE; IMPACT; CHEMOTHERAPY; GENDER; RISK	Objectives: To identify racial, ethnic, and gender disparities in the emergency department (ED) care for mild traumatic brain injury (mTBI). Methods: A secondary analysis of ED visits in the National Hospital Ambulatory Medical Care Survey for the years 1998 through 2000 was performed. Cases of mTBI were identified using ICD-9 codes 800.0, 800.5, 850.9, 801.5, 803.0, 803.5, 804.0, 804.5, 850.0, 850.1, 850.5, 850.9, 854.0, and 959.01. ED care variables related to imaging, procedures, treatments, and disposition were analyzed along racial, ethnic, and gender categories. The relationship between race, ethnicity, and selected ED care variables was analyzed using multivariate logistic regression with control for associated injuries, geographic region, and insurance type. Results: The incidence of mTBI was highest among men (590/100,000), Native Americans/Alaska Natives (1026.2/100,000), and non-Hispanics (391.1/1.00,000). After controlling for important confounders, Hispanics were more likely than non-Hispanics to receive a nasogastric tube (OR, 6.36; 95% CI = 1.2 to 33.6); nonwhites were more likely to receive ED care by a resident (OR, 3.09; 95% CI = 1.9 to 5.0) and less likely to be sent back to the referring physician after ED discharge (OR, 0.47; 95% CI = 0.3 to 0.9). Men and women received equivalent ED care. Conclusions: There are significant racial and ethnic but not gender disparities in ED care for mTBI. The causes of these disparities and the relationship between these disparities and post-mTBI outcome need to be examined.	Univ Rochester, Med Ctr, Dept Emergency Med, Rochester, NY 14642 USA; Univ Rochester, Dept Community & Prevent Med, Rochester, NY 14642 USA; Hosp Max Peralta, San Jose, Costa Rica	Bazarian, JJ (corresponding author), Univ Rochester, Med Ctr, Dept Emergency Med, Box 655,601 Elmwood Ave, Rochester, NY 14642 USA.	jeff_bazarian@urmc.rochester.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1K23 NS4195-02] Funding Source: Medline		Bazarian J, 2000, BRAIN INJURY, V14, P285; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; BIJUR PE, 1990, PEDIATRICS, V86, P337; Blustein J, 1998, J HEALTH CARE POOR U, V9, P153; BOHNEN N, 1992, NEUROSURGERY, V30, P692; BRAVEMAN P, 1995, AM J PUBLIC HEALTH, V85, P625, DOI 10.2105/AJPH.85.5.625; Carlisle DM, 1997, AM J PUBLIC HEALTH, V87, P263, DOI 10.2105/AJPH.87.2.263; CASEY R, 1986, PEDIATRICS, V78, P497; Choi DMA, 2000, BRIT MED J, V320, P980, DOI 10.1136/bmj.320.7240.980; COONLEYHOGANSON R, 1984, NEUROSURGERY, V14, P315, DOI 10.1227/00006123-198403000-00009; Cooper-Patrick L, 1999, JAMA-J AM MED ASSOC, V282, P583, DOI 10.1001/jama.282.6.583; CORONADO V, 2002, COMMUNICATION; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Earle CC, 2002, J CLIN ONCOL, V20, P1786, DOI 10.1200/JCO.2002.07.142; Earle CC, 2000, CHEST, V117, P1239, DOI 10.1378/chest.117.5.1239; Einbinder LC, 2000, MED CARE RES REV, V57, P162; ENGLANDER J, 1992, Brain Injury, V6, P161, DOI 10.3109/02699059209029654; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; FORD ES, 1995, HEALTH SERV RES, V30, P237; GORNICK ME, 2001, MINORITY HLTH TODAY, V2, P17; GUADAGNOLI E, 1995, NEW ENGL J MED, V333, P573, DOI 10.1056/NEJM199508313330908; Jackson PB, 1998, RES AGING, V20, P298, DOI 10.1177/0164027598203002; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Jay G W, 1996, J Insur Med, V27, P262; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; Johnstone B, 2003, BRAIN INJURY, V17, P95, DOI 10.1080/0269905021000010212; JORGE RE, 1994, J NEUROSURG, V81, P726, DOI 10.3171/jns.1994.81.5.0726; Kaplan JB, 2003, JAMA-J AM MED ASSOC, V289, P2709, DOI 10.1001/jama.289.20.2709; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Klassen AC, 2002, AM J PUBLIC HEALTH, V92, P811, DOI 10.2105/AJPH.92.5.811; KRAUS JF, 2003, NEUROSURG FOCUS, V8; LaVeist TA, 2000, MED CARE RES REV, V57, P146, DOI 10.1177/107755800773743637; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; Maly RC, 2003, CANCER, V97, P1517, DOI 10.1002/cncr.11211; McKenzie K, 1999, INT REV PSYCHIATR, V11, P153, DOI 10.1080/09540269974320; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; MIROWSKY J, 1995, AM SOCIOL REV, V60, P449, DOI 10.2307/2096424; Mittenberg W, 1997, NEUROPSYCHOLOGY, V11, P447, DOI 10.1037/0894-4105.11.3.447; *NIH, 2002, NIH POL REP RAC ETHN; Oddone EZ, 1999, STROKE, V30, P1350, DOI 10.1161/01.STR.30.7.1350; PARKER RS, 1994, SEMIN NEUROL, V14, P67, DOI 10.1055/s-2008-1041061; PILOTE L, 1995, NEW ENGL J MED, V333, P565, DOI 10.1056/NEJM199508313330907; QUINTANA JM, 1997, INT J QUAL HEALTH C, V9, P101; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; RUTHERFORD WH, 1977, LANCET, V1, P1; SAVILLETROIKE M, 1999, ETHNOGRAPHY COMMUNIC; Sehgal AR, 2003, JAMA-J AM MED ASSOC, V289, P996, DOI 10.1001/jama.289.8.996; Shultz, 1982, COUNSELOR GATEKEEPER; SMEDLEY BD, 2003, UNEQUAL TREATMENT CO; Snowden LR, 2003, AM J PUBLIC HEALTH, V93, P239, DOI 10.2105/AJPH.93.2.239; STRAKOWSKI SM, 1995, J CLIN PSYCHIAT, V56, P101; THURMAN DJ, 1995, GUIDELINES SURVEILAN; TODD KH, 1993, JAMA-J AM MED ASSOC, V269, P1537, DOI 10.1001/jama.269.12.1537; *US DEP HHS, RESH HLTH MIN COMM U; van Ryn M, 2003, AM J PUBLIC HEALTH, V93, P248, DOI 10.2105/AJPH.93.2.248; Vazquez LA, 1997, HISPANIC J BEHAV SCI, V19, P377, DOI 10.1177/07399863970193009; Warner TD, 2002, J LEARN DISABIL-US, V35, P500; Waxman MA, 2000, ANN EMERG MED, V36, P456, DOI 10.1067/mem.2000.108315; Weech-Maldonado R, 2001, HEALTH SERV RES, V36, P575; WRIGHTSON P, 1995, J NEUROL NEUROSUR PS, V59, P375, DOI 10.1136/jnnp.59.4.375; WRIGHTSON P, 1981, INJURY, V12, P445, DOI 10.1016/0020-1383(81)90161-3; Young BA, 2003, DIABETES CARE, V26, P495, DOI 10.2337/diacare.26.2.495	64	76	76	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1069-6563	1553-2712		ACAD EMERG MED	Acad. Emerg. Med.	NOV	2003	10	11					1209	1217		10.1197/S1069-6563(03)00491-3			9	Emergency Medicine	Emergency Medicine	740WY	WOS:000186426300011	14597497				2021-06-18	
J	Mellick, D; Gerhart, KA; Whiteneck, GG				Mellick, D; Gerhart, KA; Whiteneck, GG			Understanding outcomes based on the post-acute hospitalization pathways followed by persons with traumatic brain injury	BRAIN INJURY			English	Article							SICKNESS IMPACT PROFILE; FUNCTIONAL ASSESSMENT; UNITED-STATES; REHABILITATION; SCALES; CARE	Primary objectives : To identify the factors that determine the pathways of care people with traumatic brain injury (TBI) follow after acute care discharge, and to identify differences in outcome based on those pathways. Research design : Telephone survey of a statewide, population-based sample of persons surviving through acute hospitalization for TBI. Methods and procedures : Included were 1059 individuals who: (a) were discharged from acute care in 1996 and 1997; (b) were eligible for inclusion in the statewide, population-based TBI follow-up system, (c) had either a severe TBI or were among a 20% random sample with milder injuries, and (d) consented to participate in a 1-year post-injury follow-up survey. The survey included administration of the Functional Independence Measure (FIM), the Craig Handicap Assessment and Reporting Technique (CHART), the Alertness Behaviour Sub-scale of the Sickness Impact Profile (SIP), and the Health Status Questionnaire (HSQ-12). Medical records for all participants were abstracted for injury severity, pre-injury history (aetiologic and demographic) and discharge disposition data. Data were weighted to represent the population from which the sample was derived prior to analyses. Main outcomes and results : Almost 2/3 of TBI survivors in this population-based sample received no additional services following discharge from the acute care hospital. Six post-acute-hospitalization pathways were identified based on combinations of inpatient rehabilitation, community-based services and long-term care (LTC). In each category except for the one involving a discharge directly from acute care to home people with the most severe TBIs were disproportionately over-represented. Older people and people whose care was funded by government payers were over-represented in both care pathways involving LTC, while members of minority groups were under represented. Those who went to LTC had the poorest outcomes, but even those completing rehabilitation had relatively poor outcomes compared with those discharged directly to home. Conclusions : Of concern are the relatively large numbers of people receiving no rehabilitation and other services in all severity categories. Those in LTC typically older and government funded people reported the poorest outcomes. Unanswered questions remain relating to the poor perceived quality of life reported by those completing rehabilitation programmes. Further study is also needed to more fully understand the affects of such characteristics as gender, minority status, employment and funding sources on the care pathway that is followed.	Craig Hosp Res Dept, Englewood, CO 80110 USA	Gerhart, KA (corresponding author), Craig Hosp Res Dept, 3425 S Clarkson St, Englewood, CO 80110 USA.				ODCDC CDC HHS [U17/CCU812447] Funding Source: Medline		BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; BROOKS CA, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199508000-00002; Brooks CA, 1997, ARCH PHYS MED REHAB, V78, pS26, DOI 10.1016/S0003-9993(97)90152-0; BROOKS WB, 1990, MED CARE, V28, P793, DOI 10.1097/00005650-199009000-00009; Chesnut RM, 1999, J HEAD TRAUMA REHAB, V14, P176, DOI 10.1097/00001199-199904000-00007; Damiano AM, 1996, SICKNESS IMPACT PROF; DEYO RA, 1986, SPINE, V11, P951, DOI 10.1097/00007632-198611000-00017; DEYO RA, 1983, MED CARE, V21, P180, DOI 10.1097/00005650-198302000-00006; Dijkers M., 1991, J AM PARAPLEGIA SOC, V14, P85; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; GRANGER CV, 1997, ASSESSING MED REHABI, P103; *HLTH OUTC I, 1998, HSQ 12 US GUID; HOSACK KR, 1995, J HEAD TRAUMA REHAB, V10, P57, DOI 10.1097/00001199-199504000-00007; *J HOPK U, 1993, INJ SEV SCOR ICD MAP; MELLICK D, 1999, J REHABIL OUTCOMES, V3, P12; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Smith PM, 1996, ARCH PHYS MED REHAB, V77, P431, DOI 10.1016/S0003-9993(96)90029-5; Sosin DM, 1996, BRAIN INJURY, V10, P47; *SPSS INC, 1999, SPSS WIND VERS 10 0; *STAT U NY BUFF, 1996, GUID UN DAT SET MED; TEASDALE G, 1974, LANCET, V2, P81; TEMKIN N, 1988, J CLIN EPIDEMIOL, V41, P47, DOI 10.1016/0895-4356(88)90008-X; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Whiteneck G, 2001, COLORADO TRAUMATIC B; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; *WHO, 1989, INT CLASS DIS 9 REV; World Health Organization, 2001, INT CLASS FUNCT DIS	27	76	77	0	10	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2003	17	1					55	71		10.1080/0269905021000010159			17	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	633LK	WOS:000180284600005	12519648				2021-06-18	
J	Sherer, M; Hart, T; Nick, TG				Sherer, M; Hart, T; Nick, TG			Measurement of impaired self-awareness after traumatic brain injury: a comparison of the patient competency rating scale and the awareness questionnaire	BRAIN INJURY			English	Article							BEHAVIORAL LIMITATIONS; REHABILITATION; DISABILITY; DEFICITS; RECOVERY; OUTCOMES	Primary objective: To compare the Patient Competency Rating Scale (PCRS) and the Awareness Questionnaire (AQ) in the measurement of impaired self-awareness (ISA) in persons with traumatic brain injury (TBI). Research design: Prospective cohort of patients seen for inpatient rehabilitation following TBI. Procedures: Measures of self-awareness were collected at resolution of post-traumatic amnesia and outcomes (rated employability) were collected at discharge from inpatient rehabilitation. Outcomes and results: Subjects were 129 persons with TBI. Measures from the PCRS and AQ showed moderate correlations. Models using as predictors patient/clinician discrepancies for the PCRS and the AQ performed comparably in predicting employability (Nagelkerke R-2=0.22 and 0.20, respectively). Conclusions: The PCRS and AQ showed only moderate correlations, but performed comparably as measures of ISA after TBI. Patient/clinician discrepancies appeared to be more valid measures of ISA early after TBI than patient/family discrepancies. Preliminary cutting points for severity of ISA were presented for the two scales.	Methodist Rehabil Ctr, Jackson, MS 39216 USA; Univ Mississippi, Med Ctr, Jackson, MS 39216 USA; Moss Rehabil Res Inst, Philadelphia, PA USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Rehabil Med, Philadelphia, PA 19107 USA	Sherer, M (corresponding author), Methodist Rehabil Ctr, 1350 E Woodrow Wilson, Jackson, MS 39216 USA.	marks@mmrcrehab.org					BENYISHAY Y, 1985, SEMIN NEUROL, V5, P252, DOI 10.1055/s-2008-1041522; DIKMEN S, 1986, ARCH PHYS MED REHAB, V67, P507; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; Fleming J, 1999, OCCUP THER J RES, V19, P3, DOI 10.1177/153944929901900101; Fleming JM, 1996, BRAIN INJURY, V10, P1; FORDYCE DJ, 1986, REHABIL PSYCHOL, V31, P217, DOI 10.1037//0090-5550.31.4.217; HALL KM, 1994, ARCH PHYS MED REHAB, V75, pSC10; Hall KM., 1993, J HEAD TRAUMA REHAB, V8, DOI [DOI 10.1097/00001199-199308020-00008, 10.1097/00001199-199308020-00008]; HAMILTON BB, 1987, REHABILITATION OUTCO, P135; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Lam C S, 1988, Brain Inj, V2, P235, DOI 10.3109/02699058809150947; Leathem JM, 1998, J CLIN EXP NEUROPSYC, V20, P694, DOI 10.1076/jcen.20.5.694.1122; Levin H S, 1991, Neurosurg Clin N Am, V2, P457; MALEC J, 1990, J HEAD TRAUMA REHAB, V5, P60; Malec JF, 2000, REHABIL PSYCHOL, V45, P227, DOI 10.1037/0090-5550.45.3.227; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; Prigatano G. P., 1990, CLIN NEUROPSYCHOL, V4, P163, DOI [10.1080/13854049008401509, DOI 10.1080/13854049008401509]; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; Prigatano George P, 1993, Clin Neuropsychol, V7, P123, DOI 10.1080/13854049308401514; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Prigatano GP, 1997, NEUROPSY NEUROPSY BE, V10, P135; Prigatano GP, 1998, J HEAD TRAUMA REHAB, V13, P29, DOI 10.1097/00001199-199810000-00005; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Sherer M, 1998, BRAIN INJURY, V12, P63, DOI 10.1080/026990598122863; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; SHERER M, IN PRESS ARCH PHYSIC; TEASDALE G, 1974, LANCET, V2, P81; Wallace CA, 2000, BRAIN INJURY, V14, P549; Whyte J, 2001, ARCH PHYS MED REHAB, V82, P1355, DOI 10.1053/apmr.2001.26091	31	76	78	0	8	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2003	17	1					25	37		10.1080/0269905021000010113			13	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	633LK	WOS:000180284600002	12519645				2021-06-18	
J	Hopkins, MJ; Dywan, J; Segalowitz, SJ				Hopkins, MJ; Dywan, J; Segalowitz, SJ			Altered electrodermal response to facial expression after closed head injury	BRAIN INJURY			English	Article							FACE PROCESSING IMPAIRMENTS; TRAUMATIC BRAIN-INJURY; AMYGDALA DAMAGE; RECOGNITION; EMOTION; INDIVIDUALS; BEHAVIOR; MILD	The objective was to determine whether diffuse damage to orbital and ventromedial regions of the prefrontal cortex usually associated with moderate-to-severe closed head injury (CHI) would affect the ability to perceive and respond to socially relevant information. Methods: Participants with CHI and age-matched non-injured controls were presented with faces that varied with respect to emotional expression while electrodermal activity (EDA) was monitored. Cognitive and general adaptive functioning was also assessed. Results: CHI was associated with a failure to increase EDA in response to negative facial expressions and with reduced ability to identify negative expressions, especially fear. The groups differed on other signs of orbital/medial prefrontal damage such as anosmia and in general social adaptability and awareness-of-deficit as measured by the Brock Adaptive Functioning Questionnaire. Conclusions: CHI affected the ability to identify and respond to negative facial expression. Addressing these deficits may enhance rehabilitative efforts within the social domain.	Brock Univ, Dept Psychol, St Catharines, ON L2S 3A1, Canada; Ctr Addict & Mental Hlth, Community Support & Res Unit, Toronto, ON, Canada	Dywan, J (corresponding author), Brock Univ, Dept Psychol, St Catharines, ON L2S 3A1, Canada.	jdywan@spartan.ac.brocku.ca					Abdel-Dayem HM, 1998, CLIN NUCL MED, V23, P309, DOI 10.1097/00003072-199805000-00009; Abu-Judeh HH, 1999, NUCL MED COMMUN, V20, P505, DOI 10.1097/00006231-199906000-00003; ADAMS JH, 1980, NEUROPATH APPL NEURO, V6, P319, DOI 10.1111/j.1365-2990.1980.tb00217.x; Adolphs R, 1999, NEUROPSYCHOLOGIA, V37, P1111, DOI 10.1016/S0028-3932(99)00039-1; Adolphs R, 1999, PSYCHOL SCI, V10, P167, DOI 10.1111/1467-9280.00126; ADOLPHS R, 1994, NATURE, V372, P669, DOI 10.1038/372669a0; Bechara A, 1997, SCIENCE, V275, P1293, DOI 10.1126/science.275.5304.1293; Benton A.L., 1983, CONTRIBUTIONS NEUROP; Bigler E, 1990, TRAUMATIC BRAIN INJU, P13; Broks P, 1998, NEUROPSYCHOLOGIA, V36, P59, DOI 10.1016/S0028-3932(97)00105-X; Calder AJ, 1996, COGNITIVE NEUROPSYCH, V13, P699, DOI 10.1080/026432996381890; Cattell R. B., 1960, TEST G CULTURE FAIR; CUMMINGS JL, 1993, ARCH NEUROL-CHICAGO, V50, P873, DOI 10.1001/archneur.1993.00540080076020; DAMASIO AR, 1990, BEHAV BRAIN RES, V41, P81, DOI 10.1016/0166-4328(90)90144-4; Damasio AR, 1996, PREFRONTAL CORTEX EX, P36, DOI [10.1093/acprof:oso/9780198524410.003.0004, DOI 10.1093/ACPROF:OSO/9780198524410.003.0004]; DAWSON ME, 1995, PRINCIPLES PSYCHOPHY, P295; Dywan J, 1996, J HEAD TRAUMA REHAB, V11, P79, DOI 10.1097/00001199-199604000-00008; DYWAN J, 1995, J INT NEUROPSYCH SOC, V1, P121; Ekman P., 1976, PICTURES FACIAL AFFE; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; FOWLES DC, 1981, PSYCHOPHYSIOLOGY, V18, P232, DOI 10.1111/j.1469-8986.1981.tb03024.x; FUSTER JM, 1989, PREFRONTAL CORTEX AN; Hamann SB, 1996, NATURE, V379, P497, DOI 10.1038/379497a0; Hornak J, 1996, NEUROPSYCHOLOGIA, V34, P247, DOI 10.1016/0028-3932(95)00106-9; JACKSON HF, 1987, CORTEX, V23, P293, DOI 10.1016/S0010-9452(87)80039-4; Kraus Jess F., 1994, P3; KUSHNIRUK A, 1985, SLEEP, V8, P146, DOI 10.1093/sleep/8.2.146; Lang P. J., 1988, INT AFFECTIVE PICTUR; LEZAK MD, 1988, J LEARN DISABIL, V21, P456, DOI 10.1177/002221948802100802; LEZAK MD, 1990, TRAUMATIC BRAIN INJU, P365; Ongur D, 2000, CEREB CORTEX, V10, P206, DOI 10.1093/cercor/10.3.206; PORGES SW, 1995, PSYCHOPHYSIOLOGY, V32, P301, DOI 10.1111/j.1469-8986.1995.tb01213.x; Rapcsak SZ, 2000, NEUROLOGY, V54, P575, DOI 10.1212/WNL.54.3.575; ROLLS ET, 1998, PREFRONTAL CORTEX EX, P67; Rolls ET, 1999, BRAIN EMOTION; SCHNIDER A, 1999, SCI PRACT NEUROPSYCH, P487; Sprengelmeyer R, 1997, COGN NEUROPSYCHOL, V14, P839, DOI 10.1080/026432997381376; Sprengelmeyer R, 1996, BRAIN, V119, P1647, DOI 10.1093/brain/119.5.1647; STAMBROOK M, 1991, J CLIN EXP NEUROPSYC, V13, P521, DOI 10.1080/01688639108401068; STAMBROOK M, 1990, COGNITIVE REHABILITA, V8, P26; Stenberg G, 1998, COGNITION EMOTION, V12, P755, DOI 10.1080/026999398379420; Streit M, 1999, COGNITIVE BRAIN RES, V7, P481, DOI 10.1016/S0926-6410(98)00048-2; Varney N. R., 1993, J HEAD TRAUMA REHAB, V8, P32, DOI DOI 10.1097/00001199-199303000-00005; Wechsler, 1981, WAIS R MANUAL; Young AW, 1996, NEUROPSYCHOLOGIA, V34, P31, DOI 10.1016/0028-3932(95)00062-3; YOUNG AW, 1995, BRAIN, V118, P15, DOI 10.1093/brain/118.1.15; Zahn TP, 1999, NEUROPSYCHOLOGIA, V37, P1227, DOI 10.1016/S0028-3932(99)00020-2	47	76	76	0	7	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAR	2002	16	3					245	257		10.1080/02699050110103346			13	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	526HP	WOS:000174124800006	11874616				2021-06-18	
J	Imberti, R; Bellinzona, G; Langer, M				Imberti, R; Bellinzona, G; Langer, M			Cerebral tissue PO2 and SjvO(2) changes during moderate hyperventilation in patients with severe traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						hyperventilation; brain tissue partial pressure of oxygen; jugular venous oxygen saturation; cerebral oxygen metabolism; intracranial pressure	SEVERE HEAD-INJURY; VENOUS OXYGEN-SATURATION; BLOOD-FLOW; INTRACRANIAL-PRESSURE; PERFUSION-PRESSURE; COMATOSE PATIENTS; MANAGEMENT; METABOLISM; VASORESPONSIVITY; EXPERIENCE	Object. The aim of this study was to investigate the effects of moderate hyperventilation on intracranial pressure (ICP), jugular venous oxygen saturation ([SjvO(2)], an index of global cerebral perfusion), and brain tissue PO. (an index of local cerebral perfusion). Methods. Ninety-four tests consisting of 20-minute periods of moderate hyperventilation (27-32 mm Hg) were performed on different days in 36 patients with severe traumatic brain injury (Glasgow Coma Scale score less than or equal to 8). Moderate hyperventilation resulted in a significant reduction in average ICP, but in seven tests per-formed in five patients it was ineffective. The response of SjvO(2) and brain tissue PO2 to CO2 changes was widely variable and unpredictable. After 20 minutes of moderate hyperventilation in most tests (79.8%), both SjvO(2) and brain tissue PO2 values remained above the lower limits of normality (50% and 10 mm Hg, respectively). In contrast, in 15 tests performed in six patients (16.6% of the studied population) brain tissue PO2 decreased below 10 min Hg although the corresponding SjvO(2) values were greater than 50%. The reduction of brain tissue PO2 below 10 mm Hg was favored by the low prehyperventilation values (10 tests), higher CO, reactivity, and, possibly, by lower prehyperventilation values of cerebral per-fusion pressure. In five of those 15 tests, the prehyperventilation values of SjvO(2) were greater than 70%, a condition of relative hyperemia. The SjvO(2) decreased below 50% in four tests; the corresponding brain tissue PO. values were less than 10 min Hg in three of those tests, whereas in the fourth, the jugular venous O-2 desaturation was not detected by brain tissue PO2. The analysis of the simultaneous relative changes (prehyperventilation - posthyperventilation) of SjvO(2) and brain tissue PO2 showed that in most tests (75.5%) there was a reduction of both SjvO(2) and brain tissue PO2. In two tests moderate hyperventilation resulted in an increase of both SjvO(2) and brain tissue PO2. In the remaining 17 tests a redistribution of the cerebral blood flow was observed, leading to changes in SjvO(2) and brain tissue PO2 in opposite directions. Conclusions. Hyperventilation, even if moderate, can frequently result in harmful local reductions of cerebral perfusion that cannot be detected by assessing SjvO(2). Therefore, hyperventilation should be used with caution and should not be considered safe. This study confirms that SjvO(2) and brain tissue PO2 are two parameters that provide complementary information on brain oxygenation that is useful to reduce the risk of secondary damage. Changes in SjvO(2) and brain tissue PO2 in opposite directions indicate that data obtained from brain tissue PO2 monitoring cannot be extrapolated to evaluate the global cerebral perfusion.	IRCCS, Policlin San Matteo, Serv Anestesia & Rianimaz 2, I-27100 Pavia, Italy	Imberti, R (corresponding author), IRCCS, Policlin San Matteo, Serv Anestesia & Rianimaz 2, I-27100 Pavia, Italy.						Bruzzone P, 1998, ACT NEUR S, V71, P111; Chesnut RM, 1997, CRIT CARE MED, V25, P1275, DOI 10.1097/00003246-199708000-00011; Cruz J, 1998, CRIT CARE MED, V26, P344, DOI 10.1097/00003246-199802000-00039; CRUZ J, 1993, CRIT CARE MED, V21, P1225, DOI 10.1097/00003246-199308000-00025; Dings J, 1996, ACTA NEUROCHIR, V138, P425, DOI 10.1007/BF01420305; Diringer MN, 2000, J NEUROSURG, V92, P7, DOI 10.3171/jns.2000.92.1.0007; Doppenberg EMR, 1998, ACT NEUR S, V71, P166; FARRAR JK, 1991, J CEREB BLOOD FLOW M, V11, pS553; Feldman Z, 1997, CRIT CARE CLIN, V13, P51, DOI 10.1016/S0749-0704(05)70296-7; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; Gopinath SP, 1999, CRIT CARE MED, V27, P2337, DOI 10.1097/00003246-199911000-00003; Gupta AK, 1999, ANESTH ANALG, V88, P549, DOI 10.1097/00000539-199903000-00016; Imberti R, 2000, J NEUROSURG ANESTH, V12, P124, DOI 10.1097/00008506-200004000-00011; KARIMAN K, 1983, J APPL PHYSIOL, V55, P1057; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MARION DW, 1991, NEUROSURGERY, V29, P869, DOI 10.1227/00006123-199112000-00011; Marion DW, 2000, CRIT CARE MED, V28, P16, DOI 10.1097/00003246-200001000-00003; MARMAROU A, 1991, J NEUROSURG S, V75, P59; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; MARSHALL LF, 1992, J NEUROTRAUMA, V9, P287; McLaughlin MR, 1996, J NEUROSURG, V85, P871, DOI 10.3171/jns.1996.85.5.0871; Menzel M, 1999, J NEUROSURG ANESTH, V11, P240, DOI 10.1097/00008506-199910000-00003; MILLER JD, 1994, INTENS CARE MED, V20, P249, DOI 10.1007/BF01708957; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; Newell DW, 1996, NEUROSURGERY, V39, P35, DOI 10.1097/00006123-199607000-00008; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; RAICHLE ME, 1970, ARCH NEUROL-CHICAGO, V23, P394, DOI 10.1001/archneur.1970.00480290014002; ROBERTSON CS, 1989, J NEUROSURG, V70, P222, DOI 10.3171/jns.1989.70.2.0222; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; Skippen P, 1997, CRIT CARE MED, V25, P1402, DOI 10.1097/00003246-199708000-00031; STOCCHETTI N, 1994, NEUROSURGERY, V34, P38; Suazo JAC, 2000, CRIT CARE MED, V28, P3268, DOI 10.1097/00003246-200009000-00024; TEASDALE G, 1974, LANCET, V2, P81; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007	37	76	82	1	3	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	JAN	2002	96	1					97	102		10.3171/jns.2002.96.1.0097			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	508FY	WOS:000173079100015	11794610				2021-06-18	
J	Zhao, XR; Bausano, B; Pike, BR; Newcomb-Fernandez, JK; Wang, KKW; Shohami, E; Ringger, NC; DeFord, SM; Anderson, DK; Hayes, RL				Zhao, XR; Bausano, B; Pike, BR; Newcomb-Fernandez, JK; Wang, KKW; Shohami, E; Ringger, NC; DeFord, SM; Anderson, DK; Hayes, RL			TNF-alpha stimulates caspase-3 activation and apoptotic cell death in primary septo-hippocampal cultures	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						apoptosis; calpain; caspase; cytokine; neural injury; proteolysis	TUMOR-NECROSIS-FACTOR; EXPERIMENTAL BRAIN INJURY; FOCAL CEREBRAL-ISCHEMIA; MAITOTOXIN INDUCES CALPAIN; CLOSED-HEAD INJURY; NEURONAL APOPTOSIS; MICE LACKING; SEPTOHIPPOCAMPAL CULTURES; CEREBROSPINAL-FLUID; PROTEIN-SYNTHESIS	Primary septo-hippocampal cell cultures were incubated in varying concentrations of tumor necrosis factor (TNF-alpha; 0.3-500 ng/ml) to examine proteolysis of the cytoskeletal protein alpha -spectrin (240 kDa) to a signature 145 kDa fragment by calpain and to the apoptotic-linked 120-kDa fragment by caspase-3, The effects of TNF-alpha incubation on morphology and cell viability were assayed by fluorescein diacetate-propidium iodide (FDA-PI) staining, assays of lactate dehydrogenase (LDH) release, nuclear chromatin alterations (Hoechst 33258), and internucleosomal DNA fragmentation. Incubation with varying concentrations of TNF-alpha produced vapid increases in LDH release and nuclear PI uptake that were sustained over 48 hr. Incubation with 30 ng/ml TNF-alpha yielded maximal, 3-fold, increase in LDH release and was associated with caspase-specific 120-kDa fragment but not calpain-specific 145-kDa fragment as early as 3.5 hr after injury. Incubation with the pan-caspase inhibitor, carbobenzosy-Asp-CH2-OC (O)-2-6-dichlorobenzene (Z-D-DCB, 50-140 muM) significantly reduced LDH release produced by TNF-alpha. Apoptotic-associated oligonucleosomal-sized DNA fragmentation on agarose gels was detected from 6 to 72 hr after exposure to TNF-alpha. Histochemical changes included chromatin condensation, nuclear fragmentation, and formation of apoptotic bodies. Results of this study suggest TNf-alpha may induce caspase-3 activation but not calpain activation in septo-hippocampal cultures and that this activation of caspase-3 at least partially contributes to TNF-alpha -induced apoptosis. J. Neurosci. Res. 64,121-131, 2001. (C) 2001 Wiley-Liss, Inc.	Univ Florida, Dept Neurosci, Ctr Traumat Brain Injury Studies, Gainesville, FL 32610 USA; Univ Texas, Hlth Sci Ctr, Vivian L Smith Ctr Neurol Res, Dept Neurosurg, Houston, TX USA; Pfizer Inc, Ann Arbor, MI USA; Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel; Univ Florida, Dept Neurosci, Gainesville, FL 32610 USA; Univ Florida, Malcolm Randall VAMC, Gainesville, FL 32610 USA	Hayes, RL (corresponding author), Univ Florida, Dept Neurosci, Ctr Traumat Brain Injury Studies, 100 Newell Dr,POB 100244, Gainesville, FL 32610 USA.			Wang, Kevin/0000-0002-9343-6473	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021458, R01NS040182] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS21458-15, R01 NS40182] Funding Source: Medline		Aggarwal S, 1999, J IMMUNOL, V162, P2154; Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BARGER SW, 1995, P NATL ACAD SCI USA, V92, P9328, DOI 10.1073/pnas.92.20.9328; Barone FC, 1997, STROKE, V28, P1233, DOI 10.1161/01.STR.28.6.1233; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; Buttini M, 1996, NEUROSCIENCE, V71, P1, DOI 10.1016/0306-4522(95)00414-9; Chen X, 1999, J COLD REG ENG, V13, P139, DOI 10.1061/(ASCE)0887-381X(1999)13:3(139); CHUNG IY, 1990, J IMMUNOL, V144, P2999; Dawson DA, 1996, NEUROSCI LETT, V218, P41, DOI 10.1016/0304-3940(96)13116-5; deBock F, 1996, NEUROREPORT, V7, P1125, DOI 10.1097/00001756-199604260-00004; Eldadah BA, 1997, J NEUROSCI, V17, P6105; ENDRES M, 1998, J CEREB BLOOD FLOW M, V18, P238, DOI DOI 10.1097/00004647-199803000-00002; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; FILLIT H, 1991, NEUROSCI LETT, V129, P318, DOI 10.1016/0304-3940(91)90490-K; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; Furukawa K, 1997, J CELL BIOL, V136, P1137, DOI 10.1083/jcb.136.5.1137; GARCIAVILLALON D, 1992, ANTIVIR CHEM CHEMOTH, V3, P9, DOI 10.1177/095632029200300102; Gary DS, 1998, J CEREBR BLOOD F MET, V18, P1283, DOI 10.1097/00004647-199812000-00001; GELBARD HA, 1993, DEV NEUROSCI-BASEL, V15, P417, DOI 10.1159/000111367; Gillardon F, 1999, NEUROSCIENCE, V93, P1219, DOI 10.1016/S0306-4522(99)00292-4; Goeddel DV, 1999, CHEST, V116, p69S, DOI 10.1378/chest.116.suppl_1.69S; Gong C, 1998, BRAIN RES, V801, P1, DOI 10.1016/S0006-8993(98)00489-2; GONG JP, 1994, ANAL BIOCHEM, V218, P314, DOI 10.1006/abio.1994.1184; GRELL M, 1994, J IMMUNOL, V153, P1963; JONES KH, 1985, J HISTOCHEM CYTOCHEM, V33, P77, DOI 10.1177/33.1.2578146; Kampfl A, 1996, EUR J NEUROSCI, V8, P344, DOI 10.1111/j.1460-9568.1996.tb01218.x; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; KOH JY, 1995, EXP NEUROL, V135, P153, DOI 10.1006/exnr.1995.1074; KONDRATYEV A, 2000, BRAIN RES MOL BRAIN, V75, P216; Ksontini R, 1998, ARCH SURG-CHICAGO, V133, P558, DOI 10.1001/archsurg.133.5.558; Leker RR, 1999, J NEUROL SCI, V162, P114, DOI 10.1016/S0022-510X(98)00301-3; LIEBERMAN AP, 1989, P NATL ACAD SCI USA, V86, P6348, DOI 10.1073/pnas.86.16.6348; LIU T, 1994, STROKE, V25, P1481, DOI 10.1161/01.STR.25.7.1481; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; MATTSON MP, 1995, J NEUROCHEM, V65, P1740; MEIRSTRELL ME, 1997, SHOCK, V8, P341; MIOSSEC C, 1997, J BIOL CHEM, V272, P13489; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; Mogi M, 1996, NEUROSCI LETT, V211, P13, DOI 10.1016/0304-3940(96)12706-3; MOGI M, 1994, NEUROSCI LETT, V165, P208, DOI 10.1016/0304-3940(94)90746-3; MORGANTIKOSSMANN MC, 1992, TRENDS PHARMACOL SCI, V13, P286, DOI 10.1016/0165-6147(92)90087-M; Nath R, 1996, NEUROREPORT, V8, P249, DOI 10.1097/00001756-199612200-00050; Nath R, 1998, J NEUROCHEM, V71, P186; NATH R, 1995, J NEUROSCI, V15, P1001; Nawashiro H, 1997, J CEREBR BLOOD F MET, V17, P229, DOI 10.1097/00004647-199702000-00013; OBERHAMMER F, 1993, J CELL SCI, V104, P317; Pike BR, 1998, J NEUROSCI RES, V52, P505, DOI 10.1002/(SICI)1097-4547(19980601)52:5<505::AID-JNR3>3.3.CO;2-Y; Pulliam L, 1998, J NEUROSCI RES, V54, P530, DOI 10.1002/(SICI)1097-4547(19981115)54:4<530::AID-JNR10>3.0.CO;2-1; RUFF MR, 1981, INFECT IMMUN, V31, P380, DOI 10.1128/IAI.31.1.380-385.1981; Saito K, 1996, NEUROSCI LETT, V206, P149, DOI 10.1016/S0304-3940(96)12460-5; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; SELMAJ KW, 1988, ANN NEUROL, V23, P339, DOI 10.1002/ana.410230405; SHARIEF MK, 1993, ANN NEUROL, V33, P591, DOI 10.1002/ana.410330606; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Sullivan PG, 1999, J NEUROSCI, V19, P6248; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Uno H, 1997, J CEREBR BLOOD F MET, V17, P491, DOI 10.1097/00004647-199705000-00002; Villa P, 1997, TRENDS BIOCHEM SCI, V22, P388, DOI 10.1016/S0968-0004(97)01107-9; Wang KKW, 1998, J BIOL CHEM, V273, P22490, DOI 10.1074/jbc.273.35.22490; Wang KKW, 1996, ARCH BIOCHEM BIOPHYS, V331, P208, DOI 10.1006/abbi.1996.0300; Wang KKW, 2000, TRENDS NEUROSCI, V23, P59, DOI 10.1016/S0166-2236(99)01536-2; WANG KKW, 1994, TRENDS PHARMACOL SCI, V15, P412, DOI 10.1016/0165-6147(94)90090-6; WANG XK, 1994, MOL CHEM NEUROPATHOL, V23, P103, DOI 10.1007/BF02815404; WEISSNER C, 2000, CELL MOL BIOL, V46, P53; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Xu IS, 1998, NEUROSCIENCE, V85, P827, DOI 10.1016/S0306-4522(97)00676-3; Yamashita K, 1999, BLOOD, V93, P674, DOI 10.1182/blood.V93.2.674.402k26_674_685; YUEN P, 1996, BIOCHEM J, V319, P683; Zhao X, 1999, NEUROCHEM RES, V24, P371, DOI 10.1023/A:1020933616351; Zhivotovsky B, 1997, BIOCHEM BIOPH RES CO, V230, P481, DOI 10.1006/bbrc.1996.6016	76	76	81	0	5	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA	0360-4012			J NEUROSCI RES	J. Neurosci. Res.	APR 15	2001	64	2					121	131		10.1002/jnr.1059			11	Neurosciences	Neurosciences & Neurology	416UX	WOS:000167799500003	11288141				2021-06-18	
J	Kelly, KD; Lissel, HL; Rowe, BH; Vincenten, JA; Voaklander, DC				Kelly, KD; Lissel, HL; Rowe, BH; Vincenten, JA; Voaklander, DC			Sport and recreation-related head injuries treated in the emergency department	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						head injury, sport and recreation related; emergency department; epidemiology, outcomes	UNITED-STATES; BRAIN-INJURY; NEW-ZEALAND; EPIDEMIOLOGY; MILD; HOSPITALIZATION; ACCIDENT	Objective: Head injury (HI) in sport is common and can have serious consequences. This study examines the epidemiology of sport/recreational (SR)-related HI presenting to the emergency department (ED). Design: Retrospective review of medical records. Setting: Five EDs in the Capital Health Region (Edmonton) located in the province of Alberta, Canada. Patients: All persons in a 1-year period reporting to the EDs with an HI. HI was defined as IC9-CM coded skull fracture, loss of consciousness, or concussion. Main Outcome Measures: Hospitalization, utilization of diagnostic testing, and discharge destination. Results: In total, 10,877 (3%) of 288,948 ED encounters were for sports and recreational injuries; 358 (3%) were for HI. Males (71%) were more frequently injured; patients < 20 years old were involved in 66% of all HI cases. The highest proportion of HI occurred during ice hockey (21%), cycling (13%), and playground-related activities (8%). 9% of HI were hospitalized (versus 4% admission rate for other SR injuries; p < 0.01). Conclusions: These results demonstrate the utility of an ED-based injury registry and indicate that patients with HI presenting to the ED from SR activities are common. These injuries appear to be more severe than other types of SR injuries treated in the ED.	Univ Melbourne, Fac Med Dent & Hlth Sci, Dept Rural Hlth, Shepparton, Vic 3632, Australia; Univ Alberta, Alberta Ctr Injury Control & Res, Edmonton, AB, Canada; Univ Alberta, Div Emergency Med, Edmonton, AB, Canada	Kelly, KD (corresponding author), Univ Melbourne, Fac Med Dent & Hlth Sci, Dept Rural Hlth, POB 6500, Shepparton, Vic 3632, Australia.	karendk@unimelb.edu.au					*ALB CTR INJ CONTR, 1999, HEAD INJ FACTS; BAKER SP, 1994, AM J PUBLIC HEALTH, V84, P649, DOI 10.2105/AJPH.84.4.649; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Body C, 1996, BRAIN INJURY, V10, P567, DOI 10.1080/026990596124133; BRUST JD, 1998, MED J ALLINA, V7, P27; Cantu RC, 1998, CLIN SPORT MED, V17, P45, DOI 10.1016/S0278-5919(05)70060-0; Chorley Joseph N., 1998, Current Opinion in Pediatrics, V10, P350, DOI 10.1097/00008480-199808000-00004; DAVIS JM, 1993, AM J DIS CHILD, V147, P1001, DOI 10.1001/archpedi.1993.02160330091027; DELOES M, 1995, INT J SPORTS MED, V16, P134, DOI 10.1055/s-2007-972980; Diamond PT, 1996, BRAIN INJURY, V10, P413, DOI 10.1080/026990596124278; FIFE D, 1987, AM J PUBLIC HEALTH, V77, P810, DOI 10.2105/AJPH.77.7.810; Finch C, 1998, BRIT J SPORT MED, V32, P220, DOI 10.1136/bjsm.32.3.220; HARMON KG, 1999, AM FAM PHYSICIAN, V60, P738; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; Kelly J, 1997, JAMA-J AM MED ASSOC, V277, P1190; LeBlanc K E, 1998, J La State Med Soc, V150, P312; LINDSAY KW, 1980, BRIT MED J, V281, P789, DOI 10.1136/bmj.281.6243.789; MACKELLAR A, 1989, J PEDIATR SURG, V24, P577, DOI 10.1016/S0022-3468(89)80510-X; Mummery WK, 1998, CAN J PUBLIC HEALTH, V89, P53, DOI 10.1007/BF03405796; Naunheim RS, 2000, J TRAUMA, V48, P938, DOI 10.1097/00005373-200005000-00020; Puder DR, 1999, AM J PUBLIC HEALTH, V89, P1736, DOI 10.2105/AJPH.89.11.1736; Roberts WO, 1999, MED SCI SPORT EXER, V31, P46, DOI 10.1097/00005768-199901000-00009; Sosin DM, 1996, BRAIN INJURY, V10, P47; *SPECTR RES, 1996, SURV CYCL CHAR CYCL; STRANG I, 1978, INJURY, V10, P154; Sturmi JE, 1998, SPORTS MED, V25, P351, DOI 10.2165/00007256-199825060-00001; Terrell TR, 1999, AM FAM PHYSICIAN, V60, P738; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; WATTERS DAK, 1984, ARCH EMERG MED, V1, P105; Wrightson P, 1998, NEW ZEAL MED J, V111, P99; Ytterstad B, 1996, BRIT J SPORT MED, V30, P64, DOI 10.1136/bjsm.30.1.64	32	76	76	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	APR	2001	11	2					77	81		10.1097/00042752-200104000-00003			5	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	438LU	WOS:000169055800003	11403118				2021-06-18	
S	Weinstock, M; Kirschbaum-Slager, N; Lazarovici, P; Bejar, C; Youdim, MBH; Shoham, S		Slikker, W; Trembly, B		Weinstock, M; Kirschbaum-Slager, N; Lazarovici, P; Bejar, C; Youdim, MBH; Shoham, S			Neuroprotective effects of novel cholinesterase inhibitors derived from rasagiline as potential anti-Alzheimer drugs	NEUROPROTECTIVE AGENTS	Annals of the New York Academy of Sciences		English	Article; Proceedings Paper	5th International Conference on Neuroprotective Agents	SEP 17-21, 2000	LAKE TAHOE, NV	Natl Ctr Toxicol Res /FDA, Cent Arkansas Chapter Sigma Xi		PC12 cells; glucose-oxygen deprivation; closed head injury; streptozotocin memory deficits	OXIDASE-B INHIBITOR; NERVE GROWTH-FACTOR; CLOSED-HEAD INJURY; RAT PHEOCHROMOCYTOMA CELLS; OXIDATIVE STRESS; PC12 CELLS; CYTOCHROME-OXIDASE; LIPID-PEROXIDATION; HYDROGEN-PEROXIDE; ENERGY-METABOLISM	TV3326, (N-propargyl-(3R)-aminoindan-5-yl-ethyl,methyl carbamate) was prepared in order to combine the neuroprotective effects of rasagiline, a selective inhibitor of monoamine oxidase (MAO)-B with the cholinesterase (ChE) inhibitory activity of rivastigmine as a potential treatment for Alzheimer's disease. The study reported here examined the neuropotective effects of TV3326 against various insults in vitro and in vivo. TV3326 caused a dose related (10-500 muM) reduction in death induced in NGF differentiated rat pheochromocytoma (PC12) cells by 3-4 hour exposure to oxygen-glucose deprivation. A single sc injection of TV3326 given five minutes after closed head injury in mice significantly reduced the cerebral edema, and accelerated the recovery of motor function and spatial memory several days later. Unilateral icv injection of streptozotocin (STZ) 1.5 mg in rats, caused specific damage to myelinated neurones in the fornix and corpus callosum accompanied by microgliosis. Three bilateral injections of STZ, 0.25 mg each, caused more widespread damage, and a marked impairment in spatial memory. Chronic oral treatment with TV3326 (75 mu mols/kg) reduced the neuronal damage and microgliosis and almost completely prevented the memory impairment. The neuroprotective effect in PC12 cells may be due to a combination of ChE inhibition and antiapoptotic activity. The latter does not result from ChE inhibition. It is associated with the presence of the propargyl group, since it occurs with other propargylamines that do not inhibit MAO, but not with drugs that inhibit only ChE.	Hebrew Univ Jerusalem, Dept Pharmacol, Sch Pharm, Fac Med, IL-91120 Jerusalem, Israel; Technion Israel Inst Technol, Fac Med, Eve Topf Ctr, Haifa, Israel; Technion Israel Inst Technol, Fac Med, NPF Ctr, Haifa, Israel	Weinstock, M (corresponding author), Hebrew Univ Jerusalem, Dept Pharmacol, Sch Pharm, Fac Med, IL-91120 Jerusalem, Israel.	martar@cc.huji.ac.il					Abu-Raya S, 1999, J NEUROSCI RES, V58, P456, DOI 10.1002/(SICI)1097-4547(19991101)58:3<456::AID-JNR12>3.0.CO;2-S; Aragno M, 1999, FREE RADICAL BIO MED, V26, P1467, DOI 10.1016/S0891-5849(99)00012-X; Bastar I, 1998, RES COMMUN MOL PATH, V102, P265; Bejar C, 1999, EUR J PHARMACOL, V383, P231, DOI 10.1016/S0014-2999(99)00643-3; BENZI G, 1995, NEUROBIOL AGING, V16, P661, DOI 10.1016/0197-4580(95)00066-N; BLOKLAND A, 1994, PHARMACOL BIOCHEM BE, V47, P833, DOI 10.1016/0091-3057(94)90284-4; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; Calderon FH, 1999, J NEUROSCI RES, V56, P620; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Chen Y, 1998, J NEUROTRAUM, V15, P231, DOI 10.1089/neu.1998.15.231; COLTON CA, 1993, ADV NEUROL, V59, P321; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; COYLE JT, 1983, SCIENCE, V219, P1184, DOI 10.1126/science.6338589; DELEO JA, 1986, NEUROSCI LETT, V67, P63, DOI 10.1016/0304-3940(86)90209-0; DUELLI R, 1994, INT J DEV NEUROSCI, V12, P737, DOI 10.1016/0736-5748(94)90053-1; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; Filip V, 1999, J PSYCHIATR NEUROSCI, V24, P234; Finberg JPM, 1996, J NEURAL TRANSM-SUPP, P95; Finberg JPM, 1998, NEUROREPORT, V9, P703; GALLYAS F, 1990, ACTA NEUROPATHOL, V79, P620, DOI 10.1007/BF00294239; Gorman LK, 1996, J NEUROTRAUM, V13, P457, DOI 10.1089/neu.1996.13.457; HALLIWELL B, 1984, LANCET, V1, P1396; HELLWEG R, 1992, J NEUROSCI RES, V31, P479, DOI 10.1002/jnr.490310310; Huang W, 1999, EUR J PHARMACOL, V366, P127, DOI 10.1016/S0014-2999(98)00929-7; KISH SJ, 1992, J NEUROCHEM, V59, P776, DOI 10.1111/j.1471-4159.1992.tb09439.x; KNOLLEMA S, 1995, STROKE, V26, P1883, DOI 10.1161/01.STR.26.10.1883; Lannert H, 1998, BEHAV NEUROSCI, V112, P1199, DOI 10.1037/0735-7044.112.5.1199; LEONARD JR, 1994, J NEUROTRAUM, V11, P379, DOI 10.1089/neu.1994.11.379; Magyar K, 1998, J NEURAL TRANSM-SUPP, P109; Markesbery WR, 1999, BRAIN PATHOL, V9, P133; MCGEER PL, 1994, ALZ DIS ASSOC DIS, V8, P149, DOI 10.1097/00002093-199408030-00001; MESNER PW, 1992, J CELL BIOL, V119, P1669, DOI 10.1083/jcb.119.6.1669; Muller D, 1998, J NEURAL TRANSM, V105, P1271, DOI 10.1007/s007020050130; MULLER D, 1995, ADV BEHAV BIOL, V44, P389; MUTISYA EM, 1994, J NEUROCHEM, V63, P2179; NOAI M, 2001, IN PRESS J PHARM PHA; Prickaerts J, 1999, BEHAV BRAIN RES, V102, P73, DOI 10.1016/S0166-4328(98)00158-2; Russell JW, 1999, NEUROBIOL DIS, V6, P347, DOI 10.1006/nbdi.1999.0254; Saini KS, 1996, BIOCHEM MOL BIOL INT, V39, P1229; Sano M, 1997, NEW ENGL J MED, V336, P1216, DOI 10.1056/NEJM199704243361704; Seifert W, 1983, NEUROBIOLOGY HIPPOCA, P405; Shoham S, 1997, EXP NEUROL, V147, P361, DOI 10.1006/exnr.1997.6622; SMITH MA, 1996, ALZHEIMER DIS REV, V1, P63; Svensson AL, 1998, NEUROREPORT, V9, P1519, DOI 10.1097/00001756-199805110-00050; Tatton WG, 1996, NEUROLOGY, V47, pS171, DOI 10.1212/WNL.47.6_Suppl_3.171S; TATTON WG, 1994, J NEUROCHEM, V63, P1572; Weinstock M, 1999, CNS DRUGS, V12, P307, DOI 10.2165/00023210-199912040-00005; Weinstock M, 2000, DRUG DEVELOP RES, V50, P216, DOI 10.1002/1098-2299(200007/08)50:3/4<216::AID-DDR4>3.0.CO;2-Z; Wu RM, 1996, ANN NY ACAD SCI, V786, P379, DOI 10.1111/j.1749-6632.1996.tb39078.x; Xiao XQ, 2000, NEUROSCI LETT, V286, P155, DOI 10.1016/S0304-3940(00)01088-0; Xiao XQ, 1999, NEUROSCI LETT, V275, P73, DOI 10.1016/S0304-3940(99)00695-3; YOUDIM MBH, 1999, NEUROSCI LETT, V54, pS45	52	76	77	0	2	NEW YORK ACAD SCIENCES	NEW YORK	2 EAST 63RD ST, NEW YORK, NY 10021 USA	0077-8923		1-57331-353-X; 1-57331-352-1	ANN NY ACAD SCI	Ann.NY Acad.Sci.		2001	939						148	161					14	Multidisciplinary Sciences; Clinical Neurology	Science & Technology - Other Topics; Neurosciences & Neurology	BT12V	WOS:000172028600018	11462767				2021-06-18	
J	Mayou, RA; Black, J; Bryant, B				Mayou, RA; Black, J; Bryant, B			Unconsciousness, amnesia and psychiatric symptoms following road traffic accident injury	BRITISH JOURNAL OF PSYCHIATRY			English	Article							POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN INJURY; MOTOR-VEHICLE ACCIDENTS; MINOR HEAD-INJURY	Background Although road traffic accident injury is the most common cause of traumatic brain injury, little is known of the prevalence of psychiatric complications or the significance of unconsciousness and amnesia. Aims To describe amnesia and unconsciousness following a road traffic accident and to determine whether they are associated with later psychological symptoms. Method Information was obtained from medical and ambulance records for 1441 consecutive attenders at an emergency department aged 17-69 who had been involved in a road traffic accident. A total of 1148 (80%) subjects completed a self-report questionnaire at baseline and were followed up at 3 months and I year. Results Altogether, 1.5% suffered major head (and traumatic brain) injury and 21% suffered minor head injury. Posttraumatic stress disorder (PTSD) and anxiety and depression were more common at 3 months in those who had definitely been unconscious than in those who had not, but there were nt, differences at I year. Conclusions PTSD and other psychiatric complications are as common in those who were briefly unconscious as in those who were not.	Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford OX3 7JX, England; Univ Oxford, Dept Psychiat, Oxford OX3 7JX, England; John Radcliffe Hosp, Dept Accid & Emergency, Oxford OX3 9DU, England	Mayou, RA (corresponding author), Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford OX3 7JX, England.						American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; BRYANT RA, 2000, AM J PSYCHIAT, V157, P627; Ehlers A, 1998, J ABNORM PSYCHOL, V107, P508, DOI 10.1037/0021-843X.107.3.508; FOA EB, 1993, J TRAUMA STRESS, V6, P459, DOI 10.1002/jts.2490060405; Harvey AG, 1998, J NERV MENT DIS, V186, P333, DOI 10.1097/00005053-199806000-00002; Hickling EJ, 1998, BRAIN INJURY, V12, P265, DOI 10.1080/026990598122566; Kushner D, 1998, ARCH INTERN MED, V158, P1617, DOI 10.1001/archinte.158.15.1617; MAYOU R, 1993, BRIT MED J, V307, P647, DOI 10.1136/bmj.307.6905.647; McMillan TM, 1997, CURR OPIN NEUROL, V10, P479, DOI 10.1097/00019052-199712000-00008; Murray J., 1997, THESIS U OXFORD; Parker RS, 1996, BRAIN INJURY, V10, P287, DOI 10.1080/026990596124467; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	14	76	79	0	3	ROYAL COLLEGE OF PSYCHIATRISTS	LONDON	BRITISH JOURNAL OF PSYCHIATRY 17 BELGRAVE SQUARE, LONDON SW1X 8PG, ENGLAND	0007-1250			BRIT J PSYCHIAT	Br. J. Psychiatry	DEC	2000	177						540	545		10.1192/bjp.177.6.540			6	Psychiatry	Psychiatry	382WW	WOS:000165851200012	11102330				2021-06-18	
J	Fassbender, K; Schneider, S; Bertsch, T; Schlueter, D; Fatar, M; Ragoschke, A; Kuhl, S; Kischka, U; Hennerici, M				Fassbender, K; Schneider, S; Bertsch, T; Schlueter, D; Fatar, M; Ragoschke, A; Kuhl, S; Kischka, U; Hennerici, M			Temporal profile of release of interleukin-1 beta in neurotrauma	NEUROSCIENCE LETTERS			English	Article						interleukin-1 beta; neurotrauma; microdialysis; inflammation	RAT-BRAIN; CONVERTING-ENZYME; MESSENGER-RNA; EXPRESSION; INJURY; MICRODIALYSIS; LOCALIZATION; CYTOKINES; MICROGLIA; ISCHEMIA	Timing and extent of trauma-induced release of interleukin-1 beta (IL-1 beta) in extracellular fluid of the CNS were analyzed. In brain tissue perfusates obtained by in vivo microdialysis a marked release of IL-1 beta was unexpectedly detected within less than 60 min. At such an early stage of neurotrauma, mRNA expression of IL-1 beta was detected whereas immunoreactivity for the IL-1 beta protein was negative. Concentrations of extracellularly secreted IL-1 beta protein gradually increased, peaked at day 2 and decreased thereafter. Drugs acting on mononuclear phagocytes significantly modulated IL-1 beta secretion. This so far unrecognized acuity of IL-1 beta release demonstrated here, may represent a precondition for the orchestrating role of this mediator in the cascade of inflammatory host response. (C) 2000 Elsevier Science Ireland Ltd. AII rights reserved.	Heidelberg Univ, Univ Clin Mannheim, Dept Neurol, D-68135 Mannheim, Germany; Heidelberg Univ, Univ Clin Mannheim, Dept Clin Chem, D-68135 Mannheim, Germany; Heidelberg Univ, Univ Clin Mannheim, Dept Microbiol, D-68135 Mannheim, Germany	Fassbender, K (corresponding author), Heidelberg Univ, Univ Clin Mannheim, Dept Neurol, Theodor Kutzer Ufer 1-3, D-68135 Mannheim, Germany.	fass@neuro.ma.uni-heidelberg.de	Fatar, Marc/E-6892-2015	Fassbender, Klaus/0000-0003-3596-868X			ANDERSSON PB, 1992, NEUROSCIENCE, V48, P169, DOI 10.1016/0306-4522(92)90347-5; ANDERSSON U, 1994, CYTOKINE PRODUCING C, P48; Fassbender K, 1997, J NEUROIMMUNOL, V74, P130, DOI 10.1016/S0165-5728(96)00214-7; GIULIAN D, 1990, ANN NEUROL, V27, P33, DOI 10.1002/ana.410270107; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; Jeohn GH, 1998, J NEUROIMMUNOL, V85, P1, DOI 10.1016/S0165-5728(97)00204-X; Knauber J, 1999, J NEURAL TRANSM, V106, P35, DOI 10.1007/s007020050139; Knerlich F, 1999, MOL BRAIN RES, V68, P73, DOI 10.1016/S0169-328X(99)00064-9; Masson S, 1999, AM J PHYSIOL-GASTR L, V277, pG838; Ohtsuki T, 1996, J CEREBR BLOOD F MET, V16, P1137, DOI 10.1097/00004647-199611000-00007; PHELPS CP, 1995, BRAIN RES, V688, P193, DOI 10.1016/0006-8993(95)00491-8; Rouquet N, 1996, CURR BIOL, V6, P1192, DOI 10.1016/S0960-9822(02)70688-X; SCHLUTER D, 1995, AM J PATHOL, V146, P999; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; van der Meer JWM, 1998, ANN NY ACAD SCI, V856, P243; WONG ML, 1995, NEUROIMMUNOMODULAT, V2, P141, DOI 10.1159/000096884; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; YAMASAKI Y, 1992, NEUROSCI LETT, V142, P45, DOI 10.1016/0304-3940(92)90616-F; YAN HQ, 1992, EUR J IMMUNOL, V22, P2963, DOI 10.1002/eji.1830221131; Zhang ZG, 1998, BRAIN RES, V784, P210, DOI 10.1016/S0006-8993(97)01317-6	20	76	80	0	3	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	APR 28	2000	284	3					135	138		10.1016/S0304-3940(00)00977-0			4	Neurosciences	Neurosciences & Neurology	312FD	WOS:000086931800002	10773417				2021-06-18	
J	Fink, KB; Andrews, LJ; Butler, WE; Ona, VO; Li, M; Bogdanov, M; Endres, M; Khan, SQ; Namura, S; Stieg, PE; Beal, MF; Moskowitz, MA; Yuan, J; Friedlander, RM				Fink, KB; Andrews, LJ; Butler, WE; Ona, VO; Li, M; Bogdanov, M; Endres, M; Khan, SQ; Namura, S; Stieg, PE; Beal, MF; Moskowitz, MA; Yuan, J; Friedlander, RM			Reduction of post-traumatic brain injury and free radical production by inhibition of the caspase-1 cascade	NEUROSCIENCE			English	Article						caspase-1; interleukin-1 beta-converting enzyme; apoptosis; DNA fragmentation; TUNEL; caspase inhibition	INTERLEUKIN-1-BETA CONVERTING-ENZYME; TROPHIC FACTOR WITHDRAWAL; APOPTOTIC CELL-DEATH; NEURONAL APOPTOSIS; IL-1-BETA-CONVERTING ENZYME; MEDIATED APOPTOSIS; MAMMALIAN HOMOLOG; FAMILY PROTEASES; TRANSGENIC MICE; GENE CED-3	Necrotic and apoptotic cell death both play a role mediating tissue injury following brain trauma. Caspase-1 (interleukin-1 beta converting enzyme) is activated and oligonucleosomal DNA fragmentation is detected in traumatized brain tissue. Reduction of tissue injury and free radical production following brain trauma was achieved in a transgenic mouse expressing a dominant negative inhibitor of caspase-1 in the brain. Neuroprotection was also conferred by pharmacological inhibition of caspase-1 by intracerebroventricular administration of the selective inhibitor of caspase-1, acetyl-Tyr-Val-Ala-Asp-chloromethylketone or the non-selective caspase inhibitor N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone. These results indicate that inhibition of caspase-1-like caspases reduces trauma-mediated brain tissue injury. In addition, we demonstrate an in vivo functional interaction between interleukin-1 beta converting enyzme-like caspases and free radical production pathways, implicating free radical production as a downstream mediator of the caspase cell death cascade. (C) 1999 IBRO. Published by Elsevier Science Ltd.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Neurosurg,Neurosurg Serv, Boston, MA 02115 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Charlestown, MA 02129 USA; Univ Bonn, Sch Med, Dept Pharmacol, D-53113 Bonn, Germany; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Neurosurg Serv & Neurochem Lab, Boston, MA 02114 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Neurosurg Serv, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Friedlander, RM (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Neurosurg,Neurosurg Serv, 75 Francis St, Boston, MA 02115 USA.		Moskowitz, Michael A/D-9916-2011; Friedlander, Robert M/A-2845-2016	Friedlander, Robert M/0000-0003-4423-9219			Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; CHAN PH, 1994, ANN NY ACAD SCI, V738, P93; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Conti AC, 1998, J NEUROSCI, V18, P5663; *DEP HHS, 1989, INT HEAD INJ TASK FO; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; Enari M, 1998, NATURE, V391, P43; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; Endres H, 1998, J CEREBR BLOOD F MET, V18, P238, DOI 10.1097/00004647-199803000-00002; Estevez AG, 1998, J NEUROSCI, V18, P923; Friedlander RM, 1997, NATURE, V388, P31, DOI 10.1038/40299; Friedlander RM, 1996, J EXP MED, V184, P717, DOI 10.1084/jem.184.2.717; Friedlander RM, 1997, J EXP MED, V185, P933, DOI 10.1084/jem.185.5.933; Friedlander RM, 1998, CELL DEATH DIFFER, V5, P823, DOI 10.1038/sj.cdd.4400433; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; GREENLUND LJS, 1995, NEURON, V14, P303, DOI 10.1016/0896-6273(95)90287-2; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; Hara H, 1997, J CEREBR BLOOD F MET, V17, P370, DOI 10.1097/00004647-199704000-00002; HOGQUIST KA, 1991, P NATL ACAD SCI USA, V88, P8485, DOI 10.1073/pnas.88.19.8485; Holtzman DM, 1997, NAT MED, V3, P954, DOI 10.1038/nm0997-954; Jordan J, 1997, J NEUROSCI, V17, P1397; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; Loddick SA, 1996, NEUROREPORT, V7, P1465, DOI 10.1097/00001756-199606170-00004; MACMANUS JP, 1995, MOL NEUROSCI, V5, P493; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MIURA M, 1995, P NATL ACAD SCI USA, V92, P8318, DOI 10.1073/pnas.92.18.8318; Namura S, 1998, J NEUROSCI, V18, P3659; Park DS, 1998, J NEUROSCI, V18, P830; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Prehn JHM, 1997, J NEUROCHEM, V68, P1679; RINK A, 1995, AM J PATHOL, V147, P1575; Schulz JB, 1996, J NEUROSCI, V16, P4696; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; Shimizu S, 1996, ONCOGENE, V12, P2045; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; Slee EA, 1996, BIOCHEM J, V315, P21, DOI 10.1042/bj3150021; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THOMAS LB, 1995, EXP NEUROL, V133, P265, DOI 10.1006/exnr.1995.1029; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; TILLY JL, 1993, J CELL PHYSIOL, V154, P519, DOI 10.1002/jcp.1041540310; TOHGI H, 1995, NEUROSCI LETT, V184, P21, DOI 10.1016/0304-3940(94)11158-F; Troy CM, 1996, P NATL ACAD SCI USA, V93, P5635, DOI 10.1073/pnas.93.11.5635; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509; Xiong Y, 1997, J NEUROTRAUM, V14, P907, DOI 10.1089/neu.1997.14.907; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H; ZYCHLINSKY A, 1994, J CLIN INVEST, V94, P1328, DOI 10.1172/JCI117452	53	76	81	1	7	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience		1999	94	4					1213	1218		10.1016/S0306-4522(99)00345-0			6	Neurosciences	Neurosciences & Neurology	256PW	WOS:000083735000019	10625061				2021-06-18	
J	Xiao, F; Safar, P; Radovsky, A				Xiao, F; Safar, P; Radovsky, A			Mild protective and resuscitative hypothermia for asphyxial cardiac arrest in rats	AMERICAN JOURNAL OF EMERGENCY MEDICINE			English	Article						asphyxia; cardiac arrest; cardiopulmonary resuscitation; cerebral ischemia; cerebral protection; cerebral resuscitation; histopathology; hypothermia; rat model	PERMANENT FOCAL ISCHEMIA; TRAUMATIC BRAIN INJURY; MULTIFOCAL CEREBRAL HYPOPERFUSION; GLOBAL FOREBRAIN ISCHEMIA; MODERATE HYPOTHERMIA; POSTISCHEMIC HYPOTHERMIA; POSTTRAUMATIC HYPOTHERMIA; CARDIOPULMONARY BYPASS; TEMPERATURE MODULATION; GLYCINE CONCENTRATIONS	It has been shown in dogs that mild hypothermia (34 degrees C) during or immediately after ventricular fibrillation cardiac arrest can improve cerebral outcome, The effect of mild hypothermia on outcome after 8 minutes of asphyxiation (5 minutes cardiac arrest) was studied for the first time in rats, Restoration of spontaneous circulation was with external cardiopulmonary resuscitation and observation to 72 hours, Three groups of 10 rats each were studied, At 72 hours postarrest, compared with the normothermic control group 1, final overall performance categories (OPC) and neurological deficit scores (NDS) were numerically better in the resuscitative (post arrest) hypothermia group 2 and significantly better in the protective (pre-intra arrest) hypothermia group 3 (P < .05), Total brain histopathological damage scores (HDS) were 17 +/- 5 in group 1, 14 +/- 6 in group 2 (NS), and 6 +/- 2 in group 3 (P < .001 versus group 1), HDS correlated with OPC (r = .6, P < .05) and NDS (r = .7, P < .05), Mild hypothermia improved cerebral outcome after asphyxial cardiac arrest in rats, more when induced before than after arrest, The model's insult is within the therapeutic window, which makes it also suitable for screening other cerebral resuscitation potentials. Copyright (C) 1998 by W.B. Saunders Company.	Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Anesthesiol & Crit Care Med, Pittsburgh, PA 15260 USA	Safar, P (corresponding author), Univ Pittsburgh, Safar Ctr Resuscitat Res, 3434 5th Ave, Pittsburgh, PA 15260 USA.						ABRAMSON NS, 1991, NEW ENGL J MED, V324, P1225; ABRAMSON NS, 1992, ANN EMERG MED, V21, P1480, DOI 10.1016/S0196-0644(05)80066-6; ABRAMSON NS, 1986, NEW ENGL J MED, V314, P397; *AM HEART ASS, 1992, JAMA-J AM MED ASSOC, V268, P2199; AMES A, 1968, AM J PATHOL, V52, P437; BAKER AJ, 1991, STROKE, V22, P666, DOI 10.1161/01.STR.22.5.666; BIGELOW WG, 1950, ANN SURG, V132, P849, DOI 10.1097/00000658-195011000-00001; BIGGART MJ, 1990, J PEDIATR-US, V117, P179, DOI 10.1016/S0022-3476(05)80526-8; BORISMOLLER F, 1989, J CEREB BLOOD FLOW M, V9, pS276; BUSTO R, 1994, J NEUROCHEM, V63, P1095; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; BUSTO R, 1989, NEUROSCI LETT, V101, P299, DOI 10.1016/0304-3940(89)90549-1; CHOPP M, 1989, J CEREBR BLOOD F MET, V9, P141, DOI 10.1038/jcbfm.1989.21; CHOPP M, 1991, STROKE, V22, P37, DOI 10.1161/01.STR.22.1.37; Clark RSB, 1996, J CEREBR BLOOD F MET, V16, P253, DOI 10.1097/00004647-199603000-00010; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; COIMBRA C, 1994, ACTA NEUROPATHOL, V87, P325, DOI 10.1007/bf00313599; COLBOURNE F, 1994, BRAIN RES, V654, P265, DOI 10.1016/0006-8993(94)90488-X; COLBOURNE F, 1995, J NEUROSCI, V15, P7250; COLE SL, 1956, JAMA-J AM MED ASSOC, V161, P1454, DOI 10.1001/jama.1956.02970150022005; CONN AW, 1979, PEDIATR CLIN N AM, V26, P691; CRIPPEN D, 1991, RESUSCITATION, V21, P271, DOI 10.1016/0300-9572(91)90052-Z; DIETRICH WD, 1995, J CEREBR BLOOD F MET, V15, P960, DOI 10.1038/jcbfm.1995.122; DIETRICH WD, 1993, J CEREBR BLOOD F MET, V13, P541, DOI 10.1038/jcbfm.1993.71; EBMEYER U, 1993, CRIT CARE MED, V21, pS236; FRAZZINI VI, 1994, NEUROSURGERY, V34, P1040, DOI 10.1227/00006123-199406000-00013; GISVOLD SE, 1984, STROKE, V15, P803, DOI 10.1161/01.STR.15.5.803; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1250; GOTO Y, 1993, NEUROSURGERY, V32, P980, DOI 10.1227/00006123-199306000-00017; HENDRICKX HHL, 1984, RESUSCITATION, V12, P97, DOI 10.1016/0300-9572(84)90062-5; HENDRICKX HHL, 1984, RESUSCITATION, V12, P117, DOI 10.1016/0300-9572(84)90063-7; ILLIEVICH UM, 1994, ANESTHESIOLOGY, V80, P177, DOI 10.1097/00000542-199401000-00025; KADER A, 1992, NEUROSURGERY, V31, P1056, DOI 10.1227/00006123-199212000-00011; KADER A, 1994, NEUROSURGERY, V35, P272, DOI 10.1227/00006123-199408000-00013; KARIBE H, 1994, J CEREBR BLOOD F MET, V14, P620, DOI 10.1038/jcbfm.1994.77; KARIBE H, 1994, J NEUROSURG, V80, P112, DOI 10.3171/jns.1994.80.1.0112; KATZ L, 1995, J CEREBR BLOOD F MET, V15, P1032, DOI 10.1038/jcbfm.1995.129; KATZ L, 1994, RESUSCITATION, V28, pS10; KATZ L, 1995, CRIT CARE MED, V23, pA197; Kil HY, 1996, J CEREBR BLOOD F MET, V16, P100, DOI 10.1097/00004647-199601000-00012; Kim SH, 1997, J TRAUMA, V42, P213, DOI 10.1097/00005373-199702000-00006; KRAMER RS, 1968, J THORAC CARDIOV SUR, V56, P699, DOI 10.1016/S0022-5223(19)42797-9; KRISTIAN T, 1992, ACTA PHYSIOL SCAND, V146, P531, DOI 10.1111/j.1748-1716.1992.tb09457.x; KUBOYAMA K, 1993, CRIT CARE MED, V21, P1348, DOI 10.1097/00003246-199309000-00019; KUBOYAMA K, 1994, RESUSCITATION, V27, P231, DOI 10.1016/0300-9572(94)90037-X; LEI BP, 1994, STROKE, V25, P147, DOI 10.1161/01.STR.25.1.147; LEONOV Y, 1992, STROKE, V23, P45, DOI 10.1161/01.STR.23.1.45; LEONOV Y, 1990, J CEREBR BLOOD F MET, V10, P57, DOI 10.1038/jcbfm.1990.8; LEONOV Y, 1990, STROKE, V21, P1600, DOI 10.1161/01.STR.21.11.1600; Mansfield RT, 1996, J CEREBR BLOOD F MET, V16, P244, DOI 10.1097/00004647-199603000-00009; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Marion DW, 1996, CRIT CARE MED, V24, pS81; MICHENFELDER JD, 1970, ANESTHESIOLOGY, V33, P315, DOI 10.1097/00000542-197009000-00008; MINAMISAWA H, 1990, J CEREBR BLOOD F MET, V10, P365, DOI 10.1038/jcbfm.1990.66; MINAMISAWA H, 1990, ANN NEUROL, V28, P26, DOI 10.1002/ana.410280107; MITANI A, 1991, BRAIN RES, V562, P159, DOI 10.1016/0006-8993(91)91201-B; MITANI A, 1991, NEUROSCIENCE, V42, P661, DOI 10.1016/0306-4522(91)90035-M; MORIKAWA E, 1992, J CEREBR BLOOD F MET, V12, P380, DOI 10.1038/jcbfm.1992.55; Nakashima K, 1996, STROKE, V27, P913, DOI 10.1161/01.STR.27.5.913; NAKASHIMA K, 1995, ANESTHESIOLOGY, V82, P1199, DOI 10.1097/00000542-199505000-00015; OH SM, 1991, STROKE, V22, P915, DOI 10.1161/01.STR.22.7.915; OKU K, 1993, STROKE, V24, P1590, DOI 10.1161/01.STR.24.10.1590; POMERANZ S, 1993, J NEUROSURG, V79, P241, DOI 10.3171/jns.1993.79.2.0241; QUAN L, 1989, PEDIATRICS, V83, P1035; RADOVSKY A, 1995, STROKE, V26, P2127, DOI 10.1161/01.STR.26.11.2127; Radovsky A, 1997, TOXICOL PATHOL, V25, P500, DOI 10.1177/019262339702500512; RIDENOUR TR, 1992, STROKE, V23, P733, DOI 10.1161/01.STR.23.5.733; ROSOMOFF HL, 1954, AM J PHYSIOL, V179, P85; Rosomoff HL, 1996, CRIT CARE MED, V24, pS48; ROSOMOFF HL, 1959, ANN NY ACAD SCI, V80, P475, DOI 10.1111/j.1749-6632.1959.tb49225.x; SAFAR P, 1990, AM J EMERG MED, V8, P55, DOI 10.1016/0735-6757(90)90298-E; SAFAR P, 1976, ARCH NEUROL-CHICAGO, V33, P91, DOI 10.1001/archneur.1976.00500020019004; Safar P, 1996, STROKE, V27, P105, DOI 10.1161/01.STR.27.1.105; SAFAR P, 1997, YB NEUROANESTHESIA N, P557; SAFAR P, 1996, SCI PRACTICE RESUSCI, P702; SANO T, 1992, ANESTHESIOLOGY, V76, P221, DOI 10.1097/00000542-199202000-00011; SIEBKE H, 1975, LANCET, V1, P1275; STEEN PA, 1979, STROKE, V10, P522, DOI 10.1161/01.STR.10.5.522; STERZ F, 1992, RESUSCITATION, V24, P27, DOI 10.1016/0300-9572(92)90171-8; STERZ F, 1990, STROKE, V21, P1178, DOI 10.1161/01.STR.21.8.1178; STERZ F, 1991, CRIT CARE MED, V19, P379, DOI 10.1097/00003246-199103000-00017; TAFT WC, 1993, J CEREBR BLOOD F MET, V13, P796, DOI 10.1038/jcbfm.1993.101; THORESEN M, 1995, PEDIATR RES, V37, P667, DOI 10.1203/00006450-199505000-00019; VAAGENES P, 1988, J CEREBR BLOOD F MET, V8, P262, DOI 10.1038/jcbfm.1988.57; Vaagenes P, 1997, RESUSCITATION, V35, P41, DOI 10.1016/S0300-9572(97)01108-8; VERHAEGEN M, 1995, ANESTHESIOLOGY, V82, P1209, DOI 10.1097/00000542-199505000-00016; WEINRAUCH V, 1992, STROKE, V23, P1454, DOI 10.1161/01.STR.23.10.1454; WELSH FA, 1990, J CEREBR BLOOD F MET, V10, P557, DOI 10.1038/jcbfm.1990.98; WHITE RJ, 1978, MAYO CLIN PROC, V53, P450; Winfree CJ, 1996, NEUROSURGERY, V38, P1216, DOI 10.1097/00006123-199606000-00034; WOLFSON SK, 1973, J SURG RES, V14, P449, DOI 10.1016/0022-4804(73)90053-X; XIAO F, 1995, RESUSCITATION, V30, P51, DOI 10.1016/0300-9572(94)00858-D; XIAO F, 1994, RESUSCITATION, V28, pS21; Yager JY, 1996, STROKE, V27, P919, DOI 10.1161/01.STR.27.5.919	96	76	80	1	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0735-6757	1532-8171		AM J EMERG MED	Am. J. Emerg. Med.	JAN	1998	16	1					17	25		10.1016/S0735-6757(98)90059-6			9	Emergency Medicine	Emergency Medicine	YR508	WOS:000071502300005	9451308				2021-06-18	
J	Warden, DL; Labbate, LA; Salazar, AM; Nelson, R; Sheley, E; Staudenmeier, J; Martin, E				Warden, DL; Labbate, LA; Salazar, AM; Nelson, R; Sheley, E; Staudenmeier, J; Martin, E			Posttraumatic stress disorder in patients with traumatic brain injury and amnesia for the event?	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							PSYCHIATRIC CONSEQUENCES; POPULATION; ADULTS	Frequency of DSM-III-R posttraumatic stress disorder (PTSD) was studied in 47 active-duty service members (46 male, 1 female; mean age 27+/-7) with moderate traumatic brain injury and neurogenic amnesia for the event. Patients had attained ''oriented and cooperative'' recovery level. When evaluated with a modified Present State Examination and other questions at various points from study entry to 24-month follow-up, no patients met full criteria for PTSD or met criterion B (reexperience); 6 (13%) met both C (avoidance) and D (arousal) criteria. Five of these 6 also had organic mood disorder, depressed type, and/or organic anxiety disorder. Posttraumatic amnesia following moderate head injury may protect against recurring memories and the development of PTSD. Some patients with neurogenic amnesia may develop a form of PTSD without the reexperiencing symptoms.		Warden, DL (corresponding author), WALTER REED ARMY MED CTR,DEF & VET HEAD INJURY PROGRAM,BLDG 1,ROOM 209B,WASHINGTON,DC 20307, USA.						BRESLAU N, 1991, ARCH GEN PSYCHIAT, V48, P216; BUYDENSBRANCHEY L, 1990, J NERV MENT DIS, V178, P582, DOI 10.1097/00005053-199009000-00005; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Hagen C., 1972, LEVELS COGNITIVE FUN; HELZER JE, 1987, NEW ENGL J MED, V317, P1630, DOI 10.1056/NEJM198712243172604; LAYTON BS, 1995, CLIN NEUROPSYCHOL, V9, P2, DOI 10.1080/13854049508402050; LEDOUX J, 1992, NEUROPSYCHOLOGY MEMO, P463; Levin H. S., 1992, NEUROPSYCHOLOGY MEMO, P290; MALT U, 1988, BRIT J PSYCHIAT, V153, P810, DOI 10.1192/bjp.153.6.810; MAYOU R, 1993, BRIT MED J, V307, P647, DOI 10.1136/bmj.307.6905.647; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; PERRY S, 1992, AM J PSYCHIAT, V149, P931; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P16, DOI DOI 10.1001/ARCHNEUR.1961.00450130006002; SALAZAR AM, 1986, NEUROLOGY, V36, P178, DOI 10.1212/WNL.36.2.178; SALAZAR AM, 1987, PROGR CLIN NEUROSCIE, V1, P225; Sartorius N, 1974, MEASUREMENT CLASSIFI; WARD AA, 1966, HEAD INJURY C P, P203; WARDEN DL, 1994, NEUROLOGY, V44, pA401	19	76	76	0	1	AMER PSYCHIATRIC ASSOCIATION	WASHINGTON	1400 K ST NW, WASHINGTON, DC 20005	0895-0172			J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	WIN	1997	9	1					18	22					5	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	WD688	WOS:A1997WD68800002	9017524				2021-06-18	
J	Prince, DA; Jacobs, KM; Salin, PA; Hoffman, S; Parada, I				Prince, DA; Jacobs, KM; Salin, PA; Hoffman, S; Parada, I			Chronic focal neocortical epileptogenesis: Does disinhibition play a role?	CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY			English	Article; Proceedings Paper	Symposium of the Centre-de-Recherche-en-Sciences-Neurologiques-of-the-Universite-de-Montreal on GABA Mechanisms in the Cerebral Cortex	MAY 09-10, 1996	MONTREAL, CANADA	Univ Montreal, Ctr Rech Sci Neurol		neocortex; epileptogenesis; brain lesions; inhibition; post-traumatic epilepsy; cortical microgyri	GABA(A) RECEPTOR SUBUNIT; INHIBITORY POSTSYNAPTIC CURRENTS; INTRAHIPPOCAMPAL TETANUS TOXIN; ACTIVITY-DEPENDENT REGULATION; GLUTAMIC-ACID DECARBOXYLASE; MONKEY VISUAL-CORTEX; RAT DENTATE GYRUS; CEREBRAL-CORTEX; MESSENGER-RNAS; IMMUNOREACTIVE NEURONS	Several lines of evidence have suggested that decreases in postsynaptic inhibition may have a role in epileptogenesis in cortical structures. However, other studies have suggested that GABAergic inhibition is spared, or even augmented in some forms of post-lesional epilepsy. In the studies described here, inhibitory events were recorded in two models of post-lesional chronic epileptogenesis. (i) As previously reported (D.A. Prince and G.-F. Tseng. J. Neurophysiol. 69: 1276-1291. 1993), epileptiform activity develops in slices from partially isolated rat neocortical islands 2-3 weeks after the initial in vivo lesion. In this model of post-traumatic epilepsy, large amplitude polyphasic inhibitory postsynaptic currents (IPSCs) in layer V pyramidal neurons are associated with each interictal epileptiform field potential. The frequency of spontaneous IPSCs as well as miniature IPSCs was significantly increased in neocortical slices from the epileptogenic chronically injured cortex versus controls. Immunocytochemical reactions for parvalbumin and calbindin, calcium binding proteins present in subgroups of GABAergic neurons, showed an increased staining of both neuropil and somata within the epileptogenic tissue. Immunoreactivity for glutamic acid decarboxylase (GAB) and GABA. also appeared to be increased in the neuropil. (ii) Cortical microgyri resembling human malformations were produced by freeze lesions made transcranially in PO rat cortex (K.M. Jacobs, M.J. Gutnick, and D.A. Prince. Cereb. Cortex, 6: 514-523. 1996). The boundary between the four-layered microgyrus and surrounding cortex becomes epileptogenic within about 2 weeks, as judged by evoked extracellular field potentials and cellular activities. Epileptogenesis in the surrounding cortex is not altered when the microgyrus itself is isolated by transcortical cuts. Patch-clamp recordings from layer V neurons in the epileptogenic zone showed that spontaneous IPSCs are larger and more dependent on glutamatergic synapses than in control neurons. The amplitudes of polysynaptic IPSCs evoked by threshold stimulation were also larger than in control cells. Although evaluation of inhibitory events in these models is still incomplete, results to date suggest that GABAergic inhibition may be enhanced in epileptogenic areas associated with chronic cortical injury. Sprouting of axonal arborizations of pyramidal cells onto interneurons, upregulation of GABAergic neurons, and perhaps sprouting of inhibitory axons that make increased numbers of contacts onto pyramidal cells may all contribute to the increased inhibitory drive. Results in these models do not support the disinhibitory hypothesis of chronic epileptogenesis.		Prince, DA (corresponding author), STANFORD UNIV, SCH MED, DEPT NEUROL & NEUROL SCI, ROOM M016, STANFORD, CA 94305 USA.		Jacobs, Kimberle/AAW-7526-2020		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS012151, P50NS012151] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS12151, NS09806, NS07280] Funding Source: Medline		AGMON A, 1992, J NEUROPHYSIOL, V68, P345; Agmon A, 1996, J NEUROSCI, V16, P4684; ASHWOOD TJ, 1986, BRAIN RES, V367, P390, DOI 10.1016/0006-8993(86)91625-2; BABB TL, 1989, J NEUROSCI, V9, P2562; BEKENSTEIN JW, 1993, SCIENCE, V259, P97, DOI 10.1126/science.8093417; BENSON DL, 1991, J NEUROSCI, V11, P31; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; BRUSSAARD AB, 1995, NEUROSCI LETT, V191, P111, DOI 10.1016/0304-3940(95)11539-6; CAPOGNA M, 1995, J NEUROSCI, V15, P1249; CHAGNACAMITAI Y, 1989, J NEUROPHYSIOL, V62, P1149; CHAGNACAMITAI Y, 1989, J NEUROPHYSIOL, V61, P747; CONNORS BW, 1984, NATURE, V310, P685, DOI 10.1038/310685a0; DAVENPORT CJ, 1990, EXP NEUROL, V109, P180, DOI 10.1016/0014-4886(90)90072-Z; DEISZ RA, 1989, J PHYSIOL-LONDON, V412, P513, DOI 10.1113/jphysiol.1989.sp017629; DVORAK K, 1977, ACTA NEUROPATHOL, V38, P203; DVORAK K, 1978, ACTA NEUROPATHOL, V44, P121; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; EDWARDS FA, 1990, J PHYSIOL-LONDON, V430, P213, DOI 10.1113/jphysiol.1990.sp018289; FLEIDERVISH IA, 1995, J NEUROPHYSIOL, V73, P2591; FRANCK JE, 1985, BRAIN RES, V329, P309, DOI 10.1016/0006-8993(85)90540-2; FRANCK JE, 1988, J NEUROSCI, V8, P1991; GOLDOWITZ D, 1982, BRAIN RES, V238, P413, DOI 10.1016/0006-8993(82)90116-0; GONZALES C, 1992, NEUROSCI LETT, V135, P53, DOI 10.1016/0304-3940(92)90134-S; HALPERN LM, 1972, EXPT MODELS EPILEPSY, P17; HENDRY SHC, 1994, J NEUROSCI, V14, P2383; HENDRY SHC, 1988, NEURON, V1, P701, DOI 10.1016/0896-6273(88)90169-9; HOFFMAN SN, 1994, J NEUROPHYSIOL, V71, P1762; HUMPHREYS P, 1991, J NEUROPATH EXP NEUR, V50, P145, DOI 10.1097/00005072-199103000-00006; HUNTSMAN MM, 1995, J COMP NEUROL, V352, P235, DOI 10.1002/cne.903520207; HUNTSMAN MM, 1994, J NEUROSCI, V14, P2236; Isokawa M, 1996, J NEUROPHYSIOL, V75, P1901; Jacobs KM, 1996, CEREB CORTEX, V6, P514, DOI 10.1093/cercor/6.3.514; KAMPHUIS W, 1995, MOL BRAIN RES, V31, P33, DOI 10.1016/0169-328X(95)00022-K; KOKAIA M, 1994, MOL BRAIN RES, V23, P323, DOI 10.1016/0169-328X(94)90242-9; KREINDLER A, 1960, ARCH ITAL BIOL, V98, P10; KRISHEK BJ, 1994, NEURON, V12, P1081, DOI 10.1016/0896-6273(94)90316-6; Ling DSF, 1995, J NEUROPHYSIOL, V74, P2329; MATHERN GW, 1995, J NEUROSCI, V15, P3990; MATSUMOTO H, 1964, EXP NEUROL, V9, P286, DOI 10.1016/0014-4886(64)90025-1; MCCARREN M, 1985, J NEUROPHYSIOL, V53, P557; MCCORMICK DA, 1985, J NEUROPHYSIOL, V54, P782; MICHEVA KD, 1995, J COMP NEUROL, V361, P574, DOI 10.1002/cne.903610403; MODY I, 1994, TRENDS NEUROSCI, V17, P517, DOI 10.1016/0166-2236(94)90155-4; NAJLERAHIM A, 1992, EXP BRAIN RES, V90, P332; Nakajima S, 1991, Hippocampus, V1, P67, DOI 10.1002/hipo.450010107; OBENAUS A, 1993, J NEUROSCI, V13, P4470; OTIS TS, 1994, P NATL ACAD SCI USA, V91, P7698, DOI 10.1073/pnas.91.16.7698; PRINCE DA, 1978, ANNU REV NEUROSCI, V1, P395, DOI 10.1146/annurev.ne.01.030178.002143; PRINCE DA, 1993, J NEUROPHYSIOL, V69, P1276; PRINCE DA, 1992, EPILEPSY RES, P31; Purpura D P, 1968, Prog Brain Res, V22, P107; RIBAK CE, 1982, J NEUROSCI, V2, P1725; RIBAK CE, 1982, CAN J PHYSIOL PHARM, V60, P864, DOI 10.1139/y82-122; ROMIJN HJ, 1994, ACTA NEUROPATHOL, V87, P612; ROMIJN HJ, 1988, EXP NEUROL, V100, P332, DOI 10.1016/0014-4886(88)90112-4; Salin P, 1995, J NEUROSCI, V15, P8234; Salin PA, 1996, J NEUROPHYSIOL, V75, P1589; Salin PA, 1996, J NEUROPHYSIOL, V75, P1573; SEIL FJ, 1994, DEV BRAIN RES, V77, P123, DOI 10.1016/0165-3806(94)90219-4; SHERMAN GF, 1990, BRAIN RES, V529, P202, DOI 10.1016/0006-8993(90)90828-Y; SLOPER JJ, 1980, BRAIN RES, V198, P204, DOI 10.1016/0006-8993(80)90356-X; Sloviter R S, 1991, Hippocampus, V1, P41, DOI 10.1002/hipo.450010106; SLOVITER RS, 1992, NEUROSCI LETT, V137, P91, DOI 10.1016/0304-3940(92)90306-R; SLOVITER RS, 1987, SCIENCE, V235, P73, DOI 10.1126/science.2879352; TECOMA ES, 1989, NEUROLOGY, V39, P676, DOI 10.1212/WNL.39.5.676; THOMPSON SM, 1989, J NEUROPHYSIOL, V61, P501; WALKER AE, 1942, LANCET, V1, P732; WELKER E, 1989, EXP BRAIN RES, V74, P441, DOI 10.1007/BF00247346; WELKER E, 1989, EXP BRAIN RES, V78, P659, DOI 10.1007/BF00230256; WHITTINGTON MA, 1994, J PHYSIOL-LONDON, V481, P593, DOI 10.1113/jphysiol.1994.sp020466	70	76	77	0	0	CANADIAN SCIENCE PUBLISHING, NRC RESEARCH PRESS	OTTAWA	65 AURIGA DR, SUITE 203, OTTAWA, ON K2E 7W6, CANADA	0008-4212	1205-7541		CAN J PHYSIOL PHARM	Can. J. Physiol. Pharmacol.	MAY	1997	75	5					500	507		10.1139/cjpp-75-5-500			8	Pharmacology & Pharmacy; Physiology	Pharmacology & Pharmacy; Physiology	XM246	WOS:A1997XM24600018	9250384				2021-06-18	
J	Kim, DH; Gutin, PH; Noble, LJ; Nathan, D; Yu, JS; Nockels, RP				Kim, DH; Gutin, PH; Noble, LJ; Nathan, D; Yu, JS; Nockels, RP			Treatment with genetically engineered fibroblasts producing NGF or BDNF can accelerate recovery from traumatic spinal cord injury in the adult rat	NEUROREPORT			English	Article						spinal cord contusion; spinal cord injury; nerve growth factor; brain-derived neurotrophic factor; neurotrophin; transplantation; neuroprotection	NERVE GROWTH-FACTOR; FACTOR RECEPTOR; NEURONS; NEUROTROPHINS; LOCALIZATION; DISEASE; LESIONS; PREVENT; SYSTEM; DEATH	WE tested the hypothesis that NGF or BDNF can protect damaged neural structures following spinal cord injury. Spinal contusions were produced in adult rats by a weight drop method. Thereafter, unmodified Rat 1 fibroblasts or fibroblasts engineered to secrete NGF or BDNF were injected into the injury site. Weekly assessments of recovery were made for 6 weeks using a locomotor rating scale. All rats were immediately paraplegic, then began to recover. At 1 week after injury, the ratings of locomotor performance in rats implanted with NGF- or BDNF-secreting fibroblasts were significantly increased over those of rats implanted with unmodified fibroblasts. This trend toward enhanced recovery persisted during the duration of the experiment, although the difference became smaller. Histological examination after 6 weeks showed a larger cross-sectional area of spinal cord at the maximal injury site in the animals treated with NGF or BDNF. these results demonstrate a significant biological effect of treatment with neurotrophins in traumatic spinal cord injury.	SAN FRANCISCO GEN HOSP,SAN FRANCISCO,CA 94143; MASSACHUSETTS GEN HOSP,NEUROSURG SERV,BOSTON,MA 02129; HARVARD UNIV,SCH MED,BOSTON,MA 02129	Kim, DH (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT NEUROSURG,SAN FRANCISCO,CA 94143, USA.			Kim, Dong/0000-0002-1523-6396; Yu, John/0000-0003-1230-8494; Rui, Yanning/0000-0002-4482-5579			BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; BECK E, 1982, GENE, V19, P327, DOI 10.1016/0378-1119(82)90023-3; BECK T, 1994, J CEREBR BLOOD F MET, V14, P689, DOI 10.1038/jcbfm.1994.86; BOTHWELL M, 1995, ANNU REV NEUROSCI, V18, P223, DOI 10.1146/annurev.neuro.18.1.223; CONSTANTINI S, 1994, J NEUROSURG, V80, P97, DOI 10.3171/jns.1994.80.1.0097; DAVIES AM, 1994, J NEUROBIOL, V25, P1334, DOI 10.1002/neu.480251103; DIENER PS, 1994, NEUROREPORT, V5, P1913, DOI 10.1097/00001756-199410000-00018; EIDE FF, 1993, EXP NEUROL, V121, P200, DOI 10.1006/exnr.1993.1087; ERKENSTEIN F, 1988, BRAIN RES, V446, P149; FRIEDMAN B, 1995, J NEUROSCI, V15, P1044; FRIM DM, 1993, NEUROREPORT, V4, P367, DOI 10.1097/00001756-199304000-00006; FRIM DM, 1994, P NATL ACAD SCI USA, V91, P5104, DOI 10.1073/pnas.91.11.5104; GALL C, 1989, SCIENCE, V24, P758; KOLIATSOS VE, 1990, J NEUROSCI, V10, P3801; LINDVALL O, 1994, TRENDS NEUROSCI, V17, P490, DOI 10.1016/0166-2236(94)90139-2; OLSON L, 1993, EXP NEUROL, V124, P5, DOI 10.1006/exnr.1993.1167; PECHAN PA, 1995, NEUROREPORT, V6, P660; RENDE M, 1993, J COMP NEUROL, V338, P560, DOI 10.1002/cne.903380406; REYNOLDS ME, 1991, BRAIN RES, V559, P149, DOI 10.1016/0006-8993(91)90298-A; SCHNELL L, 1994, NATURE, V367, P169; SHIGENO T, 1991, J NEUROSCI, V11, P2914; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; TUSZYNSKI MH, 1994, EXP NEUROL, V129, P1	23	76	83	0	1	RAPID SCIENCE PUBLISHERS	LONDON	2-6 BOUNDARY ROW, LONDON, ENGLAND SE1 8NH	0959-4965			NEUROREPORT	Neuroreport	SEP 2	1996	7	13					2221	2225		10.1097/00001756-199609020-00033			5	Neurosciences	Neurosciences & Neurology	WD441	WOS:A1996WD44100035	8930993				2021-06-18	
J	Prasad, K				Prasad, K			The Glasgow coma scale: A critical appraisal of its clinimetric properties	JOURNAL OF CLINICAL EPIDEMIOLOGY			English	Article						Glasgow Coma Scale; reproducibility of results; sensitivity and specificity; brain injuries; neurological examination	SEVERE HEAD-INJURY; ASSESSING IMPAIRED CONSCIOUSNESS; OBSERVER VARIABILITY; EVOKED-POTENTIALS; TRAUMATIC COMA; INSTRUMENTS; PROGNOSIS; LEVEL; SCORE; SUM	The Glasgow Coma Scale is a commonly used instrument in clinical practice, This article examines the published evidence to assess whether the scale possesses the requisite clinimetric properties. Articles describing and using the scale were located through a MEDLINE search. The clinimetric properties of the scale were appraised using the methodological principles of sensibility, reliability, validity, and responsiveness. The scale has a good sensibility and reliability (intraclass correlation coefficient, 0.8 to 1 for trained users). It has a well established cross sectional construct validity. Its predictive validity in traumatic coma, when combined with age and brainstem reflexes, is good in the generating sample (sensitivity, 79 to 97%; specificity, 84-97%) but has not been tested in an external validation sample. Its longitudinal construct validity has not been studied adequately. Thus, the scale is an established discriminative instrument but its validity as a predictive and an evaluative instrument has not yet been studied adequately.		Prasad, K (corresponding author), ALL INDIA INST MED SCI,CTR NEUROSCI,ROOM 704,7TH FLOOR,NEW DELHI 110029,INDIA.						BAKAY RAE, 1983, J NEUROSURG, V58, P27, DOI 10.3171/jns.1983.58.1.0027; BISHARA SN, 1992, BRAIN INJURY, V4, P373; BORN JD, 1985, NEUROSURGERY, V16, P595, DOI 10.1227/00006123-198505000-00002; BOUZARTH WF, 1978, J NEUROSURG, V49, P477; DEYO RA, 1986, J CHRON DIS, V39, P897, DOI 10.1016/0021-9681(86)90038-X; Feinstein AR., 1987, CLINIMETRICS; FRANKE CL, 1992, J NEUROL NEUROSUR PS, V55, P653, DOI 10.1136/jnnp.55.8.653; GUYATT G, 1987, J CHRON DIS, V40, P171, DOI 10.1016/0021-9681(87)90069-5; Hotelling H, 1933, J EDUC PSYCHOL, V24, P417, DOI 10.1037/h0071325; Hotelling H, 1933, J EDUC PSYCHOL, V24, P498, DOI 10.1037/h0070888; Ingersoll G L, 1987, Crit Care Nurse, V7, P26; JAESCHKE R, 1989, CONTROL CLIN TRIALS, V10, P407, DOI 10.1016/0197-2456(89)90005-6; JAGGER J, 1983, LANCET, V2, P97; JENNETT B, 1979, J NEUROSURG, V50, P271; JENNETT B, 1977, LANCET, V1, P878; KIRSHNER B, 1985, J CHRON DIS, V38, P27, DOI 10.1016/0021-9681(85)90005-0; KOZIOL JA, 1990, J NEUROL, V237, P461, DOI 10.1007/BF00314762; LANGFITT TW, 1982, CLIN NEUR, V29, P353; LEVY DE, 1981, ANN INTERN MED, V94, P293, DOI 10.7326/0003-4819-94-3-293; LINDSAY KW, 1981, J NEUROL NEUROSUR PS, V44, P796, DOI 10.1136/jnnp.44.9.796; LINDSAY KW, 1983, J NEUROSURG, V58, P57, DOI 10.3171/jns.1983.58.1.0057; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; MULLIE A, 1988, LANCET, V1, P137; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; ROWLEY G, 1991, LANCET, V337, P535, DOI 10.1016/0140-6736(91)91309-I; SACCO RL, 1990, ARCH NEUROL-CHICAGO, V47, P1181, DOI 10.1001/archneur.1990.00530110035013; STANCZAK DE, 1984, J NEUROSURG, V60, P955, DOI 10.3171/jns.1984.60.5.0955; STARMARK JE, 1988, HUM TOXICOL, V7, P551, DOI 10.1177/096032718800700606; STARMARK JE, 1988, J NEUROSURG, V69, P699, DOI 10.3171/jns.1988.69.5.0699; Steiner DL, 1989, HLTH MEASUREMENT SCA; SUGIURA K, 1983, NEUROSURGERY, V12, P411, DOI 10.1227/00006123-198304000-00007; TEASDALE G, 1983, LANCET, V2, P678; TEASDALE G, 1978, J NEUROL NEUROSUR PS, V41, P603, DOI 10.1136/jnnp.41.7.603; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; TEASDALE G, 1974, LANCET, V2, P81	36	76	80	0	6	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB	0895-4356			J CLIN EPIDEMIOL	J. Clin. Epidemiol.	JUL	1996	49	7					755	763		10.1016/0895-4356(96)00013-3			9	Health Care Sciences & Services; Public, Environmental & Occupational Health	Health Care Sciences & Services; Public, Environmental & Occupational Health	VA007	WOS:A1996VA00700008	8691225				2021-06-18	
J	SALVANT, JB; MUIZELAAR, JP; MORAWETZ, RB; GROSSMAN, RG				SALVANT, JB; MUIZELAAR, JP; MORAWETZ, RB; GROSSMAN, RG			CHANGES IN CEREBRAL BLOOD-FLOW AND METABOLISM RELATED TO THE PRESENCE OF SUBDURAL-HEMATOMA	NEUROSURGERY			English	Article						CEREBRAL BLOOD FLOW; HEAD INJURY; SUBDURAL HEMATOMA	HEAD-INJURED PATIENTS; COMPUTERIZED-TOMOGRAPHY; AUTO-REGULATION; BRAIN INJURY; CIRCULATION; PRESSURE; ISCHEMIA; VOLUME	ACUTE SUBDURAL HEMATOMA (SDH) remains an important factor in head injury. The early effects of SDH on cerebral blood flow (CBF) and cerebral metabolic rate of oxygen consumption (CMRO2) in humans have not been clearly demonstrated. Patients admitted to the Medical College of Virginia with severe closed-head injury between 1982 and 1990 were studied with Xenon-133 regional CBF measurement. Data were reviewed retrospectively with regard to the presence of SDH (n = 54). A comparison group consisted of patients with head injuries without mass lesions or midline shift on admission computed tomographic scans (n = 76). CBF measurements made in patients less than 16 years of age, with concurrent administrations of mannitol or vasopressors, or with cerebral perfusion pressure under 50 mm Hg were excluded. CBF measurements were made on multiple occasions during the first 6 days after injury, and in many instances, simultaneous determinations of cerebral arteriovenous oxygen difference (AVDO2) were made through sampling of jugular bulb and arterial oxygen content. Not all patients underwent CBF measurements on each day. Differences in mean CBF, CMRO2, and AVDO2 were evaluated on each day after injury with the application of Student's t-test for independent groups. Significant reductions in CBF were demonstrated in patients with SDH on Days 1 (P < 0.0005) and 2 (P < 0.01). CMRO2 differed notably on Days 1 (P < 0.005) and 2 (P < 0.05) in patients with SDH, but when corrected for the lower Glasgow Coma Score in patients with SDH, the P values were only 0.07 and 0.12, respectively (analysis of covariance). CBF less-than-or-equal-to 18 ml/100 g/min (the threshold for infarction) occurred in 9% of patients with SDH within the first 24 hours, compared with none in those patients without mass lesions (p < 0.05 chi2). Mean PaCO2 values were compared, in which CBF was significantly reduced and no differences between groups could be demonstrated. These data demonstrate clear reductions in CBF that are paralleled by reduction in CMRO2 in the first 48 hours after injury in patients with SDH. These changes were not associated with increased AVDO2 in most patients. The lack of increased AVDO2 suggests that reductions in CBF may be related to diminished energy requirements or diminished ability for normal oxidative metabolism of the more severely injured brain.		SALVANT, JB (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DIV NEUROSURG,BOX 631 MCU STN,RICHMOND,VA 23298, USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-12587] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS012587, P01NS012587] Funding Source: NIH RePORTER		BOUMA GJ, 1992, J NEUROSURG, V77, P15, DOI 10.3171/jns.1992.77.1.0015; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; CLUBB RJ, 1980, J NEUROSURG, V52, P189, DOI 10.3171/jns.1980.52.2.0189; DESALLES AAF, 1987, NEUROSURGERY, V21, P45, DOI 10.1227/00006123-198707000-00009; HANSON EJ, 1975, CIRC RES, V36, P18, DOI 10.1161/01.RES.36.1.18; JONES TH, 1981, J NEUROSURG, V54, P773, DOI 10.3171/jns.1981.54.6.0773; KUHL DE, 1980, J NEUROSURG, V52, P309, DOI 10.3171/jns.1980.52.3.0309; KURODA Y, 1992, NEUROSURGERY, V30, P687; LANGFITT TW, 1986, J NEUROSURG, V64, P760, DOI 10.3171/jns.1986.64.5.0760; Mendelow A D, 1984, Neurol Res, V6, P189; MUIZELAAR JP, 1984, J NEUROSURG, V61, P700, DOI 10.3171/jns.1984.61.4.0700; MUIZELAAR JP, 1989, J NEUROSURG, V71, P72, DOI 10.3171/jns.1989.71.1.0072; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; MUIZELAAR JP, 1984, ADV NEUROTRAUMATOLOG, P92; OBRIST WD, 1979, NEURAL TRAUMA, P41; OBRIST WD, 1980, CEREBRAL CIRCULATION, P119; OBRIST WD, 1975, CEREBRAL CIRCULATION, P398; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; Petruk KC, 1973, STROKE, V4, P431, DOI 10.1161/01.STR.4.3.431; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; SCHETTINI A, 1989, J NEUROSURG, V71, P578, DOI 10.3171/jns.1989.71.4.0578; SIESJO BK, 1984, J NEUROSURG, V60, P883, DOI 10.3171/jns.1984.60.5.0883; SUWANWELA C, 1972, J NEUROSURG, V36, P314, DOI 10.3171/jns.1972.36.3.0314; TRAYSTMAN RJ, 1991, J APPL PHYSIOL, V71, P1185; WEBER M, 1990, NEUROSURGERY, V27, P106, DOI 10.1227/00006123-199007000-00015	26	76	77	0	0	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0148-396X			NEUROSURGERY	Neurosurgery	SEP	1993	33	3					387	393					7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	LV014	WOS:A1993LV01400006	8413868				2021-06-18	
J	FEENEY, DM; WEISEND, MP; KLINE, AE				FEENEY, DM; WEISEND, MP; KLINE, AE			NORADRENERGIC PHARMACOTHERAPY, INTRACEREBRAL INFUSION AND ADRENAL TRANSPLANTATION PROMOTE FUNCTIONAL RECOVERY AFTER CORTICAL DAMAGE	JOURNAL OF NEURAL TRANSPLANTATION & PLASTICITY			English	Article						TRAUMATIC BRAIN INJURY; STROKE; FUNCTIONAL RECOVERY; SOFT EXCITOTOXICITY HYPOTHESIS; DIASCHISIS; ADRENAL GRAFTING	SENSORIMOTOR CORTEX INJURY; RECEPTOR ANTAGONIST; LOCOMOTOR FUNCTION; MOTOR RECOVERY; BEAM-WALKING; RAT-BRAIN; AMPHETAMINE; NOREPINEPHRINE; RELEASE; EXPERIENCE	The research described in this review briefly summarizes evidence that short term pharmacological enhancement of noradrenergic (NA) synaptic activity, combined with symptom relevant experience (SRE), promotes functional recovery of some symptoms of cortical damage in rat, cat and human beings even when treatment is initiated from days to weeks after injury. A summary is provided of the numerous drugs tested in rodent cortical injury models which have been proven useful for predicting beneficial or harmful effects on behavioral outcome in human stroke. The pattern of drug effects indicates a central role for NA in functional recovery. Additionally, studies of the effects of direct intraventricular infusion of monoamine neurotransmitters are reviewed and further support the hypothesized role of NA in recovery from some symptoms of cortical injury. The site of NA/SRE interaction to promote recovery from hemiplegia apparently involves the cerebellar hemisphere contralateral to the cortical injury. Microinfusions of NA into the contra- but not ipsilateral cerebellar hemisphere dramatically enhance recovery. Furthermore, like its systemic action, microinfusion of the alpha(1)-NA receptor antagonist, phenoxybenzamine, reinstates hemiplegia. A ''permanent'' symptom of motor cortex injury in the cat is the complete loss of tactile placing contralateral to the injury which does not spontaneously recover for as long as seven years after ablation. This postural reflex is temporarily restored for 8-12 hours following amphetamine administration. However, this permanently lost reflex can be enduringly restored by transplanting catecholamine secreting adrenal tissue into the wound cavity. The experiment is reviewed in detail and involves chromaffin cell autografts into the frontal cortex ablation wound cavity producing a restoration of tactile placing for the 7-10 month duration of the study. This enduring restoration of tactile placing is considered a result of the release of catecholamines into the CNS from the grafted chromaffin cells found, by histochemical methods, surviving 7-10 months after transplant. Lastly, we attribute these delayed treatment effects to an attenuation of a diaschisis, or remote functional depression, in morphologically intact areas anatomically connected to the area of injury. The widespread reduction of glycolytic and oxidative metabolism, produced by focal cortical injury, is normalized by the same treatment which alleviates symptoms and is worsened by drugs which exacerbate deficits. These data support the hypothesis that providing SRE during a period of enhanced NA synaptic activity produces an enduring functional recovery after cortical injury by attenuating remote functional depression. This treatment for enhancing recovery is especially attractive since it is effective even when begun weeks after cortical damage.	UNIV NEW MEXICO,DEPT PHYSIOL,ALBUQUERQUE,NM 87131	FEENEY, DM (corresponding author), UNIV NEW MEXICO,DEPT PSYCHOL,LOGAN HALL,ALBUQUERQUE,NM 87131, USA.						ALBERS GW, 1989, ANN NEUROL, V25, P398, DOI 10.1002/ana.410250412; AMASSIAN VE, 1972, CORTICOTHALAMIC PROJ, P395; AZZARO AJ, 1973, BIOCHEM PHARMACOL, V22, P2801, DOI 10.1016/0006-2952(73)90147-0; BARELA PB, UNPUB YOHIMBINE FACI; BEANI L, 1986, J PHARMACOL EXP THER, V236, P230; BOGEN J, 1975, J NEUROBIOL, V6, P125, DOI 10.1002/neu.480060115; BORUCKI S J, 1992, Neurology, V42, P329; BOYESON MG, 1992, BRAIN RES BULL, V29, P435, DOI 10.1016/0361-9230(92)90080-H; BOYESON MG, 1990, PHARMACOL BIOCHEM BE, V35, P497, DOI 10.1016/0091-3057(90)90279-Q; BOYESON MG, 1993, RESTOR NEUROL NEUROS, V5, P283, DOI 10.3233/RNN-1993-5404; BOYESON MG, 1991, RESTOR NEUROL NEUROS, V3, P227, DOI 10.3233/RNN-1991-3501; BOYESON MG, 1992, BEHAV NEUROSCI, V106, P964, DOI 10.1037/0735-7044.106.6.964; BOYESON MG, 1993, IN PRESS AM J PHYS M; COLE JR, 1985, ARCH PHYS MED REHAB, V66, P38; Cools AR, 1977, COCAINE OTHER STIMUL, P97; CRISOSTOMO EA, 1988, ANN NEUROL, V23, P94, DOI 10.1002/ana.410230117; DIETRICH WD, 1990, STROKE, V21, P147; DUNBAR G, 1989, NEUR ABSTR, V19, P132; FEENEY D M, 1990, Society for Neuroscience Abstracts, V16, P779; FEENEY DM, 1990, CAN J PSYCHOL, V44, P233, DOI 10.1037/h0084243; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FEENEY DM, 1985, BRAIN RES, V342, P352, DOI 10.1016/0006-8993(85)91135-7; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FEENEY DM, 1987, CRIT REV NEUROBIOL, V3, P135; FEENEY DM, 1985, PHYSIOL PSYCHOL, V13, P197; FEENEY DM, 1983, PSYCHOPHARMACOLOGY, V79, P67, DOI 10.1007/BF00433018; FEENEY DM, 1988, PHARM APPROACHES TRE, P121; FEENEY DM, 1991, J NEUROL REHABIL, V5, P113; FEENEY DM, 1987, FEASIBILITY STUDY PH; Fuxe K., 1970, AMPHETAMINES RELATED, P257; GOLDSTEIN LB, 1992, BRAIN RES, V580, P129, DOI 10.1016/0006-8993(92)90936-4; GOLDSTEIN LB, 1990, BRAIN RES, V508, P305, DOI 10.1016/0006-8993(90)90413-6; GOLDSTEIN LB, 1989, ANN NEUROL, V26, P157; GOLDSTEIN LB, 1990, BEHAV NEUROSCI, V104, P318; GOLDSTEIN LB, 1991, J NEUROL REHABIL, V5, P129; HOMAN R, 1990, Society for Neuroscience Abstracts, V16, P439; HOVDA DA, 1984, BRAIN RES, V298, P358, DOI 10.1016/0006-8993(84)91437-9; HURWITZ BE, 1991, STROKE, V22, P648, DOI 10.1161/01.STR.22.5.648; JONASON KR, 1970, J COMP PHYSIOL PSYCH, V73, P47, DOI 10.1037/h0030013; KANNEL WB, 1983, VASCULAR DISEASE CEN, P45; Kline A. E., 1993, Society for Neuroscience Abstracts, V19, P1878; KLINE AE, 1993, UNPUB METHYLPHENIDAT; KROBERT KA, 1993, IN PRESS J NEUROCHEM; KUCZENSKI R, 1992, SYNAPSE, V11, P164, DOI 10.1002/syn.890110210; Kuczenski R, 1983, STIMULANTS NEUROCHEM, P31; LHEUREUX R, 1986, J NEUROCHEM, V46, P1794; MACKENZIE EJ, 1988, JAMA-J AM MED ASSOC, V260, P3290, DOI 10.1001/jama.260.22.3290; MALING HM, 1946, J NEUROPHYSIOL, V9, P379; MEYER PM, 1963, J COMP PHYSIOL PSYCH, V56, P402, DOI 10.1037/h0049297; NIDDAM R, 1985, N-S ARCH PHARMACOL, V329, P123, DOI 10.1007/BF00501200; OGREN SO, 1983, NEUROSCI LETT, V43, P327, DOI 10.1016/0304-3940(83)90209-4; RITCHIE GD, 1976, EXP NEUROL, V53, P227, DOI 10.1016/0014-4886(76)90294-6; Robins M, 1981, STROKE S1, V12, P145; SALO A A, 1987, Society for Neuroscience Abstracts, V13, P1268; SCHEELKRUGER J, 1971, EUR J PHARMACOL, V14, P47, DOI 10.1016/0014-2999(71)90121-X; SCHWOB JE, 1980, NEUROSCIENCE, V5, P991, DOI 10.1016/0306-4522(80)90181-5; SLOVITER RS, 1978, J PHARMACOL EXP THER, V206, P348; SUTTON R L, 1989, Brain Dysfunction, V2, P201; SUTTON RL, 1992, RESTOR NEUROL NEUROS, V4, P1, DOI 10.3233/RNN-1992-4101; SUTTON RL, 1989, BEHAV NEUROSCI, V103, P837, DOI 10.1037/0735-7044.103.4.837; SUTTON RL, 1987, J HEAD TRAUMA REHAB, V2, P50; SUTTON RL, IN PRESS NEUROLOGICA; TRUNKEY D, 1985, TRAUMA CENTRAL NERVO, P9; Walker A, 1981, STROKE S1, V12, P113; WALKERBATSON D, 1992, RESTOR NEUROL NEUROS, V4, P47, DOI 10.3233/RNN-1992-4106; 1989, INTERAGENCY HEAD INJ; 1988, REHAB BRIEF, V9, P1	67	76	77	0	3	FREUND PUBLISHING HOUSE	LONDON	STE 500, CHESHAM HOUSE, 150 REGENT ST, LONDON, ENGLAND W1R 5FA	0792-8483			J NEURAL TRANSP PLAS	J. Neural Transplant. Plast.	JUL-SEP	1993	4	3					199	213		10.1155/NP.1993.199			15	Neurosciences; Transplantation	Neurosciences & Neurology; Transplantation	NG435	WOS:A1993NG43500004	8018752	Green Published, Other Gold			2021-06-18	
J	MUIR, JK; BOERSCHEL, M; ELLIS, EF				MUIR, JK; BOERSCHEL, M; ELLIS, EF			CONTINUOUS MONITORING OF POSTTRAUMATIC CEREBRAL BLOOD-FLOW USING LASER-DOPPLER FLOWMETRY	JOURNAL OF NEUROTRAUMA			English	Article							TRAUMATIC BRAIN INJURY; FLUID-PERCUSSION MODEL; RAT; MICROCIRCULATION; ABNORMALITIES; CATS	Traumatic brain injury causes alterations in cerebral blood flow that are thought to influence secondary pathophysiology and neurologic outcome in humans. Since it is difficult to study early changes in blood flow in head-injured patients, animal models of brain injury must be employed. However, techniques to monitor brain blood flow in animals are labor intensive and generally provide discontinuous flow measurements. The present study examines the application of laser-Doppler flowmetry for measurement of cerebral blood flow following experimental brain injury. This method allows continuous monitoring of local cerebral blood flow before, during, and after injury. Rats (n = 9) were prepared for lateral fluid percussion injury under barbiturate anesthesia. Injury (2.10 +/- 0.02 atm) was induced over the right parietal cortex, and blood flow was monitored in the contralateral cortex. Seconds after the peak hypertension after injury, blood flow in the left parietal cortex increased 226 % +/- 18% (xBAR +/- SEM). This increase was transient, with blood flow falling below control values within minutes. Five minutes after injury, blood flow was 83% +/- 8% of control, and at 1 h, this value had fallen to 56% +/- 6%. Blood flow at 60 min was 93% +/- 5% of control in the sham-injured group (n = 10). The reduction in cerebral blood flow in our laser-Doppler study was of similar magnitude as previously reported in rats injured at a similar intensity when blood flow was examined with radiolabeled microspheres. Given these results, we believe laser-Doppler flowmetry can be used to continuously monitor posttraumatic blood flow following experimental brain injury.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PHARMACOL & TOXICOL,BOX 613,MCV STN,RICHMOND,VA 23298					PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [12587, 27214] Funding Source: Medline		BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; ELLIS EF, 1991, J NEUROSURG, V75, P774, DOI 10.3171/jns.1991.75.5.0774; HABERL RL, 1989, AM J PHYSIOL, V256, pH1255; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MILLER JD, 1990, NEUROSURGERY, V27, P433, DOI 10.1227/00006123-199009000-00016; SHEPHERD AP, 1987, AM J PHYSIOL, V252, pG832; SOLOMON RA, 1985, STROKE, V16, P58, DOI 10.1161/01.STR.16.1.58; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; WEI EP, 1981, CIRC RES, V48, P95, DOI 10.1161/01.RES.48.1.95; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; YOUNG W, 1992, J NEUROTRAUM, V9, pS9; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289	16	76	78	0	3	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	WIN	1992	9	4					355	362		10.1089/neu.1992.9.355			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	KH753	WOS:A1992KH75300005	1291695				2021-06-18	
J	BROOKE, MM; PATTERSON, DR; QUESTAD, KA; CARDENAS, D; FARRELROBERTS, L				BROOKE, MM; PATTERSON, DR; QUESTAD, KA; CARDENAS, D; FARRELROBERTS, L			THE TREATMENT OF AGITATION DURING INITIAL HOSPITALIZATION AFTER TRAUMATIC BRAIN INJURY	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						AGITATION; BRAIN INJURY; PROPRANOLOL	PROPRANOLOL; BEHAVIOR	Agitation after traumatic brain injury is disruptive for patient care, distressing, and difficult to treat. The use of propranolol has been advocated to control agitation after brain injury. It reportedly lacks some of the deleterious cognitive and emotional effects of other medications and physical restraints. This study was designed to test if propranolol is effective in reducing agitated behavior. Subjects had traumatic closed-head injury treated at a combined Level I Trauma Center and Rehabilitation Center. Twenty-one subjects met the criteria of agitation and were treated with propranolol or placebo in a double-blind fashion. The intensity of agitation was significantly lower in the treatment group although the number of episodes were similar. The use of restraints was also significantly lower in the treatment group. The results support the effectiveness of propranolol in reducing the intensity of agitation during the initial hospitalization after closed-head injury.	UNIV WASHINGTON,SCH MED,SEATTLE,WA 98195	BROOKE, MM (corresponding author), TUFTS UNIV,SCH MED,DEPT REHABIL MED,136 HARRISON AVE,BOSTON,MA 02111, USA.				PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [CCR49-002570] Funding Source: Medline		BROOKE MM, 1992, ARCH PHYS MED REHAB, V73, P320, DOI 10.1016/0003-9993(92)90003-F; COLE J O, 1979, Mclean Hospital Journal, V4, P40; ELLIOTT FA, 1977, ANN NEUROL, V1, P489, DOI 10.1002/ana.410010516; GREENDYKE RM, 1986, J NERV MENT DIS, V174, P290, DOI 10.1097/00005053-198605000-00005; JOHNSON G, 1976, MED J AUSTRALIA, V1, P909, DOI 10.5694/j.1326-5377.1976.tb141167.x; PETRIE WM, 1981, LANCET, V1, P324; RAO N, 1985, ARCH PHYS MED REHAB, V66, P30; SWONGER AK, 1983, DRUGS THERAPY HDB PS, P305; Tyer PJ, 1975, BMJ-BRIT MED J, V2, P14; WHITLOCK FA, 1974, DRUGS, V8, P109, DOI 10.2165/00003495-197408020-00004; YEOH PN, 1968, J PHARM SCI, V57, P340, DOI 10.1002/jps.2600570227; YORKSTON NJ, 1974, BRIT MED J, V4, P633, DOI 10.1136/bmj.4.5945.633; YOUNG RR, 1975, NEW ENGL J MED, V293, P950, DOI 10.1056/NEJM197511062931902; YUDOFSKY S, 1981, AM J PSYCHIAT, V138, P218; YUDOFSKY SC, 1986, AM J PSYCHIAT, V143, P35; 1985, LANCET, V8448, P193	16	76	77	0	3	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	OCT	1992	73	10					917	921					5	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	JU061	WOS:A1992JU06100005	1417466				2021-06-18	
J	GIULIAN, D; JOHNSON, B; KREBS, JF; GEORGE, JK; TAPSCOTT, M				GIULIAN, D; JOHNSON, B; KREBS, JF; GEORGE, JK; TAPSCOTT, M			MICROGLIAL MITOGENS ARE PRODUCED IN THE DEVELOPING AND INJURED MAMMALIAN BRAIN	JOURNAL OF CELL BIOLOGY			English	Article							CENTRAL NERVOUS-SYSTEM; COLONY-STIMULATING FACTORS; EPIDERMAL GROWTH-FACTOR; GLIA-PROMOTING FACTORS; AMEBOID MICROGLIA; ASTROGLIAL PROLIFERATION; INTERLEUKIN-1; CELLS; MACROPHAGES; PEPTIDES	The central nervous system produces growth factors that stimulate proliferation of ameboid microglia during embryogenesis and after traumatic injury. Two microglial mitogens (MMs) are recovered from the brain of newborn rat. MM1 had an approximate molecular mass of 50 kD and a pI of approximately 6.8; MM2 has a molecular mass of 22 kD and a pI of approximately 5.2. These trypsin-sensitive proteins show specificity of action upon glia in vitro serving as growth factors for ameboid microglia but not astroglia or oligodendroglia. Although the MMs did not stimulate proliferation of blood monocytes or resident peritoneal macrophage, MM1 shows granulocyte macrophage colony-stimulating activity when tested upon bone marrow progenitor cells. Microglial mitogens may help to control brain mononuclear phagocytes in vivo. The MMs first appear in the cerebral cortex of rat during early development with peak levels around embryonic day E-20, a period of microglial proliferation. Microglial mitogens are also produced by traumatized brain of adult rats within 2 days after injury. When infused into the cerebral cortex, MM1 and MM2 elicit large numbers of mononuclear phagocytes at the site of injection. In vitro study shows that astroglia from newborn brain secrete MM2. These observations point to the existence of a regulatory system whereby secretion of proteins from brain glia help to control neighboring inflammatory responses.		GIULIAN, D (corresponding author), BAYLOR UNIV, DEPT NEUROL, HOUSTON, TX 77030 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS25637] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS025637] Funding Source: NIH RePORTER		BOHLEN P, 1973, ARCH BIOCHEM BIOPHYS, V155, P213, DOI 10.1016/S0003-9861(73)80023-2; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; DAEMS WT, 1980, RETICULOENDOTHELIAL, P549; DINARELLO CA, 1984, REV INFECT DIS, V6, P51, DOI 10.1016/S1359-6101(97)00023-3; FREI K, 1986, J IMMUNOL, V137, P3521; GIULIAN D, 1986, J CELL BIOL, V102, P812, DOI 10.1083/jcb.102.3.812; GIULIAN D, 1989, J NEUROSCI, V9, P4416; GIULIAN D, 1990, EOS-RIV IMMUNOL, V10, P15; GIULIAN D, 1988, J NEUROSCI, V8, P709; GIULIAN D, 1986, J EXP MED, V164, P594, DOI 10.1084/jem.164.2.594; GIULIAN D, 1986, J NEUROSCI, V6, P2163; GIULIAN D, 1985, J CELL BIOL, V101, P2411, DOI 10.1083/jcb.101.6.2411; GIULIAN D, 1987, J NEUROSCI RES, V18, P155, DOI 10.1002/jnr.490180123; GIULIAN D, 1985, SCIENCE, V228, P497, DOI 10.1126/science.3872478; GIULIAN D, 1990, ANN NEUROL, V27, P33, DOI 10.1002/ana.410270107; GIULIAN D, 1988, J NEUROSCI, V8, P4707; GIULIAN D, 1988, J NEUROSCI, V8, P2485; GIULIAN D, 1986, J CELL BIOL, V102, P803, DOI 10.1083/jcb.102.3.803; GRAEBER MB, 1988, NEUROSCI LETT, V85, P317, DOI 10.1016/0304-3940(88)90585-X; KOSKI IR, 1976, IN VITRO METHODS CEL, P359; LEUTZ A, 1981, CELL TISSUE RES, V220, P393; LIM R, 1989, P NATL ACAD SCI USA, V86, P3901, DOI 10.1073/pnas.86.10.3901; LING EA, 1981, ADV CELL NEUROBIOL, V2, P33; LORET C, 1989, J BIOL CHEM, V264, P8319; MATSUMOTO Y, 1985, CELL TISSUE RES, V239, P271; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MCMORRIS FA, 1988, J NEUROSCI RES, V21, P199, DOI 10.1002/jnr.490210212; METCALF D, 1985, SCIENCE, V229, P16, DOI 10.1126/science.2990035; METCALF D, 1984, HEMOPOIETIC COLONIES; NEVILLE DM, 1971, J BIOL CHEM, V246, P6328; NICOLA NA, 1979, J BIOL CHEM, V254, P5290; OEHMICHEN M, 1983, PROG NEUROPATH, V5, P277; PITAS RE, 1981, ARTERIOSCLEROSIS, V1, P177, DOI 10.1161/01.ATV.1.3.177; POEHLING HM, 1981, ELECTROPHORESIS, V2, P141, DOI 10.1002/elps.1150020304; PRUSS RM, 1981, DEV BRAIN RES, V2, P19, DOI 10.1016/0165-3806(81)90056-0; RICHARDSON WD, 1988, CELL, V53, P309, DOI 10.1016/0092-8674(88)90392-3; RIOHORTEGA P, 1932, CYTOLOGY CELLULAR PA, P481; WONG DM, 1984, METHOD ENZYMOL, V108, P307	40	76	77	0	2	ROCKEFELLER UNIV PRESS	NEW YORK	950 THIRD AVE, 2ND FLR, NEW YORK, NY 10022 USA	0021-9525	1540-8140		J CELL BIOL	J. Cell Biol.	JAN	1991	112	2					323	333		10.1083/jcb.112.2.323			11	Cell Biology	Cell Biology	ET174	WOS:A1991ET17400013	1988464	Green Published, Bronze			2021-06-18	
J	POVLISHOCK, JT; BECKER, DP; MILLER, JD; JENKINS, LW; DIETRICH, WD				POVLISHOCK, JT; BECKER, DP; MILLER, JD; JENKINS, LW; DIETRICH, WD			MORPHOPATHOLOGIC SUBSTRATES OF CONCUSSION	ACTA NEUROPATHOLOGICA			English	Article									MED COLL VIRGINIA,DEPT NEUROL SURG,RICHMOND,VA 23298	POVLISHOCK, JT (corresponding author), MED COLL VIRGINIA,DEPT ANAT,RICHMOND,VA 23298, USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS020193] Funding Source: Medline		ADAMS JC, 1976, J COMP NEUROL, V170, P107, DOI 10.1002/cne.901700108; ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; BASBAUM AI, 1976, P NATL ACAD SCI USA, V73, P4685, DOI 10.1073/pnas.73.12.4685; BOWSHER D, 1970, J ANAT, V106, P23; BOWSHER D, 1971, BRAIN RES, V28, P443, DOI 10.1016/0006-8993(71)90055-2; BROWN WJ, 1972, AM J PATHOL, V67, P41; CHASON JL, 1958, J NEUROSURG, V15, P135, DOI 10.3171/jns.1958.15.2.0135; CHASON JL, 1966, J TRAUM, V6, P767, DOI 10.1097/00005373-196611000-00008; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; FRIEDE RL, 1961, ARCH NEUROL-CHICAGO, V4, P449, DOI 10.1001/archneur.1961.00450100097012; GRAHAM RC, 1966, J HISTOCHEM CYTOCHEM, V14, P291, DOI 10.1177/14.4.291; GREENBERG RP, 1977, J NEUROSURG, V47, P163, DOI 10.3171/jns.1977.47.2.0163; GRIFFITHS IR, 1974, J NEUROL SCI, V22, P291, DOI 10.1016/0022-510X(74)90002-1; GROAT RA, 1944, J NEUROSURG, V2, P26; KEEFER DA, 1978, BRAIN RES, V140, P15, DOI 10.1016/0006-8993(78)90235-4; KLATZO IGOR, 1962, ACTA NEUROPATHOLOGICA, V2, P144; LAVAIL JH, 1974, J COMP NEUROL, V157, P303, DOI 10.1002/cne.901570304; NYBERGHA.R, 1965, J COMP NEUROL, V124, P71, DOI 10.1002/cne.901240107; OLSSON Y, 1970, ACTA NEUROPATHOL, V16, P103, DOI 10.1007/BF00687665; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PERSSON L, 1976, ACTA NEUROPATHOL, V34, P125, DOI 10.1007/BF00684663; POVLISHOCK JT, 1978, BRAIN RES, V153, P223, DOI 10.1016/0006-8993(78)90404-3; POVLISHOCK JT, 1978, NEURAL TRAUMA SEMINA, V4; RINDER L, 1968, ACTA NEUROPATHOL, V11, P183; SASAKI S, 1976, ACTA NEUROPATHOL, V36, P363, DOI 10.1007/BF00699641; SEITE R, 1971, BRAIN RES, V34, P277, DOI 10.1016/0006-8993(71)90281-2; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; STRICH SJ, 1961, LANCET, V2, P443; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; TURNER PT, 1974, BRAIN RES, V74, P305, DOI 10.1016/0006-8993(74)90585-X; VANEGAS H, 1978, J COMP NEUROL, V177, P193, DOI 10.1002/cne.901770203; WARD AA, 1966, HEAD INJURY C P	32	76	76	0	1	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010	0001-6322			ACTA NEUROPATHOL	Acta Neuropathol.		1979	47	1					1	11		10.1007/BF00698266			11	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	HB010	WOS:A1979HB01000001	463502				2021-06-18	
J	FISHER, CM				FISHER, CM			CONCUSSION AMNESIA	NEUROLOGY			English	Article																BLONSTEIN JL, 1957, BRIT MED J, V1, P362, DOI 10.1136/bmj.1.5015.362; BURTON HL, 1931, P ROY SOC MED, V24, P1405; CRITCHLEY M, 1957, BMJ-BRIT MED J, V1, P357, DOI 10.1136/bmj.1.5015.357; FIELDS WS, 1963, 10 S ANN M HOUST NEU; FISHER CM, 1964, ACTA PSYCHIAT KBH S9, V40; QUIGLEY TB, 1957, HARV PUBL HLTH ALUMN, V31, P19; SYMONDS C, 1962, LANCET, V1, P1; UNPUBLISHED PERSONAL	8	76	76	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0028-3878			NEUROLOGY	Neurology		1966	16	8					826	&		10.1212/WNL.16.8.826			0	Clinical Neurology	Neurosciences & Neurology	80732	WOS:A19668073200017					2021-06-18	
J	GURDJIAN, ES; LISSNER, HR; WEBSTER, JE; LATIMER, FR; HADDAD, BF				GURDJIAN, ES; LISSNER, HR; WEBSTER, JE; LATIMER, FR; HADDAD, BF			STUDIES ON EXPERIMENTAL CONCUSSION - RELATION OF PHYSIOLOGIC EFFECT TO TIME DURATION OF INTRACRANIAL PRESSURE INCREASE AT IMPACT	NEUROLOGY			English	Article																GURDJIAN ES, 1953, NEUROLOGY, V3, P417, DOI 10.1212/WNL.3.6.417; Walker AE, 1945, A RES NERV MENT DIS, V24, P437	2	76	78	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0028-3878			NEUROLOGY	Neurology		1954	4	9					674	681		10.1212/WNL.4.9.674			8	Clinical Neurology	Neurosciences & Neurology	YD622	WOS:A1954YD62200004	13214267				2021-06-18	
J	Cross, M; Kemp, S; Smith, A; Trewartha, G; Stokes, K				Cross, Matthew; Kemp, Simon; Smith, Andrew; Trewartha, Grant; Stokes, Keith			Professional Rugby Union players have a 60% greater risk of time loss injury after concussion: a 2-season prospective study of clinical outcomes	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							STABILITY FOLLOWING CONCUSSION; TRAUMATIC BRAIN-INJURY; CONSENSUS STATEMENT; FOOTBALL PLAYERS; RECOVERY; SPORT; EPIDEMIOLOGY; SYMPTOMS; RATES; CUP	Aim To investigate incidence of concussion, clinical outcomes and subsequent injury risk following concussion. Methods In a two-season ( 2012/2013, 2013/2014) prospective cohort study, incidence of diagnosed match concussions ( injuries/1000 h), median time interval to subsequent injury of any type ( survival time) and time spent at each stage of the graduated return to play pathway were determined in 810 professional Rugby Union players ( 1176 player seasons). Results Match concussion incidence was 8.9/1000 h with over 50% occurring in the tackle. Subsequent incidence of any injury for players who returned to play in the same season following a diagnosed concussion ( 122/1000 h, 95% CI 106 to 141) was 60% higher ( IRR 1.6, 95% CI 1.4 to 1.8) than for those who did not sustain a concussion ( 76/1000 h, 95% CI 72 to 80). Median time to next injury following return to play was shorter following concussion ( 53 days, 95% CI 41 to 64) than following non-concussive injuries ( 114 days, 95% CI 85 to 143). 38% of players reported recurrence of symptoms or failed to match their baseline neurocognitive test during the graduated return to play protocol. Summary and conclusions Players who returned to play in the same season after a diagnosed concussion had a 60% greater risk of time-loss injury than players without concussion. A substantial proportion of players reported recurrence of symptoms or failed to match baseline neurocognitive test scores during graduated return to play. These data pave the way for trials of more conservative and comprehensive graduated return to play protocols, with a greater focus on active rehabilitation.	[Cross, Matthew; Trewartha, Grant; Stokes, Keith] Univ Bath, Dept Hlth, Bath BA2 7AY, Avon, England; [Kemp, Simon] Rugby Football Union, Twickenham, England; [Smith, Andrew] Mid Yorkshire Hosp NHS Trust, Wakefield, England; [Smith, Andrew] Premiership Rugby, Twickenham, England	Stokes, K (corresponding author), Univ Bath, Dept Hlth, Bath BA2 7AY, Avon, England.	K.Stokes@bath.ac.uk	Stokes, Keith/C-2605-2009	Stokes, Keith/0000-0002-5049-2838; Kemp, Simon/0000-0002-3250-2713; Trewartha, Grant/0000-0002-9021-8956	Rugby Football Union; Premiership Rugby	Rugby Football Union and Premiership Rugby.	Baillargeon A, 2012, BRAIN INJURY, V26, P211, DOI 10.3109/02699052.2012.654590; Broglio SP, 2015, CLIN SPORT MED, V34, P213, DOI 10.1016/j.csm.2014.12.005; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Fraas MR, 2014, PHYS THER SPORT, V15, P136, DOI 10.1016/j.ptsp.2013.08.002; Fuller CW, 2007, BRIT J SPORT MED, V41, P328, DOI 10.1136/bjsm.2006.033282; Fuller CW, 2015, BRIT J SPORT MED, V49, P478, DOI 10.1136/bjsports-2013-093381; Fuller CW, 2013, J SPORT SCI, V31, P795, DOI 10.1080/02640414.2012.753156; Guskiewicz KM, 2013, BRIT J SPORT MED, V47, P289, DOI 10.1136/bjsports-2013-092225; Howell DR, 2015, MED SCI SPORT EXER, V47, P673, DOI 10.1249/MSS.0000000000000462; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kemp SPT, 2008, CLIN J SPORT MED, V18, P227, DOI 10.1097/JSM.0b013e31816a1c9a; Kutcher JS, 2013, BRIT J SPORT MED, V47, P299, DOI 10.1136/bjsports-2013-092257; Louey AG, 2014, ARCH CLIN NEUROPSYCH, V29, P432, DOI 10.1093/arclin/acu020; Lynall RC, 2015, MED SCI SPORT EXER, V47, P2487, DOI 10.1249/MSS.0000000000000716; Makdissi M, 2013, BRIT J SPORT MED, V47, P308, DOI 10.1136/bjsports-2013-092255; Mayer AR, 2015, NEUROSCI BIOBEHAV R, V49, P8, DOI 10.1016/j.neubiorev.2014.11.016; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McCrory PR, 2002, PHYSICIAN SPORTSMED, V30, P43, DOI 10.3810/psm.2002.08.403; Nordstrom A, 2014, BRIT J SPORT MED, V48, P1447, DOI 10.1136/bjsports-2013-093406; Parker TM, 2005, CLIN BIOMECH, V20, P389, DOI 10.1016/j.clinbiomech.2004.12.004; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; Quarrie KL, 2007, J SPORT SCI, V25, P895, DOI 10.1080/02640410600944659; RFU, 2015, PREM RUGB INJ SURV P; Shahim P, 2016, J NEUROTRAUM, V33, P1995, DOI 10.1089/neu.2014.3741; Williams S, 2013, SPORTS MED, V43, P1043, DOI 10.1007/s40279-013-0078-1; World Rugby, 2014, IRB CONC MAN 2014	28	75	75	0	30	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	AUG	2016	50	15					926	931		10.1136/bjsports-2015-094982			6	Sport Sciences	Sport Sciences	DS7AR	WOS:000380935300010	26626266	Other Gold, Green Published			2021-06-18	
J	Akbar, M; Essa, MM; Daradkeh, G; Abdelmegeed, MA; Choi, Y; Mahmood, L; Song, BJ				Akbar, Mohammed; Essa, Musthafa Mohamed; Daradkeh, Ghazi; Abdelmegeed, Mohamed A.; Choi, Youngshim; Mahmood, Lubna; Song, Byoung-Joon			Mitochondrial dysfunction and cell death in neurodegenerative diseases through nitroxidative stress	BRAIN RESEARCH			English	Article						Oxidative stress; Mitochondrial dysfunction; Neuronal cell death; Neurodegenerative diseases; Post-translational protein modifications; Antioxidants; Translational research	NITRIC-OXIDE SYNTHASE; TRAUMATIC BRAIN-INJURY; DEPENDENT NEUROPROTECTIVE PROTEIN; MILD COGNITIVE IMPAIRMENT; TRANSGENIC MOUSE MODEL; ALZHEIMERS-DISEASE; OXIDATIVE STRESS; AMYLOID-BETA; PARKINSONS-DISEASE; S-NITROSYLATION	Mitochondria are important for providing cellular energy ATP through the oxidative phosphorylation pathway. They are also critical in regulating many cellular functions including the fatty acid oxidation, the metabolism of glutamate and urea, the anti-oxidant defense, and the apoptosis pathway. Mitochondria are an important source of reactive oxygen species leaked from the electron transport chain while they are susceptible to oxidative damage, leading to mitochondrial dysfunction and tissue injury. In fact, impaired mitochondrial function is commonly observed in many types of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, Huntington's disease, alcoholic dementia, brain ischemia-reperfusion related injury, and others, although many of these neurological disorders have unique etiological factors. Mitochondrial dysfunction under many pathological conditions is likely to be promoted by increased nitroxidative stress, which can stimulate post-translational modifications (PTMs) of mitochondrial proteins and/or oxidative damage to mitochondrial DNA and lipids. Furthermore, recent studies have demonstrated that various antioxidants, including naturally occurring flavonoids and polyphenols as well as synthetic compounds, can block the formation of reactive oxygen and/or nitrogen species, and thus ultimately prevent the PTMs of many proteins with improved disease conditions. Therefore, the present review is aimed to describe the recent research developments in the molecular mechanisms for mitochondrial dysfunction and tissue injury in neurodegenerative diseases and discuss translational research opportunities. Published by Elsevier B.V.	[Akbar, Mohammed; Abdelmegeed, Mohamed A.; Choi, Youngshim; Song, Byoung-Joon] NIAAA, Sect Mol Pharmacol & Toxicol, Lab Membrane Biochem & Biophys, NIH, Bethesda, MD USA; [Essa, Musthafa Mohamed; Daradkeh, Ghazi] Sultan Qaboos Univ, Coll Agr & Marine Sci, Dept Food Sci & Nutr, Muscat, Oman; [Essa, Musthafa Mohamed] Sultan Qaboos Univ, Ageing & Dementia Res Grp, Muscat, Oman; [Mahmood, Lubna] Qatar Univ, Dept Nutr Sci, Muscat, Qatar	Akbar, M; Song, BJ (corresponding author), NIAAA, Sect Mol Pharmacol & Toxicol, Lab Membrane Biochem & Biophys, NIH, Bethesda, MD USA.; Essa, MM (corresponding author), Sultan Qaboos Univ, Coll Agr & Marine Sci, Dept Food Sci & Nutr, Muscat, Oman.		Daradkeh, Ghazi/AAG-7759-2020; Essa, Mohamed/AAX-2596-2020	Musthafa Mohamed, Essa/0000-0001-7505-9785	National Institute on Alcohol Abuse and AlcoholismUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); Research Council, Oman [RC/AGR/FOOD/11/01]; Sultan Qaboos University, Oman [IG/AGR/FOOD/14/01]; KRIBB Research Initiative Program (Korean Biomedical Scientist Fellowship Program), Korea Research Institute of Bioscience and Biotechnology, Republic of Korea; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [ZIAAA000036] Funding Source: NIH RePORTER	The work is supported by the Intramural Program Fund of the National Institute on Alcohol Abuse and Alcoholism. The authors (MME and GD) also highly appreciate the research supports from the Research Council, Oman (RC/AGR/FOOD/11/01 to MME) and the internal grant (IG/AGR/FOOD/14/01) from Sultan Qaboos University, Oman. Youngshim Choi is supported by the KRIBB Research Initiative Program (Korean Biomedical Scientist Fellowship Program), Korea Research Institute of Bioscience and Biotechnology, Republic of Korea.	Abdelmegeed MA, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/149627; Abdelmegeed MA, 2013, FREE RADICAL BIO MED, V60, P211, DOI 10.1016/j.freeradbiomed.2013.02.018; Abdelmegeed MA, 2010, BIOCHEM PHARMACOL, V79, P57, DOI 10.1016/j.bcp.2009.07.016; Abdul-Muneer PM, 2015, MOL NEUROBIOL, V51, P966, DOI 10.1007/s12035-014-8752-3; Adwan L, 2014, NEUROPHARMACOLOGY, V79, P596, DOI 10.1016/j.neuropharm.2014.01.009; Agrawal R., 2015, J CEREB BLOOD FLOW M, V2015, P1; Akter K, 2011, BRIT J CLIN PHARMACO, V71, P365, DOI 10.1111/j.1365-2125.2010.03830.x; Al-Mansoori KM, 2013, CURR ALZHEIMER RES, V10, P559; Alano CC, 2004, J BIOL CHEM, V279, P18895, DOI 10.1074/jbc.M313329200; Alano CC, 2010, J NEUROSCI, V30, P2967, DOI 10.1523/JNEUROSCI.5552-09.2010; Alzheimer's Association, 2014, ALZHEIMERS DEMENT, V10; Antoniou X, 2011, J ALZHEIMERS DIS, V24, P633, DOI 10.3233/JAD-2011-091567; Aoyama K, 2013, INT J MOL SCI, V14, P21021, DOI 10.3390/ijms141021021; Ashrafi G, 2013, CELL DEATH DIFFER, V20, P31, DOI 10.1038/cdd.2012.81; Ashrafi G, 2014, J CELL BIOL, V206, P655, DOI 10.1083/jcb.201401070; Auburger G, 2014, PROG MOL BIOL TRANSL, V127, P155, DOI 10.1016/B978-0-12-394625-6.00006-4; Bahari-Javan S, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00160; Barbero-Camps E, 2014, AM J PATHOL, V184, P2066, DOI 10.1016/j.ajpath.2014.03.014; Barr Taura L, 2007, J Neurosci Nurs, V39, P278; Bastidas AC, 2013, BIOCHEMISTRY-US, V52, P6368, DOI 10.1021/bi400575k; Besson VC, 2009, BRIT J PHARMACOL, V157, P695, DOI 10.1111/j.1476-5381.2009.00229.x; Bihaqi SW, 2013, NEUROTOXICOLOGY, V39, P95, DOI 10.1016/j.neuro.2013.07.010; Bishop P, 2014, J BIOL CHEM, V289, P36140, DOI 10.1074/jbc.M114.557124; Borutaite V, 2013, FEBS J, V280, P4999, DOI 10.1111/febs.12353; BOVERIS A, 1972, BIOCHEM J, V128, P617, DOI 10.1042/bj1280617; Bozyczko-Coyne D, 2001, J NEUROCHEM, V77, P849, DOI 10.1046/j.1471-4159.2001.00294.x; Brown GC, 2010, NITRIC OXIDE-BIOL CH, V23, P153, DOI 10.1016/j.niox.2010.06.001; BULLOCK R, 1991, J NEUROL NEUROSUR PS, V54, P427, DOI 10.1136/jnnp.54.5.427; Bunevicius A, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/634598; Butterfield DA, 2007, BRAIN RES, V1148, P243, DOI 10.1016/j.brainres.2007.02.084; Butterfield DA, 2014, BIOCHEM J, V463, P177, DOI 10.1042/BJ20140772; Butterfield DA, 2010, J ALZHEIMERS DIS, V20, P369, DOI 10.3233/JAD-2010-1375; Byun K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104699; Byun K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037917; Calabrese V, 2012, BBA-MOL BASIS DIS, V1822, P753, DOI 10.1016/j.bbadis.2011.11.002; Calon F, 2007, PROSTAG LEUKOTR ESS, V77, P287, DOI 10.1016/j.plefa.2007.10.019; Chang HC, 2014, J AGR FOOD CHEM, V62, P3466, DOI 10.1021/jf403286w; Chaturvedi RK, 2013, FREE RADICAL BIO MED, V63, P1, DOI 10.1016/j.freeradbiomed.2013.03.018; Chen CY, 2005, BIOCHEM BIOPH RES CO, V331, P993, DOI 10.1016/j.bbrc.2005.03.237; Chen F, 2004, CURR DRUG TARGETS, V5, P503, DOI 10.2174/1389450043345236; Chen HC, 2007, CELL, V130, P548, DOI 10.1016/j.cell.2007.06.026; Cho DH, 2009, SCIENCE, V324, P102, DOI 10.1126/science.1171091; Choi BR, 2014, EXP MOL MED, V46, DOI 10.1038/emm.2013.147; Chung KKK, 2010, NITRIC OXIDE-BIOL CH, V22, P290, DOI 10.1016/j.niox.2010.02.002; Chung KKK, 2004, SCIENCE, V304, P1328, DOI 10.1126/science.1093891; Ciccone S, 2013, INT J MOL SCI, V14, P2388, DOI 10.3390/ijms14022388; Cookson MR, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a009415; Correia SC, 2010, FRONT AGING NEUROSCI, V2, DOI 10.3389/fnagi.2010.00138; Costa C, 2010, EXP NEUROL, V221, P217, DOI 10.1016/j.expneurol.2009.11.002; Dai ZL, 2013, BIOFACTORS, V39, P383, DOI 10.1002/biof.1099; Dashdorj A, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-178; de la Monte SM, 2014, BIOCHEM PHARMACOL, V88, P548, DOI 10.1016/j.bcp.2013.12.012; de la Monte SM, 2009, J ALZHEIMERS DIS, V17, P817, DOI 10.3233/JAD-2009-1098; de Vries RLA, 2013, MOL CELL NEUROSCI, V55, P37, DOI 10.1016/j.mcn.2012.07.008; Dexter DT, 2013, FREE RADICAL BIO MED, V62, P132, DOI 10.1016/j.freeradbiomed.2013.01.018; Dias V, 2013, J PARKINSON DIS, V3, P461, DOI 10.3233/JPD-130230; Dickey AS, 2011, J NEUROSCI, V31, P15716, DOI 10.1523/JNEUROSCI.3159-11.2011; DuBoff B, 2013, TRENDS NEUROSCI, V36, P325, DOI 10.1016/j.tins.2013.03.002; Eliasson MJL, 1999, J NEUROSCI, V19, P5910, DOI 10.1523/JNEUROSCI.19-14-05910.1999; Ergin V, 2013, AGING DIS, V4, P276, DOI 10.14336/AD.2013.0400276; Essa MM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120964; Ezoulin MJM, 2005, NEUROSCI LETT, V389, P61, DOI 10.1016/j.neulet.2005.07.026; Faller P, 2013, INORG CHEM, V52, P12193, DOI 10.1021/ic4003059; Fang JG, 2007, P NATL ACAD SCI USA, V104, P18742, DOI 10.1073/pnas.0705904104; Ferramosca A, 2013, BBA-MOL CELL RES, V1833, P494, DOI 10.1016/j.bbamcr.2012.11.014; Ferraris D, 2013, FUTURE MED CHEM, V5, P1923, DOI [10.4155/FMC.13.150, 10.4155/fmc.13.150]; Fischer A, 2014, NEUROPHARMACOLOGY, V80, P95, DOI 10.1016/j.neuropharm.2014.01.038; Fitzmaurice AG, 2013, P NATL ACAD SCI USA, V110, P636, DOI 10.1073/pnas.1220399110; Folmes CDL, 2010, PROTEOME SCI, V8, DOI 10.1186/1477-5956-8-38; Forlenza OV, 2011, J PSYCHIATR RES, V45, P220, DOI 10.1016/j.jpsychires.2010.06.002; Franco MC, 2013, P NATL ACAD SCI USA, V110, pE1102, DOI 10.1073/pnas.1215177110; Gacar N, 2011, PHARMACOL BIOCHEM BE, V99, P316, DOI 10.1016/j.pbb.2011.05.017; Galter D, 2003, NEUROBIOL DIS, V14, P637, DOI 10.1016/j.nbd.2003.09.001; Garcia-Bonilla L, 2014, J IMMUNOL, V193, P2531, DOI 10.4049/jimmunol.1400918; Garcia-Escudero V, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/162152; Gebriel M, 2014, J NEUROSCI RES, V92, P104, DOI 10.1002/jnr.23297; Geisler S, 2010, NAT CELL BIOL, V12, P119, DOI 10.1038/ncb2012; Gilmer LK, 2009, J NEUROTRAUM, V26, P1271, DOI 10.1089/neu.2008.0857; Goldstein DS, 2015, J NEUROCHEM, V133, P14, DOI 10.1111/jnc.13042; Goncalves M, 2015, CLIN CHIM ACTA, V438, P342, DOI 10.1016/j.cca.2014.09.011; Gould N, 2013, J BIOL CHEM, V288, P26473, DOI 10.1074/jbc.R113.460261; Gozes I, 2004, J MOL NEUROSCI, V24, P67, DOI 10.1385/JMN:24:1:067; Gozes I, 2003, J MOL NEUROSCI, V20, P315, DOI 10.1385/JMN:20:3:315; Grimm S, 2011, FREE RADICAL RES, V45, P73, DOI 10.3109/10715762.2010.512040; Guedes-Dias P, 2013, BBA-MOL BASIS DIS, V1832, P1345, DOI 10.1016/j.bbadis.2013.04.005; Han SH, 2009, J CLIN NEUROL, V5, P120, DOI 10.3988/jcn.2009.5.3.120; Hanawa N, 2008, J BIOL CHEM, V283, P13565, DOI 10.1074/jbc.M708916200; Hanna RA, 2012, J BIOL CHEM, V287, P19094, DOI 10.1074/jbc.M111.322933; Hara MR, 2006, P NATL ACAD SCI USA, V103, P3887, DOI 10.1073/pnas.0511321103; Harris C, 2002, J NEUROCHEM, V83, P992, DOI 10.1046/j.1471-4159.2002.01219.x; Haskin J, 2013, HUM MOL GENET, V22, P2083, DOI 10.1093/hmg/ddt058; Hidding U, 2002, BIOCHEM PHARMACOL, V64, P781, DOI 10.1016/S0006-2952(02)01139-5; Hoang T, 2009, FREE RADICAL BIO MED, V47, P1049, DOI 10.1016/j.freeradbiomed.2009.07.013; Hogan, 2014, AGING NATION OLDER P; Hsieh HL, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/484613; Huang HF, 2012, CNS NEUROSCI THER, V18, P811, DOI 10.1111/j.1755-5949.2012.00380.x; Ilvesmaki T, 2014, BRAIN, V137, P1876, DOI 10.1093/brain/awu095; Jang S, 2015, REDOX BIOL, V6, P552, DOI 10.1016/j.redox.2015.09.040; Jauslin ML, 2003, FASEB J, V17, P1972, DOI 10.1096/fj.03-0240fje; Jimenez S, 2011, J BIOL CHEM, V286, P18414, DOI 10.1074/jbc.M110.209718; Jin HJ, 2014, J BIOL CHEM, V289, P34743, DOI 10.1074/jbc.M114.576702; Jo J, 2011, NAT NEUROSCI, V14, P545, DOI 10.1038/nn.2785; Johri A, 2012, J PHARMACOL EXP THER, V342, P619, DOI 10.1124/jpet.112.192138; Jope RS, 2007, NEUROCHEM RES, V32, P577, DOI 10.1007/s11064-006-9128-5; Kalonia H, 2010, NEUROTOXICOLOGY, V31, P195, DOI 10.1016/j.neuro.2009.12.008; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Kanamaru T, 2015, NEUROSCI LETT, V587, P126, DOI 10.1016/j.neulet.2014.12.033; Karababa A, 2014, METAB BRAIN DIS, V29, P975, DOI 10.1007/s11011-013-9454-7; Kharbanda S, 2000, J BIOL CHEM, V275, P322, DOI 10.1074/jbc.275.1.322; Kijima K, 2005, HUM GENET, V116, P23, DOI 10.1007/s00439-004-1199-2; Kilinc M, 2010, NEUROBIOL DIS, V40, P293, DOI 10.1016/j.nbd.2010.06.003; Kim BJ, 2006, J BIOL CHEM, V281, P21256, DOI 10.1074/jbc.M510644200; Klein JA, 2003, J CLIN INVEST, V111, P785, DOI 10.1172/JCI200318182; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; Kopeikina KJ, 2011, AM J PATHOL, V179, P2071, DOI 10.1016/j.ajpath.2011.07.004; Kumar A., 2015, MOL NEUROBIOL; Kumar A, 2014, FREE RADICAL BIO MED, V73, P51, DOI 10.1016/j.freeradbiomed.2014.04.014; Kunwar A, 2011, J MED ALLIED SCI, V1, P53; Kurauchi Y, 2012, BRIT J PHARMACOL, V166, P1151, DOI 10.1111/j.1476-5381.2012.01833.x; Kwak YD, 2010, MOL NEURODEGENER, V5, DOI 10.1186/1750-1326-5-49; LaFerla FM, 2007, NAT REV NEUROSCI, V8, P499, DOI 10.1038/nrn2168; Lazo-Gomez R, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00243; Lee JM, 2004, J BIOCHEM MOL BIOL, V37, P139; Lee Y, 2015, J NEUROSCI RES, V93, P755, DOI 10.1002/jnr.23544; Li HY, 2014, NUTRITION, V30, P337, DOI 10.1016/j.nut.2013.08.021; Li J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033860; Liang JM, 2013, J INT MED RES, V41, P618, DOI 10.1177/0300060513476587; Liberatore GT, 1999, NAT MED, V5, P1403; Lipton P, 2013, TRANSL STROKE RES, V4, P672, DOI 10.1007/s12975-013-0301-2; Liu GX, 2014, J CLIN INVEST, V124, P3032, DOI 10.1172/JCI72176; Liu XY, 2015, J NEUROCHEM, V133, P187, DOI 10.1111/jnc.13069; Liu Y, 2014, BEHAV BRAIN RES, V267, P178, DOI 10.1016/j.bbr.2014.02.040; Lozano L, 2014, EXP GERONTOL, V58, P198, DOI 10.1016/j.exger.2014.08.008; Lu P, 2014, J NEUROSCI, V34, P15975, DOI 10.1523/JNEUROSCI.2499-14.2014; Maggio DM, 2012, J NEUROTRAUM, V29, P2244, DOI 10.1089/neu.2012.2371; Mailloux RJ, 2011, FREE RADICAL BIO MED, V51, P1106, DOI 10.1016/j.freeradbiomed.2011.06.022; Malinski T, 2007, J ALZHEIMERS DIS, V11, P207; Malkus KA, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-24; Manczak M, 2012, HUM MOL GENET, V21, P2538, DOI 10.1093/hmg/dds072; Mandel SA, 2008, J ALZHEIMERS DIS, V15, P211; Martin E, 2005, J NEUROSCI RES, V79, P240, DOI 10.1002/jnr.20293; McCormack D, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/575482; McCoy MK, 2012, ANTIOXID REDOX SIGN, V16, P869, DOI [10.1089/ars.2011.4019, 10.1089/ars.2011.4074]; McNeilly AD, 2012, DIABETOLOGIA, V55, P3061, DOI 10.1007/s00125-012-2686-y; Medeiros R, 2007, J NEUROSCI, V27, P5394, DOI 10.1523/JNEUROSCI.5047-06.2007; Miquel E, 2014, FREE RADICAL BIO MED, V70, P204, DOI 10.1016/j.freeradbiomed.2014.02.019; Mkhikian H, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1333; Mondragon-Rodriguez S, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/940603; Moon KH, 2008, GASTROENTEROLOGY, V135, P1344, DOI 10.1053/j.gastro.2008.06.048; Moon KH, 2006, HEPATOLOGY, V44, P1218, DOI 10.1002/hep.21372; Moon KH, 2010, FREE RADICAL BIO MED, V48, P391, DOI 10.1016/j.freeradbiomed.2009.11.008; Morrison CD, 2010, J NEUROCHEM, V114, P1581, DOI 10.1111/j.1471-4159.2010.06865.x; Mota SI, 2015, BBA-MOL BASIS DIS, V1852, P1428, DOI 10.1016/j.bbadis.2015.03.015; Naoi M, 2010, CURR PHARM DESIGN, V16, P2799, DOI 10.2174/138161210793176527; Narayan PJ, 2015, NEUROBIOL DIS, V74, P281, DOI 10.1016/j.nbd.2014.11.023; Narendra DP, 2011, ANTIOXID REDOX SIGN, V14, P1929, DOI 10.1089/ars.2010.3799; Nataraj J., 2015, NUTR NEUROSCI, V2015, P2; Nathan C, 2005, J EXP MED, V202, P1163, DOI 10.1084/jem.20051529; Navarro A, 2008, ADV DRUG DELIVER REV, V60, P1534, DOI 10.1016/j.addr.2008.05.002; Navarro A, 2009, J BIOENERG BIOMEMBR, V41, P517, DOI 10.1007/s10863-009-9250-6; Ng LF, 2014, FREE RADICAL BIO MED, V71, P390, DOI 10.1016/j.freeradbiomed.2014.03.003; Nijboer CH, 2013, NEUROBIOL DIS, V54, P432, DOI 10.1016/j.nbd.2013.01.017; Nistico R, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00063; Nobunaga M, 2014, NEUROCHEM INT, V78, P61, DOI 10.1016/j.neuint.2014.09.002; Novak I, 2010, EMBO REP, V11, P45, DOI 10.1038/embor.2009.256; Nuzzo D, 2015, CURR ALZHEIMER RES, V12, P723, DOI 10.2174/1567205012666150710115506; Ohsawa I, 2008, J NEUROSCI, V28, P6239, DOI 10.1523/JNEUROSCI.4956-07.2008; Oikawa S, 2014, FREE RADICAL RES, V48, P694, DOI 10.3109/10715762.2014.901509; Okatsu K, 2012, BIOCHEM BIOPH RES CO, V428, P197, DOI 10.1016/j.bbrc.2012.10.041; Opii WO, 2007, J NEUROTRAUM, V24, P772, DOI 10.1089/neu.2006.0229; Pan J, 2009, NEUROCHEM INT, V54, P418, DOI 10.1016/j.neuint.2009.01.013; Park SY, 2013, NEUROTOXICOLOGY, V38, P115, DOI 10.1016/j.neuro.2013.07.004; Pattaroni C, 2013, MOL NEUROBIOL, V47, P740, DOI 10.1007/s12035-012-8376-4; Pena-Altamira LE, 2013, CURR PHARM DESIGN, V19, P5085, DOI 10.2174/13816128113199990355; Pickrell AM, 2015, NEURON, V85, P257, DOI 10.1016/j.neuron.2014.12.007; Pickrell AM, 2011, J NEUROSCI, V31, P9895, DOI 10.1523/JNEUROSCI.6223-10.2011; Placido AI, 2014, BBA-MOL BASIS DIS, V1842, P1444, DOI 10.1016/j.bbadis.2014.05.003; Proitsi P, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001713; Puschmann A, 2013, PARKINSONISM RELAT D, V19, P407, DOI 10.1016/j.parkreldis.2013.01.020; Qi X, 2013, J CELL SCI, V126, P789, DOI 10.1242/jcs.114439; Qu MH, 2016, CURR TOP MED CHEM, V16, P558, DOI 10.2174/1568026615666150813144437; Quintana FJ, 2006, ANN NY ACAD SCI, V1070, P500, DOI 10.1196/annals.1317.069; Rajan KB, 2014, ALZ DIS ASSOC DIS, V28, P134, DOI 10.1097/WAD.0000000000000013; Rege SD, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/419092; Ren JW, 2011, NEUROCHEM RES, V36, P2352, DOI 10.1007/s11064-011-0561-8; Rhee S G, 2000, Sci STKE, V2000, ppe1; Ribas V, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00151; Rodrigo R, 2013, CNS NEUROL DISORD-DR, V12, P698; Rohrer JD, 2012, BBA-MOL BASIS DIS, V1822, P325, DOI 10.1016/j.bbadis.2011.07.014; Ron D, 2013, CURR TOP BEHAV NEURO, V13, P87, DOI 10.1007/7854_2011_161; Sadigh-Eteghad S, 2012, NEUROSCIENCES, V17, P321; Sanderson TH, 2015, NEUROSCIENCE, V301, P71, DOI 10.1016/j.neuroscience.2015.05.078; Sanderson TH, 2015, MOL CELL NEUROSCI, V64, P116, DOI 10.1016/j.mcn.2014.12.007; Schedin-Weiss S, 2014, FEBS J, V281, P46, DOI 10.1111/febs.12590; Schildknecht S, 2013, J NEUROCHEM, V125, P491, DOI 10.1111/jnc.12226; Schmid AW, 2013, MOL CELL PROTEOMICS, V12, P3543, DOI 10.1074/mcp.R113.032730; Schroeter H, 2003, BIOCHEM J, V372, P359, DOI 10.1042/BJ20030201; Schroeter H, 2007, J NEUROCHEM, V101, P1596, DOI 10.1111/j.1471-4159.2006.04434.x; Scorziello A, 2013, J CELL SCI, V126, P5566, DOI 10.1242/jcs.129668; Sekigawa A, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/817807; Sha YG, 2012, BBA-GEN SUBJECTS, V1820, P701, DOI 10.1016/j.bbagen.2011.05.008; Shah SA, 2015, MOL NEUROBIOL, V51, P1278, DOI 10.1007/s12035-014-8805-7; Shahani N, 2012, BBA-GEN SUBJECTS, V1820, P736, DOI 10.1016/j.bbagen.2011.07.010; Shahpasandzadeh H, 2014, J BIOL CHEM, V289, P31224, DOI 10.1074/jbc.M114.559237; Singhal NK, 2013, MOL CELL BIOCHEM, V384, P47, DOI 10.1007/s11010-013-1780-x; Slavin JL, 2012, ADV NUTR, V3, P506, DOI 10.3945/an.112.002154; Smith RAJ, 2010, ANN NY ACAD SCI, V1201, P96, DOI 10.1111/j.1749-6632.2010.05627.x; Son Y, 2013, METHOD ENZYMOL, V528, P27, DOI 10.1016/B978-0-12-405881-1.00002-1; Son Yong, 2011, J Signal Transduct, V2011, P792639, DOI 10.1155/2011/792639; Song Byoung-Joon, 2015, Adv Pharmacol, V74, P303, DOI 10.1016/bs.apha.2015.04.002; Song BJ, 2014, REDOX BIOL, V3, P109, DOI 10.1016/j.redox.2014.10.004; Song BJ, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/781050; Song BJ, 2011, J PROTEOMICS, V74, P2691, DOI 10.1016/j.jprot.2011.05.013; Song BJ, 2010, METHOD ENZYMOL, V473, P251, DOI 10.1016/S0076-6879(10)73013-5; Soustiel JF, 2007, NEUROL RES, V29, P654, DOI 10.1179/016164107X240017; Spruss A, 2011, ANTIOXID REDOX SIGN, V14, P2121, DOI 10.1089/ars.2010.3263; Subash S, 2015, NUTRITION, V31, P223, DOI 10.1016/j.nut.2014.06.004; Subash S, 2014, NEURAL REGEN RES, V9, P1557, DOI 10.4103/1673-5374.139483; Subash S, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/546357; Subramaniam S, 2010, FEBS J, V277, P22, DOI 10.1111/j.1742-4658.2009.07367.x; Sultana R, 2013, FREE RADICAL BIO MED, V62, P157, DOI 10.1016/j.freeradbiomed.2012.09.027; Sultana R, 2013, ADV ALZH DIS, V3, P243, DOI [10.3233/JAD-2012-129018, 10.3233/978-1-61499-154-0-243]; Sun J, 2014, BRAIN RES, V1589, P126, DOI 10.1016/j.brainres.2014.09.039; Sun KH, 2009, MOL BIOL CELL, V20, P4611, DOI 10.1091/mbc.E09-05-0433; Syntichaki P, 2002, NATURE, V419, P939, DOI 10.1038/nature01108; Tajuddin NF, 2013, ALCOHOL, V47, P39, DOI 10.1016/j.alcohol.2012.09.003; Tan EP, 2014, J BIOL CHEM, V289, P14719, DOI 10.1074/jbc.M113.525790; Tanaka A, 2010, J CELL BIOL, V191, P1367, DOI 10.1083/jcb.201007013; Tapias V, 2014, NEUROBIOL AGING, V35, P1162, DOI 10.1016/j.neurobiolaging.2013.10.077; Tepper K, 2014, J BIOL CHEM, V289, P34389, DOI 10.1074/jbc.M114.611368; Tolkovsky AM, 2009, BBA-MOL CELL RES, V1793, P1508, DOI 10.1016/j.bbamcr.2009.03.002; Tradewell ML, 2012, HUM MOL GENET, V21, P136, DOI 10.1093/hmg/ddr448; Twig G, 2008, EMBO J, V27, P433, DOI 10.1038/sj.emboj.7601963; Upreti VV, 2011, PROTEOMICS, V11, P202, DOI 10.1002/pmic.201000203; Vauzour D, 2012, OXID MED CELL LONGEV, V2012, DOI 10.1155/2012/914273; Vepsalainen S, 2013, J NUTR BIOCHEM, V24, P360, DOI 10.1016/j.jnutbio.2012.07.006; Verma R, 2009, NEUROCHEM INT, V55, P369, DOI 10.1016/j.neuint.2009.04.001; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vespa PM, 2003, J CEREBR BLOOD F MET, V23, P865, DOI 10.1097/01.WCB.0000076701.45782.EF; Vina J, 2010, J ALZHEIMERS DIS, V20, pS527, DOI 10.3233/JAD-2010-100501; Wagner GR, 2012, HUM MOL GENET, V21, P2688, DOI 10.1093/hmg/dds095; Walker AK, 2010, BRAIN, V133, P105, DOI 10.1093/brain/awp267; Waly MI, 2011, ALCOHOL CLIN EXP RES, V35, P277, DOI 10.1111/j.1530-0277.2010.01343.x; Wang DM, 2014, CELL MOL NEUROBIOL, V34, P1209, DOI 10.1007/s10571-014-0098-x; Wang JZ, 2013, J ALZHEIMERS DIS, V33, pS123, DOI 10.3233/JAD-2012-129031; Wang W, 2015, INT J STROKE, V10, P1261, DOI 10.1111/ijs.12560; Wang WY, 2004, NEUROSCI RES, V48, P195, DOI 10.1016/j.neures.2003.10.012; Wang XN, 2011, CELL, V147, P893, DOI 10.1016/j.cell.2011.10.018; Weinberg F, 2009, ANN NY ACAD SCI, V1177, P66, DOI 10.1111/j.1749-6632.2009.05039.x; Weinreb O, 2012, CURR DRUG TARGETS, V13, P483, DOI 10.2174/138945012799499794; Wey MCY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031522; Win S, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.522; Win S, 2011, J BIOL CHEM, V286, P35071, DOI 10.1074/jbc.M111.276089; Winklhofer KF, 2014, TRENDS CELL BIOL, V24, P332, DOI 10.1016/j.tcb.2014.01.001; Winterbourn CC, 2008, NAT CHEM BIOL, V4, P278, DOI 10.1038/nchembio.85; Wirth M, 2014, J NEUROSCI, V34, P8612, DOI 10.1523/JNEUROSCI.4612-13.2014; Wu WW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132499; Xie YC, 2014, TOXICOL APPL PHARM, V279, P266, DOI 10.1016/j.taap.2014.05.010; Xu K, 2008, ADV EXP MED BIOL, V614, P379, DOI 10.1007/978-0-387-74911-2_42; Yang S, 2013, BIOMED RES INT, V2013, DOI DOI 10.1155/2013/215798; Yarza R, 2016, FRONT PHARMACOL, V6, DOI [10.3389/fphys.2015.00321, 10.3389/fphar.2015.00321]; Yin F, 2013, BIOCHEM SOC T, V41, P101, DOI 10.1042/BST20120260; Yin L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117546; Zhang F, 2013, NEUROCHEM INT, V62, P1055, DOI 10.1016/j.neuint.2013.03.016; Zhang HY, 2012, ACTA PHARMACOL SIN, V33, P1170, DOI 10.1038/aps.2012.128; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500; Zhang J, 2010, AUTOPHAGY, V6, P405, DOI 10.4161/auto.6.3.11245; Zhu YP, 2014, J BIOL CHEM, V289, P34472, DOI 10.1074/jbc.R114.601351; Zhu ZH, 2015, BRAIN RES, V1620, P17, DOI 10.1016/j.brainres.2015.05.011	270	75	82	5	48	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	APR 15	2016	1637						34	55		10.1016/j.brainres.2016.02.016			22	Neurosciences	Neurosciences & Neurology	DK0NY	WOS:000374610700004	26883165	Green Accepted			2021-06-18	
J	Meier, TB; Brummel, BJ; Singh, R; Nerio, CJ; Polanski, DW; Bellgowan, PSF				Meier, Timothy B.; Brummel, Bradley J.; Singh, Rashmi; Nerio, Christopher J.; Polanski, David W.; Bellgowan, Patrick S. F.			The underreporting of self-reported symptoms following sports-related concussion	JOURNAL OF SCIENCE AND MEDICINE IN SPORT			English	Article						Mild traumatic brain injury; Post-concussion symptoms; Neuropsychological testing	STRUCTURED INTERVIEW GUIDE; TRAUMATIC BRAIN-INJURY; RATING-SCALE; DEPRESSION; RELIABILITY; PERFORMANCE; VALIDITY; RATES	Objectives: This cohort study was conducted to examine patterns of symptom reporting in concussed athletes in two different testing environments. Design: A prospective cohort study was conducted with repeated measures. Methods: Self-reported symptoms collected by team athletic trainers using the ImPACT Post-Concussion Scale (PCS) were compared to symptoms collected in a confidential setting using structured interviews for depression and anxiety. Ratings were scaled-to match scoring of the PCS and categorized into symptom-domains. Scores collected 2 days post-concussion were compared across different rating scales. Confidential self-report scores approximately 9 days,post-concussion in cleared athletes were compared to PCS scores collected during return-to-play decisions. Finally, confidential self-report scores collected 9 days post-concussion were compared between cleared and not cleared athletes. Results: Athletes self-reported significantly fewer symptoms to team athletic trainers using the ImPACT test compared to self-reported symptoms collected in a confidential setting during the acute phase of concussion using standard psychiatric interviews'. Athletes cleared to play continued to underreport symptoms 9 days post-concussion, particularly psychiatric symptoms. Finally, cleared athletes self-reported similar magnitude of symptoms than non-cleared athletes 9 days post-concussion in confidential research setting. Conclusions: The systematic underreporting of post-concussion symptoms may represent motivated behavior or differences in self-reporting data acquisition. By underreporting symptoms, many cleared athletes are still symptomatic over 1-week post-concussion. This study highlights the need for objective measures for somatic and psychiatric symptoms. (C) 2014 Sports Medicine Australia. Published by Elsevier Ltd. All rights reserved.	[Meier, Timothy B.; Singh, Rashmi; Bellgowan, Patrick S. F.] Laureate Inst Brain Res, Tulsa, OK 74136 USA; [Brummel, Bradley J.] Univ Tulsa, Dept Psychol, Tulsa, OK 74104 USA; [Nerio, Christopher J.; Polanski, David W.] Univ Tulsa, Dept Athlet, Tulsa, OK 74104 USA; [Bellgowan, Patrick S. F.] Univ Tulsa, Fac Community Med, Tulsa, OK 74104 USA	Meier, TB (corresponding author), Laureate Inst Brain Res, Tulsa, OK 74136 USA.	tmeier@laureateinstitute.org			Laureate Institute for Brain Research by William K. Warren Foundation	The authors would like to thank the Laureate Institute for Brain Research psychiatric assessment team for conducting the structured interviews and Dr. Sheldon Preskorn, M.D. for his insight on this project. This research was conducted using internal funds from the Laureate Institute for Brain Research, which is supported by The William K. Warren Foundation.	Cernich A, 2007, ARCH CLIN NEUROPSYCH, V22, pS101, DOI 10.1016/j.acn.2006.10.008; Chrisman SP, 2013, J ADOLESCENT HEALTH, V52, P330, DOI 10.1016/j.jadohealth.2012.10.271; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Fazio VC, 2007, NEUROREHABILITATION, V22, P207; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; HAMILTON M, 1959, BRIT J MED PSYCHOL, V32, P50, DOI 10.1111/j.2044-8341.1959.tb00467.x; Kaut KP, 2003, CLIN J SPORT MED, V13, P213, DOI 10.1097/00042752-200307000-00004; Konrad C, 2011, PSYCHOL MED, V41, P1197, DOI 10.1017/S0033291710001728; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Lau B, 2009, CLIN J SPORT MED, V19, P216, DOI 10.1097/JSM.0b013e31819d6edb; Llewellyn T, 2014, CLIN J SPORT MED, V24, P76, DOI 10.1097/01.jsm.0000432853.77520.3d; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Lovell MR, 2013, J PEDIATR-US, V163, P1192, DOI 10.1016/j.jpeds.2013.05.061; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2013, BRIT J SPORT MED, V47, P268, DOI 10.1136/bjsports-2013-092247; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McCrory Paul, 2009, Scand J Med Sci Sports, V19, P452, DOI 10.1111/j.1600-0838.2009.00978.x; Ramanathan DM, 2012, J INT NEUROPSYCH SOC, V18, P101, DOI 10.1017/S1355617711001457; Register F., 1979, PROT HUM SUBJ BELM R, V44, P23192; Shear MK, 2001, DEPRESS ANXIETY, V13, P166, DOI 10.1002/da.1033.abs; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677; Williams J. B. W., 2003, STRUCTURED INTERVIEW; WILLIAMS JBW, 1988, ARCH GEN PSYCHIAT, V45, P742; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832	26	75	76	0	24	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1440-2440	1878-1861		J SCI MED SPORT	J. Sci. Med. Sport	SEP	2015	18	5					507	511		10.1016/j.jsams.2014.07.008			5	Sport Sciences	Sport Sciences	CP9AM	WOS:000360186100003	25150463				2021-06-18	
J	Corwin, DJ; Wiebe, DJ; Zonfrillo, MR; Grady, MF; Robinson, RL; Goodman, AM; Master, CL				Corwin, Daniel J.; Wiebe, Douglas J.; Zonfrillo, Mark R.; Grady, Matthew F.; Robinson, Roni L.; Goodman, Arlene M.; Master, Christina L.			Vestibular Deficits following Youth Concussion	JOURNAL OF PEDIATRICS			English	Article							REHABILITATION; SPORT; RECOVERY; IMPACT	Objective To characterize the prevalence and recovery of pediatric patients with concussion who manifest clinical vestibular deficits and to describe the correlation of these deficits with neurocognitive function, based on computerized neurocognitive testing, in a sample of pediatric patients with concussion. Methods This was a retrospective cohort study of patients ages 5-18 years with concussion referred to a tertiary pediatric hospital-affiliated sports medicine clinic from July 1, 2010 to December 31, 2011. A random sample of all eligible patient visits was obtained, and all related visits for those patients were reviewed. Results A total of 247 patients were chosen from 3740 eligible visits for detailed review and abstraction; 81% showed a vestibular abnormality on initial clinical examination. Those patients with vestibular signs on the initial examination took a significantly longer time to return to school (median 59 days vs 6 days, P = .001) or to be fully cleared (median 106 days vs 29 days, P = .001). They additionally scored more poorly on initial computerized neurocognitive testing, and it took longer for them to recover from neurocognitive deficits. Those patients with 3 or more previous concussions had a greater prevalence of vestibular deficits, and it took longer for those deficits to resolve. Conclusion Vestibular deficits in children and adolescents with a history of concussion are highly prevalent. These deficits appear to be associated with extended recovery times and poorer performance on neurocognitive testing. Further studies evaluating the effectiveness of vestibular therapy on improving such deficits are warranted.	[Corwin, Daniel J.; Zonfrillo, Mark R.] Childrens Hosp Philadelphia, Div Emergency Med, Philadelphia, PA 19104 USA; [Wiebe, Douglas J.] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA; [Wiebe, Douglas J.; Zonfrillo, Mark R.; Grady, Matthew F.; Master, Christina L.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA; [Zonfrillo, Mark R.] Childrens Hosp Philadelphia, Ctr Injury Res & Prevent, Philadelphia, PA 19104 USA; [Grady, Matthew F.; Robinson, Roni L.; Master, Christina L.] Childrens Hosp Philadelphia, Sports Med & Performance Ctr, Philadelphia, PA 19104 USA; [Grady, Matthew F.; Master, Christina L.] Childrens Hosp Philadelphia, Dept Pediat, Philadelphia, PA 19104 USA; [Goodman, Arlene M.] St Peters Sports Med Inst, Pediat Sports Med, Somerset, NJ USA	Master, CL (corresponding author), Childrens Hosp Philadelphia, Div Pediat Orthoped, Pediat & Adolescent Sports Med, 34th & Civ Ctr Blvd, Philadelphia, PA 19104 USA.	masterc@email.chop.edu	Wiebe, Douglas J/Q-1168-2017; Zonfrillo, Mark R./H-9403-2017	Zonfrillo, Mark R./0000-0002-0610-9563; Master, Christina/0000-0002-6717-4270	Children's Hospital of Philadelphia Department of Pediatrics Chair's Initiative; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; National Center for Advancing Translational SciencesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000003]; Children's Hospital of Philadelphia Clinical Translational Sciences Award; research institute funding for the Comparative Effectiveness Program; National Institutes of Health, Eunice Kennedy Shriver National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K08HD073241]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K08HD073241] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000003] Funding Source: NIH RePORTER	Supported by the Children's Hospital of Philadelphia Department of Pediatrics Chair's Initiative, the National Institutes of Health, National Center for Advancing Translational Sciences (UL1TR000003 for the University of Pennsylvania Health System), the Children's Hospital of Philadelphia Clinical Translational Sciences Award, research institute funding for the Comparative Effectiveness Program, and the National Institutes of Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development (K08HD073241 [to M.Z.]). The authors declare no conflicts of interest.	Aligene K, 2013, NEUROREHABILITATION, V32, P543, DOI 10.3233/NRE-130876; Alsalaheen BA, 2010, J NEUROL PHYS THER, V34, P87, DOI 10.1097/NPT.0b013e3181dde568; Blume HK, 2011, PHYS MED REH CLIN N, V22, P665, DOI 10.1016/j.pmr.2011.08.007; Chamberlain G, 1994, ADV EC WORLD C, V2, P171, DOI DOI 10.1017/CCOL0521444594.005; Corwin DJ, 2014, J PEDIATR-US, V165, P1207, DOI 10.1016/j.jpeds.2014.08.034; Echemendia RJ, 2012, CLIN NEUROPSYCHOL, V26, P1077, DOI 10.1080/13854046.2012.721006; Fukushima K, 1997, EXP BRAIN RES, V117, P1, DOI 10.1007/PL00005786; Gottshall K, 2011, NEUROREHABILITATION, V29, P167, DOI 10.3233/NRE-2011-0691; Grady MF, 2010, CURR PROB PEDIATR AD, V40, P154, DOI 10.1016/j.cppeds.2010.06.002; Gurley JM, 2013, NEUROREHABILITATION, V32, P519, DOI 10.3233/NRE-130874; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Hanes DA, 2006, J VESTIBUL RES-EQUIL, V16, P75; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Lavrich JB, 2010, CURR OPIN OPHTHALMOL, V21, P356, DOI 10.1097/ICU.0b013e32833cf03a; Master CL, 2014, ANN INTERN MED, V160, DOI 10.7326/0003-4819-160-3-201402040-01002; Master CL, 2012, PEDIATR ANN, V41, pE174, DOI 10.3928/00904481-20120827-08; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meehan WP, 2010, J PEDIATR-US, V157, P889, DOI 10.1016/j.jpeds.2010.06.040; Moser RS, 2007, PROF PSYCHOL-RES PR, V38, P699, DOI 10.1037/0735-7028.38.6.699; Mucha A, 2014, AM J SPORT MED, V42, P2479, DOI 10.1177/0363546514543775; O'Reilly RC, 2010, OTOL NEUROTOL, V31, P1441, DOI 10.1097/MAO.0b013e3181f20673; Reddy CC, 2008, PHYS MED REH CLIN N, V19, P247, DOI 10.1016/j.pmr.2007.12.002; Schatz P, 2011, CLIN NEUROPSYCHOL, V25, P1042, DOI 10.1080/13854046.2011.556669; Schatz P, 2011, NEUROSURGERY, V68, P1562, DOI 10.1227/NEU.0b013e31820e382e; Theriault M, 2011, J CLIN EXP NEUROPSYC, V33, P30, DOI 10.1080/13803391003772873; Thiagarajan P, 2013, OPTOMETRY VISION SCI, V90, P57, DOI 10.1097/OPX.0b013e31827a233e; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677	31	75	75	0	22	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0022-3476	1097-6833		J PEDIATR-US	J. Pediatr.	MAY	2015	166	5					1221	1225		10.1016/j.jpeds.2015.01.039			5	Pediatrics	Pediatrics	CG6DW	WOS:000353387100026	25748568	Green Accepted			2021-06-18	
J	Tisherman, SA; Schmicker, RH; Brasel, KJ; Bulger, EM; Kerby, JD; Minei, JP; Powell, JL; Reiff, DA; Rizoli, SB; Schreiber, MA				Tisherman, Samuel A.; Schmicker, Robert H.; Brasel, Karen J.; Bulger, Eileen M.; Kerby, Jeffrey D.; Minei, Joseph P.; Powell, Judy L.; Reiff, Donald A.; Rizoli, Sandro B.; Schreiber, Martin A.			Detailed Description of All Deaths in Both the Shock and Traumatic Brain Injury Hypertonic Saline Trials of the Resuscitation Outcomes Consortium	ANNALS OF SURGERY			English	Article						clinical trial; hemorrhagic shock; mortality; trauma; traumatic brain injury	EPIDEMIOLOGY	Objective: To identify causes and timing of mortality in trauma patients to determine targets for future studies. Background: In trials conducted by the Resuscitation Outcomes Consortium in patients with traumatic hypovolemic shock (shock) or traumatic brain injury (TBI), hypertonic saline failed to improve survival. Selecting appropriate candidates is challenging. Methods: Retrospective review of patients enrolled in multicenter, randomized trials performed from 2006 to 2009. Inclusion criteria were as follows: injured patients, age 15 years or more with hypovolemic shock [systolic blood pressure (SBP) <= 70 mm Hg or SBP 71-90 mm Hg with heart rate >= 108) or severe TBI [Glasgow Coma Score (GCS) <= 8]. Initial fluid administered was 250 mL of either 7.5% saline with 6% dextran 70, 7.5% saline or 0.9% saline. Results: A total of 2061 subjects were enrolled (809 shock, 1252 TBI) and 571 (27.7%) died. Survivors were younger than nonsurvivors [30 (interquartile range 23) vs 42 (34)] and had a higher GCS, though similar hemodynamics. Most deaths occurred despite ongoing resuscitation. Forty-six percent of deaths in the TBI cohort were within 24 hours, compared with 82% in the shock cohort and 72% in the cohort with both shock and TBI. Median time to death was 29 hours in the TBI cohort, 2 hours in the shock cohort, and 4 hours in patients with both. Sepsis and multiple organ dysfunction accounted for 2% of deaths. Conclusions: Most deaths from trauma with shock or TBI occur within 24 hours from hypovolemic shock or TBI. Novel resuscitation strategies should focus on early deaths, though prevention may have a greater impact.	[Tisherman, Samuel A.] Univ Maryland, Baltimore, MD 21201 USA; [Schmicker, Robert H.; Bulger, Eileen M.; Powell, Judy L.] Univ Washington, Seattle, WA 98195 USA; [Brasel, Karen J.] Med Coll Wisconsin, Milwaukee, WI 53226 USA; [Kerby, Jeffrey D.; Reiff, Donald A.] Univ Alabama Birmingham, Birmingham, AL USA; [Minei, Joseph P.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA; [Rizoli, Sandro B.] St Michaels Hosp, Toronto, ON M5B 1W8, Canada; [Schreiber, Martin A.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA	Tisherman, SA (corresponding author), Univ Maryland, R Adams Cowley Shock Trauma Ctr, 22 S Greene St, Baltimore, MD 21201 USA.	stisherman@umm.edu	Tisherman, Samuel A./AAK-9377-2020	Tisherman, Samuel A./0000-0003-3810-3729	University of Washington Data Coordinating Center [5U01 HL077863]; University of Iowa [HL077865]; Medical College of Wisconsin [HL077866]; University of WashingtonUniversity of Washington [HL077867]; University of PittsburghUniversity of Pittsburgh [HL077871]; St Michael's Hospital [HL077872]; Oregon Health and Science University [HL077873]; University of Alabama at Birmingham [HL077881]; Ottawa Hospital Research Institute [HL077885]; University of Texas SW Medical Center/Dallas [HL077887]; National Heart, Lung and Blood InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [5U01 HL077863, HL077865, HL077866, HL077867, HL077871, HL077872, HL077873, HL077881, HL077885, HL077887, HL077908]; National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); US Army Medical Research and Material CommandU.S. Army Medical Research & Materiel Command (USAMRMC); Canadian Institutes of Health Research (CIHR)-Institute of Circulatory and Respiratory HealthCanadian Institutes of Health Research (CIHR); Defence Research and Development Canada; Heart, Stroke Foundation of CanadaHeart & Stroke Foundation of Canada; American Heart AssociationAmerican Heart Association; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [U01HL077871, U01HL077887, U01HL077881, U01HL077867, U01HL077872, U01HL077865, U01HL077885, U01HL077873, U01HL077866, U01HL077908, U01HL077863] Funding Source: NIH RePORTER	The authors have no conflicts of interest to declare. The Resuscitation Outcomes Consortium is supported by a series of cooperative agreements to 10 regional clinical centers and 1 Data Coordinating Center (5U01 HL077863-University of Washington Data Coordinating Center, HL077865-University of Iowa, HL077866-Medical College of Wisconsin, HL077867-University of Washington, HL077871-University of Pittsburgh, HL077872-St Michael's Hospital, HL077873-Oregon Health and Science University, HL077881-University of Alabama at Birmingham, HL077885-Ottawa Hospital Research Institute, HL077887-University of Texas SW Medical Center/Dallas, HL077908 University of California San Diego) from the National Heart, Lung and Blood Institute in partnership with the National Institute of Neurological Disorders and Stroke, US Army Medical Research and Material Command, The Canadian Institutes of Health Research (CIHR)-Institute of Circulatory and Respiratory Health, Defence Research and Development Canada, the Heart, Stroke Foundation of Canada, and the American Heart Association. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Heart, Lung and Blood Institute or the National Institutes of Health. The original trials are registered with clinicaltrials.gov as: NCT00316004 and NCT00316017.	BAKER CC, 1980, AM J SURG, V140, P144, DOI 10.1016/0002-9610(80)90431-6; Bulger EM, 2011, ANN SURG, V253, P431, DOI 10.1097/SLA.0b013e3181fcdb22; Bulger EM, 2010, JAMA-J AM MED ASSOC, V304, P1455, DOI 10.1001/jama.2010.1405; Dams-O'Connor K, 2013, J NEUROTRAUM, V30, P2001, DOI 10.1089/neu.2013.3047; Davidson GH, 2011, JAMA-J AM MED ASSOC, V305, P1001, DOI 10.1001/jama.2011.259; Demetriades D, 2005, J AM COLL SURGEONS, V201, P343, DOI 10.1016/j.jamcollsurg.2005.05.003; Dewar DC, 2013, J TRAUMA ACUTE CARE, V74, P774, DOI 10.1097/TA.0b013e31827a6e69; Eastridge BJ, 2012, J TRAUMA ACUTE CARE, V73, pS431, DOI 10.1097/TA.0b013e3182755dcc; Gilchrist Julie, 2012, Morbidity and Mortality Weekly Report, V61, P270; Hartholt KA, 2012, AM J PUBLIC HEALTH, V102, pS207, DOI 10.2105/AJPH.2011.300288; Hu GQ, 2009, AM J PREV MED, V37, P188, DOI 10.1016/j.amepre.2009.04.023; Hu GQ, 2010, INJURY PREV, V16, P26, DOI 10.1136/ip.2009.023481; MARSHALL JC, 1995, CRIT CARE MED, V23, P1638, DOI 10.1097/00003246-199510000-00007; McGwin G, 2009, J TRAUMA, V66, P526, DOI 10.1097/TA.0b013e3181623321; Meislin H, 1997, J TRAUMA, V43, P433, DOI 10.1097/00005373-199709000-00008; Minei JP, 2010, ANN SURG, V252, P149, DOI 10.1097/SLA.0b013e3181df0401; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; Stewart RM, 2003, J TRAUMA, V54, P66, DOI 10.1097/00005373-200301000-00009; TRUNKEY DD, 1983, SCI AM, V249, P28, DOI 10.1038/scientificamerican0883-28	19	75	78	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-4932	1528-1140		ANN SURG	Ann. Surg.	MAR	2015	261	3					586	590		10.1097/SLA.0000000000000837			5	Surgery	Surgery	CB3WK	WOS:000349559900058	25072443	Green Accepted			2021-06-18	
J	Wang, WX; Visavadiya, NP; Pandya, JD; Nelson, PT; Sullivan, PG; Springer, JE				Wang, Wang-Xia; Visavadiya, Nishant P.; Pandya, Jignesh D.; Nelson, Peter T.; Sullivan, Patrick G.; Springer, Joe E.			Mitochondria-associated microRNAs in rat hippocampus following traumatic brain injury	EXPERIMENTAL NEUROLOGY			English	Article						MicroRNA; Mitochondria; Traumatic brain injury; Controlled cortical impact; Hippocampus; Inflammation; MiR-142-3p; MiR-142-5p; MiR-146a; MiR-155; MiR-223; MiR-150	NORMAL IMMUNE FUNCTION; SPINAL-CORD-INJURY; CELL-DEATH; TRANSCRIPTION FACTORS; RNA INTERFERENCE; OXIDATIVE STRESS; P-BODIES; EXPRESSION; DYSFUNCTION; REGULATOR	Traumatic brain injury (TBI) is a major cause of death and disability. However, the molecular events contributing to the pathogenesis are not well understood. Mitochondria serve as the powerhouse of cells, respond to cellular demands and stressors, and play an essential role in cell signaling, differentiation, and survival. There is clear evidence of compromised mitochondrial function following TBI; however, the underlying mechanisms and consequences are not clear. MicroRNAs (miRNAs) are small non-coding RNA molecules that regulate gene expression post-transcriptionally, and function as important mediators of neuronal development, synaptic plasticity, and neurodegeneration. Several miRNAs show altered expression following TBI; however, the relevance of mitochondria in these pathways is unknown. Here, we present evidence supporting the association of miRNA with hippocampal mitochondria, as well as changes in mitochondria-associated miRNA expression following a controlled cortical impact (CCI) injury in rats. Specifically, we found that the miRNA processing proteins Argonaute (AGO) and Dicer are present in mitochondria fractions from uninjured rat hippocampus, and immunoprecipitation of AGO associated miRNA from mitochondria suggests the presence of functional RNA-induced silencing complexes. Interestingly, RT-qPCR miRNA array studies revealed that a subset of miRNA is enriched in mitochondria relative to cytoplasm. At 12 h following CCI, several miRNAs are significantly altered in hippocampal mitochondria and cytoplasm. In addition, levels of miR-155 and miR-223, both of which play a role in inflammatory processes, are significantly elevated in both cytoplasm and mitochondria. We propose that mitochondria-associated miRNAs may play an important role in regulating the response to TBI. (C) 2015 Elsevier Inc. All rights reserved.	[Wang, Wang-Xia; Nelson, Peter T.] Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA; [Visavadiya, Nishant P.; Springer, Joe E.] Univ Kentucky, Phys Med & Rehabil, Lexington, KY 40536 USA; [Visavadiya, Nishant P.; Pandya, Jignesh D.; Sullivan, Patrick G.; Springer, Joe E.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA; [Pandya, Jignesh D.; Sullivan, Patrick G.; Springer, Joe E.] Univ Kentucky, Anat & Neurobiol, Lexington, KY 40536 USA; [Wang, Wang-Xia; Nelson, Peter T.] Univ Kentucky, Dept Pathol, Lexington, KY 40536 USA	Wang, WX (corresponding author), Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA.	wwangc@email.uky.edu; jspring@uky.edu	Wang, Wang-Xia/AAD-6900-2019	Wang, Wang-Xia/0000-0002-8104-3779	Morton Cure Paralysis Fund; National Center for Advancing Translational SciencesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UT1TR000117]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [UL1TR000117]; PHSUnited States Department of Health & Human ServicesUnited States Public Health Service [NS085830, AG042419]; KSCHIRT endowed chair funds; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000117] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS085830] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG042419, P30AG028383] Funding Source: NIH RePORTER	The described work was supported by the Morton Cure Paralysis Fund and an endowment from Cardinal Hill Rehabilitation Hospital (JES), an ADC-Pilot grant by the National Center for Advancing Translational Sciences (UT1TR000117), National Institutes of Health through grant number UL1TR000117 (WXW), PHS grants NS085830 and AG042419 (PTN) and a KSCHIRT endowed chair funds (PGS).	Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; Atorino L, 2003, J CELL BIOL, V163, P777, DOI 10.1083/jcb.200304112; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Bandiera S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020746; Barrey E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020220; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bian Z, 2010, CELL RES, V20, P1076, DOI 10.1038/cr.2010.119; Brown MR, 2004, J NEUROSCI METH, V137, P299, DOI 10.1016/j.jneumeth.2004.02.028; Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Chen K, 2007, NAT REV GENET, V8, P93, DOI 10.1038/nrg1990; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Das S, 2012, CIRC RES, V110, P1596, DOI 10.1161/CIRCRESAHA.112.267732; Davis LM, 2008, J NEUROSCI RES, V86, P1812, DOI 10.1002/jnr.21628; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Ernoult-Lange M, 2012, BIOCHIMIE, V94, P1572, DOI 10.1016/j.biochi.2012.03.008; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fazi F, 2005, CELL, V123, P819, DOI 10.1016/j.cell.2005.09.023; Finkelstein EA., 2006, INCIDENCE EC BURDEN; Gilmer LK, 2009, J NEUROTRAUM, V26, P1271, DOI 10.1089/neu.2008.0857; Hata A, 2013, ANNU REV PHYSIOL, V75, P69, DOI 10.1146/annurev-physiol-030212-183737; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Higgs Gadareth, 2013, J Clin Bioinforma, V3, P17, DOI 10.1186/2043-9113-3-17; Hoshino K, 1999, J IMMUNOL, V162, P3749; Hu JZ, 2013, J NEUROTRAUM, V30, P1349, DOI 10.1089/neu.2012.2748; Hu ZH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039357; Huang L, 2011, J BIOL CHEM, V286, P24219, DOI 10.1074/jbc.M111.240259; Huntzinger E, 2011, NAT REV GENET, V12, P99, DOI 10.1038/nrg2936; Johnnidis JB, 2008, NATURE, V451, P1125, DOI 10.1038/nature06607; Kren BT, 2009, RNA BIOL, V6, P65, DOI 10.4161/rna.6.1.7534; Kurowska-Stolarska M, 2011, P NATL ACAD SCI USA, V108, P11193, DOI 10.1073/pnas.1019536108; Landgraf P, 2007, CELL, V129, P1401, DOI 10.1016/j.cell.2007.04.040; Latronico MVG, 2012, CIRC RES, V110, P1540, DOI 10.1161/CIRCRESAHA.112.271312; Lei P, 2009, BRAIN RES, V1284, P191, DOI 10.1016/j.brainres.2009.05.074; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; Liu L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103948; Liu NK, 2009, EXP NEUROL, V219, P424, DOI 10.1016/j.expneurol.2009.06.015; Liu X, 2008, BRAIN PATHOL, V18, P113, DOI 10.1111/j.1750-3639.2007.00121.x; Lung B, 2006, NUCLEIC ACIDS RES, V34, P3842, DOI 10.1093/nar/gkl448; Maniataki E, 2005, RNA, V11, P849, DOI 10.1261/rna.2210805; McBride HM, 2006, CURR BIOL, V16, pR551, DOI 10.1016/j.cub.2006.06.054; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Mercer TR, 2011, CELL, V146, P645, DOI 10.1016/j.cell.2011.06.051; Mestdagh P, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-6-r64; Moore CS, 2013, ANN NEUROL, V74, P709, DOI 10.1002/ana.23967; Nelson PT, 2008, BRAIN PATHOL, V18, P130, DOI 10.1111/j.1750-3639.2007.00120.x; Nelson PT, 2007, RNA, V13, P1787, DOI 10.1261/rna.646007; Nelson PT, 2008, BBA-GENE REGUL MECH, V1779, P758, DOI 10.1016/j.bbagrm.2008.03.012; Pandya JD, 2009, EXP NEUROL, V218, P381, DOI 10.1016/j.expneurol.2009.05.023; Patel SP, 2009, J NEUROSCI RES, V87, P130, DOI 10.1002/jnr.21814; Quinn SR, 2011, INT IMMUNOL, V23, P421, DOI 10.1093/intimm/dxr034; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Redell JB, 2010, J NEUROTRAUM, V27, P2147, DOI 10.1089/neu.2010.1481; Redell JB, 2009, J NEUROSCI RES, V87, P1435, DOI 10.1002/jnr.21945; RINK A, 1995, AM J PATHOL, V147, P1575; Rodriguez A, 2007, SCIENCE, V316, P608, DOI 10.1126/science.1139253; Rosenfeld JV, 2012, LANCET, V380, P1088, DOI 10.1016/S0140-6736(12)60864-2; Sabirzhanov B, 2014, J NEUROSCI, V34, P10055, DOI 10.1523/JNEUROSCI.1260-14.2014; Saraste M, 1999, SCIENCE, V283, P1488, DOI 10.1126/science.283.5407.1488; Seddiki N, 2014, IMMUNOLOGY, V142, P32, DOI 10.1111/imm.12227; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Sonkoly E, 2008, SEMIN CANCER BIOL, V18, P131, DOI 10.1016/j.semcancer.2008.01.005; Sripada L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044873; Strickland ER, 2011, NEUROSCIENCE, V186, P146, DOI 10.1016/j.neuroscience.2011.03.063; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; Sun TY, 2014, J HUAZHONG U SCI-MED, V34, P548, DOI 10.1007/s11596-014-1313-1; Sun W, 2010, CELL RES, V20, P1158, DOI 10.1038/cr.2010.134; Taibi F, 2014, BBA-MOL BASIS DIS, V1842, P1001, DOI 10.1016/j.bbadis.2014.03.005; Truettner JS, 2013, BRAIN RES, V1533, P122, DOI 10.1016/j.brainres.2013.08.011; Truettner JS, 2011, J CEREBR BLOOD F MET, V31, P1897, DOI 10.1038/jcbfm.2011.33; Vasilatou D, 2010, EUR J HAEMATOL, V84, P1, DOI 10.1111/j.1600-0609.2009.01348.x; Vigorito E, 2007, IMMUNITY, V27, P847, DOI 10.1016/j.immuni.2007.10.009; Vigorito E, 2013, IMMUNOL REV, V253, P146, DOI 10.1111/imr.12057; Wang WX, 2008, J NEUROSCI, V28, P1213, DOI 10.1523/JNEUROSCI.5065-07.2008; Wang Wang-Xia, 2014, Genomics Proteomics & Bioinformatics, V12, P19, DOI 10.1016/j.gpb.2013.10.003; Wang WX, 2010, RNA, V16, P394, DOI 10.1261/rna.1905910; Wang WX, 2008, BBA-GENE REGUL MECH, V1779, P749, DOI 10.1016/j.bbagrm.2008.01.005; Xiao CC, 2007, CELL, V131, P146, DOI 10.1016/j.cell.2007.07.021; Yu D, 2014, J MOL NEUROSCI, V53, P242, DOI 10.1007/s12031-014-0293-8; Yunta M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034534; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	84	75	78	1	22	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	MAR	2015	265						84	93		10.1016/j.expneurol.2014.12.018			10	Neurosciences	Neurosciences & Neurology	CD3ZH	WOS:000351021900009	25562527	Green Accepted, Green Published			2021-06-18	
J	Lei, BL; Mace, B; Dawson, HN; Warner, DS; Laskowitz, DT; James, ML				Lei, Beilei; Mace, Brian; Dawson, Hana N.; Warner, David S.; Laskowitz, Daniel T.; James, Michael L.			Anti-Inflammatory Effects of Progesterone in Lipopolysaccharide-Stimulated BV-2 Microglia	PLOS ONE			English	Article							TRAUMATIC BRAIN-INJURY; NF-KAPPA-B; NITRIC-OXIDE SYNTHASE; TUMOR-NECROSIS-FACTOR; CEREBRAL-ARTERY OCCLUSION; PRIMARY GLIAL CULTURES; INTRACEREBRAL HEMORRHAGE; RATS; EXPRESSION; ISCHEMIA	Female sex is associated with improved outcome in experimental brain injury models, such as traumatic brain injury, ischemic stroke, and intracerebral hemorrhage. This implies female gonadal steroids may be neuroprotective. A mechanism for this may involve modulation of post-injury neuroinflammation. As the resident immunomodulatory cells in central nervous system, microglia are activated during acute brain injury and produce inflammatory mediators which contribute to secondary injury including proinflammatory cytokines, and nitric oxide (NO) and prostaglandin E-2 (PGE(2)), mediated by inducible NO synthase (iNOS) and cyclooxygenase-2 (COX-2), respectively. We hypothesized that female gonadal steroids reduce microglia mediated neuroinflammation. In this study, the progesterone's effects on tumor necrosis factor alpha (TNF-alpha), iNOS, and COX-2 expression were investigated in lipopolysaccharide (LPS)-stimulated BV-2 microglia. Further, investigation included nuclear factor kappa B (NF-kappa B) and mitogen activated protein kinase (MAPK) pathways. LPS (30 ng/ml) upregulated TNF-alpha, iNOS, and COX-2 protein expression in BV-2 cells. Progesterone pretreatment attenuated LPS-stimulated TNF-alpha, iNOS, and COX-2 expression in a dose-dependent fashion. Progesterone suppressed LPS-induced NF-kappa B activation by decreasing inhibitory kappa B alpha and NF-kappa B p65 phosphorylation and p65 nuclear translocation. Progesterone decreased LPS-mediated phosphorylation of p38, c-Jun N-terminal kinase and extracellular regulated kinase MAPKs. These progesterone effects were inhibited by its antagonist mifepristone. In conclusion, progesterone exhibits pleiotropic anti-inflammatory effects in LPS-stimulated BV-2 microglia by down-regulating proinflammatory mediators corresponding to suppression of NF-kappa B and MAPK activation. This suggests progesterone may be used as a potential neurotherapeutic to treat inflammatory components of acute brain injury.	[Lei, Beilei; Warner, David S.; Laskowitz, Daniel T.; James, Michael L.] Duke Univ, Med Ctr, Multidisciplinary Neuroprotect Labs, Durham, NC 27708 USA; [Lei, Beilei; Warner, David S.; Laskowitz, Daniel T.; James, Michael L.] Duke Univ, Med Ctr, Dept Anesthesiol, Durham, NC 27710 USA; [Mace, Brian; Dawson, Hana N.; Laskowitz, Daniel T.; James, Michael L.] Duke Univ, Med Ctr, Dept Neurol, Durham, NC USA; [Warner, David S.; Laskowitz, Daniel T.] Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC 27710 USA	James, ML (corresponding author), Duke Univ, Med Ctr, Multidisciplinary Neuroprotect Labs, Durham, NC 27708 USA.	Michael.james@duke.edu	James, Michael L./AAJ-5592-2020	James, Michael L./0000-0002-8715-5210	American Heart Association-Scientist Development GrantAmerican Heart Association	This work was supported by American Heart Association-Scientist Development Grant (MLJ). The funders had no role in study design, data collection and analysis, decision to publish, or prearation of the manuscript.	Bachstetter AD, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-79; Bhat NR, 2002, J BIOL CHEM, V277, P29584, DOI 10.1074/jbc.M204994200; Bhat NR, 1998, J NEUROSCI, V18, P1633; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; BOCCHINI V, 1992, J NEUROSCI RES, V31, P616, DOI 10.1002/jnr.490310405; Brinton RD, 2008, FRONT NEUROENDOCRIN, V29, P313, DOI 10.1016/j.yfrne.2008.02.001; Burguillos MA, 2011, NATURE, V472, P319, DOI 10.1038/nature09788; Cervantes M, 2002, ARCH MED RES, V33, P6, DOI 10.1016/S0188-4409(01)00347-2; Chen JL, 1999, J NEUROL SCI, V171, P24, DOI 10.1016/S0022-510X(99)00247-6; Cutler SM, 2007, J NEUROTRAUM, V24, P1475, DOI 10.1089/neu.2007.0294; DAcquisto F, 1997, FEBS LETT, V418, P175, DOI 10.1016/S0014-5793(97)01377-X; Dang J, 2011, BRAIN BEHAV IMMUN, V25, P715, DOI 10.1016/j.bbi.2011.01.013; Floden AM, 2006, J NEUROSCI, V26, P4644, DOI 10.1523/JNEUROSCI.4822-05.2006; Gibson CL, 2011, BRAIN, V134, P2125, DOI 10.1093/brain/awr132; Gomes-Leal W, 2012, BRAIN BEHAV, V2, P345, DOI 10.1002/brb3.51; Gregersen R, 2000, J CEREBR BLOOD F MET, V20, P53, DOI 10.1097/00004647-200001000-00009; Hardy DB, 2008, MOL ENDOCRINOL, V22, P1812, DOI 10.1210/me.2007-0443; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; Hehlgans T, 2005, IMMUNOLOGY, V115, P1, DOI 10.1111/j.1365-2567.2005.02143.x; Henn A, 2009, ALTEX-ALTERN TIEREXP, V26, P83; Ishrat T, 2009, BRAIN RES, V1257, P94, DOI 10.1016/j.brainres.2008.12.048; Jang BC, 2005, CELL SIGNAL, V17, P625, DOI 10.1016/j.cellsig.2004.10.001; Kumon Y, 2000, J NEUROSURG, V92, P848, DOI 10.3171/jns.2000.92.5.0848; Lei BL, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-103; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Mani S, 2008, ENDOCRINOLOGY, V149, P2750, DOI 10.1210/en.2008-0097; Mani Shaila K, 2012, Front Endocrinol (Lausanne), V3, P7, DOI 10.3389/fendo.2012.00007; Marks-Konczalik J, 1998, J BIOL CHEM, V273, P22201, DOI 10.1074/jbc.273.35.22201; Morali G, 2005, NEUROSCI LETT, V382, P286, DOI 10.1016/j.neulet.2005.03.066; NELSON JF, 1992, ENDOCRINOLOGY, V130, P805, DOI 10.1210/en.130.2.805; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; Ridder DA, 2009, NEUROSCIENCE, V158, P995, DOI 10.1016/j.neuroscience.2008.07.007; Robertson CL, 2006, EXP NEUROL, V197, P235, DOI 10.1016/j.expneurol.2005.09.014; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; Shahrokhi N, 2010, CAN J PHYSIOL PHARM, V88, P414, DOI [10.1139/Y09-126, 10.1139/y09-126]; Singh M, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00159; Singh M, 2013, HORM BEHAV, V63, P284, DOI 10.1016/j.yhbeh.2012.06.003; Taylor RA, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/746068; Vallabhapurapu S, 2009, ANNU REV IMMUNOL, V27, P693, DOI 10.1146/annurev.immunol.021908.132641; Vallee M, 1997, P NATL ACAD SCI USA, V94, P14865, DOI 10.1073/pnas.94.26.14865; Waetzig V, 2005, GLIA, V50, P235, DOI 10.1002/glia.20173; Wagner CK, 2006, FRONT NEUROENDOCRIN, V27, P340, DOI 10.1016/j.yfrne.2006.07.003; Wang Z, 2011, MEDIAT INFLAMM, V2011, DOI 10.1155/2011/848309; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; XIE QW, 1994, J BIOL CHEM, V269, P4705; Yan F, 2013, NEUROSCI LETT, V543, P163, DOI 10.1016/j.neulet.2013.03.005; Zhang P, 1998, NEUROCHEM RES, V23, P219, DOI 10.1023/A:1022489127107; Zhao XR, 2007, J NEUROCHEM, V101, P652, DOI 10.1111/j.1471-4159.2006.04414.x; Zhou ZG, 2010, PAIN, V151, P296, DOI 10.1016/j.pain.2010.06.017; Zhu Y, 2008, COMP BIOCHEM PHYS C, V148, P381, DOI 10.1016/j.cbpc.2008.05.019	52	75	81	2	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 31	2014	9	7							e103969	10.1371/journal.pone.0103969			7	Multidisciplinary Sciences	Science & Technology - Other Topics	AM6EF	WOS:000339954800102	25080336	DOAJ Gold, Green Published			2021-06-18	
J	Uteshev, VV				Uteshev, Victor V.			The therapeutic promise of positive allosteric modulation of nicotinic receptors	EUROPEAN JOURNAL OF PHARMACOLOGY			English	Article						Positive allosteric modulator; Nicotinic acetylcholine receptor; PNU-120596; Choline; Cerebral ischemia; Analgesia	ACETYLCHOLINE-RECEPTOR; COMPARATIVE PHARMACOLOGY; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; COGNITIVE FUNCTION; ALPHA-7 RECEPTORS; BINDING-SITES; BRAIN-TISSUE; AGONIST; CHOLINE	In the central nervous system, deficits in cholinergic neurotransmission correlate with decreased attention and cognitive impairment, while stimulation of neuronal nicotinic acetylcholine receptors improves attention, cognitive performance and neuronal resistance to injury as well as produces robust analgesic and anti-inflammatory effects. The rational basis for the therapeutic use of orthosteric agonists and positive allosteric modulators (PAMs) of nicotinic receptors arises from the finding that functional nicotinic receptors are ubiquitously expressed in neuronal and non-neuronal tissues including brain regions highly vulnerable to traumatic and ischemic types of injury (e g, cortex and hippocampus). Moreover, functional nicotinic receptors do not vanish in age-, disease- and trauma-related neuropathologies, but their expression and/or activation levels decline in a subunit- and brain region-specific manner. Therefore, augmenting the endogenous cholinergic tone by nicotinic agents is possible and may offset neurological impairments associated with cholinergic hypofunction. Importantly, because neuronal damage elevates extracellular levels of choline (a selective agonist of alpha 7 nicotinic acetylcholine receptors) near the site of injury, alpha 7-PAM-based treatments may augment pathology-activated alpha 7-dependent auto-therapies where and when they are most needed (i.e., in the penumbra, post-injury). Thus, nicotinic-PAM-based treatments are expected to augment the endogenous cholinergic tone in a spatially and temporally restricted manner creating the potential for differential efficacy and improved, safety as compared to exogenous orthosteric nicotinic agonists that activate nicotinic receptors indiscriminately. In this review, I will summarize the existing trends in therapeutic applications of nicotinic PAMs. (C) 2014 Elsevier B.V. All rights reserved.	Univ North Texas Hlth Sci Ctr, Dept Pharmacol & Neurosci, Ft Worth, TX 76107 USA	Uteshev, VV (corresponding author), Univ North Texas Hlth Sci Ctr, Dept Pharmacol & Neurosci, Ft Worth, TX 76107 USA.	Victor.Uteshev@unthsc.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [DK082625]; Rainwater Charitable Foundation; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01DK082625] Funding Source: NIH RePORTER	I thank Dr. John Dani and Dr. Daniel McGehee for productive discussions and criticism. I thank Dr. Imad Damaj for helpful suggestions. This study was supported by the NIH grant DK082625 and a grant from the Rainwater Charitable Foundation to VU.	Akaike A, 2010, J MOL NEUROSCI, V40, P211, DOI 10.1007/s12031-009-9236-1; Alkondon M, 1997, EUR J NEUROSCI, V9, P2734, DOI 10.1111/j.1460-9568.1997.tb01702.x; ARENDASH GW, 1995, BRAIN RES, V674, P252, DOI 10.1016/0006-8993(94)01449-R; BADIO B, 1994, MOL PHARMACOL, V45, P563; BARTUS RT, 1982, SCIENCE, V217, P408, DOI 10.1126/science.7046051; Bencherif M, 2011, CELL MOL LIFE SCI, V68, P931, DOI 10.1007/s00018-010-0525-1; Cabrera SM, 2006, BEHAV NEUROSCI, V120, P298, DOI 10.1037/0735-7044.120.2.298; Callahan PM, 2013, NEUROPHARMACOLOGY, V67, P201, DOI 10.1016/j.neuropharm.2012.10.019; Damaj MI, 2000, NEUROPHARMACOLOGY, V39, P2785, DOI 10.1016/S0028-3908(00)00139-8; del Barrio L, 2011, TOXICOL SCI, V123, P193, DOI 10.1093/toxsci/kfr163; Dinklo T, 2011, J PHARMACOL EXP THER, V336, P560, DOI 10.1124/jpet.110.173245; DJURICIC B, 1991, J CEREBR BLOOD F MET, V11, P308, DOI 10.1038/jcbfm.1991.63; Egea J, 2007, NEUROSCIENCE, V145, P866, DOI 10.1016/j.neuroscience.2006.12.036; Faghih R, 2009, J MED CHEM, V52, P3377, DOI 10.1021/jm9003818; Feuerbach D, 2009, NEUROPHARMACOLOGY, V56, P254, DOI 10.1016/j.neuropharm.2008.08.025; FREEDMAN R, 1995, BIOL PSYCHIAT, V38, P22, DOI 10.1016/0006-3223(94)00252-X; Freedman R, 2008, AM J PSYCHIAT, V165, P1040, DOI 10.1176/appi.ajp.2008.07071135; Freitas K, 2013, BRIT J PHARMACOL, V169, P567, DOI 10.1111/j.1476-5381.2012.02226.x; Freitas K, 2013, J PHARMACOL EXP THER, V344, P264, DOI 10.1124/jpet.112.197871; Gasull T, 2000, J BIOL CHEM, V275, P18350, DOI 10.1074/jbc.M910468199; GERZANICH V, 1995, MOL PHARMACOL, V48, P774; Guan ZZ, 2000, J NEUROCHEM, V74, P237, DOI 10.1046/j.1471-4159.2000.0740237.x; Gusev AG, 2010, J PHARMACOL EXP THER, V332, P588, DOI 10.1124/jpet.109.162099; Guseva MV, 2008, J NEUROTRAUM, V25, P975, DOI 10.1089/neu.2008.0516; Harris JG, 2004, NEUROPSYCHOPHARMACOL, V29, P1378, DOI 10.1038/sj.npp.1300450; Hu M, 2009, BRIT J PHARMACOL, V158, P1857, DOI 10.1111/j.1476-5381.2009.00474.x; Hurst RS, 2005, J NEUROSCI, V25, P4396, DOI 10.1523/JNEUROSCI.5269-04.2005; JANOWSKY DS, 1974, PSYCHOSOM MED, V36, P248, DOI 10.1097/00006842-197405000-00008; Kalappa BI, 2013, EUR J PHARMACOL, V718, P226, DOI 10.1016/j.ejphar.2013.08.027; Kalappa BI, 2013, BRIT J PHARMACOL, V169, P1862, DOI 10.1111/bph.12247; Kalappa BI, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013964; Kaneko S, 1997, BRAIN RES, V765, P135, DOI 10.1016/S0006-8993(97)00556-8; Kelso ML, 2012, CURR DRUG TARGETS, V13, P631, DOI 10.2174/138945012800398964; Kem WR, 2000, BEHAV BRAIN RES, V113, P169, DOI 10.1016/S0166-4328(00)00211-4; Kiewert C, 2010, BRAIN RES, V1312, P101, DOI 10.1016/j.brainres.2009.11.068; Kitagawa H, 2003, NEUROPSYCHOPHARMACOL, V28, P542, DOI 10.1038/sj.npp.1300028; Lee CH, 2011, BIOCHEM PHARMACOL, V82, P959, DOI 10.1016/j.bcp.2011.06.044; Lendvai B, 2013, BRAIN RES BULL, V93, P86, DOI 10.1016/j.brainresbull.2012.11.003; Leonard S, 2000, EUR J PHARMACOL, V393, P237, DOI 10.1016/S0014-2999(00)00035-2; Levin ED, 2006, PSYCHOPHARMACOLOGY, V184, P523, DOI 10.1007/s00213-005-0164-7; Li YX, 1999, BRAIN RES, V830, P218, DOI 10.1016/S0006-8993(99)01372-4; McLean SL, 2012, J PSYCHOPHARMACOL, V26, P1265, DOI 10.1177/0269881111431747; Medhurst SJ, 2008, J PAIN, V9, P580, DOI 10.1016/j.jpain.2008.01.336; Munro G, 2012, BRIT J PHARMACOL, V167, P421, DOI 10.1111/j.1476-5381.2012.02003.x; Newhouse PA, 2004, CURR OPIN PHARMACOL, V4, P36, DOI 10.1016/j.coph.2003.11.001; Ng HJ, 2007, P NATL ACAD SCI USA, V104, P8059, DOI 10.1073/pnas.0701321104; Nirogi R, 2013, EUR J PHARMACOL, V712, P22, DOI 10.1016/j.ejphar.2013.04.021; NORDBERG A, 1986, NEUROSCI LETT, V72, P115, DOI 10.1016/0304-3940(86)90629-4; Olincy A, 2006, ARCH GEN PSYCHIAT, V63, P630, DOI 10.1001/archpsyc.63.6.630; Papke RL, 1996, NEUROSCI LETT, V213, P201; Papke RL, 2002, BRIT J PHARMACOL, V137, P49, DOI 10.1038/sj.bjp.0704833; Parada E., 2013, ANTIOXID REDOX SIGNA; PERRY EK, 1995, NEUROSCIENCE, V64, P385, DOI 10.1016/0306-4522(94)00410-7; PETERSEN RC, 1977, PSYCHOPHARMACOLOGY, V52, P283, DOI 10.1007/BF00426713; QIAN CG, 1993, EUR J PHARMACOL, V250, pR13; Rao AM, 2000, J NEUROCHEM, V75, P2528, DOI 10.1046/j.1471-4159.2000.0752528.x; Rode F, 2012, BRAIN RES, V1458, P67, DOI 10.1016/j.brainres.2012.03.064; Roncarati R, 2009, J PHARMACOL EXP THER, V329, P459, DOI 10.1124/jpet.108.150094; Rowbotham MC, 2009, PAIN, V146, P245, DOI 10.1016/j.pain.2009.06.013; Shimohama S, 1998, BRAIN RES, V779, P359, DOI 10.1016/S0006-8993(97)00194-7; Shimohama S, 2009, BIOL PHARM BULL, V32, P332, DOI 10.1248/bpb.32.332; Sun F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073581; Takeuchi H, 2009, J NEUROSCI RES, V87, P576, DOI 10.1002/jnr.21869; Thomsen MS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027014; Umana IC, 2013, BIOCHEM PHARMACOL, V86, P1208, DOI 10.1016/j.bcp.2013.08.001; Uteshev VV, 2003, J NEUROPHYSIOL, V89, P1797, DOI 10.1152/jn.00943.2002; Verbois SL, 2003, NEUROSCIENCE, V119, P1199, DOI 10.1016/S0306-4522(03)00206-9; Wallace TL, 2011, BIOCHEM PHARMACOL, V82, P891, DOI 10.1016/j.bcp.2011.06.034; Wang H, 2003, NATURE, V421, P384, DOI 10.1038/nature01339; White SH, 2012, J NEUROPHYSIOL, V107, P2083, DOI 10.1152/jn.00701.2011; Yang JS, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002612; Zhu CZ, 2011, BIOCHEM PHARMACOL, V82, P967, DOI 10.1016/j.bcp.2011.05.007	72	75	78	3	22	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0014-2999	1879-0712		EUR J PHARMACOL	Eur. J. Pharmacol.	MAR 15	2014	727						181	185		10.1016/j.ejphar.2014.01.072			5	Pharmacology & Pharmacy	Pharmacology & Pharmacy	AC8EY	WOS:000332767500023	24530419	Green Accepted			2021-06-18	
J	Begum, G; Yan, HQ; Li, L; Singh, A; Dixon, CE; Sun, D				Begum, Gulnaz; Yan, Hong Q.; Li, Liaoliao; Singh, Amneet; Dixon, C. Edward; Sun, Dandan			Docosahexaenoic Acid Reduces ER Stress and Abnormal Protein Accumulation and Improves Neuronal Function Following Traumatic Brain Injury	JOURNAL OF NEUROSCIENCE			English	Article						amyloid precursor protein; controlled cortical impact injury; docosahexaenoic acid; phosphorylated tau; unfolded protein response	ENDOPLASMIC-RETICULUM STRESS; DIFFUSE AXONAL INJURY; AMYLOID PRECURSOR PROTEIN; CORTICAL IMPACT MODEL; CELL-DEATH; CHEMICAL CHAPERONES; ASTROCYTES; BETA; NA+; HOMEOSTASIS	In this study, we investigated the development of endoplasmic reticulum (ER) stress after traumatic brain injury (TBI) and the efficacy of post-TBI administration of docosahexaenoic acid (DHA) in reducing ER stress. TBI was induced by cortical contusion injury in Sprague-Dawley rats. Either DHA (16 mg/kg in DMSO) or vehicle DMSO (1 ml/kg) was administered intraperitoneally at 5 min after TBI, followed by a daily dose for 3-21 d. TBI triggered sustained expression of the ER stress marker proteins including phosphorylated eukaryotic initiation factor-2 alpha, activating transcription factor 4, inositol requiring kinase 1, and C/EBP homologous protein in the ipsilateral cortex at 3-21 d after TBI. The prolonged ER stress was accompanied with an accumulation of abnormal ubiquitin aggregates and increased expression of amyloid precursor protein (APP) and phosphorylated tau (p-Tau) in the frontal cortex after TBI. The ER stress marker proteins were colocalized with APP accumulation in the soma. Interestingly, administration of DHA attenuated all ER stress marker proteins and reduced the accumulation of both ubiquitinated proteins and APP/p-Tau proteins. In addition, the DHA-treated animals exhibited early recovery of their sensorimotor function after TBI. In summary, our study demonstrated that TBI induces a prolonged ER stress, which is positively correlated with abnormal APP accumulation. The sustained ER stress may play a role in chronic neuronal damage after TBI. Our findings illustrate that post-TBI administration of DHA has therapeutic potentials in reducing ER stress, abnormal protein accumulation, and neurological deficits.	[Begum, Gulnaz; Li, Liaoliao; Singh, Amneet; Sun, Dandan] Univ Pittsburgh, Brain Trauma Res Ctr, Dept Neurol, Pittsburgh, PA 15213 USA; [Yan, Hong Q.; Dixon, C. Edward] Univ Pittsburgh, Brain Trauma Res Ctr, Dept Neurosurg, Pittsburgh, PA 15213 USA; [Dixon, C. Edward; Sun, Dandan] Geriatr Res Educ & Clin Ctr, Vet Affairs Pittsburgh Hlth Care Syst, Pittsburgh, PA 15213 USA	Sun, D (corresponding author), Univ Pittsburgh, Sch Med, Dept Neurol, S 598 S Biomedical Sci Tower,3500 Terrace St, Pittsburgh, PA 15213 USA.	sund@upmc.edu	soler, martha maricel m gomez/L-6025-2014	soler, martha maricel m gomez/0000-0002-4412-8108	University of Pittsburgh Neurology Departmental startup funds; University of Pittsburgh Medical Center endowed Chair Professorship on Brain Disorder Diseases; United States Department of Veterans Affairs VA RRD [B6761R]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038118] Funding Source: NIH RePORTER	This work was supported in part by University of Pittsburgh Neurology Departmental startup funds and University of Pittsburgh Medical Center endowed Chair Professorship on Brain Disorder Diseases (D.S.) and the United States Department of Veterans Affairs VA RR&D#B6761R Grant (C.E.D.).	Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Bailes JE, 2010, J NEUROTRAUM, V27, P1617, DOI 10.1089/neu.2009.1239; Bazan NG, 2009, J LIPID RES, V50, pS400, DOI 10.1194/jlr.R800068-JLR200; Begum G, 2012, J NEUROCHEM, V120, P622, DOI 10.1111/j.1471-4159.2011.07606.x; Belayev L, 2011, TRANSL STROKE RES, V2, P33, DOI 10.1007/s12975-010-0046-0; Berman DR, 2010, AM J OBSTET GYNECOL, V203, DOI 10.1016/j.ajog.2010.06.017; Boyce M, 2005, SCIENCE, V307, P935, DOI 10.1126/science.1101902; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Chen XH, 2004, AM J PATHOL, V165, P357, DOI 10.1016/S0002-9440(10)63303-2; Chen XZ, 2008, J NEUROCHEM, V106, P1563, DOI 10.1111/j.1471-4159.2008.05501.x; Chen XZ, 2010, J NEUROCHEM, V112, P173, DOI 10.1111/j.1471-4159.2009.06438.x; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; Colla E, 2012, J NEUROSCI, V32, P3301, DOI 10.1523/JNEUROSCI.5368-11.2012; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; DEWJI NN, 1995, MOL BRAIN RES, V33, P245, DOI 10.1016/0169-328X(95)00131-B; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Donnelly N, 2013, CELL MOL LIFE SCI, V70, P3493, DOI 10.1007/s00018-012-1252-6; Drexler HCA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004161; Engin F, 2010, DIABETES OBES METAB, V12, P108, DOI 10.1111/j.1463-1326.2010.01282.x; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Groenendyk J, 2005, ACTA BIOCHIM POL, V52, P381; Hasadsri L, 2013, J NEUROTRAUM, V30, P897, DOI 10.1089/neu.2012.2672; Hoozemans JJM, 2012, NEURODEGENER DIS, V10, P212, DOI 10.1159/000334536; Hoozemans JJM, 2009, AM J PATHOL, V174, P1241, DOI 10.2353/ajpath.2009.080814; Hu BR, 2001, J CEREBR BLOOD F MET, V21, P865, DOI 10.1097/00004647-200107000-00012; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Ikonomovic MD, 2012, ACTA NEUROPATHOL, V123, P433, DOI 10.1007/s00401-012-0943-2; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Innis SM, 2007, J NUTR, V137, P855; Itoh T, 2009, NEUROL RES, V31, P103, DOI 10.1179/016164108X323771; Joseph MS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041288; Kim I, 2008, NAT REV DRUG DISCOV, V7, P1013, DOI 10.1038/nrd2755; Krajewska M, 2011, BRAIN RES, V1370, P227, DOI 10.1016/j.brainres.2010.11.015; Lai ED, 2007, PHYSIOLOGY, V22, P193, DOI 10.1152/physiol.00050.2006; Lai KO, 2008, P NATL ACAD SCI USA, V105, P17175, DOI 10.1073/pnas.0803906105; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Larner SF, 2004, J NEUROCHEM, V88, P78, DOI 10.1046/j.1471-4159.2003.02141.x; Larner SF, 2006, J NEUROTRAUM, V23, P807, DOI 10.1089/neu.2006.23.807; Lenart B, 2004, J NEUROSCI, V24, P9585, DOI 10.1523/JNEUROSCI.2569-04.2004; Liu Y, 2010, J NEUROCHEM, V114, P1436, DOI 10.1111/j.1471-4159.2010.06862.x; Marcheselli VL, 2003, J BIOL CHEM, V278, P43807, DOI 10.1074/jbc.M305841200; Mills JD, 2011, J NEUROSURG, V114, P77, DOI 10.3171/2010.5.JNS08914; Mukherjee PK, 2004, P NATL ACAD SCI USA, V101, P8491, DOI 10.1073/pnas.0402531101; Ozcan U, 2006, SCIENCE, V313, P1137, DOI 10.1126/science.1128294; Oyadomari S, 2004, CELL DEATH DIFFER, V11, P381, DOI 10.1038/sj.cdd.4401373; Pan HC, 2009, J NUTR BIOCHEM, V20, P715, DOI 10.1016/j.jnutbio.2008.06.014; Paschen W, 2003, CELL CALCIUM, V34, P365, DOI 10.1016/S0143-4160(03)00139-8; Paschen W, 1999, J CEREBR BLOOD F MET, V19, P1, DOI 10.1097/00004647-199901000-00001; Petraglia Anthony L, 2011, Surg Neurol Int, V2, P146, DOI 10.4103/2152-7806.85987; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Purkayastha S, 2011, P NATL ACAD SCI USA, V108, P2939, DOI 10.1073/pnas.1006875108; Sande A, 2010, J VET EMERG CRIT CAR, V20, P177, DOI 10.1111/j.1476-4431.2010.00527.x; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; Singleton RH, 2010, J NEUROTRAUM, V27, P1091, DOI 10.1089/neu.2010.1291; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Smith DH, 2003, NEUROMOL MED, V4, P59, DOI 10.1385/NMM:4:1-2:59; Sokka AL, 2007, J NEUROSCI, V27, P901, DOI 10.1523/JNEUROSCI.4289-06.2007; Stoica BA, 2010, NEUROTHERAPEUTICS, V7, P3, DOI 10.1016/j.nurt.2009.10.023; Su G, 2002, AM J PHYSIOL-CELL PH, V282, pC1147, DOI 10.1152/ajpcell.00538.2001; Sun XT, 2013, J NEUROSCI, V33, P2398, DOI 10.1523/JNEUROSCI.2292-12.2013; Thorell WE, 2002, J NEUROTRAUM, V19, P335, DOI 10.1089/089771502753594909; Uryu K, 2003, EXP NEUROL, V184, P214, DOI 10.1016/S0014-4886(03)00245-0; Wessa P, 2014, FREE STAT SOFTW; Wu AG, 2007, J NEUROTRAUM, V24, P1587, DOI 10.1089/neu.2007.0313; Wu AG, 2011, J NEUROTRAUM, V28, P2113, DOI 10.1089/neu.2011.1872; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208; Young CN, 2012, J CLIN INVEST, V122, P3960, DOI 10.1172/JCI64583; Zhu Y, 2008, J NEUROSCI, V28, P2168, DOI 10.1523/JNEUROSCI.5232-07.2008; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	70	75	81	0	11	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	MAR 5	2014	34	10					3743	3755		10.1523/JNEUROSCI.2872-13.2014			13	Neurosciences	Neurosciences & Neurology	AC7HN	WOS:000332698900027	24599472	Green Published, Bronze			2021-06-18	
J	Hadass, O; Tomlinson, BN; Gooyit, M; Chen, SY; Purdy, JJ; Walker, JM; Zhang, CY; Giritharan, AB; Purnell, W; Robinson, CR; Shin, D; Schroeder, VA; Suckow, MA; Simonyi, A; Sun, GY; Mobashery, S; Cui, JK; Chang, M; Gu, ZZ				Hadass, Orr; Tomlinson, Brittany N.; Gooyit, Major; Chen, Shanyan; Purdy, Justin J.; Walker, Jennifer M.; Zhang, Chunyang; Giritharan, Andrew B.; Purnell, Whitley; Robinson, Christopher R., II; Shin, Dmitriy; Schroeder, Valerie A.; Suckow, Mark A.; Simonyi, Agnes; Sun, Grace Y.; Mobashery, Shahriar; Cui, Jiankun; Chang, Mayland; Gu, Zezong			Selective Inhibition of Matrix Metalloproteinase-9 Attenuates Secondary Damage Resulting from Severe Traumatic Brain Injury	PLOS ONE			English	Article							MATRIX METALLOPROTEINASES; GELATINASE INHIBITOR; KNOCK-OUT; BLOOD; DEGRADATION; EXPRESSION; NEURODEGENERATION; ACTIVATION; MICROGLIA; MECHANISM	Traumatic brain injury (TBI) is a leading cause of death and long-term disability. Following the initial insult, severe TBI progresses to a secondary injury phase associated with biochemical and cellular changes. The secondary injury is thought to be responsible for the development of many of the neurological deficits observed after TBI and also provides a window of opportunity for therapeutic intervention. Matrix metalloproteinase-9 (MMP-9 or gelatinase B) expression is elevated in neurological diseases and its activation is an important factor in detrimental outcomes including excitotoxicity, mitochondrial dysfunction and apoptosis, and increases in inflammatory responses and astrogliosis. In this study, we used an experimental mouse model of TBI to examine the role of MMP-9 and the therapeutic potential of SB-3CT, a mechanism-based gelatinase selective inhibitor, in ameliorating the secondary injury. We observed that activation of MMP-9 occurred within one day following TBI, and remained elevated for 7 days after the initial insult. SB-3CT effectively attenuated MMP-9 activity, reduced brain lesion volumes and prevented neuronal loss and dendritic degeneration. Pharmacokinetic studies revealed that SB-3CT and its active metabolite, p-OH SB-3CT, were rapidly absorbed and distributed to the brain. Moreover, SB-3CT treatment mitigated microglial activation and astrogliosis after TBI. Importantly, SB-3CT treatment improved long-term neurobehavioral outcomes, including sensorimotor function, and hippocampus-associated spatial learning and memory. These results demonstrate that MMP-9 is a key target for therapy to attenuate secondary injury cascades and that this class of mechanism-based gelatinase inhibitor-with such desirable pharmacokinetic properties-holds considerable promise as a potential pharmacological treatment of TBI.	[Hadass, Orr; Tomlinson, Brittany N.; Chen, Shanyan; Purdy, Justin J.; Zhang, Chunyang; Giritharan, Andrew B.; Purnell, Whitley; Robinson, Christopher R., II; Shin, Dmitriy; Cui, Jiankun; Gu, Zezong] Univ Missouri, Sch Med, Dept Pathol & Anat Sci, Columbia, MO USA; [Simonyi, Agnes; Sun, Grace Y.] Univ Missouri, Sch Med, Dept Biochem, Columbia, MO USA; [Hadass, Orr; Tomlinson, Brittany N.; Chen, Shanyan; Purdy, Justin J.; Zhang, Chunyang; Giritharan, Andrew B.; Purnell, Whitley; Robinson, Christopher R., II; Simonyi, Agnes; Sun, Grace Y.; Cui, Jiankun; Gu, Zezong] Univ Missouri, Sch Med, Ctr Translat Neurosci, Columbia, MO USA; [Hadass, Orr; Tomlinson, Brittany N.] Univ Missouri, MS Pathol Program, Grad Sch, Columbia, MO USA; [Chen, Shanyan] Univ Missouri, Interdisciplinary Neurosci Program, Grad Sch, Columbia, MO USA; [Walker, Jennifer M.] Univ Missouri, Dept Psychol Sci, Columbia, MO USA; [Gooyit, Major; Mobashery, Shahriar; Chang, Mayland] Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA; [Schroeder, Valerie A.; Suckow, Mark A.] Univ Notre Dame, Freimann Life Sci Ctr, Notre Dame, IN 46556 USA; [Schroeder, Valerie A.; Suckow, Mark A.] Univ Notre Dame, Dept Biol Sci, Notre Dame, IN 46556 USA	Chang, M (corresponding author), Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA.	mchang@nd.edu; guze@health.missouri.edu	Suckow, Mark/C-2696-2014	Suckow, Mark/0000-0001-7317-697X; Shin, Dmitriy/0000-0002-5571-9384	Mizzou Advantage; Department of Pathology and Anatomical Sciences; ICATS; NFL Charities Foundation; Indiana Department of Health Spinal Cord and Brain Fund; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [GM075762]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM075762] Funding Source: NIH RePORTER	This work was supported in part by funding from Mizzou Advantage, the Department of Pathology and Anatomical Sciences (to ZG) and ICATS Fellowship (to JP) at the University of Missouri; the NFL Charities Foundation and the Indiana Department of Health Spinal Cord and Brain Fund (to MC and ZG) and National Institutes of Health Training Grant GM075762 (to MG). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bell RD, 2012, NATURE, V485, P512, DOI 10.1038/nature11087; Bell RD, 2010, NEURON, V68, P409, DOI 10.1016/j.neuron.2010.09.043; Block ML, 2005, PROG NEUROBIOL, V76, P77, DOI 10.1016/j.pneurobio.2005.06.004; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Brown S, 2000, J AM CHEM SOC, V122, P6799, DOI 10.1021/ja001461n; Buss A, 2007, BMC NEUROL, V7, DOI 10.1186/1471-2377-7-17; Chen ZL, 1997, CELL, V91, P917, DOI 10.1016/S0092-8674(00)80483-3; Cui JK, 2012, MOL NEURODEGENER, V7, DOI 10.1186/1750-1326-7-21; del Zoppo GJ, 2007, STROKE, V38, P646, DOI 10.1161/01.STR.0000254477.34231.cb; Dohi K, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-41; Forbes C, 2009, CHEM BIOL DRUG DES, V74, P527, DOI 10.1111/j.1747-0285.2009.00881.x; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Garden GA, 2002, J NEUROSCI, V22, P4015, DOI 10.1523/JNEUROSCI.22-10-04015.2002; Gooyit M, 2012, ACS CHEM NEUROSCI, V3, P730, DOI 10.1021/cn300062w; Grossetete M, 2009, NEUROSURGERY, V65, P702, DOI 10.1227/01.NEU.0000351768.11363.48; Gu ZZ, 2002, SCIENCE, V297, P1186, DOI 10.1126/science.1073634; Gu ZZ, 2005, J NEUROSCI, V25, P6401, DOI 10.1523/JNEUROSCI.1563-05.2005; Guo ZD, 2010, NEUROL RES, V32, P715, DOI 10.1179/016164109X12478302362491; Helton R, 2005, J NEUROSCI, V25, P4099, DOI 10.1523/JNEUROSCI.4555-04.2005; Horstmann S, 2003, STROKE, V34, P2165, DOI 10.1161/01.STR.0000088062.86084.F2; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Kettenmann H, 2007, NATURE, V446, P987, DOI 10.1038/nature05713; Kim GW, 2003, J NEUROSCI, V23, P8733; Lam CK, 2010, NATURE, V465, P478, DOI 10.1038/nature09001; Lee M, 2007, CHEM BIOL DRUG DES, V70, P371, DOI 10.1111/j.1747-0285.2007.00577.x; Lee M, 2009, CHEM BIOL DRUG DES, V73, P189, DOI 10.1111/j.1747-0285.2008.00750.x; Liu HQ, 2011, EXP NEUROL, V231, P236, DOI 10.1016/j.expneurol.2011.06.015; Liu J, 2012, J NEUROSCI, V32, P3044, DOI 10.1523/JNEUROSCI.6409-11.2012; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Montaner J, 2001, STROKE, V32, P2762, DOI 10.1161/hs1201.99512; Mott JD, 2004, CURR OPIN CELL BIOL, V16, P558, DOI 10.1016/j.ceb.2004.07.010; Noble LJ, 2002, J NEUROSCI, V22, P7526; Pardridge WM, 2007, DRUG DISCOV TODAY, V12, P54, DOI 10.1016/j.drudis.2006.10.013; Pardridge William M, 2005, NeuroRx, V2, P3; Qiu LB, 2011, TOXICOLOGY, V285, P31, DOI 10.1016/j.tox.2011.03.019; Rosenberg GA, 2009, LANCET NEUROL, V8, P205, DOI 10.1016/S1474-4422(09)70016-X; Sheng WW, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-121; Summers CR, 2009, MT SINAI J MED, V76, P105, DOI 10.1002/msj.20100; Switzer JA, 2011, STROKE, V42, P2633, DOI 10.1161/STROKEAHA.111.618215; Toth M, 2000, J BIOL CHEM, V275, P41415, DOI 10.1074/jbc.M006871200; Walker JM, 2011, BEHAV BRAIN RES, V222, P169, DOI 10.1016/j.bbr.2011.03.049; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Yagi Y, 2008, DIAGN PATHOL, V3, DOI 10.1186/1746-1596-3-S1-S12; Yong VW, 2005, NAT REV NEUROSCI, V6, P931, DOI 10.1038/nrn1807; Yu F, 2008, J NEUROTRAUM, V25, P184, DOI 10.1089/neu.2007.0438; Zhang HQ, 2010, NEUROSCIENTIST, V16, P156, DOI 10.1177/1073858409355830; Zhang QG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034504; Zhao BQ, 2006, NAT MED, V12, P441, DOI 10.1038/nm1387	48	75	79	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 23	2013	8	10							e76904	10.1371/journal.pone.0076904			14	Multidisciplinary Sciences	Science & Technology - Other Topics	239PE	WOS:000326037000028	24194849	DOAJ Gold, Green Published			2021-06-18	
J	Dahm, J; Wong, DN; Ponsford, J				Dahm, Jane; Wong, Dana; Ponsford, Jennie			Validity of the Depression Anxiety Stress Scales in assessing depression and anxiety following traumatic brain injury	JOURNAL OF AFFECTIVE DISORDERS			English	Article						Brain injury; Assessment; Anxiety; Depression; Depression Anxiety Stress Scales; Hospital Anxiety and Depression Scale	LARGE NONCLINICAL SAMPLE; HOSPITAL ANXIETY; PSYCHIATRIC-DISORDERS; EMOTIONAL STATUS; NORMATIVE DATA; DIAGNOSIS; DASS-21; VERSION	Background: Anxiety and depression following traumatic brain injury (TBI) are associated with poorer outcomes. A brief self-report questionnaire would assist in identifying those at risk, however validity of such measures is complicated by confounding symptoms of the injury. This study investigated the validity of the Depression Anxiety Stress Scales (DASS) and Hospital Anxiety and Depression Scale (HADS), in screening for clinical diagnoses of anxiety and mood disorders following TBI. Methods: One hundred and twenty-three participants with mild to severe TBI were interviewed using the SCID (Axis I) and completed the DASS and HADS. Results: The DASS, DASS21 and HADS scales demonstrated validity compared with SOD diagnoses of anxiety and mood disorders as measured by Area Under ROC Curve, sensitivity and specificity. Validity of the DASS depression scale benefited from items reflecting symptoms of devaluation of life, self-deprecation, and hopelessness that are not present on the HADS. Validity of the HADS anxiety scale benefited from items reflecting symptoms of tension and worry that are measured separately for the DASS on the stress scale. Limitations: Participants were predominantly drawn from a rehabilitation centre which may limit the extent to which results can be generalized. Scores for the DASS21 were derived from the DASS rather than being administered separately. Conclusions: The DASS, DASS21 and RADS demonstrated validity as screening measures of anxiety and mood disorders in this TBI sample. The findings support use of these sell report questionnaires for individuals with TBI to identify those who should be referred for clinical diagnostic follow-up. (C) 2013 Elsevier B.V. All rights reserved.	[Dahm, Jane; Wong, Dana; Ponsford, Jennie] Monash Univ, Sch Psychol & Psychiat, Melbourne, Vic 3004, Australia; [Ponsford, Jennie] Epworth Med Fdn, Monash Epworth Rehabil Res Ctr, Melbourne, Vic, Australia; [Ponsford, Jennie] Natl Trauma Res Inst, Melbourne, Vic, Australia	Wong, DN (corresponding author), Monash Univ, Sch Psychol & Psychiat, Clayton Campus,Wellington Rd,Bldg 17, Clayton, Vic 3800, Australia.	dana.wong@monash.edu	Wong, Dana/AAD-3410-2020	Wong, Dana/0000-0001-9619-1929	Transport Accident Commission (TAC)	This research was supported by funding from the Transport Accident Commission (TAC).	Al-Adawi S, 2007, BRAIN INJURY, V21, P385, DOI 10.1080/02699050701311059; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Andrew MJ, 2000, J PSYCHOSOM RES, V48, P537, DOI 10.1016/S0022-3999(00)00089-1; Antony MM, 1998, PSYCHOL ASSESSMENT, V10, P176, DOI 10.1037/1040-3590.10.2.176; Crawford JR, 2003, BRIT J CLIN PSYCHOL, V42, P111, DOI 10.1348/014466503321903544; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; First MB., 2002, STRUCTURED CLIN INTE; Gould KR, 2011, PSYCHOL MED, V41, P2099, DOI 10.1017/S003329171100033X; Gould KR, 2011, J HEAD TRAUMA REHAB, V26, P79, DOI 10.1097/HTR.0b013e3182036799; Henry JD, 2005, BRIT J CLIN PSYCHOL, V44, P227, DOI 10.1348/014466505X29657; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; Lovibond S.H., 1995, MANUAL DEPRESSION AN; McMillan TM, 2001, BRAIN INJURY, V15, P39, DOI 10.1080/02699050150209110; Ownsworth T, 2005, J HEAD TRAUMA REHAB, V20, P315, DOI 10.1097/00001199-200507000-00004; Ownsworth T, 2008, BRAIN INJURY, V22, P858, DOI 10.1080/02699050802446697; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; Seel RT, 2010, J HEAD TRAUMA REHAB, V25, P99, DOI 10.1097/HTR.0b013e3181ce3966; Snaith R.P., 1994, HOSP ANXIETY DEPRESS; Sukantarat KT, 2007, ANAESTHESIA, V62, P239, DOI 10.1111/j.1365-2044.2006.04948.x; Whelan-Goodinson R, 2009, J AFFECT DISORDERS, V114, P94, DOI 10.1016/j.jad.2008.06.007; Wood BM, 2010, PAIN MED, V11, P1780, DOI 10.1111/j.1526-4637.2010.01005.x; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	23	75	76	2	40	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-0327			J AFFECT DISORDERS	J. Affect. Disord.	OCT	2013	151	1					392	396		10.1016/j.jad.2013.06.011			5	Clinical Neurology; Psychiatry	Neurosciences & Neurology; Psychiatry	213FE	WOS:000324039500054	23830002				2021-06-18	
J	Zuckerman, SL; Lee, YM; Odom, MJ; Solomon, GS; Sills, AK				Zuckerman, Scott L.; Lee, Young M.; Odom, Mitchell J.; Solomon, Gary S.; Sills, Allen K.			Baseline neurocognitive scores in athletes with attention deficit-spectrum disorders and/or learning disability Clinical article	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						sports-related concussion; age; learning disability; mild traumatic brain injury; attention deficit hyperactivity disorder; trauma; Immediate Post-Concussion Assessment and Cognitive Testing	SPORTS-RELATED CONCUSSION; TRAUMATIC BRAIN-INJURIES; TEST-RETEST RELIABILITY; HIGH-SCHOOL; UNITED-STATES; RECREATION ACTIVITIES; IMPACT; SYMPTOMS; BATTERY; SENSITIVITY	Object. Up to 16% of children in the US between the ages of 3 and 17 years have either attention deficit-spectrum disorder or a learning disability (LD). Sports-related concussions among youth athletes represent a significant public health concern, and neurocognitive testing is a method to evaluate the severity of cognitive impairment and recovery after a sports-related concussion. The goal of this study was to assess baseline neurocognitive differences between athletes with attention deficit hyperactivity disorder (ADHD) and/or LD versus those with neither disorder and to establish normative data for these special populations. Methods. Between August 2007 and March 2012,6636 young athletes underwent baseline neurocognitive testing performed using the Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) battery. Of these participants, 90 had self-reported LD only, 262 had self-reported ADHD only, and 55 reported both. Those with ADHD and/or LD were matched with 407 participants with no history of ADHD or LD by age, sex, and number of prior concussions. The mean scores and SDs were calculated for each group to obtain normative values. A pairwise comparison between each diagnostic group was done to assess whether LD and/or ADHD diagnostic status predicted participants' baseline neurocognitive scores. Results. Participants with ADHD had significantly lower verbal memory, visual memory, and visual motor processing speed scores, along with significantly higher reaction time, impulse control, and symptom scores compared with those without LD or ADHD. Participants with LD had similar results, with significantly lower verbal memory, visual memory, and visual motor processing speed scores, higher reaction time and symptom score, but did not differ in their impulse control score compared with those without LD or ADHD. Participants with both LD and ADHD had a significantly lower visual motor speed score and a significantly higher reaction time and symptom score than those without LD or ADHD, but did not differ with regard to the other composite scores. Conclusions. Athletes with ADHD and/or LD have lower baseline ImPACT neurocognitive scores compared with athletes without ADHD and LD. Preliminary normative neurocognitive data for these special populations are provided.	[Zuckerman, Scott L.; Solomon, Gary S.; Sills, Allen K.] Vanderbilt Sports Concuss Ctr, Dept Neurol Surg, Nashville, TN USA; [Lee, Young M.; Odom, Mitchell J.] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA	Zuckerman, SL (corresponding author), 1500 21st Ave South,Suite 4340, Nashville, TN 37212 USA.	scott.zuckerman@vanderbilt.edu	Meijer, Anna/K-5118-2016; Solomon, Gary/K-9011-2019				Akinbami Lara J, 2011, NCHS Data Brief, P1; American Speech-Language-Hearing Association, 1991, LEARN DIS ISS DEF; Aubry Mark, 2002, Phys Sportsmed, V30, P57, DOI 10.3810/psm.2002.02.176; Boyle CA, 2011, PEDIATRICS, V127, P1034, DOI 10.1542/peds.2010-2989; Cernich A, 2007, ARCH CLIN NEUROPSYCH, V22, pS101, DOI 10.1016/j.acn.2006.10.008; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Elbin RJ, 2011, AM J SPORT MED, V39, P2319, DOI 10.1177/0363546511417173; Erlanger D, 2001, J ATHL TRAINING, V36, P280; Frommer LJ, 2011, J ATHL TRAINING, V46, P76, DOI 10.4085/1062-6050-46.1.76; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gilchrist J., 2007, Morbidity and Mortality Weekly Report, V56, P733; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; ImPACT, 2007, IMPACT 2007 6 0 CLIN; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2004, J INT NEUROPSYCH SOC, V10, P904, DOI 10.1017/S1355617704106139; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Kessler RC, 2010, ARCH GEN PSYCHIAT, V67, P1168, DOI 10.1001/archgenpsychiatry.2010.146; LAHEY BB, 1994, AM J PSYCHIAT, V151, P1673; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Ma R, 2012, J BONE JOINT SURG AM, V94A, P1618, DOI 10.2106/JBJS.K.01127; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; Maruff P, 2009, ARCH CLIN NEUROPSYCH, V24, P165, DOI 10.1093/arclin/acp010; McCrory P, 2009, PM&R, V1, P406, DOI 10.1016/j.pmrj.2009.03.010; Moser RS, 2011, AM J SPORT MED, V39, P2325, DOI 10.1177/0363546511417114; Pastor Patricia N, 2008, Vital Health Stat 10, P1; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2006, APPL NEUROPSYCHOL, V13, P151, DOI 10.1207/s15324826an1303_2; Schatz P, 2012, J ATHL TRAINING, V47, P289, DOI 10.4085/1062-6050-47.3.14; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; Wisniewska B, 2007, Adv Med Sci, V52 Suppl 1, P215	31	75	75	1	38	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707	1933-0715		J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	AUG	2013	12	2					103	109		10.3171/2013.5.PEDS12524			7	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	187CM	WOS:000322094500002	23790088				2021-06-18	
J	Ganpule, S; Alai, A; Plougonven, E; Chandra, N				Ganpule, S.; Alai, A.; Plougonven, E.; Chandra, N.			Mechanics of blast loading on the head models in the study of traumatic brain injury using experimental and computational approaches	BIOMECHANICS AND MODELING IN MECHANOBIOLOGY			English	Article						Blast; TBI; Head; Mechanics; Experiments; Numerical models; FSI	BIOMECHANICS; GENERATION; RESPONSES; EXPOSURE; IMPACT; TISSUE; WAVE; RAT	Blast waves generated by improvised explosive devices can cause mild, moderate to severe traumatic brain injury in soldiers and civilians. To understand the interactions of blast waves on the head and brain and to identify the mechanisms of injury, compression-driven air shock tubes are extensively used in laboratory settings to simulate the field conditions. The overall goal of this effort is to understand the mechanics of blast wave-head interactions as the blast wave traverses the head/brain continuum. Toward this goal, surrogate head model is subjected to well-controlled blast wave profile in the shock tube environment, and the results are analyzed using combined experimental and numerical approaches. The validated numerical models are then used to investigate the spatiotemporal distribution of stresses and pressure in the human skull and brain. By detailing the results from a series of careful experiments and numerical simulations, this paper demonstrates that: (1) Geometry of the head governs the flow dynamics around the head which in turn determines the net mechanical load on the head. (2) Biomechanical loading of the brain is governed by direct wave transmission, structural deformations, and wave reflections from tissue-material interfaces. (3) Deformation and stress analysis of the skull and brain show that skull flexure and tissue cavitation are possible mechanisms of blast-induced traumatic brain injury.	[Ganpule, S.; Alai, A.; Plougonven, E.; Chandra, N.] Univ Nebraska, Dept Mech & Mat Engn, Lincoln, NE 68588 USA	Chandra, N (corresponding author), Univ Nebraska, Dept Mech & Mat Engn, Lincoln, NE 68588 USA.	nchandra2@unl.edu	Lang, Steven/AAE-8102-2021	Lang, Steven/0000-0003-1669-9146	U.S. Army Research Office [W911NF-08-1-0483]	The authors acknowledge the financial support provided by the U.S. Army Research Office for the project on "Army-UNL Center for Trauma Mechanics", Contract No. W911NF-08-1-0483 (Project Manager: Larry Russell, P.I: Namas Chandra). The authors thank Ruqiang Feng, Aaron Holmberg of University of Nebraska-Lincoln (UNL) for many useful discussions.	Anderson J.D, 2001, FUNDAMENTALS AERODYN, V3; Baker TJ, 2005, PROG AEROSP SCI, V41, P29, DOI 10.1016/j.paerosci.2005.02.002; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI 10.1089/neu.2009-0898; Belingardi G, 2005, 19 INT TECHN C ENH S; Bhattacharjee Y, 2008, SCIENCE, V319, P406, DOI 10.1126/science.319.5862.406; Bolander R, 2011, ANN BIOMED ENG, V39, P2550, DOI 10.1007/s10439-011-0343-0; Bourdin X, 2007, 20 ENH SAF VEH C INN; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; CERNAK I, 2005, RESTORATIVE NEUROLOG, V23, P139; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Chafi MS, 2010, ANN BIOMED ENG, V38, P490, DOI 10.1007/s10439-009-9813-z; Chandra N., 2011, U.S. provisional patent application, Patent No. 61542354; Chatelin S, 2010, BIORHEOLOGY, V47, P255, DOI 10.3233/BIR-2010-0576; Chavko M, 2007, J NEUROSCI METH, V159, P277, DOI 10.1016/j.jneumeth.2006.07.018; Chavko M, 2011, J NEUROSCI METH, V195, P61, DOI 10.1016/j.jneumeth.2010.11.019; Chen Y, 2010, ACTA MECH, V213, P155, DOI 10.1007/s00707-009-0274-0; Cifuentes A.O., 1992, FINITE ELEM ANAL DES, V12, P313; Claessans M., 1997, P 41 STAPP CAR CRASH, P315, DOI DOI 10.4271/973338; Courtney AC, 2009, MED HYPOTHESES, V72, P76, DOI 10.1016/j.mehy.2008.08.015; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Desmoulin GT, 2009, J TRAUMA, V67, P1113, DOI 10.1097/TA.0b013e3181bb8e84; Dogan A, 1999, J NEUROSURG, V90, P1078, DOI 10.3171/jns.1999.90.6.1078; El Sayed T, 2008, COMPUT METHOD APPL M, V197, P4692, DOI 10.1016/j.cma.2008.06.006; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; Ganpule S., 2011, COMPUT METHOD BIOMEC, DOI [DOI 10.1080/10255842.2011.597353, 10.1080/10255842.2011.597353]; Grujicic M, 2011, J MATER ENG PERFORM, V20, P877, DOI 10.1007/s11665-010-9724-z; Honma H, 2003, SHOCK WAVES, V13, P179, DOI 10.1007/s00193-003-0206-1; Horgan TJ, 2003, INT J CRASHWORTHINES, V8, P353, DOI 10.1533/cras.8.4.353.19278; Jiang Z, 2003, SHOCK WAVES, V13, P103, DOI 10.1007/s00193-003-0197-y; Kashimura H., 2000, J THERM SCI, V9, P30, DOI [DOI 10.1007/S11630-000-0042-X, 10.1007/s11630-000-0042-x]; Kennedy EA, 2007, THESIS VIRGINIA POLY; Khalil TB, 1982, P 26 STAPP CAR CRASH; Kleinschmit N.N., 2011, THESIS U NEBRASKA LI; Kleiven S, 2002, J BIOMECH, V35, P153, DOI 10.1016/S0021-9290(01)00202-0; Krave U, 2005, EUR J NEUROSCI, V21, P2876, DOI 10.1111/j.1460-9568.2005.04115.x; Leonardi AD, 2011, J NEUROTRAUM, V28, P85, DOI 10.1089/neu.2010.1324; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; LUBOCK P, 1980, J BIOMECH, V13, P1041, DOI 10.1016/0021-9290(80)90048-2; Marklund N, 2001, ACTA NEUROCHIR, V143, P73, DOI 10.1007/s007010170141; McElhaney JH, 1973, PERSPECTIVES BIOMEDI, P215, DOI DOI 10.1007/978-1-349-01604-4_34; Moore DF, 2009, NEUROIMAGE, V47, pT10, DOI 10.1016/j.neuroimage.2009.02.019; Moore DF, 2008, FUTUR NEUROL, V3, P243, DOI 10.2217/14796708.3.3.243; Moss WC, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.108702; Mott DR SD, 2008, 20 INT S MIL ASP BLA; Nahum AM., 1977, P 21 STAPP CAR CRASH, P339, DOI [10.4271/770922., DOI 10.4271/770922]; Nakagawa A, 2008, ACTA NEUROCHIR SUPPL, V102, P421, DOI 10.1007/978-3-211-85578-2_82; Nicolle S, 2005, BIORHEOLOGY, V42, P209; NUSHOLTZ GS, 1987, AVIAT SPACE ENVIR MD, V58, P1157; Nyein MK, 2010, P NATL ACAD SCI USA, V107, P20703, DOI 10.1073/pnas.1014786107; Pervin F, 2009, J BIOMECH, V42, P731, DOI 10.1016/j.jbiomech.2009.01.023; Prevost TP, 2011, ACTA BIOMATER, V7, P83, DOI 10.1016/j.actbio.2010.06.035; Ramos A, 2006, MED ENG PHYS, V28, P916, DOI 10.1016/j.medengphy.2005.12.006; RUAN JS, 1994, J BIOMECH ENG-T ASME, V116, P44, DOI 10.1115/1.2895703; Schneiders R, 2000, P VKI LECT SERIES CO; Stalnaker RL, 1969, THESIS W VIRGINIA U; Sundaramurthy A, 2012, J NEUROTRAUM, DOI [10.1089/neu.2012.2413, DOI 10.1089/NEU.2012.2413]]; Takhounts E., 2003, STAPP CAR CRASH J, V47, P107, DOI DOI 10.4271/2003-22-0007; Takhounts EG, 2008, STAPP CAR C, V52, P1; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Taylor PA, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3118765; TEASDALE G, 1974, LANCET, V2, P81; Trosseille X, 1992, STAPP CAR CRASH C, DOI [10.4271/922527, DOI 10.4271/922527]; Wang Y, 2011, J NEUROTRAUM, V28, P2171, DOI 10.1089/neu.2011.1990; Ward C, 1980, P 24 STAPP CAR CRASH, P161, DOI [10.2307/44632636, DOI 10.2307/446326]; Wieding J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033776; Willinger R, 1999, ANN BIOMED ENG, V27, P403, DOI 10.1114/1.165; Zhang L, 2001, Stapp Car Crash J, V45, P369; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zhang LY, 2001, J NEUROTRAUM, V18, P21, DOI 10.1089/089771501750055749; Zhu F, 2012, BIOMECH MODEL MECHAN, V11, P341, DOI 10.1007/s10237-011-0314-2; Zhu Feng, 2010, Stapp Car Crash J, V54, P211; Zoghi-Moghadam M, 2009, COMPUT METHOD BIOMEC, V12, P1, DOI 10.1080/10255840903064897	72	75	78	0	67	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1617-7959	1617-7940		BIOMECH MODEL MECHAN	Biomech. Model. Mechanobiol.	JUN	2013	12	3					511	531		10.1007/s10237-012-0421-8			21	Biophysics; Engineering, Biomedical	Biophysics; Engineering	149AA	WOS:000319289200008	22832705				2021-06-18	
J	Kontos, AP; Kotwal, RS; Elbin, RJ; Lutz, RH; Forsten, RD; Benson, PJ; Guskiewicz, KM				Kontos, Anthony P.; Kotwal, Russ S.; Elbin, R. J.; Lutz, Robert H.; Forsten, Robert D.; Benson, Peter J.; Guskiewicz, Kevin M.			Residual Effects of Combat-Related Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						mTBI; PTSD; symptoms; military	MENTAL-HEALTH PROBLEMS; RECURRENT CONCUSSION; FOOTBALL PLAYERS; HISTORY; COLLEGIATE; SERVICE; RISK; IRAQ	Mild traumatic brain injury (mTBI) has gained considerable notoriety during the past decade of conflict in Afghanistan and Iraq. However, the relationship between combat-related mTBI and residual mTBI symptoms, post-traumatic stress disorder (PTSD) symptoms, and neurocognitive deficits remains unclear. The purpose of the study was to compare residual mTBI and PTSD symptoms, and neurocognitive deficits among U.S. Army Special Operations Command (USASOC) personnel with diagnosed blunt, blast, and blast-blunt combination mTBIs. This study involved a retrospective medical records review of 27,169 USASOC personnel who completed a military version of the Immediate Post-Concussion Assessment Cognitive Test (ImPACT), Post-Concussion Symptom Scale (PCSS), and PTSD Checklist (PCL) between November 2009 and December 2011. Of the 22,203 personnel who met criteria for the study, 2,813 (12.7%) had a diagnosis of at least one mTBI. A total of 28% (n = 410) of USASOC personnel with a history of diagnosed mTBI reported clinical levels of PTSD symptoms. Personnel with a history of diagnosed blunt (OR = 3.58), blast (OR = 4.23) or combination (OR = 5.73) mTBI were at significantly (p = 0.001) greater risk of reporting clinical levels of PTSD symptoms than those with no history of mTBI. A dose-response gradient for exposure to blast/combination mTBI on clinical levels of PTSD symptoms was also significant (p = 0.001). Individuals with blast/combination mTBIs scored higher in residual mTBI (p = 0.001) and PTSD symptoms (p = 0.001), and performed worse on tests of visual memory (p = 0.001), and reaction time (p = 0.001) than those with blunt or no mTBI history. Individuals with combination mTBIs scored lower in verbal memory (p = 0.02) than those with blunt mTBIs. Residual PTSD and mTBI symptoms appear to be more prevalent in personnel with blast mTBI. A dose-response gradient for blast mTBI and symptoms suggests that repeated exposures to these injuries may have lingering effects.	[Kontos, Anthony P.; Elbin, R. J.] Univ Pittsburgh, Med Ctr, Sports Med Concuss Program, Pittsburgh, PA 15203 USA; [Kotwal, Russ S.; Lutz, Robert H.; Forsten, Robert D.; Benson, Peter J.] USA, Special Operat Command, Ft Bragg, NC USA; [Guskiewicz, Kevin M.] Univ N Carolina, Matthew Gfeller Sport Related Traumat Brain Injur, Chapel Hill, NC USA	Kontos, AP (corresponding author), Univ Pittsburgh, Sch Med, Dept Orthopaed Surg, UPMC Sports Med Concuss Program, 3200 South Water St, Pittsburgh, PA 15203 USA.	akontos@pitt.edu		Kontos, Anthony/0000-0002-3749-4310; Guskiewicz, Kevin/0000-0002-8682-2130	U.S. Special Operations Command Biomedical Initiatives Steering Committee	This research was funded by the U.S. Special Operations Command Biomedical Initiatives Steering Committee. The views expressed herein are those of the author(s) and do not reflect the official policy of the Department of the Army, Department of Defense, or the U.S. Government. Citations of commercial products or organizations do not constitute an official DoD endorsement or approval of the products or services of these organizations. This report was approved for public release by the U.S. Army Special Operations Command Operational Security Office and Public Affairs Office on March 27, 2012, and the U.S. Army Medical Department Public Affairs Office on March 27, 2012.	Bruce JM, 2009, NEUROSURGERY, V64, P100, DOI 10.1227/01.NEU.0000336310.47513.C8; Cernak I, 1999, WORLD J SURG, V23, P44, DOI 10.1007/s002689900563; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Collie A, 2006, BRIT J SPORT MED, V40, P550, DOI 10.1136/bjsm.2005.019802; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Covassin T, 2010, J NEUROL NEUROSUR PS, V81, P597, DOI 10.1136/jnnp.2009.193797; Defense and Veterans Brain Injury Center, DOD WORLDW NUMB TBI; Forsten R. D., 2008, J SPECIAL OPERATIONS, V8, P74; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Harvey AG, 2000, AM J PSYCHIAT, V157, P626, DOI 10.1176/appi.ajp.157.4.626; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2006, JAMA-J AM MED ASSOC, V295, P1023, DOI 10.1001/jama.295.9.1023; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; KAUR C, 1995, NEUROPATH APPL NEURO, V21, P369, DOI 10.1111/j.1365-2990.1995.tb01073.x; Kontos AP, 2004, J APPL SPORT PSYCHOL, V16, P220, DOI 10.1080/10413200490485568; Kotwal RS, 2011, ARCH SURG-CHICAGO, V146, P1349, DOI 10.1001/archsurg.2011.213; Krainin Benjamin M, 2011, J Spec Oper Med, V11, P38; Lew HL, 2008, J REHABIL RES DEV, V45, pXI, DOI 10.1682/JRRD.2008.05.0064; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Mental Health Advisory Team-IV (MHAT), 2006, OP IR FREED MENT HLT; Murray CK, 2005, MIL MED, V170, P516, DOI 10.7205/MILMED.170.6.516; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; Risling M, 2011, NEUROIMAGE, V54, pS89, DOI 10.1016/j.neuroimage.2010.05.031; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Vanderploeg RD, 2004, VETERANS HLTH INITIA; Zemper ED, 2003, AM J PHYS MED REHAB, V82, P653, DOI 10.1097/01.PHM.0000083666.74494.BA	31	75	76	0	30	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2013	30	8			SI		680	686		10.1089/neu.2012.2506			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	133PO	WOS:000318151500010	23031200				2021-06-18	
J	Neselius, S; Zetterberg, H; Blennow, K; Randall, J; Wilson, D; Marcusson, J; Brisby, H				Neselius, Sanna; Zetterberg, Henrik; Blennow, Kaj; Randall, Jeffrey; Wilson, David; Marcusson, Jan; Brisby, Helena			Olympic boxing is associated with elevated levels of the neuronal protein tau in plasma	BRAIN INJURY			English	Article						Diffuse axonal injury; head injury; mild brain injury	TRAUMATIC BRAIN-INJURY; FIBRILLARY ACIDIC PROTEIN; CEREBROSPINAL-FLUID; NEUROTROPHIC FACTOR; SERUM; HEAD; S100B; MILD; CONCUSSION; ENCEPHALOPATHY	Objectives: The aim of this study was to investigate if olympic (amateur) boxing is associated with elevation of brain injury biomarkers in peripheral blood compared to controls. Materials and methods: Thirty olympic boxers competing in at least 47 bouts were compared to 25 controls. Blood was collected from the controls at one occasion and from the boxers within 1-6 days after a bout and after a rest period of at least 14 days. Tau concentration in plasma was determined using a novel single molecule ELISA assay and S-100B, glial fibrillary acidic protein, brain-derived neurotrophic factor and amyloid beta 1-42 were determined using standard immunoassays. Results: None of the boxers had been knocked-out during the bout. Plasma-tau was significantly increased in the boxers after a bout compared to controls (mean +/- SD, 2.46 +/- 5.10 vs. 0.79 +/- 0.961 ngL(-1), p = 0.038). The other brain injury markers did not differ between the groups. Plasma-tau decreased significantly in the boxers after a resting period compared to after a bout (p = 0.030). Conclusions: Olympic boxing is associated with elevation of tau in plasma. The repetitive minimal head injury in boxing may lead to axonal injuries that can be diagnosed with a blood test.	[Neselius, Sanna; Brisby, Helena] Sahlgrens Univ Hosp, Dept Orthopaed, S-41345 Gothenburg, Sweden; [Neselius, Sanna; Brisby, Helena] Univ Gothenburg, Sahlgrenska Acad, Inst Clin Sci, Gothenburg, Sweden; [Zetterberg, Henrik; Blennow, Kaj] Sahlgrens Univ Hosp, Clin Neurochem Lab, Dept Psychiat & Neurochem, S-41345 Gothenburg, Sweden; [Zetterberg, Henrik; Blennow, Kaj] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Gothenburg, Sweden; [Randall, Jeffrey; Wilson, David] Quanterix Corp, Lexington, MA USA; [Marcusson, Jan] Linkoping Univ Hosp, Dept Geriatr, S-58185 Linkoping, Sweden; [Marcusson, Jan] Linkoping Univ, Inst Clin & Expt Med, S-58183 Linkoping, Sweden	Neselius, S (corresponding author), Sahlgrens Univ Hosp, Dept Orthopaed, S-41345 Gothenburg, Sweden.	sanna.neselius@vgregion.se			Marianne and Marcus Wallenberg Foundation, Sweden; ALF Grants; County Council of Vastra Gotaland, Sweden; Sahlgrenska University Hospital, Gothenburg, Sweden; Gothenburg Medical Society, Sweden; ALF Grants, County Council of Ostergotland, Sweden; The Swedish Research CouncilSwedish Research Council	The authors report no conflicts of interest. This study has been funded by: Marianne and Marcus Wallenberg Foundation, Sweden; ALF Grants, County Council of Vastra Gotaland, Sweden; Sahlgrenska University Hospital, Gothenburg, Sweden; Gothenburg Medical Society, Sweden; ALF Grants, County Council of Ostergotland, Sweden and The Swedish Research Council. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Baird LC, 2010, NEUROSURGERY, V67, P1444, DOI 10.1227/NEU.0b013e3181e5e2cd; Bartsch AJ, 2012, J NEUROSURG, V116, P1070, DOI 10.3171/2011.12.JNS111478; Blennow K, 2006, LANCET, V368, P387, DOI 10.1016/S0140-6736(06)69113-7; Bulut M, 2006, ADV THER, V23, P12, DOI 10.1007/BF02850342; CHARNAS L, 1986, HOSP PRACT, V21, P30; de boussard CN, 2004, BRAIN INJURY, V18, P671, DOI 10.1080/02699050310001646215; Donato R, 2009, BBA-MOL CELL RES, V1793, P1008, DOI 10.1016/j.bbamcr.2008.11.009; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gao X, 2009, J NEUROTRAUM, V26, P1325, DOI 10.1089/neu.2008-0744; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Graham MR, 2011, INT J IMMUNOPATH PH, V24, P119, DOI 10.1177/039463201102400114; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Honda M, 2010, J TRAUMA, V69, P104, DOI 10.1097/TA.0b013e3181bbd485; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; Jordan BD, 1996, AM J SPORT MED, V24, P704, DOI 10.1177/036354659602400526; KASTE M, 1982, LANCET, V2, P1186; Kavalci C, 2007, AM J EMERG MED, V25, P391, DOI 10.1016/j.ajem.2006.10.008; Kay AD, 2003, J NEUROTRAUM, V20, P943, DOI 10.1089/089771503770195795; Kleindienst A, 2010, ACTA NEUROCHIR SUPPL, V106, P247, DOI 10.1007/978-3-211-98811-4_46; Kleindienst A, 2006, J NEUROTRAUM, V23, P1185, DOI 10.1089/neu.2006.23.1185; Korhonen L, 1998, NEUROSCI LETT, V240, P151, DOI 10.1016/S0304-3940(97)00937-3; Kushi H, 2009, J TRAUMA, V66, P298, DOI 10.1097/TA.0b013e3181715dba; Liliang PC, 2010, RESUSCITATION, V81, P1205, DOI 10.1016/j.resuscitation.2010.05.016; Liliang PC, 2010, J SURG RES, V160, P302, DOI 10.1016/j.jss.2008.12.022; Lumpkins KM, 2008, J TRAUMA, V65, P778, DOI 10.1097/TA.0b013e318185db2d; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Neselius S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033606; Nylen K, 2006, J NEUROL SCI, V240, P85, DOI 10.1016/j.jns.2005.09.007; Olsson A, 2004, J NEUROL, V251, P870, DOI 10.1007/s00415-004-0451-y; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Rissin DM, 2010, NAT BIOTECHNOL, V28, P595, DOI 10.1038/nbt.1641; Savola O, 2004, J TRAUMA, V56, P1229, DOI 10.1097/01.TA.0000096644.08735.72; Shultz SR, 2012, J NEUROTRAUM, V29, P281, DOI 10.1089/neu.2011.2123; Slobounov S, 2007, NEUROSURGERY, V61, P338, DOI 10.1227/01.NEU.0000280001.03578.FF; Viano DC, 2005, NEUROSURGERY, V57, P1154, DOI 10.1227/01.NEU.0000187541.87937.D9; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Wiesmann M, 2010, ACTA NEUROL SCAND, V121, P178, DOI 10.1111/j.1600-0404.2009.01196.x; Zetterberg H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028263; Zetterberg H, 2009, BRAIN INJURY, V23, P723, DOI 10.1080/02699050903120399	40	75	76	0	17	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	APR	2013	27	4					425	433		10.3109/02699052.2012.750752			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	117LG	WOS:000316954300007	23473386				2021-06-18	
J	Toth, A; Kovacs, N; Perlaki, G; Orsi, G; Aradi, M; Komaromy, H; Ezer, E; Bukovics, P; Farkas, O; Janszky, J; Doczi, T; Buki, A; Schwarcz, A				Toth, Arnold; Kovacs, Noemi; Perlaki, Gabor; Orsi, Gergely; Aradi, Mihaly; Komaromy, Hedvig; Ezer, Erzsebet; Bukovics, Peter; Farkas, Orsolya; Janszky, Jozsef; Doczi, Tamas; Buki, Andras; Schwarcz, Attila			Multi-Modal Magnetic Resonance Imaging in the Acute and Sub-Acute Phase of Mild Traumatic Brain Injury: Can We See the Difference?	JOURNAL OF NEUROTRAUMA			English	Article						adult brain injury; axonal injury; brain edema; MRI; recovery	HUMAN CEREBRAL-CORTEX; SURFACE-BASED ANALYSIS; DIFFUSE AXONAL INJURY; HEAD-INJURY; GEOMETRICALLY ACCURATE; LONGITUDINAL CHANGES; CORPUS-CALLOSUM; TENSOR; MR; MODERATE	Advanced magnetic resonance imaging (MRI) methods were shown to be able to detect the subtle structural consequences of mild traumatic brain injury (mTBI). The objective of this study was to investigate the acute structural alterations and recovery after mTBI, using diffusion tensor imaging (DTI) to reveal axonal pathology, volumetric analysis, and susceptibility weighted imaging (SWI) to detect microhemorrhage. Fourteen patients with mTBI who had computed tomography with negative results underwent MRI within 3 days and 1 month after injury. High resolution T1-weighted imaging, DTI, and SWI, were performed at both time points. A control group of 14 matched volunteers were also examined following the same imaging protocol and time interval. Tract-Based Spatial Statistics (TBSS) were performed on DTI data to reveal group differences. T1-weighted images were fed into Freesurfer volumetric analysis. TBSS showed fractional anisotropy (FA) to be significantly (corrected p < 0.05) lower, and mean diffusivity (MD) to be higher in the mTBI group in several white matter tracts (FA = 40,737; MD = 39,078 voxels) compared with controls at 72 hours after injury and still 1month later for FA. Longitudinal analysis revealed significant change (i.e., normalization) of FA and MD over 1 month dominantly in the left hemisphere (FA = 3408; MD = 7450 voxels). A significant (p < 0.05) decrease in cortical volumes (mean 1%) and increase in ventricular volumes (mean 3.4%) appeared at 1 month after injury in the mTBI group. SWI did not reveal microhemorrhage in our patients. Our findings present dynamic micro- and macrostructural changes occurring in the acute to sub-acute phase in mTBI, in very mildly injured patients lacking microhemorrhage detectable by SWI. These results underscore the importance of strictly defined image acquisition time points when performing MRI studies on patients with mTBI.	[Toth, Arnold; Perlaki, Gabor; Orsi, Gergely; Janszky, Jozsef] Univ Pecs, Dept Neurol, H-7623 Pecs, Hungary; [Kovacs, Noemi; Ezer, Erzsebet; Bukovics, Peter; Doczi, Tamas; Buki, Andras; Schwarcz, Attila] Univ Pecs, Dept Neurosurg, H-7623 Pecs, Hungary; [Perlaki, Gabor; Orsi, Gergely; Aradi, Mihaly; Komaromy, Hedvig] Pecs Diagnost Ctr, Pecs, Hungary; [Farkas, Orsolya] Univ Pecs, Dept Radiol, H-7623 Pecs, Hungary; [Perlaki, Gabor; Orsi, Gergely; Bukovics, Peter; Janszky, Jozsef; Doczi, Tamas; Buki, Andras; Schwarcz, Attila] MTA PTE Clin Neurosci MR Res Grp, Pecs, Hungary	Toth, A (corresponding author), Univ Pecs, Dept Neurol, Ret U 2, H-7623 Pecs, Hungary.	prsarn@gmail.com	Bukovics, Peter/A-6019-2009; Doczi, Tamas/C-5750-2009		Developing Competitiveness of Universities in the South Transdanubian Region [SROP-4.2.1.B-10/2/KONV-2010- 0002]; Bolyai Scholarship of the Hungarian Academy of Science; OTKA PDOrszagos Tudomanyos Kutatasi Alapprogramok (OTKA) [72240]	This work was supported by Developing Competitiveness of Universities in the South Transdanubian Region (SROP-4.2.1.B-10/2/KONV-2010- 0002), J.J., A.S. was supported by the Bolyai Scholarship of the Hungarian Academy of Science. P.B. was supported by OTKA PD 72240. The Institutional Review Board protocol is U. Pecs, Medical Center IRB Project #00003108.	Akiyama Y, 2009, NEUROL MED-CHIR, V49, P97, DOI 10.2176/nmc.49.97; Alexander AL, 2007, NEUROTHERAPEUTICS, V4, P316, DOI 10.1016/j.nurt.2007.05.011; ANDERSON CV, 1994, BRAIN INJURY, V8, P565, DOI 10.3109/02699059409151008; Andersson EH, 2003, ACTA NEUROL SCAND, V107, P256, DOI 10.1034/j.1600-0404.2003.00112.x; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Bartsch A.J., 2004, 10 INT C FUNCT MAPP; BASSER PJ, 1994, J MAGN RESON SER B, V103, P247, DOI 10.1006/jmrb.1994.1037; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Beaulieu C, 2002, NMR BIOMED, V15, P435, DOI 10.1002/nbm.782; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; Bullmore ET, 1999, IEEE T MED IMAGING, V18, P32, DOI 10.1109/42.750253; Chu Z, 2010, AM J NEURORADIOL, V31, P340, DOI 10.3174/ajnr.A1806; Cohen BA, 2007, AM J NEURORADIOL, V28, P907; Colbert CA, 2010, RADIOLOGY, V256, P898, DOI 10.1148/radiol.10091842; Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395; DALE AM, 1993, J COGNITIVE NEUROSCI, V5, P162, DOI 10.1162/jocn.1993.5.2.162; Fischl B, 2004, NEUROIMAGE, V23, pS69, DOI 10.1016/j.neuroimage.2004.07.016; Fischl B, 2004, CEREB CORTEX, V14, P11, DOI 10.1093/cercor/bhg087; Fischl B, 2001, IEEE T MED IMAGING, V20, P70, DOI 10.1109/42.906426; Fischl B, 1999, NEUROIMAGE, V9, P195, DOI 10.1006/nimg.1998.0396; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Fischl B, 2000, P NATL ACAD SCI USA, V97, P11050, DOI 10.1073/pnas.200033797; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; GALE SD, 1993, BRAIN RES BULL, V32, P345, DOI 10.1016/0361-9230(93)90198-K; Han X, 2006, NEUROIMAGE, V32, P180, DOI 10.1016/j.neuroimage.2006.02.051; Hasiloglu ZI, 2011, AM J NEURORADIOL, V32, P99, DOI 10.3174/ajnr.A2250; Heiervang E, 2006, NEUROIMAGE, V33, P867, DOI 10.1016/j.neuroimage.2006.07.037; Henry-Feugeas MC, 2000, BRAIN INJURY, V14, P597; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Liang LX, 1999, AM J NEURORADIOL, V20, P1527; Lipton ML, 2012, BRAIN IMAGING BEHAV, V6, P329, DOI 10.1007/s11682-012-9175-2; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Marmarou A, 2007, NEUROSURG FOCUS, P22; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McCauley SR, 2010, DEV NEUROPSYCHOL, V35, P318, DOI 10.1080/87565641003696866; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Mittal S, 2009, AM J NEURORADIOL, V30, P232, DOI 10.3174/ajnr.A1461; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Obenaus A, 2007, J NEUROTRAUM, V24, P1147, DOI 10.1089/neu.2006.0211; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Peled S, 2007, IEEE T MED IMAGING, V26, P1448, DOI 10.1109/TMI.2007.906787; Rosenblum WI, 2007, J NEUROPATH EXP NEUR, V66, P771, DOI 10.1097/nen.0b013e3181461965; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Rutgers DR, 2008, AM J NEURORADIOL, V29, P1730, DOI 10.3174/ajnr.A1213; Segonne F, 2004, NEUROIMAGE, V22, P1060, DOI 10.1016/j.neuroimage.2004.03.032; Segonne F, 2007, IEEE T MED IMAGING, V26, P518, DOI 10.1109/TMI.2006.887364; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Sled JG, 1998, IEEE T MED IMAGING, V17, P87, DOI 10.1109/42.668698; Smith SM, 2002, NEUROIMAGE, V17, P479, DOI 10.1006/nimg.2002.1040; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Steen RG, 2007, AM J NEURORADIOL, V28, P1119, DOI 10.3174/ajnr.A0537; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Vos SB, 2012, NEUROIMAGE, V59, P2208, DOI 10.1016/j.neuroimage.2011.09.086; Wang JY, 2011, NEUROLOGY, V77, P818, DOI 10.1212/WNL.0b013e31822c61d7; Warner MA, 2010, ARCH NEUROL-CHICAGO, V67, P1336, DOI 10.1001/archneurol.2010.149; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014	68	75	77	0	26	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JAN	2013	30	1					2	10		10.1089/neu.2012.2486			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	061GU	WOS:000312837300002	22905918	Green Accepted			2021-06-18	
J	Corrigan, JD; Cuthbert, JP; Whiteneck, GG; Dijkers, MP; Coronado, V; Heinemann, AW; Harrison-Felix, C; Graham, JE				Corrigan, John D.; Cuthbert, Jeffrey P.; Whiteneck, Gale G.; Dijkers, Marcel P.; Coronado, Victor; Heinemann, Allen W.; Harrison-Felix, Cynthia; Graham, James E.			Representativeness of the Traumatic Brain Injury Model Systems National Database	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						craniocerebral trauma; methodology; rehabilitation; traumatic brain injury	FUNCTIONAL INDEPENDENCE MEASURE; INPATIENT REHABILITATION; PROSPECTIVE-PAYMENT; FOLLOW-UP; TBI; HOSPITALIZATION; IMPAIRMENT; DISABILITY; ADULTS	Objective: To determine whether the Traumatic Brain Injury Model Systems National Database (TBIMS-NDB) is representative of individuals aged 16 years and older admitted for acute, inpatient rehabilitation in the United States with a primary diagnosis of traumatic brain injury (TBI). Design: Secondary analysis of existing data sets. Setting: Acute inpatient rehabilitation facilities. Participants: Patients aged 16 years and older with a primary rehabilitation diagnosis of TBI. Main Outcome Measures: Demographic characteristics, functional status, and hospital length of stay. Results: Patients included in the TBIMS-NDB from October 2001 through December 2007 were largely representative of all individuals 16 years and older admitted for rehabilitation in the United States with a primary diagnosis of TBI. The major difference in distribution was age-the TBIMS-NDB cohort did not include as large a proportion of patients older than 65 years as were admitted for rehabilitation with a primary diagnosis of TBI in the United States. Distributional differences for age-related characteristics were observed; however, groups of patients partitioned at aged 65 years differed minimally, especially within the younger than 65 years subset. Regardless of age, the proportion of patients with a rehabilitation stay of 1 to 9 days was larger nationwide. Nationwide admissions showed an age distribution similar to patients discharged alive from acute care with moderate, severe or penetrating TBI. The proportion of patients aged 70 years and older admitted for TBI rehabilitation in the United States increased every year, a trend that was not evident in the general population, TBIMS-NDB or among TBI patients in acute care. Conclusions: These results provide substantial empirical evidence that the TBIMS-NDB is representative of patients receiving inpatient rehabilitation for TBI in the United States. Researchers utilizing the TBIMS-NDB may want to adjust statistically for the lower percentage of patients older than 65 years or those with stays less than 10 days.	[Corrigan, John D.] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA; [Cuthbert, Jeffrey P.; Whiteneck, Gale G.; Harrison-Felix, Cynthia] Craig Hosp, Res Dept, Englewood, CO USA; [Dijkers, Marcel P.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA; [Coronado, Victor] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA; [Heinemann, Allen W.] Northwestern Univ, Feinberg Sch Med, Dept Phys Med & Rehabil, Chicago, IL 60611 USA; [Heinemann, Allen W.] Rehabil Inst Chicago, Chicago, IL 60611 USA; [Graham, James E.] Univ Texas Med Branch, Div Rehabil Sci, Galveston, TX USA	Corrigan, JD (corresponding author), Ohio State Univ, Dept Phys Med & Rehabil, 480 Med Ctr Dr, Columbus, OH 43210 USA.	corrigan.1@osu.edu	Heinemann, Allen W/K-6283-2012; Heinemann, Allen W./AAI-2790-2021; Corrigan, John D./E-2921-2011	Heinemann, Allen W/0000-0003-2782-7326; Heinemann, Allen W./0000-0003-2782-7326; Dijkers, Marcel/0000-0002-8362-5596	National Institute on Disability and Rehabilitation Research, Office of Special Education and Rehabilitative Services; US Department of EducationUS Department of Education [H133A060038]; TBI Model System Center grants [H133A070022]; Ohio State UniversityOhio State University [H133A070029]; Mount Sinai School of Medicine [H133A070033]; Rehabilitation Institute of Chicago [H133A080045]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R24HD065702] Funding Source: NIH RePORTER	This research was supported by supplemental grant funding to the Traumatic Brain Injury Model Systems National Data and Statistical Center from the National Institute on Disability and Rehabilitation Research, Office of Special Education and Rehabilitative Services, US Department of Education (grant no. H133A060038), as well as TBI Model System Center grants to Craig Hospital (H133A070022), Ohio State University (H133A070029), Mount Sinai School of Medicine (H133A070033), and the Rehabilitation Institute of Chicago (H133A080045). However, the contents do not necessarily represent the policy of the Department of Education, and the reader should not assume endorsement by the Federal Government. This article does not reflect the official policy or opinions of the Centers for Disease Control and Prevention (CDC) or the US Department of Health and Human Services (HHS) and does not constitute an endorsement of the individuals or their programs-by CDC, HHS, or other components of the federal government-and none should be inferred. No commercial party having a direct financial interest in the results of the research supporting this article has or will confer a benefit upon the authors or upon any organization with which the authors are associated.	Braddom RL, 2005, ARCH PHYS MED REHAB, V86, P1287, DOI 10.1016/j.apmr.2005.01.004; Centers for Medicare & Medicaid Services, INP REH FAC PAT ASS; Coronado VG, 2005, J HEAD TRAUMA REHAB, V20, P215, DOI 10.1097/00001199-200505000-00005; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; Corrigan JD, 2007, ARCH PHYS MED REHAB, V88, P418, DOI 10.1016/j.apmr.2007.01.010; Cuthbert JP, 2011, ARCH PHYS MED REHAB, V92, P721, DOI 10.1016/j.apmr.2010.12.023; Department of Health and Human Services. Centers for Medicare & Medicaid Services. Medicare Program, MED PROGR INP REH FA; Dijkers MP, 2010, J HEAD TRAUMA REHAB, V25, P81, DOI 10.1097/HTR.0b013e3181cd3528; Dijkers MPJM, 2010, LOW COST NO COST STE; Granger CV, 2007, AM J PHYS MED REHAB, V86, P883, DOI 10.1097/PHM.0b013e318152058a; Granger CV, 2010, AM J PHYS MED REHAB, V89, P265, DOI 10.1097/PHM.0b013e3181d3eb20; Gundling R L, 2001, Healthc Financ Manage, V55, P72; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; Mallinson TR, 2008, ARCH PHYS MED REHAB, V89, P2066, DOI 10.1016/j.apmr.2008.05.014; Marr AL., 2004, CENTRAL NERVOUS SYST; National Center for Injury Prevention and Control Centers for Disease Control and Prevention, 2010, NAT HOSP DISCH SURV; Pickelsimer EE, 2006, J HEAD TRAUMA REHAB, V21, P491, DOI 10.1097/00001199-200611000-00004; Sarmiento K, 2008, J HEAD TRAUMA REHAB, V23, P164, DOI 10.1097/01.HTR.0000319933.22709.61; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Stineman MG, 2002, ARCH PHYS MED REHAB, V83, P1802, DOI 10.1053/apmr.2002.36067; Stineman MG, 1996, ARCH PHYS MED REHAB, V77, P1101, DOI 10.1016/S0003-9993(96)90130-6; TBI Model Systems National Data and Statistical Center, TRAUM BRAIN INJ MOD; U.S. Census Bureau, 2000, NCEST200901 US CENS; Whiteneck G, 2001, COLORADO TRAUMATIC B	24	75	75	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2012	27	6					391	403		10.1097/HTR.0b013e3182238cdd			13	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	039CU	WOS:000311221200010	21897288	Green Accepted			2021-06-18	
J	Swick, D; Honzel, N; Larsen, J; Ashley, V; Justus, T				Swick, Diane; Honzel, Nikki; Larsen, Jary; Ashley, Victoria; Justus, Timothy			Impaired Response Inhibition in Veterans with Post-Traumatic Stress Disorder and Mild Traumatic Brain Injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						PTSD; TBI; Go/NoGo; Executive control; Inhibitory control; Impulsivity	INFERIOR FRONTAL GYRUS; PSYCHOMETRIC PROPERTIES; EXECUTIVE FUNCTION; PREFRONTAL CORTEX; WAR VETERANS; RISK-FACTORS; NO-GO; PTSD; PERFORMANCE; SYMPTOMS	Combat veterans with post-traumatic stress disorder (PTSD) can show impairments in executive control and increases in impulsivity. The current study examined the effects of PTSD on motor response inhibition, a key cognitive control function. A Go/NoGo task was administered to veterans with a diagnosis of PTSD based on semi-structured clinical interview using DSM-IV criteria (n=40) and age-matched control veterans (n=33). Participants also completed questionnaires to assess self-reported levels of PTSD and depressive symptoms. Performance measures from the patients (error rates and reaction times) were compared to those from controls. PTSD patients showed a significant deficit in response inhibition, committing more errors on NoGo trials than controls. Higher levels of PTSD and depressive symptoms were associated with higher error rates. Of the three symptom clusters, re-experiencing was the strongest predictor of performance. Because the co-morbidity of mild traumatic brain injury (mTBI) and PTSD was high in this population, secondary analyses compared veterans with PTSD+mTBI (n=30) to veterans with PTSD only (n=10). Although preliminary, results indicated the two patient groups did not differ on any measure (p>.88). Since cognitive impairments could hinder the effectiveness of standard PTSD therapies, incorporating treatments that strengthen executive functions might be considered in the future. (JINS, 2012, 18, 917-926)	Vet Affairs No Calif Hlth Care Syst, Res Serv, Martinez, CA USA; Univ Calif Davis, Dept Neurol, Davis, CA 95616 USA	Swick, D (corresponding author), VA No Calif Hlth Care Syst, Res Serv 151, 150 Muir Rd, Martinez, CA 94553 USA.	swicklab@gmail.com			U.S. Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [W81XWH-08-2-0086]; VA Merit Review grantUS Department of Veterans Affairs	We thank Dr. Andrew Kayser for patient referrals, Dr. Juliana Baldo for providing WTAR data, Timothy Heron for statistical advice, and all participants for taking part in the study. This work was supported by the U.S. Army Medical Research and Materiel Command under W81XWH-08-2-0086 and a VA Merit Review grant. The authors declare that they have no conflicts of interest. The information in this manuscript and the manuscript itself has never been published either electronically or in print. The contents do not represent the views of the Department of Veterans Affairs or the United States Government.	Aron AR, 2003, NAT NEUROSCI, V6, P115, DOI 10.1038/nn1003; Aupperle RL, 2012, NEUROPHARMACOLOGY, V62, P686, DOI 10.1016/j.neuropharm.2011.02.008; BECK AT, 1988, CLIN PSYCHOL REV, V8, P77, DOI 10.1016/0272-7358(88)90050-5; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Botvinick MM, 2004, TRENDS COGN SCI, V8, P539, DOI 10.1016/j.tics.2004.10.003; Brenner LA, 2010, NEUROPSYCHOLOGY, V24, P160, DOI 10.1037/a0017966; Carlson KF, 2011, J HEAD TRAUMA REHAB, V26, P103, DOI 10.1097/HTR.0b013e3181e50ef1; Chambers CD, 2009, NEUROSCI BIOBEHAV R, V33, P631, DOI 10.1016/j.neubiorev.2008.08.016; Cloitre M., 2002, GENDER PTSD, P117; Dimou A, 2011, J PANCREAS, V12, P1; Donohoe G, 2006, J INT NEUROPSYCH SOC, V12, P901, DOI 10.1017/S135561770606108X; Etkin A, 2007, AM J PSYCHIAT, V164, P1476, DOI 10.1176/appi.ajp.2007.07030504; Falconer E, 2008, J PSYCHIATR NEUROSCI, V33, P413; Fan J, 2005, NEUROIMAGE, V26, P471, DOI 10.1016/j.neuroimage.2005.02.004; Fisher T, 2011, CLIN NEUROPHYSIOL, V122, P2390, DOI 10.1016/j.clinph.2011.05.010; Forbes D, 2001, BEHAV RES THER, V39, P977, DOI 10.1016/S0005-7967(00)00084-X; Gordon SN, 2011, CLIN NEUROPSYCHOL, V25, P337, DOI 10.1080/13854046.2010.550634; Hamner M B, 1999, Depress Anxiety, V9, P1; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Iversen AC, 2008, PSYCHOL MED, V38, P511, DOI 10.1017/S0033291708002778; Jakupcak M, 2009, J TRAUMA STRESS, V22, P303, DOI 10.1002/jts.20423; Koso M, 2006, EUR PSYCHIAT, V21, P167, DOI 10.1016/j.eurpsy.2005.06.004; Kroes MCW, 2011, J PSYCHIATR NEUROSCI, V36, P256, DOI 10.1503/jpn.100077; Larson GE, 2009, MIL MED, V174, P737, DOI 10.7205/MILMED-D-02-0308; Leskin LP, 2007, NEUROPSYCHOLOGY, V21, P275, DOI 10.1037/0894-4105.21.3.275; Lew HL, 2010, NEUROREHABILITATION, V26, P271, DOI 10.3233/NRE-2010-0562; Li CSR, 2006, J NEUROSCI, V26, P186, DOI 10.1523/JNEUROSCI.3741-05.2006; Lippa SM, 2010, J INT NEUROPSYCH SOC, V16, P856, DOI 10.1017/S1355617710000743; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Management of Concussion/mTBI Working Group, 2009, J Rehabil Res Dev, V46, pCP1; Marx BP, 2009, ARCH GEN PSYCHIAT, V66, P996, DOI 10.1001/archgenpsychiatry.2009.109; Mathias JL, 2004, J INT NEUROPSYCH SOC, V10, P286, DOI 10.1017/S1355617704102117; Matthews SC, 2011, NEUROIMAGE, V54, pS69, DOI 10.1016/j.neuroimage.2010.04.269; Mcnab F, 2008, NEUROPSYCHOLOGIA, V46, P2668, DOI 10.1016/j.neuropsychologia.2008.04.023; MCNALLY RJ, 1990, J ABNORM PSYCHOL, V99, P398, DOI 10.1037/0021-843X.99.4.398; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Morey RA, 2008, PSYCHIAT RES-NEUROIM, V162, P59, DOI 10.1016/j.pscychresns.2007.07.007; Mostofsky SH, 2008, J COGNITIVE NEUROSCI, V20, P751, DOI 10.1162/jocn.2008.20500; Nee DE, 2007, COGN AFFECT BEHAV NE, V7, P1, DOI 10.3758/CABN.7.1.1; Nelson LA, 2009, J HEAD TRAUMA REHAB, V24, P32, DOI 10.1097/HTR.0b013e3181957016; Patton JH, 1995, J CLIN PSYCHOL, V51, P768, DOI 10.1002/1097-4679(199511)51:6<768::AID-JCLP2270510607>3.0.CO;2-1; PETRIDES M, 1986, J NEUROSCI, V6, P2054; Picton TW, 2007, CEREB CORTEX, V17, P826, DOI 10.1093/cercor/bhk031; Qureshi SU, 2011, J NEUROPSYCH CLIN N, V23, P16, DOI 10.1176/appi.neuropsych.23.1.16; Rauch SL, 2003, NEUROREPORT, V14, P913, DOI 10.1097/01.wnr.0000071767.24455.10; Rentrop M, 2008, PSYCHOPATHOLOGY, V41, P50, DOI 10.1159/000110626; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Romesser J, 2011, MIL MED, V176, P246, DOI 10.7205/MILMED-D-10-00056; Shin LM, 2006, ANN NY ACAD SCI, V1071, P67, DOI 10.1196/annals.1364.007; Sigford B, 2009, NEW ENGL J MED, V361, P536, DOI 10.1056/NEJMc096180; Simmons AN, 2012, NEUROPHARMACOLOGY, V62, P598, DOI 10.1016/j.neuropharm.2011.03.016; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; Swick D, 2002, P NATL ACAD SCI USA, V99, P16354, DOI 10.1073/pnas.252521499; Swick D, 2011, NEUROIMAGE, V56, P1655, DOI 10.1016/j.neuroimage.2011.02.070; Swick D, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-102; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004; Vasterling JJ, 2009, J INT NEUROPSYCH SOC, V15, P826, DOI 10.1017/S1355617709990683; Vasterling JJ, 1998, NEUROPSYCHOLOGY, V12, P125, DOI 10.1037/0894-4105.12.1.125; VRANA SR, 1995, J ANXIETY DISORD, V9, P515, DOI 10.1016/0887-6185(95)00028-M; Weathers F.W., 1994, PTSD CHECKLIST MILIT; Wechsler D., 2001, WECHSLER TEST ADULT; Whyte J, 2006, NEUROPSYCHOLOGIA, V44, P2007, DOI 10.1016/j.neuropsychologia.2006.02.012; Woodward SH, 2006, BIOL PSYCHIAT, V59, P582, DOI 10.1016/j.biopsych.2005.07.033; Wu JH, 2010, NEUROSCI LETT, V486, P117, DOI 10.1016/j.neulet.2010.07.040; Zheng D, 2008, J COGNITIVE NEUROSCI, V20, P1434, DOI 10.1162/jocn.2008.20100	69	75	77	2	40	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	SEP	2012	18	5					917	926		10.1017/S1355617712000458			10	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	999KB	WOS:000308309100014	22595028				2021-06-18	
J	Farbota, KD; Bendlin, BB; Alexander, AL; Rowley, HA; Dempsey, RJ; Johnson, SC				Farbota, Kimberly D.; Bendlin, Barbara B.; Alexander, Andrew L.; Rowley, Howard A.; Dempsey, Robert J.; Johnson, Sterling C.			Longitudinal diffusion tensor imaging and neuropsychological correlates in traumatic brain injury patients	FRONTIERS IN HUMAN NEUROSCIENCE			English	Article						traumatic brain injury; diffusion tensor imaging; longitudinal; neuropsychology; recovery; DTI; TBI	CORPUS-CALLOSUM MICROSTRUCTURE; WHITE-MATTER INTEGRITY; AXONAL INJURY; DAMAGE; MODEL; MRI; ADOLESCENTS; ACTIVATION; PLASTICITY; FASCICULUS	Traumatic brain injury (TBI) often involves focal cortical injury and white matter (WM) damage that can be measured shortly after injury. Additionally, slowly evolving WM change can be observed but there is a paucity of research on the duration and spatial pattern of long-term changes several years post-injury. The current study utilized diffusion tensor imaging to identify regional WM changes in 12 TBI patients and nine healthy controls at three time points over a four year period. Neuropsychological testing was also administered to each participant at each time point. Results indicate that TBI patients exhibit longitudinal changes to WM indexed by reductions in fractional anisotropy (FA) in the corpus callosum, as well as FA increases in bilateral regions of the superior longitudinal fasciculus (SLF) and portions of the optic radiation (OR). FA changes appear to be driven by changes in radial (not axial) diffusivity, suggesting that observed longitudinal FA changes may be related to changes in myelin rather than to axons. Neuropsychological correlations indicate that regional FA values in the corpus callosum and sagittal stratum (SS) correlate with performance on finger tapping and visuomotor speed tasks (respectively) in TBI patients, and that longitudinal increases in FA in the SS, SLF, and OR correlate with improved performance on the visuomotor speed (SS) task as well as a derived measure of cognitive control (SLF, OR). The results of this study showing progressive WM deterioration for several years post-injury contribute to a growing literature supporting the hypothesis that TBI should be viewed not as an isolated incident but as a prolonged disease state. The observations of long-term neurological and functional improvement provide evidence that some ameliorative change may be occurring concurrently with progressive degeneration.	[Farbota, Kimberly D.; Bendlin, Barbara B.; Johnson, Sterling C.] William S Middleton Mem Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Madison, WI USA; [Farbota, Kimberly D.] Univ Wisconsin, Neurosci Training Program, Madison, WI 53705 USA; [Bendlin, Barbara B.; Johnson, Sterling C.] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI 53705 USA; [Alexander, Andrew L.] Univ Wisconsin, Dept Med Phys, Sch Med & Publ Hlth, Madison, WI 53705 USA; [Rowley, Howard A.] Univ Wisconsin, Dept Radiol, Sch Med & Publ Hlth, Madison, WI 53705 USA; [Dempsey, Robert J.] Univ Wisconsin, Dept Neurol Surg, Sch Med & Publ Hlth, Madison, WI 53705 USA	Johnson, SC (corresponding author), Univ Wisconsin, William S Middleton Mem VA Hosp, Dept Med, 2500 Overlook Terrace, Madison, WI 53705 USA.	scj@medicine.wisc.edu		Bendlin, Barbara/0000-0002-0580-9875	Department of Veterans AffairsUS Department of Veterans Affairs; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [MH65723, AG000213]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30HD003352] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH065723] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [T32AG000213] Funding Source: NIH RePORTER	This study was supported by a Merit Review Grant from the Department of Veterans Affairs, the NIH MH65723 (SCJ), NIH AG000213 and by the facilities and resources of the William S. Middleton Memorial Veterans Hospital. The assistance of Lisa Newman, Amy Hawley, Donald McLaren, and Erik Kastman is greatly appreciated. We would also like to acknowledge the support of researchers and staff at the Waisman Center , University of Wisconsin, Madison, where MR imaging took place . Finally, we thank all the patients who took part in this study . The contents of this report do not necessarily represent the views of the Department of Veterans Affairs or the United States Government.	Alexander AL, 2007, NEUROTHERAPEUTICS, V4, P316, DOI 10.1016/j.nurt.2007.05.011; Anderson CV, 1995, J CLIN EXP NEUROPSYC, V17, P900, DOI 10.1080/01688639508402438; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Bigler ED, 1996, BRAIN INJURY, V10, P197, DOI 10.1080/026990596124511; Blizzard CA, 2011, CEREB CORTEX, V21, P281, DOI 10.1093/cercor/bhq091; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Caeyenberghs K, 2011, J NEUROTRAUM, V28, P897, DOI 10.1089/neu.2010.1721; Caeyenberghs K, 2011, NEUROREHAB NEURAL RE, V25, P492, DOI 10.1177/1545968310394870; Chan JHM, 2003, NEURORADIOLOGY, V45, P34, DOI 10.1007/s00234-002-0891-y; Creed JA, 2011, J NEUROTRAUM, V28, P547, DOI 10.1089/neu.2010.1729; de la Plata CAM, 2008, ARCH PHYS MED REHAB, V89, P896, DOI 10.1016/j.apmr.2007.12.030; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Field AS, 2003, AM J NEURORADIOL, V24, P1461; Filippi CG, 2001, AM J NEURORADIOL, V22, P277; FORMAN SD, 1995, MAGNET RESON MED, V33, P636, DOI 10.1002/mrm.1910330508; Frye RE, 2010, DEV MED CHILD NEUROL, V52, P760, DOI 10.1111/j.1469-8749.2010.03633.x; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; Hao XJ, 2013, HUM BRAIN MAPP, V34, P253, DOI 10.1002/hbm.21440; Karlsgodt KH, 2008, BIOL PSYCHIAT, V63, P512, DOI 10.1016/j.biopsych.2007.06.017; Kim J, 2008, NEUROIMAGE, V39, P1014, DOI 10.1016/j.neuroimage.2007.10.005; Kiraly MA, 2007, THESCIENTIFICWORLDJO, V7, P1768, DOI 10.1100/tsw.2007.269; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar R, 2010, J HEAD TRAUMA REHAB, V25, P31, DOI 10.1097/HTR.0b013e3181bff331; Le Bihan D, 1991, Magn Reson Q, V7, P1; Levin HS, 2003, BRAIN INJURY, V17, P665, DOI 10.1080/0269905031000107151; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; Li J, 2011, EUR J NEUROSCI, V33, P933, DOI 10.1111/j.1460-9568.2010.07573.x; Lin MR, 2010, ARCH PHYS MED REHAB, V91, P474, DOI 10.1016/j.apmr.2009.10.031; Ljungqvist J, 2011, BRAIN INJURY, V25, P370, DOI 10.3109/02699052.2011.558038; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Makris N, 2005, CEREB CORTEX, V15, P854, DOI 10.1093/cercor/bhh186; Malec JF, 2010, ARCH PHYS MED REHAB, V91, P1087, DOI 10.1016/j.apmr.2010.04.002; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Matsukawa H, 2011, ACTA NEUROCHIR, V153, P1687, DOI 10.1007/s00701-011-1002-9; Merkley TL, 2008, J NEUROTRAUM, V25, P1343, DOI 10.1089/neu.2008.0615; Muetzel RL, 2008, NEUROIMAGE, V39, P1918, DOI 10.1016/j.neuroimage.2007.10.018; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Newcombe VFJ, 2007, BRIT J NEUROSURG, V21, P340, DOI 10.1080/02688690701400882; Povlishock J T, 2000, Clin Neurosurg, V46, P113; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Risdall JE, 2011, PHILOS T R SOC B, V366, P241, DOI 10.1098/rstb.2010.0230; Rubovitch V, 2011, EXP NEUROL, V232, P280, DOI 10.1016/j.expneurol.2011.09.018; Sharp DJ, 2011, CURR OPIN NEUROL, V24, P558, DOI 10.1097/WCO.0b013e32834cd523; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Song SK, 2002, NEUROIMAGE, V17, P1429, DOI 10.1006/nimg.2002.1267; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; Staudt M, 2010, SEMIN PERINATOL, V34, P87, DOI 10.1053/j.semperi.2009.10.009; Tasker RC, 2010, DEV NEUROSCI-BASEL, V32, P374, DOI 10.1159/000316806; Trivedi MA, 2007, J NEUROTRAUM, V24, P766, DOI 10.1089/neu.2006.0205; Wang JY, 2011, NEUROLOGY, V77, P818, DOI 10.1212/WNL.0b013e31822c61d7; Wheeler-Kingshott CAM, 2009, MAGN RESON MED, V61, P1255, DOI 10.1002/mrm.21965; Wu TC, 2010, DEV NEUROSCI-BASEL, V32, P361, DOI 10.1159/000317058; Xie MQ, 2010, J NEUROPATH EXP NEUR, V69, P704, DOI 10.1097/NEN.0b013e3181e3de90; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208	58	75	76	0	16	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-5161			FRONT HUM NEUROSCI	Front. Hum. Neurosci.	JUN 19	2012	6								160	10.3389/fnhum.2012.00160			15	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	965SK	WOS:000305787400001	22723773	DOAJ Gold, Green Published			2021-06-18	
J	Bryan, CJ; Clemans, TA; Hernandez, AM				Bryan, Craig J.; Clemans, Tracy A.; Hernandez, Ann Marie			Perceived burdensomeness, fearlessness of death, and suicidality among deployed military personnel	PERSONALITY AND INDIVIDUAL DIFFERENCES			English	Article						Suicide; Military; Interpersonal-psychological theory; Perceived burdensomeness; Acquired capability	INTERPERSONAL-PSYCHOLOGICAL THEORY; ACQUIRED CAPABILITY; BEHAVIOR; TESTS	The interpersonal-psychological theory of suicide posits that the interaction of three elements is required for lethal suicidal behaviors: the perception that one is a burden on others, the perception that one does not belong, and fearlessness about death combined with high pain tolerance (termed "acquired capability" for suicide). Although an ever expanding research base supports the theory, very limited data exist supporting the theory among military personnel, a group that has experienced a rapid increase in suicides during the past several years. The current study tests the interpersonal-psychological theory in two clinical samples of military personnel while deployed to Iraq: those seeking treatment for mild traumatic brain injury, and those seeking outpatient mental health treatment. In both samples, perceived burdensomeness and acquired capability were significantly associated with suicidality, as was their interaction term. Results partially support the interpersonal-psychological theory of suicide, and indicate that perceptions of burdensomeness combined with fearlessness about death are associated with increased suicidality among deployed military personnel. (C) 2011 Elsevier Ltd. All rights reserved.	[Bryan, Craig J.; Clemans, Tracy A.; Hernandez, Ann Marie] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA; [Bryan, Craig J.] Univ Utah, Natl Ctr Vet Studies, Salt Lake City, UT 84112 USA	Bryan, CJ (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, 7550 IH-10 W,Suite 1325, San Antonio, TX 78229 USA.	bryanc3@uthscsa.edu		Bryan, Craig/0000-0002-9714-0733			Anestis M., 2009, J MENTAL HEALTH COUN, V31, P60, DOI [10.17744/mehc.31.1.u394h1470248844n, DOI 10.17744/MEHC.31.1.U394H1470248844N, DOI 10.17744/MEHC.31.1.U394H1470]; Bliese PD, 2008, J CONSULT CLIN PSYCH, V76, P272, DOI 10.1037/0022-006X.76.2.272; Blount T. H., 2010, CONV ASS BEH COGN TH; Brenner L.A., 2008, J MENT HLTH COUNS, V30, P211; Bryan C. J., 2010, J CLIN PSYCHOL, V15, P5, DOI [10.1002/jcIp.20726, DOI 10.1002/JCIP.20726]; Bryan CJ, 2006, J CLIN PSYCHOL, V62, P185, DOI 10.1002/jclp.20222; Bryan CJ, 2011, SUICIDE LIFE-THREAT, V41, P126, DOI 10.1111/j.1943-278X.2011.00023.x; Bryan CJ, 2010, J CLIN PSYCHOL, V66, P1044, DOI 10.1002/jclp.20703; Bryan CJ, 2010, PERS INDIV DIFFER, V48, P347, DOI 10.1016/j.paid.2009.10.023; deCatanzaro D, 1995, ETHOL SOCIOBIOL, V16, P385, DOI 10.1016/0162-3095(95)00055-0; Defense and Veterans Brain Injury Center, 2007, MIL AC CONC EV; Department of Defense Task Force on the Prevention of Suicide by Members of the Armed Forces, 2010, CHALL PROM STRENGTH; Headquarters Department of the Army, 2010, ARM HLTH PROM RISK R; Joiner T. E., 2005, WHY PEOPLE DIE SUICI; Joiner TE, 2009, J ABNORM PSYCHOL, V118, P634, DOI 10.1037/a0016500; Kang HK, 2008, JAMA-J AM MED ASSOC, V300, P652, DOI 10.1001/jama.300.6.652; Kopta SM, 2002, PSYCHOTHER RES, V12, P413, DOI 10.1093/ptr/12.4.413; LINEHAN MM, 1983, J CONSULT CLIN PSYCH, V51, P276, DOI 10.1037/0022-006X.51.2.276; Nademin E, 2008, ARCH SUICIDE RES, V12, P309, DOI 10.1080/13811110802324847; Nock MK, 2006, PSYCHIAT RES, V144, P65, DOI 10.1016/j.psychres.2006.05.010; Orbach I, 1997, J CONSULT CLIN PSYCH, V65, P646, DOI 10.1037/0022-006X.65.4.646; Osman A, 2001, ASSESSMENT, V8, P443, DOI 10.1177/107319110100800409; Ritchie EC, 2003, MIL MED, V168, P177; Rudd M.D., 2001, TREAT MAN PRACTITION; Selby EA, 2010, CLIN PSYCHOL REV, V30, P298, DOI 10.1016/j.cpr.2009.12.004; Tanielian T, 2008, INVISIBLE WOUNDS WAR; TROUT DL, 1980, SUICIDE LIFE-THREAT, V10, P10; Van Orden K.A., PSYCHOL ASS IN PRESS; Van Orden KA, 2008, J CONSULT CLIN PSYCH, V76, P72, DOI 10.1037/0022-006X.76.1.72; Van Orden KA, 2006, COGNITIVE THER RES, V30, P457, DOI 10.1007/s10608-006-9057-2; Weathers F. W., 1993, ANN M INT SOC TRAUM; WOZNICA JG, 1990, J PEDIATR PSYCHOL, V15, P789, DOI 10.1093/jpepsy/15.6.789	32	75	77	1	12	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0191-8869			PERS INDIV DIFFER	Pers. Individ. Differ.	FEB	2012	52	3					374	379		10.1016/j.paid.2011.10.045			6	Psychology, Social	Psychology	884ND	WOS:000299713900025					2021-06-18	
J	Lange, RT; Pancholi, S; Bhagwat, A; Anderson-Barnes, V; French, LM				Lange, Rael T.; Pancholi, Sonal; Bhagwat, Aditya; Anderson-Barnes, Victoria; French, Louis M.			Influence of poor effort on neuropsychological test performance in US military personnel following mild traumatic brain injury	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Mild traumatic brain injury; Neuropsychological testing; Poor effort; Military; Service members	SYMPTOM VALIDITY TEST; POSTTRAUMATIC-STRESS-DISORDER; SELF-REPORTED SYMPTOMS; COMPENSATION-SEEKING; COMBAT VETERANS; RESPONSE BIAS; LITIGATION STATUS; TEST FAILURE; BASE RATES; EXAGGERATION	The purpose of this study was to examine the influence of poor effort on neuropsychological test performance in military personnel following mild traumatic brain injury (MTBI). Participants were 143 U. S. service members who sustained a TBI, divided into three groups based on injury severity and performance on the Word Memory Test and four embedded markers of poor effort: MTBI-pass (n = 87), MTBI-fail (n = 21), and STBI-pass (n = 35; where STBI denotes severe TBI). Patients were evaluated at the Walter Reed Army Medical Center on average 3.9 months (SD = 3.4) post injury. The majority of the sample was Caucasian (84.6%), was male (93.0%), and had 12+ years of education (96.5%). Measures included the Personality Assessment Inventory (PAI) and 13 common neurocognitive measures. Patients in the MTBI-fail group performed worse on the majority of neurocognitive measures, followed by the Severe TBI-Pass group and the MTBI-pass group. Using a criterion of three or more low scores <10th percentile, the MTBI-fail group had the greatest rate of impairment (76.2%), followed by the Severe TBI-Pass group (34.3%) and MTBI-pass group (16.1%). On the PAI, the MTBI-fail group had higher scores on the majority of clinical scales (p < .05). There were a greater number of elevated scales (e. g., 5 or more elevated mild or higher) in the MTBI-fail group (71.4%) than in the MTBI-pass group (32.2%) and Severe TBI-Pass group (17.1%). Effort testing is an important component of postacute neuropsychological evaluations following combat-related MTBI. Those who fail effort testing are likely to be misdiagnosed as having severe cognitive impairment, and their symptom reporting is likely to be inaccurate.	[Lange, Rael T.; Pancholi, Sonal; Bhagwat, Aditya; French, Louis M.] Def & Vet Brain Injury Ctr, Bethesda, MD 20852 USA; [Lange, Rael T.; Bhagwat, Aditya; French, Louis M.] Walter Reed Natl Mil Med Ctr, Dept Orthopaed & Rehabil, Bethesda, MD USA; [Lange, Rael T.] Univ British Columbia, Dept Psychiat, Vancouver, BC, Canada; [Pancholi, Sonal] Ft Belvoir Community Hosp, Ft Belvoir, VA USA; [Bhagwat, Aditya] United States Publ Hlth Serv, Bethesda, MD USA; [Anderson-Barnes, Victoria] Penn State Univ, Dept Psychol, State Coll, PA USA; [French, Louis M.] Uniformed Serv Univ Hlth Sci, Dept Neurol, Bethesda, MD 20814 USA	Lange, RT (corresponding author), Def & Vet Brain Injury Ctr, 11300 Rockville Pike,Suite 1100, Bethesda, MD 20852 USA.	rlange@dvbic.org	french, louis/AAB-2083-2020	french, louis/0000-0002-9451-0604; Merritt, Victoria/0000-0001-5683-4168			Ardolf BR, 2007, CLIN NEUROPSYCHOL, V21, P899, DOI 10.1080/13825580600966391; Armistead-Jehle P, 2010, APPL NEUROPSYCHOL, V17, P52, DOI 10.1080/09084280903526182; Belanger HG, 2011, CLIN NEUROPSYCHOL, V25, P702, DOI 10.1080/13854046.2011.566892; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Boone KB, 1999, CLIN NEUROPSYCHOL, V13, P414; Brenner LA, 2009, REHABIL PSYCHOL, V54, P239, DOI 10.1037/a0016908; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Conners K., 2002, CONNERS CONTINUOUS P; Constantinou M, 2005, ARCH CLIN NEUROPSYCH, V20, P191, DOI 10.1016/j.acn.2004.06.002; Defense and Veterans Brain Injury Center, 2010, TBI NUMB; Delis DC, 2000, CALIFORNIA VERBAL LE; DeViva JC, 2003, J TRAUMA STRESS, V16, P503, DOI 10.1023/A:1025766713188; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; Dobscha SK, 2009, PAIN MED, V10, P1200, DOI 10.1111/j.1526-4637.2009.00721.x; Etherton JL, 2006, J CLIN EXP NEUROPSYC, V28, P1218, DOI 10.1080/13803390500346595; Fox DD, 2011, CLIN NEUROPSYCHOL, V25, P488, DOI 10.1080/13854046.2011.554443; Frueh BC, 2000, CLIN PSYCHOL REV, V20, P853, DOI 10.1016/S0272-7358(99)00015-X; Gervais RO, 2004, ARCH CLIN NEUROPSYCH, V19, P475, DOI 10.1016/j.acn.2003.05.001; Gervais RO, 2008, CLIN NEUROPSYCHOL, V22, P1061, DOI 10.1080/13854040701756930; Gold PB, 1999, J NERV MENT DIS, V187, P680, DOI 10.1097/00005053-199911000-00005; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Green P, 2007, PHYS MED REHABILITAT, V18, pvi; Green P., 2003, GREENS WORD MEMORY T; Green Paul, 2007, Phys Med Rehabil Clin N Am, V18, P43, DOI 10.1016/j.pmr.2006.11.002; Grieger TA, 2006, AM J PSYCHIAT, V163, P1777, DOI 10.1176/appi.ajp.163.10.1777; Haggerty KA, 2007, CLIN NEUROPSYCHOL, V21, P917, DOI 10.1080/13854040600899724; Heaton RK, 2004, REVISED COMPREHENSIV; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Henry GK, 2009, CLIN NEUROPSYCHOL, V23, P153, DOI 10.1080/13854040801969524; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Iverson GL, 2002, CLIN NEUROPSYCHOL, V16, P398, DOI 10.1076/clin.16.3.398.13861; Iverson GL, 2007, BRAIN INJURY MED PRI, P333; Iverson GL, 2011, LITTLE BLACK BOOK OF NEUROPSYCHOLOGY: A SYNDROME-BASED APPROACH, P697, DOI 10.1007/978-0-387-76978-3_22; Iverson GL, 2010, CLIN NEUROPSYCHOL, V24, P17, DOI 10.1080/13854040903190797; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kim N, 2010, ARCH CLIN NEUROPSYCH, V25, P420, DOI 10.1093/arclin/acq040; Lange RT, 2010, J CLIN EXP NEUROPSYC, V32, P961, DOI 10.1080/13803391003645657; Larrabee G.J., 2005, FORENSIC NEUROPSYCHO; Larrabee GJ, 2003, ARCH CLIN NEUROPSYCH, V18, P673, DOI 10.1016/S0887-6177(02)00157-9; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P395, DOI 10.1076/clin.17.3.395.18087; Management of Concussion/mTBI Working Group, 2009, J Rehabil Res Dev, V46, pCP1; Meyers JE, 2011, ARCH CLIN NEUROPSYCH, V26, P8, DOI 10.1093/arclin/acq083; Mitrushina M., 1999, HDB NORMATIVE DATA N; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Moore BA, 2004, BRAIN INJURY, V18, P975, DOI 10.1080/02699050410001672350; Morey L. C., 1991, PERSONALITY ASSESSME; Nelson NW, 2010, ARCH CLIN NEUROPSYCH, V25, P713, DOI 10.1093/arclin/acq075; Ord JS, 2010, J CLIN EXP NEUROPSYC, V32, P380, DOI 10.1080/13803390903066881; Ramchand R, 2010, J TRAUMA STRESS, V23, P59, DOI 10.1002/jts.20486; Reitan R. M., 1992, TRAIL MAKING TEST MA; Root JC, 2006, J INT NEUROPSYCH SOC, V12, P688, DOI 10.1017/S1355617706060838; Sharland MJ, 2007, ARCH CLIN NEUROPSYCH, V22, P213, DOI 10.1016/j.acn.2006.12.004; Smith DW, 1996, PSYCHOL ASSESSMENT, V8, P3, DOI 10.1037/1040-3590.8.1.3; Spreen O., 1998, COMPENDIUM NEUROPSYC; Stevens A, 2008, PSYCHIAT RES, V157, P191, DOI 10.1016/j.psychres.2007.01.003; Suhr J, 1997, J CLIN EXP NEUROPSYC, V19, P500, DOI 10.1080/01688639708403740; Suhr J, 2008, ARCH CLIN NEUROPSYCH, V23, P521, DOI 10.1016/j.acn.2008.05.003; Sumanti M, 2006, CLIN NEUROPSYCHOL, V20, P754, DOI 10.1080/13854040500428467; Tsanadis J, 2007, J INT NEUROPSYCH SOC, V13, P196; Tsanadis J, 2008, CLIN NEUROPSYCHOL, V22, P1080, DOI 10.1080/13854040701796928; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 1997, WAIS 3 ADM SCORING M; West LK, 2011, J NEUROPSYCHOL, V5, P114, DOI 10.1348/174866410X521434; Whitney KA, 2010, APPL NEUROPSYCHOL, V17, P196, DOI 10.1080/09084282.2010.499787; Whitney KA, 2009, ARCH CLIN NEUROPSYCH, V24, P145, DOI 10.1093/arclin/acp020; Wygant DB, 2007, ARCH CLIN NEUROPSYCH, V22, P489, DOI 10.1016/j.acn.2007.01.027	69	75	75	0	16	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2012	34	5					453	466		10.1080/13803395.2011.648175			14	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	936AA	WOS:000303562100002	22273465				2021-06-18	
J	Blyth, BJ; Farahvar, A; He, H; Nayak, A; Yang, C; Shaw, G; Bazarian, JJ				Blyth, Brian J.; Farahvar, Arash; He, Hua; Nayak, Akshata; Yang, Cui; Shaw, Gerry; Bazarian, Jeffrey J.			Elevated Serum Ubiquitin Carboxy-Terminal Hydrolase L1 Is Associated with Abnormal Blood-Brain Barrier Function after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						area under the receiver operator characteristic curve; biomarkers; blood-brain barrier dysfunction; neurofilament heavy chain; phosphorylated neurofilament heavy chain; traumatic brain injury; ubiquitin carboxy-terminal hydrolase L1	AXONAL INJURY; HEAD-INJURY; NF-H; NEUROLOGICAL DISORDERS; IGG ANALYSES; PGP 9.5; PNF-H; BIOMARKER; PROTEIN; S100B	Serum S100B elevations accurately reflect blood-brain barrier (BBB) damage. Because S100B is also present in peripheral tissues, release of this protein may not be specific to central nervous system (CNS) injury. Ubiquitin C-terminal hydrolase 1 (UCHL1), and phosphorylated neurofilament heavy chain (pNF-H) are found exclusively in neurons, but their relationship to BBB dysfunction has not been determined. The objective of this study was to determine the accuracy of serum UCHL1 and pNF-H as measures of BBB integrity after traumatic brain injury (TBI), to and compare them to S100B. We performed a prospective study of 16 patients with moderate to severe TBI (Glasgow Coma Scale [GCS] score <= 12) and 6 patients with non-traumatic headache who had cerebrospinal fluid (CSF) collected by ventriculostomy or lumbar puncture (LP). Serum and CSF were collected at the time of LP for headache patients and at 12, 24, and 48 h after injury for TBI patients. BBB function was determined by calculating albumin quotients (Q(A)), where Q(A) = [albumin(CSF)]/[albumin(serum)]. S100B, UCHL1, and pNF-H were measured by enzyme-linked immunosorbent assay (ELISA). Pearson's correlation coefficient and area under the receiver operator characteristic (ROC) curve were used to determine relationships between serum markers and Q(A). At 12 hours after TBI, a significant relationship was found between Q(A) and serum UCHL1 concentrations (AUC=0.76; 95% CI 0.55,1.00), and between Q(A) and serum S100B concentrations (AUC=0.794; 95% CI 0.57,1.02). There was no significant relationship found between these markers and Q(A) at other time points, or between pNF-H and Q(A) at any time point. We conclude that serum concentrations of UCHL1 are associated with abnormal BBB status 12 h after moderate to severe TBI. This relationship is similar to that observed between serum S100B and Q(A), despite the fact that S100B may be released from peripheral tissues after multi-trauma. We conclude that peripheral release of S100B after multi-trauma is probably negligible and that UCHL1 may have some utility to monitor BBB disruption following TBI.	[Blyth, Brian J.; Nayak, Akshata; Bazarian, Jeffrey J.] Univ Rochester, Med Ctr, Dept Emergency Med, Rochester, NY 14642 USA; [Blyth, Brian J.; Nayak, Akshata; Bazarian, Jeffrey J.] Univ Rochester, Med Ctr, Ctr Neural Dev & Dis, Rochester, NY 14642 USA; [Farahvar, Arash; Nayak, Akshata; Bazarian, Jeffrey J.] Univ Rochester, Med Ctr, Dept Neurosurg, Rochester, NY 14642 USA; [He, Hua] Univ Rochester, Med Ctr, Dept Biostat & Computat Biol, Rochester, NY 14642 USA; [Nayak, Akshata; Bazarian, Jeffrey J.] Univ Rochester, Med Ctr, Dept Neurol, Rochester, NY 14642 USA; [Yang, Cui; Shaw, Gerry] Univ Florida, Coll Med, Dept Neurosci, McKnight Brain Inst, Gainesville, FL 32610 USA	Blyth, BJ (corresponding author), Univ Rochester, Med Ctr, Dept Emergency Med, 601 Elmwood Ave, Rochester, NY 14642 USA.	Brian_Blyth@urmc.rochester.edu	, Gerry/X-2377-2019				Adami C, 2001, GLIA, V33, P131, DOI 10.1002/1098-1136(200102)33:2<131::AID-GLIA1012>3.0.CO;2-D; Anderson KJ, 2008, J NEUROTRAUM, V25, P1079, DOI 10.1089/neu.2007.0488; Anderson RE, 2000, ANN THORAC SURG, V69, P847, DOI 10.1016/S0003-4975(99)01526-X; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Berger J, 2007, NEUROL RES, V29, P610, DOI 10.1179/016164107X172158; Biberthaler P, 2006, SHOCK, V25, P446, DOI 10.1097/01.shk.0000209534.61058.35; Blyth BJ, 2009, J NEUROTRAUM, V26, P1497, DOI [10.1089/neu.2008.0738, 10.1089/neu.2008-0738]; Boylan K, 2009, J NEUROCHEM, V111, P1182, DOI 10.1111/j.1471-4159.2009.06386.x; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; Day INM, 2010, PROG NEUROBIOL, V90, P327, DOI 10.1016/j.pneurobio.2009.10.020; Diomedi-Camassei F, 2005, NEPHROL DIAL TRANSPL, V20, P2714, DOI 10.1093/ndt/gfi124; DORAN JF, 1983, J NEUROCHEM, V40, P1542, DOI 10.1111/j.1471-4159.1983.tb08124.x; DOUGLASESCOBAR M, 2010, PEDIAT RES; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Flierl MA, 2010, CRIT CARE, V14, DOI 10.1186/cc9035; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Flierl MA, 2009, CRIT CARE, V13, DOI 10.1186/cc7794; Gresle MM, 2008, J NEUROSCI RES, V86, P3548, DOI 10.1002/jnr.21803; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Kobbe P, 2008, J ORTHOP TRAUMA, V22, P385, DOI 10.1097/BOT.0b013e318175dd88; Krizbai IA, 2005, SHOCK, V24, P428, DOI 10.1097/01.shk.0000183389.98519.d3; Lewis SB, 2008, J CEREBR BLOOD F MET, V28, P1261, DOI 10.1038/jcbfm.2008.12; Lewis SB, 2010, J NEUROSCI RES, V88, P1475, DOI 10.1002/jnr.22323; LINK H, 1977, SCAND J CLIN LAB INV, V37, P391, DOI 10.3109/00365517709091497; Liu MC, 2010, EUR J NEUROSCI, V31, P722, DOI 10.1111/j.1460-9568.2010.07097.x; Morganti-Kossmann MC, 1999, J NEUROTRAUM, V16, P617, DOI 10.1089/neu.1999.16.617; Papa L, 2010, CRIT CARE MED, V38, P138, DOI 10.1097/CCM.0b013e3181b788ab; Pelinka LE, 2003, BRIT J ANAESTH, V91, P595, DOI 10.1093/bja/aeg225; Pelinka LE, 2003, SHOCK, V19, P195, DOI 10.1097/00024382-200303000-00001; Petzold A, 2005, J NEUROL SCI, V233, P183, DOI 10.1016/j.jns.2005.03.015; Reiber H, 2001, CLIN CHIM ACTA, V310, P173, DOI 10.1016/S0009-8981(01)00573-3; REIBER H, 1980, J NEUROL, V224, P89, DOI 10.1007/BF00313347; Ruczinski I, 2003, J COMPUT GRAPH STAT, V12, P475, DOI 10.1198/1061860032238; Ruttan L, 2008, ARCH PHYS MED REHAB, V89, pS69, DOI 10.1016/j.apmr.2008.07.007; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Shaw G, 2005, BIOCHEM BIOPH RES CO, V336, P1268, DOI 10.1016/j.bbrc.2005.08.252; Siman R, 2008, BRAIN RES, V1213, P1, DOI 10.1016/j.brainres.2008.03.034; Siman R, 2009, J NEUROTRAUM, V26, P1867, DOI 10.1089/neu.2009.0882; Stalnacke BM, 2003, CLIN J SPORT MED, V13, P292; STERNBERGER LA, 1983, P NATL ACAD SCI-BIOL, V80, P6126, DOI 10.1073/pnas.80.19.6126; Strong MJ, 2001, J NEUROCHEM, V76, P1315, DOI 10.1046/j.1471-4159.2001.00094.x; Swann K, 2007, BRAIN RES, V1129, P26, DOI 10.1016/j.brainres.2006.10.061; Takami Y, 2007, ARTERIOSCL THROM VAS, V27, P2184, DOI 10.1161/ATVBAHA.107.142505; THOMPSON RJ, 1983, BRAIN RES, V278, P224, DOI 10.1016/0006-8993(83)90241-X; TIBBLING G, 1977, SCAND J CLIN LAB INV, V37, P385, DOI 10.3109/00365517709091496; Vilalta A, 2008, INTENS CARE MED, V34, P1384, DOI 10.1007/s00134-008-1056-1; Whitnall L, 2006, J NEUROL NEUROSUR PS, V77, P640, DOI 10.1136/jnnp.2005.078246; Wiesmann M, 1999, BIOL PSYCHIAT, V45, P1508, DOI 10.1016/S0006-3223(98)00217-0; WILKINSON KD, 1989, SCIENCE, V246, P670, DOI 10.1126/science.2530630; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208	50	75	79	0	16	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2011	28	12					2453	2462		10.1089/neu.2010.1653			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	865DS	WOS:000298291600005	21428722				2021-06-18	
J	Hutson, CB; Lazo, CR; Mortazavi, F; Giza, CC; Hovda, D; Chesselet, MF				Hutson, Che Brown; Lazo, Carlos R.; Mortazavi, Farzad; Giza, Christopher C.; Hovda, David; Chesselet, Marie-Francoise			Traumatic Brain Injury in Adult Rats Causes Progressive Nigrostriatal Dopaminergic Cell Loss and Enhanced Vulnerability to the Pesticide Paraquat	JOURNAL OF NEUROTRAUMA			English	Article						alpha-synuclein; lateral fluid percussion; microglia; paraquat; Parkinson's disease; traumatic brain injury	LIPOPOLYSACCHARIDE-INDUCED NEUROTOXICITY; INTRACEREBRAL INFLAMMATORY RESPONSE; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ENVIRONMENTAL RISK-FACTORS; NIGRA PARS COMPACTA; PARKINSONS-DISEASE; SUBSTANTIA-NIGRA; MICROGLIAL ACTIVATION; AXONAL INJURY; COMPLEX-I	Parkinson's disease (PD) is a neurodegenerative disorder characterized by the loss of nigrostriatal dopaminergic neurons and the accumulation of alpha-synuclein. Both traumatic brain injury (TBI) and pesticides are risk factors for PD, but whether TBI causes nigrostriatal dopaminergic cell loss in experimental models and whether it acts synergistically with pesticides is unknown. We have examined the acute and long-term effects of TBI and exposure to low doses of the pesticide paraquat, separately and in combination, on nigrostriatal dopaminergic neurons in adult male rats. In an acute study, rats received moderate TBI by lateral fluid percussion (LFP) injury, were injected with saline or paraquat (10 mg/kg IP) 3 and 6 days after LFP, were sacrificed 5 days later, and their brains processed for immunohistochemistry. TBI alone increased microglial activation in the substantia nigra, and caused a 15% loss of dopaminergic neurons ipsilaterally. Paraquat increased the TBI effect, causing a 30% bilateral loss of dopaminergic neurons, reduced striatal tyrosine hydroxylase (TH) immunoreactivity more than TBI alone, and induced alpha-synuclein accumulation in the substantia nigra pars compacta. In a long-term study, rats received moderate LFP, were injected with saline or paraquat at 21 and 22 weeks post-injury, and were sacrificed 4 weeks later. At 26 weeks post injury, TBI alone induced a 30% bilateral loss of dopaminergic neurons that was not exacerbated by paraquat. These data suggest that TBI is sufficient to induce a progressive degeneration of nigrostriatal dopaminergic neurons. Furthermore, TBI and pesticide exposure, when occurring within a defined time frame, could combine to increase the PD risk.	[Chesselet, Marie-Francoise] Univ Calif Los Angeles, David Geffen Sch Med, Reed Neurol Res Ctr, Dept Neurobiol, Los Angeles, CA 90095 USA; [Hutson, Che Brown; Lazo, Carlos R.; Mortazavi, Farzad; Chesselet, Marie-Francoise] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA; [Giza, Christopher C.; Hovda, David] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Los Angeles, CA 90095 USA; [Hovda, David] Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; [Giza, Christopher C.] Univ Calif Los Angeles, Mattel Childrens Hosp, Div Pediat Neurol, Los Angeles, CA 90095 USA	Chesselet, MF (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Reed Neurol Res Ctr, Dept Neurobiol, B114 710 Westwood Plaza, Los Angeles, CA 90095 USA.	mchesselet@mednet.ucla.edu	Mortazavi, Farzad/AAI-8136-2021	Mortazavi, Farzad/0000-0002-1911-5428	UC TSRTP; APA; The Michael J. Fox Foundation for Parkinson's Research; UCLA BIRC;  [1 F31 NS51163-011];  [U54 ES12078];  [P01 ES016732];  [P50 NS38367];  [NS027544];  [NS057420];  [NS02197]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [U54ES012078, P01ES016732] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K02NS057420, R01NS027544, P50NS038367, F31NS051163] Funding Source: NIH RePORTER	This work was supported by a UC TSR&TP student fellowship, and 1 F31 NS51163-011 (C.B.H.); an APA minority fellowship (C.R.L.); grants U54 ES12078, P01 ES016732, and P50 NS38367 (M.F.C.); grant NS027544 (D.H.); grants NS057420 and NS02197 (C.C.G.); The Michael J. Fox Foundation for Parkinson's Research (F.M.); and UCLA BIRC.	Aghaloo T, 2006, AM J PATHOL, V169, P903, DOI 10.2353/ajpath.2006.051210; Albers DS, 1999, NEUROSCIENCE, V89, P209, DOI 10.1016/S0306-4522(98)00328-5; Arimoto T, 2003, NEUROBIOL DIS, V12, P35, DOI 10.1016/S0969-9961(02)00017-7; Bales JW, 2009, NEUROSCI BIOBEHAV R, V33, P981, DOI 10.1016/j.neubiorev.2009.03.011; Berman SB, 1999, J NEUROCHEM, V73, P1127, DOI 10.1046/j.1471-4159.1999.0731127.x; Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; BHARUCHA NE, 1986, NEUROLOGY, V36, P284, DOI 10.1212/WNL.36.2.284; Bonneh-Barkay D, 2005, ANTIOXID REDOX SIGN, V7, P649, DOI 10.1089/ars.2005.7.649; Bonneh-Barkay D, 2005, MOL BRAIN RES, V134, P52, DOI 10.1016/j.molbrainres.2004.11.005; Bower JH, 1999, NEUROLOGY, V52, P1214, DOI 10.1212/WNL.52.6.1214; Bower JH, 2003, NEUROLOGY, V60, P1610, DOI 10.1212/01.WNL.0000068008.78394.2C; Braak H., 2002, J NEUROL, V249, pIII/1, DOI DOI 10.1007/S00415-002-1301-4; Braak H, 2006, MOVEMENT DISORD, V21, P2042, DOI 10.1002/mds.21065; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Bramlett HM, 1999, J NEUROTRAUM, V16, P1035, DOI 10.1089/neu.1999.16.1035; Carvey PM, 2003, FRONT BIOSCI-LANDMRK, V8, pS826, DOI 10.2741/1158; Chan JHM, 2003, NEURORADIOLOGY, V45, P34, DOI 10.1007/s00234-002-0891-y; Chen HL, 2003, ARCH NEUROL-CHICAGO, V60, P1059, DOI 10.1001/archneur.60.8.1059; Church AJ, 2005, J NEUROTRAUM, V22, P277, DOI 10.1089/neu.2005.22.277; Cicchetti F, 2005, NEUROBIOL DIS, V20, P360, DOI 10.1016/j.nbd.2005.03.018; Clark RSB, 2008, AUTOPHAGY, V4, P88, DOI 10.4161/auto.5173; Cocheme HM, 2008, J BIOL CHEM, V283, P1786, DOI 10.1074/jbc.M708597200; Conti AC, 1998, J NEUROSCI, V18, P5663; Costello S, 2009, AM J EPIDEMIOL, V169, P919, DOI 10.1093/aje/kwp006; Cruz-Muros I, 2007, EXP NEUROL, V204, P147, DOI 10.1016/j.expneurol.2006.10.004; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; Dikranian K, 2008, EXP NEUROL, V211, P551, DOI 10.1016/j.expneurol.2008.03.012; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DOBERSTEIN CE, 1993, ANN EMERG MED, V22, P993, DOI 10.1016/S0196-0644(05)82740-4; Farrer M, 2001, HUM MOL GENET, V10, P1847, DOI 10.1093/hmg/10.17.1847; Fernagut PO, 2007, SYNAPSE, V61, P991, DOI 10.1002/syn.20456; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; Gao HM, 2003, FASEB J, V17, P1957, DOI 10.1096/fj.03-0203fje; Gao HM, 2003, J NEUROSCI, V23, P1228; Gayle DA, 2002, DEV BRAIN RES, V133, P27, DOI 10.1016/S0165-3806(01)00315-7; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Gerhard A, 2006, NEUROBIOL DIS, V21, P404, DOI 10.1016/j.nbd.2005.08.002; GERMAN DC, 1992, ANN NY ACAD SCI, V648, P42, DOI 10.1111/j.1749-6632.1992.tb24523.x; Gerstenfeld LC, 2003, J BONE MINER RES, V18, P1584, DOI 10.1359/jbmr.2003.18.9.1584; Giannoudis PV, 1999, J BONE JOINT SURG BR, V81B, P356, DOI 10.1302/0301-620X.81B2.8988; Giza CC, 2002, J NEUROTRAUM, V19, P387, DOI 10.1089/08977150252932352; Giza CC, 2001, J ATHL TRAINING, V36, P228; GIZA RC, 2000, NEUROLOGIC ATHLETIC, P80; Goldman SM, 2006, ANN NEUROL, V60, P65, DOI 10.1002/ana.20882; Goralski KB, 2004, TOXICOL APPL PHARM, V196, P381, DOI 10.1016/j.taap.2003.12.022; GRAHAM DG, 1978, MOL PHARMACOL, V14, P633; Graham DI, 2000, ACTA NEUROPATHOL, V99, P117, DOI 10.1007/PL00007414; Greenamyre JT, 1999, BIOCHEM SOC SYMP, V66, P85, DOI 10.1042/bss0660085; GRIESBACH GS, 2002, J NEUROTRAUM, V19, P1276; Hartings JA, 2009, J NEUROTRAUM, V26, P1857, DOI [10.1089/neu.2009.0961, 10.1089/neu.2009-0961]; HERTZMAN C, 1990, AM J IND MED, V17, P349, DOI 10.1002/ajim.4700170307; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Holmin S, 2004, NEUROSCI LETT, V369, P108, DOI 10.1016/j.neulet.2004.07.044; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; Hutchison JS, 2001, J NEUROTRAUM, V18, P1333, DOI 10.1089/08977150152725632; Imamura K, 2003, ACTA NEUROPATHOL, V106, P518, DOI 10.1007/s00401-003-0766-2; Ip EY, 2003, J CEREBR BLOOD F MET, V23, P900, DOI 10.1097/01.WCB.0000076702.71231.F2; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; JENKINS LW, 1986, MECHANISMS SECONDARY, P273; Kalfas I H, 2001, Neurosurg Focus, V10, pE1; Kim JS, 2003, BIOCHEM BIOPH RES CO, V304, P463, DOI 10.1016/S0006-291X(03)00618-1; Kim WG, 2000, J NEUROSCI, V20, P6309, DOI 10.1523/JNEUROSCI.20-16-06309.2000; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Kosinski CM, 1998, NEUROSCIENCE, V86, P783, DOI 10.1016/S0306-4522(97)00654-4; Kuter K, 2007, BRAIN RES, V1155, P196, DOI 10.1016/j.brainres.2007.04.018; Langlois JA, 2006, TRAUMATIC BRAIN INJU; LANGSTON JW, 1990, NEUROLOGY, V40, P70; Law MM, 1996, SHOCK, V6, P213, DOI 10.1097/00024382-199609010-00010; Li FQ, 2004, J NEUROIMMUNOL, V148, P24, DOI 10.1016/j.jneuroim.2003.10.054; Li XY, 2009, J CLIN NEUROSCI, V16, P614, DOI 10.1016/j.jocn.2008.08.005; Liang CL, 1996, NEURODEGENERATION, V5, P313, DOI 10.1006/neur.1996.0042; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; Liou HH, 1997, NEUROLOGY, V48, P1583, DOI 10.1212/WNL.48.6.1583; Liu B, 2000, J PHARMACOL EXP THER, V295, P125; Liu YX, 2003, J PHARMACOL EXP THER, V305, P212, DOI 10.1124/jpet.102.043166; Lu XH, 2009, J NEUROSCI, V29, P1962, DOI 10.1523/JNEUROSCI.5351-08.2009; MA SY, 1995, NEUROPATH APPL NEURO, V21, P341, DOI 10.1111/j.1365-2990.1995.tb01068.x; Maeda T, 2005, J NEUROTRAUM, V22, P763, DOI 10.1089/neu.2005.22.763; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; Mazzeo AT, 2009, EXP NEUROL, V218, P363, DOI 10.1016/j.expneurol.2009.05.026; McCormack AL, 2002, NEUROBIOL DIS, V10, P119, DOI 10.1006/nbdi.2002.0507; MCGEER PL, 1988, NEUROLOGY, V38, P1285, DOI 10.1212/WNL.38.8.1285; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Meurers BH, 2009, NEUROBIOL DIS, V33, P182, DOI 10.1016/j.nbd.2008.10.001; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Miyazaki I, 2009, NEUROCHEM RES, V34, P698, DOI 10.1007/s11064-008-9843-1; MIZUNO Y, 1989, BIOCHEM BIOPH RES CO, V163, P1450, DOI 10.1016/0006-291X(89)91141-8; Mouton PR, 2002, J MICROSC-OXFORD, V206, P54, DOI 10.1046/j.1365-2818.2002.01006.x; NICKLAS WJ, 1985, LIFE SCI, V36, P2503, DOI 10.1016/0024-3205(85)90146-8; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; Oorschot DE, 1996, J COMP NEUROL, V366, P580, DOI 10.1002/(SICI)1096-9861(19960318)366:4<580::AID-CNE3>3.0.CO;2-0; Ossowska K, 2005, EUR J NEUROSCI, V22, P1294, DOI 10.1111/j.1460-9568.2005.04301.x; PAKKENBERG B, 1991, J NEUROL NEUROSUR PS, V54, P30, DOI 10.1136/jnnp.54.1.30; PARKER WD, 1989, ANN NEUROL, V26, P719, DOI 10.1002/ana.410260606; Petrovic V M, 1986, Free Radic Res Commun, V1, P305, DOI 10.3109/10715768609080969; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; Prensa L, 2001, J NEUROSCI, V21, P7247, DOI 10.1523/JNEUROSCI.21-18-07247.2001; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/0165-3806(96)00098-3; Purisai MG, 2007, NEUROBIOL DIS, V25, P392, DOI 10.1016/j.nbd.2006.10.008; Qin LY, 2007, GLIA, V55, P453, DOI 10.1002/glia.20467; Qin LY, 2004, J BIOL CHEM, V279, P1415, DOI 10.1074/jbc.M307657200; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Roberts RC, 2002, SYNAPSE, V45, P78, DOI 10.1002/syn.10081; Rodriguez-Paez AC, 2005, ACTA NEUROPATHOL, V109, P603, DOI 10.1007/s00401-005-1010-z; Rudow G, 2008, ACTA NEUROPATHOL, V115, P461, DOI 10.1007/s00401-008-0352-8; Rugbjerg K, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a2494; Saint-Pierre M, 2006, J NEUROCHEM, V98, P760, DOI 10.1111/j.1471-4159.2006.03923.x; SCHAPIRA AHV, 1989, LANCET, V1, P1269, DOI 10.1016/S0140-6736(89)92366-0; SEMCHUK KM, 1992, NEUROLOGY, V42, P1328, DOI 10.1212/WNL.42.7.1328; Sherer TB, 2003, EXP NEUROL, V179, P9, DOI 10.1006/exnr.2002.8072; Sherer TB, 2002, J NEUROSCI, V22, P7006; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Soares HD, 1995, J NEUROSCI, V15, P8223; Stokely ME, 2008, J NEUROTRAUM, V25, P52, DOI 10.1089/neu.2007.0397; Stokes AH, 1999, J NEUROSCI RES, V55, P659, DOI 10.1002/(SICI)1097-4547(19990315)55:6<659::AID-JNR1>3.0.CO;2-C; Sulzer D, 2007, TRENDS NEUROSCI, V30, P244, DOI 10.1016/j.tins.2007.03.009; Suzuki T, 2004, J NEUROTRAUM, V21, P842, DOI 10.1089/0897715041526186; Taya K, 2010, J NEUROTRAUM, V27, P229, DOI 10.1089/neu.2009.0933; Taylor CA, 1999, AM J MED GENET, V88, P742, DOI 10.1002/(SICI)1096-8628(19991215)88:6<742::AID-AJMG29>3.3.CO;2-R; Thiruchelvam M, 2003, EUR J NEUROSCI, V18, P589, DOI 10.1046/j.1460-9568.2003.02781.x; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Thompson HJ, 2005, J CEREBR BLOOD F MET, V25, P163, DOI 10.1038/sj.jcbfm.9600008; Tsuji K, 2006, NAT GENET, V38, P1424, DOI 10.1038/ng1916; Uryu K, 2003, EXP NEUROL, V184, P214, DOI 10.1016/S0014-4886(03)00245-0; Van Putten HP, 2005, J NEUROTRAUM, V22, P857; Wagner AK, 2005, J NEUROCHEM, V95, P457, DOI 10.1111/j.1471-4159.2005.03382.x; Wahner AD, 2007, NEUROLOGY, V69, P1836, DOI 10.1212/01.wnl.0000279519.99344.ad; Wahner AD, 2007, ARCH NEUROL-CHICAGO, V64, P836, DOI 10.1001/archneur.64.6.836; Wang TG, 2004, J PHARMACOL EXP THER, V308, P975, DOI 10.1124/jpet.103.059683; Werneck ALD, 1999, ARQ NEURO-PSIQUIAT, V57, P347, DOI 10.1590/S0004-282X1999000300001; West MJ, 2002, PROG BRAIN RES, V135, P43; Wu XF, 2005, ANTIOXID REDOX SIGN, V7, P654, DOI 10.1089/ars.2005.7.654; Yamamoto T, 1988, J NEUROTRAUM, V5, P69, DOI 10.1089/neu.1988.5.69; Zanier ER, 2003, J NEUROTRAUM, V20, P409, DOI 10.1089/089771503765355496	138	75	76	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2011	28	9					1783	1801		10.1089/neu.2010.1723			19	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	821AK	WOS:000294947000011	21644813	Green Published			2021-06-18	
J	Novakovic-Agopian, T; Chen, AJW; Rome, S; Abrams, G; Castelli, H; Rossi, A; McKim, R; Hills, N; D'Esposito, M				Novakovic-Agopian, Tatjana; Chen, Anthony J. -W.; Rome, Scott; Abrams, Gary; Castelli, Holli; Rossi, Annemarie; McKim, Ryan; Hills, Nancy; D'Esposito, Mark			Rehabilitation of Executive Functioning With Training in Attention Regulation Applied to Individually Defined Goals: A Pilot Study Bridging Theory, Assessment, and Treatment	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						attention regulation training; brain injury; cognitive rehabilitation; executive control; functional performance; metacognitive training	TRAUMATIC BRAIN-INJURY; COGNITIVE REHABILITATION; FRONTAL-LOBE; INTELLIGENCE; MANAGEMENT; BEHAVIOR; DEFICITS; STROKE	Objective: To assess feasibility and effects of training in goal-oriented attentional self-regulation for patients with brain injury and chronic executive dysfunction. Participants: Sixteen individuals with chronic brain injury and mild to moderate executive dysfunction. Design: Participants were divided into 2 groups: one group completed goal-oriented attentional self-regulation training during the first 5 weeks, followed by a brief (2-hour) educational instruction session as a control midway through the second 5 weeks; the other group participated in reverse order. Measures: Neuropsychological and functional performance assessed at baseline and at weeks 5 and 10. Results: Participants found training in goal-oriented attentional self-regulation engaging, incorporated some trained strategies into daily life, and reported subjective improvements in personal functioning. At week 5, participants who completed goals training significantly improved on tests of attention and executive function and had fewer functional task failures, while performance did not change after educational instruction. At week 10, participants who crossed over from educational instruction to goals training also significantly improved on attention and executive function tests. Participants who crossed from goals training to educational instruction maintained their week 5 gains. Conclusions: Training in goal-oriented attentional self-regulation is theoretically driven and feasible in a research setting. Pilot results suggest improvements in cognitive and functional domains targeted by the intervention.	[Novakovic-Agopian, Tatjana; Chen, Anthony J. -W.; Abrams, Gary; Rossi, Annemarie; McKim, Ryan] Vet Adm Med Ctr, San Francisco, CA 94121 USA; [Novakovic-Agopian, Tatjana; Chen, Anthony J. -W.; D'Esposito, Mark] Vet Adm No Calif Hlth Care Syst, Martinez, CA USA; [Novakovic-Agopian, Tatjana; Rome, Scott; Castelli, Holli; Rossi, Annemarie] Calif Pacific Reg Rehabil Ctr, San Francisco, CA USA; [Novakovic-Agopian, Tatjana; Chen, Anthony J. -W.; Abrams, Gary; Hills, Nancy] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Chen, Anthony J. -W.; D'Esposito, Mark] Univ Calif Berkeley, Berkeley, CA 94720 USA	Novakovic-Agopian, T (corresponding author), SFVA Med Ctr, 4150 Clement St,Mail Code 127, San Francisco, CA 94121 USA.	tna@cns-site.com			Office of Research and Development Rehabilitation R&D Service Department of Veterans AffairsUS Department of Veterans Affairs; California Pacific Medical Center Foundation	This material is based upon the work supported by the Office of Research and Development Rehabilitation R&D Service Department of Veterans Affairs, and the California Pacific Medical Center Foundation.	BENEDICT R, 1997, BRIEF VISUOSPATIALME; Brandt J., 2001, HOPKINS VERBAL LEARN; Burgess PW, 2006, J INT NEUROPSYCH SOC, V12, P194, DOI 10.1017/S1355617706060310; Chen AJW, 2006, J HEAD TRAUMA REHAB, V21, P107, DOI 10.1097/00001199-200603000-00004; Cicerone KD, 2002, BRAIN INJURY, V16, P185, DOI 10.1080/02699050110103959; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; D'Esposito M, 2006, PROG BRAIN RES, V157, P123, DOI 10.1016/S0079-6123(06)57008-6; Delis D.C., 2001, DELIS KAPLAN EXECUTI; DESPOSITO M, 2006, NEURAL REHABILITATIO, P475; Dewar BK, 2009, NEUROPSYCHOL REHABIL, V19, P383, DOI 10.1080/09602010802278152; DUNCAN J, 1995, NEUROPSYCHOLOGIA, V33, P261, DOI 10.1016/0028-3932(94)00124-8; Duncan J, 1996, COGNITIVE PSYCHOL, V30, P257, DOI 10.1006/cogp.1996.0008; DZURILLA TJ, 1971, J ABNORM PSYCHOL, V78, P107, DOI 10.1037/h0031360; Evans J, 2005, EFFECTIVENESS REHABI, P247; Evans JJ, 2001, BRAIN DAM B, P209; Fischer S, 2004, BRAIN INJURY, V18, P547, DOI 10.1080/02699050310001645793; Hart T, 2009, NEUROPSYCHOL REHABIL, V19, P824, DOI 10.1080/09602010902995945; Heaton R K., 2004, COMPREHENSIVE NORMS; Hecaen H., 1978, HUMAN NEUROPSYCHOLOG; Hyndman D, 2003, DISABIL REHABIL, V25, P817, DOI 10.1080/0963828031000122221; Kabat-Zinn J, 1990, FULL CATASTROPHE LIV; Kennedy MRT, 2008, NEUROPSYCHOL REHABIL, V18, P257, DOI 10.1080/09602010701748644; Levine B, 2000, J INT NEUROPSYCH SOC, V6, P299, DOI 10.1017/S1355617700633052; Levine B, 2008, COGNITIVE NEUROREHAB, P464; Levine B, 2007, J INT NEUROPSYCH SOC, V13, P143, DOI 10.1017/S1355617707070178; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Mai N, 1991, NEUROPSYCHOL REHABIL, V1, P45, DOI DOI 10.1080/09602019108401379; Manly T, 2002, NEUROPSYCHOLOGIA, V40, P271, DOI 10.1016/S0028-3932(01)00094-X; Miller BT, 2005, NEURON, V48, P535, DOI 10.1016/j.neuron.2005.11.002; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Miotto EC, 2009, NEUROPSYCHOL REHABIL, V19, P517, DOI 10.1080/09602010802332108; Nezu A. M., 2007, SOLVING LIFES PROBLE; Novakovic-Agopian T, 1999, ARCH CLIN NEUROPSYCH, V14, P640, DOI 10.1016/S0887-6177(99)80044-4; Ozdemir F, 2001, AM J PHYS MED REHAB, V80, P410, DOI 10.1097/00002060-200106000-00003; Park NW, 2001, NEUROPSYCHOLOGY, V15, P199, DOI 10.1037/0894-4105.15.2.199; Prigatano GP, 1999, ARCH PHYS MED REHAB, V80, P77, DOI 10.1016/S0003-9993(99)90311-8; Rath JF, 2003, NEUROPSYCHOL REHABIL, V13, P461, DOI 10.1080/09602010343000039; Robertson IH, 1996, GOAL MANAGEMENT TRAI; Schweizer TA, 2008, NEUROREHAB NEURAL RE, V22, P72, DOI 10.1177/1545968307305303; Sohlberg McKay Moore, 2005, Seminars in Speech and Language, V26, P268, DOI 10.1055/s-2005-922105; Sohlberg MM, 2000, J CLIN EXP NEUROPSYC, V22, P656, DOI 10.1076/1380-3395(200010)22:5;1-9;FT656; Sohlberg MM, 2003, J MED SPEECH-LANG PA, V11, pXIX; STUSS D. T., 1988, CLIN NEUROPSYCHOL, V2, P246, DOI DOI 10.1080/13854048808520107; TATEMICHI TK, 1994, J NEUROL NEUROSUR PS, V57, P202, DOI 10.1136/jnnp.57.2.202; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wilson BA, 2008, ANNU REV CLIN PSYCHO, V4, P141, DOI 10.1146/annurev.clinpsy.4.022007.141212	46	75	75	0	37	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2011	26	5					325	338		10.1097/HTR.0b013e3181f1ead2			14	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	814VO	WOS:000294485500001	21169860				2021-06-18	
J	Khan, M; Sakakima, H; Dhammu, TS; Shunmugavel, A; Im, YB; Gilg, AG; Singh, AK; Singh, I				Khan, Mushfiquddin; Sakakima, Harutoshi; Dhammu, Tajinder S.; Shunmugavel, Anandakumar; Im, Yeong-Bin; Gilg, Anne G.; Singh, Avtar K.; Singh, Inderjit			S-Nitrosoglutathione reduces oxidative injury and promotes mechanisms of neurorepair following traumatic brain injury in rats	JOURNAL OF NEUROINFLAMMATION			English	Article							FOCAL CEREBRAL-ISCHEMIA; NITRIC-OXIDE SYNTHASE; NF-KAPPA-B; RECEPTOR AGONIST 8-OH-DPAT; CORTICAL IMPACT INJURY; ENDOTHELIAL DYSFUNCTION; PROTECTS BRAIN; TNF-ALPHA; LIQUID-CHROMATOGRAPHY; SYNAPTIC PLASTICITY	Background: Traumatic brain injury (TBI) induces primary and secondary damage in both the endothelium and the brain parenchyma, collectively termed the neurovascular unit. While neurons die quickly by necrosis, a vicious cycle of secondary injury in endothelial cells exacerbates the initial injury in the neurovascular unit following TBI. In activated endothelial cells, excessive superoxide reacts with nitric oxide (NO) to form peroxynitrite. Peroxynitrite has been implicated in blood brain barrier (BBB) leakage, altered metabolic function, and neurobehavioral impairment. S-nitrosoglutathione (GSNO), a nitrosylation-based signaling molecule, was reported not only to reduce brain levels of peroxynitrite and oxidative metabolites but also to improve neurological function in TBI, stroke, and spinal cord injury. Therefore, we investigated whether GSNO promotes the neurorepair process by reducing the levels of peroxynitrite and the degree of oxidative injury. Methods: TBI was induced by controlled cortical impact (CCI) in adult male rats. GSNO or 3-Morpholinosydnonimine (SIN-1) (50 mu g/kg body weight) was administered orally two hours following CCI. The same dose was repeated daily until endpoints. GSNO-treated (GSNO group) or SIN-1-treated (SIN-1 group) injured animals were compared with vehicle-treated injured animals (TBI group) and vehicle-treated sham-operated animals (Sham group) in terms of peroxynitrite, NO, glutathione (GSH), lipid peroxidation, blood brain barrier (BBB) leakage, edema, inflammation, tissue structure, axon/myelin integrity, and neurotrophic factors. Results: SIN-1 treatment of TBI increased whereas GSNO treatment decreased peroxynitrite, lipid peroxides/aldehydes, BBB leakage, inflammation and edema in a short-term treatment (4-48 hours). GSNO also reduced brain infarctions and enhanced the levels of NO and GSH. In a long-term treatment (14 days), GSNO protected axonal integrity, maintained myelin levels, promoted synaptic plasticity, and enhanced the expression of neurotrophic factors. Conclusion: Our findings indicate the participation of peroxynitrite in the pathobiology of TBI. GSNO treatment of TBI not only reduces peroxynitrite but also protects the integrity of the neurovascular unit, indicating that GSNO blunts the deleterious effects of peroxynitrite. A long-term treatment of TBI with the same low dose of GSNO promotes synaptic plasticity and enhances the expression of neurotrophic factors. These results support that GSNO reduces the levels of oxidative metabolites, protects the neurovascular unit, and promotes neurorepair mechanisms in TBI.	[Khan, Mushfiquddin; Sakakima, Harutoshi; Dhammu, Tajinder S.; Shunmugavel, Anandakumar; Im, Yeong-Bin; Gilg, Anne G.; Singh, Inderjit] Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA; [Singh, Avtar K.] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA; [Singh, Avtar K.] Ralph H Johnson VA Med Ctr, Charleston, SC 29401 USA	Singh, I (corresponding author), Med Univ S Carolina, Dept Pediat, 171 Ashley Ave, Charleston, SC 29425 USA.	singhi@musc.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS-72511, NS-22576, NS-37766]; Betty L. Beatty Foundation; Guy E. Beatty Foundation; Veteran Administration; NIH National Center for Research ResourcesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [C06 RR018823, C06 RR015455]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [C06RR015455, C06RR018823] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS037766, R01NS072511, R01NS022576, R37NS022576] Funding Source: NIH RePORTER	These studies were supported by grants from National Institutes of Health (NS-72511, NS-22576 and NS-37766), Betty L. Beatty and Guy E. Beatty Foundations, and Veteran Administration merit awards. This work was also supported by the NIH, Grants C06 RR018823 and No C06 RR015455 from the Extramural Research Facilities Program of the National Center for Research Resources. We are grateful to Dr Tom Smith and Dr Melissa A Crofton from the MUSC Writing Center for their valuable editing and correction of the manuscript. We would like to thank Ms Joyce Bryan for procurement of animals and chemicals, and Ms Chara Williams for secretarial assistance.	Aledia AS, 2002, ASAIO J, V48, P526, DOI 10.1097/00002480-200209000-00015; Bayir H, 2007, J NEUROCHEM, V101, P168, DOI 10.1111/j.1471-4159.2006.04353.x; Beckman JS, 1996, CHEM RES TOXICOL, V9, P836, DOI 10.1021/tx9501445; Bilgen M, 2005, NEUROREHAB NEURAL RE, V19, P219, DOI 10.1177/1545968305278635; Bryan NS, 2004, P NATL ACAD SCI USA, V101, P4308, DOI 10.1073/pnas.0306706101; Chen JL, 2010, J CEREBR BLOOD F MET, V30, P102, DOI 10.1038/jcbfm.2009.187; Chen XR, 2007, J NEUROTRAUM, V24, P1119, DOI 10.1089/neu.2006.0216; Chen Z, 2011, STROKE, V42, P465, DOI 10.1161/STROKEAHA.110.602755; Cheng JP, 2008, BEHAV BRAIN RES, V194, P79, DOI 10.1016/j.bbr.2008.06.025; Chiueh CC, 1999, FREE RADICAL RES, V31, P641, DOI 10.1080/10715769900301211; Chiueh Chuang C., 2002, Pediatric Research, V51, P414, DOI 10.1203/00006450-200204000-00002; Choi YB, 2000, CELL MOL LIFE SCI, V57, P1535, DOI 10.1007/PL00000638; Chou PCT, 2011, J MAGN RESON IMAGING, V33, P1301, DOI 10.1002/jmri.22574; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Cui X, 2010, STROKE, V41, P2044, DOI 10.1161/STROKEAHA.110.589333; D'Acquisto F, 2001, N-S ARCH PHARMACOL, V364, P157, DOI 10.1007/s002100100435; Deng-Bryant Y, 2008, J CEREBR BLOOD F MET, V28, P1114, DOI 10.1038/jcbfm.2008.10; Endres M, 2002, ADV EXP MED BIOL, V513, P455; Erwin PA, 2005, J BIOL CHEM, V280, P19888, DOI 10.1074/jbc.M413058200; Fortenberry JD, 2001, INFLAMM RES, V50, P89; Foster MW, 2009, TRENDS MOL MED, V15, P391, DOI 10.1016/j.molmed.2009.06.007; Foster MW, 2003, TRENDS MOL MED, V9, P160, DOI 10.1016/S1471-4914(03)00028-5; Gursoy-Ozdemir Y, 2004, STROKE, V35, P1449, DOI 10.1161/01.STR.0000126044.83777.f4; Hall ED, 1999, ANN NY ACAD SCI, V890, P462, DOI 10.1111/j.1749-6632.1999.tb08025.x; Heiss C, 2006, J AM COLL CARDIOL, V47, P573, DOI 10.1016/j.jacc.2005.06.089; Hoda MN, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-21; Hoffman AN, 2008, LIFE SCI, V83, P602, DOI 10.1016/j.lfs.2008.08.007; Hoffmann J, 2001, J BIOL CHEM, V276, P41383, DOI 10.1074/jbc.M107566200; Jain KK, 2008, DRUG DISCOV TODAY, V13, P1082, DOI 10.1016/j.drudis.2008.09.006; Jatana M, 2006, J NEUROINFLAMM, V3, DOI 10.1186/1742-2094-3-12; Joca SRL, 2007, NEUROSCI LETT, V421, P72, DOI 10.1016/j.neulet.2007.05.026; Ju TC, 2005, FREE RADICAL BIO MED, V38, P938, DOI 10.1016/j.freeradbiomed.2004.12.019; Kaposzta Z, 2002, CIRCULATION, V106, P3057, DOI 10.1161/01.CIR.0000041251.07332.28; Kaposzta Z, 2002, CIRCULATION, V105, P1480, DOI 10.1161/01.CIR.0000012347.47001.97; Kaposzta Z, 2001, CIRCULATION, V103, P2371; Khan M, 2005, J CEREBR BLOOD F MET, V25, P177, DOI 10.1038/sj.jcbfm.9600012; Khan M, 2004, J NEUROSCI RES, V76, P519, DOI 10.1002/jnr.20087; Khan M, 2007, J NEUROCHEM, V102, P365, DOI 10.1111/j.1471-4159.2007.04526.x; Khan M, 2006, NITRIC OXIDE-BIOL CH, V15, P114, DOI 10.1016/j.niox.2006.01.008; Khan M, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-32; Kline AE, 2007, BEHAV BRAIN RES, V177, P186, DOI 10.1016/j.bbr.2006.11.036; Kluge I, 1997, J NEUROCHEM, V69, P2599; Konorev EA, 1996, BRIT J PHARMACOL, V119, P511, DOI 10.1111/j.1476-5381.1996.tb15701.x; KONOREV EA, 1995, J PHARMACOL EXP THER, V274, P200; Kuzkaya N, 2003, J BIOL CHEM, V278, P22546, DOI 10.1074/jbc.M302227200; LIGHTHALL J W, 1989, Journal of Neurotrauma, V6, P83, DOI 10.1089/neu.1989.6.83; Lima B, 2010, CIRC RES, V106, P633, DOI 10.1161/CIRCRESAHA.109.207381; Lu DY, 2004, J NEUROTRAUM, V21, P21, DOI 10.1089/089771504772695913; Marshall HE, 2001, BIOCHEMISTRY-US, V40, P1688, DOI 10.1021/bi002239y; Martinez-Ruiz A, 2004, CARDIOVASC RES, V62, P43, DOI 10.1016/j.cardiores.2004.01.013; MATSUMOTO A, 2011, NITRIC OXIDE; Mohr S, 1997, BIOCHEM BIOPH RES CO, V238, P387, DOI 10.1006/bbrc.1997.7304; Molloy J, 1998, CIRCULATION, V98, P1372, DOI 10.1161/01.CIR.98.14.1372; Nath N, 2010, J NEUROIMMUNE PHARM, V5, P240, DOI 10.1007/s11481-009-9187-x; Neumann P, 2006, AM J PHYSIOL-LUNG C, V290, pL674, DOI 10.1152/ajplung.00391.2005; Pacher P, 2007, PHYSIOL REV, V87, P315, DOI 10.1152/physrev.00029.2006; Paintlia AS, 2004, J NEUROSCI RES, V77, P63, DOI 10.1002/jnr.20130; Pannu R, 2007, J NEUROCHEM, V101, P182, DOI 10.1111/j.1471-4159.2006.04354.x; Parnham M, 2000, EXPERT OPIN INV DRUG, V9, P607, DOI 10.1517/13543784.9.3.607; PENNINGS JL, 1993, ARCH SURG-CHICAGO, V128, P787; PENNINGS JL, 1993, ARCH SURG-CHICAGO, V128, P793; Prasad A, 1999, J AM COLL CARDIOL, V34, P507, DOI 10.1016/S0735-1097(99)00216-8; Prasad R, 2007, GLIA, V55, P65, DOI 10.1002/glia.20436; RADOMSKI MW, 1992, BRIT J PHARMACOL, V107, P745, DOI 10.1111/j.1476-5381.1992.tb14517.x; Rauhala P, 1998, FASEB J, V12, P165; Rauhala P, 1996, SYNAPSE, V23, P58, DOI 10.1002/(SICI)1098-2396(199605)23:1<58::AID-SYN7>3.0.CO;2-G; Ravi K, 2004, P NATL ACAD SCI USA, V101, P2619, DOI 10.1073/pnas.0300464101; Recalcati S, 2010, ANTIOXID REDOX SIGN, V13, P1593, DOI 10.1089/ars.2009.2983; Reed TT, 2009, J NEUROSCI RES, V87, P408, DOI 10.1002/jnr.21872; Savidge TC, 2007, GASTROENTEROLOGY, V132, P1344, DOI 10.1053/j.gastro.2007.01.051; Schmidt HHHW, 1996, P NATL ACAD SCI USA, V93, P14492, DOI 10.1073/pnas.93.25.14492; Schonhoff CM, 2006, P NATL ACAD SCI USA, V103, P2404, DOI 10.1073/pnas.0507243103; Schrammel A, 2003, FREE RADICAL BIO MED, V34, P1078, DOI 10.1016/S0891-5849(03)00038-8; Selemidis S, 2007, CARDIOVASC RES, V75, P349, DOI 10.1016/j.cardiores.2007.03.030; Sharma SS, 2004, J NEUROSURG, V101, P669, DOI 10.3171/jns.2004.101.4.0669; Sheng HX, 2011, STROKE, V42, P471, DOI 10.1161/STROKEAHA.110.600569; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Shunmugavel A, 2010, J INFLAMM-LOND, V7, DOI 10.1186/1476-9255-7-17; Singh IN, 2007, J NEUROSCI RES, V85, P2216, DOI 10.1002/jnr.21360; Singh SP, 1996, P NATL ACAD SCI USA, V93, P14428, DOI 10.1073/pnas.93.25.14428; Sonmez U, 2007, NEUROSCI LETT, V420, P133, DOI 10.1016/j.neulet.2007.04.070; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; Stanimirovic DB, 1997, ACT NEUR S, V70, P12; Sydserff SG, 2002, BRIT J PHARMACOL, V135, P103, DOI 10.1038/sj.bjp.0704449; Szabo C, 2007, NAT REV DRUG DISCOV, V6, P662, DOI 10.1038/nrd2222; Szocs K, 2004, GEN PHYSIOL BIOPHYS, V23, P265; Thiyagarajan M, 2004, BRIT J PHARMACOL, V142, P899, DOI 10.1038/sj.bjp.0705811; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; Tsikas D, 1999, ANAL BIOCHEM, V273, P32, DOI 10.1006/abio.1999.4209; Wagner AK, 2004, BRAIN RES, V998, P113, DOI 10.1016/j.brainres.2003.11.027; Wagner AK, 2007, BEHAV BRAIN RES, V181, P200, DOI 10.1016/j.bbr.2007.04.006; WEISSMAN DE, 1988, J NEURO-ONCOL, V6, P339; Wu AG, 2006, EXP NEUROL, V197, P309, DOI 10.1016/j.expneurol.2005.09.004; Wu AG, 2010, NEUROREHAB NEURAL RE, V24, P290, DOI 10.1177/1545968309348318; Wu HT, 2008, J NEUROTRAUM, V25, P130, DOI 10.1089/neu.2007.0369; Yemisci M, 2009, NAT MED, V15, P1031, DOI 10.1038/nm.2022; Zhang Y, 2001, STROKE, V32, P1378, DOI 10.1161/01.STR.32.6.1378	97	75	81	0	5	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1742-2094		J NEUROINFLAMM	J. Neuroinflamm.	JUL 6	2011	8								78	10.1186/1742-2094-8-78			17	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	810UH	WOS:000294152500001	21733162	DOAJ Gold, Green Published			2021-06-18	
J	Belanger, HG; Proctor-Weber, Z; Kretzmer, T; Kim, M; French, LM; Vanderploeg, RD				Belanger, Heather G.; Proctor-Weber, Zoe; Kretzmer, Tracy; Kim, Michelle; French, Louis M.; Vanderploeg, Rodney D.			Symptom Complaints Following Reports of Blast Versus Non-Blast Mild TBI: Does Mechanism of Injury Matter?	CLINICAL NEUROPSYCHOLOGIST			English	Article						TBI; Mild TBI; Post-traumatic stress disorder; Post-concussion syndrome; Blast	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; PERSISTENT POSTCONCUSSIVE SYMPTOMS; NEUROPSYCHOLOGICAL PERFORMANCE; COGNITIVE DEFICITS; WAR VETERANS; HEAD-INJURY; IRAQ; AFGHANISTAN; CONCUSSION	Patients with a reported history of mild traumatic brain injury (mild TBI) due to blast (n = 298) or non-blast (n = 92) mechanisms were asked to complete the Neurobehavioral Symptom Inventory (NSI) and the Post-traumatic Stress Disorder Checklist (PCL). Mechanism of injury did not account for a significant amount of variance in post-concussion symptom reporting overall, nor did severity of mild TBI (i.e., brief loss of consciousness versus only an alteration of consciousness). Symptom reporting was greater in those injured more than 1 month ago compared to those injured less than 1 month ago and in those reporting higher levels versus lower levels of PTSD symptoms. When examining specific symptoms, the only symptom that significantly varied between groups was hearing difficulty (with the blast-injured group reporting more severe difficulty with hearing). Findings suggest that greater symptom reporting is most strongly related to emotional distress.	[Belanger, Heather G.; Kretzmer, Tracy; Kim, Michelle; Vanderploeg, Rodney D.] James A Haley VA, Dept Mental Hlth & Behav Sci, Tampa, FL USA; [Belanger, Heather G.; Vanderploeg, Rodney D.] Univ S Florida, Dept Psychol, Tampa, FL 33620 USA; [Vanderploeg, Rodney D.] Univ S Florida, Dept Psychiat, Tampa, FL USA; [Proctor-Weber, Zoe] Bay Pines VA Healthcare Syst, Dept Mental Hlth & Behav Sci, Bay Pines, FL USA; [Belanger, Heather G.; French, Louis M.; Vanderploeg, Rodney D.] Def & Vet Brain Injury Ctr, Washington, DC USA; [French, Louis M.] Walter Reed Army Med Ctr, Dept Orthoped & Rehabil, Washington, DC 20307 USA; [French, Louis M.] Uniformed Serv Univ Hlth Sci, Dept Neurol, Bethesda, MD 20814 USA	Belanger, HG (corresponding author), James A Haley Vet Hosp, Psychol Serv 116B, Tampa, FL 33612 USA.	Heather.Belanger@va.gov	french, louis/AAB-2083-2020	french, louis/0000-0002-9451-0604	Department of Veterans AffairsUS Department of Veterans Affairs; Veterans Health Administration (VHA)US Department of Veterans Affairs; Defense and Veterans Brain Injury Center (DVBIC)US Department of Veterans Affairs; James A. Haley Veterans HospitalUS Department of Veterans Affairs	The research reported here was supported by the Department of Veterans Affairs, Veterans Health Administration (VHA), and the Defense and Veterans Brain Injury Center (DVBIC). Further support was provided by the James A. Haley Veterans Hospital. The views expressed herein are those of the authors and do not necessarily reflect the views or the official policy of the Department of Army, Department of Defense, Department of Veterans Affairs, or U.S. Government.	Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Benge JF, 2009, REHABIL PSYCHOL, V54, P270, DOI 10.1037/a0016736; Binder LM, 1999, ARCH CLIN NEUROPSYCH, V14, P531, DOI 10.1016/S0887-6177(98)00047-X; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Brenner LA, 2010, J HEAD TRAUMA REHAB, V25, P307, DOI 10.1097/HTR.0b013e3181cada03; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cernak I, 2001, BRAIN INJURY, V15, P593, DOI 10.1080/02699050010009559; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Chafi MS, 2010, ANN BIOMED ENG, V38, P490, DOI 10.1007/s10439-009-9813-z; Chamelian L, 2006, J NEUROPSYCH CLIN N, V18, P33, DOI 10.1176/appi.neuropsych.18.1.33; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Elsayed NM, 1997, TOXICOLOGY, V121, P1, DOI 10.1016/S0300-483X(97)03651-2; French L., 2008, J SPEC OPER MED, V8, P68; Herman D., 1993, ANN CONV INT SOC TRA; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; KAUR C, 1995, NEUROPATH APPL NEURO, V21, P369, DOI 10.1111/j.1365-2990.1995.tb01073.x; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Keane, 1991, PCL C DSM 4; Kennedy JE, 2010, NEUROREHABILITATION, V26, P223, DOI 10.3233/NRE-2010-0558; Lange RT, 2009, BRAIN INJURY, V23, P83, DOI 10.1080/02699050802635281; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; Lindem K, 2003, J PSYCHOPATHOL BEHAV, V25, P121, DOI 10.1023/A:1023347016334; Lippa SM, 2010, J INT NEUROPSYCH SOC, V16, P856, DOI 10.1017/S1355617710000743; Luethcke CA, 2011, J INT NEUROPSYCH SOC, V17, P36, DOI 10.1017/S1355617710001207; Luis CA, 2003, J INT NEUROPSYCH SOC, V9, P1001, DOI 10.1017/S1355617703970044; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; Mora AG, 2009, J TRAUMA, V66, pS178, DOI 10.1097/TA.0b013e31819ce2d6; Nageris Ben I., 2008, Journal of Basic and Clinical Physiology and Pharmacology, V19, P185; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Schell T, 2008, SURVEY INDIVIDUALS P; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Spencer RJ, 2010, J REHABIL RES DEV, V47, P521, DOI 10.1682/JRRD.2009.11.0181; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Van Dyke SA, 2010, ARCH CLIN NEUROPSYCH, V25, P634, DOI 10.1093/arclin/acq063; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Wilk JE, 2010, J HEAD TRAUMA REHAB, V25, P9, DOI 10.1097/HTR.0b013e3181bd090f; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Xydakis MS, 2007, NEW ENGL J MED, V357, P830, DOI 10.1056/NEJMc076071	45	75	75	0	11	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2011	25	5					702	715		10.1080/13854046.2011.566892			14	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	882JE	WOS:000299559000002	21512958				2021-06-18	
J	Greuters, S; van den Berg, A; Franschman, G; Viersen, VA; Beishuizen, A; Peerdeman, SM; Boer, C				Greuters, Sjoerd; van den Berg, Annelies; Franschman, Gaby; Viersen, Victor A.; Beishuizen, Albertus; Peerdeman, Saskia M.; Boer, Christa		ALARM-BLEEDING Investigators	Acute and delayed mild coagulopathy are related to outcome in patients with isolated traumatic brain injury	CRITICAL CARE			English	Article							HEAD-INJURY; INTRAVASCULAR COAGULATION; DISORDERS; HYPOPERFUSION; HYPOTHERMIA; HEMOSTASIS; THROMBOSIS; SYSTEM	Introduction: The relationship between isolated traumatic brain injury (TBI) associated coagulopathy and patient prognosis frequently lacks information regarding the time course of coagulation disorders throughout the post-traumatic period. This study was conducted to assess the prevalence and time course of post-traumatic coagulopathy in patients with isolated TBI and the relationship of these hemostatic disorders with outcome. Methods: The local Human Subjects Committee approved the study. We retrospectively studied the medical records of computed tomography (CT)-confirmed isolated TBI patients with an extracranial abbreviated injury scale (AIS) <3 who were primarily referred to a Level 1 trauma centre in Amsterdam (n = 107). Hemostatic parameters including activated partial thromboplastin time (aPTT), prothrombin time (PT), platelet count, hemoglobin, hematocrit, glucose, pH and lactate levels were recorded throughout a 72-hour period as part of a routine standardized follow-up of TBI. Coagulopathy was defined as a aPPT >40 seconds and/or a PTT in International Normalized Ratio (INR) >1.2 and/or a platelet count <120*10(9)/l. Results: Patients were mostly male, aged 48 +/- 20 years with a median injury severity score of 25 (range 20 to 25). Early coagulopathy as diagnosed in the emergency department (ED) occurred in 24% of all patients. The occurrence of TBI-related coagulopathy increased to 54% in the first 24 hours post-trauma. In addition to an increased age and disturbed pupillary reflex, both coagulopathy upon ED arrival and during the first 24 hours post-trauma provided an independent prognostic factor for unfavorable outcome (odds ratio (OR) 3.75 (95% CI 1.07 to 12.51; P = 0.04) and OR 11.61 (2.79 to 48.34); P = 0.003). Conclusions: Our study confirms a high prevalence of early and delayed coagulopathy in patients with isolated TBI, which is strongly associated with an unfavorable outcome. These data support close monitoring of hemostasis after TBI and indicate that correction of coagulation disturbances might need to be considered.	[Greuters, Sjoerd; van den Berg, Annelies; Franschman, Gaby; Viersen, Victor A.; Boer, Christa] Vrije Univ Amsterdam Med Ctr, Inst Cardiovasc Res, Dept Anesthesiol, NL-1081 HV Amsterdam, Netherlands; [Beishuizen, Albertus] Vrije Univ Amsterdam Med Ctr, Inst Cardiovasc Res, Dept Intens Care Med, NL-1081 HV Amsterdam, Netherlands; [Peerdeman, Saskia M.] Vrije Univ Amsterdam Med Ctr, Dept Neurosurg, NL-1081 HV Amsterdam, Netherlands	Greuters, S (corresponding author), Vrije Univ Amsterdam Med Ctr, Inst Cardiovasc Res, Dept Anesthesiol, De Boelelaan 1117, NL-1081 HV Amsterdam, Netherlands.	s.greuters@vumc.nl		Boer, Christa/0000-0002-7781-6951			Brohi K, 2003, J TRAUMA, V54, P1127, DOI 10.1097/01.TA.0000069184.82147.06; Brohi K, 2008, J TRAUMA, V64, P1211, DOI 10.1097/TA.0b013e318169cd3c; Brown CVR, 2010, J TRAUMA, V68, P348, DOI 10.1097/TA.0b013e3181bbfb6b; Carrick MM, 2005, J TRAUMA, V58, P725, DOI 10.1097/01.TA.0000159249.68363.78; Cohan MJ, 2007, J TRAUMA, V63, P1254, DOI 10.1097/TA.0b013e318156ee4c; Cortiana M, 1986, J Neurosurg Sci, V30, P133; Cosgriff N, 1997, J TRAUMA, V42, P857, DOI 10.1097/00005373-199705000-00016; DRAKE TA, 1989, AM J PATHOL, V134, P1087; Engstrom M, 2006, J NEUROSURG ANESTH, V18, P200, DOI 10.1097/01.ana.0000211002.63774.8a; Etemadrezaie H, 2007, CLIN NEUROL NEUROSUR, V109, P166, DOI 10.1016/j.clineuro.2006.09.001; FRANSCHMAN G, 2010, RESUSCITATION; GANDO S, 1992, CRIT CARE MED, V20, P594, DOI 10.1097/00003246-199205000-00009; GOODNIGHT SH, 1974, NEW ENGL J MED, V290, P1043, DOI 10.1056/NEJM197405092901903; Halpern CH, 2008, J NEUROTRAUM, V25, P997, DOI 10.1089/neu.2008.0548; Harhangi BS, 2008, ACTA NEUROCHIR, V150, P165, DOI 10.1007/s00701-007-1475-8; Hulka F, 1996, ARCH SURG-CHICAGO, V131, P923; Jeremitsky E, 2003, J TRAUMA, V54, P312, DOI 10.1097/01.TA.0000037876.37236.D6; Maegele M, 2007, INJURY, V38, P298, DOI 10.1016/j.injury.2006.10.003; McQuay N, 2009, J NEUROSURG, V111, P666, DOI 10.3171/2009.4.JNS081611; Morel N, 2008, J TRAUMA, V64, P698, DOI 10.1097/TA.0b013e31816493ad; OLSON JD, 1989, NEUROSURGERY, V24, P825, DOI 10.1227/00006123-198906000-00007; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Saggar V, 2009, J NEUROTRAUM, V26, P1665, DOI 10.1089/neu.2008.0799; SLOAN EP, 1989, J TRAUMA, V29, P1647, DOI 10.1097/00005373-198912000-00011; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; Stein SC, 2002, J NEUROSURG, V97, P1373, DOI 10.3171/jns.2002.97.6.1373; Talving P, 2009, J TRAUMA, V66, P55, DOI 10.1097/TA.0b013e318190c3c0; Taylor FB, 2001, THROMB HAEMOSTASIS, V86, P1327; VANDERSANDE JJ, 1978, J NEUROSURG, V49, P357, DOI 10.3171/jns.1978.49.3.0357; Wafaisade A, 2010, NEUROCRIT CARE, V12, P211, DOI 10.1007/s12028-009-9281-1; Zehtabchi S, 2008, RESUSCITATION, V76, P52, DOI 10.1016/j.resuscitation.2007.06.024	31	75	83	0	6	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care		2011	15	1							R2	10.1186/cc9399			7	Critical Care Medicine	General & Internal Medicine	742RJ	WOS:000288961900002	21208418	DOAJ Gold, Green Published			2021-06-18	
J	Xilouri, M; Stefanis, L				Xilouri, Maria; Stefanis, Leonidas			Autophagy in the Central Nervous System: Implications for Neurodegenerative Disorders	CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS			English	Article						Autophagosome; chaperone-mediated autophagy; LAMP-2A receptor; LC3; macroautophagy; neurodegenerative diseases	CHAPERONE-MEDIATED AUTOPHAGY; INCLUSION-BODY FORMATION; SCRAPIE-RESPONSIVE GENE; TRAUMATIC BRAIN-INJURY; CELL-DEATH PATHWAYS; ALPHA-SYNUCLEIN; PARKINSONS-DISEASE; HUNTINGTONS-DISEASE; UP-REGULATION; PROTEIN-DEGRADATION	The autophagy-lysosomal pathway is a major proteolytic pathway that in mammalian systems mainly comprises of macroautophagy and chaperone-mediated autophagy. The former is relatively non-selective and involves bulk degradation of proteins and organelles, whereas the latter is selective for certain cytosolic proteins. These autophagy pathways are important in development, differentiation, cellular remodeling and survival during nutrient starvation. Autophagy is crucial for neuronal homeostasis and acts as a local housekeeping process, since neurons are post-mitotic cells and require effective protein degradation to prevent accumulation of toxic aggregates. A growing body of evidence now suggests that dysfunction of autophagy causes accumulation of abnormal proteins and/or damaged organelles. Such accumulation has been linked to synaptic dysfunction, cellular stress and neuronal death. Abnormal autophagy may be involved in the pathology of both chronic nervous system disorders, such as proteinopathies (Alzheimer's, Parkinson's, Huntington's disease) and acute brain injuries. Although autophagy is generally beneficial, its aberrant activation may also exert a detrimental role in neurological diseases depending on the environment and the insult, leading to autophagic neuronal death. In this review we summarize the current knowledge regarding the role of autophagy-lysosomal pathway in the central nervous system and discuss the implication of autophagy dysregulation in human neurological diseases and animal models.	[Xilouri, Maria; Stefanis, Leonidas] Acad Athens, Biomed Res Fdn, Div Basic Neurosci, Athens 11527, Greece; [Stefanis, Leonidas] Univ Athens, Sch Med, Dept Neurol 2, GR-11527 Athens, Greece	Xilouri, M (corresponding author), Acad Athens, Biomed Res Fdn, Div Basic Neurosci, 4 Soranou Efesiou St, Athens 11527, Greece.	mxilouri@bioacademy.gr	Stefanis, Leonidas/AAD-7192-2019	Xilouri, Maria/0000-0001-7038-0780			Abou-Sleiman PM, 2006, NAT REV NEUROSCI, V7, P207, DOI 10.1038/nrn1868; Adhami F, 2006, AM J PATHOL, V169, P566, DOI 10.2353/ajpath.2006.051066; Agarraberes FA, 2001, J CELL SCI, V114, P2491; Agarraberes FA, 1997, J CELL BIOL, V137, P825, DOI 10.1083/jcb.137.4.825; Aguib Y, 2009, AUTOPHAGY, V5, P361, DOI 10.4161/auto.5.3.7662; Aguzzi A, 2004, CELL, V116, P313, DOI 10.1016/S0092-8674(03)01031-6; Alegre-Abarrategui J, 2009, AUTOPHAGY, V5, P1208, DOI 10.4161/auto.5.8.9894; Alegre-Abarrategui J, 2009, HUM MOL GENET, V18, P4022, DOI 10.1093/hmg/ddp346; Anderson JP, 2006, J BIOL CHEM, V281, P29739, DOI 10.1074/jbc.M600933200; Anglade P, 1997, HISTOL HISTOPATHOL, V12, P25; Axe EL, 2008, J CELL BIOL, V182, P685, DOI 10.1083/jcb.200803137; Bandyopadhyay U, 2008, MOL CELL BIOL, V28, P5747, DOI 10.1128/MCB.02070-07; Bates G, 2003, LANCET, V361, P1642, DOI 10.1016/S0140-6736(03)13304-1; Berger Z, 2006, HUM MOL GENET, V15, P433, DOI 10.1093/hmg/ddi458; Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002; Bjorkoy G, 2006, AUTOPHAGY, V2, P138, DOI 10.4161/auto.2.2.2405; Bjorkoy G, 2009, METHOD ENZYMOL, V452, P181, DOI 10.1016/S0076-6879(08)03612-4; BOELLAARD JW, 1989, ACTA NEUROPATHOL, V78, P410, DOI 10.1007/BF00688178; BOELLAARD JW, 1991, ACTA NEUROPATHOL, V82, P225, DOI 10.1007/BF00294449; Boland B, 2008, J NEUROSCI, V28, P6926, DOI 10.1523/JNEUROSCI.0800-08.2008; Borsello T, 2003, EUR J NEUROSCI, V18, P473, DOI 10.1046/j.1460-9568.2003.02757.x; Canu N, 2005, J NEUROCHEM, V92, P1228, DOI 10.1111/j.1471-4159.2004.02956.x; Cao Y, 2006, J BIOL CHEM, V281, P20483, DOI 10.1074/jbc.M602180200; Carloni S, 2008, NEUROBIOL DIS, V32, P329, DOI 10.1016/j.nbd.2008.07.022; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; Cataldo AM, 2000, AM J PATHOL, V157, P277, DOI 10.1016/S0002-9440(10)64538-5; Cataldo AM, 2004, J NEUROPATH EXP NEUR, V63, P821, DOI 10.1093/jnen/63.8.821; CATALDO AM, 1991, P NATL ACAD SCI USA, V88, P10998, DOI 10.1073/pnas.88.24.10998; CATALDO AM, 1995, NEURON, V14, P671, DOI 10.1016/0896-6273(95)90324-0; Chartier-Harlin MC, 2004, LANCET, V364, P1167, DOI 10.1016/S0140-6736(04)17103-1; Cherra SJ, 2008, FUTUR NEUROL, V3, P309, DOI 10.2217/14796708.3.3.309; CHIANG HL, 1988, J BIOL CHEM, V263, P6797; CHIANG HL, 1989, SCIENCE, V246, P382, DOI 10.1126/science.2799391; Chiba-Falek O, 2006, MOVEMENT DISORD, V21, P1703, DOI 10.1002/mds.21007; Clark RSB, 2008, AUTOPHAGY, V4, P88, DOI 10.4161/auto.5173; Conway KA, 2001, SCIENCE, V294, P1346, DOI 10.1126/science.1063522; Cuervo AM, 2000, J BIOL CHEM, V275, P31505, DOI 10.1074/jbc.M002102200; Cuervo AM, 2000, TRAFFIC, V1, P570, DOI 10.1034/j.1600-0854.2000.010707.x; Cuervo AM, 2004, SCIENCE, V305, P1292, DOI 10.1126/science.1101738; Cuervo AM, 1997, J BIOL CHEM, V272, P5606, DOI 10.1074/jbc.272.9.5606; Cuervo AM, 2003, EMBO J, V22, P47, DOI 10.1093/emboj/cdg002; CUERVO AM, 1995, AM J PHYSIOL-CELL PH, V269, pC1200, DOI 10.1152/ajpcell.1995.269.5.C1200; Cuervo AM, 1996, SCIENCE, V273, P501, DOI 10.1126/science.273.5274.501; Cuervo AM, 2005, AUTOPHAGY, V1, P131, DOI 10.4161/auto.1.3.2017; Dagda RK, 2009, J BIOL CHEM, V284, P13843, DOI 10.1074/jbc.M808515200; Dandoy-Dron F, 2000, MOL BRAIN RES, V76, P173, DOI 10.1016/S0169-328X(00)00028-0; Dandoy-Dron F, 1998, J BIOL CHEM, V273, P7691, DOI 10.1074/jbc.273.13.7691; Darios F, 2003, HUM MOL GENET, V12, P517, DOI 10.1093/hmg/ddg044; Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3; de Duve C., 1963, LYSOSOMES; DEDUVE C, 1966, ANNU REV PHYSIOL, V28, P435, DOI 10.1146/annurev.ph.28.030166.002251; DETER RL, 1967, J CELL BIOL, V35, pC11, DOI 10.1083/jcb.35.2.C11; DETER RL, 1967, J CELL BIOL, V33, P437, DOI 10.1083/jcb.33.2.437; Di Fonzo A, 2007, NEUROLOGY, V68, P1557, DOI 10.1212/01.wnl.0000260963.08711.08; DICE JF, 1990, TRENDS BIOCHEM SCI, V15, P305, DOI 10.1016/0968-0004(90)90019-8; Ding QX, 2003, J NEUROCHEM, V86, P489, DOI 10.1046/j.1471-4159.2003.01885.x; Diskin T, 2005, J NEUROTRAUM, V22, P750, DOI 10.1089/neu.2005.22.750; Dompierre JP, 2007, J NEUROSCI, V27, P3571, DOI 10.1523/JNEUROSCI.0037-07.2007; Dron M, 2005, EUR J NEUROSCI, V22, P133, DOI 10.1111/j.1460-9568.2005.04172.x; Dron M, 1998, J BIOL CHEM, V273, P18015, DOI 10.1074/jbc.273.29.18015; Duncan C, 2010, AUTOPHAGY, V6, P312, DOI 10.4161/auto.6.2.11139; Emmanouilidou E, 2010, NEUROBIOL AGING, V31, P953, DOI 10.1016/j.neurobiolaging.2008.07.008; Erlich S, 2007, NEUROBIOL DIS, V26, P86, DOI 10.1016/j.nbd.2006.12.003; Erlich S, 2006, AUTOPHAGY, V2, P49, DOI 10.4161/auto.2156; Ertmer A, 2007, LEUKEMIA, V21, P936, DOI 10.1038/sj.leu.2404606; Ertmer A, 2004, J BIOL CHEM, V279, P41918, DOI 10.1074/jbc.M405652200; Eskelinen EL, 2008, INT REV CEL MOL BIO, V266, P207, DOI 10.1016/S1937-6448(07)66005-5; Eskelinen EL, 2002, MOL BIOL CELL, V13, P3355, DOI 10.1091/mbc.E02-02-0114; Felbor U, 2002, P NATL ACAD SCI USA, V99, P7883, DOI 10.1073/pnas.112632299; Fimia GM, 2007, NATURE, V447, P1121, DOI 10.1038/nature05925; Florez-McClure ML, 2004, J NEUROSCI, V24, P4498, DOI 10.1523/JNEUROSCI.5744-03.2004; Forno LS, 1996, J NEUROPATH EXP NEUR, V55, P259, DOI 10.1097/00005072-199603000-00001; FORNO LS, 1976, ACTA NEUROPATHOL, V34, P183, DOI 10.1007/BF00688674; Fujiwara H, 2002, NAT CELL BIOL, V4, P160, DOI 10.1038/ncb748; Gasser T, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S1462399409001148; Giasson BI, 2000, SCIENCE, V290, P985, DOI 10.1126/science.290.5493.985; Glabe C, 2001, J MOL NEUROSCI, V17, P137, DOI 10.1385/JMN:17:2:137; Gong XM, 2003, NEURON, V38, P33, DOI 10.1016/S0896-6273(03)00191-0; Gonzalez-Polo RA, 2005, J CELL SCI, V118, P3091, DOI 10.1242/jcs.02447; Guimaraes CA, 2003, J BIOL CHEM, V278, P41938, DOI 10.1074/jbc.M306547200; Hall DH, 1997, J NEUROSCI, V17, P1033; Hara T, 2006, NATURE, V441, P885, DOI 10.1038/nature04724; Hars ES, 2007, AUTOPHAGY, V3, P93, DOI 10.4161/auto.3636; HATEM CL, 1995, J CELL SCI, V108, P2093; Hayashi-Nishino M, 2009, NAT CELL BIOL, V11, P1433, DOI 10.1038/ncb1991; Heiseke A, 2009, J NEUROCHEM, V109, P25, DOI 10.1111/j.1471-4159.2009.05906.x; Heitz S, 2010, BRAIN PATHOL, V20, P119, DOI 10.1111/j.1750-3639.2008.00245.x; Heitz S, 2009, AUTOPHAGY, V5, P422, DOI 10.4161/auto.5.3.7882; HIGGINS JJ, 1992, NEUROLOGY, V42, P2286, DOI 10.1212/WNL.42.12.2286; HORNUNG JP, 1989, J COMP NEUROL, V283, P425, DOI 10.1002/cne.902830310; Hosokawa N, 2009, AUTOPHAGY, V5, P973, DOI 10.4161/auto.5.7.9296; Ichimura Y, 2008, J BIOL CHEM, V283, P22847, DOI 10.1074/jbc.M802182200; Ichimura Y, 2008, AUTOPHAGY, V4, P1063, DOI 10.4161/auto.6826; Iwata A, 2005, P NATL ACAD SCI USA, V102, P13135, DOI 10.1073/pnas.0505801102; Iwata A, 2005, J BIOL CHEM, V280, P40282, DOI 10.1074/jbc.M508786200; Iwata J, 2006, J BIOL CHEM, V281, P4035, DOI 10.1074/jbc.M512283200; Jaeger PA, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-16; Jeong H, 2009, CELL, V137, P60, DOI 10.1016/j.cell.2009.03.018; Ji ZS, 2002, J BIOL CHEM, V277, P21821, DOI 10.1074/jbc.M112109200; Jia KL, 2007, AUTOPHAGY, V3, P21, DOI 10.4161/auto.3528; Kabuta T, 2008, J BIOL CHEM, V283, P23731, DOI 10.1074/jbc.M801918200; Kanki T, 2008, J BIOL CHEM, V283, P32386, DOI 10.1074/jbc.M802403200; Kaushik S, 2008, MOL BIOL CELL, V19, P2179, DOI 10.1091/mbc.E07-11-1155; Kawaguchi Y, 2003, CELL, V115, P727, DOI 10.1016/S0092-8674(03)00939-5; Kegel KB, 2000, J NEUROSCI, V20, P7268, DOI 10.1523/jneurosci.20-19-07268.2000; Kim YJ, 2006, NEUROBIOL DIS, V22, P346, DOI 10.1016/j.nbd.2005.11.012; Kimura N, 2007, PATHOBIOLOGY, V74, P169, DOI 10.1159/000103376; Klionsky DJ, 2007, NAT REV MOL CELL BIO, V8, P931, DOI 10.1038/nrm2245; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Klionsky DJ, 2005, J CELL SCI, V118, P7, DOI 10.1242/jcs.01620; Koike M, 2005, AM J PATHOL, V167, P1713, DOI 10.1016/S0002-9440(10)61253-9; Koike M, 2000, J NEUROSCI, V20, P6898, DOI 10.1523/JNEUROSCI.20-18-06898.2000; Koike M, 2008, AM J PATHOL, V172, P454, DOI 10.2353/ajpath.2008.070876; Komatsu M, 2005, J CELL BIOL, V169, P425, DOI 10.1083/jcb.200412022; Komatsu M, 2007, CELL, V131, P1149, DOI 10.1016/j.cell.2007.10.035; Komatsu M, 2007, P NATL ACAD SCI USA, V104, P14489, DOI 10.1073/pnas.0701311104; Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723; Kon M, 2010, FEBS LETT, V584, P1399, DOI 10.1016/j.febslet.2009.12.025; Korolchuk VI, 2009, MOL CELL, V33, P517, DOI 10.1016/j.molcel.2009.01.021; Kovacs JJ, 2005, MOL CELL, V18, P601, DOI 10.1016/j.molcel.2005.04.021; Kraft C, 2009, BBA-MOL CELL RES, V1793, P1404, DOI 10.1016/j.bbamcr.2009.02.006; Kroemer G, 2008, NAT REV MOL CELL BIO, V9, P1004, DOI 10.1038/nrm2529; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029; Kunchithapautham K, 2007, AUTOPHAGY, V3, P433, DOI 10.4161/auto.4294; Kunchithapautham K, 2007, AUTOPHAGY, V3, P65, DOI 10.4161/auto.3431; Kvam E, 2007, AUTOPHAGY, V3, P85, DOI 10.4161/auto.3586; Lai YC, 2008, J CEREBR BLOOD F MET, V28, P540, DOI 10.1038/sj.jcbfm.9600551; Landles C, 2004, EMBO REP, V5, P958, DOI 10.1038/sj.embor.7400250; Larsen KE, 2002, J NEUROSCI, V22, P8951; Lee HJ, 2004, J NEUROSCI, V24, P1888, DOI 10.1523/JNEUROSCI.3809-03.2004; Lee JA, 2007, CURR BIOL, V17, P1561, DOI 10.1016/j.cub.2007.07.029; Lee JY, 2010, EMBO J, V29, P969, DOI 10.1038/emboj.2009.405; Levine B, 2005, CELL, V120, P159, DOI 10.1016/j.cell.2005.01.005; Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; Levine B, 2008, AUTOPHAGY, V4, P600, DOI 10.4161/auto.6260; Levy OA, 2009, APOPTOSIS, V14, P478, DOI 10.1007/s10495-008-0309-3; Liao GH, 2007, AM J PATHOL, V171, P962, DOI 10.2353/ajpath.2007.070052; Liberski Pawel P, 2004, Folia Neuropathol, V42 Suppl B, P59; Liberski PP, 2008, FOLIA NEUROPATHOL, V46, P1; Liberski PP, 2004, INT J BIOCHEM CELL B, V36, P2473, DOI 10.1016/j.biocel.2004.04.016; Liberski PP, 2002, ACTA NEUROBIOL EXP, V62, P141; Ling DJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004201; Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046; Mandel S, 2005, ANN NY ACAD SCI, V1053, P356, DOI 10.1196/annals.1344.031; Mao ZX, 1999, SCIENCE, V286, P785, DOI 10.1126/science.286.5440.785; Maraganore DM, 2006, JAMA-J AM MED ASSOC, V296, P661, DOI 10.1001/jama.296.6.661; Marazziti D, 2009, FASEB J, V23, P1978, DOI 10.1096/fj.08-121210; Maries E, 2003, NAT REV NEUROSCI, V4, P727, DOI 10.1038/nrn1199; Martinez-Vicente M, 2005, EXP GERONTOL, V40, P622, DOI 10.1016/j.exger.2005.07.005; Martinez-Vicente M, 2008, J CLIN INVEST, V118, P777, DOI 10.1172/JCI32806; Martinez-Vicente M, 2007, LANCET NEUROL, V6, P352, DOI 10.1016/S1474-4422(07)70076-5; Massey AC, 2006, P NATL ACAD SCI USA, V103, P5805, DOI 10.1073/pnas.0507436103; Matsunaga K, 2009, AUTOPHAGY, V5, P876, DOI 10.4161/auto.9098; Matsunaga K, 2009, NAT CELL BIOL, V11, P385, DOI 10.1038/ncb1846; MCINTIRE SL, 1992, NEURON, V8, P307, DOI 10.1016/0896-6273(92)90297-Q; Meikle PJ, 1999, JAMA-J AM MED ASSOC, V281, P249, DOI 10.1001/jama.281.3.249; Melendez A, 2003, SCIENCE, V301, P1387, DOI 10.1126/science.1087782; Menzies FM, 2010, BRAIN, V133, P93, DOI 10.1093/brain/awp292; Mercer CA, 2009, AUTOPHAGY, V5, P649, DOI 10.4161/auto.5.5.8249; Meredith GE, 2002, BRAIN RES, V956, P156, DOI 10.1016/S0006-8993(02)03514-X; Michiorri S, 2010, CELL DEATH DIFFER, V17, P962, DOI 10.1038/cdd.2009.200; Mijaljica D, 2007, AUTOPHAGY, V3, P417, DOI 10.4161/auto.4441; Mitra S, 2009, AUTOPHAGY, V5, P1037, DOI 10.4161/auto.5.7.9291; Mizushima N, 2004, INT J BIOCHEM CELL B, V36, P2491, DOI 10.1016/j.biocel.2004.02.005; Mizushima N, 2005, CELL DEATH DIFFER, V12, P1535, DOI 10.1038/sj.cdd.4401728; Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639; Mizushima N, 2009, METHOD ENZYMOL, V452, P13, DOI 10.1016/S0076-6879(08)03602-1; Mizushima Noboru, 2008, V445, P119, DOI 10.1007/978-1-59745-157-4_7; Mok SWF, 2007, BIOCHEM BIOPH RES CO, V359, P672, DOI 10.1016/j.bbrc.2007.05.163; Montie HL, 2009, HUM MOL GENET, V18, P1937, DOI 10.1093/hmg/ddp115; Mookerjee S, 2009, J NEUROSCI, V29, P15134, DOI 10.1523/JNEUROSCI.4720-09.2009; Moore RC, 1999, J MOL BIOL, V292, P797, DOI 10.1006/jmbi.1999.3108; Moreira PI, 2007, AUTOPHAGY, V3, P614, DOI 10.4161/auto.4872; Moretra PI, 2007, J NEUROPATH EXP NEUR, V66, P525, DOI 10.1097/01.jnen.0000240476.73532.b0; Muchowski PJ, 2002, P NATL ACAD SCI USA, V99, P727, DOI 10.1073/pnas.022628699; Muller O, 2000, J CELL BIOL, V151, P519, DOI 10.1083/jcb.151.3.519; Nagata E, 2004, NEUROREPORT, V15, P1325, DOI 10.1097/01.wnr.0000127073.66692.8f; Nakanishi H, 2001, J NEUROSCI, V21, P7526; Narendra D, 2008, J CELL BIOL, V183, P795, DOI 10.1083/jcb.200809125; Nishino I, 2000, NATURE, V406, P906, DOI 10.1038/35022604; Nishiyama J, 2010, J NEUROSCI, V30, P2177, DOI 10.1523/JNEUROSCI.6030-09.2010; NITATORI T, 1995, J NEUROSCI, V15, P1001; Nixon RA, 2005, J NEUROPATH EXP NEUR, V64, P113, DOI 10.1093/jnen/64.2.113; Nixon RA, 2007, J CELL SCI, V120, P4081, DOI 10.1242/jcs.019265; Nussbaum RL, 1997, HUM MOL GENET, V6, P1687, DOI 10.1093/hmg/6.10.1687; Oh JM, 2008, MOL CELL NEUROSCI, V39, P238, DOI 10.1016/j.mcn.2008.07.003; Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522; Pacheco CD, 2007, HUM MOL GENET, V16, P1495, DOI 10.1093/hmg/ddm100; Pal A, 2006, J CELL BIOL, V172, P605, DOI 10.1083/jcb.200509091; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Pandey UB, 2007, NATURE, V447, P859, DOI 10.1038/nature05853; Park J, 2009, DIS MODEL MECH, V2, P336, DOI 10.1242/dmm.003178; Pasquali L, 2008, ANN NY ACAD SCI, V1139, P191, DOI 10.1196/annals.1432.016; Perutz MF, 2001, NATURE, V412, P143, DOI 10.1038/35084141; Petersen A, 2001, HUM MOL GENET, V10, P1243, DOI 10.1093/hmg/10.12.1243; Pickford F, 2008, J CLIN INVEST, V118, P2190, DOI 10.1172/JCI33585; Plowey ED, 2008, J NEUROCHEM, V105, P1048, DOI 10.1111/j.1471-4159.2008.05217.x; POLLANEN MS, 1993, J NEUROPATH EXP NEUR, V52, P183, DOI 10.1097/00005072-199305000-00001; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Qin ZH, 2003, HUM MOL GENET, V12, P3231, DOI 10.1093/hmg/ddg346; Ramirez A, 2006, NAT GENET, V38, P1184, DOI 10.1038/ng1884; Ravikumar B, 2005, NAT GENET, V37, P771, DOI 10.1038/ng1591; Ravikumar B, 2004, NAT GENET, V36, P585, DOI 10.1038/ng1362; Ravikumar B, 2002, HUM MOL GENET, V11, P1107, DOI 10.1093/hmg/11.9.1107; Ravikumar B, 2008, J CELL SCI, V121, P1649, DOI 10.1242/jcs.025726; Reed NA, 2006, CURR BIOL, V16, P2166, DOI 10.1016/j.cub.2006.09.014; Rideout HJ, 2004, INT J BIOCHEM CELL B, V36, P2551, DOI 10.1016/j.biocel.2004.05.008; Riedel M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008753; Ross CA, 2004, NAT MED, V10, pS10, DOI 10.1038/nm1066; Rubinszfein DC, 2005, AUTOPHAGY, V1, P11, DOI 10.4161/auto.1.1.1513; Rubinsztein DC, 2006, NATURE, V443, P780, DOI 10.1038/nature05291; Sadasivan S, 2008, BIOCHEM BIOPH RES CO, V373, P478, DOI 10.1016/j.bbrc.2008.05.031; Sakaguchi S, 1996, NATURE, V380, P528, DOI 10.1038/380528a0; Sakai Y, 2006, BBA-MOL CELL RES, V1763, P1767, DOI 10.1016/j.bbamcr.2006.08.023; Samara C, 2008, CELL DEATH DIFFER, V15, P105, DOI 10.1038/sj.cdd.4402231; Samokhvalov V, 2008, AUTOPHAGY, V4, P1034, DOI 10.4161/auto.6994; Sandberg M, 2007, MOL CELL ENDOCRINOL, V277, P35, DOI 10.1016/j.mce.2007.07.007; Sapp E, 1997, ANN NEUROL, V42, P604, DOI 10.1002/ana.410420411; Sarkar S, 2009, CELL DEATH DIFFER, V16, P46, DOI 10.1038/cdd.2008.110; Sarkar S, 2007, NAT CHEM BIOL, V3, P331, DOI 10.1038/nchembio883; Scarlatti F, 2009, CELL DEATH DIFFER, V16, P12, DOI 10.1038/cdd.2008.101; Schatzl HM, 1997, J VIROL, V71, P8821; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; Shacka JJ, 2007, NEUROSCI LETT, V414, P57, DOI 10.1016/j.neulet.2006.12.025; Shacka JJ, 2007, J NEUROSCI, V27, P2081, DOI 10.1523/JNEUROSCI.5577-06.2007; Shibata M, 2006, J BIOL CHEM, V281, P14474, DOI 10.1074/jbc.M600364200; Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993; Sikorska B, 2004, INT J BIOCHEM CELL B, V36, P2563, DOI 10.1016/j.biocel.2004.04.014; Silvestri L, 2005, HUM MOL GENET, V14, P3477, DOI 10.1093/hmg/ddi377; Simon-Sanchez J, 2009, NAT GENET, V41, P1308, DOI 10.1038/ng.487; Simonsen A, 2008, AUTOPHAGY, V4, P176, DOI 10.4161/auto.5269; Simonsen A, 2007, AUTOPHAGY, V3, P499, DOI 10.4161/auto.4604; Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278; Skibinski G, 2005, NAT GENET, V37, P806, DOI 10.1038/ng1609; Skinner PJ, 2001, AM J PATHOL, V159, P905, DOI 10.1016/S0002-9440(10)61766-X; Small SA, 2005, ANN NEUROL, V58, P909, DOI 10.1002/ana.20667; Spencer B, 2009, J NEUROSCI, V29, P13578, DOI 10.1523/JNEUROSCI.4390-09.2009; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Stefanis L, 2001, J NEUROSCI, V21, P9549, DOI 10.1523/JNEUROSCI.21-24-09549.2001; Sugie K, 2005, J NEUROPATH EXP NEUR, V64, P513, DOI 10.1093/jnen/64.6.513; Suzuki K, 2007, FEBS LETT, V581, P2156, DOI 10.1016/j.febslet.2007.01.096; Syntichaki P, 2002, NATURE, V419, P939, DOI 10.1038/nature01108; Tai HC, 2008, NAT REV NEUROSCI, V9, P826, DOI 10.1038/nrn2499; Tamai K, 2008, AM J PATHOL, V173, P1806, DOI 10.2353/ajpath.2008.080684; Tanaka Y, 2000, NATURE, V406, P902, DOI 10.1038/35022595; Taylor JP, 2002, SCIENCE, V296, P1991, DOI 10.1126/science.1067122; Taylor JP, 2003, HUM MOL GENET, V12, P749, DOI 10.1093/hmg/ddg074; Uryu K, 2006, AM J PATHOL, V168, P947, DOI 10.2353/ajpath.2006.050770; Vellai T, 2009, CELL DEATH DIFFER, V16, P94, DOI 10.1038/cdd.2008.126; Vig PJS, 2009, CEREBELLUM, V8, P231, DOI 10.1007/s12311-009-0125-5; Vogiatzi T, 2008, J BIOL CHEM, V283, P23542, DOI 10.1074/jbc.M801992200; Wadsworth JD, 2003, BRIT MED BULL, V66, P241, DOI 10.1093/bmb/66.1.241; Wang QJ, 2006, J NEUROSCI, V26, P8057, DOI 10.1523/JNEUROSCI.2261-06.2006; Wang Y, 2008, AUTOPHAGY, V4, P214, DOI 10.4161/auto.5369; Wang YP, 2009, HUM MOL GENET, V18, P4153, DOI 10.1093/hmg/ddp367; Wang YJ, 2008, J BIOL CHEM, V283, P4766, DOI 10.1074/jbc.M706666200; Wang Y, 2010, MOL PAIN, V6, DOI 10.1186/1744-8069-6-5; Ward Walter F, 2002, Prog Mol Subcell Biol, V29, P35; Webb JL, 2003, J BIOL CHEM, V278, P25009, DOI 10.1074/jbc.M300227200; Webb JL, 2004, INT J BIOCHEM CELL B, V36, P2541, DOI 10.1016/j.biocel.2004.02.003; Weissmann C, 2004, NAT REV MICROBIOL, V2, P861, DOI 10.1038/nrmicro1025; Xie ZP, 2007, NAT CELL BIOL, V9, P1102, DOI 10.1038/ncb1007-1102; Xilouri M, 2008, AUTOPHAGY, V4, P917, DOI 10.4161/auto.6685; Xilouri M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005515; Xu J, 2002, NAT MED, V8, P600, DOI 10.1038/nm0602-600; Xue LZ, 1999, MOL CELL NEUROSCI, V14, P180, DOI 10.1006/mcne.1999.0780; Yamada M, 2002, ANN NEUROL, V52, P498, DOI 10.1002/ana.10328; Yan J, 1998, BIOCHEM BIOPH RES CO, V246, P222, DOI 10.1006/bbrc.1998.8546; Yang Q, 2009, SCIENCE, V323, P124, DOI 10.1126/science.1166088; Yankner BA, 1996, NAT MED, V2, P850, DOI 10.1038/nm0896-850; Yao Z, 2009, ANTIOXID REDOX SIGN, V11, P2135, DOI [10.1089/ars.2009.2624, 10.1089/ARS.2009.2624]; Yla-Anttila P, 2009, AUTOPHAGY, V5, P1180; Young JE, 2009, J BIOL CHEM, V284, P2363, DOI 10.1074/jbc.M806088200; Yu WH, 2009, AM J PATHOL, V175, P736, DOI 10.2353/ajpath.2009.080928; Yu WH, 2005, J CELL BIOL, V171, P87, DOI 10.1083/jcb.200505082; Yu WH, 2004, INT J BIOCHEM CELL B, V36, P2531, DOI 10.1016/j.biocel.2004.05.010; Yue ZY, 2009, BBA-MOL CELL RES, V1793, P1496, DOI 10.1016/j.bbamcr.2009.01.016; Yue ZY, 2002, NEURON, V35, P921, DOI 10.1016/S0896-6273(02)00861-9; Yun SW, 2007, J NEUROVIROL, V13, P328, DOI 10.1080/13550280701361516; Zaidi AU, 2001, J NEUROPATH EXP NEUR, V60, P937, DOI 10.1093/jnen/60.10.937; Zhang C, 2008, NAT MED, V14, P959, DOI 10.1038/nm.1851; Zhang Yan-Bo, 2008, Neurosci Bull, V24, P143, DOI 10.1007/s12264-008-1108-0; Zhou X, 2007, P NATL ACAD SCI USA, V104, P5842, DOI 10.1073/pnas.0701402104; Zhu JH, 2003, BRAIN PATHOL, V13, P473; Zuo J, 1997, NATURE, V388, P769, DOI 10.1038/42009	290	75	84	0	16	BENTHAM SCIENCE PUBL	BUSUM	PO BOX 294, BUSUM, 1400 AG, NETHERLANDS	1871-5273	1996-3181		CNS NEUROL DISORD-DR	CNS Neurol. Disord.-Drug Targets	DEC	2010	9	6					701	719		10.2174/187152710793237421			19	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	685HZ	WOS:000284621100006	20942791				2021-06-18	
J	Hong, YA; Yan, W; Chen, S; Sun, CR; Zhang, JM				Hong, Yuan; Yan, Wei; Chen, Sheng; Sun, Chong-ran; Zhang, Jian-min			The role of Nrf2 signaling in the regulation of antioxidants and detoxifying enzymes after traumatic brain injury in rats and mice	ACTA PHARMACOLOGICA SINICA			English	Article						nuclear factor-erythroid 2-related factor 2; sulforaphane; traumatic brain injury; oxidative stress; heme oxygenase 1; NAD(P) H:quinine oxidoreductase 1; neurological dysfunction	OXIDATIVE STRESS; CEREBRAL-ISCHEMIA; IN-VIVO; ENHANCES SUSCEPTIBILITY; TRANSCRIPTION FACTOR; ALZHEIMERS-DISEASE; LIPID-PEROXIDATION; HERNE OXYGENASE; REACTIVE OXYGEN; NERVOUS-SYSTEM	Aim: To determine whether Nrf2 signaling pathway activation could attenuate oxidative stress and neuronal damage following traumatic brain injury (TBI). Methods: Controlled cortical impact (CCI) injury was performed in Sprague-Dawley rats and Nrf2-knockout or control mice. Sulforaphane (SFN), a potent Nrf2 activator, was used to activate Nrf2. Oxidative stress, lesion volume, neuron degeneration, and neurologic dysfunction were determined using biochemical, histopathological and neuroethologic approaches. Protein and mRNA levels of Nrf2 and the antioxidant enzymes heme oxygenase 1 (HO-1) and NAD(P) H: quinine oxidoreductase 1 (NQO1) were assessed using Western blot analysis and RT-PCR. Results: Activation of Nrf2 by SFN(5 mg/kg, ip) induced the nuclear translocation and activation of Nrf2, which resulted in an up-regulation of Nrf2-dependent antioxidant enzymes and a reduction of oxidative damage after TBI. In accordance with these biochemical changes, SFN also significantly reduced neuronal death, contusion volume, and neurological dysfunction after TBI. Furthermore, Nrf2-knockout mice showed more severe oxidative stress and neurologic deficits after TBI and did not benefit from the effects of SFN. Conclusion: Nrf2 plays a pivotal role in cell defenses against the oxidative stress of TBI. In addition, pharmacological activation of the Nrf2 signaling pathway by small molecule inducers such as SFN attenuated oxidative stress and neuronal damage following TBI.	[Hong, Yuan; Yan, Wei; Chen, Sheng; Sun, Chong-ran; Zhang, Jian-min] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Neurosurg, Hangzhou 310006, Zhejiang, Peoples R China	Zhang, JM (corresponding author), Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Neurosurg, Hangzhou 310006, Zhejiang, Peoples R China.	hy0904@live.cn		Yan, Wei/0000-0002-1123-0835	Research Fund for the Doctoral Program of Higher Education of ChinaResearch Fund for the Doctoral Program of Higher Education of China (RFDP)Specialized Research Fund for the Doctoral Program of Higher Education (SRFDP) [0090101120118]; Zhejiang Provincial Natural Science Foundation in China [Y2090098]	This work was funded by the Research Fund for the Doctoral Program of Higher Education of China (Grant No 0090101120118) and Zhejiang Provincial Natural Science Foundation in China (Grant No Y2090098).	Aleksunes LM, 2007, TOXICOL PATHOL, V35, P459, DOI 10.1080/01926230701311344; Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Butterfield DA, 2002, FREE RADICAL BIO MED, V32, P1050, DOI 10.1016/S0891-5849(02)00794-3; CADENAS E, 1995, BIOCHEM PHARMACOL, V49, P127, DOI 10.1016/S0006-2952(94)00333-5; Calkins MJ, 2005, P NATL ACAD SCI USA, V102, P244, DOI 10.1073/pnas.0408487101; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Chen K, 2000, J NEUROCHEM, V75, P304, DOI 10.1046/j.1471-4159.2000.0750304.x; Chen PC, 2009, P NATL ACAD SCI USA, V106, P2933, DOI 10.1073/pnas.0813361106; Chen XR, 2007, J NEUROTRAUM, V24, P1119, DOI 10.1089/neu.2006.0216; Cho HY, 2002, AM J RESP CELL MOL, V26, P175, DOI 10.1165/ajrcmb.26.2.4501; Chong ZZ, 2005, PROG NEUROBIOL, V75, P207, DOI 10.1016/j.pneurobio.2005.02.004; Clausen F, 2004, J NEUROTRAUM, V21, P1168, DOI 10.1089/neu.2004.21.1168; Darwish RS, 2007, J TRAUMA, V63, P439, DOI 10.1097/TA.0b013e318069178a; Dash PK, 2009, NEUROSCI LETT, V460, P103, DOI 10.1016/j.neulet.2009.04.028; Gilgun-Sherki Y, 2002, PHARMACOL REV, V54, P271, DOI 10.1124/pr.54.2.271; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Jin W, 2009, J NEUROTRAUM, V26, P131, DOI 10.1089/neu.2008.0655; Jin W, 2008, MEDIAT INFLAMM, V2008, DOI 10.1155/2008/725174; Ku BM, 2006, NEUROSCI LETT, V405, P168, DOI 10.1016/j.neulet.2006.06.052; Laxton AW, 2001, NEUROREPORT, V12, P1045, DOI 10.1097/00001756-200104170-00036; Lee JM, 2003, J BIOL CHEM, V278, P12029, DOI 10.1074/jbc.M211558200; Li YJ, 2008, CLIN IMMUNOL, V128, P366, DOI 10.1016/j.clim.2008.05.005; Lucius R, 1996, BRAIN RES, V743, P56, DOI 10.1016/S0006-8993(96)01029-3; Mancuso C, 2004, ANTIOXID REDOX SIGN, V6, P878, DOI 10.1089/1523086041798097; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10925, DOI 10.1073/pnas.94.20.10925; Purdom-Dickinson SE, 2007, J MOL CELL CARDIOL, V42, P159, DOI 10.1016/j.yjmcc.2006.09.012; Radjendirane V, 1998, J BIOL CHEM, V273, P7382, DOI 10.1074/jbc.273.13.7382; Rangasamy T, 2004, J CLIN INVEST, V114, P1248, DOI 10.1172/JCI200421146; Rigg JL, 2005, J HEAD TRAUMA REHAB, V20, P389, DOI 10.1097/00001199-200507000-00010; SantaCruz KS, 2004, NEUROBIOL AGING, V25, P63, DOI 10.1016/S0197-4580(03)00117-9; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Sekhar KR, 2002, ONCOGENE, V21, P6829, DOI 10.1038/sj.onc.1205905; Shih AY, 2005, J NEUROSCI, V25, P10321, DOI 10.1523/JNEUROSCI.4014-05.2005; Singh IN, 2007, J NEUROSCI RES, V85, P2216, DOI 10.1002/jnr.21360; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; Ueda K, 2008, AM J PHYSIOL-GASTR L, V295, pG460, DOI 10.1152/ajpgi.00204.2007; van Horssen J, 2006, FREE RADICAL BIO MED, V41, P311, DOI 10.1016/j.freeradbiomed.2006.04.013; van Muiswinkel FL, 2004, NEUROBIOL AGING, V25, P1253, DOI 10.1016/j.neurobiolaging.2003.12.010; Yan W, 2008, NEUROSCI LETT, V431, P150, DOI 10.1016/j.neulet.2007.11.060; Yan W, 2009, J TRAUMA, V66, P1431, DOI 10.1097/TA.0b013e318180f5c7; Zhang C, 1998, J NEUROSCI RES, V52, P342, DOI 10.1002/(SICI)1097-4547(19980501)52:3<342::AID-JNR10>3.0.CO;2-8; Zhao J, 2006, NEUROSCI LETT, V393, P108, DOI 10.1016/j.neulet.2005.09.065; Zhao J, 2005, J NEUROSCI RES, V82, P499, DOI 10.1002/jnr.20649; Zhao J, 2007, J NEUROSCI, V27, P10240, DOI 10.1523/JNEUROSCI.1683-07.2007; Zhao XR, 2007, STROKE, V38, P3280, DOI 10.1161/STROKEAHA.107.486506; Zhu H, 2005, FEBS LETT, V579, P3029, DOI 10.1016/j.febslet.2005.04.058	48	75	82	0	10	ACTA PHARMACOLOGICA SINICA	SHANGHAI	294 TAI-YUAN RD, SHANGHAI, 200031, PEOPLES R CHINA	1671-4083	1745-7254		ACTA PHARMACOL SIN	Acta Pharmacol. Sin.	NOV	2010	31	11					1421	1430		10.1038/aps.2010.101			10	Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Chemistry; Pharmacology & Pharmacy	678EH	WOS:000284055500003	20953205	Bronze, Green Published			2021-06-18	
S	Greden, JF; Valenstein, M; Spinner, J; Blow, A; Gorman, LA; Dalack, GW; Marcus, S; Kees, M		Barchas, JD; Difede, J		Greden, John F.; Valenstein, Marcia; Spinner, Jane; Blow, Adrian; Gorman, Lisa A.; Dalack, Gregory W.; Marcus, Sheila; Kees, Michelle			Buddy-to-Buddy, a citizen soldier peer support program to counteract stigma, PTSD, depression, and suicide	PSYCHIATRIC AND NEUROLOGIC ASPECTS OF WAR	Annals of the New York Academy of Sciences		English	Article; Proceedings Paper	89th Annual Conference of the Association for Research in Nervous and Mental Disease	DEC 16, 2009	Rockefeller Univ, New York, NY		Rockefeller Univ	citizen soldiers; peer-to-peer; PTSD; depression; suicide	POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; MENTAL-HEALTH PROBLEMS; RISK PERIODS; VA PATIENTS; MILITARY; IRAQ; SERVICE; DISEASE; CARE	Citizen soldiers (National Guard and Reserves) represent approximately 40% of the two million armed forces deployed to Afghanistan and Iraq. Twenty-five to forty percent of them develop PTSD, clinical depression, sleep disturbances, or suicidal thoughts. Upon returning home, many encounter additional stresses and hurdles to obtaining care: specifically, many civilian communities lack military medical/psychiatric facilities; financial, job, home, and relationship stresses have evolved or have been exacerbated during deployment; uncertainty has increased related to future deployment; there is loss of contact with military peers; and there is reluctance to recognize and acknowledge mental health needs that interfere with treatment entry and adherence. Approximately half of those needing help are not receiving it. To address this constellation of issues, a private public partnership was formed under the auspices of the Welcome Back Veterans Initiative. In Michigan, the Army National Guard teamed with the University of Michigan and Michigan State University to develop innovative peer-to-peer programs for soldiers (Buddy-to-Buddy) and augmented programs for military families. Goals are to improve treatment entry, adherence, clinical outcomes, and to reduce suicides. This manuscript describes training approaches, preliminary results, and explores future national dissemination.	[Greden, John F.; Valenstein, Marcia; Spinner, Jane; Dalack, Gregory W.; Marcus, Sheila; Kees, Michelle] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA; [Greden, John F.; Valenstein, Marcia; Spinner, Jane; Dalack, Gregory W.; Marcus, Sheila; Kees, Michelle] Univ Michigan, Comprehens Depress Ctr, Ann Arbor, MI 48109 USA; [Valenstein, Marcia] Univ Michigan, Ann Arbor Vet Adm Hosp, Ann Arbor, MI 48109 USA; [Greden, John F.] Univ Michigan, Mol & Behav Neurosci Inst, Ann Arbor, MI 48109 USA; [Blow, Adrian; Gorman, Lisa A.] Michigan State Univ, Lansing, MI USA	Greden, JF (corresponding author), Univ Michigan Hlth Syst, 4250 Plymouth Rd, Ann Arbor, MI 48109 USA.	gredenj@umich.edu	Blow, Adrian/U-1647-2019				*ASPPS, 2009, SHOULD SHOULD NO SOL; BASU S, 2009, US MED           MAR; DALACK GW, 2010, PSYCHIAT SE IN PRESS; *DEP VET AFF, 2009, ACE SUIC PREV VET TH; EMMANUEL LO, 2009, VA HIRES VETS GO FIN; Greden JF, 2001, J CLIN PSYCHIAT, V62, pS26; Hettema J, 2005, ANNU REV CLIN PSYCHO, V1, P91, DOI 10.1146/annurev.clinpsy.1.102803.143833; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2006, JAMA-J AM MED ASSOC, V295, P1023, DOI 10.1001/jama.295.9.1023; Hunkeler EM, 2000, ARCH FAM MED, V9, P700, DOI 10.1001/archfami.9.8.700; Jacobson IG, 2008, JAMA-J AM MED ASSOC, V300, P663, DOI 10.1001/jama.300.6.663; Joiner T. E., 2005, WHY PEOPLE DIE SUICI; Keane TM, 2006, ANNU REV CLIN PSYCHO, V2, P161, DOI 10.1146/annurev.clinpsy.2.022305.095305; Kilpatrick DG, 2007, AM J PSYCHIAT, V164, P1693, DOI 10.1176/appi.ajp.2007.06122007; Kuehn BM, 2009, JAMA-J AM MED ASSOC, V301, P1111, DOI 10.1001/jama.2009.342; Ludman EJ, 2007, PSYCHIAT SERV, V58, P1065, DOI 10.1176/appi.ps.58.8.1065; Milliken CS, 2007, JAMA-J AM MED ASSOC, V298, P2141, DOI 10.1001/jama.298.18.2141; Oquendo MA, 2006, ACTA PSYCHIAT SCAND, V114, P151, DOI 10.1111/j.1600-0447.2006.00829.x; Riddle JR, 2007, J CLIN EPIDEMIOL, V60, P192, DOI 10.1016/j.jclinepi.2006.04.008; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; SHINSHEKI E, 2010, DEP DEF VA SUIC PREV; TANIELIAN T, 2008, INVISIBLE WOUNDS WAR, V3, pR3; *US MAR CORPS, 2010, NEV LEAV MAR BEH; Valenstein M, 2009, PSYCHIAT SERV, V60, P439, DOI 10.1176/appi.ps.60.4.439; Valenstein M, 2009, J AFFECT DISORDERS, V112, P50, DOI 10.1016/j.jad.2008.08.020; Waterhouse M., 2008, NATL GUARD PERSONNEL	26	75	75	0	28	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN STREET, MALDEN 02148, MA USA	0077-8923		978-1-57331-804-4	ANN NY ACAD SCI	Ann.NY Acad.Sci.		2010	1208						90	97		10.1111/j.1749-6632.2010.05719.x			8	Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	BSK28	WOS:000284742000012	20955330				2021-06-18	
J	Lange, RT; Iverson, GL; Brooks, BL; Rennison, VLA				Lange, Rael T.; Iverson, Grant L.; Brooks, Brian L.; Rennison, V. Lynn Ashton			Influence of poor effort on self-reported symptoms and neurocognitive test performance following mild traumatic brain injury	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Postconcussion symptoms; Response bias; Symptom validity testing; Test of Memory Malingering	MEMORY MALINGERING TOMM; RESPONSE BIAS SCALE; MMPI-2 VALIDITY SCALES; SPORTS-RELATED CONCUSSION; COMPLAINT BASE RATES; GOOD OLD DAYS; HEAD-INJURY; POSTCONCUSSION SYNDROME; NEUROPSYCHOLOGICAL TESTS; COGNITIVE PERFORMANCE	When considering a diagnosis of postconcussion syndrome, clinicians must systematically evaluate and eliminate the possible contribution of many differential diagnoses, comorbidities, and factors that may cause or maintain self-reported symptoms long after mild traumatic brain injury (MTBI). One potentially significant contributing factor is symptom exaggeration. The purpose of the study is to examine the influence of poor effort on self-reported symptoms (postconcussion symptoms and cognitive complaints) and neurocognitive test performance following MTBI. The MTBI sample consisted of 63 referrals to a concussion clinic, evaluated within 5 months post injury (M = 2.0, SD = 1.0, range = 0.6-4.6), who were receiving financial compensation from the Workers' Compensation Board. Participants completed the Post-Concussion Scale (PCS), British Columbia Cognitive Complaints Inventory (BC-CCI), selected tests from the Neuropsychological Assessment Battery Screening Module (S-NAB), and the Test of Memory Malingering (TOMM). Participants were divided into two groups based on TOMM performance (15 fail, 48 pass). There were significant main effects and large effect sizes for the PCS (p = .002, d = 0.79) and BC-CCI (p = .011, d = 0.98) total scores. Patients in the TOMM fail group scored higher than those in the TOMM pass group on both measures. Similarly, there were significant main effects and/or large effect sizes on the S-NAB. Patients in the TOMM fail group performed more poorly on the Attention (p = .004, d = 1.26), Memory (p = .006, d = 1.16), and Executive Functioning (p .05, d = 0.70) indexes. These results highlight the importance of considering the influence of poor effort, in conjunction with a growing list of factors that can influence, maintain, and/or mimic the persistent postconcussion syndrome.	[Lange, Rael T.] PHSA Res & Networks, British Columbia Mental Hlth & Addict Serv, Vancouver, BC V5Z 4C2, Canada; [Lange, Rael T.; Iverson, Grant L.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; [Brooks, Brian L.] Alberta Childrens Prov Gen Hosp, Calgary, AB T2T 5C7, Canada; [Brooks, Brian L.] Univ Calgary, Calgary, AB T2N 1N4, Canada; [Rennison, V. Lynn Ashton] Fraser Hlth Concuss Clin, Coquitlam, BC, Canada; [Rennison, V. Lynn Ashton] Royal Columbian Hosp, New Westminster, BC, Canada	Lange, RT (corresponding author), PHSA Res & Networks, British Columbia Mental Hlth & Addict Serv, Suite 201,601 W Broadway St, Vancouver, BC V5Z 4C2, Canada.	rael.lange@gmail.com		Iverson, Grant/0000-0001-7348-9570			American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Ashendorf L, 2004, ARCH CLIN NEUROPSYCH, V19, P125, DOI 10.1016/S0887-6177(02)00218-4; Backhaus SL, 2004, CLIN NEUROPSYCHOL, V18, P591, DOI 10.1080/13854040490888558; Bauer L, 2007, ASSESSMENT, V14, P215, DOI 10.1177/1073191106297617; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Boone KB, 1999, CLIN NEUROPSYCHOL, V13, P414; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Butcher, 1989, MINNESOTA MULTIPHASI; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Constantinou M, 2005, ARCH CLIN NEUROPSYCH, V20, P191, DOI 10.1016/j.acn.2004.06.002; Cook J B, 1972, Scand J Rehabil Med, V4, P27; Crawford JR, 2007, NEUROPSYCHOLOGY, V21, P419, DOI 10.1037/0894-4105.21.4.419; DenBoer JW, 2007, CLIN NEUROPSYCHOL, V21, P943, DOI 10.1080/13854040601020783; Donders J, 2005, CHILD NEUROPSYCHOL, V11, P221, DOI 10.1080/09297040490917298; DUNN JT, 1995, J CLIN PSYCHOL, V51, P577, DOI 10.1002/1097-4679(199507)51:4<577::AID-JCLP2270510418>3.0.CO;2-E; Ferguson RJ, 1999, NEUROPSYCHOLOGY, V13, P582, DOI 10.1037/0894-4105.13.4.582; Garden N, 2010, NEUROPSYCHOLOGY, V24, P168, DOI 10.1037/a0017431; Gavett BE, 2005, APPL NEUROPSYCHOL, V12, P1, DOI 10.1207/s15324826an1201_1; Gervais RO, 2005, ARCH CLIN NEUROPSYCH, V20, P891; Gervais RO, 2004, ARCH CLIN NEUROPSYCH, V19, P475, DOI 10.1016/j.acn.2003.05.001; Gervais RO, 2007, ASSESSMENT, V14, P196, DOI 10.1177/1073191106295861; Gervais RO, 2008, CLIN NEUROPSYCHOL, V22, P1061, DOI 10.1080/13854040701756930; Gierok SD, 2005, ARCH CLIN NEUROPSYCH, V20, P755, DOI 10.1016/j.acn.2005.04.008; Green P, 2007, PHYS MED REHABILITAT, V18, pvi; Green Paul, 2007, Phys Med Rehabil Clin N Am, V18, P43, DOI 10.1016/j.pmr.2006.11.002; Greiffenstein MF, 2001, CLIN NEUROPSYCHOL, V15, P162, DOI 10.1076/clin.15.2.162.1895; Gunstad J, 2001, J INT NEUROPSYCH SOC, V7, P323, DOI 10.1017/S1355617701733061; Haggerty KA, 2007, CLIN NEUROPSYCHOL, V21, P917, DOI 10.1080/13854040600899724; Hahn RA, 1997, PREV MED, V26, P607, DOI 10.1006/pmed.1996.0124; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Henry GK, 2009, CLIN NEUROPSYCHOL, V23, P153, DOI 10.1080/13854040801969524; Hill SK, 2003, J FORENSIC NEUROPSYC, V3, P1; Horner MD, 2006, INT J NEUROSCI, V116, P1181, DOI 10.1080/00207450500514029; Iverson G. L., 2003, CAN PSYCH ASS HAL NO; Iverson G.L., 2007, BRAIN INJURY MED PRI, P373; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; IVERSON GL, 2003, NAT AC NEUR DALL TX; Iverson GL, 2007, CLIN NEUROPSYCHOL, V21, P532, DOI 10.1080/13854040600611392; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Iverson GL, 2010, J HEAD TRAUMA REHAB, V25, P23, DOI 10.1097/HTR.0b013e3181b4b6ab; Iverson GL, 2010, CLIN NEUROPSYCHOL, V24, P17, DOI 10.1080/13854040903190797; Larrabee G. J., 2008, J INT NEUROPSYCH SOC, V14, P122; Larrabee GJ, 2003, ARCH CLIN NEUROPSYCH, V18, P673, DOI 10.1016/S0887-6177(02)00157-9; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P395, DOI 10.1076/clin.17.3.395.18087; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; Locke DEC, 2008, NEUROREHABILITATION, V23, P273; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; McCaffrey R. J., 2003, J FORENSIC NEUROPSYC, V3, P45, DOI [10.1300/J151v03n03_03, DOI 10.1300/J151V03N03_03]; Mickeviciene D, 2004, EUR J NEUROL, V11, P411, DOI 10.1111/j.1468-1331.2004.00816.x; MILLER H, 1961, BRIT MED J, V1, P919, DOI 10.1136/bmj.1.5230.919; Morey L. C., 1991, PERSONALITY ASSESSME; Nelson NW, 2007, J INT NEUROPSYCH SOC, V13, P440, DOI 10.1017/S1355617707070373; Nelson NW, 2007, J CLIN EXP NEUROPSYC, V29, P67, DOI 10.1080/13803390500488546; O'Bryant SE, 2008, APPL NEUROPSYCHOL, V15, P113, DOI 10.1080/09084280802083921; O'Bryant SE, 2007, CLIN NEUROPSYCHOL, V21, P511, DOI 10.1080/13854040600611368; Paniak C, 2002, J CLIN EXP NEUROPSYC, V24, P187, DOI 10.1076/jcen.24.2.187.999; Rees LM, 1998, PSYCHOL ASSESSMENT, V10, P10, DOI 10.1037/1040-3590.10.1.10; Rees LM, 2001, ARCH CLIN NEUROPSYCH, V16, P501, DOI 10.1016/S0887-6177(00)00064-0; Reynolds S, 2003, J HEAD TRAUMA REHAB, V18, P139, DOI 10.1097/00001199-200303000-00005; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Ruocco AC, 2008, CLIN NEUROPSYCHOL, V22, P547, DOI 10.1080/13854040701336444; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Sharland MJ, 2007, ARCH CLIN NEUROPSYCH, V22, P213, DOI 10.1016/j.acn.2006.12.004; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Stern RA, 2003, NEUROPSYCHOLOGICAL A; Stevens A, 2008, PSYCHIAT RES, V157, P191, DOI 10.1016/j.psychres.2007.01.003; Suhr J, 1997, J CLIN EXP NEUROPSYC, V19, P500, DOI 10.1080/01688639708403740; Suhr JA, 2005, J INT NEUROPSYCH SOC, V11, P23, DOI 10.1017/S1355617705050010; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P981, DOI 10.1076/jcen.24.8.981.8372; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P448, DOI 10.1076/jcen.24.4.448.1039; Suhr J, 2008, ARCH CLIN NEUROPSYCH, V23, P521, DOI 10.1016/j.acn.2008.05.003; Sullivan Michael J L, 2002, Pain Res Manag, V7, P120; Sumanti M, 2006, CLIN NEUROPSYCHOL, V20, P754, DOI 10.1080/13854040500428467; Tan JE, 2002, CLIN NEUROPSYCHOL, V16, P495, DOI 10.1076/clin.16.4.495.13909; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260; Tombaugh TN, 1996, TEST MEMORY MALINGER; Trahan DE, 2001, ARCH CLIN NEUROPSYCH, V16, P435, DOI 10.1016/S0887-6177(00)00051-2; Tsanadis J, 2007, J INT NEUROPSYCH SOC, V13, P196; Tsanadis J, 2008, CLIN NEUROPSYCHOL, V22, P1080, DOI 10.1080/13854040701796928; van Hout MSE, 2003, NEUROTOXICOLOGY, V24, P547, DOI 10.1016/S0161-813X(03)00054-8; Vickery CD, 2001, ARCH CLIN NEUROPSYCH, V16, P45, DOI 10.1016/S0887-6177(99)00058-X; White T., 2003, NEUROPSYCHOLOGICAL A; Whiteside DM, 2009, CLIN NEUROPSYCHOL, V23, P523, DOI 10.1080/13854040802389169; Whitney KA, 2008, ARCH CLIN NEUROPSYCH, V23, P777, DOI 10.1016/j.acn.2008.09.001; Wygant DB, 2007, ARCH CLIN NEUROPSYCH, V22, P489, DOI 10.1016/j.acn.2007.01.027	90	75	76	0	19	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2010	32	9					961	972	PII 921816386	10.1080/13803391003645657			12	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	676CU	WOS:000283888500006	20437284				2021-06-18	
J	Rosenbaum, AM; Arnett, PA				Rosenbaum, Aaron M.; Arnett, Peter A.			The development of a survey to examine knowledge about and attitudes toward concussion in high-school students	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Concussion survey; Survey validation; High-school athletes; Concussion attitudes; Concussion knowledge	COLLEGIATE FOOTBALL PLAYERS; CLUSTER-ANALYSIS; RECOVERY; RETURN; EPIDEMIOLOGY; ATHLETICS; INJURY; IMPACT	The development of a new measure of concussion knowledge and attitudes that is more comprehensive and psychometrically sound than previous measures is described. A group of high-school students (N = 529) completed the measure. The measure demonstrated fair to satisfactory test-retest reliability (knowledge items, r = .67; attitude items, r = .79). Exploratory factor analysis of the attitude items revealed a four-factor solution (eigenvalues ranged from 1.07-3.35) that displayed adequate internal consistency (Cohen's alpha range = .59-.72). Cluster analysis of the knowledge items resulted in a three-cluster solution distributed according to their level of difficulty. The potential uses for the measure are described.	[Rosenbaum, Aaron M.; Arnett, Peter A.] Penn State Univ, University Pk, PA 16802 USA	Rosenbaum, AM (corresponding author), Penn State Univ, 113 Moore Bldg, University Pk, PA 16802 USA.	amr262@psu.edu			Penn State University College of Liberal Arts Research and Graduate Studies Office; Pennsylvania State Education Association; Penn State University Department of Psychology	This study was part of the first author's doctoral dissertation, which was completed at Penn State University. It was partially funded by the Penn State University College of Liberal Arts Research and Graduate Studies Office, the Pennsylvania State Education Association, and the Penn State University Department of Psychology. The authors wish to thank the high schools and their administrators who participated in the project-especially Cathy Phillips at Peru High School. Finally, we would like to thank each of the undergraduate research assistants at Penn State University and Plattsburgh State University of New York for their dedication to this project.	American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Aukerman DF, 2006, SOUTH MED J, V99, P132, DOI 10.1097/01.smj.0000199749.22741.5e; Cantu RC, 1998, CLIN SPORT MED, V17, P45, DOI 10.1016/S0278-5919(05)70060-0; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P114; *CDC, 2005, HEADS CONC HIGH SCH; CONSTANTINE MG, 2006, PSYCHOL RES HDB; Crowne D.P., 1964, APPROVAL MOTIVE STUD; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Erdfelder E, 1996, BEHAV RES METH INS C, V28, P1, DOI 10.3758/BF03203630; Erlanger D, 2003, ARCH CLIN NEUROPSYCH, V18, P293, DOI 10.1016/S0887-6177(02)00138-5; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P331; Guilmette TJ, 2007, BRAIN INJURY, V21, P1039, DOI 10.1080/02699050701633080; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LIVINGSTON SC, 2004, J ATHL TRAINING, V39, pS17; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Lovell MR, 2004, STUD NEUROPSYCHOL DE, P209; Lovell MR, 2004, STUD NEUROPSYCHOL DE, P221; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; MCCREA M, 2008, MILD TRAUMATIC BRAIN, P159; McCrory Paul, 2005, Clin J Sport Med, V15, P48; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Olympia RP, 2007, PEDIATR EMERG CARE, V23, P703, DOI 10.1097/PEC.0b013e318155adfc; Pedhazur E.J., 1991, MEASUREMENT DESIGN A; REVELLE W, 1979, MULTIVAR BEHAV RES, V14, P57, DOI 10.1207/s15327906mbr1401_4; ROSENBAUM AM, 2007, THESIS PENNSYLVANIA; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; Sefton J, 2003, THESIS CENTRAL CONNE; SILVERSTEIN AB, 1974, MULTIVAR BEHAV RES, V9, P325, DOI 10.1207/s15327906mbr0903_7; Simonds C.B., 2004, DISS ABSTR INT B, V65, P3724; *SPSS INC, 2005, SPSS VERS 14 0 COMP; Stevens J.P., 2002, APPL MULTIVARIATE ST, V4th ed; Sye G, 2006, BRIT J SPORT MED, V40, P1003, DOI 10.1136/bjsm.2005.020511; Tabachnick B., 2001, USING MULTIVARIATE S; von Holst H, 2004, J REHABIL MED, V36, P8, DOI 10.1080/16501960410023633	43	75	76	0	15	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2010	32	1					44	55		10.1080/13803390902806535			12	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	550YJ	WOS:000274170400005	19381997				2021-06-18	
J	Jastrow, KM; Gonzalez, EA; McGuire, MF; Suliburk, JW; Kozar, RA; Iyengar, S; Motschall, DA; McKinley, BA; Moore, FA; Mercer, DW				Jastrow, Kenneth M., III; Gonzalez, Ernest A.; McGuire, Mary F.; Suliburk, James W.; Kozar, Rosemary A.; Iyengar, Sriram; Motschall, Deborah A.; McKinley, Bruce A.; Moore, Frederick A.; Mercer, David W.			Early Cytokine Production Risk Stratifies Trauma Patients for Multiple Organ Failure	JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS			English	Article							INTERFERON-INDUCIBLE PROTEIN-10; CHEMOKINE RECEPTORS; INFLAMMATORY RESPONSE; SHOCK RESUSCITATION; HEMORRHAGIC-SHOCK; SEVERE SEPSIS; PLASMA-LEVELS; EXPRESSION; PATTERNS; SEVERITY	BACKGROUND: Shock is a prime inciting event for postinjury multiple organ failure (MOF), believed to induce a state of injurious systemic inflammation. In animal models of hemorrhagic shock, early (< 24 hours) changes in cytokine production are an index of the systemic inflammatory response syndrome. However, their predictive value in trauma patients remains to be fully elucidated. STUDY DESIGN: In a prospective observational pilot study of > I year at an urban Level I trauma center, serial (every 4 hours) serum cytokine levels were determined during a 24-hour period using multiplex suspension immunoassay in patients with major torso trauma (excluding severe brain injury) who met criteria for standardized shock resuscitation. Temporal cytokine expression was assessed during shock resuscitation in severe trauma patients to predict risk for MOF. MOF was assessed with the Denver score. RESULTS: Of 48 study patients (mean age 39 +/- 3 years, 67% men, 88% blunt mechanism, mean Injury Severity Score 25 +/- 2), MOF developed in 11 (23%). MOF patients had a considerably higher mortality (64% versus 3%) and fewer ICU-free days (3.5 +/- 2 versus 17.8 +/- 1.3 days) compared with non-MOF patients. Traditional predictors of MOF, including age (45 +/- 7 versus 38 +/- 3 years; p = 0.21), Injury Severity Score (26 +/- 3 versus 25 +/- 2; p = 0.67), admission hemoglobin (11.4 +/- 0.9 versus 12.1 +/- 0.5 g/dL; p = 0.22), international normalized ratio (1.6 +/- 0.2 versus 1.4 +/- 0.06; p = 0.17), and base deficit (9.0 +/- 2 versus 7.1 +/- 0.8; p = 0.19), were not significantly different between MOF and non-MOF patients. Statistical analysis identified six candidate predictors of MOF: inducible protein 10, macrophage inflammatory protein-1 beta, interleukin-10, interleukin-6, interleukin-1Ra, and eotaxin. CONCLUSIONS: These data provide insight into cytokine expression during traumatic shock that can enable earlier identification of patients at risk for development of MOF. (J Am Coll Surg 2009;209: 320-331. (C) 2009 by the American College of Surgeons)	[Jastrow, Kenneth M., III; Gonzalez, Ernest A.; Suliburk, James W.; Kozar, Rosemary A.; Motschall, Deborah A.; Mercer, David W.] Univ Texas Med Sch Houston, Dept Surg, Houston, TX 77030 USA; [McGuire, Mary F.; Iyengar, Sriram] Univ Texas Sch Hlth Informat Sci Houston, Houston, TX USA; [McKinley, Bruce A.; Moore, Frederick A.] Methodist Hosp Syst, Dept Surg, Houston, TX USA	Mercer, DW (corresponding author), Univ Texas Med Sch Houston, Dept Surg, 6431 Fannin St,MSB 4-264, Houston, TX 77030 USA.	david.w.mercer@uth.tmc.edu		Suliburk, James/0000-0002-6421-269X	National Institute of General Medical SciencesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [GM-38529, GM-08792]; National Institutes of Health Clinical Research Feasibility Funds University Clinical Research CenterUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [M01RR002558]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR002558] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008792, P50GM038529] Funding Source: NIH RePORTER	Supported by National Institute of General Medical Sciences grant Nos. GM-38529 and GM-08792 and National Institutes of Health Clinical Research Feasibility Funds University Clinical Research Center grant No. M01RR002558.	ANGIOLILLO AL, 1995, J EXP MED, V182, P155, DOI 10.1084/jem.182.1.155; Asensio VC, 1999, TRENDS NEUROSCI, V22, P504, DOI 10.1016/S0166-2236(99)01453-8; Baue AE, 1998, SHOCK, V10, P79, DOI 10.1097/00024382-199808000-00001; Berney T, 1999, PANCREAS, V18, P371, DOI 10.1097/00006676-199905000-00007; Bozza FA, 2007, CRIT CARE, V11, DOI 10.1186/cc5783; BROXMEYER HE, 1991, J IMMUNOL, V147, P2586; Chow CC, 2005, SHOCK, V24, P74, DOI 10.1097/01.shk.0000168526.97716.f3; Ciesla DJ, 2005, ARCH SURG-CHICAGO, V140, P432, DOI 10.1001/archsurg.140.5.432; Gabuzda D, 2000, J NEUROVIROL, V6, pS24; Geppert A, 2002, CRIT CARE MED, V30, P1987, DOI 10.1097/00003246-200209000-00007; Glabinski AR, 1999, J NEUROVIROL, V5, P3, DOI 10.3109/13550289909029740; Gonzalez EA, 2007, J TRAUMA, V62, P112, DOI 10.1097/01.ta.0000250497.08101.8b; Hollander M, 1973, NONPARAMETRIC STAT I; Hynninen M, 2003, SHOCK, V20, P1, DOI 10.1097/01.shk.0000068322.08268.b4; Kanegane C, 1998, J LEUKOCYTE BIOL, V64, P384; Kellum JA, 2007, ARCH INTERN MED, V167, P1655, DOI 10.1001/archinte.167.15.1655; Livaditi O, 2006, CYTOKINE, V36, P283, DOI 10.1016/j.cyto.2007.02.007; LUSTER AD, 1985, NATURE, V315, P672, DOI 10.1038/315672a0; LUSTER AD, 1987, J EXP MED, V166, P1084, DOI 10.1084/jem.166.4.1084; Mahalingam S, 1999, J VIROL, V73, P1479, DOI 10.1128/JVI.73.2.1479-1491.1999; Maier B, 2007, SHOCK, V28, P668, DOI 10.1097/shk.0b013e318123e64e; Marr AB, 2004, SHOCK, V21, P300, DOI 10.1097/00024382-200404000-00002; Martin C, 1997, CRIT CARE MED, V25, P1813, DOI 10.1097/00003246-199711000-00018; McKinley BA, 2001, J TRAUMA, V50, P415, DOI 10.1097/00005373-200103000-00004; McKinley BA, 2002, J TRAUMA, V53, P825, DOI 10.1097/00005373-200211000-00004; Mennicken F, 1999, TRENDS PHARMACOL SCI, V20, P73, DOI 10.1016/S0165-6147(99)01308-5; MOORE FA, 1991, J TRAUMA, V31, P629, DOI 10.1097/00005373-199105000-00006; MYERS RD, 1993, NEUROCHEM RES, V18, P667, DOI 10.1007/BF00966780; Neidhardt R, 1997, J TRAUMA, V42, P863, DOI 10.1097/00005373-199705000-00017; Oberholzer A, 2005, SHOCK, V23, P488, DOI 10.1097/01.shk.0000163802.46355.59; Oberholzer A, 2000, CRIT CARE MED, V28, pN3, DOI 10.1097/00003246-200004001-00002; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; Rivers EP, 2007, CRIT CARE MED, V35, P2016, DOI 10.1097/01.CCM.0000281637.08984.6E; ROUMEN RMH, 1993, ANN SURG, V218, P769, DOI 10.1097/00000658-199312000-00011; SARRIS AH, 1993, J EXP MED, V178, P1127, DOI 10.1084/jem.178.3.1127; Sauaia A, 1996, WORLD J SURG, V20, P392, DOI 10.1007/s002689900062; Sauaia A, 2009, SHOCK, V31, P438, DOI 10.1097/SHK.0b013e31818ba4c6; Stewart RM, 2007, J TRAUMA, V62, pS47, DOI 10.1097/TA.0b013e31806546ab; STRIETER RM, 1995, BIOCHEM BIOPH RES CO, V210, P51, DOI 10.1006/bbrc.1995.1626; Ulvik A, 2007, CRIT CARE, V11, DOI 10.1186/cc6111; Wunder C, 2004, INFLAMM RES, V53, P158, DOI 10.1007/s00011-003-1239-3; Yamada Y, 1996, BURNS, V22, P587, DOI 10.1016/S0305-4179(96)00052-6	42	75	80	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1072-7515	1879-1190		J AM COLL SURGEONS	J. Am. Coll. Surg.	SEP	2009	209	3					320	331		10.1016/j.jamcollsurg.2009.05.002			12	Surgery	Surgery	493RH	WOS:000269755100006	19717036				2021-06-18	
J	Fear, NT; Jones, E; Groom, M; Greenberg, N; Hull, L; Hodgetts, TJ; Wessely, S				Fear, N. T.; Jones, E.; Groom, M.; Greenberg, N.; Hull, L.; Hodgetts, T. J.; Wessely, S.			Symptoms of post-concussional syndrome are non-specifically related to mild traumatic brain injury in UK Armed Forces personnel on return from deployment in Iraq: an analysis of self-reported data	PSYCHOLOGICAL MEDICINE			English	Article						Deployment; mild traumatic brain injury; military personnel; post-concussional syndrome; self-reported data	HEALTH SURVEY SF-36; SOMATIC SYMPTOMS; WAR; VALIDITY; DISORDER; FATIGUE	Background. Mild traumatic brain injury (mTBI) is being claimed as the 'signature' injury of the Iraq war, and is believed to be the cause of long-term symptomatic ill health (post-concussional syndrome; PCS) in an unknown proportion of military personnel. Method. We analysed cross-sectional data from a large, randomly selected cohort of UK military personnel deployed to Iraq (n=5869). Two markers of PCS were generated: 'PCS symptoms' (indicating the presence of mTBI-related symptoms: none, 1-2, 3+) and 'PCS symptom severity' (indicating the presence of mTBI-related symptoms at either a moderate or severe level of severity: none, 1-2, 3+). Results. PCS symptoms and PCS symptom severity were associated with self-reported exposure to blast whilst in a combat zone. However, the same symptoms were also associated with other in-theatre exposures such as potential exposure to depleted uranium and aiding the wounded. Strong associations were apparent between having PCS symptoms and other health outcomes, in particular being a post-traumatic stress disorder or General Health Questionnaire case. Conclusions. PCS symptoms are common and some are related to exposures such as blast injury. However, this association is not specific, and the same symptom complex is also related to numerous other risk factors and exposures. Post-deployment screening for PCS and/or mTBI in the absence of contemporaneous recording of exposure is likely to be fraught with hazards.	[Fear, N. T.; Greenberg, N.] Kings Coll London, Acad Ctr Def Mental Hlth, London WC2R 2LS, England; [Jones, E.; Hull, L.; Wessely, S.] Kings Coll London, Kings Ctr Mil Hlth Res, London WC2R 2LS, England; [Groom, M.] Minist Def, Def Med Serv, London, England; [Hodgetts, T. J.] Minist Def, Royal Coll Def Med, Birmingham, W Midlands, England	Fear, NT (corresponding author), Kings Coll London, Weston Educ Ctr, Ctr Def Mental Hlth, 10 Cutcombe Rd, London SE5 9RJ, England.	nicola.fear@iop.kcl.ac.uk	Wessely, Simon C/A-8713-2008; Fear, Nicola/A-1917-2012	Fear, Nicola/0000-0002-5792-2925; greenberg, neil/0000-0003-4550-2971; Jones, Edgar/0000-0002-4610-9584; Wessely, Simon Charles/0000-0002-6743-9929	UK Ministry of Defence	N.T.F. and E.J. are supported by grants from the UK Ministry of Defence. M.G. and T.H. are full-time active service medical officers who have collaborated with the authors on this piece of work. N.G. is a full-time active service medical officer who has been seconded to the ACDMH, although paid from Ministry of Defence funds they were not directed in any way by the Ministry of Defence in relation to this publication. S. W. is Honorary Civilian Consultant Advisor to the British Army.	Babor TF., 2001, AUDIT ALCOHOL USE DI, V2nd; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Breslow N.E., 1980, STAT METHODS CANC RE, V1; CHALDER T, 1993, J PSYCHOSOM RES, V37, P147, DOI 10.1016/0022-3999(93)90081-P; *DEP VET AFF VET H, 2007, VHA DIR 2007 013 SCR; Fear NT, 2007, ADDICTION, V102, P1749, DOI 10.1111/j.1360-0443.2007.01978.x; Goldberg D, 1988, USERS GUIDE GEN HLTH; Goldberg DP, 1997, PSYCHOL MED, V27, P191, DOI 10.1017/S0033291796004242; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2007, AM J PSYCHIAT, V164, P150, DOI 10.1176/appi.ajp.164.1.150; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Hotopf M, 2006, LANCET, V367, P1731, DOI 10.1016/S0140-6736(06)68662-5; Iversen A, 2006, BRIT MED J, V332, P165, DOI 10.1136/bmj.332.7534.165; Jones E, 2007, AM J PSYCHIAT, V164, P1641, DOI 10.1176/appi.ajp.2007.07071180; Kashluba S, 2006, J INT NEUROPSYCH SOC, V12, P111, DOI 10.1017/S1355617706060036; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Simon GE, 1999, NEW ENGL J MED, V341, P1329, DOI 10.1056/NEJM199910283411801; Tate AR, 2007, BMC MED RES METHODOL, V7, DOI 10.1186/1471-2288-7-51; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Wessely S, 1996, AM J PSYCHIAT, V153, P1050; Wessely S, 2003, BRIT J PSYCHIAT, V183, P314, DOI 10.1192/bjp.183.4.314; World Health Organization, 1992, ICD 10 CLASS MENT BE	24	75	75	1	10	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	0033-2917	1469-8978		PSYCHOL MED	Psychol. Med.	AUG	2009	39	8					1379	1387		10.1017/S0033291708004595			9	Psychology, Clinical; Psychiatry; Psychology	Psychology; Psychiatry	472XC	WOS:000268165300016	18945380				2021-06-18	
J	Greve, KW; Ord, JS; Bianchini, KJ; Curtis, KL				Greve, Kevin W.; Ord, Jonathan S.; Bianchini, Kevin J.; Curtis, Kelly L.			Prevalence of Malingering in Patients With Chronic Pain Referred for Psychologic Evaluation in a Medico-Legal Context	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	35th Annual Meeting of the International-Neuropsychological-Society	FEB 07-10, 2007	Portland, OR	Int Neuropsychol Soc		Chronic disease; Malingering; Pain; Prevalence; Rehabilitation	TRAUMATIC BRAIN-INJURY; VERBAL-LEARNING TEST; NEUROCOGNITIVE DYSFUNCTION; BASE RATES; NEUROPSYCHOLOGICAL EVALUATION; CLASSIFICATION ACCURACY; BELIEVABLE DEFICITS; ACCIDENT NEUROSIS; RESPONSE BIAS; DISABILITY	Prevalence of malingering in patients with chronic pain referred for psychologic evaluation in a medico-legal context. Objective: To provide an empirical estimate of the prevalence of malingered disability in patients with chronic pain who have financial incentive to appear disabled. Design: Retrospective review of cases. Setting: A private neuropsychologic clinic in a southeastern metropolitan area. Participants: Consecutive patients (N=508) referred for psychologic evaluation related to chronic pain over a 10-year period (1995-2005). Interventions: Not applicable. Main Outcome Measures: Prevalence of malingering was examined using 2 published clinical diagnostic systems (Malingered Pain-Related Disability and Malingered Neurocognitive Dysfunction) as well as statistical estimates based on well validated indicators of malingering. Results: The prevalence of malingering in patients with chronic pain with financial incentive is between 20% and 50% depending on the diagnostic system used and the statistical model's underlying assumptions. Some factors associated with the medico-legal context such as the jurisdiction of a workers' compensation claim or attorney representation were associated with slightly higher malingering rates. Conclusions: Malingering is present in a sizable minority of patients with pain seen for potentially compensable injuries. However, not all excess pain-related disability is a result of malingering. It is important not to diagnose malingering reflexively on the basis of limited or unreliable findings. A diagnosis of malingering should be explicitly based on a formal diagnostic system.	[Greve, Kevin W.; Ord, Jonathan S.; Bianchini, Kevin J.; Curtis, Kelly L.] Univ New Orleans, Dept Psychol, New Orleans, LA 70148 USA; [Greve, Kevin W.; Bianchini, Kevin J.] Jefferson Neurobehav Grp, Metairie, LA USA	Greve, KW (corresponding author), Univ New Orleans Lakefront, Dept Psychol, New Orleans, LA 70148 USA.	kgreve@uno.edu					Allum JHJ, 1999, J VESTIBUL RES-EQUIL, V9, P223; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Ardolf BR, 2007, CLIN NEUROPSYCHOL, V21, P899, DOI 10.1080/13825580600966391; Artuso A, 2004, Acta Otorhinolaryngol Ital, V24, P8; Bianchini Kevin J, 2005, Spine J, V5, P404, DOI 10.1016/j.spinee.2004.11.016; BINDER LM, 1993, J CLIN EXP NEUROPSYC, V15, P170, DOI 10.1080/01688639308402555; BINDER LM, 1993, PORTLAND DIGIT RECOG; Block A R, 2001, Spine J, V1, P274, DOI 10.1016/S1529-9430(01)00054-7; Block AR, 2003, PSYCHOL SPINE SURG; Bond CF, 2006, PERS SOC PSYCHOL REV, V10, P214, DOI 10.1207/s15327957pspr1003_2; Boone, 2007, ASSESSMENT FEIGNED C; Butcher J. N., 1989, MMPI 2 MANUAL ADM SC; Chafetz MD, 2008, CLIN NEUROPSYCHOL, V22, P529, DOI 10.1080/13854040701346104; Curtis KL, 2006, ASSESSMENT, V13, P46, DOI 10.1177/1073191105285210; DELIS D, 1987, CALIFORNIA VERBAL LE; DELIS DC, 2000, CALIFORNIA VERBAL LE; Etherton Joseph L, 2006, Spine J, V6, P61, DOI 10.1016/j.spinee.2005.05.382; Etherton JL, 2006, J CLIN EXP NEUROPSYC, V28, P1218, DOI 10.1080/13803390500346595; FAUST D, 1988, J CONSULT CLIN PSYCH, V56, P578, DOI 10.1037/0022-006X.56.4.578; FAUST D, 1995, NEUROL CLIN, V13, P255; Fink P, 2005, PSYCHOSOMATICS, V46, P540, DOI 10.1176/appi.psy.46.6.540; Fink P, 2005, AUST NZ J PSYCHIAT, V39, P772, DOI 10.1111/j.1440-1614.2005.01682.x; Fishbain DA, 1999, CLIN J PAIN, V15, P244, DOI 10.1097/00002508-199912000-00002; Gatchel RJ, 1999, NEUROL CLIN, V17, P149, DOI 10.1016/S0733-8619(05)70119-5; Gianoli G, 2000, OTOLARYNG HEAD NECK, V122, P11, DOI 10.1016/S0194-5998(00)70137-9; Green P., 2005, GREENS WORD MEMORY T; Greiffenstein M F, 1996, J Int Neuropsychol Soc, V2, P477; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; GREIFFENSTEIN MF, 2007, ASSESSMENT FEIGNED C; Greve KW, 2006, NEUROTOXICOLOGY, V27, P940, DOI 10.1016/j.neuro.2006.06.009; Greve KW, 2006, J CLIN EXP NEUROPSYC, V28, P1176, DOI 10.1080/13803390500263550; Greve KW, 2006, CLIN NEUROPSYCHOL, V20, P491, DOI 10.1080/13854040590967144; Grevitt M, 1998, Eur Spine J, V7, P218, DOI 10.1007/s005860050059; HEATON RK, 1978, J CONSULT CLIN PSYCH, V46, P892, DOI 10.1037/0022-006X.46.5.892; Heinly MT, 2005, ASSESSMENT, V12, P429, DOI 10.1177/1073191105281099; Hennekens CH, 1987, EPIDEMIOLOGY MED; Kay NRM, 1998, INJURY, V29, P305, DOI 10.1016/S0020-1383(97)00207-6; Larrabee G.J., 2007, ASSESSMENT MALINGERE; LARRABEE GJ, 2005, FORENSIC NEUROPSYCHO, P115; LEAVITT F, 1986, PAIN, V25, P357, DOI 10.1016/0304-3959(86)90239-3; Linton SJ, 2000, SPINE, V25, P1148, DOI 10.1097/00007632-200005010-00017; Mallinson AI, 2005, OTOL NEUROTOL, V26, P686, DOI 10.1097/01.mao.0000169639.48193.fb; MEEHL PE, 1955, PSYCHOL BULL, V52, P194, DOI 10.1037/h0048070; Meyers JE, 2002, ARCH CLIN NEUROPSYCH, V17, P157, DOI 10.1016/S0887-6177(00)00107-4; MILLER H, 1961, BRIT MED J, V1, P919, DOI 10.1136/bmj.1.5230.919; MILLER H, 1961, BRIT MED J, V1, P992, DOI 10.1136/bmj.1.5231.992; Millis S. R., 2004, PRINCIPLES PRACTICE, P1077; Millis SR, 1995, PSYCHOL ASSESSMENT, V7, P463; Millis SR, 2001, J CLIN EXP NEUROPSYC, V23, P809, DOI 10.1076/jcen.23.6.809.1017; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; PARK SS, 1988, AM REV RESPIR DIS, V138, P1002, DOI 10.1164/ajrccm/138.4.1002; Schapmire D, 2002, J Hand Ther, V15, P242; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Stevens A, 2008, PSYCHIAT RES, V157, P191, DOI 10.1016/j.psychres.2007.01.003; Straus SE., 2005, EVIDENCE BASED MED P, V3rd; Tombaugh TN, 1996, TEST MEMORY MALINGER; Wechsler D, 1997, WAIS 3 ADM SCORING M	57	75	78	0	8	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUL	2009	90	7					1117	1126		10.1016/j.apmr.2009.01.018			10	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	470SA	WOS:000267999000007	19577024				2021-06-18	
J	Lo, TP; Cho, KS; Garg, MS; Lynch, MP; Marcillo, AE; Koivisto, DL; Stagg, M; Abril, RM; Patel, S; Dietrich, WD; Pearse, DD				Lo, Thomas Pang, Jr.; Cho, Kyoung-Suok; Garg, Maneesh Sen; Lynch, Michael Patrick; Marcillo, Alexander Eduardo; Koivisto, Denise Leigh; Stagg, Monica; Abril, Rosa Marie; Patel, Samik; Dietrich, W. Dalton; Pearse, Damien Daniel			Systemic Hypothermia Improves Histological and Functional Outcome After Cervical Spinal Cord Contusion in Rats	JOURNAL OF COMPARATIVE NEUROLOGY			English	Article						neuroprotection; spinal cord injury; cooling; axon sparing; tissue loss; reticulospinal; forelimb function	TRAUMATIC BRAIN-INJURY; ORTHOGRADE AXONAL-TRANSPORT; OLFACTORY ENSHEATHING GLIA; AMINO-ACID RELEASE; POSTTRAUMATIC HYPOTHERMIA; HISTOPATHOLOGICAL DAMAGE; SCHWANN-CELLS; BLOOD-FLOW; INFLAMMATORY RESPONSE; ISCHEMIA-REPERFUSION	Hypothermia has been employed during the past 30 years as a therapeutic modality for spinal cord injury (SCI) in animal models and in humans. With our newly developed rat cervical model of contusive SCI, we investigated the therapeutic efficacy of transient systemic hypothermia (beginning 5 minutes post-injury for 4 hours, 33 degrees C) with gradual rewarming (1 degrees C per hour) for the preservation of tissue and the prevention of injury-induced functional loss. A moderate cervical displacement SCI was performed in female Fischer rats, and behavior was assessed for 8 weeks. Histologically, the application of hypothermia after SCI resulted in significant increases in normal-appearing white matter (31% increase) and gray matter (38% increase) volumes, greater preservation (four-fold) of neurons immediately rostral and caudal to the injury epicenter, and enhanced sparing of axonal connections from retrogradely traced reticulospinal neurons (127% increase) compared with normothermic controls. Functionally, a faster rate of recovery in open field locomotor ability (BBB score, weeks 1-3) and improved forelimb strength, as measured by both weight-supported hanging (43% increase) and grip strength (25% increase), were obtained after hypothermia. The current study demonstrates that mild systemic hypothermia is effective for retarding tissue damage and reducing neurological deficits following a clinically relevant contusive cervical SCI. J. Comp. Neurol. 514:433-448, 2009. (C) 2009 Wiley-Liss, Inc.	[Pearse, Damien Daniel] Univ Miami, Miller Sch Med, Lois Pope Life Ctr, Miami Project Cure Paralysis, Miami, FL 33101 USA; [Cho, Kyoung-Suok] Catholic Univ Med Coll, Uijongbu St Marys Hosp, Seoul 480130, South Korea; [Dietrich, W. Dalton] Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33101 USA; [Dietrich, W. Dalton; Pearse, Damien Daniel] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami, FL 33101 USA; [Dietrich, W. Dalton] Univ Miami, Miller Sch Med, Dept Cell Biol & Anat, Miami, FL 33101 USA	Pearse, DD (corresponding author), Univ Miami, Miller Sch Med, Lois Pope Life Ctr, Miami Project Cure Paralysis, Locator Code R-48,POB 016960, Miami, FL 33101 USA.	dpearse@miamiproject.med.miami.edu	Pearse, Damien D/D-3176-2011	Pearse, Damien D/0000-0003-1783-221X	Miami Project to Cure Paralysis; Buoniconti Fund; Paralysis Project of America; State of Florida; U.S. Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [W81XWH-05-1-006]	Grant sponsor: The Miami Project to Cure Paralysis; Grant sponsor: The Buoniconti Fund; Grant sponsor: The Paralysis Project of America; Grant sponsor: State of Florida; Grant sponsor: U.S. Army Medical Research and Materiel Command; Grant number: W81XWH-05-1-006.	ABERCROMBIE M, 1946, ANAT REC, V94, P239, DOI 10.1002/ar.1090940210; AKRIOTIS V, 1985, J LEUKOCYTE BIOL, V37, P51; ALBIN MS, 1967, ANESTH ANAL CURR RES, V46, P8; Albin MS, 2000, ANESTHESIOLOGY, V92, P281, DOI 10.1097/00000542-200001000-00048; Amar AP, 1999, NEUROSURGERY, V44, P1027, DOI 10.1097/00006123-199905000-00052; Barakat DJ, 2005, CELL TRANSPLANT, V14, P225, DOI 10.3727/000000005783983106; Basso DM, 2002, RESTOR NEUROL NEUROS, V20, P189; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; BERNTMAN L, 1981, ANESTHESIOLOGY, V55, P495, DOI 10.1097/00000542-198111000-00003; BIGGAR WD, 1984, INFECT IMMUN, V46, P857, DOI 10.1128/IAI.46.3.857-859.1984; BRACKEN MB, 1993, J NEUROSURG, V79, P500, DOI 10.3171/jns.1993.79.4.0500; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Bricolo A, 1976, Surg Neurol, V6, P101; BUSTO R, 1989, NEUROSCI LETT, V101, P299, DOI 10.1016/0304-3940(89)90549-1; Chatzipanteli K, 2000, J NEUROTRAUM, V17, P321, DOI 10.1089/neu.2000.17.321; Chatzipanteli K, 2000, J CEREBR BLOOD F MET, V20, P531, DOI 10.1097/00004647-200003000-00012; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Diener PS, 1998, J NEUROSCI, V18, P763; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; Dimar JR, 2000, SPINE, V25, P2294, DOI 10.1097/00007632-200009150-00006; DOLAN EJ, 1982, J NEUROSURG, V53, P350; Donnelly DJ, 2008, EXP NEUROL, V209, P378, DOI 10.1016/j.expneurol.2007.06.009; DREW T, 1990, J NEUROPHYSIOL, V64, P767; Eng LF, 2000, NEUROCHEM RES, V25, P1439, DOI 10.1023/A:1007677003387; Faden AI, 2007, ARCH NEUROL-CHICAGO, V64, P794, DOI 10.1001/archneur.64.6.794; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; Hall Edward D, 2004, NeuroRx, V1, P80, DOI 10.1602/neurorx.1.1.80; Ho CH, 2007, ARCH PHYS MED REHAB, V88, pS49, DOI 10.1016/j.apmr.2006.12.001; Inamasu J, 2003, J NEUROL SCI, V209, P55, DOI 10.1016/S0022-510X(02)00463-X; Inamasu J, 2002, ANN EMERG MED, V40, P220, DOI 10.1067/mem.2002.123697; Ishikawa T, 1999, CELL MOL NEUROBIOL, V19, P199, DOI 10.1023/A:1006973026514; Jakeman LB, 2000, J NEUROTRAUM, V17, P299, DOI 10.1089/neu.2000.17.299; JASSEN L, 1989, SPINE, V14, P23; Kakinohana M, 1999, ANESTHESIOLOGY, V90, P789, DOI 10.1097/00000542-199903000-00022; KIDA Y, 1994, SPINE, V19, P341, DOI 10.1097/00007632-199402000-00015; Kil HY, 1996, J CEREBR BLOOD F MET, V16, P100, DOI 10.1097/00004647-199601000-00012; Kilpatrick MM, 2000, NEUROSURGERY, V47, P850, DOI 10.1097/00006123-200010000-00011; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; KOONS D D, 1972, Cleveland Clinic Quarterly, V39, P109; Kuchner E F, 1976, Surg Neurol, V6, P371; LEWIN M, 1972, EFFECTS STEROIDS EDE, P101; Marsala M, 1997, J NEUROSCI METH, V74, P97, DOI 10.1016/S0165-0270(97)02270-X; MARSALA M, 1994, STROKE, V25, P2038, DOI 10.1161/01.STR.25.10.2038; MARSALA M, 1994, J CEREBR BLOOD F MET, V14, P604, DOI 10.1038/jcbfm.1994.75; MARTINEZARIZALA A, 1992, J NEUROTRAUM, V9, pS497; Matsushita Y, 2001, CRIT CARE MED, V29, P2060, DOI 10.1097/00003246-200111000-00004; McKenna JE, 1999, J NEUROSCI, V19, P1885; McKenna JE, 2000, J COMP NEUROL, V419, P286, DOI 10.1002/(SICI)1096-9861(20000410)419:3<286::AID-CNE2>3.0.CO;2-3; Meyer O A, 1979, Neurobehav Toxicol, V1, P233; MINAMISAWA H, 1990, J CEREBR BLOOD F MET, V10, P365, DOI 10.1038/jcbfm.1990.66; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; Nakashima K, 1996, STROKE, V27, P913, DOI 10.1161/01.STR.27.5.913; PADILLA S, 1986, J NEUROCHEM, V46, P1227, DOI 10.1111/j.1471-4159.1986.tb00642.x; PAXINOS G, 1998, RAT BRAIN STEREOTAXI; Pearse D, 2001, BRAIN RES, V894, P193, DOI 10.1016/S0006-8993(01)01993-X; Pearse DD, 2007, GLIA, V55, P976, DOI 10.1002/glia.20490; Pearse DD, 2005, J NEUROTRAUM, V22, P680, DOI 10.1089/neu.2005.22.680; Pearse DD, 2004, J NEUROTRAUM, V21, P1223, DOI 10.1089/0897715041953876; Pearse DD, 2004, NAT MED, V10, P610, DOI 10.1038/nm1056; Pearse DD, 2003, J NEUROPATH EXP NEUR, V62, P1096, DOI 10.1093/jnen/62.11.1096; PETERSON BW, 1979, EXP BRAIN RES, V36, P1; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; ROBERTSON CS, 1986, J NEUROSURG, V64, P633, DOI 10.3171/jns.1986.64.4.0633; ROKKAS CK, 1995, J THORAC CARDIOV SUR, V110, P27, DOI 10.1016/S0022-5223(05)80006-6; Schaal SM, 2007, CELL TRANSPLANT, V16, P207, DOI 10.3727/000000007783464768; Schallert T, 2000, NEUROPHARMACOLOGY, V39, P777, DOI 10.1016/S0028-3908(00)00005-8; SCHRIMSHER GW, 1993, EXP NEUROL, V120, P264, DOI 10.1006/exnr.1993.1060; SCHRIMSHER GW, 1992, EXP NEUROL, V117, P287, DOI 10.1016/0014-4886(92)90138-G; Schwab ME, 1996, PHYSIOL REV, V76, P319; Shibuya S, 2004, SPINAL CORD, V42, P29, DOI 10.1038/sj.sc.3101516; SIEMIONOW M, 1993, J HAND SURG-AM, V18A, P963, DOI 10.1016/0363-5023(93)90384-F; Sipski ML, 2006, NAT CLIN PRACT NEURO, V2, P402, DOI 10.1038/ncpneuro0221; Suehiro E, 2001, J NEUROSURG, V94, P493, DOI 10.3171/jns.2001.94.3.0493; TOMLINSON DR, 1984, MED BIOL, V62, P34; Truettner JS, 2005, MOL BRAIN RES, V138, P124, DOI 10.1016/j.molbrainres.2005.04.006; WEST NR, 1989, J NEUROPATH EXP NEUR, V48, P94, DOI 10.1097/00005072-198901000-00008; Westergren H, 2000, ACTA NEUROCHIR, V142, P567, DOI 10.1007/s007010050471; Westergren H, 1999, SPINAL CORD, V37, P696, DOI 10.1038/sj.sc.3100920; Westergren H, 2001, SPINAL CORD, V39, P74, DOI 10.1038/sj.sc.3101127; WHITELEY SJ, 1985, DIABETOLOGIA, V28, P847, DOI 10.1007/BF00291076; Wolf HK, 1996, J HISTOCHEM CYTOCHEM, V44, P1167, DOI 10.1177/44.10.8813082; XU XM, 1995, J COMP NEUROL, V351, P145, DOI 10.1002/cne.903510113; Yenari MA, 2006, NEUROCHEM INT, V49, P164, DOI 10.1016/j.neuint.2006.03.016; Yu C. G., 1999, Society for Neuroscience Abstracts, V25, P1443; Yu CG, 2000, J NEUROSURG, V93, P85, DOI 10.3171/spi.2000.93.1.0085	86	75	76	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0021-9967	1096-9861		J COMP NEUROL	J. Comp. Neurol.	JUN 10	2009	514	5					433	448		10.1002/cne.22014			16	Neurosciences; Zoology	Neurosciences & Neurology; Zoology	437RK	WOS:000265504400002	19350644				2021-06-18	
J	Ge, YL; Patel, MB; Chen, Q; Grossman, EJ; Zhang, K; Miles, L; Babb, JS; Reaume, J; Grossman, RI				Ge, Yulin; Patel, Mayur B.; Chen, Qun; Grossman, Elan J.; Zhang, Ke; Miles, Laura; Babb, James S.; Reaume, Joseph; Grossman, Robert I.			Assessment of thalamic perfusion in patients with mild traumatic brain injury by true FISP arterial spin labelling MR imaging at 3T	BRAIN INJURY			English	Article						Mild traumatic brain injury; cerebral blood flow; ischemia; thalamus; magnetic resonance imaging; arterial spin labelling	CEREBRAL-BLOOD-FLOW; CONTROLLED CORTICAL IMPACT; HEAD-INJURY; RATS; ABNORMALITIES; DEFICITS; MODEL	Objective: To assess cerebral blood flow (CBF) changes in patients with mild traumatic brain injury (MTBI) using an arterial spin labelling (ASL) perfusion MRI and to investigate the severity of neuropsychological functional impairment with respect to haemodynamic changes. Materials and methods: Twenty-one patients with MTBI and 20 healthy controls were studied at 3T MR. The median time since the onset of brain injury in patients was 24.6 months. Both patients and controls underwent a traditional consensus battery of neurocognitive tests. ASL was performed using true fast imaging with steady state precession and a flow-sensitive alternating inversion recovery preparation. Regional CBF were measured in both deep and cortical gray matter as well as white matter at the level of basal ganglia. Results: The mean regional CBF was significantly lower in patients with MTBI (45.9 +/- 9.8 ml/100 g min-1) as compared to normal controls (57.1 +/- 8.1 ml/100 g min-1; p = 0.002) in both sides of thalamus. The decrease of thalamic CBF was significantly correlated with several neurocognitive measures including processing and response speed, memory/learning, verbal fluency and executive function in patients. Conclusions: Haemodynamic impairment can occur and persist in patients with MTBI, the extent of which is more severe in thalamic regions and correlate with neurocognitive dysfunction during the extended course of disease.	[Ge, Yulin; Patel, Mayur B.; Chen, Qun; Grossman, Elan J.; Zhang, Ke; Miles, Laura; Babb, James S.; Reaume, Joseph; Grossman, Robert I.] NYU, Sch Med, Ctr Biomed Imaging, Dept Radiol, New York, NY 10016 USA	Ge, YL (corresponding author), NYU, Sch Med, Ctr Biomed Imaging, Dept Radiol, 650 1St Ave,6th Floor,Rm 615, New York, NY 10016 USA.	yulin.ge@med.nyu.edu	Ge, Yulin/D-9060-2019; Ge, Yulin/L-7052-2019	Ge, Yulin/0000-0002-2320-6031; Babb, James/0000-0003-1798-1186	National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [2R01NS039135-06A1, 5R01HL069023-04]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL069023] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039135] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health (NIH) grant numbers 2R01NS039135-06A1 and 5R01HL069023-04.	Abdel-Dayem HM, 1998, CLIN NUCL MED, V23, P309, DOI 10.1097/00003072-199805000-00009; Bonne O, 2003, PSYCHIAT RES-NEUROIM, V124, P141, DOI 10.1016/S0925-4927(03)00109-4; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; Bramlett HM, 1999, J NEUROTRAUM, V16, P1035, DOI 10.1089/neu.1999.16.1035; BROWN SJ, 1994, J NEUROPSYCH CLIN N, V6, P15; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; Buxton RB, 1998, MAGNET RESON MED, V40, P383, DOI 10.1002/mrm.1910400308; Coles Jonathan P, 2004, Curr Opin Crit Care, V10, P120, DOI 10.1097/00075198-200404000-00008; Dietrich WD, 1996, J CEREBR BLOOD F MET, V16, P481, DOI 10.1097/00004647-199605000-00015; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Erlanger DM, 2002, J HEAD TRAUMA REHAB, V17, P458, DOI 10.1097/00001199-200210000-00007; Forbes ML, 1997, J CEREBR BLOOD F MET, V17, P865, DOI 10.1097/00004647-199708000-00005; Forbes ML, 1997, J CEREBR BLOOD F MET, V17, P1263; GROSSMAN E, 2007, MEASUREMENT DEEP GRA; Ichimi K, 1999, NEUROL RES, V21, P579, DOI 10.1080/01616412.1999.11740980; JANE JA, 1985, J NEUROSURG, V62, P96, DOI 10.3171/jns.1985.62.1.0096; KIM SG, 1995, MAGNET RESON MED, V34, P293, DOI 10.1002/mrm.1910340303; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Kochanek PM, 2002, J NEUROTRAUM, V19, P1029, DOI 10.1089/089771502760341947; Kushner D, 1998, ARCH INTERN MED, V158, P1617, DOI 10.1001/archinte.158.15.1617; KWONG KK, 1995, MAGNET RESON MED, V34, P878, DOI 10.1002/mrm.1910340613; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Martirosian P, 2004, MAGNET RESON MED, V51, P353, DOI 10.1002/mrm.10709; Nakamizo A, 2002, J CLIN NEUROSCI, V9, P685, DOI 10.1054/jocn.2002.1146; Natale JE, 2002, NEUROSCIENCE, V112, P665, DOI 10.1016/S0306-4522(02)00098-2; OLEARY DDM, 1994, ANNU REV NEUROSCI, V17, P419, DOI 10.1146/annurev.ne.17.030194.002223; Rath JF, 2004, ARCH CLIN NEUROPSYCH, V19, P613, DOI 10.1016/j.acn.2003.08.006; ROSS DT, 1993, J NEUROTRAUM, V10, P151, DOI 10.1089/neu.1993.10.151; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Salmond CH, 2005, BRAIN, V128, P189, DOI 10.1093/brain/awh352; Shim YS, 2008, J NEUROL SCI, V266, P84, DOI 10.1016/j.jns.2007.09.016; Steriade M, 1997, THALAMUS; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Van der Werf YD, 2000, NEUROPSYCHOLOGIA, V38, P613, DOI 10.1016/S0028-3932(99)00104-9; WEISKOFF R, 1992, MAGNETIC RESONANCE I, P125; Yang YH, 1998, MAGNET RESON MED, V39, P825, DOI 10.1002/mrm.1910390520	37	75	78	0	17	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2009	23	7-8					666	674	PII 912685630	10.1080/02699050903014899			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	462QL	WOS:000267370600011	19557570	Green Accepted			2021-06-18	
J	Menon, DK				Menon, David K.			Unique challenges in clinical trials in traumatic brain injury	CRITICAL CARE MEDICINE			English	Article						clinical trials; research ethics in unconscious subjects; traumatic brain injury; outcome prediction; neuroprotection; neurocritical care	SEVERE HEAD-INJURY; THERAPEUTIC HYPOTHERMIA; CEREBRAL-ISCHEMIA; CONSENT; CARE; MANAGEMENT; GUIDELINES; PRESSURE; EFFICACY; QUALITY	Clinical trials in traumatic brain injury have shown little success in providing an evidence base for the introduction of successful new therapies into clinical practice. In addition to the problems that are common to all such studies in critical illness, trials in traumatic brain injury are complicated by the extremely short temporal window for intervention, failure of many candidate drugs to cross the blood-brain barrier, ethical and regulatory obstacles associated with research in subjects who cannot provide consent, the tendency to use small sample sizes in anticipation of unrealistic treatment benefits, and difficulty in translating experimental success into clinical practice. This article reviews the potential causes of these problems and suggests some solutions. These include the changes in regulatory frame-works that are making waived consent an acceptable strategy once more, and an increasing trend toward appropriately large trials. Other encouraging developments include the increasing use of human experimental medicine strategies before phase III trials to assess blood-brain barrier penetration and dose ranging, and provide proof of concept and proof of mechanism. Novel approaches to trial design, such as sliding dichotomy, coupled with robust outcome prediction models, can increase statistical power and improve trial design. (Crit Care Med 2009; 37[Suppl.]:S129-S135)	Univ Cambridge, Addenbrookes Hosp, Div Anaesthesia, Cambridge CB2 2QQ, England	Menon, DK (corresponding author), Univ Cambridge, Addenbrookes Hosp, Div Anaesthesia, Cambridge CB2 2QQ, England.	dkm13@wbic.cam.ac.uk			Medical Research Council, UKUK Research & Innovation (UKRI)Medical Research Council UK (MRC); British Oxygen Professorship of the Royal College of Anaesthetists, UK; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0600986, G9439390, G0001237] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0508-10327] Funding Source: researchfish	These studies were supported by a grant from the Medical Research Council, UK and the British Oxygen Professorship of the Royal College of Anaesthetists, UK.	[Anonymous], 2008, BMJ-BRIT MED J, V336, P425, DOI DOI 10.1136/bmj.39461.643438.25; BARER D, 1998, CEREBROVASC DIS, V8, P47; Booth MG, 2005, EUR J ANAESTH, V22, P933, DOI 10.1017/S0265021505001596; *BRAIN TRAUM FDN A, 2000, MAN PROGN SEV TRAU 1; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Chesnut RM, 2002, CRIT CARE MED, V30, P1927, DOI 10.1097/00003246-200208000-00055; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Clifton GL, 2002, J NEUROTRAUM, V19, P1121, DOI 10.1089/08977150260337930; Clifton GL, 2001, J NEUROSURG, V95, P751, DOI 10.3171/jns.2001.95.5.0751; Coles JP, 2004, BRAIN, V127, P2479, DOI 10.1093/brain/awh268; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P202, DOI 10.1097/01.WCB.0000103022.98348.24; Contant C, 2006, CRIT CARE MED, V34, P2049, DOI 10.1097/01.CCM.0000227649.72651.F1; Diaz-Arrastia R, 2006, J HEAD TRAUMA REHAB, V21, P361, DOI 10.1097/00001199-200607000-00007; Dickinson K, 2000, BMJ-BRIT MED J, V320, P1308, DOI 10.1136/bmj.320.7245.1308; Elf K, 2002, CRIT CARE MED, V30, P2129, DOI 10.1097/00003246-200209000-00029; Fish SS, 2004, ANN EMERG MED, V43, P449, DOI 10.1016/j.annemergmed.2003.11.004; Gaab M R, 1994, Zentralbl Neurochir, V55, P135; Garner RC, 2006, BRIT J CLIN PHARMACO, V61, P367, DOI 10.1111/j.1365-2125.2006.02575.x; Hall ED, 1996, ACT NEUR S, V66, P107; Houlden H, 2006, J NEUROL NEUROSUR PS, V77, P1106, DOI 10.1136/jnnp.2006.095513; Jansen TC, 2007, INTENS CARE MED, V33, P894, DOI 10.1007/s00134-007-0580-8; JENNETT B, 1975, LANCET, V1, P480; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Liddell K, 2006, RESUSCITATION, V69, P9, DOI 10.1016/j.resuscitation.2005.12.004; Maas AIR, 2006, LANCET NEUROL, V5, P38, DOI 10.1016/S1474-4422(05)70253-2; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Machado SG, 1999, J NEUROTRAUM, V16, P1131, DOI 10.1089/neu.1999.16.1131; Magnotti Louis J, 2004, Surg Infect (Larchmt), V5, P237, DOI 10.1089/sur.2004.5.237; Markgraf CG, 2001, J NEUROSURG, V95, P979, DOI 10.3171/jns.2001.95.6.0979; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; Mascia L, 2008, INTENS CARE MED, V34, P720, DOI 10.1007/s00134-007-0974-7; Menon D, 2008, BMJ-BRIT MED J, V336, P397, DOI 10.1136/bmj.39461.616991.80; Menon David, 2004, Curr Opin Crit Care, V10, P91, DOI 10.1097/00075198-200404000-00002; Menon DK, 2004, CRIT CARE MED, V32, P1384, DOI 10.1097/01.CCM.0000127777.16609.08; Menon DK, 1999, BRIT MED BULL, V55, P226, DOI 10.1258/0007142991902231; Murray GD, 2005, J NEUROTRAUM, V22, P511, DOI 10.1089/neu.2005.22.511; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/s0140-6736(04)17188-2; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; Perel Pablo, 2006, BMC Med Inform Decis Mak, V6, P38, DOI 10.1186/1472-6947-6-38; Polderman KH, 2002, INTENS CARE MED, V28, P1563, DOI 10.1007/s00134-002-1511-3; Polderman KH, 2004, INTENS CARE MED, V30, P757, DOI 10.1007/s00134-003-2151-y; Reid CL, 2007, BMJ-BRIT MED J, V335, P415, DOI 10.1136/bmj.39311.480949.3A; Roberts I, 2004, EMERG MED J, V21, P703, DOI 10.1136/emj.2002.004788; Robertson CS, 2007, CLIN TRIALS, V4, P631, DOI 10.1177/1740774507084977; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Sakr Y, 2005, CHEST, V128, P3098, DOI 10.1378/chest.128.5.3098; Sterz F, 2002, RESUSCITATION, V53, P237, DOI 10.1016/S0300-9572(02)00103-X; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Upton RN, 2007, CLIN EXP PHARMACOL P, V34, P695, DOI 10.1111/j.1440-1681.2007.04649.x; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; Vanpee D, 2004, J EMERG MED, V26, P127, DOI 10.1016/j.jemermed.2003.04.007; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Walia S, 2002, INJURY, V33, P339, DOI 10.1016/S0020-1383(02)00053-0; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	57	75	77	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	JAN	2009	37	1		S			S129	S135		10.1097/CCM.0b013e3181921225			7	Critical Care Medicine	General & Internal Medicine	391YO	WOS:000262270300018	19104212				2021-06-18	
J	Pertab, JL; James, KM; Bigler, ED				Pertab, Jon L.; James, Kelly M.; Bigler, Erin D.			Limitations of mild traumatic brain injury meta-analyses	BRAIN INJURY			English	Article; Proceedings Paper	27th Annual Meeting of the National-Academy-of-Neuropsychology	NOV 14-17, 2007	Scottsdale, AZ	Natl Acad Neuropsychol		Mild traumatic brain injury (mTBI); concussion; post-concussion analysis; cognition; neuropsychological assessment; clinical outcome; computed tomography (CT) imaging; magnetic resonance imaging (MRI)	DIFFUSE AXONAL INJURY; COLLEGIATE FOOTBALL PLAYERS; MINOR HEAD-INJURY; PROFESSIONAL FOOTBALL; COGNITIVE SEQUELAE; NCAA CONCUSSION; IMPACT; NEUROPSYCHOLOGY; SEVERITY; TBI	Primary objective: Mild traumatic brain injury (mTBI) meta-analyses are sometimes cited as evidence that by 3 months post-injury the clinical effects are insignificant. In contrast to these conclusions are findings that long-term mTBI outcome can vary depending on (1) the mechanism of the injury, (2) which diagnostic criteria are employed, (3) which assessment tools utilized and (4) whether symptomatic groups are considered separately. Research design: The present study was designed to clarify opposing conclusions in the mTBI literature by re-analysing meta-analytic datasets. Methods and procedures: The most frequently cited mTBI meta-analysis is by Binder, Rohling and Larrabee in 1997; this study was updated in 2005 by Frencham, Fox and Maybery. Data combined in these studies were re-categorized according to the four variables above; associated effect sizes and heterogeneity statistics were calculated. Main outcomes and results: Considerable qualitative and statistical heterogeneity was identified within the meta-analytic data under consideration. Clinically significant lasting effects were identified for a sub-set of neuropsychological measures. Conclusions: Methodological and statistical heterogeneity in studies combined in mTBI meta-analyses significantly limits the conclusions that can be drawn from small or non-significant overall effect sizes; clinically relevant information can be obscured by meta-analytic procedures. Recommendations for future meta-analytic studies of mTBI are offered.	[Pertab, Jon L.; James, Kelly M.; Bigler, Erin D.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Pertab, Jon L.; James, Kelly M.; Bigler, Erin D.] Brigham Young Univ, Ctr Neurosci, Provo, UT 84602 USA; [Bigler, Erin D.] Univ Utah, Dept Psychiat, Salt Lake City, UT USA; [Bigler, Erin D.] Brain Inst Utah, Salt Lake City, UT USA	Bigler, ED (corresponding author), Brigham Young Univ, Dept Psychol, 1190D Spencer W Kimball Tower, Provo, UT 84602 USA.	erin_bigler@byu.edu					ALTERMAN AI, 1985, INT J NEUROSCI, V28, P155, DOI 10.3109/00207458508985386; Anderson RWG, 2003, J NEUROTRAUM, V20, P961, DOI 10.1089/089771503770195812; BATCHELOR J, 1995, CLIN NEUROPSYCHOL, V9, P180, DOI 10.1080/13854049508401600; Bayly PV, 2006, J BIOMECH, V39, P1086, DOI 10.1016/j.jbiomech.2005.02.014; Bayly PV, 2005, J NEUROTRAUM, V22, P845, DOI 10.1089/neu.2005.22.845; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Bernstein DM, 2002, J INT NEUROPSYCH SOC, V8, P673, DOI 10.1017/S1355617702801400; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Blennow Kaj, 2005, Lakartidningen, V102, P2468; Bornstein R. A., 1993, NEUROPSYCHOLOGY, V7, P228, DOI DOI 10.1037/0894-4105.7.2.228; Cantu Robert C, 2006, Neurosurg Focus, V21, pE3; Casson IR, 2008, NEUROL CLIN, V26, P217, DOI 10.1016/j.ncl.2007.11.005; Christensen J, 2009, LANCET, V373, P1105, DOI 10.1016/S0140-6736(09)60214-2; Cohen J., 1977, STAT POWER ANAL BEHA, P1; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Comerford VE, 2002, J CLIN EXP NEUROPSYC, V24, P409, DOI 10.1076/jcen.24.4.409.1044; Delaney JS, 2006, CLIN J SPORT MED, V16, P162, DOI 10.1097/00042752-200603000-00013; Demakis GJ, 2006, CLIN NEUROPSYCHOL, V20, P10, DOI 10.1080/13854040500203282; Demakis GJ, 2006, CLIN NEUROPSYCHOL, V20, P5, DOI 10.1080/13854040500203266; Denney RL, 2000, J HEAD TRAUMA REHAB, V15, P804, DOI 10.1097/00001199-200004000-00005; DIKMEN S, 2009, NEUROPSYCHOLOGICAL A, P597; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; EDLUND W, 2004, CLIN PRACTISE GUIDEL; Ferguson RJ, 1999, NEUROPSYCHOLOGY, V13, P582, DOI 10.1037/0894-4105.13.4.582; Fijalkowski RJ, 2006, BIOMED SCI INSTRUM, V42, P108; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Goldstein FC, 2001, J INT NEUROPSYCH SOC, V7, P373, DOI 10.1017/S1355617701733115; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; GRONWALL D, 1975, LANCET, V2, P995; GUILMETTE TJ, 1995, NEUROPSYCHOLOGY, V9, P338, DOI 10.1037/0894-4105.9.3.338; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hayward P, 2008, LANCET NEUROL, V7, P200, DOI 10.1016/S1474-4422(08)70032-2; Hedges L.V., 1985, STAT METHODS META AN; Hessen E, 2007, BRAIN INJURY, V21, P963, DOI 10.1080/02699050701528454; HintonBayre AD, 1997, J CLIN EXP NEUROPSYC, V19, P275, DOI 10.1080/01688639708403857; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Iverson GL, 2006, BRAIN INJURY, V20, P1335, DOI 10.1080/02699050601082156; Kashluba S, 2008, ARCH PHYS MED REHAB, V89, P904, DOI 10.1016/j.apmr.2007.12.029; Kashluba S, 2008, CLIN NEUROPSYCHOL, V22, P195, DOI 10.1080/13854040701263655; Lam RW, 2005, CAN J PSYCHIAT, V50, P167, DOI 10.1177/070674370505000306; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; Liu Xuejun, 2003, Traffic Inj Prev, V4, P337, DOI 10.1080/714040491; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Maier W, 2005, EUR ARCH PSY CLIN N, V255, P369, DOI 10.1007/s00406-005-0607-5; Mangels JA, 2002, NEUROPSYCHOLOGIA, V40, P2369, DOI 10.1016/S0028-3932(02)00084-2; Mathias JL, 2004, J INT NEUROPSYCH SOC, V10, P286, DOI 10.1017/S1355617704102117; Mathias JL, 1999, J CLIN EXP NEUROPSYC, V21, P200, DOI 10.1076/jcen.21.2.200.930; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; MCGAW B, 1980, AM EDUC RES J, V17, P325, DOI 10.2307/1162619; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; MONTGOMERY EA, 1991, PSYCHOL MED, V21, P375, DOI 10.1017/S0033291700020481; Moser RS, 2007, ARCH CLIN NEUROPSYCH, V22, P909, DOI 10.1016/j.acn.2007.09.004; National Center for Injury Prevention and Control, 2003, C MILD TRAUM BRAIN I; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Potter DD, 2001, NEUROPSYCHOLOGIA, V39, P1464, DOI 10.1016/S0028-3932(01)00057-4; Potter S, 2006, J NEUROL, V253, P1603, DOI 10.1007/s00415-006-0275-z; Raskin SA, 1998, CLIN NEUROPSYCHOL, V12, P21, DOI 10.1076/clin.12.1.21.1724; Rassovsky Y, 2006, J CLIN EXP NEUROPSYC, V28, P567, DOI 10.1080/13803390500434466; Reitan RM, 1999, ARCH CLIN NEUROPSYCH, V14, P191, DOI 10.1016/S0887-6177(98)00012-2; Rosenthal R., 1991, META ANAL PROCEDURES, V1st; Ruff R.M., 1989, MILD HEAD INJURY, P176; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Sabet AA, 2008, J BIOMECH, V41, P307, DOI 10.1016/j.jbiomech.2007.09.016; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Smits M, 2008, AM J NEURORADIOL, V29, P506, DOI 10.3174/ajnr.A0852; Stapert S, 2006, BRAIN INJURY, V20, P161, DOI 10.1080/02699050500442949; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; Streiner DL, 2005, CAN J PSYCHIAT, V50, P829; Tobin MJ, 2008, CRIT CARE MED, V36, P1, DOI 10.1097/01.CCM.0000297883.04634.11; Topal NB, 2008, NEUROL RES, V30, P974, DOI 10.1179/016164108X323799; Viano DC, 2007, NEUROSURGERY, V61, P313, DOI 10.1227/01.NEU.0000279969.02685.D0; Viano DC, 2005, NEUROSURGERY, V57, P891, DOI 10.1227/01.NEU.0000186950.54075.3B; Voller B, 1999, BRAIN INJURY, V13, P821, DOI 10.1080/026990599121214; von Wild KRH, 2008, ACT NEUR S, V101, P55; Wallister TW, 2008, WORLD PSYCHIATRY, V7, P3; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Williams CW, 1999, PROF PSYCHOL-RES PR, V30, P361, DOI 10.1037/0735-7028.30.4.361; Zetterberg H, 2006, ARCH NEUROL-CHICAGO, V63, P1277, DOI 10.1001/archneur.63.9.1277; Zwahlen RA, 2007, J CRANIO MAXILL SURG, V35, P142, DOI 10.1016/j.jcms.2007.01.006	92	75	75	0	10	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2009	23	6					498	508	PII 911808900	10.1080/02699050902927984			11	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	451SF	WOS:000266489800003	19484623				2021-06-18	
J	Hoffman, AN; Cheng, JP; Zafonte, RD; Kline, AE				Hoffman, Ann N.; Cheng, Jeffrey P.; Zafonte, Ross D.; Kline, Anthony E.			Administration of haloperidol and risperidone after neurobehavioral testing hinders the recovery of traumatic brain injury-induced deficits	LIFE SCIENCES			English	Article						Antipsychotics; Brain injury; Functional recovery; Water maze	CONTROLLED CORTICAL IMPACT; WATER MAZE PERFORMANCE; RAT FRONTAL-CORTEX; ISCHEMIA IN-VIVO; ATYPICAL ANTIPSYCHOTICS; SIGMA(1) RECEPTOR; WORKING-MEMORY; DOPAMINERGIC TRANSMISSION; METHYLPHENIDATE TREATMENT; CHOLINERGIC MARKERS	Aims: Agitation and aggression are common behavioral sequelae of traumatic brain injury (TBI). The management of these symptoms is critical for effective patient care and therefore antipsychotics are routinely administered even though the benefits vs. risks of this approach on functional outcome after TBI are unclear. A recent study from our group revealed that both haloperidol and risperidone impaired recovery when administered prior to testing. However, the results may have been confounded by drug-induced sedation. Hence, the current study reevaluated the behavioral effects of haloperidol and risperidone when provided after daily testing, thus circumventing the potential sedative effect. Main methods: Fifty-four isoflurane-anesthetized mate rats received a cortical impact or sham injury and then were randomly assigned to three TBI and three sham groups that received haloperidol (0.5 mg/kg), risperidone (0.45 nng/kg), or vehicle (1.0 mL/kg). Treatments began 24 h after surgery and were administered (i.p.) every day thereafter for 19 days. Motor and cognitive function was assessed on post-operative days 1-5 and 14-19, respectively. Hippocampal CA(1)/CA(3) neurons and cortical lesion volume were quantified at 3 weeks. Key findings: Only risperidone delayed motor recovery, but both antipsychotics impaired spatial learning relative to vehicle (p<0.05). Neither swim speed nor histological outcomes were affected. No differences were observed between the haloperidol and risperidone groups in any task. Significance: These data support our previous finding that chronic haloperidol and risperidone hinder the recovery of TBI-induced deficits, and augment those data by demonstrating that the effects are not mediated by drug-induced sedation. (C) 2008 Elsevier Inc. All rights reserved.	[Kline, Anthony E.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA; [Hoffman, Ann N.; Cheng, Jeffrey P.; Kline, Anthony E.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA; [Kline, Anthony E.] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15213 USA; [Kline, Anthony E.] Univ Pittsburgh, Ctr Neural Basis Cognit, Pittsburgh, PA 15213 USA; [Zafonte, Ross D.] Harvard Univ, Sch Med, Boston, MA 02144 USA; [Zafonte, Ross D.] Spaulding Rehabil Hosp, Boston, MA 02114 USA; [Zafonte, Ross D.] Massachusetts Gen Hosp, Boston, MA 02114 USA	Kline, AE (corresponding author), Univ Pittsburgh, Dept Phys Med & Rehabil, 3471 5th Ave,Suite 201, Pittsburgh, PA 15213 USA.	klineae@upmc.edu		Cheng, Jeffrey/0000-0001-8285-3207	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HD046700]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD069620] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD046700] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS060005] Funding Source: NIH RePORTER	This work was supported, in part, by NIH grant HD046700 (AEK).	Cheng JP, 2007, NEUROSCI LETT, V416, P165, DOI 10.1016/j.neulet.2007.02.006; Didriksen M, 2006, EUR J PHARMACOL, V542, P108, DOI 10.1016/j.ejphar.2006.05.021; Dixon CE, 1999, RESTOR NEUROL NEUROS, V14, P285; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dunn-Meynell AA, 1998, BRAIN RES, V800, P245, DOI 10.1016/S0006-8993(98)00524-1; Elovic EP, 2008, J HEAD TRAUMA REHAB, V23, P132, DOI 10.1097/01.HTR.0000314532.07530.e5; Elovic EP, 2003, J HEAD TRAUMA REHAB, V18, P177, DOI 10.1097/00001199-200303000-00008; Espallergues J, 2007, BRIT J PHARMACOL, V152, P267, DOI 10.1038/sj.bjp.0707386; FEENEY DM, 1990, CAN J PSYCHOL, V44, P233, DOI 10.1037/h0084243; FEENEY DM, 1993, J NEURAL TRANSP PLAS, V4, P199, DOI 10.1155/NP.1993.199; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Gemperle AY, 2003, PSYCHOPHARMACOLOGY, V169, P354, DOI 10.1007/s00213-003-1459-1; Goldstein LB, 2002, NEUROREHAB NEURAL RE, V16, P321, DOI 10.1177/154596830201600402; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hoffman AN, 2008, NEUROSCI LETT, V431, P226, DOI 10.1016/j.neulet.2007.11.042; Karl T, 2006, BEHAV BRAIN RES, V171, P286, DOI 10.1016/j.bbr.2006.04.004; Kline AE, 2004, J NEUROTRAUM, V21, P175, DOI 10.1089/089771504322778631; Kline AE, 2000, NEUROSCI LETT, V280, P163, DOI 10.1016/S0304-3940(00)00797-7; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Kline AE, 2001, HEAD TRAUMA, P65; Kline AE, 2001, NEUROSCIENCE, V106, P547, DOI 10.1016/S0306-4522(01)00300-1; Kline AE, 2007, CRIT CARE MED, V35, P919, DOI 10.1097/01.CCM.0000256722.88854.C0; Kobayashi T, 1996, J PHARMACOL EXP THER, V279, P106; Kobayashi T, 1997, NEUROCHEM RES, V22, P1105, DOI 10.1023/A:1027361101419; Li M, 2007, NEUROPSYCHOPHARMACOL, V32, P263, DOI 10.1038/sj.npp.1301110; Lombard LA, 2005, AM J PHYS MED REHAB, V84, P797, DOI 10.1097/01.phm.0000179438.22235.08; Massucci JL, 2004, NEUROSCI LETT, V372, P127, DOI 10.1016/j.neulet.2004.09.026; McDowell S, 1998, BRAIN, V121, P1155, DOI 10.1093/brain/121.6.1155; MCINTOSH TK, 1994, J NEUROCHEM, V63, P1426; Mysiw WJ, 1997, ARCH PHYS MED REHAB, V78, P213, DOI 10.1016/S0003-9993(97)90266-5; Naiker DV, 2006, EUR J PHARMACOL, V540, P87, DOI 10.1016/j.ejphar.2006.04.048; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; Rosengarten H, 2002, PROG NEURO-PSYCHOPH, V26, P1047, DOI 10.1016/S0278-5846(02)00221-X; Sandel ME, 1996, ARCH PHYS MED REHAB, V77, P617, DOI 10.1016/S0003-9993(96)90306-8; Schotte A, 1996, PSYCHOPHARMACOLOGY, V124, P57, DOI 10.1007/BF02245606; SCHOTTE A, 1993, BRAIN RES, V631, P191, DOI 10.1016/0006-8993(93)91535-Z; Skarsfeldt T, 1996, PSYCHOPHARMACOLOGY, V124, P126, DOI 10.1007/BF02245612; Terry AV, 2006, J PHARMACOL EXP THER, V318, P709, DOI 10.1124/jpet.105.099218; Terry AV, 2002, PSYCHOPHARMACOLOGY, V164, P360, DOI 10.1007/s00213-002-1230-z; Terry AV, 2003, NEUROPSYCHOPHARMACOL, V28, P300, DOI 10.1038/sj.npp.1300039; Wagner AK, 2005, J NEUROCHEM, V95, P457, DOI 10.1111/j.1471-4159.2005.03382.x; Whyte J, 1997, AM J PHYS MED REHAB, V76, P440, DOI 10.1097/00002060-199711000-00002; Wilson MS, 2003, AM J PHYS MED REHAB, V82, P871, DOI 10.1097/01.PHM.0000091982.33232.CB; Yan HQ, 2002, NEUROREPORT, V13, P1899, DOI 10.1097/00001756-200210280-00013; Yan HQ, 2001, NEUROREPORT, V12, P2323, DOI 10.1097/00001756-200108080-00009; Yulug B, 2006, BRAIN RES BULL, V69, P656, DOI 10.1016/j.brainresbull.2006.03.017; Yulug B, 2006, BRAIN RES BULL, V71, P296, DOI 10.1016/j.brainresbull.2006.09.018; Zhao CS, 2005, BEHAV BRAIN RES, V158, P211, DOI 10.1016/j.bbr.2004.09.001	48	75	76	0	7	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0024-3205			LIFE SCI	Life Sci.	OCT 24	2008	83	17-18					602	607		10.1016/j.lfs.2008.08.007			6	Medicine, Research & Experimental; Pharmacology & Pharmacy	Research & Experimental Medicine; Pharmacology & Pharmacy	365JJ	WOS:000260401700004	18801378	Green Accepted			2021-06-18	
J	Arias, RL; Sung, MLA; Vasylyev, D; Zhang, MY; Albinson, K; Kubek, K; Kagan, N; Beyer, C; Lin, Q; Dwyer, JM; Zaleska, MM; Bowlby, MR; Dunlop, J; Monaghan, M				Arias, Robert L.; Sung, Mei-Li A.; Vasylyev, Dmytro; Zhang, Mei-Yi; Albinson, Kristin; Kubek, Katie; Kagan, Natasha; Beyer, Chad; Lin, Qian; Dwyer, Jason M.; Zaleska, Margaret M.; Bowlby, Mark R.; Dunlop, John; Monaghan, Michael			Amiloride is neuroprotective in an MPTP model of Parkinson's disease	NEUROBIOLOGY OF DISEASE			English	Article						MPTP; amiloride; psalmotoxin; substantia nigra; Parkinson's disease; dopamine transporter; tyrosine hydroxylase; ASIC	SENSING ION CHANNELS; TRAUMATIC BRAIN-INJURY; GATED CATION CHANNELS; CEREBRAL BLOOD-FLOW; MICROGLIAL ACTIVATION; INDUCED NEUROTOXICITY; MOUSE MODEL; TNF-ALPHA; ISCHEMIA; CAFFEINE	The diuretic amiloride has recently proven neuroprotective in models of cerebral ischemia, a property attributable to the drug's inhibition of central acid-sensing ion channels (ASICs). Given that Parkinson's disease (PD), like ischemia, is associated with cerebral lactic acidosis, we tested amiloride in the MPTP-treated mouse, a model of PD also manifesting lactic acidosis. Amiloride was found to protect substantia nigra (SNc) neurons from MPTP-induced degeneration, as determined by attenuated reductions in striatal tyrosine hydroxylase (TH) and dopamine transporter (DAT) immunohistochemistry, as well as smaller declines in striatal DAT radioligand binding and dopamine levels. More significantly, amiloride also preserved dopaminergic cell bodies in the SNc. Administration of psalmotoxin venom (PcTX), an ASIC1a blocker, resulted in a much more modest effect, attenuating only the deficits in striatal DAT binding and dopamine. These findings represent the first experimental evidence of a potential role for ASICs in the pathogenesis of Parkinson's disease. (C) 2008 Elsevier Inc. All rights reserved.	[Arias, Robert L.; Sung, Mei-Li A.; Vasylyev, Dmytro; Zhang, Mei-Yi; Albinson, Kristin; Kubek, Katie; Kagan, Natasha; Beyer, Chad; Lin, Qian; Dwyer, Jason M.; Zaleska, Margaret M.; Bowlby, Mark R.; Dunlop, John; Monaghan, Michael] Wyeth Discovery Neurosci, Princeton, NJ USA	Arias, RL (corresponding author), Wyeth Neurosci, CN-8000 1513, Princeton, NJ 08543 USA.	ariasr@wyeth.com					Abeliovich A, 2006, J NEUROCHEM, V99, P1062, DOI 10.1111/j.1471-4159.2006.04102.x; Alfinito PD, 2003, J NEUROSCI, V23, P10982; Ascherio A, 2001, ANN NEUROL, V50, P56, DOI 10.1002/ana.1052; Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769; Bove Jordi, 2005, NeuroRx, V2, P484, DOI 10.1602/neurorx.2.3.484; BOWEN BC, 1995, AM J NEURORADIOL, V16, P61; Braak H, 2003, NEUROBIOL AGING, V24, P197, DOI 10.1016/S0197-4580(02)00065-9; BROUILLET E, 1993, NEUROREPORT, V4, P387, DOI 10.1097/00001756-199304000-00011; Chen JF, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-10-j0001.2001; Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3; Escoubas P, 2003, PROTEIN SCI, V12, P1332, DOI 10.1110/ps.0307003; Fahn S, 2003, ANN NY ACAD SCI, V991, P1, DOI 10.1111/j.1749-6632.2003.tb07458.x; Ferger B, 2004, J NEUROCHEM, V89, P822, DOI 10.1111/j.1471-4159.2004.02399.x; Franklin KB, 2008, MOUSE BRAIN STEREOTA; Friese MA, 2007, NAT MED, V13, P1483, DOI 10.1038/nm1668; GARRITSEN A, 1990, BIOCHEM PHARMACOL, V40, P827, DOI 10.1016/0006-2952(90)90323-D; Gupta AK, 2004, J NEUROTRAUM, V21, P678, DOI 10.1089/0897715041269722; Haddad JJ, 2002, AM J RESP CELL MOL, V26, P114, DOI 10.1165/ajrcmb.26.1.4657; Horisberger JD, 1998, CURR OPIN CELL BIOL, V10, P443, DOI 10.1016/S0955-0674(98)80056-2; Immke DC, 2001, NAT NEUROSCI, V4, P869, DOI 10.1038/nn0901-869; INAMURA K, 1988, J CEREBR BLOOD F MET, V8, P375, DOI 10.1038/jcbfm.1988.73; Jenner P, 2003, ANN NEUROL, V53, pS26, DOI 10.1002/ana.10483; Joch M, 2007, MOL BIOL CELL, V18, P3105, DOI 10.1091/mbc.E05-11-1027; Kellenberger S, 2002, PHYSIOL REV, V82, P735, DOI 10.1152/physrev.00007.2002; Kitada T, 1998, NATURE, V392, P605; KLEYMAN TR, 1988, J MEMBRANE BIOL, V105, P1, DOI 10.1007/BF01871102; Koga K, 2006, EUR J NEUROSCI, V23, P1077, DOI 10.1111/j.1460-9568.2006.04610.x; Krishtal O, 2003, TRENDS NEUROSCI, V26, P477, DOI 10.1016/S0166-2236(03)00210-8; Kristian T, 2004, CELL CALCIUM, V36, P221, DOI 10.1016/j.ceca.2004.02.016; Lang AE, 2004, LANCET NEUROL, V3, P309, DOI 10.1016/S1474-4422(04)00740-9; Lee VMY, 2006, NEURON, V52, P33, DOI 10.1016/j.neuron.2006.09.026; Mandemakers W, 2007, J CELL SCI, V120, P1707, DOI 10.1242/jcs.03443; MARTONE R, 2005, DRUG DISCOV TODAY TH, V2, P299; Mccoy MK, 2006, J NEUROSCI, V26, P9365, DOI 10.1523/JNEUROSCI.1504-06.2006; Moore DJ, 2005, ANNU REV NEUROSCI, V28, P57, DOI 10.1146/annurev.neuro.28.061604.135718; Murray TK, 2003, J PHARMACOL EXP THER, V306, P752, DOI 10.1124/jpet.103.049445; Neuhoff H, 2002, J NEUROSCI, V22, P1290, DOI 10.1523/JNEUROSCI.22-04-01290.2002; Picloplichko VI, 2006, P NATL ACAD SCI USA, V103, P11376, DOI 10.1073/pnas.0600768103; Pignataro G, 2007, BRAIN, V130, P151, DOI 10.1093/brain/awl325; Ross GW, 2000, JAMA-J AM MED ASSOC, V283, P2674, DOI 10.1001/jama.283.20.2674; Schwarzschild MA, 2006, TRENDS NEUROSCI, V29, P647, DOI 10.1016/j.tins.2006.09.004; Shen J, 2004, NEURON, V43, P301, DOI 10.1016/j.neuron.2004.07.012; Siesjo BK, 1996, ADV NEUROL, V71, P209; SMITH ML, 1987, J CEREB BLOOD FLO S1, V7, pS76; Sriram K, 2006, FASEB J, V20, P670, DOI 10.1096/fj.05-5106com; Teismann P, 2001, SYNAPSE, V39, P167, DOI 10.1002/1098-2396(200102)39:2<167::AID-SYN8>3.0.CO;2-U; TOMLINSON FH, 1993, STROKE, V24, P435, DOI 10.1161/01.STR.24.3.435; Veselovsky NS, 1996, PFLUG ARCH EUR J PHY, V432, P351, DOI 10.1007/s004240050143; Waldmann R, 1998, CURR OPIN NEUROBIOL, V8, P418, DOI 10.1016/S0959-4388(98)80070-6; Wemmie JA, 2003, J NEUROSCI, V23, P5496; Wemmie JA, 2006, TRENDS NEUROSCI, V29, P578, DOI 10.1016/j.tins.2006.06.014; Wu DC, 2002, J NEUROSCI, V22, P1763, DOI 10.1523/JNEUROSCI.22-05-01763.2002; Xiong ZG, 2006, J MEMBRANE BIOL, V209, P59, DOI 10.1007/s00232-005-0840-x; Xiong ZG, 2004, CELL, V118, P687, DOI 10.1016/j.cell.2004.08.026; Xu K, 2002, NEUROSCI LETT, V322, P13, DOI 10.1016/S0304-3940(02)00069-1; Yao H, 2004, CELL CALCIUM, V36, P247, DOI 10.1016/j.ceca.2004.02.013; Yermolaieva O, 2004, P NATL ACAD SCI USA, V101, P6752, DOI 10.1073/pnas.0308636100; Zygun DA, 2004, NEUROSURGERY, V55, P877, DOI 10.1227/01.NEU.0000137658.14906.E4	58	75	79	0	7	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	SEP	2008	31	3					334	341		10.1016/j.nbd.2008.05.008			8	Neurosciences	Neurosciences & Neurology	343NY	WOS:000258862000006	18606547				2021-06-18	
J	Macciocchi, S; Seel, RT; Thompson, N; Byams, R; Bowman, B				Macciocchi, Stephen; Seel, Ronald T.; Thompson, Nicole; Byams, Rashida; Bowman, Brock			Spinal cord injury and co-occurring traumatic brain injury: Assessment and incidence	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; diagnosis; incidence; rehabilitation; spinal cord injuries	CLOSED-HEAD-INJURY; POSTTRAUMATIC AMNESIA; COGNITIVE DYSFUNCTION; ASSOCIATION; SCALE; MODEL	Objectives: To examine prospectively the incidence and severity of co-occurring traumatic brain injury (TBI) in persons with traumatic spinal cord injury (SCI) and to describe a TBI assessment process for SCI rehabilitation professionals. Design: A prospective, cohort design to collect and analyze clinical variables relevant for diagnosing co-occurring TBI. Setting: An urban, single-center National Institute of Disability and Rehabilitation Research Model Spinal Cord Injury System in the Southeastern United States. Participants: People (N=198) who met inclusion criteria and provided consent within an 18-month recruitment window. Interventions: Not applicable. Main Outcome Measure: FIM cognitive scale. Results: Based on participants' presence and duration of posttraumatic amnesia, initial Glasgow Coma Scale total score, and presence of cerebral lesion documented by neuroimaging, 60% of our traumatic SCI sample also sustained a TBI (n = 118). Most co-occurring TBIs were mild (34%). Co-occurring mild complicated (10%), moderate (6%), and severe TBI (10%) were less common but still occurred in a significant percentage (26%) of persons with traumatic SCI. Persons with traumatic SCI who were injured in motor vehicle collisions and falls were more likely to sustain a co-occurring TBI. Cervical level traumatic SCI was associated with greater rates of TBI but not more severe injuries. Tree analyses established a practical algorithm for classifying TBI severity associated with traumatic SCI. Analysis of variance established criterion validity for the algorithm's TBI severity classifications. Conclusions: Findings from our prospective study provide strong support that TBI is a common co-occurring injury with traumatic SCI. Incomplete acute care medical record documentation of TBI in the traumatic SCI population remains a considerable issue, and there is a significant need to educate emergency department and acute care personnel on the TBI clinical data needs of acute rehabilitation providers. A systematic algorithm for reviewing acute care medical records can yield valid estimates of TBI severity in the traumatic SCI population.	[Macciocchi, Stephen; Seel, Ronald T.; Thompson, Nicole; Bowman, Brock] Shepherd Ctr, Atlanta, GA 30309 USA; [Macciocchi, Stephen] Univ Georgia, Athens, GA 30602 USA; [Byams, Rashida] Georgia State Univ, Atlanta, GA 30303 USA; [Bowman, Brock] Emory Univ, Atlanta, GA 30322 USA	Macciocchi, S (corresponding author), Shepherd Ctr, 2020 Peachtree Rd, Atlanta, GA 30309 USA.	stephen_macciocchi@shepherd.org					Bowman BK, 2004, TOP SPINAL CORD INJ, V10, P58; Brown AW, 2005, J NEUROTRAUM, V22, P1040, DOI 10.1089/neu.2005.22.1040; Bush BA, 2003, ARCH PHYS MED REHAB, V84, P1803, DOI 10.1016/S0003-9993(03)00367-8; DAVIDOFF G, 1988, ARCH PHYS MED REHAB, V69, P869; DAVIDOFF G, 1985, ARCH PHYS MED REHAB, V66, P41; DAVIDOFF G, 1985, ARCH PHYS MED REHAB, V66, P489; DAVIDOFF GN, 1990, ARCH PHYS MED REHAB, V71, P326; Ellenberg JH, 1996, ARCH NEUROL-CHICAGO, V53, P782, DOI 10.1001/archneur.1996.00550080104018; Elovic E, 1999, TOP SPINAL CORD INJ, V5, P1, DOI DOI 10.1310/V75J-RE76-20GH-X7BY; Go Bette K., 1995, P21; Harris P, 1968, Paraplegia, V5, P215; Iida H, 1999, J TRAUMA, V46, P450, DOI 10.1097/00005373-199903000-00018; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Macciocchi SN, 2004, AM J PHYS MED REHAB, V83, P22, DOI 10.1097/01.PHM.0000104661.86307.91; Meinecke F W, 1968, Paraplegia, V5, P196; MICHAEL D B, 1989, Journal of Neurotrauma, V6, P177; National Data and Statistical Center, TRAUM BRAIN INJ MOD; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; PAGNI CA, 1991, ACTA NEUROCHIR, V111, P1, DOI 10.1007/BF01402506; RICHARDS JS, 1991, ARCH PHYS MED REHAB, V72, P275; RICHARDS JS, 1988, AM J PHYS MED REHAB, V67, P211, DOI 10.1097/00002060-198810000-00005; Rimel R W, 1981, J Neurosurg Nurs, V13, P132; ROTH E, 1989, PARAPLEGIA, V27, P480, DOI 10.1038/sc.1989.75; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; SABOE LA, 1991, J TRAUMA, V31, P43, DOI 10.1097/00005373-199101000-00010; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; SHRAGO GG, 1973, AM J ROENTGENOL, V118, P670, DOI 10.2214/ajr.118.3.670; SILVER JR, 1980, INJURY, V12, P219, DOI 10.1016/0020-1383(80)90011-X; Sipski ML, 2006, AM J PHYS MED REHAB, V85, P310, DOI 10.1097/01.phm.0000202105.87011.bf; Steudel W I, 1988, Acta Neurochir Suppl (Wien), V43, P85; Strubreither W, 1997, SPINAL CORD, V35, P487, DOI 10.1038/sj.sc.3100495; STUTTS M, 1991, NEUROREHABILITATION, V3, P79; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Young JS, 1982, SPINAL CORD INJURY S, P14; Zafonte RD, 1997, ARCH PHYS MED REHAB, V78, P1103, DOI 10.1016/S0003-9993(97)90135-0; Zafonte RD, 1996, AM J PHYS MED REHAB, V75, P364, DOI 10.1097/00002060-199609000-00012; ZAFONTE RD, 2002, SPINAL CORD MED, P261	37	75	78	0	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUL	2008	89	7					1350	1357		10.1016/j.apmr.2007.11.055			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	323LK	WOS:000257447400020	18586138				2021-06-18	
J	Gentry, T; Wallace, J; Kvarfordt, C; Lynch, KB				Gentry, Tony; Wallace, Joseph; Kvarfordt, Connie; Lynch, Kathleen Bodisch			Personal digital assistants as cognitive aids for individuals with severe traumatic brain injury: A community-based trial	BRAIN INJURY			English	Article						brain injury; cognition; PDA; assistive technology; occupational therapy	ELECTRONIC MEMORY AID; MENTAL-RETARDATION; EVERYDAY MEMORY; PAGING SYSTEM; HEAD-INJURY; REHABILITATION; MICROCOMPUTER; IMPAIRMENTS; NEUROPAGE; COMPUTER	Objective: The purpose of this study was to examine the efficacy of personal digital assistants (PDAs) as cognitive aids in a sample of individuals with severe traumatic brain injury (TBI). Method: The group included 23 community-dwelling individuals at least 1 year post-severe TBI, who had difficulties in performing everyday tasks due to behavioural memory problems. Participants were trained by an occupational therapist to use PDAs as cognitive aids and assessed for occupational performance (using Canadian Occupational Performance Measure (COPM)) and participation in everyday life tasks (using Craig Handicap Assessment and Rating Technique-Revised (CHART)) before training and 8 weeks after training concluded. Results: Statistically significant improvement was noted for self-ratings of occupational performance and satisfaction with occupational performance (COPM); significant improvement in a self-rating of participation was noted (CHART-R). Conclusion: A brief training intervention utilizing PDAs as cognitive aids is associated with improved self-ratings of performance in everyday life tasks among community-dwelling individuals with severe TBI.	[Gentry, Tony; Lynch, Kathleen Bodisch] Virginia Commonwealth Univ, Dept Occupat Therapy, Richmond, VA 23298 USA; [Wallace, Joseph] Assist Technol Loan Fund Author, Richmond, VA USA; [Kvarfordt, Connie] Univ Windsor, Windsor, ON N9B 3P4, Canada	Gentry, T (corresponding author), Virginia Commonwealth Univ, Dept Occupat Therapy, 730 E Broad St,POB 980008, Richmond, VA 23298 USA.	logentry@vcu.edu	Kvarfordt, C. L./AAD-7170-2020	Kvarfordt, Connie/0000-0002-8797-6596			BAESMAN B, 2006, VISION SYSTEM 1999; Bergman MM, 2003, NEUROREHABILITATION, V18, P31; CHUTE DL, 1994, EXP AGING RES, V20, P229, DOI 10.1080/03610739408253969; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; CONBOY TJ, 1986, REHABIL PSYCHOL, V31, P203, DOI 10.1037//0090-5550.31.4.203; Davies DK, 2002, EDUC TRAIN MENT RET, V37, P209; Davies DK, 2002, MENT RETARD, V40, P358, DOI 10.1352/0047-6765(2002)040<0358:EITMSO>2.0.CO;2; Doig E, 2001, BRAIN INJURY, V15, P747, DOI 10.1080/02699050110034343; GILES GM, 1989, AM J OCCUP THER, V43, P409, DOI 10.5014/ajot.43.6.409; Gollaher K, 1998, BRAIN INJURY, V12, P255, DOI 10.1080/026990598122557; Gorman P, 2003, NEUROREHABILITATION, V18, P57; Hart T, 2002, J HEAD TRAUMA REHAB, V17, P556, DOI 10.1097/00001199-200212000-00007; Hoofien D, 2001, BRAIN INJURY, V15, P189; Kim HJ, 1999, BRAIN INJURY, V13, P147, DOI 10.1080/026990599121818; Kim HJ, 2000, BRAIN INJURY, V14, P187, DOI 10.1080/026990500120844; Kirsch NL, 2004, BRAIN INJURY, V18, P725, DOI 10.1080/02699050310001646161; LEVINSON R, 1997, J HEAD TRAUMA REHAB, V45, P101; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; Mihailidis A, 2004, NEUROPSYCHOL REHABIL, V14, P135, DOI 10.1080/09602010343000156; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; SOHLBERG MM, 2001, COGNITIVE REHABILIAT; van den Broek MD, 2000, BRAIN INJURY, V14, P455; Wade TK, 2001, BRAIN INJURY, V15, P305, DOI 10.1080/026990501750111256; WILSON B, 1989, J CLIN EXP NEUROPSYC, V11, P855, DOI 10.1080/01688638908400940; Wilson B. A., 1991, RIVERMEAD BEHAV MEMO; Wilson BA, 2003, NEUROREHABILITATION, V18, P3; Wilson BA, 1997, J NEUROL NEUROSUR PS, V63, P113, DOI 10.1136/jnnp.63.1.113; Wilson BA, 2001, J NEUROL NEUROSUR PS, V70, P477, DOI 10.1136/jnnp.70.4.477; Wright P, 2001, BRAIN INJURY, V15, P787, DOI 10.1080/02699050110045161	29	75	75	0	15	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2008	22	1					19	24		10.1080/02699050701810688			6	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	250QF	WOS:000252314400003	18183505				2021-06-18	
J	Parker, TM; Osternig, LR; van Donkelaar, P; Chou, LS				Parker, Tonya M.; Osternig, Louis R.; van Donkelaar, Paul; Chou, Li-Shan			Recovery of cognitive and dynamic motor function following concussion	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							MILD HEAD-INJURY; SPORT; GAIT; STATEMENT; ATTENTION; DEFICITS; IMPACT; TIME	Objective: Neuropsychological testing has been advocated as an important tool of proper post-concussion management. Although these measures provide information that can be used in the decision of when to return an individual to previous levels of physical activity, they provide little data on motor performance following injury. The purpose of this investigation was to examine the relationship between measures of dynamic motor performance and neuropsychological function following concussion over the course of 28 days. Methods: Participants completed two experimental protocols: gait stability and neuropsychological testing. The gait stability protocol measured whole-body centre of mass motion as subjects walked under conditions of divided and undivided attention. Neuropsychological testing consisted of a computerised battery of tests designed to assess memory, reaction time, processing speed and concussion symptoms. Correlation coefficients were computed between all neuropsychological and gait variables and comparisons of neuropsychological and gait stability post-concussion recovery curves were assessed. Results: Dynamic motor tasks, such as walking under varying conditions of attention, are complex and demanding undertakings, which require a longer recovery time following a concussion than cognitive measures. Little statistical relationship was found between the neuropsychological and gait variables, and the recovery curves of neuropsychological and gait domains were observed to be independent. Conclusions: In order to fully examine the effects of concussion and determine the optimal time for a safe return to activity, a multi-factorial approach, including both cognitive and motor tasks, should be employed.	[Parker, Tonya M.; Osternig, Louis R.; van Donkelaar, Paul; Chou, Li-Shan] Univ Oregon, Dept Human Physiol, Mot Anal Lab, Eugene, OR 97403 USA	Chou, LS (corresponding author), Univ Oregon, Dept Human Physiol, Mot Anal Lab, 1240, Eugene, OR 97403 USA.	chou@uoregon.edu			PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [CCR023203, R49/CCR021735] Funding Source: Medline		Aubry Mark, 2002, Phys Sportsmed, V30, P57, DOI 10.3810/psm.2002.02.176; Basford JR, 2003, ARCH PHYS MED REHAB, V84, P343, DOI 10.1053/apmr.2003.50034; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; BELL R, 1977, AM FAM PHYSICIAN, V16, P145; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Chou LS, 2004, GAIT POSTURE, V20, P245, DOI 10.1016/j.gaitpost.2003.09.007; Collie A, 2006, J NEUROL NEUROSUR PS, V77, P241, DOI 10.1136/jnnp.2005.073155; Fan J, 2002, J COGNITIVE NEUROSCI, V14, P340, DOI 10.1162/089892902317361886; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Haggard P, 2000, J NEUROL NEUROSUR PS, V69, P479, DOI 10.1136/jnnp.69.4.479; Hahn ME, 2004, J BIOMECH, V37, P837, DOI 10.1016/j.jbiomech.2003.11.010; Halterman CI, 2006, BRAIN, V129, P747, DOI 10.1093/brain/awh705; HintonBayre AD, 1997, J CLIN EXP NEUROPSYC, V19, P275, DOI 10.1080/01688639708403857; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Johnston KM, 2001, CLIN J SPORT MED, V11, P150, DOI 10.1097/00042752-200107000-00005; Kelly JP, 1997, NEUROLOGY, V48, P581; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory Paul, 2005, Clin J Sport Med, V15, P48; Parker TM, 2005, CLIN BIOMECH, V20, P389, DOI 10.1016/j.clinbiomech.2004.12.004; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Vallee M, 2006, ARCH PHYS MED REHAB, V87, P806, DOI 10.1016/j.apmr.2006.02.031; Warden DL, 2001, NEUROLOGY, V57, P524, DOI 10.1212/WNL.57.3.524; Winter DA, 1990, BIOMECHANICS MOTOR C, P56; WOLTRING HJ, 1986, ADV ENG SOFTW WORKST, V8, P104, DOI 10.1016/0141-1195(86)90098-7	27	75	76	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	DEC	2007	41	12					868	873		10.1136/bjsm.2006.033761			6	Sport Sciences	Sport Sciences	239YS	WOS:000251554800007	17517857	Green Published			2021-06-18	
J	Byrnes, KR; Faden, AI				Byrnes, Kimberly R.; Faden, Alan I.			Role of cell cycle proteins in CNS injury	NEUROCHEMICAL RESEARCH			English	Article						brain injury; flavopiridol; proliferation; review; spinal cord injury; stroke	SPINAL-CORD-INJURY; IN-VITRO; CEREBRAL-ISCHEMIA; DEPENDENT KINASES; RAT-BRAIN; REGULATORY PROTEINS; AXONAL REGENERATION; FUNCTIONAL RECOVERY; NEURONAL APOPTOSIS; PROMOTES SURVIVAL	Following trauma or ischemia to the central nervous system (CNS), there is a marked increase in the expression of cell cycle-related proteins. This up-regulation is associated with apoptosis of post-mitotic cells, including neurons and oligodendrocytes, both in vitro and in vivo. Cell cycle activation also induces proliferation of astrocytes and microglia, contributing to the glial scar and microglial activation with release of inflammatory factors. Treatment with cell cycle inhibitors in CNS injury models inhibits glial scar formation and neuronal cell death, resulting in substantially decreased lesion volumes and improved behavioral recovery. Here we critically review the role of cell cycle pathways in the pathophysiology of experimental stroke, traumatic brain injury and spinal cord injury, and discuss the potential of cell cycle inhibitors as neuroprotective agents.	Georgetown Univ, Med Ctr, Dept Neurosci, Washington, DC 20057 USA	Byrnes, KR (corresponding author), Georgetown Univ, Med Ctr, Dept Neurosci, Room EP16A,New Res Bldg,3970 Reservoir Rd NW, Washington, DC 20057 USA.	krb27@georgetown.edu		Byrnes, Kimberly/0000-0002-7501-7734			ABRAHAM RT, 1995, BIOL CELL, V83, P105, DOI 10.1016/0248-4900(96)81298-6; Akashiba H, 2006, CELL MOL LIFE SCI, V63, P2397, DOI 10.1007/s00018-006-6194-4; Becker EBE, 2004, PROG NEUROBIOL, V72, P1, DOI 10.1016/j.pneurobio.2003.12.005; Boonstra J, 2003, J CELL BIOCHEM, V90, P244, DOI 10.1002/jcb.10617; Bossenmeyer-Pourie C, 1999, NEUROSCIENCE, V91, P221, DOI 10.1016/S0306-4522(98)00565-X; BURNS KA, 2007, CEREB CORTEX; Campagne MV, 1998, NEUROSCIENCE, V84, P1097, DOI 10.1016/S0306-4522(97)00580-0; Cernak I, 2005, CELL CYCLE, V4, P1286, DOI 10.4161/cc.4.9.1996; Cicero S, 2005, J NEUROSCI, V25, P9658, DOI 10.1523/JNEUROSCI.1773-05.2005; Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0; Dai Yun, 2004, Curr Oncol Rep, V6, P123, DOI 10.1007/s11912-004-0024-3; DeGregori J, 2006, CURR MOL MED, V6, P739; Di Giovanni S, 2005, P NATL ACAD SCI USA, V102, P8333, DOI 10.1073/pnas.0500989102; Di Giovanni S, 2003, ANN NEUROL, V53, P454, DOI 10.1002/ana.10472; Faden AI, 2005, NEUROPHARMACOLOGY, V49, P410, DOI 10.1016/j.neuropharm.2005.04.001; Faulkner JR, 2004, J NEUROSCI, V24, P2143, DOI 10.1523/JNEUROSCI.3547-03.2004; Fischer Peter M, 2003, Prog Cell Cycle Res, V5, P235; Greene LA, 2004, CELL DEATH DIFFER, V11, P49, DOI 10.1038/sj.cdd.4401341; Guadagno TM, 1996, CELL, V84, P73, DOI 10.1016/S0092-8674(00)80994-0; Hayashi T, 1999, NEUROL RES, V21, P695, DOI 10.1080/01616412.1999.11741000; HOKE A, 1994, PERSPECT DEV NEUROBI, V2, P269; Iannotti C, 2004, EXP NEUROL, V189, P317, DOI 10.1016/j.expneurol.2004.05.033; Ino H, 2001, J NEUROSCI, V21, P6086; Jorda EG, 2003, NEUROPHARMACOLOGY, V45, P672, DOI 10.1016/S0028-3908(03)00204-1; Kang SK, 2006, PROTEOMICS, V6, P2797, DOI 10.1002/pmic.200500621; Katano H, 2000, NEUROREPORT, V11, P2073, DOI 10.1097/00001756-200007140-00003; Kato H, 2003, BRAIN RES BULL, V60, P215, DOI 10.1016/S0361-9230(03)00036-4; Kaya SS, 1999, BRAIN RES, V818, P23, DOI 10.1016/S0006-8993(98)01204-9; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Kobori N, 2002, MOL BRAIN RES, V104, P148, DOI 10.1016/S0169-328X(02)00331-5; Koguchi K, 2003, J NEUROSCI RES, V74, P898, DOI 10.1002/jnr.10829; Kranenburg O, 1996, EMBO J, V15, P46, DOI 10.1002/j.1460-2075.1996.tb00332.x; Kruman II, 2004, NEURON, V41, P549, DOI 10.1016/S0896-6273(04)00017-0; Kuan CY, 2004, J NEUROSCI, V24, P10763, DOI 10.1523/JNEUROSCI.3883-04.2004; Lee MH, 1996, P NATL ACAD SCI USA, V93, P3259, DOI 10.1073/pnas.93.8.3259; LI LJ, 1993, P NATL ACAD SCI USA, V90, P3554, DOI 10.1073/pnas.90.8.3554; Liu DX, 2004, J NEUROSCI, V24, P8720, DOI 10.1523/JNEUROSCI.1821-04.2004; Liu DX, 2001, NEURON, V32, P425, DOI 10.1016/S0896-6273(01)00495-0; Love S, 2003, PROG NEURO-PSYCHOPH, V27, P267, DOI 10.1016/S0278-5846(03)00022-8; McGraw J, 2001, J NEUROSCI RES, V63, P109, DOI 10.1002/1097-4547(20010115)63:2<109::AID-JNR1002>3.0.CO;2-J; Meijer L, 2003, ACCOUNTS CHEM RES, V36, P417, DOI 10.1021/ar0201198; Mirjany M, 2002, J PHARMACOL EXP THER, V301, P494, DOI 10.1124/jpet.301.2.494; Nagy Z, 2000, NEUROBIOL AGING, V21, P761, DOI 10.1016/S0197-4580(00)00223-2; Nahle Z, 2002, NAT CELL BIOL, V4, P859, DOI 10.1038/ncb868; Nakatsuji Y, 2001, J NEUROSCI RES, V66, P487, DOI 10.1002/jnr.1240; Newcomb EW, 2004, CELL CYCLE, V3, P230; Nguyen MD, 2003, J NEUROSCI, V23, P2131; Nguyen MD, 2002, CELL DEATH DIFFER, V9, P1294, DOI 10.1038/sj.cdd.4401108; Nishitani H, 2002, GENES CELLS, V7, P523, DOI 10.1046/j.1365-2443.2002.00544.x; Obaya AJ, 2002, CELL MOL LIFE SCI, V59, P126, DOI 10.1007/s00018-002-8410-1; OKANO HJ, 1993, J NEUROSCI, V13, P2930; Osuga H, 2000, P NATL ACAD SCI USA, V97, P10254, DOI 10.1073/pnas.170144197; Otsuka Y, 2004, NEUROSCI LETT, V365, P180, DOI 10.1016/j.neulet.2004.04.083; Padmanabhan J, 1999, J NEUROSCI, V19, P8747, DOI 10.1523/JNEUROSCI.19-20-08747.1999; Park DS, 2000, NEUROBIOL AGING, V21, P771, DOI 10.1016/S0197-4580(00)00220-7; Park DS, 2000, J NEUROSCI, V20, P3104, DOI 10.1523/JNEUROSCI.20-09-03104.2000; Pietenpol JA, 2002, TOXICOLOGY, V181, P475, DOI 10.1016/S0300-483X(02)00460-2; Rashidian J, 2005, P NATL ACAD SCI USA, V102, P14080, DOI 10.1073/pnas.0500099102; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; Sakurai M, 2000, STROKE, V31, P200, DOI 10.1161/01.STR.31.1.200; Sears RC, 2002, J BIOL CHEM, V277, P11617, DOI 10.1074/jbc.R100063200; SHERR CJ, 1995, P ASSOC AM PHYSICIAN, V107, P181; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Small DL, 2001, BRAIN RES, V900, P26, DOI 10.1016/S0006-8993(01)02102-3; Strazza M, 2004, NEUROCHEM RES, V29, P923, DOI 10.1023/B:NERE.0000021236.32785.37; Swanton C, 2004, LANCET ONCOL, V5, P27, DOI 10.1016/S1470-2045(03)01321-4; Takuma K, 2004, PROG NEUROBIOL, V72, P111, DOI 10.1016/j.pneurobio.2004.02.001; Tanaka H, 2004, NEUROSCIENCE, V127, P155, DOI 10.1016/j.neuroscience.2004.05.010; Thornton BR, 2003, NAT CELL BIOL, V5, P1090, DOI 10.1038/ncb1066; Tian DS, 2006, J NEUROSCI RES, V84, P1053, DOI 10.1002/jnr.20999; Velardo MJ, 2004, J NEUROSCI, V24, P8562, DOI 10.1523/JNEUROSCI.3316-04.2004; Verdaguer E, 2004, J PHARMACOL EXP THER, V308, P609, DOI 10.1124/jpet.103.057497; Wang FH, 2002, J CEREBR BLOOD F MET, V22, P171, DOI 10.1097/00004647-200202000-00005; Wartiovaara K, 2002, J NEUROSCI, V22, P815, DOI 10.1523/JNEUROSCI.22-03-00815.2002; Wen Y, 2004, J BIOL CHEM, V279, P22684, DOI 10.1074/jbc.M311768200; Wiessner C, 1996, NEUROSCIENCE, V72, P947, DOI 10.1016/0306-4522(95)00601-X; Yamada J, 2006, BIOCHEM BIOPH RES CO, V349, P913, DOI 10.1016/j.bbrc.2006.08.126; Zhu Z, 2007, GLIA, V55, P546, DOI 10.1002/glia.20476	78	75	78	1	3	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190	1573-6903		NEUROCHEM RES	Neurochem. Res.	OCT	2007	32	10					1799	1807		10.1007/s11064-007-9312-2			9	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	212FH	WOS:000249578500025	17404835				2021-06-18	
J	Malec, JF; Testa, JA; Rush, BK; Brown, AW; Moessner, AM				Malec, James F.; Testa, Julie A.; Rush, Beth K.; Brown, Allen W.; Moessner, Anne M.			Self-assessment of impairment, impaired self-awareness, and depression after traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain; injury; depression; impaired self-awareness; rehabilitation	CLOSED-HEAD-INJURY; MAJOR DEPRESSION; SOCIAL SUPPORT; FOLLOW-UP; SCALE; CONSCIOUSNESS; PERSONALITY; RELIABILITY; INVENTORY; COGNITION	Objective: To identify patient features associated with early and late depression after traumatic brain injury (TBI). Participants: 3 clinical trauma groups (mild TBI, moderate-severe TBI, orthopedic injury) and their significant others. Measures: Preinjuiy: age, education, substance abuse, and psychiatric history; Injury severity: classification using Glasgow Coma Scale and cranial CT scan, posttraumatic amnesia; Early impairment: Neurobehavioral Functioning Inventory (NFI), Impaired Self-Awareness (ISA); Social and family support: Multidimensional Scale of Perceived Social Support, Family Assessment Device; Depression: NFI Depression Scale. Method: Regression analyses of predictor variables on early and late measures of depression. Results: Depression rates did not differ among the 3 trauma groups. Preinjury level of education, previous psychiatric history, and perceived level of social support explained a small portion of the variance in depressive symptoms. Patients' self-assessment of their impairment at discharge was most strongly correlated with both early and late depression. ISA was associated with reduced self-report of depressive symptoms. However, when those with ISA were excluded from the analysis, self-assessment of impairment remained strongly associated with depression. Conclusions: Patients' self-assessment of impairment is strongly associated with early and late depression. Presence and severity of TBI does not appear to play a direct role in depression but does appear related to ISA, which serves as a barrier to the development of depression. Focusing on impairment appears to be a cardinal feature of depression in both patients with TBI and an orthopedic trauma group.	Mayo Clin, Generose METBI, Coll Med, Dept Psychiat, Rochester, MN 55905 USA; Mayo Clin, Dept Psychol, Coll Med, Rochester, MN 55905 USA; Mayo Clin, Dept Phys Med & Rehabil, Coll Med, Rochester, MN 55905 USA; Mayo Clin, Dept Nursing, Coll Med, Rochester, MN 55905 USA	Malec, JF (corresponding author), Mayo Clin, Generose METBI, Coll Med, Dept Psychiat, Rochester, MN 55905 USA.	malec.james@mayo.edu		Brown, Allen W./0000-0001-7228-3351			Babin PR, 2003, BRAIN INJURY, V17, P889, DOI 10.1080/0269905031000088595; Beck AT, 1967, DEPRESSION CAUSES TR; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; Brown AW, 2005, J NEUROTRAUM, V22, P1040, DOI 10.1089/neu.2005.22.1040; Curran CA, 2000, J HEAD TRAUMA REHAB, V15, P1256, DOI 10.1097/00001199-200012000-00006; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; EPSTEIN NB, 1983, J MARITAL FAM THER, V9, P171, DOI 10.1111/j.1752-0606.1983.tb01497.x; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; GOLDSTEIN FC, 1994, J NEUROL NEUROSUR PS, V57, P961, DOI 10.1136/jnnp.57.8.961; Goldstein FC, 1996, NEUROPSYCHOLOGY, V10, P147; GomezHernandez R, 1997, ARCH PHYS MED REHAB, V78, P1321, DOI 10.1016/S0003-9993(97)90304-X; Greenberger D, 1995, MIND MOOD CHANGE YOU; Groom KN, 1998, ARCH CLIN NEUROPSYCH, V13, P695, DOI 10.1016/S0887-6177(98)00005-5; Hall KM, 2001, ARCH PHYS MED REHAB, V82, P367, DOI 10.1053/apmr.2001.21525; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Hoofien D, 2001, BRAIN INJURY, V15, P189; Jorge R, 2002, NEUROREHABILITATION, V17, P311; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P43; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; JORGE RE, 1994, J NEUROSURG, V81, P726, DOI 10.3171/jns.1994.81.5.0726; KAZARIAN SS, 1991, J COMMUNITY PSYCHOL, V19, P150, DOI 10.1002/1520-6629(199104)19:2<150::AID-JCOP2290190206>3.0.CO;2-J; Kreutzer JS, 1996, ARCH PHYS MED REHAB, V77, P116, DOI 10.1016/S0003-9993(96)90155-0; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Kreutzer JS., 1999, NEUROBEHAVIORAL FUNC; LEACH LR, 1994, BRAIN INJURY, V8, P599, DOI 10.3109/02699059409151012; Levin H. S., 1997, SEMINARS CLIN NEUROP, V2, P207; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Malec JF, 2004, REHABIL PSYCHOL, V49, P55, DOI 10.1037/0090-5550.49.1.55; Malec JF, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199706000-00002; Malec JF, 2000, REHABIL PSYCHOL, V45, P227, DOI 10.1037/0090-5550.45.3.227; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; Moldover JE, 2004, NEUROPSYCHOL REV, V14, P143, DOI 10.1023/B:NERV.0000048181.46159.61; MOORE AD, 1995, BRAIN INJURY, V9, P109, DOI 10.3109/02699059509008185; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; Ownsworth TL, 1998, BRAIN INJURY, V12, P735, DOI 10.1080/026990598122133; Prigatano GP, 1998, J HEAD TRAUMA REHAB, V13, P29, DOI 10.1097/00001199-199810000-00005; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; Rowland SM, 2005, BRAIN INJURY, V19, P77, DOI 10.1080/02699050410001719988; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; Satz P, 1998, BRAIN INJURY, V12, P555, DOI 10.1080/026990598122322; Satz P, 1998, BRAIN INJURY, V12, P537, DOI 10.1080/026990598122313; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P1621, DOI 10.1053/S0003-9993(03)00270-3; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Sherer M, 2003, ARCH PHYS MED REHAB, V84, P168, DOI 10.1053/apmr.2003.50045; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; TEASDALE G, 1974, LANCET, V2, P81; Testa JA, 2006, J HEAD TRAUMA REHAB, V21, P236, DOI 10.1097/00001199-200605000-00004; Varney NR, 1987, NEUROPSYCHOLOGY, V1, P7, DOI 10.1037//0894-4105.1.1.7; Wallace CA, 2000, BRAIN INJURY, V14, P549; WITOL AD, 1996, J VOCATIONAL REHABIL, V7, P159; ZIMET GD, 1988, J PERS ASSESS, V52, P30, DOI 10.1207/s15327752jpa5201_2	58	75	76	0	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2007	22	3					156	166		10.1097/01.HTR.0000271116.12028.af			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	174OH	WOS:000246951100002	17510591				2021-06-18	
J	Catena, RD; van Donkelaar, P; Chou, LS				Catena, Robert D.; van Donkelaar, Paul; Chou, Li-Shan			Altered balance control following concussion is better detected with an attention test during gait	GAIT & POSTURE			English	Article						concussion; cognition; secondary task; attention; gait	TRAUMATIC BRAIN-INJURY; CENTER-OF-MASS; DIVIDED ATTENTION; OBSTACLE; MOTION	The purpose of this study was to examine the effects of concussion on gait stability when either a cognitive or motor perturbation is imposed. Fourteen individuals suffering from a grade II concussion and 14 matched controls performed a single task of level walking, a continuous sequential question and answer task while walking, and an obstacle-crossing task. Common gait spatial/temporal measurements, whole-body center of mass motion, and center of pressure trajectory were assessed. Concussed individuals adopted a more conservative strategy to maintain gait stability. Some measurements indicating conservative gait were seen during obstacle crossing, but this was most evident during the Q&A task. Concussed individuals also displayed signs of possible instability during the Q&A task. The question and answer task was most sensitive to distinguishing concussed individuals from healthy individuals, supporting the use of a similar dual-task modality in future testing after concussion to determine a proper time for return to activity. (C) 2006 Elsevier B.V. All rights reserved.	Univ Oregon, Dept Human Physiol, Mot Anal Lab, Eugene, OR 97403 USA; Univ Oregon, Dept Human Physiol, Eye Hand Lab, Eugene, OR 97403 USA	Chou, LS (corresponding author), Univ Oregon, Dept Human Physiol, Mot Anal Lab, Eugene, OR 97403 USA.	chou@uoregon.edu		Catena, Robert/0000-0001-9128-1343	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR023203, R49/CCR021735] Funding Source: Medline		BELL R, 1977, AM FAM PHYSICIAN, V16, P145; Brown LA, 2005, J GERONTOL A-BIOL, V60, P924, DOI 10.1093/gerona/60.7.924; BRUKNER P, 2001, CLIN SPORTS MED; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P224; Chou LS, 2004, GAIT POSTURE, V20, P245, DOI 10.1016/j.gaitpost.2003.09.007; Chou LS, 2001, GAIT POSTURE, V13, P17, DOI 10.1016/S0966-6362(00)00087-4; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P2283, DOI 10.1001/jama.282.24.2283; Gage WH, 2003, EXP BRAIN RES, V150, P385, DOI 10.1007/s00221-003-1468-7; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Hahn ME, 2004, J BIOMECH, V37, P837, DOI 10.1016/j.jbiomech.2003.11.010; Kelly JP, 1997, NEUROLOGY, V48, P581; Parker TM, 2005, CLIN BIOMECH, V20, P389, DOI 10.1016/j.clinbiomech.2004.12.004; PASHLER H, 1990, J EXP PSYCHOL HUMAN, V16, P826, DOI 10.1037/0096-1523.16.4.826; Said CM, 2001, ARCH PHYS MED REHAB, V82, P1712, DOI 10.1053/apmr.2001.26247; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Vallis LA, 2004, EXP BRAIN RES, V157, P94, DOI 10.1007/s00221-003-1824-7; Weerdesteyn V, 2003, J MOTOR BEHAV, V35, P53, DOI 10.1080/00222890309602121; WOLTRING HJ, 1986, ADV ENG SOFTW WORKST, V8, P104, DOI 10.1016/0141-1195(86)90098-7	19	75	75	0	18	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0966-6362			GAIT POSTURE	Gait Posture	MAR	2007	25	3					406	411		10.1016/j.gaitpost.2006.05.006			6	Neurosciences; Orthopedics; Sport Sciences	Neurosciences & Neurology; Orthopedics; Sport Sciences	148LH	WOS:000245075600011	16787746				2021-06-18	
J	Lincoln, AE; Hinton, RY; Almquist, JL; Lager, SL; Dick, RW				Lincoln, Andrew E.; Hinton, Richard Y.; Almquist, Jon L.; Lager, Sean L.; Dick, Randall W.			Head, face, and eye injuries in scholastic and collegiate lacrosse - A 4-year prospective study	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						sports; injury; lacrosse; epidemiology	RISK HOMEOSTASIS THEORY; TRAFFIC ACCIDENT DATA; WOMENS LACROSSE; PREVENTION	Background: Risks and mechanisms of head, face, and eye injuries in high school and college lacrosse are not well documented. Purpose: To identify (1) primary mechanisms of head, face, and eye injuries in lacrosse and (2) differences in injury risk between the men's and women's game and between high school and collegiate levels. Study Design: Descriptive epidemiological study. Methods: The authors gathered data on 507 000 girls' and boys' high school and 649 573 women's and men's college lacrosse athletic exposures using sport-specific injury surveillance systems over 4 seasons. They identified the most common scenarios for head, face, and eye injuries. Results: The high school girls' head, face, and eye injury rate (0.54 per 1000 athletic exposures) was significantly higher (incident rate ratio, 1.42; 95% confidence interval, 1.09-1.86) than that for boys (0.38 per 1000 athletic exposures); college women (0.77 per 1000 athletic exposures) sustained a higher rate of injuries (incident rate ratio, 1.76; 95% confidence interval, 1.42-2.19) than did men (0.44 per 1000 athletic exposures). Concussions constituted a higher percentage of injuries among boys (73%) and men (85%) than among girls (40%) and women (41 %). Men sustained few facial injuries, whereas a substantial proportion of women's injuries involved the face and orbital area. Conclusion: Although permitting only incidental contact, women's lacrosse had higher rates of head, face, and eye injuries at both the high school and collegiate levels. Concussion was the most common injury. For men, the primary injury mechanism was player-to-player contact; women's injuries primarily resulted from stick or ball contact. High school injury rates were lower than were college rates, but the nature of injuries, body parts affected, and mechanisms were similar.	Medstar Res Inst, Hyattsville, MD USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA; Union Mem Hosp, Fairfax Cty Publ Sch, Baltimore, MD USA; Fairfax Cty Publ Sch, Athletic Training Program, Fairfax, VA USA; Natl Coll Athlet Assoc, Indianapolis, IN USA	Lincoln, AE (corresponding author), Union Mem Orthopaed, Johnston Professional Bldg 400,3333 N Calvert St, Baltimore, MD 21218 USA.	lyn.camire@medstar.net					Adams J, 2001, Inj Prev, V7, P89, DOI 10.1136/ip.7.2.89; CRISCO T, FAQS HELMETS HEAD NE; Diamond PT, 2001, BRAIN INJURY, V15, P537, DOI 10.1080/02699050010007362; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; EVANS L, 1986, RISK ANAL, V6, P81, DOI 10.1111/j.1539-6924.1986.tb00196.x; Goldenberg Michael S., 1995, Journal of Athletic Training, V30, P37; Hagel B, 2004, CLIN J SPORT MED, V14, P193, DOI 10.1097/00042752-200407000-00001; Hinton RY, 2005, AM J SPORT MED, V33, P1305, DOI 10.1177/0363546504274148; LAPIDUS CS, 1992, J TRAUMA, V32, P555, DOI 10.1097/00005373-199205000-00003; Marshall SW, 2005, INT J EPIDEMIOL, V34, P113, DOI 10.1093/ije/dyh346; *NAT COLL ATHL ASS, POS REG EYE PROT WOM; *NAT COLL ATHL ASS, 2004, 1981 82 2003 04 NCAA; *NAT COLL ATHL ASS, 2002, INJ SURV SYST 2001 0; Thompson D C, 2001, Inj Prev, V7, P86, DOI 10.1136/ip.7.2.86; *US LACR, 2003 US LACR PART SU; *US LACR, WOM LACR EYEW UPD; VENNUM T, 1994, CREATORS GAME BRIEF; VINGER PF, 1994, DUANES CLIN OPHTHALM, P1; Webster DA, 1999, MED SCI SPORT EXER, V31, P938, DOI 10.1097/00005768-199907000-00004; WILDE GJS, 1986, RISK ANAL, V6, P95, DOI 10.1111/j.1539-6924.1986.tb00197.x	20	75	76	0	8	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	FEB	2007	35	2					207	215		10.1177/0363546506293900			9	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	132ZD	WOS:000243980500004	17204586				2021-06-18	
J	Niederland, T; Makovi, H; Gal, V; Andreka, B; Abraham, CS; Kovacs, J				Niederland, Tamas; Makovi, Helga; Gal, Veronika; Andreka, Bertalan; Abraham, Csongor S.; Kovacs, Jozsef			Abnormalities of pituitary function after traumatic brain injury in children	JOURNAL OF NEUROTRAUMA			English	Article						children; head injury; pituitary dysfunction	GROWTH-HORMONE DEFICIENCY; HEAD TRAUMA; NEUROENDOCRINE DYSFUNCTION; SUBARACHNOID HEMORRHAGE; CONSENSUS GUIDELINES; HYPOPITUITARISM; HYPOGONADISM; HYPOTHYROIDISM; INSUFFICIENCY; CHILDHOOD	Traumatic brain injury (TBI) is a frequent cause of neuroendocrine dysfunction typically in male adults. Head injuries are also common in childhood, but only a few case reports outlined the endocrine consequences. The aim of this study was to reveal anterior pituitary function in children with history of hospitalization due to mild to severe head trauma. Our endocrine follow-up study was performed between October 2003 and February 2004 in the Pediatric Department of Petz Al-adar County Teaching Hospital, Gyor, Hungary. Twenty-six children (17 boys and nine girls, aged 11.47 +/- 0.75 years) at 30.6 +/- 8.3 months after head injury and 21 age-matched controls were enrolled. Basal and stimulated anterior pituitary and peripheral hormone concentrations were measured by routine laboratory methods. Pituitary dysfunction was detected in 61% of patients with TBI history. All growth hormone (GH) parameters measured and calculated were significantly (P < 0.05) lower in TBI group than in controls after L-DOPA stimulation. Similar difference was detected 60 min after insulin provocation. Forty-two percent of all TBI children showed insufficient growth hormone (GH) response in both stimulation tests, 73% of these cases were boys. Cortisol levels of TBI patients were significantly (p < 0.05) lower all through the insulin test than values measured in control group. The degree of pituitary dysfunction was independent from the severity of TBI. Our study confirms the high risk for hypopituitarism in children with TBI despite the lack of obvious clinical symptoms. We suggest screening of pituitary function after any kind of brain trauma requiring hospitalization in childhood.	Peta Aladar Cty Teaching Hosp, Dept Pediat, H-9023 Gyor, Hungary; Peta Aladar Cty Teaching Hosp, Dept Isotop Diagnost, H-9023 Gyor, Hungary; Univ Debrecen, Dept Pharmaceut Technol, H-4012 Debrecen, Hungary; Univ Szeged, Dept Pediat, H-6720 Szeged, Hungary	Niederland, T (corresponding author), Peta Aladar Cty Teaching Hosp, Dept Pediat, Vasvari P U 2, H-9023 Gyor, Hungary.	niederlandt@petz.gyor.hu					Agha A, 2004, J CLIN ENDOCR METAB, V89, P5987, DOI 10.1210/jc.2004-1058; Agha A, 2004, CLIN ENDOCRINOL, V60, P584, DOI 10.1111/j.1365-2265.2004.02023.x; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Casanueva FF, 2005, ARCH PHYS MED REHAB, V86, P463, DOI 10.1016/j.apmr.2004.05.018; Childers MK, 1998, BRAIN INJURY, V12, P517, DOI 10.1080/026990598122476; CLARK JDA, 1988, CLIN ENDOCRINOL, V29, P153, DOI 10.1111/j.1365-2265.1988.tb00257.x; Cohan P, 2005, CRIT CARE MED, V33, P2358, DOI 10.1097/01.CCM.0000181735.51183.A7; CROMPTON MR, 1971, BRAIN, V94, P165, DOI 10.1093/brain/94.1.165; Cyran E, 1918, DEUT MED WOCHENSCHR, V44, P1261; Dimopoulou L, 2004, CRIT CARE MED, V32, P404, DOI 10.1097/01.CCM.0000108885.37811.CA; EDWARDS OM, 1986, MEDICINE, V65, P281; EICHLER I, 1988, J ENDOCRINOL INVEST, V11, P409, DOI 10.1007/BF03349069; EIHOLZER U, 1986, EUR J PEDIATR, V145, P128, DOI 10.1007/BF00441873; Escamilla RF, 1942, J CLIN ENDOCRINOL, V2, P65, DOI 10.1210/jcem-2-2-65; FLEISCHER AS, 1978, J NEUROSURG, V49, P650, DOI 10.3171/jns.1978.49.5.0650; Gandrud LM, 2004, GROWTH HORM IGF RES, V14, P185, DOI 10.1016/j.ghir.2003.11.003; Ghigo E, 2005, BRAIN INJURY, V19, P711, DOI 10.1080/02699050400025315; GUNN IR, 1991, ANN CLIN BIOCHEM, V28, P327, DOI 10.1177/000456329102800402; GUZMAN AL, 1992, ACTA PAEDIATR, V81, P698, DOI 10.1111/j.1651-2227.1992.tb12337.x; Israel E, 2000, J CLIN ENDOCR METAB, V85, P3990; Juul A, 2002, HORM RES, V58, P233, DOI 10.1159/000066265; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Oertel M, 2005, J NEUROSURG, V103, P812, DOI 10.3171/jns.2005.103.5.0812; RUDMAN D, 1977, J CLIN ENDOCR METAB, V45, P747, DOI 10.1210/jcem-45-4-747; Schneider M, 2005, J NEUROTRAUM, V22, P937, DOI 10.1089/neu.2005.22.937; Simmonds M, 1914, DEUT MED WOCHENSCHR, V40, P322, DOI 10.1055/s-0029-1190185; Springer J, 2001, LANCET, V357, P1848, DOI 10.1016/S0140-6736(00)04953-9; Urban RJ, 2005, BRAIN INJURY, V19, P349, DOI 10.1080/02699050400004807; YUAN XQ, 1991, FRONT NEUROENDOCRIN, V12, P209	34	75	75	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2007	24	1					119	127		10.1089/neu.2005.369ER			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	131GX	WOS:000243858100011	17263675				2021-06-18	
J	Leal-Noval, SR; Rincon-Ferrari, MD; Marin-Niebla, A; Cayuela, A; Arellano-Orden, V; Marin-Caballos, A; Amaya-Villar, R; Ferrandiz-Millon, C; Murillo-Cabeza, F				Leal-Noval, Santiago Ramon; Rincon-Ferrari, Maria Dolores; Marin-Niebla, Ana; Cayuela, Aurelio; Arellano-Orden, Victoria; Marin-Caballos, Antonio; Amaya-Villar, Rosario; Ferrandiz-Millon, Carmen; Murillo-Cabeza, Francisco			Transfusion of erythrocyte concentrates produces a variable increment on cerebral oxygenation in patients with severe traumatic brain injury - A preliminary study	INTENSIVE CARE MEDICINE			English	Article						brain hypoxia; cerebral oxygenation; erythrocytes; neurotrauma; PtiO(2); red blood cells; severe brain injury; transfusion	BLOOD-CELL TRANSFUSION; INTENSIVE-CARE; STORED-BLOOD; ANEMIA; RISK; DELIVERY; INCREASE; TENSION	Objective: To investigate the long-term influence of erythrocyte transfusion on cerebral oxygenation in patients with severe traumatic brain injury. Design: Prospective and observational study. Setting: Neurotrauma intensive care unit of trauma center level I. Patients: Sixty consecutive, hemodynamically stable patients with severe traumatic brain injury, pretransfusion hemoglobin < 100 g/l, non-bleeding and monitored through intracranial pressure and brain tissue partial pressure of oxygen (PtiO(2)) catheters were included. Interventions: Transfusion of 1-2 units of red blood cells. Measurements and results: Ten sets of variables (pretransfusion, end of transfusion, and 1, 2, 3, 4, 5, 6, 12 and 24 h after transfusion) were recorded, including: PtiO(2), cerebral perfusion pressure (CPP), end-tidal CO2, peripheral saturation of oxygen, temperature, hemoglobin, lactate and PaO2/FiO(2) ratio. Transfusion was associated with an increase in PtiO(2) during a 6-h period, with a peak at 3 h (26.2%; p = 0.0001) in 78.3% of the patients. No relationship was observed between PtiO(2), CPP and hemoglobin increments. The relative increment in PtiO(2) at hour 3 was only correlated with baseline PtiO(2) (r(2) 0.166; p = 0.001). All of the patients with basal PtiO(2) < 15 mmHg showed an increment in PtiO(2) versus 74.5% of patients with basal PtiO(2) >= 15 mmHg (p < 0.01, hour 3). Conclusions: Erythrocyte transfusion is associated with a variable and prolonged increment of cerebral tissue oxygenation in anemic patients with severe traumatic brain injury. Low baseline PtiO(2) levels (< 15 mmHg) could define those patients who benefit the most from erythrocyte transfusion.	Hosp Univ Virgen Rocio, Seville 41013, Spain	Leal-Noval, SR (corresponding author), Hosp Univ Virgen Rocio, Avda Manuel Siurot S NR, Seville 41013, Spain.	sramon@cica.es	Noval, Santiago/K-4515-2019; Cayuela, Aurelio/AAZ-1294-2020; Cayuela, Aurelio/C-6698-2012	Cayuela, Aurelio/0000-0002-4936-9402; Marin Niebla, Ana/0000-0002-7592-6815			Casutt M, 1999, CRIT CARE MED, V27, P2194, DOI 10.1097/00003246-199910000-00021; Daugherty WP, 2004, NEUROSURGERY, V54, P1223, DOI 10.1227/01.NEU.0000119238.68938.5D; Dings J, 1998, NEUROSURGERY, V43, P1082, DOI 10.1097/00006123-199811000-00045; Fernandes CJ, 2001, CRIT CARE, V5, P362, DOI 10.1186/cc1070; Ho J, 2003, CRIT CARE MED, V31, pS687, DOI 10.1097/01.CCM.0000099349.17094.A3; Lang EW, 2003, CRIT CARE MED, V31, P267, DOI 10.1097/00003246-200301000-00042; Leal-Noval SR, 2000, CRIT CARE MED, V28, P935, DOI 10.1097/00003246-200004000-00004; Malone DL, 2003, J TRAUMA, V54, P898, DOI 10.1097/01.TA.0000060261.10597.5C; MARIK PE, 1993, JAMA-J AM MED ASSOC, V269, P3024, DOI 10.1001/jama.269.23.3024; Marin-Caballos A, 2005, CRIT CARE, V9, pR670, DOI 10.1186/cc3822; Pendem S, 2006, NEUROCRIT CARE, V4, P63, DOI 10.1385/NCC:4:1:063; Sahuquillo J, 2000, ACT NEUR S, V76, P457; Smith MJ, 2005, CRIT CARE MED, V33, P1104, DOI 10.1097/01.CCM.0000162685.60609.49; Smith MJ, 2004, J NEUROSURG, V101, P1, DOI 10.3171/jns.2004.101.1.0001; Spahn DR, 2006, ANESTHESIOLOGY, V104, P905, DOI 10.1097/00000542-200605000-00002; Suttner S, 2004, ANESTH ANALG, V99, P2, DOI 10.1213/01.ANE.0000120163.44315.47; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; Vincent JL, 2002, JAMA-J AM MED ASSOC, V288, P1499, DOI 10.1001/jama.288.12.1499; Walsh TS, 2006, INTENS CARE MED, V32, P100, DOI 10.1007/s00134-005-2855-2; Weiskopf RB, 2006, ANESTHESIOLOGY, V104, P911, DOI 10.1097/00000542-200605000-00005; Yamada S, 2005, CEREBROVASC DIS, V20, P164, DOI 10.1159/000087200; Yamada S, 2003, STROKE, V34, P2781, DOI 10.1161/01.STR.0000103857.13812.9A	23	75	76	0	2	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	NOV	2006	32	11					1733	1740		10.1007/s00134-006-0376-2			8	Critical Care Medicine	General & Internal Medicine	097MZ	WOS:000241453400012	17019549				2021-06-18	
J	Lampert, A; Hains, BC; Waxman, SG				Lampert, Angelika; Hains, Bryan C.; Waxman, Stephen G.			Upregulation of persistent and ramp sodium current in dorsal horn neurons after spinal cord injury	EXPERIMENTAL BRAIN RESEARCH			English	Article						patch-clamp; sodium channel; pain; cell dissociation	CHANNEL MESSENGER-RNAS; SENSORY NEURONS; NERVE INJURY; CENTRAL PAIN; RAT-BRAIN; EXPRESSION; HEMISECTION; MECHANISMS; HYPEREXCITABILITY; DEPOLARIZATION	Traumatic spinal cord injury (SCI) results not only in motor impairment, but also in chronic central neuropathic pain, which often is refractory to conventional treatment approaches. Upregulated expression of sodium channel Nav1.3 has been observed within the spinal dorsal horn neurons after SCI, and appears to contribute to neuronal hyperresponsiveness and pain-related behaviors. In this study we characterized the changes in sodium current properties within dorsal horn neurons after contusive SCI. Four weeks after adult male Sprague-Dawley rats underwent T9 spinal cord contusion injury, when behavioral nociceptive thresholds were decreased to both mechanical and thermal stimuli, whole-cell patch-clamp recordings were performed on acutely dissociated lumbar dorsal horn neurons. The cells demonstrated characteristic fast-activating and fast-inactivating sodium currents. SCI led to a shift of the steady-state activation and inactivation of the sodium current towards more depolarized potentials. The shifted steady-state inactivation shows similarities to that obtained from axotomized dorsal root ganglions, which were shown to upregulate Nav1.3. Small slow depolarizations below action potential threshold produced ramp currents, which were markedly enhanced by SCI (from 182 +/- 41 to 338 +/- 55 pA). The density of the noninactivating persistent sodium current was also significantly enhanced in neurons from SCI animals (from 17.4 +/- 3.2 to 27.7 +/- 4.4 pA/pF at 50-70 ms of depolarization). The increased persistent sodium current and ramp current, which are consistent with upregulation of Nav1.3 within dorsal horn neurons, suggest a basis for the hyperresponsiveness of these neurons following SCI.	Yale Univ, Sch Med, Ctr Neurosci & Regenerat Res, New Haven, CT 06510 USA; VA Connecticut Healthcare Syst, Rehabil Res Ctr, West Haven, CT 06516 USA	Waxman, SG (corresponding author), Yale Univ, Sch Med, Ctr Neurosci & Regenerat Res, 333 Cedar St,LCI-707, New Haven, CT 06510 USA.	stephen.waxman@yale.edu	Waxman, Stephen/Z-2507-2019; Lampert, Angelika/F-7198-2010	Waxman, Stephen/0000-0001-5718-7177; Lampert, Angelika/0000-0001-6319-6272	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F32NS046919] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1 F32 NS046919-01] Funding Source: Medline		Azouz R, 1996, J PHYSIOL-LONDON, V492, P211, DOI 10.1113/jphysiol.1996.sp021302; BECKH S, 1989, EMBO J, V8, P3611, DOI 10.1002/j.1460-2075.1989.tb08534.x; Black JA, 1999, J NEUROPHYSIOL, V82, P2776; BRYSCH W, 1991, EXP BRAIN RES, V86, P562; Christensen MD, 1997, J NEUROTRAUM, V14, P517, DOI 10.1089/neu.1997.14.517; Cummins TR, 1997, J NEUROSCI, V17, P3503; Cummins TR, 2001, J NEUROSCI, V21, P5952; Drew GM, 2004, PAIN, V109, P379, DOI 10.1016/j.pain.2004.02.007; Felts PA, 1997, MOL BRAIN RES, V45, P71, DOI 10.1016/S0169-328X(96)00241-0; FRANCESCHETTI S, 1995, BRAIN RES, V696, P127, DOI 10.1016/0006-8993(95)00807-3; FURUYAMA T, 1993, MOL BRAIN RES, V17, P169, DOI 10.1016/0169-328X(93)90087-6; GRUNER JA, 1992, J NEUROTRAUM, V9, P123, DOI 10.1089/neu.1992.9.123; Hains BC, 2003, J NEUROSCI, V23, P8881; Hains BC, 2003, BRAIN RES, V970, P238, DOI 10.1016/S0006-8993(03)02347-3; Hains BC, 2003, NEUROSCIENCE, V116, P1097, DOI 10.1016/S0306-4522(02)00729-7; Hains BC, 2002, NEUROSCI LETT, V320, P125, DOI 10.1016/S0304-3940(02)00026-5; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; KAY AR, 1986, J NEUROSCI METH, V16, P227, DOI 10.1016/0165-0270(86)90040-3; LOESER JD, 1968, J NEUROSURG, V29, P48, DOI 10.3171/jns.1968.29.1.0048; Pennartz CMA, 1997, J NEUROPHYSIOL, V78, P1811; Prescott SA, 2005, J NEUROSCI, V25, P4743, DOI 10.1523/JNEUROSCI.0356-05.2005; Safronov BV, 1999, J PHYSIOL-LONDON, V514, P729, DOI 10.1111/j.1469-7793.1999.729ad.x; Taddese A, 2002, NEURON, V33, P587, DOI 10.1016/S0896-6273(02)00574-3; Vreugdenhil M, 2004, EUR J NEUROSCI, V19, P2769, DOI 10.1111/j.1460-9568.2004.03400.x; Waxman SG, 2006, TRENDS NEUROSCI, V29, P207, DOI 10.1016/j.tins.2006.02.003; WAXMAN SG, 1994, J NEUROPHYSIOL, V72, P466; Waxman SG, 2000, PHILOS T R SOC B, V355, P199, DOI 10.1098/rstb.2000.0559; Wiesenfeld-Hallin Z, 1997, BEHAV BRAIN SCI, V20, P420, DOI 10.1017/S0140525X97261480	28	75	76	2	5	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013 USA	0014-4819			EXP BRAIN RES	Exp. Brain Res.	OCT	2006	174	4					660	666		10.1007/s00221-006-0511-x			7	Neurosciences	Neurosciences & Neurology	090VN	WOS:000240980800008	16718433				2021-06-18	
J	Einaudi, S; Matarazzo, P; Peretta, P; Grossetti, R; Giordano, F; Altare, F; Bondone, C; Andreo, M; Ivani, G; Genitori, L; de Sanctis, C				Einaudi, S.; Matarazzo, P.; Peretta, P.; Grossetti, R.; Giordano, F.; Altare, F.; Bondone, C.; Andreo, M.; Ivani, G.; Genitori, L.; de Sanctis, C.			Hypothalamo-hypophysial dysfunction after traumatic brain injury in children and adolescents: A preliminary retrospective and prospective study	JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM			English	Article							SALT-WASTING SYNDROME; ASSESS GROWTH-HORMONE; PITUITARY DYSFUNCTION; SUBARACHNOID HEMORRHAGE; HYPOPITUITARISM; HYPONATREMIA; SECRETION; MANAGEMENT; GLUCAGON; DISEASE	With two study protocols, one retrospective and the other prospective, we evaluated hypothalamo-hypophysial dysfunction (HHD) in paediatric patients treated for traumatic brain injury (TBI) in the neurosurgical or intensive care department at our hospital. The retrospective group comprised 22 patients who had experienced TBI 0.7-7.25 years before the study. The prospective group included 30 patients assessed at TBI (T0), 26 of 30 after 6 months (U), and 20 of 26 after 12 months (T12). Auxological and hormonal basal parameters of hypothalamo-hypophysial function were evaluated at recall in the retrospective group, and at T0, T6 and T12 in the prospective group. Basal data and standard dynamic tests in selected patients revealed one with precocious puberty, one with total anterior hypopituitarism, one with central hypogonadism, and one with growth hormone (GH) deficiency in the retrospective group; three patients with cerebral salt-wasting syndrome, one with diabetes insipidus and seven with low T-3 syndrome at T0 (all transient), one with hypocorticism at T6 confirmed at T12, and one with GH deficiency at T12 in the prospective group. The results of our study show that post-TBI HHD in our paediatric cohort is not uncommon. Of the 48 patients who underwent a complete evaluation (22 retrospective study patients and 26 prospective study patients evaluated at T6) five (10.4%) developed HHD 6 months or more after TBI. HHD was newly diagnosed in one previously normal patient from the prospective group at 12 months after TBI. GH deficiency was the most frequent disorder in our paediatric cohort.	Regina Margherita Childrens Hosp, Dept Paediat Endocrinol, I-10126 Turin, Italy; Regina Margherita Childrens Hosp, Dept Paediat Neurosurg, I-10126 Turin, Italy; Regina Margherita Childrens Hosp, Dept Pediat Intens Care Unit, I-10126 Turin, Italy; Regina Margherita Childrens Hosp, Dept Clin Pathol, I-10126 Turin, Italy	Einaudi, S (corresponding author), Regina Margherita Childrens Hosp, Dept Paediat Endocrinol, Piazza Polonia 94, I-10126 Turin, Italy.	silvein@libero.it	Bondone, Claudia/AAI-7088-2021; Genitori, Lorenzo/K-9682-2016; altare, frederic/K-8664-2015	Bondone, Claudia/0000-0003-4120-2533; altare, frederic/0000-0002-5077-4616; Peretta, Paola/0000-0001-5415-4230; Genitori, Lorenzo/0000-0002-4359-0798			Agha A, 2004, J CLIN ENDOCR METAB, V89, P5987, DOI 10.1210/jc.2004-1058; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Aimaretti G, 2004, GROWTH HORM IGF RES, V14, pS114, DOI 10.1016/j.ghir.2004.03.025; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; Albanese A, 2001, ARCH DIS CHILD, V85, P246, DOI 10.1136/adc.85.3.246; Ballerini MG, 2004, J PEDIATR ENDOCR MET, V17, P749; BARZILAY Z, 1988, J MED, V19, P47; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Berkenbosch JW, 2002, PEDIATR NEUROSURG, V36, P75, DOI 10.1159/000048356; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Bussmann C, 2001, CHILD NERV SYST, V17, P58; CHANOINE JP, 1995, J CLIN ENDOCR METAB, V80, P3032, DOI 10.1210/jc.80.10.3032; Cole TJ, 2000, BMJ-BRIT MED J, V320, P1240, DOI 10.1136/bmj.320.7244.1240; DANIEL PM, 1959, LANCET, V2, P927; DATTANI MT, 2001, CLIN PEDIAT ENDOCRIN, P477; Dimopoulou I, 2004, INTENS CARE MED, V30, P1051, DOI 10.1007/s00134-004-2257-x; EDWARDS OM, 1986, MEDICINE, V65, P281; Ghigo E, 1996, J CLIN ENDOCR METAB, V81, P3323, DOI 10.1210/jc.81.9.3323; Greulich WW, 1959, RADIOGRAPHIC ATLAS S, V2nd; JAFFE D, 1991, NEW ENGL J MED, V324, P1477; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; KORNBLUM RN, 1969, ARCH PATHOL, V88, P242; Leong KS, 2001, CLIN ENDOCRINOL, V54, P463, DOI 10.1046/j.1365-2265.2001.01169.x; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; LOPEZ AMC, 2001, MED INT, V18, P105; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Masel BE, 2004, GROWTH HORM IGF RES, V14, pS108, DOI 10.1016/j.ghir.2004.03.024; Matarazzo P, 2004, J PEDIATR ENDOCR MET, V17, P1487; Melver B, 1997, THYROID, V7, P125; NELSON PB, 1981, J NEUROSURG, V55, P938, DOI 10.3171/jns.1981.55.6.0938; Oh MS, 1999, NEPHRON, V82, P110, DOI 10.1159/000045385; RAO RH, 1987, METABOLISM, V36, P658, DOI 10.1016/0026-0495(87)90150-8; Robertson G. L., 1985, DIABETES INSIPIDUS M, P176; TANNER JM, 1976, ARCH DIS CHILD, V51, P170, DOI 10.1136/adc.51.3.170; Tenedieva VD, 2000, ACT NEUR S, V76, P385; ZADIK Z, 1992, HORM RES, V38, P250, DOI 10.1159/000182553	36	75	75	0	1	WALTER DE GRUYTER GMBH	BERLIN	GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY	0334-018X	2191-0251		J PEDIATR ENDOCR MET	J. Pediatr. Endocrinol. Metab.	MAY	2006	19	5					691	703					13	Endocrinology & Metabolism; Pediatrics	Endocrinology & Metabolism; Pediatrics	053HT	WOS:000238296900003	16789636				2021-06-18	
J	Liu, WG; Qiu, WS; Zhang, Y; Wang, WM; Lu, F; Yang, XF				Liu, WG; Qiu, WS; Zhang, Y; Wang, WM; Lu, F; Yang, XF			Effects of selective brain cooling in patients with severe traumatic brain injury: a preliminary study	JOURNAL OF INTERNATIONAL MEDICAL RESEARCH			English	Article						traumatic brain injury; hypothermia; intracranial pressure; superoxide dismutase; selective brain cooling	MILD SYSTEMIC HYPOTHERMIA; MODERATE HYPOTHERMIA; NEUROPROTECTION; MANAGEMENT; PERFUSION; EVEN	We prospectively investigated non-invasive selective brain cooling (SBC) in patients with severe traumatic brain injury. Sixty-six in-patients were randomized into three groups. In one group, brain temperature was maintained at 33 - 35 degrees C by cooling the head and neck (SBC); in a second group, mild systemic hypothermia (MSH; rectal temperature 33 - 35 degrees C) was produced with a cooling blanket; and a control group was not exposed to hypothermia. Natural re-warming began after 3 days. Mean intracranial pressure 24, 48 or 72 h after injury was significantly lower in the SBC group than in the control group. Mean serum superoxide dismutase levels on Days 3 and 7 after injury in the SBC and MSH groups were significantly higher than in the control group. The percentage of patients with a good neurological outcome 2 years after injury was 72.7%, 57.1% and 34.8% in the SBC, MSH and control groups, respectively. Complications were managed without severe sequelae. Non-invasive SBC was safe and effective.	Zhejiang Univ, Coll Med, Affiliated Hosp 2, Dept Neurosurg, Hangzhou 310009, Peoples R China; Hangzhou Normal Coll, Sch Med, Hangzhou Hosp 2, Dept Neurosurg, Hangzhou, Peoples R China	Qiu, WS (corresponding author), Zhejiang Univ, Coll Med, Affiliated Hosp 2, Dept Neurosurg, Hangzhou 310009, Peoples R China.	shihai954@163.com					Battin MR, 2003, PEDIATRICS, V111, P244, DOI 10.1542/peds.111.2.244; Clifton Guy L, 2004, Curr Opin Crit Care, V10, P116, DOI 10.1097/00075198-200404000-00007; Ding YC, 2004, NEUROSURGERY, V54, P956, DOI 10.1227/01.NEU.0000114513.96704.29; Furuse M, 2003, ACTA NEUROCHIR, V145, P983, DOI 10.1007/s00701-003-0119-x; Gluckman PD, 2005, LANCET, V365, P663, DOI 10.1016/S0140-6736(05)17946-X; GRIFFITHS AP, 1988, POSTGRAD MED J, V64, P617, DOI 10.1136/pgmj.64.754.617; Hagioka S, 2003, CRIT CARE MED, V31, P2502, DOI 10.1097/01.CCM.0000084845.76762.F4; Haranishi Y, 2005, EUR J ANAESTH, V22, P140, DOI 10.1017/S0265021505000268; Hinerfeld D, 2004, J NEUROCHEM, V88, P657, DOI 10.1046/j.1471-4159.2003.02195.x; Iwata O, 2005, ANN NEUROL, V58, P75, DOI 10.1002/ana.20528; Iwata O, 2003, PEDIATR INT, V45, P522, DOI 10.1046/j.1442-200X.2003.01784.x; Noguchi Y, 2002, ACTA MED OKAYAMA, V56, P279; Polderman KH, 2004, INTENS CARE MED, V30, P556, DOI 10.1007/s00134-003-2152-x; Polderman KH, 2004, INTENS CARE MED, V30, P757, DOI 10.1007/s00134-003-2151-y; Qiu Wu-si, 2005, Chin J Traumatol, V8, P27; Sahuquillo J, 2004, CURR PHARM DESIGN, V10, P2193, DOI 10.2174/1381612043384051; Schwab S, 2001, STROKE, V32, P2033, DOI 10.1161/hs0901.095394; Suzuki T, 2003, EXP NEUROL, V184, P1017, DOI 10.1016/S0014-4886(03)00389-3; Vincent JL, 2005, CRIT CARE MED, V33, P1392, DOI 10.1097/01.CCM.0000166890.93559.2D; Wang H, 2004, J NEUROSURG, V100, P272, DOI 10.3171/jns.2004.100.2.0272; Wen YS, 2005, J TRAUMA, V58, P577, DOI 10.1097/01.TA.0000152635.99243.30	21	75	79	0	8	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0300-0605	1473-2300		J INT MED RES	J. Int. Med. Res.	JAN-FEB	2006	34	1					58	64		10.1177/147323000603400107			7	Medicine, Research & Experimental; Pharmacology & Pharmacy	Research & Experimental Medicine; Pharmacology & Pharmacy	025KW	WOS:000236265900007	16604824				2021-06-18	
J	Holmes, JF; Palchak, MJ; MacFarlane, T; Kuppermann, N				Holmes, JF; Palchak, MJ; MacFarlane, T; Kuppermann, N			Performance of the pediatric Glasgow Coma Scale in children with blunt head trauma	ACADEMIC EMERGENCY MEDICINE			English	Article; Proceedings Paper	Annual Meeting of the Society-for-Academic-Emergency-Medicine	MAY, 2003	BOSTON, MA	Soc Acad Emergency Med		Glasgow Coma Scale; children; blunt head trauma	YOUNG-CHILDREN; INJURIES; PROGNOSIS; INFANTS	Objectives: To compare the accuracy of a pediatric Glasgow Coma Scale (GCS) score in preverbal children with blunt head trauma with the standard GCS score in older children. Methods: The authors prospectively enrolled children younger than 18 years with blunt head trauma. Patients were divided into cohorts of those 2 years and younger and those older than 2 years. The authors assigned a pediatric GCS score to the younger cohort and the standard GCS score to the older cohort. Outcomes were 1) traumatic brain injury (TBI) on computed tomography (CT) scan or 2) TBI in need of acute intervention. The authors created and compared receiver operating characteristic (ROC) curves between the age cohorts for the association of GCS scores and TBI. Results: The authors enrolled 2,043 children, and 327 were 2 years and younger. Among these 327, 15 (7.7%; 95% confidence interval [CI] = 4.4% to 12.4%) of 194 who underwent imaging with CT had TBI visible and nine (2.8%; 95% Cl = 1.3% to 5.2%) had TBI needing acute intervention. In children older than 2 years, 83 (7.7%; 95% Cl = 6.2% to 9.5%) of the 1,077 who underwent imaging with CT had TBI visible and 96 (5.6%; 95% Cl = 4.6% to 6.8%) had TBI needing acute intervention. For the pediatric GCS in children 2 years and younger, the area under the ROC curve was 0.72 (95% Cl = 0.56 to 0.87) for TBI on CT scan and 0.97 (95% Cl = 0.94 to 1.00) for TBI needing acute intervention. For the standard GCS in older children, the area under the ROC curve was 0.82 (95% Cl = 0.76 to 0.87) for TBI on CT scan and 0.87 (95% Cl = 0.83 to 0.92) for TBI needing acute intervention. Conclusions: This pediatric GCS for children 2 years and younger compares favorably with the standard GCS in the evaluation of children with blunt head trauma. The pediatric GCS is particularly accurate in evaluating preverbal children with blunt head trauma with regard to the need for acute intervention.	Univ Calif Davis, Med Ctr, Div Emergency Med, Dept Emergency Med,Sch Med, Sacramento, CA 95817 USA; Univ Calif Davis, Sch Med, Dept Pediat, Sacramento, CA 95817 USA	Holmes, JF (corresponding author), Univ Calif Davis, Med Ctr, Div Emergency Med, Dept Emergency Med,Sch Med, 2315 Stockton Blvd,PSSB 2100, Sacramento, CA 95817 USA.	jfholmes@ucdavis.edu					CHOI SC, 1988, J NEUROSURG, V69, P381, DOI 10.3171/jns.1988.69.3.0381; Fleiss JL, 1981, STAT METHODS RATES P, V2nd; Gedeit R, 2001, Pediatr Rev, V22, P118, DOI 10.1542/pir.22-4-118; JAMES HE, 1986, PEDIATR ANN, V15, P16, DOI 10.3928/0090-4481-19860101-05; LEVATI A, 1982, J NEUROSURG, V57, P779, DOI 10.3171/jns.1982.57.6.0779; MORRAY JP, 1984, CRIT CARE MED, V12, P1018, DOI 10.1097/00003246-198412000-00002; Palchak MJ, 2003, ANN EMERG MED, V42, P492, DOI 10.1067/S0196-0644(03)00425-6; RAIMONDI AJ, 1984, CHILD BRAIN, V11, P12; REILLY PL, 1988, CHILD NERV SYST, V4, P30; SIMPSON D, 1982, LANCET, V2, P450; SIMPSON DA, 1991, CHILD NERV SYST, V7, P183; Sternbach GL, 2000, J EMERG MED, V19, P67, DOI 10.1016/S0736-4679(00)00182-7; Tatman A, 1997, ARCH DIS CHILD, V77, P519, DOI 10.1136/adc.77.6.519; TEASDALE G, 1974, LANCET, V2, P81; YAGER JY, 1990, AM J DIS CHILD, V144, P1088, DOI 10.1001/archpedi.1990.02150340032019	15	75	77	0	4	HANLEY & BELFUS INC	PHILADELPHIA	210 S 13TH ST, PHILADELPHIA, PA 19107 USA	1069-6563			ACAD EMERG MED	Acad. Emerg. Med.	SEP	2005	12	9					814	819		10.1197/j.aem.2005.04.019			6	Emergency Medicine	Emergency Medicine	962GT	WOS:000231719700004	16141014	Bronze			2021-06-18	
J	Lipsky, RH; Sparling, MB; Ryan, LM; Xu, K; Salazar, AM; Goldman, D; Warden, DL				Lipsky, RH; Sparling, MB; Ryan, LM; Xu, K; Salazar, AM; Goldman, D; Warden, DL			Association of COMT Val1.58Met genotype with executive functioning following traumatic brain injury	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							CATECHOL-O-METHYLTRANSFERASE; PREFRONTAL FUNCTION; PHARMACOGENETICS; POLYMORPHISM; CORTEX; SCHIZOPHRENIA; PERFORMANCE; DISORDERS; GENE	Catechol-O-methyltransferase (COMT) is thought to functionally modulate dopamine neurons, thus likely influencing frontal-executive functioning. High enzyme activity (COMT Val) and low enzyme activity (COMT Met) are functional polymorphisms resulting from a G to A transition in exon 4 (codon 158) of the human COMT gene. Decreased cortical dopamine should result in poorer executive functioning. Therefore, the authors hypothesized that individuals with traumatic brain injury (TBI) and the low enzyme activity polymorphism would perform better on tests Of executive functioning than individuals with the high enzyme activity polymorphism. One hundred thirteen individuals referred to the Defense and Veterans Brain Injury Center underwent a comprehensive TBI evaluation and were genotyped for the COMT polymorphism. Comparison of mean differences among the COMT genotype groups for several measures of aspects of executive functioning was conducted using analysis of variance (ANOVA) with adjustment for multiple comparisons. Homozygotes for the higher activity allele made more perseverative responses on the Wisconsin Card Sorting Test, while homozygotes for the lower activity allele had the least number of perseverative responses. While it cannot be determined whether TBI influenced the association of COMT Val158Met to executive functioning, these data extend the known relationship of genotype to executive performance seen in healthy comparison subjects and individuals with schizophrenia to individuals with TBI.	Walter Reed Army Med Ctr, Def & Vet Brain Injury Ctr, Dept Neurol, Washington, DC 20012 USA; NIAAA, Neurogenet Lab, NIH, Rockville, MD 20852 USA; Walter Reed Army Med Ctr, Def & Vet Brain Injury Ctr, Dept Neurosurg, Washington, DC 20012 USA; Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA	Warden, DL (corresponding author), Walter Reed Army Med Ctr, Def & Vet Brain Injury Ctr, Dept Neurol, POB 59181, Washington, DC 20012 USA.	deborah.warden@na.amedd.army.mil	Majid, Salma/AAT-2616-2020; Goldman, David/F-9772-2010	Majid, Salma/0000-0002-1724-5405; Goldman, David/0000-0002-1724-5405; Lipsky, Robert/0000-0001-7753-1473	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [Z01AA000303, Z01AA000302] Funding Source: NIH RePORTER		BAMBAD MJ, 2003, BRAIN INJURY, V17, P1011; Benton AL, 1978, MULTILINGUAL APHASIA; Bilder RM, 2002, BIOL PSYCHIAT, V52, P701, DOI 10.1016/S0006-3223(02)01416-6; Boone KB, 1998, ARCH CLIN NEUROPSYCH, V13, P585, DOI 10.1016/S0887-6177(97)00074-7; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; DeMille MMC, 2002, HUM GENET, V111, P521, DOI 10.1007/s00439-002-0809-0; Egan MF, 2001, P NATL ACAD SCI USA, V98, P6917, DOI 10.1073/pnas.111134598; Flashman L.A., 2004, J NEUROPSYCHIATRY CL, V16, P238; Flashman LA., 1991, CLIN NEUROPSYCHOL, V5, P190, DOI [10.1080/13854049108403303, DOI 10.1080/13854049108403303]; Gasparini M, 1997, J NEURAL TRANSM, V104, P887, DOI 10.1007/BF01285556; Golden C., 1978, STROOP COLOR WORD TE; Heaton R., 1993, WISCONSIN CARD SORTI; Heaton R.K., 1991, COMPREHENSIVE NORMS; Heaton R. K., 1993, MANUAL REVISED EXPAN; Joober R, 2002, ARCH GEN PSYCHIAT, V59, P662, DOI 10.1001/archpsyc.59.7.662; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Lachman HM, 1996, PHARMACOGENETICS, V6, P243, DOI 10.1097/00008571-199606000-00007; Lewis DA, 2001, J COMP NEUROL, V432, P119, DOI 10.1002/cne.1092; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Malhotra AK, 2002, AM J PSYCHIAT, V159, P652, DOI 10.1176/appi.ajp.159.4.652; Mazei MS, 2002, BRAIN RES, V936, P58, DOI 10.1016/S0006-8993(02)02542-8; McDowell S, 1998, BRAIN, V121, P1155, DOI 10.1093/brain/121.6.1155; McLeod HL, 1998, PHARMACOGENETICS, V8, P195; Moghaddam B, 2002, BIOL PSYCHIAT, V51, P775, DOI 10.1016/S0006-3223(01)01362-2; Salazar AM, 2000, JAMA-J AM MED ASSOC, V283, P3075, DOI 10.1001/jama.283.23.3075; Weinshilboum RM, 1999, ANNU REV PHARMACOL, V39, P19, DOI 10.1146/annurev.pharmtox.39.1.19; Winterer G, 2003, BRAIN RES REV, V43, P134, DOI 10.1016/S0165-0173(03)00205-4; Wolfson D., 1993, HALSTEAD REITAN NEUR	28	75	78	0	5	AMER PSYCHIATRIC PUBLISHING, INC	WASHINGTON	800 MAINE AVE SW, SUITE 900, WASHINGTON, DC 20024 USA	0895-0172	1545-7222		J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	FAL	2005	17	4					465	471		10.1176/appi.neuropsych.17.4.465			7	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	993PH	WOS:000233966900004	16387984				2021-06-18	
J	Congedo, M; Lubar, JF; Joffe, D				Congedo, M; Lubar, JF; Joffe, D			Low-resolution electromagnetic tomography neurofeedback	IEEE TRANSACTIONS ON NEURAL SYSTEMS AND REHABILITATION ENGINEERING			English	Article						brain-computer interfaces (BCI); electroencephalograin (EEG) biofeedback; electromagnetic tomography; inverse solution; low-resolution electromagnetic tomography (LORETA); neurofeedback; p-value combination	ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; ANTERIOR CINGULATE CORTEX; EEG BIOFEEDBACK; ELECTRICAL-ACTIVITY; ALPHA RHYTHMS; BRAIN; LOCALIZATION; FEEDBACK; BEHAVIOR; ANXIETY	Through continuous feedback of the electroencephalogram (EEG) humans can learn how to shape their brain electrical activity in a desired direction. The technique is known as EEG biofeedback, or neurofeedback, and has been used since the late 1960s in research and clinical applications. A major limitation of neurofeedback relates to the limited information provided by a single or small number (if electrodes placed on the scalp. We establish a method for extracting and feeding back intracranial current density and we carry out an experimental study to ascertain the ability of the,participants to drive their own EEG power in a desired direction. To derive current density within the brain volume; we used the low-resolution electromagnetic tomography (LORETA). Six undergraduate students (three males, three females) underwent tomographic neurofeedback (based on 19 electrodes placed according,to the 10-20 system) to enhance the current density power ratio between the frequency bands beta (16-20 Hz) and alpha (8-10 Hz). According to LORETA modeling, the region of interest corresponded to the Anterior Cingulate (cognitive division). The protocol was designed to in prove the performance of the subjects on the dimension of sustained attention. Two hypotheses were tested: 1) that the beta/alpha current density power ratio increased over sessions and 2) that by the end of the training subjects acquired the ability of increasing that ratio at will. Both. hypotheses received substantial experimental support in this study. This is the first application of an EEG inverse solution to neurofeedback. Possible applications of the technique include the treatment of epileptic foci, the rehabilitation of specific brain regions damaged as, a consequence of traumatic brain injury and, in general, the training of any spatial specific cortical electrical activity. These findings may also have relevant consequences for the development of brain-computer interfaces.	Univ Tennessee, Dept Psychol, Knoxville, TN 37996 USA; Lexicor Med Technol, Boulder, CO 80301 USA	Congedo, M (corresponding author), Inst Res Informat & Random Syst IRISA, F-35042 Rennes, France.	loretabiofeedback@yahoo.com					Anderson MJ, 1999, J STAT COMPUT SIM, V62, P271, DOI 10.1080/00949659908811936; Barabasz M., 1996, CHILD STUDY J, V26, P1; Barry RJ, 2003, CLIN NEUROPHYSIOL, V114, P171, DOI 10.1016/S1388-2457(02)00362-0; BLOM JL, 1982, ELECTROEN CLIN NEURO, V54, P591, DOI 10.1016/0013-4694(82)90046-3; Bosch-Bayard J, 2001, CLIN ELECTROENCEPHAL, V32, P47, DOI 10.1177/155005940103200203; Bush G, 1999, BIOL PSYCHIAT, V45, P1542, DOI 10.1016/S0006-3223(99)00083-9; CADE BS, 1999, USER MANUAL BLOSSOM; Cichocki A., 2003, ADAPTIVE BLIND SIGNA; Congedo M., 2003, Journal of Neurotherapy, V7, P1, DOI 10.1300/J184v07n03_01; DEVINSKY O, 1995, BRAIN, V118, P279, DOI 10.1093/brain/118.1.279; EBRAHIMI T, IN PRESS SIGNAL PROC; Edgington E, 1995, RANDOMIZATION; ENGSTROM DR, 1970, NATURE, V227, P1261, DOI 10.1038/2271261a0; Fernandez-Bouzas A, 1999, CLIN ELECTROENCEPHAL, V30, P46, DOI 10.1177/155005949903000205; Fuchs M, 1999, J CLIN NEUROPHYSIOL, V16, P267, DOI 10.1097/00004691-199905000-00006; HARDT JV, 1976, BIOFEEDBACK SELF-REG, V1, P63, DOI 10.1007/BF00998691; Harland CJ, 2002, APPL PHYS LETT, V81, P3284, DOI 10.1063/1.1516861; Hernandez J L, 1994, Int J Neurosci, V76, P267; Hyvarinen A, 2001, INDEPENDENT COMPONENT ANALYSIS: PRINCIPLES AND PRACTICE, P71; Isotani T, 2001, INT J PSYCHOPHYSIOL, V41, P143, DOI 10.1016/S0167-8760(00)00197-5; James LC, 1996, BEHAV MED, V22, P77, DOI 10.1080/08964289.1996.9933767; Kennedy PE, 1996, COMMUN STAT-SIMUL C, V25, P923, DOI 10.1080/03610919608813350; Kotchoubey B, 2002, CONSCIOUS COGN, V11, P98, DOI 10.1006/ccog.2001.0535; Kubler A, 2001, PSYCHOL BULL, V127, P358, DOI 10.1037//0033-2909.127.3.358; Lancaster JL, 1997, HUM BRAIN MAPP, V5, P238, DOI 10.1002/(SICI)1097-0193(1997)5:4<238::AID-HBM6>3.0.CO;2-4; Lancaster JL, 2000, HUM BRAIN MAPP, V10, P120, DOI 10.1002/1097-0193(200007)10:3<120::AID-HBM30>3.0.CO;2-8; Leuchter AF, 1999, PSYCHIAT RES-NEUROIM, V90, P125, DOI 10.1016/S0925-4927(99)00006-2; Linden M, 1996, BIOFEEDBACK SELF-REG, V21, P35, DOI 10.1007/BF02214148; LUBAR JF, 1976, BIOFEEDBACK SELF-REG, V1, P77, DOI 10.1007/BF00998692; Lubar JF, 2003, INT J PSYCHOPHYSIOL, V49, P175, DOI 10.1016/S0167-8760(03)00115-6; LUBAR JF, 1981, ARCH NEUROL-CHICAGO, V38, P700, DOI 10.1001/archneur.1981.00510110060009; LUBAR JF, 1991, BIOFEEDBACK SELF-REG, V16, P201, DOI 10.1007/BF01000016; LUBAR JF, 1976, BIOFEEDBACK SELF-REG, V1, P293, DOI 10.1007/BF01001170; LUBAR JF, APPL PSYCHOPHYSIOL B, V22, P111; Manly B., 1997, RANDOMIZATION BOOTST; Moore NC, 2000, CLIN ELECTROENCEPHAL, V31, P1, DOI 10.1177/155005940003100105; NOWLIS DP, 1970, PSYCHOPHYSIOLOGY, V6, P476, DOI 10.1111/j.1469-8986.1970.tb01756.x; Nunez P. L., 1995, NEOCORTICAL DYNAMICS; Nunez PL, 2001, HUM BRAIN MAPP, V13, P125, DOI 10.1002/hbm.1030; Nunez PL, 2000, BRAIN TOPOGR, V13, P79, DOI 10.1023/A:1026683200895; NUNEZ PL, 1995, SOURCE LOCALIZATION, V6, P16; NUNEZ PL, 1999, INT J BIOELECTROMAGN, V1; Pascual-Marqui R., 2002, JPN J CLIN NEUROPHYS, V30, P81; Pascual-Marqui RD, 2002, METHOD FIND EXP CLIN, V24, P91; Pascual-Marqui RD, 2002, METHOD FIND EXP CLIN, V24, P5; Pascual-Marqui RD., 1999, INT J BIOELECTROMAGN, V1, P75; PASCUALMARQUI RD, 1994, INT J PSYCHOPHYSIOL, V18, P49, DOI 10.1016/0167-8760(84)90014-X; PESARIN E, 2001, MULTIVARIATE PERMUTA; Pizzagalli D, 2001, AM J PSYCHIAT, V158, P405, DOI 10.1176/appi.ajp.158.3.405; Prichep LS, 2001, CLIN ELECTROENCEPHAL, V32, P62, DOI 10.1177/155005940103200204; Rosenfeld J, 2000, AMYOTROPH LATERAL SC, V1, P1, DOI 10.1080/14660820050515638; ROSSITER T, 2003, J NEUROTHERAPY, V6, P9; STERMAN MB, 1981, NEUROSCI BIOBEHAV R, V5, P405, DOI 10.1016/0149-7634(81)90036-1; STERMAN MB, 1973, SEMIN PSYCHIAT, V5, P507; Swingle PG, 1998, BIOL PSYCHIAT, V44, P1196, DOI 10.1016/S0006-3223(97)00541-6; Talairach J., 1988, COPLANAR STEREOTAXIC; TANSEY MA, 1983, BIOFEEDBACK SELF-REG, V8, P25, DOI 10.1007/BF01000534; THOMTON KE, 2002, NEUROREHABILITATION, V17, P69; TOWLE VL, 1993, ELECTROEN CLIN NEURO, V86, P1, DOI 10.1016/0013-4694(93)90061-Y; TRAVIS TA, 1974, J NERV MENT DIS, V158, P163, DOI 10.1097/00005053-197403000-00001; Vorobyov S, 2002, BIOL CYBERN, V86, P293, DOI 10.1007/s00422-001-0298-6; Worrell GA, 2000, BRAIN TOPOGR, V12, P273, DOI 10.1023/A:1023407521772; Yoo SS, 2002, NEUROREPORT, V13, P1377, DOI 10.1097/00001756-200208070-00005	63	75	77	0	19	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	1534-4320	1558-0210		IEEE T NEUR SYS REH	IEEE Trans. Neural Syst. Rehabil. Eng.	DEC	2004	12	4					387	397		10.1109/TNSRE.2004.840492			11	Engineering, Biomedical; Rehabilitation	Engineering; Rehabilitation	879UN	WOS:000225744500003	15614994	Green Published			2021-06-18	
J	Brennan, DM; Georgeadis, AC; Baron, CR; Barker, LM				Brennan, DM; Georgeadis, AC; Baron, CR; Barker, LM			The effect of videoconference-based telerehabilitation on story retelling performance by brain-injured subjects and its implications for remote speech-language therapy	TELEMEDICINE JOURNAL AND E-HEALTH			English	Article							APHASIA; DISORDERS; ADULTS	This paper presents results from a study conducted at the Rehabilitation Engineering Research Center (RERC) on Telerehabilitation at the National Rehabilitation Hospital. The study was designed to measure performance by brain-injured subjects, with medical diagnoses of stroke or traumatic brain injury, on a standardized Speech-Language Pathology evaluation conducted in both face-to-face and videoconference-based telerehabilitation settings. The Story Retelling Procedure (SRP), which measures connected language production and comprehension of spoken narratives, was administered to each subject in both settings. The primary objectives of this study were to: (1) compare communication as measured by the SRP between experimental settings, and (2) determine if subject variables (such as age, education, technology experience or gender) had an effect on performance differences between settings. The rationale was that any difference in this aspect of performance must be identified and characterized before this mode of intervention can be used clinically. Across all subjects (n=40), no significant difference (p>0.05) was found between SRP performance measured in the two settings. Additionally, variables including age, education, technology experience, and gender did not significantly affect the difference between performance in the two settings. Overall, subjects reported a high level of acceptance of videoconferencing with 34 subjects responding "yes," 4 responding "no," and 2 responding "maybe" when asked if they would use videoconferencing again to talk to a clinician. Results of this study confirm the potential for SLP treatment using videoconferencing and indicate a need for continued research in the field.	Natl Rehabil Hosp, Rehabil Engn Res Ctr Telerehabil, Washington, DC 20010 USA; Natl Rehabil Hosp, Speech Language Pathol Serv, Washington, DC 20010 USA	Brennan, DM (corresponding author), Natl Rehabil Hosp, Rehabil Engn Res Ctr Telerehabil, 102 Irving St NW, Washington, DC 20010 USA.	david.m.brennan@medstar.net					Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Brookshire RH, 1993, DISCOURSE COMPREHENS; Czaja SJ, 1998, J GERONTOL B-PSYCHOL, V53, pP329, DOI 10.1093/geronb/53B.5.P329; Doyle PJ, 1998, APHASIOLOGY, V12, P561, DOI 10.1080/02687039808249558; Doyle PJ, 2000, APHASIOLOGY, V14, P537, DOI 10.1080/026870300401306; Duffy JR, 1997, MAYO CLIN PROC, V72, P1116, DOI 10.4065/72.12.1116; DYCK JL, 1994, J EDUC COMPUT RES, V10, P239, DOI 10.2190/E79U-VCRC-EL4E-HRYV; Kully D, 2000, J TELEMED TELECARE, V6, P39, DOI 10.1258/1357633001935509; MARQUIE JC, 1994, APPL ERGON, V25, P130, DOI 10.1016/0003-6870(94)90011-6; MATEER CM, 1987, J HEAD TRAUMA REHAB, V2, P79; McCullough A, 2001, INT J LANG COMM DIS, V36, P321, DOI 10.3109/13682820109177905; McNeil MR, 2002, APHASIOLOGY, V16, P815, DOI 10.1080/02687030244000284; McNeil MR, 2001, APHASIOLOGY, V15, P991, DOI 10.1080/02687040143000348; NICHOLAS LE, 1995, J SPEECH HEAR RES, V38, P146, DOI 10.1044/jshr.3801.145; NICHOLAS LE, 1993, J SPEECH HEAR RES, V36, P338, DOI 10.1044/jshr.3602.338; SCHOENLE P, 2001, P 4 WORLD C BRAIN IN, P55; Schopp L, 2000, TELEMED TODAY, V8, P33; Vaughn G R, 1976, ASHA, V18, P13; Wertz R. T., 1987, CLIN APHASIOLOGY, V17, P117; WERTZ RT, 1992, APHASIOLOGY, V6, P195, DOI 10.1080/02687039208248591	20	75	77	2	24	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1530-5627	1556-3669		TELEMED J E-HEALTH	Telemed. J. e-Health	SUM	2004	10	2					147	154		10.1089/tmj.2004.10.147			8	Health Care Sciences & Services	Health Care Sciences & Services	845MM	WOS:000223248400006	15319044				2021-06-18	
J	Stalnacke, BM; Tegner, Y; Sojka, P				Stalnacke, BM; Tegner, Y; Sojka, P			Playing ice hockey and basketball increases serum levels of S-100B in elite players - A pilot study	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						brain injury; concussion; head injury; sport; ice hockey; basketball	NEURON-SPECIFIC ENOLASE; TRAUMATIC BRAIN-INJURY; MYELIN BASIC-PROTEIN; MINOR HEAD-INJURY; CEREBROSPINAL-FLUID; SUBARACHNOID HEMORRHAGE; CONCUSSION; DAMAGE; MARKER; QUESTIONNAIRE	Objective: To investigate changes in serum concentrations of the biochemical markers of brain damage S-100B and neuron-specific enolase (NSE) in ice hockey and basketball players during games. Design: Descriptive clinical research. Setting; Competitive games of the Swedish Elite Ice Hockey League and the Swedish Elite Basketball League. Participants: Twenty-six male ice hockey players (from two teams) and 18 basketball players (from two teams). Interventions: None. Main Outcome Measures: S-100B and NSE were analyzed using two-site immunoluminometric assays. The numbers of acceleration/deceleration events were assessed from videotape recordings of the games. Head trauma-related symptoms were monitored 24 hours after the game using the Riverimead Post Concussion Symptoms Questionnaire. Results: Changes in serum concentrations of S-100B (post-game - pregame values) were statistically significant after both games (ice hockey, 0.072 +/- 0.108 mug/L, P = 0.00004; basketball, 0.076 +/- 0.091 mug/L, P = 0.001). In basketball, there was a significant correlation between the change in S-100B (post-game - pregame values) and jumps, which were the most frequent acceleration/deceleration (r = 0.706, P = 0.002). For NSE, no statistically significant change in serum concentration was found in either game. For one ice hockey player who experienced concussion during play, S-100B was increased more than for the other players. Conclusions: S-100B was released into the blood of the players as a consequence of game-related activities and events. Analysis of the biochemical brain damage markers (in particular S-100B) seems to have the potential to become a valuable additional tool for assessment of the degree of brain tissue damage in sport-related head trauma and probably for decision making about returning to play.	Umea Univ, Dept Community Med & Rehabil Rehabil Med, SE-90185 Umea, Sweden; Umea Univ, Dept Surg & Perioperat Sci, SE-90185 Umea, Sweden; Lulea Univ Technol, Inst Hlth Sci, Winternet, Boden, Sweden	Sojka, P (corresponding author), Umea Univ, Dept Community Med & Rehabil Rehabil Med, Bldg 9A, SE-90185 Umea, Sweden.	peter.sojka@clinphys.umu.se		Tegner, Yelverton/0000-0003-3628-0705			*AB SANGT MED, 2001, LIA SANGT 100; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Barzo P, 1997, ACT NEUR S, V70, P243; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; BIASCA N, 1995, UNFALLCHIRURG, V98, P283; Bottiger BW, 2001, CIRCULATION, V103, P2694; Cantu RC, 1996, BRIT J SPORT MED, V30, P289, DOI 10.1136/bjsm.30.4.289; CANTU RC, 2000, NEUROLOGIC ATHLETIC, P76; Crawford S, 1996, J NEUROL NEUROSUR PS, V60, P510, DOI 10.1136/jnnp.60.5.510; de Kruijk JR, 2001, ACTA NEUROL SCAND, V103, P175, DOI 10.1034/j.1600-0404.2001.103003175.x; de Vries J, 2001, J NEUROL NEUROSUR PS, V71, P671, DOI 10.1136/jnnp.71.5.671; Ergun R, 1998, NEUROL RES, V20, P418; Erlanger D, 2001, J ATHL TRAINING, V36, P280; Gasquoine PG, 1997, NEUROPSYCHOL REV, V7, P77, DOI 10.1023/B:NERV.0000005945.58251.c0; Goodman D, 2001, MED SCI SPORT EXER, V33, P2004, DOI 10.1097/00005768-200112000-00005; HAIMOTO H, 1987, LAB INVEST, V57, P489; HARDEMARK HG, 1989, ACTA NEUROCHIR, V99, P135, DOI 10.1007/BF01402322; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; Ingebrigtsen T, 1999, NEUROSURGERY, V45, P468, DOI 10.1097/00006123-199909000-00010; Ingebrigtsen T, 2000, BRAIN INJURY, V14, P1047; Jorgensen U, 1986, Br J Sports Med, V20, P7; Kapural M, 2002, BRAIN RES, V940, P102, DOI 10.1016/S0006-8993(02)02586-6; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kelly JP, 1997, NEUROLOGY, V48, P581; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; LECLERC S, 1999, MED SCI SPORTS EXERC, V31; Linstedt U, 2002, ACTA ANAESTH SCAND, V46, P384, DOI 10.1034/j.1399-6576.2002.460409.x; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; MARANGOS PJ, 1987, ANNU REV NEUROSCI, V10, P269, DOI 10.1146/annurev.ne.10.030187.001413; McCrory PR, 1997, MED SCI SPORT EXER, V29, pS207; McCrory PR, 1999, BRIT J SPORT MED, V33, P297; Missler U, 2000, CLIN CHEM, V46, P993; Otto M, 2000, INT J SPORTS MED, V21, P551, DOI 10.1055/s-2000-8480; PERSSON L, 1987, STROKE, V18, P911, DOI 10.1161/01.STR.18.5.911; PERSSON L, 1988, ACTA NEUROCHIR, V93, P116, DOI 10.1007/BF01402892; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; Romner B, 2000, J NEUROTRAUM, V17, P641, DOI 10.1089/089771500415391; Rothoerl RD, 1999, BRAIN INJURY, V13, P387; SHAABAN AM, 2000, ANAESTHESIA, V55, P802; SKOGSEID IM, 1992, ACTA NEUROCHIR, V115, P106, DOI 10.1007/BF01406367; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Sturmi JE, 1998, SPORTS MED, V25, P351, DOI 10.2165/00007256-199825060-00001; Tegner Y, 1996, BRIT J SPORT MED, V30, P251, DOI 10.1136/bjsm.30.3.251; Waterloo K, 1997, ACTA NEUROCHIR, V139, P26, DOI 10.1007/BF01850864; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977; YAMAZAKI Y, 1995, SURG NEUROL, V43, P267, DOI 10.1016/0090-3019(95)80012-6; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	52	75	77	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	SEP	2003	13	5					292	302					11	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	728JU	WOS:000185714700004	14501312				2021-06-18	
J	Hart, T; Whyte, J; Polansky, M; Millis, S; Hammond, FM; Sherer, M; Bushnik, T; Hanks, R; Kreutzer, J				Hart, T; Whyte, J; Polansky, M; Millis, S; Hammond, FM; Sherer, M; Bushnik, T; Hanks, R; Kreutzer, J			Concordance of patient and family report of neurobehavioral symptoms at 1 year after traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; neurobehavioral manifestations; rehabilitation; treatment outcome	HEAD-INJURY; IMPAIRED AWARENESS; SELF-REPORT; DISABILITY; RELATIVES; REHABILITATION; COMMUNITY; RECOVERY; ADULTS	Objective: To determine concordance between patient and family report of neurobehavioral symptoms and problems across 6 domains of function and 3 levels of injury severity at 1 year after traumatic brain injury (TBI). Design: Prospective longitudinal design with follow-up between 10 and 14 months postinjury. Setting: Seventeen Traumatic Brain Injury Model Systems centers. Participants: A total of 267 adults with primarily moderate and severe TBI who had completed self-ratings and whose neurobehavioral symptoms had also been rated by their significant others. Interventions: Not applicable. Main Outcome Measures: Neurobehavioral Functioning Inventory-Revised, a 70-item scale with subscales assessing frequency of symptoms in motor, somatic, memory and attention, depression, communication, and aggression domains. Results: Twenty-three items showed significant differences or trends between the self- and other ratings; 18 of these were in the direction of the injured individual reporting less frequent problems. Differences were most pronounced on the depression, aggression, and memory and attention subscales. On the latter 2 subscales, patient-family concordance was higher for those with less severe injuries. However, severity effects were not clear cut. Analyses of selected rating patterns indicating clinically significant "underreporting" of symptoms revealed that these affected the depression, aggression, and memory and attention subscales more than the motor or somatic subscales. Conclusions: At 1 year post-TBI, concordance between self- and other report of neurobehavioral symptoms was moderately high overall, but varied by symptom domain. For per- sons with moderate and severe TBI, reports from significant others may be needed for a full picture of the range, severity, and clinical importance of the patient's emotional, behavioral, and cognitive difficulties.	Thomas Jefferson Univ, Jefferson Med Coll, Moss Rehabil Res Inst, Philadelphia, PA 19141 USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Rehabil Med, Philadelphia, PA 19141 USA; MCP Hahnemann Sch Publ Hlth, Philadelphia, PA USA; Kessler Med Rehabil Res & Educ Corp, W Orange, NJ USA; Carolinas HealthCare Syst, Charlotte Inst Rehabil, Dept Phys Med & Rehabil, Charlotte, NC USA; Univ Mississippi, Med Ctr, Methodist Rehabil Ctr, Jackson, MS 39216 USA; Univ Mississippi, Med Ctr, Dept Neurol, Jackson, MS 39216 USA; Univ Mississippi, Med Ctr, Dept Psychiat, Jackson, MS 39216 USA; Santa Clara Valley Med Ctr, Rehabil Res Ctr, San Jose, CA 95128 USA; Wayne State Univ, Sch Med, Dept Phys Med & Rehabil, Detroit, MI USA; Rehabil Inst Michigan, Detroit, MI USA; Virginia Commonwealth Univ, Med Coll Virginia, Richmond, VA 23298 USA	Hart, T (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Moss Rehabil Res Inst, 1200 W Tabor Rd, Philadelphia, PA 19141 USA.			Bushnik, Tamara/0000-0003-3328-257X; Whyte, John/0000-0002-4381-1474			BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P132, DOI 10.1016/S0003-9993(97)90253-7; Cusick CP, 2000, J HEAD TRAUMA REHAB, V15, P739, DOI 10.1097/00001199-200002000-00012; FORDYCE DJ, 1986, REHABIL PSYCHOL, V31, P217, DOI 10.1037//0090-5550.31.4.217; Gasquoine PG, 1994, J HEAD TRAUMA REHAB, V9, P16, DOI DOI 10.1097/00001199-199412000-00004; HENDRYX PM, 1989, ARCH PHYS MED REHAB, V70, P526; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; Kreutzer JS, 1996, ARCH PHYS MED REHAB, V77, P116, DOI 10.1016/S0003-9993(96)90155-0; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; KREUTZER JS, 1991, COGNITIVE REHABILITA, P55; Kreutzer JS., 1999, NEUROBEHAVIORAL FUNC; LEVIN HS, 1997, BEHAV NEUROLOGY NEUR, P479; LIN LI, 1989, BIOMETRICS, V45, P255, DOI 10.2307/2532051; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Powell JM, 2001, ARCH PHYS MED REHAB, V82, P1025, DOI 10.1053/apmr.2001.25082; Prigatano G., 1991, AWARENESS DEFICIT AF; Prigatano George P, 1993, Clin Neuropsychol, V7, P123, DOI 10.1080/13854049308401514; Prigatano GP, 1997, NEUROPSY NEUROPSY BE, V10, P135; Prigatano GP, 1998, J HEAD TRAUMA REHAB, V13, P29, DOI 10.1097/00001199-199810000-00005; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P353, DOI 10.1016/S0003-9993(97)90225-2; Seel RT, 1997, ARCH PHYS MED REHAB, V78, P1254, DOI 10.1016/S0003-9993(97)90340-3; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Siegel S., 1988, NONPARAMETRIC STAT B; Tepper S, 1996, BRAIN INJURY, V10, P575, DOI 10.1080/026990596124142; WEHMAN PH, 1991, ARCH PHYS MED REHAB, V72, P101; Whyte J, 1998, REHABILITATION MED P, P1191; WITOL AD, 1996, J VOCATIONAL REHABIL, V7, P159	30	75	75	0	4	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	FEB	2003	84	2					204	213		10.1053/apmr.2003.50019			10	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	643QV	WOS:000180872700009	12601651				2021-06-18	
J	Bombardier, CH; Rimmele, CT; Zintel, H				Bombardier, CH; Rimmele, CT; Zintel, H			The magnitude and correlates of alcohol and drug use before traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; rehabilitation; substance-related disorders	CHANGE QUESTIONNAIRE; READINESS; ABUSE; COCAINE; INTERVENTIONS; CONSUMPTION; PREVALENCE; POPULATION; VALIDITY; DRINKERS	Objective: To describe preinjury alcohol and drug use and opportunities for secondary prevention among persons with recent traumatic brain injury (TBI). Design: Survey. Setting: Acute inpatient rehabilitation program. Participants: A total of 142 (91%) of 156 consecutive admissions who met inclusion criteria and were screened. Interventions: Not applicable. Main Outcome Measures: Alcohol and drug use questionnaires, alcohol problem questions, toxicology results, readiness to change, and treatment preference questions. Results: Subjects were on average 37 years old, 80% were men, and 80% were white. Fifty-nine percent of the sample was considered "at-risk" drinkers and, as a group, subjects reported a high degree of preinjury alcohol-related problems. Thirty-four percent reported recent illicit drug use, and 42 (37%) of 114 cases with toxicology results were positive for illicit drugs. Motivation to change alcohol use correlated positively with greater self-reported alcohol consumption and problem severity. Most at-risk drinkers wanted to change on their own, whereas a minority were interested in treatment or Alcoholics Anonymous. Conclusion: Both alcohol abuse and drug use are common before TBI. Inpatient brain injury rehabilitation represents an important opportunity to identify and intervene in substance abuse problems. (C) 2002 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	Univ Washington, Harborview Med Ctr, Sch Med, Dept Rehabil Med, Seattle, WA 98104 USA; Dept Psychiat & Behav Sci, Seattle, WA USA; Seattle Vet Adm Med Ctr, Seattle, WA USA	Bombardier, CH (corresponding author), Univ Washington, Harborview Med Ctr, Sch Med, Dept Rehabil Med, 325 9Th Ave,Box 359740, Seattle, WA 98104 USA.				ODCDC CDC HHS [R49/CCR011714-01] Funding Source: Medline		American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Babor TF, 1992, PROJECT IDENTIFICATI; Bombardier CH, 1997, ARCH PHYS MED REHAB, V78, P592, DOI 10.1016/S0003-9993(97)90424-X; Bombardier CH, 1998, ARCH PHYS MED REHAB, V79, P1110, DOI 10.1016/S0003-9993(98)90180-0; Bombardier CH, 2000, J HEAD TRAUMA REHAB, V15, P696, DOI 10.1097/00001199-200002000-00008; BRADLEY KA, 1993, ARCH INTERN MED, V153, P2734, DOI 10.1001/archinte.153.24.2734; Budney AJ, 1997, DRUG ALCOHOL DEPEN, V45, P1, DOI 10.1016/S0376-8716(97)01351-3; Cooney N, 1995, HDB ALCOHOLISM TREAT, P45; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; DIKMEN SS, 1995, ANN EMERG MED, V26, P167, DOI 10.1016/S0196-0644(95)70147-8; DIKMEN SS, 1995, ANN EMERG MED, V26, P221; Drubach D A, 1993, Md Med J, V42, P989; Fiellin DA, 2000, ARCH INTERN MED, V160, P1977, DOI 10.1001/archinte.160.13.1977; Gentilello LM, 1999, ANN SURG, V230, P473, DOI 10.1097/00000658-199910000-00003; HARBURG E, 1988, J STUD ALCOHOL, V49, P522, DOI 10.15288/jsa.1988.49.522; HEATHER N, 1993, ADDICTION, V88, P1667, DOI 10.1111/j.1360-0443.1993.tb02042.x; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Institute of Medicine Division of Mental Health and Behavioral Medicine, 1990, BROAD BAS TREATM ALC; JACOBSON GR, 1989, HDB ALCOHOLISM TREAT, P54; Jones G.A., 1992, NEUROREHABILITATION, V2, P27; Jong CN, 1999, BRAIN INJURY, V13, P1017; KAPLAN C P, 1992, Brain Injury, V6, P337, DOI 10.3109/02699059209034948; KAROL R, 1991, ALCOHOL DRUGS BRAIN; KISHLINE A, 1994, MODERATE DRINKING MO, P168; KRAUS JF, 1989, AM J PUBLIC HEALTH, V79, P294, DOI 10.2105/AJPH.79.3.294; KREUTZER J S, 1991, Brain Injury, V5, P177, DOI 10.3109/02699059109008088; Kreutzer JS, 1996, J HEAD TRAUMA REHAB, V11, P58, DOI 10.1097/00001199-199610000-00006; KREUTZER JS, 1991, J HEAD TRAUMA REHAB, V6, P12; KREUTZER JS, 1990, J HEAD TRAUMA REHAB, V5, P9, DOI DOI 10.1097/00001199-199009000-00005; LANGLEY M J, 1990, Brain Injury, V4, P77, DOI 10.3109/02699059009026151; LEIRER VO, 1991, AVIAT SPACE ENVIR MD, V62, P221; MATCH P, 1977, J STUD ALCOHOL, V58, P7; McKay JR, 1999, J STUD ALCOHOL, V60, P566, DOI 10.15288/jsa.1999.60.566; Miller WR, 1998, ADDICTION, V93, P163, DOI 10.1046/j.1360-0443.1998.9321632.x; MILLER WR, 1990, HOW CONTROL YOUR DRI; Miller WR, 1987, BRIEF DRINKER PROFIL; Pope HG, 1996, JAMA-J AM MED ASSOC, V275, P1547, DOI 10.1001/jama.1996.03530440025030; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Raven MA, 2000, EXP CLIN PSYCHOPHARM, V8, P117, DOI 10.1037/1064-1297.8.1.117; RIVARA FP, 1993, ARCH SURG-CHICAGO, V128, P907; Rivara FP, 1993, ARCH SURG-CHICAGO, V128, P912; ROLLNICK S, 1992, BRIT J ADDICT, V87, P743; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P138, DOI 10.1016/S0003-9993(97)90254-9; SELZER ML, 1975, J STUD ALCOHOL, V36, P127; SOBELL LC, 1990, BEHAV ASSESS, V12, P77; Sobell LC, 1996, AM J PUBLIC HEALTH, V86, P966, DOI 10.2105/AJPH.86.7.966; WILLIAMS GD, 1992, BRIT J ADDICT, V87, P643; WINDLE M, 1991, J DRUG EDUC, V21, P133, DOI 10.2190/F497-8GKY-0U31-XMJJ; Wong Pauline P., 1993, Brain Injury, V7, P283, DOI 10.3109/02699059309034955	49	75	75	0	8	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	DEC	2002	83	12					1765	1773		10.1053/apmr.2002.36085			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	622ZF	WOS:000179677700013	12474184				2021-06-18	
J	Iwata, A; Chen, XH; McIntosh, TK; Browne, KD; Smith, DH				Iwata, A; Chen, XH; McIntosh, TK; Browne, KD; Smith, DH			Long-term accumulation of amyloid-beta in axons following brain trauma without persistent upregulation of amyloid precursor protein genes	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						Alzheimer disease; amyloid-beta; amyloid precursor protein; axonal injury; brain atrophy; neurofilament protein; traumatic brain injury	TRANSIENT FOCAL ISCHEMIA; FLUID-PERCUSSION MODEL; FACTOR MESSENGER-RNA; SEVERE HEAD-INJURY; ALZHEIMERS-DISEASE; INHIBITOR DOMAIN; TRANSGENIC MICE; NEURON DEATH; RAT-BRAIN; EXPRESSION	Brain trauma has been shown to be a risk factor for developing Alzheimer disease (AD), and AD-like plaques containing amyloid-beta (Abeta) peptides have been found in the brain shortly following trauma. Here, we evaluated the effects of brain trauma. on the accumulation of Abeta and expression of amyloid precursor protein (APP) genes (APP695 and APP751/770) over 1 yr in a non-transgenic rodent model. Anesthetized male Sprague-Dawley rats were subjected to parasagittal fluid percussion brain injury of moderate severity (2.5-2.9 atm) or sham treatment and their brains were evaluated at 2, 4, 7, 14 days, and 1, 2, 6, 12 months following injury. Immunohistochemical analysis detected only weak Abeta staining by 2 wk following injury. However; by 1 month to 1 yr following injury, strong immunoreactivity for Abeta was found in damaged axons throughout the thalamus and white matter. Western blot analysis confirmed the accumulation of Abeta peptides in tissue from injured brains. Although in situ hybridization demonstrated an increased gene expression of APP751/770 surrounding the cortical lesion at 2 to 7 days following injury, this expression returned to baseline levels at all subsequent time points and no increase in the expression of APP695 was detected at any time point. These results demonstrate that long-term Abeta accumulation in damaged axons can be induced in a non-transgenic rodent model of brain trauma. Surprisingly, the extent of this Abeta production appeared to be dependent on the maturity of the injury, but uncoupled from the gene expression of APP Together, these data suggest a mechanism that may contribute to long-term neurodegeneration following brain trauma.	Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA	Smith, DH (corresponding author), Univ Penn, Sch Med, Dept Neurosurg, 105C Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.		smith, douglas/A-1321-2007		NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG 21527] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 38104, NS 08803] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803, P01NS008803, R01NS038104] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K08AG021527] Funding Source: NIH RePORTER		ABE K, 1991, NEUROSCI LETT, V125, P172, DOI 10.1016/0304-3940(91)90020-T; ADAMS JH, 1991, J NEUROL NEUROSUR PS, V54, P481, DOI 10.1136/jnnp.54.6.481; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; AdleBiassette H, 1996, NEUROBIOL AGING, V17, P415, DOI 10.1016/0197-4580(96)00029-2; ANDERSON CV, 1995, J NEUROPSYCH CLIN N, V7, P42; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Breteler MMB, 1995, AM J EPIDEMIOL, V142, P1300, DOI 10.1093/oxfordjournals.aje.a117597; Caswell MD, 1999, EUR J BIOCHEM, V266, P509, DOI 10.1046/j.1432-1327.1999.00886.x; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Emmerling MR, 2000, ANN NY ACAD SCI, V903, P118, DOI 10.1111/j.1749-6632.2000.tb06357.x; FRATIGLIONI L, 1993, ANN NEUROL, V33, P258, DOI 10.1002/ana.410330306; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; Gentleman SM, 1997, NEUROREPORT, V8, P1519, DOI 10.1097/00001756-199704140-00039; GRAHAM DI, 1995, NEUROPATH APPL NEURO, V21, P27, DOI 10.1111/j.1365-2990.1995.tb01025.x; Hayes R L, 1987, Brain Inj, V1, P93, DOI 10.3109/02699058709034449; Henry-Feugeas MC, 2000, BRAIN INJURY, V14, P597; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Iwata A, 1997, J NEUROTRAUM, V14, P201, DOI 10.1089/neu.1997.14.201; JOHNSON SA, 1990, SCIENCE, V248, P854, DOI 10.1126/science.2111579; JOHNSON SA, 1989, NEUROBIOL AGING, V10, P755, DOI 10.1016/0197-4580(89)90017-1; JOHNSON SA, 1988, EXP NEUROL, V102, P264, DOI 10.1016/0014-4886(88)90104-5; Johnston JA, 1996, MOL BRAIN RES, V43, P77, DOI 10.1016/S0169-328X(96)00160-X; KALARIA RN, 1993, NEUROREPORT, V4, P211, DOI 10.1097/00001756-199302000-00025; Kalaria RN, 1996, NEUROREPORT, V7, P1377, DOI 10.1097/00001756-199605310-00009; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; Koistinaho J, 1996, NEUROREPORT, V7, P2727, DOI 10.1097/00001756-199611040-00064; Leoni MJ, 2000, EXP NEUROL, V166, P442, DOI 10.1006/exnr.2000.7513; LEWEN A, 1995, NEUROREPORT, V6, P357, DOI 10.1097/00001756-199501000-00032; Masumura M, 2000, J NEUROTRAUM, V17, P123, DOI 10.1089/neu.2000.17.123; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Mehta KM, 1999, NEUROLOGY, V53, P1959, DOI 10.1212/WNL.53.9.1959; Moir RD, 1998, J BIOL CHEM, V273, P5013, DOI 10.1074/jbc.273.9.5013; MORTIMER JA, 1991, INT J EPIDEMIOL S2, V20, P528; Mrak RE, 1996, J NEUROPATH EXP NEUR, V55, P273, DOI 10.1097/00005072-199603000-00002; Murai H, 1998, J COMP NEUROL, V392, P428, DOI 10.1002/(SICI)1096-9861(19980323)392:4<428::AID-CNE2>3.0.CO;2-2; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; Pierce JES, 1996, J NEUROSCI, V16, P1083; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; POVLISHOCK JT, 1985, LAB INVEST, V52, P540; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Raby CA, 1998, J NEUROCHEM, V71, P2505; RASMUSSON DX, 1995, BRAIN INJURY, V9, P213, DOI 10.3109/02699059509008194; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SOLA C, 1993, MOL BRAIN RES, V17, P41, DOI 10.1016/0169-328X(93)90071-V; SPILLANTINI MG, 1989, P NATL ACAD SCI USA, V86, P8555, DOI 10.1073/pnas.86.21.8555; TANAKA S, 1989, BIOCHEM BIOPH RES CO, V165, P1406, DOI 10.1016/0006-291X(89)92760-5; TANAKA S, 1988, BIOCHEM BIOPH RES CO, V157, P472, DOI 10.1016/S0006-291X(88)80273-0; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; TOKUDA T, 1991, ACTA NEUROPATHOL, V82, P281; WILLIAMS DB, 1991, NEUROLOGY, V41, P1554, DOI 10.1212/WNL.41.10.1554; WILLOUGHBY DA, 1992, EXP NEUROL, V118, P332, DOI 10.1016/0014-4886(92)90191-R; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117	63	75	78	0	4	AMER ASSN NEUROPATHOLOGISTS INC	LAWRENCE	1041 NEW HAMPSHIRE ST, LAWRENCE, KS 66044 USA	0022-3069			J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	DEC	2002	61	12					1056	1068		10.1093/jnen/61.12.1056			13	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	624LY	WOS:000179762200004	12484568	Bronze			2021-06-18	
J	Cernak, I; O'Connor, C; Vink, R				Cernak, I; O'Connor, C; Vink, R			Inhibition of cyclooxygenase 2 by nimesulide improves cognitive outcome more than motor outcome following diffuse traumatic brain injury in rats	EXPERIMENTAL BRAIN RESEARCH			English	Article						neurotrauma; COX; cognition; diffuse axonal injury	INDUCIBLE CYCLOOXYGENASE; EXPRESSION; DAMAGE; INDOMETHACIN; NEURONS; COX-2; MODEL	Prostanoid synthesis is regulated by the enzyme cyclo-oxygenase (COX) that is present in at least two isoforms: COX-1, the constitutive form, and COX-2, the inducible form. Expression of COX-2 has recently been shown to be an important determinant of the cytotoxicity connected with inflammation following ischemic injury to the brain. The present study examines the temporal and spatial profiles of COX-2 expression following diffuse traumatic brain injury (TBI) in rats, and the effects of the COX-2 inhibitor nimesulide on cognitive and motor outcomes. Adult, male Sprague-Dawley rats were injured using the 2-meter impact acceleration model of diffuse TBI. At preselected time points after injury, animals were killed and the expression of COX-2 was measured in the hippocampus and parietal cortex by immunohistochemistry and Western blotting techniques. Effects of nimesulide (6 mg/kg daily over ten days) on cognitive and motor outcome was assessed in a separate group of animals using the Barnes circular maze and rotarod test, respectively. A highly significant up-regulation of COX-2 expression was found in the hippocampus as early as 3 h post-trauma and persisting for at least 12 days after TBI. In contrast, a slight but significant upregulation of COX-2 expression occurred in the cortex only at 3 days after trauma. Administration of the COX-2 inhibitor nimesulide resulted in a significant and substantial improvement in cognitive function compared to vehicle-treated controls, while motor deficits after injury was only improved at 24 It after injury. We conclude that COX-2 is involved in the development of functional deficits following diffuse TBI, particularly cognitive deficits, and that these can be improved by administration of COX-2 inhibitors.	Univ Adelaide, Dept Pathol, Adelaide, SA 5005, Australia; Georgetown Univ, Dept Neurosci, Washington, DC 20057 USA	Vink, R (corresponding author), Univ Adelaide, Dept Pathol, Adelaide, SA 5005, Australia.	Robert.Vink@adelaide.edu.au	AM, Robert Vink/S-5616-2019; Cernak, Ibolja/A-6399-2008; Vink, Robert/J-7351-2012	AM, Robert Vink/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667; Ibolja, Cernak/0000-0003-3214-698X			Adams J, 1996, J NEUROCHEM, V66, P6; BARNES CA, 1979, J COMP PHYSIOL PSYCH, V93, P74, DOI 10.1037/h0077579; BENEDEK G, 1987, CAN J NEUROL SCI, V14, P145; Brian JE, 1998, STROKE, V29, P2600, DOI 10.1161/01.STR.29.12.2600; Buccellati C, 1998, NEUROSCI LETT, V257, P123, DOI 10.1016/S0304-3940(98)00745-9; Buttar NS, 2000, MAYO CLIN PROC, V75, P1027, DOI 10.4065/75.10.1027; Candelario-Jalil E, 2000, EUR J PHARMACOL, V390, P295, DOI 10.1016/S0014-2999(99)00908-5; Dash PK, 2000, J NEUROTRAUM, V17, P69, DOI 10.1089/neu.2000.17.69; DeWitt DS, 1998, CRIT CARE MED, V26, P819, DOI 10.1097/00003246-199805000-00008; Dubois RN, 1998, FASEB J, V12, P1063; Faden AI, 1996, JAMA-J AM MED ASSOC, V276, P569, DOI 10.1001/jama.276.7.569; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Fox GB, 1998, J NEUROTRAUM, V15, P1037, DOI 10.1089/neu.1998.15.1037; Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Heath DL, 1999, J PHARMACOL EXP THER, V288, P1311; Hendrich KS, 1999, MAGN RESON MED, V42, P673, DOI 10.1002/(SICI)1522-2594(199910)42:4<673::AID-MRM8>3.0.CO;2-B; Iadecola C, 1999, ACTA NEUROPATHOL, V98, P9, DOI 10.1007/s004010051045; KIM HJ, 1989, J NEUROSURG, V71, P565, DOI 10.3171/jns.1989.71.4.0565; Koyfman L, 2000, J NEUROSURG ANESTH, V12, P44, DOI 10.1097/00008506-200001000-00009; Lasa M, 2000, MOL CELL BIOL, V20, P4265, DOI 10.1128/MCB.20.12.4265-4274.2000; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Nakayama M, 1998, P NATL ACAD SCI USA, V95, P10954, DOI 10.1073/pnas.95.18.10954; Parsadaniantz SM, 2000, J NEUROENDOCRINOL, V12, P766, DOI 10.1046/j.1365-2826.2000.00517.x; Strauss KI, 2000, J NEUROTRAUM, V17, P695, DOI 10.1089/089771500415436; Tardieu D, 2000, CARCINOGENESIS, V21, P973, DOI 10.1093/carcin/21.5.973; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; Wakita H, 1999, NEUROREPORT, V10, P1461, DOI 10.1097/00001756-199905140-00013; WEI EP, 1981, CIRC RES, V48, P95, DOI 10.1161/01.RES.48.1.95; WILLARD LB, 2000, CIRC RES, V48, P95; Willoughby DA, 2000, LANCET, V355, P646, DOI 10.1016/S0140-6736(99)12031-2; YAMAGATA K, 1993, NEURON, V11, P371, DOI 10.1016/0896-6273(93)90192-T	34	75	81	0	1	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0014-4819	1432-1106		EXP BRAIN RES	Exp. Brain Res.	NOV	2002	147	2					193	199		10.1007/s00221-002-1245-z			7	Neurosciences	Neurosciences & Neurology	621EM	WOS:000179575600007	12410334				2021-06-18	
J	Biousse, V; Suh, DY; Newman, NJ; Davis, PC; Mapstone, T; Lambert, SR				Biousse, V; Suh, DY; Newman, NJ; Davis, PC; Mapstone, T; Lambert, SR			Diffusion-weighted magnetic resonance imaging in shaken baby syndrome	AMERICAN JOURNAL OF OPHTHALMOLOGY			English	Article; Proceedings Paper	27th Annual Meeting of the American-Association-for-Pediatric-Ophthalmology-and-Strabismus	MAR 21-25, 2001	ORLANDO, FL	Amer Assoc Pediat Ophthalmol & Strabismus			TRAUMATIC BRAIN-INJURY; NONACCIDENTAL HEAD-INJURY; YOUNG-CHILDREN; INFANTS; NEUROPATHOLOGY; STROKE; ABUSE	PURPOSE: To evaluate the role of diffusion weighted magnetic resonance imaging (DWIMRI) in the diagnosis and management of children with suspected or confirmed Shaken Baby Syndrome (SBS). METHODS: This was a retrospective interventional case series of all infants and children younger than 2 years of age admitted to a children's hospital. We retrospectively reviewed medical records and neuroimaging findings of all children younger than 2 years of age with confirmed or suspected SBS admitted to a children's hospital. Inclusion criteria were documented ocular examination by an ophthalmologist and a brain MRI with DWI. Twenty-six infants and children were included. Other children were excluded. Children with proven SBS were diagnosed with "confirmed SBS," while children in whom the diagnosis of SBS remained uncertain were diagnosed with "suspected SBS." RESULTS: Twenty-six infants and children with mean age of 7.1 months (range, 6 weeks-24 months) were included, 18 with confirmed SBS. All 26 patients had a subdural hematoma, 10 had associated occult bone fractures, and 18 had retinal hemorrhages. Seven of the eight cases without retinal hemorrhages had isolated subdural hematoma without parenchymal brain lesions on both conventional MRI and DWIMRI. SBS was confirmed in only one case with a normal fundus. Among the 18 patients with retinal hemorrhages, SBS was confirmed in all but one case. All 18 patients with confirmed SBS had an abnormal DWIMRI. In 13 patients, DWI showed lesions that were larger than on conventional MRI. In patients with brain parenchymal lesions, the DWIMRI characteristics suggested cerebral ischemia, which appears to play a major role in SBS. CONCLUSIONS: In all patients with confirmed SBS, DWIMRI was abnormal and suggested diffuse or posterior cerebral ischemia, in addition to subdural hematomas in the pathogenesis of this disorder. (Am J Ophthalmol 2002;133:249-255. (C) 2002 by Elsevier Science Inc. All rights reserved.).	Emory Univ, Sch Med, Dept Ophthalmol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Neurol Surg, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Radiol, Atlanta, GA 30322 USA	Biousse, V (corresponding author), Emory Eye Ctr, Neuroophthalmol Unit, 1365-B Clifton Rd NE, Atlanta, GA 30322 USA.	vbiouss@emory.edu	Newman, Nancy/AAB-2532-2021		NEI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [P30-EY06360] Funding Source: Medline; NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [P30EY006360] Funding Source: NIH RePORTER		Adelson PD, 1997, PEDIATR NEUROSURG, V26, P200; ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; *AM COLL RAD, 2000, AM COLL RADIOL, P805; Beauchamp NJ, 1998, RADIOGRAPHICS, V18, P1269, DOI 10.1148/radiographics.18.5.9747619; Beaulieu C, 1999, Semin Pediatr Neurol, V6, P87, DOI 10.1016/S1071-9091(99)80035-7; BIRD CR, 1987, RADIOLOGY, V163, P373, DOI 10.1148/radiology.163.2.3562816; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; *CDC, 1990, AM J DIS CHILD, V44, P627; Conway EE, 1998, PEDIATR ANN, V27, P677, DOI 10.3928/0090-4481-19981001-11; COWAN EM, 1994, NEUROPEDIATRICS, V25, P172, DOI 10.1055/s-2008-1073018; Dias MS, 1998, PEDIATR NEUROSURG, V29, P77, DOI 10.1159/000028694; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Duhaime AC, 1996, PEDIATR NEUROSURG, V24, P292, DOI 10.1159/000121058; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; Ewing-Cobbs L, 1999, PEDIATR NEUROSURG, V31, P251, DOI 10.1159/000028872; Frodi A, 1985, INFANT CRYING THEORE, p[263, Boston], DOI 10.1007/978-1-4613-2381-5_12; Geddes JF, 2001, BRAIN, V124, P1299, DOI 10.1093/brain/124.7.1299; Geddes JF, 2001, BRAIN, V124, P1290, DOI 10.1093/brain/124.7.1290; Gilles EE, 1998, PEDIATR NEUROL, V19, P119, DOI 10.1016/S0887-8994(98)00038-1; HADLEY MN, 1989, NEUROSURGERY, V24, P536, DOI 10.1227/00006123-198904000-00008; HAN BK, 1989, AM J NEURORADIOL, V10, P1191; Haseler LJ, 1997, PEDIATRICS, V99, P4, DOI 10.1542/peds.99.1.4; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; Johnson DL, 1995, PEDIATR NEUROSURG, V23, P305, DOI 10.1159/000120976; Kairys SW, 2001, PEDIATRICS, V108, P206; Kivlin J D, 1999, Trans Am Ophthalmol Soc, V97, P545; Kivlin JD, 2000, OPHTHALMOLOGY, V107, P1246, DOI 10.1016/S0161-6420(00)00161-5; LEVIN A V, 1989, Pediatric Emergency Care, V5, P181, DOI 10.1097/00006565-198909000-00011; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; McCabe CF, 2000, ARCH OPHTHALMOL-CHIC, V118, P373, DOI 10.1001/archopht.118.3.373; Provenzale JM, 1999, AM J ROENTGENOL, V173, P1459, DOI 10.2214/ajr.173.6.10584783; Ruppel RA, 2001, J PEDIATR-US, V138, P18, DOI 10.1067/mpd.2001.110979; Sane SM, 2000, PEDIATRICS, V105, P1345; SATO Y, 1989, RADIOLOGY, V173, P653, DOI 10.1148/radiology.173.3.2813768; Suh DY, 2001, NEUROSURGERY, V49, P309, DOI 10.1097/00006123-200108000-00011; 1998, LANCET, V352, P335	38	75	77	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0002-9394	1879-1891		AM J OPHTHALMOL	Am. J. Ophthalmol.	FEB	2002	133	2					249	255		10.1016/S0002-9394(01)01366-6			7	Ophthalmology	Ophthalmology	518LM	WOS:000173669900011	11812430				2021-06-18	
J	Neugebauer, E; Bouillon, B; Bullinger, M; Wood-Dauphinee, S				Neugebauer, E; Bouillon, B; Bullinger, M; Wood-Dauphinee, S			Quality of life after multiple trauma - summary and recommendations of the consensus conference	RESTORATIVE NEUROLOGY AND NEUROSCIENCE			English	Article; Proceedings Paper	Consensus Conference on Quality of Life after Multiple Trauma	SEP 29-OCT 02, 1999	WERMELSKIRCHEN, GERMANY	German Minist Educ & Res		quality of life; consensus conference; multiple injuries; traumatic brain injury; spinal cord injury	BRAIN INJURY	In October 1999, an international and interdisciplinary consensus conference was held about the assessment and application of quality of life (QoL) measures after multiple trauma. Four working groups represented the following patients: children with traumatic brain injury (TBI); adults with TBI, adults with multiple injuries (but without TBI), and adults with spinal cord injury. According to predefined questions, the groups tried to identify the relevant problems of the patients, at different time points after the traumatic event. A review of the existing instruments for quality of life assessment and the evidence of their application in trauma patients in the scientific literature was performed by each group. Based on the results of these literature reviews it was concluded that there are not enough data to establish "evidence-based" guidelines for QoL assessments in these patients. Nevertheless, the groups comprised of experts clinicians and methodologists, agreed on the Glasgow Outcome Scale and the SF-36 as generic tools for QoL assessment across all trauma patients. It was further recommended to use these generic tools in combination with condition-specific instruments to better reflect the specific problems of the patients. Finally, the whole group suggested that it was not appropriate to view this conference as a "final report" about QoL assessment in trauma patients, but rather it should be seen as a starting point for increased efforts to initiate clinical research projects using QoL as an outcome, to develop better instruments, and to include QoL assessments into daily routines.	Univ Cologne, Biochem & Expt Div, Dept Surg 2, D-51109 Cologne, Germany; Univ Cologne, Surg Clin, Dept Surg 2, D-51109 Cologne, Germany; Univ Hamburg, Dept Med Psychol, Hamburg, Germany; McGill Univ, Sch Phys & Occupat Therapy, Montreal, PQ, Canada	Neugebauer, E (corresponding author), Univ Cologne, Biochem & Expt Div, Dept Surg 2, Ostmerheimerstr 200, D-51109 Cologne, Germany.						Berger E, 1999, RESTOR NEUROL NEUROS, V14, P93; Melchers P, 1999, RESTOR NEUROL NEUROS, V14, P153; Pirente N, 2002, UNFALLCHIRURG, V105, P413	3	75	75	0	1	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	0922-6028			RESTOR NEUROL NEUROS	Restor. Neurol. Neurosci.		2002	20	3-4					161	167					7	Neurosciences	Neurosciences & Neurology	633MR	WOS:000180287500010	12454364				2021-06-18	
J	Zhang, H; Zhang, XD; Zhang, TL; Liren, C				Zhang, H; Zhang, XD; Zhang, TL; Liren, C			Excitatory amino acids in cerebrospinal fluid of patients with acute head injuries	CLINICAL CHEMISTRY			English	Article							TRAUMATIC BRAIN INJURY; SUBDURAL-HEMATOMA; RELEASE; DAMAGE; RAT	Background: The excitatory amino acids (EAAs) glutamate (Glu) and aspartate (Asp) play a role in the pathogenesis of postischemic and posttraumatic brain insult. The changes of EAAs in cerebrospinal fluid (CSF) of patients with traumatic brain injury are incompletely understood. Methods: We used reversed-phase HPLC with precolumn derivatization with o-phthalaldehyde and fluorescence detection to measure Glu and Asp in CSF of 42 patients with acute head injury and 9 control adults without neurologic diseases. We assessed the Glasgow Coma Scale (GCS) on admission, the main lesion patterns on computed tomography (CT) scan within 24 h post trauma, and the Glasgow Outcome Scale (GOS) 3 months post injury. Results: The mean concentrations of Glu and Asp in CSF in the brain-injured group were significantly higher than those of the control group (Glu, P < 0.001; Asp, P < 0.05). In patients admitted within 24 h after severe injury (n = 13), peak Glu values appeared within 48 h in 11 patients (85%), and the mean value remained higher than control values at day 7 (P < 0.02). The concentrations of EAAs were higher in patients with severe injuries (GCS less than or equal to 8) than in those with milder injuries (Glu, P < 0.001; Asp, P < 0.05). GCS and peak EAAs correlated negatively (Glu, r(s) = -0.5706, P < 0.001; Asp, r(s) = -0.5503, P < 0.001). The patients with focal brain contusion on initial CT scan (n = 8) had a significantly lower peak Glu value than the patients with other patterns (n = 8-15; P < 0.02 to 0.001). The peak value of EAAs in the poor-outcome group (including severe disability, vegetative state, and death) was significantly higher than in the good-outcome group (good recovery and moderate disability; Glu, P < 0.001; Asp, P < 0.01); GOS was closely correlated to the EAA values (Glu, r(s) = 0.5737, P < 0.001; Asp, r(s) = 0.5470, P < 0.001). Conclusions: The EAA concentrations in CSF increase after acute head injury and remain higher for at least 1 week post injury in severely injured patients. The more severe the trauma, the more obvious the excitotoxicity induced by EAAs and the worse the outcome. (C) 2001 American Association for Clinical Chemistry.	Chinese Acad Sci, Lanzhou Inst Chem Phys, Chromatog Ctr, Lanzhou 730000, Peoples R China; Lanzhou Med Coll, Affiliated Hosp 2, Dept Neurosurg, Lanzhou 730030, Peoples R China; Lonzhou Med Coll, Affiliated Hosp 1, Dept Neurosurg, Lanzhou 730000, Peoples R China	Liren, C (corresponding author), Chinese Acad Sci, Lanzhou Inst Chem Phys, Chromatog Ctr, 342 Tianshui Rd, Lanzhou 730000, Peoples R China.						ALBIN RL, 1992, NEUROLOGY, V42, P733, DOI 10.1212/WNL.42.4.733; AMARA SG, 1992, NATURE, V360, P420, DOI 10.1038/360420d0; BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; BULLOCK R, 1992, J NEUROTRAUM, V9, pS443; BULLOCK R, 1991, J NEUROSURG, V74, P794, DOI 10.3171/jns.1991.74.5.0794; CHEN MH, 1991, J NEUROSURG, V74, P944, DOI 10.3171/jns.1991.74.6.0944; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FERRARO TN, 1985, BRAIN RES, V338, P53, DOI 10.1016/0006-8993(85)90247-1; GOLDSMITH RF, 1987, CLIN CHEM, V33, P1736; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; MELDRUM B, 1993, BRAIN RES REV, V18, P293, DOI 10.1016/0165-0173(93)90014-Q; Obrenovitch TP, 1996, ACT NEUR S, V66, P50	13	75	78	0	1	AMER ASSOC CLINICAL CHEMISTRY	WASHINGTON	2101 L STREET NW, SUITE 202, WASHINGTON, DC 20037-1526 USA	0009-9147			CLIN CHEM	Clin. Chem.	AUG	2001	47	8					1458	1462					5	Medical Laboratory Technology	Medical Laboratory Technology	456HP	WOS:000170077300019	11468237				2021-06-18	
J	Schwab, JM; Beschorner, R; Nguyen, TD; Meyermann, R; Schluesener, HJ				Schwab, JM; Beschorner, R; Nguyen, TD; Meyermann, R; Schluesener, HJ			Differential cellular accumulation of connective tissue growth factor defines a subset of reactive astrocytes, invading fibroblasts, and endothelial cells following central nervous system injury in rats and humans	JOURNAL OF NEUROTRAUMA			English	Article						astrocyte activation; blood-brain barrier; glial scar; secondary injury; tissue remodeling	ANGIOGENESIS IN-VIVO; BRAIN INJURY; SPINAL-CORD; FACTOR-BETA; CNS INJURY; EXPRESSION; FACTOR-BETA(1); PROLIFERATION; DEGENERATION; TGF-BETA-1	In brain injury, the primary trauma is followed by a cascade of cellular and molecular mechanisms resulting in secondary injury and scar formation. Astrogliosis and expression of transforming growth factor beta (TGF-beta) are key components of scar formation. A cytokine mediating the effects of TGF-beta is connective tissue growth factor (CTGF), a fibrogenic peptide encoded by an immediate early gene with suggested roles in tissue regeneration and aberrant deposition of extracellular matrix. In order to investigate CTGF in traumatic lesions, we evaluated 20 human brains with traumatic brain injury (TBI) and 18 rat brains with stab wound injury. Compared to remote areas and unaltered control brains, CTGF(+) cells accumulated in border zones of the traumatic lesion site (p < 0.0001). In the direct peri-lesional rim, CTGF expression was confined to invading vimentin(+), GFAP(-) fibroblastoid cells, endothelial and smooth muscle cells of laminin(+) vessels, and GFAP(+) reactive astrocytes. In the direct peri-lesional rim, CTGF(+) astrocytes (>80%) co-expressed the activation associated intermediate filaments nestin and vimentin. In injured rat brains, numbers of CTGF(+) cells peaked at day 3 and 7 and decreased to almost base level 3 weeks postinjury, whereas in humans, CTGF(+) cells remained persistently elevated up to 6 months (p < 0.0001). The restricted accumulation of CTGF(+)-reactive astrocytes and CTGF(+) fibroblastoid cells lining the adjacent laminin(+) basal lamina suggests participation of these cells in scar formation. Furthermore, peri-lesional upregulation of endothelial CTGF expression points to a role in blood-brain barrier function and angiogenesis. In addition, CTGF appears to be a sensitive marker of early astrocyte activation.	Univ Tubingen, Sch Med, Inst Brain Res, D-72076 Tubingen, Germany	Schwab, JM (corresponding author), Univ Tubingen, Sch Med, Inst Brain Res, Calwer Str 3, D-72076 Tubingen, Germany.	jmschwab@med.uni-tuebingen.de	Beschorner, Rudi/M-6397-2014	Schwab, Jan/0000-0001-6784-4919; Beschorner, Rudi/0000-0003-1109-915X			Babic AM, 1999, MOL CELL BIOL, V19, P2958; Beschorner R, 2000, ACTA NEUROPATHOL, V100, P377, DOI 10.1007/s004010000202; BIGNAMI A, 1998, NEURON GLIA INTERREL, V1, P3; CANCILLA PA, 1993, ASTROCYTES PHARM FUN, P387; Dammeier J, 1998, INT J BIOCHEM CELL B, V30, P909, DOI 10.1016/S1357-2725(98)00046-6; Duncan MR, 1999, FASEB J, V13, P1774; Eliasson C, 1999, J BIOL CHEM, V274, P23996, DOI 10.1074/jbc.274.34.23996; FADENIF, 1996, NEUROTRAUMA, P1479; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; GRAHAM DI, 1996, GREENFIELDS NEUROPAT, P197; Grotendorst Gary R., 1997, Cytokine and Growth Factor Reviews, V8, P171, DOI 10.1016/S1359-6101(97)00010-5; Hashimoto Y, 1998, J EXP MED, V187, P289, DOI 10.1084/jem.187.3.289; HenrichNoack P, 1996, STROKE, V27, P1609, DOI 10.1161/01.STR.27.9.1609; Hertel M, 2000, EUR J NEUROSCI, V12, P376, DOI 10.1046/j.1460-9568.2000.00930.x; Ito Y, 1998, KIDNEY INT, V53, P853, DOI 10.1046/j.1523-1755.1998.00820.x; Kim HS, 1997, P NATL ACAD SCI USA, V94, P12981, DOI 10.1073/pnas.94.24.12981; Kubo M, 1998, BRIT J DERMATOL, V139, P192; Lasky JA, 1998, AM J PHYSIOL-LUNG C, V275, pL365; Lawrence DA, 1996, EUR CYTOKINE NETW, V7, P363; LOGAN A, 1994, EUR J NEUROSCI, V6, P355, DOI 10.1111/j.1460-9568.1994.tb00278.x; LOGAN A, 1993, TRENDS PHARMACOL SCI, V14, P337, DOI 10.1016/0165-6147(93)90007-7; LOGAN A, 1992, BRAIN RES, V587, P216, DOI 10.1016/0006-8993(92)91000-5; MARTINERIE C, 1992, ONCOGENE, V7, P2529; MATHEWSON AJ, 1985, BRAIN RES, V327, P61, DOI 10.1016/0006-8993(85)91499-4; MAXWELL WL, 1984, HISTOCHEM J, V16, P1219, DOI 10.1007/BF01003445; MAXWELL WL, 1990, PHILOS T R SOC B, V328, P479, DOI 10.1098/rstb.1990.0121; MCKEON RJ, 1991, J NEUROSCI, V11, P3398; MILLER JD, 1996, GREENFIELDS NEUROPAT, P157; Nakanishi T, 2000, ENDOCRINOLOGY, V141, P264, DOI 10.1210/en.141.1.264; NORENBERG MD, 1994, J NEUROPATH EXP NEUR, V53, P213, DOI 10.1097/00005072-199405000-00001; Oemar BS, 1997, CIRCULATION, V95, P831; Plate KH, 1999, J NEUROPATH EXP NEUR, V58, P654, DOI 10.1097/00005072-199906000-00010; Plate KH, 1999, J NEUROPATH EXP NEUR, V58, P313, DOI 10.1097/00005072-199904000-00001; Rimaniol AC, 1995, NEUROREPORT, V7, P133, DOI 10.1097/00001756-199512290-00032; Schwab JM, 2000, ACTA NEUROPATHOL, V99, P609, DOI 10.1007/s004010051170; Schwab ME, 1996, PHYSIOL REV, V76, P319; Shimo T, 1999, J BIOCHEM-TOKYO, V126, P137, DOI 10.1093/oxfordjournals.jbchem.a022414; Steffen CL, 1998, GROWTH FACTORS, V15, P199, DOI 10.3109/08977199809002117; TATOR CH, 1995, BRAIN PATHOL, V5, P407, DOI 10.1111/j.1750-3639.1995.tb00619.x; TORUDELBAUFFE D, 1992, EXP CELL RES, V202, P316, DOI 10.1016/0014-4827(92)90081-I; Wenger C, 1999, ONCOGENE, V18, P1073, DOI 10.1038/sj.onc.1202395	41	75	77	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2001	18	4					377	388		10.1089/089771501750170930			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	425TP	WOS:000168308000002	11336439				2021-06-18	
J	Wade, TK; Troy, JC				Wade, TK; Troy, JC			Mobile phones as a new memory aid: a preliminary investigation using case studies	BRAIN INJURY			English	Article							CLOSED-HEAD-INJURY; REHABILITATION	Memory impairment is one of the most common concerns following a brain injury of any severity. The use of effective external memory aids can help minimize the devastating effects such memory impairment can have on an individual's everyday life. Reviewed in this report are case studies of five individuals suffering significant everyday memory problems that were given a new memory aid that utilizes standard mobile phones. Measurements included diary-format observations and qualitative feedback. The results of the study show promising outcomes for all of the cases, and have led to recent adaptations to allow for wider and more effective use of this memory aid.	Overdale Hosp, Dept Psychol, St Helier JE1 3UH, Jersey, England	Wade, TK (corresponding author), Overdale Hosp, Dept Psychol, Westmount Rd, St Helier JE1 3UH, Jersey, England.						*ABN AMR INV BANK, 1999, INF SHEET; CROVITZ HF, 1979, CORTEX, V15, P131, DOI 10.1016/S0010-9452(79)80013-1; Evans JJ, 1998, J INT NEUROPSYCH SOC, V4, P399, DOI 10.1017/S1355617798003993; *FIN TIM BUS LTD, 1998, INF SHEET; GODFREY H, 1985, J COUNSELLING CLIN P, V43, P555; GOUVIER W, 1997, NEUROPSYCHOLOGY HDB, V2, P3; HARRIS JE, 1992, CLIN MANAGEMENT MEMO, P59, DOI DOI 10.1007/978-1-4899-4523-5_3; Hersh N A, 1994, NeuroRehabilitation, V4, P187, DOI 10.3233/NRE-1994-4309; Intons-Peterson MJ, 1992, MEMORY IMPROVEMENT I, P101; KAPUR N, 1994, MEMORY DISORDERS CLI; KAPUR N, 1995, HDB MEMORY DISORDERS, P533; Nelson HE, 1982, NATL ADULT READING T; NEWCOMBE F, 1982, INJURY, V14, P111, DOI 10.1016/0020-1383(82)90046-8; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; SCHACHTER D, 1977, CORTEX, V13, P105; SLOAN S, 1995, TRAUMATIC BRAIN INJU, P103; Sohlberg MM, 1989, INTRO COGNITIVE REHA, P136; Thomsen I V, 1987, Brain Inj, V1, P131, DOI 10.3109/02699058709034452; TWUM M, 1994, J CLIN EXP NEUROPSYC, V16, P630, DOI 10.1080/01688639408402674; WECHSLER D, 1981, WAIS R MANUAL WESCHL; Wilson B.A, 1987, REHABILITATION MEMOR; Wilson B. A., 1985, RIVERMEAD BEHAV MEMO; Wilson BA, 1997, J NEUROL NEUROSUR PS, V63, P113, DOI 10.1136/jnnp.63.1.113; Wilson BA, 1996, BEHAV ASSESSMENT DYS	24	75	75	0	9	TAYLOR & FRANCIS LTD	LONDON	11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	APR	2001	15	4					305	320		10.1080/026990501750111256			16	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	420ZK	WOS:000168035000003	11299132				2021-06-18	
J	Crouchman, M; Rossiter, L; Colaco, T; Forsyth, R				Crouchman, M; Rossiter, L; Colaco, T; Forsyth, R			A practical outcome scale for paediatric head injury	ARCHIVES OF DISEASE IN CHILDHOOD			English	Article						head injury; traumatic brain injury; outcome scale	TRAUMATIC BRAIN INJURY; CHILDREN; CONSEQUENCES; CHILDHOOD; SEQUELAE; DAMAGE	Traumatic brain injury (TBI) is the commonest cause of acquired disability in childhood. A major obstacle to the evaluation of acute and rehabilitative therapies after TBI is the lack of simple descriptors of outcome. We developed the King's Outcome Scale for Childhood Head Injury (KOSCHI), as a specific paediatric adaptation of the original adult Glasgow Outcome Scale (GOS). The KOSCHI expands the five category GOS to provide increased sensitivity at the milder end of the disability range. The GOS category of "persistent vegetative state" was replaced by "vegetative". "Good recovery" was allocated two categories, in acknowledgement of the long term importance of relatively minor sequelae in a developing child. The scale was quick and easy to use. Inter-rater reliability studies show that even with such an apparently simple scale, some training may be required. The KOSCHI provides a practical scale for paediatric head injury which will enable clinicians to describe rate and extent of recovery, and evaluate the effects of service and research interventions.	Kings Coll London Hosp, London SE5 9RS, England; Royal Victoria Infirm, Dept Child Hlth, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England	Crouchman, M (corresponding author), Kings Coll London Hosp, Denmark Hill, London SE5 9RS, England.	marion.crouchman@kcl.ac.uk	Forsyth, Rob J/I-9226-2012; Forsyth, Rob/H-9193-2019	Forsyth, Rob J/0000-0002-5657-4180; Forsyth, Rob/0000-0002-5657-4180			Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Bonnier C, 1995, DEV MED CHILD NEUROL, V37, P943; BRINK JD, 1970, DEV MED CHILD NEUROL, V12, P565; *BRIT PAED ASS, 1991, DIAGN BRAIN STEM DEA; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; CROUCHMAN MR, 1998, INJURY YOUNG, P263; DENNIS M, 1990, BRAIN LANG, V39, P428, DOI 10.1016/0093-934X(90)90149-B; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; DUNN G, 1989, DESIGN ANAL RELIABIL, P154; ESLINGER PJ, 1992, ARCH NEUROL-CHICAGO, V49, P764, DOI 10.1001/archneur.1992.00530310112021; EWING R, 1980, Journal of Clinical Neuropsychology, V2, P147, DOI 10.1080/01688638008403789; FLEISS JL, 1971, PSYCHOL BULL, V76, P378, DOI 10.1037/h0031619; FLETCHER JM, 1995, TRAUMATIC HEAD INJUR, P22; GULBRANDSEN GB, 1984, J CLIN NEUROPSYCHOL, V6, P257, DOI 10.1080/01688638408401217; JENNETT B, 1975, LANCET, V1, P480; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; Rivara JB, 1996, ARCH PHYS MED REHAB, V77, P754, DOI 10.1016/S0003-9993(96)90253-1; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; RUTTER M, 1981, AM J PSYCHIAT, V138, P1533; Sharples PM, 1998, INJURY YOUNG, P151	21	75	77	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0003-9888			ARCH DIS CHILD	Arch. Dis. Child.	FEB	2001	84	2					120	124		10.1136/adc.84.2.120			5	Pediatrics	Pediatrics	395ZV	WOS:000166612600010	11159284	Bronze, Green Published			2021-06-18	
J	Bryant, RA; Marosszeky, JE; Crooks, J; Baguley, IJ; Gurka, JA				Bryant, RA; Marosszeky, JE; Crooks, J; Baguley, IJ; Gurka, JA			Interaction of posttraumatic stress disorder and chronic pain following traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							HEAD-INJURY; PSEUDOMEMORIES; VETERANS; COMBAT; SCALE	Objective: To investigate the association between posttraumatic stress disorder (PTSD) and chronic pain in patients who had sustained a severe traumatic brain Injury (TBI). Design: Correlational relationships between pain variables and PTSD measures were examined in a cohort study. Setting: An adult tertiary care center brain injury clinic. Patients: Ninety-six persons with severe TBI. Outcome Measures: The Posttraumatic Stress Disorder interview (PTSD-I), a modified McGill Pain Questionnaire, the Beck Depression Inventory (BDI), the General Health Questionnaire (GHQ), the Community Integration Questionnaire (CIQ), the Satisfaction with Life Scale (SWL), and the Coping Style Questionnaire (CSQ). Results: More persons with chronic pain reported PTSD than did those without pain. The relationship between pain severity and depression, functional adjustment, and satisfaction with life was mediated by severity of PTSD. Pain severity was significantly associated with an avoidant coping style. Conclusions: Effective rehabilitation of persons with chronic pain following severe TBI should recognize the role of posttraumatic stress in the maintenance of dysfunctional reactions. Specific interventions that address adaptive coping mechanisms to reduce PTSD may enhance rehabilitation for persons with TDI who suffer chronic pain.	Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia; Westmead Hosp, Brain Injury Rehabil Unit, Sydney, NSW, Australia	Bryant, RA (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.		Bryant, Richard/AAA-6479-2019; Baguley, Ian J/K-6878-2013; Baguley, Ian/AAM-5828-2021	Bryant, Richard/0000-0002-9607-819X; Baguley, Ian J/0000-0001-5650-3705; 			American Psychiatric Association, 1988, DIAGN STAT MAN MENT; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Beckham JC, 1997, J PSYCHOSOM RES, V43, P379, DOI 10.1016/S0022-3999(97)00129-3; Billings A G, 1981, J Behav Med, V4, P139, DOI 10.1007/BF00844267; BRYAN S, 1995, HEALTH POLICY, V33, P31, DOI 10.1016/0168-8510(94)00699-F; BRYANT RA, 1995, J ABNORM PSYCHOL, V104, P537, DOI 10.1037/0021-843X.104.3.537; Bryant RA, 1996, J TRAUMA STRESS, V9, P621; Bryant RA, 1998, APPL COGNITIVE PSYCH, V12, P81, DOI 10.1002/(SICI)1099-0720(199802)12:1<81::AID-ACP507>3.0.CO;2-8; BRYANT RA, IN PRESS AM J PSYCHI; BRYANT RA, 1993, PAIN, V52, P379; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Difede JA, 1997, PAIN, V72, P245, DOI 10.1016/S0304-3959(97)00045-6; DROTTNING M, 1995, NORD J PSYCHIAT, V49, P293, DOI 10.3109/08039489509011919; Hall K. M., 1992, NEUROREHABILITATION, V2, DOI [10.3233/NRE-1992-2410, DOI 10.3233/NRE-1992-2410]; JENSEN MP, 1991, PAIN, V47, P249, DOI 10.1016/0304-3959(91)90216-K; KEEFE FJ, 1990, BEHAV THER, V21, P49, DOI 10.1016/S0005-7894(05)80188-1; King LA, 1998, J PERS SOC PSYCHOL, V74, P420, DOI 10.1037/0022-3514.74.2.420; Lahz S, 1996, ARCH PHYS MED REHAB, V77, P889, DOI 10.1016/S0003-9993(96)90275-0; LAHZ S, 1997, J HEAD TRAUMA REHAB, V12, P86; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; MCMILLAN TM, 1991, BRIT J PSYCHIAT, V159, P431, DOI 10.1192/bjp.159.3.431; MUSE M, 1985, PAIN, V23, P295, DOI 10.1016/0304-3959(85)90108-3; O'Toole BI, 1998, AUST NZ J PSYCHIAT, V32, P32, DOI 10.1046/j.1440-1614.1998.00368.x; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; SCHREIBER S, 1993, PAIN, V54, P107, DOI 10.1016/0304-3959(93)90105-X; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; SMITH TW, 1986, J CONSULT CLIN PSYCH, V54, P573, DOI 10.1037/0022-006X.54.4.573; WARDA G, IN PRESS BEHAV RES T; WATSON CG, 1991, J CLIN PSYCHOL, V47, P179, DOI 10.1002/1097-4679(199103)47:2<179::AID-JCLP2270470202>3.0.CO;2-P; Willer B, 1993, J HEAD TRAUMA REHAB, V3, P75, DOI DOI 10.1097/00001199-199308020-00009; YAMAGUCHI M, 1992, HEADACHE, V32, P427, DOI 10.1111/j.1526-4610.1992.hed3209427.x	31	75	75	0	9	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	DEC	1999	14	6					588	594		10.1097/00001199-199912000-00007			7	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	269AV	WOS:000084454300006	10671704				2021-06-18	
J	Chesnut, RM; Carney, N; Maynard, H; Mann, NC; Patterson, P; Helfand, M				Chesnut, RM; Carney, N; Maynard, H; Mann, NC; Patterson, P; Helfand, M			Summary report: Evidence for the effectiveness of rehabilitation for persons with traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						rehabilitation; systematic review; traumatic brain injury	CLOSED-HEAD-INJURY; SUPPORTED EMPLOYMENT; NEUROPSYCHOLOGICAL REHABILITATION; EARLY INTERVENTION; OUTCOMES; DEFICITS; LENGTH; RETURN; STAY; WORK	We evaluated the evidence fur effectiveness of rehabilitation methods throughout the phases of recovery from traumatic brain injury (TBI) in adults. MEDLINE, HealthSTAR, CINAHL, PsycINFO, and the Cochrane Library were searched, and a total of 3,098 abstracts were reviewed. The strongest studies were critically appraised and their data placed in evidence tables. Results showed that to determine the effectiveness of rehabilitation interventions for persons with TBI. a commitment must be made to population-based studies, strong controlled research design, standardization of measures, adequate statistical analysis, and specification of health outcomes of importance to persons with TBI and their families.	Oregon Hlth & Sci Univ, Dept Neurol Surg, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Dept Emergency Med, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Div Med Informat & Outcomes Res, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Sch Nursing, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Evidence Based Practice Ctr, Portland, OR 97201 USA	Chesnut, RM (corresponding author), Oregon Hlth & Sci Univ, Dept Neurol Surg, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.			Chesnut, Randall/0000-0001-6377-3666			ANDERSEN J, 1992, J TRAUMA, V33, P219, DOI 10.1097/00005373-199208000-00009; ARONOW HU, 1987, J HEAD INJURY REHABI, V2, P24; Ashley M J, 1994, J Insur Med, V26, P348; Batchelor J, 1988, J HEAD TRAUMA REHAB, V3, P78, DOI DOI 10.1097/00001199-198809000-00012; BLACKERBY W F, 1990, Brain Injury, V4, P167, DOI 10.3109/02699059009026162; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; CHESNUT RM, IN PRESS EVIDENCE RE; Cicerone KD, 1996, BRAIN INJURY, V10, P277, DOI 10.1080/026990596124458; COPE DN, 1995, BRAIN INJURY, V9, P649, DOI 10.3109/02699059509008224; COPE DN, 1982, ARCH PHYS MED REHAB, V63, P433; COWEN TD, 1995, ARCH PHYS MED REHAB, V76, P797, DOI 10.1016/S0003-9993(95)80542-7; Curl RM, 1996, J HEAD TRAUMA REHAB, V11, P75, DOI 10.1097/00001199-199602000-00009; CURL RM, 1993, J VOCATIONAL REHABIL, V3, P72; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; FABIANO RJ, 1995, REHABIL PSYCHOL, V40, P223, DOI 10.1037/0090-5550.40.3.223; FRASER R, 1988, REHABIL COUNS BULL, V31, P276; Girard D, 1996, BRAIN INJURY, V10, P663, DOI 10.1080/026990596124089; Gray J. M., 1992, NEUROPSYCHOL REHABIL, V2, P97; GREENWOOD RJ, 1994, BRIT MED J, V308, P1199, DOI 10.1136/bmj.308.6938.1199; HAFFEY WJ, 1991, J HEAD TRAUMA REHAB, V6, P24; HEINEMANN AW, 1995, AM J PHYS MED REHAB, V74, P315, DOI 10.1097/00002060-199507000-00011; HELFFENSTEIN DA, 1982, CLIN NEUROPSYCHOLOGY, V4, P139; High WM, 1996, J HEAD TRAUMA REHAB, V11, P85, DOI 10.1097/00001199-199610000-00008; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; Johnson D, 1989, Nurs Times, V85, P25; Jorgensen H S, 1997, Ugeskr Laeger, V159, P4093; Kerner M, 1985, COGNIT REHABIL, V11, P26; Kock C, 1992, Rehabilitation (Stuttg), V31, P217; Kosubek C, 1996, Rehabilitation (Stuttg), V35, P29; MACKAY LE, 1992, ARCH PHYS MED REHAB, V73, P635; MALEC JF, 1995, MAYO CLIN PROC, V70, P1165, DOI 10.4065/70.12.1165; Mathew P, 1996, J NEUROTRAUM, V13, P465, DOI 10.1089/neu.1996.13.465; NEISTADT ME, 1992, AM J OCCUP THER, V46, P141, DOI 10.5014/ajot.46.2.141; NIEMANN H, 1990, J CONSULT CLIN PSYCH, V58, P811, DOI 10.1037/0022-006X.58.6.811; Novack TA, 1996, J HEAD TRAUMA REHAB, V11, P52, DOI 10.1097/00001199-199606000-00008; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; RUFF R M, 1990, Brain Injury, V4, P339, DOI 10.3109/02699059009026187; Ruff R. M., 1989, J HEAD TRAUMA REHAB, V4, P20, DOI [10.1097/00001199-198909000-00006, DOI 10.1097/00001199-198909000-00006]; Ryan T V, 1988, Arch Clin Neuropsychol, V3, P165, DOI 10.1016/0887-6177(88)90061-3; SCHMITTEREDGECOMBE M, 1995, J CONSULT CLIN PSYCH, V63, P484; Sherburne E, 1986, J Neurosci Nurs, V18, P140; SPETTELL CM, 1991, ARCH PHYS MED REHAB, V72, P320; SPIVACK G, 1992, Brain Injury, V6, P419, DOI 10.3109/02699059209008138; THOMASS BA, 1994, EUR J COMMUN, V9, P25, DOI 10.1177/0267323194009001002; TWUM M, 1994, J CLIN EXP NEUROPSYC, V16, P630, DOI 10.1080/01688639408402674; U.S. Preventive Services Task Force, 1996, GUID CLIN PREV SERV; Wehman P, 1989, Brain Inj, V3, P397, DOI 10.3109/02699058909004563; WEHMAN P, 1989, J APPL BEHAV ANAL, V22, P395, DOI 10.1901/jaba.1989.22-395; WEHMAN P, 1993, AM J PHYS MED REHAB, V72, P355; WEHMAN PH, 1990, ARCH PHYS MED REHAB, V71, P1047; Wilson BA, 1997, J NEUROL NEUROSUR PS, V63, P113, DOI 10.1136/jnnp.63.1.113; Wood R L, 1987, Int Disabil Stud, V9, P149; WRIGLEY JM, 1994, ARCH PHYS MED REHAB, V75, P149	55	75	75	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	APR	1999	14	2					176	188		10.1097/00001199-199904000-00007			13	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	187DN	WOS:000079771800007	10191375				2021-06-18	
J	Heath, DL; Vink, R				Heath, DL; Vink, R			Optimization of magnesium therapy after severe diffuse axonal brain injury in rats	JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS			English	Article							MAGNETIC-RESONANCE SPECTROSCOPY; HEAD-INJURY; FREE MG-2+; NEURONS; TRAUMA; METABOLISM; MG2+; PH; DEFICITS; ISCHEMIA	A number of studies have demonstrated that magnesium salts given after traumatic brain injury improve subsequent neurologic outcome. However, given that these earlier studies have used a number of different salts, dosages, and routes of administration, follow-up studies of the neuroprotective properties of magnesium are complicated, with comparisons to the earlier literature virtually impossible. The present study has therefore characterized the dose-response characteristics of the most commonly used sulfate and chloride salts of magnesium in a severe model of diffuse traumatic axonal injury in rats. Both magnesium salts improved neurologic outcome in rats when administered as a bolus at 30 min after injury. The i.v. and i.m. optima of each salt was 250 mu mol/kg and 750 mu mol/kg, respectively. The identical concentrations required for improved neurologic outcome suggest that improvement in outcome was dependent on the magnesium cation and not the associated anion. Subsequent magnetic resonance studies demonstrated that the administered magnesium penetrated the blood-brain barrier after injury and resulted in an increased brain intracellular free magnesium concentration and associated bioenergetic state as reflected in the cytosolic phosphorylation potential. Both of these metabolic parameters positively correlated with resultant neurologic outcome measured daily in the same animals immediately before the magnetic resonance determinations.	James Cook Univ N Queensland, Dept Physiol & Pharmacol, Townsville, Qld 4811, Australia	Vink, R (corresponding author), James Cook Univ N Queensland, Dept Physiol & Pharmacol, Townsville, Qld 4811, Australia.		AM, Robert Vink/S-5616-2019; Vink, Robert/J-7351-2012	AM, Robert Vink/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667			ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ALTURA BM, 1992, BIOCHIM BIOPHYS ACTA, V1111, P271, DOI 10.1016/0005-2736(92)90320-L; BOCK JL, 1987, BIOCHIM BIOPHYS ACTA, V928, P8, DOI 10.1016/0167-4889(87)90079-6; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; FADEN AI, 1992, TRENDS PHARMACOL SCI, V13, P29, DOI 10.1016/0165-6147(92)90013-V; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GUNTHER T, 1994, MAGNESIUM-B, V16, P38; GUPTA RK, 1978, J BIOL CHEM, V253, P6172; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; HEADRICK JP, 1994, J CEREBR BLOOD F MET, V14, P853, DOI 10.1038/jcbfm.1994.107; Heath DL, 1996, BRAIN RES, V738, P150, DOI 10.1016/0006-8993(96)00957-2; Heath DL, 1998, J NEUROTRAUM, V15, P183, DOI 10.1089/neu.1998.15.183; Heath DL, 1995, J NEUROTRAUM, V12, P1027, DOI 10.1089/neu.1995.12.1027; HELPERN JA, 1993, NEUROLOGY, V43, P1577, DOI 10.1212/WNL.43.8.1577; ISERI LT, 1984, AM HEART J, V108, P188, DOI 10.1016/0002-8703(84)90572-6; KAUPPINEN RA, 1992, J NEUROCHEM, V58, P831, DOI 10.1111/j.1471-4159.1992.tb09332.x; LAWSON JWR, 1979, J BIOL CHEM, V254, P6528; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MCINTOSH TK, 1989, BRAIN RES, V482, P252, DOI 10.1016/0006-8993(89)91188-8; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; Povlishock JT, 1996, ACT NEUR S, V66, P81; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; ROTHMAN SM, 1983, SCIENCE, V220, P536, DOI 10.1126/science.6836300; SIESJO BK, 1981, J CEREBR BLOOD F MET, V1, P155, DOI 10.1038/jcbfm.1981.18; SMITH DH, 1993, NEUROSCI LETT, V157, P211, DOI 10.1016/0304-3940(93)90739-8; VEECH RL, 1979, J BIOL CHEM, V254, P6538; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; VINK R, 1994, J NEUROTRAUM, V11, P265, DOI 10.1089/neu.1994.11.265; Vink R, 1996, J NEUROCHEM, V66, P2477; VINK R, 1988, J BIOL CHEM, V263, P757; VINK R, 1991, MAGNESIUM EXCITABLE, P695; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921	36	75	79	0	2	AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0022-3565			J PHARMACOL EXP THER	J. Pharmacol. Exp. Ther.	MAR	1999	288	3					1311	1316					6	Pharmacology & Pharmacy	Pharmacology & Pharmacy	172BZ	WOS:000078903600048	10027872				2021-06-18	
J	Meythaler, JM; Guin-Renfroe, S; Grabb, P; Hadley, MN				Meythaler, JM; Guin-Renfroe, S; Grabb, P; Hadley, MN			Long-term continuously infused intrathecal baclofen for spastic-dystonic hypertonia in traumatic brain injury: 1-year experience	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							SPINAL SPASTICITY; DRUG-THERAPY; DYSFUNCTION; ORIGIN; REFLEX; BOLUS; SPACE	Objective: To determine if the long-term use of continuously infused intrathecal baclofen (ITB) over a 1-year period will control spastic-dystonic hypertonia in patients with traumatic brain injury (TBI). Setting: Tertiary care outpatient and inpatient rehabilitation center directly attached to a university hospital. Subjects: Persons with TBI and intractable spasticity and dystonia for more than 6 months' duration recruited in a consecutive manner. Design: TBI patients were admitted to the study after screening via a bolus injection of either intrathecal normal saline or 50 mu g of baclofen. Data for Ashworth rigidity scores, spasm scores, and deep tendon reflex scores were collected for both the upper extremities (UE) and lower extremities (LE). Patients whose LE Ashworth scores decreased an average of 2 points were then offered implantation of a computer-controlled pump for continuous ITB. Changes over time were assessed statistically via Friedman's analysis for ordinal data and ANOVA for linear data. Differences between set points in time were also assessed via Wilcoxon signed rank. Data Set: Seventeen patients (average age 29 +/- 11yrs) with spasticity and/or dystonia treated over 1 year via a computer-controllable intrathecal delivery system for the delivery of ITB. Results: After 1 year of continuous ITB treatment the average LE Ashworth score decreased from 3.5 +/- 1.3 (SD) to 1.7 +/- 0.9 (p < .0001), spasm score from 1.8 +/- 1.3 to 0.2 +/- 0.5 (p < .0001), and reflex score from 2.5 +/- 1.1 to 0.1 +/- 0.3 (p < .0001). The average UE Ashworth score decreased from 2.9 +/- 1.5 to 1.6 +/- 1.0 (p < .0001), spasm score from 1.2 +/- 1.5 to 0.2 +/- 0.6 (p < 0.0001), and reflex score from 2.2 +/- 0.5 to 1.0 +/- 0.8 (p < .0001). The average ITB dose required to attain these effects at 1 year was 302 mu g continuously infused per day. Conclusion: Continuous intrathecal infusion of baclofen is capable of maintaining a reduction in spasticity and dystonia in both the upper and lower extremities of TBI patients. (C) 1999 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	Univ Alabama, Spain Rehabil Ctr R157, Dept Phys Med & Rehabil, Sch Med, Birmingham, AL 35233 USA; Univ Alabama, Div Neurol Surg, Sch Med, Birmingham, AL 35233 USA	Meythaler, JM (corresponding author), Univ Alabama, Spain Rehabil Ctr R157, Dept Phys Med & Rehabil, Sch Med, 1717 6th Ave S, Birmingham, AL 35233 USA.						ADAMS RD, 1993, PRINCIPLES NEUROLOGY; AKMAN MN, 1993, PARAPLEGIA, V31, P516, DOI 10.1038/sc.1993.84; ALBRIGHT AL, 1993, JAMA-J AM MED ASSOC, V270, P2475, DOI 10.1001/jama.270.20.2475; ALBRIGHT LA, 1997, INTRATHECAL BACLOFEN; ASHBY P, 1974, J NEUROL NEUROSUR PS, V37, P1352, DOI 10.1136/jnnp.37.12.1352; ASHWORTH B, 1964, PRACTITIONER, V192, P540; Becker R, 1997, J NEUROL, V244, P160, DOI 10.1007/s004150050067; BULLOCK R, 1995, GUIDELINES MANAGEMEN; BUSHMAN W, 1993, NEUROUROL URODYNAM, V12, P163, DOI 10.1002/nau.1930120210; COFFEY RJ, 1993, J NEUROSURG, V78, P226, DOI 10.3171/jns.1993.78.2.0226; Denys P, 1998, ARCH PHYS MED REHAB, V79, P494, DOI 10.1016/S0003-9993(98)90061-2; Ford B, 1996, ARCH NEUROL-CHICAGO, V53, P1241, DOI 10.1001/archneur.1996.00550120049016; FROST F, 1989, AM J PHYS MED REHAB, V68, P112, DOI 10.1097/00002060-198906000-00002; Gerszten PC, 1998, J NEUROSURG, V88, P1009, DOI 10.3171/jns.1998.88.6.1009; Hattab J.R., 1980, SPASTICITY DISORDERE, P71; KATZ R, 1982, BRAIN, V105, P103, DOI 10.1093/brain/105.1.103; KATZ RT, 1988, AM J PHYS MED REHAB, V67, P108, DOI 10.1097/00002060-198806000-00004; KATZ RT, 1992, PHYS MED CLIN N AM, V3, P319; KLOCKGETHER T, 1989, NEUROSCI LETT, V97, P221, DOI 10.1016/0304-3940(89)90167-5; KNUTSSON E, 1974, J NEUROL SCI, V23, P473, DOI 10.1016/0022-510X(74)90163-4; KROIN JS, 1984, EXP BRAIN RES, V54, P191; KROIN JS, 1991, PARENTERAL DRUG THER, P73; LAZORTHES Y, 1990, J NEUROSURG, V72, P393, DOI 10.3171/jns.1990.72.3.0393; Lee K.-C., 1989, J NEUROL REHABIL, V3, P205, DOI DOI 10.1177/136140968900300406; MACDONELL RAL, 1989, J NEUROL NEUROSUR PS, V52, P1110, DOI 10.1136/jnnp.52.9.1110; Mann NH, 1991, J NEUROL REHABIL, V5, P51; MENDELL LM, 1984, PHYSIOL REV, V64, P260; MEYTHALER JM, 1992, AM J PHYS MED REHAB, V71, P321, DOI 10.1097/00002060-199212000-00003; MEYTHALER JM, 1992, ARCH PHYS MED REHAB, V73, P794; Meythaler JM, 1997, J NEUROSURG, V87, P415, DOI 10.3171/jns.1997.87.3.0415; Meythaler JM, 1997, J HEAD TRAUMA REHAB, V12, P87, DOI 10.1097/00001199-199702000-00012; Meythaler JM, 1996, ARCH PHYS MED REHAB, V77, P461, DOI 10.1016/S0003-9993(96)90034-9; MEYTHALER JM, 1998, AM J PHYS MED REHABI, V77, P173; Meythaler JM, 1996, PERSPECT NEUROSURG, V7, P99; Muller H., 1988, LOCAL SPINAL THERAPY, P223; O'Dell MW, 1998, ARCH PHYS MED REHAB, V79, pS10, DOI 10.1016/S0003-9993(98)90114-9; PENN RD, 1989, NEW ENGL J MED, V320, P1517, DOI 10.1056/NEJM198906083202303; ROY CW, 1986, PARAPLEGIA, V24, P318, DOI 10.1038/sc.1986.45; SABBE MB, 1993, NEUROTOXICOLOGY, V14, P397; SANDYK R, 1985, CLIN NEUROPHARMACOL, V8, P294, DOI 10.1097/00002826-198509000-00011; SHEMESH Y, 1977, PARAPLEGIA, V15, P238, DOI 10.1038/sc.1977.36; SOKOL RR, 1969, BIOMETRY; STEERS WD, 1992, J UROLOGY, V148, P1849, DOI 10.1016/S0022-5347(17)37048-9; TERRENCE CF, 1981, ARCH NEUROL-CHICAGO, V38, P588, DOI 10.1001/archneur.1981.00510090082011; WILSON PR, 1978, EUR J PHARMACOL, V51, P323, DOI 10.1016/0014-2999(78)90423-5; YAKSH TL, 1981, ANESTHESIOLOGY, V54, P451, DOI 10.1097/00000542-198106000-00004; YOUNG RR, 1981, NEW ENGL J MED, V304, P28; YOUNG RR, 1981, NEW ENGL J MED, V304, P96	48	75	77	0	1	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JAN	1999	80	1					13	19		10.1016/S0003-9993(99)90301-5			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	155XZ	WOS:000077973000002	9915366				2021-06-18	
J	Skoglosa, Y; Lewen, A; Takei, N; Hillered, L; Lindholm, D				Skoglosa, Y; Lewen, A; Takei, N; Hillered, L; Lindholm, D			Regulation of pituitary adenylate cyclase activating polypeptide and its receptor type 1 after traumatic brain injury: Comparison with brain-derived neurotrophic factor and the induction of neuronal cell death	NEUROSCIENCE			English	Article						brain trauma; gene regulation; PACAP; BDNF; in situ hybridization; cell death	CEREBELLAR GRANULE NEURONS; NERVE GROWTH-FACTOR; TRANSIENT FOREBRAIN ISCHEMIA; FACTOR MESSENGER-RNA; ADULT-RAT BRAIN; CORTICAL-NEURONS; HIPPOCAMPAL-NEURONS; PACAP RECEPTORS; PC12 CELLS; NON-NMDA	Neurotrophic factors are known to promote neuronal survival during development and after acute brain injury. Recent data suggest that some neuropeptides also exhibit neurotrophic activities, as shown for the pituitary adenylate cyclase activating polypeptide, which increases the survival of various neuronal populations in culture. Employing in situ hybridization techniques, we have studied the regulation of messenger RNA for pituitary adenylate cyclase activating polypeptide and its receptor type 1 after a moderate traumatic brain injury to rat brain cortex. We have further compared their messenger RNA expression to that of brain-derived neurotrophic factor and to the amount of cell death occurring in the brain at various times after the brain injury. Levels of brain-derived neurotrophic factor messenger RNA increased rapidly within 2 h after trauma in cortex and hippocampus, and returned to control levels thereafter. The levels of messenger RNA for pituitary adenylate cyclase activating polypeptide also increased with time in the injured brains and reached maximal expression at 72 h, i.e. the end of the observation period. The alterations in pituitary adenylate cyclase activating polypeptide messenger RNA levels were particularly pronounced in the perifocal region and in the ipsilateral dentate gyrus of the brain injury. In contrast, the messenger RNA levels encoding pituitary adenylate cyclase activating polypeptide receptor type 1 first decreased after trauma and were then normalized in the dentate gyrus. There was a large increase in the number of cells labelled for DNA breaks at 12 h past-trauma, indicative of enhanced cell death. The number of labelled cells, however, decreased at later stages concomitant with an increase in the expression of pituitary adenylate cyclase activating polypeptide messenger RNA. Pituitary adenylate cyclase activating polypeptide rescued cortical neurons in cultures against ionomycin-induced cell death, supporting the concept of a neuroprotective effect for the peptide. These results demonstrate a differential regulation of messenger RNA for brain-derived neurotrophic factor and the pituitary adenylate cyclase activating polypeptide and its receptor after brain trauma. The data also suggest that pituitary adenylate cyclase activating polypeptide might have a beneficial effect in brain injury by counteracting neuronal cell death. (C) 1999 IBRO. Published by Elsevier Science Ltd.	Biomed Ctr, Dept Neurosci Dev Neurobiol, Uppsala, Sweden; Univ Uppsala Hosp, Dept Neurosci Neurosurg, Uppsala, Sweden; Univ Uppsala Hosp, Dept Med Clin Chem, Uppsala, Sweden	Lindholm, D (corresponding author), Biomed Ctr, Dept Neurosci Dev Neurobiol, Box 587, Uppsala, Sweden.		Lewen, Anders/A-5156-2013; Lindholm, Dan/B-3777-2014	Lewen, Anders/0000-0003-4925-1348; 			ARIMURA A, 1995, FRONT NEUROENDOCRIN, V16, P53, DOI 10.1006/frne.1995.1003; ARIMURA A, 1994, ANN NY ACAD SCI, V739, P228, DOI 10.1111/j.1749-6632.1994.tb19825.x; ARIMURA A, 1992, REGUL PEPTIDES, V37, P287; Banks WA, 1996, ANN NY ACAD SCI, V805, P270; BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BASILLE M, 1993, NEUROSCIENCE, V57, P329, DOI 10.1016/0306-4522(93)90066-O; BECK T, 1994, J CEREBR BLOOD F MET, V14, P689, DOI 10.1038/jcbfm.1994.86; CASTREN E, 1995, NEUROSCIENCE, V64, P71, DOI 10.1016/0306-4522(94)00386-J; Cavallaro S, 1996, MOL PHARMACOL, V50, P60; CHENG B, 1994, BRAIN RES, V650, P331, DOI 10.1016/0006-8993(94)91801-5; CHENG B, 1994, BRAIN RES, V640, P56, DOI 10.1016/0006-8993(94)91857-0; CHENG B, 1991, NEURON, V7, P1031, DOI 10.1016/0896-6273(91)90347-3; Clark RSB, 1997, J NEUROSCI, V17, P9172; DAgata V, 1996, EUR J NEUROSCI, V8, P310, DOI 10.1111/j.1460-9568.1996.tb01215.x; DAVIS RC, 1994, ARIEL-REV INT ENGL, V25, P133; DEKOSKY ST, 1994, EXP NEUROL, V130, P173, DOI 10.1006/exnr.1994.1196; DESHPANDE J, 1992, EXP BRAIN RES, V88, P91, DOI 10.1007/BF02259131; DEUTSCH PJ, 1992, J BIOL CHEM, V267, P5108; DICICCOBLOOM E, 1992, REGUL PEPTIDES, V37, P319, DOI 10.1016/0167-0115(92)90634-7; Dixon CE, 1997, EXP NEUROL, V146, P479, DOI 10.1006/exnr.1997.6557; ERNFORS P, 1990, NEURON, V5, P511, DOI 10.1016/0896-6273(90)90090-3; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GALL CM, 1989, SCIENCE, V245, P758, DOI 10.1126/science.2549634; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Hashimoto H, 1996, J COMP NEUROL, V371, P567; HAYES RL, 1995, NEUROSCI LETT, V191, P121, DOI 10.1016/0304-3940(95)11561-X; HERNANDEZ A, 1995, PEPTIDES, V16, P927, DOI 10.1016/0196-9781(95)00059-S; Hicks RR, 1997, MOL BRAIN RES, V48, P401, DOI 10.1016/S0169-328X(97)00158-7; ISACKSON PJ, 1991, NEURON, V6, P937, DOI 10.1016/0896-6273(91)90234-Q; KAISER PK, 1990, NEURON, V5, P373, DOI 10.1016/0896-6273(90)90173-D; KIVIPELTO L, 1992, J CHEM NEUROANAT, V5, P85, DOI 10.1016/0891-0618(92)90036-P; Kokaia Z, 1996, MOL BRAIN RES, V38, P139, DOI 10.1016/0169-328X(96)00002-2; Larsen JO, 1997, MOL BRAIN RES, V46, P109, DOI 10.1016/S0169-328X(96)00279-3; Lewen A, 1996, BRAIN RES, V719, P161, DOI 10.1016/0006-8993(96)00081-9; Lewen A, 1997, NEUROREPORT, V8, P475, DOI 10.1097/00001756-199701200-00020; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; LINDHOLM D, 1993, EUR J NEUROSCI, V5, P1455, DOI 10.1111/j.1460-9568.1993.tb00213.x; LINDHOLM D, 1994, J NEUROBIOL, V25, P1362, DOI 10.1002/neu.480251105; Lindholm D, 1996, EUR J NEUROSCI, V8, P1452, DOI 10.1111/j.1460-9568.1996.tb01607.x; LINDHOLM D, 1992, J CELL BIOL, V117, P395, DOI 10.1083/jcb.117.2.395; LINDSAY RM, 1994, NEUROBIOL AGING, V15, P249, DOI 10.1016/0197-4580(94)90124-4; LINDSAY RM, 1994, TRENDS NEUROSCI, V17, P182, DOI 10.1016/0166-2236(94)90099-X; LINDVALL O, 1994, TRENDS NEUROSCI, V17, P490, DOI 10.1016/0166-2236(94)90139-2; LINDVALL O, 1992, P NATL ACAD SCI USA, V89, P648, DOI 10.1073/pnas.89.2.648; Lioudyno M, 1998, J NEUROSCI RES, V51, P243, DOI 10.1002/(SICI)1097-4547(19980115)51:2<243::AID-JNR13>3.3.CO;2-N; LONGO FM, 1993, NEUROTROPHIC FACTORS, P565; Lu NR, 1997, P NATL ACAD SCI USA, V94, P3357, DOI 10.1073/pnas.94.7.3357; Marty S, 1996, NEURON, V16, P565, DOI 10.1016/S0896-6273(00)80075-6; MIYATA A, 1989, BIOCHEM BIOPH RES CO, V164, P567, DOI 10.1016/0006-291X(89)91757-9; MIYATA A, 1990, BIOCHEM BIOPH RES CO, V170, P643, DOI 10.1016/0006-291X(90)92140-U; Morio H, 1996, BRAIN RES, V741, P82, DOI 10.1016/S0006-8993(96)00920-1; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; Nilsson P, 1996, J CEREBR BLOOD F MET, V16, P262, DOI 10.1097/00004647-199603000-00011; NITATORI T, 1995, J NEUROSCI, V15, P1001; OGI K, 1990, BIOCHEM BIOPH RES CO, V173, P1271, DOI 10.1016/S0006-291X(05)80924-6; PINCUS DW, 1990, BRAIN RES, V514, P355, DOI 10.1016/0006-8993(90)91433-H; PorteraCailliau C, 1997, J COMP NEUROL, V378, P88, DOI 10.1002/(SICI)1096-9861(19970203)378:1<88::AID-CNE5>3.0.CO;2-G; Rawlings SR, 1996, ENDOCR REV, V17, P4, DOI 10.1210/er.17.1.4; RINK A, 1995, AM J PATHOL, V147, P1575; SCHWARTZ JP, 1992, INT REV NEUROBIOL, V34, P1, DOI 10.1016/S0074-7742(08)60096-3; Shuto Y, 1996, REGUL PEPTIDES, V67, P79, DOI 10.1016/S0167-0115(96)00116-4; SKOGLOSA Y, 1997, SOC NEUR 27 ANN M NE; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; TAKEI N, 1994, BRAIN RES, V652, P65, DOI 10.1016/0006-8993(94)90317-4; TATSUNO I, 1992, ENDOCRINOLOGY, V131, P73, DOI 10.1210/en.131.1.73; TATSUNO I, 1994, PEPTIDES, V15, P55, DOI 10.1016/0196-9781(94)90170-8; TSUKAHARA T, 1994, NEUROSURGERY, V34, P323, DOI 10.1227/00006123-199402000-00016; Villalba M, 1997, J NEUROSCI, V17, P83; ZAFRA F, 1990, EMBO J, V9, P3545, DOI 10.1002/j.1460-2075.1990.tb07564.x; Zhang Q, 1995, BRAIN RES, V705, P149, DOI 10.1016/0006-8993(95)01150-1; ZIRRGIEBEL U, 1995, J NEUROCHEM, V65, P2241	72	75	78	0	2	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience		1999	90	1					235	247		10.1016/S0306-4522(98)00414-X			13	Neurosciences	Neurosciences & Neurology	172RE	WOS:000078937400022	10188950				2021-06-18	
J	Martins, F; Freitas, F; Martins, L; Dartigues, JF; Barat, M				Martins, F; Freitas, F; Martins, L; Dartigues, JF; Barat, M			Spinal cord injuries - Epidemiology in Portugal's central region	SPINAL CORD			English	Article						spinal cord injury; incidence; mortality; rehabilitation	EXPERIENCE; LESIONS; TAIWAN; COUNTY	This study concerns spinal cord injuries (SCI) in a region of Portugal with a population of 1721650 inhabitants. Legislation has made it possible to identify deaths occurring during collection and transport. Between 1989 and 1992, 395 new cases of spinal cord injuries were identified, of with 77% were male and 23% female. The average age nias 50, with a range of between 1 and 92. As far as the type of injury is concerned, there were 154 isolated SCI (38.7%); in 120 cases (30.1%) there were multiple associated injuries; in 66 cases (16.6%) there was an associated traumatic brain injury; in 34 cases (8.5%) there was an associated trauma of the thorax. In the hospitals concerned no Injury Severity Score (ISS) was carried out during hospitalization. Sixty-four (16%) were dead upon arrival at hospital, and 159 (40%) died before release. The average length of hospitalization was 26.6 days, with the maximum being 539 days. The annual incidence rate is 57.8 new cases per million inhabitants, including those who died before being admitted to hospital. The annual survival rate is 25.4 new cases per million inhabitants. The death rate is very high during the first week, peaking during the first 24 h.	Ctr Hosp Coimbra, Serv Med Fis & Reabilitacad, P-3000 Coimbra, Portugal; Univ Bordeaux 2, F-33000 Bordeaux, France	Martins, F (corresponding author), Rua Miguel Torga 353,4 Esq, P-3030 Coimbra, Portugal.		DARTIGUES, Jean Francois/T-4513-2019				ACTON PA, 1993, ARCH PHYS MED REHAB, V74, P1035, DOI 10.1016/0003-9993(93)90058-I; ANDERSON DW, 1980, J NEUROSURG, V53, pS32; BIERINGSORENSEN F, 1990, PARAPLEGIA, V28, P105, DOI 10.1038/sc.1990.13; BRACKEN MB, 1981, AM J EPIDEMIOL, V113, P615, DOI 10.1093/oxfordjournals.aje.a113140; BURNEY RE, 1993, ARCH SURG-CHICAGO, V128, P596; CHEN CF, 1985, PARAPLEGIA, V23, P364, DOI 10.1038/sc.1985.58; DAPAZ AC, 1992, PARAPLEGIA, V30, P636, DOI 10.1038/sc.1992.126; DAVERAT P, 1989, J NEUROL NEUROSUR PS, V52, P403, DOI 10.1136/jnnp.52.3.403; DAVERAT P, 1987, Annales de Readaptation et de Medecine Physique, V30, P369; DAVERAT P, 1990, RENCONTRES AUTOUR BL, P135; DINEER F, 1992, PARAPLEGIA, V30, P641; DITUNNO JF, 1994, PARAPLEGIA, V32, P70, DOI 10.1038/sc.1994.13; DOLLFUS P, 1990, RECONTRES AUTOUR BLE, P197; FINE PR, 1979, PARAPLEGIA, V17, P237, DOI 10.1038/sc.1979.47; GARCIARENESES J, 1991, PARAPLEGIA, V29, P180, DOI 10.1038/sc.1991.26; GASPAR VG, 1980, PARAPLEGIA, V18, P106, DOI 10.1038/sc.1980.17; GEHRIG R, 1986, PARAPLEGIA, V5, P93; GJONE R, 1978, PARAPLEGIA, V16, P88, DOI 10.1038/sc.1978.14; GRIFFIN MR, 1985, AM J EPIDEMIOL, V121, P884, DOI 10.1093/oxfordjournals.aje.a114058; GRIFFITHS ER, 1980, PARAPLEGIA, V18, P109, DOI 10.1038/sc.1980.18; HARLID R, 1993, PARAPLEGIA, V31, P157; HART C, 1994, PARAPLEGIA, V32, P709, DOI 10.1038/sc.1994.115; *I NAC EST CENS 91, 1993, RES DEF CTR; KARAMEHMETOGLU SS, 1995, PARAPLEGIA, V33, P469, DOI 10.1038/sc.1995.102; KNUTSDOTTIR S, 1993, PARAPLEGIA, V31, P68, DOI 10.1038/sc.1993.10; KRAUS JF, 1980, J NEUROSURG, V53, pS35; KRAUS JF, 1975, J CHRON DIS, V28, P471, DOI 10.1016/0021-9681(75)90057-0; KRAUS JF, 1980, J NEUROSURG, V53, pS3; LAN C, 1993, PARAPLEGIA, V31, P398, DOI 10.1038/sc.1993.66; MARTINS F, 1990, ACTUALITIES REEDUCAT, P383; MASINI M, 1990, PARAPLEGIA, V28, P17, DOI 10.1038/sc.1990.3; MINAIRE P, 1978, PARAPLEGIA, V16, P76, DOI 10.1038/sc.1978.13; PRICE C, 1994, AM J EPIDEMIOL, V139, P37, DOI 10.1093/oxfordjournals.aje.a116933; SHINGU H, 1994, PARAPLEGIA, V32, P3, DOI 10.1038/sc.1994.2; SILBERSTEIN B, 1995, PARAPLEGIA, V33, P322, DOI 10.1038/sc.1995.72; SILVER JR, 1968, BRIT MED J, V4, P79, DOI 10.1136/bmj.4.5623.79; SOOPRAMANIEN A, 1994, PARAPLEGIA, V32, P715, DOI 10.1038/sc.1994.116; THURMAN DJ, 1994, PARAPLEGIA, V32, P665, DOI 10.1038/sc.1994.107; TOLONEN J, 1986, INJURY, V17, P154, DOI 10.1016/0020-1383(86)90321-9; YARKONY GM, 1990, PARAPLEGIA, V28, P321, DOI 10.1038/sc.1990.42; YELNIK A, 1990, RECONTRES AUTOUR BLE, P192; 1991, MMWR, V31, P535	42	75	76	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1362-4393	1476-5624		SPINAL CORD	Spinal Cord	AUG	1998	36	8					574	578		10.1038/sj.sc.3100657			5	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	106NR	WOS:000075136200007	9713927	Bronze			2021-06-18	
J	Theriault, E; Frankenstein, UN; Hertzberg, EL; Nagy, JI				Theriault, E; Frankenstein, UN; Hertzberg, EL; Nagy, JI			Connexin43 and astrocytic gap junctions in the rat spinal cord after acute compression injury	JOURNAL OF COMPARATIVE NEUROLOGY			English	Article						glial cells; gap junction proteins; neuron survival; subpial white matter; immunohistochemistry	SCANNING ELECTRON-MICROSCOPY; FIBRILLARY ACIDIC PROTEIN; VASCULAR CORROSION CASTS; KAINIC ACID; 3-DIMENSIONAL ANALYSIS; CULTURED ASTROCYTES; FREEZE-FRACTURE; NERVOUS-SYSTEM; BRAIN; EXPRESSION	To examine the possible role of interastrocytic gap junctions in the maintenance of tissue homeostasis after spinal cord damage, we initiated studies of the astrocytic gap junctional protein connexin43 (Cx43) in relation to temporal and spatial parameters of neuronal loss, reactive gliosis, and white matter survival in a rat model of traumatic spinal cord injury (SCI). Cx43 immunolocalization in normal and compression-injured spinal cord was compared by using two different sequence-specific anti-Cx43 antibodies that have previously exhibited different immunorecognition properties at lesion sites in brain. At 1- and 3-day survival times, gray matter areas with mild to moderate neuronal depletion exhibited a loss of immunolabelling with one of the two antibodies. At the lesion epicenter, these areas consisted of a zone that separated normal staining distal to the lesion from intensified labeling seen with both antibodies immediately adjacent to the lesion. Loss of immunoreactivity with only one of the two antibodies suggested masking of the corresponding Cx43 epitope. By 7 days post-SCI, Cx43 labeling was absent with both antibodies in all regions extending up to I mm from the lesion site. Reactive astrocytes displaying glial fibrillary acidic protein (GFAP) appeared by 1 day and were prominent by 3 days post-SCI. Their distribution in white and gray matter corresponded closely to that of Cx43 staining at 1 day, but less so at 3 days when GFAP-positive profiles were present at sites where Cx43 labeling was absent. By 7 days post-SCI, Cx43 again co-localized with GFAP-positive cells in the surviving subpial rim, and with astrocytic processes on radially oriented vascular profiles investing the central borders of the lesion. The results indicate that alterations in Cx43 cellular localization and Cx43 molecular modifications reflected by epitope masking, which were previously correlated with gap junction remodeling following excitotoxin-induced lesions in brain, are not responses limited to exogenously applied excitotoxins; they also occur in damaged spinal cord and are evoked by endogenous mechanisms after traumatic SCI. The GFAP/Cx43 co-localization results suggest that during their transformation to a reactive state, spinal cord astrocytes undergo a transitional phase marked by altered Cx43 localization or expression. (C) 1997 Wiley-Liss, Inc.	UNIV MANITOBA,FAC MED,DEPT PHYSIOL,WINNIPEG,MB R3E 0W3,CANADA; TORONTO HOSP,TORONTO WESTERN DIV,PLAYFAIR NEUROSCI UNIT,TORONTO,ON M5T 2S8,CANADA; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT NEUROSCI,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT ANAT & STRUCT BIOL,BRONX,NY 10461				Nagy, James Imre/0000-0003-2753-091X			Anthes DL, 1996, NEUROSURGERY, V39, P804, DOI 10.1097/00006123-199610000-00032; ANTHES DL, 1995, BRAIN RES, V702, P1, DOI 10.1016/0006-8993(95)01028-6; BELLIVEAU DJ, 1994, GLIA, V12, P24, DOI 10.1002/glia.440120104; BENNETT MVL, 1991, NEURON, V6, P305, DOI 10.1016/0896-6273(91)90241-Q; Beyer E C, 1993, Int Rev Cytol, V137C, P1; BEYER EC, 1990, J MEMBRANE BIOL, V116, P187, DOI 10.1007/BF01868459; BEYER EC, 1987, J CELL BIOL, V105, P2621, DOI 10.1083/jcb.105.6.2621; BLIGHT AR, 1989, J AM PARAPLEGIA SOC, V11, P26; Bresnahan JC, 1991, J NEUROTRAUM, V8, P91, DOI 10.1089/neu.1991.8.91; Bruzzone R, 1996, EUR J BIOCHEM, V238, P1, DOI 10.1111/j.1432-1033.1996.0001q.x; Bunge R. P., 1995, Journal of Neurotrauma, V12, P354; BUNGE RP, 1993, ADV NEUROL, V59, P75; DERMIETZEL R, 1987, J CELL BIOL, V105, P1925, DOI 10.1083/jcb.105.4.1925; DERMIETZEL R, 1990, ANAT EMBRYOL, V182, P517; DERMIETZEL R, 1989, P NATL ACAD SCI USA, V86, P10148, DOI 10.1073/pnas.86.24.10148; DERMIETZEL R, 1993, TRENDS NEUROSCI, V16, P186, DOI 10.1016/0166-2236(93)90151-B; DUSART I, 1994, EUR J NEUROSCI, V6, P712, DOI 10.1111/j.1460-9568.1994.tb00983.x; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; Federoff S, 1986, ASTROCYTES DEV MORPH, P329, DOI [10.1016/B978-0-12-250451-8.50018-7, DOI 10.1016/B978-0-12-250451-8.50018-7]; FISCHER G, 1985, EXP CELL RES, V159, P273, DOI 10.1016/S0014-4827(85)80001-X; GIAUME C, 1991, NEURON, V6, P133, DOI 10.1016/0896-6273(91)90128-M; Goodenough DA, 1996, ANNU REV BIOCHEM, V65, P475, DOI 10.1146/annurev.bi.65.070196.002355; GRAEBER MB, 1986, J NEUROCYTOL, V15, P363; HOSSAIN MZ, 1994, J NEUROCHEM, V62, P2394; HOSSAIN MZ, 1994, BRAIN RES, V652, P311, DOI 10.1016/0006-8993(94)90242-9; HOSSAIN MZ, 1994, GLIA, V10, P250, DOI 10.1002/glia.440100404; KETTENMANN H, 1988, GLIA, V1, P64, DOI 10.1002/glia.440010108; KETTENMANN H, 1983, J NEUROSCI, V3, P506; KOYANAGI I, 1993, NEUROSURGERY, V32, P260, DOI 10.1227/00006123-199302000-00015; KOYANAGI I, 1993, NEUROSURGERY, V33, P277; KOYANAGI I, 1993, NEUROSURGERY, V33, P285, DOI 10.1227/00006123-199308000-00016; KOYANAGI I, 1995, J NEUROTRAUM, V12, P357; LANG LM, 1991, AM J PHYSIOL, V260, P787; Largo C, 1996, J NEUROSCI, V16, P1219; LOEWENSTEIN WR, 1981, PHYSIOL REV, V61, P829; Marrero H, 1996, GLIA, V16, P285; MASSA PT, 1982, NEUROSCIENCE, V7, P523; NAGY JI, 1992, GLIA, V5, P1, DOI 10.1002/glia.440050102; NAUS CCG, 1991, EXP NEUROL, V111, P198, DOI 10.1016/0014-4886(91)90007-Y; OCHALSKI PAY, 1995, GLIA, V14, P279, DOI 10.1002/glia.440140405; OCHALSKI PAY, 1996, IN PRESS NEUROSCIENC; ORKLAND RK, 1966, J NEUROPHYSIOL, V29, P788; RANSOM BR, 1986, ASTROCYTES BIOCH PHY, V2, P1; ROHLMANN A, 1993, NEUROSCI LETT, V154, P206, DOI 10.1016/0304-3940(93)90208-3; SAEZ JC, 1993, ADV SEC MESS PHOSPH, V27, P163; SAWCHUK MA, 1995, BRAIN RES, V683, P153, DOI 10.1016/0006-8993(95)00337-P; SCHMIDTKASTNER R, 1993, INT J DEV NEUROSCI, V11, P157, DOI 10.1016/0736-5748(93)90076-P; SPRAY DC, 1985, ANNU REV PHYSIOL, V47, P281, DOI 10.1146/annurev.ph.47.030185.001433; SULLIVAN R, 1993, GENE, V130, P191, DOI 10.1016/0378-1119(93)90419-4; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; THERIAULT E, 1994, J COMP NEUROL, V342, P249, DOI 10.1002/cne.903420208; THERIAULT E, 1995, J NEUROTRAUM, V12, P364; VALNES K, 1985, J HISTOCHEM CYTOCHEM, V33, P755, DOI 10.1177/33.8.3926864; VUKELIC JI, 1991, NEUROSCI LETT, V130, P120, DOI 10.1016/0304-3940(91)90242-L; WALZ W, 1989, PROG NEUROBIOL, V33, P309, DOI 10.1016/0301-0082(89)90005-1; WAXMAN SG, 1984, BRAIN RES, V308, P77, DOI 10.1016/0006-8993(84)90919-3; WHITE TW, 1995, KIDNEY INT, V48, P1148, DOI 10.1038/ki.1995.398; WILLECKE K, 1991, EUR J CELL BIOL, V56, P1; WOLBURG H, 1995, INT REV CYTOL, V157, P315, DOI 10.1016/S0074-7696(08)62161-0; YAMAMOTO T, 1990, J COMP NEUROL, V302, P853, DOI 10.1002/cne.903020414; YAMAMOTO T, 1990, BRAIN RES, V508, P313, DOI 10.1016/0006-8993(90)90415-8; YEE AG, 1978, J CELL BIOL, V78, P554, DOI 10.1083/jcb.78.2.554; YOUNG W, 1986, BRAIN RES, V365, P42, DOI 10.1016/0006-8993(86)90720-1; YOUNG W, 1988, CURR OPIN NEUROL NEU, V1, P611; Young W, 1987, Cent Nerv Syst Trauma, V4, P27; ZHANG JT, 1989, J CELL BIOL, V109, P3391, DOI 10.1083/jcb.109.6.3391	66	75	79	0	1	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012	0021-9967			J COMP NEUROL	J. Comp. Neurol.	JUN 2	1997	382	2					199	214					16	Neurosciences; Zoology	Neurosciences & Neurology; Zoology	XC352	WOS:A1997XC35200005	9183689				2021-06-18	
J	King, NS; Crawford, S; Wenden, FJ; Moss, NEG; Wade, DT; Caldwell, FE				King, NS; Crawford, S; Wenden, FJ; Moss, NEG; Wade, DT; Caldwell, FE			Measurement of post-traumatic amnesia: How reliable is it?	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article						post-traumatic amnesia; measurement reliability	CLOSED HEAD-INJURY; PRACTICAL SCALE; BRAIN-DAMAGE; SEVERITY; COMA	Objective-To develop and test a clinical protocol for determining post-traumatic amnesia by retrospective questioning. To establish its limits and factors which influence reliability. Design-Two independent assessments using the Rivermead post-traumatic amnesia protocol were undertaken by separate observers on various groups of patients at various time intervals. Analysis investigated the correlations between assessments, the percentage difference between assessments, the number of patients changing category, and the differences between these analyses in the different patient subgroups. Assessments were undertaken both in hospital and in the patients' homes. Four different patient groups were studied. These were group A: 12 inpatients with very severe head injury late after injury; Group B: 40 patients interviewed at home six months after injury; group C: 22 patients interviewed within a few weeks of injury at home; group D: 116 patients interviewed initially within a few weeks and then at six months, on both occasions at home. The Rivermead post-traumatic amnesia protocol involved clinical questioning of the patient to establish how long after injury (in hours/days/weeks) the patient regained continuous day to day memory. All periods of coma were included. Severity was categorised with standard criteria. Results-Overall correlation was good (Spearman's r 0 . 79), but the correlation was lower for patients with post-traumatic amnesia < 24 hours and when there was a long delay between assessments. In all groups 19%-25% of patients changed categories between assessments, but only 2% changed by two categories. Conclusions-The assessment of posttraumatic amnesia with the Rivermead post-traumatic amnesia protocol is reasonably reliable. The misclassification rate however, is significant enough that some caution should be taken in individual cases. Other evidence does show post-traumatic amnesia to be valid, and it DT Wade probably remains the best simple prognostic item available. In clinical practice one should avoid placing too much weight on post-traumatic amnesia alone.		King, NS (corresponding author), RIVERMEAD REHABIL CTR,OXFORD HEAD INJURY SERV,ABINGDON RD,OXFORD OX1 4XD,ENGLAND.			Wade, Derick/0000-0002-1188-8442			ARTIOLA I, 1980, J NEUROL NEUROSUR PS, V43, P377; BISHARA S N, 1992, Brain Injury, V6, P373, DOI 10.3109/02699059209034952; BROOKS DN, 1980, J NEUROL NEUROSUR PS, V43, P529, DOI 10.1136/jnnp.43.6.529; BROOKS DN, 1976, J NEUROL NEUROSUR PS, V39, P593, DOI 10.1136/jnnp.39.6.593; FORRESTER G, 1994, BRAIN INJURY, V8, P175, DOI 10.3109/02699059409150969; GRONWALL D, 1980, Journal of Clinical Neuropsychology, V2, P51, DOI 10.1080/01688638008403780; JENNETT B, 1975, LANCET, V1, P480; KARZMARK P, 1992, Brain Injury, V6, P213, DOI 10.3109/02699059209029662; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A, P165; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P16, DOI DOI 10.1001/ARCHNEUR.1961.00450130006002; SCHACTER DL, 1977, CORTEX, V13, P150, DOI 10.1016/S0010-9452(77)80006-3; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; TEASDALE G, 1974, LANCET, V2, P81; WILLIAMS JM, 1984, J NEUROSURG, V61, P581, DOI 10.3171/jns.1984.61.3.0581; WILSON JTL, 1993, J NEUROL NEUROSUR PS, V56, P198; WITTY CWM, 1977, AMNESIA, P118	20	75	76	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	JAN	1997	62	1					38	42		10.1136/jnnp.62.1.38			5	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	WD449	WOS:A1997WD44900010	9010398	Green Published, Bronze			2021-06-18	
J	Coulter, DA; Rafiq, A; Shumate, M; Gong, QZ; DeLorenzo, RJ; Lyeth, BG				Coulter, DA; Rafiq, A; Shumate, M; Gong, QZ; DeLorenzo, RJ; Lyeth, BG			Brain injury-induced enhanced limbic epileptogenesis: Anatomical and physiological parallels to an animal model of temporal lobe epilepsy	EPILEPSY RESEARCH			English	Article; Proceedings Paper	3rd Workshop on the Neurobiology of Epilepsy (WONOEP III) - Mechanisms of Chronic Models of Epilepsy	AUG 29-SEP 02, 1995	KEWARRA BEACH, AUSTRALIA			traumatic brain injury; pilocarpine; mossy fiber sprouting	FIBER SYNAPTIC REORGANIZATION; HIPPOCAMPAL-FORMATION; PILOCARPINE SEIZURES; STATUS EPILEPTICUS; NEURONAL LOSS; HEAD TRAUMA; RAT; SLICE; RESPONSES; PATTERNS	Traumatic brain injury (TBI) is a leading cause of symptomatic epilepsy in young adults. This study examined physiological and anatomical epileptogenic consequences of a prior incident of TBI in rats. Rats were subjected to a fluid percussion brain injury one week prior to experimentation, and in vitro electrophysiological recording studies were conducted using combined hippocampal-entorhinal cortical slices (HEC slices). Results were compared to sham operated controls and rats in which a condition of chronic temporal lobe epilepsy was induced by a 2 h bout of pilocarpine-induced status epilepticus 2 months prior to recording (PILO). In field potential recordings, PILO HEC slices evidenced a greater degree of disinhibition in CAI than did TBI or control slices. TBI slices showed greater disinhibition in the dentate gyrus than did PILO or control rats. In in vitro kindling experiments, 86% of TBI HEC slices generated self-sustaining epileptic activity within 9 stimulus trains. This type of activity was never triggered in control slices. HEC slices prepared from PILO animals generated self-sustaining epileptic activity with fewer stimulus trains than did TBI slices. In anatomical studies, both TBI and PILO hippocampi evidenced significant loss of neurons within the hilar region. TBI induces a series of changes within the limbic system of rats, which are qualitatively similar in many aspects but quantitatively less severe than changes seen in rats with chronic temporal lobe epilepsy. These physiological and anatomical TBI-associated alterations in the limbic system may contribute to the development of epilepsy following head trauma.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PHYSIOL,RICHMOND,VA 23298; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT NEUROSURG,RICHMOND,VA 23298; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,COMPREHENS EPILEPSY INST,RICHMOND,VA 23298	Coulter, DA (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT NEUROL,RICHMOND,VA 23298, USA.			Coulter, Douglas/0000-0002-1486-119X; Lyeth, Bruce/0000-0003-4811-1474	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS025630, R01NS023350, R01NS032403, R37NS032403] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-32403, NS-23350, P01 NS-25630] Funding Source: Medline		AMARAL DG, 1989, NEUROSCIENCE, V31, P571, DOI 10.1016/0306-4522(89)90424-7; ANDERSON WW, 1990, BRAIN RES, V532, P288, DOI 10.1016/0006-8993(90)91771-8; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; ANNEGERS JF, 1993, TREATMENT EPILEPSY P, pCH12; BABB TL, 1984, EPILEPSIA, V25, P721, DOI 10.1111/j.1528-1157.1984.tb03483.x; CAVAZOS JE, 1990, BRAIN RES, V527, P1, DOI 10.1016/0006-8993(90)91054-K; CLIFFORD DB, 1987, NEUROSCIENCE, V23, P953, DOI 10.1016/0306-4522(87)90171-0; CRONIN J, 1992, BRAIN RES, V573, P305, DOI 10.1016/0006-8993(92)90777-7; DAM AM, 1980, EPILEPSIA, V21, P617, DOI 10.1111/j.1528-1157.1980.tb04315.x; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Gualtari CT, 1991, BRAIN INJURY, V5, P219; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Hill S. J., 1994, Society for Neuroscience Abstracts, V20, P424; HOUSER CR, 1990, J NEUROSCI, V10, P267; JONES RSG, 1988, J NEUROPHYSIOL, V59, P1476; LIU Z, 1994, EPILEPSY RES, V17, P237; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LYETH BG, 1988, BRAIN RES, V448, P88, DOI 10.1016/0006-8993(88)91104-3; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MATHERN GW, 1995, J NEUROSURG, V82, P211, DOI 10.3171/jns.1995.82.2.0211; MATHERN GW, 1994, EPILEPSY RES, V19, P129, DOI 10.1016/0920-1211(94)90023-X; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MELLO LEAM, 1993, EPILEPSIA, V34, P985, DOI 10.1111/j.1528-1157.1993.tb02123.x; OBENAUS A, 1993, J NEUROSCI, V13, P4470; OKAZAKI MM, 1995, J COMP NEUROL, V352, P515, DOI 10.1002/cne.903520404; RAFIQ A, 1995, J NEUROPHYSIOL, V74, P2028; RAFIQ A, 1993, J NEUROPHYSIOL, V70, P1962; Sloviter R S, 1991, Hippocampus, V1, P41, DOI 10.1002/hipo.450010106; SLOVITER RS, 1987, SCIENCE, V235, P73, DOI 10.1126/science.2879352; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SUTULA T, 1988, SCIENCE, V239, P1147, DOI 10.1126/science.2449733; SUTULA T, 1989, ANN NEUROL, V26, P321, DOI 10.1002/ana.410260303; TAUCK DL, 1985, J NEUROSCI, V5, P1016	34	75	77	1	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0920-1211			EPILEPSY RES	Epilepsy Res.	DEC	1996	26	1					81	91		10.1016/S0920-1211(96)00044-7			11	Clinical Neurology	Neurosciences & Neurology	VX953	WOS:A1996VX95300011	8985690				2021-06-18	
J	BeitYannai, E; Zhang, RL; Trembovler, V; Samuni, A; Shohami, E				BeitYannai, E; Zhang, RL; Trembovler, V; Samuni, A; Shohami, E			Cerebroprotective effect of stable nitroxide radicals in closed head injury in the rat	BRAIN RESEARCH			English	Article						closed-head injury; edema; free radical; neuroprotection; nitroxide	LIPID-PEROXIDATION; OXIDATIVE DAMAGE; OXYGEN RADICALS; NERVOUS-SYSTEM; BRAIN; PERMEABILITY; ISCHEMIA	Nitroxide stable radicals are unreactive toward most diamagnetic molecules, but readily undergo one-electron redox reactions with paramagnetic species such as free radicals and transition metals, thus serving as cell permeable antioxidants. The involvement of reactive oxygen species in the pathophysiology of neurotrauma has been well established, The neuroprotective properties of three nitroxides: 2,2,6,6-tetramethylpiperidine-1-N-oxyl (TPO), the hydrophilic analog: TPL, and its reduced form: TPH, were tested in a rat model of closed head injury (CHI). CHI was induced in ether anesthetized rats by a weight drop device and recovery was followed for up to 24 h. The 'clinical status' was evaluated according to a 'Neurological Severity Score' (NSS), at 1 h and 24 h, the difference between these scores, Delta NSS, reflecting the extent of recovery. Edema was assessed by measurement of water content at 24 h. The integrity of the blood-brain barrier (BBB) was investigated using Evans Blue extravasation. TPL, TPH and TPO facilitated clinical recovery, the latter causing a more pronounced effect (Delta NSS = 7.63 +/- 0.26 in treated rats vs 4.94 +/- 0.48 in control rats, P < 0.001). TPL was found to significantly reduce edema formation (80.13% +/- 0.26 vs 83.65% +/- 0.49, P < 0.001) and to ameliorate BBB disruption (P < 0.001). The therapeutic window of TPL was found to be in the range of 4 h after CHI. The mechanisms underlying the nitroxide neuroprotective activity presumably involve: (a) reoxidation of reduced transition metal ions; (b) a selective radical-radical reaction; and (c) catalytic removal of intracellular and extracellular O-.(2)-. The results indicate that nitroxides could be used in neuroprotective treatment of CHI.	HEBREW UNIV JERUSALEM,SCH PHARM,FAC MED,DEPT MOLEC BIOL & PHARMACOL,IL-91120 JERUSALEM,ISRAEL			Beit-Yannai, Elie/F-2141-2012	Beit-Yannai, Elie/0000-0001-9347-822X			CHAN PH, 1989, CELLULAR ANTIOXIDANT; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; DEMOPOULOS HB, 1982, PATHOLOGY OXYGEN, P127; GELVAN D, 1991, P NATL ACAD SCI USA, V88, P4680, DOI 10.1073/pnas.88.11.4680; HAHN SM, 1992, CANCER RES, V52, P1750; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; HALL ED, 1992, J NEUROTRAUM, V9, pS425; KLATZO I, 1967, J NEUROPATH EXP NEUR, V26, P1, DOI 10.1097/00005072-196701000-00001; KONTOS HA, 1985, CIRC RES, V57, P508, DOI 10.1161/01.RES.57.4.508; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; KRISHNA MC, 1994, FREE RADICAL BIO MED, V17, P379, DOI 10.1016/0891-5849(94)90164-3; MATSUMIYA N, 1991, STROKE, V22, P1193, DOI 10.1161/01.STR.22.9.1193; MEHLHORN RJ, 1992, FREE RADICAL RES COM, V17, P157, DOI 10.3109/10715769209068163; MITCHELL JB, 1990, BIOCHEMISTRY-US, V29, P2802, DOI 10.1021/bi00463a024; NILSSON UA, 1989, J BIOL CHEM, V264, P11131; PARK CK, 1994, BRAIN RES, V645, P157; POGREBNIAK H, 1991, J SURG RES, V50, P469, DOI 10.1016/0022-4804(91)90026-I; RACHMILEWITZ D, 1994, GUT, V35, P1181, DOI 10.1136/gut.35.9.1181; SAMUNI A, 1991, BIOCHEMISTRY-US, V30, P555, DOI 10.1021/bi00216a033; SAMUNI A, 1991, J CLIN INVEST, V87, P1526, DOI 10.1172/JCI115163; SHAPIRA Y, 1993, ANESTH ANALG, V77, P141; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; SHOHAMI E, 1987, J CEREBR BLOOD F MET, V7, P58, DOI 10.1038/jcbfm.1987.8; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; SHOHAMI E, 1989, J NEUROCHEM, V53, P1541, DOI 10.1111/j.1471-4159.1989.tb08550.x; SIESJPO B K, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P165; UYAMA O, 1988, J CEREBR BLOOD F MET, V8, P282, DOI 10.1038/jcbfm.1988.59	27	75	75	0	6	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	APR 22	1996	717	1-2					22	28		10.1016/0006-8993(95)01492-6			7	Neurosciences	Neurosciences & Neurology	UM505	WOS:A1996UM50500003	8738249				2021-06-18	
J	YANG, KY; MU, XS; HAYES, RL				YANG, KY; MU, XS; HAYES, RL			INCREASED CORTICAL NUCLEAR FACTOR-KAPPA-B(NF-KAPPA-B) DNA-BINDING ACTIVITY AFTER TRAUMATIC BRAIN INJURY IN RATS	NEUROSCIENCE LETTERS			English	Article						BRAIN TRAUMA; DNA BINDING PROTEIN; GENE EXPRESSION; NUCLEAR FACTOR; NF-KAPPA-B; TRANSCRIPTION FACTOR	NF-KAPPA-B; TRANSCRIPTION FACTOR; ACTIVATION	Nuclear factor-kappa B (NF-kappa B) DNA binding factor is an inducible transcription factor that responds to various cellular signals. Levels of cortical NF-kappa B DNA binding activity were measured in a controlled lateral cortical impact model of traumatic brain injury (TBI) in rats. Using electrophoretic mobility shift assays (EMSAs), we found that NF-kappa B DNA binding activity in cerebral cortex ipsilateral to the injury site increased at 1, 3, 5 and 7 days after injury. Binding activity peaked at 3 days after injury and subsided by 10 days after injury. These data indicate that TBI produces transient increases in NF-kappa B DNA binding activity. Further insights into the role of NF-kappa B in TBI may provide new therapeutic opportunities for head trauma.	UNIV TEXAS,HLTH SCI CTR,DEPT NEUROSURG,HOUSTON,TX 77030					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS031998, R01NS021458] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01 NS31998, R01 NS21458] Funding Source: Medline		AN G, 1993, ANN NEUROL, V33, P457, DOI 10.1002/ana.410330508; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.iy.12.040194.001041; DENT P, 1994, EMBO J, V15, P2842; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DIXON CE, 1991, J NEUROSCI METH, V39, P253; EICHER DM, 1994, J IMMUNOL, V152, P2710; HALL ED, 1993, RES P ARNMD, V71, P81; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; KALTSCHMIDT B, 1993, MOL ASPECTS MED, V14, P171, DOI 10.1016/0098-2997(93)90004-W; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; LOZANO J, 1994, J BIOL CHEM, V269, P19200; MACHLEIDT T, 1994, J BIOL CHEM, V13, P13760; MARAN A, 1994, SCIENCE, V265, P789, DOI 10.1126/science.7914032; MAYER R, 1991, P NATL ACAD SCI USA, V88, P966; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; PRASAD AV, 1994, NEUROSCI LETT, V170, P145, DOI 10.1016/0304-3940(94)90260-7; RATTNER A, 1993, EMBO J, V12, P4261, DOI 10.1002/j.1460-2075.1993.tb06110.x; YANG K, 1994, BRAIN RES, V664, P141, DOI 10.1016/0006-8993(94)91964-X; YANG KY, 1994, J NEUROTRAUM, V11, P523, DOI 10.1089/neu.1994.11.523; YANG KY, 1993, J NEUROTRAUM, V10, P287, DOI 10.1089/neu.1993.10.287	23	75	82	0	0	ELSEVIER SCI PUBL IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	SEP 8	1995	197	2					101	104		10.1016/0304-3940(95)11919-N			4	Neurosciences	Neurosciences & Neurology	RW406	WOS:A1995RW40600005	8552270				2021-06-18	
J	UHL, MW; BIAGAS, KV; GRUNDL, PD; BARMADA, MA; SCHIDING, JK; NEMOTO, EM; KOCHANEK, PM				UHL, MW; BIAGAS, KV; GRUNDL, PD; BARMADA, MA; SCHIDING, JK; NEMOTO, EM; KOCHANEK, PM			EFFECTS OF NEUTROPENIA ON EDEMA, HISTOLOGY, AND CEREBRAL BLOOD-FLOW AFTER TRAUMATIC BRAIN INJURY IN RATS	JOURNAL OF NEUROTRAUMA			English	Article							POLYMORPHONUCLEAR LEUKOCYTE ACCUMULATION; SPINAL-CORD INJURY; HEAD-INJURY; BARRIER PERMEABILITY; ISCHEMIA; NEUTROPHILS; REPERFUSION; ANTIBODY; STROKE; VINBLASTINE	Neutrophils accumulate during the acute inflammatory response to brain injury, but their role in the injury process remains controversial. We tested the hypothesis that neutrophils contribute to cerebral edema, tissue injury, and disturbed cerebral blood flow (CBF) (hyperemia or ischemia) during the first 24 h after traumatic brain injury. Wistar rats (n = 51) were injected with either vinblastine sulfate to induce neutropenia or the saline vehicle. Five days later, under halothane anesthesia, right hemispheric trauma was produced by weight drop (10 g x 5 cm) onto exposed dura. At 24 h after trauma, brain water (wet-dry weight), traumatic infarct size (percent of hemispheric section infarcted), or local CBF (lCBF,C-14-iodoantipyrine autoradiography) was assessed. Vinblastine treatment produced profound neutropenia on the day of trauma (absolute neutrophil count 0.024 +/- 0.008 x 10(9)/L vs 1.471 +/- 0.322 x 10(9)/L, p < 0.05 in neutropenic vs saline, respectively, mean +/- SEM). Neutropenia did not reduce the development of brain edema in the injured hemisphere (brain water 82.38 +/- 0.29 % vs 82.73 +/- 0.37 % in neutropenic and saline, respectively, mean +/- SEM) or traumatic infarct size (34.5 +/- 3.3% vs 33.2 +/- 2.1% in neutropenic vs saline respectively). In contrast, neutropenic rats exhibited 52 %, 41%, and 57% reductions in lCBF in the frontal cortex, parietal cortex, and amygdala, respectively, of the injured hemisphere 24 h after trauma (all p < 0.05 vs nonneutropenic controls). These data suggest that neutrophils and the acute inflammatory process contribute to the level of CBF observed 24 h after trauma, but effects on edema or early posttraumatic infarct size could not be demonstrated.	UNIV PITTSBURGH, DEPT ANESTHESIOL CRIT CARE MED, PITTSBURGH, PA USA; UNIV PITTSBURGH, DEPT PEDIAT, PITTSBURGH, PA 15260 USA; UNIV PITTSBURGH, DEPT PATHOL, PITTSBURGH, PA USA; UNIV PITTSBURGH, BRAIN TRAUMA RES CTR, PITTSBURGH, PA USA			Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X	NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [S07RR005507] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [S07 RR 0550726] Funding Source: Medline		BARONE FC, 1991, J NEUROSCI RES, V29, P336, DOI 10.1002/jnr.490290309; BEDNAR MM, 1991, STROKE, V22, P44, DOI 10.1161/01.STR.22.1.44; Biagas K. V., 1992, Society for Neuroscience Abstracts, V18, P1088; BIAGAS KV, 1992, J NEUROTRAUM, V9, P363, DOI 10.1089/neu.1992.9.363; CHAN PH, 1987, ANN NEUROL, V21, P540, DOI 10.1002/ana.410210604; CLARK WM, 1991, STROKE, V22, P877, DOI 10.1161/01.STR.22.7.877; CORVIN S, 1990, ACT NEUR S, V51, P55; DELZOPPO GJ, 1991, STROKE, V22, P1276, DOI 10.1161/01.STR.22.10.1276; DUTKA AJ, 1989, STROKE, V20, P390, DOI 10.1161/01.STR.20.3.390; ENGLER R, 1987, CIRC RES, V61, P20, DOI 10.1161/01.RES.61.1.20; ERNST E, 1987, JAMA-J AM MED ASSOC, V257, P2318, DOI 10.1001/jama.257.17.2318; GLANTZ SA, 1981, PRIMER BIOSTATISTICS, P156; GRAU AJ, 1992, STROKE, V23, P33, DOI 10.1161/01.STR.23.1.33; GRUNDL PD, 1994, J NEUROTRAUM, V11, P135, DOI 10.1089/neu.1994.11.135; HALLENBECK JM, 1986, STROKE, V17, P246, DOI 10.1161/01.STR.17.2.246; HERNANDEZ LA, 1987, AM J PHYSIOL, V253, pH699; HOLTZ A, 1989, ACTA NEUROL SCAND, V79, P460, DOI 10.1111/j.1600-0404.1989.tb03815.x; Horner H. C., 1992, Society for Neuroscience Abstracts, V18, P173; ISSEKUTZ AC, 1981, LAB INVEST, V45, P435; JACEWICZ M, 1990, J CEREBR BLOOD F MET, V10, P903, DOI 10.1038/jcbfm.1990.147; Kochanek P, 1991, J NEUROTRAUM, V8, P19, DOI 10.1089/neu.1991.8.19; KOCHANEK PM, 1992, STROKE, V23, P1367, DOI 10.1161/01.STR.23.9.1367; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; LUCIGNANI G, 1987, J CEREBR BLOOD F MET, V7, P309, DOI 10.1038/jcbfm.1987.68; MASET AL, 1987, J NEUROSURG, V67, P832, DOI 10.3171/jns.1987.67.6.0832; MEANS ED, 1983, J NEUROPATH EXP NEUR, V42, P707, DOI 10.1097/00005072-198311000-00009; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; PERSSON L, 1976, VIRCHOWS ARCH B, V22, P21; PFISTER HW, 1990, J CEREBR BLOOD F MET, V10, P914, DOI 10.1038/jcbfm.1990.148; RAMPART M, 1986, AM J PATHOL, V124, P66; RINALDO JE, 1988, AM REV RESPIR DIS, V137, P345, DOI 10.1164/ajrccm/137.2.345; SADRZADEH SMH, 1987, J CLIN INVEST, V79, P662, DOI 10.1172/JCI112865; SAKURADA O, 1978, AM J PHYSIOL, V234, pH59; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; SCHURER L, 1990, ACT NEUR S, V51, P49; SHARMA HS, 1987, NEUROPHARMACOLOGY, V26, P85, DOI 10.1016/0028-3908(87)90049-9; SHARMA HS, 1986, J NEUROL SCI, V72, P61, DOI 10.1016/0022-510X(86)90036-5; SIEGAL T, 1989, ANN NY ACAD SCI, V559, P488; SILBERGLEIT A, 1970, THROMB DIATH HAEMO, V42, P155; TAKESHIMA R, 1992, STROKE, V23, P247, DOI 10.1161/01.STR.23.2.247; TATE RM, 1983, AM REV RESPIR DIS, V128, P552, DOI 10.1164/arrd.1983.128.3.552; UHL MW, 1992, ADV EXP MED BIOL, V317, P701; UNTERBERG A, 1993, NEUROSURGERY, V32, P17, DOI 10.1227/00006123-199301000-00003; VASTHARE US, 1990, SURG NEUROL, V33, P261, DOI 10.1016/0090-3019(90)90046-R; VEDDER NB, 1988, J CLIN INVEST, V81, P939, DOI 10.1172/JCI113407; ZAKHIREH B, 1980, J IMMUNOL, V125, P2143; ZIMMERMAN J, 1986, CRITICAL CARE STATE, P281	47	75	75	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	1994	11	3					303	315		10.1089/neu.1994.11.303			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	PF221	WOS:A1994PF22100006	7996584				2021-06-18	
J	ALTHAUS, JS; ANDRUS, PK; WILLIAMS, CM; VONVOIGTLANDER, PF; CAZERS, AR; HALL, ED				ALTHAUS, JS; ANDRUS, PK; WILLIAMS, CM; VONVOIGTLANDER, PF; CAZERS, AR; HALL, ED			THE USE OF SALICYLATE HYDROXYLATION TO DETECT HYDROXYL RADICAL GENERATION IN ISCHEMIC AND TRAUMATIC BRAIN INJURY - REVERSAL BY TIRILAZAD MESYLATE (U-74006F)	MOLECULAR AND CHEMICAL NEUROPATHOLOGY			English	Article						TIRILAZAD MESYLATE; HYDROXYL RADICAL; ISCHEMIC BRAIN INJURY; TRAUMATIC BRAIN INJURY; RADICAL SCAVENGER; SALICYLATE HYDROXYLATION	DEPENDENT LIPID-PEROXIDATION; CEREBRAL-ARTERY OCCLUSION; FOREBRAIN ISCHEMIA; 21-AMINOSTEROID U74006F; REPERFUSION INJURY; RAT HEARTS; IRON; INVOLVEMENT; DERIVATIVES; INITIATION	Oxygen free radicals have been implicated as a causal factor in posttraumatic neuronal cell loss following cerebral ischemia and head injury. The conversion of salicylate to dihydroxybenzoic acid (DHBA) in vivo was employed to study the formation of hydroxyl radical (.OH) following central nervous system (CNS) injury. Bilateral carotid occlusion (BCO) in gerbils and concussive head trauma in mice were selected as models of brain injury. The lipid peroxidation inhibitor, tirilazad mesylate (U-74006F), was tested for its ability to attenuate hydroxyl radical formation in these models. In addition, U-74006F was studied as a scavenger of hydroxyl radical in an in vitro assay based on the Fenton reaction. For in vivo experimentation, hydroxyl radical formation was expressed as the ratio of DHBA to salicylate (DHBA/SAL) measured in brain. In the BCO model, hydroxyl radical formation increased in whole brain with 10 min of occlusion followed by 1 min of reperfusion. DHBA/SAL was also found to increase in the mouse head injury model at 1 h postinjury. In both models, U-74006F (1 or 10 mg/kg) blocked the increase in DHBA/SAL following injury. In vitro, reaction of U-74006F with hydroxyl radical gave a product with a mol wt that was 16 greater than U-74006F, indicative of hydroxyl radical scavenging. We speculate that U-74006F may function by blocking oxyradical-dependent cell damage, and thereby maintaining free iron (which catalyzes hydroxyl radical formation) concentrations at normal levels.	UNIV MARYLAND, SCH MED, BALTIMORE, MD 21201 USA	ALTHAUS, JS (corresponding author), UPJOHN CO, CNS DIS RES, 7521-209-5, KALAMAZOO, MI 49001 USA.		Hall, Edward D/F-8930-2013				BECK T, 1990, BRAIN RES, V532, P336, DOI 10.1016/0006-8993(90)91779-G; BECK T, 1991, BRAIN RES, V560, P159, DOI 10.1016/0006-8993(91)91226-Q; BRAUGHLER JM, 1986, J BIOL CHEM, V261, P282; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V7, P125, DOI 10.1016/0891-5849(89)90003-8; CAO W, 1988, NEUROSCI LETT, V88, P233, DOI 10.1016/0304-3940(88)90132-2; CHIUEH CC, 1992, SYNAPSE, V1116, P183; FLOYD R A, 1986, Journal of Free Radicals in Biology and Medicine, V2, P13, DOI 10.1016/0748-5514(86)90118-2; FLOYD RA, 1991, ARCH GERONTOL GERIAT, V12, P155, DOI 10.1016/0167-4943(91)90025-L; FUJII T, 1991, ARCH BIOCHEM BIOPHYS, V284, P120, DOI 10.1016/0003-9861(91)90273-L; GELVAN D, 1991, OXIDATIVE DAMAGE & REPAIR, P825; Giovanni A., 1992, Society for Neuroscience Abstracts, V18, P1444; GROOTVELD M, 1986, BIOCHEM J, V237, P499, DOI 10.1042/bj2370499; HALL ED, 1990, PROG CLIN BIOL RES, V361, P351; HALL ED, 1985, J NEUROSURG, V62, P882, DOI 10.3171/jns.1985.62.6.0882; HALL ED, 1988, J NEUROSURG, V68, P456, DOI 10.3171/jns.1988.68.3.0456; HALL ED, 1993, J NEUROSCI RES, V34, P107, DOI 10.1002/jnr.490340111; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; HALL ED, 1989, CEREBROVASC DIS, P387; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; HARALDSETH O, 1991, STROKE, V22, P1188, DOI 10.1161/01.STR.22.9.1188; HASELOFF RF, 1990, FREE RADICAL BIO MED, V9, P111, DOI 10.1016/0891-5849(90)90113-W; INGOLD KU, 1993, P NATL ACAD SCI USA, V90, P45, DOI 10.1073/pnas.90.1.45; JANERO DR, 1989, RES COMMUN CHEM PATH, V63, P163; KOBAYASHI A, 1989, JPN CIRC J, V53, P1122, DOI 10.1253/jcj.53.1122; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; LESIUK H, 1991, STROKE, V22, P896, DOI 10.1161/01.STR.22.7.896; MCINTOSH TK, 1992, J NEUROTRAUM, V9, P33, DOI 10.1089/neu.1992.9.33; MOORHOUSE CP, 1985, BIOCHIM BIOPHYS ACTA, V843, P261, DOI 10.1016/0304-4165(85)90147-3; PAHLMARK K, 1991, J CEREBR BLOOD FLOW, V2, pS138; PERKINS WJ, 1992, FASEB J, V5, pA1279; PIANTADOSI CA, 1990, J APPL PHYSIOL, V69, P1761; POWELL SR, 1990, FREE RADICAL BIO MED, V9, P133, DOI 10.1016/0891-5849(90)90116-Z; SAKAMOTO A, 1991, BRAIN RES, V554, P186, DOI 10.1016/0006-8993(91)90187-Z; SIMPSON JA, 1988, BIOCHEM J, V254, P519, DOI 10.1042/bj2540519; Snedecor G.W., 1967, STATISTICAL METHODS; SPINA MB, 1989, P NATL ACAD SCI USA, V86, P1398, DOI 10.1073/pnas.86.4.1398; SUTTON H C, 1985, Journal of Free Radicals in Biology and Medicine, V1, P195, DOI 10.1016/0748-5514(85)90118-7; TOSAKI A, 1990, FREE RADICAL BIO MED, V8, P363, DOI 10.1016/0891-5849(90)90102-O; YOSHIDA K, 1991, BIOCHEM BIOPH RES CO, V179, P1077, DOI 10.1016/0006-291X(91)91929-7; YOUNG W, 1988, STROKE, V19, P1013, DOI 10.1161/01.STR.19.8.1013	40	75	75	0	4	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1044-7393			MOL CHEM NEUROPATHOL	Mol. Chem. Neuropathol.	OCT	1993	20	2					147	162		10.1007/BF02815368			16	Neurosciences; Pathology	Neurosciences & Neurology; Pathology	MC691	WOS:A1993MC69100004	8297419				2021-06-18	
J	MENTIS, M; PRUTTING, CA				MENTIS, M; PRUTTING, CA			ANALYSIS OF TOPIC AS ILLUSTRATED IN A HEAD-INJURED AND A NORMAL ADULT	JOURNAL OF SPEECH AND HEARING RESEARCH			English	Article						TOPIC ANALYSIS; DISCOURSE; CLOSED HEAD INJURY	LANGUAGE; MANIPULATION; DISCOURSE		UNIV CALIF SANTA BARBARA,SANTA BARBARA,CA 93106	MENTIS, M (corresponding author), BOSTON UNIV,DEPT COMMUN DISORDERS,635 COMMONWEALTH AVE,BOSTON,MA 02215, USA.						ATKINSON JM, 1984, STRUCTURES SOCIAL AC, P165; Bayles K. A., 1984, LANGUAGE DISORDERS A, P209; Bloom L., 1978, Q NEWSLETTER I COMP, V2, P1; BRINTON B, 1984, J SPEECH HEAR RES, V27, P350, DOI 10.1044/jshr.2703.350; Chafe Wallace, 1987, TYPOLOGICAL STUDIES, V11, P21; Crow B., 1983, CONVERSATIONAL COHER, P136; ELLIS DG, 1983, CONVERSATINAL COHERE, P222; FORSYTH IJ, 1974, SPACE ENGLISH FOREIG, P77; FROMM D, 1989, J SPEECH HEAR DISORD, V54, P535, DOI 10.1044/jshd.5404.535; GARDNER R, 1987, SEMIOTICA, V65, P129, DOI 10.1515/semi.1987.65.1-2.129; Goodenough D. R., 1978, DISCOURSE PROCESS, V1, P395, DOI 10.1080/01638537809544447; GRIMES JE, 1981, ANAL DISCOURSE TEXT, P164; GROHER M, 1977, J SPEECH HEAR RES, V20, P212, DOI 10.1044/jshr.2002.212; HALLIDAY M, 1975, LEARNING HOW MEAN; Halliday M. A. K., 1973, EXPLORATIONS FUNCTIO; Halliday M. A. K., 1985, INTRO FUNCTIONAL GRA; Halliday MA., 1970, NEW HORIZONS LINGUIS, V1, P140; HALPERN H, 1973, J SPEECH HEAR DISORD, V38, P162, DOI 10.1044/jshd.3802.162; HURTIG R, 1977, ADV RES THEOR, V1, P89; KEENAN EO, 1976, SUBJECT TOPIC, P337; Kertesz A., 1979, APHASIA ASS DISORDER; Kertesz A, 1980, W APHASIA BATTERY; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; Levinson S.C., 1983, PRAGMATICS; LILES BZ, 1989, J SPEECH HEAR DISORD, V54, P356, DOI 10.1044/jshd.5403.356; MAYNARD DW, 1980, SEMIOTICA, V30, P263, DOI 10.1515/semi.1980.30.3-4.263; MENTIS M, 1987, J SPEECH HEAR RES, V30, P88, DOI 10.1044/jshr.3001.88; MILTON SB, 1984, CLIN APHASIOLOGY C P, P114; Morris W., 1969, AM HERITAGE DICT ENG; Myers Penelope S., 1979, CLIN APHASIOLOGY C P, P38; MYERS PS, 1984, LANGUAGE DISORDERS A, P117; OKOLO BA, 1987, STUDIES AFRICAN LING, V18, P211; Pei M., 1969, DICT LINGUISTICS; PIKE KL, 1967, LANGUAGE RELATION UN; Planalp S., 1980, COMMUNICATION YB, V4, P237; Prigatano G., 1986, LANG SCI, V7, P217, DOI [10.1016/S0388-0001(85)80020-6, DOI 10.1016/S0388-0001(85)80020-6]; PRUTTING CA, 1987, J SPEECH HEAR DISORD, V52, P105, DOI 10.1044/jshd.5202.105; Reichman Rachel, 1978, COGNITIVE SCI, V2, P283, DOI DOI 10.1207/S15516709COG0204_1; SCHANK RC, 1977, COGNITIVE SCI, V1, P151; SCHEGLOFF EA, 1968, AM ANTHROPOL, V70, P1075, DOI 10.1525/aa.1968.70.6.02a00030; Schiffrin Deborah., 1987, DISCOURSE MARKERS; STECH EL, 1982, SEMIOTICA, V39, P75, DOI 10.1515/semi.1982.39.1-2.75; STOVER SE, 1989, CLIN LINGUIST PHONET, V3, P137, DOI 10.3109/02699208908985277; STUBBS M, 1983, DISCOURSE ANAL; Sudnow D., 1972, STUDIES SOCIAL INTER, P294; Van Dijk, 1977, TEXT CONTEXT; van Dijk Teun A., 1981, STUDIES PRAGMATICS D; WAPNER W, 1981, BRAIN LANG, V14, P15, DOI 10.1016/0093-934X(81)90061-4; Weiner S. L., 1977, DISCOURSE RELATIONS, P213; WERTZ RT, 1981, J SPEECH HEAR RES, V24, P580, DOI 10.1044/jshr.2404.580; WYCKOFF LH, 1984, THESIS U FLORIDA GAI	51	75	75	0	6	AMER SPEECH-LANG-HEARING ASSN	ROCKVILLE	10801 ROCKVILLE PIKE RD, ROCKVILLE, MD 20852-3279	0022-4685			J SPEECH HEAR RES	J. Speech Hear. Res.	JUN	1991	34	3					583	595		10.1044/jshr.3403.583			13	Language & Linguistics; Rehabilitation	Linguistics; Rehabilitation	FQ361	WOS:A1991FQ36100016	2072683				2021-06-18	
J	LEVIN, HS; HIGH, WM; EWINGCOBBS, L; FLETCHER, JM; EISENBERG, HM; MINER, ME; GOLDSTEIN, FC				LEVIN, HS; HIGH, WM; EWINGCOBBS, L; FLETCHER, JM; EISENBERG, HM; MINER, ME; GOLDSTEIN, FC			MEMORY FUNCTIONING DURING THE 1ST YEAR AFTER CLOSED HEAD-INJURY IN CHILDREN AND ADOLESCENTS	NEUROSURGERY			English	Article									UNIV TEXAS,MED BRANCH,DEPT NEUROL,GALVESTON,TX 77550; UNIV TEXAS,SCH MED,DIV NEUROL,HOUSTON,TX 77025; UNIV TEXAS,SCH MED,DEPT PSYCHIAT & BEHAV SCI,HOUSTON,TX 77025; UNIV HOUSTON,DEPT PSYCHOL,HOUSTON,TX 77004	LEVIN, HS (corresponding author), UNIV TEXAS,MED BRANCH,DIV NEUROSURG D73,GALVESTON,TX 77550, USA.		fletcher, jack/Q-5975-2019		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889] Funding Source: Medline		Annegers J. F., 1983, PEDIATRIC HEAD TRAUM, P1; BRUCE DA, 1978, J NEUROSURG, V48, P679, DOI 10.3171/jns.1978.48.5.0679; BUSCHKE H, 1974, J EXP CHILD PSYCHOL, V18, P488, DOI 10.1016/0022-0965(74)90126-X; FRANKEL MT, 1982, J EXP CHILD PSYCHOL, V34, P113, DOI 10.1016/0022-0965(82)90034-0; Goldman P S, 1974, Neurosci Res Program Bull, V12, P217; GOLDMAN PS, 1977, NATURE, V267, P613, DOI 10.1038/267613a0; GREEN DM, 1966, SIGNAL DETECTION THE; HANNAY HJ, 1979, CORTEX, V15, P269, DOI 10.1016/S0010-9452(79)80031-3; HECAEN H, 1976, BRAIN LANG, V3, P114, DOI 10.1016/0093-934X(76)90009-2; KAIL R, 1979, DEV MEMORY CHILDREN; KRAUS JF, 1986, AM J DIS CHILD, V140, P687, DOI 10.1001/archpedi.1986.02140210085032; Levin H., 1979, J PEDIATR PSYCHOL, V4, P389, DOI DOI 10.1093/JPEPSY/4.4.389; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVIN HS, 1979, CHILD BRAIN, V5, P281; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; MORRISON FJ, 1982, J GENET PSYCHOL, V141, P233, DOI 10.1080/00221325.1982.10533478; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; PRESSLEY M, 1984, J VERB LEARN VERB BE, V23, P270, DOI 10.1016/S0022-5371(84)90181-6; RUSSELL WR, 1971, TRAUMATIC AMNESIAS; SCHARLOCK DP, 1963, SCIENCE, V141, P1197, DOI 10.1126/science.141.3586.1197; TEASDALE G, 1974, LANCET, V2, P81	21	75	75	0	1	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0148-396X			NEUROSURGERY	Neurosurgery	JUN	1988	22	6	1				1043	1052		10.1227/00006123-198806010-00012			10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	P4659	WOS:A1988P465900012	3419566				2021-06-18	
J	MCINTOSH, TK; HEAD, VA; FADEN, AI				MCINTOSH, TK; HEAD, VA; FADEN, AI			ALTERATIONS IN REGIONAL CONCENTRATIONS OF ENDOGENOUS OPIOIDS FOLLOWING TRAUMATIC BRAIN INJURY IN THE CAT	BRAIN RESEARCH			English	Article									UNIV CALIF SAN FRANCISCO,DEPT NEUROL,SAN FRANCISCO,CA 94143	MCINTOSH, TK (corresponding author), VET ADM MED CTR,CTR NEURAL INJURY 127,4150 CLEMENT ST,SAN FRANCISCO,CA 94121, USA.				NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01 GM34690-02] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER		AKIL H, 1984, ANNU REV NEUROSCI, V7, P223, DOI 10.1146/annurev.ne.07.030184.001255; BASKIN DS, 1982, LIFE SCI, V31, P2201, DOI 10.1016/0024-3205(82)90118-7; BOARDER MR, 1982, J CLIN ENDOCR METAB, V54, P715, DOI 10.1210/jcem-54-4-715; COX B, 1982, LIFE SCI, V31, P1655; COX BM, 1985, NEUROPEPTIDES, V5, P571, DOI 10.1016/0143-4179(85)90082-4; CROCKARD HA, 1977, J NEUROSURG, V46, P784, DOI 10.3171/jns.1977.46.6.0784; EISENBERG H, 1983, 5TH P INT S INTR PRE; EVANS SF, 1985, BRIT J ANAESTH, V57, P624, DOI 10.1093/bja/57.6.624; FADEN A I, 1983, Current Concepts of Cerebrovascular Disease and Stroke, V18, P27; FADEN AI, 1983, EUR J PHARMACOL, V91, P321, DOI 10.1016/0014-2999(83)90487-9; FADEN AI, 1984, BRIT J PHARMACOL, V81, P271, DOI 10.1111/j.1476-5381.1984.tb10074.x; FADEN AI, 1981, SCIENCE, V211, P493, DOI 10.1126/science.7455690; FADEN AI, 1983, STROKE, V14, P169, DOI 10.1161/01.STR.14.2.169; FADEN AI, 1981, ANN NEUROL, V10, P326, DOI 10.1002/ana.410100403; FADEN AI, 1985, ANN NEUROL, V17, P386, DOI 10.1002/ana.410170414; FADEN AI, 1985, PEPTIDES, V6, P15, DOI 10.1016/0196-9781(85)90006-3; FADEN AI, 1986, CENTRAL NERVOUS SYST, P123; FEUERSTEIN G, 1985, AM J PHYSIOL, V249, pE244; FEUERSTEIN G, 1984, NEUROPEPTIDES, V5, P295, DOI 10.1016/0143-4179(84)90086-6; FEUERSTEIN G, 1982, LIFE SCI, V31, P2197, DOI 10.1016/0024-3205(82)90117-5; FLAMM ES, 1982, NEUROSURGERY, V10, P227, DOI 10.1227/00006123-198202000-00009; GENNARELLI TA, 1982, HEAD INJURY BASIC CL; GHAZAROSSIAN VE, 1980, LIFE SCI, V27, P75, DOI 10.1016/0024-3205(80)90021-1; GLOWINSKI J, 1966, J NEUROCHEM, V13, P655, DOI 10.1111/j.1471-4159.1966.tb09873.x; GUILLEMIN R, 1977, SCIENCE, V197, P1367, DOI 10.1126/science.197601; HASSEN AH, 1984, J NEUROSCI, V4, P2213; HAYES RL, 1983, J NEUROSURG, V58, P720, DOI 10.3171/jns.1983.58.5.0720; HERMAN BH, 1985, J PHARMACOL EXP THER, V232, P27; HOLLT V, 1980, NEUROSCI LETT, V18, P149, DOI 10.1016/0304-3940(80)90318-3; HOSOBUCHI Y, 1982, SCIENCE, V215, P69, DOI 10.1126/science.6274019; HUGHES J, 1983, BR MED B, V14, P1; KHACHATURIAN H, 1985, TRENDS NEUROSCI, V8, P111, DOI 10.1016/0166-2236(85)90048-7; KHACHATURIAN H, 1986, ENDOCRINOLOGY, V119, P1409, DOI 10.1210/endo-119-3-1409; KNEPEL W, 1985, ENDOCRINOLOGY, V117, P481, DOI 10.1210/endo-117-2-481; KRUMINS SA, 1986, ANN NEUROL, V19, P498, DOI 10.1002/ana.410190514; MCINTOSH T K, 1986, Society for Neuroscience Abstracts, V12, P85; MOLINEAUX CJ, 1984, J NEUROCHEM, V43, P225; PEROUTKA SJ, 1980, SCIENCE, V208, P610, DOI 10.1126/science.6102801; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PETTIBONE DJ, 1982, ENDOCRINOLOGY, V110, P469, DOI 10.1210/endo-110-2-469; PFEIFFER A, 1982, LIFE SCI, V31, P1279, DOI 10.1016/0024-3205(82)90361-7; PRZEWLOCKI R, 1983, NEUROPEPTIDES, V3, P233, DOI 10.1016/0143-4179(83)90019-7; ROTH KA, 1983, SCIENCE, V219, P189, DOI 10.1126/science.6129700; SASAKI T, 1984, J CEREBR BLOOD F MET, V4, P166, DOI 10.1038/jcbfm.1984.24; SUDA T, 1985, LIFE SCI, V32, P865; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; WAHL M, 1985, J CEREBR BLOOD F MET, V5, P451, DOI 10.1038/jcbfm.1985.61; WEBER E, 1983, BRAIN RES, V260, P166, DOI 10.1016/0006-8993(83)90781-3; YOUNG W, 1981, J NEUROSURG, V55, P209, DOI 10.3171/jns.1981.55.2.0209; ZUKIN RS, 1981, LIFE SCI, V29, P2681	50	75	76	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	NOV 10	1987	425	2					225	233		10.1016/0006-8993(87)90505-1			9	Neurosciences	Neurosciences & Neurology	K6621	WOS:A1987K662100004	2892572				2021-06-18	
J	Varney, NR; Martzke, JS; Roberts, RJ				Varney, N. R.; Martzke, J. S.; Roberts, R. J.			Major Depression in Patients with Closed Head Injury	NEUROPSYCHOLOGY			English	Article								One hundred and twenty patients with closed bead injury (CHI) were interviewed with regqrd to depressive symptoms at least two years after the date of injury. Seventy-seven percent of these patients met DSM-III criteria for major depressive disorder. Approximately half of the depressed CHI patients did not manifest depressive symptoms until at least six months after being injured. Bipolar affective disorder and schizophrenia were quite uncommon following CHI. These findings indicate that head injury patients are at substantially increased risk for development of major depressive disorder. Findings suggest that all CHI patients be screened for depressive symptoms at a time well after they appear to have made a seemingly "full" recovery.	VA Med Ctr, Psychol Serv, Iowa City, IA 52240 USA; Univ Iowa, Dept Psychiat, Iowa City, IA 52242 USA; Univ Iowa, Dept Psychol, Iowa City, IA 52242 USA	Varney, NR (corresponding author), VA Med Ctr, Psychol Serv 116 B, Iowa City, IA 52240 USA.				Veterans AdministrationUS Department of Veterans Affairs	This research was supported by funds from the Veterans Administration. Address correspondence to Nils R. Varney Ph.D., Psychology Service (116-B), VA Medical Center, Iowa City, IA 52240, USA	FEIBEL JH, 1982, ARCH PHYS MED REHAB, V63, P276; FINKLESTEIN S, 1982, ANN NEUROL, V12, P463, DOI 10.1002/ana.410120509; FOLSTEIN MF, 1977, J NEUROL NEUROSUR PS, V40, P1018, DOI 10.1136/jnnp.40.10.1018; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; LIPSEY JR, 1984, LANCET, V1, P297; LISHMAN WA, 1978, ORGANIC PSYCHIAT; MENDEZ MF, 1986, ARCH NEUROL-CHICAGO, V43, P766, DOI 10.1001/archneur.1986.00520080014012; PERINI G, 1984, J NERV MENT DIS, V172, P287, DOI 10.1097/00005053-198405000-00006; REIFLER BV, 1982, AM J PSYCHIAT, V139, P623; Roberts A., 1980, SEVERE ACCIDENTAL HE; ROBINS AH, 1976, J CHRON DIS, V29, P279; Robinson R G, 1984, Compr Ther, V10, P19; ROBINSON RG, 1983, STROKE, V14, P736, DOI 10.1161/01.STR.14.5.736; ROBINSON RG, 1981, BRAIN LANG, V14, P282, DOI 10.1016/0093-934X(81)90080-8; ROBINSON RG, 1984, BRIT J PSYCHIAT, V144, P256, DOI 10.1192/bjp.144.3.256; ROSS ED, 1981, ARCH GEN PSYCHIAT, V38, P1344; Varney N., 1987, J CLIN EXPT IN PRESS; Winokur G., 1981, DEPRESSION THE FACTS; Woodruff R. A., 1974, PSYCHIAT DIAGNOSIS	19	75	77	0	3	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	MAY	1987	1	1					7	9		10.1037//0894-4105.1.1.7			3	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	V44JO	WOS:000209745500003					2021-06-18	
J	Gardner, RC; Byers, AL; Barnes, DE; Li, YX; Boscardin, J; Yaffe, K				Gardner, Raquel C.; Byers, Amy L.; Barnes, Deborah E.; Li, Yixia; Boscardin, John; Yaffe, Kristine			Mild TBI and risk of Parkinson disease A Chronic Effects of Neurotrauma Consortium Study	NEUROLOGY			English	Article							TRAUMATIC BRAIN-INJURY; HEAD-INJURY; ALPHA-SYNUCLEIN; DEMENTIA; PREVALENCE; SEQUELAE	Objective Our aim was to assess risk of Parkinson disease (PD) following traumatic brain injury (TBI), including specifically mild TBI (mTBI), among care recipients in the Veterans Health Administration. Methods In this retrospective cohort study, we identified all patients with a TBI diagnosis in Veterans Health Administration databases from October 2002 to September 2014 and age-matched 1: 1 to a random sample of patients without TBI. All patients were aged 18 years and older without PD or dementia at baseline. TBI exposure and severity were determined via detailed clinical assessments or ICD-9 codes using Department of Defense and Defense and Veterans Brain Injury Center criteria. Baseline comorbidities and incident PD more than 1 year post-TBI were identified using ICD-9 codes. Risk of PD after TBI was assessed using Cox proportional hazard models adjusted for demographics and medical/psychiatric comorbidities. Results Among 325,870 patients (half with TBI; average age 47.9 +/- 17.4 years; average follow-up 4.6 years), 1,462 were diagnosed with PD during follow-up. Compared to no TBI, those with TBI had higher incidence of PD (no TBI 0.31%, all-severity TBI 0.58%, mTBI 0.47%, moderate-severe TBI 0.75%). In adjusted models, all-severity TBI, mTBI, and moderate-severe TBI were associated with increased risk of PD (hazard ratio [95% confidence interval]: all-severity TBI 1.71 [1.53-1.92]; mTBI 1.56 [1.35-1.80]; moderate-severe TBI 1.83 [1.61-2.07]). Conclusions Among military veterans, mTBI is associated with 56% increased risk of PD, even after adjusting for demographics and medical/psychiatric comorbidities. This study highlights the importance of TBI prevention, long-term follow-up of TBI-exposed veterans, and the need to determine mechanisms and modifiable risk factors for post-TBI PD.	[Gardner, Raquel C.; Byers, Amy L.; Barnes, Deborah E.; Li, Yixia; Boscardin, John; Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA 94121 USA; [Gardner, Raquel C.; Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; [Byers, Amy L.; Barnes, Deborah E.; Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA; [Barnes, Deborah E.; Boscardin, John; Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; [Boscardin, John] Univ Calif San Francisco, Dept Med, San Francisco, CA USA	Gardner, RC (corresponding author), San Francisco VA Med Ctr, San Francisco, CA 94121 USA.; Gardner, RC (corresponding author), Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA.	Raquel.Gardner@ucsf.edu			US Army Medical Research and Material CommandU.S. Army Medical Research & Materiel Command (USAMRMC); US Department of Veterans Affairs [Chronic Effects of Neurotrauma Consortium]US Department of Veterans Affairs [W81XWH-13-2-0095, 1I01CX001246]; US Army Medical Research Acquisition Activity, Fort Detrick, MD; National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [Beeson K23 NS095755]; National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K24 AG031155]; American Federation for Aging Research; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS095755] Funding Source: NIH RePORTER	This study was funded by the US Army Medical Research and Material Command and by the US Department of Veterans Affairs [Chronic Effects of Neurotrauma Consortium] under awards W81XWH-13-2-0095 and 1I01CX001246. The US Army Medical Research Acquisition Activity, Fort Detrick, MD, is the awarding and administering acquisition office. Any opinions, findings, conclusions or recommendations expressed in this publication are those of the author(s) and do not necessarily reflect the views of the US Government, or the US Department of Veterans Affairs, and no official endorsement should be inferred. This work was also funded by the National Institute of Neurological Disorders and Stroke (Beeson K23 NS095755 to R.C.G.), National Institute on Aging (K24 AG031155 to K.Y.), and the American Federation for Aging Research (to R.C.G.).	AFHSC, TRAUM BRAIN INJ DOD; Albrecht JS, 2016, J HEAD TRAUMA REHAB, V31, pE1, DOI 10.1097/HTR.0000000000000190; Bailes JE, 2001, NEUROSURGERY, V48, P26, DOI 10.1097/00006123-200101000-00005; Bower JH, 2003, NEUROLOGY, V60, P1610, DOI 10.1212/01.WNL.0000068008.78394.2C; Chapman JC, 2014, ALZHEIMERS DEMENT, V10, pS97, DOI 10.1016/j.jalz.2014.04.012; Chen H, 2010, NEUROLOGY, V74, P878, DOI 10.1212/WNL.0b013e3181d55f38; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P29; Crane PK, 2016, JAMA NEUROL, V73, P1062, DOI 10.1001/jamaneurol.2016.1948; Defense & Veterans Brain Injury Center, 2017, DOD WORLDW NUMB TBI; Department of Veterans Affairs, 2010, SCREEN EV POSS TRAUM; Formisano R, 2014, J HEAD TRAUMA REHAB, V29, P387, DOI 10.1097/HTR.0000000000000027; Gao JJ, 2015, PARKINSONISM RELAT D, V21, P292, DOI 10.1016/j.parkreldis.2014.12.033; Gardner RC, 2017, J GERONTOL A-BIOL, V72, P1233, DOI 10.1093/gerona/glw341; Gardner RC, 2015, MOL CELL NEUROSCI, V66, P75, DOI 10.1016/j.mcn.2015.03.001; Gardner RC, 2015, ANN NEUROL, V77, P987, DOI 10.1002/ana.24396; Goldman SM, 2006, ANN NEUROL, V60, P65, DOI 10.1002/ana.20882; Goldman SM, 2012, ANN NEUROL, V71, P40, DOI 10.1002/ana.22499; Gustafsson H, 2015, NEUROLOGY, V84, P2422, DOI 10.1212/WNL.0000000000001684; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Institute of Medicine (US) Committee, 2008, GULF WAR HLTH, V7; Jacob EL, 2010, PARKINSONISM RELAT D, V16, P576, DOI 10.1016/j.parkreldis.2010.06.014; Jafari S, 2013, MOVEMENT DISORD, V28, P1222, DOI 10.1002/mds.25458; Kenborg L, 2015, NEUROLOGY, V84, P1098, DOI 10.1212/WNL.0000000000001362; Kotagal V, 2014, NEUROLOGY, V82, P1514, DOI 10.1212/WNL.0000000000000356; Kristman Vicki L, 2014, Arch Phys Med Rehabil, V95, pS265, DOI 10.1016/j.apmr.2013.04.026; Kuopio AM, 1999, MOVEMENT DISORD, V14, P928, DOI 10.1002/1531-8257(199911)14:6<928::AID-MDS1004>3.0.CO;2-Z; Lee PC, 2015, EUR J NEUROL, V22, P874, DOI 10.1111/ene.12585; Lee PC, 2012, NEUROLOGY, V79, P2061, DOI 10.1212/WNL.0b013e3182749f28; Mac Donald CL, 2017, JAMA NEUROL, V74, P821, DOI 10.1001/jamaneurol.2017.0143; Mac Donald CL, 2017, J NEUROTRAUM, V34, P2206, DOI 10.1089/neu.2016.4434; Marras Connie, 2014, Arch Phys Med Rehabil, V95, pS238, DOI 10.1016/j.apmr.2013.08.298; McHugo GJ, 2017, J HEAD TRAUMA REHAB, V32, pE65, DOI 10.1097/HTR.0000000000000249; Mondello S, 2013, NEUROLOGY, V80, P1662, DOI 10.1212/WNL.0b013e3182904d43; Nelson NW, 2015, BRIT J PSYCHIAT, V206, P237, DOI 10.1192/bjp.bp.114.149096; Peran P, 2014, J NEUROTRAUM, V31, P642, DOI 10.1089/neu.2013.3103; Perry DC, 2016, J NEUROSURG, V124, P511, DOI 10.3171/2015.2.JNS14503; Ritz B, 2014, NEUROLOGY, V83, P1396, DOI 10.1212/WNL.0000000000000879; Rugbjerg K, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a2494; Sayer NA, 2012, ANNU REV MED, V63, P405, DOI 10.1146/annurev-med-061610-154046; Seidler A, 1996, NEUROLOGY, V46, P1275, DOI 10.1212/WNL.46.5.1275; Spangenberg S, 2009, PARKINSONISM RELAT D, V15, P12, DOI 10.1016/j.parkreldis.2008.02.004; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Taylor KM, 2016, PARKINSONISM RELAT D, V23, P57, DOI 10.1016/j.parkreldis.2015.12.005; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Veitch DP, 2013, CURR ALZHEIMER RES, V10, P907, DOI 10.2174/15672050113109990142; Whiteneck GG, 2016, J HEAD TRAUMA REHAB, V31, pE55, DOI 10.1097/HTR.0000000000000140; Whiteneck GG, 2016, J HEAD TRAUMA REHAB, V31, pE43, DOI 10.1097/HTR.0000000000000141; WILLIAMS DB, 1991, NEUROLOGY, V41, P1554, DOI 10.1212/WNL.41.10.1554	48	74	74	2	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	MAY 15	2018	90	20					E1771	E1779		10.1212/WNL.0000000000005522			9	Clinical Neurology	Neurosciences & Neurology	GN6CO	WOS:000439159900005	29669907	Green Published			2021-06-18	
J	Henninger, N; Bouley, J; Sikoglu, EM; An, JY; Moore, CM; King, JA; Bowser, R; Freeman, MR; Brown, RH				Henninger, Nils; Bouley, James; Sikoglu, Elif M.; An, Jiyan; Moore, Constance M.; King, Jean A.; Bowser, Robert; Freeman, Marc R.; Brown, Robert H., Jr.			Attenuated traumatic axonal injury and improved functional outcome after traumatic brain injury in mice lacking Sarm1	BRAIN			English	Article						axon; knockout; traumatic axonal injury; traumatic brain injury; Wallerian degeneration	WALLERIAN DEGENERATION; CEREBROVASCULAR PATHOPHYSIOLOGY; NEUROCHEMICAL PROFILE; SECONDARY AXOTOMY; ACTIVATION; MECHANISMS; MODEL; SPECTROSCOPY; REGENERATION; CYTOSKELETON	Axon degeneration is seen consistently after traumatic brain injury (TBI). Henninger et al. show that mice lacking the kinase scaffold Sarm1, a mediator of Wallerian degeneration, display substantially attenuated axon degeneration and reduced functional deficits in a closed-head TBI model. Anti-Sarm1 therapeutics may preserve neurological function after TBI.Axon degeneration is seen consistently after traumatic brain injury (TBI). Henninger et al. show that mice lacking the kinase scaffold Sarm1, a mediator of Wallerian degeneration, display substantially attenuated axon degeneration and reduced functional deficits in a closed-head TBI model. Anti-Sarm1 therapeutics may preserve neurological function after TBI.Axonal degeneration is a critical, early event in many acute and chronic neurological disorders. It has been consistently observed after traumatic brain injury, but whether axon degeneration is a driver of traumatic brain injury remains unclear. Molecular pathways underlying the pathology of traumatic brain injury have not been defined, and there is no efficacious treatment for traumatic brain injury. Here we show that mice lacking the mouse Toll receptor adaptor Sarm1 (sterile alpha/Armadillo/Toll-Interleukin receptor homology domain protein) gene, a key mediator of Wallerian degeneration, demonstrate multiple improved traumatic brain injury-associated phenotypes after injury in a closed-head mild traumatic brain injury model. Sarm1(-/-) mice developed fewer beta-amyloid precursor protein aggregates in axons of the corpus callosum after traumatic brain injury as compared to Sarm1(+/+) mice. Furthermore, mice lacking Sarm1 had reduced plasma concentrations of the phophorylated axonal neurofilament subunit H, indicating that axonal integrity is maintained after traumatic brain injury. Strikingly, whereas wild-type mice exibited a number of behavioural deficits after traumatic brain injury, we observed a strong, early preservation of neurological function in Sarm1(-/-) animals. Finally, using in vivo proton magnetic resonance spectroscopy we found tissue signatures consistent with substantially preserved neuronal energy metabolism in Sarm1(-/-) mice compared to controls immediately following traumatic brain injury. Our results indicate that the SARM1-mediated prodegenerative pathway promotes pathogenesis in traumatic brain injury and suggest that anti-SARM1 therapeutics are a viable approach for preserving neurological function after traumatic brain injury.	[Henninger, Nils; Bouley, James; King, Jean A.; Brown, Robert H., Jr.] Univ Massachusetts, Sch Med, Dept Neurol, 55 Lake Ave North, Worcester, MA 01655 USA; [Henninger, Nils; Sikoglu, Elif M.; Moore, Constance M.; King, Jean A.] Univ Massachusetts, Sch Med, Dept Psychiat, 55 Lake Ave North, Worcester, MA 01655 USA; [An, Jiyan; Bowser, Robert] Barrow Neurol Inst, Div Neurol, Phoenix, AZ 85013 USA; [An, Jiyan; Bowser, Robert] Barrow Neurol Inst, Div Neurobiol, Phoenix, AZ 85013 USA; [Moore, Constance M.; King, Jean A.] Univ Massachusetts, Sch Med, Dept Radiol, Worcester, MA 01655 USA; [Freeman, Marc R.] Univ Massachusetts, Sch Med, Dept Neurobiol, Worcester, MA 01655 USA	Henninger, N (corresponding author), Univ Massachusetts, Sch Med, Dept Neurol, 55 Lake Ave North, Worcester, MA 01655 USA.; Henninger, N (corresponding author), Univ Massachusetts, Sch Med, Dept Psychiat, 55 Lake Ave North, Worcester, MA 01655 USA.	nils.henninger@umassmed.edu		Freeman, Marc/0000-0003-3481-3715; Henninger, Nils/0000-0002-3883-5623	Center for Comparative NeuroImaging at the University of Massachusetts Medical School; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [MH073998, OD018132-01, AG046266, DA025690-05, DA026502-04, MH098003-02, AT006963-01A1, NS068179, NS055591, NS088689-02, NS079836-04, FD004127-02, HD060848-08]; ALS Therapy Alliance; Angel Fund; ALS Association; ALSFindingaCure; Cellucci Fund for ALS Research; Project ALS; Pierre deBourghknect ALS Fund; FOOD AND DRUG ADMINISTRATIONUnited States Department of Health & Human Services [R01FD004127] Funding Source: NIH RePORTER; National Center for Complementary & Integrative HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R34AT006963] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH098003, R01MH073998] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS088689, F32NS055591, RC1NS068179, R01NS079836] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG046266] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [K01DA026502, R01DA025690] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [S10OD018132] Funding Source: NIH RePORTER	The Magnetic Resonance Spectrocopy examinations were supported by the Center for Comparative NeuroImaging at the University of Massachusetts Medical School. This study was supported by institutional grants, National Institutes of Health grant MH073998 to C.M.M., OD018132-01, AG046266, DA025690-05, DA026502-04, MH098003-02, AT006963-01A1 to J.A.K., NS068179 to R.B., NS055591 to M.R.F., and NS088689-02, NS079836-04, FD004127-02, HD060848-08 to R.H.B. R.B. is the founder of Iron Horse Diagnostics, Inc., a company focused on developing diagnostic and prognostic tests for neurologic disease and brain injury. M.R.F. received support from the ALS Therapy Alliance, and is an Investigator of the Howard Hughes Medical Institute and has been named as an inventor on patents on the Therapeutic applications targeting Sarm1 (#20140079712 and #20120328629). R.H.B. also receives support from the Angel Fund, the ALS Association, ALSFindingaCure, the Cellucci Fund for ALS Research, Project ALS and the Pierre deBourghknect ALS Fund. R.H.B. is a co-founder of AviTx.	Anderson KJ, 2008, J NEUROTRAUM, V25, P1079, DOI 10.1089/neu.2007.0488; BROWN MC, 1994, EUR J NEUROSCI, V6, P420, DOI 10.1111/j.1460-9568.1994.tb00285.x; Chuang CF, 2005, GENE DEV, V19, P270, DOI 10.1101/gad.1276505; Coleman MP, 2010, ANNU REV NEUROSCI, V33, P245, DOI 10.1146/annurev-neuro-060909-153248; Conforti L, 2014, NAT REV NEUROSCI, V15, P394, DOI 10.1038/nrn3680; Dewitt DS, 2003, J NEUROTRAUM, V20, P795, DOI 10.1089/089771503322385755; Duarte JMN, 2012, NEUROIMAGE, V61, P342, DOI 10.1016/j.neuroimage.2011.12.038; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Faul F, 2009, BEHAV RES METHODS, V41, P1149, DOI 10.3758/BRM.41.4.1149; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fleminger S, 2005, BRIT MED J, V331, P1419, DOI 10.1136/bmj.331.7530.1419; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Freeman MR, 2014, CURR OPIN NEUROBIOL, V27, P224, DOI 10.1016/j.conb.2014.05.001; Gardner A, 2014, J NEUROTRAUM, V31, P1, DOI 10.1089/neu.2013.3079; Gatson JW, 2014, J NEUROSURG, V121, P1232, DOI 10.3171/2014.7.JNS132474; Gerdts J, 2015, SCIENCE, V348, P453, DOI 10.1126/science.1258366; Gerdts J, 2013, J NEUROSCI, V33, P13569, DOI 10.1523/JNEUROSCI.1197-13.2013; Gilley J, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000300; Godzik K, 2015, J MOL NEUROSCI, V55, P865, DOI 10.1007/s12031-014-0440-2; Greer JE, 2011, J NEUROSCI, V31, P5089, DOI 10.1523/JNEUROSCI.5103-10.2011; Harris JL, 2012, J CEREBR BLOOD F MET, V32, P2122, DOI 10.1038/jcbfm.2012.114; Henninger N, 2005, EXP NEUROL, V195, P447, DOI 10.1016/j.expneurol.2005.06.013; Henninger N, 2009, EXP NEUROL, V215, P290, DOI 10.1016/j.expneurol.2008.10.013; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Kelley BJ, 2006, EXP NEUROL, V198, P350, DOI 10.1016/j.expneurol.2005.12.017; Kilinc D, 2009, EXP NEUROL, V219, P553, DOI 10.1016/j.expneurol.2009.07.014; Kim YH, 2007, J EXP MED, V204, P2063, DOI 10.1084/jem.20070868; Kirov II, 2013, J NEUROTRAUM, V30, P1200, DOI 10.1089/neu.2012.2696; Knoferle J, 2010, P NATL ACAD SCI USA, V107, P6064, DOI 10.1073/pnas.0909794107; Lamprecht MR, 2007, BIOTECHNIQUES, V42, P71, DOI 10.2144/000112257; Len TK, 2011, CLIN PHYSIOL FUNCT I, V31, P85, DOI 10.1111/j.1475-097X.2010.00990.x; Lin CW, 2014, INNATE IMMUN-LONDON, V20, P161, DOI 10.1177/1753425913485877; Longhi L, 2011, J CEREBR BLOOD F MET, V31, P1919, DOI 10.1038/jcbfm.2011.42; Ma M, 2013, NEUROBIOL DIS, V56, P34, DOI 10.1016/j.nbd.2013.03.009; Martin SM, 2010, DEVELOPMENT, V137, P3985, DOI 10.1242/dev.053611; Maxwell WL, 2015, J NEUROTRAUM, V32, P780, DOI 10.1089/neu.2014.3369; Maxwell WL, 2003, J NEUROTRAUM, V20, P151, DOI 10.1089/08977150360547071; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; O'Neill LAJ, 2003, TRENDS IMMUNOL, V24, P287, DOI 10.1016/S1471-4906(03)00115-7; Osterloh JM, 2012, SCIENCE, V337, P481, DOI 10.1126/science.1223899; Penkowa M, 2003, GLIA, V42, P287, DOI 10.1002/glia.10208; Philip S, 2009, J TRAUMA, V67, pS128, DOI 10.1097/TA.0b013e3181ad32c7; Provencher SW, 2001, NMR BIOMED, V14, P260, DOI 10.1002/nbm.698; PROVENCHER SW, 1993, MAGNET RESON MED, V30, P672, DOI 10.1002/mrm.1910300604; Samoriski GM, 1997, J NEUROSCI, V17, P5581; Schuhmann MU, 2003, J NEUROTRAUM, V20, P725, DOI 10.1089/089771503767869962; Siman R, 2009, J NEUROTRAUM, V26, P1867, DOI 10.1089/neu.2009.0882; Smith DH, 2013, J NEUROTRAUM, V30, P307, DOI 10.1089/neu.2012.2825; Staal JA, 2010, J NEUROCHEM, V112, P1147, DOI 10.1111/j.1471-4159.2009.06531.x; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Walker PA, 2010, STEM CELLS DEV, V19, P867, DOI 10.1089/scd.2009.0188; Waller A, 1850, PHILOS T R SOC LOND, V140, P423, DOI [10.1098/rspl.1843.0224, DOI 10.1098/RSTL.1850.0021, 10.1098/rstl.1850.0021]; Wang JT, 2012, J CELL BIOL, V196, P7, DOI 10.1083/jcb.201108111; Wang JQ, 2011, J NEUROTRAUM, V28, P1185, DOI 10.1089/neu.2011.1756; Warner MA, 2010, J NEUROTRAUM, V27, P2121, DOI 10.1089/neu.2010.1429; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Yang J, 2013, NEURON, V80, P1175, DOI 10.1016/j.neuron.2013.08.034; Yin TC, 2014, CELL REP, V8, P1731, DOI 10.1016/j.celrep.2014.08.030	58	74	74	0	10	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	APR	2016	139		4				1094	1105		10.1093/brain/aww001			12	Clinical Neurology; Neurosciences	Neurosciences & Neurology	DJ5GN	WOS:000374234900020	26912636	Green Published			2021-06-18	
J	Bolos, M; Llorens-Martin, M; Jurado-Arjona, J; Hernandez, F; Rabano, A; Avila, J				Bolos, Marta; Llorens-Martin, Maria; Jurado-Arjona, Jeronimo; Hernandez, Felix; Rabano, Alberto; Avila, Jesus			Direct Evidence of Internalization of Tau by Microglia In Vitro and In Vivo	JOURNAL OF ALZHEIMERS DISEASE			English	Article						Alzheimer's disease; clearance; microglia; tau protein; tauopathies	TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; TRANSGENIC MICE; EXTRACELLULAR TAU; PATHOLOGICAL TAU; ACTIVATION; TAUOPATHY; PROPAGATION; PROTEIN; CLEARANCE	The microtubule-associated protein (MAP) tau plays a critical role in the pathogenesis of tauopathies. Excess tau can be released into the extracellular medium in a physiological or pathological manner to be internalized by surrounding neurons-a process that contributes to the spread of this protein throughout the brain. Such spreading may correlate with the progression of the abovementioned diseases. In addition to neurons, tau can be internalized into other cells. Here we demonstrate that microglia take up tau in vitro and in vivo. In this regard, microglia from primary cultures internalized soluble (human recombinant tau42) and insoluble (homogenates derived from human AD brain) tau in vitro. Furthermore, using stereotaxic injection of tau in mice in vivo, we show that murine microglia internalize human tau. In addition, we demonstrate, for the first time, that microglia colocalize with various forms of tau in postmortem brain tissue of patients with Alzheimer's disease and non-demented control subjects. Our data reveal a potential role of microglia in the internalization of tau that might be relevant for the design of strategies to enhance the clearance of extracellular tau in neurodegenerative diseases characterized by the accumulation of this protein.	[Bolos, Marta; Llorens-Martin, Maria; Jurado-Arjona, Jeronimo; Hernandez, Felix; Avila, Jesus] Ctr Invest Biomed Red Enfermedades Neurodegenerat, Madrid, Spain; [Bolos, Marta; Llorens-Martin, Maria; Jurado-Arjona, Jeronimo; Hernandez, Felix; Avila, Jesus] Ctr Biol Mol Severo Ochoa CSIC UAM, Madrid, Spain; [Rabano, Alberto] CIEN Fdn, Dept Neuropathol, Madrid, Spain	Avila, J (corresponding author), Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, C Nicolas Cabrera 1, E-28049 Madrid, Spain.	jesus.avila@csic.es	Llorens-Martin, Maria/R-4613-2017; Hernandez, Felix/L-2114-2015; Avila, Jesus/I-2610-2015; Bolos, Marta/J-7620-2014	Llorens-Martin, Maria/0000-0001-9129-5198; Hernandez, Felix/0000-0001-8753-8249; Avila, Jesus/0000-0002-6288-0571; Bolos, Marta/0000-0003-2652-8607	Spanish Ministry of HealthInstituto de Salud Carlos IIISpanish Government; Comunidad de MadridComunidad de Madrid; Centro de Investigacion Biomedica en Red sobre Enfermedades Neurodegenerativas (CIBERNED, ISCIII); Alzheimer's AssociationAlzheimer's Association	This study was funded by grants from the Spanish Ministry of Health, the Comunidad de Madrid, the Centro de Investigacion Biomedica en Red sobre Enfermedades Neurodegenerativas (CIBERNED, ISCIII), and the Alzheimer's Association.	[Anonymous], 2012, BIOPRESERV BIOBANK, V10, P79, DOI DOI 10.1089/BIO.2012.1022; Bellucci A, 2004, AM J PATHOL, V165, P1643, DOI 10.1016/S0002-9440(10)63421-9; Bellucci A, 2011, NEURODEGENER DIS, V8, P221, DOI 10.1159/000322228; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Bradshaw EM, 2013, NAT NEUROSCI, V16, P848, DOI 10.1038/nn.3435; Clavaguera F, 2009, NAT CELL BIOL, V11, P909, DOI 10.1038/ncb1901; de Calignon A, 2012, NEURON, V73, P685, DOI 10.1016/j.neuron.2011.11.033; Dujardin S, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/2051-5960-2-14; Frost B, 2009, J BIOL CHEM, V284, P12845, DOI 10.1074/jbc.M808759200; Funk KE, 2015, J BIOL CHEM, V290, P21652, DOI 10.1074/jbc.M115.657924; Gebicke-Haerter PJ, 2001, MICROSC RES TECHNIQ, V54, P47, DOI 10.1002/jemt.1120; GOEDERT M, 1990, EMBO J, V9, P4225, DOI 10.1002/j.1460-2075.1990.tb07870.x; Gomez-Ramos A, 2006, FEBS LETT, V580, P4842, DOI 10.1016/j.febslet.2006.07.078; Gomez-Ramos A, 2009, EUR NEUROPSYCHOPHARM, V19, P708, DOI 10.1016/j.euroneuro.2009.04.006; Guerreiro R, 2013, NEW ENGL J MED, V368, P117, DOI 10.1056/NEJMoa1211851; Guillot-Sestier MV, 2013, CNS NEUROL DISORD-DR, V12, P593; Heneka MT, 2015, LANCET NEUROL, V14, P388, DOI 10.1016/S1474-4422(15)70016-5; Heppner FL, 2015, NAT REV NEUROSCI, V16, P358, DOI 10.1038/nrn3880; Herber DL, 2007, J NEUROIMMUNE PHARM, V2, P222, DOI 10.1007/s11481-007-9069-z; Holmes BB, 2014, P NATL ACAD SCI USA, V111, pE4376, DOI 10.1073/pnas.1411649111; Holmes BB, 2013, P NATL ACAD SCI USA, V110, pE3138, DOI 10.1073/pnas.1301440110; Iba M, 2015, ACTA NEUROPATHOL, V130, P349, DOI 10.1007/s00401-015-1458-4; Ikeda M, 2005, AM J PATHOL, V166, P521, DOI 10.1016/S0002-9440(10)62274-2; Ishizawa K, 2001, J NEUROPATH EXP NEUR, V60, P647, DOI 10.1093/jnen/60.6.647; Jiang T, 2014, MOL NEUROBIOL, V49, P529, DOI 10.1007/s12035-013-8536-1; Jonsson T, 2013, NEW ENGL J MED, V368, P107, DOI 10.1056/NEJMoa1211103; Kanmert D, 2015, J NEUROSCI, V35, P10851, DOI 10.1523/JNEUROSCI.0387-15.2015; Karch CM, 2012, J BIOL CHEM, V287, P42751, DOI 10.1074/jbc.M112.380642; Kfoury N, 2012, J BIOL CHEM, V287, P19440, DOI 10.1074/jbc.M112.346072; Kim W, 2010, FEBS LETT, V584, P3085, DOI 10.1016/j.febslet.2010.05.042; Liu L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031302; Llorens-Martin M, 2013, MOL PSYCHIATR, V18, P451, DOI 10.1038/mp.2013.4; Luo WJ, 2015, SCI REP-UK, V5, DOI 10.1038/srep11161; Magnoni S, 2012, BRAIN, V135, P1268, DOI 10.1093/brain/awr286; Maphis N, 2015, BRAIN, V138, P1738, DOI 10.1093/brain/awv081; Marklund N, 2009, J NEUROSURG, V110, P1227, DOI 10.3171/2008.9.JNS08584; Perez M, 1996, J NEUROCHEM, V67, P1183; Saito Y, 2004, J NEUROPATH EXP NEUR, V63, P911, DOI 10.1093/jnen/63.9.911; Sasaki A, 2008, BRAIN RES, V1214, P159, DOI 10.1016/j.brainres.2008.02.084; Simon D, 2012, FEBS LETT, V586, P47, DOI 10.1016/j.febslet.2011.11.022; Tahara K, 2006, BRAIN, V129, P3006, DOI 10.1093/brain/awl249; Yamada K, 2011, J NEUROSCI, V31, P13110, DOI 10.1523/JNEUROSCI.2569-11.2011; Yoshiyama Y, 2007, NEURON, V53, P337, DOI 10.1016/j.neuron.2007.01.010; Yu Y, 2015, CELL MOL NEUROBIOL, V35, P71, DOI 10.1007/s10571-014-0101-6; Zilka N, 2009, J NEUROIMMUNOL, V209, P16, DOI 10.1016/j.jneuroim.2009.01.013	45	74	76	0	16	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1387-2877	1875-8908		J ALZHEIMERS DIS	J. Alzheimers Dis.		2016	50	1					77	87		10.3233/JAD-150704			11	Neurosciences	Neurosciences & Neurology	DA8VS	WOS:000368085200010	26638867	Green Published			2021-06-18	
J	Rincon, F; Kang, J; Vibbert, M; Urtecho, J; Athar, MK; Jallo, J				Rincon, Fred; Kang, Joon; Vibbert, Matthew; Urtecho, Jacqueline; Athar, M. Kamran; Jallo, Jack			Significance of arterial hyperoxia and relationship with case fatality in traumatic brain injury: a multicentre cohort study	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							SEVERE HEAD-INJURY; NORMOBARIC HYPEROXIA; CEREBRAL METABOLISM; OXYGEN-TENSION; CARDIAC-ARREST; UNITED-STATES; RESUSCITATION; EPIDEMIOLOGY; ASSOCIATION; CONSUMPTION	Objective In this retrospective multi-centre cohort study, we tested the hypothesis that hyperoxia was not associated with higher in-hospital case fatality in ventilated traumatic brain injury TBI) patients admitted to the intensive care unit ICU). Methods Admissions of ventilated TBI patients who had arterial blood gases within 24 h of admission to the ICU at 61 US hospitals between 2003 and 2008 were identified. Hyperoxia was defined as PaO2 = 300 mm Hg 39.99 kPa), hypoxia as any PaO2 < 60 mm Hg 7.99 kPa) or PaO2/FiO(2) ratio = 300 and normoxia, not defined as hyperoxia or hypoxia. The primary outcome was in-hospital case fatality. Results Over the 5-year period, we identified 1212 ventilated TBI patients, of whom 403 33%) were normoxic, 553 46%) were hypoxic and 256 21%) were hyperoxic. The case-fatality was higher in the hypoxia group 224/ 553 [41%], crude OR 2.3, 95% CI 1.7-3.0, p<. 0001) followed by hyperoxia 80/ 256 [32%], crude OR 1.5, 95% CI 1.1-2.5, p=. 01) as compared to normoxia 87/ 403 [23%]). In a multivariate analysis adjusted for other potential confounders, the probability of being exposed to hyperoxia and hospital-specific characteristics, exposure to hyperoxia was independently associated with higher in-hospital case fatality adjusted OR 1.5, 95% CI 1.02-2.4, p= 0.04. Conclusions In ventilated TBI patients admitted to the ICU, arterial hyperoxia was independently associated with higher in-hospital case fatality. In the absence of results from clinical trials, unnecessary oxygen delivery should be avoided in critically ill ventilated TBI patients.	[Rincon, Fred; Kang, Joon; Vibbert, Matthew; Urtecho, Jacqueline] Dept Neurol, Div Crit Care, Philadelphia, PA USA; [Rincon, Fred; Kang, Joon; Vibbert, Matthew; Urtecho, Jacqueline] Dept Neurol, Div Neurotrauma, Philadelphia, PA USA; [Rincon, Fred; Vibbert, Matthew; Urtecho, Jacqueline; Athar, M. Kamran; Jallo, Jack] Dept Neurol Neurosurg, Div Crit Care, Philadelphia, PA USA; [Rincon, Fred; Vibbert, Matthew; Urtecho, Jacqueline; Athar, M. Kamran; Jallo, Jack] Dept Neurol Neurosurg, Div Neurotrauma, Philadelphia, PA USA; [Athar, M. Kamran] Dept Med Neurol, Philadelphia, PA USA	Rincon, F (corresponding author), Thomas Jefferson Univ, Div Crit Care & Neurotrauma, Dept Neurol Surg, 909 Walnut St,3rd Floor, Philadelphia, PA 19107 USA.	fred.rincon@jefferson.edu		Rincon, Fred/0000-0002-8510-118X; Jallo, Jack/0000-0002-5512-1729	American Heart AssociationAmerican Heart Association [AHA 12CRP12050342]; Department of Defense (DOD)United States Department of Defense [110398]	Dr Rincon has received salary support from the American Heart Association (AHA 12CRP12050342). Dr Jallo has received grant funding from the Department of Defense (DOD#110398).	Abelson-Mitchell N, 2008, J CLIN NURS, V17, P46, DOI 10.1111/j.1365-2702.2007.01941.x; Austin PC, 2011, MULTIVAR BEHAV RES, V46, P119, DOI 10.1080/00273171.2011.540480; Brenner M, 2012, ARCH SURG-CHICAGO, V147, P1042, DOI 10.1001/archsurg.2012.1560; Bulte DP, 2007, J CEREBR BLOOD F MET, V27, P69, DOI 10.1038/sj.jcbfm.9600319; de Jonge E, 2008, CRIT CARE, V12, DOI 10.1186/cc7150; Dellinger RP, 2013, CRIT CARE MED, V41, P580, DOI 10.1097/CCM.0b013e31827e83af; Diringer MN, 2007, J NEUROSURG, V106, P526, DOI 10.3171/jns.2007.106.4.526; Diringer MN, 2002, J NEUROSURG, V96, P103, DOI 10.3171/jns.2002.96.1.0103; Douzinas EE, 2001, INTENS CARE MED, V27, P905, DOI 10.1007/s001340100932; Farquhar H, 2009, AM HEART J, V158, P371, DOI 10.1016/j.ahj.2009.05.037; Floyd TF, 2003, J APPL PHYSIOL, V95, P2453, DOI 10.1152/japplphysiol.00303.2003; Halpern NA, 2006, CRIT CARE MED, V34, P2105, DOI 10.1097/01.CCM.0000227174.30337.3E; Johnston AJ, 2003, BRIT J ANAESTH, V90, P774, DOI 10.1093/bja/aeg104; Kang J, 2012, NEUROLOGY, V78; Kilgannon JH, 2010, JAMA-J AM MED ASSOC, V303, P2165, DOI 10.1001/jama.2010.707; Kumaria A, 2009, BRIT J NEUROSURG, V23, P576, DOI 10.3109/02688690903050352; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Localio AR, 2001, ANN INTERN MED, V135, P112, DOI 10.7326/0003-4819-135-2-200107170-00012; LODATO RF, 1989, J APPL PHYSIOL, V67, P1551; Longhi L, 2002, ACT NEUR S, V81, P315; Magnoni S, 2003, J NEUROSURG, V98, P952, DOI 10.3171/jns.2003.98.5.0952; McHugh GS, 2007, J NEUROTRAUM, V24, P287, DOI 10.1089/neu.2006.0031; Menzel M, 1999, J NEUROSURG ANESTH, V11, P240, DOI 10.1097/00008506-199910000-00003; Mushkudiani NA, 2008, J CLIN EPIDEMIOL, V61, P331, DOI 10.1016/j.jclinepi.2007.06.011; Palzur E, 2004, J NEUROTRAUM, V21, P41, DOI 10.1089/089771504772695931; Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669; RAWLES JM, 1976, BMJ-BRIT MED J, V1, P1121, DOI 10.1136/bmj.1.6018.1121; Rincon F, 2010, NEUROCRIT CARE, V13, P75, DOI 10.1007/s12028-010-9347-0; Rossi S, 2001, J NEUROTRAUM, V18, P163, DOI 10.1089/08977150150502596; Rousseau A, 2010, J VASC RES, V47, P441, DOI 10.1159/000282667; Sacho RH, 2010, J NEUROTRAUM, V27, P2157, DOI 10.1089/neu.2010.1384; Seder DB, 2012, NEUROCRIT CARE, V17, P4, DOI 10.1007/s12028-012-9753-6; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tolias CM, 2004, J NEUROSURG, V101, P435, DOI 10.3171/jns.2004.101.3.0435; Trzeciak S, 2009, CRIT CARE MED, V37, P2895, DOI 10.1097/CCM.0b013e3181b01d8c; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; von Elm E, 2007, LANCET, V370, P1453, DOI 10.1016/S0140-6736(07)61602-X; Ziegler A, 2010, METHOD INFORM MED, V49, P421, DOI 10.3414/ME10-01-0026; Ziegler A, 2010, METHOD INFORM MED, V49, P6; ZWEMER CF, 1995, RESUSCITATION, V29, P225, DOI 10.1016/0300-9572(94)00848-A	41	74	78	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	JUL	2014	85	7					799	805		10.1136/jnnp-2013-305505			7	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	AJ7YX	WOS:000337919300017	23794718				2021-06-18	
J	Wagenman, KL; Blake, TP; Sanchez, SM; Schultheis, MT; Radcliffe, J; Berg, RA; Dlugos, DJ; Topjian, AA; Abend, NS				Wagenman, Katherine L.; Blake, Taylor P.; Sanchez, Sarah M.; Schultheis, Maria T.; Radcliffe, Jerilynn; Berg, Robert A.; Dlugos, Dennis J.; Topjian, Alexis A.; Abend, Nicholas S.			Electrographic status epilepticus and long-term outcome in critically ill children	NEUROLOGY			English	Article							NONCONVULSIVE STATUS EPILEPTICUS; TRAUMATIC BRAIN-INJURY; INTENSIVE-CARE-UNIT; CONTINUOUS VIDEO-EEG; COMATOSE CHILDREN; SEIZURES; PREDICTORS; VALIDITY; VERSION; RISK	Objective:Electrographic seizures (ES) and electrographic status epilepticus (ESE) are common in children in the pediatric intensive care unit (PICU) with acute neurologic conditions. We aimed to determine whether ES or ESE was associated with worse long-term outcomes.Methods:Three hundred children with an acute neurologic condition and encephalopathy underwent clinically indicated EEG monitoring and were enrolled in a prospective observational study. We aimed to obtain follow-up data from 137 subjects who were neurodevelopmentally normal before PICU admission.Results:Follow-up data were collected for 60 of 137 subjects (44%) at a median of 2.7 years. Subjects with and without follow-up data were similar in clinical characteristics during the PICU admission. Among subjects with follow-up data, ES occurred in 12 subjects (20%) and ESE occurred in 14 subjects (23%). Multivariable analysis indicated that ESE was associated with an increased risk of unfavorable Glasgow Outcome Scale (Extended Pediatric Version) category (odds ratio 6.36, p = 0.01) and lower Pediatric Quality of Life Inventory scores (23 points lower, p = 0.001). Among subjects without prior epilepsy diagnoses ESE was associated with an increased risk of subsequently diagnosed epilepsy (odds ratio 13.3, p = 0.002). ES were not associated with worse outcomes.Conclusions:Among children with acute neurologic disorders who were reported to be neurodevelopmentally normal before PICU admission, ESE but not ES was associated with an increased risk of unfavorable global outcome, lower health-related quality of life scores, and an increased risk of subsequently diagnosed epilepsy even after adjusting for neurologic disorder category, EEG background category, and age.	[Berg, Robert A.; Topjian, Alexis A.] Univ Penn, Childrens Hosp Philadelphia, Dept Anesthesia & Crit Care Med, Philadelphia, PA 19104 USA; Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA; [Wagenman, Katherine L.; Sanchez, Sarah M.; Dlugos, Dennis J.; Abend, Nicholas S.] Childrens Hosp Philadelphia, Div Neurol, Philadelphia, PA 19104 USA; [Dlugos, Dennis J.; Abend, Nicholas S.] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA; [Dlugos, Dennis J.; Abend, Nicholas S.] Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA; [Blake, Taylor P.; Schultheis, Maria T.] Drexel Univ, Dept Psychol, Philadelphia, PA 19104 USA; [Radcliffe, Jerilynn] Univ Penn, Childrens Hosp Philadelphia, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA	Abend, NS (corresponding author), Childrens Hosp Philadelphia, Div Neurol, Philadelphia, PA 19104 USA.	abend@email.chop.edu		Schultheis, Maria/0000-0002-6558-548X	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K23NS076550]; Clinical & Translational Research Center [UL1RR024134]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD047349] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR024134] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [U01HL094345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS045911, K23NS075363, U01NS077276, K23NS076550] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM) [R01LM011124] Funding Source: NIH RePORTER	Supported by NIH (K23NS076550) to Dr. Abend and the Clinical & Translational Research Center (grant UL1RR024134).	Abend NS, 2011, NEUROLOGY, V76, P1071, DOI 10.1212/WNL.0b013e318211c19e; Abend NS, 2009, NEUROLOGY, V72, P1931, DOI 10.1212/WNL.0b013e3181a82687; Abend NS, 2007, PEDIATR NEUROL, V37, P165, DOI 10.1016/j.pediatrneurol.2007.05.012; Abend NS, 2013, NEUROLOGY, V81, P383, DOI 10.1212/WNL.0b013e31829c5cfe; Abend NS, 2013, SEIZURE-EUR J EPILEP, V22, P467, DOI 10.1016/j.seizure.2013.03.008; Abend NS, 2011, NEUROCRIT CARE, V15, P70, DOI 10.1007/s12028-010-9380-z; Abend NS, 2010, NEUROCRIT CARE, V12, P382, DOI 10.1007/s12028-010-9337-2; Arango JI, 2012, CHILD NERV SYST, V28, P1925, DOI 10.1007/s00381-012-1863-0; Beers SR, 2012, J NEUROTRAUM, V29, P1126, DOI 10.1089/neu.2011.2272; Brooks DR, 2012, EPILEPSY BEHAV, V23, P57, DOI 10.1016/j.yebeh.2011.11.002; Brophy GM, 2012, NEUROCRIT CARE, V17, P3, DOI 10.1007/s12028-012-9695-z; Carrera E, 2008, ARCH NEUROL-CHICAGO, V65, P1612, DOI 10.1001/archneur.65.12.1612; Fiser DH, 2000, CRIT CARE MED, V28, P2616, DOI 10.1097/00003246-200007000-00072; Greiner HM, 2012, PEDIATRICS, V129, pE748, DOI 10.1542/peds.2011-2067; Gutierrez-Colina AM, 2012, PEDIATR NEUROL, V46, P158, DOI 10.1016/j.pediatrneurol.2011.12.009; Gwer S, 2012, ARCH DIS CHILD, V97, P343, DOI 10.1136/archdischild-2011-300935; Hauf M, 2009, AM J NEURORADIOL, V30, P693, DOI 10.3174/ajnr.A1456; Hesdorffer DC, 1998, ANN NEUROL, V44, P908, DOI 10.1002/ana.410440609; Hosain SA, 2005, PEDIATR NEUROL, V32, P162, DOI 10.1016/j.pediatrneurol.2004.09.008; Jette N, 2006, ARCH NEUROL-CHICAGO, V63, P1750, DOI 10.1001/archneur.63.12.1750; Kirkham FJ, 2012, INTENS CARE MED, V38, P853, DOI 10.1007/s00134-012-2529-9; Lambrechtsen FACP, 2008, EPILEPSIA, V49, P615, DOI 10.1111/j.1528-1167.2007.01465.x; Leung H, 2010, EPILEPSIA, V51, P1570, DOI 10.1111/j.1528-1167.2009.02409.x; McCauley SR, 2012, J NEUROTRAUM, V29, P678, DOI 10.1089/neu.2011.1838; McCoy B, 2011, EPILEPSIA, V52, P1973, DOI 10.1111/j.1528-1167.2011.03291.x; Oddo M, 2009, CRIT CARE MED, V37, P2051, DOI 10.1097/CCM.0b013e3181a00604; Sanchez SM, 2013, J CLIN NEUROPHYSIOL, V30, P156, DOI 10.1097/WNP.0b013e31827eda27; Schreiber JM, 2012, NEUROCRIT CARE, V17, P31, DOI 10.1007/s12028-012-9715-z; Shahwan A, 2010, EPILEPSIA, V51, P1198, DOI 10.1111/j.1528-1167.2009.02517.x; Tay SKH, 2006, EPILEPSIA, V47, P1504, DOI 10.1111/j.1528-1167.2006.00623.x; Topjian AA, 2013, CRIT CARE MED, V41, P215, DOI 10.1097/CCM.0b013e3182668035; Varni JW, 2001, MED CARE, V39, P800, DOI 10.1097/00005650-200108000-00006; Varni JW, 1999, MED CARE, V37, P126, DOI 10.1097/00005650-199902000-00003; Vespa PM, 2010, NEUROLOGY, V75, P792, DOI 10.1212/WNL.0b013e3181f07334; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Williams K, 2011, EPILEPSIA, V52, P1130, DOI 10.1111/j.1528-1167.2011.03070.x; Young GB, 1996, NEUROLOGY, V47, P83	37	74	76	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	FEB 4	2014	82	5					396	404		10.1212/WNL.0000000000000082			9	Clinical Neurology	Neurosciences & Neurology	AH9WA	WOS:000336494600009	24384638	Green Published			2021-06-18	
J	Han, K; Mac Donald, CL; Johnson, AM; Barnes, Y; Wierzechowski, L; Zonies, D; Oh, J; Flaherty, S; Fang, R; Raichle, ME; Brody, DL				Han, Kihwan; Mac Donald, Christine L.; Johnson, Ann M.; Barnes, Yolanda; Wierzechowski, Linda; Zonies, David; Oh, John; Flaherty, Stephen; Fang, Raymond; Raichle, Marcus E.; Brody, David L.			Disrupted modular organization of resting-state cortical functional connectivity in US military personnel following concussive 'mild' blast-related traumatic brain injury	NEUROIMAGE			English	Article						Functional connectivity; Traumatic brain injury; Graph theory; Modularity; Functional magnetic resonance imaging (fMRI); Blast injury	DEFAULT MODE NETWORK; HUMAN CEREBRAL-CORTEX; GRAPH-THEORETICAL ANALYSIS; SURFACE-BASED ANALYSIS; SMALL-WORLD NETWORKS; GLOBAL SIGNAL; HEAD MOTION; FMRI; SEGMENTATION; ACTIVATION	Blast-related traumatic brain injury (TBI) has been one of the "signature injuries" of the wars in Iraq and Afghanistan. However, neuroimaging studies in concussive 'mild' blast-related TBI have been challenging due to the absence of abnormalities in computed tomography or conventional magnetic resonance imaging (MRI) and the heterogeneity of the blast-related injury mechanisms. The goal of this study was to address these challenges utilizing single-subject, module-based graph theoretic analysis of resting-state functional MRI (fMRI) data. We acquired 20 min of resting-state fMRI in 63 U.S. military personnel clinically diagnosed with concussive blast-related TBI and 21 U.S. military controls who had blast exposures but no diagnosis of TBI. All subjects underwent an initial scan within 90 days post-injury and 65 subjects underwent a follow-up scan 6 to 12 months later. A second independent cohort of 40 U.S. military personnel with concussive blast-related TBI served as a validation dataset The second independent cohort underwent an initial scan within 30 days post-injury. 75% of the scans were of good quality, with exclusions primarily due to excessive subject motion. Network analysis of the subset of these subjects in the first cohort with good quality scans revealed spatially localized reductions in the participation coefficient, a measure of between-module connectivity, in the TBI patients relative to the controls at the time of the initial scan. These group differences were less prominent on the follow-up scans. The 15 brain areas with the most prominent reductions in the participation coefficient were next used as regions of interest (ROIs) for single-subject analyses. In the first TBI cohort, more subjects than would be expected by chance (27/47 versus 2/47 expected, p < 0.0001) had 3 or more brain regions with abnormally low between-module connectivity relative to the controls on the initial scans. On the follow-up scans, more subjects than expected by chance (5/37, p = 0.044) but fewer subjects than on the initial scans had 3 or more brain regions with abnormally low between-module connectivity. Analysis of the second TBI cohort validation dataset with no free parameters provided a partial replication; again more subjects than expected by chance (8/31, p = 0.006) had 3 or more brain regions with abnormally low between-module connectivity on the initial scans, but the numbers were not significant (2/27, p = 0.276) on the follow-up scans. A single-subject, multivariate analysis by probabilistic principal component analysis of the between-module connectivity in the 15 identified ROIs, showed that 31/47 subjects in the first TBI cohort were found to be abnormal relative to the controls on the initial scans. In the second TB! cohort, 9/31 patients were found to be abnormal in identical multivariate analysis with no free parameters. Again, there were not substantial differences on the follow-up scans. Taken together, these results indicate that single-subject, module-based graph theoretic analysis of resting-state fMRI provides potentially useful information for concussive blast-related TBI if high quality scans can be obtained. The underlying biological mechanisms and consequences of disrupted between-module connectivity are unknown, thus further studies are required. (C) 2013 Elsevier Inc. All rights reserved.	[Han, Kihwan; Mac Donald, Christine L.; Raichle, Marcus E.; Brody, David L.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; [Johnson, Ann M.] Washington Univ, Sch Med, Ctr Clin Studies, St Louis, MO 63110 USA; [Barnes, Yolanda; Wierzechowski, Linda; Zonies, David; Oh, John; Flaherty, Stephen; Fang, Raymond] Landstuhl Reg Med Ctr, Dept Trauma & Crit Care, Landstuhl, Germany; [Raichle, Marcus E.] Washington Univ, Sch Med, Dept Radiol, St Louis, MO 63110 USA; [Raichle, Marcus E.] Washington Univ, Sch Med, Dept Neurobiol, St Louis, MO 63110 USA; [Raichle, Marcus E.] Washington Univ, Sch Med, Dept Biomed Engn, St Louis, MO 63110 USA; [Raichle, Marcus E.] Washington Univ, Sch Med, Dept Psychol, St Louis, MO 63110 USA	Brody, DL (corresponding author), Washington Univ, Dept Neurol, 660 South Euclid Ave,Box 8111, St Louis, MO 63110 USA.	brodyd@neuro.wustl.edu	Zonies, David/B-6497-2011; Oh, John/AAS-9557-2020; Han, Kihwan/I-1984-2019	Oh, John/0000-0001-9010-0627; Han, Kihwan/0000-0002-4574-7306	Department of Defense CDMRPUnited States Department of Defense [PT075299, PT090444]; Washington University Center for High Performance Computing [NCRR 1S10RR022984-01A1]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [S10RR022984] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F32NS062529] Funding Source: NIH RePORTER	First of all, we would like to thank all participants, their families, the commanding officers and the clinical care providers that supported this study. Our thanks also go to Dr. Nico U. Dosenbach, Dr. Steven E. Petersen and Dr. Abraham Z. Snyder for their helpful comments. This work has been supported by Department of Defense CDMRP grants PT075299 and PT090444 to DLB. We also would like to thank the facilities of the Washington University Center for High Performance Computing, which were partially provided through grant NCRR 1S10RR022984-01A1 for providing computational resource for conducting this study. Finally, we would like to thank the two anonymous reviewers for their comments which substantially improved this manuscript.	Achard S, 2006, J NEUROSCI, V26, P63, DOI 10.1523/JNEUROSCI.3874-05.2006; Anderson JS, 2011, HUM BRAIN MAPP, V32, P919, DOI 10.1002/hbm.21079; Arenivas A., 2012, BRAIN IMAGING BEHAV, V13, P1; Argall BD, 2006, HUM BRAIN MAPP, V27, P14, DOI 10.1002/hbm.20158; BISWAL B, 1995, MAGNET RESON MED, V34, P537, DOI 10.1002/mrm.1910340409; Blondel VD, 2008, J STAT MECH-THEORY E, DOI 10.1088/1742-5468/2008/10/P10008; Bonnelle V, 2012, P NATL ACAD SCI USA, V109, P4690, DOI 10.1073/pnas.1113455109; Bonnelle V, 2011, J NEUROSCI, V31, P13442, DOI 10.1523/JNEUROSCI.1163-11.2011; Braun U, 2012, NEUROIMAGE, V59, P1404, DOI 10.1016/j.neuroimage.2011.08.044; Bullmore ET, 2009, NAT REV NEUROSCI, V10, P186, DOI 10.1038/nrn2575; Caeyenberghs K, 2012, BRAIN, V135, P1293, DOI 10.1093/brain/aws048; Casscells SW, 2007, TRAUMATIC BRAIN INJU; Castellanos NP, 2011, NEUROIMAGE, V55, P1189, DOI 10.1016/j.neuroimage.2010.12.046; Castellanos NP, 2010, BRAIN, V133, P2365, DOI 10.1093/brain/awq174; Chai XQJ, 2012, NEUROIMAGE, V59, P1420, DOI 10.1016/j.neuroimage.2011.08.048; Chang C, 2009, NEUROIMAGE, V47, P1448, DOI 10.1016/j.neuroimage.2009.05.012; Chen ZJ, 2008, CEREB CORTEX, V18, P2374, DOI 10.1093/cercor/bhn003; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395; DALE AM, 1993, J COGNITIVE NEUROSCI, V5, P162, DOI 10.1162/jocn.1993.5.2.162; de Haan W, 2012, NEUROIMAGE, V59, P3085, DOI 10.1016/j.neuroimage.2011.11.055; de la Plata CDM, 2011, ARCH NEUROL-CHICAGO, V68, P74, DOI 10.1001/archneurol.2010.342; Dempsey Kenneth E, 2009, J Trauma Nurs, V16, P6, DOI 10.1097/01.JTN.0000348063.41099.a7; Destrieux C, 2010, NEUROIMAGE, V53, P1, DOI 10.1016/j.neuroimage.2010.06.010; Domsch S, 2013, MAGN RESON IMAGING, V31, P201, DOI 10.1016/j.mri.2012.06.020; Doppenberg EMR, 1997, J NEUROTRAUM, V14, P71, DOI 10.1089/neu.1997.14.71; DUDA R. O., 2001, PATTERN CLASSIFICATI, V2nd; EVANS AC, 1993, NUCLEAR SCIENCE SYMPOSIUM & MEDICAL IMAGING CONFERENCE, VOLS 1-3, P1813, DOI 10.1109/NSSMIC.1993.373602; Finkel MF, 2006, J NEUROL SCI, V249, P63, DOI 10.1016/j.jns.2006.06.005; Fischl B, 1999, HUM BRAIN MAPP, V8, P272, DOI 10.1002/(SICI)1097-0193(1999)8:4<272::AID-HBM10>3.0.CO;2-4; Fischl B, 2004, NEUROIMAGE, V23, pS69, DOI 10.1016/j.neuroimage.2004.07.016; Fischl B, 2004, CEREB CORTEX, V14, P11, DOI 10.1093/cercor/bhg087; Fischl B, 2001, IEEE T MED IMAGING, V20, P70, DOI 10.1109/42.906426; Fischl B, 1999, NEUROIMAGE, V9, P195, DOI 10.1006/nimg.1998.0396; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Fortunato S, 2010, PHYS REP, V486, P75, DOI 10.1016/j.physrep.2009.11.002; Fox MD, 2005, P NATL ACAD SCI USA, V102, P9673, DOI 10.1073/pnas.0504136102; Fox MD, 2009, J NEUROPHYSIOL, V101, P3270, DOI 10.1152/jn.90777.2008; Gasparovic C, 2009, J NEUROTRAUM, V26, P1635, DOI [10.1089/neu.2009.0896, 10.1089/neu.2009-0896]; Genovese CR, 2002, NEUROIMAGE, V15, P870, DOI 10.1006/nimg.2001.1037; Greicius MD, 2003, P NATL ACAD SCI USA, V100, P253, DOI 10.1073/pnas.0135058100; Guimera R, 2005, NATURE, V433, P895, DOI 10.1038/nature03288; Gujar N, 2010, J COGNITIVE NEUROSCI, V22, P1637, DOI 10.1162/jocn.2009.21331; Hagler DJ, 2006, NEUROIMAGE, V33, P1093, DOI 10.1016/j.neuroimage.2006.07.036; Hagmann P, 2008, PLOS BIOL, V6, P1479, DOI 10.1371/journal.pbio.0060159; Hayasaka S, 2010, NEUROIMAGE, V50, P499, DOI 10.1016/j.neuroimage.2009.12.051; He Y, 2007, CEREB CORTEX, V17, P2407, DOI 10.1093/cercor/bhl149; He Y, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005226; Honey CJ, 2009, P NATL ACAD SCI USA, V106, P2035, DOI 10.1073/pnas.0811168106; Horovitz SG, 2009, P NATL ACAD SCI USA, V106, P11376, DOI 10.1073/pnas.0901435106; Jacobs A, 1996, J NUCL MED, V37, P1605; Jo HJ, 2008, NEUROIMAGE, V40, P1077, DOI 10.1016/j.neuroimage.2007.12.036; Jo HJ, 2007, NEUROIMAGE, V34, P550, DOI 10.1016/j.neuroimage.2006.09.047; Johnson B, 2012, NEUROSCI LETT, V509, P5, DOI 10.1016/j.neulet.2011.11.013; Johnstone T, 2006, HUM BRAIN MAPP, V27, P779, DOI 10.1002/hbm.20219; Jovicich J, 2006, NEUROIMAGE, V30, P436, DOI 10.1016/j.neuroimage.2005.09.046; Kasahara M, 2010, NEUROLOGY, V75, P168, DOI 10.1212/WNL.0b013e3181e7ca58; Larson-Prior LJ, 2009, P NATL ACAD SCI USA, V106, P4489, DOI 10.1073/pnas.0900924106; Latora V, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.198701; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Liang X, 2013, P NATL ACAD SCI USA, V110, P1929, DOI 10.1073/pnas.1214900110; Liao YH, 2012, NEUROSCI LETT, V522, P36, DOI 10.1016/j.neulet.2012.06.009; Lin AP, 2012, BRAIN IMAGING BEHAV, V6, P208, DOI 10.1007/s11682-012-9181-4; Lowe MJ, 1998, NEUROIMAGE, V7, P119, DOI 10.1006/nimg.1997.0315; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; Meunier David, 2009, Front Neuroinform, V3, P37, DOI 10.3389/neuro.11.037.2009; Meunier D, 2009, NEUROIMAGE, V44, P715, DOI 10.1016/j.neuroimage.2008.09.062; Micheloyannis S, 2006, SCHIZOPHR RES, V87, P60, DOI 10.1016/j.schres.2006.06.028; Minka T.P., 2000, 514 MIT; Murphy K, 2009, NEUROIMAGE, V44, P893, DOI 10.1016/j.neuroimage.2008.09.036; Nakamura T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008220; Newman MEJ, 2004, PHYS REV E, V69, DOI [10.1103/PhysRevE.69.026113, 10.1103/PhysRevE.69.066133]; Nichols TE, 2002, HUM BRAIN MAPP, V15, P1, DOI 10.1002/hbm.1058; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Ojemann JG, 1997, NEUROIMAGE, V6, P156, DOI 10.1006/nimg.1997.0289; Okie S, 2006, NEW ENGL J MED, V355, P2609, DOI 10.1056/NEJMp068235; Pandit AS, 2013, NEUROLOGY, V80, P1826, DOI 10.1212/WNL.0b013e3182929f38; Peskind ER, 2011, NEUROIMAGE, V54, pS76, DOI 10.1016/j.neuroimage.2010.04.008; Ponten SC, 2007, CLIN NEUROPHYSIOL, V118, P918, DOI 10.1016/j.clinph.2006.12.002; Power JD, 2012, NEUROIMAGE, V59, P2142, DOI 10.1016/j.neuroimage.2011.10.018; Power JD, 2011, NEURON, V72, P665, DOI 10.1016/j.neuron.2011.09.006; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Rombouts SARB, 2003, NEUROIMAGE, V20, P1236, DOI 10.1016/S1053-8119(03)00386-0; Rosvall M, 2008, P NATL ACAD SCI USA, V105, P1118, DOI 10.1073/pnas.0706851105; Rubinov M, 2010, NEUROIMAGE, V52, P1059, DOI 10.1016/j.neuroimage.2009.10.003; Saad ZS, 2012, BRAIN CONNECT, V2, P25, DOI 10.1089/brain.2012.0080; Saad ZS, 2004, 2004 2ND IEEE INTERNATIONAL SYMPOSIUM ON BIOMEDICAL IMAGING: MACRO TO NANO, VOLS 1 and 2, P1510; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Salvador R, 2005, CEREB CORTEX, V15, P1332, DOI 10.1093/cercor/bhi016; Satterthwaite TD, 2012, NEUROIMAGE, V60, P623, DOI 10.1016/j.neuroimage.2011.12.063; Scheibel RS, 2012, J INT NEUROPSYCH SOC, V18, P89, DOI 10.1017/S1355617711001433; Seeley WW, 2007, J NEUROSCI, V27, P2349, DOI 10.1523/JNEUROSCI.5587-06.2007; Segonne F, 2004, NEUROIMAGE, V22, P1060, DOI 10.1016/j.neuroimage.2004.03.032; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Shumskaya E, 2012, NEUROLOGY, V79, P175, DOI 10.1212/WNL.0b013e31825f04fb; Slobounov SM, 2011, NEUROIMAGE, V55, P1716, DOI 10.1016/j.neuroimage.2011.01.024; Sponheim SR, 2011, NEUROIMAGE, V54, pS21, DOI 10.1016/j.neuroimage.2010.09.007; Stam CJ, 2007, CEREB CORTEX, V17, P92, DOI 10.1093/cercor/bhj127; Tang L, 2011, RADIOLOGY, V260, P831, DOI 10.1148/radiol.11110014; Taylor PA, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3118765; Tucholka A, 2012, NEUROIMAGE, V63, P1443, DOI 10.1016/j.neuroimage.2012.06.019; Valencia M, 2009, CHAOS, V19, DOI 10.1063/1.3129783; van den Heuvel MP, 2008, NEUROIMAGE, V43, P528, DOI 10.1016/j.neuroimage.2008.08.010; Van Dijk KRA, 2012, NEUROIMAGE, V59, P431, DOI 10.1016/j.neuroimage.2011.07.044; Van Dijk KRA, 2010, J NEUROPHYSIOL, V103, P297, DOI 10.1152/jn.00783.2009; Van Essen DC, 2007, NEUROIMAGE, V37, P1050, DOI 10.1016/j.neuroimage.2007.02.021; van Wingen GA, 2012, P NATL ACAD SCI USA, V109, P15508, DOI 10.1073/pnas.1206330109; Vincent JL, 2008, J NEUROPHYSIOL, V100, P3328, DOI 10.1152/jn.90355.2008; Wang JH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021976; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Watts DJ, 1998, NATURE, V393, P440, DOI 10.1038/30918; Wig GS, 2011, ANN NY ACAD SCI, V1224, P126, DOI 10.1111/j.1749-6632.2010.05947.x; Yeo BTT, 2011, J NEUROPHYSIOL, V106, P1125, DOI 10.1152/jn.00338.2011; Yeo RA, 2011, J NEUROTRAUM, V28, P1, DOI 10.1089/neu.2010.1578; Zhang DY, 2008, J NEUROPHYSIOL, V100, P1740, DOI 10.1152/jn.90463.2008	118	74	76	0	30	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	JAN 1	2014	84						76	96		10.1016/j.neuroimage.2013.08.017			21	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	278DF	WOS:000328868600008	23968735	Green Accepted			2021-06-18	
J	Cho, SI; Gao, SS; Xia, AP; Wang, R; Salles, FT; Raphael, PD; Abaya, H; Wachtel, J; Baek, J; Jacobs, D; Rasband, MN; Oghalai, JS				Cho, Sung-Il; Gao, Simon S.; Xia, Anping; Wang, Rosalie; Salles, Felipe T.; Raphael, Patrick D.; Abaya, Homer; Wachtel, Jacqueline; Baek, Jongmin; Jacobs, David; Rasband, Matthew N.; Oghalai, John S.			Mechanisms of Hearing Loss after Blast Injury to the Ear	PLOS ONE			English	Article							TYMPANIC-MEMBRANE PERFORATION; NERVE DEGENERATION; BRAIN-INJURY; OVERPRESSURE; EXPOSURE; MODEL; VULNERABILITY; SURVIVORS; RECOVERY; AFFERENT	Given the frequent use of improvised explosive devices (IEDs) around the world, the study of traumatic blast injuries is of increasing interest. The ear is the most common organ affected by blast injury because it is the body's most sensitive pressure transducer. We fabricated a blast chamber to re-create blast profiles similar to that of IEDs and used it to develop a reproducible mouse model to study blast-induced hearing loss. The tympanic membrane was perforated in all mice after blast exposure and found to heal spontaneously. Micro-computed tomography demonstrated no evidence for middle ear or otic capsule injuries; however, the healed tympanic membrane was thickened. Auditory brainstem response and distortion product otoacoustic emission threshold shifts were found to be correlated with blast intensity. As well, these threshold shifts were larger than those found in control mice that underwent surgical perforation of their tympanic membranes, indicating cochlear trauma. Histological studies one week and three months after the blast demonstrated no disruption or damage to the intra-cochlear membranes. However, there was loss of outer hair cells (OHCs) within the basal turn of the cochlea and decreased spiral ganglion neurons (SGNs) and afferent nerve synapses. Using our mouse model that recapitulates human IED exposure, our results identify that the mechanisms underlying blast-induced hearing loss does not include gross membranous rupture as is commonly believed. Instead, there is both OHC and SGN loss that produce auditory dysfunction.	[Cho, Sung-Il; Gao, Simon S.; Xia, Anping; Wang, Rosalie; Salles, Felipe T.; Raphael, Patrick D.; Abaya, Homer; Wachtel, Jacqueline; Oghalai, John S.] Stanford Univ, Dept Otolaryngol Head & Neck Surg, Stanford, CA 94305 USA; [Cho, Sung-Il] Chosun Univ, Dept Otolaryngol Head & Neck Surg, Kwangju, South Korea; [Gao, Simon S.] Rice Univ, Dept Bioengn, Houston, TX USA; [Baek, Jongmin; Jacobs, David] Stanford Univ, Dept Comp Sci, Stanford, CA 94305 USA; [Rasband, Matthew N.] Baylor Coll Med, Dept Neurosci, Houston, TX 77030 USA	Oghalai, JS (corresponding author), Stanford Univ, Dept Otolaryngol Head & Neck Surg, Stanford, CA 94305 USA.	joghalai@stanford.edu		Rasband, Matthew/0000-0001-8184-2477; Gao, Simon/0000-0002-7020-037X	DoDUnited States Department of Defense [W81XWH-11-2-0004 (DM090212)]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K08 DC006671, P30 DC010363]; Chosun University; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [K08DC006671, P30DC010363] Funding Source: NIH RePORTER	Support came from DoD W81XWH-11-2-0004 (DM090212) and NIH grants K08 DC006671 and P30 DC010363. Sungil Cho was supported by research funds from Chosun University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahroon WA, 1996, J ACOUST SOC AM, V100, P2247, DOI 10.1121/1.417934; Applegate BE, 2011, OPT LETT, V36, P4716, DOI 10.1364/OL.36.004716; Baalman KL, 2012, NEUROTRAUMA IN PRESS; Barden EK, 2012, J AM ACAD AUDIOL, V23, P332, DOI 10.3766/jaaa.23.5.4; Bass CR, 2008, J TRAUMA, V65, P604, DOI 10.1097/TA.0b013e3181454ab4; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI 10.1089/neu.2009-0898; Cave KM, 2007, MIL MED, V172, P726, DOI 10.7205/MILMED.172.7.726; Chavko M, 2006, J TRAUMA, V61, P933, DOI 10.1097/01.ta.0000233742.75450.47; Chen ZQ, 2010, J NEUROPHYSIOL, V103, P2581, DOI 10.1152/jn.00018.2010; Cheng JM, 2010, J NEUROL SCI, V294, P23, DOI 10.1016/j.jns.2010.04.010; Ewert DL, 2012, HEARING RES, V285, P29, DOI 10.1016/j.heares.2012.01.013; Gao SS, 2011, OPT EXPRESS, V19, P15415, DOI 10.1364/OE.19.015415; Garner Jeff, 2007, Anesthesiol Clin, V25, P147; Goldstein L.E., 2012, SCI TRANSL MED, V4; Gondusky JS, 2005, MIL MED, V170, P546, DOI 10.7205/MILMED.170.6.546; Gutierrez de Ceballos J Peral, 2005, Crit Care Med, V33, pS107; HAMERNIK RP, 1988, J ACOUST SOC AM, V84, P941, DOI 10.1121/1.396663; HAMERNIK RP, 1984, HEARING RES, V16, P143, DOI 10.1016/0378-5955(84)90004-2; HAMERNIK RP, 1984, HEARING RES, V13, P229, DOI 10.1016/0378-5955(84)90077-7; HAMERNIK RP, 1987, J ACOUST SOC AM, V81, P1118, DOI 10.1121/1.394632; Helfer Thomas M, 2005, Am J Audiol, V14, P161, DOI 10.1044/1059-0889(2005/018); Horrocks C L, 2001, J R Army Med Corps, V147, P28; Ibekwe T S, 2009, J Laryngol Otol, V123, pe2, DOI 10.1017/S0022215108003800; Jeong HK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013756; Kujawa SG, 2009, J NEUROSCI, V29, P14077, DOI 10.1523/JNEUROSCI.2845-09.2009; Lang HN, 2006, J NEUROSCI, V26, P3541, DOI 10.1523/JNEUROSCI.2488-05.2006; Legan PK, 2000, NEURON, V28, P273, DOI 10.1016/S0896-6273(00)00102-1; Lerut B, 2012, OTOL NEUROTOL, V33, P379, DOI 10.1097/MAO.0b013e318245cea5; LIBERMAN MC, 1990, J COMP NEUROL, V301, P443, DOI 10.1002/cne.903010309; Lin HW, 2011, JARO-J ASSOC RES OTO, V12, P605, DOI 10.1007/s10162-011-0277-0; Liu CC, 2011, JARO-J ASSOC RES OTO, V12, P577, DOI 10.1007/s10162-011-0269-0; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Masel BS, 2012, J NEUROTRAUMA; Mediavilla Varas Jesus, 2011, Front Neurol, V2, P58, DOI 10.3389/fneur.2011.00058; Ohlemiller KK, 2011, HEARING RES, V272, P13, DOI 10.1016/j.heares.2010.11.006; Ohlemiller KK, 2010, JARO-J ASSOC RES OTO, V11, P605, DOI 10.1007/s10162-010-0228-1; Ohlemiller KK, 2000, HEARING RES, V149, P239, DOI 10.1016/S0378-5955(00)00191-X; PATOW CA, 1994, OTOLARYNG HEAD NECK, V110, P211, DOI 10.1177/019459989411000211; Patterson JH, 1997, TOXICOLOGY, V121, P29, DOI 10.1016/S0300-483X(97)03653-6; PRICE GR, 1979, J ACOUST SOC AM, V66, P456, DOI 10.1121/1.383096; PRICE GR, 1986, J ACOUST SOC AM, V80, P1076, DOI 10.1121/1.393849; PRICE GR, 1989, J ACOUST SOC AM, V86, P2185, DOI 10.1121/1.398479; Qin ZB, 2010, HEARING RES, V263, P93, DOI 10.1016/j.heares.2009.10.002; Radford P, 2011, OTOLARYNG HEAD NECK, V145, P806, DOI 10.1177/0194599811411143; Ritzel DV, 2011, HUM FACT MED PAN S H, P1; Roberto M, 1989, Ann Otol Rhinol Laryngol Suppl, V140, P23; Saliba I, 2011, INT J PEDIATR OTORHI, V75, P527, DOI 10.1016/j.ijporl.2011.01.012; Schulz TY, 2004, TROOPS RETURN ALARMI, P18; Sharpnack D.D., 1991, TXB MILITARY MED, V1, P271; Svetlov SI, 2010, J TRAUMA, V69, P795, DOI 10.1097/TA.0b013e3181bbd885; [VA Affairs DoV], 2011, VET BEN ADM ANN BEN; Viberg A, 2004, HEARING RES, V197, P1, DOI 10.1016/j.heares.2004.04.016; Wang Y, 2002, JARO, V3, P248, DOI 10.1007/s101620020028; White CH, 2009, MAMM GENOME, V20, P207, DOI 10.1007/s00335-009-9178-5; Wightman JM, 2001, ANN EMERG MED, V37, P664, DOI 10.1067/mem.2001.114906; Xia AP, 2010, DIS MODEL MECH, V3, P209, DOI 10.1242/dmm.004135; Xydakis MS, 2007, NEW ENGL J MED, V357, P830, DOI 10.1056/NEJMc076071; Zajtchuk R, 1991, CONVENTIONAL WARFARE, P241; Zhang B, 2011, J TRAUMA, V71, P694, DOI 10.1097/TA.0b013e318224595f	59	74	77	0	28	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 1	2013	8	7							e67618	10.1371/journal.pone.0067618			15	Multidisciplinary Sciences	Science & Technology - Other Topics	175ZH	WOS:000321271900013	23840874	DOAJ Gold, Green Published			2021-06-18	
J	Spikman, JM; Milders, MV; Visser-Keizer, AC; Westerhof-Evers, HJ; Herben-Dekker, M; van der Naalt, J				Spikman, Jacoba M.; Milders, Maarten V.; Visser-Keizer, Annemarie C.; Westerhof-Evers, Herma J.; Herben-Dekker, Meike; van der Naalt, Joukje			Deficits in Facial Emotion Recognition Indicate Behavioral Changes and Impaired Self-Awareness after Moderate to Severe Traumatic Brain Injury	PLOS ONE			English	Article							DYSEXECUTIVE QUESTIONNAIRE; EXECUTIVE DYSFUNCTION; EXPRESSION; IMPAIRMENTS; VALIDITY; ADULTS; METAANALYSIS; ASSOCIATION; RELIABILITY; PERCEPTION	Traumatic brain injury (TBI) is a leading cause of disability, specifically among younger adults. Behavioral changes are common after moderate to severe TBI and have adverse consequences for social and vocational functioning. It is hypothesized that deficits in social cognition, including facial affect recognition, might underlie these behavioral changes. Measurement of behavioral deficits is complicated, because the rating scales used rely on subjective judgement, often lack specificity and many patients provide unrealistically positive reports of their functioning due to impaired self-awareness. Accordingly, it is important to find performance based tests that allow objective and early identification of these problems. In the present study 51 moderate to severe TBI patients in the sub-acute and chronic stage were assessed with a test for emotion recognition (FEEST) and a questionnaire for behavioral problems (DEX) with a self and proxy rated version. Patients performed worse on the total score and on the negative emotion subscores of the FEEST than a matched group of 31 healthy controls. Patients also exhibited significantly more behavioral problems on both the DEX self and proxy rated version, but proxy ratings revealed more severe problems. No significant correlation was found between FEEST scores and DEX self ratings. However, impaired emotion recognition in the patients, and in particular of Sadness and Anger, was significantly correlated with behavioral problems as rated by proxies and with impaired self-awareness. This is the first study to find these associations, strengthening the proposed recognition of social signals as a condition for adequate social functioning. Hence, deficits in emotion recognition can be conceived as markers for behavioral problems and lack of insight in TBI patients. This finding is also of clinical importance since, unlike behavioral problems, emotion recognition can be objectively measured early after injury, allowing for early detection and treatment of these problems.	[Spikman, Jacoba M.; Visser-Keizer, Annemarie C.; Westerhof-Evers, Herma J.] Univ Groningen, Dept Clin & Dev Neuropsychol, Groningen, Netherlands; [Spikman, Jacoba M.; Herben-Dekker, Meike; van der Naalt, Joukje] Univ Groningen, Univ Med Ctr Groningen, Dept Neurol, Groningen, Netherlands; [Milders, Maarten V.] Heriot Watt Univ, Sch Life Sci, Edinburgh, Midlothian, Scotland; [Visser-Keizer, Annemarie C.] Univ Groningen, Univ Med Ctr Groningen, Ctr Rehabil, Haren, Netherlands; [Herben-Dekker, Meike] Rehabil Ctr Friesland, Beetsterzwaag, Netherlands	Spikman, JM (corresponding author), Univ Groningen, Dept Clin & Dev Neuropsychol, Groningen, Netherlands.	j.m.spikman@rug.nl		Spikman, Jacoba/0000-0002-6477-0763	Dutch Brain Foundation [F2008-1-18]	The study was partly funded by the Dutch Brain Foundation (grant nr F2008-1-18) [https://www.hersenstichting.nl/]. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. No additional external funding received for this study.	Adolphs R, 2002, CURR OPIN NEUROBIOL, V12, P169, DOI 10.1016/S0959-4388(02)00301-X; Adolphs R, 2001, CURR OPIN NEUROBIOL, V11, P231, DOI 10.1016/S0959-4388(00)00202-6; Babbage DR, 2011, NEUROPSYCHOLOGY, V25, P277, DOI 10.1037/a0021908; Benedictus MR, 2010, ARCH PHYS MED REHAB, V91, P1436, DOI 10.1016/j.apmr.2010.06.019; Bennett PC, 2005, J INT NEUROPSYCH SOC, V11, P606, DOI 10.1017/S1355617705050721; Biehl M, 1997, J NONVERBAL BEHAV, V21, P3, DOI 10.1023/A:1024902500935; Blair RJR, 2003, PHILOS T R SOC B, V358, P561, DOI 10.1098/rstb.2002.1220; Bodenburg S, 2008, J NERV MENT DIS, V196, P75, DOI 10.1097/NMD.0b013e31815faa2b; Bornhofen C, 2008, J INT NEUROPSYCH SOC, V14, P511, DOI 10.1017/S1355617708080703; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Chan RCK, 2008, J NEUROL NEUROSUR PS, V79, P86, DOI 10.1136/jnnp.2007.117184; Chaytor N, 2007, BRAIN INJURY, V21, P615, DOI 10.1080/02699050701426949; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Croker V, 2005, BRAIN INJURY, V19, P787, DOI 10.1080/02699050500110033; Diehl-Schmid J, 2007, ARCH CLIN NEUROPSYCH, V22, P459, DOI 10.1016/j.acn.2007.01.024; Ekman P., 1976, PICTURES FACIAL AFFE; Engberg AW, 2004, BRAIN INJURY, V18, P533, DOI 10.1080/02699050310001645829; Fujiwara E, 2008, NEUROPSYCHOLOGIA, V46, P461, DOI 10.1016/j.neuropsychologia.2007.08.027; Fusar-Poli P, 2009, J PSYCHIATR NEUROSCI, V34, P418; Green REA, 2004, NEUROPSYCHOLOGIA, V42, P133, DOI 10.1016/j.neuropsychologia.2003.07.005; GURDJIAN ES, 1976, J TRAUMA, V16, P35, DOI 10.1097/00005373-197601000-00005; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P333, DOI 10.1097/00001199-200507000-00005; Hart T, 2004, ARCH PHYS MED REHAB, V85, P1450, DOI 10.1016/j.apmr.2004.01.030; Hawthorne G, 2009, J NEUROTRAUM, V26, P1623, DOI [10.1089/neu.2008.0735, 10.1089/neu.2008-0735]; Henry JD, 2006, NEUROPSYCHOLOGIA, V44, P1623, DOI 10.1016/j.neuropsychologia.2006.03.020; HOLM S, 1979, SCAND J STAT, V6, P65; Hopkins MJ, 2002, BRAIN INJURY, V16, P245, DOI 10.1080/02699050110103346; Ietswaart M, 2008, NEUROPSYCHOLOGIA, V46, P148, DOI 10.1016/j.neuropsychologia.2007.08.002; JACKSON HF, 1987, CORTEX, V23, P293, DOI 10.1016/S0010-9452(87)80039-4; Knox L, 2009, BRAIN COGNITION, V69, P442, DOI 10.1016/j.bandc.2008.09.009; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; Levine B, 2006, J NEUROTRAUM, V23, P1396, DOI 10.1089/neu.2006.23.1396; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Marsh AA, 2008, NEUROSCI BIOBEHAV R, V32, P454, DOI 10.1016/j.neubiorev.2007.08.003; Marsh AA, 2011, J CHILD PSYCHOL PSYC, V52, P834, DOI 10.1111/j.1469-7610.2010.02353.x; McDonald S, 2006, DISABIL REHABIL, V28, P1529, DOI 10.1080/09638280600646185; Milders M, 2003, NEUROPSYCHOLOGIA, V41, P1484, DOI 10.1016/S0028-3932(03)00079-4; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; Milders M, 2008, J INT NEUROPSYCH SOC, V14, P318, DOI 10.1017/S1355617708080351; Milders M, 2006, NEUROPSYCHOLOGY, V20, P400, DOI 10.1037/0894-4105.20.4.400; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; Radice-Neumann D, 2007, BRAIN INJURY, V21, P807, DOI 10.1080/02699050701504281; Rapcsak SZ, 2000, NEUROLOGY, V54, P575, DOI 10.1212/WNL.54.3.575; Sherer M, 2005, J HEAD TRAUMA REHAB, V20, P287, DOI 10.1097/00001199-200507000-00002; Simblett SK, 2011, NEUROPSYCHOL REHABIL, V21, P1, DOI 10.1080/09602011.2011.592099; Spikman JM, 2012, J NEUROTRAUM, V29, P101, DOI 10.1089/neu.2011.2084; Spikman JM, 2010, J NEUROTRAUMA; Sprengelmeyer R, 1998, P ROY SOC B-BIOL SCI, V265, P1927, DOI 10.1098/rspb.1998.0522; Struchen MA, 2008, NEUROREHABILITATION, V23, P185; Stuss D.T., 2011, J INT NEUROPSYCH SOC, V17, P1; Stuss DT, 2011, CURR OPIN NEUROL, V24, P584, DOI 10.1097/WCO.0b013e32834c7eb9; Wallesch CW, 2001, J NEUROTRAUM, V18, P11, DOI 10.1089/089771501750055730; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; Wilson BA, 1996, BEHAV ASSESSMENT DYS; Wise K, 2005, BRAIN INJURY, V19, P765, DOI 10.1080/0269905050019977; Young A., 2002, FACIAL EXPRESSIONS E; Zappala G, 2012, CORTEX, V48, P156, DOI 10.1016/j.cortex.2011.06.020	59	74	74	0	47	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 12	2013	8	6							e65581	10.1371/journal.pone.0065581			7	Multidisciplinary Sciences	Science & Technology - Other Topics	163FW	WOS:000320322400035	23776505	DOAJ Gold, Green Published			2021-06-18	
J	Messe, A; Caplain, S; Pelegrini-Issac, M; Blancho, S; Levy, R; Aghakhani, N; Montreuil, M; Benali, H; Lehericy, S				Messe, Arnaud; Caplain, Sophie; Pelegrini-Issac, Melanie; Blancho, Sophie; Levy, Richard; Aghakhani, Nozar; Montreuil, Michele; Benali, Habib; Lehericy, Stephane			Specific and Evolving Resting-State Network Alterations in Post-Concussion Syndrome Following Mild Traumatic Brain Injury	PLOS ONE			English	Article							GRAPH-THEORETICAL ANALYSIS; DEFAULT MODE NETWORK; FUNCTIONAL CONNECTIVITY; HEAD-INJURY; SYMPTOMS; SUBJECT; LEVEL; PHASE	Post-concussion syndrome has been related to axonal damage in patients with mild traumatic brain injury, but little is known about the consequences of injury on brain networks. In the present study, our aim was to characterize changes in functional brain networks following mild traumatic brain injury in patients with post-concussion syndrome using resting-state functional magnetic resonance imaging data. We investigated 17 injured patients with persistent post-concussion syndrome (under the DSM-IV criteria) at 6 months post-injury compared with 38 mild traumatic brain injury patients with no post-concussion syndrome and 34 healthy controls. All patients underwent magnetic resonance imaging examinations at the subacute (1-3 weeks) and late (6 months) phases after injury. Group-wise differences in functional brain networks were analyzed using graph theory measures. Patterns of long-range functional networks alterations were found in all mild traumatic brain injury patients. Mild traumatic brain injury patients with post-concussion syndrome had greater alterations than patients without post-concussion syndrome. In patients with post-concussion syndrome, changes specifically affected temporal and thalamic regions predominantly at the subacute stage and frontal regions at the late phase. Our results suggest that the post-concussion syndrome is associated with specific abnormalities in functional brain network that may contribute to explain deficits typically observed in PCS patients.	[Messe, Arnaud; Pelegrini-Issac, Melanie; Benali, Habib] Univ Paris 06, INSERM, Lab Imagerie Fonct, UMRS 678, Paris, France; [Messe, Arnaud; Pelegrini-Issac, Melanie; Benali, Habib; Lehericy, Stephane] Univ Paris 11, IFR49, DSV NeuroSpin I2BM, Gif Sur Yvette, France; [Caplain, Sophie; Montreuil, Michele] Univ Paris 08, EA 2027, St Denis, France; [Blancho, Sophie] Inst Rech Moelle Epiniere & Encephale, Paris, France; [Levy, Richard; Lehericy, Stephane] Univ Paris 06, INSERM, Grp Hosp Pitie Salpetriere, UMRS 975,CNRS UMR 7225,CRICM, Paris, France; [Levy, Richard] Hop St Antoine, Assistance Publ Hop Paris, F-75571 Paris, France; [Aghakhani, Nozar] Hop Univ Bicetre, Assistance Publ Hop Paris, Neurosurg Dept, Le Kremlin Bicetre, France; [Benali, Habib] Univ Montreal, MIC UNF, Montreal, PQ, Canada; [Lehericy, Stephane] Univ Paris 06, CHU Pitie Salpetriere, CENIR, Ctr Neuroimaging Res, Paris, France	Messe, A (corresponding author), Univ Paris 06, INSERM, Lab Imagerie Fonct, UMRS 678, Paris, France.	Arnaud.Messe@imed.jussieu.fr	Levy, Richard/D-8411-2011; Messe, Arnaud/I-1738-2019	Messe, Arnaud/0000-0001-9081-3088; Pelegrini-Issac, Melanie/0000-0003-3260-5795; aghakhani, nozar/0000-0001-8389-8167	IRME (Institut pour la Recherche sur la Moelle Epiniere et l'Encephale); GMF (Garantie Mutuelle des Fonctionnaires); program "Investissements d'avenir"French National Research Agency (ANR) [ANR-10-IAIHU-06]	This study was initiated by the IRME (Institut pour la Recherche sur la Moelle Epiniere et l'Encephale) and supported by a grant from the GMF (Garantie Mutuelle des Fonctionnaires). The research leading to these results has received funding from the program "Investissements d'avenir" ANR-10-IAIHU-06. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Achard S, 2006, J NEUROSCI, V26, P63, DOI 10.1523/JNEUROSCI.3874-05.2006; American Psychiatric Association (APA), 1994, DIAGN STAT MAN MENT, V4th; Azouvi P, 2001, REV NEUROPSYCHOL, V11, P383; Bassett DS, 2012, NEUROIMAGE, V59, P2196, DOI 10.1016/j.neuroimage.2011.10.002; Bassett DS, 2011, NEUROIMAGE, V54, P1262, DOI 10.1016/j.neuroimage.2010.09.006; Bassett DS, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000748; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Benjamini Y, 2001, ANN STAT, V29, P1165; Bigler ED, 2010, NEUROLOGY, V74, P626, DOI 10.1212/WNL.0b013e3181d3e43a; Biswal BB, 2010, P NATL ACAD SCI USA, V107, P4734, DOI 10.1073/pnas.0911855107; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Bressler SL, 2006, INT J PSYCHOPHYSIOL, V60, P139, DOI 10.1016/j.ijpsycho.2005.12.008; Bullmore ET, 2009, NAT REV NEUROSCI, V10, P186, DOI 10.1038/nrn2575; de la Plata CDM, 2011, ARCH NEUROL-CHICAGO, V68, P74, DOI 10.1001/archneurol.2010.342; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; EVANS RW, 1992, NEUROL CLIN, V10, P815; FitzGerald DB, 2011, INT J PSYCHOPHYSIOL, V82, P79, DOI 10.1016/j.ijpsycho.2011.02.011; Fox MD, 2007, NAT REV NEUROSCI, V8, P700, DOI 10.1038/nrn2201; Fox MD, 2009, J NEUROPHYSIOL, V101, P3270, DOI 10.1152/jn.90777.2008; FREEMAN LC, 1977, SOCIOMETRY, V40, P35, DOI 10.2307/3033543; Ginestet CE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021570; Hagmann P, 2008, PLOS BIOL, V6, P1479, DOI 10.1371/journal.pbio.0060159; Hall RCW, 2005, PSYCHOSOMATICS, V46, P195, DOI 10.1176/appi.psy.46.3.195; Hou R., 2011, J NEUROL NEUROSUR PS, V83, P217; Humphries MD, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002051; Irimia A, 2012, NEUROIMAGE, V60, P1340, DOI 10.1016/j.neuroimage.2012.01.107; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Kaiser M, 2006, PLOS COMPUT BIOL, V2, P805, DOI 10.1371/journal.pcbi.0020095; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Latora V, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.198701; Legome E, 2006, POSTCONCUSSION SYNDR; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Logothetis NK, 2004, ANNU REV PHYSIOL, V66, P735, DOI 10.1146/annurev.physiol.66.082602.092845; Lynall ME, 2010, J NEUROSCI, V30, P9477, DOI 10.1523/JNEUROSCI.0333-10.2010; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; Messe A, 2012, BRAIN IMAGING BEHAV, V6, P283, DOI 10.1007/s11682-012-9159-2; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Nakamura T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008220; Newman MEJ, 2006, P NATL ACAD SCI USA, V103, P8577, DOI 10.1073/pnas.0601602103; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Raichle ME, 2011, BRAIN CONNECT, V1, P3, DOI 10.1089/brain.2011.0019; Ravasz E, 2003, PHYS REV E, V67, DOI 10.1103/PhysRevE.67.026112; Reijneveld JC, 2007, CLIN NEUROPHYSIOL, V118, P2317, DOI 10.1016/j.clinph.2007.08.010; Rubinov M, 2010, NEUROIMAGE, V52, P1059, DOI 10.1016/j.neuroimage.2009.10.003; Sandrone S, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00261; Sandrone S, 2012, J NEUROSCI, V32, P1915, DOI 10.1523/JNEUROSCI.5637-11.2012; Schwarz AJ, 2011, NEUROIMAGE, V55, P1132, DOI 10.1016/j.neuroimage.2010.12.047; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; Shumskaya E, 2012, NEUROLOGY, V79, P175, DOI 10.1212/WNL.0b013e31825f04fb; Slobounov SM, 2011, NEUROIMAGE, V55, P1716, DOI 10.1016/j.neuroimage.2011.01.024; Smits M, 2011, NEURORADIOLOGY, V53, P553, DOI 10.1007/s00234-010-0774-6; Sporns O, 2005, PLOS COMPUT BIOL, V1, P245, DOI 10.1371/journal.pcbi.0010042; Sporns O., 2011, NETWORKS BRAIN; Sporns O, 2006, P NATL ACAD SCI USA, V103, P19219, DOI 10.1073/pnas.0609523103; Stalnacke BM, 2005, J REHABIL MED, V37, P300, DOI 10.1080/16501970510032910; Tang L, 2011, RADIOLOGY, V260, P831, DOI 10.1148/radiol.11110014; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; van den Heuvel MP, 2011, J NEUROSCI, V31, P15775, DOI 10.1523/JNEUROSCI.3539-11.2011; Van Dijk KRA, 2010, J NEUROPHYSIOL, V103, P297, DOI 10.1152/jn.00783.2009; Vanhaudenhuyse A, 2010, BRAIN, V133, P161, DOI 10.1093/brain/awp313; Varela F, 2001, NAT REV NEUROSCI, V2, P229, DOI 10.1038/35067550; von Wild KRH, 2008, ACT NEUR S, V101, P55; Watts DJ, 1998, NATURE, V393, P440, DOI 10.1038/30918; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033; Willer Barry, 2006, Curr Treat Options Neurol, V8, P415, DOI 10.1007/s11940-006-0031-9; Xia M, 2011, P 17 INT C FUNCT MAP; Zalesky A, 2012, NEUROIMAGE, V60, P1055, DOI 10.1016/j.neuroimage.2012.01.068	69	74	76	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 6	2013	8	6							e65470	10.1371/journal.pone.0065470			10	Multidisciplinary Sciences	Science & Technology - Other Topics	173SK	WOS:000321099000072	23755237	DOAJ Gold, Green Published			2021-06-18	
J	Castro, M; Paleti, R; Bhat, CR				Castro, Marisol; Paleti, Rajesh; Bhat, Chandra R.			A spatial generalized ordered response model to examine highway crash injury severity	ACCIDENT ANALYSIS AND PREVENTION			English	Article						Highway crash injury severity; Generalized ordered response model; Unobserved heterogeneity; Spatial dependence; Composite marginal likelihood; Spatial econometrics	STATISTICAL-ANALYSIS; MULTINOMIAL LOGIT; SINGLE-VEHICLE; DRIVER-INJURY; PROBIT; ACCIDENTS	This paper proposes a flexible econometric structure for injury severity analysis at the level of individual crashes that recognizes the ordinal nature of injury severity categories, allows unobserved heterogeneity in the effects of contributing factors, as well as accommodates spatial dependencies in the injury severity levels experienced in crashes that occur close to one another in space. The modeling framework is applied to analyze the injury severity sustained in crashes occurring on highway road segments in Austin, Texas. The sample is drawn from the Texas Department of Transportation (TxDOT) crash incident files from 2009 and includes a variety of crash characteristics, highway design attributes, driver and vehicle characteristics, and environmental factors. The results from our analysis underscore the value of our proposed model for data fit purposes as well as to accurately estimate variable effects. The most important determinants of injury severity on highways, according to our results, are (1) whether any vehicle occupant is ejected, (2) whether collision type is head-on, (3) whether any vehicle involved in the crash overturned, (4) whether any vehicle occupant is unrestrained by a seat-belt, and (5) whether a commercial truck is involved. (C) 2012 Elsevier Ltd. All rights reserved.	[Castro, Marisol; Paleti, Rajesh; Bhat, Chandra R.] Univ Texas Austin, Dept Civil Architectural & Environm Engn, Austin, TX 78712 USA	Bhat, CR (corresponding author), Univ Texas Austin, Dept Civil Architectural & Environm Engn, 301 E Dean Keeton St Stop C1761, Austin, TX 78712 USA.	m.castro@utexas.edu; rajeshp@mail.utexas.edu; bhat@mail.utexas.edu	Bhat, Chandra/AAC-6965-2019; Bhat, Chandra R/B-3952-2013	Bhat, Chandra/0000-0002-0715-8121; Bhat, Chandra R/0000-0002-0715-8121			Amoros E, 2006, ACCIDENT ANAL PREV, V38, P627, DOI 10.1016/j.aap.2005.11.006; Anastasopoulos PC, 2011, ACCIDENT ANAL PREV, V43, P1140, DOI 10.1016/j.aap.2010.12.024; Bagdadi O, 2013, ACCIDENT ANAL PREV, V50, P167, DOI 10.1016/j.aap.2012.04.007; Allen R. G., 1998, FAO Irrigation and Drainage Paper, DOI 10.5194/bg-9-3943-2012; Bhat CR, 2010, ADV ECONOMETRICS, V26, P65, DOI 10.1108/S0731-9053(2010)0000026007; Bhat CR, 2011, TRANSPORT RES B-METH, V45, P923, DOI 10.1016/j.trb.2011.04.005; Chen F, 2011, ACCIDENT ANAL PREV, V43, P1677, DOI 10.1016/j.aap.2011.03.026; Christoforou Z, 2010, ACCIDENT ANAL PREV, V42, P1606, DOI 10.1016/j.aap.2010.03.019; Das A, 2009, J SAFETY RES, V40, P317, DOI 10.1016/j.jsr.2009.05.003; Dissanayake S., 2006, J TRANSPORTATION RES, V45, P87; Dupont E, 2010, ACCIDENT ANAL PREV, V42, P645, DOI 10.1016/j.aap.2009.10.011; Eluru N, 2008, ACCIDENT ANAL PREV, V40, P1033, DOI 10.1016/j.aap.2007.11.010; Eluru N, 2007, ACCIDENT ANAL PREV, V39, P1037, DOI 10.1016/j.aap.2007.02.001; Eluru N, 2010, TRANSPORT RES REC, P1, DOI 10.3141/2165-01; Franzese Robert J., 2008, OXFORD HDB POLITICAL, P570; Fu V.K, 1998, STATA TECHNICAL B, V8, P27; GODAMBE VP, 1960, ANN MATH STAT, V31, P1208, DOI 10.1214/aoms/1177705693; Greene W.H., 2009, MODELING ORDERED CHO; Haleem K, 2010, J SAFETY RES, V41, P347, DOI 10.1016/j.jsr.2010.04.006; Helai H, 2008, ACCIDENT ANAL PREV, V40, P45, DOI 10.1016/j.aap.2007.04.002; Hu Jingwen, 2005, Annu Proc Assoc Adv Automot Med, V49, P119; Hu W, 2010, ACCIDENT ANAL PREV, V42, P1697, DOI 10.1016/j.aap.2010.04.009; JANSSEN W, 1994, ACCIDENT ANAL PREV, V26, P249, DOI 10.1016/0001-4575(94)90095-7; Jung SY, 2010, ACCIDENT ANAL PREV, V42, P213, DOI 10.1016/j.aap.2009.07.020; Kermanshah M., 2011, TRANSPORTATION RES J, V1, P35; Khorashadi A, 2005, ACCIDENT ANAL PREV, V37, P910, DOI 10.1016/j.aap.2005.04.009; Kochanek, 2012, NATL VITAL STAT REPO, V60; Lee J, 2002, ACCIDENT ANAL PREV, V34, P149, DOI 10.1016/S0001-4575(01)00009-4; LeSage J, 2009, STAT TEXTB MONOGR, P1; Lindsay BG, 1988, CONT MATH, V80, P221, DOI [DOI 10.1090/CONM/080/999014, 10.1090/ conm/ 080/999014]; Liu Z., 2011, P TRANSP RES BOARD 9; Lord D, 2010, TRANSPORT RES A-POL, V44, P291, DOI 10.1016/j.tra.2010.02.001; Ma ZL, 2009, IEEE INT VEH SYM, P983, DOI 10.1109/IVS.2009.5164414; Malyshkina NV, 2009, ACCIDENT ANAL PREV, V41, P829, DOI 10.1016/j.aap.2009.04.006; Milton JC, 2008, ACCIDENT ANAL PREV, V40, P260, DOI 10.1016/j.aap.2007.06.006; Molenberghs G., 2005, MODELS DISCRETE LONG, P683; Moore DN, 2011, ACCIDENT ANAL PREV, V43, P621, DOI 10.1016/j.aap.2010.09.015; Muller G, 2005, J COMPUT GRAPH STAT, V14, P320, DOI 10.1198/106186005X48687; National Highway Traffic Safety Administration (NHTSA), 2012, 811552 NHTSA DOT HS; National Highway Traffic Safety Administration (NHTSA), 2011, 811402 NHTSA DOT HS; Mujalli RO, 2011, J SAFETY RES, V42, P317, DOI 10.1016/j.jsr.2011.06.010; Paleti R, 2010, ACCIDENT ANAL PREV, V42, P1839, DOI 10.1016/j.aap.2010.05.005; Patil S, 2012, ACCIDENT ANAL PREV, V45, P646, DOI 10.1016/j.aap.2011.09.034; Petridou E, 2000, EUR J EPIDEMIOL, V16, P819, DOI 10.1023/A:1007649804201; Quddus MA, 2010, J TRANSP ENG, V136, P424, DOI 10.1061/(ASCE)TE.1943-5436.0000044; Rana TA, 2010, TRANSPORT RES REC, P75, DOI 10.3141/2147-10; Rifaat SM, 2011, ACCIDENT ANAL PREV, V43, P276, DOI 10.1016/j.aap.2010.08.024; Savolainen P, 2007, ACCIDENT ANAL PREV, V39, P955, DOI 10.1016/j.aap.2006.12.016; Savolainen PT, 2011, ACCIDENT ANAL PREV, V43, P1666, DOI 10.1016/j.aap.2011.03.025; Schneider I.V., 2009, TRANSPORT RES REC, V2102, P85, DOI DOI 10.3141/2102-11; Shankar V, 1996, J SAFETY RES, V27, P183, DOI 10.1016/0022-4375(96)00010-2; Srinivasan KK, 2002, TRANSPORT RES REC, P132, DOI 10.3141/1784-17; Ulfarsson GF, 2004, ACCIDENT ANAL PREV, V36, P135, DOI 10.1016/S0001-4575(02)00135-5; Varin C, 2011, STAT SINICA, V21, P5; Varin C, 2010, BIOSTATISTICS, V11, P127, DOI 10.1093/biostatistics/kxp042; Varin C, 2009, ECONOMET REV, V28, P170, DOI 10.1080/07474930802388009; Wang XS, 2008, ACCIDENT ANAL PREV, V40, P1674, DOI 10.1016/j.aap.2008.06.001; Wang YG, 2011, PERIOD POLYTECH-CIV, V55, P191, DOI 10.3311/pp.ci.2011-2.11; Wang ZY, 2009, TRANSP RES RECORD, P43, DOI 10.3141/2102-06; Williams R, 2006, STATA J, V6, P58, DOI 10.1177/1536867X0600600104; Winston C, 2006, J RISK UNCERTAINTY, V32, P83, DOI 10.1007/s11166-006-8288-7; Xie YC, 2009, J TRANSP ENG, V135, P18, DOI 10.1061/(ASCE)0733-947X(2009)135:1(18); Xu XM, 2011, J STAT PLAN INFER, V141, P3047, DOI 10.1016/j.jspi.2011.03.026; Yamamoto T, 2008, ACCIDENT ANAL PREV, V40, P1320, DOI 10.1016/j.aap.2007.10.016; Yan XP, 2011, ACCIDENT ANAL PREV, V43, P1751, DOI 10.1016/j.aap.2011.04.006; Ye F, 2011, TRANSPORT RES REC, P51, DOI 10.3141/2241-06; Zhang Y, 2011, PROCEDIA ENGINEER, V21, P178, DOI 10.1016/j.proeng.2011.11.2002; Zhao YS, 2005, CAN J STAT, V33, P335, DOI 10.1002/cjs.5540330303; Zhu XY, 2011, ACCIDENT ANAL PREV, V43, P49, DOI 10.1016/j.aap.2010.07.007	69	74	74	3	40	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0001-4575	1879-2057		ACCIDENT ANAL PREV	Accid. Anal. Prev.	MAR 28	2013	52						188	203		10.1016/j.aap.2012.12.009			16	Ergonomics; Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary; Transportation	Engineering; Public, Environmental & Occupational Health; Social Sciences - Other Topics; Transportation	124DN	WOS:000317444100022	23333845				2021-06-18	
J	Palacios, EM; Sala-Llonch, R; Junque, C; Fernandez-Espejo, D; Roig, T; Tormos, JM; Bargallo, N; Vendrell, P				Palacios, Eua M.; Sala-Llonch, Roser; Junque, Carme; Fernandez-Espejo, Davinia; Roig, Teresa; Tormos, Jose M.; Bargallo, Nuria; Vendrell, Pere			Long-term declarative memory deficits in diffuse TB!: Correlations with cortical thickness, white matter integrity and hippocampal volume	CORTEX			English	Article						Traumatic brain injury; Declarative memory; Cortical thickness; Diffusion tensor imaging; Hippocampus	TRAUMATIC BRAIN-INJURY; HUMAN CEREBRAL-CORTEX; STRUCTURAL CONNECTIVITY; GEOMETRICALLY ACCURATE; LONGITUDINAL CHANGES; EPISODIC MEMORY; TENSOR; ATROPHY; NETWORK; RECOVERY	We investigated structural brain damage in subjects who had suffered severe and diffuse traumatic brain injury (TBI), and examined its relationship with declarative memory impairment. Cortical thickness, diffusion tensor imaging (DTI), and volumetric and shape data of the hippocampus were assessed in a group of 26 adults with severe TBI in the chronic stage and 22 healthy matched controls. Declarative memory was evaluated by Rey's Auditory Verbal Learning Test (RAVLT). TBI patients performed significantly worse than controls on all RAVLT measures. The group comparison for cortical thickness and DTI revealed a pattern of widespread atrophy in TBI patients. In the TBI group DTI measures correlated with cortical thickness in the prefrontal and parietal regions, including the precuneus. Declarative memory correlated with both cortical thickness and DTI measures. However, although hippocampal volume was significantly decreased in TBI patients, no correlations were found. Multiple regression analysis of all the structural measures revealed that decreases in Fractional anisotropy (FA) and thinning of the left parietal region were the best predictors of memory impairment. In conclusion, cortical thickness reductions in the left hemisphere and a lack of white matter integrity are the main contributors to long-term impairment in declarative memory among patients suffering from severe and diffuse TBI. In this study the hippocampus did not make a significant contribution to memory dysfunctions, suggesting that damage to this structure is compensated for by other regions, with the definitive sequelae being mainly explained by alterations in cortico-subcortical connectivity. (C) 2012 Elsevier Ltd. All rights reserved.	[Palacios, Eua M.; Sala-Llonch, Roser; Junque, Carme; Vendrell, Pere] Univ Barcelona, Dept Psychiat & Clin Psychobiol, E-08036 Barcelona, Spain; [Palacios, Eua M.; Sala-Llonch, Roser; Junque, Carme; Vendrell, Pere] August Pi I Sunyer Biomed Res Inst IDIBAPS, Barcelona, Spain; [Fernandez-Espejo, Davinia] Univ Western Ontario, Ctr Brain & Mind, London, ON, Canada; [Roig, Teresa; Tormos, Jose M.] Inst Univ Neurorehabil Guttmann, Badalona, Spain; [Bargallo, Nuria] Hosp Clin Barcelona, Ctr Diagnost Imatge CDIC, Barcelona, Spain	Junque, C (corresponding author), Univ Barcelona, Dept Psychiat & Clin Psychobiol, C Casanova 143, E-08036 Barcelona, Spain.	cjunque@ub.edu	Sala-Llonch, Roser/E-7882-2012; Bargallo, Nuria/G-6854-2016; Junque, Carme/B-4400-2011; Sala-Llonch, Roser/L-4135-2015; Vendrell, Pere/B-4392-2011	Sala-Llonch, Roser/0000-0003-3576-0475; Bargallo, Nuria/0000-0001-6284-5402; Junque, Carme/0000-0002-6381-3063; Sala-Llonch, Roser/0000-0003-3576-0475; Vendrell, Pere/0000-0001-8918-5440; Fernandez-Espejo, Davinia/0000-0001-5941-7546; Tormos Munoz, Jose Maria/0000-0002-8764-2289	MAPFRE Foundation	The authors thank MAPFRE Foundation for the financial support. We also thank Cesar Garrido from the Centre de Diagnostic per la Imatge of the Hospital Clinic (CDIC), for his assistance with data recollection.	Adams JH, 2011, J NEUROTRAUM, V28, P701, DOI 10.1089/neu.2010.1733; Ariza M, 2006, NEUROPSYCHOLOGIA, V44, P1956, DOI 10.1016/j.neuropsychologia.2005.11.007; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Bigler ED, 1996, NEUROPSYCHOLOGY, V10, P333, DOI 10.1037/0894-4105.10.3.333; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Bonnelle V, 2011, J NEUROSCI, V31, P13442, DOI 10.1523/JNEUROSCI.1163-11.2011; Buckner RL, 2008, ANN NY ACAD SCI, V1124, P1, DOI 10.1196/annals.1440.011; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Cabeza R, 2008, NAT REV NEUROSCI, V9, P613, DOI 10.1038/nrn2459; Cavanna AE, 2006, BRAIN, V129, P564, DOI 10.1093/brain/awl004; Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395; de la Plata CDM, 2011, ARCH NEUROL-CHICAGO, V68, P74, DOI 10.1001/archneurol.2010.342; Desikan RS, 2006, NEUROIMAGE, V31, P968, DOI 10.1016/j.neuroimage.2006.01.021; Ding K, 2008, J NEUROTRAUM, V25, P1433, DOI 10.1089/neu.2008.0683; Fischl B, 2001, IEEE T MED IMAGING, V20, P70, DOI 10.1109/42.906426; Fischl B, 2000, P NATL ACAD SCI USA, V97, P11050, DOI 10.1073/pnas.200033797; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; HUTTENLOCHER PR, 1990, NEUROPSYCHOLOGIA, V28, P517, DOI 10.1016/0028-3932(90)90031-I; Hutton C, 2009, NEUROIMAGE, V48, P371, DOI 10.1016/j.neuroimage.2009.06.043; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Lerch JP, 2005, NEUROIMAGE, V24, P163, DOI 10.1016/j.neuroimage.2004.07.045; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Maxwell WL, 2010, BRAIN, V133, P139, DOI 10.1093/brain/awp264; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; McCauley SR, 2010, DEV NEUROPSYCHOL, V35, P318, DOI 10.1080/87565641003696866; Merkley TL, 2008, J NEUROTRAUM, V25, P1343, DOI 10.1089/neu.2008.0615; Mori S, 2006, NEURON, V51, P527, DOI 10.1016/j.neuron.2006.08.012; Newcombe V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019214; Palacios EM, 2012, NEUROLOGY, V20, P852; Palacios EM, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-24; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Segonne F, 2007, IEEE T MED IMAGING, V26, P518, DOI 10.1109/TMI.2006.887364; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; Shaw P, 2008, J NEUROSCI, V28, P3586, DOI 10.1523/JNEUROSCI.5309-07.2008; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; Sled JG, 1998, IEEE T MED IMAGING, V17, P87, DOI 10.1109/42.668698; Smith SM, 2002, NEUROIMAGE, V17, P479, DOI 10.1006/nimg.2002.1040; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Sowell ER, 2004, J NEUROSCI, V24, P8223, DOI 10.1523/JNEUROSCI.1798-04.2004; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; Wagner AD, 2005, TRENDS COGN SCI, V9, P445, DOI 10.1016/j.tics.2005.07.001; Wang JY, 2011, NEUROLOGY, V77, P818, DOI 10.1212/WNL.0b013e31822c61d7; Warner MA, 2010, J NEUROTRAUM, V27, P2121, DOI 10.1089/neu.2010.1429; Warner MA, 2010, ARCH NEUROL-CHICAGO, V67, P1336, DOI 10.1001/archneurol.2010.149	46	74	77	0	14	ELSEVIER MASSON, CORPORATION OFFICE	PARIS	65 CAMILLE DESMOULINS CS50083 ISSY-LES-MOULINEAUX, 92442 PARIS, FRANCE	0010-9452	1973-8102		CORTEX	Cortex	MAR	2013	49	3					646	657		10.1016/j.cortex.2012.02.011			12	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	122MT	WOS:000317322900005	22482692				2021-06-18	
J	Bailey, DM; Jones, DW; Sinnott, A; Brugniaux, JV; New, KJ; Hodson, D; Marley, CJ; Smirl, JD; Ogoh, S; Ainslie, PN				Bailey, Damian M.; Jones, Daniel W.; Sinnott, Andrew; Brugniaux, Julien V.; New, Karl J.; Hodson, Danielle; Marley, Christopher J.; Smirl, Jonathan D.; Ogoh, Shigehiko; Ainslie, Philip N.			Impaired cerebral haemodynamic function associated with chronic traumatic brain injury in professional boxers	CLINICAL SCIENCE			English	Article						boxing; cerebrovascular reactivity; chronic traumatic brain injury; cortical oxygenation; dynamic cerebral autoregulation	INITIAL ORTHOSTATIC HYPOTENSION; ACUTE MOUNTAIN-SICKNESS; BLOOD-FLOW; TRANSCRANIAL DOPPLER; HEAD-INJURY; AUTOREGULATION; HUMANS; EXERCISE; OSCILLATIONS; HYPERTENSION	The present study examined to what extent professional boxing compromises cerebral haemodynamic function and its association with CTBI (chronic traumatic brain injury). A total of 12 male professional boxers were compared with 12 age-, gender- and physical fitness-matched non-boxing controls. We assessed dCA (dynamic cerebral autoregulation; thigh-cuff technique and transfer function analysis), CVRco(2) (cerebrovascular reactivity to changes in CO2: 5% CO2 and controlled hyperventilation), orthostatic tolerance (supine to standing) and neurocognitive function (psychometric tests). Blood flow velocity in the middle cerebral artery (transcranial Doppler ultrasound), mean arterial blood pressure (finger photoplethysmography), end-tidal CO2 (capnography) and cortical oxyhaemoglobin concentration (near-IR spectroscopy) were continuously measured. Boxers were characterized by fronto-temporal neurocognitive dysfunction and impaired dCA as indicated by a lower rate of regulation and autoregulatory index (P < 0.05 compared with controls). Likewise, CVRco(2) was also reduced resulting in a lower CVRco(2) range (P < 0.05 compared with controls). The latter was most marked in boxers with the highest CTBI scores and correlated against the volume and intensity of sparring during training (r = -0.84, P < 0.05). These impairments coincided with more marked orthostatic hypotension, cerebral hypoperfusion and corresponding cortical de-oxygenation during orthostatic stress (P < 0.05 compared with controls). In conclusion, these findings provide the first comprehensive evidence for chronically impaired cerebral haemodynamic function in active boxers due to the mechanical trauma incurred by repetitive, sub-concussive head impact incurred during sparring training. This may help explain why CTBI is a progressive disease that manifests beyond the active boxing career.	[Bailey, Damian M.; Jones, Daniel W.; Sinnott, Andrew; Brugniaux, Julien V.; New, Karl J.; Hodson, Danielle; Marley, Christopher J.] Univ Glamorgan, Fac Hlth Sci & Sport, Neurovasc Res Lab, Pontypridd CF37 1DL, M Glam, Wales; [Bailey, Damian M.] Aix Marseille Univ, Inst Chim Radicalaire, CNRS UMR 7273, Marseille, France; [Smirl, Jonathan D.; Ainslie, Philip N.] Univ British Columbia Okanagan, Sch Hlth & Exercise Sci, Kelowna, BC, Canada; [Ogoh, Shigehiko] Toyo Univ, Dept Biomed Engn, Saitama, Japan	Bailey, DM (corresponding author), Univ Glamorgan, Fac Hlth Sci & Sport, Neurovasc Res Lab, Pontypridd CF37 1DL, M Glam, Wales.	dbailey1@glam.ac.uk	Marley, Chris/J-3119-2019; Bailey, Damian Miles/AAQ-1840-2020	Marley, Chris/0000-0002-6757-6448; Ogoh, Shigehiko/0000-0001-5297-6468; Smirl, Jonathan/0000-0003-1054-0038; Brugniaux, Julien/0000-0001-8076-9861	J.P.R. Williams Research Fellowships	This study was funded in part by J.P.R. Williams Research Fellowships (awarded to D.M.B. to support D.H. and C.J.M.).	AASLID R, 1989, STROKE, V20, P45, DOI 10.1161/01.STR.20.1.45; Ainslie PN, 2009, AM J PHYSIOL-REG I, V296, pR1473, DOI 10.1152/ajpregu.91008.2008; Aries MJH, 2010, STROKE, V41, P2697, DOI 10.1161/STROKEAHA.110.594168; Bailey DM, 2009, J PHYSIOL-LONDON, V587, P73, DOI 10.1113/jphysiol.2008.159855; Bailey DM, 2011, EXP PHYSIOL, V96, P1196, DOI 10.1113/expphysiol.2011.060178; Bonne O, 2003, PSYCHIAT RES-NEUROIM, V124, P141, DOI 10.1016/S0925-4927(03)00109-4; Colier WNJM, 1997, CLIN PHYSIOL, V17, P83; DELPY DT, 1988, PHYS MED BIOL, V33, P1433, DOI 10.1088/0031-9155/33/12/008; Dewitt DS, 2003, J NEUROTRAUM, V20, P795, DOI 10.1089/089771503322385755; Fadel PJ, 2003, AM J PHYSIOL-HEART C, V284, pH735, DOI 10.1152/ajpheart.00246.2002; Graham MR, 2011, INT J IMMUNOPATH PH, V24, P119, DOI 10.1177/039463201102400114; Hamner JW, 2004, J PHYSIOL-LONDON, V559, P965, DOI 10.1113/jphysiol.2004.066969; Hasiloglu ZI, 2011, AM J NEURORADIOL, V32, P99, DOI 10.3174/ajnr.A2250; Hillman CH, 2008, NAT REV NEUROSCI, V9, P58, DOI 10.1038/nrn2298; Houtman S, 1999, CLIN PHYSIOL, V19, P169; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; jordan B. D., 1999, J NEUROIMAGING, V9, P59; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Jordan BD, 2000, SEMIN NEUROL, V20, P179, DOI 10.1055/s-2000-9826; Jordan BD, 1996, PHYSICIAN SPORTSMED, V24, P87, DOI 10.3810/psm.1996.05.1358; Junger EC, 1997, J NEUROSURG, V86, P425, DOI 10.3171/jns.1997.86.3.0425; Kallenberg K, 2007, J CEREBR BLOOD F MET, V27, P1064, DOI 10.1038/sj.jcbfm.9600404; KONTOS HA, 1978, AM J PHYSIOL, V234, pH371; Lang EW, 2003, CRIT CARE MED, V31, P267, DOI 10.1097/00003246-200301000-00042; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LASSEN NA, 1959, PHYSIOL REV, V39, P183; LAUTT WW, 1989, MICROVASC RES, V37, P230, DOI 10.1016/0026-2862(89)90040-X; Len TK, 2011, CLIN PHYSIOL FUNCT I, V31, P85, DOI 10.1111/j.1475-097X.2010.00990.x; Mahony PJ, 2000, STROKE, V31, P476, DOI 10.1161/01.STR.31.2.476; McCrory P, 2004, LANCET NEUROL, V3, P435, DOI 10.1016/S1474-4422(04)00810-5; Mihalik JP, 2005, J NEUROSURG, V102, P850, DOI 10.3171/jns.2005.102.5.0850; Newell DW, 1996, NEUROSURGERY, V39, P35, DOI 10.1097/00006123-199607000-00008; Ogoh S, 2003, J PHYSIOL-LONDON, V550, P317, DOI 10.1113/jphysiol.2003.041517; Provenzano FA, 2010, NUCL MED COMMUN, V31, P952, DOI 10.1097/MNM.0b013e32833e37c4; Rey A., 1942, J EXP PSYCHOL, V28, P286; Rodriguez G, 1998, ITAL J NEUROL SCI, V19, P367, DOI 10.1007/BF02341784; RODRIGUEZ G, 1983, LANCET, V2, P858; Rossen R, 1943, ARCH NEURO PSYCHIATR, V50, P510; Stojsih S, 2010, BRIT J SPORT MED, V44, P725, DOI 10.1136/bjsm.2008.052845; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Taylor JA, 1998, CIRCULATION, V98, P547, DOI 10.1161/01.CIR.98.6.547; Thomas KN, 2009, J APPL PHYSIOL, V107, P506, DOI 10.1152/japplphysiol.91650.2008; TIECKS FP, 1995, STROKE, V26, P1014, DOI 10.1161/01.STR.26.6.1014; Trites R, 1977, NEUROPSYCHOLOGICAL T; Tzeng YC, 2010, HYPERTENSION, V56, P268, DOI 10.1161/HYPERTENSIONAHA.110.152066; Unterharnscheidt F, 2003, BOXING MED ASPECTS; VANDERZEE P, 1992, ADV EXP MED BIOL, V316, P143; Wechsler D., 1989, WAIS R MANUAL; Wechsler D, 1945, J PSYCHOL, V19, P87, DOI 10.1080/00223980.1945.9917223; Wieling W, 1997, CLIN AUTONOMIC DISOR, P73; Wieling W, 2007, CLIN SCI, V112, P157, DOI 10.1042/CS20060091; Williams JR, 2008, B WORLD HEALTH ORGAN, V86, P650, DOI 10.2471/BLT.08.050955; Willie CK, 2011, J NEUROSCI METH, V196, P221, DOI 10.1016/j.jneumeth.2011.01.011; Zazryn T, 2007, SPORTS MED, V37, P467; Zhang R, 1998, AM J PHYSIOL-HEART C, V274, pH233, DOI 10.1152/ajpheart.1998.274.1.H233; Zhang R, 2002, CIRCULATION, V106, P1814, DOI 10.1161/01.CIR.0000031798.07790.FE	56	74	74	0	23	PORTLAND PRESS LTD	LONDON	CHARLES DARWIN HOUSE, 12 ROGER STREET, LONDON WC1N 2JU, ENGLAND	0143-5221	1470-8736		CLIN SCI	Clin. Sci.	FEB	2013	124	3-4					177	189		10.1042/CS20120259			13	Medicine, Research & Experimental	Research & Experimental Medicine	078FC	WOS:000314083000005	22913765				2021-06-18	
J	Elbogen, EB; Johnson, SC; Newton, VM; Straits-Troster, K; Vasterling, JJ; Wagner, HR; Beckham, JC				Elbogen, Eric B.; Johnson, Sally C.; Newton, Virginia M.; Straits-Troster, Kristy; Vasterling, Jennifer J.; Wagner, H. Ryan; Beckham, Jean C.			Criminal Justice Involvement, Trauma, and Negative Affect in Iraq and Afghanistan War Era Veterans	JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY			English	Article						veterans; criminal arrest; posttraumatic stress disorder; traumatic brain injury	POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH; SUBSTANCE USE; VIOLENCE; RISK; AGGRESSION; SYMPTOMS; BEHAVIOR; SCALE; ABUSE	Objective: Although criminal behavior in veterans has been cited as a growing problem, little is known about why some veterans are at increased risk for arrest. Theories of criminal behavior postulate that people who have been exposed to stressful environments or traumatic events and who report negative affect such as anger and irritability are at increased risk of antisocial conduct. Method: We hypothesized veterans with posttraumatic stress disorder (FTSD) or traumatic brain injury (TBI) who report anger/irritability would show higher rates of criminal arrests. To test this, we examined data in a national survey of N = 1,388 Iraq and Afghanistan war era veterans. Results: We found that 9% of respondents reported arrests since returning home from military service. Most arrests were associated with nonviolent criminal behavior resulting in incarceration for less than 2 weeks. Unadjusted bivariate analyses revealed that veterans with probable PTSD or TBI who reported anger/irritability were more likely to be arrested than were other veterans. In multivariate analyses, arrests were found to be significantly related to younger age, male gender, having witnessed family violence, prior history of arrest, alcohol/drug misuse, and PTSD with high anger/irritability but were not significantly related to combat exposure or TBI. Conclusions: Findings show that a subset of veterans with PTSD and negative affect may be at increased risk of criminal arrest. Because arrests were more strongly linked to substance abuse and criminal history, clinicians should also consider non-PTSD factors when evaluating and treating veterans with criminal justice involvement.	[Elbogen, Eric B.] Univ N Carolina, Sch Med, Forens Psychiat Program & Clin, Dept Psychiat, Chapel Hill, NC 27599 USA; [Elbogen, Eric B.; Newton, Virginia M.; Straits-Troster, Kristy; Wagner, H. Ryan; Beckham, Jean C.] Vet Affairs Midatlantic Mental Illness Res Educ &, Durham, NC USA; [Straits-Troster, Kristy; Wagner, H. Ryan; Beckham, Jean C.] Duke Univ, Med Ctr, Durham, NC 27706 USA; [Vasterling, Jennifer J.] Vet Affairs Boston Healthcare Syst, Psychol Serv, Boston, MA USA; [Vasterling, Jennifer J.] Vet Affairs Boston Healthcare Syst, Vet Affairs Natl Ctr Posttraumat Stress Disorder, Boston, MA USA; [Vasterling, Jennifer J.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02215 USA	Elbogen, EB (corresponding author), Univ N Carolina, Sch Med, Forens Psychiat Program & Clin, Dept Psychiat, CB 7167, Chapel Hill, NC 27599 USA.	eric.elbogen@unc.edu			NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01 MH080988, R01MH080988] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH080988] Funding Source: NIH RePORTER		AGNEW R, 1992, CRIMINOLOGY, V30, P475, DOI 10.1111/j.1745-9125.1992.tb01113.x; Beckham JC, 2008, MIL MED, V173, P448, DOI 10.7205/MILMED.173.5.448; Bosworth H. B., 2005, J TRAUMA PRACTICE, V3, P1, DOI DOI 10.1300/J189V03N03_01; Bradley KA, 1998, J GEN INTERN MED, V13, P379, DOI 10.1046/j.1525-1497.1998.00118.x; Burt SA, 2009, AGGRESSIVE BEHAV, V35, P453, DOI 10.1002/ab.20324; Davidson JRT, 1997, PSYCHOL MED, V27, P153, DOI 10.1017/S0033291796004229; Day Andrew, 2003, Crim Behav Ment Health, V13, P45, DOI 10.1002/cbm.530; Defense Manpower Data Center, 2010, FY2009 ANN DEM PROF; Dillman D.A., 2009, INTERNET MAIL MIXED; Elbogen EB, 2009, ARCH GEN PSYCHIAT, V66, P152, DOI 10.1001/archgenpsychiatry.2008.537; FARRINGTON DP, 1973, J CRIM LAW CRIM, V64, P99, DOI 10.2307/1142661; Forbes D, 2008, J TRAUMA STRESS, V21, P142, DOI 10.1002/jts.20315; Grafman J, 1996, NEUROLOGY, V46, P1231, DOI 10.1212/WNL.46.5.1231; Greenberg GA, 2009, PSYCHIAT QUART, V80, P41, DOI 10.1007/s11126-009-9092-8; Institute of Medicine, 2010, RET HOM IR AFGH PREL; King DW, 2003, MANUAL DEPLOYMENT RI; Kroner DG, 2005, PERS INDIV DIFFER, V38, P413, DOI 10.1016/j.paid.2004.04.019; Maschi T, 2008, YOUTH VIOLENCE JUV J, V6, P136, DOI 10.1177/1541204007305527; Mason WA, 2009, SUBST USE MISUSE, V44, P1142, DOI 10.1080/10826080802495211; McCoy K, 2010, CLIN PSYCHOL REV, V30, P317, DOI 10.1016/j.cpr.2009.12.006; McDonald SD, 2009, J ANXIETY DISORD, V23, P247, DOI 10.1016/j.janxdis.2008.07.007; National Association of Drug Court Professionals, 2011, JUST VETS NAT CLEAR; Nieves K., 2000, J OFFENDER REHABIL, V30, P133, DOI [DOI 10.1300/J076V30N03_07, 10.1300/J076v30n03_07]; Pandiani JA, 2003, LAW HUMAN BEHAV, V27, P289, DOI 10.1023/A:1023483807731; Roberton T, 2012, AGGRESS VIOLENT BEH, V17, P72, DOI 10.1016/j.avb.2011.09.006; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Russell R., 2009, NEW ENG J CRIM CIV C, V35, P357; Savarese VW, 2001, J TRAUMA STRESS, V14, P717, DOI 10.1023/A:1013038021175; Saxon AJ, 2001, PSYCHIATR SERV, V52, P959, DOI 10.1176/appi.ps.52.7.959; Schubert CA, 2011, J AM ACAD CHILD PSY, V50, P925, DOI 10.1016/j.jaac.2011.06.006; SHAW DM, 1987, COMPR PSYCHIAT, V28, P403, DOI 10.1016/0010-440X(87)90057-5; Skeem JL, 2011, LAW HUMAN BEHAV, V35, P110, DOI 10.1007/s10979-010-9223-7; SKINNER HA, 1982, ADDICT BEHAV, V7, P363, DOI 10.1016/0306-4603(82)90005-3; Taft CT, 2007, J ABNORM PSYCHOL, V116, P498, DOI 10.1037/0021-843X.116.3.498; Tanielian T, 2008, INVISIBLE WOUNDS WAR; U.S. Bureau of Justice Statistics, 2007, VET STAT FED PRIS 20; Vogt D, 2011, J ABNORM PSYCHOL, V120, P797, DOI 10.1037/a0023452	37	74	74	0	36	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0022-006X	1939-2117		J CONSULT CLIN PSYCH	J. Consult. Clin. Psychol.	DEC	2012	80	6					1097	1102		10.1037/a0029967			6	Psychology, Clinical	Psychology	047DI	WOS:000311817500013	23025247	Green Accepted			2021-06-18	
J	Johansson, B; Bjuhr, H; Ronnback, L				Johansson, B.; Bjuhr, H.; Ronnback, L.			Mindfulness-based stress reduction (MBSR) improves long-term mental fatigue after stroke or traumatic brain injury	BRAIN INJURY			English	Article						Mental fatigue; TBI; stroke; MBSR; mindfulness; information processing speed; attention	ATTENTION; SYMPTOMS; MILD; DISORDERS; IMPACT	Objective: Patients who suffer from mental fatigue after a stroke or traumatic brain injury (TBI) have a drastically reduced capacity for work and for participating in social activities. Since no effective therapy exists, the aim was to implement a novel, non-pharmacological strategy aimed at improving the condition of these patients. Methods: This study tested a treatment with mindfulness-based stress reduction (MBSR). The results of the programme were evaluated using a self-assessment scale for mental fatigue and neuropsychological tests. Eighteen participants with stroke and 11 with TBI were included. All the subjects were well rehabilitated physically with no gross impairment to cognitive functions other than the symptom mental fatigue. Fifteen participants were randomized for inclusion in the MBSR programme for 8 weeks, while the other 14 served as controls and received no active treatment. Those who received no active treatment were offered MBSR during the next 8 weeks. Results: Statistically significant improvements were achieved in the primary end-point-the self-assessment for mental fatigue-and in the secondary end-point-neuropsychological tests; Digit Symbol-Coding and Trail Making Test. Conclusion: The results from the present study show that MBSR may be a promising non-pharmacological treatment for mental fatigue after a stroke or TBI.	[Johansson, B.; Bjuhr, H.; Ronnback, L.] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Clin Neurosci & Rehabil, SE-41345 Gothenburg, Sweden	Johansson, B (corresponding author), Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Clin Neurosci & Rehabil, Dubbsgatan 14,1Tr, SE-41345 Gothenburg, Sweden.	birgitta.johansson2@vgregion.se		, Birgitta/0000-0003-0240-1142	AFA Insurance; Health & Medical Care Committee of the Region Vastra Gotaland	The authors report no conflicts of interest. This work was supported by grants from AFA Insurance and The Health & Medical Care Committee of the Region Vastra Gotaland.	Azouvi P, 2004, NEUROPSYCHOLOGIA, V42, P1260, DOI 10.1016/j.neuropsychologia.2004.01.001; Bedard M, 2003, DISABIL REHABIL, V25, P722, DOI 10.1080/0963828031000090489; Belmont A., 2006, Annales de Readaptation et de Medecine Physique, V49, P370, DOI 10.1016/j.annrmp.2006.04.018; Bushnik T, 2008, J HEAD TRAUMA REHAB, V23, P17, DOI 10.1097/01.HTR.0000308717.80590.22; Cantor JB, 2008, J HEAD TRAUMA REHAB, V23, P41, DOI 10.1097/01.HTR.0000308720.70288.af; Carlson LE, 2005, INT J BEHAV MED, V12, P278, DOI 10.1207/s15327558ijbm1204_9; Chaudhuri A, 2004, LANCET, V363, P978, DOI 10.1016/S0140-6736(04)15794-2; Colle F., 2006, Annales de Readaptation et de Medecine Physique, V49, P361, DOI 10.1016/j.annrmp.2006.04.010; Cullen M., 2011, MINDFULNESS, V2, P186, DOI [10.1007/s12671-011-0058-1, DOI 10.1007/S12671-011-0058-1]; de Groot MH, 2003, ARCH PHYS MED REHAB, V84, P1714, DOI 10.1053/S0003-9993(03)00346-0; DeLuca J, 2005, ISS CLIN COGN NEUROP, P1; Ellis DC, 2001, DELIS KAPLAN EXECUTI; Felmingham KL, 2004, NEUROPSYCHOLOGY, V18, P564, DOI 10.1037/0894-4105.18.3.564; Grossman P, 2004, J PSYCHOSOM RES, V57, P35, DOI 10.1016/S0022-3999(03)00573-7; Ingles JL, 1999, ARCH PHYS MED REHAB, V80, P173, DOI 10.1016/S0003-9993(99)90116-8; Johansson B, 2010, BRAIN INJURY, V24, P2, DOI 10.3109/02699050903452961; Johansson B, 2009, BRAIN INJURY, V23, P1027, DOI 10.3109/02699050903421099; Kabat  Zinn J, 2001, FULL FULL CATASTROPH; KABATZINN J, 1985, J BEHAV MED, V8, P163, DOI 10.1007/BF00845519; Kilpatrick LA, 2011, NEUROIMAGE, V56, P290, DOI 10.1016/j.neuroimage.2011.02.034; Kohl AD, 2009, BRAIN INJURY, V23, P420, DOI 10.1080/02699050902788519; LINDQVIST G, 1993, ACTA PSYCHIAT SCAND, V88, P5, DOI 10.1111/j.1600-0447.1993.tb05611.x; Lundin A, 2007, THESIS STOCKHOLM U S; Lutz A, 2008, TRENDS COGN SCI, V12, P163, DOI 10.1016/j.tics.2008.01.005; Madison S., 2003, LASDIAGNOS; McMillan T, 2002, NEUROPSYCHOL REHABIL, V12, P117, DOI 10.1080/09602010143000202; Moore A, 2009, CONSCIOUS COGN, V18, P176, DOI 10.1016/j.concog.2008.12.008; Naess H, 2005, CEREBROVASC DIS, V20, P245, DOI 10.1159/000087706; O'Connor C, 2005, PSYCHOL REP, V97, P169, DOI 10.2466/PR0.97.5.169-179; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Reitan RM., 1985, HALSTEAD REITAN NEUR; Rodholm M, 2001, ACTA NEUROL SCAND, V103, P379, DOI 10.1034/j.1600-0404.2001.103006379.x; Ronnback L., 2012, LONG LASTING MENTAL; Ronnback L, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-22; Schepers VP, 2006, ARCH PHYS MED REHAB, V87, P184, DOI 10.1016/j.apmr.2005.10.005; Smith BW, 2008, J ALTERN COMPLEM MED, V14, P251, DOI 10.1089/acm.2007.0641; Staub F, 2001, CEREBROVASC DIS, V12, P75, DOI 10.1159/000047685; Stulemeijer M, 2006, J NEUROL, V253, P1041, DOI 10.1007/s00415-006-0156-5; Sundstrom A, 2007, BRAIN INJURY, V21, P1049, DOI 10.1080/02699050701630367; SVANBORG P, 1994, ACTA PSYCHIAT SCAND, V89, P21, DOI 10.1111/j.1600-0447.1994.tb01480.x; Wechsler D., 2003, WECHSLER ADULT INTEL; Winward C, 2009, STROKE, V40, P757, DOI 10.1161/STROKEAHA.108.527101; Ziino C, 2006, NEUROPSYCHOLOGY, V20, P383, DOI 10.1037/0894-4105.20.3.383	43	74	81	2	79	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	DEC	2012	26	13-14					1621	1628		10.3109/02699052.2012.700082			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	041RU	WOS:000311419700008	22794665				2021-06-18	
J	Chavez-Valdez, R; Martin, LJ; Flock, DL; Northington, FJ				Chavez-Valdez, R.; Martin, L. J.; Flock, D. L.; Northington, F. J.			NECROSTATIN-1 ATTENUATES MITOCHONDRIAL DYSFUNCTION IN NEURONS AND ASTROCYTES FOLLOWING NEONATAL HYPOXIA-ISCHEMIA	NEUROSCIENCE			English	Article						astrocytes; hypoxia ischemia; mitochondria; neurons; receptor interacting protein-1 kinase; regulated necrosis	PERMEABILITY TRANSITION PORE; INDUCED CELL-DEATH; NITRIC-OXIDE; GLUTATHIONE DEPLETION; BRAIN-INJURY; PROGRAMMED NECROSIS; INDUCED NECROPTOSIS; INTRACELLULAR ATP; BNIP3 EXPRESSION; IN-VITRO	Receptor interacting protein (RIP)-1 kinase activity mediates a novel pathway that signals for regulated necrosis, a form of cell death prominent in traumatic and ischemic brain injury. Recently, we showed that an allosteric inhibitor of RIP-1 kinase activity, necrostatin-1 (Nec-1), provides neuroprotection in the forebrain following neonatal hypoxia ischemia (HI). Because Nec-1 also prevents early oxidative injury, we hypothesized that mechanisms involved in this neuroprotection may involve preservation of mitochondrial function and prevention of secondary energy failure. Therefore, our objective was to determine if Nec-1 treatment following neonatal HI attenuates oxidative stress and mitochondrial injury. Postnatal day (p) 7 mice exposed to HI were injected intracerebroventricularly with 0.1 mu L (80 mu mol) of Nec-1 or vehicle. Nec-1 treatment prevented nitric oxide (NO center dot), inducible nitric oxide synthase (iNOS) and 3-nitrotyrosine increase, and attenuated glutathione oxidation that was found in vehicle-treated mice at 3 h following HI. Similarly, Nec-1 following HI prevented: (i) up-regulation of hypoxia inducible factor-1 alpha (HIF-1 alpha) and BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 (BNIP3) expression, (ii) decline in mitochondrial complex-I activity, (iii) decrease in ATP levels, and (iv) mitochondrial structural pathology in astrocytes and in neurons. Up-regulation of glial fibrillary acidic protein (GFAP) following HI was also prevented by Nec-1 treatment. No differences by gender were observed. We conclude that Nec-1 immediately after HI, is strongly mitoprotective and prevents secondary energy failure by blocking early NO center dot accumulation, glutathione oxidation and attenuating mitochondrial dysfunction. (C) 2012 IBRO. Published by Elsevier Ltd. All rights reserved.	[Chavez-Valdez, R.] Johns Hopkins Univ, Johns Hopkins Med Inst, Johns Hopkins Hosp, Div Neonatol,Sch Med,Dept Pediat, Baltimore, MD 21287 USA; [Chavez-Valdez, R.] Texas Tech Univ, Div Neonatol, Dept Pediat, Hlth Sci Ctr, Odessa, TX 79763 USA; [Martin, L. J.] Johns Hopkins Univ, Div Neuropathol, Dept Pathol, Sch Med, Baltimore, MD 21205 USA; [Martin, L. J.] Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA	Chavez-Valdez, R (corresponding author), Johns Hopkins Univ, Johns Hopkins Med Inst, Johns Hopkins Hosp, Div Neonatol,Sch Med,Dept Pediat, 600 N Wolfe St,CMSC 6-104, Baltimore, MD 21287 USA.	chavezva@gmail.com; frances@jhmi.edu		Chavez-Valdez, Raul/0000-0002-0788-8028	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG 016282, R01 AG016282] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD074593, R01 HD070996] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21 NS059529, NS 059529] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD074593, R01HD070996] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS059529] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG016282] Funding Source: NIH RePORTER		An HJ, 2006, J BIOL CHEM, V281, P33939, DOI 10.1074/jbc.M605819200; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; Beltran B, 2000, P NATL ACAD SCI USA, V97, P14602, DOI 10.1073/pnas.97.26.14602; Blomgren K, 2006, FREE RADICAL BIO MED, V40, P388, DOI 10.1016/j.freeradbiomed.2005.08.040; Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082; Chinta SJ, 2006, FREE RADICAL BIO MED, V41, P1442, DOI 10.1016/j.freeradbiomed.2006.08.002; Cho Y, 2009, CELL, V137, P1112, DOI 10.1016/j.cell.2009.05.037; Davis CW, 2010, FREE RADICAL BIO MED, V48, P306, DOI 10.1016/j.freeradbiomed.2009.11.001; Degterev A, 2005, NAT CHEM BIOL, V1, P112, DOI 10.1038/nchembio711; Eguchi Y, 1997, CANCER RES, V57, P1835; Faraco G, 2007, J NEUROCHEM, V103, P590, DOI 10.1111/j.1471-4159.2007.04788.x; Festjens N, 2006, BBA-BIOENERGETICS, V1757, P1371, DOI 10.1016/j.bbabio.2006.06.014; Galluzzi L, 2011, INT REV CEL MOL BIO, V289, P1, DOI 10.1016/B978-0-12-386039-2.00001-8; Ghavami S, 2009, BBA-MOL CELL RES, V1793, P546, DOI 10.1016/j.bbamcr.2009.01.002; Graham EM, 2004, NEUROBIOL DIS, V17, P89, DOI 10.1016/j.nbd.2004.05.007; Hagberg H, 2004, J BIOENERG BIOMEMBR, V36, P369, DOI 10.1023/B:JOBB.0000041770.00567.4f; Hagberg H, 2004, J NEUROCHEM, V90, P1068, DOI 10.1111/j.1471-4159.2004.02547.x; Han WD, 2009, APOPTOSIS, V14, P674, DOI 10.1007/s10495-009-0334-x; Hewett SJ, 1996, STROKE, V27, P1586, DOI 10.1161/01.STR.27.9.1586; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; Hsu TS, 2009, TOXICOL APPL PHARM, V235, P153, DOI 10.1016/j.taap.2008.12.012; Kim Sunja, 2010, Int J Physiol Pathophysiol Pharmacol, V2, P137; Kubli DA, 2008, AM J PHYSIOL-HEART C, V295, pH2025, DOI 10.1152/ajpheart.00552.2008; Laird MD, 2008, FREE RADICAL BIO MED, V45, P1103, DOI 10.1016/j.freeradbiomed.2008.07.003; Leist M, 1999, EXP CELL RES, V249, P396, DOI 10.1006/excr.1999.4514; Lim SY, 2007, CARDIOVASC DRUG THER, V21, P467, DOI 10.1007/s10557-007-6067-6; MARKOVIC SN, 1993, CELL IMMUNOL, V151, P474, DOI 10.1006/cimm.1993.1256; Nicotera P, 1998, TOXICOL LETT, V103, P139; Nicotera P, 1999, J CEREBR BLOOD F MET, V19, P583, DOI 10.1097/00004647-199906000-00001; Northington FJ, 2007, NEUROSCIENCE, V149, P822, DOI 10.1016/j.neuroscience.2007.06.060; Northington FJ, 2011, ANN NEUROL, V69, P743, DOI 10.1002/ana.22419; Northington FJ, 2011, J CEREBR BLOOD F MET, V31, P178, DOI 10.1038/jcbfm.2010.72; Northington Frances J., 1996, Developmental Brain Research, V95, P1, DOI 10.1016/0165-3806(96)00051-X; Pfaffl MW, 2004, BIOTECHNOL LETT, V26, P509, DOI 10.1023/B:BILE.0000019559.84305.47; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; PorteraCailliau C, 1997, J COMP NEUROL, V378, P70; Riobo NA, 2001, BIOCHEM J, V359, P139, DOI 10.1042/0264-6021:3590139; Smith CCT, 2007, CARDIOVASC DRUG THER, V21, P227, DOI 10.1007/s10557-007-6035-1; Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000; Vannucci RC, 1998, J NEUROCHEM, V71, P1215; Xu XS, 2007, J NEUROCHEM, V103, P2004, DOI 10.1111/j.1471-4159.2007.04884.x; YAGER JY, 1991, AM J PHYSIOL, V261, pH1102; Yook YH, 2004, BIOCHEM BIOPH RES CO, V321, P298, DOI 10.1016/j.bbrc.2004.06.144; Zhu CL, 2006, J NEUROCHEM, V96, P1016, DOI 10.1111/j.1471-4159.2005.03639.x	44	74	78	0	19	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522			NEUROSCIENCE	Neuroscience	SEP 6	2012	219						192	203		10.1016/j.neuroscience.2012.05.002			12	Neurosciences	Neurosciences & Neurology	987KY	WOS:000307417000018	22579794	Green Accepted			2021-06-18	
J	Dalgard, CL; Cole, JT; Kean, WS; Lucky, JJ; Sukumar, G; McMullen, DC; Pollard, HB; Watson, WD				Dalgard, Clifton L.; Cole, Jeffrey T.; Kean, William S.; Lucky, Jessica J.; Sukumar, Gauthaman; McMullen, David C.; Pollard, Harvey B.; Watson, William D.			The cytokine temporal profile in rat cortex after controlled cortical impact	FRONTIERS IN MOLECULAR NEUROSCIENCE			English	Article						traumatic brain injury; cytokines; inflammation; IL-8; inflammatory response	TRAUMATIC BRAIN-INJURY; MACROPHAGE INFLAMMATORY PROTEIN-3-ALPHA/CCL20; MONOCYTE CHEMOATTRACTANT PROTEIN-1; TUMOR-NECROSIS-FACTOR; CLOSED-HEAD INJURY; INTERFERON-GAMMA; UP-REGULATION; NITRIC-OXIDE; METABOLISM; INTERLEUKIN-1-BETA	Cerebral inflammatory responses may initiate secondary cascades following traumatic brain injury (TBI). Changes in the expression of both cytokines and chemokines may activate, regulate, and recruit innate and adaptive immune cells associated with secondary degeneration, as well as alter a host of other cellular processes. In this study, we quantified the temporal expression of a large set of inflammatory mediators in rat cortical tissue after brain injury. Following a controlled cortical impact (CCI) on young adult male rats, cortical and hippocampal tissue of the injured hemisphere and matching contralateral material was harvested at early (4, 12, and 24 hours) and extended (3 and 7 days) time points post-procedure. Naive rats that received only anesthesia were used as controls. Processed brain homogenates were assayed for chemokine and cytokine levels utilizing an electrochemiluminescence-based multiplex ELISA platform. The temporal profile of cortical tissue samples revealed a multi phasic injury response following brain injury. CXCL1, IFN-y, TNF-cc levels significantly peaked at four hours post-injury compared to levels found in naive or contralateral tissue. CXCL1, IFN-y, and INF-ct levels were then observed to decrease at least 3-fold by 12 hours post-injury. IL-4, and IL-13 levels were also significantly elevated at four hours post injury although their expression did not decrease more than 3-fold for up to 24 hours post injury. Additionally, IL -1 and IL -4 levels displayed a biphasic temporal profile in response to injury, which may suggest their involvement in adaptive immune responses. Interestingly, peak levels of CCL2 and CCL20 were not observed until after four hours post-injury. CCL2 levels in injured cortical tissue were significantly higher than peak levels of any other inflammatory mediator measured, thus suggesting a possible use as a biomarker. Fully elucidating chemokine and cytokine signaling properties after brain injury may provide increased insight into a number of secondary cascade events that are initiated or regulated by inflammatory responses.	[Dalgard, Clifton L.; Sukumar, Gauthaman; Pollard, Harvey B.] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA; [Cole, Jeffrey T.; Kean, William S.; Lucky, Jessica J.; McMullen, David C.; Watson, William D.] Uniformed Serv Univ Hlth Sci, Dept Neurol, Bethesda, MD 20814 USA	Cole, JT (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Neurol, B-3012,4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	jeffrey.cole@usuhs.mil	Sukumar, Gauthaman/A-1697-2018		Comprehensive National Neuroscience Program (CNNP) [W81XWH-07-0679]	This work was supported in part by the Comprehensive National Neuroscience Program (CNNP, award number W81XWH-07-0679).	Adeleye A, 2010, EUR J PHARMACOL, V629, P25, DOI 10.1016/j.ejphar.2009.11.066; Alves OL, 2005, J NEUROTRAUM, V22, P733, DOI 10.1089/neu.2005.22.733; Ambrosini E, 2003, GLIA, V41, P290, DOI 10.1002/glia.10193; Arcure Jess, 2009, J Spec Oper Med, V9, P22; Bartnik BL, 2007, J NEUROTRAUM, V24, P1079, DOI 10.1089/neu.2006.0210; Bogdan C, 1997, J IMMUNOL, V159, P4506; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Chowdhury F, 2009, J IMMUNOL METHODS, V340, P55, DOI 10.1016/j.jim.2008.10.002; Cole JT, 2011, J NEUROTRAUM, V28, P359, DOI 10.1089/neu.2010.1427; Cole JT, 2010, P NATL ACAD SCI USA, V107, P366, DOI 10.1073/pnas.0910280107; Deshpande LS, 2008, NEUROSCI LETT, V441, P115, DOI 10.1016/j.neulet.2008.05.113; Fassbender K, 2000, NEUROSCI LETT, V284, P135, DOI 10.1016/S0304-3940(00)00977-0; Finkelstein EA., 2006, INCIDENCE EC BURDEN; Fu Q, 2010, CLIN CHEM, V56, P314, DOI 10.1373/clinchem.2009.135087; Faria MHG, 2007, ACTA CIR BRAS, V22, P125, DOI 10.1590/S0102-86502007000200009; Glabinski AR, 1996, J IMMUNOL, V156, P4363; Harting MT, 2008, SURGERY, V144, P803, DOI 10.1016/j.surg.2008.05.017; Helmy A, 2011, J CEREBR BLOOD F MET, V31, P658, DOI 10.1038/jcbfm.2010.142; Helmy A, 2009, J NEUROTRAUM, V26, P549, DOI 10.1089/neu.2008.0719; Hulshof S, 2002, GLIA, V38, P24, DOI 10.1002/glia.10050; Karaoglan A, 2011, ULUS TRAVMA ACIL CER, V17, P298, DOI 10.5505/tjtes.2011.69077; Kawanokuchi J, 2006, MULT SCLER J, V12, P558, DOI 10.1177/1352458506070763; KIM KS, 1992, LYMPHOKINE CYTOK RES, V11, P293; Kinoshita K, 2002, NEUROSURGERY, V51, P195, DOI 10.1097/00006123-200207000-00027; Krzysiek R, 2000, BLOOD, V96, P2338, DOI 10.1182/blood.V96.7.2338.h8002338_2338_2345; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Muessel MJ, 2000, BRAIN RES, V870, P211, DOI 10.1016/S0006-8993(00)02450-1; Mukherjee S, 2011, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00021; Paludan SR, 1997, FEBS LETT, V414, P61, DOI 10.1016/S0014-5793(97)00987-3; Ponomarev ED, 2007, J NEUROSCI, V27, P10714, DOI 10.1523/JNEUROSCI.1922-07.2007; RAMILO O, 1990, J EXP MED, V172, P497, DOI 10.1084/jem.172.2.497; Rancan M, 2001, J NEUROSCI RES, V63, P438, DOI 10.1002/1097-4547(20010301)63:5<438::AID-JNR1039>3.0.CO;2-P; Rostworowski M, 1997, J NEUROSCI, V17, P3664; Scafidi S, 2009, J NEUROCHEM, V109, P189, DOI 10.1111/j.1471-4159.2009.05896.x; Semple BD, 2010, NEUROBIOL DIS, V40, P394, DOI 10.1016/j.nbd.2010.06.015; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Sun DA, 2008, EUR J NEUROSCI, V27, P1659, DOI 10.1111/j.1460-9568.2008.06156.x; Suzuki Y, 2005, INT J PARASITOL, V35, P83, DOI 10.1016/j.ijpara.2004.10.020; Takamiya M, 2007, J NEUROTRAUM, V24, P1833, DOI 10.1089/neu.2007.0336; Tehranian R, 2002, J NEUROTRAUM, V19, P939, DOI 10.1089/089771502320317096; Wei HH, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-19; Whalen MJ, 2000, CRIT CARE MED, V28, P929, DOI 10.1097/00003246-200004000-00003; Xiao-Sheng H, 2004, J CLIN NEUROSCI, V11, P402, DOI 10.1016/j.jocn.2004.01.001; Xing GQ, 2009, NEUROSCI LETT, V454, P38, DOI 10.1016/j.neulet.2009.01.047; Xiong Y, 2009, NEUROL RES, V31, P496, DOI 10.1179/174313208X353703; Yatsiv I, 2002, J CEREBR BLOOD F MET, V22, P971, DOI 10.1097/00004647-200208000-00008; Zhao WH, 2006, J NEUROCHEM, V99, P1176, DOI 10.1111/j.1471-4159.2006.04172.x; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	49	74	77	0	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-5099			FRONT MOL NEUROSCI	Front. Molec. Neurosci.		2012	5								6	10.3389/fnmol.2012.00006			10	Neurosciences	Neurosciences & Neurology	V36HD	WOS:000209202600006	22291617	DOAJ Gold, Green Published			2021-06-18	
J	Kan, LX; Lounev, VY; Pignolo, RJ; Duan, LH; Liu, YJ; Stock, SR; McGuire, TL; Lu, B; Gerard, NP; Shore, EM; Kaplan, FS; Kessler, JA				Kan, Lixin; Lounev, Vitali Y.; Pignolo, Robert J.; Duan, Lishu; Liu, Yijie; Stock, Stuart R.; McGuire, Tammy L.; Lu, Bao; Gerard, Norma P.; Shore, Eileen M.; Kaplan, Frederick S.; Kessler, John A.			Substance P Signaling Mediates BMP-Dependent Heterotopic Ossification	JOURNAL OF CELLULAR BIOCHEMISTRY			English	Article						HETEROTOPIC OSSIFICATION (HO); FIBRODYSPLASIA OSSIFICANS PROGRESSIVA (FOP); BONE MORPHOGENETIC PROTEIN (BMP); SUBSTANCE P (SP); TACHYKININ RECEPTOR 1 (NK1R); NK1R ANTAGONIST; MAST CELLS	TACHYKININ NK1 RECEPTOR; TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; DORSAL-ROOT GANGLION; MAST-CELLS; NEUROGENIC INFLAMMATION; IMMUNE INTERACTIONS; MESSENGER-RNA; NK-1 RECEPTOR; SPINAL-CORD	Heterotopic ossification (HO) is a disabling condition associated with neurologic injury, inflammation, and overactive bone morphogenetic protein (BMP) signaling. The inductive factors involved in lesion formation are unknown. We found that the expression of the neuro-inflammatory factor Substance P (SP) is dramatically increased in early lesional tissue in patients who have either fibrodysplasia ossificans progressiva (FOP) or acquired HO, and in three independent mouse models of HO. In Nse-BMP4, a mouse model of HO, robust HO forms in response to tissue injury; however, null mutations of the preprotachykinin (PPT) gene encoding SP prevent HO. Importantly, ablation of SP+ sensory neurons, treatment with an antagonist of SP receptor NK1r, deletion of NK1r gene, or genetic down-regulation of NK1r-expressing mast cells also profoundly inhibit injury-induced HO. These observations establish a potent neuro-inflammatory induction and amplification circuit for BMP-dependent HO lesion formation, and identify novel molecular targets for prevention of HO. J. Cell. Biochem. 112: 2759-2772, 2011. (C) 2011 Wiley-Liss, Inc.	[Kan, Lixin; Duan, Lishu; Liu, Yijie; McGuire, Tammy L.; Kessler, John A.] Northwestern Univ, Feinberg Sch Med, Dept Neurol, Chicago, IL 60611 USA; [Lounev, Vitali Y.; Pignolo, Robert J.; Shore, Eileen M.; Kaplan, Frederick S.] Univ Penn, Dept Orthopaed Surg, Perelman Sch Med, Philadelphia, PA 19104 USA; [Lounev, Vitali Y.; Pignolo, Robert J.; Shore, Eileen M.; Kaplan, Frederick S.] Univ Penn, Ctr Res FOP & Related Disorders, Perelman Sch Med, Philadelphia, PA 19104 USA; [Stock, Stuart R.] Northwestern Univ, Feinberg Sch Med, Dept Mol Pharmacol & Biol Chem, Chicago, IL 60611 USA; [Pignolo, Robert J.; Kaplan, Frederick S.] Univ Penn, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA; [Lu, Bao; Gerard, Norma P.] Childrens Hosp, Boston, MA 02215 USA; [Shore, Eileen M.] Univ Penn, Dept Genet, Perelman Sch Med, Philadelphia, PA 19104 USA	Kan, LX (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Neurol, Ward Bldg 10-233,303 E Chicago Ave, Chicago, IL 60611 USA.	l-kan@northwestern.edu	kan, lixin/I-6665-2013		Center for Research in FOP and Related Disorders; International FOP Association; Ian Cali Endowment; Weldon Family Endowment; Penn Center for Musculoskeletal Disorders; Rita Allen Foundation; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01-AR041916, NS20013, NS20778]; Center for Research in FOP and Related Disorders of The University of Pennsylvania School of Medicine; Center for Research in FOP and Related Disorders at The Perelman School of Medicine of The University of Pennsylvania; Orthopaedic Molecular Medicine; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [U54CA151880] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [R01AR041916] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS020013, R01NS020778] Funding Source: NIH RePORTER	Grant sponsor: Center for Research in FOP and Related Disorders; Grant sponsor: International FOP Association; Grant sponsor: Ian Cali Endowment; Grant sponsor: Weldon Family Endowment; Grant sponsor: Penn Center for Musculoskeletal Disorders; Grant sponsor: The Isaac & Rose Nassau Professorship of Orthopaedic Molecular Medicine; Grant sponsor: Rita Allen Foundation; Grant sponsor: NIH; Grant numbers: R01-AR041916, NS20013, NS20778.; We appreciate the help from many members of the Kessler lab, the assistance provided by CCM Animal Health Technicians in the acquisition of digital radiographs, and the professional help provided by Dr. Xiao-Qi Wang of Department of Dermatology, Northwestern University. We thank Dr. Mary Ann Keenan and Dr. John Esterhai in the Department of Orthopaedic Surgery, University of Pennsylvania, for samples of acquired HO. LK was supported in part by grants to from The Center for Research in FOP and Related Disorders of The University of Pennsylvania School of Medicine. JAK was supported by NIH grants NS20013 and NS20778. This work was also supported in part by the Center for Research in FOP and Related Disorders at The Perelman School of Medicine of The University of Pennsylvania, the International FOP Association, the Ian Cali Endowment, the Weldon Family Endowment, the Penn Center for Musculoskeletal Disorders, The Isaac & Rose Nassau Professorship of Orthopaedic Molecular Medicine and by grants from the Rita Allen Foundation and the NIH (R01-AR041916) to FSK and EMS. Author contributions: LK: conception and design, collection and assembly of data, data analysis and interpretation, manuscript writing, final approval of manuscript; SRS, RJP, EMS, and FSK: provision of study material, technical advice, data analysis, and manuscript editing, VYL, LD, YL, and TM: collection and/or assembly of data; BL and NPG: provision of study material; JAK: data analysis, manuscript editing, approval of manuscript.	Allison SJ, 2009, J BONE MINER RES, V24, P294, DOI 10.1359/JBMR.081013; Andoh T, 1996, MOL BRAIN RES, V35, P329, DOI 10.1016/0169-328X(95)00244-M; BARBUT D, 1981, BRAIN RES, V205, P289, DOI 10.1016/0006-8993(81)90340-1; BARR AJ, 1993, BRIT J PHARMACOL, V108, P223, DOI 10.1111/j.1476-5381.1993.tb13466.x; Bergstrom J, 2006, J ORTHOP RES, V24, P1193, DOI 10.1002/jor.20132; Bozic CR, 1996, SCIENCE, V273, P1722, DOI 10.1126/science.273.5282.1722; Cao YQ, 1998, NATURE, V392, P390; Castagliuolo I, 1998, J CLIN INVEST, V101, P1547, DOI 10.1172/JCI2039; Castagliuolo I, 1997, P NATL ACAD SCI USA, V94, P4788, DOI 10.1073/pnas.94.9.4788; Cullen N, 2009, J HEAD TRAUMA REHAB, V24, P69, DOI 10.1097/HTR.0b013e31819a8fcc; Czura CJ, 2005, J INTERN MED, V257, P156, DOI 10.1111/j.1365-2796.2004.01442.x; Datar P, 2004, CURR TOP MED CHEM, V4, P75, DOI 10.2174/1568026043451636; Donkin JJ, 2007, PROG BRAIN RES, V161, P97, DOI 10.1016/S0079-6123(06)61007-8; Donkin JJ, 2009, J CEREBR BLOOD F MET, V29, P1388, DOI 10.1038/jcbfm.2009.63; DUTTLINGER R, 1993, DEVELOPMENT, V118, P705; Edoff K, 1997, ANAT EMBRYOL, V195, P531, DOI 10.1007/s004290050073; Folgueras AR, 2009, P NATL ACAD SCI USA, V106, P16451, DOI 10.1073/pnas.0908507106; Forsberg Jonathan Agner, 2010, J Surg Orthop Adv, V19, P54; FORSSPETTER S, 1990, NEURON, V5, P187, DOI 10.1016/0896-6273(90)90308-3; Freeman TA, 2010, FIBROGENESIS TISSUE, V3, DOI 10.1186/1755-1536-3-17; Gannon FH, 2001, HUM PATHOL, V32, P842, DOI 10.1053/hupa.2001.26464; Goto T, 1998, CELL TISSUE RES, V293, P87, DOI 10.1007/s004410051100; Goto T, 2002, MICROSC RES TECHNIQ, V58, P91, DOI 10.1002/jemt.10123; Goto Tetsuya, 2001, Medical Electron Microscopy, V34, P77; HARMAR A, 1982, BRAIN RES, V231, P379, DOI 10.1016/0006-8993(82)90374-2; HEDBERG A, 1995, ANAT EMBRYOL, V192, P247; HOLZERPETSCHE U, 1995, BRIT J PHARMACOL, V115, P486, DOI 10.1111/j.1476-5381.1995.tb16359.x; Hong HS, 2009, NAT MED, V15, P425, DOI 10.1038/nm.1909; KAKU Y, 1993, J CEREBR BLOOD F MET, V13, P402, DOI 10.1038/jcbfm.1993.54; Kan LX, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/309287; Kan LX, 2009, STEM CELLS, V27, P150, DOI 10.1634/stemcells.2008-0576; Kan LX, 2004, AM J PATHOL, V165, P1107, DOI 10.1016/S0002-9440(10)63372-X; Kaplan FS, 2008, J BONE MINER METAB, V26, P521, DOI 10.1007/s00774-008-0879-8; Kaplan FS, 2007, J BONE JOINT SURG AM, V89A, P347, DOI 10.2106/JBJS.F.00472; Kennedy PGE, 1997, P NATL ACAD SCI USA, V94, P4167, DOI 10.1073/pnas.94.8.4167; Kulka M, 2008, IMMUNOLOGY, V123, P398, DOI 10.1111/j.1365-2567.2007.02705.x; LEE KF, 1992, CELL, V69, P737, DOI 10.1016/0092-8674(92)90286-L; Lerner U. H., 2008, Journal of Musculoskeletal & Neuronal Interactions, V8, P154; Li JA, 2010, J ORTHOP RES, V28, P1643, DOI 10.1002/jor.21169; Madsen JE, 1998, CLIN ORTHOP RELAT R, P230; Malin SA, 2007, NAT PROTOC, V2, P152, DOI 10.1038/nprot.2006.461; MANTYH PW, 1991, ANN NY ACAD SCI, V632, P263, DOI 10.1111/j.1749-6632.1991.tb33114.x; Marques-Deak A, 2005, MOL PSYCHIATR, V10, P239, DOI 10.1038/sj.mp.4001643; MCGILLIS JP, 1987, FED PROC, V46, P196; Medici D, 2010, NAT MED, V16, P1400, DOI 10.1038/nm.2252; Millward-Sadler SJ, 2003, ARTHRITIS RHEUM, V48, P146, DOI 10.1002/art.10711; MOUSSAOUI SM, 1993, BRIT J PHARMACOL, V109, P259, DOI 10.1111/j.1476-5381.1993.tb13562.x; Mukhopadhyay A, 2009, DEVELOPMENT, V136, P2633, DOI 10.1242/dev.034439; NAGY JI, 1981, NEUROSCIENCE, V6, P1923, DOI 10.1016/0306-4522(81)90032-4; NAKAYA Y, 1994, J COMP NEUROL, V347, P249, DOI 10.1002/cne.903470208; Nathan C, 2002, NATURE, V420, P846, DOI 10.1038/nature01320; NAUKKARINEN A, 1994, INT J DERMATOL, V33, P361, DOI 10.1111/j.1365-4362.1994.tb01069.x; Nelson DA, 2004, FRONT BIOSCI-LANDMRK, V9, P2166, DOI 10.2741/1372; OCHS S, 1978, J NEUROBIOL, V9, P465, DOI 10.1002/neu.480090606; Okada T, 1999, INFLAMM RES, V48, P274, DOI 10.1007/s000110050459; PAULSON JC, 1975, ANN NY ACAD SCI, V253, P517, DOI 10.1111/j.1749-6632.1975.tb19225.x; Pinto FM, 2004, EUR J PHARMACOL, V494, P233, DOI 10.1016/j.ejphar.2004.05.016; Quartara L, 1998, NEUROPEPTIDES, V32, P1, DOI 10.1016/S0143-4179(98)90015-4; REINSHAGEN M, 1994, GASTROENTEROLOGY, V106, P1208, DOI 10.1016/0016-5085(94)90011-6; Rowley D A, 1980, Contemp Top Immunobiol, V9, P205; Saban R, 2002, AM J PHYSIOL-RENAL, V283, pF616, DOI 10.1152/ajprenal.00096.2002; Salisbury E, 2010, CRIT REV EUKAR GENE, V20, P313, DOI 10.1615/CritRevEukarGeneExpr.v20.i4.30; Savastano S, 1994, Acta Neurol (Napoli), V16, P206; SAWYER JR, 1991, CALCIFIED TISSUE INT, V49, P208, DOI 10.1007/BF02556120; SHARMA HS, 1990, NEUROSCIENCE, V38, P205, DOI 10.1016/0306-4522(90)90386-I; SHEPHEARD SL, 1993, BRIT J PHARMACOL, V108, P11, DOI 10.1111/j.1476-5381.1993.tb13432.x; Shore EM, 2006, NAT GENET, V38, P525, DOI 10.1038/ng1783; Stock SR, 2004, J STRUCT BIOL, V147, P185, DOI 10.1016/j.jsb.2004.03.003; Sugimoto T, 1998, BRAIN RES, V807, P147, DOI 10.1016/S0006-8993(98)00788-4; Suzuki A, 2004, BIOL PHARM BULL, V27, P1891, DOI 10.1248/bpb.27.1891; Thornton E, 2010, MOLECULES, V15, P6598, DOI 10.3390/molecules15096598; Tracey KJ, 2002, NATURE, V420, P853, DOI 10.1038/nature01321; Wang LP, 2009, BONE, V45, P309, DOI 10.1016/j.bone.2009.04.203; YANO H, 1989, J CLIN INVEST, V84, P1276, DOI 10.1172/JCI114295; Yu PB, 2008, NAT MED, V14, P1363, DOI 10.1038/nm.1888; Zubrzycka M, 2000, Endocr Regul, V34, P195	76	74	79	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0730-2312	1097-4644		J CELL BIOCHEM	J. Cell. Biochem.	OCT	2011	112	10					2759	2772		10.1002/jcb.23259			14	Biochemistry & Molecular Biology; Cell Biology	Biochemistry & Molecular Biology; Cell Biology	829YP	WOS:000295623300014	21748788	Green Accepted			2021-06-18	
J	Schochl, H; Solomon, C; Traintinger, S; Nienaber, U; Tacacs-Tolnai, A; Windhofer, C; Bahrami, S; Voelckel, W				Schoechl, Herbert; Solomon, Cristina; Traintinger, Stefan; Nienaber, Ulrike; Tacacs-Tolnai, Astrid; Windhofer, Christian; Bahrami, Soheyl; Voelckel, Wolfgang			Thromboelastometric (ROTEM) Findings in Patients Suffering from Isolated Severe Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						brain injury; clotting time; maximum clot firmness; thromboelastometry	HEAD-INJURY; POSTINJURY COAGULOPATHY; FIBRINOGEN CONCENTRATE; MANAGEMENT; THROMBELASTOGRAPHY; HEMORRHAGE; LEVEL	Severe traumatic brain injury (sTBI) is often accompanied by coagulopathy and an increased risk of bleeding. To identify and successfully treat bleeding disorders associated with sTBI, rapid assessment of coagulation status is crucial. This retrospective study was designed to assess the potential role of whole-blood thromboelastometry (ROTEM (R), Tem International, Munich, Germany) in patients with isolated sTBI (abbreviated injury scale [AIS](head) >= 3 and AIS(extracranial) < 3). Blood samples were obtained immediately following admission to the emergency room of the Trauma Centre Salzburg in Austria. ROTEM analysis (EXTEM, INTEM, and FIBTEM tests) and standard laboratory coagulation tests (prothrombin time index [PTI, percentage of normal prothrombin time], activated partial thromboplastin time [aPTT], fibrinogen concentration, and platelet count) were compared between survivors and non-survivors. Out of 88 patients with sTBI enrolled in the study, 66 survived and 22 died. PTI, fibrinogen, and platelet count were significantly higher in survivors (p < 0.005). Accordingly, aPTT was shorter in this group (p < 0.0001). ROTEM analysis revealed shorter clotting times in extrinsically activated thromboelastometric test (EXTEM) and intrinsically activated thromboelastometric test (INTEM) (p < 0.001), shorter clot formation times in EXTEM and INTEM (p < 0.0001), and higher maximum clot firmness in EXTEM, INTEM, and FIBTEM (p < 0.01) in survivors compared with non-survivors. Logistic regression analysis revealed extrinsically activated thromboelastometric test with cytochalasin D (FIBTEM) MCF and aPTT to have the best predictive value for mortality. According to the degree of coagulopathy, non-survivors received more RBC (p = 0.016), fibrinogen concentrate (p = 0.01), and prothrombin complex concentrate (p < 0.001) within 24 h of arrival in the emergency room. ROTEM testing appeared to offer an early signal of severe life-threatening sTBI. Further studies are warranted to confirm these results and to investigate the role of ROTEM in guiding coagulation therapy.	[Schoechl, Herbert; Bahrami, Soheyl] Ludwig Boltzmann Inst Expt & Clin Traumatol, A-1200 Vienna, Austria; [Schoechl, Herbert; Bahrami, Soheyl] AUVA Res Ctr, Vienna, Austria; [Schoechl, Herbert; Solomon, Cristina; Traintinger, Stefan; Voelckel, Wolfgang] AUVA Trauma Ctr, Dept Anaesthesiol & Intens Care Med, Salzburg, Austria; [Tacacs-Tolnai, Astrid; Windhofer, Christian] AUVA Trauma Ctr, Dept Trauma Surg, Salzburg, Austria; [Solomon, Cristina] Salzburg Univ Hosp SALK, Dept Anaesthesiol Intens Care & Perioperat Med, Salzburg, Austria; [Nienaber, Ulrike] AUC Akad Unfallchirurg GmbH, Munich, Germany	Schochl, H (corresponding author), Ludwig Boltzmann Inst Expt & Clin Traumatol, Donaueschingenstr 13, A-1200 Vienna, Austria.	herbert.schoechl@trauma.lbg.ac.at		Bahrami, Soheyl/0000-0002-4563-6251	CSL Behring; GlaxoSmithKlineGlaxoSmithKline; Tem International	Herbert Schochl has received speaker's fees from CSL Behring, GlaxoSmithKline, and Tem International. Cristina Solomon has received speaker's fees from CSL Behring and Tem International. All other authors declare that no competing financial interests exist. H.S. contributed to the design of the study, analysis of the results, interpretation of the data, and manuscript draft. Authors C.S., S.T., A.T., A.T.T., and C.W. were involved in drafting the manuscript. U.N. performed statistical analyses and contributed to the manuscript. H.R., S.B., and W.V. contributed to drafting and critically revising the manuscript. All authors read and approved the final manuscript.	Carrick MM, 2005, J TRAUMA, V58, P725, DOI 10.1097/01.TA.0000159249.68363.78; Cohan MJ, 2007, J TRAUMA, V63, P1254, DOI 10.1097/TA.0b013e318156ee4c; Dzik Walter H, 2004, Curr Hematol Rep, V3, P324; Furtmuller R, 2002, J PHARMACOL EXP THER, V301, P168, DOI 10.1124/jpet.301.1.168; Gerlach R, 2002, STROKE, V33, P1618, DOI 10.1161/01.STR.0000017219.83330.FF; GOODNIGHT SH, 1974, NEW ENGL J MED, V290, P1043, DOI 10.1056/NEJM197405092901903; Huissoud C, 2009, BJOG-INT J OBSTET GY, V116, P1097, DOI 10.1111/j.1471-0528.2009.02187.x; Johansson PI, 2009, SCAND J TRAUMA RESUS, V17, DOI 10.1186/1757-7241-17-45; Johansson PI, 2010, BLOOD COAGUL FIBRIN, V21, P168, DOI 10.1097/MBC.0b013e3283367882; Kashuk JL, 2010, ANN SURG, V252, P434, DOI 10.1097/SLA.0b013e3181f09191; Kashuk JL, 2010, ANN SURG, V251, P604, DOI 10.1097/SLA.0b013e3181d3599c; Kashuk JL, 2009, J SURG RES, V156, P133, DOI 10.1016/j.jss.2009.03.046; KEARNEY TJ, 1992, J TRAUMA, V32, P608, DOI 10.1097/00005373-199205000-00012; Kitchens CS, 2005, J THROMB HAEMOST, V3, P2607, DOI 10.1111/j.1538-7836.2005.01552.x; Kuo JR, 2004, J CLIN NEUROSCI, V11, P710, DOI 10.1016/j.jocn.2003.10.011; Kushimoto S, 2003, J NEUROTRAUM, V20, P357, DOI 10.1089/089771503765172318; Lang T, 2005, BLOOD COAGUL FIBRIN, V16, P301, DOI 10.1097/01.mbc.0000169225.31173.19; Luddington RJ, 2005, CLIN LAB HAEMATOL, V27, P81, DOI 10.1111/j.1365-2257.2005.00681.x; Lustenberger T, 2010, J TRAUMA, V69, P1410, DOI 10.1097/TA.0b013e3181cdae81; Lustenberger T, 2010, INJURY, V41, P924, DOI 10.1016/j.injury.2010.04.019; Mann KG, 2003, ARTERIOSCL THROM VAS, V23, P17, DOI 10.1161/01.ATV.0000046238.23903.FC; OLSON JD, 1989, NEUROSURGERY, V24, P825, DOI 10.1227/00006123-198906000-00007; Rahe-Meyer N, 2009, BRIT J ANAESTH, V102, P785, DOI 10.1093/bja/aep089; Rahe-Meyer N, 2009, J THORAC CARDIOV SUR, V138, P694, DOI 10.1016/j.jtcvs.2008.11.065; Rossaint R., 1998, CRIT CARE MED, V26, P149; Rossaint R, 2010, CRIT CARE, V14, DOI 10.1186/cc8943; Schnuriger B, 2010, J TRAUMA, V68, P881, DOI 10.1097/TA.0b013e3181d3cc58; Schochl H, 2010, NETH J CRIT CARE, V14, P23; Schochl H, 2010, CRIT CARE, V14, DOI 10.1186/cc8948; Schochl H, 2009, J TRAUMA, V67, P125, DOI 10.1097/TA.0b013e31818b2483; Selladurai BM, 1997, BRIT J NEUROSURG, V11, P398; SHACKFORD SR, 1993, ARCH SURG-CHICAGO, V128, P571, DOI 10.1001/archsurg.1993.01420170107016; Shakur H, 2010, LANCET, V376, P23, DOI 10.1016/S0140-6736(10)60835-5; Stein SC, 2004, NEUROCRIT CARE, V1, P479, DOI 10.1385/NCC:1:4:479; Talving P, 2009, J TRAUMA, V66, P55, DOI 10.1097/TA.0b013e318190c3c0; Toulon P, 2009, THROMB HAEMOSTASIS, V101, P394, DOI 10.1160/TH08-06-0383; Wafaisade A, 2010, NEUROCRIT CARE, V12, P211, DOI 10.1007/s12028-009-9281-1; WAGNER C, 2000, LABOR DIAGNOSE, P613; Zehtabchi S, 2008, RESUSCITATION, V76, P52, DOI 10.1016/j.resuscitation.2007.06.024	39	74	76	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2011	28	10					2033	2041		10.1089/neu.2010.1744			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	839OX	WOS:000296378500004	21942848				2021-06-18	
J	de la Plata, CDM; Garces, J; Kojori, ES; Grinnan, J; Krishnan, K; Pidikiti, R; Spence, J; Devous, MD; Moore, C; McColl, R; Madden, C; Diaz-Arrastia, R				de la Plata, Carlos D. Marquez; Garces, Juanita; Kojori, Ehsan Shokri; Grinnan, Jack; Krishnan, Kamini; Pidikiti, Rajesh; Spence, Jeffrey; Devous, Michael D., Sr.; Moore, Carol; McColl, Rodderick; Madden, Christopher; Diaz-Arrastia, Ramon			Deficits in Functional Connectivity of Hippocampal and Frontal Lobe Circuits After Traumatic Axonal Injury	ARCHIVES OF NEUROLOGY			English	Article							BLUNT HEAD-INJURY; BRAIN-INJURY; ALZHEIMERS-DISEASE; CORPUS-CALLOSUM; MEMORY DEFICIT; LESIONS; DYSFUNCTION; ATTENTION; SEVERITY; EPILEPSY	Objective: To examine the functional connectivity of hippocampal and selected frontal lobe circuits in patients with traumatic axonal injury (TAI). Design: Observational study. Setting: An inpatient traumatic brain injury unit. Imaging and neurocognitive assessments were conducted in an outpatient research facility. Participants: Twenty-five consecutive patients with brain injuries consistent with TAI and acute subcortical white matter abnormalities were studied as well as 16 healthy volunteers of similar age and sex. Interventions: Echo-planar and high-resolution T1-weighted images were acquired using 3-T scanners. Regions of interest (ROI) were drawn bilaterally for the hippocampus, anterior cingulate cortex (ACC), and dorsolateral prefrontal cortex and were used to extract time series data. Blood oxygenation level-dependent data from each ROI were used as reference functions for correlating with all other brain voxels. Interhemispheric functional connectivity was assessed for each participant by correlating homologous regions using a Pearson correlation coefficient. Patient functional and neurocognitive outcomes were assessed approximately 6 months after injury. Main Outcome Measures: Interhemispheric functional connectivity, spatial patterns of functional connectivity, and associations of connectivity measures with functional and neurocognitive outcomes. Results: Patients showed significantly lower interhemispheric functional connectivity for the hippocampus and ACC. Controls demonstrated stronger and more focused functional connectivity for the hippocampi and ACC, and a more focused recruitment of the default mode network for the dorsolateral prefrontal cortex ROI. The interhemispheric functional connectivity for the hippocampus was correlated with delayed recall of verbal information. Conclusions: Traumatic axonal injury may affect interhemispheric neural activity, as patients with TAI show disrupted interhemispheric functional connectivity. More careful investigation of interhemispheric connectivity is warranted, as it demonstrated a modest association with outcome in chronic TBI.	[Garces, Juanita; Pidikiti, Rajesh; Moore, Carol; Diaz-Arrastia, Ramon] Univ Texas SW Med Ctr Dallas, Dept Neurol, Dallas, TX 75390 USA; [de la Plata, Carlos D. Marquez] Univ Texas Dallas, Ctr Brain Hlth, Richardson, TX 75083 USA; [de la Plata, Carlos D. Marquez; Kojori, Ehsan Shokri; Grinnan, Jack; Krishnan, Kamini] Univ Texas SW Med Ctr Dallas, Dept Psychiat, Dallas, TX 75390 USA; [Spence, Jeffrey] Univ Texas SW Med Ctr Dallas, Dept Clin Sci, Dallas, TX 75390 USA; [Devous, Michael D., Sr.; McColl, Rodderick] Univ Texas SW Med Ctr Dallas, Dept Radiol Neuroradiol, Dallas, TX 75390 USA; [Madden, Christopher] Univ Texas SW Med Ctr Dallas, Dept Neurol Surg, Dallas, TX 75390 USA	Diaz-Arrastia, R (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Neurol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	ramon.diaz-arrastia@utsouthwestern.edu	Pidikiti, Rajesh/E-2686-2013	Diaz-Arrastia, Ramon/0000-0001-6051-3594; McColl, Roderick/0000-0001-7022-100X	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K23 NS060827, R01 HD48179]; Department of EducationUS Department of Education [H133 A020526]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048179] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS060827] Funding Source: NIH RePORTER	This study was supported by grants K23 NS060827 (Dr Marquez de la Plata) and R01 HD48179 (Dr Diaz-Arrastia) from the National Institutes of Health and Department of Education grant H133 A020526.	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Allen G, 2007, ARCH NEUROL-CHICAGO, V64, P1482, DOI 10.1001/archneur.64.10.1482; AMARAL DG, 1984, J COMP NEUROL, V224, P307, DOI 10.1002/cne.902240302; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; Benton AL, 1983, MULTILINGUAL APHASIA; BISWAL B, 1995, MAGNET RESON MED, V34, P537, DOI 10.1002/mrm.1910340409; Bosma I, 2008, NEURO-ONCOLOGY, V10, P734, DOI 10.1215/15228517-2008-034; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Buckner RL, 2009, J NEUROSCI, V29, P1860, DOI 10.1523/JNEUROSCI.5062-08.2009; Castellanos FX, 2008, BIOL PSYCHIAT, V63, P332, DOI 10.1016/j.biopsych.2007.06.025; Cordes D, 2001, AM J NEURORADIOL, V22, P1326; Damoiseaux JS, 2008, CEREB CORTEX, V18, P1856, DOI 10.1093/cercor/bhm207; de la Plata CM, 2007, J NEUROTRAUM, V24, P591, DOI 10.1089/neu.2006.0214; Delis DC, 2000, CALIFORNIA VERBAL LE; DODRILL CB, 1978, EPILEPSIA, V19, P611, DOI 10.1111/j.1528-1157.1978.tb05041.x; Fork M, 2005, BRAIN INJURY, V19, P101, DOI 10.1080/02699050410001726086; Garnett MR, 2001, CURR OPIN NEUROL, V14, P753, DOI 10.1097/00019052-200112000-00012; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GLOOR P, 1993, BRAIN, V116, P1249, DOI 10.1093/brain/116.5.1249; Greicius MD, 2003, P NATL ACAD SCI USA, V100, P253, DOI 10.1073/pnas.0135058100; Greicius M, 2008, CURR OPIN NEUROL, V21, P424, DOI 10.1097/WCO.0b013e328306f2c5; Gupta RK, 2005, EPILEPSIA, V46, P1465, DOI 10.1111/j.1528-1167.2005.01205.x; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Johnston JM, 2008, J NEUROSCI, V28, P6453, DOI 10.1523/JNEUROSCI.0573-08.2008; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Langlois JA, 2006, TRAUMATIC BRAIN INJU; LEVIN HS, 1990, J CLIN EXP NEUROPSYC, V12, P129, DOI 10.1080/01688639008400960; Levine B, 2006, J NEUROTRAUM, V23, P1396, DOI 10.1089/neu.2006.23.1396; Lowe MJ, 1998, NEUROIMAGE, V7, P119, DOI 10.1006/nimg.1997.0315; MacDonald CL, 2008, NEUROLOGY, V71, P1199, DOI 10.1212/01.wnl.0000327521.69520.7f; Mai J.K., 2004, ATLAS HUMAN BRAIN; Mathias JL, 2007, NEUROPSYCHOLOGY, V21, P212, DOI 10.1037/0894-4105.21.2.212; McDonald BC, 2002, NEUROREHABILITATION, V17, P333; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; NG HK, 1994, CLIN NEUROL NEUROSUR, V96, P24, DOI 10.1016/0303-8467(94)90025-6; Peltier SJ, 2002, NEUROIMAGE, V16, P985, DOI 10.1006/nimg.2002.1141; Quigley M, 2003, AM J NEURORADIOL, V24, P208; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Song M, 2008, NEUROIMAGE, V41, P1168, DOI 10.1016/j.neuroimage.2008.02.036; Stein T, 2000, AM J NEURORADIOL, V21, P1397; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; van den Heuvel MP, 2009, HUM BRAIN MAPP, V30, P3127, DOI 10.1002/hbm.20737; Wallesch CW, 2001, BRAIN INJURY, V15, P401, DOI 10.1080/02699050010005959; Wang JY, 2008, ARCH NEUROL-CHICAGO, V65, P619, DOI 10.1001/archneur.65.5.619; Wang L, 2006, NEUROIMAGE, V31, P496, DOI 10.1016/j.neuroimage.2005.12.033; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Ylvisaker Mark, 1996, Seminars in Speech and Language, V17, P217, DOI 10.1055/s-2008-1064100	56	74	75	0	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0003-9942			ARCH NEUROL-CHICAGO	Arch. Neurol.	JAN	2011	68	1					74	84		10.1001/archneurol.2010.342			11	Clinical Neurology	Neurosciences & Neurology	704MO	WOS:000286057300010	21220676	Bronze, Green Accepted			2021-06-18	
J	Duffy, SO; Squires, J; Fromkin, JB; Berger, RP				Duffy, Shanna O.; Squires, Janet; Fromkin, Janet B.; Berger, Rachel P.			Use of Skeletal Surveys to Evaluate for Physical Abuse: Analysis of 703 Consecutive Skeletal Surveys	PEDIATRICS			English	Article						skeletal survey; child physical abuse; apparent life-threatening event; abusive head trauma	LIFE-THREATENING EVENT; TRAUMATIC BRAIN-INJURY; CHILD-ABUSE; HEAD TRAUMA; REASONABLE SUSPICION; YOUNG-CHILDREN; INFANTS; SERUM; IDENTIFICATION; POPULATION	OBJECTIVES: The goals were to assess the use of the skeletal survey (SS) to evaluate for physical abuse in a large consecutive sample, to identify characteristics of children most likely to have unsuspected fractures, and to determine how often SS results influenced directly the decision to make a diagnosis of abuse. METHODS: A retrospective, descriptive study of a consecutive sample of children who underwent an SS at a single children's hospital over 4 years was performed. Data on demographic characteristics, clinical presentation, SS results, and effects of SS results on clinical diagnoses were collected. A positive SS result was defined as a SS which identified a previously unsuspected fracture(s). RESULTS: Of the 703 SSs, 10.8% yielded positive results. Children <6 months of age, children with an apparent life-threatening event or seizure, and children with suspected abusive head trauma had the highest rates of positive SS results. Of children with positive SS results, 79% had >= 1 healing fracture. CONCLUSIONS: This is the largest study to date to describe the use of the SS. Almost 11% of SS results were positive. The SS results influenced directly the decision to make a diagnosis of abuse for 50% of children with positive SS results. These data, combined with the high morbidity rates for missed abuse and the large proportion of children with healing fractures detected through SS, suggest that broader use of SS, particularly for high-risk populations, may be warranted. Pediatrics 2011;127:e47-e52	[Squires, Janet; Fromkin, Janet B.; Berger, Rachel P.] UPMC, Childrens Hosp Pittsburgh, Dept Pediat, Pittsburgh, PA 15224 USA; [Duffy, Shanna O.] Wright State Univ, Boonshoft Sch Med, Dayton, OH 45435 USA	Berger, RP (corresponding author), UPMC, Childrens Hosp Pittsburgh, Dept Pediat, 4417 Penn Ave, Pittsburgh, PA 15224 USA.	rachel.berger@chp.edu		Stryker, Shanna/0000-0001-9983-1346	Pediatric Clinical and Translational Research Center, Children's Hospital of Pittsburgh of UPMC; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000005] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR024153] Funding Source: NIH RePORTER	Support was provided by the Summer Student Research Training Program of the Pediatric Clinical and Translational Research Center, Children's Hospital of Pittsburgh of UPMC.	ALEXANDER R, 1990, AM J DIS CHILD, V144, P58, DOI 10.1001/archpedi.1990.02150250068033; Altman RL, 2007, EUR J OPHTHALMOL, V17, P648; Belfer RA, 2001, AM J EMERG MED, V19, P122, DOI 10.1053/ajem.2001.21345; Berger RP, 2006, DEV NEUROSCI-BASEL, V28, P327, DOI 10.1159/000094158; Berger RP, 2006, PEDIATRICS, V117, P325, DOI 10.1542/peds.2005-0711; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; Bonkowsky JL, 2008, PEDIATRICS, V122, P125, DOI 10.1542/peds.2007-3376; Brand DA, 2005, PEDIATRICS, V115, P885, DOI 10.1542/peds.2004-0847; Chang DC, 2004, J TRAUMA, V57, P1189, DOI 10.1097/01.TA.0000145076.05111.E1; Day Fiona, 2006, J Clin Forensic Med, V13, P55, DOI 10.1016/j.jcfm.2005.08.001; Di Pietro MA, 2009, PEDIATRICS, V123, P1430, DOI 10.1542/peds.2009-0558; ELLERSTEIN NS, 1984, PEDIATRICS, V74, P1075; Ettaro L, 2004, CHILD ABUSE NEGLECT, V28, P1099, DOI 10.1016/j.chiabu.2004.06.006; Hymel KP, 1997, PEDIATRICS, V99, P371, DOI 10.1542/peds.99.3.371; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; Kairys SW, 2001, PEDIATRICS, V108, P206; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; King WK, 2006, PEDIATR EMERG CARE, V22, P211, DOI 10.1097/01.pec.0000208180.94166.dd; Levi BH, 2006, CHILD ABUSE NEGLECT, V30, P345, DOI 10.1016/j.chiabu.2005.05.004; Levi BH, 2005, PEDIATRICS, V116, pE5, DOI 10.1542/peds.2004-2649; Levi BH, 2004, THEOR MED BIOETH, V25, P277, DOI 10.1007/s11017-004-3136-8; MERTEN DF, 1983, RADIOLOGY, V146, P377, DOI 10.1148/radiology.146.2.6849085; Oral R, 2008, PEDIATR EMERG CARE, V24, P816, DOI 10.1097/PEC.0b013e31818e9f5d; Ravichandiran N, 2010, PEDIATRICS, V125, P60, DOI 10.1542/peds.2008-3794; Vellody K, 2008, CLIN PEDIATR, V47, P912, DOI 10.1177/0009922808320595; Waseem M, 2006, PEDIATR EMERG CARE, V22, P245, DOI 10.1097/01.pec.0000210176.48386.ae; Wood JN, 2009, PEDIATRICS, V123, pE247, DOI 10.1542/peds.2008-2467	27	74	74	0	6	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	JAN	2011	127	1					E47	E52		10.1542/peds.2010-0298			6	Pediatrics	Pediatrics	700YT	WOS:000285782200007	21149429	Green Published			2021-06-18	
J	Hartog, CS; Bauer, M; Reinhart, K				Hartog, Christiane S.; Bauer, Michael; Reinhart, Konrad			The Efficacy and Safety of Colloid Resuscitation in the Critically III	ANESTHESIA AND ANALGESIA			English	Article							HYDROXYETHYL STARCH SOLUTION; CARDIAC-SURGERY PATIENTS; MAJOR ORTHOPEDIC-SURGERY; SEE VOL. 37; FLUID RESUSCITATION; RENAL-FUNCTION; VOLUME REPLACEMENT; ILL PATIENTS; HES 130/0.4; PULMONARY PERMEABILITY	Despite evidence from clinical studies and meta-analyses that resuscitation with colloids or crystalloids is equally effective in critically ill patients, and despite reports from high-quality clinical trials and meta-analyses regarding nephrotoxic effects, increased risk of bleeding, and a trend toward higher mortality in these patients after the use of hydroxyethyl starch (HES) solutions, colloids remain popular and the use of HES solutions is increasing worldwide. We investigated the major rationales for colloid use, namely that colloids are more effective plasma expanders than crystalloids, that synthetic colloids are as safe as albumin, that HES solutions have the best risk/benefit profile among the synthetic colloids, and that the third-generation HES 130/0.4 has fewer adverse effects than older starches. Evidence from clinical studies shows that comparable resuscitation is achieved with considerably less crystalloid volumes than frequently suggested, namely, <2-fold the volume of colloids. Albumin is safe in intensive care unit patients except in patients with closed head injury. All synthetic colloids, namely, dextran, gelatin, and HES have dose-related side effects, which are coagulopathy, renal failure, and tissue storage. In patients with severe sepsis, higher doses of HES may be associated with excess mortality. The assumption that third-generation HES 130/0.4 has fewer adverse effects is yet unproven. Clinical trials on HES 130/0.4 have notable shortcomings. Mostly, they were not performed in intensive care unit or emergency department patients, had short observation periods of 24 to 48 hours, used cumulative doses below 1 daily dose limit (50 mL/kg), and used unsuitable control fluids such as other HES solutions or gelatins. In conclusion, the preferred use of colloidal solutions for resuscitation of patients with acute hypovolemia is based on rationales that are not supported by clinical evidence. Synthetic colloids are not superior in critically ill adults and children but must be considered harmful depending on the cumulative dose administered. Safe threshold doses need to be determined in studies in high-risk patients and observation periods of 90 days. Such studies on HES 130/0.4 are still lacking despite its widespread and increasing use. Because there are safer and equally effective alternatives in the form of crystalloids, use of synthetic colloids should be avoided except in the context of clinical studies. (Anesth Analg 2011; 112:156-64)	[Hartog, Christiane S.; Bauer, Michael; Reinhart, Konrad] Univ Jena, Dept Anaesthesiol & Intens Care Med, D-07747 Jena, Germany	Reinhart, K (corresponding author), Univ Jena, Dept Anaesthesiol & Intens Care Med, Erlanger Allee 101, D-07747 Jena, Germany.	konrad.reinhart@med.uni-jena.de	Hartog, Christiane/O-7650-2016	Bauer, Michael/0000-0002-1521-3514; Hartog, Christiane/0000-0003-1098-9775	B. Braun Melsungen	Disclosure: KR has in the past received consultancy fees from B. Braun Melsungen.	Akech S, 2006, PLOS CLIN TRIALS, V1, DOI 10.1371/journal.pctr.0010021; Auwerda JJA, 2002, ANN INTERN MED, V137, P1013, DOI 10.7326/0003-4819-137-12-200212170-00037; Auwerda JJA, 2006, TRANSFUSION, V46, P1705, DOI 10.1111/j.1537-2995.2006.00962.x; Barron ME, 2004, ARCH SURG-CHICAGO, V139, P552, DOI 10.1001/archsurg.139.5.552; Basora M, 2007, Rev Esp Anestesiol Reanim, V54, P162; Bellomo R, 2004, CRIT CARE, V8, pR204, DOI 10.1186/cc2872; Boldt J, 2008, BRIT J ANAESTH, V100, P457, DOI 10.1093/bja/aen016; Boldt J, 2004, INTENS CARE MED, V30, P416, DOI 10.1007/s00134-003-2110-7; Boldt J, 2006, SHOCK, V25, P103, DOI 10.1097/01.shk.0000189595.35661.40; Boldt J, 2003, INTENS CARE MED, V29, P763, DOI 10.1007/s00134-003-1702-6; Boldt J, 2001, INFUS THER TRANSFUS, V28, P144; Boldt J, 2001, ANASTH INTENSIV NOTF, V36, pS102; Boldt J, 2000, J CARDIOTHOR VASC AN, V14, P264; Boldt J, 2008, ANESTH ANALG, V107, P1496, DOI 10.1213/ane.0b013e31818370b2; Boldt J, 2007, CRIT CARE MED, V35, P2740, DOI 10.1097/01.CCM.0000288101.02556.DE; Boldt J, 2006, ANESTH ANALG, V103, P191, DOI 10.1213/01.ane.0000221179.07006.06; Boldt J, 2020, ANESTH ANALG, V131, pE137, DOI [10.1213/ANE.0000000000005019, 10.1213/ane.0b013e31819e9e6c]; Bork K, 2005, BRIT J DERMATOL, V152, P3, DOI 10.1111/J.1365-2133.2004.06272.X; Boussekey N, 2010, CRIT CARE, V14, DOI 10.1186/cc8920; Brunkhorst FM, 2008, NEW ENGL J MED, V358, P125, DOI 10.1056/NEJMoa070716; BUNN F, 2008, COCHRANE DB SYST REV, V1; Choi PTL, 1999, CRIT CARE MED, V27, P200, DOI 10.1097/00003246-199901000-00053; Cittanova ML, 1996, LANCET, V348, P1620, DOI 10.1016/S0140-6736(96)07588-5; Dart AB, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007594.pub2; Davidson IJ, 2006, EUR J ANAESTH, V23, P721, DOI 10.1017/S0265021506000639; Davies M J, 1989, J Clin Anesth, V1, P464, DOI 10.1016/0952-8180(89)90013-5; Dellinger RP, 2008, CRIT CARE MED, V36, P296, DOI 10.1097/01.CCM.0000298158.12101.41; Ertmer C, 2010, ANESTHESIOLOGY, V112, P936, DOI 10.1097/ALN.0b013e3181d3d493; Feinstein AJ, 2005, J AM COLL SURGEONS, V201, P536, DOI 10.1016/j.jamcollsurg.2005.05.031; Finfer S, 2004, NEW ENGL J MED, V350, P2247; FINFER S, INTENSIVE C IN PRESS; Fluids Study Investigators, 2008, ACTA ANAESTH SCAND, V52, P750, DOI 10.1111/j.1399-6576.2008.01690.x; GAMMAGE G, 1987, INT ANESTHESIOL CLIN, V25, P37, DOI 10.1097/00004311-198702510-00005; Gandhi SD, 2007, ANESTHESIOLOGY, V106, P1120, DOI 10.1097/01.anes.0000265422.07864.37; Ginz HF, 1998, ANAESTHESIST, V47, P330, DOI 10.1007/s001010050564; Godet G, 2008, EUR J ANAESTH, V25, P986, DOI 10.1017/S026502150800447X; HAGNE C, 2009, SCHWEIZ MED FORUM, V9, P304; Haynes GR, 2006, J CARDIOTHOR VASC AN, V20, P916, DOI 10.1053/j.jvca.2006.04.011; Hitosugi T, 2007, ANESTH ANALG, V105, P724, DOI 10.1213/01.ane.0000275198.84094.ad; Huet RCGG, 2000, CAN J ANAESTH, V47, P1207; Huter L, 2009, CRIT CARE, V13, DOI 10.1186/cc7726; Ickx BE, 2003, BRIT J ANAESTH, V91, P196, DOI 10.1093/bja/aeg159; James MFM, 2008, J CARDIOTHOR VASC AN, V22, P482, DOI 10.1053/j.jvca.2008.02.017; Jonville-Bera A, 2001, NEW ENGL J MED, V345, P622, DOI 10.1056/NEJM200108233450818; Jungheinrich Cornelius, 2004, Drugs R D, V5, P1, DOI 10.2165/00126839-200405010-00001; Kasper SM, 2003, ANESTHESIOLOGY, V99, P42, DOI 10.1097/00000542-200307000-00010; Kasper SM, 2001, J CLIN ANESTH, V13, P486, DOI 10.1016/S0952-8180(01)00311-7; Kozek-Langenecker SA, 2008, ANESTH ANALG, V107, P382, DOI 10.1213/ane.0b013e31817e6eac; Lang K, 2003, CAN J ANAESTH, V50, P1009, DOI 10.1007/BF03018364; Lang K, 2001, ANESTH ANALG, V93, P405, DOI 10.1097/00000539-200108000-00034; Langeron O, 2001, ANESTH ANALG, V92, P855, DOI 10.1097/00000539-200104000-00011; LAXENAIRE MC, 1994, ANN FR ANESTH, V13, P301, DOI 10.1016/S0750-7658(94)80038-3; Levi M, 2007, SEMIN THROMB HEMOST, V33, P810, DOI 10.1055/s-2007-1000370; Liu Fu-Chao, 2009, Acta Anaesthesiol Taiwan, V47, P71, DOI 10.1016/S1875-4597(09)60027-8; Lukasewitz P, 1998, J ANAESTH INTENSIVBE, V9, P42; Madigan MC, 2008, J TRAUMA, V64, P280, DOI 10.1097/TA.0b013e3181622bb6; Mahmood A, 2007, BRIT J SURG, V94, P427, DOI 10.1002/bjs.5726; Miletin MS, 2002, INTENS CARE MED, V28, P917, DOI 10.1007/s00134-002-1337-z; Myburgh J, 2007, NEW ENGL J MED, V357, P874; Neff TA, 2003, ANESTH ANALG, V96, P1453, DOI 10.1213/01.ANE.0000061582.09963.FD; NEFF TA, 2006, EUR J ANAESTHESI S37, V23, P206; Palumbo D, 2006, MINERVA ANESTESIOL, V72, P655; PEREL P, 2009, COCHRANE DB SYST REV, V4; PUYANA JC, 2005, TXB CRITICAL CARE, P1939; RACKOW EC, 1983, CRIT CARE MED, V11, P839, DOI 10.1097/00003246-198311000-00001; Rioux JP, 2009, CRIT CARE MED, V37, P1293, DOI 10.1097/CCM.0b013e31819cc1a0; Roberts I, 1998, BMJ-BRIT MED J, V317, P235; Sakr Y, 2007, BRIT J ANAESTH, V98, P216, DOI 10.1093/bja/ael333; Schabinski F, 2009, INTENS CARE MED, V35, P1539, DOI 10.1007/s00134-009-1509-1; Schick MA, 2010, INTENS CARE MED, V36, P541, DOI 10.1007/s00134-009-1704-0; Schierhout G, 1998, BMJ-BRIT MED J, V316, P961, DOI 10.1136/bmj.316.7136.961; Schmidt-Hieber M, 2006, EUR J HAEMATOL, V77, P83, DOI 10.1111/j.1600-0609.2006.00657.x; Schortgen F, 2004, INTENS CARE MED, V30, P2222, DOI 10.1007/s00134-004-2415-1; Schortgen F, 2001, LANCET, V357, P911, DOI 10.1016/S0140-6736(00)04211-2; Schortgen F, 2009, CRIT CARE, V13, DOI 10.1186/cc7745; Schortgen F, 2008, INTENS CARE MED, V34, P2157, DOI 10.1007/s00134-008-1225-2; SCHWARZ A, 2009, SCHWEIZ MED FORUM, V9, P882; Sedrakyan A, 2003, CHEST, V123, P1853, DOI 10.1378/chest.123.6.1853; Sort P, 1999, NEW ENGL J MED, V341, P403, DOI 10.1056/NEJM199908053410603; Sossdorf M, 2009, CRIT CARE, V13, DOI 10.1186/cc8223; Toomtong P, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000991.pub2; Townsend DR, 2008, NEPHRON CLIN PRACT, V109, pC205, DOI 10.1159/000142930; Tseng MY, 2008, BRIT J NEUROSURG, V22, P257, DOI 10.1080/02688690701832100; Upadhyay M, 2005, INDIAN PEDIATR, V42, P223; van der Heijden M, 2009, CRIT CARE MED, V37, P1275, DOI 10.1097/CCM.0b013e31819cedfd; Van der Linden PJ, 2005, ANESTH ANALG, V101, P629, DOI 10.1213/01.ANE.0000175216.53374.27; VELANOVICH V, 1989, SURGERY, V105, P65; Verheij J, 2006, BRIT J ANAESTH, V96, P21, DOI 10.1093/bja/aei286; Verheij J, 2006, INTENS CARE MED, V32, P1030, DOI 10.1007/s00134-006-0195-5; VINCENT JL, 1991, CRIT CARE MED, V19, P316; Vincent JL, 2006, CRIT CARE MED, V34, P344, DOI 10.1097/01.CCM.0000194725.48928.3A; Westphal M, 2009, ANESTHESIOLOGY, V111, P187, DOI 10.1097/ALN.0b013e3181a7ec82; Wiedermann CJ, 2008, BMC EMERG MED, V8, DOI 10.1186/1471-227X-8-1; Wilkes MM, 2001, ANN THORAC SURG, V72, P527, DOI 10.1016/S0003-4975(01)02745-X; Wills BA, 2005, NEW ENGL J MED, V353, P877, DOI 10.1056/NEJMoa044057; Zaar M, 2009, BRIT J ANAESTH, V102, P221, DOI 10.1093/bja/aen350; Zarychanski Ryan, 2009, Open Med, V3, pe196; ZIKRIA BA, 1989, SURGERY, V105, P625	98	74	81	0	15	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	JAN	2011	112	1					156	164		10.1213/ANE.0b013e3181eaff91			9	Anesthesiology	Anesthesiology	696PQ	WOS:000285454300025	21127276				2021-06-18	
J	Arabi, YM; Haddad, S; Tamim, HM; Al-Dawood, A; Al-Qahtani, S; Ferayan, A; Al-Abdulmughni, I; Al-Oweis, J; Rugaan, A				Arabi, Yaseen M.; Haddad, Samir; Tamim, Hani M.; Al-Dawood, Abdulaziz; Al-Qahtani, Saad; Ferayan, Ahmad; Al-Abdulmughni, Ibrahim; Al-Oweis, Jalal; Rugaan, Asia			Mortality reduction after implementing a clinical practice guidelines-based management protocol for severe traumatic brain injury	JOURNAL OF CRITICAL CARE			English	Article						Guidelines; Mortality; Protocol; Severe Head Injury; Trauma; Traumatic Brain Injury	SEVERE HEAD-INJURY; ROAD TRAFFIC ACCIDENTS; INTRACRANIAL-PRESSURE; UNITED-STATES; CRITICAL-CARE; SAUDI-ARABIA; EPIDEMIOLOGY; DEATH; DISABILITY; COMATOSE	Introduction: The objective of this study was to examine the effect of implementing a clinical practice guidelines based management protocol on the outcome of patients with severe traumatic brain injury (TBI). Methods: We carried out a pre-post guideline implementation study using previously collected data in the Intensive Care Unit (ICU). All patients older than 12 years with severe TBI, defined as a Glasgow Coma Scale score of 8 or less, from March 1999 to January 2001 (control group) and from February 2001 to December 2006 (protocol group) were identified and included in this study. Patients in the protocol group were managed using a clinical practice guidelines based management protocol, derived from the guidelines published by the Brain Trauma Foundation. Primary outcome was hospital mortality, whereas the secondary outcome was ICU mortality. To assess whether the ICU protocol might have led to an increase in the number of surviving patients with severe disability, we examined the association of the protocol use and the need for tracheostomies, mechanical ventilation duration, and ICU and hospital length of stay (LOS) among survivors. Results: During the study period, a total of 434 patients met the inclusion criteria. After adjustment for several prognostic factors, the use of protocol was independently associated with a significant reduction in hospital and ICU mortality (odds ratio, 0.45; 95% confidence interval, 0.24-0.86; and odds ratio, 0.47; 95% confidence interval, 0.23-0.96, respectively). The use of the protocol was not associated with an increase in the need for tracheostomies, mechanical ventilation duration, ICU LOS, and hospital LOS.	[Arabi, Yaseen M.; Haddad, Samir; Al-Dawood, Abdulaziz; Al-Qahtani, Saad; Al-Abdulmughni, Ibrahim; Al-Oweis, Jalal; Rugaan, Asia] King Abdul Aziz Med City, Dept Intens Care, Riyadh 11426, Saudi Arabia; [Arabi, Yaseen M.; Tamim, Hani M.; Al-Dawood, Abdulaziz; Al-Qahtani, Saad] King Saud Bin Abdulaziz Univ Hlth Sci, Riyadh 11426, Saudi Arabia; [Ferayan, Ahmad] King Abdualziz Med City, Div Neurosurg, Dept Surg, Riyadh 11426, Saudi Arabia	Arabi, YM (corresponding author), King Saud Bin Abdulaziz Univ Hlth Sci, King Fahad Natl Guard Hosp, Dept Intens Care, Riyadh, Saudi Arabia.	arabi@ngha.med.sa		Arabi, Yaseen/0000-0001-5735-6241			Adekoya Nelson, 2002, MMWR Surveill Summ, V51, P1; [Anonymous], 2007, J NEUROTRAUMA S1, V24, pS1, DOI DOI 10.1089/NEU.2006.0209; Ansari S, 2000, PUBLIC HEALTH, V114, P37, DOI 10.1016/S0033-3506(00)00306-1; Arabi Y, 2006, CRIT CARE MED, V34, P605, DOI 10.1097/01.CCM.0000203947.60552.DD; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; Cremer OL, 2008, EUR J ANAESTH, V25, P87, DOI 10.1017/S0265021507003237; Demetriades D, 1998, J AM COLL SURGEONS, V187, P373, DOI 10.1016/S1072-7515(98)00209-9; Elf K, 2002, CRIT CARE MED, V30, P2129, DOI 10.1097/00003246-200209000-00029; Engberg A, 1995, Acta Neurol Scand Suppl, V164, P1; Fakhry SM, 2004, J TRAUMA, V56, P492, DOI 10.1097/01.TA.0000115650.07193.66; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; Haddad SH, 2007, ANAESTH INTENS CARE, V35, P393, DOI 10.1177/0310057X0703500313; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Mauritz W, 2008, INTENS CARE MED, V34, P1208, DOI 10.1007/s00134-008-1079-7; Meyer AA, 1998, J TRAUMA, V44, P1, DOI 10.1097/00005373-199801000-00001; Rappaport M, 2005, NEUROPSYCHOL REHABIL, V15, P442, DOI 10.1080/09602010443000335; REGEL G, 1995, J TRAUMA, V38, P70, DOI 10.1097/00005373-199501000-00020; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; SHACKFORD SR, 1993, ARCH SURG-CHICAGO, V128, P571, DOI 10.1001/archsurg.1993.01420170107016; Shafi S, 2008, J TRAUMA, V64, P335, DOI 10.1097/TA.0b013e31815dd017; SHANKS NJ, 1994, PUBLIC HEALTH, V108, P27, DOI 10.1016/S0033-3506(05)80032-0; Sinuff T, 2008, CRIT CARE MED, V36, P1049, DOI 10.1097/CCM.0b013e31816a01ec; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Steiner LA, 2004, CRIT CARE MED, V32, P1049, DOI 10.1097/01.CCM.0000120054.32845.A6; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Vukic M, 1999, ACTA NEUROCHIR, V141, P1203, DOI 10.1007/s007010050419; Wilkins IA, 2001, ANAESTHESIA, V56, P350, DOI 10.1046/j.1365-2044.2001.01708.x	29	74	79	0	11	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0883-9441	1557-8615		J CRIT CARE	J. Crit. Care	JUN	2010	25	2					190	195		10.1016/j.jcrc.2009.05.004			6	Critical Care Medicine	General & Internal Medicine	609EM	WOS:000278638200004	19592201				2021-06-18	
J	Liliang, PC; Liang, CL; Weng, HC; Lu, K; Wang, KW; Chen, HJ; Chuang, JH				Liliang, Po-Chou; Liang, Cheng-Loong; Weng, Hui-Ching; Lu, Kang; Wang, Kuo-Wei; Chen, Han-Jung; Chuang, Jiin-Haur			tau Proteins in Serum Predict Outcome After Severe Traumatic Brain Injury	JOURNAL OF SURGICAL RESEARCH			English	Article						tau protein; outcome; traumatic brain injury; ELISA	SEVERE HEAD-INJURY; CEREBROSPINAL-FLUID; NEURONAL DAMAGE; S-100B PROTEIN; CLEAVED-TAU; BIOMARKER; MARKER	Background. The identification of reliable outcome predictors after traumatic brain injury (TBI) is crucial. The objective of our study was to investigate the role of tau protein as a serum marker of TBI. Methods. Thirty-four patients with severe TBI (Glasgow Coma Scale [GCS] score at admission <= 8) were considered. The tau protein level in the blood samples obtained at the time of admission was measured. The outcome was assessed by using the Glasgow Outcome Scale (GOS) at 6 mo post-injury. Demographic, clinical, and laboratory variables were analyzed to study their effect on the outcome. Results. tau Protein levels were higher in the poor outcome group (436.2 +/- 473.6 pg/mL) than in the good outcome group (51.6 +/- 81.5 pg/mL) (P < 0.0001). Univariate analyses demonstrated that poor outcome was significantly associated with a poor GCS score (P = 0.001), higher serum tau protein levels (P < 0.001), abnormal pupil light reflex (P = 0.013), and basal cistern compression on computed tomogram (CT) (P = 0.026). Multivariate analyses revealed that a poor GCS score (P = 0.049) and higher serum tau protein levels (P = 0.043) were independent prognostic factors for poor outcome. The receiver-operating characteristic (ROC) curve demonstrated that a tau protein level >= 114.5 pg/mL yielded 88% sensitivity and 94% specificity for predicting a poor outcome. Conclusions. These results suggest that in addition to GCS; serum tau protein levels may serve as indicators for the prediction of outcome following severe TBI. However; it should be viewed with caution because of the small sample size and wide standard deviations. (C) 2010 Elsevier Inc. All rights reserved.	[Liliang, Po-Chou] I Shou Univ, E Da Hosp, Dept Neurosurg, Yan Chau Shiang 824, Kaohsiung Cty, Taiwan; [Liliang, Po-Chou] Chang Gung Univ, Coll Med, Grad Inst Clin Med Sci, Kaohsiung, Taiwan; [Weng, Hui-Ching] I Shou Univ, Dept Hlth Management, Kaohsiung, Taiwan; [Chuang, Jiin-Haur] Chang Gung Mem Hosp, Kaohsiung Med Ctr, Dept Surg, Div Pediat Surg, Kaohsiung, Taiwan	Chen, HJ (corresponding author), I Shou Univ, E Da Hosp, Dept Neurosurg, 1 E Da Rd, Yan Chau Shiang 824, Kaohsiung Cty, Taiwan.	ed100172@edah.org.tw			Taiwan National Science CouncilMinistry of Science and Technology, Taiwan [NSC 94-2314-B-214-003, NSC 95-2314-B-214-006]	This work was supported by research grants from the Taiwan National Science Council grant nos. NSC 94-2314-B-214-003 and NSC 95-2314-B-214-006 to PCL.	Bullock RM, 2000, J NEUROTRAUM, V17, P449; Bulut M, 2006, ADV THER, V23, P12, DOI 10.1007/BF02850342; Chlu WT, 2007, J CLIN NEUROSCI, V14, P930, DOI 10.1016/j.jocn.2006.08.004; Foreman BP, 2007, J TRAUMA, V62, P946, DOI 10.1097/01.ta.0000229796.14717.3a; Franz G, 2003, NEUROLOGY, V60, P1457, DOI 10.1212/01.WNL.0000063313.57292.00; Gabbita SP, 2005, J NEUROTRAUM, V22, P83, DOI 10.1089/neu.2005.22.83; Huang SJ, 2007, J CLIN NEUROSCI, V14, P449, DOI 10.1016/j.jocn.2005.12.012; JENNETT B, 1975, LANCET, V1, P480; Johnson GVW, 1997, J NEUROCHEM, V68, P430; Kavalci C, 2007, AM J EMERG MED, V25, P391, DOI 10.1016/j.ajem.2006.10.008; Korfias S, 2007, INTENS CARE MED, V33, P255, DOI 10.1007/s00134-006-0463-4; Lin JW, 2006, SURG NEUROL, V66, pS20, DOI 10.1016/j.surneu.2006.04.005; MARION DW, 1996, NEUROTRAUMA, P767; Ost M, 2006, NEUROLOGY, V67, P1600, DOI 10.1212/01.wnl.0000242732.06714.0f; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Schreiber MA, 2002, ARCH SURG-CHICAGO, V137, P285, DOI 10.1001/archsurg.137.3.285; Shaw GJ, 2002, ANN EMERG MED, V39, P254, DOI 10.1067/mem.2002.121214; Tsai MD, 2006, SURG NEUROL, V66, pS3, DOI 10.1016/j.surneu.2006.08.046; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Woertgen C, 1999, J TRAUMA, V47, P1126, DOI 10.1097/00005373-199912000-00026; Zemlan FP, 2003, NEUROSCIENCE, V121, P399, DOI 10.1016/S0306-4522(03)00459-7; Zemlan FP, 2002, BRAIN RES, V947, P131, DOI 10.1016/S0006-8993(02)02920-7; KHB0042KHB0041	23	74	76	0	12	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804	1095-8673		J SURG RES	J. Surg. Res.	MAY 15	2010	160	2					302	307		10.1016/j.jss.2008.12.022			6	Surgery	Surgery	590VY	WOS:000277257600021	19345376				2021-06-18	
J	Bhardwaj, G; Chowdhury, V; Jacobs, MB; Moran, KT; Martin, FJ; Coroneo, MT				Bhardwaj, Gaurav; Chowdhury, Vivek; Jacobs, Mark B.; Moran, Kieran T.; Martin, Frank J.; Coroneo, Minas T.			A Systematic Review of the Diagnostic Accuracy of Ocular Signs in Pediatric Abusive Head Trauma	OPHTHALMOLOGY			English	Article							SHAKEN BABY SYNDROME; PERIMACULAR RETINAL FOLDS; SUSPECTED CHILD-ABUSE; YOUNG-CHILDREN; BRAIN-INJURY; SUBDURAL-HEMATOMA; INTRACRANIAL HEMORRHAGE; OPHTHALMOLOGIC FINDINGS; NONACCIDENTAL INJURY; INFANTS	Topic: To review systematically the diagnostic accuracy of various ocular signs for pediatric abusive head trauma (AHT). Clinical Relevance: Intraocular hemorrhages (IOH), perimacular retinal folds, traumatic retinoschisis and optic nerve sheath hemorrhages have been reported as cardinal signs of AHT. The evidence base supporting the accuracy of this interpretation, however, has not been systematically reviewed. Methods: A systematic keyword search of MEDLINE, EMBASE, and Evidence-Based Medicine Reviews was conducted for original studies reporting ocular findings in AHT. Articles were graded using a checklist for systematic reviews of diagnostic accuracy. Results: The initial search yielded 971 articles, of which 55 relevant studies were graded, and 20 studies met inclusion criteria and were included in the review. The overall sensitivity of IOH for AHT was 75% and their specificity was 94%. Intraretinal hemorrhage at the posterior pole was the most common finding, although extensive, bilateral, and multilayered IOH were the most specific for AHT. Optic nerve sheath hemorrhages had a sensitivity and specificity for AHT of 72% and 71%, respectively. Traumatic retinoschisis and perimacular retinal folds were reported in 8% and 14% of AHT, respectively, but were not reported in other conditions. Conclusions: Prospective, consecutive studies confirm that IOH in infants-particularly bilateral, extensive, and multilayered-are highly specific for AHT. Optic nerve sheath hemorrhages are significantly more common in AHT than in other conditions, in autopsy studies. Traumatic retinoschisis and perimacular folds are present in a minority of AHT, but rarely seen in other conditions.	[Martin, Frank J.] Univ Sydney, Fac Med, Sydney, NSW 2006, Australia; [Martin, Frank J.] Childrens Hosp Westmead, Dept Ophthalmol, Westmead, NSW, Australia; [Moran, Kieran T.] Sydney Childrens Hosp, Child Protect Unit, Randwick, NSW, Australia; [Chowdhury, Vivek; Jacobs, Mark B.; Martin, Frank J.; Coroneo, Minas T.] Sydney Childrens Hosp, Dept Ophthalmol, Randwick, NSW, Australia; [Bhardwaj, Gaurav; Jacobs, Mark B.; Moran, Kieran T.; Coroneo, Minas T.] Univ New S Wales, Fac Med, Randwick, NSW, Australia	Bhardwaj, G (corresponding author), Prince Wales Hosp, Dept Ophthalmol, 2nd Floor,S Wing,Edmund Blacket Bldg, Randwick, NSW 2031, Australia.	gauravb23@gmail.com	Coroneo, Minas/AAJ-4600-2020				Arlotti SA, 2007, J AAPOS, V11, P175, DOI 10.1016/j.jaapos.2006.09.023; Atwal GS, 1998, FORENSIC SCI INT, V96, P215, DOI 10.1016/S0379-0738(98)00126-1; Barlow KM, 2005, PEDIATRICS, V116, pE174, DOI 10.1542/peds.2004-2739; Bechtel K, 2004, PEDIATRICS, V114, P165, DOI 10.1542/peds.114.1.165; Betz P, 1996, FORENSIC SCI INT, V78, P71, DOI 10.1016/0379-0738(95)01866-2; BILLMIRE ME, 1985, PEDIATRICS, V75, P340; BINEBAUM G, 2009, AAPOS, V13, P268; Binenbaum G, 2009, J AAPOS, V13, P268, DOI 10.1016/j.jaapos.2009.03.005; Biousse V, 2002, AM J OPHTHALMOL, V133, P249, DOI 10.1016/S0002-9394(01)01366-6; Biron D, 2005, CHILD ABUSE NEGLECT, V29, P1347, DOI 10.1016/j.chiabu.2005.05.003; Biron DL, 2007, J PAEDIATR CHILD H, V43, P60, DOI 10.1111/j.1440-1754.2007.01004.x; Bonnier C, 2003, PEDIATRICS, V112, P808, DOI 10.1542/peds.112.4.808; BUDENZ DL, 1994, OPHTHALMOLOGY, V101, P559; BUYS YM, 1992, OPHTHALMOLOGY, V99, P1718; CANTANI A, 1990, Pediatric Emergency Care, V6, P271, DOI 10.1097/00006565-199012000-00005; CHEAH IGS, 1994, ANN TROP PAEDIATR, V14, P325, DOI 10.1080/02724936.1994.11747737; Dashti SR, 1999, PEDIATR NEUROSURG, V31, P302, DOI 10.1159/000028880; DiScala C, 2000, ARCH PEDIAT ADOL MED, V154, P16; Donohoe M, 2003, AM J FOREN MED PATH, V24, P239, DOI 10.1097/01.paf.0000083635.85457.97; Drack AV, 1999, AM J OPHTHALMOL, V128, P340, DOI 10.1016/S0002-9394(99)00147-6; DUHAIME AC, 1992, PEDIATRICS, V90, P179; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; EISENBREY AB, 1979, CHILD BRAIN, V5, P40; ELNER SG, 1990, ARCH OPHTHALMOL-CHIC, V108, P1094, DOI 10.1001/archopht.1990.01070100050033; Emerson MV, 2007, OPHTHALMOLOGY, V114, P1384, DOI 10.1016/j.ophtha.2007.04.015; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; Feldman KW, 2001, PEDIATRICS, V108, P636, DOI 10.1542/peds.108.3.636; Fishman CD, 1998, J PEDIAT OPHTH STRAB, V35, P22; FRANK Y, 1985, DEV MED CHILD NEUROL, V27, P312; Fujiwara T, 2008, PEDIATRICS, V122, pE841, DOI 10.1542/peds.2008-0387; Fung ELW, 2002, PEDIATR INT, V44, P37, DOI 10.1046/j.1442-200X.2002.01500.x; Ganesh A, 2004, OPHTHALMOLOGY, V111, P1428, DOI 10.1016/j.ophtha.2003.10.028; GAYNON MW, 1988, AM J OPHTHALMOL, V106, P423, DOI 10.1016/0002-9394(88)90877-X; Geddes JF, 2003, NEUROPATH APPL NEURO, V29, P14, DOI 10.1046/j.1365-2990.2003.00434.x; Geddes JF, 2001, BRAIN, V124, P1290, DOI 10.1093/brain/124.7.1290; Ghahreman A, 2005, J NEUROSURG, V103, P213, DOI 10.3171/ped.2005.103.3.0213; GIANGIACOMO J, 1988, OPHTHALMOLOGY, V95, P295; Gilles EE, 2003, J PEDIATR-US, V143, P494, DOI 10.1067/S0022-3476(03)00416-5; GILLILAND MGF, 1993, AM J FOREN MED PATH, V14, P187, DOI 10.1097/00000433-199309000-00003; Gleckman AM, 2000, ARCH PATHOL LAB MED, V124, P251; Gnanaraj L, 2007, EYE, V21, P5, DOI 10.1038/sj.eye.6702174; Golden N, 2005, J CLIN NEUROSCI, V12, P235, DOI 10.1016/j.jocn.2004.11.001; GOLDSTEIN B, 1993, CRIT CARE MED, V21, P1328, DOI 10.1097/00003246-199309000-00016; Graupman P, 2006, J NEUROSURG, V104, P245, DOI 10.3171/ped.2006.104.4.245; Green MA, 1996, BRIT J OPHTHALMOL, V80, P282, DOI 10.1136/bjo.80.4.282; Greenes DS, 1998, ANN EMERG MED, V32, P680, DOI 10.1016/S0196-0644(98)70067-8; GREENWALD MJ, 1986, OPHTHALMOLOGY, V93, P618; HADLEY MN, 1989, NEUROSURGERY, V24, P536, DOI 10.1227/00006123-198904000-00008; Han D P, 1990, J Pediatr Ophthalmol Strabismus, V27, P299; HARCOURT B, 1971, BMJ-BRIT MED J, V3, P398, DOI 10.1136/bmj.3.5771.398; HENDELES S, 1985, CHILD CARE HLTH DEV, V11, P345, DOI 10.1111/j.1365-2214.1985.tb00475.x; HOLLOWAY M, 1994, MED J AUSTRALIA, V160, P786, DOI 10.5694/j.1326-5377.1994.tb125947.x; Hoskote A, 2002, CHILD NERV SYST, V18, P311, DOI 10.1007/s00381-002-0616-x; JACOBI G, 1986, MONATSSCHR KINDERH, V134, P307; Jayawant S, 2007, ARCH DIS CHILD, V92, P343, DOI 10.1136/adc.2005.084988; Kafil-Hussain NA, 2000, J PEDIAT OPHTH STRAB, V37, P289; Kapoor S, 1997, PEDIATR EMERG CARE, V13, P183, DOI 10.1097/00006565-199706000-00002; Keenan HT, 2004, PEDIATRICS, V114, P633, DOI 10.1542/peds.2003-1020-L; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; KEITHAHN MAZ, 1993, OPHTHALMOLOGY, V100, P1187; KIFFNEY GT, 1964, ARCH OPHTHALMOL-CHIC, V72, P231; King WJ, 2003, CAN MED ASSOC J, V168, P155; Kivlin JD, 2008, ARCH OPHTHALMOL-CHIC, V126, P800, DOI 10.1001/archopht.126.6.800; Kivlin JD, 2000, OPHTHALMOLOGY, V107, P1246, DOI 10.1016/S0161-6420(00)00161-5; LAMBERT SR, 1986, ARCH OPHTHALMOL-CHIC, V104, P1509; Lantz PE, 2004, BRIT MED J, V328, P754, DOI 10.1136/bmj.328.7442.754; Laskey AL, 2004, J PEDIATR-US, V144, P719, DOI 10.1016/j.jpeds.2004.02.023; Leestma JE, 2005, AM J FOREN MED PATH, V26, P199, DOI 10.1097/01.paf.0000164228.79784.5a; LEVIN AV, 1999, RECENT ADV PAEDIAT, V17, P151; Loh JK, 2002, SURG NEUROL, V58, P218, DOI 10.1016/S0090-3019(02)00830-3; LUDWIG S, 1984, ANN EMERG MED, V13, P104, DOI 10.1016/S0196-0644(84)80571-5; Lueder GT, 2006, ARCH OPHTHALMOL-CHIC, V124, P1782, DOI 10.1001/archopht.124.12.1782; LUERSSEN TG, 1991, CONC PED N, V11, P87; Makoroff KL, 2005, PEDIATR RADIOL, V35, P668, DOI 10.1007/s00247-005-1441-7; Marshall DH, 2001, CAN J OPHTHALMOL, V36, P377, DOI 10.1016/S0008-4182(01)80081-8; MASSICOTTE SJ, 1991, OPHTHALMOLOGY, V98, P1124; McCabe CF, 2000, ARCH OPHTHALMOL-CHIC, V118, P373, DOI 10.1001/archopht.118.3.373; Mills M, 1998, J AAPOS, V2, P67, DOI 10.1016/S1091-8531(98)90066-0; Morad Y, 2004, J AAPOS, V8, P521, DOI 10.1016/j.jaapos.2004.07.009; Morad Y, 2004, J AAPOS, V8, P445, DOI 10.1016/j.jaapos.2004.06.007; Morad Y, 2003, J PEDIATR-US, V142, P431, DOI 10.1067/mpd.2003.161; Morad Y, 2002, AM J OPHTHALMOL, V134, P354, DOI 10.1016/S0002-9394(02)01628-8; Morris MW, 2000, PEDIATRICS, V105, P549, DOI 10.1542/peds.105.3.549; MUNGER CE, 1993, AM J FOREN MED PATH, V14, P193, DOI 10.1097/00000433-199309000-00004; MUSHIN AS, 1971, BRIT MED J, V3, P402, DOI 10.1136/bmj.3.5771.402; Naidoo S, 2000, CHILD ABUSE NEGLECT, V24, P521, DOI 10.1016/S0145-2134(00)00114-9; Nassogne MC, 2002, CHILD NERV SYST, V18, P729, DOI 10.1007/s00381-002-0630-z; Pierre-Kahn V, 2003, OPHTHALMOLOGY, V110, P1718, DOI 10.1016/S0161-6420(03)00581-5; RAO N, 1988, FORENSIC SCI INT, V39, P293, DOI 10.1016/0379-0738(88)90133-8; Reece RM, 2000, ARCH PEDIAT ADOL MED, V154, P11; RIFFENBURGH R, 2005, CLIN SURG OPHTHALMOL, V23, P178; RIFFENBURGH RS, 1991, OPHTHALMOLOGY, V98, P1519; Rubin DM, 2003, PEDIATRICS, V111, P1382, DOI 10.1542/peds.111.6.1382; Schmidt US, 1997, KLIN MONATSBL AUGENH, V211, P354, DOI 10.1055/s-2008-1035147; SMITH SM, 1974, BMJ-BRIT MED J, V3, P666, DOI 10.1136/bmj.3.5932.666; Sun DTF, 2006, CHILD NERV SYST, V22, P593, DOI 10.1007/s00381-006-0094-7; Talvik I, 2006, ACTA PAEDIATR, V95, P799, DOI 10.1080/08035250500464923; Togioka BM, 2009, J EMERG MED, V37, P98, DOI 10.1016/j.jemermed.2008.06.022; Tung GA, 2006, PEDIATRICS, V118, P626, DOI 10.1542/peds.2006-0130; Tzioumi D, 1998, CHILD ABUSE NEGLECT, V22, P1105, DOI 10.1016/S0145-2134(98)00093-3; Vinchon M, 2005, J NEUROSURG, V102, P380, DOI 10.3171/ped.2005.102.4.0380; Vinchon M, 2004, PRESSE MED, V33, P1174, DOI 10.1016/S0755-4982(04)98886-0; Watts P, 2008, EYE, V22, P1514, DOI 10.1038/eye.2008.224; Whiting Penny, 2003, BMC Med Res Methodol, V3, P25, DOI 10.1186/1471-2288-3-25; WILKINSON WS, 1989, ARCH OPHTHALMOL-CHIC, V107, P1472, DOI 10.1001/archopht.1989.01070020546037; Wygnanski-Jaffe T, 2006, AM J OPHTHALMOL, V142, P233, DOI 10.1016/j.ajo.2006.03.038	106	74	74	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0161-6420	1549-4713		OPHTHALMOLOGY	Ophthalmology	MAY	2010	117	5					983	U186		10.1016/j.ophtha.2009.09.040			27	Ophthalmology	Ophthalmology	590XM	WOS:000277261800020	20347153				2021-06-18	
J	Martini, RP; Deem, S; Yanez, ND; Chesnut, RM; Weiss, NS; Daniel, S; Souter, M; Treggiari, MM				Martini, Ross P.; Deem, Steven; Yanez, N. David; Chesnut, Randall M.; Weiss, Noel S.; Daniel, Stephen; Souter, Michael; Treggiari, Miriam M.			Management guided by brain tissue oxygen monitoring and outcome following severe traumatic brain injury Clinical article	JOURNAL OF NEUROSURGERY			English	Article						intracranial pressure; human; trauma resuscitation; neurological outcomes; cerebral ischemia	SEVERE HEAD-INJURY; CLASSIFICATION; METABOLISM; PREDICTION; PRESSURE; TENSION; PO-2; CARE	Object. The authors sought to describe changes in clinical management associated with brain tissue oxygen (PbO2) monitoring and how these changes affected outcomes and resource utilization. Methods. The cohort study comprised 629 patients admitted to a Level I trauma center with a diagnosis of severe traumatic brain injury over a period of 3 years. Hospital mortality rate, neurological outcome, and resource utilization of 123 patients who underwent both PbO2 and intracranial pressure (ICP) monitoring were compared with the same measures in 506 patients who underwent ICP monitoring only. The main outcomes were hospital mortality rate, functional independence at hospital discharge, duration of mechanical ventilation, hospital length of stay, and hospital cost. Multivariable regression with robust variance was used to estimate the adjusted differences in the main outcome measures between patient groups. The models were adjusted for patient age, severity of injury, and pathological features seen on head CT scan at admission. Results. On average, patients who underwent ICP/PbO2 monitoring were younger and had more severe injuries than patients who received ICP monitoring alone. Relatively more patients treated with PbO2 monitoring received osmotic therapy, vasopressors, and prolonged sedation. After adjustment for baseline characteristics, the hospital mortality rate was, if anything, slightly higher in patients undergoing PbO2-guided management than in patients monitored with ICP only (adjusted mortality difference 4.4%, 95% CI -3.9 to 13%). Patients who underwent PbO2-guided management also had lower adjusted functional independence scores at hospital discharge (adjusted score difference -0.75, 95% CI -1.41 to -0.09). There was a 27% relative increase (95% CI 6-53%) in the median hospital length of stay when the PbO2 group was compared with the ICP-only group. Conclusions. The mortality rate in patients with traumatic brain injury whose clinical management was guided by PbO2 monitoring was not reduced in comparison with that in patients who received ICP monitoring alone. Brain tissue oxygen monitoring was associated with worse neurological outcome and increased hospital resource utilization. (DOI: 10.3171/2009.2.JNS08998)	[Martini, Ross P.] Brown Univ, Warren Alpert Med Sch, Providence, RI 02912 USA; [Martini, Ross P.; Deem, Steven; Souter, Michael; Treggiari, Miriam M.] Univ Washington, Sch Med, Dept Anesthesiol & Pain Med, Seattle, WA USA; [Deem, Steven] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA; [Yanez, N. David; Daniel, Stephen] Univ Washington, Sch Publ Hlth & Community Med, Dept Biostat, Seattle, WA 98195 USA; [Chesnut, Randall M.; Souter, Michael; Treggiari, Miriam M.] Univ Washington, Sch Med, Dept Neurol Surg, Seattle, WA 98195 USA; [Weiss, Noel S.] Univ Washington, Sch Publ Hlth & Community Med, Dept Epidemiol, Seattle, WA 98195 USA	Martini, RP (corresponding author), Brown Univ, Warren Alpert Med Sch, Box G-8269, Providence, RI 02912 USA.	ross_martini@brown.edu	Souter, Michael/ABE-1890-2020	Chesnut, Randall/0000-0001-6377-3666; Martini, Ross/0000-0001-8811-6558	Foundation for Anesthesia Education and Research; Harborview Anesthesiology Research Center	This study was partially supported by a medical student research fellowship from the Foundation for Anesthesia Education and Research and by the Harborview Anesthesiology Research Center.	Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS65; Bratton SL, 1997, NEUROSURGERY, V40, P707, DOI 10.1097/00006123-199704000-00009; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Contant CF, 2001, J NEUROSURG, V95, P560, DOI 10.3171/jns.2001.95.4.0560; Girard TD, 2008, LANCET, V371, P126, DOI 10.1016/S0140-6736(08)60105-1; Gopinath SP, 1999, CRIT CARE MED, V27, P2337, DOI 10.1097/00003246-199911000-00003; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; Gupta AK, 2002, J NEUROSURG, V96, P263, DOI 10.3171/jns.2002.96.2.0263; Johnston AJ, 2005, CRIT CARE MED, V33, P189, DOI 10.1097/01.CCM.0000149837.09225.BD; Kress JP, 2000, NEW ENGL J MED, V342, P1471, DOI 10.1056/NEJM200005183422002; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Meixensberger J, 2003, J NEUROL NEUROSUR PS, V74, P760, DOI 10.1136/jnnp.74.6.760; Menzel M, 1999, J NEUROSURG, V91, P1, DOI 10.3171/jns.1999.91.1.0001; MUELLER BA, 1990, AM J EPIDEMIOL, V132, P550, DOI 10.1093/oxfordjournals.aje.a115691; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Rosenthal G, 2008, CRIT CARE MED, V36, P1917, DOI 10.1097/CCM.0b013e3181743d77; Servadei F, 2002, ACT NEUR S, V81, P81; Smith MJ, 2005, CRIT CARE MED, V33, P1104, DOI 10.1097/01.CCM.0000162685.60609.49; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018	30	74	76	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	OCT	2009	111	4					644	649		10.3171/2009.2.JNS08998			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	503PL	WOS:000270550000003	19392603				2021-06-18	
J	Brophy, GM; Pineda, JA; Papa, L; Lewis, SB; Valadka, AB; Hannay, HJ; Heaton, SC; Demery, JA; Liu, MC; Tepas, JJ; Gabrielli, A; Robicsek, S; Wang, KKW; Robertson, CS; Hayes, RL				Brophy, Gretchen M.; Pineda, Jose A.; Papa, Linda; Lewis, Stephen B.; Valadka, Alex B.; Hannay, H. Julia; Heaton, Shelley C.; Demery, Jason A.; Liu, Ming Cheng; Tepas, Joseph J., III; Gabrielli, Andrea; Robicsek, Steven; Wang, Kevin K. W.; Robertson, Claudia S.; Hayes, Ronald L.			alpha II-Spectrin Breakdown Product Cerebrospinal Fluid Exposure Metrics Suggest Differences in Cellular Injury Mechanisms after Severe Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						biomarker; CSF; exposure; spectrin; traumatic brain injury	CALPAIN; PROTEIN; MARKERS	Traumatic brain injury (TBI) produces alpha II-spectrin breakdown products (SBDPs) that are potential biomarkers for TBI. To further understand these biomarkers, the present study examined (1) the exposure and kinetic characteristics of SBDPs in cerebrospinal fluid (CSF) of adults with severe TBI, and (2) the relationship between these exposure and kinetic metrics and severity of injury. This clinical database study analyzed CSF concentrations of 150-, 145-, and 120-kDa SBDPs in 38 severe TBI patients. Area under the curve (AUC), mean residence time (MRT), maximum concentration (C-max), time to maximum concentration (T-max), and half-life (t(1/2)) were determined for each SBDP. Markers of calpain proteolysis (SBDP150 and SBDP145) had a greater median AUC and C-max and a shorter MRT than SBDP120, produced by caspase-3 proteolysis in the CSF in TBI patients (p < 0.001). AUC and MRT for SBDP150 and SBDP15 were significantly greater in patients with worse Glasgow Coma Scale (GCS) scores at 24 h after injury compared to those whose GCS scores improved (AUC p = 0.013, MRT p = 0.001; AUC p = 0.009, MRT p = 0.021, respectively). A positive correlation was found between patients with longer elevations in intracranial pressure (ICP) measurements of 25 mm Hg or higher and those with a greater AUC and MRT for all three biomarkers. This is the first study to show that the biomarkers of proteolysis differentially associated with calpain and caspase-3 activity have distinct CSF exposure profiles following TBI that suggest a prominent role for calpain activity. Further studies are being conducted to determine if exposure and kinetic metrics for biofluid-based biomarkers can predict clinical outcome.	[Brophy, Gretchen M.] Virginia Commonwealth Univ, Dept Pharm & Neurosurg, Richmond, VA 23298 USA; [Pineda, Jose A.] Washington Univ, Dept Pediat, St Louis, MO 63130 USA; [Pineda, Jose A.] Washington Univ, Dept Neurol, St Louis, MO USA; [Papa, Linda] Orlando Reg Healthcare, Dept Emergency Med, Orlando, FL USA; [Lewis, Stephen B.] Univ Florida, Dept Neurosurg, Gainesville, FL USA; [Heaton, Shelley C.; Demery, Jason A.] Univ Florida, Dept Clin & Hlth Psychol, Gainesville, FL USA; [Tepas, Joseph J., III; Gabrielli, Andrea] Univ Florida, Dept Surg, Gainesville, FL USA; [Tepas, Joseph J., III] Univ Florida, Dept Pediat, Gainesville, FL USA; [Gabrielli, Andrea; Robicsek, Steven] Univ Florida, Dept Anesthesia, Gainesville, FL USA; [Wang, Kevin K. W.] Univ Florida, Dept Psychiat, Gainesville, FL 32611 USA; [Valadka, Alex B.] Univ Texas Houston, Hlth Sci Ctr, Dept Neurosurg, Houston, TX USA; [Hannay, H. Julia] Univ Houston, Dept Psychol, Houston, TX USA; [Robertson, Claudia S.] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; [Liu, Ming Cheng; Wang, Kevin K. W.; Hayes, Ronald L.] Banyan Biomarkers Inc, Ctr Innovat Res, Alachua, FL USA	Brophy, GM (corresponding author), Virginia Commonwealth Univ, Dept Pharm & Neurosurg, Med Coll Virginia Campus,410 N 12th St,POB 980533, Richmond, VA 23298 USA.	gbrophy@vcu.edu	Pineda, Jose/W-2806-2019	Brophy, Gretchen/0000-0002-4749-2693; Hannay, H. Julia/0000-0001-7023-912X; Wang, Kevin/0000-0002-9343-6473	Department of Defense AwardUnited States Department of Defense [DAMD17-03-1-0772, DAMD17-03-1-0066]; National Institutes of Health AwardUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS049175-01, R01-NS052831-01, R01 NS051431-01, P01-NS38660]; Navy [N00014-06-1-1029]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS049175, P01NS038660, R01NS052831, R01NS051431] Funding Source: NIH RePORTER	This study was supported in part by Department of Defense Award numbers DAMD17-03-1-0772 and DAMD17-03-1-0066; National Institutes of Health Award numbers R01 NS049175-01, R01-NS052831-01, and R01 NS051431-01; Navy grant number N00014-06-1-1029 (University of Florida); and National Institutes of Health grant #P01-NS38660 (Baylor College of Medicine).	Binder S, 2005, J HEAD TRAUMA REHAB, V20, P189, DOI 10.1097/00001199-200505000-00002; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P493; Foerch C, 2005, ARCH NEUROL-CHICAGO, V62, P1130, DOI 10.1001/archneur.62.7.1130; Ghanem G, 2001, INT J CANCER, V94, P586, DOI 10.1002/ijc.1504; Gibaldi M., 1982, PHARMACOKINETICS; Korfias S, 2006, BRAIN INJURY, V20, P867, DOI 10.1080/02699050600832395; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P196, DOI 10.1097/00001199-200505000-00003; Liu MC, 2006, BIOCHEM J, V394, P715, DOI 10.1042/BJ20050905; LOUNEVA N, 2008, AM J PATHOL; Nath R, 2000, NEUROCHEM INT, V36, P119, DOI 10.1016/S0197-0186(99)00112-6; Pineda JA, 2007, J NEUROTRAUM, V24, P354, DOI 10.1089/neu.2006.003789; Shore PM, 2004, J NEUROTRAUM, V21, P1113; Tanaka Y, 2007, BRAIN RES, V1137, P140, DOI 10.1016/j.brainres.2006.12.025; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Wu HV, 2006, MOL NEUROBIOL, V33, P215, DOI 10.1385/MN:33:3:215; Wunderlich MT, 2006, CLIN NEUROL NEUROSUR, V108, P558, DOI 10.1016/j.clineuro.2005.12.006	16	74	78	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2009	26	4					471	479		10.1089/neu.2008.0657			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	430OV	WOS:000264999300001	19206997	Green Published			2021-06-18	
J	Nishisaki, A; Hales, R; Biagas, K; Cheifetz, I; Corriveau, C; Garber, N; Hunt, E; Jarrah, R; McCloskey, J; Morrison, W; Nelson, K; Niles, D; Smith, S; Thomas, S; Tuttle, S; Helfaer, M; Nadkarni, V				Nishisaki, Akira; Hales, Roberta; Biagas, Katherine; Cheifetz, Ira; Corriveau, Christine; Garber, Nan; Hunt, Elizabeth; Jarrah, Rima; McCloskey, John; Morrison, Wynne; Nelson, Kristen; Niles, Dana; Smith, Sophia; Thomas, Samuel; Tuttle, Stephanie; Helfaer, Mark; Nadkarni, Vinay			A multi-institutional high-fidelity simulation "boot camp" orientation and training program for first year pediatric critical care fellows	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						pediatric critical care fellowship; simulation; orientation; team training; patient safety	RESOURCE-MANAGEMENT; PERFORMANCE; SKILLS; COMPETENCE	Objective: Simulation training has been used to integrate didactic knowledge, technical skills, and crisis resource management for effective orientation and patient safety. We hypothesize multi-Institutional simulation-based training for first year pediatric critical care (PCC) fellows is feasible and effective. Design. Descriptive, educational intervention study. Setting. The simulation facility at the host institution. Interventions., A multicentered simulation-based orientation training "boot camp" for first year PCC fellows was held at a large simulation center. Immediate posttraining evaluation and 6-month follow-up surveys were distributed to participants. Measurements and Main Results: A novel simulation-based orientation training for first year PCC fellows was facilitated by volunteer faculty from seven institutions. The two and a half day course was organized to cover common PCC crises. High-fidelity simulation was integrated Into each session (airway management, vascular access, resuscitation, sepsis, trauma/traumatic brain injury, delivering bad news). Twenty-two first year PCC fellows from nine fellowship programs attended, and 13 faculty facilitated, for a total of 15.5 hours (369 person-hours) of training. This consisted of 2.75 hours for whole group didactic sessions (17.7%), 1.08 hours for a small group interactive session (7.0%), 4.67 hours for task training (30.1%), and 7 hours for training (45.2%) with high-fidelity simulation and crisis resource management. A "train to success" approach with repetitive practice of critical assessment and interventional skills yielded higher scores in training effectiveness in the end-of-course evaluation. A follow-up survey revealed this training was highly effective in improving clinical performance and self-confidence. Conclusions: The first PCC orientation training integrated with simulation was effective and logistically feasible. The train to success concept with repetitive practice was highly valued by participants. Continuation and expansion of this novel multi-institutional training is planned. (Pediatr Crit Care Med 2009; 10:157-162)	[Nishisaki, Akira; Hales, Roberta; Niles, Dana; Thomas, Samuel; Nadkarni, Vinay] Childrens Hosp Philadelphia, Ctr Simulat Adv Educ & Innovat, Philadelphia, PA 19104 USA; [Biagas, Katherine] Columbia Univ, Dept Pediat, Med Ctr, New York, NY 10027 USA; [Cheifetz, Ira] Duke Univ, Dept Anesthesiol, Durham, NC USA; [Corriveau, Christine; Smith, Sophia] Childrens Natl Med Ctr, Crit Care Med Div, Washington, DC 20010 USA; [Garber, Nan] Univ Maryland, Dept Pediat, Baltimore, MD 21201 USA; [Hunt, Elizabeth; Nelson, Kristen] Johns Hopkins Univ, Dept Anesthesiol & Crit Care Med, Baltimore, MD USA; [Tuttle, Stephanie] Jersey Shore Med Ctr, Dept Pediat, Div Crit Care Med, Neptune, NJ USA	Nishisaki, A (corresponding author), Childrens Hosp Philadelphia, Ctr Simulat Adv Educ & Innovat, Philadelphia, PA 19104 USA.	nishisaki@email.chop.edu	Cheifetz, Ira/I-8692-2019	Cheifetz, Ira/0000-0002-1174-1571			Ahlberg G, 2005, ENDOSCOPY, V37, P1198, DOI 10.1055/s-2005-921049; *AM BOARD PED, SUBSP CERT EX; Blum RH, 2004, MED EDUC, V38, P45, DOI 10.1046/j.1365-2923.2004.01696.x; Davis DA, 2006, JAMA-J AM MED ASSOC, V296, P1094, DOI 10.1001/jama.296.9.1094; DeVita MA, 2004, CRIT CARE MED, V32, pS61, DOI 10.1097/01.CCM.0000110872.86812.1C; Dieckmann Peter, 2007, Simul Healthc, V2, P183, DOI 10.1097/SIH.0b013e3180f637f5; DOWNES JJ, 1992, CRIT CARE CLIN, V8, P1; DUNN WF, 2005, SIMULATORS CRITICAL; Fanning Ruth M, 2007, Simul Healthc, V2, P115, DOI 10.1097/SIH.0b013e3180315539; Fortenberry JD, 2007, PEDIATR CRIT CARE ME, V8, pS1, DOI 10.1097/01.PCC.0000257734.84591.1F; Hamman WR, 2004, QUAL SAF HEALTH CARE, V13, pI72, DOI 10.1136/qshc.2004.009910; Hunt EA, 2008, PEDIATRICS, V121, pE34, DOI 10.1542/peds.2007-0029; Issenberg SB, 2005, MED TEACH, V27, P10, DOI 10.1080/01421590500046924; JELLINEK MS, 1993, CRIT CARE MED, V21, P775, DOI 10.1097/00003246-199305000-00023; Kim J, 2006, CRIT CARE MED, V34, P2167, DOI 10.1097/01.CCM.0000229877.45125.CC; Knudson MM, 2008, J TRAUMA, V64, P255, DOI 10.1097/TA.0b013e31816275b0; KOHN L, 1999, ERROR IS HUMAN BUILD; Kory PD, 2007, CHEST, V132, P1927, DOI 10.1378/chest.07-1554; Malec James F, 2007, Simul Healthc, V2, P4, DOI 10.1097/SIH.0b013e31802b68ee; Nishisaki Akira, 2007, Anesthesiol Clin, V25, P225, DOI 10.1016/j.anclin.2007.03.009; Reznick RK, 2006, NEW ENGL J MED, V355, P2664, DOI 10.1056/NEJMra054785; Rudolph Jenny W, 2006, Simul Healthc, V1, P49; Rudolph Jenny W, 2007, Simul Healthc, V2, P161, DOI 10.1097/SIH.0b013e31813d1035; Savoldelli GL, 2005, CAN J ANAESTH, V52, P944, DOI 10.1007/BF03022056; Seymour NE, 2002, ANN SURG, V236, P458, DOI 10.1097/00000658-200210000-00008; Slonim Anthony D, 2005, Pediatr Crit Care Med, V6, P264, DOI 10.1097/01.PCC.0000160592.87113.C6; Streiner DL., 2003, HLTH MEASUREMENT SCA, V3rd; Sundar Eswar, 2007, Anesthesiol Clin, V25, P283, DOI 10.1016/j.anclin.2007.03.011	28	74	74	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1529-7535	1947-3893		PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	MAR	2009	10	2					157	162		10.1097/PCC.0b013e3181956d29			6	Critical Care Medicine; Pediatrics	General & Internal Medicine; Pediatrics	419VK	WOS:000264247600001	19188876				2021-06-18	
J	Sayer, NA; Rettmann, NA; Carlson, KF; Bernardy, N; Sigford, BJ; Hamblen, JL; Friedman, MJ				Sayer, Nina A.; Rettmann, Nancy A.; Carlson, Kathleen F.; Bernardy, Nancy; Sigford, Barbara J.; Hamblen, Jessica L.; Friedman, Matthew J.			Veterans with history of mild traumatic brain injury and posttraumatic stress disorder: Challenges from provider perspective	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						combat disorders; comorbidity; education; health services needs and demands; mild traumatic brain injury; pain; posttraumatic stress disorder; rehabilitation; traumatic brain injury; veterans	RAPID ASSESSMENT; CARE; AFGHANISTAN; DEPRESSION; IRAQ	The Department of Veterans Affairs (VA) has separate clinical structures and care processes for traumatic brain injury (TBI) and posttraumatic stress disorder (PTSD). However, because veterans are returning from the wars in Iraq and Afghanistan with TBI (most frequently mild TBI [mTBI]) and PTSD, the VA needs to evaluate current service delivery systems. We conducted key informant interviews with 40 providers from across the United States who represented separate clinical teams providing specialized TBI or PTSD services. We identified challenges providers perceive in scheduling and engaging patients with co-occurring mTBI and PTSD (mTBI/PTSD) in treatment, determining the etiology of patients' presenting problems, coordinating services, and knowing whether or how to alter standard treatments. We found consensus that patients with mTBI/PTSD often have other morbidities requiring specialized treatment, including pain and sleep disturbance. Another important theme we found was the need for patient and family educational material on mTBI/PTSD or pain and mTBI/PTSD and provider education tailored to provider specialty. Together, findings point to the need for guidance for providers on best practices to assess and treat mTBI/PTSD given available information, a systematic approach toward patient and provider education, and research to build the evidence base for practice.	[Sayer, Nina A.; Rettmann, Nancy A.; Carlson, Kathleen F.; Sigford, Barbara J.] VAMC, Minneapolis Dept, Minneapolis, MN USA; [Sayer, Nina A.; Carlson, Kathleen F.; Sigford, Barbara J.] Univ Minnesota, Minneapolis, MN USA; [Bernardy, Nancy; Hamblen, Jessica L.; Friedman, Matthew J.] VAMC, Natl Ctr Posttraumat Stress Disorder, Execut Div, White River Jct, VT USA; [Hamblen, Jessica L.; Friedman, Matthew J.] Dartmouth Med Sch, Hanover, NH USA	Sayer, NA (corresponding author), Vet Adm Med Ctr, Ctr Chron Dis Outcomes Res, 1 Vet Dr 152-2E, Minneapolis, MN 55417 USA.	nina.sayer@va.gov	Sayer, Nina/E-3249-2016		VA Health Services Research and Development Quality Enhancement Research Initiative [PLY 08-05-3]	This material was based on work supported by a VA Health Services Research and Development Quality Enhancement Research Initiative Locally Initiated Project (grant PLY 08-05-3).	American Psychiatric Association, 1994, DIAGN STAT MAN MENT; [Anonymous], 2009, NEWSWEEK; Batten SV, 2008, J CLIN PSYCHOL, V64, P928, DOI 10.1002/jclp.20513; Beebe J., 2001, RAPID ASSESSMENT PRO; Bliese PD, 2008, J CONSULT CLIN PSYCH, V76, P272, DOI 10.1037/0022-006X.76.2.272; Bryant RA, 1996, J TRAUMA STRESS, V9, P621; Crabtree B.F., 1999, DOING QUALITATIVE RE; Defense and Veterans Brain Injury Center, 2006, DEF VET BRAIN INJ CT; *DEP VET AFF, 2008, VA LEARN CAT DIAGN M; *DEP VET AFF MAN P, 2004, VA DOD CLIN PRACT GU; Fitch C, 2004, SOC SCI MED, V59, P1819, DOI 10.1016/j.socscimed.2004.02.028; Harvey AG, 2000, AM J PSYCHIAT, V157, P626, DOI 10.1176/appi.ajp.157.4.626; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; IRAQ RR, 2007, MARINES EXPERIENCE B; Iverson G.L., 2007, BRAIN INJURY MED PRI, P373; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kennedy JE, 2007, J REHABIL RES DEV, V44, P895, DOI 10.1682/JRRD.2006.12.0166; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; Management of Concussion/mTBI Working Group, 2009, J Rehabil Res Dev, V46, pCP1; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; Miles M.B., 1994, QUALITATIVE DATA ANA; Needle RH, 2003, AM J PUBLIC HEALTH, V93, P970, DOI 10.2105/AJPH.93.6.970; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; Sigford BJ, 2008, ARCH PHYS MED REHAB, V89, P160, DOI 10.1016/j.apmr.2007.09.015; Soo C, 2007, COCHRANE DB SYST REV, V3; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Warden DL, 2005, J NEUROTRAUM, V22, P1178	32	74	74	0	3	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.		2009	46	6					703	715		10.1682/JRRD.2009.01.0008			13	Rehabilitation	Rehabilitation	531BQ	WOS:000272638100008	20104400	Bronze			2021-06-18	
J	Chen, JK; Johnston, KM; Petrides, M; Ptito, A				Chen, Jen-Kai; Johnston, Karen M.; Petrides, Michael; Ptito, Alain			Recovery from mild head injury in sports: Evidence from serial functional magnetic resonance imaging studies in male athletes	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						concussion; mild head injury; post-concussive symptoms; fMRI; recovery	TRAUMATIC BRAIN-INJURY; NEUROPSYCHOLOGICAL DEFICITS; AGREEMENT STATEMENT; FOOTBALL PLAYERS; CONCUSSION; ACTIVATION; FMRI; PERFORMANCE; SYMPTOMS; CORTEX	Objective: To examine functional brain activation patterns before and after postconcussive symptoms (PCS) resolution. Design: Prospective serial study with male athletes using functional magnetic resonance imaging (fMRI). Setting: Hospital laboratory and imaging facility. Participants: 9 symptomatic concussed athletes who experienced persisting PCS at least I month postinjury and 6 healthy athletes. Interventions: All athletes filled out a PCS checklist and underwent an fMRI session during which they performed a working-memory task. Main outcome measurements: Behavioral outcomes were response speed and accuracy on the working memory tasks performed during the fMRI session. Functional imaging outcomes were blood oxygen level-dependent fMRI activation patterns associated with a working memory task. Results: There was no difference in behavioral performance between the groups. Despite normal structural MRI findings, all symptomatic concussed athletes initially showed atypical brain activation patterns in the dorsolateral prefrontal cortex (DLPC). Compared to the initial postinjury evaluation, those athletes at follow-up with PCS resolved showed significant increases in activation in the left DLPC. Concussed athletes whose PCS status remained unchanged at follow-up continued to show atypical activation in DLPC. Healthy athletes showed remarkably clear and consistent brain activations in DLPC initially as well as in follow-up, highlighting the test-retest reliability of fMRI. Conclusions: The results demonstrate the feasibility of using fMRI to detect an underlying pathology in symptomatic concussed athletes with normal structural imaging results and its potential to document recovery. Such information may be of considerable value for clinical judgment and patient management.	[Chen, Jen-Kai; Petrides, Michael; Ptito, Alain] McGill Univ, Montreal Neurol Inst, Neuropsychol Dept, Cognit Neurosci Unit, Montreal, PQ H3A 2B4, Canada; [Johnston, Karen M.] Univ Toronto, Concuss Clin Rehabil Program, Toronto Rehabil Div Neurosurg, Toronto, ON, Canada	Ptito, A (corresponding author), McGill Univ, Montreal Neurol Inst, Neuropsychol Dept, Cognit Neurosci Unit, 3801 Univ St, Montreal, PQ H3A 2B4, Canada.	alain.ptito@mcgill.ca					Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; BOHNEN N, 1992, NEUROSURGERY, V30, P692; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; DELANEY IS, 1997, CLIN J SPORT MED, V10, P9; Gordon KE, 2006, PEDIATR NEUROL, V34, P376, DOI 10.1016/j.pediatrneurol.2005.09.007; Gross H, 1996, J NEUROPSYCH CLIN N, V8, P324; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; HintonBayre AD, 1997, J CLIN EXP NEUROPSYC, V19, P275, DOI 10.1080/01688639708403857; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Jansen HML, 1996, J NEUROL NEUROSUR PS, V60, P221, DOI 10.1136/jnnp.60.2.221; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; Johnston KM, 2001, CLIN J SPORT MED, V11, P150, DOI 10.1097/00042752-200107000-00005; Johnston KM, 2001, J AM COLL SURGEONS, V192, P515, DOI 10.1016/S1072-7515(01)00797-9; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; Lovell MR, 2007, NEUROSURGERY, V61, P352, DOI 10.1227/01.NEU.0000279985.94168.7F; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Margulies S, 2000, J CLIN NEUROSCI, V7, P400, DOI 10.1054/jocn.1999.0681; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory Paul, 2005, Clin J Sport Med, V15, P48; NEWCOMBE F, 1994, J NEUROL NEUROSUR PS, V57, P709, DOI 10.1136/jnnp.57.6.709; NEWTON MR, 1992, J NEUROL NEUROSUR PS, V55, P92, DOI 10.1136/jnnp.55.2.92; Petrides M, 2005, PHILOS T ROY SOC B, V360, P781, DOI 10.1098/rstb.2005.1631; PETRIDES M, 1993, P NATL ACAD SCI USA, V90, P878, DOI 10.1073/pnas.90.3.878; PETRIDES M, 2001, 7 INT C FUNCT MAPP H, V7, pS721; Ptito A, 2007, NEUROREHABILITATION, V22, P217; SZYMANSKI HV, 1992, INT J PSYCHIAT MED, V22, P357, DOI 10.2190/XARA-B1EF-J2HC-VAE0; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832; Worsley KJ, 2002, NEUROIMAGE, V15, P1, DOI 10.1006/nimg.2001.0933; Worsley KJ, 2003, STAT METHODS MED RES, V12, P401, DOI 10.1191/0962280203sm340ra	40	74	74	0	19	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	MAY	2008	18	3					241	247		10.1097/JSM.0b013e318170b59d			7	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	298SG	WOS:000255706800004	18469565				2021-06-18	
J	Mascia, L; Sakr, Y; Pasero, D; Payen, D; Reinhart, K; Vincent, JL				Mascia, Luciana; Sakr, Yasser; Pasero, Daniela; Payen, Didier; Reinhart, Konrad; Vincent, Jean-Louis		SOAP Investigators	Extracranial complications in patients with acute brain injury: a post-hoc analysis of the SOAP study	INTENSIVE CARE MEDICINE			English	Article						sepsis; acute respiratory distress syndrome; brain injury; stroke	SEVERE HEAD-INJURY; NEUROGENIC PULMONARY-EDEMA; ANEURYSMAL SUBARACHNOID HEMORRHAGE; INTENSIVE-CARE UNITS; ACUTE LUNG INJURY; ORGAN DYSFUNCTION; MEDICAL COMPLICATIONS; CONSENSUS CONFERENCE; MULTICENTER; SCORE	Objective: To assess the incidence and severity of nonneurological organ dysfunction and its effect on outcome in acute neurological patients in an international cohort observational study. Design and setting: Analysis of database from the observational Sepsis Occurrence in Acutely Ill Patients (SOAP) study in 198 intensive care units (ICUs) in 24 European countries. Patients: All adult patients admitted to the participating ICUs between 1 and 15 May 2002. Of the 3,147 patients in the SOAP database 373 (12%) were admitted with a neurological diagnosis, including 154 (41%) with traumatic brain injury and 186 (50%) with cerebrovascular accident. Measurements and results: Patients were followed until death, hospital discharge, or for 60 days. Neurological patients were younger and had a higher incidence of trauma and fewer comorbidities than nonneurological patients. Neurological patients developed ICU-acquired sepsis and respiratory failure more frequently than the other patients. ICU and hospital mortality rates were higher and ICU length of stay longer in neurological than in nonneurological patients. Multivariate logistic analysis showed that, in addition to the Glasgow Coma Score (GCS) and the presence of nontraumatic brain injury, cardiovascular failure, hepatic failure, and ALI/ARDS were the only factors independently associated with a higher risk of death in the ICU in patients with a neurological diagnosis. Conclusions: Although neurological patients were younger and had fewer comorbidities, they developed ICU-acquired sepsis and respiratory failure more frequently than other patients. Efforts should be oriented to reduce cardiovascular, hepatic, and respiratory complications.	[Mascia, Luciana; Pasero, Daniela] Univ Turin, Osped S Giovanni Battista, Dept Anesthesiol & Intens Care, I-10126 Turin, Italy; [Sakr, Yasser; Reinhart, Konrad] Univ Jena, Dept Anesthesiol & Intens Care, Jena, Germany; [Payen, Didier] CHU Lariboisiere, Dept Anesthesiol & Intens Care, Paris, France; [Vincent, Jean-Louis] Free Univ Brussels, Erasme Hosp, Dept Intens Care, B-1050 Brussels, Belgium	Mascia, L (corresponding author), Univ Turin, Osped S Giovanni Battista, Dept Anesthesiol & Intens Care, Corso Dogliotti 14, I-10126 Turin, Italy.	luciana.mascia@unito.it	Sierra, Rafael/I-3441-2015; Sakr, Yasser/D-9802-2013; mascia, Luciana/L-3039-2018	Sierra, Rafael/0000-0002-6021-396X; Vincent, Jean-Louis/0000-0001-6011-6951			BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; BONE RC, 1992, CRIT CARE MED, V20, P864, DOI 10.1097/00003246-199206000-00025; Bratton SL, 1997, NEUROSURGERY, V40, P707, DOI 10.1097/00006123-199704000-00009; Brienza N, 2006, INTENS CARE MED, V32, P267, DOI 10.1007/s00134-005-0023-3; Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; Chen HI, 1995, BIOL SIGNAL, V4, P186; Clifton GL, 2002, CRIT CARE MED, V30, P739, DOI 10.1097/00003246-200204000-00003; Contant CF, 2001, J NEUROSURG, V95, P560, DOI 10.3171/jns.2001.95.4.0560; Gruber A, 1999, CRIT CARE MED, V27, P505, DOI 10.1097/00003246-199903000-00026; Harbrecht BG, 2002, J TRAUMA, V53, P517, DOI 10.1097/00005373-200209000-00020; Holland MC, 2003, J TRAUMA, V55, P106, DOI 10.1097/01.TA.0000071620.27375.BE; *INT STUD UNR INTR, 1998, NEW ENGL J MED, V339, P1275; KIKUCHI T, 1995, NEUROL RES, V17, P106, DOI 10.1080/01616412.1995.11740296; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; Lennihan L, 2000, STROKE, V31, P383, DOI 10.1161/01.STR.31.2.383; MARSHALL JC, 1995, CRIT CARE MED, V23, P1638, DOI 10.1097/00003246-199510000-00007; McKeating EG, 1997, BRIT J ANAESTH, V78, P520; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROGERS FB, 1995, J TRAUMA, V39, P860, DOI 10.1097/00005373-199511000-00009; ROSENWASSER RH, 1995, NEUROSURGERY, V37, P872, DOI 10.1227/00006123-199511000-00004; SOLENSKI NJ, 1995, CRIT CARE MED, V23, P1007, DOI 10.1097/00003246-199506000-00004; TEASDALE G, 1974, LANCET, V2, P81; TOUHO H, 1989, NEUROSURGERY, V25, P762, DOI 10.1227/00006123-198911000-00011; Tracey KJ, 2007, J CLIN INVEST, V117, P289, DOI 10.1172/JCI30555; Vincent JL, 1998, CRIT CARE MED, V26, P1793, DOI 10.1097/00003246-199811000-00016; Vincent JL, 2006, CRIT CARE MED, V34, P344, DOI 10.1097/01.CCM.0000194725.48928.3A; Wartenberg KE, 2006, CRIT CARE MED, V34, P617, DOI 10.1097/01.CCM.0000201903.46435.35; Yildirim E, 2004, EUR J CARDIO-THORAC, V25, P523, DOI 10.1016/j.ejcts.2003.12.021; Zygun DA, 2005, CRIT CARE MED, V33, P654, DOI 10.1097/01.ccm.0000155911.01844.54	31	74	78	0	2	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013 USA	0342-4642			INTENS CARE MED	Intensive Care Med.	APR	2008	34	4					720	727		10.1007/s00134-007-0974-7			8	Critical Care Medicine	General & Internal Medicine	278BV	WOS:000254259400018	18175107				2021-06-18	
J	Stocchetti, N; Zanaboni, C; Colombo, A; Citerio, G; Beretta, L; Ghisoni, L; Zanier, ER; Canavesi, K				Stocchetti, Nino; Zanaboni, Clelia; Colombo, Angelo; Citerio, Giuseppe; Beretta, Luigi; Ghisoni, Laura; Zanier, Elisa Roncati; Canavesi, Katia			Refractory intracranial hypertension and "second-tier" therapies in traumatic brain injury	INTENSIVE CARE MEDICINE			English	Article						intracranial pressure; surgical decompression; barbiturates; hyperventilation; outcome; traumatic brain injury	SEVERE HEAD-INJURY; DECOMPRESSIVE CRANIECTOMY; BLOOD-FLOW; PRESSURE; HYPERVENTILATION; MANAGEMENT; SCALE	Objective: To quantify the occurrence of high intracranial pressure (HICP) refractory to conventional medical therapy after traumatic brain injury (TBI) and to describe the use of more aggressive therapies (profound hyperventilation, barbiturates, decompressive craniectomy). Design: Prospective study of 407 consecutive TBI patients Setting: Three neurosurgical intensive care units (ICU). Measurements and results: Intracranial pressure (ICP) was studied during the first week after TBI; 153 patients had at least 1 day of ICP>20mmHg. Early surgery was necessary for 221 cases, and standard medical therapy [sedation, mannitol, cerebrospinal fluid (CSF) withdrawal, PaCO2 30-35mmHg] was used in 135 patients. Reinforced treatment (PaCO2 25-29mmHg, induced arterial hypertension, muscle relaxants) was used in 179 cases (44%), and second-tier therapies in 80 (20%). Surgical decompression and/or barbiturates were used in 28 of 407 cases (7%). Six-month outcome was recorded in 367 cases using the Glasgow outcome scale (GOS). The outcome was favorable (good recovery or moderate disability) in 195 cases (53%) and unfavorable (all the other categories) in 172 (47%). HICP was associated with worse outcome. Outcome for cases who had received second-tier therapies was significantly worse (43% favorable at 6 months, p=0.03). Conclusions: HICP is frequent and is associated with worse outcome. ICP was controlled by early surgery and first-tier therapies in the majority of cases. Profound hyperventilation, surgical decompression and barbiturates were used in various combinations in a minority of cases. The indications for surgical decompression and/or barbiturates seem restricted to less than 10% of severe TBI.	[Stocchetti, Nino; Zanaboni, Clelia; Colombo, Angelo; Ghisoni, Laura; Zanier, Elisa Roncati; Canavesi, Katia] Osped Maggiore Policlin Mangiagalli & Regina Elen, Fdn IRCCS, Neurosci Intens Care Unit, I-20122 Milan, Italy; [Citerio, Giuseppe] Terapia Intens Neurochirurg Osped S Gerardo, Monza, Italy; [Beretta, Luigi] Terapia Intens Neurochirurg Osped S Gerardo, Milan, Italy	Stocchetti, N (corresponding author), Osped Maggiore Policlin Mangiagalli & Regina Elen, Fdn IRCCS, Neurosci Intens Care Unit, Via F Sforza 35, I-20122 Milan, Italy.	stocchet@policlinico.mi.it	Stocchetti, Nino/O-7444-2017; Citerio, Giuseppe/B-1839-2015; Zanier, Elisa/AAA-8095-2020	Stocchetti, Nino/0000-0003-3250-6834; Citerio, Giuseppe/0000-0002-5374-3161; Zanier, Elisa/0000-0002-3011-8718			Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P537; Citerio G, 2000, ACTA NEUROCHIR, V142, P769, DOI 10.1007/s007010070091; Citerio G, 2007, INTENS CARE MED, V33, P45, DOI 10.1007/s00134-006-0381-5; Coles JP, 2002, CRIT CARE MED, V30, P1950, DOI 10.1097/00003246-200209000-00002; Compagnone C, 2005, NEUROSURGERY, V57, P1183; *DEP HUM SERV VICT, 2003, TRAUM TREATM TRIAL N; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; GOWER DJ, 1988, NEUROSURGERY, V23, P417, DOI 10.1227/00006123-198810000-00002; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; HUKKELHOVEN CW, 2000, J NEUROSURG, V97, P549; JENNETT B, 1975, LANCET, V1, P480; Kunze E, 1998, ACT NEUR S, V71, P16; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; Munch E, 2000, NEUROSURGERY, V47, P315; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; ROBERTS I, 2004, COCHRANE LIBRARY; ROBERTS I, 2000, COCHRANE DB SYST REV, V2; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Sahuquillo J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003983.pub2; SCHALEN W, 1992, ACTA ANAESTH SCAND, V36, P369, DOI 10.1111/j.1399-6576.1992.tb03483.x; Schneider GH, 2002, ACT NEUR S, V81, P77; Skoglund TS, 2006, J NEUROTRAUM, V23, P1502, DOI 10.1089/neu.2006.23.1502; Stiefel MF, 2004, J NEUROSURG, V101, P241, DOI 10.3171/jns.2004.101.2.0241; Stocchetti N, 1999, INTENS CARE MED, V25, P371, DOI 10.1007/s001340050860; Stocchetti N, 2005, CHEST, V127, P1812, DOI 10.1378/chest.127.5.1812; UNTERBERG A, 1993, NEUROSURGERY, V32, P17, DOI 10.1227/00006123-199301000-00003; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Winkler PA, 2000, J NEUROSURG, V93, P53, DOI 10.3171/jns.2000.93.1.0053; Yoo DS, 1999, J NEUROSURG, V91, P953, DOI 10.3171/jns.1999.91.6.0953; 1988, LANCET, V1, P1204	33	74	80	0	8	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	MAR	2008	34	3					461	467		10.1007/s00134-007-0948-9			7	Critical Care Medicine	General & Internal Medicine	263EQ	WOS:000253200800011	18066523				2021-06-18	
J	Verdonck, O; Lahrech, H; Francony, G; Carle, O; Farion, R; Van de Looij, Y; Remy, C; Segebarth, C; Payen, JF				Verdonck, Olivier; Lahrech, Hana; Francony, Gilles; Carle, Olivier; Farion, Regine; Van de Looij, Yohan; Remy, Chantal; Segebarth, Christoph; Payen, Jean-Francois			Erythropoietin protects from post-traumatic edema in the rat brain	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						erythropoietin; brain edema; traumatic brain injury; magnetic resonance imaging; neuroprotection	RECOMBINANT-HUMAN-ERYTHROPOIETIN; CEREBRAL-BLOOD-FLOW; WATER-CONTENT; NEURONAL APOPTOSIS; CELLULAR EDEMA; INJURY; DIFFUSION; MODEL; MECHANISMS; ISCHEMIA	Erythropoietin (Epo) is gaining interest in various neurological insults as a possible neuroprotective agent. We determined the effects of recombinant human Epo (rhEpo, 5000 IU per kg bw) on brain edema induced in rats by traumatic brain injury (TBI; impact-acceleration model; rhEpo administration 30 mins after injury). Magnetic resonance imaging (MRI) and a gravimetric technique were applied. In the MRI experiments, the apparent diffusion coefficient (ADC) and the tissue T, relaxation time were measured hourly in the neocortex and caudoputamen, during a 6 h time span after TBI. In the gravimetric experiments, brain water content (BWC) was determined in these two regions, 6 h after TBI. Apparent diffusion coefficient measurements showed that rhEpo decreased brain edema early and durably. Gravimetric measurements showed that rhEpo decreased BWC at H, in the neocortex as well as in the caudoputamen. No significant differences in ADC, in T, or in BWC were found between rhEpo treated-TBI rats and sham-operated rats. Our findings show that post-traumatic administration of rhEpo can significantly reduce the development of brain edema in a model of diffuse TBI. Further studies should be conducted to identify the biochemical mechanisms involved in these immediate effects and to assess the use of rhEpo as a possible therapy for post-traumatic brain edema.	Hop Albert Michallon, INSERM U594, F-38043 Grenoble, France; Univ Grenoble, Grenoble, France; CHU Grenoble, Michallons Hosp, Dept Anesthesiol & Crit Care Med, F-38043 Grenoble, France	Payen, JF (corresponding author), Hop Albert Michallon, INSERM U594, Pavillon B,BP 217, F-38043 Grenoble, France.	jfpayen@ujf-grenoble.fr	Payen, Jean-Francois/L-6667-2014; Remy, Chantal/L-9459-2014; fathi, mazyar/H-1722-2016; Lahrech, Hana/M-5229-2018	Lahrech, Hana/0000-0003-3843-3410; van de Looij, Yohan/0000-0003-2830-5482			Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; Assaf Y, 1999, J NEUROTRAUM, V16, P1165, DOI 10.1089/neu.1999.16.1165; Barbier EL, 2005, NMR BIOMED, V18, P499, DOI 10.1002/nbm.979; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Bernaudin M, 2000, GLIA, V30, P271, DOI 10.1002/(SICI)1098-1136(200005)30:3<271::AID-GLIA6>3.3.CO;2-8; Bernaudin M, 1999, J CEREBR BLOOD F MET, V19, P643, DOI 10.1097/00004647-199906000-00007; Brines M, 2005, NAT REV NEUROSCI, V6, P484, DOI 10.1038/nrn1687; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Calapai G, 2000, EUR J PHARMACOL, V401, P349, DOI 10.1016/S0014-2999(00)00466-0; Cernak I, 2004, NEUROBIOL DIS, V17, P29, DOI 10.1016/j.nbd.2004.05.011; Chen IR, 2003, IEEE T MOBILE COMPUT, V2, P3, DOI 10.1109/TMC.2003.1195147; Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074; Ehrenreich H, 2002, MOL MED, V8, P495, DOI 10.1007/BF03402029; Enriquez P, 2004, CURR PHARM DESIGN, V10, P2131; Fatouros PP, 1999, J NEUROSURG, V90, P109, DOI 10.3171/jns.1999.90.1.0109; FATOUROS PP, 1991, MAGNET RESON MED, V17, P402, DOI 10.1002/mrm.1910170212; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; FREI HJ, 1973, ACTA NEUROCHIR, V29, P15, DOI 10.1007/BF01414613; Gorio A, 2005, P NATL ACAD SCI USA, V102, P16379, DOI 10.1073/pnas.0508479102; Gorio A, 2002, P NATL ACAD SCI USA, V99, P9450, DOI 10.1073/pnas.142287899; Grasso G, 2005, NEUROSURGERY, V56, P821, DOI 10.1227/01.NEU.0000156493.00904.7E; Grasso G, 2004, NEUROSCIENTIST, V10, P93, DOI 10.1177/1073858403259187; Grasso G, 2002, P NATL ACAD SCI USA, V99, P5627, DOI 10.1073/pnas.082097299; Huisman TAGM, 2003, EUR RADIOL, V13, P2283, DOI 10.1007/s00330-003-1843-6; Kawakami M, 2001, J BIOL CHEM, V276, P39469, DOI 10.1074/jbc.M105832200; Kimelberg HK, 2004, NEUROSCIENCE, V129, P851, DOI 10.1016/j.neuroscience.2004.07.033; Leist M, 2004, SCIENCE, V305, P239, DOI 10.1126/science.1098313; Lin WL, 2000, J CEREBR BLOOD F MET, V20, P37, DOI 10.1097/00004647-200001000-00007; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Maiese K, 2004, TRENDS PHARMACOL SCI, V25, P577, DOI 10.1016/j.tips.2004.09.006; MARMAROU A, 1982, J NEUROSURG, V56, P246, DOI 10.3171/jns.1982.56.2.0246; Marmarou A, 2006, J NEUROSURG, V104, P720, DOI 10.3171/jns.2006.104.5.720; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Matchett G, 2006, J NEUROSCI METH, V158, P234, DOI 10.1016/j.jneumeth.2006.06.003; Morishita E, 1997, NEUROSCIENCE, V76, P105, DOI 10.1016/s0306-4522(96)00306-5; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Silva AC, 1999, J CEREBR BLOOD F MET, V19, P871, DOI 10.1097/00004647-199908000-00006; Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598; TIO J, 1996, J NEUROSURG, V84, P97; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje	44	74	79	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	JUL	2007	27	7					1369	1376		10.1038/sj.jcbfm.9600443			8	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	180OL	WOS:000247375000007	17264861	Bronze			2021-06-18	
J	Hortobagyi, T; Wise, S; Hunt, N; Cary, N; Djurovic, V; Fegan-Earl, A; Shorrock, K; Rouse, D; Al-Sarraj, S				Hortobagyi, T.; Wise, S.; Hunt, N.; Cary, N.; Djurovic, V.; Fegan-Earl, A.; Shorrock, K.; Rouse, D.; Al-Sarraj, S.			Traumatic axonal damage in the brain can be detected using beta-APP immunohistochemistry within 35 min after head injury to human adults	NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY			English	Article						antigen retrieval; beta-amyloid precursor protein (beta-APP); diffuse traumatic axonal injury; immunohistochemistry; survival time	AMYLOID PRECURSOR PROTEIN; MICROWAVE ANTIGEN RETRIEVAL; FORENSIC PRACTICE; IMPACT MODEL; IMMUNOREACTIVITY; SWELLINGS; DIAGNOSIS; TRANSPORT; MARKER; CELLS	Immunohistochemistry staining for beta-amyloid precursor protein (beta-APP) is a sensitive method to detect early axonal damage in traumatic brain injury, which was previously estimated to be of minimum 60-90 min after head injury. We present seven cases of well- documented post-traumatic survival of 35-60 min where beta-APP detects early axonal damage. Cases were selected from routine work where documentation about survival is judged to be accurate. These are divided into three groups: group 1: severe head injury (n = 7) with documented survival between 35 and 60 min. Group 2: severe head injury (n = 4) with documented survival of less than 30 min. Group 3: cases (n = 4) where death was not due to head injury but survival is documented between 45 and 109 min. The brains were fixed in formalin for 4 weeks and six regions (frontal lobe with anterior corpus callosum, parietal lobe with deep white matter, basal ganglia with posterior limb of internal capsule, cerebellum with white matter and middle cerebellar peduncle and pons with basis pontis and superior cerebellar peduncle) were sampled. All blocks were stained for haematoxylin and eosin and beta-APP and selected ones for CD68, using antigen retrieval method. In group 1 sections revealed beta-APP immunoreactivity in forms of small globules and granules and occasionally as thin and short filaments. These were detected in the pons, corpus callosum, internal capsule and cerebral white matter, with some variation in localization and intensity. In groups 2 and 3 all the sections were negative for beta-APP staining. None of the cases showed evidence of severe brain swelling, increased intracranial pressure, ischaemia or infection. Using the antigen retrieval method, beta-APP immunohistochemistry can detect axonal damage within 35 min after severe head injury. These results may have an implication in the consideration of minimal survival time after traumatic head injury in medico-legal practice.	Kings Coll Hosp London, Dept Clin Neuropathol, London SE5 9RS, England; Forens Pathol Serv, London, England; Queen Mary Univ London, JM Cameron Inst Forens Sci, London E1 4NS, England	Al-Sarraj, S (corresponding author), Kings Coll Hosp London, Dept Clin Neuropathol, Acad Neurosci Bldg, London SE5 9RS, England.	safa.al-sarraj@kch.nhs.uk			Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0600676] Funding Source: Medline		ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Dolinak D, 2000, ACTA NEUROPATHOL, V100, P553, DOI 10.1007/s004010000218; DYRKS T, 1988, EMBO J, V7, P949, DOI 10.1002/j.1460-2075.1988.tb02900.x; FERREIRA A, 1993, J NEUROSCI, V13, P3112; Gandy S, 2005, J CLIN INVEST, V115, P1121, DOI 10.1172/JCI200525100; Geddes JF, 2000, NEUROPATH APPL NEURO, V26, P105, DOI 10.1046/j.1365-2990.2000.026002105.x; Geddes JF, 1997, NEUROPATH APPL NEURO, V23, P339, DOI 10.1046/j.1365-2990.1997.4498044.x; GEINISMAN Y, 1977, BRAIN RES, V125, P182, DOI 10.1016/0006-8993(77)90372-9; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; Gorrie C, 2002, J NEUROTRAUM, V19, P1171, DOI 10.1089/08977150260337976; Graham D I, 2002, GREENFIELDS NEUROPAT, P823; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; HORTOBAGYI T, 2004, NEUROPATHOL APPL NEU, V30, P204; Iino M, 2003, INT J LEGAL MED, V117, P153, DOI 10.1007/s00414-003-0370-y; Lambri M, 2001, CLIN NEUROPATHOL, V20, P263; LEBLANC AC, 1992, J NEUROSCI RES, V31, P635, DOI 10.1002/jnr.490310407; Leclercq PD, 2002, J NEUROTRAUM, V19, P1183, DOI 10.1089/08977150260337985; Lee JP, 2000, J NEUROSCI RES, V60, P565, DOI 10.1002/(SICI)1097-4547(20000515)60:4<565::AID-JNR16>3.0.CO;2-I; Lewis SB, 1996, J NEUROTRAUM, V13, P505, DOI 10.1089/neu.1996.13.505; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; Niess C, 2002, ACTA NEUROPATHOL, V104, P79, DOI 10.1007/s00401-002-0525-9; Ogata M, 1999, INT J LEGAL MED, V113, P19, DOI 10.1007/s004140050273; OTSUKA N, 1991, BRAIN RES, V568, P335, DOI 10.1016/0006-8993(91)91422-W; Reichard RR, 2005, NEUROPATH APPL NEURO, V31, P304, DOI 10.1111/j.1365-2990.2005.00645.x; SHERRIFF FE, 1994, NEUROREPORT, V5, P1085, DOI 10.1097/00001756-199405000-00016; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; Stone JR, 2004, EXP NEUROL, V190, P59, DOI 10.1016/j.expneurol.2004.05.022; Stone JR, 1999, ACTA NEUROPATHOL, V97, P335, DOI 10.1007/s004010050996; Van den Heuvel C, 1999, EXP NEUROL, V159, P441, DOI 10.1006/exnr.1999.7150; VIANCOUR TA, 1993, BRAIN RES, V628, P209, DOI 10.1016/0006-8993(93)90957-O; Wilkinson AE, 1999, ACTA NEUROPATHOL, V98, P197, DOI 10.1007/s004010051069; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006	35	74	85	0	6	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0305-1846			NEUROPATH APPL NEURO	Neuropathol. Appl. Neurobiol.	APR	2007	33	2					226	237		10.1111/j.1365-2990.2006.00794.x			12	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	144DV	WOS:000244776700009	17359363				2021-06-18	
J	Arango-Lasprilla, JC; Rosenthal, M; DeLuca, J; Cifu, DX; Hanks, R; Komaroff, E				Arango-Lasprilla, Juan Carlos; Rosenthal, Mitchell; DeLuca, John; Cifu, David X.; Hanks, Robin; Komaroff, Eugene			Functional outcomes from inpatient rehabilitation after traumatic brain injury: How do Hispanics fare?	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	82nd Annual Meeting of the American-Congress-of-Rehabilitation-Medicine	SEP 28-OCT 02, 2005	Chicago, IL	Amer Congress Rehabil Med			RISK-FACTORS; SYSTEMS; HEALTH; IMPACT; SCALE; MINORITIES; ETHNICITY; CARE; RACE	Objective: To examine the relation between Hispanic ethnicity and rehabilitation outcome in traumatic brain injury (TBI) survivors. Design: Retrospective study. Setting: Longitudinal dataset of the Traumatic Brain Injury Model Systems national database. Participants: Persons (N=3056; 2745 whites vs 311 Hispanics) with moderate to severe TBI hospitalized between 1989 and 2003. Interventions: Not applicable. Main Outcome Measures: Functional outcomes at discharge and 1-year follow-up (Disability Rating Scale [DRS], FIM instrument). Glasgow Outcome Scale-Extended (GOS-E), and the Community Integration Questionnaire (CIQ) were measured at follow-up only. Results: At admission, Hispanics were less educated (P <=.001), earned less money (P <=.05), and were younger (P <=.001) than whites. Hispanics had lower GOS-E scores (P <=.01) at acute hospital admission compared with whites. Despite similar functional status at inpatient rehabilitation discharge, Hispanic ethnicity was associated with poorer functional outcomes at I year postinjury (DRS, FIM, CIQ), after controlling for age, length of posttraumatic amnesia, injury severity, DRS score at admission, FIM score at admission, and preinjury educational level (P <.05). Conclusions: Hispanics showed significantly reduced long-term functional outcome after rehabilitation relative to whites. Rehabilitation professionals should recognize the possible impact of individual differences and diverse sociodemographic, injury, and rehabilitation characteristics so that differential	Kessler Med Rehabil Res & Educ Corp, Neuropsychol & Neurosci Lab, W Orange, NJ 07052 USA; Univ Med & Dent New Jersey, Dept Phys Med & Rehabil, Newark, NJ 07103 USA; Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA USA; Wayne State Univ, Dept Phys Med & Rehabil, Detroit, MI USA	Arango-Lasprilla, JC (corresponding author), Kessler Med Rehabil Res & Educ Corp, Neuropsychol & Neurosci Lab, 300 Execut Dr,Ste 010, W Orange, NJ 07052 USA.			Cifu, David/0000-0003-1600-9387	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD07522-05, T32 HD007522-5] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD007522] Funding Source: NIH RePORTER		[Anonymous], 1997, GUID UN DAT SET MED; ARTIOLA I, 2005, J CLIN EXP NEUROPSYC, V27, P555; Bazarian JJ, 2003, ACAD EMERG MED, V10, P1209, DOI 10.1197/S1069-6563(03)00491-3; Brown SA, 2004, APPL NEUROPSYCHOL, V11, P54, DOI 10.1207/s15324826an1101_7; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Burnett DM, 2000, BRAIN INJURY, V14, P713; CAVALLO MM, 1995, J HEAD TRAUMA REHAB, V10, P66, DOI 10.1097/00001199-199504000-00008; Centers for Disease Control and Prevention (CDC), 2004, MMWR Morb Mortal Wkly Rep, V53, P937; COOPER KD, 1983, NEUROEPIDEMIOLOGY, V2, P70; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; ELLIOTT P, 1994, INT J GYNECOL CANCER, V4, P84, DOI 10.1046/j.1525-1438.1994.04020084.x; Ferdinand KC, 2005, J NATL MED ASSOC, V97, P459; Hanks RA, 2003, ARCH PHYS MED REHAB, V84, P249, DOI 10.1053/apmr.2003.50096; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P158, DOI 10.1097/00001199-200503000-00004; JORGE RE, 1994, J NEUROSURG, V81, P726, DOI 10.3171/jns.1994.81.5.0726; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Levin HS, 2001, J NEUROTRAUM, V18, P575, DOI 10.1089/089771501750291819; MCCULLAGH P, 1989, GENERALIZED LINEAR M; National Institutes of Health, 1998, NIH CONSENSUS STATEM, V16, P1; O'Brien K, 2003, CA-CANCER J CLIN, V53, P208, DOI 10.3322/canjclin.53.4.208; Penn NE, 1995, HEALTH PSYCHOL, V14, P641, DOI 10.1037/0278-6133.14.7.641; Pole Nnamdi, 2005, Cultur Divers Ethnic Minor Psychol, V11, P144, DOI 10.1037/1099-9809.11.2.144; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Ramirez R.R., 2002, HISPANIC POPULATION, P20; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Ricker J H, 1998, Appl Neuropsychol, V5, P184, DOI 10.1207/s15324826an0504_3; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P40, DOI 10.1097/00001199-199610000-00005; Rosenthal M, 2000, HANDBOOK OF REHABILITATION PSYCHOLOGY, P49, DOI 10.1037/10361-003; Rubin DB., 1987, MULTIPLE IMPUTATION; Sabogal F, 1996, HISPANIC J BEHAV SCI, V18, P367, DOI 10.1177/07399863960183007; Satcher D, 2001, MENTAL HLTH CULTURE; Shai I, 2006, DIABETES CARE, V29, P1585, DOI 10.2337/dc06-0057; Stoops, 2002, DEMOGRAPHIC TRENDS 2; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; *TRAUM BRAIN INJ N, 2005, TRAUM BRAIN INJ MOD; *US CENS BUR, 2000, 2000 CENS POP HOUS; Uswatte G, 1997, REHABIL PSYCHOL, V42, P61, DOI 10.1037/0090-5550.42.1.61; Willer B., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI DOI 10.1097/00001199-199308020-00009; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; ZWEIFLER RM, 1995, STROKE, V26, P245, DOI 10.1161/01.STR.26.2.245	40	74	78	0	9	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JAN	2007	88	1					11	18		10.1016/j.apmr.2006.10.029			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	126GY	WOS:000243502000002	17207669				2021-06-18	
J	Greve, KW; Bianchini, KJ; Doane, BM				Greve, Kevin W.; Bianchini, Kevin J.; Doane, Bridget M.			Classification accuracy of the test of memory malingering in traumatic brain injury: Results of a known-groups analysis	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							ADULT INTELLIGENCE SCALE; CARD SORTING TEST; NEUROCOGNITIVE DYSFUNCTION; COGNITIVELY INTACT; NORMATIVE DATA; TOMM; VALIDATION; PERFORMANCE; DEPRESSION	This study used a known-groups design to determine the classification accuracy of the Test of Memory Malingering (Tombaugh, 1996, 1997) in detecting cognitive malingering in traumatic brain injury (TBI). Forty-one of 161 TBI patients met Slick, Sherman, and Iverson (1999) criteria for Malingered Neurocognitive Dysfunction. Twenty-two no-incentive memory disorder patients were also included. The original cutoffs (< 45) for Trial 2 and Retention demonstrated excellent specificity (less than a 5% false positive error rate) and impressive sensitivity (greater than 45%). However, these cutoffs are actually conservative in the context of mild TBI. Over 90% of the non-MND mild TBI sample scored 48 or higher on the Retention Trial and none scored less than 46 while 60% of the MND patients claiming mild TBI were detected at those levels. Trial 1 also demonstrated excellent classification accuracy. Application of these data to clinical practice is discussed.	Univ New Orleans, Dept Psychol, New Orleans, LA 70148 USA; Jefferson Neurobehav Grp, Metairie, LA USA	Greve, KW (corresponding author), Univ New Orleans, Dept Psychol, New Orleans, LA 70148 USA.	kgreve@uno.edu					ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Ashendorf L, 2004, ARCH CLIN NEUROPSYCH, V19, P125, DOI 10.1016/S0887-6177(02)00218-4; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P461, DOI 10.1076/clin.15.4.461.1890; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; BINDER LM, 1993, PORTLAND DIGIT RECOG; Butcher J. N., 1989, MMPI 2 MANUAL ADM SC; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Delis DC, 1987, CALIFORNIA VERBAL LE; Etherton JL, 2005, ARCH CLIN NEUROPSYCH, V20, P375, DOI 10.1016/j.acn.2004.09.007; Gansler DA, 1996, ARCH CLIN NEUROPSYCH, V11, P393, DOI 10.1016/0887-6177(96)83889-3; Gervais RO, 2004, ARCH CLIN NEUROPSYCH, V19, P475, DOI 10.1016/j.acn.2003.05.001; Gouvier WD, 1998, CRIT ISS NE, P55; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve KW, 2006, ARCH CLIN NEUROPSYCH, V21, P117, DOI 10.1016/j.acn.2005.06.009; Greve KW, 2004, ARCH CLIN NEUROPSYCH, V19, P533, DOI 10.1016/j.acn.2003.08.002; Greve KW, 2003, ARCH CLIN NEUROPSYCH, V18, P245, DOI 10.1016/S0887-6177(02)00137-3; Greve KW, 2002, CLIN NEUROPSYCHOL, V16, P179, DOI 10.1076/clin.16.2.179.13241; Heaton SK, 1993, WISCONSIN CARD SORTI; Hennekens CH, 1987, EPIDEMIOLOGY MED; KAGEHIRO DK, 1990, PSYCHOL SCI, V1, P194, DOI 10.1111/j.1467-9280.1990.tb00197.x; KIERNAN RJ, 1983, NEUROBEHAVIORAL COGN; Larrabee GJ, 2003, ARCH CLIN NEUROPSYCH, V18, P673, DOI 10.1016/S0887-6177(02)00157-9; LARRABEE GJ, 2005, FORENSIC NEUROPSYCHO, P115; LEESHALEY PR, 2003, J FORENSIC NEUROPSYC, V3, P167, DOI DOI 10.1300/J151V03N01_01; Mathias CW, 2002, ASSESSMENT, V9, P301, DOI 10.1177/1073191102009003009; Millis S. R., 2004, PRINCIPLES PRACTICE, P1077; Millis SR, 1995, PSYCHOL ASSESSMENT, V7, P463; MITTENBERG W, 1995, PROF PSYCHOL-RES PR, V26, P491, DOI 10.1037/0735-7028.26.5.491; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Mittenberg W, 2001, CLIN NEUROPSYCHOL, V15, P440; Rees LM, 1998, PSYCHOL ASSESSMENT, V10, P10, DOI 10.1037/1040-3590.10.1.10; Rees LM, 2001, ARCH CLIN NEUROPSYCH, V16, P501, DOI 10.1016/S0887-6177(00)00064-0; Rogers R., 1997, CLIN ASSESSMENT MALI, P398; Slick DJ, 2004, ARCH CLIN NEUROPSYCH, V19, P465, DOI 10.1016/j.acn.2003.04.001; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Suhr JA, 1999, J CLIN EXP NEUROPSYC, V21, P701, DOI 10.1076/jcen.21.5.701.868; Teichner G, 2004, ARCH CLIN NEUROPSYCH, V19, P455, DOI 10.1016/S0887-6177(03)00078-7; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260; Tombaugh TN, 1996, TEST MEMORY MALINGER; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Wechsler D, 1997, WAIS 3 ADM SCORING M; Weinborn M, 2003, J CLIN EXP NEUROPSYC, V25, P979, DOI 10.1076/jcen.25.7.979.16481	44	74	74	0	7	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	OCT	2006	28	7					1176	1190		10.1080/13803390500263550			15	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	064KV	WOS:000239089300009	16840243				2021-06-18	
J	Viano, DC; Pellman, EJ; Withnall, C; Shewchenko, N				Viano, David C.; Pellman, Elliot J.; Withnall, Chris; Shewchenko, Nick			Concussion in professional football: Performance of newer helmets in reconstructed game impacts - Part 13	NEUROSURGERY			English	Article						biomechanics; concussion; football; impact tolerances; neck injury; spearing; sport injury prevention		OBJECTIVE: The performance of five newer helmets was compared with the baseline VSR-4 helmet in 10 reconstructed cases of National Football League (NFL) collisions causing concussion. The laboratory reconstructions were conducted to determine changes in concussion risk with newer football helmets. METHODS: In 60 laboratory tests, translational and rotational head accelerations were measured in the striking and struck players represented by Hybrid III dummies. Six-axis upper neck loads and moments were measured in five cases with the struck player and five with the striking player. Biomechanical responses and concussion risks were evaluated for each collision to determine changes with newer helmet designs. RESULTS: Thirty-two out of 50 reconstructed cases showed greater than 10% reduction in severity index with newer helmets compared with the VSR-4; four cases increased. The average reduction in concussion risk with newer helmets was 10.8% (range, 6.9-16.7%) based on severity index. The reduction was 9.7% (range, 6.5-13.9%) based on translational acceleration and 18.9% (range, 10.6-23.4%) with rotational acceleration. Neck responses in the struck player showed a general reduction in moment and force with newer helmets. CONCLUSION: With newer football helmets, there was a trend toward 10 to 20% lower risks of concussion in reconstructed National Football League game collisions. However, a few designs and cases showed increased responses. The evaluation of football helmets to the proposed National Operating Committee on Standards for Athletic Equipment concussion standard should lead to more uniform reductions in concussion risk with future football helmets.	ProBiomech LLC, Bloomfield Hills, MI 48304 USA; Natl Football League, Mild Traumat Brain Injury Comm, New York, NY USA; ProHLTH Care Associates LLP, Lake Success, NY USA; Biokinet & Associates Ltd, Ottawa, ON, Canada	Viano, DC (corresponding author), ProBiomech LLC, 265 Warrington Rd, Bloomfield Hills, MI 48304 USA.	dviano@comcast.net					BACKAITIS SH, 1994, HYBRID, V3; Collins M, 2006, NEUROSURGERY, V58, P275, DOI 10.1227/01.NEU.0000200441.92742.46; Newman J A, 2000, Stapp Car Crash J, V44, P215; Newman JA, 2005, J BIOMECH, V38, P1469, DOI 10.1016/j.jbiomech.2004.06.025; *NOCSAE, 1998, 00298703 NOCSAE; *NOCSAE, 1996, LAB PROC GUID CERT N; *NOCSAE, 2004, STAND DROP TEST METH; *NOCSAE, 1987, 71487 NOCSAE; PADGAONKAR AJ, 1975, J APPL MECH-T ASME, V42, P552, DOI 10.1115/1.3423640; Pellman EJ, 2006, NEUROSURGERY, V58, P78, DOI 10.1227/01.NEU.0000196265.35238.7C; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; *SAE, 1994, SAE J, V1733; *SAE, 1980, SAE J, V855; Viano DC, 2005, NEUROSURGERY, V57, P1154, DOI 10.1227/01.NEU.0000187541.87937.D9; Viano DC, 2005, NEUROSURGERY, V57, P891, DOI 10.1227/01.NEU.0000186950.54075.3B; Viano DC, 2005, NEUROSURGERY, V56, P266, DOI 10.1227/01.neu.0000150035.54230.3C	17	74	74	1	49	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0148-396X			NEUROSURGERY	Neurosurgery	SEP	2006	59	3					591	605		10.1227/01.NEU.0000231851.97287.C2			15	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	085SE	WOS:000240623900023	16823324				2021-06-18	
J	Korner-Bitensky, N; Bitensky, J; Sofer, S; Man-Son-Hing, M; Gelinas, I				Korner-Bitensky, Nicol; Bitensky, Jamie; Sofer, Susan; Man-Son-Hing, Malcolm; Gelinas, Isabelle			Driving evaluation practices of clinicians working in the United States and Canada	AMERICAN JOURNAL OF OCCUPATIONAL THERAPY			English	Article							RISK; COMPETENCE; DEMENTIA; CRASH	OBJECTIVE. To determine off-road and on-road driving evaluation practices of clinicians in the United States and Canada who assess individuals with disabilities for fitness to drive. PARTICIPANTS. Participants were 114 clinician attendees at the 2003 annual Association of Driver Educators for the Disabled with driving assessment experience ranging from 1 month to 25 years. MEASURES. Information was elicited regarding the clinician, clientele, referral practices, and off-road and on-road driving evaluation practices and retraining practices using a self-administered questionnaire. RESULTS. Participants were largely occupational therapists (68%) who worked in 42 different states and provinces. The most prevalent clientele-were persons with traumatic brain injury (97%) and stroke (96%). Testing times greater than 60 min were common for both the off-road (61%) and on-road (49%) evaluations. Commonly performed off-road assessments included the Brake Reaction Timer; Trail Making Test, Parts A and B; and the Motor Free Visual Perception Test, used by 73%, 72%, and 66%, respectively; comprehensive computer-based driving evaluation was rare. Sixty-one percent indicated that all clients underwent on-road evaluation regardless of the off-road results. Finally, 78% used a standard driving route, whereas 24% used a scoring system to evaluate on-road driving. CONCLUSION. Driving assessment in Canada and the United States is multidimensional and time-intensive. Although the domains being assessed are similar across clincians, specific off-road and on-road assessment practices vary greatly. The majority use nonstandardized on-road assessments.	McGill Univ, Fac Med, Sch Phys & Occupat Therapy, Montreal, PQ H3G 1Y5, Canada; McGill Univ, Ctr Hlth, Montreal, PQ, Canada; Autonomy Community Therapy Inc, Montreal, PQ, Canada; Univ Ottawa, Dept Med, Elisabeth Bruyere Res Inst, Geriatr Assessment Unit, Ottawa, ON, Canada	Korner-Bitensky, N (corresponding author), McGill Univ, Fac Med, Sch Phys & Occupat Therapy, 3630 Promenade Sir William Osler, Montreal, PQ H3G 1Y5, Canada.	nicol.korner-bitensky@mcgill.ca					Akinwuntan AE, 2002, ARCH PHYS MED REHAB, V83, P334, DOI 10.1053/apmr.2002.29662; *AM MED ASS, 2003, PHYS GUID ASS COUNS, pCH3; BALL K, 1993, J AM OPTOM ASSOC, V63, P71; BRASHEAR A, 1998, AM J ALZHEIMERS DIS, V13, P131; CARR D, 1992, J AM GERIATR SOC, V40, P567, DOI 10.1111/j.1532-5415.1992.tb02104.x; Colarusso R. P., 1972, MOTOR FREE VISUAL PE; Colarusso RP, 1996, MOTOR FREE VISUAL PE; Dobbs AR, 1998, ACCIDENT ANAL PREV, V30, P363, DOI 10.1016/S0001-4575(97)00110-3; Dobbs AR, 1997, ALZ DIS ASSOC DIS, V11, P8, DOI 10.1097/00002093-199706001-00003; Dubinsky RM, 2000, NEUROLOGY, V54, P2205, DOI 10.1212/WNL.54.12.2205; Engum E. S., 1988, COGNITIVE REHABILITA, V6, P34; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fowler Jr. F. J., 1988, SURVEY RES METHODS; FREY JH, 1983, SURVEY RES TELEPHONE, P27; Goode KT, 1998, J CLIN PSYCHOL MED S, V5, P425, DOI 10.1023/A:1026206927686; GORDON W, 1984, SINGLE LETTER CANCEL; Harris M, 2000, ADV PSYCHIAT TREAT, V6, P261; Hawley CA, 2001, J NEUROL NEUROSUR PS, V70, P761, DOI 10.1136/jnnp.70.6.761; Hunt LA, 1997, ARCH NEUROL-CHICAGO, V54, P707, DOI 10.1001/archneur.1997.00550180029008; KATZMAN R, 1983, AM J PSYCHIAT, V140, P734; Korner-Bitensky NA, 1998, AM J OCCUP THER, V52, P916, DOI 10.5014/ajot.52.10.916; KORNERBITENSKY N, 2005, GERIATRICS, V23, P123; Mazer BL, 1998, ARCH PHYS MED REHAB, V79, P743, DOI 10.1016/S0003-9993(98)90350-1; McGwin G, 2000, AM J EPIDEMIOL, V152, P424, DOI 10.1093/aje/152.5.424; Money J., 1976, STANDARDIZED ROAD MA; ODENHEIMER GL, 1994, J GERONTOL, V49, pM153, DOI 10.1093/geronj/49.4.M153; Owsley C, 1998, JAMA-J AM MED ASSOC, V279, P1083, DOI 10.1001/jama.279.14.1083; Reitan R, 1986, TRAIL MAKING TEST MA; Sekuler AB, 2000, EXP AGING RES, V26, P103, DOI 10.1080/036107300243588; Shawaryn MA, 2002, ARCH PHYS MED REHAB, V83, P1123, DOI 10.1053/apmr.2002.33730; Smith A., 1968, LEARNING DISORDERS, P83; STEPHENS B, 2004, SUMMARY REPORT INT O; Streiner DL, 1989, HLTH MEASUREMENT SCA; Sudman S., 1982, ASKING QUESTIONS PRA; Wiseman EJ, 1996, GERIATRICS, V51, P36	35	74	75	0	14	AMER OCCUPATIONAL THERAPY ASSOC, INC	BETHESDA	4720 MONTGOMERY LANE, BETHESDA, MD 20814-3425 USA	0272-9490	1943-7676		AM J OCCUP THER	Am. J. Occup. Ther.	JUL-AUG	2006	60	4					428	434		10.5014/ajot.60.4.428			7	Rehabilitation	Rehabilitation	065RN	WOS:000239177100009	16915873				2021-06-18	
J	Berger, RP; Adelson, PD; Richichi, R; Kochanek, PM				Berger, Rachel Pardes; Adelson, P. David; Richichi, Rudolph; Kochanek, Patrick M.			Serum biomarkers after traumatic and hypoxemic brain injuries: Insight into the biochemical response of the pediatric brain to inflicted brain injury	DEVELOPMENTAL NEUROSCIENCE			English	Article						pediatric traumatic brain injury; serum biomarkers; child abuse; neuron-specific enolase; S100B; myelin basic protein	NEURON-SPECIFIC ENOLASE; MYELIN BASIC-PROTEIN; CEREBROSPINAL-FLUID; HEAD-INJURY; NONACCIDENTAL INJURY; PROGNOSTIC MARKER; QUINOLINIC ACID; YOUNG-CHILDREN; CYTOCHROME-C; INFANTS	Inflicted traumatic brain injury (iTBI) involves a combination of mechanical trauma and hypoxemia. Serum biomarker concentrations may provide objective information about their relative importance to the pathophysiology of iTBI. We compared the time course of neuron-specific enolase (NSE), S100B and myelin basic protein after pediatric hypoxic-ischemic brain injury, iTBI and noninflicted TBI (nTBI). The time to reach peak concentrations of all three biomarkers was shorter after nTBI. Initial and peak S100B, initial and peak myelin basic protein and peak NSE concentrations were no different between the three groups. Initial NSE concentration was highest after nTBI. These results suggest that the biochemical response of the brain to iTBI is distinct from the response to nTBI and shares temporal similarities with hypoxic-ischemic brain injury. This may have important implications for the treatment and prognosis of children with iTBI. Copyright (c) 2006 S. Karger AG, Basel.	Childrens Hosp Pittsburgh, Dept Pediat, Child Advocacy Ctr, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA USA; Univ Pittsburgh, Childrens Hosp Pittsburgh, Dept Neurosurg, Pittsburgh, PA 15213 USA; Childrens Hosp Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15213 USA; Stat Anal & Measurement Consultants Inc, Lanexa, VA USA	Berger, RP (corresponding author), 3705 5th Ave, Pittsburgh, PA 15213 USA.	rberger@pitt.edu	Adelson, David/W-2083-2019; Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X	NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01 RR00084] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD43843-01] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD043843] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000084] Funding Source: NIH RePORTER		Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Beers SR, 2004, PEDIATR RES, V55, p70A; Bell MJ, 1999, CRIT CARE MED, V27, P493, DOI 10.1097/00003246-199903000-00023; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; Berger RP, 2004, J NEUROTRAUM, V21, P1123; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; BILLMIRE ME, 1985, PEDIATRICS, V75, P340; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; Buki A, 2000, J NEUROSCI, V20, P2825; Carty H, 2002, EUR RADIOL, V12, P2919, DOI 10.1007/s00330-002-1436-9; Cho DY, 1995, PEDIATR NEUROSURG, V23, P192, DOI 10.1159/000120958; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Ewing-Cobbs L, 2000, CHILD NERV SYST, V16, P25, DOI 10.1007/s003810050006; Fridriksson T, 2000, ACAD EMERG MED, V7, P816, DOI 10.1111/j.1553-2712.2000.tb02276.x; Geddes JF, 2001, BRAIN, V124, P1290, DOI 10.1093/brain/124.7.1290; Heindl UT, 1996, NEUROPEDIATRICS, V27, P94, DOI 10.1055/s-2007-973756; Holzer M, 2002, NEW ENGL J MED, V346, P549; Hymel KP, 1997, PEDIATRICS, V99, P371, DOI 10.1542/peds.99.3.371; Ingebrigtsen T, 2002, J TRAUMA, V52, P798, DOI 10.1097/00005373-200204000-00038; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; Johnson DL, 1995, PEDIATR NEUROSURG, V23, P305, DOI 10.1159/000120976; Keenan HT, 2006, PEDIATRICS, V117, P317, DOI 10.1542/peds.2005-0979; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; King WJ, 2003, CAN MED ASSOC J, V168, P155; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; LEROUX PD, 1991, CHILD NERV SYST, V7, P34, DOI 10.1007/BF00263831; Makaroff KL, 2003, DEV MED CHILD NEUROL, V45, P497, DOI 10.1017/S0012162203000926; MUKHERJEE A, 1985, CLIN BIOCHEM, V18, P304, DOI 10.1016/S0009-9120(85)80037-0; Mussack T, 2001, WORLD J SURG, V25, P539, DOI 10.1007/s002680020082; Nagdyman N, 2001, PEDIATR RES, V49, P502, DOI 10.1203/00006450-200104000-00011; NOSEWORTHY TW, 1985, CRIT CARE MED, V13, P743, DOI 10.1097/00003246-198509000-00010; Rao P, 1999, CLIN RADIOL, V54, P495, DOI 10.1016/S0009-9260(99)90845-0; Rosen H, 1998, STROKE, V29, P473, DOI 10.1161/01.STR.29.2.473; Rosen H, 2001, RESUSCITATION, V49, P183, DOI 10.1016/S0300-9572(00)00348-8; Ross SA, 1996, BRIT J NEUROSURG, V10, P471, DOI 10.1080/02688699647104; Rovlias A, 2004, J NEUROTRAUM, V21, P886, DOI 10.1089/0897715041526249; Runyan CW, 2005, AM J PREV MED, V28, P73, DOI 10.1016/j.amepre.2004.09.010; Satchell MA, 2005, J CEREBR BLOOD F MET, V25, P919, DOI 10.1038/sj.jcbfm.9600088; Schnitzer PG, 2005, J PEDIATR PSYCHOL, V30, P413, DOI 10.1093/jpepsy/jsi065; Schoerkhuber W, 1999, STROKE, V30, P1598, DOI 10.1161/01.STR.30.8.1598; Spack L, 1997, PEDIATR EMERG CARE, V13, P98, DOI 10.1097/00006565-199704000-00004; Spinella PC, 2003, CRIT CARE MED, V31, P939, DOI 10.1097/01.CCM.0000053644.16336.52; Starling SP, 2004, ARCH PEDIAT ADOL MED, V158, P454, DOI 10.1001/archpedi.158.5.454; STARLING SP, 1995, PEDIATRICS, V95, P259; Tekgul H, 2004, PEDIATR NEUROL, V31, P326, DOI 10.1016/j.pediatrneurol.2004.05.004; THOMAS DGT, 1977, LANCET, V1, P113; THOMAS DGT, 1984, J NEUROL NEUROSUR PS, V47, P173, DOI 10.1136/jnnp.47.2.173; Thorngren-Jerneck K, 2004, PEDIATR RES, V55, P406, DOI 10.1203/01.PDR.0000106806.75086.D3	49	74	82	0	3	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0378-5866	1421-9859		DEV NEUROSCI-BASEL	Dev. Neurosci.		2006	28	4-5					327	335		10.1159/000094158			9	Developmental Biology; Neurosciences	Developmental Biology; Neurosciences & Neurology	080ZS	WOS:000240287600009	16943655				2021-06-18	
J	Gerlach, R; Demel, G; Konig, HG; Gross, U; Prehn, JHM; Raabe, A; Seifert, V; Kogel, D				Gerlach, R.; Demel, G.; Koenig, H. G.; Gross, U.; Prehn, J. H. M.; Raabe, A.; Seifert, V.; Koegel, D.			Active secretion of S100B from astrocytes during metabolic stress	NEUROSCIENCE			English	Article						S100B; CNS damage; ischemia; transcription; glial secretion; metabolic stress	TRANSGENIC MICE; PROTEINS; BRAIN; SUSCEPTIBILITY; INFUSION; DAMAGE; GENE	In patients suffering from cerebrovascular diseases and traumatic brain damage, increases in serum levels of protein S100B are positively correlated with the severity of the insult. Since high concentrations of S100B have been shown to exert neurotoxic effects, the objective of this study was to characterize the regulatory mechanisms underlying control of S100B release from astrocytes. To that end, we analyzed the kinetics and amount of S100B release in correlation with regulation of S100B gene expression in an in vitro ischemia model. Astrocyte cultures were treated with combined oxygen, serum and glucose deprivation, serum and glucose deprivation or hypoxia alone for 6, 12 and 24 h, respectively. While oxygen, serum and glucose deprivation triggered the most rapid release of S100B, serum and glucose deprivation provoked comparable levels of released S100B at the later time points. In contrast to oxygen, serum and glucose deprivation and serum and glucose deprivation, hypoxia alone elicited only marginal increases in secreted S100B. Parallel analysis of extracellular lactate dehydrogenase and the number of viable cells revealed only moderate cell death in the cultures, indicating that S100B was actively secreted during in vitro ischemia. Interestingly, S100B mRNA expression was potently downregulated after 12 and 24 h of oxygen, serum and glucose deprivation, and prolonged oxygen, serum and glucose deprivation for 48 h was associated with a significant reduction of S100B release at later time intervals, whereas lactate dehydrogenase levels remained constant. Our data suggest that secretion of S100B during the glial response to metabolic injury is an early and active process. (c) 2006 IBRO. Published by Elsevier Ltd. All rights reserved.	Univ Frankfurt, Dept Neurosurg, D-60528 Frankfurt, Germany; Royal Coll Surgeons Ireland, Dept Physiol, Dublin 2, Ireland	Gerlach, R (corresponding author), Univ Frankfurt, Dept Neurosurg, Schleusenweg 2-16, D-60528 Frankfurt, Germany.	r.gerlach@em.uni-frankfurt.de	Prehn, Jochen HM/A-3928-2010	Prehn, Jochen HM/0000-0003-3479-7794; Kogel, Donat/0000-0003-1209-0210			Adami C, 2004, BBA-MOL CELL RES, V1742, P169, DOI 10.1016/j.bbamcr.2004.09.008; BARGER SW, 1995, BRAIN RES, V677, P167, DOI 10.1016/0006-8993(95)00160-R; Craft JM, 2005, GLIA, V51, P209, DOI 10.1002/glia.20194; Davey GE, 2001, J BIOL CHEM, V276, P30819, DOI 10.1074/jbc.M103541200; Donato R, 2003, MICROSC RES TECHNIQ, V60, P540, DOI 10.1002/jemt.10296; Hu JG, 1996, J BIOL CHEM, V271, P2543, DOI 10.1074/jbc.271.5.2543; Huttunen HJ, 2000, J BIOL CHEM, V275, P40096, DOI 10.1074/jbc.M006993200; Kleindienst A, 2005, J NEUROTRAUM, V22, P645, DOI 10.1089/neu.2005.22.645; Kogel D, 2004, NEUROSCIENCE, V127, P913, DOI 10.1016/j.neuroscience.2004.06.013; LOFFNER E, 1986, BRAIN RES, V363, P205; Nickel W, 2003, EUR J BIOCHEM, V270, P2109, DOI 10.1046/j.1432-1033.2003.03577.x; Rothermundt M, 2003, MICROSC RES TECHNIQ, V60, P614, DOI 10.1002/jemt.10303; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; Tsoporis JN, 2003, AM J PHYSIOL-HEART C, V284, pH193, DOI 10.1152/ajpheart.00161.2002; Van Eldik LJ, 2003, RESTOR NEUROL NEUROS, V21, P97; Wainwright MS, 2004, ANN NEUROL, V56, P61, DOI 10.1002/ana.20142	16	74	80	0	8	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522			NEUROSCIENCE	Neuroscience		2006	141	4					1697	1701		10.1016/j.neuroscience.2006.05.008			5	Neurosciences	Neurosciences & Neurology	080BO	WOS:000240222000005	16782283				2021-06-18	
J	Wood, RL; Rutterford, NA				Wood, RL; Rutterford, NA			Psychosocial adjustment 17 years after severe brain injury	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							CLOSED-HEAD-INJURY; FOLLOW-UP; RATING-SCALE; DEPRESSION	Objectives: To examine very long term psychosocial outcome following severe brain injury in a large cohort, with the aim of evaluating Thomsen's observation that even after very serious head trauma the long term outcome in some patients is reasonably good. Methods: The cohort consisted of 80 patients who had suffered severe brain injury evaluated at a mean time of 17 years post injury ( range 10 - 32 years). Information regarding employment status and relationship status was obtained during clinical interview. Psychosocial outcome measures included the Supervision Rating Scale, Satisfaction with Life Scale, Hospital Anxiety and Depression Scale ( HADS), Patient Competency Rating Scale, and Community Integration Questionnaire. Results: Of the cohort, 72.0% lived independently, 28.7% were in full time employment, and 60.0% were married or cohabiting. The mean rating of life satisfaction was "slightly dissatisfied'', but no serious emotional problems were evident from self report ratings on the HADS. Mean functional competency ratings and community integration levels were just below those reported for non-disabled patients. Conclusions: Results indicate that although long term psychosocial functioning in patients with severe head injury remains compromised, long term adjustment may be better than expected from data reported by studies assessing psychosocial outcome at earlier stages of recovery.	Univ Coll Swansea, Dept Psychol, Swansea SA2 8PP, W Glam, Wales	Wood, RL (corresponding author), Univ Coll Swansea, Dept Psychol, Singleton Pk, Swansea SA2 8PP, W Glam, Wales.	r.l.wood@swansea.ac.uk					Boake C, 1996, ARCH PHYS MED REHAB, V77, P765, DOI 10.1016/S0003-9993(96)90254-3; Brzuzy S, 1997, SOC WORK HEALTH CARE, V26, P77, DOI 10.1300/J010v26n01_05; Colantonio A, 2004, DISABIL REHABIL, V26, P253, DOI 10.1080/09638280310001639722; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Hall KM, 2001, ARCH PHYS MED REHAB, V82, P367, DOI 10.1053/apmr.2001.21525; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; JACOBS HE, 1989, TRAUMATIC BRAIN INJU, P287; Leathem JM, 1998, J CLIN EXP NEUROPSYC, V20, P694, DOI 10.1076/jcen.20.5.694.1122; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Pavot W., 1993, PSYCHOL ASSESSMENT, V5, P164, DOI DOI 10.1037/1040-3590.5.2.164; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; TEASDALE GM, 2004448 CZH; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; THOMSEN IV, 1992, SCAND J REHABIL MED, P142; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Willer B., 1993, BRAIN INJURY REHABIL, P355; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	20	74	75	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	JAN	2006	77	1					71	73		10.1136/jnnp.2005.065540			3	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	997EJ	WOS:000234227500017	16361596	Bronze, Green Published			2021-06-18	
J	Doctor, JN; Castro, J; Temkin, NR; Fraser, RT; Machamer, JE; Dikmen, SS				Doctor, JN; Castro, J; Temkin, NR; Fraser, RT; Machamer, JE; Dikmen, SS			Workers' risk of unemployment after traumatic brain injury: A normed comparison	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						closed head injuries; employment; unemployment; vocational rehabilitation; risk factors; neuropsychology	POSTTRAUMATIC SEIZURES; FOLLOW-UP; RANDOMIZED-TRIAL; ACUTE PREDICTORS; PRACTICAL SCALE; HEAD TRAUMA; EMPLOYMENT; RETURN; REHABILITATION; PREVENTION	We examined, among those persons working preinjury, the risk of unemployment I year after traumatic brain injury (TBI) relative to expected risk of unemployment for the sample under a validated risk-adjusted econometric model of employment in the U.S. population. Results indicate that 42% of TBI cases were unemployed versus 9% expected, relative risk (RR) = 4.5, 95% confidence interval (CI) (4.12, 4.95). The relative risk for unemployment was higher among males, those with higher education, persons with more severe injuries, and more impaired early neuropsychological or functional status. Difference in unemployment rates gave similar results for gender, severity of injury, and early neuropsychological and functional status. However, for education, the excess was smaller among those more highly educated, but the unemployment rate in the more highly educated in the general population was sufficiently small to yield a larger relative risk. In conclusion, after accounting for underlying risk of unemployment in the general population, unemployment is substantially higher after TBI for people who were employed when they were injured. The differential employment status varies depending on demographics, severity of brain injury, early functional outcome, and neurobehavioral indicators. For characteristics such as education, associated with rates of unemployment in the general population, different methods used to compare the rates may yield different results.	Univ Washington, Sch Med, MEBI, Seattle, WA 98115 USA; Univ Washington, Sch Med, Dept Rehabil Med, Seattle, WA 98195 USA; Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Seattle, WA USA; Univ Washington, Sch Med, Dept Neurol Surg, Seattle, WA 98195 USA; Univ Washington, Sch Publ Hlth, Dept Biostat, Seattle, WA USA; Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA	Doctor, JN (corresponding author), Univ Washington, Sch Med, MEBI, 1959 NE Pacific St, Seattle, WA 98115 USA.	jdoctor@u.washington.edu					Armitage P., 1971, STAT METHODS MED RES; Army Individual Test Battery, 1944, MAN DIR SCOR; *BUR LAB STAT, 2002, 63RV US DEP LAB BUR; Cattelani R, 2002, BRAIN INJURY, V16, P51, DOI 10.1080/02699050110088821; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; DIKMEN S, 1980, J NERV MENT DIS, V168, P236, DOI 10.1097/00005053-198004000-00008; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Dikmen SS, 2000, NEUROLOGY, V54, P895, DOI 10.1212/WNL.54.4.895; DIKMEN SS, 1991, JAMA-J AM MED ASSOC, V265, P1271, DOI 10.1001/jama.265.10.1271; Felmingham KL, 2001, ARCH PHYS MED REHAB, V82, P435, DOI 10.1053/apmr.2001.21985; FRASER RT, 1986, EPILEPSIA, V27, P220, DOI 10.1111/j.1528-1157.1986.tb03532.x; FRASER RT, 1995, NEUROREHABILITATION, V5, P39, DOI 10.3233/NRE-1995-5104; JENNETT B, 1975, LANCET, V1, P480; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; KRAFT JF, 1993, ARCH PHYS MED REHAB, V74, P596, DOI 10.1016/0003-9993(93)90157-6; Millimet DL, 2003, J ECONOMETRICS, V113, P83, DOI 10.1016/S0304-4076(02)00168-9; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; TEASDALE G, 1974, LANCET, V2, P81; TEMKIN NR, 1995, J NEUROSURG, V82, P764, DOI 10.3171/jns.1995.82.5.0764; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593; Wagner AK, 2002, ARCH PHYS MED REHAB, V83, P107, DOI 10.1053/apmr.2002.27470; Wechsler D., 1955, MANUAL WECHSLER ADUL	24	74	74	0	7	CAMBRIDGE UNIV PRESS	NEW YORK	40 WEST 20TH ST, NEW YORK, NY 10011-4211 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	OCT	2005	11	6					747	752		10.1017/S1355617705050836			6	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	980NQ	WOS:000233025600010	16248910				2021-06-18	
J	Hillman, J; Aneman, O; Anderson, C; Sjogren, F; Saberg, C; Mellergard, P				Hillman, J; Aneman, O; Anderson, C; Sjogren, F; Saberg, C; Mellergard, P			A microdialysis technique for routine measurement of macromolecules in the injured human brain	NEUROSURGERY			English	Article						cerebral microdialysis; head trauma; intensive care; interleukin-6; monitoring; protein; subarachnoid hemorrhage	IN-VIVO; CYTOKINES; RELEASE; MARKERS; LINE	OBJECTIVE: To evaluate a new intracerebral microdialysis catheter with a high-cutoff membrane and its potential for the study of macromolecules in the human brain. METHODS: Paired intracerebral microdialysis catheters were inserted in 10 patients who became comatose after subarachnoid hemorrhage or traumatic brain injury and were then treated in our neurosurgical unit. The only differences from the routine use of microdialysis in our clinic were the length (20 mm) and cutoff properties of the catheter membranes (100 kD) and the perfusion fluids used (standard perfusion fluid, 3.5% albumin, or Ringer-dextran 60). Samples were weighed (for net fluid fluxes) and analyzed at bedside (for routine metabolites) and later in the laboratory (for total protein and interleukin-6). The in vitro recovery of glucose, glutamate, and glycerol were also investigated under different conditions. RESULTS: Even brief perfusion with standard perfusion fluid resulted in a significant loss of volume from the microdialysis system. For albumin and Ringer-dextran 60 fluid, recovery was comparable to standard settings. Interleukin-6 (highest value close to 25,000 pg/ml) was sampled from all catheters, and total protein was analyzed from catheters perfused with Ringer-dextran 60 (average concentration, 234 mu g protein/ml). There were detectable patterns of variations in the concentration of interleukin-6, seemingly related to concomitant variations in intracerebral conditions. In the present study, no direct comparison was made with the standard CMA 70 catheter (CMA Microdialysis, Stockholm, Sweden), but in vivo, the measured mean concentrations of glucose, glycerol, lactate, and pyruvate were comparable to those previously reported from standard catheters. In vitro, the recovery of metabolites was better when using Ringer-dextran 60 compared with albumin. CONCLUSION: Microdialysis catheters with high-cutoff membranes can be used in routine clinical practice, allowing for sampling and analysis of cytokines and other macromolecules.	Linkoping Univ Hosp, Dept Neurosurg, S-58185 Linkoping, Sweden; Linkoping Univ Hosp, Dept Dermatol, S-58185 Linkoping, Sweden	Hillman, J (corresponding author), Linkoping Univ Hosp, Dept Neurosurg, S-58185 Linkoping, Sweden.	Jan.Hillman@lio.se					Anderson C, 1995, Curr Probl Dermatol, V23, P121; BENVENISTE H, 1990, PROG NEUROBIOL, V35, P195, DOI 10.1016/0301-0082(90)90027-E; Billman G, 2002, CLIN CHEM, V48, P2030; Bullock R, 1995, ANN NY ACAD SCI, V765, P290, DOI 10.1111/j.1749-6632.1995.tb16586.x; Faden AI, 2002, CURR OPIN NEUROL, V15, P707, DOI 10.1097/00019052-200212000-00008; Fassbender K, 2000, NEUROSCI LETT, V284, P135, DOI 10.1016/S0304-3940(00)00977-0; Gozal E, 2002, J NEUROCHEM, V83, P331, DOI 10.1046/j.1471-4159.2002.01134.x; Hamani C, 1997, NEUROL RES, V19, P281, DOI 10.1080/01616412.1997.11740814; HILLERED L, 1990, ACTA NEUROCHIR, V102, P91, DOI 10.1007/BF01405420; Hillered L, 1999, SCAND J CLIN LAB INV, V59, P9, DOI 10.1080/00365519950185904; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Hutchinson PJ, 2000, J NEUROSURG, V93, P37, DOI 10.3171/jns.2000.93.1.0037; Ingebrigtsen T, 2002, J TRAUMA, V52, P798, DOI 10.1097/00005373-200204000-00038; McGlennen RC, 2001, CLIN CHEM, V47, P393; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; ROTHWELL NJ, 1995, TRENDS NEUROSCI, V18, P130, DOI 10.1016/0166-2236(95)93890-A; Sjogren S, 2002, BRIT J DERMATOL, V146, P375, DOI 10.1046/j.1365-2133.2002.04621.x; Stahl N, 2001, INTENS CARE MED, V27, P1215, DOI 10.1007/s001340101004; UNGERSTEDT U, 1991, J INTERN MED, V230, P365, DOI 10.1111/j.1365-2796.1991.tb00459.x; Unterberg AW, 2001, J NEUROSURG, V94, P740, DOI 10.3171/jns.2001.94.5.0740; Wilcockson DC, 2002, J CEREBR BLOOD F MET, V22, P318, DOI 10.1097/00004647-200203000-00009; Winter CD, 2002, J NEUROSCI METH, V119, P45, DOI 10.1016/S0165-0270(02)00153-X	23	74	76	0	7	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JUN	2005	56	6					1264	1268		10.1227/01.NEU.0000159711.93592.8D			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	934ES	WOS:000229690300020	15918942				2021-06-18	
J	Ernst, A; Basta, D; Seidl, RO; Todt, I; Scherer, H; Clarke, A				Ernst, A; Basta, D; Seidl, RO; Todt, I; Scherer, H; Clarke, A			Management of posttraumatic vertigo	OTOLARYNGOLOGY-HEAD AND NECK SURGERY			English	Article; Proceedings Paper	107th Annual Meeting of the American-Academy-of-Otolaryngology-Head-and-Neck-Surgery-Foundation	SEP 21-24, 2003	ORLANDO, FL	Amer Acad Otolaryngol Head & Neck Surg Fdn			PAROXYSMAL POSITIONAL VERTIGO; HEAD TRAUMA; DIFFERENTIAL-DIAGNOSIS; VESTIBULAR DEFICITS; POSTURAL STABILITY; WHIPLASH INJURIES; SUPPORT-SURFACE; DIZZINESS; POSTUROGRAPHY; DISORDERS	OBJECTIVE: To evaluate patients after blunt trauma of the head, neck, and craniocervical junction (without fractures) with vertigo and to report the results of treatment after extensive diagnostics. STUDY DESIGN: Prospective study of consecutive new cases with vertigo after trauma at different periods of onset. During 2000-2002, 63 patients were examined and treated. SETTING: Regional trauma medical center for the greater Berlin Area, tertiary referral unit. RESULTS: The primary disorders included labyrinthine concussion (18), rupture of the round window membrane (6), and cervicogenic vertigo (12). The secondary disorders included otolith disorders (5), delayed endolymphatic hydrops (12), and canalolithiasis (9). The patients were free of vertigo symptoms (except cervicogenic and otolith disorder) after treatment, which consisted of habituation training, medical and surgical therapy options. The follow-up was 1 year. CONCLUSION: Posttraumatic vertigo can be treated with a high success rate once the underlying disorder has been identified. The extent of the neurotological test battery determines the precision and quality of diagnostics. Surgical measures should be an integral part of treatment modalities if conservative treatment is not effective. SIGNIFICANCE. Minor trauma of the head, neck, and craniocervical junction can have major impact on the vestibular system at different sites. Patients need to be carefully diagnosed, even if the onset of vertigo occurs a few weeks or months after the initial trauma.	UKB, Med Ctr, Dept Otolaryngol, D-12683 Berlin, Germany; Univ Hosp Berlin Charite, Benjamin Franklin Med Ctr, Dept Otolaryngol, Vestibular Res Labs, Berlin, Germany	Ernst, A (corresponding author), UKB, Med Ctr, Dept Otolaryngol, Warener Str 7, D-12683 Berlin, Germany.	ArneborgE@ukb.de					Allum JHJ, 2002, GAIT POSTURE, V16, P264, DOI 10.1016/S0966-6362(02)00011-5; Allum JHJ, 2001, GAIT POSTURE, V14, P217, DOI 10.1016/S0966-6362(01)00142-4; Allum JHJ, 1999, J VESTIBUL RES-EQUIL, V9, P223; Basford JR, 2003, ARCH PHYS MED REHAB, V84, P343, DOI 10.1053/apmr.2003.50034; Clarke AH, 2003, J VESTIBUL RES-EQUIL, V13, P215; Clarke AH, 1998, EXP BRAIN RES, V121, P457, DOI 10.1007/s002210050481; COLEBATCH JG, 1994, J NEUROL NEUROSUR PS, V57, P190, DOI 10.1136/jnnp.57.2.190; Epley JM, 1996, OTOLARYNG CLIN N AM, V29, P323; Fitzgerald DC, 1996, J TRAUMA, V40, P488, DOI 10.1097/00005373-199603000-00034; Guyot JP, 2001, ANN OTO RHINOL LARYN, V110, P562, DOI 10.1177/000348940111000611; JACOBSON GP, 1990, ARCH OTOLARYNGOL, V116, P424; Nolle C, 2004, J NEUROTRAUM, V21, P251, DOI 10.1089/089771504322972040; PARNES LS, 1991, OTOLARYNG HEAD NECK, V104, P52, DOI 10.1177/019459989110400111; PARNES LS, 1993, ANN OTO RHINOL LARYN, V102, P325, DOI 10.1177/000348949310200501; RUBIN AM, 1995, AM J OTOL, V16, P216; SANNA M, 1983, ORL J OTO-RHINO-LARY, V45, P216, DOI 10.1159/000275645; SHEA JJ, 1995, AM J OTOL, V16, P235; Shea JJ, 2001, OTOL NEUROTOL, V22, P465, DOI 10.1097/00129492-200107000-00009; Sjostrom H, 2003, SPINE, V28, P1725, DOI 10.1097/00007632-200308010-00018; SPITZER WO, 1995, SPINE, V20, pS1; Vibert D, 2003, ANN OTO RHINOL LARYN, V112, P246, DOI 10.1177/000348940311200310	21	74	77	0	19	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0194-5998	1097-6817		OTOLARYNG HEAD NECK	Otolaryngol. Head Neck Surg.	APR	2005	132	4					554	558		10.1016/j.otohns.2004.09.034			5	Otorhinolaryngology; Surgery	Otorhinolaryngology; Surgery	912WZ	WOS:000228111900007	15806044				2021-06-18	
J	Esen, F; Erdem, T; Aktan, D; Orhan, M; Kaya, M; Eraksoy, H; Cakar, N; Telci, L				Esen, F; Erdem, T; Aktan, D; Orhan, M; Kaya, M; Eraksoy, H; Cakar, N; Telci, L			Effect of magnesium sulfate administration on blood-brain barrier in a rat model of intraperitoneal sepsis: a randomized controlled experimental study	CRITICAL CARE			English	Article						blood-brain barrier; brain edema; magnesium; sepsis; septic encephalopathy	CLOSED-HEAD INJURY; SEPTIC ENCEPHALOPATHY; CEREBRAL EDEMA; PERMEABILITY; THERAPY	Introduction Permeability changes in the blood - brain barrier (BBB) and their possible contribution to brain edema formation have a crucial role in the pathophysiology of septic encephalopathy. Magnesium sulfate has been shown to have a protective effect on BBB integrity in multiple experimental models. In this study we determine whether magnesium sulfate administration could have any protective effects on BBB derangement in a rat model of sepsis. Methods This randomized controlled experimental study was performed on adult male Sprague Dawley rats. Intraperitoneal sepsis was induced by using the infected fibrin - thrombin clot model. To examine the effect of magnesium in septic and sham-operated rats, a dose of 750 mu mol/kg magnesium sulfate was given intramuscularly immediately after surgery. Control groups for both infected and sham-operated rats were injected with equal volume of saline. Those rats surviving for 24 hours were anesthetized and decapitated for the investigation of brain tissue specific gravity and BBB integrity by the spectrophotometric assay of Evans blue dye extravasations. Another set of experiments was performed for hemodynamic measurements and plasma magnesium level analysis. Rats were allocated into four parallel groups undergoing identical procedures. Results Sepsis significantly increased BBB permeability to Evans blue. The dye content of each hemisphere was significantly lower in the magnesium-treated septic rats ( left hemisphere, 0.00218 +/- 0.0005; right hemisphere, 0.00199 +/- 0.0007 [ all results are means +/- standard deviation]) than in control septic animals ( left hemisphere, 0.00466 +/- 0.0002; right hemisphere, 0.00641 +/- 0.0003). In septic animals treated with magnesium sulfate, specific gravity was higher ( left hemisphere, 1.0438 +/- 0.0007; right hemisphere, 1.0439 +/- 0.0004) than in the untreated septic animals ( left hemisphere, 1.0429 +/- 0.0009; right hemisphere, 1.0424 +/- 0.0012), indicating less edema formation with the administration of magnesium. A significant decrease in plasma magnesium levels was observed 24 hours after the induction of sepsis. The dose of magnesium that we used maintained the baseline plasma magnesium levels in magnesium-treated septic rats. Conclusions Magnesium administration attenuated the increased BBB permeability defect and caused a reduction in brain edema formation in our rat model of intraperitoneal sepsis.	Univ Istanbul, Istanbul Fac Med, Dept Anesthesiol & Intens Care, Istanbul, Turkey; Univ Istanbul, Istanbul Fac Med, Dept Physiol, Istanbul, Turkey; Univ Istanbul, Istanbul Fac Med, Dept Infect Dis & Clin Microbiol, Istanbul, Turkey	Esen, F (corresponding author), Univ Istanbul, Istanbul Fac Med, Dept Anesthesiol & Intens Care, Istanbul, Turkey.	esenf@istanbul.edu.tr	Esen, Figen/AAS-6115-2020; Sungur, Mukadder Orhan/A-6574-2017; ERAKSOY, HALUK/AAE-4843-2020	Sungur, Mukadder Orhan/0000-0002-0770-8904; 			ARNOLD A, 1995, ANAESTHESIA, V50, P203, DOI 10.1111/j.1365-2044.1995.tb04556.x; Bareyre FM, 1999, J NEUROCHEM, V73, P271, DOI 10.1046/j.1471-4159.1999.0730271.x; Basler T, 2002, INTENS CARE MED, V28, P293, DOI 10.1007/s00134-002-1217-6; Bogdanski R, 2000, ANESTHESIOLOGY, V93, P793, DOI 10.1097/00000542-200009000-00029; BOLTON CF, 1993, ANN NEUROL, V33, P94, DOI 10.1002/ana.410330115; CLAWSON CC, 1966, J COMP NEUROL, V127, P183; DENG XM, 1995, J APPL PHYSIOL, V78, P2052; Esen F, 2003, J NEUROSURG ANESTH, V15, P119, DOI 10.1097/00008506-200304000-00009; FREUND HR, 1985, J SURG RES, V38, P267, DOI 10.1016/0022-4804(85)90037-X; Heath DL, 1998, J NEUROTRAUM, V15, P183, DOI 10.1089/neu.1998.15.183; Heath DL, 1999, J PHARMACOL EXP THER, V288, P1311; Heath DL, 1999, J NEUROSURG, V90, P504, DOI 10.3171/jns.1999.90.3.0504; JEPPSSON B, 1981, AM J SURG, V141, P136, DOI 10.1016/0002-9610(81)90026-X; Kaya M, 2001, CAN J PHYSIOL PHARM, V79, P793, DOI 10.1139/cjpp-79-9-793; MARMAROU A, 1978, J NEUROSURG, V49, P530, DOI 10.3171/jns.1978.49.4.0530; Mathiak G, 2000, CRIT CARE MED, V28, P1947, DOI 10.1097/00003246-200006000-00043; Mikawa S, 1996, J NEUROSURG, V85, P885, DOI 10.3171/jns.1996.85.5.0885; MILLER CF, 1987, AM J PHYSIOL, V253, pH956; MOULIN GC, 1985, BRAIN RES, V340, P261; OKIYAMA K, 1995, J NEUROCHEM, V64, P802; OPPELT WW, 1963, AM J PHYSIOL, V205, P959; Papadopoulos MC, 1999, CLIN SCI, V96, P461, DOI 10.1042/CS19980327; Papadopoulos MC, 2000, CRIT CARE MED, V28, P3019, DOI 10.1097/00003246-200008000-00057; PENDLEBURY WW, 1989, J NEUROPATH EXP NEUR, V48, P290, DOI 10.1097/00005072-198905000-00006; SHAPIRA Y, 1993, ANESTH ANALG, V77, P141; SPRUNG CL, 1990, CRIT CARE MED, V18, P801, DOI 10.1097/00003246-199008000-00001; Ustun ME, 2001, INTENS CARE MED, V27, P264, DOI 10.1007/s001340000780; VANDENBRINK WA, 1990, ACTA NEUROCHIR SUPP, V55, P261	28	74	76	0	9	BIOMED CENTRAL LTD	LONDON	MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND	1466-609X			CRIT CARE	Crit. Care	FEB	2005	9	1					R18	R23		10.1186/cc3004			6	Critical Care Medicine	General & Internal Medicine	905RQ	WOS:000227587700005	15693962	DOAJ Gold, Green Published			2021-06-18	
